FHR ROOM UJb.. Ui\i-T
EfiSffiQM
UNIVERSITY OF
ILLINOIS LIBRARY
AT URB/' A ..-tA.vlPAIGN
JLtn.-'j-.N w.oct
NOT TO BE TAKEN F
£0R ROCvi U:
JRARY.
^T' TO Rr >
'^SSMm;^
6r iso^
dtf
ional Institute
lental Health
The National Clearinghouse
for Mental Health Information
L. 19 CUMULATIVE INDEX June 1982
1 u^^^^^^i^^^. Abstracts °^°s,tory:
^^ I LOT AND TICKET NO.
n
81418
CLOTH COLOR
'^^SSSfi^^^
r, 7S0^
/?
ional Institute
\ental Health
^OTro
'^OOM'ust%..H?^'ARK,
The National Clearinghouse
for Mental Health Information
L. 19 CUMULATIVE INDEX June 1982
ychopharmacology Abstracts
r
DEPOS/TORV:
OCT ^\m
AT URBANA-CHAMPAIGN
— /at
PSYCHOPHARMACOLOGY ABSTRACTS is a publication of the National Clearinghouse
for Mental Health Information of the National Institute of Mental Health. It is a specialized
information medium designed to assist the Institute in meeting its obligation to foster and
support laboratory and clinical research into the nature and causes of mental disorders and
methods of treatment and prevention. Specifically, this information service is designed to meet
the needs of investigators in the field of psychopharmacology for rapid and comprehensive
information about new developments and research results. For information or correspondence
with the National Institute of Mental Health concerning Psychopharmacology Abstracts,
changes of address, or removal of names from the mailing list see the inside back cover page.
The Secretary of Health and Human Services has determined that the
publication of this periodical is necessary in the transaction of the public
business required by law of this Department. Use of funds for printing this
periodical has been approved by the Director of the Office of Management
and Budget through November 15, 1982.
JAiZ)7 V
NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION
PSYCHOPHARMACOLOGY ABSTRACTS
Volume 19
Cumulative Index
June 1982
Page
Cross Reference List 1
Subject Index S-1
Author Index A-1
Carrie Lee Rothgeb, Editor
Bette L. Shannon, Managing Editor
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Alcohol, Drug Abuse, and Mental Health Administration
National Institute of Mental Health
National Clearinghouse for Mental Health Information
5600 Fishers Lane
Rockville, Maryland 20857
DHHS Publication No. (ADM) 83-150
Printed 1983
For sale by the Superintendent of Documena, U.S. Government Printing Office, Washington, D.C. :0402.
CROSS-REFERENCE LIST
The use of a Key-Word-out-of-Context (KWOC) index, while saving time and
money, poses a problem to users seeking to locate relevant references on
a given topic, as all references are not found under one entry. To
alleviate this problem, we have prepared the following cross-reference
list.
Ability
A
see also
Learning ability
Abuse see also
Drug abuse
Access see
Continuous access
Accidents see
Cerebrovascular accidents
Acetylcholine see also
ACH
Acetylsalicylic acid see also
Aspirin
ACH see also
Acetylcholine
Acid see also
Names of individual acid;
Act see
Controlled substances ac
ACTH see also
A drenocortico tropin
Acting see
Centrally acting
CNS acting
Long-acting
Short- acting
Action(s) see
Anorectic actions
Behavioural actions
Biochemical action
Central action(s)
Dual action(s)
Hypotensive action
Inhibitory actions
Mechanism -of- action
Neurotoxic action(s)
Neurotropic action
Psychotropic action
Site-of- action
Activated see
Dopamine- activated
Na - K - ac tivate d
Active see
Centrally active
Highly active
Activity see
Alpha- adrenergic activity
Anorectic activity
Antiarrhythmic activity
Anticandidal activity
Anticholinergic activity
Anxiolytic activity
Behavioral activity
Binding activity
Bioelectric activity
Bioelectrical activity
Biological activity
Central activity
Dopaminergic activity
Electrical activity
Exploratory activity
Fast Activity
General activity
Hypersynchronous activity
Locomotor activity
Motor activity
Parasympathetic activity
Social activity
Structure- activity
Thyroid activity
AD-810 see
Sulfamoylmethylbenzisoxazole
AD-1308 see
Ethyl- 2-piperazinyl-4-phenyl-
quinoline-HCl
Adenosine monophosphate
AMP
C-AMP
Cyclic AMP
Adenosine triphosphatase
ATPASE
Adenosine triphosphate
ATP
Administered see
Centrally administered
Self -administered
Administration see also
Route-of -administration
Self -administration
Adrenaline see also
Epinephrine
A drenocortico tropin
ACTH
see
see also
see
see also
ADTN see also
Aminodihydroxytetrahydro-
naphthalene
AEP see also
Evoked potential
Affective disorders see also
Bipolar
Depression
Manic-depressive
Unipolar
Affinity see also
High affinity
Agent(s) see
Addictive agents
Anorectic agents
Antianxiety agents
Anticonvulsant agents
Antiepileptic agents
Blocking agents
Catecholamine depleting agent
Convulsant agents
Depolarizing agent
Disinhibiting agent
Dopaminergic agent(s)
Hallucinogenic agent
Narcotic agents
Neuroactive agents
Neuroleptic agents
Neuropharmacological agents
Neuropsychiatric agents
Oxotremorine-Uke agent
Pharmaceutic agents
Pharmacologic agents
Pharmacological agents
Psychopharmacologic agents
Psychopharmacological agents
Psychotropic agent
Releasing agents
Serotonergic agents
Vasoactive agents
AHR-mS see
Pridefine
Aids see
Sleeping aids
Alcohol see also
Ethanol
Ethylalcohol
Alteration see also
Attentional alteration
Rate altering
Amine(s) see also
Biogenic amine
Brain amine
Monoamine(s)
Names of specific amines
Sympathomimetic amines
Aminobutyric acid see also
GABA
Aminodihydroxytetrahydronaphthalene
see also
ADTN
Amphetamine see also
D- Amphetamine
Dextroamphetamine
L- Amphetamine
Methamphetamine
Methylamphetamine
Analysis see also
Behavioral analysis
Behavioural analysis
Mass spectral analysis
Mass spectrometric analysis
Microanalysis
Psychometric analysis
Signal detection analysis
Symptom profile analysis
Video analysis
Analyzed see
Computer analyzed
AMPT see
Methyl-p- tyrosine
Antidepressant see also
Names of specific compounds
Nontricychc antidepressant
PolycycHc antidepressants
Tetracyclic antidepressant(s)
Tricyclic antidepressant(s)
Antihypertensive effects see also
Hypotensive effect
Anxiety see also
Panic anxiety
Phobic anxiety
AOAA see
Aminooxyacetic acid
Apnea see
Sleep apnea
Application(s) see
Microiontophoretic applications
Approach(es) see
Psychodynamic approach
Psychotherapeutic approaches
Area see
Preoptic area
Artery(ies) see also
Cerebral artery (ies)
Mensenteric arteries
Pial arteries
Pulmonary arteries
Vertebral artery
^mam^
Aspect(s) see
Associative aspects
Behavioral aspect
Biochemical aspects
CUnical aspects
Metabolic aspects
Nonassociative aspects
Pathophysiological aspects
Pharmacological aspects
Psychiatric aspects
Technical aspect
Aspirin see also
Acetylsalicylic-acid
Assay see also
Microassay
Assessment see also
Electromyographic assessment
Associations see also
Verbal associations
ATPASE see also
Adenosine- triphosphatase
Autoreceptor(s) see also
Alpha2- adrenergic autoreceptor
Dopamine autoreceptor(s)
GABA autoreceptors
Presynaptic autoreceptors
Serotoninergic autoreceptor
Availability see also
Commercially available
Aversion(s) see also
Taste aversion(s)
Avoidance see also
High avoidance
Low avoidance
Passive avoidance
Shock avoidance
Sidman avoidance
B
Barnetil see
Sultopride
Barrier see
Blood brain barrier
Based see
Community based
Basis; Bases see
Biochemical basis
Neurochemical bases
Neurophysiological basis
Pathophysiologic basis
Pharmacokinetic bases
Pharmacological bases
Battery see
Neuropsychological battery
Behavior(s) see also
Abnormal behavior
Abstinence behavior
Acquisition behavior
Addictive behavior
Aggressive behavior
Ataxic behaviors
Avoidance behavior
Bar-pressing behavior
Conflict behavior
Defensive behavior
Drinking behavior
Eating behavior
Escape behavior
Exploratory behavior
Fighting behavior
Head- shaking behavior
Homing behavior
Hyperactive behavior
Learned behavior
Maternal behavior
Mating behavior
Maze behavior
Mothering behavior
Motor behavior
Mouse-killing behavior
Nest-building behavior
Nonverbal behavior
Nursing behavior
Operant behavior
Pathological behavior
Pecking behavior
Punished behavior
Reaching behavior
Rotational behavior
Scent-marking behavior
Sexual behavior
Shaking behavior
Social behavior
Stereotyped behavior
Sterotypic behavior
Violent behavior
Yawning behavior
Behaviour see also
Abstinence behaviour
Aggressive behaviour
Agonistic behaviour
Avoidance behaviour
Circling behaviour
Climbing behaviour
Disturbed behaviour
Exploratory behaviour
Rotational behaviour
Scratching behaviour
Sexual behaviour
Social behaviour
Sociosexual behaviour
Stereotyped behaviour
Timid behaviour
Biochemistry see also
Brain biochemistry
Bipolar see also
Affective disorders
Depression
Manic- depressive
Unipolar
Biting see
Self-biting
Blind see
Double blind
Single blind
Time blind
Blues see
Maternity blues
Bodies see also
Dense bodies
Lafora bodies
Bound see also
Membrane bound
Boy(s) see also
Hyperactive boys
Hyperkinetic boys
Schizophrenic boy
Brain see also
Anterior forebrain
Blood brain barrier
Forebrain
Midbrain
Mouse brain
Rat brain
Rat forebrain
Rat midbrain
Rat whole brain
Bulb(s) see
Olfactory bulb
C-AMP see also
Cyclic- adenosine monophosphate
Cyclic- AMP
C-GMP see
Cyclic- GMP
CycUc-guanosine monophosphate
Ca see also
Calcium
45Ca
Calcium see also
Ca
45Ca
Capacity see also
Mental capacity
Care see also
Sheltered care
Cardiac see also
Heart
CAT-scan see
Computerized axial tomography
Catecholamine-O-methyltransf erase
see
COMT-A
COMT-B
Cation(s) see also
Divalent cation(s)
Caused see
Psychotropic caused
CCK-8 see
Cholecystokinin octapeptide
CEEG see also
Comp-EEG
CSEEG
Cell(s) see also
Purkinje cell(s)
Red blood cell(s)
Schwann cell
Center see also
Day treatment center
Residential center
Central nervous system see also
CNS
Cerebellum see also
Rat cerebellum
Cerebral cortex
see also
Frontal cerebral cortex
Rat cerebral cortex
Cerebrospinal fluid see also
CSF
CG-3033 see
Supidimide
Chain see
Branched chain
Chamber see
Anterior chamber
Change(s) see also
Behavior change
Behavioral changes
Behavioural changes
Biochemical changes
Developmental change
Electrocardiographic changes
Electrocortical changes
Electrophysiological changes
ifi^aKss^
Electroret±iographic changes
Mechanical changes
Channel(s) see
Calcium channel
Ion channel(s)
Characterization see also
Biochemical characterization
Check see
Methodical check
Child; Children see also
Borderline children
Cerebral palsied child
Depressed child
Epileptic children
Hyperactive child(ren)
Hyperkinetic children
Special child
Chlorpromazine see also
CPZ
Cholinoceptor see also
Muscurinic cholinoceptor
Chorea see also
Huntingtons chorea
Chromatography see also
Gas Chromatography
Gas liquid chromatography
Liquid chromatography
Thin layer chromatography
TLC
Circadian see also
Ultradian
Circuit see also
Short circuit
Classification see also
Pharmacoclinical classification
Clinic see also
Mental hygiene clinic
CNS see also
Central nervous system
Coated see
Enteric coated
Colony see
Social colony
Comfort see
Social comfort
Communication see also
Preliminary communication
Comp-EEG see also
CEEG
CSEEG
Comparison see also
Controlled comparison
Complaint(s) see
Psychosomatic complaints
Complication see also
Neurological complications
Ocular complication
Component see
Two component
Compound(s) see
Hypnotic compounds
Names of specific compounds
Computer see also
Microcomputer
Concentration(s) see also
High concentrations
Conditioning see also
Appetitive conditioning
CS
Pavlovian conditioning
Conditions see also
Depressive conditions
Psychopathological conditions
Conductance see also
Ion conductance
Consequences see
Behavioral consequences
Biochemical consequences
Neurochemical consequences
Considerations see also
Behavioral considerations
Biochemical considerations
Methodological considerations
Pharmacological considerations
Control(Ied) see also
Autonomic control
Placebo controlled
Schedule controlled
Weight control
Cord see
Spinal cord
Correlates see
Behavioral correlates
Biochemical correlates
Biomedical correlates
Cortical correlates
Electrophysiological correlates
Metabolic correlates
Neurochemical correlates
Neuropsychological correlates
Peripheral correlates
Pharmacological correlates
Physiological correlates
Correlation see also
Biochemical correlation
Clinical correlation
Neuropsychiatric correlations
Cortex see also
Cerebellar cortex
Cerebral cortex
Frontal cerebral cortex
Frontal cortex
Motor cortex
Occipital cortex
Olfactory cortex
Prefrontal cortex
Rat brain cortex
Rat cerebral cortex
Rat cerebral cortical
Rat cortex
Rat frontal cortex
Cortisol see also
Hydrocortisone
Course see
Time course
Court see
Federal court
CP-36584 see
Flutroline
C?Z see also
Chlorpromazine
CS-386 see
Mexazolam
CSD see
Cysteine sulphinic acid-
decarboxylase
CSF see also
Cerebrospinal fluid
Culture see also
Cell culture
Current see
Outward current
Curve see also
Response curve
Cycle(s); Cycling see also
Circadian cycles (cycling)
Estrous cycle
Cyclic-adenosine monophosphate
see also
C-AMP
CycUc-AMP
Cyclic AMP see also
C-AMP
Cyclic-adenosine monophosphate
Cyclic-GMP see also
Cyclic-guanosine monophosphate
Cyclic-guanosine monophosphate
see also
Cyclic-GMP
Cylert see
Pemoline
D-12524 see
Lopirazepam
D- Amphetamine see also
Amphetamine
Dextroamphetamine
L- Amphetamine
Methamphetamine
Methylamphetamine
DA see
Dopamine
DAergic see
Dopaminergic
Damage(d) see also
Brain damage(d)
Dapotum-D see
Fluphenazine decanoate
Data see also
Biochemical data
Pathophysiological data
DBH see
Dopamine-beta-hydroxylase
Deaza-siba see
Deoxyisobutylthio-3-deazaadenosine
Deficiencies see also
Behavioral deficiencies
Deficits see also
Avoidance deficits
Behavioral deficits
Delirium see also
Alcoholic delirium
Delta sleep see
DSIP
Dementia see also
Senile dementia
Deoxycorticosterone see also
DOCA
Depakene see
Valproic acid
Depakine see also
Dipropylacetate
Dipropylacetic acid
Sodium dipropylacetate
Sodium valproate
Valproic acid
Dependent(ence) see also
Age dependent
Barbiturate dependence
Behavior dependent
Ca++- dependent
DNA dependent
Dopamine dependent
Dose dependent
Meal dependent
Morphine dependence(ent)
Na+- dependent
Opiate dependent
Physical dependence
Prostacyclin dependent
Rate depencency
Sodium dependent
State dependent
Time dependent
Depression see also
Affective disorders
Behavioral depression
Bipolar
Childhood depression
Manic- depressive
Motor depression
Unipolar
Deprived see also
Maternally deprived
Sleep deprivation (ed)
Water deprived
Desensitization see also
Behavioral desensitization
Desipramine see also
Desmethylimipramine
DM1
Desmethylimipramine see also
Desipramine
DM1
Despair see
Behavioural despair
Detection see also
Electrochemical detection
Determination see also
Liquid chromatographic determination
Deviants ; Deviations see
Sexual deviants; deviations
Dextroamphetamine see also
Amphetamine
D- Amphetamine
L- Amphetamine
Methamphetamine
Methylamphetamine
DHT see also
Dihydroxytryptamine
Diagnosis see also
Psychiatric diagnosis
Difference(s) see
Sex difference(s)
Species difference(s)
Difficulties see
Sexual difficulties
Diflunisal see
Difluorophenylsalicylic acid
Dihydroxyergotoxine see also
Hydergine
Dihydroxyphenylacetic acid see also
DOPAC
Dihydroxyphenethylamine see
Dopamine
Dihydroxyphenylalanine see also
DOPA
L-DOPA
Levodopa
Dihydroxytryptamine see also
DHT
Diisopropylfluorophosphate see
DFP
Dimethoxy-4-methylamphetamine
see also
DOM
Dimethylaminoethanol see
DEANOL
Diphenylhydantoin see also
Phenytoin
Dipropylacetate ; Dip ropy lace tic acid
see also
Depakine
Sodium dipropylacetate
Sodium valproate
Valproic acid
DIPT see
Diisopropyltryptamine
Disability (ies) see
Learning disabilities
Reading disabled
Discharge see also
Epileptic discharge
Disease(s) see
Alzheimers disease
Cerebrovascular diseases
Chagas disease
Gilles de la Tourettes disease
Heart disease
Hepatic disease
Huntington(s) disease
Mental diseases
Names of specific diseases
Parkinson(s) disease
Psychosomatic diseases
Renal disease
Respiratory disease
Disorder(s)(ed) see also
Affective disorder(s)
Anxiety disorders
Astheno- depressive disorders
Attention disordered
Behavior disorders
Behavioural disorders
Deficit disorders
Depressive disorder(s)
Dystonia disorders
Extrapyramidal disorders
Gilles de la Tourettes disorder
Learning disorders
Leukopenia disorders
Manic melancholic disorders
Mental disorders
Mood disorders
Movement disorders
Obsessive compulsive disorder(s)
Panic disorder
Personality disorder
Psychiatric disorders
Psychotic disorders
Schizoaffective disorder
Sexual disorders
Sleep disorders
Sleep wake disorders
Distalgesic see
Dextropropoxyphene
Disturbances see also
Behavioral disturbances
Memory disturbances
Mental disturbances
Organic brain disturbance
Psychiatric disturbance
Sensory disturbances
Sleep disturbances
DMI see also
Desipramine
Desmethylimipramine
DN-1417 see
Butyrolactone-gamma-carbonyl-
histidyl-prolin amide
DOC A see also
Deoxycorticosterone
Dogs see also
Beagle dogs
DOM see also
Dimethoxy-4-methylamphetamine
DOPA see also
Dihydroxy phenylalanine
L-DOPA
Levodopa
DOPAC see also
Dihydroxyphenylacetic acid
DOPEG-SO.
see
Dihydroxyphenylethylene- glycol-
sulfate
Dose(es) (ages) see also
High dosage(es)
Hyperthermic dose
Large doses
Large single doses
Log dose
Low dose(s) (age)
Minimum doses
Multiple dose
Overdose(age)
Single bedtime dose
Single daily dose(s)
Single dosage(e) (es)
Single nightly dose
Single oral dosages (e)
Single therapeutic dose
Small dose
Doubt see
Reasonable doubt
DPEA see
Dichloro-6-phenylphenoxyethylamine-
HBr
Drugs see also
Analgesic drugs
Anorectic drugs
Antialcoholism drug
Antianxiety drug(s)
Anticholinergic drugs
Anticonvulsant drug(s)
Antidepressant drug(s)
Antidepressive drug(s)
Antiepileptic drugs
Antihypoxidotic drugs
Antiinflammatory drugs
Antiparkinson drugs
Antiparkinsonian drugs
Antipsychotic drug(s)
Antischizophrenic drugs
Anxiolytic drugs
Blocking drugs
Cholinergic drugs
Hallucinogenic drugs
Hypnotic drug(s)
Names of specific drugs
Narcotic drugs
Neuroleptic drug(s)
Neuropharmacological drugs
Neurotropic drugs
Nicotinic drugs
Nootropic drugs
Opiate-like drugs
Psychedehc drugs
Psychiatric drug(s)
Psychoactive drug(s)
Psycholeptic drugs
Psychotherapeutic drug(s)
Psychotropic drug(s)
Stimulant drugs
Tranquilizing drugs
Two- drug
Duration see also
Long duration
Dysfunction(s) see also
Attention dysfunction
Brain dysfunction
Minimal brain dysfunction
Sensorimotor dysfunctions
Sexual dysfunction(s)
Dyskinesia(s) see also
Paroxystic dyskinesias
Tardive dyskinesia (s)
ECG see
EKG
Electrocardiogram
ECS see
ECT
Electroconvulsive shock
Electroconvulsive therapy
Electroconvulsive treatment
Electroshock
ECT see also
Electroconvulsive shock
Electroconvulsive therapy
Electroconvulsive treatment
Electroshock
EEC see also
CEEG
Comp-EEG
Electroencephalography
PharmacoEEG
Effect(s) see
Adverse effects
Anorectic effect
Antagonistic effects
Antianxiety effects
Anticholinergic effects
Antidopaminergic effects
Antiepileptic effect
Antihypertensive effects
Antimanic effect
Antinociceptive effect
Antinuretic effect
Antipsychotic effect
Associative effects
Autonomic effects
Aversive effect(s)
Behavioral effects
Behavioural effects
Biochemical effects
Biological effects
Biphasic effects
Cardiovascular effects
Cataleptic effect(s)
Choleretic effect
Clinical effect(s)
Comparative effect(s)
Contrasting effects
Convulsant effect(s)
Differential effect(s)
Dipsogenic effect
Dissociative effects
Dopaminergic effects
Dose effects
Drug effect(s)
Electrocortical effects
Electroencephalographic effects
Electrophysiological effects
Endocrine effects
Epileptogenic effect
Experimental effects
Extrapyramidal effects
Hormonal effects
Hyperthermic effects
Hypnotic effects
Hypotensive effect
Hypothermic effects
Inhibitory effect(s)
Interactive effects
Joint effects
Laryngeal effects
Locomotor effects
Lytic effects
Metabolic effects
Motor effects
Neurochemical effects
Neuroleptic effect(s)
Neurophysiological effects
Neuropsychologic effects
Opiate effects
Opposite effects
Paradoxical effect(s)
Perceptual effects
Pharmacologic effects
Pharmacological effects
Placebo effect(s)
Prohypnotic effects
Psychiatric effects
Psychic effects
Psychoactive drug effect
Psycholeptic effects
Psychopharmacological effects
Psychophysiological effects
Residual effects
Retinotoxic effects
Side effect(s)
Stimulant effect(s)
Subjective effects
Thermoregulatory effects
Transient effect
Efficacy see also
Antipsychotic efficacy
Clinical efficacy
Therapeutic efficacy
EKG see also
Electrocardiogram
Electrocardiogram see also
EKG
Electroconvulsive shock see also
ECT
Electroconvulsive therapy
Electroconvulsive treatment
Electroshock
Electroconvulsive therapy see also
ECT
Electroconvulsive shock
Electroconvulsive treatment
Electroshock
Electroconvulsive treatment see also
ECT
Electroconvulsive shock
Electroconvulsive therapy
Electroshock
Electroencephalography see also
CEEG
Comp-EEG
CSEEG
EEG
Electromyographic see also
EMG
Elements see
Mineral elements
Names of specific elements
Elicited see
Amphetamine -eUcited
Apomorphine-elicited
Shock-ehcited
Emergency (ies) see also
Medical emergencies
Psychiatric emergencies
EMG see also
Electromyographic
Eminence see
Median eminence
Ending see
Nerve ending(s)
Enhanced see
GABA-enhanced
Enriched see
K+-enriched
Entheogenic see
Hallucinogenic
Enuresis see also
Childhood enuresis
Epilepsy see also
Childhood epilepsy
Focal epilepsy
Petit mal
Epinephrine see also
Adrenaline
Episode see
Affective episode
Schizophrenic episodes
ERG see
Electroretinography
Escape see also
Water escape
Estimation see
Microestimation
ET-495 see
Piribedil
Ethanol see also
Alcohol
Ethyl alcohol
Ethyl alcohol see also
Alcohol
Ethanol
Euhypnos-forte see
Temazepam
Evaluation see also
Clinical evaluation
Preclinical evaluation
Self- evaluation
Events see
Behavioral events
Biochemical event
Endocrine events
Evidence see also
Behavioral evidence
Biochemical evidence
Evoked see also
Barbiturate-evoked
Dopamine- evoked
Flash- evoked
GABA-evoked
K+- evoked
S timulation - evoke d
Stimulus -evoked
Striatally - evoked
10
:Sm^i
Evoked Potential see also
AEP
Exchange see
Gas exchange
Execration see also
Circadian excretion
Experiences see also
Aversive experiences
Clinical experiences
Psychedelic experiences
Exposed see also
Stress exposed
Extracts see also
Coca extracts
Facilitation see
Behavioral facilitation
Factor(s) see also
Antihemophilic factor
Bass scale factors
Growth factor
Psychopharmacologic factors
Psychosocial factors
Risk factors
Thy rotrophin- releasing factor
FDA see also
Food and Drug Administration
Fear see also
Learned fear
Feeding see also
Freely feeding
Fiber see also
Thin fiber
Field see
Open field
Terminal fields
Fighting see also
Shock-induced fighting
Findings see
Preliminary findings
Firing see also
Burst firing
Fluid see also
Amniotic fluid
Crebrospinal fluid
CSF
Jejunal fluid
Spinal fluid
Flux see also
Ca++-flux
Ca-flux
Calcium flux
Focus ; Foci see
Epileptic focus (foci)
Epileptogenic focus
Food and Drug Administration
see also
FDA
Forebrain see also
Anterior forebrain
Rat forebrain
Fragmentography see
Mass fragmentography
Frequency see also
High frequency
FSH see
Follicle- stimulating hormone
Function(ing) see also
Affective functions
Autonomic functioning
Mixed functions
Sexual function(s)
Thyroid function
G
GAB A see also
Aminobutyric acid
GAD see also
Glutamic acid decarboxylase
Gain see
Weight gain
Gas liquid chromatography
see also
GLC
GBL see
Butyrolactone
GC see
Gas chromatography
Generation see also
Fl generation
Second generation
Gerbil(s) see also
Mongolian gerbil
GH see also
Growth hormone
Gilles de la Tourette syndrome
see also
Tourette syndrome
Gland see
Adrenal gland
Pineal gland
Pituitary glands
Salivary gland
Submarxillary gland
Thymus gland
Thyroid gland
11
GLC see also
Gas liquid chromatography
Glutamic acid decarboxylase see also
GAD
Growth Hormone see also
GH
GS-385 see
Chloro-4-phenylsuccinimidobenzene-
sulfonamide
Guanosine triphosphate see
GTP
Gum see also
Chewing gum
H
H-77-77 see
Dimethyl-m-tyramine
Haldol see
Haloperidol
Handicapped see also
Intellectually handicapped
Mentally handicapped
Headaches see also
Cluster headaches
Health see
Mental health
Heart see also
Cardiac
Helplessness see
Learned helplessness
Hepatic see also
Liver
HIAA see also
Hydroxyindoleacetic acid
Histamine receptors see also
HI- receptors
H2-receptors
Holidays see
Drug holidays
Homes see
Nursing homes
Sheltered care homes
Hormones see also
Adrenal hormones
Follicle- stimulating hormone
GH
Glucocortical hormones
Gonadotropin-releasing hormone
Growth hormone
LH
Luteinizing hormone
Melanocorticotropic hormone
Melanocyte- stimulating hormone
Names of specific hormones
Parathyroid hormones
Peptide hormones
Pituitary hormones
Sex hormone
Steroid hormones
STH
Thyroid hormones
Thy rotrophin- releasing hormone
TRH
TSH
Hospital see also
Day hospital
General hospital
Lima State Hospital
Psychiatric hospital
State hospital
HT see also
Hydroxy tryptamine
Serotonin
HTP see also
Hydroxy tryptophan
Hydergine see also
Dihydroxyergotoxine
Hydrocortisone see also
Cortisol
Hydroxyindoleautic acid see als
HIAA
Hydroxydopamine see also
OHDA
Hydroxytryptamine see also
HT
Serotonin
Hydroxy tryptaminergic see also
Serotonergic
Serotoninergic
Hydroxytryptophan see also
HTP
Hydroxy vanOlic acid see
HVA
Hyperactivity see also
Hyperkinesis
Hyperkinesis (ia) see also
Hyperactivity
Tardive hyperkinesia
Hypoactivity see also
Hypokinesia
Hypokinesia see also
Hypoactivity
Hypotensive effect see also
Antihypertensive effect
Hl-receptors see also
Histamine receptors
H2-receptors see also
Histamine receptors
12
ICS see
Intracranial stimulation
Illness; 111 see also
Affective illness
Chronically ill
Depressive illness
Lupus like illness
Manic-depressive illness
Medically ill
Mental illness
Psychosomatic illness
IMAP see
Fluspirilene
IMl see
Imipramine
Impact see
Pathophysiologic impact
Implication see
Clinical implications
Independent see also
Ca++-independent
Na+-independent
Voltage independent
Induced see also
ACTH-induced
Adrenaline-induced
Agonist-induced
Ala2-met5- enkephalin amide-induced
Aminophylline-induced
Amphetamine-induced
Analgesic-induced
Angiotensin-II -induced
Anticonvulsant-induced
Apomorphine-induced
Barbiturate-induced
Bicuculline-induced
Caffeine-induced
Cannabinoid-induced
Carbachol-induced
Carbamazepine-induced
Chemically-induced
Chloralose-induced
Chlorophenylalanine-induced
Chlorpromazine-induced
Chlorea- toxin-induced
Cimetidine-induced
Clonidine-induced
Cocaine-induced
Cyclophosphamide-induced
D- amphetamine-induced
Denervation-induced
Depolarization-induced
Desipramine-induced
Di-n-propylacetate-induced
Diazepam-induced
Dihydroxytryptamine-induced
Diphenylhydantoin-induced
Disease-induced
Dopamine-induced
Drug-induced
Electrically-induced
Electroshock-induced
Endogenously-induced
Endorphin-induced
Endo toxin-induced
Enkephalin-induced
Enzyme-inducing
Ethanol-induced
Exogenously-induced
Experimentally-induced
Flurazepam-induced
Haloperidol- induced
Handling-induced
Harmaline-induced
Hexobarbital- induced
Homocysteine-induced
HTP-induced
Hydroxy tryptamine-induced
Insulin-induced
Iron-induced
Isolation-induced
Isoprenaline-induced
Isoproterenol- induced
Kainic-acid-induced
L- dopa-induced
Lesion-induced
Lithium-induced
LSD-induced
MAOI-induced
Methadone-induced
Methamphetamine-induced
Methylmercury-induced
Methylphenidate-induced
Me trazol- induced
Morphine-induced
Naloxone-induced
Narcotic-induced
Neurolep tic-induced
Neurotensin-induced
Opiate-induced
Organophosphate-induced
Pemoline-induced
Penicillin-induced
Pentobarbital-induced
Pentylenetetrazol- induced
Peripherally-induced
13
Pethidine-induced
Phencyclidine-induced
Potassium-induced
Psychotropic- drug-induced
Reflex-induced
Reserpine-induced
Schedule-induced
Scopolamine-induced
Self-induced
Shock-induced
Sound-induced
Stimulation-induced
Stimulus-induced
Stress-induced
Stretch-induced
Strychnine-induced
Sulpiride-induced
Tetrabenazine-induced
THC-induced
Thiazide-induced
Thyroid-induced
Tricyclic-antidepressant-induced
Triethyltin- induced
Tryptophan-induced
Tryptophol-induced
Infarction see
Myocardial infarction
Influence(d) see
Parasympathomimetic influence
Serotonergially influenced
Infusion see also
Microinfusion
Inhibition(or) see also
MAOl
MAO inhibition(or)
Monoamine-oxidase inhibition (or)
Injection see also
Microinjection
Self-injection
Injury see also
Self-injury
Inpatient(s) see also
Depressed inpatients
Insomniac inpatients
Psychiatric inpatients
Psychogeriatric inpatients
Interaction see also
Behavioral interactions
Biologic interaction
Biological interaction
Drug interactions
Hypnotic interactions
Monoaminergic interaction
Paradoxical interaction
Pharmacokinetic interaction
Social interaction(s)
Interval see also
Fixed interval
Intervention see
Behavioral intervention
Psychiatric intervention
Interperitoneal see also
IP
Investigation(s) see also
Psychopharmacological investigation
lon(s) see
Calcium ions
Lithium ion
Sodi\im ion
Ionization see also
Chemical ionization
Flame ionization
Iontophoresis see also
Microiontophoresis
IP see also
Intraperitoneal
Isolation see also
Social isolation
Isomers see also
Cis-isomers
D-isomers
L-isomers
Optical isomers
Trans-isomers
Issue(s) see
Methodological issues
K
K
see also
Potassium
Kidney see also
Renal
Killing see
Mouse-killing
Pup -killing
L-Amphetamine see also
Amphetamine
D- Amphetamine
Dextroamphetamine
Methamphetamine
Methylamphetamine
L-DOPA see also
Dihydroxyphenylalanine
DOPA
Levodopa
14
LAAM see
Acetylmethadol
Labeled see also
Isotope labeled
Spiroperidol labeled
Lasting see
Long-lasting
Learning see also
Maze learning
Motor learning
Level(s) see
High levels
Levodopa see also
Dihydroxy phenylalanine
DOPA
L-DOPA
LH see also
Luteinizing hormone
LHM see
Lisuride hydrogen maleate
Li see also
Lithium
LiCl see also
Lithium chloride
Life see also
Sex life
Lilly-110140 see
Fluoxetine
Lithium see also
Li
Lithium carbonate see also
Li^CO^
Lithium chloride
see also
LiCl
Liver
see also
Hepatic
Li2CO„ see also
Lithium carbonate
Localization see also
Biochemical localization
Loss see also
Hair loss
LSD see also
Lysergic acid diethylamide
LU-10-171 see
Citalopram
Luteinizing hormone see also
LH
Lyorodin see
Fluphenazine-HCl
Lysergic acid diethylamide see also
LSD
M
Maladjustments see
Social maladjustments
Manic-depressive see also
Affective- disorders
Bipolar
Depression
Unipolar
Manifestations see also
Psychic manifestations
Manipulation see also
Behavioural manipulation
MAO see also
Monoamine oxidase
MAOI see also
MAO inhibition
Monamine oxidase inhibition
Maze see also
T-Maze
Y-Maze
MBD see
Minimal brain dysfunction
Measurements see also
Biochemical measurements
Mechanism(s) see also
Autonomic mechanisms
Biochemical mechanism
Dual mechanism
Mediated see
Adrenocep tor-mediated
Agonist-mediated
Alpha-adrenocep tor-mediated
Aminobutyric-acid-mediated
Dopamine-mediated
GABA-mediated
Hl-receptor-mediated
Receptor-mediated
Medication ; Medicine see also
Antipsychotic medications
Neuroleptic medication; medicine
Psychoactive medication
Psychosomatic medicine
Psychotropic medication
Self -medication
Medulla see
Adrenal medulla
Pons medulla
Meeting see
Psychopharmacological meeting
Memory see also
Verbal memory
MEO-DIPT see
Methoxydiisopropyltryptamine
Merital see
Nomifensine
Met-enkephalin see also
Methionine enkephalin
5
5
^
15
-.■■''-r>
Methamphetamine see also
Amphetamine
D- Amphetamine
Dextroamphetamine
L- Amphetamine
Methylamphetamine
Methionine enkephalin see also
Met- enkephalin
Method(s) see also
Electrochemical method
Electromyographic method
Methoxy-4-hydroxyphenylglycol
see also
MHPG
Methylamphetamine see also
Amphetamine
D- Amphetamine
Dextroamphetamine
L- Amphetamine
Methamphetamine
Methylphenidate see also
Ritalin
MHPG see also
Methoxy-4-hydroxyphenylglycol
Mianserin see also
ORG-GB-94
MIF see also
Pro-leu-gly-NH„
Milk
see also
Mothers milk
Minnesota Multiphasic Inventory
MMPI
MK-647 see
Difluorophenylsalicylic acid
MMH see
Monomethylhydrazine
Model see also
Animal model(s)
Medical model
Modification; Modifying; Modified
see also
Behavior modification
Behaviour modifying
Synthetically modified
Modulated see
Stress modulated
Monitored (ing) see also
Holtor monitored
Ion -monitoring
Monkey (s) see also
Macaca mulatta
Pigtail macaque
Rhesus macaque
Rhesus monkey(s)
see
Squirrel monkey (s)
Talapoin monkeys
Vervet monkeys
Monoamine(s) see also
Brain monoamine
Monoamine oxidase see also
MAO
Monoamine oxidase inhibitor
see also
MAO inhibitor
MAOI
MOPEG see
Methoxy-4-hydroxyphenylethylene-
glycol
Motivation see
Sexual motivation
Movement(s) see also
Abnormal movements
Choreic movements
Dyskinetic movements
Eye movements
Involuntary movements
Psychiatric movements
Rapid eye movement
REM
MS see
Mass spectrometry
MSH see
Melanocyte- stimulating hormone
MT see
Methyl-p- tyrosine
Muscle see also
Anococcygeus muscle
Cardiac muscle
Intestinal muscle
Skeletal muscle
Smooch muscle
Ventricular muscle
Mutilation see
Self -mutilation
N
Na see also
Sodium
NaCl see also
Sodium chloride
Nerve see also
Hepatic nerve
Phrenic nerve
Sciatic nerve
Sympathetic nerve
Neuralgia see
Trigeminal neuralgia
16
Neurochemistry see also
Behavioral neurochemistry
Neurones see also
Rat cortical neurones
Neurosis see also
Depressive neurosis
Obsessive-compulsive neurosis
War neurosis
Neurotransmission see also
Transmission
Neurotransmitter see also
Transmitter
NH.-tyr-pro-phe-pro-CONH^
see
Morphiceptin
Nigrostriatal see also
Striatonigrsil
Node see
Lymph node
Noradrenaline see also
Norepinephrine
Norepinephrine see also
Noradrenaline
Noveril; Noveril-240 see
Dibenzepine
Nuclear magnetic resonance
NMR
Nucleotide(s) see also
Cyclic nucleotides
Guanine nucleotides
Guanyl nucleotides
Nucleus (Nuclei) see also
Caudate nucleus
Preopticus mediaUs nucleus
Trigeminal nucleus
O
Observations see also
Biochemical observations
Ocytocin see also
Oxytocin
Offenders see also
Criminally insane offenders
Sex offenders
Sexual offenders
OHDA see also
Hydroxy dopamine
Opening see
Ring opening
ORAP see
Pimozide
Order see
see
Higher order
Randomized order
Second order
ORG-GB-94 see also
Mianserin
Organ see also
Pineal organ
Outpatient(s) see also
Depressed outpatients
Psychiatric outpatients
Psychotic outpatients
Schizophrenic outpatients
Oxidase(s) see also
Amine oxidase
Cu amine oxidase(s)
MAO
Monoamine-oxidase(s)
Oxytocin see also
Ocytocin
Papers see
Clinical papers
Parameters see also
Biochemical parameters
Parlodel see
Bromo- alpha- ergocrip tine
Parnate see
Tranylcypromine
Patient(s) see also
Aggressive patients
Alcoholic patients
Autistic patients
Bipolar- 1 patients
Bipolar patients
Borderline patients
Cancer patients
Depressed patient(s)
Depressive patients
Dysthymic patients
Elderly patients
Epileptic patients
Fibrositis patients
Geriatric patients
Gerontopsychiatric patient(s)
HospitaKzed patients
Hyperprolactinaemic patients
Hypertensive patients
Hypothyroid patients
Involuntary patients
Manic patients
Manic-depressive patient(s)
Melancholic depressed patients
Mental patients
Mentally handicapped patients
Mentally subnormal patients
ft
fie
17
Neurotic patients
Parkinson patients
Parkinsonian patients
Physically handicapped patients
Psychiatric patients
Psychogeriatric patient(s)
Psychotic patients
Schizoaffective patients
Schizophrenic patients
Subnormal patients
Patterns see also
Drinking patterns
Mood- swing patterns
PCP see also
Phencyclidine
PCPA see
Chlorophenylalanine
PEA see
Phenethylamine
Phenylethylamine
Pemoline see also
Cylert
Peptides see also
Bombesin-like peptides
Cholecystokinin peptides
Hexapeptide
Names of specific peptides
Neuroleptic peptides
Neuropeptide( s )
Opiate pentapeptide
Opiod peptide(s)
Pyrimidine peptide
Tetrapeptide
Performance(s) see also
High performance
Maze performance
Periodicity see also
Circadian periodicity
Perspective see also
Biopsychosocial perspective
Historical perspective
Neurobiological perspective
Psychiatric perspective
Therapeutic perspectives
Pharmacology see also
Behavioral pharmacology
Biochemical pharmacology
Cardiovascular pharmacology
Clinical pharmacology
Neurochemical pharmacology
Neurovascular pharmacology
Pharmacotherapy see also
Behavioral pharmacotherapy
Phencyclidine see also
PCP
Phenethylamine see also
Phenylethylamine
Phenylethylamine see also
Phenethylamine
Phenytoin see also
Diphenylhy dan torn
Picture see
Clinical picture
Pills see also
Sleeping pill(s)
Placebo see also
Double placebo
Platelets see also
Blood platelets
Postassium see also
K
Potential(s) see also
Evoked potential(s)
VEP
Visually-evoked-potentials
Practice see
Clinical practice
General medical practice
General practice
Pediatric practice
Psychiatric practice
Practitioner(s) see
General practitioner(s)
Predictors see also
Behavioral predictors
Preparations see
Anxiolytic preparations
Pressure see also
Blood pressure
Micropressure
Primed see
Estrogen-primed
Probe(s) see also
Pharmacologic probes
Pharmacological probes
Problem(s) see
Methodological problem
Personality problems
Procedures see also
Psychopharmacological procedures
Process see
Creative process
Processing see also
Information processing
Prone see
Epilepsy prone
Properties see
Anorectic properties
Antidyskinetic properties
Antipsychotic properties
18
Arrythmogenic properties
Biochemical properties
Microproperties
Pharmacological properties
Prothieden see
Dothiepin
Psychiatry see also
Biological psychiatry
Child psychiatry
Social psychiatry
Psychopharmacology see also
Pediatric psychopharmacology
Psychosis see also
Affective psychosis
Epileptic psychosis
Manic-depressive psychosis
Manic psychosis
Schizoaffective psychoses
Schizophrenic psychoses
Pulp see
Tooth pulp
Pump see
Lithium- pump
Na-pump
Sodium-pump
Pursuit see
Smooth pursuit
Putamen see
Caudate-putamen
Q
Questionnaire see also
Leeds- Sleep-Evaluation-Questionnaire
R
R 33812 see
Domperidone
Radiation ; Ray see
Gamma radiation (ray)
Radio receptor(s) see also
Dopamine radioreceptor
Rapid eye movement see also
REM
Rate see also
Firing rate
Turnover rate(s)
Rating see also
Self-rating
Ratio see
Fixed ratio
Progressive ratio
RBC see
Red blood cell
Reaction(s) see also
Adverse reactions
Behavioral reactions
Hypomanic reaction
Receptivity see
Sexual receptivity
Receptor(s) see also
Acetylcholine receptor(s)
ACH receptor
Adenosine receptors
Adrenergic receptor(s)
Alpha-adrenergic receptor(s)
Alpha-receptors
Alphal-adrenergic receptors
Alphal -receptors
Alpha2-receptors
Aminobutyric acid receptor(s)
Apomorphine receptors
Benzodiazepine receptor(s)
Beta-adrenergic receptor(s)
Beta-receptor
Bradykinesia receptor(s)
Catecholamine receptors
Cholinergic receptor(s)
Delta-receptor(s)
Diazepam receptor
Dopamine receptor(s)
Dopaminergic receptor(s)
Drug receptors
Enkepalin receptors
GABA receptor(s)
Glucocorticord receptor
Glutamate receptors
Histamine receptors
HT receptor
HTP receptors
Hydroxytryptamine receptors
Hl-receptor(s)
H2-receptor(s)
lonophore receptor
Kappa-receptor ( s )
Monamine receptor(s)
Monoaminergic receptor
Mu-receptors
Muscarinic receptor(s)
Neuroleptic receptor(s)
Neuropeptide receptor
Neurotensin receptor
Neurotransmitter receptor(s)
Nicotine receptors
Noradrenaline receptors
Noradrenergic-alpha2 receptors
Norepinephrine receptor
Opiate receptor(s)
Opiod receptor(s)
i.
i
2
19
Postsynaptic receptors
Presynaptic receptors
Progestin receptors
Quisqualate receptors
Serotonergic receptors
Serotonin receptor(s)
Recorded see
EMG recorded
Redergine see
Dihydroergotoxine
Hydergine
Reflex(es) see also
Biting reflex
Motor reflexes
Sexual reflexes
Refusal see
Drug refusal
Refuse see also
Right- to-refuse
Region see
Hippocampal CAl-reglon
Regulation see also
Central regulation
Reinforced see
Cocaine reinforced
Drug reinforced
Emotionally reinforced
Narcotic reinforced
Related see
Age related
Dose related
Drug related
Event related
Sleep related
Relaxant(s) see
Muscle relaxant(s)
Release see also
Controlled release
Sustained release
REM see also
Rapid eye movement
Renal see also
Kidney
Report(s) see
Case report
Preliminary report
Task force report
Research see also
Psychiatric research
Psychobiological research
Psychopharmacological research
Psychoneuropharmacolog^c research
Resistance see
Drug resistance
Galvanic skin resistance
Skin resistance
Stress resistance
Resistant see also
Atropine resistant
Drug resistant
Therapeutically resistant
Therapy resistant .
Responding see
FI responding
Operant responding
Punished responding
Response(s) see
Behavioral responses
Behavioural responses
Biochemical response
CR
Clinical response
Dose response
Early response
Evoked response(s)
Glycemic response
Hyperthermic response
Motor response
Operant response
Pharmacologic responses
Results see
Preliminary results
Resuscitation see
Neurosurgical resuscitation
Retardate(s); Retarded see also
Mental retardates
Mentally retarded
Reversal see also
Behavioral reversal
Review see also
Minireview
Rhythm(s) see
Biological rhythm
Circadian rhythm(s)
Rhythmicity see
Biological rhythmicity
Ribonucleic acid see
RNA
Rich see
Terminal rich
Risk see also
High risk
Ritalin see also
Methylphenidate
Roipnol see
Flunitrazepam
Rodent see also
Guinea pig
20
Sample see also
Matching- to -sample
Psychiatric sample
Satisfaction see
Job satisfaction
Scale(s) see also
Behavioral rating scales
Clinical scale
Hamilton Depression Rating Scale
Schedule see also
Automaintenance schedule
Multiple schedule
Schizophrenics (ia) see also
Childhood schizophrenia
Chronic schizophrenics
Scores see
T-scores
Seizure(s) see also
Audiogenic seizure(s)
Cephalgic seizures
Convulsive seizure .
Epileptic seizures
Organic brain seizures
Selection see also
Self- selection
Selective see also
Behaviorally selective
Biochemically selective
Sensitive see also
Calcium sensitive
Dopamine sensitive
HT sensitive
Opiate sensitive
Serotonin sensitive
Sensitivity see also
Behavioral sensitivity
High sensitivity
Sensitization see also
Behavioral sensitization
Sequelae see also
Behavioral sequelae
Serotonergic see also
Hydroxytryptaminergic
Serotoninergic
Serotonin see also
HT
Hydroxy tryptamine
Serotoninergic see also
Hydroxytryptaminergic
Serotonergic
Serum see also
Umbilical cord serum
Service(s) see
Health care services
Inpatient service
Sheet see
Fact sheet
Shake(s) see
Wet dog shake(s)
Shock(s) see also
Convulsive shock
ECS
Electric shock
Electroconvulsive shock
Electroshock
Footshock
Stimulus shock
Tail shock
Two shock
SIF see
Shock-induced fighting
Site(s) see
Binding sites
XQ fragile site
Situations see
Aversive situations
Conflict situation
Stressful situation
SKF-525-A see
Diethylaminoethyldiphenylpropyl-
acetate
SKF-69634 see
Clopipazan
Sleep see also
DSIP
Paradoxical sleep
REM
Sleep-walking see also
Somnambulism
Sodium see also
Na
Sodium chloride see also
NaCl
Sodium dipropylacetate see also
Depakine
Dipropylacetate
Dipropylacetic acid
Sodium valproate
Valproic acid
Sodium valproate see also
Depakine
Dipropylacetate
Dipropylacetic acid
Sodium diproprylacetate
Valproic acid
Solvent see also
Industrial solvent
i
I
21
-A' "•
Somnambulism see also
Sleep-walking
Specific see
Age- specific
Brain specific
Opiod specific
Spectrometry see
Audio-spectrometry
Mass spectrometry
Spider see
Black widow spider
Stability see also
Biological stability
Photochemical stability
State(s) see
Behavioral state
Confusional state
Depressive states
Manic state
Mental state
Phobic state
Steady state
Stay see
Long- stay
Stimulation (ed) see also
Behavioral stimulation
Brain stimulation
Electric stimulation
Electrical stimulation
GAB A stimulated
Intracranial stimulation
Locomotor stimulation
Pentagastrin stimulated
Self - stimulation
Stimulus see also
Discriminative stimulus
UCS
Unconditioned stimulus
Strategies see also
Video strategies
Stress(ed) see also
Emotional stress
Ether stressed
Psychological stress
Psychosomatic stress
Striatonigral see also
Nigrostriatal
Study see
Behavioral studies
Biochemical study (ies)
Biological studies
Case study (ies)
Clinical study (ies)
Collaborative study
Comparative study (ies)
Controlled comparative study
Controlled study
Cross-study
Drug studies
Early activity studies
Electrocytochemical study
Electrophysiological study (ies)
Empirical study
Endocrine study
Experimental study(ies)
Histochemical study
Interaction studies
Metabolic study (ies)
Microiontophoretic study
Morphological study
Multicenter study
MulticHnical study
Multiinstitutional study
Neuroanatomical study
Neurochemical study (ies)
Neuroendocrine study(ies)
Neurological study
Neuropharmacological study (ies)
Neurophysiological study
Neuropsychopharmacological studies
Neuropsychopharmacology study
Ontogenetic studies
Open study
Pathophysiological studies
Pharmacokinetic study
Pharmacologic studies
Pharmacological study (ies)
Pharmacomanometric studies
Physiological studies
Pilot study
Placebo controlled study
Polygraphic study
Polygraphical studies
Preliminary study (ies)
Psychopharmacological studies
Psychophysiologic studies
Relapse studies
Scientific study
Subject(s) see
Epileptic subjects
Phobic subjects
Substance(s) see also
Psychoactive substances
Psychotropic substances
Supersensitivity see also
Behavioral supersensitivity
Cholinergic supersensitivity
Dopaminergic supersensitivity
22
I
Suppression see also
Behavioral suppression
Sustained see
Self- sustained
Symposium see
Mini- symposium
Symptom(s) see also
Depressive symptoms
Manic symptoms
Mental symptoms
Obsessive symptoms
Psychotic symptoms
Schizophrenic symptoms
Symptomatology see also
Depressive symptomatology
Schizophrenic symptomatology
Syndrome(s) see also
Abstinence syndrome
Anticholinergic syndrome
Anxious depressive syndromes
Asthenic depressive syndromes
Astheno-depressive syndromes
Behavioral syndrome
Behavioural syndromes
Borderline syndromes
Brain damage syndrome
Catatonia syndrome
Chronic brain syndromes
DeLange syndrome
Depressive syndrome(s)
Dissociative syndromes
Down syndrome
Downs syndrome
Episodic dyscontrol syndrome
Extrapyramidal syndromes
Forum-fruste-du-syndrome-malin
Gilles de la Tourette(s) syndrome
Hyperactive child syndrome
Hyperactivity syndrome
Hyperkinetic syndrome
Hypertension syndrome
Hyperventilation syndrome
ICleine Levin syndrome
Lennox Gastaut syndrome
Lesch Nyhaus syndrome
Malignant hyperthermic syndromes
Malignant syndrome
Nelsons syndrome
Neurological syndrome
Organic brain syndrome
Organic mental syndrome
Organic psychosyndromes
Parkinsonian syndrome
Phobic anxiety syndrome
Premenstrual syndrome
Psychiatric syndromes
Sleep apnea syndrome
Stereotypic behavior syndrome
Stretch yawning syndrome
Tourette syndrome
Transient syndromes
Withdrawal syndrome(s)
Synthesis see also
Gas chromatographic synthesis
System(s) see ♦
Cardiovascular system
Central nervous system
Dopaminergic system(s)
HLA system
Limbic system
Sympathetic nervous system
Table see
Life table
Techniques
see also
Behavioural techniques
Temperature see also
Body temperature
Term see
Long-term
Short-term
Terrors see
Night terrors
Test(s) see also
Behavioral tests
Clinical tests
Dexamethasone Suppression Test(s)
Electroshock test
Neuroendocrine tests
Psychometric test
Psychophysiological tests
Screening test
Shock escape test
Testing see also
Behavioral testing
Clinical testing
Tetrahydrocannabinol see also
THC
Tetrahydroisoxazolopyridin-3-ol
see
THIP
THC see also
Tetrahydrocannabinol
ft
i
23
Therapy see also
Behavioral therapy
Behaviour therapy
Cognitive therapy
Drug therapy
Electroconvulsive therapy
Maintenance therapy
Monotherapy
Psychopharmaceutical therapy
Thin layer chromatography see also
TLC
Thyrotropin- releasing hormone
see also
TRH
Thy rotophin- stimulating hormone
see
TSH
Time see also
Reaction time
Sleeping time
TLC see also
Thin layer chromatography
Tolerance(ant) see also
Behavioral tolerance
Cross- tolerance
Morphine tolerance (ant)
Opiate tolerant
Opiod tolerance
Tomography see
Computed tomography
Computerized axial tomography
Positron tomography
Tourette syndrome see also
Gilles de la Tourette syndrome
Tranquilizer (s) see also
Major tranquilizers
Minor tranquilizer(s)
Names of specific tranquilizers
Transfer see also
Ion transfer
Transmission see also
Neurotransmission
Transmitter see also
Neurotransmitter
Transport see also
Cellular transport
Treatment(s) see also
Behavioral treatments
Chronic treatment
Drug treatment
Convulsive shock treatment
Electroconvulsive treatment
Electroshock treatment
Long-term treatment
Maintenance treatment
Pharmacological treatment
Psychiatric treatment
Psychologic treatment
Psychological treatment
Psychopharmacological treatment
Subchronic treatment
TRF see
Thy rotrophin- releasing factor
TRH see also
Thyrotropin- releasing hormone
Trial(s) see also
Clinical trial(s)
Comparative trial
Controlled trial
Multicenter trail
Placebo controlled trial
Preliminary trial
Prospective trial
Randomised trial
Tumescence see
Penile tumescence
Turning see also
Head turning
Twitch(es) see
Head twitches
U
U-14-624 see
Phenyl-2-thiazolyl-2- thiourea
UCS see also
Unconditioned stimulus
Ulcers see
Gastric ulcers
Peptic ulcers
Stress ulcers
Ultradian see also
Circadian
Unconditioned stimulus see also
UCS
Unipolar see also
Affective disorders
Bipolar
Depression
Manic-depressive
Valproic acid
Depakine
see also
Dipropylacetate
24
Dipropylacetic acid
Sodium dipropylacetate
Sodium valprovate
Valve see
Mitral valve
Variables see also
Biochemical variables
Clinical variables
Drug variables
Pharmacokinetic variables
Psychophysiological variables
Vasoactive intestinal peptide see
VIP
VEP see also
Visually-evoked potentials
View(s) see
Current views
Modern views
Psychological view
Visually- evoked potentials see also
VEP
W
/Wakefulness see also
Sleep wakefulness
Walking see
Sleep-walking
Wards see
Outpatients wards
Psychiatric wards
Psychogeriatric ward
Way see
Two way
Weight see also
Body weight
WHO see
World Health Organization
Women see also
Postmenopausal women
Premenopausal women
Word see
Pure word
WY-25093 see
Indol-3-ylmethylpiperid-4-yl-3-
benzoylurea
25
'jV/A
/.
SUBJECT INDEX
[The Subject Index is mochine generoted Keywords in the titles of abstrocts oppeor alphabetically in the the left hand margin; under each keyword is a list
of titles in which the keyword appeors The spelling of words in the titles of abstracts has not been changed; hence, two spellings of the same word may
oppeor in this index — for example, BEHAVIOR and BEHAVIOUR ]
ABANDONMENT
SELF-AAEDICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS.
002189 02-11
ABILITIES
MOTOR-LEARNING ABILITIES IN SUBJECTS TREATED WITH LITHIUM-SALTS
AND TRICYCLIC-ANTIDEPRESSANTS.
002058 02-09
ABILITY
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE
AND DESMETHYLIMIPRAMINE.
000113 01-03
THE HYPOTHERMIC-EFFECTS OF CLONIDINE AND OTHER IMIDAZOLIDINES
IN RELATION TO THEIR ABILITY TO ENTER THE CENTRAL-NERVOUS-
SYSTEM IN MICE.
003933 04-03
ABNORMAL
THE ALBINO LOCUS PRODUCES ABNORMAL RESPONSES TO OPIATES IN
THE MOUSE.
001675 02-04
ABNORMAL REGULATION OF PROLACTIN RELEASE IN IDIOPATHIC
PARKINSONS-DISEASE.
002255 02-13
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL
HEMORRHAGE PATIENTS.
002295 02-13
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL-
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF
ANTIBODIES TO GANGLIOSIDE.
003025 03-04
ABNORMAL TRANSMETHYLATION REACTION DURING THE METABOLISM
OF DOPAMINE, TRYPTAMINE, AND SEROTONIN, AND SCHIZOPHRENIC-
SYMPTOMS: A CRITICAL REVIEW.
003404 03-13
PREVALENCE OF PERSISTENT ABNORMAL INVOLUNTARY-MOVEMENTS
AMONG PATIENTS IN A NIGERIAN LONG-STAY PSYCHIATRIC UNIT.
004334 04-08
ABNORMAL MOVEMENTS INDUCED BY PSYCHOTROPIC-DRUGS.
004652 04-15
ABNORMAL-BEHAVIOR
PSYCHONEUROENDOCRINOLOGY AND ABNORMAL-BEHAVIOR.
002347 02-14
ABNORAAALITIES
PROTEIN ABNORMALITIES IN MACROPHAGES BEARING ASBESTOS.
(UNPUBLISHED PAPER).
001037 02-01
VITAMIN RESPONSIVE GENETIC ABNORMALITIES. (UNPUBLISHED PAPER)
001388 02-03
HORMONAL ABNORMALITIES IN ANOREXIA-NERVOSA (AN)
002099 02-11
ABNORMALITIES OF LITHIUM TRANSPORT IN PATIENTS WITH AFFECTIVE-
DISORDERS.
002269 02-13
DOPAMINERGIC ABNORMALITIES IN POSTMORTEM SCHIZOPHRENIC
BRAIN.
002575 02-17
METABOLIC AND SYMPATHOADRENAL ABNORMALITIES IN THE OBESE
ZUCKER RAT: EFFECT OF CHRONIC PHENOXYBENZAMINE TREATMENT.
003905 04-03
ABNORMALITY
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY
AFFECTIVE-ILLNESS.
002506 02-16
ABRUPT
PANIC-ANXIETY AFTER ABRUPT DISCONTINUATION OF AMITRIPTYLINE
003223 03-09
CLINICAL AND BIOCHEMICAL-CORRELATIONS IN ABRUPT
DISCONTINUATION OF PSYCHOPHARMACOTHERAPY.
004330 04-08
ABSCESSES
ABSCESSES FOLLOWING PROLONGED INTRAMUSCULAR ADMINISTRATION
OF PERPHENAZINE-ENANTATE.
000888 01-15
ABSORPTION
ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND
EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL
AND INTRODUODENAL ADMINISTRATION.
000094 01-03
EFFECT OF DOSE ON PHENYTOIN ABSORPTION.
000773 01-13
MEAL-DEPENDENT ABSORPTION OF ENTERIC-COATED SODIUM-
VALPROATE
000777 01-13
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY.
000890 01-15
PREDICTION OF THE VOLUME OF DISTRIBUTION FROM IN VITRO DATA
AND USE FOR ESTIMATING THE ABSOLUTE EXTENT OF ABSORPTION.
000907 01-16
ABSORPTION OF LEVODOPA AFTER RECTAL ADMINISTRATION.
003406 03-13
ORAL AND RECTAL ABSORPTION OF CHLORAL-HYDRATE AND ITS BETAINE
COMPLEX.
004554 04-13
CLINICAL-PHARMACOLOGY: DRUG ABSORPTION.
004740 04-17
ABSTINENCE
ENKEPHALIN LEVELS DECREASE IN RAT STRIATUM DURING MORPHINE
ABSTINENCE.
000027 01-03
AN ELECTROMYOGRAPHIC-METHOD FOR THE ASSESSMENT OF
NALOXONE-INDUCED ABSTINENCE IN MORPHINE-DEPENDENT RATS.
000433 01-04
NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO
WITHDRAWAL INDUCING BENZAZOCINES. (PH.D. DISSERTATION)
001518 02-03
CYCLIC-AMP-INDUCED CHANGES IN THE ELECTROENCEPHALOGRAM AND
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN
THE RAT.
003078 03-04
EFFECTS OF NARCOTIC ABSTINENCE ON SCHEDULE-CONTROLLED
BEHAVIOR IN DEPENDENT RATS.
004230 04-04
SUPPRESSION OF MORPHINE ABSTINENCE IN HEROIN ADDICTS BY BETA
ENDORPHIN.
004489 04-11
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY?
004553 04-13
ABSTINENCE-BEHAVIOR
EFFECTS OF BRANCHED-CHAIN FATTY-ACIDS ON GABA DEGRADATION
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI-
MORPHINE ABSTINENCE-BEHAVIOR
001809 02-04
ABSTINENCE-BEHAVIOUR
DIPROPYLACETATE-INDUCED ABSTINENCE-BEHAVIOUR AS A POSSIBLE
CORREUTE OF INCREASED GABAERGIC ACTIVITY IN THE RAT.
001606 02-04
ABSTINENCE-SYNDROME
AN ABSTINENCE-SYNDROME FOLLOWING CHRONIC ADMINISTRATION OF
DELTA9 TETRAHYDROCANNABINOL IN RHESUS-MONKEYS.
001621 02-04
THE SHORT-TERM AND LONG-TERM EFFECTS OF BETA ENDORPHIN ON THE
OPIATE ABSTINENCE-SYNDROME IN RATS.
001643 02-04
DOSE-RESPONSE STUDY OF THE PRECIPITATED ABSTINENCE-SYNDROME
FOR MORPHINE: SYSTEMIC VS PERIAQUEDUCTAL GRAY NALOXONE.
(PH.D. DISSERTATION).
002979 03-04
POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES ON THE ONSET
MAGNITUDE AND QUALITY OF THE OPIOID ABSTINENCE-SYNDROME
004610 04-15
CASE-REPORT OF UNUSUAL DIAZEPAM ABSTINENCE-SYNDROME.
004643 04-15
ABSTINENT
SEXUAL-BEHAVIOUR OF MORPHINE-DEPENDENT AND ABSTINENT MALE
RATS.
000438 01-04
ABSTRACTS
ABSTRACTS OF THE ANNUAL GENERAL CONFERENCE OF THE EUROPEAN-
BRAIN-AND-BEHAVIOUR-SOCIETY, HELD AT LOUVAIN-LA-NEUVE,
BELGIUM, ON NOVEMBER 13-15TH, 1980.
003617 03-17
S-1
Subject Index
^"" ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE
"^•^^•f-B«^'N 001320 02-03
^""tHE^HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPECT TO THE
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRACTION
ABUNDANT IN PRESYNAPTIC MEMBRANES. ^^^^ ^^^^^
^""fsSUES FOR INPATIENT TREATMENT OF CHRONIC PCP ABUSE^^^^ ^^^^
EPIDEMIOLOGY OF PCP ABUSE. THE MIDWEST PERSPECTIVE^^
000740 0 1 - 1 i!
PCP ABUSE DIAGNOSTIC AND PSYCHOPHARMACOLOGICAL-TREATMENT
APPROACHES. 000746 01-12
USE AND ABUSE OF BENZODIAZEPINES. ^^^^^ ^^^^
CHRONIC PHENCYCLIDINE (PCP) ABUSE: A PSYCHIATRIC-PERSPECTIVE.^^^
MEDICAL AND PSYCHIATRIC-COMPLICATIONS OF PENTAZOCINE AND
TRIPELENNAMINE ABUSE. 000955 01-17
THE BENZODIAZEPINES - USE AND ABUSE ^^^^^ ^ ^ ^ ^
ABUSE OF THE ANTIPARKINSON-DRUGS: A REVIEW OF THE UTERATURE^^
ABUSE POTENTIAL OF LOPERAMIDE. ^^^^^ ^^.is
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDICT RATS: A POSSIBLE MODEL FOR PREDICTING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION).
003097 03-04
PSYCHOACTIVE-MEDICATION USE AND ABUSE AMONG AN ADULT RURAL
POPULATION. (PH.D. DISSERTATION). 003627 03-17
LONG-TERM USE AND ABUSE OF BENZODIAZEPINES ^, ^oo nx i <:
004598 04- 1 5
A MULTIVARIATE ANALYSIS OF THE INFRARED SPECTRA OF DRUGS OF
*^^^^ 004688 04-16
^""pharmacodynamics AND PHARMACOKINETICS OF DIAZEPAM IN AN
'^^^^^^ 000867 01-15
ABUSERS
OUTPATIENT TREATMENT ISSUES AND STRATEGIES FOR ACUTE AND
CHRONIC PCP ABUSERS. 000919 01-17
*^ ACCELERATION OF DESIPRAMINE-INDUCED DECREASE OF RAT
CORTICOCEREBRAL BETA-ADRENERGIC-RECEPTORS BY YOHIMBINE^
000326 01-0 J
CORTICAL RECOVERY FROM EFFEaS OF MONOCULAR DEPRIVATION:
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6
HYDROXYDOPAMINE. 003024 03-04
CONDITIONED DRUG-EFFECTS OF D-AMPHETAMINE-INDUCED AND
MORPHINE-INDUCED MOTOR ACCELERATION IN MICE: EXPERIMENTAL
APPROACH FOR PLACEBO-EFFEQ. 004128 04-04
ACCIDENTAL INTRAARTERIAL INJEQION OF DIAZEPAM.
002d7O Oz- I /
**^^CO*Rt^™PERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION. „,, „, „^
004034 04-0J
ACCUMBENS
BEHAVIOURAL-RESPONSES TO STEREOTAQICALLY CONTROLLED
INJECTIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI.
001 70o Oz-04
INHIBITORY-EFFECTS OF ANTICONVULSANT-DRUGS ON CYCLIC-
NUCLEOTIOE ACCUMULATION IN BRAIN. ^^^ ^^^^
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS^
000308 0 1 *0 J
EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT
^^^^ 000524 01-05
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA.
(UNPUBLISHED PAPER). 001147 02-03
Ptychopharmacology Abstracts
STUDIES ON THE EFFECT OF ALPHA MELANOCYTE-STIMULATING-
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P
AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED
^'^^^^^ 001372 02-03
CALCIUM-SENSITIVE ACCUMULATION OF NOREPINEPHRINE IN RAT-
CEREBRAL-CORTEX. „„„,„r«o,^o
002685 03-03
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM.
002728 03-03
EFFEa OF TAURINE ON 45CA2 ACCUMULATION IN RAT BRAIN
SYNAPTOSOMES. „„^^ „^ „,
002855 03-03
EFFECTS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO-
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY
CULTURED NEURONS. „„„„.„ „o „,
002859 03-03
INCREASE OF C-GMP AND ACCUMULATION OF 45CA2 EVOKED BY DRUGS
ACTING ON SODIUM OR POTASSIUM CHANNELS.
003709 04-03
HALOTHANE ACCUMULATION IN RAT-BRAIN AND LIVER.
003774 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II FAQORS
AFFECTING THE ACCUMULATION OF CYCLIC-AMP IN PIECES OF INTAQ
^^^'"^^™" 003776 04-03
ACCUMULATION OF AMANTADINE BY ISOLATED CHROMAFFIN
^«*^^^^^ 003866 04-03
THE EFFEaS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE
PRESENCE AND ABSENCE OF CNS DEPRESSANTS. „ „ „,
004010 04-03
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C-
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM-
CHANNEL BLOCKADE. 004020 04-03
A MECHANISM FOR THE ACCUMULATION OF CHOLINE IN ERYTHROCYTES
DURING TREATMENT WITH LITHIUM. 004520 04 13
EFFECTS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND
DISTRIBUTION OF CORREQ RESPONDING ON A SIMULTANEOUS
DISCRIMINATION TASK IN THE RAT 001806 02-04
ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CLINICAL STAFF
IN DETERMINING MEDICATION COMPLIANCE. , o no i -7
003618 03- 1 /
MEPROBAMATE REDUCES ACCURACY OF PHYSIOLOGICAL DETEQION OF
■^^"P™^ 004585 04-14
SYNTHESIS OF POTENTIAL ANTICONVULSANTS: CONDENSATION OF
ISATINS WITH ACETONE AND RELATED KETONES. ^^^^ ^^^
^"Yo'^RENERGfcTEGULATION OF THE REDUQION IN ACETYL-COENZYME-
A:ARYLAMINE-N-ACETYLTRANSFERASE IN THE RAT PINEAL
(X)2654 Oo-Uo
ACETYL-ETHn-TETRAMETHn-TETRALIN
THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION
PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR
PRESERVED SCHWANN-CELL SOMAL FUNQION ^^^^ ^^^^
ACETYLATOR PHENOTYPE AND LUPUS-ERYTHEMATOSUS.
003545 Uj- 1 5
^^^THE^C^RYSUL AND MOLECULAR STRUQURE OF THE ACETYLCHOLINE
ANTAGONIST DIMETHYLAMINOBUTYNYLCYCLOHEXYLHYDROXY 2
PHENYIACETATEHCL. 000003 01-01
DOPAMINE ACETYLCHOLINE, AND GABA EFFEQS IN ACUTE DYSTONIA IN
P'^"^*^^5 000043 01-03
DIMETHYLAMINOETHANOL (DEANOL) METABOLISM IN RAT-BRAIN AND
ITS EFFECT ON ACETYLCHOLINE SYNTHESIS. ^^^^ ^^^^
THE EFFEQ OF MORPHINE ON PURINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: EVIDENCE FOR A PURINERGIC
COMPONENT IN MORPHINES AQION. ^^^^^ ^^_^^
(3H)ACETYLCH0LINE AND (3H)5 HYDROXYTRYPTAMINE RELEASE FROM
RAT-MIDBRAIN SLICES AND THE EFFECTS OF CALCIUM AND
PHENOBARBITAL. ^^^Sl 01-03
S-2
VOLUME 19, SUBJECT INDEX
Subject Index
REGULATION OF STRIATAL ACETYLCHOLINE CONCENTRATION BY D2
DOPAMINE-RECEPTORS,
000269 01-03
IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR
ACTIVITY.
000289 01-03
THE EFFECTS OF MUSCARINIC-RECEPTOR BLOCKERS ON THE TURNOVER-
RATE OF ACETYLCHOLINE IN VARIOUS REGIONS OF THE RAT-BRAIN.
000328 01-03
TOLERANCE TO INCREASES IN STRIATAL ACETYLCHOLINE
CONCENTRATIONS AFTER REPEATED ADMINISTRATION Of
APOMORPHINE-DIPIVALOYL-ESTER
000464 01-04
REGULATION OF ACETYLCHOLINE RELEASE DURING INCREASED NEURONAL
ACTIVITY. (UNPUBLISHED PAPER).
001061 02-01
EFFECT OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED
EXTRAPYRAMIDAL ALTERATIONS.
001119 02-03
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELECTRICAL-
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL
SLICES.
001130 02-03
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN
STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER.
001218 02-03
LONG-TERM ADMINISTRATION OF ATROPINE, IMIPRAMINE, AND
VILOXAZINE ALTERS RESPONSIVENESS OF RAT-CORTICAL-NEURONES
TO ACETYLCHOLINE.
001306 02-03
ASCORBIC-ACID, AN ENDOGENOUS FACTOR REQUIRED FOR
ACETYLCHOLINE RELEASE FROM THE SYNAPTIC VESICLES.
001322 02-03
DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR
TRANSMinER IN THE CAT CEREBRAL-ARTERY.
001336 02-03
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMITTERS IN EPIDURAL
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC-
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS.
001386 02-03
EFFECTS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC
MECHANISM IN ACTION OF DIAZEPAM.
001414 02-03
EFFECT OF ANTINOCICEPTIVE DOSES OF OXOTREMORINE ON MOUSE-
BRAIN ACETYLCHOLINE TURNOVER-RATE.
001513 02-03
ACTIONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON
ACETYLCHOLINE TURNOVER IN RAT-BRAIN.
001541 02-03
GLYCINE, ACETYLCHOLINE, AND SEROTONIN: NEUROTRANSMITTERS OR
NEUROMODULATORS?
002271 02-13
THE EXCITATORY ACTION OF ACETYLCHOLINE ON HIPPOCAMPAL
NEURONES OF THE GUINEA-PIG AND RAT MAINTAINED IN VITRO
002704 03-03
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
MODULATION BY ENDOGENOUS DOPAMINE OF THE RELEASE OF
ACETYLCHOLINE IN THE CAUDATE-NUCLEUS OF THE RABBIT.
PIRACETAM DIMINISHES HIPPOCAMPAL ACETYLCHOLINE LEVELS IN RATS.
THE EFFECTS OF ACETYLCHOLINE AND GLUTAMATE ON SEPTAL NEURONS
IN VITRO.
002941 03-03
RELEASE OF ACETYLCHOLINE FROM RAT-BRAIN SYNAPTOSOMES
STIMULATED WITH LEPTINOTARSIN, A NEW NEUROTOXIN.
MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS.
003744 04-03
COMPARISON OF THE EFFECTS OF THE STEREOISOMERS OF
FENFLURAMINE ON THE ACETYLCHOLINE CONTENT OF RAT STRIATUM
HIPPOCAMPUS AND NUCLEUS-ACCUMBENS
OXOTREMORINE DOES NOT ENHANCE ACETYLCHOLINE RELEASE FROM '
RAT DIAPHRAGM PREPARATIONS.
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN.
PRESYNAPTIC REGULATION OF THE RELEASE OF ACETYLCHOLINE BY 5 '
HYDROXYTRYPTAMINE.
003843 04-03
INVESTIGATION OF ACTION OF ENKEPHALIN ON THE SPONTANEOUS AND
EVOKED RELEASE OF ACETYLCHOLINE FROM RAT CORTICAL AND
STRIATAL SLICES.
003862 04-03
ACTION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
THE EFFECT OF CHRONIC NICOTINE AND WITHDRAWAL ON INTRAAXONAL
TRANSPORT OF ACETYLCHOLINE AND RELATED ENZYMES IN SCIATIC-
NERVE OF THE RAT.
003897 04-03
THE EFFECT OF ACETYLCHOLINE RELEASE ON CHOLINE FLUXES IN
ISOLATED SYNAPTIC TERMINALS.
003924 04-03
ACETYLCHOLINE AND CHOLINE-ACETYLTRANSFERASE.
003930 04-03
CORRELATIONS BETWEEN NA-K-ATPASE ACTIVITY AND ACETYLCHOLINE
RELEASE IN RAT CORTICAL SYNAPTOSOMES.
003937 04-03
EFFECTS OF ETHANOL ON ACETYLCHOLINE AND ADENOSINE EFFLUX FROM
THE IN VIVO RAT-CEREBRAL-CORTEX.
003969 04-03
INHIBITION OF THE SYNTHESIS OF ACETYLCHOLINE IN RAT-BRAIN SLICES
BY (-) HYDROXYCITRATE AND CITRATE.
004044 04-03
5' TRIPHOSPHATE RECYCLES INDEPENDENTLY OF ACETYLCHOLINE IN
CHOLINERGIC SYNAPTIC VESICLES.
004063 04-03
CHOLINE REVERSES NALOXONE-INDUCED DECREASES IN HIPPOCAMPAL
ACETYLCHOLINE CONTENT AND SUPPRESSES ESCAPE-BEHAVIOR IN
OPIATE-DEPENDENT RATS.
004076 04-04
ANTITREMOR ACTION OF ClODICHOL, A PERIPHERAL ACETYLCHOLINE
SYNTHESIS INHIBITOR.
004096 04-04
ACETYLCHOLINE TURNOVER AND AGGRESSION IN RELATED THREE
STRAINS OF MICE.
004151 04-04
ACETYLCHOLINE-INDUCED
ACETYLCHOLINE-INDUCED MODULATION OF HIPPOCAMPAL PYRAMIDAL
NEURONS.
003728 04-03
ACETYLCHOLINE-RECEPTOR
PHOSPHORYLATION OF THE MEMBRANE-BOUND ACETYLCHOLINE-
RECEPTOR: INHIBITION BY DIPHENYLHYDANTOIN.
001257 02-03
ENZYMATIC CARBOXYMETHYLATION OF THE NICOTINIC ACETYLCHOLINE-
RECEPTOR. (UNPUBLISHED PAPER).
001318 02-03
MUSCARINIC ACETYLCHOLINE-RECEPTOR. (UNPUBLISHED PAPER)
002667 03-03
ACETYLCHOLINE-RECEPTORS
LITHIUM REDUCES THE NUMBER OF ACETYLCHOLINE-RECEPTORS IN
SKELETAL-MUSCLE.
000232 01-03
THE BINDING OF SOME ANTIDEPRESSANT-DRUGS TO BRAIN MUSCARINIC
ACETYLCHOLINE-RECEPTORS.
001253 02-03
PSYCHOTHERAPEUTIC-DRUGS, HISTAMINE HI -RECEPTORS AND
MUSCARINIC ACETYLCHOLINE-RECEPTORS.
004737 04-17
ACETYLCHOLINESTERASE
ACTION OF BARBITURATES ON ACTIVITY OF ACETYLCHOLINESTERASE
FROM SYNAPTOSOMAL MEMBRANES.
000224 01-03
ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITIES IN THE
MOUSE CEREBELLUM FOLLOWING MISONIDAZOLE TREATMENT
003123 03-05
INHIBITION OF AMINOPEPTIDASE AND ACETYLCHOLINESTERASE BY
PUROMYCIN AND PUROMYCIN ANALOGS.
003835 04-03
INSEPARABILITY OF ACETYLCHOLINESTERASE AND NERVE EXCITATION
003875 04-03
ACETYLENIC-GABA
EFFECTS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL-
CORD GABA CONCENTRATION.
000145 01-03
MAPPING OF DYSKINETIC-MOVEMENTS INDUCED BY LOCAL APPLICATION
OF PICROTOXIN OR () GAMMA ACETYLENIC-GABA ON THE RAT
MOTOR-CORTEX.
000458 01-04
GAMMA ACETYLENIC-GABA IN TARDIVE-DYSKINESIA.
002101 02-11
MULTIPLE EFFECTS OF REPEATED ADMINISTRATION OF GAMMA
ACETYLENIC-GABA ON RAT-BRAIN METABOLISM.
002878 03-03
I
S-3
Subject Index
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE:
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION. „„o.c„,^o,.
003458 03-14
ACETYLENIC-GAMMA-AMINOBUTYRIC-ACID
CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC-
ACID (GAG) A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE
(GABA-TRANSAMINASE) INHIBITOR
ACETYLESTERS
GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC
ANALYSES FOR DEANOL. CHOLINE, AND THEIR ACETYLESTERS.
004683 04-16
ACETYLMANNOSAMINE
INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN
SUBCELLULAR GANGLIOSIDES: EFFECT OF PENTYLENETETRAZOL-
INDUCED CONVULSIONS IN BRAIN GANGLIOSIDES.
002937 03-03
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM)
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND
DINORLAAM DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT.
000505 01-04
OCCURRENCE OF CORNEAL OPACITIES IN RATS AFTER ACUTE
ADMINISTRATION OF L ALPHA ACETYLMETHADOL. ^^
A CHARACTERIZATION OF THE BEHAVIORAL-EFFECTS OF LEVO ALPHA
ACETYLAAETHADOL IN THE RAT AND IN THE PIGEON. (PH D
°'5S^'^^^™^^ 003047 03-04
A CLINICAL CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE
TREATMENT OF NARCOTIC ADDICTION. 003335 03-11
EFFECTS OF LEVO ALPHA ACETYLMETHADOL (LAAM) ON MORPHINE SELF-
ADMINISTRATION IN THE RAT. 004170 04-04
MORPHINE CHALLENGES IN LEVO ALPHA ACETYLMETHADOL (LAAM)
POSTADDICT RATS „„.^c„„.n.
004259 04-04
ACETYLSAIICYIIC-ACID „.^r^...^,
BEHAVIOURAL-EFFECTS OF ACETYLSALICYLIC-ACID, PARACETAMOL,
CAFFEINE GUAIPHENESIN AND THEIR COMBINATIONS.
001805 02-04
ACH
INHIBITION OF ACH RELEASE BY PROSTAGLANDIN-El IN THE RABBIT
SUPERIOR-CERVICAL-GANGLION. 00120502-03
ACH-RECEPTOR
IMMUNODETECTION OF ACH-RECEPTOR IN THE CNS (UNPUBLISHED
''''^' 003670 04-01
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF
BULLFROG SYMPATHETIC GANGLION CELLS
003710 04-03
ACID
THE CONTRIBUTION 0" ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
BINDING OF PERAZINE TO ALPHAl ACID GLYCOPROTEIN
002290 02-13
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL
AND PATHOLOGICAL (^.. NIEMANN-PICK TYPE C) HUMAN BRAIN.
003671 04-01
THE EFFECTS OF NEFOPAM ON BLOOD ACID BASE STATUS IN THE RABBIT:
INTERACTIONS WITH MORPHINE IN THE MOUSE AND RABBIT.
004279 04-05
ACIDIC
REVERSIBLE RING-OPENING REACTIONS OF NIMETAZEPAM AND
NITRAZEPAM IN ACIDIC MEDIA AT BODY-TEMPERATURE.
004517 04-13
ACOUSTIC
5 METHOXYDIMETHYLTRYPTAMINE: SPINAL-CORD AND BRAINSTEM
MEDIATION OF EXCITATORY EFFECTS ON ACOUSTIC STARTLE.
001605 02-04
SPINAL MODULATION OF THE ACOUSTIC STARTLE RESPONSE: THE ROLE
OF NOREPINEPHRINE, SEROTONIN AND DOPAMINE.
002950 03-04
ACQUISITION
EFFECT OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION,
MEMORY, AND RETRIEVAL OF SHUTTLE AVOIDANCE AND
HABITUATION LEARNING IN RATS. ^^^ ,^ „, ^^
000410 01-04
THE EFFECTS OF PIPRADROL ON THE ACQUISITION OF RESPONDING WITH
CONDITIONED REINFORCEMENT: A ROLE FOR SENSORY
PRECONDITIONING. 001572 02-04
Psychopharmacology Abstracts
EFFEQS OF A LOW-DOSE AND A HIGH-DOSE OF BETA ENDORPHIN ON
ACQUISITION AND RETENTION IN THE RAT.
001663 02-04
L-DOPA ENHANCES ACQUISITION OF AN INHIBITORY AVOIDANCE
'''''''' 00171102-04
EFFECTS OF PHENCYCLIDINE, PENTOBARBITAL, AND D-AMPHETAMINE ON
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL
DISCRIMINATIONS IN MONKEYS.
001723 02-04
CUMULATIVE AFTERDISCHARGE AS THE PRINCIPAL FAQOR IN THE
ACQUISITION OF KINDLED SEIZURES.
002862 03-03
EFFECT OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF
TOLERANCE TO THE HYPNOTIC-EFFEQS OF PENTOBARBITAL, BARBITAL,
AND ETHANOL.
003883 04-03
RAPID ACQUISITION OF A TWO-DRUG DISCRIMINATION: TIME OF DAY
EFFECT UPON SALINE STATE
004214 04-04
ACQUISITION-BEHAVIOR
EFFECTS OF METHYLPHENIDATE-HYDROCHLORIDE ON REPEATED
ACQUISITION-BEHAVIOR IN HYPERKINETIC-CHILDREN. (PH.D.
DISSERTATION)
003386 03-11
EFFEaS OF DEXTROAMPHETAMINE-SULFATE ON REPEATED ACQUISITION-
BEHAVIOR AND MOOD IN HUMANS: A PRELIMINARY REPORT.
003459 03-14
ACRYLAMIDE „ „„^,
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFEQS
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES.
000131 01-03
NEUROTRANSMIHER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS I: EFFECTS OF A SINGLE EXPOSURE TO ACRYLAMIDE.
004264 04-05
NEUROTRANSMinER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS II: EFFECTS OF EXTENDED EXPOSURE TO ACRYLAMIDE.
004265 04-05
ACTH
CHANGES OF AQH, STH, TSH AND PROLAQIN LEVELS IN ENDOTOXIN
SHOCK IN RATS ^, „,
000119 01-03
OPIATE-RECEPTORS MAY MEDIATE THE SUPPRESSIVE BUT NOT THE
EXCITATORY ACTION OF ACTH ON MOTOR-AQIVITY IN RATS.
000337 01-04
ACTH MODULATION OF MEMORY STORAGE PROCESSING. (UNPUBLISHED
^"^^^^ 001250 02-03
ACTH MEDIATION OF LEARNED-FEAR: BLOCKADE BY NALOXONE AND
^*^^^^^°'^^ 001597 02-04
AQH POTENTIATES MORPHINE-INDUCED CONDITIONED TASTE-AVERSION.
001781 02-04
TRIAL OF A PEPTIDE FRACTION OF ACTH (AaH4-10) IN THE ALCOHOLIC
BRAIN-DAMAGE-SYNDROME ^^^ , „ „o , ^
002318 02-14
EXPLORATION AND MOTOR-ACTIVITY AFTER INTRAVENTRICULAR AQH,
MORPHINE AND NALOXONE 00299103-04
*^ ACTH-INDUCED GROOMING INVOLVES HIGH-AFFINITY OPIATE-RECEPTORS.
002985 03-04
ACTH LIKE
ACTH-LIKE PEPTIDES, PITUITARY ADRENOCORTICAL FUNQION AND
AVOIDANCE-BEHAVIOR. 004109 04-04
EFf'eCTS OF ACUTE CENTRAL AND PERIPHERAL AQH 1-24
ADMINISTRATION ON LORDOSIS BEHAVIOR 002975 03-04
TESTOSTERONE POTENTIATION OF THE EFFEQIVENESS OF ACTH 1-24 ON
THE INDUCTION OF THE STRETCH-YAWNING-SYNDROME (SYS) IN MALE
S^"^^*-'''^^ 003074 03-04
HORMONAL STIMULATION AFTER INJEQION OF THYROTROPHIN-
RELEASING-FAQOR (TRF) AND AQH 1-24 IN PATIENTS FOLLOWING
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY-STUDY^
004505 04- 1 3
ACTH4-10
ACTH4-10 AND MEMORY IN EQ TREATED AND UNTREATED PATIENTS. I.
EFFEQ ON CONSOLIDATION 001982 02-09
AaH4-10 AND MEMORY IN EQ TREATED PATIENTS AND UNTREATED
CONTROLS. II. EFFEQ ON RETRIEVAL. 001983 02-09
TRIAL OF A PEPTIDE FRACTION OF AQH (AQH4-10) IN THE ALCOHOLIC
BRAIN-DAMAGE-SYNDROME. 002318 02-14
S-4
VOLUME 19, SUBJECT INDEX
Subject Index
POSSIBLE MECHANISMS OF EFFECT OF ACTH4-10 AND ITS ANALOG,
CONTAINING D ISOMER OF PHENYLALANINE, ON BEHAVIOR.
002949 03-04
IMITATION, SOCIAL FACILITATION, AND THE EFFECTS OF ACTH4-10 ON
RATS BAR-PRESSING-BEHAVIOR.
003009 03-04
ACTH4-9
Y-MAZE BEHAVIOR AFTER AN ANALOG OF ACTH4-9, EVIDENCE FOR AN
AnENTIONAL-ALTERATION .
001676 02-04
EFFECTS OF AN ACTH4-9 RELATED PEPTIDE UPON INTRACRANIAL SELF-
STIMULATION AND GENERAL-ACTIVITY IN THE RAT.
001679 02-04
INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766,
AN ANALOG OF ACTH4-9.
003112 03-04
A SYNTHETIC ACTH4-9 ANALOGUE (ORGANON-2766) AND SLEEP IN
HEALTHY MAN.
004574 04-14
AaiNOMYCIN-0
INHIBITION OF BEHAVIORAL-EFFECTS OF COCAINE BY ACTINOMYCIN-D IN
RATS.
000346 01-04
ACTIVATION
ACTIVATION OF CORTICAL CIRCUITS DURING INTERICTAL SPIKES.
000056 01-03
THE ROLE OF INTRANEURONAL 5 NT AND OF TRYPTOPHAN-
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM
000123 01-03
ANALYSIS OF THE ACTIVATION OF DOPAMINE METABOLISM BY A
SEROTONIN UPTAKE INHIBITOR.
000315 01-03
METERGOLINE ANTAGONISM OF 5 HYDROXYTRYPTAMINE-INDUCED
ACTIVATION OF RAT-CEREBRAL-CORTICAL NA-K-ATPASE.
000329 01-03
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER ACTIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT.
001095 02-03
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-ACTIVITY
RELATIONSHIPS.
001132 02-03
MIANSERIN: DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS
BY BLOCKING ALPHA2-RECEPT0RS.
001214 02-03
ACTIVATION OF PRESYNAPTIC ALPHA NORADRENALINE-RECEPTORS IN
RAT-BRAIN BY THE POTENT DOPAMINE-MIMETIC N,N DIPROPYL-ADTN
001390 02-03
BRAIN STRIATAL TYROSINE-HYDROXYLASE: ACTIVATION OF THE ENZYME
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION.
001423 02-03
THE EFFECT OF NALOXONE ON THE ACTIVATION OF EMOTIONALLY
POSITIVE REACTION PRODUCED BY DRUGS WITH A DEPENDENCE
LIABILITY.
001556 02-03
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT.
001657 02-04
VARIATIONS IN PSYCHOPHYSIOLOGICAL ACTIVATION RESPONSES IN
DEPRESSIVE-STATES.
001965 02-09
STRETCH-INDUCED MYOTUBE GROWTH CORRELATES WITH NA-PUMP
ACTIVATION. (UNPUBLISHED PAPER).
002087 02-10
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL
DOPAMINE SYNTHESIS.
002786 03-03
IDENTICAL RESPONSES OF THE TWO HIPPOCAMPAL THETA GENERATORS
TO PHYSIOLOGICAL AND PHARMACOLOGICAL ACTIVATION
002792 03-03
ACTIVATION OF SOLUBLE STRIATAL TYROSINE-HYDROXYLASE IN THE RAT
BRAIN AFTER CDP-CHOLINE ADMINISTRATION
rrrr.T^rr>„ 002816 03-03
EFFECT OF DOPAMINE ON ACTIVATION OF RAT STRIATAL ADENYLATE-
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES.
002825 03-03
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH
ANTICONVULSANT AND ANESTHETIC ACTIONS.
002885 03-03
EFFECT OF SODIUM-VALPROATE ON MOTOR FUNCTION REGULATED BY
THE ACTIVATION OF GABA-RECEPTORS.
003033 03-04
NEUROLEPTICS: ACTIVATION OR INHIBITION OF THE DOPAMINERGIC-
SYSTEM?
003424 03-13
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL
WAVES IN CATS?
003704 04-02
AN EVALUATION OF THE MECHANISM BY WHICH SEROTONERGIC
ACTIVATION DEPRESSES RESPIRATION.
003917 04-03
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCED
ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY
004018 04-03
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS.
004022 04-03
EFFECTS OF PROPRANOLOL ON THE LOCOMOTOR- STIMULATION INDUCED
BY ACTIVATION OF POSTSYNAPTIC CATECHOLAMINE-RECEPTORS.
004126 04-04
REDUCTION IN OPIATE ACTIVATION AFTER CHRONIC
ELECTROCONVULSIVE-SHOCK - POSSIBLE ROLE FOR ENDORPHINS IN
THE BEHAVIORAL-EFFECTS OF CONVULSIVE-SHOCK-TREATMENT.
(UNPUBLISHED PAPER).
004154 04-04
CONTRIBUTION OF SOCIAL FACTORS TO OPIATE-INDUCED ACTIVATION IN
THE MOUSE
004156 04-04
A COMPARATIVE EVALUATION OF THE USEFULNESS OF
PSYCHOPHYSIOLOGICAL-TESTS DURING VARIOUS LEVELS OF
ACTIVATION OF THE CENTRAL-NERVOUS-SYSTEM.
004543 04-13
ACTIVATORS
PSYCHOMOTOR STIMULANTS AS ACTIVATORS OF NORMAL AND
PATHOLOGICAL-BEHAVIOR: IMPLICATIONS FOR THE EXCESSES IN
MANIA. (UNPUBLISHED PAPER).
002353 02-14
ACTOMETRIC
THE ANOREXIC AND ACTOMETRIC EFFECTS OF COCAINE AND TWO COCA-
EXTRACTS.
000344 01-04
ACYLASE
AN EVALUATION OF THE USEFULNESS OF THE ACYLASE TEST IN
NEUROLEPTIC TREATMENT.
004426 04-10
ACYLCYANAMIOES
ACYLCYANAMIDES, ACYLUREA, AND VARIOUS SUBSTITUTED
ARYLALLOPHANATES; EFFECT ON THE CNS.
003689 04-02
ACYLUREA
ACYLCYANAMIDES, ACYLUREA, AND VARIOUS SUBSTITUTED
ARYLALLOPHANATES; EFFECT ON THE CNS.
003689 04-02
ADAPTATION
NEUROTRANSMITTER RELATED ADAPTATION IN THE CENTRAL-NERVOUS-
SYSTEM FOLLOWING CHRONIC MONOAMINE-OXIDASE-INHIBITION
000038 01-03
CENTRAL NORADRENERGIC ADAPTATION TO LONG-TERM-TREATMENT
WITH IMIPRAMINE IN RHESUS-MONKEYS.
000182 01-03
LONG-TERM-TREATMENT WITH NEUROLEPTIC-AGENTS: ADAPTATION
PHENOMENA AND THEIR SIGNIFICANCE WITH REGARD TO
SCHIZOPHRENIC-SYMPTOMATOLOGY AND SIDE-EFFECTS.
002370 02-15
IN VITRO CELLULAR ADAPTATION OF SEROTONERGIC PROCESSES AFTER
CHRONIC CENTRAL PHENOBARBITAL ADMINISTRATION.
002813 03-03
THERAPY AND SOCIAL ADAPTATION OF OLIGOPHRENICS (REVIEW OF THE
LITERATURE).
004444 04-11
ADAPTATIONS
RECEPTOR ADAPTATIONS TO CENTRALLY ACTING DRUGS.
003585 03-17
ADAPTIVE
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT
DERIVATIVES.
001156 02-03
ADDICTION
IATROGENIC OPIATE ADDICTION: SUCCESSFUL DETOXIFICATION WITH
CLONIDINE.
000666 01-11
k
If
S-5
Subject Index
THE TREATMENT OF OPIATE ADDIQION USING METHADONE-
CHLORHYDRATE.
002600 02-17
A CLINICAL, CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE
TREATMENT OF NARCOTIC ADDICTION.
003335 03-11
ACTION ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS
OF TREATING ALCOHOLISM AND DRUG ADDICTION
PATHOGENETICALLY.
003641 03-17
ADDICTIVE-AGENTS
ADDICTIVE-AGENTS AND INTRACRANIAL- STIMULATION (ICS): MORPHINE.
NALOXONE, AND PRESSING FOR AMYGDALOID ICS.
000371 01-04
ADDICTIVE-BEHAVIOR
ADDICTIVE-BEHAVIOR.
002114 02-11
ADDICTS
A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDICTS DURING
WITHDRAWAL.
004445 04-11
METHADONE TREATMENT OF HEROIN ADDICTS IN SWITZERLAND,
004452 04-11
SUPPRESSION OF MORPHINE ABSTINENCE IN HEROIN ADDICTS BY BETA
ENDORPHIN.
004489 04-1 1
ADENINE-NUCLEOTIDES
ADENINE-NUCLEOTIDES AND SYNAPTIC TRANSMISSION IN THE IN VITRO
RAT HIPPOCAMPUS.
000080 01-03
REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE-
NUCLEOTIDES AND ADENOSINE.
000210 01-03
ADENOSINE
REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE-
NUCLEOTIDES AND ADENOSINE.
000210 01-03
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE
ACTION.
000229 01-03
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS.
000308 01-03
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS.
000330 01-03
MORPHINE ENHANCES ADENOSINE RELEASE FROM THE IN VIVO RAT-
CEREBRAL-CORTEX.
000451 01-04
ADENOSINE ANALOGS AS SUBSTRATES AND INHIBITORS OF S
ADENOSYLHOMOCYSTEINE-HYDROLASE. (UNPUBLISHED PAPER).
001021 02-01
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN
IN VIVO- EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS,
AND BENZODIAZEPINES.
001303 02-03
INHIBITORY ACTION OF ADENOSINE ON SYNAPTIC TRANSMISSION IN THE
HIPPOCAMPUS OF THE GUINEA-PIG IN VITRO.
001401 02-03
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF
NEURONAL DEPRESSION BY ADENOSINE. A MICROIONTOPHORETIC-
STUDY.
001410 02-03
EFFECTS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC
MECHANISM IN ACTION OF DIAZEPAM.
001414 02-03
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM
002728 03-03
METHYLXANTHINES MODULATE ADENOSINE RELEASE FROM SLICES OF
CEREBRAL-CORTEX.
002907 03-03
DO BENZODIAZEPINES BIND AT ADENOSINE UPTAKE SITES IN CNS?
002933 03-03
EFFECTS OF MORPHINE AND CAFFEINE ON ADENOSINE RELEASE FROM
RAT-CEREBRAL-CORTEX: IS CAFFEINE A MORPHINE ANTAGONIST.
003864 04-03
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH.
003882 04-03
ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES:
EFFECTS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE-
DEAMINASE INHIBITORS.
003950 04-03
Psychopharmacology Abstracts
EFFEaS OF ETHANOL ON ACETYLCHOLINE AND ADENOSINE EFFLUX FROM
THE IN VIVO RAT-CEREBRAL-CORTEX.
003969 04-03
POTENTIATION OF THE EFFECTS OF ADENOSINE ON ISOLATED CARDIAC-
MUSCLE AND SMOOTH-MUSCLE BY DIAZEPAM.
004266 04-05
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE
REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA-INDEPENDENT
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6-
GLIOMA CELLS. (UNPUBLISHED PAPER).
001403 02-03
ADENOSINE-DEAMINASE
ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES:
EFFECTS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE-
DEAMINASE INHIBITORS.
003950 04-03
ADENOSINE-RECEPTORS
ADENOSINE-RECEPTORS IN RAT TESTES: LABELING WITH 3H
CYCLOHEXYUVDENOSINE.
002835 03-03
ADENOSINE-RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM:
RELATIONSHIP TO THE CENTRAL-AQIONS OF METHYLXANTHINES
003766 04-03
ADENOSINE-TRIPHOSPHATASE
ETHANOL SEDATIVE HYPNOTIC-INTERACTIONS: IN VITRO STUDIES ON NA-
K-ACTIVATED ADENOSINE-TRIPHOSPHATASE .
004269 04-05
ADENOSINE-TRIPHOSPHATASES
INTERACTION STUDIES OF ETHANOL AND PSYCHOTROPIC-DRUGS IN
RODENTS POSSIBLE INVOLVEMENT OF ADENOSINE-TRIPHOSPHATASES.
001281 02-03
ADENOSINE-TRIPHOSPHATE
4 AMINOPYRIDINE BLOCKADE OF NEURONAL DEPRESSANT RESPONSES TO
ADENOSINE-TRIPHOSPHATE
003963 04-03
ADENOSYL-L-HOMOCYSTEINE
ANTICONVULSANT PROPERTIES OF S ADENOSYL-L-HOMOCYSTEINE.
001227 02-03
ADENOSYL-L-METHIONINE
DECREASE OF NORADRENALINE 0 METHYUVTION IN RAT-BRAIN INDUCED
BY L-DOPA. REVERSAL EFFEQ OF S ADENOSYL-L-METHIONINE.
004019 04-03
ADENOSYLHOMOCYSTEINE-HYDROLASE
IRREVERSIBLE INHIBITION OF S ADENOSYLHOMOCYSTEINE-HYDROLASE BY
NUCLEOSIDE ANALOGS (UNPUBLISHED PAPER).
001010 02-01
ADENOSINE ANALOGS AS SUBSTRATES AND INHIBITORS OF S
ADENOSYLHOMOCYSTEINE-HYDROLASE. (UNPUBLISHED PAPER).
001021 02-01
ADENOSYLMETHIONINE
DECREASED CEREBRAL CATABOLISM OF (3H)HISTAMINE IN VIVO AFTER $■
ADENOSYLMETHIONINE ADMINISTRATION.
002883 03-03
ADENYLATE-CYCLASE
(3H)5 HT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN
GLIAL CELL MEMBRANE FRAQION.
000093 01-03
SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCUVSE SYSTEM IN BRAIN: EFFEQS OF NISOXETINE
VERSUS FLUOXETINE.
000208 01-03
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - I. KINETIC PARAMETERS
AND PHARMACOLOGICAL-PROPERTIES.
000213 01-03
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - II. RESPEQIVE REGIONAL
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC
DEVELOPMENTS „ „,
000214 01-03
OPIOID DEPENDENT DUAL-REGULATION OF ADENYLATE-CYCLASE IN A
CELL-FREE SYSTEM. (UNPUBLISHED PAPER).
001033 02-01
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUQURE-ACTIVITY
RELATIONSHIPS.
001132 02-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND RECEPTOR BINDING-
AQIVITIES FOLLOWING ACUTE AND CHRONIC NEUROLEPTIC-DRUG
TREATMENT. (UNPUBLISHED PAPER).
001172 02-03
ENDOGENOUS GUANYL-NUCLEOTIDES: COMPONENTS OF THE STRIATUM
WHICH CONFER DOPAMINE SENSITIVITY TO ADENYLATE-CYCLASE.
001313 02-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/
NEUROLEPTIC-RECEPTOR BINDING: EFFEQ OF NEUROLEPTIC-DRUGS
001358 02-03
S-6
/OLUME T9, SUBJECT INDEX
OIHYDROXY AND TRIHYOROXY ANALOGS OF CHLORPROMAZINE
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND
CYCLIC-AMP-PHOSPHODIESTERASE.
001405 02-03
STIMULATION OF ADENYLATE-CYCLASE IN RAT STRIATUM BY
PERGOLIDE: INFLUENCE OF GTP.
001448 02-03
FUNCTIONAL ASPECTS OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCUVSE SYSTEM IN THE CENTRAL-NERVOUS-SYSTEM.
001493 02-03
STIMULATION OF RETINAL ADENYLATE-CYCUkSE BY VASOACTIVE
INTESTINAL PEPTIDE (VIP).
002811 03-03
EFFECT OF DOPAMINE ON ACTIVATION OF RAT STRIATAL ADENYLATE-
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES.
002825 03-03
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE-
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1
CYCLOPROPYLMETHYL
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE.
003706 04-02
STIMULATORY ACTION OF LISURIDE ON DOPAMINE-SENSITIVE
ADENYLATE-CYCUSE IN THE RAT STRIATAL HOMOGENATE.
003718 04-03
DOPAMINE-ACTIVATED ADENYLATE-CYCLASE OF SPINAL-CORD:
SUPERSENSITIVITY FOLLOWING TRANSECTION OF THE CORD.
003800 04-03
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE-
SENSITIVE ADENYUVTE-CYCLASE IN HOMOGENATES OF CARP RETINA-
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS.
004051 04-03
WHY DOES SULPIRIDE NOT BLOCK THE EFFECT OF DOPAMINE ON THE
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE?
004055 04-03
RECEPTORS, ADENYLATE-CYCLASE, DEPRESSION, AND LITHIUM.
004353 04-09
DH
INAPPROPRIATE ADH SECRETION: THE ROLE OF DRUG RECHALLENGE.
002629 02-17
DHERENCE
ADHERENCE TO LITHIOTHERAPY.
002507 02-16
DHESION
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK
TISSUES ~ ARE THEY CELL ADHESION MOLECULES?
003724 04-03
JIPOCYTES
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM
002728 03-03
XPOSE
EFFECTS OF RATE OF BLOOD FLOW ON FRACTIONAL EXTRACTION AND ON
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN
VIVO.
)JUNCT.VE ""'''' °2-03
EFFECTS OF PSYCHOTROPIC-DRUGS ON FI-RESPONDING AND ADJUNCTIVE
DRINKING IN RATS.
001693 02-04
>JUSTMENTS
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS
,JUVANT 001242 02-03
PSYCHIATRIC MORBIDITY AND PHYSICAL TOXICITY ASSOCIATED WITH
ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY.
002433 02-15
)MINISTRATIONS
MODIFICATION OF DOPAMINE-RECEPTORS IN BRAIN BY CONTINUOUS
AMPHETAMINE ADMINISTRATIONS TO RATS.
001395 02-03
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS
ADMINISTRATIONS.
002797 03-03
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT
.u.cc.«..e 003703 04-02
AMISSIONS
PSYCHOTROPIC-DRUGS AND PSYCHIATRIC-HOSPITAL ADMISSIONS IN
VERONA, ITALY.
004717 04-17
>OLESCENCE " ' u'* i /
THE USE OF LITHIUM-CARBONATE IN ADOLESCENCE.
000992 01-17
Subject Index
ON THE QUESTION OF PARENCHYMAL DAMAGE CAUSED BY LONG-TERM
THERAPY WITH PSYCHOTROPICS IN ADOLESCENCE.
004626 04-15
ADOLESCENT
PREDICTORS OF ADOLESCENT HEIGHT AND WEIGHT IN HYPERKINETIC-
BOYS TREATED WITH METHYLPHENIDATE
003509 03-15
PHENYTOIN TOXICITY IN A BRAIN-DAMAGE ADOLESCENT: A CASE-
REPORT.
003512 03-15
MAOI-INOUCED RAPID CYCLING BIPOLAR AFFECTIVE-DISORDER IN AN
ADOLESCENT.
004637 04-15
ADOLESCENTS
MARIJUANA: A REVIEW OF MEDICAL RESEARCH WITH IMPLICATIONS
FOR ADOLESCENTS.
000871 01-15
INITIAL PRESCRIPTION OF PSYCHOTROPIC-MEDICATIONS FOR
ADOLESCENTS IN A MEDICAL/ PROFESSIONAL INSTITUTE, AND THE
ROLE OF THE PSYCHIATRIST IN A MEDICAL/PROFESSIONAL INSTITUTE.
002621 02-17
LATE RESULTS OF LITHIUM TREATMENT OF ADOLESCENTS WITH AHACK
LIKE SCHIZOPHRENIA.
003177 03-08
ON THE EFFECTS OF SULTOPRIDE ADMINISTERED IN LOW-DOSAGES TO
OLDER CHILDREN AND ADOLESCENTS.
003230 03-09
TREATMENT OF ANXIETY IN CHILDREN AND ADOLESCENTS.
003349 03-11
PHARMACOLOGICAL INFLUENCE OF SEXUAL-FUNCTIONS IN ADOLESCENTS.
004436 04-11
DRUG-INDUCED PSYCHOSIS AND SCHIZOPHRENIA IN ADOLESCENTS.
004596 04-15
EMOTIONAL-DISORDERS IN CHILDREN AND ADOLESCENTS: MEDICAL AND
PSYCHOLOGICAL APPROACHES TO TREATMENT.
004743 04-17
ADRENAL
RELEASE OF ARACHIDONIC-ACID FROM ADRENAL CHROMAFFIN CELL-
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED
PAPER).
001027 02-01
INFLUENCE OF DRUGS AFFECTING THE PITUITARY ADRENAL AXIS ON
CHROMAFFIN CELLS.
001183 02-03
ADRENAL-GLAND
EFFECT OF OXOTREMORINE ON ORNITHINE-DECARBOXYLASE ACTIVITY OF
THE ADRENAL-GLAND IN RAT.
000246 01-03
IDENTIFICATION AND QUANTIFICATION OF 1,2,3,4 TETRAHYDRO-BETA-
CARBOLINE, 2 METHYL-TETRAHYDRO-BETA-CARBOLINE, AND 6
METHOXY-TETRAHYDRO-BETA-CARBOLINE AS IN VIVO CONSTITUENTS
OF RAT-BRAIN AND ADRENAL-GLAND.
002636 03-01
ADRENAL-HORMONES
ADRENAL-HORMONES AND ETHANOL INGESTION IN C57BL/CRGL AND
C3H/CRGL/2 MICE.
002739 03-03
ADRENAL-MEDULLA
REGULATION OF CHOLINERGIC TRANSMISSION IN ADRENAL-MEDULLA.
(UNPUBLISHED PAPER).
001182 02-03
BETA ENDORPHIN-INDUCED HYPERGLYCEMIA IS MEDIATED BY INCREASED
CENTRAL SYMPATHETIC OUTFLOW TO ADRENAL-MEDULLA.
002924 03-03
EFFECTS OF TAIPOXIN ON THE ULTRASTRUCTURE OF CHOLINERGIC AXON
TERMINALS IN THE MOUSE ADRENAL-MEDULLA.
003916 04-03
ADRENALECTOMIZED
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER).
001122 02-03
ADRENALINE
INCREASED ADRENALINE, BETA-ADRENERGIC-RECEPTOR STIMULATION
AND PHOSPHOLIPID METHYLATION IN PINEAL-GL^ND OF
SPONTANEOUSLY HYPERTENSIVE-RATS. (UNPUBLISHED PAPER)
001458 02-03
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL- STRESS IN CEREBRAL
HEMORRHAGE PATIENTS.
002295 02-13
ADRENALINE: A SECRET AGENT IN MEMORY.
002345 02-14
ADRENALINE-INDUCED
THE BLOOD-BRAIN-BARRIER IN ADRENALINE-INDUCED HYPERTENSION
000147 01-03
S-7
Subject Index
ADDENERfilC
SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE:
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT.
000095 01-03
THE RELEASE OF CATECHOLAMINES FROM ADRENERGIC NEURONS.
000974 01-17
AN EXAMINATION OF FACTORS INFLUENCING ADRENERGIC
TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNCTIONAL
ALPHA-ADRENOCEPTORS. 001196 02-03
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC
''^^^^ 001330 02-03
INDIRECT ADRENERGIC EFFECT OF HISTAMINE IN CAT CEREBRAL-
^•^™IES. 001355 02-03
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE
AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS.
(UNPUBLISHED PAPER). 001488 02-03
AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION
IN RATS- EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING-
^^^^^5 00153102-03
DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT-
BEHAVIOR BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL-
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS
001726 02-04
ADRENERGIC MODUUVTION OF THE HYPOTHALAMIC CHOLINERGIC
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN
T^^^^T 00176102-04
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS.
002047 02-09
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF
ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS
INCLUDING ANTIDEPRESSANTS „„...^ „„ ,-,
002532 02-17
ADRENERGIC REGULATION OF THE REDUCTION IN ACETYL-COENZYME-
A ARYLAMINE-N-ACETYLTRANSFERASE IN THE RAT PINEAL.
002654 03-03
DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC-
^'''''''' 002914 03-03
ROLE OF ADRENERGIC BLOCKING-AGENTS AND GLUCOCORTICOIDS ON
THE REGULATION OF PITUITARY OPIOID-PEPTIDES LEVELS.
003801 04-03
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS
INVOLVED IN THE HIPPOCAMPUS OF RABBITS
003842 04-03
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN
INDIREa ADRENERGIC CHOLINERGIC INTERAQION.
003887 04-03
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE
REVERSAL OF GUANETHIDINE BLOCKADE OF ADRENERGIC NEURONS.
003900 04-03
SPINAL-CORD PHARMACOLOGY OF ADRENERGIC AGONIST-MEDIATED
ANTINOCICEPTION. „„ „^ „^
004206 04-04
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS.
004231 04-04
PERIPHERAL SEROTONERGIC AND ADRENERGIC RESPONSES IN
DEPRESSION. „„ ^, „^„„
004364 04-09
THE STATE OF THE ADRENERGIC AND CHOLINERGIC SYSTEMS IN
SCHIZOPHRENIC-PATIENTS DURING PSYCHPHARMACOTHERAPY.
004526 04-13
ADRENERGIC-RECEPTOR
MORPHINE WITHDRAWAL CAUSES SUBSENSITIVITY OF ADRENERGIC-
RECEPTOR RESPONSE.
002838 03-03
ADRENERGIC-RECEPTORS
ASSESSMENT OF ADRENERGIC-RECEPTORS IN VIVO IN EXPERIMENTAL
ANIMALS AND MAN. (UNPUBLISHED PAPER).
001034 02-01
ACUTE AND CHRONIC EFFECTS OF PSYCHOACTIVE-DRUGS ON
ADRENERGIC-RECEPTORS AND CALMODULIN.
004750 04-17
ADRENOCEPTOR ^ ,^,
A NEUROENDOCRINE-STUDY OF ADRENOCEPTOR FUNCTION IN
ENDOGENOUS DEPRESSION. 004362 04-09
PtychopharmQCology Abstracts
ADRENOCEPTORS
DESENSITIZATION OF ADRENOCEPTORS AFTER IMMOBILIZATION STRESS
OR REPEATED INJECTION OF ISOPROTERENOL IN RATS. (UNPUBLISHED
PAPER),
001546 02-03
ADRENOCORTICAL
THE EFFECT OF PROPYLNORANTIFEIN ON BEHAVIORAL-REAaiONS,
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE
ANIMAL BRAIN,
004075 04-04
ACTH-LIKE PEPTIDES. PITUITARY ADRENOCORTICAL FUNQION AND
AVOIDANCE-BEHAVIOR
004109 04-04
ADRENOCORTICOTROPIN
THE EFFECT OF NEUROPEPTIDE FRAGMENTS OF ADRENOCORTICOTROPIN
AND VASOPRESSIN ON BEHAVIORAL-ACTIVITY IN RATS.
001812 02-04
ADRENORECEPTOR
PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFEGS OF
GANGLIONIC AND ADRENORECEPTOR BLOCKADE.
002863 03-03
ADTN
(3H) 2 AMINODIHYDROXYTETRAHYDRONAPHTHALENE (ADTN):
REGIONAL DISTRIBUTION AND IN VIVO BINDING AFTER ACUTE AND
CHRONIC DRUG-TREATMENT
000052 01-03
SELECTIVE STORAGE IN VIVO OF 5,6 ADTN IN DOPAMINE RICH AREAS OF
THE RAT-BRAIN.
000324 01-03
HYPERACTIVITY FOLLOWING INJEQION OF A GLUTAMATE AGONIST AND
6,7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY
THIP.
004066 04-04
ADULT
PLASMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE.
000102 01-03
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS.
000509 01-05
DEXTROAMPHETAMINE: COGNITIVE AND BEHAVIORAL-EFFEaS IN
NORMAL AND HYPERACTIVE-BOYS AND NORMAL ADULT MALES.
00071601-11
NEONATAL ADMINISTRATION OF MET-ENKEPHALIN FACILITATES MAZE-
PERFORMANCE OF ADULT RATS,
001673 02-04
NEUROLEPTIC TREATMENT FOR A SUBSTANTIAL PROPORTION OF ADULT
LIFE: BEHAVIOURAL-SEQUELAE OF 9 MONTHS HALOPERIDOL
ADMINISTRATION
001858 02-05
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND
DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY
OF ADULT SENSORY GANGLION CELLS.
002692 03-03
EFFECTS OF FETAL TREATMENT WITH METHYLAZOXYMETHANOL-ACETATE
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE
ADULT NEOCORTEX OF THE RAT. „„„,„ „o ,x,
002770 03-03
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL-
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF
ANTIBODIES TO GANGLIOSIDE. ^ ^, ^^
003025 03-04
SUPPRESSION OF ACTIVE SLEEP BY CHRONIC-TREATMENT WITH
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT:
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT.
003056 03-04
BEHAVIOURAL-CHANGES IN ADULT RATS FOLLOWING ADMINISTRATION
OF ANTIBODIES AGAINST BRAIN GANGLIOSIDES.
003071 03-04
PSYCHOACTIVE-MEDICATION USE AND ABUSE AMONG AN ADULT RURAL
POPULATION. (PH.D. DISSERTATION) ^^^^^ ^^^^
THE EFFECTS OF P CHLOROAMPHETAMINE ADMINISTRATION ON
LOCOMOTOR-ACTIVITY AND SEROTONIN IN NEONATAL AND ADULT
RATS. (UNPUBLISHED PAPER). 004169 04-04
ADULT-ONSET
ADULT-ONSET STUHERING TREATED WITH ANTICONVULSANTS.
003290 03-11
ADULTS
EFFECTS OF METHYLPHENIDATE ON LEARNING A BEGINNING READING
VOCABULARY BY NORMAL ADULTS. 000812 01-14
EFFECT OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND
NORMAL ADULTS. 002222 02-13
S-8
/OLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE IN MENTALLY-RETARDED
ADULTS
002471 02-15
EPILEPSY IN ADULTS.
003375 03-11
THE MANAGEMENT OF CHRONIC BEHAVIOR-DISORDERS IN MENTALLY-
RETARDED ADULTS WITH LITHIUM-CARBONATE
003376 03-11
ATTENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNCTION) IN
ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG-
TREATMENT.
003389 03-1 1
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED
ADULTS,
003392 03-11
HYPERACTIVES AS YOUNG ADULTS: PROSPECTIVE TEN-YEAR FOLLOWUP.
004454 04-11
lOVANTAGE
ADVANTAGE OF PHARMACOKINETIC DATA DURING TREATMENT OF
PSYCHOSES WITH HALOPERIDOL.
000577 01-08
STUDY OF MAPROTILINE IN OUTPATIENT TREATMENT OF DEPRESSIVE-
STATES BY THE GENERAL-PRACTITIONER: ADVANTAGE OF SINGLE-
NIGHTLY-DOSE.
001961 02-09
ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT
AND POSHREATMENT OF ALCOHOLIC WITHDRAWAL.
002140 02-11
DVANTAGES
ADVANTAGES AND DISADVANTAGES OF PROLONGED USE OF
NEUROLEPTICS.
003470 03-15
DVERSE
CLINICAL-PHARMACOLOGY: ADVERSE DRUG INTERACTIONS.
003399 03-13
OVERSE-EFFECTS
PREVENTION OF TARDIVE-DYSKINESIA AND OTHER DRUG RELATED
ADVERSE-EFFECTS.
004601 04-15
ADVERSE-EFFECTS OF ANTIPARKINSON-DRUG WITHDRAWAL.
(UNPUBLISHED PAPER).
004623 04-15
DVERSE-REACTIONS
PSYCHOTHERAPEUTIC-DRUGS: IMPORTANT ADVERSE-REACTIONS AND
INTERACTIONS.
002383 02-15
ADVERSE-REAQIONS TO MEDICATIONS PRESCRIBED FOR HYPERKINESIS.
(PH.D. DISSERTATION).
002411 02-15
EP
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD
003412 03-13
FFECTIVE-DISORDER
INCREASED VULNERABILITY TO CHOLINERGIC STIMULATION IN
AFFECTIVE-DISORDER PATIENTS.
002003 02-09
MAOI-INDUCED RAPID CYCLING BIPOLAR AFFECTIVE-DISORDER IN AN
ADOLESCENT.
004637 04-15
FFECTIVE-DISORDERS
COGNITIVE AND AFFECTIVE-FUNCTIONS IN PATIENTS WITH AFFECTIVE-
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY
QUESTIONNAIRE.
000604 01-09
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS: THERAPEUTIC PLASMA
000635 01-09
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS FROM VIEWPOINT OF
TRANSCULTURAL PSYCHOPHARMACOLOGY: THERAPEUTIC PLASMA
000636 01-09
AMITRIPTYLINE, NORTRIPTYLINE PLASMA LEVELS AND CLINICAL-
RESPONSE IN WOMEN WITH AFFECTIVE-DISORDERS.
000757 01-13
RENAL FUNCTION IN LITHIUM AND NONLITHIUM TREATED PATIENTS
WITH AFFECTIVE-DISORDERS.
DISCUSSION OF CLINICAL-PAPERS ON LITHIUM TRANSPORT IN AFFECTIVE-
DISORDERS.
001987 02-09
LITHIUM TRANSPORT STUDIES IN AFFECTIVE-DISORDERS.
002024 02-09
ABNORMALITIES OF LITHIUM TRANSPORT IN PATIENTS WITH AFFECTIVE-
DISORDERS.
002269 02-13
THE ROLE OF NOREPINEPHRINE IN AFFECTIVE-DISORDERS.
002278 02-13
A TEST OF A NEUROTRANSMITTER MODEL OF THE AFFECTIVE-DISORDERS.
(PH.D. DISSERTATION).
003063 03-04
THE EFFECT OF SODIUM-VALPROATE ON MANIA: THE GABA HYPOTHESIS
OF AFFECTIVE-DISORDERS.
003218 03-09
PSYCHOTROPIC-DRUGS AND THEIR RELATIONSHIP WITH
PSYCHOPATHOLOGY OF AFFECTIVE-DISORDERS.
004361 04-09
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFECTIVE-DISORDERS
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDICTORS TO
CLINICAL-RESPONSE).
004365 04-09
LITHIUM USE IN AFFECTIVE-DISORDERS.
004367 04-09
EFFECT OF LITHIUM ON GLYCINE LEVELS IN PATIENTS WITH AFFECTIVE-
DISORDERS.
004606 04-15
KIDNEY FUNCTION IN PATIENTS WITH AFFECTIVE-DISORDERS WITH AND
WITHOUT LITHIUM THERAPY.
004664 04-15
AFFECTIVE-EPISODE
AFFECTIVE-EPISODE FREQUENCY AND LITHIUM THERAPY.
000587 01-09
AFFECTIVE-FUNCTIONS
COGNITIVE AND AFFECTIVE-FUNCTIONS IN PATIENTS WITH AFFECTIVE-
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY
QUESTIONNAIRE.
000604 01-09
AFFECTIVE-ILLNESS
ANTIDEPRESSANT POTENTIATION OF 5 HYDROXYTRYPTOPHAN BY L
DEPRENIL IN AFFECTIVE-ILLNESS.
000608 01-09
AMPHETAMINE AND PIRIBEDIL IN AFFECTIVE-ILLNESS.
000618 01-09
SENSITIZATION AND OSCILLATION FOLLOWING REPEATED STIMULATION-
RELATIONSHIP TO AFFECTIVE-ILLNESS AND ITS TREATMENT WITH
LITHIUM AND CARBAMAZEPINE.
002031 02-09
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY
AFFECTIVE-ILLNESS
002506 02-16
BIOLOGICAL-RHYTHM DISTURBANCES IN AFFECTIVE-ILLNESS.
002628 02-17
THYROTROPHIN RESPONSE TO THYROTROPHIN-RELEASING-HORMONE IN
UNIPOLAR AND BIPOLAR AFFECTIVE-ILLNESS.
003237 03-09
UNWANTED EFFECTS OF LITHIUM-CARBONATE USED IN THE PREVENTION
OF RELAPSES OF AFFECTIVE-ILLNESS.
004625 04-15
AFFECTIVE-PSYCHOSES
COMPARATIVE CHARACTERISTICS OF THE PROPHYLACTIC PROPERTIES OF
SHORT-TERM AND LONG-ACTING LITHIUM-CARBONATE PREPARATIONS
IN ENDOGENOUS AFFECTIVE-PSYCHOSES.
004390 04-09
AFFECTIVE-PSYCHOSIS
BIPOLAR AFFECTIVE-PSYCHOSIS WITH ONSET BEFORE AGE 16 YEARS:
REPORT OF 10 CASES.
002001 02-09
AN ATTEMPT TO ASSESS THE EFFECT OF LITHIUM ON THE NEUTROPHIL
LEUKOCYTE SYSTEM IN AFFECTIVE-PSYCHOSIS.
004416 04-09
AFFERENT
CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC-
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE
(GABA-TRANSAMINASE) INHIBITOR.
000174 01-03
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER)
001024 02-01
AFFERENTS
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
NALOXONE EFFECTS ON THE BLOOD-PRESSURE RESPONSE INDUCED BY
THIN-FIBER MUSCULAR AFFERENTS.
002794 03-03
i
f
S-9
Subject Index
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS:
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE.
003778 04-03
AFFINITIES
THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND
DOPAMINE ANTAGONIST RECEPTOR SITES.
001254 02-03
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR
BRAIN SPECIFIC BENZODIAZEPINE BINDING.
002903 03-03
AFFINITY
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
^''''''^' 000323 01-03
AFFINITY CHROMATOGRAPHY OF THE BETA-ADRENERGIC-RECEPTOR AND
CHARACTERIZATION OF ANTIBODIES RAISED AGAINST PURIFIED
RECEPTOR PREPARATIONS.
001009 02-01
NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR
CENTRAL ALPHA 1 -ADRENOCEPTORS.
001508 02-03
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS,
001516 02-03
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES.
001554 02-03
RELATIONSHIPS BETWEEN STRUCTURE AND ALPHA-ADRENERGIC-
RECEPTOR AFFINITY OF CLONIDINE AND AND SOME RELATED CYCLIC-
AMIDINES.
002698 03-03
PENTOBARBITAL: DUAL-ACTIONS TO INCREASE BRAIN BENZODIAZEPINE-
RECEPTOR AFFINITY. ^^^^^^ ^^ ^,
002896 03-03
EFFECT OF THE POSITION OF THE PHENOLIC GROUP IN MORPHINANS ON
THEIR AFFINITY FOR OPIATE-RECEPTOR BINDING.
003702 04-02
AFTERCARE
DOUBLE-BLIND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH
AFTERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS
WITH SCHIZOPHRENIA. „ „„
000574 01-08
FOLLOWUP TREATMENT AND AFTERCARE OF DISCHARGED
SCHIZOPHRENIC-PATIENTS.
000944 01-17
AFTERDISCHARGE
FLASH-EVOKED AFTERDISCHARGE IN RAT AS A MODEL OF THE ABSENCE
SEIZURE: DOSE-RESPONSE STUDIES WITH THERAPEUTIC DRUGS
000160 01-03
THE ROLE OF BIOGENIC-AMINES IN AMYGDALAR KINDLING. I. LOCAL
AMYGDALAR AFTERDISCHARGE.
000327 01-03
RELATION OF MONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION
IN CATS.
000474 01-04
A STUDY ON EFFECTS OF ANTIEPILEPTIC-DRUGS UPON THE HIPPOCAMPAL
AFTERDISCHARGE.
002844 03-03
CUMULATIVE AFTERDISCHARGE AS THE PRINCIPAL FAQOR IN THE
ACQUISITION OF KINDLED SEIZURES.
002862 03-03
POWER SPECTRAL ANALYSIS OF THE FLASH-EVOKED AFTERDISCHARGE.
003133 03-06
AFTERDISCHARGES
INFLUENCE OF CARBAMAZEPINE ON THALAMOCORTICAL AND
HIPPOCAMPOCORTICAL SELF-SUSTAINED AFTERDISCHARGES IN RATS.
001356 02-03
THE EFFECT OF ELECTRICAL-STIMULATION OF THE LOCUS-COERULEUS AND
INTRAPERITONEAL INJECTION OF CERTAIN PHARMACOLOGICAL
SUBSTANCES ON THE THRESHOLD OF HIPPOCAMPAL
AFTERDISCHARGES.
003885 04-03
AFTEREFFECTS
PERSONALITY AND DRUGS IN VISUAL FIGURAL AFTEREFFECTS.
004581 04-14
AG-3-5
PHARMACOLOGICAL-ASPECTS OF SHAKING-BEHAVIOR PRODUCED BY
TRH, AG-3-5, AND MORPHINE WITHDRAWAL.
004248 04-04
AGE
AGE, DEMENTIA, DYSKINESIAS, AND LITHIUM RESPONSE.
000594 01-09
EFFECTS OF AGE AND OTHER DRUGS ON BENZODIAZEPINE KINETICS.
000681 01-11
EFFECT OF AGE AND ROUTE-OF-ADMINISTRATION ON LD50 OF LITHIUAA-
CHLORIDE IN THE RAT.
001413 02-03
Ptychopharmacology Abstracts
BIPOLAR AFFEaiVE-PSYCHOSIS WITH ONSET BEFORE AGE 16 YEARS:
REPORT OF 10 CASES. '
002001 02-09
OPEN-STUDY OF L 5 HTP IN MELANCHOLIC-DEPRESSED-PATIENTS OVER
50 YEARS OF AGE.
002016 02-09
SPECIFIC 3H IMIPRAMINE BINDING IN HUMAN PLATELETS: INFLUENCE OF
AGE AND SEX.
002254 02-13
CHANGES IN PREVALENCE, SEVERITY, AND RECOVERY IN TARDIVE-
DYSKINESIA WITH AGE.
002455 02-15
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF
DISCRETE RAT-BRAIN NUCLEI.
002635 03-01
MIND/BRAIN IN THE AGE OF PSYCHOPHARMACOLOGY: A CROSSROADS
FOR MEDICINE AND MINISTRY.
003624 03-17
PIRACETAM ACTIVITY MAY DIFFER ACCORDING TO THE AGE OF THE
RECIPIENT MOUSE.
003705 04-02
EFFECTS OF AGE ON DOPAMINERGIC-SUPERSENSITIVITY INDUCED BY
CHRONIC FLUPHENAZINE.
003940 04-03
EFFECTS OF ANIMAL AGE AND PHENOBARBITAL ON RAT LIVER GLUCOSE-
6-PHOSPHATASE ACTIVITY
003997 04-03
EFFECTS OF ANISOMYCIN ON RETENTION OF THE PASSIVE-AVOIDANCE
HABIT AS A FUNQION OF AGE.
004097 04-04
AGE-DEPENDENT
AGE-DEPENDENT MODIFICATION OF DRUG INTERFERENCE ON THE
ENZYMATIC ACTIVITIES OF THE RAT-BRAIN.
003730 04-03
AGE-RELATED
AGE-RELATED ELECTROPHYSIOLOGICAL CHANGES IN RAT-CEREBELLUM.
000197 01-03
AGE-RELATED CHANGES IN BODY-TEMPERATURE RESPONSES TO
MORPHINE IN RATS.
001366 02-03
AGE-RELATED FAQORS AFFEQING ANTIDEPRESSANT-DRUG METABOLISM
AND CLINICAL-RESPONSE.
002035 02-09
CLINICAL PHARMACOKINETICS IN NEWBORNS AND INFANTS: AGE-
RELATED DIFFERENCES AND THERAPEUTIC IMPLICATIONS
003343 03-1 1
PHARMACOTHERAPY FOR AGE-RELATED BEHAVIORAL-DEFICIENCIES.
003391 03-11
AGE-SPECIFIC
AGE-SPECIFIC DOSES OF LORMETAZEPAM AS A NIGHT SEDATIVE IN
CASES OF CHRONIC SLEEP-DISTURBANCE
004309 04-07
AGED
ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE
AND DESMETHYLIMIPRAMINE.
00011301-03
DRUGS AND THE AGED.
002593 02-17
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL
HEMISPHERES OF AGED MALE RATS.
003936 04-03
PSYCHOPHARMACOTHERAPY OF SEXUAL-DISORDERS IN THE AGED.
004466 04-11
AN OVERVIEW OF PHARMACOLOGIC-TREATMENT OF COGNITIVE DECLINE
IN THE AGED.
004482 04-11
PSYCHOPHARMACOLOGY FOR THE AGED.
004701 04-17
AGENT
ADRENALINE: A SECRET AGENT IN MEMORY.
002345 02-14
AGES
MORPHINE TREATMENT AT DIFFERENT INFANT AGES: INFLUENCE ON
LATER MORPHINE EFFECTS IN RATS. (PH.D. DISSERTATION).
000511 01-05
AGGRAVATED
A CASE OF PETIT-MAL EPILEPSY AGGRAVATED BY LITHIUM.
004641 04-15
AGGREGATED
POSSIBLE MECHANISM FOR THE ENHANCED LETHALITY OF MORPHINE IN
AGGREGATED MICE.
000437 01-04
AGGREGATES
EFFEQS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA-
ADRENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES.
002932 03-03
S-10
I
mssmi^^^Mmm
VOLUME 19, SUBJECT INDEX
Subject Index
AGGREGATION
PLATELET AGGREGATION, 5 HYDROXYTRYPTAMINE UPTAKE AND
RELEASE IN HUNTINGTONS-CHOREA.
002112 02-11
CANALIZATION OF AROUSAL IN THE PREWEANLING RAT; EFFECTS OF
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI.
002965 03-04
SELECTIVE INHIBITORY-EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE
ON PLATELET AGGREGATION.
004518 04-13
AGGRESSION
ALCOHOL AND CHLORDIAZEPOXIDE INCREASE SUPPRESSED AGGRESSION
IN MICE.
000434 01-04
PSYCHOPHARMACOLOGY OF AGGRESSION.
000721 01-11
PSYCHOPHARMACOLOGY OF AGGRESSION.
000995 01-17
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
NALOXONE PRETREATMENT ENHANCES SHOCK-ELICITED AGGRESSION.
001615 02-04
AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE
ANALYSIS OF APOMORPHINE-INDUCED-FIGHTING AND STEREOTYPY IN
THE RAT.
002983 03-04
DRUG REGIMENS FACILITATING AGGRESSION: BEHAVIOR, AMINE, AND
RECEPTOR ALTERATIONS.
002987 03-04
AGGRESSION ALTERING EFFECTS OF CYCLIC-AMP.
003021 03-04
LITHIUM AND PORCINE AGGRESSION.
003048 03-04
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION.
003052 03-04
FACILITATED SHOCK-INDUCED AGGRESSION AFTER CHRONIC-TREATMENT
WITH ANTIDEPRESSANT-DRUGS IN THE RAT.
003058 03-04
FAILURE TO FIND SEX-DIFFERENCES IN TESTOSTERONE ACTIVATED
AGGRESSION IN TWO STRAINS OF RATS.
003107 03-04
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION.
003140 03-06
ERGOT DRUGS SUPPRESS PLASMA PROLACTIN AND LACTATION BUT NOT
AGGRESSION IN PARTURIENT MICE.
003159 03-07
PRENATAL EXPOSURE TO SYNTHETIC PROGESTINS INCREASES POTENTIAL
FOR AGGRESSION IN HUMANS.
003527 03-15
ACETYLCHOLINE TURNOVER AND AGGRESSION IN RELATED THREE
STRAINS OF MICE.
AGGRESSIVE ""'''' ''-''
BICUCULLINE ANTAGONIZES EFFECTS OF DIAZEPAM ON AGGRESSIVE AND
TIMID-BEHAVIOUR IN MICE.
000485 01-04
COMPARISON OF SCH-12679 AND THIORIDAZINE IN AGGRESSIVE
MENTAL-RETARDATES.
002119 02-11
LITHIUM THERAPY IN AGGRESSIVE MENTALLY-SUBNORMAL-PATIENTS.
MOLINDONE-HYDROCHLORIDE IN THE TREATMENT OF AGGRESSIVE
HOSPITALIZED CHILDREN.
003321 03-1 1
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE, HOSPITALIZED SCHOOL-AGE CHILDREN.
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN.
POSSIBLE MUSCARINIC CHOLINERGIC MEDIATION OF PATTERNED
AGGRESSIVE REFLEXES IN THE CAT.
AGGRESSIVE-BEHAVIOR 004153 04-04
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE-
BEHAVIOR: INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON
THREE EXPERIMENTAL MODELS.
EFFECTS OF SODIUM-DIPROPYLACETATE, MUSCIMOL-HYDROBROMIDE
AND (R,S) NIPECOTIC-ACID-AMIDE ON ISOLATION-INDUCED
AGGRESSIVE-BEHAVIOR IN MICE.
INHIBITION OF AGGRESSIVE-BEHAVIOR IN RHESUS-MONKEYS BY '°''
BUSPIRONE.
003103 03-04
AGGRESSIVE-BEHAVIOR INDUCED BY APOMORPHINE IN RATS SUBMinED
TO FOUR STRESSFUL-SITUATIONS,
003163 03-07
LITHIUM AND AGGRESSIVE-BEHAVIOR.
004409 04-09
AGGRESSIVE-BEHAVIOUR
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMUUNTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
AGGRESSIVE-BEHAVIOURAL-PHENOMENA
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA
ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF
CONSCIOUS CATS.
001569 02-04
AGGRESSIVE-PATIENT
ACUTE MANAGEMENT OF THE VIOLENT AGGRESSIVE-PATIENT.
000586 01-09
AGING
SERUM PROLACTIN DURING AGING AND THE EFFECTS OF ERGOTS.
001171 02-03
BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE-
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL-
CONSIDERATIONS.
001550 02-03
PSYCHOPHARMACOLOGY OF THE AGING.
002142 02-11
NEUROPSYCHIATRIC SIDE-EFFECTS OF DRUGS IN THE ELDERLY. VOL 9
AGING.
002573 02-17
THE PSYCHOBIOLOGY OF AGING.
003861 04-03
MEMORY, OPIATE-RECEPTORS, AND AGING.
004143 04-04
PSYCHOPHARMACOLOGY OF AGING.
004710 04-17
AGITATED
TREATMENT OF TARDIVE-DYSKINESIA IN AN AGITATED DEPRESSED-
PATIENT.
002038 02-09
AGITATION
AGITATION, DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON
CIMETIDINE: A REPORT OF THREE CASES AND LITERATURE REVIEW.
000896 01-15
AGONIST
CLENBUTEROL, A CENTRAL BETA-ADRENOCEPTOR AGONIST.
000120 01-03
DIFFERENTIAL REGULATION OF MUSCARINIC AGONIST BINDING-SITES
FOLLOWING CHRONIC CHOLINESTERASE INHIBITION.
000279 01-03
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF
AlO DOPAMINERGIC NEURONS.
000320 01-03
TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC-
DISCHARGE IN HUMANS BY APOMORPHINE, A DOPAMINE-RECEPTOR
AGONIST.
000714 01-11
EFFECT OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED
EXTRAPYRAMIDAL ALTERATIONS.
001119 02-03
EFFECT OF GABA AGONIST AND ANTAGONISTS ON CARDIOVASCULAR
AND SYMPATHETIC RESPONSES IN SHR AND WKY RATS.
(UNPUBLISHED PAPER).
001224 02-03
THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND
DOPAMINE ANTAGONIST RECEPTOR SITES.
001254 02-03
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES.
001342 02-03
BENZODIAZEPINES MODIFY THE AGONIST RESPONSES AT A PRESYNAPTIC
GABA-RECEPTOR.
001377 02-03
SOME CENTRAL-EFFECTS OF IMPROMIDINE, A POTENT AGONIST OF
HISTAMINE H2-RECEPT0RS.
001417 02-03
ACTIONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON
ACETYLCHOLINE TURNOVER IN RAT-BRAIN.
001541 02-03
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT.
001657 02-04
1?
it
S-11
Subject Index
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST,
CHLORNALTREXAMINE. 001695 02-04
PHENCYCLIDINE AS AN INDIRECT DOPAMINE AGONIST.
001719 02-04
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A
SELECTIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST.
002236 02-13
PERGOLIDE A POTENT LONG-ACTING DOPAMINE-RECEPTOR AGONIST.
002257 02-13
DOPAMINE ANTAGONIST AND AGONIST TREATMENT OF TARDIVE-
■^^^^'^^^'^ 002377 02-15
PIPERIDINE-4-SULPHONIC-ACID, A NEW SPECIFIC GABA AGONIST.
002647 03-02
EFFECT OF KAINIC-ACID LESIONS ON MUSCARINIC AGONIST RECEPTOR
SUBTYPES IN RAT STRIATUM. 002679 03-03
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE
AGONIST AND ANTAGONIST RECEPTOR INTERACTIONS.
002688 03-03
CHRONOLOGY OF NEUROCHEMICAL ALTERATIONS INDUCED BY GABA
AGONIST ADMINISTRATION. 002713 03-03
PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN
MAMMALIAN RETINA. 002814 03-03
THE NEUROLATHYROGEN, BETA N OXALYL-L-ALPHA-BETA-
DIAMINOPROPIONIC-ACID, IS A POTENT AGONIST AT GLUTAMATE
PREFERRING RECEPTORS IN THE FROG SPINAL-CORD.
002858 03-03
DOPAMINERGIC AGONIST AND ANTAGONIST EFFECTS ON STRIATAL
TYROSINE-HYDROXYLASE DISTRIBUTION. „„.„„„ „, „,
002898 03-03
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF LOW-DOSES OF A
DOPAMINE AGONIST ON DRINKING AND LOCOMOTOR-ACTIVITY IN THE
RAT
002982 03-04
CLINICAL-PHARMACOLOGY OF MIXED AGONIST ANTAGONIST DRUGS.
003329 03-1 1
MORPHICEPTIN (NH4-TYR-PR0-PHE-PR0-C0NH2). A POTENT AND
SPECIFIC AGONIST FOR MORPHINE MU-RECEPTORS.
003746 04-03
RESPONSE OF STRIATONIGRAL SUBSTANCE-P SYSTEMS TO A DOPAMINE-
RECEPTOR AGONIST AND ANTAGONIST.
003826 04-03
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA-
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL
^^'"^^^- 003879 04-03
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID-
RECEPTOR AGONIST, TO MEMBRANES OF THE BOVINE RETINA
003954 04-03
AaiONS OF MU KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION
004053 04-03
HYPERACTIVITY FOLLOWING INJEQION OF A GLUTAMATE AGONIST AND
6,7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY
THIP
004066 04-04
PHARMACOLOGICAL-STUDIES WITH AN ALKYLATING NARCOTIC
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST,
CHLORNALTREXAMINE „„„„.„.„.
004082 04-04
AGONIST-INDUCED
AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT-
CEREBRAL-CORTEX. ^„,„ „, „„
000072 01-03
AGONIST-MEDIATED
SPINAL-CORD PHARMACOLOGY OF ADRENERGIC AGONIST-MEDIATED
ANTINOCICEPTION. „ „^ „^
004206 04-04
AGONISTIC-BEHAVIOUR
EFFECTS OF SCOPOLAMINE ON AGONISTIC-BEHAVIOUR IN MICE.
001690 02-04
EFFECT OF PIRACETAM ON AGONISTIC-BEHAVIOUR IN MICE.
001796 02-04
AGONISTS
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING. „„„„„„ „, „o
000099 01-03
COMPARTMENT ATION OF CATECHOLAMINES IN RAT-BRAIN: EFFECTS OF
AGONISTS AND ANTAGONISTS. 000125 01-03
Ptychopharmacology Abstracts
REDUaiON IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS.
000258 01-03
EFFECTS OF NORADRENERGIC AGONISTS AND ANTAGONISTS ON
GROWTH-HORMONE SECRETION UNDER GAMMA HYDROXYBUTYRATE
NARCOANALGESIA IN THE RAT.
000262 01-03
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-AQIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
'''''"' 000309 01-03
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
'''''''''' 000323 01-03
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFECTS ON
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE
PARADIGM „„„^,^„, „.
000372 01-04
AHEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED
SPINAL FEMALE RATS WITH MONOAMINE AGONISTS.
000421 01-04
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS
AND ANTAGONISTS: ZONE-SPECIFIC EFFEaS.
000422 01-04
PSYCHIATRIC MANIFESTATIONS INDUCED BY DOPAMINE PRECURSORS OR
DOPAMINE AGONISTS.
000865 01-15
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS. (UNPUBLISHED
^"^^^^ 001035 02-01
GABA AGONISTS AND UPTAKE INHIBITORS DESIGNED AS AGENTS WITH
IRREVERSIBLE AQIONS ,„ „o «n
001079 02-02
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON
BETWEEN DEPRESSION OF SPINAL SYNAPTIC AQIVITY AND
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT
001104 02-03
INTRACELLULAR OBSERVATIONS ON THE EFFEQS OF MUSCARINIC
AGONISTS ON RAT SYMPATHETIC NEURONES.
001143 02-03
EFFEQS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS. 001146 02-03
A PROPOSED MODE OF AQION FOR NARCOTIC AGONISTS AND
^^'^^^^^^'^ 001168 02-03'
DOPAMINERGIC-SUPERSENSITIVITY: INFLUENCE OF DOPAMINE AGONISTS
AND DRUGS USED FOR THE TREATMENT OF TARDIVE-DYSKINESIA
001169 02-03
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN
IN VIVO EFFEa OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS,
AND BENZODIAZEPINES. 001303 02-03
AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL
DOPAMINE-RECEPTORS ARER VARIOUS TREATMENTS WITH
ANTAGONISTS OR AGONISTS. 001350 02-03
PRESYNAPTIC AND POSTSYNAPTIC MECHANISMS IN HALOPERIDOL-
INDUCED SENSITIZATION TO DOPAMINERGIC AGONISTS.
DECREASE IN (3H) SEROTONIN BINDING IN RAT-BRAIN PRODUCED BY THE
REPEATED ADMINISTRATION OF EITHER MONOAMINE-OXIDASE-
INHIBITORS ON CENTRALLY-AQING SEROTONIN AGONISTS^ , , „o n,
001463 02-03
GABA AGONISTS DISSOCIATE STRIATAL UNIT AQIVITY FROM DRUG-
INDUCED STEREOTYPED-BEHAVIOUR. ^^^^^ ^^^
DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFEQS ON OPERANT-
BEHAVIOR BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL-
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS.
CIRCLING PRODUCED BY SEROTONIN AND DOPAMINE AGONISTS IN
RAPHE LESIONED RATS: A SEROTONIN MODEL. ^^^^^ ^^^
EFFEQS OF INTRAPALLIDAL OPIATE-RECEPTOR AGONISTS ON
STRIATALLY-EVOKED HEAD-TURNING. ^^^^^ ^^^
BEHAVIORAL-EFFECTS OF DOPAMINE AGONISTS ACROSS THE ESTROUS-
CYCLEINRATS. 001792 02^
DISCRIMINATIVE-STIMULUS EFFEQS OF PROTOTYPE OPIATE-RECEPTOR
AGONISTS IN MONKEYS 001803 02-(W
S-12
1
OLUME 19, SUBJECT INDEX
Subject Index
COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT.
001841 02-05
THE ROLE OF DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC AGONISTS
IN CHLORPROMAZINE-INOUCEO HYPOTENSION.
001851 02-05
ANTIPSYCHOTIC-PROPERTIES AND ANTIDYSKINETIC-PROPERTIES OF
ERGOT DOPAMINE AGONISTS.
002178 02-11
DOPA AND DOPAMINE AGONISTS IN DEPRESSION.
002310 02-13
TARDIVE-HYPERKINESIA. EFFECTS OF SULPIRIDE AND GABA SYSTEM
AGONISTS.
002405 02-15
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL-
EFFEQS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D-
AMPHETAMINE AND APOMORPHINE.
002484 02-16
HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE
CAUDATE-NUCLEUS BY GABA AGONISTS.
002640 03-01
EFFECTS OF ELECTROCONVULSIVE-TREATMENT ON GROWTH-HORMONE
SECRETION INDUCED BY MONOAMINE-RECEPTOR AGONISTS IN
RESERPINE PRETREATED RATS.
002664 03-03
A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC
AGONISTS: CHARACTERISTICS.
002670 03-03
GABA-AUTORECEPTORS: STRUCTURE-ACTIVITY RELATIONSHIPS FOR
AGONISTS.
002678 03-03
GABA AGONISTS AS ANTIEPILEPTIC-AGENTS.
002826 03-03
ESTROGEN POTENTIATES THE STEREOTYPY INDUCED BY DOPAMINE
AGONISTS IN THE RAT.
002968 03-04
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NICTITATING MEMBRANE OF THE CAT.
003822 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE-
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA,
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS.
004051 04-03
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT
KIDNEY.
004054 04-03
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
004112 04-04
INTERAQIONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
004127 04-04
DOPAMINERGIC AGONISTS DIFFERENTIALLY AFFECT OPEN-FIELD ACTIVITY
OF RATS WITH AlO LESIONS.
004135 04-04
MINI-SYMPOSIUM: III. SIMPLE IN VIVO TESTS THAT DIFFERENTIATE
PROTOTYPE AGONISTS AT OPIATE-RECEPTORS.
004289 04-06
SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS: DESIGN,
DEVELOPMENT AND STRUCTURE-ACTIVITY STUDIES.
004725 04-17
iRANULOCYTOSIS
MIANSERIN: A POSSIBLE CAUSE OF NEUTROPENIA AND
AGRANULOCYTOSIS.
003517 03-15
A CASE OF ACUTE AGRANULOCYTOSIS DURING TREATMENT WITH
CLOZAPINE.
004642 04-15
MS
LONG-TERM CHANGES IN AIMS RATINGS AND THEIR RELATION TO
MEDICATION HISTORY.
003537 03-15
RCRAFT
AIRCRAFT NOISE AND MENTAL-HEALTH: II. USE OF MEDICINES AND
HEALTH-CARE-SERVtCES.
003647 03-17
CINESIA
IMPORTANCE OF AKINESIA: PLASMA CHLORPROMAZINE AND PROLACTIN
LEVELS.
000891 01-15
PARADOXICAL AKINESIA INDUCED BY ANTIDEPRESSANT-DRUGS
002378 02-15
AKINETON
A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED
PARKINSONISM.
002146 02-11
ALANINE
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES.
001402 02-03
MODULATORY INTERACTIONS BETWEEN NOREPINEPHRINE AND TAURINE,
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS.
004058 04-03
ALA2-MET-ENKEPHALINAMIDE
SELF-ADMINISTRATION OF D ALA2-MET-ENKEPHALINAMIDE AT
HYPOTHALAMIC SELF-STIMULATION SITES.
001738 02-04
ALA2-METHIONINE-ENKEPHALIN
DIFFERENCE IN THE DEVELOPMENT OF TOLERANCE TO MORPHINE AND D
ALA2-METHI0NINE-ENKEPHALIN IN C57 BL/6J AND DBA/2J MICE.
003126 03-05
ALA2-METHIONINE-ENKEPHALINAMIDE
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL-TOLERANCE TO AND
CROSS-TOLERANCE BETWEEN D ALA2-METHI0NINE-ENKEPHALINAMIDE
AND MORPHINE IN THE RAT.
004038 04-03
ALA2-MET5-ENKEPHALINAMIDE-INDUCED
NALOXONE REVERSIBLE EFFECTS OF D ALA2-MET5-ENKEPHALINAMIDE-
INDUCED BEHAVIORAL-ACTIVITY IN RATS.
000402 01-04
ALBINO
THE ALBINO LOCUS PRODUCES ABNORMAL RESPONSES TO OPIATES IN
THE MOUSE.
001675 02-04
ALBINO-RATS
INFERENCES DERIVED FROM ELECTROENCEPHALOGRAPHIC RESPONSES TO
ACUTE ADMINISTRATION OF CLOMIPHENE-CITRATE IN MALE ALBINO-
RATS.
000155 01-03
ALBUMIN
EFFECTS OF LEAD ON MOVEMENT OF ALBUMIN INTO BRAIN.
000076 01-03
ALBUMIN BINDING INTERACTIONS OF SODIUM-VALPROATE.
000762 01-13
THE CONTRIBUTION OF ALPHA 1 ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
EFFECTS OF ALBUMIN, AMINO-ACIDS, AND CLOFIBRATE ON THE UPTAKE
OF TRYPTOPHAN BY THE RAT-BRAIN.
002673 03-03
ALCOHOL
ALCOHOL AND CHLORDIAZEPOXIDE INCREASE SUPPRESSED AGGRESSION
IN MICE.
000434 01-04
IN UTERO ALCOHOL HEIGHTENS JUVENILE REACTIVITY.
000510 01-05
PHARMACOPSYCHOLOGICAL INVESTIGATION OF CHANGES IN MOOD
INDUCED BY DIPOTASSIUM-CHLORAZEPATE WITH AND WITHOUT
SIMULTANEOUS ALCOHOL ADMINISTRATION.
000825 01-14
INFLUENCE OF CHRONIC ALCOHOL INTOXICATION ON CIRCADIAN-RHYTHM
OF NEUROSECRETORY CENTERS OF RAT HYPOTHALAMUS.
001549 02-03
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT.
001580 02-04
ACTION OF TOFISOPAM ON THE ERGONOMIC VIGILANCE LEVEL. ITS
INTERACTION WITH THE EFFECTS OF ALCOHOL. CLINICAL
PHARMACOLOGICAL-STUDY .
001891 02-07
SODIUM-VALPROATE IN THE TREATMENT OF ALCOHOL WITHDRAWAL-
SYNDROME.
002)39 02-11
USE OF INJECTABLE LORAZEPAM IN ALCOHOL WITHDRAWAL.
002176 02-11
THE EFFECTS OF ALCOHOL AND CAFFEINE ON CONCENTRATION TEST
PERFORMANCE.
002337 02-14
ALCOHOL WITHDRAWAL-SYNDROME: TREATMENT WITH TRAZODONE.
002356 02-14
EFFECTS OF LITHIUM, AND LITHIUM AND ALCOHOL ADMINISTRATION ON
NA-K-ATPASE.
002744 03-03
COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION
IN THE RAT MODEL.
002928 03-03
it
S-13
Subject Index
Psychopharmacoiogy Abstracts
PINEAL-GLAND AND MELATONIN INFLUENCE ON CHRONIC ALCOHOL
CONSUMPTION BY HAMSTERS.
003076 03-04
ALCOHOL WITHDRAWAL USING TIAPRIDE: QUANTITATIVE
PSYCHOPATHOLOGY.
003293 03-11
DOUBLE-BUND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR
SUBCHRONIC WITHDRAWAL FROM ALCOHOL.
003332 03-11
SMOOTH-PURSUIT EYE-MOVEMENTS: EFFECTS OF ALCOHOL AND
CHLORAL-HYDRATE.
003448 03-14
INTERACTIONS BETWEEN ALCOHOL AND MEDICATIONS.
003629 03-17
SUPPRESSION OF ALCOHOL DRINKING WITH BRAIN ALDEHYDE-
DEHYDROGENASE INHIBITION.
004220 04-04
MEMORY: THE EFFECTS OF ALCOHOL AND OF MARIHUANA.
004570 04-14
DRUGS, ALCOHOL AND SEX.
004706 04-17
ALCOHOL-DEHYDROGENASE
INHIBITION OF ALCOHOL-DEHYDROGENASE BY DISULFIRAM, POSSIBLE
RELATION TO THE DISULFIRAM ETHANOL REACTION.
000270 01-03
ALCOHOLIC
ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT
AND POSHREATMENT OF ALCOHOLIC WITHDRAWAL.
002140 02-11
TRIAL OF A PEPTIDE FRACTION OF ACTH (ACTH4-10) IN THE ALCOHOLIC
BRAIN-DAMAGE-SYNDROME.
002318 02-14
CLINICAL PHARMACOKINETICS OF CHLORDIAZEPOXIDE IN PATIENTS WITH
ALCOHOLIC HEPATITIS.
004473 04-1 1
DISULFIRAM AND NOCTURNAL PENILE-TUMESCENCE IN THE CHRONIC
ALCOHOLIC.
004556 04-13
TRICYCLIC-ANTIDEPRESSANTS AND ALCOHOLIC BLACKOUTS.
004617 04-15
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS.
004658 04-15
ALCOHOLIC-DELIRIUM
CHOICE OF TACTICS IN TREATING ALCOHOLIC-DELIRIUM.
000688 01-11
ALCOHOLIC-PATIENTS
SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN
DETOXIFYING ALCOHOLIC-PATIENTS.
004671 04-16
ALCOHOLICS
CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL-
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY.
002095 02-1 1
SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN
PRAZEPAM TREATMENT IN 30 CASES.
003296 03-11
ALCOHOLISM
TOFIZOPAM IN THE TREATMENT OF CHRONIC ALCOHOLISM.
000706 01-11
POSSIBILITIES OF INFLUENCE ON THE ORGANIC-PSYCHOSYNDROME WITH
NOOTROPIC-DRUGS IN CHRONIC ALCOHOLISM.
000707 01-11
A POSSIBLE ECOPHARMACOGENETIC MODEL IN
NEUROPSYCHOPHARMACOLOGY ASPECTS IN ALCOHOLISM AND
PHARMACODEPENDENCE.
002596 02-17
ACTION ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS
OF TREATING ALCOHOLISM AND DRUG ADDiaiON
PATHOGENETICALLY.
003641 03-17
ALDEHYDE-OEHYDROGENASE
SUPPRESSION OF ALCOHOL DRINKING WITH BRAIN ALDEHYDE-
DEHYDROGENASE INHIBITION.
004220 04-04
ALDOSTERONE
RENIN AND ALDOSTERONE SECRETIONS DURING HYPOVOLEMIA IN RATS:
RELATION TO NACL INTAKE.
000484 01-04
ALERTING
CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL
ALERTING.
002997 03-04
ALEXIA
REVERSIBLE ALEXIA, MITOCHONDRIAL MYOPATHY, AND LACTIC-
ACIDEMIA.
000723 01-11
ALGORITHMS
PHENCYCLIDINE (PCP) INTOXICATION: DIAGNOSIS IN STAGES AND
ALGORITHMS OF TREATMENT.
003525 03-15
ALIMENTARY
INTRAHYPOTHALAMIC MICROINJECTIONS OF NORADRENALINE WITH AND
WITHOUT INDUCTION OF THE ALIMENTARY DRIVE AS A REWARD IN A
T-MAZE LEARNING IN RATS.
001604 02-04
THE EFFEaS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY
REACTIONS IN DOGS.
003030 03-04
INHIBITION OF MONOAMINE-OXIDASE BY FURAZOLIDONE IN THE
CHICKEN AND THE INFLUENCE OF THE ALIMENTARY FLORA THEREON.
003711 04-03
ALIVAL
COOPERATIVE PSYCHIATRIC-STUDY OF ALIVAL: PRELIMINARY RESULTS.
002045 02-09
ALIVAL: NEW CLINICAL APPLICATIONS, STUDIES IN PROGRESS, AND NEW
POSSIBILITIES.
002530 02-17
ALIVALS
ROUNDTABLE DISCUSSION: ALIVALS PLACE IN PSYCHIATRIC-PRAQICE.
002585 02-17
ALKALOID
HYPERTHERMIC-RESPONSE TO (-) CATHINONE, AN ALKALOID OF CATHA-
EDULIS (KHAT).
003694 04-02
SINGLE-CASE STUDY OF CLINICAL-RESPONSE TO HIGH-DOSE ERGOT
ALKALOID TREATMENT FOR DEMENTIA. PRELIMINARY REPORT.
004493 04-1 1
ALKALOIDS
SELECTIVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS.
001447 02-03
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS.
001516 02-03
DESIGN ASPEaS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS: A
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING-SCALES.
002512 02-16
ALKOXYALKYL
N TETRAHYDROFURYLALKYL AND N ALKOXYALKYL DERIVATIVES OF (-)
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID AQION
PROFILES.
000013 01-02
ALKYLATED
N ALKYLATED 2 AMINOTETRALINS: CENTRAL DOPAMINE-RECEPTOR
STIMULATING ACTIVITY.
000399 01-04
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG SOME D N ALKYLATED
AMPHETAMINES.
001542 02-03
ALKYLATING
PHARMACOLOGICAL- STUDIES WITH AN ALKYLATING NARCOTIC
AGONIST CHLOROXYMORPHAMINE, AND ANTAGONIST,
CHLORNALTREXAMINE
004082 04-04
IN VIVO EFFEaS OF TWO NOVEL ALKYLATING BENZODIAZEPINE,
IRAZEPINE AND KENAZEPINE,
004251 04-04
ALL-NIGHT
THE EFFEa OF BUTOCTAMIDE-HYDROGEN-SUCCINATE ON NOQURNAL
SLEEP: ALL-NIGHT POLYGRAPHICAL-STUDIES.
002350 02-14
ALL-OR-NONE
A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY
PRODUCED BY OPIATE ANALGESICS.
000425 01-04
ALLERGIC-ENCEPHALOMYELITIS
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH LEWIS-RAT LYMPH-NODE CELLS. (UNPUBLISHED PAPER)
001434 02-03
CENTRAL SEROTONIN-RECEPTOR SENSITIVITY IN RATS WITH
EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS.
001821 02-04
ALLOGENIC
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS; REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
S-14
VOLUME 19, SUBJECT INDEX
Subject Index
ALLOXAN
GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT
AFFECTED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN
TREATMENT.
001145 02-03
ALLYl
COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT.
001841 02-05
ALLYLNORCOCAINE
DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE, NORCOCAINE, AND
N ALLYLNORCOCAINE.
002954 03-04
ALPHA-ADRENERGIC
MORPHINE ACTS THROUGH ALPHA-ADRENERGIC AND SEROTONINERGIC
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG.
000088 01-03
CHANGES IN ALPHA-ADRENERGIC-RECEPTORS IN RAT-BRAIN IN VITRO BY
PREINCUBATION WITH ALPHA-ADRENERGIC LIGANDS.
001272 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
THE ROLE OF DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC AGONISTS
IN CHLORPROMAZINE-INDUCED HYPOTENSION.
001851 02-05
AMITRIPTYLINE: LONG-TERM-TREATMENT ELEVATES ALPHA-ADRENERGIC
AND MUSCARINIC-RECEPTOR BINDING IN MOUSE-BRAIN.
002875 03-03
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL
EVALUATION.
003685 04-02
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON
CHLORPROMAZINE-INDUCED ELEVATION OF PLASMA GLUCOSE AND
CYCLIC-AMP IN FED MICE.
003946 04-03
IkLPHA-ADRENERGIC-ACTIVITY
CYCLOHEXYLPHENOXYAMIDOXIMES AND IMIDAZOLINES WITH
ANTIDEPRESSIVE AND ALPHA-ADRENERGIC-ACTIVITY.
001051 02-01
MPHA-ADRENERGIC-RECEPTOR
PERIPHERAL ALPHA-ADRENERGIC-RECEPTOR SUBTYPES.
000901 01-16
RELATIONSHIPS BETWEEN STRUCTURE AND ALPHA-ADRENERGIC-
RECEPTOR AFFINITY OF CLONIDINE AND AND SOME RELATED CYCLIC-
AMIDINES.
002698 03-03
CHARACTERIZATION AND QUANTITATION OF ALPHA-ADRENERGIC-
RECEPTOR SUBTYPES IN RAT HYPOTHALAMUS.
002839 03-03
^LPHA-ADRENERGIC-RECEPTORS
AMITRIPTYLINE BINDING TO SPECIFIC ALPHA-ADRENERGIC-RECEPTORS IN
VITRO.
000181 01-03
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRACTIONS.
000299 01-03
TRICYCLIC-ANTIDEPRESSANT DRUG-INTERACTIONS WITH HISTAMINE AND
ALPHA-ADRENERGIC-RECEPTORS .
000791 01-13
CHANGES IN ALPHA-ADRENERGIC-RECEPTORS IN RAT-BRAIN IN VITRO BY
PREINCUBATION WITH ALPHA-ADRENERGIC LIGANDS.
001272 02-03
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF ALPHA-
ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA HYBRID
CELLS.
003823 04-03
MPHA-ADRENOCEPTOR
SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA-
ADRENOCEPTOR ANTAGONISTS: EVIDENCE AGAINST GABA
MEDIATION.
000024 01-03
EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS.
001146 02-03
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON
BARORECEPTOR REFLEXES IN CONSCIOUS CATS.
„„,, 001514 02-03
POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CARDIOVASCULAR-
EFFECTS OF CENTRAL ALPHA-ADRENOCEPTOR STIMULATION IN
SPONTANEOUSLY HYPERTENSIVE-RATS.
003791 04-03
PRESYNAPTIC AND POSTSYNAPTIC ALPHA-ADRENOCEPTOR ANTAGONISM
BY NEUROLEPTICS IN VIVO.
003966 04-03
ALPHA-ADRENOCEPTOR-MEDIATED
ALPHA-ADRENOCEPTOR-MEDIATED MODULATION OF 5
HYDROXYTRYPTAMINE RELEASE FROM RAT-BRAIN-CORTEX SLICES.
000111 01-03
ALPHA-ADRENOCEPTORS
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
THE EFFECTS OF BROMOCRIPTINE ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS IN THE MOUSE VAS-DEFERENS.
000108 01-03
EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS.
001146 02-03
AN EXAMINATION OF FACTORS INFLUENCING ADRENERGIC
TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNCTIONAL
ALPHA-ADRENOCEPTORS.
001196 02-03
PRESYNAPTIC ALPHA-ADRENOCEPTORS AND THE ACTION OF TRICYCLIC-
ANTIDEPRESSANT DRUGS IN BEHAVIOURAL-DESPAIR IN RATS.
001829 02-04
FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS
BY YOHIMBINE DIASTEREOMERS.
002748 03-03
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF-
STIMULATION MODEL USING CLONIDINE.
003016 03-04
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT
NICTITATING MEMBRANE.
003777 04-03
EFFECTS ON THE PINNA-REFLEX OF DRUGS ACTING AT ALPHA-
ADRENOCEPTORS.
004078 04-04
ALPHA-ADRENORECEPTOR
ALPHA-ADRENORECEPTOR MEDIATED ALTERATION OF ETHANOL EFFECTS
ON NA-K-ATPASE OF RAT NEURONAL MEMBRANES.
001425 02-03
ALPHA-PAHERN
THE TWO SURVIVAL CASES OF ALPHA-PATTERN COMA CAUSED BY
LARGE AMOUNTS OF HYPNOTICA AND NEUROLEPTICA.
004608 04-15
ALPHA-RECEPTORS
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
RECEPTORS.
000323 01-03
ALPHA METHYLEPINEPHRINE, A METHYLDOPA METABOLITE THAT BINDS
TO ALPHA-RECEPTORS IN RAT-BRAIN.
002734 03-03
ALPHA 1
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
BINDING OF PERAZINE TO ALPHAl ACID GLYCOPROTEIN.
002290 02-13
ALPHA 1 -ADRENERGIC-RECEPTORS
ONTOGENY OF MAMMALIAN CARDIAC ALPHAl -ADRENERGIC-
RECEPTORS.
001545 02-03
ALPHA 1 -ADRENOCEPTOR
DIFFERENTIAL INHIBITION OF ALPHAl -ADRENOCEPTOR AND ALPHA2-
ADRENOCEPTOR MEDIATED PRESSOR RESPONSES IN PITHED RATS.
004057 04-03
ALPHAl -ADRENOCEPTORS
3H PRAZOSIN BINDS SPECIFICALLY TO ALPHAl -ADRENOCEPTORS IN RAT-
BRAIN.
000205 01-03
NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR
CENTRAL ALPHAl -ADRENOCEPTORS.
001508 02-03
THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A
COMPETITIVE ANTAGONIST AT ALPHA1-ADREN0CEPT0RS.
003785 04-03
REGULATION OF ALPHAl -ADRENOCEPTORS IN THE CEREBRAL-CORTEX OF
THE RAT BY THYROID-HORMONES.
003816 04-03
ALPHAl -ADRENOCEPTORS AND ALPHA2-ADREN0CEPT0RS IN RAT-
CEREBRAL-CORTEX: EFFECT OF FRONTAL LOBOTOMY.
003944 04-03
I
S-15
Subject Index
Psychopharmacology Abstracts
ALPHA1 -RECEPTORS
AN IN VIVO MODEL FOR INVESTIGATING ALPHA 1 -RECEPTORS AND
ALPHA2-RECEPT0RS IN THE CNS: STUDIES WITH MIANSERIN.
000053 01-03
ALPHA2-ADRENERGIC
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM.
002728 03-03
ALPHA2-ADRENERGIC-AUTORECEPTOR
ANTIDEPRESSANTS AND ALPHA2-ADRENERGIC-AUT0RECEPT0R
DESENSITIZATION.
004659 04-15
ALPHA2-ADRENERGIC-RECEPTORS
HUMAN PLATELET ALPHA2-ADRENERGIC-RECEPT0RS: LABELING WITH 3H
YOHIMBINE, A SELECTIVE ANTAGONIST LIGAND.
004676 04-16
ALPHA2-ADRENOCEPTOR
EFFECTS OF DESIPRAMINE AND YOHIMBINE ON ALPHA2-ADREN0CEPT0R
AND BETA-ADRENOCEPTOR SENSITIVITY.
001305 02-03
DIFFERENTIAL INHIBITION OF ALPHA 1 -ADRENOCEPTOR AND ALPHA2-
ADRENOCEPTOR MEDIATED PRESSOR RESPONSES IN PITHED RATS.
004057 04-03
ALPHA2-ADRENOCEPTORS
ALPHA2-ADREN0CEPT0RS IN RAT-BRAIN: THE DIVALENT-CATION SITE.
001246 02-03
THE BLOCKADE OF ALPHA2-ADREN0CEPT0RS BY THE PNMT INHIBITOR
SKF-64139.
001255 02-03
THE INABILITY OF CHRONIC MIANSERIN TO BLOCK CENTRAL ALPHA2-
ADRENOCEPTORS.
001492 02-03
ALPHA 1 -ADRENOCEPTORS AND ALPHA2-ADREN0CEPT0RS IN RAT-
CEREBRAL-CORTEX: EFFECT OF FRONTAL LOBOTOMY
003944 04-03
ALPHA2-ADRENORECEPTORS
TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT DECREASES ALPHA2-
ADRENORECEPTORS ON HUMAN PLATELET MEMBRANES
003408 03-13
ALPHA2-ADREN0RECEPT0RS IN RAT-BRAIN ARE DECREASED AFTER
LONG-TERM TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT.
004008 04-03
ALPHA2-NORADRENERGIC-RECEPTOR
MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN:
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS
003992 04-03
CLONIDINE-INDUCED HYPERPHAGIA IN MONKEYS: EVIDENCE FOR
ALPHA2-N0RADRENERGIC-RECEPT0R MEDIATION .
004215 04-04
ALPHA2-RECEPTORS
AN IN VIVO MODEL FOR INVESTIGATING ALPHA 1 -RECEPTORS AND
ALPHA2-RECEPT0RS IN THE CNS: STUDIES WITH MIANSERIN.
000053 01-03
MIANSERIN: DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS
BY BLOCKING ALPHA2-RECEPT0RS.
001214 02-03
ALPRAZOLAM
ANXIOLYTIC EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND
PLACEBO.
000648 01-10
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO
SEVERE ANXIETY.
002070 02-10
DOUBLE-BLIND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR
SUBCHRONIC WITHDRAWAL FROM ALCOHOL.
003332 03-11
ALPRAZOLAM, A NEW TYPE ANXIOLYTIC IN NEUROTIC-PATIENTS: A
PILOT-STUDY.
004422 04-10
ALTERATION
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
DEXAMETHASONE TREATMENT.
000321 01-03
ELECTIVE ALTERATION OF THE STATE OF CONSCIOUSNESS SUBJEQED TO
THE EFFECTS OF PSYCHOAaiVE-SUBSTANCES.
000994 01-17
ALTERATION OF PROLACTIN SECRETION BY CENTRALLY-AQING DRUGS.
001127 02-03
ALPHA-ADRENORECEPTOR MEDIATED ALTERATION OF ETHANOL EFFEaS
ON NA-K-ATPASE OF RAT NEURONAL MEMBRANES.
001425 02-03
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN
HUNTINGTONS-DISEASE.
002163 02-11
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT,
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL
EVOLUTION.
002165 02-11
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY
PRETREATMENT WITH THYROID-HORMONES.
002259 02-13
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING:
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN
HYPERTENSION.
002874 03-03
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
ETHANOL,
003725 04-03
STRESS-MODULATED ALTERATION OF BRAIN BIOGENIC-AMINES IN THE
RAT: EFFECTS OF L TRYPTOPHAN
003978 04-03
ALTERATIONS
LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL
CAPILLARY PERMEABILITY.
000239 01-03
GABA LEVELS IN HUMAN CEREBROSPINAL-FLUID: ALTERATIONS IN
PSYCHIATRIC-DISORDERS. (UNPUBLISHED PAPER)
000764 01-13
EFFECT OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED
EXTRAPYRAMIDAL ALTERATIONS
001119 02-03
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN
001167 02-03
DRUG-INDUCED ALTERATIONS IN NEUROTRANSMIHER-RECEPTOR
BINDING AND FUNCTION.
001215 02-03
CHRONOLOGY OF NEUROCHEMICAL ALTERATIONS INDUCED BY GABA
AGONIST ADMINISTRATION
002713 03-03
DRUG REGIMENS FACILITATING AGGRESSION: BEHAVIOR, AMINE, AND
RECEPTOR ALTERATIONS.
002987 03-04
BEHAVIORAL AND METABOLIC ALTERATIONS IN PROGENY OF
METHADONE-TREATED RATS. (PHD DISSERTATION)
003113 03-04
ALTERATIONS IN CEREBROSPINAL-FLUID DOPAMINE METABOLITES
FOLLOWING PHYSOSTIGMINE INFUSION.
003477 03-15
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN.
003820 04-03
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL
HEMISPHERES OF AGED MALE RATS,
003936 04-03
ALTERATIONS IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY
FOLLOWING ACUTE AND CHRONIC ETHANOL TREATMENTS
004037 04-03
ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN ATTENTION-
DYSFUNQION TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA.
004316 04-08
ALTERATIONS IN NORADRENERGIC FUNQION DURING CLORGYLINE
TREATMENT.
004393 04-09
DRUG-INDUCED ALTERATIONS OF THE HYPOTHALAMUS HYPOPHYSIS
AXIS.
004535 04-13
ALTERING
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFECTS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN.
002990 03-04
AGGRESSION ALTERING EFFECTS OF CYCLIC-AMP.
003021 03-04
LITHIUM DRUG INTERAQIONS ALTERING THE INTRACELLULAR LITHIUM
LEVEL: AN IN VITRO STUDY.
003142 03-06
CHLORPROMAZINE EFFECTS ON COCAINE-REINFORCED RESPONDING IN
RHESUS-MONKEYS: RECIPROCAL MODIFICATION OF RATE ALTERING
EFFEaS OF THE DRUGS.
004133 04-04
MECHANISMS AND PHARMACOLOGICAL IMPLICATIONS OF ALTERING
CALMODULIN ACTIVITY.
004751 04-17
ALTERNATION
AROUSAL AND SHORT-TERM MEMORY: EFFECTS OF CAFFEINE AND TRIAL
SPACING ON DELAYED ALTERNATION PERFORMANCE.
000487 01-04
S-16
.23flSS^
VOLUME 19, SUBJECT INDEX
Subject Index
ALTERNATIVE
ELECTROLYTIC AAICROINFUSION TRANSDUCER SYSTEM: AN ALTERNATIVE
METHOD OF INTRACRANIAL DRUG APPLICATION.
001861 02-06
ALTHESIN
EFFECTS OF ALTHESIN IN PSYCHOTHERAPY OF SCHIZOPHRENICS:
PRELIMINARY REPORT.
004331 04-08
ALUMINUM
ORAL ALUMINUM AND NEUROPSYCHOLOGICAL FUNCTIONING: A STUDY
OF DIALYSIS PATIENTS RECEIVING ALUMINUM-HYDROXIDE GELS.
002283 02-13
ALUMINUM-HYDROXIDE
ORAL ALUMINUM AND NEUROPSYCHOLOGICAL FUNCTIONING: A STUDY
OF DIALYSIS PATIENTS RECEIVING ALUMINUM-HYDROXIDE GELS.
002283 02-13
ALZHEIMER-LIKE
USE OF THA IN TREATMENT OF ALZHEIMER-LIKE DEMENTIA: PILOT-STUDY
IN TWELVE PATIENTS.
003377 03-11
ALZHEIMER-TYPE
CHOLINE-BITARTRATE TREATMENT OF ALZHEIMER-TYPE DEMENTIAS.
000675 01-11
ALZHEIMERS-DISEASE
LECITHIN AND MEMORY TRAINING IN ALZHEIMERS-DISEASE. (PH.D.
DISSERTATION).
003299 03-11
EFFECTS OF CHOLINERGIC-DRUGS ON MEMORY IN ALZHEIMERS-DISEASE.
003454 03-14
ALZHEIMERS-TYPE
THE EFFECTS OF LECITHIN ON MEMORY IN PATIENTS WITH SENILE-
DEMENTIA OF THE ALZHEIMERS-TYPE.
003385 03-11
AMANITIN
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA-
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER).
003998 04-03
AMANTADINE
REVIEW OF 38 CASES OF SUBACUTE SCLEROSING PANENCEPHALITIS:
EFFECT OF AMANTADINE ON THE NATURAL COURSE OF THE DISEASE.
000718 01-11
LITHIUM-INDUCED COGWHEEL RIGIDITY: TREATMENT WITH
AMANTADINE.
000748 01-13
CLINICAL-TRIAL WITH AMANTADINE AND HYDERGINE IN ELDERLY-
PATIENTS.
002093 02-1 1
EDEMAS AND MYOCLONIES IN A PATIENT WITH PARKINSONS-DISEASE
TREATED BY AMANTADINE: PROBLEM WITH ASSOCIATED
MEDICATIONS.
002389 02-15
THE EFFECT OF AMANTADINE ON PROLACTIN LEVELS AND
GALACTORRHEA ON NEUROLEPTIC TREATED PATIENTS.
003373 03-1 1
COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON
DOPAMINE METABOLISM IN RAT-BRAIN.
003796 04-03
ACCUMULATION OF AMANTADINE BY ISOLATED CHROMAFFIN
GRANULES.
003866 04-03
^MBIENT
THE EFFECTS OF THEOPHYLLINE AND CAFFEINE ON THERMOREGULATORY
FUNaiONS OF RATS AT DIFFERENT AMBIENT TEMPERATURES
003907 04-03
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-03
\MBLYOPIA
ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA
REVERSAL BY MICROIONTOPHORETIC BICUCULLINE.
002684 03-03
AMBULATORY
COVERT DYSKINESIA IN AMBULATORY SCHIZOPHRENIA.
000836 01-15
EVALUATIONS OF LOXAPINE-SUCCINATE IN THE AMBULATORY
TREATMENT OF ACUTE SCHIZOPHRENIC-EPISODES.
004345 04-08
PHARMACOTHERAPY AND PSYCHOTHERAPY FOR AMBULATORY
DEPRESSION: EFFICACY AND CHOICES.
004413 04-09
AMELIORATES
CLONIDINE AMELIORATES GILLES-DE-LA-TOUREnE-SYNDROME
002106 02-11
AMELIORATION
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE-
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION.
003458 03-14
LITHIUM AMELIORATION OF RESERPINE-INDUCED HYPOACTIVITY IN
RATS.
004167 04-04
AMERICA
THE TRANQUILIZING OF AMERICA.
003602 03-17
AMERICAN-PSYCHIATRIC-ASSOCIATION
TARDIVE-DYSKINESIA: SUMMARY OF A TASK-FORCE-REPORT OF THE
AMERICAN-PSYCHIATRIC-ASSOCIATION.
000875 01-15
AMFONELIC-ACIO
DIFFERENT DOPAMINERGIC MECHANISMS FOR AMFONELIC-ACID
AMPHETAMINE AND APOMORPHINE.
000465 01-04
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE
FORMATION FROM PHENYLALANINE.
001113 02-03
COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON
DOPAMINE METABOLISM IN RAT-BRAIN.
003796 04-03
AMILORiDE
ATTENUATION OF THE LITHIUM-INDUCED DIABETES-INSIPIDUS-LIKE
SYNDROME BY AMILORIDE IN RATS.
002717 03-03
AMINE
TRICYCLIC-ANTIDEPRESSANT DRUGS AND INDIVIDUAL DIFFERENCES IN
THE EXPLORATORY-ACTIVITY OF RATS: CONTRASTING-EFFECTS OF
TERTIARY AND SECONDARY AMINE COMPOUNDS.
000401 01-04
DOPAMINE BIOSYNTHESIS IS REGULATED BY THE AMINE NEWLY
RECAPTURED BY DOPAMINERGIC NERVE-ENDINGS.
001163 02-03
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
002219 02-13
DRUG REGIMENS FACILITATING AGGRESSION: BEHAVIOR, AMINE, AND
RECEPTOR ALTERATIONS.
002987 03-04
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION-
EVIDENCE FOR AMINE SPECIFICITY.
003250 03-09
NONCOMPETITIVE AMINE UPTAKE INHIBITION BY THE NEW
ANTIDEPRESSANT PRIDEFINE.
003771 04-03
AMINE UPTAKE INHIBITORS: CRITERIA OF SELECTIVITY.
003921 04-03
THE INTERACTION OF AMINE LOCAL ANESTHETICS WITH MUSCARINIC-
RECEPTORS.
004031 04-03
A SIMPLE HISTOCHEMICAL SCREENING METHOD FOR AMINE UPTAKE.
004295 04-06
A RAPID AND SENSITIVE RADIORECEPTOR ASSAY FOR TERTIARY AMINE
TRICYCLIC-ANTIDEPRESSANTS.
004689 04-16
AMINE-OXIDASE
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL
GROUPS IN THE ACTIVE SITE. (UNPUBLISHED PAPER).
001066 02-01
CU-AMINE-OXIDASES: STUDIES RELATED TO THE MECHANISM-OF-ACTION
OF BOVINE PLASMA AMINE-OXIDASE (UNPUBLISHED PAPER).
003680 04-01
AMINEPTINE
AMINEPTINE: CLINICAL REVIEW.
001896 02-07
AMINEPTINE, A NEW ANTIDEPRESSANT: PHARMACOLOGICAL REVIEW.
001898 02-07
THE IMPORTANCE OF AMINEPTINE IN THE TREATMENT OF NONPSYCHOTIC
DEPRESSIVE-STATES IN THE ELDERLY.
001999 02-09
COMPARATIVE EXPERIMENT OF THE ANTIDEPRESSANT EFFECTS OF
AMINEPTINE AND CHLORIMIPRAMINE.
002029 02-09
ANTIDEPRESSANT ACTION OF AMINEPTINE: CONTROLLED DOUBLE-BLIND
STUDY.
002030 02-09
DOUBLE-BLIND CONTROLLED EXPERIMENT: AMINEPTINE VERSUS
AMITRIPTYLINE USING THE HAMILTON-DEPRESSION-RATING- SCALE.
002050 02-09
DOUBLE-BLIND CONTROLLED-STUDY: AMINEPTINE VERSUS
TRIMIPRAMINE.
002051 02-09
1*1
S-17
Subject Index
Psychopharmacology Abstracts
COMPARATIVE CROSS-STUDY ON THE EFFECTS OF AMINEPTINE AND
MAPROTILINE.
002065 02-10
DOUBLE-BUND CONTROLLED-STUDY ON THE PSYCHOLEPTIC-EFFECTS OF
AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT
PERSONALITY-PROBLEMS.
002116 02-n
A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDIQS DURING
WITHDRAWAL.
004445 04-1 1
AMINERGIC
CENTRAL AMINERGIC AND PEPTIDERGIC MECHANISMS IN
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS. (UNPUBLISHED
PAPER).
001459 02-03
SELF-ADMINISTRATION OF D-AMPHET AMINE AND AMINERGIC SYSTEMS
IN THE RAT.
001696 02-04
AMINES
PHARMACOLOGY OF PHENETHYLAMINE TRACE AMINES IN THE DOG ~
DISCUSSION.
000469 01-04
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMUUVTION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM.
002728 03-03
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF
AMINES INFLUENCING CEREBROSPINAL-FLUID FORMATION
002807 03-03
REGULATION OF BIOGENESIS OF PSYCHOTOMIMETIC AMINES.
(UNPUBLISHED PAPER).
003818 04-03
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE
MOUSE AND THE RAT.
003870 04-03
AMINO-ACID
INTERACTIONS OF NOREPINEPHRINE WITH PURKINJE-CELL RESPONSES TO
PUTATIVE AMINO-ACID NEUROTRANSMIHERS APPLIED BY
MICROIONTOPHORESIS
000209 01-03
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMIHERS IN EPIDURAL
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC-
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS.
001386 02-03
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND
EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES.
002799 03-03
ACTIONS OF BETA BUNGAROTOXIN ON AMINO-ACID TRANSMIHER
RELEASE.
002897 03-03
PHARMACOLOGICAL ANTAGONISTS OF EXCITANT AMINO-ACID ACTION.
003587 03-17
EXCITATORY AMINO-ACID TRANSMIHERS.
003648 03-17
BACLOFEN: STEREOSELECTIVE INHIBITION OF EXCITANT AMINO-ACID
RELEASE.
003867 04-03
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE
AMINO-ACID POOL.
004039 04-03
AMINO-ACIDS
INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERACTION OF AMINO-
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG.
000034 01-03
EFFECTS OF L AND D AMINO-ACIDS ON ANALGESIA AND LOCOMOTOR-
ACTIVITY OF MICE: THEIR INTERACTION WITH MORPHINE.
000336 01-04
LITHIUM-INDUCED CHANGES IN THE BRAIN LEVELS OF FREE AMINO-ACIDS
IN STRESS-EXPOSED RATS.
001217 02-03
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN
IN VIVO: EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS,
AND BENZODIAZEPINES.
001303 02-03
EFFECTS OF ALBUMIN, AMINO-ACIDS, AND CLOFIBRATE ON THE UPTAKE
OF TRYPTOPHAN BY THE RAT-BRAIN.
002673 03-03
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
CELLS.
TRANSPORT OF NEUTRAL AMINO-ACIDS AT THE BLOOD-BRAIN-BARRIER.
002764 03-03
L HISTIDINE: EFFEaS ON SENSITIVITY OF CAT SPINAL NEURONES TO
AMINO-ACIDS.
002808 03-03
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMIHER AMINO-
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFAaORY-BULB
002836 03-03
EFFEaS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO-
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY
CULTURED NEURONS.
002859 03-03
AMINO-3-ETHOXYCARBONYL-4-PHENYLTHIOPHENE
SYNTHESIS AND PHARMACOLOGY OF 2 AMIN0-3-ETH0XYCARB0NYL-4-
PHENYLTHIOPHENE DERIVATIVES.
001083 02-02
AMINO-4-METHYLPYRIDINE
ON THE MECHANISM-OF-AaiON OF 2 AMINO-4-METHYLPYRIDINE, A
MORPHINE-LIKE ANALGESIC.
001574 02-04
AMINO-4-PHOSPHONOBUTYRIC-ACID
2 AMINO-4-PHOSPHONOBUTYRIC-ACID: A NEW PHARMACOLOGICAL
TOOL FOR RETINA RESEARCH.
003145 03-06
AMINO-4H-S-TRIAZOLOBENZODIAZEPINES
6 SUBSTITUTED AMIN0-4H-S-TRIAZ0L0BENZ0DIAZEPINES AND 4 ■
SUBSTITUTED AMIN0-6H-S-TRIAZ0L0BENZ0DIAZEPINES WITH ■
POTENTIAL ANTIANXIETY ACTIVITY.
001076 02-02
AMINO-6H-S-TRIAZOLOBENZODIAZEPINES
6 SUBSTITUTED AMIN0-4H-S-TRIAZ0L0BENZ0DIAZEPINES AND 4
SUBSTITUTED AMINO-6H-S-TRIAZOLOBENZO0IAZEPINES WITH
POTENTIAL ANTIANXIETY ACTIVITY.
001076 02-02
AMINOADIPATE
TOXIC EFFECTS OF ALPHA AMINOADIPATE ON CULTURED CEREBELLAR |
002729 03-03
SELEQIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
DEPRESSION OF VENTRAL ROOT DORSAL ROOT POTENTIAL BY DL ALPHA
AMINOADIPATE IN FROG SPINAL-CORD
002755 03-03
AMINOADIPIC-ACID
LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID
002828 03-03
AMINOALKYL-«-ARYL-4H-S-TRIAZOLOBENZODIAZEPINES
1 AMIN0ALKYL-6-ARYL-4H-S-TRIAZ0L0BENZ0DIAZEPINES WITH
ANTIANXIETY AND ANTIDEPRESSANT AQIVITY.
001074 02-02
AMINOBUTYRIC-ACID
DIFFERENTIAL-EFFECTS OF N DIPROPYLACETATE AND AMINOOXYACETIC-
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS
OF RAT-BRAIN.
000140 01-03
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT.
001104 02-03
EFFEQ OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED
EXTRAPYRAMIDAL ALTERATIONS.
001119 02-03
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELEQRICAL-
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL
SLICES.
001130 02-03
ROLES OF SEROTONIN AND GAMMA AMINOBUTYRIC-ACID IN OPIOID
EFFEaS.
001140 02-03
PRESYNAPTIC AQIONS OF 4 AMINOPYRIDINE AND GAMMA
AMINOBUTYRIC-ACID ON RAT SYMPATHETIC GANGLIA IN VITRO.
001244 02-03
BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERAQION
WITH GAMMA AMINOBUTYRIC-ACID.
001287 02-03
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES.
001402 02-03
THE ROLE OF GAMMA AMINOBUTYRIC-ACID IN ACUTE AND CHRONIC
NEUROLEPTIC AQION.
001465 02-03
S-18
i^OLUME 19, SUBJECT INDEX
Subject Index
A STUDY OF A GLIAL GAMMA AMINOBUTYRIC-ACID SYSTEM; ITS
REGULATION, FUNCTION AND THE EFFECTS OF DIAZEPAM. (PH.D.
DISSERTATION).
001524 02-03
PRELIMINARY-STUDIES ON CSF GAMMA AMINOBUTYRIC-ACID LEVELS IN
PSYCHIATRIC-PATIENTS BEFORE AND DURING TREATMENT WITH
DIFFERENT PSYCHOTROPIC-DRUGS.
001959 02-08
INCREASED CSF GAMMA AMINOBUTYRIC-ACID AFTER TREATMENT WITH
GAMMA VINYL-GABA
002237 02-13
INHIBITION OF VASOPRESSIN RELEASE TO CAROTID OCCLUSION BY
GAMMA AMINOBUTYRIC-ACID AND GLYCINE.
002715 03-03
DOPAMINE-RECEPTOR SUPERSENSITIVITY IN THE CORPUS-STRIATUM
FOLLOWING CHRONIC ELEVATION OF BRAIN GAMMA AMINOBUTYRIC-
ACID.
002716 03-03
CENTRAL HYPOTENSIVE-EFFECT OF GAMMA AMINOBUTYRIC-ACID IN
ANESTHETIZED DOGS.
003772 04-03
A STUDY OF GAMMA AMINOBUTYRIC-ACID UPTAKE IN NORMAL AND
DOWNS-SYNDROME PLATELETS.
003787 04-03
THE EFFECT OF SODIUM-DIPROPYLACETATE ON GAMMA AMINOBUTYRIC-
ACID DEPENDENT INHIBITION IN THE RAT-CORTEX AND SUBSTANTIA-
NIGRA IN RELATION TO ITS ANTICONVULSANT ACTIVITY.
003880 04-03
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN
REGIONS OF RAT-BRAIN WITH KETAMINE ANESTHESIA.
003891 04-03
STUDIES ON THE MECHANISM-OF-ACTION OF AVERMECTIN-BIA:
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM
BRAIN SYNAPTOSOMES.
003973 04-03
STUDIES ON GAMMA AMINOBUTYRIC-ACID TRANSPORT IN COBALT
EXPERIMENTAL EPILEPSY IN THE RAT.
003990 04-03
MODULATORY INTERACTIONS BETWEEN NOREPINEPHRINE AND TAURINE,
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS.
004058 04-03
ANTAGONISM OF SOME CENTRAL-EFFECTS OF D TUBOCURARINE BY
GAMMA AMINOBUTYRIC-ACID.
004102 04-04
MINOBUTYRIC-ACID-MEDIATED
REDUCTION OF GAMMA AMINOBUTYRIC-ACID-MEDIATED (GABA)
TRANSMISSION BY A CONVULSANT BENZODIAZEPINE.
000015 01-02
MINOBUTYRIC-ACID-RECEPTOR
DIFFERENCES IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY IN
INBRED STRAINS OF MICE.
000303 01-03
SUSTAINED GAMMA AMINOBUTYRIC-ACID-RECEPTOR STIMULATION AND
CHRONIC NEUROLEPTIC-EFFECTS.
001345 02-03
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID-
RECEPTOR AGONIST. TO MEMBRANES OF THE BOVINE RETINA
003954 04-03
THE EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND
ITS WITHDRAWAL ON GAMMA AMINOBUTYRIC-ACID-RECEPTOR
BINDING IN RAT-BRAIN.
...r„ 004035 04-03
ALTERATIONS IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY
FOLLOWING ACUTE AND CHRONIC ETHANOL TREATMENTS
004037 04-03
MINOBUTYRIC-ACID-RECEPTORS
INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERACTION OF AMINO-
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG.
000034 01-03
MINOBUTYRIC-ACID-TRANSAMINASE
CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC-
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE
(GABA-TRANSAMINASE) INHIBITOR.
000174 01-03
INHIBITION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE WITH 6
AMINONICOTINAMIDE IN REGIONS OF THE RAT-BRAIN.
002868 03-03
THE INACTIVATION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE IN
DISSOCIATED NEURONAL CULTURES FROM SPINAL-CORD.
003980 04-03
MINODIHYDROXYTETRAHYDRONAPHTHALENE
(3H) 2 AMINODIHYDROXYTETRAHYDRONAPHTHALENE (ADTN)-
REGIONAL DISTRIBUTION AND IN VIVO BINDING AFTER ACUTE AND
CHRONIC DRUG-TREATMENT.
000052 01-03
MINOHIPPURIC-ACID
STUDIES ON THE EFFECT OF ALPHA MELANOCYTE- STIMULATING-
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P
AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED
PAPER).
001372 02-03
AMINOLAEVULINIC-ACID
EFFECTS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO-
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY
CULTURED NEURONS,
002859 03-03
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID
THE SYNTHESIS AND ACTIVITY OF CIS AND TRANS 2
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID AS
CONFORMATIONALLY RESTRICTED ANALOGUES OF GABA.
002633 03-01
AMINONICOTINAMIDE
INHIBITION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE WITH 6
AMINONICOTINAMIDE IN REGIONS OF THE RAT-BRAIN.
002868 03-03
AMINOOXYACETIC-ACIO
EFFECT OF AMINOOXYACETIC-ACID (AOAA) ON GABA LEVELS IN SOME
PARTS OF THE RAT-BRAIN.
000040 01-03
DIFFERENTIAL-EFFECTS OF N DIPROPYLACETATE AND AMINOOXYACETIC-
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS
OF RAT-BRAIN.
000140 01-03
EFFECT OF AMINOOXYACETIC-ACID AND BICUCULLINE ON PROLACTIN
RELEASE IN CASTRATED MALE RATS.
001194 02-03
CONVULSANT-EFFECTS OF AMINOOXYACETIC-ACID DURING ONTOGENESIS
IN RATS.
001439 02-03
AMINOPEPTIDASE
INHIBITION OF AMINOPEPTIDASE AND ACETYLCHOLINESTERASE BY
PUROMYCIN AND PUROMYCIN ANALOGS.
003835 04-03
AMINOPHYLUNE
EFFECTS OF RESERPINE, PROPRANOLOL, AND AMINOPHYLLINE ON
SEIZURE ACTIVITY AND CNS CYCLIC-NUCLEOTIDES.
000115 01-03
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE
ACTION.
000229 01-03
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC-
STUDY.
001410 02-03
AMINOPHYLLINE AND IMIDAZOLE AS CONVULSANTS.
004232 04-04
AMINOPHYLLINE-INDUCED
CAFFEINE-INDUCED AND AMINOPHYLLINE-INDUCED SEIZURES
002689 03-03
AMINOPYRIDINE
PRESYNAPTIC ACTIONS OF 4 AMINOPYRIDINE AND GAMMA
AMINOBUTYRIC-ACID ON RAT SYMPATHETIC GANGLIA IN VITRO.
001244 02-03
EFFECTS OF 4 AMINOPYRIDINE ON THE TURNOVER OF MONOAMINES IN
THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.
002658 03-03
AQION OF 4 AMINOPYRIDINE ON THE CEREBRAL CIRCULATION.
003781 04-03
4 AMINOPYRIDINE BLOCKADE OF NEURONAL DEPRESSANT RESPONSES TO
ADENOSINE-TRIPHOSPHATE.
003963 04-03
AMINOPYRINE
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS.
004022 04-03
AMINOSULFONIC-ACIDS
EFFECT OF INTRAVENTRICULAR INJECTIONS OF ALPHA AMINOSULFONIC-
ACIDS ON THE CENTRAL-NERVOUS-SYSTEM OF CONSCIOUS MICE.
000009 01-02
AMINOTETRALINS
PRODRUGS OF SOME DOPAMINERGIC 2 AMINOTETRALINS: A REVIEW OF
THEIR SYNTHESES AND NEUROCHEMICAL PROFILES.
000004 01-01
N ALKYLATED 2 AMINOTETRALINS: CENTRAL DOPAMINE-RECEPTOR
STIMULATING ACTIVITY.
000399 01-04
AMITRIPTYLINE
AMITRIPTYLINE BINDING TO SPECIFIC ALPHA-ADRENERGIC-RECEPTORS IN
VITRO.
000181 01-03
A REEXAMINATION OF THE CLINICAL-EFFECTS OF IMIPRAMINE AND
AMITRIPTYLINE IN DEPRESSIVE-ILLNESS.
000579 01-09
STUDY OF INTRAVENOUS AMITRIPTYLINE IN ACUTE DEPRESSIONS
000581 01-09
a
C
6
S-19
Subject Index
Psychopharmacology Abstracts
PREDiaiON OF STEADY-STATE PLASMA LEVELS OF AMITRIPTYLINE AND
NORTRIPTYLINE FROM A SINGLE-DOSE 24-HR. LEVEL IN DEPRESSED-
PATIENTS.
000582 01-09
COMPARATIVE-STUDY OF THE CARDIOTOXICITY OF AMITRIPTYLINE AND
MAPROTILINE IN DEPRESSIVE-PATIENTS.
000595 01-09
ON THE RELATIONSHIP OF NORTRIPTYLINE: AMITRIPTYLINE RATIO TO
CLINICAL IMPROVEMENT OF AMITRIPTYLINE TREATED DEPRESSIVE-
PATIENTS.
000599 01-09
D-AMPHET AMINE AS A PREDICTOR FOR RESPONSE TO IMIPRAMINE AND
AMITRIPTYLINE.
000621 01-09
URINARY MHPG AND CLINICAL-RESPONSE TO AMITRIPTYLINE IN
DEPRESSED-PATIENTS.
000631 01-09
INTERACTION BETV^EEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN:
METABOLITE NORTRIPTYLINE AND THE CORRELATION WITH CLINICAL-
^'''''''' 000640 01-09
AMITRIPTYLINE THERAPY OF OBSESSIVE-COMPULSIVE-NEUROSIS.
000656 01-10
AMITRIPTYLINE, NORTRIPTYLINE PLASMA LEVELS AND CLINICAL-
RESPONSE IN WOMEN WITH AFFECTIVE-DISORDERS.
000757 01-13
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL
EVOKED-POTENTIALS.
000763 01-13
HYPNAGOGIC AND HYPNOPOMPIC HALLUCINATIONS DURING
AMITRIPTYLINE TREATMENT.
000850 01-15
POSSIBLE INVOLVEMENT OF CYCLIC-AMP AND FRONTAL-CORTEX IN
AMITRIPTYLINE MEDIATED SUPPRESSION OF THE HYPOTENSIVE-EFFEQ
OFCLONIDINE. „„,o.^^.^o
001259 02-03
ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION:
CYPROHEPTADINIUM-METHIODIDE.
001534 02-03
EFFECTS OF AMITRIPTYLINE AND CLOMIPRAMINE IN THE ISOLATED,
PERFUSED RABBIT HEART. „ „^
001852 02-05
EFFECT OF AMITRIPTYLINE ANTIDOTES ON REPETITIVE EXTRASYSTOLE
THESHOLD.
001856 02-05
AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL-EFFEQ: A
WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY.
001976 02-09
DOUBLE-BLIND CONTROLLED EXPERIMENT: AMINEPTINE VERSUS
AMITRIPTYLINE USING THE HAMILTON-DEPRESSION-RATING- SCALE.
002050 02-09
BLOOD LEVEL OF AMITRIPTYLINE, NORTRIPTYLINE, NORADRENALINE,
SEROTONIN AND THERAPEUTIC RESPONSE.
002057 02-09
TRICHOTILLOMANIA TREATED WITH AMITRIPTYLINE
002083 02-10
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
CARDIOVASCULAR-EFFECTS OF AMITRIPTYLINE, MIANSERIN AND
ZIMELIDINE IN DEPRESSED-PATIENTS.
002215 02-13
HIGH-LEVELS OF AMITRIPTYLINE AND CLINICAL-RESPONSE.
002266 02-13
INTERINDIVIDUAL DIFFERENCES IN AMITRIPTYLINE DEMETHYLATION.
002282 02-13
THE PERIPHERAL ANTICHOLINERGIC-ACTIVITY OF TRICYCLIC-
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND
DESIPRAMINE IN HUMAN VOLUNTEERS.
002298 02-13
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE
NORTRIPTYLINE.
002304 02-13
TERATOGENICITY OF IMIPRAMINE AND AMITRIPTYLINE IN FETAL
HAMSTERS.
002410 02-15
HYPOMANIC-REACTION TO AMITRIPTYLINE IN A DEPRESSED-CHILD.
002418 02-15
CARDIOVASCULAR-EFFEQS OF MIANSERIN AND AMITRIPTYLINE IN
HEALTHY VOLUNTEERS.
002469 02-15
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
AMITRIPTYLINE: LONG-TERM-TREATMENT ELEVATES ALPHA-ADRENERGIC
AND MUSCARINIC-RECEPTOR BINDING IN MOUSE-BRAIN.
002875 03-03
DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC-
RECEPTORS.
002914 03-03
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST
SUDDEN CARDIAC DEATH FROM COCAINE.
003122 03-05
AMOXAPINE AND AMITRIPTYLINE IN THE OUTPATIENT TREATMENT OF
ENDOGENOUS DEPRESSION.
003217 03-09
PANIC-ANXIETY AFTER ABRUPT DISCONTINUATION OF AMITRIPTYLINE
003223 03-09
DOUBLE-BUND STUDY OF MIANSERIN AND AMITRIPTYLINE.
003231 03-09
A DOUBLE-BLIND COMPARISON BETWEEN AMOXAPINE AND
AMITRIPTYLINE IN DEPRESSED-INPATIENTS.
003234 03-09
DEPRESSION SUBTYPES AFFECT THE STEADY-STATE PLASMA LEVELS AND
THERAPEUTIC-EFFICACY OF AMITRIPTYLINE AND NORTRIPTYLINE.
003244 03-09
PHENEUINE AND AMITRIPTYLINE IN NEUROTIC DEPRESSION.
(UNPUBLISHED PAPER)
003248 03-09
EFFEaS OF PHENELZINE AND AMITRIPTYLINE ON DEPRESSION.
003249 03-09
BEHAVIORAL-PREDiaORS OF AMITRIPTYLINE RESPONSE IN DEPRESSION.
003253 03-09
PHARMACOKINETICS OF AMITRIPTYLINE, IMIPRAMINE, AND
MAPROTILINE IN THE ELDERLY.
003324 03-1 1
CARDIOVASCULAR-EFFECTS OF MIANSERIN - A COMPARATIVE-STUDY
WITH AMITRIPTYLINE AND A PLACEBO IN HEALTHY SUBJEQS.
003503 03-15
A TARDIVE-DYSKINESIA-LIKE SYNDROME AFTER AMITRIPTYLINE
TREATMENT
003552 03-15
FIRST RESULTS OF AN ORIGINAL METHOD FOR MEASURING BLOOD
LEVELS OF ANTIDEPRESSANTS (AMITRIPTYLINE AND NORTRIPTYLINE)
003559 03-16
INTERAQION OF THE TRICYCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH
PREJUNCTIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG
SAPHENOUS VEIN
003756 04-03
DRUG-INTERACTIONS OF AMITRIPTYLINE AND NORTRIPTYLINE WITH
WARFARIN IN THE RAT.
003912 04-03
REGULATION OF SER0T0NIN2-RECEPT0RS (5 HT2) LABELED WITH
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT AMITRIPTYLINE
003964 04-03
COMPARATIVE-EFFEQS OF PHENELZINE AND AMITRIPTYLINE: A
PLACEBO-CONTROLLED-TRIAL.
004402 04-09
THE RELATIONSHIPS BETWEEN CLINICAL-RESPONSE,
PSYCHOPHYSIOLOGICAL-VARIABLES AND PLASMA LEVELS OF
AMITRIPTYLINE AND DIAZEPAM IN NEUROTIC-OUTPATIENTS.
004423 04-10
AMITRIPTYLINE AND NORTRIPTYLINE PLASMA LEVELS MONITORING.
PERSPECTIVE IN CLINICAL-PRAQICE.
004675 04-16
AMITRIPTYLINE-HYDROCHLORIDE
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIOE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
SIMULTANEOUS HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC-
DETERMINATION OF AMITRIPTYLINE-HYDROCHLORIDE IN TWO-
COMPONENT TABLET FORMULATIONS.
004673 04-16
AMMONIA
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN
RATS
001199 02-03
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM-
ACETATE MONOFLUOROACETATE AND INSULIN-INDUCED
HYPOGLYCEMIA.
004276 04-05
AMMONIUM-ACETATE
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM-
ACETATE MONOFLUOROACETATE AND INSULIN-INDUCED
HYPOGLYCEMIA.
004276 04-05
S-20
VOLUME 19, SUBJECT INDEX
Subject Index
IkMNESIA
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL- STIMULATION OF THE
AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS.
(UNPUBLISHED PAPER).
001488 02-03
BETA ENDORPHIN CAUSES RETROGRADE AMNESIA AND IS RELEASED
FROM THE RAT-BRAIN BY VARIOUS FORMS OF TRAINING AND
STIMULATION.
001664 02-04
TIME-DEPENDENT CHANGES IN ANTEROGRADE SCOPOLAMINE-INDUCED
AMNESIA IN RATS.
004182 04-04
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS.
004231 04-04
USE OF LYSINE-VASOPRESSIN IN THE TREATMENT OF POSnRAUMATIC
AMNESIA.
004583 04-14
^NIOTIC-FLUID
CONCENTRATIONS OF CIS(Z) FLUPENTHIXOL IN MATERNAL SERUM,
AMNIOTIC-FLUID, UMBILICAL-CORD-SERUM, AND MILK.
002423 02-15
^MOXAPINE
AMOXAPINE IN EXPERIMENTAL PSYCHOPHARMACOLOGY: A
NEUROLEPTIC OR AN ANTIDEPRESSANT?
001070 02-02
AMOXAPINE AND AMITRIPTYLINE IN THE OUTPATIENT TREATMENT OF
ENDOGENOUS DEPRESSION.
003217 03-09
A DOUBLE-BUND COMPARISON BETWEEN AMOXAPINE AND
AMITRIPTYLINE IN DEPRESSED-INPATIENTS.
003234 03-09
AMOXAPINE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSED-
OUTPATIENTS: A CONTROLLED- STUDY.
003254 03-09
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE.
004356 04-09
AMOXAPINE: A REVIEW OF LITERATURE.
004702 04-17
KMP
STUDY ON THE STABILITY OF THE FACTORIAL STRUCTURE OF THE AMP
SYSTEM DURING TREATMENT.
004696 04-16
VMPHET AMINE
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
ACUTE AND CHRONIC EFFECTS OF NEUROLEPTICS AND ACUTE EFFECTS OF
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN.
000215 01-03
DECREASED SPIROPERIDOL AND LSD BINDING IN RAT-BRAIN AFTER
CONTINUOUS AMPHETAMINE.
000216 01-03
LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN
MICE.
000287 01-03
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHAUMIC OR DORSOLATERAL TEGMENTAL
DAMAGE.
000322 01-03
REWARD SYSTEM DEPRESSION FOLLOWING CHRONIC AMPHETAMINE:
ANTAGONISM BY HALOPERIDOL.
000342 01-04
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFECTS OF
COCAINE AND D-AMPHET AMINE FOLLOWING CHRONIC AMPHETAMINE
ADMINISTRATION.
000350 01-04
DISRUPTION OF SELECTIVE AHENTION BY APOMORPHINE, BUT NOT
AMPHETAMINE, IN THE MONGOLIAN-GERBIL.
000358 01-04
RELATIONSHIPS BETWEEN SELECTIVE DENERVATION OF DOPAMINE
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL-
RESPONSES TO AMPHETAMINE AND APOMORPHINE.
000384 01-04
EFFECTS OF 6 HYDROXYDOPAMINE AND AMPHETAMINE ON RAT
MOTHERING-BEHAVIOR AND OFFSPRING DEVELOPMENT.
000452 01-04
FACILITATION OF SELF-STIMULATION OF THE PREFRONTAL-CORTEX IN
RATS FOLLOWING CHRONIC ADMINISTRATION OF SPIROPERIDOL OR
AMPHETAMINE.
000457 01-04
DIFFERENT DOPAMINERGIC MECHANISMS FOR AMFONELIC-ACID,
AMPHETAMINE AND APOMORPHINE.
000465 01-04
TEMPORAL PROPERTIES OF THE REWARDING AND AVERSIVE-EFFECTS OF
AMPHETAMINE IN RATS.
000471 01-04
THE INFLUENCE OF GABAERGIC SUBSTANCES ON THE EFFECTS OF
STIMULATION OF THE CAUDATE-NUCLEUS AND AMPHETAMINE
STEREOTYPY IN CATS.
000489 01-04
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL-
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL
SEROTONERGIC FUNCTION.
000491 01-04
ATTENUATION OF AMPHETAMINE ANOREXIA IN RATS FOLLOWING
SUBCHRONIC-TREATMENT WITH A TRICYCLIC-ANTIDEPRESSANT.
000501 01-04
AMPHETAMINE AND PIRIBEDIL IN AFFECTIVE-ILLNESS.
000618 01-09
REINFORCING, DISCRIMINATIVE AND ACTIVATING PROPERTIES OF
AMPHETAMINE.
000804 01-14
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE
FORMATION FROM PHENYLALANINE.
001113 02-03
EPINEPHRINE IS RELEASED FROM HYPOTHALAMUS BY DEPOLARIZING-
AGENTS AND AMPHETAMINE.
001155 02-03
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES
001207 02-03
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS
INDUCED BY AMPHETAMINE IN CATS.
001340 02-03
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFECT
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE.
001353 02-03
MODIFICATION OF DOPAMINE-RECEPTORS IN BRAIN BY CONTINUOUS
AMPHETAMINE ADMINISTRATIONS TO RATS.
001395 02-03
SUPERSENSITIVITY AND THE EFFECTS OF LONG-TERM AMPHETAMINE IN
THE RAT NIGROSTRIATAL SYSTEM. (PH.D. DISSERTATION).
001485 02-03
AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION
IN RATS: EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING-
AGENTS.
001531 02-03
REDUCTION OF DOPAMINERGIC-SUPERSENSITIVITY BY A SINGLE-DOSE OF
AMPHETAMINE.
001642 02-04
BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFECTS OF CHRONIC
AMPHETAMINE INTOXICATION.
001653 02-04
EFFECTS OF RESERPINE AND AMPHETAMINE ON THE DEVELOPMENT OF
HYPERACTIVITY IN MATERNALLY-DEPRIVED RAT PUPS.
001654 02-04
ENHANCED LATERAL HYPOTHALAMIC SELF- STIMULATION RESPONDING
AFTER CHRONIC EXPOSURE TO AMPHETAMINE.
001688 02-04
EFFECTS OF CHRONIC AMPHETAMINE OR RESERPINE ON SELF-
STIMULATION RESPONDING: ANIMAL-MODEL OF DEPRESSION?
001699 02-04
GENETIC AND EXPERIMENTAL FACTORS AFFECTING THE PARADOXICAL-
EFFECTS OF AMPHETAMINE IN DOGS.
001704 02-04
INTERACTION OF PROSTAGLANDINS AND THE EFFECTS OF MORPHINE AND
AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
001732 02-04
AMPHETAMINE AND MATERNAL-BEHAVIOR: DOSE-RESPONSE
RELATIONSHIPS.
001752 02-04
APPARENT TOLERANCE TO SOME ASPECTS OF AMPHETAMINE
STEREOTYPY WITH LONG-TERM-TREATMENT.
001758 02-04
GO-HERE-GO-THERE PERFORMANCE AFTER AMPHETAMINE: THE
IMPORTANCE OF THE RESPONSE REQUIREMENT IN SUCCESSIVE
DISCRIMINATION.
001759 02-04
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR
DORSOLATERAL TEGMENTAL DAMAGE.
001818 02-04
A SILICONE PELLET FOR LONG-TERM CONTINUOUS ADMINISTRATION OF
AMPHETAMINE.
001875 02-06
DIFFERENTIAL-EFFECTS OF AMPHETAMINE AND NEUROLEPTICS ON
NEGATIVE VS. POSITIVE SYMPTOMS IN SCHIZOPHRENIA.
001906 02-08
5
s
fe'
S-21
Subject Index
Ptychopharmacology Abstracts
PARADOXICAL IMPROVEMENT FOLLOWING IV AMPHETAMINE IN
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
001951 02-08
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE
INTOXICATION.
002210 02-13
EFFECTS OF AMPHETAMINE ON VIGILANCE PERFORMANCE IN NORMAL
AND HYPERACTIVE-CHILDREN.
002359 02-14
SUBJECTIVE DRUG-EFFECTS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFECTS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
SEX-DIFFERENCES IN THE AMPHETAMINE STIMULATED RELEASE OF
CATECHOLAMINES FROM RAT STRIATAL TISSUE IN VITRO.
002668 03-03
MIDBRAIN DOPAMINE NEURONS: DIFFERENTIAL RESPONSES TO
AMPHETAMINE ISOMERS.
002680 03-03
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
002801 03-03
INCREASED AMPHETAMINE STEREOTYPY AND LONGER HALOPERIDOL
CATALEPSY IN SPONTANEOUSLY HYPERTENSIVE-RATS
002891 03-03
CANALIZATION OF AROUSAL IN THE PREWEANLING RAT: EFFECTS OF
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI.
002965 03-04
HYPERACTIVITY IN DEVELOPING RATS: SEX-DIFFERENCES IN 6
HYDROXYDOPAMINE AND AMPHETAMINE EFFECTS.
002970 03-04
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE
INTOXICATION.
002988 03-04
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN
MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF
AMPHETAMINE. (PH.D. DISSERTATION).
002996 03-04
GONADECTOMY AND SEX-DIFFERENCES IN THE BEHAVIORAL-RESPONSES
TO AMPHETAMINE AND APOMORPHINE OF RATS
003084 03-04
RELATIVE POTENCY OF AMPHETAMINE ISOMERS IN CAUSING THE
SEROTONIN BEHAVIORAL-SYNDROME IN RATS.
003094 03-04
COMPUTER-ANALYZED EEG IN AMPHETAMINE RESPONSIVE
HYPERACTIVE-CHILDREN.
003338 03-11
THE STIMULATING EFFECT OF AMPHETAMINE ON THE VISUAL SYSTEM
003398 03-13
EFFECT OF AMPHETAMINE ON THE METABOLISM AND INCORPORATION
OF (3H) THYMIDINE INTO DNA OF DEVELOPING RAT-BRAIN
003729 04-03
UNIT ACTIVITY IN MEDIAL THALAMUS: COMPARATIVE-EFFECTS OF
CAFFEINE AND AMPHETAMINE.
003752 04-03
EFFECTS OF ACUTE AND CHRONIC AMPHETAMINE TREATMENT ON
PURKINJE NEURON DISCHARGE IN RAT CEREBELLUM.
003793 04-03
EFFECT OF AMPHETAMINE ON PLASMA CORTICOSTERONE IN THE
CONSCIOUS RAT.
003888 04-03
EFFECTS OF IN VIVO AMPHETAMINE ADMINISTRATION ON DOPAMINE
SYNTHESIS REGULATION IN RAT-BRAIN STRIATAL SYNAPTOSOMES.
(UNPUBLISHED PAPER).
003960 04-03
SUSTAINED DECREASE IN FAT CONSUMPTION PRODUCED BY
AMPHETAMINE IN RATS MAINTAINED ON A DIETARY SELF-SELECTION
REGIME.
004150 04-04
HABITUATION OF THE THE HEAD-POKE RESPONSE: EFFECTS OF AN
AMPHETAMINE BARBITURATE MIXTURE, PLG AND FENFLURAMINE.
004159 04-04
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL.
004208 04-04
SELECTIVE EFFECTS OF BARBITURATE AND AMPHETAMINE ON
INFORMATION-PROCESSING AND RESPONSE EXECUTION.
004563 04-14
INTERACTION OF P CHLOROPHENYLALANINE, MIANSERINE AND
DANITRACEN WITH AMPHETAMINE.
004599 04-15
AMPHETAMINE-ELICITED
SEX-DIFFERENCES IN AMPHETAMINE-ELICITED ROTATIONAL-BEHAVIOR
AND THE LATERALIZATION OF STRIATAL DOPAMINE IN RATS
000459 01-04
AMPHETAMINE-INDUCED
AMPHETAMINE-INDUCED HYPERSENSITIVITY IN GUINEA-PIGS.
000498 01-04
DOSE-DEPENDENT, AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND
SPONTANEOUSLY HYPERTENSIVE-RATS.
001197 02-03
5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE
AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED-
BEHAVIOUR IN THE RAT.
001589 02-04
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON AMPHETAMINE-
INDUCED LOCOMOTOR-STIMULATION IN MICE.
001767 02-04
SUPPRESSION OF AMPHETAMINE-INDUCED EEG AROUSAL IN THE
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS.
002683 03-03
AMPHETAMINE-INDUCED ROTATION IN NORMAL CATS.
003002 03-04
AMPHETAMINE-INDUCED MOTILITY AND NIGROSTRIATAL IMPULSE FLOW
003005 03-04
A PRIMATE ANALOGUE OF AMPHETAMINE-INDUCED BEHAVIORS IN
HUMANS.
003006 03-04
AMPHETAMINE-INDUCED OVEREATING AND OVERWEIGHT IN RATS.
003015 03-04
EFFECTS OF DORSOLATERAL TEGMENTAL LESIONS ON AMPHETAMINE-
INDUCED AND LITHIUM-INDUCED TASTE-AVERSIONS.
003114 03-04
NEUROTENSIN BLOCKS CERTAIN AMPHETAMINE-INDUCED BEHAVIOURS.
004111 04-04
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH
UNILATERAL NIGROSTRIATAL LESIONS.
004117 04-04
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND
CONDITIONED TASTE-AVERSION
004121 04-04
CENTRAL AND PERIPHERAL EFFECTS OF LITHIUM ON AMPHETAMINE-
INDUCED HYPERACTIVITY IN RATS.
004223 04-04
AMPHETAMINE-LIKE
A CONSTITUENT OF KHAT-LEAVES WITH AMPHETAMINE-LIKE RELEASING
PROPERTIES.
001307 02-03
AMPHETAMINE-LIKE REACTIONS TO PHENYLPROPANOLAMINE.
003480 03-15
AMPHETAMINES
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG SOME D N ALKYLATED
AMPHETAMINES.
001542 02-03
AMPHETAMINIL
AMPHETAMINIL IN THE TREATMENT OF DISTURBED EREQION POTENCY.
002129 02-11
AMYGDALA
EFFECT OF NALOXONE, HALOPERIDOL AND PROPRANOLOL ON CYCLIC-
ADENOSINE-MONOPHOSPHATE CONTENT OF RAT AMYGDALA.
000071 01-03
LOCOMOTOR AND CONVULSIVE RESPONSES TO PICROTOXIN IN
AMYGDALA KINDLED RATS
000416 01-04
EFFECTS OF MORPHINE ON EVOK ED-POTENTIALS RECORDED FROM THE
AMYGDALA BY TOOTH-PULP STIMULATION IN CATS.
001379 02-03
A PHARMACOLOGICAL ANALYSIS OF THE ROLE OF THE AMYGDALA IN
THE CONTROL OF GONADOTROPIN AND PROLACTIN SECRETION.
001418 02-03
RETROGRADE AMNESIA PRODUCED BY ELEQRICAL- STIMULATION OF THE
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS.
(UNPUBLISHED PAPER).
001488 02-03
5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE
AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED-
BEHAVIOUR IN THE RAT,
001589 02-04
AMYGDALA OPIATE-SENSITIVE MECHANISMS INFLUENCE FEAR
MOTIVATED RESPONSES AND MEMORY PROCESSES FOR AVERSIVE-
EXPERIENCES. (UNPUBLISHED PAPER).
001628 02-04
MODULATION OF OPIATE-RECEPTOR BINDING IN STRIATUM AND
AMYGDALA BY SELECTIVE MESENCEPHALIC LESIONS.
001629 02-04
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR
FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY.
002986 03-04
EFFECT OF PHENTOLAMINE ADMINISTRATION INTO THE AMYGDALA
COMPLEX OF RATS ON TIME-DEPENDENT MEMORY PROCESSES.
002998 03-04
THE EFFECT OF AMYGDALA KINDLING ON SPONTANEOUS AND COCAINE-
INDUCED MOTOR-AaiVITY AND LIDOCAINE SEIZURES.
003067 03-04
S-22
4
VOLUME 19, SUBJECT INDEX
Subject Index
OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE
CONDITIONING IN RABBITS.
003798 04-03
EFFECTS OF 3 SULFAMOYLMETHYL-BENZISOXAZOLE (AD-810) AND SOME
ANTIEPILEPTICS ON THE KINDLED SEIZURES IN THE NEOCORTEX,
HIPPOCAMPUS AND AMYGDALA IN RATS.
004149 04-04
SEROTONERGIC MECHANISM IN SEIZURES KINDLED FROM THE RABBIT
AMYGDALA.
004227 04-04
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE
AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS.
004231 04-04
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION.
004273 04-05
AMYGDALAR
THE ROLE OF BIOGENIC-AMINES IN AMYGDALAR KINDLING. I. LOCAL
AMYGDALAR AFTERDISCHARGE.
000327 01-03
AMYGDALOID
MODIFICATION OF DOPAMINERGIC-RECEPTOR SENSITIVITY IN RAT-BRAIN
AFTER AMYGDALOID KINDLING.
000106 01-03
ADDICTIVE-AGENTS AND INTRACRANIAL- STIMULATION (ICS): MORPHINE,
NALOXONE, AND PRESSING FOR AMYGDALOID ICS.
000371 01-04
RELATION OF MONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION
IN CATS.
000474 01-04
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
ENHANCED SENSITIVITY OF AMYGDALOID NEURONS TO SEROTONIN AND
NOREPINEPHRINE AFTER CHRONIC ANTIDEPRESSANT TREATMENT.
001523 02-03
BARBITURATE SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
001559 02-04
PHARMACOLOGICAL MODIFICATION OF AMYGDALOID KINDLED
SEIZURES.
001588 02-04
NALOXONE FACILITATES AMYGDALOID KINDLING IN RATS.
001644 02-04
VALPROIC-ACID SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
002946 03-04
THE EFFECTS OF VARIOUS ANESTHETICS ON AMYGDALOID KINDLED
SEIZURES.
002959 03-04
DIFFERENTIAL ACTIONS OF CLASSICAL AND ATYPICAL ANTIPSYCHOTIC-
DRUGS ON SPONTANEOUS NEURONAL ACTIVITY IN THE AMYGDALOID
COMPLEX.
003131 03-05
AMYLOBARBITONE
AMYLOBARBITONE AND FORGEHING.
001763 02-04
AMYOTROPHY
THE USE OF LITHIUM-CARBONATE FOR TREATING KUGELBERG-WELANDER
SPINAL AMYOTROPHY PATIENTS.
003326 03-11
ANAFRANIL
THE BIOAVAILABILITY OF ORAL AND PARENTERAL CHLORIMIPRAMINE
(ANAFRANIL).
002232 02-13
ANALGESIA
COMPARATIVE-STUDY OF ANALGESIA INDUCED BY N VAL5-ENKEPHALIN
AND PR05-ENKEPHALIN ANALOGS.
000021 01-03
REVERSIBLE INACTIVATION OF RAPHE-MAGNUS NEURONS: EFFECTS ON
NOCICEPTIVE THRESHOLD AND MORPHINE-INDUCED ANALGESIA.
000240 01-03
THE POSSIBILITY THAT A COMPONENT OF MORPHINE-INDUCED
ANALGESIA IS CONTRIBUTED INDIRECTLY VIA THE RELEASE OF
ENDOGENOUS OPIOIDS.
000263 01-03
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFECTS OF
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS
ON MORPHINE-INDUCED ANALGESIA.
000311 01-03
EFFECTS OF L AND D AMINO-ACIDS ON ANALGESIA AND LOCOMOTOR-
ACTIVITY OF MICE: THEIR INTERACTION WITH MORPHINE.
000336 01-04
METHIONINE-ENKEPHALIN ANTAGONISM AND ENDORPHIN POTENTIATION
OF NARCOTIC-INDUCED ANALGESIA.
000357 01-04
PSYCHOPHARMACOLOGY OF ANALGESIA AND PAIN. (UNPUBLISHED
PAPER),
001411 02-03
EFFECTS OF RAPHE-MAGNUS AND RAPHE-PALLIDUS LESIONS ON
MORPHINE-INDUCED ANALGESIA AND SPINAL-CORD MONOAMINES
001420 02-03
MORPHINE ANALGESIA FOLLOWING ITS INFUSION INTO DIFFERENT
LIQUOR SPACES IN RAT-BRAIN.
001429 02-03
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJECTION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS.
001446 02-03
INFLUENCE OF THYROTROPIN-RELEASING-HORMONE AND HISTIDYL-
PROLINE-DIKETOPIPERAZINE ON SPONTANEOUS LOCOMOTOR-ACTIVITY
AND ANALGESIA INDUCED BY DELTA9 TETRAHYDROCANNABINOL IN
THE MOUSE.
001575 02-04
ANTAGONISTIC-EFFECTS OF PSYCHOLEPTIC-DRUGS ON STRESS-INDUCED
ANALGESIA.
001609 02-04
ETHANOL-INDUCED ANALGESIA IN RATS SELECTIVELY BRED FOR ETHANOL
SENSITIVITY.
001625 02-04
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST,
CHLORNALTREXAMINE.
001695 02-04
OPIATE AND PEPTIDE INTERACTION: EFFECT OF ENKEPHALINS ON
MORPHINE ANALGESIA.
001698 02-04
BRIEF SOCIAL-ISOLATION, PAIN RESPONSIVITY, AND MORPHINE
ANALGESIA IN YOUNG RATS.
001744 02-04
AN INHIBITOR OF OPIOID-PEPTIDE DEGRADATION PRODUCES ANALGESIA
IN MICE.
001780 02-04
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN
MAN: POSSIBLE CENTRAL-ACTION IN BRAIN.
002195 02-12
MECHANISMS OF OPIATE ANALGESIA AND THE ROLE OF ENDORPHINS IN
PAIN SUPPRESSION. (UNPUBLISHED PAPER).
002275 02-13
ENKEPHALIN-LIKE CHARACTER AND ANALGESIA.
002650 03-02
PHARMACOLOGICAL-STUDIES ON STIMULATION PRODUCED ANALGESIA
IN MICE.
002964 03-04
DYNORPHIN: A POSSIBLE MODULATORY PEPTIDE ON MORPHINE OR BETA
ENDORPHIN ANALGESIA IN MOUSE.
002994 03-04
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
CLONIDINE ANALGESIA AND SUPPRESSION OF OPERANT RESPONDING:
DISSOCIATION OF MECHANISM.
003046 03-04
SUBSTANCE-P, HEXAPEPTIDE-PGLU6(SP6-1 1), ANALGESIA AND
SEROTONIN DEPLETION.
003050 03-04
FOOTSHOCK ANALGESIA: PREVENTION BY BEHAVIOURAL-MANIPULATION
BUT NOT BY NALOXONE.
003073 03-04
EVIDENCE FOR INVOLVEMENT OF SEPARATE MECHANISMS IN THE
PRODUCTION OF ANALGESIA BY ELECTRICAL- STIMULATION OF THE
NUCLEUS-RETICULARIS-PARAGIGANTOCELLULARIS AND NUCLEUS-
RAPHE-MAGNUS IN THE RAT.
003083 03-04
EFFECTS OF METHYSERGIDE AND NALOXONE ON ANALGESIA INDUCED BY
THE PERIPHERAL ELECTRIC-STIMULATION IN MICE.
003093 03-04
A NEUROANATOMICAL-STUDY OF ANALGESIA AND CATATONIA INDUCED
BY ETORPHINE IN THE RAT. (PH.D. DISSERTATION).
003102 03-04
INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766,
AN ANALOG OF ACTH4-9.
003112 03-04
A COMPARISON OF THE EFFECTS OF MORPHINE-SULPHATE AND NITROUS-
OXIDE ANALGESIA ON CHRONIC PAIN STATES IN MAN.
003442 03-14
ANALGESIA FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF 2
DEOXY-D-GLUCOSE.
004074 04-04
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFECTS ON
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING
IN VITRO.
004198 04-04
'IT
ti-
ll"
^
S-23
Subject Index
Ptychopharmacology Abstracts
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND
BODY-TEMPERATURE CHANGES IN RATS.
004238 04-04
ANALGESIC
INHIBITION OF (3H)NAL0X0NE BINDING IN HOMOGENATES OF RAT-
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC ACTIVITY, RELATED
TO PHYSOSTIGMINE.
000104 01-03
CHANGES IN BRAIN N DEMETHYLATION AND OPIATE-RECEPTOR CONTENT
CORREUTE WITH ANALGESIC EFFECTIVENESS OF MORPHINE.
000400 01-04
ANALGESIC ACTIVITY OF DIFLUNISAL (MK-647; 5 2,4
DIFLUOROPHENYLSALICYLIC-ACID) IN RATS WITH HYPERALGESIA
INDUCED BY FREUNDS-ADJUVANT.
000502 01-04
THE ANALGESIC AND RESPIRATORY EFFECTS OF MEPTAZINOL, MORPHINE
AND PENTAZOCINE IN THE RAT.
000516 01-05
MECHANISMS OF PAIN AND ANALGESIC COMPOUNDS.
000916 01-17
BETA ENDORPHIN: DISSOCIATION OF RECEPTOR BINDING-ACTIVITY FROM
ANALGESIC POTENCY.
001081 02-02
ON THE MECHANISM-OF-ACTION OF 2 AMINO-4-METHYLPYRIDINE, A
MORPHINE-LIKE ANALGESIC.
001574 02-04
ANALGESIC ACTION OF INTRATHECAL AND INTRACEREBRAL BETA
ENDORPHIN IN RATS: COMPARISON WITH MORPHINE
001691 02-04
OPIATE ANTAGONISTS AND LONG-TERM ANALGESIC REACTION INDUCED
BY INESCAPABLE SHOCK IN RATS
001707 02-04
NEUROCHEMICAL- STUDIES OF AN ANALGESIC, 1,3 DIPHENYL-5-2-
DIMETHYLAMINOPROPIONAMIDE-PYRAZOLE (DIFENAMIZOLE) ,
002771 03-03
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC,
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL
DOPAMINE SYNTHESIS.
002786 03-03
ANALGESIC TOLERANCE PRODUCED BY MORPHINE PELLETS IS
FACILITATED BY ANALGESIC TESTING
002943 03-04
ENVIRONMENTAL MODULATION OF ANALGESIC TOLERANCE INDUCED BY
MORPHINE PELLETS.
002944 03-04
ANALGESIC PROPERTIES OF THE GABAMIMETIC THIP.
003013 03-04
COMPARATIVE ANALGESIC, BEHAVIORAL, AND DEPENDENCE PROPERTIES
OF MORPHINE AND 0
METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME
HCL.
003707 04-02
ANALGESIC AND OTHER PHARMACOLOGICAL ACTIVITIES OF A NEW
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3
METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS
ENANTIOMORPH IN EXPERIMENTAL ANIMALS,
004185 04-04
ANALGESIC-DRUGS
EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERACTIONS WITH MU-
RECEPTORS AND DELTA-RECEPTORS
000168 01-03
THE EFFECT OF PSYCHOTROPIC-SUBSTANCES AND NARCOTIC ANALGESIC-
DRUGS ON 14C NORADRENALINE UPTAKE BY SYNAPTOSOMES OF THE
CEREBRAL-CORTEX OF RATS.
001363 02-03
GUIDELINES FOR THE CLINICAL-EVALUATION OF ANALGESIC-DRUGS.
002584 02-17
ANALGESIC-INDUCED
EFFECT OF QUIPAZINE AND FLUOXETINE ON ANALGESIC-INDUCED
CATALEPSY AND ANTINOCICEPTION IN THE RAT.
001709 02-04
ANALGESICS
INFLUENCE OF GLUCOSE (IN VIVO OR IN VITRO) ON DURATION OF
NARCOTIC ANALGESICS AND ON THE KINETICS OF DRUG METABOLISM.
000292 01-03
ANTINOCICEPTIVE-EFFECT OF MORPHINE, OPIOID ANALGESICS AND
HALOPERIDOL INJECTED INTO THE CAUDATE-NUCLEUS OF THE RAT.
000414 01-04
A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY
PRODUCED BY OPIATE ANALGESICS.
000425 01-04
THE INFLUENCE OF 5 HT-RECEPTOR BLOCKING-AGENTS ON THE
BEHAVIORAL-EFFECTS OF ANALGESICS IN RATS.
000429 01-04
INTERACTION-STUDIES BETWEEN NARCOTIC ANALGESICS, NARCOTIC
ANTAGONISTS AND ETHANOL: STUDIES DURING ACUTE AND CHRONIC-
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE (PH.D.
DISSERTATION).
001165 02-03
AaiONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON
ACETYLCHOLINE TURNOVER IN RAT-BRAIN.
001541 02-03
NARCOTIC ANALGESICS AND STEREOTYPED-BEHAVIOUR IN MICE.
001694 02-04
CLASSIFICATION OF ANALGESICS.
002570 02-17
STRUaURE-ACTIVITY AND RECEPTOR BINDING OF ANTAGONIST
ANALGESICS.
003611 03-17
BLOCKADE BY L LYSINE OF NONNARCOTIC ANALGESICS.
003857 04-03
EFFECTS OF ANALGESICS AND CNS-AQING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS,
004148 04-04
ANALOG
UNUSUAL DOSE-RELATED EFFECT OF AN ENDORPHIN ANALOG IN A
COMPLEX MAZE
001674 02-04
Y-MAZE BEHAVIOR AFTER AN ANALOG OF ACTH4-9, EVIDENCE FOR AN
ATTENTIONAL-ALTERATION ,
001676 02-04
METKEPHAMID, A SYSTEMICALLY ACTIVE ANALOG OF METHIONINE-
ENKEPHALIN WITH POTENT OPIOID DELTA-RECEPTOR ACTIVITY.
002720 03-03
POSSIBLE MECHANISMS OF EFFEa OF AaH4-10 AND ITS ANALOG,
CONTAINING D ISOMER OF PHENYLALANINE, ON BEHAVIOR
002949 03-04
GAMMA BUTYROLACTONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE
CITRATE (DN-1417): A NOVEL TRH ANALOG WITH POTENT EFFEaS ON
THE CENTRAL-NERVOUS-SYSTEM.
003057 03-04
INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766,
AN ANALOG OF AaH4-9.
003112 03-04
HIGH-AFFINITY BINDING-SITES FOR A SOMATOSTATIN-28 ANALOG IN
RAT-BRAIN.
003985 04-03
GLC MASS-SPECTROMETRIC-DETERMINATION OF MAPROTILINE AND ITS
MAJOR METABOLITE USING STABLE ISOTOPE-LABELED ANALOG AS
INTERNAL STANDARD
004291 04-06
ANALOGS
COMPARATIVE-STUDY OF ANALGESIA INDUCED BY N VAL5-ENKEPHALIN
AND PR05-ENKEPHALIN ANALOGS.
000021 01-03
THE EFFECTS OF TWO ANALOGS OF DOPAMINE ON GANGLIONIC
TRANSMISSION IN THE SYMPATHETIC-NERVOUS-SYSTEM.
000162 01-03
STRUCTURE-ACTIVITY RELATIONSHIPS IN THE EFFEaS OF PHENACEMIDE
ANALOGS ON SERUM CREATININE AND ANTICONVULSANT ACTIVITY
000249 01-03
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFEQS OF
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS
ON MORPHINE-INDUCED ANALGESIA.
000311 01-03
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
00040401-04
HISTORY AND PHARMACOLOGY OF PCP AND PCP RELATED ANALOGS
000737 01-12
IRREVERSIBLE INHIBITION OF S ADENOSYLHOMOCYSTEINE-HYDROLASE BY
NUCLEOSIDE ANALOGS. (UNPUBLISHED PAPER).
001010 02-01
ADENOSINE ANALOGS AS SUBSTRATES AND INHIBITORS OF S
ADENOSYLHOMOCYSTEINE-HYDROLASE. (UNPUBLISHED PAPER)
001021 02-01
BETA ENDORPHIN AND ANALOGS: 360 MHZ PROTON NMR
SPEaROSCOPY.
001028 02-01
SYNTHESIS OF 180 ANALOGS OF BIOGENIC-AMINES (UNPUBLISHED
PAPER)
001044 02-01
DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE
INFLUENCE THE CENTRAL-AQIVITY OF ADENYLATE-CYCLASE AND
CYCLIC-AMP-PHOSPHODIESTERASE
001405 02-03
MOTOR-AQIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF
COCAINE: CORRELATION WITH DOPAMINE UPTAKE BLOCKADE
001650 02-04
ENKEPHALIN ANALOGS AND PHYSICAL-DEPENDENCE
003572 03-16
SYNTHESIS AND BIOLOGICAL-AQIVITY OF HUMAN BETA ENDORPHIN
ANALOGS WITH DISULFIDE BRIDGES.
003655 04-01
S-24
VOLUME 19, SUBJECT INDEX
Subject Index
SYNTHESIS AND PHARMACOLOGICAL-STUDY Of SOME ENKEPHALIN
ANALOGS IN RELATION TO THE PLURALITY Of OPIATE-RECEPTORS.
003682 04-02
CENTRALLY ACTIVE N SUBSTITUTED ANALOGS Of 3,4
METHYLENEDIOXYPHENYLISOPROPYLAMINE (3,4
METHYLENEDIOXYAMPHETAMINE).
003683 04-02
INHIBITION Of AMINOPEPTIDASE AND ACETYLCHOLINESTERASE BY
PUROMYCIN AND PUROMYCIN ANALOGS.
003835 04-03
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
N,N DIISOPROPYLTRYPT AMINE (DIPT) AND 5
METHOXYDIISOPROPYLTRYPTAMINE (5 MEO-DIPT). TWO ORALLY
ACTIVE TRYPTAMINE ANALOGS WITH CNS ACTIVITY.
004310 04-07
ANALOGUE
AN ANALOGUE Of THYROTROPIN-RELEASING-HORMONE WITH IMPROVED
BIOLOGICAL-STABILITY BOTH IN VITRO AND IN VIVO.
000032 01-03
EffECTS Of ENKEPHALIN ANALOGUE AND NALOXONE ON CAT SPINAL-
CORD DORSAL ROOT POTENTIALS.
000236 01-03
APPLICATION Of A SYNTHETIC ENKEPHALIN ANALOGUE DURING HEROIN
WITHDRAWAL.
000685 01-11
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION Of MORPHINE AND ENKEPHALIN ANALOGUE fK-33-824 IN
RATS.
001669 02-04
BIPHASIC-EffECTS Of A POTENT ENKEPHALIN ANALOGUE D MET2-PR05-
ENKEPHALINAMIDE AND MORPHINE ON LOCOMOTOR-ACTIVITY IN
MICE.
001799 02-04
A PRIMATE ANALOGUE Of AMPHETAMINE-INDUCED BEHAVIORS IN
HUMANS.
003006 03-04
BIOLOGICAL EVALUATION Of A TRH ANALOGUE WITH A MODIflED
PROLINE RESIDUE,
003662 04-01
INTERACTIONS BETWEEN A MONOfLUORINATED ANALOGUE Of P
CHLOROAMPHET AMINE AND 5 HYDROXYTRYPTAMINE IN BRAIN.
003719 04-03
A SYNTHETIC ACTH4-9 ANALOGUE (ORGANON-2766) AND SLEEP IN
HEALTHY MAN.
004574 04-14
ANALOGUES
fLUORINATED ANALOGUES Of THE TRICYCLIC NEUROLEPTICS- 2 3
DIfLUORO DERIVATIVE Of CLOROTEPIN.
000001 01-01
EffECT Of GABA ANALOGUES ON BLOOD-PRESSURE AND CENTRAL GABA
METABOLISM IN THE RAT.
000231 01-03
DISPLACEMENT Of (3H)CL0NIDINE BINDING BY CLONIDINE ANALOGUES
IN MEMBRANES fROM RAT-CEREBRAL-CORTEX.
000536 01-06
THE EffECTS Of LSD AND SOME ANALOGUES ON THE RESPONSES Of
SINGLE CORTICAL NEURONS Of THE CAT TO OPTICAL- STIMULATION
000738 01-12
ANTIARRHYTHMIC-ACTIVITY Of AMITRIPTYLINE ANALOGUES IN
CONSCIOUS DOGS AfTER MYOCARDIAL-INfARCTION:
CYPROHEPTADINIUM-METHIODIDE.
001534 02-03
CONfORMATIONALLY RESTRICTED TRICYCLIC-ANTIDEPRESSANTS 1
OCTAHYDRODIBENZAZEPINONAPHTHYRIDINES AS RIGID IMIPRAMINE
ANALOGUES.
001710 02-04
THE EffECT Of SOME STRUCTURAL GABA ANALOGUES ON THE
SEROTONIN AND DOPAMINERGIC MECHANISMS
001736 02-04
THE SYNTHESIS AND ACTIVITY Of CIS AND TRANS 2
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID AS
CONfORMATIONALLY RESTRICTED ANALOGUES Of GABA.
002633 03-01
GABA ANALOGUES ACTIVATE CHANNELS Of DIffERENT DURATION ON
CULTURED MOUSE SPINAL NEURONS.
002665 03-03
KINETIC DATA ON THE INHIBITION Of HIGH-AfflNITY CHOLINE
TRANSPORT INTO RAT-fOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES
002879 03-03
DISCRIMINATIVE-STIMULUS PROPERTIES Of PHENCYCLIDINE AND fIVE
ANALOGUES IN THE SQUIRREL-MONKEY.
002961 03-04
SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES Of
ANALOGUES AND DERIVATIVES Of P CHLOROPHENYLALANINE
003691 04-02
EFfECTS Of CONfORMATIONALLY RESTRAINED ANALOGUES Of
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN.
003794 04-03
IBOTENIC-ACID ANALOGUES AS INHIBITORS Of (3H)GLUTAMIC-ACID
BINDING TO CEREBELLAR MEMBRANES.
003848 04-03
ACTION Of ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIffERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
ANALYSE
THE USE Of PSYCHOPHARMACOLOGICAL-PROCEDURES TO ANALYSE THE
ONTOGENY Of LEARNING AND RETENTION: ISSUES AND CONCERNS.
000482 01-04
ANALYSES
MULTIDIMENSIONAL ANALYSES Of BEHAVIOR IN MICE TREATED WITH
ALPHA ENDORPHIN.
003020 03-04
STATISTICAL ANALYSES Of PHYSIOLOGIC DATA fROM fEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES
IN THIS PHASE.
003251 03-09
CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND
NATURAL SETTINGS: CORRELATIONAL AND VARIANCE COMPONENTS
ANALYSES.
004508 04-13
GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC
ANALYSES fOR DEANOL, CHOLINE, AND THEIR ACETYLESTERS.
004683 04-16
ANALYSIS
ANALYSIS fOR DIAZEPAM AND NORDIAZEPAM BY ELECTRON-CAPTURE
GAS-CHROMATOGRAPHY AND BY LIQUID-CHROMATOGRAPHY
000006 01-01
NONLINEAR REGRESSION ANALYSIS Of NOREPINEPHRINE RESPONSE
KINETICS IN CEREBRAL VASCULATURE.
000256 01-03
ANALYSIS Of THE ACTIVATION Of DOPAMINE METABOLISM BY A
SEROTONIN UPTAKE INHIBITOR.
000315 01-03
DRUG-VARIABLES IN THE ETIOLOGY Of TARDIVE-DYSKINESIA:
APPLICATION Of DISCRIMINANT fUNCTION ANALYSIS
000844 01-15
AN HPLC AND RIA ANALYSIS Of THE CHOLECYSTOKININ-PEPTIDES IN
RAT-BRAIN. (UNPUBLISHED PAPER).
001004 02-01
DECOMPOSITION Of PHARMACOLOGICAL ACTIVITY INDICES INTO
MUTUALLY INDEPENDENT COMPONENTS USING PRINCIPAL
COMPONENT ANALYSIS.
001039 02-01
QUANTITATIVE ANALYSIS Of 6 HYDROXYMELATONIN IN HUMAN URINE
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS-
SPECTROMETRY. (UNPUBLISHED PAPER).
001058 02-01
REGIONAL 5 HT ANALYSIS IN ROMAN HIGH-AVOIDANCE AND LOW-
AVOIDANCE RATS fOLLOWING MAO-INHIBITION.
001202 02-03
AUTOCORRELATION ANALYSIS Of SINGLE NEURON ACTIVITY AfTER
ADMINISTRATION Of PENTOBARBITAL.
001268 02-03
ACUTE AND CHRONIC OPIATE-EffECTS ON SINGLE UNITS AND EEG Of
MEDIAL THALAMUS AND HIPPOCAMPUS: A LATENCY ANALYSIS.
001344 02-03
A PHARMACOLOGICAL ANALYSIS Of THE ROLE Of THE AMYGDALA IN
THE CONTROL Of GONADOTROPIN AND PROLACTIN SECRETION.
001418 02-03
MULTIPLE CNS RECEPTOR INTERACTIONS Of ERGOT ALKALOIDS: AfflNITY
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS.
001516 02-03
AN ANALYSIS Of SOME PERCEPTUAL-EffECTS Of MORPHINE,
CHLORPROMAZINE, AND LSD.
001652 02-04
NEUROPHARMACOLOGICAL ANALYSIS Of HANDLING-INDUCED SEIZURES
IN GERBILS.
001876 02-06
PSYCHOACTIVE-DRUG-EffECTS IN A HYPERACTIVE-CHILD: A CASE-STUDY
ANALYSIS Of BEHAVIOR-CHANGE AND TEACHER ATTENTION.
002313 02-14
VIGILANCE IMPAIRING DRUGS: ANALYSIS Of SUBJECTIVE RESPONSES.
002332 02-14
USE Of SURVIVAL CURVES IN ANALYSIS Of ANTIPSYCHOTIC RELAPSE-
STUDIES.
002481 02-16
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO: A DISCRIMINANT fUNCTION ANALYSIS.
002482 02-16
COORDINATING CLINICAL-TRIALS IN PSYCHOPHARMACOLOGY:
PLANNING, DOCUMENTATION, AND ANALYSIS.
002574 02-17
fe
S-25
Subject Index
Psychopharmacology Abstracts
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS
INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJECTION OF
CYCLOHEXIMIDE.
002780 03-03
AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE
ANALYSIS OF APOMORPHINE-INDUCED-FIGHTING AND STEREOTYPY IN
THE RAT.
002983 03-04
AN ANALYSIS OF SPECIFICITY OF DRUG-INDUCED CHANGES IN DRUG-
REINFORCED RESPONDING. (PH.D. DISSERTATION).
003010 03-04
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED
REFLEXES IN RATS.
003100 03-04
POWER SPECTRAL ANALYSIS OF THE FLASH-EVOKED AFTERDISCHARGE,
003133 03-06
ANALYSIS OF SINGLE-BUND, DOUBLE-BUND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFECTS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS ~ BRIEF REPORT.
003298 03-11
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BUND TRIAL USING AN
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
OPERANT ANALYSIS OF HUMAN HEROIN SELF-ADMINISTRATION AND THE
EFFECTS OF NALTREXONE.
003449 03-14
TIME-BLIND ANALYSIS AND OTHER VIDEO-STRATEGIES IN PHASE II
TRIALS OF PSYCHOTROPIC-DRUGS.
003568 03-16
DRUG DEPENDENCE: REFLECTIONS ON AND ANALYSIS OF AN EXPERIENCE
IN THE PROVINCE OF RIGGIO-EMIUA.
003591 03-17
AN ANALYSIS OF DRUG DECISIONS IN A STATE PSYCHIATRIC-HOSPITAL.
003593 03-17
FURTHER ANALYSIS OF THE MECHANISMS OF ACTION OF
BATRACHOTOXIN ON THE MEMBRANE OF MYELINATED NERVE.
003884 04-03
RX-336-M, A NEW CHEMICAL TOOL IN THE ANALYSIS OF THE QUASI-
MORPHINE WITHDRAWAL-SYNDROME,
004093 04-04
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL.
004208 04-04
PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW
METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES.
004286 04-06
PROPHYLACTIC-EFFECT OF LITHIUM AGAINST DEPRESSION IN
CYCLOTHYMIC-PATIENTS: A LIFE-TABLE ANALYSIS.
004391 04-09
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO. A DISCRIMINANT FUNCTION ANALYSIS (UNPUBUSHED
PAPER).
004420 04-10
ANALYSIS OF SINGLE-BUND AND DOUBLE-BUND PROCEDURES,
MAINTENANCE OF PUCEBO-EFFECTS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON.
004437 04-11
MECHANISM OF LITHIUM INCLUDED ELEVATION IN RED-BLOOD-CELL
CHOUNE CONTENT: AN IN VITRO ANALYSIS
004511 04-13
COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPUED TO DRUG
EVALUATION: MIDAZOLAM IN NORMAL SUBJECTS.
004564 04-14
CHLORPROMAZINE ANALYSIS IN HUMAN PLASMA. (UNPUBUSHED
PAPER).
004591 04-15
MILD, MODERATE, SEVERE - THE STATISTICAL ANALYSIS OF SHORT
ORDINAL SCALES.
004677 04-16
GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA
DERIVATIZATION TECHNIQUES.
004687 04-16
A MULTIVARIATE ANALYSIS OF THE INFRARED SPEQRA OF DRUGS OF
ABUSE.
004688 04-16
ANALYTICAL
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL
CONFRONTATION OF ENDOGENOUS DEURIUM WITH DELUSIONS IN
PSYCHEDELIC-EXPERIENCES.
002200 02-12
ANALYZING
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO.
004387 04-09
ANASTOMOSIS
ORAL BIOAVAILABILITY OF APOMORPHINE IN THE RAT WITH A
PORTACAVAL VENOUS ANASTOMOSIS.
001158 02-03
ANATOMICOPHYSIOLOGICAL
ANATOMICOPHYSIOLOGICAL AND NEUROCHEMICAL-STUDY OF THE
UMBIC-SYSTEM: EFFECT OF NOMIFENSINE.
001160 02-03
ANATOMOBIOCHEMICAL
ANATOMOBIOCHEMICAL MAPPING OF THE BRAIN; NEUROPSYCHIATRIC-
CORRELATIONS.
002630 02-17
ANATOMY
STEREOCHEMICAL ANATOMY OF MORPHINOMIMETICS.
002197 02-12
ANESTHESIA
THE INFLUENCE OF CHLORALOSE ANESTHESIA ON THE AQIVITY OF RED
NUCLEUS NEURONS IN CATS.
000245 01-03
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA.
001151 02-03
INFLUENCE OF IMIPRAMINE AND PARGYUNE ON THE
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE,
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS.
001539 02-03
REDUaiON OF BARBITURATE ANESTHESIA BY NEW GLUTARIMIDE
COMPOUNDS IN MICE.
001748 02-04
ACCELERATED EXTINQION AFTER POSHRIAL HALOTHANE ANESTHESIA IN
RATS: AN AVERSIVE-EFFECT.
003001 03-04
EFFECTS OF ANESTHESIA ON PATIENTS TAKING PSYCHOTROPIC-DRUGS
003603 03-17
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN
REGIONS OF RAT-BRAIN WITH KETAMINE ANESTHESIA,
003891 04-03
RESPIRATORY DEPRESSION PRODUCED BY DIAZEPAM IN CATS: EFFEQ OF
ANESTHESIA.
004272 04-05
ANESTHETIC
ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS
000194 01-03
REGULATION OF THE STATE OF PHOSPHORYLATION OF SPECIFIC
NEURONAL PROTEINS IN MOUSE-BRAIN BY IN VIVO ADMINISTRATION
OF ANESTHETIC AND CONVULSANT-AGENTS.
000291 01-03
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND
AaiVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH
ANTICONVULSANT AND ANESTHETIC AQIONS.
002885 03-03
ANESTHETICS
FACTORS INFLUENCING SEIZURE DURATION AND NUMBER OF SEIZURES
APPLIED IN UNILATERAL ELECTROCONVULSIVE-THERAPY: ANESTHETICS
AND BENZODIAZEPINES.
000792 01-13
INHIBITION BY LOCAL ANESTHETICS, PHENTOLAMINE AND PROPRANOLOL
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL
MUSCARINIC-RECEPTORS
001097 02-03
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND
EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES
002799 03-03
THE EFFECTS OF VARIOUS ANESTHETICS ON AMYGDALOID KINDLED
SEIZURES.
002959 03-04
ANESTHETICS AND THE HABENULO-INTERPEDUNCULAR SYSTEM:
SELEQIVE SPARING OF METABOLIC AQIVITY.
003833 04-03
THE INTERAaiON OF AMINE LOCAL ANESTHETICS WITH MUSCARINIC-
RECEPTORS.
004031 04-03
ANESTHETIZED
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES:
EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION
IN THE ANESTHETIZED CAT.
001203 02-03
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE
ANESTHETIZED RATS.
002687 03-03
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED
CAT.
002740 03-03
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS.
003027 03-04
S-26
/OLUME 19, SUBJECT INDEX
Subject Index
CENTRAL HYPOTENSIVE-EFFECT Of GAMMA AMINOBUTYRIC-ACID IN
ANESTHETIZED DOGS.
003772 04-03
PRESSOR EFFECTS OF ELECTRICAL-STIMULATION OF THE DORSAL AND
MEDIAN RAPHE NUCLEI IN ANESTHETIZED RATS.
003892 04-03
kNOINA
TREATMENT OF UNSTABLE ANGINA BY DILTIAZEM.
004307 04-07
ANGIOTENSIN
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND )25l SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME ACTIVITY
IN THE RAT-BRAIN
001614 02-04
kNGIOTENSIN-ll
EVIDENCE OF A DIRECT ACTION OF ANGIOTENSIN-II ON NEURONES IN THE
SEPTUM AND IN THE MEDIAL PREOPTIC-AREA.
000272 01-03
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST,
1251 SARC0SINE1-LEUCINE8-ANG10TENSIN-II, WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES,
001125 02-03
NEURONAL SENSITIVITY OF SOME BRAIN REGIONS TO ANGIOTENSIN-II IN
RABBITS.
003716 04-03
CENTRAL-EFFECTS OF ANGIOTENSIN-II IN WATER AND SALINE LOADED
RATS.
003845 04-03
.NGIOTENSIN-II-INDUCED
INTRACRANIAL INJECTION PARAMETERS WHICH AFFECT ANGIOTENSIN-II-
INDUCED DRINKING.
000534 01-06
MIMAL
CHOLINERGIC ASPECTS OF TARDIVE-DYSKINESIA: HUMAN AND ANIMAL
STUDIES.
000928 01-17
ANIMAL ACTIVITY MONITOR FOR CHRONIC DRUG-STUDIES.
(UNPUBLISHED PAPER).
001794 02-04
QUANTITATIVE STUDY OF THE DISTRIBUTION OF LITHIUM IN THE MOUSE-
BRAIN FOR VARIOUS DOSES OF LITHIUM GIVEN TO THE ANIMAL.
002299 02-13
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION.
003052 03-04
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION.
003140 03-06
POSITRON-TOMOGRAPHY. A NEW METHOD FOR IN VIVO BRAIN STUDIES
OF BENZODIAZEPINE, IN ANIMAL AND IN MAN.
003564 03-16
EFFECTS OF ANIMAL AGE AND PHENOBARBITAL ON RAT LIVER GLUCOSE-
6-PHOSPHATASE AQIVITY.
003997 04-03
THE EFFECT OF PROPYLNORANTIFEIN ON BEHAVIORAL-REACTIONS
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE
ANIMAL BRAIN.
004075 04-04
EFFECTS OF PAIN, MORPHINE AND NALOXONE ON THE DURATION OF
ANIMAL HYPNOSIS.
004081 04-04
LACK OF SPECIFICITY OF AN ANIMAL BEHAVIOR MODEL FOR
HALLUCINOGENIC DRUG ACTION.
004250 04-04
NIMAL-MODEL
BIOCHEMICAL-STUDY OF THE ANIMAL-MODEL DEPRESSION INDUCED BY
TETRABENAZINE.
001506 02-03
DOPAMINERGIC INVOLVEMENT IN AHENTION A NOVEL ANIMAL-MODEL
001678 02-04
EFFECTS OF CHRONIC AMPHETAMINE OR RESERPINE ON SELF-
STIMULATION RESPONDING: ANIMAL-MODEL OF DEPRESSION?
001699 02-04
PRESYNAPTIC AND POSTSYNAPTIC SEROTONERGIC MANIPULATIONS IN
AN ANIMAL-MODEL OF DEPRESSION.
001730 02-04
A PHARMACOLOGICAL INVESTIGATION OF AN ANIMAL-MODEL OF THE
PETIT-MAL SEIZURE. (PH.D. DISSERTATION).
,„__^ 001870 02-06
EFFECTS OF D-AMPHETAMINE AND APOMORPHINE IN A NEW ANIMAL-
MODEL OF PETIT-MAL EPILEPSY.
002493 02-16
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE
INTOXICATION.
002988 03-04
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY
STUDY.
00308S 03-04
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN:
NEUROCHEMICAL-STUDIES IN AN ANIMAL-MODEL OF TARDIVE-
DYSKINESIA.
004268 04-05
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT
VERTEBRAL-ARTERY OF THE CAT,- A MODIFIED ANIMAL-MODEL FOR
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE
LOWER BRAINSTEM.
004297 04-06
ANIMAL-MODELS
ANIMAL-MODELS OF ANXIETY AND BENZODIAZEPINE ACTIONS.
000531 01-06
INTERACTION OF PSYCHOPHARMALOGIC-FACTORS AND PSYCHOSOCIAL-
FACTORS IN THE TREATMENT OF ANIMAL-MODELS OF
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR.
001602 02-04
ANIMAL-MODELS OF PSYCHIATRIC-DISORDERS.
001871 02-06
ANIMAL-MODELS OF RELEVANCE TO BIOLOGICAL-PSYCHIATRY.
002490 02-16
ANIMAL-MODELS OF TARDIVE-DYSKINESIA.
003476 03-15
ANIMALS
IMIPRAMINE AND REM SLEEP: CHOLINERGIC MEDIATION IN ANIMALS.
000406 01-04
ASSESSMENT OF ADRENERGIC-RECEPTORS IN VIVO IN EXPERIMENTAL
ANIMALS AND MAN. (UNPUBLISHED PAPER).
001034 02-01
A CLASSIFICATION OF OPIATE-RECEPTORS THAT MEDIATE
ANTINOCICEPTION IN ANIMALS.
001807 02-04
BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS
AND MAN.
002527 02-17
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE
INJECTION IN NEWBORN ANIMALS.
002774 03-03
PLASMA IMIPRAMINE LEVELS AND DEMETHYLASE ACTIVITY IN THE
LIVER OF STRESSED ANIMALS.
002793 03-03
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID:
DIFFERENTIAL-EFFECT IN TOLERANT ANIMALS.
003038 03-04
SPECIFIC AND NONSPECIFIC MULTIPLE UNIT ACTIVITIES DURING
PENTYLENETETRAZOL SEIZURES. I. ANIMALS WITH ENCEPHALE ISOLE.
004046 04-03
ANALGESIC AND OTHER PHARMACOLOGICAL ACTIVITIES OF A NEW
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3
METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS
ENANTIOMORPH IN EXPERIMENTAL ANIMALS.
004185 04-04
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFECTS ON
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING
IN VITRO.
004198 04-04
LITHIUM AND MOTOR-ACTIVITY OF ANIMALS: EFFECTS AND POSSIBLE
MECHANISM-OF-ACTION.
004222 04-04
THE EFFECT OF MEBICAR ON THE CONDITION OF ANIMALS UNDER
CERTAIN EXTREME CIRCUMSTANCES.
004262 04-04
ANIONS
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR
BRAIN SPECIFIC BENZODIAZEPINE BINDING.
002903 03-03
ANISAMIDE
NEUROPHYSIOLOGICAL-STUDY OF TWO 0 ANISAMIDE DERIVATIVES:
SULPIRIDE AND SULTOPRIDE.
001170 02-03
ANISAMIDES
PHARMACOLOGICAL REFLECTIONS ON 0 ANISAMIDES.
002292 02-13
ANISOMYCIN
EFFECTS OF ANISOMYCIN ON RETENTION OF THE PASSIVE-AVOIDANCE
HABIT AS A FUNCTION OF AGE.
004097 04-04
ANOCOCCYGEUS-MUSCLE
EFFECT OF MIANSERIN ON NORADRENERGIC TRANSMISSION IN THE RAT
ANOCOCCYGEUS-MUSCLE.
000075 01-03
2
fe
I
S-27
Subject Index
Psychopharmacology Abstracts
ANORECTIC-ACTIONS
DOUBLE-BUND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS.
002314 02-14
THE EFFEQ OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON
THE STIMULANT AND ANORECTIC-ACTIONS OF DEXTROAMPHETAMINE
IN MAN.
004580 04-14
ANORECTIC-ACTIVITY
EFFECT OF DESMETHYLIMIPRAMINE ON TISSUE DISTRIBUTION AND
ANORECTIC-ACTIVITY OF CHLORPHENTERMINE IN RATS.
004179 04-04
ANORECTIC-AGENTS
EFFECTS OF SPIPERONE ALONE AND IN COMBINATION WITH ANOREQIC-
AGENTS ON FEEDING PARAMETERS IN THE RAT.
001598 02-04
INTERACTIONS OF CHLORDIAZEPOXIDE AND ANORECTIC-AGENTS ON RATE
AND DURATION PARAMETERS OF FEEDING IN THE RAT.
001600 02-04
ANORECTIC-DRUGS
PSYCHOPHARMACOLOGY OF ANORECTIC-DRUGS IN MAN.
002607 02-17
ANORECTIC-EFFECT
ANORECTIC-EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES IN THE
RAT
000042 01-03
ANORECTIC-PROPERTIES
ANORECTIC-PROPERTIES OF A NEW LONG ACTING SEROTONIN UPTAKE
INHIBITOR.
004105 04-04
ANOREXIA
AnENUATION OF AMPHETAMINE ANOREXIA IN RATS FOLLOWING
SUBCHRONIC-TREATMENT WITH A TRICYCLIC-ANTIDEPRESSANT
000501 01-04
THE EFFECTS OF PARA CHLOROAMPHETAMINE ON FENFLURAMINE
ANOREXIA IN AD LIBITUM AND STIMULATION-INDUCED FEEDING IN
THE RAT.
001823 02-04
DIFFERENTIAL-EFFECTS OF PHARMACOLOGICAL-AGENTS ACTING ON
MONOAMINERGIC SYSTEMS ON DRUG-INDUCED ANOREXIA
002533 02-17
SUBSTITUTED PHENETHYLAMINES AND ANOREXIA.
002541 02-17
EVIDENCE THAT IT IS POSSIBLE TO CAUSE ANOREXIA BY INCREASING
RELEASE AND/OR DIREQLY STIMULATING POSTSYNAPTIC SEROTONIN-
RECEPTORS IN THE BRAIN
002602 02-17
EFFECTS OF A HIGH-DOSE TREATMENT OF METHAMPHETAMINE ON
CAUDATE DOPAMINE AND ANOREXIA IN RATS
004073 04-04
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND
CONDITIONED TASTE-AVERSION.
004121 04-04
ANOREXIA-NERVOSA
BODY-WEIGHT AND RESPONSES TO LHRH INFUSION IN ANOREXIA-
NERVOSA.
002062 02-10
HORMONAL ABNORMALITIES IN ANOREXIA-NERVOSA (AN).
002099 02-11
NALOXONE IN THE TREATMENT OF ANOREXIA-NERVOSA: EFFECT ON
WEIGHT-GAIN AND LIPOLYSIS.
003342 03-11
TREATMENT OF UNDERNUTRITION AND ELEaROLYTE-DISTURBANCES IN
ANOREXIA-NERVOSA.
004531 04-13
ANOREXIA-NERVOSA. SYMPTOMS, COURSE AND POSSIBILITIES FOR
TREATMENT.
004711 04-17
ANOREXIC
THE ANOREXIC AND ACTOMETRIC EFFECTS OF COCAINE AND TWO COCA-
EXTRACTS.
000344 01-04
ANOSMIA
EFFECTS OF OLFACTORY-BULBEaOMY AND PERIPHERALLY-INDUCED
ANOSMIA ON THERMOREGULATION IN THE RAT: SUSCEPTIBILITY TO
ANTIDEPRESSANT-DRUGS.
004113 04-04
ANOXIC
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
ANTAGONISE
CONVULSANTS ANTAGONISE INHIBITION IN THE OLFAQORY-CORTEX
SLICE.
001466 02-03
ANTAGONISES
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONISES THE EFFECT OF
DIAZEPAM ON A FUNCTIONAL GABA-RECEPTOR.
001378 02-03
ANTAGONISM I
NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE '
POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS.
000116 01-03
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND
GABAMIMETICS.
000188 01-03
METERGOLINE ANTAGONISM OF 5 HYDROXYTRYPTAMINE-INDUCED
AQIVATION OF RAT-CEREBRAL-CORTICAL NA-K-ATPASE.
000329 01-03
MORPHINE EFFECTS UPON DISCRIMINATED APPROACH AND
DISCRIMINATED AVOIDANCE IN RATS: ANTAGONISM BY NALOXONE.
000338 01-04
REWARD SYSTEM DEPRESSION FOLLOWING CHRONIC AMPHETAMINE:
ANTAGONISM BY HALOPERIDOL.
000342 01-04
METHIONINE-ENKEPHALIN ANTAGONISM AND ENDORPHIN POTENTIATION
OF NARCOTIC-INDUCED ANALGESIA.
000357 01-04
STEREOSPECIFIC, DOSE-DEPENDENT ANTAGONISM BY NALOXONE OF
NONOPIATE BEHAVIOR IN MICE
000411 01-04
ANTAGONISM BY CLASSICAL ANTIEPILEPTICS AND SODIUM-VALPROATE
OF CEFAZOLIN-INDUCED EXPERIMENTAL EPILEPSY IN RATS.
000442 01-04
THE NEW ANTIDEPRESSANT PIRLINDOLE: ANTAGONISM OF ACUTE
OVERDOSAGE IN THE MOUSE.
001082 02-02
ANTAGONISM OF THE RENAL VASODILATOR AQIVITY OF DOPAMINE BY
METOCLOPRAMIDE
001265 02-03
ANTAGONISM OF 5 HYDROXYTRYPTAMINE-RECEPTORS BY QUIPAZINE.
001329 02-03
ANTAGONISM OF 2 DEOXY-D-GLUCOSE-INDUCED HYPERPHAGIA BY
NALOXONE: POSSIBLE INVOLVEMENT OF ENDORPHINS.
001773 02-04
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE
002242 02-13
APOMORPHINE HALOPERIDOL INTERACTIONS: DIFFERENT TYPES OF
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS.
002662 03-03
SELEQIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFEQS OF FENTANYL ON
THE CONTRAQION OF THE NICTITATING MEMBRANE IN CATS.
002876 03-03
ANTAGONISM BY CHLORNALTREXAMINE OF SOME EFFEQS OF DELTA9
TETRAHYDROCANNABINOL IN RATS.
003104 03-04
ANTAGONISM OF INTRAVENOUS COCAINE LETHALITY IN NONHUMAN
PRIMATES.
003127 03-05
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE JL
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY ■
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED
SEROTONERGIC MECHANISMS
003748 04-03
PRESYNAPTIC AND POSTSYNAPTIC ALPHA-AORENOCEPTOR ANTAGONISM
BY NEUROLEPTICS IN VIVO.
003966 04-03
USE OF THE INTRACEREBRAL INJEQION TECHNIQUE TO ELUCIDATE
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN
THE MOUSE.
004092 04-04
ANTAGONISM OF SOME CENTRAL-EFFEaS OF D TUBOCURARINE BY
GAMMA AMINOBUTYRIC-ACID.
004102 04-04
IS DOPAMINE ANTAGONISM A REQUISITE OF NEUROLEPTIC AQIVITY?
004122 04-04
BENZODIAZEPINE ANTAGONISM BY HARMANE AND OTHER BETA
CARBOLINES IN VITRO AND IN VIVO
004211 04-04
ANTAGONISM BY PHENOXYBENZAMINE AND PENTAZOCINE OF THE
ANTINOCICEPTIVE-EFFECTS OF MORPHINE IN THE SPINAL-CORD.
004213 04-04
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN:
NEUROCHEMICAL-STUDIES IN AN ANIMAL-MODEL OF TARDIVE-
DYSKINESIA.
004268 04-05
S-28
VOLUME 19, SUBJECT INDEX
Subject Index
ANTAGONISMS
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA
D(AND L) GLUTAMYLGLYCINE.
002696 03-03
ANTAGONIST
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE ACETYLCHOLINE
ANTAGONIST DIMETHYLAMINOBUTYNYLCYCLOHEXYLHYDROXY 2
PHENYLACETATE HCL.
000003 01-01
ALPHA FLUPENTHIXOL: AN ANTAGONIST OF DOPAMINE-EVOKED FLUID
SECRETION BY AN INSECT SALIVARY-GLAND PREPARATION.
000031 01-03
HYPOALGESIA INDUCED BY MICROINJECTION OF A NOREPINEPHRINE
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL
ADMINISTRATION OF A SEROTONIN ANTAGONIST.
000121 01-03
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING
DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS
OF MAMMALIAN FOREBRAIN IN VITRO.
001114 02-03
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND
DOPAMINE ANTAGONIST RECEPTOR SITES.
001254 02-03
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES.
001342 02-03
EFFEaS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A
DELAYED TYPE HYPERSENSITIVITY REACTION TO 1
CHLORODINITROBENZENE IN MICE.
001473 02-03
NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO
WITHDRAWAL INDUCING BENZAZOCINES. (PH.D. DISSERTATION)
001518 02-03
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST
CHLORNALTREXAMINE.
001695 02-04
DOPAMINE ANTAGONIST AND AGONIST TREATMENT OF TARDIVE-
DYSKINESIA.
002377 02-15
RECEPTOR BINDING PROFILE OF R-41-468, A NOVEL ANTAGONIST AT 5
HT2-RECEPT0RS.
002648 03-02
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE
AGONIST AND ANTAGONIST RECEPTOR INTERACTIONS.
002688 03-03
OPIATE ANTAGONIST IMPROVES NEUROLOGIC RECOVERY AFTER SPINAL
INJURY.
002714 03-03
PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN
MAMMALIAN RETINA.
002814 03-03
DOPAMINERGIC AGONIST AND ANTAGONIST EFFECTS ON STRIATAL
TYROSINE-HYDROXYLASE DISTRIBUTION.
002898 03-03
A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE (PH D
DISSERTATION).
002918 03-03
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS.
003068 03-04
MORPHINE-LIKE STIMULUS EFFEaS IN THE MONKEY: OPIOIDS WITH
ANTAGONIST PROPERTIES.
003086 03-04
GABA AND SCHIZOPHRENIA: STUDY OF THE ACTION OF A GABAERGIC
ANTAGONIST. PROGABIDE OR SL-76-002.
003175 03-08
THE USE OF A MORPHINE ANTAGONIST (NALOXONE) IN THE TREATMENT
OF DISSOCIATIVE-SYNDROMES.
003194 03-08
CLINICAL-PHARMACOLOGY OF MIXED AGONIST ANTAGONIST DRUGS
003329 03-11
STRUaURE-ACTIVITY AND RECEPTOR BINDING OF ANTAGONIST
ANALGESICS.
T,,r„„„ 00361103-17
THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A
COMPETITIVE ANTAGONIST AT ALPH A 1 -ADRENOCEPTORS
003785 04-03
RESPONSE OF STRIATONIGRAL SUBSTANCE-P SYSTEMS TO A DOPAMINE-
RECEPTOR AGONIST AND ANTAGONIST.
003826 04-03
ISOMERIZATION OF THE MUSCARINIC-RECEPTOR ANTAGONIST COMPLEX.
003860 04-03
EFFECTS OF MORPHINE AND CAFFEINE ON ADENOSINE RELEASE FROM
RAT-CEREBRAL-CORTEX: IS CAFFEINE A MORPHINE ANTAGONIST.
003864 04-03
ACTIONS OF MU, KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION.
004053 04-03
PHARMACOLOGICAL-STUDIES WITH AN ALKYLATING NARCOTIC
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST
CHLORNALTREXAMINE.
004082 04-04
ANALGESIC AND OTHER PHARMACOLOGICAL ACTIVITIES OF A NEW
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3
METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS
ENANTIOMORPH IN EXPERIMENTAL ANIMALS.
004185 04-04
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFECTS ON
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING
IN VITRO.
004198 04-04
HUMAN PLATELET ALPHA2-ADRENERGIC-RECEPT0RS: LABELING WITH 3H
YOHIMBINE, A SELECTIVE ANTAGONIST LIGAND.
004676 04-16
ANTAGONISTIC-EFFECTS
ANTAGONISTIC-EFFECTS OF PROPRANOLOL UPON ETHANOL-INDUCED
NARCOSIS IN MICE.
000439 01-04
ANTAGONISTIC-EFFECTS OF PSYCHOLEPTIC-DRUGS ON STRESS-INDUCED
ANALGESIA.
001609 02-04
ANTAGONISTS
SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA-
ADRENOCEPTOR ANTAGONISTS: EVIDENCE AGAINST GABA
MEDIATION.
000024 01-03
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING.
000099 01-03
HYPOALGESIA FOLLOWING MICROINJECTION OF NORADRENERGIC
ANTAGONISTS IN THE NUCLEUS-RAPHE-MAGNUS.
000122 01-03
COMPARTMENTATION OF CATECHOLAMINES IN RAT-BRAIN: EFFECTS OF
AGONISTS AND ANTAGONISTS.
000125 01-03
EFFECTS OF NORADRENERGIC AGONISTS AND ANTAGONISTS ON
GROWTH-HORMONE SECRETION UNDER GAMMA HYDROXYBUTYRATE
NARCOANALGESIA IN THE RAT.
000262 01-03
EFFECTS OF ANTICONVULSANTS AND GLUTAMATE ANTAGONISTS ON THE
CONVULSIVE ACTION OF KAINIC-ACID.
000288 01-03
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
RECEPTORS.
000323 01-03
POSTSWIM GROOMING IN MICE INHIBITED BY DOPAMINE-RECEPTOR
ANTAGONISTS AND BY CANNABINOIDS.
000359 01-04
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFECTS ON
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE
PARADIGM.
000372 01-04
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS
AND ANTAGONISTS: ZONE-SPECIFIC EFFECTS.
000422 01-04
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED
DIFFERENTIATION) IN THE MONKEY (MACACA-MULAHA).
000440 01-04
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELECTIVE
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR-
STIMULATION INDUCEn BY INDIRECTLY ACTING SYMPATHOMIMETIC-
AMINES IN MICE.
000492 01-04
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS. (UNPUBLISHED
PAPER).
001035 02-01
EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS.
001146 02-03
^
S-29
Subject Index
INTERACTION-STUDIES BETWEEN NARCOTIC ANALGESICS, NARCOTIC
ANTAGONISTS AND ETHANOL: STUDIES DURING ACUTE AND CHRONIC-
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE. (PH.D.
■^'SSE^TATION). 001165 02-03
A PROPOSED MODE OF ACTION FOR NARCOTIC AGONISTS AND
^^^^^°'^'S^^- 001168 02-03
EFFECT OF GABA AGONIST AND ANTAGONISTS ON CARDIOVASCULAR
AND SYMPATHETIC RESPONSES IN SHR AND WKY RATS.
(UNPUBLISHED PAPER). 001224 02-03
AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL
DOPAMINE-RECEPTORS AFTER VARIOUS TREATMENTS WITH
ANTAGONISTS OR AGONISTS. 001350 02-03
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC-
STUDY
^ 001410 02-03
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE
AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS.
(UNPUBLISHED PAPER). 001488 02-03
NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR
CENTRAL ALPHAl-ADRENOCEPTORS. 001508 02-03
OPIATE ANTAGONISTS AND LONG-TERM ANALGESIC REACTION INDUCED
BY INESCAPABLE SHOCK IN RATS. 001707 02-04
OPIATE ANTAGONISTS AND FEMALE FUNCTIONING. (UNPUBLISHED
^'^^^^'> 001735 02-04
LACK OF EFFECT OF CHOLINE AND NARCOTIC ANTAGONISTS UPON
APOMORPHINE DISCRIMINATION. „„,-,-,„ „o /^>.
001770 02-04
BIPHASIC-EFFECTS OF DIRECT, BUT NOT INDIRECT, GABAMIMETICS AND
ANTAGONISTS ON HALOPERIDOL-INDUCED CATALEPSY,
OUIozO Uz-U4
DISPOSITION AND ACTIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY.
001878 Oz-Oo
CHARACTERIZATION OF ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLAQIN AND GROWTH-HORMONE PROFILES
DURING WAKEFULNESS AND SLEEP. ^^^^^ ^^.is
EFFECT OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND
NORMAL ADULTS, 002222 02-13
SELECTIVE ANTAGONISTS OF BENZODIAZEPINES.
00z64o Uo-U/
GABA ANTAGONISTS ENHANCE DOPAMINE TURNOVER IN THE RAT
^™^'^^'^° 002772 03-03
THE EFFECTS OF OPIATE ANTAGONISTS ON THE DISCRIMINATIVE
STIMULUS PROPERTIES OF ETHANOL, ^^^^^ ^^_^^
THE EFFECTS OF OPIATE ANTAGONISTS ON FOOD INTAKE ARE
^^^^^OSPKmC 003080 03-04
SUPERSENSITIVITY TO THE BEHAVIORAL-EFFEQS OF OPIATE
^^^^^°^'^^^ 003096 03-04
THE RELATIONSHIP BETWEEN THE ACUTE BEHAVIORAL-EFFEQS OF
NARCOTIC ANTAGONISTS AND THE NARCOTIC DEPENDENT STATE,
003106 03-04
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMIHER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
^^^^^^^^^'^'^ 003134 03-06
PHARMACOLOGICAL ANTAGONISTS OF EXCITANT AMINO-ACID ACTION,
003587 03-17
PRESYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION IN HELIX-
POMATIA: THE EFFECTS OF SEROTONIN AND DOPAMINE
^^^^^°^'^^^- 003869 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE-
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA;
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS.
004051 04-03
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT
^'°^^^- 004054 04-03
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFECTS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
«^S''0^5^- 004119 04-04
Ptychopharmacology Abstracts
INTERAQIONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR,
004127 04-04
EFFECTS OF NARCOTIC ANTAGONISTS ON L-DOPA REVERSAL OF
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE.
004186 04-04
MORPHINE ANTAGONISTS AND CONSUMMATORY-BEHAVIORS.
004196 04-04
RETROGRADE AMNESIA PRODUCED BY ELEaRICAL-STIMULATION OF THE
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS.
004231 04-04
ANTAGONIZE ^^ ,^
ANTICONVULSANTS SPECIFIC FOR PETIT-MAL ANTAGONIZE
EPILEPTOGENIC-EFFECT OF LEUCINE-ENKEPHALIN.
000477 01-04
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN. _^^^, ^^ ^,
002801 03-03
THE BENZODIAZEPINES AND INOSINE ANTAGONIZE CAFFEINE-INDUCED
'''''''' 004172 04-04
ANTAGONIZED „_
BEHAVIORAL-EFFEaS AND ELEaROCORTICAL-EFFECTS AFTER
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS
ENHANCING GABAERGIC TRANSMISSION
000443 01-04
EFFECTS OF 5 HYDROXYTRYPTAMINE ON CENTRAL NEURONES
ANTAGONIZED BY BICUCULLINE AND PICROTOXIN.
003931 04-03
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES
BEHAVIOURAL-EFFEaS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN
^'^^^ 000420 01-04
BICUCULLINE ANTAGONIZES EFFEQS OF DIAZEPAM ON AGGRESSIVE AND
TIMID-BEHAVIOUR IN MICE.
000485 01-04
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC,
ANTAGONIZES HALOPERIDOL-INDUCED AQIVATION OF STRIATAL
DOPAMINE SYNTHESIS. «„o-,n, «o «-,
002786 03-03
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONIZES DIAZEPAM
ACTIVITY. „„o^,r^, „,
002915 03-03
ETHYL-BETA-CARBOLINE-CARBOXYLATE LOWERS SEIZURE THRESHOLD
AND ANTAGONIZES FLURAZEPAM-INDUCED SEDATION IN RATS.
002971 03-04
A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/
BENZODIAZEPINE-RECEPTOR INTERAQION.
3 HYDROXYMETHYL-BETA-CARBOLINE ANTAGONIZES SOME
PHARMACOLOGIC AQIONS OF DIAZEPAM. ^
^'^^Am-^EDE^TS OF SELF-INDUCED WATER INTOXICATION: A PRELIMINARY-
'^EPO''^ 002414 02-15
AUTEI CpCIIJ
TREATMENT OF EPILEPSIES WITH CLONAZEPAM (ANTELEPSIN).
00448 1 04- 1 I
^''"nf DEVELOPMENT OF PROGENY IN CASES OF ANTENATAL EXPOSURE TO
^»^^^^^'^^ 001854 02-Of
^'^"aILURE of ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELEQRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
'-^^^ 000520 01-0;
THE EFFECTS OF BOMBESIN INJEQED INTO THE ANTERIOR AND ^„^^^,
POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN
CONSUMPTION. 001544 02-0-
THE INFLUENCE OF ANTERIOR NEOSTRIATAL LESIONS ON THE
BEHAVIOURAL-EFFECTS OF SPIROPERIDOL IN RATS. ^^^^^ ^^^
TEMPORAL PAHERNING OF NEURONAL AQIVITY DURING THERMAL ANC
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT. ^^^^^ ^^_^,
ANTERIOR PITUITARY GABA-RECEPTORS AND THEIR REGULATION OF
PROLAQIN SECRETION. 002738 03-0:
THE DIREQ EFFECT OF RESERPINE IN VITRO ON PROLAQIN RELEASE
FROM RAT ANTERIOR PITUITARY-GLANDS. ^^^^^ ^^^
S-30
I
/OLUME 19, SUBJECT INDEX
Subject Index
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR
002945 03-04
ROLE OF THE ANTERIOR PITUITARY GABA-RECEPTOR IN THE CONTROL OF
PROLACTIN RELEASE.
003809 04-03
EFFECTS OF CAFFEINE ON ANTERIOR PITUITARY AND THYROID-FUNCTION
IN THE RAT.
004014 04-03
lNTERIOR-CH AMBER
SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE:
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT.
000095 01-03
lNTERIOR-FOREBRAIN
RELATIONSHIPS BETWEEN SELECTIVE DENERVATION OF DOPAMINE
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL-
RESPONSES TO AMPHETAMINE AND APOMORPHINE.
000384 01-04
kNTEROGRADE
TIME-DEPENDENT CHANGES IN ANTEROGRADE SCOPOLAMINE-INDUCED
AMNESIA IN RATS.
004182 04-04
iNTI-BETA-ENDORPHIN
SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI-
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS.
002871 03-03
iNTI-DElTA9-TETRAHYDROCANNABINOL
IN VIVO AND IN VITRO PROPERTIES OF ANTI-DELTA9-
TETRAHYDROCANNABINOL ANTIBODY.
003751 04-03
iNTI-RAT
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER).
001122 02-03
lNTI-THY-1-2
ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT
CELL TYPE SPECIFIC TOXIN. (UNPUBLISHED PAPER).
001064 02-01
lNTIADRENERGIC
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC
DRUGS.
001330 02-03
iNTIALCOHOLISM-DRUG
ARCALION-200 PRESCRIBED AS A PSYCHIATRIC-DRUG AND
ANTIALCOHOLISM-DRUG ON AN OUTPATIENT AND INPATIENT BASIS.
002103 02-11
lNTIANOROGENS
PHARMACOTHERAPY FOR SEXUAL-OFFENDERS: REVIEW OF THE ACTION
OF ANTIANDROGENS WITH SPECIAL REFERENCE TO THEIR PSYCHIC-
EFFECTS.
004455 04-1 1
CLINICAL APPLICATION OF ANTIANDROGENS IN PSYCHIATRY.
004457 04-1 1
ANTIANXIETY
1 AMIN0ALKYL-6-ARYL-4H-S-TRIAZ0L0BENZ0DIAZEPINES WITH
ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY.
001074 02-02
2,4 DIHYDRO-6-PHENYL-lH-S-TRIAZOLOBENZODIAZEPIN-l-ONES WITH
ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY.
001075 02-02
6 SUBSTITUTED AMIN0-4H-S-TRIAZ0L0BENZ0DIAZEPINES AND 4
SUBSTITUTED AMIN0-6H-S-TRIAZ0L0BENZ0DIAZEPINES WITH
POTENTIAL ANTIANXIETY ACTIVITY.
001076 02-02
PHARMACOLOGY OF 1 DICHLOROBENZYL-TETRAHYDROPYRIMIDONE, A
NOVEL ANTIDEPRESSANT COMPOUND WITH ANTIANXIETY ACTIVITY.
003688 04-02
THE EFFECTS OF ANTIANXIETY AND ANTIPSYCHOTIC-DRUGS ON SEXUAL-
BEHAVIOR.
004657 04-15
AN EVALUATION OF THE ANTIANXIETY ACTION AND SIDE-EFFECTS OF
PROPRANOLOL.
004660 04-15
lNTIANXIETY-AGENT
HOSTILITY PRODUCTION AS A COMMON FEATURE OF ANTIANXIETY-
AGENT ACTION.
004654 04-15
kNTIANXIETY-AGENTS
ANTIANXIETY-AGENTS AND SYNAPTIC TRANSMISSION IN THE BRAIN:
ELECTROPHYSIOLOGICAL-STUDIES. (PH.D. DISSERTATION).
002840 03-03
kNTIANXIETY-DRUG
PERSONALITY TRAIT AND ANTIANXIETY-DRUG EFFECTS ON
PSYCHOMOTOR PERFORMANCE.
002336 02-14
ANTIANXIETY-DRUGS
EFFECT OF ANTIANXIETY-DRUGS ON FEAR AND STRESS.
000801 01-14
POSSIBLE LIMBIC SITES OF ACTION OF ANTIANXIETY-DRUGS
002069 02-10
DISINHIBITION OF BEHAVIOR BY ANTIANXIETY-DRUGS
002403 02-15
ANTIANXIETY-EFFECTS
METHODS AND METHODOLOGICAL-CONSIDERATIONS IN MEASURING
ANTIANXIETY-EFFECTS OF TRANQUILIZING-DRUGS
002537 02-17
ANTIARRHYTHMIC-ACTIVITY
ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION:
CYPROHEPTADINIUM-METHIODIDE
001534 02-03
ANTIAVOIDANCE
CORRELATION BETWEEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC-
DRUGS IN RATS AND DAILY CLINICAL DOSES.
003032 03-04
ANTIBIOTICS
EFFECTS OF THREE ANTIBIOTICS ON THEOPHYLLINE KINETICS.
000784 01-13
ANTIBODIES
AFFINITY CHROMATOGRAPHY OF THE BETA-ADRENERGIC-RECEPTOR AND
CHARACTERIZATION OF ANTIBODIES RAISED AGAINST PURIFIED
RECEPTOR PREPARATIONS.
001009 02-01
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL-
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF
ANTIBODIES TO GANGLIOSIDE.
003025 03-04
BEHAVIOURAL-CHANGES IN ADULT RATS FOLLOWING ADMINISTRATION
OF ANTIBODIES AGAINST BRAIN GANGLIOSIDES.
003071 03-04
ANTIBODY
PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID-
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY
COMPLEX. (UNPUBLISHED PAPER).
001047 02-01
ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT
CELL TYPE SPECIFIC TOXIN. (UNPUBLISHED PAPER).
001064 02-01
IN VIVO AND IN VITRO PROPERTIES OF ANTI-DELTA9-
TETRAHYDROCANNABINOL ANTIBODY.
003751 04-03
ANTICANDIDAL-ACTIVITY
ANTICANDIDAL-ACTIVITY OF PYRIMIDINE-PEPTIDE CONJUGATES.
001059 02-01
ANTICHOLINERGIC
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES
BEHAVIOURAL-EFFECTS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN
RATS.
000420 01-04
LONG-TERM APPLICATION OF HALOPERIDOL: EFFECT OF ANTICHOLINERGIC
TREATMENT ON THE RATE OF DOPAMINE SYNTHESIS.
001490 02-03
ANTICHOLINERGIC-ACTIVITY
THE PERIPHERAL ANTICHOLINERGIC-ACTIVITY OF TRICYCLIC-
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND
DESIPRAMINE IN HUMAN VOLUNTEERS.
002298 02-13
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT
ANTICHOLINERGIC-ACTIVITY BY AN ATYPICAL NEUROLEPTIC
(THIORIDAZINE).
0035') 03-16
ANTICHOLINERGIC-DRUGS
INDIVIDUAL DIFFERENCES IN EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS
AND ANTICHOLINERGIC-DRUGS ON OPERANT-BEHAVIOR IN THE
SQUIRREL-MONKEY.
004176 04-04
ANTICHOLINERGIC-EFFECTS
STUDIES ON THE PUTATIVE ANTICHOLINERGIC-EFFECTS OF
DESMETHYLIMIPRAMINE.
000228 01-03
ANTICHOLINERGIC-EFFECTS AND PLASMA DESIPRAMINE LEVELS.
004550 04-13
ANTICHOLINERGIC-SYNDROME
THE INTERACTION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS.
000389 01-04
ANTICHOLINERGICS
ANTICHOLINERGICS PROMOTE NEUROLEPTIC-INDUCED TARDIVE-
DYSKINESIA.
001834 02-05
ANTICHOLINESTERASES
THE INTERACTION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS.
000389 01-04
^
S-31
Subject Index
Psychopharmacology Abstracts
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
ANTICONFLICT
RELATIONSHIP OF ANTICONFLICT ACTIVITY OF BENZODIAZEPINES TO
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA.
000057 01-03
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK-
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES).
003898 04-03
ANTICONVULSANT
EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL
AND DIPHENYLHYDANTOIN IN THE ELECTROSHOCK-TEST IN MICE.
000163 01-03
single-dose pharmacokinetics and anticonvulsant efficacy of
pria;\idone in mice.
000177 01-03
ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS,
000194 01-03
STRUCTURE-ACTIVITY RELATIONSHIPS IN THE EFFECTS OF PHENACEMIDE
ANALOGS ON SERUM CREATININE AND ANTICONVULSANT ACTIVITY.
000249 01-03
CORRELATION BETWEEN BENZODIAZEPINE-RECEPTOR OCCUPATION AND
ANTICONVULSANT EFFECTS OF DIAZEPAM.
000450 01-04
PROCONVULSANT AND ANTICONVULSANT ACTION OF MORPHINE IN
RATS
000494 01-04
3 CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE {GS-385), A
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION,
PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE
LIQUID-CHROMATOGRAPHY.
000705 01-11
EVALUATION OF CLORAZEPATE (TRANXENE) AS AN ANTICONVULSANT -
A PILOT-STUDY.
000728 01-11
ON THE GENETIC SIDE-EFFECTS OF PSYCHOTROPIC-SUBSTANCES: I
PSYCHOPHARMACEUTICALS, NARCOTICS, AND ANTICONVULSANT.
000845 01-15
CONVULSANT AND ANTICONVULSANT BARBITURATES 1 . MOLECULAR
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY
CALCULATIONS.
001029 02-01
EEG AND ANTICONVULSANT EFFECTS OF DIPROPYLACETIC-ACID AND
DIPROPYLACETAMIDE IN THE BABOON PAPIO-PAPIO.
001210 02-03
ANTICONVULSANT PROPERTIES OF S ADENOSYL-L-HOMOCYSTEINE.
001227 02-03
DRUG-INDUCED ELEVATION OF GABA AFTER INTRACEREBRAL
MICROINJECTION: SITE OF ANTICONVULSANT ACTION.
001627 02-04
SUBACUTE CANNABINOID TREATMENT: ANTICONVULSANT ACTIVITY AND
WITHDRAWAL EXCITABILITY IN MICE.
001671 02-04
THE ANTICONVULSANT PROPERTIES OF MELATONIN ON KINDLED
SEIZURES IN RATS.
002653 03-03
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH
ANTICONVULSANT AND ANESTHETIC ACTIONS.
002885 03-03
CORRELATION OF (14C)MUSCIM0L CONCENTRATION IN RAT-BRAIN WITH
ANTICONVULSANT ACTIVITY.
003045 03-04
KETAMINE: CONVULSANT OR ANTICONVULSANT?
003060 03-04
A POSSIBLE ROLE FOR CATECHOLAMINE NEUROTRANSMITTERS IN THE
ANTICONVULSANT ACTIVITY OF CHLORDIAZEPOXIDE.
003119 03-04
ON THE ANTICONVULSANT BLOOD LEVEL IN THERAPY-RESISTANT
EPILEPTIC-PATIENTS.
003300 03-1 1
A PROSPECTIVE RANDOMISED-TRIAL ON THE EFFECT OF MONITORING
PLASMA ANTICONVULSANT LEVELS IN EPILEPSY.
003314 03-11
ANTICONVULSANT PROPERTIES OF SELECTED PYRROLOPYRIMIDINEDIONES
AND INTERMEDIATES.
003700 04-02
THE EFFEQ OF SODIUM-DIPROPYLACETATE ON GAMMA AMINOBUTYRIC-
ACID DEPENDENT INHIBITION IN THE RAT-CORTEX AND SUBSTANTIA-
NIGRA IN RELATION TO ITS ANTICONVULSANT ACTIVITY.
003880 04-03
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION I
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK- '
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES).
003898 04-03
ANTICONVULSANT ACTIVITY OF METABOLITES OF VALPROIC-ACID.
004168 04-04
BIOCHEMICAL-STUDIES OF HUMAN EPILEPTICS DURING ANTICONVULSANT
THERAPY
004490 04-11
ANTICONVULSANT-AGENTS
SYNTHESIS OF PHENYLURETHANS OF 1,2 DIALKYL-4-PYRAZOLIDINOLS AS
ANTICONVULSANT-AGENTS.
003695 04-02
ANTICONVULSANT-DRUG
3 SULFAMOYLMETHYL-l-2-BENZISOXAZOLE, A NEW TYPE OF
ANTICONVULSANT-DRUG: PHARMACOLOGICAL PROFILE.
000012 01-02
3 SULFAMOYLMETHYL-l-2-BENZISOXAZOLE, A NEW TYPE OF
ANTICONVULSANT-DRUG: ELECTROENCEPHALOGRAPHIC PROFILE
000142 01-03
PERINATAL EFFECTS OF PSYCHOTROPIC-DRUGS: THE ANTICONVULSANT-
DRUG DIPHENYLHYDANTOIN (UNPUBLISHED PAPER).
001842 02-05
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO
GABA REGULATED CHLORIDE ION-CHANNELS.
002848 03-03
ANTICONVULSANT-DRUGS
INHIBITORY-EFFECTS OF ANTICONVULSANT-DRUGS ON CYCLIC-
NUCLEOTIDE ACCUMULATION IN BRAIN,
000090 01-03
COMPARATIVE-STUDY OF THE INHIBITION OF GABA-AMINOTRANSFERASE
BY DIFFERENT ANTICONVULSANT-DRUGS
000192 01-03
PREGNANCY AND EPILEPSY: SHOULD ANTICONVULSANT-DRUGS BE
CONTINUED?
000679 01-11
ANTICONVULSANT-DRUGS AND CANCER.
000855 01-15
PSYCHIATRIC IMPLICATIONS OF ANTICONVULSANT-DRUGS
002463 02-15
EFFECT OF ANTICONVULSANT-DRUGS ON INHIBITORY AND EXCITATORY
PATHWAYS
002724 03-03
ACCELERATED METABOLISM OF PROBENECID DURING LONG-TERM-
TREATMENT OF RATS WITH ANTICONVULSANT-DRUGS: EFFEQ ON
CENTRAL SEROTONIN TURNOVER STUDIES.
002890 03-03
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMinERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT,
003961 04-03
VARIOUS ASPEQS OF THE EFFEQ Of ANTICONVULSANT-DRUGS ON
MEMORY
004602 04-15
PHARMACOKINETICS OF ANTICONVULSANT-DRUGS.
004738 04-17
ANTICONVULSANT-INDUCED
ANTICONVULSANT-INDUCED STATUS-EPILEPTICUS IN LENNOX-GASTAUT-
SYNDROME.
003467 03-15
ANTICONVULSANTS
CORRELATION BETWEEN MONOAMINE-OXIDASE-INHIBITORS AND
ANTICONVULSANTS,
000081 01-03
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND
GABAMIMETICS.
000188 01-03
EFFEQS OF ANTICONVULSANTS AND GLUTAMATE ANTAGONISTS ON THE
CONVULSIVE AQION OF KAINIC-ACID.
000288 01-03
ANTICONVULSANTS SPECIFIC FOR PETIT-MAL ANTAGONIZE
EPILEPTOGENIC-EFFECT OF LEUCINE-ENKEPHALIN.
000477 01-04
ANTICONVULSANTS AND TREATMENT OF EPILEPSY.
000661 01-11
EFFECTS OF ANTICONVULSANTS AND METHOTREXATE ON CALCIUM
DISPOSITION. „ „ ^„o«c
001840 02-05
PLASMA HDL CHOLESTEROL AND GROWTH-HORMONE IN EPILEPTICS
TREATED WITH ANTICONVULSANTS.
002260 02-13
THE QUESTION OF MINIMUM-DOSES OF ANTICONVULSANTS IN THE
TREATMENT OF EPILEPSY. ^^^ ^^ ,,
002306 02-13
CLINICAL-TRIALS OF DEPAKENE (VALPROIC-ACID) COADMINISTERED WITH
OTHER ANTICONVULSANTS IN EPILEPTIC-PATIENTS.
002367 02-14
S-32
VOLUME 19, SUBJECT INDEX
THE ROLE OF FOLATE DEFICIENCY IN THE DEVELOPMENT OF PERIPHERAL
NEUROPATHY CAUSED BY ANTICONVULSANTS
002402 02-15
HEPATOTOXICITY OF SODIUM-VALPROATE AND OTHER
ANTICONVULSANTS IN RAT HEPATOCYTE CULTURES.
002422 02-15
A RAPID GAS-LIQUID-CHROMATOGRAPHY METHOD FOR SIMULTANEOUS
DETERMINATION OF VARIOUS ANTICONVULSANTS.
002501 02-16
SAFETY OF ANTICONVULSANTS IN HEPATIC PORPHYRIAS.
003132 03-05
ADULT-ONSET STUHERING TREATED WITH ANTICONVULSANTS.
003290 03-11
SYNTHESIS OF POTENTIAL ANTICONVULSANTS. CONDENSATION OF
ISATINS WITH ACETONE AND RELATED KETONES.
003699 04-02
GUANYLATE-CYCLASE - CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND
CEREBELLUM: MODIFICATION BY ANTICONVULSANTS.
003956 04-03
THERAPEUTIC PLASMA LEVELS OF SOME ANTICONVULSANTS IN FOCAL
EPILEPSY IN RELATION TO COMPUTERIZED-AXIAL-TOMOGRAPHY.
004439 04-11
SERUM CONCENTRATION OF ANTICONVULSANTS. PHARMACOKINETIC
FINDINGS AND THEIR PRACTICAL APPLICATION.
004443 04-11
ANTICONVULSANTS AND MENTAL-SYMPTOMS.
004649 04-15
iNTICONVULSIVE
VALPROIC-ACID IN CHILDHOOD-EPILEPSY: ANTICONVULSIVE EFFICACY IN
RELATION TO ITS PLASMA LEVELS.
004525 04-13
ANTIDEPRESSANT
A PHARMACOLOGICAL-STUDY OF THE NEW SOVIET ANTIDEPRESSANT
INKASAN.
000008 01-02
HISTAMINE HI -RECEPTORS LABELED IN VIVO: ANTIDEPRESSANT AND
ANTIHISTAMINE INTERACTIONS.
000074 01-03
ANTIDEPRESSANT PROPERTIES OF 2 4 ETHYL-2-PIPERAZINYL-4-
PHENYLQUINOLINE-HCL (AD- 1308) AND ITS MECHANISM-OF-ACTION
AS COMPARED WITH TRICYCLIC-ANTIDEPRESSANTS.
000152 01-03
LONG-TERM ANTIDEPRESSANT TREATMENT DECREASES SPIROPERIDOL-
LABELED SEROTONIN-RECEPTOR BINDING.
000230 01-03
LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL
CAPILLARY PERMEABILITY.
000239 01-03
AQION OF THE ANTIDEPRESSANT PRIDEFINE (AHR-1 1 18) ON BIOGENIC-
AMINES IN THE RAT-BRAIN.
000312 01-03
ANTIDEPRESSANT TREATMENT BY INTRAVENOUS ADMINISTRATION
COMPARED TO PERORAL ADMINISTRATION: A DOUBLE-BUND STUDY
OF QUINUPRAMINE.
000552 01-08
ANTIDEPRESSANT POTENTIATION OF 5 HYDROXYTRYPTOPHAN BY L
DEPRENIL IN AFFECTIVE-ILLNESS.
000608 01-09
THE INFLUENCE OF LITHIUM-SALTS AND ANTIDEPRESSANT MEDICATION
ON SERUM PROLACTIN LEVEL.
000780 01-13
MHPG AS A PREDICTOR OF ANTIDEPRESSANT RESPONSE TO IMIPRAMINE
AND MAPROTILINE.
000787 01-13
EXPERIMENTAL EVALUATION OF ANTIDEPRESSANT ACTIVITY OF
CLOMIPRAMINE, A NEW TRICYCLIC-ANTIDEPRESSANT DRUG.
001068 02-02
AMOXAPINE IN EXPERIMENTAL PSYCHOPHARMACOLOGY- A
NEUROLEPTIC OR AN ANTIDEPRESSANT?
001070 02-02
1 AMIN0ALKYL-6-ARYL-4H-S-TRIAZ0L0BEN20DIAZEPINES WITH
ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY.
001074 02-02
2,4 DIHYDRO-6-PHENYL-lH-S-TRIAZOLOBENZODIAZEPIN-l-ONES WITH
ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY.
001075 02-02
THE NEW ANTIDEPRESSANT PIRLINDOLE: ANTAGONISM OF ACUTE
OVERDOSAGE IN THE MOUSE.
001082 02 02
THE NEUROVASCULAR-PHARMACOLOGY AND CARDIOVASCULAR-
PHARMACOLOGY OF RS-51324, A POTENTIAL ANTIDEPRESSANT.
001091 02-02
THE NEW ANTIDEPRESSANT PIRLINDOLE: A COMPARISON WITH
IMIPRAMINE AND TRANYLCYPROMINE.
001360 02-03
ENHANCED SENSITIVITY OF AMYGDALOID NEURONS TO SEROTONIN AND
NOREPINEPHRINE AFTER CHRONIC ANTIDEPRESSANT TREATMENT.
001523 02-03
Subject Index
PHARMACOLOGICAL-STUDIES ON A NEW THYMOLEPTIC
ANTIDEPRESSANT DIMETHYUMINOPROPYL-5-METHYL-3-PHENYL- 1 H-
INDAZOLE (FS-32).
001659 02-04
AMINEPTINE, A NEW ANTIDEPRESSANT: PHARMACOLOGICAL REVIEW.
001898 02-07
ANTIDEPRESSANT ACTION OF INJECTABLE 1694
001960 02-09
PROFILE OF THE ANTIDEPRESSANT ACTION OF NOMIFENSINE.
002025 02-09
COMPARATIVE EXPERIMENT OF THE ANTIDEPRESSANT EFFECTS OF
AMINEPTINE AND CHLORIMIPRAMINE
002029 02-09
ANTIDEPRESSANT ACTION OF AMINEPTINE: CONTROLLED DOUBLE-BLIND
STUDY.
002030 02-09
EFFECT OF PIRIBEDIL (ET-495) ON PLASMA NOREPINEPHRINE:
RELATIONSHIP TO ANTIDEPRESSANT RESPONSE.
002034 02-09
RATING OF ANTIDEPRESSANT ACTIVITY.
002487 02-16
NEW DEVELOPMENT IN ANTIDEPRESSANT MEDICATION - A REVIEW.
002558 02-17
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-USTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY?
002659 03-03
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1 H-INDAZOLE (FS-32)
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR
ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER
CHRONIC ANTIDEPRESSANT TREATMENT
002788 03-03
THE ANTIDEPRESSANT ACTION OF SULPHO-ADENOSYL-L-METHIONINE
(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE-
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-ACTION
003150 03-07
RAPIDITY OF CLINICAL ANTIDEPRESSANT RESPONSE TO IMIPRAMINE
(UNPUBLISHED PAPER).
003164 03-07
THERAPEUTIC TRIAL OF A NEW ANTIDEPRESSANT: MIANSERIN.
003208 03-09
CLINICAL-EFFICACY OF THE NEW ANTIDEPRESSANT BUPROPION
(WELLBUTRIN).
003227 03-09
RELATIONSHIP BETWEEN BLOOD CONCENTRATIONS AND CLINICAL-
EFFECTS OF A NEW ANTIDEPRESSANT MAPROTILINE.
003271 03-09
HEPATIC SIDE-EFFECTS OF ANTIDEPRESSANT MEDICATIONS.
003523 03-15
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF A
PYRIMIDOPYRIMIDINE DERIVATIVE WITH ANTIDEPRESSANT ACTIVITY
003653 04-01
PHARMACOLOGY OF 1 DICHLOROBENZYL-TETRAHYDROPYRIMIDONE A
NOVEL ANTIDEPRESSANT COMPOUND WITH ANTIANXIETY ACTIVITY
003688 04-02
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC-
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT MIANSERIN.
003745 04-03
NONCOMPETITIVE AMINE UPTAKE INHIBITION BY THE NEW
ANTIDEPRESSANT PRIDEFINE.
003771 04-03
REGULATION OF SER0T0NIN2-RECEPT0RS (5 '•T2) LABELED WITH
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT AMITRIPTYLINE.
003964 04-03
PHARMACOLOGICAL-PROPERTIES OF 2,3,3A,4,5,6 HEXAHYDROMETHYL-
IH-PYRAZINOCARBAZOL-HCL (PIRLINDOLE), A NEW ANTIDEPRESSANT
004174 04-04
THE EFFECT OF THE NEW ANTIDEPRESSANT INKAjAN ON THE
BIOELECTRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED
REFLEXES.
004212 04-04
ELECTROCARDIOGRAPHIC-CHANGES IN RATS DURING CHRONIC-
TREATMENT WITH ANTIDEPRESSANT AND NEUROLEPTIC-DRUGS.
004284 04-05
THE ANTIDEPRESSANT EFFECTS OF TRAZODONE AND INHIBITION OF
PLATELET SEROTONIN REUPTAKE.
004383 04-09
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
004406 04-09
fe
S-33
Subject Index
MAPROTILINE, NOMIFENSINE, MIANSERIN, ZIMELIDINE: A REVIEW OF
ANTIDEPRESSANT EFFICACY IN INPATIENTS.
004731 04-17
ANTIDEPRESSANT-DRUG
3H MIANSERIN PINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG AQION.
000325 01-03
AGE-RELATED FACTORS AFFECTING ANTIDEPRESSANT-DRUG METABOLISM
AND CLINICAL-RESPONSE. ^^ „^ „„
002035 02-09
FACTORS WHICH AFFECT ANTIDEPRESSANT-DRUG RESPONSE IN A
MULTICENTER-TRIAL. „„.^o^ ^o o^
003239 03-09
FLUVOXAMINE AS AN ANTIDEPRESSANT-DRUG.
003775 04-03
THE PHARMACOLOGICAL PROFILE OF LOFEPRAMINE, A NEW
ANTIDEPRESSANT-DRUG. ^ ^ „^ „„
004006 04-03
PHARMACOLOGICAL AND BIOCHEMICAL-PROPERTIES OF BRL- 14342, A
NOVEL POTENTIAL ANTIDEPRESSANT-DRUG.
004086 04-04
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE.
004356 04-09
ANTIDEPRESSANT-DRUGS „ ^. „„ .,,r
RELATION BETWEEN THE EFFECTS OF ANTIDEPRESSANT-DRUGS ON THE
UPTAKE OF MONOAMINES AND ON THE SPONTANEOUS ACTIVITY OF
CENTRAL NEURONS. „„,.., „, «^
000267 01-03
PROGNOSTIC FACTORS DETERMINING RESPONSE TO ANTIDEPRESSANT-
DRUGS IN PSYCHIATRIC-OUTPATIENTS AND GENERAL-PRACTICE.
000638 01-09
EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS. „„ „,
001146 02-03
NEW DATA ON THE USE OF ANTIDEPRESSANT-DRUGS.
001195 02-03
THE BINDING OF SOME ANTIDEPRESSANT-DRUGS TO BRAIN MUSCARINIC
ACETYLCHOLINE-RECEPTORS. „„,„,-, „. ^,
001253 02-03
ANTIDEPRESSANT-DRUGS SLOW CIRCADIAN-RHYTHMS IN BEHAVIOR AND
BRAIN NEUROTRANSMITTER-RECEPTORS.
001536 02-03
SEROTONINMIMETIC AND ANTIDEPRESSANT-DRUGS ON PASSIVE-
AVOIDANCE LEARNING BY OLFAQORY BULBECTOMISED RATS
001585 02-04
ENHANCEMENT OF 5 HYDROXYTRYPTAMINE-INDUCED BEHAVIORAL-
EFFECTS FOLLOWING CHRONIC ADMINISTRATION OF ANTIDEPRESSANT-
DRUGS.
001667 02-04
CLASSIFICATION OF THE ANTIDEPRESSANT-DRUGS.
002015 02-09
TREATMENT OF CHRONIC PAIN WITH ANTIDEPRESSANT-DRUGS.
002048 02-09
OBSESSIVE-SYMPTOM RESPONSE TO BEHAVIOUR-THERAPY AND TO
ANTIDEPRESSANT-DRUGS.
002084 02-10
PARADOXICAL AKINESIA INDUCED BY ANTIDEPRESSANT-DRUGS.
002378 02-15
REFLECTIONS ON THE CLASSIFICATION OF ANTIDEPRESSANT-DRUGS.
002610 02-17
NEW PER:PECTIVES on the mode of ACTION OF ANTIDEPRESSANT-
DRUGS.
002617 02-17
HOW ANTIDEPRESSANT-DRUGS AQ.
002694 03-03
3H SEROTONIN BINDING-SITES IN RAT-BRAIN: EFFECTS OF REPEATED
ADMINISTRATION OF ANTIDEPRESSANT-DRUGS. (PH.D.
DISSERTATION).
002881 03-03
FACILITATED SHOCK-INDUCED ACGRESSION AFTER CHRONIC-TREATMENT
WITH ANTIDEPRESSANT-DRUGS IN THE RAT.
003058 03-04
SYNAPTIC AND BEHAVIOURAL-ACTIONS OF ANTIDEPRESSANT-DRUGS:
FURTHER THOUGHTS ON THE IMPLICATIONS FOR THEORIES OF
DEPRESSION.
003229 03-09
EFFECTS OF ANTIDEPRESSANT-DRUGS ON DIFFERENT RECEPTORS IN THE
BRAIN.
003824 04-03
DIFFERENTIAL-EFFEaS OF ELECTROCONVULSIVE-SHOCK AND
ANTIDEPRESSANT-DRUGS ON SER0T0NIN2-RECEPT0RS IN RAT-BRAIN.
003878 04-03
EFFECTS OF OLFACTORY-BULBECTOMY AND PERIPHERALLY-INDUCED
ANOSMIA ON THERMOREGULATION IN THE RAT: SUSCEPTIBILITY TO
ANTIDEPRESSANT-DRUGS.
004113 04-04
POTENTIATION OF THE EFFECT OF ANTIDEPRESSANT-DRUGS BY
TRYPTOPHAN.
004412 04-09
Ptychopharmacology Abstracts
CARDIOTOXICITY OF ANTIDEPRESSANT-DRUGS.
004597 04-15
NEW ANTIDEPRESSANT-DRUGS AND THE SEIZURE THRESHOLD.
004662 04-15
THE USE OF CLINICAL KINETIC DATA IN TREATMENT WITH
ANTIDEPRESSANT-DRUGS.
004686 04-16
RECEPTOR TECHNIQUES IN THE STUDY OF PLASMA LEVELS OF
NEUROLEPTICS AND ANTIDEPRESSANT-DRUGS.
004694 04-16
PHARMACOLOGICAL-PROPERTIES OF SOME SECOND-GENERATION
ANTIDEPRESSANT-DRUGS.
004726 04-17
DOWN REGULATION OF NORADRENERGIC-RECEPTOR FUNCTION BY
ANTIDEPRESSANT-DRUGS: FUNCTIONAL SIGNIFICANCE AND
DISTINCTION FROM ANTIPSYCHOTIC-DRUGS. (UNPUBLISHED PAPER).
004746 04-17
ANTIDEPRESSANTS j
EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA- |
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN. "
000135 01-03
THE EFFECT OF ANTIDEPRESSANTS ON L 5 HTP-INDUCED CHANGES IN RAT
PLASMA CORTICOSTEROIDS.
000170 01-03
INTERACTION OF ANTIDEPRESSANTS WITH CLONIDINE ON RAT-BRAIN
TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL.
000300 01-03
PHARMACOLOGY: CURRENT ANTIDEPRESSANTS.
000793 01-13
PHARMACOLOGY: NEW ANTIDEPRESSANTS.
000936 01-17
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC
DRUGS.
001330 02-03
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH
ANTIDEPRESSANTS.
001620 02-04
NEUROCHEMICAL BASIS OF THE ACTION OF ANTIDEPRESSANTS ON
LEARNED-HELPLESSNESS.
001775 02-04
CARDIOTOXICITY OF ANTIDEPRESSANTS.
001843 02-05
OEXAMETHASONE-SUPPRESSION-TEST IDENTIFIES SUBTYPES OF
DEPRESSION WHICH RESPOND TO DIFFERENT ANTIDEPRESSANTS
001971 02-09
CLINICAL-EXPERIENCE WITH SECOND-GENERATION ANTIDEPRESSANTS IN
ENDOGENOUS DEPRESSIONS.
001975 02-09
USE OF ANTIDEPRESSANTS: PHARMACOKINETIC-BASES.
001981 02-09
EVALUATION OF THE CLINICAL-EFFICACY OF SINGLE-DAILY-DOSES OF
ANTIDEPRESSANTS.
001985 02-09
EFFECTS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN
HEALTHY TEST SUBJEQS, NEUROTIC-PATIENTS, AND ENDOGENOUS
DEPRESSIVE-PATIENTS. „„„,^ „. ~>
002009 02-09
INNOVATIONS IN TREATMENT WITH ANTIDEPRESSANTS.
002019 02-09
TARDIVE-DYSKINESIA IN DEPRESSED-PATIENTS: SUCCESSFUL THERAPY
WITH ANTIDEPRESSANTS AND LITHIUM.
002037 02-09
SECOND-GENERATION ANTIDEPRESSANTS. ^
002042 02-09
MECHANISMS OF AQION OF THE ANTIDEPRESSANTS.
002218 02-13
ON THE PROPOSED MECHANISM-OF-ACTION OF ANTIDEPRESSANTS
002256 02-13
PSYCHIATRIC-ASPECTS OF ACUTE POISONING WITH TRiaCLIC AND
RELATED ANTIDEPRESSANTS - 1980 .„„„,.
002458 02-15
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF
ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS
INCLUDING ANTIDEPRESSANTS. „^„,„„ ^„ ,-,
002532 02-17
ANTIPSYCHOTICS AND ANTIDEPRESSANTS: NEW TRENDS AND EXPECTED
''''''■ 002539 02-17
THE RESEARCH FOR NEW ANTIDEPRESSANTS: PRESENT ORIENTATIONS.
002543 02-17
RESPECTIVE POSITION OF ANTIDEPRESSANTS IN THERAPEUTICS
002581 02-17
STUDY OF METABOLISM AND BLOOD LEVELS OF ANTIDEPRESSANTS:
TOWARDS A RATIONALIZATION OF THEIR THERAPEUTIC USE.
002625 02-17
S-34
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF ACUTELY AND CHRONICALLY ADMINISTERED
ANTIDEPRESSANTS ON THE CLONIDINE-INDUCED DECREASE IN RAT-
BRAIN 3 METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL-SULPHATE
CONTENT.
002908 03-03
THE DEXAMETHASONE-SUPPRESSION-TEST IN THE IDENTIFICATION OF
SUBTYPES OF DEPRESSION DIFFERENTIALLY RESPONSIVE TO
ANTIDEPRESSANTS.
003211 03-09
LIFE EVENTS AND RESPONSE TO ANTIDEPRESSANTS.
003238 03-09
NOVEL ANTIDEPRESSANTS: A CLINICAL-TRIAL OF MIANSERIN.
003240 03-09
COMPARISON OF STANDARD AND HOLTOR-MONITORED EKGS IN A
PATIENT TREATED WITH SEVERAL ANTIDEPRESSANTS.
003304 03-11
FIRST RESULTS OF AN ORIGINAL METHOD FOR MEASURING BLOOD
LEVELS OF ANTIDEPRESSANTS (AMITRIPTYLINE AND NORTRIPTYLINE)
003559 03-16
THERAPEUTIC INTEREST OF BLOOD LEVELS DETERMINATION FOR
ANTIDEPRESSANTS: METHODOLOGICAL APPROACH.
003571 03-16
THE USE OF ANTIDEPRESSANTS IN PSYCHIATRY.
003597 03-17
SECOND-GENERATION ANTIDEPRESSANTS: A CLINICAL
PHARMACOTHERAPEUTIC RESEARCH STRATEGY.
003632 03-17
THE EFFECTS OF ANTIDEPRESSANTS ON THE RETENTION AND
METABOLISM OF (3H) NOREPINEPHRINE IN RAT-BRAIN SLICES.
003763 04-03
STUDIES ON THE KINETIC PROPERTIES OF TRYPTOPHAN-HYDROXYLASE OF
RABBIT MESENCEPHALON AND PONS-MEDULLA: EFFECT OF LONG-
TERM-TREATMENT WITH NEUROLEPTICS AND ANTIDEPRESSANTS
003852 04-03
THE EFFECT OF ANTIDEPRESSANTS ON THE HYPOTENSIVE-EFFECT OF
CLOFELIN IN RATS.
003934 04-03
ON THE KINETICS OF IMIPRAMINE AND RELATED ANTIDEPRESSANTS.
003945 04-03
INTERACTIONS BETWEEN ANTIDEPRESSANTS AND OTHER DRUGS
004371 04-09
CLINICAL NEUROPHYSIOLOGICAL PROPERTIES OF ANTIDEPRESSANTS
004373 04-09
CHANGES IN PSYCHOPATHOLOGIC SYMPTOMS DURING 20 DAYS OF
TREATMENT WITH ANTIDEPRESSANTS AND NEUROLEPTIC-DRUGS
004415 04-09
SEXUAL-EFFECTS OF ANTIDEPRESSANTS AND PSYCHOMOTOR STIMULANT-
DRUGS.
004646 04-15
ANTIDEPRESSANTS AND ALPHA2-ADRENERGIC-AUT0RECEPT0R
DESENSITIZATION.
004659 04-15
DO WE NEED ANY MORE ANTIDEPRESSANTS?
004707 04-17
ANTIDEPRESSANTS AND THE SEROTONIN UPTAKE IN PLATELETS
004727 04-17
iNTIDEPRESSIVE
ANTIDEPRESSIVE TREATMENT AND MOOD-SWING-PAHERNS IN
ENDOGENOUS DEPRESSION.
000633 01-09
ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLED-
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH
PARKINSONS-DISEASE TREATED WITH L-DOPA.
000659 01-11
CYCLOHEXYLPHENOXYAMIDOXIMES AND IMIDAZOLINES WITH
ANTIDEPRESSIVE AND ALPHA-ADRENERGIC-ACTIVITY.
CAN THE ANTIDEPRESSIVE PROPERTIES OF LITHIUM BE DETERMINED
EXPERIMENTALLY?
003089 03-04
NTIDEPRESSIVE-ORUGS
EFFECTS OF ANTIDEPRESSIVE-DRUGS UPON THE HEART AND
CIRCULATION.
NT.DEPRESS.VES 000863 01-15
ANTIDEPRESSIVES IN RENAL FAILURE.
NT.DOPAM.NERG.C 002284 02-13
DISCRIMINATION OF FUNCTIONALLY HETEROGENEOUS RECEPTOR
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC
PROPERTIES OF METOCLOPRAMIDE.
002877 0*^ 0"?
ANTIDOPAMINERGIC EFFECT OF ESTROGENS AT THE STRIATAL LEVEL.
003789 04-03
ANTIDOPAMINERGIC PROPERTIES OF YOHIMBINE
NT.DOPAM.NER6.C-EFFECTS 003995 04-03
BEHAVIORAL-EFFECTS, ANTIDOPAMINERGIC-EFFECTS AND PROHYPNOTIC-
EFFECTS OF NEUROLEPTICS DURING AND AFTER PROLONGED
TREATMENT.
001577 02-04
ANTIDOTES
EFFECT OF AMITRIPTYLINE ANTIDOTES ON REPETITIVE EXTRASYSTOLE
THESHOLD.
001856 02-05
ANTIDYSKINETIC-PROPERTIES
ANTIPSYCHOTIC-PROPERTIES AND ANTIDYSKINETIC-PROPERTIES OF
ERGOT DOPAMINE AGONISTS.
002178 02-11
ANTIENURETIC-EFFECT
CHILDHOOD-ENURESIS: II PSYCHOPATHOLOGY, TRICYCLIC
CONCENTRATION IN PLASMA, AND ANTIENURETIC-EFFECT.
002354 02-14
ANTIEPILEPTiC
TRANSFER FROM MULTIPLE TO SINGLE ANTIEPILEPTIC DRUG-THERAPY
003316 03-11
ANTIEPILEPTIC THERAPY WITH PHENYTOIN: WHICH IS THE OPTIMUM
SERUM LEVEL?
004586 04-14
THE PROGNOSIS OF EPILEPSY AND THE STRATEGY FOR TERMINATING
ANTIEPILEPTIC THERAPY.
004724 04-17
ANTIEPILEPTIC-AGENTS
GABA AGONISTS AS ANTIEPILEPTIC-AGENTS.
002826 03-03
ANTIEPILEPTIC-DRUGS
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH
ANTIEPILEPTIC-DRUGS.
000695 01-11
INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY-STATE SERUM LEVELS
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-DRUGS IN MAN
000767 01-13
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/AND
DIPHENYLHYDANTOIN IN SERUM LIPIDS.
002281 02-13
CORRELATIONS BETWEEN PLASMA LEVELS OF ANTIEPILEPTIC-DRUGS AND
EEG INTENSIVE MONITORING.
002288 02-13
MULTIINSTITUTIONAL-STUDY ON THE TERATOGENICITY AND FETAL
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE-
STUDY GROUP IN JAPAN.
002442 02-15
A STUDY ON EFFECTS OF ANTIEPILEPTIC-DRUGS UPON THE HIPPOCAMPAL
AFTERDISCHARGE.
002844 03-03
SIMULTANEOUS ADMINISTRATION OF FIVE ANTIEPILEPTIC-DRUGS IN
PLASMA THROUGH GAS-LIQUID-CHROMATOGRAPHY.
003563 03-16
BEHAVIORAL-INTERACTIONS BETWEEN OPIATE AND ANTIEPILEPTIC-DRUGS
IN THE MOUSE.
004155 04-04
ASPECTS OF PHARMACOLOGICAL-EFFECTS OF ANTIEPILEPTIC-DRUGS
004462 04-11
ANTIEPILEPTIC-EFFECT
ANTIEPILEPTIC-EFFECT OF CLOBAZAM IN LENNOX-GASTAUT-SYNDROME
004479 04-11
ANTIEPILEPTICS
ANTAGONISM BY CLASSICAL ANTIEPILEPTICS AND SODIUM-VALPROATE
OF CEFAZOLIN-INDUCED EXPERIMENTAL EPILEPSY IN RATS
000442 01-04
SERUM CONCENTRATION AND JNICAL-EFFECT OF ANTIEPILEPTICS
003315 03-11
EFFECTS OF 3 SULFAMOYLMETHYL-BENZISOXAZOLE (AD-810) AND SOME
ANTIEPILEPTICS ON THE KINDLED SEIZURES IN THE NEOCORTEX
HIPPOCAMPUS AND AMYGDALA IN RATS.
004149 04-04
ANTIGEN
PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID-
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY
COMPLEX. (UNPUBLISHED PAPER).
001047 02-01
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
ANTIHEMOPHILIC-FACTOR
EFFECT OF PSYCHIATRIC-INTERVENTION ON USE OF ANTIHEMOPHILIC-
FACTOR CONCENTRATE.
000945 01-17
ANTIHISTAMINE
ANTIHISTAMINE EFFECT ON SYNAPTOSOMAL UPTAKE OF SEROTONIN
NOREPINEPHRINE AND DOPAMINE.
000035 01-03
HISTAMINE HI -RECEPTORS LABELED IN VIVO: ANTIDEPRESSANT AND
ANTIHISTAMINE INTERACTIONS.
000074 01-03
^
S-35
Subfect Index
Psychopharmacology Abstracts
AMTIMYPERTENSIVE
DIETARY PROTEIN INTAKE INFLUENCES THE ANTIHYPERTENSIVE POTENCY
OF AAETHYLDOPA IN SPONTANEOUSLY HYPERTENSIVE-RATS.
004025 04-03
ANTIHYPERTENSIVE-EFFECTS ^ „„.^. „r
FENFLURAMINE POTENTIATION OF ANTIHYPERTENSIVE-EFFECTS OF
THIAZIDES. „ „„,,
002138 02-11
ANTIHYPOXIDOTIC-DRUGS
ANTIHYPOXIDOTIC-DRUGS AND NOOTROPIC-DRUGS: PROOF OF THEIR
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
QUANTITATIVE EEC INVESTIGATIONS. 002166 02
ANTIINFLAMMATORY-DRUGS
LOWERING OF THE CONVULSIVE THRESHOLD BY NONSTEROIDAL
ANTIINFLAMMATORY-DRUGS. „„^„„. „o ^o
002904 03-03
SPECIES-DIFFERENCES IN CLOBAZAM METABOLISM AND ANTILEPTAZOL
^^^^''^' 001157 02-03
*'*TROSPEaS FOR THE TREATMENT OF POSTENCEPHALITIC PARKINSONISM
WITH ANTILYMPHOCYTIC IMMUNOGLOBULIN.
004572 04-14
ANTIMANIC-EFFECT
ANTIMANIC-EFFECTOFCLONIDINE. 000598 01-09
ANTINEOPHOBIC
FOOD PREFERENCE FOLLOWING ACUTE OR CHRONIC CHLORDIAZEPOXIDE
ADMINISTRATION: TOLERANCE TO AN ANTINEOPHOBIC ACTION
004090 04-04
ANTINEOPLASTIC ^ ^„,,^
THE IMMUNOSTIMULANT ANTINEOPLASTIC ACTION OF SOME
PSYCHOTROPIC-DRUGS OF THE SYDNONIMINE SERIES.
001520 02-03
ANTINOCICEPTION
CHLORDIAZEPOXIDE ANTINOCICEPTION: CROSS-TOLERANCE WITH
OPIATES AND WITH STRESS. ^„„^ „ ^, „^
000348 01-04
STRAIN DEPENDENT EFFECTS OF KET AMINE ON LOCOMOTOR-ACTIVITY
AND ANTINOCICEPTION IN MICE. ^ ^ ^
000382 01-04
EFFECT OF QUIPAZINE AND FLUOXETINE ON ANALGESIC-INDUCED
CATALEPSY AND ANTINOCICEPTION IN THE RAT
001709 02-04
EFFECT OF SELECTIVE DESTRUCTION OF SEROTONERGIC NEURONS IN
NUCLEUS-RAPHE-MAGNUS ON MORPHINE-INDUCED ANTINOCICEPTION.
001724 02-04
FURTHER STUDIES ON OPIATE-RECEPTORS THAT MEDIATE
ANTINOCICEPTION: TOOTH-PULP STIMULATION IN THE DOG.
001782 02-04
A CLASSIFICATION OF OPIATE-RECEPTORS THAT MEDIATE
ANTINOCICEPTION IN ANIMALS.
001807 02-04
AHENUATION OF PETHIDINE-INDUCED ANTINOCICEPTION BY ZIMELIDINE,
AN INHIBITOR OF 5 HYDROXYTRYPTAMINE REUPTAKE.
004118 04-04
SPINAL-CORD PHARMACOLOGY OF ADRENERGIC AGONIST-MEDIATED
ANTINOCICEPTION.
004206 04-04
ANTINOCICEPTIVE
ANTINOCICEPTIVE COMPARISON OF QUIPAZINE AND MORPHINE.
000435 01-04
EFFECT OF ANTINOCICEPTIVE DOSES OF OXOTREMORINE ON MOUSE-
BRAIN ACETYLCHOLINE TURNOVER-RATE.
001513 02-03
ANTINOCICEPTIVE ACTION OF MORPHINE AND PENTAZOCINE ON UNIT
ACTIVITY IN THE NUCLEUS-CENTRALIS-LATERALIS, NUCLEUS-
VENTRALIS-LATERALIS AND NEARBY STRUCTURES OF THE CAT.
002837 03-03
ANTINOCICEPTIVE-EFFECT
ANTINOCICEPTIVE-EFFECT OF MORPHINE, OPIOID ANALGESICS AND
HALOPERIDOL INJECTED INTO THE CAUDATE-NUCLEUS OF THE RAT
000414 01-04
THE ANTINOCICEPTIVE-EFFECT OF INTRACEREBROVENTRICULARLY
ADMINISTERED PROSTAGLANDIN-El IN THE RAT.
001769 02-04
ANTINOCICEPTIVE-EFFECTS
A REEVALUATION OF THE NEUROCHEMICAL-EFFECTS AND
ANTINOCICEPTIVE-EFFECTS OF INTRATHECAL CAPSAICIN IN THE RAT.
004184 04-04
ANTAGONISM BY PHENOXYBENZAMINE AND PENTAZOCINE OF THE
ANTINOCICEPTIVE-EFFECTS OF MORPHINE IN THE SPINAL-CORD.
004213 04-04
ANTIPARKINSON-DRUG
ADVERSE-EFFECTS OF ANTIPARKINSON-DRUG WITHDRAWAL.
(UNPUBLISHED PAPER) „„,„o„.,c
004623 04-15
ANTIPARKINSON-DRUGS
ABUSE OF THE ANTIPARKINSON-DRUGS: A REVIEW OF THE LITERATURE.
000989 01-17
ANTIPARKINSONIAN
THE NEED FOR CONTINUOUS USE OF ANTIPARKINSONIAN MEDICATION
WITH CHRONIC SCHIZOPHRENIC-PATIENTS RECEIVING LONG-TERM ]
NEUROLEPTIC THERAPY. '
003186 03-08
ANTIPARKINSONIAN-DRUGS
ELECTRORETINOGRAPHIC-CHANGES IN PATIENTS WITH PARKINSONISM
TREATED WITH VARIOUS CLASSES OF ANTIPARKINSONIAN-DRUGS.
000674 01-11
PROGRESSIVE SUPRANUCLEAR PALSY, COMPUTED-TOMOGRAPHY, AND
RESPONSE TO ANTIPARKINSONIAN-DRUGS.
003322 03-11
RELEVANCE OF DOPAMINE-RECEPTOR BINDING STUDIES FOR EVALUATION
OF ANTIPARKINSONIAN-DRUGS
004120 04-04
ANTIPEROXIDANT
ANTIPEROXIDANT PRETREATMENT AND IRON-INDUCED EPILEPTIFORM
DISCHARGES IN THE RAT: EEG AND HISTOPATHOLOGIC STUDIES.
002930 03-03
ANTIPSYCHOTIC
INHIBITION OF IN VIVO 3H SPIPERONE BINDING BY THE PROPOSED
ANTIPSYCHOTIC DES-TYR 1 -GAMMA-ENDORPHIN
000226 01-03
USE OF SURVIVAL CURVES IN ANALYSIS OF ANTIPSYCHOTIC RELAPSE-
STUDIES.
002481 02- 1<
DISCRIMINATION OF FUNQIONALLY HETEROGENEOUS RECEPTOR
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC
PROPERTIES OF METOCLOPRAMIDE.
002877 03-0:
REFLECTIONS ON ANTIPSYCHOTIC CHEMOTHERAPY: THE BEGINNING OF
PHARMACOLOGICAL-TREATMENT.
003292 03-11
DYSTONIC REAaiON DURING MAINTENANCE ANTIPSYCHOTIC THERAPY.
003485 03-1.'
PROLACTIN RELEASING POTENCIES OF ANTIPSYCHOTIC AND RELATED
NONANTIPSYCHOTIC COMPOUNDS IN FEMALE RATS: RELATION TO
CLINICAL POTENCIES.
003830 04-0:
ANTIPSYCHOTIC-AGENT
PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALLIUM, ARSENIC,
INDUSTRIAL- SOLVENT INTOXICATION, AND OTHER
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT.
003348 03-1
ANTIPSYCHOTIC-DRUG
PREDICTING OUTCOME OF ANTIPSYCHOTIC-DRUG TREATMENT FROM
EARLY-RESPONSE „„„.,r^, „.
000565 01-01
FOLLOWUP STUDY ON THE INFLUENCE OF AN ANTIPSYCHOTIC-DRUG
(PROPERICIAZINE) ON LIVER FUNQION, ELEaROCARDIOGRAM AND
ELEQROENCEPHALOGRAM
000639 01-0'
CLINICAL HANDBOOK OF ANTIPSYCHOTIC-DRUG THERAPY.
000961 01-V
A STUDY OF ANTIPSYCHOTIC-DRUG USE IN NURSING-HOMES:
EPIDEMIOLOGIC EVIDENCE SUGGESTING MISUSE.
000979 01-1
EEG AND BEHAVIORAL-PROFILE OF FLUTROLINE (CP-36-584), A NOVEL
ANTIPSYCHOTIC-DRUG ^^^^^ ^^^
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME . „„^ ,„„„-«
003189 03-0
A SYMPTOM-PROFILE-ANALYSIS OF ANTIPSYCHOTIC-DRUG TREATMENT:
NONPARAMETRIC MULTIDIMENSIONAL TECHNIQUE.
003196 03-0
DISCONTINUATION OF ANTIPSYCHOTIC-DRUG THERAPY
003514 03-1
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT, TARDIVE
DYSKINESIA AND THE TRAINING OF RESEARCH PSYCHIATRISTS
004603 04-1
ANTIPSYCHOTIC-DRUGS
THE ROLE OF CHOLINERGIC-SUPERSENSITIVITY IN THE MEDICAL
SYMPTOMS ASSOCIATED WITH WITHDRAWAL OF ANTIPSYCHOTIC-
°^^^^ 000869 01-1
EFFEaS OF LONG-TERM ADMINISTRATION OF ANTIPSYCHOTIC-DRUGS 01
ENKEPHAUNERGIC NEURONS. ^^^^^^^
DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINERGIC MECHANISMS.
001839 02-C
S-36
OLUME 19, SUBJECT INDEX
Subject Index
ANTIPSYCHOTIC-ORUGS IN COMMUNITY-BASED SHELTERED-CARE-HOMES
002171 02-11
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES
002285 02-13
ANTIPSYCHOTIC-DRUGS: MEASUREMENT AND ENDOCRINE-EFFECTS
(UNPUBLISHED PAPER).
002287 02-13
DISTURBED-BEHAVIOUR INDUCED BY HIGH-DOSE ANTIPSYCHOTIC-DRUGS
002375 02-15
COMPARATIVE-STUDY OF VARIATIONS IN PROLACTIN LEVELS DURING
TREATMENT WITH ANTIPSYCHOTIC-DRUGS
002412 02-15
LONG-ACTING ANTIPSYCHOTIC-DRUGS.
002519 02-17
LONG-ACTING ANTIPSYCHOTIC-DRUGS AND CEREBRAL 5
HYDROXYTRYPTAMINE.
002851 03-03
CORRELATION BETWEEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC-
DRUGS IN RATS AND DAILY CLINICAL DOSES.
003032 03-04
DIFFERENTIAL ACTIONS OF CLASSICAL AND ATYPICAL ANTIPSYCHOTIC-
DRUGS ON SPONTANEOUS NEURONAL ACTIVITY IN THE AMYGDALOID
COMPLEX.
003131 03-05
SUBJECTIVE RESPONSE TO ANTIPSYCHOTIC-DRUGS.
003202 03-08
THERAPEUTIC (III): GENERAL CHARACTERISTICS OF ANTIPSYCHOTIC-
DRUGS.
003644 03-17
THE EFFECTS OF ANTIANXIETY AND ANTIPSYCHOTIC-DRUGS ON SEXUAL-
BEHAVIOR.
004657 04-15
DOWN REGULATION OF NORADRENERGIC-RECEPTOR FUNCTION BY
ANTIDEPRESSANT-DRUGS: FUNCTIONAL SIGNIFICANCE AND
DISTINCTION FROM ANTIPSYCHOTIC-DRUGS. (UNPUBLISHED PAPER)
004746 04-17
ITIPSYCHOTIC-EFFECT
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFECT IN SCHIZOPHRENIA AND
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO
NEUROLEPTIC-MEDICATION.
001911 02-08
ANTIPSYCHOTIC-EFFECT OF PROPRANOLOL ON CHRONIC
SCHIZOPHRENICS: STUDY OF A GRADUAL TREATMENT REGIMEN
001915 02-08
ANTIPSYCHOTIC-EFFECT OF GAMMA-TYPE ENDORPHINS IN
SCHIZOPHRENIA.
001953 02-08
TIPSYCHOTIC-EFFICACY
STRIATAL DOPAC LEVELS AS A PREDICTOR OF ANTIPSYCHOTIC-EFFICACY.
00 1 533 02-03
METOCLOPRAMIDE: ANTIPSYCHOTIC-EFFICACY OF A DRUG LACKING
POTENCY IN RECEPTOR MODELS.
T.PSYCHOT.C-MED.CAT.ONS 001948 02-08
THE CONSTITUTIONAL RIGHT-TO-REFUSE ANTIPSYCHOTIC-MEDICATIONS
T.PSYCHOT.CPROPERT,ES 004496 04-12
ANTIPSYCHOTIC-PROPERTIES AND ANTIDYSKINETIC-PROPERTIES OF
ERGOT DOPAMINE AGONISTS.
flPSYCHOTICS 002178 02-11
HIGH AND VERY HIGH-DOSAGE ANTIPSYCHOTICS: A CRITICAL REVIEW.
THERAPEUTICS V - THE UNWANTED EFFECTS OF ANTIPSYCHOTICS . ' ^ '
PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS - PARtT^'^ °^"'^
PROTOCOL FOR THE TREATMENT OF PSYCHOSIS WITH
ANTIPSYCHOTICS.
ANTIPSYCHOTICS AND ANTIDEPRESSANTS: NEW TRENDS AND ExI'ECTED^
0025^9 07-17
CLINICAL USE OF THE ANTIPSYCHOTICS.
riPYRINE 003607 03-17
EFFECTS OF UREA ON HEXOBARBITAL AND ANTIPYRINE DISPOSITION IN
RATS.
NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN REIATIOnT^^'' °^"°^
DEBRISOQUINE HYDROXYLATION IN MAN
nSCHIZOPHRENIC-DRUGS 000754 01-13
REGULATION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS.
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMITTERS IN EPIDURAL
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC-
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS.
001386 02-03
ANTISECRETORY
INHIBITION OF PENTAGASTRIN-STIMULATED AND OVERNIGHT GASTRIC
SECRETION BY LM24056, A NEW PHENOTHIAZINE DERIVED
ANTISECRETORY DRUG.
004306 04-07
ANTISERUM
PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID-
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY
COMPLEX. (UNPUBLISHED PAPER).
001047 02-01
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM
(UNPUBLISHED PAPER).
001122 02-03
SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI-
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS
002871 03-03
ANTISOMATOSTATIN
ADMINISTRATION OF ANTISOMATOSTATIN SERUM TO RATS REVERSES
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION
PRODUCED BY INJECTION OF METERGOLINE BUT NOT YOHIMBINE
(UNPUBLISHED PAPER).
000019 01-03
ANTISTEREOTYPIC
DIFFERENTIAL REVERSAL BY SCOPOLAMINE AND THIP OF THE
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS
002948 03-04
ANTITREMOR
ANTITREMOR ACTION OF C10DICH0L, A PERIPHERAL ACETYLCHOLINE
SYNTHESIS INHIBITOR.
004096 04-04
ANTITUSSIVE
HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO
GUINEA-PIG BRAIN.
000061 01-03
ANTITUSSIVES
INVESTIGATION OF NARCOTICS AND ANTITUSSIVES USING DRUG
DISCRIMINATION TECHNIQUES.
000447 01-04
ANTIVIRAL
ANTIVIRAL ACTIVITY OF 3 DEAZAADENOSINE AND 5'
DEOXYISOBUTYLTHIO-3-DEAZAADENOSINE (3 DEAZA-SIBA)
(UNPUBLISHED PAPER).
001006 02-01
ANTIWITHDRAWAL
CLONIDINE AND THE PRIMATE LOCUS-COERULEUS: EVIDENCE SUGGESTING
ANXIOLYTIC AND ANTIWITHDRAWAL EFFECTS. (UNPUBLISHED PAPER)
003982 04-03
ANTIYOHIMBINE
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC
DRUGS
001330 02-03
ANXIETY
BENZODIAZEPINES: A TOOL TO EXPLORE THE BIOCHEMICAL-BASIS AND
NEUROPHYSIOLOGICAL-BASIS OF ANXIETY.
000397 01-04
ANIMAL-MODELS OF ANXIETY AND BENZODIAZEPINE ACTIONS
000531 01-06
THE EFFECT OF BETADRENOL ON EXAMINATION ANXIETY
000650 01-10
KETAZOUM AND DIAZEPAM IN ANXIETY: A CONTROLLED-STUDY
000655 01-10
ANXIETY AND THYROID-ACTIVITY IN PSYCHIATRIC-PATIENTS
000786 01-13
ANXIETY RECONCEPTUALIZED.
000951 01-17
RATIONAL USE OF BENZODIAZEPINES FOR ANXIETY AND INSOMNIA
002063 02-10
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM A NEW
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO
SEVERE ANXIETY.
002070 02-10
KETAZOLAM COMPARED TO DIAZEPAM AND PLACEBO IN THE
TREATMENT OF ANXIETY.
^„„^ 002074 02-10
CORONARY-HEART-DISEASE: TREATING THE ANXIETY COMPONENT
002088 02-10
CLINICAL-ASPECTS OF ANXIETY AND ITS THERAPY.
002089 02-10
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE-
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A
CONTROLLED-TRIAL.
002329 02-14
EFFECTS OF ANXIETY REDUCTION BY BEHAVIOURAL-TECHNIQUES AND
MEPROBAMATE ON CERTAIN PARAMETERS OF INFORMATION THEORY
003108 03-04
fe
S-37
Subject Index
CURRENT BIOLOGIC STRATEGIES FOR ANXIETY, ^^^^^^ ^^^^
COMPARISON OF ANXIETY REDUCING SUBSTANCES. (PH.D.
DISSERTATION). 003278 03-10
BENZODIAZEPINE TREATMENT OF SPECIFIC ANXIETY STATES^
00Jzo4 Oj- IU
TREATMENT OF ANXIETY IN CHILDREN AND ADOLESCENTS.^^^^^^ ^^^ ^
A DOUBLE-BUND TRIAL: THE USE OF OXPRENOLOL AND DIAZEPAM IN
ANXIETY. 004428 04-10
CLINICAL-REVIEW OF BETA-BLOCKERS IN ANXIETY.
004464 04- 1 1
NEW BIOLOGICAL RESEARCH RELEVANT TO ANXIETY.
004705 04-17
PSYCHOPHARMACOLOGY AND PSYCHOTHERAPY IN THE TREATMENT OF
^^^'^^ 004712 04-17
^'^^pK^NOLOL IN CHRONIC ANXIETY-DISORDERS: A CONTROLLED-|T^U^DY^
RECENT ADVANCES IN THE DIAGNOSIS AND TREATMENT OF ANXIETY-
D'SORDERS. 0Q3275 03.,0
^"''oTsSmATIVE-STIMULUS PROPERTIES OF COCAINE RELATED TO AN
ANXIOGENICAaiON. 004219 04-04
^"''anxiolytic EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND
P^^BO- 000648 01-10
COMPARATIVE ANXIOLYTIC AND HYPNOTIC-EFFECTS OF 3
BENZODIAZEPINES ON BABOONS. 00158102-04
CLONIDINE AND THE PRIMATE LOCUS-COERULEUS: EVIDENCE SUGGESTING
ANXIOLYTIC AND ANTIWITHDRAWAL EFFEQS (UNPUBLISHED PAPER).
OOSVoz U4-Uo
ALPRAZOLAM A NEW TYPE ANXIOLYTIC IN NEUROTIC-PATIENTS: A
PILOT-STUDY. 004422 04-10
DOXEPIN PLASMA LEVELS AND ANXIOLYTIC RESPONSE.
004477 04- 1 1
SYNTHEsIs AND ANXIOLYTIC-ACTIVITY OF A SERIES OF
PYRAZINOBENZODIAZEPINE DERIVATIVES. ^^^^^ ^^^^
THE USE OF SOCIAL-INTERACTION AS A METHOD FOR DETECTING
ANXIOLYTIC-ACTIVITY OF CHLORDIAZEPOXIDE-LIKE DRUGS^
00 1 000 UZ-Vo
DIAZEPAM ANXIOLYTIC-AaiVITY IN HIPPOCAMPUS.
003743 04-03
^''^'woI'aSS-'sCALE-FACTORS AND RESPONSE TO PLACEBO AND
ANXIOLYTIC-DRUGS. 000649 01-10
*''^THEVFFtcT"oF*COMBINEl SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPEQS OF SLEEP AND OBJEaiVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOQURNAL
MEDICATION: II. REPEATED DOSES. 00233102-14
ANXIOLYTICS
TO THE CLINICAL-EVALUATION OF ANXIOLYTICS (TOFISOPAM)^
002494 02-16
THERAPEUTICS VI - ANXIOLYTICS (BENZODIAZEPINES).
003546 Oj-13
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL
BY ANXIOLYTICS WITH DRUGS AQING ON THE GABA SYSTEM^
004193 04-04
^'"'tHE*ANXIOMIMETIC properties of PENTYLENETETRAZOL IN THE RAT.
(PH.D. DISSERTATION). • Q^gQ^j 03-04
ANXIOUS-DEPRESSED
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A
MONOSUBSTANCE(DOXEPINE). 002028 02-09
^''^PRAZEPAm""nEW BENZODIAZEPINE FOR THE TREATMENT OF ANXIOUS-
DEPRESSIVE STATES. 004419 04-10
ANXIOUS-DEPRESSIVE-SYNDROME
ANXIOUS-DEPRESSIVE- SYNDROME. CLINICAL-STUDY OF A NEW
BENZODIAZEPINE, PRAZEPAM. 004354 04-09
ANXIOUS-DEPRESSIVE-SYNDROMES
THE TREATMENT OF ANXIOUS-DEPRESSIVE-SYNDROMES WITH
^Ofi^OPm. 000615 01-09
Psychopharmacology Abstracts
AORTIC
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
001024 02-01
APATHY
INHIBITION AND APATHY: TREATMENT WITH SURVEaOR.
002066 02-10
APHAGIA
APHAGIA GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNCTIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS:
EFFEaS OF INSULIN PRETREATMENTS.
001638 02-04
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARAQERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
'''^'''' 002657 03-03
TRIMETHADIONE EFFECTS ON CHOLINERGIC RESPONSES IN APLYSIA
NEURONS. „„„^„^ „„ „o
002782 03-03
DIPHENYLHYDANTOIN REDUCES THE OUTWARD-CURRENT OF THE ACTION
POTENTIAL IN APLYSIA.
002805 03-03
EFFECTS OF BARBITURATES ON INHIBITORY AND EXCITATORY RESPONSES
TO APPLIED NEUROTRANSMIHERS IN APLYSIA.
003762 04-03
APLYSIA-CALIFORNICA
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE
RELATIONSHIP. „„^„„, „. „,
003806 04-03
APOMORPHINE
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPH1NE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING ^^^ ^ ^,
000099 01-0;
ACUTE AND CHRONIC EFFEaS OF NEUROLEPTICS AND ACUTE EFFECTS OF
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN
000215 01-0;
DISRUPTION OF SELECTIVE AHENTION BY APOMORPHINE, BUT NOT
AMPHETAMINE, IN THE MONGOLIAN-GERBIL „„„..„ „, „
000358 01-0'
RELATIONSHIPS BETWEEN SELEQIVE DENERVATION OF DOPAMINE
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL-
RESPONSES TO AMPHETAMINE AND APOMORPHINE
EFFEaS OF APOMORPHINE ON ESCAPE PERFORMANCE AND AQIVITY IN
DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6
°"°^' 000426 01-0
APOMORPHINE EFFEQS ON THE TIMING AND SEQUENCING OF PECKING-
BEHAVIOR IN CHICKS. 000428 01^
DIFFERENT DOPAMINERGIC MECHANISMS FOR AMFONELIC-ACID,
AMPHETAMINE AND APOMORPHINE. ^^^^^^^ ^^_^
APOMORPHINE REDUCES SCHIZOPHRENIC-SYMPTOMS. ^^^^^ ^^^
TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC-
KaRGE IN HUMANS BY APOMORPHINE, A DOPAMINE-RECEPTOR
^GO^'S"^ 000714 01-1
DOPAMINE SYNTHESIS: TOLERANCE TO HALOPERIDOL AND
SUPERSENSITIVITY TO APOMORPHINE DEPEND ON PRESYNAPTIC-
RECEPTORS. 001129 02^
ORAL BIOAVAILABILITY OF APOMORPHINE IN THE RAT WITH A
PORTACAVAL VENOUS ANASTOMOSIS. ^^ ^ ^^ ^^^
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE-
RECEPTOR MECHANISMS IN CNS ^^^^^ ^^^
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT:
K PSYCHOPHARMACOLOGICAL RESPONSES TO APOMORPHINE
ANDARECOLINE 001470 02-0
EFFEQS OF APOMORPHINE ON ELICITED AND OPERANT PECKING IN
PIGEONS. 001557 02-0
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD K)R
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT.
S-38
)LUME 19, SUBJECT INDEX
EffECT Of APOMORPHINE ON MORPHINE-INDUCED DECREASE IN
LOCOMOTOR-ACTIVITY AND INCREASE IN DOPAMINE TURNOVER IN
RATS.
001728 02-04
STEREOTYPED-BEHAVIOUR AND ELECTROCORTICAL-CHANGES AETER
INTRACEREBRAL MICROINFUSION OF DOPAMINE AND APOMORPHINE
IN FOWLS.
001734 02-04
LACK OF EFFECT OF CHOLINE AND NARCOTIC ANTAGONISTS UPON
APOMORPHINE DISCRIMINATION.
001770 02-04
PSYCHOPHARMACOLOGICAL-EFFECTS OF LOW-DOSES AND HIGH-DOSES
Of APOMORPHINE DURING ONTOGENY.
001774 02-04
SUPERSENSITIVITY TO APOMORPHINE IN EXPERIMENTALLY-INDUCED
HYPOKINESIA AND DRUG-INDUCED MODIFICATIONS OF THE
APOMORPHINE RESPONSE.
001814 02-04
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE-
DECANOATE TREATMENT.
001820 02-04
APOMORPHINE HYPOTHERMIA: AN INDEX OF CENTRAL DOPAMINE-
RECEPTOR FUNCTION IN MAN.
002221 02-13
APOMORPHINE: SELECTIVE INHIBITION OF THE AVERSIVE COMPONENT OF
LATERAL HYPOTHALAMIC SELF-STIMULATION.
002476 02-16
\U OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL-
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFEQS OF D-
AMPHET AMINE AND APOMORPHINE.
002484 02-16
EffECTS OF D-AMPHETAMINE AND APOMORPHINE IN A NEW ANIMAL-
MODEL OF PETIT-MAL EPILEPSY.
002493 02-16
SPONTANEOUS ACTIVITY AND APOMORPHINE STEREOTYPY DURING AND
AFTER WITHDRAWAL FROM 3 1 /2 MONTHS CONTINUOUS
ADMINISTRATION OF HALOPERIDOL: SOME METHODOLOGICAL-ISSUES
002509 02-16
APOMORPHINE HALOPERIDOL INTERACTIONS: DIFFERENT TYPES OF
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS.
002662 03-03
FHREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE
002900 03-03
ilPHASIC-EFFECTS AND OPPOSITE-EFFECTS OF DOPAMINE AND
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT
SUBSTANTIA-NIGRA.
002923 03-03
'OTENTIATION OF APOMORPHINE AND D-AMPHETAMINE EFFEaS BY
NALOXONE.
002942 03-04
IINGLE OR REPEATED ADMINISTRATION OF SMALL DOSES OF
APOMORPHINE ON WATER INTAKE AND ACTIVITY IN WATER-
DEPRIVED RATS.
002981 03-04
;ONADECTOMY AND SEX-DIFFERENCES IN THE BEHAVIORAL-RESPONSES
TO AMPHETAMINE AND APOMORPHINE OF RATS.
003084 03-04
AGGRESSIVE-BEHAVIOR INDUCED BY APOMORPHINE IN RATS SUBMIHED
TO FOUR STRESSFUL-SITUATIONS.
003163 03-07
'RESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS-
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (MOGABA RELEASE IN VITRO.
003741 04-03
REJUNCTIONAL ACTIONS OF PIRIBEDIL ON THE ISOLATED KIDNEY OF THE
RABBIT: COMPARISON WITH APOMORPHINE.
003749 04-03
HARMACOLOGICAL DIFFERENCE OF L-DOPA, APOMORPHINE AND
BROMOCRIPTINE AGAINST METOCLOPRAMIDE.
003790 04-03
FFECTS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC-
ACID, HALOPERIDOL AND PIMOZIDE ON REFLEX BRADYCARDIA IN
RATS.
004085 04-04
ISE OF THE INTRACEREBRAL INJECTION TECHNIQUE TO ELUCIDATE
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN
THE MOUSE.
004092 04-04
'JDUCTION OF BEHAVIORAL-SUPERSENSITIVITY TO APOMORPHINE BY
DFP TREATMENT.
„„..„ 004099 04-04
POMORPHINE IN SCHIZOPHRENIA.
POMORPHINE, HALOPERIDOL AND THE AVERAGE EVOKED-POTENTIALS
IN NORMAL HUMAN VOLUNTEERS.
004549 04-13
Subject Index
APOMORPHINE-DIPIVALOYL-ESTER
TOLERANCE TO INCREASES IN STRIATAL ACETYLCHOLINE
CONCENTRATIONS AFTER REPEATED ADMINISTRATION OF
APOMORPHINE-DIPIVALOYL-ESTER.
000464 01-04
APOMORPHINE-ELICITED
EFFECTS OF THIORIDAZINE ON APOMORPHINE-ELICITED STEREOTYPIC-
BEHAVIOR AND MOTOR-ACTIVITY.
000424 01-04
APOMORPHINE-INDUCED
EFFECTS OF THE POTENTIAL NEUROLEPTIC-PEPTIDE DES-TYRl-GAMMA-
ENOORPHIN AND HALOPERIDOL ON. APOMORPHINE-INDUCED
BEHAVIOURAL-SYNDROMES IN RATS AND MICE.
000441 01-04
5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE
AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED-
BEHAVIOUR IN THE RAT.
001589 02-04
MODULATION OF APOMORPHINE-INDUCED STEREOTYPY BY ESTROGEN
TIME-COURSE AND DOSE-RESPONSE.
001636 02-04
EMERGENCE OF APOMORPHINE-INDUCED VACUOUS CHEWING DURING 6
MONTHS CONTINUOUS TREATMENT WITH FLUPHENAZINE-DECANOATE
001817 02-04
EFFECT OF L TRYPTOPHAN ON APOMORPHINE-INDUCED GROWTH-
HORMONE SECRETION IN NORMAL SUBJECTS.
002253 02-13
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE
CLIMBING IN MICE.
003031 03-04
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS
003068 03-04
EFFECT OF L HISTIDINE AND CHLORCYCLIZINE ON APOMORPHINE-INDUCED
CLIMBING-BEHAVIOUR AND METHAMPHETAMINE STEREOTYPY IN
MICE.
004147 04-04
PHARMACOKINETIC-STUDY OF APOMORPHINE-INDUCED STEREOTYPY IN
FOOD DEPRIVED RATS.
004247 04-04
APOMORPHINE-INDUCED STEREOTYPY IN MATURE AND SENESCENT RATS
FOLLOWING CESSATION OF CHRONIC HALOPERIDOL TREATMENT
004651 04-15
APOMORPHINE-INDUCED-FIGHTING
AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE
ANALYSIS OF APOMORPHINE-INDUCED-FIGHTING AND STEREOTYPY IN
THE RAT.
002983 03-04
APOMORPHINE-RECEPTORS
3H APOMORPHINE-RECEPTORS IN VARIOUS RAT-BRAIN REGIONS- A
STUDY OF SPECIFIC AND NONSPECIFIC BINDING AND THE INFLUENCE OF
CHRONIC NEUROLEPTIC TREATMENT.
001846 02-05
APPETITIVE
INTRAVENTRICULAR CORTICOSTERONE INJECTION FACILITATES MEMORY
OF AN APPETITIVE DISCRIMINATIVE TASK IN MICE.
003051 03-04
APPETITIVE-CONDITIONING
SENSORY AND ASSOCIATIVE-EFFECTS OF LSD ON CLASSICAL APPETITIVE-
CONDITIONING OF THE RABBIT JAW MOVEMENT RESPONSE.
001637 02-04
APROTIC
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
ARACHIOONIC-ACID
RELEASE OF ARACHIDONIC-ACID FROM ADRENAL CHROMAFFIN CELL-
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED
PAPER).
001027 02-01
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER)
001188 02-03
ARCALION-200
ARCALION-200 PRESCRIBED AS A PSYCHIATRIC-DRUG AND
ANTIALCOHOLISM-DRUG ON AN OUTPATIENT AND INPATIENT BASIS
002103 02-11
ARCHITECTURE
THE MOLECULAR ARCHITECTURE OF ERGOPEPTINES: A BASIS FOR
BIOLOGICAL-INTERACTION.
001527 02-03
AREA-POSTREAAA
ABSENCE OF LITHIUM-INDUCED TASTE-AVERSION AFTER AREA-POSTREMA
LESION.
000456 01-04
fe
S-39
Subject Index
^"^^HRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT:
S PSYCHOPHARMACOLOGICAL RESPONSES TO APOMORPHINE
ANDARECOLINE. 001470 02-03
^"'*HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJ^^^^^^
DURING COMBINED STATIC DYNAMIC ARM EXERCISE '^ MONKm^ ^^
^"^DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRA^: EFFECT
OF AMPHETAMINE FOLLOWING" INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE. ^^^^^^ ^^.qs
^"^I'^E^fR^slt^^rNm^Z-^'^R^^^^^^^
BY ALPHA DIFLUOROMETHYL-DOPA AND METABOLISM OF THE
INHIBITOR. 000248 01-03
^"°AROUSAL AND SHORT-TERM MEMORY: EFFECTS OF CAFFEINE AND TRIAL
SPACING ON DELAYED ALTERNATION PERFORMANCE . ^^^_^ ^ ^ ^^
THE EFFECT OF SMALL AND MODERATE DOSES OF D-AMPHET AMINE ON
HUNGER. MOOD, AND AROUSAL IN MAN. ^^^^^ ^^^^
THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPECTS OF SLEEP AND OBJECTIVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOCTURNAL
MEDICATION: II. REPEATED DOSES. ^^^331 02-14
SUPPRESSION OF AMPHETAMINE-INDUCED EEG AROUSAL IN THE
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS. ^^^^^ ^^^^
CATECHOIAMINERGIC INVOLVEMENT IN PHASIC VERSUS TONIC
ELECTROCORTICAL AROUSAL. 002723 03-03
CANALIZATION OF AROUSAL IN THE PREWEANLING RAT: EFFECTS OF
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI^ ^^^^
EFFECT OF FLURAZEPAM, PENTOBARBITAL, AND CAFFEINE ON AROUSAL
THRESHOLD. 003439 03-14
AUDITORY AROUSAL THRESHOLDS OF GOOD SLEEPERS AND POOR
SLEEPERS WITH AND WITHOUT FLURAZEPAM ^^^^ ^^_^^
^** ARRHnHMIA INDUCED BY A TRICYCLIC-ANTIDEPRESSANT IN A PATIENT
WITH UNDIAGNOSED MITRAL-VALVE PROLAPSE. ^^^^^ ^^^^
^""ffluL°CoKL°rN"uRA^ MEDIATED ARRHYTHMOGENIC-
PROPERTIES OF DESACETYLLANATOSIDE-C. ^^^^4 qS-OS
INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE,
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS^^^_^^ ^^_^^
ARSENIC
PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALLIUM, ARSENIC.
INDUSTRIAL-SOLVENT INTOXICATION, AND OTHER
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT.^ ^^^ ^
^*^ ^COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED
PARKINSONISM. 002146 02-11
^" HIG^-AFFINITY BINDING OF TRICYCLIC-ANTIDEPRESSANTS TO HISTAMINE
Hl-RECEPTORS: FACT AND ARTIFACT. ^^^^^ ^^-Od
^*^^y\.CYANAM|"eS. ACYLUREA, and various SUBSTITUTED
ARYLALLOPHANATES; EFFEQ ON THE CNS. ^^^^^ ^^^^
^""^Src'^REG^illtl'^Orre'REDUCTION IN ACETYL-COENZYME-
A:ARYLAMINE-N-ACETYLTRANSFERASE IN THE RAT PINEAL.^^^^^ ^^^^
^"''A^L^SlMS^f^Ss AS SELECTIVE AND VERY POTENT
INHIBITORS OF DOPAMINE UPTAKE. 000005 01-01
^*^INHIBITION^b"aRYLSULPHATASE a of NA-INDEPENDENT (3H) gaba
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES. 001208 02-03
Psychopharmacology Abstracts
PROTEIN ABNORMALITIES IN MACROPHAGES BEARING ASBESTOS.
(UNPUBLISHED PAPER). 001037 02-01
ASCORBATE DECREASES LIGAND BINDING TO NEUROTRANSMITTER-
^^«™^^ 002804 03-03
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL
TISSUE BY ASCORBATE. 003876 04-03
ASCORBIC-ACID. AN ENDOGENOUS FAQOR REQUIRED FOR
ACETYLCHOLINE RELEASE FROM THE SYNAPTIC VESICLES^^_^^^ ^^^^
PSYCHOPHARMACOLOGY FOR ASIAN-AMERICANS AND PACIFIC-
'SL^'^D^'^S. 000734 01-11
THE RELATIONSHIP BETWEEN MORPHINE, ASPARTIC-ACID AND L
ASPARAGINASE IN RATS 000169 01-03
^^'* TOTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3-
HYDROXYASPARTATE. 002768 03-03
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO
SYNAPTIC MEMBRANES 004000 04-03
ASPARTIC-ACID
THE RELATIONSHIP BETWEEN MORPHINE, ASPARTIC-ACID AND L
ASPARAGINASE IN RATS. 000169 01-03
TWO CONDUCTANCE MECHANISMS AQIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES . ^ ^ ^^^ ^^^
**'''mED1CATI0N use AND DEATHS AHRIBUTED TO ASPHYXIA AMONG
PSYCHIATRIC-PATIENTS 000838 Ol-li
^^•"'ji^ EFFECT OF ASPIRIN AND PARACETAMOL ON THE INCREASED
NALOXONE POTENCY INDUCED BY MORPHINE P^ETREATMENT^^ ^^^
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN
MAN: POSSIBLE CENTRAL-AQION IN BRAIN. ^^^^^ ^^^^^
ASPIRIN AND HUMAN SLEEP. ^^241 02-1
^"^HE DOPAMINE-RADIORECEPTOR ASSAY - A CLINICAL APP^TION^^^^
AN IMPROVED ASSAY OF CYCLIC-NUCLEOTIDE-PHOSPHODIESTERASES
WITH QAE-SEPHADEX COLUMNS 001860 02-0
DISPOSITION AND AQIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY.^^^_^^ ^^^
DETERMINATION OF GABA LEVELS BY A (3H)MUSaM0L RADIORECEPTO
ASSAY 003135 03-0
A rOMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH
* PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIGPATIE^NTS
NEUROLEPTIC SERUM LEVELS MEASURED BY RADIORECEPTOR ASSAY
AND CLINICAL-RESPONSE IN SCHIZOPHRENIC-PATIENTS. ^^^^^ ^^
A SELEQED ION-MONITORING ASSAY FOR BIOGENIC-AMINE
METABOLITES AND PROBENECID, IN HUMAN LUMBAR
CEREBROSPINAL-FLUID. ^^^^^ ^
TISSUE CHOLINE STUDIED USING A SIMPLE CHEMICAL ASSAYV _^^^^ ^
MEASUREMENT OF NEUROLEPTIC CONCENTRATIONS BY GLC AND
RADIORECEPTOR ASSAY 004682 04-
A RAPID AND SENSITIVE RADIORECEPTOR ASSAY FOR TERTIARY AMINI
TRICYCLIC-ANTIDEPRESSANTS. ^^^^g^ ^
*"irSAYlNG GABA-MODULIN ACTIVITY IN BRAIN EXTRAQS: RESOLUTIOI
OF INHERENT DIFFICULTIES (UNPUBLISHED PAPER) ^^^^ ^^^
S-40
rOLUME 19, SUBJECT INDEX
Subject Index
SSAYS
PSYCHOTROPIC-DRUGS DO NOT INTERFERE WITH RADIOLIGAND ASSAYS
FOR PROLACTIN, CORTISOL, AND GROWTH-HORMONE.
002511 02-16
SSERTIVENESS
THE EFFECT OF ASSERTIVENESS TRAINING, PROVERA AND SEX OF
THERAPIST IN THE TREATMENT OF GENITAL EXHIBITIONISM.
000697 01-11
SSESSMENT
ASSESSMENT OF TOLERANCE TO AND PHYSICAL-DEPENDENCE ON
PENTOBARBITAL, INDUCED BY MULTIPLE PELLET IMPLANTATION
000385 01-04
AN ELECTROMYOGRAPHIC-METHOD FOR THE ASSESSMENT OF
NALOXONE-INDUCED ABSTINENCE IN MORPHINE-DEPENDENT RATS.
000433 01-04
CLINICAL ASSESSMENT OF ONCE A DAY PHENOTHIAZINE
ADMINISTRATION.
000573 01-08
COGNITIVE AND AFFECTIVE-FUNCTIONS IN PATIENTS WITH AFFECTIVE-
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY
QUESTIONNAIRE.
000604 01-09
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF
LOPIRAZEPAM (D- 12524) BY QUANTITATIVE EEG AND
PSYCHOMETRIC-ANALYSIS.
000720 01-11
ASSESSMENT OF MULTIVARIATE RELATIONSHIPS IN REACTIVITY OF
PATIENTS RECEIVING LITHIUM THERAPY.
000819 01-14
A NEW APPROACH TO THE ASSESSMENT OF THE POTENCY OF
REVERSIBLE MONOAMINE-OXIDASE-INHIBITORS IN VIVO, AND ITS
APPLICATION TO D-AMPHET AMINE, P METHOXYAMPHETAMINE AND
HARMALINE.
000900 01-16
AN ASSESSMENT PROGRAM TO REDUCE DRUG USE WITH THE
MENTALLY-RETARDED.
000937 01-17
ASSESSMENT OF ADRENERGIC-RECEPTORS IN VIVO IN EXPERIMENTAL
ANIMALS AND MAN. (UNPUBLISHED PAPER).
001034 02-01
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO
SEVERE ANXIETY.
002070 02-10
TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERACTIVE-
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL
PARADIGM - A PILOT-STUDY.
002126 02-11
QUANTITATIVE ASSESSMENT OF SMOOTH-PURSUIT EYE-MOVEMENTS IN
HEALTHY AND EPILEPTIC-SUBJECTS.
002376 02-15
CASE 3: ASSESSMENT AND TREATMENT OF DRUG-INDUCED TREMOR
002407 02-15
SUBJECTIVE ASSESSMENT OF SEXUAL-DYSFUNCTION OF PATIENTS ON
LONG-TERM ADMINISTRATION OF DIGOXIN.
,,,„ 002443 02-15
ELEQROPHYSIOLOGIC ASSESSMENT OF RECEPTOR CHANGES FOLLOWING
CHRONIC DRUG-TREATMENT.
^„,,^ 003136 03-06
DRUG PREFERENCE AND MOOD IN HUMANS: REPEATED ASSESSMENT OF
D-AMPHETAMINE.
003445 03-14
EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED
COGNITIVE ASSESSMENT SYSTEM.
003557 03-16
PHARMACOLOGICAL-BASES OF PSYCHONEUROENDOCRINOLOGY-
PRECLINICAL ASSESSMENT OF CLINICAL FACTS.
003735 04-03
OPIATE-DEPENDENCE FOLLOWING ACUTE INJECTIONS OF MORPHINE AND
NALOXONE: THE ASSESSMENT OF VARIOUS WITHDRAWAL SIGNS
004209 04-04
SESSMENTS
EEG ASSESSMENTS OF DOSAGE AND SLEEP PROFILES FOR A HYPNOTIC-
DRUG OF THE TRIAZOLOTHIENODIACEPINE SERIES.
002338 02-14
SIMILATION
LITHIUM, ASSIMILATION OF NUTRIENTS AND REPRODUCTION
(UNPUBLISHED PAPER),
002777 03-03
SOCIATION
HUMAN PLATELET 5 HT-RECEPTORS: CHARACTERISATION AND
FUNCTIONAL ASSOCIATION.
001412 02-03
THE ASSOCIATION OF RETARD NEUROLEPTICS TO OTHER NEUROLEPTICS
IN THE REHABILITATION OF PSYCHOTIC-PATIENTS.
002108 02-11
HYPERPARATHYROIDISM IN ASSOCIATION WITH LITHIUM THERAPY
003489 03-15
ASSOCIATIVE-ASPECTS
INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY
PREEXPOSURE TO THE UNCONDITIONED-STIMULUS: ASSOCIATIVE-
ASPECTS AND NONASSOCIATIVE-ASPECTS.
001610 02-04
ASSOCIATIVE-EFFECTS
SENSORY AND ASSOCIATIVE-EFFECTS OF LSD ON CLy\SSICAL APPETITIVE-
CONDITIONING OF THE RABBIT JAW MOVEMENT RESPONSE
001637 02-04
ASTERIXIS
ASTERIXIS ASSOCIATED WITH SODIUM-VALPROATE.
003468 03-15
ASTHENIA
ATTEMPT AT PSYCHOLOGICAL UNDERSTANDING AND TREATMENT OF
PSYCHOLOGICAL ASTHENIA AND ASTHENO-DEPRESSIVE-SYNDROMES
USING ERGADYL.
001974 02-09
DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL-SYNDROME.
004472 04-1 1
ASTHENIC-DEPRESSIVE-SYNDROMES
CLINICAL-TESTING OF MINAPRINE ON ELDERLY SUBJECTS WITH THE
ASTHENIC-DEPRESSIVE-SYNDROMES.
002123 02-11
ASTHENO-DEPRESSIVE-DISORDERS
TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE
FATIGUE STUDY GROUPS NO. 4 CLINICAL- SCALE.
001980 02-09
ASTHENO-DEPRESSIVE-SYNDROMES
ATTEMPT AT PSYCHOLOGICAL UNDERSTANDING AND TREATMENT OF
PSYCHOLOGICAL ASTHENIA AND ASTHENO-DEPRESSIVE-SYNDROMES
USING ERGADYL.
001974 02-09
ASTHMA
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: EFFECT OF HYPOXIA
OR DRUGS?
003482 03-15
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: BRAIN-DAMAGE OR
DRUG-EFFECTS?
003538 03-15
ASTHMA THERAPY MAY UNDERCUT KIDS AT SCHOOL.
004475 04-11
ASTROCYTES
BENZODIAZEPINE-RECEPTORS ON PRIMARY CULTURES OF MOUSE
ASTROCYTES.
004029 04-03
ASTROGLIAL
DOXEPIN, A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTACT
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL-
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION.
003836 04-03
ASYMMETRY
POSTURAL ASYMMETRY AND DIRECTIONALITY OF ROTATION IN RATS
001729 02-04
DOES POSTURAL ASYMMETRY INDICATE DIRECTIONALITY OF ROTATION
IN RATS: ROLE OF SEX AND HANDLING.
003061 03-04
ATARACTIC-DRUG
PHARMACOLOGICAL PECULIARITIES OF A BENZODIAZEPINE/ATARACTIC-
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF
CLORAZEPATE-DIPOTASSIUM (TRANXILIUM) .
004527 04-13
ATAXIA
ORAL CHOLINE IN CEREBELLAR ATAXIA.
000722 01-11
DIAZEPAM-INDUCED ATAXIA IN TROHING SQUIRREL-MONKEYS.
004138 04-04
ATAXIC-BEHAVIORS
EFFECTS OF CHRONIC ADMINISTRATION OF PHENCYCLIDINE ON
STEREOTYPED-BEHAVIORS AND ATAXIC-BEHAVIORS IN THE RAT
003095 03-04
ATENOLOL
EFFECTS OF ATENOLOL AND PROPRANOLOL ON HUMAN PERFORMANCE
AND SUBJECTIVE FEELINGS.
002340 02-14
ATMOSPHERE
CORRELATED STUDY OF THE EFFECTS OF SE-5023 IN AN HYPOXIC
ATMOSPHERE ON QUANTIFIED EEG, VIGILANCE, MEMORY, AND
MOOD.
003440 03-14
ATP
.t
i.
&
•r
fe
ATP COMPLEXES WITH THE ATPASE INHIBITOR QUERCETIN.
ATPASE
ATP COMPLEXES WITH THE ATPASE INHIBITOR QUERCETIN.
000045 01-03
000045 01-03
S-41
Subject Index
Psychopharmacology Abstracts
THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REAQION
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN.
001052 02-01
EFFECTS OF MALNUTRITION AND QUIPAZINE ON RAT-CEREBRAL-CORTEX
ATPASE ACTIVITY DURING DEVELOPMENT.
001276 02-uJ
ATPASES
CERTAIN MECHANISMS OF THE ACTION OF PSYCHOTROPIC-DRUGS ON
TRANSPORT ATPASES. 00133102-03
IMIPRAMINE AFFECTS AUTONOMIC-CONTROL OF SINOATRIAL RATE IN
ISOLATED RIGHT ATRIAL PREPARATIONS. 000195 01-03
^^*?N*VIVO EFFECT OF PROTEASE INHIBITORS IN DENERVATION ATROPHY.
^^" THe'?FFECT of DIAZEPAM ON EEG CHANGES FOLLOWING INTRASEPTAL
ADMINISTRATION OF ATROPINE. 000127 01-03
BEHAVIOR-DEPENDENT EVOKED-POTENTIALS IN THE HIPPOCAMPAL-CAl
REGION OF THE RAT. II. EFFECTS OF ESERINE, ATROPINE, ETHER AND
P^'^™^'^'^^'^^^ 000184 01-03
THE EFFEQ OF CLONAZEPAM ON ATROPINE SPIKES IN THE LIMBIC-
S^S™. 001274 02-03
LONG-TERM ADMINISTRATION OF ATROPINE, IMIPRAMINE, AND
VILOXAZINE ALTERS RESPONSIVENESS OF RAT-CORTICAL-NEURONES
TO ACETYLCHOLINE. 001306 02-03
ATROPINE AND NATURAL SLEEP: ACTIVITY DATA OF THE STRIATUM IN
RATS
001551 02-03
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA)
SLEEP ELICITED BY OLFACTORY TUBERCLE STIMULATION AND THE EFFEQ
Of^^^OPm. 002955 03-04
THE EXCITATORY EFFECT OF ATROPINE ON THE NEURONS OF THE FROG
SYMPATHETIC GANGLIA. 00404104-03
DEVELOPMENTAL-CHANGE IN REARING RESPONSE TO ATROPINE IN RATS
TREATED WITH 6 HYDROXYDOPA.
004191 04-04
ATROPINE-RESISTANT
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-ACTIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
*^^'^'^ 000309 01-03
RESERPINE ABOLISHES MOVEMENT CORRELATED ATROPINE-RESISTANT
NEOCORTICAL LOW VOLTAGE FAST-ACTIVITY.
000310 01-03
ATTACK
LATE RESULTS OF LITHIUM TREATMENT OF ADOLESCENTS WITH AHACK
LIKE SCHIZOPHRENIA.
003177 03-08
AHACKS , „.,„, ...r«
DIFFERENTIAL DIAGNOSIS AND TREATMENT OF PANIC AHACKS AND
PHOBIC-STATES. „„ „.„.,«
004424 04-10
A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF
SCHIZOPHRENIA. „„.co.«>,,.
004584 04-14
ATTEMPTS
AHEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED
SPINAL FEMALE RATS WITH MONOAMINE AGONISTS.
000421 01-04
AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL
DOPAMINE-RECEPTORS AFTER VARIOUS TREATMENTS WITH
ANTAGONISTS OR AGONISTS. „„,..„ „o no
001350 02-03
PRESENT AHEMPTS AT TREATING TARDIVE-DYSKINESIA.
004629 04-15
BEHAVIORAL-INTERVENTION FOR SELF- STIMULATORY, AHENDING AND
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILD.
002104 02-11
DISRUPTION OF SELECTIVE AHENTION BY APOMORPHINE, BUT NOT
AMPHETAMINE, IN THE MONGOLIAN-GERBIL. „ „, „.
000358 01-04
THE EFFECTS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERACTION
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED
AHENTION. (PH.D. DISSERTATION).
001563 02-04
DOPAMINERGIC INVOLVEMENT IN AHENTION A NOVEL ANIMAL-MODEL.
001678 02-04
EFFECTS OF METHYLPHENIDATE ON SELEQIVE AND SUSTAINED
AHENTION IN HYPERACTIVE, READING-DISABLED, AND PRESUMABLY
AHENTION-DISORDERED BOYS.
002118 02-11
PSYCHOACTIVE-DRUG-EFFEaS IN A HYPERACTIVE-CHILD: A CASE-STUDY
ANALYSIS OF BEHAVIOR-CHANGE AND TEACHER AHENTION.
002313 02-14
EFFEaS OF LITHIUM ON EVOKED-POTENTIALS AND PERFORMANCE
DURING SUSTAINED AHENTION.
002419 02-15
PREDICTING OUTCOME FROM MEASURES OF AHENTION AND
AUTONOMIC-FUNQIONING.
003205 03-08
AHENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNQION) IN
ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG-
TREATMENT.
003389 03-11
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS EFFEaS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300.
003451 03-14
AHENTION-DISORDERED
EFFECTS OF METHYLPHENIDATE ON SELECTIVE AND SUSTAINED
AUENTION IN HYPERACTIVE, READING-DISABLED, AND PRESUMABLY
ATTENTION-DISORDERED BOYS.
002118 02-11
AHENTION-DYSFUNCTION
ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN AHENTION-
DYSFUNCTION TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA.
004316 04-08
AnENTIONAL-ALTERATION
Y-MAZE BEHAVIOR AFTER AN ANALOG OF AaH4-9, EVIDENCE FOR AN
ATTENTION AL-ALTERATION.
001676 02-04
AUENTUATION
POSTINGESTION INTERFERENCE WITH BRAIN FUNQION PREVENTS
AHENTUATION OF NEOPHOBIA IN RATS.
000352 01-04
MORPHINE INJECTIONS INTO THE PERIAQUEDUQAL PERIVENTRICULAR
GRAY AHENUATE SEPTAL HYPERREAQIVITY
000390 01-04
PHENOXYBENZAMINE AND BROMOCRIPTINE AHENUATE NEED FOR REM
SLEEP IN RATS. ^.o„o «. n.
004203 04-04
LOCOMOTOR-AQIVITY ELICITED BY INJEQIONS OF PICROTOXIN INTO THE
VENTRAL TEGMENTAL AREA IS AHENUATED BY INJECTIONS OF GABA
INTO THE GLOBUS-PALLIDUS _^^^^ „, „^
000436 01-04
PATIENT CHARACTERISTICS AND CLINICIAN AHITUDES INFLUENCING THE
PRESCRIBING OF BENZODIAZEPINES. ^^^^^„ ^^ ,,
003598 03-17
ATTRIBUTED
MEDICATION USE AND DEATHS AHRIBUTED TO ASPHYXIA AMONG
PSYCHIATRIC-PATIENTS. 000838 01-15
ATTRIBUTION
CASE-REPORT USING AHRIBUTION THEORY TO LIMIT NEED FOR
NEUROLEPTIC-MEDICINE. 000559 01-08
REGULATION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS.
DIFFERENTIAL ACTIONS OF CLASSICAL AND ATYPICAL ANTI PSYCHOTIC-
DRUGS ON SPONTANEOUS NEURONAL AQIVITY IN THE AMYGDALOID
C°^''^^^ 003131 03^5
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT
ANTICHOLINERGIC-AQIVITY BY AN ATYPICAL NEUROLEPTIC
^^»^ORmzm. 003560 03-16
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF
(3H)SPIR0PERID0L IN CALF CAUDATE. ^^^^ ^_^j
DRUG AND SEIZURE IDENTIFICATION BY AUDIO-SPEaROMETRY. (PH.D.
D'SSERTATION). 000532 01^
S-42
VOLUME 19, SUBJECT INDEX
AUOIOGENIC-SEIZURE
DIFFERENCES IN ACTIVITY IN CEREBRAL METHYLTRANSFERASES AND
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE
AND RESISTANT MICE AND DEERMICE.
000377 01-04
EFFECT OF RO-4-1284 ON AUDIOGENIC-SEIZURE SUSCEPTIBILITY AND
INTENSITY IN EPILEPSY-PRONE RATS,
003865 04-03
IkUDIOOENIC-SEIZURES
AUDIOGENIC-SEIZURES; INCREASED BENZODIAZEPINE-RECEPTOR BINDING
IN A SUSCEPTIBLE STRAIN OF MICE.
000252 01-03
THE EFFECTS OF NOOTROPIC-DRUGS ON THE SUSCEPTIBILITY TO
AUDIOGENIC-SEIZURES IN RATS.
001571 02-04
EFFEQS OF WITHDRAWAL FROM LONG-TERM DIPHENYLHYDANTOIN
TREATMENT ON AUDIOGENIC-SEIZURES AND MAXIMAL
ELECTROSHOCK-INDUCED SEIZURES IN RATS.
004101 04-04
kUDITORY
BRAINSTEM AUDITORY EVOKEO-POTENTIALS AND MYELIN CHANGES IN
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS.
000509 01-05
EFFECTS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED
SUBJECTS.
002320 02-14
PHASIC ACTIVITY INDUCED BY P CHLOROPHENYLALANINE IN THE
AUDITORY PATHWAY.
002661 03-03
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
AUDITORY BRAINSTEM EVOKED-RESPONSES IN HOSPITALIZED-PATIENTS
UNDERGOING DRUG-TREATMENT OR ECT.
003430 03-13
AUDITORY AROUSAL THRESHOLDS OF GOOD SLEEPERS AND POOR
SLEEPERS WITH AND WITHOUT FLURAZEPAM.
003446 03-14
THE BRAINSTEM AUDITORY EVOKED-RESPONSE AS A TOOL IN
NEUROBEHAVIORAL TOXICOLOGY AND MEDICINE.
004277 04-05
kUGMENTER
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE.
002305 02-13
AUGMENTING
INHIBITORY-AQION OF THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS.
004022 04-03
lUTHORITIES
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES
003599 03-17
lUTISM
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFECTS OF ORAL MAGNESIUM
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM.
003291 03-11
lUTISTIC-PATIENT
TARDIVE TOUREHE-SYNDROME IN AN AUTISTIC-PATIENT AFTER LONG-
TERM NEUROLEPTIC ADMINISTRATION.
000887 01-15
AUTOCORRELATION
AUTOCORRELATION ANALYSIS OF SINGLE NEURON ACTIVITY AFTER
ADMINISTRATION OF PENTOBARBITAL.
001268 02-03
UTOINDUCTION
THE AUTOINDUCTION OF CARBAMAZEPINE DURING LONG-TERM
THERAPY.
000785 01-13
UTOMAINTENANCE-SCHEDULE
DRUG-EFFEQS ON THE PERFORMANCE OF PIGEONS UNDER A NEGATIVE
AUTOMAINTENANCE-SCHEDULE .
UTOMATED 001754 02-04
AN AUTOMATED ELECTROCHEMICAL-METHOD FOR IN VIVO MONITORING
OF CATECHOLAMINE RELEASE.
001873 02-06
AN AUTOMATED METHOD FOR STUDYING STEREOTYPED GNAWING.
002500 02-16
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BUND TRIAL USING AN
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
Subject Index
AUTONOMIC
THE EFFECTS OF ALPHA AND BETA NEUROTOXINS FROM THE VENOMS OF
VARIOUS SNAKES ON TRANSMISSION IN AUTONOMIC GANGLIA.
003750 04-03
AUTONOMIC-ACTIVITY
THE INFLUENCE OF METHYLPHENIOATE ON SPONTANEOUS AUTONOMIC-
ACTIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE.
003363 03-11
AUTONOMIC-CONTROL
IMIPRAMINE AFFECTS AUTONOMIC-CONTROL OF SINOATRIAL RATE IN
ISOLATED RIGHT ATRIAL PREPARATIONS.
000195 01-03
AUTONOMIC-EFFECTS
AUTONOMIC-EFFEaS OF DEXTROAMPHETAMINE IN NORMAL MEN:
IMPLICATIONS FOR HYPERACTIVITY AND SCHIZOPHRENIA.
003437 03-13
AUTONOMIC-FUNCTIONING
PREDICTING OUTCOME FROM MEASURES OF ATTENTION AND
AUTONOMIC-FUNCTIONING.
003205 03-08
AUTONOMIC-MECHANISMS
PERIPHERAL AUTONOMIC-MECHANISMS AND PAVLOVIAN-CONDITIONING
IN THE RABBIT (ORYCTOLAGUS-CUNICULUS).
001560 02-04
AUTORADIOGRAPHIC
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3 4
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN.
003941 04-03
AUTORADIOGRAPHIC LOCALIZATION OF DRUG AND NEUROTRANSMIHER-
RECEPTORS IN THE BRAIN.
004292 04-06
AUTORAOIOGRAPHICAL
BENZODIAZEPINE-RECEPTORS: AUTORAOIOGRAPHICAL AND
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN
REGIONS OF GABAERGIC SYNAPTIC CONTACTS.
002643 03-01
AUTORADIOGRAPHY
IN VITRO AUTORADIOGRAPHY OF OPIATE-RECEPTORS IN RAT-BRAIN
SUGGESTS LOCI OF OPIATE-ERGIC PATHWAYS. (UNPUBLISHED PAPER)
001025 02-01
NEUROTENSIN-RECEPTOR LOCALIZATION BY LIGHT MICROSCOPIC
AUTORADIOGRAPHY IN RAT-BRAIN.
002938 03-03
AUTORECEPTOR
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH
IN THE ELEaROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO
AUTORECEPTOR STIMULATION.
000046 01-03
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN.
001167 02-03
AUTOSHAPED
DISRUPTION OF AUTOSHAPED RESPONDING TO A SIGNAL OF BRAIN-
STIMULATION REWARD BY NEUROLEPTIC-DRUGS.
004199 04-04
AVAILABILITY
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH
PSYCHOSTIMULANTS: II. EFFECT OF METHAMPHETAMINE ON
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC
SUBSTRATES.
001613 02-04
AVAILABILITY OF ISOSORBIDE-DINITRATE, DIAZEPAM AND
CHLORMETHIAZOLE, FROM I.V. DELIVERY SYSTEMS.
003558 03-16
AVERAGE
APOMORPHINE, HALOPERIDOL AND THE AVERAGE EVOKED-POTENTIALS
IN NORMAL HUMAN VOLUNTEERS.
004549 04-13
AVERAGED
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD
003412 03-13
AVERMECTIN-B1A
STUDIES ON THE MECHANISM-OF-ACTION OF AVERMECTIN-BIA-
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM
BRAIN SYNAPTOSOMES.
003973 04-03
IN VITRO MODULATION BY AVERMECTIN-BIA OF THE GABA/
BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-CEREBELLUM.
004023 04-03
AVERSION
INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY
PREEXPOSURE TO THE UNCONDITIONED- STIMULUS: ASSOCIATIVE-
ASPECTS AND NONASSOCIATIVE-ASPECTS.
001610 02-04
fe:
S-43
Subject Index
Psychopharmacology Abttrocft
ETHANOL AVERSION INDUCED BY PARENTERALLY ADMINISTERED
ETHANOL ACTING BOTH AS CS AND UCS.
001721 02-04
AVERSIONS
LITHIUM-CHLORIDE AND DELTA9 THC LEAD TO CONDITIONED AVERSIONS
IN THE PIGEON.
003003 03-04
AVERSIVE
APOMORPHINE: SELECTIVE INHIBITION OF THE AVERSIVE COMPONENT OF
LATERAL HYPOTHALAMIC SELF-STIMULATION.
002476 02-16
PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS
MECHANISMS RESPONSIBLE FOR MOTOR ACT INHIBITION BY AVERSIVE
EVENTS.
002671 03-03
AVERSIVE-EFFECT
ACCELERATED EXTINCTION AFTER POSHRIAL HALOTHANE ANESTHESIA IN
RATS; AN AVERSIVE-EFFECT.
003001 03-04
AVERSIVE-EFFECTS
REWARDING AND AVERSIVE-EFFECTS OF MORPHINE: TEMPORAL AND
PHARMACOLOGICAL-PROPERTIES.
000470 01-04
TEMPORAL PROPERTIES OF THE REWARDING AND AVERSIVE-EFFECTS OF
AMPHETAMINE IN RATS.
000471 01-04
CALCITONIN: AVERSIVE-EFFECTS IN RATS?
002977 03-04
CALCITONIN: AVERSIVE-EFFECTS IN RATS?
002992 03-04
AVERSIVE-EXPERIENCES
AMYGDALA OPIATE-SENSITIVE MECHANISMS INFLUENCE FEAR
MOTIVATED RESPONSES AND MEMORY PROCESSES FOR AVERSIVE-
EXPERIENCES. (UNPUBLISHED PAPER).
001628 02-04
AVERSIVE-PROPERTIES
A COMPARISON BETWEEN THE EFFECTS OF MORPHINE ON THE
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC
AND CENTRAL GRAY STIMULATION.
001771 02-04
AVERSIVE-SITUATIONS
DIFFERENTIAL-EFFECTS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS
000480 01-04
AVERSIVENESS
SOCIAL CROWDING ENHANCES AVERSIVENESS OF NALOXONE IN RATS.
004201 04-04
AVFAIL
DEPENDENCE OF THE AVFAIL EFFECT ON THE SEQUENCE OF TRAINING
OPERATIONS.
001086 02-02
AVOIDANCE
ENHANCED SUPPRESSION OF CONDITIONED AVOIDANCE RESPONSE BY
HALOPERIDOL BUT NOT PHENOXYBENZAMINE IN RATS WITH
BILATERAL PARAFASCICULAR LESIONS.
000334 01-04
MORPHINE EFFECTS UPON DISCRIMINATED APPROACH AND
DISCRIMINATED AVOIDANCE IN RATS: ANTAGONISM BY NALOXONE
000338 01-04
EFFEQ OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION,
MEMORY, AND RETRIEVAL OF SHUTTLE AVOIDANCE AND
HABITUATION LEARNING IN RATS.
000410 01-04
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT.
001580 02-04
TWO-WAY AVOIDANCE LEARNING UNDER THE INFLUENCE OF NOOTROPIC-
DRUGS.
001647 02-04
L-DOPA ENHANCES ACQUISITION OF AN INHIBITORY AVOIDANCE
RESPONSE.
001711 02-04
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL
BY ANXIOLYTICS WITH DRUGS ACTING ON THE GABA SYSTEM.
004193 04-04
EFFEaS OF CHLORPROMAZINE ON ESCAPE AND AVOIDANCE RESPONSES:
A CLOSER LOOK.
004226 04-04
AVOIDANCE RESPONSE IN RATS AFTER INJEQION OF DOPAMINE INTO
THE NEOSTRIATUM.
004255 04-04
AVOIDANCE-BEHAVIOR
IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM
INGESTION OF ETHANOL, TERTIARY BUTANOL, OR PENTOBARBITAL IN
MICE.
000479 01-04
INTERACTION AMONG D-AMPHETAMINE, SCOPOLAMINE AND GENOTYPE
IN AVOIDANCE-BEHAVIOR OF RATS.
003082 03-04
ACTH-LIKE PEPTIDES, PITUITARY ADRENOCORTICAL FUNQION AND
AVOIDANCE-BEHAVIOR.
004109 04-04
AVOIDANCE-BEHAVIOUR
EFFECTS OF MORPHINE AND CHLORDIAZEPOXIDE ON AVOIDANCE-
BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
002973 03-04
AVOIDANCE-DEFICITS
THE USE OF EXTINCTION TO INVESTIGATE THE NATURE OF NEUROLEPTIC-
INDUCED AVOIDANCE-DEFICITS.
000345 01-04
THE USE OF CONDITIONED SUPPRESSION TO EVALUATE THE NATURE OF
NEUROLEPTIC-INDUCED AVOIDANCE-DEFICITS.
004070 04-04
AVOIDING
APPROACHES TO THE PROBLEM OF PREVENTING HAZARDS OF LONG-
TERM NEUROLEPTIC TREATMENT AND OF AVOIDING UNNECESSARY
DRUGS.
002426 02-15
AVP
DIFFERENTIAL-EFFECTS OF VARIOUS STIMULI ON AVP LEVELS IN BLOOD
AND CEREBROSPINAL-FLUID.
001370 02-03
AWAKE
A COMPARISON OF HUMAN TAQILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE
ANESTHETIZED RATS.
002687 03-03
TEMPORAL PAHERNING OF NEURONAL AQIVITY DURING THERMAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
AWAKENING
COMPARATIVE-STUDY OF SLEEP AND STATE ON AWAKENING WITH TWO
HYPNOTIC DIAZEPINES.
000817 01-14
AXIS
INFLUENCE OF DRUGS AFFEQING THE PITUITARY ADRENAL AXIS ON
CHROMAFFIN CELLS.
001183 02-03
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFEaS OF NALOXONE ON
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE
MALE RAT
002853 03-03
DRUG-INDUCED ALTERATIONS OF THE HYPOTHALAMUS HYPOPHYSIS
AXIS.
004535 04-13
AXON
EFFECTS OF TAIPOXIN ON THE ULTRASTRUQURE OF CHOLINERGIC AXON
TERMINALS IN THE MOUSE ADRENAL-MEDULLA.
003916 04-03
AXONAL
BIOSYNTHESIS, AXONAL TRANSPORT AND RELEASE OF POSTERIOR
PITUITARY-HORMONES. (UNPUBLISHED PAPER).
001148 02-03
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT.
003734 04-03
STUDIES ON AXONAL TRANSPORT IN DOPAMINERGIC NEURONS: EFFEQ
OF NEUROPHARMACOLOGIC LESIONS.
003858 04-03
RESERPINE EFFECT ON THE AXONAL TRANSPORT OF DOPAMINE-BETA-
HYDROXYLASE AND TYROSINE-HYDROXYLASE IN RAT-BRAIN.
003904 04-03
AXONS
ABSENCE OF POTASSIUM CONDUQANCE IN CENTRAL MYELINATED
AXONS.
000166 01-03
AZETIDINYIBUTYNYL
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF N-4 1
AZETIDINYLBUTYNYL 2 PYRROLIDONE, A HIGHLY POTENT
OXOTREMORINE-LIKE-AGENT.
003701 04-02
A10
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF
AlO DOPAMINERGIC NEURONS.
000320 01-03
DOPAMINERGIC AGONISTS DIFFERENTIALLY AFFEQ OPEN-FIELD AQIVITY
OF RATS WITH AlO LESIONS.
004135 04-04
S-44
VOLUME 19, SUBJECT INDEX
Subject Index
BABOON
EEG AND ANTICONVULSANT EFFECTS OF DIPROPYLACETIC-ACID AND
DIPROPYLACETAMIDE IN THE BABOON PAPIO-PAPIO.
001210 02-03
BABOONS
PROGRESSIVE-RATIO AND FIXED-RATIO SCHEDULES OF COCAINE
MAINTAINED RESPONDING IN BABOONS.
000395 01-04
COMPARATIVE ANXIOLYTIC AND HYPNOTIC-EFFECTS OF 3
BENZODIAZEPINES ON BABOONS.
001581 02-04
BACKGROUND
THE BIOCHEMICAL BACKGROUND TO TARDIVE-DYSKINESIA
004588 04- 1 5
BACKWARD
THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS.
003397 03-12
BACLOFEN
CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL INJECTION OF
BACLOFEN IN RATS.
000415 01-04
MANIC-PSYCHOSIS FOLLOWING RAPID WITHDRAWAL FROM BACLOFEN.
000832 01-15
THE EFFECTS OF ETHANOL, PHENOBARBITAL, AND BACLOFEN ON
ETHANOL WITHDRAWAL IN THE RHESUS-MONKEY.
001802 02-04
BACLOFEN IN TRIGEMINAL-NEURALGIA: ITS EFFECT ON THE SPINAL
TRIGEMINAL-NUCLEUS: A PILOT-STUDY.
002122 02-11
EFFECT OF SODIUM-VALPROATE AND BACLOFEN IN TARDIVE-DYSKINESIA:
CLINICAL-STUDIES AND NEUROENDOCRINE-STUDIES.
002441 02-15
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA
BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY
TUBERCLE OF THE RAT.
002681 03-03
GABA AND BACLOFEN POTENTIATE THE K-EVOKED RELEASE OF
METHIONINE-ENKEPHALIN FROM RAT STRIATAL SLICES.
002882 03-03
BACLOFEN: BROADER ASPECTS OF ACTIVITY.
003429 03-13
3H BACLOFEN AND 3H GABA BIND TO BICUCULLINE INSENSITIVE GABAB
SITES IN RAT-BRAIN.
003839 04-03
BACLOFEN: STEREOSELECTIVE INHIBITION OF EXCITANT AMINO-ACID
RELEASE.
003867 04-03
CENTRAL CARDIOVASCULAR-EFFEQS AND BIOCHEMICAL-EFFECTS OF
BACLOFEN IN THE CONSCIOUS RAT.
003965 04-03
BACLOFEN IN THE TREATMENT OF TARDIVE-DYSKINESIA: OPEN LABEL
STUDY.
004619 04-15
BACTERIAL
SYNTHETIC IMMUNOSTIMULANTS DERIVED FROM THE BACTERIAL CELL
WALL.
001080 02-02
BAR-PRESSING-BEHAVIOR
FIRST DOSE BEHAVIORAL-TOLERANCE TO PHENCYCLIDINE ON FOOD
REWARDED BAR-PRESSING-BEHAVIOR IN THE RAT.
000462 01-04
IMITATION, SOCIAL FACILITATION, AND THE EFFECTS OF ACTH4-10 ON
RATS BAR-PRESSING-BEHAVIOR.
003009 03-04
BARBITAL
EFFECT OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF
TOLERANCE TO THE HYPNOTIC-EFFEQS OF PENTOBARBITAL, BARBITAL,
AND ETHANOL.
003883 04-03
BARBITURATE
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH
ANTIEPILEPTIC-DRUGS.
000695 01-11
INTRAVENOUS PHENOBARBITAL THERAPY IN BARBITURATE AND OTHER
HYPNOSEDATIVE WITHDRAWAL REACTIONS: A KINETIC APPROACH.
000703 01-11
BARBITURATE SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
001559 02-04
REDUCTION OF BARBITURATE ANESTHESIA BY NEW GLUTARIMIDE
COMPOUNDS IN MICE.
001748 02-04
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND
EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES.
002799 03-03
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH
ANTICONVULSANT AND ANESTHETIC ACTIONS.
002885 03-03
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID:
DIFFERENTIAL-EFFECT IN TOLERANT ANIMALS.
003038 03-04
NEUTRALIZATION OF THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL
ON BARBITURATE SLEEPING-TIME BY SPECIFIC ACTIVE IMMUNIZATION
003803 04-03
HABITUATION OF THE THE HEAD-POKE RESPONSE: EFFECTS OF AN
AMPHETAMINE BARBITURATE MIXTURE, PLG AND FENFLURAMINE.
004159 04-04
SELECTIVE EFFECTS OF BARBITURATE AND AMPHETAMINE ON
INFORMATION-PROCESSING AND RESPONSE EXECUTION.
004563 04-14
BARBITURATE-DEPENDENCE
BARBITURATE-DEPENDENCE IN MICE: EFFECTS OF PROPRANOLOL ON THE
WITHDRAWAL-SYNDROME (40798).
000313 01-03
BARBITURATE-DEPENDENCE AND DRUG PREFERENCE.
004235 04-04
BARBITURATE-EVOKED
A BARBITURATE-EVOKED INTENSIFICATION OF POSTSYNAPTIC INHIBITION
IN THE PREOPTIC OVULATORY TRIGGER REGION OF THE
HYPOTHALAMUS.
002818 03-03
BARBITURATE-INDUCED
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION).
001213 02-03
BARBITURATES
ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS.
000194 01-03
ACTION OF BARBITURATES ON ACTIVITY OF ACETYLCHOLINESTERASE
FROM SYNAPTOSOMAL MEMBRANES.
000224 01-03
CONVULSANT AND ANTICONVULSANT BARBITURATES. 1. MOLECULAR
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY
CALCULATIONS.
001029 02-01
LACK OF INFLUENCE OF BRAIN CATECHOLAMINES ON ACUTE EFFECTS OF
BARBITURATES.
001138 02-03
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE
DEVELOPMENT OF DEPENDENCE IN RATS.
001800 02-04
THE EFFECT OF BARBITURATES ON THE DEGRADATION OF ENKEPHALIN BY
BRAIN ENZYMES.
002656 03-03
BARBITURATES AND GABA-RECEPTORS.
002769 03-03
EFFECTS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO-
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY
CULTURED NEURONS.
002859 03-03
MECHANISM-OF-ACTION OF BARBITURATES.
003600 03-17
EFFEQS OF BARBITURATES ON INHIBITORY AND EXCITATORY RESPONSES
TO APPLIED NEUROTRANSMIHERS IN APLYSIA.
003762 04-03
SOME BARBITURATES ENHANCE THE EFFECT OF MUSCIMOL ON
DOPAMINE TURNOVER IN THE RAT RETINA.
003873 04-03
INTERACTION OF STEREOISOMERS OF BARBITURATES WITH (3H)ALPHA
DIHYDROPICROTOXININ BINDING-SITES.
004036 04-03
SEPARATION OF BARBITURATES USING REVERSE PHASE THIN-LAYER-
CHROMATOGRAPHY.
004670 04-16
BARORECEPTOR
EVIDENCE SUGGESTING A TRANSMITTER OR NEUROMODULATORY ROLE
FOR SUBSTANCE-P AT THE FIRST SYNAPSE OF THE BARORECEPTOR
REFLEX.
001264 02-03
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON
BARORECEPTOR REFLEXES IN CONSCIOUS CATS.
001514 02-03
BASAL
PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN
VITRO. INHIBITION BY MELATONIN AT SUBMICROMOLAR
CONCENTRATIONS.
001159 02-03
i1
is-
S-45
Subject Index
Psychopharmacology Abstracts
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN.
001167 02-03
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM:
FUNCTIONAL CHANGES FOLLOWED USING (-)N N
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL AQIVITY LEVELS
OF RATS.
001603 02-04
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH
NEUROLEPTICS.
001935 02-08
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES.
002285 02-13
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR
FUNaiONS RELATED TO MOTIVATED BEHAVIOR.
002815 03-03
KAINIC-ACID AND NEUROTRANSMinER INTERAQIONS IN THE BASAL
GANGLIA.
002824 03-03
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC
NEURONS.
002880 03-03
SELECTIVE MODIFICATION BY OPIATES OF NEURONAL AQIVITY OF THE
MEDIAL BASAL HYPOTHALAMUS.
003773 04-03
BASAL PROLACTINAEMIA AND RESPONSES TO TRH AND SULPIRIDE IN
DIFFERENT CATEGORIES OF MALE SEXUAL-DYSFUNCTIONS.
004503 04-13
BASELINE
EFFEaS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROFILES.
002239 02-13
BASILAR
A COMPARISON OF THE CONTRAQILE RESPONSES OF THE RABBIT
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC
AGONISTS: CHARACTERISTICS.
002670 03-03
BASOPHILIC
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER).
001188 02-03
BASS-SCALE-FACTORS
TWO BASS-SCALE-FAaORS AND RESPONSE TO PLACEBO AND
ANXIOLYTIC-DRUGS.
000649 01-10
BATRACHOTOXIN
FURTHER ANALYSIS OF THE MECHANISMS OF AQION OF
BATRACHOTOXIN ON THE MEMBRANE OF MYELINATED NERVE.
003884 04-03
BEAGLE-DOGS
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYOANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
BEARING
PROTEIN ABNORMALITIES IN MACROPHAGES BEARING ASBESTOS.
(UNPUBLISHED PAPER).
001037 02-01
BED
CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE
CANINE FEMORAL VASCULAR BED.
00391 1 04-03
BEHAVIOR
TRANYLCYPROMINE STEREOISOMERS, MONOAMINERGIC
NEUROTRANSMISSION AND BEHAVIOR. A MINIREVIEW.
000016 01-02
SCHEDULE-CONTROLLED BEHAVIOR IN THE MORPHINE-DEPENDENT AND
POSTDEPENDENT RAT.
000349 01-04
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFEQS OF
COCAINE AND D-AMPHET AMINE FOLLOWING CHRONIC AMPHETAMINE
ADMINISTRATION.
000350 01-04
BEHAVIORAL-PHARMACOLOGY AND THE STIMULUS CONTROL OF
BEHAVIOR.
000381 01-04
STEREOSPECIFIC, DOSE-DEPENDENT ANTAGONISM BY NALOXONE OF
NONOPIATE BEHAVIOR IN MICE.
000411 01-04
DIFFERENTIAL-EFFEaS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS.
000480 01-04
CONFIRMATION BEHAVIOR OF PHENCYCLIDINES AND BIOLOGICAL-
ACTIVITY.
001031 02-01
ANTIDEPRESSANT-DRUGS SLOW CIRCADIAN-RHYTHMS IN BEHAVIOR AND
BRAIN NEUROTRANSMITTER-RECEPTORS.
001536 02-03
THE EFFECTS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERACTION
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED
AHENTION. (PH.D. DISSERTATION).
001563 02-04
ACUTE AND CHRONIC EFFEaS OF DELTA9 TETRAHYDROCANNABINOL ON
COMPLEX BEHAVIOR OF SQUIRREL-MONKEYS.
001583 02-04
EFFECTS OF LILLY-1 10140 (FLUOXETINE) ON SELF-STIMULATION
BEHAVIOR IN THE DORSAL AND VENTRAL REGIONS OF THE LATERAL
HYPOTHALAMUS IN THE MOUSE.
001590 02-04
INTERAQION OF PSYCHOPHARMALOGIC-FAaORS AND PSYCHOSOCIAL-
FACTORS IN THE TREATMENT OF ANIMAL-MODELS OF
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR.
001602 02-04
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS, UNDER
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REAQION TYPE
(EMOTIVE AND NONEMOTIVE)
001624 02-04
INTERACTIONS BETWEEN NALTREXONE AND NONOPIATE DRUGS
EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
001645 02-04
Y-MAZE BEHAVIOR AFTER AN ANALOG OF AaH4-9, EVIDENCE FOR AN
AnENTIONAL-ALTERATION .
001676 02-04
THE EFFEaS OF D-AMPHETAMINE, CHLORDIAZEPOXIDE, AND
PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM
PUNISHMENT IN PIGEONS (PHD DISSERTATION).
001713 02-04
INTERRELATIONS AMONG PRIOR EXPERIENCE AND CURRENT CONDITIONS
IN THE DETERMINATION OF BEHAVIOR AND THE EFFECTS OF DRUGS.
001715 02-04
EFFEaS OF NEONATAL 6 HYDROXYDOPA ON BEHAVIOR IN FEMALE
RATS.
001717 02-04
EFFECTS OF ACUTE VS. CHRONIC PHENCYCLIDINE ON BRAIN-
BIOCHEMISTRY AND BEHAVIOR.
001789 02-04
EFFECTS OF BRANCHED-CHAIN FATTY-ACIDS ON GABA DEGRADATION
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI-
MORPHINE ABSTINENCE-BEHAVIOR
001809 02-04
BEHAVIOR MAINTAINED BY INTRAVENOUS INJEQION OF CODEINE,
COCAINE, AND ETORPHINE IN THE RHESUS-MACAQUE AND THE
PIGTAIL-MACAQUE
001828 02-04
BEHAVIORAL-INTERVENTION FOR SELF- STIMULATORY, AHENDING AND
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILO.
002104 02-1 1
DISINHIBITION OF BEHAVIOR BY ANTIANXIETY-DRUGS.
002403 02-15
THE EFFEa OF ALTERED DOPAMINERGlC-AaiVITY ON FOOD INTAKE IN
THE RAT: EVIDENCE FOR AN OPTIMAL LEVEL OF DOPAMINERGIC-
AaiVITY FOR BEHAVIOR.
002632 02-17
FUNDAMENTAL MECHANISMS UNDERLYING ALTERED BEHAVIOR
FOLLOWING CHRONIC ADMINISTRATION OF PSYCHOMOTOR
STIMULANTS.
002711 03-03
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR
FUNQIONS RELATED TO MOTIVATED BEHAVIOR.
002815 03-03
POSSIBLE MECHANISMS OF EFFEQ OF AaH4-10 AND ITS ANALOG,
CONTAINING D ISOMER OF PHENYLALANINE, ON BEHAVIOR.
002949 03-04
FACILITATION OF LORDOSIS BEHAVIOR IN THE OVARIEaOMIZED
ESTROGEN-PRIMED RAT BY DIBUTYRYL-C-AMP.
002957 03-04
EFFECTS OF ACUTE CENTRAL AND PERIPHERAL AaHl-24
ADMINISTRATION ON LORDOSIS BEHAVIOR.
002975 03-04
VASOTOCIN, PROSTAGLANDIN, AND FEMALE REPRODUaiVE BEHAVIOR
IN THE FROG, RANA-PIPIENS.
002978 03-04
S-46
VOLUME 19, SUBJECT INDEX
Subject Index
DRUG REGIMENS FACILITATING AGGRESSION; BEHAVIOR, AMINE, AND
RECEPTOR ALTERATIONS
002987 03-04
CONFLICT-SITUATION BASED ON INTRACRANIAL SELF-STIMULATION
BEHAVIOR AND THE EFFECT OF BENZODIAZEPINES.
003004 03-04
MULTIDIMENSIONAL ANALYSES OF BEHAVIOR IN MICE TREATED WITH
ALPHA ENDORPHIN.
003020 03-04
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY
REACTIONS IN DOGS.
003030 03-04
SUPPRESSION OF ACTIVE SLEEP BY CHRONIC-TREATMENT WITH
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT:
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT.
003056 03-04
CYCLIC-AMP-INDUCED CHANGES IN THE ELECTROENCEPHALOGRAM AND
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN
THE RAT.
003078 03-04
RESEARCH STRATEGIES FOR ASSESSING THE EFFECTS OF
METHYLMERCURY ON BEHAVIOR.
003128 03-05
THE INFLUENCE OF METHYLPHENIDATE ON SPONTANEOUS AUTONOMIC-
ACTIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE.
003363 03-11
SENSORY PROCESSING, CARDIOVASCULAR REACTIVITY, AND THE TYPE A
CORONARY-PRONE BEHAVIOR PAHERN.
003405 03-13
COMPARISON OF THE EFFECTS OF FOUR BENZODIAZEPINES ON FRAME OF
MIND AND BEHAVIOR IN HEALTHY SUBJECTS.
003441 03-14
EFFECTS OF NORCOCAINE AND SOME NORCOCAINE DERIVATIVES ON
SCHEDULE-CONTROLLED BEHAVIOR OF PIGEONS AND SQUIRREL-
MONKEYS.
004012 04-03
EFFECTS OF DOPAMINERGIC DRUGS ON PHENCYCLIDINE-INDUCED
BEHAVIOR IN THE RAT.
004083 04-04
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS; EFFECTS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
RESPONSE.
004119 04-04
INTERAaiONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
004127 04-04
EFFEaS OF NARCOTIC ABSTINENCE ON SCHEDULE-CONTROLLED
BEHAVIOR IN DEPENDENT RATS.
004230 04-04
STUDIES OF CARBACHOL-INDUCED WET-DOG-SHAKE BEHAVIOR IN RATS.
004241 04-04
LACK OF SPECIFICITY OF AN ANIMAL BEHAVIOR MODEL FOR
HALLUCINOGENIC DRUG AQION.
004250 04-04
BEHAVIOR OF RATS AND MICE ADMINISTERED ACTIVE METABOLITES OF
FLUPHENAZINE, 7 HYDROXYFLUPHENAZINE AND FLUPHENAZINE-
SULFOXIDE.
004256 04-04
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS.
004551 04-13
SEROTONERGIC APPROACHES TO THE MODIFICATION OF BEHAVIOR IN
THE LESCH-NYHANS-SYNDROME.
004576 04-14
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS.
004658 04-15
BEHAVIOR-CHANGE
PSYCHOACTIVE-ORUG-EFFECTS IN A HYPERACTIVE-CHILD: A CASE-STUDY
ANALYSIS OF BEHAVIOR-CHANGE AND TEACHER AHENTION.
002313 02-14
BEHAVIOR-DEPENDENT
BEHAVIOR-DEPENDENT EVOKED-POTENTIALS IN THE HIPPOCAMPAL-CAl
REGION OF THE RAT. II. EFFECTS Of ESERINE, ATROPINE, ETHER AND
PENTOBARBITAL.
000184 01-03
BEHAVIOR-DISORDERS
UNDERSTANDING AND USE OF CHEMOTHERAPY BY LEARNING-
DISABILITIES AND BEHAVIOR-DISORDERS TEACHERS.
000965 01-17
THE MANAGEMENT OF CHRONIC BEHAVIOR-DISORDERS IN MENTALLY-
RETARDED ADULTS WITH LITHIUM-CARBONATE.
003376 03-11
PREVALENCE OF DRUG-TREATMENT FOR HYPERACTIVITY AND OTHER
CHILDHOOD BEHAVIOR-DISORDERS.
004713 04-17
BEHAVIOR-MODIFICATION
A CONTROLLED-TRIAL Of BEHAVIOR-MODIFICATION AND
METHYLPHENIDATE IN HYPERACTIVE-CHILDREN.
000678 01-11
EVALUATION Of THE RELATIVE EfFECTIVENESS OF METHYLPHENIDATE
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF
KINDERGARTEN-AGED HYPERACTIVE-CHILDREN
003306 03-11
BEHAVIORAL
BEHAVIORAL CONFIRMATION Of DIffUSE NOXIOUS INHIBITORY
CONTROLS (DNIC) AND EVIDENCE fOR A ROLE OF ENDOGENOUS
OPIATES.
002791 03-03
THE EFFECTS OF INJECTIONS OF BOMBESIN INTO THE CEREBRAL
VENTRICLES ON BEHAVIORAL THERMOREGULATION.
002952 03-04
BRIEF COMMUNICATION: BEHAVIORAL RECOVERY AFTER TOLUENE
EXPOSURE IN RATS.
002969 03-04
CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL
ALERTING.
002997 03-04
BOMBESIN ALTERS BEHAVIORAL THERMOREGULATION IN FISH.
003026 03-04
BEHAVIORAL AND METABOLIC ALTERATIONS IN PROGENY Of
METHADONE-TREATED RATS. (PH.D. DISSERTATION).
003113 03-04
A RADIOIMMUNOASSAY fOR EPENDYMINS BETA AND GAMMA: TWO
GOLDFISH BRAIN PROTEINS INVOLVED IN BEHAVIORAL PLASTICITY.
003677 04-01
DOM AND RELATED 2,5 DIMETHOXY-4-ALKYLPHENYLISOPROPYLAMINES:
BEHAVIORAL AND SEROTONIN-RECEPTOR PROPERTIES.
003690 04-02
COMPARATIVE ANALGESIC, BEHAVIORAL. AND DEPENDENCE PROPERTIES
Of MORPHINE AND 0
METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME
HCL.
003707 04-02
BEHAVIORAL AND REGIONAL NEUROCHEMICAL SEQUELAE Of
HIPPOCAMPAL DESTRUCTION IN THE RAT.
003721 04-03
THE EffECT Of SMALL DOSES Of HALOPERIDOL AND CLOZAPINE ON
BEHAVIORAL SHIfTS IN CATS, ARISING AfTER CESSATION Of
ELECTRICAL-STIMULATION Of THE CAUDATE-NUCLEUS.
004067 04-04
BEHAVIORAL AND BIOCHEMICAL- STUDIES Of THE SCOPOLAMINE-INDUCED
REVERSAL Of NEUROLEPTIC ACTIVITY.
004195 04-04
PHYSIOLOGICAL AND BEHAVIORAL APPROACHES TO THE STUDY Of THE
QUASI-MORPHINE WITHDRAWAL- SYNDROME.
004242 04-04
A MICROCOMPUTER SYSTEM fOR THE CONTROL Of BEHAVIORAL
EXPERIMENTS.
004287 04-06
BEHAVIORAL-ACTIVITY
NALOXONE REVERSIBLE EffECTS Of D ALA2-MET5-ENKEPHAL1NAMIDE-
INDUCED BEHAVIORAL-ACTIVITY IN RATS.
000402 01-04
COMPARISON Of BIOLOGICAL-ACTIVITY AND BEHAVIORAL-ACTIVITY Of
ALPHA AND GAMMA MELANOCYTE-STIMUIATING-HORMONES.
(UNPUBLISHED PAPER).
001398 02-03
THE EffECT Of NEUROPEPTIDE fRAGMENTS Of ADRENOCORTICOTROPIN
AND VASOPRESSIN ON BEHAVIORAL-ACTIVITY IN RATS.
001812 02-04
BEHAVIORAL-ANALYSIS
MORPHINE VERSUS HALOPERIDOL CATALEPSY IN THE RAT: A
BEHAVIORAL-ANALYSIS Of POSTURAL SUPPORT MECHANISMS.
000376 01-04
BEHAVIORAL-ANALYSIS Of AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EffECTS Of CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
BEHAVIORAL-ASPECT
MECHANISM-OF-ACTION OF THE BENZODIAZEPINES: BEHAVIORAL-
ASPECT.
000468 01-04
BEHAVIORAL-ASPECTS
THE ROLE OF NICOTINE IN THE BEHAVIORAL-ASPECTS Of CIGAREHE
SMOKING.
004575 04-14
BEHAVIORAL-CHANGES
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AfTER
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY
PRETREATMENT WITH THYROID-HORMONES.
002259 02-13
IT
fe
S-47
Subject Index
Psychopharmacology Abstracts
BEHAVIORAL-CHANGES AND BIOCHEMICAL-CHANGES AFTER
HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION).
003069 03-04
BEHAVrORAL-CONSEQUENCES
LARGE-DOSES OF VITAMINS AND BEHAVIORAL-CONSEQUENCES. (PH.D.
DISSERTATION).
001633 02-04
BEHAVIORAL-CONSEQUENCES OF LONG-TERM-TREATMENT WITH
NEUROLEPTIC-DRUGS.
001661 02-04
BEHAVIORAL-CONSIDERATIONS
RAPID TREATMENT OF ACUTE PSYCHOTIC-SYMPTOMS WITH HIGH-DOSE
AND LOW-DOSE HALOPERIDOL: BEHAVIORAL-CONSIDERATIONS.
003346 03-1 1
BEHAVIORAL-CORRELATES
BEHAVIORAL-CORRELATES AND BIOCHEMICAL-CORRELATES AFTER
HALOPERIDOL AND CLOZAPINE LONG-TERM-TREATMENT.
001422 02-03
BEHAVIORAL-DEFICIENCIES
PHARMACOTHERAPY FOR AGE-RELATED BEHAVIORAL-DEFICIENCIES.
003391 03-11
BEHAVIORAL-DEFICIT
PHENYLACETATE AND THE ENDURING BEHAVIORAL-DEFICIT IN
EXPERIMENTAL PHENYLKETONURIA.
000388 01-04
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL-
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF
ANTIBODIES TO GANGLIOSIDE.
003025 03-04
BEHAVIORAL-DEPRESSION
BEHAVIORAL-DEPRESSION AND ITS NEUROCHEMICAL-CORRELATES AT
HIGH-DOSES OF D-AMPHETAMINE IN RATS
001601 02-04
BEHAVIORAL-DESENSITIZATION
BEHAVIORAL-DESENSITIZATION OF PHOBIC-ANXIETY USING THIOPENTAL-
SODIUM.
002352 02-14
BEHAVIORAL-DISORDERS
PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH
BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS.
000717 01-11
INVESTIGATION INTO THE EFFECT OF FLUPHENAZINE-HCL (LYORODIN) IN
CHILDREN WITH BEHAVIORAL-DISORDERS BY MEANS OF
PSYCHOPHYSIOLOGICAL PARAMETERS
003344 03-11
POLYPHARMACY REGIMEN AS AN EXACERBATING RISK IN THERAPY-
RESISTANT EPILEPTIC-SEIZURES AND BEHAVIORAL-DISORDERS.
004720 04-17
BEHAVIORAL-DISTURBANCES
BEHAVIORAL-DISTURBANCES IN PSYCHIATRY: A THERAPEUTIC
APPROACH.
002321 02-14
BEHAVIORAL-EFFECTS
INHIBITION OF BEHAVIORAL-EFFEQS OF COCAINE BY AQINOMYCIN-D IN
RATS.
000346 01-04
ENHANCEMENT OF THE BEHAVIORAL-EFFEQS OF 2,5 DIMETHOXY-4-
METHYLAMPHETAMINE (DOM) BY PRETREATMENT WITH P
CHLOROPHENYLALANINE.
000364 01-04
THE INFLUENCE OF 5 HT-RECEPTOR BLOCKING-AGENTS ON THE
BEHAVIORAL-EFFECTS OF ANALGESICS IN RATS.
000429 01-04
BEHAVIORAL-EFFEaS AND ELECTROCORTICAL-EFFECTS AFTER
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS
ENHANCING GABAERGIC TRANSMISSION.
000443 01-04
NALOXONE OVERCOMES THE DOPAMINERGIC, EEG, AND BEHAVIORAL-
EFFECTS OF GAMMA HYDROXYBUTYRATE.
000478 01-04
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT:
BEHAVIORAL-EFFECTS AND PSYCHOPHARMACOLOGICAL-EFFECTS.
000481 01-04
BEHAVIORAL-EFFECTS OF ETHYNYL ESTROGENS IN THE FEMALE RAT.
000483 01-04
DEXTROAMPHETAMINE: COGNITIVE AND BEHAVIORAL-EFFEaS IN
NORMAL AND HYPERACTIVE-BOYS AND NORMAL ADULT MALES.
00071601-11
BEHAVIORAL-EFFEQS OF DRUGS: THE ROLE OF THE STIMULUS
REINFORCER CONTINGENCY. (PH.D. DISSERTATION).
001537 02-03
BEHAVIORAL-EFFECTS, ANTIDOPAMINERGIC-EFFECTS, AND PROHYPNOTIC-
EFFECTS OF NEUROLEPTICS DURING AND AFTER PROLONGED
TREATMENT.
001577 02-04
BEHAVrORAL-EFFECTS AND ELEQROPHYSIOLOGICAL-EFFEQS OF OPIOID-
PEPTIDES IN CATS.
001612 02-04
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: II. NURSING-BEHAVIOR AND
DEVELOPMENT OF THE SUCKLINGS.
001626 02-04
BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFECTS OF CHRONIC
AMPHETAMINE INTOXICATION.
001653 02-04
DIFFERENT BEHAVIORAL-EFFECTS FOLLOWING INTRACEREBRAL,
INTRACEREBROVENTRICULAR OR INTRAPERITONEAL INJEQION OF
NALOXONE IN THE RAT.
001665 02-04
ENHANCEMENT OF 5 HYDROXYTRYPTAMINE-INDUCED BEHAVIORAL-
EFFECTS FOLLOWING CHRONIC ADMINISTRATION OF ANTIDEPRESSANT-
DRUGS.
001667 02-04
NEUROCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF CHRONIC D-
AMPHETAMINE TREATMENT IN GENETICALLY OBESE (OBOB) MICE
(PH.D. DISSERTATION).
001739 02-04
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: III. SOCIAL-INTERAQIONS
BETWEEN TWO RESIDENTS AND AN INTRUDER MALE.
001776 02-04
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: I. SOCIAL-INTERAQIONS
AND NEST-BUILDING-BEHAVIOR OF MALES.
001777 02-04
BEHAVIORAL-EFFECTS OF DOPAMINE AGONISTS ACROSS THE ESTROUS-
CYCLE IN RATS
001792 02-04
BEHAVIORAL-EFFECTS AND SUBJEQIVE-EFFEQS OF BETA-ADRENERGIC
BLOCKADE IN PHOBIC-SUBJEQS.
002060 02-10
MOOD AND BEHAVIORAL-EFFEQS OF PHYSOSTIGMINE ON HUMANS ARE
ACCOMPANIED BY ELEVATIONS IN PLASMA BETA ENDORPHIN AND
CORTISOL
002280 02-13
BIOCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF ACUTE ETHANOL IN
RATS AT DIFFERENT ENVIRONMENTAL TEMPERATURES.
002864 03-03
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN
MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF
AMPHETAMINE. (PH.D. DISSERTATION).
002996 03-04
A CHARACTERIZATION OF THE BEHAVIORAL-EFFEQS OF LEVO ALPHA
ACETYLMETHADOL IN THE RAT AND IN THE PIGEON. (PH.D.
DISSERTATION) i
003047 03-04
2,4,5 TRICHLOROPHENOXYACETIC-ACID CAUSES BEHAVIORAL-EFFEQS IN
CHICKENS AT ENVIRONMENTALLY RELEVANT DOSES. I
003079 03-04 I
SUPERSENSITIVITY TO THE BEHAVIORAL-EFFEQS OF OPIATE
ANTAGONISTS
003096 03-04 '\
THE RELATIONSHIP BETWEEN THE ACUTE BEHAVIORAL-EFFEQS OF
NARCOTIC ANTAGONISTS AND THE NARCOTIC DEPENDENT STATE.
003106 03-04 ,
BEHAVIORAL-EFFECTS OF METHADONE IN SCHIZOPHRENIC-PATIENTS. '
(X)3178 03-08
BEHAVIORAL-EFFEQS AND BIOLOGICAL-EFFEQS OF ACUTE BETA
ENDORPHIN INJEQION IN SCHIZOPHRENIC-PATIENTS AND DEPRESSED-
PATIENTS
003357 03-11
THE BEHAVIORAL-EFFECTS OF D-AMPHETAMINE ALONE AND IN
COMBINATION WITH ACUTE AND CHRONIC MORPHINE TREATMENTS IN |
RATS.
003915 04-03
A COMMON MECHANISM FOR LYSERGIC-ACID, INDOLEALKYLAMINE AND
PHENETHYLAMINE HALLUCINOGENS: SEROTONERGIC MEDIATION OF
BEHAVIORAL-EFFECTS IN RATS.
004007 04-03
REDUQION IN OPIATE AQIVATION AFTER CHRONIC
ELEQROCONVULSIVE-SHOCK - POSSIBLE ROLE FOR ENDORPHINS IN
THE BEHAVIORAL-EFFEQS OF CONVULSIVE-SHOCK-TREATMENT.
(UNPUBLISHED PAPER).
004154 04-04
SAME OR DIFFERENT? AN EXPLORATION OF THE BEHAVIORAL-EFFEQS OF
BENZAMIDES.
004207 04-04
INTRACEREBRAL SUBSTANCE-P IN MICE; BEHAVIORAL-EFFEQS AND
NARCOTIC-AGENTS.
004218 04-04
BEHAVIORAL-EFFEQS OF SELF-ADMINISTERED COCAINE: RESPONDING
MAINTAINED ALTERNATELY BY COCAINE AND ELECTRIC-SHOCK IN
SQUIRREL-MONKEYS.
004225 04-04
CANNABINOIDS. I. BEHAVIORAL-EFFEQS.
004228 04-04
BEHAVIORAL-EVENTS
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELTVTIOn OF IN VIVO UPTAKE
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS,
AND NEUROPHARMACOLOGICAL EVENTS.
002515 02-17
S-48
VOLUME 19, SUBJECT INDEX
Subject Index
BEHAVIORAL-EVIDENCE
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL-
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL
SEROTONERGIC FUNCTION.
00049) 01-04
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A
SELECTIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST,
002236 02-) 3
BEHAVIORAL-EVIDENCE THAT SUBSTANCE-P MAY BE A SPINAL-CORD
SENSORY NEUROTRANSMITTER.
004200 04-04
BEHAVIORAL-FACILITATION
BEHAVIORAL-FACILITATION FOLLOWING CHRONIC ADMINISTRATION OF N
N PROPYLNORAPOMORPHINE.
001822 02-04
BEHAVIORAL-INTERACTIONS
BEHAVIORAL-INTERACTIONS BETV\/EEN OPIATE AND ANTIEPILEPTIC-DRUGS
IN THE MOUSE.
004155 04-04
BEHAVIORAL-INTERVENTION
BEHAVIORAL-INTERVENTION FOR SELF-STIMULATORY, AHENDING AND
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILD.
002104 02-11
BEHAVIORAL-NEUROCHEMISTRY
BEHAVIORAL-NEUROCHEMISTRY OF BENZODIAZEPINES.
000991 01-17
BEHAVIORAL-PHARMACOLOGY
BEHAVIORAL-PHARMACOLOGY AND THE STIMULUS CONTROL OF
BEHAVIOR.
00038) 0)-04
CUMULATIVE DOSE RESPONSE-CURVES IN BEHAVIORAL-
PHARMACOLOGY.
001883 02-06
ADVANCES IN BEHAVIORAL-PHARMACOLOGY. VOL. 2.
002364 02-14
BEHAVIORAL-PHARMACOLOGY OF TETRAHYDROCANNABINOL
CONVULSIONS IN RABBITS.
004288 04-06
BEHAVIORAL-PHARMACOTHERAPY
A COMBINED BEHAVIORAL-PHARMACOTHERAPY APPROACH TO
OBSESSIVE-COMPULSIVE-DISORDERS.
002082 02-10
BEHAVIORAL-PREDICTORS
BEHAVIORAL-PREDICTORS OF AMITRIPTYLINE RESPONSE IN DEPRESSION.
003253 03-09
BEHAVIORAL-PROFILE
EEG AND BEHAVIORAL-PROFILE OF FLUTROLINE (CP-36-584), A NOVEL
ANTIPSYCHOTIC-DRUG.
001071 02-02
BEHAVIORAL-RATING-SCALES
DESIGN ASPECTS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS: A
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING-SCALES.
002512 02-16
BEHAVIORAL-REACTIONS
ON CORRELATION OF BEHAVIORAL-REACTIONS AND NEURONAL ACTIVITY
IN THE HYPOTHALAMUS UNDER SUBCUTANEOUS GASTRIN INJECTION.
002892 03-03
THE EFFECT OF PROPYLNORANTIFEIN ON BEHAVIORAL-REACTIONS,
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE
ANIMAL BRAIN.
004075 04-04
BEHAVIORAL-RESPONSES
RELATIONSHIPS BETWEEN SELECTIVE DENERVATION OF DOPAMINE
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL-
RESPONSES TO AMPHETAMINE AND APOMORPHINE.
000384 01-04
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9
TETRAHYDROCANNABINOL ON THE CARDIOVASCULAR SYSTEM, AND
PRESSOR AND BEHAVIORAL-RESPONSES TO BRAIN-STIMULATION IN
FREELY-MOVING-RATS.
000417 01-04
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON THE
CARDIOVASCULAR-SYSTEM, AND PRESSOR AND BEHAVIORAL-
RESPONSES TO BRAIN-STIMULATION IN RATS.
001681 02-04
GONADECTOMY AND SEX-DIFFERENCES IN THE BEHAVIORAL-RESPONSES
TO AMPHETAMINE AND APOMORPHINE OF RATS.
003084 03-04
BEHAVIORAL-REVERSAL
5,7 DIHYDROXYTRYPTAMINE-INDUCED MOUSE-KILLING AND
BEHAVIORAL-REVERSAL WITH VENTRICULAR ADMINISTRATION OF
SEROTONIN IN RATS.
001562 02-04
BEHAVIORAL-SENSITIVITY
THE INFLUENCE OF GENOTYPE AND SEX ON BEHAVIORAL-SENSITIVITY TO
NICOTINE IN MICE
001648 02-04
BEHAVIORAL-SENSITIZATION
DRUG ENVIRONMENT INTERACTION: CONTEXT DEPENDENCY OF COCAINE-
INDUCED BEHAVIORAL-SENSITIZATION.
002866 03-03
BEHAVIORAL-STIMULATION
NEUROPHARMACOLOGICAL-STUDIES OF PHENCYCLIDINE-INDUCED
BEHAVIORAL STIMULATION IN MICE.
001622 02-04
BEHAVIORAL-STUDIES
BEHAVIORAL-STUDIES AND NEUROCHEMICAL-STUDIES OF LESCH-NYHANS-
SYNDROME,
001743 02-04
PHYSIOLOGICAL- STUDIES AND BEHAVIORAL-STUDIES WITH MUSCIMOL.
002538 02-17
BEHAVIORAL-SUPERSENSITIVITY
SELECTIVE INHIBITION OF MESOLIMBIC BEHAVIORAL-SUPERSENSITIVITY
BY NALOXONE.
000467 01-04
INDUCTION OF BEHAVIORAL-SUPERSENSITIVITY TO APOMORPHINE BY
DFP TREATMENT.
004099 04-04
THE EFFECT OF CHRONIC LEVODOPA ON HALOPERIDOL-INDUCED
BEHAVIORAL-SUPERSENSITIVITY IN THE GUINEA-PIG.
004249 04-04
BEHAVIORAL-SUPPRESSION
DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT-
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL-
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS.
001726 02-04
BEHAVIORAL-SYNDROME
RELATIVE POTENCY OF AMPHETAMINE ISOMERS IN CAUSING THE
SEROTONIN BEHAVIORAL-SYNDROME IN RATS.
003094 03-04
BEHAVIORAL-TEST
BEHAVIORAL-TEST FOR DETECTION OF SUBCLINICAL BRAIN-DAMAGE: AN
EXPERIMENTAL MODEL.
003120 03-04
BEHAVIORAL-TESTING
CYCLOPHOSPHAMIDE-INDUCED SPERMATOGENIC EFFECTS DETEQED IN
THE Fl -GENERATION BY BEHAVIORAL-TESTING.
003121 03-05
BEHAVIORAL-TESTS
EFFECT OF DRUGS ON LEARNING AND MEMORY PROCESSES IN SIMPLE
BEHAVIORAL-TESTS.
000809 01-14
BEHAVIORAL-THERAPY
PSYCHOPHARMACOLOGY AND BEHAVIORAL-THERAPY.
003584 03-17
BEHAVIORAL-TOLERANCE
FIRST DOSE BEHAVIORAL-TOLERANCE TO PHENCYCLIDINE ON FOOD
REWARDED BAR-PRESSING-BEHAVIOR IN THE RAT.
000462 01-04
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL-TOLERANCE TO AND
CROSS-TOLERANCE BETWEEN D ALA2-METHI0NINE-ENKEPHALINAMIDE
AND MORPHINE IN THE RAT.
004038 04-03
BEHAVIORAL-TREATMENT
BEHAVIORAL-TREATMENT AND PHARMACOLOGICAL-TREATMENT OF
OBSESSIVE-COMPULSIVE-DISORDERS.
000657 01-10
BEHAVIORAL-TREATMENTS
DOUBLE-BLIND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS.
002314 02-14
BEHAVIORALLY-SELECTIVE
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELECTIVE
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR-
STIMULATION INDUCED BY INDIRECTLY ACTING SYMPATHOMIMETIC-
AMINES IN MICE.
000492 01-04
BEHAVIORS
EFFECTS OF PHENCYCLIDINE AND METHYLPHENIDATE ON D-
AMPHETAMINE-INDUCED BEHAVIORS IN RESERPINE PRETREATED RATS.
001616 02-04
DIFFERENTIAL DOPAMINERGIC FUNCTION IN YOUNG AND OLD FEMALE
RATS AS MEASURED BY THREE BEHAVIORS.
001683 02-04
DRUG-EFFECTS ON SCHEDULE-INDUCED BEHAVIORS. (PH.D.
DISSERTATION).
001786 02-04
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE
INTOXICATION.
002988 03-04
A PRIMATE ANALOGL" OF AMPHETAMINE-INDUCED BEHAVIORS IN
HUMANS.
003006 03-04
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
004112 04-04
i'5
I
I
S-49
Subject Index
Ptychopharmocology Abttractt
HIPPOCAMPAL INVOLVEMENT IN THE PHARMACOLOGIC INDUQION OF
WITHDRAWAL-LIKE BEHAVIORS.
004140 04-04
PERIPHERAL-CORRELATES OF SEROTONERGICALLY-INFLUENCED
BEHAVIORS IN VERVET-MONKEYS (CERCOPITHECUS-AETHIOPS-
SABAEUS).
004204 04-04
BEHAVIOUR
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED
DIFFERENTIATION) IN THE MONKEY (MACACA-MULAHA).
000440 01-04
EPILEPSY: NEUROTRANSMIHER, BEHAVIOUR AND PREGNANCY.
002466 02-15
EFFECTS OF NEONATAL TESTOSTERONE AND ESTROGEN ON OPEN-FIELD
BEHAVIOUR IN RATS.
003098 03-04
EFFECTS OF LITHIUM ON BEHAVIOUR AND CENTRAL MONOAMINES.
004110 04-04
ATTENUATION OF DELTA9 TETRAHYDROCANNABINOL-INDUCED
WITHDRAWAL-LIKE BEHAVIOUR BY DELTA9
TETRAHYDROCANNABINOL.
004243 04-04
ON MONOAMINERGIC-INTERACTION WITH BEHAVIOUR MODIFYING
PEPTIDE-HORMONES.
004700 04-17
BEHAVIOUR-THERAPY
CONTROLLED-TRIAL OF BEHAVIOUR-THERAPY, PHARMACOTHERAPY. AND
THEIR COMBINATION IN THE TREATMENT OF OBESITY.
000725 01-11
OBSESSIVE-SYMPTOM RESPONSE TO BEHAVIOUR-THERAPY AND TO
ANTIDEPRESSANT-DRUGS.
002084 02-10
BEHAVIOURAL
BEHAVIOURAL AND NEUROCHEMICAL PROPERTIES OF 1 1 INDOL-3-
YLMETHYLPIPERID-4-YL-3-BENZ0YLUREA (WY-25093) IN RODENTS.
003686 04-02
BEHAVIOURAL-ACTIONS
SYNAPTIC AND BEHAVIOURAL-ACTIONS OF ANTIDEPRESSANT-DRUGS:
FURTHER THOUGHTS ON THE IMPLICATIONS FOR THEORIES OF
DEPRESSION.
003229 03-09
BEHAVIOURAL-ANALYSIS
BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS
AND MAN.
002527 02-17
BEHAVIOURAL-CHANGES
GABA DEPLETION AND BEHAVIOURAL-CHANGES PRODUCED BY
INTRAVENTRICULAR PUTRESCINE IN CHICKS.
000218 01-03
BEHAVIOURAL-CHANGES INDUCED BY N,N DIMETHYLTRYPTAMINE IN
RODENTS.
000413 01-04
BEHAVIOURAL-CHANGES IN ADULT RATS FOLLOWING ADMINISTRATION
OF ANTIBODIES AGAINST BRAIN GANGLIOSIDES.
003071 03-04
BEHAVIOURAL-DESPAIR
PRESYNAPTIC ALPHA-ADRENOCEPTORS AND THE AQION OF TRICYCLIC-
ANTIDEPRESSANT DRUGS IN BEHAVIOURAL-DESPAIR IN RATS.
001829 02-04
BEHAVIOURAL-EFFECTS
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES
BEHAVIOURAL-EFFECTS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN
RATS.
000420 01-04
OXOTREMORINE BEHAVIOURAL-EFFEaS AS A SCREENING-TEST IN MICE.
001072 02-02
STUDIES ON THE BIOCHEMICAL-EFFECTS AND BEHAVIOURAL-EFFEQS OF
ORAL NICOTINE.
001115 02-03
THE INFLUENCE OF ANTERIOR NEOSTRIATAL LESIONS ON THE
BEHAVIOURAL-EFFECTS OF SPIROPERIDOL IN RATS.
001702 02-04
BEHAVIOURAL-EFFECTS AND ENDOCRINE-EFFEaS OF NALTREXONE IN
MALE TALAPOIN-MONKEYS.
001718 02-04
ENHANCED BEHAVIOURAL-EFFECTS, ELECTROCORTICAL-EFFEaS AND
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN.
001733 02-04
BEHAVIOURAL-EFFECTS OF ACETYLSALICYLIC-ACID, PARACETAMOL,
CAFFEINE, GUAIPHENESIN AND THEIR COMBINATIONS.
001805 02-04
ELECTROENCEPHALOGRAPHIC-EFFECTS AND BEHAVIOURAL-EFFEQS OF
SODIUM-VALPROATE IN PATIENTS WITH PHOTOSENSITIVE EPILEPSY. A
SINGLE-DOSE TRIAL.
002154 02-11
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL-
EFFEaS OF DOPAMINE AGONISTS: CONTRASTING-EFFEQS OF D-
AMPHETAMINE AND APOMORPHINE.
002484 02-16
A COMPARISON BETWEEN SOME BIOCHEMICAL-EFFEaS AND
BEHAVIOURAL-EFFECTS PRODUCED BY NEUROLEPTICS.
004116 04-04
BEHAVIOURAL-MANIPULATION
FOOTSHOCK ANALGESIA: PREVENTION BY BEHAVIOURAL-MANIPULATION
BUT NOT BY NALOXONE.
003073 03-04
BEHAVIOURAL-RESPONSES
BEHAVIOURAL-RESPONSES TO STEREOTACTICALLY CONTROLLED
INJECTIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI.
001708 02-04
EFFECT OF ACUTE AND CHRONIC TRIIODOTHYRONINE (T3)
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE-
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN-
BIOCHEMISTRY.
002951 03-04
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFECTS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN.
002990 03-04
BEHAVIOURAL-SEQUELAE
NEUROLEPTIC TREATMENT FOR A SUBSTANTIAL PROPORTION OF ADULT
LIFE: BEHAVIOURAL-SEQUELAE OF 9 MONTHS HALOPERIDOL
ADMINISTRATION.
001858 02-05
BEHAVIOURAL-STATE
THE BEHAVIOURAL-STATE DURING CLIMAX (HATCHING) IN THE
DOMESTIC-FOWL (GALLUS-DOMESTICUS) .
001564 02-04
BEHAVIOURAL-STRATEGIES
ROLE OF THE NEOSTRIATAL DOPAMINERGIC-AQIVITY IN SEQUENCING
AND SELECTING BEHAVIOURAL- STRATEGIES: FACILITATION OF
PROCESSES INVOLVED IN SELECTING THE BEST STRATEGY IN A
STRESSFUL-SITUATION.
000366 01-04
BEHAVIOURAL-STUDIES
EVIDENCE FOR A GABAERGIC NIGROTHALAMIC PATHWAY IN THE RAT: I
BEHAVIOURAL-STUDIES AND BIOCHEMICAL-STUDIES.
000158 01-03
EFFECT OF SINGLE AND REPEATED ELECTROCONVULSIVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN - II. BEHAVIOURAL-STUDIES.
001697 02-04
BEHAVIOURAL-SYNDROMES
EFFECTS OF THE POTENTIAL NEUROLEPTIC-PEPTIDE DES-TYRl-GAMMA-
ENDORPHIN AND HALOPERIDOL ON APOMORPHINE-INDUCED
BEHAVIOURAL-SYNDROMES IN RATS AND MICE.
000441 01-04
BEHAVIOURAL-TECHNIQUES
EFFEaS OF ANXIETY REDUCTION BY BEHAVIOURAL-TECHNIQUES AND
MEPROBAMATE ON CERTAIN PARAMETERS OF INFORMATION THEORY.
003108 03-04
BEHAVIOURS
THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA.
002976 03-04
NEUROTENSIN BLOCKS CERTAIN AMPHETAMINE-INDUCED BEHAVIOURS.
004111 04-04
BELGIUM
ABSTRACTS OF THE ANNUAL GENERAL CONFERENCE OF THE EUROPEAN-
BRAIN-AND-BEHAVIOUR-SOCIETY, HELD AT LOUVAIN-LA-NEUVE,
BELGIUM, ON NOVEMBER 13-15TH, 1980.
003617 03-17
BELIEFS
THE INFLUENCE OF PATIENT BELIEFS ON COMPLIANCE TO THERAPY FOR
DIABETES-MELLITUS. (PH.D. DISSERTATION)
003631 03-17
BENSERASIDE
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE).
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION.
000712 01-11
BENSERAZIDE
EFFEQS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L
TRYPTOPHAN BY ISOLATED RAT LIVER CELLS.
002899 03-03
BENSERAZIDE-HCL
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL, ON
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC-STUDY.
002309 02-13
BENZAMIDE
STEREOSELEaiVE AQIONS OF SUBSTITUTED BENZAMIDE DRUGS ON
CEREBRAL DOPAMINE MECHANISMS.
001301 02-03
NEUROPSYCHOPHARMACOLOGICAL-STUDIES ON SOME BENZAMIDE
DERIVATIVES.
002220 02-13
S-50
VOLUME 19, SUBJECT INDEX
Subject Index
COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRACT OF THE GUINEA-PIG AND RAT.
003928 04-03
BENZAMIDES
SODIUM-DEPENDENT INTERACTION OF BENZAMIDES WITH DOPAMINE-
RECEPTORS.
000285 01-03
THE EFFECTS OF SUBSTITUTED BENZAMIDES ON FROG RECTUS-
ABDOMINIS.
001228 02-03
CLINICAL-EXPERIENCE WITH SUBSTITUTED BENZAMIDES IN FRENCH-
SPEAKING COUNTRIES.
002036 02-09
SAME OR DIFFERENT? AN EXPLORATION OF THE BEHAVIORAL-EFFECTS OF
BENZAMIDES.
004207 04-04
BENZAZOCINES
NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO
WITHDRAWAL INDUCING BENZAZOCINES. (PH.D. DISSERTATION).
001518 02-03
BENZHEXOL
A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED
PARKINSONISM.
002146 02-11
BENZILATE
QUINUCLIDINYL BENZILATE BINDING IN HOUSEFLY HEADS AND RAT-
BRAIN.
003868 04-03
BENZOCTAMINE
THE INFLUENCE OF BENZOCTAMINE ON DOPAMINE AND NOREPINEPHRINE
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH
REFLEX OF THE CAT.
000054 01-03
ACUTE EFFECT OF BENZOCTAMINE (10 MG). SODIUM-
HYDROXYBUTYRATE (2 G) AND FENCAMFAMINE (10 MG) ON VERBAL-
ASSOCIATIONS.
000806 01-14
BENZODIAZEPINE
REDUCTION OF GAMMA AMINOBUTYRIC-ACID-MEDIATED (GABA)
TRANSMISSION BY A CONVULSANT BENZODIAZEPINE.
000015 01-02
GABA BENZODIAZEPINE INTERACTIONS: PHYSIOLOGICAL,
PHARMACOLOGICAL AND DEVELOPMENTAL ASPECTS.
000103 01-03
ANIMAL-MODELS OF ANXIETY AND BENZODIAZEPINE ACTIONS.
000531 01-06
EFFECTS OF AGE AND OTHER DRUGS ON BENZODIAZEPINE KINETICS.
000681 01-11
DIFFERENTIAL-EFFECTS ON BENZODIAZEPINE DISPOSITION BY DISULFIRAM
AND ETHANOL.
000789 01-13
INTROVERSION AND SEVERITY OF THE BENZODIAZEPINE WITHDRAWAL.
000923 01-17
THE REGULATION OF GABA-RECEPTORS AS A POSSIBLE MECHANISM FOR
GABA 1,4 BENZODIAZEPINE INTERACTIONS. (UNPUBLISHED PAPER).
001012 02-01
ETHANOL ENHANCES (3H)DIAZEPAM BINDING AT THE BENZODIAZEPINE
GABA-RECEPTOR lONOPHORE COMPLEX.
001154 02-03
PHARMACOLOGICAL EVIDENCE AND BIOCHEMICAL-EVIDENCE FOR AN
INTERACTION BETWEEN THE BENZODIAZEPINE AND GABA-RECEPTORS.
001261 02-03
GABA-MODULIN REGULATES SOLUBILIZED BENZODIAZEPINE AND GABA
RECOGNITION SITES. (UNPUBLISHED PAPER).
001263 02-03
BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERACTION
WITH GAMMA AMINOBUTYRIC-ACID.
001287 02-03
RENAL BENZODIAZEPINE BINDING INCREASES DURING
DEOXYCORTICOSTERONE/SALT HYPERTENSION IN RATS.
001430 02-03
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME
BENZODIAZEPINE RECOGNITION SITES ARE COUPLED TO GABA-
RECEPTORS AND lONOPHORES.
001484 02-03
CHARACTERIZATION OF BENZODIAZEPINE BINDING-SITES. (UNPUBLISHED
PAPER).
001503 02-03
BENZODIAZEPINE BINDING-SITES: PROPERTIES AND MODULATION.
(UNPUBLISHED PAPER).
001504 02-03
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON AMPHETAMINE-
INDUCED LOCOMOTOR- STIMULATION IN MICE.
001767 02-04
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON SCOPOLAMINE-
INDUCED LOCOMOTOR-STIMULATION IN MICE.
001768 02-04
CLINICAL AQIVITY OF A NEW BENZODIAZEPINE: CLOXAZOLAM.
001904 02-07
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO
SEVERE ANXIETY.
002070 02-10
THE REGULATION OF BENZODIAZEPINE RECOGNITION SITES BY
ENDOGENOUS MODULATORS.
002642 03-01
RADIOHISTOCHEMICAL STUDIES OF BENZODIAZEPINE AND GABA-
RECEPTORS AND THEIR INTERACTIONS.
002644 03-01
BENZODIAZEPINE RECOGNITION SITES ON GABA-RECEPTORS.
002730 03-03
THE EFFECTS OF A BENZODIAZEPINE ON THE HYPERPOLARIZING AND THE
DEPOLARIZING RESPONSES OF HIPPOCAMPAL CELLS TO GABA
002763 03-03
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS
CULTURED FROM RAT-CEREBRAL-CORTEX.
002820 03-03
THE BENZODIAZEPINE GABA-CHLORIDE lONOPHORE-RECEPTOR COMPLEX:
COMMON SITE OF MINOR-TRANQUILIZER ACTION.
002857 03-03
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR
BRAIN SPECIFIC BENZODIAZEPINE BINDING.
002903 03-03
BENZODIAZEPINE BINDING-SITES: PROPERTIES AND MODULATION.
002912 03-03
INTERACTION BETWEEN PURINE AND BENZODIAZEPINE: INOSINE
REVERSES DIAZEPAM-INDUCED STIMULATION OF MOUSE
EXPLORATORY-BEHAVIOR.
002972 03-04
BENZODIAZEPINE TREATMENT OF SPECIFIC ANXIETY STATES.
003284 03-10
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF
BENZODIAZEPINE TREATMENT: SIX CLINICAL CASES.
003505 03-15
BENZODIAZEPINE WITHDRAWAL SYMPTOMS AND PROPRANOLOL.
003543 03-15
POSITRON-TOMOGRAPHY. A NEW METHOD FOR IN VIVO BRAIN STUDIES
OF BENZODIAZEPINE, IN ANIMAL AND IN MAN.
003564 03-16
BENZODIAZEPINE ANTAGONISM BY HARMANE AND OTHER BETA
CARBOLINES IN VITRO AND IN VIVO.
004211 04-04
IN VIVO EFFECTS OF TWO NOVEL ALKYLATING BENZODIAZEPINE,
IRAZEPINE AND KENAZEPINE,
004251 04-04
ANXIOUS-DEPRESSIVE-SYNDROME. CLINICAL-STUDY OF A NEW
BENZODIAZEPINE, PRAZEPAM.
004354 04-09
PRAZEPAM: A NEW BENZODIAZEPINE FOR THE TREATMENT OF ANXIOUS-
DEPRESSIVE STATES.
004419 04-10
CLINICAL USE OF A NEW BENZODIAZEPINE, PRAZEPAM.
004421 04-10
PHARMACOLOGICAL PECULIARITIES OF A BENZODIAZEPINE/ATARACTIC-
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF
CLORAZEPATE-DIPOTASSIUM (TRANXILIUM) .
004527 04-13
EFFECTS OF A SHORT-ACTING BENZODIAZEPINE ON BRAIN ELECTRICAL-
ACTIVITY DURING SLEEP.
004568 04-14
PROLONGED BENZODIAZEPINE COMA.
004653 04-15
SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN
DETOXIFYING ALCOHOLIC-PATIENTS.
004671 04-16
A SENSITIVE BENZODIAZEPINE RADIOIMMUNOASSAY OF BROAD
SPECIFICITY.
004693 04-16
BENZODIAZEPINE-LIKE
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS AND PUTATIVE
ENDOGENOUS BENZODIAZEPINE-LIKE COMPOUNDS.
000225 01-03
PHARMACOLOGY OF 2 0 CHLOROBENZOYL-CHLORO-METHYL-NA-
GLYCYLGLYCINANILIDE HYDRATE (45-0088-S), A COMPOUND WITH
BENZODIAZEPINE-LIKE PROPERTIES.
003692 04-02
BENZODIAZEPINE-RECEPTOR
AUDIOGENIC-SEIZURES: INCREASED BENZODIAZEPINE-RECEPTOR BINDING
IN A SUSCEPTIBLE STRAIN OF MICE.
000252 01-03
PURINES AS ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTOR.
000276 01-03
CORRELATION BETWEEN BENZODIAZEPINE-RECEPTOR OCCUPATION AND
ANTICONVULSANT EFFECTS OF DIAZEPAM.
000450 01-04
CHARACTERIZATION OF GABA-STIMULATED BENZODIAZEPINE-RECEPTOR
BINDING.
001309 02-03
S-51
Subject Index
Psychopharmacology Abstracts
DECREASED BENZODIAZEPINE-RECEPTOR DENSITY IN RAT-CEREBELLUM
FOLLOWING NEUROTOXIC DOSES OF PHENYTOIN.
001373 02-03
BENZODIAZEPINE-RECEPTOR: LOCALIZATION BY PHOTOAFFINITY
LABELING AND ISOLATION OF A POSSIBLE ENDOGENOUS LIGAND.
001381 02-03
HARMALINE-INDUCED TREMOR: THE BENZODIAZEPINE-RECEPTOR AS A
SITE-OF-ACTION.
001436 02-03
1 METHYL-BETA-CARBOLINE (HARMANE), A POTENT ENDOGENOUS
INHIBITOR OF BENZODIAZEPINE-RECEPTOR BINDING.
001440 02-03
INCREASED BENZODIAZEPINE-RECEPTOR NUMBER ELICITED IN VITRO BY A
NOVEL PURINE, EMD-28422.
001475 02-03
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME
BENZODIAZEPINE RECOGNITION SITES ARE COUPLED TO GABA-
RECEPTORS AND lONOPHORES.
001484 02-03
MODULATION BY PICROTOXIN AND IPTBO OF 3H FLUNITRAZEPAM
BINDING TO THE GABA/ BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-
CEREBELLUM.
002775 03-03
THE BENZODIAZEPINE-RECEPTOR: AN UPDATE.
002833 03-03
PENTOBARBITAL: DUAL-ACTIONS TO INCREASE BRAIN BENZODIAZEPINE-
RECEPTOR AFFINITY.
002896 03-03
ACTION OF PYRAZOLOPYRIDINES AS MODULATORS OF
(3H)FLUNITRAZEPAM BINDING TO THE GABA/BENZODIAZEPINE-
RECEPTOR COMPLEX OF THE CEREBELLUM.
002909 03-03
A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/
BENZODIAZEPINE-RECEPTOR INTERACTION .
003851 04-03
IN VITRO MODULATION BY AVERMECTIN-BIA OF THE GABA/
BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-CEREBELLUM.
004023 04-03
BENZODIAZEPINE-RECEPTOR: HETEROGENEITY IN RABBIT BRAIN.
004060 04-03
BENZODIAZEPINE-RECEPTORS
DISSIMILAR EFFECTS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE
000173 01-03
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS AND PUTATIVE
ENDOGENOUS BENZODIAZEPINE-LIKE COMPOUNDS.
000225 01-03
PENTOBARBITAL POTENTIATES GABA-ENHANCED (3H) DIAZEPAM
BINDING TO BENZODIAZEPINE-RECEPTORS.
000275 01-03
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS ARE LOCALIZED IN THE
INNER PLEXIFORM LAYER OF RAT RETINA.
000277 01-03
BENZODIAZEPINE-RECEPTORS.
000918 01-17
TWO OR MORE CONFORMATIONS OF BENZODIAZEPINE-RECEPTORS
DEPENDING ON GABA-RECEPTORS AND OTHER VARIABLES.
001139 02-03
STUDIES ON BENZODIAZEPINE-RECEPTORS.
001502 02-03
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS IN THE OFFSPRING
OF DAMS RECEIVING DIAZEPAM: ONTOGENETIC-STUDIES.
001849 02-05
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN
HUNTINGTONS-DISEASE.
002163 02-11
DIFFERENTIAL-EFFECTS OF KAINIC-ACID ON BENZODIAZEPINE-RECEPTORS,
GABA-RECEPTORS, AND GABA-MODULIN IN THE CEREBELLAR-CORTEX.
002477 02-16
BENZODIAZEPINE-RECEPTORS: AUTORADIOGRAPHICAL AND
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN
REGIONS OF GABAERGIC SYNAPTIC CONTACTS.
002643 03-01
BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND
CELLULAR LOCALIZATION.
002655 03-03
BETA CARBOLINE-3-CARBOXYLATES AND BENZODIAZEPINE-RECEPTORS.
002676 03-03
EFFEQ OF PICROTOXIN ON BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS WITH REFERENCE TO THE EFFECT OF CHLORIDE ION.
002725 03-03
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN.
002727 03-03
KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFECT ON
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS.
002743 03-03
NEURONAL LOCALIZATION OF BENZODIAZEPINE-RECEPTORS IN THE
MURINE CEREBELLUM.
002902 03-03
MULTIPLE BENZODIAZEPINE-RECEPTORS.
003579 03-17
ENDOGENOUS LIGANDS FOR BENZODIAZEPINE-RECEPTORS.
003615 03-17
BRAIN BENZODIAZEPINE-RECEPTORS AND THEIR RAPID CHANGES ARER
SEIZURES IN THE MONGOLIAN-GERBIL.
003717 04-03
NEURONAL LOCALISATION OF BENZODIAZEPINE-RECEPTORS IN
CEREBELLUM.
003739 04-03
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK-
8165 AND PK-9084 (TWO QUINOUNE DERIVATIVES).
003898 04-03
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN
BRAIN CELL-CULTURES.
004002 04-03
BENZODIAZEPINE-RECEPTORS: EFFECT OF TISSUE PREINCUBATION AT 37
DEGREES C.
004013 04-03
BENZODIAZEPINE-RECEPTORS ON PRIMARY CULTURES OF MOUSE
ASTROCYTES.
004029 04-03
BENZODIAZEPINES
RELATIONSHIP OF ANTICONFLIQ ACTIVITY OF BENZODIAZEPINES TO
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA
000057 01-03
ELEaROPHYSIOLOGICAL ACTIONS OF BENZODIAZEPINES.
000107 01-03
RELATIONSHIPS BETWEEN PLASMA CORTICOSTEROIDS AND
BENZODIAZEPINES IN STRESS
000176 01-03
CARDIOVASCULAR RESPONSE TO THE INTERAaiON OF ETHANOL AND
SOME BENZODIAZEPINES IN RATS.
000332 01-03
BENZODIAZEPINES: A TOOL TO EXPLORE THE BIOCHEMICAL-BASIS AND
NEUROPHYSIOLOGICAL-BASIS OF ANXIETY.
000397 01-04
MECHANISM-OF-AaiON OF THE BENZODIAZEPINES: BEHAVIORAL-
ASPECT
000468 01-04
FACTORS INFLUENCING SEIZURE DURATION AND NUMBER OF SEIZURES
APPLIED IN UNILATERAL ELECTROCONVULSIVE-THERAPY: ANESTHETICS
AND BENZODIAZEPINES.
000792 01-13
THE DIFFERENTIAL-EFFEQS OF SHORT-ACTING AND LONG-AQING
BENZODIAZEPINES UPON NOQURNAL SLEEP AND DAYTIME
PERFORMANCE.
000822 01-14
USE AND ABUSE OF BENZODIAZEPINES.
000877 01-15
USE OF BENZODIAZEPINES IN PSYCHIATRIC-INPATIENTS.
00091001-17
PHARMACOKINETICS OF BENZODIAZEPINES: SHORT-AQING VERSUS
LONG-AQING.
000920 01-17
BENZODIAZEPINES AND NEUROTRANSMIHERS.
000925 01-17
THE PRESENT STATUS OF BENZODIAZEPINES IN PSYCHOPHARMACOLOGY.
000948 01-17
THE PRESENT STATUS OF THE BENZODIAZEPINES IN PSYCHIATRY AND
MEDICINE.
000954 01-17
THE BENZODIAZEPINES - USE AND ABUSE.
000960 01-17
THE SHORT-TERM USE OF BENZODIAZEPINES.
000962 01-17
BEHAVIORAL-NEUROCHEMISTRY OF BENZODIAZEPINES.
000991 01-17
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN
IN VIVO: EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS,
AND BENZODIAZEPINES.
001303 02-03
BENZODIAZEPINES MODIFY THE AGONIST RESPONSES AT A PRESYNAPTIC
GABA-RECEPTOR
001377 02-03
COMPARATIVE ANXIOLYTIC AND HYPNOTIC-EFFEQS OF 3
BENZODIAZEPINES ON BABOONS.
001581 02-04
RATIONAL USE OF BENZODIAZEPINES FOR ANXIETY AND INSOMNIA.
002063 02-10
THE LONG-TERM TREATMENT WITH BENZODIAZEPINES: SUGGESTIONS
FOR FURTHER RESEARCH.
002085 02-10
S-52
VOLUME 19, SUBJECT INDEX
MECHANISM-OF-ACTION OF BENZODIAZEPINES,
002302 02-13
BENZODIAZEPINES CAUSE SMALL LOSS Of BODY-WEIGHT
002446 02-15
DEPENDENCE ON BENZODIAZEPINES.
002464 02-15
BENZODIAZEPINES: CLINICAL-PHARMACOLOGY AND THERAPEUTIC USE.
002521 02-17
SELECTIVE ANTAGONISTS OF BENZODIAZEPINES.
002646 03-02
THE ACTION OF BENZODIAZEPINES ON THE LIMBIC-SYSTEM COMPARED
TO OTHER TRANQUILIZERS
002731 03-03
DO BENZODIAZEPINES BIND AT ADENOSINE UPTAKE SITES IN CNS?
002933 03-03
CONFLICT-SITUATION BASED ON INTRACRANIAL SELF-STIMULATION
BEHAVIOR AND THE EFFECT OF BENZODIAZEPINES.
003004 03-04
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS.
003027 03-04
BENZODIAZEPINES, STRESS AND RAT PLASMA CORTICOSTEROIDS: THE
ROLE OF INDOLEAMINES.
003034 03-04
COMPARISON OF THE EFFECTS OF FOUR BENZODIAZEPINES ON FRAME OF
MIND AND BEHAVIOR IN HEALTHY SUBJECTS.
003441 03-14
THERAPEUTICS VI - ANXIOLYTICS (BENZODIAZEPINES).
003546 03-15
PATIENT CHARACTERISTICS AND CLINICIAN ATTITUDES INFLUENCING THE
PRESCRIBING OF BENZODIAZEPINES.
003598 03-17
NEW TRENDS CONCERNING THE BIOCHEMICAL-MECHANISM OF ACTION
OF BENZODIAZEPINES.
003642 03-17
THE BENZODIAZEPINES AND INOSINE ANTAGONIZE CAFFEINE-INDUCED
SEIZURES.
004172 04-04
CLINICAL PHARMACOKINETICS OF BENZODIAZEPINES.
004524 04-13
LONG-TERM USE AND ABUSE OF BENZODIAZEPINES.
004598 04-15
BENZODIAZEPINES IN SCHIZOPHRENIA: A NEED FOR REASSESSMENT.
004733 04-17
BENZTROPINE-MESYLATE
THE EFFECT OF BENZTROPINE-MESYLATE ON THE PROLACTIN RESPONSE
TO HALOPERIDOL.
002238 02-13
BENZYL
ON-COLUMN GAS-CHROMATOGRAPHIC- SYNTHESIS OF 1,3 DIALYKYL
(C=l-10), BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES.
003656 04-01
BENZYLTETRAHYDROPYRIMIDONES
1 SUBSTITUTED BENZYLTETRAHYDROPYRIMIDONES: A SERIES WITH
STIMULANT AND DEPRESSANT ACTIVITIES.
003687 04-02
BETA-ADRENERGIC
ISOLATION INCREASES THE RESPONSES TO BETA-ADRENERGIC
STIMULATION IN MICE.
001232 02-03
BEHAVIORAL-EFFECTS AND SUBJECTIVE-EFFECTS OF BETA-ADRENERGIC
BLOCKADE IN PHOBIC-SUBJECTS.
002060 02-10
SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKING-DRUGS: A
METHODOLOGICAL-PROBLEM .
002395 02-15
PROPRANOLOL (INDERAL) FOR TARDIVE-DYSKINESIA AND
EXTRAPYRAMIDAL SIDE-EFFECTS FROM NEUROLEPTICS: POSSIBLE
INVOLVEMENT OF BETA-ADRENERGIC MECHANISMS.
002470 02-15
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL
EVALUATION.
003685 04-02
BETA-ADRENERGIC INFLUENCE ON CARDIAC DYNAMICS DURING SHOCK-
AVOIDANCE IN DOGS.
003813 04-03
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON
CHLORPROMAZINE-INDUCED ELEVATION OF PLASMA GLUCOSE AND
CYCLIC-AMP IN FED MICE.
003946 04-03
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA-
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER).
003998 04-03
BETA-ADRENERGIC-RECEPTOR
AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT-
CEREBRAL-CORTEX.
000072 01-03
Subject Index
EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA-
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN
000135 01-03
COMPARISON OF BETA-ADRENERGIC-RECEPTOR SUBTYPES IN
MAMMALIAN TISSUES.
000207 01-03
DOPAMINE-BETA-HYDROXYLASE: A MODULATOR OF BETA-ADRENERGIC-
RECEPTOR ACTIVITY.
000302 01-03
AFFINITY CHROMATOGRAPHY OF THE BETA-ADRENERGIC-RECEPTOR AND
CHARACTERIZATION OF ANTIBODIES RAISED AGAINST PURIFIED
RECEPTOR PREPARATIONS
001009 02-01
LONG-TERM HALOPERIDOL TREATMENT OF MICE: A CHANGE IN BETA-
ADRENERGIC-RECEPTOR RESPONSIVENESS
001206 02-03
REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA-INDEPENDENT
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6-
GLIOMA CELLS. (UNPUBLISHED PAPER).
001403 02-03
INCREASED ADRENALINE, BETA-ADRENERGIC-RECEPTOR STIMULATION
AND PHOSPHOLIPID METHYLATION IN PINEAL-GLAND OF
SPONTANEOUSLY HYPERTENSIVE-RATS. (UNPUBLISHED PAPER).
001458 02-03
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS.
002071 02-10
BETA-ADRENERGIC-RECEPTOR SUBTYPES: PROPERTIES, DISTRIBUTION,
AND REGULATION.
002829 03-03
BETA-ADRENERGIC-RECEPTORS
ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE
AND DESMETHYLIMIPRAMINE.
000113 01-03
ACCELERATION OF DESIPRAMINE-INDUCED DECREASE OF RAT
CORTICOCEREBRAL BETA-ADRENERGIC-RECEPTORS BY YOHIMBINE
000326 01-03
MODULATION OF BETA-ADRENERGIC-RECEPTORS AND CALMODULIN
FOLLOWING ACUTE AND CHRONIC-TREATMENT WITH NEUROLEPTICS.
001529 02-03
MEPACRINE TREATMENT PREVENTS IMMOBILIZATION-INDUCED
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT
HYPOTHALAMUS AND BRAINSTEM.
002919 03-03
EFFECTS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA-
ADRENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES.
002932 03-03
DEVELOPMENTAL-CHANGE OF BETA-ADRENERGIC-RECEPTORS IN RAT-
BRAIN.
004050 04-03
BETA-ADRENOCEPTOR
CLENBUTEROL, A CENTRAL BETA-ADRENOCEPTOR AGONIST.
000120 01-03
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED
DIFFERENTIATION) IN THE MONKEY (MACACA-MULATTA).
000440 01-04
EFFECTS OF DESIPRAMINE AND YOHIMBINE ON ALPHA2-ADREN0CEPT0R
AND BETA-ADRENOCEPTOR SENSITIVITY.
001305 02-03
EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS.
001570 02-04
DISPOSITION AND ACTIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY.
001878 02-06
BETA-ADRENORECEPTOR
REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY
NORADRENALINE INFUSION.
002672 03-03
BETA-BLOCKERS
BETA-BLOCKERS IN PSYCHIATRY.
CLINICAL-REVIEW OF BETA-BLOCKERS IN ANXIETY.
PSYCHIATRIC USES OF BETA-BLOCKERS.
002109 02-11
004464 04-11
004709 04-17
BETA-RECEPTOR
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL- STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS.
000520 01-05
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM:
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON.
002884 03-03
a.
fe
I
S-53
Subject Index
Ptychopharmacology Abstracts
HYPERVENTILATION-SYNDROME AND BETA-RECEPTOR FUNCTION -
CLINICAL-EFFECT OF BETA BLOCKER UPON THE SYNDROME.
004459 04-11
BETA-SYMPATHOMIMETICS
SPONTANEOUS MOTOR-ACTIVITY IN RATS GIVEN REPEATEDLY BETA-
SYMPATHOMIMETICS - ISOPRENALIN AND SALBUTAMOL.
001804 02-04
BETAORENOL
THE EFFECT OF BETADRENOL ON EXAMINATION ANXIETY.
000650 01-10
BETAINE
ORAL AND RECTAL ABSORPTION OF CHLORAL-HYDRATE AND ITS BETAINE
COMPLEX.
004554 04-13
BEHA-SPLENDENS
BETTA-SPLENDENS MAZE-BEHAVIOR UNDER THE INFLUENCE OF THE BETA
FENIL-ISOPROPIL-AMINA-SULFATE.
001558 02-04
BIBLIOGRAPHY
BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM.
003630 03-17
BICUCULLINE
BICUCULLINE ANTAGONIZES EFFECTS OF DIAZEPAM ON AGGRESSIVE AND
TIMID-BEHAVIOUR IN MICE.
000485 01-04
EFFECT OF AMINOOXYACETIC-ACID AND BICUCULLINE ON PROLACTIN
RELEASE IN CASTRATED MALE RATS.
001194 02-03
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA:
REVERSAL BY MICROIONTOPHORETIC BICUCULLINE.
002684 03-03
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS:
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE.
003778 04-03
3H BACLOFEN AND 3H GABA BIND TO BICUCULLINE INSENSITIVE GABAB
SITES IN RAT-BRAIN.
003839 04-03
EFFECTS OF 5 HYDROXYTRYPTAMINE ON CENTRAL NEURONES
ANTAGONIZED BY BICUCULLINE AND PICROTOXIN.
003931 04-03
BICUCULUNE-iNDUCED
EFFECTS OF BICUCULUNE-INDUCED SEIZURES ON CEREBRAL METABOLISM
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY
STARVATION.
001134 02-03
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING
ELECTROCONVULSIVE-SHOCK OR BICUCULUNE-INDUCED CONVULSIONS
IN RATS.
003736 04-03
EFFECT OF GAMMA VINYL-GABA ON BICUCULUNE-INDUCED SEIZURES.
004157 04-04
BICYCLIC
CLINICAL-TRIALS WITH NEW BICYCUC AND TETRACYCLIC COMPOUNDS:
ZIMEUDINE AND MAPROTIUNE.
003213 03-09
BILE
COMPARISON OF BLOOD AND BILE LEVELS OF OXYPROTHEPIN AND
DOCLOXYTHEPIN IN RATS.
000242 01-03
BIND
DO BENZODIAZEPINES BIND AT ADENOSINE UPTAKE SITES IN CNS?
002933 03-03
3H BACLOFEN AND 3H GABA BIND TO BICUCULUNE INSENSITIVE GABAB
SITES IN RAT-BRAIN.
003839 04-03
BINDING
OXAZEPAM-ESTERS. 2. CORRELATION OF HYDROPHOBICITY WITH SERUM
BINDING, BRAIN PENETRATION, AND EXCRETION.
000011 01-02
3H IMIPRAMINE BINDING IN NEURONAL AND GUAL FRACTIONS OF
HORSE STRIATUM.
000033 01-03
(3H) 2 AMINODIHYDROXYTETRAHYDRt JAPHTHALENE (ADTN):
REGIONAL DISTRIBUTION AND IN Vi /O BINDING AFTER ACUTE AND
CHRONIC DRUG-TREATMENT.
000052 01-03
RELATIONSHIP OF ANTICONFLICT ACTIVITY OF BENZODIAZEPINES TO
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA
000057 01-03
HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO
GUINEA-PIG BRAIN.
000061 01-03
CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN
MEMBRANES.
000062 01-03
REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS.
000066 01-03
STEREOSPECIFIC BINDING OF 3H HALOPERIDOL IN RAT DORSAL SPINAL-
CORD.
000070 01-03
INCREASED MESOUMBIC 3H SPIROPERIDOL BINDING IN 4 WEEK OLD
OFFSPRING OF NURSING RAT MOTHERS TREATED WITH PENFLURIDOL.
000087 01-03
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING.
000099 01-03
INHIBITION OF (3H)NAL0X0NE BINDING IN H0M06ENATES OF RAT-
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC AQIVITY, RELATED
TO PHYSOSTIGMINE.
000104 01-03
HIGH-AFFINITY BINDING OF 3H ETHYLKETOCYCLAZOCINE TO RAT-BRAIN
HOMOGENATE.
000124 01-03
3H ETHYLKETOCYCLAZOCINE BINDING: LACK OF EVIDENCE FOR A
SEPARATE KAPPA-RECEPTOR IN RAT CNS.
000128 01-03
EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA-
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN.
000135 01-03
CHARACTERIZATION OF 3H GABA-RECEPTOR BINDING TO RAT-BRAIN
SYNAPTOSOMAL MEMBRANES: EFFEQ OF NONGABAERGIC
COMPOUNDS.
000139 01-03
AMITRIPTYLINE BINDING TO SPECIFIC ALPHA-ADRENERGIC-RECEPTORS IN
VITRO.
000181 01-03
DECREASED SPIROPERIDOL AND LSD BINDING IN RAT-BRAIN AFTER
CONTINUOUS AMPHETAMINE.
000216 01-03
INHIBITION OF IN VIVO 3H SPIPERONE BINDING BY THE PROPOSED
ANTIPSYCHOTIC DES-TYRl-GAMMA-ENDORPHIN.
000226 01-03
LONG-TERM ANTIDEPRESSANT TREATMENT DECREASES SPIROPERIDOL-
LABELED SEROTONIN-RECEPTOR BINDING
000230 01-03
CHRONIC SYMPATHETIC DENERVATION INCREASES MUSCARINIC-
CHOLINOCEPTOR BINDING IN THE RAT SUBMAXILLARY-GLAND.
000235 01-03
AUDIOGENIC-SEIZURES: INCREASED BENZODIAZEPINE-RECEPTOR BINDING
IN A SUSCEPTIBLE STRAIN OF MICE.
000252 01-03
EFFEQS OF CHRONIC HALOPERIDOL ON CAUDATE 3H SPIROPERIDOL
BINDING IN LESIONED RATS
000255 01-03
PENTOBARBITAL POTENTIATES GABA-ENHANCED (3H) DIAZEPAM
BINDING TO BENZODIAZEPINE-RECEPTORS.
000275 01-03
CHANGES IN MOUSE-BRAIN DIAZEPAM-RECEPTOR BINDING AFTER
PHENOBARBITAL ADMINISTRATION.
000281 01-03
BIOCHEMICAL-PROPERTIES OF SPIPERONE BINDING TO RAT-BRAIN
MEMBRANES.
000294 01-03
(3H)QUINUCUDINYL-BENZIUTE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRAQIONS.
000299 01-03
3H MIANSERIN BINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG AQION.
000325 01-03
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS.
000330 01-03
INCREASED DOPAMINE-RECEPTOR BINDING IN THE STRIATUM OF RATS
AFTER LONG-TERM ISOLATION.
000398 01-04
DISPLACEMENT OF (3H)CL0NIDINE BINDING BY CLONIDINE ANALOGUES
IN MEMBRANES FROM RAT-CEREBRAL-CORTEX.
000536 01-06
VALPROIC-ACID DOSAGE AND PLASMA PROTEIN BINDING AND
CLEARANCE.
000755 01-13
ALBUMIN BINDING INTERAQIONS OF SODIUM-VALPROATE.
000762 01-13
INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY- STATE SERUM LEVELS
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-DRUGS IN MAN.
000767 01-13
SPECIFIC BINDING FOR OPIATE-LIKE-DRUGS IN THE PLACENTA.
000797 01-13
S-54
VOLUME 19, SUBJECT INDEX
Subject Index
TECHNIQUES FOR PLASMA PROTEIN BINDING OF
DEMETHYLCHLORIMIPRAMINE ,
000897 01-16
DISEASE-INDUCED CHANGES IN THE PLASMA BINDING OF BASIC DRUGS.
000975 01-17
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS (UNPUBLISHED
PAPER).
001035 02-01
HISTAMINE-RECEPTORS IN THE BRAIN: CHARACTERIZATION BY BINDING
STUDIES AND BIOCHEMICAL-EFFECTS.
001054 02-01
INHIBITION BY LOCAL ANESTHETICS, PHENTOLAMINE AND PROPRANOLOL
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL
MUSCARINIC-RECEPTORS.
001097 02-03
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST,
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II. WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
IN VIVO (3H)SPIPER0NE BINDING TO THE RAT HIPPOCAMPAL
FORMATION: INVOLVEMENT OF DOPAMINE-RECEPTORS.
001131 02-03
ETHANOL ENHANCES (3H)DIAZEPAM BINDING AT THE BENZODIAZEPINE
GABA-RECEPTOR lONOPHORE COMPLEX.
001154 02-03
RADIOLIGAND BINDING STUDIES: EVIDENCE FOR MULTIPLE DOPAMINE-
RECEPTORS.
001186 02-03
HIGH-AFFINITY BINDING OF (3H)MIANSERIN TO RAT-CEREBRAL-CORTEX.
001204 02-03
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES.
001208 02-03
DRUG-INDUCED ALTERATIONS IN NEUROTRANSMITTER-RECEPTOR
BINDING AND FUNCTION.
001215 02-03
THE EFFECT OF GABAMIMETICS ON NEUROTRANSMITTER-RECEPTOR
BINDING AND FUNCTION IN RAT-BRAIN. (PH.D. DISSERTATION).
001221 02-03
THE BINDING OF SOME ANTIDEPRESSANT-DRUGS TO BRAIN MUSCARINIC
ACETYLCHOLINE-RECEPTORS .
001253 02-03
OPIATES AND SPECIFIC RECEPTOR BINDING OF (3H)CL0NIDINE.
001256 02-03
PERSISTENT EFFECTS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC-
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS.
001266 02-03
BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERACTION
WITH GAMMA AMINOBUTYRIC-ACID.
001287 02-03
NO EVIDENCE FOR INCREASED DOPAMINE-RECEPTOR BINDING IN
SUPERRESPONSIVE MICE AFTER A SINGLE-DOSE OF NEUROLEPTICS.
001292 02-03
EVIDENCE FOR AN ENDOGENOUS COMPOUND INTERFERING WITH 3H
DIAZEPAM BINDING TO RAT-BRAIN MEMBRANES.
001308 02-03
CHARACTERIZATION OF GABA-STIMULATED BENZODIAZEPINE-RECEPTOR
BINDING.
001309 02-03
INCREASED MUSCARINIC-RECEPTOR BINDING IN RAT-FOREBRAIN AFTER
SCOPOLAMINE.
001351 02-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/
NEUROLEPTIC-RECEPTOR BINDING: EFFECT OF NEUROLEPTIC-DRUGS.
001358 02-03
CHARACTERIZATION AND RADIOAUTOGRAPHY OF (3H)LSD BINDING BY
RAT-BRAIN SLICES IN VITRO: THE EFFECT OF 5 HYDROXYTRYPT AMINE.
001369 02-03
FURTHER CHARACTERIZATION OF THE BINDING OF SUBSTANCE-P TO A
FRAaiON FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES.
001394 02-03
RENAL BENZODIAZEPINE BINDING INCREASES DURING
DEOXYCORTICOSTERONE/SALT HYPERTENSION IN RATS.
001430 02-03
1 METHYL-BETA-CARBOLINE (HARMANE), A POTENT ENDOGENOUS
INHIBITOR OF BENZODIAZEPINE-RECEPTOR BINDING.
001440 02-03
CHRONIC LITHIUM REDUCES (3H)SPIR0PERID0L BINDING IN RAT
STRIATUM.
001443 02-03
INCREASED RENAL NEUROLEPTIC BINDING IN SPONTANEOUSLY
HYPERTENSIVE-RATS.
001444 02-03
EFFECTS OF HALOPERIDOL AND D-AMPHETAMINE ON IN VIVO 3H
SPIROPERIDOL BINDING IN THE RAT-FOREBRAIN
001461 02-03
DECREASE IN (3H) SEROTONIN BINDING IN RAT-BRAIN PRODUCED BY THE
REPEATED ADMINISTRATION OF EITHER MONOAMINE-OXIDASE-
INHIBITORS ON CENTRALLY-ACTING SEROTONIN AGONISTS.
001463 02-03
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS
001516 02-03
BINDING OF (3H)PERG0LIDE-MESYLATE TO DOPAMINE-RECEPTORS OF
MAMMALIAN BRAINS.
001538 02-03
(3H) PHENCYCLIDINE BINDING TO SPECIFIC BRAIN RECEPTOR SITES
001555 02-03
MODULATION OF OPIATE-RECEPTOR BINDING IN STRIATUM AND
AMYGDALA BY SELECTIVE MESENCEPHALIC LESIONS.
001629 02-04
3H APOMORPHINE-RECEPTORS IN VARIOUS RAT-BRAIN REGIONS: A
STUDY OF SPECIFIC AND NONSPECIFIC BINDING AND THE INFLUENCE OF
CHRONIC NEUROLEPTIC TREATMENT.
001846 02-05
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. I.
PROTEIN BINDING.
001867 02-06
DISPOSITION AND ACTIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY.
001878 02-06
HIGH-AFFINITY BINDING OF TRICYCLIC-ANTIDEPRESSANTS TO HISTAMINE
HI -RECEPTORS: FACT AND ARTIFACT.
001880 02-06
BINDING OF PHENCYCLIDINE TO RAT-BRAIN MEMBRANES: TECHNICAL-
ASPECT.
001882 02-06
COMPARATIVE PROTEIN BINDING OF DIAZEPAM AND
DESMETHYLDIAZEPAM.
002206 02-13
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
002219 02-13
SPECIFIC 3H IMIPRAMINE BINDING IN HUMAN PLATELETS: INFLUENCE OF
AGE AND SEX.
002254 02-13
EFFECTS OF CAFFEINE ON PLASMA FREE FATTY-ACIDS, URINARY
CATECHOLAMINES, AND DRUG BINDING.
002272 02-13
INTERACTION BETWEEN PHENYTOIN AND VALPROIC-ACID: PLASMA
PROTEIN BINDING AND METABOLIC-EFFECTS.
002276 02-13
BINDING OF PERAZINE TO ALPHAl ACID GLYCOPROTEIN.
002290 02-13
THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON
GABA-RECEPTOR BINDING.
002301 02-13
DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM
BOVINE CEREBRAL-CORTEX.
002645 03-01
RECEPTOR BINDING PROFILE OF R-41-468, A NOVEL ANTAGONIST AT 5
HT2-RECEPT0RS.
002648 03-02
REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY
NORADRENALINE INFUSION.
002672 03-03
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
002699 03-03
THE EFFECT OF GUANOSINE-NUCLEOTIDES ON (3H)SULPIRIDE BINDING TO
RAT STRIATAL MEMBRANES.
002722 03-03
SIMILARITIES BETWEEN THE BINDING OF 3H PIFLUTIXOL AND 3H
FLUPENTIXOL TO RAT STRIATAL DOPAMINE-RECEPTORS IN VITRO.
002760 03-03
MODULATION BY PICROTOXIN AND IPTBO OF 3H FLUNITRAZEPAM
BINDING TO THE GABA/BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-
CEREBELLUM.
002775 03-03
IMIPRAMINE: EFFECT OF OVARIAN STEROIDS ON MODIFICATIONS IN
SEROTONIN-RECEPTOR BINDING.
002778 03-03
I
5
■>
fi:
S-55
Subject Index
Psychopharmacology Abstracts
THE EFFECT OF SPECIFIC BRAIN LESIONS ON THE HIGH-AFFINITY BINDING
OF GABA IN THE SUBSTANTIA-NIGRA.
002795 03-03
ASCORBATE DECREASES LIGAND BINDING TO NEUROTRANSAAinER-
RECEPTORS.
002804 03-03
BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH-
AVOIDANCE AND LOW-AVOIDANCE RATS.
002852 03-03
TWO DISTINCT SEROTONIN-RECEPTORS: REGIONAL VARIATIONS IN
RECEPTOR BINDING IN MAMMALIAN BRAIN.
002861 03-03
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING:
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN
HYPERTENSION.
002874 03-03
AMITRIPTYLINE: LONG-TERM-TREATMENT ELEVATES ALPHA-ADRENERGIC
AND MUSCARINIC-RECEPTOR BINDING IN MOUSE-BRAIN.
002875 03-03
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM:
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON.
002884 03-03
EFFECTS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC
MEMBRANES.
002888 03-03
THREE CLASSES OF OOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE.
002900 03-03
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR
BRAIN SPECIFIC BENZODIAZEPINE BINDING
002903 03-03
ACTION OF PYRAZOLOPYRIDINES AS MODULATORS OF
(3H)FLUNITRAZEPAM BINDING TO THE GABA/BENZODIAZEPINE-
RECEPTOR COMPLEX OF THE CEREBELLUM.
002909 03-03
REGULATION BY CATIONS OF (3H)SPIR0PERID0L BINDING ASSOCIATED
WITH DOPAMINE-RECEPTORS OF RAT-BRAIN.
002922 03-03
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF
BINDING-SITES IN DEPRESSED-PATIENTS.
003427 03-13
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS:
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD.
003556 03-16
HIGH-AFFINITY 3H IMIPRAMINE BINDING: A NEW BIOLOGICAL TOOL FOR
STUDIES IN DEPRESSION.
003610 03-17
STRUCTURE-ACTIVITY AND RECEPTOR BINDING OF ANTAGONIST
ANALGESICS
003611 03-17
EFFECT OF THE POSITION OF THE PHENOLIC GROUP IN MORPHINANS ON
THEIR AFFINITY FOR OPIATE-RECEPTOR BINDING.
003702 04-02
EFFECT OF CHRONIC SULPIRIDE ON STRIATAL SPIPERONE BINDING.
003720 04-03
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT.
003734 04-03
INHIBITION OF (3H)DIAZEPAM BINDING BY AN ENDOGENOUS FRACTION
FROM RAT-BRAIN SYNAPTOSOMES.
003768 04-03
EFFECTS OF CONFORMATIONALLY RESTRAINED ANALOGUES OF
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN.
003794 04-03
COMPARISON OF THE BINDING CHARACTERISTICS OF TRITIATED OPIATES
AND OPIOID-PEPTIDES.
003802 04-03
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF ALPHA-
ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA HYBRID
CELLS.
003823 04-03
SPECIFIC, HIGH-AFFINITY (3H)ETHYLKET0CYCLAZ0CINE BINDING IN RAT
CENTRAL-NERVOUS-SYSTEM: LACK OF EVIDENCE FOR KAPPA-
RECEPTORS.
003840 04-03
REGIONAL CHANGES IN {3H)DIAZEPAM BINDING IN THE BRAINS OF MICE
AFTER REMOVAL OF THE OLFACTORY-BULBS.
003844 04-03
IBOTENIC-ACID ANALOGUES AS INHIBITORS OF (3H)GLUTAMIC-ACID
BINDING TO CEREBELLAR MEMBRANES.
003848 04-03
QUINUCLIDINYL BENZILATE BINDING IN HOUSEFLY HEADS AND RAT-
BRAIN.
003868 04-03
INCREASED MESOLIMBIC DOPAMINE BINDING FOLLOWING CHRONIC
HALOPERIDOL TREATMENT.
003872 04-03
OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES:
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES.
003902 04-03
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF
(3H)SPIR0PERID0L IN CALF CAUDATE.
003906 04-03
EFFECTS OF HALOPEMIDE ON GABA-RECEPTOR BINDING, UPTAKE AND
RELEASE.
003913 04-03
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL
HEMISPHERES OF AGED MALE RATS.
003936 04-03
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRACTION
003948 04-03
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID-
RECEPTOR AGONIST, TO MEMBRANES OF THE BOVINE RETINA
003954 04-03
REGIONAL DISTRIBUTION OF (3H)IMIPRAMINE BINDING IN RAT-BRAIN
003955 04-03
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN
REUPTAKE SITES IN BRAIN AND PLATELET?
003962 04-03
MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN:
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS.
003992 04-03
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO
SYNAPTIC MEMBRANES
004000 04-03
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE
PITUITARY MEMBRANES
004003 04-03
CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF
(3H)SULPIRIDE AND (3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS.
004032 04-03
THE EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND
ITS WITHDRAWAL ON GAMMA AMINOBUTYRIC-ACID-RECEPTOR
BINDING IN RAT-BRAIN
004035 04-03
RELEVANCE OF DOPAMINE-RECEPTOR BINDING STUDIES FOR EVALUATION
OF ANTIPARKINSONIAN-DRUGS
004120 04-04
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS
004129 04-04
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFEaS ON
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING
IN VITRO.
004198 04-04
SPECIFIC IN VIVO BINDING OF 77BR P BROMOSPIROPERIDOL IN RAT-
BRAIN: A POTENTIAL TOOL FOR GAMMA-RAY IMAGING.
004293 04-06
PROTEIN BINDING OF CHLORPROMAZINE IN CEREBROSPINAL-FLUID AND
SERUM
004311 04-08
DECREASED 3H IMIPRAMINE BINDING IN DEPRESSED MALES AND
FEMALES.
004349 04-09
(3H) IMIPRAMINE BINDING IN HUMAN PLATELETS: A NEW
BIOCHEMICAL-PARAMETER IN DEPRESSION.
004358 04-09
BINDING-ACTIVITIES
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND RECEPTOR BINDING-
AQIVITIES FOLLOWING ACUTE AND CHRONIC NEUROLEPTIC-DRUG
TREATMENT. (UNPUBLISHED PAPER).
001172 02-03
BINDING-ACTIVITY
IDENTIFICATION AND PARTIAL PURIFICATION OF A HYDROPHOBIC
PROTEIN COMPONENT ASSOCIATED WITH (3H)SPIR0PERID0L BINDING-
AQIVITY. (UNPUBLISHED PAPER).
001007 02-01
BETA ENDORPHIN: DISSOCIATION OF RECEPTOR BINDING-AQIVITY FROM
ANALGESIC POTENCY.
001081 02-02
SYNTHESIS AND GABA-RECEPTOR BINDING-AQIVITY OF TWO
FLUOROAMINOMETHYLPHENOLS.
003693 04-02
BINDING-SITE ^ , ,^
ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE
IN RAT-BRAIN.
001320 02-03
A HIGH-AFFINITY GTP BINDING-SITE IN RAT-BRAIN. (UNPUBLISHED
''^''^'^' 001442 02-03
S-56
VOLUME 19, SUBJECT INDEX
Subject Index
THE PHARMACOLOGICAL RELEVANCE OF THE COCAINE BINDING-SITE IN
MOUSE-BRAIN.
001772 02-04
BINDINO-SITES
LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES
Of THE DEVELOPING CHICK RETINA.
000065 01-03
(3H)5 HT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN
GLIAL CELL MEMBRANE FRACTION.
000093 01-03
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING-
SITES IN RAT STRIATUM.
000186 01-03
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT ~ I. KINETIC PARAMETERS
AND PHARMACOLOGICAL-PROPERTIES.
000213 01-03
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - II. RESPECTIVE REGIONAL
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC
DEVELOPMENTS.
000214 01-03
REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 1251 TYR8-
SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES.
000259 01-03
DIFFERENTIAL REGULATION OF MUSCARINIC AGONIST BINDING-SITES
FOLLOWING CHRONIC CHOLINESTERASE INHIBITION.
000279 01-03
PROPERTIES OF (3H)DIAZEPAM BINDING-SITES ON RAT BLOOD-
PLATELETS.
000317 01-03
SOLUBILIZATION OF THE DIHYDROPICROTOXININ BINDING-SITES.
001192 02-03
DOWN REGULATION OF DIHYDROALPRENOLOL AND IMIPRAMINE
BINDING-SITES IN BRAIN OF RATS REPEATEDLY TREATED WITH
IMIPRAMINE.
001317 02-03
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES.
001342 02-03
LOCALIZATION OF NALOXONE SENSITIVE (3H)DIHYDR0M0RPHINE
BINDING-SITES WITHIN THE HIPPOCAMPUS OF THE RAT.
001368 02-03
CHARACTERIZATION OF BENZODIAZEPINE BINDING-SITES. (UNPUBLISHED
PAPER).
001503 02-03
BENZODIAZEPINE BINDING-SITES: PROPERTIES AND MODULATION.
(UNPUBLISHED PAPER).
001504 02-03
COMPARED PROPERTIES OF CENTRAL AND PERIPHERAL BINDING-SITES
FOR PHENCYCLIDINE.
001521 02-03
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES.
001554 02-03
KAINATE LESION DISSOCIATES STRIATAL DOPAMINE-RECEPTOR
RADIOLIGAND BINDING-SITES.
002803 03-03
PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN
MAMMALIAN RETINA.
002814 03-03
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS
CULTURED FROM RAT-CEREBRAL-CORTEX.
002820 03-03
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMITTER AMINO-
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFACTORY-BULB.
002836 03-03
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO
GABA REGULATED CHLORIDE ION-CHANNELS.
002848 03-03
3H SEROTONIN BINDING-SITES IN RAT-BRAIN: EFFECTS OF REPEATED
ADMINISTRATION OF ANTIDEPRESSANT-DRUGS. (PH.D.
DISSERTATION).
002881 03-03
BENZODIAZEPINE BINDING-SITES: PROPERTIES AND MODULATION.
002912 03-03
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF
BINDING-SITES IN DEPRESSED-PATIENTS.
003427 03-13
CHARACTERIZATION OF TWO (3H)GLUTAMATE BINDING-SITES IN RAT
HIPPOCAMPAL MEMBRANES.
003726 04-03
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL
TISSUE BY ASCORBATE.
003876 04-03
HIGH-AFFINITY BINDING-SITES FOR A SOMATOSTATIN-28 ANALOG IN
RAT-BRAIN.
003985 04-03
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON Of
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO
SYNAPTIC MEMBRANES.
004000 04-03
INTERACTION OF STEREOISOMERS OF BARBITURATES WITH (3H)ALPHA
DIHYDROPICROTOXININ BINDING-SITES.
004036 04-03
BIOAVAILABILITY
BIOAVAILABILITY OF 14C SULPIRIDE IN DOGS.
000017 01-03
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF
LOPIRAZEPAM (D-1 2524) BY QUANTITATIVE EEG AND
PSYCHOMETRIC-ANALYSIS.
000720 01-11
BIOAVAILABILITY OF SULPIRIDE TABLET AND ''APSULE IN DOGS.
001101 02-03
ORAL BIOAVAILABILITY OF APOMORPHINE IN THE RAT WITH A
PORTACAVAL VENOUS ANASTOMOSIS,
001158 02-03
LOW ORAL CPZ BIOAVAILABILITY IN CHRONIC SCHIZOPHRENIA.
(UNPUBLISHED PAPER).
001938 02-08
BIOAVAILABILITY AND KINETICS OF MAPROTILINE.
002204 02-13
THE BIOAVAILABILITY OF ORAL AND PARENTERAL CHLORIMIPRAMINE
(ANAFRANIL).
002232 02-13
BIOAVAILABILITY AND RELATED PHARMACOKINETICS IN MAN OF
ORALLY ADMINISTERED L 5 HYDROXYTRYPTOPHAN IN STEADY- ST ATE.
002261 02-13
PHARMACOKINETICS AND BIOAVAILABILITY OF CHLORDIAZEPOXIDE IN
HUMANS.
002564 02-17
EFFECT OF DOSE ON BIOAVAILABILITY OF ORAL DIGOXIN.
003161 03-07
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS.
004551 04-13
BIOCHEMICAL
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE).
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION.
000712 01-11
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM:
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON.
002884 03-03
RECENT REVIEWS OF BIOCHEMICAL, NEUROCHEMICAL, AND
PHARMACOLOGICAL TOPICS.
003649 03-17
BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF THE MOUSE BRAIN
ENOLASES PURIFIED BY A SIMPLE METHOD.
003668 04-01
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL
EVALUATION.
003685 04-02
SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES OF
ANALOGUES AND DERIVATIVES OF P CHLOROPHENYLALANINE.
003691 04-02
BIOCHEMICAL INVESTIGATIONS INTO THE MODE Of ACTION OF
TRAZODONE.
003753 04-03
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
004406 04-09
PROLACTIN AND NEUROLEPTIC-DRUGS: A BIOCHEMICAL INDEX OF
CLINICAL-RESPONSE?
004539 04-13
THE BIOCHEMICAL BACKGROUND TO TARDIVE-DYSKINESIA.
004588 04-15
BIOCHEMICAL AND NEUROENDOCRINE APPROACHES TO A MALIGNANT-
SYNDROME OF NEUROLEPTIC.
004589 04-15
BIOCHEMICAL-ACTION
CLINICAL AND BIOCHEMICAL-ACTION OF PIRACETAM (NOOTROPIL) IN
DRUG-RESISTANT DEPRESSION.
000600 01-09
BIOCHEMICAL-ASPECTS
SOME PHARMACOLOGICAL-ASPECTS AND BIOCHEMICAL-ASPECTS OF
TRH: EXPERIMENTAL AND CLINICAL DATA.
001189 02-03
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: II.
BIOCHEMICAL-ASPECTS.
002300 02-13
d..
•T
■t
"lit
S-57
Subject Index
Psychopharmacology Abstracit
BIOCHEMICAL-BASIS
BENZODIAZEPINES: A TOOL TO EXPLORE THE BIOCHEMICAL-BASIS AND
NEUROPHYSIOLOGICAL-BASIS OF ANXIETY.
000397 01-04
BIOCHEMICAL-CHANGES
BEHAVIORAL-CHANGES AND BIOCHEMICAL-CHANGES AFTER
HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION).
003069 03-04
BIOCHEMICAL-CHARACTERIZATION
BIOCHEMICAL-CHARACTERIZATION OF THE RAT SYMPATHETIC
GANGLION; PHARMACOLOGICAL-EFFECTS OF RESERPINE ON
GANGLIONIC CATECHOLAMINES.
000153 01-03
BIOCHEMICAL-CHARACTERIZATION AND PHARMACOLOGICAL
CHARACTERIZATION OF A PEPTIDE FROM THE HEMODIALYSATE OF
PSYCHOTIC-PATIENTS.
001049 02-01
BIOCHEMICAL-CONSEQUENCES
THE DOPAMINE-RECEPTOR COMPLEX: BIOCHEMICAL-CONSEQUENCES OF
SUPERSENSITIVITY INDUCED BY TREATMENT WITH 6
HYDROXYDOPAMINE OR MORPHINE.
003958 04-03
BIOCHEMICAL-CONSIDERATIONS
BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE-
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL-
CONSIDERATIONS.
001550 02-03
BIOCHEMICAL-CORRELATES
SODIUM-VALPROATE IN SCHIZOPHRENIA: SOME BIOCHEMICAL-
CORRELATES.
000561 01-08
RECEPTOR PLASTICITY: BIOCHEMICAL-CORRELATES AND
PHARMACOLOGICAL SIGNIFICANCE.
001181 02-03
BEHAVIORAL-CORRELATES AND BIOCHEMICAL-CORRELATES AFTER
HALOPERIDOL AND CLOZAPINE LONG-TERM-TREATMENT
001422 02-03
BIOCHEMICAL-CORRELATION
CLINICAL-CORRELATION, BIOCHEMICAL-CORRELATION, AND
PSYCHOPHARMACOLOGICAL-CORRELATION IN PATIENTS WITH
DEPRESSIVE-SYMPTOMATOLOGY.
002018 02-09
BIOCHEMICAL-CORRELATIONS
CLINICAL AND BIOCHEMICAL-CORRELATIONS IN ABRUPT
DISCONTINUATION OF PSYCHOPHARMACOTHERAPY.
004330 04-08
BIOCHEMICAL-DATA
CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE
AND CLOMIPRAMINE IN DEPRESSIVE-STATES (PRELIMINARY
OBSERVATION).
002032 02-09
BIOCHEMICAL-EFFECTS
HISTAMINE-RECEPTORS IN THE BRAIN: CHARACTERIZATION BY BINDING
STUDIES AND BIOCHEMICAL-EFFECTS.
001054 02-01
STUDIES ON THE BIOCHEMICAL-EFFECTS AND BEHAVIOURAL-EFFECTS OF
ORAL NICOTINE.
001115 02-03
BIOCHEMICAL-EFFECTS OF ZIMELIDINE IN MAN.
001967 02-09
BIOCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF ACUTE ETHANOL IN
RATS AT DIFFERENT ENVIRONMENTAL TEMPERATURES.
002864 03-03
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN
MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF
AMPHETAMINE (PH.D. DISSERTATION).
002996 03-04
CENTRAL CARDIOVASCULAR-EFFECTS AND BIOCHEMICAL-EFFECTS OF
BACLOFEN IN THE CONSCIOUS RAT.
003965 04-03
A COMPARISON BETWEEN SOME BIOCHEMICAL-EFFECTS AND
BEHAVIOURAL-EFFECTS PRODUCED BY NEUROLEPTICS.
004116 04-04
LONG-TERM NEUROLEPTIC TREATMENT OF CHRONIC SCHIZOPHRENIC-
PATIENTS: CLINICAL AND BIOCHEMICAL-EFFECTS OF WITHDRAWAL.
004344 04-08
BIOCHEMICAL-EVENT
PHOSPHOLIPID METHYLATION: A BIOCHEMICAL-EVENT OF SIGNAL
TRANSDUCTION. (UNPUBLISHED PAPER).
001279 02-03
BIOCHEMICAL-EVIDENCE
BIOCHEMICAL-EVIDENCE FOR TYPE-1 AND TYPE-2 OPIATE-RECEPTORS.
(UNPUBLISHED PAPER).
001050 02-01
PHARMACOLOGICAL EVIDENCE AND BIOCHEMICAL-EVIDENCE FOR AN
INTERACTION BETWEEN THE BENZODIAZEPINE AND GABA-RECEPTORS.
001261 02-03
BIOCHEMICAL-EVIDENCE FOR OSTEOMALACIA WITH CARBAMAZEPINE
THERAPY.
002445 02-15
BIOCHEMICAL-LOCALIZATION
BIOCHEMICAL-LOCALIZATION AND CHARACTERIZATION OF BOMBESIN-
UKE-PEPTIDES IN DISCRETE REGIONS OF RAT-BRAIN. (UNPUBLISHED
PAPER).
001046 02-01
BIOCHEMICAL-MEASUREMENTS
BIOCHEMICAL-MEASUREMENTS DURING (-)DEPRENYL TREATMENT OF
PARKINSONISM.
000673 01-11
BIOCHEMICAL-MECHANISM
BIOCHEMICAL-MECHANISM OF SIGNAL TRANSDUCTION ACROSS
BIOMEMBRANES. (UNPUBLISHED PAPER).
001026 02-01
NEW TRENDS CONCERNING THE BIOCHEMICAL-MECHANISM OF ACTION
OF BENZODIAZEPINES.
003642 03-17
BIOCHEMICAL-OBSERVATIONS
TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAN AND
CARBIDOPA: CLINICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL-
OBSERVATIONS.
002180 02-11
BIOCHEMICAL-PARAMETER
(3H) IMIPRAMINE BINDING IN HUMAN PLATELETS: A NEW
BIOCHEMICAL-PARAMETER IN DEPRESSION.
004358 04-09
BIOCHEMICAL-PARAMETERS
DRUG INTERFERENCE ON SOME BIOCHEMICAL-PARAMETERS OF RAT-
CEREBRAL-CORTEX DURING POSTISCHEMIC RECOVERY.
001126 02-03
BIOCHEMICAL-PHARMACOLOGY
NEUROCHEMICAL-PHARMACOLOGY AND BIOCHEMICAL-PHARMACOLOGY.
003639 03-17
BIOCHEMICAL-PROPERTIES
REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 1251 TYR8-
SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES.
000259 01-03
BIOCHEMICAL-PROPERTIES OF SPIPERONE BINDING TO RAT-BRAIN
MEMBRANES
000294 01-03
PHARMACOLOGICAL AND BIOCHEMICAL-PROPERTIES OF BRL- 14342, A
NOVEL POTENTIAL ANTIDEPRESSANT-DRUG.
004086 04-04
BIOCHEMICAL-RESPONSE
RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN
PLASMA AND CEREBROSPINAL-FLUIO AND CLINICAL-RESPONSE AND
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS.
001905 02-08
BIOCHEMICAL-STUDIES
EVIDENCE FOR A GABAERGIC NIGROTHALAMIC PATHWAY IN THE RAT: I.
BEHAVIOURAL-STUDIES AND BIOCHEMICAL-STUDIES
000158 01-03
BIOCHEMICAL- STUDIES AFTER CHRONIC ADMINISTRATION OF
NEUROLEPTICS TO MONKEYS.
000523 01-05
TARDIVE-DYSKINESIA: BIOCHEMICAL-STUDIES. (UNPUBLISHED PAPER).
002245 02-13
BEHAVIORAL AND BIOCHEMICAL- STUDIES OF THE SCOPOLAMINE-INDUCEO
REVERSAL OF NEUROLEPTIC AQIVITY.
004 1 95 04-04
BIOCHEMICAL-STUDIES OF HUMAN EPILEPTICS DURING ANTICONVULSANT
THERAPY
004490 04-11
BIOCHEMICAL-STUDY
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND
MORPHOLOGICAL-STUDY.
001407 02-03
BIOCHEMICAL-STUDY OF THE ANIMAL-MODEL DEPRESSION INDUCED BY
TETRABENAZINE.
001506 02-03
A BIOCHEMICAL-STUDY OF LUMBAR CEREBROSPINAL-FLUID IN
EXTRAPYRAMIDAL-DISORDERS.
002186 02-11
BIOCHEMICAL-VARIABLES
RELATIONSHIPS AMONG BIOCHEMICAL-VARIABLES, CLINICAL-
VARIABLES, AND PHARMACOKINETIC-VARIABLES IN NEUROLEPTIC
TREATED SCHIZOPHRENIC-PATIENTS.
001946 02-08
BIOCHEMICALLY-SELECTIVE
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELEQIVE
AND BEHAVIORALLY-SELEaiVE ANTAGONISTS OF THE LOCOMOTOR-
STIMULATION INDUCED BY INDIRECTLY ACTING SYMPATHOMIMETIC-
AMINES IN MICE.
000492 01-04
BIOCHEMISTRY
INFLUENCE OF CANNABIS AND DELTA9 TETRAHYDROCANNABINOL ON
THE BIOCHEMISTRY OF THE MALE REPRODUCTIVE ORGANS.
002686 03-03
S-58
VOLUME 19, SUBJECT INDEX
Subject Index
BIOELECTRIC-ACTIVITY
THE EFFECT OF CLOFELIN ON THE BIOELECTRIC-ACTIVITY OF THE BRAIN.
001449 02-03
BIOELECTRICAUACTIVITY
BIOELECTRICAL-ACTIVITY OF THE RAT BRAIN AFTER PREMATURE
WEANING AND AFTER RNA ADMINISTRATION.
002865 03-03
THE EFFECT OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELECTRICAL-
ACTIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUCTURES OF
THE RABBIT BRAIN.
003994 04-03
THE EFFECT OF THE NEW ANTIDEPRESSANT INKASAN ON THE
BIOELEQRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED
REFLEXES.
004212 04-04
BIOGENESIS
REGULATION OF BIOGENESIS OF PSYCHOTOMIMETIC AMINES.
(UNPUBLISHED PAPER).
003818 04-03
BIOGENIC- AMINE
INTERACTION OF BIOGENIC-AMINE SYSTEMS IN BRAIN. (UNPUBLISHED
PAPER).
001141 02-03
SHORT-TERM AND LONG-TERM EFFECTS OF METHAMPHETAMINE ON
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC
NUCLEI.
001384 02-03
A SELECTED ION-MONITORING ASSAY FOR BIOGENIC-AMINE
METABOLITES AND PROBENECID, IN HUMAN LUMBAR
CEREBROSPINAL-FLUID.
003663 04-01
BIOGENIC-AMINES
REUPTAKE OF BIOGENIC-AMINES BY BRAIN SLICES: EFFECT OF
HYDROCORTISONE.
000187 01-03
ACTION OF THE ANTIDEPRESSANT PRIDEFINE (AHR-1 1 18) ON BIOGENIC-
AMINES IN THE RAT-BRAIN.
000312 01-03
THE ROLE OF BIOGENIC-AMINES IN AMYGDALAR KINDLING. I. LOCAL
AMYGDALAR AFTERDISCHARGE.
000327 01-03
HIGH-SENSITIVITY NEGATIVE CHEMICAL-IONIZATION MASS-SPECTRAL-
ANALYSIS OF BIOGENIC-AMINES AND METABOLITES. (UNPUBLISHED
PAPER).
001042 02-01
SYNTHESIS OF 180 ANALOGS OF BIOGENIC-AMINES. (UNPUBLISHED
PAPER).
001044 02-01
BIOGENIC-AMINES AND NEUROPEPTIDES PLAY A ROLE IN THE CENTRAL-
REGULATION OF GENETIC HYPERTENSION. (UNPUBLISHED PAPER).
001455 02-03
CENTRAL BIOGENIC-AMINES AND NEUROPEPTIDES IN GENETIC
HYPERTENSION. (UNPUBLISHED PAPER).
001456 02-03
EFFEa OF LOW-DOSE LITHIUM ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL ON BIOGENIC-AMINES IN RAT-BRAIN.
003708 04-03
STRESS-MODULATED ALTERATION OF BRAIN BIOGENIC-AMINES IN THE
RAT: EFFEaS OF L TRYPTOPHAN.
003978 04-03
THE EFFEQ OF P CHLOROPHENYLALANINE ON THE DISTRIBUTION OF
BIOGENIC-AMINES IN THE BRAIN, AND ON MEMORY IN RATS.
004068 04-04
BIOLOGIC
CURRENT BIOLOGIC STRATEGIES FOR ANXIETY.
003276 03-10
BIOLOGIC-INTERACTION
BIOLOGIC-INTERACTION OF GAMMA-RADIATION WITH
PHENYLBUTAZONE, PHENYTOIN, OR HYDRALAZINE.
000518 01-05
BIOLOGICAL
INFLUENCE OF NICERGOLINE ON MOLECULAR BIOLOGICAL PROCESSES IN
THE BRAIN AND LEARNING-ABILITY OF THE RAT.
000449 01-04
LITHIUM LEVEL IN SOME BIOLOGICAL FLUIDS AT ITS PROPHYLAQIC
THERAPEUTIC APPLICATION.
000605 01-09
DETERMINATION OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS AND OF THEIR METABOLIC PRODUCTS IN
BIOLOGICAL FLUIDS.
002498 02-16
HIGH-AFFINITY 3H IMIPRAMINE BINDING: A NEW BIOLOGICAL TOOL FOR
STUDIES IN DEPRESSION.
003610 03-17
BIOLOGICAL EVALUATION OF A TRH ANALOGUE WITH A MODIFIED
PROLINE RESIDUE.
003662 04-01
PREPARATION AND BIOLOGICAL ACTIONS OF N 2,2,2 TRIFLUOROETHYL-
DIHYDROXYPHENYLETHYLAMINE .
003697 04-02
NEW BIOLOGICAL RESEARCH RELEVANT TO ANXIETY.
004705 04-17
BIOLOGICAL AND PHYSIOLOGICAL PREDICTORS OF DRUG RESPONSE.
(UNPUBLISHED PAPER).
004708 04-17
BIOLOGICAL-ACTIVITY
MODIFICATION OF THE PROLINE RESIDUE OF TRH ENHANCES BIOLOGICAL-
ACTIVITY AND INHIBITS DEGRADATION.
000351 01-04
CONFIRMATION BEHAVIOR OF PHENCYCLIDINES AND BIOLOGICAL-
ACTIVITY.
001031 02-01
COMPARISON OF BIOLOGICAL-ACTIVITY AND BEHAVIORAL-ACTIVITY OF
ALPHA AND GAMMA MELANOCYTE-STIMULATING-HORMONES.
(UNPUBLISHED PAPER).
001398 02-03
BIOLOGICAL-ACTIVITY OF THE TETRAHYDROCANNABINOLS.
002556 02-17
DIFFERENTIAL LOSS OF BIOLOGICAL-ACTIVITY OF THE ENKEPHALINS
INDUCED BY CURRENT.
002783 03-03
SYNTHESIS AND BIOLOGICAL-ACTIVITY OF HUMAN BETA ENDORPHIN
ANALOGS WITH DISULFIDE BRIDGES.
003655 04-01
BIOLOGICAL-EFFECTS
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. III. THE MUTUAL RELATION OF EACH INDEX.
003179 03-08
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFECTS OF ORAL MAGNESIUM
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM.
003291 03-11
BEHAVIORAL-EFFECTS AND BIOLOGICAL-EFFECTS OF ACUTE BETA
ENDORPHIN INJECTION IN SCHIZOPHRENIC-PATIENTS AND DEPRESSED-
PATIENTS.
003357 03-11
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. I. WITH REFERENCE TO PITUITARY-HORMONES.
003415 03-13
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. II. WITH REFERENCE TO SYMPATHETIC NEURONAL
FUNCTION.
003416 03-13
BIOLOGICAL-INTERACTION
THE MOLECULAR ARCHITECTURE OF ERGOPEPTINES: A BASIS FOR
BIOLOGICAL-INTERACTION.
001527 02-03
BIOLOGICAL-MATERIAL
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS,
BRAIN, AND PINEAL-ORGAN OF THE RAT.
002503 02-16
BIOLOGICAL-PSYCHIATRY
ANIMAL-MODELS OF RELEVANCE TO BIOLOGICAL-PSYCHIATRY.
002490 02-16
DISCUSSION OF WHO ACTIVITY IN BIOLOGICAL-PSYCHIATRY WITH
SPECIAL REFERENCE TO TRAINING.
002520 02-17
CONVERGENCES AND DIVERGENCES BETWEEN BIOLOGICAL-PSYCHIATRY
AND PSYCHOTHERAPY.
002536 02-17
BIOLOGICAL-PSYCHIATRY TODAY ~ VOL. B.
002588 02-17
BIOLOGICAL-PSYCHIATRY TODAY ~ VOL. A.
002589 02-17
A QUANTITATIVE PROBE F.OR BIOLOGICAL-PSYCHIATRY: SELECTED ION-
MONITORING.
004685 04-16
THE PROMISE OF BIOLOGICAL-PSYCHIATRY.
004752 04-17
BIOLOGICAL-RHYTHM
BIOLOGICAL-RHYTHM DISTURBANCES IN AFFECTIVE-ILLNESS.
002628 02-17
BIOLOGICAL-RHYTHMICITY
THE INFLUENCE OF DAILY BIOLOGICAL-RHYTHMICITY ON THE HOMING-
BEHAVIOR, PSYCHOPHARMACOLOGICAL RESPONSIVENESS, LEARNING
AND RETENTION OF SUCKLING RATS. (PH.D. DISSERTATION).
001660 02-04
BIOLOGICAL-STABILITY
AN ANALOGUE OF THYROTROPIN-RELEASING-HORMONE WITH IMPROVED
BIOLOGICAL- STABILITY BOTH IN VITRO AND IN VIVO.
000032 01-03
BIOLOGICAL-STUDIES
CLINICAL-STUDIES AND BIOLOGICAL-STUDIES OF L TRYPTOPHAN IN
DEPRESSION.
001977 02-09
BIOLOGY
BIOLOGY OF MANIC-MELANCHOLIC-DISORDERS.
000978 01-17
I
(3;
'1*
5
5T
S-59
Subject Index
Psychopharmacology Abstracts
BIOLOGY AND THERAPY OF VIOLENT-BEHAVIOUR IN CHILDREN.
002608 02-17
BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM.
003630 03-17
BIOMEDICAL-CORRELATES
LECITHIN ADMINISTRATION IN TARDIVE-DYSKINESIA: CLINICAL AND
BIOMEDICAL-CORRELATES.
003496 03-15
BrOMEMBRANES
BIOCHEMICAL-MECHANISM OF SIGNAL TRANSDUCTION ACROSS
BIOMEMBRANES. (UNPUBLISHED PAPER).
001026 02-01
BIOPSY
RENAL FUNCTION AND BIOPSY IN PATIENTS ON LITHIUM THERAPY.
000830 01-15
BIOPSYCHOSOCIAL-PERSPECTIVE
LITHIUM: A BIOPSYCHOSOCIAL-PERSPECTIVE.
003247 03-09
BIOPTERIN
THE INFLUENCE OF D-AMPHETAMINE ON RAT-BRAIN STRIATAL REDUCED
BIOPTERIN CONCENTRATION.
003922 04-03
BIOSYNTHESIS
HYPOTHALAMIC CATECHOLAMINE BIOSYNTHESIS IN VITRO AS
MEASURED BY LIQUID-CHROMATOGRAPHY AND ELECTROCHEMICAL-
DETECTION.
000537 01-06
BIOSYNTHESIS OF POSTERIOR PITUITARY-HORMONES (UNPUBLISHED
PAPER).
001053 02-01
INHIBITORS OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND
EPINEPHRINE BIOSYNTHESIS 2 1 ,2,3,4 TETRAHYDROISOQUlNOLINE-7-
SULFONANILIDES.
001069 02-02
BIOSYNTHESIS, AXONAL TRANSPORT AND RELEASE OF POSTERIOR
PITUITARY-HORMONES (UNPUBLISHED PAPER).
001148 02-03
DOPAMINE BIOSYNTHESIS IS REGULATED BY THE AMINE NEWLY
RECAPTURED BY DOPAMINERGIC NERVE-ENDINGS.
001163 02-03
EFFECT OF OPIATES ON MACROMOLECULE BIOSYNTHESIS.
001335 02-03
EFFECT OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRACTI0NS
001472 02-03
EFFECT OF PROSTAGLANDIN-El AND ITS BIOSYNTHESIS INHIBITOR
INDOMETHACIN ON DRINKING IN THE RAT.
001749 02-04
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN
HUMAN CELLS.
002830 03-03
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM
INTERMEDIATE/POSTERIOR LOBES OF PITUITARY.
003846 04-03
BIOTRANSFORMATION
EFFECTS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS:
RELATION TO MICROSOMAL BIOTRANSFORMATION AND
DOPAMINERGIC-RECEPTOR STIMULATION .
001161 02-03
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II.
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT.
004516 04-13
BIPERIDEN-HYDROCHIORIDE
A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED
PARKINSONISM.
002146 02-11
BIPHASIC
BIPHASIC RESPONSIVENESS OF RAT PIAL-ARTERIOLES TO DOPAMINE:
DIRECT OBSERVATIONS ON THE MICROCIRCULATION.
001105 02-03
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 C2-03
APPARENT SEROTONERGIC MODULATION OF THE DOSE-DEPENDENT
BIPHASIC RESPONSE OF NEOSTRIATAL NEURONS PRODUCED BY D-
AMPHETAMINE.
003981 04-03
BIPHASIC-EFFECTS
BIPHASIC-EFFECTS OF PIMOZIDE ON SLEEP-WAKEFULNESS IN DOGS.
000495 01-04
BIPHASIC-EFFECTS OF A POTENT ENKEPHALIN ANALOGUE D MET2-PR05-
ENKEPHALINAMIDE AND MORPHINE ON LOCOMOTOR-ACTIVITY IN
MICE.
001799 02-04
BIPHASIC-EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON
EXPLORATORY-BEHAVIOR IN MICE.
001808 02-04
BIPHASIC-EFFECTS OF DIRECT, BUT NOT INDIREQ, GABAMIMETICS AND
ANTAGONISTS ON HALOPERIDOL-INDUCED CATALEPSY.
001826 02-04
BIPHASIC-EFFECTS AND OPPOSITE-EFFECTS OF DOPAMINE AND
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT
SUBSTANTIA-NIGRA.
002923 03-03
BIPOLAR
BIPOLAR AFFECTIVE-PSYCHOSIS WITH ONSET BEFORE AGE 16 YEARS:
REPORT OF 10 CASES.
002001 02-09
THYROTROPHIN RESPONSE TO THYROTROPHIN-RELEASING-HORMONE IN
UNIPOLAR AND BIPOLAR AFFECTIVE-ILLNESS.
003237 03-09
MAOI-INDUCED RAPID CYCLING BIPOLAR AFFEQIVE-DISORDER IN AN
ADOLESCENT,
004637 04-15
BIPOLAR-I-PATIENTS
PROPHYLACTIC LITHIUM WITH AND WITHOUT IMIPRAMINE FOR BIPOLAR-
I-PATIENTS: A DOUBLE-BUND STUDY.
003233 03-09
BIPOLAR-M
LITHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND
BIPOLAR-II DEPRESSION: A PROSPECTIVE, PLACEBO-CONTROLLED
COMPARISON.
003252 03-09
BIPOLAR-PATIENTS
THE RELATIVE PROPHYLACTIC EFFICACY OF LITHIUM AGAINST MANIC
AND DEPRESSIVE RECURRENCES IN BIPOLAR-PATIENTS.
002040 02-09
BIS-TETRAHYDRO-2-FURANYL-5-FLUOROPYRIMIDINEDIONE
EFFECTS OF 1,3 BIS-TETRAHYDRO-2-FURANYL-5-
FLUOROPYRIMIDINEDIONE (FD-1) ON THE CENTRAL-NERVOUS-SYSTEM:
1. EFFECTS OF MONOAMINES IN THE BRAIN
001857 02-05
BISFLUOROPHENYL-BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE NEUROLEPTIC
PIMOZIDE-HYDROCHLORIDE, BISFLUOROPHENYL-
BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL.
001015 02-01
BITING-REFLEX
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT
001657 02-04
BLACK-WIDOW-SPIDER
METABOLISM OF 3H NORADRENALINE RELEASED FROM ISOLATED RAT
HYPOTHALAMUS BY EXTRACTS OF BLACK-WIDOW-SPIDER GLANDS.
000223 01-03
BLACKOUTS
TRICYCLIC-ANTIDEPRESSANTS AND ALCOHOLIC BLACKOUTS.
004617 04-15
BLEPHAROPTOSIS
EFFECTS OF NARCOTIC ANTAGONISTS ON L-DOPA REVERSAL OF
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE.
004186 04-04
BLINK
BLINK RATES AND RECEPTOR SUPERSENSITIVITY.
003022 03-04
DRUG-EFFEa ON BLINK RATES IN RHESUS-MONKEYS: PRELIMINARY
STUDIES
003023 03-04
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND
LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJEQS.
003311 03-11
BLINKS
EYE BLINKS. (UNPUBLISHED PAPER).
001672 02-04
BLOCK
THE INABILITY OF CHRONIC MIANSERIN TO BLOCK CENTRAL ALPHA2-
ADRENOCEPTORS.
001492 02-03
DIPHENYLHYDANTOIN-INDUCED BLOCK OF THE RAT PHRENIC-NERVE
DIAPHRAGM PREPARATION PRETREATED WITH P
HYDROXYMERCURIBENZOATE.
002749 03-03
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND
GANGLIONIC SYNAPSES.
002870 03-03
WHY DOES SULPIRIDE NOT BLOCK THE EFFECT OF DOPAMINE ON THE
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE?
004055 04-03
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND
CONDITIONED TASTE-AVERSION.
004121 04-04
S-60
VOLUME 19, SUBJECT INDEX
Subject Index
KLOCKADE
BLOCKADE OF METHAMPHETAMINE-INDUCED DEPRESSION OF TYROSINE-
HYDROXYLASE BY GABA-TRANSAMINASE INHIBITORS.
000130 01-03
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE
ACTION.
000229 01-03
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: REUTION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS.
000258 01-03
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND
L-AMPHETAMINE: NO INTERACTION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES.
000387 01-04
EXTINCTION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMITTENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL
EQUIVALENCE.
000490 01-04
THE BLOCKADE OF ALPHA2-ADREN0CEPT0RS BY THE PNMT INHIBITOR
SKF-64139
001255 02-03
DOPAMINE-RECEPTOR BLOCKADE IN RAT-BRAIN AFTER ACUTE AND
SUBCHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANTS.
001314 02-03
PSYCHOTROPIC-DRUG BLOCKADE OF HISTAMINE Hl-RECEPTORS.
001432 02-03
ACTH MEDIATION OF LEARNED-FEAR: BLOCKADE BY NALOXONE AND
NALTREXONE.
001597 02-04
MOTOR-AQIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF
COCAINE: CORRELATION WITH DOPAMINE UPTAKE BLOCKADE.
001650 02-04
DOPAMINE-RECEPTOR BLOCKADE BY IMIDOLINE AND ITS PROPOSED
ACTIVE CONFORMATION.
001687 02-04
OPIOID BLOCKADE AND SOCIAL-COMFORT IN CHICKS.
001745 02-04
HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY
UNILATERAL 6 OHDA INJECTIONS INTO SUBSTANTIA-NIGRA AND
CAUDATE-NUCLEUS.
001778 02-04
THE ROLE OF DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC AGONISTS
IN CHLORPROMAZINE-INDUCED HYPOTENSION.
001851 02-05
BEHAVIORAL-EFFEaS AND SUBJECTIVE-EFFECTS OF BETA-ADRENERGIC
BLOCKADE IN PHOBIC-SUBJEaS.
002060 02-10
DURING ONE YEARS NEUROLEPTIC TREATMENT IN RATS STRIATAL
DOPAMINE-RECEPTOR BLOCKADE DECREASES BUT SERUM PROLACTIN
LEVELS REMAIN ELEVATED.
002707 03-03
NALOXONE REVERSAL OF THE PENTOBARBITAL-INDUCED BLOCKADE OF
OVULATION IN THE RAT.
002817 03-03
PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFECTS OF
GANGLIONIC AND ADRENORECEPTOR BLOCKADE.
002863 03-03
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF-
STIMULATION MODEL USING CLONIDINE.
003016 03-04
BLOCKADE OF ENDOGENOUS OPIATES REDUCES ACTIVITY IN THE RAT.
003111 03-04
NEUROLEPTIC MALIGNANT-SYNDROME: A PATHOGENETIC ROLE FOR
DOPAMINE-RECEPTOR BLOCKADE?
003492 03-15
BLOCKADE BY L LYSINE OF NONNARCOTIC ANALGESICS.
003857 04-03
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA-
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL
UPTAKE.
003879 04-03
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE
REVERSAL OF GUANETHIDINE BLOCKADE OF ADRENERGIC NEURONS.
003900 04-03
4 AMINOPYRIDINE BLOCKADE OF NEURONAL DEPRESSANT RESPONSES TO
ADENOSINE-TRIPHOSPHATE.
003963 04-03
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA-
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER).
003998 04-03
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C-
GMP) ACCUMULATION IN NEUROBL^STOMA CELLS BY CALCIUM-
CHANNEL BLOCKADE.
004020 04-03
PHYSIOLOGICAL SIGNIFICANCE OF DOPAMINEAUTORECtPIORS AS
STUDIED FOLLOWING THEIR SELECTIVE BLOCKADE BY MOLINDONE
004065 0404
BLOCKADE BY IMIPRAMINE OR DESIPRAMINE OF PANIC-INDUCED BY
SODIUM-LACTATE.
004427 04-10
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
LOAD.
004600 04-15
BLOCKER
HYPERVENTILATION-SYNDROME AND BETA-RECEPTOR FUNCTION -
CLINICAL-EFFECT OF BETA BLOCKER UPON THE SYNDROME.
004459 04-11
BLOCKERS
ACUTE VERSUS CHRONIC EFFECTS OF SEROTONIN UPTAKE BLOCKERS ON
POTENTIATION OF THE SEROTONIN SYNDROME.
000050 01-03
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE:
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER
SEROTONIN UPTAKE BLOCKERS.
000316 01-03
THE EFFECTS OF MUSCARINIC-RECEPTOR BLOCKERS ON THE TURNOVER-
RATE OF ACETYLCHOLINE IN VARIOUS REGIONS OF THE RAT-BRAIN.
000328 01-03
INHIBITION OF i3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS.
000330 01-03
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON
CHLORPROMAZINE-INDUCED ELEVATION OF PLASMA GLUCOSE AND
CYCLIC-AMP IN FED MICE.
003946 04-03
EFFECT OF NOREPINEPHRINE UPTAKE BLOCKERS ON NOREPINEPHRINE
KINETICS.
004506 04-13
BLOCKING
MIANSERIN: DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS
BY BLOCKING ALPHA2-RECEPT0RS
001214 02-03
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMITTER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS.
003182 03-08
BLOCKING-AGENT
EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS.
001570 02-04
BLOCKING-AGENTS
THE INFLUENCE OF 5 HT-RECEPTOR BLOCKING-AGENTS ON THE
BEHAVIORAL-EFFECTS OF ANALGESICS IN RATS.
000429 01-04
METOCLOPRAMIDE AND SULPIRIDE AS SELECTIVE BLOCKING-AGENTS
PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS.
001102 02-03
AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION
IN RATS: EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING-
AGENTS.
001531 02-03
ROLE OF ADRENERGIC BLOCKING-AGENTS AND GLUCOCORTICOIDS ON
THE REGULATION OF PITUITARY OPIOID-PEPTIDES LEVELS.
003801 04-03
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH
UNILATERAL NIGROSTRIATAL LESIONS.
004117 04-04
BLOCKING-DRUG
THE EFFECT OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON
THE STIMULANT AND ANORECTIC-ACTIONS OF DEXTROAMPHETAMINE
IN MAN.
004580 04-14
BLOCKING-DRUGS
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS.
000520 01-05
INTERACTION OF HISTAMINE H2-RECEPT0R BLOCKING-DRUGS WITH THE
NORADRENERGIC SYSTEM IN RAT-BRAIN AND HEART.
001397 02-03
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS.
002071 02-10
SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKING-DRUGS: A
METHODOLOGICAL-PROBLEM.
002395 02-15
u.
S-61
Subject Index
Psychopharmacology Abstracts
BLOCKS
PREEXPOSURE TO DELTA9 THC BLOCKS THC-INDUCEO CONDITIONED
TASTE-AVERSION IN RATS.
001618 02-04
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS.
002700 03-03
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOLLUSCAN
NEURONS.
003834 04-03
NEUROTENSIN BLOCKS CERTAIN AMPHETAMINE-INDUCED BEHAVIOURS.
004111 04-04
BLOOD
COMPARISON OF BLOOD AND BILE LEVELS OF OXYPROTHEPIN AND
DOCLOXYTHEPIN IN RATS.
000242 01-03
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH
ANTIEPILEPTIC-DRUGS. „„„,„.„,,,
000695 01-11
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIRECT VASODILATOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRICTION . ^ „^ „^
001109 02-03
EFFECT OF PAPAVERINE ON REGIONAL CEREBRAL BLOOD FLOW AND
SMALL VESSEL BLOOD CONTENT .
001177 02-03
EFFECTS OF RATE OF BLOOD FLOW ON FRACTIONAL EXTRACTION AND ON
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN
VIVO.
001231 02-03
DIFFERENTIAL-EFFECTS OF VARIOUS STIMULI ON AVP LEVELS IN BLOOD
AND CEREBROSPINAL-FLUID. ^
001370 02-03
THE EFFECT OF SODIUM-SALICYLATE ON CEREBRAL BLOOD FLOW AND
METABOLISM. „„,.,, ^o«o
001416 02-03
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD
ETHANOL LEVELS IN RATS' DRINKING A LIQUID DIET.
001865 02-06
ENDOGENOUS DEPRESSION AND IMIPRAMINE LEVELS IN THE BLOOD.
001979 02-09
BLOOD LEVEL OF AMITRIPTYLINE, NORTRIPTYLINE, NORADRENALINE,
SEROTONIN AND THERAPEUTIC RESPONSE
002057 02-09
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS.
002071 02-10
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE
INTOXICATION.
002210 02-13
CARDIOVASCULAR-EFFECTS OF THERAPEUTIC DOSES OF TRICYCLIC-
ANTIDEPRESSANTS: IMPORTANCE OF BLOOD LEVEL MONITORING.
002456 02-15
NEUROLEPTIC BLOOD LEVELS AND THERAPEUTIC EFFEQ.
002480 02-16
HALOPERIDOL STIMULATION OF PROLACTIN SECRETION: HOW MANY
BLOOD SAMPLES ARE NEEDED TO DEFINE THE HORMONE RESPONSE?
002505 02-16
THE CHANGE OF BLOOD PROLACTIN LEVEL DUE TO THE WITHDRAWAL OF
MAINTENANCE NEUROLEPTICS.
002559 02-17
STUDY OF METABOLISM AND BLOOD LEVELS OF ANTIDEPRESSANTS:
TOWARDS A RATIONALIZATION OF THEIR THERAPEUTIC USE.
002625 02-17
STEADY- STATE LITHIUM BLOOD LEVEL FLUCTUATIONS IN MAN
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FORM.
003151 03-07
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME.
003189 03-08
CORRELATIONS BETWEEN LITHIUM LEVELS IN CEREBROSPINAL-FLUID AND
LITHIUM LEVELS IN BLOOD PLASMA AND ERYTHROCYTES.
003210 03-09
RELATIONSHIP BETWEEN BLOOD CONCENTRATIONS AND CLINICAL-
EFFEaS OF A NEW ANTIDEPRESSANT MAPROTILINE.
003271 03-09
ON THE ANTICONVULSANT BLOOD LEVEL IN THERAPY-RESISTANT
EPILEPTIC-PATIENTS. „„„^„„ „„ , ,
003300 03-11
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE
HYPERAQIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN
DEFICIENCY HYPOTHESIS . _ „ , ,
003312 03-11
PHENYTOIN CONCENTRATIONS IN VENOUS VERSUS CAPILLARY BLOOD OF
GERIATRIC-PATIENTS.
003381 03-1 1
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION.
003419 03-13
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS:
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD.
003556 03-16
FIRST RESULTS OF AN ORIGINAL METHOD FOR MEASURING BLOOD
LEVELS OF ANTIDEPRESSANTS (AMITRIPTYLINE AND NORTRIPTYLINE).
003559 03-16
THERAPEUTIC INTEREST OF BLOOD LEVELS DETERMINATION FOR
ANTIDEPRESSANTS: METHODOLOGICAL APPROACH.
003571 03-16
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN
INDIRECT ADRENERGIC CHOLINERGIC INTERACTION.
003887 04-03
EFFECTS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE-
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC
BUNDLE IN THE RAT.
003910 04^3
THE EFFEQS OF NEFOPAM ON BLOOD ACID BASE STATUS IN THE RABBIT:
INTERACTIONS WITH MORPHINE IN THE MOUSE AND RABBIT.
004279 04-05
CHANGES IN BLOOD PLASMA OSMOLALITY AND STATES OF MANIA.
004352 04-09
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE.
004356 04-09 ;
BLOOD LEVEL MEASUREMENTS OF TRICYCLIC DRUGS AS A DIAGNOSTIC 1
TOOL.
004368 04-09 ,
CORREQION OF THE EXTRAPYRAMIDAL NEUROLEPTIC-SYNDROME BY
TRYPTOPHAN AND THE TIME-COURSE OF ITS CONTENT IN THE BLOOD
OF PATIENTS.
004434 04-11 :
THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE
PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION
WITH PHYTOHEMAGGLUTININ.
004541 04-13
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD :
BY USE OF SELEa ION-MONITORING AND DEUTERATED INTERNAL
STANDARDS
004690 04-16
COMPARISON OF SPEaROFLUOROMETRIC AND GAS-
CHROMATOGRAPHY/MASS-SPEaROMETRY PROCEDURES FOR THE
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN.
004692 04-16
BLOOD-BRAIN-BARRIER
THE BLOOD-BRAIN-BARRIER IN ADRENALINE-INDUCED HYPERTENSION.
000147 01-03
DOSE-DEPENDENT, AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND
SPONTANEOUSLY HYPERTENSIVE-RATS.
001197 02-03
INFLUENCE OF RESPIRATORY STRESS AND HYPERTENSION UPON THE ,
BLOOD-BRAIN-BARRIER. ^ „ ^^ „,
001437 02-03
TRANSPORT OF NEUTRAL AMINO-ACIDS AT THE BLOOD-BRAIN-BARRIER
002764 03-03
INDICATIONS FOR A BRAIN UPTAKE OF LABELLED VASOPRESSIN AND
OCYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER
003669 04-01
H2-RECEPT0RS MEDIATE INCREASES IN PERMEABIUTY OF THE BLOOD-
BRAIN-BARRIER DURING ARTERIAL HISTAMINE INFUSION.
003817 04-03
PASSAGE THROUGH THE BLOOD-BRAIN-BARRIER OF THYROTROPIN-
RELEASING-HORMONE ENCAPSULATED IN LIPOSOMES.
004298 04-06
BLOOD-PLATELET
THE AQIVITY OF BLOOD-PLATELET MONOAMINE-OXIDASE IN
ENDOGENOUS DEPRESSION. ^..-,„. ,,
004547 04-13
BLOOD-PLATELETS , „
LITHIUM LEVELS IN BLOOD-PIATELETS, SERUM, RED-BLOOD-CELLS AND
BRAIN REGIONS IN RATS GIVEN ACUTE OR CHRONIC UTHIUM-SALT
TREATMENTS. „„^„„ „, no
000082 01-03
PROPERTIES OF (3H)DIAZEPAM BINDING-SITES ON RAT BLOOD-
P^^^^^^- 000317 01^3
DECREASED UPTAKE OF 5 HYDROXYTRYPTAMINE IN BLOOD-PLATELETS
FROM PATIENTS WITH ENDOGENOUS DEPRESSION.
000637 01-09
S-62
y^OLUME 19, SUBJECT INDEX
Subject Index
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPT AMINES:
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY
HUMAN BLOOD-PLATELETS.
001067 02-02
EFFECT OF DOXEPIN ON SEROTONIN METABOLISM IN RAT-BRAIN AND
SEROTONIN UPTAKE BY HUMAN BLOOD-PLATELETS.
002243 02-13
LIBERATION OF CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE FROM
HUMAN BLOOD-PLATELETS.
003967 04-03
ILOOD-PRESSURE
EFFECT OF GABA ANALOGUES ON BLOOD-PRESSURE AND CENTRAL GABA
METABOLISM IN THE RAT.
000231 01-03
CENTRAL BLOOD-PRESSURE EFFECTS OF GUANYLYLIMIDODIPHOSPHATE
ANDCYCLIC-GUANOSINE-MONOPHOSPHATE.
000266 01-03
TYROSINE ADMINISTRATION REDUCES BLOOD-PRESSURE AND ENHANCES
BRAIN NOREPINEPHRINE RELEASE IN SPONTANEOUSLY HYPERTENSIVE-
RATS.
000296 01-03
HALLUCINATORY AND DELUSIONAL-STATES IN CONNECTION WITH BLOOD-
PRESSURE AND EEG.
000814 01-14
EFFECT OF PROSTAGLANDINS ON PLASMA CATECHOLAMINES, HEART
AND BLOOD-PRESSURE RESPONSES TO HEMORRHAGE. (UNPUBLISHED
PAPER).
001223 02-03
NALOXONE EFFECTS ON THE BLOOD-PRESSURE RESPONSE INDUCED BY
THIN-FIBER MUSCULAR AFFERENTS.
002794 03-03
COVARIANCE OF PLASMA FREE 3 METHOXY-4-
HYDROXYPHENETHYLENEGLYCOL AND DIASTOLIC BLOOD-PRESSURE.
003418 03-13
BLOOD-PRESSURE AND COGNITIVE FUNCTIONING.
004492 04-11
^LOOD-PRESSURES
NICOTINE INGESTION REDUCES ELEVATED BLOOD-PRESSURES IN RATS
AND SQUIRREL-MONKEYS.
002759 03-03
lOOIES
EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC-
SYSTEMS IN THE RAT-BRAIN.
001464 02-03
lODY
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS,
001096 02-03
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJECTION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS.
001446 02-03
COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION
IN THE RAT MODEL.
002928 03-03
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
iODY-TEMPERATURE
EFFECTS OF GAMMA HYDROXYBUTYRIC-ACID ON METABOLIC
RESPIRATORY AND VASOMOTOR ACTIVITIES AND BODY-
TEMPERATURE IN RATS.
000189 01-03
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL
DAMAGE.
000322 01-03
EFFECTS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS:
RELATION TO MICROSOMAL BIOTRANSFORMATION AND
DOPAMINERGIC-RECEPTOR STIMULATION.
001161 02-03
THE MECHANISM-OF-ACTION OF DELTA9 TETRAHYDROCANNABINOL ON
BODY-TEMPERATURE IN MICE.
001190 02-03
COMPARISON OF THE EFFECTS OF CENTRAL ADMINISTRATION OF SERINE
AND GLYCINE ON BODY-TEMPERATURE OF THE RABBIT.
001248 02-03
AGE-RELATED CHANGES IN BODY-TEMPERATURE RESPONSES TO
MORPHINE IN RATS.
001366 02-03
PHENOBARBITAL EFFECTS ON WEIGHT-GAIN AND CIRCADIAN-CYCLING OF
FOOD INTAKE AND BODY-TEMPERATURE.
001409 02-03
EFFECTS OF KAINIC-ACID ON BODY-TEMPERATURE OF RATS: ROLE OF
CATECHOLAMINERGIC AND SEROTONERGIC SYSTEMS
001515 02-03
THE EFFECTS OF BOMBESIN INJECTED INTO THE ANTERIOR AND
POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN
CONSUMPTION.
001544 02-03
CHRONIC DELTA9 TETRAHYDROCANNABINOL IN RATS: EFFECT ON
SOCIAL-INTERACTIONS, MOUSE-KILLING, MOTOR-ACTIVITY,
CONSUMMATORY-BEHAVIOR, AND BODY-TEMPERATURE
001722 02-04
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF
ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS
INCLUDING ANTIDEPRESSANTS.
002532 02-17
INTERACTION BETWEEN THE EFFECTS OF STRESS AND MORPHINE ON
BODY-TEMPERATURE IN RATS.
002906 03-03
THE EFFECT OF PHARMACOLOGICAL DESTRUCTION OF HYPOTHALAMIC
MONOAMINERGIC STRUCTURES ON BODY-TEMPERATURE AND GAS-
EXCHANGE DURING EXTREME COOLING.
004016 04-03
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND
BODY-TEMPERATURE CHANGES IN RATS.
004238 04-04
REVERSIBLE RING-OPENING REACTIONS OF NIMETAZEPAM AND
NITRAZEPAM IN ACIDIC MEDIA AT BODY-TEMPERATURE.
004517 04-13
BODY-WEIGHT
BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH
KAINIC-ACID-INDUCED LESIONS OF STRIATAL NEURONS - WITH A
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS-
DISEASE.
000463 01-04
EFFECTS OF BODY-WEIGHT LEVELS ON CANNABIS SELF-INJECTION.
001801 02-04
BODY-WEIGHT AND RESPONSES TO LHRH INFUSION IN ANOREXIA-
NERVOSA,
002062 02-10
BENZODIAZEPINES CAUSE SMALL LOSS OF BODY-WEIGHT.
002446 02-15
SUSTAINED INTRACEREBROVENTRICULAR INFUSION OF BRAIN FUELS
REDUCES BODY-WEIGHT AND FOOD INTAKE IN RATS.
004098 04-04
BOLUS
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS
ADMINISTRATIONS.
002797 03-03
BOMBESIN
THE EFFECTS OF BOMBESIN INJECTED INTO THE ANTERIOR AND
POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN
CONSUMPTION.
001544 02-03
BOMBESIN PRODUCES TASTE-AVERSION IN RATS.
002702 03-03
THE EFFECTS OF INJECTIONS OF BOMBESIN INTO THE CEREBRAL
VENTRICLES ON BEHAVIORAL THERMOREGULATION.
002952 03-04
BOMBESIN ALTERS BEHAVIORAL THERMOREGULATION IN FISH.
003026 03-04
ENHANCEMENT OF ETHANOL-INDUCED SEDATION AND HYPOTHERMIA BY
CENTRALLY ADMINISTERED NEUROTENSIN, BETA ENDORPHIN AND
BOMBESIN.
003037 03-04
BOMBESIN INHIBITS STRESS-INDUCED EATING.
003059 03-04
BOMBESIN-LIKE-PEPTIDES
BIOCHEMICAL-LOCALIZATION AND CHARACTE'^'ZATION OF BOMBESIN-
LIKE-PEPTIDES IN DISCRETE REGIONS OF RAl -BRAIN. (UNPUBLISHED
PAPER).
001046 02-01
BONDS
COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE
BONDS.
003927 04-03
BORDERLINE-CHILDREN
IMIPRAMINE TREATMENT OF BORDERLINE-CHILDREN: CASE-REPORTS
WITH A CONTROLLED-STUDY.
003356 03-11
BORDERLINE-PATIENT
THE INTERACTION OF PSYCHOPHARMACOLOGY AND PSYCHOANALYSIS IN
THE BORDERLINE-PATIENT.
004430 04-10
BORDERLINE-SYNDROMES
EXTRAPYRAMIDAL-DISORDERS AND BORDERLINE-SYNDROMES:
EREDOATAXIAS AND DEMENTIA.
003518 03-15
BORN
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS.
004658 04-15
■t:
5?;:
«
«<».
S-63
Subject Index
Psychopharmacology Abstracts
BOUND
ISOLATION OF SELECTIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES,
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE.
001162 02-03
DISSOCIATION BETWEEN FREE AND BOUND PHENYTOIN LEVELS IN
PRESENCE OF SODIUM-VALPROATE.
003367 03-11
BOVINE
ESR STUDIES OF SPIN LABELLED BOVINE LIVER MONOAMINE-OXIDASE-B.
(UNPUBLISHED PAPER).
001065 02-01
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL
GROUPS IN THE ACTIVE SITE (UNPUBLISHED PAPER).
001066 02-01
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES.
001208 02-03
DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM
BOVINE CEREBRAL-CORTEX.
002645 03-01
PHYSICAL AND KINETIC PROPERTIES OF CHOLINE-ACETYL-TRANSFERASE
FROM RAT AND BOVINE BRAIN.
003676 04-01
CU-AMINE-OXIDASES: STUDIES RELATED TO THE MECHANISM-OF-ACTION
OF BOVINE PLASMA AMINE-OXIDASE (UNPUBLISHED PAPER).
003680 04-01
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE
CAUDATE; ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRACTION.
003948 04-03
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID-
RECEPTOR AGONIST, TO MEMBRANES OF THE BOVINE RETINA
003954 04-03
ELECTROPHYSIOLOGICAL-EFFECTS OF IMIPRAMINE ON BOVINE
VENTRICULAR-MUSCLE AND PURKINJE-FIBRES.
003988 04-03
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE
PITUITARY MEMBRANES.
004003 04-03
BOYS
EFFECTS OF METHYLPHENIDATE ON SELECTIVE AND SUSTAINED
ATTENTION IN HYPERACTIVE, READING-DISABLED, AND PRESUMABLY
ATTENTION-DISORDERED BOYS.
002118 02-11
ACUTE EFFECTS OF CAFFEINE IN NORMAL PREPUBERTAL BOYS.
003310 03-11
EFFECT OF PIRACETAM ON EEG SPECTRA OF BOYS WITH LEARNING-
DISORDERS.
003383 03-1 1
BRADYCARDIA
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS.
000520 01-05
BRADYCARDIA, PERSISTENT DIABETES-INSIPIDUS, AND TARDIVE-
DYSKINESIA WITH LITHIUM INTOXICATION
002427 02-15
MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS.
003744 04-03
EFFECTS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC-
ACID, HALOPERIDOL AND PIMOZIDE ON REFLEX BRADYCARDIA IN
RATS.
004085 04-04
BRADYKININ
CENTRALLY INDUCED CARDIOVASCULAR AND SYMPATHETIC-NERVE
RESPONSES TO BRADYKININ IN RATS.
003099 03-04
BRADYKININ-LIKE
INHIBITORY ACTION OF MORPHINE ON THE RELEASE OF A BRADYKININ-
LIKE SUBSTANCE AFTER SCIATIC-NERVE STIMULATION.
001293 02-03
BRADYKININ-RECEPTOR
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
BRAIN
OXAZEPAM-ESTERS. 1. CORRELATION BETWEEN HYDROLYSIS RATES AND
BRAIN APPEARANCE OF OXAZEPAM.
000010 01-02
OXAZEPAM-ESTERS. 2. CORRELATION OF HYDROPHOBICITY WITH SERUM
BINDING, BRAIN PENETRATION, AND EXCRETION.
000011 01-02
PHARMACOLOGICAL ACTIVITIES OF CLOBAZAM AND DIAZEPAM IN THE
RAT: RELATION TO DRUG BRAIN LEVELS.
000036 01-03
RELATIONSHIP OF ANTICONFLICT ACTIVITY OF BENZODIAZEPINES TO
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA.
000057 01-03
ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS.
(UNPUBLISHED PAPER).
000060 01-03
HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO
GUINEA-PIG BRAIN.
000061 01-03
CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN
MEMBRANES.
000062 01-03
EFFECTS OF LEAD ON MOVEMENT OF ALBUMIN INTO BRAIN.
000076 01-03
LITHIUM LEVELS IN BLOOD-PLATELETS, SERUM. RED-BLOOD-CELLS AND
BRAIN REGIONS IN RATS GIVEN ACUTE OR CHRONIC LITHIUM-SALT
TREATMENTS.
000082 01-03
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT
PROPERTIES.
000084 01-03
RELATIONSHIPS BETWEEN SEIZURE ACTIVITY AND CYCLIC-NUCLEOTIDE
LEVELS IN BRAIN.
000089 01-03
INHIBITORY-EFFECTS OF ANTICONVULSANT-DRUGS ON CYCLIC-
NUCLEOTIDE ACCUMULATION IN BRAIN.
000090 01-03
ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE
AND DESMETHYLIMIPRAMINE 1
00011301-03 1
ACTIONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID :
METABOLISM IN GUINEA-PIG BRAIN SLICES
000129 01-03
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFEQS
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES
000131 01-03
EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA-
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN.
000135 01-03
REUPTAKE OF BIOGENIC-AMINES BY BRAIN SLICES: EFFEQ OF
HYDROCORTISONE.
000187 01-03
SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM IN BRAIN: EFFECTS OF NISOXETINE
VERSUS FLUOXETINE.
000208 01-03
THE MECHANISM OF EFFECT OF NEUROPHARMACOLOGICAL-DRUGS VI: ,
EFFECT OF NORADRENALINE AND 5 HYDROXYTRYPTAMINE ON BRAIN
FREE FATTY-ACIDS
000274 01-03
LONG-TERM EFFEQS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN
MICE.
000287 01-03
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
TYROSINE ADMINISTRATION REDUCES BLOOD-PRESSURE AND ENHANCES
BRAIN NOREPINEPHRINE RELEASE IN SPONTANEOUSLY HYPERTENSIVE-
RATS.
000296 01-03
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS.
000308 01-03
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE-
BEHAVIOR: INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON
THREE EXPERIMENTAL MODELS.
000340 01-04
POSTINGESTION INTERFERENCE WITH BRAIN FUNCTION PREVENTS
AHENTUATION OF NEOPHOBIA IN RATS.
000352 01-04
HANDLING IN INFANCY, TASTE-AVERSION, AND BRAIN LATERALITY IN
RATS.
000375 01-04
CHANGES IN BRAIN N DEMETHYLATION AND OPIATE-RECEPTOR CONTENT
CORRELATE WITH ANALGESIC EFFECTIVENESS OF MORPHINE
000400 01-04
INFLUENCE OF NICERGOLINE ON MOLECULAR BIOLOGICAL PROCESSES IN
THE BRAIN AND LEARNING-ABILITY OF THE RAT.
000449 01-04
S-64
VOLUME 19, SUBJECT INDEX
Subject Index
RELATIONSHIP BETWEEN DELTA9 TETRAHYDROCANNABINOL-INDUCED
MOUSE-KILLING-BEHAVIOR ON THE RAT AND THE METABOLISM OF
MONOAMINES IN THE BRAIN, PARTICULARLY THE OLFACTORY-BULB.
000472 01-04
BRAIN FUNCTION IN OLD-AGE: EVALUATION OF CHANGES AND
DISORDERS
000684 01-11
INFLUENCING BRAIN CONCUSSION BY NOOTROPIL.
000724 01-11
ELECTRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFECTS OF
HIGH-FREQUENCY STIMULATION ON DENDRITIC ULTRASTRUCTURE.
(UNPUBLISHED PAPER).
001036 02-01
ASSAYING GABA-MODULIN ACTIVITY IN BRAIN EXTRACTS: RESOLUTION
OF INHERENT DIFFICULTIES. (UNPUBLISHED PAPER).
001045 02-01
COMPARISON OF CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE (CSD)
ISOENZYMES AND GLUTAMIC-ACID-DECARBOXYLASE (GAD) IN RAT: IS
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH
GAD? (UNPUBLISHED PAPER).
001048 02-01
HISTAMINE-RECEPTORS IN THE BRAIN: CHARACTERIZATION BY BINDING
STUDIES AND BIOCHEMICAL-EFFECTS.
001054 02-01
THE EFFECT OF PHENELZINE AND SOME OF ITS PARA HALOGENATED
DERIVATIVES ON THE LEVELS OF BRAIN TYRAMINE AND OCTOPAMINE
IN THE MOUSE.
001077 02-02
DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN
FRAGMENTS OF MALE AND FEMALE RATS.
001121 02-03
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST,
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
LACK OF INFLUENCE OF BRAIN CATECHOLAMINES ON ACUTE EFFECTS OF
BARBITURATES.
001138 02-03
INTERACTION OF BIOGENIC-AMINE SYSTEMS IN BRAIN. (UNPUBLISHED
PAPER).
001141 02-03
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA.
(UNPUBLISHED PAPER).
001147 02-03
BRAIN SEROTONIN AND 5 HYDROXYINDOLEACETIC-ACID
CONCENTRATIONS AND SEROTONIN SYNTHESIS FOLLOWING
TETRAHYDRO-BETA-CARBOLINE ADMINISTRATION IN MICE.
001152 02-03
ROLE OF PROTEIN-KINASES IN OPIATE ACTIONS IN BRAIN.
001173 02-03
EFFECT OF TABERNANTHINE ON THE TURNOVER TIME OF BRAIN
CATECHOLAMINES IN NORMAL AND HYPOBARIC HYPOXIC RATS.
001187 02-03
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION).
001213 02-03
MIANSERIN: DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS
BY BLOCKING ALPHA2-RECEPT0RS.
001214 02-03
EFFECT OF LITHIUM ON STRESS-INDUCED CHANGES IN THE BRAIN LEVELS
OF MONOAMINES IN RATS.
601216 02-03
LITHIUM-INDUCED CHANGES IN THE BRAIN LEVELS OF FREE AMINO-ACIOS
IN STRESS-EXPOSED RATS.
001217 02-03
TRYPTOPHOL-INDUCED CHANGE IN BRAIN 5 HYDROXYTRYPTAMINE
METABOLISM.
001236 02-03
EFFECTS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE.
001243 02-03
THE BINDING OF SOME ANTIDEPRESSANT-DRUGS TO BRAIN MUSCARINIC
ACETYLCHOLINE-RECEPTORS .
001253 02-03
SEX-DIFFERENCE IN BRAIN IRON. (UNPUBLISHED PAPER).
001278 02-03
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 02-03
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION.
001300 02-03
DOWN REGULATION OF DIHYDROALPRENOLOL AND IMIPRAMINE
BINDING-SITES IN BRAIN OF RATS REPEATEDLY TREATED WITH
IMIPRAMINE
001317 02-03
INTERACTION OF TRIAZOLAM WITH DESIPRAMINE: EFFECTS OF SINGLE
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC-
RESPONSES AND BRAIN CATECHOLAMINE LEVELS.
001323 02-03
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFECT
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE
001353 02-03
SUBCELLULAR REACTION OF THE BRAIN TO HYPOXIA.
001354 02-03
FURTHER CHARACTERIZATION OF THE BINDING OF SUBSTANCE-P TO A
FRACTION FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES.
001394 02-03
MODIFICATION OF DOPAMINE-RECEPTORS IN BRAIN BY CONTINUOUS
AMPHETAMINE ADMINISTRATIONS TO RATS.
001395 02-03
BRAIN STRIATAL TYROSINE-HYDROXYLASE: ACTIVATION OF THE ENZYME
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION.
001423 02-03
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR
THE POTENTIATION OF IMIPRAMINE EFFECTS ON THE METABOLISM
AND UPTAKE OF BRAIN CATECHOLAMINES.
001427 02-03
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE ACTION OF
DIAZEPAM: POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE
ACTION IN THE BRAIN
001428 02-03
THE EFFECT OF CLOFELIN ON THE BIOELECTRIC-ACTIVITY OF THE BRAIN.
001449 02-03
PROSTAGLANDINS IN THE BRAIN OF RATS GIVEN, ACUTELY, AND
CHRONICALLY, A HYPERTHERMIC-DOSE OF MET-ENKEPHALIN.
001468 02-03
THE EFFECTS OF PIRACETAM ON FREE FAHY-ACIDS IN THE BRAIN.
001474 02-03
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND
TOLERANT RATS AND MICE.
001476 02-03
GLUCOCORTICOIDS AS A REGULATORY FACTOR FOR BRAIN TRYPTOPHAN-
HYDROXYLASE DURING DEVELOPMENT.
001500 02-03
ANTIDEPRESSANT-DRUGS SLOW CIRCADIAN-RHYTHMS IN BEHAVIOR AND
BRAIN NEUROTRANSMITTER-RECEPTORS.
001536 02-03
BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE-
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL-
CONSIDERATIONS.
001550 02-03
(3H) PHENCYCLIDINE BINDING TO SPECIFIC BRAIN RECEPTOR SITES.
001555 02-03
BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFECTS OF CHRONIC
AMPHETAMINE INTOXICATION.
001653 02-04
BRAIN CATECHOLAMINES MODIFICATIONS. THE EFFECTS ON MEMORY
FACILITATION INDUCED BY OXOTREMORINE IN MICE.
001658 02-04
DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT-
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL-
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS.
001726 02-04
ENHANCED BEHAVIOURAL-EFFECTS, ELECTROCORTICAL-EFFECTS AND
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN.
001733 02-04
PLASMA AND BRAIN LEVELS OF DELTA6 THC AND SEVEN
MONOOXYGENATED METABOLITES CORRELATED TO THE CATALEPTIC-
EFFECT IN THE MOUSE.
001737 02-04
CHANGES OF PHYSICAL MORPHINE-DEPENDENCE IN RATS CHRONICALLY
TREATED WITH DRUGS ACTING ON BRAIN 5 HYDROXYTRYPTAMINE.
001764 02-04
P CHLOROAMPHETAMINE: EVALUATION OF A BRAIN METABOLITE.
001779 02-04
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE
DEVELOPMENT OF DEPENDENCE IN RATS.
001800 02-04
EFFECT OF L FUCOSE ON BRAIN PROTEIN METABOLISM AND RETENTION
OF A LEARNED-BEHAVIOR IN RATS.
001819 02-04
REGIONAL CHANGES IN BRAIN GLUCOSE UTILIZATION IN RATS GIVEN A
PYRETHROID INSECTICIDE.
001838 02-05
I
a.
J
is
"I*
it:
S-65
Subject Index
EFFECTS OF 1,3 BIS-TETRAHYDRO-2-FURANYL-5-
FLUOROPYRIMIDINEDIONE (FD-1) ON THE CENTRAL-NERVOUS- SYSTEM:
1 EFFECTS OF MONOAMINES IN THE BRAIN.
001857 02-05
THE IN VITRO BRAIN SLICE AS A USEFUL NEUROPHYSIOLOGICAL
PREPARATION FOR INTRACELLULAR RECORDING.
001864 02-06
ESTIMATING IN VIVO THE TURNOVER-RATE OF BRAIN ENKEPHALINS.
001884 02-06
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFECT IN SCHIZOPHRENIA AND
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO
NEUROLEPTIC-MEDICATION. ^ ^ , „^ „„
001911 02-08
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN
HUNTINGTONS-DISEASE. „^^, ,. „o , ,
002163 02-11
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN
MAN: POSSIBLE CENTRAL-ACTION IN BRAIN.
002195 02-12
SPECIES-DIFFERENCES IN THE DEAMINATION OF DOPAMINE AND OTHER
SUBSTRATES FOR MONOAMINE-OXIDASE IN BRAIN.
002233 02-13
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL-STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN)
002286 02-13
POSSIBLE INVOLVEMENT OF BRAIN DOPAMINERGIC-SYSTEMS IN THE
EXPRESSION OF EMOTIONS IN DREAMS.
002325 02-14
NOOTROPIC-DRUGS AND RELATED DRUGS INTERACTING WITH THE
INTEGRATIVE ACTIVITY OF THE BRAIN.
002327 02-14
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS,
BRAIN, AND PINEAL-ORGAN OF THE RAT.
002503 02-16
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS,
AND NEUROPHARMACOLOGICAL EVENTS.
002515 02-17
DOPAMINERGIC ABNORMALITIES IN POSTMORTEM SCHIZOPHRENIC
^'""^ 002575 02-17
EVIDENCE THAT IT IS POSSIBLE TO CAUSE ANOREXIA BY INCREASING
RELEASE AND/OR DIRECTLY STIMULATING POSTSYNAPTIC SEROTONIN-
RECEPTORS IN THE BRAIN.
002602 02-17
ANATOMOBIOCHEMICAL MAPPING OF THE BRAIN: NEUROPSYCHIATRIC-
CORRELATIONS.
002630 02-17
THE EFFECT OF BARBITURATES ON THE DEGRADATION OF ENKEPHALIN BY
BRAIN ENZYMES.
002656 03-03
APOMORPHINE HALOPERIDOL INTERACTIONS: DIFFERENT TYPES OF
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS.
002662 03-03
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
002699 03-03
DOPAMINE-RECEPTOR SUPERSENSITIVITY IN THE CORPUS-STRIATUM
FOLLOWING CHRONIC ELEVATION OF BRAIN GAMMA AMINOBUTYRIC-
^^'°' 002716 03-03
EFFECT OF MAZINDOL ON BRAIN DOPAMINE TURNOVER IN SPIPERONE
TREATED RATS.
002726 03-03
EFFECT OF NEUROLEPTICS ON INDOLEAMINE-N-METHYLTRANSFERASE
ACTIVITY AND BRAIN METABOLISM OF BUFOTENIN.
002735 03-03
CANNABIS-SATIVA: EFFECTS ON BRAIN FUNCTION AND ULTRASTRUQURE
IN RHESUS-MONKEYS.
002747 03-03
EFFECTS OF LITHIUM ON MORPHOLOGICAL CHARACTERISTICS OF
DISSOCIATED BRAIN CELLS IN CULTURE.
002765 03-03
THE FUNCTIONAL IMPORTANCE OF INCREASED BRAIN TRYPTOPHAN IN
THE SEROTONERGIC RESPONSE TO RESTRAINT STRESS.
002779 03-03
THE EFFECT OF SPECIFIC BRAIN LESIONS ON THE HIGH-AFFINITY BINDING
OF GABA IN THE SUBSTANTIA-NIGRA.
002795 03-03
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED
'^'^^' 002800 03-03
ACTIVATION OF SOLUBLE STRIATAL TYROSINE-HYDROXYLASE IN THE RAT
BRAIN AFTER CDP-CHOLINE ADMINISTRATION.
002816 03-03
Psychopharmacology Abstracts
ANTIANXIETY-AGENTS AND SYNAPTIC TRANSMISSION IN THE BRAIN:
ELECTROPHYSIOLOGICAL- STUDIES. (PHD DISSERTATION).
002840 03-03
BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH-
AVOIDANCE AND LOW-AVOIDANCE RATS.
002852 03-03
EFFECT OF TAURINE ON 45CA2 ACCUMULATION IN RAT BRAIN
SYNAPTOSOMES.
002855 03-03
TWO DISTINCT SEROTONIN-RECEPTORS: REGIONAL VARIATIONS IN
RECEPTOR BINDING IN MAMMALIAN BRAIN.
002861 03-03
BIOELECTRICAL-ACTIVITY OF THE RAT BRAIN AFTER PREMATURE
WEANING AND AFTER RNA ADMINISTRATION.
002865 03-03
PENTOBARBITAL; DUAL-ACTIONS TO INCREASE BRAIN BENZODIAZEPINE-
RECEPTOR AFFINITY.
002896 03-03
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR
BRAIN SPECIFIC BENZODIAZEPINE BINDING
002903 03-03
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNQION IN CAT BRAIN
00291 1 03-03
BRAIN MECHANISMS OF LEARNING.
002916 03-03
EFFECTS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA-
ADRENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES.
002932 03-03
INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN
SUBCELLULAR GANGLIOSIDES: EFFECT OF PENTYLENETETRAZOL-
INDUCED CONVULSIONS IN BRAIN GANGLIOSIDES.
002937 03-03
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPTAMINE AND CATECHOLAMINES; EFFEaS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN.
002990 03-04
INDUCTION OF HYPERSENSITIVITY OF BRAIN BY HYDRALAZINE
TREATMENT IN RATS.
003008 03-04
BEHAVIOURAL-CHANGES IN ADULT RATS FOLLOWING ADMINISTRATION
OF ANTIBODIES AGAINST BRAIN GANGLIOSIDES.
003071 03-04
DIFFERENTIATION OF OPIATE-RECEPTORS IN THE BRAIN BY THE SELEQIVE
DEVELOPMENT OF TOLERANCE.
003088 03-04
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC-
ACID IN BRAIN USING HPLC WITH ELEaROCHEMICAL-OETECTION.
003139 03-06
A NEW METHOD FOR APPLICATION OF HORSERADISH-PEROXIDASE INTO
A RESTRICTED AREA OF THE BRAIN
003141 03-06
MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND
UPTAKE OF NEUROTRANSMinERS IN BRAIN SLICES.
003147 03-06
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION
OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY.
003433 03-13
POSITRON-TOMOGRAPHY. A NEW METHOD FOR IN VIVO BRAIN STUDIES
OF BENZODIAZEPINE, IN ANIMAL AND IN MAN.
003564 03-16
MIND/BRAIN IN THE AGE OF PSYCHOPHARMACOLOGY: A CROSSROADS
FOR MEDICINE AND MINISTRY.
003624 03-17
AaiON ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS
OF TREATING ALCOHOLISM AND DRUG ADDIQION
PATHOGENETICALLY. ^^^ , „^ ,,
003641 03-17
BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF THE MOUSE BRAIN
ENOLASES PURIFIED BY A SIMPLE METHOD.
003668 04-01
INDICATIONS FOR A BRAIN UPTAKE OF LABELLED VASOPRESSIN AND
OCYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER.
003669 04-01
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL
AND PATHOLOGICAL (M. NIEMANN-PICK TYPE C) HUMAN BRAIN.
003671 04-01
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID-
CHROMATOGRAPHY WITH ELEaROCHEMICAL DETEQION.
003674 04-01
PHYSICAL AND KINETIC PROPERTIES OF CHOLINE-ACETYL-TRANSFERASE
FROM RAT AND BOVINE BRAIN. 003676 04-01
A RADIOIMMUNOASSAY FOR EPENDYMINS BETA AND GAMMA: TWO
GOLDFISH BRAIN PROTEINS INVOLVED IN BEHAVIORAL PLASTICITY.
003677 04-01
S-66
VOLUME 19, SUBJECT INDEX
Subject Index
NEURONAL SENSITIVITY OF SOME BRAIN REGIONS TO ANGIOTENSIN-II IN
RABBITS.
003716 04-03
BRAIN BENZODIAZEPINE-RECEPTORS AND THEIR RAPID CHANGES AFTER
SEIZURES IN THE MONGOLIAN-GERBIL.
003717 04-03
INTERACTIONS BETWEEN A MONOFLUORINATED ANALOGUE OF P
CHLOROAMPHETAMINE AND 5 HYDROXYTRYPTAMINE IN BRAIN.
003719 04-03
EFFECT OF ALPHA METHYLPHENYLALANINE AND PHENYLALANINE ON
BRAIN POLYRIBOSOMES AND PROTEIN SYNTHESIS.
003733 04-03
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INOUCED CONVULSIONS
IN RATS.
003736 04-03
MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS.
003744 04-03
EFFECT OF INTRAVENOUS ADMINISTRATION OF D LYSERGIC-ACID-
DIETHYLAMIDE ON SUBSEQUENT PROTEIN SYNTHESIS IN A CELL-FREE
SYSTEM DERIVED FROM BRAIN.
003761 04-03
SOLUBILIZATION OF NEUROLEPTIC/DOPAMINE-RECEPTORS OF HUMAN
BRAIN STRIATUM.
003767 04-03
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFECTS OF
HALOPERIDOL AND PARGYLINE.
003792 04-03
OPPOSITE EFFECTS OF NALOXONE ON SUBSTANCE-P-INDUCED IN BRAIN
DOPA SYNTHESIS AND IN LOCOMOTOR-ACTIVITY IN RATS.
003799 04-03
EFFECTS OF ANTIDEPRESSANT-DRUGS ON DIFFERENT RECEPTORS IN THE
BRAIN.
003824 04-03
COMPARISON OF THE EFFEQ OF INTRAVENOUS ADMINISTRATION OF D
LYSERGIC-ACID-DIETHYLAMIDE ON FREE AND MEMBRANE-BOUND
POLYSOMES IN THE RABBIT BRAIN.
003831 04-03
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO.
003832 04-03
PHARMACOLOGIC MANIPULATION OF BRAIN AND PITUITARY ENDORPHIN
CONTENT AND RELEASE.
003837 04-03
COMPARATIVE-EFFECTS OF SUBSTITUTED PHENYLETHYLAMINES ON BRAIN
SEROTONERGIC MECHANISMS.
003854 04-03
AQION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE
MOUSE AND THE RAT.
003870 04-03
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH.
003882 04-03
OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES:
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES.
003902 04-03
EFFEQ OF INHIBITORS OF GABA-AMINOTRANSFERASE ON THE
METABOLISM OF GABA IN BRAIN TISSUE AND SYNAPTOSOMAL
FRAQIONS.
003914 04-03
EFFEQ OF DIAZEPAM ON STRESS-INDUCED CHANGES IN BRAIN
HISTAMINE.
003932 04-03
THE EFFEQ OF PRENATAL EXPOSURE TO ETHANOL OR OPIATES ON BRAIN
CATECHOLAMINE AQIVITY.
003939 04-03
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN.
003941 04-03
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC-
AMP.
003952 04-03
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMinERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN
REUPTAKE SITES IN BRAIN AND PLATELET?
003962 04-03
STUDIES ON THE MECHANISM-OF-ACTION OF AVERMECTIN-BIA:
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM
BRAIN SYNAPTOSOMES.
003973 04-03
STRESS-MODULATED ALTERATION OF BRAIN BIOGENIC-AMINES IN THE
RAT: EFFECTS OF L TRYPTOPHAN
003978 04-03
EFFECT OF PR0STAGLANDIN-D2, PR0STAGLANDIN-E2 AND
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES
OF RAT AND RABBIT BRAIN.
003983 04-03
PROPERTIES OF A CDP-DIGLYCERIDE-HYDROLASE FROM GUINEA-PIG
BRAIN.
003987 04-03
EFFECT OF PRENATAL NEUROLEPTIC TREATMENT ON MEMBRANE
RECEPTOR DEVELOPMENT IN THE BRAIN,
003989 04-03
THE EFFECT OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELECTRICAL-
ACTIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUCTURES OF
THE RABBIT BRAIN.
003994 04-03
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN
BRAIN CELL-CULTURES.
004002 04-03
THE ROLE OF OPIATE-RECEPTORS OF DIFFERENT BRAIN REGIONS IN
DETERMINING THE EMOTIONAL REACTIONS OF RATS.
004017 04-03
OXIDATION OF BETA PHENYLETHYLAMINE BY BOTH TYPES OF
MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND
LIVER MITOCHONDRIA OF EIGHT SPECIES.
004024 04-03
EFFECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC
NEURONS.
004026 04-03
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL
VESICLES.
004042 04-03
POSTMORTEM STABILITY OF BRAIN 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND 3,4
DIHYDROXYPHENYLETHYLENEGLYCOL IN THE RAT AND MOUSE.
004048 04-03
BENZODIAZEPINE-RECEPTOR: HETEROGENEITY IN RABBIT BRAIN.
004060 04-03
RELATIONSHIP BETWEEN PENTYLENETETRAZOL-INDUCED SEIZURES AND
BRAIN PENTYLENETETRAZOL LEVELS IN MICE.
004061 04-03
EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON TETRABENAZINE-INDUCED
DEPLETION OF BRAIN MONOAMINES IN RATS. 1. NOREPINEPHRINE.
004062 04-03
THE EFFECT OF P CHLOROPHENYLALANINE ON THE DISTRIBUTION OF
BIOGENIC-AMINES IN THE BRAIN, AND ON MEMORY IN RATS.
004068 04-04
THE EFFECT OF PROPYLNORANTIFEIN ON BEHAVIORAL-REACTIONS,
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE
ANIMAL BRAIN.
004075 04-04
DOES RAPID-EYE-MOVEMENT SLEEP PLAY A ROLE IN BRAIN
DEVELOPMENT?
004091 04-04
SUSTAINED INTRACEREBROVENTRICULAR INFUSION OF BRAIN FUELS
REDUCES BODY-WEIGHT AND FOOD INTAKE IN RATS.
004098 04-04
COCAINE AND SEIZURE PROTECTION IN MICE OF VARYING BRAIN
WEIGHTS.
004103 04-04
EFFECT OF PRENATAL PHENYTOIN ADMINISTRATION ON BRAIN
TRYPTOPHAN METABOLISM OF RAT OFFSPRING DURING THE
PREWEANING PERIOD.
004108 04-04
RELATION BETWEEN BRAIN CATECHOLAMINE-RECEPTORS AND
DOPAMINERGIC STEREOTYPY IN RAT STRAINS.
004131 04-04
MORPHINE DIFFERENTIALLY AFFECTS VENTRAL TEGMENTAL AND
SUBSTANTIA-NIGRA BRAIN REWARD THRESHOLDS.
004187 04-04
THE EFFECT OF THE NEW ANTIDEPRESSANT INKASAN ON THE
BIOELECTRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED
REFLEXES.
004212 04-04
SUPPRESSION OF ALCOHOL DRINKING WITH BRAIN ALDEHYDE-
DEHYDROGENASE INHIBITION.
004220 04-04
NEUROTRANSMITTER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS. I: EFFECTS OF A SINGLE EXPOSURE TO ACRYLAMIDE.
004264 04-05
."if
^
X
ft,
it:
S-67
Subject Index
Psychopharmacology Abstracts
NEUROTRANSMITTER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS. Ih EFFECTS OF EXTENDED EXPOSURE TO ACRYLAMIDE.
004265 04-05
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION.
004273 04-05
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION.
004281 04-05
AUTORADIOGRAPHIC LOCALIZATION OF DRUG AND NEUROTRANSMITTER-
RECEPTORS IN THE BRAIN.
004292 04-06
LSD PSYCHOTOGENIC PROCEDURES AND BRAIN NEUROHUMORS.
(UNPUBLISHED PAPER).
004448 04-11
EFFECTS OF A SHORT-ACTING BENZODIAZEPINE ON BRAIN ELECTRICAL-
ACTIVITY DURING SLEEP.
004568 04-14
THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE BRAIN AS AN
OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING
DRUGS.
004669 04-16
COMPARISON OF SPECTROFLUOROMETRIC AND GAS-
CHROMATOGRAPHY/MASS-SPECTROMETRY PROCEDURES FOR THE
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN.
004692 04-16
BRAIN DOPAMINE-RECEPTORS.
004741 04-17
BRAIN-AMINE
MONOAMINE-OXIDASE-INHIBITION AND BRAIN-AMINE METABOLISM
AFTER ORAL TREATMENT WITH TOLOXATONE IN THE RAT
000156 01-03
BRAIN-BIOCHEMISTRY
EFFECTS OF ACUTE VS CHRONIC PHENCYCLIDINE ON BRAIN-
BIOCHEMISTRY AND BEHAVIOR.
001789 02-04
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN
SCHIZOPHRENIA
002390 02-15
EFFECT OF ACUTE AND CHRONIC TRIIODOTHYRONINE {T3)
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE-
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN-
BIOCHEMISTRY.
002951 03-04
BRAIN-DAMAGE
EFFECTS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED
SUBJECTS.
002320 02-14
BEHAVIORAL-TEST FOR DETECTION OF SUBCLINICAL BRAIN-DAMAGE: AN
EXPERIMENTAL MODEL.
003120 03-04
PHENYTOIN TOXICITY IN A BRAIN-DAMAGE ADOLESCENT: A CASE-
REPORT.
003512 03-15
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: BRAIN-DAMAGE OR
DRUG-EFFECTS?
003538 03-15
BRAIN-DAMAGE-SYNDROME
TRIAL OF A PEPTIDE FRACTION OF AQH (AaH4-10) IN THE ALCOHOLIC
BRAIN-DAMAGE-SYNDROME .
002318 02-14
BRAIN-DAMAGED
ORAL DYSKINESIA IN BRAIN-DAMAGED RATS WITHDRAWN FROM A
NEUROLEPTIC: IMPLICATION FOR MODELS OF TARDIVE-DYSKINESIA
000393 01-04
BRAIN-DYSFUNCTION
PHENYLACETATE AND BRAIN-DYSFUNCTION IN EXPERIMENTAL
PHENYLKETONURIA: SYNAPTIC DEVELOPMENT.
000191 01-03
BRAIN-MONOAMINE
EFFECTS OF BRAIN-MONOAMINE DEPLETION ON THERMOREGULATORY
RESPONSES OF RABBITS TO DIFFERENT HYPOTHALAMIC
TEMPERATURES.
000190 01-03
BRAIN-MONOAMINES
BRAIN-MONOAMINES IN THE RHESUS-MONKEY DURING LONG-TERM
NEUROLEPTIC ADMINISTRATION.
001471 02-03
EFFECT OF BROMOCRIPTINE ON EXPLORATORY-ACTIVITY, BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS.
001635 02-04
BRAIN-MONOAMINES AND THE HIGH PRESSURE NEUROLOGICAL-
SYNDROME.
001686 02-04
EFFECT OF NEONATAL HYDROCORTISONE TREATMENT ON BRAIN-
MONOAMINES IN DEVELOPING RATS
003893 04-03
BRAIN-SPECIFIC
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS AND PUTATIVE
ENDOGENOUS BENZODIAZEPINE-LIKE COMPOUNDS.
000225 01-03
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS ARE LOCALIZED IN THE
INNER PLEXIFORM LAYER OF RAT RETINA.
000277 01-03
BRAIN-STIMULATION
EFFECTS OF KINDLING OR BRAIN-STIMULATION ON PENTYLENETETRAZOL-
INDUCED CONVULSION SUSCEPTIBILITY.
000037 01-03
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9
TETRAHYDROCANNABINOL ON THE CARDIOVASCULAR SYSTEM, AND
PRESSOR AND BEHAVIORAL-RESPONSES TO BRAIN-STIMULATION IN
FREELY-MOVING-RATS.
000417 01-04
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON THE
CARDIOVASCULAR-SYSTEM, AND PRESSOR AND BEHAVIORAL-
RESPONSES TO BRAIN-STIMULATION IN RATS.
001681 02-04
EFFECTS OF CHRONIC NALOXONE TREATMENT ON BRAIN-STIMULATION
REWARD
003066 03-04
REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION:
DISSOCIATIVE-EFFECTS OF COCAINE.
004160 04-04
DISRUPTION OF AUTOSHAPED RESPONDING TO A SIGNAL OF BRAIN-
STIMULATION REWARD BY NEUROLEPTIC-DRUGS.
004199 04-04
BRAINS
ISOLATION OF SELECTIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES,
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE.
001162 02-03
THE EFFECT OF CARBIDINE ON DOPAMINE TURNOVER IN THE CORPUS-
STRIATUM OF THE BRAINS OF RATS.
001352 02-031
BINDING OF (3H)PERG0LIDE-MESYLATE TO DOPAMINE-RECEPTORS OF |
MAMMALIAN BRAINS.
001538 02-03
REGIONAL CHANGES IN (3H)DIAZEPAM BINDING IN THE BRAINS OF MICE '
AFTER REMOVAL OF THE OLFAQORY-BULBS.
003844 04-03
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION.
004281 04-05
BRAINSTEM
REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS.
000066 01-03
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS
000258 01-03
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS.
000509 01-05
EFFECT OF QUIPAZINE ON BRAINSTEM MONOAMINE NEURONS
HISTOFLUORESCENCE STUDIES.
001477 02-03
5 METHOXYDIMETHYLTRYPTAMINE: SPINAL-CORD AND BRAINSTEM
MEDIATION OF EXCITATORY EFFEaS ON ACOUSTIC STARTLE.
001605 02-04
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR
INJECTION OF CEFAZOLIN.
002762 03-03
MEPACRINE TREATMENT PREVENTS IMMOBILIZATION-INDUCED
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT
HYPOTHALAMUS AND BRAINSTEM.
002919 03-03
EFFICACY OF LITHIUM IN TREATING MOOD-DISORDER OCCURRING AFTER
BRAINSTEM INJURY.
003354 03-11
AUDITORY BRAINSTEM EVOKED-RESPONSES IN HOSPITALIZED-PATIENTS
UNDERGOING DRUG-TREATMENT OR EQ.
003430 03-13
DIFFERENTIAL-EFFECTS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS.
003947 04-03
THE BRAINSTEM AUDITORY EVOKED-RESPONSE AS A TOOL IN
NEUROBEHAVIORAL TOXICOLOGY AND MEDICINE.
004277 04-05
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT
VERTEBRAL-ARTERY OF THE CAT; A MODIFIED ANIMAL-MODEL FOR
S-68
VOLUME 19, SUBJECT INDEX
»THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE
LOWER BRAINSTEM.
004297 04-06
BRANCHED-CHAIN
EFFECTS OF BRANCHED-CHAIN FATTY-ACIDS ON GABA DEGRADATION
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI-
MORPHINE ABSTINENCE-BEHAVIOR.
001809 02-04
MEAKDOWN
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF
AMINES INFLUENCING CEREBROSPINAL-FLUID FORMATION.
002807 03-03
MEAKING-POINT
DRUG-INDUCED STIMULUS CONTROL AND THE CONCEPT OF BREAKING-
POINT: LSD AND QUIPAZINE.
003116 03-04
BRED
TOLERANCE TO ETHANOL-INDUCED IMPAIRMENT OF WATER-ESCAPE IN
RATS BRED FOR ETHANOL SENSITIVITY
001567 02-04
ETHANOL-INDUCED ANALGESIA IN RATS SELECTIVELY BRED FOR ETHANOL
SENSITIVITY.
001625 02-04
MIDGES
SYNTHESIS AND BIOLOGICAL-ACTIVITY OF HUMAN BETA ENDORPHIN
ANALOGS WITH DISULFIDE BRIDGES.
003655 04-01
IRITISH-PHARMACOLOGICAL-SOCIETY
PROCEEDINGS OF THE BRITISH-PHARMACOLOGICAL-SOCIETY, 12TH-14TH
SEPTEMBER, 1979, UNIVERSITY-OF-LEEDS.
000966 01-17
IRL- 14342
PHARMACOLOGICAL AND BIOCHEMICAL-PROPERTIES OF BRL- 14342 A
NOVEL POTENTIAL ANTIDEPRESSANT-DRUG.
004086 04-04
iROMAZEPAM
CONTROLLED-STUDY WITH BROMAZEPAM AND CLOROTEPIN IN CHILD
INSTABILITY,
002190 02-11
ACTIVITY OF BROMAZEPAM AND LORAZEPAM IN NEUROTIC
DEPRESSIONS.
004384 04-09
IROMISM
BROMISM, HYSTERIA AND NARCOLEPSY.
002472 02-15
tROMO-ALPHA-ERGOCRIPTINE
PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN CHRONIC
SCHIZOPHRENIC-PATIENTS TESTED WITH SINGLE-DOSE OF 2 BROMO-
ALPHA-ERGOCRIPTINE (PARLODEL).
004343 04-08
BROMOCRIPTINE
THE EFFECTS OF BROMOCRIPTINE ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS IN THE MOUSE VAS-DEFERENS.
000108 01-03
DISTRIBUTION AND EXCRETION IN THE RAT AND MONKEY OF (82BR)
BROMOCRIPTINE.
000196 01-03
LONG-TERM EFFICACY OF BROMOCRIPTINE IN PARKINSONS-DISEASE.
000698 01-11
BROMOCRIPTINE AND DOPAMINERGIC FUNCTION IN HUNTINGTON-
DISEASE.
IMPROVEMENT OF L-DOPA-INDUCED DYSKINESIA AND OF ON-OFF-
PHENOMENON BY BROMOCRIPTINE.
NEUROPHARMACOLOGY OF BROMOCRIPTINE AND DIHYDROERGOTOXINE
(HYDERGINE).
EFFECT OF BROMOCRIPTINE ON EXPLORATORY-ACTIVITY BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS. GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS.
USE OF LARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC-
PATIENTS WITH ELEVATED SERUM PROLACTIN LEVELS AND
EXTRAPYRAMIDAL SIDE-EFFEQS ASSOCIATED WITH NEUROLEPTIC
TREATMENT.
00 1 944 02-08
AN AnEMPT TO TREAT THE SIDE-EFFECTS OF PSYCHOTROPIC THERAPY
WITH BROMOCRIPTINE.
A COMPARATIVE-STUDY OF BROMOCRIPTINE AND LEVODOPA IN
PARKINSONS-DISEASE.
BROMOCRIPTINE AND PARKINSONS-DISEASE: A 16-HOUR CLINICAL-
EVALUATION.
THE ROLE OF BROMOCRIPTINE IN THE TREATMENT OF PARKINSONS-
DISEASE.
002177 02-11
Subject Index
THE USE OF BROMOCRIPTINE FOR TESTING CENTRAL DOPAMINERGIC
REACTIVITY.
002205 02-13
THE PHARMACOKINETICS OF BROMOCRIPTINE IN MAN.
002291 02-13
BROMOCRIPTINE IN PARKINSONS-DISEASE: REPORT ON 106 PATIENTS
TREATED FOR UP TO 5 YEARS.
002342 02-14
FURTHER EXPERIENCES WITH LOW-DOSES OF BROMOCRIPTINE IN
PARKINSONS-DISEASE.
002401 02-15
LEVODOPA COMPARED WITH BROMOCRIPTINE IN THE TREATMENT OF
PARKINSONS-DISEASE.
002406 02-15
PSYCHIATRIC-EFFECTS OF BROMOCRIPTINE AND LERGOTRILE IN
PARKINSONIAN-PATIENTS.
002453 02-15
PHARMACOLOGICAL DIFFERENCE OF L-DOPA, APOMORPHINE AND
BROMOCRIPTINE AGAINST METOCLOPRAMIDE,
003790 04-03
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NICTITATING MEMBRANE OF THE CAT.
003822 04-03
PHENOXYBENZAMINE AND BROMOCRIPTINE AHENUATE NEED FOR REM
SLEEP IN RATS.
004203 04-04
BROMOCRYPTINE
EVIDENCE FOR AN IRREVERSIBLE INTERACTION OF BROMOCRYPTINE
WITH CENTRAL DOPAMINE-RECEPTORS.
000023 01-03
BROMOSPIROPERIDOL
SPECIFIC IN VIVO BINDING OF 77BR P BROMOSPIROPERIDOL IN RAT-
BRAIN: A POTENTIAL TOOL FOR GAMMA-RAY IMAGING.
004293 04-06
BROMPERIDOL
CLINICAL-EVALUATION OF BROMPERIDOL VERSUS HALOPERIDOL IN
PSYCHOTIC-PATIENTS.
004562 04-14
BUCCOLINGUOFACIAL
THE TREATMENT OF BUCCOLINGUOFACIAL DYSKINESIA IN THE ELDERLY-
THE CHOICE OF A NEUROLEPTIC-AGENT.
002223 02-13
BUFFERS
EFFECT OF STRUCTURE ON PHEN0THIA2INE CATION RADICAL REACTIONS
IN AQUEOUS BUFFERS.
000014 01-02
BUFOTENIN
EFFECT OF NEUROLEPTICS ON INDOLEAMINE-N-METHYLTRANSFERASE
ACTIVITY AND BRAIN METABOLISM OF BUFOTENIN.
002735 03-03
BULBECTOMISED
SEROTONINMIMETIC AND ANTIDEPRESSANT-DRUGS ON PASSIVE-
AVOIDANCE LEARNING BY OLFACTORY BULBECTOMISED RATS
001585 02-04
BULLFROG
CALCIUM LOCALIZATION IN THE SYMPATHETIC GANGLION OF THE
BULLFROG AND EFFECTS OF CAFFEINE.
000098 01-03
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF
BULLFROG SYMPATHETIC GANGLION CELLS.
003710 04-03
BUMETANIDE
THE EFFECT OF FRUSEMIDE PIRETANIDE AND BUMETANIDE ON COCHLEAR
SUCCINIC-DEHYDROGENASE.
003757 04-03
BUNDLE
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND
ELECTROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE
MIDBRAIN.
001593 02-04
DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT-
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL-
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS
001726 02-04
EFFECTS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE-
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC
BUNDLE IN THE RAT.
003910 04-03
BUNGAROTOXIN
LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES
OF THE DEVELOPING CHICK RETINA.
000065 01-03
ACTIONS OF BETA BUNGAROTOXIN ON AMINO-ACID TRANSMITTER
RELEASE.
002897 03-03
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN
003820 04-03
K
13.
■1
1'5
<5;
S-69
Subject Index
Psychopharmacology Abstracts
BUPRENORPHINE
A COMPARISON OF THE NEUROCHEMICAL-EFFECTS OF BUPRENORPHINE
WITH THOSE OF MORPHINE AND HALOPERIDOL IN RATS.
002701 03-03
BUPRENORPHINE: DEMONSTRATION OF PHYSICAL-DEPENDENCE LIABILITY.
004104 04-04
BUPROPION
CLINICAL-EFFICACY OF THE NEW ANTIDEPRESSANT BUPROPION
(WELLBUTRIN).
003227 03-09
BURST-FIRING
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE
RELATIONSHIP.
003806 04-03
BURYING _
CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNaiON
OF ELAVIL AND THORAZINE INJECTION.
002974 03-04
BUSPIRONE
INHIBITION OF AGGRESSIVE-BEHAVIOR IN RHESUS-MONKEYS BY
BUSPIRONE.
003103 03-04
BUTACLAMOL
CALMODULIN RELEASE FROM STRIATAL MEMBRANES AFTER ACUTE AND
CHRONIC TREATMENT WITH BUTACLAMOL.
001249 02-03
BUTANOL
IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM
INGESTION OF ETHANOL, TERTIARY BUTANOL, OR PENTOBARBITAL IN
MICE.
000479 01-04
BUTOCTAMIDE-HYDROGEN-SUCCINATE
THE EFFECT OF BUTOaAMIDE-HYDROGEN-SUCCINATE ON NOCTURNAL
SLEEP: ALL-NIGHT POLYGRAPHICAL-STUDIES.
002350 02-14
BUTORPHANOL
SERUM LEVELS OF BUTORPHANOL BY RADIOIMMUNOASSAY.
004691 04-16
BUTRIPTYLINE-HYDROCHLORIDE
ACTION OF BUTRIPTYLINE-HYDROCHLORIDE IN THE
GERONTOPSYCHIATRIC-PATIENT.
003358 03-11
BUTYROLAaONE
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA
BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY
TUBERCLE OF THE RAT.
002681 03-03
BUTYROLACTONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE
GAMMA BUTYROLAaONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE
CITRATE (DN-1417): A NOVEL TRH ANALOG WITH POTENT EFFEaS ON
THE CENTRAL-NERVOUS-SYSTEM.
003057 03-04
BUTYROPHENONE
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP
CORREaiON IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS.
001869 02-06
INCREASED SERUM PROLAQIN LEVELS DURING PHENOTHIAZINE AND
BUTYROPHENONE TREATMENT OF SIX POSTPARTUM WOMEN.
003318 03-11
C-AMP
HALOTHANE EFFEQ ON C-\MP GENERATION AND HYDROLYSIS IN RAT-
BRAIN.
000305 01-03
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
C-GMP
INCREASE OF C-GMP AND ACCUMULATION OF 45CA2 EVOKED BY DRUGS
AaiNG ON SODIUM OR POTASSIUM CHANNELS.
003709 04-03
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C-
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM-
CHANNEL BLOCKADE.
004020 04-03
C-TYPE
SELECTIVE NEUROTOXIC-AaiON OF CAPSAICIN ON GLOMERULAR C-TYPE
TERMINALS IN RAT SUBSTANTIA-GELATINOSA.
003143 03-06
CA
CA DIAZEPAM LINK? NO SCIENTIFIC TAKERS SO FAR.
003519 03-15
CA -DEPENDENT
SEROTONIN-RECEPTOR MEDIATED MODULATION OF CA-DEPENDENT 5
HYDROXYTRYPTAMINE RELEASE FROM NEURONES OF THE RAT-BRAIN-
CORTEX.
001258 02-03
CA-FLUX
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER).
001188 02-03
CA -INDEPENDENT
REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA -INDEPENDENT
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6-
GLIOMA CELLS (UNPUBLISHED PAPER)
001403 02-03
CA-FLUX
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
AQIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
CACTUS
CATECHOLAMINE METABOLISM IN A PSYCHOAQIVE CAQUS.
004722 04-17
CAERULEIN
CENTRAL DEPRESSANT EFFEaS OF CAERULEIN AND CHOLECYSTOKININ-
OaAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND
HALOPERIDOL
002652 03-02
CAFFEINE
CALCIUM LOCALIZATION IN THE SYMPATHETIC GANGLION OF THE
BULLFROG AND EFFEaS OF CAFFEINE.
000098 01-03
CAFFEINE PRODUCES REM SLEEP REBOUND IN RATS.
000244 01-03
AROUSAL AND SHORT-TERM MEMORY: EFFEaS OF CAFFEINE AND TRIAL
SPACING ON DELAYED ALTERNATION PERFORMANCE.
000487 01-04
BEHAVIOURAL-EFFEaS OF ACETYLSALICYLIC-ACID, PARACETAMOL,
CAFFEINE, GUAIPHENESIN AND THEIR COMBINATIONS.
001805 02-04
EFFEQS OF CAFFEINE ON PLASMA FREE FATTY-ACIDS, URINARY
CATECHOLAMINES, AND DRUG BINDING.
002272 02-13
THE EFFECTS OF ALCOHOL AND CAFFEINE ON CONCENTRATION TEST
PERFORMANCE.
002337 02-14
EFFECTS OF CAFFEINE ADMINISTRATION ON FOOD AND WATER
CONSUMPTION UNDER VARIOUS EXPERIMENTAL CONDITIONS.
003049 03-04
ACUTE EFFEQS OF CAFFEINE IN NORMAL PREPUBERTAL BOYS.
003310 03-11
EFFECT OF FLURAZEPAM, PENTOBARBITAL, AND CAFFEINE ON AROUSAL
THRESHOLD.
003439 03-14
UNIT AaiVITY IN MEDIAL THALAMUS: COMPARATIVE-EFFEaS OF
CAFFEINE AND AMPHETAMINE.
003752 04-03
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOaUSCAN
NEURONS.
003834 04-03
EFFEQS OF MORPHINE AND CAFFEINE ON ADENOSINE RELEASE FROM
RAT-CEREBRAL-CORTEX: IS CAFFEINE A MORPHINE ANTAGONIST.
003864 04-03
THE EFFEQS OF THEOPHYLLINE AND CAFFEINE ON THERMOREGULATORY
FUNQIONS OF RATS AT DIFFERENT AMBIENT TEMPERATURES.
003907 04-03
EFFECTS OF CAFFEINE ON ANTERIOR PITUITARY AND THYROID-FUNCTION
IN THE RAT.
004014 04-03
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL
VESICLES.
004042 04-03
CAFFEINE-INDUCED
CAFFEINE-INDUCED AND AMINOPHYLLINE-INDUCED SEIZURES.
002689 03-03
THE BENZODIAZEPINES AND INOSINE ANTAGONIZE CAFFEINE-INDUCED
SEIZURES.
004172 04-04
CAGE
REPEATED ELECTROCONVULSIVE-SHOCK DOES NOT INCREASE THE
SUSCEPTIBILITY OF RATS TO A CAGE CONVULSANT
(ISOPROPYLBICYCLOPHOSPHATE) .
001184 02-03
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE
CLIMBING IN MICE.
003031 03-04
CAIMAN-SCLEROPS
INFLUENCE OF MONOAMINE DEPLETING PHARMACOLOGIC-AGENTS ON
LEVELS OF ACTIVITY IN CAIMAN-SCLEROPS.
001810 02-04
S-70
VOLUME 19, SUBJECT INDEX
Subject Index
CALCITONIN
ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE
IN RAT-BRAIN.
001320 02-03
IMMUNOREACTIVE CALCITONIN IN CEREBROSPINAL-FLUID OF MAN.
002637 03-01
EVOKED-POTENTIAL STUDIES OF PORCINE CALCITONIN IN RABBITS.
002936 03-03
CALCITONIN: AVERSIVE-EFFECTS IN RATS?
002977 03-04
CALCITONIN: AVERSIVE-EFFECTS IN RATS?
002992 03-04
CALOUM
CALCIUM LOCALIZATION IN THE SYMPATHETIC GANGLION OF THE
BULLFROG AND EFFECTS OF CAFFEINE.
000098 01-03
EFFECT OF MORPHINE ON CALCIUM UPTAKE BY LYSED SYNAPTOSOMES.
000117 01-03
EFFEQS OF CHLORDIAZEPOXIDE ON DEPOLARIZATION-INDUCED CALCIUM
INFLUX INTO SYNAPTOSOMES.
000183 01-03
(3H)ACETYLCH0LINE AND (3H)5 HYDROXYTRYPTAMINE RELEASE FROM
RAT-MIDBRAIN SLICES AND THE EFFECTS OF CALCIUM AND
PHENOBARBITAL.
000251 01-03
TWENTY YEARS CLINICAL THERAPEUTIC EXPERIENCE WITH CALCIUM
GLUTAMATES EFFICACY.
000963 01-17
ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED
PAPER).
001014 02-01
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA.
(UNPUBLISHED PAPER).
001147 02-03
NERVE CELL CALCIUM AS A MESSENGER FOR OPIATE AND ENDORPHIN
ACTONS.
001450 02-03
EFFEQS OF ANTICONVULSANTS AND METHOTREXATE ON CALCIUM
DISPOSITION.
001840 02-05
EFFECT OF LITHIUM ON POTASSIUM AND CALCIUM IN SERUM,
ERYTHOCYTES AND IN URINE.
002054 02-09
INTERACTIONS OF NARCOTICS WITH SYNAPTOSOMAL CALCIUM
TRANSPORT.
002712 03-03
EFFECTS OF NEOMYCIN ON CALCIUM AND POLYPHOSPHOINOSITIDE
METABOLISM OF GUINEA-PIG SYNAPTOSOMES.
002741 03-03
EFFEQS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO-
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY
CULTURED NEURONS.
002859 03-03
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFEQS OF FENTANYL ON
THE CONTRACTION OF THE NICTITATING MEMBRANE IN CATS.
002876 03-03
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN
MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF
AMPHETAMINE. (PH.D. DISSERTATION).
002996 03-04
GLOMERULAR FILTRATION RATE AND CALCIUM METABOLISM IN LONG-
TERM LITHIUM TREATMENT.
003542 03-15
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INDUCED CONVULSIONS
IN RATS.
003736 04-03
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
003783 04-03
INHIBITION OF SYNAPTOSOMAL CALCIUM UPTAKE BY ETHANOL
003827 04-03
INFLUENCE OF CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5
HYDROXYTRYPTAMINE, TYRAMINE AND POTASSIUM FROM GOAT
PIAL-ARTERIES.
003925 04-03
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL
VESICLES.
004042 04-03
^LCIUM-ACTIVATED
REGULATION OF HIPPOCAMPAL GLUTAMATE-RECEPTORS: EVIDENCE FOR
THE INVOLVEMENT OF A CALCIUM-ACTIVATED PROTEASE.
.^,,. 001120 02-03
:alcium-carbimide
a comparative review of the pharmacological and
TOXICOLOGICAL PROPERTIES OF DISULFIRAM AND CALCIUM-
CARBIMIDE,
003522 03-15
calcium-channel
phenytoin inhibition of cyclic-guanosine-monophosphate (c-
gmp) accumulation in neuroblastoma cells by calcium-
channel blockade.
004020 04-03
CALCIUM-FLUX
PHOSPHOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR-
MEDIATED INDUCTION OF CHEMOTAXIS IN RABBIT NEUTROPHILS.
(UNPUBLISHED PAPER).
001118 02-03
CALCIUM-IONS
RELATIONSHIP BETWEEN THE ACTIONS OF CALCIUM-IONS, OPIOIDS, AND
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN
NEUROBLASTOMA-X GLIOMA HYBRID CELLS.
002677 03-03
CALCIUM-SENSITIVE
CALCIUM-SENSITIVE ACCUMULATION OF NOREPINEPHRINE IN RAT-
CEREBRAL-CORTEX.
002685 03-03
CALCULATIONS
CONVULSANT AND ANTICONVULSANT BARBITURATES. 1. MOLECULAR
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY
CALCULATIONS.
001029 02-01
CALF
CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN
MEMBRANES.
000062 01-03
3H MIANSERIN BINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG ACTION.
000325 01-03
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF
(3H)SPIR0PERID0L IN CALF CAUDATE.
003906 04-03
CALM
PSYCHOPHARMACEUTICAL-THERAPY TO CALM DRIVE, AQIVITY AND
RESTLESSNESS IN CHILDHOOD.
002604 02-17
CALMODULIN
CALMODULIN RELEASE FROM STRIATAL MEMBRANES AFTER ACUTE AND
CHRONIC TREATMENT WITH BUTACLAMOL.
001249 02-03
ROLE OF CALMODULIN IN DOPAMINERGIC TRANSMISSION.
(UNPUBLISHED PAPER).
001270 02-03
MODULATION OF BETA-ADRENERGIC-RECEPTORS AND CALMODULIN
FOLLOWING ACUTE AND CHRONIC-TREATMENT WITH NEUROLEPTICS.
001529 02-03
CALMODULIN: ITS ROLE IN SYNAPTIC TRANSMISSION.
003162 03-07
PHARMACOLOGICAL REGULATION OF CALMODULIN.
004052 04-03
ACUTE AND CHRONIC EFFECTS OF PSYCHOACTIVE-DRUGS ON
ADRENERGIC-RECEPTORS AND CALMODULIN.
004750 04-17
MECHANISMS AND PHARMACOLOGICAL IMPLICATIONS OF ALTERING
CALMODULIN ACTIVITY.
004751 04-17
CANALIZATION
CANALIZATION OF AROUSAL IN THE PREWEANLING RAT: EFFECTS OF
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI.
002965 03-04
CANCER
ANTICONVULSANT-DRUGS AND CANCER.
000855 01-15
INTRAVENOUS LORAZEPAM TO PREVENT NAUSEA AND VOMITING
ASSOCIATED WITH CANCER CHEMOTHERAPY.
003614 03-17
TREATMENT OF CANCER PAIN.
003619 03-17
CANCER-PATIENTS
SERIAL COGNITIVE TESTING IN CANCER-PATIENTS RECEIVING
CHEMOTHERAPY.
000876 01-15
CANINE
REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE-
NUCLEOTIDES AND ADENOSINE.
000210 01-03
PROTEQIVE EFFECT OF PRENYLAMINE AGAINST VULNERABILITY TO
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE
MYOCARDIUM.
000265 01-03
CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE
CANINE FEMORAL VASCULAR BED.
003911 04-03
CANNABIDIOL
CHRONIC ADMINISTRATION OF CANNABIDIOL TO HEALTHY VOLUNTEERS
AND EPILEPTIC-PATIENTS.
000669 01-11
I
S-71
Subject Index
Psychopharmacoiogy Abstracts
THE EFFEaS OF 0ELTA9 TETRAHYDROCANNABINOL ALONE AND IN
COMBINATION WITH CANNABIDIOL ON FIXED-INTERVAL
PERFORMANCE IN RHESUS-MONKEYS.
001582 02-04
METABOLIC- STUDIES AND PSYCHOPHYSIOLOGIC- STUDIES OF
CANNABIDIOL HEXOBARBITAL INTERACTION.
002209 02-13
EFFECT OF CANNABIDIOL ON CYTOCHROME-P-450 AND HEXOBARBITAL
SLEEP-TIME.
002675 03-03
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL AND CANNABIDIOL ON
SODIUM-DEPENDENT HIGH-AFFINITY CHOLINE UPTAKE IN THE RAT
HIPPOCAMPUS.
003908 04-03
CHARACTERISTICS OF THE STIMULUS PRODUCED BY THE MIXTURE OF
CANNABIDIOL WITH DELTA9 TETRAHYDROCANNABINOL.
004263 04-04
CANNABINOID
ISOLATION OF PSYCHOACTIVE CANNABINOID PRECURSORS FROM
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI.
001023 02-01
SUBACUTE CANNABINOID TREATMENT: ANTICONVULSANT ACTIVITY AND
WITHDRAWAL EXCITABILITY IN MICE.
001671 02-04
INTERCANNABINOID AND CANNABINOID ETHANOL INTERACTIONS AND
THEIR EFFECTS ON HUMAN PERFORMANCE.
002193 02-12
A SINGLE-DOSE STUDY OF NABILONE, A SYNTHETIC CANNABINOID
002328 02-14
DIFFERENTIAL-EFFECTS OF CANNABINOID EXPOSURE AND STRESS ON
PLASMA PROLACTIN, GROWTH-HORMONE AND CORTICOSTERONE
LEVELS IN MALE MICE.
002695 03-03
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC,
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL
DOPAMINE SYNTHESIS.
002786 03-03
CANNABINOID-INDUCED
CANNABINOID-INDUCED ENHANCEMENT AND DEPRESSION OF CAT
MONOSYNAPTIC REFLEXES.
004040 04-03
CANNABINOIDS
EFFECTS OF SYSTEMIC AND INTRAVENTRICULAR ADMINISTRATION OF
CANNABINOIDS ON SCHEDULE-CONTROLLED RESPONDING IN THE
SQUIRREL-MONKEY.
000354 01-04
POSTSWIM GROOMING IN MICE INHIBITED BY DOPAMINE-RECEPTOR
ANTAGONISTS AND BY CANNABINOIDS.
000359 01-04
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOAQIVE CANNABINOIDS
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN
HUMAN CELLS.
002830 03-03
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOAQIVE CANNABINOIDS
ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS
002831 03-03
EFFECTS OF CANNABINOIDS ON CATECHOLAMINE UPTAKE AND RELEASE
IN HYPOTHALAMIC AND STRIATAL SYNAPTOSOMES.
003970 04-03
CANNABINOIDS. I. BEHAVIORAL-EFFECTS.
004228 04-04
CANNABINOIDS. II. CARDIOVASCULAR-EFFEaS.
004280 04-05
CANNABIS
INTERACTIVE-EFFECTS OF NUTRITION AND CANNABIS UPON RAT
PERINATAL DEVELOPMENT.
000513 01-05
ISOLATION OF PSYCHOACTIVE CANNABINOID PRECURSORS FROM
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI.
001023 02-01
EFFECTS OF BODY-WEIGHT LEVELS ON CANNABIS SELF-INJECTION.
001801 02-04
SIMILARITIES BETWEEN CANNABIS AND OPIUM.
002554 02-17
INFLUENCE OF CANNABIS AND DELTA9 TETRAHYDROCANNABINOL ON
THE BIOCHEMISTRY OF THE MALE REPRODUCTIVE ORGANS.
002686 03-03
CANNABIS-SATIVA
CANNABIS-SATIVA: EFFECTS ON BRAIN FUNQION AND ULTRASTRUCTURE
IN RHESUS-MONKEYS.
002747 03-03
CANNED
TYRAMINE CONTENT OF CANNED AND PACKET SOUPS.
002394 02-15
CANNULA
QUICKLY-MADE CANNULA FOR REPEATED CEREBROSPINAL-FLUID
SAMPLING IN RATS.
001879 02-06
CANTOR
TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE
FATIGUE STUDY GROUPS NO. 4 CLINICAL- SCALE.
001980 02-09
CAPACITIES
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS; EFFECTS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300.
003451 03-14
CAPACITY
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
RECEPTORS.
000323 01-03
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH
PSYCHOSTIMULANTS: II. EFFEQ OF METHAMPHETAMINE ON
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC
SUBSTRATES.
001613 02-04
EFFECTS OF PSYCHOPHARMACEUTICALS ON DRIVING CAPACITY
003453 03-14
CAPILLARIES
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES
000202 01-03
CAPILLARY
LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL
CAPILLARY PERMEABILITY.
000239 01-03
PHENYTOIN CONCENTRATIONS IN VENOUS VERSUS CAPILLARY BLOOD OF
GERIATRIC-PATIENTS.
003381 03-1 1
THE EFFECT OF DIBENZAZEPINES (TRICYCLIC-ANTIDEPRESSANTS) ON
CEREBRAL CAPILLARY PERMEABILITY IN THE RAT IN VIVO.
003974 04-03
CAPSAICIN
NEUROPHYSIOLOGICAL-EFFEaS AND THERMOREGULATORY-EFFEaS OF
CAPSAICIN.
001421 02-03
SELECTIVE NEUROTOXIC-ACTION OF CAPSAICIN ON GLOMERULAR C-TYPE
TERMINALS IN RAT SUBSTANTIA-GELATINOSA.
003143 03-06
INTRANIGRAL INJECTION OF CAPSAICIN ENHANCES MOTOR-AQIVITY ;
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE BUT NOT SUBSTANCE- '
P.
004100 04-04
A REEVALUATION OF THE NEUROCHEMICAL-EFFEaS AND
ANTINOCICEPTIVE-EFFEaS OF INTRATHECAL CAPSAICIN IN THE RAT.
004184 04-04
CAPSULE
BIOAVAILABILITY OF SULPIRIDE TABLET AND CAPSULE IN DOGS.
001101 02-03
CAPTOPRIL
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME AQIVITY
IN THE RAT-BRAIN.
001614 02-04'
POTENTIATION OF THE MORPHINE-INDUCED RESPIRATORY RATE
DEPRESSION BY CAPTOPRIL.
004275 04-05
CAPTURE
A METHOD FOR MEASUREMENT OF TRANYLCYPROMINE IN RAT-BRAIN
REGIONS USING GAS-CHROMATOGRAPHY WITH ELEaRON CAPTURE
DETEQION.
003137 03-06
CARBACHOL
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIREQ VASODILATOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRiaiON.
001109 02-03
FUNQIONAL ORGANIZATION OF THE CAUDATE-NUCLEUS AFTER
ADMINISTRATION OF CARBACHOL.
001495 02-03
EFFECT OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE
DISCHARGE INDUCED BY CARBACHOL IN Th£ RABBIT.
003951 04-03
CARBACHOL-INDUCED
STUDIES OF CARBACHOL-INDUCED WET-DOG-SHAKE BEHAVIOR IN RATS.
004241 04-04
CARBAMAZEPINE
PHARMACOKINETICS OF CARBAMAZEPINE IN THE DOG.
000096 01-03
CARBAMAZEPINE-EPOXIDE DETERMINED BY EMIT CARBAMAZEPINE
REAGENT.
000533 01-06
S-72
VOLUME 19, SUBJECT INDEX
Subject Index
THE AUTOINDUCTION OF CARBAMAZEPINE DURING LONG-TERM
THERAPY.
000785 01-13
CORRELATION BETWEEN DAILY FLUCTUATIONS OF CARBAMAZEPINE
SERUM LEVELS AND INTERMITTENT SIDE-EFFECTS.
000851 01-15
CARBAMAZEPINE INTOXICATION DUE TO TRIACETYLOLEANDOMYCIN
ADMINISTRATION IN EPILEPTIC-PATIENTS.
000873 01-15
VALUE OF SALIVA SAMPLES IN MONITORING CARBAMAZEPINE
CONCENTRATIONS IN EPILEPTIC-PATIENTS.
000903 01-16
INFLUENCE OF CARBAMAZEPINE ON THALAMOCORTICAL AND
HIPPOCAMPOCORTICAL SELF-SUSTAINED AFTERDISCHARGES IN RATS.
001356 02-03
SENSITIZATION AND OSCILLATION FOLLOWING REPEATED STIMULATION:
RELATIONSHIP TO AFFECTIVE-ILLNESS AND ITS TREATMENT WITH
LITHIUM AND CARBAMAZEPINE
002031 02-09
CARBAMAZEPINE THERAPY IN TRIGEMINAL-NEURALGIA: CLINICAL-
EFFECTS IN RELATION TO PLASMA CONCENTRATION.
002181 02-11
SALIVARY IMMUNOGLOBULIN CONCENTRATIONS IN PATIENTS WITH
EPILEPSY TREATED WITH CARBAMAZEPINE.
002234 02-13
BIOCHEMICAL-EVIDENCE FOR OSTEOMALACIA WITH CARBAMAZEPINE
THERAPY.
002445 02-15
A DOUBLE-BUND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF
CARBAMAZEPINE IN OVERACTIVE, SEVERELY MENTALLY-
HANDICAPPED PATIENTS.
003365 03-11
A PRELIMINARY DOUBLE-BUND STUDY ON THE EFFICACY OF
CARBAMAZEPINE IN PROPHYLAXIS OF MANIC-DEPRESSIVE-ILLNESS.
004388 04-09
MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT.
004441 04-11
INFLUENCE OF CARBAMAZEPINE ON SERUM THYROXINE AND
TRIIODOTHYRONINE IN PATIENTS WITH EPILEPSY.
004488 04-11
CONCENTRATIONS AND KINETICS OF CARBAMAZEPINE IN WHOLE
SAUVA, PAROTID SALIVA, SERUM ULTRAFILTRATE, AND SERUM.
004545 04-13
CARBAMAZEPINE-EPOXIDE
CARBAMAZEPINE-EPOXIDE DETERMINED BY EMIT CARBAMAZEPINE
REAGENT.
000533 01-06
CARBAMAZEPINE-ETHOSUXIMIDE
KINETICS OF A CARBAMAZEPINE-ETHOSUXIMIDE INTERACTION.
004558 04-13
CARBAAAAZEPINE-INDUCED
REVERSAL BY PHENYTOIN OF CARBAMAZEPINE-INDUCED WATER
INTOXICATION: A PHARMACOKINETIC-INTERACTION.
000783 01-13
CARBAMAZEPINE-INDUCED OROFACIAL DYSKINESIA.
002415 02-15
CARBIDINE
THE EFFECT OF CARBIDINE ON DOPAMINE TURNOVER IN THE CORPUS-
STRIATUM OF THE BRAINS OF RATS.
001352 02-03
CARBIDOPA
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE)
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION.
000712 01-11
TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAN AND
CARBIDOPA: CLINICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL-
OBSERVATIONS.
002180 02-11
INCREASED RATIO OF CARBIDOPA TO LEVODOPA IN TREATMENT OF
PARKINSONS-DISEASE.
002182 02-11
EFFECTS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L
TRYPTOPHAN BY ISOLATED RAT LIVER CELLS.
002899 03-03
ELECTRORETINOGRAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN
PSYCHOPHARMACOLOGY. ELECTRORETINOGRAPHIC-CHANGES INDUCED
BY A COMBINATION OF CARBIDOPA AND LEVODOPA.
004507 04-13
ELECTROENCEPHALOGRAPHIC CHANGE IN PARKINSONIAN-PATIENTS
TREATED WITH LEVODOPA CARBIDOPA.
004557 04-13
CARBOHYDRATE
ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS.
(UNPUBUSHED PAPER).
000060 01-03
CARBOLINE-3-CARBOXYLATES
BETA CARBOUNE-3-CARBOXYLATES AND BENZODIAZEPINE-RECEPTORS.
002676 03-03
CARBOLINES
BENZODIAZEPINE ANTAGONISM BY HARMANE AND OTHER BETA
CARBOUNES IN VITRO AND IN VIVO.
004211 04-04
CARBOXAMIDOSTRYCHNINE
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT
PROPERTIES.
000084 01-03
CARBOXYMETHYLATION
ENZYMATIC CARBOXYMETHYLATION OF THE NICOTINIC ACETYLCHOLINE-
RECEPTOR. (UNPUBLISHED PAPER).
001318 02-03
CARDIAC
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTIUNE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
THE REGULATION OF CARDIAC MUSCARINIC CHOLINERGIC-RECEPTORS BY
ISOPROTERENOL.
001441 02-03
ONTOGENY OF MAMMALIAN CARDIAC ALPHA 1-ADRENERGIC-
RECEPTORS.
001545 02-03
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST
SUDDEN CARDIAC DEATH FROM COCAINE.
003122 03-05
BETA-ADRENERGIC INFLUENCE ON CARDIAC DYNAMICS DURING SHOCK-
AVOIDANCE IN DOGS.
003813 04-03
CARDIAC-MUSCLE
POTENTIATION OF THE EFFECTS OF ADENOSINE ON ISOLATED CARDIAC-
MUSCLE AND SMOOTH-MUSCLE BY DIAZEPAM.
004266 04-05
CARDIOLOGICAL
PLASMA NOMIFENSINE CONCENTRATION: CARDIOLOGICAL EFFECTS AND
CLINICAL-RESPONSE.
004639 04-15
CARDIOLOGY
INTERFACES OF PSYCHOPHARMACOLOGY AND CARDIOLOGY - PART
TWO.
003529 03-15
INTERFACES OF PSYCHOPHARMACOLOGY AND CARDIOLOGY - PART
ONE.
003530 03-15
CARDIOMYOPATHY
INTRAVENOUS QUINIDINE IN CONGESTIVE CARDIOMYOPATHY.
003352 03-11
CARDIOTOXICITY
COMPARATIVE-STUDY OF THE CARDIOTOXICITY OF AMITRIPTYLINE AND
MAPROTIUNE IN DEPRESSIVE-PATIENTS.
000595 01-09
CARDIOTOXICITY OF ANTIDEPRESSANTS.
001843 02-05
CARDIOTOXICITY OF ANTIDEPRESSANT-DRUGS.
004597 04-15
CARDIOVASCULAR
CARDIOVASCULAR RESPONSE TO THE INTERAQION OF ETHANOL AND
SOME BENZODIAZEPINES IN RATS.
000332 01-03
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9
TETRAHYDROCANNABINOL ON THE CARDIOVASCULAR SYSTEM, AND
PRESSOR AND BEHAVIORAL-RESPONSES TO BRAIN-STIMULATION IN
FREELY-MOVING-RATS.
000417 01-04
A COMPARISON OF THE CARDIOVASCULAR EFFECTS OF HALOPERIDOL,
THIORIDAZINE AND CHLORPROMAZINE-HCL.
000512 01-05
A CASE OF CARDIOVASCULAR COLLAPSE DURING UTHIUM-CARBONATE
THERAPY.
000860 01-15
CARDIOVASCULAR EFFECTS OF NORTRIPTYLINE IN GERIATRIC-PATIENTS.
000882 01-15
DESIPRAMINE: CARDIOVASCULAR EFFECTS AND PLASMA LEVELS.
000884 01-15
EFFECT OF GABA AGONIST AND ANTAGONISTS ON CARDIOVASCULAR
AND SYMPATHETIC RESPONSES IN SHR AND WKY RATS.
(UNPUBUSHED PAPER).
001224 02-03
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS.
001242 02-03
CENTRALLY INDUCED CARDIOVASCULAR AND SYMPATHETIC-NERVE
RESPONSES TO BRADYKININ IN RATS.
003099 03-04
I
S-73
Subject Index
Ptychopharmacology Abstracts
SENSORY PROCESSING, CARDIOVASCULAR REACTIVITY, AND THE TYPE A
CORONARY-PRONE BEHAVIOR PATTERN,
003405 03-13
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFECTS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
RESPONSE. „„,,,„«.«„
004119 04-04
CARDIOVASCULAR-EFFECTS
CARDIOVASCULAR-EFFECTS OF AMITRIPTYLINE, MIANSERIN AND
ZIMELIDINE IN DEPRESSED-PATIENTS.
002215 02-13
CARDIOVASCULAR-EFFECTS OF THERAPEUTIC DOSES OF TRICYCLIC-
ANTIDEPRESSANTS: IMPORTANCE OF BLOOD LEVEL MONITORING.
002456 02-15
CARDIOVASCULAR-EFFECTS OF MIANSERIN AND AMITRIPTYLINE IN
HEALTHY VOLUNTEERS. 002469 02-15
TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFECTS OF
CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS.
003428 03-13
CARDIOVASCULAR-EFFECTS OF MIANSERIN - A COMPARATIVE-STUDY
WITH AMITRIPTYLINE AND A PLACEBO IN HEALTHY SUBJEQS.
003503 03-15
POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CARDIOVASCULAR-
EFFECTS OF CENTRAL ALPHA-ADRENOCEPTOR STIMULATION IN
SPONTANEOUSLY HYPERTENSIVE-RATS. ^^^^^ ^^^^
CENTRAL CARDIOVASCULAR-EFFECTS AND BIOCHEMICAL-EFFECTS OF
BACLOFEN IN THE CONSCIOUS RAT. 003965 04-03
CANNABINOIDS. II. CARDIOVASCULAR-EFFECTS. ^^
CARDIOVASCULAR-PHARMACOLOGY
THE NEUROVASCUIAR-PHARMACOLOGY AND CARDIOVASCULAR-
PHARMACOLOGY OF RS-51324, A POTENTIAL ANTIDEPRESSANT.
001091 02-02
CARDIOVASCULAR-SYSTEM
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON THE
CARDIOVASCULAR- SYSTEM, AND PRESSOR AND BEHAVIORAL-
RESPONSES TO BRAIN-STIMULATION IN RATS.
001681 02-04
CARE
HOSPITAL AND OUTPATIENT CARE FOR PSYCHOTIC-PATIENTS DURING THE
LAST THREE DECADES: SUBSEQUENT HOSPITAL AND OUTPATIENT
TREATMENT OF PSYCHOTIC-PATIENTS HOSPITALIZED FOR THE FIRST
TIME IN 1949-50, 1959-60 OR 1969-70. „,„,„„
000571 01-08
OUTPATIENT CARE OF DEPRESSIVE-PATIENTS WITH MIANSERIN.
002041 02-09
PSYCHOPHARMACOLOGY - AN AREA OF RESEARCH TO IMPROVE
MENTAL-HEALTH CARE. „„„.„, „o ,-,
002586 02-17
THE MEDICATION SEMINAR AND PRIMARY CARE EDUCATION.
003592 03-17
CARNITINE „ ^
THE UPTAKE OF CARNITINE BY SLICES OF RAT-CEREBRAL-CORTEX.
. 003853 04-03
CAROTID
INHIBITION OF VASOPRESSIN RELEASE TO CAROTID OCCLUSION BY
GAMMA AMINOBUTYRIC-ACID AND GLYCINE.
002715 03-03
CARP
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE-
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1
CYCLOPROPYLMETHYL
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE.
003706 04-02
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II. FACTORS
AFFECTING THE ACCUMULATION OF CYCLIC-AMP IN PIECES OF INTAQ
CARP RETINA.
003776 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE-
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA,
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS
004051 04-03
CARPIPRAMINE
THE INTEREST OF THE STIMULATING EFFECT OF CARPIPRAMINE IN
PSYCHOSOMATIC-MEDICINE.
002061 02-10
PERSPECTIVES ON PRAZINIL (CARPIPRAMINE): A DISINHIBITING-AGENT
WITH NO NEUROLEPTIC ACTIVITY. A REVIEW OF 38 CASES.
003149 03-07
CARPIPRAMINE: A DISINHIBITORY DRUG COMPOUND IN CHRONIC
SCHIZOPHRENIA. ^ „, „o
003192 03-08
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS- EFFECTS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300. , „. , .
003451 03-14
CARRIER
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN
MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFEQS OF
AMPHETAMINE. (PH.D. DISSERTATION).
002996 03-04
CASE
A CASE OF TRIGEMINAL-NEURALGIA TREATED WITH LITHIUM-
CARBONATE.
000690 01-11
A CASE OF CARDIOVASCULAR COLLAPSE DURING LITHIUM-CARBONATE
THERAPY.
000860 01-15
METHODOLOGICAL-ISSUES IN SPINAL-FLUID STUDIES OF SCHIZOPHRENIA:
THE CASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE.
(UNPUBLISHED PAPER).
001952 02-08
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE
INTOXICATION.
002210 02-13
CASE 3 ASSESSMENT AND TREATMENT OF DRUG-INDUCED TREMOR.
002407 02-15
ON A CASE OF MEMORY-DISTURBANCES TREATED WITH VASOPRESSIN.
003301 03-11
A CASE OF REVERSIBLE PURE-WORD DEAFNESS DURING LITHIUM
TOXICITY.
003481 03-15
AN UNUSUAL CASE OF THIORIDAZINE AND LEVOMEPROMAZINE
DEPENDENCE.
004634 04-15
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN.
004638 04-15
A CASE OF PETIT-MAL EPILEPSY AGGRAVATED BY LITHIUM
004641 04-15
A CASE OF ACUTE AGRANULOCYTOSIS DURING TREATMENT WITH
CLOZAPINE.
004642 04-15
CASE-HISTORY
THE ROLE OF LITHIUM IN THE PRODUQION OF INTERSTITIAL NEPHRITIS:
A CASE-HISTORY ^ ,,
004655 04-15
CASE-REPORT „ ,^„ I
CASE-REPORT: USING AHRIBUTION THEORY TO LIMIT NEED FOR
NEUROLEPTIC-MEDICINE. „„„„„ „, „„
000559 01-08
FAILURE OF NALOXONE TO REVERSE CATALEPSY ASSOCIATED WITH
SCHIZOPHRENIA: A CASE-REPORT
000560 01-08
A CASE-REPORT OF CIMETIDINE-INDUCED DEPRESSIVE-SYNDROME.
000839 01-15
CUTANEOUS REACTION TO LITHIUM-CARBONATE: A CASE-REPORT.
000872 01-15
A CASE-REPORT OF LORAZEPAM WITHDRAWAL.
000889 01-15
PHENYTOIN TOXICITY IN A BRAIN-DAMAGE ADOLESCENT: A CASE-
^^''^^^ 003512 03-15
LITHIUM NEUROTOXICITY AT THERAPEUTIC LEVELS: A CASE-REPORT^
003533 03-15
CASE-REPORT OF UNUSUAL DIAZEPAM ABSTINENCE-SYNDROME
004643 04- 1 -
CASE-REPORTS
IMIPRAMINE TREATMENT OF BORDERLINE-CHILDREN: CASE-REPORTS
WITHACONTROLLED-STUDY. 003356 03-11
d'ePENDENCE on TRANQUILIZERS (AN OVERVIEW WITH (CASE-STUDIES) _
003580 03-1/
CASE-STUDY
SATYRIASIS: A CASE-STUDY. 000709 01-11
PSYCHOAaiVE-DRUG-EFFEaS IN A HYPERACTIVE-CHILD: A CASE-STUDY
ANALYSIS OF BEHAVIOR-CHANGE AND TEACHER AHENTION.
002313 02-1'
SYNERGISM OF COMBINED LITHIUM NEUROLEPTIC THERAPY: A DOUBLE-
BUND, PLACEBO-CONTROLLED CASE-STUDY.
003 loj Oo-Oc
CORTICAL EVOKED-POTENTIALS IN GILLES-DE-IA-TOUREHES-SYNDROME
-A SINGLE CASE-STUDY. 00343103-1:
TREATMENT OF NARCOLEPSY AND SLEEP-APNEA WITH GAMMA
HYDROXYBUTYRATE: A CLINICAL AND POLYSOMNOGRAPHIC CASE-
5™°^ 004571 04-1.
^"^RUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY
GABA DEFICIENCY CLINICALLY DETEQED: 38 NEW CASES ^^^
S-74
^;;
VOLUME 19, SUBJECT INDEX
THREE CASES OF UNIPOLAR DELUSIONAL DEPRESSION RESPONSIVE TO L-
DOPA
000628 01-09
REVIEW OF 38 CASES OF SUBACUTE SCLEROSING PANENCEPHALITIS:
EFFECT OF AMANTADINE ON THE NATURAL COURSE OF THE DISEASE
000718 01-11
TARDIVE-DYSKINESIAS (OBSERVATIONS CONCERNING THREE CASES).
000861 01-15
AGITATION DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON
CIMETIDINE: A REPORT OF THREE CASES AND LITERATURE REVIEW.
000896 01-15
THE DEVELOPMENT OF PROGENY IN CASES OF ANTENATAL EXPOSURE TO
PHENAZEPAM „„,„.. „^„c
001854 02-05
TREATMENT OF ASTHENO-DEPRESSIVE-DISOROERS WITH MINAPRINE
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE
FATIGUE STUDY GROUPS NO. 4 CLINICAL-SCALE.
001980 02-09
BIPOLAR AFFECTIVE-PSYCHOSIS WITH ONSET BEFORE AGE 16 YEARS:
REPORT OF 10 CASES. „„„„„, „o «o
002001 02-09
MINAPRINE IN SEVERE PSYCHOPATHOLOGY: STUDY OF 20 CASES.
002135 02-11
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF
ENURESIS: A COMPARATIVE-STUDY.
002175 02-11
PERSPECTIVES ON PRAZINIL (CARPIPRAMINE): A DISINHIBITING-AGENT
WITH NO NEUROLEPTIC ACTIVITY. A REVIEW OF 38 CASES.
003149 03-07
THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL-
MEDICAL-PRACTICE: 48 CASES TREATED ON AN OUTPATIENT BASIS.
003268 03-09
SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN
PRAZEPAM TREATMENT IN 30 CASES.
003296 03-11
EXCESSIVE PLASMA CONCENTRATIONS OF TRICYCLIC-ANTIDEPRESSANTS
RESULTING FROM USUAL DOSES: A REPORT OF SIX CASES.
003479 03-15
EXCEPTIONAL CASES OF DEATH CAUSED BY TRICYCLIC-ANTIDEPRESSANT
AGENTS.
003490 03-15
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF
BENZODIAZEPINE TREATMENT: SIX CLINICAL CASES.
003505 03-15
AGE-SPECIFIC DOSES OF LORMETAZEPAM AS A NIGHT SEDATIVE IN
CASES OF CHRONIC SLEEP-DISTURBANCE.
004309 04-07
NEUROLOGICAL TOLERANCE OF LITHIUM AND PSYCHOTROPIC-DRUGS IN
COMBINATION: 265 CASES.
004594 04-15
THE TWO SURVIVAL CASES OF ALPHA-PATTERN COMA CAUSED BY
LARGE AMOUNTS OF HYPNOTICA AND NEUROLEPTICA.
004608 04-15
TWO CASES OF FORM-FRUSTE-DU-SYNDROME-MALIN WITH HIGH-LEVELS
OF SERUM CPK.
004636 04-15
CASQMQRPHINS
OPIOID ACTIVITIES OF BETA CASOMORPHINS.
003740 04-03
CASTRATED
MORPHINE EXERTS TESTOSTERONE-LIKE EFFEQS IN THE HYPOTHALAMUS
OF THE CASTRATED MALE RAT.
000051 01-03
EFFECT OF AMINOOXY ACETIC-ACID AND BICUCULLINE ON PROLACTIN
RELEASE IN CASTRATED MALE RATS.
001194 02-03
SUPPRESSIVE EFFECT OF MORPHINE ON SERUM GONADOTROPIN LEVELS
IN CASTRATED RATS.
001393 02-03
CAT
THE INFLUENCE OF BENZOCTAMINE ON DOPAMINE AND NOREPINEPHRINE
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH
REFLEX OF THE CAT.
000054 01-03
EFFEQS OF ALPHA CHLORALOSE ON THE ACTIVITY OF THE
NIGROSTRIATAL DOPAMINERGIC SYSTEM IN THE CAT.
000217 01-03
EFFECTS OF ENKEPHALIN ANALOGUE AND NALOXONE ON CAT SPINAL-
CORD DORSAL ROOT POTENTIALS.
000236 01-03
EFFECTS OF CENTRALLY-ADMINISTERED PENTAZOCINE AND
ETHYLKETOCYCLAZOCINE ON THERMOREGULATION IN THE CAT.
000361 01-04
THE EFFECTS OF LSD AND SOME ANALOGUES ON THE RESPONSES OF
SINGLE CORTICAL NEURONS OF THE CAT TO OPTICAL-STIMULATION.
000738 01-12
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE
CAT. (PH.D. DISSERTATION).
001179 02-03
Subject Index
DEPRESSION AND FACILITATION OF SYNAPTIC RESPONSES IN CAT
DORSAL-HORN BY SUBSTANCE-P ADMINISTERED INTO SUBSTANTIA-
GELATINOSA.
001191 02-03
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES:
EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION
IN THE ANESTHETIZED CAT.
001203 02-03
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY
SPECTRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND
NEUROLEPTICS.
001220 02-03
METHYLDOPA PRODUCES CENTRAL INHIBITION OF PARASYMPATHETIC-
ACTIVITY IN THE CAT.
001321 02-03
DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR
TRANSMinER IN THE CAT CEREBRAL-ARTERY.
001336 02-03
INDIRECT ADRENERGIC EFFECT OF HISTAMINE IN CAT CEREBRAL-
ARTERIES.
001355 02-03
DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND NORADRENALINE
CONTENT IN PIAL-ARTERIES OF CAT AND GOAT.
001357 02-03
ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN
THE CAT.
001761 02-04
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE
SPINAL-CORD OF THE CAT: ENKEPHALIN-CONTAINING MARGINAL
NEURONS AND PAIN MODULATION.
002638 03-01
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA
D(AND L) GLUTAMYLGLYCINE.
002696 03-03
PRESYNAPTIC REGULATION OF THE RELEASE OF CATECHOLAMINES IN THE
CAT HYPOTHALAMUS.
002703 03-03
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED
CAT.
002740 03-03
POTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3-
HYDROXYASPARTATE.
002768 03-03
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND
EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES.
002799 03-03
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
002801 03-03
L HISTIDINE: EFFECTS ON SENSITIVITY OF CAT SPINAL NEURONES TO
AMINO-ACIDS.
002808 03-03
ANTINOCICEPTIVE ACTION OF MORPHINE AND PENTAZOCINE ON UNIT
ACTIVITY IN THE NUCLEUS-CENTRALIS-LATERALIS, NUCLEUS-
VENTRALIS-LATERALIS AND NEARBY STRUCTURES OF THE CAT.
002837 03-03
VOLTAGE CLAMP STUDY OF CAT SPINAL MOTONEURONS DURING
STRYCHNINE-INDUCED SEIZURES.
002886 03-03
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNCTION IN CAT BRAIN.
00291 1 03-03
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT.
003703 04-02
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT
NICTITATING MEMBRANE.
003777 04-03
THE EFFECT OF NOOTROPIL ON THE TRANSCALLOSAL AND PRIMARY
EVOKED-RESPONSES OF THE CAT CEREBRAL-CORTEX.
003780 04-03
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NICTITATING MEMBRANE OF THE CAT.
003822 04-03
A.
U
S-75
Subject Index
Psychopharmacology Abstracts
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN.
003941 04-03
IN VIVO EVIDENCE FOR GABAERGIC CONTROL OF SEROTONIN RELEASE IN
THE CAT SUBSTANTIA-NIGRA.
00401 1 04-03
CANNABINOID-INDUCED ENHANCEMENT AND DEPRESSION OF CAT
MONOSYNAPTIC REFLEXES.
004040 04-03
NALOXONE SUPPRESSES FOOD/WATER CONSUMPTION IN THE DEPRIVED
CAT.
004114 04-04
SELECTIVE EFFECT OF ETHANOL ON THE VESTIBULAR NUCLEUS NEURONS
IN THE CAT.
004139 04-04
POSSIBLE MUSCARINIC CHOLINERGIC MEDIATION OF PAHERNED
AGGRESSIVE REFLEXES IN THE CAT.
004153 04-04
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM-
ACETATE, MONOFLUOROACETATE AND INSULIN-INDUCED
HYPOGLYCEMIA.
004276 04-05
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT
VERTEBRAL-ARTERY OF THE CAT, A MODIFIED ANIMAL-MODEL FOR
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE
LOWER BRAINSTEM.
004297 04-06
CATABOLISM
DECREASED CEREBRAL CATABOLISM OF (3H)HISTAMINE IN VIVO AFTER S
ADENOSYLMETHIONINE ADMINISTRATION.
002883 03-03
PROPERTIES OF THE OPTICAL-ISOMERS AND METABOLITES OF KETAMINE
ON THE HIGH-AFFINITY TRANSPORT AND CATABOLISM OF
MONOAMINES.
004009 04-03
CATALEPSY
EFFECTS OF DOPAMINERGIC AND CHOLINERGIC-DRUGS, NALOXONE AND
L PROLYL-LEUCYL-GLYCINAMIDE ON LSD-INDUCED CATALEPSY
000360 01-04
MORPHINE VERSUS HALOPERIDOL CATALEPSY IN THE RAT: A
BEHAVIORAL-ANALYSIS OF POSTURAL SUPPORT MECHANISMS.
000376 01-04
FAILURE OF NALOXONE TO REVERSE CATALEPSY ASSOCIATED WITH
SCHIZOPHRENIA: A CASE-REPORT
000560 01-08
STRESS-INDUCED FACILITATION OF OPIATE CATALEPSY IN THE RAT
001680 02-04
EFFECT OF QUIPAZINE AND FLUOXETINE ON ANALGESIC-INDUCED
CATALEPSY AND ANTINOCICEPTION IN THE RAT
001709 02-04
BIPHASIC-EFFECTS OF DIRECT, BUT NOT INDIRECT, GABAMIMETICS AND
ANTAGONISTS ON HALOPERIDOL-INDUCED CATALEPSY.
001826 02-04
INCREASED AMPHETAMINE STEREOTYPY AND LONGER HALOPERIDOL
CATALEPSY IN SPONTANEOUSLY HYPERTENSIVE-RATS.
002891 03-03
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR
FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY.
002986 03-04
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCED
ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY.
004018 04-03
EFFECTS OF NARCOTIC ANTAGONISTS ON L-OOPA REVERSAL OF
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE.
004186 04-04
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND
BODY-TEMPERATURE CHANGES IN RATS
004238 04-04
CATALEPTIC-EFFECT
PLASMA AND BRAIN LEVELS OF DELTA6 THC AND SEVEN
MONOOXYGENATED METABOLITES CORRELATED TO THE CATALEPTIC-
EFFECT IN THE MOUSE.
001737 02-04
CATALEPTIC-EFFECTS
DIFFERENTIAL REVERSAL BY SCOPOLAMINE AND THIP OF THE
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS.
002948 03-04
THE EFFECTS OF PEPTIDES ON TOLERANCE TO THE CATALEPTIC-EFFECTS
AND HYPOTHERMIC-EFFECTS OF MORPHINE IN THE RAT.
004072 04-04
CATALYTIC
COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE
BONDS.
003927 04-03
CATAPLEXY
CHOLINERGIC MECHANISMS AND CATAPLEXY IN DOGS.
000374 01-04
CATATONIA
EPIDURAL MORPHINE-INDUCED CATATONIA.
002400 02-15
A NEUROANATOMICAL-STUDY OF ANALGESIA AND CATATONIA INDUCED
BY ETORPHINE IN THE RAT. (PH.D. DISSERTATION)
003102 03-04
MODIFICATION OF DRUG-INDUCED CATATONIA AND TREMORS BY
QUIPAZINE IN RATS AND MICE.
004164 04-04
CATATONIA-SYNDROME
DISULFIRAM ENCEPHALOPATHY AS A CAUSE OF THE CATATONIA-
SYNDROME.
000894 01-15
CATCH-UP
ACTIVITY AND CATCH-UP GROWTH IN HYPOTHYROID RATS.
004190 04-04
CATECHOl-O-METHYLTRANSFERASE
THE ACTIVITY OF ERYTHROCYTE CATECHOL-O-METHYLTRANSFERASE IN
ENDOGENOUS DEPRESSIVE-SYNDROMES.
004546 04-13
CATECHOLAMINE
EFFECTS OF MORPHINE, BETA ENDORPHIN AND NALOXONE ON
CATECHOLAMINE LEVELS AND SEXUAL-BEHAVIOR IN THE MALE RAT.
000430 01-04
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS
000466 01-04
HYPOTHALAMIC CATECHOLAMINE BIOSYNTHESIS IN VITRO AS
MEASURED BY LIQUID-CHROMATOGRAPHY AND ELECTROCHEMICAL-
DETECTION
000537 01-06
CATECHOLAMINE TRANSMIHER SYSTEMS.
000580 01-09
THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REAQION
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN.
001052 02-01
DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN
FRAGMENTS OF MALE AND FEMALE RATS
001121 02-03
INTERACTION OF TRIAZOLAM WITH DESIPRAMINE EFFECTS OF SINGLE
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC-
RESPONSES AND BRAIN CATECHOLAMINE LEVELS.
001323 02-03
ERGOT AND CATECHOLAMINE POTENCIES AT CATECHOLAMINE-
RECEPTORS
001510 02-03
THE PHARMACOLOGY OF CATECHOLAMINE INVOLVEMENT IN THE
NEURAL MECHANISMS OF REWARD
001526 02-03
DOSE-DEPENDENT PHARMACOKINETICS OF ALPHA METHYL-P-TYROSINE
(ALPHA MT) AND COMPARISON OF CATECHOLAMINE TURNOVER-
RATES AFTER TWO DOSES OF ALPHA MT.
001532 02-03
DORSAL TEGMENTAL BUNDLE DESTRUCTION EFFEaS ON OPERANT-
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL-
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS.
001726 02-04
AN AUTOMATED ELECTROCHEMICAL-METHOD FOR IN VIVO MONITORING
OF CATECHOLAMINE RELEASE
001873 02-06
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS.
002047 02-09
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA
AND MEDIAL NUCLEUS-TRACTUS-SOLITARIUS OF RAT-BRAIN.
002634 03-01
CENTRAL AND PERIPHERAL CATECHOLAMINE FUNQION IN LEARNING
AND MEMORY PROCESSES.
002823 03-03
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION.
003052 03-04
A POSSIBLE ROLE FOR CATECHOLAMINE NEUROTRANSMIHERS IN THE
ANTICONVULSANT ACTIVITY OF CHLORDIAZEPOXIDE.
003119 03-04
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION.
003140 03-06
CATECHOLAMINE TURNOVER IN RAT-CEREBRAL-CORTEX AND CAUDATE
FOLLOWING REPEATED TREATMENT WITH DIHYDROERGOTOXINE
003765 04-03
CATECHOLAMINE AND 5 HYDROXYTRYPTAMINE SYNTHESIS AND
METABOLISM FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF
DIBUTYRYL-CYCLIC-AMP.
003769 04-03
CATECHOLAMINE SYNTHESIS REGULATION IN HYPOTHALAMIC
SYNAPTOSOMES. (UNPUBLISHED PAPER).
003829 04-03
S-76
VOLUME 19, SUBJECT INDEX
Subject Index
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS
003871 04-03
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE
REVERSAL OF GUANETHIOINE BLOCKADE OF ADRENERGIC NEURONS.
003900 04-03
THE EFFECT OF PRENATAL EXPOSURE TO ETHANOL OR OPIATES ON BRAIN
CATECHOLAMINE ACTIVITY
003939 04-03
CATECHOLAMINE MODULATION OF ENKEPHALIN-INDUCED
ELECTROPHYSIOLOGICAL RESPONSES IN CEREBRAL-CORTEX.
003957 04-03
EFFECTS OF CANNABINOIDS ON CATECHOLAMINE UPTAKE AND RELEASE
IN HYPOTHALAMIC AND STRIATAL SYNAPTOSOMES.
003970 04-03
EFFECT OF PR0STAGLANDIN-D2, PR0STAGLANDIN-E2 AND
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES
OF RAT AND RABBIT BRAIN.
003983 04-03
CATECHOLAMINE SEROTONIN INTERACTION EFFECTS ON ACTIVITY IN
RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE.
004194 04-04
CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND
NATURAL SEniNGS. CORRELATIONAL AND VARIANCE COMPONENTS
ANALYSES.
004508 04-13
CATECHOLAMINE METABOLISM IN A PSYCHOACTIVE CACTUS.
004722 04-17
CATECHOLAMINE-DEPLETING-AGENT
EFFECT OF THE CATECHOLAMINE-DEPLETING-AGENT 1 PHENYL-2-
THIAZOLYL-2-THIOUREA (U-14-624) ON DRUG METABOLISM IN THE
RAT
000280 01-03
CATECHOLAMINE-RECEPTORS
ERGOT AND CATECHOLAMINE POTENCIES AT CATECHOLAMINE-
RECEPTORS.
001510 02-03
EFFECTS OF PROPRANOLOL ON THE LOCOMOTOR- STIMULATION INDUCED
BY ACTIVATION OF POSTSYNAPTIC CATECHOLAMINE-RECEPTORS.
004126 04-04
RELATION BETWEEN BRAIN CATECHOLAMINE-RECEPTORS AND
DOPAMINERGIC STEREOTYPY IN RAT STRAINS.
004131 04-04
CATECHOLAMINE-SULFATES
PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW
METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES.
004286 04-06
CATECHOLAMINERGIC
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-ACTIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
ACTIVITY.
000309 01-03
SEROTONERGIC AND CATECHOLAMINERGIC INFLUENCE ON THYROID-
FUNCTION IN THE VERVET-MONKEY
001385 02-03
EFFEQS OF KAINIC-ACID ON BODY-TEMPERATURE OF RATS: ROLE OF
CATECHOLAMINERGIC AND SEROTONERGIC SYSTEMS.
001515 02-03
PATHOPHYSIOLOGIC-IMPACT OF CENTRAL CATECHOLAMINERGIC
FUNCTION IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES.
002174 02-11
CATECHOLAMINERGIC INVOLVEMENT IN PHASIC VERSUS TONIC
ELECTROCORTICAL AROUSAL.
002723 03-03
CATECHOLAMINES
COMPARTMENTATION OF CATECHOLAMINES IN RAT-BRAIN: EFFECTS OF
AGONISTS AND ANTAGONISTS.
000125 01-03
BIOCHEMICAL-CHARACTERIZATION OF THE RAT SYMPATHETIC
GANGLION: PHARMACOLOGICAL-EFFECTS OF RESERPINE ON
GANGLIONIC CATECHOLAMINES.
000153 01-03
INCREASED URINARY EXCRETION OF CATECHOLAMINES AND THEIR
METABOLITES IN STREPTOZOTOCIN DIABETIC RAT.
000154 01-03
FALSE LABELLING OF COMMERCIALLY-AVAILABLE 3H CATECHOLAMINES?
000535 01-06
THE RELEASE OF CATECHOLAMINES FROM ADRENERGIC NEURONS.
000974 01-17
LACK OF INFLUENCE OF BRAIN CATECHOLAMINES ON ACUTE EFFECTS OF
BARBITURATES.
001138 02-03
EFFECT OF TABERNANTHINE ON THE TURNOVER TIME OF BRAIN
CATECHOLAMINES IN NORMAL AND HYPOBARIC HYPOXIC RATS.
001187 02-03
EFFECT OF PROSTAGLANDINS ON PLASMA CATECHOLAMINES, HEART
AND BLOOD-PRESSURE RESPONSES TO HEMORRHAGE. (UNPUBLISHED
PAPER).
001223 02-03
PERIPHERAL CATECHOLAMINES AND MEMORY MODULATION
(UNPUBLISHED PAPER)
f 001251 02-03
EFFECTS OF PRENATAL METHADONE ON RAT-BRAIN CATECHOLAMINES.
001367 02-03
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR
THE POTENTIATION OF IMIPRAMINE EFFECTS ON THE METABOLISM
AND UPTAKE OF BRAIN CATECHOLAMINES.
001427 02-03
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND
TOLERANT RATS AND MICE
001476 02-03
BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE-
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL-
CONSIDERATIONS.
001550 02-03
BRAIN CATECHOLAMINES MODIFICATIONS. THE EFFECTS ON MEMORY
FACILITATION INDUCED BY OXOTREMORINE IN MICE.
001658 02-04
OPIATE ACTIONS AND CATECHOLAMINES.
001662 02-04
EFFECTS OF CAFFEINE ON PLASMA FREE FATTY-ACIDS, URINARY
CATECHOLAMINES, AND DRUG BINDING.
002272 02-13
SEX-DIFFERENCES IN THE AMPHETAMINE STIMULATED RELEASE OF
CATECHOLAMINES FROM RAT STRIATAL TISSUE IN VITRO
002668 03-03
PRESYNAPTIC REGULATION OF THE RELEASE OF CATECHOLAMINES IN THE
CAT HYPOTHALAMUS.
002703 03-03
PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFECTS OF
GANGLIONIC AND ADRENORECEPTOR BLOCKADE.
002863 03-03
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFECTS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN.
002990 03-04
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH.
003882 04-03
LIBERATION OF CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE FROM
HUMAN BLOOD-PLATELETS.
003967 04-03
HYPOTENSION ALTERS THE RELEASE OF CATECHOLAMINES IN THE
HYPOTHALAMUS OF THE CONSCIOUS RABBIT.
003968 04-03
PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW
METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES.
004286 04-06
CATECHOLESTROGEN
DEVELOPMENTAL ASPECTS OF CATECHOLESTROGEN SYNTHESIS.
(UNPUBLISHED PAPER).
001282 02-03
CATECHOLIC
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE
MOUSE AND THE RAT.
003870 04-03
CATEGORIES
ON THE USE OF CERTAIN PHARMACOLOGICAL CATEGORIES IN HYSTERIA.
004347 04-09
BASAL PROLACTINAEMIA AND RESPONSES TO TRH AND SULPIRIDE IN
DIFFERENT CATEGORIES OF MALE SEXUAL-DYSFUNCTIONS.
004503 04-13
CATHA-EDULIS
RELATIVE POTENCIES OF TWO PHENYLALKYLAMINES FOUND IN THE
ABUSED PLANT CATHA-EDULIS, KHAT.
001084 02-02
HYPERTHERMIC-RESPONSE TO (-) CATHINONE, AN ALKALOID OF CATHA-
EDULIS (KHAT).
003694 04-02
CATHINONE
HYPERTHERMIC-RESPONSE TO (-) CATHINONE, AN ALKALOID OF CATHA-
EDULIS (KHAT).
003694 04-02
CATION
EFFECT OF STRUCTURE ON PHENOTHIAZINE CATION RADICAL REACTIONS
IN AQUEOUS BUFFERS.
000014 01-02
MEASUREMENT OF THE MEMBRANE POTENTIAL OF ISOLATED NERVE
TERMINALS BY THE LIPOPHILIC CATION
(3H)TRIPHENYLMETHYLPH0SPH0NIUM-BR0MIDE.
002746 03-03
CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF
(3H)SULPIRIDE AND (3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS.
004032 04-03
tic
S-77
Subject Index
CATIONS
REGULATION BY CATIONS OF (3H)SPIR0PERID0L BINDING ASSOCIATED
WITH DOPAMINE-RECEPTORS OF RAT-BRAIN.
002922 03-03
SPECTRA OF RADICAL CATIONS OF PHENOTHIAZINE DERIVATIVES IN
SOLUTION AND SOLID STATE.
003673 04-01
CATS
NEURONAL ACTIVITY IN CHRONIC FERRIC-CHLORIDE EPILEPTIC-FOCI IN
CATS AND MONKEY.
000172 01-03
THE INFLUENCE OF CHLORALOSE ANESTHESIA ON THE ACTIVITY OF RED
NUCLEUS NEURONS IN CATS.
000245 01-03
RELATION OF AAONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION
IN CATS.
000474 01-04
THE INFLUENCE OF GABAERGIC SUBSTANCES ON THE EFFECTS OF
STIMULATION OF THE CAUDATE-NUCLEUS AND AMPHETAMINE
STEREOTYPY IN CATS.
000489 01-04
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL-
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL
SEROTONERGIC FUNCTION.
000491 01-04
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS
000520 01-05
THE EFFECT OF EMOTIONAL- STRESS AND DIAZEPAM ON MONOAMINE
METABOLITES IN THE CEREBROSPINAL-FLUID OF CATS. (PH.D.
DISSERTATION). „^,„,„„. „,
001260 02-03
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS
INDUCED BY AMPHETAMINE IN CATS.
001340 02-03
EFFECTS OF MORPHINE ON EVOKED-POTENTIALS RECORDED FROM THE
AMYGDALA BY TOOTH-PULP STIMULATION IN CATS.
001379 02-03
INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRICTION
BY CLONIDINE IN CATS.
001431 02-03
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON
BARORECEPTOR REFLEXES IN CONSCIOUS CATS
001514 02-03
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA
ELICITED BY MUSCARINE INJEQED INTO THE CEREBRAL VENTRICLES OF
CONSCIOUS CATS.
001569 02-04
BEHAVIORAL-EFFECTS AND ELECTROPHYSIOLOGICAL-EFFECTS OF OPIOID-
PEPTIDES IN CATS.
001612 02-04
EFFECT OF CHOLINE ON CONDITIONED FOOD MOTOR-REFLEXES IN CATS
001731 02-04
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFECTS OF FENTANYL ON
THE CONTRACTION OF THE NICTITATING MEMBRANE IN CATS.
002876 03-03
AMPHETAMINE-INDUCED ROTATION IN NORMAL CATS.
003002 03-04
CATS DEVELOP TOLERANCE TO D-AMPHETAMINES EFFECTS UPON
LOCOMOTION AND STEREOTYPED-BEHAVIORS.
003018 03-04
MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJECTIONS OF
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS
003101 03-04
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING,
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL
WAVES IN CATS?
003704 04-02
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON
BEHAVIORAL SHIFTS IN CATS, ARISING AFTER CESSATION OF
ELECTRICAL-STIMULATION OF THE CAUDATE-NUCLEUS.
004067 04-04
RESPIRATORY DEPRESSION PRODUCED BY DIAZEPAM IN CATS: EFFEQ OF
ANESTHESIA.
004272 04-05
CAUDATE
EFFECTS OF CHRONIC HALOPERIDOL ON CAUDATE 3H SPIROPERIDOL
BINDING IN LESIONED RATS.
000255 01-03
Psychopharmacology Abstracts
3H MIANSERIN BINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG AQION.
000325 01-03
GLYCINE ENHANCEMENT OF CAUDATE NEURONAL ACTIVITIES:
RELATIONSHIP WITH THE DOPAMINERGIC NIGROSTRIATAL PATHWAY.
001225 02-03
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS
INDUCED BY AMPHETAMINE IN CATS.
001340 02-03
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPACTA AND
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE
SPONTANEOUS NEURONAL ACTIVITIES IN THE RAT.
002718 03-03
DOPAMINE METABOLITES IN CAUDATE AND CORTEX AFTER LITHIUM AND
HALOPERIDOL. (UNPUBLISHED PAPER).
003738 04-03
CATECHOLAMINE TURNOVER IN RAT-CEREBRAL-CORTEX AND CAUDATE
FOLLOWING REPEATED TREATMENT WITH DIHYDROERGOTOXINE.
003765 04-03
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF
(3H)SPIR0PERID0L IN CALF CAUDATE.
003906 04-03
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRACTION.
003948 04-03
EFFECTS OF A HIGH-DOSE TREATMENT OF METHAMPHETAMINE ON
CAUDATE DOPAMINE AND ANOREXIA IN RATS.
004073 04-04
CAUDATE-NUCLEI
MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJEQIONS OF
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS.
003)01 03-04
CAUDATE-NUCLEUS
IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR
ACTIVITY
000289 01-03
ANTINOCICEPTIVE-EFFEQ OF MORPHINE, OPIOID ANALGESICS AND
HALOPERIDOL INJECTED INTO THE CAUDATE-NUCLEUS OF THE RAT.
000414 01-04
THE INFLUENCE OF GABAERGIC SUBSTANCES ON THE EFFECTS OF
STIMULATION OF THE CAUDATE-NUCLEUS AND AMPHETAMINE
STEREOTYPY IN CATS.
000489 01-04
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT
CAUDATE-NUCLEUS.
001298 02-03
FUNCTIONAL ORGANIZATION OF THE CAUDATE-NUCLEUS AFTER
ADMINISTRATION OF CARBACHOL.
001495 02-03
OPIOID-RECEPTORS IN THE CAUDATE-NUCLEUS CAN MEDIATE EMG-
RECOROED RIGIDITY IN RATS.
001649 02-04
HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY
UNILATERAL 6 OHDA INJECTIONS INTO SUBSTANTIA-NIGRA AND
CAUDATE-NUCLEUS.
001778 02-04
HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE
CAUDATE-NUCLEUS BY GABA AGONISTS.
002640 03-01
MODULATION BY ENDOGENOUS DOPAMINE OF THE RELEASE OF
ACETYLCHOLINE IN THE CAUDATE-NUCLEUS OF THE RABBIT.
002751 03-03
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR
FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY.
002986 03-04
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON
BEHAVIORAL SHIFTS IN CATS, ARISING ARER CESSATION OF
ELEQRICAL- STIMULATION OF THE CAUDATE-NUCLEUS.
004067 04-04
CAUDATE-PUT AMEN
BEHAVIOURAL-RESPONSES TO STEREOTAQICALLY CONTROLLED
INJEQIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI.
001708 02-04
EFFEaS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE- .
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC |
BUNDLE IN THE RAT. ^ I
003910 04-03
CDP-CHOLINE
ACTIVATION OF SOLUBLE STRIATAL TYROSINE-HYDROXYLASE IN THE RAT
BRAIN AFTER CDP-CHOLINE ADMINISTRATION.
002816 03-03
S-78
VOLUME 19, SUBJECT INDEX
Subject Index
CDP-DIGLYCERIDE-HYDROLASE
PROPERTIES OF A CDPDIGLYCERIDE-HYOROLASE FROM GUINEA-PIG
BRAIN.
003987 04-03
CEEO
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT;
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL
EVOLUTION.
002165 02-11
CEFAZOLIN
BEHAVIORAL-EFFECTS AND ELECTROCORTICAL-EFFECTS AFTER
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS
ENHANCING GABAERGIC TRANSMISSION.
000443 01-04
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR
INJECTION OF CEFAZOLIN.
002762 03-03
CEFAZOLIN-INDUCED
ANTAGONISM BY CLASSICAL ANTIEPILEPTICS AND SODIUM-VALPROATE
OF CEFAZOLIN-INDUCED EXPERIMENTAL EPILEPSY IN RATS.
000442 01-04
CELL
CEREBELLAR GRANULE CELL GENESIS IN THE HYDROCORTISONE TREATED
RAT.
000030 01-03
(3H)5 NT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN
GLIAL CELL MEMBRANE FRACTION.
000093 01-03
GLIAL CELL EFFECTS OF SUBACUTE FORMIC-ACID VAPOUR EXPOSURE.
000527 01-05
ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT
CELL TYPE SPECIFIC TOXIN. (UNPUBLISHED PAPER).
001064 02-01
SYNTHETIC IMMUNOSTIMULANTS DERIVED FROM THE BACTERIAL CELL
WALL.
001080 02-02
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
CHEMOTAXIS BY MOUSE MACROPHAGE CELL LINES. (UNPUBLISHED
PAPER).
001099 02-03
INHIBITION OF CHEMOTAXIS BY S 3 DEAZAADENOSYLHOMOCYSTEINE IN
A MOUSE MACROPHAGE CELL LINE. (UNPUBLISHED PAPER).
001100 02-03
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-ACTIVITY
RELATIONSHIPS.
001132 02-03
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION.
001300 02-03
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND
MORPHOLOGICAL-STUDY.
001407 02-03
NERVE CELL CALCIUM AS A MESSENGER FOR OPIATE AND ENDORPHIN
ACTIONS.
001450 02-03
EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC-
SYSTEMS IN THE RAT-BRAIN.
001464 02-03
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN
HUMAN CELLS.
002830 03-03
A REEVALUATION OF THE MECHANISMS UNDERLYING SIMPLE CELL
ORIENTATION SELECTIVITY.
002894 03-03
EFFECTS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA-
AORENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES.
002932 03-03
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK
TISSUES - ARE THEY CELL ADHESION MOLECULES?
003724 04-03
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE
RELATIONSHIP.
003806 04-03
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
004112 04-04
CELL-CULTURE
NEURONAL MATURATION IN MAMMALIAN CELL-CULTURE IS DEPENDENT
ON SPONTANEOUS ELECTRICAL-ACTIVITY.
002669 03-03
CELL-CULTURES
RELEASE OF ARACHIDONIC-ACID FROM ADRENAL CHROMAFFIN CELL-
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED
PAPER).
001027 02-01
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN
BRAIN CELL-CULTURES.
004002 04-03
CELL-FREE
OPIOID DEPENDENT DUAL-REGULATION OF ADENYLATE-CYCLASE IN A
CELL-FREE SYSTEM. (UNPUBLISHED PAPER).
001033 02-01
EFFECT OF INTRAVENOUS ADMINISTRATION OF D LYSERGIC-ACID-
DIETHYLAMIDE ON SUBSEQUENT PROTEIN SYNTHESIS IN A CELL-FREE
SYSTEM DERIVED FROM BRAIN.
003761 04-03
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO.
003832 04-03
CELLS
PSYCHOTROPIC-DRUGS AND HISTAMINE HI -RECEPTORS OF CULTURED
MOUSE NEUROBLASTOMA CELLS.
000250 01-03
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS.
000308 01-03
HYBRID PROTEINS USED TO STUDY THE MECHANISM OF TOXIN
ENTRANCE INTO CELLS. (UNPUBLISHED PAPER).
001063 02-01
INFLUENCE OF DRUGS AFFECTING THE PITUITARY ADRENAL AXIS ON
CHROMAFFIN CELLS.
001183 02-03
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER).
001188 02-03
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN- 13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
EXCITATORY ACTION OF OPIOID-PEPTIDES AND OPIATES ON CULTURED
HIPPOCAMPAL PYRAMIDAL CELLS.
001241 02-03
REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA -INDEPENDENT
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6-
GLIOMA CELLS. (UNPUBLISHED PAPER).
001403 02-03
LITHIUM-ION ENTRY INTO CULTURED CELLS OF NEURAL ORIGIN.
001433 02-03
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH LEWIS-RAT LYMPH-NODE CELLS. (UNPUBLISHED PAPER).
001434 02-03
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
RELATIONSHIP BETWEEN THE ACTIONS OF CALCIUM-IONS, OPIOIDS, AND
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN
NEUROBLASTOMA-X GLIOMA HYBRID CELLS.
002677 03-03
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND
DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY
Of ADULT SENSORY GANGLION CELLS.
002692 03-03
TOXIC EFFECTS OF ALPHA AMINOADIPATE ON CULTURED CEREBELLAR
CELLS.
002729 03-03
THE EFFECTS OF A BENZODIAZEPINE ON THE HYPERPOLARIZING AND THE
DEPOLARIZING RESPONSES OF HIPPOCAMPAL CELLS TO GABA.
002763 03-03
EFFECTS OF LITHIUM ON MORPHOLOGICAL CHARACTERISTICS OF
DISSOCIATED BRAIN CELLS IN CULTURE.
002765 03-03
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS
CULTURED FROM RAT-CEREBRAL-CORTEX.
002820 03-03
LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID.
002828 03-03
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN
HUMAN CELLS.
002830 03-03
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS.
002831 03-03
'•i
S
S-79
Subject Index
Psychopharmacology Abstracts
k.','.'' -V'
EFFECTS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L
TRYPTOPHAN BY ISOLATED RAT LIVER CELLS.
002899 03-03
LITHIUM UPTAKE IN RED CELLS OF CYCLOID AND UNIPOUVR DYSTHYMIC-
PATIENTS.
003258 03-09
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS:
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD.
003556 03-16
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF
BULLFROG SYMPATHETIC GANGLION CELLS.
003710 04-03
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBL^STOMA CELLS.
003783 04-03
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF
ALPHA-ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA
HYBRID CELLS.
003823 04-03
DOXEPIN A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTACT
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL-
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION.
003836 04-03
OPIOIDS NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA-
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER)
003998 04-03
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C-
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM-
CHANNEL BLOCKADE.
004020 04-03
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
004030 04-03
RELATIVE ACTIVITIES OF SUBSTANCES RELATED TO 5
HYDROXYTRYPTAMINE AS DEPOLARIZING-AGENTS OF SUPERIOR
CERVICAL GANGLION CELLS.
004047 04-03
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP-
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF
MOUSE NEUROBLASTOMA CELLS USING
(3H)TETRAPHENYLPH0SPH0NIUM.
004049 04-03
CELLULAR
BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND
CELLULAR LOCALIZATION.
002655 03-03
IN VITRO CELLULAR ADAPTATION OF SEROTONERGIC PROCESSES AFTER
CHRONIC CENTRAL PHENOBARBITAL ADMINISTRATION.
002813 03-03
CELLULAR-TRANSPORT
INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERACTION OF AMINO-
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG.
000034 01-03
CENTER
SATIETY CENTER NEUROANATOMY. (UNPUBLISHED PAPER).
003678 04-01
CENTERS
INFLUENCE OF CHRONIC ALCOHOL INTOXICATION ON CIRCADIAN-RHYTHM
OF NEUROSECRETORY CENTERS OF RAT HYPOTHALAMUS.
001549 02-03
CENTRAL
EVIDENCE FOR AN IRREVERSIBLE INTERACTION OF BROMOCRYPTINE
WITH CENTRAL DOPAMINE-RECEPTORS.
000023 01-03
EVIDENCE FOR A RECEPTOR SUPERSENSITIVITY FOLLOWING IMPAIRMENT
OF CENTRAL SEROTONERGIC ACTIVITY IN THE RABBIT.
000041 01-03
NUCIFERINE AND CENTRAL GLUTAMATE-RECEPTORS.
000063 01-03
CLENBUTEROL, A CENTRAL BETA-ADRENOCEPTOR AGONIST.
000120 01-03
ABSENCE OF POTASSIUM CONDUCTANCE IN CENTRAL MYELINATED
AXONS.
000166 01-03
CENTRAL NORADRENERGIC ADAPTATION TO LONG-TERM-TREATMENT
WITH IMIPRAMINE IN RHESUS-MONKEYS.
000182 01-03
EFFECT OF GABA ANALOGUES ON BLOOD-PRESSURE AND CENTRAL GABA
METABOLISM IN THE RAT.
000231 01-03
DIAZEPAM POTENTIATION OF PURINERGIC DEPRESSION OF CENTRAL
NEURONS.
000233 01-03
INVOLVEMENT OF CENTRAL CHOLINOCEPTORS IN METRAZOL-INDUCED
CONVULSIONS.
000247 01-03
CENTRAL BLOOD-PRESSURE EFFEaS OF GUANYLYLIMIDODIPHOSPHATE
AND CYCLIC-GUANOSINE-MONOPHOSPHATE.
000266 01-03
RELATION BETWEEN THE EFFEQS OF ANTIDEPRESSANT-DRUGS ON THE
UPTAKE OF MONOAMINES AND ON THE SPONTANEOUS AQIVITY OF
CENTRAL NEURONS.
000267 01-03
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL ACTIVITY.
000314 01-03
N ALKYLATED 2 AMINOTETRAUNS: CENTRAL DOPAMINE-RECEPTOR
STIMULATING ACTIVITY.
000399 01-04
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS
000466 01-04
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL-
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL
SEROTONERGIC FUNCTION.
000491 01-04
CENTRAL EXCITATORY ACTIONS OF FLURAZEPAM.
000526 01-05
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER ACTIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT.
001095 02-03
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
INHIBITION BY LOCAL ANESTHETICS. PHENTOLAMINE AND PROPRANOLOL
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL
MUSCARINIC-RECEPTORS.
001097 02-03
CENTRAL SYMPATHETIC REAQIVITY INHIBITED BY INDORAMIN
001193 02-03
CENTRAL MONOAMINE SYNAPSES AS SITES OF ACTION FOR ERGOT I
DRUGS.
001238 02-03
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL I
ON CENTRAL MONOAMINERGIC MECHANISMS.
001240 02-03
CENTRAL ADMINISTRATION OF SERINE CAUSES HYPOTHERMIA AND
INHIBITS FEVER IN RABBITS
001247 02-03
COMPARISON OF THE EFFECTS OF CENTRAL ADMINISTRATION OF SERINE
AND GLYCINE ON BODY-TEMPERATURE OF THE RABBIT.
001248 02-03
METHYLDOPA PRODUCES CENTRAL INHIBITION OF PARASYMPATHETIC-
AQIVITY IN THE CAT.
001321 02-03
TWO CONDUCTANCE MECHANISMS AQIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES
001349 02-03
EFFECTS OF DIFFERENT MONOAMINE-OXIDASE-INHIBITORS ON
RESPIRATORY ACTIVITY IN RATS WITH CHRONICALLY IMPAIRED
CENTRAL SEROTONERGIC FUNCTION
001389 02-03
DIFFERENTIAL-EFFEQS OF SYSTEMIC VERSUS INTRACRANIAL INJEQION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS
001446 02-03
CENTRAL BIOGENIC-AMINES AND NEUROPEPTIDES IN GENETIC
HYPERTENSION. (UNPUBLISHED PAPER).
001456 02-03
CENTRAL AMINERGIC AND PEPTIDERGIC MECHANISMS IN
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS. (UNPUBLISHED
PAPER).
001459 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTAQ RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
THE INABILITY OF CHRONIC MIANSERIN TO BLOCK CENTRAL ALPHA2-
ADRENOCEPTORS.
001492 02-03
NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR
CENTRAL ALPHAl -ADRENOCEPTORS.
001508 02-03
S-80
VOLUME 19, SUBJECT INDEX
Subject Index
COMPARED PROPERTIES OF CENTRAL AND PERIPHERAL BINDING-SITES
FOR PHENCYCLIDINE.
001521 02-03
KAINIC-ACID-INDUCED WET-DOG-SHAKES IN RATS: THE RELATION TO
CENTRAL NEUROTRANSMITTERS
001685 02-04
INVESTIGATIONS ON THE INTERACTION OF THYROTROPIN-RELEASING-
HORMONE (TRH) AND MK-771 WITH CENTRAL NORADRENERGIC
MECHANISMS
001701 02-04
A COMPARISON BETWEEN THE EFFECTS OF MORPHINE ON THE
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC
AND CENTRAL GRAY STIMULATION.
001771 02-04
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE-
DECANOATE TREATMENT
001820 02-04
CENTRAL SEROTONIN-RECEPTOR SENSITIVITY IN RATS WITH
EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS,
001821 02-04
ELECTROPHYSIOLOGICAL-CHANGES AT A CENTRAL NORADRENERGIC
SYNAPSE DURING THALLIUM TOXICOSIS.
001848 02-05
CLINICAL PROCESSES AND CENTRAL DOPAMINERGIC-ACTIVITY IN
PSYCHOTIC-DISORDERS.
002098 02-11
PATHOPHYSIOLOGIC-IMPACT OF CENTRAL CATECHOLAMINERGIC
FUNCTION IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES.
002174 02-11
THE USE OF BROMOCRIPTINE FOR TESTING CENTRAL DOPAMINERGIC
REACTIVITY,
002205 02-13
APOMORPHINE HYPOTHERMIA; AN INDEX OF CENTRAL DOPAMINE-
RECEPTOR FUNCTION IN MAN.
002221 02-13
CENTRAL DOPAMINERGIC-EFFECTS OF ERGOLINE DERIVATIVES.
002540 02-17
CENTRAL NEUROPHARMACOLOGY OF ENDORPHINS.
002599 02-17
CENTRAL DEPRESSANT EFFECTS OF CAERULEIN AND CHOLECYSTOKININ-
OCTAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND
HALOPERIDOL.
002652 03-02
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN.
002727 03-03
FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS
BY YOHIMBINE DIASTEREOMERS.
002748 03-03
IN VITRO CELLULAR ADAPTATION OF SEROTONERGIC PROCESSES AFTER
CHRONIC CENTRAL PHENOBARBITAL ADMINISTRATION.
002813 03-03
CENTRAL AND PERIPHERAL CATECHOLAMINE FUNCTION IN LEARNING
AND MEMORY PROCESSES.
002823 03-03
IN VIVO VOLTAMMETRIC INVESTIGATIONS INTO THE ACTION OF HA-966
ON CENTRAL DOPAMINERGIC NEURONS.
002832 03-03
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND
GANGLIONIC SYNAPSES.
002870 03-03
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC
NEURONS.
002880 03-03
ACCELERATED METABOLISM OF PROBENECID DURING LONG-TERM-
TREATMENT OF RATS WITH ANTICONVULSANT-DRUGS: EFFECT ON
CENTRAL SEROTONIN TURNOVER STUDIES.
002890 03-03
BETA ENDORPHIN-INDUCED HYPERGLYCEMIA IS MEDIATED BY INCREASED
CENTRAL SYMPATHETIC OUTFLOW TO ADRENAL-MEDULLA.
002924 03-03
ACTION OF CYCLIC-ADENOSINE-MONOPHOSPHATE ON CENTRAL
NEURONS.
002940 03-03
EFFECT OF ACUTE AND CHRONIC TRIIODOTHYRONINE (T3)
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE-
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN-
BIOCHEMISTRY.
002951 03-04
EFFECTS OF ACUTE CENTRAL AND PERIPHERAL ACTHl-24
ADMINISTRATION ON LORDOSIS BEHAVIOR.
002975 03-04
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766,
AN ANALOG OF ACTH4-9
003112 03-04
THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS
003397 03-12
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC-
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT MIANSERIN.
003745 04-03
CENTRAL HYPOTENSIVE-EFFECT OF GAMMA AMINOBUTYRIC-ACID IN
ANESTHETIZED DOGS.
003772 04-03
POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CARDIOVASCULAR-
EFFECTS OF CENTRAL ALPHA-ADRENOCEPTOR STIMULATION IN
SPONTANEOUSLY HYPERTENSIVE-RATS.
003791 04-03
OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE
CONDITIONING IN RABBITS.
003798 04-03
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC
AND DOCA-SALT HYPERTENSION IN THE RAT.
003899 04-03
EFFECTS OF 5 HYDROXYTRYPTAMINE ON CENTRAL NEURONES
ANTAGONIZED BY BICUCULLINE AND PICROTOXIN.
003931 04-03
CENTRAL CARDIOVASCULAR-EFFECTS AND BIOCHEMICAL-EFFECTS OF
BACLOFEN IN THE CONSCIOUS RAT.
003965 04-03
OPIATE SYSTEM INFLUENCES CENTRAL RESPIRATORY CHEMOSENSORS.
003971 04-03
EFFECT OF IMIPRAMINE ON CENTRAL 5 HYDROXYTRYPTAMINE
TURNOVER AND METABOLISM IN RATS.
003999 04-03
EFFECTS OF LITHIUM ON BEHAVIOUR AND CENTRAL MONOAMINES.
004110 04-04
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
004112 04-04
CENTRAL AND PERIPHERAL EFFECTS OF LITHIUM ON AMPHETAMINE-
INDUCED HYPERACTIVITY IN RATS.
004223 04-04
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND
BODY-TEMPERATURE CHANGES IN RATS.
004238 04-04
A POSSIBLE NEUROCHEMICAL BASIS OF THE CENTRAL STIMULATORY
EFFECTS OF PP'DDT.
004274 04-05
THE EFFICACY OF PIRACETAM IN VERTIGO: A DOUBLE-BUND STUDY IN
PATIENTS WITH VERTIGO OF CENTRAL ORIGIN.
004478 04-11
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY?
004553 04-13
CENTRAL-ACTION
CENTRAL-ACTION OF INTRAVENTRICULARLY INJECTED MIDODRINE IN
RATS.
001684 02-04
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN
MAN: POSSIBLE CENTRAL-ACTION IN BRAIN.
002195 02-12
CENTRAL-ACTIONS
CENTRAL-ACTIONS OF NOREPINEPHRINE, PHENTOLAMINE AND 6
HYDROXYDOPAMINE IN SPONTANEOUSLY HYPERTENSIVE-RATS.
001553 02-03
KINETICS OF CENTRAL-ACTIONS OF ISOFLOXYTHEPIN, AN ORAL
NEUROLEPTIC-DRUG WITH PROLONGED ACTION IN RODENTS.
001720 02-04
ADENOSINE-RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM:
RELATIONSHIP TO THE CENTRAL-ACTIONS OF METHYLXANTHINES.
003766 04-03
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT
VERTEBRAL-ARTERY OF THE CAT, A MODIFIED ANIMAL-MODEL FOR
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE
LOWER BRAINSTEM.
004297 04-06
CENTRAL-ACTIVITY
DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND
CYCLIC-AMP-PHOSPHODIESTERASE .
001405 02-03
CENTRAL-EFFECTS
MECHANISMS INVOLVED IN CENTRAL-EFFECTS OF PROSTAGLANDIN-
F2ALPHA. (UNPUBLISHED PAPER).
001222 02-03
ill;'
S-81
Subject Index
Psychopharmacology Abstracts
SOME CENTRAL-EFFECTS OF IMPROMIDINE, A POTENT AGONIST OF
HISTAMINE H2-RECEPT0RS.
001417 02-03
CYCLIC-NUCLEOTIDES AND THE CENTRAL-EFFECTS OF OPIATES: AN
OVERVIEW OF CURRENT RESEARCH.
001445 02-03
CENTRAL-EFFECTS OF SUBSTANCE-P IN FOWLS.
003075 03-04
CENTRAL-EFFECTS OF ANGIOTENSIN-II IN WATER AND SALINE LOADED
RATS.
003845 04-03
ANTAGONISM OF SOME CENTRAL-EFFECTS OF D TUBOCURARINE BY
GAMMA AMINOBUTYRIC-ACID.
004102 04-04
CENTRAL-NERVOUS-SYSTEM
EFFECT OF INTRAVENTRICULAR INJECTIONS OF ALPHA AMINOSULFONIC-
ACIDS ON THE CENTRAL-NERVOUS-SYSTEM OF CONSCIOUS MICE.
000009 01-02
NEUROTRANSMITTER RELATED ADAPTATION IN THE CENTRAL-NERVOUS-
SYSTEM FOLLOWING CHRONIC MONOAMINE-OXIDASE-INHIBITION.
000038 01-03
THE EFFECTS OF OPIATES ON THE LEVELS OF CYCLIC-GUANOSINE-
MONOPHOSPHATE IN DISCRETE AREAS OF THE RAT CENTRAL-
NERVOUS-SYSTEM.
000220 01-03
THE INVOLVEMENT OF SEROTONERGIC NEURONS IN THE CENTRAL-
NERVOUS-SYSTEM AS THE POSSIBLE MECHANISM FOR SLOW HEAD-
SHAKING-BEHAVIOR INDUCED BY METHAMPHET AMINE IN RATS.
000408 01-04
MOTOR-EFFECTS OF SEROTONIN IN THE CENTRAL-NERVOUS-SYSTEM.
000941 01-17
DERIVATIVES OF 1 1 1 PIPERAZINYL-5H-PYRR0L0BENZ0DIAZEPINE AS
CENTRAL-NERVOUS-SYSTEM AGENTS.
001093 02-02
CENTRAL-NERVOUS-SYSTEM DOPAMINE-RECEPTORS .
001185 02-03
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION)
001213 02-03
PERIPHERAL PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS:
ARE THEY DIFFERENT FROM DOPAMINE-RECEPTORS IN THE CENTRAL-
NERVOUS-SYSTEM.
001252 02-03
FURTHER EVIDENCE FOR THE EXISTENCE OF MULTIPLE RECEPTORS FOR
DOPAMINE IN THE CENTRAL-NERVOUS-SYSTEM
001296 02-03
PINEAL INTERACTIONS WITH THE CENTRAL-NERVOUS-SYSTEM:
NEUROENDOCRINE IMPLICATIONS. (PH D. DISSERTATION).
001341 02-03
THE ELECTROPHYSIOLOGICAL-EFFECTS OF ENKEPHALIN AND
PHENCYCLIDINE IN THE RAT CENTRAL-NERVOUS-SYSTEM. (PH.D.
DISSERTATION).
001406 02-03
FUNCTIONAL ASPECTS OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM IN THE CENTRAL-NERVOUS-SYSTEM.
001493 02-03
ON THE USE OF OPERANT-BEHAVIOR TO STUDY THE
NEUROPSYCHOPHARMACOLOGY OF OPIATES WITH SPECIAL REFERENCE
TO MORPHINE AND ITS RELATIONSHIP TO DOPAMINE IN THE CENTRAL-
NERVOUS-SYSTEM.
001790 02-04
EFFECTS OF 1,3 BIS-TETRAHYDRO-2-FURANYL-5-
FLUOROPYRIMIDINEDIONE (FD-1) ON THE CENTRAL-NERVOUS-SYSTEM:
1 . EFFECTS OF MONOAMINES IN THE BRAIN.
001857 02-05
THEORY, PROCEDURE, AND APPLICATIONS OF THE RADIOACTIVE
DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL GLUCOSE
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM. (UNPUBLISHED
PAPER).
001877 02-06
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL-
NERVOUS-SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE-
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS).
002459 02-15
EFFECTS OF 4 AMINOPYRIDINE ON THE TURNOVER OF MONOAMINES IN
THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.
002658 03-03
GAMMA BUTYROLACTONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE
CITRATE (DN-1417): A NOVEL TRH ANALOG WITH POTENT EFFECTS ON
THE CENTRAL-NERVOUS-SYSTEM.
003057 03-04
ADENOSINE-RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM:
RELATIONSHIP TO THE CENTRAL-ACTIONS OF METHYLXANTHINES.
003766 04-03
SPECIFIC, HIGH-AFFINITY (3H)ETHYLKET0CYCLAZ0CINE BINDING IN RAT
CENTRAL-NERVOUS- SYSTEM: LACK OF EVIDENCE FOR KAPPA-
RECEPTORS.
003840 04-03
THE HYPOTHERMIC-EFFECTS OF CLONIDINE AND OTHER IMIDAZOLIDINES
IN RELATION TO THEIR ABILITY TO ENTER THE CENTRAL-NERVOUS-
SYSTEM IN MICE.
003933 04-03
KINETIC STUDIES ON THE ENTRY OF D-AMPHETAMINE INTO THE
CENTRAL-NERVOUS-SYSTEM: I. CEREBROSPINAL-FLUID
004005 04-03
A COMPARATIVE EVALUATION OF THE USEFULNESS OF
PSYCHOPHYSIOLOGICAL-TESTS DURING VARIOUS LEVELS OF
ACTIVATION OF THE CENTRAL-NERVOUS-SYSTEM
004543 04-13
CENTRAL-REGULATION
BIOGENIC-AMINES AND NEUROPEPTIDES PLAY A ROLE IN THE CENTRAL-
REGULATION OF GENETIC HYPERTENSION. (UNPUBLISHED PAPER).
001455 02-03
CENTRALLY-ACTING
EFFECTS OF MORPHINE AND OTHER CENTRALLY-ACTING DRUGS ON 3,4
DIHYDROXYPHENYLETHYLENE-GLYCOL-SULFATE (D0PEG-S04) IN RAT- I
BRAIN. J
000136 01-03 1
ALTERATION OF PROLACTIN SECRETION BY CENTRALLY-AQING DRUGS.
001127 02-03
DECREASE IN (3H) SEROTONIN BINDING IN RAT-BRAIN PRODUCED BY THE
REPEATED ADMINISTRATION OF EITHER MONOAMINE-OXIDASE-
INHIBITORS ON CENTRALLY-ACTING SEROTONIN AGONISTS.
001463 02-03 I
THE EFFECT OF REPEATED ELECTROCONVULSIVE-SHOCK ON 1
CORTICOSTERONE RESPONSES TO CENTRALLY-ACTING
PHARMACOLOGICAL STIMULI IN THE MALE RAT
001486 02-03
CENTRALLY-ACTIVE
A SIGNAL-DETECTION-ANALYSIS OF CENTRALLY-ACTIVE DRUGS IN MICE.
001631 02-04
CENTRALLY-ADMINISTERED
EFFECTS OF CENTRALLY-ADMINISTERED PENTAZOCINE AND
ETHYLKETOCYCLAZOCINE ON THERMOREGULATION IN THE CAT
000361 01-04
EFFECTS OF CENTRALLY-ADMINISTERED AND SYSTEMICALLY
ADMINISTERED L TYROSINE AND L LEUCINE ON OVARIAN FUNQION IN
THE OLD RAT
001180 02-03
THE HYPOTENSIVE-EFFEa OF CENTRALLY-ADMINISTERED TYROSINE
001548 02-03
CENTURIES
THE OPIATES: TWO CENTURIES OF SCIENTIFIC-STUDY.
000952 01-17
CEPHALALGIA
DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL- SYNDROME
004472 04-11
CEPHALGIC-SEIZURES
CEPHALGIC-SEIZURES.
002172 02-11
CERCOPITHECUS-AETHIOPS-SABAEUS
PERIPHERAL-CORRELATES OF SEROTONERGICALLY-INFLUENCED
BEHAVIORS IN VERVET-MONKEYS (CERCOPITHECUS-AETHIOPS-
SABAEUS).
004204 04-04
CEREBELLAR
CEREBELLAR GRANULE CELL GENESIS IN THE HYDROCORTISONE TREATED
RAT
000030 01-03
A PROBABLE SITE-OF-ACTION OF DIAZEPAM IN RAT CEREBELLAR GABA
SYSTEM
000151 01-03
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJECTION.
000261 01-03
ORAL CHOLINE IN CEREBELLAR ATAXIA
000722 01-11
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES.
001208 02-03
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES.
001402 02-03
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE.
002242 02-13
TOXIC EFFECTS OF ALPHA AMINOADIPATE ON CULTURED CEREBELLAR
CELLS.
002729 03-03
S-82
VOLUME 19, SUBJECT INDEX
Subject Index
INHIBITORY ACTIONS OF TAUROCYAMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
EFFECTS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC
MEMBRANES.
002888 03-03
EFFECTS OF PHENYTOIN ON MOUSE CEREBELLAR 5 HYDROXYTRYPTAMINE
AND NOREPINEPHRINE.
003795 04-03
ACTION OF DRUGS ON THE CEREBELLAR ELECTRICAL-ACTIVITIES.
003804 04-03
IBOTENIC-ACID ANALOGUES AS INHIBITORS OF (3H)GLUTAMIC-ACID
BINDING TO CEREBELLAR MEMBRANES.
003848 04-03
MODULATORY INTERACTIONS BETWEEN NOREPINEPHRINE AND TAURINE,
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS,
004058 04-03
CEREBEILAR-CORTEX
DIFFERENTIAL-EFFECTS OF KAINIC-ACID ON BENZODIAZEPINE-RECEPTORS,
GABA-RECEPTORS, AND GABA-MODULIN IN THE CEREBELLAR-CORTEX.
002477 02-16
CEREBELLUM
GABA FACILITATION BY NORADRENALINE SHOWED SUPERSENSITIVITY IN
CEREBELLUM AFTER 6 HYDROXYDOPAMINE.
001382 02-03
NEURONAL LOCALIZATION OF BENZODIAZEPINE-RECEPTORS IN THE
MURINE CEREBELLUM.
002902 03-03
ACTION OF PYRAZOLOPYRIDINES AS MODULATORS OF
(3H)FLUNITRAZEPAM BINDING TO THE GABA/BENZODIAZEPINE-
RECEPTOR COMPLEX OF THE CEREBELLUM.
002909 03-03
ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITIES IN THE
MOUSE CEREBELLUM FOLLOWING MISONIDAZOLE TREATMENT.
003123 03-05
THE EFFECTS OF LITHIUM ON MYOINOSITOL LEVELS IN LAYERS OF
FRONTAL-CEREBRAL-CORTEX, IN CEREBELLUM, AND IN CORPUS-
CALLOSUM OF THE RAT.
003712 04-03
NEURONAL LOCALISATION OF BENZODIAZEPINE-RECEPTORS IN
CEREBELLUM.
003739 04-03
EFFECTS OF ACUTE AND CHRONIC AMPHETAMINE TREATMENT ON
PURKINJE NEURON DISCHARGE IN RAT CEREBELLUM
003793 04-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR PRESYNAPTIC ACTIONS OF
PHENCYCLIDINE ON NORADRENERGIC TRANSMISSION IN RAT
CEREBELLUM.
003926 04-03
GUANYLATE-CYCLASE - CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND
CEREBELLUM: MODIFICATION BY ANTICONVULSANTS.
003956 04-03
THE EFFECT OF PROPRANOLOL AND ITS ISOMERS ON PURKINJE
NEURONES IN RAT CEREBELLUM.
004059 04-03
CEREBRAL
EFFECT OF ISOPROTERENOL ON CEREBRAL CIRCULATION IN DOGS.
000199 01-03
CEREBRAL CIRCULATORY AND METABOLIC-EFFECTS OF PIRIBEDIL.
000200 01-03
LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL
CAPILLARY PERMEABILITY.
000239 01-03
IN VIVO OCCUPATION OF CEREBRAL HISTAMINE HI -RECEPTORS
EVALUATED WITH 3H MEPYRAMINE MAY PREDICT SEDATIVE
PROPERTIES OF PSYCHOTROPIC-DRUGS.
000241 01-03
NONLINEAR REGRESSION ANALYSIS OF NOREPINEPHRINE RESPONSE
KINETICS IN CEREBRAL VASCULATURE.
000256 01-03
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJECTION.
000261 01-03
DIFFERENCES IN ACTIVITY IN CEREBRAL METHYLTRANSFERASES AND
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE
AND RESISTANT MICE AND DEERMICE.
000377 01-04
IMPROVEMENT OF RESTITUTION FROM CEREBRAL ISCHEMIA IN
HYPERGLYCEMIC RATS BY PENTOBARBITAL OR DIAZEPAM.
000475 01-04
CONTRIBUTION TO THE CLINICAL-STUDY OF CEREBRAL DOPAMINERGIC
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST
RESULTS.
000616 01-09
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF
LOPIRAZEPAM (D- 12524) BY QUANTITATIVE EEG AND
PSYCHOMETRIC-ANALYSIS.
000720 01-11
CONTRIBUTION TO STUDY OF CEREBRAL DOPAMINERGIC MECHANISMS:
REALITY OF THE PROBLEM.
000782 01-13
OPIOID MECHANISMS IN REGULATION OF CEREBRAL MONOAMINES IN
VIVO.
001098 02-03
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIRECT VASODILATOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRICTION.
001109 02-03
EFFECTS OF BICUCULLINE-INDUCED SEIZURES ON CEREBRAL METABOLISM
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY
STARVATION.
001134 02-03
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR
SUBSEQUENT WITHDRAWAL.
001175 02-03
EFFECT OF PAPAVERINE ON REGIONAL CEREBRAL BLOOD FLOW AND
SMALL VESSEL BLOOD CONTENT,
001177 02-03
STEREOSELECTIVE ACTIONS OF SUBSTITUTED BENZAMIDE DRUGS ON
CEREBRAL DOPAMINE MECHANISMS.
001301 02-03
LOCAL CEREBRAL GLUCOSE UTILIZATION (LCGU) IN RAT-BRAIN DURING
HYPOXEMIA. (UNPUBLISHED PAPER).
001380 02-03
THE EFFECT OF SODIUM-SALICYLATE ON CEREBRAL BLOOD FLOW AND
METABOLISM.
001416 02-03
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION
001568 02-04
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA
ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF
CONSCIOUS CATS.
001569 02-04
CEREBRAL VENTRICLES AND DOPAMINE IN SCHIZOPHRENIA.
(UNPUBLISHED PAPER).
001928 02-08
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS.
002071 02-10
CEREBRAL SENESCENCE AND ITS PSYCHIC-MANIFESTATIONS. THE
EFFECTIVENESS OF DEBRUMYL.
002105 02-11
LSD-INDUCED ULTRASTRUCTURAL MODIFICATIONS OF LIMBIC-SYSTEM
NUCLEI AND OTHER CEREBRAL ZONES.
002198 02-12
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE
INTOXICATION.
002210 02-13
HEMODYNAMIC AND CEREBRAL METABOLIC-STUDY OF DIAZEPAM IN
NEUROSURGICAL-RESUSCITATION.
002231 02-13
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL
HEMORRHAGE PATIENTS.
002295 02-13
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS
DURING ONE- YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN
SCHIZOPHRENIA.
002390 02-15
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS,
BRAIN, AND PINEAL-ORGAN OF THE RAT.
002503 02-16
PURSUING THE ACTIONS OF PSYCHOTROPIC-DRUGS: RECEPTOR SITES
AND ENDOGENOUS CEREBRAL PROGRAMMES.
002578 02-17
NOREPINEPHRINE DEPLETION ALTERS CEREBRAL OXIDATIVE METABOLISM
IN THE ACTIVE STATE.
002798 03-03
PHENOTHIAZINE ACTION ON CEREBRAL 5 HYDROXYTRYPTAMINE.
002850 03-03
LONG-ACTING ANTIPSYCHOTIC-DRUGS AND CEREBRAL 5
HYDROXYTRYPTAMINE.
002851 03-03
Hi
51::
S-83
'<■:<■•.:■
Subject Index
NOREPINEPHRINE AND DOPAMINE CEREBRAL LEVELS AFTER CHRONIC-
TREATMENT WITH NOMIFENSINE.
002872 03-03
DECREASED CEREBRAL CATABOLISM OF (3H)HISTAMINE IN VIVO AFTER S
ADENOSYLMETHIONINE ADMINISTRATION .
002883 03-03
THE EFFECTS OF INJECTIONS OF BOMBESIN INTO THE CEREBRAL
VENTRICLES ON BEHAVIORAL THERMOREGULATION.
002952 03-04
DOSAGE OF INTRATUMORAL LITHIUM (CEREBRAL GLIOBLASTOMA): ON A
FAILURE OF TREATMENT OF MANIC-DEPRESSIVE-PSYCHOSIS.
003226 03-09
CEREBRAL EVOKED-POTENTIAL CHANGES PRODUCED BY TREATMENT
WITH LITHIUM-CARBONATE.
003263 03-09
CAPACITIES OF ATTENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS: EFFECTS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300.
003451 03-14
ACUTE PHARMACOTOXIC PSYCHOSES IN CHRONIC CEREBRAL
CONDITIONS.
003475 03-15
ACTION OF 4 AMINOPYRIDINE ON THE CEREBRAL CIRCULATION.
003781 04-03
NA-GAMMA-HYDROXYBUTYRATE IN CEREBRAL PROTECTION DURING
SEVERE HYPOXEMIA IN THE RAT.
003895 04-03
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL
HEMISPHERES OF AGED MALE RATS.
003936 04-03
THE EFFECT OF DIBENZAZEPINES (TRICYCLIC-ANTIDEPRESSANTS) ON
CEREBRAL CAPILLARY PERMEABILITY IN THE RAT IN VIVO.
003974 04-03
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE
AMINO-ACID POOL.
004039 04-03
CLASSICAL NEUROLEPTICS AND DECONDITIONING ACTIVITY AFTER SINGLE
OR REPEATED TREATMENTS: ROLE OF DIFFERENT CEREBRAL
NEUROTRANSMITTERS.
004115 04-04
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION
004281 04-05
PECULIARITIES OF THE CEREBRAL PATHOMORPHOLOGY OF PATIENTS
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS
(PHARMACOLOGICAL PATHOMORPHOSIS)
004528 04-13
CEREBRAL FLUORIDE IN MAHiA AND THE EFFECT OF LITHIUM: A
HYPOTHESIS.
004715 04-17
CEREBRAL-ARTERIES
REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE-
NUCLEOTIDES AND ADENOSINE.
000210 01-03
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE
TREATED DOGS.
001273 02-03
INDIRECT ADRENERGIC EFFECT OF HISTAMINE IN CAT CEREBRAL-
ARTERIES.
001355 02-03
CEREBRAL-ARTERY
RELEASE OF ENDOGENOUS NOREPINEPHRINE FROM A RABBIT CEREBRAL-
ARTERY.
000079 01-03
DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR
TRANSMIHER IN THE CAT CEREBRAL-ARTERY.
001336 02-03
CEREBRAL-CORTEX
FUNCTIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY
NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS
WITH SCHIZOPHRENIA.
000059 01-03
THE EFFECT OF PSYCHOTROPIC-SUBSTANCES AND NARCOTIC ANALGESIC-
DRUGS ON 14C NORADRENALINE UPTAKE BY SYNAPTOSOMES OF THE
CEREBRAL-CORTEX OF RATS.
001363 02-03
OPIATE-RECEPTOR GRADIENTS IN MONKEY CEREBRAL-CORTEX:
CORRESPONDENCE WITH SENSORY PROCESSING HIERARCHIES.
002641 03-01
DEMONSTRATION AND CHARAQERIZATION OF AN ENDOGENOUS
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM
BOVINE CEREBRAL-CORTEX.
002645 03-01
METHYLXANTHINES MODULATE ADENOSINE RELEASE FROM SLICES OF
CEREBRAL-CORTEX.
002907 03-03
Psychopharmacology Abstracts
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL-
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF
ANTIBODIES TO GANGLIOSIDE.
003025 03-04
THE EFFECT OF NOOTROPIL ON THE TRANSCALLOSAL AND PRIMARY
EVOKED-RESPONSES OF THE CAT CEREBRAL-CORTEX.
003780 04-03
REGULATION OF ALPHAl -ADRENOCEPTORS IN THE CEREBRAL-CORTEX OF
THE RAT BY THYROID-HORMONES
003816 04-03
STIMULATION OF FRUCTOSEBIPHOSPHATASE AQIVITY AND SYNTHESIS
IN THE CEREBRAL-CORTEX OF RATS SUBMIHED TO THE CONVULSANT
METHIONINE-SULFOXIMINE.
003838 04-03
THE EFFECT OF PSYCHOSTIMULANTS ON CHANGES IN THE EXCITABILITY
OF THE VISUAL CEREBRAL-CORTEX.
003919 04-03
GUANYLATE-CYCLASE ~ CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND
CEREBELLUM: MODIFICATION BY ANTICONVULSANTS.
003956 04-03
CATECHOLAMINE MODULATION OF ENKEPHALIN-INDUCED
ELECTROPHYSIOLOGICAL RESPONSES IN CEREBRAL-CORTEX
003957 04-03
CEREBRAL-PALSIED-CHILD
BEHAVIORAL-INTERVENTION FOR SELF- STIMULATORY, AHENDING AND
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILD.
002104 02-11
CEREBROARTERIAL
INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRIQION
BY CLONIDINE IN CATS.
001431 02-03
CEREBROCORTICAL
EFFEQS OF HALOPEMIDE ON POTASSIUM-INDUCED RELEASE OF
RADIOLABELED NEUROTRANSMIHERS FROM RAT CEREBROCORTICAL
SLICES IN VITRO.
001347 02-03
THE EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE
PRESENCE AND ABSENCE OF CNS DEPRESSANTS.
004010 04-03
CEREBROSPINAL-FLUID
ENTRY OF DIAZEPAM AND ITS MAJOR METABOLITE INTO
CEREBROSPINAL-FLUID.
000114 01-03
PATHOPHYSIOLOGICAL- STUDIES ON SCHIZOPHRENIA WITH SPECIAL
REFERENCE TO HOMOVANILLIC-ACID CONCENTRATION IN
CEREBROSPINAL-FLUID
000271 01-03
GABA LEVELS IN HUMAN CEREBROSPINAL-FLUID: ALTERATIONS IN
PSYCHIATRIC-DISORDERS (UNPUBLISHED PAPER).
000764 01-13
THE EFFECT OF EMOTIONAL-STRESS AND DIAZEPAM ON MONOAMINE
METABOLITES IN THE CEREBROSPINAL-FLUID OF CATS. (PH.D.
DISSERTATION).
001260 02-03
DIFFERENTIAL-EFFECTS OF VARIOUS STIMULI ON AVP LEVELS IN BLOOD
AND CEREBROSPINAL-FLUID
001370 02-03
EFFECTS OF TIAPRIOE ON HOMOVANILLIC-ACID LEVELS IN HUMAN
CEREBROSPINAL-FLUID DRAWN AT PNEUMOENCEPHALOGRAPHY.
001483 02-03
QUICKLY-MADE CANNULA FOR REPEATED CEREBROSPINAL-FLUID
SAMPLING IN RATS
001879 02-06
REL^TIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN
PUVSMA AND CEREBROSPINAL-FLUID AND CLINICAL-RESPONSE AND
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS.
001905 02-08
CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL-
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY.
002095 02-11
CEREBROSPINAL-FLUID GABA IN PSYCHOTIC-DISORDERS.
002097 02-11
A BIOCHEMICAL- STUDY OF LUMBAR CEREBROSPINAL-FLUID IN
EXTRAPYRAMIDAL-DISORDERS.
002186 02-11
METHOD FOR THE DETERMINATION OF TRYPTOPHAN IN SERUM AND
CEREBROSPINAL-FLUID. ^ „ ^^ ,,
002208 02-13
IMMUNOREAQIVE CALCITONIN IN CEREBROSPINAL-FLUID OF MAN.
002637 03-01
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF
AMINES INFLUENCING CEREBROSPINAL-FLUID FORMATION.
002807 03-03
BETA ENDORPHIN LEVELS IN THE CEREBROSPINAL-FLUID OF
SCHIZOPHRENICS. „„„,,, „o«t
003176 03-OE
S-84
VOLUME 19, SUBJECT INDEX
Subject Index
CORRELATIONS BETWEEN LITHIUM LEVELS IN CEREBROSPINAL-FLUID AND
LITHIUM LEVELS IN BLOOD PLASMA AND ERYTHROCYTES
003210 03-09
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION.
003419 03-13
DOPAMINE CONJUGATE IN CEREBROSPINAL-FLUID.
003432 03-13
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION
OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY.
003433 03-13
ALTERATIONS IN CEREBROSPINAL-FLUID DOPAMINE METABOLITES
FOLLOWING PHYSOSTIGMINE INFUSION
003477 03-15
CEREBROSPINAL-FLUID CONCENTRATIONS OF THIORIDAZINE AND ITS
MAIN METABOLITES IN PSYCHIATRIC-PATIENTS.
003569 03-16
A SELECTED ION-MONITORING ASSAY FOR BIOGENIC-AMINE
METABOLITES AND PROBENECID, IN HUMAN LUMBAR
CEREBROSPINAL-FLUID.
003663 04-01
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
ETHANOL.
003725 04-03
KINETIC STUDIES ON THE ENTRY OF D-AMPHETAMINE INTO THE
CENTRAL-NERVOUS-SYSTEM: I. CEREBROSPINAL-FLUID.
004005 04-03
THE DYNAMICS OF SYSTEMIC VENOUS, ARTERIAL, AND CEREBROSPINAL-
FLUID PRESSURE UNDER I.V. ADMINISTRATION OF POLYETHYLENE-
GLYCOL.
004045 04-03
PROTEIN BINDING OF CHLORPROMAZINE IN CEREBROSPINAL-FLUID AND
SERUM.
004311 04-08
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH
ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT.
004382 04-09
CEREBROSPINAL-FLUID HOMOVANILLIC-ACID PATTERNS DURING
NEUROLEPTIC TREATMENT. (UNPUBLISHED PAPER).
004502 04-13
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS ACTIVE
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC-
PATIENTS TREATED WITH FIXED DRUG DOSES.
004559 04-13
CEREBROVASCULAR-ACCIDENTS
EFFECTS OF CYCLOSPASMOL UPON SENSORY PARAMETERS IN PATIENTS
RECOVERING FROM CEREBROVASCULAR-ACCIDENTS.
002360 02-14
CEREBROVASCULAR-DISEASES
THERAPEUTIC TREATMENT OF INSUFFICIENT PERFORMANCE IN
CEREBROVASCULAR-DISEASES .
004718 04-17
CESIUM
CESIUM.
001090 02-02
DISTRIBUTION OF CESIUM IN THE ORGANISM AND ITS EFFECT ON THE
NUCLEOTIDE METABOLISM ENZYMES.
003696 04-02
CESSATION
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF
BENZODIAZEPINE TREATMENT. SIX CLINICAL CASES.
003505 03-15
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON
BEHAVIORAL SHIFTS IN CATS, ARISING AFTER CESSATION OF
ELECTRICAL- STIMULATION OF THE CAUDATE-NUCLEUS.
004067 04-04
THE EFFECT OF AN INTENSIVE COURSE OF NEUROLEPTIC-DRUGS ON
SCHIZOPHRENIC-PATIENTS AND THEIR SUBSEQUENT COURSE
FOLLOWING THE CESSATION OF ALL NEUROLEPTIC-MEDICATION.
004341 04-08
WITHDRAWAL SYMPTOMS AFTER GRADUATED CESSATION OF
IMIPRAMINE IN CHILDREN.
004630 04-15
APOMORPHINE-INDUCED STEREOTYPY IN MATURE AND SENESCENT RATS
FOLLOWING CESSATION OF CHRONIC HALOPERIDOL TREATMENT.
004651 04-15
CF-25-397
TREATMENT OF DYSKINETIC AND DYSTONIC-DISORDERS WITH CF-25-
397: CLINICAL-ASPECTS AND PHARMACOLOGICAL ASPECTS.
002121 02-11
CFF
SMOKING AND VIGILANCE: THE EFFECTS OF TOBACCO SMOKING ON CFF
AS RELATED TO PERSONALITY AND SMOKING HABITS.
002368 02-14
C6P-6085-A
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE:
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER
SEROTONIN UPTAKE BLOCKERS
000316 01-03
CH-757
PHARMACOKINETIC-STUDY IN MAN OF THE CH-757 PREPARATION.
004440 04-11
CHAGAS-DISEASE
EPILEPSY AND CHRONIC CHAGAS-DISEASE.
003328 03-11
CHALLENGE
PHENCYCLIDINE-HCL: A CHALLENGE TO MEDICINE.
003395 03-12
NEUROENDOCRINE-TESTS DURING TREATMENT WITH NEUROLEPTIC-
DRUGS: I. PLASMA PROLACTIN RESPONSE TO CHLORPROMAZINE
CHALLENGE
004329 04-08
CHALLENGE-DOSE
THE EFFECT OF THIORIDAZINE ON PROLACTIN LEVELS IN ACUTELY
SCHIZOPHRENIC-PATIENTS: CHALLENGE-DOSE AND STEADY-STATE
LEVELS.
000558 01-08
CHALLENGES
MORPHINE CHALLENGES IN LEVO ALPHA ACETYLMETHADOL (LAAM)
POSTADDICT RATS.
004259 04-04
CLINICAL DEPRESSIONS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES.
004350 04-09
CHANCES
SOME WAYS TO INCREASE CHANCES TO DISCOVER THE CNS DRUGS OF
THE FUTURE.
002528 02-17
CHANGE
A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY
PRODUCED BY OPIATE ANALGESICS.
000425 01-04
HOW TO SUCCESSFULLY CHANGE A PATIENT FROM ONE DRUG TO
ANOTHER.
000913 01-17
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA.
(UNPUBLISHED PAPER).
001147 02-03
LONG-TERM HALOPERIDOL TREATMENT OF MICE: A CHANGE IN BETA-
ADRENERGIC-RECEPTOR RESPONSIVENESS.
001206 02-03
TRYPTOPHOL-INDUCED CHANGE IN BRAIN 5 HYDROXYTRYPTAMINE
METABOLISM.
001236 02-03
EEG CHANGE IN THE CONSCIOUS RAT DURING IMMOBILITY INDUCED BY
PSYCHOLOGICAL-STRESS.
001297 02-03
CHANGE IN OVERINCLUSIVE THINKING OF SCHIZOPHRENIC-PATIENTS IS
RELATED TO PLASMA PHENOTHIAZINE CONCENTRATION.
001941 02-08
THERAPEUTIC RESULTS IN A PSYCHOGERIATRIC-WARD AFTER CHANGE OF
MEDICATION.
002136 02-11
THE CHANGE OF BLOOD PROLACTIN LEVEL DUE TO THE WITHDRAWAL OF
MAINTENANCE NEUROLEPTICS.
002559 02-17
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS.
003871 04-03
SCHEDULE DEPENDENT CHANGE OF PUNISHED-RESPONDING AFTER
DIAZEPAM IN RATS.
004165 04-04
ELECTROENCEPHALOGRAPHIC CHANGE IN PARKINSONIAN-PATIENTS
TREATED WITH LEVODOPA CARBIDOPA.
004557 04-13
CHANGES
ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS.
(UNPUBLISHED PAPER).
000060 01-03
AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT-
CEREBRAL-CORTEX.
000072 01-03
CHANGES IN PLASMA CORTICOSTERONE LEVELS AS A MEASURE OF
ACUTE DEPENDENCE UPON LEVORPHANOL IN RATS.
000085 01-03
CHANGES OF ACTH, STH, TSH AND PROLACTIN LEVELS IN ENDOTOXIN
SHOCK IN RATS.
000119 01-03
I
a.
Si:
S-85
Subject Index
Psychopharmacology Abstracts
THE EFFECT OF DIAZEPAM ON EEG CHANGES FOLLOWING INTRASEPTAL
ADMINISTRATION OF ATROPINE.
000127 01-03
CORTICAL NEUROCHEMICAL CHANGES AFTER INTRASTRIATAL INJECTION
OF KAINIC-ACID.
000133 01-03
EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERAQIONS WITH MU-
RECEPTORS AND DELTA-RECEPTORS
000168 01-03
THE EFFECT OF ANTIDEPRESSANTS ON L 5 HTP-INDUCED CHANGES IN RAT
PLASMA CORTICOSTEROIDS.
000170 01-03
CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC-
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE
(GABA-TRANSAMINASE) INHIBITOR.
000174 01-03
AGE-RELATED ELECTROPHYSIOLOGICAL CHANGES IN RAT-CEREBELLUM
000197 01-03
CHANGES IN MOUSE-BRAIN DIAZEPAM-RECEPTOR BINDING AFTER
PHENOBARBITAL ADMINISTRATION.
000281 01-03
CHANGES IN OPIATE ACTIVITY OF RAT PITUITARY FOLLOWING ACUTE
ADMINISTRATION OF NEUROLEPTICS.
000282 01-03
CHANGES IN BRAIN N DEMETHYLATION AND OPIATE-RECEPTOR CONTENT
CORRELATE WITH ANALGESIC EFFECTIVENESS OF MORPHINE.
000400 01-04
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS.
000509 01-05
BRAIN FUNCTION IN OLD-AGE: EVALUATION OF CHANGES AND
DISORDERS.
000684 01-11
PROLACTIN CHANGES IN MAJOR DEPRESSIVE-DISORDERS
000752 01-13
THE ULTRASTRUCTURAL CHANGES OF SYNAPSES IN RAT FOLLOWING
LONG-TERM ADMINISTRATION OF THE NEUROLEPTICS RESERPINE AND
HALOPERIDOL
000795 01-13
PHARMACOPSYCHOLOGICAL INVESTIGATION OF CHANGES IN MOOD
INDUCED BY DIPOTASSIUM-CHLORAZEPATE WITH AND WITHOUT
SIMULTANEOUS ALCOHOL ADMINISTRATION
000825 01-14
NEUROLOGICAL SIDE-EFFECTS OF LITHIUM: ORGANIC-BRAIN-SYNDROME,
SEIZURES, EXTRAPYRAMIDAL SIDE-EFFECTS, AND EEG CHANGES
000847 01-15
ENDOCRINOLOGICAL CHANGES IN PATIENTS WITH SEXUAL-DYSFUNCTION
UNDER LONG-TERM NEUROLEPTIC TREATMENT
000912 01-17
DISEASE-INDUCED CHANGES IN THE PLASMA BINDING OF BASIC DRUGS.
000975 01-17
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI, OR
ETHANOL DETECTED BY ELECTROPHYSIOLOGICAL-CORRELATES.
001136 02-03
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT
DERIVATIVES.
001156 02-03
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR
SUBSEQUENT WITHDRAWAL.
001175 02-03
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE
CAT. (PH.D. DISSERTATION)
001179 02-03
DOSE-DEPENDENT, AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND
SPONTANEOUSLY HYPERTENSIVE-RATS.
001197 02-03
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN
RATS.
001199 02-03
EFFECT OF LITHIUM ON STRESS-INDUCED CHANGES IN THE BRAIN LEVELS
OF MONOAMINES IN RATS.
001216 02-03
LITHIUM-INDUCED CHANGES IN THE BRAIN LEVELS OF FREE AMINO-ACIDS
IN STRESS-EXPOSED RATS
001217 02-03
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN
STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER
001218 02-03
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY
SPECTRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND
NEUROLEPTICS.
001220 02-03
CHANGES IN ALPHA-ADRENERGIC-RECEPTORS IN RAT-BRAIN IN VITRO BY
PREINCUBATION WITH ALPHA-ADRENERGIC LIGANDS.
001272 02-03
AGE-RELATED CHANGES IN BODY-TEMPERATURE RESPONSES TO
MORPHINE IN RATS.
001366 02-03
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND
TOLERANT RATS AND MICE.
001476 02-03
IN VIVO CHANGES IN THE GABA CONTENT OF NERVE-ENDINGS
(SYNAPTOSOMES) INDUCED BY INHIBITORS OF GABA UPTAKE.
001540 02-03
NEUROPHARMACOLOGICAL-AGENTS MODIFYING ENDOTOXIN-INDUCED
CHANGES IN MICE.
001543 02-03
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM:
FUNCTIONAL CHANGES FOLLOWED USING (-)N N
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL AQIVITY LEVELS
OF RATS.
001603 02-04
CHANGES OF PHYSICAL MORPHINE-DEPENDENCE IN RATS CHRONICALLY
TREATED WITH DRUGS ACTING ON BRAIN 5 HYDROXYTRYPTAMINE.
001764 02-04
REGIONAL CHANGES IN BRAIN GLUCOSE UTILIZATION IN RATS GIVEN A
PYRETHROID INSEQICIDE.
001838 02-05
LONG-TERM CHLORPROMAZINE IN RHESUS-MONKEYS: PRODUQION OF
DYSKINESIAS AND CHANGES IN SOCIAL-BEHAVIOR.
001850 02-05
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFECT IN SCHIZOPHRENIA AND
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO
NEUROLEPTIC-MEDICATION.
001911 02-08
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS AFTER A SINGLE
INJECTION OF BETA ENDORPHIN
001962 02-09
EEG CHANGES IN CHILDREN WITH TREATED PHENYLKETONURIA AFTER
PHENYLALANINE LOAD.
002115 02-11
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY
PRETREATMENT WITH THYROID-HORMONES.
002259 02-13
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY I. CHANGES INDUCED BY PHENOBARBITAL OR/AND
DIPHENYLHYDANTOIN IN SERUM LIPIDS
002281 02-13
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE.
002305 02-13
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN
SCHIZOPHRENIA.
002390 02-15
ON THE MEASUREMENT IN RATS OF THE CONVULSANT-EFFEQ OF DRUGS
AND THE CHANGES WHICH FOLLOW ELECTROCONVULSIVE-SHOCK
002444 02-15
CHANGES IN PREVALENCE, SEVERITY, AND RECOVERY IN TARDIVE-
DYSKINESIA WITH AGE
002455 02-15
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF
ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS
INCLUDING ANTIDEPRESSANTS.
002532 02-17
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF
DISCRETE RAT-BRAIN NUCLEI
002635 03-01
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE
INJECTION IN NEWBORN ANIMALS.
002774 03-03
CHANGES IN THE CORTICAL AQIVITY OF SUCCINATE-DEHYDROGENASE
UNDER THE INFLUENCE OF CHLORPROMAZINE (A HISTOCHEMICAL-
STUDY AND ELECTROCYTOCHEMICAL- STUDY).
002784 03-03
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED
'^""^ 002800 03-03
LACK OF CORRELATION BETWEEN NALOXONE-INDUCED CHANGES IN
SEXUAL-BEHAVIOR AND SERUM LH IN MALE RATS
002821 03-03
CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN
HYPOTHALAMUS.
002842 03-03
S-86
VOLUME 19, SUBJECT INDEX
Subject Index
CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL
ALERTING
002997 03-04
AN ANALYSIS OF SPECIFICITY OF DRUG-INDUCED CHANGES IN DRUG-
REINFORCED RESPONDING. (PHD, DISSERTATION).
003010 03-04
CYCLIC-AMP-INDUCED CHANGES IN THE ELECTROENCEPHALOGRAM AND
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN
THE RAT
003078 03-04
ELECTROPHYSIOLOGIC ASSESSMENT OF RECEPTOR CHANGES FOLLOWING
CHRONIC DRUG-TREATMENT,
003136 03-06
CEREBRAL EVOKED-POTENTIAL CHANGES PRODUCED BY TREATMENT
WITH LITHIUM-CARBONATE
003263 03-09
CHANGES IN THE PSYCHOPATHOLOGY OF PSYCHOSIS DUE TO
NEUROLEPTIC TREATMENT.
003281 03-10
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
INTRAOCULAR PRESSURE CHANGES FOLLOWING MODIFIED ECT.
003536 03-15
LONG-TERM CHANGES IN AIMS RATINGS AND THEIR RELATION TO
MEDICATION HISTORY.
003537 03-15
CHANGES IN AND CURRENT PROGRESS OF NEUROLOGY AND
PSYCHIATRY.
003550 03-15
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT
ANTICHOLINERGIC-ACTIVITY BY AN ATYPICAL NEUROLEPTIC
(THIORIDAZINE).
003560 03-16
BRAIN BENZODIAZEPINE-RECEPTORS AND THEIR RAPID CHANGES AFTER
SEIZURES IN THE MONGOLIAN-GERBIL.
003717 04-03
ETHANOL-INDUCED CHANGES IN CYCLIC-GUANOSINE-PHOSPHATE
METABOLISM IN MOUSE VESTIBULAR REGION.
003784 04-03
CHANGES OF ELECTRORETINOGRAM AND NEUROCHEMICAL ASPECTS OF
GABAERGIC NEURONS OF RETINA AFTER INTRAOCULAR INJECTION OF
KAINIC-ACID IN RATS.
003807 04-03
REGIONAL CHANGES IN (3H)DIAZEPAM BINDING IN THE BRAINS OF MICE
AFTER REMOVAL OF THE OLFACTORY-BULBS.
003844 04-03
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN
REGIONS OF RAT-BRAIN WITH KETAMINE ANESTHESIA.
003891 04-03
THE EFFECT OF PSYCHOSTIMULANTS ON CHANGES IN THE EXCITABILITY
OF THE VISUAL CEREBRAL-CORTEX.
003919 04-03
EFFECT OF DIAZEPAM ON STRESS-INDUCED CHANGES IN BRAIN
HISTAMINE.
003932 04-03
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES.
003984 04-03
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-03
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE
AMINO-ACID POOL.
004039 04-03
TIME-DEPENDENT CHANGES IN ANTEROGRADE SCOPOLAMINE-INDUCED
AMNESIA IN RATS.
004182 04-04
DOPAMINE-RECEPTOR CHANGES FOLLOWING DESTRUCTION OF THE
NIGROSTRIATAL PATHWAY: LACK OF A RELATIONSHIP TO
ROTATIONAL-BEHAVIOR.
004229 04-04
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND
BODY-TEMPERATURE CHANGES IN RATS.
004238 04-04
CHANGES OF RESPONSE TO DOPAMINERGIC DRUGS IN RATS SUBMIHED
TO REM SLEEP DEPRIVATION.
004239 04-04
METHYLMERCURY-INDUCED CHANGES IN OPERANT DISCRIMINATION BY
THE PIGEON.
004271 04-05
CHANGES IN BLOOD PLASMA OSMOLALITY AND STATES OF MANIA
004352 04-09
CHANGES IN PSYCHOPATHOLOGIC SYMPTOMS DURING 20 DAYS OF
TREATMENT WITH ANTIDEPRESSANTS AND NEUROLEPTIC-DRUGS.
004415 04-09
ELECTROPHYSIOLOGICAL AND PSYCHOLOGICAL CHANGES INDUCED BY
STEROID-HORMONES IN MEN AND WOMEN.
004500 04-13
EVENT-RELATED POTENTIAL CHANGES WITH MORPHINE IN NONADDICTED
HUMANS.
004512 04-13
PATHOPHYSIOLOGICAL AND MORPHOLOGICAL CHANGES IN THE CNS
DURING LONG-TERM ADMINISTRATION OF HALOPERIDOL.
004633 04-15
DEPOT FLUPHENAZINE MAINTENANCE-TREATMENT AND ASSOCIATED
WEIGHT CHANGES.
004635 04-15
CHANGES IN THE CLINICAL-PICTURE AND THE COURSE OF PSYCHOSES
DURING MASSIVE PSYCHOPHARMACOTHERAPY AND THE
SIGNIFICANCE OF THESE CHANGES FOR IMPROVEMENTS IN
PSYCHIATRIC-TREATMENT.
004699 04-17
FLURAZEPAM-INDUCED SLEEP-APNEA- SYNDROME IN A PATIENT WITH
INSOMNIA AND MILD SLEEP-RELATED RESPIRATORY CHANGES.
004729 04-17
CHARACTER
ENKEPHALIN-LIKE CHARACTER AND ANALGESIA.
002650 03-02
EFFECTS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETECT THE NARCOTIC CHARACTER OF A DRUG.
003555 03-16
CHARACTER AND MEANING OF QUASI-MORPHINE WITHDRAWAL
PHENOMENA ELICITED BY METHYLXANTHINES.
004087 04-04
CHARACTERISATION
HUMAN PLATELET 5 HT-RECEPTORS: CHARACTERISATION AND
FUNCTIONAL ASSOCIATION.
001412 02-03
CHARACTERISTIC
CHARACTERISTIC HYPERPYREXIA INDUCED BY LICL AND
TRANYLCYPROMINE IN RATS.
004278 04-05
CHARACTERISTICS
CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN
MEMBRANES.
000062 01-03
CHARACTERISTICS OF OSCILLATORY CONTRACTIONS ELICITED BY
NALOXONE IN ILEUM PREPARATION FROM MORPHINE-DEPENDENT
GUINEA-PIGS.
001491 02-03
THE STRIATONIGRAL GABA PATHWAY: FUNCTIONAL AND
NEUROCHEMICAL CHARACTERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN
HUNTINGTONS-DISEASE.
002163 02-11
PHYSICAL AND PHYSIOLOGICAL CHARACTERISTICS OF MICROPRESSURE
EJECTION OF DRUGS FROM MULTIBARRELED PIPETTES.
002502 02-16
A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC
AGONISTS: CHARACTERISTICS.
002670 03-03
EFFECTS OF LITHIUM ON MORPHOLOGICAL CHARACTERISTICS OF
DISSOCIATED BRAIN CELLS IN CULTURE.
002765 03-03
PATIENT CHARACTERISTICS AND CLINICIAN ATTITUDES INFLUENCING THE
PRESCRIBING OF BENZODIAZEPINES.
003598 03-17
THERAPEUTIC (III): GENERAL CHARACTERISTICS OF ANTIPSYCHOTIC-
DRUGS.
003644 03-17
COMPARISON OF THE BINDING CHARACTERISTICS OF TRITIATED OPIATES
AND OPIOID-PEPTIDES.
003802 04-03
CHARACTERISTICS OF THE INHIBITION OF RAT-BRAIN MONOAMINE-
OXIDASE IN VITRO BY MD780515.
003874 04-03
THE PHARMACOLOGICAL CHARACTERISTICS OF THE TRANQUILIZING
EFFECT OF HYDIPHEN.
004261 04-04
CHARACTERISTICS OF THE STIMULUS PRODUCED BY THE MIXTURE OF
CANNABIDIOL WITH DELTA9 TETRAHYDROCANNABINOL.
004263 04-04
a.
i'5
<5:
>.
At
S-87
Subject Index
Psychopharmacology Abstracts
COMPARATIVE CHARACTERISTICS OF THE PROPHYLACTIC PROPERTIES OF
SHORT-TERM AND LONG-ACTING LITHIUM-CARBONATE PREPARATIONS
IN ENDOGENOUS AFFECTIVE-PSYCHOSES,
004390 04-09
CHARACTERIZATION
ENDORPHIN-INDUCED HYPERTHERMIA: CHARACTERIZATION OF THE
EXOGENOUSLY-INDUCED AND ENDOGENOUSLY-INDUCED EFFECTS.
000029 01-03
CHARACTERIZATION OF 3H GABA-RECEPTOR BINDING TO RAT-BRAIN
SYNAPTOSOMAL MEMBRANES. EFFECT OF NONGABAERGIC
COMPOUNDS.
000139 01-03
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFECTS OF
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS
ON MORPHINE-INDUCED ANALGESIA.
000311 01-03
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE:
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER
SEROTONIN UPTAKE BLOCKERS.
000316 01-03
AFFINITY CHROMATOGRAPHY OF THE BETA-ADRENERGIC-RECEPTOR AND
CHARACTERIZATION OF ANTIBODIES RAISED AGAINST PURIFIED
RECEPTOR PREPARATIONS.
001009 02-01
PREPARATION AND CHARACTERIZATION OF SYNTHETIC MODELS FOR THE
DENSE-BODIES OF HUMAN PLATELETS (UNPUBLISHED PAPER).
001013 02-01
CHARACTERIZATION OF LRF-LIKE IMMUNOREACTIVITY IN THE FROG
SYMPATHETIC GANGLIA: NONIDENTITY WITH LRF-DECAPEPTIDE.
(UNPUBLISHED PAPER).
001018 02-01
BIOCHEMICAL-LOCALIZATION AND CHARACTERIZATION OF BOMBESIN-
LIKE-PEPTIDES IN DISCRETE REGIONS OF RAT-BRAIN. (UNPUBLISHED
PAPER).
001046 02-01
BIOCHEMICAL-CHARACTERIZATION AND PHARMACOLOGICAL
CHARACTERIZATION OF A PEPTIDE FROM THE HEMODIALYSATE OF
PSYCHOTIC-PATIENTS.
001049 02-01
HISTAMINE-RECEPTORS IN THE BRAIN: CHARACTERIZATION BY BINDING
STUDIES AND BIOCHEMICAL-EFFECTS.
001054 02-01
CHARACTERIZATION OF GABA-STIMULATED BENZODIAZEPINE-RECEPTOR
BINDING.
001309 02-03
CHARACTERIZATION AND RADIOAUTOGRAPHY OF (3H)LSD BINDING BY
RAT-BRAIN SLICES IN VITRO: THE EFFECT OF 5 HYDROXYTRYPTAMINE
001369 02-03
FURTHER CHARACTERIZATION OF THE BINDING OF SUBSTANCE-P TO A
FRACTION FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES.
001394 02-03
CHARACTERIZATION OF BENZODIAZEPINE BINDING-SITES. (UNPUBLISHED
PAPER).
001503 02-03
CHARACTERIZATION OF ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLACTIN AND GROWTH-HORMONE PROFILES
DURING WAKEFULNESS AND SLEEP.
002217 02-13
OPIATE-RECEPTORS: PROBLEMS OF DEFINITION AND CHARAQERIZATION.
002620 02-17
DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM
BOVINE CEREBRAL-CORTEX.
002645 03-01
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS
BY YOHIMBINE DIASTEREOMERS.
002748 03-03
CHARACTERIZATION AND QUANTITATION OF ALPHA-ADRENERGIC-
RECEPTOR SUBTYPES IN RAT HYPOTHALAMUS.
002839 03-03
CHARACTERIZATION OF HALOPERIDOL MEDIATED EFFECTS ON RAT
STRIATAL TYROSINE-HYDROXYLASE.
002867 03-03
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING:
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN
HYPERTENSION.
002874 03-03
SUPPRESSION OF DRINKING BY NALOXONE IN THE RAT: A FURTHER
CHARACTERIZATION.
002963 03-04
PHARMACOLOGICAL CHARACTERIZATION OF SCRATCHING-BEHAVIOUR
INDUCED BY INTRACRANIAL INJECTION OF SUBSTANCE-P AND
SOMATOSTATIN.
002980 03-04
A CHARACTERIZATION OF THE BEHAVIORAL-EFFECTS OF LEVO ALPHA
ACETYLMETHADOL IN THE RAT AND IN THE PIGEON. (PHD
DISSERTATION).
003047 03-04
CHARACTERIZATION OF THE ISOLATED PERFUSED MOUSE-BRAIN AS A
SYSTEM FOR NEUROCHEMICAL-STUDIES.
003146 03-06
PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND
DEMENTIA.
003347 03-11
DOPAMINE-RECEPTOR PURIFICATION AND CHARAQERIZATION.
(UNPUBLISHED PAPER).
003661 04-01
PURIFICATION AND CHARACTERIZATION OF RAT PHEOCHROMOCYTOMA
DOPAMINE-BETA-HYDROXYLASE.
003664 04-01
CHARACTERIZATION OF THE BASIC PROTEINS FROM RODENT
PERIPHERAL-NERVOUS-SYSTEM MYELIN.
003665 04-01
CHARACTERIZATION OF TWO (3H)GLUTAMATE BINDING-SITES IN RAT
HIPPOCAMPAL MEMBRANES.
003726 04-03
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF ALPHA-
ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA HYBRID
CELLS
003823 04-03
CHARACTERIZATION OF ENKEPHALIN RELEASE FROM RAT STRIATUM
003909 04-03
CHARGED
VOLUNTARY INTOXICATION FROM PHENCYCLIDINE WILL IT RAISE A
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL-
STATE''.
000914 01-17
CHECKLIST
A REVISED CHECKLIST TO OBTAIN CONSENT TO TREATMENT WITH
MEDICATION.
000984 01-17
CHEESE
IS THE FAILURE OF (-)DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM
THE CHEESE EFFEQ?
004640 04-15
CHEMICAL
GASTRIC AND PYLORIC MOTOR-RESPONSE TO SYMPATHETIC-NERVE
STIMULATION AFTER CHEMICAL SYMPATHECTOMY. (UNPUBLISHED
PAPER).
001337 02-03
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN
MICE.
001435 02-03
A MODEL FOR PSYCHONEUROENDOCRINE INVESTIGATION: SPECIFIC
CHEMICAL LESIONING OF THE MEDIAN-EMINENCE
001478 02-03
CHEMICAL STRUCTURE OF SURVEQOR STRUaURE-AQIVITY
RELATIONSHIP
002262 02-13
TIME-COURSE OF CLINICAL CHEMICAL PARAMETERS UNDER LONG-TERM
LITHIUM TREATMENT
003515 03-15
NEUROLEPTICS: INTERACTIONS WITH FOOD ~ CHEMICAL AND
PHARMACODYNAMIC STUDIES ON THE INTERAQIONS OF COFFEE AND
TEA
003612 03-17
TISSUE CHOLINE STUDIED USING A SIMPLE CHEMICAL ASSAY.
003828 04-03
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS
003972 04-03
RX-336-M A NEW CHEMICAL TOOL IN THE ANALYSIS OF THE OUASI-
MORPHINE WITHDRAWAL-SYNDROME.
004093 04-04
CHEMICAL-IONIZATION
HIGH-SENSITIVITY NEGATIVE CHEMICAL-IONIZATION MASS-SPEQRAL-
ANALYSIS OF BIOGENIC-AMINES AND METABOLITES. (UNPUBLISHED
PAPER).
001042 02-01
QUANTITATIVE ANALYSIS OF 6 HYDROXYMELATONIN IN HUMAN URINE
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS-
SPEQROMETRY. (UNPUBLISHED PAPER).
001058 02-01
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
S-88
VOLUME 19, SUBJECT INDEX
Subject Index
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
CHEMICALLY-INDUCED
SENSORY NEUROTOXINS: CHEMICALLY-INDUCED SELECTIVE DESTRUCTION
OF PRIMARY SENSORY NEURONS,
003859 04-03
CHEMISTRY
CHEMISTRY OF BETA ENDORPHIN.
001038 02-01
CHEMOSENSORS
OPIATE SYSTEM INFLUENCES CENTRAL RESPIRATORY CHEMOSENSORS.
003971 04-03
CHEMOTAXIS
CHEMOTAXIS BY MOUSE MACROPHAGE CELL LINES. (UNPUBLISHED
PAPER).
001099 02-03
INHIBITION OF CHEMOTAXIS BY S 3 DEAZAADENOSYLHOMOCYSTEINE IN
A MOUSE MACROPHAGE CELL LINE. (UNPUBLISHED PAPER).
001100 02-03
PHOSPHOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR-
MEDIATED INDUCTION OF CHEMOTAXIS IN RABBIT NEUTROPHILS.
(UNPUBLISHED PAPER).
001118 02-03
PHAGOCYTIC FUNCTION IN DOWN-SYNDROME - I. CHEMOTAXIS.
003401 03-13
CHEMOTHERAPY
SERIAL COGNITIVE TESTING IN CANCER-PATIENTS RECEIVING
CHEMOTHERAPY.
000876 01-15
UNDERSTANDING AND USE OF CHEMOTHERAPY BY LEARNING-
DISABILITIES AND BEHAVIOR-DISORDERS TEACHERS
000965 01-17
PHARMACOMANOMETRIC-STUDIES OF COLONIC MOTILITY AS A GUIDE
TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001930 02-08
THE RELATIVE EFFICACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY
FOR THE TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY.
(PH.D. DISSERTATION).
002148 02-11
PSYCHIATRIC MORBIDITY AND PHYSICAL TOXICITY ASSOCIATED WITH
ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY.
002433 02-15
ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY.
002546 02-17
CONSIDERATIONS ON LONG-ACTING CHEMOTHERAPY: AN EXPERIENCE
WITH FLUPHENAZINE-DECANOATE.
003173 03-08
REFLECTIONS ON ANTIPSYCHOTIC CHEMOTHERAPY: THE BEGINNING OF
PHARMACOLOGICAL-TREATMENT .
003292 03-11
INTRAVENOUS LORAZEPAM TO PREVENT NAUSEA AND VOMITING
ASSOCIATED WITH CANCER CHEMOTHERAPY.
003614 03-17
CHEWING
EMERGENCE OF APOMORPHINE-INDUCED VACUOUS CHEWING DURING 6
MONTHS CONTINUOUS TREATMENT WITH FLUPHENAZINE-DECANOATE.
001817 02-04
CHEWING-GUM
THE USE OF NICOTINE CHEWING-GUM AS AN AID TO STOPPING
SMOKING.
002343 02-14
CHICK
LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES
OF THE DEVELOPING CHICK RETINA.
000065 01-03
THE EFFECT OF FLA-63 ON PENTOBARBITONE-INDUCED SLEEP IN THE
CHICK.
001741 02-04
BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND
CELLULAR LOCALIZATION.
002655 03-03
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR
INJEQIONOFCEFAZOLIN.
002762 03-03
THE EFFECT OF COLCHICINE AND CYTOCHALASIN B ON THE RELEASE OF
TAURINE FROM THE CHICK RETINA.
002856 03-03
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK
TISSUES - ARE THEY CELL ADHESION MOLECULES?
003724 04-03
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC-
AMP.
003952 04-03
CHICKEN
BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERACTION
WITH GAMMA AMINOBUTYRIC-ACID.
001287 02-03
INHIBITION OF MONOAMINE-OXIDASE BY FURAZOLIDONE IN THE
CHICKEN AND THE INFLUENCE OF THE ALIMENTARY FLORA THEREON.
003711 04-03
CHICKENS
2,4,5 TRICHLOROPHENOXYACETIC-ACID CAUSES BEHAVIORAL-EFFECTS IN
CHICKENS AT ENVIRONMENTALLY RELEVANT DOSES.
003079 03-04
THE EFFECTS OF TRYPTOPHAN AND MANIPULATIONS OF SEROTONERGIC-
RECEPTORS ON TONIC IMMOBILITY IN CHICKENS
004245 04-04
CHICKS
GABA DEPLETION AND BEHAVIOURAL-CHANGES PRODUCED BY
INTRAVENTRICULAR PUTRESCINE IN CHICKS.
000218 01-03
APOMORPHINE: EFFECTS ON THE TIMING AN'^ SEQUENCING OF PECKING-
BEHAVIOR IN CHICKS.
000428 01-04
OPIOID BLOCKADE AND SOCIAL-COMFORT IN CHICKS.
001745 02-04
THE EFFECTS OF COLCHICINE AND VINBLASTINE ON MEMORY IN CHICKS,
004069 04-04
CHILD
THE PARENT CHILD INTERACTIONS OF HYPERACTIVE-CHILDREN AND THEIR
MODIFICATION BY STIMULANT-DRUGS.
002092 02-11
CONTROLLED-STUDY WITH BROMAZEPAM AND CLOROTEPIN IN CHILD
INSTABILITY.
002190 02-11
HALOPERIDOL-INDUCED TARDIVE-DYSKINESIA IN A CHILD WITH GILLES-
DE-LA-TOURETTES-DISEASE.
002437 02-15
004470 04-11
004497 04-12
CHILD PSYCHOPHARMACOLOGY.
LSD: MY PROBLEM CHILD.
CHILD-PSYCHIATRY
USE OF PIMOZIDE (ORAP) 1N CHILD-PSYCHIATRY.
002100 02-11
THE USE OF MINAPRINE IN CHILD-PSYCHIATRY IN HOSPITALS AND
OUTPATIENT CLINICS.
002169 02-11
EXPERIMENTATION WITH MINAPRINE IN CHILD-PSYCHIATRY.
002344 02-14
CHILD-PSYCHIATRY AND PSYCHOPHARMACOTHERAPY IN GENERAL
PRACTICE, IN PEDIATRICS, AND IN NEUROLOGY.
003288 03-1 1
CHILDHOOD
PSYCHOPHARMACOLOGY IN CHILDHOOD: CURRENT STATUS AND FUTURE
PROSPECTIVES.
002192 02-11
PSYCHOPHARMACEUTICAL-THERAPY TO CALM DRIVE, ACTIVITY, AND
RESTLESSNESS IN CHILDHOOD.
002604 02-17
ON THE EVALUATION OF A PROVOCATIVE EEG METHOD USING
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUCTION THROUGH
MEDICATION.
003387 03-1 1
PREVALENCE OF DRUG-TREATMENT FOR HYPERACTIVITY AND OTHER
CHILDHOOD BEHAVIOR-DISORDERS.
004713 04-17
CHILDHOOD-DEPRESSION
CHILDHOOD-DEPRESSION.
000680 01-11
CHILDHOOD-ENURESIS
CHILDHOOD-ENURESIS: II. PSYCHOPATHOLOGY, TRICYCLIC
CONCENTRATION IN PLASMA, AND ANTIENURETIC-EFFECT.
002354 02-14
CHILDHOOD-EPILEPSY
VALPROIC-ACID IN CHILDHOOD-EPILEPSY: ANTICONVULSIVE EFFICACY IN
RELATION TO ITS PLASMA LEVELS.
004525 04-13
CHILDHOOD-SCHIZOPHRENIA
CLINICAL-RESPONSE AND SERUM NEUROLEPTIC LEVELS IN CHILDHOOD-
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
000566 01-08
CHILDREN
OUR EXPERIENCE WITH PIRACETAM (NOOTROPIL-UCB) TREATMENT IN
CHILDREN FROM HIGH-RISK PREGNANCIES WITH SUBSEQUENT
MINIMAL-BRAIN-DYSFUNCTION .
000544 01-07
PYRITINOL ADMINISTRATION AS PART OF EPILEPSY TREATMENT IN
CHILDREN.
000671 01-11
CHILDREN ON MEDICATION: A PRIMER FOR SCHOOL PERSONNEL.
000676 01-11
PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH
BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS.
000717 01-11
I
15
A,
"I*
S-89
Subject Index
Psychopharmacology Abstracts
TARDIVE-DYSKINESIA AND OTHER MOVEMENT-DISORDERS IN CHILDREN
TREATED WITH PSYCHOTROPIC-DRUGS.
000849 01-15
DYSKINETIC AND NEUROLOGICAL-COMPLICATIONS IN CHILDREN TREATED
WITH PSYCHOTROPIC-MEDICATIONS,
000880 01-15
PHENYTOIN KINETICS IN CHILDREN.
002113 02-11
EEG CHANGES IN CHILDREN WITH TREATED PHENYLKETONURIA AFTER
PHENYLALANINE LOAD
002115 02-11
DOUBLE-BLIND CONTROLLED- STUDY ON THE PSYCHOLEPTIC-EFFECTS OF
AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT
PERSONALITY-PROBLEMS.
002116 02-11
5 HYDROXYTRYPTOPHAN AND PYRIDOXINE: THEIR EFFECTS IN YOUNG
CHILDREN WITH DOWNS-SYNDROME.
002161 02-11
IMIPRAMINE AND EEG SLEEP IN CHILDREN WITH DEPRESSIVE-
SYMPTOMS.
002339 02-14
EFFECTS OF IMIPRAMINE ON LEFT VENTRICULAR PERFORMANCE IN
CHILDREN.
002385 02-15
THE INFLUENCE OF NEUROLEPTIC-DRUGS ON PROLACTIN SECRETION IN
CHILDREN.
002409 02-15
BIOLOGY AND THERAPY OF VIOLENT-BEHAVIOUR IN CHILDREN.
002608 02-17
ON THE EFFECTS OF SULTOPRIDE ADMINISTERED IN LOW-DOSAGES TO
OLDER CHILDREN AND ADOLESCENTS.
003230 03-09
LITHIUM IN CHILDREN OF LITHIUM RESPONDING PARENTS.
003242 03-09
MOLINDONE-HYDROCHLORIDE IN THE TREATMENT OF AGGRESSIVE,
HOSPITALIZED CHILDREN.
003321 03-11
A COMPARATIVE-STUDY ON THE CLINICALEFFECTS OF RECTAL
DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP
BETWEEN PLASMA LEVEL AND EFFECT.
003330 03-11
INVESTIGATION INTO THE EFFECT OF FLUPHENAZINE-HCL (LYORODIN) IN
CHILDREN WITH BEHAVIORAL-DISORDERS BY MEANS OF
PSYCHOPHYSIOLOGICAL PARAMETERS.
003344 03-11
TREATMENT OF ANXIETY IN CHILDREN AND ADOLESCENTS.
003349 03-11
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE, HOSPITALIZED SCHOOL-AGE CHILDREN
003360 03-11
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN.
003361 03-11
THE INFLUENCE OF METHYLPHENIDATE ON SPONTANEOUS AUTONOMIC-
ACTIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE.
003363 03-11
HALOPERIDOL - ITS USE IN CHILDREN.
003370 03-1 1
STOPPING MEDICATION IN CHILDREN WITH EPILEPSY.
004447 04-11
PREVALENCE OF HYPERACTIVITY AND RELATED TREATMENTS AMONG
ELEMENTARY SCHOOL CHILDREN.
004469 04-1 1
TARDIVE-DYSKINESIA AND OTHER DRUG-INDUCED MOVEMENT-
DISORDERS AMONG HANDICAPPED CHILDREN AND YOUTH.
004614 04-15
WITHDRAWAL SYMPTOMS AFTER GRADUATED CESSATION OF
IMIPRAMINE IN CHILDREN.
004630 04-15
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS.
004658 04-15
EMOTIONAL-DISORDERS IN CHILDREN AND ADOLESCENTS: MEDICAL AND
PSYCHOLOGICAL APPROACHES TO TREATMENT.
004743 04-17
CHILEAN
PU\SMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE.
000102 01-03
CHLORAL-HYDRATE
EFFICACY AND SIDE-EFFECTS OF CHLORAL-HYDRATE AND TRYPTOPHAN
AS SLEEPING-AIDS IN PSYCHOGERIATRIC-PATIENTS.
002077 02-10
THE EFFICACY OF TRIAZOLAM AND CHLORAL-HYDRATE IN GERIATRIC
INSOMNIACS.
002160 02-11
SMOOTH-PURSUIT EYE-MOVEMENTS: EFFECTS OF ALCOHOL AND
CHLORAL-HYDRATE.
003448 03-14
ORAL AND RECTAL ABSORPTION OF CHLORAL-HYDRATE AND ITS BETAINE
COMPLEX.
004554 04-13
CHLORALOSE
EFFECTS OF ALPHA CHLORALOSE ON THE ACTIVITY OF THE
NIGROSTRIATAL DOPAMINERGIC SYSTEM IN THE CAT.
000217 01-03
THE INFLUENCE OF CHLORALOSE ANESTHESIA ON THE AQIVITY OF RED
NUCLEUS NEURONS IN CATS.
000245 01-03
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS.
003027 03-04
CHLORALOSE-INDUCEO
OBSERVATIONS ON CHLORALOSE-INDUCED MYOCLONUS IN GUINEA-PIGS.
001164 02-03
CHLORCYCLIZINE
EFFECT OF L HISTIDINE AND CHLORCYCLIZINE ON APOMORPHINE-INOUCED
CLIMBING-BEHAVIOUR AND METHAMPHETAMINE STEREOTYPY IN
MICE
004147 04-04
CHLORDIAZEPOXIDE
THE SENSITIVITY OF THE RAT CORTICOSTERONE RESPONSE TO
ENVIRONMENTAL MANIPULATIONS AND TO CHRONIC
CHLORDIAZEPOXIDE TREATMENT.
000092 01-03
EFFECTS OF CHLORDIAZEPOXIDE ON DEPOLARIZATION-INDUCED CALCIUM
INFLUX INTO SYNAPTOSOMES.
000 18301 -03
CHLORDIAZEPOXIDE ANTINOCICEPTION: CROSS-TOLERANCE WITH
OPIATES AND WITH STRESS
000348 01-04
RATS REACTIONS TO A PREDATOR: MODIFICATION BY
CHLORDIAZEPOXIDE.
000353 01-04
TOLERANCE TO SUPPRESSIVE EFFECTS OF CHLORDIAZEPOXIDE ON
OPERANT-BEHAVIOR: LACK OF CROSS-TOLERANCE TO PENTOBARBITAL.
000356 01-04
EFFECTS OF CHLORDIAZEPOXIDE AND DIAZEPAM ON FEEDING
PERFORMANCE IN A FOOD PREFERENCE TEST
000367 01-04
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF
CHLORDIAZEPOXIDE ON FEEDING PARAMETERS USING TWO FOOD
TEXTURES IN THE RAT.
000368 01-04
WATER INTAKE AND TIME-COURSE OF DRINKING AFTER SINGLE OR
REPEATED CHLORDIAZEPOXIDE INJECTIONS
000369 01-04
ALCOHOL AND CHLORDIAZEPOXIDE INCREASE SUPPRESSED AGGRESSION
IN MICE.
000434 01-04
CHLORDIAZEPOXIDE AND OXAZEPAM DISPOSITION IN CIRRHOSIS.
000790 01-13
INTERACTIONS OF CHLORDIAZEPOXIDE AND ANOREQIC-AGENTS ON RATE
AND DURATION PARAMETERS OF FEEDING IN THE RAT
001600 02-04
THE EFFECTS OF D-AMPHETAMINE, CHLORDIAZEPOXIDE, AND
PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM
PUNISHMENT IN PIGEONS. (PH.D. DISSERTATION).
001713 02-04
EFFEQS OF CHLORDIAZEPOXIDE MORPHINE COMBINATIONS ON
SPONTANEOUS LOCOMOTOR-ACTIVITY IN THREE INBRED STRAINS OF
MICE.
001766 02-04
AnENUATION OF THE EFFEQS OF PUNISHMENT BY ETHANOL:
COMPARISONS WITH CHLORDIAZEPOXIDE.
001813 02-04
SHORT-TERM ETHANOL ADMINISTRATION IMPAIRS THE ELIMINATION OF
CHLORDIAZEPOXIDE (LIBR"'M) IN MAN
002224 02-13
RESPONDERS AND NONRESHONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO: A DISCRIMINANT FUNQION ANALYSIS.
002482 02-16
PHARMACOKINETICS AND BIOAVAILABILITY OF CHLORDIAZEPOXIDE IN
HUMANS.
002564 02-17
INTERACTION OF CHLORDIAZEPOXIDE AND SODIUM-VALPROATE IN THE
NUCLEUS-ACCUMBENS OF THE RAT.
002796 03-03
EFFEaS OF MORPHINE AND CHLORDIAZEPOXIDE ON AVOIDANCE-
BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
002973 03-04
EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING
SUPPRESSED BY CONDITIONED PUNISHMENT.
003105 03-04
A POSSIBLE ROLE FOR CATECHOLAMINE NEUROTRANSMIHERS IN THE
ANTICONVULSANT AQIVITY OF CHLORDIAZEPOXIDE.
003119 03-04
S-90
VOLUME 19, SUBJECT INDEX
Subject Index
FOOD PREFERENCE FOLLOWING ACUTE OR CHRONIC CHLORDIAZEPOXIDE
ADMINISTRATION: TOLERANCE TO AN ANTINEOPHOBIC ACTION.
004090 04-04
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFECTS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
RESPONSE
0041)9 04-04
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO. A DISCRIMINANT FUNCTION ANALYSIS. (UNPUBLISHED
PAPER).
004420 04-10
CLINICAL PHARMACOKINETICS OF CHLORDIAZEPOXIDE IN PATIENTS WITH
ALCOHOLIC HEPATITIS.
004473 04-11
CHLORDIAZEPOXIDE-HCL
THE EFFECTS OF CHLORDIAZEPOXIDE-HCL ADMINISTRATION UPON
PUNISHMENT AND CONDITIONED SUPPRESSION IN THE RAT.
001757 02-04
CHLORDIAZEPOXIDE-HYDROCHLORIDE
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
CHLORDIAZEPOXIDE-LIKE
THE USE OF SOCIAL-INTERACTION AS A METHOD FOR DETECTING
ANXIOLYTIC-ACTIVITY OF CHLORDIAZEPOXIDE-LIKE DRUGS.
001866 02-06
CHLORIDE
EFFECT OF PICROTOXIN ON BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS WITH REFERENCE TO THE EFFECT OF CHLORIDE ION.
002725 03-03
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO
GABA REGULATED CHLORIDE ION-CHANNELS.
002848 03-03
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH
ANTICONVULSANT AND ANESTHETIC ACTIONS.
002885 03-03
CHLORIMIPRAMINE
PROLONGATION OF THE EJACULATION LATENCY IN THE MALE RAT BY
THIORIDAZINE AND CHLORIMIPRAMINE.
000335 01-04
COMPARATIVE EXPERIMENT OF THE ANTIDEPRESSANT EFFECTS OF
AMINEPTINE AND CHLORIMIPRAMINE.
002029 02-09
THE BIOAVAILABILITY OF ORAL AND PARENTERAL CHLORIMIPRAMINE
(ANAFRANIL).
002232 02-13
INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS.
002341 02-14
SUPPRESSION OF ACTIVE SLEEP BY CHRONIC-TREATMENT WITH
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT:
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT.
003056 03-04
THE ANTIDEPRESSANT ACTION OF SULPHO-ADENOSYL-L-METHIONINE
(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE:
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-ACTION.
003150 03-07
TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFEaS OF
CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS.
003428 03-13
A DOUBLE-BUND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND
SIDE-EFFEQS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED-
INPATIENTS AND DEPRESSED-OUTPATIENTS.
004395 04-09
CHLORMETHIAZOLE
SORPTION OF CHLORMETHIAZOLE BY INTRAVENOUS INFUSION GIVING
SETS.
002508 02-16
AVAILABILITY OF ISOSORBIDE-DINITRATE, DIAZEPAM AND
CHLORMETHIAZOLE, FROM I.V. DELIVERY SYSTEMS.
003558 03-16
CHLORNALTREXAMINE
ISOLATION OF SELECTIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES,
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE.
001162 02-03
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST,
CHLORNALTREXAMINE.
001695 02-r ■
ANTAGONISM BY CHLORNALTREXAMINE OF SOME EFFECTS OF DELTA9
TETRAHYDROCANNABINOL IN RATS.
003104 03-04
PHARMACOLOGICAL- STUDIES WITH AN ALKYLATING NARCOTIC
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST,
CHLORNALTREXAMINE.
004082 04-04
CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE
3 CHLORO-4-PHENYLSUCCINIMIOOBENZENESULFONAMIDE (GS-385), A
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION,
PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE
LIQUID-CHROMATOGRAPHY.
000705 01-11
CHLOROAMPHET AMINE
COMPARATIVE-EFFECTS OF P CHLOROAMPHETAMINE AND L P
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN
RAT-BRAIN.
000101 01-03
P CHLOROAMPHETAMINE: EVALUATION OF A BRAIN METABOLITE.
001779 02-04
THE EFFECTS OF PARA CHLOROAMPHETAMINE ON FENFLURAMINE
ANOREXIA IN AD LIBITUM AND STIMULATION-INDUCED FEEDING IN
THE RAT.
001823 02-04
INTERACTIONS BETWEEN A MONOFLUORINATED ANALOGUE OF P
CHLOROAMPHETAMINE AND 5 HYDROXYTRYPT AMINE IN BRAIN
003719 04-03
THE EFFECTS OF P CHLOROAMPHETAMINE ADMINISTRATION ON
LOCOMOTOR-ACTIVITY AND SEROTONIN IN NEONATAL AND ADULT
RATS. (UNPUBLISHED PAPER).
004169 04-04
CHLOROBENZOYL-CHLORO-METHYL-NA-GLYCYLGLYCINANIIIDE
PHARMACOLOGY OF 2 0 CHLOROBENZOYL-CHLORO-METHYL-NA-
GLYCYLGLYCINANILIDE HYDRATE (45-0088-S), A COMPOUND WITH
BENZODIAZEPINE-LIKE PROPERTIES.
003692 04-02
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE
PHARMACOKINETICS AND METABOLISM OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE) IN RAT,
MOUSE, DOG AND MAN.
000219 01-03
PHARMACOLOGICAL-STUDY OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW
NEUROLEPTIC-DRUG.
000493 01-04
TOXICOLOGICAL AND TERATOLOGICAL STUDIES OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW
NEUROLEPTIC-DRUG.
000515 01-05
CHLORODINITROBENZENE
EFFECTS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A
DELAYED TYPE HYPERSENSITIVITY REACTION TO 1
CHLORODINITROBENZENE IN MICE.
001473 02-03
CHLOROETHYLNORAPOMORPHINE
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING
DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS
OF MAMMALIAN FOREBRAIN IN VITRO.
001114 02-03
CHLOROPHENYL-CYCLOPROPYLAMINE
EFFECT OF 2 P CHLOROPHENYL-CYCLOPROPYLAMINE ON 5
HYDROXYINDOLE CONCENTRATION AND MONOAMINE-OXIDASE
ACTIVITY IN RAT-BRAIN.
001237 02-03
CHLOROPHENYL-4-HYDROXYPIPERIDINE-4-FLUOROBUTYROPHENONE
THE STRUCTURE OF HALOPERIDOL-HYDROBROMIDE (CHLOROPHENYL-4-
HYDROXYPIPERIDINE-4-FLUOROBUTYROPHENONE HBR) .
000002 01-01
CHLOROPHENYLALANINE
ENHANCEMENT OF THE BEHAVIORAL-EFFECTS OF 2,5 DIMETHOXY-4-
METHYLAMPHETAMINE (DOM) BY PRETREATMENT WITH P
CHLOROPHENYLALANINE.
000364 01-04
EFFECT OF P CHLOROPHENYLALANINE ON DIAZEPAM WITHDRAWAL
SIGNS IN RATS.
001797 02-04
PHASIC ACTIVITY INDUCED BY P CHLOROPHENYLALANINE IN THE
AUDITORY PATHWAY.
002661 03-03
EFFECT OF P CHLOROPHENYLALANINE AND TRYPTOPHAN ON SLEEP, EEG
AND MOTOR-ACTIVITY IN THE RAT.
002958 03-04
SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES OF
ANALOGUES AND DERIVATIVES OF P CHLOROPHENYLALANINE.
003691 04-02
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING,
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL
WAVES IN CATS?
003704 04-02
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED
SEROTONERGIC MECHANISMS.
003748 04-03
I
■■T
St:
S-91
Subject Index
Psychopharmacology Abstracts
EFFECT OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF
TOLERANCE TO THE HYPNOTIC-EFFECTS OF PENTOBARBITAL, BARBITAL,
AND ETHANOL.
003883 04-03
THE EFFECT OF P CHLOROPHENYLALANINE ON THE DISTRIBUTION OF
BIOGENIC-AMINES IN THE BRAIN, AND ON MEMORY IN RATS.
004068 04-04
INTERACTION OF P CHLOROPHENYLALANINE, MIANSERINE AND
DANITRACEN WITH AMPHETAMINE.
004599 04-15
CHLOROPHENYLALANINE-INDUCED
REVERSAL OF PARA CHLOROPHENYLALANINE-INDUCED INSOMNIA BY 5
HYDROXYTRYPTOPHAN IN THE RAT.
000423 01-04
CHLOROPHENYLPIPERAZINE
COMPARATIVE-EFFECTS OF P CHLOROAMPHETAMINE AND L P
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN
RAT-BRAIN.
000101 01-03
1-M CHLOROPHENYLPIPERAZINE: A METABOLITE OF TRAZODONE
ISOLATED FROM RAT URINE.
000204 01-03
DISPOSITION AND PHARMACOLOGICAL-EFFECTS OF M
CHLOROPHENYLPIPERAZINE IN RATS.
002995 03-04
5 HYDROXYTRYPTAMINE-LIKE PROPERTIES OF M
CHLOROPHENYLPIPERAZINE: COMPARISON WITH QUIPAZINE.
004210 04-04
CHLOROXYMORPHAMINE
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST,
CHLORNALTREXAMINE.
001695 02-04
PHARMACOLOGICAL-STUDIES WITH AN ALKYLATING NARCOTIC
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST,
CHLORNALTREXAMINE.
004082 04-04
CHLORPHENTERMINE
EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT
LUNG.
000524 01-05
EFFECT OF DESMETHYLIMIPRAMINE ON TISSUE DISTRIBUTION AND
ANORECTIC-ACTIVITY OF CHLORPHENTERMINE IN RATS.
004179 04-04
CHLORPROMAZINE
ACTIONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID
METABOLISM IN GUINEA-PIG BRAIN SLICES.
000129 01-03
MECHANISM OF CHLORPROMAZINE ACTION ON PLASMA GLUCOSE AND
CYCLIC-AMP LEVELS.
000211 01-03
PRIOR AND ONGOING EXPERIENCE AS DETERMINANTS OF THE EFFECTS OF
D-AMPHETAMINE AND CHLORPROMAZINE ON PUNISHED-BEHAVIOR
000339 01-04
EXPERIMENTAL DYSTONIA INDUCED BY QUATERNARY
CHLORPROMAZINE.
000461 01-04
EFFECT OF MORPHINE IN COMBINATION WITH CHLORPROMAZINE AND
HALOPERIDOL ON OPERANT-BEHAVIOR.
000486 01-04
EFFECTS OF TRIFLUOPERAZINE, CHLORPROMAZINE, AND HALOPERIDOL
UPON TEMPORAL INFORMATION-PROCESSING BY SCHIZOPHRENIC-
PATIENTS.
000554 01-08
COMPARATIVE ENZYME-INDUCING EFFECTS OF CHLORPROMAZINE AND
FLUPHENAZINE THERAPIES IN PSYCHOTIC-PATIENTS.
000682 01-11
PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH
BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS.
000717 01-11
PLASMA CHLORPROMAZINE SERUM PROLACTIN RELATIONSHIP IN A
SINGLE-DOSE EXPERIMENT.
000761 01-13
PHARMACOKINETICS OF CHLORPROMAZINE IN NORMAL VOLUNTEERS.
000778 01-13
PLASMA AND SALIVA LEVELS OF CHLORPROMAZINE AND SUBJECTIVE
RESPONSE.
000826 01-14
IMPORTANCE OF AKINESIA: PLASMA CHLORPROMAZINE AND PROLACTIN
LEVELS.
000891 01-15
PERSISTENT EFFECTS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC-
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS.
001266 02-03
DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND
CYCLIC-AMP-PHOSPHODIESTERASE .
001405 02-03
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND
MORPHOLOGICAL-STUDY.
001407 02-03
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE AQION OF
DIAZEPAM: POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE
ACTION IN THE BRAIN.
001428 02-03
MECHANISMS OF CHLORPROMAZINE AND CHLORPROMAZINE ISOSTERES
ON THE GLYCEMIC-RESPONSE IN MICE. (PH.D. DISSERTATION).
001525 02-03
AN ANALYSIS OF SOME PERCEPTUAL-EFFEaS OF MORPHINE,
CHLORPROMAZINE, AND LSD.
001652 02-04
CORRELATION BETWEEN DAILY DOSAGE OF CHLORPROMAZINE AND
SUBSEQUENT SUPERSENSITIVITY.
001845 02-05
LONG-TERM CHLORPROMAZINE IN RHESUS-MONKEYS: PRODUQION OF
DYSKINESIAS AND CHANGES IN SOCIAL-BEHAVIOR.
001850 02-05
RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN
PLASMA AND CEREBROSPINAL-FLUID AND CLINICAL-RESPONSE AND
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS.
001905 02-08
PHARMACOKINETIC INTERACTION BETWEEN PROPRANOLOL AND
CHLORPROMAZINE IN SCHIZOPHRENIC-PATIENTS.
001940 02-08
THE RELATIONSHIP OF ALPHA AND DELTA EEG FREQUENCIES TO PAIN
AND MOOD IN FIBROSITIS-PATIENTS TREATED WITH CHLORPROMAZINE
AND L TRYPTOPHAN.
002152 02-n
LUPUS-LIKE-ILLNESS ASSOCIATED WITH CHLORPROMAZINE.
002408 02-15
THE DISTRIBUTION OF CHLORPROMAZINE BETWEEN PLASMA AND
ERYTHROCYTES.
002496 02-16
EFFECTS OF CHLORPROMAZINE ON DOPAMINERGIC-RECEPTOR FUNQIONS
IN RAT-BRAIN - DIFFERENCE OF THE RESPONSE OF SEVERAL
DOPAMINERGIC-SYSTEMS AFTER CHRONIC ADMINISTRATION.
002773 03-03
CHANGES IN THE CORTICAL ACTIVITY OF SUCCINATE-DEHYDROGENASE
UNDER THE INFLUENCE OF CHLORPROMAZINE (A HISTOCHEMICAL-
STUDY AND ELECTROCYTOCHEMICAL- STUDY).
002784 03-03
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS III THE MUTUAL RELATION OF EACH INDEX.
003179 03-08
CHLORPROMAZINE LEVELS AND THE OUTCOME OF TREATMENT IN
SCHIZOPHRENIC-PATIENTS.
003188 03-08 '
PLASMA LEVELS OF CHLORPROMAZINE AND CLINICAL-RESPONSE.
003201 03-08 ,
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC J
SCHIZOPHRENICS. I WITH REFERENCE TO PITUITARY-HORMONES. 1
003415 03-131
BIOLOGICAL-EFFEaS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. II. WITH REFERENCE TO SYMPATHETIC NEURONAL
FUNCTION.
003416 03-13 j
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CEUS:
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD.
003556 03-16
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
THE EFFEQ OF LONG-TERM CONCURRENT ADMINISTRATION OF
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL
CORTICAL DOPAMINE METABOLISM IN RATS.
003788 04-03
INHIBITION OF LYSOSOMAL LIPASES BY CHLORPROMAZINE: A POSSIBLE
MECHANISMS OF STABILIZATION '
003993 04-03
INTERACTIONS BETWEEN CHLORPROMAZINE AND SOME OF ITS
METABOLITES.
004001 04-03
CHLORPROMAZINE EFFEQS ON COCAINE-REINFORCED RESPONDING IN
RHESUS-MONKEYS: RECIPROCAL MODIFICATION OF RATE ALTERING
EFFEaS OF THE DRUGS.
004133 04-04
EFFEQS OF CHLORPROMAZINE ON ESCAPE AND AVOIDANCE RESPONSES:
A CLOSER LOOK.
004226 04-04
PROTEIN BINDING OF CHLORPROMAZINE IN CEREBROSPINAL-FLUID AND
SERUM.
004311 04-08
S-92
VOLUME 19, SUBJECT INDEX
Subject Index
A TWELVE-YEAR FOLLOWUP OF THE NIMH-PRB HIGH-DOSE
CHL0RPR0MA2INE STUDY OF CHRONIC SCHIZOPHRENICS -
IMPLICATIONS FOR DEINSTITUTIONALIZATION. (UNPUBLISHED PAPER).
004323 04-08
NEUROENDOCRINE-TESTS DURING TREATMENT WITH NEUROLEPTIC-
DRUGS: I. PLASMA PROLACTIN RESPONSE TO CHLORPROMAZINE
CHALLENGE.
004329 04-08
SELECTIVE INHIBITORY-EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE
ON PLATELET AGGREGATION
004518 04-13
INTERACTION OF CHLORPROMAZINE WITH THE TRANSPORT SYSTEM OF
GLUCOSE IN HUMAN ERYTHROCYTES
004529 04-13
THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE
PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION
WITH PHYTOHEMAGGLUTININ.
004541 04-13
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO.
004544 04-13
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS ACTIVE
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC-
PATIENTS TREATED WITH FIXED DRUG DOSES.
004559 04-13
HUMAN SOCIAL CONVERSATION: EFFEQS OF ETHANOL, SECOBARBITAL
AND CHLORPROMAZINE.
004582 04-14
CHLORPROMAZINE ANALYSIS IN HUMAN PLASMA. (UNPUBLISHED
PAPER).
004591 04-15
:hlorpromazine-hcl
a comparison of the cardiovascular effects of haloperidol,
thioridazine and chlorpromazine-hcl.
000512 01-05
ORIENTATIONAL TESTING OF CHLORPROMAZINE-HCL ON HOSPITALIZED
MENTAL-PATIENTS.
002131 02-11
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION
PRODUaS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH-
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE
DETECTION.
004302 04-06
:hlorpromazine-induced
the role of differential blockade of alpha-adrenergic agonists
in chlorpromazine-induced hypotension.
001851 02-05
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON
CHLORPROMAZINE-INDUCED ELEVATION OF PLASMA GLUCOSE AND
CYCLIC-AMP IN FED MICE.
003946 04-03
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCED
ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY
004018 04-03
IHOICE
HYPOMANIA AND TRICYCLIC-ANTIDEPRESSANT CHOICE.
000545 01-07
CHOICE OF TACTICS IN TREATING ALCOHOLIC-DELIRIUM.
000688 01-11
THE EFFECTS OF LITHIUM ON CHOICE BETWEEN COCAINE AND FOOD IN
THE RHESUS-MONKEY.
001825 02-04
THE TREATMENT OF BUCCOLINGUOFACIAL DYSKINESIA IN THE ELDERLY
THE CHOICE OF A NEUROLEPTIC-AGENT.
002223 02-13
AN INVOLVEMENT OF DOPAMINE IN HIGHER-ORDER CHOICE
MECHANISMS IN THE MONKEY.
003072 03-04
CHOICE BETWEEN FOOD AND HEROIN: EFFECTS OF MORPHINE
NALOXONE, AND SECOBARBITAL.
004123 04-04
DRUG PREFERENCE IN HUMANS: DOUBLE-BLIND CHOICE COMPARISON OF
PENTOBARBITAL, DIAZEPAM AND PLACEBO.
004566 04-14
HOICES
PHARMACOTHERAPY AND PSYCHOTHERAPY FOR AMBULATORY
DEPRESSION: EFFICACY AND CHOICES.
004413 04-09
HOLECYSTOKININ
THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN
REGULATION OF NEUROSECRETION. (UNPUBLISHED PAPER)
001003 02-01
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE-
ENKEPHALIN AND CHOLECYSTOKININ IN THE NEURAL RETINA OF
SEVERAL VERTEBRATE SPECIES. (UNPUBLISHED PAPER).
001017 02-01
NEWLY SYNTHESIZED CHOLECYSTOKININ IN SUBCELLULAR FRACTIONS OF
THE RAT-BRAIN.
003805 04-03
CHOLECYSTOKININ-LIKE
EFFECTS OF CHOLECYSTOKININ-LIKE PEPTIDES ON REARING ACTIVITY AND
HEXOBARBITAL-INDUCED SLEEP
000507 01-04
CHOLECYSTOKININ-OCTAPEPTIDE
INHIBITION OF THE ACTION OF CHOLECYSTOKININ-OCTAPEPTIDE ON THE
GUINEA-PIG ILEUM MYENTERIC PLEXUS BY DIBUTYRYL-CYCLIC-
GUANOSINE-MONOPHOSPHATE ,
001291 02-03
CENTRAL DEPRESSANT EFFECTS OF CAERULEIN AND CHOLECYSTOKININ-
OCTAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND
HALOPERIDOL.
002652 03-02
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE
CLIMBING IN MICE.
003031 03-04
OPERANT FEEDING AND DRINKING IN PIGS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF SYNTHETIC
CHOLECYSTOKININ-OCTAPEPTIDE,
003064 03-04
INTRAVENTRICULAR CHOLECYSTOKININ-OCTAPEPTIDE PRODUCES
HYPERGLYCEMIA IN RATS.
003943 04-03
CHOLECYSTOKININ-PEPTIDES
AN HPLC AND RIA ANALYSIS OF THE CHOLECYSTOKININ-PEPTIDES IN
RAT-BRAIN. (UNPUBLISHED PAPER).
001004 02-01
HPLC SEPARATION OF CHOLECYSTOKININ-PEPTIDES - TWO SYSTEMS.
(UNPUBLISHED PAPER).
001005 02-01
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN
FOLLOWING INTERAVENTRICULAR INJECTION.
001239 02-03
CHOLERA-TOXIN
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
CHOLERA-TOXIN-INDUCED
CHOLERA-TOXIN-INDUCED EPILEPTOGENIC-FOCUS - SPECIAL REFERENCE
TO CYCLIC-AMP METABOLISM AND EPILEPTOGENIC-FOCUS.
000522 01-05
CHOLERETIC-EFFECT
DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT
METABOLISM, DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND
CHOLERETIC-EFFECT.
000073 01-03
CHOLESTEROL
PLASMA HDL CHOLESTEROL AND GROWTH-HORMONE IN EPILEPTICS
TREATED WITH ANTICONVULSANTS.
002260 02-13
CHOLINE
INHIBITION OF HIGH-AFFINITY CHOLINE UPTAKE: STRUCTURE-ACTIVITY
STUDIES.
000026 01-03
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT
PROPERTIES.
000084 01-03
ORAL CHOLINE IN CEREBELLAR ATAXIA.
000722 01-11
EFFECTS OF CHOLINE CONTAINING COMPOUNDS ON TARDIVE-DYSKINESIA
AND OTHER MOVEMENT-DISORDERS.
000942 01-17
EFFECTS OF HEMICHOLINIUM-3 AND CHOLINE ON HIPPOCAMPAL
ELECTRICAL-ACTIVITY DURING IMMOBILITY VS. MOVEMENT
001438 02-03
EFFECT OF CHOLINE ON CONDITIONED FOOD MOTOR-REFLEXES IN CATS.
001731 02-04
UCK OF EFFECT OF CHOLINE AND NARCOTIC ANTAGONISTS UPON
APOMORPHINE DISCRIMINATION.
001770 02-04
EFFECTS OF ORAL CHOLINE ON HUMAN COMPLEX PARTIAL SEIZURES.
002149 02-11
USE OF CHOLINE AND LECITHIN IN THE TREATMENT OF TARDIVE-
DYSKINESIA.
002473 02-15
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES.
002879 03-03
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN.
003820 04-03
TISSUE CHOLINE STUDIED USING A SIMPLE CHEMICAL ASSAY
003828 04-03
I
9
it*
ii-
S5
fe:
K
S-93
Subject Index
Psychopharmacology Abstracts
■•:-':'i
M
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL AND CANNABIDIOL ON
SODIUM-DEPENDENT HIGH-AFFINITY CHOLINE UPTAKE IN THE RAT
HIPPOCAMPUS
003908 04-03
THE EFFECT OF ACETYLCHOLINE RELEASE ON CHOLINE FLUXES IN
ISOLATED SYNAPTIC TERMINALS.
003924 04-03
CNS EFFECTS OF CHOLINE ADMINISTRATION: EVIDENCE FOR TEMPORAL
DEPENDENCE.
003996 04-03
THE HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPECT TO THE
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRACTION
ABUNDANT IN PRESYNAPTIC MEMBRANES.
004028 04-03
CHOLINE REVERSES NALOXONE-INDUCED DECREASES IN HIPPOCAMPAL
ACETYLCHOLINE CONTENT AND SUPPRESSES ESCAPE-BEHAVIOR IN
OPIATE-DEPENDENT RATS.
004076 04-04
MECHANISM OF LITHIUM INCLUDED ELEVATION IN RED-BLOOD-CELL
CHOLINE CONTENT; AN IN VITRO ANALYSIS.
004511 04-13
A MECHANISM FOR THE ACCUMULATION OF CHOLINE IN ERYTHROCYTES
DURING TREATMENT WITH LITHIUM.
004520 04-13
ERYTHROCYTE CHOLINE CONCENTRATIONS ARE ELEVATED IN MANIC-
"^^'^^^^ 004521 04-13
GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC
ANALYSES FOR OEANOL, CHOLINE, AND THEIR ACETYLESTERS.
004683 04-16
CHOLINE-ACETYL-TRANSFERASE
PHYSICAL AND KINETIC PROPERTIES OF CHOLINE-ACETYL-TRANSFERASE
FROM RAT AND BOVINE BRAIN.
003676 04-01
CHOLINE-ACETYLTRANSFERASE
ACETYLCHOLINE AND CHOLINE-ACETYLTRANSFERASE
003930 04-03
CHOLINE-BITARTRATE
CHOLINE-BITARTRATE TREATMENT OF ALZHEIMER-TYPE DEMENTIAS.
000675 01-11
CHOLINE-CHLORIDE „ „^
HUMAN MEMORY AND THE EFFECTS OF PHYSOSTIGMINE AND CHOLINE-
'''''''' 002317 02-14
PHARMACOKINETIC-STUDIES WITH CHOLINE-CHLORIDE: A PRELIMINARY
REPORT.
004514 04-13
CLINICAL AND PRECLINICAL EXPERIENCE WITH CHOLINE-CHLORIDE IN
HUNTINGTONS-DISEASE AND TARDIVE-DYSKINESIA: UNANSWERED
QUESTIONS.
004604 04-15
CHOLINE-LIKE
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES.
002879 03-03
CHOLINERGIC
SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE:
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT.
000095 01-03
ENKEPHALINS PRESYNAPTICALLY INHIBIT CHOLINERGIC TRANSMISSION
IN SYMPATHETIC GANGLIA.
000167 01-03
CHOLINERGIC MECHANISMS AND CATAPLEXY IN DOGS.
000374 01-04
IMIPRAMINE AND REM SLEEP: CHOLINERGIC MEDIATION IN ANIMALS.
000406 01-04
CHOLINERGIC MECHANISMS IN SCENT-MARKING-BEHAVIOR BY
MONGOLIAN-GERBILS (MERIONES-UNGUICULATUS) .
000504 01-04
CHOLINERGIC ASPECTS OF TARDIVE-DYSKINESIA: HUMAN AND ANIMAL
STUDIES.
000928 01-17
INTERACTIONS OF NEUROPEPTIDES WITH CHOLINERGIC
SEPTOHIPPOCAMPAL PATHWAY: INDICATION FOR A POSSIBLE
TRANSSYNAPTIC REGULATION. (UNPUBLISHED PAPER).
001062 02-01
MARIJUANA AND CHOLINERGIC DYNAMICS. (UNPUBLISHED PAPER).
001166 02-03
REGULATION OF CHOLINERGIC TRANSMISSION IN ADRENAL-MEDULLA.
(UNPUBLISHED PAPER).
001182 02-03
OPIATE INTERACTIONS WITH CHOLINERGIC NEURONS.
001198 02-03
LONG-TERM EFFECTS OF HALOPERIDOL, CLOZAPINE, AND METHADONE
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNAMICS.
001325 02-03
INTRINSIC CHOLINERGIC EXCITATION IN THE RAT NEOSTRIATUM:
NICOTINIC AND MUSCARINIC-RECEPTORS.
001374 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
INTERACTION OF CHOLINERGIC AND DOPAMINERGIC INFLUENCES ON
YAWNING-BEHAVIOR.
001656 02-04
ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN
THE CAT.
001761 02-04
INVOLVEMENT OF CHOLINERGIC AND GABAERGiC SYSTEMS IN
SCHIZOPHRENIA.
001907 02-08
INCREASED VULNERABILITY TO CHOLINERGIC STIMULATION IN
AFFECTIVE-DISORDER PATIENTS
002003 02-09
CHOLINERGIC ASPEQS OF TARDIVE-DYSKINESIA.
002102 02-11
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY
AFFEQIVE-ILLNESS.
002506 02-16
DYSFUNCTIONS OF CHOLINERGIC PROCESSES IN SCHIZOPHRENIA.
002611 02-17
TRIMETHADIONE EFFECTS ON CHOLINERGIC RESPONSES IN APLYSIA
NEURONS
002782 03-03
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR.
002945 03-04
INJECTIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINERGIC AND
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS EFFECTS ON
LOCOMOTOR-ACTIVITY IN THE RAT.
003019 03-04
PHYSOSTIGMINE IN TOUREHE-SYNDROME: EVIDENCE FOR CHOLINERGIC
UNDERAQIVITY.
003286 03-10
CHOLINERGIC REBOUND IN NEUROLEPTIC WITHDRAWAL-SYNDROMES.
003506 03-15
THE EFFECT OF CHOLINERGIC SUBSTANCES ON NOCICEPTIVE EVOKED-
RESPONSES IN SPECIFIC NUCLEI OF THE THALAMUS.
003770 04-03
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS
INVOLVED IN THE HIPPOCAMPUS OF RABBITS.
003842 04^3
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN
INDIRECT ADRENERGIC CHOLINERGIC INTERAQION.
003887 04-03 j
EFFECTS OF TAIPOXIN ON THE ULTRASTRUQURE OF CHOLINERGIC AXON
TERMINALS IN THE MOUSE ADRENAL-MEDULLA.
003916 04-03
5' TRIPHOSPHATE RECYCLES INDEPENDENTLY OF ACETYLCHOLINE IN
CHOLINERGIC SYNAPTIC VESICLES
004063 04-03
POSSIBLE MUSCARINIC CHOLINERGIC MEDIATION OF PAHERNEO
AGGRESSIVE REFLEXES IN THE CAT.
004153 04-04
CHOLINERGIC MECHANISMS IN MANIA AND DEPRESSION: QUESTIONS OF
SPECIFICITY. „ ^
004374 04-09
THE STATE OF THE ADRENERGIC AND CHOLINERGIC SYSTEMS IN
SCHIZOPHRENIC-PATIENTS DURING PSYCHPHARMACOTHERAPY.
004526 04-13
CHOLINERGIC-DRUGS
EFFECTS OF DOPAMINERGIC AND CHOLINERGIC-DRUGS, NALOXONE AND
L PROLYL-LEUCYL-GLYCINAMIDE ON LSD-INDUCED CATALEPSY.
000360 01-04
THE EFFECS OF CHOLINERGIC-DRUGS ON THE INVOLUNTARY-
MOVEMENTS OF TARDIVE-DYSKINESIA.
000726 01-11
EFFEaS OF CHOLINERGIC-DRUGS ON MEMORY IN ALZHEIMERS-DISEASE.
003454 03-14
CHOLINERGIC-RECEPTOR
AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR
ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER
CHRONIC ANTIDEPRESSANT TREATMENT.
002788 03-03
BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH-
AVOIDANCE AND LOW-AVOIDANCE RATS. ^^^^ „^ „,
002852 03-03
A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE. (PH.D.
DISSERTATION). „„^,o „, „,
002918 03-03
S-94
VOLUME 19, SUBJECT INDEX
Subject Index
CHOLINEROIC-RECEPTORS
THE REGULATION OF CARDIAC MUSCARINIC CHOLINERGIC-RECEPTORS BY
ISOPROTERENOL
001441 02-03
CHOllNERGIC-SUPERSENSmVITY
THE ROLE Of CHOLINERGIC-SUPERSENSITIVITY IN THE MEDICAL
SYMPTOMS ASSOCIATED WITH WITHDRAWAL OF ANTIPSYCHOTIC-
DRUGS.
000869 01-15
CHOLINESTERASE
DIFFERENTIAL REGUL*TION OF MUSCARINIC AGONIST BINDING-SITES
FOLLOWING CHRONIC CHOLINESTERASE INHIBITION.
000279 01-03
ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITIES IN THE
MOUSE CEREBELLUM FOLLOWING MISONIDAZOLE TREATMENT.
003123 03-05
CHOLINOCEPTORS
INVOLVEMENT OF CENTRAL CHOLINOCEPTORS IN METRAZOL-INOUCED
CONVULSIONS.
000247 01-03
CHOLINOLYTIC
SCOPOLAMINE IN CHOLINOLYTIC TREATMENT,
004468 04-1 1
CHOLINOMIMETICS
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATSr FAILURE Of NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
CHOLINOMIMETICS IN HUNTINGTONS-DISEASE.
004442 04-11
CHOLINOMIMETICS IN MANIA, SCHIZOPHRENIA, AND MEMORY-
DISORDERS.
004703 04-17
CHOREA
PEMOLINE-INDUCED CHOREA.
003516 03-15
CHOREIC-MOVEMENTS
CHOREIC-MOVEMENTS INDUCED BY THE USE OF METHADONE.
002467 02-15
CHORIONIC
INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN
CHORIONIC GONADOTROPHIN.
003012 03-04
CHOROID
EVIDENCE FOR THE PRESENCE OF TWO TYPES Of MONOAMINE-OXIDASE
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF
AMINES INFLUENCING CEREBROSPINAL-fLUID fORMATION
002807 03-03
CHROMAFFIN
RELEASE Of ARACHIDONIC-ACID fROM ADRENAL CHROMAffIN CELL-
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED
PAPER).
001027 02-01
INFLUENCE OF DRUGS AFfECTING THE PITUITARY ADRENAL AXIS ON
CHROMAFFIN CELLS.
001183 02-03
ACCUMULATION OF AMANTADINE BY ISOLATED CHROMAFFIN
GRANULES.
003866 04-03
CHROMATIN
INFLUENCE Of PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS
002831 03-03
CHROMATOGRAPHY
AfflNITY CHROMATOGRAPHY Of THE BETA-ADRENERGIC-RECEPTOR AND
CHARACTERIZATION Of ANTIBODIES RAISED AGAINST PURIflED
RECEPTOR PREPARATIONS.
001009 02-01
GAS-CHROMATOGRAPHY, MASS-SPECTROMETRY, AND COMBINED
CHROMATOGRAPHY MASS-SPECTROMETRY.
^„_^ 004290 04-06
CHROMOSOMES
fRAGILE SITES IN HUMAN CHROMOSOMES I THE EfFECT OF METHIONINE
ON THE XQ-FRAGILE-SITE.
^„.^ 004515 04-13
CHRONIC-BRAIN-SYNOROMES
PROPRANOLOL IN THE TREATMENT OF RAGE AND VIOLENT-BEHAVIOR IN
PATIENTS WITH CHRONIC-BRAIN-SYNDROMES.
,„„^ 003394 03-1 1
CHRONIC-OUTPATIENTS
USING DRUG-HOLIDAYS FOR CHRONIC-OUTPATIENTS.
^—^ 004742 04-17
CHRONIC-SCHIZOPHRENICS
THE EFFECTS OF A DRUG-HOLIDAY ON RELAPSE AND TARDIVE-
DYSKINESIA IN CHRONIC-SCHIZOPHRENICS.
003487 03-15
CHRONIC-TREATMENT
EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA-
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN
000135 01-03
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
INTERACTION-STUDIES BETWEEN NARCOTIC ANALGESICS, NARCOTIC
ANTAGONISTS AND ETHANOL: STUDIES DURING ACUTE AND CHRONIC-
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE. (PHD
DISSERTATION).
001165 02-03
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL MONOAMINERGIC MECHANISMS.
001240 02-03
REGUL^TION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS.
001262 02-03
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMITTERS IN EPIDURAL
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC-
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS.
001386 02-03
MODULATION OF BETA-ADRENERGIC-RECEPTORS AND CALMODULIN
FOLLOWING ACUTE AND CHRONIC-TREATMENT WITH NEUROLEPTICS
001529 02-03
CHRONIC-TREATMENT WITH VALIUM (DIAZEPAM) FAILS TO AFFECT THE
REPRODUCTIVE SYSTEM OF THE MALE RAT.
001535 02-03
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFECT OF
CHRONIC-TREATMENT.
002847 03-03
NOREPINEPHRINE AND DOPAMINE CEREBRAL LEVELS AFTER CHRONIC-
TREATMENT WITH NOMIFENSINE.
002872 03-03
SUPPRESSION OF ACTIVE SLEEP BY CHRONIC-TREATMENT WITH
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT.
003056 03-04
FACILITATED SHOCK-INDUCED AGGRESSION AFTER CHRONIC-TREATMENT
WITH ANTIDEPRESSANT-DRUGS IN THE RAT.
003058 03-04
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC-
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT MIANSERIN.
003745 04-03
REGULATION OF SER0T0NIN2-RECEPT0RS (5 HT2) LABELED WITH
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT AMITRIPTYLINE.
003964 04-03
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN
BRAIN CELL-CULTURES.
004002 04-03
EffECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC
NEURONS.
004026 04-03
ELECTROCARDIOGRAPHIC-CHANGES IN RATS DURING CHRONIC-
TREATMENT WITH ANTIDEPRESSANT AND NEUROLEPTIC-DRUGS.
004284 04-05
HORMONAL STIMULATION AFTER INJECTION OF THYROTROPHIN-
RELEASING-FACTOR (TRF) AND ACTH1-24 IN PATIENTS FOLLOWING
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY-STUDY.
004505 04-13
CHRONIC-TREATMENTS
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI OR
ETHANOL DETECTED BY ELECTROPHYSIOLOGICAL-CORRELATES.
001136 02-03
CHRONICALLY-ILL
CHRONIC DRUG-TREATMENT OF THE CHRONICALLY-ILL: BENEFITS AND
RISKS.
003625 03-17
CHRONOLOGICAL
CHRONOLOGICAL ELECTROENCEPHALOGRAPHIC AND
NEUROPHARMACOLOGICAL- STUDY IN CORTICAL KINDLING RABBITS.
002761 03-03
CHRONOLOGY
CHRONOLOGY Of EXTRAPYRAMIDAL-EfFECTS OF NEUROLEPTIC-DRUGS
AND THE NIGROSTRIATAL DOPAMINERGIC-SYSTEM
002449 02-15
CHRONOLOGY OF NEUROCHEMICAL ALTERATIONS INDUCED BY GABA
AGONIST ADMINISTRATION.
002713 03-03
CICLAZINDOL
INFLUENCE Of CICLAZINDOL ON MONOAMINE UPTAKE AND CNS
FUNCTION IN NORMAL SUBJECTS.
002268 02-13
J
S
.■.•i«'
5?5
S-95
Subject Index
Psychopharmacology Abstracto
CIGAREHE
NALOXONE REDUCES CIGARETTE SMOKING.
000808 01-14
THE ROLE OF NICOTINE IN THE BEHAVIORAL-ASPECTS OF CIGAREHE
SMOKING.
004575 04-14
CIMETIDINE
SYNERGISTIC ACTIONS OF PROPANTHELINE-BROMIDE WITH CIMETIDINE
AND THIOPROPAZATE-HYDROCHLORIDE IN THE PREVENTION OF
STRESS-ULCER FORMATION IN RATS
000064 01-03
DELAYED CLEARANCE OF DIAZEPAM DUE TO CIMETIDINE.
000164 01-03
CIMETIDINE TOXICITY MANIFESTED AS PARANOIA AND
HALLUCINATIONS.
000829 01-15
AGITATION, DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON
CIMETIDINE: A REPORT OF THREE CASES AND LITERATURE REVIEW.
000896 01-15
INFLUENCE OF CIMETIDINE ON THE PHARMACOKINETICS OF
DESMETHYLDIAZEPAM AND OXAZEPAM.
002249 02-13
CIMETIDINE-INDUCED
A CASE-REPORT OF CIMETIDINE-INDUCED DEPRESSIVE-SYNDROME.
000839 01-15
DIFFERENTIAL DIAGNOSIS OF CIMETIDINE-INDUCED DELIRIUM.
003488 03-15
CIRCADIAN-CYCLES
THE EFFECTS OF PROGESTERONE ON THE CIRCADIAN-CYCLES AND
ESTROUS-CYCLES IN THE RAT. (PH D. DISSERTATION).
001 1 1 1 02-03
ORCADIAN-CYCLING
PHENOBARBITAL EFFECTS ON WEIGHT-GAIN AND CIRCADIAN-CYCLING OF
FOOD INTAKE AND BODY-TEMPERATURE.
001409 02-03
CIRCADIAN-EXCRETION
EFFECT OF FLUPHENAZINE ON THE CIRCADIAN-EXCRETION OF CYCLIC-
NUCLEOTIDES AND ELECTROLYTES IN THE URINE OF CHRONIC
SCHIZOPHRENICS.
001927 02-08
CIRCADIAN-PERIODICITY
EFFECT OF LITHIUM-CARBONATE ON CIRCADIAN-PERIODICITY IN
HUMANS,
000772 01-13
CIRCADIAN-RHYTHM
CIRCADIAN-RHYTHM OF CYCLIC-NUCLEOTIDE AND GABA LEVELS IN THE
RAT-BRAIN.
000049 01-03
INFLUENCE OF CHRONIC ALCOHOL INTOXICATION ON CIRCADIAN-RHYTHM
OF NEUROSECRETORY CENTERS OF RAT HYPOTHALAMUS
001549 02-03
CIRCADIAN-RHYTHMc
antidepressant-lRugs slow circadian-rhythms in behavior and
BRAIN NEUROTRANSMITTER-RECEPTORS.
001536 02-03
circadian-variation
circadian-variation of cyclic-amp in the rat pineal-gland.
003938 04-03
CIRCLING
MORPHINE-DEPENDENCE AND DOPAMINERGIC-ACTIVITY: TESTS OF
CIRCLING RESPONSES IN RATS WITH UNILATERAL NIGRAL LESIONS.
001641 02-04
CIRCLING PRODUCED BY SEROTONIN AND DOPAMINE AGONISTS IN
RAPHE LESIONED RATS. A SEROTONIN MODEL.
001783 02-04
INVOLVEMENT OF DOPAMINE IN CIRCLING RESPONSES TO MUSCIMOL
DEPENDS ON INTRANIGRAL SITE OF INJEQION.
004158 04-04
CIRCLING-BEHAVIOR
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH
UNILATERAL NIGROSTRIATAL LESIONS.
004117 04-04
CIRCLING-BEHAVIOUR
CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL INJECTION OF
BACLOFEN IN RATS.
000415 01-04
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN
RATS.
001669 02-04
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF TAURINE IN RATS.
001670 02-04
THE ROLE OF NIGRAL PROJECTIONS TO THE THALAMUS IN DRUG-
INDUCED CIRCLING-BEHAVIOUR IN THE RAT.
004205 04-04
CIRCUITS
ACTIVATION OF CORTICAL CIRCUITS DURING INTERIQAL SPIKES.
000056 01-03
CIRCULATION
EFFECT OF ISOPROTERENOL ON CEREBRAL CIRCULATION IN DOGS.
000199 01-03
EFFECTS OF ANTIDEPRESSIVE-DRUGS UPON THE HEART AND
CIRCULATION.
000863 01-15
EFFECTS OF BICUCULLINE-INDUCED SEIZURES ON CEREBRAL METABOLISM
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY
STARVATION.
001134 02-03
ACTION OF 4 AMINOPYRIDINE ON THE CEREBRAL CIRCULATION.
003781 04-03
CIRCULATIONS
ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND
EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL
AND INTRODUODENAL ADMINISTRATION
000094 01-03
CIRCULATORY
CEREBRAL CIRCUUTORY AND METABOLIC-EFFEaS OF PIRIBEDIL.
000200 01-03
CIRCUMSTANCES
THE EFFECT OF MEBICAR ON THE CONDITION OF ANIMALS UNDER
CERTAIN EXTREME CIRCUMSTANCES.
004262 04-04
CIRCUMVENTRICULAR
INHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN
CIRCUMVENTRICULAR STRUCTURES OF RAT-BRAIN.
000159 01-03
MONOAMINE-OXIDASE-B ACTIVITIES TOWARD BETA PHENYLETHYLAMINE
IN DISCRETE HYPOTHALAMIC AND CIRCUMVENTRICULAR NUCLEI OF
THE RAT.
002781 03-03
CIRRHOSIS
CHLORDIAZEPOXIDE AND OXAZEPAM DISPOSITION IN CIRRHOSIS
000790 01-13
CIS-ISOMERS
THE PHOTOCHEMICAL-STABILITY OF CIS-ISOMERS AND TRANS-ISOMERS
OF TRICYCLIC NEUROLEPTIC-DRUGS
001872 02-06
PLASMA LEVELS OF THE CIS-ISOMERS AND TRANS-ISOMERS OF DOXEPIN
AND DESMETHYLDOXEPIN AFTER ADMINISTRATION OF DOXEPIN TO
PATIENTS.
004355 04-09
CISMETHRIN
THE EFFECT OF CISMETHRIN ON THE RAT DORSAL ROOT POTENTIALS.
000528 01-05
CITALOPRAM
INITIAL, CLINICAL-TRIAL OF A NEW, SPECIFIC 5 HT REUPTAKE INHIBITOR, I
CITALOPRAM (LU-10-171). i
000591 01-09
EFFECT OF CITALOPRAM (LU-10-171) ON TRANYLCYPROMINE AND
TRYPTOPHAN-INDUCED WET-DOG-SHAKES IN RATS.
001682 02-04
CITICOLINE ^
OBSERVATIONS ON THE USE OF CITICOLINE IN DYSTHYMIC-PATIENTS.
003207 03-09 ,
CITRATE
GAMMA BUTYROLACTONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE
CITRATE (DN-1417): A NOVEL TRH ANALOG WITH POTENT EFFECTS ON ,
THE CENTRAL-NERVOUS-SYSTEM.
003057 03-04
INHIBITION OF THE SYNTHESIS OF ACETYLCHOLINE IN RAT-BRAIN SLICES
BY (-) HYDROXYCITRATE AND CITRATE.
004044 04-03
LITHIUM EFFEQS ON CITRATE METABOLISM IN HUMANS AND RATS.
004537 04-13
CLAMP
VOLTAGE CLAMP STUDY OF CAT SPINAL MOTONEURONS DURING
STRYCHNINE-INDUCED SEIZURES.
002886 03-03
CLARE-BISHOP
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
CLASSIC
REGULATION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS.
001262 02-03
CLASSICALLY
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS.
004180 04-04
CLASSIFICATION
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF
LOPIRAZEPAM (D-12524) BY QUANTITATIVE EEG AND
PSYCHOMETRIC-ANALYSIS.
000720 01-11
S-96
'i*3**'
:1fSf
VOLUME 19, SUBJECT rNDEX
Subject Index
CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM.
000988 0)-l 7
A CLASSIFICATION OF OPIATE-RECEPTORS THAT MEDIATE
ANTINOCICEPTION IN ANIMALS.
001807 02-04
AN OBJECTIVE CLASSIFICATION OF PSYCHOACTIVE-DRUGS.
001894 02-07
CLASSIFICATION OF PSYCHOTROPIC-DRUGS IN PEDIATRIC-
PSYCHOPHARMACOLOGY.
001903 02-07
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA; INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES. (UNPUBLISHED PAPER)
001910 02-08
CLASSIFICATION OF THE ANTIDEPRESSANT-DRUGS.
002015 02-09
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL- STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN).
002286 02-13
CLASSIFICATION OF DRUGS AND PATIENTS TO ACHIEVE MAXIMUM
THERAPEUTIC RESPONSE.
002560 02-17
CLASSIFICATION OF ANALGESICS.
002570 02-17
CLASSIFICATION AND PSYCHOTROPIC-DRUGS.
002605 02-17
REFLECTIONS ON THE CLASSIFICATION OF ANTIDEPRESSANT-DRUGS.
002610 02-17
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES.
003167 03-08
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
004406 04-09
THE CLASSIFICATION OF SLEEP-DISORDERS AND THE TREATMENT OF
VARIOUS FORMS OF SOMNAMBULISM.
004461 04-11
CLEARANCE
DELAYED CLEARANCE OF DIAZEPAM DUE TO CIMETIDINE.
000164 01-03
NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN RELATION TO
DEBRISOQUINE HYOROXYLATION IN MAN.
000754 01-13
VALPROIC-ACID DOSAGE AND PLASMA PROTEIN BINDING AND
CLEARANCE.
000755 01-13
CLEBOPRIDE
COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRACT OF THE GUINEA-PIG AND RAT.
003928 04-03
CLEFTS
FACIAL CLEFTS AMONG EPILEPTIC-PATIENTS.
003484 03-15
CLENBUTEROL
CLENBUTEROL, A CENTRAL BETA-ADRENOCEPTOR AGONIST.
000120 01-03
CLIMAX
THE BEHAVIOURAL-STATE DURING CLIMAX (HATCHING) IN THE
DOMESTIC-FOWL (GALLUS-DOMESTICUS) .
001564 02-04
CLIMBING
THE MESOLIMBIC SYSTEM, DENERVATION AND THE CLIMBING RESPONSE
IN THE MOUSE.
000370 01-04
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE
CLIMBING IN MICE.
003031 03-04
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS.
003068 03-04
USE OF THE INTRACEREBRAL INJECTION TECHNIQUE TO ELUCIDATE
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN
THE MOUSE.
004092 04-04
CLIMBING-BEHAVIOUR
EFFECT OF L HISTIDINE AND CHLORCYCLIZINE ON APOMORPHINE-INDUCED
CLIMBING-BEHAVIOUR AND METHAMPHETAMINE STEREOTYPY IN
MICE.
004147 04-04
CLINIC
NONCOOPERATION: AN EXAMINATION OF FACTORS LEADING TO
NONCOMPLIANCE IN A HYPERTENSION CLINIC.
002557 02-17
THE TREATMENT OF INSOMNIA THROUGH HOMEOPATHY IN A CLINIC.
004484 04-11
CLINICAL
CLINICAL COMPARISON OF OXYPROTHEPIN AND CLOTEPINE IN
SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY)
000568 01-08
CLINICAL ASSESSMENT OF ONCE A DAY PHENOTHIAZINE
ADMINISTRATION.
000573 01-08
CLINICAL AND LABORATORY DIAGNOSTICS APPLICATIONS IN
DEPRESSION. (UNPUBLISHED PAPER)
000588 01-09
ON THE RELATIONSHIP OF NORTRIPTYLINE: AMITRIPTYLINE RATIO TO
CLINICAL IMPROVEMENT OF AMITRIPTYLINE TREATED DEPRESSIVE-
PATIENTS
000599 01-09
CLINICAL AND BIOCHEMICAL-ACTION OF PIRACETAM (NOOTROPIL) IN
DRUG-RESISTANT DEPRESSION.
000600 01-09
PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPED-PATIENTS: A
PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED.
000668 01-11
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH
ANTIEPILEPTIC-DRUGS.
000695 01-11
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIOOPA, BENSERASIDE).
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION
000712 01-11
THE DOPAMINE-RADIORECEPTOR ASSAY - A CLINICAL APPLICATION.
000904 01-16
ROTTING WITH THEIR RIGHTS ON: CONSTITUTIONAL THEORY AND
CLINICAL REALITY IN DRUG-REFUSAL BY PSYCHIATRIC-PATIENTS.
000911 01-17
TEXTBQOK OF CLINICAL PSYCHOPHARMACOLOGY.
000929 01-17
CLINICAL HANDBOOK OF ANTIPSYCHOTIC-DRUG THERAPY.
000961 01-17
TWENTY YEARS CLINICAL THERAPEUTIC EXPERIENCE WITH CALCIUM
GLUTAMATES EFFICACY.
000963 01-17
MONOAMINE-OXIDASE AND ITS INHIBITION: SOME CLINICAL
IMPLICATIONS.
000983 01-17
CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM.
000988 01-17
BASIC AND CLINICAL NEUROBIOLOGICAL APPLICATIONS OF NEURONAL
(NSE) AND NONNEURONAL (NNE) ENOLASE. (UNPUBLISHED PAPER).
001041 02-01
SOME PHARMACOLOGICAL-ASPECTS AND BIOCHEMICAL-ASPECTS OF
TRH: EXPERIMENTAL AND CLINICAL DATA.
001189 02-03
POSSIBLE CLINICAL APPLICATIONS OF NOOTROPICS.
001890 02-07
ACTION OF TOFISOPAM ON THE ERGONOMIC VIGILANCE LEVEL. ITS
INTERACTION WITH THE EFFECTS OF ALCOHOL. CLINICAL
PHARMACOLOGICAL-STUDY.
001891 02-07
AMINEPTINE: CLINICAL REVIEW.
001896 02-07
CLINICAL ACTIVITY OF A NEW BENZODIAZEPINE: CLOXAZOLAM.
001904 02-07
CLINICAL STATE, PLASMA LEVELS OF HALOPERIDOL AND PROLACTIN:
001943 02-08
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS AFTER A SINGLE
INJECTION OF BETA ENDORPHIN.
001962 02-09
CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE
AND CLOMIPRAMINE IN DEPRESSIVE-STATES (PRELIMINARY
OBSERVATION).
002032 02-09
FIRST CLINICAL IMPRESSIONS IN DAILY PRACTICE.
002046 02-09
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO
SEVERE ANXIETY.
002070 02-10
CLINICAL PROCESSES AND CENTRAL DOPAMINERGIC-ACTIVITY IN
PSYCHOTIC-DISORDERS.
002098 02-11
THE USE AND MISUSE OF SLEEPING-PILLS: A CLINICAL GUIDE.
002150 02-11
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT;
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL
EVOLUTION.
002165 02-11
I
5
&.
in
ttl;-
to;.
S-97
Subject Index
Psychopharmacology Abstracts
TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAN AND
CARBIDOPA: CLINICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL-
OBSERVATIONS.
002180 02-11
CLINICAL USE OF SULPIRIDE IN ITALY.
002187 02-11
ON THE CLINICAL PHARMACOKINETICS OF THIORIDAZINE AND ITS
METABOLITES.
002207 02-13
CLINICAL EVIDENCE FOR MULTIPLE DOPAMINE-RECEPTORS IN MAN.
002264 02-13
CLINICAL NEUROPHYSIOLOGICAL ASPECTS OF PSYCHOPATHOLOGICAL-
CONDITIONS.
002274 02-13
CLINICAL COMPARABILITY OF PSYCHOTROPIC-DRUGS.
002526 02-17
ALIVAL: NEW CLINICAL APPLICATIONS, STUDIES IN PROGRESS, AND NEW
POSSIBILITIES.
002530 02-17
CLINICAL NEUROPHARMACOLOGY.
002567 02-17
REGULATION OF NEUROTRANSMISSION THROUGH PRESYNAPTIC-
RECEPTORS AND OTHER MECHANISMS: POSSIBLE CLINICAL RELEVANCE
AND THERAPEUTIC POTENTIAL.
002569 02-16
LIMITS, VALUE AND PERSPECTIVES OF THE PSYCHIATRIC-DIAGNOSIS IN
CLINICAL PSYCHOPHARMACOLOGY.
002631 02-17
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY?
002659 03-03
CORRELATION BETWEEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC-
DRUGS IN RATS AND DAILY CLINICAL DOSES.
003032 03-04
RAPIDITY OF CLINICAL ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
(UNPUBLISHED PAPER).
003164 03-07
DIFFERENCES IN THE CLINICAL ACTION OF SOME NEUROLEPTIC-DRUGS.
003204 03-08
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS. A
CLINICAL DOUBLE-BUND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER).
003327 03-11
A CLINICAL, CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE
TREATMENT OF NARCOTIC ADDICTION.
003335 03-11
CLINICAL PHARMACOKINETICS IN NEWBORNS AND INFANTS: AGE-
RELATED DIFFERENCES AND THERAPEUTIC IMPLICATIONS.
003343 03-11
CLINICAL SIGNIFICANCE OF PYRIDOXINE ADMINISTRATION IN L-DOPA
THERAPY OF PARKINSONISM.
003345 03-11
PHENYTOIN: PHARMACOKINETICS AND CLINICAL THERAPEUTICS.
003353 03-1 1
CLINICAL PHARMACOKINETICS OF OXAZEPAM AND LORAZEPAM.
003410 03-13
SPINOCEREBELLAR DEGENERATION WITH PARKINSONIAN FEATURES: A
CLINICAL AND PATHOLOGICAL REPORT.
003436 03-13
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE:
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION.
003458 03-14
EFFECTS OF GRADUAL DECREASE AND DISCONTINUATION OF
NEUROLEPTICS ON CLINICAL CONJITION AND TARDIVE-DYSKINESIA.
003469 03-15
LECITHIN ADMINISTRATION IN TARDIVE-DYSKINESIA: CLINICAL AND
BIOMEDICAL-CORRELATES.
003496 03-15
THE CLINICAL DYNAMICS OF TETRAETHYL-LEAD POISONING.
003500 03-15
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF
BENZODIAZEPINE TREATMENT: SIX CLINICAL CASES.
003505 03-15
TIME-COURSE OF CLINICAL CHEMICAL PARAMETERS UNDER LONG-TERM
LITHIUM TREATMENT.
003515 03-15
CLINICAL USE OF THE ANTIPSYCHOTICS.
003607 03-17
ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CLINICAL STAFF
IN DETERMINING MEDICATION COMPLIANCE.
003618 03-17
SECOND-GENERATION ANTIDEPRESSANTS: A CLINICAL
PHARMACOTHERAPEUTIC RESEARCH STRATEGY.
003632 03-17
PHARMACOLOGICAL-BASES OF PSYCHONEUROENDOCRINOLOGY:
PRECLINICAL ASSESSMENT OF CLINICAL FACTS.
003735 04-03
PROLACTIN RELEASING POTENCIES OF ANTIPSYCHOTIC AND RELATED
NONANTIPSYCHOTIC COMPOUNDS IN FEMALE RATS: RELATION TO
CLINICAL POTENCIES.
003830 04-03
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH.
003882 04-03
CLINICAL AND BIOCHEMICAL-CORRELATIONS IN ABRUPT
DISCONTINUATION OF PSYCHOPHARMACOTHERAPY.
004330 04-08
HALOPERIDOL AND DROPERIDOL TREATMENT IN SCHIZOPHRENICS:
CLINICAL APPLICATION OF THE PROLAQIN MODEL.
004332 04-08
THE USE OF CLINICAL AND PHARMACOKINETIC CRITERIA IN FORECASTING
THE EFFICACY OF THERAPY IN SCHIZOPHRENIA.
004335 04-08
A CLINICAL AND PHARMACODYNAMIC EVALUATION OF SULPIRIDE.
004338 04-08
LONG-TERM NEUROLEPTIC TREATMENT OF CHRONIC SCHIZOPHRENIC-
PATIENTS: CLINICAL AND BIOCHEMICAL-EFFECTS OF WITHDRAWAL.
004344 04-08
CLINICAL DEPRESSIONS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES
004350 04-09
CLINICAL SIGNIFICANCE OF THE ERYTHROPLASMATIC RATIO OF LITHIUM.
004357 04-09
CLINICAL NEUROPHYSIOLOGICAL PROPERTIES OF ANTIDEPRESSANTS
004373 04-09
CLINICAL RESULTS OBTAINED WITH THE USE OF LYSONEURO IN
DEPRESSIVE-SYNDROMES
004397 04-09
CLINICAL USE OF A NEW BENZODIAZEPINE, PRAZEPAM.
004421 04-10
ARE THE ENKEPHALINS INVOLVED IN PARKINSONS-DISEASE? CLINICAL
AND NEUROENDOCRINE RESPONSES TO NALOXONE ADMINISTRATION.
004431 04-11
MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZiPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT.
004441 04-11
CLINICAL APPLICATION OF ANTIANOROGENS IN PSYCHIATRY.
004457 04-11
CLINICAL PHARMACOKINETICS OF CHLORDIAZEPOXIDE IN PATIENTS WITH
ALCOHOLIC HEPATITIS.
004473 04-11
CLINICAL PHARMACOKINETICS OF BENZODIAZEPINES.
004524 04-13
TREATMENT OF NARCOLEPSY AND SLEEP-APNEA WITH GAMMA
HYDROXYBUTYRATE: A CLINICAL AND POLYSOMNOGRAPHIC CASE-
STUDY.
004571 04-14
EFFECTS OF NEUROLEPTIC ADJUSTMENT ON CLINICAL CONDITION AND
TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-PATIENTS.
004595 04-15
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT, TARDIVE-
DYSKINESIA, AND THE TRAINING OF RESEARCH PSYCHIATRISTS.
004603 04-15
CLINICAL AND PRECLINICAL EXPERIENCE WITH CHOLINE-CHLORIDE IN
HUNTINGTONS-DISEASE AND TARDIVE-DYSKINESIA: UNANSWERED
QUESTIONS.
004604 04-15
EPILEPTOGENIC PROPERTIES OF ENFLURANE AND THEIR CLINICAL
INTERPRETATION.
004609 04-15
ACUTE PHENCYCLIDINE (PCP) INTOXICATION: QUANTITATIVE URINE
LEVELS AND CLINICAL MANAGEMENT.
004665 04-15
SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN
DETOXIFYING ALCOHOLIC-PATIENTS.
004671 04-16
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC-
ANTIDEPRESSANTS: PERSPEQIVE OF THE CLINICAL LABORATORY.
004681 04-16
THE USE OF CLINICAL KINETIC DATA IN TREATMENT WITH
ANTIDEPRESSANT-DRUGS.
004686 04-16
CLINICAL-ASPECTS
SOME CLINICAL-ASPECTS AND METABOLIC-ASPEaS OF PROPRANOLOL IN
CHRONIC SCHIZOPHRENIA.
001926 02-08
CLINICAL-ASPECTS OF ANXIETY AND ITS THERAPY
002089 02-10
TREATMENT OF DYSKINETIC AND DYSTONIC-DISORDERS WITH CF-25-
397: CLINICAL-ASPECTS AND PHARMACOLOGICAL ASPEQS.
002121 02-11
CLINICAL-ASPECTS OF LITHIUM EFFLUX FROM ERYTHROCYTES.
002228 02-13
S-98
VOLUME 19, SUBJECT INDEX
Subject Index
CLINICAL-ASPECTS ON PROLACTIN RESPONSE TO NEUROLEPTIC-DRUGS
002590 02-17
THE NEUROPHYSIOLOGICAL AND CLINICAL-ASPECTS OF PAIN.
003457 03-14
CLINICAL-ASPECTS OF DYSKINESIA
003461 03-15
CLINICAL-CORRELATION
CLINICAL-CORRELATION, BIOCHEMICAL-CORRELATION, AND
PSYCHOPHARMACOLOGICAL-CORRELATION IN PATIENTS WITH
DEPRESSIVE-SYMPTOMATOLOGY.
002018 02-09
CLINICAL-EFFECT
AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL-EFFECT: A
WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY.
001976 02-09
SERUM CONCENTRATION AND CLINICAL-EFFECT OF ANTIEPILEPTICS.
003315 03-11
HYPERVENTILATION-SYNDROME AND BETA-RECEPTOR FUNCTION -
CLINICAL-EFFECT OF BETA BLOCKER UPON THE SYNDROME,
004459 04-11
CLINICAL-EFFECTIVENESS
TWENTY YEARS HALOPERIOOL; CLINICAL-EFFECTIVENESS AND
THEORETICAL IMPLICATIONS.
000938 01-17
CLINICAL-EFFECTS
A REEXAMINATION OF THE CLINICAL-EFFECTS OF IMIPRAMINE AND
AMITRIPTYLINE IN DEPRESSIVE-ILLNESS.
000579 01-09
A COMPARATIVE-STUDY ON THE CLINICAL-EFFECTS OF FLUNITRAZEPAM
AND LORAZEPAM.
000702 01-11
CLOMIPRAMINE: PLASMA LEVELS AND CLINICAL-EFFECTS.
002033 02-09
HUNTINGTONS-DISEASE: CLINICAL-EFFECTS OF A SHORT-TERM
TREATMENT WITH PIMOZIDE.
002091 02-11
CARBAMAZEPINE THERAPY IN TRIGEMINAL-NEURALGIA: CLINICAL-
EFFECTS IN RELATION TO PLASMA CONCENTRATION.
, 00218102-11
A CONTROLLED DOUBLE-BLIND STUDY OF HALOPERIDOE VERSUS
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY-
SUBNORMAL-PATIENTS: SERUM LEVELS AND CLINICAL-EFFECTS.
002185 02-11
PLASMA DELTA9 TETRAHYDROCANNABINOL CONCENTRATIONS AND
CLINICAL-EFFECTS AFTER ORAL AND INTRAVENOUS ADMINISTRATION
AND SMOKING.
002201 02-12
RELATIONSHIP BETWEEN BLOOD CONCENTRATIONS AND CLINICAL-
EFFECTS OF A NEW ANTIDEPRESSANT MAPROTILINE.
003271 03-09
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFECTS OF ORAL MAGNESIUM
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM.
003291 03-11
A COMPARATIVE- STUDY ON THE CLINICAL-EFFECTS OF RECTAL
DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP
BETWEEN PLASMA LEVEL AND EFFECT.
003330 03-11
CLINICAL-EFFECTS OF BETA ENDORPHIN INFUSIONS.
004360 04-09
CLINICAL-EFFICACY
THE CLINICAL-EFFICACY OF CLOZAPINE AS COMPARED TO LABORATORY
PARAMETERS.
001955 02-08
EVALUATION OF THE CLINICAL-EFFICACY OF SINGLE-DAILY-DOSES OF
ANTIDEPRESSANTS.
001985 02-09
PHENOTHIAZINE PLASMA AND RED-BLOOD-CELL CONCENTRATIONS THEIR
RELATIONSHIP TO SIDE-EFFECTS AND CLINICAL-EFFICACY.
002386 02-15
CLINICAL-EFFICACY OF THE NEW ANTIDEPRESSANT BUPROPION
(WELLBUTRIN).
„„..^ 003227 03-09
CLINICAL-EVALUATION
CLINICAL-EVALUATION OF THE EFFECTS OF MINAPRINE.
001899 02-07
AN AnEMPT AT A CLINICAL-EVALUATION OF MINAPRINE.
... „ 001900 02-07
AN AHEMPT TO MAKE A CLINICAL-EVALUATION OF MINAPRINE
(CONTINUATION OF THE STUDY).
001901 02-07
BROMOCRIPTINE AND PARKINSONS-DISEASE: A 16-HOUR CLINICAL-
EVALUATION.
002127 02-11
TO THE CLINICAL-EVALUATION OF ANXIOLYTICS (TOFISOPAM)
002494 02-16
GUIDELINES FOR THE CLINICAL-EVALUATION OF ANALGESIC-DRUGS
002584 02-17
CLINICAL-EVALUATION OF THE PROPHYLACTIC EFFECTIVENESS OF
PROLONGED LITHIUM-CARBONATE THERAPY IN ENDOGENOUS
DEPRESSIVE-SYNDROMES.
004404 04-09
A CLINICAL-EVALUATION OF THE EFFECTS OF A NEW PSYCHOTROPIC-
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE
DOUBLE-BLIND METHOD.
004491 04-11
CLINICAL-EVALUATION OF BROMPERIDOL VERSUS HALOPERIOOL IN
PSYCHOTIC-PATIENTS,
004562 04-14
CLINICAL-EXPERIENCE
NOMIFENSIN IN THE TREATMENT OF ENDOGENOUS DEPRESSIONS
CLINICAL-EXPERIENCE AND EEG FINDINGS.
000613 01-09
CLINICAL-EXPERIENCE WITH NOMIFENSINE.
000642 01-09
CLINICAL-EXPERIENCE WITH LOW-DOSES OF HALOPERIOOL IN THE
TREATMENT OF NEUROSES.
000654 01-10
CLINICAL-EXPERIENCE WITH PIRACETAM THERAPY IN GERONTOLOGY.
000686 01-11
TREATMENT OF TARDIVE-DYSKINESIA WITH OXYPERTINE - PRELIMINARY
CLINICAL-EXPERIENCE AND A BRIEF REVIEW OF THE LITERATURE.
000692 01-11
TRIMIPRAMINE: TWENTY YEARS WORLDWIDE CLINICAL-EXPERIENCE.
000985 01-17
CLINICAL-EXPERIENCE WITH SECOND-GENERATION ANTIDEPRESSANTS IN
ENDOGENOUS DEPRESSIONS.
001975 02-09
CLINICAL-EXPERIENCE WITH LITHIUM-CARBONICUM-RETARD IN
PSYCHIATRY.
002000 02-09
CLINICAL-EXPERIENCE WITH SUBSTITUTED BENZAMIDES IN FRENCH-
SPEAKING COUNTRIES.
002036 02-09
CLINICAL-EXPERIENCE WITH PSYCHIATRIC-TREATMENT OF THE ELDERLY
INVOLVING THE USE OF PIRACETAM.
002188 02-11
CLINICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG-
RESISTANCE.
003245 03-09
CLINICAL-IMPLICATIONS
STRESS AND HYPERTENSION: CLINICAL-IMPLICATIONS.
002307 02-13
PSYCHOTROPIC-DRUGS AND THE HEART: CLINICAL-IMPLICATIONS.
002425 02-15
CLINICAL-IMPLICATIONS OF ENZYME INDUCTION AND ENZYME
INHIBITION.
003621 03-17
CLINICAL-PAPERS
DISCUSSION OF CLINICAL-PAPERS ON LITHIUM TRANSPORT IN AFFECTIVE-
DISORDERS.
001987 02-09
CLINICAL-PHARMACOLOGY
OBSERVATIONS ON CLINICAL-PHARMACOLOGY.
000970 01-17
CLINICAL-PHARMACOLOGY.
002247 02-13
BENZODIAZEPINES: CLINICAL-PHARMACOLOGY AND THERAPEUTIC USE
002521 02-17
DRUGS AND THE ELDERLY: PERSPECTIVES IN GERIATRIC CLINICAL-
PHARMACOLOGY
002534 02-17
CLINICAL-PHARMACOLOGY: DRUG DEVELOPMENT.
002547 02-17
CLINICAL-PHARMACOLOGY OF MIXED AGONIST ANTAGONIST DRUGS.
003329 03-11
CLINICAL-PHARMACOLOGY: ADVERSE DRUG INTERACTIONS,
003399 03-13
CLINICAL-PHARMACOLOGY: ELIMINATION OF DRUGS.
003400 03-13
CLINICAL-PHARMACOLOGY: DRUG ABSORPTION.
004740 04-17
CLINICAL-PICTURE
GERIATRIC ASPECTS OF PARKINSONISM (CLINICAL-PICTURE
PATHOLOGICAL MECHANISMS, AND MULTIPLE TREATMENT).
003643 03-17
CHANGES IN THE CLINICAL-PICTURE AND THE COURSE OF PSYCHOSES
DURING MASSIVE PSYCHOPHARMACOTHERAPY AND THE
SIGNIFICANCE OF THESE CHANGES FOR IMPROVEMENTS IN
PSYCHIATRIC-TREATMENT.
004699 04-17
I
(Si,
■■?•'
ft*,.
ft;.
S-99
Subject Index
Ptychopharmacology Abstracts
CLINICAL-PRACTICE
THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG-TREATMENT
FOR HYPERACTIVE-CHILDREN: RECENT FINDINGS AND A REPORT FROM
CLINICAL-PRACTICE. „„„^,.„, ,,
000715 01-11
NOOTROPIC-DRUGS IN CLINICAL-PRACTICE.
000811 01-14
RELIEF OF PAIN IN CLINICAL-PRACTICE.
003613 03-17
AMITRIPTYLINE AND NORTRIPTYLINE PLASMA LEVELS MONITORING.
PERSPECTIVE IN CLINICAL-PRACTICE.
004675 04-16
CLINICAL-RESPONSE
CLINICAL-RESPONSE AND SERUM NEUROLEPTIC LEVELS IN CHILDHOOD-
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
000566 01-08
VILOXAZINE PLASMA CONCENTRATIONS AND CLINICAL-RESPONSE.
000614 01-09
PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE-
DISORDER: A PRELIMINARY REPORT
000619 01-09
IMIPRAMINE TREATMENT OF PREPUBERTAL MAJOR DEPRESSIVE-
DISORDERS: PLASMA LEVELS AND CLINICAL-RESPONSE -
PRELIMINARY REPORT.
000620 01-09
URINARY MHPG AND CLINICAL-RESPONSE TO AMITRIPTYLINE IN
DEPRESSED-PATIENTS. ^, ^, „„
000631 01-09
INTERACTION BETWEEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN:
METABOLITE NORTRIPTYLINE AND THE CORREUVTION WITH CLINICAL-
RESPONSE. „„„, ,„ „, „„
000640 01-09
AMITRIPTYLINE, NORTRIPTYLINE PLASMA LEVELS AND CLINICAL-
RESPONSE IN WOMEN WITH AFFECTIVE-DISORDERS.
000757 01-13
INTERINDIVIDUAL VARIATION OF CLINICAL-RESPONSE TO HALOPERIDOL.
001230 02-03
RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN
PLASMA AND CEREBROSPINAL-FLUID AND CLINICAL-RESPONSE AND
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS
001905 02-08
CLINICAL-RESPONSE, PLASMA LEVELS AND PHARMACOKINETICS OF
DESIPRAMINE IN DEPRESSED-INPATIENTS.
002002 02-09
AGE-RELATED FACTORS AFFECTING ANTIDEPRESSANT-DRUG METABOLISM
AND CLINICAL-RESPONSE.
002035 02-09
HIGH-LEVELS OF AMITRIPTYLINE AND CLINICAL-RESPONSE.
002266 02-13
NEUROLEPTIC SERUM LEVELS MEASURED BY RADIORECEPTOR ASSAY
AND CLINICAL-RESPONSE IN SCHIZOPHRENIC-PATIENTS.
003199 03-08
PLASMA LEVELS OF CHLORPROMAZINE AND CLINICAL-RESPONSE.
003201 03-08
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE.
004356 04-09
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFECTIVE-DISORDERS
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDICTORS TO
CLINICAL-RESPONSE).
004365 04-09
PHARMACOKINETICS AND CLINICAL-RESPONSE TO TRICYCLIC-
ANTIDEPRESSANTS.
004370 04-09
THE RELATIONSHIPS BETWEEN CLINICAL-RESPONSE,
PSYCHOPHYSIOLOGICAL-VARIABLES AND PLASMA LEVELS OF
AMITRIPTYLINE AND DIAZEPAM IN NEUROTIC-OUTPATIENTS.
004423 04-10
SINGLE-CASE STUDY OF CLINICAL-RESPONSE TO HIGH-DOSE ERGOT
ALKALOID TREATMENT FOR DEMENTIA. PRELIMINARY REPORT.
004493 04-1 1
PROLACTIN AND NEUROLEPTIC-DRUGS: A BIOCHEMICAL INDEX OF
CLINICAL-RESPONSE?
004539 04-13
PLASMA NOMIFENSINE CONCENTRATION: CARDIOLOGICAL EFFECTS AND
CLINICAL-RESPONSE.
004639 04-15
CLINICAL-REVIEW
CLINICAL-REVIEW OF BETA-BLOCKERS IN ANXIETY.
004464 04-11
CLINICAL-SCALE
TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE
(CANTOR). MULTICENTER- STUDY OF 248 CASES EVALUATED WITH THE
FATIGUE STUDY GROUPS NO. 4 CLINICAL-SCALE.
001980 02-09
CLINICAL-STUDIES
HYDERGINE: A REVIEW OF 26 CLINICAL-STUDIES.
000704 01-11
MINAPRINE-CHLOROHYDRATE: SURVEY OF THE FIRST CLINICAL-STUDIES
OF THE FOURTH STAGE.
001902 02-07
CLINICAL-STUDIES AND BIOLOGICAL-STUDIES OF L TRYPTOPHAN IN
DEPRESSION.
001977 02-09
EFFECT OF SODIUM-VALPROATE AND BACLOFEN IN TARDIVE-DYSKINESIA:
CLINICAL-STUDIES AND NEUROENDOCRINE-STUDIES.
002441 02-15
REVIEW OF CLINICAL- STUDIES WITH ERGOTS IN GERONTOLOGY.
002624 02-17
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL- STUDIES WITH
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND
DEPOT NEUROLEPTICS.
003183 03-08
CLINICAL-STUDY
CONTRIBUTION TO THE CLINICAL-STUDY OF CEREBRAL DOPAMINERGIC
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST
RESULTS.
00061601-09
TRANSIENT-EFFECT OF L TRYPTOPHAN IN PROGRESSIVE MYOCLONUS
EPILEPSY WITHOUT UkFORA-BODIES: CLINICAL-STUDY AND
ELECTROPHYSIOLOGICAL-STUDY.
000694 01-11
CLINICAL-STUDY OF VILOXAZINE
001972 02-09
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A
CONTROLLED CLINICAL-STUDY WITH DOXEPIN AND PLACEBO
002080 02-10
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL- STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN) .
002286 02-13
A CLINICAL- STUDY AND ENDOCRINE-STUDY OF MESTEROLONE IN
SECONDARY IMPOTENCE
002315 02-14
A DOUBLE-BLIND CROSSED CLINICAL- STUDY WITH A NEW
PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008). DIAZEPAM, AND
A PLACEBO
003153 03-07
CLINICAL-STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE-
STATES: COMPILATION OF 1520 OBSERVATIONS
003206 03-09
ANXIOUS-DEPRESSIVE-SYNDROME CLINICAL-STUDY OF A NEW
BENZODIAZEPINE, PRAZEPAM.
004354 04-09
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO
AND STANDARD (IMIPRAMINE) CONTROLLED CLINICAL-STUDY.
004392 04-09
CLINICAL-TESTING
CLINICAL-TESTING OF MINAPRINE ON ELDERLY SUBJECTS WITH THE
ASTHENIC-DEPRESSIVE-SYNDROMES.
002123 02-11
RESULTS OF CLINICAL-TESTS OF VILOXAZINE (VIVALAN ICI): PART OF A
MULTICLINICAL-STUDY. ^^^^^ „^ ^„
002006 02-09
CLINICAL-TRIAL
CLINICAL-TRIAL OF OXYPROTHEPIN-DECANOATE. 000540 01^7
CLINICAL-TRIAL OF VILOXAZINE IN DEPRESSIVE-CONDITIONS.
000589 01-09
INITIAL CLINICAL-TRIAL OF A NEW. SPECIFIC 5 HT REUPTAKE INHIBITOR,
CITAL0PRAM(LU-10-171). 00059101-09
A CLINICAL-TRIAL OF ZIMELIDINE IN DEPRESSION. 001992 02-09
CLINICAL-TRIAL OF PYRAZIDOL IN ENDOGENOUS DEPRESSIVE-STATES.
002021 02-09
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: I A
CONTROLLED CLINICAL-TRIAL.
002086 02-10
CLINICAL-TRIAL WITH AMANTADINE AND HYDERGINE IN ELDERLY-
PATIENTS. „„„„^oo«,,
002093 02-11
FREE DESCRIPTION OF DRUG-EFFECTS AS A METHOD OF CLINICAL-TRIAL,
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND
THEIR COMBINATION 00256102-17
NOVEL ANTIDEPRESSANTS: A CLINICAL-TRIAL OF '^'^^SERIKL
AN OPEN CLINICAL-TRIAL OF MIANSERIN. ^^^^^ ^^^
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL
003256 03-Ot
CLINICAL-TRIAL OF HALAZEPAM AND CLORAZEPATE: CONSIDERATIONS
OF A SINGLE-BEDTIME-DOSE. 003277 03-10
S-100
(VOLUME 19, SUBJECT INDEX
Subject Index
CLINICAL-TRIAL Of PSYCHOTHERAPIES IS UNDER WAY
004378 04-09
A COMPARATIVE CLINICAL-TRIAL WITH THE TRANQUILIZER TRAZODONE
AND THE TRICYCLIC-ANTIDEPRESSANT CLOMIPRAMINE.
004380 04-09
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
(UNPUBLISHED PAPER).
004401 04-09
CONTROLLED CLINICAL-TRIAL OF NOMIFENSINE IN THE TREATMENT OF
DEPRESSION.
004417 04-09
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL.
004620 04-15
:linical-trials
clonidine for opiate detoxification: outpatient clinical-trials.
000731 01-11
CLINICAL-TRIALS WITH RUBIDIUM-CHLORIDE IN DEPRESSED-PATIENTS.
001893 02-07
CLINICAL-TRIALS OF DEPAKENE (VALPROIC-ACID) COADMINISTERED WITH
OTHER ANTICONVULSANTS IN EPILEPTIC-PATIENTS.
002367 02-14
DESIGN ASPECTS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS: A
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING-SCALES.
002512 02-16
PSYCHOTROPIC-DRUG REGISTRATION IN THE SCANDINAVIAN-COUNTRIES:
THE ROLE OF CLINICAL-TRIALS.
002550 02-17
COORDINATING CLINICAL-TRIALS IN PSYCHOPHARMACOLOGY:
PL^NNING, DOCUMENTATION, AND ANALYSIS.
002574 02-17
PREDICTION AND PROGNOSTIC FACTORS IN CLINICAL-TRIALS OF
PSYCHOTROPIC-DRUGS.
002615 02-17
CLINICAL-TRIALS WITH NEW BICYCLIC AND TETRACYCLIC COMPOUNDS:
ZIMELIDINE AND MAPROTILINE.
003213 03-09
CLINICAL-TRIALS WITH CLOBAZAM IN GERIATRICS.
003279 03-10
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES.
003599 03-17
:linical-variables
relationships among biochemical-variables, clinical-
variables, and pharmacokinetic-variables in neuroleptic
treated schizophrenic-patients.
001946 02-08
:UNICALLY
DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES.
000584 01-09
CLINICALLY SIGNIFICANT SIDE-EFFECTS OF LITHIUM TREATMENT.
000893 01-15
:UNICIAN
PATIENT CHARACTERISTICS AND CLINICIAN AHITUDES INFLUENCING THE
PRESCRIBING OF BENZODIAZEPINES.
003598 03-17
:UNICIANS
PREDICTABILITY OF PHENYTOIN SERUM LEVELS BY NOMOGRAMS AND
CLINICIANS.
000909 01-16
THE CLINICIANS ROLE IN PSYCHOPHARMACOLOGICAL-RESEARCH.
002563 02-17
aiNICOEPIDEMIOLOGICAL
TARDIVE-DYSKINESIA: CLINICOEPIDEMIOLOGICAL REVISION AND
CONTRIBUTION.
003466 03-15
:linics
the use of minaprine in child-psychiatry in hospitals and
outpatient clinics.
002169 02-11
:lobazam
pharmacological activities of clobazam and diazepam in the
rat: relation to drug brain levels.
000036 01-03
SPECIES-DIFFERENCES IN CLOBAZAM METABOLISM AND ANTILEPTAZOL
EFFECT.
001157 02-03
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A
MONOSUBSTANCE (DOXEPINE).
002028 02-09
ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT
AND POSHREATMENT OF ALCOHOLIC WITHDRAWAL.
,-,,... 002140 02-11
CLINICAL-TRIALS WITH CLOBAZAM IN GERIATRICS.
■003279 03-10
ANTIEPILEPTIC-EFFECT OF CLOBAZAM IN LENNOX-GASTAUT-SYNDROME.
004479 04-1 1
CLOCK
THE CLOCK AND THE BLUE GUITAR: STUDIES OF HUMAN GROWTH-
HORMONE SECRETION IN SLEEP AND WAKING (UNPUBLISHED PAPER)
002346 02-14
CLOFELIN
THE EFFECT OF CLOFELIN ON THE BIOELECTRIC-ACTIVITY OF THE BRAIN.
001449 02-03
THE EFFECT OF ANTIDEPRESSANTS ON THE HYPOTENSIVE-EFFECT OF
CLOFELIN IN RATS.
003934 04-03
CLOFIBRATE
EFFECTS OF ALBUMIN, AMINO-ACIDS, AND CLOFIBRATE ON THE UPTAKE
OF TRYPTOPHAN BY THE RAT-BRAIN.
002673 03-03
CLOMIPHENE-CITRATE
INFERENCES DERIVED FROM ELECTROENCEPHALOGRAPHIC RESPONSES TO
ACUTE ADMINISTRATION OF CLOMIPHENE-CITRATE IN MALE ALBINO-
RATS.
000155 01-03
CLOMIPRAMIN
INFUSION OF MAPROTILIN AND CLOMIPRAMIN AND THEIR COMBINATION
IN THE TREATMENT OF DEPRESSION.
002056 02-09
CLOMIPRAMINE
EXPERIMENTAL EVALUATION OF ANTIDEPRESSANT ACTIVITY OF
CLOMIPRAMINE, A NEW TRICYCLIC-ANTIDEPRESSANT DRUG.
001068 02-02
EFFECTS OF AMITRIPTYLINE AND CLOMIPRAMINE IN THE ISOLATED,
PERFUSED RABBIT HEART.
001852 02-05
OUR FIRST EXPERIENCE WITH CLOMIPRAMINE.
002008 02-09
CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE
AND CLOMIPRAMINE IN DEPRESSIVE- STATES (PRELIMINARY
OBSERVATION).
002032 02-09
CLOMIPRAMINE: PLASMA LEVELS AND CLINICAL-EFFECTS.
002033 02-09
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: I. A
CONTROLLED CLINICAL-TRIAL.
002086 02-10
CLOMIPRAMINE AND DOXEPIN IN DEPRESSIVE-NEUROSIS: PLASMA
LEVELS AND THERAPEUTIC RESPONSE.
002258 02-13
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: II.
BIOCHEMICAL-ASPECTS.
002300 02-13
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFECT OF
CHRONIC-TREATMENT.
002847 03-03
PHARMACOKINETICS OF CLOMIPRAMINE IN DEPRESSIVE-PATIENTS.
003216 03-09
THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL-
MEDICAL-PRACTICE: 48 CASES TREATED ON AN OUTPATIENT BASIS.
003268 03-09
A COMPARATIVE CLINICAL-TRIAL WITH THE TRANQUILIZER TRAZODONE
AND THE TRICYCLIC-ANTIDEPRESSANT CLOMIPRAMINE.
004380 04-09
CLONAZEPAM
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
CLONAZEPAM AND DITHIADEN IN HYPERKINETIC-CHILDREN.
000729 01-11
THE EFFECT OF CLONAZEPAM ON ATROPINE SPIKES IN THE LIMBIC-
SYSTEM.
001274 02-03
COMPARISON OF CLONAZEPAM AND DIAZEPAM IN EXPERIMENTAL-
STUDIES.
001815 02-04
INFLUENCE OF PHENYTOIN AND PHENOBARBITAL ON THE DISPOSITION OF
A SINGLE-ORAL-DOSE OF CLONAZEPAM.
002248 02-13
CLONAZEPAM AND PHENOBARBITAL IN TARDIVE-DYSKINESIA.
003294 03-11
TREATMENT OF EPILEPSIES WITH CLONAZEPAM (ANTELEPSIN).
004481 04-11
A COMPARATIVE-STUDY OF INTRAVENOUS LORAZEPAM AND
CLONAZEPAM IN STATUS-EPILEPTICUS.
004487 04-11
CLONIDINE
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFECTS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
9
liL
1
a
5
Ml
4ir
S-101
Subject Index
INTERACTION OF ANTIDEPRESSANTS WITH CLONIDINE ON RAT-BRAIN
TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL. ^^^ ^ ^ ^^
THE LOCOMOTOR-EFFECT OF CLONIDINE AND ITS INTERACTION WITH
ALPHA FLUPENTHIXOL OR HALOPERIDOL IN THE DEVELOPING^AT^^^^
DISPLACEMENT OF (3H)CL0NIDINE BINDING BY CLONIDINE ANALOGUES
IN MEMBRANES FROM RAT-CEREBRAL-CORTEX ^^^^^ ^ ^ ^^
ANTIMANIC-EFFECT OF CLONIDINE. ^^^^^ ^^^^
IATROGENIC OPIATE ADDICTION: SUCCESSFUL DETOXIFICATION WITH
CLONIDINE. 000666 01-11
CLONIDINE IN TOUREHE-SYNDROME. ^^^^^ ^^^ ^
CLONIDINE FOR OPIATE DETOXIFICATION: OUTPATIENT CI-INIO^L^-TRIALS. ^
RAPID OPIATE DETOXIFICATION WITH CLONIDINE AND NALOXONE^ ^^^^
■ CLONIDINE FOR OUTPATIENT OPIATE DETOXIFICATION. qoo827 01-14
OPIATES AND SPECIFIC RECEPTOR BINDING OF (3H)CL0NIDINE.^^^^ ^^^^
POSSIBLE INVOLVEMENT OF CYCLIC-AMP AND FRONTAL-CORTEX IN
AMrrRIPTYLINE MEDIATED SUPPRESSION OF THE HYPOTENSIVE-EFFECT
OF CLONIDINE. 001259 02-03
CLONIDINE ON THE PRESSOR RESPONSE TO RAISED INTRACRANIAL
''■'^^^^''^ 001316 02-03
INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRICTION
BY CLONIDINE IN CATS. 00143102-03
CLONIDINE AMELIORATES GILLES-DE-LA-TOUREHE-SYNDROME^ ^ ^^ ^^^ ^
CLONIDINE AND PSYCHOPHYSICAL PAIN . ^^^^^ ^^ ^ ^
RELATIONSHIPS BETWEEN STRUCTURE AND ALPHA-ADRENERGIC-
RECEPTOR AFFINITY OF CLONIDINE AND AND SOME RELATED CYCLIC-
A'^'°'^^5 002698 03-03
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF-
STIMULATION MODEL USING CLONIDINE. ^^^^^ ^^^
PROSTAGLANDINS, CLONIDINE AND SEXUAL-RECEPTIVITY IN THE GUINEA-
^'^ 003017 03-04
CLONIDINE ANALGESIA AND SUPPRESSION OF OPERANT RESPONDING:
DISSOCIATION OF MECHANISM. 003046 03-04
EFFICACY OF CLONIDINE IN OPIATE WITHDRAWAL: A STUDY OF THIRTY
PATIENTS. 003317 03-11
CLONIDINE IN TOURETTE-SYNDROME . ^^^^^ ^^ ^ ^
DELIRIUM SECONDARY TO CLONIDINE THERAPY ^^^^^ ^^ ^ ^
THE HYPOTHERMIC-EFFECTS OF CLONIDINE AND OTHER IMIDAZOLIDINES
IN RELATION TO THEIR ABILITY TO ENTER THE CENTRAL-NERVOUS-
SYSTEM IN MICE. 003933 04-03
DIFFERENTIAL-EFFECTS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS. 003947 04-03
CLONIDINE AND THE PRIMATE LOCUS-COERULEUS: EVIDENCE SUGGESTING
ANXIOLYTIC AND ANTIWITHDRAWAL EFFEaS. (UNPUBLISHED PAPER).
0039oz u4-Uj
MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN:
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CLONI0INE BINDING BY
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS.
003992 04-Oj
PRELIMINARY TRIAL OF CLONIDINE TREATMENT IN TWO PATIENTS
SUFFERING FROM CHRONIC SCHIZOPHRENIA. ^^^^^ ^^^^
"° SERotSKeCHANISMS of CLONIDINE-INDUCEO HYPOTHERMIA IN
■^AT^- 002806 03-03
EFFEQS OF ACUTELY AND CHRONICALLY ADMINISTERED
ANTIDEPRESSANTS ON THE CLONIDINE-INDUCED DECREASE IN RAT-
BRAIN 3 METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL-SULPHATE
CO'^T^^T 002908 03-03
CLONIDINE-INDUCED HYPERPHAGIA IN MONKEYS: EVIDENCE FOR
ALPHA2-N0RADRENERGIC-RECEPT0R MEDIATION „„,„,. n^ n>,
0042 1 5 04-04
Psychopharmacology Abstracts
^""^CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL. 004620 04-15
FAILURE OF CLORAZEPATE TO CAUSE MALFORMATIONS OR FETAL
WASTAGE IN THE RAT. 000514 01-05
DELAYED MAZE-LEARNING IN RATS AFTER PRENATAL EXPOSURE TO
CLO^A^^'"^^^ 000521 01-05
EVALUATION OF CLORAZEPATE (TRANXENE) AS AN ANTICONVULSANT ~
^^^^OVmO^. 000728 01-11
INDIVIDUAL VARIATIONS IN THE EFFECTS OF FLURAZEPAM,
CLORAZEPATE L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON
REM SLEEP IN MAN. 002349 02-14
CLINICAL-TRIAL OF HfKlMlPm AND CLORAZEPATE: CONSIDERATIONS
OF A SINGLE-BEDTIME-DOSE. 003277 03-10
^^'■^PHARAfAODLOGICAL PECULIARITIES OF A BENZODIAZEPINE /ATARACTIC-
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF
CLORAZEPATE-DIPOTASSIUM (TRANXILIUM).
004527 04-13
^"■^^NHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN
CIRCUMVENTRICULAR STRUQURES OF RAT-BRAIN.
(XX) I jV \) I *UJ
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS
tX/U I / I U I "UJ
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFEQ OF
CHRONIC-TREATMENT 002847 03-03
ALTERATIONS IN NORADRENERGIC FUNQION DURING CLORGYLINE
^^^^'^'^' 004393 04^
*^''°"u[oRINATED ANALOGUES OF THE TRICYCLIC NEUROLEPTICS: 2,3
DIFLUORO DERIVATIVE OF CLOROTEPIN. • ^^^^^^^ ^^^^
CONTROLLED-COMPARISON OF MEDIUM AND HIGH CLOROTEPIN DOSES j
IN CHRONIC SCHIZOPHRENIA. 000548 01-08
LONG-TERM APPLICATION OF HIGH-DOSES OF CLOROTEPIN TO CHRONIC
SCHIZOPHRENIC-PATIENTS. 001908 02-08
THE USE OF CLOROTEPIN AND DIAZEPAM IN A COMPLEX THERAPY OF
NEUROSES (CONTROLLED-COMPARISON) ^^^^ ^^^^
CONTROLLED-STUDY WITH BROMAZEPAM AND CLOROTEPIN IN CHILD
INSTABILITY. 002190 02-11
ACUTE EFFECT OF CLOROTEPIN (0.5MG AND 1 OMG) AND
METHAQUALONE (300MG) ON VERBAL-ASSOCIATIONS. ^^^^^ ^^^^
^^''^O.In'iCAL comparison OF OXYPROTHEPIN AND CLOTEPINE IN
SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY) ^^^^ ^ ^ _^
^^°CLINICAL^CTIVITY OF A NEW BENZODIAZEPINE: CLOXAZOUM^ ^^_^^
PHARMACOKINETICS OF CLOXAZOLAM IN MAN AFTER SINGLE AND
MULTIPLE ORAL DOSES. 004530 04-1:
"° Hx'd^RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK
TERMINATION EFFEaS OF D-AMPHETAMINE, MORPHINE, AND
CLOZAPINE. 000^3, g,^
CLOZAPINE IN THE TREATMENT OF TARDIVE-DYSKINESIA: AN INTERIM
^^^^^'^ 000677 01 -r
LONG-TERM EFFEaS OF HALOPERIDOL, CLOZAPINE, AND METHADONE
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNA^«^2-0:
BEHAVIORAL-CORRELATES AND BIOCHEMICAL-CORREIATES AFTER
HALOPERIDOL AND CLOZAPINE LONG-TERM-TREATMENT ^^^^^ ^^^
THE CLINICAL-EFFICACY OF CLOZAPINE AS COMPARED TO LABORATORY
PARAMETERS. 001955 02-0!
S-102
I/OLUME 19, SUBJECT INDEX
Subject Index
AN INVESTIGATION OF SOME SIDE-EFfECTS IN 47 PSYCHOTIC-PATIENTS
DURING TREATMENT WITH CLOZAPINE AND DISCONTINUING OF THE
TREATMENT.
002424 02-) 5
TIME-COURSE OF CHRONIC HALOPERIDOL AND CLOZAPINE UPON
OPERANT RATE AND DURATION
002989 03-04
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE.
003172 03-08
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON
BEHAVIORAL SHIFTS IN CATS, ARISING AFTER CESSATION OF
ELECTRICAL-STIMUUVTION OF THE CAUDATE-NUCLEUS.
004067 04-04
SOME EFFECTS Of CLOZAPINE ON PUNISHED-RESPONDING BY MICE AND
SQUIRREL-MONKEYS.
004224 04-04
A CASE OF ACUTE AGRANULOCYTOSIS DURING TREATMENT WITH
CLOZAPINE.
004642 04-15
:lues
family-tree gives clues to treating psychoses.
002363 02-14
:luster-headaches
lithium-carbonate in the treatment of cluster-headaches.
000670 01-11
:ns
an in vivo model for investigating alpha 1 -receptors and
alpha2-recept0rs in the cns: studies with mianserin.
000053 01-03
EFFECTS OF RESERPINE, PROPRANOLOL, AND AMINOPHYLLINE ON
SEIZURE ACTIVITY AND CNS CYCLIC-NUCLEOTIDES.
000115 01-03
3H ETHYLKETOCYCLAZOCINE BINDING: LACK OF EVIDENCE FOR A
SEPARATE KAPPA-RECEPTOR IN RAT CNS.
000128 01-03
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - I. KINETIC PARAMETERS
AND PHARMACOLOGICAL-PROPERTIES.
000213 01-03
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - II. RESPECTIVE REGIONAL
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC
DEVELOPMENTS.
000214 01-03
STEROID-HORMONES AND CNS AQIVITY.
000794 01-13
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE-
RECEPTOR MECHANISMS IN CNS.
001178 02-03
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN
RATS.
001199 02-03
EFFEQ OF REPEATED ELECTROCONVULSIVE-SHOCKS (ECS) ON
SUBTHRESHOLD DOSES OF SOME CNS STIMULANTS.
001361 02-03
EFFEQS OF GUANINE-NUCLEOTIDES ON CNS NEUROPEPTIDE-RECEPTORS.
(UNPUBLISHED PAPER).
001383 02-03
NEW EXPERIMENTAL TECHNIQUES IN THE PHARMACOLOGICAL
EVALUATION OF CNS ACTING DRUGS.
001479 02-03
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2
DOPAMINE-RECEPTORS IN THE CNS.
001480 02-03
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS.
001516 02-03
EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS.
001570 02-04
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF
12 CNS DEPRESSANTS IN INTAQ AND PITHED RATS.
001855 02-05
INFLUENCE OF CICLAZINDOL ON MONOAMINE UPTAKE AND CNS
FUNCTION IN NORMAL SUBJECTS.
002268 02-13
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY
AFFECTIVE-ILLNESS.
002506 02-16
SOME WAYS TO INCREASE CHANCES TO DISCOVER THE CNS DRUGS OF
THE FUTURE.
002528 02-17
PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS
MECHANISMS RESPONSIBLE FOR MOTOR ACT INHIBITION BY AVERSIVE
EVENTS.
002671 03-03
NEUROCHEMICAL-CONSEQUENCES FOLLOWING ADMINISTRATION OF CNS
STIMULANTS TO THE NEONATAL RAT.
002926 03-03
DO BENZODIAZEPINES BIND AT ADENOSINE UPTAKE SITES IN CNS?
002933 03-03
IMMUNODETECTION OF ACH-RECEPTOR IN THE CNS. (UNPUBLISHED
PAPER).
003670 04-01
ACYLCYANAMIDES, ACYLUREA, AND VARIOUS SUBSTITUTED
ARYLALLOPHANATES; EFFECT ON THE CNS.
003689 04-02
CNS EFFECTS OF CHOLINE ADMINISTRATION: EVIDENCE FOR TEMPORAL
DEPENDENCE.
003996 04-03
THE EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE
PRESENCE AND ABSENCE OF CNS DEPRESSANTS.
004010 04-03
N,N DIISOPROPYLTRYPTAMINE (DIPT) AND 5
METHOXYDIISOPROPYLTRYPTAMINE (5 MEO-DIPT). TWO ORALLY
ACTIVE TRYPTAMINE ANALOGS WITH CNS ACTIVITY.
004310 04-07
CNS EFFECTS OF ISF-2522, A NEW NOOTROPIC (A PHASE I SAFETY AND
CNS EFFICACY STUDY WITH QUANTITATIVE PHARMACOEEG AND
PHARMACOPSYCHOLOGY) .
004519 04-13
PATHOPHYSIOLOGICAL AND MORPHOLOGICAL CHANGES IN THE CNS
DURING LONG-TERM ADMINISTRATION OF HALOPERIDOL.
004633 04-15
CNS-ACTIN6
EFFECTS OF ANALGESICS AND CNS-ACTING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS.
004148 04-04
CNV
CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM,
HALOPERIDOL, PHENELZINE AND D-AMPHETAMINE.
002355 02-14
COADMINISTERED
CLINICAL-TRIALS OF DEPAKENE (VALPROIC-ACID) COADMINISTERED WITH
OTHER ANTICONVULSANTS IN EPILEPTIC-PATIENTS.
002367 02-14
COBALT
STUDIES ON GAMMA AMINOBUTYRIC-ACID TRANSPORT IN COBALT
EXPERIMENTAL EPILEPSY IN THE RAT.
003990 04-03
COCA-EXTRACTS
THE ANOREXIC AND ACTOMETRIC EFFEaS OF COCAINE AND TWO COCA-
EXTRACTS.
000344 01-04
COCA-LEAF
A CONTRIBUTION TO OUR KNOWLEDGE OF COCA-LEAF CONTENT
SUBSTANCES.
001022 02-01
COCAINE
THE ANOREXIC AND ACTOMETRIC EFFECTS OF COCAINE AND TWO COCA-
EXTRACTS.
000344 01-04
INHIBITION OF BEHAVIORAL-EFFECTS OF COCAINE BY ACTINOMYCIN-D IN
RATS.
000346 01-04
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFECTS OF
COCAINE AND D-AMPHETAMINE FOLLOWING CHRONIC AMPHETAMINE
ADMINISTRATION.
000350 01-04
EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE
ROLE FOR BETA PHENYLETHYLAMINE IN THE COCAINE CUE.
000363 01-04
PROGRESSIVE-RATIO AND FIXED-RATIO SCHEDULES OF COCAINE
MAINTAINED RESPONDING IN BABOONS.
000395 01-04
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
A COMPARISON OF THE EFFECTS OF D-AMPHETAMINE, COCAINE,
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE.
000508 01-04
PROLONGED EFFECTS OF COCAINE ON HIPPOCAMPAL ACTIVITY.
001338 02-03
5
5
'lit'
tic
(fir
rliM
S-103
Subject Index
Ptychopharmacology Abstract!
DIFFERENTIAL-EFFECTS OF COCAINE ON LIMBIC EXCITABILITY^^ ^^^ ^^^^
MOTOR-ACTIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF
cocaine! CORRELATION WITH DOPAMINE UPTAKE BLOCKADE^^ ^^^^
INTRAVENOUS SELF-ADMINISTRATION OF COCAINE AND NORCOCAINE BY
DOGS. 001760 02-04
THE PHARMACOLOGICAL RELEVANCE OF THE COCAINE BINDING-SITE IN
MOUSE-BRAIN. 001772 02-04
THE EFFECTS OF LITHIUM ON CHOICE BETV/EEN COCAINE AND FOOD IN
THE RHESUS-MONKEY. 001825 02-04
BEHAVIOR MAINTAINED BY INTRAVENOUS INJECTION OF CODEINE,
COCAINE AND ETORPHINE IN THE RHESUS-MACAQUE AND THE
PIGTAIL-MACAQUE. 001828 02-04
COCAINE EFFECTS IN SLEEP-DEPRIVED HUMANS. ^^^^3 02-14
rnfAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF ^^,^,,,,^
SdrENERQC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
SSt POTENtIX^E THeTnHIBITION by ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN. ^^^801 03-03
DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE, NORCOCAINE, AND
N ALLYLNORCOCAINE. ^^2954 03-04
INTERACTIONS OF DIAZEPAM AND COCAINE IN THE MORPHINE TREATED
RAT. (PH.D. DISSERTATION). ^q^i 15 03-04
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST
SUDDEN CARDIAC DEATH FROM COCAINE ^^ ^ ^2 03-05
ANTAGONISM OF INTRAVENOUS COCAINE LETHALITY IN NONHUMAN
PRIMATES. 003127 03-05
THE EFFECTS OF ELECTRIC-SHOCK ON RESPONDING MAINTAINED BY
COCAINE IN RHESUS-MONKEYS. ^^^^^ q^ q^
COCAINE AND SEIZURE PROTECTION IN MICE OF VARYING BRAIN
WEIGHTS. 004103 04-04
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN
THE SQUIRREL^ONKEY: COMPARISONS WITH FOOD PRESENTATION
AND EFFECTS OF D-AMPHETAMINE AND PROMAZINE. ^^^ ^^ ^^ ^^
REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION:
DISSOCIATIVE-EFFECTS OF COCAINE. ^^^^^ ^^^^
DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE RELATED TO AN
ANXIOGENIC ACTION. ^^^219 04-04
BEHAVIORAL-EFFECTS OF SELF-ADMINISTERED COCAINE: RESPONDING
MA^TAINED ALTERNATELY BY COCAINE AND ELECTRIC-SHOCK IN
SQUIRREL-MONKEYS. ^^^225 04-04
EFFECT OF COCAINE AND LIDOCAINE ON THE EXPRESSION OF KINDLED
SEIZURES IN THE RAT. ^^^233 04-04
^°*^RUgS"nMENT INTERAaiON: CONTEXT DEPENDENCY OF COCAINE-
INDUCED BEHAVIORAL-SENSITIZATION . ^^866 03-03
THE EFFECT OF AMYGDALA KINDLING ON SPONTANEOUS AND COCAINE-
INDUCED MOTOR-ACTIVITY AND LIDOCAINE SEIZURES. ^^^^^ ^^^^
^°^HLORPROMAZIn"eFFECTS on COCAINE-REINFORCED RESPONDING IN
RHESuSkEYS RECIPROCAL MODIFICATION OF RATE ALTERING
EFFECTS OF THE DRUGS. 004133 04-04
^^^theIffect of frusemide piretanide and bumetanide on cochlear
SUCCINIC-DEHYDROGENASE. ^^^^^ ^^ qj
*^°°IeHAVIOR maintained by intravenous injection of CODEINE,
COCAINE AND ETORPHINE IN THE RHESUS-MACAQUE AND THE
PIGTAIL-MACAQUE. 001828 02-04
COMPARATIVE-STUDIES OF THE PHARMACOLOGICAL-EFFECTS OF THE D-
ISOMERS AND L-ISOMERS OF CODEINE. ^^^ ^^^
GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA
DERIVATIZATION TECHNIQUES. ^^^^^ q^,^^
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD
^Y USE OF SELECTION -MONITORING AND DEUTERATED INTERNAL
STANDARDS. 004690 04-16
MCiipni PPTir>;. INTERACTIONS WITH FOOD - CHEMICAL AND
KmACOdZKuDIES ON THE INTERAQIONS OF COFFEE AND
^E* 003612 03-17
COGNITION
COGNITION AND PSYCHOSOMATICS 002312 02-14
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE, HOSPITALIZED SCHOOL-AGE CHILDREN. ^^^^^ ^^^ ^
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN. ^^^^^ ^^_^ ^
COONITIVl ^^ THIORIDAZINE ON THE COGNITIVE FUNQIONING OF A
HYPOTONIC SCHIZOPHRENIC-BOY. ^^^^^ ^^^^
COGNITIVE AND AFFECTIVE-FUNaiONS IN PATIENTS WITH AFFEQIVE-
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY
QUESTIONNAIRE 000604 01-09
DEXTROAMPHETAMINE : COGNITIVE AND BEHAVlORAL-EFFEm
NORMAL AND HYPERACTIVE-BOYS AND NORMAL ADULT^ALES.^^^^ ^
MEMORY AND COGNITIVE FUNQION IN THE ELDERLY: A PRELIMINARY-
TRIAL OF PHYSOSTIGMINE 000802 01-14
EFFECTS OF LITHIUM-CARBONATE ON MEMORY AND OTHER COGNITIVE
FUNaiONS. 000824 01-14
SERIAL COGNITIVE TESTING IN CANCER-PATIENTS RECEIVING
CHEMOTHERAPY. 000876 01-15
RESIDUAL-EFFECTS OF TEMAZEPAM AND OTHER HYPNOTIC-COMPOUNDS
ON COGNITIVE FUNCTION. 000879 01-15
EVALUATION OF THE RELATIVE EFFECTIVENESS OF METHYLPHENIDATE
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF
KINDERGARTEN-AGED HYPERACTIVE-CHILDREN ^^^^^ ^^^ ^
EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED
COGNITIVE ASSESSMENT SYSTEM. ^^^^^ ^^.ift
AN OVERVIEW OF PHARMACOLOGIC-TREATMENT OF COGNITIVE DECLINE
IN THE AGED. 004482 04-11
BLOOD-PRESSURE AND COGNITIVE FUNCTIONING ^^^^^^ ^^^ ^
THE EFFECTS OF PSYCHOTROPIC-MEDICATION ON COGNITIVE CONTROL
MEASURES. (PH D. DISSERTATION) ^^^^3 04-1 •
*^°°THE'RELATIVE*EFnCACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY
FOR T>1E TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY.
(PH . D . DISSERTATION) 002 1 48 02- 1
DEPRESSED-OUTPATIENTS TREATED WITH COGNITIVE-THERAPY OR
PHARMACOTHERAPY: A ONE-YEAR FOLLOWUP ^^^35 OS-C
GROUP VERSUS INDIVIDUAL COGNITIVE-THERAPY: A PILOT-^TUD^ ^^^
^°°UTHIUM-INDUCED COGWHEEL RIGIDITY: TREATMENT WITH
AMANTADINE. 000748 01-1
^°"rELEa1e'0F*G0NAD0TR0PIN-RELEASING-H0RM0NE BY VERATRINE IN A
HYPOTHALAMIC PITUITARY COINCUBATION ^^^^^ ^^^
^°^THE^EF'FEa OF COLCHICINE AND CYTOCHALASIN B ON THE RELEASE OF
TAURINE FROM THE CHICK RETINA. ^2356 03-0
THE EFFEQS OF COLCHICINE AND VINBLASTINE ON ^EMORYm^HlCKS^
^°''°PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFEaS OF
GANGLIONIC AND ADRENORECEPTOR BLOCKADE. ^^^^^ ^^_^
rnPF TFMPFRATURE CHANGES FOLLOWING ADMINISTRATION OF
nLoS AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
amb°enTtempermures. ^^^J^^Vr^^'^^Zm'"''''^^
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION. ^^^^^ ^^
•"""fMSffNE^Py^lMA CONCENTRATION AND CLINICAL-EFFEa: A
WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY^ ^_^^^ ^^_^
S-104
VOLUME 19, SUBJECT INDEX
Subject Index
MULTIINSTITUTIONAL-STUDY ON THE TERATOGENICITY AND FETAL
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE-
STUDY GROUP IN JAPAN.
002442 02-15
COLLAPSE
A CASE OF CARDIOVASCULAR COLLAPSE DURING LITHIUM-CARBONATE
THERAPY.
000860 01-15
COLLECTION
A NOVEL PSYCHOMETRIC-TEST MODEL APPLYING TAILORED TESTING FOR
ECONOMIC AND EFFICIENT COLLECTION OF
PSYCHOPHARMACOLOGICAL-EFFECTS.
002479 02-16
COLONIC
PHARMACOMANOMETRIC-STUDIES OF COLONIC MOTILITY AS A GUIDE
TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001930 02-08
COLONIES
A DRUG DISPENSER TO MEASURE INDIVIDUAL DRINKING IN RAT
COLONIES.
000530 01-06
COLUMNS
AN IMPROVED ASSAY OF CYCLIC-NUCLEOTIDE-PHOSPHODIESTERASES
WITH QAE-SEPHAOEX COLUMNS.
001860 02-06
COMA
THE TWO SURVIVAL CASES OF ALPHA-PAHERN COMA CAUSED BY
LARGE AMOUNTS OF HYPNOTICA AND NEUROLEPTICA.
004608 04-15
PROLONGED BENZODIAZEPINE COMA.
004653 04-15
COMBINATION
EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL
AND DIPHENYLHYDANTOIN IN THE ELECTROSHOCK-TEST IN MICE.
000163 01-03
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES
BEHAVIOURAL-EFFECTS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN
RATS.
000420 01-04
EFFECT OF MORPHINE IN COMBINATION WITH CHLORPROMAZINE AND
HALOPERIDOL ON OPERANT-BEHAVIOR.
000486 01-04
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE).
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION.
000712 01-11
CONTROLLED-TRIAL OF BEHAVIOUR-THERAPY, PHARMACOTHERAPY, AND
THEIR COMBINATION IN THE TREATMENT OF OBESITY.
000725 01-11
PROBLEMS INVOLVED IN THE COMBINATION OF PHARMACEUTIC-AGENTS
WITH PSYCHOTHERAPY OR PSYCHOANALYSIS.
000971 01-17
PRODUCTION OF CONVULSIONS IN MICE BY THE COMBINATION OF
METHIONINE AND HOMOCYSTEINE.
001233 02-03
THE EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ALONE AND IN
COMBINATION WITH CANNABIDIOL ON FIXED-INTERVAL
PERFORMANCE IN RHESUS-MONKEYS
001582 02-04
EFFECTS OF SPIPERONE ALONE AND IN COMBINATION WITH ANORECTIC-
AGENTS ON FEEDING PARAMETERS IN THE RAT.
001598 02-04
EFFECTS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN
COMBINATION WITH NALOXONE ON ELECTRIC-SHOCK TITRATION IN
THE SQUIRREL-MONKEY.
001611 02-04
A COMPARISON OF HALOPERIDOL, LITHIUM-CARBONATE AND THEIR
COMBINATION IN THE TREATMENT OF MANIA.
001990 02-09
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A
MONOSUBSTANCE (DOXEPINE).
002028 02-09
INFUSION OF MAPROTILIN AND CLOMIPRAMIN AND THEIR COMBINATION
IN THE TREATMENT OF DEPRESSION.
002056 02-09
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL ON
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC-STUDY.
002309 02-13
FREE DESCRIPTION OF DRUG-EFFECTS AS A METHOD OF CLINICAL-TRIAL
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND
THEIR COMBINATION.
002561 02-17
THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA.
002976 03-04
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL-STUDIES WITH
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND
DEPOT NEUROLEPTICS.
003183 03-08
THE BEHAVIORAL-EFFECTS OF D-AMPHETAMINE ALONE AND IN
COMBINATION WITH ACUTE AND CHRONIC MORPHINE TREATMENTS IN
RATS,
003915 04-03
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS,
004022 04-03
NEUROLEPTIC TRICYCLIC-ANTIDEPRESSANT COMBINATION:
PHARMACOLOGICAL-ASPECTS AND THERAPEUTIC INTEREST.
004501 04-13
ELECTRORETINOGRAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN
PSYCHOPHARMACOLOGY. ELECTRORETINOGRAPHIC-CHANGES INDUCED
BY A COMBINATION OF CARBIDOPA AND LEVODOPA.
004507 04-13
NEUROLOGICAL TOLERANCE OF LITHIUM AND PSYCHOTROPIC-DRUGS IN
COMBINATION: 265 CASES.
004594 04-15
COMBINATIONS
POTENTIATION OF LETHALITY IN MICE BY COMBINATIONS OF
PENTAZOCINE AND TRIPELENNAMINE.
000529 01-05
EFFECTS OF CHLORDIAZEPOXIDE MORPHINE COMBINATIONS ON
SPONTANEOUS LOCOMOTOR-ACTIVITY IN THREE INBRED STRAINS OF
MICE.
001766 02-04
BEHAVIOURAL-EFFECTS OF ACETYLSALICYLIC-ACID, PARACETAMOL,
CAFFEINE, GUAIPHENESIN AND THEIR COMBINATIONS.
001805 02-04
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
SIDE-EFFECTS AND UNDESIRABLE COMBINATIONS OF PSYCHOTROPIC-
MEDICATIONS.
004663 04-15
COMBINED
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS.
000466 01-04
COMBINED MONOAMINE-OXIDASE-INHIBITOR TRICYCLIC-
ANTIDEPRESSANT TREATMENT: A PILOT- STUDY.
000644 01-09
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
001024 02-01
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS.
001242 02-03
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND
MORPHOLOGICAL-STUDY.
001407 02-03
A COMBINED BEHAVIORAL-PHARMACOTHERAPY APPROACH TO
OBSESSIVE-COMPULSIVE-DISORDERS.
002082 02-10
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF
ENURESIS: A COMPARATIVE-STUDY.
002175 02-11
THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPECTS OF SLEEP AND OBJECTIVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOCTURNAL
MEDICATION: II. REPEATED DOSES.
002331 02-14
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY.
002639 03-01
COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION
IN THE RAT MODEL.
002928 03-03
SYNERGISM OF COMBINED LITHIUM NEUROLEPTIC THERAPY: A DOUBLE-
BLIND, PLACEBO-CONTROLLED CASE-STUDY.
003165 03-08
LITHIUM COMBINED WITH NEUROLEPTICS IN CHRONIC SCHIZOPHRENIC-
PATIENTS AND SCHIZOAFFECTIVE-PATIENTS.
003168 03-08
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE.
003172 03-08
I
ii'iit
a
S-105
Subject Index
COMBINED ADMINISTRATION OF NIALAMIDE AND VILOXAZINE TO
DEPRESSIVE-PATIENTS. 003232 03-09
SENILE-DEMENTIA: COMBINED PHARMACOLOGIC-TREATMENT AND
PSYCHOLOGIC-TREATMENT. ^^^^^ ^^_^ ^
PHARMACOPSYCHOLOGICAL INVESTIGATIONS CONCERNING THE
COMBINED EFFECTS OF DIPOTASSIUM-CLORAZEPATE AND ETHANOL^
003456 03-14
GAS-CHROMATOGRAPHY, MASS-SPECTROMETRY, AND COMBINED
CHROMATOGRAPHY MASS-SPECTROMETRY.
004290 04-06
NEUROTROPIC-DRUGS AS COMEDICATION TO PSYCHOTROPICS:
COMBINED ADMINISTRATION OF A NEUROTROPIC-DRUG AND A
TETRACYCLIC-ANTIDEPRESSANT. 004396 04-09
A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF
SCHIZOPHRENIA. 004584 04-14
^°*?He"b1nEFITS and risks of COMBINING AN MAO-INHIBITOR AND A
TRICYCLIC-ANTIDEPRESSANT. 003273 03-09
^°**NEUR0TR0PIC-DRUGS as COMEDICATION TO PSYCHOTROPICS:
COMBINED ADMINISTRATION OF A NEUROTROPIC-DRUG AND A
TETRACYCLIC-ANTIDEPRESSANT. 004396 04-09
^°**FS'llBEl[l^rO^Co'LERCIALLY-AVAILABLE 3H CATECHOl^^^
COMMUNAL
COMMUNAL MEDICATION . ^^595 02- 1 7
^°%*is"cUS*SIOrCOMMUNlCATION AND POLYPHARMACY: DRUGS AND THE
^'-'^^'^'■^ 000957 01-17
BRIEF COMMUNICATION: BEHAVIORAL RECOVERY AFTER TOLUENE
EXPOSURE IN RATS. 002969 03-04
^°TNTrPsVcHOTIGDRUGS IN COMMUNITY-BASED SHELTERED-CARE-HOMES.
002 \ I I Oz" 1 I
^°Te""cOMP-EEG, REO-EG AND PHARMACOLOGICAL-CORRELATES OF
GERIATRICS. 002162 02-11
COMPARABILITY ^ „„..^.
CLINICAL COMPARABILITY OF PSYCHOTROPIC-DRUGS . ^^^^^ ^^ ^ ^
COMPARATIVE
A COMPARATIVE EVALUATION OF DOTHIEPIN (PROTHIEDEN) AND
"^"'^^'^'^E- 000583 01-09
COMPARATIVE ENZYME-INDUCING EFFECTS OF CHLORPROMAZINE AND
FLUPHENAZINE THERAPIES IN PSYCHOTIC-PATIENTS.
OOOooz 01-11
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE).
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION
000/ \ i. 01"! I
THE COMPARATIVE DISPOSITION OF NOMIFENSINE (MERITAL) IN THE
PREGNANT AND NONPREGNANT RAT. 000853 01-15
COMPARATIVE ANXIOLYTIC AND HYPNOTIC-EFFEQS OF 3
BENZODIAZEPINES ON BABOONS. 00158102-04
COMPARATIVE EXPERIMENT OF THE ANTIDEPRESSANT EFFEaS OF
AMINEPTINE AND CHLORIMIPRAMINE. ^^^^^ ^^_^
COMPARATIVE CROSS-STUDY ON THE EFFEaS OF AMINEPTINE AND
^APROTILINE. 002065 02-10
SELF-MEDICATION ABANDONMENT, MANIPULATION, AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS.
0021 89 02- 1 I
COMPARATIVE PROTEIN BINDING OF DIAZEPAM AND
DESMETHYLDIAZEPAM. 002206 02-13
A COMPARATIVE REVIEW OF THE PHARMACOLOGICAL AND
TOXICOLOGICAL PROPERTIES OF DISULFIRAM AND CALCIUM-
CARBIMIDE. 003522 03-15
COMPARATIVE ANALGESIC, BEHAVIORAL, AND DEPENDENCE PROPERTIES
OF MORPHINE AND 0
Psychopharmacology Abstracts
METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME
Hfl
003707 04-02
A COMPARATIVE CLINICAL-TRIAL WITH THE TRANQUILIZER TRAZODONE
AND THE TRICYCLIC-ANTIDEPRESSANT CLOMIPRAMINE.
004380 04-09
COMPARATIVE CHARAQERISTICS OF THE PROPHYLAQIC PROPERTIES OF
SHORT-TERM AND LONG-ACTING LITHIUM-CARBONATE PREPARATIONS
IN ENDOGENOUS AFFECTIVE-PSYCHOSES.
004390 04-09
A COMPARATIVE EVALUATION OF THE EFFICACY OF SOME THERAPEUTIC
METHODS USED IN DELIRIUM-TREMENS.
004486 04-11
A COMPARATIVE EVALUATION OF THE USEFULNESS OF
PSYCHOPHYSIOLOGICAL-TESTS DURING VARIOUS LEVELS OF
ACTIVATION OF THE CENTRAL-NERVOUS-SYSTEM.
004543 04-13
COMPARATIVE-EFFECT
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL
EVOKED-POTENTIALS. 000763 01-13
COMPARATIVE-EFFECTS ^ ^,„ , „
COMPARATIVE-EFFECTS OF P CHLOROAMPHETAMINE AND L P
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN
^^^-^"^^'^ 000101 01-03
COMPARATIVE-EFFEaS OF SOMATOSTATIN AND ENKEPHALINS ON THE
GUINEA-PIG ILEUM AND THE RAT VAS-DEFERENS.
UNIT AaiVITY IN MEDIAL THALAMUS: COMPARATIVE-EFFEQS OF
CAFFEINE AND AMPHETAMINE. 003752 04-03
COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON
DOPAMINE METABOLISM IN RAT-BRAIN. 003796 04-03
COMPARATIVE-EFFEaS OF SUBSTITUTED PHENYLETHYLAMINES ON BRAIN
SEROTONERGIC MECHANISMS 003854 04-03
COMPARATIVE-EFFECTS OF PHENELZINE AND AMITRIPTYLINE: A
PLACEBO-CONTROLLED-TRIAL. 004402 04-09
COMPARATIVE-STUDIES
COMPARATIVE-STUDIES OF MAO-A AND MAO-B INHIBITORSIN MAN. •
0006 1 2 0 1 -OV
COMPARATIVE-STUDIES ON THE METABOLISM AND THE DISTRIBUTION OF
SULPIRIDE AND SULTOPRIDE 002240 02-13
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A
PERIPHERAL DOPA-DECARBOXYL*SE INHIBITOR, BENSERAZIDE-HCL, ON
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC-STUDY^^^ ^^^^
COMPARATIVE-STUDIES OF THE PHARMACOLOGICAL-EFFEQS OF THE D-
ISOMERS AND L-ISOMERS OF CODEINE ^^^ ^^
COMPABATiVE-STUDY
COMPARATIVE-STUDY OF ANALGESIA INDUCED BY N VAL5-ENKEPHALIN
AND PR05-ENKEPHALIN ANALOGS. 00002101-03
COMPARATIVE- STUDY OF THE INHIBITION OF GABA-AMINOTRANSFERASE
BY DIFFERENT ANTICONVULSANT-DRUGS. ^^^^^ ^^^^
COMPARATIVE-STUDY OF THE CARDIOTOXICITY OF AMITRIPTYLINE AND
MAPROTILINE IN DEPRESSIVE-PATIENTS ^^^^^ ^^_^
COMPARATIVE-STUDY OF PROPHYLAQIC LITHIUM AND
DIETHYLSTILBESTROL IN SEXUAL-DEVIANTS. ^^^^^ ^^ ^ ^
A COMPARATIVE-STUDY ON THE CLINICAL-EFFEaS OF FLUNITRAZEPAM
ANDLORAZEPAM 000702 01-11
COMPARATIVE-STUDY OF SLEEP AND STATE ON AWAKENING WITH TWO
HYPNOTIC DIAZEPINES 000817 01-14
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJEQION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION. 001568 02-04
COMPARATIVE-STUDY OF THE INDUQIVE EFFEQ OF TWO
PSYCHOMODERATORS - TETRABAMATE AND COMPLEXE-1656 - AND
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS-
0018/4 Kil-Kjo
MAINTENANCE-THERAPY WITH f LUPHENAZINE-pECANOATE AND
OXYPROTHEPINE-DECANOATE IN SCHIZOPHRENIC-PATIENTS - A
DOUBLE-BUND CROSS-OVER COMPARATIVE-STUDY.
S-106
VOLUME 19, SUBJECT INDEX
Subject Index
A COMPARATIVE-STUDY OF BROMOCRIPTINE AND LEVODOPA IN
PARKINSONS-DISEASE.
002117 02-11
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF
ENURESIS: A COMPARATIVE-STUDY.
002175 02-11
COMPARATIVE-STUDY OF VARIATIONS IN PROLACTIN LEVELS DURING
TREATMENT WITH ANTIPSYCHOTIC-DRUGS.
002412 02-15
COMPARATIVE-STUDY ON THE EFFECT OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS: STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS.
002757 03-03
A COMPARATIVE-STUDY OF THE PHARMACOLOGY OF INHIBITORS OF
GABA METABOLISM.
003036 03-04
A COMPARATIVE-STUDY ON THE CLINICAL-EFFECTS OF RECTAL
DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP
BETWEEN PLASMA LEVEL AND EFFECT.
003330 03-1 1
CARDIOVASCULAR-EFFECTS OF MIANSERIN - A COMPARATIVE-STUDY
WITH AMITRIPTYLINE AND A PLACEBO IN HEALTHY SUBJECTS.
003503 03-15
A COMPARATIVE-STUDY OF THE PHARMACOLOGICAL-PROPERTIES OF THE
POSITIVE POTENTIAL RECORDED FROM THE SUPERIOR CERVICAL
GANGLIA OF SEVERAL SPECIES.
003779 04-03
A COMPARATIVE-STUDY OF INTRAVENOUS LORAZEPAM AND
CLONAZEPAM IN STATUS-EPILEPTICUS.
004487 04-11
A CLINICAL-EVALUATION OF THE EFFECTS OF A NEW PSYCHOTROPIC-
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE
DOUBLE-BLIND METHOD.
004491 04-11
COMPARATIVE-TRIAL
A DOUBLE-BLIND GROUP COMPARATIVE-TRIAL OF MIANSERIN AND
DIAZEPAM IN DEPRESSED-OUTPATIENTS.
000592 01-09
SINGLE-DOSE VERSUS MULTIPLE-DOSE COMPARATIVE-TRIAL OF
DESIPRAMINE-HYDROCHLORIDE: A DOUBLE-PLACEBO METHOD.
002059 02-10
COMPARED
ANTIDEPRESSANT PROPERTIES OF 2 4 ETHYL-2-PIPERAZINYL-4-
PHENYLQUINOLINE-HCL (AD-1308) AND ITS MECHANISM-OF-ACTION
AS COMPARED WITH TRICYCLIC-ANTIDEPRESSANTS.
000152 01-03
ANTIDEPRESSANT TREATMENT BY INTRAVENOUS ADMINISTRATION
COMPARED TO PERORAL ADMINISTRATION: A DOUBLE-BLIND STUDY
OF QUINUPRAMINE.
000552 01-08
ANXIOLYTIC EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND
PLACEBO.
000648 01-10
COMPARED PROPERTIES OF CENTRAL AND PERIPHERAL BINDING-SITES
FOR PHENCYCLIDINE.
001521 02-03
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND
ELECTROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE
MIDBRAIN.
001593 02-04
OXYPROTHEPINE-DECANOATE COMPARED WITH FLUPHENAZINE-
DECANOATE IN THE TREATMENT OF SCHIZOPHRENIA: PRELIMINARY-
COMMUNICATION.
001934 02-08
THE CLINICAL-EFFICACY OF CLOZAPINE AS COMPARED TO LABORATORY
PARAMETERS.
001955 02-08
KETAZOLAM COMPARED TO DIAZEPAM AND PLACEBO IN THE
TREATMENT OF ANXIETY.
002074 02-10
LEVODOPA COMPARED WITH BROMOCRIPTINE IN THE TREATMENT OF
PARKINSONS-DISEASE.
002406 02-15
THE ACTION OF BENZODIAZEPINES ON THE LIMBIC-SYSTEM COMPARED
TO OTHER TRANQUILIZERS.
002731 03-03
THE ANTIDEPRESSANT ACTION OF SULPHO-ADENOSYL-L-METHIONINE
(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE:
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-ACTION.
003150 03-07
COMPARING
EFFICACY AND PAHERN VALENCE OF PSYCHOACTIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER.
000699 01-11
A DOUBLE-BUND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND
SIDE-EFFECTS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED-
INPATIENTS AND DEPRESSED-OUTPATIENTS.
004395 04-09
COMPARISON
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND
GABAMIMETICS.
000188 01-03
COMPARISON OF BETA-ADRENERGIC-RECEPTOR SUBTYPES IN
MAMMALIAN TISSUES.
000207 01-03
COMPARISON OF BLOOD AND BILE LEVELS OF OXYPROTHEPIN AND
DOCLOXYTHEPIN IN RATS.
000242 01-03
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRACTIONS.
000299 01-03
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL ACTIVITY.
000314 01-03
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE:
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER
SEROTONIN UPTAKE BLOCKERS.
000316 01-03
GABAERGIC ACTIONS OF THIP IN VIVO AND IN VITRO: A COMPARISON
WITH MUSCIMOL AND GABA.
000319 01-03
ANTINOCICEPTIVE COMPARISON OF QUIPAZINE AND MORPHINE.
000435 01-04
A COMPARISON OF THE EFFECTS OF D-AMPHETAMINE, COCAINE,
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE.
000508 01-04
A COMPARISON OF THE CARDIOVASCULAR EFFECTS OF HALOPERIDOL,
THIORIDAZINE AND CHLORPROMAZINE-HCL.
000512 01-05
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY:
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS.
000543 01-07
COMPUTERIZED EEG IN THE COMPARISON OF OXYPROTHEPIN AND
FLUPHENAZINE-DECANOATE.
000567 01-08
CLINICAL COMPARISON OF OXYPROTHEPIN AND CLOTEPINE IN
SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY) .
000568 01-08
DOUBLE-BUND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH
AFTERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS
WITH SCHIZOPHRENIA.
000574 01-08
COMPARISON OF SINGLE-DOSE PHARMACOKINETICS OF IMIPRAMINE
AND MAPROTILINE IN THE ELDERLY.
000596 01-09
SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF
SINGLE VS. DIVIDED DOSE ADMINISTRATION.
000629 01-09
DOUBLE-BLIND COMPARISON OF KETAZOLAM, DIAZEPAM AND PLACEBO
IN ONCE-A-DAY VS T.I.D. DOSING.
000660 01-11
COMPARISON OF SUSTAINED-RELEASE AND STANDARD
METHYLPHENIDATE IN THE TREATMENT OF MINIMAL-BRAIN-
DYSFUNCTION.
000732 01-11
COMPARISON OF CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE (CSD)
ISOENZYMES AND GLUTAMIC-ACID-OECARBOXYLASE (GAD) IN RAT: IS
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH
GAD? (UNPUBLISHED PAPER).
001048 02-01
COMPARISON OF HIGHLY-ACTIVE AND ACTIVITY DEPLETED HEPARIN BY
CIRCULAR DICHROISM SPECTROSCOPY. (UNPUBLISHED PAPER).
001057 02-01
til.
■•■It;
'•til:
tic,
S-l 07
Subject index
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT.
001104 02-03
ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA.
001151 02-03
A COMPARISON OF STRIATAL AND MESOLIMBIC DOPAMINE FUNCTION IN
THE RAT DURING 6-MONTH TRIFLUOPERAZINE ADMINISTRATION.
001174 02-03
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES.
001207 02-03
COMPARISON OF THE EFFECTS OF CENTRAL ADMINISTRATION OF SERINE
AND GLYCINE ON BODY-TEMPERATURE OF THE RABBIT.
001248 02-03
MORPHINE AND ELEaROACUPUNCTURE: COMPARISON OF THE EFFECTS
ON THE CORTICAL EVOKED-RESPONSES AFTER TOOTH-PULP
STIMULATION IN RATS. 001294 02-03
THE NEW ANTIDEPRESSANT PIRLINDOLE; A COMPARISON WITH
IMIPRAMINE AND TRANYLCYPROMINE.
001360 02-03
COMPARISON OF BIOLOGICAL-ACTIVITY AND BEHAVIORAL-ACTIVITY OF
ALPHA AND GAMMA MELANOCYTE-STIMULATING-HORMONES.
(UNPUBLISHED PAPER). 001398 02-03
DOPAMINE-AUTORECEPTORS: PHARMACOLOGY, FUNCTION AND
COMPARISON WITH POSTSYNAPTIC DOPAMINE-RECEPTORS
001453 02-03
DOSE-DEPENDENT PHARMACOKINETICS OF ALPHA METHYL-P-TYROSINE
(ALPHA MT) AND COMPARISON OF CATECHOLAMINE TURNOVER-
RATES AFTER TWO DOSES OF ALPHA MT. ^^ ^^^ ^^^^
ANALGESIC ACTION OF INTRATHECAL AND INTRACEREBRAL BETA
ENDORPHIN IN RATS: COMPARISON WITH MORPHINE.
001691 02-04
A COMPARISON BETWEEN THE EFFECTS OF MORPHINE ON THE
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC
AND CENTRAL GRAY STIMULATION 00 1 77 1 02 04
COMPARISON OF CLONAZEPAM AND DIAZEPAM IN EXPERIMENTAL-
^™°'^5 001815 02-04
COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT.
001841 02-05
COMPARISON OF THE CLASSICAL AND RETARDED FORM OF LITHIUM-
CARBONATE. „„,„„„ „^„-,
001888 02-07
A COMPARISON OF HALOPERIDOL, LITHIUM-CARBONATE AND THEIR
COMBINATION IN THE TREATMENT OF MANIA.
001990 02-09
COMPARISON OF THE EFFECTS OF LOFEPRAMINE AND MIANSERIN IN
DEPRESSED-PATIENTS IN A DOUBLE-BLIND TRIAL.
001996 02-09
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS:
RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BLIND TRIAL
001998 02-09
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A
MONOSUBSTANCE (DOXEPINE). ^^^^^^ ^^ ^^
002028 02-09
DOUBLE-BUND COMPARISON OF KETAZOLAM AND PLACEBO USING
ONCE-A-DAY DOSING. „„„„,^ „^ ,„
002067 02-10
NOMIFENSINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE-NEUROSIS.
THERAPEUTIC-EFFICACY AND TOLERABILITY IN COMPARISON TO
IMIPRAMINE. „„,„„^,„
002078 02-10
A DOUBLE-BUND PARALLEL GROUP COMPARISON OF SINGLE-BEDTIME-
DOSES OF HALAZEPAM AND PLACEBO.
002079 02-10
COMPARISON OF NITRAZEPAM 5 MG WITH TRIAZOLAM 0.5 MG IN
YOUNG PSYCHIATRIC INSOMNIAC-INPATIENTS.
002096 02-1 1
COMPARISON OF SCH- 12679 AND THIORIDAZINE IN AGGRESSIVE
MENTAL-RETARDATES. „„o, ,^ /,o , ,
002119 02-11
A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED
PARKINSONISM. „„„,., „o,,
002146 02-11
THE PERIPHERAL ANTICHOUNERGIC-ACTIVITY OF TRICYCUC-
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND
DESIPRAMINE IN HUMAN VOLUNTEERS. „ „„ ,.
002298 02-13
Psychopharmacology Abstracts
EFFEaS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED
SUBJEaS.
002320 02-14
AN EVALUATION OF MAPROTILINE INTRAVENOUS KINETICS AND
COMPARISON OF TWO ORAL DOSES.
002497 02-16
DESIGN ASPECTS OF CUNICAL-TRIALS WITH ERGOT ALKALOIDS: A
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING- SCALES.
002512 02-16
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS
AFTER HOSPITAL DISCHARGE IN THE DISTRIQS TEPLICE AND UHERSKE-
HRADISTE.
002518 02-17
UTIUZATION OF PSYCHOTROPIC-DRUGS. AN INTERNATIONAL
COMPARISON.
002616 02-16
A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC
AGONISTS: CHARACTERISTICS.
002670 03-03
A COMPARISON OF THE EFFEQS OF PENTOBARBITAL AND
DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY
OF ADULT SENSORY GANGLION CELLS.
002692 03-03
A COMPARISON OF THE NEUROCHEMICAL-EFFECTS OF BUPRENORPHINE
WITH THOSE OF MORPHINE AND HALOPERIDOL IN RATS.
002701 03-03
PULMONARY METABOLISM OF IMIPRAMINE IN THE RAT AND RABBIT:
COMPARISON WITH HEPATIC METABOLISM.
002845 03-03
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCUC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM:
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON.
002884 03-03
A COMPARISON OF HUMAN MUSCARINIC CHOUNERGIC-RECEPTOR
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE
RADIOLABELED ANTAGONIST, (3H) QUINUCUDINYL-BENZILATE. (PHD
DISSERTATION). „ „. ,xo
002918 03-03
A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS.
003182 03-08
A DOUBLE-BLIND COMPARISON BETWEEN AMOXAPINE AND
AMITRIPTYUNE IN DEPRESSED-INPATIENTS. ^ _
003234 03-09
UTHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND
BIPOLAR-II DEPRESSION: A PROSPEaiVE, PLACEBO-CONTROLLED
COMPARISON. „„ „^^
003252 03-09
COMPARISON OF ANXIETY REDUCING SUBSTANCES. (PH.D.
'^'^^^•^^^^'^'^^ 003278 03-10
COMPARISON OF STANDARD AND HOLTOR-MONITORED EKGS IN A
PATIENT TREATED WITH SEVERAL ANTIDEPRESSANTS.
003304 03-11
DOUBLE-BLIND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR
SUBCHRONIC WITHDRAWAL FROM ALCOHOL. „„,--- „-»
COMPARISON OF SODIUM-VALPROATE AND PHENYTOIN AS SINGLE
DRUG-TREATMENT IN EPILEPSY. 00337103-11
COMPARISON OF THE EFFEQS OF FOUR BENZODIAZEPINES ON FRAME OF
MIND AND BEHAVIOR IN HEALTHY SUBJEQS „„..., „o ,.
003441 0o-14
A COMPARISON OF THE EFFECTS OF MORPHINE-SULPHATE AND NITROUS-
OXIDE ANALGESIA ON CHRONIC PAIN STATES IN MAN.
(X)3442 Oj-14
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA SAUVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
E™^^OL 003725 04-03
PREJUNQIONAL AQIONS OF PIRIBEDIL ON THE ISOLATED KIDNEY OF THE
RABBIT: COMPARISON WITH APOMORPHINE.
003/4y 04-UJ
COMPARISON OF THE EFFEaS OF THE STEREOISOMERS OF
FENFLURAMINE ON THE ACETYLCHOUNE CONTENT OF RAT STRIATUM.
HIPPOCAMPUS AND NUCLEUS-ACCUMBENS. ^^^^^ ^^^
COMPARISON OF THE BINDING CHARACTERISTICS OF TRITIATED OPIATES
AND OPIOID-PEPTIDES. 003802 04-03
COMPARISON OF THE EFFEQ OF INTRAVENOUS ADMINISTRATION OF D
LYSERGIC-ACID-DIETHYLAMIDE ON FREE AND MEMBRANE-BOUND
POLYSOMES IN THE RABBIT BRAIN. 00383104-03
S-108
VOLUME 19, SUBJECT INDEX
Subject Index
COMPARISON Of THE POTENCIES OF CLEBOPRIOE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRACT OF THE GUINEA-PIG AND RAT
003928 04-03
IN VIVO INTRANEURONAL MAO-INHIBITION IN RAT-BRAIN SKF-64139,
COMPARISON TO OTHER POTENT PNMT INHIBITORS
003935 04-03
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO
SYNAPTIC MEMBRANES.
004000 04-03
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT
KIDNEY.
004054 04-03
A COMPARISON BETW/EEN SOME BIOCHEMICAL-EFFECTS AND
BEHAVIOURAL-EFFECTS PRODUCED BY NEUROLEPTICS.
004)16 04-04
COMPARISON OF THE EFFECTS OF BETA ENDORPHIN AND MORPHINE ON
EXPLORATORY-BEHAVIOUR AND SOCIOSEXUAL-BEHAVIOUR IN THE
MALE RAT.
004178 04-04
5 HYDROXYTRYPTAMINE-LIKE PROPERTIES OF M
CHLOROPHENYLPIPERAZINE: COMPARISON WITH QUIPAZINE.
004210 04-04
A DOUBLE-BLIND COMPARISON OF THREE DOSAGES OF FLUTROLINE (CP-
36584) IN THE TREATMENT OF SCHIZOPHRENIA.
004333 04-08
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION: A
DOUBLE-BLIND COMPARISON WITH IMIPRAMINE.
004346 04-09
VALUE OF PROPANIDID IN ELECTROCONVULSIVE-THERAPY (COMPARISON
WITH THIOPENTONE).
004379 04-09
A COMPARISON OF TRAZODONE AND DOTHIEPIN IN DEPRESSION.
004394 04-09
COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS.
004438 04-1 1
DRUG PREFERENCE IN HUMANS: DOUBLE-BLIND CHOICE COMPARISON OF
PENTOBARBITAL, DIAZEPAM AND PLACEBO.
004566 04-14
A COMPARISON OF RADIOIMMUNOASSAY WITH SPECTROPHOTOMETRY
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN
CONCENTRATIONS.
004684 04-16
COMPARISON OF SPECTROFLUOROMETRIC AND GAS-
CHROMATOGRAPHY/MASS-SPECTROMETRY PROCEDURES FOR THE
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN.
004692 04-16
COMPARISONS
EFFEQS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE.
001243 02-03
COMPARISONS OF THE EFFECTS OF GUANETHIDINE, 6
HYDROXYDOPAMINE AND DIETHYLDITHIOCARBAMATE ON RETENTION
OF PASSIVE-AVOIDANCE.
001742 02-04
AHENUATION OF THE EFFECTS OF PUNISHMENT BY ETHANOL:
COMPARISONS WITH CHLORDIAZEPOXIDE.
001813 02-04
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION
AND EFFEQS OF D-AMPHETAMINE AND PROMAZINE.
004152 04-04
COMPARTMENT ALIZAION
HA-966 EFFEQS ON STRIATAL DOPAMINE METABOLISM: IMPLICATIONS
FOR DOPAMINE COMPARTMENTALIZAION.
001150 02-03
COMPARTMENTATION
COMPARTMENTATION OF CATECHOLAMINES IN RAT-BRAIN: EFFECTS OF
AGONISTS AND ANTAGONISTS.
000125 01-03
COMPARTMENTS
EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE
RELEASE.
000067 01-03
COMPETITION
EFFECTS OF MORPHINE WITHDRAWAL ON FOOD COMPETITION
HIERARCHIES AND FIGHTING-BEHAVIOR IN RATS.
001632 02-04
COMPETITIVE
THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A
COMPETITIVE ANTAGONIST AT ALPHA 1 -ADRENOCEPTORS.
003785 04-03
COMPILATION
CLINICAL-STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE-
STATES: COMPILATION OF 1520 OBSERVATIONS.
003206 03-09
COMPLEXE-I6S6
COMPARATIVE-STUDY OF THE INDUCTIVE EFFECT OF TWO
PSYCHOMODERATORS - TETRABAMATE AND COMPLEXE-1656 - AND
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS.
001874 02-06
COMPLEXES
ATP COMPLEXES WITH THE ATPASE INHIBITOR QUERCETIN.
000045 01-03
ISOLATION OF SELECTIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES,
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE.
001162 02-03
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME
BENZODIAZEPINE RECOGNITION SITES ARE COUPLED TO GABA-
RECEPTORS AND lONOPHORES,
001484 02-03
COMPLIANCE
THE LITHIUM RATIO AS A GUIDE TO PATIENT COMPLIANCE.
000940 01-17
ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CLINICAL STAFF
IN DETERMINING MEDICATION COMPLIANCE.
003618 03-17
THE INFLUENCE OF PATIENT BELIEFS ON COMPLIANCE TO THERAPY FOR
DIABETES-MELLITUS. (PH.D. DISSERTATION).
003631 03-17
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF
ASSESSING COMPLIANCE.
004495 04-11
THE NEGATIVE INFLUENCE OF FAMILIES ON COMPLIANCE.
004745 04-17
COMPLICATING
ILEUS COMPLICATING HALOPERIDOL THERAPY.
003511 03-15
COMPLICATIONS
COMPLICATIONS OF CHRONIC LEVODOPA THERAPY: LONG-TERM
EFFICACY OF DRUG-HOLIDAY.
003502 03-15
COMPOSED
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING-
SITES IN RAT STRIATUM.
000186 01-03
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES.
001342 02-03
COMPOSITION
COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION
IN THE RAT MODEL.
002928 03-03
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE
AMINO-ACID POOL.
004039 04-03
COMPOUND-48-80
COMPOUND-48-80 INHIBITS NEUROTENSIN-INDUCED HYPOTENSION IN
RATS.
000243 01-03
COMPREHENSIVE
STUDIES ON THE COMPREHENSIVE MEDICAL TREATMENT OF PEPTIC-
ULCERS (3) ~ UTILIZATION OF TRANQUILIZERS IN THE TREATMENT OF
GASTRIC-ULCERS.
000653 01-10
IS IT POSSIBLE TO SET UP ANY RULES FOR A COMPREHENSIVE
TREATMENT OF DEPRESSIVE-STATES?
001997 02-09
SOME PRINCIPLES OF DIFFERENTIATED METABOLIC DRUG-TREATMENT IN
COMPREHENSIVE THERAPY OF MENTAL-DISORDERS.
004433 04-1 1
CORRECTION OF HORMONAL ACTIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
COMPRESSED
TOLERANCE IN A COMPRESSED GASTRORESISTANT FORM IN
PSYCHIATRIC-PATIENTS.
003157 03-07
COMPUTED-TOMOGRAPHY
PROGRESSIVE SUPRANUCLEAR PALSY, COMPUTED-TOMOGRAPHY, AND
RESPONSE TO ANTIPARKINSONIAN-DRUGS.
003322 03-1 1
COMPUTER
A COMPUTER OCULOGRAPHIC AND EEG DOUBLE-BLIND STUDY INCLUDING
WELL-BEING FOR DETERMINING CHANGED VIGILANCE UNDER THERAPY
WITH TIAPRIDE.
000751 01-13
iil.
S-109
Subject Index
Psychopharmacology Abstracts
^°**DISCOVERY OF PSYCHOTROPIC-DRUGS BY MEANS OF COMPUTER-
^N^^Y^^'^"'^- 002203 02-13
COMPUTER-ANALYZED EEC IN AMPHETAMINE RESPONSIVE
HYPERACTIVE-CHILDREN. - 003338 03-11
COMPUTER-ANALYZED ELECTROENCEPHALOGRAM TO PREDIQ THE
THERAPEUTIC OUTCOME IN SCHIZOPHRENIA.
004680 04-16
COMPUTERIZED
COMPUTERIZED EEC IN THE COMPARISON OF OXYPROTHEPIN AND
FLUPHENAZINE-DECANOATE. 000567 01-08
COMPUTERIZED SLEEP EEC (CSEEG) IN PSYCHIATRY AND
PSYCHOPHARMACOLOGY. 002614 02-17
EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED
COGNITIVE ASSESSMENT SYSTEM. 003557 03-16
COMPUTERIZED MONITORING OF PSYCHOTROPIC-DRUG ORDERS: SOME
TRENDS AND REVELATIONS. 003566 03-16
COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPLIED TO DRUG
EVALUATION: MIDAZOLAM IN NORMAL SUBJECTS.
004564 04- 1 4
COMPUTERIZED-AXIAl-TOMOGRAPHY ^^ ., .„^.,
THERAPEUTIC PLASMA LEVELS OF SOME ANTICONVULSANTS IN FOCAL
EPILEPSY IN RELATION TO COMPUTERIZED-AXIAL-TOMOGRAPHY.
004439 04- 1 I
^°ToMPUT^ERIZING THE MMPI IN THE STUDY OF A NEW PSYCHOTROPIC-
^GmJ^^?mi. 000585 01-09
COMT-A
COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE
^O'^'^S 003927 04-03
COMT-B
COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE
^°^°5 003927 04-03
^°'*E?FEaOpPSYCHIATRIC-INTERVENTION ON USE OF ANTIHEMOPHILIC-
FACTOR CONCENTRATE. 000945 01-17
CONCENTRATION
COMPARATIVE-EFFECTS OF P CHLOROAMPHETAMINE AND L P
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN
■^^^-^^^"^ 000101 01-03
EFFEaS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL-
CORD GABA CONCENTRATION. 000145 01-03
REGULATION OF STRIATAL ACETYLCHOLINE CONCENTRATION BY 02
DOPAMINE-RECEPTORS. 000269 01-03
PATHOPHYSIOLOGICAL-STUDIES ON SCHIZOPHRENIA WITH SPECIAL
REFERENCE TO HOMOVANILLIC-ACID CONCENTRATION IN
CEREBROSPINAL-FLUID. ^^^^ ^, ^3
LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN
'^'"' 000287 01-03
INTRA AND EXTRA ERYTHROCYTE LITHIUM-ION CONCENTRATION RATIOS
IN MANIC-PATIENTS. 000627 01-09
PRAQICAL AND THEORETICAL ASPEQS OF PHENYTOIN
ADMINISTRATION. I. RELATIONSHIP BETWEEN DOSE AND PLASMA
^O^^^^^^^™"^- 000760 01-13
TRANSCULTURAL PHARMACOKINETIC STUDY ON LI CONCENTRATION IN
PLASMA AND SALIVA. 000769 01-13
LEVORPHANOL: RADIOIMMUNOASSAY AND PLASMA CONCENTRATION
PROFILES IN DOG AND MAN. 000898 01-16
DETERMINATION OF DOSE PLASMA CONCENTRATION RELATIONSHIP OF
PHENOBARBITAL IN EPILEPTIC-PATIENTS BY A NEW SPECIFIC
RADIOIMMUNOASSAY. „„„„„„«, ,^
000902 01-16
EFFECT OF 2 P CHLOROPHENYL-CYCLOPROPYLAMINE ON 5
HYDROXYINDOLE CONCENTRATION AND MONOAMINE-OXIDASE
ACTIVITY IN RAT-BRAIN. 001237 02-03
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION. 001300 02-03
CHANGE IN OVERINCLUSIVE THINKING OF SCHIZOPHRENIC-PATIENTS IS
RELATED TO PLASMA PHENOTHIAZINE CONCENTRATION.
001941 02-08
AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL-EFFEQ: A
WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY.
001976 02-09
CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL-
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY.
002095 02-11
CARBAMAZEPINE THERAPY IN TRIGEMINAL-NEURALGIA: CLINICAL-
EFFEaS IN RELATION TO PLASMA CONCENTRATION.
002181 02-11
THE EFFECTS OF ALCOHOL AND CAFFEINE ON CONCENTRATION TEST
PERFORMANCE.
002337 02-14
CHILDHOOD-ENURESIS: II PSYCHOPATHOLOGY, TRICYCLIC
CONCENTRATION IN PLASMA, AND ANTIENURETIC-EFFEQ.
002354 02-14
CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN
HYPOTHALAMUS.
002842 03-03
CORRELATION OF (14C)MUSCIM0L CONCENTRATION IN RAT-BRAIN WITH
ANTICONVULSANT AQIVITY.
003045 03-04
SERUM CONCENTRATION AND CLINICAL-EFFEQ OF ANTIEPILEPTICS.
003315 03-11
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION
OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY.
003433 03-13
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE
MOUSE AND THE RAT.
003870 04-03
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN
ISOLATED TISSUES INCREASED MAXIMAL RESPONSES OF RAT VASA-
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL
UPTAKE.
003879 04-03
THE INFLUENCE OF D-AMPHET AMINE ON RAT-BRAIN STRIATAL REDUCED
BIOPTERIN CONCENTRATION.
003922 04-03
SERUM CONCENTRATION OF ANTICONVULSANTS. PHARMACOKINETIC
FINDINGS AND THEIR PRACTICAL APPLICATION.
004443 04-11
USE OF PLASMA CONCENTRATION DETERMINATIONS.
004498 04-13
PLASMA NOMIFENSINE CONCENTRATION: CARDIOLOGICAL EFFEaS AND
CLINICAL-RESPONSE. _ ^^^^^ ,^
004639 04-15
CONCENTRATIONS
TOLERANCE TO INCREASES IN STRIATAL ACETYLCHOLINE
CONCENTRATIONS AFTER REPEATED ADMINISTRATION OF
APOMORPHINE-DIPIVALOYL-ESTER
000464 01-04
VILOXAZINE PLASMA CONCENTRATIONS AND CLINICAL-RESPONSE.
000614 01-09
EFFEQ OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND
RIGIDITY A QUANTITATIVE STUDY OF REFLEXES AND PLASMA
CONCENTRATIONS. 00070101-11
PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH
BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS. 000717 01 11
CONVERSION SCALES FOR COMMONLY REQUESTED SERUM
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE. AND OF
"0'^^°'^^^ 000759 01-13
NEUROLEPTIC-EFFEQ ON DESIPRAMINE STEADY-STATE PLASMA
CONCENTRATIONS. 00078101-13
SERUM CONCENTRATIONS OF PHENOBARBITAL AND „_^ .„„
DIPHENYLHYDANTOIN IN SEVERE MENTAUY-HANDICAPPED AND
PHYSICALLY-HANDICAPPED-PATIENTS. ,^„c. n, ,c
000856 01-15
VALUE OF SALIVA SAMPLES IN MONITORING CARBAMAZEPINE
CONCENTRATIONS IN EPILEPTIC-PATIENTS. „„,^, „, ,,
000903 01-16
BRAIN SEROTONIN AND 5 HYDROXYINDOLEACETIC-ACID
CONCENTRATIONS AND SEROTONIN SYNTHESIS FOLLOWING
TETRAHYDRO-BETA-CARBOLINE ADMINISTRATION IN MICE.
CXJ I I jz Uz"Uo
PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN
VITRO INHIBITION BY MELATONIN AT SUBMICROMOLAR
CONCENTRATIONS. 001159 02-03
s-no
VOLUME 19, SUBJECT INDEX
Subject Indsx
RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN
PLASMA AND CEREBROSPINAL-f LUID AND CLINICAL-RESPONSE AND
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS.
001905 02-08
SERUM NEUROLEPTIC CONCENTRATIONS IN SCHIZOPHRENIA.
(UNPUBLISHED PAPER).
001945 02-08
LONG-TERM MONITORING OF TRICYCLIC-ANTIDEPRESSANT PLASMA
CONCENTRATIONS.
002014 02-09
PLASMA DELTA9 TETRAHYDROCANNABINOL CONCENTRATIONS AND
CLINICAL-EFFECTS AFTER ORAL AND INTRAVENOUS ADMINISTRATION
AND SMOKING.
002201 02-12
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRUG
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA.
002225 02-13
SALIVARY IMMUNOGLOBULIN CONCENTRATIONS IN PATIENTS WITH
EPILEPSY TREATED WITH CARBAMAZEPINE.
002234 02-13
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE
NORTRIPTYLINE.
002304 02-13
PHENOTHIAZINE PLASMA AND RED-BLOOD-CELL CONCENTRATIONS, THEIR
RELATIONSHIP TO SIDE-EFFECTS AND CLINICAL-EFFICACY.
002386 02-15
CONCENTRATIONS OF CIS(Z) FLUPENTHIXOL IN MATERNAL SERUM,
AMNIOTIC-FLUID, UMBILICAL-CORD-SERUM, AND MILK.
002423 02-15
MEASUREMENT OF PLASMA CONCENTRATIONS OF DRUGS AS A
FEEDBACK CONTROL MECHANISM DURING DRUG-THERAPY.
002525 02-17
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED
MICE.
002800 03-03
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFECTS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN.
002990 03-04
RELATIONSHIP BETWEEN BLOOD CONCENTRATIONS AND CLINICAL-
EFFECTS OF A NEW ANTIDEPRESSANT MAPROTILINE.
003271 03-09
PHENYTOIN CONCENTRATIONS IN VENOUS VERSUS CAPILLARY BLOOD OF
GERIATRIC-PATIENTS.
003381 03-11
EXCESSIVE PLASMA CONCENTRATIONS OF TRICYCLIC-ANTIDEPRESSANTS
RESULTING FROM USUAL DOSES: A REPORT OF SIX CASES.
003479 03-15
RESPIRATORY-DISEASE AND NASAL IMMUNOGLOBULIN
CONCENTRATIONS IN PHENYTOIN TREATED EPILEPTIC-PATIENTS.
003486 03-15
CEREBROSPINAL-FLUID CONCENTRATIONS OF THIORIDAZINE AND ITS
MAIN METABOLITES IN PSYCHIATRIC-PATIENTS.
003569 03-16
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INDUCED CONVULSIONS
IN RATS.
003736 04-03
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC-
AMP.
003952 04-03
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF
ASSESSING COMPLIANCE.
004495 04-11
ERYTHROCYTE CHOLINE CONCENTRATIONS ARE ELEVATED IN MANIC-
PATIENTS.
004521 04-13
CONCENTRATIONS AND KINETICS OF CARBAMAZEPINE IN WHOLE
SALIVA, PAROTID SALIVA, SERUM ULTRAFILTRATE, AND SERUM.
004545 04-13
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS ACTIVE
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC-
PATIENTS TREATED WITH FIXED DRUG DOSES.
004559 04-13
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC-
ANTIDEPRESSANTS: PERSPECTIVE OF THE CLINICAL LABORATORY.
004681 04-16
MEASUREMENT OF NEUROLEPTIC CONCENTRATIONS BY GLC AND
RADIORECEPTOR ASSAY.
004682 04-16
A COMPARISON OF RADIOIMMUNOASSAY WITH SPECTROPHOTOMETRY
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN
CONCENTRATIONS,
004684 04-16
DRUG CONCENTRATIONS IN NEUROPSYCHIATRY.
004735 04-17
CONCERNS
THE USE OF PSYCHOPHARMACOLOGICAL-PROCEDURES TO ANALYSE THE
ONTOGENY OF LEARNING AND RETENTION: ISSUES AND CONCERNS.
000482 01-04
CONCUSSION
INFLUENCING BRAIN CONCUSSION BY NOOTROPIL.
000724 01-11
CONDENSATION
SYNTHESIS OF POTENTIAL ANTICONVULSANTS: CONDENSATION OF
ISATINS WITH ACETONE AND RELATED KETONES.
003699 04-02
CONDITIONAL
EFFECTS OF PHENCYCLIDINE, PENTOBARBITAL, AND D-AMPHET AMINE ON
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL
DISCRIMINATIONS IN MONKEYS.
001723 02-04
CONDITIONED
ENHANCED SUPPRESSION OF CONDITIONED AVOIDANCE RESPONSE BY
HALOPERIDOL BUT NOT PHENOXYBENZAMINE IN RATS WITH
BILATERAL PARAFASCICULAR LESIONS.
000334 01-04
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFECTS ON
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE
PARADIGM.
000372 01-04
THE EFFECTS OF PIPRADROL ON THE ACQUISITION OF RESPONDING WITH
CONDITIONED REINFORCEMENT: A ROLE FOR SENSORY
PRECONDITIONING.
001572 02-04
MODULATION OF CONDITIONED TASTE-AVERSION BY SODIUM-
PENTOBARBITAL.
001596 02-04
EFFECTS OF DRUGS ON THE EFFECTIVENESS OF CONDITIONED STIMULI.
001608 02-04
PREEXPOSURE TO DELTA9 THC BLOCKS THC-INDUCED CONDITIONED
TASTE-AVERSION IN RATS.
001618 02-04
EFFECT OF CHOLINE ON CONDITIONED FOOD MOTOR-REFLEXES IN CATS.
001731 02-04
CONDITIONED SUPPRESSION OF DRINKING: A MEASURE OF THE CR
ELICITED BY A LITHIUM CONDITIONED FLAVOR.
001747 02-04
THE EFFECTS OF CHLORDIAZEPOXIDE-HCL ADMINISTRATION UPON
PUNISHMENT AND CONDITIONED SUPPRESSION IN THE RAT.
001757 02-04
ACTH POTENTIATES MORPHINE-INDUCED CONDITIONED TASTE-AVERSION.
001781 02-04
THE RELATIONSHIP BETWEEN POSITIVE REINFORCEMENT AND
CONDITIONED TASTE-AVERSION PRODUCED BY SELF-ADMINISTERED
DRUGS. (PH.D. DISSERTATION).
001798 02-04
EFFECTS OF DESGLYCINAMIDE-LYSINE-VASOPRESSIN ON A CONDITIONED
TASTE-AVERSION IN RATS.
001811 02-04
TEMPORAL AND ENVIRONMENTAL CUES IN CONDITIONED HYPOTHERMIA
AND HYPERTHERMIA ASSOCIATED WITH MORPHINE.
002709 03-03
LITHIUM-CHLORIDE AND DELTA9 THC LEAD TO CONDITIONED AVERSIONS
IN THE PIGEON.
003003 03-04
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY
REACTIONS IN DOGS.
003030 03-04
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED
REFLEXES IN RATS.
003100 03-04
EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING
SUPPRESSED BY CONDITIONED PUNISHMENT.
003105 03-04
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE
BUT NOT LITHIUM-CHLORIDE.
003110 03-04
THE USE OF CONDITIONED SUPPRESSION TO EVALUATE THE NATURE OF
NEUROLEPTIC-INDUCED AVOIDANCE-DEFICITS.
004070 04-04
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND
CONDITIONED TASTE-AVERSION.
004121 04-04
lii,
I
5
S-111
Subject Index
Psychopharmacology Abstracts
CONDITIONED DRUG-EFFECTS OF D-AMPHETAMINE-INDUCED AND
MORPHINE-INDUCED MOTOR ACCELERATION IN MICE. EXPERIMENTAL
APPROACH FOR PLACEBO-EFFECT. 004128 04-04
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS.
004180 04-04
THE EFFECT OF THE NEW ANTIDEPRESSANT INKASAN ON THE
BIOELECTRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED
'^^'''-^^"- 004212 04-04
CONDITIONING
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT.
00 1 DoO Uz-U4
THE EFFECTS OF PIMOZIDE DURING PAIRING ON THE TRANSFER OF
CLASSICAL CONDITIONING TO AN OPERANT DISCRIMINATION^ ^^
CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNCTION
OF ELAVIL AND THORAZINE INJECTION. ^^^^^ ^^^^
MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJECTIONS OF
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS.
003101 03-04
PHOSPHODIESTERASE INHIBITORS FACILITATE MEMORY FOR PASSIVE-
AVOIDANCE CONDITIONING. 003109 03-04
OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE
CONDITIONING IN RABBITS. 003798 04-03
CONDITIONING OF AN INTEROCEPTIVE DRUG STIMULUS TO DIFFERENT
EXTEROCEPTIVE CONTEXTS. 004142 04-04
*^°'^INTERRELATIONS AMONG PRIOR EXPERIENCE AND CURRENT CONDITIONS
IN THE DETERMINATION OF BEHAVIOR AND THE EFFEaS OF DRUGS.
00 1 7 1 5 02-04
THE EFFECT OF CONDITIONS INFLUENCING ENDOGENOUS
PROSTAGLANDINS ON THE ACTIVITY OF DELTA'
TETRAHYDROCANNABINOL. 002196 02-12
EFFECTS OF CAFFEINE ADMINISTRATION ON FOOD AND WATER
CONSUMPTION UNDER VARIOUS EXPERIMENTAL CONDITIONS^ „ „, „,
003049 03-04
ACUTE PHARMACOTOXIC PSYCHOSES IN CHRONIC CEREBRAL
^O^-^'^'^^^ 003475 03-15
CONDUCTANCE
ABSENCE OF POTASSIUM CONDUCTANCE IN CENTRAL MYELINATED
^'^^^^ 000166 01-03
TWO CONDUCTANCE MECHANISMS ACTIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES. ^^^^^ ^^^^
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK
REFLEX MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO. „„.c „. ,,
004544 04-13
CONDUCTION
MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZEPINE MEDICATION. A CLINICAL NEUROPHYSIOLOGICAL
^^'°'^ 00444104-11
CONFERENCE
ABSTRACTS OF THE ANNUAL GENERAL CONFERENCE OF THE EUROPEAN-
BRAIN-AND-BEHAVIOUR-SOCIETY, HELD AT LOUVAIN-LA-NEUVE,
BELGIUM, ON NOVEMBER 13-15TH, 1980. 003617
CONFERENCES
PSYCHOPHARMACOLOGY AFTER 20 YEARS OF CONFERENCES IN JESENIK^
003646 03-17
CONFIRMATION „^^..
CONFIRMATION BEHAVIOR OF PHENCYCLIDINES AND BIOLOGICAL-
ACTIVITY. „„,„o, ««n,
001031 02-01
BEHAVIORAL CONFIRMATION OF DIFFUSE NOXIOUS INHIBITORY
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS
^'''^^^ 002791 03-03
MASS SCREENING AND CONFIRMATION OF DIAZEPAM IN URINE BY EMIT
THIN-LAYER-CHROMATOGRAPHY.
004672 04-16
^^^^HOSTILITY CONFLICT AND REPORTING OF SIDE-EFFECTS BY PSYCHIATRIC-
O^^''^^'^'^^^ 000840 01-15
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLia? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
003256 03-09
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
(UNPUBLISHED PAPER).
004401 04-09
CONFLICT-BEHAVIOR
AN INTERFERENCE REDUCTION THEORY OF THE EFFEQS OF ETHANOL ON
CONFLICT-BEHAVIOR.
001586 02-04
EFFECT OF SODIUM-DIPROPYLACETATE ON CONFLia-BEHAVIOR IN RATS
004192 04-04
CONFLICT-SITUATION
CONFLICT-SITUATION BASED ON INTRACRANIAL SELF- STIMULATION
BEHAVIOR AND THE EFFECT OF BENZODIAZEPINES.
003004 03-04
CONFORMATION
DOPAMINE-RECEPTOR BLOCKADE BY IMIDOLINE AND ITS PROPOSED
ACTIVE CONFORMATION
001687 02-04
CONFORMATIONALLY
CONFORMATIONALLY RESTRICTED PHENOTHIAZINE NEUROLEPTICS. 1. 3
DIMETHYLAMINO-TETRAHYDROAZEPINOPHENOTHIAZINE
001359 02-03
CONFORMATIONALLY RESTRICTED TRICYCLIC-ANTIDEPRESSANTS. 1
OCTAHYDRODIBENZAZEPINONAPHTHYRIDINES AS RIGID IMIPRAMINE
ANALOGUES.
001710 02-04
THE SYNTHESIS AND AQIVITY OF CIS AND TRANS 2
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID AS
CONFORMATIONALLY RESTRICTED ANALOGUES OF GABA.
002633 03-01
EFFEaS OF CONFORMATIONALLY RESTRAINED ANALOGUES OF
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN.
003794 04-03
CONFORMATIONS
CONVULSANT AND ANTICONVULSANT BARBITURATES. 1 . MOLECULAR
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY
CALCULATIONS.
001029 02-01
TV/O OR MORE CONFORMATIONS OF BENZODIAZEPINE-RECEPTORS
DEPENDING ON GABA-RECEPTORS ANDOTHER VARIABLES.
001139 02-03
CONFRONTATION
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL
CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN
PSYCHEDELIC-EXPERIENCES. „ „^ ,^
002200 02-12
CONFUSIONAL-STATE
PROLONGED CONFUSIONAL-STATE AND EEG SEIZURE AQIVITY
FOLLOWING CONCURRENT EQ AND LITHIUM USE.
000895 01-15
CONGESTIVE
INTRAVENOUS QUINIDINE IN CONGESTIVE CARDIOMYOPATHY.
003352 03-11
TRANSFER OF LORAZEPAM AND ITS CONJUGATE ACROSS THE HUMAN
^^"^^* 000774 01-13
DOPAMINE CONJUGATE IN CEREBROSPINAL-FLUID. 003439
' CONJUGATED
PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW
METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES.
004286 04-06
CONJUGATES
ANTICANDIDAL-AQIVITY OF PYRIMIDINE-PEPTIDE CONJUGATES.
001059 02-01
BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND ;
2 4 DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR (DPEA) INHIBITION
OF FAHY-ACID CONJUGATION TO 11 HY0R0XY-DELTA9-
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM.
000179 01-03 ;
^°'*EF"FE'aS°?CYCLOHEXIMIDE ADMINISTERED IN CONJUNQION WITH
NICOTINE ON RETENTION OF A PASSIVE-AVOIDANCE TASK IN MICE^
001791 02-04
CONNECTION
HALLUCINATORY AND DELUSIONAL-STATES IN CONNEQION WITH BLOOD-
PRESSURE AND EEG. 000814 01-14
VARIOUS FAQORS IN THE PATHOGENESIS OF PATHOLOGICAL REAQIONS
OBSERVED IN CONNEQION WITH THE ADMINISTRATION OF
PSYCHOTROPIC-DRUGS. 003532 03-15
S-112
VOLUME 19, SUBJECT INDEX
Subject Index
CONSCIOUS
EFFECT OF INTRAVENTRICULAR INJECTIONS OF ALPHA AMINOSULFONIC-
ACIDS ON THE CENTRAL-NERVOUS-SYSTEM OF CONSCIOUS MICE
000009 01-02
EEC CHANGE IN THE CONSCIOUS RAT DURING IMMOBILITY INDUCED BY
PSYCHOLOGICAL-STRESS
001297 02-03
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON
BARORECEPTOR REFLEXES IN CONSCIOUS CATS.
00)514 02-03
ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION:
CYPROHEPTADINIUM-METHIODIDE.
001534 02-03
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA
ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF
CONSCIOUS CATS.
001569 02-04
VASOPRESSIN STIMULATES RELEASE OF BETA LIPOTROPIN AND BETA
ENDORPHIN IN CONSCIOUS RATS AS MEASURED BY
RADIOIMMUNOASSAY OF UNEXTRACTED PLASMA.
003715 04-03
MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS.
003744 04-03
EFFECT OF AMPHETAMINE ON PLASMA CORTICOSTERONE IN THE
CONSCIOUS RAT.
003888 04-03
CENTRAL CARDIOVASCULAR-EFFECTS AND BIOCHEMICAL-EFFECTS OF
BACLOFEN IN THE CONSCIOUS RAT.
003965 04-03
HYPOTENSION ALTERS THE RELEASE OF CATECHOLAMINES IN THE
HYPOTHALAMUS OF THE CONSCIOUS RABBIT.
003968 04-03
CONSCIOUSNESS
ELECTIVE ALTERATION OF THE STATE OF CONSCIOUSNESS SUBJECTED TO
THE EFFECTS OF PSYCHOACTIVE-SUBSTANCES.
000994 01-17
CONSENT
A REVISED CHECKLIST TO OBTAIN CONSENT TO TREATMENT WITH
MEDICATION.
000984 01-17
MISINFORMED CONSENT.
004326 04-08
CONSIDERATIONS
CONSIDERATIONS ON PSYCHOACTIVE-DRUGS.
002622 02-17
CONSIDERATIONS ON LONG-ACTING CHEMOTHERAPY: AN EXPERIENCE
WITH FLUPHENAZINE-DECANOATE.
003173 03-08
NOMIFENSINE: CONSIDERATIONS ON A NEW NONTRICYCLIC-
ANTIDEPRESSANT.
003222 03-09
CLINICAL-TRIAL OF HALAZEPAM AND CLORAZEPATE: CONSIDERATIONS
OF A SINGLE-BEDTIME-DOSE.
003277 03-10
CONSTITUENT
A CONSTITUENT OF KHAT-LEAVES WITH AMPHETAMINE-LIKE RELEASING
PROPERTIES.
001307 02-03
CONSTITUTIONAL
ROniNG WITH THEIR RIGHTS ON: CONSTITUTIONAL THEORY AND
CLINICAL REALITY IN DRUG-REFUSAL BY PSYCHIATRIC-PATIENTS.
000911 01-17
THE CONSTITUTIONAL RIGHT-TO-REFUSE ANTIPSYCHOTIC-MEDICATIONS.
004496 04-12
CONSTRICTION
INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRICTION
BY CLONIDINE IN CATS.
001431 02-03
CONSUMMATORY-BEHAVIOR
CHRONIC DELTA9 TETRAHYDROCANNABINOL IN RATS: EFFECT ON
SOCIAL-INTERACTIONS, MOUSE-KILLING, MOTOR-ACTIVITY,
CONSUMMATORY-BEHAVIOR, AND BODY-TEMPERATURE.
001722 02-04
CONSUMMATORY-BEHAVIORS
MORPHINE ANTAGONISTS AND CONSUMMATORY-BEHAVIORS.
004196 04-04
CONTAaS
BENZODIAZEPINE-RECEPTORS: AUTORADIOGRAPHICAL AND
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN
REGIONS OF GABAERGIC SYNAPTIC CONTACTS.
002643 03-01
CONTAMINATION
STREET PCP SCENE: ISSUES ON SYNTHESIS AND CONTAMINATION.
000744 01-12
CONTEMPORARY
CONTEMPORARY PROBLEMS IN THE PHARMACOLOGICAL-TREATMENT OF
PARKINSONISM.
004628 04-15
CONTEXT
DRUG ENVIRONMENT INTERACTION: CONTEXT DEPENDENCY Of COCAINE-
INDUCED BEHAVIORAL-SENSITIZATION
002866 03-03
CONTEXTS
CONDITIONING OF AN INTEROCEPTIVE DRUG STIMULUS TO DIFFERENT
EXTEROCEPTIVE CONTEXTS.
004142 04-04
CONTINGENCY
BEHAVIORAL-EFFECTS OF DRUGS: THE ROLE OF THE STIMULUS
REINFORCER CONTINGENCY. (PH.D. DISSERTATION).
001537 02-03
CONTINGENT
CAPACITIES OF ATTENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS: EFFECTS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300.
003451 03-14
CONTINUOUS-ACCESS
CONTINUOUS-ACCESS PHENCYCLIDINE SELF-ADMINISTRATION BY RHESUS-
MONKEYS LEADING TO PHYSICAL-DEPENDENCE.
000341 01-04
CONTRACEPTIVE
PHENOBARBITONE INTERACTION WITH ORAL CONTRACEPTIVE STEROIDS
IN THE RABBIT AND RAT.
001832 02-05
CONTRACEPTIVES
EFFECT OF IMIPRAMINE ON HEPATIC GAMMA GLUTAMYLTRANSFERASE
IN FEMALE RATS. INTERACTION WITH CONTRACEPTIVES.
001507 02-03
CONTRACTILE
A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC
AGONISTS: CHARACTERISTICS.
002670 03-03
CONTRACTION
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFECTS OF FENTANYL ON
THE CONTRACTION OF THE NICTITATING MEMBRANE IN CATS.
002876 03-03
CONTRACTIONS
CHARACTERISTICS OF OSCILLATORY CONTRACTIONS ELICITED BY
NALOXONE IN ILEUM PREPARATION FROM MORPHINE-DEPENDENT
GUINEA-PIGS.
001491 02-03
CONTRALATERAL
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN
RATS.
001669 02-04
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF TAURINE IN RATS.
001670 02-04
CONTRASTING-EFFECTS
TRICYCLIC-ANTIDEPRESSANT DRUGS AND INDIVIDUAL DIFFERENCES IN
THE EXPLORATORY-ACTIVITY OF RATS: CONTRASTING-EFFECTS OF
TERTIARY AND SECONDARY AMINE COMPOUNDS.
000401 01-04
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL-
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D-
AMPHET AMINE AND APOMORPHINE.
002484 02-16
CONTRIBUTE
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
CONTRIBUTED
THE POSSIBILITY THAT A COMPONENT OF MORPHINE-INDUCED
ANALGESIA IS CONTRIBUTED INDIRECTLY VIA THE RELEASE OF
ENDOGENOUS OPIOIDS.
000263 01-03
CONTRIBUTION
CONTRIBUTION TO THE CLINICAL- STUDY OF CEREBRAL DOPAMINERGIC
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST
RESULTS.
000616 01-09
CONTRIBUTION TO STUDY OF CEREBRAL DOPAMINERGIC MECHANISMS:
REALITY OF THE PROBLEM.
000782 01-13
A CONTRIBUTION TO OUR KNOWLEDGE OF COCA-LEAF CONTENT
SUBSTANCES.
001022 02-01
9
-■fc
a
m
tic
f ll >M>
S-113
Subject Index
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
CONTRIBUTION TO THE PHARMACOKINETICS AND METABOLISM OF
OXYPROTHEPIN. ,„„.,,
002279 02-13
CONFESSION OF A MELANCHOLIAC: CONTRIBUTION TO THE PROBLEM OF
PROPHYLAXIS OF MANIC-DEPRESSIVE-PSYCHOSIS USING LITHIUM.
003267 03-09
TARDIVE-DYSKINESIA: CLINICOEPIDEMIOLOGICAL REVISION AND
CONTRIBUTION. „„..., „-,,c
003466 03-15
CONTRIBUTION OF SOCIAL FACTORS TO OPIATE-INDUCED ACTIVATION IN
THE MOUSE. „ „
004156 04-04
CONTRIBUTIONS
CONTRIBUTIONS OF INDIVIDUAL DIFFERENCES TO SUBJECTIVE
INTOXICATION. „„„o«. «oio
002202 02-12
CONTRIBUTORS
CONTRIBUTORS TO FEMALE USE OF PSYCHOPHARMACOLOGICAL-AGENTS:
DISSERTATION).
000956 01-17
CONTROL
PLASMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE.
000102 01-03
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN-
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM.
000123 01-03
ROLE OF DOPAMINE STORAGE FUNCTION IN THE CONTROL OF RAT
STRIATAL TYROSINE-HYDROXYLASE ACTIVITY.
000201 01-03
THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL ON THE POSITIVE AND
NEGATIVE FEEDBACK CONTROL OF LUTEINIZING-HORMONE RELEASE.
000286 01-03
BEHAVIORAL-PHARMACOLOGY AND THE STIMULUS CONTROL OF
BEHAVIOR.
000381 01-04
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL
EVOKED-POTENTIALS.
000763 01-13
RAPID CONTROL OF ACUTE PATIENTS THROUGH THE ADMINISTRATION OF
HALOPERIDOL.
000818 01-14
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE
TREATED DOGS.
001273 02-03
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT
CAUDATE-NUCLEUS.
001298 02-03
A PHARMACOLOGICAL ANALYSIS OF THE ROLE OF THE AMYGDALA IN
THE CONTROL OF GONADOTROPIN AND PROLACTIN SECRETION.
001418 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
THE EFFECTS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5
DIMETHOXY-4-METHYLAMPHETAMINE (DOM) AND D-AMPHETAMINE
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE
TREATED RATS.
001595 02-04
ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN
THE CAT.
001761 02-04
A TRIPEPTIDE FOR CONTROL OF SCHIZOPHRENIC-SYMPTOMS.
001919 02-08
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE
NORTRIPTYLINE.
002304 02-13
INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJEQS.
002341 02-14
A SIMPLE SYSTEM FOR CONTROL OF THE CONTINUOUS PERFORMANCE
TEST IN PSYCHOPHARMACOLOGICAL-RESEARCH.
002474 02-16
MEASUREMENT OF PLASMA CONCENTRATIONS OF DRUGS AS A
FEEDBACK CONTROL MECHANISM DURING DRUG-THERAPY.
002525 02-17
GABAERGIC MECHANISMS IN THE CONTROL OF PRL AND GH RELEASE.
002690 03-03
Psychopharmacology Abstracts
EVIDENCE FOR A TONIC GABAERGIC CONTROL OF SEROTONIN NEURONS
IN THE MEDIAN RAPHE NUCLEUS.
002719 03-03
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR
FUNCTIONS RELATED TO MOTIVATED BEHAVIOR.
002815 03-03
DISCRIMINATIVE RESPONSE CONTROL BY NALOXONE IN MORPHINE
PRETREATED RATS.
003053 03-04
DRUG-INDUCED STIMULUS CONTROL AND THE CONCEPT OF BREAKING-
POINT: LSDANDQUIPAZINE.
003116 03-04
CORTICAL CONTROL OF NEURALLY MEDIATED ARRHYTHMOGENIC-
PROPERTIES OF DESACETYLLANATOSIDE-C.
003124 03-05
PLACEBO-EFFEQ: FROM CONTROL TO EXPERIMENTAL CONDITION
003195 03-08
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES
003599 03-17
ROLE OF THE ANTERIOR PITUITARY GABA-RECEPTOR IN THE CONTROL OF
PROLACTIN RELEASE.
003809 04-03
NEUROTRANSMITTER CONTROL OF HYPOTHALAMIC PITUITARY THYROID-
FUNCTION IN RATS.
003942 04-03
IN VIVO EVIDENCE FOR GABAERGIC CONTROL OF SEROTONIN RELEASE IN
THE CAT SUBSTANTIA-NIGRA
004011 04-03
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL
BY ANXIOLYTICS WITH DRUGS ACTING ON THE GABA SYSTEM
004193 04-04
A MICROCOMPUTER SYSTEM FOR THE CONTROL OF BEHAVIORAL
EXPERIMENTS
004287 04-06
THE EFFEQS OF PSYCHOTROPIC-MEDICATION ON COGNITIVE CONTROL
MEASURES. (PH D DISSERTATION)
004523 04-13
CONTROLLED
BEHAVIOURAL-RESPONSES TO STEREOTAQICALLY CONTROLLED
INJECTIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI.
001708 02-04
TREATMENT OF THERAPY-RESISTANT DEPRESSED-PATIENTS WITH IV.
INFUSIONS OF NOMIFENSINE CONTROLLED BY GALVANIC-SKIN-
RESISTANCE.
002012 02-09
ANTIDEPRESSANT AQION OF AMINEPTINE: CONTROLLED DOUBLE-BUND
STUDY.
002030 02-09
DOUBLE-BUND CONTROLLED EXPERIMENT: AMINEPTINE VERSUS
AMITRIPTYUNE USING THE HAMILTON-DEPRESSION-RATING-SCALE
002050 02-09
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A
CONTROLLED CLINICAL-STUDY WITH DOXEPIN AND PLACEBO.
002080 02-10
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: I A
CONTROLLED CLINICAL-TRIAL.
002086 02-10
A CONTROLLED DOUBLE-BLIND STUDY OF HALOPERIDOL VERSUS
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY-
SUBNORMAL-PATIENTS: SERUM LEVELS AND CUNICAL-EFFEaS.
002185 02-11
DIFFICULTIES ENCOUNTERED DURING A CONTROLLED STUDY OF A NEW
HYPNOTIC-DRUG (TRIAZOLAM) BY A GROUP OF GENERAL- .
PRACTITIONERS.
003155 03-071
PIPERIDONE IN CHRONIC SCHIZOPHRENIC-PATIENTS: A CONTROLLED
DOUBLE-BUND STUDY.
003184 03-08
MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION.
003782 04-03
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO
AND STANDARD (IMIPRAMINE) CONTROU.ED CUNICAL-STUDY
004392 04-09
CONTROLLED CLINICAL-TRIAL OF NOMIFENSINE IN THE TREATMENT OF
DEPRESSION. „ ^
004417 04-09
CONTROLLED-COMPARATIVE-STUDY
TREATMENT OF DRUG-INDUCED DRYNESS OF MOUTH IN PSYCHIATRIC-
PATIENTS - A CONTROLLED-COMPARATIVE-STUDY.
000799 01-13
CONTROLLED-COMPARISON ^^^^ (
CONTROLLED-COMPARISON OF MEDIUM AND HIGH CLOROTEPIN DOSES
IN CHRONIC SCHIZOPHRENIA.
000548 01-08.
S-114
(
VOLUME 19, SUBJECT INDEX
Subject Index
CONTROLLED-COMPARISON OF MIANSERINE WITH IMIPRAMINE IN
ENDOGENOUS DEPRESSIONS
000634 01-09
CONTROLLED-COMPARISON OF THE THERAPEUTIC EFFECTS OF NATRIUM-
OXYBUTYRATE AND OXAZEPAM.
000658 01-10
CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN
SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BUND CROSS-
OVER DESIGN.
001937 02-08
LONG-TERM CONTROLLED-COMPARISON OF INJECTION OXYPROTHEPIN
AND FLUPHENAZINE-DECANOATES IN PSYCHOTICS IN REMISSION.
001949 02-08
THE USE OF CLOROTEPIN AND DIAZEPAM IN A COMPLEX THERAPY OF
NEUROSES (CONTROLLED-COMPARISON)
002064 02-10
THERAPEUTIC EFFECT OF MIANSERINE AND IMIPRAMINE IN ENDOGENOUS
DEPRESSIONS (CONTROLLED-COMPARISON) .
003264 03-09
CONTROLLED-RELEASE
STEADY-STATE LITHIUM BLOOD LEVEL FLUCTUATIONS IN MAN
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FORM.
003151 03-07
CONTROLLED-STUDY
CLINICAL COMPARISON OF OXYPROTHEPIN AND CLOTEPINE IN
SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY) .
000568 01-08
KETAZOLAM AND DIAZEPAM IN ANXIETY; A CONTROLLED-STUDY.
000655 01-10
DISCONTINUATION OF ORAL AND DEPOT FLUPHENAZINE IN
SCHIZOPHRENIC-PATIENTS AFTER ONE YEAR OF CONTINUOUS
MEDICATION: A CONTROLLED-STUDY.
001931 02-08
NOMIFENSINE IN THE TREATMENT OF ENDOGENOUS DEPRESSION. A
CONTROLLED-STUDY VS. NORTRIPTYLINE.
001978 02-09
DOUBLE-BLIND CONTROLLED-STUDY: AMINEPTINE VERSUS
TRIMIPRAMINE.
002051 02-09
PROPRANOLOL IN CHRONIC ANXIETY-DISORDERS: A CONTROLLED-STUDY.
002073 02-10
DOUBLE-BLIND CONTROLLED-STUDY ON THE PSYCHOLEPTIC-EFFECTS OF
AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT
PERSONALITY-PROBLEMS.
002116 02-11
CONTROLLED-STUDY WITH BROMAZEPAM AND CLOROTEPIN IN CHILD
INSTABILITY.
002190 02-11
AMOXAPINE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSED-
OUTPATIENTS: A CONTROLLED-STUDY.
003254 03-09
A CLINICAL, CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE
TREATMENT OF NARCOTIC ADDICTION.
003335 03-11
IMIPRAMINE TREATMENT OF BORDERLINE-CHILDREN: CASE-REPORTS
WITH A CONTROLLED-STUDY.
003356 03-11
A CONTROLLED-STUDY OF L-DOPA IN SCHIZOPHRENIA WITH REFERENCE
TO THE THEORY OF DOPAMINERGIC-RECEPTOR HYPERSENSITIVITY.
004312 04-08
CONTROLLEO-SUBSTANCES-ACT
GUIDELINES FOR SCHEDULING DRUGS UNDER THE CONTROLLED-
SUBSTANCES-ACT.
003606 03-17
CONTROLLED-TRIAL
ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLED-
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH
PARKINSONS-DISEASE TREATED WITH L-DOPA.
000659 01-11
A CONTROLLED-TRIAL OF BEHAVIOR-MODIFICATION AND
METHYLPHENIDATE IN HYPERACTIVE-CHILDREN.
000678 01-11
CONTROLLED-TRIAL OF BEHAVIOUR-THERAPY, PHARMACOTHERAPY, AND
THEIR COMBINATION IN THE TREATMENT OF OBESITY.
000725 01-11
CONTROLLED-TRIAL OF SULPIRIDE IN CHRONIC SCHIZOPHRENIC-PATIENTS.
001914 02-08
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE-
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A
CONTROLLED-TRIAL.
002329 02-14
A CONTROLLED-TRIAL OF OXYPERTINE IN TARDIVE-DYSKINESIA,
004611 04-15
CONTROLLING
BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFECTS OF CHRONIC
AMPHETAMINE INTOXICATION.
001653 02-04
COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS.
004438 04-11
CONTROLS
DOES SYSTEMIC MORPHINE INCREASE DESCENDING INHIBITORY
CONTROLS OF DORSAL-HORN NEURONES INVOLVED IN NOCICEPTION?
000175 01-03
ACTH4-10 AND MEMORY IN ECT TREATED PATIENTS AND UNTREATED
CONTROLS. II. EFFECT ON RETRIEVAL.
001983 02-09
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC
DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL
CONTROLS.
002004 02-09
BEHAVIORAL CONFIRMATION OF DIFFUSE NOXIOUS INHIBITORY
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS
OPIATES.
002791 03-03
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF
BULLFROG SYMPATHETIC GANGLION CELLS.
003710 04-03
PROLACTIN AND GROWTH-HORMONE STUDIES IN SCHIZOPHRENIC-
PATIENTS AND NORMAL CONTROLS.
004538 04-13
CONVALESCING
SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN
PRAZEPAM TREATMENT IN 30 CASES,
003296 03-11
CONVERGENCES
CONVERGENCES AND DIVERGENCES BETWEEN BIOLOGICAL-PSYCHIATRY
AND PSYCHOTHERAPY.
002536 02-17
CONVERGENT
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS.
003972 04-03
CONVERSATION
HUMAN SOCIAL CONVERSATION: EFFECTS OF ETHANOL, SECOBARBITAL
AND CHLORPROMAZINE.
004582 04-14
CONVERSION
THE CONVERSION OF (3H)TRYPT0PHAN TO 5 (3H)HYDR0XYTRYPTAMINE
IN MOUSE-BRAIN FOLLOWING DEPLETION OF PHENYLALANINE AND
TYROSINE.
000148 01-03
CONVERSION SCALES FOR COMMONLY REQUESTED SERUM
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE, AND OF
HORMONES.
000759 01-13
CONVERTING
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME ACTIVITY
IN THE RAT-BRAIN.
001614 02-04
CONVULSANT
REDUCTION OF GAMMA AMINOBUTYRIC-ACID-MEDIATED (GABA)
TRANSMISSION BY A CONVULSANT BENZODIAZEPINE.
000015 01-02
SYSTEMIC DIPIPERIDINOETHANE MIMICS THE CONVULSANT AND
NEUROTOXIC-ACTIONS OF KAINIC-ACID.
000222 01-03
CONVULSANT AND ANTICONVULSANT BARBITURATES. 1. MOLECULAR
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY
CALCULATIONS.
001029 02-01
REPEATED ELECTROCONVULSIVE-SHOCK DOES NOT INCREASE THE
SUSCEPTIBILITY OF RATS TO A CAGE CONVULSANT
(ISOPROPYLBICYCLOPHOSPHATE) .
001184 02-03
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO
GABA REGULATED CHLORIDE ION-CHANNELS.
002848 03-03
KET AMINE: CONVULSANT OR ANTICONVULSANT?
003060 03-04
STIMULATION OF FRUCTOSEBIPHOSPHATASE ACTIVITY AND SYNTHESIS
IN THE CEREBRAL-CORTEX OF RATS SUBMITTED TO THE CONVULSANT
METHIONINE-SULFOXIMINE.
003838 04-03
CONVULSANT-AGENTS
REGULATION OF THE STATE OF PHOSPHORYLATION OF SPECIFIC
NEURONAL PROTEINS IN MOUSE-BRAIN BY IN VIVO ADMINISTRATION
OF ANESTHETIC AND CONVULSANT-AGENTS.
000291 01-03
CONVULSANT-EFFECT
ON THE MEASUREMENT IN RATS OF THE CONVULSANT-EFFECT OF DRUGS
AND THE CHANGES WHICH FOLLOW ELECTROCONVULSIVE-SHOCK.
002444 02-15
I
a,
I
't,f
It-
m..
iiii'iji"
S-115
Subject Index
Psychopharmacology Abstracts
CONVULSANT-EFFECTS
CONVULSANT-EFFECTS OF AMINOOXY ACETIC-ACID DURING ONTOGENESIS
IN RATS.
001439 02-03
CONVULSANTS
CONVULSANTS ANTAGONISE INHIBITION IN THE OLFACTORY-CORTEX
SLICE,
001466 02-03
AMINOPHYLLINE AND IMIDAZOLE AS CONVULSANTS.
004232 04-04
CONVULSION
EFFECTS OF KINDLING OR BRAIN-STIMULATION ON PENTYLENETETRAZOL-
INDUCED CONVULSION SUSCEPTIBILITY.
000037 01-03
CONVULSIONS
EFFECTS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL-
CORD GABA CONCENTRATION.
000145 01-03
INVOLVEMENT OF CENTRAL CHOLINOCEPTORS IN METRAZOL-INDUCED
CONVULSIONS.
000247 01-03
PRODUCTION OF CONVULSIONS IN MICE BY THE COMBINATION OF
METHIONINE AND HOMOCYSTEINE.
001233 02-03
EFFECT OF ERGOT DERIVATIVES ON POSTDECAPITATION CONVULSIONS.
001288 02-03
HOMOCYSTEINE-INDUCED CONVULSIONS: ENHANCEMENT BY VITAMIN-B6
AND INHIBITION BY HYDRAZINE.
002758 03-03
INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN
SUBCELLULAR GANGLIOSIDES: EFFECT OF PENTYLENETETRAZOL-
INDUCED CONVULSIONS IN BRAIN GANGLIOSIDES
002937 03-03
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INDUCED CONVULSIONS
IN RATS.
003736 04-03
PYRAZOLE EXACERBATES HANDLING-INDUCED CONVULSIONS IN MICE.
004094 04-04
BEHAVIORAL-PHARMACOLOGY OF TETRAHYDROCANNABINOL
CONVULSIONS IN RABBITS.
004288 04-06
CONVULSIVE
EFFECTS OF ANTICONVULSANTS AND GLUTAMATE ANTAGONISTS ON THE
CONVULSIVE ACTION OF KAINIC-ACID.
000288 01-03
LOCOMOTOR AND CONVULSIVE RESPONSES TO PICROTOXIN IN
AMYGDALA KINDLED RATS.
000416 01-04
LOWERING OF THE CONVULSIVE THRESHOLD BY NONSTEROIDAL
ANTIINFLAMMATORY-DRUGS.
002904 03-03
THE ROLE OF GABA-MEDIATED NEUROTRANSMISSION IN CONVULSIVE
STATES.
003334 03-11
CONVULSIVE AND DRUG-THERAPIES OF DEPRESSION.
004366 04-09
CONVULSIVE-SEIZURE
ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA.
001151 02-03
ON SOME RELATIONSHIPS BETWEEN GABAERGIC AND 5 HT-ERGIC
MECHANISMS IN PENTYLENETETRAZOL CONVULSIVE-SEIZURE
REACTIONS.
004166 04-04
CONVULSIVE-SHOCK-TREATMENT
REDUCTION IN OPIATE ACTIVATION AFTER CHRONIC
ELECTROCONVULSIVE-SHOCK - POSSIBLE ROLE FOR ENDORPHINS IN
THE BEHAVIORAL-EFFECTS OF CONVULSIVE-SHOCK-TREATMENT.
(UNPUBLISHED PAPER).
004154 04-04
COOLING
THE EFFECT OF PHARMACOLOGICAL DESTRUCTION OF HYPOTHALAMIC
MONOAMINERGIC STRUCTURES ON BODY-TEMPERATURE AND GAS-
EXCHANGE DURING EXTREME COOLING.
004016 04-03
COOPERATIVE
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING.
000099 01-03
COOPERATIVE PSYCHIATRIC- STUDY OF ALIVAL: PRELIMINARY RESULTS.
002045 02-09
COOPERATIVELY
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING-
SITES IN RAT STRIATUM.
000186 01-03
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES.
001342 02-03
COORDINATING
COORDINATING CLINICAL-TRIALS IN PSYCHOPHARMACOLOGY:
PLANNING, DOCUMENTATION, AND ANALYSIS
002574 02-17
COPULATORY-BEHAVIOR
INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN
CHORIONIC GONADOTROPHIN
003012 03-04
COPULATORY-BEHAVIOR AND SEXUAL-REFLEXES OF MALE RATS TREATED
WITH NALOXONE.
003077 03-04
CORNEAL
OCCURRENCE OF CORNEAL OPACITIES IN RATS AFTER ACUTE
ADMINISTRATION OF L ALPHA ACETYLMETHADOL.
001853 02-05
CORONARY-HEART-DISEASE
CORONARY-HEART-DISEASE: TREATING THE ANXIETY COMPONENT
002088 02-10
CORONARY-PRONE
SENSORY PROCESSING, CARDIOVASCULAR REACTIVITY, AND THE TYPE A
CORONARY-PRONE BEHAVIOR PAHERN.
003405 03-13
CORPUS-CALLOSUM
THE EFFECTS OF LITHIUM ON MYOINOSITOL LEVELS IN LAYERS OF
FRONTAL-CEREBRAL-CORTEX, IN CEREBELLUM, AND IN CORPUS-
CALLOSUM OF THE RAT.
003712 04-03
CORPUS-STRIATUM
ACUTE AND CHRONIC EFFECTS OF NEUROLEPTICS AND ACUTE EFFECTS OF
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN.
000215 01-03
DRUG-INDUCED RELEASE OF DOPAMINE FROM CORPUS-STRIATUM.
(PH.D. DISSERTATION).
001343 02-03
THE EFFECT OF CARBIDINE ON DOPAMINE TURNOVER IN THE CORPUS-
STRIATUM OF THE BRAINS OF RATS.
001352 02-03
DOPAMINE-RECEPTOR SUPERSENSITIVITY IN THE CORPUS-STRIATUM
FOLLOWING CHRONIC ELEVATION OF BRAIN GAMMA AMINOBUTYRIC- :
ACID
002716 03-03
ROTATIONAL-BEHAVIOUR ELICITED BY 5 HT IN THE RAT: EVIDENCE FOR
AN INHIBITORY ROLE OF 5 HT IN THE SUBSTANTIA-NIGRA AND
CORPUS-STRIATUM
004141 04-04
CORRECT
EFFECTS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND
DISTRIBUTION OF CORRECT RESPONDING ON A SIMULTANEOUS
DISCRIMINATION TASK IN THE RAT
001806 02-04'
CORRECTION
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I SLEEP
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS
001869 02-06
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL
HEMORRHAGE PATIENTS.
002295 02-13
CORRECTION OF THE EXTRAPYRAMIDAL NEUROLEPTIC-SYNDROME BY
TRYPTOPHAN AND THE TIME-COURSE OF ITS CONTENT IN THE BLOOD
OF PATIENTS.
004434 04-11
CORRECTION OF HORMONAL ACTIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
CORRELATION
OXAZEPAM-ESTERS 1 CORRELATION BETWEEN HYDROLYSIS RATES AND
BRAIN APPEARANCE OF OXAZEPAM.
000010 01-02
OXAZEPAM-ESTERS. 2 CORRELATION OF HYDROPHOBICITY WITH SERUM
BINDING, BRAIN PENETRATION, AND EXCRETION.
000011 01-02
CORRELATION BETWEEN MONOAMINE-OXIDASE-INHIBITORS AND
ANTICONVULSANTS.
000081 01-03
CORRELATION BETWEEN BENZODIAZEPINE-RECEPTOR OCCUPATION AND
ANTICONVULSANT EFFEQS OF DIAZEPAM.
000450 01-04
S-116
VOLUME 19, SUBJECT INDEX
INTERACTION BETWEEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN:
METABOLITE NORTRIPTYLINE AND THE CORRELATION WITH CLINICAL-
RESPONSE.
000640 01-09
CORRELATION BETWEEN DAILY FLUCTUATIONS OF CARBAMAZEPINE
SERUM LEVELS AND INTERMITTENT SIDE-EFFECTS.
000851 01-15
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES.
001554 02-03
MOTOR-ACTIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF
COCAINE: CORRELATION WITH DOPAMINE UPTAKE BLOCKADE.
001650 02-04
CORRELATION BETWEEN DAILY DOSAGE OF CHLORPROMAZINE AND
SUBSEQUENT SUPERSENSITIVITY.
001845 02-05
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS.
002047 02-09
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT;
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL
EVOLUTION.
002165 02-11
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS,
AND NEUROPHARMACOLOGICAL EVENTS.
002515 02-17
STRUCTURE OF VARIABILITY AND CORRELATION IN LEARNING AFTER
DRUG ADMINISTRATION.
002562 02-17
LACK OF CORRELATION BETWEEN NALOXONE-INDUCED CHANGES IN
SEXUAL-BEHAVIOR AND SERUM LH IN MALE RATS.
002821 03-03
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORREL^TION WITH
ANTICONVULSANT AND ANESTHETIC ACTIONS.
002885 03-03
ON CORRELATION OF BEHAVIORAL-REACTIONS AND NEURONAL ACTIVITY
IN THE HYPOTHALAMUS UNDER SUBCUTANEOUS GASTRIN INJECTION.
002892 03-03
CORRELATION BETVi^EEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC-
DRUGS IN RATS AND DAILY CLINICAL DOSES.
003032 03-04
CORRELATION OF (14C)MUSCIM0L CONCENTRATION IN RAT-BRAIN WITH
ANTICONVULSANT ACTIVITY.
003045 03-04
AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF
DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREACTIVITY
IN DMI RESPONSIVE DEPRESSIVES.
003228 03-09
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED
SEROTONERGIC MECHANISMS.
003748 04-03
A SIMPLE DETERMINATION OF SEROTONIN, 5 HYDROXYINDOLEACETIC-
ACID AND 5 HYDROXYTRYPTOPHAN-DECARBOXYLASE ACTIVITY IN
RAT-BRAIN AREAS AND PARALLEL CORRELATION AMONG THE LEVELS.
004301 04-06
CORRELATIONAL
CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND
NATURAL SEHINGS: CORRELATIONAL AND VARIANCE COMPONENTS
ANALYSES.
004508 04-13
CORRELATIONS
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN
THE DOG.
001547 02-03
CORRELATIONS BETWEEN PUVSMA LEVELS OF ANTIEPILEPTIC-DRUGS AND
EEG INTENSIVE MONITORING.
002288 02-13
CORRELATIONS BETWEEN LITHIUM LEVELS IN CEREBROSPINAL-FLUID AND
LITHIUM LEVELS IN BLOOD PLASMA AND ERYTHROCYTES.
003210 03-09
CORRELATIONS BETWEEN NA-K-ATPASE ACTIVITY AND ACETYLCHOLINE
RELEASE IN RAT CORTICAL SYNAPTOSOMES.
003937 04-03
CORRELATIONS BETWEEN VISUAL-EVOKED-POTENTIALS AND
PSYCHOPATHOLOGICAL-FINDINGS IN SCHIZOPHRENIC-PATIENTS UNDER
TREATMENT WITH VARIOUS PSYCHOPHARMACOLOGICAL-DRUGS
004315 04-08
CORRESPONDENCE
OPIATE-RECEPTOR GRADIENTS IN MONKEY CEREBRAL-CORTEX:
CORRESPONDENCE WITH SENSORY PROCESSING HIERARCHIES.
002641 03-01
CORRESPONDING
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY
HUMAN BLOOD-PLATELETS.
001067 02-02
Subject Index
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES
001078 02-02
CORTEX
DOPAMINE METABOLITES IN CAUDATE AND CORTEX AFTER LITHIUM AND
HALOPERIDOL, (UNPUBLISHED PAPER)
003738 04-03
EFFECTS OF PENTOBARBITAL AND ETHANOL UPON SINGLE NEURON
ACTIVITY IN THE PRIMARY SOMATOSENSORY CORTEX OF THE RHESUS-
MONKEY,
003755 04-03
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES.
003984 04-03
THE EFFECT OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELECTRICAL-
ACTIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUCTURES OF
THE RABBIT BRAIN.
003994 04-03
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION.
004273 04-05
CORTICAL
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
ACTIVATION OF CORTICAL CIRCUITS DURING INTERICTAL SPIKES.
000056 01-03
CORTICAL NEUROCHEMICAL CHANGES AFTER INTRASTRIATAL INJECTION
OF KAINIC-ACID.
000133 01-03
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS.
000330 01-03
THE EFFECTS OF LSD AND SOME ANALOGUES ON THE RESPONSES OF
SINGLE CORTICAL NEURONS OF THE CAT TO OPTICAL- STIMULATION.
000738 01-12
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL
EVOKED-POTENTIALS.
000763 01-13
PRESSURE REVERSAL OF THE EFFECT OF URETHANE ON THE EVOKED
SOMATOSENSORY CORTICAL RESPONSE IN THE RAT
001106 02-03
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELECTRICAL-
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL
SLICES.
001130 02-03
MORPHINE AND ELECTROACUPUNCTURE: COMPARISON OF THE EFFECTS
ON THE CORTICAL EVOKED-RESPONSES AFTER TOOTH-PULP
STIMULATION IN RATS.
001294 02-03
STUDIES ON THE EFFECT OF ALPHA MELANOCYTE-STIMULATING-
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P
AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED
PAPER).
001372 02-03
SELECTIVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS.
001447 02-03
APOMORPHINE HALOPERIDOL INTERACTIONS: DIFFERENT TYPES OF
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS.
002662 03-03
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE
ANESTHETIZED RATS.
002687 03-03
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
CHRONOLOGICAL ELECTROENCEPHALOGRAPHIC AND
NEUROPHARMACOLOGICAL-STUDY IN CORTICAL KINDLING RABBITS.
002761 03-03
CHANGES IN THE CORTICAL ACTIVITY OF SUCCINATE-DEHYDROGENASE
UNDER THE INFLUENCE OF CHLORPROMAZINE (A HISTOCHEMICAL-
STUDY AND ELECTROCYTOCHEMICAL- STUDY).
002784 03-03
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFECT OF
CHRONIC-TREATMENT.
002847 03-03
I
9
'Jit;
a-
Ji.,
m
'll'HI*
s-nz
Subject Index
Ptychopharmacology Abstracts
CORTICAL RECOVERY FROM EFFECTS OF MONOCULAR DEPRIVATION:
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6
HYDROXYDOPAMINE.
003024 03-04
CORTICAL CONTROL OF NEURALLY MEDIATED ARRHYTHMOGENIC-
PROPERTIES OF DESACETYLLANATOSIDE-C.
003124 03-05
CORTICAL EVOKED-POTENTIALS IN GILLES-DE-LA-TOURETTES-SYNDROME
- A SINGLE CASE-STUDY.
003431 03-13
THYROXIN SENSITIVITY OF SENSORIMOTOR CORTICAL NEURONS AND THE
HYPOTHALAMIC VENTROMEDIAL NUCLEUS.
003713 04-03
THE EFFECT OF LONG-TERM CONCURRENT ADMINISTRATION OF
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL
CORTICAL DOPAMINE METABOLISM IN RATS.
003788 04-03
INVESTIGATION OF ACTION OF ENKEPHALIN ON THE SPONTANEOUS AND
EVOKED RELEASE OF ACETYLCHOLINE FROM RAT CORTICAL AND
STRIATAL SLICES.
003862 04-03
CORRELATIONS BETWEEN NA-K-ATPASE ACTIVITY AND ACETYLCHOLINE
RELEASE IN RAT CORTICAL SYNAPTOSOMES
003937 04-03
CORTICAL-CORRELATES
CORTICAL-CORRELATES OF VIGILANCE REGUUTION AND THEIR USE IN
EVALUATING THE EFFECTS OF TREATMENT
002147 02-11
CORTICOCEREBRAL
ACCELERATION OF DESIPRAMINE-INDUCED DECREASE OF RAT
CORTICOCEREBRAL BETA-ADRENERGIC-RECEPTORS BY YOHIMBINE
000326 01-03
CORTICOSTERIODS
PLASMA CORTICOSTERIODS IN MANIA: THE EFFECTS OF PIMOZIDE
004363 04-09
CORTICOSTEROID
SIDE-EFFECTS OF CORTICOSTEROID THERAPY: PSYCHIATRIC-ASPECTS.
003508 03-15
CORTICOSTEROIDS
THE EFFECT OF ANTIDEPRESSANTS ON L 5 HTP-INDUCED CHANGES IN RAT
PLASMA CORTICOSTEROIDS.
000170 01-03
RELATIONSHIPS BETWEEN PLASMA CORTICOSTEROIDS AND
BENZODIAZEPINES IN STRESS.
000176 01-03
BENZODIAZEPINES, STRESS AND RAT PLASMA CORTICOSTEROIDS: THE
ROLE OF INDOLEAMINES.
003034 03-04
CORTICOSTERONE
CHANGES IN PLASMA CORTICOSTERONE LEVELS AS A MEASURE OF
ACUTE DEPENDENCE UPON LEVORPHANOL IN RATS.
000085 01-03
THE SENSITIVITY OF THE RAT CORTICOSTERONE RESPONSE TO
ENVIRONMENTAL MANIPULATIONS AND TO CHRONIC
CHLORDIAZEPOXIDE TREATMENT.
000092 01-03
EFFECTS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT.
000180 01-03
LONG-TERM EFFECT OF NEUROLEPTICS ON CORTICOSTERONE
SEPTOHIPPOCAMPAL UPTAKE IN RATS.
001107 02-03
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER).
001122 02-03
LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHALIN PRODUCE OPPOSING
EFFEQS ON PLASMA CORTICOSTERONE LEVELS IN ETHER-STRESSED
MICE.
001245 02-03
THE EFFECT OF REPEATED ELECTROCONVULSIVE-SHOCK ON
CORTICOSTERONE RESPONSES TO CENTRALLY-ACTING
PHARMACOLOGICAL STIMULI IN THE MALE RAT.
001486 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
EFFECT OF BROMOCRIPTINE ON EXPLORATORY-ACTIVITY, BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS
001635 02-04
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS,
AND NEUROPHARMACOLOGICAL EVENTS.
002515 02-17
DIFFERENTIAL-EFFEaS OF CANNABINOID EXPOSURE AND STRESS ON
PLASMA PROL^aiN, GROWTH-HORMONE AND CORTICOSTERONE
LEVELS IN MALE MICE
002695 03-03
INTRAVENTRICULAR CORTICOSTERONE INJEQION FACILITATES MEMORY
OF AN APPETITIVE DISCRIMINATIVE TASK IN MICE.
003051 03-04
EFFECT OF AMPHETAMINE ON PLASMA CORTICOSTERONE IN THE
CONSCIOUS RAT.
003888 04-03
CORTICOSTRIATAL
A NOVEL GABA-RECEPTOR MODULATES STIMULUS-INDUCED GLUTAMATE
RELEASE FROM CORTICOSTRIATAL TERMINALS.
001376 02-03
CORTICOTROPIN
EFFECT OF TREATMENT WITH SODIUM-VALPROATE AND DIAZEPAM ON
PLASMA CORTICOTROPIN IN NELSONS- SYNDROME.
004463 04-1 1
CORTISOL
THE EFFEQ OF CORTISOL MICROIONOPHORETIC-APPLICATIONS ON THE
ACTIVITY OF HIPPOCAMPAL NEURONS IN UNRESTRAINED RABBITS
001123 02-03
EFFECTS OF NALOXONE UPON PROLACTIN AND CORTISOL IN NORMAL
WOMEN
002213 02-13
MOOD AND BEHAVIORAL-EFFECTS OF PHYSOSTIGMINE ON HUMANS ARE
ACCOMPANIED BY ELEVATIONS IN PLASMA BETA ENDORPHIN AND
CORTISOL.
002280 02-13
PSYCHOTROPIC-DRUGS DO NOT INTERFERE WITH RADIOLIGAND ASSAYS
FOR PROLACTIN, CORTISOL, AND GROWTH-HORMONE
002511 02-16
TSH, HGH, HPR, AND CORTISOL RESPONSE TO TRH IN DEPRESSED-
PATIENTS.
004399 04-09
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS
004403 04-09
COST
COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS
004438 04-11
COTARDS-SYNDROME
BETA ENDORPHIN IN COTARDS-SYNDROME.
003187 03-08
COUNT
THE SPECIFIC ACTIVITY OF PLATELET MONOAMINE-OXIDASE VARIES
WITH PLATELET COUNT DURING SEVERE EXERCISE AND
NORADRENALINE INFUSION.
004509 04-13
COUNTERAa
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO
COUNTERACT CURATIVE EFFECTS Of NEUROLEPTIC-DRUGS
004321 04-08
COUNTERTRANSPORT
NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTRODUQION.
002227 02-13
COUNTRIES
CLINICAL-EXPERIENCE WITH SUBSTITUTED BENZAMIDES IN FRENCH-
SPEAKING COUNTRIES.
002036 02-09
COUPLED
SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM IN BRAIN: EFFEQS OF NISOXETINE
VERSUS FLUOXETINE.
000208 01-03
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME
BENZODIAZEPINE RECOGNITION jITES ARE COUPLED TO GABA-
RECEPTORS AND lONOPHORES
001484 02-03
FUNCTIONAL ASPECTS OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYIATE-CYCIASE SYSTEM IN THE CENTRAL-NERVOUS- SYSTEM
001493 02-03
COUPLING
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION).
001213 02-03
COVALENTLY-BONDED
THIOLS LIBERATE COVALENTLY-BONDED FLAVIN FROM MONOAMINE-
OXIDASE (UNPUBLISHED PAPER).
001060 02-01
COVARIANCE
COVARIANCE OF PLASMA FREE 3 METHOXY-4-
HYDROXYPHENETHYLENEGLYCOL AND DIASTOLIC BLOOD-PRESSURE.
003418 03-13
S-118
VOLUME 19, SUBJECT INDEX
Subject Index
COVERT
COVERT DYSKINESIA IN AMBULATORY SCHIZOPHRENIA.
COYOTE
EFFECT OF LITHIUM-CHLORIDE IN COYOTE PUP DIET.
000836 0)-15
001835 02-05
CPK
CPZ
CR
TWO CASES OF FORM-FRUSTE-DU-SYNDROME-MALIN WITH HIGH-LEVELS
OF SERUM CPK
004636 04-15
LOW ORAL CPZ BIOAVAILABILITY IN CHRONIC SCHIZOPHRENIA.
(UNPUBLISHED PAPER)
001938 02-08
CONDITIONED SUPPRESSION OF DRINKING: A MEASURE OF THE CR
ELICITED BY A LITHIUM CONDITIONED FLAVOR.
001747 02-04
CRAB
MECHANICAL-CHANGES IN CRAB NERVE FIBERS DURING ACTION
POTENTIALS. (UNPUBLISHED PAPER).
001505 02-03
CREATININE
STRUCTURE-ACTIVITY RELATIONSHIPS IN THE EFFECTS OF PHENACEMIDE
ANALOGS ON SERUM CREATININE AND ANTICONVULSANT ACTIVITY.
000249 01-03
CREATIVE-PROCESS
PSYCHEDELIC-DRUGS AND THE CREATIVE-PROCESS.
002199 02-12
CRIME
VOLUNTARY INTOXICATION FROM PHENCYCLIDINE. WILL IT RAISE A
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL-
STATE?.
000914 01-17
PCP AND VIOLENT CRIME: THE PEOPLE VS. PEACE.
000986 01-17
CRIMINAL
CYCLICAL CRIMINAL ACTS IN PREMENSTRUAL-SYNDROME.
000927 01-17
CRIMINALLY-INSANE-OFFENDERS
RECIDIVISM AND REHABILITATION RATES FOR 135 CRIMINALLY-INSANE-
OFFENDERS. (D.ED. DISSERTATION).
002514 02-17
CRITERIA
CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM.
000988 01-17
PREDiaiVE CRITERIA FOR LITHIUM-SALTS ACTIVITY.
002619 02-17
AMINE UPTAKE INHIBITORS: CRITERIA OF SELECTIVITY.
003921 04-03
THE USE OF CLINICAL AND PHARMACOKINETIC CRITERIA IN FORECASTING
THE EFFICACY OF THERAPY IN SCHIZOPHRENIA.
004335 04-08
CROSS-OVER
MAINTENANCE-THERAPY WITH FLUPHENAZINE-DECANOATE AND
OXYPROTHEPINE-DECANOATE IN SCHIZOPHRENIC-PATIENTS - A
DOUBLE-BLIND CROSS-OVER COMPARATIVE-STUDY.
001924 02-08
CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN
SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BLIND CROSS-
OVER DESIGN.
001937 02-08
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION:
EVIDENCE FOR AMINE SPECIFICITY.
003250 03-09
A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF
CARBAMAZEPINE IN OVERACTIVE, SEVERELY MENTALLY-
HANDICAPPED PATIENTS.
003365 03-1 1
CROSS-STUDY
COMPARATIVE CROSS- STUDY ON THE EFFECTS OF AMINEPTINE AND
MAPROTILINE.
002065 02-10
CROSS-TOLERANCE
CHLORDIAZEPOXIDE ANTINOCICEPTION: CROSS-TOLERANCE WITH
OPIATES AND WITH STRESS.
000348 01-04
TOLERANCE TO SUPPRESSIVE EFFECTS OF CHLORDIAZEPOXIDE ON
OPERANT-BEHAVIOR: LACK OF CROSS-TOLERANCE TO PENTOBARBITAL.
000356 01-04
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA
BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY
TUBERCLE OF THE RAT.
002681 03-03
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE
AND CROSS-TOLERANCE TO THE INHIBITORY ACTION OF BETA
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS.
002756 03-03
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL-TOLERANCE TO AND
CROSS-TOLERANCE BETWEEN D ALA2-METHI0NINE-ENKEPHALINAMIDE
AND MORPHINE IN THE RAT.
004038 04-03
CROSSED
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS.
003027 03-04
A DOUBLE-BLIND CROSSED CLINICAL-STUDY WITH A NEW
PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008), DIAZEPAM, AND
A PLACEBO.
003153 03-07
CROSSING
EFFECTS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROFILES.
002239 02-13
CROSSROADS
MIND/BRAIN IN THE AGE OF PSYCHOPHARMACOLOGY: A CROSSROADS
FOR MEDICINE AND MINISTRY.
003624 03-17
CROWDING
SOCIAL CROWDING ENHANCES AVERSIVENESS OF NALOXONE IN RATS.
004201 04-04
CRYSTAL
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE ACETYLCHOLINE
ANTAGONIST DIMETHYLAMINOBUTYNYLCYCLOHEXYLHYDROXY 2
PHENYLACETATE HCL.
000003 01-01
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE NEUROLEPTIC
PIMOZIDE-HYDROCHLORIDE, BISFLUOROPHENYL-
BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL.
001015 02-01
CS
ETHANOL AVERSION INDUCED BY PARENTERALLY ADMINISTERED
ETHANOL ACTING BOTH AS CS AND UCS.
001721 02-04
CSEEG
COMPUTERIZED SLEEP EEG (CSEEG) IN PSYCHIATRY AND
PSYCHOPHARMACOLOGY.
002614 02-17
CSF
PRELIMINARY-STUDIES ON CSF GAMMA AMINOBUTYRIC-ACID LEVELS IN
PSYCHIATRIC-PATIENTS BEFORE AND DURING TREATMENT WITH
DIFFERENT PSYCHOTROPIC-DRUGS
001959 02-08
INCREASED CSF GAMMA AMINOBUTYRIC-ACID AFTER TREATMENT WITH
GAMMA VINYL-GABA.
002237 02-13
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE:
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION.
003458 03-14
CU-AMINE-OXIDASES
CU-AMINE-OXIDASES: STUDIES RELATED TO THE MECHANISM-OF-ACTION
OF BOVINE PLASMA AMINE-OXIDASE (UNPUBLISHED PAPER).
003680 04-01
CUE
EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE
ROLE FOR BETA PHENYLETHYIAMINE IN THE COCAINE CUE.
000363 01-04
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
CUES
TEMPORAL AND ENVIRONMENTAL CUES IN CONDITIONED HYPOTHERMIA
AND HYPERTHERMIA ASSOCIATED WITH MORPHINE.
002709 03-03
CULTIVATION
THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE
PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION
WITH PHYTOHEMAGGLUTININ.
004541 04-13
CULTURE
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
EFFEQS OF LITHIUM ON MORPHOLOGICAL CHARACTERISTICS OF
DISSOCIATED BRAIN CELLS IN CULTURE.
002765 03-03
I
lai,
5
fft:ii'.
S-119
Subject Index
Psychopharmacology Abstracts
CULTURED
NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE
POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS.
000116 01-03
ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS.
000194 01-03
(-)PENTOBARBITAL OPENS ION-CHANNELS OF LONG-DURATION IN
CULTURED MOUSE SPINAL NEURONS.
000198 01-03
PSYCHOTROPiC-DRUGS AND HISTAMINE HI -RECEPTORS OF CULTURED
MOUSE NEUROBLASTOMA CELLS.
000250 01-03
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS.
000308 01-03
GABA SYNTHESIS BY CULTURED FIBROBLASTS OBTAINED FROM PERSONS
WITH HUNTINGTONS-DISEASE.
000765 01-13
EXCITATORY ACTION OF OPIOID-PEPTIDES AND OPIATES ON CULTURED
HIPPOCAMPAL PYRAMIDAL CELLS.
001241 02-03
TWO CONDUCTANCE MECHANISMS ACTIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES.
001349 02-03
LITHIUM-ION ENTRY INTO CULTURED CELLS OF NEURAL ORIGIN.
001433 02-03
GABA ANALOGUES ACTIVATE CHANNELS OF DIFFERENT DURATION ON
CULTURED MOUSE SPINAL NEURONS.
002665 03-03
TOXIC EFFECTS OF ALPHA AMINOADIPATE ON CULTURED CEREBELLAR
CELLS.
002729 03-03
HISTAMINE ACTIONS ON ACTIVITY OF CULTURED HYPOTHALAMIC
NEURONS: EVIDENCE FOR MEDIATION BY HISTAMINE Hl-RECEPTORS
AND H2-RECEPT0RS.
002732 03-03
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS
CULTURED FROM RAT-CEREBRAL-CORTEX.
002820 03-03
EFFECTS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO-
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY
CULTURED NEURONS.
002859 03-03
CULTURES
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION.
001300 02-03
HEPATOTOXICITY OF SODIUM-VALPROATE AND OTHER
ANTICONVULSANTS IN RAT HEPATOCYTE CULTURES
002422 02-15
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
002699 03-03
DOXEPIN, A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTAQ
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL-
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION
003836 04-03
THE INACTIVATION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE IN
DISSOCIATED NEURONAL CULTURES FROM SPINAL-CORD
003980 04-03
BENZODIAZEPINE-RECEPTORS ON PRIMARY CULTURES OF MOUSE
ASTROCYTES.
004029 04-03
CUMULATIVE
CUMULATIVE DOSE RESPONSE-CURVES IN BEHAVIORAL-
PHARMACOLOGY.
001883 02-06
CUMULATIVE AFTERDISCHARGE AS THE PRINCIPAL FACTOR IN THE
ACQUISITION OF KINDLED SEIZURES.
002862 03-03
CUP
MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND
UPTAKE OF NEUROTRANSMIHERS IN BRAIN SLICES.
003147 03-06
CUPS
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMIHERS IN EPIDURAL
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC-
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS.
001386 02-03
CURATIVE
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIEN"^S: FAILURE OF NALOXONE TO
COUNTERACT CURATIVE EFFECTS OF NcUROLEPTIC-DRUGS.
004321 04-08
CURRENT-VIEWS
ACTION MECHANISMS OF INSULIN THERAPY IN PSYCHIATRY, AND
CURRENT-VIEWS ON THESE MECHANISMS.
002553 02-17
CURVES
USE OF SURVIVAL CURVES IN ANALYSIS OF ANTIPSYCHOTIC RELAPSE-
STUDIES.
002481 02-16
THE EFFECT OF DIPHENYLHYDANTOIN ON EEG CURVES IN EPILEPTICS.
004494 04-11
CUTANEOUS
CUTANEOUS REAQION TO LITHIUM-CARBONATE: A CASE-REPORT.
000872 01-15
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE
ANESTHETIZED RATS.
002687 03-03
MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION.
003782 04-03
CYCLAZOCINE
EFFECTS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN
COMBINATION WITH NALOXONE ON ELEaRIC-SHOCK TITRATION IN
THE SQUIRREL-MONKEY
001611 02-04
DISCRIMINATIVE-STIMULUS EFFEaS OF CYCLAZOCINE IN THE RAT.
004236 04-04
CYCLE
INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS.
002341 02-14
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT.
003703 04-02
CYCLIC
THE LONG-TERM-TREATMENT OF PERIODICAL AND CYCLIC DEPRESSIONS
WITH FLUPENTHIXOL-DECANOATE.
000603 01-09
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES.
003984 04-03
CYCLIC-ADENOSINE-MONOPHOSPHATE
EFFECT OF NALOXONE, HALOPERIDOL AND PROPRANOLOL ON CYCLIC-
ADENOSINE-MONOPHOSPHATE CONTENT OF RAT AMYGDALA.
000071 01-03
ACTION OF CYCLIC-ADENOSINE-MONOPHOSPHATE ON CENTRAL
NEURONS
002940 03-03
CYCLIC- AMIDINES
RELATIONSHIPS BETWEEN STRUQURE AND ALPHA-ADRENERGIC-
RECEPTOR AFFINITY OF CLONIDINE AND AND SOME RELATED CYCLIC-
AMIDINES.
002698 03-03
CYCLIC- AMP
MECHANISM OF CHLORPROMAZINE AQION ON PLASMA GLUCOSE AND
CYCLIC-AMP LEVELS.
000211 01-03
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS.
000308 01-03
CHOLERA-TOXIN-INDUCED EPILEPTOGENIC-FOCUS - SPECIAL REFERENCE
TO CYCLIC-AMP METABOLISM AND EPILEPTOGENIC-FOCUS.
000522 01-05
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER AaiVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT.
001095 02-03
POSSIBLE INVOLVEMENT OF CYCLIC-AMP AND FRONTAL-CORTEX IN
AMITRIPTYLINE MEDIATED SUPPRESSION OF THE HYPOTENSIVE-EFFEa
OF CLONIDINE.
001259 02-03
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFEQ
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE.
001353 02-03
BRAIN STRIATAL TYROSINE-HYDROXYLASE: AQIVATION OF THE ENZYME
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION.
001423 02-03
CYCLIC-AMP IN PSYCHOSES AND THE EFFEQ OF DRUGS
002294 02-13
RELATIONSHIP BETWEEN THE AQIONS OF CALCIUM-IONS, OPIOIDS, AND
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN
NEUROBLASTOMA-X GLIOMA HYBRID CELLS.
002677 03-03
S-120
VOLUME 19, SUBJECT INDEX
Subject Index
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM
002728 03-03
INCREASE IN PLASMA CYCLIC-AMP LEVELS ELICITED BY NALOXONE IN
MORPHINE-DEPENDENT MALE MICE.
002834 03-03
AGGRESSION ALTERING EFFECTS OF CYCLIC-AMP
PLASMA LEVEL OF CYCLIC-AMP AND MENTAL-DISEASES.
003021 03-04
003170 03-08
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II FACTORS
AFFECTING THE ACCUMULATION OF CYCLIC-AMP IN PIECES OF INTACT
CARP RETINA,
003776 04-03
DOXEPIN, A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTACT
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL-
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION.
003836 04-03
CIRCADIAN-VARIATION OF CYCLIC-AMP IN THE RAT PINEAL-GLAND.
003938 04-03
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON
CHLORPROMAZINE-INDUCEO ELEVATION OF PLASMA GLUCOSE AND
CYCLIC-AMP IN FED MICE.
003946 04-03
ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES:
EFFECTS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE-
DEAMINASE INHIBITORS.
003950 04-03
EVIDENCE TO SUGGEST THAT DOPAMINE-INOUCED INCREASE IN GABA
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC-
AMP.
003952 04-03
THE EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE
PRESENCE AND ABSENCE OF CNS DEPRESSANTS.
004010 04-03
CYCLIC- AMP-INDUCED
CYCLIC-AMP-INDUCED CHANGES IN THE ELECTROENCEPHALOGRAM AND
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN
THE RAT.
003078 03-04
CYCLIC- AMP-PHOSPHODIESTERASE
DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND
CYCLIC-AMP-PHOSPHODIESTERASE.
001405 02-03
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA-
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER).
003998 04-03
CYCLIC-GMP
KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFECT ON
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS.
002743 03-03
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
003783 04-03
GUANYLATE-CYCLASE - CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND
CEREBELLUM: MODIFICATION BY ANTICONVULSANTS.
003956 04-03
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
004030 04-03
CYCIIC-GMP-DEPENDENT
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP-
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF
MOUSE NEUROBLASTOMA CELLS USING
(3H)TETRAPHENYLPH0SPH0NIUM .
004049 04-03
CYCLIC-GUANOSINE-MONOPHOSPHATE
THE EFFECTS OF OPIATES ON THE LEVELS OF CYCLIC-GUANOSINE-
MONOPHOSPHATE IN DISCRETE AREAS OF THE RAT CENTRAL-
NERVOUS-SYSTEM.
000220 01-03
CENTRAL BLOOD-PRESSURE EFFECTS OF GUANYLYLIMIDODIPHOSPHATE
AND CYCLIC-GUANOSINE-MONOPHOSPHATE .
000266 01-03
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C-
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM-
CHANNEL BLOCKADE.
004020 04-03
CYCLIC-GUANOSINE-PHOSPHATE
ETHANOL-INDUCED CHANGES IN CYCLIC-GUANOSINE-PHOSPHATE
METABOLISM IN MOUSE VESTIBULAR REGION.
003784 04-03
CYCIIC-NUCIEOTIDE
CIRCADIAN-RHYTHM OF CYCLIC-NUCLEOTIDE AND GABA LEVELS IN THE
RAT-BRAIN,
000049 01-03
RELATIONSHIPS BETWEEN SEIZURE ACTIVITY AND CYCLIC-NUCLEOTIDE
LEVELS IN BRAIN.
000089 01-03
INHIBITORY-EFFECTS OF ANTICONVULSANT-DRUGS ON CYCLIC-
NUCLEOTIDE ACCUMULATION IN BRAIN.
000090 01-03
INTERACTION OF DOPAMINERGIC ERGOT DERIVATIVES WITH CYCLIC-
NUCLEOTIDE SYSTEM,
001482 02-03
CYCLIC-NUCLEOTIDE-PHOSPHODIESTERASES
AN IMPROVED ASSAY OF CYCLIC-NUCLEOTirCPHOSPHODIESTERASES
WITH QAE-SEPHADEX COLUMNS,
001860 02-06
CYCLIC-NUCLEOTIDES
EFFECTS OF RESERPINE, PROPRANOLOL, AND AMINOPHYLLINE ON
SEIZURE ACTIVITY AND CNS CYCLIC-NUCLEOTIDES.
000115 01-03
RAT-BRAIN STEADY-STATE LEVELS OF CYCLIC-NUCLEOTIDES AS AN
ENDPOINT OF LSD-LIKE HALLUCINOGEN EFFECTS. (PH D
DISSERTATION).
001426 02-03
CYCLIC-NUCLEOTIDES AND THE CENTRAL-EFFECTS OF OPIATES: AN
OVERVIEW OF CURRENT RESEARCH.
001445 02-03
EFFECT OF FLUPHENAZINE ON THE CIRCADIAN-EXCRETION OF CYCLIC-
NUCLEOTIDES AND ELECTROLYTES IN THE URINE OF CHRONIC
SCHIZOPHRENICS.
001927 02-08
CYCLIC-NUCLEOTIDES AND THE NERVOUS-SYSTEM
004542 04-13
CYCLICAL
CYCLICAL CRIMINAL ACTS IN PREMENSTRUAL- SYNDROME.
000927 01-17
CYCLING
MAOI-INDUCED RAPID CYCLING BIPOLAR AFFECTIVE-DISORDER IN AN
ADOLESCENT.
004637 04-15
CYCLO-LEU-GLY
THE EFFEQ OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN
MICE.
001435 02-03
INHIBITION OF NEUROLEPTIC-INDUCED DOPAMINE-RECEPTOR
SUPERSENSITIVITY BY CYCLO-LEU-GLY.
001576 02-04
CYCLOHEXIMIDE
EFFECTS OF CYCLOHEXIMIDE ADMINISTERED IN CONJUNCTION WITH
NICOTINE ON RETENTION OF A PASSIVE-AVOIDANCE TASK IN MICE.
001791 02-04
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS
INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJECTION OF
CYCLOHEXIMIDE.
002780 03-03
CYCLOHEXYLADENOSINE
ADENOSINE-RECEPTORS IN RAT TESTES: LABELING WITH 3H
CYCLOHEXYLADENOSINE.
002835 03-03
CYCLOHEXYLBARBITURATE
ON-COLUMN GAS-CHROMATOGRAPHIC-SYNTHESIS OF 1,3 DIALYKYL
(C=l-10), BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES.
003656 04-01
CYCLOHEXYLPHENOXYAMIDOXIMES
CYCLOHEXYLPHENOXYAMIDOXIMES AND IMIDAZOLINES WITH
ANTIDEPRESSIVE AND ALPHA-ADRENERGIC-ACTIVITY.
001051 02-01
CYCLOID
LITHIUM UPTAKE IN RED CELLS OF CYCLOID AND UNIPOLAR DYSTHYMIC-
PATIENTS.
003258 03-09
CYCLOPHOSPHAMIDE-INDUCED
CYCLOPHOSPHAMIDE-INDUCED SPERMATOGENIC EFFECTS DETECTED IN
THE Fl -GENERATION BY BEHAVIORAL-TESTING.
003121 03-05
CYCLOPROPYL-N-ARYLALKYLAMINES
MECHANISM OF INACTIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES.
001055 02-01
MECHANISM OF INACTIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES.
001088 02-02
CYCLOPROPYLMETHYL
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE-
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1
tai.
M
•ST
:-t
fe:
Ifc,
S-121
Subject index
Psychopharmacology Abstracts
CYCLOPROPYLMETHYL
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE.
003706 04-02
CYCLOSPASMOl
EFFECTS OF CYCLOSPASMOL UPON SENSORY PARAMETERS IN PATIENTS
RECOVERING FROM CEREBROVASCULAR-ACCIDENTS.
002360 02-14
CYCIOTHYMIC-PATIENTS
PROPHYLACTIC-EFFECT OF LITHIUM AGAINST DEPRESSION IN
CYCLOTHYMIC-PATIENTS: A LIFE-TABLE ANALYSIS.
004391 04-09
CYPROHEPTADINE
METERGOLINE AND CYPROHEPTADINE SUPPRESS PROLACTIN RELEASE BY
A NON-5-HYDROXYTRYPTAMINERGIC, NONDOPAMINERGIC
MECHANISM.
003732 04-03
CYPROHEPTADiNIUM-METHIODIDE
ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION:
CYPROHEPTADINIUM-METHIODIDE.
001534 02-03
CYPROTERONACETATE
CYPROTERONACETATE IN THE THERAPY OF SEXUAL-DEVIATIONS.
000735 01-11
CYSTEINE
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE
INJECTION IN NEWBORN ANIMALS.
002774 03-03
CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE
COMPARISON OF CYSTEINE-SUlPHINIC-ACID-DECARBOXYUkSE (CSD)
ISOENZYMES AND GLUTAMIC-ACID-DECARBOXYLASE (GAD) IN RAT: IS
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH
GAD? (UNPUBLISHED PAPER).
001048 02-01
CYTOCHALASIN
THE EFFECT OF COLCHICINE AND CYTOCHALASIN B ON THE RELEASE OF
TAURINE FROM THE CHICK RETINA.
002856 03-03
CYTOCHROME-P-450
EFFECT OF CANNABIDIOL ON CYTOCHROME-P-450 AND HEXOBARBITAL
SLEEP-TIME.
002675 03-03
CYTOPLASMATIC
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS. A
CLINICAL DOUBLE-BLIND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER).
003327 03-11
CYTOPLASMIC
CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN
HYPOTHALAMUS.
002842 03-03
THE NA-K-ATPASE: A PLAUSIBLE TRIGGER FOR VOLTAGE-INDEPENDENT
RELEASE OF CYTOPLASMIC NEUROTRANSMITTERS.
003953 04-03
CYTOSKELETAL
SYNTHESIS OF CYTOSKELETAL PROTEINS IN BULK ISOLATED NEURONAL
PERIKARYA
003672 04-01
CZECHOSLOVAK
21 ANNUAL CZECHOSLOVAK PSYCHOPHARMACOLOGICAL-MEETING.
000917 01-17
CZECHOSLOVAKIA
CONSUMPTION OF PSYCHOTROPIC-DRUGS IN CZECHOSLOVAKIA.
002542 02-17
C10DICHOL
ANTITREMOR ACTION OF ClODICHOL, A PERIPHERAL ACETYLCHOLINE
SYNTHESIS INHIBITOR.
004096 04-04
C6-GLIOMA
REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA-INDEPENDENT
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6-
GLIOMA CELLS. (UNPUBLISHED PAPER).
001403 02-03
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA-
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER).
003998 04-03
D-AMPHET AMINE
PRIOR AND ONGOING EXPERIENCE AS DETERMINANTS OF THE EFFEQS OF
D-AMPHETAMINE AND CHLORPROMAZINE ON PUNISHED-BEHAVIOR.
000339 01-04
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFEQS OF
COCAINE AND D-AMPHETAMINE FOLLOWING CHRONIC AMPHETAMINE
ADMINISTRATION.
000350 01-04
EFFECTS OF ACUTE AND CHRONIC INTERAQIONS OF DIAZEPAM AND D-
AMPHETAMINE ON PUNISHED-BEHAVIOR OF RATS.
000386 01-04
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND
L-AMPHETAMINE: NO INTERAQION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES.
000387 01-04
JOINT-EFFECTS OF D-AMPHETAMINE AND ETHANOL OR PENTOBARBITAL
IN PIGEONS
000403 01-04
FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK
TERMINATION: EFFECTS OF D-AMPHETAMINE, MORPHINE, AND
CLOZAPINE.
000431 01-04
OPPOSITE EFFECTS OF D-AMPHETAMINE ON SPONTANEOUS NEURONAL
ACTIVITY IN THE NEOSTRIATUM AND NUCLEUS-ACCUMBENS.
000454 01-04
THE EFFECTS OF THE METHYLPHENIDATE AND D-AMPHETAMINE RELATED
TO ROUTE-OF-ADMINISTRATION.
000476 01-04
A COMPARISON OF THE EFFEQS OF D-AMPHETAMINE, COCAINE,
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE.
000508 01-04
D-AMPHETAMINE AS A PREDICTOR FOR RESPONSE TO IMIPRAMINE AND
AMITRIPTYLINE
000621 01-09
THE EFFECT OF SMALL AND MODERATE DOSES OF D-AMPHETAMINE ON
HUNGER, MOOD, AND AROUSAL IN MAN.
000807 01-14
A NEW APPROACH TO THE ASSESSMENT OF THE POTENCY OF
REVERSIBLE MONOAMINE-OXIDASE-INHIBITORS IN VIVO, AND ITS
APPLICATION TO D-AMPHETAMINE, P METHOXYAMPHETAMINE AND
HARMALINE.
000900 01-16
EFFECTS OF HALOPERIDOL AND D-AMPHETAMINE ON IN VIVO 3H
SPIROPERIDOL BINDING IN THE RAT-FOREBRAIN.
001461 02-03
THE EFFECTS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5
DIMETHOXY-4-METHYLAMPHETAMINE (DOM) AND D-AMPHETAMINE
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE
TREATED RATS
001595 02-04
BEHAVIORAL-DEPRESSION AND ITS NEUROCHEMICAL-CORRELATES AT
HIGH-DOSES OF D-AMPHETAMINE IN RATS.
001601 02-04
EFFECTS OF MORPHINE, D-AMPHETAMINE, AND PENTOBARBITAL ON
SHOCK AND LIGHT DISCRIMINATION PERFORMANCE IN RATS.
001639 02-04
EFFECTS OF REPEATED ADMINISTRATION OF D-AMPHETAMINE ON
SIDMAN-AVOIDANCE RESPONDING IN RATS.
001692 02-04
SELF-ADMINISTRATION OF D-AMPHETAMINE AND AMINERGIC SYSTEMS
IN THE RAT i
001696 02-04
THE EFFECTS OF D-AMPHETAMINE, CHLORDIAZEPOXIDE, AND J
PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM
PUNISHMENT IN PIGEONS. (PH D. DISSERTATION).
001713 02-04
EFFECTS OF PHENCYCLIDINE, PENTOBARBITAL, AND D-AMPHETAMINE ON ,
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL
DISCRIMINATIONS IN MONKEYS.
001723 02-04
NEUROCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF CHRONIC D- |
AMPHETAMINE TREATMENT IN GENETICALLY OBESE (OBOB) MICE.
(PH.D. DISSERTATION).
001739 02-04
THERMOREGULATORY AND LOCOMOTOR-EFFECTS OF DSIP:
PARADOXICAL-INTERACTION WITH D-AMPHETAMINE.
001827 02-04
DRUG PREFERENCE AND MOOD IN HUMANS: D-AMPHETAMINE. I
002335 02-14;
CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM,
HALOPERIDOL, PHENELZINE AND D-AMPHETAMINE.
002355 02-141
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL-
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D-
AMPHETAMINE AND APOMORPHINE.
002484 02-16
EFFECTS OF D-AMPHETAMINE AND APOMORPHINE IN A NEW ANIMAL-
MODEL OF PETIT-MAL EPILEPSY
002493 02-16
THE EFFECTS OF D-AMPHETAMINE AND POTASSIUM ON SEROTONIN
RELEASE AND METABOLISM IN RAT-CEREBRAL-CORTEX TISSUE
002754 03-03
POTENTIATION OF APOMORPHINE AND D-AMPHETAMINE EFFECTS BY
NALOXONE. ^ ^,
002942 03-041
S-122
VOLUME 19, SUBJECT INDEX
Subject Index
TOLERANCE TO THE DISCRIMINATIVE- STIMULUS PROPERTIES OF D-
AMPHETAMINE.
002953 03-04
INTERACTION AMONG D-AMPHETAMINE, SCOPOLAMINE AND GENOTYPE
IN AVOIDANCE-BEHAVIOR OF RATS.
003082 03-04
EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING
SUPPRESSED BY CONDITIONED PUNISHMENT.
003105 03-04
THE HYPERACTIVE-CHILD-SYNDROME: PERIPHERAL SYMPATHETIC-
NERVOUS-SYSTEM FUNCTION AND THE EFFECT OF D-AMPHETAMINE.
003340 03-1 1
DRUG PREFERENCE AND MOOD IN HUMANS; REPEATED ASSESSMENT OF
D-AMPHETAMINE.
003445 03-14
MYOINOSITOL TURNOVER IN THE INTACT RAT-BRAIN: INCREASED
PRODUCTION AFTER D-AMPHETAMINE.
003723 04-03
THE BEHAVIORAL-EFFECTS OF D-AMPHETAMINE ALONE AND IN
COMBINATION WITH ACUTE AND CHRONIC MORPHINE TREATMENTS IN
RATS.
003915 04-03
THE INFLUENCE OF D-AMPHETAMINE ON RAT-BRAIN STRIATAL REDUCED
BIOPTERIN CONCENTRATION.
003922 04-03
APPARENT SEROTONERGIC MODULATION OF THE DOSE-DEPENDENT
BIPHASIC RESPONSE OF NEOSTRIATAL NEURONS PRODUCED BY D-
AMPHET AMINE.
003981 04-03
KINETIC STUDIES ON THE ENTRY OF D-AMPHETAMINE INTO THE
CENTRAL-NERVOUS-SYSTEM: I. CEREBROSPINAL-FLUID.
004005 04-03
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION
AND EFFECTS OF D-AMPHETAMINE AND PROMAZINE.
004152 04-04
SEX, PLASMA PROLACTIN AND PLASMA 3 METHOXY-4-
HYDROXYPHENYLGLYCOL (MHPG) PREDICT HERITABLE D-
AMPHETAMINE EXCITATION IN MAN. (UNPUBLISHED PAPER).
004565 04-14
D-AMPHETAMINE-INDUCED
EFFECTS OF PHENCYCLIDINE AND METHYLPHENIDATE ON D-
AMPHETAMINE-INDUCED BRHAVIORS IN RESERPINE PRETREATED RATS.
001616 02-04
DISSOCIATION OF D-AMPHETAMINE-INDUCED LOCOMOTOR-ACTIVITY AND
STEREOTYPED-BEHAVIOUR BY LESIONS OF THE SUPERIOR-COLLICULUS.
001755 02-04
CONDITIONED DRUG-EFFECTS OF D-AMPHETAMINE-INDUCED AND
MORPHINE-INDUCED MOTOR ACCELERATION IN MICE: EXPERIMENTAL
APPROACH FOR PLACEBO-EFFEQ.
004128 04-04
0- AMPHETAMINES
CATS DEVELOP TOLERANCE TO D-AMPHET AMINES EFFECTS UPON
LOCOMOTION AND STEREOTYPED-BEHAVIORS.
003018 03-04
D-ISOMERS
COMPARATIVE-STUDIES OF THE PHARMACOLOGICAL-EFFEaS OF THE D-
ISOMERS AND L-ISOMERS OF CODEINE.
004084 04-04
D-1
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL
TISSUE BY ASCORBATE.
003876 04-03
D-2
THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE.
002900 03-03
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL
TISSUE BY ASCORBATE.
003876 04-03
THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE.
002900 03-03
D-4
THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE.
002900 03-03
DAILY
REPEATED TRICYCLICS INDUCE A PROGRESSIVE DOPAMINE-
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT OF DAILY DRUG-
TREATMENT.
000047 01-03
CORRELATION BETWEEN DAILY FLUCTUATIONS OF CARBAMAZEPINE
SERUM LEVELS AND INTERMIHENT SIDE-EFFECTS.
000851 01-15
LOG-DOSE/RESPONSE-CURVE FLAHENING IN RATS AFTER DAILY
INJECTION OF OPIATES.
001387 02-03
D-3
THE INFLUENCE OF DAILY BIOLOGICAL-RHYTHMICITY ON THE HOMING-
BEHAVIOR, PSYCHOPHARMACOLOGICAL RESPONSIVENESS, LEARNING
AND RETENTION OF SUCKLING RATS (PH D DISSERTATION)
001660 02-04
THE INFLUENCE OF SINGLE DAILY HEROIN INJECTIONS ON DRINKING-
PATTERNS IN THE RAT.
001746 02-04
CORRELATION BETWEEN DAILY DOSAGE OF CHLORPROMAZINE AND
SUBSEQUENT SUPERSENSITIVITY.
001845 02-05
FIRST CLINICAL IMPRESSIONS IN DAILY PRACTICE.
002046 02-09
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY?
002659 03-03
CORRELATION BETWEEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC-
DRUGS IN RATS AND DAILY CLINICAL DOSES.
003032 03-04
DAMAGE
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL
DAMAGE.
000322 01-03
FACILITATION OF RECOVERY BY PROPANTHELINE-BROMIDE AFTER
LATERAL HYPOTHALAMIC DAMAGE,
000396 01-04
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR
DORSOLATERAL TEGMENTAL DAMAGE.
001818 02-04
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF
METHAMPHET AMINE.
002812 03-03
BEHAVIORAL-CHANGES AND BIOCHEMICAL-CHANGES AFTER
HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION).
003069 03-04
ON THE QUESTION OF PARENCHYMAL DAMAGE CAUSED BY LONG-TERM
THERAPY WITH PSYCHOTROPICS IN ADOLESCENCE.
004626 04-15
DAMS
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS IN THE OFFSPRING
OF DAMS RECEIVING DIAZEPAM: ONTOGENETIC- STUDIES.
001849 02-05
DANGER
ON THE DANGER OF USING PSYCHOPHARMACEUTICALS DURING
PREGNANCY: CRITICAL REVIEW OF THE LITERATURE.
000833 01-15
DANGEROUS
DIURETICS ARE DANGEROUS WITH LITHIUM.
002420 02-15
RECENT DEVELOPMENTS IN LITHIUM TREATMENT: IS IT DANGEROUS FOR
THE KIDNEY?
002465 02-15
DANITRACEN
INTERACTION OF P CHLOROPHENYLALANINE, MIANSERINE AND
DANITRACEN WITH AMPHETAMINE.
004599 04-15
DARK
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO.
004544 04-13
DATA
PRELIMINARY DATA ON ETHOSUXIMIDE AND THE EPISODIC-DYSCONTROL-
SYNDROME.
000539 01-07
ADVANTAGE OF PHARMACOKINETIC DATA DURING TREATMENT OF
PSYCHOSES WITH HALOPERIDOL.
000577 01-08
PREDICTION OF THE VOLUME OF DISTRIBUTION FROM IN VITRO DATA
AND USE FOR ESTIMATING THE ABSOLUTE EXTENT OF ABSORPTION.
000907 01-16
SOME PHARMACOLOGICAL-ASPECTS AND BIOCHEMICAL-ASPECTS OF
TRH: EXPERIMENTAL AND CLINICAL DATA.
001189 02-03
NEW DATA ON THE USE OF ANTIDEPRESSANT-DRUGS.
001195 02-03
ATROPINE AND NATURAL SLEEP: ACTIVITY DATA OF THE STRIATUM IN
RATS.
001551 02-03
ACUTE AND CHRONIC LSD EFFECTS ON RAT STARTLE: DATA SUPPORTING
AN LSD RAT MODEL OF SCHIZOPHRENIA.
002194 02-12
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRUG
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA.
002225 02-13
I
lai.
S-123
Subject Index
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES.
002879 03-03
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES
IN THIS PHASE.
003251 03-09
USE OF CURRENTLY AVAILABLE DATA SOURCES TO ASSESS DRUG
SCHEDULING.
003594 03-17
PRACTICAL IMPLICATIONS OF MODERN PSYCHOPHARMACOLOGICAL
DATA
003596 03-17
SINGLE-DOSE PHARMACOKINETIC DATA ON ZIMELIDINE IN DEPRESSED-
PATIENTS.
004385 04-09
THE USE OF CLINICAL KINETIC DATA IN TREATMENT WITH
ANTIDEPRESSANT-DRUGS.
004686 04-16
DATES
EFFECTS OF FETAL TREATMENT WITH METHYUVZOXYMETHANOL-ACETATE
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE
ADULT NEOCORTEX OF THE RAT
002770 03-03
DAY-HOSPITAL
PSYCHIATRIC-DRUG-STUDY. PART II. MENTAL-HYGIENE-CLINIC SURVEY,
DAY-TREATMENT-CENTER SURVEY, DAY-HOSPITAL SURVEY.
004716 04-17
DAY-TREATMENT-CENTER
PSYCHIATRIC-DRUG-STUDY. PART II. MENTAL-HYGIENE-CLINIC SURVEY,
DAY-TREATMENT-CENTER SURVEY, DAY-HOSPITAL SURVEY
004716 04-17
DAYTIME
THE DIFFERENTIAL-EFFECTS OF SHORT-ACTING AND LONG-ACTING
BENZODIAZEPINES UPON NOCTURNAL SLEEP AND DAYTIME
PERFORMANCE.
000822 01-14
INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS.
002341 02-14
DAYTIME EFFECTS OF L TRYPTOPHAN.
003455 03-14
DDT
A POSSIBLE NEUROCHEMICAL BASIS OF THE CENTRAL STIMULATORY
EFFECTS OF PP'DDT
004274 04-05
DEACYLATION
PHYSIOLOGIC AND PHARMACOLOGIC IMPLICATIONS IN THE
DEACYLATION OF PHOSPHATIDYLSERINE IN MICE.
002682 03-03
DEAE
DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL- SYNDROME.
004472 04-1 1
DEAFNESS
A CASE OF REVERSIBLE PURE-WORD DEAFNESS DURING LITHIUM
TOXICITY.
003481 03-15
DEALING
EXPERIMENTATION WITH MINAPRINE IN DEALING WITH CERTAIN
SEXUAL-DISORDERS: IMPOTENCE OR FRIGIDITY.
002153 02-11
DEAMINATION
SPECIES-DIFFERENCES IN THE DEAMINATION OF DOPAMINE AND OTHER
SUBSTRATES FOR MONOAMINE-OXIDASE IN BRAIN.
002233 02-13
DEANOL
DIMETHYLAMINOETHANOL (DEANOL) METABOLISM IN RAT-BRAIN AND
ITS EFFECT ON ACETYLCHOLINE SYNTHESIS.
000150 01-03
ON THE THERAPY OF NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA WITH
DIMETHYLAMINOETHANOL (DEANOL).
004627 04-15
GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC
ANALYSES FOR DEANOL, CHOLINE. AND THEIR ACETYLESTERS.
004683 04-16
DEATH
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL
CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN
PSYCHEDELIC-EXPERIENCES.
002200 02-12
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST
SUDDEN CARDIAC DEATH FROM COCAINE.
003122 03-05
EXCEPTIONAL CASES OF DEATH CAUSED BY TRICYCLIC-ANTIDEPRESSANT
AGENTS.
003490 03-15
Ptychopharmacology Abstracts
THE EFFEQ OF ADENOSINE AND GUANOSINE ON THE CONTENT OF
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH.
003882 04-03
DEATHS
MEDICATION USE AND DEATHS AHRIBUTED TO ASPHYXIA AMONG
PSYCHIATRIC-PATIENTS.
000838 01-15
DEAZAADENOSINE
ANTIVIRAL ACTIVITY OF 3 DEAZAADENOSINE AND 5'
DEOXYISOBUTYLTHIO-3-DEAZAADENOSINE (3 DEAZA-SIBA).
(UNPUBLISHED PAPER).
001006 02-01
THE HYPOTENSIVE-ACTION OF 3 DEAZAADENOSINE.
001415 02-03
DEAZAADENOSYLHOMOCYSTEINE
INHIBITION OF CHEMOTAXIS BY S 3 DEAZAADENOSYLHOMOCYSTEINE IN
A MOUSE MACROPHAGE CELL LINE. (UNPUBLISHED PAPER).
001100 02-03
DEBATE
DEBATE: THERAPEUTIC TRIALS IN A NATURAL ENVIRONMENT.
003635 03-17
DEBRISOQUINE
NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN RELATION TO
DEBRISOQUINE HYDROXYLATION IN MAN.
000754 01-13
DEBRUMYL
CEREBRAL SENESCENCE AND ITS PSYCHIC-MANIFESTATIONS. THE
EFFECTIVENESS OF DEBRUMYL.
002105 02-11
DECARBOXYLASE
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE).
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION.
000712 01-11
DECARBOXYLATION
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES
000202 01-03
DECEPTION
MEPROBAMATE REDUCES ACCURACY OF PHYSIOLOGICAL DETEQION OF
DECEPTION.
004585 04-14,
DECISIONS
AN ANALYSIS OF DRUG DECISIONS IN A STATE PSYCHIATRIC-HOSPITAL.
003593 03-17
DECOMPOSITION
DECOMPOSITION OF PHARMACOLOGICAL AQIVITY INDICES INTO
MUTUALLY INDEPENDENT COMPONENTS USING PRINCIPAL
COMPONENT ANALYSIS.
001039 02-01 ■
DECONDITIONING
CLASSICAL NEUROLEPTICS AND DECONDITIONING AQIVITY AFTER SINGLE.
OR REPEATED TREATMENTS: ROLE OF DIFFERENT CEREBRAL
NEUROTRANSMIHERS
004115 04-04
DECORTICATION
INTERMIHENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA,
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE
lOTHALAMATE VENTRICULOGRAM.
003520 03-15
DECREASING
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
MEASUREMENTS OF NERVE CONDUQION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF |
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT.
004441 04-11
DEEPER *
THE STEREOSPECIFIC EFFEQ OF NALOXONE ON RAT DORSAL-HORN
NEURONES, INHIBITION IN SUPERFICIAL LAMINAE AND EXCITATION IN
DEEPER LAMINAE
001226 02-03
DEERMICE
DIFFERENCES IN AQIVITY IN CEREBRAL METHYLTRANSFERASES AND
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE
AND RESISTANT MICE AND DEERMICE
000377 01-04
DEFENSE
THE INFLUENCE OF NOOTROPIC-DRUGS ON LEARNING AND MEMORY OF
DEFENSE REAQIONS.
00081501-14
S-124
\
::^y.
VOLUME 19, SUBJECT INDEX
Subject Index
DEFENSIVE
CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNCTION
OF ELAVIL AND THORAZINE INJECTION
002974 03-04
DEFENSIVE-BEHAVIOR
ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN
THE CAT.
001761 02-04
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR.
002945 03-04
DEFICIENCY
DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES.
000584 01-09
THE ROLE OF FOLATE DEFICIENCY IN THE DEVELOPMENT OF PERIPHERAL
NEUROPATHY CAUSED BY ANTICONVULSANTS.
002402 02-15
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE
HYPERACTIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN
DEFICIENCY HYPOTHESIS.
003312 03-11
DEFICIENT
A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDICTS DURING
WITHDRAWAL.
004445 04-1 1
DEFICIT-DISORDER
AHENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNCTION) IN
ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG-
TREATMENT.
003389 03-1 1
DEFICITS
LATERALIZED DEFICITS AND DRUG INFLUENCES ON THE DICHOTIC
LISTENING OF SCHIZOPHRENIC-PATIENTS.
003443 03-14
DEFINITION
OPIATE-RECEPTORS: PROBLEMS OF DEFINITION AND CHARACTERIZATION.
002620 02-17
DEFORMING
PROBLEMS OF TREATING DEFORMING MYODYSTONIA WITH L-DOPA,
AND PREDICTION OF ITS THERAPEUTIC EFFECT.
004536 04-13
DEGENERATION
LOCAL AND DISTANT NEURONAL DEGENERATION FOLLOWING
INTRASTRIATAL INJEQION OF KAINIC-ACID.
001885 02-06
SPINOCEREBELLAR DEGENERATION WITH PARKINSONIAN FEATURES: A
CLINICAL AND PATHOLOGICAL REPORT.
003436 03-13
DEGRADATION
MODIFICATION OF THE PROLINE RESIDUE OF TRH ENHANCES BIOLOGICAL-
AQIVITY AND INHIBITS DEGRADATION.
000351 01-04
AN INHIBITOR OF OPIOID-PEPTIDE DEGRADATION PRODUCES ANALGESIA
IN MICE.
001780 02-04
EFFEaS OF BRANCHED-CHAIN FAHY-ACIOS ON GABA DEGRADATION
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI-
MORPHINE ABSTINENCE-BEHAVIOR.
001809 02-04
THE EFFECT OF BARBITURATES ON THE DEGRADATION OF ENKEPHALIN BY
BRAIN ENZYMES.
002656 03-03
DEINSTITUTIONALIZATION
A TWELVE-YEAR FOLLOWUP OF THE NIMH-PRB HIGH-DOSE
CHLORPROMAZINE STUDY OF CHRONIC SCHIZOPHRENICS -
IMPLICATIONS FOR DEINSTITUTIONALIZATION. (UNPUBLISHED PAPER)
004323 04-08
DELANGE-SYNDROME
PEMOLINE-INDUCED SELF-BITING IN RATS AND SELF-MUTILATION IN THE
DELANGE-SYNDROME.
001727 02-04
DELAYED
DELAYED CLEARANCE OF DIAZEPAM DUE TO CIMETIDINE.
000164 01-03
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED
DIFFERENTIATION) IN THE MONKEY (MACACA-MULAHA).
000440 01-04
AROUSAL AND SHORT-TERM MEMORY: EFFECTS OF CAFFEINE AND TRIAL
SPACING ON DELAYED ALTERNATION PERFORMANCE.
000487 01-04
DELAYED MAZE-LEARNING IN RATS AFTER PRENATAL EXPOSURE TO
CLORAZEPATE.
000521 01-05
EFFECTS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A
DELAYED TYPE HYPERSENSITIVITY REACTION TO 1
CHLORODINITROBENZENE IN MICE.
001473 02-03
THE EFFECT OF PHRENOLON ON DELAYED REACTIONS IN LOWER
MONKEYS.
001640 02-04
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE IN MENTALLY-RETARDED
ADULTS,
002471 02-15
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DEUYED
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED
ADULTS.
003392 03-1 1
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOLLUSCAN
NEURONS.
003834 04-03
THE EFFECT OF THIOPROPERAZINE ON DELAYED REACTIONS IN LOWER
MONKEYS.
004125 04-04
DELIMITED
PSYCHIATRIC-ILLNESS AND USE OF PSYCHOTROPIC-DRUGS IN THE
GEOGRAPHICALLY DELIMITED POPULATION OF SAMSO, DENMARK.
004734 04-17
DELIRIUM
DELIRIUM: TREATMENT POSSIBILITIES.
002141 02-11
DELIRIUM OR PSYCHOSIS? DIAGNOSTIC USE OF THE SODIUM-
AMOBARBITAL INTERVIEW.
002167 02-11
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL
CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN
PSYCHEDELIC-EXPERIENCES.
002200 02-12
DIFFERENTIAL DIAGNOSIS OF CIMETIDINE-INDUCED DELIRIUM.
003488 03-15
DELIRIUM SECONDARY TO CLONIDINE THERAPY.
003494 03-15
DELIRIUM-TREMENS
FLUNITRAZEPAM IN THE TREATMENT OF DELIRIUM-TREMENS -
PRELIMINARY REPORT.
000719 01-11
PHYSOSTIGMINE FOR TREATMENT OF DELIRIUM-TREMENS.
003364 03-11
A COMPARATIVE EVALUATION OF THE EFFICACY OF SOME THERAPEUTIC
METHODS USED IN DELIRIUM-TREMENS.
004486 04-11
DELIVERY
AVAILABILITY OF ISOSORBIDE-DINITRATE, DIAZEPAM AND
CHLORMETHIAZOLE, FROM I.V. DELIVERY SYSTEMS.
003558 03-16
DELTA-FORMS
INTERCONVERTING MU AND DELTA-FORMS OF TYPE-1 OPIATE-RECEPTORS
IN THE RAT STRIATAL PATCHES.
003737 04-03
DELTA-RECEPTOR
METKEPHAMID, A SYSTEMICALLY ACTIVE ANALOG OF METHIONINE-
ENKEPHALIN WITH POTENT OPIOID DELTA-RECEPTOR ACTIVITY.
002720 03-03
DELTA-RECEPTORS
EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERACTIONS WITH MU-
RECEPTORS AND DELTA-RECEPTORS.
000168 01-03
DELUSIONAL
THREE CASES OF UNIPOLAR DELUSIONAL DEPRESSION RESPONSIVE TO L-
DOPA.
000628 01-09
DELUSIONAL-STATES
HALLUCINATORY AND DELUSIONAL-STATES IN CONNECTION WITH BLOOD-
PRESSURE AND EEG.
000814 01-14
DELUSIONS
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL
CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN
PSYCHEDELIC-EXPERIENCES.
002200 02-12
DEMENTIA
AGE, DEMENTIA, DYSKINESIAS, AND LITHIUM RESPONSE.
000594 01-09
NEUROLOGICAL-STUDY AND NEUROPSYCHOPHARMACOLOGY-STUDY ON
DEMENTIA.
001090 02-11
DRUG-INDUCED DEMENTIA.
002431 02-15
PHARMACOLOGIC AND THERAPEUTIC-PERSPECTIVES ON DEMENTIA: AN
EXPERIMENTAL APPROACH
003065 03-04
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY
STUDY.
003085 03-04
I
•at
Hi-
*t!lMi>i
A
tin-.,
IL'Li"
S-125
Subiect Index
PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND
DEMENTIA. „„^o.-,^o,,
003347 03-11
USE OF THA IN TREATMENT OF ALZHEIMER-LIKE DEMENTIA: PILOT-STUDY
IN TWELVE PATIENTS. „„oo-,-, «o , ,
003377 03-11
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION. ^ ^
003419 03-13
EXTRAPYRAMIDAL-DISORDERS AND BORDERLINE-SYNDROMES.
EREDOATAXIAS AND DEMENTIA. 003518 03-15
EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED
COGNITIVE ASSESSMENT SYSTEM. 003557 03-16
SINGLE-CASE STUDY OF CLINICAL-RESPONSE TO HIGH-DOSE ERGOT
ALKALOID TREATMENT FOR DEMENTIA. PRELIMINARY REPORT.
004493 04-11
CHOLINE-BITARTRATE TREATMENT OF ALZHEIMER-TYPE DEMENTIAS.
000675 01-11
PLASMA IMIPRAMINE LEVELS AND DEMETHYLASE ACTIVITY IN THE
LIVER OF STRESSED ANIMALS. „„„,„, „„ „,
002793 03-03
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM)
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND
DINORLAAM DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT.
000505 01-04
CHANGES IN BRAIN N DEMETHYUVTION AND OPIATE-RECEPTOR CONTENT
CORRELATE WITH ANALGESIC EFFECTIVENESS OF MORPHINE
000400 01-04
INTERINDIVIDUAL DIFFERENCES IN AMITRIPTYLINE DEMETHYLATION.
002282 02-13
DEMETHYLCHLORIMIPRAMINE
TECHNIQUES FOR PLASMA PROTEIN BINDING OF
DEMETHYLCHLORIMIPRAMINE. ^„„, „, ,,
000897 01-16
DEMETRIN
THE TRANQUILIZER DEMETRIN (PRAZEPAM).
003331 03-11
DEMONSTRATION
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
001024 02-01
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
^'^^'^- 001234 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM
BOVINE CEREBRAL-CORTEX.
002645 03-01
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
^™^^°^ 003725 04-03
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP-
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF
MOUSE NEUROBLASTOMA CELLS USING
(3H)TETRAPHENYLPH0SPH0NIUM.
004049 04-03
BUPRENORPHINE: DEMONSTRATION OF PHYSICAL-DEPENDENCE LIABILITY.
004104 04-04
DEMYELINATION
THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION
PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR
PRESERVED SCHWANN-CELL SOMAL FUNCTION.
002905 03-03
DENDRITIC
EFFECTS OF LEAD EXPOSURE DURING DEVELOPMENT ON NEOCORTICAL
DENDRITIC AND SYNAPTIC STRUCTURE.
000525 01-05
ELECTRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFECTS OF
HIGH-FREQUENCY STIMULATION ON DENDRITIC ULTRASTRUCTURE.
(UNPUBLISHED PAPER). „„,„^, „o ^,
001036 02-01
Psychopharmacology Abstracts
DENDROASPIS
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND
GANGLIONIC SYNAPSES
002870 03-03
DENERVATED
REINNERVATION OF THE DENERVATED STRIATUM BY SUBSTANTIA-NIGRA
TRANSPLANTS: FUNCTIONAL CONSEQUENCES AS REVEALED BY
PHARMACOLOGICAL AND SENSORIMOTOR TESTING.
000347 01-04
DENERVATION
MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS:
MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN
000068 01-03
CHRONIC SYMPATHETIC DENERVATION INCREASES MUSCARINIC-
CHOLINOCEPTOR BINDING IN THE RAT SUBMAXILLARY-GLAND.
000235 01-03
IN VIVO EFFEQ OF PROTEASE INHIBITORS IN DENERVATION ATROPHY.
000290 01-03
THE MESOLIMBIC SYSTEM, DENERVATION AND THE CLIMBING RESPONSE
IN THE MOUSE
000370 01-04
RELATIONSHIPS BETWEEN SELEQIVE DENERVATION OF DOPAMINE
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL-
RESPONSES TO AMPHETAMINE AND APOMORPHINE.
000384 01-04
DENERVATION SUPERSENSITIVITY TO SEROTONIN IN THE FACIAL
NUCLEUS.
001364 02-03
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN
'^'" 001435 02-03
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM:
FUNCTIONAL CHANGES FOLLOWED USING (-)N N
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL AQIVITY LEVELS
OF RATS. „„,
001603 02-04
DENERVATION SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN RATS
FOLLOWING SPINAL TRANSECTION AND 5,7 DIHYDROXYTRYPTAMINE
"^^^™ 003722 04-03
DENERVATION-INDUCED
REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY
NORADRENALINE INFUSION.
002672 03-03 i
DENMARK , , ,^
PSYCHIATRIC-ILLNESS AND USE OF PSYCHOTROPIC-DRUGS IN THE
GEOGRAPHICALLY DELIMITED POPULATION OF SAMSO, DENMARK.
004734 04-17
DENSE-BODIES
PREPARATION AND CHARACTERIZATION OF SYNTHETIC MODELS FOR THE
DENSE-BODIES OF HUMAN PLATELETS (UNPUBLISHED PAPER) j
001013 02-01 I
ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED
''^''^'^' 001014 02-01.
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT-
CEREBRAL-CORTEX. 000072 01^
DECREASED BENZODIAZEPINE-RECEPTOR DENSITY IN RAT-CEREBELLUM
FOLLOWING NEUROTOXIC DOSES OF PHENYTOIN qq, 373 02-03
DEOXY-D-GLUCOSE
METABOLIC-CORRELATES OF THE EFFEQS OF 2 DEOXY-D-GLUCOSE ON
MEAL SIZE AND POST MEAL SATIETY IN RATS. ^^^^^ ^^^
ANALGESIA FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF 2
DEOXY-D-GLUCOSE. 004074 04-04
DEOXY-D-GLUCOSE-INDUCED
ANTAGONISM OF 2 DEOXY-D-GLUCOSE-INDUCED HYPERPHAGIA BY
NALOXONE: POSSIBLE INVOLVEMENT OF ENDORPHINS. ^^^^ ^^^
DEOXYCORTICOSTERONE
RENAL BENZODIAZEPINE BINDING INCREASES DURING
DEOXYCORTICOSTERONE /SALT HYPERTENSION IN RATS.
001430 02-03
S-126
VOLUME 19, SUBJECT INDEX
Subject Index
lEOXYOLUCOSE
THEORY, PROCEDURE, AND APPLICATIONS OF THE RADIOACTIVE
DEOXYGLUCOSE METHOD FOR THE MEASUREMENT Of LOCAL GLUCOSE
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM. (UNPUBLISHED
PAPER).
001877 02-06
)EOXYISOBUTYLTHIO-3-DEAZAADENOSINE
ANTIVIRAL ACTIVITY OF 3 DEAZAADENOSINE AND 5'
OEOXYISOBUTYLTHIO-3-DEAZAADENOSINE (3 DEAZA-SIBA).
(UNPUBLISHED PAPER).
001006 02-01
>EOXYPIPRA0ROL
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
>EPAKINE
PRELIMINARY EVALUATION OF THE EFFECTS OF DEPAKINE IN EPILEPSY.
000664 01-11
lEPENDENCE
CHANGES IN PLASMA CORTICOSTERONE LEVELS AS A MEASURE OF
ACUTE DEPENDENCE UPON LEVORPHANOL IN RATS.
000085 01-03
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
DEPENDENCE OF THE AVFAIL EFFECT ON THE SEQUENCE OF TRAINING
OPERATIONS.
001086 02-02
DEVELOPMENT OF ACUTE OPIOID-TOLERANCE AND DEPENDENCE IN RAT
STRIATAL NEURONES.
001235 02-03
THE EFFECT OF NALOXONE ON THE ACTIVATION OF EMOTIONALLY
POSITIVE REACTION PRODUCED BY DRUGS WITH A DEPENDENCE
LIABILITY.
001556 02-03
PENTYLENETETRAZOL SEIZURE THRESHOLD: A QUANTITATIVE MEASURE
OF ETHANOL DEPENDENCE IN RATS.
001750 02-04
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE
DEVELOPMENT OF DEPENDENCE IN RATS.
001800 02-04
SELF-MEDICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS.
002189 02-11
TREATMENT OF IATROGENIC DRUG DEPENDENCE IN THE GENERAL-
HOSPITAL.
002460 02-15
DEPENDENCE ON BENZODIAZEPINES.
002464 02-15
DEPENDENCE ON TRANQUILIZERS (AN OVERVIEW WITH (CASE-STUDIES).
003580 03-17
DRUG DEPENDENCE: REFLECTIONS ON AND ANALYSIS OF AN EXPERIENCE
IN THE PROVINCE OF RIGGIO-EMILIA.
003591 03-17
A REFORMULATION OF THE DUAL-ACTION MODEL OF OPIOID
DEPENDENCE: OPIOID-SPECIFIC NEURONAL KINDLING.
003645 03-17
COMPARATIVE ANALGESIC, BEHAVIORAL, AND DEPENDENCE PROPERTIES
OF MORPHINE AND 0
METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME
HCL.
003707 04-02
GABA-ENHANCEMENT OF (3H)D0PAMINE RELEASE FROM SLICES OF RAT
STRIATUM: DEPENDENCE ON SLICE SIZE.
003786 04-03
CNS EFFECTS OF CHOLINE ADMINISTRATION: EVIDENCE FOR TEMPORAL
DEPENDENCE.
003996 04-03
OPIOID DEPENDENCE: MECHANISMS AND TREATMENT.
004587 04-14
AN UNUSUAL CASE OF THIORIDAZINE AND LEVOMEPROMAZINE
DEPENDENCE.
004634 04-15
lEPENDENCY
DRUG ENVIRONMENT INTERACTION: CONTEXT DEPENDENCY OF COCAINE-
INDUCED BEHAVIORAL-SENSITIZATION .
002866 03-03
A NOTE ON THE PARADOXICAL-EFFECT OF STIMULANTS ON
HYPERACTIVITY WITH REFERENCE TO THE RATE DEPENDENCY EFFECT
OF DRUGS.
003320 03-11
lEPENDENT
THE EFFECT OF PROPRANOLOL ON THE ELEaROENCEPHALOGRAM IN
NORMAL AND ETHANOL DEPENDENT RATS.
000126 01-03
STRAIN DEPENDENT EFFECTS OF KETAMINE ON LOCOMOTOR-ACTIVITY
AND ANTINOCICEPTION IN MICE.
000382 01-04
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM)
AND ITS N DEMETHYUVTED METABOLITES, NORLAAM AND
DINORLAAM, DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT.
000505 01-04
OPIOID DEPENDENT DUAL-REGULATION OF ADENYLATE-CYCLASE IN A
CELL-FREE SYSTEM (UNPUBLISHED PAPER).
001033 02-01
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
BRAIN.
001234 02-03
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF
DISCRETE RAT-BRAIN NUCLEI.
002635 03-01
NEURONAL MATURATION IN MAMMALIAN CELL-CULTURE IS DEPENDENT
ON SPONTANEOUS ELECTRICAL-ACTIVITY.
002669 03-03
THE RELATIONSHIP BETWEEN THE ACUTE BEHAVIORAL-EFFECTS OF
NARCOTIC ANTAGONISTS AND THE NARCOTIC DEPENDENT STATE.
003106 03-04
THE EFFECT OF SODIUM-DIPROPYLACETATE ON GAMMA AMINOBUTYRIC-
ACID DEPENDENT INHIBITION IN THE RAT-CORTEX AND SUBSTANTIA-
NIGRA IN RELATION TO ITS ANTICONVULSANT ACTIVITY.
003880 04-03
SCHEDULE DEPENDENT CHANGE OF PUNISHED-RESPONDING AFTER
DIAZEPAM IN RATS.
004165 04-04
EFFECTS OF NARCOTIC ABSTINENCE ON SCHEDULE-CONTROLLED
BEHAVIOR IN DEPENDENT RATS.
004230 04-04
DEPENDING
TWO OR MORE CONFORMATIONS OF BENZODIAZEPINE-RECEPTORS
DEPENDING ON GABA-RECEPTORS AND OTHER VARIABLES.
001139 02-03
DEPENDS
INVOLVEMENT OF DOPAMINE IN CIRCLING RESPONSES TO MUSCIMOL
DEPENDS ON INTRANIGRAL SITE OF INJECTION.
004158 04-04
DEPLETED
COMPARISON OF HIGHLY-ACTIVE AND ACTIVITY DEPLETED HEPARIN BY
CIRCULAR DICHROISM SPECTROSCOPY. (UNPUBLISHED PAPER).
001057 02-01
DEPLETES
INTRANIGRAL INJECTION OF CAPSAICIN ENHANCES MOTOR-ACTIVITY
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE BUT NOT SUBSTANCE-
P.
004100 04-04
DEPLETING
INFLUENCE OF MONOAMINE DEPLETING PHARMACOLOGIC-AGENTS ON
LEVELS OF ACTIVITY IN CAIMAN-SCLEROPS.
001810 02-04
DEPLETION
DEPLETION OF EPINEPHRINE IN RAT HYPOTHALAMUS BY RO-4-1284:
INFLUENCE OF PARGYLINE AND HARMALINE.
000100 01-03
THE CONVERSION OF (3H)TRYPT0PHAN TO 5 (3H)HYDR0XYTRYPTAMINE
IN MOUSE-BRAIN FOLLOWING DEPLETION OF PHENYLALANINE AND
TYROSINE.
000148 01-03
EFFECTS OF BRAIN-MONOAMINE DEPLETION ON THERMOREGULATORY
RESPONSES OF RABBITS TO DIFFERENT HYPOTHALAMIC
TEMPERATURES.
000190 01-03
GABA DEPLETION AND BEHAVIOURAL-CHANGES PRODUCED BY
INTRAVENTRICULAR PUTRESCINE IN CHICKS.
000218 01-03
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL ACTIVITY.
000314 01-03
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY: NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNCTION.
000448 01-04
THE EFFECT OF SEROTONIN DEPLETION ON THE DISCRIMINABILITY OF LSD.
000499 01-04
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE.
002242 02-13
DOPAMINE DEPLETION SLOWS RETINAL TRANSMISSION.
002708 03-03
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR
INJECTION OF CEFAZOLIN.
002762 03-03
.11
•IS'
iic
«B;.
Ac
S-127
Subject Index
NOREPINEPHRINE DEPLETION ALTERS CEREBRAL OXIDATIVE METABOLISM
IN THE ACTIVE STATE.
002798 03-03
SUBSTANCE-P, HEXAPEPTIDE-PGLU6(SP6-1 1), ANALGESIA AND
SEROTONIN DEPLETION . ^^^^^^ ^^ „ _
003050 03-04
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE
BUT NOT LITHIUM-CHLORIDE.
003110 03-04
EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON TETRABENAZINE-INDUCED
DEPLETION OF BRAIN MONOAMINES IN RATS. 1. NOREPINEPHRINE.
004062 04-03
DEPOLARIZATION
CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC-
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE
(GABA-TRANSAMINASE) INHIBITOR.
000174 01-03
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT.
001104 02-03
DEPOLARIZATION-INDUCED
EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE
RELEASE. „„„„,-, „, „o
000067 01-03
EFFECTS OF CHLORDIAZEPOXIDE ON DEPOLARIZATION-INDUCED CALCIUM
INFLUX INTO SYNAPTOSOMES.
000183 01-03
THE EFFECTS OF A BENZODIAZEPINE ON THE HYPERPOLARIZING AND THE
DEPOLARIZING RESPONSES OF HIPPOCAMPAL CELLS TO GABA.
002763 03-03
DEPOLARiZING-AGENTS
EPINEPHRINE IS RELEASED FROM HYPOTHALAMUS BY DEPOLARIZING-
AGENTS AND AMPHETAMINE.
001155 02-03
RELATIVE ACTIVITIES OF SUBSTANCES RELATED TO 5
HYOROXYTRYPTAMINE AS DEPOLARIZING-AGENTS OF SUPERIOR
CERVICAL GANGLION CELLS.
004047 04-03
DEPOT
PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPED-PATIENTS: A
PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED.
000668 01-11
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY.
000890 01-15
DISCONTINUATION OF ORAL AND DEPOT FLUPHENAZINE IN
SCHIZOPHRENIC-PATIENTS AFTER ONE YEAR OF CONTINUOUS
MEDICATION: A CONTROLLED-STUDY.
001931 02-08
PLASMA FLUPHENAZINE LEVELS BY RADIOIMMUNOASSAY IN
SCHIZOPHRENIC-PATIENTS TREATED WITH DEPOT INJECTIONS OF
FLUPHENAZINE-DECANOATE.
002510 02-16
TWELVE YEARS EXPERIENCE WITH THE TOTAL USE OF DEPOT
NEUROLEPTICS IN A DEFINED POPULATION.
002544 02-17
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE.
003172 03-08
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL- STUDIES WITH
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND
DEPOT NEUROLEPTICS.
003183 03-08
A FOLLOWUP STUDY OF SCHIZOPHRENIC-OUTPATIENTS TREATED WITH
DEPOT NEUROLEPTICS.
004342 04-08
DEPOT FLUPHENAZINE MAINTENANCE-TREATMENT AND ASSOCIATED
WEIGHT CHANGES
004635 04-15
RESULTS OF TREATMENT BY MODITEN DEPOT IN OUTPATIENTS-WARDS IN
THE SOUTH MORAVIAN REGION.
004648 04-15
DEPRENIL
ANTIDEPRESSANT POTENTIATION OF 5 HYDROXYTRYPTOPHAN BY L
DEPRENIL IN AFFECTIVE-ILLNESS.
000608 01-09
DEPRENYL
INHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN
CIRCUMVENTRICULAR STRUCTURES OF RAT-BRAIN.
000159 01-03
Psychopharmacology Abstracts
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS.
000171 01-03
BIOCHEMICAL-MEASUREMENTS DURING (-)DEPRENYL TREATMENT OF
PARKINSONISM.
000673 01-11
DEPRENYL IN THE MANAGEMENT OF RESPONSE FLUCTUATIONS IN
PATIENTS WITH PARKINSONS-DISEASE ON LEVODOPA.
002358 02-14
THE EFFECT OF DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, ON SLEEP AND MOOD IN MAN.
002365 02-14
DEPRENYL IN PARKINSON-DISEASE
003309 03-1 1
DEPRENYL DOES NOT CAUSE INSOMNIA IN PARKINSONIAN-PATIENTS.
004569 04-14
IS THE FAILURE OF (-)DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM
THE CHEESE EFFECT?
004640 04-15
DEPRESSANT
CENTRAL DEPRESSANT EFFECTS OF CAERULEIN AND CHOLECYSTOKININ-
OCTAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND
HALOPERIDOL.
002652 03-02
GABA-RECEPTORS AND THE DEPRESSANT ACTION OF PENTOBARBITAL.
002666 03-03
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS.
003027 03-04
1 SUBSTITUTED BENZYLTETRAHYDROPYRIMIDONES: A SERIES WITH
STIMULANT AND DEPRESSANT ACTIVITIES.
003687 04-02
4 AMINOPYRIDINE BLOCKADE OF NEURONAL DEPRESSANT RESPONSES TO
ADENOSINE-TRIPHOSPHATE.
003963 04-03
DEPRESSANTS
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF
12 CNS DEPRESSANTS IN INTAQ AND PITHED RATS.
001855 02-05
THE EFFECTS C' THYROTROPIN-RELEASING-HORMONE ON CYCLtC-AMP
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE
PRESENCE AND ABSENCE OF CNS DEPRESSANTS.
004010 04-03
DEPRESSED
GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT
AFFECTED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN
TREATMENT
001145 02-03
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH
ANTIDEPRESSANTS.
001620 02-04
VILOXAZINE AND THE DEPRESSED SCHIZOPHRENIC - METHODOLOGICAL-
'^^"^^^ 003181 03-08
THE PHARMACOLOGICAL-TREATMENT OF SCHIZOAFFEaiVE-DISORDER
DEPRESSED, A REVIEW OF THE LITERATURE.
003634 03-17
DECREASED 3H IMIPRAMINE BINDING IN DEPRESSED MALES AND
fEMALES. „„ „.„„.«,
004349 04-09
DEPRESSED-CHILD
HYPOMANIC-REACTION TO AMITRIPTYLINE IN A DEPRESSED-CHILD.
002418 02-15
DEPRESSED-INPATIENTS
CLINICAL-RESPONSE, PLASMA LEVELS AND PHARMACOKINETICS OF
DESIPRAMINE IN DEPRESSED-INPATIENTS. ^^ ^
002002 02-09
A DOUBLE-BLIND COMPARISON BETWEEN AMOXAPINE AND
AMITRIPTYLINE IN DEPRESSED-INPATIENTS.
003234 03-09
A DOUBLE-BUND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND
SIDE-EFFEQS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED-
INPATIENTS AND DEPRESSED-OUTPATIENTS. .„. „,^
004395 04-09
DEPRESSED-OUTPATIENTS
A DOUBLE-BUND GROUP COMPARATIVE-TRIAL OF MIANSERIN AND
DIAZEPAM IN DEPRESSED-OUTPATIENTS. „„„.„„ „, ^
000592 01-09
CHRONIC MOOD-DISORDERS IN DEPRESSED-OUTPATIENTS: DIAGNOSIS
AND RESPONSE TO PHARMACOTHERAPY.
000624 0 1 -Or
DEPRESSED-OUTPATIENTS TREATED WITH COGNITIVE-THERAPY OR
PHARMACOTHERAPY: A ONE-YEAR FOLLOWUP.
S-128
VOLUME 19, SUBJECT INDEX
Subject Index
AMOXAPINE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSED-
OUTPATIENTS: A CONTROLLED-STUOY.
003254 03-09
DEPRESSED-OUTPATIENTS; RESULTS ONE YEAR AFTER TREATMENT WITH
DRUGS AND/OR INTERPERSONAL PSYCHOTHERAPY.
003272 03-09
A DOUBLE-BLIND MULTICENTRETRIAL COMPARING THE EFFICACY AND
SIDE-EFFECTS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED-
INPATIENTS AND DEPRESSED-OUTPATIENTS.
004395 04-09
PERSONALITY AS A PREDICTOR OF PSYCHOTHERAPY AND
PHARMACOTHERAPY-OUTCOME FOR DEPRESSED-OUTPATIENTS.
(UNPUBLISHED PAPER).
004418 04-09
DEPRESSED-PATIENT
TREATMENT OF TARDIVE-DYSKINESIA IN AN AGITATED, DEPRESSED-
PATIENT.
002038 02-09
DEPRESSED-PATIENTS
PREDICTION OF STEADY-STATE PLASMA LEVELS OF AMITRIPTYLINE AND
NORTRIPTYLINE FROM A SINGLE-DOSE 24-HR. LEVEL IN DEPRESSED-
PATIENTS.
000582 01-09
URINARY MHPG AND CLINICAL-RESPONSE TO AMITRIPTYLINE IN
DEPRESSED-PATIENTS.
000631 01-09
EFFICACY OF DESIPRAMINE IN ENDOGENOMORPHICALLY DEPRESSED-
PATIENTS.
000632 01-09
CLINICAL-TRIALS WITH RUBIDIUM-CHLORIDE IN DEPRESSED-PATIENTS.
001893 02-07
COMPARISON OF THE EFFECTS OF LOFEPRAMINE AND MIANSERIN IN
DEPRESSED-PATIENTS IN A DOUBLE-BLIND TRIAL.
001996 02-09
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS:
RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BLIND TRIAL.
001998 02-09
TREATMENT OF THERAPY-RESISTANT DEPRESSED-PATIENTS WITH IV.
INFUSIONS OF NOMIFENSINE CONTROLLED BY GALVANIC-SKIN-
RESISTANCE.
002012 02-09
TARDIVE-DYSKINESIA IN DEPRESSED-PATIENTS: SUCCESSFUL THERAPY
WITH ANTIDEPRESSANTS AND LITHIUM.
002037 02-09
CARDIOVASCULAR-EFFECTS OF AMITRIPTYLINE, MIANSERIN AND
ZIMELIDINE IN DEPRESSED-PATIENTS.
002215 02-13
EFFICACY OF DESIPRAMINE IN MILDLY DEPRESSED-PATIENTS: A DOUBLE-
BUND, PLACEBO-CONTROLLED-TRIAL.
003262 03-09
BEHAVIORAL-EFFECTS AND BIOLOGICAL-EFFECTS OF ACUTE BETA
ENDORPHIN INJECTION IN SCHIZOPHRENIC-PATIENTS AND DEPRESSED-
PATIENTS.
003357 03-11
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF
BINDING-SITES IN DEPRESSED-PATIENTS.
003427 03-13
MULTICENTRE- STUDY WITH VILOXAZINE (VIVALAN) IN DEPRESSED-
PATIENTS.
004375 04-09
SINGLE-DOSE PHARMACOKINETIC DATA ON ZIMELIDINE IN DEPRESSED-
PATIENTS.
004385 04-09
TSH, HGH, HPR, AND CORTISOL RESPONSE TO TRH IN DEPRESSED-
PATIENTS.
004399 04-09
DEPRESSION
BLOCKADE OF METHAMPHETAMINE-INDUCED DEPRESSION OF TYROSINE-
HYDROXYLASE BY GABA-TRANSAMINASE INHIBITORS.
000130 01-03
DIAZEPAM POTENTIATION OF PURINERGIC DEPRESSION OF CENTRAL
NEURONS.
000233 01-03
REWARD SYSTEM DEPRESSION FOLLOWING CHRONIC AMPHETAMINE:
ANTAGONISM BY HALOPERIDOL.
000342 01-04
POSTAMPHET AMINE DEPRESSION OF SELF-STIMULATION RESPONDING
FROM THE SUBSTANTIA-NIGRA: REVERSAL BY TRICYCLIC-
ANTIDEPRESSANTS.
000419 01-04
LITHIUM TREATMENT IN POSTPSYCHOTIC DEPRESSION.
000575 01-08
DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES.
000584 01-09
CLINICAL AND LABORATORY DIAGNOSTICS APPLICATIONS IN
DEPRESSION. (UNPUBLISHED PAPER).
000588 01-09
CLINICAL AND BIOCHEMICAL-ACTION OF PIRACETAM (NOOTROPIL) IN
DRUG-RESISTANT DEPRESSION.
000600 01-09
TREATMENT OF DEPRESSION IN THE MEDICALLY-ILL ELDERLY WITH
METHYLPHENIDATE
000602 01-09
PREDICTION OF LOFEPRAMINE RESPONSE IN DEPRESSION BASED ON
RESPONSE TO PARTIAL SLEEP-DEPRIVATION
000617 01-09
THREE CASES OF UNIPOLAR DELUSIONAL DEPRESSION RESPONSIVE TO L-
DOPA.
000628 01-09
SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF
SINGLE VS. DIVIDED DOSE ADMINISTRATION.
000629 01-09
ANTIDEPRESSIVE TREATMENT AND MOOD-SWING-PATTERNS IN
ENDOGENOUS DEPRESSION.
000633 01-09
DECREASED UPTAKE OF 5 HYDROXYTRYPTAMINE IN BLOOD-PLATELETS
FROM PATIENTS WITH ENDOGENOUS DEPRESSION.
000637 01-09
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL
EVOKED-POTENTIALS.
000763 01-13
DEXAMETHASONE-SUPPRESSION-TESTS IN DEPRESSION AND RESPONSE
TO TREATMENT.
000899 01-16
MONOAMINES AND DEPRESSION: AN INTERIM REPORT. I. SEROTONIN
AND SEROTONIN PRECURSORS.
000996 01-17
DEPRESSION IN THE ELDERLY: RESEARCH DIRECTIONS IN
PSYCHOPATHOLOGY, EPIDEMIOLOGY, AND TREATMENT.
000998 01-17
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON
BETV\/EEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT.
001104 02-03
DEPRESSION AND FACILITATION OF SYNAPTIC RESPONSES IN CAT
DORSAL-HORN BY SUBSTANCE-P ADMINISTERED INTO SUBSTANTIA-
GELATINOSA.
001191 02-03
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS- SYSTEM
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION).
001213 02-03
AMINOPHYILINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC-
STUDY.
001410 02-03
BIOCHEMICAL-STUDY OF THE ANIMAL-MODEL DEPRESSION INDUCED BY
TETRABENAZINE.
001506 02-03
EFFECTS OF CHRONIC AMPHETAMINE OR RESERPINE ON SELF-
STIMULATION RESPONDING: ANIMAL-MODEL OF DEPRESSION?
001699 02-04
PRESYNAPTIC AND POSTSYNAPTIC SEROTONERGIC MANIPULATIONS IN
AN ANIMAL-MODEL OF DEPRESSION.
001730 02-04
RESULTS OF A SURVEY ON THE PRESENT TREATMENT OF DEPRESSION IN
SPAIN.
001963 02-09
NOMIFENSINE IN THE TREATMENT OF VARIOUS TYPES OF DEPRESSION.
001968 02-09
DEXAMETHASONE-SUPPRESSION-TEST IDENTIFIES SUBTYPES OF
DEPRESSION WHICH RESPOND TO DIFFERENT ANTIDEPRESSANTS
001971 02-09
CLINICAL-STUDIES AND BIOLOGICAL-STUDIES OF L TRYPTOPHAN IN
DEPRESSION
001977 02-09
NOMIFENSINE IN THE TREATMENT OF ENDOGENOUS DEPRESSION. A
CONTROLLED-STUDY VS. NORTRIPTYLINE.
001978 02-09
ENDOGENOUS DEPRESSION AND IMIPRAMINE LEVELS IN THE BLOOD.
001979 02-09
DEPRESSION: HOW TO RATIONALISE DRUG-THERAPY.
001988 02-09
A CLINICAL-TRIAL OF ZIMELIDINE IN DEPRESSION.
001992 02-09
TRAZODONE IN THE TREATMENT OF NEUROTIC DEPRESSION.
001994 02-09
AN OVERVIEW OF SEVENTEEN YEARS OF EXPERIENCE WITH DOTHIEPIN IN
THE TREATMENT OF DEPRESSION IN EUROPE.
001995 02-09
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC
DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL
CONTROLS.
002004 02-09
INFUSION THERAPY IN THERAPY-RESISTANT DEPRESSION.
002007 02-09
LONG-TERM-TREATMENT OF DEPRESSION WITH ISOCARBOXAZIDE,
002011 02-09
I
in;!,'
to;,
S-129
Subject Index
D PHENYLALANINE IN ENDOGENOUS DEPRESSION.
002017 02-09
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE- SYNDROME. PART 1:
TREATMENT OF ACUTE DEPRESSION.
002044 02-09
INFUSION OF MAPROTILIN AND CLOMIPRAMIN AND THEIR COMBINATION
IN THE TREATMENT OF DEPRESSION.
002056 02-09
PHARMACOTHERAPY OF DEPRESSION IN THE ELDERLY.
002144 02-11
THE RELATIVE EFFICACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY
FOR THE TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY.
(PH.D. DISSERTATION).
002148 02-11
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY
PRETREATMENT WITH THYROID-HORMONES.
002259 02-13
DORA AND DOPAMINE AGONISTS IN DEPRESSION.
002310 02-13
L HTP AND THE SEROTONIN HYPOTHESIS: THEIR MEANING FOR
TREATMENT OF DEPRESSION.
002326 02-14
THEOPHYLLINE AND DEPRESSION.
002439 02-15
SUBTYPES OF DEPRESSION BASED ON EXCRETION OF MHPG AND
RESPONSE TO NORTRIPTYLINE.
002488 02-16
HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE
CAUDATE-NUCLEUS BY GABA AGONISTS.
002640 03-01
NONSEROTONERGIC DEPRESSION OF SPINAL MONOSYNAPTIC REFLEX
TRANSMISSION BY 5 HYDROXYTRYPTOPHAN.
002745 03-03
DEPRESSION OF VENTRAL ROOT DORSAL ROOT POTENTIAL BY DL ALPHA
AMINOADIPATE IN FROG SPINAL-CORD.
002755 03-03
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GEU^TINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
ROLE OF MONOAMINERGIC SYSTEMS IN MORPHINE-INDUCED
RESPIRATORY DEPRESSION.
002827 03-03
NEUROTRANSMIHERS AND DEPRESSION: TOO MUCH, TOO LIHLE, TOO
UNSTABLE - OR NOT UNSTABLE ENOUGH?
002931 03-03
DEPRESSION OF RESERPINE-INDUCED MUSCULAR RIGIDITY IN RATS AFTER
ADMINISTRATION OF LISURIDE INTO THE SPINAL SUBARACHNOID
SPACE.
002962 03-04
THE DEXAMETHASONE-SUPPRESSION-TEST IN THE IDENTIFICATION OF
SUBTYPES OF DEPRESSION DIFFERENTIALLY RESPONSIVE TO
ANTIDEPRESSANTS.
003211 03-09
PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS ~ PART II:
PROTOCOL FOR THE TREATMENT OF DEPRESSION WITH TRICYCLIC-
ANTIDEPRESSANTS.
003214 03-09
AMOXAPINE AND AMITRIPTYLINE IN THE OUTPATIENT TREATMENT OF
ENDOGENOUS DEPRESSION.
003217 03-09
METHADONE AND MORPHINE IN DEPRESSION.
003220 03-09
SYNAPTIC AND BEHAVIOURAL-ACTIONS OF ANTIDEPRESSANT-DRUGS:
FURTHER THOUGHTS ON THE IMPLICATIONS FOR THEORIES OF
DEPRESSION.
003229 03-09
SLEEP AND TREATMENT PREDICTION IN ENDOGENOUS DEPRESSION.
003236 03-09
DEPRESSION SUBTYPES AFFECT THE STEADY-STATE PLASMA LEVELS AND
THERAPEUTIC-EFFICACY OF AMITRIPTYLINE AND NORTRIPTYLINE.
003244 03-09
PHENELZINE AND AMITRIPTYLINE IN NEUROTIC DEPRESSION.
(UNPUBLISHED PAPER).
003248 03-09
EFFECTS OF PHENELZINE AND AMITRIPTYLINE ON DEPRESSION.
003249 03-09
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION:
EVIDENCE FOR AMINE SPECIFICITY.
003250 03-09
LITHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND
BIPOLAR-II DEPRESSION: A PROSPECTIVE, PLACEBO-CONTROLLED
COMPARISON.
003252 03-09
BEHAVIORAL-PREDICTORS OF AMITRIPTYLINE RESPONSE IN DEPRESSION.
003253 03-09
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
003256 03-09
Ptychopharmacology Abstracts
THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL-
MEDICAL-PRACTICE: 48 CASES TREATED ON AN OUTPATIENT BASIS.
003268 03-09
MANAGEMENT OF DEPRESSION WITH SEROTONIN PRECURSORS.
003269 03-09
MAPROTILINE VERSUS IMIPRAMINE AND PLACEBO IN NEUROTIC
DEPRESSION.
003287 03-10
NEUROENDOCRINOLOGY OF DEPRESSION - A DISCUSSION.
003402 03-13
HIGH-AFFINITY 3H IMIPRAMINE BINDING: A NEW BIOLOGICAL TOOL FOR
STUDIES IN DEPRESSION.
003610 03-17
SPREADING DEPRESSION INDUCED BY MICROINJEQION OF ENKEPHALINS
INTO THE HIPPOCAMPUS AND NEOCORTEX
004015 04-03
CANNABINOID-INDUCED ENHANCEMENT AND DEPRESSION OF CAT
MONOSYNAPTIC REFLEXES.
004040 04-03
RESPIRATORY DEPRESSION PRODUCED BY DIAZEPAM IN CATS: EFFEQ OF
ANESTHESIA
004272 04-05
POTENTIATION OF THE MORPHINE-INDUCED RESPIRATORY RATE
DEPRESSION BY CAPTOPRIL.
004275 04-05
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION: A
DOUBLE-BLIND COMPARISON WITH IMIPRAMINE.
004346 04-09
PHARMACOTHERAPY FOR DEPRESSION.
004351 04-09
RECEPTORS, ADENYLATE-CYCLASE, DEPRESSION, AND LITHIUM.
004353 04-09
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE.
004356 04-09
(3H) IMIPRAMINE BINDING IN HUMAN PLATELETS: A NEW
BIOCHEMICAL-PARAMETER IN DEPRESSION.
004358 04-09
A NEUROENDOCRINE-STUDY OF ADRENOCEPTOR FUNQION IN
ENDOGENOUS DEPRESSION.
004362 04-09
PERIPHERAL SEROTONERGIC AND ADRENERGIC RESPONSES IN
DEPRESSION.
004364 04-09
CONVULSIVE AND DRUG-THERAPIES OF DEPRESSION.
004366 04-09
LONG-TERM-TREATMENT FOR DEPRESSION.
004372 04-09
CHOLINERGIC MECHANISMS IN MANIA AND DEPRESSION: QUESTIONS OF
SPECIFICITY
004374 04-09
GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF DEPRESSION
004376 04-09
TREATMENT OF DEPRESSION WITH AN MAO-INHIBITOR FOLLOWED BY 5
HTP - AN UNFINISHED RESEARCH PROJECT.
004377 04-09
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH
ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT
004382 04-09
AN EVALUATION OF TRAZODONE IN THE TREATMENT OF DEPRESSION.
004386 04-09
THE NOSOLOGICAL INDEPENDENCE OF INVOLUTIONAL DEPRESSION AND
ITS DYNAMICS DURING PSYCHOPHARMACOTHERAPY.
004389 04-09
PROPHYLACTIC-EFFEQ OF LITHIUM AGAINST DEPRESSION IN
CYCLOTHYMIC-PATIENTS: A LIFE-TABLE ANALYSIS.
004391 04-09
A COMPARISON OF TRAZODONE AND DOTHIEPIN IN DEPRESSION
004394 04-09
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
(UNPUBLISHED PAPER). „,„.„„
004401 04-09
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS.
004403 04-09
NEUROENDOCRINE DISTURBANCE IN DEPRESSION.
004405 04-09
ELECTROCARDIOGRAM-CHANGES AND PLASMA DESIPRAMINE LEVELS
DURING TREATMENT OF DEPRESSION.
004411 04-09
PHARMACOTHERAPY AND PSYCHOTHERAPY FOR AMBULATORY
DEPRESSION: EFFICACY AND CHOICES. ^^^^ ^^
TRAZODONE IN DEPRESSION. CX)44 14 04-09
CONTROLLED CLINICAL-TRIAL OF NOMIFENSINE IN THE TREATMENT OF
'''^'''^'''- 004417 04-09
S-130
VOLUME 19, SUBJECT INDEX
DOSE-EFFECT OF OtAE ON SUBJECTIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL-SYNDROME .
004472 04-11
THE ACTIVITY OF BLOOD-PLATELET MONOAMINE-OXIDASE IN
ENDOGENOUS DEPRESSION
004547 04-13
IS THE FAILURE OF (-)DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM
THE CHEESE EFFECT?
004640 04-15
DEPRESSIONS
STUDY OF INTRAVENOUS AMITRIPTYLINE IN ACUTE DEPRESSIONS.
000581 01-09
THE LONG-TERM-TREATMENT OF PERIODICAL AND CYCLIC DEPRESSIONS
WITH FLUPENTHIXOL-DECANOATE.
000603 01-09
NOMIFENSIN IN THE TREATMENT OF ENDOGENOUS DEPRESSIONS.
CLINICAL-EXPERIENCE AND EEG FINDINGS.
000613 01-09
CONTROLLED-COMPARISON OF MIANSERINE WITH IMIPRAMINE IN
ENDOGENOUS DEPRESSIONS.
000634 01-09
TRAZODONE IN DEPRESSIONS.
000643 01-09
CLINICAL-EXPERIENCE WITH SECOND-GENERATION ANTIDEPRESSANTS IN
ENDOGENOUS DEPRESSIONS.
001975 02-09
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS.
002047 02-09
PYRAZIDOL IN THE TREATMENT OF DEPRESSIONS.
002055 02-09
IATROGENIC DEPRESSIONS.
002388 02-15
CLINICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG-
RESISTANCE.
003245 03-09
THERAPEUTIC EFFECT OF MIANSERINE AND IMIPRAMINE IN ENDOGENOUS
DEPRESSIONS (CONTROLLED-COMPARISON) .
003264 03-09
THERAPEUTICS (I) - PHARMACOLOGICAL-TREATMENT OF DEPRESSIONS.
003270 03-09
CLINICAL DEPRESSIONS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES
004350 04-09
ACTIVITY OF BROMAZEPAM AND LORAZEPAM IN NEUROTIC
DEPRESSIONS.
004384 04-09
DEPRESSIVE
THE RELATIVE PROPHYLAQIC EFFICACY OF LITHIUM AGAINST MANIC
AND DEPRESSIVE RECURRENCES IN BIPOLAR-PATIENTS.
002040 02-09
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES
IN THIS PHASE.
003251 03-09
DEPRESSIVE-CONDITIONS
CLINICAL-TRIAL OF VILOXAZINE IN DEPRESSIVE-CONDITIONS
000589 01-09
THE TREATMENT OF DEPRESSIVE-CONDITIONS WITH NOMIFENSINE
000609 01-09
VARIATIONS IN URINARY EXCRETION OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN DEPRESSIVE-CONDITIONS
002013 02-09
TREATMENT OF DEPRESSIVE-CONDITIONS IN THE ELDERLY.
003578 03-17
DEPRESSIVE-DISORDER
PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE-
DISORDER: A PRELIMINARY REPORT.
000619 01-09
DEPRESSIVE-DISORDERS
IMIPRAMINE TREATMENT OF PREPUBERTAL MAJOR DEPRESSIVE-
DISORDERS: PLASMA LEVELS AND CLINICAL-RESPONSE ~
PRELIMINARY REPORT.
000620 01-09
PROLACTIN CHANGES IN MAJOR DEPRESSIVE-DISORDERS.
000752 01-13
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
004406 04-09
DEPRESSIVE-ILLNESS
A REEXAMINATION OF THE CLINICAL-EFFECTS OF IMIPRAMINE AND
AMITRIPTYLINE IN DEPRESSIVE-ILLNESS.
000579 01-09
GROWTH-HORMONE AFTER TRH IN WOMEN WITH DEPRESSIVE-ILLNESS
000606 01-09
Subject Index
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME PART 2:
PROPHYLAXIS OF RECURRENT DEPRESSIVE-ILLNESS
002043 02-09
DEPRESSIVE-NEUROSIS
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A
CONTROLLED CLINICAL-STUDY WITH DOXEPIN AND PLACEBO.
002080 02-10
CLOMIPRAMINE AND DOXEPIN IN DEPRESSIVE-NEUROSIS: PLASMA
LEVELS AND THERAPEUTIC RESPONSE,
002258 02-13
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO
AND STANDARD (IMIPRAMINE) CONTROLLED CLINICAL-STUDY.
004392 04-09
DEPRESSIVE-PATIENTS
COMPARATIVE-STUDY OF THE CARDIOTOXICITY OF AMITRIPTYLINE AND
MAPROTILINE IN DEPRESSIVE-PATIENTS.
000595 01-09
ON THE RELATIONSHIP OF NORTRIPTYLINE: AMITRIPTYLINE RATIO TO
CLINICAL IMPROVEMENT OF AMITRIPTYLINE TREATED DEPRESSIVE-
PATIENTS.
000599 01-09
A PRELIMINARY STUDY ON DETERMINATION OF THE OPTIMUM
OPIPRAMOL DOSAGE IN DEPRESSIVE-PATIENTS.
000601 01-09
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS AFTER A SINGLE
INJECTION OF BETA ENDORPHIN.
001962 02-09
EFFECTS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN
HEALTHY TEST SUBJECTS, NEUROTIC-PATIENTS, AND ENDOGENOUS
DEPRESSIVE-PATIENTS.
002009 02-09
OUTPATIENT CARE OF DEPRESSIVE-PATIENTS WITH MIANSERIN.
002041 02-09
PHARMACOKINETICS OF CLOMIPRAMINE IN DEPRESSIVE-PATIENTS.
003216 03-09
COMBINED ADMINISTRATION OF NIALAMIDE AND VILOXAZINE TO
DEPRESSIVE-PATIENTS.
003232 03-09
DEPRESSIVE-STATES
OUR EXPERIENCE WITH MAPROTILIN TREATMENT OF DEPRESSIVE-STATES.
000623 01-09
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-STATES.
000626 01-09
STUDY OF MAPROTILINE IN OUTPATIENT TREATMENT OF DEPRESSIVE-
STATES BY THE GENERAL-PRACTITIONER: ADVANTAGE OF SINGLE-
NIGHTLY-DOSE.
001961 02-09
VARIATIONS IN PSYCHOPHYSIOLOGICAL ACTIVATION RESPONSES IN
DEPRESSIVE-STATES.
001965 02-09
IS IT POSSIBLE TO SET UP ANY RULES FOR A COMPREHENSIVE
TREATMENT OF DEPRESSIVE-STATES?
001997 02-09
THE IMPORTANCE OF AMINEPTINE IN THE TREATMENT OF NONPSYCHOTIC
DEPRESSIVE-STATES IN THE ELDERLY.
001999 02-09
LARGE-DOSES OF DIBENZEPINE NOVERIL IN THE TREATMENT OF
DEPRESSIVE-STATES.
002020 02-09
CLINICAL-TRIAL OF PYRAZIDOL IN ENDOGENOUS DEPRESSIVE-STATES.
002021 02-09
CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE
AND CLOMIPRAMINE IN DEPRESSIVE-STATES (PRELIMINARY
OBSERVATION).
002032 02-09
AN OPEN-STUDY OF MAPROTILINE 75MG IN THE TREATMENT OF
DEPRESSIVE-STATES.
003152 03-07
CLINICAL-STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE-
STATES: COMPILATION OF 1520 OBSERVATIONS.
003206 03-09
DEPRESSIVE-SYMPTOMATOLOGY
CLINICAL-CORRELATION, BIOCHEMICAL-CORRELATION, AND
PSYCHOPHARMACOLOGICAL-CORRELATION IN PATIENTS WITH
DEPRESSIVE-SYMPTOMATOLOGY .
002018 02-09
PHYSOSTIGMINE INDUCTION OF DEPRESSIVE-SYMPTOMATOLOGY IN
■ NORMAL HUMAN SUBJECTS.
003255 03-09
DEPRESSIVE-SYMPTOMS
IMIPRAMINE AND EEG SLEEP IN CHILDREN WITH DEPRESSIVE-
SYMPTOMS.
002339 02-14
DEPRESSIVE-SYNDROME
PSYCHOTROPIC-DRUGS AND DEPRESSIVE-SYNDROME IN SCHIZOPHRENIA.
000569 01-08
A CASE-REPORT OF CIMETIDINE-INDUCED DEPRESSIVE-SYNDROME.
000839 01-15
5
IS;,
p..
S-131
Subject Index
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME. PART 1.
PROPHYLAXIS OF RECURRENT DEPRESSIVE-ILLNESS.
002043 02-09
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME. PART 1:
TREATMENT OF ACUTE DEPRESSION.
002044 02-09
DEPRESSIVE-SYNDROMES
THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH
DEPRESSIVE-SYNDROMES. 000625 01-09
CLINICAL RESULTS OBTAINED WITH THE USE OF LYSONEURO IN
DEPRESSIVE-SYNDROMES. „„.oo-, «. «n
004397 04-09
CLINICAL-EVALUATION OF THE PROPHYLACTIC EFFECTIVENESS OF
PROLONGED LITHIUM-CARBONATE THERAPY IN ENDOGENOUS
DEPRESSIVE-SYNDROMES. „„..„. «. „„
004404 04-09
VARIATIONS IN URINARY LEVELS OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN PATIENTS WITH DEPRESSIVE-
^^^■^^^^^^ 004533 04-13
THE ACTIVITY OF ERYTHROCYTE CATECHOL-0-METHYLTRANSFERASE IN
ENDOGENOUS DEPRESSIVE-SYNDROMES
004546 04-13
THE ACTIVITY OF DOPAMINE-BETA-HYDROXYLASE IN THE PLASMA OF
PATIENTS WITH ENDOGENOUS DEPRESSIVE-SYNDROMES
004548 04-13
DEPRESSIVES
AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF
DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREACTIVITY
IN DMI RESPONSIVE DEPRESSIVES. „„..on «o nn
003228 03-09
THE THERAPEUTIC PROFILE OF MIANSERIN IN MILD ELDERLY
■^^^^^^^'^^^ 003297 03-11
DEPRESSOR
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS
000520 01-05
DEPRIVATION
ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA:
REVERSAL BY MICROIONTOPHORETIC BICUCULLINE.
002684 03-03
CORTICAL RECOVERY FROM EFFECTS OF MONOCULAR DEPRIVATION:
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6
HYDROXYDOPAMINE „„o^^. „^ „^
003024 03-04
CHANGES OF RESPONSE TO DOPAMINERGIC DRUGS IN RATS SUBMIHED
TO REM SLEEP DEPRIVATION. „„.„.„ „. „.
004239 04-04
DEPRIVED
NALOXONE: EFFECTS ON FOOD AND WATER CONSUMPTION IN THE
NONDEPRIVED AND DEPRIVED RAT. „„„„„.
001599 02-04
DIFFERENTIAL-EFFECTS OF MORPHINE ON FOOD AND WATER INTAKE IN
FOOD DEPRIVED AND FREELY-FEEDING RATS.
001765 02-04
NALOXONE SUPPRESSES FOOD/WATER CONSUMPTION IN THE DEPRIVED
CAT
004114 04-04
PHARMACOKINETIC- STUDY OF APOMORPHINE-INDUCED STEREOTYPY IN
FOOD DEPRIVED RATS.
004247 04-04
DERIVATIVE ^. ^ n
FLUORINATED ANALOGUES OF THE TRICYCLIC NEUROLEPTICS: 2,3
DIFLUORO DERIVATIVE OF CLOROTEPIN.
000001 01-01
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A
LIGAND FOR NEUROLEPTIC-RECEPTORS - I. IN VITRO STUDIES.
001133 02-03
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A
LIGAND FOR NEUROLEPTIC-RECEPTORS - II. IN VIVO STUDIES.
001137 02-03
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS.
001869 02-06
DOUBLE-BUND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO
SEVERE ANXIETY.
002070 02-10
DU-24565, A QUIPAZINE DERIVATIVE, A POTENT SELECTIVE SEROTONIN
UPTAKE INHIBITOR.
002651 03-02
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF A
PYRIMIDOPYRIMIDINE DERIVATIVE WITH ANTIDEPRESSANT ACTIVITY.
003653 04-01
Psychopharmacology Abstracts
A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/
BENZODIAZEPINE-RECEPTORINTERAaiON.
003851 04-03
DERIVATIVES
N TETRAHYDROFURYLALKYL AND N ALKOXYALKYL DERIVATIVES OF (-)
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID AQION
PROFILES.
000013 01-02
EFFECTS OF PHENOTHIAZINE DERIVATIVES AND RELATED COMPOUNDS ON
TYROSINE-AMINOTRANSFERASE AQIVITY.
000018 01-03
ANORECTIC-EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES IN THE
RAT
000042 01-03
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT
PROPERTIES.
000084 01-03
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES
BEHAVIOURAL-EFFEQS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN
RATS.
000420 01-04
STRUCTURE-AQIVITY RELATIONSHIP OF PHENCYCLIDINE DERIVATIVES.
001030 02-01 ,
THE EFFECT OF PHENELZINE AND SOME OF ITS PARA HALOGENATED "
DERIVATIVES ON THE LEVELS OF BRAIN TYRAMINE AND OQOPAMINE
IN THE MOUSE
001077 02-02 .
SYNTHESIS AND PHARMACOLOGY OF 2 AMIN0-3-ETHOXYCARB0NYL-4- '
PHENYLTHIOPHENE DERIVATIVES.
001083 02-02
SYNTHESIS AND ANXIOLYTIC-ACTIVITY OF A SERIES OF
PYRAZINOBENZODIAZEPINE DERIVATIVES.
001089 02-02
DERIVATIVES OF 1 1 1 PIPERAZINYL-5H-PYRR0L0BENZ0DIAZEPINE AS
CENTRAL-NERVOUS-SYSTEM AGENTS.
001093 02-02
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT
DERIVATIVES.
001156 02-03
NEUROPHYSIOLOGICAL-STUDY OF TWO 0 ANISAMIDE DERIVATIVES:
SULPIRIDE AND SUlTOPRIDE.
001170 02-03
EFFECT OF ERGOT DERIVATIVES ON POSTDECAPITATION CONVULSIONS.
001288 02-03
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN
IN VIVO EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS,
AND BENZODIAZEPINES.
001303 02-03
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC-
^™^^ 001410 02-03
INTERACTION OF DOPAMINERGIC ERGOT DERIVATIVES WITH CYCLIC-
NUCLEOTIDE SYSTEM.
001482 02-03
PHENCYCLIDINE (PCP) AND DERIVATIVES: PHARMACOLOGY AND
STRUCTURE-ACTIVITY RELATIONSHIPS. 001706 02^
COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT.
001841 02-05
NEUROPSYCHOPHARMACOLOGICAL-STUDIES ON SOME BENZAMIDE
DERIVATIVES. ^ „ „^ ,,
002220 02-13
NEUROPHARMACOLOGY OF SYNTHETIC ERGOT DERIVATIVES IN MAN^
002429 02-15
CENTRAL DOPAMINERGIC-EFFEaS OF ERGOLINE DERIVATIVES.
002540 02-17
ON-COLUMN GAS-CHROMATOGRAPHIC-SYNTHESIS OF 1,3 DIALYKYL
{C=l-10) BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES.
003656 04-01
GAS-CHROMATOGRAPHIC-PROPERTIES OF 1,3 DIALKYLBARBITURATE
^^^'^*^'^^^ 003658 04-01
SPECTRA OF RADICAL CATIONS OF PHENOTHIAZINE DERIVATIVES IN
SOLUTION AND SOLID STATE 003673 04-01
SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES OF
ANALOGUES AND DERIVATIVES OF P CHLOROPHENYLALANINE.
003691 04-02
SYNTHESIS AND PHARMACOLOGICAL AQIVITY OF SOME 2 IMINO-3-
ALKYLTHIAZOLINE DERIVATIVES. 003698 04-02
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK-
8 1 65 AND PK-9084 (TWO QUINOLINE DERIVATIVES)
003898 04-UJ
S-132
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF NORCOCAINE AND SOME NORCOCAINE DERIVATIVES ON
SCHEDULE-CONTROLLED BEHAVIOR OF PIGEONS AND SQUIRREL-
MONKEYS.
004012 04-03
CRIVATIZATION
GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA
DERIVATIZATION TECHNIQUES
004687 04-16
ERMATOLOGIC
DERMATOLOGIC MANIFESTATIONS OF LITHIUM: A REVIEW.
003462 03-15
CS-TYR-GAMMA-ENDORPHIN
EFFECTS OF DES-TYR-GAMMA-ENDORPHIN ON DOPAMINE RELEASE FROM
VARIOUS RAT-BRAIN REGIONS IN VITRO.
000264 01-03
DES-TYR-GAMMA-ENDORPHIN ADMINISTRATION IN CHRONIC
SCHIZOPHRENICS: A PRELIMINARY REPORT.
003198 03-08
EFFECT OF DES-TYR-GAMMA-ENDORPHIN IN TARDIVE-DYSKINESIA.
003472 03-15
ES-TYROSINE-GAMMA-ENDORPHIN
DES-TYROSINE-GAMMA-ENDORPHIN: H-REFLEX RESPONSE SIMILAR TO
NEUROLEPTICS.
004540 04-13
ES-TYROSYL-GAMMA-ENDORPHIN
DES-TYROSYL-GAMMA-ENDORPHIN IN SCHIZOPHRENIA: A DOUBLE-BLIND
TRIAL IN 13 PATIENTS.
004322 04-08
ES-TYR 1 -GAMMA-ENDORPHIN
INHIBITION OF IN VIVO 3H SPIPERONE BINDING BY THE PROPOSED
ANTIPSYCHOTIC DES-TYR 1 -GAMMA-ENDORPHIN .
000226 01-03
EFFEQS OF THE POTENTIAL NEUROLEPTIC-PEPTIDE DES-TYR 1 -GAMMA-
ENDORPHIN AND HALOPERIDOL ON APOMORPHINE-INDUCED
BEHAVIOURAL-SYNDROMES IN RATS AND MICE.
000441 01-04
DES-TYR 1 -GAMMA-ENDORPHIN IN SCHIZOPHRENIA.
001918 02-08
ESACETYLLANATOSIDE-C
CORTICAL CONTROL OF NEURALLY MEDIATED ARRHYTHMOGENIC-
PROPERTIES OF DESACETYLLANATOSIDE-C.
003124 03-05
ESCRIPTION
FREE DESCRIPTION OF DRUG-EFFECTS AS A METHOD OF CLINICAL-TRIAL
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND
THEIR COMBINATION.
002561 02-17
ESENSITIZATION
DESENSITIZATION OF ADRENOCEPTORS AFTER IMMOBILIZATION STRESS
OR REPEATED INJECTION OF ISOPROTERENOL IN RATS. (UNPUBLISHED
PAPER).
001546 02-03
MEPACRINE TREATMENT PREVENTS IMMOBILIZATION-INDUCED
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT
HYPOTHALAMUS AND BRAINSTEM.
002919 03-03
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
003783 04-03
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
004030 04-03
ANTIDEPRESSANTS AND ALPHA2-ADRENERGIC-AUT0RECEPT0R
DESENSITIZATION.
004659 04-15
:S6LYCINAMIDE-LYSINE-VASOPRESSIN
EFFECTS OF DESGLYCINAMIDE-LYSINE-VASOPRESSIN ON A CONDITIONED
TASTE-AVERSION IN RATS.
■SIGN 00181102-04
CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN
SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BUND CROSS-
OVER DESIGN.
„..,^ 001937 02-08
DESIGN ASPECTS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS A
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING-SCALES
^„,.^ 002512 02-16
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS.
SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS: DESIGN
DEVELOPMENT AND STRUCTURE-ACTIVITY STUDIES
•SIGNS 004725 04-17
ON THE USE OF REPEATED MEASURES DESIGNS IN
PSYCHOPHARMACOLOGY.
004695 04-16
DESIPRAMINE
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROIILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS
000044 01-03
FUNCTIONAL EVIDENCE FOR SUBSENSITIVITY OF NORADRENERGIC-
ALPHA2-RECEPT0RS AFTER CHRONIC DESIPRAMINE TREATMENT.
000283 01-03
EFFICACY OF DESIPRAMINE IN ENDOGENOMORPHICALLY DEPRESSED-
PATIENTS.
000632 01-09
NEUROLEPTIC-EFFECT ON DESIPRAMINE STEADY-STATE PLASMA
CONCENTRATIONS,
000781 01-13
DESIPRAMINE: CARDIOVASCULAR EFFECTS AND PLASMA LEVELS.
000884 01-15
THE TIME-COURSE OF NORADRENERGIC PRESYNAPTIC AND
POSTSYNAPTIC ACTIVITY DURING CHRONIC DESIPRAMINE
TREATMENT.
001289 02-03
EFFECTS OF DESIPRAMINE AND YOHIMBINE ON ALPHA2-ADREN0CEPT0R
AND BETA-ADRENOCEPTOR SENSITIVITY
001305 02-03
INTERACTION OF TRIAZOLAM WITH DESIPRAMINE: EFFECTS OF SINGLE
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC-
RESPONSES AND BRAIN CATECHOLAMINE LEVELS.
001323 02-03
EFFECTS OF NOMIFENSINE AND DESIPRAMINE ON THE SEQUELAE OF
INTRACEREBRALLY INJECTED 6 OHDA AND 5 6 DHT
001522 02-03
CLINICAL-RESPONSE, PLASMA LEVELS AND PHARMACOKINETICS OF
DESIPRAMINE IN DEPRESSED-INPATIENTS.
002002 02-09
PLASMA DESIPRAMINE LEVELS AFTER SINGLE-DOSAGE AND AT STEADY-
STATE IN OUTPATIENTS.
002039 02-09
THE PERIPHERAL ANTICHOLINERGIC-ACTIVITY OF TRICYCLIC-
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND
DESIPRAMINE IN HUMAN VOLUNTEERS.
002298 02-13
DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC-
RECEPTORS.
002914 03-03
DESIPRAMINE AND 2 HYDROXYDESIPRAMINE PHARMACOKINETICS IN
NORMAL VOLUNTEERS.
003154 03-07
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION:
EVIDENCE FOR AMINE SPECIFICITY.
003250 03-09
EFFICACY OF DESIPRAMINE IN MILDLY DEPRESSED-PATIENTS: A DOUBLE-
BLIND, PLACEBO-CONTROLLED-TRIAL.
003262 03-09
ELECTROCARDIOGRAM-CHANGES AND PLASMA DESIPRAMINE LEVELS
DURING TREATMENT OF DEPRESSION.
004411 04-09
BLOCKADE BY IMIPRAMINE OR DESIPRAMINE OF PANIC-INDUCED BY
SODIUM-LACTATE.
004427 04-10
ANTICHOLINERGIC-EFFECTS AND PLASMA DESIPRAMINE LEVELS.
004550 04-13
DESIPRAMINE-HYDROCHLORIDE
SINGLE-DOSE VERSUS MULTIPLE-DOSE COMPARATIVE-TRIAL OF
DESIPRAMINE-HYDROCHLORIDE: A DOUBLE-PLACEBO METHOD
002059 02-10
DESIPRAMINE-INDUCED
ACCELERATION OF DESIPRAMINE-INDUCED DECREASE OF RAT
CORTICOCEREBRAL BETA-ADRENERGIC-RECEPTORS BY YOHIMBINE.
000326 01-03
DESMETHYL
KINETICS AND NEUROPSYCHOLOGIC-EFFECTS OF IV DIAZEPAM IN THE
PRESENCE AND ABSENCE OF ITS ACTIVE N DESMETHYL METABOLITE IN
HUMANS.
002229 02-13
OESMETHYLATED-COMPOUND
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1 H-INDAZOLE (FS-32)
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
DESMETHYLDIAZEPAM
EFFECT OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND
RIGIDITY: A QUANTITATIVE STUDY OF REFLEXES AND PLASMA
CONCENTRATIONS.
000701 01-11
COMPARATIVE PROTEIN BINDING OF DIAZEPAM AND
DESMETHYLDIAZEPAM.
002206 02-13
««.:
t'."
£'!'
"IrW'
S-133
Subject Index
INFLUENCE OF CIMETIDINE ON THE PHARMACOKINETICS OF
DESMETHYLDIAZEPAM AND OXAZEPAM.
002249 02-13
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE-
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A
CONTROLLED-TRIAL.
002329 02-14
DESMETHYLDIAZEPAM KINETICS IN THE ELDERLY AFTER ORAL
PRAZEPAM. „„..o„^. ,,
004432 04-11
RADIOIMMUNOASSAY FOR TOTAL DOXEPIN AND N DESMETHYLDOXEPIN
IN PLASMA. „„^.„„„ow
002499 02-16
PLASMA LEVELS OF THE CIS-ISOMERS AND TRANS-ISOMERS OF DOXEPIN
AND DESMETHYLDOXEPIN AFTER ADMINISTRATION OF DOXEPIN TO
"^^'^^^^ 004355 04-09
DESMETHYLIMIPRAMINE
ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE
AND DESMETHYLIMIPRAMINE. „„„, , o «, „o
000113 01-03
STUDIES ON THE PUTATIVE ANTICHOLINERGIC-EFFEaS OF
DESMETHYLIMIPRAMINE. „„„..„ „, „.
000228 01-03
EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT
LUNG.
000524 01-05
PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE-
DISORDER: A PRELIMINARY REPORT.
000619 01-09
AN INVERSE CORRELATION BETV/EEN SERUM LEVELS OF
DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREAQIVITY
IN DMI RESPONSIVE DEPRESSIVES. „„..„„ „. „„
003228 03-09
EFFECT OF DESMETHYLIMIPRAMINE ON TISSUE DISTRIBUTION AND
ANORECTIC-AQIVITY OF CHLORPHENTERMINE IN RATS.
004179 04-04
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS.
004180 04-04
DESMETHYLMETHSUXIMIDE
ELECTRON-CAPTURE GAS-LIQUID-CHROMATOGRAPHIC-DETERMINATION
OF ETHOSUXIMIDE AND DESMETHYLMETHSUXIMIDE IN PLASMA OR
^^■^^^ 000538 01-06
DESORPTION
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS:
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD
003556 03-16
DESTROYS
EXPOSURE OF MITOCHONDRIAL OUTER MEMBRANES TO NEURAMINIDASE
SELECTIVELY DESTROYS MONOAMINE-OXIDASE-A ACTIVITY.
001286 02-03
DESTRUCTION
EFFEaS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS.
000466 01-04
EFFECT OF SELECTIVE DESTRUQION OF SEROTONERGIC NEURONS IN
NUCLEUS-RAPHE-MAGNUS ON MORPHINE-INDUCED ANTINOCICEPTION
001724 02-04
DORSAL TEGMENTAL BUNDLE DESTRUQION: EFFECTS ON OPERANT-
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL-
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS.
001726 02-04
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY
STUDY.
003085 03-04
BEHAVIORAL AND REGIONAL NEUROCHEMICAL SEQUELAE OF
HIPPOCAMPAL DESTRUCTION IN THE RAT.
003721 04-03
SENSORY NEUROTOXINS: CHEMICALLY-INDUCED SELEQIVE DESTRUCTION
OF PRIMARY SENSORY NEURONS.
003859 04-03
THE EFFEQ OF PHARMACOLOGICAL DESTRUQION OF HYPOTHALAMIC
MONOAMINERGIC STRUCTURES ON BODY-TEMPERATURE AND GAS-
EXCHANGE DURING EXTREME COOLING.
004016 04-03
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER
FOREBRAIN REGIONS OF THE RAT.
004171 04-04
DOPAMINE-RECEPTOR CHANGES FOLLOWING DESTRUCTION OF THE
NIGROSTRIATAL PATHWAY: LACK OF A RELATIONSHIP TO
ROTATIONAL-BEHAVIOR.
004229 04-04
Psychopharmacology Abstracts k
DETECT
USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETEQ AND
DISCRIMINATE ACTIONS OF DRUGS AND TOXICANTS.
000503 01-04
EFFECTS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETECT THE NARCOTIC CHARACTER OF A DRUG.
003555 03-16
DETECTED
DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES.
000584 01-09
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI. DMI, OR
ETHANOL DETECTED BY ELECTROPHYSIOLOGICAL-CORRELATES
001136 02-03
CYCLOPHOSPHAMIDE-INDUCED SPERMATOGENIC EFFECTS DETECTED IN
THE Fl-GENERATION BY BEHAVIORAL-TESTING.
003121 03-05
DETECTING
THE USE OF SOCIAL-INTERACTION AS A METHOD FOR DETECTING
ANXIOLYTIC-ACTIVITY OF CHLORDIAZEPOXIDE-LIKE DRUGS.
001866 02-06
DETECTION
APPLICATION OF A RADIOIMMUNOASSAY SCREENING-TEST FOR
DETECTION AND MANAGEMENT OF PHENCYCLIDINE INTOXICATION.
000859 01-15
LEVODOPA AND PRESYMPTOMATIC DETECTION OF HUNTINGTONS-
DISEASE - EIGHT-YEAR FOLLOWUP.
000950 01-17
DETECTION OF MULTIPLE RECEPTORS FOR DOPAMINE.
001481 02-03
BEHAVIORAL-TEST FOR DETECTION OF SUBCLINICAL BRAIN-DAMAGE: AN
EXPERIMENTAL MODEL.
003120 03-04
A METHOD FOR MEASUREMENT OF TRANYLCYPROMINE IN RAT-BRAIN
REGIONS USING GAS-CHROMATOGRAPHY WITH ELECTRON CAPTURE
DETECTION.
003137 03-06
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND
LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJECTS.
003311 03-11
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID-
CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION.
003674 04-01
REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION:
DISSOCIATIVE-EFFECTS OF COCAINE.
004160 04-04
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION
PRODUCTS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH-
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE
DETECTION
004302 04-06
MEPROBAMATE REDUCES ACCURACY OF PHYSIOLOGICAL DETECTION OF
DECEPTION. „. „ ,.
004585 04-14 ,
DETERMINANTS ,_, „,
PRIOR AND ONGOING EXPERIENCE AS DETERMINANTS OF THE EFFECTS OF
D-AMPHETAMINE AND CHLORPROMAZINE ON PUNISHED-BEHAVIOR.
000339 01-04
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFECTS OF
COCAINE AND D-AMPHETAMINE FOLLOWING CHRONIC AMPHETAMINE
ADMINISTRATION. ,,^„,„ „, „. '
000350 01-04
DETERMINATION
A PRELIMINARY STUDY ON DETERMINATION OF THE OPTIMUM
OPIPRAMOL DOSAGE IN DEPRESSIVE-PATIENTS
000601 01-09
3 CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE (GS-385), A
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION. ,
PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE
LIQUID-CHROMATOGRAPHY. 000705 01-11
DETERMINATION OF THE ENCEPHALOTROPIC, PSYCHOTROPIC AND
PHARMACODYNAMIC PROPERTIES OF NICERGOLINE BY MEANS OF
QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY AND
PSYCHOMETRIC-ANALYSES. 000788 01-13
DETERMINATION OF DOSE PLASMA CONCENTRATION RELATIONSHIP OF
PHENOBARBITAL IN EPILEPTIC-PATIENTS BY A NEW SPECIFIC
RADIOIMMUNOASSAY. „„„„„^ „, ,^
000902 01-16
DETERMINATION OF VALPROIC-ACID BY FLAME-IONIZATION GAS-LIQUID-
CHROMATOGRAPHY 000906 01-16
INTERRELATIONS AMONG PRIOR EXPERIENCE AND CURRENT CONDITIONS
IN THE DETERMINATION OF BEHAVIOR AND THE EFFECTS OF DRUGS.
0017)5 02-04
S-134
fOLUME 19, SUBJECT INDEX
Subject Index
DETERMINATION OF PHARMACODYNAMICS OF PSYCHOTROPIC-DRUGS BY
PSYCHOMETRIC-ANALYSIS,
001895 02-07
MIANSERIN: DETERMINATION OF THERAPEUTIC DOSE RANGE.
002026 02-09
METHOD FOR THE DETERMINATION OF TRYPTOPHAN IN SERUM AND
CEREBROSPINAL-FLUID.
002208 02-13
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
DETERMINATION OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS AND OF THEIR METABOLIC PRODUCTS IN
BIOLOGICAL FLUIDS.
002498 02-16
A RAPID GAS-LIQUID-CHROMATOGRAPHY METHOD FOR SIMULTANEOUS
DETERMINATION OF VARIOUS ANTICONVULSANTS.
002501 02-16
DETERMINATION OF GABA LEVELS BY A (3H)MUSCIM0L RADIORECEPTOR
ASSAY.
003135 03-06
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC-
ACID IN BRAIN USING HPLC WITH ELECTROCHEMICAL-DETECTION.
003139 03-06
THERAPEUTIC INTEREST OF BLOOD LEVELS DETERMINATION FOR
ANTIDEPRESSANTS: METHODOLOGICAL APPROACH.
003571 03-16
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID-
CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION.
003674 04-01
A SIMPLE DETERMINATION OF SEROTONIN, 5 HYDROXYINDOLEACETIC-
ACID AND 5 HYDROXYTRYPTOPHAN-DECARBOXYLASE ACTIVITY IN
RAT-BRAIN AREAS AND PARALLEL CORRELATION AMONG THE LEVELS.
004301 04-06
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION
PRODUCTS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH-
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE
DETEQION.
004302 04-06
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
bFFECTS OF RO-1 1-2465, A NEW PSYCHOTROPIC-AGENT ON THE UPTAKE
OF SEROTONIN BY HUMAN PLATELETS - IN VITRO DETERMINATION OF
THE IC50.
004532 04-13
A COMPARISON OF RADIOIMMUNOASSAY WITH SPEQROPHOTOMETRY
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN
CONCENTRATIONS.
004684 04-16
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD
BY USE OF SELECT ION-MONITORING AND DEUTERATED INTERNAL
STANDARDS.
004690 04-16
ETERMINATIONS
USE OF PLASMA CONCENTRATION DETERMINATIONS.
004498 04-13
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II.
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT.
004516 04-13
ETOXIFICATION
IATROGENIC OPIATE ADDICTION: SUCCESSFUL DETOXIFICATION WITH
CLONIDINE.
000666 01-11
CLONIDINE FOR OPIATE DETOXIFICATION: OUTPATIENT CLINICAL-TRIALS.
000731 01-11
RAPID OPIATE DETOXIFICATION WITH CLONIDINE AND NALOXONE.
000820 01-14
CLONIDINE FOR OUTPATIENT OPIATE DETOXIFICATION.
000827 01-14
ETOXIFYIN6
SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN
DETOXIFYING ALCOHOLIC-PATIENTS.
004671 04-16
EUTERATED
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD
BY USE OF SELECT ION-MONITORING AND DEUTERATED INTERNAL
STANDARDS.
004690 04-16
DEUTERIUM
NOREPINEPHRINE METABOLISM IN MAN USING DEUTERIUM LABELLING: 4
HYDROXY-3-METHOXYMANDELIC-ACID
004534 04-13
DEVELOPED
A STUDY ON MENTAL-SYMPTOMS DEVELOPED DURING THE TREATMENT
OF PARKINSONS-DISEASE.
004618 04-15
DEVELOPING
LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES
OF THE DEVELOPING CHICK RETINA.
000065 01-03
EFFECTS OF APOMORPHINE ON ESCAPE PERFORMANCE AND ACTIVITY IN
DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6
OHDA).
000426 01-04
THE LOCOMOTOR-EFFECT OF CLONIDINE AND ITS INTERACTION WITH
ALPHA FLUPENTHIXOL OR HALOPERIDOL IN THE DEVELOPING RAT.
000445 01-04
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL- STUDY AND
MORPHOLOGICAL-STUDY.
001407 02-03
HYPERACTIVITY IN DEVELOPING RATS: SEX-DIFFERENCES IN 6
HYDROXYDOPAMINE AND AMPHETAMINE EFFECTS.
002970 03-04
EFFECT OF AMPHETAMINE ON THE METABOLISM AND INCORPORATION
OF (3H) THYMIDINE INTO DNA OF DEVELOPING RAT-BRAIN.
003729 04-03
THE EFFECTS OF CHRONIC METHYLPHENIDATE TREATMENT ON GROWTH
AND ENDOCRINE FUNCTION IN THE DEVELOPING RAT.
003811 04-03
EFFECT OF NEONATAL HYDROCORTISONE TREATMENT ON BRAIN-
MONOAMINES IN DEVELOPING RATS.
003893 04-03
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN
BRAIN CELL-CULTURES.
004002 04-03
DEVELOPMENT
REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS.
000066 01-03
PHENYLACETATE AND BRAIN-DYSFUNCTION IN EXPERIMENTAL
PHENYLKETONURIA: SYNAPTIC DEVELOPMENT.
000191 01-03
EFFECTS OF 6 HYDROXYDOPAMINE AND AMPHETAMINE ON RAT
MOTHERING-BEHAVIOR AND OFFSPRING DEVELOPMENT.
000452 01-04
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT:
BEHAVIORAL-EFFECTS AND PSYCHOPHARMACOLOGICAL-EFFECTS.
000481 01-04
INTERACTIVE-EFFECTS OF NUTRITION AND CANNABIS UPON RAT
PERINATAL DEVELOPMENT.
000513 01-05
EFFECTS OF LEAD EXPOSURE DURING DEVELOPMENT ON NEOCORTICAL
DENDRITIC AND SYNAPTIC STRUCTURE.
000525 01-05
CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM.
000988 01-17
PRESYNAPTIC DOPAMINE-RECEPTORS: INSENSITIVITY TO KAINIC-ACID
AND THE DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING CHRONIC
HALOPERIDOL.
001117 02-03
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE-
RECEPTOR MECHANISMS IN CNS.
001178 02-03
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE
CAT. (PH.D. DISSERTATION).
001179 02-03
DEVELOPMENT OF ACUTE OPIOID-TOLERANCE AND DEPENDENCE IN RAT
STRIATAL NEURONES.
001235 02-03
EFFECTS OF MALNUTRITION AND QUIPAZINE ON RAT-CEREBRAL-CORTEX
ATPASE ACTIVITY DURING DEVELOPMENT.
001276 02-03
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 02-03
EFFECTS OF PAVLOVIAN-CONDITIONING AND MIF-1 ON THE
DEVELOPMENT OF MORPHINE-TOLERANCE IN RATS.
001327 02-03
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFECT
I
if
•lit
iic
liktn
S-135
Subject Index
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE.
001353 02-03
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT:
LATER PSYCHOPHARMACOLOGICAL RESPONSES TO APOMORPHINE
AND ARECOLINE.
001470 02-03
GLUCOCORTICOIDS AS A REGULATORY FACTOR FOR BRAIN TRYPTOPHAN-
HYDROXYLASE DURING DEVELOPMENT.
001500 02-03
POSTNATAL ALCOHOL EXPOSURE IN THE RAT. ITS EFFECTS ON
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT.
001580 02-04
TOLERANCE DEVELOPMENT TO PHENCYCLIDINE BY CHRONIC
ADMINISTRATION.
001619 02-04
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: II. NURSING-BEHAVIOR AND
DEVELOPMENT OF THE SUCKLINGS.
001626 02-04
EFFECTS OF RESERPINE AND AMPHETAMINE ON THE DEVELOPMENT OF
HYPERACTIVITY IN MATERNALLY-DEPRIVED RAT PUPS.
001654 02-04
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE
DEVELOPMENT OF DEPENDENCE IN RATS.
001800 02-04
THE DEVELOPMENT OF PROGENY IN CASES OF ANTENATAL EXPOSURE TO
PHENAZEPAM.
001854 02-05
THE ROLE OF FOLATE DEFICIENCY IN THE DEVELOPMENT OF PERIPHERAL
NEUROPATHY CAUSED BY ANTICONVULSANTS.
002402 02-15
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL-
NERVOUS- SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE-
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS).
002459 02-15
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN
MAN- EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY
AFFECTIVE-ILLNESS
002506 02-16
CLINICAL-PHARMACOLOGY: DRUG DEVELOPMENT.
002547 02-17
NEW DEVELOPMENT IN ANTIDEPRESSANT MEDICATION - A REVIEW.
002558 02-17
BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND
CELLULAR LOCALIZATION
002655 03-03
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE
AND CROSS-TOLERANCE TO THE INHIBITORY ACTION OF BETA
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS.
002756 03-03
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFECTS OF NALOXONE ON
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE
MALE RAT.
002853 03-03
EFFECTS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA-
ADRENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES.
002932 03-03
SUPPRESSION OF AQIVE SLEEP BY CHRONIC-TREATMENT WITH
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT:
EFFEaS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT.
003056 03-04
DIFFERENTIATION OF OPIATE-RECEPTORS IN THE BRAIN BY THE SELECTIVE
DEVELOPMENT OF TOLERANCE.
003088 03-04
DIFFERENCE IN THE DEVELOPMENT OF TOLERANCE TO MORPHINE AND D
ALA2-METHI0NINE-ENKEPHALIN IN C57 BL/6J AND DBA/2J MICE.
003126 03-05
PRELIMINARY-FINDINGS WITH REGARD TO RISK-FACTORS IN THE
DEVELOPMENT OF TARDIVE-DYSKINESIA.
003501 03-15
THE NECESSITY OF PSYCHOPHARMACOLOGY IN THE DEVELOPMENT OF
PSYCHIATRY.
003575 03-17
NERVE GROWTH-FACTOR STIMULATES DEVELOPMENT OF SUBSTANCE-P
IN THE EMBRYONIC SPINAL-CORD.
003881 04-03
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC
AND DOCA-SALT HYPERTENSION IN THE RAT.
003899 04-03
EFFECT OF PRENATAL NEUROLEPTIC TREATMENT ON MEMBRANE
RECEPTOR DEVELOPMENT IN THE BRAIN.
003989 04-03
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN- CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
Psychopharmacology Abstracts
DOES RAPID-EYE-MOVEMENT SLEEP PLAY A ROLE IN BRAIN
DEVELOPMENT?
004091 04^
DEVELOPMENT OF PSYCHOPHARMACOLOGY.
004667 04-15
PSYCHOPHARMACOTHERAPY: THE PRESENT STATE AND THE
DEVELOPMENT OF TRENDS.
004723 04-17
SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS: DESIGN,
DEVELOPMENT AND STRUCTURE-ACTIVITY STUDIES.
004725 04-17
DEVELOPMENTAL
GABA BENZODIAZEPINE INTERACTIONS: PHYSIOLOGICAL,
PHARMACOLOGICAL AND DEVELOPMENTAL ASPEQS.
000103 01-03
PERINATAL NEUROLEPTIC ACTIONS - DEVELOPMENTAL RESULTS.
(UNPUBLISHED PAPER)
001277 02-03
DEVELOPMENTAL ASPECTS OF CATECHOLESTROGEN SYNTHESIS.
(UNPUBLISHED PAPER).
001282 02-03
DEVELOPMENTAL-CHANGE
DEVELOPMENTAL-CHANGE OF BETA-ADRENERGIC-RECEPTORS IN RAT-
BRAIN
004050 04-03
DEVELOPMENTAL-CHANGE IN REARING RESPONSE TO ATROPINE IN RATS
TREATED WITH 6 HYDROXYDOPA.
004191 04-04 -
DEVELOPMENTAL-CHANGES
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART III DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES.
000025 01-03
DEVELOPMENTALLY
RETINAL TOXICITY OF MAM-ACETATE IS DEVELOPMENTALLY SPECIFIC. i
(UNPUBLISHED PAPER).
001212 02-03
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK
TISSUES - ARE THEY CELL ADHESION MOLECULES' i
003724 04-03
DEXAMETHASONE
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
DEXAMETHASONE TREATMENT.
000321 01-03
SELEaiVE REDUCTION BY DEXAMETHASONE OF STRESS RELATED
HYPERPHAGIAS.
001703 02-04
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART VII SUPPRESSION OF SYMPATHETIC RESPONSES BY
DEXAMETHASONE.
002802 03-03
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS ,
004403 04-09
DEXAMETHASONE-SUPPRESSION-TEST
DEXAMETHASONE-SUPPRESSION-TEST IDENTIFIES SUBTYPES OF
DEPRESSION WHICH RESPOND TO DIFFERENT ANTIDEPRESSANTS.
001971 02-09
THE DEXAMETHASONE-SUPPRESSION-TEST IN THE IDENTIFICATION OF
SUBTYPES OF DEPRESSION DIFFERENTIALLY RESPONSIVE TO
ANTIDEPRESSANTS. ^
003211 03-09
STANDARDIZATION OF THE DEXAMETHASONE-SUPPRESSION-TEST FOR
THE DIAGNOSIS OF MELANCHOLIA. (UNPUBLISHED PAPER).
004359 04-09
DEXAMETHASONE-SUPPRESSION-TESTS
DEXAMETHASONE-SUPPRESSION-TESTS IN DEPRESSION AND RESPONSE
TO TREATMENT.
000899 01-16
DEXETIMIDE
TREATMENT OF PARKINSONIAN-SYNDROME WITH DEXETIMIDE.
002111 02-11
DEXTROAMPHETAMINE
DEXTROAMPHETAMINE: COGNITIVE AND BEHAVIORAL-EFFEaS IN
NORMAL AND HYPERAQIVE-BOYS AND NORMAL ADULT MALES.
000716 01-11
DIURNAL GROWTH-HORMONE RESPONSES TO DEXTROAMPHETAMINE IN
NORMAL YOUNG MEN AND POSTMENOPAUSAL-WOMEN.
00341 1 03-13
AUTONOMIC-EFFEaS OF DEXTROAMPHETAMINE IN NORMAL MEN:
IMPLICATIONS FOR HYPERACTIVITY AND SCHIZOPHRENIA.
003437 03-13
THE EFFECT OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON
THE STIMULANT AND ANOREQIC-AQIONS OF DEXTROAMPHETAMINE
IN MAN. „ ,,
004580 04-14
S-136
I/OLUME 19, SUBJECT INDEX
Subject Index
>EXTROAMPHET AMINE-SULFATE
TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERACTIVE-
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL
PARADIGM - A PILOT-STUDY
002126 02-11
EFFECTS OF DEXTROAMPHETAMINE-SULFATE ON REPEATED ACQUISITION-
BEHAVIOR AND MOOD IN HUMANS: A PRELIMINARY REPORT.
003459 03-14
)EXTROMETHORPHAN
HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO
GUINEA-PIG BRAIN
000061 01-03
>EXTROPROPOXYPHENE
INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY-STATE SERUM LEVELS
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-DRUGS IN MAN.
000767 01-13
)FP
INDUCTION OF BEHAVIORAL-SUPERSENSITIVITY TO APOMORPHINE BY
DFP TREATMENT.
004099 04-04
>HT
EFFECTS OF NOMIFENSINE AND DESIPRAMINE ON THE SEQUELAE OF
INTRACEREBRALLY INJECTED 6 OHDA AND 5,6 DHT.
001522 02-03
HIPPOCAMPAL SEROTONIN REUPTAKE AND NOCTURNAL LOCOMOTOR-
ACTIVITY AFTER MICROINJECTIONS OF 5,7 DHT IN THE FORNIX-
FIMBRIA.
002929 03-03
MABETES-INSIPIDUS
BRADYCARDIA, PERSISTENT DIABETES-INSIPIDUS, AND TARDIVE-
DYSKINESIA WITH LITHIUM INTOXICATION.
002427 02-15
)IABETES-INSIPIDUS-LIKE
AnENUATION OF THE LITHIUM-INDUCED DIABETES-INSIPIDUS-LIKE
SYNDROME BY AMILORIDE IN RATS.
002717 03-03
IIABETES-MELIITUS
THE INFLUENCE OF PATIENT BELIEFS ON COMPLIANCE TO THERAPY FOR
DIABETES-MELLITUS. (PH.D. DISSERTATION).
003631 03-17
IIABETIC
ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS.
(UNPUBLISHED PAPER).
000060 01-03
INCREASED URINARY EXCRETION OF CATECHOLAMINES AND THEIR
METABOLITES IN STREPTOZOTOCIN DIABETIC RAT,
000154 01-03
tIAGNOSED
THE INFLUENCE OF METHYLPHENIDATE ON SPONTANEOUS AUTONOMIC-
ACTIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE.
003363 03-1 1
IIAGNOSING
IS MANIA OVERDIAGNOSED?: THE THREE COMMON PITFALLS IN
DIAGNOSING MANIC-DEPRESSIVE-ILLNESS.
003260 03-09
IIAGNOSIS
CHRONIC MOOD-DISORDERS IN DEPRESSED-OUTPATIENTS: DIAGNOSIS
AND RESPONSE TO PHARMACOTHERAPY.
000624 01-09
DIAGNOSIS AND TREATMENT OF ACUTE SCHIZOPHRENIC-PSYCHOSES.
003191 03-08
RECENT ADVANCES IN THE DIAGNOSIS AND TREATMENT OF ANXIETY-
DISORDERS.
003275 03-10
ON THE EVALUATION OF A PROVOCATIVE EEG METHOD USING
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUCTION THROUGH
MEDICATION.
003387 03-1 1
ATTENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNCTION) IN
ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG-
TREATMENT.
003389 03-11
DIFFERENTIAL DIAGNOSIS OF CIMETIDINE-INDUCED DELIRIUM
003488 03-15
THE DIAGNOSIS AND TREATMENT OF NEUROLEPTIC-INDUCED
PARKINSONISM.
003493 03-15
PHENCYCLIDINE (PCP) INTOXICATION: DIAGNOSIS IN STAGES AND
ALGORITHMS OF TREATMENT.
003525 03-15
STANDARDIZATION OF THE DEXAMETHASONE-SUPPRESSION-TEST FOR
THE DIAGNOSIS OF MELANCHOLIA. (UNPUBLISHED PAPER).
004359 04-09
GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF DEPRESSION
004376 04-09
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO.
004387 04-09
DIFFERENTIAL DIAGNOSIS AND TREATMENT OF PANIC AHACKS AND
PHOBIC-STATES.
004424 04-10
DIAGNOSTIC
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF
ELECTROENCEPHALOGRAPHY WITH INTRAVENOUS DIAZEPAM IN
EPILEPSY.
000696 01-11
PCP ABUSE: DIAGNOSTIC AND PSYCHOPHARMACOLOGICAL-TREATMENT
APPROACHES.
000746 01-12
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES. (UNPUBLISHED PAPER)
001910 02-08
DELIRIUM OR PSYCHOSIS? DIAGNOSTIC USE OF THE SODIUM-
AMOBARBITAL INTERVIEW.
002167 02-11
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES.
003167 03-08
CLINICAL DEPRESSIONS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES.
004350 04-09
BLOOD LEVEL MEASUREMENTS OF TRICYCLIC DRUGS AS A DIAGNOSTIC
TOOL.
004368 04-09
DIAGNOSTICS
CLINICAL AND LABORATORY DIAGNOSTICS APPLICATIONS IN
DEPRESSION. (UNPUBLISHED PAPER).
000588 01-09
THE USE OF SENSORY INTEGRATIVE DIAGNOSTICS TO PREDICT
HYPERACTIVE-CHILDRENS RESPONSIVENESS TO METHYLPHENIDATE
(RITALIN) AND PEMOLINE (CYLERT). (PH.D. DISSERTATION).
002133 02-11
DIALKYL-4-PYRAZOLIDINOLS
SYNTHESIS OF PHENYLURETHANS OF 1,2 DIALKYL-4-PYRAZOLIDINOLS AS
ANTICONVULSANT-AGENTS.
003695 04-02
DIALKYLBARBITURATE
GAS-CHROMATOGRAPHIC-PROPERTIES OF 1,3 DIALKYLBARBITURATE
DERIVATIVES.
003658 04-01
DIALYKYl
ON-COLUMN GAS-CHROMATOGRAPHIC-SYNTHESIS OF 1,3 DIALYKYL
(C=l-10), BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES.
003656 04-01
DIALYSIS
ORAL ALUMINUM AND NEUROPSYCHOLOGICAL FUNCTIONING: A STUDY
OF DIALYSIS PATIENTS RECEIVING ALUMINUM-HYDROXIDE GELS.
002283 02-13
DIAMINODIPHENOXYBUTANE
RETINOTOXIC-EFFECTS OF DIAMINODIPHENOXYBUTANE IN RATS.
000444 01-04
DIAPHRAGM
DIPHENYLHYDANTOIN-INDUCED BLOCK OF THE RAT PHRENIC-NERVE
DIAPHRAGM PREPARATION PRETREATED WITH P
HYDROXYMERCURIBENZOATE.
002749 03-03
OXOTREMORINE DOES NOT ENHANCE ACETYLCHOLINE RELEASE FROM
RAT DIAPHRAGM PREPARATIONS.
003819 04-03
DIASTEREOMERS
FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS
BY YOHIMBINE DIASTEREOMERS.
002748 03-03
DIASTOLIC
COVARIANCE OF PLASMA FREE 3 METHOXY-4-
HYDROXYPHENETHYLENEGLYCOL AND DIASTOLIC BLOOD-PRESSURE
003418 03-13
DIAZEPAM
ANALYSIS FOR DIAZEPAM AND NORDIAZEPAM BY ELECTRON-CAPTURE
GAS-CHROMATOGRAPHY AND BY LIQUID-CHROMATOGRAPHY.
000006 01-01
PHARMACOLOGICAL ACTIVITIES OF CLOBAZAM AND DIAZEPAM IN THE
RAT: RELATION TO DRUG BRAIN LEVELS.
000036 01-03
THE EFFECT OF DIAZEPAM ON TENSION AND ELECTROLYTE DISTRIBUTION
IN FROG MUSCLE.
000069 01-03
ENTRY OF DIAZEPAM AND ITS MAJOR METABOLITE INTO
CEREBROSPINAL-FLUID.
000114 01-03
THE EFFECT OF DIAZEPAM ON EEG CHANGES FOLLOWING INTRASEPTAL
ADMINISTRATION OF ATROPINE.
000127 01-03
A PROBABLE SITE-OF-ACTION OF DIAZEPAM IN RAT CEREBELLAR GABA
SYSTEM.
000151 01-03
a,
■if
fe:
S-137
Subject Index
DELAYED CLEARANCE OF DIAZEPAM DUE TO CIMETIDINE.
000164 01-03
INTERACTION OF DIAZEPAM WITH SYNAPTIC TRANSMISSION IN THE IN
VITRO RAT HIPPOCAMPUS.
000178 01-03
DIAZEPAM POTENTIATION OF PURINERGIC DEPRESSION OF CENTRAL
NEURONS.
000233 01-03
PENTOBARBITAL POTENTIATES GABA-ENHANCED (3H) DIAZEPAM
BINDING TO BENZODIAZEPINE-RECEPTORS.
000275 01-03
PROPERTIES OF (3H)DIAZEPAM BINDING-SITES ON RAT BLOOD-
''^''''''- 000317 01-03
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS.
000330 01-03
EFFEaS OF CHLORDIAZEPOXIDE AND DIAZEPAM ON FEEDING
PERFORMANCE IN A FOOD PREFERENCE TEST.
000367 01-04
EFFECTS OF ACUTE AND CHRONIC INTERACTIONS OF DIAZEPAM AND D-
AMPHETAMINE ON PUNISHED-BEHAVIOR OF RATS.
000386 01-04
THE INTERACTION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS.
000389 01-04
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES
BEHAVIOURAL-EFFECTS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN
RATS
000420 01-04
CORRELATION BETWEEN BENZODIAZEPINE-RECEPTOR OCCUPATION AND
ANTICONVULSANT EFFECTS OF DIAZEPAM.
000450 01-04
IMPROVEMENT OF RESTITUTION FROM CEREBRAL ISCHEMIA IN
HYPERGLYCEMIC RATS BY PENTOBARBITAL OR DIAZEPAM.
000475 01-04
BICUCULLINE ANTAGONIZES EFFECTS OF DIAZEPAM ON AGGRESSIVE AND
TIMID-BEHAVIOUR IN MICE.
000485 01-04
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
A DOUBLE-BUND GROUP COMPARATIVE-TRIAL OF MIANSERIN AND
DIAZEPAM IN DEPRESSED-OUTPATIENTS.
000592 01-09
ANXIOLYTIC EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND
PLACEBO. „„ ,„
000648 01-10
KETAZOLAM AND DIAZEPAM IN ANXIETY: A CONTROLLED-STUDY.
000655 01-10
DOUBLE-BUND COMPARISON OF KETAZOLAM, DIAZEPAM AND PLACEBO
IN ONCE-A-DAY VS T.I.D. DOSING.
000660 01-11
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF
ELECTROENCEPHALOGRAPHY WITH INTRAVENOUS DIAZEPAM IN
EPILEPSY.
000696 01-11
EFFECT OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND
RIGIDITY: A QUANTITATIVE STUDY OF REFLEXES AND PLASMA
CONCENTRATIONS.
000701 01-11
INTERSUBJECT AND INTRASUBJEQ VARIATION IN DIAZEPAM FREE
FRACTION.
000747 01-13
PHARMACODYNAMICS AND PHARMACOKINETICS OF DIAZEPAM IN AN
ABUSER.
000867 01-15
EFFEaS OF GABA AND DIAZEPAM ON 3H SEROTONIN RELEASE FROM
HIPPOCAMPAL SYNAPTOSOMES.
001116 02-03
ETHANOL ENHANCES (3H)DIAZEPAM BINDING AT THE BENZODIAZEPINE
GABA-RECEPTOR lONOPHORE COMPLEX.
001154 02-03
THE EFFECT OF EMOTIONAL- STRESS AND DIAZEPAM ON MONOAMINE
METABOLITES IN THE CEREBROSPINAL-FLUID OF CATS. (PH.D.
DISSERTATION).
001260 02-03
EVIDENCE FOR AN ENDOGENOUS COMPOUND INTERFERING WITH 3H
DIAZEPAM BINDING TO RAT-BRAIN MEMBRANES.
001308 02-03
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONISES THE EFFEQ OF
DIAZEPAM ON A FUNCTIONAL GABA-RECEPTOR.
001378 02-03
THE PROCONVULSANT AND DIAZEPAM REVERSING EFFEaS OF ETHYL-
BET A-CARBOLINE-3-CARBOXYLATE.
001399 02-03
Psychopharmacology Abstracts
EFFEaS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC
MECHANISM IN ACTION OF DIAZEPAM.
001414 02-03
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE AQION OF
DIAZEPAM: POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE
AQION IN THE BRAIN.
001428 02-03
A STUDY OF A GLIAL GAMMA AMINOBUTYRIC-ACID SYSTEM: ITS
REGULATION, FUNCTION AND THE EFFECTS OF DIAZEPAM. (PH.D.
DISSERTATION).
001524 02-03
CHRONIC-TREATMENT WITH VALIUM (DIAZEPAM) FAILS TO AFFEQ THE
REPRODUatVE SYSTEM OF THE MALE RAT.
001535 02-03
VESTIBULO-OCULAR REFLEXES IN RABBITS: REDUQION BY INTRAVENOUS
INJEQION OF DIAZEPAM.
001566 02-04
EFFECT OF P CHLOROPHENYLALANINE ON DIAZEPAM WITHDRAWAL
SIGNS IN RATS.
001797 02-04
COMPARISON OF CLONAZEPAM AND DIAZEPAM IN EXPERIMENTAL-
STUDIES.
001815 02-04
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS IN THE OFFSPRING
OF DAMS RECEIVING DIAZEPAM: ONTOGENETIC-STUDIES.
001849 02-05
HIGH-DOSE DIAZEPAM IN SCHIZOPHRENIA
001909 02-08
THE USE OF CLOROTEPIN AND DIAZEPAM IN A COMPLEX THERAPY OF
NEUROSES (CONTROLLED-COMPARISON) .
002064 02-10
KETAZOLAM COMPARED TO DIAZEPAM AND PLACEBO IN THE
TREATMENT OF ANXIETY
002074 02-10
COMPARATIVE PROTEIN BINDING OF DIAZEPAM AND
DESMETHYLDIAZEPAM.
002206 02-13
KINETICS AND NEUROPSYCHOLOGIC-EFFECTS OF IV DIAZEPAM IN THE
PRESENCE AND ABSENCE OF ITS AQIVE N DESMETHYL METABOLITE IN
HUMANS
002229 02-13
HEMODYNAMIC AND CEREBRAL METABOLIC-STUDY OF DIAZEPAM IN
NEUROSURGICAL-RESUSCITATION
002231 02-13
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE-
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A
CONTROLLED-TRIAL.
002329 02-14
DRUG PREFERENCE AND MOOD IN HUMANS: DIAZEPAM.
002334 02-14
CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM,
HALOPERIDOL, PHENELZINE AND D-AMPHET AMINE.
002355 02-14
ACCIDENTAL INTRAARTERIAL INJEQION OF DIAZEPAM.
002598 02-17
DEMONSTRATION AND CHARAQERIZATION OF AN ENDOGENOUS
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM
BOVINE CEREBRAL-CORTEX.
002645 03-01
CENTRAL DEPRESSANT EFFECTS OF CAERULEIN AND CHOLECYSTOKININ-
OQAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND
HALOPERIDOL.
002652 03-02
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONIZES DIAZEPAM
*^'^'^ 002915 03-03
ELECTRICAL-ACTIVITY AND NA-K-ATPASE LEVEL IN THE PENICILLIN-
INDUCED EPILEPTOGENIC-FOCUS OF THE RAT-BRAIN-CORTEX, AND THE
EFFEQ OF DIAZEPAM. 003070 03-04
INTERAQIONS OF DIAZEPAM AND COCAINE IN THE MORPHINE TREATED
RAT. (PH.D. DISSERTATION,. 003115 03-04
A DOUBLE-BLIND CROSSED CLINICAL- STUDY WITH A NEW
PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008), DIAZEPAM, AND
^"^"^^ 003153 03-07
A COMPARATIVE-STUDY ON THE CLINICAL-EFFEQS OF REQAL
DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP
BETWEEN PLASMA LEVEL AND EFFECT. „„.o.„ ^, , ,
003330 03-11
DOUBLE-BUND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR
SUBCHRONIC WITHDRAWAL FROM ALCOHOL
003332 03-11
THE REPLICABILITY OF THE PSYCHOPHYSIOLOGICAL-EFFEQS OF
°'^^^f^^ 003413 03-13
S-138
/OLUME 19, SUBJECT INDEX
DIAZEPAM AS TUMOUR PROMOTER.
ABSENCE OF EFFECT OF DIAZEPAM ON TUMOURS.
CA DIAZEPAM LINK? NO SCIENTIFIC TAKERS SO FAR.
Subject Index
003495 03-15
003497 03-15
003519 03-15
AVAILABILITY OF ISOSORBIDE-DINITRATE, DIAZEPAM AND
CHLORMETHIAZOLE, FROM I.V. DELIVERY SYSTEMS.
003558 03-16
DIAZEPAM ANXIOLYTIC-ACTIVITY IN HIPPOCAMPUS.
003743 04-03
INHIBITION OF (3H)DIAZEPAM BINDING BY AN ENDOGENOUS FRACTION
FROM RAT-BRAIN SYNAPTOSOMES.
003768 04-03
REGIONAL CHANGES IN (3H)DIAZEPAM BINDING IN THE BRAINS OF MICE
AFTER REMOVAL OF THE OLfACTORY-BULBS.
003844 04-03
EFFECT OF DIAZEPAM ON STRESS-INDUCED CHANGES IN BRAIN
HISTAMINE.
003932 04-03
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES.
003984 04-03
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN
BRAIN CELL-CULTURES.
004002 04-03
SCHEDULE DEPENDENT CHANGE OF PUNISHED-RESPONDING AFTER
DIAZEPAM IN RATS.
004165 04-04
3 HYDROXYMETHYL-BETA-CARBOLINE ANTAGONIZES SOME
PHARMACOLOGIC ACTIONS OF DIAZEPAM.
004221 04-04
POTENTIATION OF THE EFFECTS OF ADENOSINE ON ISOLATED CARDIAC-
MUSCLE AND SMOOTH-MUSCLE BY DIAZEPAM.
004266 04-05
RESPIRATORY DEPRESSION PRODUCED BY DIAZEPAM IN CATS: EFFECT OF
ANESTHESIA.
004272 04-05
THE RELATIONSHIPS BETWEEN CLINICAL-RESPONSE,
PSYCHOPHYSIOLOGICAL-VARIABLES AND PU^SMA LEVELS OF
AMITRIPTYLINE AND DIAZEPAM IN NEUROTIC-OUTPATIENTS.
004423 04-10
A DOUBLE-BUND TRIAL: THE USE OF OXPRENOLOL AND DIAZEPAM IN
ANXIETY.
004428 04-10
EFFECT OF TREATMENT WITH SODIUM-VALPROATE AND DIAZEPAM ON
PLASMA CORTICOTROPIN IN NELSONS-SYNDROME.
004463 04-1 1
PROMETHAZINE AND DIAZEPAM POTENTIATE THE HALOPERIDOL-INDUCED
PROLACTIN RESPONSES.
004499 04-13
INTRAVENOUS DIAZEPAM AND ORAL ETHANOL INTERACTION.
004552 04-13
DRUG PREFERENCE IN HUMANS: DOUBLE-BUND CHOICE COMPARISON OF
PENTOBARBITAL, DIAZEPAM AND PLACEBO.
004566 04-14
CASE-REPORT OF UNUSUAL DIAZEPAM ABSTINENCE-SYNDROME.
004643 04-15
MASS SCREENING AND CONFIRMATION OF DIAZEPAM IN URINE BY EMIT
THIN-LAYER-CHROMATOGRAPHY.
004672 04-16
lAZEPAM-INDUCED
DIFFERENTIAL-EFFECTS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS.
000480 01-04
INTERAQION BETWEEN PURINE AND BENZODIAZEPINE: INOSINE
REVERSES DIAZEPAM-INDUCED STIMULATION OF MOUSE
EXPLORATORY-BEHAVIOR.
002972 03-04
DIAZEPAM-INDUCED ATAXIA IN TROTTING SQUIRREL-MONKEYS
004138 04-04
lAZEPAM-RECEPTOR
CHANGES IN MOUSE-BRAIN DIAZEPAM-RECEPTOR BINDING AFTER
PHENOBARBITAL ADMINISTRATION.
000281 01-03
lAZEPINES
COMPARATIVE-STUDY OF SLEEP AND STATE ON AWAKENING WITH TWO
HYPNOTIC DIAZEPINES.
000817 01-14
IBENZAZEPINES
THE EFFECT OF DIBENZAZEPINES (TRICYCUC-ANTIDEPRESSANTS) ON
CEREBRAL CAPILLARY PERMEABIUTY IN THE RAT IN VIVO.
003974 04-03
IBENZEPINE
LARGE-DOSES OF DIBENZEPINE NOVERIL IN THE TREATMENT OF
DEPRESSIVE-STATES.
002020 02-09
CUNICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG-
RESISTANCE.
003245 03-09
DIBUTYRYL-C-AMP
FACILITATION OF LORDOSIS BEHAVIOR IN THE OVARIECTOMIZED
ESTROGEN-PRIMED RAT BY DIBUTYRYL-C-AMP
002957 03-04
DIBUTYRYL-CYCLIC-AMP
CATECHOLAMINE AND 5 HYDROXYTRYPTAMINE SYNTHESIS AND
METABOLISM FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF
DIBUTYRYL-CYCLIC-AMP.
003769 04-03
OIBUTYRYL-CYCLIC-GUANOSINE-MONOPHOSPHATE
INHIBITION OF THE ACTION OF CHOLECYSTOKININ-OCTAPEPTIDE ON THE
GUINEA-PIG ILEUM MYENTERIC PLEXUS BY DIBUTYRYL-CYCLIC-
GUANOSINE-MONOPHOSPHATE.
001291 02-03
DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR
BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND
2,4 DICHLORO-6-PHENYLPHENOXYETHYLAMrNE-HBR (DPEA) INHIBITION
OF FAHY-ACID CONJUGATION TO 1 1 HYDR0XY-DELTA9-
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM.
000179 01-03
DICHLOROBENZYL-TETRAHYDROPYRIMIOONE
PHARMACOLOGY OF 1 DICHLOROBENZYL-TETRAHYDROPYRIMIDONE, A
NOVEL ANTIDEPRESSANT COMPOUND WITH ANTIANXIETY ACTIVITY.
003688 04-02
DICHOTIC
LATERAUZED DEFICITS AND DRUG INFLUENCES ON THE DICHOTIC
LISTENING OF SCHIZOPHRENIC-PATIENTS.
003443 03-14
DICHROISM
COMPARISON OF HIGHLY-ACTIVE AND ACTIVITY DEPLETED HEPARIN BY
CIRCULAR DICHROISM SPECTROSCOPY. (UNPUBLISHED PAPER).
001057 02-01
DIET
EFFECT OF LITHIUM-CHLORIDE IN COYOTE PUP DIET.
001835 02-05
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD
ETHANOL LEVELS IN RATS DRINKING A UQUID DIET.
001865 02-06
DIETARY
FUNCTIONAL AND STRUCTURAL CONSEQUENCES OF LONG-TERM DIETARY
L-DOPA TREATMENT IN MICE.
000257 01-03
EFFECTS OF CHRONIC DIETARY UTHIUM ON ACTIVITY AND REGULATION
OF NA-K-ADENOSINE-TRIPHOSPHATASE IN RAT-BRAIN.
000297 01-03
DIETARY PROTEIN INTAKE INFLUENCES THE ANTIHYPERTENSIVE POTENCY
OF METHYLDOPA IN SPONTANEOUSLY HYPERTENSIVE-RATS.
004025 04-03
SUSTAINED DECREASE IN FAT CONSUMPTION PRODUCED BY
AMPHETAMINE IN RATS MAINTAINED ON A DIETARY SELF-SELEQION
REGIME.
004150 04-04
DIETETIC
DRUG AND DIETETIC THERAPIES FOR HYPERKINETIC-CHILDREN. (PH.D.
DISSERTATION).
003576 03-17
DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE
BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND
2,4 DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR (DPEA) INHIBITION
OF FAHY-ACID CONJUGATION TO 1 1 HYDR0XY-DELTA9-
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM.
000179 01-03
DIETHYLDITHIOCARBAMATE
COMPARISONS OF THE EFFEQS OF GUANETHIDINE, 6
HYDROXYDOPAMINE AND DIETHYLDITHIOCARBAMATE ON RETENTION
OF PASSIVE-AVOIDANCE.
001742 02-04
DIETHYLSTILBESTROL
COMPARATIVE-STUDY OF PROPHYLACTIC LITHIUM AND
DIETHYLSTILBESTROL IN SEXUAL-DEVIANTS.
000663 01-11
DIFENAMIZOLE
NEUROCHEMICAL-STUDIES OF AN ANALGESIC, 1,3 DIPHENYL-5-2-
DIMETHYLAMINOPROPIONAMIDE-PYRAZOLE (DIFENAMIZOLE) .
002771 03-03
DIFFERENTIAL
DIFFERENTIAL REGULATION OF MUSCARINIC AGONIST BINDING-SITES
FOLLOWING CHRONIC CHOUNESTERASE INHIBITION.
000279 01-03
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION.
001310 02-03
DIFFERENTIAL DOPAMINERGIC FUNCTION IN YOUNG AND OLD FEMALE
RATS AS MEASURED BY THREE BEHAVIORS.
001683 02-04
I
3
ISk
'5
4te.
>»
S-139
Subject Index
Psychopharmacology Abstracts
THE ROLE OF DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC AGONISTS
IN CHLORPROMAZINE-INDUCED HYPOTENSION.
001851 02-05
THE DIFFERENTIAL DOSE-EFFECTS OF METHYLPHENIDATE ON
HYPERACTIVE-CHILDREN AND THEIR MOTHERS. (PH.D.
DISSERTATION).
002143 02-11
MIDBRAIN DOPAMINE NEURONS: DIFFERENTIAL RESPONSES TO
AMPHETAMINE ISOMERS.
002680 03-03
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE
AGONIST AND ANTAGONIST RECEPTOR INTERACTIONS.
002688 03-03
DIFFERENTIAL LOSS OF BIOLOGICAL-AQIVITY OF THE ENKEPHALINS
INDUCED BY CURRENT.
002783 03-03
(3H)MIANSERIN: DIFFERENTIAL LABELING OF SEROTONIN AND
HISTAMINE-RECEPTORS IN RAT-BRAIN
002860 03-03
DIFFERENTIAL REVERSAL BY SCOPOLAMINE AND THIP OF THE
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS.
002948 03-04
THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA.
002976 03-04
DIFFERENTIAL ACTIONS OF CLASSICAL AND ATYPICAL ANTIPSYCHOTIC-
DRUGS ON SPONTANEOUS NEURONAL ACTIVITY IN THE AMYGDALOID
COMPLEX.
003131 03-05
DIFFERENTIAL DIAGNOSIS OF CIMETIDINE-INDUCED DELIRIUM.
003488 03-15
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS:
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD
003556 03-16
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS:
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO
003741 04-03
DIFFERENTIAL TOLERANCE TO THE EFFECTS OF MORPHINE ON EVOKED
ACTIVITY IN THE HIPPOCAMPAL SLICE.
003760 04-03
ACTION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
DIFFERENTIAL INHIBITION OF ALPHA 1 -ADRENOCEPTOR AND ALPHA2-
ADRENOCEPTOR MEDIATED PRESSOR RESPONSES IN PITHED RATS
004057 04-03
DIFFERENTIAL DIAGNOSIS AND TREATMENT OF PANIC AHACKS AND
PHOBIC-STATES.
004424 04-10
DIFFERENTIAL-EFFECT
KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFEQ ON
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS.
002743 03-03
DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC-
RECEPTORS.
002914 03-03
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID:
DIFFERENTIAL-EFFECT IN TOLERANT ANIMALS.
003038 03-04
DIFFERENTIAL-EFFECTS
DIFFERENTIAL-EFFECTS OF N DIPROPYLACETATE AND AMINOOXYACETIC-
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS
OF RAT-BRAIN.
000140 01-03
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFEaS OF
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS
ON MORPHINE-INDUCED ANALGESIA.
000311 01-03
DIFFERENTIAL-EFFECTS OF METHYLPHENIDATE ON SIGNALLED AND
NONSIGNALLED REINFORCEMENT.
000380 01-04
DIFFERENTIAL-EFFECTS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS.
000480 01-04
PRINCIPAL AND DIFFERENTIAL-EFFECTS OF HALOPERIDOL AND PLACEBO
TREATMENTS UPON SPEECH DISFLUENCIES IN STUHERERS.
000713 01-11
DIFFERENTIAL-EFFECTS ON BENZODIAZEPINE DISPOSITION BY DISULFIRAM
AND ETHANOL.
000789 01-13
THE DIFFERENTIAL-EFFECTS OF SHORT-ACTING AND LONG-AQING
BENZODIAZEPINES UPON NOCTURNAL SLEEP AND DAYTIME
PERFORMANCE.
000822 01-14
DIFFERENTIAL-EFFECTS OF COCAINE ON LIMBIC EXCITABILITY.
001339 02-03
DIFFERENTIAL-EFFECTS OF VARIOUS STIMULI ON AVP LEVELS IN BLOOD
AND CEREBROSPINAL-FLUID.
001370 02-03
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJEQION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS.
001446 02-03
DIFFERENTIAL-EFFECTS OF IMIPRAMINE IN RATS AS A FUNQION OF DRL
SCHEDULE VALUE.
001714 02-04
DIFFERENTIAL-EFFEaS OF MORPHINE ON FOOD AND WATER INTAKE IN
FOOD DEPRIVED AND FREELY-FEEDING RATS.
001765 02-04
DIFFERENTIAL-EFFEaS OF AMPHETAMINE AND NEUROLEPTICS ON
NEGATIVE VS POSITIVE SYMPTOMS IN SCHIZOPHRENIA
001906 02-08
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES.
002285 02-13
DIFFERENTIAL-EFFECTS OF KAINIC-ACID ON BENZODIAZEPINE-RECEPTORS,
GABA-RECEPTORS, AND GABA-MODULIN IN THE CEREBELLAR-CORTEX
002477 02-16
DIFFERENTIAL-EFFECTS OF PHARMACOLOGICAL-AGENTS AQING ON
MONOAMINERGIC SYSTEMS ON DRUG-INDUCED ANOREXIA.
002533 02-17
DIFFERENTIAL-EFFECTS OF CANNABINOID EXPOSURE AND STRESS ON
PLASMA PROLACTIN, GROWTH-HORMONE AND CORTICOSTERONE
LEVELS IN MALE MICE
002695 03-03
DIFFERENTIAL-EFFEaS OF CLOMIPRAMINE AND CLORGYLINE ON THE
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFEQ OF
CHRONIC-TREATMENT.
002847 03-03
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNCTION IN CAT BRAIN.
002911 03-03
DIFFERENTIAL-EFFECTS OF POTASSIUM ON THE POTENCY OF DIFFERENT
OPIOIDS IN THE MOUSE VAS-DEFERENS.
002935 03-03
DIFFERENTIAL-EFFEaS OF ELECTROCONVULSIVE-SHOCK AND
ANTIDEPRESSANT-DRUGS ON SER0T0NIN2-RECEPT0RS IN RAT-BRAIN.
003878 04-03
DIFFERENTIAL-EFFECTS OF PENTOBARBITAL AND ETHER ON THE SYNAPTIC
TRANSMISSION OF THE HIPPOCAMPAL-CAl -REGION IN THE RAT
003903 04-03
DIFFERENTIAL-EFFEQS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS.
003947 04-03
DIFFERENTIAL-EFFEaS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND
RELEASING-AGENTS ON LOCOMOTOR-AQIVITY IN NORMAL AND IN
RESERPINIZED MICE.
004130 04-04
DIFFERENTIAL-REINFORCEMENT-OF-LOW-RATES
THE EFFEQS OF TRICYCLIC-ANTIDEPRESSANTS ON PERFORMANCE UNDER
A DIFFERENTIAL-REINFORCEMENT-OF-LOW-RATES SCHEDULE IN RATS.
004175 04-04
DIFFERENTIATE
MINI-SYMPOSIUM: III. SIMPLE IN VIVO TESTS THAT DIFFERENTIATE
PROTOTYPE AGONISTS AT OPIATE-RECEPTORS.
004289 04-06
DIFFERENTIATED
N TETRAHYDROFURYIALKYL AND N ALKOXYALKYL DERIVATIVES OF (-)
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID AQION
PROFILES.
000013 01-02
QUESTIONS OF DIFFERENTIATED TREATMENT FOR EPILEPTIC-PATIENTS.
003605 03-17
SOME PRINCIPLES OF DIFFERENTIATED METABOLIC DRUG-TREATMENT IN
COMPREHENSIVE THERAPY OF MENTAL-DISORDERS.
004433 04-1 1
DIFFERENTIATES
CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF
(3H)SULPIRIDE AND (3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS.
004032 04-03
DIFFERENTIATION
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED
DIFFERENTIATION) IN THE MONKEY (MACACA-MULAHA).
00044001-04
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA
D(AND L) GLUTAMYLGLYCINE.
002696 03-03
DIFFERENTIATION OF OPIATE-RECEPTORS IN THE BRAIN BY THE SELEQIVE
DEVELOPMENT OF TOLERANCE.
003088 03-04
S-140
VOLUME 19, SUBJECT INDEX
Subject Index
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT
NICTITATING MEMBRANE.
003777 04-03
MINI-SYMPOSIUM. I. THE IN VIVO DIFFERENTIATION OF OPIATE-
RECEPTORS: INTRODUCTION
004697 04-17
DIFFUSE
BEHAVIORAL CONFIRMATION Of DIFFUSE NOXIOUS INHIBITORY
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS
OPIATES.
002791 03-03
DIFLUORO
FLUORINATED ANALOGUES OF THE TRICYCLIC NEUROLEPTICS: 2,3
DIFLUORO DERIVATIVE OF CLOROTEPIN.
000001 01-01
DIFLUOROMETHYL-DOPA
IRREVERSIBLE INHIBITION OF AROMATIC-L-AMINO-ACID-DECARBOXYLASE
BY ALPHA DIFLUOROMETHYL-DOPA AND METABOLISM OF THE
INHIBITOR.
000248 01-03
DIFLUOROPHENYLSALiCYLIC-ACID
ANALGESIC ACTIVITY OF DIFLUNISAL (MK-647; 5 2,4
OIFLUOROPHENYLSALICYLIC-ACID) IN RATS WITH HYPERALGESIA
INDUCED BY FREUNDS-ADJUVANT.
000502 01-04
DIGITOXIN
NONINTERACTION OF DIGITOXIN AND QUINIDINE.
000968 01-17
DI60XIN
SUBJECTIVE ASSESSMENT OF SEXUAL-DYSFUNCTION OF PATIENTS ON
LONG.TERM ADMINISTRATION OF DIGOXIN.
002443 02-15
EFFECT OF DOSE ON BIOAVAILABILITY OF ORAL DIGOXIN.
003161 03-07
DIHYDRO-6-PHENYL-1 H-S-TRIAZOLOBENZODIAZEPIN-1 -ONES
2,4 DIHYDRO-6-PHENYL-lH-S-TRIAZOLOBENZODIAZEPIN-l-ONES WITH
ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY.
001075 02-02
DIHYDROALPRENOLOL
DOWN REGULATION OF DIHYDROALPRENOLOL AND IMIPRAMINE
BINDING-SITES IN BRAIN OF RATS REPEATEDLY TREATED WITH
IMIPRAMINE.
001317 02-03
DIHYDROCAPSAICIN
EXCITATORY EFFECTS OF DIHYDROCAPSAICIN ON NOCICEPTIVE NEURONS
IN THE MEDIAL THALAMUS.
003714 04-03
DIHYDROERGOCRISTINE
INHIBITION OF SULPIRIDE-INDUCED PROLACTIN SECRETION BY
DIHYDROERGOCRISTINE IN MAN.
002277 02-13
DIHYDROERGOCRYPTINE
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF
ALPHA-ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA
HYBRID CELLS.
003823 04-03
DIHYDROERGOTAMINE
DRUG-INDUCED ARTERIAL HYPOTENSION IN PSYCHIATRIC-PATIENTS
TREATED WITH DIHYDROERGOTAMINE.
001950 02-08
DIHYDROERGOTOXINE
NEUROPHARMACOLOGY OF BROMOCRIPTINE AND DIHYDROERGOTOXINE
(HYDERGINE).
001346 02-03
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT.
003703 04-02
CATECHOLAMINE TURNOVER IN RAT-CEREBRAL-CORTEX AND CAUDATE
FOLLOWING REPEATED TREATMENT WITH DIHYDROERGOTOXINE.
003765 04-03
DIHYDROMORPHINE
LOCALIZATION OF NALOXONE SENSITIVE (3H)DIHYDR0M0RPHINE
BINDING-SITES WITHIN THE HIPPOCAMPUS OF THE RAT.
001368 02-03
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL
HEMISPHERES OF AGED MALE RATS.
003936 04-03
DIHYDROPICROTOXININ
SOLUBILIZATION OF THE DIHYDROPICROTOXININ BINDING-SITES.
001192 02-03
INTERACTION OF STEREOISOMERS OF BARBITURATES WITH (3H)ALPHA
DIHYDROPICROTOXININ BINDING-SITES.
004036 04-03
DIHYDROXY
DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND
CYCLIC-AMP-PHOSPHODIESTERASE .
001405 02-03
DIHYDROXYNOMIFENSINE
EFFECTS OF 3', 4' DIHYDROXYNOMIFENSINE ON THE DOPAMINE
VASCULAR RECEPTOR.
003890 04-03
DIHYDROXYPHENYLACETIC-ACID
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID
(DOPAC) LEVELS Of INDIVIDUAL BRAIN NUCLEI, EFFECTS OF
HALOPERIDOL AND PARGYLINE.
003792 04-03
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-IO, USING HIGH.
004305 04-06
DIHYDROXYPHENYLALANINE
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN.
003941 04-03
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
DIHYDROXYPHENYLETHYLENE-GLYCOL-SULFATE
EFFECTS OF MORPHINE AND OTHER CENTRALLY-ACTING DRUGS ON 3,4
DIHYDROXYPHENYLETHYLENE-GLYCOL-SULFATE (D0PEG-S04) IN RAT-
BRAIN.
000136 01-03
DIHYDROXYPHENYLETHYLENEGLYCOL
POSTMORTEM STABILITY OF BRAIN 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND 3,4
DIHYDROXYPHENYLETHYLENEGLYCOL IN THE RAT AND MOUSE.
004048 04-03
DIHYDROXYTRYPTAMINE
UNILATERAL 5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE DORSAL
RAPHE NUCLEUS (DRN) AND RAT ROTATIONAL-BEHAVIOUR.
001578 02-04
5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE
AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED-
BEHAVIOUR IN THE RAT.
001589 02-04
THE EFFECTS OF INTRAVENTRICULAR 6 HYDROXYDOPAMINE AND 5,6
DIHYDROXYTRYPTAMINE ON MORPHINE-INDUCED LOCOMOTOR-
STIMULATION.
001784 02-04
DENERVATION SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN RATS
FOLLOWING SPINAL TRANSECTION AND 5,7 DIHYDROXYTRYPTAMINE
INJECTION.
003722 04-03
DIHYDROXYTRYPTAMINE-INDUCED
5,7 DIHYDROXYTRYPTAMINE-INDUCED MOUSE-KILLING AND
BEHAVIORAL-REVERSAL WITH VENTRICULAR ADMINISTRATION OF
SEROTONIN IN RATS.
001562 02-04
DIISOPROPYLTRYPT AMINE
N,N DIISOPROPYLTRYPTAMINE (DIPT) AND 5
METHOXYDIISOPROPYLTRYPT AMINE (5 MEO-DIPT). TWO ORALLY
ACTIVE TRYPTAMINE ANALOGS WITH CNS ACTIVITY.
004310 04-07
DIKETOPIPERAZINE
HISTIDYL-PROLINE DIKETOPIPERAZINE DECREASES FOOD INTAKE IN RATS.
004181 04-04
DILATION
CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE
CANINE FEMORAL VASCUUR BED.
003911 04-03
DILATOR
DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR
TRANSMITTER IN THE CAT CEREBRAL-ARTERY.
001336 02-03
DILTIAZEM
TREATMENT OF UNSTABLE ANGINA BY DILTIAZEM.
004307 04-07
DILUTION
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
DIMENSIONS
SOME OBSERVATIONS ON THE PSYCHOLOGICAL DIMENSIONS OF
PLACEBO-EFFECTS.
003573 03-17
I
^5?
lai.
'lit
etc
fi5
tu.
*
If*
'C
S-141
Subject Index
DIMETHOXY-4-ALKYLPHENYLISOPROPYI.AMINES
DOM AND RELATED 2,5 DIMETHOXY-4-ALKYLPHENYLISOPROPYLAMINES:
BEHAVIORAL AND SEROTONIN-RECEPTOR PROPERTIES.
003690 04-02
DIMETHOXY-4-METHYI.AMPHET AMINE
ENHANCEMENT OF THE BEHAVIORAL-EFFECTS OF 2,5 DIMETHOXY-4-
METHYLAMPHET AMINE (DOM) BY PRETREATMENT WITH P
CHLOROPHENYLALANINE.
000364 01-04
THE EFFECTS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5
DIMETHOXY-4-METHYLAMPHET AMINE (DOM) AND D-AMPHETAMINE
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE
TREATED RATS. „„,.„. „o„.
001595 02-04
THE EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON
OPERANT-BEHAVIOR: INTERACTIONS WITH OTHER NEUROACTIVE-
*^'''^- 004089 04-04
DIMETHOXYMETHYL-PHENOBARBITAL
METABOLISM OF DIMETHOXYMETHYL-PHENOBARBITAL (ETEROBARB) IN
PATIENTS WITH EPILEPSY. ^^ „^ ,^
002235 02-13
DIMETHYL-M-TYRAMINE
THE ROLE OF DOPAMINE IN THE HYPERMOTILITY INDUCED BY H-77-77
(4 ALPHA DIMETHYL-M-TYRAMINE) IN MICE.
001762 02-04
DIMETHYLAMINO-TETRAHYDROAZEPINOPHENOTHIAZINE
CONFORMATIONALLY RESTRICTED PHENOTHIAZINE NEUROLEPTICS. 1. 3
DIMETHYLftMINO-TETRAHYDROAZEPINOPHENOTHIAZINE.
001359 02-03
DIMETHYLAMINOBUTYNYICYCIOHEXYLHYDROXY
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE ACETYLCHOLINE
ANTAGONIST OIMETHYL^MINOBUTYNYLCYCLOHEXYLHYDROXY 2
PHENYLACETATE HCL. „ „
000003 01-01
DIMETHYLAMINOPROPYI-5-METHYI-3-PHENYL-1H-INDAZOIE
PHARMACOLOGICAL- STUDIES ON A NEW THYMOLEPTIC
ANTIDEPRESSANT. DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1 H-
INDAZOLE (FS-32).
001659 02-04
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT,
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL- 1 H-INOAZOLE (FS-32)
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
DIMETHYLTRYPT AMINE
BEHAVIOURAL-CHANGES INDUCED BY N.N DIMETHYLTRYPTAMINE IN
RODENTS
000413 01-04
DIMETHYLTRYPT AMINES
STUDIES ON SEVERAL 7 SUBSTITUTED N,N DIMETHYLTRYPTAMINES.
001020 02-01
DIMINISHES
PIRACETAM DIMINISHES HIPPOCAMPAL ACETYLCHOLINE LEVELS IN RATS.
002934 03-03
DIMINUTION
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF
BINDING-SITES IN DEPRESSED-PATIENTS.
003427 03-13
DINORLAAM
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM)
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND
DINORLAAM, DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT.
000505 01-04
DIPHENYL-5-2-DIMETHYLAMINOPROPIONAMIDE-PYRAZOLE
NEUROCHEMICAL-STUDIES OF AN ANALGESIC, 1,3 DIPHENYL-5-2-
DIMETH YLAMINOPROPIONAMIDE-PYRAZOLE (DIFENAMIZOLE) .
002771 03-03
DIPHENYLHYDANTOIN
PLASMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE.
000102 01-03
EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL
AND DIPHENYLHYDANTOIN IN THE ELEQROSHOCK-TEST IN MICE.
000163 01-03
EFFECTS OF DIPHENYLHYDANTOIN ON SPONTANEOUS MOTOR-AQIVITY.
000284 01-03
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
SERUM CONCENTRATIONS OF PHENOBARBITAL AND
DIPHENYLHYDANTOIN IN SEVERE MENTALLY-HANDICAPPED AND
PHYSICALLY-HANDICAPPED-PATIENTS.
000856 01-15
PHOSPHORYLATION OF THE MEMBRANE-BOUND ACETYLCHOLINE-
RECEPTOR: INHIBITION BY DIPHENYLHYDANTOIN.
001257 02-03
Psychopharmacology Abstracts
CRITICAL PERIODS FOR DIPHENYLHYDANTOIN AND PHENOBARBITAL
ADMINISTRATION DURING GESTATION.
001630 02-04
PERINATAL EFFECTS OF PSYCHOTROPIC-DRUGS: THE ANTICONVULSANT-
DRUG DIPHENYLHYDANTOIN. (UNPUBLISHED PAPER).
001842 02-05
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/AND
DIPHENYLHYDANTOIN IN SERUM LIPIDS.
002281 02-13
PAROXYSTIC-DYSKINESIAS DURING TREATMENT WITH
DIPHENYLHYDANTOIN.
002319 02-14
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND
DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY
OF ADULT SENSORY GANGLION CELLS.
002692 03-03
DIPHENYLHYDANTOIN REDUCES THE OUTWARD-CURRENT OF THE AQION
POTENTIAL IN APLYSIA.
002805 03-03
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMinERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM- VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
EFFECTS OF WITHDRAWAL FROM LONG-TERM DIPHENYLHYDANTOIN
TREATMENT ON AUDIOGENIC-SEIZURES AND MAXIMAL
ELECTROSHOCK-INDUCED SEIZURES IN RATS.
004101 04-04
MEASUREMENTS OF NERVE CONDUQION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT
004441 04-11
THE EFFECT OF DIPHENYLHYDANTOIN ON EEG CURVES IN EPILEPTICS
004494 04-11
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN.
004638 04-15
A COMPARISON OF RADIOIMMUNOASSAY WITH SPEQROPHOTOMETRY
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN
CONCENTRATIONS.
004684 04-16
DIPHENYLHYDANTOIN-INDUCED
OIPHENYLHYDANTOIN-INDUCED BLOCK OF THE RAT PHRENIC-NERVE
DIAPHRAGM PREPARATION PRETREATED WITH P
HYDROXYMERCURIBENZOATE
002749 03-03
DIPIPERIDINOETHANE
SYSTEMIC DIPIPERIDINOETHANE MIMICS THE CONVULSANT AND
NEUROTOXIC-ACTIONS OF KAINIC-ACIO.
000222 01-03
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN
STRUaURES DUE TO DIPIPERIDINOETHANE INTOXICATION.
004273 04-05
DIPOLAR
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYOROCHLORIDE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
DIPOTASSIUM-CHLORAZEPATE
PHARMACOPSYCHOLOGICAL INVESTIGATION OF CHANGES IN MOOD
INDUCED BY DIPOTASSIUM-CHLORAZEPATE WITH AND WITHOUT
SIMULTANEOUS ALCOHOL ADMINISTRATION.
000825 01-14
PHARMACOKINETICS OF DIPOTASSIUM-CHLORAZEPATE IN PATIENTS
AFTER REPEATED 50MG ORAL DOSES.
002211 02-13
DIPOTASSIUM-CLORAZEPATE
PHARMACOPSYCHOLOGICAL INVESTIGATIONS CONCERNING THE
COMBINED EFFECTS OF DIPOTASSIUM-CLORAZEPATE AND ETHANOL.
003456 03-14
DIPROPYL-ADTN
AQIVATION OF PRESYNAPTIC ALPHA NORADRENALINE-RECEPTORS IN
RAT-BRAIN BY THE POTENT DOPAMINE-MIMETIC N,N DIPROPYL-ADTN.
001390 02-03
DIPROPYLACET AMIDE
EEG AND ANTICONVULSANT EFFEQS OF DIPROPYLACETIC-ACID AND
DIPROPYLACET AMIDE IN THE BABOON PAPIO-PAPIO.
001210 02-03
DIPROPYLACETATE ^„,^
DIFFERENTIAL-EFFEaS OF N DIPROPYLACETATE AND AMINOOXY ACETIC-
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS
OF RAT-BRAIN. „ „, „,
000140 01-03
S-142
VOLUME 19, SUBJECT INDEX
Subject Index
DIPROPYLACETATE-INDUCED
DIPROPYLACETATE-INDUCED ABSTINENCE-BEHAVIOUR AS A POSSIBLE
CORRELATE OF INCREASED GABAERGIC ACTIVITY IN THE RAT.
001606 02-04
DIPROPYLACETIC-ACID
EEC AND ANTICONVULSANT EFFECTS OF DIPROPYLACETIC-ACID AND
DIPROPYLACETAMIDE IN THE BABOON PAPIO-PAPIO.
001210 02-03
INFLUENCE OF DIPROPYLACETIC-ACID ON THALAMOCORTICAL RESPONSES
IN RATS.
001419 02-03
DIPSOGENIC-EFFECT
DIPSOGENIC-EFFECT OF L 5 HYDROXYTRYPTOPHAN IN RATS
001623 02-04
DIRECTIONALITY
POSTURAL ASYMMETRY AND DIRECTIONALITY OF ROTATION IN RATS.
001729 02-04
DOES POSTURAL ASYMMETRY INDICATE DIRECTIONALITY OF ROTATION
IN RATS: ROLE OF SEX AND HANDLING.
003061 03-04
DIRECTIONS
DEPRESSION IN THE ELDERLY; RESEARCH DIRECTIONS IN
PSYCHOPATHOLOGY, EPIDEMIOLOGY, AND TREATMENT.
000998 01-17
DISADVANTAGES
ADVANTAGES AND DISADVANTAGES OF PROLONGED USE OF
NEUROLEPTICS.
003470 03-15
DISAGGREGATION
AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION
IN RATS: EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING-
AGENTS.
001531 02-03
DISCHARGE
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL
HEMORRHAGE PATIENTS
002295 02-13
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS
AFER HOSPITAL DISCHARGE IN THE DISTRICTS TEPLICE AND UHERSKE-
HRADISTE.
002518 02-17
EFFEQS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM:
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON.
002884 03-03
EFFECTS OF ACUTE AND CHRONIC AMPHETAMINE TREATMENT ON
PURKINJE NEURON DISCHARGE IN RAT CEREBELLUM.
003793 04-03
EFFECT OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE
DISCHARGE INDUCED BY CARBACHOL IN THE RABBIT.
003951 04-03
DISCHARGED
FOLLOWUP TREATMENT AND AFTERCARE OF DISCHARGED
SCHIZOPHRENIC-PATIENTS.
000944 01-17
DISCHARGES
INHIBITORY AQIONS OF TAUROCYAMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
ANTIPEROXIDANT PRETREATMENT AND IRON-INDUCED EPILEPTIFORM
DISCHARGES IN THE RAT: EEG AND HISTOPATHOLOGIC STUDIES.
002930 03-03
DISCONTINUATION
DISCONTINUATION OF ORAL AND DEPOT FLUPHENAZINE IN
SCHIZOPHRENIC-PATIENTS AFTER ONE YEAR OF CONTINUOUS
MEDICATION: A CONTROLLED- STUDY.
001931 02-08
PANIC-ANXIETY AFTER ABRUPT DISCONTINUATION OF AMITRIPTYLINE.
003223 03-09
EFFEQS OF GRADUAL DECREASE AND DISCONTINUATION OF
NEUROLEPTICS ON CLINICAL CONDITION AND TARDIVE-DYSKINESIA.
003469 03-15
DISCONTINUATION OF ANTIPSYCHOTIC-DRUG THERAPY.
003514 03-15
CLINICAL AND BIOCHEMICAL-CORRELATIONS IN ABRUPT
DISCONTINUATION OF PSYCHOPHARMACOTHERAPY
004330 04-08
A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF
SCHIZOPHRENIA.
004584 04-14
DISCONTINUING
AN INVESTIGATION OF SOME SIDE-EFFECTS IN 47 PSYCHOTIC-PATIENTS
DURING TREATMENT WITH CLOZAPINE AND DISCONTINUING OF THE
TREATMENT.
002424 02-15
DISCRETE
DIFFERENTIAL-EFFECTS OF N DIPROPYLACETATE AND AMINOOXYACETIC-
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS
OF RAT-BRAIN,
000140 01-03
THE EFFECTS OF OPIATES ON THE LEVELS OF CYCLIC-GUANOSINE-
MONOPHOSPHATE IN DISCRETE AREAS OF THE RAT CENTRAL-
NERVOUS-SYSTEM.
000220 01-03
BIOCHEMICAL-LOCALIZATION AND CHARACTERIZATION OF BOMBESIN-
LIKE-PEPTIDES IN DISCRETE REGIONS OF RAT-BRAIN. (UNPUBLISHED
PAPER).
001046 02-01
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN
DISCRETE BRAIN AREAS. (PHD DISSERTATION).
001213 02-03
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN
FOLLOWING INTERAVENTRICULAR INJECTION.
001239 02-03
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF
DISCRETE RAT-BRAIN NUCLEI,
002635 03-01
MONOAMINE-OXIDASE-B ACTIVITIES TOWARD BETA PHENYLETHYLAMINE
IN DISCRETE HYPOTHALAMIC AND CIRCUMVENTRICULAR NUCLEI OF
THE RAT.
002781 03-03
INFLUENCE OF ESTROGEN AND PROGESTERONE ON GLUTAMIC-ACID-
DECARBOXYLASE ACTIVITY IN DISCRETE REGIONS OF RAT-BRAIN.
002927 03-03
DISCRIMINABILITY
THE EFFECT OF SEROTONIN DEPLETION ON THE DISCRIMINABILITY OF LSD.
000499 01-04
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
DISCRIMINANT
DRUG-VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA:
APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.
000844 01-15
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO: A DISCRIMINANT FUNCTION ANALYSIS.
002482 02-16
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO. A DISCRIMINANT FUNCTION ANALYSIS. (UNPUBLISHED
PAPER).
004420 04-10
DISCRIMINATE
USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETECT AND
DISCRIMINATE ACTIONS OF DRUGS AND TOXICANTS.
000503 01-04
DISCRIMINATED
MORPHINE EFFECTS UPON DISCRIMINATED APPROACH AND
DISCRIMINATED AVOIDANCE IN RATS: ANTAGONISM BY NALOXONE.
000338 01-04
DISCRIMINATION
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
INVESTIGATION OF NARCOTICS AND ANTITUSSIVES USING DRUG
DISCRIMINATION TECHNIQUES.
000447 01-04
DRUGS AND THE DISCRIMINATION OF DURATION.
001561 02-04
EFFECTS OF MORPHINE, D-AMPHET AMINE, AND PENTOBARBITAL ON
SHOCK AND LIGHT DISCRIMINATION PERFORMANCE IN RATS.
001639 02-04
THE EFFECT OF MORPHINE, PIMOZIDE AND NALOXONE ON
DISCRIMINATION BY RATS IN A SHOCK-ESCAPE-TEST.
001700 02-04
GO-HERE-GO-THERE PERFORMANCE AFTER AMPHETAMINE: THE
IMPORTANCE OF THE RESPONSE REQUIREMENT IN SUCCESSIVE
DISCRIMINATION.
001759 02-04
LACK OF EFFECT OF CHOLINE AND NARCOTIC ANTAGONISTS UPON
APOMORPHINE DISCRIMINATION.
001770 02-04
EFFECTS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND
DISTRIBUTION OF CORRECT RESPONDING ON A SIMULTANEOUS
DISCRIMINATION TASK IN THE RAT.
001806 02-04
a.
m
•«it
■'it
He
IS'
I
S-143
Subject Index
DISCRIMINATION OF FUNCTIONALLY HETEROGENEOUS RECEPTOR
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC
PROPERTIES OF METOCLOPRAMIDE.
002877 03-03
THE EFFECTS OF PIMOZIDE DURING PAIRING ON THE TRANSFER OF
CLASSICAL CONDITIONING TO AN OPERANT DISCRIMINATION.
002956 03-04
EXTENDED SCHEDULE TRANSFER OF ETHANOL DISCRIMINATION.
003087 03-04
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
METHADONE-INDUCED ATTENUATION OF THE EFFECTS OF DELTA9
TETRAHYDROCANNABINOL ON TEMPORAL DISCRIMINATION IN
PIGEONS.
004095 04-04
DISCRIMINATION OF ELECTRIC-SHOCK: EFFECTS OF SOME OPIOID AND
NONOPIOID DRUGS.
004106 04-04
A SIGNAL-DETECTION-ANALYSIS OF MORPHINE EFFECTS ON THE
RESPONSE BIAS OF RATS IN A TWO-SHOCK DISCRIMINATION TASK
004124 04-04
NARCOTIC DISCRIMINATION IN PIGEONS.
004132 04-04
RAPID ACQUISITION OF A TWO-DRUG DISCRIMINATION: TIME OF DAY
EFFECT UPON SALINE STATE.
004214 04-04
METHYLMERCURY-INDUCED CHANGES IN OPERANT DISCRIMINATION BY
THE PIGEON.
004271 04-05
DISCRIMINATIONS
EFFECTS OF PHENCYCUDINE, PENTOBARBITAL, AND D-AMPHETAMINE ON
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL
DISCRIMINATIONS IN MONKEYS.
001723 02-04
DISCRIMINATIVE
REINFORCING, DISCRIMINATIVE AND ACTIVATING PROPERTIES OF
AMPHETAMINE.
000804 01-14
THE EFFECTS OF OPIATE ANTAGONISTS ON THE DISCRIMINATIVE
STIMULUS PROPERTIES OF ETHANOL.
002947 03-04
INTRAVENTRICULAR CORTICOSTERONE INJECTION FACILITATES MEMORY
OF AN APPETITIVE DISCRIMINATIVE TASK IN MICE.
003051 03-04
DISCRIMINATIVE RESPONSE CONTROL BY NALOXONE IN MORPHINE
PRETREATED RATS.
003053 03-04
PHENCYCLIDINE-LIKE DISCRIMINATIVE EFFEQS OF OPIOIDS IN THE RAT
004136 04-04
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL
BY ANXIOLYTICS WITH DRUGS ACTING ON THE GABA SYSTEM.
004193 04-04
DISCRIMINATIVE-STIMULUS
DISCRIMINATIVE- STIMULUS EFFECTS OF NALTREXONE IN THE MORPHINE-
DEPENDENT RAT.
000391 01-04
LSD-25 AS A DISCRIMINATIVE-STIMULUS FOR RESPONSE SELECTION BY
PIGEONS.
000412 01-04
DISCRIMINATIVE-STIMULUS EFFECTS OF PENTOBARBITAL IN PIGEONS.
001651 02-04
DELTA9 THC AS A DISCRIMINATIVE-STIMULUS IN RATS AND PIGEONS:
GENERALIZATION TO THC METABOLITES AND SP-1 1 1 .
001666 02-04
DISCRIMINATIVE-STIMULUS EFFECTS OF PROTOTYPE OPIATE-RECEPTOR
AGONISTS IN MONKEYS.
001803 02-04
TOLERANCE TO THE DISCRIMINATIVE-STIMULUS PROPERTIES OF D-
AMPHET AMINE.
002953 03-04
DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE, NORCOCAINE, AND
N ALLYLNORCOCAINE.
002954 03-04
DISCRIMINATIVE-STIMULUS PROPERTIES OF PHENCYCUDINE AND FIVE
ANALOGUES IN THE SQUIRREL-MONKEY.
002961 03-04
INFLUENCE OF MORPHINE ON THE DISCRIMINATIVE-STIMULUS
PROPERTIES OF REWARDING LATERAL HYPOTHALAMIC STIMULATION.
(PH.D. DISSERTATION).
003041 03-04
DISCRIMINATIVE-STIMULUS EFFEQS OF ETORPHINE IN RHESUS-
MONKEYS.
004134 04-04
DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE RELATED TO AN
ANXIOGENIC ACTION.
004219 04-04
DISCRIMINATIVE-STIMULUS EFFEaS OF CYCLAZOCINE IN THE RAT
004236 04-04
Psychopharmacology Abstracts
DISCRIMINATIVE-STIMULUS PROPERTIES OF THE HALLUCINOGENIC-AGENT
DOM.
004260 04-04
MINI-SYMPOSIUM. IV. DISCRIMINATIVE-STIMULUS EFFECTS OF
NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED AQIONS.
004719 04-17
DISEASE-INDUCED
DISEASE-INDUCED CHANGES IN THE PLASMA BINDING OF BASIC DRUGS.
000975 01-17
DISFLUENCIES
PRINCIPAL AND DIFFERENTIAL-EFFECTS OF HALOPERIDOL AND PLACEBO
TREATMENTS UPON SPEECH DISFLUENCIES IN STUHERERS.
00071301-11
DISINHIBITING-AGENT
PERSPECTIVES ON PRAZINIL (CARPIPRAMINE): A DISINHIBITING-AGENT
WITH NO NEUROLEPTIC ACTIVITY. A REVIEW OF 38 CASES
003149 03-07
DISINHIBITION
DISINHIBITION OF BEHAVIOR BY ANTIANXIETY-DRUGS.
002403 02-15
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM-
ACETATE, MONOFLUOROACETATE AND INSULIN-INDUCED
HYPOGLYCEMIA,
004276 04-05
DISINHIBITORS
METHODOLOGICAL-CONSIDERATIONS CONCERNING THE PRESCRIPTION
AND USE OF SO CALLED DISINHIBITORS
002571 02-17
DISINHIBITORY
CARPIPRAMINE: A DISINHIBITORY DRUG COMPOUND IN CHRONIC
SCHIZOPHRENIA
003192 03-08
DISORDERS
THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH
DEPRESSIVE-SYNDROMES
000625 01-09
BRAIN FUNQION IN OLD-AGE: EVALUATION OF CHANGES AND
DISORDERS.
000684 01-11
DISORDERS OF SMOOTH-PURSUIT EYE-MOVEMENTS IN SCHIZOPHRENICS
AND THE EFFECT OF NEUROLEPTICS IN THERAPEUTIC DOSES.
001912 02-08
DRUG-INDUCED DISORDERS OF THE URINARY TRAQ.
002393 02-15
DRUG-INDUCED DISORDERS OF THE EYE.
002396 02-15
DRUG-INDUCED DISORDERS OF THE LIVER.
002397 02-15
DRUG-INDUCED DISORDERS OF MUSCLE.
002435 02-15
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFEaS OF ORAL MAGNESIUM
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM.
003291 03-11
DISORIENTATION
AGITATION DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON
CIMETIDINE A REPORT OF THREE CASES AND LITERATURE REVIEW.
000896 01-15
DISPENSER
A DRUG DISPENSER TO MEASURE INDIVIDUAL DRINKING IN RAT
COLONIES.
000530 01-06
DISPOSITION
DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT
METABOLISM DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND
CHOLERETIC-EFFECT
000073 01-03
EFFEaS OF UREA ON HEXOBARBITAL AND ANTIPYRINE DISPOSITION IN
RATS
000307 01-03
DIFFERENTIAL-EFFECTS ON BENZODIAZEPINE DISPOSITION BY DISULFIRAM
AND ETHANOL. „ ,„
000789 01-13
CHLORDIAZEPOXIDE AND OXAZEPAM DISPOSITION IN CIRRHOSIS
000790 01-13
THE COMPARATIVE DISPOSITION OF NOMIFENSINE (MERITAL) IN THE
PREGNANT AND NONPREGNANT RAT
000853 01-15
DISPOSITION OF (3H) PHENCYCUDINE IN THE RAT AFTER SINGLE-DOSES
AND MULTIPLE-DOSES.
001375 02-03
EFFECTS OF ANTICONVULSANTS AND METHOTREXATE ON CALCIUM
DISPOSITION, „^
001840 02-05
DISPOSITION AND AQIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY.
001878 02-06
S-144
VOLUME 19, SUBJECT INDEX
Subject Index
INFLUENCE OF PHENYTOIN AND PHENOBARBITAL ON THE DISPOSITION OF
A SINGLE-ORAL-DOSE OF CLONAZEPAM
002248 02-13
DISPOSITION AND PHARMACOLOGICAL-EFFECTS OF M
CHLOROPHENYLPIPERAZINE IN RATS
002995 03-04
DISPOSITION OF METHADONE IN THE OVINE MATERNAL FETAL UNIT.
004027 04-03
DISRUPTION
DISRUPTION OF SELECTIVE AHENTION BY APOMORPHINE, BUT NOT
AMPHETAMINE, IN THE MONGOLIAN-GERBIL.
000358 01-04
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS
002700 03-03
DISRUPTION OF AUTOSHAPED RESPONDING TO A SIGNAL OF BRAIN-
STIMULATION REWARD BY NEUROLEPTIC-DRUGS.
004199 04-04
DISRUPTIVE
NALOXONE POTENTIATES THE DISRUPTIVE EFFECTS OF MESCALINE ON
OPERANT-RESPONDING IN THE RAT.
000365 01-04
DISSIMILAR
DISSIMILAR EFFECTS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE.
000173 01-03
DISSIMILARITIES
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2
DOPAMINE-RECEPTORS IN THE CNS.
001480 02-03
DISSOCIATION
DISSOCIATION OF THE STRYCHNINE EFFECT ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES.
000816 01-14
BETA ENDORPHIN: DISSOCIATION OF RECEPTOR BINDING-ACTIVITY FROM
ANALGESIC POTENCY.
001081 02-02
DISSOCIATION OF D-AMPHETAMINE-INDUCED LOCOMOTOR-ACTIVITY AND
STEREOTYPED-BEHAVIOUR BY LESIONS OF THE SUPERIOR-COLLICULUS.
001755 02-04
DISSOCIATION OF THE STRYCHNINE EFFECT ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES.
002155 02-11
CLONIDINE ANALGESIA AND SUPPRESSION OF OPERANT RESPONDING:
DISSOCIATION OF MECHANISM.
003046 03-04
DISSOCIATION BETWEEN FREE AND BOUND PHENYTOIN LEVELS IN
PRESENCE OF SODIUM-VALPROATE.
003367 03-1 1
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK-
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES)
003898 04-03
DISSOCIATIVE-EFFECTS
REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION:
DISSOCIATIVE-EFFECTS OF COCAINE.
004160 04-04
DISSOCIATIVE-SYNDROMES
THE USE OF A MORPHINE ANTAGONIST (NALOXONE) IN THE TREATMENT
OF DISSOCIATIVE-SYNDROMES.
003194 03-08
DISTRESS
ASCENDING ENDORPHIN INHIBITION OF DISTRESS VOCALIZATION.
003011 03-04
DISTRIBUTION
(3H) 2 AMINODIHYDROXYTETRAHYDRONAPHTHALENE (ADTN):
REGIONAL DISTRIBUTION AND IN VIVO BINDING AFTER ACUTE AND
CHRONIC DRUG-TREATMENT.
000052 01-03
EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE
RELEASE.
000067 01-03
THE EFFECT OF DIAZEPAM ON TENSION AND ELECTROLYTE DISTRIBUTION
IN FROG MUSCLE.
000069 01-03
DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT
METABOLISM, DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND
CHOLERETIC-EFFECT.
000073 01-03
STUDIES ON THE DISTRIBUTION OF 14C SULPIRIDE AND ITS METABOLITES
IN THE RAT AND GUINEA-PIG.
000078 01-03
DISTRIBUTION AND EXCRETION IN THE RAT AND MONKEY OF (82BR)
BROMOCRIPTINE.
000196 01-03
REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 125! TYR8-
SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES.
000259 01-03
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJECTION.
000261 01-03
PREDICTION OF THE VOLUME OF DISTRIBUTION FROM IN VITRO DATA
AND USE FOR ESTIMATING THE ABSOLUTE EXTENT OF ABSORPTION
000907 01-16
ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA.
001151 02-03
EFFECTS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND
DISTRIBUTION OF CORRECT RESPONDING ON A SIMULTANEOUS
DISCRIMINATION TASK IN THE RAT.
001806 02-04
NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTRODUCTION
002227 02-13
COMPARATIVE-STUDIES ON THE METABOLISM AND THE DISTRIBUTION OF
SULPIRIDE AND SULTOPRIDE.
002240 02-13
QUANTITATIVE STUDY OF THE DISTRIBUTION OF LITHIUM IN THE MOUSE-
BRAIN FOR VARIOUS DOSES OF LITHIUM GIVEN TO THE ANIMAL.
002299 02-13
THE DISTRIBUTION OF CHLORPROMAZINE BETWEEN PLASMA AND
ERYTHROCYTES.
002496 02-16
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
BETA-ADRENERGIC-RECEPTOR SUBTYPES: PROPERTIES, DISTRIBUTION,
AND REGULATION.
002829 03-03
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMinER AMINO-
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFACTORY-BULB.
002836 03-03
DOPAMINERGIC AGONIST AND ANTAGONIST EFFECTS ON STRIATAL
TYROSINE-HYDROXYLASE DISTRIBUTION .
002898 03-03
DISTRIBUTION OF CESIUM IN THE ORGANISM AND ITS EFFECT ON THE
NUCLEOTIDE METABOLISM ENZYMES.
003696 04-02
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN.
003941 04-03
REGIONAL DISTRIBUTION OF (3H)IMIPRAMINE BINDING IN RAT-BRAIN.
003955 04-03
THE EFFECT OF P CHLOROPHENYL^LANINE ON THE DISTRIBUTION OF
BIOGENIC-AMINES IN THE BRAIN, AND ON MEMORY IN RATS.
004068 04-04
EFFECT OF DESMETHYLIMIPRAMINE ON TISSUE DISTRIBUTION AND
ANORECTIC-ACTIVITY OF CHLORPHENTERMINE IN RATS.
004179 04-04
DISTRIBUTIONS
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - II. RESPECTIVE REGIONAL
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC
DEVELOPMENTS.
000214 01-03
EXTRAHYPOTHALAMIC DISTRIBUTIONS AND FUNCTIONS OF
HYPOTHALAMIC PEPTIDE-HORMONES. (UNPUBLISHED PAPER).
001211 02-03
DISTRICTS
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS
AFTER HOSPITAL DISCHARGE IN THE DISTRICTS TEPLICE AND UHERSKE-
HRADISTE.
002518 02-17
DISTURBANCE
NEUROENDOCRINE DISTURBANCE IN DEPRESSION.
004405 04-09
DISTURBANCES
BIOLOGICAL-RHYTHM DISTURBANCES IN AFFECTIVE-ILLNESS.
002628 02-17
DISTURBED
AMPHETAMINIL IN THE TREATMENT OF DISTURBED ERECTION POTENCY.
002129 02-11
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING,
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL
WAVES IN CATS?
003704 04-02
DISTURBED-BEHAVIOUR
DISTURBED-BEHAVIOUR INDUCED BY HIGH-DOSE ANTIPSYCHOTIC-DRUGS.
002375 02-15
I
(
'»ll£
«5r:
m
S-145
Subject Index
Psychopharmacology Abstracts
DISULFIDE
SYNTHESIS AND BIOLOGICAL-ACTIVITY OF HUMAN BETA ENDORPHIN
ANALOGS WITH DISULFIDE BRIDGES.
003655 04-01
COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE
BONDS.
003927 04-03
DISULFIRAM ^,, ^
INHIBITION OF ALCOHOL-DEHYDROGENASE BY DISULFIRAM, POSSIBLE
RELATION TO THE DISULFIRAM ETHANOL REACTION
000270 01-03
DIFFERENTIAL-EFFECTS ON BENZODIAZEPINE DISPOSITION BY DISULFIRAM
AND ETHANOL „„„,„„„, ,,
000789 01-13
METHADONE DISULFIRAM INTERACTION DURING METHADONE
MAINTENANCE. ^^„,„, „, ,^
000796 01-13
DISULFIRAM ENCEPHALOPATHY AS A CAUSE OF THE CATATONIA-
SYNDROME.
000894 01-15
EXPERIMENTAL-STUDIES ON HEPATOTOXICITY OF DISULFIRAM.
001844 02-05
A COMPARATIVE REVIEW OF THE PHARMACOLOGICAL AND
TOXICOLOGICAL PROPERTIES OF DISULFIRAM AND CALCIUM-
CARBIMIDE. „„,,
003522 03-15
DISULFIRAM AND NOCTURNAL PENILE-TUMESCENCE IN THE CHRONIC
ALCOHOLIC. „„^„, „^ ,,
004556 04-13
DITHIADEN
CLONAZEPAM AND DITHIADEN IN HYPERKINETIC-CHILDREN.
000729 01-11
DIURETICS
DIURETICS ARE DANGEROUS WITH LITHIUM.
002420 02-15
A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF
SCHIZOPHRENIA. „„.c„.„. ,.
004584 04-14
DIURNAL GROWTH-HORMONE RESPONSES TO DEXTROAMPHETAMINE IN
NORMAL YOUNG MEN AND POSTMENOPAUSAL- WOMEN.
003411 03-13
EFFECT OF LITHIUM ON REACTION-TIME ~ A STUDY OF DIURNAL
VARIATIONS
004607 04-15
DIVALENT-CATION
ALPHA2-ADREN0CEPT0RS IN RAT-BRAIN: THE DIVALENT-CATION SITE.
001246 02-03
DIVALENT-CATIONS
MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN:
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS.
003992 04-03
DIVERGENCES
CONVERGENCES AND DIVERGENCES BETWEEN BIOLOGICAL-PSYCHIATRY
AND PSYCHOTHERAPY.
002536 02-17
DIVERGENT
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE
FORMATION FROM PHENYLALANINE.
001113 02-03
DIVIDED
SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF
SINGLE VS. DIVIDED DOSE ADMINISTRATION.
000629 01-09
THERAPEUTIC-EFFICACY OF DOXEPIN IN DIVIDED AND SINGLE-DOSE
REGIME.
003259 03-09
DNA
DMI
PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE-
DISORDER: A PRELIMINARY REPORT.
000619 01-09
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI, OR
ETHANOL DETECTED BY ELEaROPHYSIOLOGICAL-CORRELATES.
001136 02-03
AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF
DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREACTIVITY
IN DMI RESPONSIVE DEPRESSIVES.
003228 03-09
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS.
004180 04-04
SUBCHRONIC-TREATMENT WITH THE TRICYCLIC-ANTIDEPRESSANT DMI
INCREASES ISOLATION-INDUCED FIGHTING IN RATS.
004252 04-04
EFFECT OF AMPHETAMINE ON THE METABOLISM AND INCORPORATION
OF (3H) THYMIDINE INTO DNA OF DEVELOPING RAT-BRAIN.
003729 04-03
DMA-DEPENDENT
PURIFICATION AND SUBUNIT STRUCTURE OF DNA-DEPENDENT RNA-
POLYMERASE-BII FROM RAT-BRAIN NUCLEI.
003679 04-01
DOCA-SALT
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC
AND DOCA-SALT HYPERTENSION IN THE RAT.
003899 04-03
DOCLOXYTHEPIN
COMPARISON OF BLOOD AND BILE LEVELS OF OXYPROTHEPIN AND
DOCLOXYTHEPIN IN RATS.
000242 01-03
DOCUMENTATION
COORDINATING CLINICAL-TRIALS IN PSYCHOPHARMACOLOGY:
PLANNING, DOCUMENTATION, AND ANALYSIS.
002574 02-17
DOG
MORPHINE ACTS THROUGH ALPHA-ADRENERGIC AND SEROTONINERGIC
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG.
000088 01-03
PHARMACOKINETICS OF CARBAMAZEPINE IN THE DOG.
000096 01-03
PHARMACOKINETICS OF PRIMIDONE AND ITS ACTIVE METABOLITES IN
THE DOG.
000097 01-03
THE EFFECT OF MONOAMINE-OXIDASE-INHIBITORS ON FIRST-PASS
METABOLISM OF TYRAMINE IN DOG INTESTINE
000141 01-03
PHARMACOKINETICS AND METABOLISM OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE) IN RAT,
MOUSE, DOG AND MAN
000219 01-03
PHARMACOLOGY OF PHENETHYLAMINE TRACE AMINES IN THE DOG -
DISCUSSION
000469 01-04
TOXICOLOGIC AND PHARMACOLOGIC-EFFEaS OF PHENCYCLIDINE-HCL IN
THE DOG. (PH.D. DISSERTATION).
000519 01-05
LEVORPHANOL: RADIOIMMUNOASSAY AND PLASMA CONCENTRATION
PROFILES IN DOG AND MAN.
000898 01-16
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN
THE DOG
001547 02-03
FURTHER STUDIES ON OPIATE-RECEPTORS THAT MEDIATE
ANTINOCICEPTION: TOOTH-PULP STIMULATION IN THE DOG.
001782 02-04 ,
THE EFFECTS OF THIORIDAZINE ON ELECTRICAL AND ISCHEMIC
VENTRICULAR FIBRILLATION IN THE DOG HEART IN SITU. .|
002697 03-03
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMIHER AMINO-
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFACTORY-BULB.
002836 03-03
PHARAAACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG.
002889 03-03
INTERACTION OF THE TRiaCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH
PREJUNCTIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG j
SAPHENOUS VEIN. „ „,
003756 04-03
DOGS
BIOAVAILABILITY OF 14C SULPIRIDE IN DOGS. I
000017 01-03]
ENZYME INDUCING EFFEQS OF PHENOBARBITAL ON NITRAZEPAM
METABOLISM IN DOGS. „ „^
000086 01-03
EFFEQ OF ISOPROTERENOL ON CEREBRAL CIRCULATION IN DOGS.
000199 01-031
CHOLINERGIC MECHANISMS AND CATAPLEXY IN DOGS. •
000374 01-04
THE INTERAQION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS.
000389 01-04
BIPHASIC-EFFEaS OF PIMOZIDE ON SLEEP-WAKEFULNESS IN DOGS.
000495 01-04'
BIOAVAILABILITY OF SULPIRIDE TABLET AND CAPSULE IN DOGS.
001101 02-03
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE
TREATED DOGS «„,„,o«-,«,
001273 02-03
S-146
VOLUME 19, SUBJECT INDEX
Subject Index
ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION:
CYPROHEPTADINIUM-METHIODIDE .
001534 02-03
INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE,
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS.
001539 02-03
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH
ANTIDEPRESSANTS
001620 02-04
GENETIC AND EXPERIMENTAL FACTORS AFFECTING THE PARADOXICAL-
EFFECTS OF AMPHETAMINE IN DOGS.
001704 02-04
INTRAVENOUS SELF-ADMINISTRATION OF COCAINE AND NORCOCAINE BY
DOGS.
001760 02-04
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY
REACTIONS IN DOGS.
003030 03-04
CENTRAL HYPOTENSIVE-EFFECT OF GAMMA AMINOBUTYRIC-ACID IN
ANESTHETIZED DOGS.
003772 04-03
BETA-ADRENERGIC INFLUENCE ON CARDIAC DYNAMICS DURING SHOCK-
AVOIDANCE IN DOGS.
003813 04-03
EFFECT OF MORPHINE AND NALOXONE ON LEU-ENKEPHALIN-LIKE
IMMUNOREACTIVITY IN DOGS.
003894 04-03
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS.
004551 04-13
DOM
ENHANCEMENT OF THE BEHAVIORAL-EFFECTS OF 2,5 DIMETHOXY-4-
METHYLAMPHETAMINE (DOM) BY PRETREATMENT WITH P
CHLOROPHENYLALANINE.
000364 01-04
THE EFFEQS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5
DIMETHOXY-4-METHYLAMPHETAMINE (DOM) AND D-AMPHETAMINE
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE
TREATED RATS.
001595 02-04
DOM AND RELATED 2,5 DIMETHOXY-4-ALKYLPHENYLISOPROPYLAMINES:
BEHAVIORAL AND SEROTONIN-RECEPTOR PROPERTIES.
003690 04-02
THE EFFEQS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON
OPERANT-BEHAVIOR: INTERACTIONS WITH OTHER NEUROACTIVE-
AGENTS.
004P89 04-04
DISCRIMINATIVE-STIMULUS PROPERTIES OF THE HALLUCINOGENIC-AGENT
DOM.
004260 04-04
DOMESTIC
TONIC IMMOBILITY IN DOMESTIC FOWL: POSSIBLE INTERACTION OF
SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
004246 04-04
DOMESTIC-FOWL
THE BEHAVIOURAL-STATE DURING CLIMAX (HATCHING) IN THE
DOMESTIC-FOWL (GALLUS-DOMESTICUS) .
001564 02-04
DOMPERIDONE
THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE.
002900 03-03
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A
COMPETITIVE ANTAGONIST AT ALPH A 1 -ADRENOCEPTORS.
003785 04-03
DOPA
DOPA AND DOPAMINE AGONISTS IN DEPRESSION.
002310 02-13
OPPOSITE EFFECTS OF NALOXONE ON SUBSTANCE-P-INDUCED IN BRAIN
DOPA SYNTHESIS AND IN LOCOMOTOR-ACTIVITY IN RATS.
003799 04-03
DOPA-DECARBOXYLASE
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL, ON
PARKINSONS-DISEASE ~ PART II: PHARMACOKINETIC-STUDY.
002309 02-13
THE INTERAQION OF 2,3,4 TRIHYDROXYBENZYLHYDRAZINE WITH
DOPA-DECARBOXYLASE FROM PIG KIDNEY.
002925 03-03
DOPAC
STRIATAL DOPAC LEVELS AS A PREDICTOR OF ANTIPSYCHOTIC-EFFICACY
001533 02-03
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFECTS OF
HALOPERIDOL AND PARGYLINE.
003792 04-03
DOPAMINE
ARYLDIALKENYLPIPERAZINES AS SELECTIVE AND VERY POTENT
INHIBITORS OF DOPAMINE UPTAKE.
000005 01-01
ANTIHISTAMINE EFFECT ON SYNAPTOSOMAL UPTAKE OF SEROTONIN,
NOREPINEPHRINE AND DOPAMINE.
000035 01-03
DOPAMINE, ACETYLCHOLINE, AND GABA EFFECTS IN ACUTE DYSTONIA IN
PRIMATES.
000043 01-03
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH
IN THE ELECTROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO
AUTORECEPTOR STIMULATION.
000046 01-03
THE INFLUENCE OF BENZOCTAMINE ON DOPAMINE AND NOREPINEPHRINE
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH
REFLEX OF THE CAT.
000054 01-03
EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE
RELEASE.
000067 01-03
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
THE EFFECTS OF TWO ANALOGS OF DOPAMINE ON GANGLIONIC
TRANSMISSION IN THE SYMPATHETIC-NERVOUS- SYSTEM.
000162 01-03
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS.
000171 01-03
EFFECTS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT.
000180 01-03
ROLE OF DOPAMINE STORAGE FUNCTION IN THE CONTROL OF RAT
STRIATAL TYROSINE-HYDROXYLASE ACTIVITY.
000201 01-03
ACUTE AND CHRONIC EFFECTS OF NEUROLEPTICS AND ACUTE EFFECTS OF
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN
CORPUS- STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN.
000215 01-03
EFFECTS OF DES-TYR-GAMMA-ENDORPHIN ON DOPAMINE RELEASE FROM
VARIOUS RAT-BRAIN REGIONS IN VITRO.
000264 01-03
LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN
MICE.
000287 01-03
THE EFFECT OF A NEW FLUORINATED TRICYCLIC NEUROLEPTIC-DRUG
ISOFLOXYTHEPIN ON THE RAT STRIATAL DOPAMINE METABOLISM.
000306 01-03
ANALYSIS OF THE ACTIVATION OF DOPAMINE METABOLISM BY A
SEROTONIN UPTAKE INHIBITOR.
000315 01-03
SELECTIVE STORAGE IN VIVO OF 5,6 ADTN IN DOPAMINE RICH AREAS OF
THE RAT-BRAIN.
000324 01-03
MESOLIMBICOCORTICAL DOPAMINE TERMINAL-FIELDS ARE NECESSARY
FOR NORMAL LOCOMOTOR AND INVESTIGATORY EXPLORATION IN
RATS.
000383 01-04
RELATIONSHIPS BETWEEN SELECTIVE DENERVATION OF DOPAMINE
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL-
RESPONSES TO AMPHETAMINE AND APOMORPHINE.
000384 01-04
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY: NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNCTION.
000448 01-04
SEX-DIFFERENCES IN AMPHETAMINE-ELICITED ROTATIONAL-BEHAVIOR
AND THE LATERALIZATION OF STRIATAL DOPAMINE IN RATS.
000459 01-04
lai,
I
'O.X
/;ii-
u.
S-147
Subject Index
Ptychopharmacology Abstracts
PSYCHIATRIC MANIFESTATIONS INDUCED BY DOPAMINE PRECURSORS OR
DOPAMINE AGONISTS. „„„„,. „, ,c
000865 01-15
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY
HUMAN BLOOD-PLATELETS „„,„,, „^ „o
001067 02-02
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES.
001078 02-02
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
INCREASED METABOLISM OF DOPAMINE AND SEROTONIN INDUCED IN
FOREBRAIN AREAS BY ETORPHINE MICROINJECTION IN
PERIAQUEDUCTAL GRAY. ^ ^^ ^^
001103 02-03
BIPHASIC RESPONSIVENESS OF RAT PIAL-ARTERIOLES TO DOPAMINE:
DIRECT OBSERVATIONS ON THE MICROCIRCULATION.
001105 02-03
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE
FORMATION FROM PHENYLALANINE.
001113 02-03
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING
DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS
OF MAMMALIAN FOREBRAIN IN VITRO.
DOPAMINE SYNTHESIS: TOLERANCE TO HALOPERIDOL AND
SUPERSENSITIVITY TO APOMORPHINE DEPEND ON PRESYNAPTIC-
RECEPTORS. „„,,^^„o«^
001129 02-03
DOPAMINE HYPOACTIVITY MEASURED BY IN VIVO VOLTAMMETRY.
001149 02-03
HA-966 EFFECTS ON STRIATAL DOPAMINE METABOLISM: IMPLICATIONS
FOR DOPAMINE COMPARTMENTALIZAION.
001150 02-03
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT
DERIVATIVES. „„,,., „„ „o
001156 02-03
DOPAMINE BIOSYNTHESIS IS REGULATED BY THE AMINE NEWLY
RECAPTURED BY DOPAMINERGIC NERVE-ENDINGS.
001163 02-03
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN.
001167 02-03
DOPAMINERGIC-SUPERSENSITIVITY: INFLUENCE OF DOPAMINE AGONISTS
AND DRUGS USED FOR THE TREATMENT OF TARDIVE-DYSKINESIA.
001169 02-03
A COMPARISON OF STRIATAL AND MESOLIMBIC DOPAMINE FUNCTION IN
THE RAT DURING 6-MONTH TRIFLUOPERAZINE ADMINISTRATION.
001174 02-03
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR
SUBSEQUENT WITHDRAWAL.
001175 02-03
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES.
001207 02-03
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN
STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER.
001218 02-03
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN
FOLLOWING INTERAVENTRICULAR INJECTION.
001239 02-03
THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND
DOPAMINE ANTAGONIST RECEPTOR SITES.
001254 02-03
ANTAGONISM OF THE RENAL VASODILATOR AQIVITY OF DOPAMINE BY
METOCLOPRAMIDE.
001265 02-03
FURTHER EVIDENCE FOR THE EXISTENCE OF MULTIPLE RECEPTORS FOR
DOPAMINE IN THE CENTRAL-NERVOUS-SYSTEM.
001296 02-03
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT
CAUDATE-NUCLEUS.
001298 02-03
THE HYPERKINETIC-SYNDROME FOLLOWING LONG-TERM HALOPERIDOL
TREATMENT: INVOLVEMENT OF DOPAMINE AND NORADRENALINE.
001299 02-03
STEREOSELECTIVE ACTIONS OF SUBSTITUTED BENZAMIDE DRUGS ON
CEREBRAL DOPAMINE MECHANISMS.
001301 02-03
ENDOGENOUS GUANYL-NUCLEOTIDES: COMPONENTS OF THE STRIATUM
WHICH CONFER DOPAMINE SENSITIVITY TO ADENYLATE-CYCLASE.
001313 02-03
DRUG-INDUCED RELEASE OF DOPAMINE FROM CORPUS- STRIATUM.
(PH.D. DISSERTATION).
001343 02-03
THE EFFEa OF CARBIDINE ON DOPAMINE TURNOVER IN THE CORPUS-
STRIATUM OF THE BRAINS OF RATS.
001352 02-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/
NEUROLEPTIC-RECEPTOR BINDING: EFFECT OF NEUROLEPTIC-DRUGS.
001358 02-03
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE AQION OF
DIAZEPAM POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE
ACTION IN THE BRAIN.
001428 02-03
EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC-
SYSTEMS IN THE RAT-BRAIN.
001464 02-03
EFFEa OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRAaiONS.
001472 02-03
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2
DOPAMINE-RECEPTORS IN THE CNS
001480 02-03
DETEQION OF MULTIPLE RECEPTORS FOR DOPAMINE.
001481 02-03
LONG-TERM APPLICATION OF HALOPERIDOL: EFFEQ OF ANTICHOLINERGIC
TREATMENT ON THE RATE OF DOPAMINE SYNTHESIS
001490 02-03
EVIDENCE THAT NORADRENALINE MODULATES THE INCREASE IN
STRIATAL DOPAMINE METABOLISM INDUCED BY MUSCARINIC-
RECEPTOR STIMULATION.
001518 02-03
EVALUATION OF THE EFFEQ OF DRUGS ON DOPAMINE METABOLISM IN
THE RAT SUPERIOR-CERVICAL-GANGLION BY HPLC WITH
ELECTROCHEMICAL-DETECTION .
001530 02-03
MOTOR-AQIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF
COCAINE CORRELATION WITH DOPAMINE UPTAKE BLOCKADE.
001650 02-04
PHENCYCLIDINE AS AN INDIRECT DOPAMINE AGONIST.
001719 02-04
EFFECT OF APOMORPHINE ON MORPHINE-INDUCED DECREASE IN
LOCOMOTOR-ACTIVITY AND INCREASE IN DOPAMINE TURNOVER IN
RATS.
001728 02-04
STEREOTYPED-BEHAVIOUR AND ELECTROCORTICAL-CHANGES AFTER
INTRACEREBRAL MICROINFUSION OF DOPAMINE AND APOMORPHINE ,
IN FOWLS.
001734 02-04
THE ROLE OF DOPAMINE IN THE HYPERMOTILITY INDUCED BY H-77-77 ■
(4 ALPHA DIMETHYL-M-TYRAMINE) IN MICE.
001762 02-04
CIRCLING PRODUCED BY SEROTONIN AND DOPAMINE AGONISTS IN
RAPHE LESIONED RATS: A SEROTONIN MODEL.
001783 02-04
ON THE USE OF OPERANT-BEHAVIOR TO STUDY THE
NEUROPSYCHOPHARMACOLOGY OF OPIATES WITH SPECIAL REFERENCE
TO MORPHINE AND ITS RELATIONSHIP TO DOPAMINE IN THE CENTRAL-
NERVOUS-SYSTEM.
001790 02-04
BEHAVIORAL-EFFECTS OF DOPAMINE AGONISTS ACROSS THE ESTROUS-
CYCLEINRATS
001792 02-04
EFFECT OF NICKEL ON THE LEVELS OF DOPAMINE, NORADRENALINE AND
SEROTONIN IN DIFFERENT REGIONS OF THE RAT-BRAIN.
001831 02-05
CEREBRAL VENTRICLES AND DOPAMINE IN SCHIZOPHRENIA.
(UNPUBLISHED PAPER). „
001928 02-08
PHENYLETHYLAMINE, DOPAMINE AND NOREPINEPHRINE IN
SCHIZOPHRENIA. (UNPUBLISHED PAPER)
001957 02-08
ANTIPSYCHOTIC-PROPERTIES AND ANTIDYSKINETIC-PROPERTIES OF
ERGOT DOPAMINE AGONISTS.
002178 02-11
SPECIES-DIFFERENCES IN THE DEAMINATION OF DOPAMINE AND OTHER
SUBSTRATES FOR MONOAMINE-OXIDASE IN BRAIN
002233 02-13
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE.
002242 02-13
S-148
VOLUME 19, SUBJECT INDEX
Subject Index
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES.
002285 02-13
DOPA AND DOPAMINE AGONISTS IN DEPRESSION.
0023)0 02-13
SHORT-TERM AND LONG-TERM EFFECTS ON GABA AND DOPAMINE
NEURONS DURING TREATMENT WITH SULPIRIDE.
002311 02-13
DOPAMINE ANTAGONIST AND AGONIST TREATMENT OF TARDIVE-
DYSKINESIA.
002377 02-15
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN
SCHIZOPHRENIA
002390 02-15
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL-
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D-
AMPHET AMINE AND APOMORPHINE.
002484 02-16
PLASMA LEVODOPA, DOPAMINE AND THERAPEUTIC RESPONSE
FOLLOWING LEVODOPA THERAPY OF PARKINSONIAN-PATIENTS.
002504 02-16
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY.
002639 03-01
PHENYLETHYLAMINE EFFECTS ON DOPAMINE SYNTHESIS. STRUCTURE-
ACTIVITY RELATIONSHIPS.
002649 03-02
MIDBRAIN DOPAMINE NEURONS: DIFFERENTIAL RESPONSES TO
AMPHETAMINE ISOMERS.
002680 03-03
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA
BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY
TUBERCLE OF THE RAT.
002681 03-03
DOPAMINE AS A POSSIBLE NEUROTRANSMIHER IN THE SPINAL-CORD.
002705 03-03
METHYLPHENIDATE-LIKE STIMULANTS IN VITRO RELEASE (3H)TYRAMINES
BUT NOT (14C)D0PAMINE.
002706 03-03
DOPAMINE DEPLETION SLOWS RETINAL TRANSMISSION.
002708 03-03
EFFECT OF MAZINDOL ON BRAIN DOPAMINE TURNOVER IN SPIPERONE
TREATED RATS.
002726 03-03
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN.
002727 03-03
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
MODULATION BY ENDOGENOUS DOPAMINE OF THE RELEASE OF
ACETYLCHOLINE IN THE CAUDATE-NUCLEUS OF THE RABBIT
002751 03-03
THE EFFECT OF PHENCYCLIDINE ON DOPAMINE METABOLISM IN THE
MOUSE-BRAIN.
002766 03-03
GABA ANTAGONISTS ENHANCE DOPAMINE TURNOVER IN THE RAT
RETINA IN VIVO.
002772 03-03
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC,
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL
DOPAMINE SYNTHESIS.
002786 03-03
NEUROLEPTIC-INDUCED ACUTE DYSTONIC REACTIONS MAY BE DUE TO
ENHANCED DOPAMINE RELEASE ON TO SUPERSENSITIVE
POSTSYNAPTIC-RECEPTORS.
002789 03-03
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF
METHAMPHET AMINE.
002812 03-03
PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN
MAMMALIAN RETINA.
002814 03-03
EFFECT OF DOPAMINE ON ACTIVATION OF RAT STRIATAL ADENYLATE-
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES.
002825 03-03
NOREPINEPHRINE AND DOPAMINE CEREBRAL LEVELS AFTER CHRONIC-
TREATMENT WITH NOMIFENSINE.
002872 03-03
ACUTE ACTION OF NOMIFENSINE ON NOREPINEPHRINE AND DOPAMINE
LEVELS IN THE RAT-BRAIN.
002873 03-03
BIPHASIC-EFFECTS AND OPPOSITE-EFFECTS OF DOPAMINE AND
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT
SUBSTANTIA-NIGRA
002923 03-03
SPINAL MODULATION OF THE ACOUSTIC STARTLE RESPONSE: THE ROLE
OF NOREPINEPHRINE, SEROTONIN AND DOPAMINE.
002950 03-04
ESTROGEN POTENTIATES THE STEREOTYPY INDUCED BY DOPAMINE
AGONISTS IN THE RAT.
002968 03-04
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF LOW-DOSES OF A
DOPAMINE AGONIST ON DRINKING AND LOCOMOTOR-ACTIVITY IN THE
RAT.
002982 03-04
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN
MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF
AMPHETAMINE. (PH.D. DISSERTATION).
002996 03-04
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE
CLIMBING IN MICE.
003031 03-04
AN INVOLVEMENT OF DOPAMINE IN HIGHER-ORDER CHOICE
MECHANISMS IN THE MONKEY.
003072 03-04
DOPAMINE AND DEMENTIA, AN ANIMAL-MODEL WITH DESTRUCTION OF
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY
STUDY.
003085 03-04
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE
BUT NOT LITHIUM-CHLORIDE.
003110 03-04
ABNORMAL TRANSMETHYLATION REACTION DURING THE METABOLISM
OF DOPAMINE, TRYPTAMINE, AND SEROTONIN, AND SCHIZOPHRENIC-
SYMPTOMS: A CRITICAL REVIEW.
003404 03-13
DOPAMINE CONJUGATE IN CEREBROSPINAL-FLUID.
003432 03-13
ALTERATIONS IN CEREBROSPINAL-FLUID DOPAMINE METABOLITES
FOLLOWING PHYSOSTIGMINE INFUSION.
003477 03-15
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
DOPAMINE METABOLITES IN CAUDATE AND CORTEX AFTER LITHIUM AND
HALOPERIDOL. (UNPUBLISHED PAPER).
003738 04-03
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS:
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO.
003741 04-03
GABA-ENHANCEMENT OF (3H)D0PAMINE RELEASE FROM SLICES OF RAT
STRIATUM: DEPENDENCE ON SLICE SIZE.
003786 04-03
THE EFFECT OF LONG-TERM CONCURRENT ADMINISTRATION OF
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL
CORTICAL DOPAMINE METABOLISM IN RATS.
003788 04-03
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFECTS OF
HALOPERIDOL AND PARGYLINE.
003792 04-03
COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON
DOPAMINE METABOLISM IN RAT-BRAIN.
003796 04-03
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE
RELATIONSHIP.
003806 04-03
PRESYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION IN HELIX-
POMATIA: THE EFFECTS OF SEROTONIN AND DOPAMINE
ANTAGONISTS.
003869 04-03
INCREASED MESOLIMBIC DOPAMINE BINDING FOLLOWING CHRONIC
HALOPERIDOL TREATMENT
003872 04-03
SOME BARBITURATES ENHANCE THE EFFECT OF MUSCIMOL ON
DOPAMINE TURNOVER IN THE RAT RETINA.
003873 04-03
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL
TISSUE BY ASCORBATE.
003876 04-03
EFFECTS OF 3',4' DIHYDROXYNOMIFENSINE ON THE DOPAMINE
VASCULAR RECEPTOR
003890 04-03
lai,
n'ffi
«€
■•;i::
•Mlt
fc:
:i>i;
■iBi,
IE
S-149
Subject Index
Psychopharmacology Abstracts
4!;'
PHENYLETHYLAMINE EFFECTS ON DOPAMINE SYNTHESIS: STRUQURE-
ACTIVITY RELATIONSHIPS. (UNPUBLISHED PAPER).
003959 04-03
EFFECTS OF IN VIVO AMPHETAMINE ADMINISTRATION ON DOPAMINE
SYNTHESIS REGULATION IN RAT-BRAIN STRIATAL SYNAPTOSOMES.
(UNPUBLISHED PAPER).
003960 04-03
WHY DOES SULPIRIDE NOT BLOCK THE EFFEQ OF DOPAMINE ON THE
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE?
004055 04-03
EFFECTS OF A HIGH-DOSE TREATMENT OF METHAMPHETAMINE ON
CAUDATE DOPAMINE AND ANOREXIA IN RATS
004073 04-04
EFFECTS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC-
ACID, HALOPERIDOL AND PIMOZIDE ON REFLEX BRADYCARDIA IN
RATS.
004085 04-04
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER)
004)12 04-04
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH
UNILATERAL NIGROSTRIATAL LESIONS
004117 04-04
IS DOPAMINE ANTAGONISM A REQUISITE OF NEUROLEPTIC ACTIVITY?
004122 04-04
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS.
004129 04-04
DIFFERENTIAL-EFFECTS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND
RELEASING-AGENTS ON LOCOMOTOR-ACTIVITY IN NORMAL AND IN
RESERPINIZED MICE.
004130 04-04
INVOLVEMENT OF DOPAMINE IN CIRCLING RESPONSES TO MUSCIMOL
DEPENDS ON INTRANI6RAL SITE OF INJECTION.
004158 04-04
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER
FOREBRAIN REGIONS OF THE RAT.
004171 04-04
AVOIDANCE RESPONSE IN RATS AFTER INJECTION OF DOPAMINE INTO
THE NEOSTRIATUM.
004255 04-04
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN:
NEUROCHEMICAL- STUDIES IN AN ANIMAL-MODEL OF TARDIVE-
DYSKINESIA.
004268 04-05
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY?
004553 04-13
DOPAMINE-ACTIVATED
DOPAMINE-ACTIVATED ADENYLATE-CYCLASE OF SPINAL-CORD:
SUPERSENSITIVITY FOLLOWING TRANSECTION OF THE CORD.
003800 04-03
DOPAMINE-AUTORECEPTOR
REPEATED TRICYCLICS INDUCE A PROGRESSIVE DOPAMINE-
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT OF DAILY DRUG-
TREATMENT.
000047 01-03
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY?
002659 03-03
DOPAMINE-AUTORECEPTORS
TRICYCLIC-ANTIDEPRESSANTS INDUCE SUBSENSITIVITY OF PRESYNAPTIC
DOPAMINE-AUTORECEPTORS .
000048 01-03
DOPAMINE-AUTORECEPTORS: PHARMACOLOGY, FUNCTION AND
COMPARISON WITH POSTSYNAPTIC DOPAMINE-RECEPTORS
001453 02-03
PHYSIOLOGICAL SIGNIFICANCE OF DOPAMINE-AUTORECEPTORS AS
STUDIED FOLLOWING THEIR SELECTIVE BLOCKADE BY MOLINDONE.
004065 04-04
DOPAMINE-BETA-HYDROXYLASE
DOPAMINE-BETA-HYDROXYLASE: A MODULATOR OF BETA-ADRENERGIC-
RECEPTOR ACTIVITY.
000302 01-03
DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND NORADRENALINE
CONTENT IN PIAL-ARTERIES OF CAT AND GOAT.
001357 02-03
METHODOLOGICAL-ISSUES IN SPINAL-FLUID STUDIES OF SCHIZOPHRENIA:
THE CASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE.
(UNPUBLISHED PAPER).
001952 02-08
PURIFICATION AND CHARAaERIZATION OF RAT PHEOCHROMOCYTOMA
DOPAMINE-BETA-HYDROXYLASE.
003664 04-01
REDUCTION IN THE LEVEL OF IMMUNOTITRATABLE DOPAMINE-BETA-
HYDROXYLASE AFTER CHRONIC ADMINISTRATION OF L-DOPA OR
ALPHA METHYLDOPA.
003764 04-03
RESERPINE EFFECT ON THE AXONAL TRANSPORT OF DOPAMINE-BETA-
HYDROXYLASE AND TYROSINE-HYDROXYLASE IN RAT-BRAIN.
003904 04^3
PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN CHRONIC
SCHIZOPHRENIC-PATIENTS TESTED WITH SINGLE-DOSE OF 2 BROMO-
ALPHA-ERGOCRIPTINE (PARLODEL).
004343 04-08
NORMAL PLASMA DOPAMINE-BETA-HYDROXYLASE IN NONTREATED AND
TREATED PARKINSON-PATIENTS
004471 04-11
THE ACTIVITY OF DOPAMINE-BETA-HYDROXYLASE IN THE PLASMA OF
PATIENTS WITH ENDOGENOUS DEPRESSIVE-SYNDROMES.
004548 04-13
DOPAMINE-DEPENDENT
THE ROLE OF 5 HYDROXYTRYPT AMINE IN DOPAMINE-DEPENDENT
STEREOTYPED-BEHAVIOUR.
002966 03-04
DOPAMINE-DEPENDENT HYPERACTIVITY IN THE FOLLOWING
MANIPULATION OF GABA MECHANISMS IN THE REGION OF THE
NUCLEUS-ACCUMBENS.
003976 04-03
DOPAMINE-EVOKED
ALPHA FLUPENTHIXOL: AN ANTAGONIST OF DOPAMINE-EVOKED FLUID
SECRETION BY AN INSECT SALIVARY-GLAND PREPARATION.
000031 01-03
DOPAMINE-INDUCEO
CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE
CANINE FEMORAL VASCULAR BED
003911 04-03
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC-
AMP
003952 04-03
DOPAMINE-MEDIATED
ACTIONS OF TETRAHYDRONORHARMANE (TETRAHYDRO-BETA-
CARBOLINE) ON 5 HYDROXYTRYPTAMINE AND DOPAMINE-MEDIATED
MECHANISMS
002854 03-03
EFFECT OF ACUTE AND CHRONIC TRIIODOTHYRONINE (T3)
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE-
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN-
BIOCHEMISTRY
002951 03-04
DOPAMINE-MIMETIC
AQIVATION OF PRESYNAPTIC ALPHA NORADRENALINE-RECEPTORS IN
RAT-BRAIN BY THE POTENT DOPAMINE-MIMETIC N,N Dl PROPYL- ADTN.
001390 02-03
DOPAMINE-RADIORECEPTOR
THE DOPAMINE-RADIORECEPTOR ASSAY - A CLINICAL APPLICATION.
000904 01-16
DOPAMINE-RECEPTOR
CHRONIC HIGH-DOSE PROPRANOLOL DOES NOT INCREASE DOPAMINE-
RECEPTOR NUMBER
000083 01-03
HYPOPHYSECTOMY PREVENTS THE STRIATAL DOPAMINE-RECEPTOR
SUPERSENSITIVITY PRODUCED BY CHRONIC HALOPERIDOL TREATMENT.
000132 01-03
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BIN-^ING-
SITES IN RAT STRIATUM.
000186 01-03
IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR
ACTIVITY.
000289 01-03
REDUCTION OF FOOD INTAKE BY PIRIBEDIL IN THE RAT: RELATION TO
DOPAMINE-RECEPTOR STIMULATION.
000355 01-04
POSTSWIM GROOMING IN MICE INHIBITED BY DOPAMINE-RECEPTOR
ANTAGONISTS AND BY CANNABINOIDS.
000359 01-04
INCREASED DOPAMINE-RECEPTOR BINDING IN THE STRIATUM OF RATS
AFTER LONG-TERM ISOLATION
000398 01-04
N ALKYLATED 2 AMINOTETRALINS: CENTRAL DOPAMINE-RECEPTOR
STIMULATING AQIVITY.
000399 01-04
S-150
VOLUME 19, SUBJECT INDEX
Subject Index
EXTINCTION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMITTENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL
EQUIVALENCE
000490 01-04
TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC-
DISCHARGE IN HUMANS BY APOMORPHINE, A DOPAMINE-RECEPTOR
AGONIST.
000714 01-11
DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION, AND REGULATION.
OOlOn 02-01
NO EVIDENCE FOR INCREASED DOPAMINE-RECEPTOR BINDING IN
SUPERRESPONSIVE MICE AFTER A SINGLE-DOSE OF NEUROLEPTICS.
001292 02-03
DOPAMINE-RECEPTOR BLOCKADE IN RAT-BRAIN AFTER ACUTE AND
SUBCHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANTS.
001314 02-03
THE PITUITARY DOPAMINE-RECEPTOR,
001324 02-03
DOPAMINE-RECEPTOR: FROM SYNAPTIC MEMBRANES TO
SOLUBILIZATION.
001326 02-03
EFFECTS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A
DELAYED TYPE HYPERSENSITIVITY REACTION TO 1
CHLORODINITROBENZENE IN MICE.
001473 02-03
INHIBITION OF NEUROLEPTIC-INDUCED DOPAMINE-RECEPTOR
SUPERSENSITIVITY BY CYCLO-LEU-GLY.
001576 02-04
DOPAMINE-RECEPTOR BLOCKADE BY IMIDOLINE AND ITS PROPOSED
ACTIVE CONFORMATION.
001687 02-04
CHRONIC NEUROLEPTIC TREATMENT AND DOPAMINE-RECEPTOR
REGULATION.
001837 02-05
APOMORPHINE HYPOTHERMIA: AN INDEX OF CENTRAL DOPAMINE-
RECEPTOR FUNCTION IN MAN.
002221 02-13
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A
SELECTIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST.
002236 02-13
PERGOLIDE, A POTENT LONG-ACTING DOPAMINE-RECEPTOR AGONIST.
002257 02-13
DURING ONE YEARS NEUROLEPTIC TREATMENT IN RATS STRIATAL
DOPAMINE-RECEPTOR BLOCKADE DECREASES BUT SERUM PROLACTIN
LEVELS REMAIN ELEVATED.
002707 03-03
DOPAMINE-RECEPTOR SUPERSENSITIVITY IN THE CORPUS-STRIATUM
FOLLOWING CHRONIC ELEVATION OF BRAIN GAMMA AMINOBUTYRIC-
ACID.
002716 03-03
KAINATE LESION DISSOCIATES STRIATAL DOPAMINE-RECEPTOR
RADIOLIGAND BINDING-SITES.
002803 03-03
LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID.
002828 03-03
THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY
BINDING STUDIES WITH 3H APOMORPHINE AND 3H OOMPERIDONE.
002900 03-03
A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS.
003182 03-08
NEUROLEPTIC MALIGNANT- SYNDROME: A PATHOGENETIC ROLE FOR
DOPAMINE-RECEPTOR BLOCKADE?
003492 03-15
THE DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION AND REGULATION.
003660 04-01
DOPAMINE-RECEPTOR PURIFICATION AND CHARACTERIZATION.
(UNPUBLISHED PAPER).
003661 04-01
THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A
COMPETITIVE ANTAGONIST AT ALPHAl -ADRENOCEPTORS.
003785 04-03
RESPONSE OF STRIATONIGRAL SUBSTANCE-P SYSTEMS TO A DOPAMINE-
RECEPTOR AGONIST AND ANTAGONIST.
003826 04-03
THE DOPAMINE-RECEPTOR COMPLEX: BIOCHEMICAL-CONSEQUENCES OF
SUPERSENSITIVITY INDUCED BY TREATMENT WITH 6
HYDROXYDOPAMINE OR MORPHINE.
003958 04-03
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE
PITUITARY MEMBRANES.
004003 04-03
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT
KIDNEY.
004054 04-03
RELEVANCE OF DOPAMINE-RECEPTOR BINDING STUDIES FOR EVALUATION
OF ANTIPARKINSONIAN-DRUGS.
004120 04-04
DOPAMINE-RECEPTOR CHANGES FOLLOWING DESTRUCTION OF THE
NIGROSTRIATAL PATHWAY: LACK OF A REUTIONSHIP TO
ROTATIONAL-BEHAVIOR
004229 04-04
LITHIUM EFFECTS ON HALOPERIDOL-INDUCEO PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINE-RECEPTOR SUPERSENSITIVITY
004244 04-04
THE EFFECT OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON
THE STIMULANT AND ANORECTIC-ACTIONS OF DEXTROAMPHETAMINE
IN MAN.
004580 04-14
DOPAMINE-RECEPTORS
EVIDENCE FOR AN IRREVERSIBLE INTERACTION OF BROMOCRYPTINE
WITH CENTRAL DOPAMINE-RECEPTORS.
000023 01-03
REGULATION OF STRIATAL ACETYLCHOLINE CONCENTRATION BY D2
DOPAMINE-RECEPTORS.
000269 01-03
SODIUM-DEPENDENT INTERACTION OF BENZAMIDES WITH DOPAMINE-
RECEPTORS.
000285 01-03
DOPAMINE-RECEPTORS AND SCHIZOPHRENIA: DRUG-EFFECT OR ILLNESS?
000564 01-08
METOCLOPRAMIDE AND SULPIRIDE AS SELECTIVE BLOCKING-AGENTS
PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS.
001102 02-03
DOPAMINE-RECEPTORS IN RAT-FRONTAL-CORTEX: PHARMACOLOGICAL-
PROPERTIES IN VIVO AND IN VITRO.
001112 02-03
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING
DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS
OF MAMMALIAN FOREBRAIN IN VITRO.
001114 02-03
PRESYNAPTIC DOPAMINE-RECEPTORS: INSENSITIVITY TO KAINIC-ACID
AND THE DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING CHRONIC
HALOPERIDOL.
001117 02-03
IN VIVO (3H)SPIPER0NE BINDING TO THE RAT HIPPOCAMPAL
FORMATION: INVOLVEMENT OF DOPAMINE-RECEPTORS.
001131 02-03
CENTRAL-NERVOUS-SYSTEM DOPAMINE-RECEPTORS.
001185 02-03
RADIOLIGAND BINDING STUDIES: EVIDENCE FOR MULTIPLE DOPAMINE-
RECEPTORS.
001186 02-03
PERIPHERAL PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS:
ARE THEY DIFFERENT FROM DOPAMINE-RECEPTORS IN THE CENTRAL-
NERVOUS-SYSTEM.
001252 02-03
AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL
DOPAMINE-RECEPTORS AFTER VARIOUS TREATMENTS WITH
ANTAGONISTS OR AGONISTS.
001350 02-03
MODIFICATION OF DOPAMINE-RECEPTORS IN BRAIN BY CONTINUOUS
AMPHETAMINE ADMINISTRATIONS TO RATS.
001395 02-03
PRESYNAPTIC DOPAMINE-RECEPTORS IN STRIATAL NERVE-ENDINGS:
ABSENCE OF HALOPERIDOL-INDUCED SUPERSENSITIVITY
001424 02-03
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN
MICE.
001435 02-03
DOPAMINE-AUTORECEPTORS: PHARMACOLOGY, FUNCTION AND
COMPARISON WITH POSTSYNAPTIC DOPAMINE-RECEPTORS
001453 02-03
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2
DOPAMINE-RECEPTORS IN THE CNS.
001480 02-03
HIGH-AFFINITY DOPAMINE-RECEPTORS (D3) IN RAT-BRAIN.
001509 02-03
RADIORECEPTOR LABELING OF PRESYNAPTIC AND POSTSYNAPTIC
DOPAMINE-RECEPTORS.
001511 02-03
BINDING OF (3H)PERG0LIDE-MESYLATE TO DOPAMINE-RECEPTORS OF
MAMMALIAN BRAINS.
001538 02-03
NEUROLEPTIC/DOPAMINE-RECEPTORS: ELEVATION AND REVERSAL.
001847 02-05
NEUROLEPTICS AND DOPAMINE-RECEPTORS, THERAPEUTIC
IMPLICATIONS.
001942 02-08
CLINICAL EVIDENCE FOR MULTIPLE DOPAMINE-RECEPTORS IN MAN.
002264 02-13
DRUG-EFFECTS ON PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-
RECEPTORS.
002372 02-15
1
lllf
I
••til'
ill"
fc:
i
S-151
Subject Index
SIMILARITIES BETWEEN THE BINDING OF 3H PIFLUTIXOL AND 3H
FLUPENTIXOL TO RAT STRIATAL DOPAMINE-RECEPTORS IN VITRO.
002760 03-03
REGULATION BY CATIONS OF (3H)SPIR0PERID0L BINDING ASSOCIATED
WITH DOPAMINE-RECEPTORS OF RAT-BRAIN.
002922 03-03
DOPAMINE-RECEPTORS, NEUROLEPTICS, AND SCHIZOPHRENIA.
003197 03-08
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS:
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO.
003741 04-03
SOLUBILIZATION OF NEUROLEPTIC/DOPAMINE-RECEPTORS OF HUMAN
BRAIN STRIATUM. „„..,.„.„„
003767 04-03
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRACTION.
003948 04-03
MODULATION OF DOPAMINE-RECEPTORS BY OPIATES. (UNPUBLISHED
^'^^^^^ 003949 04-03
CHRONIC NEUROLEPTIC TREATMENT SPECIFICALLY ALTERS THE NUMBER
OF DOPAMINE-RECEPTORS IN RAT-BRAIN.
004033 04-03
BRAIN DOPAMINE-RECEPTORS. „„,,,„.,-,
004741 04-17
DOPAMINE-SENSITIVE „ ^
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND RECEPTOR BINDING-
ACTIVITIES FOLLOWING ACUTE AND CHRONIC NEUROLEPTIC-DRUG
TREATMENT. (UNPUBLISHED PAPER). ^^ ^^^ ^^_^^
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/
NEUROLEPTIC-RECEPTOR BINDING: EFFECT OF NEUROLEPTIC-DRUGS.
001358 02-03
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE-
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1
CYCLOPROPYLMETHYL
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE
003706 04-02
STIMULATORY ACTION OF LISURIDE ON DOPAMINE-SENSITIVE
ADENYLATE-CYCLASE IN THE RAT STRIATAL HOMOGENATE
003718 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA I DOPAMINE-
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA;
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS
004051 04-03
WHY DOES SULPIRIDE NOT BLOCK THE EFFECT OF DOPAMINE ON THE
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE?
004055 04-03
DOPAMINERGIC
PRODRUGS OF SOME DOPAMINERGIC 2 AMINOTETRALINS: A REVIEW OF
THEIR SYNTHESES AND NEUROCHEMICAL PROFILES
000004 01-01
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING.
000099 01-03
EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN
COMBINATION ON THE ANTICONVULSANT AQION OF PHENOBARBITAL
AND DIPHENYLHYDANTOIN IN THE ELECTROSHOCK-TEST IN MICE.
000163 01-03
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES
000202 01-03
STRIATAL DOPAMINERGIC ACTIVITY DURING WITHDRAWAL FROM
CHRONIC NEUROLEPTIC TREATMENT IN RATS.
000203 01-03
EFFECTS OF ALPHA CHLORALOSE ON THE ACTIVITY OF THE
NIGROSTRIATAL DOPAMINERGIC SYSTEM IN THE CAT.
000217 01-03
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF
AlO DOPAMINERGIC NEURONS.
000320 01-03
EFFECT OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO
STIMULATION OF THE NUCLEUS-ACCUMBENS.
000331 01-03
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE-
BEHAVIOR- INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON
THREE EXPERIMENTAL MODELS.
000340 01-04
EFFECTS OF DOPAMINERGIC AND CHOLINERGIC-DRUGS, NALOXONE AND
L PROLYL-LEUCYL-GLYCINAMIDE ON LSD-INDUCED CATALEPSY.
000360 01-04
DIFFERENT DOPAMINERGIC MECHANISMS FOR AMFONELIC-ACID,
AMPHETAMINE AND APOMORPHINE.
000465 01-04
Psychopharmacology Abstracts
NALOXONE OVERCOMES THE DOPAMINERGIC. EEG, AND BEHAVIORAL-
EFFECTS OF GAMMA HYDROXYBUTYRATE.
000478 01-04
CONTRIBUTION TO THE CLINICAL- STUDY OF CEREBRAL DOPAMINERGIC
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST
RESULTS.
000616 01-09
BROMOCRIPTINE AND DOPAMINERGIC FUNCTION IN HUNTINGTON-
DISEASE.
000700 01-11
DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: A
PITUITARY MODEL FOR THE STUDY OF A NEUROENDOCRINE SYSTEM IN
MAN.
000776 01-13
CONTRIBUTION TO STUDY OF CEREBRAL DOPAMINERGIC MECHANISMS:
REALITY OF THE PROBLEM.
000782 01-13
DOPAMINE BIOSYNTHESIS IS REGULATED BY THE AMINE NEWLY
RECAPTURED BY DOPAMINERGIC NERVE-ENDINGS.
001163 02-03
GLYCINE ENHANCEMENT OF CAUDATE NEURONAL ACTIVITIES:
RELATIONSHIP WITH THE DOPAMINERGIC NIGROSTRIATAL PATHWAY.
001225 02-03
EFFECTS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE
001243 02-03
ROLE OF CALMODULIN IN DOPAMINERGIC TRANSMISSION.
(UNPUBLISHED PAPER)
001270 02-03
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT
CAUDATE-NUCLEUS
001298 02-03
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION.
001310 02-03
LONG-TERM EFFECTS OF HALOPERIDOL, CLOZAPINE, AND METHADONE
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNAMICS.
001325 02-03
SHORT-TERM AND LONG-TERM EFFEQS OF METHAMPHETAMINE ON
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC
NUCLEI
001384 02-03
PRESYNAPTIC AND POSTSYNAPTIC MECHANISMS IN HALOPERIDOL-
INDUCED SENSITIZATION TO DOPAMINERGIC AGONISTS.
001392 02-03
INTERACTION OF DOPAMINERGIC ERGOT DERIVATIVES WITH CYCUC-
NUCLEOTIDE SYSTEM ^
001482 02-03
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM:
FUNCTIONAL CHANGES FOLLOWED USING (-)N N
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL AQIVITY LEVELS
°^'^"^^ 001603 02-04
INTERACTION OF CHOLINERGIC AND DOPAMINERGIC INFLUENCES ON
YAWNING-BEHAVIOR „„,,., „.«.
001656 02-04
DOPAMINERGIC INVOLVEMENT IN AHENTION A NOVEL ANIMAL-MODEL.
001678 02-04
DIFFERENTIAL DOPAMINERGIC FUNQION IN YOUNG AND OLD FEMALE
RATS AS MEASURED BY THREE BEHAVIORS.
001683 02-04
THE EFFECT OF SOME STRUQURAL GABA ANALOGUES ON THE
SEROTONIN AND DOPAMINERGIC MECHANISMS.
001736 02-04
DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINERGIC MECHANISMS.
001839 02-05
THE USE OF BROMOCRIPTINE FOR TESTING CEf'TRAL DOPAMINERGIC
'^^^^^'^'^ 002205 02-13
THE HYPOTHALAMIC DOPAMINERGIC REGULATION OF PROLAQIN: A
MODEL FOR THE STUDY OF NEUROHORMONAL MECHANISMS IN MAN
002568 02-17
DOPAMINERGIC ABNORMALITIES IN POSTMORTEM SCHIZOPHRENIC
^•^^"^ 002575 02-17
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS. 002700 03-03
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
S-152
i
VOLUME 19, SUBJECT INDEX
Subject Index
DOPAMINERGIC INVOLVEMENT IN THE HYPERALGESIC EFFECT OF
NOMIFENSINE.
002736 03-03
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR
FUNCTIONS RELATED TO MOTIVATED BEHAVIOR.
002815 03-03
IN VIVO VOLTAMMETRIC INVESTIGATIONS INTO THE ACTION OF HA-966
ON CENTRAL DOPAMINERGIC NEURONS.
002832 03-03
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC
NEURONS.
002880 03-03
DOPAMINERGIC AGONIST AND ANTAGONIST EFFECTS ON STRIATAL
TYROSINE-HYDROXYLASE DISTRIBUTION.
002898 03-03
CHOLINERGIC, DOPAMINERGIC. NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR.
002945 03-04
INJECTIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINERGIC AND
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS: EFFECTS ON
LOCOMOTOR-ACTIVITY IN THE RAT.
003019 03-04
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY
STUDY.
003085 03-04
DOPAMINERGIC AND GABAERGIC ASPECTS OF TARDIVE-DYSKINESIA.
003302 03-1 1
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II. FACTORS
AFFECTING THE ACCUMUL^^TION OF CYCLIC-AMP IN PIECES OF INTACT
CARP RETINA.
003776 04-03
RELATIONSHIP BETWEEN THE PRESENCE OF DOPAMINERGIC NEURONS
AND GABA-RECEPTORS IN SUBSTANTIA-NIGRA: EFFECTS OF LESIONS.
003797 04-03
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NICTITATING MEMBRANE OF THE CAT.
003822 04-03
STUDIES ON AXONAL TRANSPORT IN DOPAMINERGIC NEURONS: EFFECT
OF NEUROPHARMACOLOGIC LESIONS.
003858 04-03
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS.
003871 04-03
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC
AND DOCA-SALT HYPERTENSION IN THE RAT.
003899 04-03
EFFECTS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE-
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC
BUNDLE IN THE RAT.
003910 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE-
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA;
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS.
004051 04-03
ACTIONS OF MU, KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION.
004053 04-03
EFFECTS OF DOPAMINERGIC DRUGS ON PHENCYCLIDINE-INDUCEO
BEHAVIOR IN THE RAT.
004083 04-04
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
004112 04-04
RELATION BETWEEN BRAIN CATECHOLAMINE-RECEPTORS AND
DOPAMINERGIC STEREOTYPY IN RAT STRAINS.
004131 04-04
DOPAMINERGIC AGONISTS DIFFERENTIALLY AFFECT OPEN-FIELD ACTIVITY
OF RATS WITH AlO LESIONS.
004135 04-04
DOPAMINERGIC NEURONS OF SPINAL-CORD: A POSSIBLE SITE FOR THE
ACTION OF NEUROLEPTIC-DRUGS.
004188 04-04
GENOTYPIC INFLUENCES ON STRIATAL DOPAMINERGIC REGULATION IN
MICE.
004217 04-04
CHANGES OF RESPONSE TO DOPAMINERGIC DRUGS IN RATS SUBMITTED
TO REM SLEEP DEPRIVATION.
004239 04-04
TONIC IMMOBILITY IN DOMESTIC FOWL: POSSIBLE INTERACTION OF
SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
004246 04-04
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
LOAD.
004600 04-15
DOPAMINERGIC-ACTIVITY
ROLE OF THE NEOSTRIATAL DOPAMINERGIC-ACTIVITY IN SEQUENCING
AND SELECTING BEHAVIOURAL-STRATEGIES: FACILITATION OF
PROCESSES INVOLVED IN SELECTING THE BEST STRATEGY IN A
STRESSFUL-SITUATION,
000366 01-04
MORPHINE-DEPENDENCE AND DOPAMINERGIC-ACTIVITY: TESTS OF
CIRCLING RESPONSES IN RATS WITH UNILATERAL NIGRAL LESIONS.
001641 02-04
CLINICAL PROCESSES AND CENTRAL DOPAMINERGIC-ACTIVITY IN
PSYCHOTIC-DISORDERS
002098 02-11
THE EFFECT OF ALTERED DOPAMINERGIC-ACTIVITY ON FOOD INTAKE IN
THE RAT: EVIDENCE FOR AN OPTIMAL LEVEL OF DOPAMINERGIC-
ACTIVITY FOR BEHAVIOR.
002632 02-17
DOPAMINERGIC-AGENT
A NEW DOPAMINERGIC-AGENT IN CURRENT PSYCHIATRIC-PRACTICE.
003156 03-07
DOPAMINERGIC-AGENTS
THE EFFECTS OF DOPAMINERGIC-AGENTS ON THE LOCOMOTOR-ACTIVITY
OF RATS AFTER HIGH-DOSES OF METHYLAMPHETAMINE.
000427 01-04
DOPAMINERGIC-EFFECTS
CENTRAL DOPAMINERGIC-EFFECTS OF ERGOLINE DERIVATIVES.
002540 02-17
DOPAMINERGIC-RECEPTOR
MODIFICATION OF DOPAMINERGIC-RECEPTOR SENSITIVITY IN RAT-BRAIN
AFTER AMYGDALOID KINDLING.
000106 01-03
EFFECTS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS:
RELATION TO MICROSOMAL BIOTRANSFORMATION AND
DOPAMINERGIC-RECEPTOR STIMULATION .
001161 02-03
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES.
001342 02-03
EFFECTS OF CHLORPROMAZINE ON DOPAMINERGIC-RECEPTOR FUNCTIONS
IN RAT-BRAIN - DIFFERENCE OF THE RESPONSE OF SEVERAL
DOPAMINERGIC-SYSTEMS AFTER CHRONIC ADMINISTRATION.
002773 03-03
AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR
ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER
CHRONIC ANTIDEPRESSANT TREATMENT.
002788 03-03
A CONTROLLED-STUDY OF L-DOPA IN SCHIZOPHRENIA WITH REFERENCE
TO THE THEORY OF DOPAMINERGIC-RECEPTOR HYPERSENSITIVITY.
004312 04-08
DOPAMINERGIC-RECEPTORS
SELECTIVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS.
001447 02-03
EFFECT OF LONG-TERM-TREATMENT WITH HALOPERIDOL AND SULPIRIDE
ON DIFFERENT TYPES OF DOPAMINERGIC-RECEPTORS.
001512 02-03
EVIDENCE FOR THERMOREGULATORY DOPAMINERGIC-RECEPTORS
LOCATED IN THE PREOPTICUS-MEDIALIS-NUCLEUS OF THE RAT
HYPOTHALAMUS.
003754 04-03
EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF PHENCYCLIDINE
ON DOPAMINERGIC-RECEPTORS IN RAT STRIATUM.
003901 04-03
DOPAMINERGIC-SUPERSENSITIVITY
DOPAMINERGIC-SUPERSENSITIVITY: INFLUENCE OF DOPAMINE AGONISTS
AND DRUGS USED FOR THE TREATMENT OF TARDIVE-DYSKINESIA.
001169 02-03
STUDIES ON THE SPECIFICITY AND REVERSAL OF NEUROLEPTIC-INDUCED
DOPAMINERGIC-SUPERSENSITIVITY. (PH.D. DISSERTATION).
001469 02-03
REDUCTION OF DOPAMINERGIC-SUPERSENSITIVITY BY A SINGLE-DOSE OF
AMPHETAMINE.
001642 02-04
EFFECTS OF AGE ON DOPAMINERGIC-SUPERSENSITIVITY INDUCED BY
CHRONIC FLUPHENAZINE.
003940 04-03
DOPAMINERGIC-SYSTEM
ACUTE AND CHRONIC HALOPERIDOL TREATMENT: EFFECTS ON
NIGROSTRIATAL DOPAMINERGIC-SYSTEM ACTIVITY.
001153 02-03
CHRONOLOGY OF EXTRAPYRAMIDAL-EFFECTS OF NEUROLEPTIC-DRUGS
AND THE NIGROSTRIATAL DOPAMINERGIC-SYSTEM.
002449 02-15
NEUROLEPTICS: ACTIVATION OR INHIBITION OF THE DOPAMINERGIC-
SYSTEM?
003424 03-13
"ijf
lai.
M
tU..
iiii'»
inlT
Hi!,
S-153
Subject Index
Psychopharmacology Abstracts
*iii
DOPAMINER6IC-SYSTEMS
DOPAMINERGIC-SYSTEMS AND SPEECH FLUENCY.
000821 01-14
INFLUENCE OF DOPAMINERGIC-SYSTEMS ON THE LATERAL HABENULAR
NUCLEUS OF THE RAT.
001365 02-03
EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC-
SYSTEMS IN THE RAT-BRAIN.
001464 02-03
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE-
DECANOATE TREATMENT.
001820 02-04
POSSIBLE INVOLVEMENT OF BRAIN DOPAMINERGIC-SYSTEMS IN THE
EXPRESSION OF EMOTIONS IN DREAMS.
002325 02-14
EFFECTS OF CHLORPROMAZINE ON DOPAMINERGIC-RECEPTOR FUNCTIONS
IN RAT-BRAIN - DIFFERENCE OF THE RESPONSE OF SEVERAL
DOPAMINERGIC-SYSTEMS AFTER CHRONIC ADMINISTRATION.
002773 03-03
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
004112 04-04
DORSAL-HORN
THE EFFECTS OF MORPHINE ON THE ACTIVITY OF CERTAIN DORSAL-HORN
NEURONS OF THE SPINAL-CORD INVOLVED IN NOCICEPTIVE PROCESSES
000028 01-03
DOES SYSTEMIC MORPHINE INCREASE DESCENDING INHIBITORY
CONTROLS OF DORSAL-HORN NEURONES INVOLVED IN NOCICEPTION?
000175 01-03
DEPRESSION AND FACILITATION OF SYNAPTIC RESPONSES IN CAT
DORSAL-HORN BY SUBSTANCE-P ADMINISTERED INTO SUBSTANTIA-
GELATINOSA.
001191 02-03
THE STEREOSPECIFIC EFFECT OF NALOXONE ON RAT DORSAL-HORN
NEURONES; INHIBITION IN SUPERFICIAL LAMINAE AND EXCITATION IN
DEEPER LAMINAE.
001226 02-03
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS:
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE.
003778 04-03
MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION.
003782 04-03
DORSOLATERAL
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL
DAMAGE.
000322 01-03
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR
DORSOLATERAL TEGMENTAL DAMAGE.
001818 02-04
EFFECTS OF DORSOLATERAL TEGMENTAL LESIONS ON AMPHETAMINE-
INDUCED AND LITHIUM-INDUCED TASTE-AVERSIONS.
003114 03-04
DOSAGE
DRUG RESPONSE DIFFERENCES OF HIGH AND STANDARD DOSAGE OF
FLUPHENAZINE-DECANOATE IN RELATION TO SCHIZOPHRENIC-
SYMPTOMS.
000562 01-08
A PRELIMINARY STUDY ON DETERMINATION OF THE OPTIMUM
OPIPRAMOL DOSAGE IN DEPRESSIVE-PATIENTS.
000601 01-09
VALPROIC-ACID DOSAGE AND PLASMA PROTEIN BINDING AND
CLEARANCE.
000755 01-13
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY: EFFICACY, DOSAGE SCHEDULE AND PLASMA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
CORRELATION BETWEEN DAILY DOSAGE OF CHLORPROMAZINE AND
SUBSEQUENT SUPERSENSITIVITY.
001845 02-05
PREDICTION OF DOSAGE OF LITHIUM-CARBONATE: USE OF A STANDARD
PREDiaiVE METHOD.
001991 02-09
A NEW DOSAGE SCHEDULE FOR PIMOZIDE IN THE ACUTE STABILIZATION
AND MAINTENANCE-TREATMENT OF PSYCHOSIS.
002022 02-09
EUHYPNOS-FORTE, HIGH-DOSE TEMAZEPAM FOR RESISTANT INSOMNIA:
POSTMARKETING SURVEILLANCE IN 10,057 PATIENTS UNRESPONSIVE
TO CONVENTIONAL HYPNOTIC DOSAGE.
002324 02-14
EEG ASSESSMENTS OF DOSAGE AND SLEEP PROFILES FOR A HYPNOTIC-
DRUG OF THE TRIAZOLOTHIENODIACEPINE SERIES
002338 02-14
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMIHER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL AaiVITY.
003134 03-06
STEADY-STATE LITHIUM BLOOD LEVEL FLUCTUATIONS IN MAN
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FORM.
003151 03-07
DOSAGE OF INTRATUMORAL LITHIUM (CEREBRAL GLIOBLASTOMA): ON A
FAILURE OF TREATMENT OF MANIC-DEPRESSIVE-PSYCHOSIS.
003226 03-09
NATURAL AND THERAPEUTIC ENVIRONMENTAL INDICATORS OF
MAINTENANCE DOSAGE REQUIREMENTS.
003561 03-16
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS.
004551 04-13
DOSAGES
A DOUBLE-BLIND COMPARISON OF THREE DOSAGES OF FLUTROLINE (CP-
36584) IN THE TREATMENT OF SCHIZOPHRENIA.
004333 04-08
DOSE
FIRST DOSE BEHAVIORAL-TOLERANCE TO PHENCYCLIDINE ON FOOD
REWARDED BAR-PRESSING-BEHAVIOR IN THE RAT.
000462 01-04
DOSE AND PHYSICAL-DEPENDENCE AS FACTORS IN THE SELF-
ADMINISTRATION OF MORPHINE BY RATS
000497 01-04
WHAT IS THE BEST MAINTENANCE DOSE OF NEUROLEPTICS IN
SCHIZOPHRENIA?
000547 01-08
SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF
SINGLE VS DIVIDED DOSE ADMINISTRATION.
000629 01-09
PRACTICAL AND THEORETICAL ASPEQS OF PHENYTOIN
ADMINISTRATION I RELATIONSHIP BETWEEN DOSE AND PLASAAA
CONCENTRATION.
000760 01-13
EFFECT OF DOSE ON PHENYTOIN ABSORPTION.
000773 01-13
DETERMINATION OF DOSE PLASMA CONCENTRATION RELATIONSHIP OF
PHENOBARBITAL IN EPILEPTIC-PATIENTS BY A NEW SPECIFIC
RADIOIMMUNOASSAY
000902 01-16
CUMULATIVE DOSE RESPONSE-CURVES IN BEHAVIORAL-
PHARMACOLOGY
001883 02-06
MIANSERIN: DETERMINATION OF THERAPEUTIC DOSE RANGE.
002026 02-09
DOSE SIZE AND INTERDOSE INTERVAL EFFECTS ON MORPHINE-TOLERANCE
IN THE RAT. (PH D. DISSERTATION).
003090 03-04
EFFECT OF DOSE ON BIOAVAILABILITY OF ORAL OIGOXIN
003161 03-07
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME
003189 03-08
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS.
004551 04-13
DOSE-DEPENDENT
DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT
METABOLISM, DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND
CHOLERETIC-EFFECT.
000073 01-03
STEREOSPECIFIC, DOSE-DEPENDENT ANTAGONISM BY NALOXONE OF
NONOPIATE BEHAVIOR IN MICE.
000411 01-04
DOSE-DEPENDENT AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND
SPONTANEOUSLY HYPERTENSIVE-RATS.
001197 02-03
DOSE-DEPENDENT PHARMACOKINETICS OF ALPHA METHYL-P-TYROSINE
(ALPHA MT) AND COMPARISON OF CATECHOLAMINE TURNOVER-
RATES AFTER TWO DOSES OF ALPHA MT
001532 02-03
S-154
VOLUME 19, SUBJECT INDEX
Subject Index
APPARENT SEROTONERGIC MODULATION OF THE DOSE-DEPENDENT
BIPHASIC RESPONSE OF NEOSTRIATAL NEURONS PRODUCED BY D-
AMPHETAMINE,
003981 04-03
DOSE-EFFECT
DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL-SYNDROME
004472 04-11
DOSE-EFFECTS
THE DIFFERENTIAL DOSE-EFFECTS OF METHYLPHENIDATE ON
HYPERACTIVE-CHILDREN AND THEIR MOTHERS, (PH.D.
DISSERTATION).
002143 02-11
DOSE-EFFECTS OF SECOBARBITAL IN A STERNBERG MEMORY SCANNING
TASK.
003460 03-14
DOSE-RELATED
UNUSUAL DOSE-RELATED EFFECT OF AN ENDORPHIN ANALOG IN A
COMPLEX MAZE.
001674 02-04
LITHIUM INDUCES DOSE-RELATED INCREASES AND DECREASES IN
ACTIVITY LEVELS IN THE RAT.
004079 04-04
DOSE-RESPONSE
FLASH-EVOKED AFTERDISCHARGE IN RAT AS A MODEL OF THE ABSENCE
SEIZURE: DOSE-RESPONSE STUDIES WITH THERAPEUTIC DRUGS.
000160 01-03
MODULATION OF APOMORPHINE-INDUCEO STEREOTYPY BY ESTROGEN:
TIME-COURSE AND DOSE-RESPONSE.
001636 02-04
AMPHETAMINE AND MATERNAL-BEHAVIOR: DOSE-RESPONSE
RELATIONSHIPS.
001752 02-04
DOSE-RESPONSE STUDY OF THE PRECIPITATED ABSTINENCE-SYNDROME
FOR MORPHINE: SYSTEMIC VS PERIAQUEDUCTAL GRAY NALOXONE.
(PH.D. DISSERTATION).
002979 03-04
AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE
ANALYSIS OF APOMORPHINE-INDUCED-FIGHTING AND STEREOTYPY IN
THE RAT.
002983 03-04
DOSE-RESPONSE RELATIONSHIP BETWEEN NALOXONE INJECTIONS AND
INTAKE OF SUCROSE SOLUTION.
003118 03-04
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE
RELATIONSHIP.
003806 04-03
DOSES
A COMPARISON OF HUMAN TAQILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
CONTROLLED-COMPARISON OF MEDIUM AND HIGH CLOROTEPIN DOSES
IN CHRONIC SCHIZOPHRENIA.
000548 01-08
THE EFFECT OF SMALL AND MODERATE DOSES OF D-AMPHETAMINE ON
HUNGER. MOOD, AND AROUSAL IN MAN.
000807 01-14
PERSPECTIVE ON ADEQUATE INDIVIDUALIZED DRUG DOSES.
000959 01-17
EFFEQ OF REPEATED ELEQROCONVULSIVE-SHOCKS (ECS) ON
SUBTHRESHOLD DOSES OF SOME CNS STIMULANTS.
001361 02-03
DECREASED BENZODIAZEPINE-RECEPTOR DENSITY IN RAT-CEREBELLUM
FOLLOWING NEUROTOXIC DOSES OF PHENYTOIN.
001373 02-03
EFFECT OF ANTINOCICEPTIVE DOSES OF OXOTREMORINE ON MOUSE-
BRAIN ACETYLCHOLINE TURNOVER-RATE.
001513 02-03
DOSE-DEPENDENT PHARMACOKINETICS OF ALPHA METHYL-P-TYROSINE
(ALPHA MT) AND COMPARISON OF CATECHOLAMINE TURNOVER-
RATES AFTER TWO DOSES OF ALPHA MT.
001532 02-03
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF
12 CNS DEPRESSANTS IN INTACT AND PITHED RATS.
001855 02-05
DISORDERS OF SMOOTH-PURSUIT EYE-MOVEMENTS IN SCHIZOPHRENICS
AND THE EFFECT OF NEUROLEPTICS IN THERAPEUTIC DOSES.
001912 02-08
PHARMACOKINETICS OF DIPOTASSIUM-CHLORAZEPATE IN PATIENTS
AFTER REPEATED 50MG ORAL DOSES.
002211 02-13
QUANTITATIVE STUDY OF THE DISTRIBUTION OF LITHIUM IN THE MOUSE-
BRAIN FOR VARIOUS DOSES OF LITHIUM GIVEN TO THE ANIMAL.
002299 02-13
THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPECTS OF SLEEP AND OBJECTIVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOCTURNAL
MEDICATION: II. REPEATED DOSES
002331 02-14
CARDIOVASCULAR-EFFECTS OF THERAPEUTIC DOSES OF TRICYCLIC-
ANTIDEPRESSANTS: IMPORTANCE OF BLOOD LEVEL MONITORING.
002456 02-15
AN EVALUATION OF MAPROTILINE INTRAVENOUS KINETICS AND
COMPARISON OF TWO ORAL DOSES.
002497 02-16
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF
METHAMPHETAMINE.
002812 03-03
SINGLE OR REPEATED ADMINISTRATION OF SMALL DOSES OF
APOMORPHINE ON WATER INTAKE AND ACTIVITY IN WATER-
DEPRIVED RATS.
002981 03-04
CORRELATION BETWEEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC-
DRUGS IN RATS AND DAILY CLINICAL DOSES.
003032 03-04
2,4,5 TRICHLOROPHENOXYACETIC-ACID CAUSES BEHAVIORAL-EFFECTS IN
CHICKENS AT ENVIRONMENTALLY RELEVANT DOSES
003079 03-04
EXCESSIVE PUVSMA CONCENTRATIONS OF TRICYCLIC-ANTIDEPRESSANTS
RESULTING FROM USUAL DOSES: A REPORT OF SIX CASES.
003479 03-15
LONG-TERM EFFECTS OF MULTIPLE DOSES OF METHAMPHETAMINE ON
TRYPTOPHAN-HYDROXYLASE AND TYROSINE-HYDROXYLASE ACTIVITY
IN RAT-BRAIN.
003850 04-03
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON
BEHAVIORAL SHIFTS IN CATS, ARISING AFTER CESSATION OF
ELECTRICAL-STIMULATION OF THE CAUDATE-NUCLEUS.
004067 04-04
AGE-SPECIFIC DOSES OF LORMETAZEPAM AS A NIGHT SEDATIVE IN
CASES OF CHRONIC SLEEP-DISTURBANCE.
004309 04-07
PHARMACOKINETICS OF CLOXAZOLAM IN MAN AFTER SINGLE AND
MULTIPLE ORAL DOSES.
004530 04-13
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS ACTIVE
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC-
PATIENTS TREATED WITH FIXED DRUG DOSES.
004559 04-13
DOSING
DOUBLE-BLIND COMPARISON OF KETAZOLAM, DIAZEPAM AND PLACEBO
IN ONCE-A-DAY VS T.I.D. DOSING.
000660 01-11
DOUBLE-BLIND COMPARISON OF KETAZOLAM AND PLACEBO USING
ONCE-A-DAY DOSING.
002067 02-10
SINGLE POINT ESTIMATION OF PHENYTOIN DOSING REQUIREMENT.
003562 03-16
DOTHIEPIN
A COMPARATIVE EVALUATION OF DOTHIEPIN (PROTHIEDEN) AND
IMIPRAMINE.
000583 01-09
AN OVERVIEW OF SEVENTEEN YEARS OF EXPERIENCE WITH DOTHIEPIN IN
THE TREATMENT OF DEPRESSION IN EUROPE.
001995 02-09
A COMPARISON OF TRAZODONE AND DOTHIEPIN IN DEPRESSION.
004394 04-09
DOUBLE-BUND
ANTIDEPRESSANT TREATMENT BY INTRAVENOUS ADMINISTRATION
COMPARED TO PERORAL ADMINISTRATION: A DOUBLE-BLIND STUDY
OF QUINUPRAMINE.
000552 01-08
DOUBLE-BLIND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH
AFTERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS
WITH SCHIZOPHRENIA.
000574 01-08
A DOUBLE-BUND GROUP COMPARATIVE-TRIAL OF MIANSERIN AND
DIAZEPAM IN DEPRESSED-OUTPATIENTS.
000592 01-09
DOUBLE-BLIND COMPARISON OF KETAZOLAM, DIAZEPAM AND PLACEBO
IN ONCE-A-DAY VS T.I.D. DOSING.
000660 01-11
PSYCHOPATHOMETRIC DOUBLE-BLIND COURSE STUDY WITH NICERGOLINE
VERSUS PLACEBO IN GERIATRIC-PATIENTS WITH TRANSIENT-
SYNDROMES.
000665 01-11
A COMPUTER OCULOGRAPHIC AND EEG DOUBLE-BLIND STUDY INCLUDING
WELL-BEING FOR DETERMINING CHANGED VIGILANCE UNDER THERAPY
WITH TIAPRIDE.
000751 01-13
.1
Mil,
"Wit
»tii:
•itir
tic
S-155
i'!!
11!
* llll '
Subject Index
MAINTENANCE-THERAPY WITH FLUPHENAZINE-DECANOATE AND
OXYPROTHEPINE-DECANOATE IN SCHIZOPHRENIC-PATIENTS - A
DOUBLE-BLIND CROSS-OVER COMPARATIVE-STUDY.
001924 02-08
CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN
SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BUND CROSS-
OVER DESIGN.
001937 02-08
COMPARISON OF THE EFFECTS OF LOFEPRAMINE AND MIANSERIN IN
DEPRESSED-PATIENTS IN A DOUBLE-BLIND TRIAL.
■ 001996 02-09
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS:
RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BLIND TRIAL.
001998 02-09
ANTIDEPRESSANT ACTION OF AMINEPTINE: CONTROLLED DOUBLE-BLIND
STUDY.
002030 02-09
DOUBLE-BUND CONTROLLED EXPERIMENT: AMINEPTINE VERSUS
AMITRIPTYUNE USING THE HAMILTON-DEPRESSION-RATING-SCALE.
002050 02-09
DOUBLE-BUND CONTROLLED-STUDY: AMINEPTINE VERSUS
TRIMIPRAMINE,
002051 02-09
DOUBLE-BLIND COMPARISON OF KETAZOLAM AND PLACEBO USING
ONCE-A-DAY DOSING.
002067 02-10
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO
SEVERE ANXIETY.
002070 02-10
A DOUBLE-BUND PARALLEL GROUP COMPARISON OF SINGLE-BEDTIME-
DOSES OF HALAZEPAM AND PLACEBO.
002079 02-10
DOUBLE-BLIND CONTROLLED-STUDY ON THE PSYCHOLEPTIC-EFFECTS OF
AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT
PERSONAUTY-PROBLEMS.
002116 02-11
NOMIFENSINE AS CONCOMITANT THERAPY IN THE TREATMENT OF
PARKINSON-PATIENTS. A DOUBLE-BUND PLACEBO-CONTROLLED-
STUDY.
002130 02-11
A DOUBLE-BLIND STUDY WITH ORG-GB-94 IN PREMENOPAUSAL-WOMEN
002173 02-11
A CONTROLLED DOUBLE-BUND STUDY OF HALOPERIDOL VERSUS
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY-
SUBNORMAL-PATIENTS: SERUM LEVELS AND CUNICAL-EFFECTS.
002185 02-11
DOUBLE-BUND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS.
002314 02-14
FACTORS DETERMINING PATIENT TENURE ON A 3-YEAR DOUBLE-BUND
INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE-HCL.
002513 02-17
A DOUBLE-BLIND CROSSED CLINICAL-STUDY WITH A NEW
PSYCHOPHARMACEUTICAL: TIADIPONE {QM-6008), DIAZEPAM, AND
A PLACEBO
003153 03-07
SYNERGISM OF COMBINED UTHIUM NEUROLEPTIC THERAPY: A DOUBLE-
BLIND PLACEBO-CONTROLLED CASE-STUDY
003165 03-08
PIPERIDONE IN CHRONIC SCHIZOPHRENIC-PATIENTS: A CONTROLLED
DOUBLE-BUND STUDY.
003184 03-08
DOUBLE-BUND STUDY OF MIANSERIN AND AMITRIPTYLINE
003231 03-09
PROPHYLACTIC LITHIUM WITH AND WITHOUT IMIPRAMINE FOR BIPOLAR-
l-PATIENTS: A DOUBLE-BUND STUDY
003233 03-09
A DOUBLE-BLIND COMPARISON BETWEEN AMOXAPINE AND
AMITRIPTYUNE IN DEPRESSED-INPATIENTS.
003234 03-09
EFFICACY OF DESIPRAMINE IN MILDLY DEPRESSED-PATIENTS: A DOUBLE-
BUND, PLACEBO-CONTROLLED-TRIAL.
003262 03-09
ANALYSIS OF SINGLE-BLIND, DOUBLE-BUND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFECTS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS - BRIEF REPORT.
003298 03-1 1
A DOUBLE-BUND, PLACEBO-CONTROLLED-STUDY OF PIRACETAM IN
ELDERLY PSYCHIATRIC-PATIENTS.
003305 03-1 1
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS. A
CUNICAL DOUBLE-BUND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER).
003327 03-11
DOUBLE-BLIND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR
SUBCHRONIC WITHDRAWAL FROM ALCOHOL.
003332 03-11
Ptychopharmacology Abstracts
A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF
CARBAMAZEPINE IN OVERACTIVE, SEVERELY MENTALLY-
HANDICAPPED PATIENTS.
003365 03-11
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
DES-TYROSYL-GAMMA-ENDORPHIN IN SCHIZOPHRENIA: A DOUBLE-BUND
TRIAL IN 13 PATIENTS.
004322 04-08
A DOUBLE-BLIND COMPARISON OF THREE DOSAGES OF FLUTROUNE (CP-
36584) IN THE TREATMENT OF SCHIZOPHRENIA.
004333 04-08
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION: A
DOUBLE-BLIND COMPARISON WITH IMIPRAMINE.
004346 04-09
A PRELIMINARY DOUBLE-BLIND STUDY ON THE EFFICACY OF
CARBAMAZEPINE IN PROPHYLAXIS OF MANIC-DEPRESSIVE-ILLNESS.
004388 04-09
A DOUBLE-BLIND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND
SIDE-EFFECTS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED-
INPATIENTS AND DEPRESSED-OUTPATIENTS.
004395 04-09
A DOUBLE-BLIND TRIAL: THE USE OF OXPRENOLOL AND DIAZEPAM IN
ANXIETY.
004428 04-10
ANALYSIS OF SINGLE-BUND AND DOUBLE-BUND PROCEDURES,
MAINTENANCE OF PLACEBO-EFFECTS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON
004437 04-11
THE EFFICACY OF PIRACETAM IN VERTIGO: A DOUBLE-BLIND STUDY IN
PATIENTS WITH VERTIGO OF CENTRAL ORIGIN.
004478 04-11
A CLINICAL-EVALUATION OF THE EFFEaS OF A NEW PSYCHOTROPIC-
AGENT MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE
DOUBLE-BUND METHOD
004491 04-11
DRUG PREFERENCE IN HUMANS: DOUBLE-BLIND CHOICE COMPARISON OF
PENTOBARBITAL, DIAZEPAM AND PLACEBO.
004566 04-14
DOUBLE-PLACEBO
SINGLE-DOSE VERSUS MULTIPLE-DOSE COMPARATIVE-TRIAL OF
DESIPRAMINE-HYDROCHLORIDE: A DOUBLE-PLACEBO METHOD.
002059 02-10
DOWN-SYNDROME
PHAGOCYTIC FUNCTION IN DOWN-SYNDROME
CHEMOTAXIS.
003401 03-13
DOWNS-SYNDROME
5 HYDROXYTRYPTOPHAN AND PYRIDOXINS: THEIR EFFEQS IN YOUNG
CHILDREN WITH DOWNS-SYNDROME.
002161 02-11
A STUDY OF GAMMA AMINOBUTYRIC-ACID UPTAKE IN NORMAL AND
DOWNS-SYNDROME PLATELETS.
003787 04-03
DOXEPIN
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYUNE ON CORTICAL
EVOKED-POTENTIALS.
000763 01-13
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A
CONTROLLED CLINICAL- STUDY WITH DOXEPIN AND PLACEBO.
002080 02-10
EFFECT OF DOXEPIN ON SEROTONIN METABOUSM IN RAT-BRAIN AND
SEROTONIN UPTAKE BY HUMAN BLOOD-PLATELETS.
002243 02-13
CLOMIPRAMINE AND DOXEPIN IN DEPRESSIVE-NEUROSIS: PLASMA
LEVELS AND THERAPEUTIC RESPONSE.
002258 02-13
SINGLE-DOSE PHARMACOKINETICS OF DOXEPIN IN HEALTHY
VOLUNTEERS. „„o^„o ^o ,o
002303 02-13
RADIOIMMUNOASSAY FOR TOTAL DOXEPIN AND N DESMETHYLDOXEPIN
IN PLASMA. ^^„ ^„„ w
002499 02-16
THERAPEUTIC-EFFICACY OF DOXEPIN IN DIVIDED AND SINGLE-DOSE
^^^'^^ 003259 03-09
DOXEPIN A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTAQ
ASTRO'GUAL cells IN CULTURES AND INHIBITS THE ISOPROTERENOL-
INDUCED INCREASE IN CYCUC-AMP PRODUQION
003836 04-03
PLASMA LEVELS OF THE CIS-ISOMERS AND TRANS-ISOMERS OF DOXEPIN
AND DESMETHYLDOXEPIN ARER ADMINISTRATION OF DOXEPIN TO
'''^''''' 004355 04^
DOXEPIN PLASMA LEVELS AND ANXIOLYTIC RESPONSE.
004477 04-11
S-156
VOLUME 19, SUBJECT INDEX
Subject Index
DOXEPINE
TREATMENT Of ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A
MONOSUBSTANCE (DOXEPINE).
002028 02-09
DREAMS
POSSIBLE INVOLVEMENT OF BRAIN DOPAMINERGIC-SYSTEMS IN THE
EXPRESSION OF EMOTIONS IN DREAMS,
002325 02-14
DRINKING
WATER INTAKE AND TIME-COURSE OF DRINKING AFTER SINGLE OR
REPEATED CHLORDIAZEPOXIDE INJECTIONS.
000369 01-04
USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETECT AND
DISCRIMINATE ACTIONS OF DRUGS AND TOXICANTS.
000503 01-04
A DRUG DISPENSER TO MEASURE INDIVIDUAL DRINKING IN RAT
COLONIES.
000530 01-06
INTRACRANIAL INJECTION PARAMETERS WHICH AFFECT ANGIOTENSIN-II-
INDUCED DRINKING.
000534 01-06
EFFECTS Of PSYCHOTROPIC-DRUGS ON FI-RESPONDING AND ADJUNCTIVE
DRINKING IN RATS.
001693 02-04
CONDITIONED SUPPRESSION OF DRINKING; A MEASURE Of THE CR
ELICITED BY A LITHIUM CONDITIONED FLAVOR
001747 02-04
EFFECT Of PROSTAGLANDIN-El AND ITS BIOSYNTHESIS INHIBITOR
INDOMETHACIN ON DRINKING IN THE RAT.
001749 02-04
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE Of HIGH BLOOD
ETHANOL LEVELS IN RATS DRINKING A LIQUID DIET.
001865 02-06
SUPPRESSION Of DRINKING BY NALOXONE IN THE RAT: A FURTHER
CHARACTERIZATION.
002963 03-04
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF LOW-DOSES OF A
DOPAMINE AGONIST ON DRINKING AND LOCOMOTOR-ACTIVITY IN THE
RAT
002982 03-04
OPERANT FEEDING AND DRINKING IN PIGS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF SYNTHETIC
CHOLECYSTOKININ-OCTAPEPTIDE.
003064 03-04
NALOXONE SUPPRESSES FEEDING AND DRINKING BUT NOT WHEEL
RUNNING IN RATS.
004080 04-04
SUPPRESSION OF ALCOHOL DRINKING WITH BRAIN ALDEHYDE-
DEHYDROGENASE INHIBITION.
004220 04-04
L 5 HYDROXYTRYPTOPHAN-INDUCED DRINKING IN RATS: POSSIBLE
MECHANISMS FOR INDUCTION.
004237 04-04
DRINKING-BEHAVIORS
BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH
KAINIC-ACID-INDUCED LESIONS Of STRIATAL NEURONS - WITH A
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS-
DISEASE.
000463 01-04
DRINKING-PATTERNS
THE INfLUENCE Of SINGLE DAILY HEROIN INJECTIONS ON DRINKING-
PAHERNS IN THE RAT.
001746 02-04
DRIVE
INTRAHYPOTHALAMIC MICROINJECTIONS Of NORADRENALINE WITH AND
WITHOUT INDUCTION Of THE ALIMENTARY DRIVE AS A REWARD IN A
T-MAZE LEARNING IN RATS.
001604 02-04
PSYCHOPHARMACEUTICAL-THERAPY TO CALM DRIVE, ACTIVITY, AND
RESTLESSNESS IN CHILDHOOD.
002604 02-17
DRIVING
EffECTS Of PSYCHOPHARMACEUTICALS ON DRIVING CAPACITY.
003453 03-14
DRL
DIffERENTIAL-EffECTS Of IMIPRAMINE IN RATS AS A fUNCTION Of DRL
SCHEDULE VALUE.
001714 02-04
DROPERIDOL
HALOPERIDOL AND DROPERIDOL TREATMENT IN SCHIZOPHRENICS:
CLINICAL APPLICATION Of THE PROLACTIN MODEL.
004332 04-08
DRUG
PHARMACOLOGICAL ACTIVITIES Of CLOBAZAM AND DIAZEPAM IN THE
RAT: RELATION TO DRUG BRAIN LEVELS.
000036 01-03
INHIBITION Of (3H)NAL0X0NE BINDING IN HOMOGENATES Of RAT-
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC ACTIVITY, RELATED
TO PHYSOSTIGMINE,
000104 01-03
EffECT Of THE CATECHOLAMINE-DEPLETING-AGENT 1 PHENYL-2-
THIAZOLYL-2-THIOUREA (U- 14-624) ON DRUG METABOLISM IN THE
RAT.
000280 01-03
INfLUENCE Of GLUCOSE (IN VIVO OR IN VITRO) ON DURATION Of
NARCOTIC ANALGESICS AND ON THE KINETICS Of DRUG METABOLISM
000292 01-03
INVESTIGATION Of NARCOTICS AND ANTITUSSIVES USING DRUG
DISCRIMINATION TECHNIQUES,
000447 01-04
A DRUG DISPENSER TO MEASURE INDIVIDUAL DRINKING IN RAT
COLONIES.
000530 01-06
DRUG AND SEIZURE IDENTIflCATION BY AUDIO-SPECTROMETRY. (PH D
DISSERTATION)
000532 01-06
DRUG RESPONSE DIffERENCES Of HIGH AND STANDARD DOSAGE Of
fLUPHENAZINE-DECANOATE IN RELATION TO SCHIZOPHRENIC-
SYMPTOMS.
000562 01-08
TRICYCLIC-ANTIDEPRESSANT DRUG TOLERANCE IN ORIENTAL AND
OCCIDENTAL POPULATIONS.
000590 01-09
THE PCP PSYCHOSIS: PROLONGED INTOXICATION OR DRUG PRECIPITATED
fUNCTIONAL ILLNESS?
000739 01-12
DRUG SENSITIVE ECTO-ATPASE IN HUMAN LEUKOCYTES.
000779 01-13
HOW TO SUCCESSfULLY CHANGE A PATIENT fROM ONE DRUG TO
ANOTHER.
000913 01-17
AN ASSESSMENT PROGRAM TO REDUCE DRUG USE WITH THE
MENTALLY-RETARDED.
000937 01-17
HAZARDS Of DRUG USE AMONG THE ELDERLY.
000953 01-17
PERSPECTIVE ON ADEQUATE INDIVIDUALIZED DRUG DOSES.
000959 01-17
A NOTE ON PATTERNS Of DRUG PRESCRIBING IN A RESIDENTIAL-CENTER
fOR THE INTELLECTUALLY-HANDICAPPED
000982 01-17
EXPERIMENTAL EVALUATION Of ANTIDEPRESSANT ACTIVITY OF
CLOMIPRAMINE, A NEW TRICYCLIC-ANTIDEPRESSANT DRUG.
001068 02-02
DRUG INTERFERENCE ON SOME BIOCHEMICAL-PARAMETERS OF RAT-
CEREBRAL-CORTEX DURING POSTISCHEMIC RECOVERY.
001126 02-03
ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA.
001151 02-03
PROCEDURES FOR REDUCING DRUG INTAKE: NONHUMAN STUDIES.
001753 02-04
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE
DEVELOPMENT OF DEPENDENCE IN RATS.
001800 02-04
ELECTROLYTIC MICROINFUSION TRANSDUCER SYSTEM: AN ALTERNATIVE
METHOD OF INTRACRANIAL DRUG APPLICATION.
001861 02-06
METOCLOPRAMIDE: ANTIPSYCHOTIC-EFFICACY OF A DRUG LACKING
POTENCY IN RECEPTOR MODELS.
001948 02-08
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRI i
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA.
002225 02-13
EffECTS Of CAFFEINE ON PLASMA FREE fATTY-ACIDS, URINARY
CATECHOLAMINES, AND DRUG BINDING.
002272 02-13
DRUG PREFERENCE AND MOOD IN HUMANS: DIAZEPAM.
002334 02-14
DRUG PREFERENCE AND MOOD IN HUMANS: D-AMPHETAMINE.
002335 02-14
EARLY-ACTIVITY-STUDIES AND INTENSIVE DRUG EVALUATIONS OF NEW
PSYCHOPHARMACOLOGIC-AGENTS .
002348 02-14
SUBJECTIVE DRUG-EFFECTS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFECTS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
TREATMENT OF IATROGENIC DRUG DEPENDENCE IN THE GENERAL-
HOSPITAL.
002460 02-15
DRUG CONTENT OF THE MOTHERS-MILK.
002461 02-15
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS
AFTER HOSPITAL DISCHARGE IN THE DISTRICTS TEPLICE AND UHERSKE-
HRADISTE,
002518 02-17
'If
iSi.
tic
S-157
J'
Subject Index
CLINICAL-PHARMACOLOGY: DRUG DEVELOPMENT.
STRUCTURE OF VARIABILITY AND CORRELATION IN LEARNING AFTER
DRUG ADMINISTRATION. 002562 02-17
INAPPROPRIATE ADH SECRETION: THE ROLE OF DRUG RECHALLENGE.
002629 02-17
DRUG ENVIRONMENT INTERACTION: CONTEXT DEPENDENCY OF COCAINE-
INDUCED BEHAVIORAL-SENSITIZATION. 002866 03-03
DRUG REGIMENS FACILITATING AGGRESSION: BEHAVIOR, AMINE, AND
RECEPTOR ALTERATIONS. 002987 03-04
LITHIUM DRUG INTERACTIONS ALTERING THE INTRACELLULAR LITHIUM
LEVEL: AN IN VITRO STUDY. 003142 03-06
A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS.
003182 03-08
CARPIPRAMINE A DISINHIBITORY DRUG COMPOUND IN CHRONIC
5^"'^°''"^^^^^ 003192 03-08
METHODOLOGY OF OUTPATIENT DRUG RESEARCH. (UNPUBLISHED
''^''^'^' 003282 03-10
CLINICAL-PHARMACOLOGY: ADVERSE DRUG INTERACTIONS,^
LATERALIZED DEFICITS AND DRUG INFLUENCES ON THE DICHOTIC
LISTENING OF SCHIZOPHRENIC-PATIENTS. 003443
DRUG PREFERENCE AND MOOD IN HUMANS: REPEATED ASSESSMENT OF
D-AMPHETAMINE. 003445 03-14
HOW TO TREAT AND PREVENT DRUG TOXICITY . _^ ,.,,„,, ,
003541 03-15
EFFECTS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETECT THE NARCOTIC CHARACTER OF A DRUG.
003555 03-16
EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED
COGNITIVE ASSESSMENT SYSTEM. 003557 03-16
DRUG AND DIETETIC THERAPIES FOR HYPERKINETIC-CHILDREN. (PH.D.
■^'5^^^^^^'°'^' 003576 03-17
GUIDELINES EMPLOYED BY THE FOOD-AND-DRUG-ADMINISTRATION IN
DRUG SCHEDULING. 003586 03-17
DRUG DEPENDENCE: REFLECTIONS ON AND ANALYSIS OF AN EXPERIENCE
IN THE PROVINCE OF RIGGIO-EMILIA. ^^^^^ ^^^^
AN ANALYSIS OF DRUG DECISIONS IN A STATE PSYCHIATRIC-HOSPITAL.
003593 03-17
USE OF CURRENTLY AVAILABLE DATA SOURCES TO ASSESS DRUG
^^"™^'^^ 003594 03-17
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES.
003599 03-17
IMPACT OF DRUG SCHEDULING ON UTILIZATION. ^^ ^
003601 03-17
ACTION ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS
OF TREATING ALCOHOLISM AND DRUG ADDICTION
PATHOGENETICALLY. ,„,,-,
003641 03-17
HEPATIC-DISEASE AND DRUG PHARMACOKINETICS.
003650 03-17
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
ETHANOL. „o,„r,^.^,
003725 04-03
AGE-DEPENDENT MODIFICATION OF DRUG INTERFERENCE ON THE
ENZYMATIC AQIVITIES OF THE RAT-BRAIN.
003730 04-03
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
CONDITIONING OF AN INTEROCEPTIVE DRUG STIMULUS TO DIFFERENT
EXTEROCEPTIVE CONTEXTS.
004142 04-04
BARBITURATE-DEPENDENCE AND DRUG PREFERENCE.
004235 04-04
LACK OF SPECIFICITY OF AN ANIMAL BEHAVIOR MODEL FOR
HALLUCINOGENIC DRUG ACTION . „„.„.„„.„.
004250 04-04
AUTORADIOGRAPHIC LOCALIZATION OF DRUG AND NEUROTRANSMITTER-
RECEPTORS IN THE BRAIN.
004292 04-06
Psychopharmacology Abstracts
INHIBITION OF PENTAGASTRIN-STIMULATED AND OVERNIGHT GASTRIC
SECRETION BY LM24056, A NEW PHENOTHIAZINE DERIVED
ANTISECRETORY DRUG.
004306 04-07
CONCENTRATIONS OF CHLORPROMAZINE AND TV^^O OF ITS AQIVE
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC-
PATIENTS TREATED WITH FIXED DRUG DOSES.
004559 04-13
COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPLIED TO DRUG
EVALUATION: MIDAZOLAM IN NORMAL SUBJECTS.
004564 04-14
DRUG PREFERENCE IN HUMANS: DOUBLE-BUND CHOICE COMPARISON OF
PENTOBARBITAL, DIAZEPAM AND PLACEBO.
004566 04-14
PREVENTION OF TARDIVE-DYSKINESIA AND OTHER DRUG RELATED
ADVERSE-EFFECTS.
004601 04-15
BIOLOGICAL AND PHYSIOLOGICAL PREDIQORS OF DRUG RESPONSE.
(UNPUBLISHED PAPER).
THE DRUG PATHOMORPHOSIS OF SCHIZOPHRENIA
DRUG CONCENTRATIONS IN NEUROPSYCHIATRY.
CLINICAL-PHARMACOLOGY: DRUG ABSORPTION.
004708 04-17
004732 04-17
004735 04-17
004740 04-17
DRUG-ABUSE
PARAPROFESSIONAL AND PROFESSIONAL TEAMWORK AND TRAINING IN
MANAGING PCP AND OTHER DRUG-ABUSE PROBLEMS.
000924 01-17
DRUG-EFFECT
DOPAMINE-RECEPTORS AND SCHIZOPHRENIA: DRUG-EFFEQ OR ILLNESS?
000564 01-08
DRUG-EFFECT ON BLINK RATES IN RHESUS-MONKEYS: PRELIMINARY
STUDIES.
003023 03-04
DRUG-EFFECTS
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFEaS ON
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFEQS OF
COCAINE AND D-AMPHETAMINE FOLLOWING CHRONIC AMPHETAMINE
ADMINISTRATION „„„.,„„,„.
000350 01-04
DRUG-EFFECTS ON THE PERFORMANCE OF PIGEONS UNDER A NEGATIVE
AUTOMAINTENANCE-SCHEDULE .
001754 02-04
DRUG-EFFEaS ON SCHEDULE-INDUCED BEHAVIORS. (PH.D.
DISSERTATION) ^,-,„, „. n.
001786 02-04
SUBJECTIVE DRUG-EFFECTS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFEQS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
DRUG-EFFECTS ON PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-
RECEPTORS. „„^o-,o/^o ,.:
002372 02-15
FREE DESCRIPTION OF DRUG-EFFEaS AS A METHOD OF CLINICAL-TRIAL,
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND
THEIR COMBINATION. 00256102-17
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: BRAIN-DAMAGE OR
^^^^-^^'^^'■^ 003538 03-15
CONDITIONED DRUG-EFFEQS OF D-AMPHETAMINE-INDUCED AND
MORPHINE-INDUCED MOTOR ACCELERATION IN MICE: EXPERIMENTAL
APPROACH FOR PLACEBO-EFFEa. 004128 04-04
NONSPECIFIC FAQORS IN DRUG-EFFEaS: PLACEBO PERSONALITY.
004704 04-17
DRUG-HOLIDAY
DRUG-HOLIDAY AND MANAGEMENT OF PARKINSON-DISEASE.
002468 02-15
THE EFFEaS OF A DRUG-HOLIDAY ON RELAPSE AND TARDIVE-
DYSKINESIA IN CHRONIC-SCHIZOPHRENICS. 003487 03 1 5
COMPLICATIONS OF CHRONIC LEVODOPA THERAPY: LONG-TERM
EFFICACY OF DRUG-HOLIDAY 003502 03-15
DRUG-HOLIDAYS
USING DRUG-HOLIDAYS FOR CHRONIC-OUTPATIENTS.
(X)4742 04-17
DRUG-INDUCED
TREATMENT OF DRUG-INDUCED DRYNESS OF MOUTH IN PSYCHIATRIC-
PATIENTS - A CONTROLLED-COMPARATIVE-STUDY. ^^^^ ^^^^
DRUG-INDUCED ALTERATIONS IN NEUROTRANSMIHER-RECEPTOR
BINDING AND FUNCTION. 001215 02-03
S-158
VOLUME 19, SUBJECT INDEX
Subject Index
DRUG-INDUCED RELEASE OE DOPAMINE FROM CORPUS- STRIATUM.
(PH D DISSERTATION).
001343 02-03
DRUG-INDUCED ELEVATION OF GABA AFTER INTRACEREBRAL
MICROINJECTION: SITE OF ANTICONVULSANT ACTION
001627 02-04
IMIPRAMINE NORMALIZES NATURALLY OCCURRING AND DRUG-INDUCED
DIFFERENCES IN THE EXPLORATORY-ACTIVITY OF RATS
001646 02-04
GABA AGONISTS DISSOCIATE STRIATAL UNIT ACTIVITY FROM DRUG-
INDUCED STEREOTYPED-BEHAVIOUR.
001716 02-04
SUPERSENSITIVITY TO APOMORPHINE IN EXPERIMENTALLY-INDUCED
HYPOKINESIA AND DRUG-INDUCED MODIFICATIONS OF THE
APOMORPHINE RESPONSE.
001814 02-04
DRUG-INDUCED ARTERIAL HYPOTENSION IN PSYCHIATRIC-PATIENTS
TREATED WITH DIHYDROERGOTAMINE.
001950 02-08
A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED
PARKINSONISM
002146 02-11
DRUG-INDUCED DISORDERS OF THE URINARY TRACT.
002393 02-15
DRUG-INDUCED DISORDERS OF THE EYE.
002396 02-15
DRUG-INDUCED DISORDERS OF THE LIVER.
002397 02-15
CASE 3: ASSESSMENT AND TREATMENT OF DRUG-INDUCED TREMOR.
002407 02-15
DRUG-INDUCED DEMENTIA.
002431 02-15
DRUG-INDUCED DISORDERS OF MUSCLE.
002435 02-15
DIFFERENTIAL-EFFECTS OF PHARMACOLOGICAL-AGENTS ACTING ON
MONOAMINERGIC SYSTEMS ON DRUG-INDUCED ANOREXIA.
002533 02-17
AN ANALYSIS OF SPECIFICITY OF DRUG-INDUCED CHANGES IN DRUG-
REINFORCED RESPONDING. (PH.D. DISSERTATION).
003010 03-04
DRUG-INDUCED STIMULUS CONTROL AND THE CONCEPT OF BREAKING-
POINT: LSD AND QUIPAZINE.
003116 03-04
ANALYSIS OF SINGLE-BLIND, DOUBLE-BUND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFECTS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS - BRIEF REPORT.
003298 03-11
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE
AMINO-ACID POOL.
004039 04-03
MODIFICATION OF DRUG-INDUCED CATATONIA AND TREMORS BY
QUIPAZINE IN RATS AND MICE.
004164 04-04
THE ROLE OF NIGRAL PROJECTIONS TO THE THALAMUS IN DRUG-
INDUCED CIRCLING-BEHAVIOUR IN THE RAT.
004205 04-04
ANALYSIS OF SINGLE-BLIND AND DOUBLE-BUND PROCEDURES,
MAINTENANCE OF PLACEBO-EFFECTS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON.
004437 04-11
DRUG-INDUCED ALTERATIONS OF THE HYPOTHALAMUS HYPOPHYSIS
AXIS.
004535 04-13
DRUG-INDUCED PSYCHOSIS AND SCHIZOPHRENIA IN ADOLESCENTS.
004596 04-15
TARDIVE-DYSKINESIA AND OTHER DRUG-INDUCED MOVEMENT-
DISORDERS AMONG HANDICAPPED CHILDREN AND YOUTH.
004614 04-15
DRUG-INTERACTIONS
TRICYCUC-ANTIDEPRESSANT DRUG-INTERACTIONS WITH HISTAMINE AND
ALPHA-ADRENERGIC-RECEPTORS.
000791 01-13
DRUG-INTERACTIONS IN PSYCHOPHARMACOLOGY.
000915 01-17
DRUG-INTERACTIONS IN EPILEPSY.
003622 03-17
DRUG-INTERACTIONS OF AMITRIPTYLINE AND NORTRIPTYLINE WITH
WARFARIN IN THE RAT.
003912 04-03
DRUG-RECEPTORS
GABA-RECEPTOR ASSOCIATED DRUG-RECEPTORS.
002893 03-03
DRUG-REFUSAL
ROniNG WITH THEIR RIGHTS ON: CONSTITUTIONAL THEORY AND
CLINICAL REAUTY IN DRUG-REFUSAL BY PSYCHIATRIC-PATIENTS.
000911 01-17
DRUG-REINFORCED
AN ANALYSIS OF SPECIFICITY OF DRUG-INDUCED CHANGES IN DRUG-
REINFORCED RESPONDING. (PH.D. DISSERTATION).
003010 03-04
DRUG-RESISTANCE
CUNICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG-
RESISTANCE
003245 03-09
DRUG-RESISTANT
CLINICAL AND BIOCHEMICAL-ACTION OF PIRACETAM (NOOTROPIL) IN
DRUG-RESISTANT DEPRESSION.
000600 01-09
DRUG-STUDIES
ANIMAL ACTIVITY MONITOR FOR CHRONIC DRUG-STUDIES.
(UNPUBLISHED PAPER).
001794 02-04
DRUG-THERAPIES
CONVULSIVE AND DRUG-THERAPIES OF DEPRESSION
004366 04-09
DRUG-THERAPY
DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES.
000584 01-09
THE PSYCHODYNAMIC-APPROACH TO DRUG-THERAPY
000969 01-17
DEPRESSION: HOW TO RATIONAUSE DRUG-THERAPY.
001988 02-09
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS.
002047 02-09
SELF-MEDICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS.
002189 02-11
MEASUREMENT OF PLASMA CONCENTRATIONS OF DRUGS AS A
FEEDBACK CONTROL MECHANISM DURING DRUG-THERAPY.
002525 02-17
TRANSFER FROM MULTIPLE TO SINGLE ANTIEPILEPTIC DRUG-THERAPY.
003316 03-11
RELAPSE AFTER SHORT-TERM DRUG-THERAPY IN NEUROTIC-
OUTPATIENTS.
004400 04-09
DRUG-THERAPY FOR HYPERACTIVITY: TREATMENT PROCEDURES IN
NATURAL SETTINGS.
004449 04-11
PROBLEMS REMAIN IN REVIEWS OF MEDICAID FINANCED DRUG-THERAPY
IN NURSING-HOMES.
004736 04-17
DRUG-TREATMENT
REPEATED TRICYCUCS INDUCE A PROGRESSIVE DOPAMINE-
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT OF DAILY DRUG-
TREATMENT.
000047 01-03
(3H) 2 AMINODIHYDROXYTETRAHYDRONAPHTHALENE (ADTN):
REGIONAL DISTRIBUTION AND IN VIVO BINDING AFTER ACUTE AND
CHRONIC DRUG-TREATMENT.
000052 01-03
A NEW DRUG-TREATMENT FOR PREMENSTRUAL EXACERBATION OF
SCHIZOPHRENIA.
000553 01-08
THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG-TREATMENT
OR HYPERACTIVE-CHILDREN: RECENT FINDINGS AND A REPORT FROM
CLINICAL-PRACTICE.
000715 01 11
PROBLEMS OF DRUG-TREATMENT OF MENTAL-DISORDERS.
002623 02-17
ELECTROPHYSIOLOGIC ASSESSMENT OF RECEPTOR CHANGES FOLLOWING
CHRONIC DRUG-TREATMENT.
003136 03-06
DRUG-TREATMENT OF THE PHOBIC-ANXIETY-SYNDROME.
003280 03-10
COMPARISON OF SODIUM-VALPROATE AND PHENYTOIN AS SINGLE
DRUG-TREATMENT IN EPILEPSY.
003371 03-11
AHENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNCTION) IN
ADULTS: A REPUCATION STUDY OF DIAGNOSIS AND DRUG-
TREATMENT.
003389 03-11
TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT DECREASES ALPHA2-
ADRENORECEPTORS ON HUMAN PLATELET MEMBRANES.
003408 03-13
AUDITORY BRAINSTEM EVOKED-RESPONSES IN HOSPITALIZED-PATIENTS
UNDERGOING DRUG-TREATMENT OR ECT.
003430 03-13
PSYCHIATRIC-SYNDROMES AND DRUG-TREATMENT.
003608 03-17
CHRONIC DRUG-TREATMENT OF THE CHRONICALLY-ILL: BENEFITS AND
RISKS.
003625 03-17
ALPHA2-ADREN0RECEPT0RS IN RAT-BRAIN ARE DECREASED AFTER
LONG-TERM TRICYCUC-ANTIDEPRESSANT DRUG-TREATMENT.
004008 04-03
I
Ol,
•S.l!
iic
S-159
Subject index
Ptychopharmacology Abstracts
SOME PRINCIPLES OF DIFFERENTIATED METABOLIC DRUG-TREATMENT IN
COMPREHENSIVE THERAPY OF MENTAL-DISORDERS.
004433 04-11
PREVALENCE OF DRUG-TREATMENT FOR HYPERACTIVITY AND OTHER
CHILDHOOD BEHAVIOR-DISORDERS.
004713 04-17
PSYCHOSOCIAL-ASPECTS OF DRUG-TREATMENT FOR HYPERACTIVITY.
004714 04-17
DRUG-VARIABLES
DRUG-VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA:
APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.
000844 01-15
DRUGS
EFFECTS OF MORPHINE AND OTHER CENTRALLY-ACTING DRUGS ON 3,4
DIHYDROXYPHENYLETHYLENE-GLYCOL-SULFATE (D0PEG-S04) IN RAT-
BRAIN.
000136 01-03
FLASH-EVOKED AFTERDISCHARGE IN RAT AS A MODEL OF THE ABSENCE
SEIZURE: DOSE-RESPONSE STUDIES WITH THERAPEUTIC DRUGS.
000160 01-03
EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL
AND DIPHENYLHYDANTOIN IN THE ELECTROSHOCK-TEST IN MICE.
000163 01-03
IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR
ACTIVITY.
000289 01-03
TRICYCLIC-ANTIDEPRESSANT DRUGS AND INDIVIDUAL DIFFERENCES IN
THE EXPLORATORY-ACTIVITY OF RATS: CONTRASTING-EFFECTS OF
TERTIARY AND SECONDARY AMINE COMPOUNDS.
000401 01-04
BEHAVIORAL-EFFECTS AND ELECTROCORTICAL-EFFECTS AFTER
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS
ENHANCING GABAERGIC TRANSMISSION
000443 01-04
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY: NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNCTION.
000448 01-04
USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETECT AND
DISCRIMINATE ACTIONS OF DRUGS AND TOXICANTS.
000503 01-04
EFFECTS OF AGE AND OTHER DRUGS ON BENZODIAZEPINE KINETICS
000681 01-11
EFFICACY AND PAHERN VALENCE OF PSYCHOACTIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER.
000699 01-11
CONVERSION SCALES FOR COMMONLY REQUESTED SERUM
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE, AND OF
HORMONES.
000759 01-13
EFFEa OF DRUGS ON LEARNING AND MEMORY PROCESSES IN SIMPLE
BEHAVIORAL-TESTS.
000809 01-14
DRUGS AND SEXUAL-FUNCTION.
000852 01-15
DRUGS FOR SENILE-DEMENTIA.
000947 01-17
DISCUSSION: COMMUNICATION AND POLYPHARMACY: DRUGS AND THE
ELDERLY.
000957 01-17
DISEASE-INDUCED CHANGES IN THE PLASMA BINDING OF BASIC DRUGS.
000975 01-17
ALTERATION OF PROLACTIN SECRETION BY CENTRALLY-ACTING DRUGS.
001127 02-03
DOPAMINERGIC- SUPERSENSITIVITY: INFLUENCE OF DOPAMINE AGONISTS
AND DRUGS USED FOR THE TREATMENT OF TARDIVE-DYSKINESIA.
001169 02-03
INFLUENCE OF DRUGS AFFECTING THE PITUITARY ADRENAL AXIS ON
CHROMAFFIN CELLS.
001183 02-03
STUDIES ON THIORIDAZINE AND MESORIOAZINE METABOLISM. II IN
VIVO METABOLISM OF TRITIATED DRUGS IN RHESUS-MONKEYS.
001229 02-03
CENTRAL MONOAMINE SYNAPSES AS SITES OF AQION FOR ERGOT
DRUGS.
001238 02-03
EFFEaS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE.
001243 02-03
STEREOSELEQIVE ACTIONS OF SUBSTITUTED BENZAMIDE DRUGS ON
CEREBRAL DOPAMINE MECHANISMS.
001301 02-03
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE AQION OF ANTIADRENERGIC AND SEROTONERGIC
DRUGS.
001330 02-03
NEW EXPERIMENTAL TECHNIQUES IN THE PHARMACOLOGICAL
EVALUATION OF CNS ACTING DRUGS.
001479 02-03
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON
BARORECEPTOR REFLEXES IN CONSCIOUS CATS.
001514 02-03
EVALUATION OF THE EFFECT OF DRUGS ON DOPAMINE METABOLISM IN
THE RAT SUPERIOR-CERVICAL-GANGLION BY HPLC WITH
ELECTROCHEMICAL-DETECTION .
001530 02-03
BEHAVIORAL-EFFECTS OF DRUGS: THE ROLE OF THE STIMULUS
REINFORCER CONTINGENCY. (PH.D. DISSERTATION).
001537 02-03
THE EFFECT OF NALOXONE ON THE ACTIVATION OF EMOTIONALLY
POSITIVE REACTION PRODUCED BY DRUGS WITH A DEPENDENCE
LIABILITY
001556 02-03
DRUGS AND THE DISCRIMINATION OF DURATION.
001561 02-04
EFFECTS OF DRUGS ON THE EFFEQIVENESS OF CONDITIONED STIMULI
001608 02-04
A SIGNAL-DETECTION-ANALYSIS OF CENTRALLY-AQIVE DRUGS IN MICE.
001631 02-04
INTERACTIONS BETWEEN NALTREXONE AND NONOPIATE DRUGS
EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
001645 02-04
INTERRELATIONS AMONG PRIOR EXPERIENCE AND CURRENT CONDITIONS
IN THE DETERMINATION OF BEHAVIOR AND THE EFFEaS OF DRUGS.
001715 02-04
CHANGES OF PHYSICAL MORPHINE-DEPENDENCE IN RATS CHRONICALLY
TREATED WITH DRUGS ACTING ON BRAIN 5 HYDROXYTRYPT AMINE.
001764 02-04
THE RELATIONSHIP BETWEEN POSITIVE REINFORCEMENT AND
CONDITIONED TASTE-AVERSION PRODUCED BY SELF-ADMINISTERED
DRUGS. (PH.D. DISSERTATION).
001798 02-04
PRESYNAPTIC ALPHA-ADRENOCEPTORS AND THE ACTION OF TRICYCLIC-
ANTIDEPRESSANT DRUGS IN BEHAVIOURAL-DESPAIR IN RATS.
001829 02-04
THE USE OF SOCIAL-INTERACTION AS A METHOD FOR DETECTING
ANXIOLYTIC-ACTIVITY OF CHLORDIAZEPOXIDE-LIKE DRUGS.
001866 02-06
TWO NEW DRUGS MAY PICK UP WHERE L-DOPA LEAVES OFF
001897 02-07
THE PLACE OF SURVECTOR AMONG THE VARIOUS DRUGS USED IN
TREATMENT OF MOOD-DISORDERS.
001969 02-09
DRUGS AND THE SPECIAL-CHILD.
002107 02-11
0 METHOXYBENZAMIDES: RELATIONSHIPS BETWEEN STRUQURE-
ACTIVITY AND PHARMACOKINETICS OF THESE DRUGS
002246 02-13
CYCLIC-AMP IN PSYCHOSES AND THE EFFECT OF DRUGS
002294 02-13
NOOTROPIC-DRUGS AND RELATED DRUGS INTERAQING WITH THE
INTEGRATIVE ACTIVITY OF THE BRAIN.
002327 02-14
VIGILANCE IMPAIRING DRUGS: ANALYSIS OF SUBJEQIVE RESPONSES
002332 02-14
SUBJECTIVE DRUG-EFFEQS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFEQS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
APPROACHES TO THE PROBLEM OF PREVENTING HAZARDS OF LONG-
TERM NEUROLEPTIC TREATMENT AND OF AVOIDING UNNECESSARY
DRUGS.
002426 02-15
ON THE MEASUREMENT IN RATS OF THE CONVULSANT-EFFEQ OF DRUGS
AND THE CHANGES WHICH FOLLOW ELEaROCONVULSIVE-SHOCK.
002444 02-15
DRUGS IN THE ELDERLY.
002451 02-15
PHYSICAL AND PHYSIOLOGICAL CHARAQERISTICS OF MICROPRESSURE
EJEQION OF DRUGS FROM MULTIBARRELED PIPEHES.
002502 02-16
MEASUREMENT OF PLASMA CONCENTRATIONS OF DRUGS AS A
FEEDBACK CONTROL MECHANISM DURING DRUG-THERAPY
002525 02-17
SOME WAYS TO INCREASE CHANCES TO DISCOVER THE CNS DRUGS OF
THE FUTURE.
002528 02-17
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF
ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS
INCLUDING ANTIDEPRESSANTS.
002532 02-17
S-160
VOLUME 19, SUBJECT INDEX
Subject Index
DRUGS AND THE ELDERLY: PERSPECTIVES IN GERIATRIC CLINICAL-
PHARMACOLOGY.
002534 02-17
CLASSIFICATION OF DRUGS AND PATIENTS TO ACHIEVE MAXIMUM
THERAPEUTIC RESPONSE.
002560 02-17
DRUGS OF THE FUTURE.
002572 02-17
NEUROPSYCHIATRIC SIDE-EFFECTS OF DRUGS IN THE ELDERLY. VOL. 9,
AGING
002573 02-17
DRUGS AND THE AGED
002593 02-17
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPT AMINE AND CATECHOLAMINES: EFFECTS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN
002990 03-04
INJECTIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINERGIC AND
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS: EFFECTS ON
LOCOMOTOR-ACTIVITY IN THE RAT.
003019 03-04
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS
003068 03-04
ERGOT DRUGS SUPPRESS PLASMA PROLACTIN AND LACTATION BUT NOT
AGGRESSION IN PARTURIENT MICE.
003159 03-07
DEPRESSED-OUTPATIENTS: RESULTS ONE YEAR AFTER TREATMENT WITH
DRUGS AND/OR INTERPERSONAL PSYCHOTHERAPY.
003272 03-09
A NOTE ON THE PARADOXICAL-EFFECT OF STIMULANTS ON
HYPERACTIVITY WITH REFERENCE TO THE RATE DEPENDENCY EFFECT
OF DRUGS.
003320 03-11
CLINICAL-PHARMACOLOGY OF MIXED AGONIST ANTAGONIST DRUGS.
003329 03-1 1
CLINICAL-PHARMACOLOGY: ELIMINATION OF DRUGS.
003400 03-13
CAN DRUGS HALT MEMORY LOSS?
003447 03-14
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: EFFECT OF HYPOXIA
OR DRUGS?
003482 03-15
RECEPTOR ADAPTATIONS TO CENTRALLY ACTING DRUGS.
003585 03-17
GUIDELINES FOR SCHEDULING DRUGS UNDER THE CONTROLLED-
SUBSTANCES-ACT.
003606 03-17
INCREASE OF C-GMP AND ACCUMULATION OF 45CA2 EVOKED BY DRUGS
ACTING ON SODIUM OR POTASSIUM CHANNELS.
003709 04-03
ACTION OF DRUGS ON THE CEREBELLAR ELECTRICAL-ACTIVITIES.
003804 04-03
COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRACT OF THE GUINEA-PIG AND RAT.
003928 04-03
EFFECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC
NEURONS.
004026 04-03
EFFECTS ON THE PINNA-REFLEX OF DRUGS ACTING AT ALPHA-
ADRENOCEPTORS.
004078 04-04
EFFECTS OF DOPAMINERGIC DRUGS ON PHENCYCLIDINE-INDUCED
BEHAVIOR IN THE RAT.
004083 04-04
DISCRIMINATION OF ELEQRIC-SHOCK: EFFECTS OF SOME OPIOID AND
NONOPIOID DRUGS.
004106 04-04
A STUDY OF THE EFFECT OF NEUROPHARMACOLOGICAL DRUGS ON THE
FUNCTIONAL ACTIVITY OF RAT-BRAIN.
004107 04-04
CHLORPROMAZINE EFFECTS ON COCAINE-REINFORCED RESPONDING IN
RHESUS-MONKEYS: RECIPROCAL MODIFICATION OF RATE ALTERING
EFFECTS OF THE DRUGS.
004133 04-04
EFFECTS OF ANALGESICS AND CNS-ACTING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS.
004148 04-04
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL
BY ANXIOLYTICS WITH DRUGS ACTING ON THE GABA SYSTEM
004193 04-04
CHANGES OF RESPONSE TO DOPAMINERGIC DRUGS IN RATS SUBMITTED
TO REM SLEEP DEPRIVATION.
004239 04-04
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT
VERTEBRAL-ARTERY OF THE CAT; A MODIFIED ANIMAL-MODEL FOR
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE
LOWER BRAINSTEM
004297 04-06
AN IMPROVED PNEUMATIC SYRINGE FOR SELF-ADMINISTRATION OF
DRUGS BY RATS
004304 04-06
DRUGS AND SCHIZOPHRENIA.
004314 04-08
BLOOD LEVEL MEASUREMENTS OF TRICYCLIC DRUGS AS A DIAGNOSTIC
TOOL.
004368 04-09
INTERACTIONS BETWEEN ANTIDEPRESSANTS AND OTHER DRUGS.
004371 04-09
ACUTE EFFECT OF DRUGS UPON MEMORY OF PATIENTS WITH SENILE-
DEMENTIA.
004561 04-14
PERSONALITY AND DRUGS IN VISUAL FIGURAL AFTEREFFECTS.
004581 04-14
IMPURITIES IN DRUGS V: MEPROBAMATE.
004631 04-15
DRUGS AND RENAL-DISEASE.
004645 04-15
THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE BRAIN AS AN
OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING
DRUGS.
004669 04-16
SYMPATHOMIMETIC-AMINES AND TRICYCLIC-ANTIDEPRESSANT DRUGS.
004678 04-16
A MULTIVARIATE ANALYSIS OF THE INFRARED SPECTRA OF DRUGS OF
ABUSE.
004688 04-16
DRUGS, ALCOHOL AND SEX.
004706 04-17
DRUGS, TRANSMITTERS AND HORMONES, AND MATING-BEHAVIOR.
004721 04-17
DRYNESS
TREATMENT OF DRUG-INDUCED DRYNESS OF MOUTH IN PSYCHIATRIC-
PATIENTS - A CONTROLLED-COMPARATIVE-STUDY.
000799 01-13
DSIP
THERMOREGULATORY AND LOCOMOTOR-EFFECTS OF DSIP:
PARADOXICAL-INTERACTION WITH D-AMPHETAMINE,
001827 02-04
DU-24565
DU-24565, A QUIPAZINE DERIVATIVE, A POTENT SELECTIVE SEROTONIN
UPTAKE INHIBITOR.
002651 03-02
DUAL-ACTION
A REFORMULATION OF THE DUAL-ACTION MODEL OF OPIOID
DEPENDENCE: OPIOID-SPECIFIC NEURONAL KINDLING.
003645 03-17
DUAL-ACTIONS
PENTOBARBITAL: DUAL-ACTIONS TO INCREASE BRAIN BENZODIAZEPINE-
RECEPTOR AFFINITY.
002896 03-03
DUAL-EFFECTS
DUAL-EFFECTS OF MESCALINE: THE TRANSMETHYLATION HYPOTHESIS
REVISITED.
001584 02-04
DUAL-MECHANISM
EXCITATORY AND INHIBITORY-EFFECTS OF OPIATES IN THE RAT VAS-
DEFERENS: A DUAL-MECHANISM OF OPIATE ACTION.
000143 01-03
DUAL-REGULATION
OPIOID DEPENDENT DUAL-REGULATION OF ADENYLATE-CYCLASE IN A
CELL-FREE SYSTEM. (UNPUBLISHED PAPER).
001033 0 01
DUCKS
LONG-TERM EFFECTS OF TESTOSTERONE INJECTIONS ON THE SOCIAL-
BEHAVIOUR OF MALE DUCKS AND THEIR PHYSIOLOGICAL-CORRELATES.
001565 02-04
DUPLICATION
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
DURATION
INFLUENCE OF GLUCOSE (IN VIVO OR IN VITRO) ON DURATION OF
NARCOTIC ANALGESICS AND ON THE KINETICS OF DRUG METABOLISM.
000292 01-03
FACTORS INFLUENCING SEIZURE DURATION AND NUMBER OF SEIZURES
APPLIED IN UNILATERAL ELECTROCONVULSIVE-THERAPY: ANESTHETICS
AND BENZODIAZEPINES.
000792 01-13
DRUGS AND THE DISCRIMINATION OF DURATION.
001561 02-04
INTERACTIONS OF CHLORDIAZEPOXIDE AND ANORECTIC-AGENTS ON RATE
AND DURATION PARAMETERS OF FEEDING IN THE RAT.
001600 02-04
<ai.
'Stii:
••It
«3r:
S-161
Subject Index
GABA ANALOGUES ACTIVATE CHANNELS OF DIFFERENT DURATION ON
CULTURED MOUSE SPINAL NEURONS. 002665 03-03
TIME-COURSE OF CHRONIC HALOPERIDOL AND CLOZAPINE UPON
OPERANT RATE AND DURATION. 002989 03-04
CHRONIC EFFECTS OF NEUROLEPTICS HAVING HIGH OR LOW INCIDENCE
OF EXTRAPYRAMIDAL SIDE-EFFECTS UPON FORCE, DURATION AND
RATE OF OPERANT-RESPONSE IN RATS. (PH.D. DISSERTATION)^^ ^^ ^^
EFFECTS OF PAIN, MORPHINE AND NALOXONE ON THE DURATION OF
ANIMAL HYPNOSIS. 00408104-04
LITHIUM ELIMINATION HALF-LIFE AND DURATION OF THERAPY.
004369 04-09
"^"^HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS_^
001242 02-03
'*^'*DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN
FRAGMENTS OF MALE AND FEMALE RATS . ^^^^^ ^^^^
MARIJUANA AND CHOLINERGIC DYNAMICS. (UNPUBLISHED PAPER) ^
001 166 Oz-UJ
LONG-TERM EFFECTS OF HALOPERIDOL, CLOZAPINE, AND METHADONE
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNAMICS^
DYNAMICS AND PROSPECTS OF THE PSYCHOTHERAPY AND
PSYCHOPHARMACOTHERAPY RELATIONSHIP.
002594 02- 1 /
THE CLINICAL DYNAMICS OF TETRAETHYL-LEAD POISONING^
OOjdUU Uo- ID
BETA-ADRENERGIC INFLUENCE ON CARDIAC DYNAMICS DURING SHOCK-
AVOIDANCE IN DOGS. 003813 04-03
THE DYNAMICS OF SYSTEMIC VENOUS, ARTERIAL, AND CEREBROSPINAL-
FLUID PRESSURE UNDER I.V. ADMINISTRATION OF POLYETHYLENE-
^'-^'^°'- 004045 04-03
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER
FOREBRAIN REGIONS OF THE RAT . „„.,-,, a. ^.
004171 04-04
THE NOSOLOGICAL INDEPENDENCE OF INVOLUTIONAL DEPRESSION AND
ITS DYNAMICS DURING PSYCHOPHARMACOTHERAPY. ^^^ ^^ ^^
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS^
004403 04-09
DYNORPHIN
SODIUM-CHLORIDE INHIBITION DECREASES LEVELS OF IMMUNOREAaiVE
DYNORPHIN IN THE NEUROINTERMEDIATE PITUITARY OF RATI
001 283 02-03
DYNORPHIN A POSSIBLE MODULATORY PEPTIDE ON MORPHINE OR BETA
ENDORPHIN ANALGESIA IN MOUSE. ^^^^^ ^^_^^
DYSFUNCTIONS
DYSFUNCTIONS OF CHOLINERGIC PROCESSES IN SCHIZOPHRENIA.
002611 02-17
ORAL DYSKINESIA IN BRAIN-DAMAGED RATS WITHDRAWN FROM A
NEUROLEPTIC; IMPLICATION FOR MODELS OF TARDIVE-DYSKINESIA.
000393 01-04
IMPROVEMENT OF L-DOPA-INDUCED DYSKINESIA AND OF ON-OFF-
PHENOMENON BY BROMOCRIPTINE. „„„„,. a, , .
000813 01-14
SPONTANEOUS DYSKINESIA IN THE ELDERLY AND TARDIVE-DYSKINESIA
FROM NEUROLEPTICS A SURVEY OF 270 ELDERLY-PATIENTS^
COVERT DYSKINESIA IN AMBULATORY SCHIZOPHRENIA.
DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINERGIC MECHANISMS.
001839 02-05
THE TREATMENT OF BUCCOLINGUOFACIAL DYSKINESIA IN THE ELDERLY:
THE CHOICE OF A NEUROLEPTIC-AGENT. ^^^^^ ^^_^^
CARBAMAZEPINE-INDUCED OROFACIAL DYSKINESIA. oq241 5 02
EXPERIMENTAL-STUDIES ON L-DOPA-INDUCED DYSKINESIA.
OOo I zV U J-UD
ANALYSIS OF SINGLE-BUND, DOUBLE-BUND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFEQS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS - BRIEF REPORT. ^^ ^ ^
PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND
■^E^^^T'^- 003347 03-11
Ptychopharmacology Abstracts
CUNICAL-ASPEQS OF DYSKINESIA.
003461 03-15
ANALYSIS OF SINGLE-BUND AND DOUBLE-BLIND PROCEDURES,
MAINTENANCE OF PLACEBO-EFFECTS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON.
004437 04-1 1
DYSKINESIAS
AGE DEMENTIA, DYSKINESIAS, AND LITHIUM RESPONSE.
000594 01-09
LONG-TERM CHLORPROMAZINE IN RHESUS-MONKEYS: PRODUQION OF
DYSKINESIAS AND CHANGES IN SOCIAL-BEHAVIOR.
001850 02-05
DYSKINETIC AND NEUROLOGICAL-COMPUCATIONS IN CHILDREN TREATED
WITH PSYCHOTROPIC-MEDICATIONS.
000880 01-15
TREATMENT OF DYSKINETIC AND DYSTONIC-DISORDERS WITH CF-25-
397 CUNICAL-ASPECTS AND PHARMACOLOGICAL ASPEQS.
00212102-11
DYSKINETIC-MOVEMENTS
MAPPING OF DYSKINETIC-MOVEMENTS INDUCED BY LOCAL APPUCATION
OF PICROTOXIN OR 0 GAMMA ACETYLENIC-GABA ON THE RAT
MOTOR-CORTEX,
000458 01-04
DYSPNOEA
PSYCHOTHERAPY AND DYSPNOEA.
002164 02-11
DYSTHYMIC-PATIENTS
OBSERVATIONS ON THE USE OF CITICOUNE IN DYSTHYMIC-PATIENTS.
003207 03-09
LITHIUM UPTAKE IN RED CELLS OF CYCLOID AND UNIPOLAR DYSTHYMIC-
''''''''' 003258 03-09
DOPAMINE, ACETYLCHOUNE. AND GABA EFFEQS IN ACUTE DYSTONIA IN
PRIMATES, „„,„„
000043 01-03
EXPERIMENTAL DYSTONIA INDUCED BY QUATERNARY
CHLORPROMAZINE „„„..,„,„.
000461 01-04
DYSTONIC
NEUROLEPTIC-INDUCED ACUTE DYSTONIC REAQIONS MAY BE DUE TO
ENHANCED DOPAMINE RELEASE ON TO SUPERSENSITIVE
POSTSYNAPTIC-RECEPTORS
002789 03-03
DYSTONIC REAQION DURING MAINTENANCE ANTIPSYCHOTIC THERAPY.
003485 03-15
DYSTONIC-DISORDERS ^ ^, „^
TREATMENT OF DYSKINETIC AND DYSTONIC-DISORDERS WITH CF-25-
397: CUNICAL-ASPEQS AND PHARMACOLOGICAL ASPEQS.
002121 02-11
D2
D3
REGULATION OF STRIATAL ACETYLCHOUNE CONCENTRATION BY 02
DOPAMINE-RECEPTORS. „„«„,„ „, «o
000269 01-03
HIGH-AFFINITY DOPAMINE-RECEPTORS (D3) IN RAT-BRAIN.
001509 02-03
EARLY-ACTIVITY-STUDIES
EARLY-ACTIVITY-STUDIES AND INTENSIVE DRUG EVALUATIONS OF NEW
PSYCHOPHARMACOLOGIC-AGENTS. ^^^^ ^^^^
EARLY RESPONSE
PREDiaiNG OUTCOME OF ANTIPSYCHOTIC-DRUG TREATMENT FROM
EARLY-RESPONSE. 000565 01-08
SUBSTANCE-P SUPPRESSES STRESS-INDUCED EATING.
001725 02-O4
BOMBESIN INHIBITS STRESS-INDUCED EATING.
(X)3059 0J-U4
^^^'emInG-BEHAVIOR REVEALS RATS PREFERENCE FOR MORPHINE^
004257 04-04
ECONOMIC
A NOVEL PSYCHOMETRIC-TEST MODEL APPLYING TAILORED TESTING FOR
ECONOMIC AND EFFICIENT COLLEaiON OF
PSYCHOPHARMACOLOGICAL-EFFECTS ^^^^^ ^^ ^ ^
ECOPHARMACOGENETIC
A POSSIBLE ECOPHARMACOGENETIC MODEL IN
NEUROPSYCHOPHARMACOLOGY ASPEQS IN ALCOHOLISM AND
PHARMACODEPENDENCE. 002596 02-17
ECT
INTOXICATION ASSOCIATED WITH LITHIUM AND EQ.
000870 01-15
S-162
VOLUME 19, SUBJECT INDEX
Subject Index
PROLONGED CONFUSIONAL-STATE AND EEC SEIZURE ACTIVITY
FOLLOWING CONCURRENT ECT AND LITHIUM USE.
000895 01-15
ACTH4-10 AND MEMORY IN ECT TREATED AND UNTREATED PATIENTS. I.
EFFECT ON CONSOLIDATION.
001982 02-09
ACTH4-10 AND MEMORY IN ECT TREATED PATIENTS AND UNTREATED
CONTROLS. II EFFECT ON RETRIEVAL.
001983 02-09
PROTECTIVE ACTION OF L 5 HYDROXYTRYPTOPHAN L GLUTAMATE
(MADE- 1932) DURING ELECTROSHOCK-TREATMENT (ECT).
003043 03-04
AUDITORY BRAINSTEM EVOKED-RESPONSES IN HOSPITALIZED-PATIENTS
UNDERGOING DRUG-TREATMENT OR ECT.
003430 03-13
INTRAOCULAR PRESSURE CHANGES FOLLOWING MODIFIED ECT.
003536 03-15
ECTO-ATPASE
DRUG SENSITIVE ECTO-ATPASE IN HUMAN LEUKOCYTES.
000779 01-13
EDEMA
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS.
000509 01-05
EDEMAS
EDEMAS AND MYOCLONIES IN A PATIENT WITH PARKINSONS-DISEASE
TREATED BY AMANTADINE: PROBLEM WITH ASSOCIATED
MEDICATIONS.
002389 02-15
EDINGER-WESTPHAl
PHARMACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG.
002889 03-03
EDUCATION
THE MEDICATION SEMINAR AND PRIMARY CARE EDUCATION.
003592 03-17
EEG
THE EFFECT OF DIAZEPAM ON EEG CHANGES FOLLOWING INTRASEPTAL
ADMINISTRATION OF ATROPINE.
000127 01-03
NALOXONE OVERCOMES THE DOPAMINERGIC, EEG, AND BEHAVIORAL-
EFFECTS OF GAMMA HYDROXYBUTYRATE.
000478 01-04
COMPUTERIZED EEG IN THE COMPARISON OF OXYPROTHEPIN AND
FLUPHENAZINE-DECANOATE.
000567 01-08
EEG IN PATIENTS TREATED WITH LITHIUM.
000593 01-09
NOMIFENSIN IN THE TREATMENT OF ENDOGENOUS DEPRESSIONS.
CLINICAL-EXPERIENCE AND EEG FINDINGS.
000613 01-09
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF
LOPIRAZEPAM (D-12524) BY QUANTITATIVE EEG AND
PSYCHOMETRIC-ANALYSIS.
000720 01-11
A COMPUTER OCULOGRAPHIC AND EEG DOUBLE-BLIND STUDY INCLUDING
WELL-BEING FOR DETERMINING CHANGED VIGILANCE UNDER THERAPY
WITH TIAPRIDE.
000751 01-13
EEG AND PSYCHOEXPERIMENTAL-STUDIES IN HEALTHY SUBJECTS ON
LITHIUM MEDICATION.
000768 01-13
THE EEG EFFECTS OF THYROTROPIN-RELEASING-HORMONE IN HEALTHY
SUBJECTS AND CHRONIC SCHIZOPHRENICS.
000770 01-13
HALLUCINATORY AND DELUSIONAL-STATES IN CONNECTION WITH BLOOD-
PRESSURE AND EEG.
000814 01-14
NEUROLOGICAL SIDE-EFFECTS OF LITHIUM: ORGANIC-BRAIN-SYNDROME
SEIZURES, EXTRAPYRAMIDAL SIDE-EFFECTS, AND EEG CHANGES
000847 01-15
PROLONGED CONFUSIONAL-STATE AND EEG SEIZURE ACTIVITY
FOLLOWING CONCURRENT ECT AND LITHIUM USE
000895 01-15
EEG AND BEHAVIORAL-PROFILE OF FLUTROLINE (CP-36-584) A NOVEL
ANTIPSYCHOTIC-DRUG.
001071 02-02
EEG AND ANTICONVULSANT EFFEQS OF DIPROPYLACETIC-ACID AND
DIPROPYLACETAMIDE IN THE BABOON PAPIO-PAPIO
001210 02-03
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY
SPECTRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND
NEUROLEPTICS.
001220 02-03
EEG CHANGE IN THE CONSCIOUS RAT DURING IMMOBILITY INDUCED BY
PSYCHOLOGICAL- STRESS.
001297 02-03
SYNCHRONIZATION OF EEG ACTIVITY OF MALE RHESUS-MONKEYS
MACACA-MULAHA TREATED WITH OVOCYCLIN.
001312 02-03
ACUTE AND CHRONIC OPIATE-EFFECTS ON SINGLE UNITS AND EEG OF
MEDIAL THALAMUS AND HIPPOCAMPUS: A LATENCY ANALYSIS.
001344 02-03
RELATIONSHIP BETWEEN SERUM LEVELS AND FAST EEG ACTIVITIES IN
RATS BY A SINGLE ADMINISTRATION OF PHENOBARBITAL
001462 02-03
EFFECTS OF THE BETA-AORENOCEPTOR BLOCKING-AGENT SOTALOL ON
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS
001570 02-04
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS AFTER A SINGLE
INJECTION OF BETA ENDORPHIN.
001962 02-09
EEG CHANGES IN CHILDREN WITH TREATED PHENYLKETONURIA AFTER
PHENYLALANINE LOAD.
002115 02-11
THE RELATIONSHIP OF ALPHA AND DELTA EEG FREQUENCIES TO PAIN
AND MOOD IN FIBROSITIS-PATIENTS TREATED WITH CHLORPROMAZINE
AND L TRYPTOPHAN.
002152 02-11
EEG, COMP-EEG, REO-EG AND PHARMACOLOGICAL-CORRELATES OF
GERIATRICS.
002162 02-11
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT,-
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL
EVOLUTION.
002165 02-11
ANTIHYPOXIDOTIC-DRUGS AND NOOTROPIC-DRUGS: PROOF OF THEIR
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
QUANTITATIVE EEG INVESTIGATIONS.
002166 02-11
DISCOVERY OF PSYCHOTROPIC-DRUGS BY MEANS OF COMPUTER-
ANALYZED EEG.
002203 02-13
EFFECTS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROFILES.
002239 02-13
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL-STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN).
002286 02-13
CORREUTIONS BETWEEN PLASMA LEVELS OF ANTIEPILEPTIC-DRUGS AND
EEG INTENSIVE MONITORING.
002288 02-13
EEG ASSESSMENTS OF DOSAGE AND SLEEP PROFILES FOR A HYPNOTIC-
DRUG OF THE TRIAZOLOTHIENODIACEPINE SERIES
002338 02-14
IMIPRAMINE AND EEG SLEEP IN CHILDREN WITH DEPRESSIVE-
SYMPTOMS.
002339 02-14
COMPUTERIZED SLEEP EEG (CSEEG) IN PSYCHIATRY AND
PSYCHOPHARMACOLOGY.
002614 02-17
SUPPRESSION OF AMPHETAMINE-INDUCED EEG AROUSAL IN THE
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS
002683 03-03
ANTIPEROXIDANT PRETREATMENT AND IRON-INDUCED EPILEPTIFORM
DISCHARGES IN THE RAT: EEG AND HISTOPATHOLOGIC STUDIES.
002930 03-03
EFFECT OF P CHLOROPHENYLALANINE AND TRYPTOPHAN ON SLEEP, EEG
AND MOTOR-ACTIVITY IN THE RAT.
002958 03-04
COMPUTER-ANALYZED EEG IN AMPHETAMINE RESPONSIVE
HYPERACTIVE-CHILDREN.
003338 03-11
EFFECT OF PIRACETAM ON EEG SPECTRA OF BOYS WITH LEARNING-
DISORDERS.
003383 03-11
ON THE EVALUATION OF A PROVOCATIVE EEG METHOD USING
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUCTION THROUGH
MEDICATION.
003387 03-1 1
STUDY OF THE EFFECTS OF PC-63-14 ON THE QUANTIFIED EEG.
003403 03-13
CORRELATED STUDY OF THE EFFECTS OF SE-5023 IN AN HYPOXIC
ATMOSPHERE ON QUANTIFIED EEG, VIGILANCE, MEMORY, AND
MOOD.
003440 03-14
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS
004022 04-03
THE EFFECT OF DIPHENYLHYDANTOIN ON EEG CURVES IN EPILEPTICS.
004494 04-1 1
mLu
i«;ti:
£&■■
S-163
Subject Index
Psychopharmacology Abstracts
CHANGES IN BRAIN N DEMETHYLATION AND OPIATE-RECEPTOR CONTENT
CORRELATE WITH ANALGESIC EFFECTIVENESS OF MORPHINE.
000400 01-04
EFFECTS OF DRUGS ON THE EFFECTIVENESS OF CONDITIONED STIMULI.
001608 02-04
CEREBRAL SENESCENCE AND ITS PSYCHIC-MANIFESTATIONS. THE
EFFECTIVENESS OF DEBRUMYL. 002105 02-11
TESTOSTERONE POTENTIATION OF THE EFFECTIVENESS OF ACTHl-24 ON
THE INDUCTION OF THE STRETCH-YAWNING-SYNDROME (SYS) IN MALE
•^"J"^^^-^"^^- 003074 03-04
EVALUATION OF THE RELATIVE EFFECTIVENESS OF METHYLPHENIDATE
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF
KINDERGARTEN-AGED HYPERACTIVE-CHILDREN ^^ ^ ^
THE EFFECTIVENESS OF IMIPRAMINE IN THE TREATMENT OF ENURESIS:
THE SIGNIFICANCE OF TYPE OF ENURESIS AND REPORTED LEVEL OF
SLEEP. (PH.D. DISSERTATION). 003337 03-11
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFECTIVE-DISORDERS
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDICTORS TO
CLINICAL-RESPONSE). 004365 04-09
CLINICAL-EVALUATION OF THE PROPHYLACTIC EFFECTIVENESS OF
PROLONGED LITHIUM-CARBONATE THERAPY IN ENDOGENOUS
DEPRESSIVE-SYNDROMES. 004404 04-09
D PROPOXYPHENE ACTS DIFFERENTLY FROM MORPHINE ON OPIOID-
RECEPTOR EFFECTOR MECHANISMS. 003062 03-04
EFFICACY
SINGLE-DOSE PHARMACOKINETICS AND ANTICONVULSANT EFFICACY OF
PRIMIDONE IN MICE. 000177 01-03
EFFICACY OF DESIPRAMINE IN ENDOGENOMORPHICALLY DEPRESSED-
f"^^'^^^^ 000632 01-09
ANXIOLYTIC EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND
''^"^° 000648 01-10
LONG-TERM EFFICACY OF BROMOCRIPTINE IN PARKINSONS-DISEASE
000698 01-11
EFFICACY AND PAHERN VALENCE OF PSYCHOACTIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER. „„„,„„„, ,,
000699 01-11
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY: EFFICACY, DOSAGE SCHEDULE AND PLASMA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
TWENTY YEARS CLINICAL THERAPEUTIC EXPERIENCE WITH CALCIUM
GLUTAMATES EFFICACY.
000963 01-17
PLASMA LEVELS AND THERAPEUTIC EFFICACY OF FLUPHENAZINE-HCL
AND FLUPHENAZINE-DECANOATE.
001913 02-08
THE RELATIVE PROPHYLACTIC EFFICACY OF LITHIUM AGAINST MANIC
AND DEPRESSIVE RECURRENCES IN BIPOLAR-PATIENTS.
002040 02-09
EFFICACY AND SIDE-EFFECTS OF LORAZEPAM, OXAZEPAM, AND
TEMAZEPAM AS SLEEPING-AIDS IN PSYCHOGERIATRIC-INPATIENTS.
002076 02-10
EFFICACY AND SIDE-EFFECTS OF CHLORAL-HYDRATE AND TRYPTOPHAN
AS SLEEPING-AIDS IN PSYCHOGERIATRIC-PATIENTS.
002077 02-10
THE RELATIVE EFFICACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY
FOR THE TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY.
(PH D. DISSERTATION). „^, „ „. , ,
002148 02-11
THE EFFICACY OF TRIAZOLAM AND CHLORAL-HYDRATE IN GERIATRIC
INSOMNIACS. „„^,,„„o,,
002160 02-11
LITHIUM: PROBLEMS OF APPLICATION, TOLERANCE, AND EFFICACY.
002434 02-15
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY?
002659 03-03
EFFICACY OF DESIPRAMINE IN MILDLY DEPRESSED-PATIENTS: A DOUBLE-
BLIND, PLACEBO-CONTROLLED-TRIAL.
003262 03-09
EFFICACY OF CLONIDINE IN OPIATE WITHDRAWAL: A STUDY OF THIRTY
PATIENTS. „^„.,-,^o ,,
003317 03-11
EFFICACY OF LITHIUM IN TREATING MOOD-DISORDER OCCURRING AFTER
BRAINSTEM INJURY. 003354 03-11
COMPLICATIONS OF CHRONIC LEVODOPA THERAPY: LONG-TERM
EFFICACY OF DRUG-HOLIDAY.
003502 03-15
EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED
COGNITIVE ASSESSMENT SYSTEM.
003557 03-16
THE USE OF CLINICAL AND PHARMACOKINETIC CRITERIA IN FORECASTING
THE EFFICACY OF THERAPY IN SCHIZOPHRENIA.
004335 04-08
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION: A
DOUBLE-BLIND COMPARISON WITH IMIPRAMINE.
004346 04-09
A PRELIMINARY DOUBLE-BLIND STUDY ON THE EFFICACY OF
CARBAMAZEPINE IN PROPHYLAXIS OF MANIC-DEPRESSIVE-ILLNESS.
004388 04-09
A DOUBLE-BLIND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND
SIDE-EFFECTS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED-
INPATIENTS AND DEPRESSED-OUTPATIENTS
004395 04-09
PHARMACOTHERAPY AND PSYCHOTHERAPY FOR AMBULATORY
DEPRESSION: EFFICACY AND CHOICES.
004413 04-09
THE EFFICACY OF PIRACETAM IN VERTIGO: A DOUBLE-BLIND STUDY IN
PATIENTS WITH VERTIGO OF CENTRAL ORIGIN.
004478 04-1 1
A COMPARATIVE EVALUATION OF THE EFFICACY OF SOME THERAPEUTIC
METHODS USED IN DELIRIUM-TREMENS
004486 04-11
CNS EFFECTS OF ISF-2522, A NEW NOOTROPIC (A PHASE I SAFETY AND
CNS EFFICACY STUDY WITH QUANTITATIVE PHARMACOEEG AND
PHARMACOPSYCHOLOGY).
004519 04-13
VALPROIC-ACID IN CHILDHOOD-EPILEPSY: ANTICONVULSIVE EFFICACY IN
RELATION TO ITS PLASMA LEVELS
004525 04-13
MAPROTILINE NOMIFENSINE, MIANSERIN, ZIMELIDINE: A REVIEW OF
ANTIDEPRESSANT EFFICACY IN INPATIENTS
004731 04-17
EFFLUX
PARTITIONING AND EFFLUX OF PHENOTHIAZINES FROM LIPOSOMES.
000007 01-02
THE EFFLUX OF LITHIUM FROM RED-BLOOD-CELLS AND THE EFFEQ OF
LITHIUM PROPHYLAXIS „„„,„„ „, ^
000630 01-09
CLINICAL-ASPECTS OF LITHIUM EFFLUX FROM ERYTHROCYTES.
002228 02-13
EFFEaS OF ETHANOL ON ACETYLCHOLINE AND ADENOSINE EFFLUX FROM
THE IN VIVO RAT-CEREBRAL-CORTEX.
003969 04-03
EJACULATION
PROLONGATION OF THE EJACULATION LATENCY IN THE MALE RAT BY
THIORIDAZINE AND CHLORIMIPRAMINE. ,
000335 01-04 ■
PHYSICAL AND PHYSIOLOGICAL CHARAQERISTICS OF MICROPRESSURE j
EJECTION OF DRUGS FROM MULTIBARRELED PIPETTES.
002502 02-16
EK6S
COMPARISON OF STANDARD AND HOLTOR-MONITORED EKGS IN A
PATIENT TREATED WITH SEVERAL ANTIDEPRESSANTS. ^ ^
CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNQION
OF ELAVIL AND THORAZINE INJEQION. ^^^^^ ^^^
ELDERLY
COMPARISON OF SINGLE-DOSE PHARMACOKINETICS OF IMIPRAMINE
AND MAPROTILINE IN THE ELDERLY. 000596 01-09
TREATMENT OF DEPRESSION IN THE MEDICALLY-ILL ELDERLY WITH
METHYLPHENIDATE. 000602 01-09
LORAZEPAM KINETICS IN THE ELDERLY.
000766 U I - 1 o
MEMORY AND COGNITIVE FUNCTION IN THE ELDERLY: A PRELIMINARY-
TRIAL OF PHYSOSTIGMINE. ,w^o«o n, , ,.
000802 01-14
SPONTANEOUS DYSKINESIA IN THE ELDERLY AND TARDIVE-DYSKINESIA
FROM NEUROLEPTICS. A SURVEY OF 270 ELDERI-Y-PAT1ENTS_ ^^
HAZARDS OF DRUG USE AMONG THE ELDERLY ^^ ^^^_^
DISCUSSION: COMMUNICATION AND POLYPHARMACY: DRUGS AND THE
ELDERLY. 000957 01-17
DEPRESSION IN THE ELDERLY: RESEARCH DIREQIONS IN
PSYCHOPATHOLOGY, EPIDEMIOLOGY, ^^D TREATMENT.^^ ^^
S-164
VOLUME 19, SUBJECT INDEX
PAVING THE WAY TO SAFE PRESCRIBING FOR THE ELDERLY
000999 0)-) 7
THE IMPORTANCE OF AAAINEPTINE IN THE TREATMENT OF NONPSYCHOTIC
DEPRESSIVE-STATES IN THE ELDERLY.
00)999 02-09
CLINICAL-TESTING OF MINAPRINE ON ELDERLY SUBJECTS WITH THE
ASTHENIC-DEPRESSIVE-SYNDROMES.
002)23 02-))
PHARMACOTHERAPY OF DEPRESSION IN THE ELDERLY.
002)44 02-))
THE RELATIVE EFFICACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY
FOR THE TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY
(PH.D. DISSERTATION)
002148 02-))
TREATMENTS FOR SLEEP-WAKE-DISORDERS IN THE ELDERLY.
002)57 02-1)
PIRIBEDIL IN ELDERLY PSYCHIATRIC-PATIENTS.
002)70 02-))
PHARMACOKINETICS OF NORTRIPTYLINE IN ELDERLY VOLUNTEERS
002)84 02-))
CLINICAL-EXPERIENCE WITH PSYCHIATRIC-TREATMENT OF THE ELDERLY
INVOLVING THE USE OF PIRACETAM.
002)88 02-))
THE TREATMENT OF BUCCOLINGUOFACIAL DYSKINESIA IN THE ELDERLY-
THE CHOICE OF A NEUROLEPTIC-AGENT.
002223 02-) 3
PNEUMONIA AND PSYCHOTROPIC-DRUG USE IN ELDERLY PSYCHIATRIC-
PATIENTS.
002391 02-15
DRUGS IN THE ELDERLY.
002451 02-15
DRUGS AND THE ELDERLY: PERSPECTIVES IN GERIATRIC CLINICAL-
PHARMACOLOGY.
002534 02-17
NEUROPSYCHIATRIC SIDE-EFFECTS OF DRUGS IN THE ELDERLY. VOL 9
AGING.
002573 02-17
THE THERAPEUTIC PROFILE OF MIANSERIN IN MILD ELDERLY
DEPRESSIVES,
003297 03-1 1
A DOUBLE-BLIND, PLACEBO-CONTROLLED-STUDY OF PIRACETAM IN
ELDERLY PSYCHIATRIC-PATIENTS.
003305 03-1 1
PHARMACOKINETICS OF AMITRIPTYLINE, IMIPRAMINE, AND
MAPROTILINE IN THE ELDERLY.
003324 03-11
TREATMENT OF DEPRESSIVE-CONDITIONS IN THE ELDERLY.
003578 03-17
DESMETHYLDIAZEPAM KINETICS IN THE ELDERLY AFTER ORAL
PRA2EPAM.
004432 04-11
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM- II
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT.
004516 04-13
ELDERLY-PATIENTS
SPONTANEOUS DYSKINESIA IN THE ELDERLY AND TARDIVE-DYSKINESIA
FROM NEUROLEPTICS. A SURVEY OF 270 ELDERLY-PATIENTS.
000834 01-) 5
PSYCHOTROPIC-DRUGS AND POLYPHARMACY IN ELDERLY-PATIENTS IN A
GENERAL-HOSPITAL.
000981 0)-)7
CLINICAL-TRIAL WITH AMANTADINE AND HYDERGINE IN ELDERLY-
PATIENTS.
002093 02-))
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS A
CLINICAL DOUBLE-BLIND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER).
003327 03-) )
THE ROLE OF PSYCHOPHARMACOTHERAPY IN THE TREATMENT OF
ELDERLY-PATIENTS WITH ORGANIC-MENTAL-SYNDROMES
■IECT.VE 003368 03-))
ELECTIVE ALTERATION OF THE STATE OF CONSCIOUSNESS SUBJECTED TO
THE EFFECTS OF PSYCHOACTIVE-SUBSTANCES.
000994 0)-)7
•LECTRIC-SHOCK
NALORPHINES EFFECT UNDER SEVERAL SCHEDULES OF ELECTRIC-SHOCK
TITRATION.
EFFECTS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN
COMBINATION WITH NALOXONE ON ELECTRIC-SHOCK TITRATION IN
THE SQUIRREL-MONKEY.
THE EFFECTS OF ELECTRIC-SHOCK ON RESPONDING MAINTAINED BY
COCAINE IN RHESUS-MONKEYS.
DISCRIMINATION OF ELECTRIC-SHOCK: EFFECTS OF SOME OPIOID AND
NONOPIOID DRUGS.
004)06 04-04
Subject Index
BEHAVIORAL-EFFECTS OF SELF-ADMINISTERED COCAINE: RESPONDING
MAINTAINED ALTERNATELY BY COCAINE AND ELECTRIC-SHOCK IN
SQUIRREL-MONKEYS
004225 04-04
ELECTRIC-STIMULATION
EFFECTS OF METHYSERGIDE AND NALOXONE ON ANALGESIA INDUCED BY
THE PERIPHERAL ELECTRIC-STIMULATION IN MICE.
003093 03-04
ELECTRICAL
THE EFFECTS OF THIORIDAZINE ON ELECTRICAL AND ISCHEMIC
VENTRICULAR FIBRILLATION IN THE DOG HEART IN SITU.
002697 03-03
ELECTRICAL-ACTIVITIES
ACTION OF DRUGS ON THE CEREBELLAR ELECTRICAL-ACTIVITIES.
003804 04-03
ELECTRICAL-ACTIVITY
EFFECTS OF HEMICHOLINIUM-3 AND CHOLINE ON HIPPOCAMPAL
ELECTRICAL-ACTIVITY DURING IMMOBILITY VS. MOVEMENT.
00)438 02-03
NEURONAL MATURATION IN MAMMALIAN CELL-CULTURE IS DEPENDENT
ON SPONTANEOUS ELECTRICAL-ACTIVITY.
002669 03-03
ELECTRICAL-ACTIVITY AND NA-K-ATPASE LEVEL IN THE PENICILLIN-
INDUCED EPILEPTOGENIC-FOCUS OF THE RAT-BRAIN-CORTEX AND THE
EFFECT OF DIAZEPAM.
003070 03-04
EFFECTS OF ENKEPHALIN, MORPHINE, AND NALOXONE ON THE
ELECTRICAL-ACTIVITY OF THE IN VITRO HIPPOCAMPAL SLICE
PREPARATION.
0039)8 04-03
EFFECTS OF A SHORT-ACTING BENZODIAZEPINE ON BRAIN ELECTRICAL-
ACTIVITY DURING SLEEP.
004568 04-) 4
ELECTRICAL-STIMULATION
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS.
000520 01-05
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELECTRICAL-
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL
SLICES.
001)30 02-03
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE
AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS
(UNPUBLISHED PAPER).
00)488 02-03
EFFECTS OF ELECTROLYTIC AND 6 HYDROXYDOPAMINE LESIONS OF THE
LATERAL HYPOTHALAMUS ON ROTATION EVOKED BY ELEQRICAL-
STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.
00308) 03-04
EVIDENCE FOR INVOLVEMENT OF SEPARATE MECHANISMS IN THE
PRODUCTION OF ANALGESIA BY ELECTRICAL- STIMULATION OF THE
NUCLEUS-RETICULARIS-PARAGIGANTOCELLULARIS AND NUCLEUS-
RAPHE-MAGNUS IN THE RAT.
003083 03-04
THE EFFECT OF ELECTRICAL- STIMULATION OF THE LOCUS-COERULEUS AND
INTRAPERITONEAL INJECTION OF CERTAIN PHARMACOLOGICAL
SUBSTANCES ON THE THRESHOLD OF HIPPOCAMPAL
AFTERDISCHARGES.
003885 04-03
PRESSOR EFFECTS OF ELECTRICAL-STIMULATION OF THE DORSAL AND
MEDIAN RAPHE NUCLEI IN ANESTHETIZED RATS.
003892 04-03
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON
BEHAVIORAL SHIFTS IN CATS, ARISING AFTER CESSATION OF
ELECTRICAL-STIMULATION OF THE CAUDATE-NUCLEUS.
004067 04-04
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE
AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS.
00423) 04-04
ELECTRICALLY-INDUCED
EFFECTS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL-
CORD GABA CONCENTRATION.
000145 01-03
THE EFFECTS OF RESERPINE, IPRONIAZID AND L-DOPA ON ELECTRICALLY-
INDUCED SPINAL-CORD SEIZURES.
000146 01-03
EFFECTS OF NOREPINEPHRINE AND 5 HYDROXYTRYPTAMINE REUPTAKE
INHIBITORS ON ELECTRICALLY-INDUCED SPINAL-CORD SEIZURES IN
RATS.
004144 04-04
EFFECTS OF FLUOXETINE ON ELECTRICALLY-INDUCED SPINAL-CORD
SEIZURES IN RATS.
004145 04-04
3
mTu
nit
<iiir;
S-165
i\
Subject Index
ElECTROACUPUNCTURE __^
MORPHINE AND ELECTROACUPUNaURE: COMPARISON OF THE EFFECTS
ON THE CORTICAL EVOKED-RESPONSES AFTER TOOTH-PULP
STIMULATION IN RATS . „„,„„. „o ^^
001294 02-03
ELECTROCARDIOGRAM
FOLLOWUP STUDY ON THE INFLUENCE OF AN ANTIPSYCHOTIC-DRUG
(PROPERICIAZINE) ON LIVER FUNQION, ELECTROCARDIOGRAM AND
ELECTROENCEPHALOGRAM . „ , o« ^ , ,^r>
000639 01-09
ELEaROCARDIOGRAM-CHANGES
ELEaROCARDIOGRAM-CHANGES AND PLASMA DESIPRAMINE LEVELS
DURING TREATMENT OF DEPRESSION 00441104-09
ELECTROCARDIOGRAPHIC-CHANGES
ELECTROCARDIOGRAPHIC-CHANGES DURING LITHIUM TREATMENT.
000881 01-15
ELECTROCARDIOGRAPHIC-CHANGES IN RATS DURING CHRONIC-
TREATMENT WITH ANTIDEPRESSANT AND NEUROLEPTIC-DRUGS.
004284 04-05
ELECTROCHEMICAL
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID-
CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION.
003674 04-01
ElEaROCHEMICAL-DETECTION
HYPOTHALAMIC CATECHOLAMINE BIOSYNTHESIS IN VITRO AS
MEASURED BY LIQUID-CHROMATOGRAPHY AND ELECTROCHEMICAL-
^"^^™^ 000537 01-06
EVALUATION OF THE EFFECT OF DRUGS ON DOPAMINE METABOLISM IN
THE RAT SUPERIOR-CERVICAL-GANGLION BY HPLC WITH
ELECTROCHEMICAL-DETECTION. 001530 02-03
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC-
ACID IN BRAIN USING HPLC WITH ELECTROCHEMICAL-DETECTION.
003139 03-06
ELECTROCHEMICAL-METHOD ^„ ,^
AN AUTOMATED ELECTROCHEMICAL-METHOD FOR IN VIVO MONITORING
OF CATECHOLAMINE RELEASE
001873 02-06
ELECTROCONVULSIVE-SHOCK
REPEATED ELECTROCONVULSIVE-SHOCK DOES NOT INCREASE THE
SUSCEPTIBILITY OF RATS TO A CAGE CONVULSANT
(ISOPROPYLBICYCLOPHOSPHATE) .
EFFECT OF SINGLE AND REPEATED ELECTROCONVULSIVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN - I. METABOLIC-STUDIES.
001332 02-03
THE EFFECT OF REPEATED ELECTROCONVULSIVE-SHOCK ON
CORTICOSTERONE RESPONSES TO CENTRALLY-ACTING
PHARMACOLOGICAL STIMULI IN THE MALE RAT.
001486 02-03
EFFEQ OF SINGLE AND REPEATED ELEaROCONVULSlVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN - II. BEHAVIOURAL- STUDIES
001697 02-04
ON THE MEASUREMENT IN RATS OF THE CONVULSANT-EFFECT OF DRUGS
AND THE CHANGES WHICH FOLLOW ELECTROCONVULSIVE-SHOCK.
002444 02-15
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INDUCED CONVULSIONS
'^ ^'^^^ 003736 04-03
DIFFERENTIAL-EFFEaS OF ELECTROCONVULSIVE-SHOCK AND
ANTIDEPRESSANT-DRUGS ON SER0T0NIN2-RECEPT0RS IN RAT-BRAIN.
003878 04-03
REDUCTION IN OPIATE ACTIVATION AFTER CHRONIC
ELECTROCONVULSIVE-SHOCK - POSSIBLE ROLE FOR ENDORPHINS IN
THE BEHAVIORAL-EFFEQS OF CONVULSIVE-SHOCK-TREATMENT.
(UNPUBLISHED PAPER). „„,,.„.„.
004154 04-04
ELECTROCONVULSIVE-SHOCKS
EFFECT OF REPEATED ELEQROCONVULSIVE-SHOCKS (ECS) ON
SUBTHRESHOLD DOSES OF SOME CNS STIMULANTS.
001361 02-03
ELECTROCONVULSIVE-THERAPY
FAQORS INFLUENCING SEIZURE DURATION AND NUMBER OF SEIZURES
APPLIED IN UNILATERAL ELECTROCONVULSIVE-THERAPY: ANESTHETICS
AND BENZODIAZEPINES.
000792 01-13
ADMINISTRATION OF FLUNITRAZEPAM IN ELECTROCONVULSIVE-
™^^^^^ 004319 04-08
VALUE OF PROPANIDID IN ELECTROCONVULSIVE-THERAPY (COMPARISON
WITH THIOPENTONE). . „ „ „„
004379 04-09
Psychopharmacology Abstracts
ELECTROCONVULSIVE-TREATMENT
EFFECTS OF ELECTROCONVULSIVE-TREATMENT ON GROWTH-HORMONE
SECRETION INDUCED BY MONOAMINE-RECEPTOR AGONISTS IN
RESERPINE PRETREATED RATS.
002664 03-03
ELECTROCORTICAL
CATECHOLAMINERGIC INVOLVEMENT IN PHASIC VERSUS TONIC
ELECTROCORTICAL AROUSAL.
002723 03-03
ELECTROCORTICAL-CHANGES
STEREOTYPED-BEHAVIOUR AND ELECTROCORTICAL-CHANGES AFTER
INTRACEREBRAL MICROINFUSION OF DOPAMINE AND APOMORPHINE
IN FOWLS.
001734 02-04
ELEaROCORTICAL-EFFECTS
BEHAVIORAL-EFFECTS AND ELECTROCORTICAL-EFFECTS AFTER
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS
ENHANCING GABAERGIC TRANSMISSION.
000443 01-04
ENHANCED BEHAVIOURAL-EFFECTS, ELECTROCORTICAL-EFFECTS AND
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN.
001733 02-04
ELECTROCORTICOGRAPHIC
ELECTROCORTICOGRAPHIC ACTIVITY ELICITED BY METRAZOL DURING
ONTOGENESIS IN RATS.
004064 04-03
ElEaROCYTOCHEMICAL-STUDY
CHANGES IN THE CORTICAL ACTIVITY OF SUCCINATE-DEHYDROGENASE
UNDER THE INFLUENCE OF CHLORPROMAZINE (A HISTOCHEMICAL-
STUDY AND ELECTROCYTOCHEMICAL-STUDY).
002784 03-03
ELECTRODE
ON THE NEUROCHEMICAL BASIS OF SELF-STIMULATION WITH MIDBRAIN \
RAPHE ELECTRODE PLACEMENTS.
000373 01-04
ELECTRODERMAl
EFFECT OF PROPRANOLOL AND PHENOTHIAZINES ON ELEaRODERMAL
ORIENTING AND HABITUATION IN SCHIZOPHRENIA.
003174 03-08
HABITUATION OF ELECTRODERMAL AND RESPIRATORY RESPONSES TO
VISUAL STIMULI AS A FUNCTION OF PERSONALITY DIFFERENCES IN J
AFFECT LEVEL „^ ,,.i
003414 03-13'
ELECTRODES
NALOXONE AND FOCAL EPILEPSY: A STUDY WITH DEPTH ELEaRODES.
003341 03-11
ELECTROENCEPHALOGRAM
THE EFFECT Of PROPRANOLOL ON THE ELEQROENCEPHALOGRAM IN
NORMAL AND ETHANOL DEPENDENT RATS.
000126 01-03.
FOLLOWUP STUDY ON THE INFLUENCE OF AN ANTIPSYCHOTIC-DRUG
(PROPERICIAZINE) ON LIVER FUNQION, ELEQROCARDIOGRAM AND
ELECTROENCEPHALOGRAM. 000639 01 V
CYCLIC-AMP-INDUCED CHANGES IN THE ELEQROENCEPHALOGRAM AND
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN
T"^^*^ 003078 03-04
COMPUTER-ANALYZED ELEQROENCEPHALOGRAM TO PREDICT THE
THERAPEUTIC OUTCOME IN SCHIZOPHRENIA. „„„.,,
004680 04-161
ElECTROENCEPHALOGRAPHIC
3 SULFAMOYLMETHYL-l-2-BENZISOXAZOLE. A NEW TYPE OF
ANTICONVULSANT-DRUG: ELECTROENCEPHALOGRAPHIC PROFILE.
000142 01-03
INFERENCES DERIVED FROM ELECTROENCEPHALOGRAPHIC RESPONSES TO
ACUTE ADMINISTRATION OF CLOMIPHENE-CITRATE IN MALE ALBINO-
RATS
000155 01-03
CHRONOLOGICAL ELECTROENCEPHALOGRAPHIC AND
NEUROPHARMACOLOGICAL-STUDY IN CORTICAL KINDLING RABBITS.
002761 03-03
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL-TOLERANCE TO AND
CROSS-TOLERANCE BETWEEN D ALA2-METHI0NINE-ENKEPHALINAMIM
AND MORPHINE IN THE RAT 004038 04-03
ELECTROENCEPHALOGRAPHIC CHANGE IN PARKINSONIAN-PATIENTS
TREATED WITH LEVODOPA CARBIDOPA. ^^^
ELECTROENCEPHALOGRAPHIC-EFFECTS
ELECTROENCEPHALOGRAPHIC-EFFECTS AND BEHAVIOURAL-EFFECTS OF
SODIUM-VALPROATE IN PATIENTS WITH PHOTOSENSITIVE EPILEPSY. A
SINGLE-DOSE TRIAL. 002154 02-11
S-166
VOLUME 19, SUBJECT INDEX
ELECTROENCEPHALOGRAPHY
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF
ELECTROENCEPHALOGRAPHY WITH INTRAVENOUS DIAZEPAM IN
EPILEPSY.
000696 01-11
ELECTROLYTE
THE EFFECT OF DIAZEPAM ON TENSION AND ELECTROLYTE DISTRIBUTION
IN FROG MUSCLE.
000069 01-03
ELECTROLYTE-DISTURBANCES
TREATMENT OF UNDERNUTRITION AND ELECTROLYTE-DISTURBANCES IN
ANOREXIA-NERVOSA
004531 04-13
ELECTROLYTES
EFFECT OF FLUPHENAZINE ON THE CIRCADIAN-EXCRETION OF CYCLIC-
NUCLEOTIDES AND ELECTROLYTES IN THE URINE OF CHRONIC
SCHIZOPHRENICS.
001927 02-08
ELECTROLYTIC
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND
ELECTROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE
MIDBRAIN.
001593 02-04
ELECTROLYTIC MICROINFUSION TRANSDUCER SYSTEM; AN ALTERNATIVE
METHOD OF INTRACRANIAL DRUG APPLICATION.
001861 02-06
EFFECTS OF ELECTROLYTIC AND 6 HYDROXYDOPAMINE LESIONS OF THE
LATERAL HYPOTHALAMUS ON ROTATION EVOKED BY ELECTRICAL-
STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.
003081 03-04
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS
003871 04-03
ELECTROMYOGRAPHIC-ASSESSMENT
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH
ANTIDEPRESSANTS.
001620 02-04
ELECTROMYOGRAPHIC-METHOD
AN ELECTROMYOGRAPHIC-METHOD FOR THE ASSESSMENT OF
NALOXONE-INDUCED ABSTINENCE IN MORPHINE-DEPENDENT RATS.
000433 01-04
ELECTRON
ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED
PAPER).
001014 02-01
ELECTRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFECTS OF
HIGH-FREQUENCY STIMULATION ON DENDRITIC ULTRASTRUCTURE
(UNPUBLISHED PAPER).
001036 02-01
A METHOD FOR MEASUREMENT OF TRANYLCYPROMINE IN RAT-BRAIN
REGIONS USING GAS-CHROMATOGRAPHY WITH ELECTRON CAPTURE
DETECTION.
, _ 003137 03-06
ELECTRON-CAPTURE
ANALYSIS FOR DIAZEPAM AND NORDIAZEPAM BY ELECTRON-CAPTURE
GAS-CHROMATOGRAPHY AND BY LIQUID-CHROMATOGRAPHY.
000006 01-01
ELECTRON-CAPTURE GAS-LIQUID-CHROMATOGRAPHIC-DETERMINATION
OF ETHOSUXIMIDE AND DESMETHYLMETHSUXIMIDE IN PLASMA OR
SERUM.
000538 01-06
ELECTRONYSTAGMOGRAPHY
PROGRESSIVE SUPRANUCLEAR PALSY: PNEUMOENCEPHALOGRAPHY
ELECTRONYSTAGMOGRAPHY AND TREATMENT WITH METHYSERCJIDE
ELECTROPHYSIOLOGIC 003355 03-11
ELECTROPHYSIOLOGIC ASSESSMENT OF RECEPTOR CHANGES FOLLOWING
CHRONIC DRUG-TREATMENT.
„.„ 003136 03-06
ELECTROPHYSIOLOGICAL
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH
IN THE ELECTROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO
AUTORECEPTOR STIMULATION.
000046 01-03
ELECTROPHYSIOLOGICAL ACTIONS OF BENZODIAZEPINES.
000107 01-03
AGE-RELATED ELECTROPHYSIOLOGICAL CHANGES IN RAT-CEREBELLUM
000197 01-03
TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAN AND
CARBIDOPA: CLINICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL-
OBSERVATIONS.
002180 02-11
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM-
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON
002884 03-03
Subject Index
ELECTROPHYSIOLOGICAL EVIDENCE FOR PRESYNAPTIC ACTIONS OF
PHENCYCLIDINE ON NORADRENERGIC TRANSMISSION IN RAT
CEREBELLUM
003926 04-03
AN ELECTROPHYSIOLOGICAL MODEL OF GABA-MEDIATED
NEUROTRANSMISSION.
003929 04-03
CATECHOLAMINE MODULATION OF ENKEPHALIN-INDUCED
ELECTROPHYSIOLOGICAL RESPONSES IN CEREBRAL-CORTEX.
003957 04-03
ELECTROPHYSIOLOGICAL AND PSYCHOLOGICAL CHANGES INDUCED BY
STEROID-HORMONES IN MEN AND WOMEN.
004500 04-13
ELECTROPHYSIOLOGICAL-CHANGES
ELECTROPHYSIOLOGICAL-CHANGES AT A CENTRAL NORADRENERGIC
SYNAPSE DURING THALLIUM TOXICOSIS.
001848 02-05
ELECTROPHYSIOLOGICAL-CORRELATES
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI, OR
ETHANOL DETECTED BY ELECTROPHYSIOLOGICAL-CORRELATES
001136 02-03
ELECTROPHYSIOLOGICAL-EFFECTS
THE ELECTROPHYSIOLOGICAL-EFFECTS OF ENKEPHALIN AND
PHENCYCLIDINE IN THE RAT CENTRAL-NERVOUS-SYSTEM. (PH D
DISSERTATION).
001406 02-03
BEHAVIORAL-EFFECTS AND ELECTROPHYSIOLOGICAL-EFFECTS OF OPIOID-
PEPTIDES IN CATS.
001612 02-04
ELECTROPHYSIOLOGICAL-EFFECTS OF IMIPRAMINE ON BOVINE
VENTRICULAR-MUSCLE AND PURKINJE-FIBRES.
003988 04-03
ELECTROPHYSIOLOGICAL-STUDIES
ANTIANXIETY-AGENTS AND SYNAPTIC TRANSMISSION IN THE BRAIN
ELECTROPHYSIOLOGICAL-STUDIES (PH.D. DISSERTATION).
002840 03-03
ELECTROPHYSIOLOGICAL-STUDY
TRANSIENT-EFFECT OF L TRYPTOPHAN IN PROGRESSIVE MYOCLONUS
EPILEPSY WITHOUT LAFORA-BODIES: CLINICAL-STUDY AND
ELECTROPHYSIOLOGICAL-STUDY.
000694 01-11
ELECTRORETINOGRAM
THE ELECTRORETINOGRAM IN PARKINSONS-DISEASE.
001295 02-03
CHANGES OF ELECTRORETINOGRAM AND NEUROCHEMICAL ASPECTS OF
GABAERGIC NEURONS OF RETINA AFTER INTRAOCULAR INJECTION OF
KAINIC-ACID IN RATS.
003807 04-03
ELECTRORETINOGRAPHIC-CHANGES
ELECTRORETINOGRAPHIC-CHANGES IN PATIENTS WITH PARKINSONISM
TREATED WITH VARIOUS CLASSES OF ANTIPARKINSONIAN-DRUGS.
000674 01-11
ELECTRORETINOGRAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN
PSYCHOPHARMACOLOGY. ELECTRORETINOGRAPHIC-CHANGES INDUCED
BY A COMBINATION OF CARBIDOPA AND LEVODOPA.
004507 04-13
ELECTRORETINOGRAPHY
ELECTRORETINOGRAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN
PSYCHOPHARMACOLOGY. ELECTRORETINOGRAPHIC-CHANGES INDUCED
BY A COMBINATION OF CARBIDOPA AND LEVODOPA.
004507 04-13
ELECTROSHOCK-INDUCED
EFFECTS OF WITHDRAWAL FROM LONG-TERM DIPHENYLHYDANTOIN
TREATMENT ON AUDIOGENIC-SEIZURES AND MAXIMAL
ELECTROSHOCK-INDUCED SEIZURES IN RATS
004101 04-04
ELECTROSHOCK-TEST
EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL
AND DIPHENYLHYDANTOIN IN THE ELECTROSHOCK-TEST IN MICE
000163 01-03
ELECTROSHOCK-TREATMENT
PROTECTIVE ACTION OF L 5 HYDROXYTRYPTOPHAN L GLUTAMATE
(MADE- 1932) DURING ELECTROSHOCK-TREATMENT (ECT).
003043 03-04
ELEMENTARY
PREVALENCE OF HYPERACTIVITY AND RELATED TREATMENTS AMONG
ELEMENTARY SCHOOL CHILDREN.
004469 04-11
ELIMINATION
SHORT-TERM ETHANOL ADMINISTRATION IMPAIRS THE ELIMINATION OF
CHLORDIAZEPOXIDE (LIBRIUM) IN MAN.
002224 02-13
INFLUENCE OF PSYCHOTROPIC-DRUGS ON THE URINARY ELIMINATION OF
LITHIUM.
002895 03-03
CLINICAL-PHARMACOLOGY: ELIMINATION OF DRUGS.
003400 03-13
4'fc;
if
S-167
Subject Index
Ptychopharmacology Abstracts
'III'!
EFFECTS OF INDOMETHACIN AND METHYLPREDNISOLONE ON RENAL
ELIMINATION OF LITHIUM IN THE RAT.
004270 04-05
LITHIUM ELIMINATION HALF-LIFE AND DURATION OF THERAPY.
004369 04-09
EMBRYONIC
EFFECTS OF SOME NOOTROPIC-DRUGS UPON THE EMBRYONIC
MORPHOGENETIC SYSTEMS.
000144 01-03
NERVE GROWTH-FACTOR STIMULATES DEVELOPMENT OF SUBSTANCE-P
IN THE EMBRYONIC SPINAL-CORD.
003881 04-03
EMBRYOS
MATERNAL GLUCOCORTICOID-HORMONES INFLUENCE
NEUROTRANSMIHER PHENOTYPIC EXPRESSION IN EMBRYOS.
000149 01-03
EMD 28422
INCREASED BENZODIAZEPINE-RECEPTOR NUMBER ELICITED IN VITRO BY A
NOVEL PURINE, EMD-28422.
001475 02-03
EMERGENCIES
EMERGENCIES IN MANIC-DEPRESSIVE-PSYCHOSES.
003540 03-15
EM6-RECORDED
OPIOID-RECEPTORS IN THE CAUDATE-NUCLEUS CAN MEDIATE EMG-
RECORDED RIGIDITY IN RATS. „, ,„ „o «.
001649 02-04
EMIT
CARBAMAZEPINE-EPOXIDE DETERMINED BY EMIT CARBAMAZEPINE
'''''''' 000533 01-06
MASS SCREENING AND CONFIRMATION OF DIAZEPAM IN URINE BY EMIT
THIN-LAYER-CHROMATOGRAPHY. ^ ,^
004672 04-16
EMOTIONAL
ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN
™^^^ 00176102-04
THE ROLE OF OPIATE-RECEPTORS OF DIFFERENT BRAIN REGIONS IN
DETERMINING THE EMOTIONAL REACTIONS OF RATS.
004017 04-03
EMOTIONAL-BEHAVIOR
LONG-LASTING EFFECTS OF CHRONIC ADMINISTRATION OF
HALLUCINOGENIC-DRUGS ON RAT SOCIAL AND EMOTIONAL-BEHAVIOR.
(PHD. DISSERTATION).
003029 03-04
EMOTIONAL-DISORDERS
EMOTIONAL-DISORDERS IN CHILDREN AND ADOLESCENTS: MEDICAL AND
PSYCHOLOGICAL APPROACHES TO TREATMENT
004743 04-17
EMOTIONAL-STRESS
THE EFFECT OF EMOTIONAL- STRESS AND DIAZEPAM ON MONOAMINE
METABOLITES IN THE CEREBROSPINAL-FLUID OF CATS. (PHD
DISSERTATION) „ „ „o
001260 02-03
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL
HEMORRHAGE PATIENTS.
002295 02-13
EMOTIONALLY
THE EFFECT OF NALOXONE ON THE ACTIVATION OF EMOTIONALLY
POSITIVE REACTION PRODUCED BY DRUGS WITH A DEPENDENCE
LIABILITY
001556 02-03
EMOTIONALLY-REINFORCED
ACTION ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS
OF TREATING ALCOHOLISM AND DRUG ADDICTION
PATHOGENETICALLY.
003641 03-17
EMOTIONS
POSSIBLE INVOLVEMENT OF BRAIN DOPAMINERGIC-SYSTEMS IN THE
EXPRESSION OF EMOTIONS IN DREAMS.
002325 02-14
EMOTIVE
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS, UNDER
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REACTION TYPE
(EMOTIVE AND NONEMOTIVE).
001624 02-04
EMPIRICAL
TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERACTIVE-
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL
PARADIGM - A PILOT-STUDY.
002126 02-11
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
003256 03-09
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
(UNPUBLISHED PAPER).
004401 04-09
EMPIRICAL-STUDY
PREDICTING THE RESPONSE OF HYPERAQIVE-CHILDREN TO RITALIN: AN
EMPIRICAL-STUDY.
002120 02-11
ENANTIOMERS
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE-
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1
CYCLOPROPYLMETHYL
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE.
003706 04-02
ENANTIOMORPH
ANALGESIC AND OTHER PHARMACOLOGICAL AaiVITIES OF A NEW
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3
METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS
ENANTIOMORPH IN EXPERIMENTAL ANIMALS.
004185 04-04
ENCAPSULATED
PASSAGE THROUGH THE BLOOD-BRAIN-BARRIER OF THYROTROPIN-
RELEASING-HORMONE ENCAPSULATED IN LIPOSOMES.
004298 04-06
ENCEPHALE
SPECIFIC AND NONSPECIFIC MULTIPLE UNIT AaiVITIES DURING
PENTYLENETETRAZOL SEIZURES. I. ANIMALS WITH ENCEPHALE ISOLE.
004046 04-03
ENCEPHALOPATHY
DISULFIRAM ENCEPHALOPATHY AS A CAUSE OF THE CATATONIA-
SYNDROME.
000894 01-15
ENCEPHALOTROPIC
DETERMINATION OF THE ENCEPHALOTROPIC, PSYCHOTROPIC AND
PHARMACODYNAMIC PROPERTIES OF NICERGOLINE BY MEANS OF
QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY AND
PSYCHOMETRIC-ANALYSES.
000788 01-13
ANTIHYPOXIDOTIC-DRUGS AND NOOTROPIC-DRUGS: PROOF OF THEIR
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
QUANTITATIVE EEG INVESTIGATIONS.
002166 02-11
ENCOPRESIS
TREATMENT OF ENCOPRESIS WITH IMIPRAMINE.
004451 04-11
ENDOCRINE , „ „„
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY
PRETREATMENT WITH THYROID-HORMONES.
002259 02-13
THE EFFECTS OF CHRONIC METHYLPHENIDATE TREATMENT ON GROWTH
AND ENDOCRINE FUNCTION IN THE DEVELOPING RAT.
003811 04-03
ENDOCRINE-EFFECTS „.„„..r ...
BEHAVIOURAL-EFFECTS AND ENDOCRINE-EFFEQS OF NALTREXONE IN
MALE TALAPOIN-MONKEYS. „„,,,„ „. o.
001718 02-04
ENDOCRINE-EFFEaS OF LITHIUM IN MANIC-DEPRESSIVE-PATIENTS.
001970 02-09
ANTIPSYCHOTIC-DRUGS: MEASUREMENT AND ENDOCRINE-EFFEQS.
(UNPUBLISHED PAPER). 002287 02-13
BRAIN g'lUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS,
AND NEUROPHARMACOLOGICAL EVENTS.
002515 02-17
ENDOCRINE-STUDY
A CLINICAL-STUDY AND ENDOCRINE-STUDY OF MESTEROLONE IN
SECONDARY IMPOTENCE 002315 02-14
ENDOCRINOLOGICAL
ENDOCRINOLOGICAL CHANGES IN PATIENTS WITH SEXUAL-DYSFUNQION
UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000912 01-17
ENDOGENOMORPHICALLY
EFFICACY OF DESIPRAMINE IN ENDOGENOMORPHICALLY DEPRESSED-
'•^^'^^^^ 000632 01^
ENDOGENOUS
RELEASE OF ENDOGENOUS NOREPINEPHRINE FROM A RABBIT CEREBRAL-
^■^^^■^^ 000079 01-03
DISSIMILAR EFFEaS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF '^^'CE^
S-168
VOLUME 19, SUBJECT INDEX
Subject Index
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS AND PUTATIVE
ENDOGENOUS BENZODIAZEPINE-LIKE COMPOUNDS
000225 01-03
THE POSSIBILITY THAT A COMPONENT OF MORPHINE-INDUCED
ANALGESIA IS CONTRIBUTED INDIRECTLY VIA THE RELEASE OF
ENDOGENOUS OPIOIDS.
000263 0)-03
PURINES AS ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTOR.
000276 01-03
DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES.
000584 01-09
NOMIFENSIN IN THE TREATMENT OF ENDOGENOUS DEPRESSIONS
CLINICAL-EXPERIENCE AND EEG FINDINGS.
000613 01-09
ANTIDEPRESSIVE TREATMENT AND MOOD-SWING-PATTERNS IN
ENDOGENOUS DEPRESSION.
000633 01-09
CONTROLLED-COMPARISON OF MIANSERINE WITH IMIPRAMINE IN
ENDOGENOUS DEPRESSIONS.
000634 01-09
DECREASED UPTAKE OF 5 HYDROXYTRYPTAMINE IN BLOOD-PLATELETS
FROM PATIENTS WITH ENDOGENOUS DEPRESSION.
000637 01-09
DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN
FRAGMENTS OF MALE AND FEMALE RATS.
001121 02-03
EVIDENCE FOR AN ENDOGENOUS COMPOUND INTERFERING WITH 3H
DIAZEPAM BINDING TO RAT-BRAIN MEMBRANES.
001308 02-03
ENDOGENOUS GUANYL-NUCLEOTIDES: COMPONENTS OF THE STRIATUM
WHICH CONFER DOPAMINE SENSITIVITY TO ADENYLATE-CYCLASE.
001313 02-03
ASCORBIC-ACID, AN ENDOGENOUS FACTOR REQUIRED FOR
ACETYLCHOLINE RELEASE FROM THE SYNAPTIC VESICLES.
001322 02-03
BENZODIAZEPINE-RECEPTOR: LOCALIZATION BY PHOTOAFFINITY
LABELING AND ISOLATION OF A POSSIBLE ENDOGENOUS LIGAND
001381 02-03
1 METHYL-BETA-CARBOLINE (HARMANE), A POTENT ENDOGENOUS
INHIBITOR OF BENZODIAZEPINE-RECEPTOR BINDING
001440 02-03
CLINICAL-EXPERIENCE WITH SECOND-GENERATION ANTIDEPRESSANTS IN
ENDOGENOUS DEPRESSIONS.
001975 02-09
NOMIFENSINE IN THE TREATMENT OF ENDOGENOUS DEPRESSION A
CONTROLLED-STUDY VS. NORTRIPTYLINE.
001978 02-09
ENDOGENOUS DEPRESSION AND IMIPRAMINE LEVELS IN THE BLOOD
001979 02-09
EFFEQS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN
HEALTHY TEST SUBJECTS, NEUROTIC-PATIENTS, AND ENDOGENOUS
DEPRESSIVE-PATIENTS.
002009 02-09
D PHENYLALANINE IN ENDOGENOUS DEPRESSION.
002017 02-09
CLINICAL-TRIAL OF PYRAZIDOL IN ENDOGENOUS DEPRESSIVE-STATES.
002021 02-09
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS
002047 02-09
PHENYLALANINE LEVELS IN ENDOGENOUS PSYCHOSES.
002049 02-09
THE EFFECT OF CONDITIONS INFLUENCING ENDOGENOUS
PROSTAGLANDINS ON THE ACTIVITY OF DELTA'
TETRAHYDROCANNABINOL.
002196 02-12
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL
CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN
PSYCHEDELIC-EXPERIENCES.
002200 02-12
PURSUING THE ACTIONS OF PSYCHOTROPIC-DRUGS: RECEPTOR SITES
AND ENDOGENOUS CEREBRAL PROGRAMMES.
002578 02-17
THE REGULATION OF BENZODIAZEPINE RECOGNITION SITES BY
ENDOGENOUS MODULATORS.
002642 03-01
DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM
BOVINE CEREBRAL-CORTEX.
MODULATION BY ENDOGENOUS DOPAMINE OF THE RELEASE OF
ACETYLCHOLINE IN THE CAUDATE-NUCLEUS OF THE RABBIT.
002751 03-03
BEHAVIORAL CONFIRMATION OF DIFFUSE NOXIOUS INHIBITORY
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS
OPIATES.
002791 03-03
BIPHASIC-EFFECTS AND OPPOSITE-EFFECTS OF DOPAMINE AND
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT
SUBSTANTIA-NIGRA.
002923 03-03
BLOCKADE OF ENDOGENOUS OPIATES REDUCES ACTIVITY IN THE RAT
003111 03-04
AMOXAPINE AND AMITRIPTYLINE IN THE OUTPATIENT TREATMENT OF
ENDOGENOUS DEPRESSION.
003217 03-09
SLEEP AND TREATMENT PREDICTION IN ENDOGENOUS DEPRESSION
003236 03-09
CLINICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG-
RESISTANCE.
003245 03-09
THERAPEUTIC EFFECT OF MIANSERINE AND IMIPRAMINE IN ENDOGENOUS
DEPRESSIONS (CONTROLLED-COMPARISON) .
003264 03-09
ON THE INTENSIVE TREATMENT OF ENDOGENOUS PSYCHOSES.
003384 03-11
ENDOGENOUS LIGANDS FOR BENZODIAZEPINE-RECEPTORS
003615 03-17
INHIBITION OF (3H)DIAZEPAM BINDING BY AN ENDOGENOUS FRACTION
FROM RAT-BRAIN SYNAPTOSOMES.
003768 04-03
POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CARDIOVASCULAR-
EFFECTS OF CENTRAL ALPHA-ADRENOCEPTOR STIMULATION IN
SPONTANEOUSLY HYPERTENSIVE-RATS.
003791 04-03
SEXUAL-BEHAVIOR DECREASES PAIN SENSITIVITY AND STIMULATES
ENDOGENOUS OPIOIDS IN MALE RATS.
004234 04-04
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION- A
DOUBLE-BUND COMPARISON WITH IMIPRAMINE.
004346 04-09
A NEUROENDOCRINE-STUDY OF ADRENOCEPTOR FUNCTION IN
ENDOGENOUS DEPRESSION.
004362 04-09
THE EFFECT OF NALOXONE ON THE CONDITION OF PATIENTS WITH
ENDOGENOUS PSYCHOSES.
004381 04-09
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH
ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT.
004382 04-09
COMPARATIVE CHARACTERISTICS OF THE PROPHYLACTIC PROPERTIES OF
SHORT-TERM AND LONG-ACTING LITHIUM-CARBONATE PREPARATIONS
IN ENDOGENOUS AFFECTIVE-PSYCHOSES.
004390 04-09
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS
004403 04-09
CLINICAL-EVALUATION OF THE PROPHYLACTIC EFFECTIVENESS OF
PROLONGED LITHIUM-CARBONATE THERAPY IN ENDOGENOUS
DEPRESSIVE-SYNDROMES.
004404 04-09
THE ACTIVITY OF ERYTHROCYTE CATECHOL-0-METHYLTRANSFERASE IN
ENDOGENOUS DEPRESSIVE-SYNDROMES.
004546 04-13
THE ACTIVITY OF BLOOD-PLATELET MONOAMINE-OXIDASE IN
ENDOGENOUS DEPRESSION.
004547 04-13
THE ACTIVITY OF DOPAMINE-BETA-HYDROXYLASE IN THE PLASMA OF
PATIENTS WITH ENDOGENOUS DEPRESSIVE-SYNDROMES.
004548 04-13
ENDOGENOUSLY-INDUCED
ENDORPHIN-INDUCED HYPERTHERMIA: CHARACTERIZATION OF THE
EXOGENOUSLY-INDUCED AND ENDOGENOUSLY-INDUCED EFFECTS.
000029 01-03
ENDOMORPHOUS
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES
IN THIS PHASE.
003251 03-09
ENDORPHIN
STUDIES ON THE HYPERTHERMIC-RESPONSE OF BETA ENDORPHIN IN
MICE.
000137 01-03
METHIONINE-ENKEPHALIN ANTAGONISM AND ENDORPHIN POTENTIATION
OF NARCOTIC-INDUCED ANALGESIA.
000357 01-04
EFFECT OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION
MEMORY, AND RETRIEVAL OF SHUTTLE AVOIDANCE AND
HABITUATION LEARNING IN RATS.
000410 01-04
EFFECTS OF MORPHINE, BETA ENDORPHIN AND NALOXONE ON
CATECHOLAMINE LEVELS AND SEXUAL-BEHAVIOR IN THE MALE RAT.
000430 01-04
a.
c>,.
'•Ui;
S-169
Subject Index
Psychopharmacology Abstracts
BETA ENDORPHIN AND ANALOGS: 360 MHZ PROTON NMR
SPECTROSCOPY. 001028 02-01
CHEMISTRY OF BETA ENDORPHIN. 001038 02-01
BETA ENDORPHIN: DISSOCIATION OF RECEPTOR BINDING-AQIVITY FROM
ANALGESIC POTENCY. 00108102-02
EVIDENCE THAT VASOPRESSIN IS INVOLVED IN THE ISOPRENALINE-
INDUCED BETA ENDORPHIN RELEASE. ^^^^^^ ^^^^
ALTERED LEVELS OF BETA ENDORPHIN FRAGMENTS AFTER CHRONIC
MORPHINE TREATMENT OF GUINEA-PIG ILEUM IN VITRO AND IN VIVa
001404 02-0o
NERVE CELL CALCIUM AS A MESSENGER FOR OPIATE AND ENDORPHIN
'^'-^'°'^S- 001450 02-03
THE SHORT-TERM AND LONG-TERM EFFECTS OF BETA ENDORPHIN ON THE
OPIATE ABSTINENCE-SYNDROME IN RATS.
001643 02-04
EFFECTS OF A LOW-DOSE AND A HIGH-DOSE OF BETA ENDORPHIN ON
ACQUISITION AND RETENTION IN THE RAT.
00 1 663 02-04
BETA ENDORPHIN CAUSES RETROGRADE AMNESIA AND IS RELEASED
FROM THE RAT-BRAIN BY VARIOUS FORMS OF TRAINING AND
STIMULATION. 001664 02-04
UNUSUAL DOSE-RELATED EFFEQ OF AN ENDORPHIN ANALOG IN A
COMPLEX MAZE. 001674 02-04
ANALGESIC ACTION OF INTRATHECAL AND INTRACEREBRAL BETA
ENDORPHIN IN RATS: COMPARISON WITH MORPHINE.
001691 02-04
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES. <UNPUBLISHED^PAPER)^^_^^
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS ARER A SINGLE
INJECTION OF BETA ENDORPHIN 001962 02-09
MOOD AND BEHAVIORAL-EFFECTS OF PHYSOSTIGMINE ON HLIMANS ARE
ACCOMPANIED BY ELEVATIONS IN PLASMA BETA ENDORPHIN AND
CO'^TISOL. 002280 02-13
ENDORPHIN OPIATE INTERACTIONS WITH NEUROENDOCRINE SYSTEM^S^ ^^
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF
DISCRETE RAT-BRAIN NUCLEI. 002635 03-01
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE
AND CROSS-TOLERANCE TO THE INHIBITORY ACTION OF BETA
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS
002756 OJ-Uj
DYNORPHIN- A POSSIBLE MODULATORY PEPTIDE ON MORPHINE OR BETA
ENDORPHIN ANALGESIA IN MOUSE ^^^^^ ^^^^
ASCENDING ENDORPHIN INHIBITION OF DISTRESS VOCALIZATION
00301 1 03-04
MULTIDIMENSIONAL ANALYSES OF BEHAVIOR IN MICE TREATED WITH
ALPHA ENDORPHIN. 003020 03-04
ENHANCEMENT OF ETHANOL-INDUCED SEDATION AND HYPOTHERMIA BY
CENTRALLY ADMINISTERED NEUROTENSIN, BETA ENDORPHIN AND
BO'^BESIN. 003037 03-04
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES „„o , z-, «o no
BETA ENDORPHIN LEVELS IN THE CEREBROSPINAL-FLUID OF
SCHIZOPHRENICS. 003176 03-08
BETA ENDORPHIN IN COTARDS-SYNDROME. «„,,„, «, «»
003 1 87 Oo-Oo
BETA ENDORPHIN AND SCHIZOPHRENIA. ^^^^^ ^^_^^
ENDORPHIN RESEARCH IN SCHIZOPHRENIC-PSYCHOSES. ^^^^^ ^^^^
BEHAVIORAL-EFFECTS AND BIOLOGICAL-EFFECTS OF ACUTE BETA
ENDORPHIN INJECTION IN SCHIZOPHRENIC-PATIENTS AND DEPRESSED-
P^TIENTS. 003357 03-11
SYNTHESIS AND BIOLOGICAL-ACTIVITY OF HUMAN BETA ENDORPHIN
ANALOGS WITH DISULFIDE BRIDGES.
003655 04-0 1
VASOPRESSIN STIMULATES RELEASE OF BETA LIPOTROPIN AND BETA
ENDORPHIN IN CONSCIOUS RATS AS MEASURED BY
RADIOIMMUNOASSAY OF UNEXTRACTED PLASMA.
0037 1 5 U4-UJ
PHARMACOLOGIC MANIPULATION OF BRAIN AND PITUITARY ENDORPHIN
CONTENT AND RELEASE.
003837 04-03
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM
INTERMEDIATE/POSTERIOR LOBES OF PITUITARY.
003846 04-03
COMPARISON OF THE EFFECTS OF BETA ENDORPHIN AND MORPHINE ON
EXPLORATORY-BEHAVIOUR AND SOCIOSEXUAL-BEHAVIOUR IN THE
'^ALERAT. „„,,-,„„.«.
004178 04-04
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND
BODY-TEMPERATURE CHANGES IN RATS.
004238 04-04
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO
COUNTERAQ CURATIVE EFFEaS OF NEUROLEPTIC-DRUGS.
004321 04-08
CLINICAL-EFFECTS OF BETA ENDORPHIN INFUSIONS. '
004360 04-09
SUPPRESSION OF MORPHINE ABSTINENCE IN HEROIN ADDIQS BY BETA
ENDORPHIN. „„..„„„. ,, I
004489 04-1 1 I
ENDORPHIN-INDUCED
ENDORPHIN-INDUCED HYPERTHERMIA: CHARAQERIZATION OF THE
EXOGENOUSLY-INDUCED AND ENDOGENOUSLY-INDUCED EFFEQS
000029 01-03
BETA ENDORPHIN-INDUCED HYPERGLYCEMIA IS MEDIATED BY INCREASED
CENTRAL SYMPATHETIC OUTFLOW TO ADRENAL-MEDULLA.
002924 03-03
ENDORPHINS
NEUROCHEMICAL MECHANISMS OF OPIATES AND ENDORPHINS.
000958 01-17
TURNING ON THE ENDORPHINS. _, „„ „o «,
001489 02-03
ANTAGONISM OF 2 DEOXY-D-GLUCOSE-INDUCED HYPERPHAGIA BY
NALOXONE POSSIBLE INVOLVEMENT OF ENDORPHINS.
001773 02-04
ON A POSSIBLE ROLE OF ENDORPHINS IN PSYCHIATRIC-DISORDERS -
ACTIONS OF NALOXONE IN PSYCHIATRIC-PATIENTS.
001917 02-08
ANTIPSYCHOTIC-EFFECT OF GAMMA-TYPE ENDORPHINS IN
SCHIZOPHRENIA. 001953 02-08
MECHANISMS OF OPIATE ANALGESIA AND THE ROLE OF ENDORPHINS IN
PAIN SUPPRESSION. (UNPUBLISHED PAPER). 002275 02 13
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL-STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN). ^^ ^^
CENTRAL NEUROPHARMACOLOGY OF ENDORPHINS ^^^^^ ^^^^
ENDORPHINS IN MENTAL-ILLNESSES, AND PARTICULARLY IN
SCHIZOPHRENIA. 003203 03-08
ON THE PHYSIOLOGY AND PHARMACOLOGY OF ENDORPHINS^
003417 03- IJ
ENDORPHINS. 003434 03-13
ENDORPHINS ^^3^5, ^^_^^
TORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
nIlOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-0;
REDUaiON IN OPIATE AQIVATION AFTER CHRONIC ^^,^„„„^,^,^ ,„
ELECTROCONVULSIVE-SHOCK - POSSIBLE ROLE FOR ENDORPHINS IN
THE BEHAVIORAL-EFFEQS OF CONVULSIVE-SHOCK-TREATMENT.
(UNPUBLISHED PAPER). 004154 04-0^
ENDORPHINS IN PSYCHOPATHOLOGY. ^^^^^ ^^
PSYCHOPATHOLOGY AND ENDORPHINS. ^^^^^^ ^^^^
^'^'^CHANGES OF AQH, STH, TSH AND PROLAQIN LEVELS IN ENDOTOXIN
SHOCK IN RATS. 000119 01^:
OPEN-FIELD PERFORMANCE OF RATS ARER ENDOTOXIN ^R^ENT^ ^^
^*"*NE°R0PHAr'mACOLOGICAL-AGENTS MODIFYING ENDOTOXIN-INDUCED
CHANGES IN MICE. 001543 02-0:
S-170
VOLUME 19, SUBJECT INDEX
Subject Index
ENOPOINT
RAT-BRAIN STEADY-STATE LEVELS OE CYCLIC-NUCLEOTIOES AS AN
ENDPOINT OE LSD-LIKE HALLUCINOGEN EFFECTS, (PH.D.
DISSERTATION).
001426 02-03
ENERGY
CONVULSANT AND ANTICONVULSANT BARBITURATES. 1 . MOLECULAR
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY
CALCULATIONS.
001029 02-01
ENERGY RESERVES AND SOUND-INDUCED SEIZURES. (UNPUBLISHED
PAPER).
001467 02-03
NEURONAL ACTIVITY AND ENERGY METABOLISM: A SUMMARY OF A
SYMPOSIUM. (UNPUBLISHED PAPER).
002308 02-13
THE EFFECT OF PROPYLNORANTIFEIN ON BEHAVIORAL-REACTIONS,
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE
ANIMAL BRAIN.
004075 04-04
EFFECT OF INORGANIC LEAD ON RAT-BRAIN MITOCHONDRIAL
RESPIRATION AND ENERGY PRODUCTION.
004267 04-05
ENFLURANE
INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE,
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS.
001539 02-03
EPILEPTOGENIC PROPERTIES OF ENFLURANE AND THEIR CLINICAL
INTERPRETATION.
004609 04-15
ENGLAND
THE HLA- SYSTEM AND SCHIZOPHRENIA IN ENGLAND.
001933 02-08
ENKEPHALIN
ENKEPHALIN LEVELS DECREASE IN RAT STRIATUM DURING MORPHINE
ABSTINENCE.
000027 01-03
EFFEQS OF ENKEPHALIN ANALOGUE AND NALOXONE ON CAT SPINAL-
CORD DORSAL ROOT POTENTIALS.
000236 01-03
APPLICATION OF A SYNTHETIC ENKEPHALIN ANALOGUE DURING HEROIN
WITHDRAWAL.
000685 01-11
THE ELECTROPHYSIOLOGICAL-EFFECTS OF ENKEPHALIN AND
PMENCYCLIDINE IN THE RAT CENTRAL-NERVOUS- SYSTEM. (PH.D.
DISSERTATION).
001406 02-03
ACTIONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON
ACETYLCHOLINE TURNOVER IN RAT-BRAIN.
001541 02-03
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJEQION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN
RATS.
001669 02-04
BIPHASIC-EFFECTS OF A POTENT ENKEPHALIN ANALOGUE D MET2-PR05-
ENKEPHALINAMIDE AND MORPHINE ON LOCOMOTOR-ACTIVITY IN
MICE.
001799 02-04
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY.
002639 03-01
THE EFFECT OF BARBITURATES ON THE DEGRADATION OF ENKEPHALIN BY
BRAIN ENZYMES.
002656 03-03
ENKEPHALIN ANALOGS AND PHYSICAL-DEPENDENCE.
003572 03-16
SYNTHESIS AND PHARMACOLOGICAL-STUDY OF SOME ENKEPHALIN
ANALOGS IN RELATION TO THE PLURALITY OF OPIATE-RECEPTORS
003682 04-02
INVESTIGATION OF ACTION OF ENKEPHALIN ON THE SPONTANEOUS AND
EVOKED RELEASE OF ACETYLCHOLINE FROM RAT CORTICAL AND
STRIATAL SLICES.
003862 04-03
AQION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
CHARACTERIZATION OF ENKEPHALIN RELEASE FROM RAT STRIATUM
„„„, 003909 04-03
EFFEQS OF ENKEPHALIN, MORPHINE, AND NALOXONE ON THE
ELECTRICAL-ACTIVITY OF THE IN VITRO HIPPOCAMPAL SLICE
PREPARATION.
003918 04-03
ENKEPHALIN-CONTAINING
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE
SPINAL-CORD OF THE CAT: ENKEPHALIN-CONTAINING MARGINAL
NEURONS AND PAIN MODULATION
002638 03-01
ENKEPHALIN-INDUCED
CATECHOLAMINE MODULATION OF ENKEPHALIN-INDUCED
ELECTROPHYSIOLOGICAL RESPONSES IN CEREBRAL-CORTEX.
003957 04-03
ENKEPHALIN-LIKE
ENKEPHALIN-LIKE CHARACTER AND ANALGESIA.
002650 03-02
ENKEPHALIN-RECEPTOR
ENKEPHALIN-RECEPTOR IN THE RABBIT ILEUM.
000221 01-03
ENKEPHALINER6IC
EFFECTS OF LONG-TERM ADMINISTRATION OF ANTIPSYCHOTIC-DRUGS ON
ENKEPHALINERGIC NEURONS.
001284 02-03
ENKEPHALINS
ENKEPHALINS PRESYNAPTICALLY INHIBIT CHOLINERGIC TRANSMISSION
IN SYMPATHETIC GANGLIA.
000167 01-03
EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERACTIONS WITH MU-
RECEPTORS AND DELTA-RECEPTORS.
000168 01-03
COMPARATIVE-EFFECTS OF SOMATOSTATIN AND ENKEPHALINS ON THE
GUINEA-PIG ILEUM AND THE RAT VAS-DEFERENS.
001302 02-03
OPIATE AND PEPTIDE INTERACTION: EFFECT OF ENKEPHALINS ON
MORPHINE ANALGESIA.
001698 02-04
ESTIMATING IN VIVO THE TURNOVER-RATE OF BRAIN ENKEPHALINS
001884 02-06
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL-STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN) .
002286 02-13
HISTOCHEMICAL LOCALIZATION OF OPIATE-RECEPTORS AND THE
ENKEPHALINS.
002566 02-17
NEUROBIOLOGY AND NEUROPHARMACOLOGY OF THE ENKEPHALINS.
002580 02-17
MOLECULAR ACTIONS OF OPIATES: HISTORICAL OVERVIEW AND NEW
FINDINGS ON OPIATE-RECEPTOR INTERACTIONS WITH ENKEPHALINS
AND GUANYL-NUCLEOTIDES.
002613 02-17
DIFFERENTIAL LOSS OF BIOLOGICAL-AQIVITY OF THE ENKEPHALINS
INDUCED BY CURRENT.
002783 03-03
POTENT TETRAPEPTIDE ENKEPHALINS.
003684 04-02
SPREADING DEPRESSION INDUCED BY MICROINJECTION OF ENKEPHALINS
INTO THE HIPPOCAMPUS AND NEOCORTEX.
004015 04-03
ARE THE ENKEPHALINS INVOLVED IN PARKINSONS-DISEASE? CLINICAL
AND NEUROENDOCRINE RESPONSES TO NALOXONE ADMINISTRATION.
004431 04-11
ENOLASE
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFECTS
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES.
000131 01-03
BASIC AND CLINICAL NEUROBIOLOGICAL APPLICATIONS OF NEURONAL
(NSE) AND NONNEURONAL (NNE) ENOLASE. (UNPUBLISHED PAPER).
001041 02-01
ENOLASES
BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF THE MOUSE BRAIN
ENOLASES PURIFIED BY A SIMPLE METHOD.
003668 04-01
ENRICHMENT
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRACTION.
003948 04-03
ENTERIC-COATED
MEAL-DEPENDENT ABSORPTION OF ENTERIC-COATED SODIUM-
VALPROATE.
000777 01-13
ENTEROHEPATIC
DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT
METABOLISM, DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND
CHOLERETIC-EFFECT.
000073 01-03
ENURESIS
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF
ENURESIS: A COMPARATIVE-STUDY.
002175 02-11
THE EFFECTIVENESS OF IMIPRAMINE IN THE TREATMENT OF ENURESIS:
THE SIGNIFICANCE OF TYPE OF ENURESIS AND REPORTED LEVEL OF
SLEEP. (PH.D. DISSERTATION).
003337 03-11
(31,
I
'ntt
<>«K
•«l!|l'
*llr:
If
S-171
Subject Index
Ptychopharmacology Abttrocfs
* 1(1(1'
ENVIRONMENT ^ „ ^,,^
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL
GROUPS IN THE ACTIVE SITE. (UNPUBLISHED PAPER).
001066 02-01
ERGOTISM IN A PSYCHIATRIC ENVIRONMENT ASSOCIATED WITH
ERYTHROMYCIN-DIHYDROERGOTAMINE-PROPIONATE. AN
OBSERVATION.
002379 02-15
SURGICAL MANIPULATION OF THE UTERINE ENVIRONMENT OF RAT
FETUSES.
002478 02-16
DRUG ENVIRONMENT INTERACTION: CONTEXT DEPENDENCY OF COCAINE-
INDUCED BEHAVIORAL-SENSITIZATION .
002866 03-03
DEBATE: THERAPEUTIC TRIALS IN A NATURAL ENVIRONMENT.
003635 03-17
ENVIRONMENTAL
THE SENSITIVITY OF THE RAT CORTICOSTERONE RESPONSE TO
ENVIRONMENTAL MANIPULATIONS AND TO CHRONIC
CHLORDIAZEPOXIDE TREATMENT.
000092 01-03
TEMPORAL AND ENVIRONMENTAL CUES IN CONDITIONED HYPOTHERMIA
AND HYPERTHERMIA ASSOCIATED WITH MORPHINE.
002709 03-03
BIOCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF ACUTE ETHANOL IN
RATS AT DIFFERENT ENVIRONMENTAL TEMPERATURES
002864 03-03
ENVIRONMENTAL MODULATION OF ANALGESIC TOLERANCE INDUCED BY
MORPHINE PELLETS. ^^ ^^ „_,
002944 03-04
NATURAL AND THERAPEUTIC ENVIRONMENTAL INDICATORS OF
MAINTENANCE DOSAGE REQUIREMENTS.
003561 03-16
ENVIRONMENTALLY „„„, ,.,
2 4 5 TRICHLOROPHENOXYACETIC-ACID CAUSES BEHAVIORAL-EFFECTS IN
'chickens AT ENVIRONMENTALLY RELEVANT DOSES.
003079 03-04
ENZYMATIC
enzymatic carboxymethylation of the nicotinic acetylcholine-
receptor. (unpublished paper).
001318 02-03
NEUROLEPTIC ACTION ON HEPATIC ENZYMATIC ACTIVITY.
002849 03-03
AGE-DEPENDENT MODIFICATION OF DRUG INTERFERENCE ON THE
ENZYMATIC ACTIVITIES OF THE RAT-BRAIN.
003730 04-03
ENZYME
ENZYME INDUCING EFFECTS OF PHENOBARBITAL ON NITRAZEPAM
METABOLISM IN DOGS.
000086 01-03
BRAIN STRIATAL TYROSINE-HYDROXYLASE: ACTIVATION OF THE ENZYME
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION.
001423 02-03
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME ACTIVITY
IN THE RAT-BRAIN.
001614 02-04
CLINICAL-IMPLICATIONS OF ENZYME INDUCTION AND ENZYME
INHIBITION.
003621 03-17
ENZYME-INDUCING
COMPARATIVE ENZYME-INDUCING EFFECTS OF CHLORPROMAZINE AND
FLUPHENAZINE THERAPIES IN PSYCHOTIC-PATIENTS.
000682 01-11
ENZYMES
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFECTS
OF ACRYLAMIDE AND 2,5 HEXANEOIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES.
000131 01-03
EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON
NEUROTRANSMIHER ENZYMES IN RAT-BRAIN.
000134 01-03
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 02-03
COMPARATIVE-STUDY OF THE INDUCTIVE EFFECT OF TWO
PSYCHOMODERATORS - TETRABAMATE AND COMPLEXE-1656 - AND
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS.
001874 02-06
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA
AND MEDIAL NUCLEUS-TRACTUS-SOLITARIUS OF RAT-BRAIN.
002634 03-01
THE EFFEa OF BARBITURATES ON THE DEGRADATION OF ENKEPHALIN BY
BRAIN ENZYMES.
002656 03-03
REGIONAL AND SUBCELLULAR LOCALIZATION IN RAT-BRAIN OF THE
ENZYMES THAT CAN SYNTHESIZE GAMMA HYDROXYBUTYRIC-ACID.
003675 04-01
DISTRIBUTION OF CESIUM IN THE ORGANISM AND ITS EFFEQ ON THE
NUCLEOTIDE METABOLISM ENZYMES.
003696 04-02
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN
REGIONS OF RAT-BRAIN WITH KETAMINE ANESTHESIA.
003891 04-03
THE EFFECT OF CHRONIC NICOTINE AND WITHDRAWAL ON INTRAAXONAL
TRANSPORT OF ACETYLCHOLINE AND RELATED ENZYMES IN SCIATIC-
NERVE OF THE RAT.
003897 04-03
DIFFERENTIAL-EFFECTS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS. |
003947 04-03
OXIDATION OF BETA PHENYLETHYLAMINE BY BOTH TYPES OF !
MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND
LIVER MITOCHONDRIA OF EIGHT SPECIES.
004024 04-03
EPENDYMINS
A RADIOIMMUNOASSAY FOR EPENDYMINS BETA AND GAMMA: TWO
GOLDFISH BRAIN PROTEINS INVOLVED IN BEHAVIORAL PLASTICITY.
003677 04-01
EPIDEMIC
THE URBAN EPIDEMIC OF PHENCYCLIDINE USE: LABORATORY EVIDENCE
FROM A PUBLIC PSYCHIATRIC-HOSPITAL INPATIENT-SERVICE
003554 03-16
EPIDEMIOLOGIC
A STUDY OF ANTIPSYCHOTIC-DRUG USE IN NURSING-HOMES:
EPIDEMIOLOGIC EVIDENCE SUGGESTING MISUSE.
000979 01-17
EPIDEMIOLOGY
EPIDEMIOLOGY OF PCP ABUSE: THE MIDWEST PERSPEQIVE.
000740 01-12
THE EPIDEMIOLOGY OF PCP USE IN THE LATE 1970S.
000741 01-12
DEPRESSION IN THE ELDERLY: RESEARCH DIREQIONS IN
PSYCHOPATHOLOGY, EPIDEMIOLOGY, AND TREATMENT.
000998 01-17
EPIDURAL
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMinERS IN EPIDURAL
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC-
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS
001386 02-03
EPIDURAL MORPHINE-INDUCED CATATONIA.
002400 02-15
EPILEPSIES
TREATMENT OF EPILEPSIES WITH CLONAZEPAM (ANTELEPSIN).
004481 04-11
EPILEPSY
THE PARADOXICAL-EFFECT OF LIDOCAINE ON AN EXPERIMENTAL MODEL
'''''''''' 000039 01^3
ANTAGONISM BY CLASSICAL ANTIEPILEPTICS AND SODIUM-VALPROATE
OF CEFAZOLIN-INDUCED EXPERIMENTAL EPILEPSY IN RATS
000442 01-04
ANTICONVULSANTS AND TREATMENT OF EPILEPSY.
000661 01-11
PRELIMINARY EVALUATION OF THE EFFEaS OF DEPAKINE IN EPILEPSY.
000664 01-11
PYRITINOL ADMINISTRATION AS PART OF EPILEPSY TREATMENT IN
CHILDREN. ,^^^-,, „, ,,
000671 01-11
PREGNANCY AND EPILEPSY: SHOULD ANTICONVULSANT-DRUGS BE
CONTINUED? ^„,-,„n, ,,
000679 01-11
TRANSIENT-EFFEQ OF L TRYPTOPHAN IN PROGRESSIVE MYOCLONUS
EPILEPSY WITHOUT LAFORA-BODIES: CLINICAL-STUDY AND
ELEaROPHYSIOLOGICAL-STUDY. 000694 01-11
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF
ELECTROENCEPHALOGRAPHY WITH INTRAVENOUS DIAZEPAM IN
''^''''' 000696 01-11
MODERN-VIEWS ON THE PRINCIPLES OF THE PHARMACOLOGICAL-
TREATMENT OF EPILEPSY. „„„„o, n, n
000931 01-17
ELECTROENCEPHALOGRAPHIC-EFFECTS AND BEHAVIOURAL-EFFECTS OF
SODIUM-VALPROATE IN PATIENTS WITH PHOTOSENSITIVE EPILEPSY. A
SINGLE-DOSE TRIAL. 002154 02-11
MONOAMINES, EPILEPSY AND SCHIZOPHRENIA.
(X)2 1 8 J UZ" I '
S-172
VOLUME 19, SUBJECT INDEX
Subject Index
SALIVARY IMMUNOGLOBULIN CONCENTRATIONS IN PATIENTS WITH
EPILEPSY TREATED WITH CARBAMAZEPINE,
002234 02-13
METABOLISM OF DIMETHOXYMETHYL-PHENOBARBITAL (ETEROBARB) IN
PATIENTS WITH EPILEPSY
002235 02-13
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY I CHANGES INDUCED BY PHENOBARBITAL OR/AND
DIPHENYLHYDANTOIN IN SERUM LIPIDS,
002281 02-13
THE QUESTION OF MINIMUM-DOSES OF ANTICONVULSANTS IN THE
TREATMENT OF EPILEPSY.
002306 02-13
EPILEPSY: NEUROTRANSMinER, BEHAVIOUR AND PREGNANCY.
002466 02-15
EFFECTS OF D-AMPHETAMINE AND APOMORPHINE IN A NEW ANIMAL-
MODEL OF PETIT-MAL EPILEPSY
002493 02-16
RECENT ADVANCES IN THE TREATMENT OF EPILEPSY.
003307 03-1
A PROSPECTIVE RANDOMISED-TRIAL ON THE EFFECT OF MONITORING
PUSMA ANTICONVULSANT LEVELS IN EPILEPSY.
003314 03-1
EPILEPSY AND CHRONIC CHAGAS-DISEASE.
003328 03-1
NALOXONE AND FOCAL EPILEPSY: A STUDY WITH DEPTH ELECTRODES.
003341 03-1
MONOTHERAPY OR POLYTHERAPY FOR EPILEPSY?
003366 03-1
COMPARISON OF SODIUM-VALPROATE AND PHENYTOIN AS SINGLE
DRUG-TREATMENT IN EPILEPSY.
003371 03-1
EPILEPSY IN ADULTS.
003375 03-1
INTENSIVE MONITORING IN REFRACTORY EPILEPSY.
003378 03-1
DRUG-INTERAQIONS IN EPILEPSY.
003622 03-17
STUDIES ON GAMMA AMINOBUTYRIC-ACID TRANSPORT IN COBALT
EXPERIMENTAL EPILEPSY IN THE RAT.
003990 04-03
THERAPEUTIC PLASMA LEVELS OF SOME ANTICONVULSANTS IN FOCAL
EPILEPSY IN RELATION TO COMPUTERIZED-AXIAL-TOMOGRAPHY.
004439 04-1 1
STOPPING MEDICATION IN CHILDREN WITH EPILEPSY.
004447 04-1 1
INFLUENCE OF CARBAMAZEPINE ON SERUM THYROXINE AND
TRIIODOTHYRONINE IN PATIENTS WITH EPILEPSY.
004488 04-11
CORRECTION OF HORMONAL ACTIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
A CASE OF PETIT-MAL EPILEPSY AGGRAVATED BY LITHIUM.
004641 04-15
THE PROGNOSIS OF EPILEPSY AND THE STRATEGY FOR TERMINATING
ANTIEPILEPTIC THERAPY.
004724 04-17
EPILEPSY-PRONE
EFFECT OF RO-4-1284 ON AUDIOGENIC-SEIZURE SUSCEPTIBILITY AND
INTENSITY IN EPILEPSY-PRONE RATS.
003865 04-03
EPILEPTIC-CHILDREN
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF
ASSESSING COMPLIANCE.
004495 04-11
EPILEPTIC-DISCHARGE
TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC-
DISCHARGE IN HUMANS BY APOMORPHINE, A DOPAMINE-RECEPTOR
AGONIST.
000714 01-11
EPILEPTIC-FOCI
NEURONAL ACTIVITY IN CHRONIC FERRIC-CHLORIDE EPILEPTIC-FOCI IN
CATS AND MONKEY.
000172 01-03
EPILEPTIC-FOCUS
THE EFFECT OF jIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES.
003984 04-03
EPILEPTIC-PATIENTS
CHRONIC ADMINISTRATION OF CANNABIDIOL TO HEALTHY VOLUNTEERS
AND EPILEPTIC-PATIENTS.
000669 01-11
CARBAMAZEPINE INTOXICATION DUE TO TRIACETYLOLEANDOMYCIN
ADMINISTRATION IN EPILEPTIC-PATIENTS.
000873 01-15
DETERMINATION OF DOSE PLASMA CONCENTRATION RELATIONSHIP OF
PHENOBARBITAL IN EPILEPTIC-PATIENTS BY A NEW SPECIFIC
RADIOIMMUNOASSAY.
000902 01-16
VALUE OF SALIVA SAMPLES IN MONITORING CARBAMAZEPINE
CONCENTRATIONS IN EPILEPTIC-PATIENTS.
000903 01-16
CLINICAL-TRIALS OF DEPAKENE (VALPROIC-ACID) COADMINISTERED WITH
OTHER ANTICONVULSANTS IN EPILEPTIC-PATIENTS.
002367 02-14
THE THERAPEUTIC ACTIVITY OF TRYPTOPHAN AND ITS EFFECT ON
SEROTONIN METABOLISM IN EPILEPTIC-PATIENTS.
003289 03-11
ON THE ANTICONVULSANT BLOOD LEVEL IN THERAPY-RESISTANT
EPILEPTIC-PATIENTS.
003300 03-1 1
FACIAL CLEFTS AMONG EPILEPTIC-PATIENTS.
003484 03-15
RESPIRATORY-DISEASE AND NASAL IMMUNOGLOBULIN
CONCENTRATIONS IN PHENYTOIN TREATED EPILEPTIC-PATIENTS.
003486 03-15
QUESTIONS OF DIFFERENTIATED TREATMENT FOR EPILEPTIC-PATIENTS.
003605 03-17
MECHANISM OF VALPROATE PHENOBARBITAL INTERACTION IN EPILEPTIC-
PATIENTS.
004522 04-13
NEUROLOGICAL-COMPLICATIONS DUE TO THE PHARMACOLOGICAL-
TREATMENT OF EPILEPTIC-PATIENTS.
004593 04-15
EPILEPTIC-PSYCHOSES
PATHOMORPHOSIS OF CHRONIC EPILEPTIC-PSYCHOSES.
003209 03-09
EPILEPTIC-SEIZURES
PLASMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE.
000102 01-03
POLYPHARMACY REGIMEN AS AN EXACERBATING RISK IN THERAPY-
RESISTANT EPILEPTIC-SEIZURES AND BEHAVIORAL-DISORDERS.
004720 04-17
EPILEPTIC-SUBJECTS
QUANTITATIVE ASSESSMENT OF SMOOTH-PURSUIT EYE-MOVEMENTS IN
HEALTHY AND EPILEPTIC-SUBJECTS.
002376 02-15
EPILEPTICS
PLASMA HDL CHOLESTEROL AND GROWTH-HORMONE IN EPILEPTICS
TREATED WITH ANTICONVULSANTS.
002260 02-13
BIOCHEMICAL-STUDIES OF HUMAN EPILEPTICS DURING ANTICONVULSANT
THERAPY.
004490 04-11
THE EFFECT OF DIPHENYLHYDANTOIN ON EEG CURVES IN EPILEPTICS.
004494 04-11
EPILEPTIFORM
SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE:
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT.
000095 01-03
ANTIPEROXIDANT PRETREATMENT AND IRON-INDUCED EPILEPTIFORM
DISCHARGES IN THE RAT: EEG AND HISTOPATHOLOGIC STUDIES.
002930 03-03
EPILEPTOGENIC
THE METABOLISM OF 5 HYDROXYTRYPTAMINE IN THE METHIONINE-
SULFOXIMINE EPILEPTOGENIC RAT-BRAIN.
002887 03-03
EPILEPTOGENIC PROPERTIES OF ENFLURANE AND THEIR CLINICAL
INTERPRETATION.
004609 04-15
EPILEPTOGENIC-EFFECT
ANTICONVULSANTS SPECIFIC FOR PETIT-MAL ANTAGONIZE
EPILEPTOGENIC-EFFECT OF LEUCINE-ENKEPHALIN.
000477 01-04
EPILEPTOGENIC-FOCUS
CHOLERA-TOXIN-INDUCED EPILEPTOGENIC-FOCUS - SPECIAL REFERENCE
TO CYCLIC-AMP METABOLISM AND EPILEPTOGENIC-FOCUS.
000522 01-05
ELECTRICAL-ACTIVITY AND NA-K-ATPASE LEVEL IN THE PENICILLIN-
INDUCED EPILEPTOGENIC-FOCUS OF THE RAT-BRAIN-CORTEX, AND THE
EFFECT OF DIAZEPAM.
003070 03-04
EPINEPHRINE
DEPLETION OF EPINEPHRINE IN RAT HYPOTHALAMUS BY RO-4-1284:
INFLUENCE OF PARGYLINE AND HARMALINE.
000100 01-03
RELEASE OF ARACHIDONIC-ACID FROM ADRENAL CHROMAFFIN CELL-
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED
PAPER).
001027 02-01
a.
.'•Uir
IK:
S-173
Subject index
Psychopharmacology Abttracis
pi.
INHIBITORS OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND
EPINEPHRINE BIOSYNTHESIS. 2. 1,2,3,4 TETRAHYDROISOQUINOLINE-7-
S^JLFONANILIDES. 001069 02-02
EPINEPHRINE IS RELEASED FROM HYPOTHALAMUS BY DEPOLARIZING-
AGENTS AND AMPHETAMINE. 001155 02-03
INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE,
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN ^OGS
EFFECTS OF AN EPINEPHRINE SYNTHESIS INHIBITOR. SKF-64139, ON THE
SECRETION OF LUTEINIZING-HORMONE IN OVARIECTOMIZED FEMALE
^^^ 002693 03-03
DIFFERENTIAL-EFFECTS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS. 003947 04-03
EPISODIC-DYSCONTROL-SYNDROME
PRELIMINARY DATA ON ETHOSUXIMIDE AND THE EPISODIC-DYSCONTROL-
5^'^^^°^^ 000539 01-07
^^^OTNCTION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMIHENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL
EQU'^^L^'^" 000490 01-04
^"^^MPHETAMINIL IN THE TREATMENT OF DISTURBED ^'^^'^'^'O'^jTJI'oiz^ 1 1
EXTRAPYRAMIDAL-DISORDERS AND BORDERLINE-SYNDROMES:
EREDOATAXIAS AND DEMENTIA. 003518 03-15
ERGADYL
AHEMPT AT PSYCHOLOGICAL UNDERSTANDING AND TREATMENT OF
PSYCHOLOGICAL ASTHENIA AND ASTHENO-DEPRESSIVE-SYNDROMES
^S"^^^^^^°^^ 001974 02-09
ERGOLINE
CENTRAL DOPAMINERGIC-EFFECTS OF ERGOLINE DERIVATIVES.
002540 02-17
ERGONOMIC
ACTION OF TOFISOPAM ON THE ERGONOMIC VIGILANCE LEVEL. ITS
INTERACTION WITH THE EFFECTS OF ALCOHOL. CLINICAL
PHARMACOLOGICAL-STUDY. ^^^^^ ^^_^^
THE MOLECULAR ARCHITECTURE OF ERGOPEPTINES: A BASIS FOR
BIOLOGICAL-INTERACTION. 001527 02-03
ERGOT
ANORECTIC-EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES IN THE
RAT
000042 01-03
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT
''^^'^^^'^^ 00115602-03
CENTRAL MONOAMINE SYNAPSES AS SITES OF AQION FOR ERGOT
°^^^^ 001238 02-03
THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND
DOPAMINE ANTAGONIST RECEPTOR SITES.
EFFECT OF ERGOT DERIVATIVES ON POSTDECAPITATION CONVULSIONS.
001288 02-03
SELECTIVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS.
001447 02-03
INTERACTION OF DOPAMINERGIC ERGOT DERIVATIVES WITH CYCLIC-
NUCLEOTIDE SYSTEM. „„ ^^ „,
001482 02-03
ERGOT AND CATECHOLAMINE POTENCIES AT CATECHOLAMINE-
«^«"°^^- 001510 02-03
MULTIPLE CNS RECEPTOR INTERAQIONS OF ERGOT ALKALOIDS: AFFINITY
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS.
001516 02-03
ANTIPSYCHOTIC-PROPERTIES AND ANTIDYSKINETIC-PROPERTIES OF
ERGOT DOPAMINE AGONISTS. 002178 02-11
CHARACTERIZATION OF ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLACTIN AND GROWTH-HORMONE PROFILES
DURING WAKEFULNESS AND SLEEP. ^^^^^ ^^^^
NEUROPHARMACOLOGY OF SYNTHETIC ERGOT DERIVATIVES IN MAN^
002429 02-15
DESIGN ASPEaS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS: A
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING- SCALES.
002512 02-16
ERGOT COMPOUNDS: A SYNOPSIS.
002522 02-17
ERGOT DRUGS SUPPRESS PLASMA PROLAQIN AND LACTATION BUT NOT
AGGRESSION IN PARTURIENT MICE.
003159 03-07
SINGLE-CASE STUDY OF CLINICAL-RESPONSE TO HIGH-DOSE ERGOT
ALKALOID TREATMENT FOR DEMENTIA. PRELIMINARY REPORT.
004493 04-11
ERGOTISM
ERGOTISM IN A PSYCHIATRIC ENVIRONMENT ASSOCIATED WITH
ERYTHROMYCIN-DIHYDROERGOTAMINE-PROPIONATE. AN
OBSERVATION.
002379 02-15
ERGOTS
SERUM PROLAQIN DURING AGING AND THE EFFEQS OF ERGOTS.
001171 02-03
ERGOTS IN THE TREATMENT OF MENTAL-DISORDERS OF OLD-AGE.
002545 02-17
REVIEW OF CLINICAL-STUDIES WITH ERGOTS IN GERONTOLOGY.
002624 02-17
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE-
SENSITIVE ADENYUVTE-CYCUkSE IN HOMOGENATES OF CARP RETINA,
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS.
004051 04-03
ERYTHOCYTES
EFFECT OF LITHIUM ON POTASSIUM AND CALCIUM IN SERUM,
ERYTHOCYTES AND IN URINE
002054 02-09
ERYTHROCYTE
THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH
DEPRESSIVE-SYNDROMES.
000625 01-09
INTRA AND EXTRA ERYTHROCYTE LITHIUM-ION CONCENTRATION RATIOS
IN MANIC-PATIENTS.
000627 01-09
EFFEQ OF NEUROLEPTIC-DRUGS ON LITHIUM UPTAKE BY THE HUMAN
ERYTHROCYTE.
000973 01-17
NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTRODUCTION.
002227 02-13
ERYTHROCYTE CHOLINE CONCENTRATIONS ARE ELEVATED IN MANIC-
"''^''*'' 00452104-13
THE AQIVITY OF ERYTHROCYTE CATECHOL-0-METHYLTRANSFERASE IN
ENDOGENOUS DEPRESSIVE-SYNDROMES.
004546 04-13
ERYTHROCYTES „„,.^.,.
CLINICAL-ASPEaS OF LITHIUM EFFLUX FROM ERYTHROCYTES.
002228 02-13
THE DISTRIBUTION OF CHLORPROMAZINE BETWEEN PLASMA AND
ERYTHROCYTES. „„„.„. „o ,^
002496 02-16
CORRELATIONS BETWEEN LITHIUM LEVELS IN CEREBROSPINAL-FLUIO AND
LITHIUM LEVELS IN BLOOD PLASMA AND ERYTHROCYTES.
003210 03-09
A MECHANISM FOR THE ACCUMULATION OF CHOLINE IN ERYTHROCYTES
DURING TREATMENT WITH LITHIUM. 00452O 04
INTERACTION OF CHLORPROMAZINE WITH THE TRANSPORT SYSTEM OF
GLUCOSE IN HUMAN ERYTHROCYTES. ^ ^^
ERYTHROMYCIN-DIHYDROERGOTAMINE-PROPIONATE
ERGOTISM IN A PSYCHIATRIC ENVIRONMENT ASSOCIATED WITH
ERYTHROMYCIN-DIHYDROERGOTAMINE-PROPIONATE. AN
°«5^«^^^'°^ 002379 02-15
ERYTHRO PLASMATIC
CLINICAL SIGNIFICANCE OF THE ERYTHROPLASMATIC RATIO OF LITHIUM^
004357 04-09
ESCAPE
EFFEQS OF APOMORPHINE ON ESCAPE PERFORMANCE AND AQIVITY IN
DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6
O"''^' 000426 01-04
THE EFFECTS OF D-AMPHET AMINE, CHLORDIAZEPOXIDE, AND
PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM
PUNISHMENT IN PIGEONS. (PH.D. DISSERTATION). ^^
EFFEQS OF CHLORPROMAZINE ON ESCAPE AND AVOIDANCE RESPONSES:
\^^°^^^^°°'- 004226 04-04
S-174
VOLUME 19, SUBJECT INDEX
ESCAPE-BEHAVIOR
CHOLINE REVERSES NALOXONE-INDUCED DECREASES IN HIPPOCAMPAL
ACETYLCHOLINE CONTENT AND SUPPRESSES ESCAPE-BEHAVIOR IN
OPIATE-DEPENDENT RATS
004076 04-04
ESERINE
BEHAVIOR-DEPENDENT EVOKED-POTENTIALS IN THE HIPPOCAMPAL-CAl
REGION OF THE RAT. II. EFFECTS OF ESERINE. ATROPINE, ETHER AND
PENTOBARBITAL. „„„,„ „, „^
000184 01-03
ESEROLINE
INHIBITION OF (3H)NAL0X0NE BINDING IN HOMOGENATES OF RAT-
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC ACTIVITY, RELATED
TO PHYSOSTIGMINE. ^^„,„^ „, „,
000104 01-03
ESR
ESR STUDIES OF SPIN LABELLED BOVINE LIVER MONOAMINE-OXIDASE-B.
(UNPUBLISHED PAPER). „„,„,r«o«,
001065 02-01
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE. PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL
GROUPS IN THE ACTIVE SITE. (UNPUBLISHED PAPER).
001066 02-01
ESSENTIALLY
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL.
004620 04-15
ESTERASE
NEUROTOXIC ESTERASE IN HUMAN NERVOUS-TISSUE.
003510 03-15
ESTROGEN
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN.
001167 02-03
MODULATION OF APOMORPHINE-INDUCED STEREOTYPY BY ESTROGEN:
TIME-COURSE AND DOSE-RESPONSE.
001636 02-04
INFLUENCE OF ESTROGEN AND PROGESTERONE ON GLUTAMIC-ACID-
DECAR80XYLASE ACTIVITY IN DISCRETE REGIONS OF RAT-BRAIN.
002927 03-03
ESTROGEN POTENTIATES THE STEREOTYPY INDUCED BY DOPAMINE
AGONISTS IN THE RAT.
002968 03-04
EFFEQS OF NEONATAL TESTOSTERONE AND ESTROGEN ON OPEN-FIELD
BEHAVIOUR IN RATS.
003098 03-04
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN:
NEUROCHEMICAL-STUDIES IN AN ANIMAL-MODEL OF TARDIVE-
DYSKINESIA.
004268 04-05
THE EFFECTS OF ESTROGEN THERAPY ON THE SEX-LIFE OF
POSTMENOPAUSAL-WOMEN .
004573 04-14
ESTROGEN-PRIMED
AnEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED
SPINAL FEMALE RATS WITH MONOAMINE AGONISTS.
000421 01-04
FACILITATION OF LORDOSIS BEHAVIOR IN THE OVARIECTOMIZED
ESTROGEN-PRIMED RAT BY DIBUTYRYL-C-AMP.
002957 03-04
ESTROGENS
BEHAVIORAL-EFFECTS OF ETHYNYL ESTROGENS IN THE FEMALE RAT.
000483 01-04
ANTIDOPAMINERGIC EFFECT OF ESTROGENS AT THE STRIATAL LEVEL.
003789 04-03
ESTROUS-CYCLE
BEHAVIORAL-EFFECTS OF DOPAMINE AGONISTS ACROSS THE ESTROUS-
CYCLE IN RATS.
001792 02-04
ESTROUS-CYCLES
THE EFFEQS OF PROGESTERONE ON THE CIRCADIAN-CYCLES AND
ESTROUS-CYCLES IN THE RAT. (PH.D. DISSERTATION).
001111 02-03
ETEROBARB
METABOLISM OF DIMETHOXYMETHYL-PHENOBARBITAL (ETEROBARB) IN
PATIENTS WITH EPILEPSY.
002235 02-13
ETHANOL
ENHANCEMENT OF RAT-BRAIN METABOLISM OF A TRYPTOPHAN LOAD
BY CHRONIC ETHANOL ADMINISTRATION.
000022 01-03
THE EFFECT OF PROPRANOLOL ON THE ELECTROENCEPHALOGRAM IN
NORMAL AND ETHANOL DEPENDENT RATS.
000126 01-03
INHIBITION OF ALCOHOL-DEHYDROGENASE BY DISULFIRAM; POSSIBLE
RELATION TO THE DISULFIRAM ETHANOL REAQION.
000270 01-03
Subject Index
CARDIOVASCULAR RESPONSE TO THE INTERACTION OF ETHANOL AND
SOME BENZODIAZEPINES IN RATS
000332 01-03
JOINT-EFFECTS OF D-AMPHETAMINE AND ETHANOL OR PENTOBARBITAL
IN PIGEONS.
000403 01-04
IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM
INGESTION OF ETHANOL, TERTIARY BUTANOL, OR PENTOBARBITAL IN
MICE.
000479 01-04
DIFFERENTIAL-EFFECTS ON BENZODIAZEPINE DISPOSITION BY DISULFIRAM
AND ETHANOL.
000789 01-13
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI, OR
ETHANOL DETECTED BY ELECTROPHYSIOLOGICAL-CORRELATES.
001136 02-03
ETHANOL ENHANCES (3H)DIAZEPAM BINDING AT THE BENZODIAZEPINE
GABA-RECEPTOR lONOPHORE COMPLEX
001154 02-03
INTERACTION-STUDIES BETWEEN NARCOTIC ANALGESICS, NARCOTIC
ANTAGONISTS AND ETHANOL; STUDIES DURING ACUTE AND CHRONIC-
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE. (PH.D.
DISSERTATION). •
001165 02-03
INTERACTION STUDIES OF ETHANOL AND PSYCHOTROPIC-DRUGS IN
RODENTS: POSSIBLE INVOLVEMENT OF ADENOSINE-TRIPHOSPHATASES.
001281 02-03
ALPHA-ADRENORECEPTOR MEDIATED ALTERATION OF ETHANOL EFFECTS
ON NA-K-ATPASE OF RAT NEURONAL MEMBRANES.
001425 02-03
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
TOLERANCE TO ETHANOL-INDUCED IMPAIRMENT OF WATER-ESCAPE IN
RATS BRED FOR ETHANOL SENSITIVITY.
001567 02-04
AN INTERFERENCE REDUCTION THEORY OF THE EFFECTS OF ETHANOL ON
CONFLICT-BEHAVIOR.
001586 02-04
ETHANOL-INDUCED ANALGESIA IN RATS SELEQIVELY BRED FOR ETHANOL
SENSITIVITY.
001625 02-04
THE EXCITATORY COMPONENT OF ETHANOL IN MICE: A CHRONIC STUDY.
001712 02-04
ETHANOL AVERSION INDUCED BY PARENTERALLY ADMINISTERED
ETHANOL ACTING BOTH AS CS AND UCS.
001721 02-04
PENTYLENETETRAZOL SEIZURE THRESHOLD: A QUANTITATIVE MEASURE
OF ETHANOL DEPENDENCE IN RATS.
001750 02-04
THE EFFECTS OF ETHANOL, PHENOBARBITAL, AND BACLOFEN ON
ETHANOL WITHDRAWAL IN THE RHESUS-MONKEY.
001802 02-04
AHENUATION OF THE EFFECTS OF PUNISHMENT BY ETHANOL:
COMPARISONS WITH CHLORDIAZEPOXIDE.
001813 02-04
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD
ETHANOL LEVELS IN RATS DRINKING A LIQUID DIET.
001865 02-06
INTERCANNABINOID AND CANNABINOID ETHANOL INTERACTIONS AND
THEIR EFFECTS ON HUMAN PERFORMANCE.
002193 02-12
SHORT-TERM ETHANOL ADMINISTRATION IMPAIRS THE ELIMINATION OF
CHLORDIAZEPOXIDE (LIBRIUM) IN MAN.
002224 02-13
SEX-DIFFERENCES IN THE EFFECTS OF LOW-DOSES OF ETHANOL ON
HUMAN REACTION-TIME.
002361 02-14
ADRENAL-HORMONES AND ETHANOL INGESTION IN C57BL/CRGL AND
C3H/CRGL/2 MICE.
002739 03-03
BIOCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF ACUTE ETHANOL IN
RATS AT DIFFERENT ENVIRONMENTAL TEMPERATURES.
002864 03-03
THE EFFECTS OF OPIATE ANTAGONISTS ON THE DISCRIMINATIVE
STIMULUS PROPERTIES OF ETHANOL.
002947 03-04
EXTENDED SCHEDULE TRANSFER OF ETHANOL DISCRIMINATION.
003087 03-04
PHARMACOPSYCHOLOGICAL INVESTIGATIONS CONCERNING THE
COMBINED EFFECTS OF DIPOTASSIUM-CLORAZEPATE AND ETHANOL.
003456 03-14
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
ETHANOL.
003725 04-03
I
£?!
oellC
.9:
S-175
Subject Index
Psychopharmacology Abstracts
ib'i
EFFECTS OF PENTOBARBITAL AND ETHANOL UPON SINGLE NEURON
ACTIVITY IN THE PRIMARY SOMATOSENSORY CORTEX OF THE RHESUS-
MONKEY.
003755 04-03
INHIBITION OF SYNAPTOSOMAL CALCIUM UPTAKE BY ETHANOL.
003827 04-03
EFFECT OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF
TOLERANCE TO THE HYPNOTIC-EFFECTS OF PENTOBARBITAL. BARBITAL,
AND ETHANOL.
003883 04-03
THE EFFECT OF PRENATAL EXPOSURE TO ETHANOL OR OPIATES ON BRAIN
CATECHOLAMINE ACTIVITY.
003939 04-03
EFFECTS OF ETHANOL ON ACETYLCHOLINE AND ADENOSINE EFFLUX FROM
THE IN VIVO RAT-CEREBRAL-CORTEX.
003969 04-03
EFFECTS OF ETHANOL ADMINISTRATION AND WITHDRAWAL ON
NEUROTRANSMITTER-RECEPTOR SYSTEMS IN C57 MICE.
003979 04-03
THE EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND
ITS WITHDRAWAL ON GAMMA AMINOBUTYRIC-ACID-RECEPTOR
BINDING IN RAT-BRAIN.
004035 04-03
ALTERATIONS IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY
FOLLOWING ACUTE AND CHRONIC ETHANOL TREATMENTS.
004037 04-03
SELECTIVE EFFECT OF ETHANOL ON THE VESTIBULAR NUCLEUS NEURONS
IN THE CAT.
004139 04-04
ETHANOL SEDATIVE HYPNOTIC-INTERACTIONS: IN VITRO STUDIES ON NA-
K-ACTIVATED ADENOSINE-TRIPHOSPHATASE .
004269 04-05
INTRAVENOUS DIAZEPAM AND ORAL ETHANOL INTERACTION.
004552 04-13
HUMAN SOCIAL CONVERSATION: EFFECTS OF ETHANOL, SECOBARBITAL
AND CHLORPROMAZINE.
004582 04-14
ETHANOL-INDUCED
ANTAGONISTIC-EFFECTS OF PROPRANOLOL UPON ETHANOL-INDUCED
NARCOSIS IN MICE
000439 01-04
TOLERANCE TO ETHANOL-INDUCED IMPAIRMENT OF WATER-ESCAPE IN
RATS BRED FOR ETHANOL SENSITIVITY
001567 02-04
ETHANOL-INDUCED ANALGESIA IN RATS SELECTIVELY BRED FOR ETHANOL
SENSITIVITY.
001625 02-04
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE
002242 02-13
ENHANCEMENT OF ETHANOL-INDUCED SEDATION AND HYPOTHERMIA BY
CENTRALLY ADMINISTERED NEUROTENSIN, BETA ENDORPHIN AND
BOMBESIN.
003037 03-04
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED
SEROTONERGIC MECHANISMS
003748 04-03
ETHANOL-INDUCED CHANGES IN CYCLIC-GUANOSINE-PHOSPHATE
METABOLISM IN MOUSE VESTIBULAR REGION.
003784 04-03
ETHER
BEHAVIOR-DEPENDENT EVOKED-POTENTIALS IN THE HIPPOCAMPAL-CAl
REGION OF THE RAT. II. EFFECTS OF ESERINE, ATROPINE, ETHER AND
PENTOBARBITAL.
000184 01-03
DIFFERENTIAL-EFFECTS OF PENTOBARBITAL AND ETHER ON THE SYNAPTIC
TRANSMISSION OF THE HIPPOCAMPAL-CAl -REGION IN THE RAT
003903 04-03
ETHER-STRESSED
LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHALIN PRODUCE OPPOSING
EFFECTS ON PLASMA CORTICOSTERONE LEVELS IN ETHER-STRESSED
MICE.
001245 02-03
ETHOSUXIMIDE
ELEQRON-CAPTURE GAS-LIQUID-CHROMATOGRAPHIC-DETERMINATION
OF ETHOSUXIMIDE AND DESMETHYLMETHSUXIMIDE IN PLASMA OR
SERUM.
000538 01-06
PRELIMINARY DATA ON ETHOSUXIMIDE AND THE EPISODIC-DYSCONTROL-
SYNDROME.
000539 01-07
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
ETHYL-ALCOHOL
OPIATE-RECEPTORS AND SLEEP. II. EFFECTS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUCTAL GRAY MAHER AND NUCLEUS-TRAQUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
ETHYL-BETA-CARBOLINE-CARBOXYLATE
ETHYL-BETA-CARBOLINE-CARBOXYLATE LOWERS SEIZURE THRESHOLD
AND ANTAGONIZES FLURAZEPAM-INDUCED SEDATION IN RATS.
002971 03-04
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE
ETHYL-BETA-CARBOLINE-S-CARBOXYLATE ANTAGONISES THE EFFEQ OF
DIAZEPAM ON A FUNCTIONAL GABA-RECEPTOR.
001378 02-03
THE PROCONVULSANT AND DIAZEPAM REVERSING EFFECTS OF ETHYL-
BETA-CARBOLINE-3-CARBOXYLATE.
001399 02-03
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONIZES DIAZEPAM
ACTIVITY.
002915 03-03
ETHYL-2-PIPERAZINYL-4-PHENYLQUINOLINE-HCL
ANTIDEPRESSANT PROPERTIES OF 2 4 ETHYL-2-PIPERAZINYL-4-
PHENYLQUINOLINE-HCL (AD- 1308) AND ITS MECHANISM-OF-AaiON
AS COMPARED WITH TRICYCLIC-ANTIDEPRESSANTS.
000152 01-03
ETHYLKETOCYCLAZOCINE
HIGH-AFFINITY BINDING OF 3H ETHYLKETOCYCLAZOCINE TO RAT-BRAIN
HOMOGENATE.
000124 01-03
3H ETHYLKETOCYCLAZOCINE BINDING: LACK OF EVIDENCE FOR A
SEPARATE KAPPA-RECEPTOR IN RAT CNS.
000128 01-03
EFFECTS OF CENTRALLY-ADMINISTERED PENTAZOCINE AND
ETHYLKETOCYCLAZOCINE ON THERMOREGULATION IN THE CAT.
000361 01-04
SPECIFIC, HIGH-AFFINITY (3H)ETHYLKET0CYCLAZ0CINE BINDING IN RAT
CENTRAL-NERVOUS-SYSTEM: LACK OF EVIDENCE FOR KAPPA-
RECEPTORS.
003840 04-03
ETHYNYL
BEHAVIORAL-EFFECTS OF ETHYNYL ESTROGENS IN THE FEMALE RAT.
000483 01-04
ETIOLOGY
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFEaS
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES.
000131 01-03
DRUG-VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA:
APPLICATION OF DISCRIMINANT FUNQION ANALYSIS.
000844 01-15
NEUROLEPTIC-INDUCED ELEVATIONS IN SERUM PROLAQIN LEVELS:
ETIOLOGY AND SIGNIFICANCE
003190 03-08
THE TREATMENT AND ETIOLOGY OF TICS AND TOUREHE-SYNOROME
003372 03-11
ETOMIDATE
NEUROPHYSIOLOGICAL-EFFECTS OF ETOMIDATE, A NEW SHORT-AQING
HYPNOTIC.
002263 02-13
ETORPHINE
TIME-COURSE OF ETORPHINE LEVELS IN TISSUES OF OPIATE-TOLERANT
AND NONTOLERANT RATS.
000301 01-03
INCREASED METABOLISM OF DOPAMINE AND SEROTONIN INDUCED IN
FOREBRAIN AREAS BY ETORPHINE MICROINJECTION IN
PERIAQUEDUQAL GRAY.
001103 02-03
BEHAVIOR MAINTAINED BY INTRAVENOUS INJEQION OF CODEINE,
COCAINE AND ETORPHINE IN THE RHESUS-MACAQUE AND THE
PIGTAIL-MACAQUE
001828 02-04
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED
MICE.
002800 03-03
A NEUROANATOMICAL- STUDY OF ANALGESIA AND CATATONIA INDUCED
BY ETORPHINE IN THE RAT. (PH D. DISSERTATION).
003102 03-04
DISCRIMINATIVE-STIMULUS EFFEaS OF ETORPHINE IN RHESUS-
MONKEYS.
004134 04-04
EUROPE
AN OVERVIEW OF SEVENTEEN YEARS OF EXPERIENCE WITH OOTHIEPIN IN
THE TREATMENT OF DEPRESSION IN EUROPE.
001995 02-09
EUROPEAN-BRAIN-AND-BEHAVIOUR-SOCIETY
ABSTRACTS OF THE ANNUAL GENERAL CONFERENCE OF THE EUROPEAN-
BRAIN-AND-BEHAVIOUR-SOCIETY, HELD AT LOUVAIN-LA-NEUVE,
BELGIUM, ON NOVEMBER 13-15TH, 1980.
003617 03-17
S-176
VOLUME 19, SUBJECT INDEX
Subject Index
EVALUATE
THE USE OF CONDITIONED SUPPRESSION TO EVALUATE THE NATURE OF
NEUROLEPTIC-INDUCED AVOIDANCE-DEFICITS.
004070 04-04
EVALUATED
IN VIVO OCCUPATION OF CEREBRAL HISTAMINE HI -RECEPTORS
EVALUATED WITH 3H MEPYRAMINE MAY PREDICT SEDATIVE
PROPERTIES OF PSYCHOTROPIC-DRUGS.
000241 01-03
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
INTERACTIONS BETWEEN NALTREXONE AND NONOPIATE DRUGS
EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
001645 02-04
TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE
FATIGUE STUDY GROUPS NO. 4 CLINICAL-SCALE.
001980 02-09
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN
MAN; POSSIBLE CENTRAL-ACTION IN BRAIN
002195 02-12
STUDY ON THE EFFECTS OF L 5 HTP ON THE STAGES OF SLEEP IN MAN AS
EVALUATED BY USING SLEEP-DEPRIVATION.
003450 03-14
INTERACTIONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
004127 04-04
EVALUATING
CORTICAL-CORRELATES OF VIGILANCE REGULATION AND THEIR USE IN
EVALUATING THE EFFECTS OF TREATMENT.
002147 02-11
EVALUATION
DOUBLE-BLIND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH
AFTfRCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS
WITH SCHIZOPHRENIA.
000574 01-08
A COMPARATIVE EVALUATION OF DOTHIEPIN (PROTHIEDEN) AND
IMIPRAMINE,
000583 01-09
THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH
DEPRESSIVE-SYNDROMES.
000625 01-09
PRELIMINARY EVALUATION OF THE EFFECTS OF DEPAKINE IN EPILEPSY.
000664 01-11
BRAIN FUNCTION IN OLD-AGE: EVALUATION OF CHANGES AND
DISORDERS.
000684 01-11
EVALUATION OF CLORAZEPATE (TRANXENE) AS AN ANTICONVULSANT ~
A PILOT-STUDY.
000728 01-11
EXPERIMENTAL EVALUATION OF ANTIDEPRESSANT ACTIVITY OF
CLOMIPRAMINE, A NEW TRICYCLIC-ANTIDEPRESSANT DRUG.
001068 02-02
NEW EXPERIMENTAL TECHNIQUES IN THE PHARMACOLOGICAL
EVALUATION OF CNS ACTING DRUGS.
001479 02-03
EVALUATION OF THE EFFECT OF DRUGS ON DOPAMINE METABOLISM IN
THE RAT SUPERIOR-CERVICAL-GANGLION BY HPLC WITH
ELECTROCHEMICAL-DETECTION .
001530 02-03
P CHLOROAMPHETAMINE: EVALUATION OF A BRAIN METABOLITE.
001779 02-04
EVALUATION Of THE CLINICAL-EFFICACY OF SINGLE-DAILY-DOSES OF
ANTIDEPRESSANTS.
001985 02-09
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC
DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL
CONTROLS.
002004 02-09
EVALUATION OF SYMPTOMATIC TREATMENT OF HYPERACTIVE-BEHAVIOR
BY STIMULANT-DRUGS.
002134 02-11
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
002219 02-13
DOUBLE-BUND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS.
002314 02-14
AN EVALUATION OF MAPROTILINE INTRAVENOUS KINETICS AND
COMPARISON OF TWO ORAL DOSES.
002497 02-16
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND
GANGLIONIC SYNAPSES.
002870 03-03
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF-
STIMULATION MODEL USING CLONIDINE
003016 03-04
EVALUATION OF THE RELATIVE EFFECTIVENESS OF METHYLPHENIDATE
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF
KINDERGARTEN-AGED HYPERACTIVE-CHILDREN
003306 03-11
ON THE EVALUATION OF A PROVOCATIVE EEG METHOD USING
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUCTION THROUGH
MEDICATION.
003387 03-11
EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED
COGNITIVE ASSESSMENT SYSTEM.
003557 03-16
BIOLOGICAL EVALUATION OF A TRH ANALOGUE WITH A MODIFIED
PROLINE RESIDUE.
003662 04-01
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL
EVALUATION.
003685 04-02
OPIATE MECHANISMS: EVALUATION OF RESEARCH INVOLVING
NEURONAL ACTION POTENTIALS.
003886 04-03
AN EVALUATION OF THE MECHANISM BY WHICH SEROTONERGIC
ACTIVATION DEPRESSES RESPIRATION.
003917 04-03
RELEVANCE OF DOPAMINE-RECEPTOR BINDING STUDIES FOR EVALUATION
OF ANTIPARKINSONIAN-DRUGS.
004120 04-04
NARCOTIC-REINFORCED RESPONDING: A RAPID EVALUATION PROCEDURE.
004253 04-04
A CLINICAL AND PHARMACODYNAMIC EVALUATION OF SULPIRIDE.
004338 04-08
EVALUATION OF LITHIUM RESPONSE: PSYCHOMETRIC-FINDINGS.
004348 04-09
AN EVALUATION OF TRAZODONE IN THE TREATMENT OF DEPRESSION.
004386 04-09
AN EVALUATION OF THE USEFULNESS OF THE ACYLASE TEST IN
NEUROLEPTIC TREATMENT.
004426 04-10
A COMPARATIVE EVALUATION OF THE EFFICACY OF SOME THERAPEUTIC
METHODS USED IN DELIRIUM-TREMENS.
004486 04-1 1
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF
ASSESSING COMPLIANCE.
004495 04-11
A COMPARATIVE EVALUATION OF THE USEFULNESS OF
PSYCHOPHYSIOLOGICAL-TESTS DURING VARIOUS LEVELS OF
ACTIVATION OF THE CENTRAL-NERVOUS-SYSTEM.
004543 04-13
COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPLIED TO DRUG
EVALUATION: MIDAZOLAM IN NORMAL SUBJECTS.
004564 04-14
AN EVALUATION OF THE ANTIANXIETY ACTION AND SIDE-EFFECTS OF
PROPRANOLOL.
004660 04-15
EVALUATIONS
EARLY-ACTIVITY-STUDIES AND INTENSIVE DRUG EVALUATIONS OF NEW
PSYCHOPHARMACOLOGIC-AGENTS .
002348 02-14
EVALUATIONS OF LOXAPINE-SUCCINATE IN THE AMBULATORY
TREATMENT OF ACUTE SCHIZOPHRENIC-EPISODES.
004345 04-08
EVENT-RELATED
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN
MAN: POSSIBLE CENTRAL-ACTION IN BRAIN.
002195 02-12
EVENT-RELATED POTENTIAL CHANGES WITH MORPHINE IN NONADDICTED
HUMANS.
004512 04-13
THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE BRAIN AS AN
OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING
DRUGS.
004669 04-16
EVIDENCE
EVIDENCE FOR AN IRREVERSIBLE INTERACTION OF BROMOCRYPTINE
WITH CENTRAL DOPAMINE-RECEPTORS.
000023 01-03
SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA-
ADRENOCEPTOR ANTAGONISTS: EVIDENCE AGAINST GABA
MEDIATION.
000024 01-03
EVIDENCE FOR A RECEPTOR SUPERSENSITIVITY FOLLOWING IMPAIRMENT
OF CENTRAL SEROTONERGIC ACTIVITY IN THE RABBIT.
000041 01-03
S-1 77
Subject Index
Psychopharmacology Abstracts
3H ETHYLKETOCYCLAZOCINE BINDING: LACK OF EVIDENCE FOR A
SEPARATE KAPPA-RECEPTOR IN RAT CNS.
000128 01-03
EVIDENCE FOR A GABAERGIC NIGROTHAU\MIC PATHWAY IN THE RAT; I.
BEHAVIOURAL-STUDIES AND BIOCHEMICAL-STUDIES.
000158 01-03
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING-
SITES IN RAT STRIATUM.
000186 01-03
EVIDENCE FOR A DIRECT INHIBITORY-EFFECT OF MORPHINE ON THE
SECRETION OF POSTERIOR PITUITARY-HORMONES.
000193 01-03
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE
ACTION.
000229 01-03
THE EFFECT OF MORPHINE ON PURINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX. EVIDENCE FOR A PURINERGIC
COMPONENT IN MORPHINES ACTION.
000234 01-03
EVIDENCE OF A DIRECT ACTION OF ANGIOTENSIN-II ON NEURONES IN THE
SEPTUM AND IN THE MEDIAL PREOPTIC-AREA.
000272 01-03
FUNCTIONAL EVIDENCE FOR SUBSENSITIVITY OF NORADRENERGIC-
ALPHA2-RECEPT0RS AFTER CHRONIC DESIPRAMINE TREATMENT
000283 01-03
EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE
ROLE FOR BETA PHENYLETHYLAMINE IN THE COCAINE CUE
000363 01-04
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL-
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL
SEROTONERGIC FUNCTION.
000491 01-04
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY.
000890 01-15
A STUDY OF ANTIPSYCHOTIC-DRUG USE IN NURSING-HOMES:
EPIDEMIOLOGIC EVIDENCE SUGGESTING MISUSE.
000979 01-17
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE-
ENKEPHALIN AND CHOLECYSTOKININ IN THE NEURAL RETINA OF
SEVERAL VERTEBRATE SPECIES. (UNPUBLISHED PAPER).
001017 02-01
REGULATION OF HIPPOCAMPAL GLUTAMATE-RECEPTORS: EVIDENCE FOR
THE INVOLVEMENT OF A CALCIUM-ACTIVATED PROTEASE.
001120 02-03
RADIOLIGAND BINDING STUDIES: EVIDENCE FOR MULTIPLE DOPAMINE-
RECEPTORS
001186 02-03
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES:
EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION
IN THE ANESTHETIZED CAT.
001203 02-03
PHARMACOLOGICAL EVIDENCE AND BIOCHEMICAL-EVIDENCE FOR AN
INTERACTION BETWEEN THE BENZODIAZEPINE AND GABA-RECEPTORS.
001261 02-03
EVIDENCE SUGGESTING A TRANSMIHER OR NEUROMODULATORY ROLE
FOR SUBSTANCE-P AT THE FIRST SYNAPSE OF THE BARORECEPTOR
REFLEX.
001264 02-03
NO EVIDENCE FOR INCREASED DOPAMINE-RECEPTOR BINDING IN
SUPERRESPONSIVE MICE AFTER A SINGLE-DOSE OF NEUROLEPTICS.
001292 02-03
FURTHER EVIDENCE FOR THE EXISTENCE OF MULTIPLE RECEPTORS FOR
DOPAMINE IN THE CENTRAL-NERVOUS-SYSTEM.
001296 02-03
EVIDENCE FOR AN ENDOGENOUS COMPOUND INTERFERING WITH 3H
DIAZEPAM BINDING TO RAT-BRAIN MEMBRANES.
001308 02-03
EVIDENCE THAT VASOPRESSIN IS INVOLVED IN THE ISOPRENALINE-
INDUCED BETA ENDORPHIN RELEASE.
001319 02-03
DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR
TRANSMIHER IN THE CAT CEREBRAL-ARTERY.
001336 02-03
EFFECTS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC
MECHANISM IN ACTION OF DIAZEPAM.
001414 02-03
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR
THE POTENTIATION OF IMIPRAMINE EFFECTS ON THE METABOLISM
AND UPTAKE OF BRAIN CATECHOLAMINES.
001427 02-03
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE ACTION OF
DIAZEPAM: POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE
ACTION IN THE BRAIN.
001428 02-03
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND
NEUROLEPTIC-RECEPTORS. FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2
DOPAMINE-RECEPTORS IN THE CNS.
001480 02-03
LITHIUM EFFECTS ON HIGH-AFFINITY TRYPTOPHAN UPTAKE: EVIDENCE
AGAINST A STABILIZATION MECHANISM.
001496 02-03
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELEQIVE
5 HT UPTAKE INHIBITOR.
001517 02-03
EVIDENCE THAT NORADRENALINE MODULATES THE INCREASE IN
STRIATAL DOPAMINE METABOLISM INDUCED BY MUSCARINIC-
RECEPTOR STIMULATION.
001518 02-03
Y-MAZE BEHAVIOR AFTER AN ANALOG OF ACTH4-9, EVIDENCE FOR AN
AHENTIONAL-ALTERATION.
001676 02-04
EFFECTS OF BRANCHED-CHAIN FAHY-ACIDS ON GABA DEGRADATION
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI-
MORPHINE ABSTINENCE-BEHAVIOR.
001809 02-04
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A
SELECTIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST.
002236 02-13
CLINICAL EVIDENCE FOR MULTIPLE DOPAMINE-RECEPTORS IN MAN
002264 02-13
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY
AFFECTIVE-ILLNESS.
002506 02-16
EVIDENCE THAT IT IS POSSIBLE TO CAUSE ANOREXIA BY INCREASING
RELEASE AND/OR DIRECTLY STIMULATING POSTSYNAPTIC SEROTONIN-
RECEPTORS IN THE BRAIN.
002602 02-17
THE EFFEa OF ALTERED DOPAMINERGIC-ACTIVITY ON FOOD INTAKE IN
THE RAT: EVIDENCE FOR AN OPTIMAL LEVEL OF DOPAMINERGIC-
ACTIVITY FOR BEHAVIOR.
002632 02-17
BENZODIAZEPINE-RECEPTORS: AUTORADIOGRAPHICAL AND
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN
REGIONS OF GABAERGIC SYNAPTIC CONTAQS.
002643 03-01
PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS
MECHANISMS RESPONSIBLE FOR MOTOR AQ INHIBITION BY AVERSIVE
EVENTS.
002671 03-03
EVIDENCE FOR A TONIC GABAERGIC CONTROL OF SEROTONIN NEURONS
IN THE MEDIAN RAPHE NUCLEUS.
002719 03-03
HISTAMINE AQIONS ON ACTIVITY OF CULTURED HYPOTHALAMIC
NEURONS: EVIDENCE FOR MEDIATION BY HISTAMINE Hl-RECEPTORS
AND H2-RECEPT0RS.
002732 03-03
COMPARATIVE-STUDY ON THE EFFECT OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS: STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS
002757 03-03
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
BEHAVIORAL CONFIRMATION OF DIFFUSE NOXIOUS INHIBITORY
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS
'''^''' 002791 03-03
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF
AMINES INFLUENCING CEREBROSPINAL-FLUID FORMATION
002807 03-03
PHARMACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG.
002889 03-03
THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION
PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR
PRESERVED SCHWANN-CELL SOMAL FUNQION.
002905 03-03
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION.
003052 03-04
EVIDENCE FOR INVOLVEMENT OF SEPARATE MECHANISMS IN THE
PRODUaiON OF ANALGESIA BY ELEaRICAL- STIMULATION OF THE
NUCLEUS-RETICULARIS-PARAGIGANTOCELLULARIS AND NUCLEUS-
RAPHE-MAGNUS IN THE RAT.
003083 03-04
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION. ^^ ^^
003140 03-06
S-178
VOLUME 19, SUBJECT INDEX
Subject Index
CROSS-OVER STUDY Of ZIMELIDINE AND DESIPRAMINE IN DEPRESSION:
EVIDENCE FOR AMINE SPECIFICITY
003250 03-09
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
003256 03-09
PHYSOSTIGMINE IN TOURETTE-SYNDROME: EVIDENCE FOR CHOLINERGIC
UNDERACTIVITY.
003286 03-10
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE
HYPERACTIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN
DEFICIENCY HYPOTHESIS.
003312 03-11
EVIDENCE TO SUPPORT EARLY LEVODOPA THERAPY IN PARKINSON-
DISEASE.
003336 03-11
THE URBAN EPIDEMIC OF PHENCYCLIDINE USE: LABORATORY EVIDENCE
FROM A PUBLIC PSYCHIATRIC-HOSPITAL INPATIENT-SERVICE.
003554 03-16
EVIDENCE FOR THERMOREGULATORY DOPAMINERGIC-RECEPTORS
LOCATED IN THE PREOPTICUS-MEDIALIS-NUCLEUS OF THE RAT
HYPOTHALAMUS.
003754 04-03
SPECIFIC, HIGH-AFFINITY (3H)ETHYLKET0CYCLAZ0CINE BINDING IN RAT
CENTRAL-NERVOUS-SYSTEM: LACK OF EVIDENCE FOR KAPPA-
RECEPTORS.
003840 04-03
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION
BETWEEN ANTICONFUCT AND ANTICONVULSANT PROPERTIES BY PK-
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES).
003898 04-03
OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES:
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES.
003902 04-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR PRESYNAPTIC ACTIONS OF
PHENCYCLIDINE ON NORADRENERGIC TRANSMISSION IN RAT
CEREBELLUM.
003926 04-03
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC-
AMP.
003952 04-03
CLONIDINE AND THE PRIMATE LOCUS-COERULEUS: EVIDENCE SUGGESTING
ANXIOLYTIC AND ANTIWITHDRAWAL EFFECTS. (UNPUBLISHED PAPER).
003982 04-03
CNS EFFECTS OF CHOLINE ADMINISTRATION: EVIDENCE FOR TEMPORAL
DEPENDENCE.
003996 04-03
EVIDENCE THAT THERE ARE SUBCELLULAR POOLS OF NOREPINEPHRINE
AND THAT THERE IS FLUX OF NOREPINEPHRINE BETWEEN THESE
POOLS.
004004 04-03
IN VIVO EVIDENCE FOR GABAERGIC CONTROL OF SEROTONIN RELEASE IN
THE CAT SUBSTANTIA-NIGRA.
00401 1 04-03
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-03
ROTATIONAL-BEHAVIOUR ELICITED BY 5 HT IN THE RAT: EVIDENCE FOR
AN INHIBITORY ROLE OF 5 HT IN THE SUBSTANTIA-NIGRA AND
CORPUS-STRIATUM.
004141 04-04
EVIDENCE FOR SEDATIVE EFFECTS OF LOW-DOSES OF MORPHINE IN MICE
INVOLVING RECEPTORS INSENSITIVE TO NALOXONE.
004173 04-04
CLONIDINE-INDUCED HYPERPHAGIA IN MONKEYS: EVIDENCE FOR
ALPHA2-N0RADRENERGIC-RECEPT0R MEDIATION .
004215 04-04
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
(UNPUBLISHED PAPER).
004401 04-09
MINI-SYMPOSIUM. IV. DISCRIMINATIVE-STIMULUS EFFECTS OF
NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS.
004719 04-17
EVIL
MEDICATION: A NECESSARY EVIL?
002549 02-17
EVOKE
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
EVOKED
SUPPRESSION OF EVOKED AND SPONTANEOUS RELEASE OF
NEUROTRANSMITTERS IN VIVO BY MORPHINE.
000058 01-03
PRESSURE REVERSAL OF THE EFFECT OF URETHANE ON THE EVOKED
SOMATOSENSORY CORTICAL RESPONSE IN THE RAT.
001106 02-03
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELECTRICAL-
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL
SLICES.
001130 02-03
SUBSTANCE-P, MORPHINE AND METHIONINE-ENKEPHALIN: EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE NUCLEUS-
RETICULARIS-GIGANTOCELLULARIS OF THE RAT.
001267 02-03
EFFECTS OF ELECTROLYTIC AND 6 HYDROXYDOPAMINE LESIONS OF THE
LATERAL HYPOTHALAMUS ON ROTATION EVOKED BY ELECTRICAL-
STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.
003081 03-04
INCREASE OF C-GMP AND ACCUMULATION OF 45CA2 EVOKED BY DRUGS
ACTING ON SODIUM OR POTASSIUM CHANNELS.
003709 04-03
DIFFERENTIAL TOLERANCE TO THE EFFECTS OF MORPHINE ON EVOKED
ACTIVITY IN THE HIPPOCAMPAL SLICE.
003760 04-03
MORPHINE AND METHIONINE-ENKEPHALIN: DIFFERENT EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE
MESENCEPHALIC RETICULAR FORMATION OF THE RAT.
003849 04-03
INVESTIGATION OF ACTION OF ENKEPHALIN ON THE SPONTANEOUS AND
EVOKED RELEASE OF ACETYLCHOLINE FROM RAT CORTICAL AND
STRIATAL SLICES.
003862 04-03
INFLUENCE OF CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5
HYDROXYTRYPTAMINE, TYRAMINE AND POTASSIUM FROM GOAT
PIAL-ARTERIES.
003925 04-03
EVOKED-POTENTIAL
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE
CAT. (PH.D. DISSERTATION),
001179 02-03
EVOKED-POTENTIAL STUDIES OF PORCINE CALCITONIN IN RABBITS.
002936 03-03
CEREBRAL EVOKED-POTENTIAL CHANGES PRODUCED BY TREATMENT
WITH LITHIUM-CARBONATE.
003263 03-09
EVOKED-POTENTIALS
BEHAVIOR-DEPENDENT EVOKED-POTENTIALS IN THE HIPPOCAMPAL-CAl
REGION OF THE RAT. II. EFFECTS OF ESERINE, ATROPINE, ETHER AND
PENTOBARBITAL.
000184 01-03
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS.
000509 01-05
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL
EVOKED-POTENTIALS.
000763 01-13
EFFECTS OF MORPHINE ON EVOKED-POTENTIALS RECORDED FROM THE
AMYGDALA BY TOOTH-PULP STIMULATION IN CATS.
001379 02-03
EFFECT OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND
NORMAL ADULTS.
002222 02-13
EFFECTS OF LITHIUM ON EVOKED-POTENTIALS AND PERFORMANCE
DURING SUSTAINED AHENTION.
002419 02-15
MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJECTIONS OF
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS.
003101 03-04
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
CORTICAL EVOKED-POTENTIALS IN GILLES-DE-LA-TOURETTES-SYNDROME
- A SINGLE CASE-STUDY.
003431 03-13
ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN AHENTION-
DYSFUNCTION TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA.
004316 04-08
APOMORPHINE, HALOPERIDOL AND THE AVERAGE EVOKED-POTENTIALS
IN NORMAL HUMAN VOLUNTEERS.
004549 04-13
EVOKED-RESPONSE
THE BRAINSTEM AUDITORY EVOKED-RESPONSE AS A TOOL IN
NEUROBEHAVIORAL TOXICOLOGY AND MEDICINE.
004277 04-05
a.
3f:
•UBI,"
iU..
S-179
Subject Index
Psychopharmacology Abstracts
EVOKED-RESPONSES
MORPHINE AND ELECTROACUPUNCTURE: COMPARISON OF THE EFFECTS
ON THE CORTICAL EVOKED-RESPONSES AFTER TOOTH-PULP
STIMULATION IN RATS.
001294 02-03
AUDITORY BRAINSTEM EVOKED-RESPONSES IN HOSPITALIZED-PATIENTS
UNDERGOING DRUG-TREATMENT OR ECT.
003430 03-13
THE EFFECT OF CHOLINERGIC SUBSTANCES ON NOCICEPTIVE EVOKED-
RESPONSES IN SPECIFIC NUCLEI OF THE THALAMUS.
003770 04-03
THE EFFECT OF NOOTROPIL ON THE TRANSCALLOSAL AND PRIMARY
EVOKED-RESPONSES OF THE CAT CEREBRAL-CORTEX.
003780 04-03
EVOLUTION
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT;
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL
EVOLUTION.
002165 02-11
MINI-SYMPOSIUM: II. MULTIPLE OPIOID-RECEPTORS. A LIHLE ABOUT
THEIR HISTORY AND SOME IMPLICATIONS RELATED TO EVOLUTION.
004728 04-17
EVOLVING
MANIA: AN EVOLVING CONCEPT.
001966 02-09
EXACERBATE
DO STIMULANTS PROVOKE, CAUSE, OR EXACERBATE TICS AND
TOURETTE-SYNDROME?
004485 04-11
EXACERBATES
PYRAZOLE EXACERBATES HANDLING-INDUCED CONVULSIONS IN MICE.
004094 04-04
EXACERBATING
POLYPHARMACY REGIMEN AS AN EXACERBATING RISK IN THERAPY-
RESISTANT EPILEPTIC-SEIZURES AND BEHAVIORAL-DISORDERS.
004720 04-17
EXACERBATION
A NEW DRUG-TREATMENT FOR PREMENSTRUAL EXACERBATION OF
SCHIZOPHRENIA.
000553 01-08
EXAMINATION
THE EFFECT OF BETADRENOL ON EXAMINATION ANXIETY.
000650 01-10
AN EXAMINATION OF FACTORS INFLUENCING ADRENERGIC
ll I TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO
dl I NORADRENALINE UPTAKE MECHANISMS AND POSTJUNCTIONAL
ALPHA-ADRENOCEPTORS.
«; ; 001196 02-03
*' NONCOOPERATION: AN EXAMINATION OF FACTORS LEADING TO
ISlii ' NONCOMPLIANCE IN A HYPERTENSION CLINIC.
Hb 1 002557 02-17
*W ! OXIDATION OF BETA PHENYLETHYLAMINE BY BOTH TYPES OF
Wll ; MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND
Iff LIVER MITOCHONDRIA OF EIGHT SPECIES.
Z2' 004024 04-03
EXCESSES
PSYCHOMOTOR STIMULANTS AS ACTIVATORS OF NQRMAL AND
PATHOLOGICAL-BEHAVIOR: IMPLICATIONS FOR THE EXCESSES IN
MANIA. (UNPUBLISHED PAPER).
002353 02-14
EXCESSIVE
SYSTEMIC AND INTRAVENTRICULAR PROLACTIN INDUCES EXCESSIVE
GROOMING.
000378 01-04
INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS.
002341 02-14
EXCESSIVE PLASMA CONCENTRATIONS OF TRICYCLIC-ANTIDEPRESSANTS
RESULTING FROM USUAL DOSES: A REPORT OF SIX CASES.
003479 03-15
EXCITABILITY
DIFFERENTIAL-EFFECTS OF COCAINE ON LIMBIC EXCITABILITY.
001339 02-03
SUBACUTE CANNABINOID TREATMENT: ANTICONVULSANT ACTIVITY AND
WITHDRAWAL EXCITABILITY IN MICE.
001671 02-04
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND
DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY
OF ADULT SENSORY GANGLION CELLS.
002692 03-03
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS
INVOLVED IN THE HIPPOCAMPUS OF RABBITS.
003842 04-03
THE EFFECT OF PSYCHOSTIMULANTS ON CHANGES IN THE EXCITABILITY
OF THE VISUAL CEREBRAL-CORTEX.
003919 04-03
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES
003984 04-03
EXCITANT
PHARMACOLOGICAL ANTAGONISTS OF EXCITANT AMINO-ACID AQION,
003587 03-17
BACLOFEN: STEREOSELECTIVE INHIBITION OF EXCITANT AMINO-ACID
RELEASE.
003867 04-03
EXCITATION
THE STEREOSPECIFIC EFFECT OF NALOXONE ON RAT DORSAL-HORN
NEURONES, INHIBITION IN SUPERFICIAL LAMINAE AND EXCITATION IN
DEEPER LAMINAE.
001226 02-03
INTRINSIC CHOLINERGIC EXCITATION IN THE RAT NEOSTRIATUM:
NICOTINIC AND MUSCARINIC-RECEPTORS.
001374 02-03
THE EFFECTS OF 5 HT UPTAKE AND MAO-INHIBITORS ON L 5 HTP-
INDUCED EXCITATION IN RATS.
001740 02-04
POTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3-
HYDROXYASPARTATE.
002768 03-03
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS:
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE.
003778 04-03
INSEPARABILITY OF ACETYLCHOLINESTERASE AND NERVE EXCITATION.
003875 04-03
SEX, PLASMA PROLACTIN AND PLASMA 3 METHOXY-4-
HYDROXYPHENYLGLYCOL (MHPG) PREDICT HERITABLE D-
AMPHETAMINE EXCITATION IN MAN. (UNPUBLISHED PAPER).
004565 04-14
EXCITATORY
EXCITATORY AND INHIBITORY-EFFECTS OF OPIATES IN THE RAT VAS-
DEFERENS: A DUAL-MECHANISM OF OPIATE ACTION.
000143 01-03
OPIATE-RECEPTORS MAY MEDIATE THE SUPPRESSIVE BUT NOT THE
EXCITATORY ACTION OF ACTH ON MOTOR-AQIVITY IN RATS.
000337 01-04
CENTRAL EXCITATORY ACTIONS OF FLURAZEPAM.
000526 01-05
EXCITATORY ACTION OF OPIOID-PEPTIDES AND OPIATES ON CULTURED
HIPPOCAMPAL PYRAMIDAL CELLS.
001241 02-03
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN
IN VIVO EFFEQ OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS,
AND BENZODIAZEPINES
001303 02-03
5 METHOXYDIMETHYLTRYPT AMINE: SPINAL-CORD AND BRAINSTEM
MEDIATION OF EXCITATORY EFFEQS ON ACOUSTIC STARTLE
001605 02-04
THE EXCITATORY COMPONENT OF ETHANOL IN MICE: A CHRONIC STUDY.
001712 02-04
THE EXCITATORY ACTION OF ACETYLCHOLINE ON HIPPOCAMPAL
NEURONES OF THE GUINEA-PIG AND RAT MAINTAINED IN VITRO.
002704 03-03
EFFECT OF ANTICONVULSANT-DRUGS ON INHIBITORY AND EXCITATORY
PATHWAYS
002724 03-03
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE
AND CROSS-TOLERANCE TO THE INHIBITORY AQION OF BETA
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS.
002756 03-03
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND
EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES.
002799 03-03
EXCITATORY AND INHIBITORY-ACTIONS OF IBOTENIC-ACID ON FROG
SPINAL MOTONEURONES IN VITRO.
002841 03-03
EXCITATORY AMINO-ACID TRANSMIHERS.
003648 03-17
EXCITATORY EFFEQS OF DIHYDROCAPSAICIN ON NOCICEPTIVE NEURONS
IN THE MEDIAL THALAMUS.
003714 04-03
EFFECTS OF BARBITURATES ON INHIBITORY AND EXCITATORY RESPONSES
TO APPLIED NEUROTRANSMIHERS IN APLYSIA.
003762 04-03
THE EXCITATORY EFFECT OF ATROPINE ON THE NEURONS OF THE FROG
SYMPATHETIC GANGLIA.
004041 04-03
EXCITEMENT
PSYCHOTIC EXCITEMENT IN MEDICAL-EMERGENCIES.
004480 04-11
EXCRETION
OXAZEPAM-ESTERS. 2. CORRELATION OF HYDROPHOBICITY WITH SERUM
BINDING, BRAIN PENETRATION, AND EXCRETION.
000011 01-02
INCREASED URINARY EXCRETION OF CATECHOLAMINES AND THEIR
METABOLITES IN STREPTOZOTOCIN DIABETIC RAT.
000154 01-03
S-180
VOLUME 19, SUBJECT INDEX
Subject Index
DISTRIBUTION AND EXCRETION IN THE RAT AND MONKEY OF (82BR)
BROMOCRIPTINE.
000196 01-03
VARIATIONS IN URINARY EXCRETION OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN DEPRESSIVE-CONDITIONS
002013 02-09
SUBTYPES OF DEPRESSION BASED ON EXCRETION OF MHPG AND
RESPONSE TO NORTRIPTYLINE.
002488 02-16
EXCRETION OF NORTRIPTYLINE INTO SALIVA.
003435 03-13
HYPERVENTILATION-SYNDROME, TREATMENT WITH L TRYPTOPHAN AND
PYRIOOXINE, PREDICTIVE VALUES OF XANTHURENIC-ACID EXCRETION,
004456 04-11
CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND
NATURAL SETTINGS: CORRELATIONAL AND VARIANCE COMPONENTS
ANALYSES.
004508 04-13
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
004600 04-15
EXECUTION
SELECTIVE EFFECTS OF BARBITURATE AND AMPHETAMINE ON
INFORMATION-PROCESSING AND RESPONSE EXECUTION.
004563 04-14
EXERCISE
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS.
001242 02-03
THE SPECIFIC ACTIVITY OF PLATELET MONOAMINE-OXIDASE VARIES
WITH PLATELET COUNT DURING SEVERE EXERCISE AND
NORADRENALINE INFUSION.
004509 04-13
EXERTS
MORPHINE EXERTS TESTOSTERONE-LIKE EFFECTS IN THE HYPOTHALAMUS
OF THE CASTRATED MALE RAT.
000051 01-03
EXHIBITIONISM
THE EFFECT OF ASSERTIVENESS TRAINING, PROVERA AND SEX OF
THERAPIST IN THE TREATMENT OF GENITAL EXHIBITIONISM.
000697 01-11
EXISTENCE
FURTHER EVIDENCE FOR THE EXISTENCE OF MULTIPLE RECEPTORS FOR
DOPAMINE IN THE CENTRAL-NERVOUS-SYSTEM.
001296 02-03
EXOGENOUS
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES.
000202 01-03
EXOGENOUSLY-INDUCED
ENDORPHIN-INDUCED HYPERTHERMIA: CHARACTERIZATION OF THE
EXOGENOUSLY-INDUCED AND ENDOGENOUSLY-INDUCED EFFECTS.
000029 01-03
EXOSECRETORY
THE EFFECT OF SEROTONIN ON THE EXOSECRETORY ACTION OF THE
PANCREAS.
004043 04-03
EXPERIENCE
PLASMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE.
000102 01-03
PRIOR AND ONGOING EXPERIENCE AS DETERMINANTS OF THE EFFECTS OF
D-AMPHETAMINE AND CHLORPROMAZINE ON PUNISHED-BEHAVIOR.
000339 01-04
OUR EXPERIENCE WITH PIRACETAM (NOOTROPIL-UCB) TREATMENT IN
CHILDREN FROM HIGH-RISK PREGNANCIES WITH SUBSEQUENT
MINIMAL-BRAIN-DYSFUNCTION.
000544 01-07
OXYPROTHEPIN-DECANOATE INJECTIONS: EXPERIENCE WITH A LONG-
TERM-TREATMENT OF SCHIZOPHRENIC-PSYCHOSES.
000576 01-08
OUR EXPERIENCE WITH MAPROTILIN TREATMENT OF DEPRESSIVE- STATES.
000623 01-09
OUR EXPERIENCE WITH TOFISOPAM (GRANDAXIN-EGYPT).
000647 01-10
EXPERIENCE WITH FLUSPIRILENE IN GERONTOPSYCHIATRY.
000691 01-11
TWENTY YEARS CLINICAL THERAPEUTIC EXPERIENCE WITH CALCIUM
GLUTAMATES EFFICACY.
000963 01-17
INTERRELATIONS AMONG PRIOR EXPERIENCE AND CURRENT CONDITIONS
IN THE DETERMINATION OF BEHAVIOR AND THE EFFECTS OF DRUGS.
001715 02-04
EXPERIENCE WITH OXYPROTHEPINE-DECANOATE IN THE MAINTENANCE-
THERAPY OF SCHIZOPHRENIA.
001925 02-08
AN OVERVIEW OF SEVENTEEN YEARS OF EXPERIENCE WITH DOTHIEPIN IN
THE TREATMENT OF DEPRESSION IN EUROPE.
001995 02-09
OUR FIRST EXPERIENCE WITH CLOMIPRAMINE
002008 02-09
TWELVE YEARS EXPERIENCE WITH THE TOTAL USE OF DEPOT
NEUROLEPTICS IN A DEFINED POPULATION.
002544 02-17
CONSIDERATIONS ON LONG-ACTING CHEMOTHERAPY: AN EXPERIENCE
WITH FLUPHENAZINE-DECANOATE
003173 03-08
EXPERIENCE IN USING THE HORMONES OF THE HYPOPHYSIS POSTERIOR
LOBE IN MEMORY-DISTURBANCES OF VARYING GENESES
003438 03-14
DRUG DEPENDENCE: REFLECTIONS ON AND ANALYSIS OF AN EXPERIENCE
IN THE PROVINCE OF RIGGIO-EMILIA
003591 03-17
CLINICAL AND PRECLINICAL EXPERIENCE WITH CHOLINE-CHLORIDE IN
HUNTINGTONS-DISEASE AND TARDIVE-DYSKINESIA: UNANSWERED
QUESTIONS.
004604 04-15
EXPERIENCED
NEUROLEPTIC TREATMENT AS EXPERIENCED BY A PSYCHIATRIST.
004613 04-15
EXPERIENCES
FURTHER EXPERIENCES WITH LOW-DOSES OF BROMOCRIPTINE IN
PARKINSONS-DISEASE
002401 02-15
EXPERIMENT
PLASMA CHLORPROMAZINE SERUM PROLACTIN RELATIONSHIP IN A
SINGLE-DOSE EXPERIMENT.
000761 01-13
COMPARATIVE EXPERIMENT OF THE ANTIDEPRESSANT EFFECTS OF
AMINEPTINE AND CHLORIMIPRAMINE.
002029 02-09
DOUBLE-BUND CONTROLLED EXPERIMENT: AMINEPTINE VERSUS
AMITRIPTYLINE USING THE HAMILTON-DEPRESSION-RATING-SCALE.
002050 02-09
EXPERIMENTAL
THE PARADOXICAL-EFFECT OF LIDOCAINE ON AN EXPERIMENTAL MODEL
OF EPILEPSY.
000039 01-03
INFLUENCE OF PYRITHIOXINE ON EXPERIMENTAL HYPOXIA IN RATS.
000077 01-03
PHENYLACETATE AND BRAIN-DYSFUNCTION IN EXPERIMENTAL
PHENYLKETONURIA: SYNAPTIC DEVELOPMENT.
000191 01-03
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE-
BEHAVIOR: INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON
THREE EXPERIMENTAL MODELS.
000340 01-04
PHENYLACETATE AND THE ENDURING BEHAVIORAL-DEFICIT IN
EXPERIMENTAL PHENYLKETONURIA.
000388 01-04
ANTAGONISM BY CLASSICAL ANTIEPILEPTICS AND SODIUM-VALPROATE
OF CEFAZOLIN-INDUCED EXPERIMENTAL EPILEPSY IN RATS.
000442 01-04
EXPERIMENTAL DYSTONIA INDUCED BY QUATERNARY
CHLORPROMAZINE.
000461 01-04
ASSESSMENT OF ADRENERGIC-RECEPTORS IN VIVO IN EXPERIMENTAL
ANIMALS AND MAN. (UNPUBLISHED PAPER).
001034 02-01
EXPERIMENTAL EVALUATION OF ANTIDEPRESSANT ACTIVITY OF
CLOMIPRAMINE, A NEW TRICYCLIC-ANTIDEPRESSANT DRUG.
001068 02-02
AMOXAPINE IN EXPERIMENTAL PSYCHOPHARMACOLOGY: A
NEUROLEPTIC OR AN ANTIDEPRESSANT?
001070 02-02
SOME PHARMACOLOGICAL-ASPECTS AND BIOCHEMICAL-ASPECTS OF
TRH: EXPERIMENTAL AND CLINICAL DATA.
001189 02-03
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH LEWIS-RAT LYMPH-NODE CELLS. (UNPUBLISHED PAPER).
001434 02-03
NEW EXPERIMENTAL TECHNIQUES IN THE PHARMACOLOGICAL
EVALUATION OF CNS ACTING DRUGS.
001479 02-03
EFFECTS OF EXPERIMENTAL HYPOTHYROIDISM ON LEARNING IN RATS.
001587 02-04
GENETIC AND EXPERIMENTAL FACTORS AFFECTING THE PARADOXICAL-
EFFECTS OF AMPHETAMINE IN DOGS.
001704 02-04
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE
DEVELOPMENT OF DEPENDENCE IN RATS.
001800 02-04
IX
iiir
S1..JI
I
£&:
5S'
S-181
Subject Index
Ptychopharmacology Abstracts
CENTRAL SEROTONIN-RECEPTOR SENSITIVITY IN RATS WITH
EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS.
001821 02-04
EFFECTS OF CAFFEINE ADMINISTRATION ON FOOD AND WATER
CONSUMPTION UNDER VARIOUS EXPERIMENTAL CONDITIONS.
003049 03-04
PHARMACOLOGIC AND THERAPEUTIC-PERSPECTIVES ON DEMENTIA: AN
EXPERIMENTAL APPROACH.
003065 03-04
BEHAVIORAL-TEST FOR DETECTION OF SUBCLINICAL BRAIN-DAMAGE: AN
EXPERIMENTAL MODEL.
003120 03-04
PLJ^CEBO-EFFECT: FROM CONTROL TO EXPERIMENTAL CONDITION.
003195 03-08
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH.
003882 04-03
STUDIES ON GAMMA AMINOBUTYRIC-ACID TRANSPORT IN COBALT
EXPERIMENTAL EPILEPSY IN THE RAT.
003990 04-03
CONDITIONED DRUG-EFFECTS OF D-AMPHETAMINE-INDUCED AND
MORPHINE-INDUCED MOTOR ACCELERATION IN MICE: EXPERIMENTAL
APPROACH FOR PLACEBO-EFFECT.
004128 04-04
ANALGESIC AND OTHER PHARMACOLOGICAL ACTIVITIES OF A NEW
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3
METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS
ENANTIOMORPH IN EXPERIMENTAL ANIMALS.
004185 04-04
EXPERIMENTAL-EFFECTS
SOME EXPERIMENTAL-EFFECTS WITH TRAZODONE.
000105 01-03
EXPERIMENTAL-STUDIES
COMPARISON OF CLONAZEPAM AND DIAZEPAM IN EXPERIMENTAL-
STUDIES.
001815 02-04
EXPERIMENTAL- STUDIES ON HEPATOTOXICITY OF DISULFIRAM.
001844 02-05
EXPERIMENTAL-STUDIES ON L-DOPA-INDUCED DYSKINESIA.
003129 03-05
EXPERIMENTAL-STUDY
PHENOBARBITONE AND SODIUM-VALPROATE INTERACTION: AN
EXPERIMENTAL-STUDY.
001371 02-03
AN EXPERIMENTAL-STUDY OF THE NEUROTROPIC-ACTION OF LITHIUM-
OXYBUTYRATE.
001705 02-04
THE COMPLEX SPECIFIC PATHOGENETIC THERAPY OF THE STEREOTYPIC-
BEHAVIOR-SYNDROME (AN EXPERIMENTAL- STUDY).
004162 04-04
EXPERIMENTALLY
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH
ANTIDEPRESSANTS.
001620 02-04
CAN THE ANTIDEPRESSIVE PROPERTIES OF LITHIUM BE DETERMINED
EXPERIMENTALLY?
003089 03-04
EXPERIMENTALLY-INDUCED
SUPERSENSITIVITY TO APOMORPHINE IN EXPERIMENTALLY-iNDUCED
HYPOKINESIA AND DRUG-INDUCED MODIFICATIONS OF W
APOMORPHINE RESPONSE
001814 02-04
EXPERIMENTATION
EXPERIMENTATION WITH MINAPRINE IN DEALING WITH CERTAIN
SEXUAL-DISORDERS: IMPOTENCE OR FRIGIDITY.
002153 02-11
EXPERIMENTATION WITH MINAPRINE IN CHILD-PSYCHIATRY.
002344 02-14
EXPERIMENTER
EFFECTS OF EXPERIMENTER AND TEST LOCATION NOVELTY ON
NONSPECIFIC ACTIVITY IN RATS AND ITS MODIFICATION BY
METHAMPHETAMINE.
000409 01-04
EXPERIMENTS
A MICROCOMPUTER SYSTEM FOR THE CONTROL OF BEHAVIORAL
EXPERIMENTS.
004287 04-06
EXPLORATION
MESOLIMBICOCORTICAL DOPAMINE TERMINAL-FIELDS ARE NECESSARY
FOR NORMAL LOCOMOTOR AND INVESTIGATORY EXPLORATION IN
RATS.
000383 01-04
EXPLORATION AND MOTOR-AQIVITY AFTER INTRAVENTRICULAR ACTH,
MORPHINE AND NALOXONE.
002991 03-04
SAME OR DIFFERENT? AN EXPLORATION OF THE BEHAVIORAL-EFFECTS OF
BENZAMIDES.
004207 04-04
EXPLORATORY-AaiVITY
TRICYCLIC-ANTIDEPRESSANT DRUGS AND INDIVIDUAL DIFFERENCES IN
THE EXPLORATORY-ACTIVITY OF RATS: CONTRASTING-EFFEaS OF
TERTIARY AND SECONDARY AMINE COMPOUNDS
000401 01-04
NALOXONE REDUCES SOCIAL-ACTIVITY AND EXPLORATORY-AQIVITY IN
THE RAT.
001617 02-04
EFFEQ OF BROMOCRIPTINE ON EXPLORATORY-AaiVITY, BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS.
001635 02-04
IMIPRAMINE NORMALIZES NATURALLY OCCURRING AND DRUG-INDUCED
DIFFERENCES IN THE EXPLORATORY-AaiVITY OF RATS.
001646 02-04
EXPLORATORY-BEHAVIOR
BIPHASIC-EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON
EXPLORATORY-BEHAVIOR IN MICE.
001808 02-04
INTERACTION BETWEEN PURINE AND BENZODIAZEPINE: INOSINE
REVERSES DIAZEPAM-INDUCED STIMULATION OF MOUSE
EXPLORATORY-BEHAVIOR
002972 03-04
EFFECTS OF SCOPOLAMINE, PILOCARPINE, AND OXOTREMORINE ON THE
EXPLORATORY-BEHAVIOR OF TWO PSYCHOGENETICALLY SELEQED
LINES OF RATS IN A COMPLEX MAZE.
003042 03-04
EXPLORATORY-BEHAVIOUR
COMPARISON OF THE EFFECTS OF BETA ENDORPHIN AND MORPHINE ON
EXPLORATORY-BEHAVIOUR AND SOCIOSEXUAL-BEHAVIOUR IN THE
MALE RAT.
004178 04-04
EXPLORE
BENZODIAZEPINES: A TOOL TO EXPLORE THE BIOCHEMICAL-BASIS AND
NEUROPHYSIOLOGICAL-BASIS OF ANXIETY.
000397 01-04
EXPLOSIVE
HEROIN, BUT NOT LEVORPHANOL, PRODUCES EXPLOSIVE MOTOR-
BEHAVIOR IN NALOXONE TREATED RATS.
001579 02-04
EXPOSED
PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFEQS OF
GANGLIONIC AND ADRENORECEPTOR BLOCKADE
002863 03-03
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION
004034 04-03
EXPOSURE
LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN
MICE.
000287 01-03
DELAYED MAZE-LEARNING IN RATS AFTER PRENATAL EXPOSURE TO
CLORAZEPATE.
000521 01-05
EFFECTS OF LEAD EXPOSURE DURING DEVELOPMENT ON NEOCORTICAL
DENDRITIC AND SYNAPTIC STRUQURE.
000525 01-05
GLIAL CELL EFFEQS OF SUBACUTE FORMIC-ACID VAPOUR EXPOSURE.
000527 01-05
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN.
001167 02-03
EXPOSURE OF MITOCHONDRIAL OUTER MEMBRANES TO NEURAMINIDASE
SELECTIVELY DESTROYS MONOAMINE-OXIDASE-A AQIVITY.
001286 02-03
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFEQS ON
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT.
001580 02-04
ENHANCED LATERAL HYPOTHALAMIC SELF-STIMULATION RESPONDING
AFTER CHRONIC EXPOSURE TO AMPHETAMINE.
001688 02-04
THE DEVELOPMENT OF PROGENY IN CASES OF ANTENATAL EXPOSURE TO
PHENAZEPAM.
001854 02-05
DIFFERENTIAL-EFFECTS OF CANNABINOID EXPOSURE AND STRESS ON
PLASMA PROLACTIN, GROWTH-HORMONE AND CORTICOSTERONE
LEVELS IN MALE MICE.
002695 03-03
S-182
VOLUME 19, SUBJECT INDEX
Subject Index
BRIEF COMMUNICATION: BEHAVIORAL RECOVERY AFTER TOLUENE
EXPOSURE IN RATS.
002969 03-04
PHENELZINE AND EXPOSURE IN THE TREATMENT OF PHOBIAS
003285 03-10
PRENATAL EXPOSURE TO SYNTHETIC PROGESTINS INCREASES POTENTIAL
FOR AGGRESSION IN HUMANS.
003527 03-15
THE EFFECT OF PRENATAL EXPOSURE TO ETHANOL OR OPIATES ON BRAIN
CATECHOLAMINE ACTIVITY.
003939 04-03
NEUROTRANSMITTER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS, h EFFECTS OF A SINGLE EXPOSURE TO ACRYLAMIDE.
004264 04-05
NEUROTRANSMIHER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS. II: EFFECTS OF EXTENDED EXPOSURE TO ACRYLAMIDE.
004265 04-05
EXPRESSION
MATERNAL GLUCOCORTICOID-HORMONES INFLUENCE
NEUROTRANSMinER PHENOTYPIC EXPRESSION IN EMBRYOS.
000149 01-03
POSSIBLE INVOLVEMENT OF BRAIN DOPAMINERGIC-SYSTEMS IN THE
EXPRESSION OF EMOTIONS IN DREAMS.
002325 02-14
EFFECT OF COCAINE AND LIDOCAINE ON THE EXPRESSION OF KINDLED
SEIZURES IN THE RAT.
004233 04-04
EXTENSION
DELTA9 THC IN PIGEONS: A REPLICATION AND EXTENSION.
000394 01-04
EXTENSOR
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS.
003027 03-04
EXTENT
PREDiaiON OF THE VOLUME OF DISTRIBUTION FROM IN VITRO DATA
AND USE FOR ESTIMATING THE ABSOLUTE EXTENT OF ABSORPTION.
000907 01-16
EXTERNAL
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION.
001300 02-03
EXTEROCEPTIVE
CONDITIONING OF AN INTEROCEPTIVE DRUG STIMULUS TO DIFFERENT
EXTEROCEPTIVE CONTEXTS.
004142 04-04
EXTINCTION
THE USE OF EXTINCTION TO INVESTIGATE THE NATURE OF NEUROLEPTIC-
INDUCED AVOIDANCE-DEFICITS.
000345 01-04
EXTINCTION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMIHENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL
EQUIVALENCE.
000490 01-04
ACCELERATED EXTINCTION AFTER POSHRIAL HALOTHANE ANESTHESIA IN
RATS: AN AVERSIVE-EFFEQ.
003001 03-04
EXTRACELLULAR
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM.
002728 03-03
EXTRACTION
EFFECTS OF RATE OF BLOOD FLOW ON FRACTIONAL EXTRACTION AND ON
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN
VIVO.
001231 02-03
EXTRACTS
METABOLISM OF 3H NORADRENALINE RELEASED FROM ISOLATED RAT
HYPOTHALAMUS BY EXTRACTS OF BLACK-WIDOW-SPIDER GLANDS.
000223 01-03
ASSAYING GABA-MODULIN ACTIVITY IN BRAIN EXTRACTS: RESOLUTION
OF INHERENT DIFFICULTIES. (UNPUBLISHED PAPER).
001045 02-01
EXTRAHYPOTHALAMIC
EXTRAHYPOTHALAMIC DISTRIBUTIONS AND FUNCTIONS OF
HYPOTHALAMIC PEPTIDE-HORMONES. (UNPUBLISHED PAPER).
001211 02-03
EXTRAPORTAL
ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND
EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL
AND INTRODUODENAL ADMINISTRATION.
000094 01-03
EXTRAPYRAMIDAL
PROLACTIN RESPONSE AND EXTRAPYRAMIDAL SIDE-EFFECTS DURING
PROPRANOLOL AND NEUROLEPTIC-DRUGS TREATMENT IN CHRONIC
SCHIZOPHRENIC-PATIENTS.
000841 01-15
NEUROLOGICAL SIDE-EFFECTS OF LITHIUM: ORGANIC-BRAIN-SYNDROME,
SEIZURES, EXTRAPYRAMIDAL SIDE-EFFECTS, AND EEG CHANGES
000847 01-15
THE OCCURRENCE OF TARDIVE EXTRAPYRAMIDAL SYMPTOMS IN
SCHIZOPHRENIC-PATIENTS UNDERGOING PROLONGED NEUROLEPTIC
TREATMENT.
000885 01-15
EFFECT OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED
EXTRAPYRAMIDAL ALTERATIONS
001119 02-03
USE OF LARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC-
PATIENTS WITH ELEVATED SERUM PROLACTIN LEVELS AND
EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH NEUROLEPTIC
TREATMENT.
001944 02-08
PIRACETAM ACTION IN NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL SIDE-
EFFECTS.
002132 02-11
PROPRANOLOL (INDERAL) FOR TARDIVE-DYSKINESIA AND
EXTRAPYRAMIDAL SIDE-EFFECTS FROM NEUROLEPTICS: POSSIBLE
INVOLVEMENT OF BETA-ADRENERGIC MECHANISMS.
002470 02-15
CHRONIC EFFECTS OF NEUROLEPTICS HAVING HIGH OR LOW INCIDENCE
OF EXTRAPYRAMIDAL SIDE-EFFECTS UPON FORCE, DURATION AND
RATE OF OPERANT-RESPONSE IN RATS. (PH.D. DISSERTATION).
003125 03-05
EXTRAPYRAMIDAL REACTION OF FLUPHENAZINE POTENTIATED BY
THYROTOXICOSIS.
003551 03-15
CORRECTION OF THE EXTRAPYRAMIDAL NEUROLEPTIC- SYNDROME BY
TRYPTOPHAN AND THE TIME-COURSE OF ITS CONTENT IN THE BLOOD
OF PATIENTS.
004434 04-1 1
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL.
004620 04-15
EXTRAPYRAMIDAL-DISORDERS
A BIOCHEMICAL- STUDY OF LUMBAR CEREBROSPINAL-FLUID IN
EXTRAPYRAMIDAL-DISORDERS.
002186 02-11
EXTRAPYRAMIDAL-DISORDERS AND BORDERLINE-SYNDROMES:
EREOOATAXIAS AND DEMENTIA.
003518 03-15
EXTRAPYRAMIDAL-EFFECTS
CHRONOLOGY OF EXTRAPYRAMIDAL-EFFECTS OF NEUROLEPTIC-DRUGS
AND THE NIGROSTRIATAL DOPAMINERGIC-SYSTEM.
002449 02-15
EXTRAPYRAMIDAL-SYNDROMES
A TRIAL TREATMENT WITH TIAPRIDE FOR SOME EXTRAPYRAMIDAL-
SYNDROMES CAUSED BY NEUROLEPTIC-AGENTS.
003553 03-15
EXTRASTRIATAL
SHORT-TERM AND LONG-TERM EFFECTS OF METHAMPHET AMINE ON
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC
NUCLEI.
001384 02-03
EXTRASYSTOLE
EFFECT OF AMITRIPTYLINE ANTIDOTES ON REPETITIVE EXTRASYSTOLE
THESHOLD.
001856 02-05
EXUDATE
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN- 13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
EYE
SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE:
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT.
000095 01-03
EYE BLINKS. (UNPUBLISHED PAPER).
001672 02-04
DRUG-INDUCED DISORDERS OF THE EYE.
002396 02-15
EYE-MOVEMENTS
DISORDERS OF SMOOTH-PURSUIT EYE-MOVEMENTS IN SCHIZOPHRENICS
AND THE EFFECT OF NEUROLEPTICS IN THERAPEUTIC DOSES.
001912 02-08
QUANTITATIVE ASSESSMENT OF SMOOTH-PURSUIT EYE-MOVEMENTS IN
HEALTHY AND EPILEPTIC-SUBJECTS.
002376 02-15
SMOOTH-PURSUIT EYE-MOVEMENTS: EFFECTS OF ALCOHOL AND
CHLORAL-HYDRATE.
003448 03-14
ill
i "wr
I Hi
■nir
I '
•wit
.'Mil:
*«l!l!'
S-183
Subject Index
Psychopharmacology Abstracts
Mil
at
EYEBLINK
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS.
004180 04-04
FACIAL
DENERVATION SUPERSENSITIVITY TO SEROTONIN IN THE FACIAL
NUCLEUS.
001364 02-03
PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND
DEMENTIA.
003347 03-11
FACIAL CLEFTS AMONG EPILEPTIC-PATIENTS.
003484 03-15
FACT-SHEET
FACT-SHEET: TOURETTE-SYNDROME.
004474 04-1 1
FACTOR
ASCORBIC-ACID, AN ENDOGENOUS FACTOR REQUIRED FOR
ACETYLCHOLINE RELEASE FROM THE SYNAPTIC VESICLES.
001322 02-03
GLUCOCORTICOIDS AS A REGULATORY FACTOR FOR BRAIN TRYPTOPHAN-
HYDROXYLASE DURING DEVELOPMENT.
001500 02-03
CUMULATIVE AFTERDISCHARGE AS THE PRINCIPAL FACTOR IN THE
ACQUISITION OF KINDLED SEIZURES.
002862 03-03
FACTORIAL
STUDY ON THE STABILITY OF THE FACTORIAL STRUCTURE OF THE AMP
SYSTEM DURING TREATMENT
004696 04-16
FACTS
PHARMACOLOGICAL-BASES OF PSYCHONEUROENDOCRINOLOGY:
PRECLINICAL ASSESSMENT OF CLINICAL FACTS.
003735 04-03
FAILS
CHRONIC-TREATMENT WITH VALIUM (DIAZEPAM) FAILS TO AFFECT THE
REPRODUCTIVE SYSTEM OF THE MALE RAT.
001535 02-03
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND
CONDITIONED TASTE-AVERSION.
004121 04-04
FAILURE
A STATE-DEPENDENT FAILURE OF RATS TO MAXIMIZE REWARDS
000392 01-04
EXTINCTION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMITTENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL
EQUIVALENCE.
000490 01-04
FAILURE OF CLORAZEPATE TO CAUSE MALFORMATIONS OR FETAL
WASTAGE IN THE RAT.
000514 01-05
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL- STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS.
000520 01-05
FAILURE OF NALOXONE TO REVERSE CATALEPSY ASSOCIATED WITH
SCHIZOPHRENIA: A CASE-REPORT.
000560 01-08
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF
12 CNS DEPRESSANTS IN INTACT AND PITHED RATS
001855 02-05
FAILURE OF NALOXONE TO REDUCE MANIC-SYMPTOMS.
001984 02-09
ANTIDEPRESSIVES IN RENAL FAILURE.
002284 02-13
FAILURE OF LITHIUM TREATMENT IN ESTABLISHED TARDIVE-DYSKINESIA.
002432 02-15
FAILURE TO FIND SEX-DIFFERENCES IN TESTOSTERONE ACTIVATED
AGGRESSION IN TWO STRAINS OF RATS.
003107 03-04
DOSAGE OF INTRATUMORAL LITHIUM (CEREBRAL GLIOBLASTOMA): ON A
FAILURE OF TREATMENT OF MANIC-DEPRESSIVE-PSYCHOSIS.
003226 03-09
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO
COUNTERACT CURATIVE EFFECTS OF NEUROLEPTIC-DRUGS.
004321 04-08
IS THE FAILURE OF (-)DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM
THE CHEESE EFFECT?
004640 04-15
FALSE
FALSE LABELLING OF COMMERCIALLY-AVAILABLE 3H CATECHOLAMINES?
000535 01-06
FAMILIAL
FAMILIAL OCCURRENCE OF TARDIVE-DYSKINESIA.
003548 03-15
FAMILIES
THE NEGATIVE INFLUENCE OF FAMILIES ON COMPLIANCE.
004745 04-17
FAMILY-TREE
FAMILY-TREE GIVES CLUES TO TREATING PSYCHOSES.
002363 02-14
FAST-ACTIVITY
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-ACTIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
ACTIVITY.
000309 01-03
RESERPINE ABOLISHES MOVEMENT CORRELATED ATROPINE-RESISTANT
NEOCORTICAL LOW VOLTAGE FAST-ACTIVITY.
000310 01-03
FAT
SUSTAINED DECREASE IN FAT CONSUMPTION PRODUCED BY
AMPHETAMINE IN RATS MAINTAINED ON A DIETARY SELF-SELEaiON
REGIME.
004150 04-04
FATALITIES
LOXAPINE FATALITIES.
004650 04-15
FATIGUE
TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE
(CANTOR) MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE
FATIGUE STUDY GROUPS NO. 4 CLINICAL- SCALE.
001980 02-09
FATTY-ACID
BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND
2,4 DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR (DPEA) INHIBITION
OF FAHY-ACID CONJUGATION TO 1 1 HYDR0XY-DELTA9-
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM.
000179 01-03
FATTY-ACIDS
THE MECHANISM OF EFFECT OF NEUROPHARMACOLOGICAL-DRUGS. VI:
EFFECT OF NORADRENALINE AND 5 HYDROXYTRYPT AMINE ON BRAIN
FREE FAHY-ACIDS
000274 01-03
THE EFFECTS OF PIRACETAM ON FREE FATTY-ACIDS IN THE BRAIN,
001474 02-03
EFFECTS OF BRANCHED-CHAIN FATTY-ACIDS ON GABA DEGRADATION
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI-
MORPHINE ABSTINENCE-BEHAVIOR.
001809 02-04
EFFECTS OF CAFFEINE ON PLASMA FREE FAHY-ACIDS, URINARY
CATECHOLAMINES, AND DRUG BINDING
002272 02-13
FD-1
EFFECTS OF 1,3 BIS-TETRAHYDR0-2-FURANYL-5-
FLUOROPYRIMIDINEDIONE (FD-1) ON THE CENTRAL-NERVOUS-SYSTEM:
1 . EFFECTS OF MONOAMINES IN THE BRAIN.
001857 02-05
FDA
FDA CLIPS PSYCHODRUG PIONEERS IND WINGS.
003160 03-07
FEAR
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFECTS ON
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE
PARADIGM.
000372 01-04
EFFECT OF ANTIANXIETY-DRUGS ON FEAR AND STRESS
000801 01-14
AMYGDALA OPIATE-SENSITIVE MECHANISMS INFLUENCE FEAR
MOTIVATED RESPONSES AND MEMORY PROCESSES FOR AVERSIVE-
EXPERIENCES (UNPUBLISHED PAPER).
001628 02-04
FEATURE
HOSTILITY PRODUCTION AS A COMMON FEATURE OF ANTIANXIETY-
AGENT ACTION.
004654 04-15
FEATURES
SPINOCEREBELLAR DEGENERATION WITH PARKINSONIAN FEATURES: A
CLINICAL AND PATHOLOGICAL REPORT
003436 03-13
FEDERAL-COURT
FEDERAL-COURT UPHOLDS RIGHT-TO-REFUSE PSYCHOTROPIC-DRUGS,
ORDERS IMPROVEMENTS AT LIMA-STATE-HOSPITAL.
002583 02-17
FEEDBACK
THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL ON THE POSITIVE AND
NEGATIVE FEEDBACK CONTROL OF LUTEINIZING-HORMONE RELEASE.
000286 01-03
S-184
VOLUME 19, SUBJECT INDEX
Subject Index
MEASUREMENT OF PLASMA CONCENTRATIONS OF DRUGS AS A
FEEDBACK CONTROL MECHANISM DURING DRUG-THERAPY.
002525 02-17
FEEDING
EFFECTS OF CHLORDIAZEPOXIDE AND DIAZEPAM ON FEEDING
PERFORMANCE IN A FOOD PREFERENCE TEST
000367 01-04
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF
CHLORDIAZEPOXIDE ON FEEDING PARAMETERS USING TWO FOOD
TEXTURES IN THE RAT.
000368 01-04
BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH
KAINIC-ACID-INDUCED LESIONS OF STRIATAL NEURONS - WITH A
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS-
OISEASE.
000463 01-04
EFFECTS OF SPIPERONE ALONE AND IN COMBINATION WITH ANORECTIC-
AGENTS ON FEEDING PARAMETERS IN THE RAT.
001598 02-04
INTERACTIONS OF CHLORDIAZEPOXIDE AND ANORECTIC-AGENTS ON RATE
AND DURATION PARAMETERS OF FEEDING IN THE RAT.
001600 02-04
THE EFFECTS OF PARA CHLOROAMPHETAMINE ON FENFLURAMINE
ANOREXIA IN AD LIBITUM AND STIMULATION-INDUCED FEEDING IN
THE RAT.
001823 02-04
BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS
AND MAN.
002527 02-17
OPERANT FEEDING AND DRINKING IN PIGS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF SYNTHETIC
CHOLECYSTOKININ-OCTAPEPTIDE.
003064 03-04
NALOXONE SUPPRESSES FEEDING AND DRINKING BUT NOT WHEEL
RUNNING IN RATS.
004080 04-04
FEELINGS
EFFECTS OF ATENOLOL AND PROPRANOLOL ON HUMAN PERFORMANCE
AND SUBJECTIVE FEELINGS.
002340 02-14
FEMALE
THE EFFECTS OF GONADECTOMY AND HYPOPHYSECTOMY ON THE
METABOLISM OF IMIPRAMINE AND LIDOCAINE BY THE LIVER OF MALE
AND FEMALE RATS.
000273 01-03
AHEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED
SPINAL FEMALE RATS WITH MONOAMINE AGONISTS.
000421 01-04
BEHAVIORAL-EFFECTS OF ETHYNYL ESTROGENS IN THE FEMALE RAT.
000483 01-04
PHENCYCLIDINE; EFFECTS OF CHRONIC ADMINISTRATION IN THE FEMALE
MOUSE ON GESTATION, MATERNAL-BEHAVIOR, AND THE NEONATES.
000517 01-05
CONTRIBUTORS TO FEMALE USE OF PSYCHOPHARMACOLOGICAL-AGENTS:
DISSERTATION).
000956 01-17
DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN
FRAGMENTS OF MALE AND FEMALE RATS.
001121 02-03
EFFECT OF IMIPRAMINE ON HEPATIC GAMMA GLUTAMYLTRANSFERASE
IN FEMALE RATS. INTERACTION WITH CONTRACEPTIVES.
001507 02-03
DIFFERENTIAL DOPAMINERGIC FUNCTION IN YOUNG AND OLD FEMALE
RATS AS MEASURED BY THREE BEHAVIORS.
001683 02-04
EFFEQS OF NEONATAL 6 HYDROXYDOPA ON BEHAVIOR IN FEMALE
RATS.
001717 02-04
OPIATE ANTAGONISTS AND FEMALE FUNCTIONING. (UNPUBLISHED
PAPER).
001735 02-04
THROMBOCYTOSIS IN THE OFFSPRING OF FEMALE MICE RECEIVING DL
METHADONE.
001836 02-05
EFFEaS OF AN EPINEPHRINE SYNTHESIS INHIBITOR, SKF-64139, ON THE
SECRETION OF LUTEINIZING-HORMONE IN OVARIECTOMIZED FEMALE
RATS.
002693 03-03
VASOTOCIN, PROSTAGLANDIN, AND FEMALE REPRODUCTIVE BEHAVIOR
IN THE FROG, RANA-PIPIENS.
002978 03-04
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES
IN THIS PHASE.
003251 03-09
PROLACTIN RELEASING POTENCIES OF ANTIPSYCHOTIC AND RELATED
NONANTIPSYCHOTIC COMPOUNDS IN FEMALE RATS: RELATION TO
CLINICAL POTENCIES.
003830 04-03
PHARMACOTHERAPY AND FEMALE SEXUALITY.
PRAZEPAM METABOLISM IN FEMALE SUBJECTS
004483 04-11
004504 04-13
FEMALES
DECREASED 3H IMIPRAMINE BINDING IN DEPRESSED MALES AND
FEMALES.
004349 04-09
FEMORAL
CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE
CANINE FEMORAL VASCULAR BED.
003911 04-03
FEMTOMOLE
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5
HYDROXYTRYPTOPHAN, SEROTONIN AND _, HYDROXYINDOLEACETIC-
ACID IN BRAIN USING HPLC WITH ELECTROCHEMICAL-DETECTION.
003139 03-06
FENCAMFAMINE
ACUTE EFFECT OF BENZOCTAMINE (10 MG), SODIUM-
HYDROXYBUTYRATE (2 G) AND FENCAMFAMINE (10 MG) ON VERBAL-
ASSOCIATIONS.
000806 01-14
FENFLURAMINE
THE EFFECTS OF PARA CHLOROAMPHETAMINE ON FENFLURAMINE
ANOREXIA IN AD LIBITUM AND STIMULATION-INDUCED FEEDING IN
THE RAT.
001823 02-04
FENFLURAMINE POTENTIATION OF ANTIHYPERTENSIVE-EFFECTS OF
THIAZIDES.
002138 02-11
COMPARISON OF THE EFFECTS OF THE STEREOISOMERS OF
FENFLURAMINE ON THE ACETYLCHOLINE CONTENT OF RAT STRIATUM,
HIPPOCAMPUS AND NUCLEUS-ACCUMBENS.
003758 04-03
HABITUATION OF THE THE HEAD-POKE RESPONSE: EFFECTS OF AN
AMPHETAMINE BARBITURATE MIXTURE, PLG AND FENFLURAMINE.
004159 04-04
FENIL-ISOPROPIL-AMINA-SULFATE
BETTA-SPLENDENS MAZE-BEHAVIOR UNDER THE INFLUENCE OF THE BETA
FENIL-ISOPROPIL-AMINA-SULFATE.
001558 02-04
FENTANYL
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFECTS OF FENTANYL ON
THE CONTRACTION OF THE NICTITATING MEMBRANE IN CATS.
002876 03-03
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
FERRIC-CHLORIDE
NEURONAL ACTIVITY IN CHRONIC FERRIC-CHLORIDE EPILEPTIC-FOCI IN
CATS AND MONKEY.
000172 01-03
FETAL
FUNCTIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY
NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS
WITH SCHIZOPHRENIA.
000059 01-03
REDUCTION OF FETAL RAT SPINAL-CORD VOLUME FOLLOWING
MATERNAL MORPHINE INJECTION.
000161 01-03
FAILURE OF CLORAZEPATE TO CAUSE MALFORMATIONS OR FETAL
WASTAGE IN THE RAT.
000514 01-05
TERATOGENICITY OF IMIPRAMINE AND AMITRIPTYLINE IN FETAL
HAMSTERS.
002410 02-15
MULTIINSTITUTIONAL- STUDY ON THE TERATOGENICITY AND FETAL
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE-
STUDY GROUP IN JAPAN.
002442 02-15
EFFECTS OF FETAL TREATMENT WITH METHYLAZOXYMETHANOL-ACETATE
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE
ADULT NEOCORTEX OF THE RAT.
002770 03-03
DISPOSITION OF METHADONE IN THE OVINE MATERNAL FETAL UNIT.
004027 04-03
FETUSES
SURGICAL MANIPULATION OF THE UTERINE ENVIRONMENT OF RAT
FETUSES.
002478 02-16
FEVER
CENTRAL ADMINISTRATION OF SERINE CAUSES HYPOTHERMIA AND
INHIBITS FEVER IN RABBITS.
001247 02-03
THE ROLE OF PROTEIN SYNTHESIS IN THE HYPOTHALAMIC MECHANISM
MEDIATING PYROGEN FEVER.
001454 02-03
a.
I
•MIC
'KL'II'
iic
u»
S-185
Subject Index
Psychopharmacology Abstracts
*m
FI-RESPONDING
EFFECTS OF PSYCHOTROPIC-DRUGS ON FI-RESPONDING AND ADJUNCTIVE
DRINKING IN RATS.
001693 02-04
FIBERS
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
00)024 02-01
MECHANICAL-CHANGES IN CRAB NERVE FIBERS DURING ACTION
POTENTIALS. (UNPUBLISHED PAPER).
001505 02-03
ULTRASTRUCTURAL LOCALIZATION OF MONOAMINES IN NERVE FIBERS
OF THE PINEAL-GLAND IN GOLDEN HAMSTERS.
003666 04-01
FIBRES
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT.
001104 02-03
FIBRILLATION
PROTECTIVE EFFECT OF PRENYLAMINE AGAINST VULNERABILITY TO
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE
MYOCARDIUM.
000265 01-03
THE EFFECTS OF THIORIDAZINE ON ELECTRICAL AND ISCHEMIC
VENTRICULAR FIBRILLATION IN THE DOG HEART IN SITU.
002697 03-03
FIBROBLASTS
GABA SYNTHESIS BY CULTURED FIBROBLASTS OBTAINED FROM PERSONS
WITH HUNTINGTONS-DISEASE.
000765 01-13
FIBROSITIS-PATIENTS
THE RELATIONSHIP OF ALPHA AND DELTA EEG FREQUENCIES TO PAIN
AND MOOD IN FIBROSITIS-PATIENTS TREATED WITH CHLORPROMAZINE
AND L TRYPTOPHAN.
002152 02-11
FIGHTING
SELECTIVE INHIBITION BY NICOTINE OF SHOCK-INDUCED FIGHTING IN THE
RAT.
002984 03-04
SUBCHRONIC-TREATMENT WITH THE TRICYCLIC-ANTIDEPRESSANT OMI
INCREASES ISOLATION-INDUCED FIGHTING IN RATS.
004252 04-04
FIGHTING-BEHAVIOR
EFFECTS OF MORPHINE WITHDRAWAL ON FOOD COMPETITION
HIERARCHIES AND FIGHTING-BEHAVIOR IN RATS.
001632 02-04
FIGURAL
PERSONALITY AND DRUGS IN VISUAL FIGURAL AFTEREFFEQS.
004581 04-14
FILTRATION
GLOMERULAR FILTRATION RATE AND CALCIUM METABOLISM IN LONG-
TERM LITHIUM TREATMENT.
003542 03-15
FINNISH
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES.
003599 03-17
FIRING
SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA-
ADRENOCEPTOR ANTAGONISTS; EVIDENCE AGAINST GABA
MEDIATION.
000024 01-03
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF
AlO DOPAMINERGIC NEURONS
000320 01-03
SUBSTANCE-P, MORPHINE AND METHIONINE-ENKEPHALIN: EFFEQS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE NUCLEUS-
RETICULARIS-GIGANTOCELLULARIS OF THE RAT.
001267 02-03
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS
INDUCED BY AMPHETAMINE IN CATS.
001340 02-03
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC
NEURONS.
002880 03-03
MORPHINE AND METHIONINE-ENKEPHALIN: DIFFERENT EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE
MESENCEPHALIC RETICULAR FORMATION OF THE RAT.
003849 04-03
FIRING-RATE
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE f .URONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTf DED EXPOSURE TO ESTROGEN.
001167 02-03
GLUCOSE SUPPRE, :ES BASAL FIRING AND HALOPERIDOL-INDUCED
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC
NEURONS.
002880 03-03
FIRST-PASS
THE EFFECT OF MONOAMINE-OXIDASE-INHIBITORS ON FIRST-PASS
METABOLISM OF TYRAMINE IN DOG INTESTINE.
000141 01-03
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II.
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT.
004516 04-13
FISH
BOMBESIN ALTERS BEHAVIORAL THERMOREGULATION IN FISH.
003026 03-04
FIXED-INTERVAL
A COMPARISON OF THE EFFECTS OF D-AMPHETAMINE, COCAINE,
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE
000508 01-04
THE EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ALONE AND IN
COMBINATION WITH CANNABIDIOL ON FIXED-INTERVAL
PERFORMANCE IN RHESUS-MONKEYS.
001582 02-04
FIXED-RATIO
PROGRESSIVE-RATIO AND FIXED-RATIO SCHEDULES OF COCAINE
MAINTAINED RESPONDING IN BABOONS.
000395 01-04
FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK
TERMINATION: EFFECTS OF D-AMPHETAMINE, MORPHINE. AND
CLOZAPINE
000431 01-04
FK-33-824
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN
RATS.
001669 02-04
FLA-63
THE EFFECT OF FLA-63 ON PENTOBARBITONE-INDUCED SLEEP IN THE
CHICK.
001741 02-04
FLAME-IONIZATION
DETERMINATION OF VALPROIC-ACID BY FLAME-IONIZATION GAS-LIQUID-
CHROMATOGRAPHY
000906 01-16
FLASH-EVOKED
FLASH-EVOKED AFTERDISCHARGE IN RAT AS A MODEL OF THE ABSENCE
SEIZURE: DOSE-RESPONSE STUDIES WITH THERAPEUTIC DRUGS
000160 01-03
POWER SPECTRAL ANALYSIS OF THE FLASH-EVOKED AFTERDISCHARGE.
003133 03-06
FLAHENING
LOG-DOSE/RESPONSE-CURVE FLAHENING IN RATS ARER DAILY
INJECTION OF OPIATES
001387 02-03
FLAVIN
THIOLS LIBERATE COVALENTLY-BONDED FLAVIN FROM MONOAMINE-
OXIDASE, (UNPUBLISHED PAPER).
001060 02-01
FLAVOR
CONDITIONED SUPPRESSION OF DRINKING: A MEASURE OF THE CR
ELICITED BY A LITHIUM CONDITIONED FLAVOR.
001747 02-04
FLEXOR
EFFEaS OF ANALGESICS AND CNS-AQING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS
004148 04-04
FLICKER
PSYCHOAQIVE-DRUG QUANTIFICATION BY VISUAL FLICKER SENSITIVITY
MEASUREMENT. (PH.D. DISSERTATION).
002485 02-16
FLORA
INHIBITION OF MONOAMINE-OXIDASE BY FURAZOLIDONE IN THE
CHICKEN AND THE INFLUENCE OF THE ALIMENTARY FLORA THEREON.
003711 04-03
FLOURESCENT
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
001024 02-01
FLOW
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIREQ VASODILATOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRICTION.
001 109 02-03
EFFEa OF PAPAVERINE ON REGIONAL CEREBRAL BLOOD FLOW AND
SMALL VESSEL BLOOD CONTENT.
001177 02-03
S-186
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF RATE OF BLOOD FLOW ON FRACTIONAL EXTRACTION AND ON
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN
VIVO.
001231 02-03
THE EFFECT OF SODIUM-SALICYLATE ON CEREBRAL BLOOD FLOW AND
METABOLISM.
001416 02-03
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS.
002071 02-10
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE
INTOXICATION.
002210 02-13
AMPHETAMINE-INDUCED MOTILITY AND NIGROSTRIATAL IMPULSE FLOW.
003005 03-04
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN
INDIRECT ADRENERGIC CHOLINERGIC INTERACTION
003887 04-03
EFFECTS OF METHAMPHET AMINE ON BLOOD FLOW IN THE CAUDATE-
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC
BUNDLE IN THE RAT.
003910 04-03
THE EFFECT OF FIVE TRICYCLIC-ANTIDEPRESSANTS ON SALIVARY FLOW
AND MOOD IN HEALTHY VOLUNTEERS.
004560 04-14
FLUCTUATIONS
CORRELATION BETWEEN DAILY FLUCTUATIONS OF CARBAMAZEPINE
SERUM LEVELS AND INTERMIHENT SIDE-EFFECTS.
000851 01-15
DEPRENYL IN THE MANAGEMENT OF RESPONSE FLUCTUATIONS IN
PATIENTS WITH PARKINSONS-DISEASE ON LEVODOPA.
002358 02-14
STEADY-STATE LITHIUM BLOOD LEVEL FLUCTUATIONS IN MAN
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FORM.
003151 03-07
FLUENCY
DOPAMINERGIC-SYSTEMS AND SPEECH FLUENCY.
000821 01-14
FLUID
ALPHA FLUPENTHIXOL: AN ANTAGONIST OF DOPAMINE-EVOKED FLUID
SECRETION BY AN INSECT SALIVARY-GLAND PREPARATION.
000031 01-03
FLUIDS
LITHIUM LEVEL IN SOME BIOLOGICAL FLUIDS AT ITS PROPHYLACTIC
THERAPEUTIC APPLICATION.
000605 01-09
DETERMINATION OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS AND OF THEIR METABOLIC PRODUCTS IN
BIOLOGICAL FLUIDS.
002498 02-16
FLUNARIZINE
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
FLUNITRAZEPAM
A COMPARATIVE- STUDY ON THE CLINICAL-EFFECTS OF FLUNITRAZEPAM
AND LORAZEPAM.
000702 01-11
FLUNITRAZEPAM IN THE TREATMENT OF DELIRIUM-TREMENS -
PRELIMINARY REPORT.
000719 01-11
MODULATION BY PICROTOXIN AND IPTBO OF 3H FLUNITRAZEPAM
BINDING TO THE GABA/BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-
CEREBELLUM.
002775 03-03
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING:
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN
HYPERTENSION.
002874 03-03
ACTION OF PYRAZOLOPYRIDINES AS MODULATORS OF
(3H)FLUNITRAZEPAM BINDING TO THE GABA/BENZODIAZEPINE-
RECEPTOR COMPLEX OF THE CEREBELLUM.
002909 03-03
HYPNOTIC AQION OF FLUNITRAZEPAM (ROCHES ROIPNOL) IN PATIENTS
WITH SEVERE PSYCHIATRIC-DISORDERS.
003295 03-1 1
FLUNITRAZEPAM IN THE TREATMENT OF INSOMNIA: A STUDY OF 50
PSYCHIATRIC-PATIENTS.
003444 03-14
ACUTE OVERDOSAGE WITH FLUNITRAZEPAM.
003513 03-15
ADMINISTRATION OF FLUNITRAZEPAM IN ELEaROCONVULSIVE-
THERAPY.
004319 04-08
FLUORESCENCE
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF
METHAMPHETAMINE.
002812 03-03
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION
PRODUCTS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH-
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE
DETECTION.
004302 04-06
FLUORESCENT
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL
EVALUATION.
003685 04-02
FLUORIDE
CEREBRAL FLUORIDE IN MANIA AND THE EFFECT OF LITHIUM: A
HYPOTHESIS.
004715 04-17
FLUORINATED
FLUORINATED ANALOGUES OF THE TRICYCLIC NEUROLEPTICS: 2,3
DIFLUORO DERIVATIVE OF CLOROTEPIN.
000001 01-01
THE EFFECT OF A NEW FLUORINATED TRICYCLIC NEUROLEPTIC-DRUG
ISOFLOXYTHEPIN ON THE RAT STRIATAL DOPAMINE METABOLISM.
000306 01-03
FLUORO-5-FLUOROPHENYL-2-FLUOROPHENYL
FLUORO-5-FLUOROPHENYL-2-FLUOROPHENYL4
HYDROXYBUTYLHEXAHYDROPYRIDOINDOLE-HCL, A NEW POTENT
NEUROLEPTIC.
001092 02-02
FLUOROAMINOMETHYLPHENOLS
SYNTHESIS AND GABA-RECEPTOR BINDING-ACTIVITY OF TWO
FLUOROAMINOMETHYLPHENOLS.
003693 04-02
FLUOROTRYPTOPHAN
0 6 FLUOROTRYPTOPHAN, AN INHIBITOR OF TRYPTOPHAN-
HYDROXYLASE: SLEEP AND WAKEFULNESS IN THE RAT.
004189 04-04
FLUOXETINE
EFFECTS OF CHRONIC FLUOXETINE ADMINISTRATION ON SEROTONIN
METABOLISM.
000138 01-03
SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM IN BRAIN: EFFECTS OF NISOXETINE
VERSUS FLUOXETINE.
000208 01-03
THE INABILITY OF CHRONIC FLUOXETINE TO POTENTIATE A SEROTONIN
MEDIATED EFFECT.
000293 01-03
EFFECTS OF LILLY-1 10140 (FLUOXETINE) ON SELF- STIMULATION
BEHAVIOR IN THE DORSAL AND VENTRAL REGIONS OF THE LATERAL
HYPOTHALAMUS IN THE MOUSE.
001590 02-04
EFFECT OF QUIPAZINE AND FLUOXETINE ON ANALGESIC-INDUCED
CATALEPSY AND ANTINOCICEPTION IN THE RAT.
001709 02-04
EFFECTS OF FLUOXETINE ON ELECTRICALLY-INDUCED SPINAL-CORD
SEIZURES IN RATS.
004145 04-04
FLUPENTHIXOL
ALPHA FLUPENTHIXOL: AN ANTAGONIST OF DOPAMINE-EVOKED FLUID
SECRETION BY AN INSECT SALIVARY-GLAND PREPARATION.
000031 01-03
CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN
MEMBRANES.
000062 01-03
THE LOCOMOTOR-EFFECT OF CLONIDINE AND ITS INTERACTION WITH
ALPHA FLUPENTHIXOL OR HALOPERIDOL IN THE DEVELOPING RAT.
000445 01-04
CONCENTRATIONS OF CIS(Z) FLUPENTHIXOL IN MATERNAL SERUM,
AMNIOTIC-FLUID, UMBILICAL-CORD-SERUM, AND MILK.
002423 02-15
SEQUELAE OF 6 MONTHS CONTINUOUS ADMINISTRATION OF CIS(Z)- AND
TRANS(E) FLUPENTHIXOL IN THE RAT.
004282 04-05
FLUPENTHIXOL-DECANOATE
THE LONG-TERM-TREATMENT OF PERIODICAL AND CYCLIC DEPRESSIONS
WITH FLUPENTHIXOL-DECANOATE.
000603 01-09
FLUPENTIXOL
SIMIURITIES BETWEEN THE BINDING OF 3H PIFLUTIXOL AND 3H
FLUPENTIXOL TO RAT STRIATAL DOPAMINE-RECEPTORS IN VITRO.
002760 03-03
FLUPHENAZINE
PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPED-PATIENTS: A
PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED.
000668 01-11
a.
S-187
Subject Index
Ptychopharmacology Abstracts
COMPARATIVE ENZYME-INDUCING EFFECTS OF CHLORPROMAZINE AND
FLUPHENAZINE THERAPIES IN PSYCHOTIC-PATIENTS.
000682 01-11
RADIOIMMUNOASSAY FOR FLUPHENAZINE IN HUMAN PLASMA.
000905 01-16
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE-
DECANOATE TREATMENT.
001820 02-04
EFFECT OF FLUPHENAZINE ON THE CIRCADIAN-EXCRETION OF CYCLIC-
NUCLEOTIDES AND ELECTROLYTES IN THE URINE OF CHRONIC
SCHIZOPHRENICS.
001927 02-08
DISCONTINUATION OF ORAL AND DEPOT FLUPHENAZINE IN
SCHIZOPHRENIC-PATIENTS AFTER ONE YEAR OF CONTINUOUS
MEDICATION: A CONTROLLED-STUDY.
001931 02-08
PLASMA FLUPHENAZINE AND PROLACTIN LEVELS IN SCHIZOPHRENIC-
PATIENTS DURING TREATMENT WITH LOW-DOSES AND HIGH-DOSES OF
FLUPHENAZINE-ENANTHATE.
001956 02-08
MEASUREMENT OF FLUPHENAZINE BY GAS-CHROMATOGRAPHY IN
HUMAN PLASMA AND RED-BLOOD-CELLS.
002491 02-16
PLASMA FLUPHENAZINE LEVELS BY RADIOIMMUNOASSAY IN
SCHIZOPHRENIC-PATIENTS TREATED WITH DEPOT INJECTIONS OF
FLUPHENAZINE-DECANOATE
002510 02-16
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE.
003172 03-08
EXTRAPYRAMIDAL REACTION OF FLUPHENAZINE POTENTIATED BY
THYROTOXICOSIS.
003551 03-15
FLUPHENAZINE, TRIFLUOPERAZINE AND PERPHENAZINE IN VACUTAINERS
003565 03-16
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE
MOUSE AND THE RAT.
003870 04-03
EFFECTS OF AGE ON DOPAMINERGIC-SUPERSENSITIVITY INDUCED BY
CHRONIC FLUPHENAZINE.
003940 04-03
BEHAVIOR OF RATS AND MICE ADMINISTERED ACTIVE METABOLITES OF
FLUPHENAZINE, 7 HYDROXYFLUPHENAZINE AND FLUPHENAZINE-
SULFOXIDE.
004256 04-04
DEPOT FLUPHENAZINE MAINTENANCE-TREATMENT AND ASSOCIATED
WEIGHT CHANGES.
004635 04-15
FLUPHENAZINE-DECANOATE
DRUG RESPONSE DIFFERENCES OF HIGH AND STANDARD DOSAGE OF
FLUPHENAZINE-DECANOATE IN RELATION TO SCHIZOPHRENIC-
SYMPTOMS.
000562 01-08
COMPUTERIZED EEG IN THE COMPARISON OF OXYPROTHEPIN AND
FLUPHENAZINE-DECANOATE.
000567 01-08
EMERGENCE OF APOMORPHINE-INDUCED VACUOUS CHEWING DURING 6
MONTHS CONTINUOUS TREATMENT WITH FLUPHENAZINE-DECANOATE
001817 02-04
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE-
DECANOATE TREATMENT.
001820 02-04
PUSMA LEVELS AND THERAPEUTIC EFFICACY OF FLUPHENAZINE-HCL
AND FLUPHENAZINE-DECANOATE.
001913 02-08
MAINTENANCE-THERAPY WITH FLUPHENAZINE-DECANOATE AND
OXYPROTHEPINE-DECANOATE IN SCHIZOPHRENIC-PATIENTS - A
DOUBLE-BLIND CROSS-OVER COMPARATIVE-STUDY.
001924 02-08
METHODOLOGY AND RESULTS OF A LONG-TERM STUDY OF LONG-AQING
NEUROLEPTICS: PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-
DECANOATE.
001929 02-08
INTERMITTENT PIMOZIDE VERSUS FLUPHENAZINE-DECANOATE AS
MAINTENANCE-THERAPY IN CHRONIC SCHIZOPHRENIA.
001932 02-08
OXYPROTHEPINE-DECANOATE COMPARED WITH FLUPHENAZINE-
DECANOATE IN THE TREATMENT OF SCHIZOPHRENIA: PRELIMINARY-
COMMUNICATION.
001934 02-08
STUDY OF PROLACTIN VARIATIONS IN PSYCHIATRIC-PATIENTS TREATED
WITH FLUPHENAZINE-DECANOATE.
002226 02-13
PLASMA FLUPHENAZINE LEVELS BY RADIOIMMUNOASSAY IN
SCHIZOPHRENIC-PATIENTS TREATED WITH DEPOT INJECTIONS OF
FLUPHENAZINE-DECANOATE.
002510 02-16
CONSIDERATIONS ON LONG-AQING CHEMOTHERAPY: AN EXPERIENCE
WITH FLUPHENAZINE-DECANOATE.
003173 03-08
THE PROLACTIN RESPONSE IN PATIENTS RECEIVING NEUROLEPTIC
THERAPY. THE EFFECT OF FLUPHENAZINE-DECANOATE.
004318 04-08
THE COURSE OF LONG-TERM-TREATMENT WITH FLUPHENAZINE-
DECANOATE (DAPOTUM-D).
004605 04-15
FLUPHENAZINE-DECANOATES
LONG-TERM CONTROLLED-COMPARISON OF INJEQION OXYPROTHEPIN
AND FLUPHENAZINE-DECANOATES IN PSYCHOTICS IN REMISSION
001949 02-08
FLUPHENAZINE-ENANTHATE
PLASMA FLUPHENAZINE AND PROLAQIN LEVELS IN SCHIZOPHRENIC-
PATIENTS DURING TREATMENT WITH LOW-DOSES AND HIGH-DOSES OF
FLUPHENAZINE-ENANTHATE.
001956 02-08
FLUPHENAZINE-HCL
PLASMA LEVELS AND THERAPEUTIC EFFICACY OF FLUPHENAZINE-HCL
AND FLUPHENAZINE-DECANOATE.
001913 02-08
FACTORS DETERMINING PATIENT TENURE ON A 3-YEAR DOUBLE-BLIND
INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE-HCL.
002513 02-17
INVESTIGATION INTO THE EFFECT OF FLUPHENAZINE-HCL (LYORODIN) IN
CHILDREN WITH BEHAVIORAL-DISORDERS BY MEANS OF
PSYCHOPHYSIOLOGICAL PARAMETERS.
003344 03-11
FLUPHENAZINE-SULFOXIDE
BEHAVIOR OF RATS AND MICE ADMINISTERED AQIVE METABOLITES OF
FLUPHENAZINE, 7 HYDROXYFLUPHENAZINE AND FLUPHENAZINE-
SULFOXIDE.
004256 04-04
FLURAZEPAM
FLURAZEPAM EFFECTS ON METHYLPHENIDATE-INDUCED STEREOTYPED-
BEHAVIOR.
000455 01-04
CENTRAL EXCITATORY ACTIONS OF FLURAZEPAM.
000526 01-05
INDIVIDUAL VARIATIONS IN THE EFFECTS OF FLURAZEPAM,
CLORAZEPATE, L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON
REM SLEEP IN MAN
002349 02-14
THE EFFECTS OF FLURAZEPAM, LORAZEPAM, AND TRIAZOLAM ON SLEEP
AND MEMORY
002357 02-14
EFFECT OF FLURAZEPAM, PENTOBARBITAL, AND CAFFEINE ON AROUSAL
THRESHOLD
003439 03-14
AUDITORY AROUSAL THRESHOLDS OF GOOD SLEEPERS AND POOR
SLEEPERS WITH AND WITHOUT FLURAZEPAM.
003446 03-14
FLURAZEPAM-INDUCED
ETHYL-BETA-CARBOLINE-CARBOXYLATE LOWERS SEIZURE THRESHOLD
AND ANTAGONIZES FLURAZEPAM-INDUCED SEDATION IN RATS.
002971 03-04
FLURAZEPAM-INDUCED SLEEP-APNEA-SYNDROME IN A PATIENT WITH
INSOMNIA AND MILD SLEEP-RELATED RESPIRATORY CHANGES.
004729 04-17
FLUSPIRILENE
EXPERIENCE WITH FLUSPIRILENE IN GERONTOPSYCHIATRY.
000691 01-11
FLUSPIRILENE (IMAP) IN THE TREATMENT OF PSYCHOSOMATIC-
COMPLAINTS IN HYPOCHONDRIACAL-PATIENTS.
002072 02-10
MAINTENANCE-TREATMENT WITH SEMIDEPOTE NEUROLEPTIC
FLUSPIRILENE.
002151 02-11
FLUTROLINE
EEG AND BEHAVIORAL-PROFILE OF FLUTROLINE (CP-36-584). A NOVEL
ANTIPSYCHOTIC-DRUG.
001071 02-02
A DOUBLE-BLIND COMPARISON OF THREE DOSAGES OF FLUTROLINE (CP-
36584) IN THE TREATMENT OF SCHIZOPHRENIA.
004333 04-08
FLUVOXAMINE
FLUVOXAMINE AS AN ANTIDEPRESSANT-DRUG.
003775 04-03
FLUX
EVIDENCE THAT THERE ARE SUBCELLULAR POOLS OF NOREPINEPHRINE
AND THAT THERE IS FLUX OF NOREPINEPHRINE BETWEEN THESE
POOLS.
004004 04-03
FLUXES
GABA FLUXES IN PRESYNAPTIC NERVE-ENDINGS FROM IMMATURE RATS.
000185 01-03
S-188
VOLUME 19, SUBJECT INDEX
Subject Index
THE EFFECT OF ACETYLCHOLINE RELEASE ON CHOLINE FLUXES IN
ISOLATED SYNAPTIC TERMINALS.
003924 04-03
FOCAL
NALOXONE AND FOCAL EPILEPSY: A STUDY WITH DEPTH ELECTRODES.
003341 03-11
THERAPEUTIC PLASMA LEVELS OF SOME ANTICONVULSANTS IN FOCAL
EPILEPSY IN RELATION TO COMPUTERIZED-AXIAL-TOMOGRAPHY.
004439 04-11
FOLATE
THE ROLE OF FOLATE DEFICIENCY IN THE DEVELOPMENT OF PERIPHERAL
NEUROPATHY CAUSED BY ANTICONVULSANTS.
002402 02-15
FOLLICLE-STIMULATING-HORMONE
EFFECTS OF MORPHINE AND NALOXONE ON PHASIC RELEASE OF
LUTEINIZING-HORMONE AND FOLLICLE-STIMULATING-HORMONE
(40849).
000298 01-03
FOLLOWUP
FOLLOWUP STUDY ON THE INFLUENCE OF AN ANTIPSYCHOTIC-DRUG
(PROPERICIAZINE) ON LIVER FUNCTION, ELECTROCARDIOGRAM AND
ELECTROENCEPHALOGRAM.
000639 01-09
THE LONG-TERM RESULTS OF STEREOTAXIC SURGERY AND L-DOPA
THERAPY IN PATIENTS WITH PARKINSONS-DISEASE: A 10-YEAR
FOLLOWUP STUDY.
000693 01-11
FOLLOWUP TREATMENT AND AFTERCARE OF DISCHARGED
SCHIZOPHRENIC-PATIENTS.
000944 01-17
LEVODOPA AND PRESYMPTOMATIC DETECTION OF HUNTINGTONS-
DISEASE - EIGHT-YEAR FOLLOWUP.
000950 01-17
A TEN YEAR FOLLOWUP OF LITHIUM-CARBONATE TREATMENT OF MANIC-
DEPRESSIVE-ILLNESS: PRELIMINARY-RESULTS.
002053 02-09
DEPRESSED-OUTPATIENTS TREATED WITH COGNITIVE-THERAPY OR
PHARMACOTHERAPY: A ONE-YEAR FOLLOWUP.
003235 03-09
THE USE OF PHARMACOKINETICS IN THE FOLLOWUP OF PSYCHIATRIC-
PATIENTS.
003616 03-17
A TWELVE-YEAR FOLLOWUP OF THE NIMH-PRB HIGH-DOSE
CHLORPROMAZINE STUDY OF CHRONIC SCHIZOPHRENICS -
IMPLICATIONS FOR DEINSTITUTIONALIZATION. (UNPUBLISHED PAPER).
004323 04-08
A FOLLOWUP STUDY OF SCHIZOPHRENIC-OUTPATIENTS TREATED WITH
DEPOT NEUROLEPTICS.
004342 04-08
HYPERACTIVES AS YOUNG ADULTS: PROSPECTIVE TEN-YEAR FOLLOWUP.
004454 04-1 1
FOOD
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL
DAMAGE.
000322 01-03
REDUCTION OF FOOD INTAKE BY PIRIBEDIL IN THE RAT: RELATION TO
DOPAMINE-RECEPTOR STIMULATION.
000355 01-04
EFFECTS OF CHLORDIAZEPOXIDE AND DIAZEPAM ON FEEDING
PERFORMANCE IN A FOOD PREFERENCE TEST.
000367 01-04
EFFEQS OF ACUTE OR CHRONIC ADMINISTRATION OF
CHLORDIAZEPOXIDE ON FEEDING PARAMETERS USING TWO FOOD
TEXTURES IN THE RAT.
000368 01-04
FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK
TERMINATION: EFFECTS OF D-AMPHETAMINE, MORPHINE, AND
CLOZAPINE.
000431 01-04
FIRST DOSE BEHAVIORAL-TOLERANCE TO PHENCYCLIDINE ON FOOD
REWARDED BAR-PRESSING-BEHAVIOR IN THE RAT.
000462 01-04
PHENOBARBITAL EFFECTS ON WEIGHT-GAIN AND CIRCADIAN-CYCLING OF
FOOD INTAKE AND BODY-TEMPERATURE.
001409 02-03
NALOXONE: EFFEaS ON FOOD AND WATER CONSUMPTION IN THE
NONDEPRIVED AND DEPRIVED RAT.
001599 02-04
EFFECTS OF MORPHINE WITHDRAWAL ON FOOD COMPETITION
HIERARCHIES AND FIGHTING-BEHAVIOR IN RATS.
001632 02-04
EFFEQ OF CHOLINE ON CONDITIONED FOOD MOTOR-REFLEXES IN CATS.
001731 02-04
DIFFERENTIAL-EFFECTS OF MORPHINE ON FOOD AND WATER INTAKE IN
FOOD DEPRIVED AND FREELY-FEEDING RATS.
001765 02-04
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR
DORSOLATERAL TEGMENTAL DAMAGE.
001818 02-04
THE EFFECTS OF LITHIUM ON CHOICE BETWEEN COCAINE AND FOOD IN
THE RHESUS-MONKEY
001825 02-04
BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS
AND MAN.
002527 02-17
THE EFFECT OF ALTERED DOPAMINERGIC-ACTIVITY ON FOOD INTAKE IN
THE RAT: EVIDENCE FOR AN OPTIMAL LEVEL OF DOPAMINERGIC-
ACTIVITY FOR BEHAVIOR.
002632 02-17
EFFECTS OF CAFFEINE ADMINISTRATION ON FOOD AND WATER
CONSUMPTION UNDER VARIOUS EXPERIMENTAL CONDITIONS.
003049 03-04
THE EFFECTS OF OPIATE ANTAGONISTS ON FOOD INTAKE ARE
STEREOSPECIFIC.
003080 03-04
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED
REFLEXES IN RATS.
003100 03-04
NEUROLEPTICS: INTERACTIONS WITH FOOD - CHEMICAL AND
PHARMACODYNAMIC STUDIES ON THE INTERACTIONS OF COFFEE AND
TEA.
003612 03-17
FOOD PREFERENCE FOLLOWING ACUTE OR CHRONIC CHLORDIAZEPOXIDE
ADMINISTRATION: TOLERANCE TO AN ANTINEOPHOBIC ACTION
004090 04-04
SUSTAINED INTRACEREBROVENTRICULAR INFUSION OF BRAIN FUELS
REDUCES BODY-WEIGHT AND FOOD INTAKE IN RATS.
004098 04-04
NALOXONE SUPPRESSES FOOD/WATER CONSUMPTION IN THE DEPRIVED
CAT.
004114 04-04
CHOICE BETWEEN FOOD AND HEROIN: EFFECTS OF MORPHINE,
NALOXONE, AND SECOBARBITAL.
004123 04-04
THE SITE OF ACTION OF NALOXONE IN SUPPRESSING FOOD AND WATER
INTAKE IN RATS.
004146 04-04
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION
AND EFFECTS OF D-AMPHETAMINE AND PROMAZINE.
004152 04-04
HISTIDYL-PROLINE DIKETOPIPERAZINE DECREASES FOOD INTAKE IN RATS.
004181 04-04
PHARMACOKINETIC-STUDY OF APOMORPHINE-INDUCED STEREOTYPY IN
FOOD DEPRIVED RATS.
004247 04-04
FOOD-AND-DRUG-ADMINISTRATION
GUIDELINES EMPLOYED BY THE FOOD-AND-DRUG-ADMINISTRATION IN
DRUG SCHEDULING.
003586 03-17
FOOTSHOCK
SELECTIVE SENSITIZATION INDUCED BY LITHIUM MALAISE AND
FOOTSHOCK IN RATS.
003055 03-04
FOOTSHOCK ANALGESIA: PREVENTION BY BEHAVIOURAL-MANIPULATION
BUT NOT BY NALOXONE.
003073 03-04
FORCIBLE
MADNESS AND MEDICINE: THE FORCIBLE ADMINISTRATION OF
PSYCHOTROPIC-DRUGS.
002523 02-17
FOREBRAIN
INCREASED METABOLISM OF DOPAMINE AND SEROTONIN INDUCED IN
FOREBRAIN AREAS BY ETORPHINE MICROINJECTION IN
PERIAQUEDUCTAL GRAY.
001103 02-03
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING
DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS
OF MAMMALIAN FOREBRAIN IN VITRO.
001114 02-03
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER
FOREBRAIN REGIONS OF THE RAT.
004171 04-04
FORECASTING
THE USE OF CLINICAL AND PHARMACOKINETIC CRITERIA IN FORECASTING
THE EFFICACY OF THERAPY IN SCHIZOPHRENIA.
004335 04-08
FORENSIC
THE NEUROLOGICAL FORENSIC ASPECTS OF THALLIUM POISONING
002438 02-15
a,
■II ir,'
I
•tat
m'
S-189
Subject Index
Ptychopharmacology Abstracts
-1*1)''
5Si»ii
•HI**
FORGEniNG
AMYLOBARBITONE AND FORGETTING.
001763 02-04
FORM-FRUSTE-DU-SYNDROME-MALIN
TWO CASES Of FORM-FRUSTE-DU-SYNDROME-MALIN WITH HIGH-LEVELS
OF SERUM CPK.
004636 04-15
FORMATION
SYNERGISTIC ACTIONS OF PROPANTHELINE-BROMIDE WITH CIMETIDINE
AND THIOPROPAZATE-HYDROCHLORIDE IN THE PREVENTION OF
STRESS-ULCER FORMATION IN RATS.
000064 01-03
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE
FORMATION FROM PHENYLALANINE.
001113 02-03
IN VIVO (3H)SPIPER0NE BINDING TO THE RAT HIPPOCAMPAL
FORMATION: INVOLVEMENT OF DOPAMINE-RECEPTORS.
001131 02-03
STRYCHNINE EFFECTS ON THE SENSORY RESPONSE PATTERNS OF
RETICULAR FORMATION NEURONS.
001219 02-03
THE EFFECTS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERACTION
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED
AHENTION. (PH.D. DISSERTATION).
001563 02-04
EFFECTS OF SOCIAL-ISOLATION ON MEMORY FORMATION
001607 02-04
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF
AMINES INFLUENCING CEREBROSPINAL-FLUID FORMATION.
002807 03-03
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR
FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY.
002986 03-04
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
003783 04-03
MORPHINE AND METHIONINE-ENKEPHALIN: DIFFERENT EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE
MESENCEPHALIC RETICULAR FORMATION OF THE RAT.
003849 04-03
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS
003972 04-03
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
004030 04-03
THE ROLE OF RETICULOSEPTAL INPUTS IN THE FORMATION OF DIFFERENT
TYPES OF SENSORY REACTIONS OF THE HIPPOCAMPAL NEURONS.
004510 04-13
PHARMACOLOGICAL MODULATION OF FORMATION OF LONG-TERM
MEMORY.
004578 04-14
FORMIC-ACID
GLIAL CELL EFFECTS OF SUBACUTE FORMIC-ACID VAPOUR EXPOSURE.
000527 01-05
FORMULATIONS
SIMULTANEOUS HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC-
DETERMINATION OF AMITRIPTYLINE-HYDROCHLORIDE IN TWO-
COMPONENT TABLET FORMULATIONS.
004673 04-16
FORNIX
FORNIX LESION PREVENTS AN ORGANOPHOSPHATE-INDUCED DECREASE
IN MUSCARINIC-RECEPTOR LEVEL IN RAT HIPPOCAMPUS.
001833 02-05
FORNIX-FIMBRIA
HIPPOCAMPAL SEROTONIN REUPTAKE AND NOQURNAL LOCOMOTOR-
ACTIVITY AFTER MICROINJEQIONS OF 5,7 DHT IN THE FORNIX-
FIMBRIA.
002929 03-03
FOUR-COMPONENT
A COMPARISON OF THE EFFECTS OF D-AMPHETAMINE, COCAINE.
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE.
000508 01-04
FOWL
ENHANCED BEHAVIOURAL-EFFECTS, ELEaROCORTICAL-EFFECTS AND
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN.
001733 02-04
TONIC IMMOBILITY IN DOMESTIC FOWL: POSSIBLE INTERAQION OF
SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
004246 04-04
FOWLS
STEREOTYPED-BEHAVIOUR AND ELECTROCORTICAL-CHANGES AFTER
INTRACEREBRAL MICROINFUSION OF DOPAMINE AND APOMORPHINE
IN FOWLS.
001734 02-04
CENTRAL-EFFEQS Of SUBSTANCE-P IN FOWLS.
003075 03-04
FRACTION
(3H)5 HT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN
GLIAL CELL MEMBRANE FRAQION.
000093 01-03
INTERSUBJECT AND INTRASUBJEQ VARIATION IN DI/^ZEPAM FREE
FRAQION.
000747 01-13
FURTHER CHARACTERIZATION OF THE BINDING OF SUBSTANCE-P TO A
FRACTION FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES.
001394 02-03
TRIAL OF A PEPTIDE FRAQION Of AQH (AaH4-10) IN THE ALCOHOLIC
BRAIN-DAMAGE-SYNDROME
002318 02-14
INHIBITION OF (3H)DIAZEPAM BINDING BY AN ENDOGENOUS FRAQION
FROM RAT-BRAIN SYNAPTOSOMES
003768 04-03
DOPAMINE-RECEPTORS IN SUBCELLULAR FRAQIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRAQION.
003948 04-03
THE HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPEQ TO THE
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRAQION
ABUNDANT IN PRESYNAPTIC MEMBRANES.
004028 04-03
FRACTIONAL
EPFECTS OF RATE OF BLOOD FLOW ON FRAQIONAL EXTRACTION AND ON
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN
VIVO.
001231 02-03
FRACTIONS
3H IMIPRAMINE BINDING IN NEURONAL AND GUAL FRACTIONS OF
HORSE STRIATUM.
000033 01-03
(3H)QUINUCL1DINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRACTIONS.
000299 01-03
NEWLY SYNTHESIZED CHOLECYSTOKININ IN SUBCELLULAR FRACTIONS OF
THE RAT-BRAIN
003805 04-03
EFFECT OF INHIBITORS Of GABA-AMINOTRANSFERASE ON THE
METABOLISM OF GABA IN BRAIN TISSUE AND SYNAPTOSOMAL
FRACTIONS.
003914 04-03
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRACTION.
003948 04-03
FRAGILE
FRAGILE SITES IN HUMAN CHROMOSOMES I. THE EFFECT OF METHIONINE
ON THE XQ-FRAGILE-SITE.
004515 04-13
FRAGMENT
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT.
003734 04-03
FRAGMENTS
DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN
FRAGMENTS OF MALE AND FEMALE RATS.
001121 02-03
ALTERED LEVELS OF BETA ENDORPHIN FRAGMENTS AFTER CHRONIC
MORPHINE TREATMENT Of GUINEA-PIG ILEUM IN VITRO AND IN VIVO.
001404 02-03
THE EffECT OF NEUROPEPTIDE FRAGMENTS Of ADRENOCORTICOTROPIN
AND VASOPRESSIN ON BEHAVIORAL-ACTIVITY IN RATS.
001812 02-04
NEUROTENSIN RELEASE BY RAT HYPOTHALAMIC fRAGMENTS IN VITRO
003920 04-03
FRAME
COMPARISON Of THE EFFECTS OF FOUR BENZODIAZEPINES ON FRAME OF
MIND AND BEHAVIOR IN HEALTHY SUBJECTS.
003441 03-14
FREE
THE MECHANISM OF EffECT Of NEUROPHARMACOLOGICAL-DRUGS. VI:
EffECT Of NORADRENALINE AND 5 HYDROXYTRYPTAMINE ON BRAIN
fREE fATTY-ACIDS.
000274 01-03
S-190
VOLUME 19, SUBJECT INDEX
Subject Index
INTERSUBJECT AND INTRASUBJECT VARIATION IN DIAZEPAM FREE
FRACTION.
000747 01-13
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN
RATS.
001199 02-03
LITHIUM-INDUCED CHANGES IN THE BRAIN LEVELS OF FREE AMINO-ACIDS
IN STRESS-EXPOSED RATS.
001217 02-03
THE EFFECTS OF PIRACETAM ON FREE FATTY-ACIDS IN THE BRAIN.
001474 02-03
EFFECTS OF CAFFEINE ON PLASMA FREE FATTY-ACIDS, URINARY
CATECHOLAMINES, AND DRUG BINDING.
002272 02-13
FREE DESCRIPTION OF DRUG-EFFECTS AS A METHOD OF CLINICAL-TRIAL,
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND
THEIR COMBINATION.
002561 02-17
EFFECT OF DOPAMINE ON ACTIVATION OF RAT STRIATAL ADENYLATE-
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES
002825 03-03
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE
HYPERACTIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN
DEFICIENCY HYPOTHESIS.
003312 03-11
DISSOCIATION BETV/EEN FREE AND BOUND PHENYTOIN LEVELS IN
PRESENCE OF SODIUM- VALPROATE.
003367 03-1 1
COVARIANCE OF PLASMA FREE 3 METHOXY-4-
HYOROXYPHENETHYLENEGLYCOL AND DIASTOLIC BLOOD-PRESSURE.
003418 03-13
COMPARISON OF THE EFFECT OF INTRAVENOUS ADMINISTRATION OF D
LYSERGIC-ACID-DIETHYLAMIDE ON FREE AND MEMBRANE-BOUND
POLYSOMES IN THE RABBIT BRAIN.
003831 04-03
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO.
003832 04-03
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE
AMINO-ACID POOL.
004039 04-03
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
LOAD.
004600 04-15
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL.
004620 04-15
FREEDOM
IS THE FAILURE OF (-)DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM
THE CHEESE EFFECT?
004640 04-15
FREELY-FEEDING
DIFFERENTIAL-EFFECTS OF MORPHINE ON FOOD AND WATER INTAKE IN
FOOD DEPRIVED AND FREELY-FEEDING RATS.
001765 02-04
FREELY-MOVING-RATS
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9
TETRAHYDROCANNABINOL ON THE CARDIOVASCULAR SYSTEM, AND
PRESSOR AND BEHAVIORAL-RESPONSES TO BRAIN-STIMULATION IN
FREELY-MOVING-RATS.
000417 01-04
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMIHERS IN EPIDURAL
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC-
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS.
001386 02-03
FRENCH
PRINCIPLES OF FRENCH PHARMACOCLINICAL-CLASSIFICATION.
001892 02-07
FRENCH-GUIANA
PSYCHOTOMIMETIC USE OF TOBACCO IN SURINAM AND FRENCH-
GUIANA.
002592 02-17
FRENCH-SPEAKING
CLINICAL-EXPERIENCE WITH SUBSTITUTED BENZAMIDES IN FRENCH-
SPEAKING COUNTRIES.
002036 02-09
FREQUENCIES
THE RELATIONSHIP OF ALPHA AND DELTA EEG FREQUENCIES TO PAIN
AND MOOD IN FIBROSITIS-PATIENTS TREATED WITH CHLORPROMAZINE
AND L TRYPTOPHAN.
002152 02-11
FREQUENCY
AFFECTIVE-EPISODE FREQUENCY AND LITHIUM THERAPY.
000587 01-09
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY
SPECTRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND
NEUROLEPTICS.
001220 02-03
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM:
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON
002884 03-03
FREUNDS-ADJUVANT
ANALGESIC ACTIVITY OF DIFLUNISAL (MK-647; 5 2,4
DIFLUOROPHENYLSALICYLIC-ACID) IN RATS WITH HYPERALGESIA
INDUCED BY FREUNDS-ADJUVANT.
000502 01-04
FRIGIDITY
EXPERIMENTATION WITH MINAPRINE IN DEALING WITH CERTAIN
SEXUAL-DISORDERS: IMPOTENCE OR FRIGIDITY.
002153 02-11
FROG
THE EFFECT OF DIAZEPAM ON TENSION AND ELECTROLYTE DISTRIBUTION
IN FROG MUSCLE.
000069 01-03
CHARACTERIZATION OF LRF-LIKE IMMUNOREACTIVITY IN THE FROG
SYMPATHETIC GANGLIA: NONIDENTITY WITH LRF-DECAPEPTIDE.
(UNPUBLISHED PAPER).
001018 02-01
THE EFFECTS OF SUBSTITUTED BENZAMIDES ON FROG RECTUS-
ABDOMINIS.
001228 02-03
DEPRESSION OF VENTRAL ROOT DORSAL ROOT POTENTIAL BY DL ALPHA
AMINOADIPATE IN FROG SPINAL-CORD.
002755 03-03
EXCITATORY AND INHIBITORY-ACTIONS OF IBOTENIC-ACID ON FROG
SPINAL MOTONEURONES IN VITRO.
002841 03-03
THE NEUROLATHYROGEN, BETA N OXALYL-L-ALPHA-BETA-
DIAMINOPROPIONIC-ACID, IS A POTENT AGONIST AT GLUTAMATE
PREFERRING RECEPTORS IN THE FROG SPINAL-CORD.
002858 03-03
VASOTOCIN, PROSTAGLANDIN, AND FEMALE REPRODUCTIVE BEHAVIOR
IN THE FROG, RANA-PIPIENS.
002978 03-04
THE EXCITATORY EFFECT OF ATROPINE ON THE NEURONS OF THE FROG
SYMPATHETIC GANGLIA
004041 04-03
FRONTAL
THE EFFECT OF LONG-TERM CONCURRENT ADMINISTRATION OF
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL
CORTICAL DOPAMINE METABOLISM IN RATS.
003788 04-03
ALPHAl -ADRENOCEPTORS AND ALPHA2-ADREN0CEPT0RS IN RAT-
CEREBRAL-CORTEX: EFFECT OF FRONTAL LOBOTOMY.
003944 04-03
FRONTAL-CEREBRAL-CORTEX
THE EFFECTS OF LITHIUM ON MYOINOSITOL LEVELS IN LAYERS OF
FRONTAL-CEREBRAL-CORTEX, IN CEREBELLUM, AND IN CORPUS-
CALLOSUM OF THE RAT.
003712 04-03
FRONTAL-CORTEX
DOES (3H)SPIR0PERID0L LABEL A 5 HT-RECEPTOR IN THE FRONTAL-
CORTEX OF THE RAT?.
000206 01-03
SEROTONIN-RECEPTORS IN HIPPOCAMPUS AND FRONTAL-CORTEX.
000268 01-03
POSSIBLE INVOLVEMENT OF CYCLIC-AMP AND FRONTAL-CORTEX IN
AMITRIPTYLINE MEDIATED SUPPRESSION OF THE HYPOTENSIVE-EFFECT
OF CLONIDINE.
001259 02-03
FRUCTOSEBIPHOSPHATASE
STIMULATION OF FRUCTOSEBIPHOSPHATASE ACTIVITY AND SYNTHESIS
IN THE CEREBRAL-CORTEX OF RATS SUBMITTED TO THE CONVULSANT
METHIONINE-SULFOXIMINE.
003838 04-03
FRUSEMIDE
THE EFFECT OF FRUSEMIDE PIRETANIDE AND BUMETANIDE ON COCHLEAR
SUCCINIC-DEHYDROGENASE.
003757 04-03
FS-32
PHARMACOLOGICAL-STUDIES ON A NEW THYMOLEPTIC
ANTIDEPRESSANT. DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1 H-
INDAZOLE (FS-32).
001659 02-04
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT,
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1 H-INDAZOLE (FS-32)
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
I
'lie
•»
i'tJ
mt
iiz
S-191
Subject Index
Psychopharmacology Abstracts
lib;
CI
FS-97
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT,
DIMETHYUMINOPROPYL-5-METHYL-3-PHENYL-1 H-INDAZOLE (FS-32)
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
FUCOSE
EFFECT OF L FUCOSE ON BRAIN PROTEIN METABOLISM AND RETENTION
OF A LEARNED-BEHAVIOR IN RATS.
001819 02-04
FUELS
SUSTAINED INTRACEREBROVENTRICULAR INFUSION OF BRAIN FUELS
REDUCES BODY-WEIGHT AND FOOD INTAKE IN RATS.
004098 04-04
FUNCTION
ROLE OF DOPAMINE STORAGE FUNCTION IN THE CONTROL OF RAT
STRIATAL TYROSINE-HYDROXYLASE ACTIVITY.
000201 01-03
POSTINGESTION INTERFERENCE WITH BRAIN FUNCTION PREVENTS
ATTENTUATION OF NEOPHOBIA IN RATS.
000352 01-04
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL-
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL
SEROTONERGIC FUNCTION.
000491 01-04
FOLLOWUP STUDY ON THE INFLUENCE OF AN ANTIPSYCHOTIC-DRUG
(PROPERICIAZINE) ON LIVER FUNCTION, ELECTROCARDIOGRAM AND
ELECTROENCEPHALOGRAM.
000639 01-09
BRAIN FUNCTION IN OLD-AGE: EVALUATION OF CHANGES AND
DISORDERS.
000684 01-11
BROMOCRIPTINE AND DOPAMINERGIC FUNCTION IN HUNTINGTON-
DISEASE
000700 01-11
MEMORY AND COGNITIVE FUNCTION IN THE ELDERLY: A PRELIMINARY-
TRIAL OF PHYSOSTIGMINE.
000802 01-14
RENAL FUNCTION AND BIOPSY IN PATIENTS ON LITHIUM THERAPY
000830 01-15
RENAL FUNCTION IN LITHIUM AND NONLITHIUM TREATED PATIENTS
WITH AFFECTIVE-DISORDERS
000837 01-15
DRUG-VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA:
APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.
000844 01-15
RESIDUAL-EFFECTS OF TEMAZEPAM AND OTHER HYPNOTIC-COMPOUNDS
ON COGNITIVE FUNCTION
000879 01-15
A COMPARISON OF STRIATAL AND MESOLIMBIC DOPAMINE FUNCTION IN
THE RAT DURING 6-MONTH TRIFLUOPERAZINE ADMINISTRATION
001174 02-03
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR
SUBSEQUENT WITHDRAWAL.
001175 02-03
EFFECTS OF CENTRALLY-ADMINISTERED AND SYSTEMICALLY
ADMINISTERED L TYROSINE AND L LEUCINE ON OVARIAN FUNQION IN
THE OLD RAT.
001180 02-03
DRUG-INDUCED ALTERATIONS IN NEUROTRANSMIHER-RECEPTOR
BINDING AND FUNCTION.
001215 02-03
THE EFFECT OF GABAMIMETICS ON NEUROTRANSMIHER-RECEPTOR
BINDING AND FUNCTION IN RAT-BRAIN. (PH.D. DISSERTATION).
001221 02-03
INFLUENCE OF MORPHINE ON MEMBRANE TURNOVER AND FUNCTION
001280 02-03
EFFECTS OF DIFFERENT MONOAMINE-OXIDASE-INHIBITORS ON
RESPIRATORY ACTIVITY IN RATS WITH CHRONICALLY IMPAIRED
CENTRAL SEROTONERGIC FUNCTION
001389 02-03
DOPAMINE-AUTORECEPTORS: PHARMACOLOGY, FUNCTION AND
COMPARISON WITH POSTSYNAPTIC DOPAMINE-RECEPTORS.
001453 02-03
A STUDY OF A GLIAL GAMMA AMINOBUTYRIC-ACID SYSTEM: ITS
REGULATION, FUNCTION AND THE EFFECTS OF DIAZEPAM. (PH.D.
DISSERTATION).
001524 02-03
DIFFERENTIAL DOPAMINERGIC FUNCTION IN YOUNG AND OLD FEMALE
RATS AS MEASURED BY THREE BEHAVIORS.
001683 02-04
DIFFERENTIAL-EFFECTS OF IMIPRAMINE IN RATS AS A FUNCTION OF DRL
SCHEDULE VALUE.
001714 02-04
PATHOPHYSIOLOGIC-IMPACT OF CENTRAL CATECHOLAMINERGIC
FUNCTION IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES.
002174 02-11
APOMORPHINE HYPOTHERMIA: AN INDEX OF CENTRAL DOPAMINE-
RECEPTOR FUNCTION IN MAN.
002221 02-13
EFFECT OF PSYCHOTROPIC-DRUGS ON NEUROENDOCRINE FUNQION.
002265 02-13
INFLUENCE OF CICLAZINDOL ON MONOAMINE UPTAKE AND CNS
FUNCTION IN NORMAL SUBJECTS.
002268 02-13
LITHIUM AND RENAL FUNCTION.
002416 02-15
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO: A DISCRIMINANT FUNCTION ANALYSIS.
002482 02-16
PLACEBO, MEDICINE AND PAIN, OR THE RELATIVE FUNCTION OF
MEDICATION IN THE TREATMENT OF PAIN.
002577 02-17
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNQION
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS.
002700 03-03
CANNABIS-SATIVA: EFFECTS ON BRAIN FUNQION AND ULTRASTRUCTURE
IN RHESUS-MONKEYS.
002747 03-03
CENTRAL AND PERIPHERAL CATECHOLAMINE FUNQION IN LEARNING
AND MEMORY PROCESSES.
002823 03-03
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOAQIVE CANNABINOIDS
ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS.
002831 03-03
THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION
PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR
PRESERVED SCHWANN-CELL SOMAL FUNCTION.
002905 03-03
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNCTION IN CAT BRAIN.
002911 03-03
CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNCTION
OF ELAVIL AND THORAZINE INJECTION.
002974 03-04
EFFECT OF SODIUM-VALPROATE ON MOTOR FUNQION REGULATED BY
THE ACTIVATION OF GABA-RECEPTORS.
003033 03-04
THE HYPERACTIVE-CHILD-SYNDROME: PERIPHERAL SYMPATHETIC-
NERVOUS-SYSTEM FUNCTION AND THE EFFEQ OF D-AMPHETAMINE.
003340 03-11
PHAGOCYTIC FUNCTION IN DOWN-SYNDROME - I CH&MOTAXIS.
003401 03-13
HABITUATION OF ELECTRODERMAL AND RESPIRATORY RESPONSES TO
VISUAL STIMULI AS A FUNCTION OF PERSONALITY DIFFERENCES IN
AFFECT LEVEL
003414 03-13
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS II WITH REFERENCE TO SYMPATHETIC NEURONAL
FUNCTION.
003416 03-13
THE EFFECTS OF CHRONIC METHYLPHENIDATE TREATMENT ON GROWTH
AND ENDOCRINE FUNCTION IN THE DEVELOPING RAT.
00381 1 04-03 .
ACTIONS OF MU KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION.
004053 04-03
EFFECTS OF ANISOMYCIN ON RETENTION OF THE PASSIVE-AVOIDANCE
HABIT AS A FUNCTION OF AGE.
004097 04-04
ACTH-LIKE PEPTIDES, PITUITARY ADRENOCORTICAL FUNQION AND
AVOIDANCE-BEHAVIOR.
004109 04-04
A NEUROENDOCRINE-STUDY OF ADRENOCEPTOR FUNQION IN
ENDOGENOUS DEPRESSION.
004362 04-09
ALTERATIONS IN NORADRENERGIC FUNCTION DURING CLORGYLINE
TREATMENT.
004393 04-09
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO. A DISCRIMINANT FUNCTION ANALYSIS. (UNPUBLISHED
PAPER).
004420 04-10
HYPERVENTILATION-SYNDROME AND BETA-RECEPTOR FUNCTION -
CLINICAL-EFFECT OF BETA BLOCKER UPON THE SYNDROME
004459 04-11
KIDNEY FUNCTION IN PATIENTS WITH AFFECTIVE-DISORDERS WITH AND
WITHOUT LITHIUM THERAPY.
004664 04-15
DOWN REGULATION OF NORADRENERGIC-RECEPTOR FUNCTION BY
ANTIDEPRESSANT-DRUGS: FUNCTIONAL SIGNIFICANCE AND
DISTINCTION FROM ANTIPSYCHOTIC-DRUGS. (UNPUBLISHED PAPER).
004746 04-17
FUNCTIONAL
FUNCTIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY
NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS
WITH SCHIZOPHRENIA.
000059 01-03
S-192
VOLUME 19, SUBJECT INDEX
Subject Index
FUNCTIONAL AND STRUCTURAL CONSEQUENCES OF LONG-TERM DIETARY
L-DOPA TREATMENT IN MICE
000257 01-03
FUNCTIONAL EVIDENCE FOR SUBSENSITIVITY OF NORADRENERGIC-
ALPHA2-RECEPT0RS AFTER CHRONIC DESIPRAMINE TREATMENT.
000283 01-03
REINNERVATION OF THE DENERVATED STRIATUM BY SUBSTANTIA-NIGRA
TRANSPLANTS: FUNCTIONAL CONSEQUENCES AS REVEALED BY
PHARMACOLOGICAL AND SENSORIMOTOR TESTING.
000347 01-04
EXTINCTION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMITTENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL
EQUIVALENCE.
000490 01-04
THE PCP PSYCHOSIS: PROLONGED INTOXICATION OR DRUG PRECIPITATED
FUNCTIONAL ILLNESS?
000739 01-12
PSYCHOPHARMACOLOGICAL AND PSYCHOTHERAPEUTIC-APPROACHES TO
THE TREATMENT OF FUNCTIONAL PSYCHOSES.
000977 01-17
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONISES THE EFFECT OF
DIAZEPAM ON A FUNCTIONAL GABA-RECEPTOR.
001378 02-03
HUMAN PLATELET 5 HT-RECEPTORS: CHARACTERISATION AND
FUNCTIONAL ASSOCIATION.
001412 02-03
FUNCTIONAL ASPECTS OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM IN THE CENTRAL-NERVOUS-SYSTEM.
001493 02-03
FUNCTIONAL ORGANIZATION OF THE CAUDATE-NUCLEUS AFTER
ADMINISTRATION OF CARBACHOL.
001495 02-03
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM:
FUNCTIONAL CHANGES FOLLOWED USING (-)N N
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL ACTIVITY LEVELS
OF RATS.
001603 02-04
THE STRIATONIGRAL GABA PATHWAY: FUNCTIONAL AND
NEUROCHEMICAL CHARACTERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS
BY YOHIMBINE DIASTEREOMERS.
002748 03-03
THE FUNCTIONAL IMPORTANCE OF INCREASED BRAIN TRYPTOPHAN IN
THE SEROTONERGIC RESPONSE TO RESTRAINT STRESS.
002779 03-03
A STUDY OF THE EFFECT OF NEUROPHARMACOLOGICAL DRUGS ON THE
FUNCTIONAL ACTIVITY OF RAT-BRAIN.
004107 04-04
DOWN REGULATION OF NORADRENERGIC-RECEPTOR FUNCTION BY
ANTIDEPRESSANT-DRUGS: FUNCTIONAL SIGNIFICANCE AND
DISTINCTION FROM ANTIPSYCHOTIC-DRUGS. (UNPUBLISHEP PAPER).
004746 04-17
NOTES ON PHARMACOTHERAPY OF FUNCTIONAL PSYCHOSES.
004748 04-17
FUNCTIONALLY
DISCRIMINATION OF FUNCTIONALLY HETEROGENEOUS RECEPTOR
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC
PROPERTIES OF METOCLOPRAMIDE.
002877 03-03
FUNCTIONING
EFFECTS OF THIORIDAZINE ON THE COGNITIVE FUNCTIONING OF A
HYPOTONIC SCHIZOPHRENIC-BOY.
000557 01-08
OPIATE ANTAGONISTS AND FEMALE FUNCTIONING. (UNPUBLISHED
PAPER).
001735 02-04
ORAL ALUMINUM AND NEUROPSYCHOLOGICAL FUNCTIONING: A STUDY
OF DIALYSIS PATIENTS RECEIVING ALUMINUM-HYDROXIDE GELS
002283 02-13
BLOOD-PRESSURE AND COGNITIVE FUNCTIONING.
004492 04-11
FUNCTIONS
EFFECTS OF LITHIUM-CARBONATE ON MEMORY AND OTHER COGNITIVE
FUNCTIONS.
000824 01-14
EXTRAHYPOTHALAMIC DISTRIBUTIONS AND FUNCTIONS OF
HYPOTHALAMIC PEPTIDE-HORMONES. (UNPUBLISHED PAPER).
001211 02-03
EFFECTS OF CHLORPROMAZINE ON DOPAMINERGIC-RECEPTOR FUNCTIONS
IN RAT-BRAIN - DIFFERENCE OF THE RESPONSE OF SEVERAL
DOPAMINERGIC- SYSTEMS AFTER CHRONIC ADMINISTRATION.
002773 03-03
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR
FUNCTIONS RELATED TO MOTIVATED BEHAVIOR.
002815 03-03
EFFECTS OF VASOPRESSIN ON HUMAN MEMORY FUNCTIONS.
003388 03-11
THE EFFECTS OF THEOPHYLLINE AND CAFFEINE ON THERMOREGULATORY
FUNCTIONS OF RATS AT DIFFERENT AMBIENT TEMPERATURES
003907 04-03
FUNDAMENTAL
FUNDAMENTAL MECHANISMS UNDERLYING ALTERED BEHAVIOR
FOLLOWING CHRONIC ADMINISTRATION OF PSYCHOMOTOR
STIMULANTS.
002711 03-03
FUNGAL
ACTIONS OF TREMORGENIC FUNGAL TOXINS ON NEUROTRANSMITTER
RELEASE.
002843 03-03
FURAZOLIDONE
INHIBITION OF MONOAMINE-OXIDASE BY FURAZOLIDONE IN THE
CHICKEN AND THE INFLUENCE OF THE ALIMENTARY FLORA THEREON.
0037 1 1 04-03
F1 -GENERATION
CYCLOPHOSPHAMIDE-INDUCED SPERMATOGENIC EFFECTS DETECTED IN
THE Fl-GENERATION BY BEHAVIORAL-TESTING.
003121 03-05
GABA
REDUCTION OF GAMMA AMINOBUTYRIC-ACID-MEDIATED (GABA)
TRANSMISSION BY A CONVULSANT BENZODIAZEPINE.
000015 01-02
SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA-
ADRENOCEPTOR ANTAGONISTS: EVIDENCE AGAINST GABA
MEDIATION.
000024 01-03
INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERACTION OF AMINO-
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG.
000034 01-03
EFFECT OF AMINOOXYACETIC-ACID (AOAA) ON GABA LEVELS IN SOME
PARTS OF THE RAT-BRAIN.
000040 01-03
DOPAMINE, ACETYLCHOLINE, AND GABA EFFECTS IN ACUTE DYSTONIA IN
PRIMATES.
000043 01-03
CIRCADIAN-RHYTHM OF CYCLIC-NUCLEOTIDE AND GABA LEVELS IN THE
RAT-BRAIN.
000049 01-03
RELATIONSHIP OF ANTICONFLICT ACTIVITY OF BENZODIAZEPINES TO
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA.
000057 01-03
GABA BENZODIAZEPINE INTERACTIONS: PHYSIOLOGICAL,
PHARMACOLOGICAL AND DEVELOPMENTAL ASPECTS.
000103 01-03
EFFECTS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL-
CORD GABA CONCENTRATION.
000145 01-03
A PROBABLE SITE-OF-ACTION OF DIAZEPAM IN RAT CEREBELLAR GABA
SYSTEM.
000151 01-03
GABA INHIBITION OF 3H GLYCINE RELEASE FROM SLICES OF RAT
SUBSTANTIA-NIGRA IN VITRO.
000157 01-03
GABA FLUXES IN PRESYNAPTIC NERVE-ENDINGS FROM IMMATURE RATS
000185 01-03
GABA DEPLETION AND BEHAVIOURAL-CHANGES PRODUCED BY
INTRAVENTRICULAR PUTRESCINE IN CHICKS,
000218 01-03
EFFECT OF GABA ANALOGUES ON BLOOD-PRESSURE AND CENTRAL GABA
METABOLISM IN THE RAT.
000231 01-03
GABAERGIC ACTIONS OF THIP IN VIVO AND IN VITRO: A COMPARISON
WITH MUSCIMOL AND GABA.
000319 01-03
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF
AlO DOPAMINERGIC NEURONS.
000320 01-03
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS
AND ANTAGONISTS: ZONE-SPECIFIC EFFECTS.
000422 01-04
LOCOMOTOR-ACTIVITY ELICITED BY INJECTIONS OF PICROTOXIN INTO THE
VENTRAL TEGMENTAL AREA IS ATTENUATED BY INJECTIONS OF GABA
INTO THE GLOBUS-PALLIDUS.
000436 01-04
DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES.
000584 01-09
GABA LEVELS IN HUMAN CEREBROSPINAL-FLUID: ALTERATIONS IN
PSYCHIATRIC-DISORDERS. (UNPUBLISHED PAPER).
000764 01-13
GABA SYNTHESIS BY CULTURED FIBROBLASTS OBTAINED FROM PERSONS
WITH HUNTINGTONS-DISEASE.
000765 01-13
491,
;'Biii
*«l!|l'
S-193
Subject Index
Psychopharmacology Abstracts
5|.ii,
THE REGULATION OF GABA-RECEPTORS AS A POSSIBLE MECHANISM FOR
GABA 1,4 BENZODIAZEPINE INTERACTIONS. (UNPUBLISHED PAPER).
001012 02-01
GABA AGONISTS AND UPTAKE INHIBITORS DESIGNED AS AGENTS WITH
IRREVERSIBLE ACTIONS.
001079 02-02
EFFECTS OF GABA AND DIAZEPAM ON 3H SEROTONIN RELEASE FROM
HIPPOCAMPAL SYNAPTOSOMES.
001116 02-03
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES.
001208 02-03
EFFECT OF GABA AGONIST AND ANTAGONISTS ON CARDIOVASCULAR
AND SYMPATHETIC RESPONSES IN SHR AND WKY RATS.
(UNPUBLISHED PAPER).
001224 02-03
GABA-MODULIN REGULATES SOLUBILIZED BENZODIAZEPINE AND GABA
RECOGNITION SITES. (UNPUBLISHED PAPER).
00)263 02-03
GABA FACILITATION BY NORADRENALINE SHOWED SUPERSENSITIVITY IN
CEREBELLUM AFTER 6 HYDROXYOOPAMINE
001382 02-03
IN VIVO CHANGES IN THE GABA CONTENT OF NERVE-ENDINGS
(SYNAPTOSOMES) INDUCED BY INHIBITORS OF GABA UPTAKE.
001540 02-03
DRUG-INDUCED ELEVATION OF GABA AFTER INTRACEREBRAL
MICROINJECTION: SITE OF ANTICONVULSANT ACTION.
001627 02-04
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT.
001657 02-04
GABA AGONISTS DISSOCIATE STRIATAL UNIT AQIVITY FROM DRUG-
INDUCED STEREOTYPED-BEHAVIOUR.
001716 02-04
THE EFFECT OF SOME STRUCTURAL GABA ANALOGUES ON THE
SEROTONIN AND DOPAMINERGIC MECHANISMS.
001736 02-04
MOTOR-DEPRESSION AND HEAD-TWITCHES INDUCED BY IP INJECTION OF
GABA.
001788 02-04
EFFECTS OF BRANCHED-CHAIN FATTY-ACIDS ON GABA DEGRADATION
AND BEHAVIOR. FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI-
MORPHINE ABSTINENCE-BEHAVIOR.
001809 02-04
THE STRIATONIGRAL GABA PATHWAY: FUNCTIONAL AND
NEUROCHEMICAL CHARACTERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
STUDIES ON GABA RELEASE IN VIVO USING A SIMPLE METHOD FOR
PERFUSION OF THE FOURTH VENTRICLE OF THE RAT.
001881 02-06
CEREBROSPINAL-FLUID GABA IN PSYCHOTIC-DISORDERS.
002097 02-11
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN
HUNTINGTONS-DISEASE.
002163 02-11
SHORT-TERM AND LONG-TERM EFFECTS ON GABA AND DOPAMINE
NEURONS DURING TREATMENT WITH SULPIRIDE.
002311 02-13
TARDIVE-HYPERKINESIA. EFFECTS OF SULPIRIDE AND GABA SYSTEM
AGONISTS.
002405 02-15
THE SYNTHESIS AND ACTIVITY OF CIS AND TRANS 2
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID AS
CONFORMATIONALLY RESTRICTED ANALOGUES OF GABA.
002633 03-01
HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE
CAUDATE-NUCLEUS BY GABA AGONISTS.
002640 03-01
PIPERIDINE-4-SULPHONIC-ACID, A NEW SPECIFIC GABA AGONIST.
002647 03-02
GABA ANALOGUES ACTIVATE CHANNELS OF DIFFERENT DURATION ON
CULTURED MOUSE SPINAL NEURONS.
002665 03-03
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND
DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY
OF ADULT SENSORY GANGLION CELLS.
002692 03-03
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
002699 03-03
CHRONOLOGY OF NEUROCHEMICAL ALTERATIONS INDUCED BY GABA
AGONIST ADMINISTRATION.
002713 03-03
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR
INJECTION OF CEFAZOLIN.
002762 03-03
THE EFFECTS OF A BENZODIAZEPINE ON THE HYPERPOLARIZING AND THE
DEPOLARIZING RESPONSES OF HIPPOCAMPAL CELLS TO GABA.
002763 03-03
GABA ANTAGONISTS ENHANCE DOPAMINE TURNOVER IN THE RAT
RETINA IN VIVO.
002772 03-03
MODULATION BY PICROTOXIN AND IPTBO OF 3H FLUNITRAZEPAM
BINDING TO THE GABA/BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-
CEREBELLUM.
002775 03-03
THE EFFECT OF SPECIFIC BRAIN LESIONS ON THE HIGH-AFFINITY BINDING
OF GABA IN THE SUBSTANTIA-NIGRA.
002795 03-03
GABA AGONISTS AS ANTIEPILEPTIC-AGENTS.
002826 03-03
INHIBITORY ACTIONS OF TAUROCY AMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO
GABA REGULATED CHLORIDE ION-CHANNELS.
002848 03-03
GABA AND BACLOFEN POTENTIATE THE K -EVOKED RELEASE OF
METHIONINE-ENKEPHALIN FROM RAT STRIATAL SLICES.
002882 03-03
ACTION OF PYRAZOLOPYRIDINES AS MODULATORS OF
(3H)FLUNITRAZEPAM BINDING TO THE GABA/BENZODIAZEPINE-
RECEPTOR COMPLEX OF THE CEREBELLUM
002909 03-03
BIPHASIC-EFFECTS AND OPPOSITE-EFFECTS OF DOPAMINE AND
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT
SUBSTANTIA-NIGRA.
002923 03-03
A COMPARATIVE-STUDY OF THE PHARMACOLOGY OF INHIBITORS OF
GABA METABOLISM.
003036 03-04
DETERMINATION OF GABA LEVELS BY A (3H)MUSCIM0L RADIORECEPTOR
ASSAY.
003135 03-06
GABA AND SCHIZOPHRENIA: STUDY OF THE AQION OF A GABAERGIC
ANTAGONIST PROGABIDE OR SL-76-002. i
003175 03-08
THE EFFECT OF SODIUM-VALPROATE ON MANIA: THE GABA HYPOTHESIS
OF AFFECTIVE-DISORDERS.
003218 03-09
ON A POSSIBLE ROLE OF GABA IN MANIA THERAPEUTIC-EFFICACY OF
SODIUM-VALPROATE.
003219 03-09
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE:
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION
003458 03-14
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS:
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO.
003741 04-03
3H BACLOFEN AND 3H GABA BIND TO BICUCULLINE INSENSITIVE GABAB
SITES IN RAT-BRAIN.
003839 04-03
A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/
BENZODI AZEPINE-RECEPTOR INTERACTION .
003851 04-03
SENSITIVITY TO GABA OF NEURONS OF THE DORSAL AND VENTRAL
LATERAL GENICULATE NUCLEI IN THE RAT
003877 04-03
EFFECT OF INHIBITORS OF GABA-AMINOTRANSFERASE ON THE
METABOLISM OF GABA IN BRAIN TISSUE AND SYNAPTOSOMAL
FRACTIONS.
003914 04-03
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC-
AMP.
003952 04-03
DOPAMINE-DEPENDENT HYPERAQIVITY IN THE FOLLOWING
MANIPULATION OF GABA MECHANISMS IN THE REGION OF THE
NUCLEUS-ACCUMBENS
003976 04-03
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN
BRAIN CELL-CULTURES. „ „,
004002 04-03
S-194
VOLUME 19, SUBJECT INDEX
Subject Index
IN VITRO MODULATION BY AVERMECTIN-B1A OF THE GABA/
BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-CEREBELLUM.
004023 04-03
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL
BY ANXIOLYTICS WITH DRUGS ACTING ON THE GABA SYSTEM
004193 04-04
OABA-AMINOTRANSFERASE
COMPARATIVE-STUDY OF THE INHIBITION OF GABA-AMINOTRANSFERASE
BY DIFFERENT ANTICONVULSANT-DRUGS.
000192 01-03
EFFECT OF INHIBITORS OF GABA-AMINOTRANSFERASE ON THE
METABOLISM OF GABA IN BRAIN TISSUE AND SYNAPTOSOMAL
FRACTIONS.
003914 04-03
GABA-AUTORECEPTORS
GABA-AUTORECEPTORS: STRUCTURE-ACTIVITY RELATIONSHIPS FOR
AGONISTS.
002678 03-03
6ABA-CHLORIDE
THE BENZODIAZEPINE GABA-CHLORIDE lONOPHORE-RECEPTOR COMPLEX:
COMMON SITE OF MINOR-TRANQUILIZER ACTION.
002857 03-03
GABA-ENHANCED
PENTOBARBITAL POTENTIATES GABA-ENHANCED (3H) DIAZEPAM
BINDING TO BENZODIAZEPINE-RECEPTORS.
000275 01-03
DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM
BOVINE CEREBRAL-CORTEX.
002645 03-01
GABA-ENHANCEMENT
GABA-ENHANCEMENT OF (3H)D0PAMINE RELEASE FROM SLICES OF RAT
STRIATUM: DEPENDENCE ON SLICE SIZE.
003786 04-03
GABA-EVOKED
NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE
POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS.
000116 01-03
GABA-MEDIATED
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH
ANTICONVULSANT AND ANESTHETIC ACTIONS.
002885 03-03
THE ROLE OF GABA-MEDIATED NEUROTRANSMISSION IN CONVULSIVE
STATES.
003334 03-11
AN ELECTROPHYSIOLOGICAL MODEL OF GABA-MEDIATED
NEUROTRANSMISSION.
003929 04-03
GABA-MODULIN
ASSAYING GABA-MODULIN ACTIVITY IN BRAIN EXTRACTS: RESOLUTION
OF INHERENT DIFFICULTIES. (UNPUBLISHED PAPER).
001045 02-01
GABA-MODULIN REGULATES SOLUBILIZED BENZODIAZEPINE AND GABA
RECOGNITION SITES. (UNPUBLISHED PAPER).
001263 02-03
DIFFERENTIAL-EFFECTS OF KAINIC-ACID ON BENZODIAZEPINE-RECEPTORS,
GABA-RECEPTORS, AND GABA-MODULIN IN THE CEREBELLAR-CORTEX.
002477 02-16
GABA-RECEPTOR
CHARAQERIZATION OF 3H GABA-RECEPTOR BINDING TO RAT-BRAIN
SYNAPTOSOMAL MEMBRANES: EFFECT OF NONGABAERGIC
COMPOUNDS.
000139 01-03
ETHANOL ENHANCES (3H)DIAZEPAM BINDING AT THE BENZODIAZEPINE
GABA-RECEPTOR lONOPHORE COMPLEX.
001154 02-03
A NOVEL GABA-RECEPTOR MODULATES STIMULUS-INDUCED GLUTAMATE
RELEASE FROM CORTICOSTRIATAL TERMINALS.
001376 02-03
BENZODIAZEPINES MODIFY THE AGONIST RESPONSES AT A PRESYNAPTIC
GABA-RECEPTOR.
001377 02-03
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONISES THE EFFECT OF
DIAZEPAM ON A FUNCTIONAL GABA-RECEPTOR.
001378 02-03
THE EFFEQS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON
GABA-RECEPTOR BINDING.
002301 02-13
LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID.
002828 03-03
GABA-RECEPTOR ASSOCIATED DRUG-RECEPTORS.
002893 03-03
SYNTHESIS AND GABA-RECEPTOR BINDING-ACTIVITY OF TWO
FLUOROAMINOMETHYLPHENOLS.
003693 04-02
ROLE OF THE ANTERIOR PITUITARY GABA-RECEPTOR IN THE CONTROL OF
PROLACTIN RELEASE.
003809 04-03
EFFECTS OF HALOPEMIDE ON GABA-RECEPTOR BINDING. UPTAKE AND
RELEASE.
003913 04-03
SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS DESIGN,
DEVELOPMENT AND STRUCTURE-ACTIVITY STUDIES
004725 04-17
GABA-RECEPTORS
THE REGULATION OF GABA-RECEPTORS AS A POSSIBLE MECHANISM FOR
GABA 1,4 BENZODIAZEPINE INTERACTIONS. (UNPUBLISHED PAPER)
001012 02-01
TWO OR MORE CONFORMATIONS OF BENZODIAZEPINE-RECEPTORS
DEPENDING ON GABA-RECEPTORS AND OTHER VARIABLES.
001139 02-03
PHARMACOLOGICAL EVIDENCE AND BIOCHEMICAL-EVIDENCE FOR AN
INTERACTION BETWEEN THE BENZODIAZEPINE AND GABA-RECEPTORS
001261 02-03
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME
BENZODIAZEPINE RECOGNITION SITES ARE COUPLED TO GABA-
RECEPTORS AND lONOPHORES.
001484 02-03
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS IN THE OFFSPRING
OF DAMS RECEIVING DIAZEPAM: ONTOGENETIC-STUDIES.
001849 02-05
DIFFERENTIAL-EFFECTS OF KAINIC-ACID ON BENZODIAZEPINE-RECEPTORS,
GABA-RECEPTORS, AND GABA-MODULIN IN THE CEREBELLAR-CORTEX.
002477 02-16
RADIOHISTOCHEMICAL STUDIES OF BENZODIAZEPINE AND GABA-
RECEPTORS AND THEIR INTERACTIONS.
002644 03-01
GABA-RECEPTORS AND THE DEPRESSANT ACTION OF PENTOBARBITAL.
002666 03-03
EFFECT OF PICROTOXIN ON BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS WITH REFERENCE TO THE EFFECT OF CHLORIDE ION.
002725 03-03
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN.
002727 03-03
BENZODIAZEPINE RECOGNITION SITES ON GABA-RECEPTORS.
002730 03-03
ANTERIOR PITUITARY GABA-RECEPTORS AND THEIR REGULATION OF
PROLACTIN SECRETION.
002738 03-03
KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFECT ON
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS.
002743 03-03
BARBITURATES AND GABA-RECEPTORS.
002769 03-03
GABA-RECEPTORS AS SUPRAMOLECULAR UNITS.
002819 03-03
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR
BRAIN SPECIFIC BENZODIAZEPINE BINDING.
002903 03-03
EFFECT OF SODIUM-VALPROATE ON MOTOR FUNCTION REGULATED BY
THE ACTIVATION OF GABA-RECEPTORS.
003033 03-04
RELATIONSHIP BETWEEN THE PRESENCE OF DOPAMINERGIC NEURONS
AND GABA-RECEPTORS IN SUBSTANTIA-NIGRA: EFFECTS OF LESIONS.
003797 04-03
GABA-STIMULATED
CHARACTERIZATION OF GABA-STIMULATED BENZODIAZEPINE-RECEPTOR
BINDING.
001309 02-03
GABA-TRANSAMINASE
BLOCKADE OF METHAMPHETAMINE-INDUCED DEPRESSION OF TYROSINE-
HYDROXYLASE BY GABA-TRANSAMINASE INHIBITORS.
000130 01-03
CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC-
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE
(GABA-TRANSAMINASE) INHIBITOR.
000174 01-03
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE:
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION.
003458 03-14
THE PHARMACOLOGY OF GABA-TRANSAMINASE INHIBITORS.
003620 03-17
GABAB
3H BACLOFEN AND 3H GABA BIND TO BICUCULLINE INSENSITIVE GABAB
SITES IN RAT-BRAIN.
003839 04-03
GABAERGIC
EVIDENCE FOR A GABAERGIC NIGROTHALAMIC PATHWAY IN THE RAT: I.
BEHAVIOURAL- STUDIES AND BIOCHEMICAL-STUDIES.
000158 01-03
a.
'M
'nlUt'
Ulul
I
'lull'
S-195
Subject Index
Ptychopharmacoiogy Abstracts
EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL
AND DIPHENYLHYDANTOIN IN THE ELEQROSHOCK-TEST IN MICE.
000163 01-03
GABAERGIC ACTIONS OF THIP IN VIVO AND IN VITRO: A COMPARISON
WITH MUSCIMOL AND GABA.
000319 01-03
BEHAVIORAL-EFFECTS AND ELECTROCORTICAL-EFFECTS AFTER
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS
ENHANCING GABAERGIC TRANSMISSION.
000443 01-04
THE INFLUENCE OF GABAERGIC SUBSTANCES ON THE EFFECTS OF
STIMULATION OF THE CAUDATE-NUCLEUS AND AMPHETAMINE
STEREOTYPY IN CATS.
000489 01-04
MODIFICATION OF GABAERGIC ACTIVITY AND THYROTROPIN SECRETION
IN MALE RATS.
001362 02-03
DIPROPYLACETATE-INDUCED ABSTINENCE-BEHAVIOUR AS A POSSIBLE
CORRELATE OF INCREASED GABAERGIC ACTIVITY IN THE RAT.
001606 02-04
INVOLVEMENT OF CHOLINERGIC AND GABAERGIC SYSTEMS IN
SCHIZOPHRENIA.
001907 02-08
BENZODIAZEPINE-RECEPTORS: AUTORADIOGRAPHICAL AND
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN
REGIONS OF GABAERGIC SYNAPTIC CONTACTS.
002643 03-01
GABAERGIC MECHANISMS IN THE CONTROL OF PRL AND GH RELEASE.
002690 03-03
EVIDENCE FOR A TONIC GABAERGIC CONTROL OF SEROTONIN NEURONS
IN THE MEDIAN RAPHE NUCLEUS
002719 03-03
INJECTIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINERGIC AND
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS: EFFECTS ON
LOCOMOTOR-ACTIVITY IN THE RAT
003019 03-04
GABA AND SCHIZOPHRENIA: STUDY OF THE ACTION OF A GABAERGIC
ANTAGONIST PROGABIDE OR SL-76-002.
003175 03-08
DOPAMINERGIC AND GABAERGIC ASPECTS OF TARDIVE-DYSKINESIA
003302 03-11
CHANGES OF ELECTRORETINOGRAM AND NEUROCHEMICAL ASPECTS OF
GABAERGIC NEURONS OF RETINA AFTER INTRAOCULAR INJECTION OF
KAINIC-ACID IN RATS.
003807 04-03
IN VIVO EVIDENCE FOR GABAERGIC CONTROL OF SEROTONIN RELEASE IN
THE CAT SUBSTANTIA-NIGRA
00401 1 04-03
ON SOME RELATIONSHIPS BETWEEN GABAERGIC AND 5 HT-ERGIC
MECHANISMS IN PENTYLENETETRAZOL CONVULSIVE-SEIZURE
REACTIONS.
004166 04-04
GABAMIMETIC
ANALGESIC PROPERTIES OF THE GABAMIMETIC THIP
003013 03-04
GABAMIMETICS
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND
GABAMIMETICS.
000188 01-03
THE EFFECT OF GABAMIMETICS ON NEUROTRANSMIHER-RECEPTOR
BINDING AND FUNCTION IN RAT-BRAIN. (PH D. DISSERTATION).
001221 02-03
BIPHASIC-EFFECTS OF DIRECT, BUT NOT INDIRECT, GABAMIMETICS AND
ANTAGONISTS ON HALOPERIDOL-INDUCED CATALEPSY.
001826 02-04
GAD
PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID-
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY
COMPLEX. (UNPUBLISHED PAPER).
001047 02-01
COMPARISON OF CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE (CSD)
ISOENZYMES AND GLUTAMIC-ACID-DECARBOXYLASE (GAD) IN RAT: IS
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH
GAD? (UNPUBLISHED PAPER).
001048 02-01
DECREASE OF GAD IMMUNOREACTIVE NERVE TERMINALS IN THE
SUBSTANTIA-NIGRA AFTER KAINIC-ACID LESION OF THE STRIATUM
(UNPUBLISHED PAPER)
001400 02-03
GALACTORRHEA
THE EFFECT OF AMANTADINE ON PROLACTIN LEVELS AND
GALACTORRHEA ON NEUROLEPTIC TREATED PATIENTS.
003373 03-1 1
GALLUS-DOMESTICUS
THE BEHAVIOURAL-STATE DURING CLIMAX (HATCHING) IN THE
DOMESTIC-FOWL (GALLUS-DOMESTICUS) .
001564 02-04
GALVANIC-SKIN-RESISTANCE
TREATMENT OF THERAPY-RESISTANT DEPRESSED-PATIENTS WITH IV.
INFUSIONS OF NOMIFENSINE CONTROLLED BY GALVANIC-SKIN-
RESISTANCE.
002012 02-09
GAMMA-RADIATION
BIOLOGIC-INTERACTION OF GAMMA-RADIATION WITH
PHENYLBUTAZONE, PHENYTOIN, OR HYDRALAZINE.
000518 01-05
GAMMA-RAY
SPECIFIC IN VIVO BINDING OF 77BR P BROMOSPIROPERIDOL IN RAT-
BRAIN: A POTENTIAL TOOL FOR GAMMA-RAY IMAGING.
004293 04-06
GANGLIA
ENKEPHALINS PRESYNAPTICALLY INHIBIT CHOLINERGIC TRANSMISSION
IN SYMPATHETIC GANGLIA
000167 01-03
CHARACTERIZATION OF LRF-LIKE IMMUNOREACTIVITY IN THE FROG
SYMPATHETIC GANGLIA: NONIDENTITY WITH LRF-DECAPEPTIDE.
(UNPUBLISHED PAPER)
001018 02-01
MUSCARINIC-RECEPTORS IN RAT SYMPATHETIC GANGLIA.
001 144 02-03
PRESYNAPTIC ACTIONS OF 4 AMINOPYRIDINE AND GAMMA
AMINOBUTYRIC-ACID ON RAT SYMPATHETIC GANGLIA IN VITRO
001244 02-03
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES.
002285 02-13
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR
FUNCTIONS RELATED TO MOTIVATED BEHAVIOR.
002815 03-03
KAINIC-ACID AND NEUROTRANSMinER INTERAQIONS IN THE BASAL
GANGLIA.
002824 03-03
THE EFFECTS OF ALPHA AND BETA NEUROTOXINS FROM THE VENOMS OF
VARIOUS SNAKES ON TRANSMISSION IN AUTONOMIC GANGLIA
003750 04-03
A COMPARATIVE-STUDY OF THE PHARMACOLOGICAL-PROPERTIES OF THE
POSITIVE POTENTIAL RECORDED FROM THE SUPERIOR CERVICAL
GANGLIA OF SEVERAL SPECIES.
003779 04-03
THE EXCITATORY EFFECT OF ATROPINE ON THE NEURONS OF THE FROG
SYMPATHETIC GANGLIA.
004041 04-03
GANGLION
CALCIUM LOCALIZATION IN THE SYMPATHETIC GANGLION OF THE
BULLFROG AND EFFECTS OF CAFFEINE.
000098 01-03
BIOCHEMICAL-CHARACTERIZATION OF THE RAT SYMPATHETIC
GANGLION: PHARMACOLOGICAL-EFFECTS OF RESERPINE ON
GANGLIONIC CATECHOLAMINES
000153 01-03
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND
DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY J
OF ADULT SENSORY GANGLION CELLS.
002692 03-03
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF
BULLFROG SYMPATHETIC GANGLION CELLS
003710 04-03
RELATIVE ACTIVITIES OF SUBSTANCES RELATED TO 5
HYDROXYTRYPTAMINE AS DEPOLARIZING-AGENTS OF SUPERIOR
CERVICAL GANGLION CELLS.
004047 04-03
GANGLIONIC , i
BIOCHEMICAL-CHARAQERIZATION OF THE RAT SYMPATHETIC
GANGLION: PHARMACOLOGICAL-EFFECTS OF RESERPINE ON 1
GANGLIONIC CATECHOLAMINES.
000153 01-03
THE EFFEQS OF TWO ANALOGS OF DOPAMINE ON GANGLIONIC
TRANSMISSION IN THE SYMPATHETIC-NERVOUS-SYSTEM.
000162 01-03
THE LONG-TERM REGULATION OF GANGLIONIC TYROSINE-HYDROXYLASE
BY PREGANGLIONIC NERVE ACTIVITY.
000333 01-03 ,
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJEQION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION. „„,..„ „on.
001568 02-04
PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFEQS OF
GANGLIONIC AND ADRENORECEPTOR BLOCKADE.
002863 03-03
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND
GANGLIONIC SYNAPSES. „^^„,„ „, „,
002870 03-03
S-196
VOLUME 19, SUBJECT INDEX
Subject Index
OANOLIOSIDE
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL-
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF
ANTIBODIES TO GANGLIOSIDE
003025 03-04
OANOUOSIDES
INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN
SUBCELLULAR GANGLIOSIDES: EFFECT OF PENTYLENETETRAZOL-
INDUCED CONVULSIONS IN BRAIN GANGLIOSIDES
002937 03-03
BEHAVIOURAL-CHANGES IN ADULT RATS FOLLOWING ADMINISTRATION
OF ANTIBODIES AGAINST BRAIN GANGLIOSIDES.
003071 03-04
OAS-CHROMATOGRAPHIC-PROPERTIES
GAS-CHROMATOGRAPHIC-PROPERTIES OF 1,3 DIALKYLBARBITURATE
DERIVATIVES.
003658 04-01
OAS-CHROMATOGRAPHIC-SYNTHESIS
ON-COLUMN GAS-CHROMATOGRAPHIC-SYNTHESIS OF 1,3 DIALYKYL
(C=l-10), BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES.
003656 04-01
OAS-CHROMATOGRAPHY
ANALYSIS FOR DIAZEPAM AND NORDIAZEPAM BY ELECTRON-CAPTURE
GAS-CHROMATOGRAPHY AND BY LIQUIO-CHROMATOGRAPHY.
000006 01-01
QUANTITATIVE ANALYSIS OF 6 HYDROXYMELATONIN IN HUMAN URINE
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS-
SPEaROMETRY. (UNPUBLISHED PAPER).
001058 02-01
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
MEASUREMENT OF FLUPHENAZINE BY GAS-CHROMATOGRAPHY IN
HUMAN PLASMA AND RED-BLOOD-CELLS.
002491 02-16
A METHOD FOR MEASUREMENT OF TRANYLCYPROMINE IN RAT-BRAIN
REGIONS USING GAS-CHROMATOGRAPHY WITH ELECTRON CAPTURE
DETEQION.
003137 03-06
GAS-CHROMATOGRAPHY, MASS-SPEQROMETRY, AND COMBINED
CHROMATOGRAPHY MASS-SPECTROMETRY.
004290 04-06
RAT-BRAIN AND PLASMA NOREPINEPHRINE GLYCOL METABOLITES
DETERMINED BY GAS-CHROMATOGRAPHY MASS-
FRAGMENTOGRAPHY.
004303 04-06
GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC
ANALYSES FOR DEANOL, CHOLINE, AND THEIR ACETYLESTERS.
004683 04-16
COMPARISON OF SPEaROFLUOROMETRIC AND GAS-
CHROMATOGRAPHY/MASS-SPECTROMETRY PROCEDURES FOR THE
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN.
004692 04-16
GAS-EXCHANGE
THE EFFECT OF PHARMACOLOGICAL DESTRUCTION OF HYPOTHALAMIC
MONOAMINERGIC STRUQURES ON BODY-TEMPERATURE AND GAS-
EXCHANGE DURING EXTREME COOLING.
004016 04-03
GAS-LIQUID-CHRO«AATOGRAPHIC-DETERMINATION
ELEaRON-CAPTUREGAS-LIQUID-CHROMATOGRAPHIC-DETERMINATION
OF ETHOSUXIMIDE AND DESMETHYLMETHSUXIMIDE IN PLASMA OR
SERUM.
000538 01-06
6AS-LIQUID-CHROMATOGRAPHY
DETERMINATION OF VALPROIC-ACID BY FLAME-IONIZATION GAS-LIQUID-
CHROMATOGRAPHY.
000906 01-16
A RAPID GAS-LIQUID-CHROMATOGRAPHY METHOD FOR SIMULTANEOUS
DETERMINATION OF VARIOUS ANTICONVULSANTS.
002501 02-16
SIMULTANEOUS ADMINISTRATION OF FIVE ANTIEPILEPTIC-DRUGS IN
PLASMA THROUGH GAS-LIQUID-CHROMATOGRAPHY.
003563 03-16
GASTRIC
GASTRIC AND PYLORIC MOTOR-RESPONSE TO SYMPATHETIC-NERVE
STIMULATION AFTER CHEMICAL SYMPATHECTOMY. (UNPUBLISHED
PAPER).
001337 02-03
APHAGIA, GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNaiONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS:
EFFEQS OF INSULIN PRETREATMENTS.
001638 02-04
INHIBITION OF PENTAGASTRIN-STIMUUVTEO AND OVERNIGHT GASTRIC
SECRETION BY LM24056, A NEW PHENOTHIAZINE DERIVED
ANTISECRETORY DRUG.
004306 04-07
OASTRIC-UICERS
STUDIES ON THE COMPREHENSIVE MEDICAL TREATMENT OF PEPTIC-
ULCERS (3) - UTILIZATION OF TRANQUILIZERS IN THE TREATMENT OF
GASTRIC-ULCERS
000653 01-10
GASTRIN
ON CORRELATION OF BEHAVIORAL-REACTIONS AND NEURONAL ACTIVITY
IN THE HYPOTHALAMUS UNDER SUBCUTANEOUS GASTRIN INJECTION.
002892 03-03
GASTROINTESTINAL
COMPARISON OF THE POTENCIES OF CLEBOPRIOE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRACT OF THE GUINEA-PIG AND RAT.
003928 04-03
GASTRORESISTANT
TOLERANCE IN A COMPRESSED GASTRORESISTANT FORM IN
PSYCHIATRIC-PATIENTS.
003157 03-07
GAVAGE
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME ACTIVITY
IN THE RAT-BRAIN.
001614 02-04
GENE
ENHANCED RESPONSES TO OPIATES PRODUCED BY A SINGLE GENE
SUBSTITUTION IN THE MOUSE.
001677 02-04
GENERAL-ACTIVITY
EFFECTS OF AN ACTH4-9 RELATED PEPTIDE UPON INTRACRANIAL SELF-
STIMULATION AND GENERAL-ACTIVITY IN THE RAT.
001679 02-04
GENERAL-HOSPITAL
PSYCHOTROPIC-DRUGS AND POLYPHARMACY IN ELDERLY-PATIENTS IN A
GENERAL-HOSPITAL.
000981 01-17
TREATMENT OF IATROGENIC DRUG DEPENDENCE IN THE GENERAL-
HOSPITAL.
002460 02-15
PSYCHOTROPIC-DRUG USE AND POLYPHARMACY IN A GENERAL-
HOSPITAL.
003369 03-1 1
GENERAL-MEDICAL-PRACTICE
THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL-
MEDICAL-PRAQICE: 48 CASES TREATED ON AN OUTPATIENT BASIS.
003268 03-09
GENERAL-PRACTICE
PROGNOSTIC FACTORS DETERMINING RESPONSE TO ANTIDEPRESSANT-
DRUGS IN PSYCHIATRIC-OUTPATIENTS AND GENERAL-PRAQICE.
000638 01-09
MAPROTILINE ADMINISTERED IN A SINGLE-DAILY-DOSE IN GENERAL-
PRAQICE.
002027 02-09
JOB-SATISFACTION IN GENERAL-PRACTICE: IMPLICATIONS FOR
PRESCRIBING.
002579 02-17
GENERAL-PRACTITIONER
STUDY OF MAPROTILINE IN OUTPATIENT TREATMENT OF DEPRESSIVE-
STATES BY THE GENERAL-PRAQITIONER: ADVANTAGE OF SINGLE-
NIGHTLY-DOSE.
001961 02-09
GENERAL-PRACTITIONERS
DIFFICULTIES ENCOUNTERED DURING A CONTROLLED STUDY OF A NEW
HYPNOTIC-DRUG (TRIAZOLAM) BY A GROUP OF GENERAL-
PRACTITIONERS.
003155 03-07
GENERATING
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFECT
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE.
001353 02-03
GENERATION
HALOTHANE EFFEQ ON C-AMP GENERATION AND HYDROLYSIS IN RAT-
BRAIN.
000305 01-03
GENERATORS
IDENTICAL RESPONSES OF THE TWO HIPPOCAMPAL THETA GENERATORS
TO PHYSIOLOGICAL AND PHARMACOLOGICAL AQIVATION.
002792 03-03
GENESES
EXPERIENCE IN USING THE HORMONES OF THE HYPOPHYSIS POSTERIOR
LOBE IN MEMORY-DISTURBANCES OF VARYING GENESES.
003438 03-14
GENESIS
CEREBELLAR GRANULE CELL GENESIS IN THE HYDROCORTISONE TREATED
RAT
000030 01-03
a.
'M
I
'Sill:
'Hit'
at
Si:
S-197
I
Subject Index
GENETIC
ON THE GENETIC SIDE-EFFECTS OF PSYCHOTROPIC-SUBSTANCES: 1.
PSYCHOPHARMACEUTICALS, NARCOTICS, AND ANTICONVULSANT.
000845 01-15
VITAMIN RESPONSIVE GENETIC ABNORMALITIES. (UNPUBLISHED PAPER).
001388 02-03
BIOGENIC-AMINES AND NEUROPEPTIDES PLAY A ROLE IN THE CENTRAL-
REGULATION OF GENETIC HYPERTENSION. (UNPUBLISHED PAPER).
001455 02-03
CENTRAL BIOGENIC-AMINES AND NEUROPEPTIDES IN GENETIC
HYPERTENSION . (UNPUBLISHED PAPER)
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS PRESENT A NALOXONE
SENSITIVE DECREASE IN PAIN SENSITIVITY. (UNPUBLISHED PAPER).
001457 02-03
CENTRAL AMINERGIC AND PEPTIDERGIC MECHANISMS IN
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS. (UNPUBLISHED
^^^^^^- 001459 02-03
GENETIC AND EXPERIMENTAL FACTORS AFFEQING THE PARADOXICAL-
EFFEaS OF AMPHETAMINE IN DOGS.
001704 02-04
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC
AND DOCA-SALT HYPERTENSION IN THE RAT.
003899 04-03
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
00411204-04
EFFEa OF BROMOCRIPTINE ON EXPLORATORY-ACTIVITY, BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS. „„,,.. „^„.
001635 02-04
NEUROCHEMICAL-EFFEQS AND BEHAVIORAL-EFFEaS OF CHRONIC D-
AMPHET AMINE TREATMENT IN GENETICALLY OBESE (OBOB) MICE.
(PH.D. DISSERTATION). „„,,,„ „o «.
001739 02-04
GENICULATE
SENSITIVITY TO GABA OF NEURONS OF THE DORSAL AND VENTRAL
LATERAL GENICULATE NUCLEI IN THE RAT.
003877 04-03
THE EFFECT OF ASSERTIVENESS TRAINING, PROVERA AND SEX OF
THERAPIST IN THE TREATMENT OF GENITAL EXHIBITIONISM.
000697 01-11
STUDY OF LITHIUM LEVELS IN THE SERUM AND GENITAL ORGANS OF
MALE RATS. „«,,«.«o^^
001494 02-03
THE INFLUENCE OF GENOTYPE AND SEX ON BEHAVIORAL-SENSITIVITY TO
NICOTINE IN MICE. _,, „„„„.
001648 02-04
INTERACTION AMONG D-AMPHETAMINE, SCOPOLAMINE AND GENOTYPE
IN AVOIDANCE-BEHAVIOR OF RATS.
003082 03-04
GENOTYPIC
GENOTYPIC INFLUENCES ON STRIATAL DOPAMINERGIC REGULATION IN
'^'" 004217 04-04
GEOGRAPHICALLY
PSYCHIATRIC-ILLNESS AND USE OF PSYCHOTROPIC-DRUGS IN THE
GEOGRAPHICALLY DELIMITED POPULATION OF SAMSO, DENMARK.
004734 04-17
GERBILS
NEUROPHARMACOLOGICAL ANALYSIS OF HANDLING-INDUCED SEIZURES
IN GERBILS. „„,„,, „o„.
001876 02-06
GERIATRIC
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC
DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL
^°^^^°^^ 002004 02-09
THE EFFICACY OF TRIAZOLAM AND CHLORAL-HYDRATE IN GERIATRIC
INSOMNIACS. „„„w^«o,,
002160 02-11
DESIGN ASPEaS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS: A
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING-SCALES.
002512 02-16
DRUGS AND THE ELDERLY: PERSPEQIVES IN GERIATRIC CLINICAL-
PHARMACOLOGY. „„„.o. „o ,-,
002534 02-17
GERIATRIC PSYCHOPHARMACOLOGY.
002582 02-17
GERIATRIC ASPEQS OF PARKINSONISM (CLINICAL-PIQURE,
PATHOLOGICAL MECHANISMS, AND MULTIPLE TREATMENT).
003643 03-17
Psychopharmacology Abstracts
GERIATRIC-PATIENTS
PSYCHOPATHOMETRIC DOUBLE-BUND COURSE STUDY WITH NICERGOLINE
VERSUS PLACEBO IN GERIATRIC-PATIENTS WITH TRANSIENT-
SYNDROMES.
000665 01-11
CARDIOVASCULAR EFFEQS OF NORTRIPTYLINE IN GERIATRIC-PATIENTS.
000882 01-15
PHENYTOIN CONCENTRATIONS IN VENOUS VERSUS CAPILLARY BLOOD OF
GERIATRIC-PATIENTS.
003381 03-11
GERIATRICS
EEG COMP-EEG, REO-EG AND PHARMACOLOGICAL-CORRELATES OF
GERIATRICS.
002162 02-11
CLINICAL-TRIALS WITH CLOBAZAM IN GERIATRICS.
003279 03-10
GERONTOLOGY
CLINICAL-EXPERIENCE WITH PIRACETAM THERAPY IN GERONTOLOGY.
000686 01-11
REVIEW OF CLINICAL-STUDIES WITH ERGOTS IN GERONTOLOGY.
002624 02-17
GERONTOPSYCHIATRIC-PATIENT
AQION OF BUTRIPTYLINE-HYDROCHLORIDE IN THE
GERONTOPSYCHIATRIC-PATIENT.
003358 03-1 1
GERONTOPSYCHIATRIC-PATIENTS
INFLUENCE OF STRYCHNINE ON THE CONSOLIDATION PHASE OF VISUAL-
MEMORY IN GERONTOPSYCHIATRIC-PATIENTS.
002156 02-11
GERONTOPSYCHIATRY
EXPERIENCE WITH FLUSPIRILENE IN GERONTOPSYCHIATRY.
000691 01-11
GEROPSYCHIATRY
PSYCHOSTIMULANTS AND NEUROPEPTIDES IN GEROPSYCHIATRY.
002125 02-11
GESTATION i
PHENCYCLIDINE: EFFEaS OF CHRONIC ADMINISTRATION IN THE FEMALE
MOUSE ON GESTATION, MATERNAL-BEHAVIOR, AND THE NEONATES.
000517 01-05
CRITICAL PERIODS FOR DIPHENYLHYDANTOIN AND PHENOBARBITAL
ADMINISTRATION DURING GESTATION.
001630 02-04
GESTATIONAL ,„ _
EFFECTS OF FETAL TREATMENT WITH METHYLAZOXYMETHANOL-ACETATE
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE
ADULT NEOCORTEX OF THE RAT.
002770 03-03
GH
GROWTH-HORMONE (GH) RELEASE FOLLOWING THYROTROPIN-
RELEASING-HORMONE (TRH) INJEQION IN MANIC-PATIENTS
RECEIVING LITHIUM-CARBONATE. 000645 01^-
GABAERGIC MECHANISMS IN THE CONTROL OF PRL AND GH RELEASE. ■
002690 03-03
GILLES-DE-LA-TOURETTE-SYNDROME
CLONIDINE AMELIORATES GILLES-DE-LA-TOUREHE-SYNDROME. '
002106 02-11
SERUM HALOPERIDOL LEVELS IN GILLES-DE-LA-TOURETTE-SYNDROME.
003374 03-11
GILLES-DE-LA-TOURETTES-DiSEASE , ,
HALOPERIDOL-INDUCED TARDIVE-DYSKINESIA IN A CHILD WITH GILLES-
DE-IA-TOUREHES-DISEASE. 002437 02-15
GILLES-DE-LA-TOURETTES-DISORDER
GILLES-DE-LA-TOUREHES-DISORDER ASSOCIATED WITH PEMOUNE.
002436 02-15
GILLE$-0E-LA-TOURETTES-SYNDROME ,^.,„.„rc
PENFLURIDOL IN THE TREATMENT OF GILLES-DE-LA-TOUREHES-
5^'^'^'^°^^ 002158 02-11
CORTICAL EVOKED-POTENTIALS IN GILLES-DE-LA-TOUREHES-SYNDROME
-A SINGLE CASE-STUDY. 00343103-13
METABOLISM OF 3H NORADRENALINE RELEASED FROM ISOLATED RAT
HYPOTHALAMUS BY EXTRAQS OF BLACK-WIDOW-SPIDER GLANDS^
000223 01-03
GLAUCOMA
PSYCHOTROPIC-MEDICATIONS AND GLAUCOMA. 004647 04 1 5
GLC
GLC MASS-SPECTROMETRIC-DETERMINATION OF MAPROTILINE AND ITS
MAJOR METABOLITE USING STABLE ISOTOPE-LABELED ANALOG AS
INTERNAL STANDARD. 00429104^
MEASUREMENT OF NEUROLEPTIC CONCENTRATIONS BY GLC AND
RADIORECEPTOR ASSAY. 004682 04-16
S-198
VOLUME 19, SUBJECT INDEX
Subject Index
GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA
DERIVATIZATION TECHNIQUES.
004687 04-16
OLIAL
3H IMIPRAMINE BINDING IN NEURONAL AND GLIAL FRACTIONS OF
HORSE STRIATUM
000033 01-03
(3H)5 HT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN
GLIAL CELL MEMBRANE FRACTION.
000093 01-03
GLIAL CELL EFFECTS OF SUBACUTE FORMIC-ACID VAPOUR EXPOSURE.
000527 01-05
A STUDY OF A GLIAL GAMMA AMINOBUTYRIC-ACID SYSTEM: ITS
REGULATION, FUNCTION AND THE EFFECTS OF DIAZEPAM. (PH.D.
DISSERTATION).
001524 02-03
LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID.
002828 03-03
GLIOBLASTOMA
DOSAGE OF INTRATUMORAL LITHIUM (CEREBRAL GLIOBLASTOMA): ON A
FAILURE OF TREATMENT OF MANIC-DEPRESSIVE-PSYCHOSIS.
003226 03-09
GLIOMA
RELATIONSHIP BETWEEN THE ACTIONS OF CALCIUM-IONS, OPIOIDS, AND
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN
NEUROBLASTOMA-X GLIOMA HYBRID CELLS.
002677 03-03
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF
ALPHA-ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA
HYBRID CELLS.
003823 04-03
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
GLOBUS-PALLIDUS
LOCOMOTOR-ACTIVITY ELICITED BY INJEQIONS OF PICROTOXIN INTO THE
VENTRAL TEGMENTAL AREA IS AHENUATED BY INJECTIONS OF GABA
INTO THE GLOBUS-PALLIDUS.
000436 01-04
GLOMERULAR
SELECTIVE NEUROTOXIC-AQION OF CAPSAICIN ON GLOMERULAR C-TYPE
TERMINALS IN RAT SUBSTANTIA-GELATINOSA.
003143 03-06
GLOMERULAR FILTRATION RATE AND CALCIUM METABOLISM IN LONG-
TERM LITHIUM TREATMENT.
003542 03-15
GLOWINSKIS
NEUROLEPTIC ACTIVITY: A SUMMARY OF PROFESSOR JACQUES
GLOWINSKIS PRESENTATION.
003628 03-17
5LUCOCORTICOI0-HORMONES
MATERNAL GLUCOCORTICOID-HORMONES INFLUENCE
NEUROTRANSMIHER PHENOTYPIC EXPRESSION IN EMBRYOS.
000149 01-03
6LUCOCORTICOID-RECEPTOR
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS,
AND NEUROPHARMACOLOGICAL EVENTS.
002515 02-17
GLUCOCORTICOIDS
GLUCOCORTICOIDS AS A REGULATORY FACTOR FOR BRAIN TRYPTOPHAN-
HYDROXYLASE DURING DEVELOPMENT.
001500 02-03
ROLE OF ADRENERGIC BLOCKING-AGENTS AND GLUCOCORTICOIDS ON
THE REGULATION OF PITUITARY OPIOID-PEPTIDES LEVELS.
003801 04-03
GLUCOPRIVATION
INCREASED HUNGER AND THIRST DURING GLUCOPRIVATION IN HUMANS.
000828 01-14
GLUCOSAMINE
THE EFFECT OF LITHIUM ON THE INCORPORATION OF 3H GLUCOSAMINE
INTO GLYCOPEPTIDES AND THE TRANSFORMATION OF 3H
GLUCOSAMINE INTO SIALIC-ACID IN RAT-BRAIN.
001209 02-03
GLUCOSE
MECHANISM OF CHLORPROMAZINE AQION ON PLASMA GLUCOSE AND
CYCLIC-AMP LEVELS.
000211 01-03
INFLUENCE OF GLUCOSE (IN VIVO OR IN VITRO) ON DURATION OF
NARCOTIC ANALGESICS AND ON THE KINETICS OF DRUG METABOLISM.
000292 01-03
IMPAIRED GLUCOSE TOLERANCE IN LONG-TERM LITHIUM TREATED
PATIENTS.
00061101-09
GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT
AFFEaED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN
TREATMENT.
001 145 02-03
LOCAL CEREBRAL GLUCOSE UTILIZATION (LCGU) IN RAT-BRAIN DURING
HYPOXEMIA. (UNPUBLISHED PAPER).
001380 02-03
REGIONAL CHANGES IN BRAIN GLUCOSE UTILIZATION IN RATS GIVEN A
PYRETHROID INSECTICIDE.
001838 02-05
THEORY, PROCEDURE, AND APPLICATIONS OF THE RADIOACTIVE
DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL GLUCOSE
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM. (UNPUBLISHED
PAPER).
001877 02-06
HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE
CAUDATE-NUCLEUS BY GABA AGONISTS.
002640 03-01
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC
NEURONS.
002880 03-03
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON
CHLORPROMAZINE-INDUCED ELEVATION OF PLASMA GLUCOSE AND
CYCLIC-AMP IN FED MICE.
003946 04-03
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION.
004281 04-05
INTERACTION OF CHLORPROMAZINE WITH THE TRANSPORT SYSTEM OF
GLUCOSE IN HUMAN ERYTHROCYTES.
004529 04-13
GLUCOSE-6-PHOSPHATASE
EFFECTS OF ANIMAL AGE AND PHENOBARBITAL ON RAT LIVER GLUCOSE-
6-PHOSPHATASE ACTIVITY.
003997 04-03
GLUTAMATE
EFFECTS OF ANTICONVULSANTS AND GLUTAMATE ANTAGONISTS ON THE
CONVULSIVE AQION OF KAINIC-ACID.
000288 01-03
A NOVEL GABA-RECEPTOR MODULATES STIMULUS-INDUCED GLUTAMATE
RELEASE FROM CORTICOSTRIATAL TERMINALS.
001376 02-03
POTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3-
HYDROXYASPARTATE.
002768 03-03
THE NEUROLATHYROGEN, BETA N OXALYL-L-ALPHA-BETA-
DIAMINOPROPIONIC-ACID, IS A POTENT AGONIST AT GLUTAMATE
PREFERRING RECEPTORS IN THE FROG SPINAL-CORD.
002858 03-03
EFFECTS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC
MEMBRANES.
002888 03-03
THE EFFECTS OF ACETYLCHOLINE AND GLUTAMATE ON SEPTAL NEURONS
IN VITRO.
002941 03-03
PROTECTIVE ACTION OF L 5 HYDROXYTRYPTOPHAN L GLUTAMATE
(MADE- 1932) DURING ELECTROSHOCK-TREATMENT (ECT).
003043 03-04
CHARACTERIZATION OF TWO (3H)GLUTAMATE BINDING-SITES IN RAT
HIPPOCAMPAL MEMBRANES.
003726 04-03
THE HUMAN PLATELET AS A MODEL FOR THE GLUTAMATERGIC NEURON:
PLATELET UPTAKE OF L GLUTAMATE.
003923 04-03
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO
SYNAPTIC MEMBRANES.
004000 04-03
HYPERACTIVITY FOLLOWING INJECTION OF A GLUTAMATE AGONIST AND
6,7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY
THIP.
004066 04-04
GLUTAMATE-RECEPTORS
NUCIFERINE AND CENTRAL GLUTAMATE-RECEPTORS.
000063 01-03
REGULATION OF HIPPOCAMPAL GLUTAMATE-RECEPTORS: EVIDENCE FOR
THE INVOLVEMENT OF A CALCIUM-ACTIVATED PROTEASE.
001120 02-03
GLUTAMATERGIC
THE HUMAN PLATELET AS A MODEL FOR THE GLUTAMATERGIC NEURON:
PLATELET UPTAKE OF L GLUTAMATE.
003923 04-03
GLUTAAAATES
TWENTY YEARS CLINICAL THERAPEUTIC EXPERIENCE WITH CALCIUM
GLUTAMATES EFFICACY.
000963 01-17
GLUTAMIC-ACID
TWO CONDUCTANCE MECHANISMS ACTIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
■li;
M
■WUfi
S-199
Subject index
Psychophormacology Abstracts
•^w»
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES.
001349 02-03
IBOTENIC-ACID ANALOGUES AS INHIBITORS OF (3H)GLUTAMIC-ACID
BINDING TO CEREBELLAR MEMBRANES.
003848 04-03
GLUTAMIC-ACID-DECARBOXYLASE
PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID-
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY
COMPLEX. (UNPUBLISHED PAPER).
001047 02-01
COMPARISON OF CYSTEINE-SULPHINIC-ACID-DECAR80XYLASE (CSD)
ISOENZYMES AND GLUTAMIC-ACID-DECARBOXYLASE (GAD) IN RAT: IS
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH
GAD? (UNPUBLISHED PAPER).
001048 02-01
INFLUENCE OF ESTROGEN AND PROGESTERONE ON GLUTAMIC-ACID-
DECARBOXYLASE ACTIVITY IN DISCRETE REGIONS OF RAT-BRAIN.
002927 03-03
GLUTAMIC-ACID-DIETHYL-ESTER
IMPAIRMENT OF INSTRUMENTAL LEARNING IN RATS BY GLUTAMIC-
ACID-DIETHYL-ESTER.
002993 03-04
GLUTAMINERGIC
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR.
002945 03-04
GLUTAMYLGLYCINE
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA
D(AND L) GLUTAMYLGLYCINE.
002696 03-03
GLUTAMYLTRANSFERASE
EFFECT OF IMIPRAMINE ON HEPATIC GAMMA GLUTAMYLTRANSFERASE
IN FEMALE RATS. INTERACTION WITH CONTRACEPTIVES.
001507 02-03
GLUTARIMIDE
REDUCTION OF BARBITURATE ANESTHESIA BY NEW GLUTARIMIDE
COMPOUNDS IN MICE.
001748 02-04
GLYCEMIC-RESPONSE
MECHANISMS OF CHLORPROMAZINE AND CHLORPROMAZINE ISOSTERES
ON THE GLYCEMIC-RESPONSE IN MICE. (PH.D. DISSERTATION).
001525 02-03
GLYCEROL
EFFEaS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION.
004281 04-05
GLYCINE
GABA INHIBITION OF 3H GLYCINE RELEASE FROM SLICES OF RAT
SUBSTANTIA-NIGRA IN VITRO.
000157 01-03
GLYCINE ENHANCEMENT OF CAUDATE NEURONAL ACTIVITIES:
RELATIONSHIP WITH THE DOPAMINERGIC NIGROSTRIATAL PATHWAY.
001225 02-03
COMPARISON OF THE EFFECTS OF CENTRAL ADMINISTRATION OF SERINE
AND GLYCINE ON BODY-TEMPERATURE OF THE RABBIT.
001248 02-03
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES.
001402 02-03
GLYCINE, ACETYLCHOLINE, AND SEROTONIN: NEUROTRANSMIHERS OR
NEUROMODULATORS?
002271 02-13
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS, INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
INHIBITION OF VASOPRESSIN RELEASE TO CAROTID OCCLUSION BY
GAMMA AMINOBUTYRIC-ACID AND GLYCINE.
002715 03-03
EFFECT OF LITHIUM ON GLYCINE LEVELS IN PATIENTS WITH AFFEQIVE-
DISORDERS.
004606 04-15
GLYCOL
RAT-BRAIN AND PLASMA NOREPINEPHRINE GLYCOL METABOLITES
DETERMINED BY GAS-CHROMATOGRAPHY MASS-
FRAGMENTOGRAPHY.
004303 04-06
GLYCOLYTIC
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFECTS
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES.
000131 01-03
GLYCOPEPTIDES
THE EFFECT OF LITHIUM ON THE INCORPORATION OF 3H GLUCOSAMINE
INTO GLYCOPEPTIDES AND THE TRANSFORMATION OF 3H
GLUCOSAMINE INTO SIALIC-ACID IN RAT-BRAIN.
001209 02-03
GLYCOPROTEIN
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
BINDING OF PERAZINE TO ALPHAl ACID GLYCOPROTEIN.
002290 02-13
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
GLYCOPROTEINS
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
SELECTIVE EFFEQS OF LSD AND HYPERTHERMIA ON THE SYNTHESIS OF
SYNAPTIC PROTEINS AND GLYCOPROTEINS.
002721 03-03
GNAWING
AN AUTOMATED METHOD FOR STUDYING STEREOTYPED GNAWING
002500 02-16
GO-HERE-GO-THERE
GO-HERE-GO-THERE PERFORMANCE AFTER AMPHETAMINE: THE
IMPORTANCE OF THE RESPONSE REQUIREMENT IN SUCCESSIVE
DISCRIMINATION.
001759 02-04
GOAT
DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND NORADRENALINE
CONTENT IN PIAL-ARTERIES OF CAT AND GOAT.
001357 02-03
INFLUENCE OF CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5
HYDROXYTRYPTAMINE, TYRAMINE AND POTASSIUM FROM GOAT
PIAL-ARTERIES.
003925 04-03
GOLDFISH
A RADIOIMMUNOASSAY FOR EPENDYMINS BETA AND GAMMA: TWO
GOLDFISH BRAIN PROTEINS INVOLVED IN BEHAVIORAL PLASTICITY
003677 04-01
GONADECTOMY
THE EFFEQS OF GONADEaOMY AND HYPOPHYSEaOMY ON THE
METABOLISM OF IMIPRAMINE AND LIDOCAINE BY THE LIVER OF MALE
AND FEMALE RATS.
000273 01-03
GONADECTOMY AND SEX-DIFFERENCES IN THE BEHAVIORAL-RESPONSES
TO AMPHETAMINE AND APOMORPHINE OF RATS.
003084 03-04
GONADOTROPHIN
INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN
CHORIONIC GONADOTROPHIN.
003012 03-04
GONADOTROPIN
EFFEaS OF NEUROLEPTICS ON NEUROENDOCRINE MECHANISMS FOR
GONADOTROPIN SECRETION.
001391 02-03
SUPPRESSIVE EFFECT OF MORPHINE ON SERUM GONADOTROPIN LEVELS
IN CASTRATED RATS.
001393 02-03
A PHARMACOLOGICAL ANALYSIS OF THE ROLE OF THE AMYGDALA IN
THE CONTROL OF GONADOTROPIN AND PROLAQIN SECRETION.
001418 02-03
GONADOTROPIN-RELEASING-HORMONE
RELEASE OF GONADOTROPIN-RELEASING-HORMONE BY VERATRINE IN A
HYPOTHALAMIC PITUITARY COINCUBATION.
000237 01-03
GRADUATED
WITHDRAWAL SYMPTOMS AFTER GRADUATED CESSATION OF
IMIPRAMINE IN CHILDREN
004630 04-15
GRANDAXIN-EGYPT
OUR EXPERIENCE WITH TOFISOPAM (GRANDAXIN-EGYPT).
000647 01-10
GRANULE
CEREBELLAR GRANULE CELL GENESIS IN THE HYDROCORTISONE TREATED
RAT
000030 01-03
GRANULES
ACCUMULATION OF AMANTADINE BY ISOLATED CHROMAFFIN
GRANULES.
003866 04-03
S-200
VOLUME 19, SUBJECT INDEX
Subject Index
OKAY
MORPHINE INJECTIONS INTO THE PERIAQUEDUCTAL PERIVENTRICULAR
GRAY ATTENUATE SEPTAL HYPERREACTIVITY,
000390 01-04
INCREASED METABOLISM Of DOPAMINE AND SEROTONIN INDUCED IN
FOREBRAIN AREAS BY ETORPHINE MICROINJECTION IN
PERIAQUEDUCTAL GRAY.
001103 02-03
A COMPARISON BETWEEN THE EFFECTS OF MORPHINE ON THE
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC
AND CENTRAL GRAY STIMULATION
001771 02-04
OPIATE-RECEPTORS AND SLEEP. II. EFFECTS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUCTAL GRAY MAHER AND NUCLEUS-TRACTUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
DOSE-RESPONSE STUDY OF THE PRECIPITATED ABSTINENCE-SYNDROME
FOR MORPHINE: SYSTEMIC VS PERIAQUEDUCTAL GRAY NALOXONE.
(PH.D. DISSERTATION).
002979 03-04
GREY
EFFECT Of CHRONIC MORPHINE TREATMENT ON THE INTERACTION
BETWEEN THE PERIAQUEDUCTAL GREY AND THE NUCLEUS-RAPHE-
MAGNUS OF THE RAT.
003727 04-03
GROOMING
POSTSWIM GROOMING IN MICE INHIBITED BY DOPAMINE-RECEPTOR
ANTAGONISTS AND BY CANNABINOIDS.
000359 01-04
SYSTEMIC AND INTRAVENTRICULAR PROLACTIN INDUCES EXCESSIVE
GROOMING.
000378 01-04
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL
THE LESION-INDUCED DEVELOPMENT Of GROOMING REfLEXES IN THE
CAT. (PH.D. DISSERTATION).
001179 02-03
ACTH-INDUCED GROOMING INVOLVES HIGH-AfflNITY OPIATE-RECEPTORS.
002985 03-04
GROUP
A DOUBLE-BLIND GROUP COMPARATIVE-TRIAL OF MIANSERIN AND
DIAZEPAM IN DEPRESSED-OUTPATIENTS.
000592 01-09
A DOUBLE-BUND PARALLEL GROUP COMPARISON OF SINGLE-BEDTIME-
DOSES OF HALAZEPAM AND PLACEBO.
002079 02-10
MULTIINSTITUTIONAL-STUDY ON THE TERATOGENICITY AND FETAL
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE-
STUDY GROUP IN JAPAN.
002442 02-15
DIfflCULTIES ENCOUNTERED DURING A CONTROLLED STUDY Of A NEW
HYPNOTIC-DRUG (TRIAZOLAM) BY A GROUP Of GENERAL-
PRACTITIONERS.
003155 03-07
GROUP VERSUS INDIVIDUAL COGNITIVE-THERAPY: A PILOT-STUDY.
003257 03-09
EFFECT OF THE POSITION OF THE PHENOLIC GROUP IN MORPHINANS ON
THEIR AfflNITY fOR OPIATE-RECEPTOR BINDING.
003702 04-02
GROUPS
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL
GROUPS IN THE ACTIVE SITE. (UNPUBLISHED PAPER).
001066 02-01
TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE
(CANTOR). MULTICENTER-STUDY Of 248 CASES EVALUATED WITH THE
fATIGUE STUDY GROUPS NO. 4 CLINICAL-SCALE.
001980 02-09
A RESEARCH PARADIGM TO INVESTIGATE THE EffECT Of MANIPULATION
ON SOCIAL-BEHAVIOR IN GROUPS.
003007 03-04
MEDICATION GROUPS FOR PSYCHIATRIC-PATIENTS.
003582 03-17
GROWTH
INHIBITION Of GROWTH IN YOUNG MICE TREATED WITH PENTAZOCINE:
REVERSAL BY NALTREXONE.
000318 01-03
STRETCH-INDUCED MYOTUBE GROWTH CORRELATES WITH NA-PUMP
ACTIVATION. (UNPUBLISHED PAPER).
002087 02-10
THE EfFECTS Of CHRONIC METHYLPHENIDATE TREATMENT ON GROWTH
AND ENDOCRINE fUNCTION IN THE DEVELOPING RAT.
003811 04-03
AQIVITY AND CATCH-UP GROWTH IN HYPOTHYROID RATS.
004190 04-04
GROWTH-FACTOR
NERVE GROWTH-fACTOR STIMULATES DEVELOPMENT Of SUBSTANCE-P
IN THE EMBRYONIC SPINAL-CORD.
003881 04-03
GROWTH-HORMONE
ADMINISTRATION Of ANTISOMATOSTATIN SERUM TO RATS REVERSES
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION
PRODUCED BY INJECTION OF METERGOLINE BUT NOT YOHIMBINE.
(UNPUBLISHED PAPER).
000019 01-03
L TRYPTOPHAN INJECTION ENHANCES PULSATILE GROWTH-HORMONE
SECRETION IN THE RAT. (UNPUBLISHED PAPER).
000020 01-03
MORPHINE ACTS THROUGH ALPHA-ADRENERGIC AND SEROTONINERGIC
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG.
000088 01-03
EFFECTS Of NORADRENERGIC AGONISTS AND ANTAGONISTS ON
GROWTH-HORMONE SECRETION UNDER GAMMA HYDROXYBUTYRATE
NARCOANALGESIA IN THE RAT.
000262 01-03
GROWTH-HORMONE AfTER TRH IN WOMEN WITH DEPRESSIVE-ILLNESS.
000606 01-09
GROWTH-HORMONE (GH) RELEASE fOLLOWING THYROTROPIN-
RELEASING-HORMONE (TRH) INJECTION IN MANIC-PATIENTS
RECEIVING LITHIUM-CARBONATE.
000645 01-09
CORTICOSTERONE INCREASES THE SYNTHESIS Of A SOLUBLE PROTEIN IN
PITUITARY-GLANDS fROM ADRENALECTOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER).
001122 02-03
INfLUENCE Of NOMIfENSINE ON GROWTH-HORMONE, PROLACTIN
LUTEINISING-HORMONE AND THYREOTROPIN IN HEALTHY SUBJECTS
AND HYPERPROLACTINAEMIC-PATIENTS.
002137 02-11
CHARACTERIZATION Of ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLACTIN AND GROWTH-HORMONE PROflLES
DURING WAKEfULNESS AND SLEEP.
002217 02-13
EffECT Of L TRYPTOPHAN ON APOMORPHINE-INOUCED GROWTH-
HORMONE SECRETION IN NORMAL SUBJECTS.
002253 02-13
PLASMA HDL CHOLESTEROL AND GROWTH-HORMONE IN EPILEPTICS
TREATED WITH ANTICONVULSANTS.
002260 02-13
THE CLOCK AND THE BLUE GUITAR: STUDIES Of HUMAN GROWTH-
HORMONE SECRETION IN SLEEP AND WAKING. (UNPUBLISHED PAPER).
002346 02-14
PSYCHOTROPIC-DRUGS DO NOT INTERfERE WITH RADIOLIGAND ASSAYS
FOR PROLACTIN, CORTISOL, AND GROWTH-HORMONE.
002511 02-16
EFFECTS Of ELECTROCONVULSIVE-TREATMENT ON GROWTH-HORMONE
SECRETION INDUCED BY MONOAMINE-RECEPTOR AGONISTS IN
RESERPINE PRETREATED RATS.
002664 03-03
DIffERENTIAL-EffECTS Of CANNABINOID EXPOSURE AND STRESS ON
PLASMA PROLACTIN, GROWTH-HORMONE AND CORTICOSTERONE
LEVELS IN MALE MICE.
002695 03-03
EFFECT Of GROWTH-HORMONE ON MEMORY IN MICE.
003014 03-04
DIURNAL GROWTH-HORMONE RESPONSES TO DEXTROAMPHETAMINE IN
NORMAL YOUNG MEN AND POSTMENOPAUSAL-WOMEN.
003411 03-13
LYMPHOCYTE MONOAMINE-OXIDASE AND PLASMA PROLACTIN AND
GROWTH-HORMONE IN TARDIVE-DYSKINESIA.
003499 03-15
DIffERENT EffECTS Of TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS ON THE RELEASE Of TSH, PROLACTIN, AND
GROWTH-HORMONE AfTER ADMINISTRATION Of THYROSTIMULATING-
RELEASING-HORMONE IN MANIC-DEPRESSIVES.
004407 04-09
PROLACTIN AND GROWTH-HORMONE STUDIES IN SCHIZOPHRENIC-
PATIENTS AND NORMAL CONTROLS.
004538 04-13
GTP
A HIGH-AfFINITY GTP BINDING-SITE IN RAT-BRAIN. (UNPUBLISHED
PAPER).
001442 02-03
STIMULATION Of ADENYLATE-CYCLASE IN RAT STRIATUM BY
PERGOLIDE: INfLUENCE OF GTP.
001448 02-03
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
GUAIPHENESIN
BEHAVIOURAL-EffECTS Of ACETYLSALICYLIC-ACID, PARACETAMOL,
CAffEINE, GUAIPHENESIN AND THEIR COMBINATIONS.
001805 02-04
I
'M
I
"we
;:i;iii:
«l(l!|l'
S-201
Subject Index
Psychopharmacology Abstracts
at,
•Ito
•in.
GUANETHIDINE
COMPARISONS OF THE EFFEQS OF GUANETHIDINE, 6
HYDROXYDOPAMINE AND DIETHYLDITHtOCARBAMATE ON RETENTION
OF PASSIVE-AVOIDANCE.
001742 02-04
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE
REVERSAL OF GUANETHIDINE BLOCKADE OF ADRENERGIC NEURONS.
003900 04-03
GUANINE-NUCLEOTIDES
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS. (UNPUBLISHED
PAPER).
001035 02-01
EFFEaS OF GUANINE-NUCLEOTIDES ON CNS NEUROPEPTIDE-RECEPTORS.
(UNPUBLISHED PAPER).
001383 02-03
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE
AGONIST AND ANTAGONIST RECEPTOR INTERAQIONS.
002688 03-03
MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN:
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS.
003992 04-03
6UANOSINE
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH.
003882 04-03
GUANOSINE-CYCLIC-MONOPHOSPHATE
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE.
002242 02-13
GUANOSINE-NUCLEOTIDES
THE EFFECT OF GUANOSINE-NUCLEOTIDES ON (3H)SULPIRIDE BINDING TO
RAT STRIATAL MEMBRANES.
002722 03-03
GUANYL-NUCLEOTIDES
ENDOGENOUS GUANYL-NUCLEOTIDES: COMPONENTS OF THE STRIATUM
WHICH CONFER DOPAMINE SENSITIVITY TO ADENYLATE-CYCLASE.
001313 02-03
MOLECULAR AQIONS OF OPIATES: HISTORICAL OVERVIEW AND NEW
FINDINGS ON OPIATE-RECEPTOR INTERACTIONS WITH ENKEPHALINS
AND GUANYL-NUCLEOTIDES.
002613 02-17
EFFECT OF DOPAMINE ON AQtVATION OF RAT STRIATAL ADENYLATE-
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES.
002825 03-03
GUANYLATE-CYCLASE
GUANYLATE-CYCLASE ~ CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND
CEREBELLUM: MODIFICATION BY ANTICONVULSANTS.
003956 04-03
6UANYLYLIMIDODIPHOSPHATE
CENTRAL BLOOD-PRESSURE EFFECTS OF GUANYLYLIMIDODIPHOSPHATE
ANDCYCLIC-GUANOSINE-MONOPHOSPHATE.
000266 01-03
GUIDE
THE LITHIUM RATIO AS A GUIDE TO PATIENT COMPLIANCE.
000940 01-17
PHARMACOMANOMETRIC-STUDIES OF COLONIC MOTILITY AS A GUIDE
TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001930 02-08
THE USE AND MISUSE OF SLEEPING-PILLS: A CLINICAL GUIDE.
002150 02-11
LITHIUM TREATMENT OF MANIC-DEPRESSIVE-ILLNESS. A PRAQICAL
GUIDE.
004408 04-09
GUIDELINES
GUIDELINES FOR THE CLINICAL-EVALUATION OF ANALGESIC-DRUGS.
002584 02-17
GUIDELINES EMPLOYED BY THE FOOD-AND-DRUG-ADMINISTRATION IN
DRUG SCHEDULING.
003586 03-17
GUIDELINES FOR SCHEDULING DRUGS UNDER THE CONTROLLED-
SUBSTANCES-ACT.
003606 03-17
GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF DEPRESSION.
004376 04-09
GUINEA-PIG
INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERAQION OF AMINO-
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE
ISOLATED OLFAaORY-CORTEX OF THE GUINEA-PIG.
000034 01-03
HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO
GUINEA-PIG BRAIN.
000061 01-03
STUDIES ON THE DISTRIBUTION OF 14C SULPIRIDE AND ITS METABOLITES
IN THE RAT AND GUINEA-PIG.
000078 01-03
AaiONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID
METABOLISM IN GUINEA-PIG BRAIN SLICES.
000129 01-03
EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA-
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN.
000135 01-03
MET-ENKEPHALIN-ARG6-PHE7 INTERAQS WITH THE KAPPA-RECEPTORS
ON GUINEA-PIG ILEUM.
001110 02-03
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
PERSISTENT EFFEaS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC-
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS.
001266 02-03
INHIBITION OF THE AQION OF CHOLECYSTOKININ-OQAPEPTIDE ON THE
GUINEA-PIG ILEUM MYENTERIC PLEXUS BY DIBUTYRYL-aCLIC-
GUANOSINE-MONOPHOSPHATE .
001291 02-03
COMPARATIVE-EFFECTS OF SOMATOSTATIN AND ENKEPHALINS ON THE
GUINEA-PIG ILEUM AND THE RAT VAS-DEFERENS.
001302 02-03
INHIBITORY AaiON OF ADENOSINE ON SYNAPTIC TRANSMISSION IN THE
HIPPOCAMPUS OF THE GUINEA-PIG IN VITRO.
001401 02-03
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES.
001402 02-03
ALTERED LEVELS OF BETA ENDORPHIN FRAGMENTS AFTER CHRONIC
MORPHINE TREATMENT OF GUINEA-PIG ILEUM IN VITRO AND IN VIVO.
001404 02-03
THE EXCITATORY ACTION OF ACETYLCHOLINE ON HIPPOCAMPAL
NEURONES OF THE GUINEA-PIG AND RAT MAINTAINED IN VITRO.
002704 03-03
EFFEQS OF NEOMYCIN ON CALCIUM AND POLYPHOSPHOINOSITIDE
METABOLISM OF GUINEA-PIG SYNAPTOSOMES.
002741 03-03
INHIBITORY ACTIONS OF TAUROCY AMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES
002846 03-03
PROSTAGLANDINS, CLONIOINE AND SEXUAL-RECEPTIVITY IN THE GUINEA-
PIG
003017 03-04
COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRACT OF THE GUINEA-PIG AND RAT.
003928 04-03
PROPERTIES OF A CDP-DIGLYCERIDE-HYDROLASE FROM GUINEA-PIG
BRAIN.
003987 04-03
THE EFFECT OF CHRONIC LEVODOPA ON HALOPERIDOL-INDUCED
BEHAVIORAL-SUPERSENSITIVITY IN THE GUINEA-PIG.
004249 04-04
GUINEA-PIGS
AMPHETAMINE-INDUCED HYPERSENSITIVITY IN GUINEA-PIGS.
000498 01-04
OBSERVATIONS ON CHLORALOSE-INDUCED MYOCLONUS IN GUINEA-PIGS.
001164 02-03
CHARACTERISTICS OF OSCILLATORY CONTRACTIONS ELICITED BY
NALOXONE IN ILEUM PREPARATION FROM MORPHINE-DEPENDENT
GUINEA-PIGS.
001491 02-03
TESTOSTERONE POTENTIATION OF THE EFFEQIVENESS OF AaHl-24 ON
THE INDUaiON OF THE STRETCH-Y AWNING-SYNDROME (SYS) IN MALE
GUINEA-PIGS.
003074 03-04
GUITAR
THE CLOCK AND THE BLUE GUITAR: STUDIES OF HUMAN GROWTH-
HORMONE SECRETION IN SLEEP AND WAKING. (UNPUBLISHED PAPER).
002346 02-14
GUT
SEROTONIN PARTICIPATION IN GUT WITHDRAWAL FROM OPIATES.
000109 01-03
H-REFLEX
DES-TYROSINE-GAMMA-ENDORPHIN: H-REFLEX RESPONSE SIMILAR TO
NEUROLEPTICS.
004540 04-13
HA-966
HA-966 EFFEQS ON STRIATAL DOPAMINE METABOLISM: IMPLICATIONS
FOR DOPAMINE COMPARTMENTALIZAION.
001150 02-03
S-202
VOLUME 19, SUBJECT INDEX
Subject Index
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA
BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY
TUBERCLE OF THE RAT.
002681 03-03
IN VIVO VOLTAMMETRIC INVESTIGATIONS INTO THE ACTION OF HA-966
ON CENTRAL DOPAMINERGIC NEURONS.
002832 03-03
HABENULAR
INFLUENCE OF DOPAMINERGIC-SYSTEMS ON THE LATERAL HABENULAR
NUCLEUS OF THE RAT.
001365 02-03
HABENULO-INTERPEDUNCULAR
ANESTHETICS AND THE HABENULO-INTERPEDUNCULAR SYSTEM:
SELECTIVE SPARING OF METABOLIC ACTIVITY.
003833 04-03
HABIT
THE SMOKING HABIT AND PSYCHOPHARMACOLOGICAL-EFFEQS OF
NICOTINE.
003577 03-17
EFFECTS OF ANISOMYCIN ON RETENTION OF THE PASSIVE-AVOIDANCE
HABIT AS A FUNCTION OF AGE.
004097 04-04
HABITS
SMOKING AND VIGILANCE: THE EFFECTS OF TOBACCO SMOKING ON CFF
AS RELATED TO PERSONALITY AND SMOKING HABITS.
002368 02-14
HABITUATION
EFFECT OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION,
MEMORY, AND RETRIEVAL OF SHUHLE AVOIDANCE AND
HABITUATION LEARNING IN RATS.
000410 01-04
EFFECT OF PROPRANOLOL AND PHENOTHIAZINES ON ELECTRODERMAL
ORIENTING AND HABITUATION IN SCHIZOPHRENIA.
003174 03-08
HABITUATION OF ELEaRODERMAL AND RESPIRATORY RESPONSES TO
VISUAL STIMULI AS A FUNQION OF PERSONALITY DIFFERENCES IN
AFFEQ LEVEL.
003414 03-13
HABITUATION OF THE THE HEAD-POKE RESPONSE: EFFECTS OF AN
AMPHETAMINE BARBITURATE MIXTURE, PLG AND FENFLURAMINE.
004159 04-04
HAIR-LOSS
LITHIUM AND HAIR-LOSS. (UNPUBLISHED PAPER).
002005 02-09
HALAZEPAM
A DOUBLE-BUND PARALLEL GROUP COMPARISON OF SINGLE-BEDTIME-
DOSES OF HALAZEPAM AND PLACEBO.
002079 02-10
CLINICAL-TRIAL OF HALAZEPAM AND CLORAZEPATE: CONSIDERATIONS
OF A SINGLE-BEDTIME-DOSE.
003277 03-10
HALF-LIFE
LITHIUM ELIMINATION HALF-LIFE AND DURATION OF THERAPY.
004369 04-09
HALLUCINATIONS
CIMETIDINE TOXICITY MANIFESTED AS PARANOIA AND
HALLUCINATIONS.
000829 01-15
HYPNAGOGIC AND HYPNOPOMPIC HALLUCINATIONS DURING
AMITRIPTYLINE TREATMENT.
000850 01-15
AN OLD SIDE-EFFEa REVISITED: VISUAL HALLUCINATIONS.
000886 01-15
AGITATION, DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON
CIMETIDINE: A REPORT OF THREE CASES AND LITERATURE REVIEW.
000896 01-15
HALLUCINATORY
HALLUCINATORY AND DELUSIONAL-STATES IN CONNEQION WITH BLOOD-
PRESSURE AND EEG.
000814 01-14
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE
INTOXICATION.
002988 03-04
HALLUCINOGEN
RAT-BRAIN STEADY-STATE LEVELS OF CYCLIC-NUCLEOTIDES AS AN
ENDPOINT OF LSD-LIKE HALLUCINOGEN EFFEQS. (PH.D.
DISSERTATION).
001426 02-03
HALLUCINOGENIC
ENTHEOGENIC (HALLUCINOGENIC) EFFEQS OF METHYLERGONOVINE.
000742 01-12
THE WORLD OF HALLUCINOGENIC PLANTS.
003396 03-12
LACK OF SPECIFICITY OF AN ANIMAL BEHAVIOR MODEL FOR
HALLUCINOGENIC DRUG AQION.
004250 04-04
HALLUCINOGENIC-AGENT
DISCRIMINATIVE- STIMULUS PROPERTIES OF THE HALLUCINOGENIC-AGENT
DOM.
004260 04-04
HALLUCINOGENIC-DRUGS
LONG-LASTING EFFECTS OF CHRONIC ADMINISTRATION OF
HALLUCINOGENIC-DRUGS ON RAT SOCIAL AND EMOTIONAL-BEHAVIOR.
(PH D. DISSERTATION).
003029 03-04
THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS.
003397 03-12
HALLUCINOGENS
HALLUCINOGENS.
002587 02-17
A COMMON MECHANISM FOR LYSERGIC-ACID, INDOLEALKYLAMINE AND
PHENETHYLAMINE HALLUCINOGENS: SEROTONERGIC MEDIATION OF
BEHAVIORAL-EFFECTS IN RATS.
004007 04-03
HALOGENATED
THE EFFECT OF PHENELZINE AND SOME OF ITS PARA HALOGENATED
DERIVATIVES ON THE LEVELS OF BRAIN TYRAMINE AND OaOPAMINE
IN THE MOUSE.
001077 02-02
HALOPEMIDE
EFFECTS OF HALOPEMIDE ON POTASSIUM-INDUCED RELEASE OF
RADIOLABELED NEUROTRANSMinERS FROM RAT CEREBROCORTICAL
SLICES IN VITRO.
001347 02-03
EFFECTS OF HALOPEMIDE ON GABA-RECEPTOR BINDING, UPTAKE AND
RELEASE.
003913 04-03
HALOPERIDOL
STEREOSPECIFIC BINDING OF 3H HALOPERIDOL IN RAT DORSAL SPINAL-
CORD.
000070 01-03
EFFECT OF NALOXONE, HALOPERIDOL AND PROPRANOLOL ON CYCLIC-
ADENOSINE-MONOPHOSPHATE CONTENT OF RAT AMYGDALA.
000071 01-03
INCORPORATION OF 4.5 3H LEUCINE INTO THE LIMBIC-SYSTEM OF ICR
MICE AS A LONG-TERM EFFECT OF HALOPERIDOL APPLICATION.
000118 01-03
AQIONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID
METABOLISM IN GUINEA-PIG BRAIN SLICES.
000129 01-03
HYPOPHYSECTOMY PREVENTS THE STRIATAL OOPAMINE-RECEPTOR
SUPERSENSITIVITY PRODUCED BY CHRONIC HALOPERIDOL TREATMENT.
000132 01-03
EFFECTS OF CHRONIC HALOPERIDOL ON CAUDATE 3H SPIROPERIDOL
BINDING IN LESIONED RATS.
000255 01-03
ENHANCED SUPPRESSION OF CONDITIONED AVOIDANCE RESPONSE BY
HALOPERIDOL BUT NOT PHENOXYBENZAMINE IN RATS WITH
BILATERAL PARAFASCICULAR LESIONS.
000334 01-04
REWARD SYSTEM DEPRESSION FOLLOWING CHRONIC AMPHETAMINE:
ANTAGONISM BY HALOPERIDOL.
000342 01-04
MORPHINE VERSUS HALOPERIDOL CATALEPSY IN THE RAT: A
BEHAVIORAL-ANALYSIS OF POSTURAL SUPPORT MECHANISMS.
000376 01-04
ANTINOCICEPTIVE-EFFEa OF MORPHINE, OPIOID ANALGESICS AND
HALOPERIDOL INJEQED INTO THE CAUDATE-NUCLEUS OF THE RAT.
000414 01-04
EFFECTS OF THE POTENTIAL NEUROLEPTIC-PEPTIDE DES-TYR1-GAMMA-
ENDORPHIN AND HALOPERIDOL ON APOMORPHINE-INDUCED
BEHAVIOURAL-SYNDROMES IN RATS AND MICE.
000441 01-04
THE LOCOMOTOR-EFFECT OF CLONIDINE AND ITS INTERAQION WITH
ALPHA FLUPENTHIXOL OR HALOPERIDOL IN THE DEVELOPING RAT.
000445 01-04
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT:
BEHAVIORAL-EFFECTS AND PSYCHOPHARMACOLOGICAL-EFFECTS.
000481 01-04
EFFECT OF MORPHINE IN COMBINATION WITH CHLORPROMAZINE AND
HALOPERIDOL ON OPERANT-BEHAVIOR.
000486 01-04
A COMPARISON OF THE CARDIOVASCULAR EFFECTS OF HALOPERIDOL,
THIORIDAZINE AND CHLORPROMAZINE-HCL.
000512 01-05
INFLUENCE OF ROUTE-OF-ADMINISTRATION ON HALOPERIDOL PLASMA
LEVELS IN PSYCHOTIC-PATIENTS.
000549 01-08
EFFECTS OF TRIFLUOPERAZINE, CHLORPROMAZINE, AND HALOPERIDOL
UPON TEMPORAL INFORMATION-PROCESSING BY SCHIZOPHRENIC-
PATIENTS.
000554 01-08
DOUBLE-BLIND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH
AFTERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS
WITH SCHIZOPHRENIA.
000574 01-08
a.
I
»aii::
S-203
Subject Index
Psychopharmacology Abstracts
at
ADVANTAGE OF PHARMACOKINETIC DATA DURING TREATMENT OF
PSYCHOSES WITH HALOPERIDOL.
000577 01-08
CLINICAL-EXPERIENCE WITH LOW-DOSES OF HALOPERIDOL IN THE
TREATMENT OF NEUROSES.
000^54 01-10
PRINCIPAL AND DIFFERENTIAL-EFFECTS OF HALOPERIDOL AND PLACEBO ,
TREATMENTS UPON SPEECH DISFLUENCIES IN STUHERERS.
00071301-11
PSYCHOPHARMACOLOGY OF HALOPERIDOL.
000771 01-13
THE ULTRASTRUCTORAL CHANGES OF SYNAPSES IN RAT FOLLOWING
LONG-TERM ADMINISTRATION OF THE NEUROLEPTICS RESERPINE AND
HALOPERIDOL.
000795 01-13
RAPID CONTROL OF ACUTE PATIENTS THROUGH THE ADMINISTRATION OF
HALOPERIDOL. „„„„,„„, ,.
000818 01-14
TWENTY YEARS HALOPERIDOL: CLINICAL-EFFEQIVENESS AND
THEORETICAL IMPLICATIONS.
000938 01-17
EFFEQS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
PRESYNAPTIC DOPAMINE-RECEPTORS; INSENSITIVITY TO KAINIC-ACID
AND THE DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING CHRONIC
HALOPERIDOL.
001117 02-03
DOPAMINE SYNTHESIS: TOLERANCE TO HALOPERIDOL AND
SUPERSENSITIVITY TO APOMORPHINE DEPEND ON PRESYNAPTIC-
''''"'''' 00112902-03
ACUTE AND CHRONIC HALOPERIDOL TREATMENT: EFFEaS ON
NIGROSTRIATAL DOPAMINERGIC-SYSTEM AQIVITY.
001153 02-03
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE-
RECEPTOR MECHANISMS IN CNS.
001178 02-03
LONG-TERM HALOPERIDOL TREATMENT OF MICE: A CHANGE IN BETA-
ADRENERGIC-RECEPTOR RESPONSIVENESS.
001206 02-03
INTERINDIVIDUAL VARIATION OF CLINICAL-RESPONSE TO HALOPERIDOL.
001230 02-03
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL MONOAMINERGIC MECHANISMS.
001240 02-03
THE HYPERKINETIC- SYNDROME FOLLOWING LONG-TERM HALOPERIDOL
TREATMENT: INVOLVEMENT OF DOPAMINE AND NORADRENALINE.
001299 02-03
LONG-TERM EFFEaS OF HALOPERIDOL. CLOZAPINE. AND METHADONE
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNAMICS.
001325 02-03
LONG-TERM HALOPERIDOL TREATMENT AND FAQORS EFFEQING THE
AQIVITY OF STRIATAL TYROSINE-HYDROXYLASE.
001348 02-03
BEHAVIORAL-CORRELATES AND BIOCHEMICAL-CORRELATES AFTER
HALOPERIDOL AND CLOZAPINE LONG-TERM-TREATMENT.
001422 02-03
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE ACTION OF
DIAZEPAM: POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE
AQION IN THE BRAIN.
001428 02-03
EFFEQS OF HALOPERIDOL AND D-AMPHET AMINE ON IN VIVO 3H
SPIROPERIDOL BINDING IN THE RAT-FOREBRAIN.
001461 02-03
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT:
LATER PSYCHOPHARMACOLOGICAL RESPONSES TO APOMORPHINE
AND ARECOLINE.
001470 02-03
EFFECTS OF HALOPERIDOL. A DOPAMINE-RECEPTOR ANTAGONIST. ON A
DELAYED TYPE HYPERSENSITIVITY REAQION TO 1
CHLORODINITROBENZENE IN MICE.
001473 02-03
LONG-TERM APPLICATION OF HALOPERIDOL: EFFEQ OF ANTICHOLINERGIC
TREATMENT ON THE RATE OF DOPAMINE SYNTHESIS.
001490 02-03
EFFEQ OF LONG-TERM-TREATMENT WITH HALOPERIDOL AND SULPIRIDE
ON DIFFERENT TYPES OF DOPAMINERGIC-RECEPTORS.
001512 02-03
NEUROLEPTIC TREATMENT FOR A SUBSTANTIAL PROPORTION OF ADULT
LIFE: BEHAVIOURAL-SEQUELAE OF 9 MONTHS HALOPERIDOL
ADMINISTRATION.
001858 02-05
CLINICAL STATE, PLASMA LEVELS OF HALOPERIDOL AND PROLAQIN:
001943 02-08
A COMPARISON OF HALOPERIDOL. LITHIUM-CARBONATE AND THEIR
COMBINATION IN THE TREATMENT OF MANIA.
001990 02-09
A CONTROLLED DOUBLE-BUND STUDY OF HALOPERIDOL VERSUS
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTAUY-
SUBNORMAL-PATIENTS: SERUM LEVELS AND CLINICAL-EFFEQS.
002185 02-11
THE EFFEQ OF BENZTROPINE-MESYLATE ON THE PROLAQIN RESPONSE
TO HALOPERIDOL.
002238 02-13
HALOPERIDOL PLASMA LEVEL MONITORING IN PSYCHIATRIC-PATIENTS.
002267 02-13
CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM.
HALOPERIDOL, PHENELZINE AND D-AMPHET AMINE.
002355 02-14
HALOPERIDOL STIMULATION OF PROLAQIN SECRETION: HOW MANY
BLOOD SAMPLES ARE NEEDED TO DEFINE THE HORMONE RESPONSE?
002505 02-16
SPONTANEOUS AQIVITY AND APOMORPHINE STEREOTYPY DURING AND
AFTER WITHDRAWAL FROM 3 1/2 MONTHS CONTINUOUS
ADMINISTRATION OF HALOPERIDOL: SOME METHODOLOGICAL-ISSUES.
002509 02-16
HALOPERIDOL UPDATE: 1958-1980.
002517 02-17
THERAPEUTIC PROFILE OF HALOPERIDOL
002603 02-17
CENTRAL DEPRESSANT EFFEQS OF CAERULEIN AND CHOLECYSTOKININ-
OQAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND
HALOPERIDOL.
002652 03-02
APOMORPHINE HALOPERIDOL INTERAQIONS: DIFFERENT TYPES OF
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS.
002662 03-03
SUPPRESSION OF AMPHETAMINE-INDUCED EEC AROUSAL IN THE
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS.
002683 03-03
A COMPARISON OF THE NEUROCHEMICAL-EFFEQS OF BUPRENORPHINE
WITH THOSE OF MORPHINE AND HALOPERIDOL IN RATS.
002701 03-03
CHARAQERIZATION OF HALOPERIDOL MEDIATED EFFEQS ON RAT
STRIATAL TYROSINE-HYDROXYLASE.
002867 03-03
INCREASED AMPHETAMINE STEREOTYPY AND LONGER HALOPERIDOL
CATALEPSY IN SPONTANEOUSLY HYPERTENSIVE-RATS
002891 03-03
TIME-COURSE OF CHRONIC HALOPERIDOL AND CLOZAPINE UPON
OPERANT RATE AND DURATION
002989 03-04
A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS.
003182 03-08
RAPID TREATMENT OF ACUTE PSYCHOTIC-SYMPTOMS WITH HIGH-DOSE
AND LOW-DOSE HALOPERIDOL: BEHAVIORAL-CONSIDERATIONS.
003346 03-11
EFFEQS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE. HOSPITALIZED SCHOOL-AGE CHILDREN
003360 03-11
EFFEQS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN.
003361 03-11
HALOPERIDOL - ITS USE IN CHILDREN.
003370 03-11
SERUM HALOPERIDOL LEVELS IN GiaES-DE-LA-TOUREHE-SYNDROME
003374 03-11
ILEUS COMPLICATING HALOPERIDOL THERAPY.
003511 03-15
MEASUREMENT OF HALOPERIDOL IN HUMAN PLASMA USING REVERSED
PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
(UNPUBLISHED PAPER).
003667 04-01
CHLORPROMAZINE, HALOPERIDOL. METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLAQIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
DOPAMINE METABOLITES IN CAUDATE AND CORTEX AFTER LITHIUM AND
HALOPERIDOL. (UNPUBLISHED PAPER).
003738 04-03
DOPAMINE. NORADRENALINE AND 3.4 DIHYDROXYPHENYLACETIC-ACID
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFEQS OF
HALOPERIDOL AND PARGYLINE.
003792 04-03
INCREASED MESOLIMBIC DOPAMINE BINDING FOLLOWING CHRONIC
HALOPERIDOL TREATMENT.
003872 04-03
THE EFFEQ OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON
BEHAVIORAL SHIFTS IN CATS. ARISING AFTER CESSATION OF
ELEQRICAL-STIMULATION OF THE CAUDATE-NUCLEUS
004067 04-04
S-204
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC-
ACID, HALOPERIDOL AND PIMOZIOE ON REFLEX BRADYCARDIA IN
RATS.
004085 04-04
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL.
004208 04-04
HALOPERIDOL AND DROPERIDOL TREATMENT IN SCHIZOPHRENICS:
CLINICAL APPLICATION OF THE PROLACTIN MODEL.
004332 04-08
MOBILIZATION OF REFRACTORY CHRONIC SCHIZOPHRENICS WITH
HALOPERIDOL.
004337 04-08
• BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO.
004544 04-13
APOMORPHINE, HALOPERIDOL AND THE AVERAGE EVOKED-POTENTIALS
IN NORMAL HUMAN VOLUNTEERS.
004549 04-13
CLINICAL-EVALUATION OF BROMPERIDOL VERSUS HALOPERIDOL IN
PSYCHOTIC-PATIENTS.
004562 04-14
PATHOPHYSIOLOGICAL AND MORPHOLOGICAL CHANGES IN THE CNS
DURING LONG-TERM ADMINISTRATION OF HALOPERIDOL.
004633 04-15
APOMORPHINE-INDUCED STEREOTYPY IN MATURE AND SENESCENT RATS
FOLLOWING CESSATION OF CHRONIC HALOPERIDOL TREATMENT.
004651 04-15
HALOPERIDOL-DECANOATE
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY: EFFICACY, DOSAGE SCHEDULE AND PLASMA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
HALOPERIDOL-HYDROBROMIDE
THE STRUaURE OF HALOPERIDOL-HYDROBROMIDE (CHLOROPHENYL-4-
HYOROXYPIPERIDINE-4-FLUOROBUTYROPHENONE HBR) .
000002 01-01
HALOPERIDOL-INDUCED
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN
STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER.
001218 02-03
PRESYNAPTIC AND POSTSYNAPTIC MECHANISMS IN HALOPERIDOL-
INDUCED SENSITIZATION TO DOPAMINERGIC AGONISTS.
001392 02-03
PRESYNAPTIC DOPAMINE-RECEPTORS IN STRIATAL NERVE-ENDINGS:
ABSENCE OF HALOPERIDOL-INDUCED SUPERSENSITIVITY.
001424 02-03
BIPHASIC-EFFEQS OF DIRECT, BUT NOT INDIRECT, GABAMIMETICS AND
ANTAGONISTS ON HALOPERIDOL-INDUCED CATALEPSY.
001826 02-04
HALOPERIDOL-INDUCED TARDIVE-DYSKINESIA IN A CHILD WITH GILLES-
DE-LA-TOURETTES-DISEASE.
002437 02-15
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC,
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL
DOPAMINE SYNTHESIS.
002786 03-03
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC
NEURONS.
002880 03-03
LITHIUM EFFECTS ON HALOPERIDOL-INDUCED PRESYNAPTIC AND
POSTSYNAPTIC OOPAMINE-RECEPTOR SUPERSENSITIVITY.
004244 04-04
THE EFFECT OF CHRONIC LEVODOPA ON HALOPERIDOL-INDUCED
BEHAVIORAL-SUPERSENSITIVITY IN THE GUINEA-PIG.
004249 04-04
PROMETHAZINE AND DIAZEPAM POTENTIATE THE HALOPERIDOL-INDUCED
PROLAQIN RESPONSES.
004499 04-13
HALOTHANE
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
HALOTHANE EFFECT ON C-AMP GENERATION AND HYDROLYSIS IN RAT-
BRAIN.
000305 01-03
INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE,
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS.
001539 02-03
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE
ANESTHETIZED RATS.
002687 03-03
ACCELERATED EXTINCTION AFTER POSHRIAL HALOTHANE ANESTHESIA IN
RATS: AN AVERSIVE-EFFEQ.
003001 03-04
HALOTHANE ACCUMULATION IN RAT-BRAIN AND LIVER.
003774 04-03
HALT
CAN DRUGS HALT MEMORY LOSS?
003447 03-14
HALTING
A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF
DIURETICS) AS A METHOD OF HALTING PROLONGED ATTACKS OF
SCHIZOPHRENIA
004584 04-14
HAMILTON-DEPRESSION-RATING-SCALE
DOUBLE-BUND CONTROLLED EXPERIMENT: AMINEPTINE VERSUS
AMITRIPTYLINE USING THE HAMILTON-DEPRESSION-RATING-SCALE.
002050 02-09
HAMSTER
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM.
002728 03-03
EFFECT OF 6 HYDROXYDOPAMINE ON THE FINE STRUCTURE OF THE
HAMSTER PINEAL-GLAND.
003747 04-03
METHADONE REDUCES SEXUAL-PERFORMANCE AND SEXUAL-
MOTIVATION IN THE MALE SYRIAN GOLDEN HAMSTER.
004183 04-04
HAMSTERS
TERATOGENICITY OF IMIPRAMINE AND AMITRIPTYLINE IN FETAL
HAMSTERS.
002410 02-15
PINEAL-GLAND AND MELATONIN INFLUENCE ON CHRONIC ALCOHOL
CONSUMPTION BY HAMSTERS.
003076 03-04
ULTRASTRUCTURAL LOCALIZATION OF MONOAMINES IN NERVE FIBERS
OF THE PINEAL-GLAND IN GOLDEN HAMSTERS.
003666 04-01
HANDBOOK
HANDBOOK OF LITHIUM THERAPY.
000597 01-09
CLINICAL HANDBOOK OF ANTIPSYCHOTIC-DRUG THERAPY.
000961 01-17
HANDEDNESS
HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY
UNILATERAL 6 OHDA INJEQIONS INTO SUBSTANTIA-NIGRA AND
CAUDATE-NUCLEUS.
001778 02-04
HANDICAPPED
TARDIVE-DYSKINESIA AND OTHER DRUG-INDUCED MOVEMENT-
DISORDERS AMONG HANDICAPPED CHILDREN AND YOUTH.
004614 04-15
HANDLING
HANDLING IN INFANCY, TASTE-AVERSION, AND BRAIN LATERALITY IN
RATS.
000375 01-04
DOES POSTURAL ASYMMETRY INDICATE DIRECTIONALITY OF ROTATION
IN RATS: ROLE OF SEX AND HANDLING.
003061 03-04
HANDLING-INDUCED
NEUROPHARMACOLOGICAL ANALYSIS OF HANDLING-INDUCED SEIZURES
IN GERBILS.
001876 02-06
PYRAZOLE EXACERBATES HANDLING-INDUCED CONVULSIONS IN MICE.
004094 04-04
HANDLING-INDUCED SEIZURES AND ROTATIONAL-BEHAVIOR IN THE
MONGOLIAN-GERBIL.
004216 04-04
HARMALINE
DEPLETION OF EPINEPHRINE IN RAT HYPOTHALAMUS BY RO-4-1284:
INFLUENCE OF PARGYLINE AND HARMALINE.
000100 01-03
A NEW APPROACH TO THE ASSESSMENT OF THE POTENCY OF
REVERSIBLE MONOAMINE-OXIDASE-INHIBITORS IN VIVO, AND ITS
APPLICATION TO D-AMPHETAMINE, P METHOXYAMPHETAMINE AND
HARMALINE.
000900 01-16
HARMALINE-INDUCED
HARMALINE-INDUCED TREMOR: THE BENZODIAZEPINE-RECEPTOR AS A
SITE-OF-ACTION.
001436 02-03
HARMANE
1 METHYL-BET A-CARBOLINE (HARMANE), A POTENT ENDOGENOUS
INHIBITOR OF BENZODIAZEPINE-RECEPTOR BINDING.
001440 02-03
BENZODIAZEPINE ANTAGONISM BY HARMANE AND OTHER BETA
CARBOLINES IN VITRO AND IN VIVO.
004211 04-04
HASHISH
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: II. NURSING-BEHAVIOR AND
DEVELOPMENT OF THE SUCKLINGS.
001626 02-04
<ai,
S-205
iitiii
Lid.
"•»(»•
Subject Index
BEHAVIORAL-EFFEQS OF HASHISH IN MICE: III. SOCIAL-INTERAaiONS
BETWEEN TWO RESIDENTS AND AN INTRUDER MALE.
001776 02-04
BEHAVIORAL-EFFEQS OF HASHISH IN MICE: I. SOCIAL-INTERAQIONS
AND NEST-BUILDING-BEHAVIOR OF MALES.
001777 02-04
HATCHING
THE BEHAVIOURAL-STATE DURING CLIMAX (HATCHING) IN THE
DOMESTIC-FOWL (GALLUS-DOMESTICUS) .
001564 02-04
HAZARDS
HAZARDS OF DRUG USE AMONG THE ELDERLY.
000953 01-17
APPROACHES TO THE PROBLEM OF PREVENTING HAZARDS OF LONG-
TERM NEUROLEPTIC TREATMENT AND OF AVOIDING UNNECESSARY
DRUGS.
002426 02-15
SOME HAZARDS OF LITHIUM USE.
003498 03-15
HDL
PLASMA HDL CHOLESTEROL AND GROWTH-HORMONE IN EPILEPTICS
TREATED WITH ANTICONVULSANTS.
002260 02-13
HEAD-POKE
HABITUATION OF THE THE HEAD-POKE RESPONSE: EFFEaS OF AN
AMPHETAMINE BARBITURATE MIXTURE, PLC AND FENFLURAMINE.
004159 04-04
HEAD-SHAKING-BEHAVIOR
THE INVOLVEMENT OF SEROTONERGIC NEURONS IN THE CENTRAL-
NERVOUS-SYSTEM AS THE POSSIBLE MECHANISM FOR SLOW HEAD-
SHAKING-BEHAVIOR INDUCED BY METHAMPHET AMINE IN RATS.
000408 01-04
HEAD-TURNING
EFFECTS OF INTRAPALLIDAL OPIATE-RECEPTOR AGONISTS ON
STRIATALLY-EVOKED HEAD-TURNING.
001785 02-04
HEAD-TWITCH
THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS.
003397 03-12
HEAD-TWITCHES
MOTOR-DEPRESSION AND HEAD-TWITCHES INDUCED BY IP INJEQION OF
GABA.
001788 02-04
HEADACHES
TOFISOPAM IN PSEUDONEURASTHENIA WITH HEADACHES.
002075 02-10
HEADS
QUINUCLIDINYL BENZILATE BINDING IN HOUSEFLY HEADS AND RAT-
BRAIN.
003868 04-03
HEALTH-CARE-SERVICES
AIRCRAFT NOISE AND MENTAL-HEALTH: II. USE OF MEDICINES AND
HEALTH-CARE-SERVICES.
003647 03-17
HEALTHY
CHRONIC ADMINISTRATION OF CANNABIDIOL TO HEALTHY VOLUNTEERS
AND EPILEPTIC-PATIENTS.
000669 01-11
THE INFLUENCE OF LITHIUM-CARBONATE ON MOOD AND PERFORMANCE
IN HEALTHY SUBJECTS.
000711 01-11
EEG AND PSYCHOEXPERIMENTAL-STUDIES IN HEALTHY SUBJEQS ON
LITHIUM MEDICATION.
000768 01-13
THE EEG EFFEQS OF THYROTROPIN-RELEASING-HORMONE IN HEALTHY
SUBJECTS AND CHRONIC SCHIZOPHRENICS.
000770 01-13
EFFECTS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN
HEALTHY TEST SUBJEaS, NEUROTIC-PATIENTS, AND ENDOGENOUS
DEPRESSIVE-PATIENTS.
002009 02-09
INFLUENCE OF NOMIFENSINE ON GROWTH-HORMONE, PROLAQIN,
LUTEINISING-HORMONE AND THYREOTROPIN IN HEALTHY SUBJEQS
AND HYPERPROLAQINAEMIC-PATIENTS.
002137 02-11
THE CONTRIBUTION OF ALPHA1 ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
LEVELS OF MINERAL-ELEMENTS IN THE SERUM AND SALIVA OF HEALTHY
MALE VOLUNTEERS AFTER A SINGLE-DOSE OF LI2C03.
002297 02-13
SINGLE-DOSE PHARMACOKINETICS OF DOXEPIN IN HEALTHY
VOLUNTEERS.
002303 02-13
SUBJEQIVE DRUG-EFFEQS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFEQS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
Psychopharmocology Abstracts
QUANTITATIVE ASSESSMENT OF SMOOTH-PURSUIT EYE-MOVEMENTS IN
HEALTHY AND EPILEPTIC-SUBJEQS.
002376 02-15
CARDIOVASCULAR-EFFEQS OF MIANSERIN AND AMITRIPTYLINE IN
HEALTHY VOLUNTEERS.
002469 02-15
TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFEQS OF
CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS.
003428 03-13
COMPARISON OF THE EFFEQS OF FOUR BENZODIAZEPINES ON FRAME OF
MIND AND BEHAVIOR IN HEALTHY SUBJECTS.
003441 03-14
CARDIOVASCULAR-EFFECTS OF MIANSERIN - A COMPARATIVE-STUDY
WITH AMITRIPTYLINE AND A PLACEBO IN HEALTHY SUBJECTS.
003503 03-15
THE EFFECT OF FIVE TRICYCLIC-ANTIDEPRESSANTS ON SALIVARY FLOW
AND MOOD IN HEALTHY VOLUNTEERS.
004560 04-14
A SYNTHETIC ACTH4-9 ANALOGUE (ORGANON-2766) AND SLEEP IN
HEALTHY MAN.
004574 04-14
HEART
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. III. DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES.
000025 01-03
EFFECTS OF ANTIDEPRESSIVE-DRUGS UPON THE HEART AND
CIRCULATION.
000863 01-15
EFFECT OF PROSTAGLANDINS ON PLASMA CATECHOLAMINES, HEART
AND BLOOD-PRESSURE RESPONSES TO HEMORRHAGE. (UNPUBLISHED
PAPER).
001223 02-03
INTERACTION OF HISTAMINE H2-RECEPT0R BLOCKING-DRUGS WITH THE
NORADRENERGIC SYSTEM IN RAT-BRAIN AND HEART.
001397 02-03
EFFECTS OF AMITRIPTYLINE AND CLOMIPRAMINE IN THE ISOLATED,
PERFUSED RABBIT HEART.
001852 02-05
PSYCHOTROPIC-DRUGS AND THE HEART: CLINICAL-IMPLICATIONS.
002425 02-15
THE EFFECTS OF THIORIDAZINE ON ELECTRICAL AND ISCHEMIC
VENTRICULAR FIBRILLATION IN THE DOG HEART IN SITU.
002697 03-03
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART VII. SUPPRESSION OF SYMPATHETIC RESPONSES BY
DEXAMETHASONE.
002802 03-03
OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE
CONDITIONING IN RABBITS.
003798 04-03
HEART-DISEASE
MAJOR-TRANQUILIZERS AND HEART-DISEASE: TO USE OR NOT TO USE.
000866 01-15
HEBS-WILUAMS
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON
AVOIDANCE CONDITIONING, HEBB-WiaiAMS MAZE-PERFORMANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT.
001580 02-04
HEBEPHRENICS
A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDICTS DURING
WITHDRAWAL.
004445 04-11
HEIGHT
PREDICTORS OF ADOLESCENT HEIGHT AND WEIGHT IN HYPERKINETIC-
BOYS TREATED WITH METHYLPHENIDATE.
003509 03-15
HEIGHTENS
IN UTERO ALCOHOL HEIGHTENS JUVENILE REACTIVITY.
000510 01-05
HELIX-POMATIA
PRESYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION IN HELIX-
POMATIA: THE EFFECTS OF SEROTONIN AND DOPAMINE
ANTAGONISTS.
003869 04-03
HEMICHOLINIUM-3
EFFECTS OF HEMICHOLINIUM-3 AND CHOLINE ON HIPPOCAMPAL
ELECTRICAL-ACTIVITY DURING IMMOBILITY VS. MOVEMENT.
001438 02-03
HEMISPHERES
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL
HEMISPHERES OF AGED MALE RATS.
003936 04-03
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES.
003984 04-03
S-206
VOLUME 19, SUBJECT INDEX
Subject Index
HEMODIALYSATE
BIOCHEMICAL-CHARACTERIZATION AND PHARMACOLOGICAL
CHARACTERIZATION OF A PEPTIDE FROM THE HEMODIALYSATE OF
PSYCHOTIC-PATIENTS.
001049 02-01
HEMODIALYSIS
LITHIUM KINETICS DURING HEMODIALYSIS IN A PATIENT WITH LITHIUM
POISONING.
003524 03-15
HEMODYNAMIC
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN
THE DOG.
001547 02-03
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF
12 CNS DEPRESSANTS IN INTACT AND PITHED RATS.
001855 02-05
HEMODYNAMIC AND CEREBRAL METABOLIC-STUDY OF DIAZEPAM IN
NEUROSURGICAL-RESUSCITATION .
002231 02-13
HEMOPERFUSION
HEMOPERFUSION FOR CHRONIC SCHIZOPHRENIA: PRELIMINARY
PSYCHIATRIC RESULTS.
003180 03-08
HEMORRHAGE
EFFECT OF PROSTAGLANDINS ON PLASMA CATECHOLAMINES, HEART
AND BLOOD-PRESSURE RESPONSES TO HEMORRHAGE. (UNPUBLISHED
PAPER).
001223 02-03
CORREQION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL
HEMORRHAGE PATIENTS.
002295 02-13
HEPARIN
COMPARISON OF HIGHLY-ACTIVE AND ACTIVITY DEPLETED HEPARIN BY
CIRCULAR DICHROISM SPEaROSCOPY. (UNPUBLISHED PAPER).
001057 02-01
HEPATIC
EFFEQ OF IMIPRAMINE ON HEPATIC GAMMA GLUTAMYLTRANSFERASE
IN FEMALE RATS. INTERACTION WITH CONTRACEPTIVES.
001507 02-03
EFFECT OF CHRONIC ADMINISTRATION OF PHENCYCLIDINE ON HEPATIC
MIXED-FUNCTION OXIDASES IN THE MOUSE.
002753 03-03
PUL/WONARY METABOLISM OF IMIPRAMINE IN THE RAT AND RABBIT:
COMPARISON WITH HEPATIC METABOLISM.
002845 03-03
NEUROLEPTIC ACTION ON HEPATIC ENZYMATIC AQIVITY.
002849 03-03
SAFETY OF ANTICONVULSANTS IN HEPATIC PORPHYRIAS.
003132 03-05
HEPATIC SIDE-EFFECTS OF ANTIDEPRESSANT MEDICATIONS.
003523 03-15
HEPATIC-DISEASE
HEPATIC-DISEASE AND DRUG PHARMACOKINETICS.
003650 03-17
HEPATIC-NERVE
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN
THE DOG.
001547 02-03
HEPATITIS
CLINICAL PHARMACOKINETICS OF CHLORDIAZEPOXIDE IN PATIENTS WITH
ALCOHOLIC HEPATITIS.
004473 04-11
HEPATOCYTE
HEPATOTOXICITY OF SODIUM-VALPROATE AND OTHER
ANTICONVULSANTS IN RAT HEPATOCYTE CULTURES.
002422 02-15
HEPATOTOXICITY
EXPERIMENTAL-STUDIES ON HEPATOTOXICITY OF DISULFIRAM.
001844 02-05
HEPATOTOXICITY OF SODIUM-VALPROATE AND OTHER
ANTICONVULSANTS IN RAT HEPATOCYTE CULTURES.
002422 02-15
HERITABLE
SEX, PLASMA PROLACTIN AND PLASMA 3 METHOXY-4-
HYDROXYPHENYLGLYCOL (MHPG) PREDICT HERITABLE D-
AMPHETAMINE EXCITATION IN MAN. (UNPUBLISHED PAPER).
004565 04-14
HEROIN
REVERSAL OF SCHEDULE-INDUCED SELF-INJEQION OF HEROIN BY
NALOXONE.
000446 01-04
APPLICATION OF A SYNTHETIC ENKEPHALIN ANALOGUE DURING HEROIN
WITHDRAWAL.
000685 01-11
HEROIN, BUT NOT LEVORPHANOL, PRODUCES EXPLOSIVE MOTOR-
BEHAVIOR IN NALOXONE TREATED RATS.
001579 02-04
THE INFLUENCE OF SINGLE DAILY HEROIN INJECTIONS ON DRINKING-
PATTERNS IN THE RAT.
001746 02-04
SMALL-DOSE INTRAVENOUS HEROIN FACILITATES HYPOTHALAMIC SELF-
STIMULATION WITHOUT RESPONSE SUPPRESSION IN RATS
002999 03-04
OPERANT ANALYSIS OF HUMAN HEROIN SELF-ADMINISTRATION AND THE
EFFECTS OF NALTREXONE.
003449 03-14
CHOICE BETWEEN FOOD AND HEROIN: EFFECTS OF MORPHINE,
NALOXONE, AND SECOBARBITAL.
004123 04-04
METHADONE TREATMENT OF HEROIN ADDICTS IN SWITZERLAND.
004452 04-11
SUPPRESSION OF MORPHINE ABSTINENCE IN HEROIN ADDICTS BY BETA
ENDORPHIN.
004489 04-11
HETEROGENEITY
OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES:
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES.
003902 04-03
BENZODIAZEPINE-RECEPTOR: HETEROGENEITY IN RABBIT BRAIN.
004060 04-03
HETEROGENEOUS
HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE
CAUDATE-NUCLEUS BY GABA AGONISTS.
002640 03-01
DISCRIMINATION OF FUNCTIONALLY HETEROGENEOUS RECEPTOR
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC
PROPERTIES OF METOCLOPRAMIDE.
002877 03-03
HEXAHYDROMETHYL-1H-PYRAZINOCARBAZOL-HCL
PHARMACOLOGICAL-PROPERTIES OF 2, 3, 3A, 4,5, 6 HEXAHYDROMETHYL-
IH-PYRAZINOCARBAZOL-HCL (PIRLINDOLE), A NEW ANTIDEPRESSANT.
004174 04-04
HEXAMETHONIUM
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS.
001242 02-03
HEXANEDIONE
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFECTS
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES.
000131 01-03
HEXAPEPTIDE-PGLU6
SUBSTANCE-P, HEXAPEPTIDE-PGLU6(SP6-1 1), ANALGESIA AND
SEROTONIN DEPLETION.
003050 03-04
HEXOBARBITAL
EFFECTS OF UREA ON HEXOBARBITAL AND ANTIPYRINE DISPOSITION IN
RATS.
000307 01-03
METABOLIC-STUDIES AND PSYCHOPHYSIOLOGIC-STUDIES OF
CANNABIDIOL HEXOBARBITAL INTERACTION.
002209 02-13
EFFEQ OF CANNABIDIOL ON CYTOCHROME-P-450 AND HEXOBARBITAL
SLEEP-TIME.
002675 03-03
HEXOBARBITAL-INDUCED
EFFEQS OF CHOLECYSTOKININ-LIKE PEPTIDES ON REARING.ACTIVITY AND
HEXOBARBITAL-INDUCED SLEEP.
000507 01-04
ENHANCEMENT OF HEXOBARBITAL-INDUCED SLEEP BY LYSINE AND ITS
METABOLITES.
002967 03-04
HGH
TSH, HGH, HPR, AND CORTISOL RESPONSE TO TRH IN DEPRESSED-
PATIENTS.
004399 04-09
HIAA
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH
ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT.
004382 04-09
HIERARCHIES
EFFECTS OF MORPHINE WITHDRAWAL ON FOOD COMPETITION
HIERARCHIES AND FIGHTING-BEHAVIOR IN RATS.
001632 02-04
OPIATE-RECEPTOR GRADIENTS IN MONKEY CEREBRAL-CORTEX:
CORRESPONDENCE WITH SENSORY PROCESSING HIERARCHIES.
002641 03-01
HIERARCHY
THE INTEGRITY OF THE SOCIAL HIERARCHY IN MICE FOLLOWING
ADMINISTRATION OF PSYCHOTROPIC-DRUGS.
004202 04-04
HIGH
CONTROLLED-COMPARISON OF MEDIUM AND HIGH CLOROTEPIN DOSES
IN CHRONIC SCHIZOPHRENIA.
000548 01-08
ii!.i.:i
I
•milt
'Kill!"
Milk,
«■»!..
S-207
Subject Index
Ptychopharmacology Abstracts
DRUG RESPONSE DIFFERENCES OF HIGH AND STANDARD DOSAGE OF
FLUPHENAZINE-DECANOATE IN RELATION TO SCHIZOPHRENIC-
SYMPTOMS.
000562 01-08
HIGH AND VERY HIGH-DOSAGE ANTIPSYCHOTICS: A CRITICAL REVIEW.
000662 01-11
BRAIN-MONOAMINES AND THE HIGH PRESSURE NfUROLOGICAL-
SYNDROME.
001686 02-04
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD
ETHANOL LEVELS IN RATS DRINKING A LIQUID DIET.
001865 02-06
CHRONIC EFFECTS OF NEUROLEPTICS HAVING HIGH OR LOW INCIDENCE
OF EXTRAPYRAMIDAL SIDE-EFFECTS UPON FORCE, DURATION AND
RATE OF OPERANT-RESPONSE IN RATS. (PH.D. DISSERTATION).
003125 03-05
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
HIGH-AFFINITY
INHIBITION OF HIGH-AFFINITY CHOLINE UPTAKE: STRUCTURE-ACTIVITY
STUDIES.
000026 01-03
HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO
GUINEA-PIG BRAIN.
000061 01-03
HIGH-AFFINITY BINDING OF 3H ETHYLKETOCYCLAZOCINE TO RAT-BRAIN
HOMOGENATE.
000124 01-03
HIGH-AFFINITY BINDING OF (3H)MIANSERIN TO RAT-CEREBRAL-CORTEX.
001204 02-03
A HIGH-AFFINITY GTP BINDING-SITE IN RAT-BRAIN. (UNPUBLISHED
PAPER).
001442 02-03
LITHIUM EFFECTS ON HIGH-AFFINITY TRYPTOPHAN UPTAKE: EVIDENCE
AGAINST A STABILIZATION MECHANISM.
001496 02-03
HIGH-AFFINITY DOPAMINE-RECEPTORS (D3) IN RAT-BRAIN.
001509 02-03
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES.
001554 02-03
HIGH-AFFINITY BINDING OF TRICYCLIC-ANTIDEPRESSANTS TO HISTAMINE
HI -RECEPTORS: FACT AND ARTIFAQ.
001880 02-06
THE EFFECT OF SPECIFIC BRAIN LESIONS ON THE HIGH-AFFINITY BINDING
OF GABA IN THE SUBSTANTIA-NIGRA.
002795 03-03
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING:
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN
HYPERTENSION.
002874 03-03
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES
002879 03-03
ACTH-INDUCED GROOMING INVOLVES HIGH-AFFINITY OPIATE-RECEPTORS.
002985 03-04
HIGH-AFFINITY 3H IMIPRAMINE BINDING: A NEW BIOLOGICAL TOOL FOR
STUDIES IN DEPRESSION.
003610 03-17
SPECIFIC, HIGH-AFFINITY (3H)ETHYLKET0CYCLAZ0CINE BINDING IN RAT
CENTRAL-NERVOUS-SYSTEM: UVCK OF EVIDENCE FOR KAPPA-
RECEPTORS.
003840 04-03
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL AND CANNABIDIOL ON
SODIUM-DEPENDENT HIGH-AFFINITY CHOLINE UPTAKE IN THE RAT
HIPPOCAMPUS.
003908 04-03
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN
REUPTAKE SITES IN BRAIN AND PLATELET?
003962 04-03
HIGH-AFFINITY BINDING-SITES FOR A SOMATOSTATIN-28 ANALOG IN
RAT-BRAIN.
003985 04-03
MULTIPLE ALPHA2-N0RADRENERG1C-RECEPT0R SITES IN RAT-BRAIN:
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS.
003992 04-03
PROPERTIES OF THE OPTICAL-ISOMERS AND METABOLITES OF KET AMINE
ON THE HIGH-AFFINITY TRANSPORT AND CATABOLISM OF
MONOAMINES.
004009 04-03
THE HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPECT TO THE
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRAQION
ABUNDANT IN PRESYNAPTIC MEMBRANES.
004028 04-03
HIGH-AVOIDANCE
REGIONAL 5 HT ANALYSIS IN ROMAN HIGH-AVOIDANCE AND LOW-
AVOIDANCE RATS FOLLOWING MAO-INHIBITION.
001202 02-03
BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH-
AVOIDANCE AND LOW-AVOIDANCE RATS.
002852 03-03
HIGH-CONCENTRATIONS
PERSISTENT EFFECTS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC-
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS.
001266 02-03
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
OOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
HIGH-DOSAGE
HIGH AND VERY HIGH-DOSAGE ANTIPSYCHOTICS: A CRITICAL REVIEW.
000662 01-11
EFFECTS OF HIGH-DOSAGE USURIDE-HYDROGEN-MALEATE (LHM) IN
PARKINSON-SYNDROME.
004460 04-11
HIGH-DOSAGES
NEUROLEPTICS ADMINISTERED IN HIGH-DOSAGES.
003185 03-08
HIGH-DOSE
CHRONIC HIGH-DOSE PROPRANOLOL DOES NOT INCREASE DOPAMINE-
RECEPTOR NUMBER.
000083 01-03
EFFEQS OF A LOW-DOSE AND A HIGH-DOSE OF BETA ENDORPHIN ON
ACQUISITION AND RETENTION IN THE RAT.
001663 02-04
HIGH-DOSE DIAZEPAM IN SCHIZOPHRENIA.
001909 02-08
EUHYPNOS-FORTE, HIGH-DOSE TEMAZEPAM FOR RESISTANT INSOMNIA:
POSTMARKETING SURVEILLANCE IN 10,057 PATIENTS UNRESPONSIVE
TO CONVENTIONAL HYPNOTIC DOSAGE.
002324 02-14
DISTURBED-BEHAVIOUR INDUCED BY HIGH-DOSE ANTIPSYCHOTIC-DRUGS.
002375 02-15
RAPID TREATMENT OF ACUTE PSYCHOTIC-SYMPTOMS WITH HIGH-DOSE
AND LOW-DOSE HALOPERIDOL: BEHAVIORAL-CONSIDERATIONS.
003346 03-11
EFFEaS OF A HIGH-DOSE TREATMENT OF METHAMPHETAMINE ON
CAUDATE DOPAMINE AND ANOREXIA IN RATS.
004073 04-04
INTRATHECAL HIGH-DOSE MORPHINE PRODUCES HYPERALGESIA IN THE
RAT
004254 04-04
A TWELVE-YEAR FOLLOWUP OF THE NIMH-PRB HIGH-DOSE
CHLORPROMAZINE STUDY OF CHRONIC SCHIZOPHRENICS -
IMPLICATIONS FOR DEINSTITUTIONALIZATION. (UNPUBLISHED PAPER)
004323 04-08
SINGLE-CASE STUDY OF CLINICAL-RESPONSE TO HIGH-DOSE ERGOT
ALKALOID TREATMENT FOR DEMENTIA. PRELIMINARY REPORT
004493 04-11
HIGH-DOSES
THE EFFECTS OF DOPAMINERGIC-AGENTS ON THE LOCOMOTOR-AaiVITY
OF RATS AFTER HIGH-DOSES OF METHYLAMPHET AMINE.
000427 01-04
BEHAVIORAL-DEPRESSION AND ITS NEUROCHEMICAL-CORRELATES AT
HIGH-DOSES OF D-AMPHETAMINE IN RATS.
001601 02-04
PSYCHOPHARMACOLOGICAL-EFFEQS OF LOW-DOSES AND HIGH-DOSES
OF APOMORPHINE DURING ONTOGENY.
001774 02-04
LONG-TERM APPLICATION OF HIGH-DOSES OF CLOROTEPIN TO CHRONIC
SCHIZOPHRENIC-PATIENTS.
001908 02-08
PLASMA FLUPHENAZINE AND PROLAQIN LEVELS IN SCHIZOPHRENIC-
PATIENTS DURING TREATMENT WITH LOW-DOSES AND HIGH-DOSES OF
FLUPHENAZINE-ENANTHATE.
001956 02-08
HIGH-FREQUENCY
ELECTRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFEaS OF
HIGH-FREQUENCY STIMULATION ON DENDRITIC ULTRASTRUQURE.
(UNPUBLISHED PAPER).
001036 02-01
HIGH-LEVELS
HIGH-LEVELS OF AMITRIPTYLINE AND CLINICAL-RESPONSE.
002266 02-13
TWO CASES OF FORM-FRUSTE-DU-SYNDROME-MALIN WITH HIGH-LEVELS
OF SERUM CPK.
004636 04-15
HIGH-PERFORMANCE
3 CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE (GS-385), A
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION,
S-208
VOLUME 19, SUBJECT INDEX
Subject Index
PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE
LIQUID-CHROMATOGRAPHY
000705 01-11
MEASUREMENT OF HALOPERIOOL IN HUMAN PLASMA USING REVERSED
PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY.
(UNPUBLISHED PAPER).
003667 04-01
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY IN THE
NEUROSCIENCES: METHODOLOGY.
004285 04-06
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY IN THE
NEUROSCIENCES: APPLICATIONS.
004296 04-06
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION
PRODUCTS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH-
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE
DETECTION.
004302 04-06
SIMULTANEOUS HIGH-PERFORMANCE LIQUIO-CHROMATOGRAPHIC-
DETERMINATION OF AMITRIPTYLINE-HYDROCHLORIDE IN TWO-
COMPONENT TABLET FORMULATIONS.
004673 04-16
IIGH-RISK
OUR EXPERIENCE WITH PIRACETAM (NOOTROPIL-UCB) TREATMENT IN
CHILDREN FROM HIGH-RISK PREGNANCIES WITH SUBSEQUENT
MINIMAL-BRAIN-DYSFUNQION .
000544 01-07
STRATEGY FOR THE STUDY OF PATIENTS AT HIGH-RISK FOR TARDIVE-
DYSKINESIA.
000858 01-15
IIGH-SENSITIVITY
HIGH-SENSITIVITY NEGATIVE CHEMICAL-IONIZATION MASS-SPECTRAL-
ANALYSIS OF BIOGENIC-AMINES AND METABOLITES. (UNPUBLISHED
PAPER).
001042 02-01
1IGHER-ORDER
AN INVOLVEMENT OF DOPAMINE IN HIGHER-ORDER CHOICE
MECHANISMS IN THE MONKEY.
003072 03-04
HIGHLIGHTS
HISTORICAL-PERSPEQIVES AND CURRENT HIGHLIGHTS ON LITHIUM
TREATMENT IN MANIC-DEPRESSIVE-ILLNESS.
003224 03-09
IIGHLY-ACTIVE
COMPARISON OF HIGHLY-ACTIVE AND ACTIVITY DEPLETED HEPARIN BY
CIRCULAR DICHROISM SPEQROSCOPY. (UNPUBLISHED PAPER).
001057 02-01
IIPPOCAMPAL
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND
L-AMPHET AMINE: NO INTERACTION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES.
000387 01-04
EFFECTS OF GABA AND DIAZEPAM ON 3H SEROTONIN RELEASE FROM
HIPPOCAMPAL SYNAPTOSOMES.
001116 02-03
REGULATION OF HIPPOCAMPAL GLUTAMATE-RECEPTORS; EVIDENCE FOR
THE INVOLVEMENT OF A CALCIUM-ACTIVATED PROTEASE.
001120 02-03
THE EFFECT OF CORTISOL MICROIONOPHORETIC-APPLICATIONS ON THE
AQIVITY OF HIPPOCAMPAL NEURONS IN UNRESTRAINED RABBITS.
001123 02-03
IN VIVO (3H)SPIPER0NE BINDING TO THE RAT HIPPOCAMPAL
FORMATION: INVOLVEMENT OF DOPAMINE-RECEPTORS.
001131 02-03
EXCITATORY ACTION OF OPIOID-PEPTIDES AND OPIATES ON CULTURED
HIPPOCAMPAL PYRAMIDAL CELLS.
001241 02-03
PROLONGED EFFECTS OF COCAINE ON HIPPOCAMPAL ACTIVITY.
001338 02-03
EFFECTS OF HEMICHOLINIUM-3 AND CHOLINE ON HIPPOCAMPAL
ELECTRICAL-ACTIVITY DURING IMMOBILITY VS. MOVEMENT.
001438 02-03
EFFECTS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED
SUBJECTS.
002320 02-14
THE EXCITATORY ACTION OF ACETYLCHOLINE ON HIPPOCAMPAL
NEURONES OF THE GUINEA-PIG AND RAT MAINTAINED IN VITRO.
002704 03-03 »
THE EFFECTS OF A BENZODIAZEPINE ON THE HYPERPOLARIZING AND THE
DEPOLARIZING RESPONSES OF HIPPOCAMPAL CELLS TO GABA.
002763 03-03
IDENTICAL RESPONSES OF THE TWO HIPPOCAMPAL THETA GENERATORS
TO PHYSIOLOGICAL AND PHARMACOLOGICAL ACTIVATION.
002792 03-03
A STUDY ON EFFECTS OF ANTIEPILEPTIC-ORUGS UPON THE HIPPOCAMPAL
AFTERDISCHARGE.
002844 03-03
HIPPOCAMPAL SEROTONIN REUPTAKE AND NOCTURNAL LOCOMOTOR-
ACTIVITY AFTER MICROINJECTIONS OF 5,7 DHT IN THE FORNIX-
FIMBRIA.
002929 03-03
PIRACETAM DIMINISHES HIPPOCAMPAL ACETYLCHOLINE LEVELS IN RATS.
002934 03-03
BEHAVIORAL-CHANGES AND BIOCHEMICAL-CHANGES AFTER
HIPPOCAMPAL DAMAGE. (PH.D. DI::ERTATI0N).
003069 03-04
BEHAVIORAL AND REGIONAL NEUROCHEMICAL SEQUELAE OF
HIPPOCAMPAL DESTRUCTION IN THE RAT.
003721 04-03
CHARACTERIZATION OF TWO (3H)GLUTAMATE BINDING-SITES IN RAT
HIPPOCAMPAL MEMBRANES.
003726 04-03
ACETYLCHOLINE-INDUCED MODULATION OF HIPPOCAMPAL PYRAMIDAL
NEURONS.
003728 04-03
DIFFERENTIAL TOLERANCE TO THE EFFECTS OF MORPHINE ON EVOKED
ACTIVITY IN THE HIPPOCAMPAL SLICE.
003760 04-03
HIPPOCAMPAL SLOW ACTIVITY: TWO INPUT SYSTEMS? (UNPUBLISHED
PAPER).
003812 04-03
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS
INVOLVED IN THE HIPPOCAMPUS OF RABBITS.
003842 04-03
THE EFFECT OF ELECTRICAL-STIMULATION OF THE LOCUS-COERULEUS AND
INTRAPERITONEAL INJECTION OF CERTAIN PHARMACOLOGICAL
SUBSTANCES ON THE THRESHOLD OF HIPPOCAMPAL
AFTERDISCHARGES.
003885 04-03
EFFECTS OF ENKEPHALIN, MORPHINE, AND NALOXONE ON THE
ELECTRICAL-ACTIVITY OF THE IN VITRO HIPPOCAMPAL SLICE
PREPARATION.
003918 04-03
EFFECT OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE
DISCHARGE INDUCED BY CARBACHOL IN THE RABBIT.
003951 04-03
CHOLINE REVERSES NALOXONE-INDUCED DECREASES IN HIPPOCAMPAL
ACETYLCHOLINE CONTENT AND SUPPRESSES ESCAPE-BEHAVIOR IN
OPIATE-DEPENDENT RATS.
004076 04-04
HIPPOCAMPAL INVOLVEMENT IN THE PHARMACOLOGIC INDUCTION OF
WITHDRAWAL-LIKE BEHAVIORS.
004140 04-04
THE ROLE OF RETICULOSEPTAL INPUTS IN THE FORMATION OF DIFFERENT
TYPES OF SENSORY REACTIONS OF THE HIPPOCAMPAL NEURONS.
004510 04-13
HIPPOCAMPAL-CA1
BEHAVIOR-DEPENDENT EVOKED-POTENTIALS IN THE HIPPOCAMPAL-CAl
REGION OF THE RAT. II. EFFECTS OF ESERINE, ATROPINE. ETHER AND
PENTOBARBITAL.
000184 01-03
HIPPOCAMPAL-CA1-REGION
DIFFERENTIAL-EFFECTS OF PENTOBARBITAL AND ETHER ON THE SYNAPTIC
TRANSMISSION OF THE HIPPOCAMPAL-CAl -REGION IN THE RAT.
003903 04-03
HIPPOCAMPOCORTICAL
INFLUENCE OF CARBAMAZEPINE ON THALAMOCORTICAL AND
HIPPOCAMPOCORTICAL SELF-SUSTAINED AFTERDISCHARGES IN RATS.
001356 02-03
HIPPOCAMPUS
MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS:
MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN.
000068 01-03
ADENINE-NUCLEOTIDES AND SYNAPTIC TRANSMISSION IN THE IN VITRO
RAT HIPPOCAMPUS.
000080 01-03
SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE:
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT.
000095 01-03
INTERACTION OF DIAZEPAM WITH SYNAPTIC TRANSMISSION IN THE IN
VITRO RAT HIPPOCAMPUS.
000178 01-03
SEROTONIN-RECEPTORS IN HIPPOCAMPUS AND FRONTAL-CORTEX.
000268 01-03
ACUTE AND CHRONIC OPIATE-EFFECTS ON SINGLE UNITS AND EEG OF
MEDIAL THALAMUS AND HIPPOCAMPUS: A LATENCY ANALYSIS.
001344 02-03
LOCALIZATION OF NALOXONE SENSITIVE (3H)DIHYDR0M0RPHINE
BINDING-SITES WITHIN THE HIPPOCAMPUS OF THE RAT.
001368 02-03
INHIBITORY ACTION OF ADENOSINE ON SYNAPTIC TRANSMISSION IN THE
HIPPOCAMPUS OF THE GUINEA-PIG IN VITRO.
001401 02-03
1
a.
Ml
•I'liir
I
■WE
S-209
Subject Index
Psychopharmacology Abstracts
i>»
FORNIX LESION PREVENTS AN ORGANOPHOSPHATE-INDUCED DECREASE
IN MUSCARINIC-RECEPTOR LEVEL IN RAT HIPPOCAMPUS.
001833 02-05
SUPPRESSION OF AMPHETAMINE-INDUCED EEG AROUSAL IN THE
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS.
002683 03-03
GABA-RECEPTORS AND BENZODIAZrpiNE-RECEPTORS. STUDIES ON THEIR
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN.
002727 03-03
EFFEQS OF PHENYTOIN ON PYRAMIDAL NEURONS OF THE RAT
HIPPOCAMPUS.
002750 03-03
SOMATOSTATIN FACILITATES THE SEROTONIN RELEASE FROM RAT-
CEREBRAL-CORTEX, HIPPOCAMPUS, AND HYPOTHALAMUS SLICES.
002913 03-03
DIAZEPAM ANXIOLYTIC-AQIVITY IN HIPPOCAMPUS.
003743 04-03
COMPARISON OF THE EFFEQS OF THE STEREOISOMERS OF
FENFLURAMINE ON THE ACETYLCHOLINE CONTENT OF RAT STRIATUM,
HIPPOCAMPUS AND NUCLEUS-ACCUMBENS.
003758 04-03
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS
INVOLVED IN THE HIPPOCAMPUS OF RABBITS.
003842 04-03
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL AND CANNABIDIOL ON
SODIUM-DEPENDENT HIGH-AFFINITY CHOLINE UPTAKE IN THE RAT
HIPPOCAMPUS.
003908 04-03
SPREADING DEPRESSION INDUCED BY MICROINJECTION OF ENKEPHALINS
INTO THE HIPPOCAMPUS AND NEOCORTEX.
004015 04-03
EFFECTS OF 3 SULFAMOYLMETHYL-BENZISOXAZOLE (AD-810) AND SOME
ANTIEPILEPTICS ON THE KINDLED SEIZURES IN THE NEOCORTEX,
HIPPOCAMPUS AND AMYGDALA IN RATS.
004149 04-04
HISTAMINE
HISTAMINE HI -RECEPTORS LABELED IN VIVO: ANTIDEPRESSANT AND
ANTIHISTAMINE INTERAQIONS.
000074 01-03
HISTAMINE AND PSYCHOTROPIC-DRUGS.
000112 01-03
IN VIVO OCCUPATION OF CEREBRAL HISTAMINE HI -RECEPTORS
EVALUATED WITH 3H MEPYRAMINE MAY PREDICT SEDATIVE
PROPERTIES OF PSYCHOTROPIC-DRUGS.
000241 01-03
PSYCHOTROPIC-DRUGS AND HISTAMINE HI -RECEPTORS OF CULTURED
MOUSE NEUROBLASTOMA CELLS.
000250 01-03
TRICYCLIC-ANTIDEPRESSANT DRUG-INTERAQIONS WITH HISTAMINE AND
ALPHA-ADRENERGIC-RECEPTORS .
000791 01-13
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS; RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER).
001188 02-03
INDIRECT ADRENERGIC EFFEQ OF HISTAMINE IN CAT CEREBRAL-
ARTERIES.
001355 02-03
INTERACTION OF HISTAMINE H2-RECEPT0R BLOCKING-DRUGS WITH THE
NORADRENERGIC SYSTEM IN RAT-BRAIN AND HEART.
001397 02-03
SOME CENTRAL-EFFEQS OF IMPROMIDINE, A POTENT AGONIST OF
HISTAMINE H2-RECEPT0RS.
001417 02-03
PSYCHOTROPIC-DRUG BLOCKADE OF HISTAMINE HI -RECEPTORS.
001432 02-03
NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR
CENTRAL ALPHAl-ADRENOCEPTORS.
001508 02-03
HIGH-AFFINITY BINDING OF TRICYCLIC-ANTIDEPRESSANTS TO HISTAMINE
HI -RECEPTORS: FAQ AND ARTIFACT.
001880 02-06
HISTAMINE ACTIONS ON AQIVITY OF CULTURED HYPOTHALAMIC
NEURONS: EVIDENCE FOR MEDIATION BY HISTAMINE Hl-RECEPTORS
AND H2-RECEPT0RS.
002732 03-03
DECREASED CEREBRAL CATABOLISM OF (3H)HISTAMINE IN VIVO AFTER S
ADENOSYLMETHIONINE ADMINISTRATION.
002883 03-03
H2-RECEPT0RS MEDIATE INCREASES IN PERMEABILITY OF THE BLOOD-
BRAIN-BARRIER DURING ARTERIAL HISTAMINE INFUSION.
003817 04-03
EFFEQ OF DIAZEPAM ON STRESS-INDUCED CHANGES IN BRAIN
HISTAMINE.
003932 04-03
TRICYCLIC-ANTIDEPRESSANTS AND HISTAMINE Hl-RECEPTORS.
003986 04-03
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN: CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
004030 04-03
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFEQS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
RESPONSE.
004119 04-04
PSYCHOTHERAPEUTIC-DRUGS, HISTAMINE Hl-RECEPTORS AND
MUSCARINIC ACETYLCHOLINE-RECEPTORS.
004737 04-17
HISTAMINE-RECEPTORS
HISTAMINE-RECEPTORS IN THE BRAIN: CHARAQERIZATION BY BINDING
STUDIES AND BIOCHEMICAL-EFFECTS.
001054 02-01
(3H)MIANSERIN: DIFFERENTIAL LABELING OF SEROTONIN AND
HISTAMINE-RECEPTORS IN RAT-BRAIN.
002860 03-03
HISTAMINERGIC
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN: CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
HISTIDINE
L HISTIDINE: EFFECTS ON SENSITIVITY OF CAT SPINAL NEURONES TO
AMINO-ACIDS.
002808 03-03
EFFEQ OF L HISTIDINE AND CHLORCYCLIZINE ON APOMORPHINE-INDUCED
CLIMBING-BEHAVIOUR AND METHAMPHETAMINE STEREOTYPY IN
MICE.
004147 04-04
HISTIDYL-PROLINE
HISTIOYL-PROLINE DIKETOPIPERAZINE DECREASES FOOD INTAKE IN RATS.
004181 04-04
HISTIDYL-PROLINE-D1KETOPIPERAZINE
INFLUENCE OF THYROTROPIN-RELEASING-HORMONE AND HISTIDYL-
PROLINE-DIKETOPIPERAZINE ON SPONTANEOUS LOCOMOTOR-AQIVITY
AND ANALGESIA INDUCED BY DELTA9 TETRAHYDROCANNABINOL IN
THE MOUSE.
001575 02-04
HISTOCHEMICAL
HISTOCHEMICAL LOCALIZATION OF OPIATE-RECEPTORS AND THE
ENKEPHALINS.
002566 02-17
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL
EVALUATION.
003685 04-02
A SIMPLE HISTOCHEMICAL SCREENING METHOD FOR AMINE UPTAKE.
004295 04-06
HISTOCHEMICAL-STUDY
CHANGES IN THE CORTICAL ACTIVITY OF SUCCINATE-DEHYDROGENASE
UNDER THE INFLUENCE OF CHLORPROMAZINE (A HISTOCHEMICAL-
STUDY AND ELEQROCYTOCHEMICAL-STUDY).
002784 03-03
HISTOCHEMISTRY
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF
METHAMPHETAMINE.
002812 03-03
HISTOFLUORESCENCE
EFFECT OF QUIPAZINE ON BRAINSTEM MONOAMINE NEURONS
HISTOFLUORESCENCE STUDIES.
001477 02-03
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY.
002639 03-01
HISTOPATHOLOGIC
ANTIPEROXIDANT PRETREATMENT AND IRON-INDUCED EPILEPTIFORM
DISCHARGES IN THE RAT: EEG AND HISTOPATHOLOGIC STUDIES
002930 03-03
HISTORICAL
MOLECULAR ACTIONS OF OPIATES: HISTORICAL OVERVIEW AND NEW
FINDINGS ON OPIATE-RECEPTOR INTERACTIONS WITH ENKEPHALINS
AND GUANYL-NUCLEOTIDES.
002613 02-17
HISTORICAL-PERSPECTIVES
HISTORICAL-PERSPECTIVES AND CURRENT HIGHLIGHTS ON LITHIUM
TREATMENT IN MANIC-DEPRESSIVE-ILLNESS. ^
003224 03-09
HISTORY
HISTORY AND PHARMACOLOGY OF PCP AND PCP RELATED ANALOGS
000737 01-12
S-210
000939 01-17
VOLUME 19, SUBJECT INDEX
THE HISTORY OF RECENT DEVELOPMENTS IN PSYCHIATRY.
HISTORY AND PHARMACOLOGY OF MINAPRINE.
002270 02-13
LONG-TERM CHANGES IN AIMS RATINGS AND THEIR RELATION TO
MEDICATION HISTORY.
003537 03-15
THE HISTORY OF PSYCHOTROPIC-DRUGS.
003609 03-17
MINI-SYMPOSIUM: II. MULTIPLE OPIOID-RECEPTORS. A LITTLE ABOUT
THEIR HISTORY AND SOME IMPLICATIONS RELATED TO EVOLUTION.
004728 04-17
HLA-SYSTEM
THE HLA-SYSTEM AND SCHIZOPHRENIA IN ENGLAND.
001933 02-08
HLA-SYSTEM AND PSYCHOPHARMACOLOGY.
002293 02-13
HOLEBOARD
EFFECTS OF SEROTONERGIC LESIONS ON INVESTIGATORY RESPONDING BY
RATS IN A HOLEBOARD.
001634 02-04
HOLTOR-MONITORED
COMPARISON OF STANDARD AND HOLTOR-MONITORED EKGS IN A
PATIENT TREATED WITH SEVERAL ANTIDEPRESSANTS.
003304 03-11
HOMEOPATHY
THE TREATMENT OF INSOMNIA THROUGH HOMEOPATHY IN A CLINIC.
004484 04-11
HOMING-BEHAVIOR
THE INFLUENCE OF DAILY BIOLOGICAL-RHYTHMICITY ON THE HOMING-
BEHAVIOR, PSYCHOPHARMACOLOGICAL RESPONSIVENESS, LEARNING
AND RETENTION OF SUCKLING RATS. (PH.D. DISSERTATION).
001660 02-04
HOMOCARNOSINE
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE:
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION.
003458 03-14
HOMOCYSTEIC-ACID
TWO CONDUCTANCE MECHANISMS AQIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES.
001349 02-03
HOMOCYSTEINE
PRODUCTION OF CONVULSIONS IN MICE BY THE COMBINATION OF
METHIONINE AND HOMOCYSTEINE.
001233 02-03
HOMOCYSTEINE-INDUCED
HOMOCYSTEINE-INDUCED CONVULSIONS: ENHANCEMENT BY VITAMIN-B6
AND INHIBITION BY HYDRAZINE.
002758 03-03
HOMOGENATE
HIGH-AFFINITY BINDING OF 3H ETHYLKETOCYCLAZOCINE TO RAT-BRAIN
HOMOGENATE.
000124 01-03
STIMULATORY AQION OF LISURIDE ON DOPAMINE-SENSITIVE
ADENYLATE-CYCLASE IN THE RAT STRIATAL HOMOGENATE.
003718 04-03
HOMOGENATES
INHIBITION OF (3H)NAL0X0NE BINDING IN HOMOGENATES OF RAT-
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC ACTIVITY, RELATED
TO PHYSOSTIGMINE.
000104 01-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE-
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA;
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS.
004051 04-03
HOMOTAURINE
INHIBITORY ACTIONS OF TAUROCY AMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
HOMOVANIILIC-ACID
PATHOPHYSIOLOGICAL- STUDIES ON SCHIZOPHRENIA WITH SPECIAL
REFERENCE TO HOMOVANILLIC-ACID CONCENTRATION IN
CEREBROSPINAL-FLUID
000271 01-03
EFFECTS OF TIAPRIDE ON HOMOVANILLIC-ACID LEVELS IN HUMAN
CEREBROSPINAL-FLUID DRAWN AT PNEUMOENCEPHALOGRAPHY.
001483 02-03
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
Subject Index
CEREBROSPINAL-FLUID HOMOVANILLIC-ACID PATTERNS DURING
NEUROLEPTIC TREATMENT (UNPUBLISHED PAPER).
004502 04-13
HORIZONTAL
CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL
ALERTING.
002997 03-04
HORMONAL
EFFECTS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN
HEALTHY TEST SUBJECTS, NEUROTIC-PATIENTS, AND ENDOGENOUS
DEPRESSIVE-PATIENTS.
002009 02-09
HORMONAL ABNORMALITIES IN ANOREXIA-NERVOSA (AN).
002099 02-11
HORMONAL STIMULATION AFTER INJECTION OF THYROTROPHIN-
RELEASING-FACTOR (TRF) AND ACTHl-24 IN PATIENTS FOLLOWING
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY-STUDY.
004505 04-13
CORRECTION OF HORMONAL ACTIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
HORMONAL-EFFECTS
SHORT-TERM HORMONAL-EFFECTS OF NALOXONE IN MAN.
000798 01-13
HORMONE
HORMONE LEVELS IN ACUTE SCHIZOPHRENIA WITH AND WITHOUT
NEUROLEPTIC-MEDICATION.
001923 02-08
HALOPERIDOL STIMULATION OF PROLACTIN SECRETION: HOW MANY
BLOOD SAMPLES ARE NEEDED TO DEFINE THE HORMONE RESPONSE?
002505 02-16
HORMONES
CONVERSION SCALES FOR COMMONLY REQUESTED SERUM
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE, AND OF
HORMONES.
000759 01-13
EXPERIENCE IN USING THE HORMONES OF THE HYPOPHYSIS POSTERIOR
LOBE IN MEMORY-DISTURBANCES OF VARYING GENESES.
003438 03-14
DRUGS, TRANSMinERS AND HORMONES, AND MATING-BEHAVIOR.
004721 04-17
HORSE
3H IMIPRAMINE BINDING IN NEURONAL AND GLIAL FRAQIONS OF
HORSE STRIATUM.
000033 01-03
HORSERADISH-PEROXIDASE
A NEW METHOD FOR APPLICATION OF HORSERADISH-PEROXIDASE INTO
A RESTRICTED AREA OF THE BRAIN.
003141 03-06
HOSPITAL
HOSPITAL AND OUTPATIENT CARE FOR PSYCHOTIC-PATIENTS DURING THE
LAST THREE DECADES: SUBSEQUENT HOSPITAL AND OUTPATIENT
TREATMENT OF PSYCHOTIC-PATIENTS HOSPITALIZED FOR THE FIRST
TIME IN 1949-50, 1959-60 OR 1969-70.
000571 01-08
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS
AFTER HOSPITAL DISCHARGE IN THE DISTRIQS TEPLICE AND UHERSKE-
HRADISTE.
002518 02-17
HOSPITALIZED
HOSPITAL AND OUTPATIENT CARE FOR PSYCHOTIC-PATIENTS DURING THE
LAST THREE DECADES: SUBSEQUENT HOSPITAL AND OUTPATIENT
TREATMENT OF PSYCHOTIC-PATIENTS HOSPITALIZED FOR THE FIRST
TIME IN 1949-50, 1959-60 OR 1969-70.
000571 01-08
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS:
RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BUND TRIAL.
001998 02-09
ORIENTATIONAL TESTING OF CHLORPROMAZINE-HCL ON HOSPITALIZED
MENTAL-PATIENTS.
002131 02-11
MOLINDONE-HYDROCHLORIDE IN THE TREATMENT OF AGGRESSIVE,
HOSPITALIZED CHILDREN.
003321 03-11
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE, HOSPITALIZED SCHOOL-AGE CHILDREN.
003360 03-11
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN.
003361 03-11
THE EFFECTS OF NEUROLEPTIC-DRUGS ON THE SOCIAL INTERACTIONS OF
HOSPITALIZED PSYCHOTIC-PATIENTS.
004577 04-14
a.
I
mt
mi
zf
k:
S-211
Subject Index
111 I
i^'■
HOSPITALIZED-PATIENTS
AUDITORY BRAINSTEM EVOKED-RESPONSES IN HOSPITALIZED-PATIENTS
UNDERGOING DRUG-TREATMENT OR ECT.
003430 03-13
HOSPITALS
PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPED-PATIENTS: A
PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED.
000668 01-11
THE USE OF MINAPRINE IN CHILD-PSYCHIATRY IN HOSPITALS AND
OUTPATIENT CLINICS. _„ ^^ , ,
002169 02-11
HOSTILITY CONFLia AND REPORTING OF SIOE-EFFEQS BY PSYCHIATRIC-
OUTPATIENTS. „„„„.„ ^, ,c
000840 01-15
HOSTILITY PRODUCTION AS A COMMON FEATURE OF ANTIANXIETY-
AGENTAaiON. „„.,..„. ,c
004654 04-15
HOT
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-03
QUINUCLIDINYL BENZILATE BINDING IN HOUSEFLY HEADS AND RAT-
^'^^"^- 003868 04-03
HPLC
HPR
HT
AN HPLC AND RIA ANALYSIS OF THE CHOLECYSTOKININ-PEPTIDES IN
RAT-BRAIN. (UNPUBLISHED PAPER).
001004 02-01
HPLC SEPARATION OF CHOLECYSTOKININ-PEPTIDES - TWO SYSTEMS.
(UNPUBLISHED PAPER).
001005 02-01
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE-
ENKEPHALIN AND CHOLECYSTOKININ IN THE NEURAL RETINA OF
SEVERAL VERTEBRATE SPECIES. (UNPUBLISHED PAPER).
001017 02-01
EVALUATION OF THE EFFECT OF DRUGS ON DOPAMINE METABOLISM IN
THE RAT SUPERIOR-CERVICAL-GANGLION BY HPLC WITH
ELECTROCHEMICAL-DETECTION .
001530 02-03
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC-
ACID IN BRAIN USING HPLC WITH ELEaROCHEMICAL-DETEQION.
003139 03-06
'tSH, HGH, HPR, AND CORTISOL RESPONSE TO TRH IN DEPRESSED-
"^^•^^^^ 004399 04-09
(3H)5 HT BINDING-SITES AND 5 HT- SENSITIVE ADENYLATE-CYCLASE IN
GLIAL CELL MEMBRANE FRAQION.
000093 01-03
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN-
HYDROXYLASE AQIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM.
000123 01-03
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHET AMINE AND
L-AMPHETAMINE: NO INTERACTION IN SELF-STIMUIATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES.
000387 01-04
INITIAL, CLINICAL-TRIAL OF A NEW, SPECIFIC 5 HT REUPTAKE INHIBITOR,
CITAL0PRAM(LU-10-171).
000591 01-09
REGIONAL 5 HT ANALYSIS IN ROMAN HIGH-AVOIDANCE AND LOW-
AVOIDANCE RATS FOLLOWING MAO-INHIBITION.
001202 02-03
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELEQIVE
5 HT UPTAKE INHIBITOR.
001517 02-03
THE EFFEQS OF 5 HT UPTAKE AND MAO-INHIBITORS ON L 5 HTP-
INDUCED EXCITATION IN RATS.
001740 02-04
EFFEQ OF ACUTE AND CHRONIC TRIIODOTHYRONINE (T3)
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE-
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN-
BIOCHEMISTRY.
002951 03-04
ROTATIONAL-BEHAVIOUR ELICITED BY 5 HT IN THE RAT: EVIDENCE FOR
AN INHIBITORY ROLE OF 5 HT IN THE SUBSTANTIA-NIGRA AND
CORPUS-STRIATUM.
004141 04-04
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY?
004553 04-13
Ptychopharmacology Abstracts
HT-ERGIC
ON SOME RELATIONSHIPS BETWEEN GABAERGIC AND 5 HT-ERGIC
MECHANISMS IN PENTYLENETETRAZOL CONVULSIVE-SEIZURE
REAQIONS.
004166 04-04
HT-RECEPTOR
DOES (3H)SPIR0PERID0L LABEL A 5 HT-RECEPTOR IN THE FRONTAL- •
CORTEX OF THE RAT?.
000206 01-03
THE INFLUENCE OF 5 HT-RECEPTOR BLOCKING-AGENTS ON THE
BEHAVIORAL-EFFECTS OF ANALGESICS IN RATS.
000429 01-04
HT-RECEPTORS
HUMAN PLATELET 5 HT-RECEPTORS: CHARAQERISATION AND
FUNQIONAL ASSOCIATION.
001412 02-03
HT-SENStTIVE
(3H)5 HT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN
GLIAL CELL MEMBRANE FRAQION.
000093 01-03
HTP
OPEN-STUDY OF L 5 HTP IN MELANCHOLIC-DEPRESSED-PATIENTS OVER
50 YEARS OF AGE.
002016 02-09
L HTP AND THE SEROTONIN HYPOTHESIS: THEIR MEANING FOR
TREATMENT OF DEPRESSION.
002326 02-14
STUDY ON THE EFFEQS OF L 5 HTP ON THE STAGES OF SLEEP IN MAN AS
EVALUATED BY USING SLEEP-DEPRIVATION.
003450 03-14
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN.
003941 04^3
TREATMENT OF DEPRESSION WITH AN MAO-INHIBITOR FOUOWED BY 5
HTP - AN UNFINISHED RESEARCH PROJEQ.
004377 04-09
HTP-INDUCED
THE EFFECT OF ANTIDEPRESSANTS ON L 5 HTP-INDUCED CHANGES IN RAT
PLASMA CORTICOSTEROIDS.
000170 01-03
THE EFFEQS OF 5 HT UPTAKE AND MAO-INHIBITORS ON L 5 HTP-
INDUCED EXCITATION IN RATS.
001740 02-04
HT3
REGULATION OF SER0T0NIN2-RECEPT0RS (5 HT2) LABELED WITH
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT AMITRIPTYLINE.
003964 04-03
HT2-RECEPTORS
RECEPTOR BINDING PROFILE OF R-41-468, A NOVEL ANTAGONIST AT 5
HT2-RECEPT0RS.
002648 03-02
HUMAN
A COMPARISON OF HUMAN TAQILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL
000055 01-03
IN VITRO EFFEQ OF PHENCYCLIDINE AND OTHER PSYCHOMOTOR
STIMULANTS ON SEROTONIN UPTAKE IN HUMAN PLATELETS.
000750 01-13
GABA LEVELS IN HUMAN CEREBROSPINAL-FLUID: ALTERATIONS IN
PSYCHIATRIC-DISORDERS. (UNPUBLISHED PAPER).
000764 01-13
TRANSFER OF LORAZEPAM AND ITS CONJUGATE ACROSS THE HUMAN
PLACENTA.
000774 01-13
DOPAMINERGIC FACTORS IN HUMAN PROLAQIN REGULATION: A
PITUITARY MODEL FOR THE STUDY OF A NEUROENDOCRINE SYSTEM IN
^^^ 000776 01-13
DRUG SENSITIVE EQO-ATPASE IN HUMAN LEUKOCYTES.
000779 01-13
RADIOIMMUNOASSAY FOR FLUPHENAZINE IN HUMAN PLASMA.
000905 01-16
CHOLINERGIC ASPEQS OF TARDIVE-DYSKINESIA: HUMAN AND ANIMAL
'''°''' 000928 01-17
EFFEQ OF NEUROLEPTIC-DRUGS ON LITHIUM UPTAKE BY THE HUMAN
ERYTHROCYTE. ,„^,, „, ,-,
000973 01-17
PREPARATION AND CHARAQERIZATION OF SYNTHETIC MODELS FOR THE
DENSE-BODIES OF HUMAN PLATELETS. (UNPUBLISHED PAPER).
001013 02-01
S-212
VOLUME 19, SUBJECT INDEX
Subject Index
ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED
PAPER).
001014 02-01
QUANTITATIVE ANALYSIS OF 6 HYOROXYMELATONIN IN HUMAN URINE
BY GAS-CHROMATOGRAPHt' NEGATIVE CHfMICAL-IONIZATION MASS-
SPECTROMETRY. (UNPUBLISHED PAPER).
001058 02-01
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY
HUMAN BLOOD-PLATELETS.
001067 02-02
HUMAN PLATELET 5 HT-RECEPTORS: CHARACTERISATION AND
FUNCTIONAL ASSOCIATION.
001412 02-03
EFFECTS OF TIAPRIDE ON HOMOVANILLIC-ACID LEVELS IN HUMAN
CEREBROSPINAL-FLUID DRAWN AT PNEUMOENCEPHALOGRAPHY.
001483 02-03
EFFEQS OF ORAL CHOLINE ON HUMAN COMPLEX PARTIAL SEIZURES
002149 02-11
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN
HUNTINGTONS-DISEASE.
002163 02-11
INTERCANNABINOID AND CANNABINOID ETHANOL INTERACTIONS AND
THEIR EFFECTS ON HUMAN PERFORMANCE.
002193 02-12
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
002219 02-13
NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTRODUCTION.
002227 02-13
EFFEQS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROFILES.
002239 02-13
ASPIRIN AND HUMAN SLEEP.
002241 02-13
EFFEQ OF DOXEPIN ON SEROTONIN METABOLISM IN RAT-BRAIN AND
SEROTONIN UPTAKE BY HUMAN BLOOD-PLATELETS.
002243 02-13
SPECIFIC 3H IMIPRAMINE BINDING IN HUMAN PLATELETS: INFLUENCE OF
AGE AND SEX.
002254 02-13
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES.
002285 02-13
THE PERIPHERAL ANTICHOLINERGIC-AQIVITY OF TRICYCLIC-
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND
DESIPRAMINE IN HUMAN VOLUNTEERS.
002298 02-13
HUMAN MEMORY AND THE EFFEQS OF PHYSOSTIGMINE AND CHOLINE-
CHLORIDE.
002317 02-14
INFLUENCE OF OXYTOCIN ON HUMAN MEMORY PROCESSES.
002322 02-14
EFFEQS OF ATENOLOL AND PROPRANOLOL ON HUMAN PERFORMANCE
AND SUBJECTIVE FEELINGS.
002340 02-14
THE CLOCK AND THE BLUE GUITAR: STUDIES OF HUMAN GROWTH-
HORMONE SECRETION IN SLEEP AND WAKING. (UNPUBLISHED PAPER).
002346 02-14
SEX-DIFFERENCES IN THE EFFECTS OF LOW-DOSES OF ETHANOL ON
HUMAN REACTION-TIME.
002361 02-14
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
MEASUREMENT OF FLUPHENAZINE BY GAS-CHROMATOGRAPHY IN
HUMAN PLASMA AND RED-BLOOD-CELLS.
002491 02-16
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN
HUMAN CELLS.
002830 03-03
INFLUENCE OF PSYCHOAQIVE AND NONPSYCHOAQIVE CANNABINOIDS
ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS.
002831 03-03
A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE. (PH.D.
DISSERTATION).
002918 03-03
INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN
CHORIONIC GONADOTROPHIN.
003012 03-04
PHYSOSTIGMINE INDUCTION OF DEPRESSIVE-SYMPTOMATOLOGY IN
NORMAL HUMAN SUBJECTS.
003255 03-09
EFFECTS OF VASOPRESSIN ON HUMAN MEMORY FUNCTIONS.
003388 03-11
NONGENETIC FACTORS AFFECTING HUMAN PLATELET MONOAMINE-
OXIDASE.
003407 03-13
TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT DECREASES ALPHA2-
ADRENORECEPTORS ON HUMAN PLATELET MEMBRANES.
003408 03-13
PSYCHOSOMATIC-STRESS AND LIPOPEROXIDES OF HUMAN PLATELET
RICH PLASMA.
003423 03-13
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF
BINDING-SITES IN DEPRESSED-PATIENTS.
003427 03-13
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION
OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY.
003433 03-13
OPERANT ANALYSIS OF HUMAN HEROIN SELF-ADMINISTRATION AND THE
EFFECTS OF NALTREXONE.
003449 03-14
NEUROTOXIC ESTERASE IN HUMAN NERVOUS-TISSUE.
003510 03-15
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS:
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD.
003556 03-16
SYNTHESIS AND BIOLOGICAL-ACTIVITY OF HUMAN BETA ENDORPHIN
ANALOGS WITH DISULFIDE BRIDGES.
003655 04-01
A SELECTED ION-MONITORING ASSAY FOR BIOGENIC-AMINE
METABOLITES AND PROBENECID, IN HUMAN LUMBAR
CEREBROSPINAL-FLUID.
003663 04-01
MEASUREMENT OF HALOPERIDOL IN HUMAN PLASMA USING REVERSED
PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY.
(UNPUBLISHED PAPER).
003667 04-01
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL
AND PATHOLOGICAL (M. NIEMANN-PICK TYPE C) HUMAN BRAIN.
003671 04-01
SOLUBILIZATION OF NEUROLEPTIC/OOPAMINE-RECEPTORS OF HUMAN
BRAIN STRIATUM.
003767 04-03
THE HUMAN PLATELET AS A MODEL FOR THE GLUTAMATERGIC NEURON:
PLATELET UPTAKE OF L GLUTAMATE.
003923 04-03
LIBERATION OF CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE FROM
HUMAN BLOOD-PIATELETS.
003967 04-03
(3H) IMIPRAMINE BINDING IN HUMAN PLATELETS: A NEW
BIOCHEMICAL-PARAMETER IN DEPRESSION.
004358 04-09
BIOCHEMICAL-STUDIES OF HUMAN EPILEPTICS DURING ANTICONVULSANT
THERAPY.
004490 04-1 1
ELECTRORETINOGRAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN
PSYCHOPHARMACOLOGY. ELECTRORETINOGRAPHIC-CHANGES INDUCED
BY A COMBINATION OF CARBIOOPA AND LEVODOPA.
004507 04-13
FRAGILE SITES IN HUMAN CHROMOSOMES I. THE EFFECT OF METHIONINE
ON THE XQ-FRAGILE-SITE.
004515 04-13
INTERACTION OF CHLORPROMAZINE WITH THE TRANSPORT SYSTEM OF
GLUCOSE IN HUMAN ERYTHROCYTES.
004529 04-13
EFFECTS OF RO-1 1-2465, A NEW PSYCHOTROPIC-AGENT ON THE UPTAKE
OF SEROTONIN BY HUMAN PLATELETS - IN VITRO DETERMINATION OF
THE IC50.
004532 04-13
APOMORPHINE, HALOPERIDOL AND THE AVERAGE EVOKED-POTENTIALS
IN NORMAL HUMAN VOLUNTEERS.
004549 04-13
HUMAN SOCIAL CONVERSATION: EFFECTS OF ETHANOL, SECOBARBITAL
AND CHLORPROMAZINE.
004582 04-14
CHLORPROMAZINE ANALYSIS IN HUMAN PLASMA. (UNPUBLISHED
PAPER).
004591 04-15
HUMAN PLATELET ALPHA2-ADRENERGIC-RECEPT0RS: LABELING WITH 3H
YOHIMBINE, A SELECTIVE ANTAGONIST LIGAND.
004676 04-16
IE
'M
"Hilt
iic
S-213
Subject Index
Psychopharmacology Abstracts
HUMANS
TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC-
DISCHARGE IN HUMANS BY APOAAORPHINE, A DOPAMINE-RECEPTOR
AGONIST.
000714 01-11
EFFECT OF LITHIUM-CARBONATE ON CIRCADIAN-PERIODICITY IN
HUMANS.
000772 01-13
INCREASED HUNGER AND THIRST DURING GLUCOPRIVATION IN HUMANS.
000828 01-14
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY.
000890 01-15
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS.
001869 02-06
KINETICS AND NEUROPSYCHOLOGIC-EFFEaS OF IV DIAZEPAM IN THE
PRESENCE AND ABSENCE OF ITS ACTIVE N DESMETHYL METABOLITE IN
HUMANS.
002229 02-13
MOOD AND BEHAVIORAL-EFFECTS OF PHYSOSTIGMINE ON HUMANS ARE
ACCOMPANIED BY ELEVATIONS IN PLASMA BETA ENDORPHIN AND
CORTISOL.
002280 02-13
COCAINE EFFECTS IN SLEEP-DEPRIVED HUMANS.
002323 02-14
DRUG PREFERENCE AND MOOD IN HUMANS: DIAZEPAM.
002334 02-14
DRUG PREFERENCE AND MOOD IN HUMANS: D-AMPHETAMINE.
002335 02-14
PHARMACOKINETICS AND BIOAVAILABILITY OF CHLOROIAZEPOXIDE IN
HUMANS.
002564 02-17
A PRIMATE ANALOGUE OF AMPHETAMINE-INDUCED BEHAVIORS IN
HUMANS.
003006 03-04
DRUG PREFERENCE AND MOOD IN HUMANS: REPEATED ASSESSMENT OF
D-AMPHETAMINE.
003445 03-14
EFFECTS OF DEXTROAMPHETAMINE-SULFATE ON REPEATED ACQUISITION-
BEHAVIOR AND MOOD IN HUMANS: A PRELIMINARY REPORT.
003459 03-14
PRENATAL EXPOSURE TO SYNTHETIC PROGESTINS INCREASES POTENTIAL
FOR AGGRESSION IN HUMANS.
003527 03-15
EVENT-RELATED POTENTIAL CHANGES WITH MORPHINE IN NONADDIQED
HUMANS.
004512 04-13
LITHIUM EFFECTS ON CITRATE METABOLISM IN HUMANS AND RATS.
004537 04-13
DRUG PREFERENCE IN HUMANS: DOUBLE-BLIND CHOICE COMPARISON OF
PENTOBARBITAL, DIAZEPAM AND PLACEBO.
004566 04-14
HUNGARIAN
ABSENCE OF SEVERE TARDIVE-DYSKINESIA IN HUNGARIAN
SCHIZOPHRENIC-OUTPATIENTS.
002404 02-15
TARDIVE-DYSKINESIA ON HUNGARIAN PSYCHIATRIC-WARDS.
002447 02-15
HUNGER
THE EFFECT OF SMALL AND MODERATE DOSES OF D-AMPHETAMINE ON
HUNGER, MOOD, AND AROUSAL IN MAN.
000807 01-14
INCREASED HUNGER AND THIRST DURING GLUCOPRIVATION IN HUMANS.
000828 01-14
HUNTINGTON-DISEASE
BROMOCRIPTINE AND DOPAMINERGIC FUNQION IN HUNTINGTON-
DISEASE.
000700 01-11
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE:
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION.
003458 03-14
HUNTINGTONS-CHOREA
PLATELET AGGREGATION, 5 HYDROXYTRYPTAMINE UPTAKE AND
RELEASE IN HUNTINGTONS-CHOREA.
002112 02-11
HUNTINGTONS-DISEASE
BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH
KAINIC-ACID-INDUCED LESIONS OF STRIATAL NEURONS - WITH A
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS-
DISEASE.
000463 01-04
GABA SYNTHESIS BY CULTURED FIBROBLASTS OBTAINED FROM PERSONS
WITH HUNTINGTONS-DISEASE.
000765 01-13
LEVODOPA AND PRESYMPTOMATIC DETEQION OF HUNTINGTONS-
DISEASE - EIGHT-YEAR FOLLOWUP.
000950 01-17
HUNTINGTONS-DISEASE: CLINICAL-EFFECTS Of A SHORT-TERM
TREATMENT WITH PIMOZIDE.
00209102-11
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR
CHARAQERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN
HUNTINGTONS-DISEASE.
002163 02-11
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND
LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJEQS.
003311 03-11
CHOLINOMIMETICS IN HUNTINGTONS-DISEASE.
004442 04-11 J
CLINICAL AND PRECLINICAL EXPERIENCE WITH CHOLINE-CHLORIDE IN I
HUNTINGTONS-DISEASE AND TARDIVE-DYSKINESIA: UNANSWERED ^
QUESTIONS.
004604 04-15
HUSSER
THE TREATMENT OF CHRONIC SCHIZOPHRENIC-PATIENTS: AN INTERVIEW
WITH DR. J. HUSSER.
004328 04-08
HVA
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH
ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT
004382 04-09
HYBRID
HYBRID PROTEINS USED TO STUDY THE MECHANISM OF TOXIN
ENTRANCE INTO CELLS (UNPUBLISHED PAPER).
001063 02-01
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUQURE-AQIVITY
RELATIONSHIPS
001132 02-03
RELATIONSHIP BETWEEN THE ACTIONS OF CALCIUM-IONS, OPIOIDS, AND
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN
NEUROBLASTOMA-X GLIOMA HYBRID CELLS.
002677 03-03
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF
ALPHA-ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA
HYBRID CELLS
003823 04-03
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
HYDERGINE
HYDERGINE: A REVIEW OF 26 CLINICAL-STUDIES.
000704 01-11
NEUROPHARMACOLOGY OF BROMOCRIPTINE AND DIHYDROERGOTOXINE
(HYDERGINE).
001346 02-03
CLINICAL-TRIAL WITH AMANTADINE AND HYDERGINE IN ELDERLY-
PATIENTS.
002093 02-11
HYDIPHEN
THE PHARMACOLOGICAL CHARAQERISTICS OF THE TRANQUILIZING
EFFECT OF HYDIPHEN.
004261 04-04
HYDRALAZINE
BIOLOGIC-INTERAQION OF GAMMA-RADIATION WITH
PHENYLBUTAZONE, PHENYTOIN, OR HYDRALAZINE.
000518 01-05
INDUCTION OF HYPERSENSITIVITY OF BRAIN BY HYDRALAZINE
TREATMENT IN RATS.
003008 03-04
DIFFERENTIAL-EFFECTS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS.
003947 04-03
HYDRATE '
PHARMACOLOGY OF 2 0 CHLOROBENZOYL-CHLORO-METHYL-NA-
GLYCYLGLYCINANILIDE HYDRATE (45-0088-S), A COMPOUND WITH
BENZODIAZEPINE-LIKE PROPERTIES.
003692 04-02
HYDRAZINE
HOMOCYSTEINE-INDUCED CONVULSIONS: ENHANCEMENT BY VITAMIN-B6
AND INHIBITION BY HYDRAZINE.
002758 03-03
HYDROCEPHALUS
LEVELS OF 5 HYDROXYINDOLEACETIC-ACIO AND TRYPTOPHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION.
003419 03-13
S-214
VOLUME 19, SUBJECT INDEX
Subject Index
HYDROCORTISONE
CEREBELLAR GRANULE CELL GENESIS IN THE HYDROCORTISONE TREATED
RAT
000030 01-03
REUPTAKE OF BIOGENIC AMINES BY BRAIN SLICES: EFFECT OF
-HYDROCORTISONE.
000187 01-03
EFFECT OF NEONATAL HYDROCORTISONE TREATMENT ON BRAIN-
MONOAMINES IN DEVELOPING RATS.
003893 04-03
HYDROLYSIS
OXAZEPAM-ESTERS. 1. CORRELATION BETWEEN HYDROLYSIS RATES AND
BRAIN APPEARANCE OF OXAZEPAM.
000010 01-02
HALOTHANE EFFECT ON C-AMP GENERATION AND HYDROLYSIS IN RAT-
BRAIN.
000305 01-03
HYDROPHOBIC
IDENTIFICATION AND PARTIAL PURIFICATION OF A HYDROPHOBIC
PROTEIN COMPONENT ASSOCIATED WITH (3H)SPIR0PERID0L BINDING-
ACTIVITY. (UNPUBLISHED PAPER).
001007 02-01
HYDROPHOBICITY
OXAZEPAM-ESTERS. 2. CORRELATION OF HYDROPHOBICITY WITH SERUM
BINDING, BRAIN PENETRATION, AND EXCRETION.
000011 01-02
HYDROXY-DELTA9-TETRAHYDROCANNABINOI
BETA DIETHYLAMINOETHYLDIPHENYLPROPYU\CETATE (SKF-525-A) AND
2,4 DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR (DPEA) INHIBITION
OF FATTY-ACID CONJUGATION TO 1 1 HYDR0XY-DELTA9-
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM.
000179 01-03
HYDROXY-3-METHOXYMANDELIC-ACID
NOREPINEPHRINE METABOLISM IN MAN USING DEUTERIUM LABELLING: 4
HYDROXY-3-METHOXYMANDELIC-ACID.
004534 04-13
HYDROXY AMITRIPTYLINE
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXY AMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
HYDROXYBUTYLHEXAHYDROPYRIDOINDOLE-HCL
FLU0R0-5-FLU0R0PHENYL-2-FLU0R0PHENYL4
HYDROXYBUTYLHEXAHYDROPYRIDOINDOLE-HCL, A NEW POTENT
NEUROLEPTIC.
001092 02-02
HYDROXYBUTYRATE
EFFEQS OF NORADRENERGIC AGONISTS AND ANTAGONISTS ON
GROWTH-HORMONE SECRETION UNDER GAMMA HYDROXYBUTYRATE
NARCOANALGESIA IN THE RAT.
000262 01-03
HYPERSYNCHRONOUS-AQIVITY ELICITED BY GAMMA
HYDROXYBUTYRATE DURING ONTOGENESIS IN RATS.
000460 01-04
NALOXONE OVERCOMES THE DOPAMINERGIC, EEG, AND BEHAVIORAL-
EFFECTS OF GAMMA HYDROXYBUTYRATE.
000478 01-04
TREATMENT OF NARCOLEPSY AND SLEEP-APNEA WITH GAMMA
HYDROXYBUTYRATE: A CLINICAL AND POLYSOMNOGRAPHIC CASE-
STUDY.
004571 04-14
HYDROXYBUTYRIC-ACID
EFFECTS OF GAMMA HYDROXYBUTYRIC-ACID ON METABOLIC,
RESPIRATORY AND VASOMOTOR ACTIVITIES AND BODY-
TEMPERATURE IN RATS.
000189 01-03
GAMMA HYDROXYBUTYRIC-ACID AS HYPNOTIC.
000541 01-07
REGIONAL AND SUBCELLULAR LOCALIZATION IN RAT-BRAIN OF THE
ENZYMES THAT CAN SYNTHESIZE GAMMA HYDROXYBUTYRIC-ACID.
003675 04-01
EFFEaS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC-
ACID, HALOPERIDOL AND PIMOZIDE ON REFLEX BRADYCARDIA IN
RATS.
004085 04-04
HYDROXYCITRATE
INHIBITION OF THE SYNTHESIS OF ACETYLCHOLINE IN RAT-BRAIN SLICES
BY (-) HYDROXYCITRATE AND CITRATE.
004044 04-03
HYDROXYDESIPRAMINE
DESIPRAMINE AND 2 HYDROXYDESIPRAMINE PHARMACOKINETICS IN
NORMAL VOLUNTEERS.
003154 03-07
HYDROXYDOPA
EFFEQS OF NEONATAL 6 HYDROXYDOPA ON BEHAVIOR IN FEMALE
RATS.
001717 02-04
DEVELOPMENTAL-CHANGE IN REARING RESPONSE TO ATROPINE IN RATS
TREATED WITH 6 HYDROXYDOPA.
004191 04-04
HYDROXYDOPAMINE
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6/HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
EFFECTS OF APOMORPHINE ON ESCAPE PERFORMANCE AND ACTIVITY IN
DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6
OHDA).
000426 01-04
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY: NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNCTION
000448 01-04
EFFECTS OF 6 HYDROXYDOPAMINE AND AMPHETAMINE ON RAT
MOTHERING-BEHAVIOR AND OFFSPRING DEVELOPMENT.
000452 01-04
GABA FACILITATION BY NORADRENALINE SHOWED SUPERSENSITIVITY IN
CEREBELLUM AFTER 6 HYDROXYDOPAMINE.
001382 02-03
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN
MICE.
001435 02-03
CENTRAL-ACTIONS OF NOREPINEPHRINE, PHENTOLAMINE AND 6
HYDROXYDOPAMINE IN SPONTANEOUSLY HYPERTENSIVE-RATS.
001553 02-03
THE EFFECTS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5
DIMETHOXY-4-METHYLAMPHETAMINE (DOM) AND D-AMPHET AMINE
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE
TREATED RATS.
001595 02-04
PERIPHERAL 6 HYDROXYDOPAMINE ADMINISTRATION IN THE RABBIT
(ORYCTOLAGUS-CUNICULUS): EFFECTS ON PAVLOVIAN-CONDITIONING
001668 02-04
COMPARISONS OF THE EFFECTS OF GUANETHIDINE, 6
HYDROXYDOPAMINE AND DIETHYLDITHIOCARBAMATE ON RETENTION
OF PASSIVE-AVOIDANCE.
001742 02-04
THE EFFECTS OF INTRAVENTRICULAR 6 HYDROXYDOPAMINE AND 5,6
DIHYDROXYTRYPTAMINE ON MORPHINE-INDUCED LOCOMOTOR-
STIMULATION.
001784 02-04
EFFECT OF 6 HYDROXYDOPAMINE LESIONS OF THE MEDIAL PREFRONTAL-
CORTEX ON NEUROTRANSMIHER SYSTEMS IN SUBCORTICAL SITES IN
THE RAT.
002869 03-03
HYPERACTIVITY IN DEVELOPING RATS: SEX-DIFFERENCES IN 6
HYDROXYDOPAMINE AND AMPHETAMINE EFFECTS.
002970 03-04
CORTICAL RECOVERY FROM EFFECTS OF MONOCULAR DEPRIVATION:
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6
HYDROXYDOPAMINE.
003024 03-04
EFFECTS OF ELECTROLYTIC AND 6 HYDROXYDOPAMINE LESIONS OF THE
LATERAL HYPOTHALAMUS ON ROTATION EVOKED BY ELECTRICAL-
STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.
003081 03-04
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE
BUT NOT LITHIUM-CHLORIDE.
003110 03-04
EFFECT OF 6 HYDROXYDOPAMINE ON THE FINE STRUCTURE OF THE
HAMSTER PINEAL-GLAND.
003747 04-03
THE DOPAMINE-RECEPTOR COMPLEX: BIOCHEMICAL-CONSEQUENCES OF
SUPERSENSITIVITY INDUCED BY TREATMENT WITH 6
HYDROXYDOPAMINE OR MORPHINE.
003958 04-03
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS.
004129 04-04
CATECHOLAMINE SEROTONIN INTERACTION EFFECTS ON ACTIVITY IN
RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE.
004194 04-04
THE INFLUENCE OF UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE
SUBSTANTIA-NIGRA IN THE ABSENCE OF THE TELENCEPHALON.
004197 04-04
HYDROXYDOPAMINE-INDUCED
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS
003871 04-03
4
lilts'."
I
"mat
'iSlii:
S-215
Subject Index
Psychopharmacology Abstracts
HYDROXYFLUPHENAZINE
BEHAVIOR OF RATS AND MICE ADMINISTERED ACTIVE METABOLITES OF
FLUPHENAZINE, 7 HYDROXYFLUPHENAZINE AND FLUPHENAZINE-
SULFOXIDE.
004256 04-04
HYDROXYINDOLE
COMPARATIVE-EFFECTS OF P CHLOROAMPHET AMINE AND L P
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN
RAT-BRAIN.
000101 01-03
EFFECT OF 2 P CHLOROPHENYL-CYCLOPROPYLAMINE ON 5
HYDROXYINDOLE CONCENTRATION AND MONOAMINE-OXIDASE
ACTIVITY IN RAT-BRAIN.
001237 02-03
HYDROXYINDOLEACETIC-ACID
BRAIN SEROTONIN AND 5 HYDROXYINDOLEACETIC-ACID
CONCENTRATIONS AND SEROTONIN SYNTHESIS FOLLOWING
TETRAHYDRO-BETA-CARBOLINE ADMINISTRATION IN MICE.
001152 02-03
THE EFFECT OF MORPHINE ON THE CONTENT OF SEROTONIN, 5
HYDROXYINDOLEACETIC-ACID AND SUBSTANCE-P IN THE NUCLEI
RAPHE-MAGNUS AND RETICULARIS-GIGANTOCELLULARIS.
001328 02-03
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC-
ACID IN BRAIN USING HPLC WITH ELECTROCHEMICAL-DETECTION.
003139 03-06
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION.
003419 03-13
A SIMPLE DETERMINATION OF SEROTONIN, 5 HYDROXYINDOLEACETIC-
ACID AND 5 HYDROXYTRYPTOPHAN-DECARBOXYLASE ACTIVITY IN
RAT-BRAIN AREAS AND PARALLEL CORRELATION AMONG THE LEVELS.
004301 04-06
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYIACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
HYDROXYINDOLES
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN
BIOLOGICAL-MATERIAL ~ APPLICATION FOR CEREBRAL MICROVESSELS,
BRAIN, AND PINEAL-ORGAN OF THE RAT.
002503 02-16
HYDROXYLATION
NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN RELATION TO
DEBRISOQUINE HYDROXYLATION IN MAN
000754 01-13
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFEQ
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE.
001353 02-03
HYDROXYMELATONIN
QUANTITATIVE ANALYSIS OF 6 HYDROXYMELATONIN IN HUMAN URINE
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS-
SPECTROMETRY. (UNPUBLISHED PAPER).
001058 02-01
HYDROXYMERCURIBENZOATE
DIPHENYLHYDANTOIN-INDUCED BLOCK OF THE RAT PHRENIC-NERVE
DIAPHRAGM PREPARATION PRETREATED WITH P
HYDROXYMERCURIBENZOATE
002749 03-03
HYDROXYMETHYL-BETA-CARBOLINE
3 HYDROXYMETHYL-BETA-CARBOLINE ANTAGONIZES SOME
PHARMACOLOGIC ACTIONS OF DIAZEPAM.
004221 04-04
HYDROXYNORTRIPTYLINE
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXY AMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
HYDROXYTRYPTAMINE
EFFEQ OF ACUTE ADMINISTRATION OF MORPHINE ON NEWLY
SYNTHESIZED 5 HYDROXYTRYPTAMINE IN SPINAL-CORD OF THE RAT.
000110 01-03
ALPHA-ADRENOCEPTOR-MEDIATED MODULATION OF 5
HYDROXYTRYPTAMINE RELEASE FROM RAT-BRAIN-CORTEX SLICES.
000111 01-03
THE CONVERSION OF (3H)TRYPT0PHAN TO 5 (3H)HYDR0XYTRYPTAMINE
IN MOUSE-BRAIN FOLLOWING DEPLETION OF PHENYLALANINE AND
TYROSINE.
000148 01-03
(3H)ACETYLCH0LINE AND (3H)5 HYDROXYTRYPTAMINE RELEASE FROM
RAT-MIDBRAIN SLICES AND THE EFFECTS OF CALCIUM AND
PHENOBARBITAL.
000251 01-03
THE MECHANISM OF EFFECT OF NEUROPHARMACOLOGICAL-DRUGS. VI:
EFFECT OF NORADRENALINE AND 5 HYDROXYTRYPTAMINE ON BRAIN
FREE FATTY-ACIDS.
000274 01-03
DECREASED UPTAKE OF 5 HYDROXYTRYPTAMINE IN BLOOD-PLATELETS
FROM PATIENTS WITH ENDOGENOUS DEPRESSION.
000637 01-09
TRYPTOPHOL-INDUCED CHANGE IN BRAIN 5 HYDROXYTRYPTAMINE
METABOLISM.
001236 02-03
SEROTONIN-RECEPTOR MEDIATED MODULATION OF CA -DEPENDENT 5
HYDROXYTRYPTAMINE RELEASE FROM NEURONES OF THE RAT-BRAIN-
CORTEX.
001258 02-03
CHARACTERIZATION AND RADIOAUTOGRAPHY OF (3H)LSD BINDING BY
RAT-BRAIN SLICES IN VITRO: THE EFFEQ OF 5 HYDROXYTRYPTAMINE.
001369 02-03
NEURONAL TRANSPORT OF 5 HYDROXYTRYPTAMINE.
001451 02-03
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND
TOLERANT RATS AND MICE.
001476 02-03
CHANGES OF PHYSICAL MORPHINE-DEPENDENCE IN RATS CHRONICALLY
TREATED WITH DRUGS ACTING ON BRAIN 5 HYDROXYTRYPTAMINE.
001764 02-04
THE IONIZATION OF 5 HYDROXYTRYPTAMINE AND RELATED
COMPOUNDS AND AN APPRAISAL OF METHODS FOR THE ESTIMATION
OF ZWITTERION CONSTANTS.
001859 02-06
PLATELET AGGREGATION, 5 HYDROXYTRYPTAMINE UPTAKE AND
RELEASE IN HUNTINGTONS-CHOREA.
002112 02-11
PHENOTHIAZINE ACTION ON CEREBRAL 5 HYDROXYTRYPTAMINE.
002850 03-03
LONG-ACTING ANTIPSYCHOTIC-DRUGS AND CEREBRAL 5
HYDROXYTRYPTAMINE.
002851 03-03
ACTIONS OF TETRAHYDRONORHARMANE (TETRAHYDRO-BETA-
CARBOLINE) ON 5 HYDROXYTRYPTAMINE AND DOPAMINE-MEDIATEO
MECHANISMS.
002854 03-03
THE METABOLISM OF 5 HYDROXYTRYPTAMINE IN THE METHIONINE-
SDLFOXIMINE EPILEPTOGENIC RAT-BRAIN.
002887 03-03
THE ROLE OF 5 HYDROXYTRYPTAMINE IN DOPAMINE-DEPENDENT
STEREOTYPED-BEHAVIOUR.
002966 03-04
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFEaS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN
002990 03-04
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF
BULLFROG SYMPATHETIC GANGLION CELLS.
003710 04-03
INTERAQIONS BETWEEN A MONOFLUORINATEO ANALOGUE OF P
CHLOROAMPHET AMINE AND 5 HYDROXYTRYPTAMINE IN BRAIN.
003719 04-03
CATECHOLAMINE AND 5 HYDROXYTRYPTAMINE SYNTHESIS AND
METABOLISM FOLLOWING INTRACEREBROVENTRICULAR INJEQION OF
DIBUTYRYL-CYCLIC-AMP
003769 04-03
EFFECTS OF PHENYTOIN ON MOUSE CEREBELLAR 5 HYDROXYTRYPTAMINE
AND NOREPINEPHRINE.
003795 04-03
PRESYNAPTIC REGULATION OF THE RELEASE OF ACETYLCHOLINE BY 5
HYDROXYTRYPTAMINE.
003843 04-03
INFLUENCE OF CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5
HYDROXYTRYPTAMINE, TYRAMINE AND POTASSIUM FROM GOAT
PIAL-ARTERIES.
003925 04-03
EFFECTS OF 5 HYDROXYTRYPTAMINE ON CENTRAL NEURONES
ANTAGONIZED BY BICUCULLINE AND PICROTOXIN.
003931 04-03
LIBERATION OF CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE FROM
HUMAN BLOOD-PLATELETS.
003967 04-03
EFFECT OF IMIPRAMINE ON CENTRAL 5 HYDROXYTRYPTAMINE
TURNOVER AND METABOLISM IN RATS.
003999 04-03
RELATIVE ACTIVITIES OF SUBSTANCES RELATED TO 5
HYDROXYTRYPTAMINE AS DEPOLARIZING-AGENTS OF SUPERIOR
CERVICAL GANGLION CELLS
004047 04-03
S-216
VOLUME 19, SUBJECT INDEX
Subject Index
INTRANIGRAL INJECTION OF CAPSAICIN ENHANCES MOTOR-ACTIVITY
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE 8UT NOT SUBSTANCE-
P
004100 04-04
ATTENUATION OF PETHIDINE-INDUCED ANTINOCICEPTION BY ZIMELIDINE,
AN INHIBITOR OF 5 HYDROXYTRYPTAMINE REUPTAKE
004118 04-04
EFFECTS OF NOREPINEPHRINE AND 5 HYDROXYTRYPTAMINE REUPTAKE
INHIBITORS ON ELECTRICALLY-INDUCED SPINAL-CORD SEIZURES IN
RATS.
004144 04-04
HYDROXYTRYPTAMINE-INDUCED
METERGOLINE ANTAGONISM OF 5 HYDROXYTRYPTAMINE-INDUCED
ACTIVATION OF RAT-CEREBRAL-CORTICAL NA-K-ATPASE.
000329 01-03
ENHANCEMENT OF 5 HYDROXYTRYPTAMINE-INDUCED BEHAVIORAL-
EFFECTS FOLLOWING CHRONIC ADMINISTRATION OF ANTIDEPRESSANT-
DRUGS.
001667 02-04
HYDROXYTRYPTAMINE-LIKE
5 HYDROXYTRYPTAMINE-LIKE PROPERTIES OF M
CHLOROPHENYLPIPERAZINE: COMPARISON WITH QUIPAZINE.
004210 04-04
HYDROXYTRYPTAMINE-RECEPTORS
ANTAGONISM OF 5 HYDROXYTRYPTAMINE-RECEPTORS BY QUIPAZINE.
001329 02-03
HYDROXYTRYPTAMINER6IC
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS.
002700 03-03
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER
FOREBRAIN REGIONS OF THE RAT.
004171 04-04
HYDROXYTRYPTOPHAN
REVERSAL OF PARA CHLOROPHENYLALANINE-INDUCED INSOMNIA BY 5
HYDROXYTRYPTOPHAN IN THE RAT.
000423 01-04
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS.
000466 01-04
ANTIDEPRESSANT POTENTIATION OF 5 HYDROXYTRYPTOPHAN BY L
DEPRENIL IN AFFECTIVE-ILLNESS.
000608 01-09
DIPSOGENIC-EFFECT OF L 5 HYDROXYTRYPTOPHAN IN RATS.
001623 02-04
5 HYDROXYTRYPTOPHAN AND PYRIDOXINE: THEIR EFFECTS IN YOUNG
CHILDREN WITH DOWNS-SYNDROME.
002161 02-11
TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAN AND
CARBIDOPA: CLINICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL-
OBSERVATIONS.
002180 02-11
BIOAVAILABILITY AND RELATED PHARMACOKINETICS IN MAN OF
ORALLY ADMINISTERED L 5 HYDROXYTRYPTOPHAN IN STEADY-STATE.
002261 02-13
NONSEROTONERGIC DEPRESSION OF SPINAL MONOSYNAPTIC REFLEX
TRANSMISSION BY 5 HYDROXYTRYPTOPHAN.
002745 03-03
PROTECTIVE ACTION OF L 5 HYDROXYTRYPTOPHAN L GLUTAMATE
(MADE-1932) DURING ELECTROSHOCK-TREATMENT (ECT).
003043 03-04
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC-
ACID IN BRAIN USING HPLC WITH ELECTROCHEMICAL-DETECTION.
003139 03-06
DENERVATION SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN RATS
FOLLOWING SPINAL TRANSECTION AND 5,7 DIHYDROXYTRYPTAMINE
INJECTION.
003722 04-03
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN.
003941 04-03
HYDROXYTRYPTOPHAN-DECARBOXYLASE
A SIMPLE DETERMINATION OF SEROTONIN, 5 HYDROXYINDOLEACETIC-
ACID AND 5 HYDROXYTRYPTOPHAN-DECARBOXYLASE ACTIVITY IN
RAT-BRAIN AREAS AND PARALLEL CORRELATION AMONG THE LEVELS.
004301 04-06
HYDROXYTRYPTOPHAN-INDUCED
L 5 HYDROXYTRYPTOPHAN-INDUCED DRINKING IN RATS: POSSIBLE
MECHANISMS FOR INDUCTION.
004237 04-04
HYGROSCOPIC
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS:
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD.
003556 03-16
HYPERACTIVE
EFFECTS OF METHYLPHENIDATE ON SELECTIVE AND SUSTAINED
ATTENTION IN HYPERACTIVE, READING-DISABLED, AND PRESUMABLY
ATTENTION-DISORDERED BOYS
002118 02-11
THE INFLUENCE OF METHYLPHENIDATE ON SPONTANEOUS AUFONOMIC-
ACTIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE
003363 03-11
HYPERACTIVE-BEHAVIOR
EVALUATION OF SYMPTOMATIC TREATMENT OF HYPERACTIVE-BEHAVIOR
BY STIMULANT-DRUGS.
002134 02-11
HYPERACTIVE-BOYS
DEXTROAMPHETAMINE: COGNITIVE AND BEHAVIORAL-EFFECTS IN
NORMAL AND HYPERACTIVE-BOYS AND NORMAL ADULT MALES.
000716 01-11
EFFECTS OF METHYLPHENIDATE ON OPERANT-RESPONDING IN
HYPERACTIVE-BOYS, (PH.D. DISSERTATION).
002191 02-11
HYPERACTIVE-CHILD
PSYCHOACTIVE-DRUG-EFFECTS IN A HYPERACTIVE-CHILD: A CASE-STUDY
ANALYSIS OF BEHAVIOR-CHANGE AND TEACHER ATTENTION
002313 02-14
HYPERACTIVE-CHILD-SYNDROME
THE HYPERACTIVE-CHILD-SYNDROME: PERIPHERAL SYMPATHETIC-
NERVOUS-SYSTEM FUNCTION AND THE EFFECT OF D-AMPHETAMINE.
003340 03-11
HYPERACTIVE-CHILDREN
A CONTROLLED-TRIAL OF BEHAVIOR-MODIFICATION AND
METHYLPHENIDATE IN HYPERACTIVE-CHILDREN.
000678 01-11
THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG-TREATMENT
FOR HYPERACTIVE-CHILDREN: RECENT FINDINGS AND A REPORT FROM
CLINICAL-PRACTICE.
000715 01-11
THE PARENT CHILD INTERACTIONS OF HYPERACTIVE-CHILDREN AND THEIR
MODIFICATION BY STIMULANT-DRUGS.
002092 02-1 1
PREDICTING THE RESPONSE OF HYPERACTIVE-CHILDREN TO RITALIN: AN
EMPIRICAL-STUDY.
002120 02-11
TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERACTIVE-
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL
PARADIGM - A PILOT-STUDY.
002126 02-11
THE DIFFERENTIAL DOSE-EFFECTS OF METHYLPHENIDATE ON
HYPERACTIVE-CHILDREN AND THEIR MOTHERS. (PH.D.
DISSERTATION).
002143 02-11
EFFECTS OF AMPHETAMINE ON VIGILANCE PERFORMANCE IN NORMAL
AND HYPERACTIVE-CHILDREN
002359 02-14
EVALUATION OF THE RELATIVE EFFECTIVENESS OF METHYLPHENIDATE
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF
KINDERGARTEN-AGED HYPERACTIVE-CHILDREN.
003306 03-11
COMPUTER-ANALYZED EEG IN AMPHETAMINE RESPONSIVE
HYPERACTIVE-CHILDREN.
003338 03-11
PREDICTING STIMULANT-EFFECTIVENESS IN HYPERACTIVE-CHILDREN WITH
A REPEATABLE NEUROPSYCHOLOGICAL-BATTERY: A PRELIMINARY-
STUDY.
004453 04-1 1
HYPERACTIVE-CHILDRENS
THE USE OF SENSORY INTEGRATIVE DIAGNOSTICS TO PREDICT
HYPERACTIVE-CHILDRENS RESPONSIVENESS TO METHYLPHENIDATE
(RITALIN) AND PEMOLINE (CYLERT) (PH.D. DISSERTATION).
002133 02-11
HYPERACTIVES
HYPERACTIVES AS YOUNG ADULTS: PROSPECTIVE TEN-YEAR FOLLOWUP.
004454 04-11
HYPERACTIVITY
EFFECTS OF RESERPINE AND AMPHETAMINE ON THE DEVELOPMENT OF
HYPERACTIVITY IN MATERNALLY-DEPRIVED RAT PUPS.
001654 02-04
HYPERACTIVITY IN DEVELOPING RATS: SEX-DIFFERENCES IN 6
HYDROXYDOPAMINE AND AMPHETAMINE EFFECTS.
002970 03-04
A NOTE ON THE PARADOXICAL-EFFECT OF STIMULANTS ON
HYPERACTIVITY WITH REFERENCE TO THE RATE DEPENDENCY EFFECT
OF DRUGS.
003320 03-11
AUTONOMIC-EFFECTS OF DEXTROAMPHETAMINE IN NORMAL MEN:
IMPLICATIONS FOR HYPERACTIVITY AND SCHIZOPHRENIA.
003437 03-13
DOPAMINE-DEPENDENT HYPERACTIVITY IN THE FOLLOWING
MANIPULATION OF GABA MECHANISMS IN THE REGION OF THE
NUCLEUS-ACCUMBENS.
003976 04-03
IE
will
<iiiJir'
I
ouiii:
^•191!,':
S-217
i I
r
I nit*
Subject Index
HYPERACTIVITY FOLLOWING INJECTION OF A GLUTAMATE AGONIST AND
6 7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY
THIP.
004066 04-04
CENTRAL AND PERIPHERAL EFFECTS OF LITHIUM ON AMPHETAMINE-
INDUCED HYPERACTIVITY IN RATS.
004223 04-04
DRUG-THERAPY FOR HYPERACTIVITY: TREATMENT PROCEDURES IN
NATURAL SETTINGS.
004449 04-1 1
PREVALENCE OF HYPERACTIVITY AND RELATED TREATMENTS AMONG
ELEMENTARY SCHOOL CHILDREN.
004469 04-11
PREVALENCE OF DRUG-TREATMENT FOR HYPERACTIVITY AND OTHER
CHILDHOOD BEHAVIOR-DISORDERS.
004713 04-17
PSYCHOSOCIAL-ASPECTS OF DRUG-TREATMENT FOR HYPERACTIVITY.
004714 04-17
HYPERACTIVITY-SYNDROME
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE
HYPERACTIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN
DEFICIENCY HYPOTHESIS.
003312 03-11
REPEATED ADMINISTRATION OF NALTREXONE PRODUCES TOLERANCE TO
NALOXONE-INDUCED HYPERALGESIA.
000453 01-04
ANALGESIC ACTIVITY OF DIFLUNISAL (MK-647; 5 2,4
DIFLUOROPHENYLSALICYLIC-ACID) IN RATS WITH HYPERALGESIA
INDUCED BY FREUNDS-ADJUVANT.
000502 01-04
INTRATHECAL HIGH-DOSE MORPHINE PRODUCES HYPERALGESIA IN THE
RAT
004254 04-04
HYPERAL6ESIC
DOPAMINERGIC INVOLVEMENT IN THE HYPERALGESIC EFFECT OF
NOMIFENSINE.
002736 03-03
HYPERCALCEMIA
THIAZIDE-INDUCED HYPERCALCEMIA IN A MANIC-DEPRESSIVE-PATIENT.
000843 01-15
RENAL IMPAIRMENT, HYPERCALCEMIA, AND LITHIUM THERAPY
003473 03-15
HYPERGLYCEMIA
BETA ENDORPHIN-INDUCED HYPERGLYCEMIA IS MEDIATED BY INCREASED
CENTRAL SYMPATHETIC OUTFLOW TO ADRENAL-MEDULLA.
002924 03-03
INTRAVENTRICULAR CHOLECYSTOKININ-OCTAPEPTIDE PRODUCES
HYPERGLYCEMIA IN RATS.
003943 04-03
HYPERGLYCEMIC
IMPROVEMENT OF RESTITUTION FROM CEREBRAL ISCHEMIA IN
HYPERGLYCEMIC RATS BY PENTOBARBITAL OR DIAZEPAM.
000475 01-04
HYPERINNERVATION
FUNCTIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY
NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS
WITH SCHIZOPHRENIA.
000059 01-03
HYPERKINESIA
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN.
004638 04-15
HYPERKINESIS
ADVERSE-REACTIONS TO MEDICATIONS PRESCRIBED FOR HYPERKINESIS.
(PH.D. DISSERTATION).
002411 02-15
HYPERKINETIC
INTERACTION OF PSYCHOPHARMALOGIC-FACTORS AND PSYCHOSOCIAL-
FACTORS IN THE TREATMENT OF ANIMAL-MODELS OF
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR.
001602 02-04
HYPERKINETIC-BOYS
PREDICTORS OF ADOLESCENT HEIGHT AND WEIGHT IN HYPERKINETIC-
BOYS TREATED WITH METHYLPHENIDATE.
003509 03-15
HYPERKINETIC-CHILDREN
CLONAZEPAM AND DITHIADEN IN HYPERKINETIC-CHILDREN.
000729 01-11
EFFECTS OF METHYLPHENIDATE-HYDROCHLORIDE ON REPEATED
ACQUISITION-BEHAVIOR IN HYPERKINETIC-CHILDREN. (PH.D.
DISSERTATION).
003386 03-1 1
DRUG AND DIETETIC THERAPIES FOR HYPERKINETIC-CHILDREN. (PH.D.
DISSERTATION).
003576 03-17
HYPERKINETIC-SYNDROME
MINIMAL-BRAIN-DYSFUNaiON - HYPERKINETIC-SYNDROME.
000730 01-11
Psychopharmacology Abstracts
THE HYPERKINETIC-SYNDROME FOLLOWING LONG-TERM HALOPERIDOL
TREATMENT: INVOLVEMENT OF DOPAMINE AND NORADRENALINE.
001299 02-03
HYPERMOTILITY
THE ROLE OF DOPAMINE IN THE HYPERMOTILITY INDUCED BY H-77-77
(4, ALPHA DIMETHYL-M-TYRAMINE) IN MICE.
001762 02-04
HYPERPARATHYROIDISM
HYPERPARATHYROIDISM IN ASSOCIATION WITH LITHIUM THERAPY.
003489 03-15
HYPERPHAGIA
ANTAGONISM OF 2 DEOXY-D-GLUCOSE-INDUCED HYPERPHAGIA BY
NALOXONE: POSSIBLE INVOLVEMENT OF ENDORPHINS.
001773 02-04
CLONIDINE-INDUCED HYPERPHAGIA IN MONKEYS: EVIDENCE FOR
ALPHA2-N0RADRENERGIC-RECEPT0R MEDIATION .
004215 04-04
HYPERPHAGIAS
SELEaiVE REDUaiON BY DEXAMETHASONE OF STRESS RELATED
HYPERPHAGIAS.
001703 02-04
HYPERPOLARIZATION
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP-
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF
MOUSE NEUROBLASTOMA CELLS USING
(3H)TETRAPHENYLPH0SPH0NIUM
004049 04-03
HYPERPOLARIZE
OPIATES AND OPIOID-PEPTIDES HYPERPOLARIZE LOCUS-COERULEUS
NEURONS IN VITRO.
001408 02-03
HYPERPOLARIZING
THE EFFEQS OF A BENZODIAZEPINE ON THE HYPERPOLARIZING AND THE
DEPOLARIZING RESPONSES OF HIPPOCAMPAL CELLS TO GABA.
002763 03-03
HYPERPROLACTINAEMIC-PATIENTS
INFLUENCE OF NOMIFENSINE ON GROWTH-HORMONE, PROLAQIN,
LUTEINISING-HORMONE AND THYREOTROPIN IN HEALTHY SUBJEQS
AND HYPERPROLACTINAEMIC-PATIENTS.
002137 02-11
HYPERPYREXIA
CHARACTERISTIC HYPERPYREXIA INDUCED BY LICL AND
TRANYLCYPROMINE IN RATS.
004278 04-05
HYPERREACTIVITY
MORPHINE INJECTIONS INTO THE PERIAQUEDUQAL PERIVENTRICULAR
GRAY AnENUATE SEPTAL HYPERREAQIVITY.
000390 01-04
HYPERSENSITIVITY
AMPHETAMINE-INDUCED HYPERSENSITIVITY IN GUINEA-PIGS.
000498 01-04
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE-
RECEPTOR MECHANISMS IN CNS.
001178 02-03
EFFEQS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A
DELAYED TYPE HYPERSENSITIVITY REAQION TO 1
CHLORODINITROBENZENE IN MICE.
001473 02-03
INDUCTION OF HYPERSENSITIVITY OF BRAIN BY HYDRALAZINE
TREATMENT IN RATS.
003008 03-04
A CONTROLLED-STUDY OF L-DOPA IN SCHIZOPHRENIA WITH REFERENCE
TO THE THEORY OF DOPAMINERGIC-RECEPTOR HYPERSENSITIVITY.
004312 04-08
HYPERSYNCHRONOUS-ACTIVITY
HYPERSYNCHRONOUS-AaiVITY ELICITED BY GAMMA
HYDROXYBUTYRATE DURING ONTOGENESIS IN RATS.
000460 01-04
HYPERTENSION
THE BLOOD-BRAIN-BARRIER IN ADRENALINE-INDUCED HYPERTENSION.
000147 01-03
RENAL BENZODIAZEPINE BINDING INCREASES DURING
DEOXYCORTICOSTERONE /SALT HYPERTENSION IN RATS.
001430 02-03
INFLUENCE OF RESPIRATORY STRESS AND HYPERTENSION UPON THE
BLOOD-BRAIN-BARRIER. 001437 02^3
BIOGENIC-AMINES AND NEUROPEPTIDES PLAY A ROLE IN THE CENTRAL-
REGULATION OF GENETIC HYPERTENSION. (UNPUBLISHED PAPER).
001455 02-03
CENTRAL BIOGENIC-AMINES AND NEUROPEPTIDES IN GENETIC
HYPERTENSION (UNPUBLISHED PAPER). 0014S6 02-03
THE SYMPATHETIC-NERVOUS-SYSTEM AND HYPERTENSION: A POSITION
PAPER. (UNPUBLISHED PAPER).
002250 02-13
STRESS AND HYPERTENSION: CLINICAL-IMPLICATIONS ^-.q.
S-218
VOLUME 19, SUBJECT INDEX
Subject Index
NONCOOPERATION: AN EXAMINATION Of FACTORS LEADING TO
NONCOMPLIANCE IN A HYPERTENSION CLINIC.
002557 02-17
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING:
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN
HYPERTENSION.
002874 03-03
INTERMIHENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA,
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE
lOTHALAMATE VENTRICULOGRAM.
003520 03-15
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC
AND DOCA-SALT HYPERTENSION IN THE RAT.
003899 04-03
HYPERTENSIVE
EFFECT OF BROMOCRIPTINE ON EXPLORATORY-ACTIVITY, BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS.
001635 02-04
HYPERTENSIVE-PATIENTS
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS.
002071 02-10
HYPERTENSIVE-RAT
PRESSOR EFFECTS OF DORSAL RAPHE STIMULATION AND
INTRAHYPOTHALAMIC APPLICATION OF SEROTONIN IN THE
SPONTANEOUSLY HYPERTENSIVE-RAT.
003117 03-04
HYPERTENSIVE-RATS
TYROSINE ADMINISTRATION REDUCES BLOOD-PRESSURE AND ENHANCES
BRAIN NOREPINEPHRINE RELEASE IN SPONTANEOUSLY HYPERTENSIVE-
RATS.
000296 01-03
DOSE-DEPENDENT, AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND
SPONTANEOUSLY HYPERTENSIVE-RATS.
001197 02-03
INCREASED RENAL NEUROLEPTIC BINDING IN SPONTANEOUSLY
HYPERTENSIVE-RATS.
001444 02-03
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS PRESENT A NALOXONE
SENSITIVE DECREASE IN PAIN SENSITIVITY. (UNPUBLISHED PAPER).
001457 02-03
INCREASED ADRENALINE, BETA-ADRENERGIC-RECEPTOR STIMULATION
AND PHOSPHOLIPID METHYLATION IN PINEAL-GLAND OF
SPONTANEOUSLY HYPERTENSIVE-RATS. (UNPUBLISHED PAPER).
001458 02-03
CENTRAL AMINERGIC AND PEPTIDERGIC MECHANISMS IN
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS. (UNPUBLISHED
PAPER).
001459 02-03
CENTRAL-AaiONS OF NOREPINEPHRINE, PHENTOLAMINE AND 6
HYDROXYDOPAMINE IN SPONTANEOUSLY HYPERTENSIVE-RATS.
001553 02-03
EFFEQ OF BROMOCRIPTINE ON EXPLORATORY-AQIVITY, BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS.
001635 02-04
SELF-STIMULATION REAQION IN NORMOTENSIVE-RATS AND
HYPERTENSIVE-RATS.
002663 03-03
INCREASED AMPHETAMINE STEREOTYPY AND LONGER HALOPERIDOL
CATALEPSY IN SPONTANEOUSLY HYPERTENSIVE-RATS.
002891 03-03
POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CARDIOVASCULAR-
EFFECTS OF CENTRAL ALPHA-ADRENOCEPTOR STIMULATION IN
SPONTANEOUSLY HYPERTENSIVE-RATS.
003791 04-03
DIFFERENTIAL-EFFEaS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS.
003947 04-03
DIETARY PROTEIN INTAKE INFLUENCES THE ANTIHYPERTENSIVE POTENCY
OF METHYLDOPA IN SPONTANEOUSLY HYPERTENSIVE-RATS.
004025 04-03
HYPERTHERMIA
ENDORPHIN-INDUCED HYPERTHERMIA: CHARACTERIZATION OF THE
EXOGENOUSLY-INDUCED AND ENDOGENOUSLY-INDUCED EFFECTS
000029 01-03
APHAGIA, GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNQIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS-
EFFEaS OF INSULIN PRETREATMENTS.
001638 02-04
TEMPORAL AND ENVIRONMENTAL CUES IN CONDITIONED HYPOTHERMIA
AND HYPERTHERMIA ASSOCIATED WITH MORPHINE.
002709 03-03
SELECTIVE EFFECTS OF LSD AND HYPERTHERMIA ON THE SYNTHESIS OF
SYNAPTIC PROTEINS AND GLYCOPROTEINS,
002721 03-03
INTERMIHENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA,
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE
lOTHALAMATE VENTRICULOGRAM
003520 03-15
HYPERTHERMIC-DOSE
PROSTAGLANDINS IN THE BRAIN OF RATS GIVEN, ACUTELY, AND
CHRONICALLY, A HYPERTHERMIC-DOSE OF MET-ENKEPHALIN.
001468 02-03
HYPERTHERMIC-EFFECTS
ENHANCED BEHAVIOURAL-EFFECTS, ELECTROCORTICAL-EFFECTS AND
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN.
001733 02-04
HYPERTHERMIC-RESPONSE
STUDIES ON THE HYPERTHERMIC-RESPONSE OF BETA ENDORPHIN IN
MICE.
000137 01-03
HYPERTHERMIC-RESPONSE TO (-) CATHINONE, AN ALKALOID OF CATHA-
EDULIS (KHAT).
003694 04-02
HYPERVENTILATION-SYNDROME
HYPERVENTILATION-SYNDROME, TREATMENT WITH L TRYPTOPHAN AND
PYRIDOXINE; PREDiaiVE VALUES OF XANTHURENIC-ACID EXCRETION.
004456 04-11
HYPERVENTILATION-SYNDROME AND BETA-RECEPTOR FUNCTION -
CLINICAL-EFFECT OF BETA BLOCKER UPON THE SYNDROME.
004459 04-11
HYPNAGOGIC
HYPNAGOGIC AND HYPNOPOMPIC HALLUCINATIONS DURING
AMITRIPTYLINE TREATMENT.
000850 01-15
HYPNOPOMPIC
HYPNAGOGIC AND HYPNOPOMPIC HALLUCINATIONS DURING
AMITRIPTYLINE TREATMENT.
000850 01-15
HYPNOSEDATIVE
INTRAVENOUS PHENOBARBITAL THERAPY IN BARBITURATE AND OTHER
HYPNOSEDATIVE WITHDRAWAL REACTIONS: A KINETIC APPROACH.
000703 01-11
HYPNOSIS
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID:
DIFFERENTIAL-EFFECT IN TOLERANT ANIMALS.
003038 03-04
EFFECTS OF PAIN, MORPHINE AND NALOXONE ON THE DURATION OF
ANIMAL HYPNOSIS.
004081 04-04
HYPNOTIC
GAMMA HYDROXYBUTYRIC-ACID AS HYPNOTIC.
000541 01-07
COMPARATIVE-STUDY OF SLEEP AND STATE ON AWAKENING WITH TWO
HYPNOTIC DIAZEPINES.
000817 01-14
NEUROPHYSIOLOGICAL-EFFECTS OF ETOMIDATE, A NEW SHORT-ACTING
HYPNOTIC.
002263 02-13
EUHYPNOS-FORTE, HIGH-DOSE TEMAZEPAM FOR RESISTANT INSOMNIA:
POSTMARKETING SURVEILLANCE IN 10,057 PATIENTS UNRESPONSIVE
TO CONVENTIONAL HYPNOTIC DOSAGE.
002324 02-14
HYPNOTIC ACTION OF FLUNITRAZEPAM (ROCHES ROIPNOL) IN PATIENTS
WITH SEVERE PSYCHIATRIC-DISORDERS.
003295 03-11
HYPNOTIC-COMPOUNDS
RESIDUAL-EFFECTS OF TEMAZEPAM AND OTHER HYPNOTIC-COMPOUNDS
ON COGNITIVE FUNCTION.
000879 01-15
HYPNOTIC-DRUG
PHARMACOLOGICAL-PROPERTIES OF TAGLUTIMIDE, A NEW SEDATIVE
HYPNOTIC-DRUG.
001087 02-02
EEG ASSESSMENTS OF DOSAGE AND SLEEP PROFILES FOR A HYPNOTIC-
DRUG OF THE TRIAZOLOTHIENODIACEPINE SERIES.
002338 02-14
DIFFICULTIES ENCOUNTERED DURING A CONTROLLED STUDY OF A NEW
HYPNOTIC-DRUG (TRIAZOLAM) BY A GROUP OF GENERAL-
. PRACTITIONERS.
003155 03-07
HYPNOTIC-DRUGS
HYPNOTIC-DRUGS AND TREATMENT OF INSOMNIA.
003350 03-11
HYPNOTIC-EFFECTS
COMPARATIVE ANXIOLYTIC AND HYPNOTIC-EFFEQS OF 3
BENZODIAZEPINES ON BABOONS.
001581 02-04
•«<
'M
'C«:i
I
&x:..
S-219
Subject Index
111
EFFECT OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF
TOLERANCE TO THE HYPNOTIC-EFFECTS OF PENTOBARBITAL, BARBITAL,
ANDETHANOL. „-,„.„o
003883 04-03
HYPNOTIC-INTERACTIONS
ETHANOL SEDATIVE HYPNOTIC-INTERACTIONS: IN VITRO STUDIES ON NA-
K-ACTIVATED ADENOSINE-TRIPHOSPHATASE.
004269 04-05
THE mo SURVIVAL CASES OF ALPHA-PAHERN COMA CAUSED BY
LARGE AMOUNTS OF HYPNOTICA AND NEUROLEPTICA.
004608 04-15
HYPNOTICS
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY
SPECTRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND
NEUROLEPTICS. „„,„o^«^«o
001220 02-03
HYPNOTIZABILITY
HYPNOTIZABILITY AND PSYCHOACTIVE-MEDICATION.
000823 01-14
DOPAMINE HYPOACTIVITY MEASURED BY IN VIVO VOLTAMMETRY.
001149 02-03
LITHIUM AMELIORATION OF RESERPINE-INDUCED HYPOAaiVITY IN
RATS
004167 04-04
HYPOALGESIA INDUCED BY MICROINJECTION OF A NOREPINEPHRINE
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL
ADMINISTRATION OF A SEROTONIN ANTAGONIST.
000121 01-03
HYPOALGESIA FOLLOWING MICROINJECTION OF NORADRENERGIC
ANTAGONISTS IN THE NUCLEUS-RAPHE-MAGNUS.
000122 01-03
HYPOBARIC
EFFECT OF TABERNANTHINE ON THE TURNOVER TIME OF BRAIN
CATECHOLAMINES IN NORMAL AND HYPOBARIC HYPOXIC RATS.
001187 02-03
HYPOCHONDRIACAL
THE PROBLEM OF PSYCHOPHARMACOTHERAPY OF SLOWLY PROGRESSIVE
HYPOCHONDRIACAL SCHIZOPHRENIA. „ „ „„
004340 04-08
HYPOCHONDRIACAL-PATIENTS
FLUSPIRILENE (IMAP) IN THE TREATMENT OF PSYCHOSOMATIC-
COMPLAINTS IN HYPOCHONDRIACAL-PATIENTS.
002072 02-10
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM-
ACETATE, MONOFLUOROACETATE AND INSULIN-INDUCED
HYPOGLYCEMIA. „^ ^, „^ „^
004276 04-05
HYPOGLYCEMIC
EFFECTS OF BICUCULLINE-INDUCED SEIZURES ON CEREBRAL METABOLISM
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY
STARVATION. ^
001134 02-03
HYPOINHIBITORY
INTERACTION OF PSYCHOPHARMALOGIC-FAaORS AND PSYCHOSOCIAL-
FACTORS IN THE TREATMENT OF ANIMAL-MODELS OF
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR.
001602 02-04
HYPOKINESIA
SUPERSENSITIVITY TO APOMORPHINE IN EXPERIMENTALLY-INDUCED
HYPOKINESIA AND DRUG-INDUCED MODIFICATIONS OF THE
APOMORPHINE RESPONSE.
001814 02-04
HYPOMANIA
HYPOMANIA AND TRICYCLIC-ANTIDEPRESSANT CHOICE.
000545 01-07
HYPOMANIA AS A STABLE STATE: LITHIUM PROPHYLAXIS IN TWO
"^^'^'^^^ 003212 03-09
HYPOMANIA AND MANIA AFTER WITHDRAWAL OF TRICYCLIC-
ANTIDEPRESSANTS. , „, „„
003243 03-09
HYPOMANIC-REACTION
HYPOMANIC-REACTION TO AMITRIPTYLINE IN A DEPRESSED-CHILD.
002418 02-15
HYPOPHYSECTOMY .^.„^„„
HYPOPHYSECTOMY PREVENTS THE STRIATAL DOPAMINE-RECEPTOR
SUPERSENSITIVITY PRODUCED BY CHRONIC HALOPERIDOL TREATMENT.
000132 01-03
THE EFFECTS OF GONADECTOMY AND HYPOPHYSECTOMY ON THE
METABOLISM OF IMIPRAMINE AND LIDOCAINE BY THE LIVER OF MALE
AND FEMALE RATS.
000273 01-03
HYPOPHYSECTOMY INCREASES THE SENSITIVITY OF RATS TO NALOXONE-
INDUCED HYPOTHERMIA. 002710 03-03
Ptychopharmacology Abstracts
HYPOPHYSIS
EXPERIENCE IN USING THE HORMONES OF THE HYPOPHYSIS POSTERIOR
LOBE IN MEMORY-DISTURBANCES OF VARYING GENESES.
003438 03-14
DRUG-INDUCED ALTERATIONS OF THE HYPOTHALAMUS HYPOPHYSIS
AXIS.
004535 04-13
HYPOSENSITIVITY
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE-
RECEPTOR MECHANISMS IN CNS.
001178 02-03
HYPOTAURINE
INHIBITORY AQIONS OF TAUROCY AMINE, HYPOTAURINE,
HOMOTAURINE. TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
HYPOTENSION
COMPOUND-48-80 INHIBITS NEUROTENSIN-INDUCED HYPOTENSION IN
RATS
000243 01-03
THE ROLE OF DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC AGONISTS
IN CHLORPROMAZINE-INDUCED HYPOTENSION.
001851 02-05
DRUG-INDUCED ARTERIAL HYPOTENSION IN PSYCHIATRIC-PATIENTS
TREATED WITH DIHYDROERGOT AMINE.
001950 02-08
TREATMENT OF PSYCHOTROPIC-CAUSED ORTHOSTATIC HYPOTENSION.
002428 02-15
HYPOTENSION ALTERS THE RELEASE OF CATECHOLAMINES IN THE
HYPOTHALAMUS OF THE CONSCIOUS RABBIT.
003968 04-03
HYPOTENSION-SYNDROMES
PHARMACOLOGIC DISTINQION OF DIFFERENT ORTHOSTATIC
HYPOTENSION-SYNDROMES.
003362 03-1 1
HYPOTENSIVE-ACTION
THE HYPOTENSIVE-ACTION OF 3 DEAZAADENOSINE.
001415 02-03
HYPOTENSIVE-EFFECT
POSSIBLE INVOLVEMENT OF CYCLIC-AMP AND FRONTAL-CORTEX IN
AMITRIPTYLINE MEDIATED SUPPRESSION OF THE HYPOTENSIVE-EFFEQ
OF CLONIDINE.
001259 02-03
THE HYPOTENSIVE-EFFEQ OF CENTRALLY-ADMINISTERED TYROSINE
001548 02-03
CENTRAL HYPOTENSIVE-EFFEQ OF GAMMA AMINOBUTYRIC-ACID IN
ANESTHETIZED DOGS.
003772 04-03
THE EFFECT OF ANTIDEPRESSANTS ON THE HYPOTENSIVE-EFFEQ OF
CLOFELIN IN RATS. _^„^ ^
003934 04-03
HYPOTHALAMIC
EFFECTS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT.
000180 01-03
EFFECTS OF BRAIN-MONOAMINE DEPLETION ON THERMOREGULATORY
RESPONSES OF RABBITS TO DIFFERENT HYPOTHALAMIC
"^"«*™^^^ 000190 01-03
RELEASE OF GONADOTROPIN-RELEASING-HORMONE BY VERATRINE IN A
HYPOTHALAMIC PITUITARY COINCUBATION ^ ^^
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL
°^*^^ 000322 01-03
FACILITATION OF RECOVERY BY PROPANTHELINE-BROMIDE AFTER
LATERAL HYPOTHALAMIC DAMAGE. ^^^^ ^^^
HYPOTHALAMIC CATECHOLAMINE BIOSYNTHESIS IN VITRO AS
MEASURED BY LIQUID-CHROMATOGRAPHY AND ELEQROCHEMICAL-
'^^^^^^'O'^ 000537 01-06
THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN
REGULATION OF NEUROSECRETION. (UNPUBLISHED PAPERS
EXTRAHYPOTHALAMIC DISTRIBUTIONS AND FUNQIONS OF
HYPOTHALAMIC PEPTIDE-HORMONES. (UNPUBLISHED PAPER).
SYSTEMIC INSULIN DECREASES LATERAL HYPOTHALAMIC UNIT ACTIVITY^
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION^
(X) I J I U Ui"U J
S-220
VOLUME 19, SUBJECT INDEX
Subject Index
THE ROLE Of PROTEIN SYNTHESIS IN THE HYPOTHALAMIC MECHANISM
MEDIATING PYROGEN FEVER.
001454 02-03
APHAGIA, GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNCTIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS:
EFFECTS OF INSULIN PRETREATMENTS.
001638 02-04
ENHANCED LATERAL HYPOTHALAMIC SELF-STIMULATION RESPONDING
AFTER CHRONIC EXPOSURE TO AMPHETAMINE.
001688 02-04
SELF-ADMINISTRATION OF D ALA2-MET-ENKEPHALINAMIDE AT
HYPOTHALAMIC SELF-STIMULATION SITES.
001738 02-04
ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN
THE CAT.
001761 02-04
A COMPARISON BETWEEN THE EFFECTS OF MORPHINE ON THE
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC
AND CENTRAL GRAY STIMULATION.
001771 02-04
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR
DORSOLATERAL TEGMENTAL DAMAGE.
001818 02-04
APOMORPHINE: SELECTIVE INHIBITION OF THE AVERSIVE COMPONENT OF
LATERAL HYPOTHALAMIC SELF-STIMULATION.
002476 02-16
THE HYPOTHALAMIC DOPAMINERGIC REGULATION OF PROLACTIN: A
MODEL FOR THE STUDY OF NEUROHORMONAL MECHANISMS IN MAN.
002568 02-17
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS,- INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
HISTAMINE ACTIONS ON ACTIVITY OF CULTURED HYPOTHALAMIC
NEURONS; EVIDENCE FOR MEDIATION BY HISTAMINE HI -RECEPTORS
AND H2-RECEPT0RS.
002732 03-03
MONOAMINE-OXIDASE-B AQIVITIES TOWARD BETA PHENYLETHYLAMINE
IN DISCRETE HYPOTHALAMIC AND CIRCUMVENTRICULAR NUCLEI OF
THE RAT.
002781 03-03
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFECTS OF NALOXONE ON
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE
MALE RAT.
002853 03-03
SMALL-DOSE INTRAVENOUS HEROIN FACILITATES HYPOTHALAMIC SELF-
STIMULATION WITHOUT RESPONSE SUPPRESSION IN RATS.
002999 03-04
INFLUENCE OF MORPHINE ON THE DISCRIMINATIVE-STIMULUS
PROPERTIES OF REWARDING LATERAL HYPOTHALAMIC STIMULATION.
(PH.D. DISSERTATION).
003041 03-04
THYROXIN SENSITIVITY OF SENSORIMOTOR CORTICAL NEURONS AND THE
HYPOTHALAMIC VENTROMEDIAL NUCLEUS.
003713 04-03
UNIMPAIRED QUININE METABOLISM IN RATS WITH VENTROMEDIAL
HYPOTHALAMIC LESIONS.
003821 04-03
CATECHOLAMINE SYNTHESIS REGULATION IN HYPOTHALAMIC
SYNAPTOSOMES. (UNPUBLISHED PAPER).
003829 04-03
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN
INDIRECT ADRENERGIC CHOLINERGIC INTERAQION.
003887 04-03
NEUROTENSIN RELEASE BY RAT HYPOTHALAMIC FRAGMENTS IN VITRO
003920 04-03
NEUROTRANSMIHER CONTROL OF HYPOTHALAMIC PITUITARY THYROID-
FUNCTION IN RATS.
003942 04-03
EFFEQS OF CANNABINOIDS ON CATECHOLAMINE UPTAKE AND RELEASE
IN HYPOTHALAMIC AND STRIATAL SYNAPTOSOMES.
003970 04-03
THE EFFEQ OF PHARMACOLOGICAL DESTRUCTION OF HYPOTHALAMIC
MONOAMINERGIC STRUCTURES ON BODY-TEMPERATURE AND GAS-
EXCHANGE DURING EXTREME COOLING.
004016 04-03
HYPOTHALAMUS
MORPHINE EXERTS TESTOSTERONE-LIKE EFFECTS IN THE HYPOTHALAMUS
OF THE CASTRATED MALE RAT.
000051 01-03
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS
000091 01-03
DEPLETION OF EPINEPHRINE IN RAT HYPOTHALAMUS BY RO-4-1284
INFLUENCE OF PARGYLINE AND HARMALINE.
000100 01-03
METABOLISM OF 3H NORADRENALINE RELEASED FROM ISOLATED RAT
HYPOTHALAMUS BY EXTRACTS OF BLACK-WIDOW-SPIDER GLANDS.
000223 01-03
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND
L-AMPHETAMINE: NO INTERACTION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES
000387 01-04
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS.
000520 01-05
GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT
AFFECTED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN
TREATMENT.
001145 02-03
EPINEPHRINE IS RELEASED FROM HYPOTHALAMUS BY DEPOIARIZING-
AGENTS AND AMPHETAMINE.
001155 02-03
PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN
VITRO. INHIBITION BY MELATONIN AT SUBMICROMOLAR
CONCENTRATIONS,
001159 02-03
THE EFFECTS OF BOMBESIN INJECTED INTO THE ANTERIOR AND
POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN
CONSUMPTION.
001544 02-03
INFLUENCE OF CHRONIC ALCOHOL INTOXICATION ON CIRCADIAN-RHYTHM
OF NEUROSECRETORY CENTERS OF RAT HYPOTHALAMUS.
001549 02-03
EFFECTS OF LILLY-1 10140 (FLUOXETINE) ON SELF-STIMULATION
BEHAVIOR IN THE DORSAL AND VENTRAL REGIONS OF THE LATERAL
HYPOTHALAMUS IN THE MOUSE.
001590 02-04
PRESYNAPTIC REGULATION OF THE RELEASE OF CATECHOLAMINES IN THE
CAT HYPOTHALAMUS.
002703 03-03
TEMPORAL PAHERNING OF NEURONAL AQIVITY DURING THERMAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
A BARBITURATE-EVOKED INTENSIFICATION OF POSTSYNAPTIC INHIBITION
IN THE PREOPTIC OVULATORY TRIGGER REGION OF THE
HYPOTHALAMUS.
002818 03-03
CHARACTERIZATION AND QUANTITATION OF ALPHA-ADRENERGIC-
RECEPTOR SUBTYPES IN RAT HYPOTHALAMUS.
002839 03-03
CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN
HYPOTHALAMUS.
002842 03-03
ON CORRELATION OF BEHAVIORAL-REACTIONS AND NEURONAL ACTIVITY
IN THE HYPOTHALAMUS UNDER SUBCUTANEOUS GASTRIN INJECTION.
002892 03-03
SOMATOSTATIN FACILITATES THE SEROTONIN RELEASE FROM RAT-
CEREBRAL-CORTEX, HIPPOCAMPUS, AND HYPOTHALAMUS SLICES.
002913 03-03
MEPACRINE TREATMENT PREVENTS IMMOBILIZATION-INDUCED
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT
HYPOTHALAMUS AND BRAINSTEM.
002919 03-03
TRH INCREASES LOCOMOTOR-ACTIVITY IN RATS AFTER INJECTION INTO
THE HYPOTHALAMUS.
003044 03-04
EFFECTS OF ELECTROLYTIC AND 6 HYDROXYDOPAMINE LESIONS OF THE
LATERAL HYPOTHALAMUS ON ROTATION EVOKED BY ELECTRICAL-
STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.
003081 03-04
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED
REFLEXES IN RATS.
003100 03-04
EVIDENCE FOR THERMOREGULATORY DOPAMINERGIC-RECEPTORS
LOCATED IN THE PREOPTICUS-MEDIALIS-NUCLEUS OF THE RAT
HYPOTHALAMUS.
003754 04-03
SELECTIVE MODIFICATION BY OPIATES OF NEURONAL ACTIVITY OF THE
MEDIAL BASAL HYPOTHALAMUS.
003773 04-03
HYPOTENSION ALTERS THE RELEASE OF CATECHOLAMINES IN THE
HYPOTHALAMUS OF THE CONSCIOUS RABBIT.
003968 04-03
DRUG-INDUCED ALTERATIONS OF THE HYPOTHALAMUS HYPOPHYSIS
AXIS.
004535 04-13
'"IW
I
OHtlE
.;SR|i!:
•«B|1'
S-221
Subject Index
III
^''
Mm
I
HYPOTHERMIA
CENTRAL ADMINISTRATION OF SERINE CAUSES HYPOTHERMIA AND
INHIBITS FEVER IN RABBITS. 001247 02-03
APOMORPHINE HYPOTHERMIA: AN INDEX OF CENTRAL DOPAMINE-
RECEPTOR FUNCTION IN MAN . ^^22 1 02- 1 3
TEMPORAL AND ENVIRONMENTAL CUES IN CONDITIONED HYPOTHERMIA
AND HYPERTHERMIA ASSOCIATED WITH MORPHINE. ^^^^^^ ^^^^
HYPOPHYSECTOMY INCREASES THE SENSITIVITY OF RATS TO NALOXONE-
INDUCED HYPOTHERMIA. 002710 03-03
SEROTONERGIC MECHANISMS OF CLONIDINE-INOUCED HYPOTHERMIA IN
^^^- 002806 03-03
EFFEaS OF MORPHINE AND NALORPHINE ON KAINIC-ACID-INDUCED
HYPOTHERMIA IN RATS. 00292103-03
ENHANCEMENT OF ETHANOL-INDUCED SEDATION AND HYPOTHERMIA BY
CENTRALLY ADMINISTERED NEUROTENSIN, BETA ENDORPHIN AND
BO^B^S'^ 003037 03-04
"^''th^hypotor'iwgeffects of clonidine and other imidazolidines
IN relation to their ability to enter the central-nervous-
system in mice. 003933 04-03
THE EFFEQS of PEPTIDES ON TOLERANCE TO THE CATALEPTIC-EFFEQS
AND HYPOTHERMIC-EFFECTS OF MORPHINE IN THE RAT.
004072 04-04
HYPOTHESES
LITHIUM AND MANIA: HYPOTHESES. ^^^^^ ^^.09
"^'duKfECTS of MESCALINE: THE TRANSMETHYLATION HYPOTHESIS
^EV'SITED. 001584 02-04
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES. ("NPUBLISHED^APER).^^^^
L HTP AND THE SEROTONIN HYPOTHESIS: THEIR MEANING FOR
TREATMENT OF DEPRESSION 002326 02-14
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES ^^ ^ ^^ ^^^^
THE EFFECT OF SODIUM-VALPROATE ON MANIA: THE GABA HYPOTHESIS
OF AFFECTIVE-DISORDERS. 003218 03-09
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN. AND THE
HYPERACTIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN
DEFICIENCY HYPOTHESIS. 003312 03-11
CEREBRAL FLUORIDE IN MANIA AND THE EFFECT OF LITHIUM: A
"^''OT"^^'^ 004715 04-17
THE ANTIDEPRESSANT AQION OF SULPHO-ADENOSYL-L-METHIONINE
(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE:
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-ACTION.
OuJ 1 jU UJ"U/
"^"^ ACTIVITY AND CATCH-UP GROWTH IN HYPOTHYROID RATS^
004190 04-04
HYPOTHYROID-PATIENTS
THYROID-INDUCED MANIA IN HYPOTHYROID-PATIENTS.
000857 0 1- 1 J
HYPOTHYROIDISM
EFFECTS OF EXPERIMENTAL HYPOTHYROIDISM ON LEARNING IN RATS_
001 587 02-04
HYPOTONIC
EFFECTS OF THIORIDAZINE ON THE COGNITIVE FUNQIONING OF A
HYPOTONIC SCHIZOPHRENiC-BOY. 000557 01-08
HYPOVOLEMIA
RENIN AND ALDOSTERONE SECRETIONS DURING HYPOVOLEMIA IN RATS:
REIT^TION TO NACL INTAKE. 000484 01-04
HYPOXEMIA
LOCAL CEREBRAL GLUCOSE UTILIZATION (LCGU) IN RAT-BRAIN DURING
HYPOXEMIA. (UNPUBLISHED PAPER). 001380 02-03
NA-GAMMA-HYDROXYBUTYRATE IN CEREBRAL PROTEaiON DURING
SEVERE HYPOXEMIA IN THE RAT. 003895 04-03
"^'fNaUENCE OF PYRITHIOXINE ON EXPERIMENTAL HYPOXIA IN RATS.
Psychopharmacology Abstracts
SUBCELLULAR REAQION OF THE BRAIN TO HYPOXIA.
001354 02-03
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: EFFEQ OF HYPOXIA
OR DRUGS? ^o.»^«, ,c
00348203-15
HYSTERIA
BROMISM. HYSTERIA AND NARCOLEPSY. ,„„„,,
002472 02-15
ON THE USE OF CERTAIN PHARMACOLOGICAL CATEGORIES IN HYSTERIA.
004347 04-09
POSSIBILITIES OF PATHOGENETIC THERAPY OF HYSTERIA.
004429 04-10
HI -RECEPTOR
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFEQS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
RESPONSE „«.,,„,,.«>,
00411904-04
H 1 -RECEPTOR-MEDIATED
ONTOGENY OF HISTAMINERGtC NEUROTRANSMISSION IN THE RAT-
BRAIN CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS. AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER „, r,.^^
004021 04-03
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
004030 04-03
HI -RECEPTORS
HISTAMINE HI -RECEPTORS LABELED IN VIVO: ANTIDEPRESSANT AND
ANTIHISTAMINE INTERACTIONS. ^^^^,^ „, ^,
000074 01-03
IN VIVO OCCUPATION OF CEREBRAL HISTAMINE HI -RECEPTORS
EVALUATED WITH 3H MEPYRAMINE MAY PREDO SEDATIVE
PROPERTIES OF PSYCHOTROPIC-DRUGS. „, „,
000241 01-03
PSYCHOTROPIC-DRUGS AND HISTAMINE HI -RECEPTORS OF CULTURED
MOUSE NEUROBLASTOMA CELLS „„„oc„ „, 00
000250 01-03
PSYCHOTROPIC-DRUG BLOCKADE OF HISTAMINE H 1 -RECEPTORS.
001432 02-03
HIGH-AFFINITY BINDING OF TRICYCLIC-ANTIDEPRESSANTS TO HISTAMINE
Hl-RECEPTORS: FACT AND ARTIFAQ.
001880 02-06
HISTAMINE AaiONS ON ACTIVITY OF CULTURED HYPOTHALAMIC
NEURONS EVIDENCE FOR MEDIATION BY HISTAMINE Hl-RECEPTORS
ANDH2-RECEPT0RS. 002732 03^3
TRICYCLIC-ANTIDEPRESSANTS AND HISTAMINE Hl-RECEPTORS^
003986 04^3
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER 00402104-03
PSYCHOTHERAPEUTIC-DRUGS, HISTAMINE Hl-RECEPTORS AND
MUSCARINIC ACETYLCHOLINE-RECEPTORS. ^.,0-, „. „
0047 J/ 04-1 /
H9 -RECEPTOR
INTERAQION OF HISTAMINE H2-RECEPT0R BLOCKING-DRUGS WITH THE
NORADRENERGIC SYSTEM IN RAT-BRAIN AND HEART. ^^^^^ ^^^^
NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR
CENTRAL ALPHAl-ADRENOCEPTORS. ^^^^^ ^^-03
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFEQS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND Hl-RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
'^"PO'^SE. 004119 04-04
m-RECEPTORS
SOME CENTRAL-EFFEQS OF IMPROMIDINE, A POTENT AGONIST OF
HISTAMINE H2-RECEPT0RS. 001417 02-03
HISTAMINE AQIONS ON AQIVITY OF CULTURED HYPOTHALAMIC
NEURONS EVIDENCE FOR MEDIATION BY HISTAMINE Hl-RECEPTORS
ANDH2-RECEPT0RS 002732 03-03
H2-RECEPT0RS MEDIATE INCREASES IN PERMEABILITY OF THE BLOOO-
BRAIN-BARRIER DURING ARTERIAL HISTAMINE INFUSION^_^^^^ ^^^^
'^™IATR0g1nIC OPIATE ADDIQION: SUCCESSFUL DETOXIFICATION WITH
CLONIDINE. 000666 01-11
IATROGENIC DEPRESSIONS. 002388 02-15
TREATMENT OF IATROGENIC DRUG DEPENDENCE IN THE GENERAL-
^^OSPITAL. 002460 02-15
S-222
VOLUME 19, SUBJECT INDEX
IBOTENIC-ACID
EXCITATORY AND INHIBITORY-ACTIONS OF IBOTENIC-ACID ON FROG
SPINAL MOTONEURONES IN VITRO
002841 03-03
IBOTENIC-ACID ANALOGUES AS INHIBITORS OF (3H)GLUTAMIC-ACID
BINDING TO CEREBELLAR MEMBRANES.
003848 04-03
WUPROFEN
INTERACTION OF INDOMETHACIN AND IBUPROFEN WITH LITHIUM IN
MANIC-PATIENTS UNDER A STEADY-STATE LITHIUM LEVEL.
000622 01-09
IC50
EFFECTS OF RO-1 1-2465, A NEW PSYCHOTROPIC-AGENT ON THE UPTAKE
OF SEROTONIN BY HUMAN PLATELETS - IN VITRO DETERMINATION OF
THE IC50.
004532 04-13
IDEAL
THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG-TREATMENT
FOR HYPERACTIVE-CHILDREN: RECENT FINDINGS AND A REPORT FROM
CLINICAL-PRACTICE.
000715 01-11
IDENTICAL
EFFICACY AND PAHERN VALENCE OF PSYCHOACTIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER.
000699 01-11
COMPARISON OF CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE (CSD)
ISOENZYMES AND GLUTAMIC-ACID-DECARBOXYLASE (GAD) IN RAT: IS
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH
GAD? (UNPUBLISHED PAPER).
001048 02-01
IDENTICAL RESPONSES OF THE TWO HIPPOCAMPAL THETA GENERATORS
TO PHYSIOLOGICAL AND PHARMACOLOGICAL ACTIVATION.
002792 03-03
IDENTIFICATION
DRUG AND SEIZURE IDENTIFICATION BY AUDIO-SPECTROMETRY. (PH.D.
DISSERTATION).
000532 01-06
IDENTIFICATION OF A SUBGROUP OF TARDIVE-DYSKINESIA PATIENTS BY
PHARMACOLOGIC-PROBES.
000708 01-11
IDENTIFICATION AND PARTIAL PURIFICATION OF A HYDROPHOBIC
PROTEIN COMPONENT ASSOCIATED WITH (3H)SPIR0PERID0L BINDING-
AQIVITY. (UNPUBLISHED PAPER).
001007 02-01
IDENTIFICATION AND QUANTIFICATION OF 1,2,3,4 TETRAHYDRO-BETA-
CARBOLINE, 2 METHYL-TETRAHYDRO-BETA-CARBOLINE, AND 6
METHOXY-TETRAHYDRO-BETA-CARBOLINE AS IN VIVO CONSTITUENTS
OF RAT-BRAIN AND ADRENAL-GLAND.
002636 03-01
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS
CULTURED FROM RAT-CEREBRAL-CORTEX.
002820 03-03
THE DEXAMETHASONE-SUPPRESSION-TEST IN THE IDENTIFICATION OF
SUBTYPES OF DEPRESSION DIFFERENTIALLY RESPONSIVE TO
ANTIDEPRESSANTS.
00321103-09
IDENTIFIED
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE '
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE
002900 03-03
EFFECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC
NEURONS.
IDENTIFIES 004026 04-03
DEXAMETHASONE-SUPPRESSION-TEST IDENTIFIES SUBTYPES OF
DEPRESSION WHICH RESPOND TO DIFFERENT ANTIDEPRESSANTS
IDENTITY °°''^' °2-09
THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN
REGULATION OF NEUROSECRETION. (UNPUBLISHED PAPER)
IDIOPATHIC 001003 02-01
ABNORMAL REGULATION OF PROLAQIN RELEASE IN IDIOPATHIC
PARKINSONS-DISEASE.
002255 02-13
A NEUROPHARMACOLOGICAL-STUDY AND NEUROENDOCRINE-STUDY ON
IDIOPATHIC AND CHRONIC PHARMACOLOGICAL PARKINSONISM
002371 02-15
Subject Index
lOE
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER).
001188 02-03
ILEUM
ENKEPHALIN-RECEPTOR IN THE RABBIT ILEUM.
000221 01-03
MET-ENKEPHALIN-ARG6-PHE7 INTERACTS WITH THE KAPPA-RECEPTORS
ON GUINEA-PIG ILEUM.
001110 02-03
INHIBITION OF THE ACTION OF CHOLECYSTOKININ-OCTAPEPTIDE ON THE
GUINEA-PIG ILEUM MYENTERIC PLEXUS BY DIBUTYRYL-CYCLIC-
GUANOSINE-MONOPHOSPHATE.
001291 02-03
COMPARATIVE-EFFECTS OF SOMATOSTATIN AND ENKEPHALINS ON THE
GUINEA-PIG ILEUM AND THE RAT VAS-DEFERENS.
001302 02-03
ALTERED LEVELS OF BETA ENDORPHIN FRAGMENTS AFTER CHRONIC
MORPHINE TREATMENT OF GUINEA-PIG ILEUM IN VITRO AND IN VIVO
001404 02-03
CHARACTERISTICS OF OSCILLATORY CONTRACTIONS ELICITED BY
NALOXONE IN ILEUM PREPARATION FROM MORPHINE-DEPENDENT
GUINEA-PIGS.
001491 02-03
ILEUS
ILEUS COMPLICATING HALOPERIDOL THERAPY.
003511 03-15
ILLNESS
DOPAMINE-RECEPTORS AND SCHIZOPHRENIA: DRUG-EFFECT OR ILLNESS?
000564 01-08
THE PCP PSYCHOSIS: PROLONGED INTOXICATION OR DRUG PRECIPITATED
FUNCTIONAL ILLNESS?
000739 01-12
IMAGING
SPECIFIC IN VIVO BINDING OF 77BR P BROMOSPIROPERIDOL IN RAT-
BRAIN: A POTENTIAL TOOL FOR GAMMA-RAY IMAGING.
004293 04-06
IMIDAZOLE
AMINOPHYLLINE AND IMIDAZOLE AS CONVULSANTS.
004232 04-04
IMIDAZOLIDINES
THE HYPOTHERMIC-EFFECTS OF CLONIDINE AND OTHER IMIDAZOLIDINES
IN RELATION TO THEIR ABILITY TO ENTER THE CENTRAL-NERVOUS-
SYSTEM IN MICE.
003933 04-03
IMIDAZOLINES
CYCLOHEXYLPHENOXYAMIDOXIMES AND IMIDAZOLINES WITH
ANTIDEPRESSIVE AND ALPHA-ADRENERGIC-ACTIVITY.
001051 02-01
IMIDOLINE
DOPAMINE-RECEPTOR BLOCKADE BY IMIDOLINE AND ITS PROPOSED
ACTIVE CONFORMATION.
001687 02-04
IMINO-3-ALKYLTHIAZOLINE
SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME 2 IMINO-3-
ALKYLTHIAZOLINE DERIVATIVES.
003698 04-02
IMINODIBENZYLS
POSSIBLE MODE OF ACTION OF NEUROPSYCHIATRIC-AGENTS:
PHENOTHIAZINES AND IMINODIBENZYLS.
001271 02-03
IMIPRAMINE
3H IMIPRAMINE BINDING IN NEURONAL AND GLIAL FRACTIONS OF
HORSE STRIATUM.
000033 01-03
CENTRAL NORADRENERGIC ADAPTATION TO LONG-TERM-TREATMENT
WITH IMIPRAMINE IN RHESUS-MONKEYS.
000182 01-03
IMIPRAMINE AFFECTS AUTONOMIC-CONTROL OF SINOATRIAL RATE IN
ISOLATED RIGHT ATRIAL PREPARATIONS.
000195 01-03
THE EFFECTS OF GONADECTOMY AND HYPOPHYSECTOMY ON THE
METABOLISM OF IMIPRAMINE AND LIDOCAINE BY THE LIVER OF MALE
AND FEMALE RATS.
000273 01-03
IMIPRAMINE AND REM SLEEP: CHOLINERGIC MEDIATION IN ANIMALS.
000406 01-04
A COMPARISON OF THE EFFECTS OF D-AMPHET AMINE, COCAINE,
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE.
000508 01-04
A REEXAMINATION OF THE CLINICAL-EFFECTS OF IMIPRAMINE AND
AMITRIPTYLINE IN DEPRESSIVE-ILLNESS.
000579 01-09
A COMPARATIVE EVALUATION OF DOTHIEPIN (PROTHIEDEN) AND
IMIPRAMINE.
000583 01-09
'M
'"«!:■
lilKH^l
I
"Wilt
•nit'
S-223
Ill
it
jail
Subject Index
COMPARISON OF SINGLE-DOSE PHARMACOKINETICS OF IMIPRAMINE
AND MAPROTILINE IN THE ELDERLY. 000596 01-09
PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE-
DISORDER. A PRELIMINARY REPORT. 000619 01-09
IMIPRAMINE TREATMENT OF PREPUBERTAL MAJOR DEPRESSIVE-
DISORDERS. PLASMA LEVELS AND CLINICAL-RESPONSE -
PRELIMINARY REPORT. 000620 01-09
D-AMPHETAMINE AS A PREDICTOR FOR RESPONSE TO IMIPRAMINE AND
'^^'^^"'^^'-'^^ 000621 01-09
CONTROLLED-COMPARISON OF MIANSERINE WITH IMIPRAMINE IN
ENDOGENOUS DEPRESSIONS. 000634 01-09
MHPG AS A PREDICTOR OF ANTIDEPRESSANT RESPONSE TO IMIPRAMINE
AND MAPROTILINE. 000787 01-13
RESPONSES TO TYRAMINE AND NOREPINEPHRINE AFTER IMIPRAMINE
AND TRAZODONE. 000864 01-15
LONG-TERM ADMINISTRATION OF ATROPINE, IMIPRAMINE. AND
VILOXAZINE ALTERS RESPONSIVENESS OF RAT-CORTICAL-NEURONES
TO ACETYLCHOLINE. 001306 02-03
DOWN REGULATION OF DIHYDROALPRENOLOL AND IMIPRAMINE
BINDING-SITES IN BRAIN OF RATS REPEATEDLY TREATED WITH
IMIPRAMINE. 001317 02-03
THE NEW ANTIDEPRESSANT PIRLINDOLE: A COMPARISON WITH
IMIPRAMINE AND TRANYLCYPROMINE.
Uu 1 ooU Uz-Uo
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR
THE POTENTIATION OF IMIPRAMINE EFFECTS ON THE METABOLISM
AND UPTAKE OF BRAIN CATECHOLAMINES. ^^^^^^ ^^^^
EFFECT OF IMIPRAMINE ON HEPATIC GAMMA GLUTAMYLTRANSFERASE
IN FEMALE RATS INTERACTION WITH CONTRACEPTIVES .^^^^^_^ ^^^^
INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE,
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS_
001 J jV U^*UJ
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS, UNDER
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REACTION TYPE
(EMOTIVE AND NONEMOTIVE). 001624 02-04
IMIPRAMINE NORMALIZES NATURALLY OCCURRING AND DRUG-INDUCED
DIFFERENCES IN THE EXPLORATORY-ACTIVITY OF RATS
001646 02-04
CONFORMATIONALLY RESTRICTED TRICYCLIC-ANTIDEPRESSANTS^ 1
OCTAHYDRODIBENZAZEPINONAPHTHYRIDINES AS RIGID iMIPRAMINE
^'^^'°^'^'' 001710 02-04
DIFFERENTIAL-EFFECTS OF IMIPRAMINE IN RATS AS A FUNCTION OF DRL
SCHEDULE VALUE. 001714 02-04
REVERSAL OF LEARNED-HELPLESSNESS BY IMIPRAMINE.
001751 02-04
ENDOGENOUS DEPRESSION AND IMIPRAMINE LEVELS IN THE BLOOD^
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS:
RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BUND TRIAL^
001998 02-OV
NOMIFENSINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE-NEUROSIS.
THERAPEUTIC-EFFICACY AND TOLERABILITY IN COMPARISON TO
"^"'^^^'^^ 002078 02-10
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRUG
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA.
002225 02- 1 S
SPECIFIC 3H IMIPRAMINE BINDING IN HUMAN PLATELETS: INFLUENCE OF
^<^^^^^^^^ 002254 02-13
IMIPRAMINE AND EEG SLEEP IN CHILDREN WITH DEPRESSIVE-
^^'^''TOMS. 002339 02-14
EFFECTS OF IMIPRAMINE ON LEFT VENTRICULAR PERFORMANCE IN
CH'LDREN. 002385 02-15
TERATOGENICITY OF IMIPRAMINE AND AMITRIPTYLINE IN FETAL
HA^^STERS 002410 02-15
IMIPRAMINE EFFECT OF OVARIAN STEROIDS ON MODIFICATIONS IN
SEROTONIN-RECEPTOR BINDING. 002778 03-03
Ptychopharmacology Abstracts
PLASMA IMIPRAMINE LEVELS AND DEMETHYLASE AQIVITY IN THE
LIVER OF STRESSED ANIMALS. ^ ^^
002793 03-03
PULMONARY METABOLISM OF IMIPRAMINE IN THE RAT AND RABBIT:
COMPARISON WITH HEPATIC METABOLISM.
002845 03-03
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY
REACTIONS IN DOGS. ^„ „^ „^
003030 03-04
RAPIDITY OF CLINICAL ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
(UNPUBLISHED PAPER) . „„.,,. ^^ ^-,
003164 03-07
PROPHYLACTIC LITHIUM WITH AND WITHOUT IMIPRAMINE FOR BIPOLAR-
l-PATIENTS: A DOUBLE-BUND STUDY. __
003233 03-09
LITHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND
BIPOLAR-II DEPRESSION: A PROSPEQIVE, PLACEBO-CONTROLLED
COMPARISON. „„oo.^^o~,
003252 03-09
AMOXAPINE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSED-
OUTPATIENTS: A CONTROLLED-STUDY
003254 03-09
THERAPEUTIC EFFECT OF MIANSERINE AND IMIPRAMINE IN ENDOGENOUS
DEPRESSIONS (CONTROLLED-COMPARISON).
003264 03-09
MAPROTIUNE VERSUS IMIPRAMINE AND PLACEBO IN NEUROTIC
'''^'''''' 003287 03-10
PHARMACOKINETICS OF AMITRIPTYUNE, IMIPRAMINE, AND
MAPROTILINE IN THE ELDERLY.
003324 03-11
THE EFFEQIVENESS OF IMIPRAMINE IN THE TREATMENT OF ENURESIS:
THE SIGNIFICANCE OF TYPE OF ENURESIS AND REPORTED LEVEL OF
SLEEP. (PH.D. DISSERTATION) 003337 03-11
IMIPRAMINE TREATMENT OF BORDERUNE-CHILDREN: CASE-REPORTS
WITH A CONTROLLED-STUDY
003356 03-11
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF
BINDING-SITES IN DEPRESSED-PATIENTS 003427 03 13
MMPI PREDICTION OF IMIPRAMINE RESPONSE: A REPUCATION STUDY.
003570 03-16
HIGH-AFFINITY 3H IMIPRAMINE BINDING: A NEW BIOLOGICAL TOOL FOR
STUDIES IN DEPRESSION. 003610 03-17
ON THE KINETICS OF IMIPRAMINE AND RELATED ANTIDEPRESSANTS^
(X)3945 04-03
REGIONAL DISTRIBUTION OF (3H)IMIPRAMINE BINDING IN RA^-BRAIN
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN
REUPTAKE SITES IN BRAIN AND PLATELET? ^^^^^ ^^^ ^
ELECTROPHYSIOLOGICAL-EFFECTS OF IMIPRAMINE ON BOVINE
VENTRICULAR-MUSCLE AND PURKINJE-FIBRES. ^^^^^ ^^^^
EFFECT OF IMIPRAMINE ON CENTRAL 5 HYDROXYTRYPTAMINE
TURNOVER AND METABOLISM IN RATS. ^^^^ ^^^
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION: A
DOUBLE-BUND COMPARISON WITH IMIPRAMINE.
004346 U4-0V
DECREASED 3H IMIPRAMINE BINDING IN DEPRESSED MALES AND
FEMALES. QQ^^9 04^
(3H) IMIPRAMINE BINDING IN HUMAN PLATELETS: A NEW
BIOCHEMICAL-PARAMETER IN DEPRESSION. ^^^^^ ^^
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO
AND STANDARD (IMIPRAMINE) CONTROLLED CUNICAL-STUDY^
00A3WZ 04-UV
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS
IV PRETREATMENT URINARY MHPG LEVELS AS PREDIQORS OF
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE. ^^^^ ^_^
BLOCKADE BY IMIPRAMINE OR DESIPRAMINE OF PANIC-INDUCED BY
SODIUM-LACTATE 004427 04-10
TREATMENT OF ENCOPRESIS WITH IMIPRAMINE ^^^^^^ ^^ ^
SELECTIVE INHIBITORY-EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE
ON PLATELET AGGREGATION. 004518 04-13
WITHDRAWAL SYMPTOMS ARER GRADUATED CESSATION OF
IMIPRAMINE IN CHILDREN. ^^^^^ ^,.
S-224
VOLUME 19, SUBJECT INDEX
Subject Index
IMITATION
IMITATION, SOCIAL FACILITATION, AND THE EFFECTS OF ACTH4-10 ON
RATS BAR-PRESSING-BEHAVIOR
003009 03-04
IMMATURE
GABA FLUXES IN PRESYNAPTIC NERVE-ENDINGS FROM IMMATURE RATS.
000185 01-03
IMMOBILITY
EEG CHANGE IN THE CONSCIOUS RAT DURING IMMOBILITY INDUCED BY
PSYCHOLOGICAL-STRESS.
001297 02-03
EFFECTS OF HEMICHOLINIUM-3 AND CHOLINE ON HIPPOCAMPAL
ELECTRICAL-ACTIVITY DURING IMMOBILITY VS. MOVEMENT.
001438 02-03
THE EFFECTS OF TRYPTOPHAN AND MANIPULATIONS OF SEROTONERGIC-
RECEPTORS ON TONIC IMMOBILITY IN CHICKENS.
004245 04-04
TONIC IMMOBILITY IN DOMESTIC FOWL. POSSIBLE INTERACTION OF
SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
004246 04-04
IMMOBILIZATION
DESENSITIZATION OF ADRENOCEPTORS AFTER IMMOBILIZATION STRESS
OR REPEATED INJECTION OF ISOPROTERENOL IN RATS. (UNPUBLISHED
PAPER).
00)546 02-03
IMMOBILIZATION-INDUCED
MEPACRINE TREATMENT PREVENTS IMMOBILIZATION-INDUCED
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT
HYPOTHALAMUS AND BRAINSTEM.
002919 03-03
IMMUNIZATION
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST
SUDDEN CARDIAC DEATH FROM COCAINE.
003122 03-05
NEUTRALIZATION OF THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL
ON BARBITURATE SLEEPING-TIME BY SPECIFIC ACTIVE IMMUNIZATION.
003803 04-03
IMMUNOCYTOCHEMICAL
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA
AND MEDIAL NUCLEUS-TRACTUS-SOLITARIUS OF RAT-BRAIN.
002634 03-01
BENZODIAZEPINE-RECEPTORS: AUTORADIOGRAPHICAL AND
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN
REGIONS OF GABAERGIC SYNAPTIC CONTACTS.
002643 03-01
IMMUNOCYTOCHEMISTRY
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER)
001024 02-01
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY.
002639 03-01
IMMUNODETECTION
IMMUNODETECTION OF ACH-RECEPTOR IN THE CNS. (UNPUBLISHED
PAPER).
003670 04-01
IMMUNOGLOBULIN
SALIVARY IMMUNOGLOBULIN CONCENTRATIONS IN PATIENTS WITH
EPILEPSY TREATED WITH CARBAMAZEPINE.
002234 02-13
RESPIRATORY-DISEASE AND NASAL IMMUNOGLOBULIN
CONCENTRATIONS IN PHENYTOIN TREATED EPILEPTIC-PATIENTS
003486 03-15
PROSPECTS FOR THE TREATMENT OF POSTENCEPHALITIC PARKINSONISM
WITH ANTILYMPHOCYTIC IMMUNOGLOBULIN.
IMMUNOHISTOCHEMICAl 004572 04-14
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE
SPINAL-CORD OF THE CAT: ENKEPHALIN-CONTAINING MARGINAL
NEURONS AND PAIN MODULATION.
002638 03-01
IMMUNOLOGICAL
BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF THE MOUSE BRAIN
ENOLASES PURIFIED BY A SIMPLE METHOD.
003668 04-01
IMMUNOLOGICAL COMPONENTS IN SCHIZOPHRENIA
.MMUNOREACTIVE 004324 04-08
SODIUM-CHLORIDE INHIBITION DECREASES LEVELS OF IMMUNOREACTIVE
DYNORPHIN IN THE NEUROINTERMEDIATE PITUITARY OF RATS.
001 283 02-03
DECREASE OF GAD IMMUNOREACTIVE NERVE TERMINALS IN THE
SUBSTANTIA-NIGRA AFTER KAINIC-ACID LESION OF THE STRIATUM
(UNPUBLISHED PAPER).
IMMUNOREACTIVE CALCITONIN IN CEREBROSPINAL-FLUID OF MAN
002637 03-01
IMMUNOREACTIVITY
CHARACTERIZATION OF LRF-LIKE IMMUNOREACTIVITY IN THE FROG
SYMPATHETIC GANGLIA: NONIDENTITY WITH LRF-DECAPEPTIDE
(UNPUBLISHED PAPER).
001018 02-01
AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF
DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREACTIVITY
IN DMI RESPONSIVE DEPRESSIVES
003228 03-09
EFFECT OF MORPHINE AND NALOXONE ON LEU-ENKEPHALIN-LIKE
IMMUNOREACTIVITY IN DOGS.
003894 04-03
IMMUNOSTIMULANT
THE IMMUNOSTIMULANT ANTINEOPLASTIC ACTION OF SOME
PSYCHOTROPIC-DRUGS OF THE SYDNONIMINE SERIES.
001520 02-03
IMMUNOSTIMULANTS
SYNTHETIC IMMUNOSTIMULANTS DERIVED FROM THE BACTERIAL CELL
WALL.
001080 02-02
IMMUNOTITRATABLE
REDUCTION IN THE LEVEL OF IMMUNOTITRATABLE DOPAMINE-BETA-
HYDROXYLASE AFTER CHRONIC ADMINISTRATION OF L-DOPA OR
ALPHA METHYLDOPA.
003764 04-03
IMPAIR
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
LOAD.
004600 04-15
IMPAIRED
IMPAIRED GLUCOSE TOLERANCE IN LONG-TERM LITHIUM TREATED
PATIENTS,
000611 01-09
EFFECTS OF DIFFERENT MONOAMINE-OXIDASE-INHIBITORS ON
RESPIRATORY ACTIVITY IN RATS WITH CHRONICALLY IMPAIRED
CENTRAL SEROTONERGIC FUNCTION.
001389 02-03
IMPAIRING
VIGILANCE IMPAIRING DRUGS: ANALYSIS OF SUBJECTIVE RESPONSES.
002332 02-14
IMPAIRMENT
EVIDENCE FOR A RECEPTOR SUPERSENSITIVITY FOLLOWING IMPAIRMENT
OF CENTRAL SEROTONERGIC ACTIVITY IN THE RABBIT.
000041 01-03
IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM
INGESTION OF ETHANOL, TERTIARY BUTANOL, OR PENTOBARBITAL IN
MICE.
000479 01-04
TOLERANCE TO ETHANOL-INDUCED IMPAIRMENT OF WATER-ESCAPE IN
RATS BRED FOR ETHANOL SENSITIVITY.
001567 02-04
ENHANCED BEHAVIOURAL-EFFECTS, ELECTROCORTICAL-EFFECTS AND
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN.
001733 02-04
IMPAIRMENT OF INSTRUMENTAL LEARNING IN RATS BY GLUTAMIC-
ACID-DIETHYL-ESTER.
002993 03-04
RENAL IMPAIRMENT, HYPERCALCEMIA, AND LITHIUM THERAPY.
003473 03-15
IMPAIRS
SHORT-TERM ETHANOL ADMINISTRATION IMPAIRS THE ELIMINATION OF
CHLORDIAZEPOXIDE (LIBRIUM) IN MAN.
002224 02-13
IMPLANTATION
ASSESSMENT OF TOLERANCE TO AND PHYSICAL-DEPENDENCE ON
PENTOBARBITAL, INDUCED BY MULTIPLE PELLET IMPLANTATION.
000385 01-04
IMPLANTS
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD
ETHANOL LEVELS IN RATS DRINKING A LIQUID DIET.
001865 02-06
IMPOTENCE
EXPERIMENTATION WITH MINAPRINE IN DEALING WITH CERTAIN
SEXUAL-DISORDERS: IMPOTENCE OR FRIGIDITY.
002153 02-11
A CLINICAL-STUDY AND ENDOCRINE-STUDY OF MESTEROLONE IN
SECONDARY IMPOTENCE.
002315 02-14
IMPRESSIONS
FIRST CLINICAL IMPRESSIONS IN DAILY PRACTICE.
002046 02-09
IMPROMIDINE
SOME CENTRAL-EFFECTS OF IMPROMIDINE, A POTENT AGONIST OF
HISTAMINE H2-RECEPT0RS.
001417 02-03
Mdkl
"Mill:
•■Mill:
'Uttll'
•ar:r
S-225
ail
J''! !
fer
^4
laii.
•«».
Subject Index
IMPROVEMENTS
FEDERAL-COURT UPHOLDS RIGHT-TO-REFUSE PSYCHOTROPIC-DRUGS,
ORDERS IMPROVEMENTS AT LIMA-STATE-HOSPITAL. ^^
CHANGES IN THE CLINICAL-PICTURE AND THE COURSE OF PSYCHOSES
DURING MASSIVE PSYCHOPHARMACOTHERAPY AND THE
SIGNIFICANCE OF THESE CHANGES FOR IMPROVEMENTS IN
PSYCHIATRICTREATMENT. 004699 04-17
IMPULSE
AMPHETAMINE-INDUCED MOTILITY AND NIGROSTRIATAL IMPULSE FLOW^
003005 03-04
"^''"evidence THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS. ^^^^^ ^^^^
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS-.
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE.
003778 04-Uo
IMPURITIES
IMPURITIES IN DRUGS V: MEPROBAMATE.
004631 04- Id
"**"th"|NABILITY of chronic FLUOXETINE TO POTENTIATE A SEROTONIN
'^^•^'^T^'^^ff^^ 000293 01-03
THE INABILITY OF CHRONIC MIANSERIN TO BLOCK CENTRAL ALPHA2-
ADRENOCEPTORS. 001492 02-03
'"^^^EVE^SIBLE INACTIVATION OF RAPHE-MAGNUS NEURONS: EFFECTS ON
NOCICEPTIVE THRESHOLD AND MORPHINE-INDUCED ANALGESIA^
000240 01-03
MECHANISM OF INACTIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES.
001055 \jZ-\j I
MECHANISM OF INACTIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCLOPROPYL-N-ARYLALK YIAMINES
00 lOoo Uz-Uz
THE INACTIVATION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE IN
DISSOCIATED NEURONAL CULTURES FROM S'''^*'-"'^°''° QQo^go 04 03
INBRED
DIFFERENCES IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY IN
INBRED STRAINS OF MICE. 000303 01-03
EFFECTS OF CHLORDIAZEPOXIDE MORPHINE COMBINATIONS ON
SPONTANEOUS LOCOMOTOR-AQIVITY IN THREE INBRED STRAINS OF
'^'" 001766 02-04
EFFECTS OF MORPHINE AND CHLORDIAZEPOXIDE ON AVOIDANCE-
BEHAVIOUR IN TWO INBRED STRAINS OF MICE. 002973 03 04
INCIDENCE
CHRONIC EFFECTS OF NEUROLEPTICS HAVING HIGH OR LOW INCIDENCE
OF EXTRAPYRAMIDAL SIDE-EFFECTS UPON FORCE. DURATION AND
RATE OF OPERANT-RESPONSE IN RATS. (PH.D. DISSERTATIONS
00>3 1 2. J UJ'U J
LITHIUM AND THE CHANGING INCIDENCE OF MANIA.
003265 OJ-UV
INCIPIENT
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND
LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJEQS.
003311 03-11
INCUBATED
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN-
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED '^'^^^'^'^ qqq,,, 01^3
IND
FDA CLIPS PSYCHODRUG PIONEERS IND WINGS. ^^^ ^^^^
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELEQIVE
5 HT UPTAKE INHIBITOR. 001517 02-03
"^^^THE^NOSOLOGICAL INDEPENDENCE OF INVOLUTIONAL DEPRESSION AND
ITS DYNAMICS DURING PSYCHOPHARMACOTHERAPY.
004389 04 -OV
REPEATED TRICYCLICS INDUCE A PROGRESSIVE DOPAMINE-
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT OF DAILY DRUG-
TREATMENT. 000047 01-03
Ptychopharmacology Abstracts
DECOMPOSITION OF PHARMACOLOGICAL ACTIVITY INDICES INTO
MUTUALLY INDEPENDENT COMPONENTS USING PRINCIPAL
COMPONENT ANALYSIS. „„,„o« «^ «,
001039 02-01
BRAIN STRIATAL TYROSINE-HYDROXYLASE: AQIVATION OF THE ENZYME
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION.
001423 02-03
INDERAL
PROPRANOLOL (INDERAL) FOR TARDIVE-DYSKINESIA AND
EXTRAPYRAMIDAL SIDE-EFFEaS FROM NEUROLEPTICS: POSSIBLE
INVOLVEMENT OF BETA-ADRENERGIC MECHANISMS.
002470 02-15
THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH
DEPRESSIVE-SYNDROMES. ^ ^ ^, ^
000625 01-09
APOMORPHINE HYPOTHERMIA: AN INDEX OF CENTRAL DOPAMINE-
RECEPTOR FUNQION IN MAN.
002221 02-13
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. III. THE MUTUAL RELATION OF EACH INDEX.
003179 03-08
PROLACTIN AND NEUROLEPTIC-DRUGS: A BIOCHEMICAL INDEX OF
CLINICAL-RESPONSE? 004539 04-13
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT
ANTICHOLINERGIC-ACTIVITY BY AN ATYPICAL NEUROLEPTIC
(THIORIDAZINE). ^.,^.^^^,^
003560 03-16
INDICATION *
INTERACTIONS OF NEUROPEPTIDES WITH CHOLINERGIC
SEPTOHIPPOCAMPAL PATHWAY: INDICATION FOR A POSSIBLE
TRANSSYNAPTIC REGULATION. (UNPUBLISHED PAPER).
001062 02-01
INDICATIONS
PRESENT INDICATIONS OF LONG-AQING NEUROLEPTICS.
002576 02-17
INDICATIONS FOR A BRAIN UPTAKE OF LABELLED VASOPRESSIN AND
OCYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER. 1
003669 04-01
LITHIUM-PUMP REPRESSION AS AN INDICATOR OF PROPHYLAQIC
^^^''O^SE. 001989 02-09
THE REPRESSION OF THE LITHIUM-PUMP AS AN INDICATOR OF RESPONSE
TO PROPHYLAQIC TREATMENT. 00322103-09
NATURAL AND THERAPEUTIC ENVIRONMENTAL INDICATORS OF
MAINTENANCE DOSAGE REQUIREMENTS. 003561 03 16
DECOMPOSITION OF PHARMACOLOGICAL AQIVITY INDICES INTO
MUTUALLY INDEPENDENT COMPONENTS USING PRINCIPAL
COMPONENT ANALYSIS. 001039 02^1
TRICYCLIC-ANTIDEPRESSANT DRUGS AND INDIVIDUAL DIFFERENCES IN
THE EXPLORATORY-AQIVITY OF RATS: CONTRASTING-EFFEQS OF
TERTIARY AND SECONDARY AMINE COMPOUNDS.
0004UI UI-U4
A DRUG DISPENSER TO MEASURE INDIVIDUAL DRINKING IN RAT
COLONIES. 000530 01-06
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS, UNDER
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REAQION TYPE
(EMOTIVE AND NONEMOTIVE). 001624 02-04
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES. ^UNPUBLISHED^APER).^^^
EFFECT OF TRICYCLIC-ANTIDEPRESSANTS ON INDIVIDUAL SYMPTOMS^
00205/ o/-uy
CONTRIBUTIONS OF INDIVIDUAL DIFFERENCES TO SUBJEQIVE
INTOXICATION. 002202 02-12
INDIVIDUAL VARIATIONS IN THE EFFEaS OF fLURAZ|PAM
CLORAZEPATE L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON
REM SLEEP IN MAN. 002349 02-14
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES.
S-226
VOLUME 19, SUBJECT INDEX
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TI^EATMENT OUTCOME.
003189 03-08
GROUP VERSUS INDIVIDUAL COGNITIVE-THERAPY: A PILOT-STUDY
003257 03-09
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFECTS OF
HALOPERIDOL AND PARGYLINE
003792 04-03
INDIVIDUAL DIFFERENCES IN EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS
AND ANTICHOLINERGIC-DRUGS ON OPERANT-BEHAVIOR IN THE
SQUIRREL-MONKEY
004176 04-04
INDIVIDUALIZATION
INDIVIDUALIZATION OF PHENYTOIN THERAPY.
002495 02-16
INDIVIDUALIZED
PERSPECTIVE ON ADEQUATE INDIVIDUALIZED DRUG DOSES.
000959 01-17
INDOL-3-YLMETHYLPIPERID-4-YL-3-BENZOYLUREA
BEHAVIOURAL AND NEUROCHEMICAL PROPERTIES OF 1 1 INDOL-3-
YLMETHYLPIPERID-4-YL-3-BENZ0YLUREA (WY-25093) IN RODENTS.
003686 04-02
INDOLEALKYLAMINE
A COMMON MECHANISM FOR LYSERGIC-ACID, INDOLEALKYLAMINE AND
PHENETHYLAMINE HALLUCINOGENS: SEROTONERGIC MEDIATION OF
BEHAVIORAL-EFFECTS IN RATS.
004007 04-03
NDOLEAMINE-N-METHYLTRANSFERASE
EFFEQ OF NEUROLEPTICS ON INDOLEAMINE-N-METHYLTRANSFERASE
AQIVITY AND BRAIN METABOLISM OF BUFOTENIN.
002735 03-03
NDOLEAMINES
MASS-SPECTROMETRIC-ASSAYS OF INDOLEAMINES. (UNPUBLISHED
PAPER).
001043 02-01
BENZODIAZEPINES, STRESS AND RAT PLASMA CORTICOSTEROIDS: THE
ROLE OF INDOLEAMINES.
003034 03-04
NDOMETHACIN
INTERAQION OF INDOMETHACIN AND IBUPROFEN WITH LITHIUM IN
MANIC-PATIENTS UNDER A STEADY-STATE LITHIUM LEVEL
000622 01-09
EFFEQ OF PROSTAGLANDIN-El AND ITS BIOSYNTHESIS INHIBITOR
INDOMETHACIN ON DRINKING IN THE RAT.
001749 02-04
EFFEQS OF INDOMETHACIN AND METHYLPREDNISOLONE ON RENAL
ELIMINATION OF LITHIUM IN THE RAT.
004270 04-05
NDORAMIN
CENTRAL SYMPATHETIC REACTIVITY INHIBITED BY INOORAMIN
001193 02-03
NDUCE
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH
IN THE ELECTROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO
AUTORECEPTOR STIMULATION.
000046 01-03
REPEATED TRICYCLICS INDUCE A PROGRESSIVE OOPAMINE-
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT OF DAILY DRUG-
TREATMENT.
,„,,„, 000047 01-03
TRICYCLIC-ANTIDEPRESSANTS INDUCE SUBSENSITIVITY OF PRESYNAPTIC
DOPAMINE-AUTORECEPTORS.
nrnr.^r 000048 01-03
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY?
EDUCED 002659 03-03
COMPARATIVE-STUDY OF ANALGESIA INDUCED BY N VAL5-ENKEPHALIN
AND PR05-ENKEPHALIN ANALOGS.
000021 01-03
HYPOALGESIA INDUCED BY MICROINJEQION OF A NOREPINEPHRINE
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL
ADMINISTRATION OF A SEROTONIN ANTAGONIST.
ASSESSMENT OF TOLERANCE TO AND PHYSICAL-DEPENDENCE ON
PENTOBARBITAL, INDUCED BY MULTIPLE PELLET IMPLANTATION.
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
THE INVOLVEMENT OF SEROTONERGIC NEURONS IN THE CENTRAL-
NERVOUS-SYSTEM AS THE POSSIBLE MECHANISM FOR SLOW HEAD-
SHAKING-BEHAVIOR INDUCED BY METHAMPHETAMINE IN RATS
000408 01-04
Subject Index
BEHAVIOURAL-CHANGES INDUCED BY N,N DIMETHYLTRYPTAMINE IN
RODENTS.
000413 01-04
CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL INJECTION OF
BACLOFEN IN RATS.
000415 01-04
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS
AND ANTAGONISTS: ZONE-SPECIFIC EFFECTS.
000422 01-04
MAPPING OF DYSKINETIC-MOVEMENTS INDUCED BY LOCAL APPLICATION
OF PICROTOXIN OR () GAMMA ACETYLENIC-GABA ON THE RAT
MOTOR-CORTEX.
000458 01-04
EXPERIMENTAL DYSTONIA INDUCED BY QUATERNARY
CHLORPROMAZINE.
000461 01-04
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELECTIVE
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR-
STIMULATION INDUCED BY INDIRECTLY ACTING SYMPATHOMIMETIC-
AMINES IN MICE.
000492 01-04
ANALGESIC ACTIVITY OF DIFLUNISAL (MK-647; 5 2 4
DIFLUOROPHENYLSALICYLIC-ACID) IN RATS WITH HYPERALGESIA
INDUCED BY FREUNDS-ADJUVANT.
000502 01-04
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS.
000520 01-05
PHARMACOPSYCHOLOGICAL INVESTIGATION OF CHANGES IN MOOD
INDUCED BY DIPOTASSIUM-CHLORAZEPATE WITH AND WITHOUT
SIMULTANEOUS ALCOHOL ADMINISTRATION.
000825 01-14
PSYCHIATRIC MANIFESTATIONS INDUCED BY DOPAMINE PRECURSORS OR
DOPAMINE AGONISTS.
000865 01-15
INCREASED METABOLISM OF DOPAMINE AND SEROTONIN INDUCED IN
FOREBRAIN AREAS BY ETORPHINE MICROINJECTION IN
PERIAQUEDUCTAL GRAY.
001103 02-03
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT
DERIVATIVES.
001156 02-03
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR
SUBSEQUENT WITHDRAWAL.
001175 02-03
EEG CHANGE IN THE CONSCIOUS RAT DURING IMMOBILITY INDUCED BY
PSYCHOLOGICAL-STRESS.
001297 02-03
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS
INDUCED BY AMPHETAMINE IN CATS.
001340 02-03
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN
MICE.
001435 02-03
BIOCHEMICAL-STUDY OF THE ANIMAL-MODEL DEPRESSION INDUCED BY
TETRABENAZINE.
001506 02-03
EVIDENCE THAT NORADRENALINE MODULATES THE INCREASE IN
STRIATAL DOPAMINE METABOLISM INDUCED BY MUSCARINIC-
RECEPTOR STIMULATION.
001518 02-03
IN VIVO CHANGES IN THE GABA CONTENT OF NERVE-ENDINGS
(SYNAPTOSOMES) INDUCED BY INHIBITORS OF GABA UPTAKE
001540 02-03
INFLUENCE OF THYROTROPIN-RELEASING-HORMONE AND HISTIDYL-
PROLINE-DIKETOPIPERAZINE ON SPONTANEOUS LOCOMOTOR-ACTIVITY
AND ANALGESIA INDUCED BY DELTA9 TETRAHYDROCANNABINOL IN
THE MOUSE.
001575 02-04
BRAIN CATECHOLAMINES MODIFICATIONS. THE EFFECTS ON MEMORY
FACILITATION INDUCED BY OXOTREMORINE IN MICE.
001658 02-04
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN
RATS.
001669 02-04
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF TAURINE IN RATS.
001670 02-04
OPIATE ANTAGONISTS AND LONG-TERM ANALGESIC REACTION INDUCED
BY INESCAPABLE SHOCK IN RATS.
001707 02-04
I
I
:«»li!:
S-227
Subject Index
ETHANOL AVERSION INDUCED BY PARENTERALLY ADMINISTERED
ETHANOL ACTING BOTH AS CS AND UCS. ^^^^^ ^^^^
THE ROLE Of DOPAMINE IN THE HYPERMOTIUTY INDUCED BY H-77-77
(4, ALPHA DIMETHYL-M-TYRAMINE) IN MICE . ^^ ^ ^^^ ^^^
MOTOR-DEPRESSION AND HEAD-TWITCHES INDUCED BY IP INJECTION OF
^'^^^ 001788 02-04
THE EFFECT OF ASPIRIN AND PARACETAMOL ON THE INCREASED
NALOXONE POTENCY INDUCED BY MORPHINE P^ETREATMENL ^ ^^^
DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINERGIC MECHANISMS. ^^^^^ ^^^^
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF
12 CNS DEPRESSANTS IN INTACT AND PITHED RATS. ^^^^^ ^^^^
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY I CHANGES INDUCED BY PHENOBARBITAL OR/AND
DIPHENYLHYDANTOIN IN SERUM LIPIDS. ^^^^^ ^^^^
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL
HEMORRHAGE PATIENTS . ^^295 02- 1 3
CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM,
HALOPERIDOL. PHENELZINE AND D-AMPHETAMINE ^^^^^ ^^ ^ ^
DISTURBED-BEHAVIOUR INDUCED BY HIGH-DOSE ^^^TIPSYCHOTIODRUGS^
PARADOXICAL AKINESIA INDUCED BY ANTIDEPRESSANT-DR^G|^^^ ^^^^
CHOREIC-MOVEMENTS INDUCED BY THE USE OF '^'^^THADON^^^^ ^^^^
PHASIC ACTIVITY INDUCED BY P CHLOROPHENYLALANINE IN THE
AUDITORY PATHWAY. 00266103-03
EFFEaS OF ELEaROCONVULSIVE-TREATMENT ON GROWTH-HORMONE
SECRETION INDUCED BY MONOAMINE-RECEPTOR AGONISTS IN
RESERPINEPRETREATEDRATS. 002664 03-03
CHRONOLOGY OF NEUROCHEMICAL ALTERATIONS INDUCED BY GABA
AGONIST ADMINISTRATION. 002713 03^3
KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFECT ON
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS. 002743 03-03
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE
INJECTION IN NEWBORN ANIMALS. ^^^^^ ^^_^^
DIFFERENTIAL LOSS OF BIOLOGICAL-ACTIVITY OF THE ENKEPHALINS
INDUCED BY CURRENT. 002783 03-03
NALOXONE EFFEQS ON THE BLOOD-PRESSURE RESPONSE INDUCED BY
THIN-FIBER MUSCULAR AFFERENTS. ^^794 03-03
ENVIRONMENTAL MODULATION OF ANALGESIC TOLERANCE INDUCED BY
MORPHINE PELLETS. 002944 03-04
ESTROGEN POTENTIATES THE STEREOTYPY INDUCED BY DOPAMINE
AGONISTS IN THE RAT. 002968 03-04
PHARMACOLOGICAL CHARACTERIZATION OF SCRATCHING-BEHAVIOUR
INDUCED BY INTRACRANIAL INJEQION OF SUBSTANCE-P AND
SOMATOSTATIN. 002980 03-04
SELEaiVE SENSITIZATION INDUCED BY LITHIUM MALAISE AND
FOOTSHOCKINRATS. 003055 03-04
EFFEaS OF METHYSERGIDE AND NALOXONE ON ANALGESIA INDUCED BY
THE PERIPHERAL ELEQRIC-STIMULATION IN MICE ^^^^ ^^^
CENTRALLY INDUCED CARDIOVASCULAR AND SYMPATHETIC-NERVE
RESPONSES TO BRADYKININ IN RATS. 003099 03-04
A NEUROANATOMICAL-STUDY OF ANALGESIA AND CATATONIA INDUCED
BY ETORPHINE IN THE RAT. (PH.D. DISSERTATION). ^^^^^ ^^^^
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS
cSwNED TASTE-AVERSION INDUCED BY METHYIAMPHETAMINE
BUT NOT LITHIUM-CHLORIDE. 003110 03-04
AGGRESSIVE-BEHAVIOR INDUCED BY APOMORPHINE IN RATS SUBMIHED
TO FOUR STRESSFUL-SITUATIONS. 003163 03-07
Ptychopharmocology Abstracts i
THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS.
003397 03-12
ARRHYTHMIA INDUCED BY A TRICYCLIC-ANTIDEPRESSANT IN A PATIENT
WITH UNDIAGNOSED MITRAL-VALVE PROLAPSE. 03 15
EFFECTS OF AGE ON DOPAMINERGIC-SUPERSENSITIVITY INDUCED BY |
CHRONIC FLUPHENAZINE. 003940 04-03 i
EFFEQ OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE ]
DISCHARGE INDUCED BY CARBACHOL IN THE RABBIT. ^^^^^ ^^^^
THE DOPAMINE-RECEPTOR COMPLEX: BIOCHEMICAL-CONSEQUENCES OF
SUPERSENSITIVITY INDUCED BY TREATMENT WITH 6
HYDROXYDOPAMINE OR MORPHINE. ^^^^^ ^^^
SPREADING DEPRESSION INDUCED BY MICROINJEQION OF ENKEPHALINS
INTO THE HIPPOCAMPUS AND NEOCORTEX „„.„,.„.„,
0040 1 5 04-03 I
DECREASE OF NORADRENALINE 0 METHYLATION IN RAT-BRAIN INDUCED
BYL-DOPA REVERSAL EFFEa OF SADENOSYL-L-METHIONINE.
004019 04-03
EFFECTS OF PROPRANOLOL ON THE LOCOMOTOR-STIMUIATION INDUCED •
BY AaiVATION OF POSTSYNAPTIC CATECHOLAMINE-RECEPTORS.
004126 04-04
CHARAQERISTIC HYPERPYREXIA INDUCED BY LICL AND
TRANYLCYPROMINE IN RATS. 004278 04-05
ELEQROPHYSIOLOGICAL AND PSYCHOLOGICAL CHANGES INDUCED BY
STEROID-HORMONES IN MEN AND WOMEN ^ . .^ „ . , , '
004500 04- 1 3
ELEQRORETINOGRAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN
PSYCHOPHARMACOLOGY. ELEaRORETINOGRAPHIC-CHANGES INDUCED
BY A COMBINATION OF CARBIDOPA AND LEVODOPA. ,
MANIC-STATE INDUCED BY SALBUTAMOL TAKEN ORAUY
004622 04-15
ABNORMAL MOVEMENTS INDUCED BY PSYCHOTROPIC-DRUGS.
(X)4652 04-15'
"*°"s"sTEMIC AND INTRAVENTRICULAR PROLAaiN INDUCES EXCESSIVE
^«°°^"^^ 000378 01^'
LITHIUM INDUCES DOSE-RELATED INCREASES AND DECREASES IN
AQIVITY LEVELS IN THE RAT. 004079 0404
""'"eNz'yME inducing EFFEaS OF PHENOBARBITAL ON NITRAZEPAM
METABOLISM IN DOGS. 000086 01-03
NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO |
wiVHORAWAL INDUCING BENZAZOCINES. (PH.D. DISSERTATION)^
"*''"p*HOSp'hOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR- 1
MEDIATED INDUCTION OF CHEMOTAXIS IN RABBIT NEUTROPHILS.
(UNPUBLISHED PAPER). 001118 02-03
INTRAHYPOTHALAMIC MICROINJEQIONS OF NORADRENALINE WITH AND
wItHOUT INDUaiON OF THE ALIMENTARY DRIVE AS A REWARD IN A
T-MAZE LEARNING IN RATS. 001604 02-04
INDUaiON OF HYPERSENSITIVITY OF BRAIN BY HYDRALAZINE
TREATMENT IN RATS. 003008 03^
TESTOSTERONE POTENTIATION OF THE EFFEQIVENESS OF AaHl-24 ON
THE 1NDU(JI0N OF THE STRETCH-YAWNING-SYNDROME (SYS) IN MAU
GUINEA-PIGS. QQ3074 ^3^
INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766,
AN ANALOG Of ACTH4-9. 003112 03-0^
PHYSOSTIGMINE INDUQION OF DEPRESSIVE-SYMPTOMATOLOGY IN
NORMAL HUMAN SUBJECTS. 003255 03^
m THE EVALUATION OF A PROVOCATIVE EEG METHOD USING
MEDOTION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN
SlS WITH SPECIAL EMPHASIS ON SLEEP INDUQION THROUGH
MEDICATION. ^^333^ ^3.,
CLINICAL-IMPLICATIONS OF ENZYME INDUQION AND ENZYME
INHIBITION. QQ3^21 03-V
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADf
OF CYCLnMP PHOSPHODIESTERASE INDUQION BY BETA-
ADRENERGIC STIMULATION (UNPUBLISHED PAPER) ^^^^ ^^
S-228
/OLUME 19, SUBJECT INDEX
INDUCTION OF BEHAVIORAL-SUPERSENSITIVITY TO APOMORPHINE BY
DfP TREATMENT.
004099 04-04
HIPPOCAMPAL INVOLVEMENT IN THE PHARMACOLOGIC INDUCTION OF
WITHDRAWAL-LIKE BEHAVIORS.
004140 04-04
L 5 HYDROXYTRYPTOPHAN-INDUCED DRINKING IN RATS: POSSIBLE
MECHANISMS FOR INDUCTION.
004237 04-04
NOUCTIVE
COMPARATIVE-STUDY OF THE INDUCTIVE EFFECT OF TWO
PSYCHOMODERATORS - TETRABAMATE AND COMPLEXE-1656 - AND
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS.
001874 02-06
MDUSTRIAL-SOLVENT
PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALLIUM, ARSENIC,
INDUSTRIAL-SOLVENT INTOXICATION, AND OTHER
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT.
003348 03-11
lOUSTRY
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES.
003599 03-17
4FANCY
HANDLING IN INFANCY, TASTE-AVERSION, AND BRAIN LATERALITY IN
RATS.
000375 01-04
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY: NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNCTION
000448 01-04
IFANT
MORPHINE TREATMENT AT DIFFERENT INFANT AGES: INFLUENCE ON
LATER MORPHINE EFFECTS IN RATS. (PH.D. DISSERTATION)
000511 01-05
IFANTILE
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFEQS OF ORAL MAGNESIUM
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM.
003291 03-11
IFANTS
CLINICAL PHARMACOKINETICS IN NEWBORNS AND INFANTS: AGE-
RELATED DIFFERENCES AND THERAPEUTIC IMPLICATIONS.
003343 03-11
IFERENCES
INFERENCES DERIVED FROM ELEaROENCEPHALOGRAPHIC RESPONSES TO
ACUTE ADMINISTRATION OF CLOMIPHENE-CITRATE IN MALE ALBINO-
RATS.
000155 01-03
IFERENTIAL
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI OR
ETHANOL OETEQED BY ELECTROPHYSIOLOGICAL-CORRELATES
,HUX 001136 02-03
EFFEQS OF CHLORDIAZEPOXIDE ON DEPOLARIZATION-INDUCED CALCIUM
INFLUX INTO SYNAPTOSOMES.
IFORMAT.ON 000183 01-03
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED
CAT.
EFFEQS OF ANXIETY REDUQION BY BEHAVIOURAL-TECHNIQUES AND
MEPROBAMATE ON CERTAIN PARAMETERS OF INFORMATION THEORY
003108 03-04
PUBLIC JUDGMENTS ON THE IMPORTANCE OF VALIUM INFORMATION
003590 03-17
IFORAAATION-PROCESSING
EFFECTS OF TRIFLUOPERAZINE, CHLORPROMAZINE, AND HALOPERIDOL
UPON TEMPORAL INFORMATION-PROCESSING BY SCHIZOPHRENIC-
PATIENTS.
SELEQIVE EFFEQS OF BARBITURATE AND AMPHETAMINE ON
INFORMATION-PROCESSING AND RESPONSE EXECUTION
FRAREO 004563 04-14
A MULTIVARIATE ANALYSIS OF THE INFRARED SPECTRA OF DRUGS OF
ABUSE.
FUSION 004688 04-16
MORPHINE ANALGESIA FOLLOWING ITS INFUSION INTO DIFFERENT
LIQUOR SPACES IN RAT-BRAIN.
001429 02 0*^
INFUSION THERAPY IN THERAPY-RESISTANT DEPRESSION.
INFUSION OF MAPROTILIN AND CLOMIPRAMIN AND THEIR COMBINATION
IN THE TREATMENT OF DEPRESSION.
BODY-WEIGHT AND RESPONSES TO LHRH INFUSION IN ANOREXIA-*^ °^'°'
NERVOSA.
002062 02-10
Subject Index
SORPTION OF CHLORMETHIAZOLE BY INTRAVENOUS INFUSION GIVING
SETS.
002508 02-16
REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY
NORADRENALINE INFUSION.
002672 03-03
ALTERATIONS IN CEREBROSPINAL-FLUID DOPAMINE METABOLITES
FOLLOWING PHYSOSTIGMINE INFUSION.
003477 03-15
H2-RECEPT0RS MEDIATE INCREASES IN PERMEABILITY OF THE BLOOD-
BRAIN-BARRIER DURING ARTERIAL HISTAMINE INFUSION.
003817 04-03
SUSTAINED INTRACEREBROVENTRICULAR INFUSION OF BRAIN FUELS
REDUCES BODY-WEIGHT AND FOOD INTAKE IN RATS.
004098 04-04
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT
VERTEBRAL-ARTERY OF THE CAT, A MODIFIED ANIMAL-MODEL FOR
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE
LOWER BRAINSTEM.
004297 04-06
THE SPECIFIC ACTIVITY OF PLATELET MONOAMINE-OXIDASE VARIES
WITH PLATELET COUNT DURING SEVERE EXERCISE AND
NORADRENALINE INFUSION.
004509 04-13
INFUSIONS
TREATMENT OF THERAPY-RESISTANT DEPRESSED-PATIENTS WITH IV
INFUSIONS OF NOMIFENSINE CONTROLLED BY GALVANIC-SKIN-
RESISTANCE.
002012 02-09
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMIHER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
CLINICAL-EFFECTS OF BETA ENDORPHIN INFUSIONS.
004360 04-09
INGESTION
ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS.
(UNPUBLISHED PAPER).
000060 01-03
IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM
INGESTION OF ETHANOL. TERTIARY BUTANOL, OR PENTOBARBITAL IN
MICE.
000479 01-04
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS
000543 01-07
ADRENAL-HORMONES AND ETHANOL INGESTION IN C57BL/CRGL AND
C3H/CRGL/2 MICE.
002739 03-03
NICOTINE INGESTION REDUCES ELEVATED BLOOD-PRESSURES IN RATS
AND SQUIRREL-MONKEYS.
002759 03-03
INGESTIONAL
INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY
PREEXPOSURE TO THE UNCONDITIONED-STIMULUS: ASSOCIATIVE-
ASPECTS AND NONASSOCIATIVE-ASPECTS.
001610 02-04
INHIBIT
ENKEPHALINS PRESYNAPTICALLY INHIBIT CHOLINERGIC TRANSMISSION
IN SYMPATHETIC GANGLIA.
000167 01-03
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS. (UNPUBLISHED
PAPER).
001035 02-01
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM
002728 03-03
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
INHIBITED
POSTSWIM GROOMING IN MICE INHIBITED BY DOPAMINE-RECEPTOR
ANTAGONISTS AND BY CANNABINOIDS.
000359 01-04
CENTRAL SYMPATHETIC REAQIVITY INHIBITED BY INDORAMIN
001193 02-03
I
wlru
•■"lie
<Sl,
I
"Wtlt
an::
-.Ir::'
S-229
it:
t'fi:
Subject Index
IMHIRITION
ADMINISTRATION OF ANTISOMATOSTATIN SERUM TO RATS REVERSES
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION
PRODUCED BY INJECTION OF METERGOLINE BUT NOT YOHIMBINE.
(UNPUBLISHED PAPER), 000019 01-03
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART III DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES
OOOOzD U I -Uo
INHIBITION OF HIGH-AFFINITY CHOLINE UPTAKE: STRUQURE-AQIVITY
^^"^'^^ 000026 01-03
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT
P^OPimiS. 000084 01-03
INHIBITION OF (3H)NAL0X0NE BINDING IN HOMOGENATES OF RAT-
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC ACTIVITY, RELATED
TOPHYSOSTIGMINE. 000104 01-03
GABA INHIBITION OF 3H GLYCINE RELEASE FROM SLICES OF RAT
SUBSTANTIA-NI6RA IN VITRO. 000157 01-03
INHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN
CIRCUMVENTRICULAR STRUCTURES OF RAT-BRAIN . qqq , 59 q , .03
BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE(SKF-525-A) AND
2 4 DICHLORO-6-PHENYLPHENOXYETHYLAMlNE-HBR (DPEA) INHIBITION
OF FATTY-ACID CONJUGATION TO 11 HYDR0XY-DELTA9-
TETRAHYDROCANNABINOL BY THE RAT LIVER 'MICROSOMAL SYSTEM^
COMPARATIVE-STUDY OF THE INHIBITION OF GABA-AMINOTRANSFERASE
BY DIFFERENT ANTICONVULSANT-DRUGS . 000 1 92 0 1 -03
INHIBITION OF IN VIVO 3H SPIPERONE BINDING BY THE PROPOSED
ANTIPSYCHOTIC DES-TYRl-GAMMA-ENDORPHIN. ^^^^^ ^^^^
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFECTS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES. 000227 01-03
IRREVERSIBLE INHIBITION OF AROMATIC-L-AMINO-ACID-DECARBOXYLASE
BY ALPHA DIFLUOROMETHYL-DOPA AND METABOLISM OF THE
'N^'B'™"^ 000248 01-03
MICROIONTOPHORETIC STUDIES ON NORADRENERGIC INHIBITION FROM
LOCUS-COERULEUS OF SPINAL TRIGEMINAL-NUCLEUS NEURONS.
000260 01-0 J
INHIBITION OF ALCOHOL-DEHYDROGENASE BY DISULFIRAM; POSSIBLE
RELATION TO THE DISULFIRAM ETHANOL REACTION.
000270 0 1 "Oo
DIFFERENTIAL REGULATION OF MUSCARINIC AGONIST BINDING-SITES
FOLLOWING CHRONIC CHOLINESTERASE INHIBITION.
OOOz / V U t "U J
INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH PENTAZOCINE:
REVERSAL BY NALTREXONE. 000318 01-03
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS^
000330 01-03
INHIBITION OF BEHAVIORAL-EFFEQS OF COCAINE BY ACTINOMYCIN-D IN
^^^^- 000346 01-04
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
SELEQIVE INHIBITION OF MESOLIMBIC BEHAVIORAL-SUPERSENSITIVITY
«Y^^L°^°^^- 000467 01-04
MONOAMINE-OXIDASE AND ITS INHIBITION: SOME CLINICAL
"^''^'^^™^5. 000983 01-17
IRREVERSIBLE INHIBITION OF S AOENOSYLHOMOCYSTEINE-HYDROLASE BY
NUCLEOSIDE ANALOGS. (UNPUBLISHED PAPER). ^^^^^ ^^^^
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY
HUMAN BLOOD-PLATELETS. 001067 02-02
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES.
001078 Oz-Oz
INHIBITION BY LOCAL ANESTHETICS, PHENTOLAMINE AND PROPRANOLOL
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL
MUSCARINIC-RECEPTORS. 001097 02-03
Psychopharmacology Abstracts
INHIBITION OF CHEMOTAXIS BY S 3 DEAZAAOENOSYLHOMOCYSTEINE IN
A MOUSE MACROPHAGE CELL LINE. (UNPUBLISHED PAPER).
001100 02-03
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIREQ VASODILATOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRiaiON. _, ,^ ^^ „,
001109 02-03
FURTHER STUDIES ON THE INHIBITION OF MONOAMINE SYNTHESIS BY
MONOFLUOROMETHYLDOPA.
001128 02-03
PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN
VITRO INHIBITION BY MELATONIN AT SUBMICROMOLAR
CONCENTRATIONS.
001159 02-03
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES:
EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION
IN THE ANESTHETIZED CAT .
001203 02-03
INHIBITION OF ACH RELEASE BY PROSTAGLANDIN-E 1 IN THE RABBIT
SUPERIOR-CERVICAL-GANGLION.
001205 02-03
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES. „«,o^oo^«',
001208 02-03
THE STEREOSPECIFIC EFFEQ OF NALOXONE ON RAT DORSAL-HORN
NEURONES, INHIBITION IN SUPERFICIAL LAMINAE AND EXCITATION IN
DEEPER LAMINAE.
001226 02-03
PHOSPHORYLATION OF THE MEMBRANE-BOUND ACETYLCHOLINE-
RECEPTOR INHIBITION BY DIPHENYLHYDANTOIN.
001257 02-03
SODIUM-CHLORIDE INHIBITION DECREASES LEVELS OF IMMUNOREAQIVE
DYNORPHIN IN THE NEUROINTERMEDIATE PITUITARY OF RATS.
001283 02-03
INHIBITION OF THE ACTION OF CHOLECYSTOKININ-OQAPEPTIDE ON THE
GUINEA-PIG ILEUM MYENTERIC PLEXUS BY DIBUTYRYL-CYCLIC-
GUANOSINE-MONOPHOSPHATE ^^^^^ ^^^^
METHYLDOPA PRODUCES CENTRAL INHIBITION OF PARASYMPATHETIC-
AQIVITYINTHECAT 00132102-03
OPIATE-RECEPTOR MEDIATED INHIBITION OF RAT JEJUNAL-FLUID
S^C^^^'O'^ 001334 02-03
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFEG
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYL^TION BY IPRINDOLE ^^^^^ ^^^^
INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRIQION
BY CLONIDINE IN CATS. 00143102^
CONVULSANTS ANTAGONISE INHIBITION IN THE OLFAQORY-CORTEX
^'■"-^ 001466 02-03
INHIBITION OF NEUROLEPTIC-INDUCED DOPAMINE-RECEPTOR
SUPERSENSITIVITY BY CYCLO-LEU-GLY. ^^^^^ ^^^
MINAPRINE AND INHIBITION. 001887 02^7
INHIBITION AND APATHY: TREATMENT WITH SURVEQOR. ^^^ ^^^^
INHIBITION OF SULPIRIDE-INDUCED PROLAQIN SECRETION BY
DIHYDROERGOCRISTINE IN MAN. ^^^^^ ^^.la
APOMORPHINE SELEQIVE INHIBITION OF THE AVERSIVE COMPONENT OF
LATERAL HYPOTHALAMIC SELF-STIMULATION. ^^^^^ ^^^^
PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS
MECHANISMS RESPONSIBLE FOR MOTOR AQ INHIBITION BY AVERSIVE
^^^^"^^ 002671 03-03
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC '^HIBITION^^^^^ ^^^
ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA:
REVERSAL BY MICROIONTOPHORETIC BICUCULLINE. ^^^^ ^^^^
INHIBITION OF VASOPRESSIN RELEASE TO CAROTID OCCLUSION BY
GAMMA AMINOBUTYRIC-ACID AND GLYCINE. 002715 03-03
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED
^^ 002740 03-03
S-230
VOLUME 19, SUBJECT INDEX
HOMOCYSTEINE-INDUCED CONVULSIONS: ENHANCEMENT BY VITAMIN-B6
AND INHIBITION BY HYDRAZINE.
002758 03-03
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS
INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJECTION OF
CYCLOHEXIMIDE.
002780 03-03
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE Of
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
002801 03-03
A BARBITURATE-EVOKED INTENSIFICATION OF POSTSYNAPTIC INHIBITION
IN THE PREOPTIC OVULATORY TRIGGER REGION OF THE
HYPOTHALAMUS.
0028)8 03-03
INHIBITION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE WITH 6
AMINONICOTINAMIDE IN REGIONS OF THE RAT-BRAIN.
002868 03-03
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES.
002879 03-03
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH
ANTICONVULSANT AND ANESTHETIC ACTIONS.
002885 03-03
SELECTIVE INHIBITION BY NICOTINE OF SHOCK-INDUCED FIGHTING IN THE
RAT.
002984 03-04
ASCENDING ENDORPHIN INHIBITION OF DISTRESS VOCALIZATION
00301 1 03-04
INHIBITION OF AGGRESSIVE-BEHAVIOR IN RHESUS-MONKEYS BY
BUSPIRONE.
003103 03-04
NEUROLEPTICS: ACTIVATION OR INHIBITION OF THE DOPAMINERGIC-
SYSTEM?
003424 03-13
CLINICAL-IMPLICATIONS OF ENZYME INDUQION AND ENZYME
INHIBITION.
003621 03-17
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE-
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1
CYCLOPROPYLMETHYL
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE.
003706 04-02
INHIBITION OF MONOAMINE-OXIDASE BY FURAZOLIDONE IN THE
CHICKEN AND THE INFLUENCE OF THE ALIMENTARY FLORA THEREON
003711 04-03
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO.
INHIBITION OF (3H)DIAZEPAM BINDING BY AN ENDOGENOUS FRACTION
FROM RAT-BRAIN SYNAPTOSOMES.
NONCOMPETITIVE AMINE UPTAKE INHIBITION BY THE NEW ^'
ANTIDEPRESSANT PRIDEFINE.
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN^^ °'*"°"'
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS-
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE.
INHIBITION OF SYNAPTOSOMAL CALCIUM UPTAKE BY ETHAN^OL^^ ^^''^^
AAOQOy (\A no
INHIBITION OF AMINOPEPTIDASE AND ACETYLCHOLINESTERASE BY
PUROMYCIN AND PUROMYCIN ANALOGS.
BACLOFEN: STEREOSELEQIVE INHIBITION OF EXCITANT AMINO-ACID
RELEASE.
CHARACTERISTICS OF THE INHIBITION OF RAT-BRAIN MONOAMINE- '*'
OXIDASE IN VITRO BY MD780515.
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL
TISSUE BY ASCORBATE.
THE EFFECT OF SODIUM-DIPROPYLACETATE ON GAMMA AMINOBUTYRIC-
ACID DEPENDENT INHIBITION IN THE RAT-CORTEX AND SUBSTANTIA-
NIGRA IN RELATION TO ITS ANTICONVULSANT ACTIVITY.
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE
REVERSAL OF GUANETHIDINE BLOCKADE OF ADRENERGIC NEURONS.
INHIBITION OE LYSOSOMAL LIPASES BY CHLORPROMAZINE: A POSS°BlP
MECHANISMS OF STABILIZATION.
003993 04-03
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C-
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM-
CHANNEL BLOCKADE.
004020 04-03
Subject Index
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL
VESICLES.
004042 04-03
INHIBITION OF THE SYNTHESIS OF ACETYLCHOLINE IN RAT-BRAIN SLICES
BY (-) HYDROXYCITRATE AND CITRATE
004044 04-03
DIFFERENTIAL INHIBITION OF ALPHA 1 -ADRENOCEPTOR AND ALPHA2-
ADRENOCEPTOR MEDIATED PRESSOR RESPONSES IN PITHED RATS
004057 04-03
HYPERACTIVITY FOLLOWING INJECTION OF A GLUTAMATE AGONIST AND
6,7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY
THIP.
004066 04-04
SUPPRESSION OF ALCOHOL DRINKING WITH BRAIN ALDEHYDE-
DEHYDROGENASE INHIBITION.
004220 04-04
INHIBITION OF PENTAGASTRIN-STIMULATED AND OVERNIGHT GASTRIC
SECRETION BY LM24056, A NEW PHENOTHIAZINE DERIVED
ANTISECRETORY DRUG.
004306 04-07
THE ANTIDEPRESSANT EFFECTS OF TRAZODONE AND INHIBITION OF
PLATELET SEROTONIN REUPTAKE.
004383 04-09
INHIBITOR
ATP COMPLEXES WITH THE ATPASE INHIBITOR QUERCETIN.
000045 01-03
CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC-
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE
(GABA-TRANSAMINASE) INHIBITOR.
000174 01-03
IRREVERSIBLE INHIBITION OF AROMATIC-L-AMINO-ACID-DECARBOXYLASE
BY ALPHA DIFLUOROMETHYL-DOPA AND METABOLISM OF THE
INHIBITOR.
000248 01-03
ANALYSIS OF THE ACTIVATION OF DOPAMINE METABOLISM BY A
SEROTONIN UPTAKE INHIBITOR.
.^„,„„ 000315 01-03
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE-
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER
SEROTONIN UPTAKE BLOCKERS.
000316 01-03
INITIAL, CLINICAL-TRIAL OF A NEW, SPECIFIC 5 HT REUPTAKE INHIBITOR
CITALOPRAM (LU-10-171).
000591 01-09
THE BLOCKADE OF ALPHA2-ADREN0CEPT0RS BY THE PNMT INHIBITOR
SKF-64139.
001255 02-03
1 METHYL-BETA-CARBOLINE (HARMANE), A POTENT ENDOGENOUS
INHIBITOR OF BENZODIAZEPINE-RECEPTOR BINDING.
001440 02-03
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELECTIVE
5 HT UPTAKE INHIBITOR.
001517 02-03
EFFECT OF PROSTAGLANDIN-El AND ITS BIOSYNTHESIS INHIBITOR
INDOMETHACIN ON DRINKING IN THE RAT.
001749 02-04
AN INHIBITOR OF OPIOID-PEPTIDE DEGRADATION PRODUCES ANALGESIA
IN MICE.
001780 02-04
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE.
002305 02-13
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL ON
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC-STUDY
002309 02-13
DEMONSTRATION AND CHARAQERIZATION OF AN ENDOGENOUS
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM
BOVINE CEREBRAL-CORTEX.
002645 03-01
DU-24565, A QUIPAZINE DERIVATIVE, A POTENT SELECTIVE SEROTONIN
UPTAKE INHIBITOR.
002651 03-02
EFFECTS OF AN EPINEPHRINE SYNTHESIS INHIBITOR, SKF-64139 ON THE
SECRETION OF LUTEINIZING-HORMONE IN OVARIECTOMIZED FEMALE
RATS.
002693 03-03
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE-
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION.
003458 03-14
ANTITREMOR ACTION OF ClODICHOL, A PERIPHERAL ACETYLCHOLINE
SYNTHESIS INHIBITOR.
004096 04-04
'!!!
m
«ijir'
I
"Wit
«Kli;:
m'
x:,
3c
S-231
Mtr.
I
Subject Index
ANORECTIC-PROPERTIES OF A NEW LONG ACTING SEROTONIN UPTAKE
INHIBITOR. 004105 04-04
ATTENUATION OF PETHIDINE-INDUCED ANTINOCICEPTION BY ZIMELIDINE,
AN INHIBITOR OF 5 HYDROXYTRYPTAMINE REUPTAKE.
0041 18 04-04
0 6 FLUOROTRYPTOPHAN, AN INHIBITOR OF TRYPTOPHAN-
HYDROXYLASE: SLEEP AND WAKEFULNESS IN THE RAT. ^^^^^^ ^^^^
"*"'ar?ldialkenylpiperazines as selective and very potent
INHIBITORS OF DOPAMINE UPTAKE. 000005 01-01
BLOCKADE OF METHAMPHETAMINE-INDUCED DEPRESSION OF TYROSINE-
HYDROXYLASE BY GABA-TRANSAMINASE INHIBITORS. ^^^^^ ^^^^
IN VIVO EFFECT OF PROTEASE INHIBITORS IN DENERVATION^ATROPH^Y._^_^
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELECTIVE
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR-
STIMUIATION INDUCED BY INDIRECTLY ACTING SYMPATHOMIMETIC-
AMINES IN MICE. 000492 01-04
COMPARATIVE-STUDIES OF MAO-A AND MAO-B INHIBHORS^N^MAN.^^^
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERAS!DE)
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION^.^ ^^_^ ^
ADENOSINE ANALOGS AS SUBSTRATES AND INHIBITORS OF S
ADENOSYLHOMOCYSTEINE-HYDROLASE. (UNPUBLISHED PAPER).^ ^^_^^
INHIBITORS OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND
EPINEPHRINE BIOSYNTHESIS. 2. 1,2,3,4 TETRAHYDROISOQUINOLlNE-7-
SULFONANILIDES. 001069 02-02
GABA AGONISTS AND UPTAKE INHIBITORS DESIGNED AS AGENTS WITH
IRREVERSIBLE ACTIONS 001079 02-02
IN VIVO CHANGES IN THE GABA CONTENT OF NERVE-ENDINGS
(SYNAPTOSOMES) INDUCED BY INHIBITORS OF GABA UPTAKE^^ ^^_^^
A COMPARATIVE-STUDY OF THE PHARMACOLOGY OF INHIBITORS OF
GABA METABOLISM. 003036 03-04
PHOSPHODIESTERASE INHIBITORS FACILITATE MEMORY FOR PASSIVE-
AVOIDANCE CONDITIONING. 003109 03-04
THE PHARMACOLOGY OF GABA-TRANSAMINASE INHIBITOR^S^^^^^ ^^^^
IBOTENIC-ACID ANALOGUES AS INHIBITORS OF (3H)GLUTAMIC-ACID
BINDING TO CEREBELLAR MEMBRANES. ^^^^^^ ^^_^^
EFFECT OF INHIBITORS OF GABA-AMINOTRANSFERASE ON THE
METABOLISM OF GABA IN BRAIN TISSUE AND SYNAPTOSOMAL
f^ACTIONS. 003914 04-03
AMINE UPTAKE INHIBITORS: CRITERIA OF SELECTIVITY ^^^^^ ^^^^
IN VIVO INTRANEURONAL MAO-INHIBITION IN RAT-BRAIN SKF-64139,
COMPARISON TO OTHER POTENT PNMT INHIBITORS.
003935 04-03
ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES:
EFFECTS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE-
DEAMINASE INHIBITORS. 003950 04-03
DIFFERENTIAL-EFFECTS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND
RELEASING-AGENTS ON LOCOMOTOR-AQIVITY IN NORMAL AND IN
RESERPINIZEDMICE. 004130 04-04
EFFECTS OF NOREPINEPHRINE AND 5 HYDROXYTRYPTAMINE REUPTAKE
INHIBITORS ON ELECTRICALLY-INDUCED SPINAL-CORD SEIZURES IN
^'^^^ 004144 04-04
SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS: DESIGN,
DEVELOPMENT AND STRUaURE-ACTIVITY STUDIES.
004/ZD U4- 1 /
INHIBITORY
DOES SYSTEMIC MORPHINE INCREASE DESCENDING INHIBITORY
CONTROLS OF DORSAL-HORN NEURONES INVOLVED IN NOCICEPTION?
0001 75 01 -Uo
EFFECT OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO
STIMULATION OF THE NUCLEUS-ACCUMBENS. ^^^^^ ^^^^
INHIBITORY ACTION OF MORPHINE ON THE RELEASE OF A BRADYKININ-
LIKE SUBSTANCE AFTER SCIATIC-NERVE STIMULATION. ^^^^^ ^^_^^
INHIBITORY AaiON OF ADENOSINE ON SYNAPTIC TRANSMISSION IN THE
HIPPOCAMPUS OF THE GUINEA-PIG IN VITRO. ^^^^^ ^^_^^
Psychopharmacology Abstracts
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
L-DOPA ENHANCES ACQUISITION OF AN INHIBITORY AVOIDANCE
RESPONSE. „„,-,,, „o«^
001711 02-04
EFFEa OF ANTICONVULSANT-DRUGS ON INHIBITORY AND EXCITATORY
PATHWAYS. „„„^-,.«o«o
002724 03-03
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFEQ OF MORPHINE
AND CROSS-TOLERANCE TO THE INHIBITORY AQION OF BETA
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS.
002756 03-03
BEHAVIORAL CONFIRMATION OF DIFFUSE NOXIOUS INHIBITORY
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS
OPIATES. „„„-,„, „o ^,
002791 03-03
INHIBITORY ACTIONS OF TAUROCYAMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES. „„o„ .. „, „,
002846 03-03
PHARMACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG.
002889 03-03
EFFEaS OF BARBITURATES ON INHIBITORY AND EXCITATORY RESPONSES
TO APPLIED NEUROTRANSMinERS IN APLYSIA.
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT
NICTITATING MEMBRANE 003777 04-03
ROTATIONAL-BEHAVIOUR ELICITED BY 5 HT IN THE RAT: EVIDENCE FOR
AN INHIBITORY ROLE OF 5 HT IN THE SUBSTANTIA-NIGRA AND
CORPUS-STRIATUM. ^^^, ^^^
INHIBITORY-ACTION Of THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS ^^^^ ^^^
"^"'eXOTAt'oRY and INHIBITORY-ACTIONS OF IBOTENIC-ACID ON FROG
SPINAL MOTONEURONES IN VITRO. ^^^^ ^^^
EVIDENCE FOR A DIRECT INHIBITORY-EFFEQ OF MORPHINE ON THE
SECRETION OF POSTERIOR PITUITARY-HORMONES. ^^^^^ ^^^^
INHIBITORY-EFFECTS OF ANTICONVULSANT-DRUGS ON CYCLIC-
NUCLEOTIDE ACCUMULATION IN BRAIN. ^^^^^ ^^^
EXCITATORY AND INHIBITORY-EFFECTS OF OPIATES IN THE RAT VAS-
DEFERENS: A DUAL-MECHANISM OF OPIATE ACTION.
000143 Ol-Oo
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFECTS OF FENTANYL ON
THE CONTRAQION OF THE NICTITATING MEMBRANE IN CATS^.^^ ^^^^
SELEQIVE INHIBITORY-EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE
ON PLATELET AGGREGATION. 004518 04-1-
INHIBITS
COMPOUND-48-80 INHIBITS NEUROTENSIN-INDUCED HYPOTENSION IN
•^^^^ 000243 01-0;
MODIFICATION OF THE PROLINE RESIDUE OF TRH ENHANCES BIOLOGICAL-
AQIVITY AND INHIBITS DEGRADATION. ^^^^^ ^^_^
CENTRAL ADMINISTRATION OF SERINE CAUSES HYPOTHERMIA AND
INHIBITS FEVER IN RABBITS. ^^^47 02-0:
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLYSUBmANEOUSLY^^
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME AQIVITY
IN THE RAT-BRAIN 001614 02-0-
BOMBESIN INHIBITS STRESS-INDUCED EATING. ^^^^^ ^^^
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R_1 5 IN
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE
RELATIONSHIP. 003806 04^:
nnxFPIN A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTAQ
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL-
INDUCEO INCREASE IN CYCLIC-AMP PRODUCTION ^^^^^ ^^,
S-232
VOLUME 19, SUBJECT INDEX
Subject Index
INITIAL
INITIAL, CLINICAL-TRIAL OF A NEW, SPECIFIC 5 HT REUPTAKE INHIBITOR,
CITALOPRAM(LU-10-171).
000591 01-09
INITIAL PRESCRIPTION OF PSYCHOTROPIC-MEDICATIONS FOR
ADOLESCENTS IN A MEDICAL/PROFESSIONAL INSTITUTE, AND THE
ROLE OF THE PSYCHIATRIST IN A MEDICAL/PROFESSIONAL INSTITUTE.
002621 02-17
SENILE-DEMENTIA IN ITS STILL GUIDABLE INITIAL PHASE.
004698 04-17
INJECTABLE
ANTIDEPRESSANT ACTION OF INJECTABLE 1694.
001960 02-09
USE OF INJECTABLE LORAZEPAM IN ALCOHOL WITHDRAWAL.
002176 02-11
INJECTED
ANTINOCICEPTIVE-EFFECT OF MORPHINE, OPIOID ANALGESICS AND
HALOPERIDOL INJECTED INTO THE CAUDATE-NUCLEUS OF THE RAT.
000414 01-04
EFFECTS OF NOMIFENSINE AND DESIPRAMINE ON THE SEQUELAE OF
INTRACEREBRALLY INJECTED 6 OHDA AND 5,6 DHT.
001522 02-03
THE EFFECTS OF BOMBESIN INJECTED INTO THE ANTERIOR AND
POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN
CONSUMPTION.
001544 02-03
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA
ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF
CONSCIOUS CATS.
001569 02-04
CENTRAL-ACTION OF INTRAVENTRICULARLY INJECTED MIDODRINE IN
RATS.
001684 02-04
INJECTION
ADMINISTRATION OF ANTISOMATOSTATIN SERUM TO RATS REVERSES
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION
PRODUCED BY INJECTION OF METERGOLINE BUT NOT YOHIMBINE.
(UNPUBLISHED PAPER).
000019 01-03
L TRYPTOPHAN INJECTION ENHANCES PULSATILE GROWTH-HORMONE
SECRETION IN THE RAT. (UNPUBLISHED PAPER).
000020 01-03
CORTICAL NEUROCHEMICAL CHANGES AFTER INTRASTRIATAL INJECTION
OF KAINIC-ACID.
000133 01-03
REDUCTION OF FETAL RAT SPINAL-CORD VOLUME FOLLOWING
MATERNAL MORPHINE INJECTION.
000161 01-03
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJECTION.
000261 01-03
CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL INJECTION OF
BACLOFEN IN RATS.
000415 01-04
INTRACRANIAL INJECTION PARAMETERS WHICH AFFECT ANGIOTENSIN-II-
INDUCED DRINKING.
000534 01-06
GROWTH-HORMONE (GH) RELEASE FOLLOWING THYROTROPIN-
RELEASING-HORMONE (TRH) INJECTION IN MANIC-PATIENTS
RECEIVING LITHIUM-CARBONATE.
000645 01-09
PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID-
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY
COMPLEX. (UNPUBLISHED PAPER).
001047 02-01
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN
FOLLOWING INTERAVENTRICULAR INJECTION.
001239 02-03
LOG-DOSE /RESPONSE-CURVE FLAHENING IN RATS AFTER DAILY
INJECTION OF OPIATES.
001387 02-03
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN
MICE.
001435 02-03
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJECTION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS
001446 02-03
DESENSITIZATION OF ADRENOCEPTORS AFTER IMMOBILIZATION STRESS
OR REPEATED INJECTION OF ISOPROTERENOL IN RATS. (UNPUBLISHED
PAPER).
001546 02-03
VESTIBULO-OCULAR REFLEXES IN RABBITS: REDUCTION BY INTRAVENOUS
INJEQION OF DIAZEPAM.
.^..„ 001566 02-04
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION
001568 02-04
DIFFERENT BEHAVIORAL-EFFECTS FOLLOWING INTRACEREBRAL,
INTRACEREBROVENTRICULAR OR INTRAPERITONEAL INJECTION OF
NALOXONE IN THE RAT.
001665 02-04
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN
RATS.
001669 02-04
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF TAURINE IN RATS.
001670 02-04
MOTOR-DEPRESSION AND HEAD-TWITCHES INDUCED BY IP INJECTION OF
GABA.
001788 02-04
BEHAVIOR MAINTAINED BY INTRAVENOUS INJECTION OF CODEINE
COCAINE, AND ETORPHINE IN THE RHESUS-MACAQUE AND THE
PIGTAIL-MACAQUE.
001828 02-04
LOCAL AND DISTANT NEURONAL DEGENERATION FOLLOWING
INTRASTRIATAL INJECTION OF KAINIC-ACID.
001885 02-06
LONG-TERM CONTROLLED-COMPARISON OF INJECTION OXYPROTHEPIN
AND FLUPHENAZINE-DECANOATES IN PSYCHOTICS IN REMISSION.
001949 02-08
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS AFTER A SINGLE
INJECTION OF BETA ENDORPHIN.
001962 02-09
THE TSH RESPONSE TO TRH INJECTION IN PSYCHIATRIC-PATIENTS: A
REVIEW.
002145 02-11
ACCIDENTAL INTRAARTERIAL INJECTION OF DIAZEPAM.
002598 02-17
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR
INJECTION OF CEFAZOLIN.
002762 03-03
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE
INJECTION IN NEWBORN ANIMALS.
002774 03-03
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS
INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJECTION OF
CYCLOHEXIMIDE.
002780 03-03
ON CORRELATION OF BEHAVIORAL-REACTIONS AND NEURONAL ACTIVITY
IN THE HYPOTHALAMUS UNDER SUBCUTANEOUS GASTRIN INJECTION.
002892 03-03
CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNCTION
OF ELAVIL AND THORAZINE INJECTION.
002974 03-04
PHARMACOLOGICAL CHARACTERIZATION OF SCRATCHING-BEHAVIOUR
INDUCED BY INTRACRANIAL INJECTION OF SUBSTANCE-P AND
SOMATOSTATIN.
002980 03-04
SEIZURES ELICITED BY SUBCUTANEOUS INJECTION OF METRAZOL DURING
ONTOGENESIS IN RATS.
003039 03-04
TRH INCREASES LOCOMOTOR-ACTIVITY IN RATS AFTER INJECTION INTO
THE HYPOTHALAMUS.
003044 03-04
INTRAVENTRICULAR CORTICOSTERONE INJECTION FACILITATES MEMORY
OF AN APPETITIVE DISCRIMINATIVE TASK IN MICE.
003051 03-04
OPERANT FEEDING AND DRINKING IN PIGS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF SYNTHETIC
CHOLECYSTOKININ-OCTAPEPTIDE.
003064 03-04
INCREASES IN SKIN-RESISTANCE OF WHITE RATS FOLLOWING
SCOPOLAMINE INJECTION.
003138 03-06
BEHAVIORAL-EFFECTS AND BIOLOGICAL-EFFECTS OF ACUTE BETA
ENDORPHIN INJECTION IN SCHIZOPHRENIC-PATIENTS AND DEPRESSED-
PATIENTS.
003357 03-1 1
DENERVATION SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN RATS
FOLLOWING SPINAL TRANSEQION AND 5,7 DIHYDROXYTRYPTAMINE
INJECTION.
003722 04-03
CATECHOLAMINE AND 5 HYDROXYTRYPTAMINE SYNTHESIS AND
METABOLISM FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF
DIBUTYRYL-CYCLIC-AMP.
003769 04-03
CHANGES OF ELECTRORETINOGRAM AND NEUROCHEMICAL ASPECTS OF
GABAERGIC NEURONS OF RETINA AFTER INTRAOCULAR INJECTION OF
KAINIC-ACID IN RATS.
003807 04-03
1«:
d\
<i:!fL,
VlHtui
I
"Kill:
m'
.Irr
S-233
«sri
Subject Index
THE EFFECT OF ELECTRICAL-STIMULATION OF THE LOCUS-COERULEUS AND
INTRAPERITONEAL INJECTION OF CERTAIN PHARMACOLOGICAL
SUBSTANCES ON THE THRESHOLD OF HIPPOCAMPAL
AFTERDISCHARGES. „„.„„r ^. «o
003885 04-03
HYPERACTIVITY FOLLOWING INJEQION OF A GLUTAMATE AGONIST AND
6,7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY
THIP
004066 04-04
USE OF THE INTRACEREBRAL INJEQION TECHNIQUE TO ELUCIDATE
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN
THE MOUSE.
004092 04-04
INTRANIGRAL INJEQION OF CAPSAICIN ENHANCES MOTOR-ACTIVITY
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE BUT NOT SUBSTANCE-
'' 004100 04-04
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJEQION IN
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION
AND EFFECTS OF D-AMPHETAMINE AND PROMAZINE.
004152 04-04
INVOLVEMENT OF DOPAMINE IN CIRCLING RESPONSES TO MUSCIMOL
DEPENDS ON INTRANIGRAL SITE OF INJECTION.
004158 04-04
AVOIDANCE RESPONSE IN RATS AFTER INJEQION OF DOPAMINE INTO
THE NEOSTRIATUM. „„.„„ „. «.
004255 04-04
HORMONAL STIMULATION AFTER INJECTION OF THYROTROPHIN-
RELEASING-FACTOR (TRF) AND ACTHl-24 IN PATIENTS FOLLOWING
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY-STUDY.
004505 04-13
INJECTIONS
EFFECT OF INTRAVENTRICULAR INJECTIONS OF ALPHA AMINOSULFONIC-
ACIDS ON THE CENTRAL-NERVOUS-SYSTEM OF CONSCIOUS MICE.
000009 01-02
WATER INTAKE AND TIME-COURSE OF DRINKING AFTER SINGLE OR
REPEATED CHLORDIAZEPOXIDE INJECTIONS. ^^ ^, ^^
000369 01-04
MORPHINE INJECTIONS INTO THE PERIAQUEDUQAL PERIVENTRICULAR
GRAY AHENUATE SEPTAL HYPERREAQIVITY.
000390 01-04
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS
AND ANTAGONISTS: ZONE-SPECIFIC EFFECTS. „„„,„.
000422 01-04
LOCOMOTOR-ACTIVITY ELICITED BY INJECTIONS OF PICROTOXIN INTO THE
VENTRAL TEGMENTAL AREA IS AHENUATED BY INJECTIONS OF GABA
INTO THE GLOBUS-PALLIDUS. _^ ^, „^
000436 01-04
OXYPROTHEPIN-DECANOATE INJECTIONS: EXPERIENCE WITH A LONG-
TERM-TREATMENT OF SCHIZOPHRENIC-PSYCHOSES.
000576 01-08
LONG-TERM EFFECTS OF TESTOSTERONE INJECTIONS ON THE SOCIAL-
BEHAVIOUR OF MALE DUCKS AND THEIR PHYSIOLOGICAL-CORRELATES.
001565 02-04
BEHAVIOURAL-RESPONSES TO STEREOTACTICALLY CONTROLLED
INJECTIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI.
001708 02-04
THE INFLUENCE OF SINGLE DAILY HEROIN INJECTIONS ON DRINKING-
PAHERNS IN THE RAT. „,,,,., ^o «.
001746 02-04
HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY
UNILATERAL 6 OHDA INJECTIONS INTO SUBSTANTIA-NIGRA AND
CAUDATE-NUCLEUS. „„,,-.„ „. „.
001778 02-04
PLASMA FLUPHENAZINE LEVELS BY RADIOIMMUNOASSAY IN
SCHIZOPHRENIC-PATIENTS TREATED WITH DEPOT INJECTIONS OF
FLUPHENAZINE-DECANOATE.
002510 02-16
THE EFFECTS OF INJECTIONS OF BOMBESIN INTO THE CEREBRAL
VENTRICLES ON BEHAVIORAL THERMOREGULATION.
002952 03-04
INJECTIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINERGIC AND
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS: EFFECTS ON
LOCOMOTOR-ACTIVITY IN THE RAT.
003019 03-04
DOSE-RESPONSE RELATIONSHIP BETWEEN NALOXONE INJECTIONS AND
INTAKE OF SUCROSE SOLUTION.
003118 03-04
OPIATE-DEPENDENCE FOLLOWING ACUTE INJECTIONS OF MORPHINE AND
NALOXONE: THE ASSESSMENT OF VARIOUS WITHDRAWAL SIGNS.
004209 04-04
INJURY
OPIATE ANTAGONIST IMPROVES NEUROLOGIC RECOVERY AFTER SPINAL
'^^"^^ 002714 03-03
EFFICACY OF LITHIUM IN TREATING MOOD-DISORDER OCCURRING AFTER
BRAINSTEM INJURY . „„on c . «o , ,
003354 03-1 1
Psychopharmacology Abstracts
INKASAN
A PHARMACOLOGICAL-STUDY OF THE NEW SOVIET ANTIDEPRESSANT j
INKASAN. I
000008 01-02 I
THE EFFECT OF THE NEW ANTIDEPRESSANT INKASAN ON THE
BIOELECTRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED
REFLEXES.
004212 04-04
INMATES
THE USE OF MINOR-TRANQUILIZERS WITH JAIL INMATES.
003308 03-11
INNER
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS ARE LOCALIZED IN THE
INNER PLEXIFORM LAYER OF RAT RETINA.
000277 01-03
INNOVATIONS
INNOVATIONS IN TREATMENT WITH ANTIDEPRESSANTS.
002019 02-09
INORGANIC
EFFECT OF INORGANIC LEAD ON RAT-BRAIN MITOCHONDRIAL
RESPIRATION AND ENERGY PRODUCTION.
004267 04-05
INOSINE
DISSIMILAR EFFECTS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE.
000173 01-03
INTERACTION BETWEEN PURINE AND BENZODIAZEPINE: INOSINE
REVERSES DIAZEPAM-INDUCED STIMULATION OF MOUSE
EXPLORATORY-BEHAVIOR.
002972 03-04
THE BENZODIAZEPINES AND INOSINE ANTAGONIZE CAFFEINE-INDUCED
SEIZURES.
004172 04-04
INPATIENT
ISSUES FOR INPATIENT TREATMENT OF CHRONIC PCP ABUSE.
000736 01-12
ARCALION-200 PRESCRIBED AS A PSYCHIATRIC-DRUG AND
ANTIALCOHOLISM-DRUG ON AN OUTPATIENT AND INPATIENT BASIS.
002103 02-n I
INPATIENT-SERVICE
THE URBAN EPIDEMIC OF PHENCYCLIDINE USE: LABORATORY EVIDENCE
FROM A PUBLIC PSYCHIATRIC-HOSPITAL INPATIENT-SERVICE.
003554 03-16
INPATIENTS ^ , „^
MAPROTILINE NOMIFENSINE, MIANSERIN, ZIMELIOINE: A REVIEW OF
ANTIDEPRESSANT EFFICACY IN INPATIENTS.
004731 04-17
INPUT
SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE:
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT.
000095 01-03
PHARMACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG.
002889 03-03
HIPPOCAMPAL SLOW ACTIVITY: TWO INPUT SYSTEMS? (UNPUBLISHED
^^^^^^ 003812 04-03
INPUTS
THE ROLE OF RETICULOSEPTAL INPUTS IN THE FORMATION OF DIFFERENT
TYPES OF SENSORY REACTIONS OF THE HIPPOCAMPAL NEURONS.
004510 04-13
INSECT
ALPHA FLUPENTHIXOL: AN ANTAGONIST OF DOPAMINE-EVOKED FLUID
SECRETION BY AN INSECT SALIVARY-GLAND PREPARATION.
000031 01-03
INSECTIODE
REGIONAL CHANGES IN BRAIN GLUCOSE UTILIZATION IN RATS GIVEN A
PYRETHROIO INSECTICIDE. ^, „,„ „, «
001838 02-05
INSENSITIVE
3H BACLOFEN AND 3H GABA BIND TO BICUCULUNE INSENSITIVE GABAB
SITES IN RAT-BRAIN. 003839 04-03
EVIDENCE FOR SEDATIVE EFFECTS OF LOW-DOSES OF MORPHINE IN MO
INVOLVING RECEPTORS INSENSITIVE TO NALOXONE.
INSENSITIVITY
PRESYNAPTIC DOPAMINE-RECEPTORS: INSENSITIVITY TO KAINIC-ACID
AND THE DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING CHRONIC
"^^°«^"^°^ 001117 024)3
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN
BRAIN CELL-CULTURES. 004002 0403
S-234
VOLUME 19, SUBJECT INDEX
Subject Index
INSEPARABILITY
INSEPARABILITY OF ACETYLCHOLINESTERASE AND NERVE EXCITATION.
003875 04-03
INSOMNIA
REVERSAL OF PARA CHLOROPHENYLALANINE-INDUCED INSOMNIA BY 5
HYDROXYTRYPTOPHAN IN THE RAT
000423 01-04
RATIONAL USE OF BENZODIAZEPINES FOR ANXIETY AND INSOMNIA.
002063 02-10
EUHYPNOS-FORTE, HIGH-DOSE TEMAZEPAM FOR RESISTANT INSOMNIA:
POSTMARKETING SURVEILLANCE IN 10,057 PATIENTS UNRESPONSIVE
TO CONVENTIONAL HYPNOTIC DOSAGE.
002324 02-14
HYPNOTIC-DRUGS AND TREATMENT OF INSOMNIA.
003350 03-1 1
FLUNITRAZEPAM IN THE TREATMENT OF INSOMNIA: A STUDY OF 50
PSYCHIATRIC-PATIENTS.
003444 03-14
THE TREATMENT OF INSOMNIA THROUGH HOMEOPATHY IN A CLINIC.
004484 04-11
DEPRENYL DOES NOT CAUSE INSOMNIA IN PARKINSONIAN-PATIENTS.
004569 04-14
FLURAZEPAM-INDUCED SLEEP-APNEA-SYNDROME IN A PATIENT WITH
INSOMNIA AND MILD SLEEP-RELATED RESPIRATORY CHANGES.
004729 04-17
INSOMNIAC-INPATIENTS
COMPARISON OF NITRAZEPAM 5 MG WITH TRIAZOLAM 0.5 MG IN
YOUNG PSYCHIATRIC INSOMNIAC-INPATIENTS.
002096 02-11
INSOMNIACS
CHRONIC USE OF TRIAZOLAM: THE EFFECTS ON THE SLEEP PAHERNS OF
INSOMNIACS.
000710 01-11
THE EFFICACY OF TRIAZOLAM AND CHLORAL-HYDRATE IN GERIATRIC
INSOMNIACS.
002160 02-11
INSTABILITY
CONTROLLED-STUDY WITH BROMAZEPAM AND CLOROTEPIN IN CHILD
INSTABILITY.
002190 02-11
INSTITUTE
INITIAL PRESCRIPTION OF PSYCHOTROPIC-MEDICATIONS FOR
ADOLESCENTS IN A MEDICAL/PROFESSIONAL INSTITUTE, AND THE
ROLE OF THE PSYCHIATRIST IN A MEDICAL/ PROFESSIONAL INSTITUTE.
002621 02-17
INSTITUTIONALIZED
COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS.
004438 04-11
INSTRUMENTAL
IMPAIRMENT OF INSTRUMENTAL LEARNING IN RATS BY GLUTAMIC-
ACID-DIETHYL-ESTER.
002993 03-04
INSUFFICIENT
THERAPEUTIC TREATMENT OF INSUFFICIENT PERFORMANCE IN
CEREBROVASCULAR-DISEASES.
004718 04-17
INSULIN
GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT
AFFEQED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN
TREATMENT.
001145 02-03
SYSTEMIC INSULIN DECREASES LATERAL HYPOTHALAMIC UNIT AQIVITY
001275 02-03
APHAGIA, GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNQIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS:
EFFEaS OF INSULIN PRETREATMENTS.
001638 02-04
AQION MECHANISMS OF INSULIN THERAPY IN PSYCHIATRY AND
CURRENT-VIEWS ON THESE MECHANISMS.
002553 02-17
INSULIN-INDUCED
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM-
ACETATE, MONOFLUOROACETATE AND INSULIN-INDUCED
HYPOGLYCEMIA.
004276 04-05
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE, AQIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL
DAMAGE.
000322 01-03
REDUCTION OF FOOD INTAKE BY PIRI8EDIL IN THE RAT: RELATION TO
DOPAMINE-RECEPTOR STIMULATION.
000355 01-04
WATER INTAKE AND TIME-COURSE OF DRINKING AFTER SINGLE OR
REPEATED CHLORDIAZEPOXIDE INJECTIONS.
000369 01-04
RENIN AND ALDOSTERONE SECRETIONS DURING HYPOVOLEMIA IN RATS:
RELATION TO NACL INTAKE.
000484 01-04
PHENOBARBITAL EFFECTS ON WEIGHT-GAIN AND CIRCADIAN-CYCLING OF
FOOD INTAKE AND BODY-TEMPERATURE,
001409 02-03
PROCEDURES FOR REDUCING DRUG INTAKE: NONHUMAN STUDIES.
001753 02-04
DIFFERENTIAL-EFFECTS OF MORPHINE ON FOOD AND WATER INTAKE IN
FOOD DEPRIVED AND FREELY-FEEDING RATS.
001765 02-04
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR
DORSOLATERAL TEGMENTAL DAMAGE.
001818 02-04
BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS
AND MAN.
002527 02-17
PAHERNS OF USE IN THE INTAKE OF ORAL MEDICATION.
002591 02-17
THE EFFECT OF ALTERED DOPAMINERGIC-ACTIVITY ON FOOD INTAKE IN
THE RAT: EVIDENCE FOR AN OPTIMAL LEVEL OF DOPAMINERGIC-
ACTIVITY FOR BEHAVIOR.
002632 02-17
SINGLE OR REPEATED ADMINISTRATION OF SMALL DOSES OF
APOMORPHINE ON WATER INTAKE AND ACTIVITY IN WATER-
DEPRIVED RATS.
002981 03-04
THE EFFECTS OF OPIATE ANTAGONISTS ON FOOD INTAKE ARE
STEREOSPECIFIC.
003080 03-04
DOSE-RESPONSE RELATIONSHIP BETWEEN NALOXONE INJECTIONS AND
INTAKE OF SUCROSE SOLUTION.
003118 03-04
DIETARY PROTEIN INTAKE INFLUENCES THE ANTIHYPERTENSIVE POTENCY
OF METHYLDOPA IN SPONTANEOUSLY HYPERTENSIVE-RATS.
004025 04-03
SUSTAINED INTRACEREBROVENTRICULAR INFUSION OF BRAIN FUELS
REDUCES BODY-WEIGHT AND FOOD INTAKE IN RATS.
004098 04-04
THE SITE OF ACTION OF NALOXONE IN SUPPRESSING FOOD AND WATER
INTAKE IN RATS.
004146 04-04
HISTIDYL-PROLINE DIKETOPIPERAZINE DECREASES FOOD INTAKE IN RATS.
004181 04-04
INTEGRATIVE
THE USE OF SENSORY INTEGRATIVE DIAGNOSTICS TO PREDICT
HYPERACTIVE-CHILDRENS RESPONSIVENESS TO METHYLPHENIDATE
(RITALIN) AND PEMOLINE (CYLERT). (PH.D. DISSERTATION).
002133 02-11
NOOTROPIC-DRUGS AND RELATED DRUGS INTERAQING WITH THE
INTEGRATIVE ACTIVITY OF THE BRAIN.
002327 02-14
INTEGRITY
THE INTEGRITY OF THE SOCIAL HIERARCHY IN MICE FOLLOWING
ADMINISTRATION OF PSYCHOTROPIC-DRUGS.
004202 04-04
INTELLECTUALLY-HANDICAPPED
A NOTE ON PATTERNS OF DRUG PRESCRIBING IN A RESIDENTIAL-CENTER
FOR THE INTELLECTUALLY-HANDICAPPED.
000982 01-17
INTELLIGENCE
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS.
004658 04-15
INTENSIFICATION
A BARBITURATE-EVOKED INTENSIFICATION OF POSTSYNAPTIC INHIBITION
IN THE PREOPTIC OVULATORY TRIGGER REGION OF THE
HYPOTHALAMUS.
002818 03-03
INTERACTING
NOOTROPIC-DRUGS AND RELATED DRUGS INTERACTING WITH THE
INTEGRATIVE ACTIVITY OF THE BRAIN.
002327 02-14
INTERACTION
EVIDENCE FOR AN IRREVERSIBLE INTERACTION OF BROMOCRYPTINE
WITH CENTRAL DOPAMINE-RECEPTORS.
000023 01-03
INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERACTION OF AMINO-
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG.
000034 01-03
INTERACTION OF DIAZEPAM WITH SYNAPTIC TRANSMISSION IN THE IN
VITRO RAT HIPPOCAMPUS.
000178 01-03
SODIUM-DEPENDENT INTERAaiON OF BENZAMIDES WITH DOPAMINE-
RECEPTORS.
000285 01-03
'IF
L'il
.".llff"
Illtlfcl^t
owiii:
an::
k;;.
S-235
■a^^sSBOSSHi:-
■Hi'
Mm
Subject Index
INTERACTION OF ANTIDEPRESSANTS WITH CLONIDINE ON RAT-BRAIN
TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL.
000300 01-03
CARDIOVASCULAR RESPONSE TO THE INTERAQION OF ETHANOL AND
SOME BENZODIAZEPINES IN RATS. „„„..„ „, „,
000332 01-03
EFFEQS OF L AND D AMINO-ACIDS ON ANALGESIA AND LOCOMOTOR-
ACTIVITY OF MICE: THEIR INTERACTION WITH MORPHINE.
000336 01-04
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND
L-AMPHETAMINE: NO INTERAQION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPEQED LETHALITY IN HIPPOCAMPAL SITES. ^ ^
000387 01-04
THE INTERACTION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS.
000389 01-04
THE LOCOMOTOR-EFFECT OF CLONIDINE AND ITS INTERAQION WITH
ALPHA FLUPENTHIXOL OR HALOPERIDOL IN THE DEVELOPING RAT.
000445 01-04
INTERAQION OF INDOMETHACIN AND IBUPROFEN WITH LITHIUM IN
MANIC-PATIENTS UNDER A STEADY-STATE LITHIUM LEVEL.
000622 01-09
INTERAQION BETWEEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN:
METABOLITE NORTRIPTYLINE AND THE CORRELATION WITH CLINICAL-
RESPONSE. „„„^ ^„ „, „
000640 01-09
METHADONE DISULFIRAM INTERACTION DURING METHADONE
MAINTENANCE. „„„-,„, „, ,^
000796 01-13
INTERACTION OF BIOGENIC-AMINE SYSTEMS IN BRAIN. (UNPUBLISHED
'^''^'>- 00114102-03
PHARMACOLOGICAL EVIDENCE AND BIOCHEMICAL-EVIDENCE FOR AN
INTERACTION BETWEEN THE BENZODIAZEPINE AND GABA-RECEPTORS.
001261 02-03
INTERAQION STUDIES OF ETHANOL AND PSYCHOTROPIC-DRUGS IN
RODENTS POSSIBLE INVOLVEMENT OF ADENOSINE-TRIPHOSPHATASES.
001281 02-03
BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERAQION
WITH GAMMA AMINOBUTYRIC-ACID.
001287 02-03
INTERAQION OF TRIAZOLAM WITH DESIPRAMINE: EFFEQS OF SINGLE
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC-
RESPONSES AND BRAIN CATECHOLAMINE LEVELS.
001323 02-03
PHENOBARBITONE AND SODIUM-VALPROATE INTERACTION: AN
EXPERIMENTAL-STUDY . ^ , ^„ „,
001371 02-03
INTERACTION OF HISTAMINE H2-RECEPT0R BLOCKING-DRUGS WITH THE
NORADRENERGIC SYSTEM IN RAT-BRAIN AND HEART.
001397 02-03
INTERACTION OF DOPAMINERGIC ERGOT DERIVATIVES WITH CYCLIC-
NUCLEOTIDE SYSTEM. _, „„„.„.
001482 02-03
EFFECT OF IMIPRAMINE ON HEPATIC GAMMA GLUTAMYLTRANSFERASE
IN FEMALE RATS. INTERACTION WITH CONTRACEPTIVES.
001507 02-03
THE EFFECTS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERACTION
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED
AHENTION. (PH D. DISSERTATION).
001563 02-04
INTERACTION OF PSYCHOPHARMALOGIC-FACTORS AND PSYCHOSOCIAL-
FACTORS IN THE TREATMENT OF ANIMAL-MODELS OF
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR.
001602 02-04
INTERACTION OF CHOLINERGIC AND DOPAMINERGIC INFLUENCES ON
YAWNING-BEHAVIOR.
001656 02-04
OPIATE AND PEPTIDE INTERACTION: EFFECT OF ENKEPHALINS ON
MORPHINE ANALGESIA.
001698 02-04
INVESTIGATIONS ON THE INTERACTION OF THYROTROPIN-RELEASING-
HORMONE (TRH) AND MK-771 WITH CENTRAL NORADRENERGIC
MECHANISMS.
001701 02-04
INTERACTION OF PROSTAGLANDINS AND THE EFFECTS OF MORPHINE AND
AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
001732 02-04
PHENOBARBITONE INTERACTION WITH ORAL CONTRACEPTIVE STEROIDS
IN THE RABBIT AND RAT . „,, , „,. „o „c
001832 02-05
ACTION OF TOFISOPAM ON THE ERGONOMIC VIGILANCE LEVEL. ITS
INTERACTION WITH THE EFFECTS OF ALCOHOL. CLINICAL
PHARMACOLOGICAL-STUDY.
001891 02-07
PHARMACOKINETIC INTERACTION BETWEEN PROPRANOLOL AND
CHLORPROMAZINE IN SCHIZOPHRENIC-PATIENTS.
001940 02-08
Psychopharmacology Abstracts
METABOLIC- STUDIES AND PSYCHOPHYSIOLOGIC-STUDIES OF
CANNABIDIOL HEXOBARBITAL INTERACTION.
002209 02-13
INTERACTION BETWEEN PHENYTOIN AND VALPROIC-ACID: PLASMA
PROTEIN BINDING AND METABOLIC-EFFECTS.
002276 02-13
DOUBLE-BUND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS.
002314 02-14
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN.
002727 03-03
PHENYTOIN VALPROIC-ACID INTERACTION IN RHESUS-MONKEY,
002785 03-03
INTERACTION OF CHLORDIAZEPOXIDE AND SODIUM-VALPROATE IN THE
NUCLEUS-ACCUMBENS OF THE RAT.
002796 03-03
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND
EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES.
002799 03-03
DRUG ENVIRONMENT INTERACTION: CONTEXT DEPENDENCY OF COCAINE-
INDUCED BEHAVIORAL-SENSITIZATION.
002866 03-03
INTERACTION BETWEEN THE EFFECTS OF STRESS AND MORPHINE ON
BODY-TEMPERATURE IN RATS.
002906 03-03
THE INTERACTION OF 2,3,4 TRIHYDROXYBENZYLHYDRAZINE WITH
DOPA-DECARBOXYLASE FROM PIG KIDNEY.
002925 03-03
INTERACTION BETWEEN PURINE AND BENZODIAZEPINE: INOSINE
REVERSES DIAZEPAM-INDUCED STIMULATION OF MOUSE
EXPLORATORY-BEHAVIOR.
002972 03-04
INTERACTION AMONG D-AMPHETAMINE, SCOPOLAMINE AND GENOTYPE
IN AVOIDANCE-BEHAVIOR OF RATS.
003082 03-04
EFFECT OF CHRONIC MORPHINE TREATMENT ON THE INTERACTION
BETWEEN THE PERIAQUEDUCTAL GREY AND THE NUCLEUS-RAPHE-
MAGNUS OF THE RAT
003727 04-03
INTERACTION OF THE TRICYCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH
PREJUNCTIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG
SAPHENOUS VEIN „„„,.,„.„,
003756 04-03
A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/
BENZODI AZEPINE-RECEPTOR INTERACTION .
003851 04-03
THE INTERACTION OF TRAZODONE WITH RAT-BRAIN MUSCARINIC-
CHOLINOCEPTORS. „«oor. «. no
003855 04-03
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN
INDIRECT ADRENERGIC CHOLINERGIC INTERACTION.
003887 04-03
THE INTERACTION OF AMINE LOCAL ANESTHETICS WITH MUSCARINIC-
^^«''™^^ 004031 04-03
INTERACTION OF STEREOISOMERS OF BARBITURATES WITH (3H)ALPHA
DIHYDROPICROTOXININ BINDING-SITES. 004036 04-03
CATECHOLAMINE SEROTONIN INTERACTION EFFECTS ON ACTIVITY IN
RATS NEONATALLY TREATED WITH 6 HYDROXYDOP AMINE.
004194 04-04
TONIC IMMOBILITY IN DOMESTIC FOWL: POSSIBLE INTERACTION OF
SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
004246 04-04
RECENT STUDIES ON INTERACTION BETWEEN OPIOID-PEPTIDES AND THEIR
«^«''^°'^^ 004300 04-06
THE INTERACTION OF PSYCHOPHARMACOLOGY AND PSYCHOANALYSIS IN
THE BORDERLINE-PATIENT. 004430 04-10
MECHANISM OF VALPROATE PHENOBARBITAL INTERACTION IN EPILEPTIC-
'^'^'''''- 004522 04-13
INTERACTION OF CHLORPROMAZINE WITH THE TRANSPORT SYSTEM OF
GLUCOSE IN HUMAN ERYTHROCYTES.
QOAbJrr 04- I J
INTRAVENOUS DIAZEPAM AND ORAL ETHANOL INTERACTION.
004552 04-1 J
KINETICS OF A CARBAMAZEPINE-ETHOSUXIMIDE INTERACTION.
004558 04-1 J
INTERACTION OF P CHLOROPHENYLALANINE. MIANSERINE AND
DANITRACEN WITH AMPHETAMINE. ,^„.c«n n. ic
CXMoSrV 04-13
'^"interaction-studies between narcotic ANALGESICS, NARCOTIC
ANTAGONISTS AND ETHANOL: STUDIES DURING ACUTE AND CHRONIC-
S-236
VOLUME 19, SUBJECT INDEX
Subject Indax
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE. (PH.D.
DISSERTATION)
001165 02-03
INTfRACTIONS
HISTAMINE HI -RECEPTORS LABELED IN VIVO: ANTIDEPRESSANT AND
ANTIHISTAMINE INTERACTIONS.
000074 01-03
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)APOM0RPHINE BINDING.
000099 01-03
GABA BENZODIAZEPINE INTERACTIONS: PHYSIOLOGICAL,
PHARMACOLOGICAL AND DEVELOPMENTAL ASPECTS.
000103 01-03
EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERACTIONS WITH MU-
RECEPTORS AND DELTA-RECEPTORS.
000168 01-03
INTERACTIONS OF NOREPINEPHRINE WITH PURKINJE-CELL RESPONSES TO
PUTATIVE AMINO-ACID NEUROTRANSMIHERS APPLIED BY
MICROIONTOPHORESIS.
000209 01-03
INTERACTIONS OF OXYPERTINE WITH RAT-BRAIN MONOAMINE-
RECEPTORS.
000212 01-03
EFFEQS OF ACUTE AND CHRONIC INTERACTIONS OF DIAZEPAM AND 0-
AMPHET AMINE ON PUNISHED-BEHAVIOR OF RATS.
000386 01-04
ALBUMIN BINDING INTERAQIONS OF SODIUM-VALPROATE.
000762 01-13
THE REGULATION OF GABA-RECEPTORS AS A POSSIBLE MECHANISM FOR
GABA 1,4 BENZODIAZEPINE INTERACTIONS. (UNPUBLISHED PAPER).
001012 02-01
INTERACTIONS OF NEUROPEPTIDES WITH CHOLINERGIC
SEPTOHIPPOCAMPAL PATHWAY: INDICATION FOR A POSSIBLE
TRANSSYNAPTIC REGULATION. (UNPUBLISHED PAPER).
001062 02-01
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING
DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS
OF MAMMALIAN FOREBRAIN IN VITRO.
001114 02-03
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
RECEPTOR BINDING INTERAQIONS OF THE ANGIOTENSIN-II ANTAGONIST,
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
OPIATE INTERAQIONS WITH CHOLINERGIC NEURONS.
001198 02-03
INTERAQIONS BETWEEN MORPHINE AND THE OPIOID-LIKE PEPTIDES IN
THE RAT VAS-DEFERENS.
001290 02-03
PINEAL INTERAQIONS WITH THE CENTRAL-NERVOUS-SYSTEM:
NEUROENDOCRINE IMPLICATIONS. (PH.D. DISSERTATION).
001341 02-03
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY
AND INTRINSIC AQIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS.
001516 02-03
INTERAQIONS OF CHLOROIAZEPOXIDE AND ANORECTIC-AGENTS ON RATE
AND DURATION PARAMETERS OF FEEDING IN THE RAT.
001600 02-04
INTERAQIONS BETWEEN NALTREXONE AND NONOPIATE DRUGS
EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
001645 02-04
THE PARENT CHILD INTERACTIONS OF HYPERACTIVE-CHILDREN AND THEIR
MODIFICATION BY STIMULANT-DRUGS.
002092 02-11
INTERCANNABINOID AND CANNABINOID ETHANOL INTERAQIONS AND
THEIR EFFECTS ON HUMAN PERFORMANCE.
002193 02-12
PSYCHOTHERAPEUTIC-DRUGS: IMPORTANT ADVERSE-REACTIONS AND
INTERACTIONS.
002383 02-15
ENDORPHIN OPIATE INTERAQIONS WITH NEUROENDOCRINE SYSTEMS.
002552 02-17
MOLECULAR AQIONS OF OPIATES: HISTORICAL OVERVIEW AND NEW
FINDINGS ON OPIATE-RECEPTOR INTERAQIONS WITH ENKEPHALINS
AND GUANYL-NUCLEOTIDES.
002613 02-17
RADIOHISTOCHEMICAL STUDIES OF BENZODIAZEPINE AND GABA-
RECEPTORS AND THEIR INTERAQIONS.
002644 03-01
INTERAQIONS OF TRICYCLIC-ANTIDEPRESSANTS WITH A SYNAPTIC ION-
CHANNEL.
002660 03-03
APOMORPHINE HALOPERIDOL INTERACTIONS: DIFFERENT TYPES OF
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS.
002662 03-03
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE
AGONIST AND ANTAGONIST RECEPTOR INTERACTIONS.
002688 03-03
INTERACTIONS OF NARCOTICS WITH SYNAPTOSOMAL CALCIUM
TRANSPORT.
002712 03-03
KAINIC-ACID AND NEUROTRANSMIHER INTERACTIONS IN THE BASAL
GANGLIA.
002824 03-03
INTERACTIONS OF DIAZEPAM AND COCAINE IN THE MORPHINE TREATED
RAT. (PH.D. DISSERTATION).
003115 03-04
LITHIUM DRUG INTERACTIONS ALTERING THE INTRACELLULAR LITHIUM
LEVEL: AN IN VITRO STUDY.
003142 03-06
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES
IN THIS PHASE.
003251 03-09
CLINICAL-PHARMACOLOGY: ADVERSE DRUG INTERACTIONS.
003399 03-13
NEUROLEPTICS: INTERACTIONS WITH FOOD - CHEMICAL AND
PHARMACODYNAMIC STUDIES ON THE INTERACTIONS OF COFFEE AND
TEA.
003612 03-17
INTERACTIONS BETWEEN ALCOHOL AND MEDICATIONS.
003629 03-17
INTERACTIONS BETWEEN A MONOFLUORINATED ANALOGUE OF P
CHLOROAMPHETAMINE AND 5 HYDROXYTRYPTAMINE IN BRAIN.
003719 04-03
INTERACTIONS BETWEEN CHLORPROMAZINE AND SOME OF ITS
METABOLITES.
004001 04-03
MODULATORY INTERACTIONS BETWEEN NOREPINEPHRINE AND TAURINE,
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS.
004058 04-03
THE EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHET AMINE (DOM) ON
OPERANT-BEHAVIOR: INTERACTIONS WITH OTHER NEUROACTIVE-
AGENTS.
004089 04-04
INTERACTIONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
004127 04-04
THE EFFECTS OF NEFOPAM ON BLOOD ACID BASE STATUS IN THE RABBIT:
INTERACTIONS WITH MORPHINE IN THE MOUSE AND RABBIT.
004279 04-05
INTERACTIONS BETWEEN ANTIDEPRESSANTS AND OTHER DRUGS.
004371 04-09
THE EFFECTS OF NEUROLEPTIC-DRUGS ON THE SOCIAL INTERACTIONS OF
HOSPITALIZED PSYCHOTIC-PATIENTS.
004577 04-14
INTERACTIVE-EFFECTS
INTERACTIVE-EFFECTS OF NUTRITION AND CANNABIS UPON RAT
PERINATAL DEVELOPMENT.
000513 01-05
INTERAVENTRICULAR
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN
FOLLOWING INTERAVENTRICULAR INJECTION.
001239 02-03
INTERCANNABINOID
INTERCANNABINOID AND CANNABINOID ETHANOL INTERACTIONS AND
THEIR EFFECTS ON HUMAN PERFORMANCE.
002193 02-12
INTERCONVERTING
INTERCONVERTING MU AND DELTA-FORMS OF TYPE-1 OPIATE-RECEPTORS
IN THE RAT STRIATAL PATCHES.
003737 04-03
INTEROOSE
DOSE SIZE AND INTERDOSE INTERVAL EFFECTS ON MORPHINE-TOLERANCE
IN THE RAT. (PH.D. DISSERTATION).
003090 03-04
INTEREST
THE INTEREST OF THE STIMULATING EFFECT OF CARPIPRAMINE IN
PSYCHOSOMATIC-MEDICINE.
002061 02-10
SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN
PRAZEPAM TREATMENT IN 30 CASES.
003296 03-11
THERAPEUTIC INTEREST OF BLOOD LEVELS DETERMINATION FOR
ANTIDEPRESSANTS: METHODOLOGICAL APPROACH.
003571 03-16
NEUROLEPTIC TRICYCLIC-ANTIDEPRESSANT COMBINATION:
PHARMACOLOGICAL-ASPECTS AND THERAPEUTIC INTEREST.
004501 04-13
M
I
iinllii:
lr,r
S-237
•Ji6SSS6BiS6Sli,-
Subject Index
Psychopharmacology Abstracts
«5:;
I
INTERFACES
INTERFACES OF PSYCHOPHARMACOLOGY AND CARDIOLOGY - PART
TWO.
003529 03-15
INTERFACES OF PSYCHOPHARMACOLOGY AND CARDIOLOGY - PART
ONE.
003530 03-15
INTERFERENCE
POSTINGESTION INTERFERENCE WITH BRAIN FUNQION PREVENTS
AnENTUATION OF NEOPHOBIA IN RATS.
000352 01-04
DRUG INTERFERENCE ON SOME BIOCHEMICAL-PARAMETERS OF RAT-
CEREBRAL-CORTEX DURING POSTISCHEMIC RECOVERY.
001126 02-03
AN INTERFERENCE REDUQION THEORY OF THE EFFEaS OF ETHANOL ON
CONFUa-BEHAVIOR.
001586 02-04
INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY
PREEXPOSURE TO THE UNCONDITIONED-STIMULUS; ASSOCIATIVE-
ASPECTS AND NONASSOCIATIVE-ASPECTS.
001610 02-04
AGE-DEPENDENT MODIFICATION OF DRUG INTERFERENCE ON THE
ENZYMATIC AQIVITIES OF THE RAT-BRAIN.
003730 04-03
INTERICTAL
AQIVATION OF CORTICAL CIRCUITS DURING INTERIQAL SPIKES.
000056 01-03
INTERINDIVIDUAL
INTERINDIVIDUAL VARIATION OF CLINICAL-RESPONSE TO HALOPERIDOL.
001230 02-03
INTERINDIVIDUAL DIFFERENCES IN AMITRIPTYLINE DEMETHYLATION.
002282 02-13
INTERMEDIATE
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM
INTERMEDIATE /POSTERIOR LOBES OF PITUITARY.
003846 04-03
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE
PITUITARY MEMBRANES.
004003 04-03
INTERMEDIATES
ANTICONVULSANT PROPERTIES OF SELEQED PYRROLOPYRIMIDINEDIONES
AND INTERMEDIATES.
003700 04-02
INTERMIHENT
EXTINQION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMITTENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNQIONAL
EQUIVALENCE.
000490 01-04
CORRELATION BETWEEN DAILY FLUQUATIONS OF CARBAMAZEPINE
SERUM LEVELS AND INTERMIHENT SIDE-EFFEQS.
000851 01-15
JNTERMIHENT PIMOZIDE VERSUS FLUPHENAZINE-DECANOATE AS
MAINTENANCE-THERAPY IN CHRONIC SCHIZOPHRENIA.
001932 02-08
INTERMIHENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA,
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE
lOTHALAMATE VENTRICULOGRAM.
003520 03-15
INTERNAL
GLC MASS-SPECTROMETRIC-DETERMINATION OF MAPROTILINE AND ITS
MAJOR METABOLITE USING STABLE ISOTOPE-LABELED ANALOG AS
INTERNAL STANDARD.
004291 04-06
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD
BY USE OF SELECT ION-MONITORING AND DEUTERATED INTERNAL
STANDARDS.
004690 04-16
INTERNEURONES
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT
CAUDATE-NUCLEUS.
001298 02-03
INTERNODAL
THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION
PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR
PRESERVED SCHWANN-CELL SOMAL FUNQION.
002905 03-03
INTEROCEPTIVE
CONDITIONING OF AN INTEROCEPTIVE DRUG STIMULUS TO DIFFERENT
EXTEROCEPTIVE CONTEXTS.
004142 04-04
INTERPERSONAL
EFFEaS OF TRICYCLIC-ANTIDEPRESSANTS ON INTERPERSONAL LEARNING.
003225 03-09
DEPRESSED-OUTPATIENTS: RESULTS ONE YEAR AFTER TREATMENT WITH
DRUGS AND/OR INTERPERSONAL PSYCHOTHERAPY.
003272 03-09
INTERPRETATION
EPILEPTOGENIC PROPERTIES OF ENFLURANE AND THEIR CLINICAL
INTERPRETATION.
004609 04-15
INTERPRETATIONS
THE ANTIDEPRESSANT ACTION OF SULPHO-ADENOSYL-L-METHIONINE
(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE:
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-AQION.
003150 03-07
INTERRELATION
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/AND
OIPHENYLHYDANTOIN IN SERUM LIPIDS.
002281 02-13
INTERRELATIONS
INTERRELATIONS AMONG PRIOR EXPERIENCE AND CURRENT CONDITIONS
IN THE DETERMINATION OF BEHAVIOR AND THE EFFEaS OF DRUGS.
001715 02-04
INTERSTITIAL
THE ROLE OF LITHIUM IN THE PRODUQION OF INTERSTITIAL NEPHRITIS:
A CASE-HISTORY.
004655 04-15
INTERSUBJECT
INTERSUBJEa AND INTRASUBJEQ VARIATION IN DIAZEPAM FREE
FRAQION.
000747 01-13
INTERVAL
DOSE SIZE AND INTERDOSE INTERVAL EFFEQS ON MORPHINE-TOLERANCE
IN THE RAT (PH D DISSERTATION)
003090 03-04
INTERVIEW
DELIRIUM OR PSYCHOSIS? DIAGNOSTIC USE OF THE SODIUM-
AMOBARBITAL INTERVIEW.
002167 02-11
THE TREATMENT OF CHRONIC SCHIZOPHRENIC-PATIENTS: AN INTERVIEW
WITH DR. J. HUSSER.
004328 04-08
INTERVIEWS
ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CUNICAL STAFF
IN DETERMINING MEDICATION COMPLIANCE.
003618 03-17
INTESTINAL
STIMULATION OF RETINAL ADENYLATE-CYCLASE BY VASOAQIVE
INTESTINAL PEPTIDE (VIP).
002811 03-03
INTESTINAL-MUSCLE
PERSISTENT EFFEQS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC-
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS.
001266 02-03
INTESTINE
THE EFFEQ OF MONOAMINE-OXIDASE-INHIBITORS ON FIRST-PASS
METABOLISM OF TYRAMINE IN DOG INTESTINE.
000141 01-03
INTOXICATED
EFFEQS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED
SUBJECTS.
002320 02-14
INTOXICATION
THE PCP PSYCHOSIS: PROLONGED INTOXICATION OR DRUG PRECIPITATED
FUNCTIONAL ILLNESS?
000739 01-12
REVERSAL BY PHENYTOIN OF CARBAMAZEPINE-INDUCED WATER
INTOXICATION: A PHARMACOKINETIC-INTERACTION.
000783 01-13
APPLICATION OF A RADIOIMMUNOASSAY SCREENING-TEST FOR
DETECTION AND MANAGEMENT OF PHENaCLIDINE INTOXICATION.
000859 01-15
INTOXICATION ASSOCIATED WITH LITHIUM AND ECT.
000870 01-15
CARBAMAZEPINE INTOXICATION DUE TO TRIACETYLOLEANDOMYCIN
ADMINISTRATION IN EPILEPTIC-PATIENTS.
000873 01-15
VOLUNTARY INTOXICATION FROM PHENCYCLIDINE. Wia IT RAISE A
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL-
STATE?.
000914 01-17
INFLUENCE OF CHRONIC ALCOHOL INTOXICATION ON CIRCADIAN-RHYTHM
OF NEUROSECRETORY CENTERS OF RAT HYPOTHALAMUS.
001549 02-03
BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFECTS OF CHRONIC
AMPHETAMINE INTOXICATION.
001653 02-04
CONTRIBUTIONS OF INDIVIDUAL DIFFERENCES TO SUBJECTIVE
INTOXICATION.
002202 02-12
S-238
VOLUME 19, SUBJECT INDEX
Subject Index
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE
INTOXICATION.
002210 02-13
ANTECEDENTS OF SELF-INDUCED WATER INTOXICATION: A PRELIMINARY-
REPORT
002414 02-15
BRADYCARDIA, PERSISTENT DIABETES-INSIPIDUS, AND TARDIVE-
DYSKINESIA WITH LITHIUM INTOXICATION,
002427 02-15
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE
INTOXICATION.
002988 03-04
PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALLIUM, ARSENIC,
INDUSTRIAL-SOLVENT INTOXICATION, AND OTHER
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT.
003348 03-11
PHENCYCLIDINE (PCP) INTOXICATION: DIAGNOSIS IN STAGES AND
ALGORITHMS OF TREATMENT.
003525 03-15
PERIPHERAL NEUROPATHY DUE TO LITHIUM INTOXICATION.
003544 03-15
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION.
004273 04-05
ACUTE PHENCYCLIDINE (PCP) INTOXICATION: QUANTITATIVE URINE
LEVELS AND CLINICAL MANAGEMENT.
004665 04-15
INTRAARTERIAL
ACCIDENTAL INTRAARTERIAL INJECTION OF DIAZEPAM.
002598 02-17
INTRAAXONAL
THE EFFECT OF CHRONIC NICOTINE AND WITHDRAWAL ON INTRAAXONAL
TRANSPORT OF ACETYLCHOLINE AND RELATED ENZYMES IN SCIATIC-
NERVE OF THE RAT.
•003897 04-03
INTRACELLULAR
AN INTRACELLULAR OPIATE-RECEPTOR.
000278 01-03
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
INTRACELLULAR OBSERVATIONS ON THE EFFECTS OF MUSCARINIC
AGONISTS ON RAT SYMPATHETIC NEURONES.
001143 02-03
PERSISTENT EFFECTS OF CHRONIC ADMINISTRATION OF LSD ON
INTRACELLULAR SEROTONIN CONTENT IN RAT-MIDBRAIN.
001333 02-03
THE IN VITRO BRAIN SLICE AS A USEFUL NEUROPHYSIOLOGICAL
PREPARATION FOR INTRACELLULAR RECORDING.
001864 02-06
LITHIUM DRUG INTERAQIONS ALTERING THE INTRACELLULAR LITHIUM
LEVEL: AN IN VITRO STUDY.
003142 03-06
INTRACELLULAR LITHIUM: ITS VALUE IN THE PREDICTION OF A POSITIVE
RESPONSE TO LITHIUM.
003382 03-11
INTRACEREBRAL
DRUG-INDUCED ELEVATION OF GABA AFTER INTRACEREBRAL
MICROINJECTION: SITE OF ANTICONVULSANT ACTION.
001627 02-04
DIFFERENT BEHAVIORAL-EFFECTS FOLLOWING INTRACEREBRAL,
INTRACEREBROVENTRICULAR OR INTRAPERITONEAL INJECTION OF
NALOXONE IN THE RAT.
001665 02-04
ANALGESIC AQION OF INTRATHECAL AND INTRACEREBRAL BETA
ENDORPHIN IN RATS: COMPARISON WITH MORPHINE.
001691 02-04
STEREOTYPED-BEHAVIOUR AND ELECTROCORTICAL-CHANGES AFTER
INTRACEREBRAL MICROINFUSION OF DOPAMINE AND APOMORPHINE
IN FOWLS.
001734 02-04
USE OF THE INTRACEREBRAL INJEQION TECHNIQUE TO ELUCIDATE
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN
THE MOUSE.
004092 04-04
INTRACEREBRAL SUBSTANCE-P IN MICE: BEHAVIORAL-EFFECTS AND
NARCOTIC-AGENTS.
004218 04-04
INTRACEREBRAllY
EFFECTS OF NOMIFENSINE AND DESIPRAMINE ON THE SEQUELAE OF
INTRACEREBRALLY INJEQED 6 OHDA AND 5,6 DHT.
001522 02-03
INTRACEREBROVENTRICULAR
THE EFFEQ OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN
MICE.
001435 02-03
DIFFERENT BEHAVIORAL-EFFECTS FOLLOWING INTRACEREBRAL,
INTRACEREBROVENTRICULAR OR INTRAPERITONEAL INJECTION OF
NALOXONE IN THE RAT.
001665 02-04
OPERANT FEEDING AND DRINKING IN PIGS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF SYNTHETIC
CHOLECYSTOKININ-OCTAPEPTIDE.
003064 03-04
CATECHOLAMINE AND 5 HYDROXYTRYPTAMINE SYNTHESIS AND
METABOLISM FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF
DIBUTYRYL-CYCLIC-AMP.
003769 04-03
SUSTAINED INTRACEREBROVENTRICULAR INFUSION OF BRAIN FUELS
REDUCES BODY-WEIGHT AND FOOD INTAKE IN RATS.
004098 04-04
INTRACEREBROVENTRICULARLY
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME ACTIVITY
IN THE RAT-BRAIN.
001614 02-04
THE ANTINOCICEPTIVE-EFFECT OF INTRACEREBROVENTRICULARLY
ADMINISTERED PROSTAGLANDIN-El IN THE RAT.
001769 02-04
INTRACORTICAL
ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA:
REVERSAL BY MICROIONTOPHORETIC BICUCULLINE.
002684 03-03
INTRACRANIAL
INTRACRANIAL INJECTION PARAMETERS WHICH AFFEQ ANGIOTENSIN-II-
INDUCED DRINKING.
000534 01-06
CLONIDINE ON THE PRESSOR RESPONSE TO RAISED INTRACRANIAL
PRESSURE.
001316 02-03
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJECTION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS.
001446 02-03
EFFECTS OF AN ACTH4-9 RELATED PEPTIDE UPON INTRACRANIAL SELF-
STIMULATION AND GENERAL-ACTIVITY IN THE RAT.
001679 02-04
ELECTROLYTIC MICROINFUSION TRANSDUCER SYSTEM: AN ALTERNATIVE
METHOD OF INTRACRANIAL DRUG APPLICATION.
001861 02-06
INTRACRANIAL SELF-ADMINISTRATION OF MORPHINE INTO THE VENTRAL
TEGMENTAL AREA IN RATS.
002960 03-04
PHARMACOLOGICAL CHARAQERIZATION OF SCRATCHING-BEHAVIOUR
INDUCED BY INTRACRANIAL INJECTION OF SUBSTANCE-P AND
SOMATOSTATIN.
002980 03-04
CONFLia-SITUATION BASED ON INTRACRANIAL SELF-STIMULATION
BEHAVIOR AND THE EFFECT OF BENZODIAZEPINES.
003004 03-04
INTRACRANIAL-STIMULATION
ADDICTIVE-AGENTS AND INTRACRANIAL-STIMULATION (ICS): MORPHINE,
NALOXONE, AND PRESSING FOR AMYGDALOID ICS.
000371 01-04
INTRACRANIALLY
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMIHER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
INTRAHYPOTHALAMIC
INTRAHYPOTHALAMIC MICROINJECTIONS OF NORADRENALINE WITH AND
WITHOUT INDUCTION OF THE ALIMENTARY DRIVE AS A REWARD IN A
T-MAZE LEARNING IN RATS.
001604 02-04
PRESSOR EFFECTS OF DORSAL RAPHE STIMULATION AND
INTRAHYPOTHALAMIC APPLICATION OF SEROTONIN IN THE
SPONTANEOUSLY HYPERTENSIVE-RAT.
003117 03-04
INTRAMUSCULAR
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY: EFFICACY, DOSAGE SCHEDULE AND PLASMA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
ABSCESSES FOLLOWING PROLONGED INTRAMUSCULAR ADMINISTRATION
OF PERPHENAZINE-ENANTATE.
000888 01-15
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION
AND EFFEaS OF D-AMPHETAMINE AND PROMAZINE.
004152 04-04
m
liihliiJ
I
•uiiB
iKilii:
««'
ii.'i;.
Ic*
S-239
JsBBaab^k
Subiect Index
Ptychopharmacology Abstracts
ISli.
INTRAMUSCULARLY
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY. „„„„„„„, ,r
000890 01-15
INTRANEURONAL
THE ROLE OF INTRANEURONAL 5 NT AND OF TRYPTOPHAN-
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM.
000123 01-03
IN VIVO INTRANEURONAL MAO-INHIBITION IN RAT-BRAIN SKF-64139,
COMPARISON TO OTHER POTENT PNMT INHIBITORS.
003935 04-03
INTRANIGRAL
CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL INJECTION OF
BACLOFEN IN RATS. „„„.,.„,„.
000415 01-04
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS
AND ANTAGONISTS. ZONE-SPECIFIC EFFECTS.
000422 01-04
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT.
001657 02-04
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN
RATS
001669 02-04
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF TAURINE IN RATS. ^ ,„„.„,
001670 02-04
INTRANIGRAL INJECTION OF CAPSAICIN ENHANCES MOTOR-ACTIVITY
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE BUT NOT SUBSTANCE-
''■ 004100 04-04
INVOLVEMENT OF DOPAMINE IN CIRCLING RESPONSES TO MUSCIMOL
DEPENDS ON INTRANIGRAL SITE OF INJECTION.
004158 04-04
INTRAOCULAR
INTRAOCULAR PRESSURE CHANGES FOLLOWING MODIFIED ECT.
003536 03-15
CHANGES OF ELECTRORETINOGRAM AND NEUROCHEMICAL ASPECTS OF
GABAERGIC NEURONS OF RETINA AFTER INTRAOCULAR INJECTION OF
KAINIC-ACID IN RATS.
003807 04-03
INTRAPALLIDAL
EFFEQS OF INTRAPALLIDAL OPIATE-RECEPTOR AGONISTS ON
STRIATALLY-EVOKED HEAD-TURNING.
001785 02-04
INTRAPERITONEAL
ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND
EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL
AND INTRODUODENAL ADMINISTRATION
000094 01-03
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJECTION.
000261 01-03
DIFFERENT BEHAVIORAL-EFFEaS FOLLOWING INTRACEREBRAL,
INTRACEREBROVENTRICULAR OR INTRAPERITONEAL INJECTION OF
NALOXONE IN THE RAT.
001665 02-04
THE EFFECT OF ELECTRICAL-STIMULATION OF THE LOCUS-COERULEUS AND
INTRAPERITONEAL INJECTION OF CERTAIN PHARMACOLOGICAL
SUBSTANCES ON THE THRESHOLD OF HIPPOCAMPAL
AFTERDISCHARGES.
003885 04-03
INTRASEPTAL
THE EFFECT OF DIAZEPAM ON EEG CHANGES FOLLOWING INTRASEPTAL
ADMINISTRATION OF ATROPINE.
000127 01-03
INTRASPECIFIC
AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE
ANALYSIS OF APOMORPHINE-INDUCED-FIGHTING AND STEREOTYPY IN
THE RAT.
002983 03-04
INTRASTRIATAL
CORTICAL NEUROCHEMICAL CHANGES AFTER INTRASTRIATAL INJECTION
OF KAINIC-ACID.
000133 01-03
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND
GABAMIMETICS.
000188 01-03
BEHAVIORAL-EFFEaS AND ELECTROCORTICAL-EFFECTS AFTER
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS
ENHANCING GABAERGIC TRANSMISSION.
000443 01-04
LOCAL AND DISTANT NEURONAL DEGENERATION FOLLOWING
INTRASTRIATAL INJECTION OF KAINIC-ACID.
001885 02-06
INTRASUBJECT
INTERSUBJECT AND INTRASUBJEQ VARIATION IN DIAZEPAM FREE
FRACTION.
000747 01-13
INTRATHECAL
HYPOALGESIA INDUCED BY MICROINJECTION OF A NOREPINEPHRINE
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL
ADMINISTRATION OF A SEROTONIN ANTAGONIST.
000121 01-03
ANALGESIC ACTION OF INTRATHECAL AND INTRACEREBRAL BETA
ENDORPHIN IN RATS: COMPARISON WITH MORPHINE.
001691 02-04
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST,
CHLORNALTREXAMINE
001695 02-04
INTRATHECAL MORPHINE IN MICE: A NEW TECHNIQUE.
001868 02-06
A REEVALUATION OF THE NEUROCHEMICAL-EFFEaS AND
ANTINOCICEPTIVE-EFFEQS OF INTRATHECAL CAPSAICIN IN THE RAT
004184 04-04
INTRATHECAL HIGH-DOSE MORPHINE PRODUCES HYPERALGESIA IN THE
RAT.
004254 04-04
INTRATUMORAL
DOSAGE OF INTRATUMORAL LITHIUM (CEREBRAL GLIOBLASTOMA): ON A
FAILURE OF TREATMENT OF MANIC-DEPRESSIVE-PSYCHOSIS.
003226 03-09
INTRAVENOUS
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND
GABAMIMETICS.
000188 01-03
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF
AlO DOPAMINERGIC NEURONS.
000320 01-03
ANTIDEPRESSANT TREATMENT BY INTRAVENOUS ADMINISTRATION
COMPARED TO PERORAL ADMINISTRATION: A DOUBLE-BUND STUDY
OF QUINUPRAMINE.
000552 01-08
STUDY OF INTRAVENOUS AMITRIPTYLINE IN ACUTE DEPRESSIONS.
000581 01-09
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF
ELECTROENCEPHALOGRAPHY WITH INTRAVENOUS DIAZEPAM IN
EPILEPSY.
000696 01-11
INTRAVENOUS PHENOBARBITAL THERAPY IN BARBITURATE AND OTHER
HYPNOSEDATIVE WITHDRAWAL REAQIONS: A KINETIC APPROACH
000703 01-11
VESTIBULO-OCULAR REFLEXES IN RABBITS: REDUQION BY INTRAVENOUS
INJECTION OF DIAZEPAM.
001566 02-04
INFLUENCE OF INTRAVENOUS SELF-ADMINISTERED PSYCHOMOTOR
STIMULANTS ON PERFORMANCE OF RHESUS-MONKEYS IN A MULTIPLE-
SCHEDULE PARADIGM
001655 02-04
INTRAVENOUS SELF-ADMINISTRATION OF COCAINE AND NORCOCAINE BY
DOGS.
001760 02-04
BEHAVIOR MAINTAINED BY INTRAVENOUS INJEQION OF CODEINE,
COCAINE AND ETORPHINE IN THE RHESUS-MACAQUE AND THE
PIGTAIL-MACAQUE. „^
001828 02-04
PLASMA DELTA9 TETRAHYDROCANNABINOL CONCENTRATIONS AND
CLINICAL-EFFEQS AFTER ORAL AND INTRAVENOUS ADMINISTRATION
AND SMOKING
002201 02-12
INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS
002341 02-14
AN EVALUATION OF MAPROTILINE INTRAVENOUS KINETICS AND
COMPARISON OF TWO ORAL DOSES.
002497 02-16
SORPTION OF CHLORMETHIAZOLE BY INTRAVENOUS INFUSION GIVING
^^^^ 002508 02-16
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS
ADMINISTRATIONS.
002797 03-03
SMALL-DOSE INTRAVENOUS HEROIN FACILITATES HYPOTHALAMIC SELF-
STIMULATION WITHOUT RESPONSE SUPPRESSION IN RATS.
002999 03-04
S-240
/OLUME 19, SUBJECT INDEX
Subject Index
ANTAGONISM OF INTRAVENOUS COCAINE LETHALITY IN NONHUMAN
PRIMATES.
003127 03-05
INTRAVENOUS QUINIDINE IN CONGESTIVE CARDIOMYOPATHY.
003352 03-11
INTRAVENOUS VALPROATE: EFFECTS ON PLASMA AND SALIVA
PHENYTOIN LEVELS.
003359 03-11
INTRAVENOUS LORAZtPAM TO PREVENT NAUSEA AND VOMITING
ASSOCIATED WITH CANCER CHEMOTHERAPY.
003614 03-17
EFFECT OF INTRAVENOUS ADMINISTRATION OF D LYSERGIC-ACID-
DIETHYLAMIDE ON SUBSEQUENT PROTEIN SYNTHESIS IN A CELL-FREE
SYSTEM DERIVED FROM BRAIN.
003761 04-03
COMPARISON OF THE EFFECT OF INTRAVENOUS ADMINISTRATION OF D
LYSERGIC-ACID-DIETHYLAMIDE ON FREE AND MEMBRANE-BOUND
POLYSOMES IN THE RABBIT BRAIN.
003831 04-03
A COMPARATIVE-STUDY OF INTRAVENOUS LORAZEPAM AND
CLONAZEPAM IN STATUS-EPILEPTICUS.
004487 04-11
INTRAVENOUS DIAZEPAM AND ORAL ETHANOL INTERACTION.
004552 04-13
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN.
004638 04-15
NTRAVENTRICULAR
EFFECT OF INTRAVENTRICULAR INJECTIONS OF ALPHA AMINOSULFONIC-
ACIDS ON THE CENTRAL-NERVOUS-SYSTEM OF CONSCIOUS MICE.
000009 01-02
GABA DEPLETION AND BEHAVIOURAL-CHANGES PRODUCED BY
INTRAVENTRICULAR PUTRESCINE IN CHICKS.
000218 01-03
EFFECTS OF SYSTEMIC AND INTRAVENTRICULAR ADMINISTRATION OF
CANNABINOIDS ON SCHEDULE-CONTROLLED RESPONDING IN THE
SQUIRREL-MONKEY.
000354 01-04
SYSTEMIC AND INTRAVENTRICULAR PROLACTIN INDUCES EXCESSIVE
GROOMING.
000378 01-04
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY: NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNCTION.
000448 01-04
THE EFFECTS OF INTRAVENTRICULAR 6 HYDROXYDOPAMINE AND 5,6
DIHYDROXYTRYPTAMINE ON MORPHINE-INDUCED LOCOMOTOR-
STIMULATION.
001784 02-04
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR
INJECTION OF CEFAZOLIN.
002762 03-03
EXPLORATION AND MOTOR-ACTIVITY AFTER INTRAVENTRICULAR ACTH,
MORPHINE AND NALOXONE.
002991 03-04
INTRAVENTRICULAR CORTICOSTERONE INJECTION FACILITATES MEMORY
OF AN APPETITIVE DISCRIMINATIVE TASK IN MICE.
003051 03-04
INTRAVENTRICULAR CHOLECYSTOKININ-OCTAPEPTIDE PRODUCES
HYPERGLYCEMIA IN RATS.
003943 04-03
ANALGESIA FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF 2
DEOXY-D-GLUCOSE.
004074 04-04
INTRAVENTRICULARLY
CENTRAL-ACTION OF INTRAVENTRICULARLY INJECTED MIDODRINE IN
RATS.
001684 02-04
INTRINSIC
INTRINSIC CHOLINERGIC EXCITATION IN THE RAT NEOSTRIATUM:
NICOTINIC AND MUSCARINIC-RECEPTORS.
001374 02-03
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS.
001516 02-03
INTRODUOOENAL
ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND
EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL
AND INTRODUOOENAL ADMINISTRATION.
000094 01-03
INTROVERSION
INTROVERSION AND SEVERITY OF THE BENZODIAZEPINE WITHDRAWAL.
000923 01-17
INTRUDER
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: III. SOCIAL-INTERACTIONS
BETWEEN TWO RESIDENTS AND AN INTRUDER MALE.
001776 02-04
INVERSE
AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF
DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREACTIVITY
IN DMI RESPONSIVE DEPRESSIVES
003228 03-09
INVESTIGATE
THE USE OF EXTINCTION TO INVESTIGATE THE NATURE OF NEUROLEPTIC-
INDUCED AVOIDANCE-DEFICITS
000345 01-04
A RESEARCH PARADIGM TO INVESTIGATE THE EFFECT OF MANIPULATION
ON SOCIAL-BEHAVIOR IN GROUPS.
003007 03-04
INVESTIGATING
AN IN VIVO MODEL FOR INVESTIGATING ALPHA 1 -RECEPTORS AND
ALPHA2-RECEPT0RS IN THE CNS: STUDIES WITH MIANSERIN.
000053 01-03
INVESTIGATORY
MESOLIMBICOCORTICAL DOPAMINE TERMINAL-FIELDS ARE NECESSARY
FOR NORMAL LOCOMOTOR AND INVESTIGATORY EXPLORATION IN
RATS.
000383 01-04
EFFECTS OF SEROTONERGIC LESIONS ON INVESTIGATORY RESPONDING BY
RATS IN A HOLEBOARD.
001634 02-04
INVOLUNTARY-MOVEMENTS
THE EFFECTS OF CHOLINERGIC-DRUGS ON THE INVOLUNTARY-
MOVEMENTS OF TARDIVE-DYSKINESIA.
000726 01-11
PREVALENCE OF PERSISTENT ABNORMAL INVOLUNTARY-MOVEMENTS
AMONG PATIENTS IN A NIGERIAN LONG-STAY PSYCHIATRIC UNIT.
004334 04-08
INVOLUNTARY-PATIENTS
THE RIGHTS OF INVOLUNTARY-PATIENTS TO REFUSE
PHARMACOTHERAPY: WHAT IS REASONABLE?
004730 04-17
INVOLUTIONAL
THE NOSOLOGICAL INDEPENDENCE OF INVOLUTIONAL DEPRESSION AND
ITS DYNAMICS DURING PSYCHOPHARMACOTHERAPY.
004389 04-09
ION-CHANNEL
INTERACTIONS OF TRICYCLIC-ANTIDEPRESSANTS WITH A SYNAPTIC ION-
CHANNEL.
002660 03-03
ION-CHANNELS
(-)PENTOBARBITAL OPENS ION-CHANNELS OF LONG-DURATION IN
CULTURED MOUSE SPINAL NEURONS.
000198 01-03
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO
GABA REGULATED CHLORIDE ION-CHANNELS.
002848 03-03
ION-CONDUCTANCE
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH
ANTICONVULSANT AND ANESTHETIC ACTIONS.
002885 03-03
ION-MONITORING
A SELECTED ION-MONITORING ASSAY FOR BIOGENIC-AMINE
METABOLITES AND PROBENECID, IN HUMAN LUMBAR
CEREBROSPINAL-FLUID.
003663 04-01
A QUANTITATIVE PROBE FOR BIOLOGICAL-PSYCHIATRY: SELECTED ION-
MONITORING.
004685 04-16
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD
BY USE OF SELECT ION-MONITORING AND DEUTERATED INTERNAL
STANDARDS.
004690 04-16
ION-TRANSFER
THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH
DEPRESSIVE-SYNDROMES.
000625 01-09
IONIZATION
THE IONIZATION OF 5 HYDROXYTRYPTAMINE AND RELATED
COMPOUNDS AND AN APPRAISAL OF METHODS FOR THE ESTIMATION
OF ZWITTERION CONSTANTS.
001859 02-06
lONOPHORE
ETHANOL ENHANCES (3H)DIAZEPAM BINDING AT THE BENZODIAZEPINE
GABA-RECEPTOR lONOPHORE COMPLEX.
001154 02-03
lONOPHORE-RECEPTOR
THE BENZODIAZEPINE GABA-CHLORIDE lONOPHORE-RECEPTOR COMPLEX:
COMMON SITE OF MINOR-TRANQUILIZER ACTION.
002857 03-03
I
iMiii:
iiJii'
v..
S-241
Subject Index
Psychopharmacology Abstracts
lONOPHORES
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME
BENZODIAZEPINE RECOGNITION SITES ARE COUPLED TO GABA-
RECEPTORS AND lONOPHORES.
ir-'
Mi
I
lONOPHORESIS
lONOPHORESIS -- PROGRESS AND PITFALLS.
IONTOPHORESIS
QUANTIFICATION OF NORADRENALINE IONTOPHORESIS.
IONTOPHORESIS OF KAINIC-ACID.
lONTOPHORETIC
THE PHYSICS OF lONTOPHORETIC PIPEHES.
001484 02-03
003144 03-06
002475 02-16
004294 04-06
004299 04-06
lONTOPHORETICALLY
MODULATORY INTERAQIONS BETWEEN NOREPINEPHRINE AND TAURINE,
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS.
004058 04-03
lOTHALAMATE
INTERMIHENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA,
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE
lOTHALAMATE VENTRICULOGRAM.
003520 03-15
IP
MOTOR-DEPRESSION AND HEAD-TWITCHES INDUCED BY IP INJECTION OF
GABA.
001788 02-04
IPRINDOLE
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFECT
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE.
001353 02-03
IPRONIAZID
THE EFFECTS OF RESERPINE, IPRONIAZID AND L-DOPA ON ELECTRICALLY-
INDUCED SPINAL-CORD SEIZURES.
000146 01-03
IPTBO
MODULATION BY PICROTOXIN AND IPTBO OF 3H FLUNITRAZEPAM
BINDING TO THE GABA/BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-
CEREBELLUM.
002775 03-03
IRAZEPINE
IN VIVO EFFEaS OF TWO NOVEL ALKYLATING BENZODIAZEPINE,
IRAZEPINE AND KENAZEPINE,
004251 04-04
IRIS
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRAaiONS.
000299 01-03
OPIATE-RECEPTORS IN THE RABBIT IRIS.
001200 02-03
IRON
SEX-DIFFERENCE IN BRAIN IRON. (UNPUBLISHED PAPER).
001278 02-03
TOXICITY OF OXYGEN IN IRON RICH AREAS OF RAT-BRAIN.
(UNPUBLISHED PAPER).
001498 02-03
IRON-INDUCED
ANTIPEROXIDANT PRETREATMENT AND IRON-INDUCED EPILEPTIFORM
DISCHARGES IN THE RAT: EEG AND HISTOPATHOLOGIC STUDIES.
002930 03-03
IRREVERSIBLE
EVIDENCE FOR AN IRREVERSIBLE INTERAQION OF BROMOCRYPTINE
WITH CENTRAL DOPAMINE-RECEPTORS.
QQQQ23 01-03
IRREVERSIBLE INHIBITION OF AROMATIC-L-AMINO-ACID-DECARBOXYLASE
BY ALPHA DIFLUOROMETHYL-DOPA AND METABOLISM OF THE
INHIBITOR.
000248 01-03
IRREVERSIBLE INHIBITION OF S ADENOSYLHOMOCYSTEINE-HYDROLASE BY
NUCLEOSIDE ANALOGS. (UNPUBLISHED PAPER).
001010 02-01
GABA AGONISTS AND UPTAKE INHIBITORS DESIGNED AS AGENTS WITH
IRREVERSIBLE ACTIONS.
001079 02-02
PATHOPHYSIOLOGICAL-ASPEaS OF REVERSIBLE AND IRREVERSIBLE
TARDIVE-DYSKINESIA.
002124 02-11
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS.
003068 03-04
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE:
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION.
003458 03-14
ISATINS
SYNTHESIS OF POTENTIAL ANTICONVULSANTS: CONDENSATION OF
ISATINS WITH ACETONE AND RELATED KETONES.
003699 04-02
ISCHEMIA
IMPROVEMENT OF RESTITUTION FROM CEREBRAL ISCHEMIA IN
HYPERGLYCEMIC RATS BY PENTOBARBITAL OR DIAZEPAM.
000475 01-04
ISCHEMIC
PROTEQIVE EFFEQ OF PRENYLAMINE AGAINST VULNERABILITY TO
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE
MYOCARDIUM.
000265 01-03
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
OEXAMETHASONE TREATMENT
000321 01-03
THE EFFEQS OF THIORIDAZINE ON ELEQRICAL AND ISCHEMIC
VENTRICULAR FIBRILLATION IN THE DOG HEART IN SITU.
002697 03-03
ISF-2522
CNS EFFEQS OF ISF-2522, A NEW NOOTROPIC (A PHASE I SAFETY AND
CNS EFFICACY STUDY WITH QUANTITATIVE PHARMACOEEG AND
PHARMACOPSYCHOLOGY).
004519 04-13
ISOCARBOXAZIDE
LONG-TERM-TREATMENT OF DEPRESSION WITH ISOCARBOXAZIDE.
00201 1 02-09
ISOENZYMES
COMPARISON OF CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE (CSD)
ISOENZYMES AND GLUTAMIC-ACIO-DECARBOXYLASE (GAD) IN RAT: IS
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH
GAD? (UNPUBLISHED PAPER).
001048 02-01
ISOFLOXYTHEPIN
THE EFFEQ OF A NEW FLUORINATED TRICYCLIC NEUROLEPTIC-DRUG
ISOFLOXYTHEPIN ON THE RAT STRIATAL DOPAMINE METABOLISM.
000306 01-03
KINETICS OF CENTRAL-AQIONS OF ISOFLOXYTHEPIN, AN ORAL
NEUROLEPTIC-DRUG WITH PROLONGED AQION IN RODENTS.
001720 02-04
ISOLATED
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. III. DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES.
000025 01-03
INFLUENCE OF CEUULAR-TRANSPORT ON THE INTERAQION OF AMINO-
ACIOS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG.
000034 01-03
IMIPRAMINE AFFECTS AUTONOMIC-CONTROL OF SINOATRIAL RATE IN
ISOLATED RIGHT ATRIAL PREPARATIONS.
000195 01-03
1-M CHLOROPHENYLPIPERAZINE: A METABOLITE OF TRAZODONE
ISOLATED FROM RAT URINE.
000204 01-03
REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE-
NUCLEOTIDES AND ADENOSINE.
000210 01-03
METABOLISM OF 3H NORADRENALINE RELEASED FROM ISOLATED RAT
HYPOTHALAMUS BY EXTRACTS OF BLACK-WIDOW-SPIDER GLANDS.
000223 01-03
EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT
LUNG.
000524 01-05
ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED
PAPER).
001014 02-01
ACUTE AND CHRONIC EFFECTS OF MORPHINE ON TRANSMEMBRANE
POTENTIAL AND ON SHORT-CIRCUIT CURRENT IN ISOLATED TOAD
SKIN: APPARENT MORPHINE-DEPENDENCE.
001176 02-03
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE
TREATED DOGS.
001273 02-03
EFFECTS OF AMITRIPTYLINE AND CLOMIPRAMINE IN THE ISOLATED,
PERFUSED RABBIT HEART.
001852 02-05
S-242
VOLUME 19, SUBJECT INDEX
Subject Index
MEASUREMENT OF THE MEMBRANE POTENTIAL OF ISOLATED NERVE
TERMINALS BY THE LIPOPHILIC CATION
(3H)TRIPHENYLMETHYLPH0SPH0NIUM-BR0MIDE.
002746 03-03
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE
AND CROSS-TOLERANCE TO THE INHIBITORY ACTION OF BETA
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS
002756 03-03
THE EFFECT OF MONOAMINES ON MOTONEURONS OF THE ISOLATED RAT
SPINAL-CORD.
002790 03-03
EFFEQS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L
TRYPTOPHAN BY ISOLATED RAT LIVER CELLS.
002899 03-03
CHARACTERIZATION OF THE ISOLATED PERFUSED MOUSE-BRAIN AS A
SYSTEM FOR NEUROCHEMICAL-STUDIES.
003146 03-06
SYNTHESIS OF CYTOSKELETAL PROTEINS IN BULK ISOLATED NEURONAL
PERIKARYA.
003672 04-01
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT.
003734 04-03
PREJUNCTIONAL ACTIONS OF PIRIBEDIL ON THE ISOLATED KIDNEY OF THE
RABBIT: COMPARISON WITH APOMORPHINE.
003749 04-03
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: KINETIC STUDIES.
003814 04-03
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: PHARMACOLOGICAL-STUDIES.
003815 04-03
ACCUMULATION OF AMANTADINE BY ISOLATED CHROMAFFIN
GRANULES.
003866 04-03
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA-
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL
UPTAKE.
003879 04-03
THE EFFEQ OF ACETYLCHOLINE RELEASE ON CHOLINE FLUXES IN
ISOLATED SYNAPTIC TERMINALS.
003924 04-03
COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRAQ OF THE GUINEA-PIG AND RAT.
003928 04-03
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT
KIDNEY.
004054 04-03
POTENTIATION OF THE EFFECTS OF ADENOSINE ON ISOLATED CARDIAC-
MUSCLE AND SMOOTH-MUSCLE BY DIAZEPAM.
004266 04-05
ISOLATION
INCREASED DOPAMINE-RECEPTOR BINDING IN THE STRIATUM OF RATS
AFTER LONG-TERM ISOLATION.
000398 01-04
DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION, AND REGULATION
001011 02-01
ISOLATION OF PSYCHOAQIVE CANNABINOID PRECURSORS FROM
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI
001023 02-01
ISOLATION OF SELEQIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE.
001162 02-03
ISOLATION INCREASES THE RESPONSES TO BETA-ADRENERGIC
STIMULATION IN MICE.
001232 02-03
BENZODIAZEPINE-RECEPTOR: LOCALIZATION BY PHOTOAFFINITY
LABELING AND ISOLATION OF A POSSIBLE ENDOGENOUS LIGAND
00138102-03
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
x,,n^„ 002657 03-03
THE DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION AND REGULATION
003660 04-01
ISOLATION-INDUCED
EFFEaS OF SODIUM-DIPROPYLACETATE, MUSCIMOL-HYDROBROMIDE
AND (R,S) NIPECOTIC-ACID-AMIDE ON ISOLATION-INDUCED
AGGRESSIVE-BEHAVIOR IN MICE.
,, „^ 001756 02-04
SUBCHRONIC-TREATMENT WITH THE TRICYCLIC-ANTIDEPRESSANT DMI
INCREASES ISOLATION-INDUCED FIGHTING IN RATS.
004252 04-04
ISOLE
SPECIFIC AND NONSPECIFIC MULTIPLE UNIT ACTIVITIES DURING
PENTYLENETETRAZOL SEIZURES. I. ANIMALS WITH ENCEPHALE ISOLE.
004046 04-03
ISOMER
POSSIBLE MECHANISMS OF EFFECT OF ACTH4-10 AND ITS ANALOG
CONTAINING D ISOMER OF PHENYLALANINE, ON BEHAVIOR.
002949 03-04
ISOMERIZATION
ISOMERIZATION OF THE MUSCARINIC-RECEPTOR ANTAGONIST COMPLEX.
003860 04-03
ISOMERS
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
MIDBRAIN DOPAMINE NEURONS: DIFFERENTIAL RESPONSES TO
AMPHETAMINE ISOMERS.
002680 03-03
RELATIVE POTENCY OF AMPHETAMINE ISOMERS IN CAUSING THE
SEROTONIN BEHAVIORAL-SYNDROME IN RATS.
003094 03-04
THE EFFECT OF PROPRANOLOL AND ITS ISOMERS ON PURKINJE
NEURONES IN RAT CEREBELLUM,
004059 04-03
ISOPRENALIN
SPONTANEOUS MOTOR-ACTIVITY IN RATS GIVEN REPEATEDLY BETA-
SYMPATHOMIMETICS - ISOPRENALIN AND SALBUTAMOL.
001804 02-04
iSOPRENALINE
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF
CATS.
000520 01-05
ISOPRENALINE-INDUCED
EVIDENCE THAT VASOPRESSIN IS INVOLVED IN THE ISOPRENALINE-
INDUCED BETA ENDORPHIN RELEASE.
001319 02-03
ISOPRINOSINE
ISOPRINOSINE IN SUBACUTE SCLEROSING PANENCEPHALITIS.
000687 01-11
ISOPROPYLBICYCLOPHOSPHATE
REPEATED ELECTROCONVULSIVE-SHOCK DOES NOT INCREASE THE
SUSCEPTIBILITY OF RATS TO A CAGE CONVULSANT
(ISOPROPYLBICYCLOPHOSPHATE) .
001184 02-03
ISOPROTERENOL
EFFECT OF ISOPROTERENOL ON CEREBRAL CIRCULATION IN DOGS.
000199 01-03
THE REGULATION OF CARDIAC MUSCARINIC CHOLINERGIC-RECEPTORS BY
ISOPROTERENOL.
001441 02-03
DESENSITIZATION OF ADRENOCEPTORS AFTER IMMOBILIZATION STRESS
OR REPEATED INJECTION OF ISOPROTERENOL IN RATS. (UNPUBLISHED
PAPER).
001546 02-03
EFFECTS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA-
ADRENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES.
002932 03-03
ISOPROTERENOL-INDUCED
DOXEPIN, A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTACT
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL-
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION.
003836 04-03
ISOSORBIDE-DINITRATE
AVAILABILITY OF ISOSORBIDE-DINITRATE, DIAZEPAM AND
CHLORMETHIAZOLE, FROM I.V. DELIVERY SYSTEMS.
003558 03-16
ISOSTERES
MECHANISMS OF CHLORPROMAZINE AND CHLORPROMAZINE ISOSTERES
ON THE GLYCEMIC-RESPONSE IN MICE. (PH.D. DISSERTATION).
001525 02-03
ISOTOPE
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXY AMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
ISOTOPE-LABELED
GLC MASS-SPECTROMETRIC-DETERMINATION OF MAPROTILINE AND ITS
MAJOR METABOLITE USING STABLE ISOTOPE-LABELED ANALOG AS
INTERNAL STANDARD.
004291 04-06
ISOTOPES
STABLE ISOTOPES USED IN STUDIES OF METRIFONATE.
003847 04-03
ill
Co
I
S-243
Subject Index
Ptychopharmacology Abstracts
St I
^i»«»
i
ISOTOPIC
GAS-CHROMATOGRAPHY/MASS-SPEaROMETRY STABLE ISOTOPIC
ANALYSES FOR DEANOL, CHOLINE. AND THEIR ACETYLESTERS.
004683 04-16
ITALY
CLINICAL USE OF SULPIRIDE IN ITALY.
002187 02-11
PSYCHOTROPIC-DRUGS AND PSYCHIATRIC-HOSPITAL ADMISSIONS IN
VERONA, ITALY.
004717 04-17
JAIL
THE USE OF MINOR-TRANQUILIZERS WITH JAIL INMATES.
003308 03-1 1
JAPAN
MULTIINSTITUTIONAL-STUDY ON THE TERATOGENICITY AND FETAL
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE-
STUDY GROUP IN JAPAN.
002442 02-15
JAW
SENSORY AND ASSOCIATIVE-EFFEaS OF LSD ON CLASSICAL APPETITIVE-
CONDITIONING OF THE RABBIT JAW MOVEMENT RESPONSE.
001637 02-04
JEJUNAL-FLUID
OPIATE-RECEPTOR MEDIATED INHIBITION OF RAT JEJUNAL-FLUID
SECRETION.
001334 02-03
JESENIK
PSYCHOPHARMACOLOGY AFTER 20 YEARS OF CONFERENCES IN JESENIK.
003646 03-17
JOB-SATISFACTION
JOB-SATISFACTION IN GENERAL-PRACTICE: IMPLICATIONS FOR
PRESCRIBING.
002579 02-17
JOINT-EFFECTS
JOINT-EFFECTS OF D-AMPHETAMINE AND ETHANOL OR PENTOBARBITAL
IN PIGEONS.
000403 01-04
JUDGMENTS
PUBLIC JUDGMENTS ON THE IMPORTANCE OF VALIUM INFORMATION.
003590 03-17
JUMPING
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS.
000258 01-03
JUNCTURES
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNQURES
IN THIS PHASE.
003251 03-09
JUVENILE
IN UTERO ALCOHOL HEIGHTENS JUVENILE REAQIVITY.
000510 01-05
K
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOLLUSCAN
NEURONS.
003834 04-03
K-ENRICHED
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN-
HYDROXYLASE AQIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM.
000123 01-03
K-EVOKED
GABA AND BACLOFEN POTENTIATE THE K-EVOKED RELEASE OF
METHIONINE-ENKEPHALIN FROM RAT STRIATAL SLICES.
002882 03-03
KAINATE
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA
D(AND L) GLUTAMYLGLYCINE.
002696 03-03
KAINATE LESION DISSOCIATES STRIATAL DOPAMINE-RECEPTOR
RADIOLIGAND BINDING-SITES.
002803 03-03
KAINIC-ACID
CORTICAL NEUROCHEMICAL CHANGES AFTER INTRASTRIATAL INJEQION
OF KAINIC-ACID.
000133 01-03
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND
GABAMIMETICS.
000 1 88 0 1 -03
SYSTEMIC DIPIPERIDINOETHANE MIMICS THE CONVULSANT AND
NEUROTOXIC-AQIONS OF KAINIC-ACID.
000222 01-03
EFFEQS OF ANTICONVULSANTS AND GLUTAMATE ANTAGONISTS ON THE
CONVULSIVE ACTION OF KAINIC-ACID.
000288 01-03
PRESYNAPTIC OOPAMINE-RECEPTORS: INSENSITIVITY TO KAINIC-ACID
AND THE DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING CHRONIC
HALOPERIDOL.
001117 02-03
TWO CONDUQANCE MECHANISMS AQIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES.
001349 02-03
DECREASE OF GAD IMMUNOREAQIVE NERVE TERMINALS IN THE
SUBSTANTIA-NIGRA AFTER KAINIC-ACID LESION OF THE STRIATUM.
(UNPUBLISHED PAPER).
001400 02-03
EFFEQS OF KAINIC-ACID ON BODY-TEMPERATURE OF RATS: ROLE OF
CATECHOLAMINERGIC AND SEROTONERGIC SYSTEMS.
001515 02-03
THE STRIATONIGRAL GABA PATHWAY: FUNQIONAL AND
NEUROCHEMICAL CHARAQERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
LOCAL AND DISTANT NEURONAL DEGENERATION FOLLOWING
INTRASTRIATAL INJEQION OF KAINIC-ACID
001885 02-06
DIFFERENTIAL-EFFEaS OF KAINIC-ACID ON BENZODIAZEPINE-RECEPTORS,
GABA-RECEPTORS, AND GABA-MOOULIN IN THE CEREBELLAR-CORTEX.
002477 02-16
EFFEQ OF KAINIC-ACID LESIONS ON MUSCARINIC AGONIST RECEPTOR
SUBTYPES IN RAT STRIATUM.
002679 03-03
KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFEQ ON
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS
002743 03-03
KAINIC-ACID AND NEUROTRANSMIHER INTERAQIONS IN THE BASAL
GANGLIA.
002824 03-03
KAINIC-ACID NEUROTOXICITY AND SEIZURES.
002939 03-03
CHANGES OF ELEQRORETINOGRAM AND NEUROCHEMICAL ASPEQS OF
GABAERGIC NEURONS OF RETINA ARER INTRAOCULAR INJEQION OF
KAINIC-ACID IN RATS.
003807 04-03
IONTOPHORESIS OF KAINIC-ACID.
004294 04-06
KAINIC-ACID-INDUCED
BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH
KAINIC-ACID-INDUCED LESIONS OF STRIATAL NEURONS - WITH A
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS-
DISEASE.
000463 01-04
KAINIC-ACID-INDUCED WET-DOG-SHAKES IN RATS: THE RELATION TO
CENTRAL NEUROTRANSMIHERS.
001685 02-04
EFFECTS OF MORPHINE AND NALORPHINE ON KAINIC-ACID-INDUCED
HYPOTHERMIA IN RATS.
002921 03-03
KAPPA-RECEPTOR
3H ETHYLKETOCYCLAZOCINE BINDING: LACK OF EVIDENCE FOR A
SEPARATE KAPPA-RECEPTOR IN RAT CNS.
000128 01-03
KAPPA-RECEPTORS
MET-ENKEPHALIN-ARG6-PHE7 INTERACTS WITH THE KAPPA-RECEPTORS
ON GUINEA-PIG ILEUM.
001110 02-03
SPECIFIC, HIGH-AFFINITY (3H)ETHYLKET0CYCLAZ0CINE BINDING IN RAT
CENTRAL-NERVOUS-SYSTEM: LACK OF EVIDENCE FOR KAPPA-
RECEPTORS.
003840 04-03
KENAZEPINE
IN VIVO EFFECTS OF TWO NOVEL ALKYLATING BENZODIAZEPINE,
IRAZEPINE AND KENAZEPINE,
004251 04-04
KET AMINE
STRAIN DEPENDENT EFFECTS OF KET AMINE ON LOCOMOTOR-ACTIVITY
AND ANTINOCICEPTION IN MICE.
000382 01-04
KETAMINE: CONVULSANT OR ANTICONVULSANT?
003060 03-04
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN
REGIONS OF RAT-BRAIN WITH KETAMINE ANESTHESIA.
003891 04-03
PROPERTIES OF THE OPTICAL-ISOMERS AND METABOLITES OF KETAMINE
ON THE HIGH-AFFINITY TRANSPORT AND CATABOLISM OF
MONOAMINES.
004009 04-03
KETAZOLAM
KETAZOLAM AND DIAZEPAM IN ANXIETY: A CONTROLLED- STUDY
000655 01-10
S-244
VOLUME 19, SUBJECT INDEX
Subject Index
DOUBLE-BLIND COMPARISON OF KETAZOLAM, DIAZEPAM AND PLACEBO
IN ONCE-A-DAY VS T.I.O. DOSING.
000660 01-11
DOUBLE-BLIND COMPARISON OF KETAZOLAM AND PLACEBO USING
ONCE-A-DAY DOSING,
002067 02-10
KETAZOLAM COMPARED TO DIAZEPAM AND PLACEBO IN THE
TREATMENT OF ANXIETY.
002074 02-10
KETONES
SYNTHESIS OF POTENTIAL ANTICONVULSANTS: CONDENSATION OF
ISATINS WITH ACETONE AND RELATED KETONES.
003699 04-02
KHAT
RELATIVE POTENCIES OF TWO PHENYLALKYLAMINES FOUND IN THE
ABUSED PLANT CATHA-EDULIS, KHAT.
001084 02-02
HYPERTHERMIC-RESPONSE TO (-) CATHINONE, AN ALKALOID OF CATHA-
EOULIS (KHAT).
003694 04-02
KHAT-LEAVES
A CONSTITUENT OF KHAT-LEAVES WITH AMPHETAMINE-LIKE RELEASING
PROPERTIES.
001307 02-03
KIDNEY
LITHIUM AND THE KIDNEY.
002244 02-13
RECENT DEVELOPMENTS IN LITHIUM TREATMENT: IS IT DANGEROUS FOR
THE KIDNEY?
002465 02-15
THE INTERAaiON OF 2,3,4 TRIHYDROXYBENZYLHYDRAZINE WITH
OOPA-DECARBOXYLASE FROM PIG KIDNEY.
002925 03-03
LITHIUM PROPHYLAXIS AND THE KIDNEY.
003463 03-15
LITHIUM-CARBONATE AND THE KIDNEY.
003478 03-15
LITHIUM AND THE KIDNEY SCARE.
003534 03-15
PREJUNCTIONAL AQIONS OF PIRIBEDIL ON THE ISOLATED KIDNEY OF THE
RABBIT: COMPARISON WITH APOMORPHINE.
003749 04-03
A COMPARISON OF THE RESPONSES TO SOME OOPAMINE-RECEPTOR
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT
KIDNEY.
004054 04-03
KIDNEY FUNQION IN PATIENTS WITH AFFEQIVE-DISORDERS WITH AND
WITHOUT LITHIUM THERAPY.
004664 04-15
KIDS
ASTHMA THERAPY MAY UNDERCUT KIDS AT SCHOOL.
004475 04-11
KINDERGARTEN-AGED
EVALUATION OF THE RELATIVE EFFECTIVENESS OF METHYLPHENIDATE
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF
KINDERGARTEN-AGED HYPERACTIVE-CHILDREN.
003306 03-11
KINDLED
LOCOMOTOR AND CONVULSIVE RESPONSES TO PICROTOXIN IN
AMYGDALA KINDLED RATS.
000416 01-04
BARBITURATE SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
001559 02-04
PHARMACOLOGICAL MODIFICATION OF AMYGDALOID KINDLED
SEIZURES.
001588 02-04
THE ANTICONVULSANT PROPERTIES OF MELATONIN ON KINDLED
SEIZURES IN RATS.
002653 03-03
CUMULATIVE AFTERDISCHARGE AS THE PRINCIPAL FAQOR IN THE
ACQUISITION OF KINDLED SEIZURES.
002862 03-03
VALPROIC-ACID SERUM LEVELS AND PROTEQION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
002946 03-04
THE EFFECTS OF VARIOUS ANESTHETICS ON AMYGDALOID KINDLED
SEIZURES.
002959 03-04
EFFEQS OF 3 SULFAMOYLMETHYL-BENZISOXAZOLE (AD-810) AND SOME
ANTIEPILEPTICS ON THE KINDLED SEIZURES IN THE NEOCORTEX,
HIPPOCAMPUS AND AMYGDALA IN RATS.
004149 04-04
SEROTONERGIC MECHANISM IN SEIZURES KINDLED FROM THE RABBIT
AMYGDALA.
004227 04-04
EFFEQ OF COCAINE AND LIDOCAINE ON THE EXPRESSION OF KINDLED
SEIZURES IN THE RAT.
004233 04-04
KINDLING
EFFECTS OF KINDLING OR BRAIN-STIMULATION ON PENTYLENETETRAZOL-
INDUCED CONVULSION SUSCEPTIBILITY.
000037 01-03
MODIFICATION OF DOPAMINERGIC-RECEPTOR SENSITIVITY IN RAT-BRAIN
AFTER AMYGDALOID KINDLING.
000106 01-03
THE ROLE OF BIOGENIC-AMINES IN AMYGDALAR KINDLING. I. LOCAL
AMYGDALAR AFTERDISCHARGE.
000327 01-03
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
NALOXONE FACILITATES AMYGDALOID KINDLING IN RATS.
001644 02-04
CHRONOLOGICAL ELECTROENCEPHALOGRAPHIC AND
NEUROPHARMACOLOGICAL-STUDY IN CORTICAL KINDLING RABBITS.
002761 03-03
THE EFFECT OF AMYGDALA KINDLING ON SPONTANEOUS AND COCAINE-
INDUCED MOTOR-ACTIVITY AND LIDOCAINE SEIZURES,
003067 03-04
A REFORMULATION OF THE DUAL-ACTION MODEL OF OPIOID
DEPENDENCE: OPIOID-SPECIFIC NEURONAL KINDLING.
003645 03-17
KINETIC
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - I. KINETIC PARAMETERS
AND PHARMACOLOGICAL-PROPERTIES.
000213 01-03
INTRAVENOUS PHENOBARBITAL THERAPY IN BARBITURATE AND OTHER
HYPNOSEDATIVE WITHDRAWAL REAQIONS: A KINETIC APPROACH.
000703 01-11
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES.
002879 03-03
PHYSICAL AND KINETIC PROPERTIES OF CHOLINE-ACETYL-TRANSFERASE
FROM RAT AND BOVINE BRAIN.
003676 04-01
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: KINETIC STUDIES.
003814 04-03
STUDIES ON THE KINETIC PROPERTIES OF TRYPTOPHAN-HYDROXYLASE OF
RABBIT MESENCEPHALON AND PONS-MEDULLA: EFFECT OF LONG-
TERM-TREATMENT WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
003852 04-03
KINETIC STUDIES ON THE ENTRY OF D-AMPHETAMINE INTO THE
CENTRAL-NERVOUS-SYSTEM: I. CEREBROSPINAL-FLUID.
004005 04-03
THE USE OF CLINICAL KINETIC DATA IN TREATMENT WITH
ANTIDEPRESSANT-DRUGS.
004686 04-16
KINETICS
NONLINEAR REGRESSION ANALYSIS OF NOREPINEPHRINE RESPONSE
KINETICS IN CEREBRAL VASCULATURE.
000256 01-03
INFLUENCE OF GLUCOSE (IN VIVO OR IN VITRO) ON DURATION OF
NARCOTIC ANALGESICS AND ON THE KINETICS OF DRUG METABOLISM.
000292 01-03
EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT
LUNG.
000524 01-05
EFFEaS OF AGE AND OTHER DRUGS ON BENZODIAZEPINE KINETICS.
000681 01-11
LORAZEPAM KINETICS IN THE ELDERLY.
000766 01-13
EFFECTS OF THREE ANTIBIOTICS ON THEOPHYLLINE KINETICS.
000784 01-13
THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REACTION
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN.
001052 02-01
KINETICS OF CENTRAL-ACTIONS OF ISOFLOXYTHEPIN, AN ORAL
NEUROLEPTIC-DRUG WITH PROLONGED ACTION IN RODENTS.
001720 02-04
PHENYTOIN KINETICS IN CHILDREN.
002113 02-11
BIOAVAILABILITY AND KINETICS OF MAPROTILINE.
002204 02-13
KINETICS AND NEUROPSYCHOLOGIC-EFFECTS OF IV DIAZEPAM IN THE
PRESENCE AND ABSENCE OF ITS ACTIVE N DESMETHYL METABOLITE IN
HUMANS.
002229 02-13
FACTORS INFLUENCING NORTRIPTYLINE STEADY-STATE KINETICS:
PLASMA AND SALIVA LEVELS.
002251 02-13
■;i:
-.Ml?
'M
I
liil.'i:
S-245
Subject Index
Psychopharmacology Abstract*
AN EVALUATION OF MAPROTILINE INTRAVENOUS KINETICS AND
COMPARISON OF TWO ORAL DOSES.
002497 02-16
LITHIUM KINETICS DURING HEMODIALYSIS IN A PATIENT WITH LITHIUM
POISONING.
003524 03-15
ON THE KINETICS OF IMIPRAMINE AND RELATED ANTIDEPRESSANTS.
003945 04-03
DESMETHYLOIAZEPAM KINETICS IN THE ELDERLY AFTER ORAL
PRAZEPAM.
004432 04-11
EFFECT OF NOREPINEPHRINE UPTAKE BLOCKERS ON NOREPINEPHRINE
KINETICS.
004506 04-13
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II.
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT.
004516 04-13
CONCENTRATIONS AND KINETICS OF CARBAMAZEPINE IN WHOLE
SALIVA, PAROTID SALIVA, SERUM ULTRAFILTRATE, AND SERUM.
004545 04-13
KINETICS OF A CARBAMAZEPINE-ETHOSUXIMIDE INTERACTION.
004558 04-13
THE KINETICS OF PSYCHIATRIC-DRUGS.
004739 04-17
KLEINE-LEVIN-SYNDROME
LITHIUM TREATMENT OF THE KLEINE-LEVIN-SYNDROME.
003390 03-11
KNOWLEDGE
A CONTRIBUTION TO OUR KNOWLEDGE OF COCA-LEAF CONTENT
SUBSTANCES.
001022 02-01
KUGELBERG-WELANDER
THE USE OF LITHIUM-CARBONATE FOR TREATING KUGELBERG-WELANDER
SPINAL AMYOTROPHY PATIENTS.
003326 03-11
L-AMPHETAMINE
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHET AMINE AND
L-AMPHETAMINE: NO INTERACTION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES
000387 01-04
L-DOPA
THE EFFECTS OF RESERPINE, IPRONIAZIO AND L-DOPA ON ELECTRICALLY-
INDUCED SPINAL-CORD SEIZURES.
000146 01-03
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES.
000202 01-03
FUNCTIONAL AND STRUCTURAL CONSEQUENCES OF LONG-TERM DIETARY
L-DOPA TREATMENT IN MICE.
000257 01-03
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS.
000466 01-04
THREE CASES OF UNIPOLAR DELUSIONAL DEPRESSION RESPONSIVE TO L-
DOPA.
000628 01-09
ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLED-
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH
PARKINSONS-DISEASE TREATED WITH L-DOPA.
000659 01-11
THE LONG-TERM RESULTS OF STEREOTAXIC SURGERY AND L-DOPA
THERAPY IN PATIENTS WITH PARKINSONS-DISEASE: A 10-YEAR
FOLLOWUP STUDY.
000693 01-11
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE).
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION.
000712 01-11
L-DOPA ENHANCES ACQUISITION OF AN INHIBITORY AVOIDANCE
RESPONSE.
001711 02-04
TWO NEW DRUGS MAY PICK UP WHERE L-DOPA LEAVES OFF.
001897 02-07
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL, ON
PARKINSONS-DISEASE - PART Ih PHARMACOKINETIC-STUDY.
002309 02-13
INDIVIDUAL VARIATIONS IN THE EFFECTS OF FLURAZEPAM,
CLORAZEPATE, L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON
REM SLEEP IN MAN.
002349 02-14
THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA.
002976 03-04
CLINICAL SIGNIFICANCE OF PYRIDOXINE ADMINISTRATION IN L-DOPA
THERAPY OF PARKINSONISM.
003345 03-11
REDUCTION IN THE LEVEL OF IMMUN0TITRA7ABLE DOPAMINE-BETA-
HYDROXYIASE AFTER CHRONIC ADMINISTRATION OF L-DOPA OR
ALPHA METHYLDOPA
003764 04-03
PHARMACOLOGICAL DIFFERENCE OF L-DOPA, APOMORPHINE, AND
BROMOCRIPTINE AGAINST METOCLOPRAMIDE.
003790 04-03
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN.
003941 04-03
DECREASE OF NORADRENALINE 0 METHYLATION IN RAT-BRAIN INDUCED
BY L-DOPA. REVERSAL EFFEQ OF S ADENOSYL-L-METHIONINE
004019 04-03
EFFECTS OF NARCOTIC ANTAGONISTS ON L-DOPA REVERSAL OF
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE.
004186 04-04
A CONTROLLED-STUDY OF L-DOPA IN SCHIZOPHRENIA WITH REFERENCE
TO THE THEORY OF DOPAMINERGIC-RECEPTOR HYPERSENSITIVITY.
004312 04-08
ASSESSING L-DOPA THERAPY FOR PARKINSONS.
004465 04-11
PROBLEMS OF TREATING DEFORMING MYODYSTONIA WITH L-DOPA,
AND PREDiaiON OF ITS THERAPEUTIC EFFEQ.
004536 04-13
L-DOPA-INDUCED
IMPROVEMENT OF L-DOPA-INDUCED DYSKINESIA AND OF ON-OFF-
PHENOMENON BY BROMOCRIPTINE.
000813 01-14
EXPERIMENTAL- STUDIES ON L-DOPA-INDUCED DYSKINESIA.
003129 03-05
STUDIES ON THE MECHANISMS OF L-DOPA-INDUCED SALIVARY
SECRETION.
003130 03-05
L-DOPAS
L-DOPAS MECHANISM-OF-AQION IN PARKINSONS-DISEASE.
003323 03-11
L-ISOMERS
COMPARATIVE-STUDIES OF THE PHARMACOLOGICAL-EFFEaS OF THE D-
ISOMERS AND L-ISOMERS OF CODEINE.
004084 04-04
LABEL
DOES (3H)SPIR0PERID0L LABEL A 5 HT-RECEPTOR IN THE FRONTAL-
CORTEX OF THE RAT?.
000206 01-03
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN
REUPTAKE SITES IN BRAIN AND PLATELET?
003962 04-03
BACLOFEN IN THE TREATMENT OF TARDIVE-DYSKINESIA: OPEN LABEL
STUDY.
004619 04-15
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL.
004620 04-15
LABELED
HISTAMINE Hl-RECEPTORS LABELED IN VIVO: ANTIDEPRESSANT AND
ANTIHISTAMINE INTERACTIONS.
000074 01-03
ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND
EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL
AND INTRODUODENAL ADMINISTRATION.
000094 01-03
REGULATION OF SER0T0NIN2-RECEPT0RS (5 HT2) LABELED WITH
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT AMITRIPTYLINE
003964 04-03
LABELING
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
001024 02-01
BENZODIAZEPINE-RECEPTOR: LOCALIZATION BY PHOTOAFFINITY
LABELING AND ISOLATION OF A POSSIBLE ENDOGENOUS LIGAND.
001381 02-03
RADIORECEPTOR LABELING OF PRESYNAPTIC AND POSTSYNAPTIC
DOPAMINE-RECEPTORS.
001511 02-03
AOENOSINE-RECEPTORS IN RAT TESTES: LABELING WITH 3H
CYCLOHEXYLADENOSINE.
002835 03-03
(3H)MIANSERIN: DIFFERENTIAL LABELING OF SEROTONIN AND
HISTAMINE-RECEPTORS IN RAT-BRAIN.
002860 03-03
S-246
VOLUME 19, SUBJECT INDEX
Subject Index
HUMAN PLATELET ALPHA2-ADRENERGIC-RECEPT0RS: LABELING WITH 3H
YOHIMBINE, A SELECTIVE ANTAGONIST LIGANO.
004676 04-16
LAftELLED
ESR STUDIES OF SPIN LABELLED BOVINE LIVER MONOAMINE-OXIDASE-B.
(UNPUBLISHED PAPER).
00)065 02-01
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA
AMINOBUTYRIC-ACIO AND ACETYLCHOLINE EVOKED BY ELECTRICAL-
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL
SLICES.
001130 02-03
INDICATIONS FOR A BRAIN UPTAKE OF LABELLED VASOPRESSIN AND
OCYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER.
003669 04-01
LABELLING
FALSE LABELLING OF COMMERCIALLY-AVAILABLE 3H CATECHOLAMINES?
000535 01-06
NOREPINEPHRINE METABOLISM IN MAN USING DEUTERIUM LABELLING: 4
HYDROXY-3-METHOXYMANDELIC-ACID.
004534 04-13
LABORATORY
TESTOSTERONE AND PERSISTENCE OF SOCIAL INVESTIGATION IN
LABORATORY RATS.
000488 01-04
CLINICAL AND LABORATORY DIAGNOSTICS APPLICATIONS IN
DEPRESSION. (UNPUBLISHED PAPER).
000588 01-09
THE CLINICAL-EFFICACY OF CLOZAPINE AS COMPARED TO LABORATORY
PARAMETERS.
001955 02-08
THE URBAN EPIDEMIC OF PHENCYCLIDINE USE: LABORATORY EVIDENCE
FROM A PUBLIC PSYCHIATRIC-HOSPITAL INPATIENT-SERVICE.
003554 03-16
CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND
NATURAL SETTINGS: CORRELATIONAL AND VARIANCE COMPONENTS
ANALYSES.
004508 04-13
EFFECTS OF SUPIDIMIDE (CG-3033) ON OBJECTIVE AND SUBJECTIVE SLEEP
PARAMETERS (A SLEEP LABORATORY STUDY).
004567 04-14
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC-
ANTIDEPRESSANTS: PERSPECTIVE OF THE CLINICAL LABORATORY.
004681 04-16
LAaATION
ERGOT DRUGS SUPPRESS PLASMA PROLAQIN AND LACTATION BUT NOT
AGGRESSION IN PARTURIENT MICE.
003159 03-07
LAaiC-ACIDEMIA
REVERSIBLE ALEXIA, MITOCHONDRIAL MYOPATHY, AND LACTIC-
ACIDEMIA.
000723 01-11
LAFORA-BODIES
TRANSIENT-EFFEQ OF L TRYPTOPHAN IN PROGRESSIVE MYOCLONUS
EPILEPSY WITHOUT LAFORA-BODIES: CLINICAL-STUDY AND
ELECTROPHYSIOLOGICAL-STUDY.
000694 01-11
LAMINAE
THE STEREOSPECIFIC EFFEQ OF NALOXONE ON RAT DORSAL-HORN
NEURONES; INHIBITION IN SUPERFICIAL LAMINAE AND EXCITATION IN
DEEPER LAMINAE.
001226 02-03
LAMINAR
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMIHER AMINO-
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFACTORY-BULB.
002836 03-03
LANTHANUM
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
LARGE-DOSES
LARGE-DOSES OF VITAMINS AND BEHAVIORAL-CONSEQUENCES. (PH.D.
DISSERTATION).
001633 02-04
LARGE-DOSES OF DIBENZEPINE NOVERIL IN THE TREATMENT OF
DEPRESSIVE-STATES.
002020 02-09
URGE-SINGLE-DOSES
USE OF LARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC-
PATIENTS WITH ELEVATED SERUM PROLACTIN LEVELS AND
EXTRAPYRAMIDAL SIDE-EFFEaS ASSOCIATED WITH NEUROLEPTIC
TREATMENT.
001944 02-08
LARYNGEAL-EFFECTS
LARYNGEAL-EFFECTS OF SEROTONIN IN RABBITS.
001501 02-03
LATENCY
PROLONGATION OF THE EJACULATION LATENCY IN THE MALE RAT BY
THIORIDAZINE AND CHLORIMIPRAMINE.
000335 01-04
A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX UTENCY
PRODUCED BY OPIATE ANALGESICS.
000425 01-04
ACUTE AND CHRONIC OPIATE-EFFECTS ON SINGLE UNITS AND EEG OF
MEDIAL THALAMUS AND HIPPOCAMPUS: A LATENCY ANALYSIS.
001344 02-03
LATENT
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT
ANTICHOLINERGIC-ACTIVITY BY AN ATYPICAL NEUROLEPTIC
(THIORIDAZINE).
003560 03-16
LATERAL
FACILITATION OF RECOVERY BY PROPANTHELINE-BROMIDE AFTER
LATERAL HYPOTHALAMIC DAMAGE.
000396 01-04
SYSTEMIC INSULIN DECREASES LATERAL HYPOTHALAMIC UNIT ACTIVITY.
001275 02-03
INFLUENCE OF DOPAMINERGIC-SYSTEMS ON THE LATERAL HABENULAR
NUCLEUS OF THE RAT.
001365 02-03
EFFECTS OF LILLY-1 10140 (FLUOXETINE) ON SELF-STIMULATION
BEHAVIOR IN THE DORSAL AND VENTRAL REGIONS OF THE LATERAL
HYPOTHALAMUS IN THE MOUSE.
001590 02-04
APHAGIA, GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNCTIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS:
EFFECTS OF INSULIN PRETREATMENTS.
001638 02-04
ENHANCED LATERAL HYPOTHALAMIC SELF-STIMULATION RESPONDING
AFTER CHRONIC EXPOSURE TO AMPHETAMINE.
001688 02-04
A COMPARISON BETWEEN THE EFFEQS OF MORPHINE ON THE
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC
AND CENTRAL GRAY STIMULATION.
001771 02-04
APOMORPHINE: SELECTIVE INHIBITION OF THE AVERSIVE COMPONENT OF
LATERAL HYPOTHALAMIC SELF-STIMULATION.
002476 02-16
INFLUENCE OF MORPHINE ON THE DISCRIMINATIVE-STIMULUS
PROPERTIES OF REWARDING LATERAL HYPOTHALAMIC STIMULATION.
(PH.D. DISSERTATION).
003041 03-04
EFFECTS OF ELECTROLYTIC AND 6 HYDROXYDOPAMINE LESIONS OF THE
LATERAL HYPOTHALAMUS ON ROTATION EVOKED BY ELECTRICAL-
STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.
003081 03-04
SENSITIVITY TO GABA OF NEURONS OF THE DORSAL AND VENTRAL
LATERAL GENICULATE NUCLEI IN THE RAT.
003877 04-03
LATERALITY
HANDLING IN INFANCY, TASTE-AVERSION, AND BRAIN LATERALITY IN
RATS.
000375 01-04
LATERALIZATION
SEX-DIFFERENCES IN AMPHETAMINE-ELICITED ROTATIONAL-BEHAVIOR
AND THE LATERALIZATION OF STRIATAL DOPAMINE IN RATS.
000459 01-04
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT.
001657 02-04
LATERALIZED
LATERALIZED DEFICITS AND DRUG INFLUENCES ON THE DICHOTIC
LISTENING OF SCHIZOPHRENIC-PATIENTS.
003443 03-14
LAYERS
THE EFFECTS OF LITHIUM ON MYOINOSITOL LEVELS IN LAYERS OF
FRONTAL-CEREBRAL-CORTEX, IN CEREBELLUM, AND IN CORPUS-
CALLOSUM OF THE RAT.
003712 04-03
LCGU
LOCAL CEREBRAL GLUCOSE UTILIZATION (LCGU) IN RAT-BRAIN DURING
HYPOXEMIA. (UNPUBLISHED PAPER).
001380 02-03
LD50
EFFECT OF AGE AND ROUTE-OF-ADMINISTRATION ON LD50 OF LITHIUM-
CHLORIDE IN THE RAT.
001413 02-03
LEAD
EFFECTS OF LEAD ON MOVEMENT OF ALBUMIN INTO BRAIN.
000076 01-03
EFFECTS OF LEAD EXPOSURE DURING DEVELOPMENT ON NEOCORTICAL
DENDRITIC AND SYNAPTIC STRUCTURE.
000525 01-05
LITHIUM-CHLORIDE AND DELTA9 THC LEAD TO CONDITIONED AVERSIONS
IN THE PIGEON.
003003 03-04
M
■nnilt"
'<lll>l<l
I
LltiB
S-247
Subject Index
Pfychopharmocology Abstracts
nil [
iiei!' 1
131...
EFFECT OF INORGANIC LEAD ON RAT-BRAIN MITOCHONDRIAL
RESPIRATION AND ENERGY PRODUCTION.
004267 04-05
LEARNED-BEHAVIOR
EFFECT OF L FUCOSE ON BRAIN PROTEIN METABOLISM AND RETENTION
OF A LEARNED-BEHAVIOR IN RATS.
001819 02-04
LEARNED-FEAR
ACTH MEDIATION OF LEARNED-FEAR; BLOCKADE BY NALOXONE AND
NALTREXONE.
001597 02-04
LEARNED-HELPLESSNESS
REVERSAL OF LEARNED-HELPLESSNESS BY IMIPRAMINE.
001751 02-04
NEUROCHEMICAL BASIS OF THE ACTION OF ANTIDEPRESSANTS ON
LEARNED-HELPLESSNESS.
001775 02-04
LEARNING
EFFECT OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION,
MEMORY, AND RETRIEVAL OF SHUHLE AVOIDANCE AND
HABITUATION LEARNING IN RATS.
000410 01-04
THE USE OF PSYCHOPHARMACOLOGICAL-PROCEDURES TO ANALYSE THE
ONTOGENY OF LEARNING AND RETENTION: ISSUES AND CONCERNS.
000482 01-04
INFLUENCE OF PYRITHIOXINE, MECLOPHENOXATE AND PIRACETAM ON
THE LEARNING PROCESS IN MAN.
000805 01-14
EFFECT OF DRUGS ON LEARNING AND MEMORY PROCESSES IN SIMPLE
BEHAVIORAL-TESTS.
000809 01-14
EFFECTS OF METHYLPHENIDATE ON LEARNING A BEGINNING READING
VOCABULARY BY NORMAL ADULTS.
000812 01-14
THE INFLUENCE OF NOOTROPIC-DRUGS ON LEARNING AND MEMORY OF
DEFENSE REACTIONS.
000815 01-14
SEROTONINMIMETIC AND ANTIDEPRESSANT-DRUGS ON PASSIVE-
AVOIDANCE LEARNING BY OLFACTORY BULBECTOMISED RATS.
001585 02-04
EFFECTS OF EXPERIMENTAL HYPOTHYROIDISM ON LEARNING IN RATS.
001587 02-04
INTRAHYPOTHALAMIC MICROINJECTIONS OF NORADRENALINE WITH AND
WITHOUT INDUCTION OF THE ALIMENTARY DRIVE AS A REWARD IN A
T-MAZE LEARNING IN RATS.
001604 02-04
INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY
PREEXPOSURE TO THE UNCONDITIONED- STIMULUS; ASSOCIATIVE-
ASPECTS AND NON ASSOCIATIVE-ASPECTS.
001610 02-04
TWO-WAY AVOIDANCE LEARNING UNDER THE INFLUENCE OF NOOTROPIC-
DRUGS.
001647 02-04
THE INFLUENCE OF DAILY BIOLOGICAL-RHYTHMICITY ON THE HOMING-
BEHAVIOR, PSYCHOPHARMACOLOGICAL RESPONSIVENESS, LEARNING
AND RETENTION OF SUCKLING RATS. (PH.D. DISSERTATION).
001660 02-04
PIRACETAM EFFECT ON LEARNING AND MEMORY IN RATS.
001689 02-04
STRUCTURE OF VARIABILITY AND CORRELATION IN LEARNING AFTER
DRUG ADMINISTRATION.
002562 02-17
CENTRAL AND PERIPHERAL CATECHOLAMINE FUNCTION IN LEARNING
AND MEMORY PROCESSES.
002823 03-03
BRAIN MECHANISMS OF LEARNING,
002916 03-03
IMPAIRMENT OF INSTRUMENTAL LEARNING IN RATS BY GLUTAMIC-
ACID-DIETHYL-ESTER.
002993 03-04
EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON INTERPERSONAL LEARNING.
003225 03-09
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL.
004208 04-04
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS.
004658 04-15
LEARNING-ABILITY
INFLUENCE OF NICERGOLINE ON MOLECULAR BIOLOGICAL PROCESSES IN
THE BRAIN AND LEARNING-ABILITY OF THE RAT.
000449 01-04
LEARNING-DISABILITIES
UNDERSTANDING AND USE OF CHEMOTHERAPY BY LEARNING-
DISABILITIES AND BEHAVIOR-DISORDERS TEACHERS.
000965 01-17
LEARNING-DISORDERS
EFFECT OF PIRACETAM ON EEG SPECTRA OF BOYS WITH LEARNING-
DISORDERS
003383 03-11
LECITHIN
LECITHIN IN THE TREATMENT OF TARDIVE-DYSKINESIA.
002380 02-15
USE OF CHOLINE AND LECITHIN IN THE TREATMENT OF TARDIVE-
DYSKINESIA.
002473 02-15
LECITHIN AND MEMORY TRAINING IN ALZHEIMERS-DISEASE. (PH.D.
DISSERTATION).
003299 03-1 1
PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND
DEMENTIA.
003347 03-11
THE EFFECTS OF LECITHIN ON MEMORY IN PATIENTS WITH SENILE-
DEMENTIA OF THE ALZHEIMERS-TYPE.
003385 03-11
LECITHIN ADMINISTRATION IN TARDIVE-DYSKINESIA: CLINICAL AND
BIOMEDICAL-CORRELATES.
003496 03-15
LECITHIN FOR THE TREATMENT OF TARDIVE-DYSKINESIA.
004612 04-15
LECTINS
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK
TISSUES - ARE THEY CELL ADHESION MOLECULES?
003724 04-03
LEEDS-SLEEP-EVAIUATION-QUESTIONNAIRE
THE LEEDS-SLEEP-EVALUATION-QUESTIONNAIRE IN
PSYCHOPHARMACOLOGICAL-INVESTIGATIONS - A REVIEW.
002351 02-14
LEFT
EFFEaS OF IMIPRAMINE ON LEFT VENTRICULAR PERFORMANCE IN
CHILDREN.
002385 02-15
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LER AND RIGHT
VERTEBRAL-ARTERY OF THE CAT, A MODIFIED ANIMAL-MODEL FOR
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE
LOWER BRAINSTEM.
004297 04-06
LEGAL
MEDICAL AND LEGAL IMPLICATIONS OF SIDE-EFFEQS FROM
NEUROLEPTIC-DRUGS A ROUND-TABLE DISCUSSION
003471 03-15
LENNOX-GASTAUT-SYNDROME
ANTICONVULSANT-INDUCED STATUS-EPILEPTICUS IN LENNOX-GASTAUT-
SYNDROME.
003467 03-15
ANTIEPILEPTIC-EFFEQ OF CLOBAZAM IN LENNOX-GASTAUT-SYNDROME.
004479 04-1 1
LEPTINOTARSIN
RELEASE OF ACETYLCHOLINE FROM RAT-BRAIN SYNAPTOSOMES
STIMULATED WITH LEPTINOTARSIN, A NEW NEUROTOXIN.
003148 03-06
LERGOTRILE
PSYCHIATRIC-EFFECTS OF BROMOCRIPTINE AND LERGOTRILE IN
PARKINSONIAN-PATIENTS.
002453 02-15
LESCH-NYHANS-SYNDROME
BEHAVIORAL-STUDIES AND NEUROCHEMICAL-STUDIES OF LESCH-NYHANS-
SYNDROME.
001743 02-04
SEROTONERGIC APPROACHES TO THE MODIFICATION OF BEHAVIOR IN
THE LESCH-NYHANS-SYNDROME.
004576 04-14
LESION
ABSENCE OF LITHIUM-INDUCED TASTE-AVERSION ARER AREA-POSTREMA
LESION.
000456 01-04
DECREASE OF GAD IMMUNOREACTIVE NERVE TERMINALS IN THE
SUBSTANTIA-NIGRA AFTER KAINIC-ACID LESION OF THE STRIATUM.
(UNPUBLISHED PAPER)
001400 02-03
FORNIX LESION PREVENTS AN ORGANOPHOSPHATE-INDUCED DECREASE
IN MUSCARINIC-RECEPTOR LEVEL IN RAT HIPPOCAMPUS.
001833 02-05
KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFEQ ON
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS.
002743 03-03
KAINATE LESION DISSOCIATES STRIATAL DOPAMINE-RECEPTOR
RADIOLIGAND BINDING-SITES.
002803 03-03
LESION-INDUCED
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE
CAT. (PH D. DISSERTATION).
001179 02-03
S-248
VOLUME 19, SUBJECT INDEX
Subject Index
lESIONED
EFFECTS OF CHRONIC HALOPERIDOL ON CAUDATE 3H SPIROPERIDOL
BINDING IN LESIONED RATS
000255 01-03
CIRCLING PRODUCED BY SEROTONIN AND DOPAMINE AGONISTS IN
RAPHE LESIONED RATS: A SEROTONIN MODEL.
001783 02-04
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS.
004129 04-04
LESIONINO
A MODEL FOR PSYCHONEUROENDOCRINE INVESTIGATION: SPECIFIC
CHEMICAL LESIONING OF THE MEDIAN-EMINENCE
001478 02-03
LESIONS
FUNCTIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY
NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS
WITH SCHIZOPHRENIA.
000059 01-03
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES.
000202 01-03
ENHANCED SUPPRESSION OF CONDITIONED AVOIDANCE RESPONSE BY
HALOPERIDOL BUT NOT PHENOXYBENZAMINE IN RATS WITH
BILATERAL PARAFASCICULAR LESIONS.
000334 01-04
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH
KAINIC-ACID-INDUCED LESIONS OF STRIATAL NEURONS - WITH A
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS-
DISEASE.
000463 01-04
EFFECTS OF RAPHE-MAGNUS AND RAPHE-PALLIDUS LESIONS ON
MORPHINE-INDUCED ANALGESIA AND SPINAL-CORD MONOAMINES.
001420 02-03
UNILATERAL 5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE DORSAL
RAPHE NUCLEUS (DRN) AND RAT ROTATIONAL-BEHAVIOUR.
001578 02-04
5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE
AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED-
BEHAVIOUR IN THE RAT.
001589 02-04
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND
ELECTROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE
MIDBRAIN.
001593 02-04
MODULATION OF OPIATE-RECEPTOR BINDING IN STRIATUM AND
AMYGDALA BY SELECTIVE MESENCEPHALIC LESIONS.
001629 02-04
EFFECTS OF SEROTONERGIC LESIONS ON INVESTIGATORY RESPONDING BY
RATS IN A HOLEBOARD.
001634 02-04
APHAGIA, GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNCTIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS:
EFFECTS OF INSULIN PRETREATMENTS.
001638 02-04
MORPHINE-DEPENDENCE AND DOPAMINERGIC-ACTIVITY: TESTS OF
CIRCLING RESPONSES IN RATS WITH UNILATERAL NIGRAL LESIONS.
001641 02-04
THE INFLUENCE OF ANTERIOR NEOSTRIATAL LESIONS ON THE
BEHAVIOURAL-EFFECTS OF SPIROPERIDOL IN RATS.
001702 02-04
DISSOCIATION OF D-AMPHETAMINE-INDUCED LOCOMOTOR-ACTIVITY AND
STEREOTYPED-BEHAVIOUR BY LESIONS OF THE SUPERIOR-COLLICULUS.
001755 02-04
THE STRIATONIGRAL GABA PATHWAY: FUNCTIONAL AND
NEUROCHEMICAL CHARACTERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
EFFECT OF KAINIC-ACID LESIONS ON MUSCARINIC AGONIST RECEPTOR
SUBTYPES IN RAT STRIATUM.
002679 03-03
THE EFFECT OF SPECIFIC BRAIN LESIONS ON THE HIGH-AFFINITY BINDING
OF GABA IN THE SUBSTANTIA-NIGRA.
002795 03-03
EFFECT OF 6 HYDROXYDOPAMINE LESIONS OF THE MEDIAL PREFRONTAL-
CORTEX ON NEUROTRANSMITTER SYSTEMS IN SUBCORTICAL SITES IN
THE RAT.
002869 03-03
EFFECTS OF ELECTROLYTIC AND 6 HYDROXYDOPAMINE LESIONS OF THE
LATERAL HYPOTHALAMUS ON ROTATION EVOKED BY ELECTRICAL-
STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.
003081 03-04
EFFECTS OF DORSOLATERAL TEGMENTAL LESIONS ON AMPHETAMINE-
INDUCED AND LITHIUM-INDUCED TASTE-AVERSIONS.
003114 03-04
RELATIONSHIP BETWEEN THE PRESENCE OF DOPAMINERGIC NEURONS
AND GABA-RECEPTORS IN SUBSTANTIA-NIGRA: EFFECTS OF LESIONS.
003797 04-03
UNIMPAIRED QUININE METABOLISM IN RATS WITH VENTROMEDIAL
HYPOTHALAMIC LESIONS.
003821 04-03
STUDIES ON AXONAL TRANSPORT IN DOPAMINERGIC NEURONS: EFFECT
OF NEUROPHARMACOLOGIC LESIONS.
003858 04-03
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS.
003871 04-03
EFFECTS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE-
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC
BUNDLE IN THE RAT.
003910 04-03
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH
UNILATERAL NIGROSTRIATAL LESIONS.
004117 04-04
DOPAMINERGIC AGONISTS DIFFERENTIALLY AFFECT OPEN-FIELD ACTIVITY
OF RATS WITH AlO LESIONS.
004135 04-04
THE INFLUENCE OF UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE
SUBSTANTIA-NIGRA IN THE ABSENCE OF THE TELENCEPHALON.
004197 04-04
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION.
004273 04-05
LETHAL
LETHAL SELF-ADMINISTRATION OF MORPHINE BY RATS.
000343 01-04
LETHALITY
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND
L-AMPHETAMINE: NO INTERACTION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES.
000387 01-04
POSSIBLE MECHANISM FOR THE ENHANCED LETHALITY OF MORPHINE IN
AGGREGATED MICE.
000437 01-04
POTENTIATION OF LETHALITY IN MICE BY COMBINATIONS OF
PENTAZOCINE AND TRIPELENNAMINE.
000529 01-05
ANTAGONISM OF INTRAVENOUS COCAINE LETHALITY IN NONHUMAN
PRIMATES.
003127 03-05
LEU-ENKEPHALIN-LIKE
EFFECT OF MORPHINE AND NALOXONE ON LEU-ENKEPHALIN-LIKE
IMMUNOREACTIVITY IN DOGS.
003894 04-03
LEUCINE
INCORPORATION OF 4.5 3H LEUCINE INTO THE LIMBIC-SYSTEM OF ICR
MICE AS A LONG-TERM EFFECT OF HALOPERIDOL APPLICATION.
000118 01-03
EFFECTS OF CENTRALLY-ADMINISTERED AND SYSTEMICALLY
ADMINISTERED L TYROSINE AND L LEUCINE ON OVARIAN FUNCTION IN
THE OLD RAT.
001180 02-03
LEUCINE-ENKEPHALIN
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFECTS OF
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS
ON MORPHINE-INDUCED ANALGESIA.
000311 01-03
ANTICONVULSANTS SPECIFIC FOR PETIT-MAL ANTAGONIZE
EPILEPTOGENIC-EFFECT OF LEUCINE-ENKEPHALIN.
000477 01-04
LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHALIN PRODUCE OPPOSING
EFFECTS ON PLASMA CORTICOSTERONE LEVELS IN ETHER-STRESSED
MICE.
001245 02-03
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE
SPINAL-CORD OF THE CAT: ENKEPHALIN-CONTAINING MARGINAL
NEURONS AND PAIN MODULATION.
002638 03-01
LEUKEMIA
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER).
001188 02-03
LEUKOCYTE
AN ATTEMPT TO ASSESS THE EFFECT OF LITHIUM ON THE NEUTROPHIL
LEUKOCYTE SYSTEM IN AFFECTIVE-PSYCHOSIS.
004416 04-09
LEUKOCYTES
DRUG SENSITIVE ECTO-ATPASE IN HUMAN LEUKOCYTES.
000779 01-13
•Mil Mi
i<il...:i
I
WE
S-249
iseasissua^y
Subject Index
Psychopharmacoiogy Abstracts
«S:,
LEUKOPENIC-DISORDERS
LITHIUM-SALTS IN LEUKOPENIC-DISORDERS.
001000 01-17
LEVER-PRESSING
PIMOZIDE AHENUATES LEVER-PRESSING FOR WATER REINFORCEMENT IN
RATS.
003000 03-04
LEVODOPA
LEVODOPA AND PRESYMPTOMATIC DETECTION OF HUNTINGTONS-
DISEASE - EIGHT-YEAR FOLLOWUP.
000950 01-17
A COMPARATIVE-STUDY OF BROMOCRIPTINE AND LEVODOPA IN
PARKINSONS-DISEASE.
002117 02-11
INCREASED RATIO OF CARBIOOPA TO LEVODOPA IN TREATMENT OF
PARKINSONS-DISEASE.
002182 02-11
DEPRENYL IN THE MANAGEMENT OF RESPONSE FLUCTUATIONS IN
PATIENTS WITH PARKINSONS-DISEASE ON LEVODOPA.
002358 02-14
LEVODOPA COMPARED WITH BROMOCRIPTINE IN THE TREATMENT OF
PARKINSONS-DISEASE.
002406 02-15
PLASMA LEVODOPA, DOPAMINE AND THERAPEUTIC RESPONSE
FOLLOWING LEVODOPA THERAPY OF PARKINSONIAN-PATIENTS.
002504 02-16
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND
LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJECTS.
003311 03-11
EVIDENCE TO SUPPORT EARLY LEVODOPA THERAPY IN PARKINSON-
DISEASE.
003336 03-11
ABSORPTION OF LEVODOPA AFTER RECTAL ADMINISTRATION.
003406 03-13
COMPLICATIONS OF CHRONIC LEVODOPA THERAPY: LONG-TERM
EFFICACY OF DRUG-HOLIDAY.
003502 03-15
THE EFFECT OF CHRONIC LEVODOPA ON HALOPERIDOL-INDUCED
BEHAVIORAL-SUPERSENSITIVITY IN THE GUINEA-PIG.
004249 04-04
LEVODOPA: LONG-TERM IMPACT ON PARKINSONS-DISEASE.
004476 04-1 1
ELECTRORETINOGRAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN
PSYCHOPHARMACOLOGY ELECTRORETINOGRAPHIC-CHANGES INDUCED
BY A COMBINATION OF CARBIDOPA AND LEVODOPA.
004507 04-13
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS.
004551 04-13
ELECTROENCEPHALOGRAPHIC CHANGE IN PARKINSONIAN-PATIENTS
TREATED WITH LEVODOPA CARBIDOPA.
004557 04-13
LEVOMEPROMAZINE
AN UNUSUAL CASE OF THIORIDAZINE AND LEVOMEPROMAZINE
DEPENDENCE.
004634 04-15
LEVONANTRADOL
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC,
ANTAGONIZES HALOPERIDOL-INDUCED AQIVATION OF STRIATAL
DOPAMINE SYNTHESIS.
002786 03-03
LEVORPHANOL
CHANGES IN PLASMA CORTICOSTERONE LEVELS AS A MEASURE OF
ACUTE DEPENDENCE UPON LEVORPHANOL IN RATS.
000085 01-03
LEVORPHANOL: RADIOIMMUNOASSAY AND PLASMA CONCENTRATION
PROFILES IN DOG AND MAN.
000898 01-16
HEROIN, BUT NOT LEVORPHANOL. PRODUCES EXPLOSIVE MOTOR-
BEHAVIOR IN NALOXONE TREATED RATS.
001579 02-04
LEWIS-RAT
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH LEWIS-RAT LYMPH-NODE CELLS. (UNPUBLISHED PAPER).
001434 02-03
LH
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH
NEUROLEPTICS.
001935 02-08
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
LACK OF CORRELATION BETWEEN NALOXONE-INDUCED CHANGES IN
SEXUAL-BEHAVIOR AND SERUM LH IN MALE RATS.
002821 03-03
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED
SEROTONERGIC MECHANISMS.
003748 04-03
LHRH
BODY-WEIGHT AND RESPONSES TO LHRH INFUSION IN ANOREXIA-
NERVOSA.
002062 02-10
LI
LI
TRANSCULTURAL PHARMACOKINETIC STUDY ON LI CONCENTRATION IN
PLASMA AND SALIVA.
000769 01-13
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI, OR
ETHANOL DETECTED BY ELECTROPHYSIOLOGICAL-CORRELATES.
001136 02-03
NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTROOUQION.
002227 02-13
LIABILITY
THE EFFECT OF NALOXONE ON THE AQIVATION OF EMOTIONALLY
POSITIVE REAQION PRODUCED BY DRUGS WITH A DEPENDENCE
LIABILITY.
001556 02-03
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDia RATS: A POSSIBLE MODEL FOR PREDIQING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION).
003097 03-04
BUPRENORPHINE: DEMONSTRATION OF PHYSICAL-DEPENDENCE LIABILITY.
004104 04-04
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL
004620 04-15
LIABLE
TARDIVE-DYSKINESIA AND LITHIUM ASSOCIATED NEPHROPATHY: ARE
YOU LIABLE?
000846 01-15
LIBERATE
THIOLS LIBERATE COVALENTLY-BONDED FLAVIN FROM MONOAMINE-
OXIDASE. (UNPUBLISHED PAPER).
001060 02-01
LIBERAHD
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL
GROUPS IN THE AQIVE SITE. (UNPUBLISHED PAPER).
001066 02-01
LIBERATION
LIBERATION OF CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE FROM
HUMAN BLOOD-PLATELETS.
003967 04-03
LIBRIUM
SHORT-TERM ETHANOL ADMINISTRATION IMPAIRS THE ELIMINATION OF
CHLORDIAZEPOXIDE (LIBRIUM) IN MAN.
002224 02-13
LICL
CHARAQERISTIC HYPERPYREXIA INDUCED BY LICL AND
TRANYLCYPROMINE IN RATS.
004278 04-05
LIDOCAINE
THE PARADOXICAL-EFFEQ OF LIDOCAINE ON AN EXPERIMENTAL MODEL
OF EPILEPSY.
000039 01-03
THE EFFEaS OF GONADEaOMY AND HYPOPHYSEQOMY ON THE
METABOLISM OF IMIPRAMINE AND LIDOCAINE BY THE LIVER OF MALE
AND FEMALE RATS.
000273 01-03
THE EFFECT OF AMYGDALA KINDLING ON SPONTANEOUS AND COCAINE-
INDUCED MOTOR-AQIVITY AND LIDOCAINE SEIZURES.
003067 03-04
EFFEQ OF COCAINE AND LIDOCAINE ON THE EXPRESSION OF KINDLED
SEIZURES IN THE RAT.
004233 04-04
LIFE
NEUROLEPTIC TREATMENT FOR A SUBSTANTIAL PROPORTION OF ADULT
LIFE: BEHAVIOURAL-SEQUELAE OF 9 MONTHS HALOPERIDOL
ADMINISTRATION.
001858 02-05
LIFE EVENTS AND RESPONSE TO ANTIDEPRESSANTS.
003238 03-09
LIFE-TABLE
PROPHYLAQIC-EFFEa OF LITHIUM AGAINST DEPRESSION IN
CYCLOTHYMIC-PATIENTS: A LIFE-TABLE ANALYSIS.
004391 04-09
Lie AND
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A
LIGAND FOR NEUROLEPTIC-RECEPTORS - I. IN VITRO STUDIES.
001133 02-03
S-250
VOLUME 19, SUBJECT INDEX
Subject Index
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A
LIGANO FOR NEUROLEPTIC-RECEPTORS -- II. IN VIVO STUDIES.
001137 02-03
BENZODIAZEPINE-RECEPTOR: LOCALIZATION BY PHOTOAFFINITY
LABELING AND ISOLATION OF A POSSIBLE ENDOGENOUS LIGAND.
001381 02-03
ASCORBATE DECREASES LIGAND BINDING TO NEUROTRANSMITTER-
RECEPTORS.
002804 03-03
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMIHER AMINO-
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFACTORY-BULB.
002836 03-03
(3H)METERG0LINE: A NEW LIGAND OF SEROTONIN-RECEPTORS IN THE
RAT-BRAIN.
003825 04-03
OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES:
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES.
003902 04-03
HUMAN PLATELET ALPHA2-ADRENERGIC-RECEPT0RS: LABELING WITH 3H
YOHIMBINE, A SELEQIVE ANTAGONIST LIGAND.
004676 04-16
UOANDS
DISSIMILAR EFFECTS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE.
000173 01-03
PURINES AS ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTOR.
000276 01-03
CHANGES IN ALPHA-ADRENERGIC-RECEPTORS IN RAT-BRAIN IN VITRO BY
PREINCUBATION WITH ALPHA-ADRENERGIC LIGANDS.
001272 02-03
ENDOGENOUS LIGANDS FOR BENZODIAZEPINE-RECEPTORS.
003615 03-17
UOHT
EFFEQS OF MORPHINE, D-AMPHET AMINE, AND PENTOBARBITAL ON
SHOCK AND LIGHT DISCRIMINATION PERFORMANCE IN RATS.
001639 02-04
NEUROTENSIN-RECEPTOR LOCALIZATION BY LIGHT MICROSCOPIC
AUTORADIOGRAPHY IN RAT-BRAIN.
002938 03-03
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT.DARK
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO.
004544 04-13
UMA-STATE-HOSPITAL
FEDERAL-COURT UPHOLDS RIGHT-TO-REFUSE PSYCHOTROPIC-DRUGS,
ORDERS IMPROVEMENTS AT LIMA-STATE-HOSPITAL.
002583 02-17
UMBIC
DIFFERENTIAL-EFFEQS OF COCAINE ON LIMBIC EXCITABILITY.
001339 02-03
POSSIBLE LIMBIC SITES OF ACTION OF ANTIANXIETY-DRUGS.
002069 02-10
UMBIC-SYSTEM
INCORPORATION OF 4.5 3H LEUCINE INTO THE UMBIC-SYSTEM OF ICR
MICE AS A LONG-TERM EFFECT OF HALOPERIDOL APPLICATION.
000118 01-03
ANATOMICOPHYSIOLOGICAL AND NEUROCHEMICAL-STUDY OF THE
UMBIC-SYSTEM: EFFEQ OF NOMIFENSINE.
001160 02-03
THE EFFEQ OF CLONAZEPAM ON ATROPINE SPIKES IN THE UMBIC-
SYSTEM,
001274 02-03
LSD-INDUCED ULTRASTRUQURAL MODIFICATIONS OF UMBIC-SYSTEM
NUCLEI AND OTHER CEREBRAL ZONES.
002198 02-12
THE AQION OF BENZODIAZEPINES ON THE UMBIC-SYSTEM COMPARED
TO OTHER TRANQUIUZERS.
002731 03-03
UMIT
CASE-REPORT: USING AHRIBUTION THEORY TO UMIT NEED FOR
NEUROLEPTIC-MEDICINE.
000559 01-08
UMITS
UMITS, VALUE AND PERSPECTIVES OF THE PSYCHIATRIC-DIAGNOSIS IN
CUNICAL PSYCHOPHARMACOLOGY.
002631 02-17
FAQORS REGULATING DRUG CUE SENSITIVITY: UMITS OF
DISCRIMINABIUTY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SAUNE DISCRIMINATION.
004088 04-04
LINE
LINK
INHIBITION OF CHEMOTAXIS BY S 3 DEAZAADENOSYLHOMOCYSTEINE IN
A MOUSE MACROPHAGE CELL UNE, (UNPUBUSHED PAPER).
001100 02-03
CA DIAZEPAM LINK? NO SCIENTIFIC TAKERS SO FAR.
003519 03-15
ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN AHENTION-
DYSFUNaiON TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA.
004316 04-08
LINKED
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING-
SITES IN RAT STRIATUM.
000186 01-03
ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT
CELL TYPE SPECIFIC TOXIN. (UNPUBUSHED PAPER).
001064 02-01
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY
UNKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES.
001342 02-03
LIPASES
INHIBITION OF LYSOSOMAL LIPASES BY CHLORPROMAZINE: A POSSIBLE
MECHANISMS OF STABIUZATION.
003993 04-03
LIPID
ACTIONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID
METABOUSM IN GUINEA-PIG BRAIN SLICES.
000129 01-03
LIPIDS
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/AND
DIPHENYLHYDANTOIN IN SERUM UPIDS.
002281 02-13
LIPOLYSIS
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT UPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM.
002728 03-03
NALOXONE IN THE TREATMENT OF ANOREXIA-NERVOSA: EFFECT ON
WEIGHT-GAIN AND LIPOLYSIS.
003342 03-11
LIPOPEROXIDES
PSYCHOSOMATIC-STRESS AND UPOPEROXIDES OF HUMAN PLATELET
RICH PLASMA.
003423 03-13
LIPOPHILIC
MEASUREMENT OF THE MEMBRANE POTENTIAL OF ISOLATED NERVE
TERMINALS BY THE LIPOPHIUC CATION
(3H)TRIPHENYUV\ETHYLPH0SPH0NIUM-BR0MIDE.
002746 03-03
LIPOPROTEINS
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYUNE, AND NORTRIPTYUNE IN HEALTHY MAN.
002214 02-13
LIPOSOMES
PARTITIONING AND EFFLUX OF PHENOTHIAZINES FROM LIPOSOMES.
000007 01-02
PASSAGE THROUGH THE BLOOD-BRAIN-BARRIER OF THYROTROPIN-
RELEASING-HORMONE ENCAPSULATED IN UPOSOMES.
004298 04-06
LIPOTROPIN
VASOPRESSIN STIMULATES RELEASE OF BETA LIPOTROPIN AND BETA
ENDORPHIN IN CONSCIOUS RATS AS MEASURED BY
RADIOIMMUNOASSAY OF UNEXTRACTED PLASMA.
003715 04-03
LIQUID
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD
ETHANOL LEVELS IN RATS DRINKING A UQUID DIET.
001865 02-06
LIQUID-CHR0MAT06RAPHIC-DETERMINATI0N
SIMULTANEOUS HIGH-PERFORMANCE UQUID-CHROMATOGRAPHIC-
DETERMINATION OF AMITRIPTYUNE-HYDROCHLORIDE IN TWO-
COMPONENT TABLET FORMULATIONS.
004673 04-16
LIQUID-CHROMATOGRAPHY
ANALYSIS FOR DIAZEPAM AND NORDIAZEPAM BY ELEQRON-CAPTURE
GAS-CHROMATOGRAPHY AND BY LIQUID-CHROMATOGRAPHY.
000006 01-01
HYPOTHALAMIC CATECHOLAMINE BIOSYNTHESIS IN VITRO AS
MEASURED BY UQUID-CHROMATOGRAPHY AND ELECTROCHEMICAL-
DETECTION.
000537 01-06
3 CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE (GS-385), A
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION,
PHARMACOKINETICS AND METABOUSM USING HIGH-PERFORMANCE
LIQUID-CHROMATOGRAPHY.
000705 01-11
MEASUREMENT OF HALOPERIDOL IN HUMAN PLASMA USING REVERSED
PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY.
(UNPUBUSHED PAPER).
003667 04-01
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID-
CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION.
003674 04-01
'M
,iiit
S-251
Subject Index
Ptychopharmacology Abstracts
I
HIGH-PERFORMANCE LIQUID-CHROAAATOGRAPHY IN THE
NEUROSCIENCES: METHODOLOGY.
004285 04-06
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY IN THE
NEUROSCIENCES: APPLICATIONS.
004296 04-06
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION
PRODUCTS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH-
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE
DETECTION.
004302 04-06
LIQUOR
MORPHINE ANALGESIA FOLLOWING ITS INFUSION INTO DIFFERENT
LIQUOR SPACES IN RAT-BRAIN.
001429 02-03
LISTENING
LATERALIZED DEFICITS AND DRUG INFLUENCES ON THE DICHOTIC
LISTENING OF SCHIZOPHRENIC-PATIENTS.
003443 03-14
LISURIDE
ANORECTIC-EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES IN THE
RAT
000042 01-03
EFFECTS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS:
RELATION TO MICROSOMAL BIOTRANSFORMATION AND
DOPAMINERGIC-RECEPTOR STIMULATION .
001161 02-03
LISURIDE IN THE TREATMENT OF PARKINSONISM.
002168 02-11
DEPRESSION OF RESERPINE-INDUCED MUSCULAR RIGIDITY IN RATS AFTER
ADMINISTRATION OF LISURIDE INTO THE SPINAL SUBARACHNOID
SPACE.
002962 03-04
LISURIDE IN PARKINSONISM.
003319 03-11
LISURIDE IN PARKINSONISM.
003422 03-13
STIMULATORY ACTION OF LISURIDE ON DOPAMINE-SENSITIVE
ADENYLATE-CYCLASE IN THE RAT STRIATAL HOMOGENATE.
003718 04-03
LISURIDE-HYDROGEN-MALEATE
EFFECTS OF HIGH-DOSAGE LISURIDE-HYDROGEN-MALEATE (LHM) IN
PARKINSON-SYNDROME.
004460 04-11
L1THIOTHERAPY
ADHERENCE TO LITHIOTHERAPY.
002507 02-16
LITHIUM
LITHIUM LEVELS IN BLOOD-PLATELETS. SERUM, RED-BLOOD-CELLS AND
BRAIN REGIONS IN RATS GIVEN ACUTE OR CHRONIC LITHIUM-SALT
TREATMENTS.
000082 01-03
LITHIUM REDUCES THE NUMBER OF ACETYLCHOLINE-RECEPTORS IN
SKELETAL-MUSCLE.
000232 01-03
THE ACUTE AND CHRONIC EFFECT OF LITHIUM ON SERUM TESTOSTERONE
IN RATS.
000238 01-03
EFFECTS OF CHRONIC DIETARY LITHIUM ON ACTIVITY AND REGULATION
OF NA-K-ADENOSINE-TRIPHOSPHATASE IN RAT-BRAIN,
000297 01-03
LITHIUM: EFFEQS ON SEROTONIN-RECEPTORS IN RAT-BRAIN.
000304 01-03
LITHIUM RESPONSE IN GOOD PROGNOSIS SCHIZOPHRENIA.
000555 01-08
LITHIUM TREATMENT IN POSTPSYCHOTIC DEPRESSION.
000575 01-08
AFFECTIVE-EPISODE FREQUENCY AND LITHIUM THERAPY.
000587 01-09
EEG IN PATIENTS TREATED WITH LITHIUM.
000593 01-09
AGE, DEMENTIA, DYSKINESIAS, AND LITHIUM RESPONSE.
000594 01-09
HANDBOOK OF LITHIUM THERAPY.
000597 01-09
COGNITIVE AND AFFECTIVE-FUNQIONS IN PATIENTS WITH AFFEQIVE-
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY
QUESTIONNAIRE.
000604 01-09
LITHIUM LEVEL IN SOME BIOLOGICAL FLUIDS AT ITS PROPHYLAQIC
THERAPEUTIC APPLICATION.
000605 01-09
IMPAIRED GLUCOSE TOLERANCE IN LONG-TERM LITHIUM TREATED
PATIENTS.
000611 01-09
INTERACTION OF INDOMETHACIN AND IBUPROFEN WITH LITHIUM IN
MANIC-PATIENTS UNDER A STEADY-STATE LITHIUM LEVEL.
000622 01-09
THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH
DEPRESSIVE-SYNDROMES.
000625 01-09
THE EFFLUX OF LITHIUM FROM RED-BLOOD-CELLS AND THE EFFEQ OF
LITHIUM PROPHYLAXIS.
000630 01-09
LITHIUM TREATMENT IN AFFEQIVE-DISORDERS: THERAPEUTIC PLASMA
LEVEL.
000635 01-09
LITHIUM TREATMENT IN AFFEQIVE-DISOROERS FROM VIEWPOINT OF
TRANSCULTURAL PSYCHOPHARMACOLOGY: THERAPEUTIC PLASMA
LEVEL.
000636 01-09
THERAPEUTICS (II): LITHIUM
000641 01-09
COMPARATIVE-STUDY OF PROPHYLAQIC LITHIUM AND
DIETHYLSTILBESTROL IN SEXUAL-DEVIANTS.
000663 01-11
METHODOLOGICAL REMARKS ON LONG-TERM LITHIUM TREATMENT.
000749 01-13
IS LITHIUM MUTAGENIC IN MAN?
000753 01-13
EEG AND PSYCHOEXPERIMENTAL-STUDIES IN HEALTHY SUBJEQS ON
LITHIUM MEDICATION.
000768 01-13
A PSYCHOLOGICAL-VIEW ON PROBLEMS AND CONCEPTS OF LITHIUM
RESEARCH.
000810 01-14
ASSESSMENT OF MULTIVARIATE RELATIONSHIPS IN REAQIVITY OF
PATIENTS RECEIVING LITHIUM THERAPY
000819 01-14
RENAL FUNaiON AND BIOPSY IN PATIENTS ON LITHIUM THERAPY.
000830 01-15
ACUTE GENERALIZED POLYNEUROPATHY ACCOMPANYING LITHIUM
POISONING.
000835 01-15
RENAL FUNCTION IN LITHIUM AND NONLITHIUM TREATED PATIENTS
WITH AFFECTIVE-DISORDERS.
000837 01-15
TARDIVE-DYSKINESIA AND LITHIUM ASSOCIATED NEPHROPATHY: ARE
YOU LIABLE?
000846 01-15.
NEUROLOGICAL SIDE-EFFEaS OF LITHIUM: ORGANIC-BRAIN-SYNDROME, .
SEIZURES, EXTRAPYRAMIDAL SIDE-EFFEaS. AND EEG CHANGES.
000847 01-15
INTOXICATION ASSOCIATED WITH LITHIUM AND EQ.
000870 01-15
ELECTROCARDIOGRAPHIC-CHANGES DURING LITHIUM TREATMENT.
000881 01-15
NEUROTOXICITY OF LITHIUM. II.
000883 01-15.
CLINICALLY SIGNIFICANT SlDE-EFFEaS OF LITHIUM TREATMENT.
000893 01-15
PROLONGED CONFUSIONAL- STATE AND EEG SEIZURE AQIVITY
FOLLOWING CONCURRENT EQ AND LITHIUM USE.
000895 01-15
USE OF THE LITHIUM RESPONSE SCALE WITH AN OUTPATIENT
PSYCHIATRIC-SAMPLE.
000921 01-17
THE LITHIUM RATIO AS A GUIDE TO PATIENT COMPLIANCE.
000940 01-17
EFFECT OF NEUROLEPTIC-DRUGS ON LITHIUM UPTAKE BY THE HUMAN
ERYTHROCYTE.
000973 01-17
THE SELEQION OF LITHIUM RESPONDERS.
000997 01-17
THE EFFEa OF LITHIUM ON THE INCORPORATION OF 3H GLUCOSAMINE
INTO GLYCOPEPTIDES AND THE TRANSFORMATION OF 3H
GLUCOSAMINE INTO SIALIC-ACID IN RAT-BRAIN.
001209 02-03
EFFEQ OF LITHIUM ON STRESS-INDUCED CHANGES IN THE BRAIN LEVELS
OF MONOAMINES IN RATS.
001216 02-03
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION ^ „^ «„ „,
001300 02-03
CHRONIC LITHIUM REDUCES (3H)SPIR0PERID0L BINDING IN RAT
STRIATUM. ^„„,
001443 02-03
STUDY OF LITHIUM LEVELS IN THE SERUM AND GENITAL ORGANS OF
MALE RATS.
001494 02-03
LITHIUM EFFEaS ON HIGH-AFFINITY TRYPTOPHAN UPTAKE: EVIDENCE
AGAINST A STABILIZATION MECHANISM.
001496 02-03
S-252
VOLUME 19, SUBJECT INDEX
Subject Index
CONDITIONED SUPPRESSION OF DRINKING: A MEASURE OF THE CR
ELICITED BY A LITHIUM CONDITIONED FLAVOR.
001747 02-04
THE EFFECTS OF LITHIUM ON CHOICE BETWEEN COCAINE AND FOOD IN
THE RHESUS-MONKEY.
001825 02-04
ENDOCRINE-EFFECTS OF LITHIUM IN MANIC-DEPRESSIVE-PATIENTS.
001970 02-09
LITHIUM AND MANIA: HYPOTHESES.
001986 02-09
DISCUSSION OF CLINICAL-PAPERS ON LITHIUM TRANSPORT IN AFFECTIVE-
DISORDERS.
001987 02-09
LITHIUM AND HAIR-LOSS. (UNPUBLISHED PAPER).
002005 02-09
RAPID RECURRENCE OF MANIA FOLLOWING LITHIUM WITHDRAWAL.
002010 02-09
LITHIUM TRANSPORT STUDIES IN AFFECTIVE-DISORDERS.
002024 02-09
SENSITIZATION AND OSCILLATION FOLLOWING REPEATED STIMULATION:
RELATIONSHIP TO AFFECTIVE-ILLNESS AND ITS TREATMENT WITH
LITHIUM AND CARBAMAZEPINE.
002031 02-09
TARDIVE-DYSKINESIA IN DEPRESSED-PATIENTS: SUCCESSFUL THERAPY
WITH ANTIDEPRESSANTS AND LITHIUM.
002037 02-09
THE RELATIVE PROPHYLACTIC EFFICACY OF LITHIUM AGAINST MANIC
AND DEPRESSIVE RECURRENCES IN BIPOLAR-PATIENTS.
002040 02-09
EFFECT OF LITHIUM ON POTASSIUM AND CALCIUM IN SERUM,
ERYTHOCYTES AND IN URINE.
002054 02-09
PHARMACODYNAMIC ASPEQS OF LONG-TERM PROPHYLACTIC LITHIUM.
002212 02-13
NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTRODUCTION.
002227 02-13
CLINICAL-ASPEQS OF LITHIUM EFFLUX FROM ERYTHROCYTES.
002228 02-13
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE.
002242 02-13
LITHIUM AND THE KIDNEY.
002244 02-13
ABNORMALITIES OF LITHIUM TRANSPORT IN PATIENTS WITH AFFECTIVE-
DISORDERS.
002269 02-13
QUANTITATIVE STUDY OF THE DISTRIBUTION OF LITHIUM IN THE MOUSE-
BRAIN FOR VARIOUS DOSES OF LITHIUM GIVEN TO THE ANIMAL.
002299 02-13
LITHIUM THERAPY IN AGGRESSIVE MENTALLY-SUBNORMAL-PATIENTS.
002316 02-14
AN UNUSUAL SIDE-EFFEQ OF LITHIUM.
002381 02-15
LITHIUM AND RENAL FUNCTION.
002416 02-15
EFFEQS OF LITHIUM ON EVOKED-POTENTIALS AND PERFORMANCE
DURING SUSTAINED AHENTION.
002419 02-15
DIURETICS ARE DANGEROUS WITH LITHIUM.
002420 02-15
BRADYCARDIA, PERSISTENT DIABETES-INSIPIDUS, AND TARDIVE-
DYSKINESIA WITH LITHIUM INTOXICATION.
002427 02-15
FAILURE OF LITHIUM TREATMENT IN ESTABLISHED TARDIVE-DYSKINESIA.
002432 02-15
LITHIUM: PROBLEMS OF APPLICATION, TOLERANCE, AND EFFICACY
002434 02-15
UPDATE ON LITHIUM: 1979-1980.
002450 02-15
NEUROTOXICITY OF LITHIUM. I.
002452 02-15
LITHIUM IN 1979.
002457 02-15
RECENT DEVELOPMENTS IN LITHIUM TREATMENT: IS IT DANGEROUS FOR
THE KIDNEY?
rrrr^o-, 002465 02-15
EFFEQS OF LITHIUM, AND LITHIUM AND ALCOHOL ADMINISTRATION ON
NA-K-ATPASE.
002744 03-03
EFFEQS OF LITHIUM ON MORPHOLOGICAL CHARACTERISTICS OF
DISSOCIATED BRAIN CELLS IN CULTURE.
002765 03-03
LITHIUM, ASSIMILATION OF NUTRIENTS AND REPRODUCTION
(UNPUBLISHED PAPER).
rr„. (Xtllll 03-03
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM-
ELEQROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON.
002884 03-03
INFLUENCE OF PSYCHOTROPIC-DRUGS ON THE URINARY ELIMINATION OF
LITHIUM,
002895 03-03
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNCTION IN CAT BRAIN
002911 03-03
COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION
IN THE RAT MODEL.
002928 03-03
LITHIUM AND PORCINE AGGRESSION.
003048 03-04
SELECTIVE SENSITIZATION INDUCED BY LITHIUM MALAISE AND
FOOTSHOCK IN RATS.
003055 03-04
CAN THE ANTIDEPRESSIVE PROPERTIES OF LITHIUM BE DETERMINED
EXPERIMENTALLY?
003089 03-04
LITHIUM DRUG INTERACTIONS ALTERING THE INTRACELLULAR LITHIUM
LEVEL: AN IN VITRO STUDY.
003142 03-06
STEADY-STATE LITHIUM BLOOD LEVEL FLUCTUATIONS IN MAN
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FORM.
003151 03-07
SYNERGISM OF COMBINED LITHIUM NEUROLEPTIC THERAPY: A DOUBLE-
BLIND, PLACEBO-CONTROLLED CASE-STUDY.
003165 03-08
LITHIUM COMBINED WITH NEUROLEPTICS IN CHRONIC SCHIZOPHRENIC-
PATIENTS AND SCHI20AFFECTIVE-PATIENTS.
003168 03-08
LATE RESULTS OF LITHIUM TREATMENT OF ADOLESCENTS WITH AHACK
LIKE SCHIZOPHRENIA.
003177 03-08
CORRELATIONS BETWEEN LITHIUM LEVELS IN CEREBROSPINAL-FLUID AND
LITHIUM LEVELS IN BLOOD PLASMA AND ERYTHROCYTES.
003210 03-09
HYPOMANIA AS A STABLE STATE: LITHIUM PROPHYLAXIS IN TWO
PATIENTS.
003212 03-09
LITHIUM EFFECT ON PARATHYROID-HORMONE.
003215 03-09
HISTORICAL-PERSPECTIVES AND CURRENT HIGHLIGHTS ON LITHIUM
TREATMENT IN MANIC-DEPRESSIVE-ILLNESS.
003224 03-09
DOSAGE OF INTRATUMORAL LITHIUM (CEREBRAL GLIOBLASTOMA): ON A
FAILURE OF TREATMENT OF MANIC-DEPRESSIVE-PSYCHOSIS.
003226 03-09
PROPHYLACTIC LITHIUM WITH AND WITHOUT IMIPRAMINE FOR BIPOLAR-
l-PATIENTS; A DOUBLE-BUND STUDY.
003233 03-09
LITHIUM IN CHILDREN OF LITHIUM RESPONDING PARENTS.
003242 03-09
LITHIUM: A BIOPSYCHOSOCIAL-PERSPECTIVE.
003247 03-09
LITHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND
BIPOLAR-II DEPRESSION: A PROSPECTIVE, PLACEBO-CONTROLLED
COMPARISON.
003252 03-09
LITHIUM UPTAKE IN RED CELLS OF CYCLOID AND UNIPOLAR DYSTHYMIC-
PATIENTS.
003258 03-09
LITHIUM IN 1978.
003261 03-09
LITHIUM AND THE CHANGING INCIDENCE OF MANIA.
003265 03-09
EFFECT OF LITHIUM ON PROLACTIN RESPONSES TO THYROTROPIN-
RELEASING-HORMONE IN PATIENTS WITH MANIC- STATE.
003266 03-09
CONFESSION OF A MELANCHOLIAC: CONTRIBUTION TO THE PROBLEM OF
PROPHYLAXIS OF MANIC-DEPRESSIVE-PSYCHOSIS USING LITHIUM.
003267 03-09
THE EFFECT OF WITHDRAWAL FROM PROLONGED PROPHYLACTIC
TREATMENT WITH LITHIUM.
003339 03-11
EFFICACY OF LITHIUM IN TREATING MOOD-DISORDER OCCURRING AFTER
BRAINSTEM INJURY.
003354 03-11
INTRACELLULAR LITHIUM: ITS VALUE IN THE PREDICTION OF A POSITIVE
RESPONSE TO LITHIUM.
003382 03-11
LITHIUM TREATMENT OF THE KLEINE-LEVIN-SYNDROME.
003390 03-1 1
DERMATOLOGIC MANIFESTATIONS OF LITHIUM: A REVIEW.
003462 03-15
LITHIUM PROPHYLAXIS AND THE KIDNEY.
003463 03-15
RENAL IMPAIRMENT, HYPERCALCEMIA, AND LITHIUM THERAPY.
003473 03-15
(IHM^I
S-253
/ias66sussiSk
Subject Index
Ptychopharmacology Abstracts
III,
Ml';
'«B!il
a' ■
*1lt
1
A CASE OF REVERSIBLE PURE-WORD DEAFNESS DURING LITHIUM
TO^'C'^^ 003481 03-15
HYPERPARATHYROIDISM IN ASSOCIATION WITH LITHIUM THERAPY
003489 OJ" I ->
SOME HAZARDS OF LITHIUM USE. 003498 03-15
LITHIUM THERAPY AND THYROID-FUNCTION: A LONG-TERM STUDY
003504 03-15
TIME-COURSE OF CLINICAL CHEMICAL PARAMETERS UNDER LONG-TERM
LITHIUM TREATMENT. 003515 03-15
LITHIUM KINETICS DURING HEMODIALYSIS IN A PATIENT WITH LITHIUM
PO'SONING. 003524 03-15
LITHIUM AND MARIJUANA. 003526 03-15
LITHIUM NEUROTOXICITY AT THERAPEUTIC LEVELS: A ^ASE^RETO^RT^^^^
LITHIUM AND THE KIDNEY SCARE. 003534 03-15
GLOMERULAR FILTRATION RATE AND CALCIUM METABOLISM IN LONG-
TERM LITHIUM TREATMENT. 003542 03-15
PERIPHERAL NEUROPATHY DUE TO LITHIUM INTOXICATION.
003544 OJ- 1 3
RENAL SIDE-EFFECTS OF LITHIUM: THE IMPORTANCE OF THE SERUM
LITHIUM LEVEL. 003547 03-15
BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY Of^L^U^L^ ,^
LITHIUM AND MANIA, 003640 03-17
EFFECT OF LOW-DOSE LITHIUM ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL ON BIOGENIC-AMINES IN RAT-BRAIN.
00 J 700 U4-U0
THE EFFECTS OF LITHIUM ON MYOINOSITOL LEVELS IN LAYERS OF
FRONTAL-CEREBRAL-CORTEX. IN CEREBELLUM, AND IN CORPUS-
CALLOSUMOFTHERAT. 003712 04-03
DOPAMINE METABOLITES IN CAUDATE AND CORTEX AFTER LITHIUM AND
HALOPERIDOL. (UNPUBLISHED PAPER). ^^^^^ ^^^
THE EFFECT OF LONG-TERM CONCURRENT ADMINISTRATION OF
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL
CORTICAL DOPAMINE METABOLISM IN RATS. ^^^^^ ^^^^
LITHIUM INDUCES DOSE-RELATED INCREASES AND DECREASES IN
ACTIVITY LEVELS IN THE RAT. 004079 04-04
EFFECTS OF LITHIUM ON BEHAVIOUR AND CENTRAL MONOAMINES.
0041 10 04-04
LITHIUM AMELIORATION OF RESERPINE-INDUCED HYPOAQIVITY IN
^'^^^ 004167 04-04
LITHIUM AND MOTOR-ACTIVITY OF ANIMALS: EFFEQS AND POSSIBLE
MECHANISM-OF-ACTION. 004222 04-04
CENTRAL AND PERIPHERAL EFFEaS OF LITHIUM ON AMPHETAMINE-
INDUCED HYPERACTIVITY IN RATS. 004223 04-04
LITHIUM EFFECTS ON HALOPERIDOL-INDUCED PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINE-RECEPTOR SUPERSENSITIVITY^
004244 04-04
EFFECTS OF INDOMETHACIN AND METHYLPREDNISOLONE ON RENAL
ELIMINATION OF LITHIUM IN THE RAT.
004270 04-05
EVALUATION OF LITHIUM RESPONSE: PSYCHOMETRIC-FINDINGS^
004348 04-UV
RECEPTORS, ADENYUVTE-CYCLASE, DEPRESSION, AND LITHIUM^
004353 04-Ov
CLINICAL SIGNIFICANCE OF THE ERYTHROPLASMATIC RATIO OF LJTHIUM.
004357 04-OV
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFEQIVE-DISORDERS
(EFFEaiVENESS OF LOW PLASMA LEVELS AND PREDIQORS TO
CLINICAL-RESPONSE). 004365 04-09
LITHIUM USE IN AFFECTIVE-DISORDERS. ^^^^^ ^^^^
LITHIUM ELIMINATION HALF-LIFE AND DURATION OF THERAPY^
004367 04-uy
PROPHYLACTIC-EFFECT OF LITHIUM AGAINST DEPRESSION IN
CYCLOTHYMIC-PATIENTS: A LIFE-TABLE ANALYSIS.
004391 04-09
LITHIUM TREATMENT OF MANIC-DEPRESSIVE-ILLNESS. A PRAQICAL
^"'°^- 004408 04-09
LITHIUM AND AGGRESSIVE-BEHAVIOR. ^^^^ ^^^
AN AHEMPT TO ASSESS THE EFFEQ OF LITHIUM ON THE NEUTROPHIL
LEUKOCYTE SYSTEM IN AFFEQIVE-PSYCHOSIS. ^,,,. „. no
004416 04-09
MECHANISM OF LITHIUM INCLUDED ELEVATION IN RED-BLOOD-CEU
CHOLINE CONTENT: AN IN VITRO ANALYSIS.
004511 04-13
A MECHANISM FOR THE ACCUMULATION OF CHOLINE IN ERYTHROCYTES
DURING TREATMENT WITH LITHIUM.
004520 04-13
LITHIUM EFFEaS ON CITRATE METABOLISM IN HUMANS AND RATS.
004537 04-13
NEUROLOGICAL TOLERANCE OF LITHIUM AND PSYCHOTROPIC-DRUGS IN
COMBINATION: 265 CASES. ^.,„. „. ,c
004594 04-15
EFFECT OF LITHIUM ON GLYCINE LEVELS IN PATIENTS WITH AFFEQIVE-
DISORDERS. ^..„, „. ,c
004606 04-15
EFFECT OF LITHIUM ON REAQION-TIME - A STUDY OF DIURNAL
VARIATIONS. „„.,„, „.,c
004607 04-15 1
OPHTHALMOLOGICAL SIDE-EFFEQS OF LITHIUM.
004615 04-15
A CASE OF PETIT-MAL EPILEPSY AGGRAVATED BY LITHIUM.
004641 04-15 ]
THE ROLE OF LITHIUM IN THE PRODUCTION OF INTERSTITIAL NEPHRITIS:
A CASE-HISTORY. „„.,,.„. ,c
004655 04-15
MITIGATING ACUTE SKIN RASHES AND NAUSEA FROM LITHIUM.
004661 04-15
KIDNEY FUNQION IN PATIENTS WITH AFFEaiVE-DISORDERS WITH AND
WITHOUT LITHIUM THERAPY „„,,.„,,,
004664 04-15
CEREBRAL FLUORIDE IN MANIA AND THE EFFEQ OF LITHIUM: A
HYPOTHESIS. ^.-,,c«. ,,
004715 04-17
LITHIUM-CARBONATE
THE TREATMENT OF SCHIZOAFFEQIVE-PSYCHOSES WITH LITHIUM-
CARBONATE „„„,„-, „, ^
000607 01-09
GROWTH-HORMONE (GH) RELEASE FOLLOWING THYROTROPIN-
RELEASING-HORMONE (TRH) INJEQION IN MANIC-PATIENTS
RECEIVING LITHIUM-CARBONATE 000645 01-09
LITHIUM-CARBONATE IN THE TREATMENT OF CLUSTER-HEADACHES.
000670 01-11
A CASE OF TRIGEMINAL-NEURALGIA TREATED WITH LITHIUM-
C^'^^°'^*^^ 000690 01-11
THE INFLUENCE OF LITHIUM-CARBONATE ON MOOD AND PERFORMANCE
IN HEALTHY SUBJEQS. 00071101-11
EFFEQ OF LITHIUM-CARBONATE ON CIRCADIAN-PERIODICITY IN
"^^^'^^ 000772 01-13
EFFEQS OF LITHIUM-CARBONATE ON MEMORY AND OTHER COGNITIVE
fU^^'O'^S 000824 01-14
A CASE OF CARDIOVASCULAR COLLAPSE DURING LITHIUM-CARBONATE ,
^"^'^^'"^ 000860 01-15
CUTANEOUS REAQION TO LITHIUM-CARBONATE: A CASE-REPORT
000872 01- 1 J
BILATERAL PAPILLOEDEMA IN LONG-TERM THERAPY WITH UTHIUM-
CARBONATE. 000878 01-15
THE USE OF LITHIUM-CARBONATE IN ADOLESCENCE. ^^^^^ ^^^^
COMPARISON OF THE CLASSICAL AND RETARDED FORM OF LITHIUM-
CARBONATE. 001888 02-07
A COMPARISON OF HALOPERIDOL, LITHIUM-CARBONATE AND THEIR
COMBINATION IN THE TREATMENT OF MANIA. ^^ ^ ^^_^
PREDIQION OF DOSAGE OF LITHIUM-CARBONATE: USE OF A STANDARD
PREDIQIVE METHOD. 00199102-09
A TEN YEAR FOLLOWUP OF LITHIUM-CARBONATE TREATMENT OF MANIC-
DEPRESSIVE-ILLNESS: PRELIMINARY-RESULTS. ^^^^ ^^^
LITHIUM-CARBONATE AND WEIGHT-GAIN. ^^^^ ^^^^
STEADY-STATE LITHIUM BLOOD LEVEL FLUQUATIONS IN MAN
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FOR^^^j, ^^^^
CEREBRAL EVOKED-POTENTIAL CHANGES PRODUCED BY TREATMENT
WITH LITHIUM-CARBONATE. 003263 03-09
THE USE OF LITHIUM-CARBONATE FOR TREATING KUGELBERG-WELANDER
SPINAL AMYOTROPHY PATIENTS. 003326 03-11
S-254
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE, HOSPITALIZED SCHOOL-AGE CHILDREN,
003360 03-11
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN.
003361 03-11
THE MANAGEMENT OF CHRONIC BEHAVIOR-DISORDERS IN MENTALLY-
RETARDED ADULTS WITH LITHIUM-CARBONATE.
003376 03-11
LITHIUM-URBONATE AND THE KIDNEY.
003478 03-15
COMPARATIVE CHARACTERISTICS OF THE PROPHYLACTIC PROPERTIES OF
SHORT-TERM AND LONG-ACTING LITHIUM-CARBONATE PREPARATIONS
IN ENDOGENOUS AFFECTIVE-PSYCHOSES.
004390 04-09
CLINICAL-EVALUATION OF THE PROPHYLACTIC EFFECTIVENESS OF
PROLONGED LITHIUM-CARBONATE THERAPY IN ENDOGENOUS
DEPRESSIVE-SYNDROMES.
004404 04-09
UNWANTED EFFECTS OF LITHIUM-CARBONATE USED IN THE PREVENTION
OF RELAPSES OF AFFECTIVE-ILLNESS.
004625 04-15
LITHIUM-CARBONATE IN THE TREATMENT OF MOVEMENT-DISORDERS. A
CRITICAL REVIEW.
004668 04-15
UTHIUM-CARBONICUM-RETARD
CLINICAL-EXPERIENCE WITH UTHIUM-CARBONICUM-RETARD IN
PSYCHIATRY.
002000 02-09
UTHIUM-CHLORIDE
EFFECT OF AGE AND ROUTE-OF-ADMINISTRATION ON LD50 OF LITHIUM-
CHLORIDE IN THE RAT.
001413 02-03
EFFECT OF LITHIUM-CHLORIDE IN COYOTE PUP DIET.
001835 02-05
LITHIUM-CHLORIDE AND DELTA9 THC LEAD TO CONDITIONED AVERSIONS
IN THE PIGEON.
003003 03-04
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE
BUT NOT LITHIUM-CHLORIDE.
003110 03-04
UTHIUM-HYDROXYBUTYRATE
THE EFFECT OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELECTRICAL-
AQIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUCTURES OF
THE RABBIT BRAIN.
003994 04-03
LITHIUM-INDUCED
ABSENCE OF LITHIUM-INDUCED TASTE-AVERSION AFTER AREA-POSTREMA
LESION.
000456 01-04
LITHIUM-INDUCED COGWHEEL RIGIDITY: TREATMENT WITH
AMANTADINE.
LITHIUM-INDUCED CHANGES IN THE BRAIN LEVELS OF FREE AMINO-ACIDS
IN STRESS-EXPOSED RATS.
001217 02-03
ATTENUATION OF THE LITHIUM-INDUCED DIABETES-INSIPIDUS-LIKE
SYNDROME BY AMILORIDE IN RATS.
EFFEaS OF DORSOLATERAL TEGMENTAL LESIONS ON AMPHETAMINE- '
INDUCED AND LITHIUM-INDUCED TASTE-AVERSIONS
IITHIUM-ION 003114 03-04
INTRA AND EXTRA ERYTHROCYTE LITHIUM-ION CONCENTRATION RATIOS
IN MANIC-PATIENTS.
LITHIUM-ION ENTRY INTO CULTURED CELLS OF NEURAL ORIGIi?.*^^^ °^'°'
THE LITHIUM-ION: IS IT SPECIFIC FOR MANIA? °°''*^^ °^"°^
UTHIUM-OXYBUTYRATE 002516 02-16
AN EXPERIMENTAL-STUDY OF THE NEUROTROPIC-AQION OF UTHIUM-
OXYBUTYRATE.
UTHIUM-PUMP 001705 02-04
UTHIUM-PUMP REPRESSION AS AN INDICATOR OF PROPHYLACTIC
RESPONSE.
001989 02-09
' to'KTl^Ct[c mAlMEN^'f''''^'' ^' "' ""'^™'^ °' ''''°'^^
LITHIUM-SALT °°3221 03-09
UTHIUM LEVELS IN BLOOD-PLATELETS, SERUM, RED-BLOOD-CELLS AND
BRAIN REGIONS IN RATS GIVEN ACUTE OR CHRONIC UTHIUM-SALT
TREATMENTS.
LITHIUM-SALTS 000082 01-03
THE INFLUENCE OF UTHIUM-SALTS AND ANTIDEPRESSANT MEDICATION
ON SERUM PROLACTIN LEVEL.
000780 01-13
LITHIUM-SALTS IN LEUKOPENIC-DISORDERS.
001000 01-17
MOTOR-LEARNING ABIUTIES IN SUBJECTS TREATED WITH UTHIUM-SALTS
AND TRICYCLIC-ANTIDEPRESSANTS.
002058 02-09
PREDICTIVE CRITERIA FOR LITHIUM-SALTS ACTIVITY.
002619 02-17
LIVER
BETA OIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND
2,4 DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR (DPEA) INHIBITION
OF FATTY-ACID CONJUGATION TO 1 1 HYDR0XY-DELTA9-
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM
000179 01-03
THE EFFECTS OF GONADECTOMY AND HYPOPHYSECTOMY ON THE
METABOUSM OF IMIPRAMINE AND UDOCAINE BY THE UVER OF MALE
AND FEMALE RATS.
000273 01-03
FOLLOWUP STUDY ON THE INFLUENCE OF AN ANTIPSYCHOTIC-DRUG
(PROPERICIAZINE) ON LIVER FUNCTION, ELECTROCARDIOGRAM AND
ELECTROENCEPHALOGRAM.
000639 01-09
COMPARISON OF CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE (CSD)
ISOENZYMES AND GLUTAMIC-ACID-DECARBOXYLASE (GAD) IN RAT- IS
BRAIN CSD-I IDENTICAL WITH UVER CSD AND BRAIN CSD-II WITH
GAD? (UNPUBLISHED PAPER).
. ' 001048 02-01
ESR STUDIES OF SPIN LABELLED BOVINE LIVER MONOAMINE-OXIDASE-B
(UNPUBUSHED PAPER).
001065 02-01
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN
THE DOG.
001547 02-03
COMPARATIVE-STUDY OF THE INDUCTIVE EFFECT OF TWO
PSYCHOMODERATORS ~ TETRABAMATE AND COMPLEXE-1656 - AND
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS
001874 02-06
DRUG-INDUCED DISORDERS OF THE UVER.
002397 02-15
PLASMA IMIPRAMINE LEVELS AND DEMETHYLASE ACTIVITY IN THE
UVER OF STRESSED ANIMALS.
002793 03-03
EFFECTS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L
TRYPTOPHAN BY ISOLATED RAT LIVER CELLS.
002899 03-03
HALOTHANE ACCUMULATION IN RAT-BRAIN AND UVER.
003774 04-03
EFFECTS OF ANIMAL AGE AND PHENOBARBITAL ON RAT LIVER GLUCOSE-
6-PHOSPHATASE ACTIVITY.
003997 04-03
OXIDATION OF BETA PHENYLETHYLJ^MINE BY BOTH TYPES OF
MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND
LIVER MITOCHONDRIA OF EIGHT SPECIES.
004024 04-03
LI2C03
LEVELS OF MINERAL-ELEMENTS IN THE SERUM AND SALIVA OF HEALTHY
MALE VOLUNTEERS AFTER A SINGLE-DOSE OF LI2C03.
002297 02-13
LM24056
INHIBITION OF PENTAGASTRIN-STIMULATED AND OVERNIGHT GASTRIC
SECRETION BY LM24056, A NEW PHENOTHIAZINE DERIVED
ANTISECRETORY DRUG.
004306 04-07
LOAD
ENHANCEMENT OF RAT-BRAIN METABOLISM OF A TRYPTOPHAN LOAD
BY CHRONIC ETHANOL ADMINISTRATION.
000022 01-03
EEG CHANGES IN CHILDREN WITH TREATED PHENYLKETONURIA AFTER
PHENYLALANINE LOAD.
002115 02-11
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND
LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJECTS
003311 03-11
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
LOAD.
004600 04-15
LOADED
CENTRAL-EFFECTS OF ANGIOTENSIN-II IN WATER AND SAUNE LOADED
RATS.
003845 04-03
LOBE
EXPERIENCE IN USING THE HORMONES OF THE HYPOPHYSIS POSTERIOR
LOBE IN MEMORY-DISTURBANCES OF VARYING GENESES.
003438 03-14
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE
PITUITARY MEMBRANES.
004003 04-03
"''It
M
III!!:
StC
S-255
Subject Index
Ptychopharmocology Abstracts
dill' I
4E111.
I
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM
INTERMEDIATE/POSTERIOR LOBES OF PITUITARY.
003846 04-03
LOBOTOMY
ALPHA 1 -ADRENOCEPTORS AND ALPHA2-ADREN0CEPT0RS IN RAT-
CEREBRAL-CORTEX: EFFECT OF FRONTAL LOBOTOMY.
003944 04-03
""^^HE ROLE OF BIOGENIC-AMINES IN AMYGDALAR KINDLING. I. LOCAL
AMYGDALARAFTERDISCHARGE. 000327 01-03
MAPPING OF DYSKINETIC-MOVEMENTS INDUCED BY LOCAL APPLICATION
OF PICROTOXIN OR 0 GAMMA ACETYLENIC-GABA ON THE RAT
f^O^OR-ZORliX. 000458 01-04
A COMPARISON OF THE EFFECTS OF D-AMPHETAMINE, COCAINE,
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE. 000508 01-04
INHIBITION BY LOCAL ANESTHETICS. PHENTOLAMINE AND PROPRANOLOL
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL
MUSCARINIC-RECEPTORS. 001097 02-03
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIRECT VASODIUVTOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRICTION. 001109 02-03
LOCAL CEREBRAL GLUCOSE UTILIZATION (LCGU) IN RAT-BRAIN DURING
HYPOXEMIA. (UNPUBLISHED PAPER). 001380 02-03
THEORY PROCEDURE, AND APPLICATIONS OF THE RADIOACTIVE
DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL GLUCOSE
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM. (UNPUBLISHED
^'^^^^'^ 001877 02-06
LOCAL AND DISTANT NEURONAL DEGENERATION FOLLOWING
INTRASTRIATAL INJECTION OF KAINIC-ACID
00 I ooD Uz-Uo
THE INTERACTION OF AMINE LOCAL ANESTHETICS WITH MUSCARINIC-
^^"''TO^S 004031 04-03
NEURONAL LOCALISATION OF BENZODIAZEPINE-RECEPTORS IN
"^^^^^^^'^ 003739 04-03
""^^^OCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES
OF THE DEVELOPING CHICK RETINA. 000065 01-03
CALCIUM LOCALIZATION IN THE SYMPATHETIC GANGLION OF THE
BULLFROG AND EFFECTS OF CAFFEINE. 000098 01-03
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING-
SITES IN RAT STRIATUM. 000186 01-03
LOCALIZATION OF NALOXONE SENSITIVE (3H)DIHYDR0M0RPHINE
BINDING-SITES WITHIN THE HIPPOCAMPUS OF THE RAT.
001368 02-03
BENZODIAZEPINE-RECEPTOR: LOCALIZATION BY PHOTOAFFINITY
LABELING AND ISOLATION OF A POSSIBLE ENDOGENOUS LIGAND.
001381 02-03
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES.
001402 02-03
HISTOCHEMICAL LOCALIZATION OF OPIATE-RECEPTORS AND THE
^^^^''"^^"^^ 002566 02-17
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA
AND MEDIAL NUCLEUS-TRACTUS-SOLITARIUS OF RAT-BRAIN.
002634 03-01
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE
SPINAL-CORD OF THE CAT. ENKEPHALIN-CONTAINING MARGINAL
NEURONS AND PAIN MODULATION. 002638 03-01
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY. 002639 03-01
BENZODIAZEPINE-RECEPTORS: AUTORADIOGRAPHICAL AND
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN
REGIONS OF GABAERGIC SYNAPTIC CONTACTS.
00/643 03-U I
BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND
CELLULAR LOCALIZATION.
002655 03-03
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERAQION WITH
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN.
002727 03-03
LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID.
002828 03-03
INHIBITORY ACTIONS OF TAUROCY AMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES
002846 03-03
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING:
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN
HYPERTENSION
002874 03-03
NEURONAL LOCALIZATION OF BENZODIAZEPINE-RECEPTORS IN THE
MURINE CEREBELLUM. „„.„„. „. «o
002902 03-03
NEUROTENSIN-RECEPTOR LOCALIZATION BY LIGHT MICROSCOPIC 1
AUTORADIOGRAPHY IN RAT-BRAIN. I
002938 03-03
ULTRASTRUCTURAL LOCALIZATION OF MONOAMINES IN NERVE FIBERS
OF THE PINEAL-GL^ND IN GOLDEN HAMSTERS.
003666 04-01
REGIONAL AND SUBCELLULAR LOCALIZATION IN RAT-BRAIN OF THE
ENZYMES THAT CAN SYNTHESIZE GAMMA HYDROXYBUTYRIC-ACID
003675 04-01
AUTORADIOGRAPHIC LOCALIZATION OF DRUG AND NEUROTRANSMIHER-
RECEPTORS IN THE BRAIN.
004292 04-06
LOCALIZED
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS ARE LOCALIZED IN THE
INNER PLEXIFORM LAYER OF RAT RETINA.
000277 01-03
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS
INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJEQION OF
CYCLOHEXIMIDE „„„,„„ „o no
002780 03-03
EFFECTS OF EXPERIMENTER AND TEST LOCATION NOVELTY ON
NONSPECIFIC ACTIVITY IN RATS AND ITS MODIFICATION BY
METHAMPHETAMINE.
000409 01-04
ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE
IN RAT-BRAIN. „„,„„„ „o«-,
001320 02-03
BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFEQS OF CHRONIC
AMPHETAMINE INTOXICATION. 001653 02^
CATS DEVELOP TOLERANCE TO D-AMPHET AMINES EFFEaS UPON
LOCOMOTION AND STEREOTYPED-BEHAVIORS. ^^^^ ^^^
THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS^
""^^MESOLIMBICOCORTICAL DOPAMINE TERMINAL-FIELDS ARE NECESSARY
FOR NORMAL LOCOMOTOR AND INVESTIGATORY EXPLORATION IN
^'^^^ 000383 01-04
LOCOMOTOR AND CONVULSIVE RESPONSES TO PICROTOXIN IN
AMYGDALA KINDLED RATS. 000416 01-04
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNQION.
00044o 01*04
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT
ANTICHOLINERGIC-AQIVITY BY AN ATYPICAL NEUROLEPTIC
(THIORIDAZINE). 003560 03-16
"■^^^tFTEaS OR. AND D AMINO-ACIDS ON ANALGESIA AND LOCOMOTOR-
ACTIVITY OF MICE: THEIR INTERACTION WITH MORPHINE^^
000336 Ul-W
STRAIN DEPENDENT EFFEQS OF KETAMINE ON LOCOMOTOR-ACTIVITY
ANDANTINOCICEPTIONINMICE. 000382 01-04
THE EFFECTS OF DOPAMINERGIC-AGENTS ON THE LOCOMOTOR-AQIVITY
OF RATS AFTER HIGH-DOSES OF METHYLAMPHETAMINE.^^^^^^ ^^^
S-256
VOLUME 19, SUBJECT INDEX
Subject Index
LOCOMOTOR-ACTIVITY ELICITED BY INJECTIONS OF PICROTOXIN INTO THE
VENTRAL TEGMENTAL AREA IS ATTENUATED BY INJECTIONS OF GABA
INTO THE GLOBUSPALLIDUS
000436 01-04
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS.
000466 01-04
INFLUENCE OF THYROTROPIN-RELEASING-HORMONE AND HISTIDYL-
PROLINE-DIKETOPIPERAZINE ON SPONTANEOUS LOCOMOTOR-ACTIVITY
AND ANALGESIA INDUCED BY DELTA9 TETRAHYDROCANNABINOL IN
THE MOUSE.
001575 02-04
EFFECT OF APOMORPHINE ON MORPHINE-INDUCED DECREASE IN
LOCOMOTOR-ACTIVITY AND INCREASE IN DOPAMINE TURNOVER IN
RATS.
001728 02-04
DISSOCIATION OF D-AMPHETAMINE-INDUCED LOCOMOTOR-ACTIVITY AND
STEREOTYPED-BEHAVIOUR BY LESIONS OF THE SUPERIOR-COLLICULUS.
001755 02-04
EFFECTS OF CHLORDIAZEPOXIDE MORPHINE COMBINATIONS ON
SPONTANEOUS LOCOMOTOR-ACTIVITY IN THREE INBRED STRAINS OF
MICE.
001766 02-04
BIPHASIC-EFFECTS OF A POTENT ENKEPHALIN ANALOGUE D MET2-PR05-
ENKEPHALINAMIDE AND MORPHINE ON LOCOMOTOR-ACTIVITY IN
MICE.
001799 02-04
HIPPOCAMPAL SEROTONIN REUPTAKE AND NOCTURNAL LOCOMOTOR-
ACTIVITY AFTER MICROINJECTIONS OF 5,7 DHT IN THE FORNIX-
FIMBRIA.
002929 03-03
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF LOW-DOSES OF A
DOPAMINE AGONIST ON DRINKING AND LOCOMOTOR-ACTIVITY IN THE
RAT.
002982 03-04
INJECTIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINERGIC AND
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS: EFFECTS ON
LOCOMOTOR-ACTIVITY IN THE RAT.
003019 03-04
TRH INCREASES LOCOMOTOR-ACTIVITY IN RATS AFTER INJECTION INTO
THE HYPOTHALAMUS.
003044 03-04
OPPOSITE EFFECTS OF NALOXONE ON SUBSTANCE-P-INDUCED IN BRAIN
DOPA SYNTHESIS AND IN LOCOMOTOR-ACTIVITY IN RATS.
003799 04-03
LOCOMOTOR-ACTIVITY IN MORPHINE-DEPENDENT AND POSTDEPENDENT
RATS.
004077 04-04
DIFFERENTIAL-EFFECTS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND
RELEASING-AGENTS ON LOCOMOTOR-ACTIVITY IN NORMAL AND IN
RESERPINIZED MICE.
004130 04-04
THE EFFEQS OF P CHLOROAMPHETAMINE ADMINISTRATION ON
LOCOMOTOR-ACTIVITY AND SEROTONIN IN NEONATAL AND ADULT
RATS. (UNPUBLISHED PAPER).
004169 04-04
LOCOMOTOR-EFFECT
THE LOCOMOTOR-EFFECT OF CLONIDINE AND ITS INTERACTION WITH
ALPHA FLUPENTHIXOL OR HALOPERIDOL IN THE DEVELOPING RAT
000445 01-04
lOCOMOTOR-EFFECTS
THERMOREGULATORY AND LOCOMOTOR-EFFECTS OF DSIP:
PARADOXICAL-INTERACTION WITH D-AMPHETAMINE.
001827 02-04
LOCOMOTOR-STIMULATION
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELECTIVE
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR-
STIMULATION INDUCED BY INDIRECTLY ACTING SYMPATHOMIMETIC-
AMINES IN MICE.
000492 01-04
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON AMPHETAMINE-
INDUCED LOCOMOTOR-STIMULATION IN MICE.
001767 02-04
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON SCOPOLAMINE-
INDUCED LOCOMOTOR-STIMULATION IN MICE.
001768 02-04
THE EFFECTS OF INTRAVENTRICULAR 6 HYDROXYDOPAMINE AND 5 6
DIHYDROXYTRYPTAMINE ON MORPHINE-INDUCED LOCOMOTOR-
STIMULATION.
001784 02-04
EFFECTS OF PROPRANOLOL ON THE LOCOMOTOR-STIMULATION INDUCED
BY ACTIVATION OF POSTSYNAPTIC CATECHOLAMINE-RECEPTORS.
004126 04-04
LOCUS
THE ALBINO LOCUS PRODUCES ABNORMAL RESPONSES TO OPIATES IN
THE MOUSE.
001675 02-04
LOCUS-COERULEUS
MICROIONTOPHORETIC STUDIES ON NORADRfNERGIC INHIBITION FROM
LOCUS-COERULEUS OF SPINAL TRIGEMINAL-NUCLEUS NEURONS,
000260 01-03
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER ACTIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT,
001095 02-03
OPIATES AND OPIOID-PEPTIDES HYPERPOLARIZE LOCUS-COERULEUS
NEURONS IN VITRO,
001408 02-03
THE NEUROANATOMY AND PHARMACOLOGY OF THE NUCLEUS LOCUS-
COERULEUS. (UNPUBLISHED PAPER).
003810 04-03
THE EFFECT OF ELECTRICAL-STIMULATION OF THE LOCUS-COERULEUS AND
INTRAPERITONEAL INJECTION OF CERTAIN PHARMACOLOGICAL
SUBSTANCES ON THE THRESHOLD OF HIPPOCAMPAL
AFTERDISCHARGES.
003885 04-03
CLONIDINE AND THE PRIMATE LOCUS-COERULEUS. EVIDENCE SUGGESTING
ANXIOLYTIC AND ANTIWITHDRAWAL EFFECTS. (UNPUBLISHED PAPER)
003982 04-03
LOFEPRAMINE
PREDICTION OF LOFEPRAMINE RESPONSE IN DEPRESSION BASED ON
RESPONSE TO PARTIAL SLEEP-DEPRIVATION,
000617 01-09
COMPARISON OF THE EFFECTS OF LOFEPRAMINE AND MIANSERIN IN
DEPRESSED-PATIENTS IN A DOUBLE-BLIND TRIAL.
001996 02-09
THE PHARMACOLOGICAL PROFILE OF LOFEPRAMINE, A NEW
ANTIDEPRESSANT-DRUG.
004006 04-03
LOG-DOSE
LOG-DOSE/RESPONSE-CURVE FLATTENING IN RATS AFTER DAILY
INJECTION OF OPIATES.
001387 02-03
LONG-ACTING
THE PLACE OF LONG-ACTING NEUROLEPTICS IN THE TREATMENT OF
SCHIZOPHRENIA.
000563 01-08
THE DIFFERENTIAL-EFFECTS OF SHORT-ACTING AND LONG-ACTING
BENZODIAZEPINES UPON NOCTURNAL SLEEP AND DAYTIME
PERFORMANCE.
000822 01-14
PHARMACOKINETICS OF BENZODIAZEPINES: SHORT-ACTING VERSUS
LONG-ACTING.
000920 01-17
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING
DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS
OF MAMMALIAN FOREBRAIN IN VITRO.
001114 02-03
METHODOLOGY AND RESULTS OF A LONG-TERM STUDY OF LONG-ACTING
NEUROLEPTICS: PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-
DECANOATE.
001929 02-08
PERGOLIDE, A POTENT LONG-ACTING DOPAMINE-RECEPTOR AGONIST.
002257 02-13
MALIGNANT-HYPERTHERMIC-SYNDROMES IN THE COURSE OF
TREATMENT WITH LONG-ACTING NEUROLEPTICS.
LONG-ACTING ANTIPSYCHOTIC-DRUGS.
PRESENT INDICATIONS OF LONG-ACTING NEUROLEPTICS.
002430 02-15
002519 02-17
002576 02-17
LONG-ACTING ANTIPSYCHOTIC-DRUGS AND CEREBRAL 5
HYDROXYTRYPT AMINE.
002851 03-03
CONSIDERATIONS ON LONG-ACTING CHEMOTHERAPY: AN EXPERIENCE
WITH FLUPHENAZINE-DECANOATE.
003173 03-08
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFECTS ON
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING
IN VITRO.
004198 04-04
COMPARATIVE CHARACTERISTICS OF THE PROPHYLACTIC PROPERTIES OF
SHORT-TERM AND LONG-ACTING LITHIUM-CARBONATE PREPARATIONS
IN ENDOGENOUS AFFECTIVE-PSYCHOSES.
004390 04-09
LONG-DURATION
(-)PENTOBARBITAL OPENS ION-CHANNELS OF LONG-DURATION IN
CULTURED MOUSE SPINAL NEURONS.
000198 01-03
LONG-EVANS-RATS
RAT PUP-KILLING AND MATERNAL-BEHAVIOR IN MALE LONG-EVANS-
RATS: PRENATAL STIMULATION AND POSTNATAL TESTOSTERONE.
003054 03-04
1
"iiMl"
'iiitir
S-257
msas».
Subject Index
Ptychopharmacology Abstracts
iiiii
I
^^^REpfATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY? ^^^^^ ^^^^
LONG-LASTING EFFEQS OF CHRONIC ADMINISTRATION OF
HALUJCINOGENIC-DRUGS ON RAT SOCIAL AND EMOTIONAL-BEHAVIOR.
(PH.D. DISSERTATION). 003029 03-04
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST
SUDDEN CARDIAC DEATH FROM COCAINE . ^^^^^ ^^^^
'■'^"prevalence of PERSISTENT ABNORMAL INVOLUNTARY-MOVEMENTS
AMONG PATIENTS IN A NIGERIAN LONG-STAY PSYCHIATRIC UNIT^
004334 04-0o
^°'*fNCORPORATION OF 4.5 3H LEUCINE INTO THE LIMBIC-SYSTEM OF ICR
MICE AS A LONG-TERM EFFECT OF HALOPERIDOL APPLICATION.^ ^^^^
LONG-TERM ANTIDEPRESSANT TREATMENT DECREASES SPIROPERIDOL-
LABELED SEROTONIN-RECEPTOR BINDING. ^^^^^ ^^^^
LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL
CAPILLARY PERMEABILITY. 000239 01-03
FUNCTIONAL AND STRUCTURAL CONSEQUENCES OF LONG-TERM DIETARY
L-DOPA TREATMENT IN MICE. 000257 01-03
LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN
'^"-^- 000287 01-03
THE LONG-TERM REGULATION OF GANGLIONIC TYROSINE-HYDROXYLASE
BY PREGANGLIONIC NERVE ACTIVITY. 000333 01-03
INCREASED DOPAMINE-RECEPTOR BINDING IN THE STRIATUM OF RATS
AFTER LONG-TERM ISOLATION. 000398 01-04
IMPAIRED GLUCOSE TOLERANCE IN LONG-TERM LITHIUM TREATED
''^^'^^^^ 000611 01-09
THE LONG-TERM RESULTS OF STEREOTAXIC SURGERY AND L-DOPA
THERAPY IN PATIENTS WITH PARKINSONS-DISEASE: A lO-YEAR
FOLLOWUP STUDY. 000693 01-11
LONG-TERM EFFICACY OF BROMOCRIPTINE IN PARKINSONS^EASE^^^^
METHODOLOGICAL REMARKS ON LONG-TERM LITHIUM ^REATMENT^^^^
THE AUTOINDUCTION OF CARBAMAZEPINE DURING LONG-TERM
™^'^'^''^- 000785 01-13
THE ULTRASTRUCTURAL CHANGES OF SYNAPSES IN RAT FOLLOWING
LONG-TERM ADMINISTRATION OF THE NEUROLEPTICS RESERPINE AND
"^LOP^^'^^OL 000795 01-13
BILATERAL PAPILLOEDEMA IN LONG-TERM THERAPY WITH LITHIUM-
^^^^OmU. 000878 01-15
TARDIVE TOURETTE-SYNDROME IN AN AUTISTIC-PATIENT AFTER LONG-
TERM NEUROLEPTIC ADMINISTRATION ^^^^^ ^ ^ ^ ^
ENDOCRINOLOGICAL CHANGES IN PATIENTS WITH SEXUAL-DYSFUNCTION
UNDER LONG-TERM NEUROLEPTIC TREATMENT. ^^^^^ ^^^^
LONG-TERM EFFEQ OF NEUROLEPTICS ON CORTICOSTERONE
SEPTOHIPPOCAMPAL UPTAKE IN RATS ^ ^ ^ ^^ ^^.03
LONG-TERM HALOPERIDOL TREATMENT OF MICE: A CHANGE IN BETA-
ADRENERGIC-RECEPTOR RESPONSIVENESS. ^^ ^^^ ^^^^
EFFECTS OF LONG-TERM ADMINISTRATION OF ANTIPSYCHOTIC-DRUGS ON
ENKEPHALINERGIC NEURONS. 001284 02-03
THE HYPERKINETIC-SYNDROME FOLLOWING LONG-TERM HALOPERIDOL
TREATMENT: INVOLVEMENT OF DOPAMINE AND NORADRENALINE^
L/U I JUT 7 U^~U<5
LONG-TERM ADMINISTRATION OF ATROPINE. IMIPRAMINE, AND
VILOXAZINE ALTERS RESPONSIVENESS OF RAT-CORTICAL-NEURONES
TO ACETYLCHOLINE. 001306 02-03
LONG-TERM EFFECTS OF HALOPERIDOL. CLOZAPINE, AND METHADONE
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNAMICS,^
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS
INDUCED BY AMPHETAMINE IN CATS. ^^^^^ ^^.qs
LONG-TERM HALOPERIDOL TREATMENT AND FAQORS EFFECTING THE
ACTIVITY OF STRIATAL TYROSINE-HYDROXYLASE . ^ ^ ^^^ ^^^^
SHORT-TERM AND LONG-TERM EFFEQS OF METHAMPHETAMINE ON
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC
^''''' 001384 02-03
BRAIN-MONOAMINES IN THE RHESUS-MONKEY DURING LONG-TERM
NEUROLEPTIC ADMINISTRATION. 00147102^3
SUPERSENSITIVITY AND THE EFFEaS OF LONG-TERM AMPHETAMINE IN
THE RAT NIGROSTRIATAL SYSTEM. (PH.D. DISSERTATION).
001485 02-03
LONG-TERM APPLICATION OF HALOPERIDOL: EFFEQ OF ANTICHOLINERGIC
TREATMENT ON THE RATE OF DOPAMINE SYNTHESIS. ^^^^
SHORT-TERM AND LONG-TERM MODIFICATION OF SKELETAL-MUSCLE
SODIUM-PUMP ACTIVITY AND MUSCLE PROTEIN TURNOVER.
(UNPUBLISHED PAPER). 001519 02-03
LONG-TERM EFFEaS OF TESTOSTERONE INJEQIONS ON THE SOCIAL-
BEHAVIOUR OF MALE DUCKS AND THEIR PHYSIOLOGICAL-CORRELATES.
001565 02-04
ROLE OF NEUROTRANSMinERS AND PROTEIN SYNTHESIS IN SHORT-
TERM AND LONG-TERM MEMORY. ^^ ^^^ ^^^
THE SHORT-TERM AND LONG-TERM EFFEQS OF BETA ENDORPHIN ON THE
OPIATE ABSTINENCE-SYNDROME IN RATS ^^^
OPIATE ANTAGONISTS AND LONG-TERM ANALGESIC REAQION INDUCED
BY INESCAPABLE SHOCK IN RATS. 001707 02-04 '
LONG-TERM CHLORPROMAZINE IN RHESUS-MONKEYS: PRODUQION OF
DYSKINESIAS AND CHANGES IN SOCIAL-BEHAVIOR.
A SILICONE PELLET FOR LONG-TERM CONTINUOUS ADMINISTRATION OF
^^''"^T*'^'^^ 001875 02-06
LONG-TERM APPLICATION OF HIGH-DOSES OF CLOROTEPIN TO CHRONIC
SCHIZOPHRENICPATIENTS. 001908 02-08
LONG-TERM EFFECTS OF PIPOTHI AZINE-PALMITATE
METHODOLOGY AND RESULTS OF A LONG-TERM STUDY OF LONG-AQING ,
NEUROLEPTICS: PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-
^^^^^^^'^ 001929 02-08'
BASAL AND STIMULATED LEVELS OF PROLAQIN. TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS. LONG-TERM TREATED WITH
N^'J^O^^''^'" 001935 02-08
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH. AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY. ^^^^^ ^^^
LONG-TERM CONTROLLED-COMPARISON OF INJEQION OXYPROTHEPIN
AND FLUPHENAZINE-DECANOATES IN PSYCHOTICS IN REMISSION. ^^^^
LONG-TERM MONITORING OF TRICYCLIC-ANTIDEPRESSANT PLASMA
CONCENTRATIONS. 002014 024)9^
THE LONG-TERM TREATMENT WITH BENZODIAZEPINES: SUGGESTIONS
FOR FURTHER RESEARCH. 002085 02-10
PHARMACODYNAMIC ASPEQS OF LONG-TERM P'*0''"^^'^52T2"o203
SHORT-TERM AND LONG-TERM EFFEaS ON GABA AND DOPAMINE
NEURONS DURING TREATMENT WITH SULPIRIDE ^^^^ ^ ^^^^
APPROACHES TO THE PROBLEM OF PREVENTING HAZARDS OF LONG-
TERM NEUROLEPTIC TREATMENT AND OF AVOIDING UNNECESSARY
°''^^^- 002426 02-15
SUBJEQIVE ASSESSMENT OF SEXUAL-OYSFUNQION OF PATIENTS ON
LONG-TERM ADMINISTRATION OF DIGOXIN. ^^^^ ^^^^
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNQION IN OV^T^fRAIN^
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL-STUDIES WITH
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND
DEPOT NEUROLEPTICS. 003183 03^
THE NEED FOR CONTINUOUS USE OF ANTIPARKINSONIAN MEDICATION
WITH CHRONIC SCHIZOPHRENIC-PATIENTS RECEIVING LONG-TERM
NEUROLEPTIC THERAPY. 003186 03-08
COMPLICATIONS OF CHRONIC LEVODOPA THERAPY: LONG-TERM
EFFICACY OF DRUG-HOLIDAY. 003502 03-15
LITHIUM THERAPY AND THYROID-FUNQION: A '-ONG-TERM^TUDY ^^^^
S-258
VOLUME 19, SUBJECT INDEX
Subject Index
TIME-COURSE OF CLINICAL CHEMICAL PARAMETERS UNDER LONG-TERM
LITHIUM TREATMENT.
003515 03-15
LONG-TERM CHANGES IN AIMS RATINGS AND THEIR RELATION TO
MEDICATION HISTORY.
003537 03-15
GLOMERULAR FILTRATION RATE AND CALCIUM METABOLISM IN LONG-
TERM LITHIUM TREATMENT
003542 03-15
THE EFFECT OF LONG-TERM CONCURRENT ADMINISTRATION OF
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL
CORTICAL DOPAMINE METABOLISM IN RATS.
003788 04-03
LONG-TERM EFFECTS OF MULTIPLE DOSES OF METHAMPHETAMINE ON
TRYPTOPHAN-HYDROXYLASE AND TYROSINE-HYDROXYLASE ACTIVITY
IN RAT-BRAIN.
003850 04-03
ALPHA2-ADREN0RECEPT0RS IN RAT-BRAIN ARE DECREASED AFTER
LONG-TERM TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT.
004008 04-03
EFFECTS OF WITHDRAWAL FROM LONG-TERM DIPHENYLHYDANTOIN
TREATMENT ON AUDIOGENIC-SEIZURES AND MAXIMAL
ELECTROSHOCK-INDUCED SEIZURES IN RATS.
004101 04-04
THE EFFECT OF LONG-TERM MAINTENANCE-THERAPY ON SCHIZOPHRENIC-
PATIENTS USING SOMATOTHERAPEUTIC MEASURES.
004325 04-08
LONG-TERM NEUROLEPTIC TREATMENT OF CHRONIC SCHIZOPHRENIC-
PATIENTS: CLINICAL AND BIOCHEMICAL-EFFECTS OF WITHDRAWAL.
004344 04-08
LEVODOPA: LONG-TERM IMPACT ON PARKINSONS-DISEASE.
004476 04-11
PHARMACOLOGICAL MODULATION OF FORMATION OF LONG-TERM
MEMORY.
004578 04-14
LONG-TERM USE AND ABUSE OF BENZODIAZEPINES.
004598 04-15
ON THE QUESTION OF PARENCHYMAL DAMAGE CAUSED BY LONG-TERM
THERAPY WITH PSYCHOTROPICS IN ADOLESCENCE.
004626 04-15
PATHOPHYSIOLOGICAL AND MORPHOLOGICAL CHANGES IN THE CNS
DURING LONG-TERM ADMINISTRATION OF HALOPERIOOL.
004633 04-15
LONG-TERM-TREATMENT
CENTRAL NORADRENERGIC ADAPTATION TO LONG-TERM-TREATMENT
WITH IMIPRAMINE IN RHESUS-MONKEYS.
000182 01-03
OXYPROTHEPIN-DECANOATE INJECTIONS: EXPERIENCE WITH A LONG-
TERM-TREATMENT OF SCHIZOPHRENIC-PSYCHOSES.
000576 01-08
THE LONG-TERM-TREATMENT OF PERIODICAL AND CYCLIC DEPRESSIONS
WITH FLUPENTHIXOL-DECANOATE.
000603 01-09
BEHAVIORAL-CORRELATES AND BIOCHEMICAL-CORRELATES AFTER
HALOPERIOOL AND CLOZAPINE LONG-TERM-TREATMENT.
001422 02-03
EFFECT OF LONG-TERM-TREATMENT WITH HALOPERIOOL AND SULPIRIDE
ON DIFFERENT TYPES OF DOPAMINERGIC-RECEPTORS.
001512 02-03
BEHAVIORAL-CONSEQUENCES OF LONG-TERM-TREATMENT WITH
NEUROLEPTIC-DRUGS.
001661 02-04
APPARENT TOLERANCE TO SOME ASPECTS OF AMPHETAMINE
STEREOTYPY WITH LONG-TERM-TREATMENT.
001758 02-04
DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINERGIC MECHANISMS.
001839 02-05
LONG-TERM-TREATMENT OF DEPRESSION WITH ISOCARBOXAZIDE.
00201 1 02-09
LONG-TERM-TREATMENT WITH NEUROLEPTIC-AGENTS: ADAPTATION
PHENOMENA AND THEIR SIGNIFICANCE WITH REGARD TO
SCHIZOPHRENIC-SYMPTOMATOLOGY AND SIDE-EFFECTS
002370 02-15
AMITRIPTYLINE: LONG-TERM-TREATMENT ELEVATES ALPHA-ADRENERGIC
AND MUSCARINIC-RECEPTOR BINDING IN MOUSE-BRAIN.
002875 03-03
ACCELERATED METABOLISM OF PROBENECID DURING LONG-TERM-
TREATMENT OF RATS WITH ANTICONVULSANT-DRUGS: EFFECT ON
CENTRAL SEROTONIN TURNOVER STUDIES.
002890 03-03
LONG-TERM-TREATMENT OF SCHIZOPHRENIA.
003171 03-08
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM
INTERMEDIATE/POSTERIOR LOBES OF PITUITARY.
003846 04-03
STUDIES ON THE KINETIC PROPERTIES OF TRYPTOPHAN-HYDROXYLASE OF
JIABBIT MESENCEPHALON AND PONS-MEDULLA: EFFECT OF LONG-
TERM-TREATMENT WITH NEUROLEPTICS AND ANTIDEPRESSANTS,
003852 04-03
LONG-TERM-TREATMENT FOR DEPRESSION.
004372 04-09
THE COURSE OF LONG-TERM-TREATMENT WITH FLUPHENAZINE-
DECANOATE (DAPOTUM-D).
004605 04-15
LOOK
LOOK AND OLD-AGE.
000930 01-17
EFFECTS OF CHLORPROMAZINE ON ESCAPE AND AVOIDANCE RESPONSES:
A CLOSER LOOK.
004226 04-04
LOPERAMIDE
ABUSE POTENTIAL OF LOPERAMIDE.
002413 02-15
LOPIRAZEPAM
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF
LOPIRAZEPAM (D-12524) BY QUANTITATIVE EEG AND
PSYCHOMETRIC-ANALYSIS.
000720 01-11
LORAZEPAM
A COMPARATIVE-STUDY ON THE CLINICAL-EFFECTS OF FLUNITRAZEPAM
AND LORAZEPAM.
000702 01-11
LORAZEPAM KINETICS IN THE ELDERLY.
000766 01-13
TRANSFER OF LORAZEPAM AND ITS CONJUGATE ACROSS THE HUMAN
PLACENTA.
000774 01-13
PHARMACOKINETIC-STUDY OF LORAZEPAM OVERDOSAGE.
000831 01-15
A CASE-REPORT OF LORAZEPAM WITHDRAWAL.
000889 01-15
EFFICACY AND SIDE-EFFECTS OF LORAZEPAM, OXAZEPAM, AND
TEMAZEPAM AS SLEEPING-AIDS IN PSYCHOGERIATRIC-INPATIENTS.
002076 02-10
USE OF INJECTABLE LORAZEPAM IN ALCOHOL WITHDRAWAL.
002176 02-11
THE EFFECTS OF FLURAZEPAM, LORAZEPAM, AND TRIAZOLAM ON SLEEP
AND MEMORY.
002357 02-14
CLINICAL PHARMACOKINETICS OF OXAZEPAM AND LORAZEPAM.
003410 03-13
EFFECT OF MATERNAL LORAZEPAM ON THE NEONATE.
003549 03-15
INTRAVENOUS LORAZEPAM TO PREVENT NAUSEA AND VOMITING
ASSOCIATED WITH CANCER CHEMOTHERAPY.
003614 03-17
ACTIVITY OF BROMAZEPAM AND LORAZEPAM IN NEUROTIC
DEPRESSIONS.
004384 04-09
A COMPARATIVE-STUDY OF INTRAVENOUS LORAZEPAM AND
CLONAZEPAM IN STATUS-EPILEPTICUS.
004487 04-1 1
LORDOSIS
ATTEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED
SPINAL FEMALE RATS WITH MONOAMINE AGONISTS.
000421 01-04
FACILITATION OF LORDOSIS BEHAVIOR IN THE OVARIECTOMIZED
ESTROGEN-PRIMED RAT BY DIBUTYRYL-C-AMP.
002957 03-04
EFFECTS OF ACUTE CENTRAL AND PERIPHERAL ACTHl-24
ADMINISTRATION ON LORDOSIS BEHAVIOR.
002975 03-04
LORMETAZEPAM
AGE-SPECIFIC DOSES OF LORMETAZEPAM AS A NIGHT SEDATIVE IN
CASES OF CHRONIC SLEEP-DISTURBANCE.
004309 04-07
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II.
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT.
004516 04-13
LOSS
BENZODIAZEPINES CAUSE SMALL LOSS OF BODY-WEIGHT.
002446 02-15
DIFFERENTIAL LOSS OF BIOLOGICAL-ACTIVITY OF THE ENKEPHALINS
INDUCED BY CURRENT.
002783 03-03
CAN DRUGS HALT MEMORY LOSS?
003447 03-14
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS.
004129 04-04
:;,i!'
''A;
'Ml
ill:
S-259
Subject Index
Will '
^ita*
a
I
ABSTRACTS OF THE ANNUAL GENERAL CONFERENCE OF THE EUROPEAN-
BRAIN-AND-BEHAVIOUR-SOCIETY, HELD AT LOUVAtN-LA-NEUVE,
BELGIUM, ON NOVEMBER 13-15TH, 1980. „„oz,-, no n
0036 17 Oo- 1 /
LOW
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-AQIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
ACTIVITY
^ 000309 01-03
RESERPINE ABOLISHES MOVEMENT CORRELATED ATROPINE-RESISTANT
NEOCORTICAL LOW VOLTAGE FAST-ACTIVITY ^^^ i Q 0 1 -03
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES
001554 02-0o
LOW ORAL CPZ BIOAVAILABILITY IN CHRONIC SCHIZOPHRENIA.
(UNPUBLISHED PAPER). 001938 02-08
CHRONIC EFFECTS OF NEUROLEPTICS HAVING HIGH OR LOW INCIDENCE
OF EXTRAPYRAMIDAL SIDE-EFFECTS UPON FORCE, DURATION AND
RATE OF OPERANT-RESPONSE IN RATS. (PH.D. DISSERTATION)^
003125 03-05
LOW SERUM PROLACTIN AND EARLY RELAPSE FOLLOWING NEUROLEPTIC
W'^^^^^^L 003166 03-08
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.^_^_^^^ ^^^
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFECTIVE-DISORDERS
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDiaORS TO
CLINICAL-RESPONSE). 004365 04-09
"■^^REGIONAL 5 HT ANALYSIS IN ROMAN HIGH-AVOIDANCE AND LOW-
AVOIDANCE RATS FOLLOWING MAO-INHIBITION. qq-^202 02-03
BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH-
AVOIDANCE AND LOW-AVOIDANCE RATS. ^^^^^ ^^^^
lOW-DOSAGES
ON THE EFFECTS OF SULTOPRIDE ADMINISTERED IN LOW-DOSAGES TO
OLDER CHILDREN AND ADOLESCENTS. 003230 03-09
LOW-DOSE
EFFEaS OF A LOW-DOSE AND A HIGH-DOSE OF BETA ENDORPHIN ON
ACQUISITION AND RETENTION IN THE RAT. ^ ^^^
RAPID TREATMENT OF ACUTE PSYCHOTIC-SYMPTOMS WITH HIGH-DOSE
AND LOW-DOSE HALOPERIDOL: BEHAVIORAL-CONSIDERATIONS.
003346 03-11
EFFECT OF LOW-DOSE LITHIUM ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL ON BIOGENIC-AMINES IN RAT-BRAIN.
LOW-DOSES
CLINICAL-EXPERIENCE WITH LOW-DOSES OF HALOPERIDOL IN THE
TREATMENT OF NEUROSES. 000654 01-10
PSYCHOPHARMACOLOGICAL-EFFECTS OF LOW-DOSES AND HIGH-DOSES
OF APOMORPHINE DURING ONTOGENY. 001774 02-04
PLASMA FLUPHENAZINE AND PROLACTIN LEVELS IN SCHIZOPHRENIC-
PATIENTS DURING TREATMENT WITH LOW-DOSES AND HIGH-DOSES OF
FLUPHENAZINE-ENANTHATE. 001956 02-08
SEX-DIFFERENCES IN THE EFFEQS OF LOW-DOSES OF ETHANOL ON
HUMAN REACTION-TIME. 00236102-14
TARDIVE-DYSKINESIA FOLLOWING LOW-DOSES OF PIPERACETAZINE.
002399 02-15
FURTHER EXPERIENCES WITH LOW-DOSES OF BROMOCRIPTINE IN
PARKINSONS-DISEASE. ^^^^ ^^^^
EFFEQS OF ACUTE OR CHRONIC ADMINISTRATION OF LOW-DOSES OF A
DOPAMINE AGONIST ON DRINKING AND LOCOMOTOR-AQIVITY IN THE
RAT
002982 03-04
EVIDENCE FOR SEDATIVE EFFECTS OF LOW-DOSES OF MORPHINE IN MICE
INVOLVING RECEPTORS INSENSITIVE TO NALOXONE _-^ , ,. q. „,
LOWERING
LOWERING OF THE CONVULSIVE THRESHOLD BY NONSTEROIDAL
ANTIINFLAMMATORY-DRUGS. 002904 03-03
'■°'^HE PLACE OF LOXAPINE - A NEW NEUROLEPTIC-DRUG ^ ^ ^^^ ^^^^
LOXAPINE FATALITIES.
Psychopharmacology Abstracts
004650 04-15
LOXAPiNE-SUCCINATE
LOXAPINE-SUCCINATE: A NEW NEUROLEPTIC-DRUG.
000551 01-08
EVALUATIONS OF LOXAPINE-SUCCINATE IN THE AMBULATORY
TREATMENT OF ACUTE SCHIZOPHRENIC-EPISODES.
004345 04-08
LRF-DECAPEPTIDE
CHARAQERIZATION Of LRF-LIKE IMMUNOREAQIVITY IN THE FROG
SYMPATHETIC GANGLIA: NONIDENTITY WITH LRF-DECAPEPTIDE.
(UNPUBLISHED PAPER).
001018 02-01
LRF-LIKE
CHARACTERIZATION OF LRF-LIKE IMMUNOREAQIVITY IN THE FROG
SYMPATHETIC GANGLIA: NONIDENTITY WITH LRF-DECAPEPTIDE.
(UNPUBLISHED PAPER).
001018 02-01
LSD
DECREASED SPIROPERIDOL AND LSD BINDING IN RAT-BRAIN AFTER
CONTINUOUS AMPHETAMINE.
000216 01-03
THE EFFECT OF SEROTONIN DEPLETION ON THE DISCRIMINABILITY OF LSD.
000499 01-04
THE EFFEaS OF LSD AND SOME ANALOGUES ON THE RESPONSES OF
SINGLE CORTICAL NEURONS OF THE CAT TO OPTICAL-STIMULATION.
000738 01-12
PERSISTENT EFFECTS OF CHRONIC ADMINISTRATION OF LSD ON
INTRACELLULAR SEROTONIN CONTENT IN RAT-MIDBRAIN.
001333 02-03
CHARAQERIZATION AND RADIOAUTOGRAPHY OF (3H)LSD BINDING BY
RAT-BRAIN SLICES IN VITRO: THE EFFEQ OF 5 HYDROXYTRYPTAMINE.
001369 02-03
THE EFFEQS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5
DIMETHOXY-4-METHYLAMPHETAMINE (DOM) AND D-AMPHETAMINE
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE
TREATED RATS. ^,.„, „„„.
001595 02-04
SENSORY AND ASSOCIATIVE-EFFEQS OF LSD ON CLASSICAL APPETITIVE-
CONDITIONING OF THE RABBIT JAW MOVEMENT RESPONSE.
001637 02-04
AN ANALYSIS OF SOME PERCEPTUAL-EFFECTS OF MORPHINE,
CHLORPROMAZINE, AND LSD.
001652 02-04
ACUTE AND CHRONIC LSD EFFEQS ON RAT STARTLE: DATA SUPPORTING
AN LSD RAT MODEL OF SCHIZOPHRENIA.
002194 02-12
SELECTIVE EFFECTS OF LSD AND HYPERTHERMIA ON THE SYNTHESIS OF
SYNAPTIC PROTEINS AND GLYCOPROTEINS.
002721 03-03
DRUG-INDUCED STIMULUS CONTROL AND THE CONCEPT OF BREAKING-
POINT: LSD AND QUIPAZINE. 003116 03^
LSD PSYCHOTOGENIC PROCEDURES AND BRAIN NEUROHUMORS.
(UNPUBLISHED PAPER). 004448 04-11
LSD: MY PROBLEM CHILD. 004497 04-12
EFFEQS OF DOPAMINERGIC AND CHOLINERGIC-DRUGS, NALOXONE AND
L PROLYL-LEUCYL-GLYCINAMIDE ON LSD-INDUCED CATALEPSY.
000360 01-04
LSD-INDUCED ULTRASTRUCTURAL MODIFICATIONS OF LIMBIC- SYSTEM
NUCLEI AND OTHER CEREBRAL ZONES. ^^^^^ ^^^^
RAT-BRAIN STEADY-STATE LEVELS OF CYCLIC-NUCLEOTIDES AS AN
ENDPOINT OF LSD-LIKE HALLUCINOGEN EFFECTS. (PH.D.
■^•SSERTATION). 001426 02^3
LSD-25 AS A DISCRIMINATIVE-STIMULUS FOR RESPONSE SELECTION BY
'"G^O'^S. 000412 01-04
LUMBAR
A BIOCHEMICAL-STUDY OF LUMBAR CEREBROSPINAL-FLUID IN
EXTRAPYRAMIDAL-DISORDERS. 002186 02-11
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPT()PHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION. 003419 03-13
A SELECTED ION-MONITORING ASSAY FOR BIOGENIC-AMINE
METABOLITES AND PROBENECID, IN HUMAN LUMBAR
CEREBROSPINAL-FLUID. 003663 04^1
S-260
VOLUME 19, SUBJECT INDEX
Subject Index
LUNO
EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT
LUNG
000524 01-05
LUPUS-CRYTHEMATOSUS
ACETYLATOR PHENOTYPE AND LUPUS-ERYTHEMATOSUS.
003545 03-15
LUrUS-LIKE-ILLNESS
LUPUS-LIKE-ILLNESS ASSOCIATED WITH CHLORPROMAZINE.
002408 02-) 5
LUTEINISINO-HORMONE
INFLUENCE OF NOMIFENSINE ON GROWTH-HORMONE PROUCTIN
LUTEINISING-HORMONE AND THYREOTROPIN IN HEALTHY SUBJECTS
AND HYPERPROLACTINAEMIC-PATIENTS.
002137 02-1)
LUTEINIZING-NORMONE
THE EFFEQ OF 0ELTA9 TETRAHYDROCANNABINOL ON THE POSITIVE AND
NEGATIVE FEEDBACK CONTROL OF LUTEINIZING-HORMONE RELEASE.
000286 01-03
EFFECTS OF MORPHINE AND NALOXONE ON PHASIC RELEASE OF
LUTEINIZING-HORMONE AND FOLLICLE-STIMULATING-HORMONE
(40849).
000298 01-03
EFFEQS OF AN EPINEPHRINE SYNTHESIS INHIBITOR, SKF-64139 ON THE
SECRETION OF LUTEINIZING-HORMONE IN OVARIEQOMIZED FEMALE
RATS.
002693 03-03
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFECTS OF NALOXONE ON
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE
MALE RAT.
002853 03-03
LYMPH-NODE
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-)3 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH LEWIS-RAT LYMPH-NODE CELLS. (UNPUBLISHED PAPER).
001434 02-03
LYMPHOCYTE
LYMPHOCYTE MONOAMINE-OXIDASE AND PLASMA PROLACTIN AND
GROWTH-HORMONE IN TARDIVE-DYSKINESIA.
LYMPHOCYTES 003499 03-15
THE EFFEQ OF CHLORPROMAZINE AND MAGEPTIL ON THE
Wi?l;';KKGS^fN"^ ''°'° '''''''''''' '^ ^^^^'^^^'°^
LYMPHOGENIC °°'5'' °^-'3
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY.
LYSATES 000890 01-15
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS A
CLINICAL DOUBLE-BUND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER)
YSEO 003327 03-1 1
EFFEQ OF MORPHINE ON CALCIUM UPTAKE BY LYSED SYNAPTOSOMES
.YSER6IC-ACID 000117 01-03
A COMMON MECHANISM FOR LYSERGIC-ACID, INDOLEALKYLAMINE AND
K^R^LSffikTs^^^^^ ^^^°™^^^^'^ MEDIATION ^Or°
.YSEROIC-ACID-DIETHYLAMIDE °°'°°' °'-°^
LYSERGIC-ACID-OIETHYLAMIDE: MORPHOLOGICAL-STUDY OF ITS EFFEQ
THE EFFECTS OF D LYSERGIC-ACID-DIETHYIAMIDE (LSD) 2 5^^^^^ °^'°^
K«A\T;t^cSt'l^^''"^^'^'NE ('^O'^) AND d'-AMPHETAMINE
ON OPERANT-RESPONDING in CONTROL AND 6 HYDROXYDOPAMINE
TREATED RATS.
EFFECT OF INTRAVENOUS ADMINISTRATION OF D LYSERGIC°aCId'^ °^'°'^
?v?x"rTl^'^"^^ °^ SUBSEQUENT PROTEIN SYNTHESIS IN A CELL-FREE
SYSTEM DERIVED FROM BRAIN.
^^^^.^^1^9^ 9^ ™^ ^^^^'^^ Of INTRAVENOUS ADMINISTRATION 'of1)°^
^I?^c^'f "*^"^-°'f^"^^'^"^E ON FREE AND MEMBRANE-BOUND
POLYSOMES IN THE RABBIT BRAIN.
ArtoQoi f\A no
'■^^kf^^^J^'^^^^^^'^^ O'' f'E^ AND MEMBRANE-BOUND POLYSOMES
^^?.,^?c^^ADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO
003832 04-03
LYSINE
ENHANCEMENT OF HEXOBARBITAL-INDUCED SLEEP BY LYSINE AND ITS
METABOLITES.
002967 03-04
BLOCKADE BY L LYSINE OF NONNARCOTIC ANALGESICS.
003857 04-03
LYSINE-VASOPRESSIN
USE OF LYSINE-VASOPRESSIN IN THE TREATMENT OF POSHRAUMATIC
AMNESIA.
004583 04-14
LYSONEURO
CLINICAL RESULTS OBTAINED WITH THE USE OF LYSONEURO IN
DEPRESSIVE-SYNDROMES.
004397 04-09
LYSOSOMAL
INHIBITION OF LYSOSOMAL LIPASES BY CHLORPROMAZINE: A POSSIBLE
MECHANISMS OF STABILIZATION.
LYTIC-EFFEaS 003993 04-03
MECHANISM OF MEMBRANE STABILIZING AND LYTIC-EFFECTS OF
TRICYCLIC-ANTIDEPRESSANTS.
004283 04-05
AAACACA-MULAHA
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED
DIFFERENTIATION) IN THE MONKEY (MACACA-MUIAHA).
000440 01-04
SYNCHRONIZATION OF EEG ACTIVITY OF MALE RHESUS-MONKEYS
MACACA-MULAHA TREATED WITH OVOCYCLIN.
001312 02-03
EFFECTS OF METHAQUALONE ON SOCIAL-BEHAVIOR IN MONKEYS
(MACACA-MULATTA).
001594 02-04
AAACROMOLECULAR
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN
HUMAN CELLS.
002830 0*^-0*^
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS A
CLINICAL DOUBLE-BUND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER).
003327 03-))
MACROMOLECULE
EFFECT OF OPIATES ON MACROMOLECULE BIOSYNTHESIS
MACROPHAGE 001335 02-03
CHEMOTAXIS BY MOUSE MACROPHAGE CELL UNES. (UNPUBLISHED
PAPER).
00)099 02-03
INHIBITION OF CHEMOTAXIS BY S 3 DEAZAADENOSYLHOMOCYSTEINE IN
A MOUSE MACROPHAGE CELL UNE. (UNPUBUSHED PAPER).
00)) 00 02-03
MACROPHAGES
PROTEIN ABNORMAUTIES IN MACROPHAGES BEARING ASBESTOS
(UNPUBUSHED PAPER).
MAOE-,932 °°'°^^°2-01
PROTECTIVE ACTION OF L 5 HYDROXYTRYPTOPHAN L GLUTAMATE
(MADE-) 932) DURING ELECTROSHOCK-TREATMENT (ECT)
MADNESS 003043 03-04
MADNESS AND MEDICINE: THE FORCIBLE ADMINISTRATION OF
PSYCHOTROPIC-DRUGS.
MAGEPTIL 002523 02-17
THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE
PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION
WITH PHYTOHEMAGGLUTININ.
004541 04-13
MAGNESIUM
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFECTS OF ORAL MAGNESIUM
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM.
003291 03-1 1
A«AGNITUDE
POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES ON THE ONSET
MAGNITUDE AND QUALITY OF THE OPIOID ABSTINENCE-SYNDROME.
004610 04-15
MAINTENANCE
WHAT IS THE BEST MAINTENANCE DOSE OF NEUROLEPTICS IN
SCHIZOPHRENIA?
000547 01-08
METHADONE DISULFIRAM INTERACTION DURING METHADONE
MAINTENANCE.
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD
ETHANOL LEVELS IN RATS DRINKING A LIQUID DIET.
001865 02-06
ml*
'titjti"
■tit
'in:
1!'
S-261
^^IS
Subject Index
Psychopharmacology Abstracts
SI-
a',
an
4E11K1
^ik«»
THE CHANGE OF BLOOD PROLAaiN LEVEL DUE TO THE WITHDRAWAL OF
MAINTENANCE NEUROLEPTICS. „„„„„ „^ ,-,
002559 02-17
ANALYSIS OF SINGLE-BUND, DOUBLE-BLIND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFEaS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS - BRIEF REPORT.
003298 03-11
DYSTONIC REAQION DURING MAINTENANCE ANTIPSYCHOTIC THERAPY.
003485 03-15
NATURAL AND THERAPEUTIC ENVIRONMENTAL INDICATORS OF
MAINTENANCE DOSAGE REQUIREMENTS. _^_ , ^^ , ^
003561 03-16
ANALYSIS OF SINGLE-BLIND AND DOUBLE-BUND PROCEDURES,
MAINTENANCE OF PLACEBO-EFFECTS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON. „„,.., „. , ,
004437 04-1 1
MAINTENANCE-THERAPY
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY. EFFICACY, DOSAGE SCHEDULE AND PLASMA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
MAINTENANCE-THERAPY WITH FLUPHENAZINE-DECANOATE AND
OXYPROTHEPINE-DECANOATE IN SCHIZOPHRENIC-PATIENTS - A
DOUBLE-BUND CROSS-OVER COMPARATIVE-STUDY.
001924 02-08
EXPERIENCE WITH OXYPROTHEPINE-DECANOATE IN THE MAINTENANCE-
THERAPY OF SCHIZOPHRENIA. ^^,^^^ ^^ ^^
001925 02-08
INTERMinENT PIMOZIDE VERSUS FLUPHENAZINE-DECANOATE AS
MAINTENANCE-THERAPY IN CHRONIC SCHIZOPHRENIA.
001932 02-08
THE EFFEQ OF LONG-TERM MAINTENANCE-THERAPY ON SCHIZOPHRENIC-
PATIENTS USING SOMATOTHERAPEUTIC MEASURES.
004325 04-08
A NEW DOSAGE SCHEDULE FOR PIMOZIDE IN THE ACUTE STABIUZATION
AND MAINTENANCE-TREATMENT OF PSYCHOSIS.
002022 02-09
MAINTENANCE-TREATMENT WITH SEMIDEPOTE NEUROLEPTIC
^L^5^'«'^^^^- 00215102-11
DEPOT FLUPHENAZINE MAINTENANCE-TREATMENT AND ASSOCIATED
WEIGHT CHANGES. „„.,or «. ,r
004635 04-15
MAJOR-TRANQUILIZERS
MAJOR-TRANQUIUZERS AND HEART-DISEASE: TO USE OR NOT TO USE.
000866 01-15
MAJOR-TRANQUILLIZERS
MAJOR-TRANQUILLIZERS IN PSYCHIATRY.
000987 01-17
SELEQIVE SENSITIZATION INDUCED BY LITHIUM MALAISE AND
FOOTSHOCK IN RATS. „„.„„ «, «.
003055 03-04
MALE
MORPHINE EXERTS TESTOSTERONE-UKE EFFEQS IN THE HYPOTHALAMUS
OF THE CASTRATED MALE RAT. „ „, „.
000051 01-03
INFERENCES DERIVED FROM ELEaROENCEPHALOGRAPHIC RESPONSES TO
ACUTE ADMINISTRATION OF CLOMIPHENE-CITRATE IN MALE ALBINO-
RATS
000155 01-03
THE EFFEaS OF GONADECTOMY AND HYPOPHYSEaOMY ON THE
METABOUSM OF IMIPRAMINE AND UDOCAINE BY THE UVER OF MALE
AND FEMALE RATS.
000273 01-03
PROLONGATION OF THE EJACULATION LATENCY IN THE MALE RAT BY
THIORIDAZINE AND CHLORIMIPRAMINE.
000335 01-04
EFFEaS OF MORPHINE, BETA ENDORPHIN AND NALOXONE ON
CATECHOLAMINE LEVELS AND SEXUAL-BEHAVIOR IN THE MALE RAT.
000430 01-04
SEXUAL-BEHAVIOUR OF MORPHINE-DEPENDENT AND ABSTINENT MALE
RATS
000438 01-04
DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN
FRAGMENTS OF MALE AND FEMALE RATS.
001121 02-03
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALEaOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER). 001122 02-03
EFFEa OF AMINOOXYACETIC-ACID AND BICUCULUNE ON PROLACTIN
RELEASE IN CASTRATED MALE RATS. ^ ^ ^^ ^^
001194 02-03
SYNCHRONIZATION OF EEG AQIVITY OF MALE RHESUS-MONKEYS
MACACA-MULAHA TREATED WITH OVOCYCUN.
001312 02-03
MODIFICATION OF GABAERGIC AQIVITY AND THYROTROPIN SECRETION
IN MALE RATS.
001362 02-03
THE EFFEa OF REPEATED ELEQROCONVULSIVE-SHOCK ON
CORTICOSTERONE RESPONSES TO CENTRALLY-AQING
PHARMACOLOGICAL STIMUU IN THE MALE RAT.
001486 02-03
STUDY OF LITHIUM LEVELS IN THE SERUM AND GENITAL ORGANS OF
MALE RATS.
001494 02-03
CHRONIC-TREATMENT WITH VALIUM (DIAZEPAM) FAILS TO AFFEQ THE
REPRODUCTIVE SYSTEM OF THE MALE RAT.
001535 02-03 j
LONG-TERM EFFEQS OF TESTOSTERONE INJEQIONS ON THE SOCIAL-
BEHAVIOUR OF MALE DUCKS AND THEIR PHYSIOLOGICAL-CORRELATES.
001565 02-04
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND '
ELEQROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE
MIDBRAIN.
001593 02-04
BEHAVIOURAL-EFFEQS AND ENDOCRINE-EFFEaS OF NALTREXONE IN
MALE TALAPOIN-MONKEYS.
001718 02-04
BEHAVIORAL-EFFEaS OF HASHISH IN MICE: III. SOCIAL-INTERAQIONS
BETWEEN TWO RESIDENTS AND AN INTRUDER MALE.
001776 02-04
LEVELS OF MINERAL-ELEMENTS IN THE SERUM AND SALIVA OF HEALTHY
MALE VOLUNTEERS AFTER A SINGLE-DOSE OF U2C03.
002297 02-13
INFLUENCE OF CANNABIS AND DELTA9 TETRAHYDROCANNABINOL ON
THE BIOCHEMISTRY OF THE MALE REPRODUQIVE ORGANS.
002686 03-03
DIFFERENTIAL-EFFEQS OF CANNABINOID EXPOSURE AND STRESS ON
PLASMA PROLACTIN, GROWTH-HORMONE AND CORTICOSTERONE
LEVELS IN MALE MICE.
002695 03-03
LACK OF CORRELATION BETWEEN NALOXONE-INDUCED CHANGES IN
SEXUAL-BEHAVIOR AND SERUM LH IN MALE RATS.
002821 03-03
INCREASE IN PLASMA CYCLIC-AMP LEVELS EUCITED BY NALOXONE IN
MORPHINE-DEPENDENT MALE MICE.
002834 03-03
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFECTS OF NALOXONE ON
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE
'^'''''' 002853 03^3
INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN
CHORIONIC GONADOTROPHS. ^^ ^^
003012 03-04
RAT PUP-KILLING AND MATERNAL-BEHAVIOR IN MALE LONG-EVANS-
RATS PRENATAL STIMULATION AND POSTNATAL TESTOSTERONE.
003054 03-04
TESTOSTERONE POTENTIATION OF THE EFFEQIVENESS OF AaHl-24 ON
THE INDUaiON OF THE STRETCH-YAWNING-SYNDROME (SYS) IN MALE
'^^"^^^■'"^^ 003074 03^
COPULATORY-BEHAVIOR AND SEXUAL-REFLEXES OF MALE RATS TREATED
WITH NALOXONE. ^o«-,-, «o m
003077 03-04
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL
HEMISPHERES OF AGED MALE RATS. 003936 04-03
COMPARISON OF THE EFFECTS OF BETA ENDORPHIN AND MORPHINE ON
EXPLORATORY-BEHAVIOUR AND SOCIOSEXUAL-BEHAVIOUR IN THE
^^^^^^^ 004178 04-04
METHADONE REDUCES SEXUAL-PERFORMANCE AND SEXUAL-
MOTIVATION IN THE MALE SYRIAN GOLDEN HAMSTER. „^ „, „,
004183 04-04
SEXUAL-BEHAVIOR DECREASES PAIN SENSITIVITY AND STIMULATES
ENDOGENOUS OPIOIDS IN MALE RATS. ^.„,. „. „.
004234 04-04
PHARMACOTHERAPY OF SEXUAL-IMPOTENCE IN THE MALE.
004435 04-11
BASAL PROLAQINAEMIA AND RESPONSES TO TRH AND SULPIRIDE IN
DIFFERENT CATEGORIES OF MALE SEXUAL-DYSFUNQIONS^
004503 04-13
DEXTROAMPHETAMINE: COGNITIVE AND BEHAVIORAL-EFFEaS IN
NORMAL AND HYPERAQIVE-BOYS AND NORMAL ADULT MAliS.
000716 01-11
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: 1. SOCIAL-INTERAQIONS
AND NEST-BUILDING-BEHAVIOR OF MALES. ^^^^ ^^^
DECREASED 3H IMIPRAMINE BINDING IN DEPRESSED MALES AND
f^^^"-^^ 004349 04-09
S-262
VOLUME 19, SUBJECT INDEX
MALFORMATIONS
FAILURE Of CLORAZEPATE TO CAUSE MALFORMATIONS OR FETAL
WASTAGE IN THE RAT.
000514 01-05
MAUONANT-HYPERTHERMIC-SYNDROMES
MALIGNANT-HYPfRTHERMICSYNDROMES IN THE COURSE OF
TREATMENT WITH LONG-ACTING NEUROLEPTICS.
002430 02-15
UtALIONANT-SYNDROME
NEUROLEPTIC MALIGNANT-SYNDROME: A PATHOGENETIC ROLE FOR
DOPAMINE-RECEPTOR BLOCKADE?
003492 03-15
BIOCHEMICAL AND NEUROENDOCRINE APPROACHES TO A MALIGNANT-
SYNDROME OF NEUROLEPTIC.
004589 04-15
AALNUTRITION
EFFECTS OF MALNUTRITION AND QUIPAZINE ON RAT-CEREBRAL-CORTEX
ATPASE ACTIVITY DURING DEVELOPMENT.
001276 02-03
«AM-ACETAn
RETINAL TOXICITY OF MAM-ACETATE IS DEVELOPMENTALLY SPECIFIC.
(UNPUBLISHED PAPER).
001212 02-03
lAMMALIAN
ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS.
000194 01-03
COMPARISON OF BETA-ADRENERGIC-RECEPTOR SUBTYPES IN
MAMMALIAN TISSUES.
000207 01-03
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING
DOPAMINE ANTAGONIST: INTERAQIONS WITH DOPAMINE-RECEPTORS
OF MAMMALIAN FOREBRAIN IN VITRO,
001114 02-03
RECEPTOR BINDING INTERAQIONS OF THE ANGIOTENSIN-II ANTAGONIST
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
TWO CONDUQANCE MECHANISMS ACTIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES.
001349 02-03
BINDING OF (3H)PERG0LIDE-MESYLATE TO DOPAMINE-RECEPTORS OF
MAMMALIAN BRAINS.
001538 02-03
ONTOGENY OF MAMMALIAN CARDIAC ALPHA 1-ADRENERGIC-
RECEPTORS.
001545 02-03
NEURONAL MATURATION IN MAMMALIAN CELL-CULTURE IS DEPENDENT
ON SPONTANEOUS ELECTRICAL-AQIVITY.
002669 03-03
PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN
MAMMALIAN RETINA.
002814 03-03
TWO DISTINQ SEROTONIN-RECEPTORS: REGIONAL VARIATIONS IN
RECEPTOR BINDING IN MAMMALIAN BRAIN.
002861 03-03
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN
003820 04-03
PHARMACOKINETICS AND METABOLISM OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE) IN RAT
MOUSE, DOG AND MAN.
000219 01-03
COMPARATIVE-STUDIES OF MAO-A AND MAO-B INHIBITORS IN MAN.
000612 01-09
INTERAQION BETWEEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN
METABOLITE NORTRIPTYLINE AND THE CORRELATION WITH CLINICAL-
RESPONSE.
IS LITHIUM MUTAGENIC IN MAN? °°°*^° ° ' "°'
NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN RELATION TO '^^
DEBRISOQUINE HYDROXYLATION IN MAN.
riooy CA ni 1 'i
INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY-STATE SERUM LEVELS
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-DRUGS IN MAN.
nnoTAT m i '^
DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION- A
PITUITARY MODEL FOR THE STUDY OF A NEUROENDOCRINE SYSTEM IN
MAN.
00077A ni 1 "^
SHORT-TERM HORMONAL-EFFEaS OF NALOXONE IN MAN.
nnoTQft m 1*5
INFLUENCE OF PYRITHIOXINE, MECLOPHENOXATE AND PIRACETAM On"
THE LEARNING PROCESS IN MAN.
000805 01-14
Subject Index
THE EFFECT OF SMALL AND MODERATE DOSES OF D-AMPHETAMINE ON
HUNGER, MOOD, AND AROUSAL IN MAN.
000807 01-14
LEVORPHANOL: RADIOIMMUNOASSAY AND PLASMA CONCENTRATION
PROFILES IN DOG AND MAN.
000898 01-16
ASSESSMENT OF ADRENERGIC-RECEPTORS IN VIVO IN EXPERIMENTAL
ANIMALS AND MAN. (UNPUBLISHED PAPER).
001034 02-01
BIOCHEMICAL-EFFECTS OF ZIMELIDINE IN MAN.
001967 02-09
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN
MAN: POSSIBLE CENTRAL-ACTION IN BRAIN.
002195 02-12
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
APOMORPHINE HYPOTHERMIA: AN INDEX OF CENTRAL DOPAMINE-
RECEPTOR FUNQION IN MAN.
002221 02-13
SHORT-TERM ETHANOL ADMINISTRATION IMPAIRS THE ELIMINATION OF
CHLORDIAZEPOXIDE (LIBRIUM) IN MAN.
002224 02-13
TELE-METHYLHISTAMINE IS A SPECIFIC MAO-B SUBSTRATE IN MAN.
002230 02-13
BIOAVAILABILITY AND RELATED PHARMACOKINETICS IN MAN OF
ORALLY ADMINISTERED L 5 HYDROXYTRYPTOPHAN IN STEADY-STATE.
002261 02-13
CLINICAL EVIDENCE FOR MULTIPLE DOPAMINE-RECEPTORS IN MAN.
002264 02-13
INHIBITION OF SULPIRIDE-INDUCED PROUQIN SECRETION BY
DIHYDROERGOCRISTINE IN MAN.
002277 02-13
THE PHARMACOKINETICS OF BROMOCRIPTINE IN MAN.
002291 02-13
INDIVIDUAL VARIATIONS IN THE EFFEQS OF FLURAZEPAM
CLORAZEPATE, L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON
REM SLEEP IN MAN.
002349 02-14
THE EFFECT OF DEPRENYL, A SELEQIVE MONOAMINE-OXIDASE-B-
INHIBITOR, ON SLEEP AND MOOD IN MAN.
002365 02-14
NEUROPHARMACOLOGY OF SYNTHETIC ERGOT DERIVATIVES IN MAN.
002429 02-15
DEVELOPMENT AND USE Of PHARMACOLOGICAL-PROBES OF THE CNS IN
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY
AFFEQIVE-ILLNESS.
002506 02-16
BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS
AND MAN.
002527 02-17
THE HYPOTHALAMIC DOPAMINERGIC REGULATION OF PROLAQIN A
MODEL FOR THE STUDY OF NEUROHORMONAL MECHANISMS IN MAN.
002568 02-17
PSYCHOPHARMACOLOGY OF ANORECTIC-DRUGS IN MAN,
002607 02-17
IMMUNOREAQIVE CALCITONIN IN CEREBROSPINAL-FLUIO OF MAN,
002637 03-01
STEADY-STATE LITHIUM BLOOD LEVEL FLUQUATIONS IN MAN
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FORM.
003151 03-07
EFFECT OF A PSYCHOACTIVE-DRUG, TRAZODONE, ON PROLACTIN
SECRETION IN MAN.
003425 03-13
A COMPARISON OF THE EFFEQS OF MORPHINE-SULPHATE AND NITROUS-
OXIDE ANALGESIA ON CHRONIC PAIN STATES IN MAN.
003442 03-14
STUDY ON THE EFFECTS OF L 5 HTP ON THE STAGES OF SLEEP IN MAN AS
EVALUATED BY USING SLEEP-DEPRIVATION.
003450 03-14
POSITRON-TOMOGRAPHY. A NEW METHOD FOR IN VIVO BRAIN STUDIES
OF BENZODIAZEPINE, IN ANIMAL AND IN MAN.
003564 03-16
PHARMACOKINETIC-STUDY IN MAN OF THE CH-757 PREPARATION.
004440 04-1 1
PHARMACOKINETICS OF CLOXAZOLAM IN MAN AFTER SINGLE AND
MULTIPLE ORAL DOSES.
004530 04-13
NOREPINEPHRINE METABOLISM IN MAN USING DEUTERIUM LABELLING- 4
HYDROXY-3-METHOXYMANDELIC-ACID .
004534 04-13
THE PHARMACOKINETICS OF MIDAZOLAM IN MAN,
004555 04-13
•(&'.
'Ml
■iitit"
:';«?:■
I
f.iB
S-263
fill -I :
^l»i»
13^
1
Subject Index
SEX PLASMA PROLACTIN AND PLASMA 3 METHOXY-4-
HYDROXYPHENYLGLYCOL (MHPG) PREDICT HERITABLE D-
AMPHETAMINE EXCITATION IN MAN. (UNPUBLISHED PAPER)^
004565 04-14
A SYNTHETIC ACTH4-9 ANALOGUE (ORGANON-2766) AND SLEEP IN
"^^L^Y^^"^- 004574 04-14
THE EFFECT OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON
THE STIMULANT AND ANORECTIC-AQIONS OF DEXTROAMPHETAMINE
"^^^'^- 004580 04-14
ACUTE MANAGEMENT OF THE VIOLENT AGGRESSIVE-PATIENT.
000 5oo 0 i-OV
THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG-TREATMENT
FOR HYPERACTIVE-CHILDREN: RECENT FINDINGS AND A REPORT FROM
CLINICAL-PRAQICE. 000715 01-11
APPLICATION OF A RADIOIMMUNOASSAY SCREENING-TEST FOR
DETECTION AND MANAGEMENT OF PHENCYCLIDINE INTOXICATION^
000859 01-15
DEPRENYL IN THE MANAGEMENT OF RESPONSE FLUCTUATIONS IN
PATIENTS WITH PARKINSONS-DISEASE ON LEVODOPA.
002358 02- 14
TARDIVE-DYSKINESIA: RECOGNITION, MANAGEMENT, ^^^^^^^^^9^^
MONOAMINE-OXIDASE-INHIBITORS: PRESCRIPTION AND PATIENT
'^^^^^^^'^^ 002454 02-15
DRUG-HOLIDAY AND MANAGEMENT OF PARKINSON-DISEASE^
002468 02-15
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL-STUDIES WITH
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND
DEPOT NEUROLEPTICS. 003183 03-08
MANAGEMENT OF DEPRESSION WITH SEROTONIN PRECURSORS^
THE MANAGEMENT OF CHRONIC BEHAVIOR-DISORDERS IN MENTALLY-
RETARDED ADULTS WITH LITHIUM-CARBONATE.
003376 Oo- 1 t
ACUTE PHENCYCLIDINE (PCP) INTOXICATION: QUANTITATIVE URINE
LEVELS AND CLINICAL MANAGEMENT. „„.,.c ^. ,c
004665 04- 1 5
PARAPROFESSIONAL AND PROFESSIONAL TEAMWORK AND TRAINING IN
MANAGING PCP AND OTHER DRUG-ABUSE PROBLEMS. ^^
**^'mENTAL-DISTURBANCES IN CHRONIC MANGANESE PO'SONIN^^ ^^ ^^
THYROID-INDUCED MANIA IN HYPOTHYROID-PATIENTS ^^g,, q, ,.
MANIA: AN EVOLVING CONCEPT. 001966 02-09
LITHIUM AND MANIA: HYPOTHESES. 001986 02-09
A COMPARISON OF HALOPERIDOL, LITHIUM-CARBONATE AND THEIR
COMBINATION IN THE TREATMENT OF MANIA.
001990 02-09
RAPID RECURRENCE OF MANIA FOLLOWING LITHIUM WITHDRAWAL.
002010 02-09
PSYCHOMOTOR STIMULANTS AS ACTIVATORS OF NORMAL AND
PATHOLOGICAL-BEHAVIOR: IMPLICATIONS FOR THE EXCESSES IN
MANIA. (UNPUBLISHED PAPER) ^^^^^ ^^ ^ ^
THE LITHIUM-ION: IS IT SPECIFIC FOR MANIA? ^^
THE EFFECT OF SODIUM-VALPROATE ON MANIA: THE GABA HYPOTHESIS
OF AFFECTIVE-DISORDERS. „„^„,„ „o ^o
003218 03-09
ON A POSSIBLE ROLE OF GABA IN MANIA. THERAPEUTIC-EFFICACY OF
SODIUM-VALPROATE. „„o^,n «o An
003219 03-09
HYPOMANIA AND MANIA ARER WITHDRAWAL OF TRICYCLIC-
ANTIDEPRESSANTS.
003243 03-09
IS MANIA OVERDIAGNOSED?: THE THREE COMMON PITFALLS IN
DIAGNOSING MANIC-DEPRESSIVE-ILLNESS. ^^^^^ ^^_^
LITHIUM AND THE CHANGING INCIDENCE OF MANIA. ^^ ^^
LITHIUM AND MANIA. 003640 03-17
CHANGES IN BLOOD PLASMA OSMOLALITY AND STATES OF MANIA.
004352 04-09
PLASMA CORTICOSTERIODS IN MANIA: THE EFFEaS OF PIMOZIDE.
004363 04-09
CHOLINERGIC MECHANISMS IN MANIA AND DEPRESSION: QUESTIONS OF
SPEC'^'C'^ 004374 04-09
Ptychopharmacology Abttracfs
TRICYCLIC-ANTIDEPRESSANT-INDUCED MANIA.
004656 04-15
CHOLINOMIMETICS IN MANIA, SCHIZOPHRENIA, AND MEMORY-
DISORDERS.
004703 04-17
CEREBRAL FLUORIDE IN MANIA AND THE EFFEQ OF LITHIUM: A
HYPOTHESIS. „ ,
004715 04-17
THE RELATIVE PROPHYLACTIC EFFICACY OF LITHIUM AGAINST MANIC
AND DEPRESSIVE RECURRENCES IN BIPOLAR-PATIENTS.
002040 02-09
MANIC-DEPRESSIVE-ILLNESS j
PSYCHOBIOLOGICAL-RESEARCH IN MANIC-DEPRESSIVE-ILLNESS. \
(UNPUBLISHED PAPER).
001973 02-09
A TEN YEAR FOLLOWUP OF LITHIUM-CARBONATE TREATMENT OF MANIC-
DEPRESSIVE-ILLNESS: PRELIMINARY-RESULTS.
002053 02-09
HISTORICAL-PERSPECTIVES AND CURRENT HIGHLIGHTS ON LITHIUM
TREATMENT IN MANIC-DEPRESSIVE-ILLNESS.
003224 03-09
IS MANIA OVERDIAGNOSED?: THE THREE COMMON PITFALLS IN
DIAGNOSING MANIC-DEPRESSIVE-ILLNESS.
003260 03-09
A PRELIMINARY DOUBLE-BLIND STUDY ON THE EFFICACY OF
CARBAMAZEPINE IN PROPHYLAXIS OF MANIC-DEPRESSIVE-ILLNESS
004388 04-09
LITHIUM TREATMENT OF MANIC-DEPRESSIVE-ILLNESS. A PRAQICAL
GUIDE.
004408 04-09
MANIC-DEPRESSIVE-PATIENT
THIAZIDE-INDUCED HYPERCALCEMIA IN A MANIC-DEPRESSIVE-PATIENT
000843 01-15
MANIC-DEPRESSIVE-PATIENTS
ENDOCRINE-EFFECTS OF LITHIUM IN MANIC-DEPRESSIVE-PATIENTS.
001970 02-09
MANIC-DEPRESSIVE-PSYCHOSES
EMERGENCIES IN MANIC-DEPRESSIVE-PSYCHOSES.
003540 03-15
MANIC-DEPRESSIVE-PSYCHOSIS ^ , ^.. '
DOSAGE OF INTRATUMORAL LITHIUM (CEREBRAL GLIOBLASTOMA): ON A
FAILURE OF TREATMENT OF MANIC-DEPRESSIVE-PSYCHOSIS
003226 03-09
CONFESSION OF A MELANCHOLIAC: CONTRIBUTION TO THE PROBLEM OF
PROPHYLAXIS OF MANIC-DEPRESSIVE-PSYCHOSIS USING LITHIUM.
003267 03-09
MANIC-DEPRESSIVES
DIFFERENT EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS AND TETRAaCLIC-
ANTIDEPRESSANTS ON THE RELEASE OF TSH, PROLAQIN, AND
GROWTH-HORMONE AFTER ADMINISTRATION OF THYROSTIMULATING- i
RELEASING-HORMONE IN MANIC-DEPRESSIVES. ,
004407 04-09
MANIC-MELANCHOLIC-DISORDERS
BIOLOGY OF MANIC-MELANCHOLIC-DISORDERS.
000978 01-17
INTERAQION OF INDOMETHACIN AND IBUPROFEN WITH LITHIUM IN
MANIC-PATIENTS UNDER A STEADY-STATE LITHIUM LEVEL ^^^
INTRA AND EXTRA ERYTHROCYTE LITHIUM-ION CONCENTRATION RATIOS
IN MANIC-PATIENTS. 000627 01-09
GROWTH-HORMONE (GH) RELEASE FOLLOWING THYROTROPIN-
RELEASING-HORMONE (TRH) INJEQION IN MANIC-PATIENTS
RECEIVING LITHIUM-CARBONATE. 000645 01-09
ERYTHROCYTE CHOLINE CONCENTRATIONS ARE ELEVATED IN MANIC-
''^TIENTS. 0^521 04-13
MANIC-PSYCHOSIS
MANIC-PSYCHOSIS FOLLOWING RAPID WITHDRAWAL FROMBACLOFEN.
000832 0 I-Ij
EFFECT OF LITHIUM ON PROLAQIN RESPONSES TO THYROTROPIN-
RELEASING-HORMONE IN PATIENTS WITH '^*'^'^'^"^*^^ oqo,^* 03-09
MANIC-STATE INDUCED BY SALBUTAMOL TAKEN ORALLY.
004622 U4-ID
MANIC-SYMPTOMS
FAILURE OF NALOXONE TO REDUCE MANIC-SYMPTOMS. ^^^^ ^^^
***'bEHAVIORAL-ANALYSIS of amygdaloid KINDLING IN BEAGLE-DOCSS
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION. 000496 01-04
S-264
VOLUME 19, SUBJECT INDEX
Subject Index
MANIFESTATIONS
PSYCHIATRIC MANIFESTATIONS INDUCED BY DOPAMINE PRECURSORS OR
DOPAMINE AGONISTS.
000865 01-15
DERMATOLOGIC MANIFESTATIONS OF LITHIUM: A REVIEW.
003462 03-15
MANIFESTED
CIMETIDINE TOXICITY MANIFESTED AS PARANOIA AND
HALLUCINATIONS.
000829 01-15
MANIPULATION
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION.
001310 02-03
SELF-MEDICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS.
002189 02-11
SURGICAL MANIPULATION OF THE UTERINE ENVIRONMENT OF RAT
FETUSES,
002478 02-16
BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS
AND MAN.
002527 02-17
A RESEARCH PARADIGM TO INVESTIGATE THE EFFECT OF MANIPULATION
ON SOCIAL-BEHAVIOR IN GROUPS.
003007 03-04
PHARMACOLOGIC MANIPULATION OF BRAIN AND PITUITARY ENDORPHIN
CONTENT AND RELEASE.
003837 04-03
DOPAMINE-DEPENDENT HYPERACTIVITY IN THE FOLLOWING
MANIPULATION OF GABA MECHANISMS IN THE REGION OF THE
NUCLEUS-ACCUMBENS.
003976 04-03
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO.
004544 04-13
MANIPULATIONS
THE SENSITIVITY OF THE RAT CORTICOSTERONE RESPONSE TO
ENVIRONMENTAL MANIPULATIONS AND TO CHRONIC
CHLORDIAZEPOXIDE TREATMENT.
000092 01-03
PRESYNAPTIC AND POSTSYNAPTIC SEROTONERGIC MANIPULATIONS IN
AN ANIMAL-MODEL OF DEPRESSION.
001730 02-04
THE EFFECTS OF TRYPTOPHAN AND MANIPULATIONS OF SEROTONERGIC-
RECEPTORS ON TONIC IMMOBILITY IN CHICKENS.
004245 04-04
MAO-A
COMPARATIVE-STUDIES OF MAO-A AND MAO-B INHIBITORS IN MAN.
000612 01-09
MAO-B
COMPARATIVE-STUDIES OF MAO-A AND MAO-B INHIBITORS IN MAN.
000612 01-09
TELE-METHYLHISTAMINE IS A SPECIFIC MAO-B SUBSTRATE IN MAN.
002230 02-13
MAO-INHIBITION
REGIONAL 5 HT ANALYSIS IN ROMAN HIGH-AVOIDANCE AND LOW-
AVOIDANCE RATS FOLLOWING MAO-INHIBITION.
001202 02-03
MAO-INHIBITORS AND PLATELET MAO-INHIBITION.
001993 02-09
IN VIVO INTRANEURONAL MAO-INHIBITION IN RAT-BRAIN SKF-64139,
COMPARISON TO OTHER POTENT PNMT INHIBITORS.
003935 04-03
MAO-INHIBITOR
THE BENEFITS AND RISKS OF COMBINING AN MAO-INHIBITOR AND A
TRICYCLIC-ANTIDEPRESSANT.
003273 03-09
TREATMENT OF DEPRESSION WITH AN MAO-INHIBITOR FOLLOWED BY 5
HTP - AN UNFINISHED RESEARCH PROJECT.
004377 04-09
MAO-INHIBITORS
EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE
ROLE FOR BETA PHENYLETHYLAMINE IN THE COCAINE CUE.
000363 01-04
THE EFFECTS OF 5 HT UPTAKE AND MAO-INHIBITORS ON L 5 HTP-
INDUCED EXCITATION IN RATS.
001740 02-04
MAO-INHIBITORS AND PLATELET MAO-INHIBITION.
001993 02-09
MAOI-INDUCED
MAOI-INDUCED RAPID CYCLING BIPOLAR AFFECTIVE-DISORDER IN AN
ADOLESCENT.
004637 04-15
MAPPING
MAPPING OF DYSKINETIC-MOVEMENTS INDUCED BY LOCAL APPLICATION
OF PICROTOXIN OR () GAMMA ACETYLENIC-GABA ON THE RAT
MOTOR-CORTEX.
000458 01-04
ANATOMOBIOCHEMICAL MAPPING OF THE BRAIN: NEUROPSYCHIATRIC-
CORRELATIONS.
002630 02-17
MAPROTILIN
OUR EXPERIENCE WITH MAPROTILIN TREATMENT OF DEPRESSIVE-STATES.
000623 01-09
INFUSION OF MAPROTILIN AND CLOMIPRAMIN AND THEIR COMBINATION
IN THE TREATMENT OF DEPRESSION
002056 02-09
MAPROTILINE
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
COMPARATIVE-STUDY OF THE CARDIOTOXICITY OF AMITRIPTYLINE AND
MAPROTILINE IN DEPRESSIVE-PATIENTS.
000595 01-09
COMPARISON OF SINGLE-DOSE PHARMACOKINETICS OF IMIPRAMINE
AND MAPROTILINE IN THE ELDERLY.
000596 01-09
MHPG AS A PREDICTOR OF ANTIDEPRESSANT RESPONSE TO IMIPRAMINE
AND MAPROTILINE.
000787 01-13
STUDY OF MAPROTILINE IN OUTPATIENT TREATMENT OF DEPRESSIVE-
STATES BY THE GENERAL-PRACTITIONER: ADVANTAGE OF SINGLE-
NIGHTLY-DOSE.
001961 02-09
MAPROTILINE ADMINISTERED IN A SINGLE-DAILY-DOSE IN GENERAL-
PRACTICE.
002027 02-09
CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE
AND CLOMIPRAMINE IN DEPRESSIVE-STATES (PRELIMINARY
OBSERVATION).
002032 02-09
COMPARATIVE CROSS-STUDY ON THE EFFECTS OF AMINEPTINE AND
MAPROTILINE.
002065 02-10
BIOAVAILABILITY AND KINETICS OF MAPROTILINE.
002204 02-13
AN EVALUATION OF MAPROTILINE INTRAVENOUS KINETICS AND
COMPARISON OF TWO ORAL DOSES.
002497 02-16
AN OPEN-STUDY OF MAPROTILINE 75MG IN THE TREATMENT OF
DEPRESSIVE-STATES.
003152 03-07
CLINICAL-STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE-
STATES: COMPILATION OF 1520 OBSERVATIONS.
003206 03-09
CLINICAL-TRIALS WITH NEW BICYCLIC AND TETRACYCLIC COMPOUNDS:
ZIMELIDINE AND MAPROTILINE.
003213 03-09
RELATIONSHIP BETWEEN BLOOD CONCENTRATIONS AND CLINICAL-
EFFECTS OF A NEW ANTIDEPRESSANT MAPROTILINE.
003271 03-09
MAPROTILINE VERSUS IMIPRAMINE AND PLACEBO IN NEUROTIC
DEPRESSION.
003287 03-10
PHARMACOKINETICS OF AMITRIPTYLINE. IMIPRAMINE, AND
MAPROTILINE IN THE ELDERLY.
003324 03-1 1
6LC MASS-SPECTROMETRIC-DETERMINATION OF MAPROTILINE AND ITS
MAJOR METABOLITE USING STABLE ISOTOPE-LABELED ANALOG AS
INTERNAL STANDARD.
004291 04-06
MAPROTILINE, NOMIFENSINE, MIANSERIN, ZIMELIDINE: A REVIEW OF
ANTIDEPRESSANT EFFICACY IN INPATIENTS.
004731 04-17
MARGINAL
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE
SPINAL-CORD OF THE CAT: ENKEPHALIN-CONTAINING MARGINAL
NEURONS AND PAIN MODULATION.
002638 03-01
MARIHUANA
THERAPEUTIC ASPECTS OF MARIHUANA.
000667 01-11
EFFECTS OF MARIHUANA ON PREGNANT RATS AND THEIR OFFSPRING.
001830 02-05
MEMORY: THE EFFECTS OF ALCOHOL AND OF MARIHUANA.
004570 04-14
AAARIJUANA
MARIJUANA: A REVIEW OF MEDICAL RESEARCH WITH IMPLICATIONS
FOR ADOLESCENTS.
000871 01-15
•..(16.
Jill
,"■'?'
>lla!>l
I
tiE
:j;:
I!'
S.265
-«%2ftafi»a»Ss
m
4!")!
^1:
Subject Index
MARIJUANA AND CHOLINERGIC DYNAMICS. (UNPUBLISHED PAPER).
001166 02-03
EFFECTS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED
SUBJECTS.
002320 02-14
LITHIUM AND MARIJUANA.
003526 03-15
MARKED
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUQION OF
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN
FOLLOWING INTERAVENTRICULAR INJECTION,
001239 02-03
MARMOSET
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL.
004208 04-04
MASS-FRAGMENTOGRAPHY
RAT-BRAIN AND PLASMA NOREPINEPHRINE GLYCOL METABOLITES
DETERMINED BY GAS-CHROMATOGRAPHY MASS-
FRAGMENTOGRAPHY.
004303 04-06
MASS-SPECTRAL-ANALYSIS
HIGH-SENSITIVITY NEGATIVE CHEMICAL-IONIZATION MASS-SPEaRAL-
ANALYSIS OF BIOGENIC-AMINES AND METABOLITES. (UNPUBLISHED
^^^^^^- 001042 02-01
MASS-SPECTROMETRIC-ASSAYS
MASS-SPEaROMETRIC-ASSAYS OF INDOLEAMINES. (UNPUBLISHED
^"^^^^ 001043 02-01
MASS-SPECTROMETRIC-DETERMINATION
GLC MASS-SPECTROMETRIC-DETERMINATION OF MAPROTILINE AND ITS
MAJOR METABOLITE USING STABLE ISOTOPE-LABELED ANALOG AS
INTERNAL STANDARD.
004291 04-06
MASS-SPECTROMETRY
QUANTITATIVE ANALYSIS OF 6 HYDROXYMELATONIN IN HUMAN URINE
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS-
SPEQROMETRY. (UNPUBLISHED PAPER).
001058 02-01
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
GAS-CHROMATOGRAPHY, MASS-SPECTROMETRY, AND COMBINED
CHROMATOGRAPHY MASS-SPECTROMETRY.
004290 04-06
GAS-CHROMATOGRAPHY/MASS-SPEaROMETRY STABLE ISOTOPIC
ANALYSES FOR DEANOL. CHOLINE. AND THEIR ACETYLESTERS.
004683 04-16
COMPARISON OF SPEaROFLUOROMETRIC AND GAS-
CHROMATOGRAPHY /MASS-SPEQROMETRY PROCEDURES FOR THE
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN.
004692 04-16
MASTECTOMY
PSYCHIATRIC MORBIDITY AND PHYSICAL TOXICITY ASSOCIATED WITH
ADJUVANT CHEMOTHERAPY AFTER MASTEQOMY.
002433 02-15
MATCHING-TO-SAMPLE
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE IN MENTALLY-RETARDED
ADULTS.
002471 02-15
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED
ADULTS.
003392 03-11
MATERNAL
MATERNAL GLUCOCORTICOID-HORMONES INFLUENCE
NEUROTRANSMIHER PHENOTYPIC EXPRESSION IN EMBRYOS.
000149 01-03
REDUaiON OF FETAL RAT SPINAL-CORD VOLUME FOLLOWING
MATERNAL MORPHINE INJEQION.
000161 01-03
CONCENTRATIONS OF CIS(Z) FLUPENTHIXOL IN MATERNAL SERUM,
AMNIOTIC-FLUID, UMBILICAL-CORD-SERUM, AND MILK.
002423 02-15
EFFEQ OF MATERNAL LORAZEPAM ON THE NEONATE.
003549 03-15
DISPOSITION OF METHADONE IN THE OVINE MATERNAL FETAL UNIT.
004027 04-03
MATERNAL-BEHAVIOR
PHENCYCLIDINE: EFFEQS OF CHRONIC ADMINISTRATION IN THE FEMALE
MOUSE ON GESTATION, MATERNAL-BEHAVIOR, AND THE NEONATES.
000517 01-05
Psychophormacology Abstracts
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFEQS ON
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT.
001580 02-04
AMPHETAMINE AND MATERNAL-BEHAVIOR: DOSE-RESPONSE
RELATIONSHIPS.
001752 02-04
RAT PUP-KILLING AND MATERNAL-BEHAVIOR IN MALE LONG-EVANS-
RATS: PRENATAL STIMULATION AND POSTNATAL TESTOSTERONE.
003054 03-04
MATERNALLY-DEPRIVED
EFFECTS OF RESERPINE AND AMPHETAMINE ON THE DEVELOPMENT OF
HYPERAQIVITY IN MATERNALLY-DEPRIVED RAT PUPS.
001654 02-04
MATERNITY-BLUES
PROSPEQIVE-TRIAL OF L TRYPTOPHAN IN MATERNITY-BLUES.
000683 01-11
MATING-BEHAVIOR
DRUGS, TRANSMIHERS AND HORMONES, AND MATING-BEHAVIOR.
004721 04-17
MATURATION
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. III. DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES.
000025 01-03
NEURONAL MATURATION IN MAMMALIAN CEU-CULTURE IS DEPENDENT
ON SPONTANEOUS ELEQRICAL-AaiVITY.
002669 03-03
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. VII. SUPPRESSION OF SYMPATHETIC RESPONSES BY
DEXAMETHASONE.
002802 03-03
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL-
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF
ANTIBODIES TO GANGLIOSIDE
003025 03-04
MATURE
APOMORPHINE-INDUCED STEREOTYPY IN MATURE AND SENESCENT RATS
FOLLOWING CESSATION OF CHRONIC HALOPERIDOL TREATMENT.
004651 04-15
MAXIMIZE
A STATE-DEPENDENT FAILURE OF RATS TO MAXIMIZE REWARDS.
000392 01-04
MAXIMUM
CLASSIFICATION OF DRUGS AND PATIENTS TO ACHIEVE MAXIMUM
THERAPEUTIC RESPONSE.
002560 02-17
MAZE
UNUSUAL DOSE-RELATED EFFEQ OF AN ENDORPHIN ANALOG IN A
COMPLEX MAZE.
001674 02-04
EFFEQS OF SCOPOLAMINE, PILOCARPINE, AND OXOTREMORINE ON THE
EXPLORATORY-BEHAVIOR OF TWO PSYCHOGENETICAUY SELECTED
LINES OF RATS IN A COMPLEX MAZE.
003042 03-04
MAZE-BEHAVIOR „
BETTA-SPLENDENS MAZE-BEHAVIOR UNDER THE INFLUENCE OF THE BETA
FENIL-ISOPROPIL-AMINA-SULFATE
001558 02-04
MAZE-LEARNING
DELAYED MAZE-LEARNING IN RATS AFTER PRENATAL EXPOSURE TO
CLORAZEPATE.
000521 01-05
MAZE-PERFORMANCE
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON
AVOIDANCE CONDITIONING, HEBB-WIUIAMS MAZE-PERFORMANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT.
001580 02-04
NEONATAL ADMINISTRATION OF MET-ENKEPHALIN FACILITATES MAZE-
PERFORMANCE OF ADULT RATS .
001673 02-04
MAZINDOL
EFFECT OF MAZINDOL ON BRAIN DOPAMINE TURNOVER IN SPIPERONE
TREATED RATS. ^„,^, „, „.
002726 03-03
CHARACTERISTICS OF THE INHIBITION OF RAT-BRAIN MONOAMINE-
OXIDASE IN VITRO BY MD7805 15.
003874 04-03
MEAL
METABOLIC-CORRELATES OF THE EFFEQS OF 2 DEOXY-D-GLUCOSE ON
MEAL SIZE AND POST MEAL SATIETY IN RATS.
003035 03-04
MEAL-DEPENDENT
MEAL-DEPENDENT ABSORPTION OF ENTERIC-COATED SODIUM-
VALPROATE. ^^,„ „, ,,
000777 01-13
S-266
VOLUME 19, SUBJECT INDEX
Subject Index
MfANINO
i HTP AND THE SEROTONIN HYPOTHESIS: THEIR MEANING FOR
TREATMENT OF DEPRESSION.
002326 02-14
CHARACTER AND MEANING OF QUASI-MORPHINE WITHDRAWAL
PHENOMENA ELICITED BY METHYUANTHINES
004087 04-04
MIASUKEMENTS
BLOOD LEVEL MEASUREMENTS OF TRICYCLIC DRUGS AS A DIAGNOSTIC
TOOL.
004368 04-09
MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT.
004441 04-11
MEBICAR
THE EFFECT OF MEBICAR ON THE CONDITION OF ANIMALS UNDER
CERTAIN EXTREME CIRCUMSTANCES.
004262 04-04
MECHANICAL-CHANGES
MECHANICAL-CHANGES IN CRAB NERVE FIBERS DURING ACTION
POTENTIALS. (UNPUBLISHED PAPER).
001505 02-03
MECHANISM
MECHANISM OF CHLORPROMAZINE ACTION ON PLASMA GLUCOSE AND
CYCLIC-AMP LEVELS.
000211 01-03
THE MECHANISM OF EFFEQ OF NEUROPHARMACOLOGICAL-DRUGS. VI:
EFFEa OF NORADRENALINE AND 5 HYDROXYTRYPTAMINE ON BRAIN
FREE FATTY-ACIDS.
000274 01-03
THE INVOLVEMENT OF SEROTONERGIC NEURONS IN THE CENTRAL-
NERVOUS-SYSTEM AS THE POSSIBLE MECHANISM FOR SLOW HEAD-
SHAKING-BEHAVIOR INDUCED BY METHAMPHETAMINE IN RATS.
000408 01-04
POSSIBLE MECHANISM FOR THE ENHANCED LETHALITY OF MORPHINE IN
AGGREGATED MICE.
000437 01-04
ON THE MECHANISM OF THERAPEUTIC ACTIONS OF PSYCHOTROPIC-
DRUGS.
000964 01-17
THE REGULATION OF GABA-RECEPTORS AS A POSSIBLE MECHANISM FOR
GABA 1,4 BENZODIAZEPINE INTERACTIONS. (UNPUBLISHED PAPER).
001012 02-01
MECHANISM OF INAQIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES.
001055 02-01
HYBRID PROTEINS USED TO STUDY THE MECHANISM OF TOXIN
ENTRANCE INTO CELLS. (UNPUBLISHED PAPER).
001063 02-01
MECHANISM OF INAQIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCL0PR0PYL-N-ARYLALKY17\MINES.
001088 02-02
ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA
„, „, 00115102-03
EFFEQS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC
MECHANISM IN AQION OF DIAZEPAM.
001414 02-03
THE ROLE OF PROTEIN SYNTHESIS IN THE HYPOTHALAMIC MECHANISM
MEDIATING PYROGEN FEVER.
001454 02-03
LITHIUM EFFEQS ON HIGH-AFFINITY TRYPTOPHAN UPTAKE: EVIDENCE
AGAINST A STABILIZATION MECHANISM.
001496 02-03
ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN
THE CAT.
001761 02-04
MEASUREMENT OF PLASMA CONCENTRATIONS OF DRUGS AS A
FEEDBACK CONTROL MECHANISM DURING DRUG-THERAPY
002525 02-17
CLONIDINE ANALGESIA AND SUPPRESSION OF OPERANT RESPONDING-
DISSOCIATION OF MECHANISM.
003046 03-04
METERGOLINE AND CYPROHEPTADINE SUPPRESS PROLACTIN RELEASE BY
A NON-5-HYDROXYTRYPTAMINERGIC, NONDOPAMINERGIC
MECHANISM.
003732 04-03
AN EVALUATION OF THE MECHANISM BY WHICH SEROTONERGIC
AQIVATION DEPRESSES RESPIRATION.
003917 04-03
A COMMON MECHANISM FOR LYSERGIC-ACID, INDOLEALKYLAMINE AND
PHENETHYLAMINE HALLUCINOGENS: SEROTONERGIC MEDIATION OF
BEHAVIORAL-EFFECTS IN RATS.
004007 04-03
SEROTONERGIC MECHANISM IN SEIZURES KINDLED FROM THE RABBIT
AMYGDALA.
004227 04-04
MECHANISM OF MEMBRANE STABILIZING AND LYTIC-EFFECTS OF
TRICYCLIC-ANTIDEPRESSANTS ,
004283 04-05
MECHANISM OF LITHIUM INCLUDED ELEVATION IN RED-BLOOD-CELL
CHOLINE CONTENT: AN IN VITRO ANALYSIS.
004511 04-13
A MECHANISM FOR THE ACCUMULATION OF CHOLINE IN ERYTHROCYTES
DURING TREATMENT WITH LITHIUM.
004520 04-13
MECHANISM OF VALPROATE PHENOBARBITAL INTERACTION IN EPILEPTIC-
PATIENTS.
004522 04-13
MECHANISM-OF-ACTION
ANTIDEPRESSANT PROPERTIES OF 2 4 ETHYL-2-PIPERAZINYL-4-
PHENYLQUINOLINE-HCL (AD- 1308) AND ITS MECHANISM-OF-ACTION
AS COMPARED WITH TRICYCLIC-ANTIDEPRESSANTS.
000152 01-03
MECHANISM-OF-ACTION OF THE BENZODIAZEPINES: BEHAVIORAL-
ASPECT.
000468 01-04
THE MECHANISM-OF-ACTION OF DELTA9 TETRAHYDROCANNABINOL ON
BODY-TEMPERATURE IN MICE.
001190 02-03
ON THE MECHANISM-OF-AQION OF 2 AMINO-4-METHYLPYRIDINE, A
MORPHINE-LIKE ANALGESIC.
001574 02-04
ON THE PROPOSED MECHANISM-OF-ACTION OF ANTIDEPRESSANTS.
002256 02-13
RECENT INVESTIGATIONS ON THE MECHANISM-OF-AQION OF
NOMIFENSINE.
002289 02-13
MECHANISM-OF-AQION OF BENZODIAZEPINES.
002302 02-13
THE ANTIDEPRESSANT ACTION OF SULPHO-ADENOSYL-L-METHIONINE
(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE:
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-ACTION.
003150 03-07
L-DOPAS MECHANISM-OF-ACTION IN PARKINSONS-DISEASE.
003323 03-11
MECHANISM-OF-ACTION OF BARBITURATES.
003600 03-17
CU-AMINE-OXIDASES: STUDIES RELATED TO THE MECHANISM-OF-AQION
OF BOVINE PLASMA AMINE-OXIDASE (UNPUBLISHED PAPER).
003680 04-01
STUDIES ON THE MECHANISM-OF-AQION OF AVERMEQIN-BIA:
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM
BRAIN SYNAPTOSOMES.
003973 04-03
LITHIUM AND MOTOR-ACTIVITY OF ANIMALS: EFFECTS AND POSSIBLE
MECHANISM-OF-ACTION.
004222 04-04
MECHANISMS
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE-
BEHAVIOR: INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON
THREE EXPERIMENTAL MODELS.
00()340 01-04
CHOLINERGIC MECHANISMS AND CATAPLEXY IN DOGS.
000374 01-04
MORPHINE VERSUS HALOPERIDOL CATALEPSY IN THE RAT: A
BEHAVIORAL-ANALYSIS OF POSTURAL SUPPORT MECHANISMS.
000376 01-04
DIFFERENT DOPAMINERGIC MECHANISMS FOR AMFONELIC-ACID,
AMPHETAMINE AND APOMORPHINE.
000465 01-04
CHOLINERGIC MECHANISMS IN SCENT-MARKING-BEHAVIOR BY
MONGOLIAN-GERBILS (MERIONES-UNGUICULATUS) .
000504 01-04
CONTRIBUTION TO THE CLINICAL- STUDY OF CEREBRAL DOPAMINERGIC
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST
RESULTS.
000616 01-09
CONTRIBUTION TO STUDY OF CEREBRAL DOPAMINERGIC MECHANISMS:
REALITY OF THE PROBLEM.
000782 01-13
MECHANISMS OF PAIN AND ANALGESIC COMPOUNDS.
000916 01-17
NEUROCHEMICAL MECHANISMS OF OPIATES AND ENDORPHINS.
000958 01-17
OPIOID MECHANISMS IN REGULATION OF CEREBRAL MONOAMINES IN
VIVO.
001098 02-03
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE-
RECEPTOR MECHANISMS IN CNS.
001178 02-03
AN EXAMINATION OF FACTORS INFLUENCING ADRENERGIC
TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO
••"''PI.
m
S-267
Subject Index
•CD
XtK.
it
I
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNaiONAL
ALPHA-ADRENOCEPTORS.
001196 02-03
MECHANISMS INVOLVED IN CENTRAL-EFFECTS OF PROSTAGLANDIN-
F2ALPHA. (UNPUBLISHED PAPER).
001222 02-03
EFFEQS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL MONOAMINERGIC MECHANISMS.
001240 02-03
EFFEaS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE.
001243 02-03
STEREOSELECTIVE ACTIONS OF SUBSTITUTED BENZAMIDE DRUGS ON
CEREBRAL DOPAMINE MECHANISMS.
001301 02-03
CERTAIN MECHANISMS OF THE ACTION OF PSYCHOTROPIC-DRUGS ON
TRANSPORT ATPASES.
001331 02-03
TWO CONDUCTANCE MECHANISMS ACTIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES.
001349 02-03
EFFEQS OF NEUROLEPTICS ON NEUROENDOCRINE MECHANISMS FOR
GONADOTROPIN SECRETION.
001391 02-03
PRESYNAPTIC AND POSTSYNAPTIC MECHANISMS IN HALOPERIDOL-
INDUCED SENSITIZATION TO DOPAMINERGIC AGONISTS.
001392 02-03
CENTRAL AMINERGIC AND PEPTIDERGIC MECHANISMS IN
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS. (UNPUBLISHED
PAPER).
001459 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTAQ RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
MECHANISMS OF CHLORPROMAZINE AND CHLORPROMAZINE ISOSTERES
ON THE GLYCEMIC-RESPONSE IN MICE. (PH.D. DISSERTATION).
001525 02-03
THE PHARMACOLOGY OF CATECHOLAMINE INVOLVEMENT IN THE
NEURAL MECHANISMS OF REWARD.
001526 02-03
AMYGDALA OPIATE-SENSITIVE MECHANISMS INFLUENCE FEAR
MOTIVATED RESPONSES AND MEMORY PROCESSES FOR AVERSIVE-
EXPERIENCES. (UNPUBLISHED PAPER).
001628 02-04
INVESTIGATIONS ON THE INTERACTION OF THYROTROPIN-RELEASING-
HORMONE (TRH) AND MK-771 WITH CENTRAL NORADRENERGIC
MECHANISMS.
001701 02-04
THE EFFEQ OF SOME STRUCTURAL GABA ANALOGUES ON THE
SEROTONIN AND DOPAMINERGIC MECHANISMS.
001736 02-04
DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINERGIC MECHANISMS.
001839 02-05
MECHANISMS OF AQION OF THE ANTIDEPRESSANTS.
002218 02-13
MECHANISMS OF OPIATE ANALGESIA AND THE ROLE OF ENDORPHINS IN
PAIN SUPPRESSION. (UNPUBLISHED PAPER).
002275 02-13
REFLEQIONS ON AQION MECHANISMS OF PSYCHOTROPIC-
MEDICATIONS.
002296 02-13
PROPRANOLOL (INDERAL) FOR TARDIVE-DYSKINESIA AND
EXTRAPYRAMIDAL SIDE-EFFECTS FROM NEUROLEPTICS: POSSIBLE
INVOLVEMENT OF BETA-ADRENERGIC MECHANISMS.
002470 02-15
AQION MECHANISMS OF INSULIN THERAPY IN PSYCHIATRY, AND
CURRENT-VIEWS ON THESE MECHANISMS.
002553 02-17
THE HYPOTHALAMIC DOPAMINERGIC REGULATION OF PROLACTIN: A
MODEL FOR THE STUDY OF NEUROHORMONAL MECHANISMS IN MAN.
002568 02-17
REGULATION OF NEUROTRANSMISSION THROUGH PRESYNAPTIC-
RECEPTORS AND OTHER MECHANISMS: POSSIBLE CLINICAL RELEVANCE
AND THERAPEUTIC POTENTIAL.
002569 02-16
PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS
MECHANISMS RESPONSIBLE FOR MOTOR ACT INHIBITION BY AVERSIVE
EVENTS.
002671 03-03
GABAERGIC MECHANISMS IN THE CONTROL OF PRL AND GH RELEASE.
002690 03-03
Psychopharmacology Abstracts
FUNDAMENTAL MECHANISMS UNDERLYING ALTERED BEHAVIOR
FOLLOWING CHRONIC ADMINISTRATION OF PSYCHOMOTOR
STIMULANTS.
002711 03-03
SEROTONERGIC MECHANISMS OF CLONIDINE-INDUCED HYPOTHERMIA IN
RATS.
002806 03-03
ACTIONS OF TETRAHYDRONORHARMANE (TETRAHYDRO-BETA-
CARBOLINE) ON 5 HYDROXYTRYPTAMINE AND DOPAMINE-MEDIATED
MECHANISMS.
002854 03-03
A REEVALUATION OF THE MECHANISMS UNDERLYING SIMPLE CELL
ORIENTATION SELECTIVITY.
002894 03-03
BRAIN MECHANISMS OF LEARNING.
002916 03-03
POSSIBLE MECHANISMS OF EFFECT OF ACTH4-10 AND ITS ANALOG,
CONTAINING D ISOMER OF PHENYLALANINE, ON BEHAVIOR.
002949 03-04
D PROPOXYPHENE ACTS DIFFERENTLY FROM MORPHINE ON OPIOID-
RECEPTOR EFFECTOR MECHANISMS.
003062 03-04
AN INVOLVEMENT OF DOPAMINE IN HIGHER-ORDER CHOICE
MECHANISMS IN THE MONKEY.
003072 03-04
EVIDENCE FOR INVOLVEMENT OF SEPARATE MECHANISMS IN THE
PRODUCTION OF ANALGESIA BY ELECTRICAL-STIMULATION OF THE
NUCLEUS-RETICULARIS-PARAGIGANTOCELLULARIS AND NUCLEUS-
RAPHE-MAGNUS IN THE RAT.
003083 03-04
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED
REFLEXES IN RATS.
003100 03-04
STUDIES ON THE MECHANISMS OF L-DOPA-INDUCED SALIVARY
SECRETION.
003130 03-05
THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS.
003397 03-12
GERIATRIC ASPECTS OF PARKINSONISM (CLINICAL-PICTURE,
PATHOLOGICAL MECHANISMS, AND MULTIPLE TREATMENT).
003643 03-17
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED
SEROTONERGIC MECHANISMS.
003748 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II. FACTORS
AFFECTING THE ACCUMULATION OF CYCUC-AMP IN PIECES OF INTACT
CARP RETINA.
003776 04-03
COMPARATIVE-EFFECTS OF SUBSTITUTED PHENYLETHYLAMINES ON BRAIN
SEROTONERGIC MECHANISMS.
003854 04-03
FURTHER ANALYSIS OF THE MECHANISMS OF ACTION OF
BATRACHOTOXIN ON THE MEMBRANE OF MYELINATED NERVE.
003884 04-03
OPIATE MECHANISMS: EVALUATION OF RESEARCH INVOLVING
NEURONAL ACTION POTENTIALS.
003886 04-03 i
DOPAMINE-OEPENOENT HYPERACTIVITY IN THE FOUOWING
MANIPULATION OF GABA MECHANISMS IN THE REGION OF THE
NUCLEUS-ACCUMBENS
003976 04-03
INHIBITION OF LYSOSOMAL LIPASES BY CHLORPROMAZINE: A POSSIBLE
MECHANISMS OF STABILIZATION.
003993 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. 1. DOPAMINE-
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA;
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS.
004051 04-03
USE OF THE INTRACEREBRAL INJECTION TECHNIQUE TO ELUCIDATE
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN
THE MOUSE. ^ „^
004092 04^
ON SOME RELATIONSHIPS BETWEEN GABAERGIC AND 5 HT-ERGIC
MECHANISMS IN PENTYLENETETRAZOL CONVULSIVE-SEIZURE
REACTIONS. „ „,
004166 04-04
L 5 HYDROXYTRYPTOPHAN-INDUCED DRINKING IN RATS: POSSIBLE
MECHANISMS FOR INDUCTION. ^ „^
004237 04-04
TONIC IMMOBILITY IN DOMESTIC FOWL: POSSIBLE INTERACTION OF
SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
004246 04-04
CHOLINERGIC MECHANISMS IN MANIA AND DEPRESSION: QUESTIONS OF
S"^^'^'^'^ 004374 04^
S-268
VOLUME 19, SUBJECT INDEX
OPIOID DEPENDENCE: MECHANISMS AND TREATMENT
004587 04-14
MECHANISMS AND PHARMACOLOGICAL IMPLICATIONS Of ALTERING
CALMODULIN ACTIVITY.
004751 04-17
MKLOPHENOXATE
INFLUENCE OF PYRITHIOXINE, MECLOPHENOXATE AND PIRACETAM ON
THE LEARNING PROCESS IN MAN.
000805 01-14
MEMAN
EVIDENCE FOR A TONIC GABAERGIC CONTROL OF SEROTONIN NEURONS
IN THE MEDIAN RAPHE NUCLEUS.
002719 03-03
OPIATE-RECEPTORS AND SLEEP. II. EFFECTS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUCTAL GRAY MAHER AND NUCLEUS-TRAQUS-SOLITARIUS
OF THE RABBIT
002917 03-03
PRESSOR EFFEQS OF ELEaRICAL-STIMULATION OF THE DORSAL AND
MEDIAN RAPHE NUCLEI IN ANESTHETIZED RATS.
003892 04-03
EFFEQ OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE
DISCHARGE INDUCED BY CARBACHOL IN THE RABBIT.
003951 04-03
MEDIAN-EMINENCE
A MODEL FOR PSYCHONEUROENDOCRINE INVESTIGATION: SPECIFIC
CHEMICAL LESIONING OF THE MEDIAN-EMINENCE.
001478 02-03
MEDICAID
PROBLEMS REMAIN IN REVIEWS OF MEDICAID FINANCED DRUG-THERAPY
IN NURSING-HOMES.
004736 04-17
MEDICAL
STUDIES ON THE COMPREHENSIVE MEDICAL TREATMENT OF PEPTIC-
ULCERS (3) - UTILIZATION OF TRANQUILIZERS IN THE TREATMENT OF
GASTRIC-ULCERS.
000653 01-10
THE ROLE OF CHOLINERGIC-SUPERSENSITIVITY IN THE MEDICAL
SYMPTOMS ASSOCIATED WITH WITHDRAWAL OF ANTIPSYCHOTIC-
0RU6S.
000869 01-15
MARIJUANA: A REVIEW OF MEDICAL RESEARCH WITH IMPLICATIONS
FOR ADOLESCENTS.
000871 01-15
MEDICAL AND PSYCHIATRIC-COMPLICATIONS OF PENTAZOCINE AND
TRIPELENNAMINE ABUSE.
000955 01-17
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF
ENURESIS: A COMPARATIVE-STUDY.
002175 02-11
INITIAL PRESCRIPTION OF PSYCHOTROPIC-MEDICATIONS FOR
ADOLESCENTS IN A MEDICAL/ PROFESSIONAL INSTITUTE, AND THE
ROLE OF THE PSYCHIATRIST IN A MEDICAL/ PROFESSIONAL INSTITUTE.
002621 02-17
MEDICAL AND LEGAL IMPLICATIONS Of SIDE-EFFECTS FROM
NEUROLEPTIC-DRUGS. A ROUND-TABLE DISCUSSION.
003471 03-15
EMOTIONAL-DISORDERS IN CHILDREN AND ADOLESCENTS: MEDICAL AND
PSYCHOLOGICAL APPROACHES TO TREATMENT.
004743 04-17
MEDICAL-EMERGENCIES
PSYCHOTIC EXCITEMENT IN MEDICAL-EMERGENCIES.
004480 04-1 1
MEDICAL-MODEL
HOW APPROPRIATE IS A MEDICAL-MODEL IN PSYCHIATRIC-PRAQICE?
002531 02-17
MEDICALLY-ILL
TREATMENT OF DEPRESSION IN THE MEDICALLY-ILL ELDERLY WITH
METHYLPHENIDATE.
000602 01-09
MEDICATION
CHILDREN ON MEDICATION: A PRIMER FOR SCHOOL PERSONNEL.
000676 01-11
EEG AND PSYCHOEXPERIMENTAL-STUDIES IN HEALTHY SUBJECTS ON
LITHIUM MEDICATION.
000768 01-13
THE INFLUENCE OF LITHIUM-SALTS AND ANTIDEPRESSANT MEDICATION
ON SERUM PROLACTIN LEVEL.
000780 01-13
MEDICATION USE AND DEATHS AHRIBUTED TO ASPHYXIA AMONG
PSYCHIATRIC-PATIENTS.
000838 01-15
A REVISED CHECKLIST TO OBTAIN CONSENT TO TREATMENT WITH
MEDICATION.
000984 01-17
DISCONTINUATION OF ORAL AND DEPOT FLUPHENAZINE IN
SCHIZOPHRENIC-PATIENTS AFTER ONE YEAR OF CONTINUOUS
MEDICATION: A CONTROLLED-STUDY.
001931 02-08
Subject lnd«x
THERAPEUTIC RESULTS IN A PSYCHOGERIATRIC-WARD AFTER CHANGE OF
MEDICATION.
002136 02-11
THE EffECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPEQS Of SLEEP AND OBJECTIVE MEASURE Of
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOQURNAL
MEDICATION: II. REPEATED DOSES.
002331 02-14
MEDICATION AND PREGNANCY.
002424 02-17
MEDICATION: A NECESSARY EVIL?
002549 02-17
NEW DEVELOPMENT IN ANTIDEPRESSANT MEDICATION - A REVIEW.
002558 02-17
PLACEBO, MEDICINE AND PAIN, OR THE RELATIVE FUNCTION OF
MEDICATION IN THE TREATMENT OF PAIN.
002577 02-17
PAHERNS OF USE IN THE INTAKE OF ORAL MEDICATION.
002591 02-17
COMMUNAL MEDICATION.
002595 02-17
THE NEED FOR CONTINUOUS USE OF ANTIPARKINSONIAN MEDICATION
WITH CHRONIC SCHIZOPHRENIC-PATIENTS RECEIVING LONG-TERM
NEUROLEPTIC THERAPY.
003186 03-08
ON THE EVALUATION OF A PROVOCATIVE EEG METHOD USING
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUCTION THROUGH
MEDICATION.
003387 03-1 1
LONG-TERM CHANGES IN AIMS RATINGS AND THEIR RELATION TO
MEDICATION HISTORY.
003537 03-15
MEDICATION GROUPS FOR PSYCHIATRIC-PATIENTS.
003582 03-17
THE MEDICATION SEMINAR AND PRIMARY CARE EDUCATION.
003592 03-17
ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CLINICAL STAFF
IN DETERMINING MEDICATION COMPLIANCE.
003618 03-17
WIDOWS AND WIDOWERS AND THEIR MEDICATION USE: NURSING
IMPLICATIONS.
003626 03-17
MEASUREMENTS OF NERVE CONDUQION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT.
004441 04-11
STOPPING MEDICATION IN CHILDREN WITH EPILEPSY.
004447 04-11
MEDICATIONS
DOUBLE-BLIND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS
Of WEIGHT-CONTROL MEDICATIONS: INTERAQION OF
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS.
002314 02-14
EDEMAS AND MYOCLONIES IN A PATIENT WITH PARKINSONS-DISEASE
TREATED BY AMANTADINE: PROBLEM WITH ASSOCIATED
MEDICATIONS.
002389 02-15
ADVERSE-REAQIONS TO MEDICATIONS PRESCRIBED FOR HYPERKINESIS.
(PH.D. DISSERTATION).
002411 02-15
HEPATIC SIDE-EFFECTS OF ANTIDEPRESSANT MEDICATIONS.
003523 03-15
INTERAaiONS BETWEEN ALCOHOL AND MEDICATIONS.
003629 03-17
MEDICINE
THE RATIONAL USE Of MUSCLE-RELAXANTS IN REHABILITATION
MEDICINE.
000943 01-17
THE PRESENT STATUS Of THE BENZODIAZEPINES IN PSYCHIATRY AND
MEDICINE.
000954 01-17
MADNESS AND MEDICINE: THE fORCIBLE ADMINISTRATION Of
PSYCHOTROPIC-DRUGS.
002523 02-17
PLACEBO, MEDICINE AND PAIN, OR THE RELATIVE fUNCTION Of
MEDICATION IN THE TREATMENT Of PAIN.
002577 02-17
PHENCYCLIDINE-HCL: A CHALLENGE TO MEDICINE.
003395 03-12
MIND/BRAIN IN THE AGE Of PSYCHOPHARMACOLOGY: A CROSSROADS
fOR MEDICINE AND MINISTRY.
003624 03-17
THE BRAINSTEM AUDITORY EVOKED-RESPONSE AS A TOOL IN
NEUROBEHAVIORAL TOXICOLOGY AND MEDICINE.
004277 04-05
S-269
Subject Index
Psychophormacology Abttractt
Kin
it
MEDICINES
AIRCRAFT NOISE AND MENTAL-HEALTH: II. USE OF MEDICINES AND
HEALTH-CARE-SERVICES.
003647 03-17
UNDESIRABLE EFFECTS OF MEDICINES: A REVIEW OF SEVERAL
PUBLICATIONS ISSUED FROM 1977-1979.
004632 04-15
MEDIUM
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN-
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM.
000123 01-03
CONTROLLED-COMPARISON OF MEDIUM AND HIGH CLOROTEPIN DOSES
IN CHRONIC SCHIZOPHRENIA.
000548 01-08
MEDROXYPROGESTERONE
MEDROXYPROGESTERONE TREATMENT OF OBSTRUQIVE SLEEP-APNEA.
002128 02-11
MEDR0XYPR06ESTER0NE-ACETATE
TREATMENT OF SEX-OFFENDERS WITH MEDROXYPROGESTERONE-
ACETATE.
004450 04-11
MELANCHOLIA
STANDARDIZATION OF THE DEXAMETHASONE-SUPPRESSION-TEST FOR
THE DIAGNOSIS OF MELANCHOLIA. (UNPUBLISHED PAPER).
004359 04-09
MELANCHOLIAC
CONFESSION OF A MELANCHOLIAC: CONTRIBUTION TO THE PROBLEM OF
PROPHYLAXIS OF MANIC-DEPRESSIVE-PSYCHOSIS USING LITHIUM.
003267 03-09
MELANCHOLIC-DEPRESSED-PATIENTS
OPEN-STUDY OF L 5 HTP IN MELANCHOLIC-DEPRESSED-PATIENTS OVER
50 YEARS OF AGE.
002016 02-09
MELANOCORTICOTROPIC-HORMONES
EFFEQ OF NICOTINE ON IN VIVO SECRETION OF MELANOCORTICOTROPIC-
HORMONES IN THE RAT.
003759 04-03
MELANOCYTE-STIMULATING-HORMONE
STUDIES ON THE EFFECT OF ALPHA MELANOCYTE-STIMULATING-
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P
AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED
PAPER).
001372 02-03
MELANOCYTE-STIMULATING-HORMONES
COMPARISON OF BIOLOGICAL-AQIVITY AND BEHAVIORAL-AQIVITY OF
ALPHA AND GAMMA MELANOCYTE-STIMULATING-HORMONES.
(UNPUBLISHED PAPER).
001398 02-03
MELANOSTATIN
EFFEa OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRAaiONS.
001472 02-03
MELATONIN
EFFEaS OF MELATONIN AND PROPRANOLOL ON SLEEP OF THE RAT.
000432 01-04
PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN
VITRO. INHIBITION BY MELATONIN AT SUBMICROMOLAR
CONCENTRATIONS.
001159 02-03
THE ANTICONVULSANT PROPERTIES OF MELATONIN ON KINDLED
SEIZURES IN RATS.
002653 03-03
PINEAL-GLAND AND MELATONIN INFLUENCE ON CHRONIC ALCOHOL
CONSUMPTION BY HAMSTERS.
003076 03-04
MELATONIN-UKE
AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF
DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREAQIVITY
IN DMI RESPONSIVE DEPRESSIVES.
003228 03-09
MELLARIL
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE IN MENTALLY-RETARDED
ADULTS.
002471 02-15
EFFEQS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED
ADULTS.
003392 03-1 1
MEMBERS
THE ACUTE AND CHRONIC EFFEQ OF 5 METHOXYTRYPT AMINE ON
SELEQED MEMBERS OF A PRIMATE SOCIAL-COLONY.
001073 02-02
MEMBRANE
(3H)5 HT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN
GLIAL CELL MEMBRANE FRAQION.
000093 01-03
NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE
POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS.
000116 01-03
INFLUENCE OF MORPHINE ON MEMBRANE TURNOVER AND FUNQION.
001280 02-03
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTRODUQION.
002227 02-13
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARAQERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
MEASUREMENT OF THE MEMBRANE POTENTIAL OF ISOLATED NERVE
TERMINALS BY THE LIPOPHILIC CATION
(3H)TRIPHENYLMETHYLPH0SPH0NIUM-BR0MI0E.
002746 03-03
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFEaS OF FENTANYL ON
THE CONTRACTION OF THE NICTITATING MEMBRANE IN CATS.
002876 03-03
EFFEaS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC
MEMBRANES.
002888 03-03
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN
MEDIATING THE BEHAVIORAL-EFFEaS AND BIOCHEMICAL-EFFEaS OF
AMPHETAMINE. (PH.D. DISSERTATION).
002996 03-04
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT
NICTITATING MEMBRANE.
003777 04-03
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NiaiTATING MEMBRANE OF THE CAT.
003822 04-03
FURTHER ANALYSIS OF THE MECHANISMS OF AQION OF
BATRACHOTOXIN ON THE MEMBRANE OF MYELINATED NERVE.
003884 04-03
DOPAMINE-RECEPTORS IN SUBCELLULAR FRAQIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRAQION.
003948 04-03
EFFEQ OF PRENATAL NEUROLEPTIC TREATMENT ON MEMBRANE
RECEPTOR DEVELOPMENT IN THE BRAIN.
003989 04-03
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP-
DEPENDENT HYPERPGLARIZATION OF THE MEMBRANE POTENTIAL OF
MOUSE NEUROBLASTOMA CELLS USING
(3H)TETRAPHENYLPH0SPH0NIUM.
004049 04-03
MECHANISM OF MEMBRANE STABILIZING AND LYTIC-EFFEaS OF
TRICYCLIC-ANTIDEPRESSANTS.
004283 04-05
MEMBRANE-BOUND
PHOSPHORYLATION OF THE MEMBRANE-BOUND ACETYLCHOLINE-
RECEPTOR: INHIBITION BY DIPHENYLHYDANTOIN.
001257 02-03
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 02-03
COMPARISON OF THE EFFEQ OF INTRAVENOUS ADMINISTRATION OF D
LYSERGIC-ACID-DIETHYLAMIDE ON FREE AND MEMBRANE-BOUND
POLYSOMES IN THE RABBIT BRAIN.
003831 04-03
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO.
003832 04-03
MEMBRANES
CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN
MEMBRANES.
000062 01-03
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING.
000099 01-03
CHARACTERIZATION OF 3H GABA-RECEPTOR BINDING TO RAT-BRAIN
SYNAPTOSOMAL MEMBRANES: EFFECT OF NONGABAERGIC
COMPOUNDS.
000139 01-03
ACTION OF BARBITURATES ON ACTIVITY OF ACETYLCHOLINESTERASE
FROM SYNAPTOSOMAL MEMBRANES.
000224 01-03
STEREOSPECIFIC NICOTINE-RECEPTORS ON RAT-BRAIN MEMBRANES.
000254 01-03
S-270
VOLUME 19, SUBJECT INDEX
Subject lnd«x
BIOCHEMICAL-PROPERTIES OF SPIPERONE BINDING TO RAT-BRAIN
MEMBRANES.
000294 01-03
INHIBITION OF {3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS.
000330 01-03
DISPLACEMENT OF (3H)CL0NIDINE BINDING BY CLONIDINE ANALOGUES
IN MEMBRANES FROM RAT-CEREBRAL-CORTEX.
000536 01-06
OPIATE-RECEPTORS IN MEMBRANES AND IN SOLUTION. (UNPUBLISHED
PAPER).
001032 02-01
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES.
QO 1208 02-03
CALMODULIN RELEASE FROM STRIATAL MEMBRANES ARER ACUTE AND
CHRONIC TREATMENT WITH BUTACLAMOL.
001249 02-03
EXPOSURE OF MITOCHONDRIAL OUTER MEMBRANES TO NEURAMINIDASE
SELECTIVELY DESTROYS MONOAMINE-OXIDASE-A AQIVITY.
001286 02-03
EVIDENCE FOR AN ENDOGENOUS COMPOUND INTERFERING WITH 3H
DIAZEPAM BINDING TO RAT-BRAIN MEMBRANES.
001308 02-03
DOPAMINE-RECEPTOR: FROM SYNAPTIC MEMBRANES TO
SOLUBILIZATION.
001326 02-03
FURTHER CHARACTERIZATION OF THE BINDING OF SUBSTANCE-P TO A
FRAaiON FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES.
001394 02-03
ALPHA-ADRENORECEPTOR MEDIATED ALTERATION OF ETHANOL EFFEQS
ON NA-K-ATPASE OF RAT NEURONAL MEMBRANES.
001425 02-03
BINDING OF PHENCYCLIDINE TO RAT-BRAIN MEMBRANES: TECHNICAL-
ASPECT.
001882 02-06
THE EFFEa OF GUANOSINE-NUCLEOTIDES ON (3H)SULPIRIDE BINDING TO
RAT STRIATAL MEMBRANES.
002722 03-03
EFFEQS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC
MEMBRANES.
002888 03-03
TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT DECREASES ALPHA2-
ADRENORECEPTORS ON HUMAN PLATELET MEMBRANES.
003408 03-13
CHARAQERIZATION OF TWO (3H)GLUTAMATE BINDING-SITES IN RAT
HIPPOCAMPAL MEMBRANES.
003726 04-03
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT,
003734 04-03
IBOTENIC-ACID ANALOGUES AS INHIBITORS OF (3H)GLUTAM1C-ACID
BINDING TO CEREBELLAR MEMBRANES.
003848 04-03
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID-
RECEPTOR AGONIST, TO MEMBRANES OF THE BOVINE RETINA.
003954 04-03
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO
SYNAPTIC MEMBRANES.
004000 04-03
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE
PITUITARY MEMBRANES.
004003 04-03
THE HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPECT TO THE
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRAQION
ABUNDANT IN PRESYNAPTIC MEMBRANES.
004028 04-03
MEMORY
EFFEa OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION,
MEMORY, AND RETRIEVAL OF SHUHLE AVOIDANCE AND
HABITUATION LEARNING IN RATS.
000410 01-04
, AROUSAL AND SHORT-TERM MEMORY: EFFEQS OF CAFFEINE AND TRIAL
SPACING ON DELAYED ALTERNATION PERFORMANCE.
000487 01-04
MEMORY AND COGNITIVE FUNCTION IN THE ELDERLY: A PRELIMINARY-
TRIAL OF PHYSOSTIGMINE.
000802 01-14
PIRACETAM AND RETRIEVAL OF MEMORY IN YOUNG RATS.
000803 01-14
EFFEQ OF DRUGS ON LEARNING AND MEMORY PROCESSES IN SIMPLE
BEHAVIORAL-TESTS.
000809 01-14
THE INFLUENCE OF NOOTROPIC-DRUGS ON LEARNING AND MEMORY OF
DEFENSE REACTIONS.
000815 01-14
EFFECTS OF LITHIUM-CARBONATE ON MEMORY AND OTHER COGNITIVE
FUNCTIONS.
000824 01-14
ACTH MODULATION OF MEMORY STORAGE PROCESSING. (UNPUBLISHED
PAPER).
001250 02-03
PERIPHERAL CATECHOLAMINES AND MEMORY MODULATION.
(UNPUBLISHED PAPER).
001251 02-03
ROLE OF NEUROTRANSMinERS AND PROTEIN SYNTHESIS IN SHORT-
TERM AND LONG-TERM MEMORY.
001573 02-04
EFFECTS OF SOCIAL-ISOLATION ON MEMORY FORMATION.
001607 02-04
AMYGDALA OPIATE-SENSITIVE MECHANISMS INFLUENCE FEAR
MOTIVATED RESPONSES AND MEMORY PROCESSES FOR AVERSIVE-
EXPERIENCES. (UNPUBLISHED PAPER).
001628 02-04
BRAIN CATECHOLAMINES MODIFICATIONS. THE EFFEQS ON MEMORY
FACILITATION INDUCED BY OXOTREMORINE IN MICE.
001658 02-04
PIRACETAM EFFECT ON LEARNING AND MEMORY IN RATS.
001689 02-04
ACTH4-10 AND MEMORY IN ECT TREATED AND UNTREATED PATIENTS. I.
EFFECT ON CONSOLIDATION.
001982 02-09
ACTH4-10 AND MEMORY IN ECT TREATED PATIENTS AND UNTREATED
CONTROLS. II. EFFECT ON RETRIEVAL.
001983 02-09
HUMAN MEMORY AND THE EFFECTS OF PHYSOSTIGMINE AND CHOLINE-
CHLORIDE.
002317 02-14
EFFECTS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED
SUBJECTS.
002320 02-14
INFLUENCE OF OXYTOCIN ON HUMAN MEMORY PROCESSES.
002322 02-14
ADRENALINE: A SECRET AGENT IN MEMORY.
002345 02-14
sJHE EFFECTS OF FLURAZEPAM, LORAZEPAM, AND TRIAZOLAM ON SLEEP
AND MEMORY.
002357 02-14
CENTRAL AND PERIPHERAL CATECHOLAMINE FUNCTION IN LEARNING
AND MEMORY PROCESSES.
002823 03-03
A PSYCHOPHARMACOLOGICAL APPROACH TO MEMORY PROCESSING.
002901 03-03
EFFECT OF PHENTOLAMINE ADMINISTRATION INTO THE AMYGDALA
COMPLEX OF RATS ON TIME-DEPENDENT MEMORY PROCESSES.
002998 03-04
EFFECT OF GROWTH-HORMONE ON MEMORY IN MICE.
003014 03-04
INTRAVENTRICULAR CORTICOSTERONE INJECTION FACILITATES MEMORY
OF AN APPETITIVE DISCRIMINATIVE TASK IN MICE.
003051 03-04
PHOSPHODIESTERASE INHIBITORS FACILITATE MEMORY FOR PASSIVE-
AVOIDANCE CONDITIONING.
003109 03-04
LECITHIN AND MEMORY TRAINING IN ALZHEIMERS-DISEASE. (PH.D.
DISSERTATION).
003299 03-1 1
THE EFFECTS OF LECITHIN ON MEMORY IN PATIENTS WITH SENILE-
DEMENTIA OF THE ALZHEIMERS-TYPE.
003385 03-1 1
EFFECTS OF VASOPRESSIN ON HUMAN MEMORY FUNCTIONS.
003388 03-11
CORRELATED STUDY OF THE EFFECTS OF SE-5023 IN AN HYPOXIC
ATMOSPHERE ON QUANTIFIED EEG, VIGILANCE, MEMORY, AND
MOOD.
003440 03-14
CAN DRUGS HALT MEMORY LOSS?
003447 03-14
EFFECTS OF CHOLINERGIC-DRUGS ON MEMORY IN ALZHEIMERS-DISEASE.
003454 03-14
DOSE-EFFECTS OF SECOBARBITAL IN A STERNBERG MEMORY SCANNING
TASK.
003460 03-14
THE PHARMACOLOGY OF MEMORY: A NEUROBIOLOGICAL-PERSPECTIVE.
003636 03-17
THE EFFECT OF P CHLOROPHENYLALANINE ON THE DISTRIBUTION OF
BIOGENIC-AMINES IN THE BRAIN, AND ON MEMORY IN RATS.
004068 04-04
THE EFFECTS OF COLCHICINE AND VINBLASTINE ON MEMORY IN CHICKS.
004069 04-04
MEMORY, OPIATE-RECEPTORS, AND AGING.
004143 04-04
OPIATE MODULATION OF MEMORY. (UNPUBLISHED PAPER).
004177 04-04
m
IE
S-271
Subject Index
out I
fBli",\ ■
fe
X
h
t
ACUTE EFFECT OF DRUGS UPON MEMORY OF PATIENTS WITH SENILE-
DEMENTIA.
004561 04-14
^ MEMORY: THE EFFECTS OF ALCOHOL AND OF MARIHUANA.
004570 04-14
PHARMACOLOGICAL MODULATION OF FORMATION OF LONG-TERM
''"^'^'' 004578 04-14
VARIOUS ASPECTS OF THE EFFECT OF ANTICONVULSANT-DRUGS ON
004602 04-15
MEMORY-DISORDERS
CHOLINOMIMETICS IN MANIA, SCHIZOPHRENIA, AND MEMORY-
DISORDERS. „„.^„„„. ,-,
004703 04-17
MEMORY-DISTURBANCES
ON A CASE OF MEMORY-DISTURBANCES TREATED WITH VASOPRESSIN.
003301 03-11
EXPERIENCE IN USING THE HORMONES OF THE HYPOPHYSIS POSTERIOR
LOBE IN MEMORY-DISTURBANCES OF VARYING GENESES.
003438 03-14
MEN
DIURNAL GROWTH-HORMONE RESPONSES TO DEXTROAMPHETAMINE IN
NORMAL YOUNG MEN AND POSTMENOPAUSAL-WOMEN.
003411 03-13
AUTONOMIC-EFFECTS OF DEXTROAMPHETAMINE IN NORMAL MEN:
IMPLICATIONS FOR HYPERACTIVITY AND SCHIZOPHRENIA.
003437 03-13
ELECTROPHYSIOLOGICAL AND PSYCHOLOGICAL CHANGES INDUCED BY
STEROID-HORMONES IN MEN AND WOMEN.
004500 04-13
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
^^'^^ 004600 04-15
MENTAL-CAPACITY
VOLUNTARY INTOXICATION FROM PHENCYCLIOINE. WILL IT RAISE A
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL-
STATE'
000914 01-17
MENTAL-DISEASES
PLASMA LEVEL OF CYCLIC-AMP AND MENTAL-DISEASES.
003170 03-08
MENTAL-DISORDERS
ERGOTS IN THE TREATMENT OF MENTAL-DISORDERS OF OLD-AGE.
002545 02-17
PROBLEMS OF DRUG-TREATMENT OF MENTAL-DISORDERS.
002623 02-17
SOME PRINCIPLES OF DIFFERENTIATED METABOLIC DRUG-TREATMENT IN
COMPREHENSIVE THERAPY OF MENTAL-DISORDERS.
004433 04-11
MENTAL-DISTURBANCES
MENTAL-DISTURBANCES IN CHRONIC MANGANESE POISONING.
004621 04-15
MENTAL-HEALTH
PSYCHOPHARMACOLOGY ~ AN AREA OF RESEARCH TO IMPROVE
MENTAL-HEALTH CARE.
002586 02-17
AIRCRAFT NOISE AND MENTAL-HEALTH: II. USE OF MEDICINES AND
HEALTH-CARE-SERVICES.
003647 03-17
MENTAL-HYGIENE-CLINIC
PSYCHIATRIC-DRUG-STUDY. PART II. MENTAL-HYGIENE-CLINIC SURVEY,
DAY-TREATMENT-CENTER SURVEY, DAY-HOSPITAL SURVEY.
004716 04-17
MENTAL-ILLNESS
PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH
BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS.
000717 01-11
OBSERVATIONS ABOUT STATES OF MENTAL-ILLNESS AS ILLUMINATED BY
THEIR RESPONSE TO PHARMACEUTIC-AGENTS.
000972 01-17
POSSIBLE ROLE OF THE THYMUS-GLAND IN MENTAL-ILLNESS.
002273 02-13
MENTAL-ILLNESSES
BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE-
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL-
CONSIDERATIONS.
001550 02-03
ENDORPHINS IN MENTAL-ILLNESSES, AND PARTICULARLY IN
SCHIZOPHRENIA.
003203 03-08
MENTAL-PATIENTS
ORIENTATIONAL TESTING OF CHLORPROMAZINE-HCL ON HOSPITALIZED
MENTAL-PATIENTS.
002131 02-11
MENTAL-RETARDATES
COMPARISON OF SCH-12679 AND THIORIDAZINE IN AGGRESSIVE
MENTAL-RETARDATES.
002119 02-11
Psychopharmacology Abstracts
MENTAL-STATE
VOLUNTARY INTOXICATION FROM PHENCYCLIOINE. WILL IT RAISE A
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL-
STATE?.
000914 01-17
MENTAL-SYMPTOMS
A STUDY ON MENTAL-SYMPTOMS DEVELOPED DURING THE TREATMENT
OF PARKINSONS-DISEASE.
004618 04-15
ANTICONVULSANTS AND MENTAL- SYMPTOMS.
004649 04-15
MENTALLY-HANDICAPPED
PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPEO-PATIENTS: A
PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED.
000668 01-11
SERUM CONCENTRATIONS OF PHENOBARBITAL AND
DIPHENYLHYDANTOIN IN SEVERE MENTALLY-HANDICAPPED AND
PHYSICALLY-HANDICAPPED-PATIENTS.
000856 01-15
DOUBLE-BUND CONTROLLED-STUDY ON THE PSYCHOLEPTIC-EFFECTS OF
AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT
PERSONALITY-PROBLEMS.
002116 02-11
A DOUBLE-BUND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF
CARBAMAZEPINE IN OVERACTIVE, SEVERELY MENTALLY-
HANDICAPPED PATIENTS,
003365 03-11
MENTALLY-HANDICAPPED-PATIENTS
PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPED-PATIENTS: A
PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED.
000668 01-11
MENTALLY-RETARDED
AN ASSESSMENT PROGRAM TO REDUCE DRUG USE WITH THE
MENTALLY-RETARDED
000937 01-17
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE IN MENTALLY-RETARDED
ADULTS.
002471 02-15
ANALYSIS OF SINGLE-BUND, DOUBLE-BUND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFECTS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS - BRIEF REPORT
003298 03-11
THE MANAGEMENT OF CHRONIC BEHAVIOR-DISORDERS IN MENTALLY-
RETARDED ADULTS WITH LITHIUM-CARBONATE.
003376 03-11
EFFEaS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED
ADULTS.
003392 03-11
ANALYSIS OF SINGLE-BLIND AND DOUBLE-BUND PROCEDURES,
MAINTENANCE OF PUVCEBO-EFFEQS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON
004437 04-11
COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS.
004438 04-1 1
MENTALLY-SUBNORMAL-PATIENTS
A CONTROLLED DOUBLE-BLIND STUDY OF HALOPERIDOL VERSUS
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY-
SUBNORMAL-PATIENTS: SERUM LEVELS AND CUNICAL-EFFECTS.
002185 02-11
UTHIUM THERAPY IN AGGRESSIVE MENTALLY-SUBNORMAL-PATIENTS.
002316 02-14
MEPACRINE
MEPACRINE TREATMENT PREVENTS IMMOBIUZATION-INDUCED
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT
HYPOTHALAMUS AND BRAINSTEM.
002919 03-03
MEPROBAMATE
EFFECTS OF ANXIETY REDUQION BY BEHAVIOURAL-TECHNIQUES AND
MEPROBAMATE ON CERTAIN PARAMETERS OF INFORMATION THEORY.
003108 03-04
MEPROBAMATE REDUCES ACCURACY OF PHYSIOLOGICAL DETEQION OF
DECEPTION.
004585 04-14
IMPURITIES IN DRUGS V: MEPROBAMATE.
004631 04-15
MEPTAZINOL ^„
THE ANALGESIC AND RESPIRATORY EFFEaS OF MEPTAZINOL, MORPHINE
AND PENTAZOCINE IN THE RAT.
000516 01-05
S-272
VOLUME 19, SUBJECT INDEX
Subject Index
MEPYRAMINE
IN VIVO OCCUPATION OF CEREBRAL HISTAMINE HI -RECEPTORS
EVALUATED WITH 3H MEPYRAMINE MAY PREDICT SEDATIVE
PROPERTIES OF PSYCHOTROPIC-DRUGS.
000241 01-03
MERIONES-UNOUICULATUS
CHOLINERGIC MECHANISMS IN SCENT-MARKING-BEHAVIOR BY
MONGOLIAN-GERBILS (MERIONES-UNGUICULATUS).
000504 01-04
MESCALINE
NALOXONE POTENTIATES THE DISRUPTIVE EFFECTS OF MESCALINE ON
OPERANT-RESPONDING IN THE RAT.
000365 01-04
DUAL-EFFECTS OF MESCALINE: THE TRANSMETHYLATION HYPOTHESIS
REVISITED.
001584 02-04
MESENCEPHALIC
EFFECTS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT
000180 01-03
THE EFFECTS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC
RETICULAR FORMATION ON BEHAVIOR IN THE RAT; INTERACTION
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED
AnENTION. (PH.D. DISSERTATION).
001563 02-04
MODULATION OF OPIATE-RECEPTOR BINDING IN STRIATUM AND
AMYGDALA BY SELECTIVE MESENCEPHALIC LESIONS.
001629 02-04
MORPHINE AND METHIONINE-ENKEPHALIN: DIFFERENT EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE
MESENCEPHALIC RETICULAR FORMATION OF THE RAT.
003849 04-03
MESENCEPHALON
STUDIES ON THE KINETIC PROPERTIES OF TRYPTOPHAN-HYDROXYLASE OF
RABBIT MESENCEPHALON AND PONS-MEDULLA: EFFECT OF LONG-
TERM-TREATMENT WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
003852 04-03
MESENTERIC-ARTERIES
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE
TREATED DOGS.
001273 02-03
MESOCORTEX
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES.
002285 02-13
MESOCORTICAL
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY
STUDY.
003085 03-04
MESOLIMBIC
INCREASED MESOLIMBIC 3H SPIROPERIDOL BINDING IN 4 WEEK OLD
OFFSPRING OF NURSING RAT MOTHERS TREATED WITH PENFLURIDOL.
000087 01-03
THE MESOLIMBIC SYSTEM, DENERVATION AND THE CLIMBING RESPONSE
IN THE MOUSE.
000370 01-04
SELECTIVE INHIBITION OF MESOLIMBIC BEHAVIORAL-SUPERSENSITIVITY
BY NALOXONE.
000467 01-04
A COMPARISON OF STRIATAL AND MESOLIMBIC DOPAMINE FUNCTION IN
THE RAT DURING 6-MONTH TRIFLUOPERAZINE ADMINISTRATION.
001174 02-03
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM:
FUNCTIONAL CHANGES FOLLOWED USING (-)N N
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL ACTIVITY LEVELS
OF RATS.
001603 02-04
INCREASED MESOLIMBIC DOPAMINE BINDING FOLLOWING CHRONIC
HALOPERIDOL TREATMENT.
003872 04-03
MESOLIMBICOCORTICAL
MESOLIMBICOCORTICAL DOPAMINE TERMINAL-FIELDS ARE NECESSARY
FOR NORMAL LOCOMOTOR AND INVESTIGATORY EXPLORATION IN
RATS.
000383 01-04
MESORIDAZINE
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. II. IN
VIVO METABOLISM OF TRITIATED DRUGS IN RHESUS-MONKEYS.
001229 02-03
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. I.
PROTEIN BINDING.
001867 02-06
MESSENGER
NERVE CELL CALCIUM AS A MESSENGER FOR OPIATE AND ENDORPHIN
ACTIONS.
001450 02-03
MESTEROLONE
A CLINICAL-STUDY AND ENDOCRINE-STUDY OF MESTEROLONE IN
SECONDARY IMPOTENCE
002315 02-14
MET-ENKEPHALIN
PROSTAGLANDINS IN THE BRAIN OF RATS GIVEN, ACUTELY, AND
CHRONICALLY, A HYPERTHERMIC-DOSE OF MET-ENKEPHALIN
001468 02-03
NEONATAL ADMINISTRATION OF MET-ENKEPHALIN FACILITATES MAZE-
PERFORMANCE OF ADULT RATS.
001673 02-04
MET-ENKEPHALIN-ARG6-PHE7
MET-ENKEPHALIN-ARG6-PHE7 INTERACTS WITH THE KAPPA-RECEPTORS
ON GUINEA-PIG ILEUM.
001110 02-03
METABOLIC
EFFECTS OF GAMMA HYDROXYBUTYRIC-ACID ON METABOLIC,
RESPIRATORY AND VASOMOTOR ACTIVITIES AND BODY-
TEMPERATURE IN RATS.
000189 01-03
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH
PSYCHOSTIMULANTS: II. EFFECT OF METHAMPHET AMINE ON
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC
SUBSTRATES,
001613 02-04
DETERMINATION OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS AND OF THEIR METABOLIC PRODUCTS IN
BIOLOGICAL FLUIDS.
002498 02-16
BEHAVIORAL AND METABOLIC ALTERATIONS IN PROGENY OF
METHADONE-TREATED RATS. (PH.D. DISSERTATION).
003113 03-04
ANESTHETICS AND THE HABENULO-INTERPEDUNCULAR SYSTEM:
SELECTIVE SPARING OF METABOLIC ACTIVITY.
003833 04-03
METABOLIC AND SYMPATHOADRENAL ABNORMALITIES IN THE OBESE
ZUCKER RAT: EFFECT OF CHRONIC PHENOXYBENZAMINE TREATMENT.
003905 04-03
SOME PRINCIPLES OF DIFFERENTIATED METABOLIC DRUG-TREATMENT IN
COMPREHENSIVE THERAPY OF MENTAL-DISORDERS.
004433 04-11
METABOLIC-ASPECTS
SOME CLINICAL-ASPECTS AND METABOLIC-ASPECTS OF PROPRANOLOL IN
CHRONIC SCHIZOPHRENIA.
001926 02-08
METABOLIC-CORRELATES
METABOLIC-CORRELATES OF THE EFFECTS OF 2 DEOXY-D-GLUCOSE ON
MEAL SIZE AND POST MEAL SATIETY IN RATS.
003035 03-04
METABOLIC-EFFECTS
CEREBRAL CIRCULATORY AND METABOLIC-EFFECTS OF PIRIBEDIL.
000200 01-03
INTERACTION BETWEEN PHENYTOIN AND VALPROIC-ACID: PLASMA
PROTEIN BINDING AND METABOLIC-EFFECTS.
002276 02-13
METABOLIC-STUDIES
EFFECT OF SINGLE AND REPEATED ELECTROCONVULSIVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN ~ I. METABOLIC-STUDIES.
001332 02-03
METABOLIC-STUDIES AND PSYCHOPHYSIOLOGIC-STUDIES OF
CANNABIDIOL HEXOBARBITAL INTERACTION.
002209 02-13
METABOLIC-STUDY
HEMODYNAMIC AND CEREBRAL METABOLIC-STUDY OF DIAZEPAM IN
NEUROSURGICAL-RESUSCITATION.
002231 02-13
METABOLISM
ENHANCEMENT OF RAT-BRAIN METABOLISM OF A TRYPTOPHAN LOAD
BY CHRONIC ETHANOL ADMINISTRATION.
000022 01-03
DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT
METABOLISM, DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND
CHOLERETIC-EFFECT.
000073 01-03
ENZYME INDUCING EFFECTS OF PHENOBARBITAL ON NITRAZEPAM
METABOLISM IN DOGS.
000086 01-03
ACTIONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID
METABOLISM IN GUINEA-PIG BRAIN SLICES.
000129 01-03
EFFECTS OF CHRONIC FLUOXETINE ADMINISTRATION ON SEROTONIN
METABOLISM.
000138 01-03
THE EFFECT OF MONOAMINE-OXIDASE-INHIBITORS ON FIRST-PASS
METABOLISM OF TYRAMINE IN DOG INTESTINE.
000141 01-03
DIMETHYLAMINOETHANOL (DEANOL) METABOLISM IN RAT-BRAIN AND
ITS EFFECT ON ACETYLCHOLINE SYNTHESIS.
000150 01-03
M|i«[||.
liaf
. >.i':i
S-273
Subject Index
Ptychepharmacology Abstracts
WW I
:i3|:ii
MONOAMINE-OXIDASE-INHIBITION AND BRAIN-AMINE METABOLISM
AFTER ORAL TREATMENT WITH TOLOXATONE IN THE RAT.
000156 01-03
PHARMACOKINETICS AND METABOLISM OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE) IN RAT,
MOUSE, DOG AND MAN.
000219 01-03
METABOLISM OF 3H NORADRENALINE RELEASED FROM ISOLATED RAT
HYPOTHALAMUS BY EXTRAQS OF BLACK-WIDOW-SPIDER GLANDS.
000223 01-03
EFFEQ OF GABA ANALOGUES ON BLOOD-PRESSURE AND CENTRAL GABA
METABOLISM IN THE RAT.
000231 01-03
IRREVERSIBLE INHIBITION OF AROMATIC-L-AMINO-ACID-DECARBOXYLASE
BY ALPHA DIFLUOROMETHYL-DOPA AND METABOLISM OF THE
INHIBITOR.
000248 01-03
THE EFFECTS OF GONADEQOMY AND HYPOPHYSECTOMY ON THE
METABOLISM OF IMIPRAMINE AND LIDOCAINE BY THE LIVER OF MALE
AND FEMALE RATS.
000273 01-03
EFFECT OF THE CATECHOLAMINE-DEPLETING-AGENT 1 PHENYL-2-
THIAZOLYL-2-THIOUREA {U-14-624) ON DRUG METABOLISM IN THE
RAT
000280 01-03
INFLUENCE OF GLUCOSE (IN VIVO OR IN VITRO) ON DURATION OF
NARCOTIC ANALGESICS AND ON THE KINETICS OF DRUG METABOLISM.
000292 01-03
THE EFFEQ OF A NEW FLUORINATED TRICYCLIC NEUROLEPTIC-DRUG
ISOFLOXYTHEPIN ON THE RAT STRIATAL DOPAMINE METABOLISM.
000306 01-03
ANALYSIS OF THE AQIVATION OF DOPAMINE METABOLISM BY A
SEROTONIN UPTAKE INHIBITOR.
000315 01-03
RELATIONSHIP BETWEEN DELTA9 TETRAHYDROCANNABINOL-INDUCED
MOUSE-KILLING-BEHAVIOR ON THE RAT AND THE METABOLISM OF
MONOAMINES IN THE BRAIN, PARTICULARLY THE OLFAQORY-BULB.
000472 01-04
CHOLERA-TOXIN-INDUCED EPILEPTOGENIC-FOCUS - SPECIAL REFERENCE
TO CYCLIC-AMP METABOLISM AND EPILEPTOGENIC-FOCUS.
000522 01-05
3 CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE (GS-385), A
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION,
PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE
LIQUID-CHROMATOGRAPHY.
000705 01-11
INCREASED METABOLISM OF DOPAMINE AND SEROTONIN INDUCED IN
FOREBRAIN AREAS BY ETORPHINE MICROINJEQION IN
PERIAQUEDUCTAL GRAY.
001 103 02-03
PHOSPHOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR-
MEDIATED INDUaiON OF CHEMOTAXIS IN RABBIT NEUTROPHILS.
(UNPUBLISHED PAPER).
001118 02-03
EFFEQS OF BICUCULLINE-INDUCED SEIZURES ON CEREBRAL METABOLISM
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY
STARVATION.
001134 02-03
HA-966 EFFEQS ON STRIATAL DOPAMINE METABOLISM: IMPLICATIONS
FOR DOPAMINE COMPARTMENTALIZAION.
001150 02-03
SPECIES-DIFFERENCES IN CLOBAZAM METABOLISM AND ANTILEPTAZOL
EFFEQ.
001157 02-03
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. II. IN
VIVO METABOLISM OF TRITIATED DRUGS IN RHESUS-MONKEYS.
001229 02-03
TRYPTOPHOL-INDUCED CHANGE IN BRAIN 5 HYDROXYTRYPTAMINE
METABOLISM.
001236 02-03
SHORT-TERM AND LONG-TERM EFFEQS OF METHAMPHETAMINE ON
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC
NUCLEI.
001384 02-03
THE EFFEQ OF SODIUM-SALICYLATE ON CEREBRAL BLOOD FLOW AND
METABOLISM.
001416 02-03
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR
THE POTENTIATION OF IMIPRAMINE EFFEQS ON THE METABOLISM
AND UPTAKE OF BRAIN CATECHOLAMINES.
001427 02-03
EFFEQ OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC-
SYSTEMS IN THE RAT-BRAIN.
001464 02-03
EVIDENCE THAT NORADRENALINE MODULATES THE INCREASE IN
STRIATAL DOPAMINE METABOLISM INDUCED BY MUSCARINIC-
RECEPTOR STIMULATION,
001518 02-03
EVALUATION OF THE EFFEQ OF DRUGS ON DOPAMINE METABOLISM IN
THE RAT SUPERIOR-CERVICAL-GANGLION BY HPLC WITH
ELEQROCHEMICAL-DETEQION .
001530 02-03
EFFEQ OF L FUCOSE ON BRAIN PROTEIN METABOLISM AND RETENTION
OF A LEARNED-BEHAVIOR IN RATS.
001819 02-04
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. I.
PROTEIN BINDING.
001867 02-06
AGE-RELATED FAQORS AFFEQING ANTIDEPRESSANT-DRUG METABOLISM
AND CLINICAL-RESPONSE.
002035 02-09
METABOLISM OF DIMETHOXYMETHYL-PHENOBARBITAL (ETEROBARB) IN
PATIENTS WITH EPILEPSY.
002235 02-13
COMPARATIVE-STUDIES ON THE METABOLISM AND THE DISTRIBUTION OF
SULPIRIDE AND SULTOPRIDE.
002240 02-13
EFFEQ OF DOXEPIN ON SEROTONIN METABOLISM IN RAT-BRAIN AND
SEROTONIN UPTAKE BY HUMAN BLOOD-PLATELETS.
002243 02-13
TOXICOLOGY - PHARMACOLOGY - METABOLISM.
002252 02-13
CONTRIBUTION TO THE PHARMACOKINETICS AND METABOLISM OF
OXYPROTHEPIN.
002279 02-13
NEURONAL AQIVITY AND ENERGY METABOLISM: A SUMMARY OF A
SYMPOSIUM. (UNPUBLISHED PAPER).
002308 02-13
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN
SCHIZOPHRENIA.
002390 02-15
STUDY OF METABOLISM AND BLOOD LEVELS OF ANTIDEPRESSANTS:
TOWARDS A RATIONALIZATION OF THEIR THERAPEUTIC USE.
002625 02-17
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA •
BUTYROLAQONE AND HA-966 IN THE STRIATUM AND OLFAQORY
TUBERCLE OF THE RAT.
002681 03-03
EFFEQ OF NEUROLEPTICS ON INDOLEAMINE-N-METHYLTRANSFERASE
AQIVITY AND BRAIN METABOLISM OF BUFOTENIN.
002735 03-03
EFFEQS OF NEOMYCIN ON CALCIUM AND POLYPHOSPHOINOSITIDE
METABOLISM OF GUINEA-PIG SYNAPTOSOMES.
002741 03-03
THE EFFEQS OF D-AMPHET AMINE AND POTASSIUM ON SEROTONIN
RELEASE AND METABOLISM IN RAT-CEREBRAL-CORTEX TISSUE.
002754 03-03
THE EFFEQ OF PHENaCLIOINE ON DOPAMINE METABOLISM IN THE
MOUSE-BRAIN.
002766 03-03
NOREPINEPHRINE DEPLETION ALTERS CEREBRAL OXIDATIVE METABOLISM
IN THE AQIVE STATE.
002798 03-03
PULMONARY METABOLISM OF IMIPRAMINE IN THE RAT AND RABBIT:
COMPARISON WITH HEPATIC METABOLISM.
002845 03-03
MULTIPLE EFFEQS OF REPEATED ADMINISTRATION OF GAMMA
ACETYLENIC-GABA ON RAT-BRAIN METABOLISM.
002878 03-03
THE METABOLISM OF 5 HYDROXYTRYPTAMINE IN THE METHIONINE-
SULFOXIMINE EPILEPTOGENIC RAT-BRAIN.
002887 03-03
ACCELERATED METABOLISM OF PROBENECID DURING LONG-TERM-
TREATMENT OF RATS WITH ANTICONVULSANT-DRUGS: EFFEQ ON
CENTRAL SEROTONIN TURNOVER STUDIES.
002890 03-03
EFFEQS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L
TRYPTOPHAN BY ISOLATED RAT LIVER CELLS.
002899 03-03
EFFEQS OF CHOLECYSTOKININ-OQAPEPTIDE ON STRIATAL DOPAMINE
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE
CLIMBING IN MICE.
003031 03-04
A COMPARATIVE- STUDY OF THE PHARMACOLOGY OF INHIBITORS OF
GABA METABOLISM.
003036 03-04
THE THERAPEUTIC ACTIVITY OF TRYPTOPHAN AND ITS EFFECT ON
SEROTONIN METABOLISM IN EPILEPTIC-PATIENTS.
003289 03-1 1
THE EFFECTS OF PHENYTOIN ON PHENOBARBITONE AND PRIMIDONE
METABOLISM.
003333 03-11
S-274
VOLUME 19, SUBJECT INDEX
Subject Index
ABNORMAL TRANSMETHYLATION REACTION DURING THE METABOLISM
OF DOPAMINE, TRYPT AMINE, AND SEROTONIN, AND SCHIZOPHRENIC-
SYMPTOMS: A CRITICAL REVIEW.
003404 03-13
GLOMERULAR FILTRATION RATE AND CALCIUM METABOLISM IN LONG-
TERM LITHIUM TREATMENT.
003542 03-15
DISTRIBUTION OF CESIUM IN THE ORGANISM AND ITS EFFECT ON THE
NUCLEOTIDE METABOLISM ENZYMES.
003696 04-02
EFFECT OF AMPHETAMINE ON THE METABOLISM AND INCORPORATION
OF (3H) THYMIDINE INTO DNA OF DEVELOPING RAT-BRAIN.
003729 04-03
THE EFFECTS OF ANTIDEPRESSANTS ON THE RETENTION AND
METABOLISM OF (3H) NOREPINEPHRINE IN RAT-BRAIN SLICES.
003763 04-03
CATECHOLAMINE AND 5 HYDROXYTRYPTAMINE SYNTHESIS AND
METABOLISM FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF
DIBUTYRYL-CYCLIC-AMP.
003769 04-03
ETHANOL-INDUCED CHANGES IN CYCLIC-GUANOSINE-PHOSPHATE
METABOLISM IN MOUSE VESTIBULAR REGION.
003784 04-03
THE EFFECT OF LONG-TERM CONCURRENT ADMINISTRATION OF
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL
CORTICAL DOPAMINE METABOLISM IN RATS.
003788 04-03
COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON
DOPAMINE METABOLISM IN RAT-BRAIN.
003796 04-03
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN.
003820 04-03
UNIMPAIRED QUININE METABOLISM IN RATS WITH VENTROMEDIAL
HYPOTHALAMIC LESIONS.
003821 04-03
EFFECT OF INHIBITORS OF GABA-AMINOTRANSFERASE ON THE
METABOLISM OF GABA IN BRAIN TISSUE AND SYNAPTOSOMAL
FRAaiONS.
003914 04-03
EFFEQ OF IMIPRAMINE ON CENTRAL 5 HYDROXYTRYPTAMINE
TURNOVER AND METABOLISM IN RATS.
003999 04-03
THE EFFEQ OF PROPYLNORANTIFEIN ON BEHAVIORAL-REAQIONS,
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE
ANIMAL BRAIN.
004075 04-04
EFFEQ OF PRENATAL PHENYTOIN ADMINISTRATION ON BRAIN
TRYPTOPHAN METABOLISM OF RAT OFFSPRING DURING THE
PREWEANING PERIOD.
004108 04-04
EFFEQS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION.
004281 04-05
PRAZEPAM METABOLISM IN FEMALE SUBJECTS.
004504 04-13
NOREPINEPHRINE METABOLISM IN MAN USING DEUTERIUM LABELLING: 4
HYDROXY-3-METHOXYMANDELIC-ACID.
004534 04-13
LITHIUM EFFEQS ON CITRATE METABOLISM IN HUMANS AND RATS.
004537 04-13
CATECHOLAMINE METABOLISM IN A PSYCHOAQIVE CAQUS.
004722 04-17
METABOLITE
ENTRY OF DIAZEPAM AND ITS MAJOR METABOLITE INTO
CEREBROSPINAL-FLUID.
000114 01-03
1-M CHLOROPHENYLPIPERAZINE: A METABOLITE OF TRAZODONE
ISOLATED FROM RAT URINE.
000204 01-03
INTERAQION BETWEEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN:
METABOLITE NORTRIPTYLINE AND THE CORRELATION WITH CLINICAL-
RESPONSE.
000640 01-09
P CHLOROAMPHET AMINE: EVALUATION OF A BRAIN METABOLITE.
001779 02-04
KINETICS AND NEUROPSYCHOLOGIC-EFFEQS OF IV DIAZEPAM IN THE
PRESENCE AND ABSENCE OF ITS ACTIVE N DESMETHYL METABOLITE IN
HUMANS.
002229 02-13
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE
NORTRIPTYLINE.
002304 02-13
ALPHA METHYLEPINEPHRINE, A METHYLDOPA METABOLITE THAT BINDS
TO ALPHA-RECEPTORS IN RAT-BRAIN.
002734 03-03
GLC MASS-SPECTROMETRIC-DETERMINATION OF MAPROTILINE AND ITS
MAJOR METABOLITE USING STABLE ISOTOPE-LABELED ANALOG AS
INTERNAL STANDARD.
004291 04-06
METABOLITES
STUDIES ON THE DISTRIBUTION OF 14C SULPIRIDE AND ITS METABOLITES
IN THE RAT AND GUINEA-PIG.
000078 01-03
PHARMACOKINETICS OF PRIMIDONE AND ITS ACTIVE METABOLITES IN
THE DOG.
000097 01-03
INCREASED URINARY EXCRETION OF CATECHOLAMINES AND THEIR
METABOLITES IN STREPTOZOTOCIN DIABETIC RAT.
000154 01-03
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM)
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND
DINORLAAM, DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT.
000505 01-04
HIGH-SENSITIVITY NEGATIVE CHEMICAL-IONIZATION MASS-SPECTRAL-
ANALYSIS OF BIOGENIC-AMINES AND METABOLITES. (UNPUBLISHED
PAPER).
001042 02-01
THE EFFECT OF EMOTIONAL-STRESS AND DIAZEPAM ON MONOAMINE
METABOLITES IN THE CEREBROSPINAL-FLUID OF CATS. (PH.D.
DISSERTATION).
001260 02-03
DELTA9 THC AS A DISCRIMINATIVE-STIMULUS IN RATS AND PIGEONS:
GENERALIZATION TO THC METABOLITES AND SP-1 1 1 .
001666 02-04
PLASMA AND BRAIN LEVELS OF DELTA6 THC AND SEVEN
MONOOXYGENATED METABOLITES CORRELATED TO THE CATALEPTIC-
EFFEQ IN THE MOUSE.
001737 02-04
CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL-
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY.
002095 02-11
ON THE CLINICAL PHARMACOKINETICS OF THIORIDAZINE AND ITS
METABOLITES.
002207 02-13
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXY AMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
ENHANCEMENT OF HEXOBARBITAL-INDUCED SLEEP BY LYSINE AND ITS
METABOLITES.
002967 03-04
ALTERATIONS IN CEREBROSPINAL-FLUID DOPAMINE METABOLITES
FOLLOWING PHYSOSTIGMINE INFUSION.
003477 03-15
CEREBROSPINAL-FLUID CONCENTRATIONS OF THIORIDAZINE AND ITS
MAIN METABOLITES IN PSYCHIATRIC-PATIENTS.
003569 03-16
A SELECTED ION-MONITORING ASSAY FOR BIOGENIC-AMINE
METABOLITES AND PROBENECID, IN HUMAN LUMBAR
CEREBROSPINAL-FLUID.
003663 04-01
DOPAMINE METABOLITES IN CAUDATE AND CORTEX AFTER LITHIUM AND
HALOPERIDOL. (UNPUBLISHED PAPER).
003738 04-03
INTERACTIONS BETWEEN CHLORPROMAZINE AND SOME OF ITS
METABOLITES.
004001 04-03
PROPERTIES OF THE OPTICAL-ISOMERS AND METABOLITES OF KET AMINE
ON THE HIGH-AFFINITY TRANSPORT AND CATABOLISM OF
MONOAMINES.
004009 04-03
ANTICONVULSANT AQIVITY OF METABOLITES OF VALPROIC-ACID.
004168 04-04
BEHAVIOR OF RATS AND MICE ADMINISTERED ACTIVE METABOLITES OF
FLUPHENAZINE, 7 HYDROXYFLUPHENAZINE AND FLUPHENAZINE-
SULFOXIDE.
004256 04-04
RAT-BRAIN AND PLASMA NOREPINEPHRINE GLYCOL METABOLITES
DETERMINED BY GAS-CHROMATOGRAPHY MASS-
FRAGMENTOGRAPHY.
004303 04-06
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS ACTIVE
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC-
PATIENTS TREATED WITH FIXED DRUG DOSES.
004559 04-13
METERGOLINE
ADMINISTRATION OF ANTI SOMATOSTATIN SERUM TO RATS REVERSES
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION
PRODUCED BY INJEQION OF METERGOLINE BUT NOT YOHIMBINE.
(UNPUBLISHED PAPER).
000019 01-03
' 15"
S-275
Subject Index
Ptychopharmacology Abstracts
■mi
IISII
K.
fill';::
METERGOLINE ANTAGONISM OF 5 HYDROXYTRYPTAMINE-INDUCED
ACTIVATION OF RAT-CEREBRAL-CORTICAL NA-K-ATPASE.
000329 01-03
METERGOLINE AND CYPROHEPTADINE SUPPRESS PROLAQIN RELEASE BY
A NON-5-HYDROXYTRYPTAMINERGIC, NONDOPAMINERGIC
MECHANISM.
003732 04-03
(3H)METERG0LINE: A NEW LIGAND OF SEROTONIN-RECEPTORS IN THE
RAT-BRAIN.
003825 04-03
METHADONE
ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND
EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL
AND INTRODUODENAL ADMINISTRATION.
000094 01-03
METHADONE DISULFIRAM INTERAQION DURING METHADONE
MAINTENANCE.
000796 01-13
LONG-TERM EFFECTS OF HALOPERIDOL, CLOZAPINE, AND METHADONE
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNAMICS.
001325 02-03
EFFEQS OF PRENATAL METHADONE ON RAT-BRAIN CATECHOLAMINES.
001367 02-03
FACILITATION OF SELF-STIMULATION IN RATS BY METHADONE.
001795 02-04
THROMBOCYTOSIS IN THE OFFSPRING OF FEMALE MICE RECEIVING DL
METHADONE.
001836 02-05
CHOREIC-MOVEMENTS INDUCED BY THE USE OF METHADONE.
002467 02-15
BEHAVIORAL-EFFEQS OF METHADONE IN SCHIZOPHRENIC-PATIENTS.
003178 03-08
METHADONE AND MORPHINE IN DEPRESSION.
003220 03-09
DISPOSITION OF METHADONE IN THE OVINE MATERNAL FETAL UNIT.
004027 04-03
METHADONE REDUCES SEXUAL-PERFORMANCE AND SEXUAL-
MOTIVATION IN THE MALE SYRIAN GOLDEN HAMSTER.
004183 04-04
METHADONE TREATMENT OF HEROIN ADDIQS IN SWITZERLAND.
004452 04-11
METHADONE USE IN PATIENTS WITH CHRONIC RENAL-DISEASE.
004467 04-11
METHADONE-CHLORHYDRATE
THE TREATMENT OF OPIATE ADDIQION USING METHADONE-
CHLORHYDRATE.
002600 02-17
METHADONE-INDUCED
METHADONE-INDUCED AHENUATION OF THE EFFEQS OF DELTA9
TETRAHYDROCANNABINOL ON TEMPORAL DISCRIMINATION IN
PIGEONS.
004095 04-04
METHADONE-TREATED
BEHAVIORAL AND METABOLIC ALTERATIONS IN PROGENY OF
METHADONE-TREATED RATS. (PH.D. DISSERTATION).
003113 03-04
METHAMPHET AMINE
THE INVOLVEMENT OF SEROTONERGIC NEURONS IN THE CENTRAL-
NERVOUS-SYSTEM AS THE POSSIBLE MECHANISM FOR SLOW HEAD-
SHAKING-BEHAVIOR INDUCED BY METHAMPHET AMINE IN RATS.
000408 01-04
EFFEQS OF EXPERIMENTER AND TEST LOCATION NOVELTY ON
NONSPECIFIC ACTIVITY IN RATS AND ITS MODIFICATION BY
METHAMPHET AMINE.
000409 01-04
SHORT-TERM AND LONG-TERM EFFECTS OF METHAMPHET AMINE ON
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC
NUCLEI.
001384 02-03
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH
PSYCHOSTIMULANTS: II. EFFECT OF METHAMPHETAMINE ON
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC
SUBSTRATES.
001613 02-04
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF
METHAMPHETAMINE.
002812 03-03
METHAMPHETAMINE AND TIME ESTIMATION.
003040 03-04
LONG-TERM EFFECTS OF MULTIPLE DOSES OF METHAMPHETAMINE ON
TRYPTOPHAN-HYDROXYLASE AND TYROSINE-HYDROXYLASE ACTIVITY
IN RAT-BRAIN.
003850 04-03
EFFECTS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE-
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC
BUNDLE IN THE RAT.
003910 04-03
EFFECTS OF A HIGH-DOSE TREATMENT OF METHAMPHETAMINE ON
CAUDATE DOPAMINE AND ANOREXIA IN RATS.
004073 04-04
EFFECT OF L HISTIDINE AND CHLORCYCLIZINE ON APOMORPHINE-INDUCED
CLIMBING-BEHAVIOUR AND METHAMPHETAMINE STEREOTYPY IN
MICE.
004147 04-04
METHAMPHET AMINE-INDUCED
BLOCKADE OF METHAMPHETAMINE-INDUCED DEPRESSION OF TYROSINE-
HYDROXYLASE BY GABA-TRANSAMINASE INHIBITORS.
000130 01-03
METHAQUALONE
EFFECTS OF METHAQUALONE ON SOCIAL-BEHAVIOR IN MONKEYS
(MACACA-MULAHA).
ACUTE EFFECT OF CLOROTEPIN (0.5MG AND l.OMG) AND
METHAQUALONE (300MG) ON VERBAL-ASSOCIATIONS.
METHAQUALONE RIA STRUCTURE VERSUS REACTIVITY.
001594 02-04
002333 02-14
003657 04-01
METHIONINE
PRODUCTION OF CONVULSIONS IN MICE BY THE COMBINATION OF
METHIONINE AND HOMOCYSTEINE.
001233 02-03
FRAGILE SITES IN HUMAN CHROMOSOMES I. THE EFFECT OF METHIONINE
ON THE XQ-FRAGILE-SITE.
004515 04-13
METHIONINE-ENKEPHALIN
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFECTS OF
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS
ON MORPHINE-INDUCED ANALGESIA.
000311 01-03
METHIONINE-ENKEPHALIN ANTAGONISM AND ENDORPHIN POTENTIATION
OF NARCOTIC-INDUCED ANALGESIA.
000357 01-04
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE-
ENKEPHALIN AND CHOLEaSTOKININ IN THE NEURAL RETINA OF
SEVERAL VERTEBRATE SPECIES (UNPUBLISHED PAPER).
001017 02-01
LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHAUN PRODUCE OPPOSING
EFFECTS ON PLASMA CORTICOSTERONE LEVELS IN ETHER-STRESSED
MICE.
001245 02-03
SUBSTANCE-P, MORPHINE AND METHIONINE-ENKEPHALIN: EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE NUCLEUS-
RETICULARIS-GIGANTOCELLULARIS OF THE RAT.
001267 02-03
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL-STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN).
002286 02-13
METKEPHAMID, A SYSTEMICALLY ACTIVE ANALOG OF METHIONINE-
ENKEPHALIN WITH POTENT OPIOID DELTA-RECEPTOR ACTIVITY.
002720 03-03
GABA AND BACLOFEN POTENTIATE THE K-EVOKED RELEASE OF
METHIONINE-ENKEPHALIN FROM RAT STRIATAL SLICES.
002882 03-03
MORPHINE AND METHIONINE-ENKEPHALIN: DIFFERENT EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE
MESENCEPHALIC RETICULAR FORMATION OF THE RAT.
003849 04-03
METHIONINE-SULFOXIMINE
THE METABOLISM OF 5 HYDROXYTRYPTAMINE IN THE METHIONINE-
SULFOXIMINE EPILEPTOGENIC RAT-BRAIN.
(X)2887 03-03
STIMULATION OF FRUCTOSEBIPHOSPHATASE ACTIVITY AND SYNTHESIS
IN THE CEREBRAL-CORTEX OF RATS SUBMIHEO TO THE CONVULSANT
METHIONINE-SULFOXIMINE.
003838 04-03
METHOD
EFFICACY AND PAHERN VALENCE OF PSYCHOACTIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER.
000699 01-11
ELECTROLYTIC MICROINFUSION TRANSDUCER SYSTEM: AN ALTERNATIVE
METHOD OF INTRACRANIAL DRUG APPLICATION.
001861 02-06
THE USE OF SOCIAL-INTERACTION AS A METHOD FOR DETECTING
ANXIOLYTIC-ACTIVITY OF CHLORDIAZEPOXIDE-LIKE DRUGS.
001866 02-06
THEORY, PROCEDURE, AND APPLICATIONS OF THE RADIOACTIVE
DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL GLUCOSE
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM. (UNPUBLISHED
PAPER).
001877 02-06
STUDIES ON GABA RELEASE IN VIVO USING A SIMPLE METHOD FOR
PERFUSION OF THE FOURTH VENTRICLE OF THE RAT.
001881 02-06
PREDICTION OF DOSAGE OF LITHIUM-CARBONATE: USE OF A STANDARD
PREDICTIVE METHOD. _,
001991 02-09
S-276
VOLUME 19, SUBJECT INDEX
Subject lnd«x
SINGLE-DOSE VERSUS MULTIPLE-DOSE COMPARATIVE-TRIAL OF
DESIPRAMINE-HYDROCHLORIDE: A DOUBLE-PLACEBO METHOD.
002059 02-10
METHOD FOR THE DETERMINATION OF TRYPTOPHAN IN SERUM AND
CEREBROSPINAL-FLUIO.
002208 02-13
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL-
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D-
AMPHETAMINE AND APOMORPHINE.
002484 02-16
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE. 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
AN AUTOMATED METHOD FOR STUDYING STEREOTYPED GNAWING
002500 02-16
A RAPID GAS-LIQUID-CHROMATOGRAPHY METHOD FOR SIMULTANEOUS
DETERMINATION OF VARIOUS ANTICONVULSANTS.
002501 02-16
FREE DESCRIPTION OF DRUG-EFFEaS AS A METHOD OF CLINICAL-TRIAL,
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND
THEIR COMBINATION.
002561 02-17
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMITTER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
A METHOD FOR MEASUREMENT OF TRANYLCYPROMINE IN RAT-BRAIN
REGIONS USING GAS-CHROMATOGRAPHY WITH ELEQRON CAPTURE
DETEQION.
003137 03-06
A NEW METHOD FOR APPLICATION OF HORSERADISH-PEROXIDASE INTO
A RESTRICTED AREA OF THE BRAIN.
003141 03-06
ON THE EVALUATION OF A PROVOCATIVE EEG METHOD USING
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUCTION THROUGH
MEDICATION.
003387 03-11
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN
OBJEaiVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS:
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD.
003556 03-16
FIRST RESULTS OF AN ORIGINAL METHOD FOR MEASURING BLOOD
LEVELS OF ANTIDEPRESSANTS (AMITRIPTYLINE AND NORTRIPTYLINE).
003559 03-16
POSITRON-TOMOGRAPHY. A NEW METHOD FOR IN VIVO BRAIN STUDIES
OF BENZODIAZEPINE, IN ANIMAL AND IN MAN.
003564 03-16
BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF THE MOUSE BRAIN
ENOLASES PURIFIED BY A SIMPLE METHOD.
003668 04-01
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID-
CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION.
003674 04-01
PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW
METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES.
004286 04-06
A SIMPLE HISTOCHEMICAL SCREENING METHOD FOR AMINE UPTAKE.
004295 04-06
A CLINICAL-EVALUATION OF THE EFFEaS OF A NEW PSYCHOTROPIC-
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE
DOUBLE-BLIND METHOD.
004491 04-11
CORREaiON OF HORMONAL AQIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF
SCHIZOPHRENIA.
004584 04-14
THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE BRAIN AS AN
OBJEQIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING
DRUGS.
004669 04-16
METHODICAL-CHECK
CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN
SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BLIND CROSS-
OVER DESIGN.
001937 02-08
METHODOLOGICAL
METHODOLOGICAL REMARKS ON LONG-TERM LITHIUM TREATMENT.
000749 01-13
SOME METHODOLOGICAL WAYS OF MONITORING THE EFFECTS OF
PSYCHOTHERAPEUTIC-DRUGS.
003567 03-16
THERAPEUTIC INTEREST OF BLOOD LEVELS DETERMINATION FOR
ANTIDEPRESSANTS: METHODOLOGICAL APPROACH.
003571 03-16
METHODOLOGICAL-CONSIDERATIONS
METHODS AND METHODOLOGICAL-CONSIDERATIONS IN MEASURING
ANTIANXIETY-EFFECTS OF TRANQUILIZING-DRUGS.
002537 02-17
METHODOLOGICAL-CONSIDERATIONS CONCERNING THE PRESCRIPTION
AND USE OF SO CALLED DISINHIBITORS.
002571 02-17
METHODOLOGICAL-ISSUES
METHODOLOGICAL-ISSUES IN SPINAL-FLUID STUDIES OF SCHIZOPHRENIA:
THE CASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE.
(UNPUBLISHED PAPER).
001952 02-08
SPONTANEOUS AQIVITY AND APOMORPHINE STEREOTYPY DURING AND
AFTER WITHDRAWAL FROM 3 1 /2 MONTHS CONTINUOUS
ADMINISTRATION OF HALOPERIDOL: SOME METHODOLOGICAL-ISSUES.
002509 02-16
VILOXAZINE AND THE DEPRESSED SCHIZOPHRENIC - METHODOLOGICAL-
ISSUES.
003181 03-08
METHODOLOGICAL-PROBLEM
SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKING-DRUGS: A
METHODOLOGICAL-PROBLEM.
002395 02-15
METHODOLOGIES
PHYSICO-CHEMICAL METHODOLOGIES IN PSYCHIATRIC-RESEARCH.
004679 04-16
METHODOLOGY
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY:
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS.
000543 01-07
METHODOLOGY AND RESULTS OF A LONG-TERM STUDY OF LONG-AQING
NEUROLEPTICS: PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-
DECANOATE.
001929 02-08
METHODOLOGY OF OUTPATIENT DRUG RESEARCH. (UNPUBLISHED
PAPER).
003282 03-10
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY IN THE
NEUROSCIENCES: METHODOLOGY.
004285 04-06
METHODS
THE IONIZATION OF 5 HYDROXYTRYPTAMINE AND RELATED
COMPOUNDS AND AN APPRAISAL OF METHODS FOR THE ESTIMATION
OF ZWIHERION CONSTANTS.
001859 02-06
METHODS OF MULTICENTER-TRIALS IN PSYCHIATRY - PART I: REVIEW.
002483 02-16
METHODS AND METHODOLOGICAL-CONSIDERATIONS IN MEASURING
ANTIANXIETY-EFFEaS OF TRANQUILIZING-DRUGS.
002537 02-17
A COMPARATIVE EVALUATION OF THE EFFICACY OF SOME THERAPEUTIC
METHODS USED IN DELIRIUM-TREMENS.
004486 04-1 1
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF
ASSESSING COMPLIANCE.
004495 04-1 1
METHOTREXATE
EFFEQS OF ANTICONVULSANTS AND METHOTREXATE ON CALCIUM
DISPOSITION.
001840 02-05
METHOXY-TETRAHYDRO-BETA-CARBOLINE
IDENTIFICATION AND QUANTIFICATION OF 1,2,3,4 TETRAHYDRO-BETA-
CARBOLINE, 2 METHYL-TETRAHYDRO-BETA-CARBOLINE, AND 6
METHOXY-TETRAHYDRO-BETA-CARBOlINE AS IN VIVO CONSTITUENTS
OF RAT-BRAIN AND ADRENAL-GLAND.
002636 03-01
METHOXY-4-HYDROXYPHENETHYLENEGLYCOL
COVARIANCE OF PLASMA FREE 3 METHOXY-4-
HYDROXYPHENETHYLENEGLYCOL and DIASTOLIC BLOOD-PRESSURE.
003418 03-13
METHOXY-4-HYDROXYPHENYlETHYLENEGLYCOL
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER ACTIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT.
001095 02-03
at
S-277
Subject Index
Psychopharmacology Abstracts
mi''
m
Sill
SPECIFIC AND SENSITIVE RADIOIMMUNOASSAY FOR 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL (MOPEG) .
002776 03-03
POSTMORTEM STABILITY OF BRAIN 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND 3,4
DIHYDROXYPHENYLETHYLENEGLYCOL IN THE RAT AND MOUSE.
004048 04-03
METHOXY-4-HY0ROXYPHENYLETHYLENE6LYCOL-SULPHATE
EFFECTS OF ACUTELY AND CHRONICALLY ADMINISTERED
ANTIDEPRESSANTS ON THE CLONIDINE-INDUCED DECREASE IN RAT-
BRAIN 3 METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL-SULPHATE
CONTENT.
002908 03-03
METHOXY-4-HYDROXYPHENYLGLYCOl
INTERACTION OF ANTIDEPRESSANTS WITH CLONIDINE ON RAT-BRAIN
TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL.
000300 01-03
SEX, PLASMA PROLACTIN AND PLASMA 3 METHOXY-4-
HYDROXYPHENYLGLYCOL (MHPG) PREDICT HERITABLE D-
AMPHET AMINE EXCITATION IN MAN. (UNPUBLISHED PAPER).
004565 04-14
METHOXY-4-HYDROXYPHENYL6LYCOL-SULFATE
VARIATIONS IN URINARY EXCRETION OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN DEPRESSIVE-CONDITIONS.
002013 02-09
VARIATIONS IN URINARY LEVELS OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN PATIENTS WITH DEPRESSIVE-
SYNDROMES.
004533 04-13
METHOXYAMPHET AMINE
A NEW APPROACH TO THE ASSESSMENT OF THE POTENCY OF
REVERSIBLE MONOAMINE-OXIDASE-INHIBITORS IN VIVO, AND ITS
APPLICATION TO D-AMPHETAMINE, P METHOXYAMPHETAMINE AND
HARMALINE.
000900 01-16
METHOXYBENZAMIDES
0 METHOXYBENZAMIDES; RELATIONSHIPS BETWEEN STRUQURE-
ACTIVITY, AND PHARMACOKINETICS OF THESE DRUGS.
002246 02-13
METHOXYDIISOPROPYLTRYPTAMINE
N,N DIISOPROPYLTRYPTAMINE (DIPT) AND 5
METHOXYDIISOPROPYLTRYPTAMINE (5 MEO-DIPT). TWO ORALLY
ACTIVE TRYPTAMINE ANALOGS WITH CNS AQIVITY.
004310 04-07
METHOXYDIMETHYLTRYPT AMINE
5 METHOXYDIMETHYLTRYPTAMINE: SPINAL-CORD AND BRAINSTEM
MEDIATION OF EXCITATORY EFFECTS ON ACOUSTIC STARTLE.
001605 02-04
METHOXYFLURANE
INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE,
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS.
001539 02-03
METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME
COMPARATIVE ANALGESIC, BEHAVIORAL, AND DEPENDENCE PROPERTIES
OF MORPHINE AND 0
METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME
HCL.
003707 04-02
METHOXYTRYPT AMINE
THE ACUTE AND CHRONIC EFFECT OF 5 METHOXYTRYPTAMINE ON
SELECTED MEMBERS OF A PRIMATE SOCIAL-COLONY.
001073 02-02
METHOXYTYRAMINE
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID-
CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION.
003674 04-01
METHYL-BETA-CARBOLINE
1 METHYL-BETA-CARBOLINE (HARMANE), A POTENT ENDOGENOUS
INHIBITOR OF BENZODIAZEPINE-RECEPTOR BINDING.
001440 02-03
METHYL-D-ASPARTIC-ACID
TWO CONDUCTANCE MECHANISMS AQIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES.
001349 02-03
METHYL-P-TYROSINE
DOSE-DEPENDENT PHARMACOKINETICS OF ALPHA METHYL-P-TYROSINE
(ALPHA MT) AND COMPARISON OF CATECHOLAMINE TURNOVER-
RATES AFTER TWO DOSES OF ALPHA MT.
001532 02-03
METHYL-TETRAHYDRO-BETA-CARBOLINE
IDENTIFICATION AND QUANTIFICATION OF 1,2,3,4 TETRAHYDRO-BETA-
CARBOLINE, 2 METHYL-TETRAHYDRO-BETA-CARBOLINE, AND 6
METHOXY-TETRAHYDRO-BETA-CARBOLINE AS IN VIVO CONSTITUENTS
OF RAT-BRAIN AND ADRENAL-GLAND.
002636 03-01
METHYLAMPHET AMINE
THE EFFECTS OF DOPAMINERGIC-AGENTS ON THE LOCOMOTOR-AQIVITY
OF RATS AFTER HIGH-DOSES OF METHYLAMPHET AMINE.
000427 01-04
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE
BUT NOT LITHIUM-CHLORIDE.
003110 03-04
METHYLATION
PHOSPHOLIPID METHYLATION AND TRANSMEMBRANE SIGNALLING.
(UNPUBLISHED PAPER).
001001 02-01
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER).
001188 02-03
PHOSPHOLIPID METHYLATION: A BIOCHEMICAL-EVENT OF SIGNAL
TRANSDUCTION (UNPUBLISHED PAPER).
001279 02-03
INCREASED ADRENALINE, BETA-ADRENERGIC-RECEPTOR STIMULATION
AND PHOSPHOLIPID METHYLATION IN PINEAL-GLAND OF
SPONTANEOUSLY HYPERTENSIVE-RATS (UNPUBLISHED PAPER).
001458 02-03
DECREASE OF NORADRENALINE 0 METHYLATION IN RAT-BRAIN INDUCED
BY L-DOPA. REVERSAL EFFECT OF S ADENOSYL-L-METHIONINE.
004019 04-03
METHYLAZOXYMETHANOL-ACETATE
EFFECTS OF FETAL TREATMENT WITH METHYLAZOXYMETHANOL-ACETATE
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE
ADULT NEOCORTEX OF THE RAT.
002770 03-03
METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE
ANALGESIC AND OTHER PHARMACOLOGICAL AQIVITIES OF A NEW
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3
METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS
ENANTIOMORPH IN EXPERIMENTAL ANIMALS.
004185 04-04
METHYLDOPA
METHYLDOPA PRODUCES CENTRAL INHIBITION OF PARASYMPATHETIC-
ACTIVITY IN THE CAT.
001321 02-03
ALPHA METHYLEPINEPHRINE. A METHYLDOPA METABOLITE THAT BINDS
TO ALPHA-RECEPTORS IN RAT-BRAIN.
002734 03-03
REDUaiON IN THE LEVEL OF IMMUNOTITRATABLE DOPAMINE-BETA-
HYDROXYLASE AFTER CHRONIC ADMINISTRATION OF L-DOPA OR
ALPHA METHYLDOPA.
003764 04-03
DIETARY PROTEIN INTAKE INFLUENCES THE ANTIHYPERTENSIVE POTENCY
OF METHYLDOPA IN SPONTANEOUSLY HYPERTENSIVE-RATS.
004025 04-03
METHYLDOP AMINE
DIFFERENTIAL-EFFEQS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS.
003947 04-03
METHYLENEDIOXYAMPHET AMINE
CENTRALLY ACTIVE N SUBSTITUTED ANALOGS OF 3,4
METHYLENEDIOXYPHENYLISOPROPYLAMINE (3,4
METHYLENEDIOXYAMPHET AMINE).
METHYLENEDIOXYPHENYUSOPROPYLAMINE
CENTRALLY AQIVE N SUBSTITUTED ANALOGS OF 3,4
METHYLENEDIOXYPHENYLISOPROPYLAMINE (3,4
METHYLENEDIOXYAMPHET AMINE).
003683 04-02
METHYLEPINEPHRINE
ALPHA METHYLEPINEPHRINE, A METHYLDOPA METABOLITE THAT BINDS
TO ALPHA-RECEPTORS IN RAT-BRAIN.
002734 03-03
METHYLERGONOVINE
ENTHEOGENIC (HALLUCINOGENIC) EFFEQS OF METHYLERGONOVINE.
000742 01-12
METHYLGLUCAMINE
INTERMIHENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA,
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE
lOTHALAMATE VENTRICULOGRAM.
003520 03-15
METHYLMERCURY
RESEARCH STRATEGIES FOR ASSESSING THE EFFEQS OF
METHYLMERCURY ON BEHAVIOR.
003128 03-05
003683 04-02
S-278
VOLUME 19, SUBJECT INDEX
Subject Index
MfTHYLMERCURY-INDUCED
METHYLMERCURY-INDUCED CHANGES IN OPERANT DISCRIMINATION BY
THE PIGEON.
004271 04-05
METHYLNORADItENAllNE
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFECTS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
METHYLNOREPINEPHRINE
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
002801 03-03
METHYLPHENIDATE
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
DIFFERENTIAL-EFFECTS OF METHYLPHENIDATE ON SIGNALLED AND
NONSIGNALLED REINFORCEMENT.
000380 01-04
THE EFFEaS OF THE METHYLPHENIDATE AND D-AMPHET AMINE RELATED
TO ROUTE-OF-ADMINISTRATION.
000476 01-04
TREATMENT OF DEPRESSION IN THE MEDICALLY-ILL ELDERLY WITH
METHYLPHENIDATE.
000602 01-09
A CONTROLLED-TRIAL OF BEHAVIOR-MODIFICATION AND
METHYLPHENIDATE IN HYPERACTIVE-CHILDREN.
000678 01-11
COMPARISON OF SUSTAINED-RELEASE AND STANDARD
METHYLPHENIDATE IN THE TREATMENT OF MINIMAL-BRAIN-
DYSFUNQION.
000732 01-11
EFFEQS OF METHYLPHENIDATE ON LEARNING A BEGINNING READING
VOCABULARY BY NORMAL ADULTS.
000812 01-14
A COMPARISON OF THE EFFEQS OF METHYLPHENIDATE AND
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES.
001207 02-03
EFFEaS OF PHENCYCLIDINE AND METHYLPHENIDATE ON D-
AMPHETAMINE-INDUCED BEHAVIORS IN RESERPINE PRETREATED RATS.
001616 02-04
EFFEQS OF METHYLPHENIDATE ON SELEQIVE AND SUSTAINED
AHENTION IN HYPERACTIVE, READING-DISABLED, AND PRESUMABLY
AHENTION-DISORDERED BOYS.
002118 02-11
THE USE OF SENSORY INTEGRATIVE DIAGNOSTICS TO PREDICT
HYPERAQIVE-CHILDRENS RESPONSIVENESS TO METHYLPHENIDATE
(RITALIN) AND PEMOLINE (CYLERT). (PH.D. DISSERTATION).
002133 02-11
THE DIFFERENTIAL DOSE-EFFECTS OF METHYLPHENIDATE ON
HYPERACTIVE-CHILDREN AND THEIR MOTHERS. (PH.D.
DISSERTATION).
002143 02-11
EFFEQS OF METHYLPHENIDATE ON OPERANT-RESPONDING IN
HYPERAQIVE-BOYS. (PH.D. DISSERTATION).
002191 02-11
EVALUATION OF THE RELATIVE EFFEQIVENESS OF METHYLPHENIDATE
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF
KINDERGARTEN-AGED HYPERAQI VE-CHILDREN .
003306 03-1 1
THE INFLUENCE OF METHYLPHENIDATE ON SPONTANEOUS AUTONOMIC-
AQIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE.
003363 03-11
PREDIQORS OF ADOLESCENT HEIGHT AND WEIGHT IN HYPERKINETIC-
BOYS TREATED WITH METHYLPHENIDATE.
003509 03-15
THE EFFEQS OF CHRONIC METHYLPHENIDATE TREATMENT ON GROWTH
AND ENDOCRINE FUNQION IN THE DEVELOPING RAT.
003811 04-03
METHYLPHENIDATE-HYDROCHLORIDE
EFFEQS OF METHYLPHENIDATE-HYDROCHLORIDE ON REPEATED
ACQUISITION-BEHAVIOR IN HYPERKINETIC-CHILDREN. (PH.D.
DISSERTATION).
003386 03-11
MnHYLPHENIDATE-INDUCED
FLURAZEPAM EFFEQS ON METHYLPHENIDATE-INDUCED STEREOTYPED-
BEHAVIOR.
000455 01-04
MnHYLPHENIDATE-LIKE
METHYLPHENIDATE-LIKE STIMULANTS IN VITRO RELEASE (3H)TYRAMINES
BUT NOT (14C)D0PAMINE.
002706 03-03
METHYLPHENYLALANINE
EFFECT OF ALPHA METHYLPHENYLALANINE AND PHENYLALANINE ON
BRAIN POLYRIBOSOMES AND PROTEIN SYNTHESIS
003733 04-03
METHYLPREDNISOLONE
EFFECTS OF INDOMETHACIN AND METHYLPREDNISOLONE ON RENAL
ELIMINATION OF LITHIUM IN THE RAT.
004270 04-05
METHYLTRANSFERASES
DIFFERENCES IN ACTIVITY IN CEREBRAL METHYLTRANSFERASES AND
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE
AND RESISTANT MICE AND OEERMICE.
000377 01-04
METHYLXANTHINES
METHYLXANTHINES MODULATE ADENOSINE RELEASE FROM SLICES OF
CEREBRAL-CORTEX.
002907 03-03
ADENOSINE-RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM:
RELATIONSHIP TO THE CENTRAL-ACTIONS OF METHYLXANTHINES.
003766 04-03
CHARACTER AND MEANING OF QUASI-MORPHINE WITHDRAWAL
PHENOMENA ELICITED BY METHYLXANTHINES.
004087 04-04
METHYSERGIDE
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED
CAT.
002740 03-03
EFFECTS OF METHYSERGIDE AND NALOXONE ON ANALGESIA INDUCED BY
THE PERIPHERAL ELECTRIC-STIMULATION IN MICE.
003093 03-04
PROGRESSIVE SUPRANUCLEAR PALSY: PNEUMOENCEPHALOGRAPHY,
ELECTRONYSTAGMOGRAPHY AND TREATMENT WITH METHYSERGIDE.
003355 03-11
METKEPHAMID
METKEPHAMID, A SYSTEMICALLY ACTIVE ANALOG OF METHIONINE-
ENKEPHALIN WITH POTENT OPIOID DELTA-RECEPTOR AQIVITY.
002720 03-03
METOCLOPRAMIDE
METOCLOPRAMIDE AND SULPIRIDE AS SELEQIVE BLOCKING-AGENTS
PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS.
001102 02-03
ANTAGONISM OF THE RENAL VASODILATOR AQIVITY OF DOPAMINE BY
METOCLOPRAMIDE.
001265 02-03
METOCLOPRAMIDE: ANTIPSYCHOTIC-EFFICACY OF A DRUG LACKING
POTENCY IN RECEPTOR MODELS.
001948 02-08
DISCRIMINATION OF FUNQIONALLY HETEROGENEOUS RECEPTOR
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC
PROPERTIES OF METOCLOPRAMIDE.
002877 03-03
CHLORPROMAZINE, HALOPERIOOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLAQIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLAQIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
PHARMACOLOGICAL DIFFERENCE OF L-DOPA, APOMORPHINE, AND
BROMOCRIPTINE AGAINST METOCLOPRAMIDE.
003790 04-03
METRAZOL
SEIZURES ELICITED BY SUBCUTANEOUS INJEQION OF METRAZOL DURING
ONTOGENESIS IN RATS.
003039 03-04
ELEQROCORTICOGRAPHIC AQIVITY ELICITED BY METRAZOL DURING
ONTOGENESIS IN RATS.
004064 04-03
METRAZOl-INDUCED
INVOLVEMENT OF CENTRAL CHOLINOCEPTORS IN METRAZOL-INDUCED
CONVULSIONS.
000247 01-03
METRIFONATE
STABLE ISOTOPES USED IN STUDIES OF METRIFONATE.
003847 04-03
MET2-PR05-ENKEPHALINAMIDE
BIPHASIC-EFFECTS OF A POTENT ENKEPHALIN ANALOGUE D MET2-PR05-
ENKEPHALINAMIDE AND MORPHINE ON LOCOMOTOR-ACTIVITY IN
MICE.
001799 02-04
MEXAZOLAM
A CLINICAL-EVALUATION OF THE EFFEQS OF A NEW PSYCHOTROPIC-
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE
DOUBLE-BUND METHOD.
004491 04-11
M62
EFFECT OF DOPAMINE ON AQIVATION OF RAT STRIATAL ADENYLATE-
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES.
002825 03-03
m
m':i
S-279
Subject Index
Psychopharmacology Abttrocft
1*1
ft
MHPG
URINARY MHPG AND CLINICAL-RESPONSE TO AMITRIPTYLINE IN
DEPRESSED-PATIENTS.
000631 01-09
MHPG AS A PREDICTOR OF ANTIDEPRESSANT RESPONSE TO IMIPRAMINE
AND MAPROTILINE.
000787 01-13
SUBTYPES OF DEPRESSION BASED ON EXCRETION OF MHPG AND
RESPONSE TO NORTRIPTYLINE.
002488 02-16
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
004406 04-09
SEX, PLASMA PROLACTIN AND PLASMA 3 METHOXY-4-
HYDROXYPHENYLGLYCOL (MHPG) PREDICT HERITABLE D-
AMPHET AMINE EXCITATION IN MAN. (UNPUBLISHED PAPER).
004565 04-14
MIANSERIN
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
AN IN VIVO MODEL FOR INVESTIGATING ALPHA 1 -RECEPTORS AND
ALPHA2-RECEPT0RS IN THE CNS: STUDIES WITH MIANSERIN.
000053 01-03
EFFECT OF MIANSERIN ON NORADRENERGIC TRANSMISSION IN THE RAT
ANOCOCCYGEUS-MUSCLE.
000075 01-03
3H MIANSERIN BINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG ACTION.
000325 01-03
A DOUBLE-BLIND GROUP COMPARATIVE-TRIAL OF MIANSERIN AND
DIAZEPAM IN DEPRESSED-OUTPATIENTS
000592 01-09
HIGH-AFFINITY BINDING OF (3H)MIANSERIN TO RAT-CEREBRAL-CORTEX.
001204 02-03
MIANSERIN: DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS
BY BLOCKING ALPHA2-RECEPT0RS.
001214 02-03
THE INABILITY OF CHRONIC MIANSERIN TO BLOCK CENTRAL ALPHA2-
ADRENOCEPTORS.
001492 02-03
COMPARISON OF THE EFFECTS OF LOFEPRAMINE AND MIANSERIN IN
DEPRESSED-PATIENTS IN A DOUBLE-BLIND TRIAL.
001996 02-09
MIANSERIN: DETERMINATION OF THERAPEUTIC DOSE RANGE.
002026 02-09
OUTPATIENT CARE OF DEPRESSIVE-PATIENTS WITH MIANSERIN.
002041 02-09
CARDIOVASCULAR-EFFECTS OF AMITRIPTYLINE, MIANSERIN AND
ZIMELIDINE IN DEPRESSED-PATIENTS.
002215 02-13
CARDIOVASCULAR-EFFECTS OF MIANSERIN AND AMITRIPTYLINE IN
HEALTHY VOLUNTEERS.
002469 02-15
(3H)MIANSERIN: DIFFERENTIAL LABELING OF SEROTONIN AND
HISTAMINE-RECEPTORS IN RAT-BRAIN.
002860 03-03
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF-
STIMULATION MODEL USING CLONIDINE.
003016 03-04
THERAPEUTIC TRIAL OF A NEW ANTIDEPRESSANT: MIANSERIN.
003208 03-09
DOUBLE-BLIND STUDY OF MIANSERIN AND AMITRIPTYLINE.
003231 03-09
NOVEL ANTIDEPRESSANTS: A CLINICAL-TRIAL OF MIANSERIN.
003240 03-09
AN OPEN CLINICAL-TRIAL OF MIANSERIN.
003241 03-09
THE THERAPEUTIC PROFILE OF MIANSERIN IN MILD ELDERLY
DEPRESSIVES.
003297 03-11
CARDIOVASCULAR-EFFECTS OF MIANSERIN - A COMPARATIVE-STUDY
WITH AMITRIPTYLINE AND A PLACEBO IN HEALTHY SUBJECTS.
003503 03-15
MIANSERIN: A POSSIBLE CAUSE OF NEUTROPENIA AND
AGRANULOCYTOSIS.
003517 03-15
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC-
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT MIANSERIN.
003745 04-03
A DOUBLE-BUND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND
SIDE-EFFECTS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED-
INPATIENTS AND DEPRESSED-OUTPATIENTS.
004395 04-09
MAPROTILINE, NOMIFENSINE, MIANSERIN, ZIMELIDINE: A REVIEW OF
ANTIDEPRESSANT EFFICACY IN INPATIENTS.
004731 04-17
MIANSERINE
CONTROLLED-COMPARISON OF MIANSERINE WITH IMIPRAMINE IN
ENDOGENOUS DEPRESSIONS.
000634 01-09
THERAPEUTIC EFFECT OF MIANSERINE AND IMIPRAMINE IN ENDOGENOUS
DEPRESSIONS (CONTROLLED-COMPARISON) .
003264 03-09
INTERAQION OF P CHLOROPHENYLALANINE, MIANSERINE AND
DANITRACEN WITH AMPHETAMINE.
004599 04-15
MICROANALYSIS
ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED
PAPER).
001014 02-01
MICROASSAY
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS,
BRAIN, AND PINEAL-ORGAN OF THE RAT.
002503 02-16
MICROCIRCULATION
BIPHASIC RESPONSIVENESS OF RAT PIAL-ARTERIOLES TO DOPAMINE:
DIRECT OBSERVATIONS ON THE MICROCIRCULATION.
001105 02-03
MICROCOMPUTER
A MICROCOMPUTER SYSTEM FOR THE CONTROL OF BEHAVIORAL
EXPERIMENTS.
004287 04-06
MICROESTIMATION
MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND
UPTAKE OF NEUROTRANSMIHERS IN BRAIN SLICES.
003147 03-06
MICROINFUSION
STEREOTYPED-BEHAVIOUR AND ELECTROCORTICAL-CHANGES ARER
INTRACEREBRAL MICROINFUSION OF DOPAMINE AND APOMORPHINE
IN FOWLS.
001734 02-04
ELEaROLYTIC MICROINFUSION TRANSDUCER SYSTEM: AN ALTERNATIVE
METHOD OF INTRACRANIAL DRUG APPLICATION.
001861 02-06
MICROINJECTION
HYPOALGESIA INDUCED BY MICROINJECTION OF A NOREPINEPHRINE
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL
ADMINISTRATION OF A SEROTONIN ANTAGONIST.
000121 01-03
HYPOALGESIA FOLLOWING MICROINJECTION OF NORADRENERGIC
ANTAGONISTS IN THE NUCLEUS-RAPHE-MAGNUS.
000122 01-03
INCREASED METABOLISM OF DOPAMINE AND SEROTONIN INDUCED IN
FOREBRAIN AREAS BY ETORPHINE MICROINJEQION IN
PERIAQUEDUCTAL GRAY.
001103 02-03
DRUG-INDUCED ELEVATION OF GABA AFTER INTRACEREBRAL
MICROINJECTION: SITE OF ANTICONVULSANT AQION.
001627 02-04
SPREADING DEPRESSION INDUCED BY MICROINJEQION OF ENKEPHALINS
INTO THE HIPPOCAMPUS AND NEOCORTEX.
004015 04-03
MICROINJECTIONS
INTRAHYPOTHALAMIC MICROINJEQIONS OF NORADRENALINE WITH AND
WITHOUT INDUCTION OF THE ALIMENTARY DRIVE AS A REWARD IN A
T-MAZE LEARNING IN RATS.
001604 02-04
OPIATE-RECEPTORS AND SLEEP. II EFFECTS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUCTAL GRAY MAHER AND NUCLEUS-TRAQUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
HIPPOCAMPAL SEROTONIN REUPTAKE AND NOQURNAL LOCOMOTOR-
ACTIVITY AFTER MICROINJECTIONS OF 5,7 DHT IN THE FORNIX-
FIMBRIA.
002929 03-03
MODIFICATION OF MOTOR-AQIVITY, PASSIVE-AVOIDANCE
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJEQIONS OF
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS.
003101 03-04
MICROIONOPHORETIC-APPLICATIONS
THE EFFEQ OF CORTISOL MICROIONOPHORETIC-APPLICATIONS ON THE
ACTIVITY OF HIPPOCAMPAL NEURONS IN UNRESTRAINED RABBITS.
001123 02-03
MICROIONTOPHORESIS
INTERACTIONS OF NOREPINEPHRINE WITH PURKINJE-CELL RESPONSES TO
PUTATIVE A,\AINO-ACID NEUROTRANSMIHERS APPLIED BY
MICROIONTOPHORESIS.
000209 01-03
S-280
VOLUME 19, SUBJECT INDEX
Subject Index
MICROIONTOPHORETIC
MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS;
MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN
000068 01-03
MICROIONTOPHORETIC STUDIES ON NORADRENERGIC INHIBITION FROM
LOCUS-COERULEUS OF SPINAL TRIGEMINAL-NUCLEUS NEURONS.
000260 01 03
ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA:
REVERSAL BY MICROIONTOPHORETIC BICUCULLINE
002684 03-03
MICROIONTOPHORETIC-STUDY
EFFECT OF CHRONIC TRICYCLIC-ANTIDEPRESSANT TREATMENT ON THE
SEROTONINERGIC-AUTORECEPTOR: A MICROIONTOPHORETIC-STUDY IN
THE RAT.
001135 02-03
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC-
STUDY.
001410 02-03
MICROPRESSURE
PHYSICAL AND PHYSIOLOGICAL CHARACTERISTICS OF MICROPRESSURE
EJECTION OF DRUGS FROM MULTIBARRELED PIPETTES.
002502 02-16
MICROPROPERTIES
MICROPROPERTIES OF OPERANT-BEHAVIOR AS ASPECTS OF TOXICITY.
004666 04-15
MICROSCOPIC
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY.
000890 01-15
ELECTRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFECTS OF
HIGH-FREQUENCY STIMULATION ON DENDRITIC ULTRASTRUCTURE.
(UNPUBLISHED PAPER).
001036 02-01
NEUROTENSIN-RECEPTOR LOCALIZATION BY LIGHT MICROSCOPIC
AUTORADIOGRAPHY IN RAT-BRAIN.
002938 03-03
MICROSOMAL
BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND
2.4 DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR (DPEA) INHIBITION
OF FAHY-ACID CONJUGATION TO 1 1 HYDR0XY-DELTA9-
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM.
000179 01-03
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRACTIONS.
000299 01-03
EFFECTS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS:
RELATION TO MICROSOMAL BIOTRANSFORMATION AND
DOPAMINERGIC-RECEPTOR STIMULATION .
001161 02-03
COMPARATIVE- STUDY OF THE INDUCTIVE EFFECT OF TWO
PSYCHOMODERATORS - TETRABAMATE AND COMPLEXE-1656 - AND
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS.
001874 02-06
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL
VESICLES.
004042 04-03
MICROSOMES
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS.
003871 04-03
MICROVESSELS
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS,
BRAIN, AND PINEAL-ORGAN OF THE RAT.
002503 02-16
MIDAZOLAM
THE PHARMACOKINETICS OF MIDAZOLAM IN MAN.
004555 04-13
COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPLIED TO DRUG
EVALUATION: MIDAZOLAM IN NORMAL SUBJECTS.
004564 04-14
MIDBRAIN
ON THE NEUROCHEMICAL BASIS OF SELF-STIMULATION WITH MIDBRAIN
RAPHE ELECTRODE PLACEMENTS.
000373 01-04
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND
ELEQROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE
MIDBRAIN.
001593 02-04
MIDBRAIN DOPAMINE NEURONS: DIFFERENTIAL RESPONSES TO
AMPHETAMINE ISOMERS.
002680 03-03
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS.
003972 04-03
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS (UNPUBLISHED PAPER).
004 1 1 2 04-04
MIDODRINE
CENTRAL-ACTION OF INTRAVENTRICULARLY INJECTED MIDODRINE IN
RATS.
001684 02-04
MIDWEST
EPIDEMIOLOGY OF PCP ABUSE: THE MIDWEST PERSPECTIVE.
000740 01-12
MIF-1
NALOXONE-LIKE ACTIONS OF MIF-1 DO NOT REQUIRE THE PRESENCE OF
THE PITUITARY.
001311 02-03
EFFECTS OF PAVLOVIAN-CONDITIONING AND MIF-1 ON THE
DEVELOPMENT OF MORPHINE-TOLERANCE IN RATS.
001327 02-03
MIGRAINE
PHARMACOLOGY OF MIGRAINE.
003623 03-17
MILK
CONCENTRATIONS OF CIS(Z) FLUPENTHIXOL IN MATERNAL SERUM,
AMNIOTIC-FLUID, UMBILICAL-CORD-SERUM, AND MILK.
002423 02-15
MIMICKING
NEUROLEPTIC-INDUCED SYNDROME MIMICKING MYASTHENIA-GRAVIS.
003474 03-15
MIMICS
SYSTEMIC DIPIPERIDINOETHANE MIMICS THE CONVULSANT AND
NEUROTOXIC-ACTIONS OF KAINIC-ACID.
000222 01-03
MINAPRINE
MINAPRINE AND INHIBITION.
001887 02-07
TRIAL WITH MINAPRINE IN SUBJECTS WITH PSYCHIATRIC-DISORDERS.
001889 02-07
CLINICAL-EVALUATION OF THE EFFECTS OF MINAPRINE.
001899 02-07
AN AHEMPT AT A CLINICAL-EVALUATION OF MINAPRINE.
001900 02-07
AN ATTEMPT TO MAKE A CLINICAL-EVALUATION OF MINAPRINE,
(CONTINUATION OF THE STUDY).
001901 02-07
TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE
FATIGUE STUDY GROUPS NO. 4 CLINICAL-SCALE.
001980 02-09
CLINICAL-TESTING OF MINAPRINE ON ELDERLY SUBJECTS WITH THE
ASTHENIC-DEPRESSIVE-SYNDROMES.
002123 02-11
MINAPRINE IN SEVERE PSYCHOPATHOLOGY: STUDY OF 20 CASES.
002135 02-11
EXPERIMENTATION WITH MINAPRINE IN DEALING WITH CERTAIN
SEXUAL-DISORDERS: IMPOTENCE OR FRIGIDITY.
002153 02-11
THE USE OF MINAPRINE IN CHILD-PSYCHIATRY IN HOSPITALS AND
OUTPATIENT CLINICS.
002169 02-11
HISTORY AND PHARMACOLOGY OF MINAPRINE.
002270 02-13
EXPERIMENTATION WITH MINAPRINE IN CHILD-PSYCHIATRY.
002344 02-14
POLYGRAPHIC-STUDY OF NIGHT SLEEP UNDER THE EFFECTS OF
MINAPRINE.
003313 03-11
MINAPRINE-CHLOROHYDRATE
MINAPRINE-CHLOROHYDRATE: SURVEY OF THE FIRST CLINICAL-STUDIES
OF THE FOURTH STAGE.
001902 02-07
MIND
COMPARISON OF THE EFFECTS OF FOUR BENZODIAZEPINES ON FRAME OF
MIND AND BEHAVIOR IN HEALTHY SUBJECTS.
003441 03-14
MIND/BRAIN IN THE AGE OF PSYCHOPHARMACOLOGY: A CROSSROADS
FOR MEDICINE AND MINISTRY,
003624 03-17
MINERAL-ELEMENTS
LEVELS OF MINERAL-ELEMENTS IN THE SERUM AND SALIVA OF HEALTHY
MALE VOLUNTEERS AFTER A SINGLE-DOSE OF LI2C03.
002297 02-13
MINI-MULT
PSYCHOTHERAPEUTIC-DRUG RECOMMENDATIONS BASED ON THE MINI-
MULT.
002606 02-17
II
S-28T
Subject Index
Psychopharmacology Abtfractt
mil I
a I
«||J|J''
k
MINI-SYMPOSIUM
MINI-SYMPOSIUMi III. SIMPLE IN VIVO TESTS THAT DIFFERENTIATE
PROTOTYPE AGONISTS AT OPIATE-RECEPTORS.
004289 04-06
MINI-SYMPOSIUM. I. THE IN VIVO DIFFERENTIATION OF OPIATE-
RECEPTORS: INTRODUCTION.
004697 04-17
MINI-SYMPOSIUM. IV. DISCRIMINATIVE-STIMULUS EFFEQS OF
NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED AQIONS.
004719 04-17
MINI-SYMPOSIUM: II. MULTIPLE OPIOID-RECEPTORS. A LIHLE ABOUT
THEIR HISTORY AND SOME IMPLICATIONS RELATED TO EVOLUTION.
004728 04-17
MINIMAL-BRAIN-DYSFUNCTION
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY: NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-OYSFUNQION.
000448 01-04
OUR EXPERIENCE WITH PIRACETAM (NOOTROPIL-UCB) TREATMENT IN
CHILDREN FROM HIGH-RISK PREGNANCIES WITH SUBSEQUENT
MINIMAL-BRAIN-DYSFUNCTION .
000544 01-07
MINIMAL-BRAIN-DYSFUNCTION ~ HYPERKINETIC-SYNDROME.
000730 01-11
COMPARISON OF SUSTAINED-RELEASE AND STANDARD
METHYLPHENIDATE IN THE TREATMENT OF MINIMAL-BRAIN-
DYSFUNCTION.
000732 01-11
AHENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNQION) IN
ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG-
TREATMENT.
003389 03-1 1
MINIMUM-DOSES
THE QUESTION OF MINIMUM-DOSES OF ANTICONVULSANTS IN THE
TREATMENT OF EPILEPSY.
002306 02-13
MINIREVIEW
TRANYLCYPROMINE STEREOISOMERS, MONOAMINERGIC
NEUROTRANSMISSION AND BEHAVIOR. A MINIREVIEW.
000016 01-02
MINISTRY
MIND/BRAIN IN THE AGE OF PSYCHOPHARMACOLOGY: A CROSSROADS
FOR MEDICINE AND MINISTRY.
003624 03-17
MINOR-TRANQUIliZER
THE BENZODIAZEPINE GABA-CHLORIDE lONOPHORE-RECEPTOR COMPLEX:
COMMON SITE OF MINOR-TRANQUILIZER AQION.
002857 03-03
MINOR-TRANQUILIZERS
THE USE OF MINOR-TRANQUILIZERS WITH JAIL INMATES.
003308 03-11
MISINFORMED
MISINFORMED CONSENT.
004326 04-08
MISONIDAZOLE
ACETYLCHOLINESTERASE AND CHOLINESTERASE AQIVITIES IN THE
MOUSE CEREBELLUM FOLLOWING MISONIDAZOLE TREATMENT.
003123 03-05
MISSISSIPPI
ISOLATION OF PSYCHOACTIVE CANNABINOID PRECURSORS FROM
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI.
001023 02-01
MISUSE
A STUDY OF ANTIPSYCHOTIC-DRUG USE IN NURSING-HOMES:
EPIDEMIOLOGIC EVIDENCE SUGGESTING MISUSE.
000979 01-17
THE USE AND MISUSE OF SLEEPING-PILLS: A CLINICAL GUIDE.
002150 02-11
MITOCHONDRIA
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA.
(UNPUBLISHED PAPER).
001147 02-03
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 02-03
OXIDATION OF BETA PHENYLETHYLAMINE BY BOTH TYPES OF
MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND
LIVER MITOCHONDRIA OF EIGHT SPECIES.
004024 04-03
MITOCHONDRIAL
REVERSIBLE ALEXIA. MITOCHONDRIAL MYOPATHY, AND LAQIC-
ACIDEMIA.
000723 01-11
MECHANISM OF INACTIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES.
001055 02-01
MECHANISM OF INAQIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES.
001088 02-02
EXPOSURE OF MITOCHONDRIAL OUTER MEMBRANES TO NEURAMINIDASE
SELEQIVELY DESTROYS MONOAMINE-OXIDASE-A AQIVITY.
001286 02-03
EFFEQ OF INORGANIC LEAD ON RAT-BRAIN MITOCHONDRIAL
RESPIRATION AND ENERGY PRODUaiON.
004267 04-05
MITRAL-VALVE
EFFEQ OF SODIUM-LAQATE ON PATIENTS WITH PANIC-DISORDER AND
MITRAL-VALVE PROLAPSE.
003409 03-13
ARRHYTHMIA INDUCED BY A TRICYCLIC-ANTIDEPRESSANT IN A PATIENT
WITH UNDIAGNOSED MITRAL-VALVE PROLAPSE.
003521 03-15
MIXED-FUNCTION
EFFECT OF CHRONIC ADMINISTRATION OF PHENCYCLIDINE ON HEPATIC
MIXED-FUNQION OXIDASES IN THE MOUSE.
002753 03-03
MIXTURE
HABITUATION OF THE THE HEAD-POKE RESPONSE: EFFEaS OF AN
AMPHETAMINE BARBITURATE MIXTURE, PLG AND FENFLURAMINE.
004159 04-04
CHARAQERISTICS OF THE STIMULUS PRODUCED BY THE MIXTURE OF
CANNABIDIOL WITH DELTA9 TETRAHYDROCANNABINOL
004263 04-04
MK-771
INVESTIGATIONS ON THE INTERAQION OF THYROTROPIN-RELEASING-
HORMONE (TRH) AND MK-771 WITH CENTRAL NORADRENERGIC
MECHANISMS.
001701 02-04
MMPI
COMPUTERIZING THE MMPI IN THE STUDY OF A NEW PSYCHOTROPIC-
AGENT: TIAPRIDE.
000585 01-09
MMPI PREDiaiON OF IMIPRAMINE RESPONSE: A REPLICATION STUDY.
003570 03-16
MOBIUZATION
MOBILIZATION OF REFRAQORY CHRONIC SCHIZOPHRENICS WITH
HALOPERIDOL.
004337 04-08
MODEL
THE PARADOXICAL-EFFEQ OF LIOOCAINE ON AN EXPERIMENTAL MODEL
OF EPILEPSY.
000039 01-03
AN IN VIVO MODEL FOR INVESTIGATING ALPHAl -RECEPTORS AND
ALPHA2-RECEPT0RS IN THE CNS: STUDIES WITH MIANSERIN.
000053 01-03
FLASH-EVOKED ARERDISCHARGE IN RAT AS A MODEL OF THE ABSENCE
SEIZURE: DOSE-RESPONSE STUDIES WITH THERAPEUTIC DRUGS
000160 01-03
IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR
AaiVITY.
000289 01-03
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANa: NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNQION.
000448 01-04
DOPAMINERGIC FAQORS IN HUMAN PROLAQIN REGULATION: A
PITUITARY MODEL FOR THE STUDY OF A NEUROENDOCRINE SYSTEM IN
MAN.
000776 01-13
A MODEL FOR PSYCHONEUROENDOCRINE INVESTIGATION: SPECIFIC
CHEMICAL LESIONING OF THE MEDIAN-EMINENCE.
001478 02-03
CIRCLING PRODUCED BY SEROTONIN AND DOPAMINE AGONISTS IN
RAPHE LESIONED RATS: A SEROTONIN MODEL.
001783 02-04
ACUTE AND CHRONIC LSD EFFEaS ON RAT STARTLE: DATA SUPPORTING
AN LSD RAT MODEL OF SCHIZOPHRENIA.
002194 02-12
SUBJEQIVE DRUG-EFFEQS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFEaS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL-
NERVOUS-SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE-
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS).
002459 02-15
A NOVEL PSYCHOMETRIC-TEST MODEL APPLYING TAILORED TESTING FOR
ECONOMIC AND EFFICIENT COLLEQION OF
PSYCHOPH ARMACOLOGICAL-EFFEQS .
002479 02-16
THE HYPOTHALAMIC DOPAMINERGIC REGULATION OF PROLAQIN: A
MODEL FOR THE STUDY OF NEUROHORMONAL MECHANISMS IN MAN.
002568 02-17
S-282
VOLUME 19, SUBJECT INDEX
Subject Index
A POSSIBLE ECOPHARMACOGENETIC MODEL IN
NEUROPSYCHOPHARMACOLOGY ASPECTS IN ALCOHOLISM AND
PHARMACODEPENDENCE.
002596 02-17
COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION
IN THE RAT MODEL.
002928 03-03
AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE
ANALYSIS OF APOMORPHINE-INOUCED-FIGHTING AND STEREOTYPY IN
THE RAT.
002983 03-04
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF-
STIMULATION MODEL USING CLONIDINE.
003016 03-04
A TEST OF A NEUROTRANSMITTER MODEL OF THE AFFECTIVE-DISORDERS.
(PH.D. DISSERTATION).
003063 03-04
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDICT RATS: A POSSIBLE MODEL FOR PREDICTING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION).
003097 03-04
BEHAVIORAL-TEST FOR DETECTION OF SUBCLINICAL BRAIN-DAMAGE: AN
EXPERIMENTAL MODEL.
003120 03-04
A REFORMULATION OF THE DUAL-ACTION MODEL OF OPIOID
DEPENDENCE: OPIOID-SPECIFIC NEURONAL KINDLING.
003645 03-17
THE HUMAN PLATELET AS A MODEL FOR THE GLUTAMATERGIC NEURON:
PLATELET UPTAKE OF L GLUTAMATE.
003923 04-03
AN ELEaROPHYSIOLOGICAL MODEL OF GABA-MEDIATED
NEUROTRANSMISSION.
003929 04-03
THE STEREOTYPED-BEHAVIOR-SYNDROME: A NEW MODEL AND
PROPOSED THERAPY.
004163 04-04
LACK OF SPECIFICITY OF AN ANIMAL BEHAVIOR MODEL FOR
HALLUCINOGENIC DRUG ACTION.
004250 04-04
HALOPERIDOL AND DROPERIDOL TREATMENT IN SCHIZOPHRENICS:
CLINICAL APPLICATION OF THE PROLAQIN MODEL.
004332 04-08
MODELS
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE-
BEHAVIOR: INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON
THREE EXPERIMENTAL MODELS.
000340 01-04
ORAL DYSKINESIA IN BRAIN-DAMAGED RATS WITHDRAWN FROM A
NEUROLEPTIC: IMPLICATION FOR MODELS OF TARDIVE-DYSKINESIA.
000393 01-04
PREPARATION AND CHARAQERIZATION OF SYNTHETIC MODELS FOR THE
DENSE-BODIES OF HUMAN PLATELETS. (UNPUBLISHED PAPER).
001013 02-01
METOCLOPRAMIDE: ANTIPSYCHOTIC-EFFICACY OF A DRUG LACKING
POTENCY IN RECEPTOR MODELS.
001948 02-08
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
002219 02-13
THE VALIDITY OF MODELS IN PSYCHOPHARMACOLOGY.
003633 03-17
MODERN-VIEWS
MODERN-VIEWS ON THE PRINCIPLES OF THE PHARMACOLOGICAL-
TREATMENT OF EPILEPSY.
000931 01-17
MODIFICATION
MODIFICATION OF DOPAMINERGIC-RECEPTOR SENSITIVITY IN RAT-BRAIN
AFTER AMYGDALOID KINDLING.
000106 01-03
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFEQS ON
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFEQS OF
COCAINE AND D-AMPHET AMINE FOLLOWING CHRONIC AMPHETAMINE
ADMINISTRATION.
000350 01-04
MODIFICATION OF THE PROLINE RESIDUE OF TRH ENHANCES BIOLOGICAL-
AaiVITY AND INHIBITS DEGRADATION.
000351 01-04
RATS REACTIONS TO A PREDATOR: MODIFICATION BY
CHLORDIAZEPOXIDE.
000353 01-04
EFFEQS OF EXPERIMENTER AND TEST LOCATION NOVELTY ON
NONSPECIFIC ACTIVITY IN RATS AND ITS MODIFICATION BY
METHAMPHETAMINE.
000409 01-04
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS.
001242 02-03
MODIFICATION OF GABAERGIC AQIVITY AND THYROTROPIN SECRETION
IN MALE RATS.
001362 02-03
MODIFICATION OF DOPAMINE-RECEPTORS IN BRAIN BY CONTINUOUS
AMPHETAMINE ADMINISTRATIONS TO RATS,
001395 02-03
SHORT-TERM AND LONG-TERM MODIFICATION OF SKELETAL-MUSCLE
SODIUM-PUMP ACTIVITY AND MUSCLE PROTEIN TURNOVER.
(UNPUBLISHED PAPER).
001519 02-03
PHARMACOLOGICAL MODIFICATION OF AMYGDALOID KINDLED
SEIZURES.
001588 02-04
THE PARENT CHILD INTERAQIONS OF HYPERACTIVE-CHILDREN AND THEIR
MODIFICATION BY STIMULANT-DRUGS.
002092 02-11
MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJECTIONS OF
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS.
003101 03-04
AGE-DEPENDENT MODIFICATION OF DRUG INTERFERENCE ON THE
ENZYMATIC ACTIVITIES OF THE RAT-BRAIN.
003730 04-03
SELECTIVE MODIFICATION BY OPIATES OF NEURONAL ACTIVITY OF THE
MEDIAL BASAL HYPOTHALAMUS.
003773 04-03
GUANYLATE-CYCLASE - CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND
CEREBELLUM: MODIFICATION BY ANTICONVULSANTS.
003956 04-03
CHLORPROMAZINE EFFECTS ON COCAINE-REINFORCED RESPONDING IN
RHESUS-MONKEYS: RECIPROCAL MODIFICATION OF RATE ALTERING
EFFEaS OF THE DRUGS.
004133 04-04
MODIFICATION OF DRUG-INDUCED CATATONIA AND TREMORS BY
QUIPAZINE IN RATS AND MICE.
004164 04-04
SEROTONERGIC APPROACHES TO THE MODIFICATION OF BEHAVIOR IN
THE LESCH-NYHANS-SYNDROME.
004576 04-14
MODIFICATIONS
BRAIN CATECHOLAMINES MODIFICATIONS. THE EFFECTS ON MEMORY
FACILITATION INDUCED BY OXOTREMORINE IN MICE.
001658 02-04
SUPERSENSITIVITY TO APOMORPHINE IN EXPERIMENTALLY-INDUCED
HYPOKINESIA AND DRUG-INDUCED MODIFICATIONS OF THE
APOMORPHINE RESPONSE.
001814 02-04
LSD-INDUCED ULTRASTRUCTURAL MODIFICATIONS OF LIMBIC-SYSTEM
NUCLEI AND OTHER CEREBRAL ZONES.
002198 02-12
IMIPRAMINE: EFFECT OF OVARIAN STEROIDS ON MODIFICATIONS IN
SEROTONIN-RECEPTOR BINDING.
002778 03-03
MODIFYING
NEUR0PHARMAC0L0GICAL-A6ENTS MODIFYING ENDOTOXIN-INDUCED
CHANGES IN MICE.
001543 02-03
EFFECTS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC
MEMBRANES.
002888 03-03
ON MONOAMINERGIC-INTERACTION WITH BEHAVIOUR MODIFYING
PEPTIDE-HORMONES.
004700 04-17
MODITEN
RESULTS OF TREATMENT BY MODITEN DEPOT IN OUTPATIEKlS-WARDS IN
THE SOUTH MORAVIAN REGION.
004648 04-15
MOLECULAR
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE ACETYLCHOLINE
ANTAGONIST DtMETHYLAMINOBUTYNYLCYCLOHEXYLHYDROXY 2
PHENYLACETATE HCL.
000003 01-01
INFLUENCE OF NICERGOLINE ON MOLECULAR BIOLOGICAL PROCESSES IN
THE BRAIN AND LEARNING-ABILITY OF THE RAT.
000449 01-04
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE NEUROLEPTIC
PIMOZIDE-HYDROCHLORIDE, BISFLUOROPHENYL-
BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL.
001015 02-01
CONVULSANT AND ANTICONVULSANT BARBITURATES. 1. MOLECULAR
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY
CALCULATIONS.
001029 02-01
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES.
001402 02-03
S-283
ml;
■a I!
III
•Mill;:
ill::
Subject Index
THE MOLECULAR ARCHITECTURE OF ERGOPEPTINES: A BASIS FOR
BIOLOGICAL-INTERACTION.
001527 02-03
MOLECULAR ACTIONS OF OPIATES: HISTORICAL OVERVIEW AND NEW
FINDINGS ON OPIATE-RECEPTOR INTERACTIONS WITH ENKEPHALINS
AND GUANYL-NUCLEOTIDES.
002613 02-17
MOLECULES
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK
TISSUES ~ ARE THEY CELL ADHESION MOLECULES?
003724 04-03
MOLINDONE
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE
MOUSE AND THE RAT.
003870 04-03
PHYSIOLOGICAL SIGNIFICANCE OF DOPAMINE-AUTORECEPTORS AS
STUDIED FOLLOWING THEIR SELECTIVE BLOCKADE BY MOLINDONE.
004065 04-04
MOLINDONE-HYDROCHLORIDE
MOLINDONE-HYDROCHLORIDE IN THE TREATMENT OF AGGRESSIVE,
HOSPITALIZED CHILDREN.
003321 03-11
MOLLUSCAN
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOLLUSCAN
NEURONS. .
003834 04-03
M0N60LIAN-GERBIL
DISRUPTION OF SELECTIVE AHENTION BY APOMORPHINE, BUT NOT
AMPHETAMINE, IN THE MONGOLIAN-GERBIL.
000358 01-04
BRAIN BENZODIAZEPINE-RECEPTORS AND THEIR RAPID CHANGES AFTER
SEIZURES IN THE MONGOLIAN-GERBIL.
003717 04-03
HANDLING-INDUCED SEIZURES AND ROTATIONAL-BEHAVIOR IN THE
MONGOLIAN-GERBIL.
004216 04-04
MONGOLIAN-GERBILS
CHOLINERGIC MECHANISMS IN SCENT-MARKING-BEHAVIOR BY
MONGOLIAN-GERBILS (MERIONES-UNGUICULATUS) .
000504 01-04
MONITOR
ANIMAL ACTIVITY MONITOR FOR CHRONIC DRUG-STUDIES.
(UNPUBLISHED PAPER).
001794 02-04
MONITORING
VALUE OF SALIVA SAMPLES IN MONITORING CARBAMAZEPINE
CONCENTRATIONS IN EPILEPTIC-PATIENTS
000903 01-16
AN AUTOMATED ELECTROCHEMICAL-METHOD FOR IN VIVO MONITORING
OF CATECHOLAMINE RELEASE.
001873 02-06
LONG-TERM MONITORING OF TRICYCLIC-ANTIDEPRESSANT PLASMA
CONCENTRATIONS.
002014 02-09
HALOPERIDOL PLASMA LEVEL MONITORING IN PSYCHIATRIC-PATIENTS.
002267 02-13
CORRELATIONS BETWEEN PLASMA LEVELS OF ANTIEPILEPTIC-DRUGS AND
EEG INTENSIVE MONITORING.
002288 02-13
CARDIOVASCULAR-EFFECTS OF THERAPEUTIC DOSES OF TRICYCLIC-
ANTIDEPRESSANTS: IMPORTANCE OF BLOOD LEVEL MONITORING.
002456 02-15
A PROSPECTIVE RANDOMISED-TRIAL ON THE EFFEQ OF MONITORING
PLASMA ANTICONVULSANT LEVELS IN EPILEPSY.
003314 03-11
INTENSIVE MONITORING IN REFRAQORY EPILEPSY.
003378 03-1 1
COMPUTERIZED MONITORING OF PSYCHOTROPIC-DRUG ORDERS: SOME
TRENDS AND REVELATIONS.
003566 03-16
' SOME METHODOLOGICAL WAYS OF MONITORING THE EFFECTS OF
PSYCHOTHERAPEUTIC-DRUGS .
003567 03-16
AMITRIPTYLINE AND NORTRIPTYLINE PLASMA LEVELS MONITORING.
PERSPEQIVE IN CLINICAL-PRACTICE.
004675 04-16
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC-
ANTIDEPRESSANTS: PERSPEQIVE OF THE CLINICAL LABORATORY.
004681 04-16
MONKEY
NEURONAL AQIVITY IN CHRONIC FERRIC-CHLORIDE EPILEPTIC-FOCI IN
CATS AND MONKEY.
000172 01-03
DISTRIBUTION AND EXCRETION IN THE RAT AND MONKEY OF (82BR)
BROMOCRIPTINE.
000196 01-03
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
Psychopharmocology Abstracts
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED
DIFFERENTIATION) IN THE MONKEY (MACACA-MULAHA) .
00044001-04
OPIATE-RECEPTOR GRADIENTS IN MONKEY CEREBRAL-CORTEX:
CORRESPONDENCE WITH SENSORY PROCESSING HIERARCHIES.
002641 03-01
AN INVOLVEMENT OF DOPAMINE IN HIGHER-ORDER CHOICE
MECHANISMS IN THE MONKEY.
003072 03-04
MORPHINE-LIKE STIMULUS EFFEaS IN THE MONKEY: OPIOIDS WITH
ANTAGONIST PROPERTIES.
003086 03-04
MONKEYS
BIOCHEMICAL-STUDIES AFTER CHRONIC ADMINISTRATION OF
NEUROLEPTICS TO MONKEYS.
000523 01-05
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS.
001242 02-03
EFFECTS OF METHAQUALONE ON SOCIAL-BEHAVIOR IN MONKEYS
(MACACA-MULAHA).
001594 02-04
THE EFFEQ OF PHRENOLON ON DELAYED REAQIONS IN LOWER
MONKEYS.
001640 02-04
EFFEaS OF PHENCYCLIDINE, PENTOBARBITAL, AND D-AMPHETAMINE ON
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL
DISCRIMINATIONS IN MONKEYS.
001723 02-04
DISCRIMINATIVE-STIMULUS EFFEQS OF PROTOTYPE OPIATE-RECEPTOR
AGONISTS IN MONKEYS.
001803 02-04
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE
INTOXICATION.
002988 03-04
THE EFFEQ OF THIOPROPERAZINE ON DELAYED REAQIONS IN LOWER
MONKEYS.
004125 04-04
CLONIDINE-INDUCED HYPERPHAGIA IN MONKEYS: EVIDENCE FOR
ALPHA2-N0RA0RENERGIC-RECEPT0R MEDIATION .
004215 04-04
MONOAMINE
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-AQIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
AQIVITY,
000309 01-03
AHEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED
SPINAL FEMALE RATS WITH MONOAMINE AGONISTS.
000421 01-04
FURTHER STUDIES ON THE INHIBITION OF MONOAMINE SYNTHESIS BY
MONOFLUOROMETHYLDOPA.
001128 02-03
CENTRAL MONOAMINE SYNAPSES AS SITES OF ACTION FOR ERGOT
DRUGS.
001238 02-03
THE EFFECT OF EMOTIONAL-STRESS AND DIAZEPAM ON MONOAMINE
METABOLITES IN THE CEREBROSPINAL-FLUID OF CATS. (PH.D.
DISSERTATION).
001260 02-03
EFFECT OF QUIPAZINE ON BRAINSTEM MONOAMINE NEURONS
HISTOFLUORESCENCE STUDIES.
001477 02-03
BEHAVIOURAL-RESPONSES TO STEREOTACTICAUY CONTROLLED
INJECTIONS OF MONOAMINE NEUROTRANSMinERS INTO THE
ACCUMBENS AND CAUDATE-PUT AMEN NUCLEI.
001708 02-04
INFLUENCE OF MONOAMINE DEPLETING PHARMACOLOGIC-AGENTS ON
LEVELS OF ACTIVITY IN CAIMAN-SCLEROPS.
001810 02-04
INFLUENCE OF CICLAZINDOL ON MONOAMINE UPTAKE AND CNS
FUNCTION IN NORMAL SUBJECTS.
002268 02-13
MONOAMINE-OXIDASE
INHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN
CIRCUMVENTRICULAR STRUCTURES OF RAT-BRAIN.
000159 01-03
MONOAMINE-OXIDASE AND ITS INHIBITION: SOME CUNICAL
IMPLICATIONS.
000983 01-17
MECHANISM OF INACTIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES.
001055 02-01
THIOLS LIBERATE COVALENTLY-BONDED FLAVIN FROM MONOAMINE-
OXIDASE. (UNPUBLISHED PAPER).
001060 02-01
S-284
VOLUME 19, SUBJECT INDEX
Subject Index
MECHANISM OF INACTIVATION OF MITOCHONDRIAL MONOAMINE-
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES
001088 02-02
EFFECT OF 2 P CHLOROPHENYL-CYCLOPROPYLAMINE ON 5
HYDROXYINDOLE CONCENTRATION AND MONOAMINE-OXIDASE
ACTIVITY IN RAT-BRAIN.
001237 02-03
MONOAMINE-OXIDASE. PHENYLETHYLAMINE, NOREPINEPHRINE AND
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
001958 02-08
SPECIES-DIFFERENCES IN THE DEAMINATION OF DOPAMINE AND OTHER
SUBSTRATES FOR MONOAMINE-OXIDASE IN BRAIN
002233 02-13
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF
AMINES INFLUENCING CERE8R0SPINAL-FLUID FORMATION.
002807 03-03
A PROBABLE NEUROLEPTIC-EFFECT ON PLATELET MONOAMINE-OXIDASE
IN CHRONIC SCHIZOPHRENIC-PATIENTS.
003169 03-08
NONGENETIC FACTORS AFFEQING HUMAN PLATELET MONOAMINE-
OXIDASE.
003407 03-13
LYMPHOCYTE MONOAMINE-OXIDASE AND PLASMA PROLACTIN AND
GROWTH-HORMONE IN TARDIVE-DYSKINESIA.
003499 03-15
INHIBITION OF MONOAMINE-OXIDASE BY FURAZOLIDONE IN THE
CHICKEN AND THE INFLUENCE OF THE ALIMENTARY FLORA THEREON.
003711 04-03
CHARAQERISTICS OF THE INHIBITION OF RAT-BRAIN MONOAMINE-
OXIDASE IN VITRO BY MD780515.
003874 04-03
OXIDATION OF BETA PHENYLETHYLAMINE BY BOTH TYPES OF
MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND
LIVER MITOCHONDRIA OF EIGHT SPECIES.
004024 04-03
THE SPECIFIC ACTIVITY OF PLATELET MONOAMINE-OXIDASE VARIES
WITH PLATELET COUNT DURING SEVERE EXERCISE AND
NORADRENALINE INFUSION.
004509 04-13
THE AQIVITY OF BLOOD-PLATELET MONOAMINE-OXIDASE IN
ENDOGENOUS DEPRESSION.
004547 04-13
MONOAMINE-OXIDASE-A
EXPOSURE OF MITOCHONDRIAL OUTER MEMBRANES TO NEURAMINIDASE
SELEQIVELY DESTROYS MONOAMINE-OXIDASE-A AQIVITY.
001286 02-03
MONOAMINE-OXIDASE-B
EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE
ROLE FOR BETA PHENYLETHYLAMINE IN THE COCAINE CUE.
000363 01-04
ESR STUDIES OF SPIN LABELLED BOVINE LIVER MONOAMINE-OXIDASE-B.
(UNPUBLISHED PAPER).
001065 02-01
MONOAMINE-OXIDASE-B ACTIVITIES TOWARD BETA PHENYLETHYLAMINE
IN DISCRETE HYPOTHALAMIC AND CIRCUMVENTRICULAR NUCLEI OF
THE RAT.
002781 03-03
MONOAMINE-OXIDASE-ft-INHIBITOR
THE EFFECT OF DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, ON SLEEP AND MOOD IN MAN.
002365 02-14
IS THE FAILURE OF (-)DEPRENYL, A SELEQIVE MONOAMINE-OXIDASE-B-
INHIBITOR, TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM
THE CHEESE EFFEQ?
004640 04-15
MONOAMINE-OXIDASE-INHIBITION
NEUROTRANSMinER RELATED ADAPTATION IN THE CENTRAL-NERVOUS-
SYSTEM FOLLOWING CHRONIC MONOAMINE-OXIDASE-INHIBITION
000038 01-03
MONOAMINE-OXIDASE-INHIBITION AND BRAIN-AMINE METABOLISM
AFTER ORAL TREATMENT WITH TOLOXATONE IN THE RAT.
000156 01-03
MONOAMINE-OXIDASE-INHIBITOR
COMBINED MONOAMINE-OXIDASE-INHIBITOR TRICYCLIC-
ANTIDEPRESSANT TREATMENT: A PILOT- STUDY.
000644 01-09
THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA.
002976 03-04
MONOAMINE-OXIDASE-INHIBITORS
CORRELATION BETWEEN MONOAMINE-OXIDASE-INHIBITORS AND
ANTICONVULSANTS.
000081 01-03
THE EFFEQ OF MONOAMINE-OXIDASE-INHIBITORS ON FIRST-PASS
METABOLISM OF TYRAMINE IN DOG INTESTINE.
000141 01-03
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS
000171 01-03
A NEW APPROACH TO THE ASSESSMENT OF THE POTENCY OF
REVERSIBLE MONOAMINE-OXIDASE-INHIBITORS IN VIVO, AND ITS
APPLICATION TO D-AMPHETAMINE, P METHOXYAMPHETAMINE AND
HARMALINE.
000900 01-16
EFFECTS OF DIFFERENT MONOAMINE-OXIDASE-INHIBITORS ON
RESPIRATORY ACTIVITY IN RATS WITH CHRONICALLY IMPAIRED
CENTRAL SEROTONERGIC FUNCTION.
001389 02-03
DECREASE IN (3H) SEROTONIN BINDING IN RAT-BRAIN PRODUCED BY THE
REPEATED ADMINISTRATION OF EITHER MONOAMINE-OXIDASE-
INHIBITORS ON CENTRALLY-ACTING SEROTONIN AGONISTS.
001463 02-03
MONOAMINE-OXIDASE-INHIBITORS: PRESCRIPTION AND PATIENT
MANAGEMENT.
002454 02-15
MONOAMINE-OXIDASES
DIFFERENCES IN ACTIVITY IN CEREBRAL METHYLTRANSFERASES AND
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE
AND RESISTANT MICE AND DEERMICE.
000377 01-04
MONOAMINE-RECEPTOR
EFFECTS OF ELECTROCONVULSIVE-TREATMENT ON GROWTH-HORMONE
SECRETION INDUCED BY MONOAMINE-RECEPTOR AGONISTS IN
RESERPINE PRETREATED RATS.
002664 03-03
MONOAMINE-RECEPTORS
INTERACTIONS OF OXYPERTINE WITH RAT-BRAIN MONOAMINE-
RECEPTORS.
000212 01-03
MONOAMINERGIC
TRANYLCYPROMINE STEREOISOMERS, MONOAMINERGIC
NEUROTRANSMISSION AND BEHAVIOR. A MINIREVIEW.
000016 01-02
MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS:
MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN.
000068 01-03
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL MONOAMINERGIC MECHANISMS.
001240 02-03
NEUROPEPTIDES AND MONOAMINERGIC NEUROTRANSMIHERS: THEIR
RELATION TO PAIN.
001497 02-03
DIFFERENTIAL-EFFECTS OF PHARMACOLOGICAL-AGENTS ACTING ON
MONOAMINERGIC SYSTEMS ON DRUG-INDUCED ANOREXIA.
002533 02-17
ROLE OF MONOAMINERGIC SYSTEMS IN MORPHINE-INDUCED
RESPIRATORY DEPRESSION.
002827 03-03
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED
REFLEXES IN RATS.
003100 03-04
THE EFFEQ OF PHARMACOLOGICAL DESTRUCTION OF HYPOTHALAMIC
MONOAMINERGIC STRUCTURES ON BODY-TEMPERATURE AND GAS-
EXCHANGE DURING EXTREME COOLING.
004016 04-03
MONOAMINERGIC-INTERACTION
ON MONOAMINERGIC-INTERACTION WITH BEHAVIOUR MODIFYING
PEPTIDE-HORMONES.
004700 04-17
MONOAMINERGIC-RECEPTOR
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT,
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL- 1 H-INDAZOLE (FS-32)
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
MONOAMINES
RELATION BETWEEN THE EFFECTS OF ANTIDEPRESSANT-DRUGS ON THE
UPTAKE OF MONOAMINES AND ON THE SPONTANEOUS ACTIVITY OF
CENTRAL NEURONS.
000267 01-03
RELATIONSHIP BETWEEN DELTA9 TETRAHYDROCANNABINOL-INDUCED
MOUSE-KILLING-BEHAVIOR ON THE RAT AND THE METABOLISM OF
MONOAMINES IN THE BRAIN, PARTICULARLY THE OLFACTORY-BULB.
000472 01-04
MONOAMINES AND DEPRESSION: AN INTERIM REPORT. I. SEROTONIN
AND SEROTONIN PRECURSORS.
000996 01-17
OPIOID MECHANISMS IN REGUUTION OF CEREBRAL MONOAMINES IN
VIVO.
001098 02-03
m
;iur
I
S-285
Subject Index
Psychopharmacology Abstracts
liii;
Willi
'«!..
Si:'
ik
h
*H»
EFFECT OF LITHIUM ON STRESS-INDUCED CHANGES IN THE BRAIN LEVELS
OF MONOAMINES IN RATS.
001216 02-03
EFFEQS OF RAPHE-MAGNUS AND RAPHE-PALLIDUS LESIONS ON
MORPHINE-INDUCED ANALGESIA AND SPINAL-CORD MONOAMINES.
001420 02-03
EFFEQS OF 1,3 BIS-TETRAHYDRO-2-FURANYL-5-
FLUOROPYRIMIDINEDIONE (FD-1) ON THE CENTRAL-NERVOUS-SYSTEM;
1 . EFFEaS OF MONOAMINES IN THE BRAIN.
001857 02-05
MONOAMINES, EPILEPSY AND SCHIZOPHRENIA.
002183 02-11
EFFECTS OF 4 AMINOPYRIDINE ON THE TURNOVER OF MONOAMINES IN
THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.
002658 03-03
THE EFFECT OF MONOAMINES ON MOTONEURONS OF THE ISOLATED RAT
SPINAL-CORD.
002790 03-03
ULTRASTRUCTURAL LOCALIZATION OF MONOAMINES IN NERVE FIBERS
OF THE PINEAL-GLAND IN GOLDEN HAMSTERS.
003666 04-01
PROPERTIES OF THE OPTICAL-ISOMERS AND METABOLITES OF KETAMINE
ON THE HIGH-AFFINITY TRANSPORT AND CATABOLISM OF
MONOAMINES.
004009 04-03
EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON TETRABENAZINE-INDUCED
DEPLETION OF BRAIN MONOAMINES IN RATS. 1. NOREPINEPHRINE.
004062 04-03
EFFECTS OF LITHIUM ON BEHAVIOUR AND CENTRAL MONOAMINES.
004110 04-04
MONOCLONAL
ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT
CELL TYPE SPECIFIC TOXIN. (UNPUBLISHED PAPER).
001064 02-01
MONOCULAR
CORTICAL RECOVERY FROM EFFECTS OF MONOCULAR DEPRIVATION:
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6
HYDROXYDOPAMINE.
003024 03-04
MONOFLUORINATED
INTERACTIONS BETWEEN A MONOFLUORINATED ANALOGUE OF P
CHLOROAMPHETAMINE AND 5 HYDROXYTRYPTAMINE IN BRAIN.
003719 04-03
MONOFLUOROACETATE
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM-
ACETATE, MONOFLUOROACETATE AND INSULIN-INDUCED
HYPOGLYCEMIA.
004276 04-05
MONOFLUOROMETHYLDOPA
FURTHER STUDIES ON THE INHIBITION OF MONOAMINE SYNTHESIS BY
MONOFLUOROMETHYLDOPA.
001128 02-03
MONOMETHYLHYDRAZINE
RELATION OF MONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION
IN CATS.
000474 01-04
MONOOXYGENATED
PLASMA AND BRAIN LEVELS OF DELTA6 THC AND SEVEN
MONOOXYGENATED METABOLITES CORRELATED TO THE CATALEPTIC-
EFFECT IN THE MOUSE.
001737 02-04
MONOSODIUM-GLUTAMATE
MONOSODIUM-GLUTAMATE; INCREASED NEUROTOXICITY ARER
REMOVAL OF NEURONAL REUPTAKE SITES.
003889 04-03
MONOSUBSTANCE
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A
MONOSUBSTANCE (DOXEPINE).
002028 02-09
MONOSYNAPTIC
NONSEROTONERGIC DEPRESSION OF SPINAL MONOSYNAPTIC REFLEX
TRANSMISSION BY 5 HYDROXYTRYPTOPHAN.
002745 03-03
CANNABINOID-INDUCED ENHANCEMENT AND DEPRESSION OF CAT
MONOSYNAPTIC REFLEXES.
004040 04-03
MONOTHERAPY
ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT
AND POSHREATMENT OF ALCOHOLIC WITHDRAWAL.
002140 02-1 1
MONOTHERAPY OR POLYTHERAPY FOR EPILEPSY?
003366 03-11
MOOD
THE INFLUENCE OF LITHIUM-CARBONATE ON MOOD AND PERFORMANCE
IN HEALTHY SUBJEQS.
000711 01-11
THE EFFEQ OF SMALL AND MODERATE DOSES OF D-AMPHET AMINE ON
HUNGER, MOOD, AND AROUSAL IN MAN.
000807 01-14
PHARMACOPSYCHOLOGICAL INVESTIGATION OF CHANGES IN MOOD
INDUCED BY DIPOTASSIUM-CHLORAZEPATE WITH AND WITHOUT
SIMULTANEOUS ALCOHOL ADMINISTRATION.
000825 01-14
THE RELATIONSHIP OF ALPHA AND DELTA EEG FREQUENCIES TO PAIN
AND MOOD IN FIBROSITIS-PATIENTS TREATED WITH CHLORPROMAZINE
AND L TRYPTOPHAN.
002152 02-11
MOOD AND BEHAVIORAL-EFFEQS OF PHYSOSTIGMINE ON HUMANS ARE
ACCOMPANIED BY ELEVATIONS IN PLASMA BETA ENDORPHIN AND
CORTISOL.
002280 02-13
DRUG PREFERENCE AND MOOD IN HUMANS: DIAZEPAM.
002334 02-14
DRUG PREFERENCE AND MOOD IN HUMANS: D-AMPHET AMINE.
002335 02-14
THE EFFEQ OF DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, ON SLEEP AND MOOD IN MAN.
002365 02-14
CORRELATED STUDY OF THE EFFEQS OF SE-5023 IN AN HYPOXIC
ATMOSPHERE ON QUANTIFIED EEG, VIGILANCE, MEMORY, AND
MOOD.
003440 03-14
DRUG PREFERENCE AND MOOD IN HUMANS: REPEATED ASSESSMENT OF
D-AMPHET AMINE.
003445 03-14
EFFEQS OF DEXTROAMPHETAMINE-SULFATE ON REPEATED ACQUISITION-
BEHAVIOR AND MOOD IN HUMANS: A PRELIMINARY REPORT.
003459 03-14
ON THE RELATIONSHIP BETWEEN MEASURES OBTAINED BY VIDEO-
ANALYSIS OF NONVERBAL-BEHAVIOR AND SELF-RATING OF MOOD.
004410 04-09
THE EFFEQ OF FIVE TRICYCLIC-ANTIDEPRESSANTS ON SALIVARY FLOW
AND MOOD IN HEALTHY VOLUNTEERS.
004560 04-14
MOOD-DISORDER
EFFICACY OF LITHIUM IN TREATING MOOD-DISORDER OCCURRING ARER
BRAINSTEM INJURY.
003354 03-11
MOOD-DISORDERS
CHRONIC MOOD-DISORDERS IN DEPRESSED-OUTPATIENTS: DIAGNOSIS
AND RESPONSE TO PHARMACOTHERAPY.
000624 01-09
THE PLACE OF SURVEQOR AMONG THE VARIOUS DRUGS USED IN
TREATMENT OF MOOD-DISORDERS.
001969 02-09
MOOD-SWING-PATTERNS
ANTIDEPRESSIVE TREATMENT AND MOOD-SWING-PAHERNS IN
ENDOGENOUS DEPRESSION.
000633 01-09
MORAVIAN
RESULTS OF TREATMENT BY MODITEN DEPOT IN OUTPATIENTS-WARDS IN
THE SOUTH MORAVIAN REGION.
004648 04-15
MORBIDITY
PSYCHIATRIC MORBIDITY AND PHYSICAL TOXICITY ASSOCIATED WITH
ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY.
002433 02-15
MORPHICEPTIN
MORPHICEPTIN (NH4-TYR-PR0-PHE-PR0-C0NH2): A POTENT AND
SPECIFIC AGONIST FOR MORPHINE MU-RECEPTORS.
003746 04-03
MORPHINANS
EFFECT OF THE POSITION OF THE PHENOLIC GROUP IN MORPHINANS ON
THEIR AFFINITY FOR OPIATE-RECEPTOR BINDING.
003702 04-02
MORPHINE
ENKEPHALIN LEVELS DECREASE IN RAT STRIATUM DURING MORPHINE
ABSTINENCE.
000027 01-03
THE EFFECTS OF MORPHINE ON THE ACTIVITY OF CERTAIN DORSAL-HORN
NEURONS OF THE SPINAL-CORD INVOLVED IN NOCICEPTIVE PROCESSES.
000028 01-03
MORPHINE EXERTS TESTOSTERONE-LIKE EFFECTS IN THE HYPOTHALAMUS
OF THE CASTRATED MALE RAT.
000051 01-03
SUPPRESSION OF EVOKED AND SPONTANEOUS RELEASE OF
NEUROTRANSMITTERS IN VIVO BY MORPHINE.
000058 01-03
REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS.
000066 01-03
MORPHINE ACTS THROUGH ALPHA-ADRENERGIC AND SEROTONINERGIC
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG
000088 01-03
EFFECT OF ACUTE ADMINISTRATION OF MORPHINE ON NEWLY
SYNTHESIZED 5 HYDROXYTRYPTAMINE IN SPINAL-CORD OF THE RAT.
00011001-03
S-286
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECT OF MORPHINE ON CALCIUM UPTAKE BY LYSED SYNAPTOSOMES.
000117 01-03
EFFECTS OF MORPHINE AND OTHER CENTRALLY-ACTING DRUGS ON 3,4
DIHYDROXYPHENYLETHYLENE-GLYCOL-SULFATE (D0PEG-S04) IN RAT-
BRAIN.
000136 01-03
REDUCTION OF FETAL RAT SPINAL-CORD VOLUME FOLLOWING
MATERNAL MORPHINE INJECTION.
000161 01-03
THE RELATIONSHIP BETWEEN MORPHINE, ASPARTIC-ACID AND L
ASPARAGINASE IN RATS.
000169 01-03
DOES SYSTEMIC MORPHINE INCREASE DESCENDING INHIBITORY
CONTROLS OF DORSAL-HORN NEURONES INVOLVED IN NOCICEPTION?
000175 01-03
EVIDENCE FOR A DIRECT INHIBITORY-EFFECT OF MORPHINE ON THE
SECRETION OF POSTERIOR PITUITARY-HORMONES
000193 01-03
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE
ACTION.
000229 01-03
THE EFFEQ OF MORPHINE ON PURINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: EVIDENCE FOR A PURINERGIC
COMPONENT IN MORPHINES AQION.
000234 01-03
REDUCTION OF VOLUNTARY MORPHINE CONSUMPTION FOLLOWING
TREATMENT WITH ZIMELIDINE.
000253 01-03
EFFECTS OF MORPHINE AND NALOXONE ON PHASIC RELEASE OF
LUTEINIZING-HORMONE AND FOLLICLE-STIMULATING-HORMONE
(40849).
000298 01-03
EFFEQS OF L AND D AMINO-ACIDS ON ANALGESIA AND LOCOMOTOR-
AaiVITY OF MICE: THEIR INTERACTION WITH MORPHINE.
000336 01-04
MORPHINE EFFEQS UPON DISCRIMINATED APPROACH AND
DISCRIMINATED AVOIDANCE IN RATS: ANTAGONISM BY NALOXONE.
000338 01-04
LETHAL SELF-ADMINISTRATION OF MORPHINE BY RATS.
000343 01-04
ADDiaiVE-AGENTS AND INTRACRANIAL-STIMULATION (ICS): MORPHINE
NALOXONE, AND PRESSING FOR AMYGDALOID ICS.
000371 01-04
MORPHINE VERSUS HALOPERIDOL CATALEPSY IN THE RAT: A
BEHAVIORAL-ANALYSIS OF POSTURAL SUPPORT MECHANISMS.
000376 01-04
MORPHINE INJEQIONS INTO THE PERIAQUEDUCTAL PERIVENTRICULAR
GRAY ATTENUATE SEPTAL HYPERREAQIVITY.
000390 01-04
CHANGES IN BRAIN N DEMETHYLATION AND OPIATE-RECEPTOR CONTENT
CORRELATE WITH ANALGESIC EFFECTIVENESS OF MORPHINE.
000400 01-04
ANTINOCICEPTIVE-EFFECT OF MORPHINE, OPIOID ANALGESICS AND
HALOPERIDOL INJEQED INTO THE CAUDATE-NUCLEUS OF THE RAT.
000414 01-04
EFFECTS OF MORPHINE, BETA ENDORPHIN AND NALOXONE ON
CATECHOLAMINE LEVELS AND SEXUAL-BEHAVIOR IN THE MALE RAT
000430 01-04
FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK
TERMINATION: EFFECTS OF D-AMPHET AMINE, MORPHINE, AND
CLOZAPINE.
000431 01-04
ANTINOCICEPTIVE COMPARISON OF QUIPAZINE AND MORPHINE.
000435 01-04
POSSIBLE MECHANISM FOR THE ENHANCED LETHALITY OF MORPHINE IN
AGGREGATED MICE.
000437 01-04
MORPHINE ENHANCES ADENOSINE RELEASE FROM THE IN VIVO RAT-
CEREBRAL-CORTEX.
000451 01-04
REWARDING AND AVERSIVE-EFFEQS OF MORPHINE: TEMPORAL AND
PHARMACOLOGICAL-PROPERTIES.
000470 01-04
EFFEQ OF MORPHINE IN COMBINATION WITH CHLORPROMAZINE AND
HALOPERIDOL ON OPERANT-BEHAVIOR.
000486 01-04
PROCONVULSANT AND ANTICONVULSANT AQION OF MORPHINE IN
RATS.
000494 01-04
DOSE AND PHYSICAL-DEPENDENCE AS FACTORS IN THE SELF-
ADMINISTRATION OF MORPHINE BY RATS.
000497 01-04
MORPHINE TREATMENT AT DIFFERENT INFANT AGES: INFLUENCE ON
LATER MORPHINE EFFEQS IN RATS. (PH.D. DISSERTATION).
00051101-05
THE ANALGESIC AND RESPIRATORY EFFEQS OF MEPTAZINOL, MORPHINE
AND PENTAZOCINE IN THE RAT.
000516 01-05
ACUTE AND CHRONIC EFFECTS OF MORPHINE ON TRANSMEMBRANE
POTENTIAL AND ON SHORT-CIRCUIT CURRENT IN ISOLATED TOAD
SKIN: APPARENT MORPHINE-DEPENDENCE.
001176 02-03
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES:
EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION
IN THE ANESTHETIZED CAT.
001203 02-03
SUBSTANCE-P, MORPHINE AND METHIONINE-ENKEPHALIN: EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE NUCLEUS-
RETICULARIS-GIGANTOCELLULARIS OF THE RAT.
001267 02-03
INFLUENCE OF MORPHINE ON MEMBRANE TURNOVER AND FUNCTION
001280 02-03
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 02-03
INTERACTIONS BETWEEN MORPHINE AND THE OPIOID-LIKE PEPTIDES IN
THE RAT VAS-DEFERENS.
001290 02-03
INHIBITORY ACTION OF MORPHINE ON THE RELEASE OF A BRADYKININ-
LIKE SUBSTANCE AFTER SCIATIC-NERVE STIMULATION.
001293 02-03
MORPHINE AND ELECTROACUPUNCTURE: COMPARISON OF THE EFFEQS
ON THE CORTICAL EVOKED-RESPONSES AFTER TOOTH-PULP
STIMULATION IN RATS.
001294 02-03
THE EFFECT OF MORPHINE ON THE CONTENT OF SEROTONIN, 5
HYDROXYINDOLEACETIC-ACID AND SUBSTANCE-P IN THE NUCLEI
RAPHE-MAGNUS AND RETICULARIS-GIGANTOCELLULARIS.
001328 02-03
AGE-RELATED CHANGES IN BODY-TEMPERATURE RESPONSES TO
MORPHINE IN RATS.
001366 02-03
EFFECTS OF MORPHINE ON EVOKED-POTENTIALS RECORDED FROM THE
AMYGDALA BY TOOTH-PULP STIMULATION IN CATS.
001379 02-03
SUPPRESSIVE EFFECT OF MORPHINE ON SERUM GONADOTROPIN LEVELS
IN CASTRATED RATS.
001393 02-03
ALTERED LEVELS OF BETA ENDORPHIN FRAGMENTS AFTER CHRONIC
MORPHINE TREATMENT OF GUINEA-PIG ILEUM IN VITRO AND IN VIVO
001404 02-03
MORPHINE ANALGESIA FOLLOWING ITS INFUSION INTO DIFFERENT
LIQUOR SPACES IN RAT-BRAIN.
001429 02-03
EFFEQS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN
COMBINATION WITH NALOXONE ON ELECTRIC-SHOCK TITRATION IN
THE SQUIRREL-MONKEY.
001611 02-04
EFFECTS OF MORPHINE WITHDRAWAL ON FOOD COMPETITION
HIERARCHIES AND FIGHTING-BEHAVIOR IN RATS.
001632 02-04
EFFECTS OF MORPHINE, D-AMPHETAMINE, AND PENTOBARBITAL ON
SHOCK AND LIGHT DISCRIMINATION PERFORMANCE IN RATS.
001639 02-04
AN ANALYSIS OF SOME PERCEPTUAL-EFFEQS OF MORPHINE,
CHLORPROMAZINE, AND LSD.
001652 02-04
CONTRAUTERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL
INJECTION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN
RATS.
001669 02-04
ANALGESIC ACTION OF INTRATHECAL AND INTRACEREBRAL BETA
ENDORPHIN IN RATS: COMPARISON WITH MORPHINE.
001691 02-04
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST,
CHLORNALTREXAMINE.
001695 02-04
OPIATE AND PEPTIDE INTERAQION: EFFECT OF ENKEPHALINS ON
MORPHINE ANALGESIA.
001698 02-04
THE EFFECT OF MORPHINE, PIMOZIDE AND NALOXONE ON
DISCRIMINATION BY RATS IN A SHOCK-ESCAPE-TEST
001700 02-04
INTERACTION OF PROSTAGLANDINS AND THE EFFECTS OF MORPHINE AND
AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
001732 02-04
BRIEF SOCIAL-ISOLATION, PAIN RESPONSIVITY, AND MORPHINE
ANALGESIA IN YOUNG RATS.
001744 02-04
DIFFERENTIAL-EFFECTS OF MORPHINE ON FOOD AND WATER INTAKE IN
FOOD DEPRIVED AND FREELY-FEEDING RATS.
001765 02-04
m
;ir
S-287
Subject Index
Psychophormacology Abstracts
HI 1 11
Kim
■aim
*lll|;:l;
"lilll:;;
EFFECTS OF CHLORDIAZEPOXIDE MORPHINE COMBINATIONS ON
SPONTANEOUS LOCOMOTOR-ACTIVITY IN THREE INBRED STRAINS OF
MICE.
001766 02-04
A COMPARISON BETWEEN THE EFFECTS OF MORPHINE ON THE
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC
AND CENTRAL GRAY STIMULATION
001771 02-04
ON THE USE OF OPERANT-BEHAVIOR TO STUDY THE
NEUROPSYCHOPHARMACOLOGY OF OPIATES WITH SPECIAL REFERENCE
TO MORPHINE AND ITS RELATIONSHIP TO DOPAMINE IN THE CENTRAL-
NERVOUS-SYSTEM.
001790 02-04
BIPHASIC-EFFECTS OF A POTENT ENKEPHALIN ANALOGUE D MET2-PR05-
ENKEPHALINAMIDE AND MORPHINE ON LOCOMOTOR-ACTIVITY IN
MICE.
001799 02-04
THE EFFECT OF ASPIRIN AND PARACETAMOL ON THE INCREASED
NALOXONE POTENCY INDUCED BY MORPHINE PRETREATMENT
001824 02-04
INTRATHECAL MORPHINE IN MICE: A NEW TECHNIQUE.
001868 02-06
THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON
GABA-RECEPTOR BINDING
002301 02-13
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS
002700 03-03
A COMPARISON OF THE NEUROCHEMICAL-EFFECTS OF BUPRENORPHINE
WITH THOSE OF MORPHINE AND HALOPERIDOL IN RATS
002701 05-03
TEMPORAL AND ENVIRONMENTAL CUES IN CONDITIONED HYPOTHERMIA
AND HYPERTHERMIA ASSOCIATED WITH MORPHINE
002709 03-03
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPACTA AND
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE
SPONTANEOUS NEURONAL ACTIVITIES IN THE RAT.
002718 03-03
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE
AND CROSS-TOLERANCE TO THE INHIBITORY ACTION OF BETA
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS
002756 03-03
COMPARATIVE-STUDY ON THE EFFECT OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS: STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS.
002757 03-03
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED
MICE.
002800 03-03
REDUCED TOLERANCE TO MORPHINE THERMOREGUIATORY-EFFECTS IN
SENESCENT RATS.
002822 03-03
ANTINOCICEPTIVE ACTION OF MORPHINE AND PENTAZOCINE ON UNIT
ACTIVITY IN THE NUCLEUS-CENTRALIS-LATERALIS, NUCLEUS-
VENTRALIS-LATERALIS AND NEARBY STRUCTURES OF THE CAT.
002837 03-03
MORPHINE WITHDRAWAL CAUSES SUBSENSITIVITY OF ADRENERGIC-
RECEPTOR RESPONSE.
002838 03-03
INTERACTION BETWEEN THE EFFEaS OF STRESS AND MORPHINE ON
BODY-TEMPERATURE IN RATS.
002906 03-03
EFFECTS OF MORPHINE AND NALORPHINE ON KAINIC-ACID-INDUCED
HYPOTHERMIA IN RATS.
002921 03-03
ANALGESIC TOLERANCE PRODUCED BY MORPHINE PELLETS IS
FACILITATED BY ANALGESIC TESTING.
002943 03-04
ENVIRONMENTAL MODULATION OF ANALGESIC TOLERANCE INDUCED BY
MORPHINE PELLETS.
002944 03-04
INTRACRANIAL SELF-ADMINISTRATION OF MORPHINE INTO THE VENTRAL
TEGMENTAL AREA IN RATS.
002960 03-04
EFFECTS OF MORPHINE AND CHLORDIAZEPOXIDE ON AVOIDANCE-
BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
002973 03-04
DOSE-RESPONSE STUDY OF THE PRECIPITATED ABSTINENCE-SYNDROME
FOR MORPHINE: SYSTEMIC VS PERIAQUEDUCTAL GRAY NALOXONE.
(PH.D. DISSERTATION),
002979 03-04
EXPLORATION AND MOTOR-ACTIVITY AFTER INTRAVENTRICULAR AQH,
MORPHINE AND NALOXONE.
002991 03-04
DYNORPHIN: A POSSIBLE MODULATORY PEPTIDE ON MORPHINE OR BETA
ENDORPHIN ANALGESIA IN MOUSE.
002994 03-04
INFLUENCE OF MORPHINE ON THE DISCRIMINATIVE-STIMULUS
PROPERTIES OF REWARDING LATERAL HYPOTHALAMIC STIMULATION.
(PH.D. DISSERTATION).
003041 03-04
DISCRIMINATIVE RESPONSE CONTROL BY NALOXONE IN MORPHINE
PRETREATED RATS.
003053 03-04
D PROPOXYPHENE ACTS DIFFERENTLY FROM MORPHINE ON OPIOID-
RECEPTOR EFFECTOR MECHANISMS.
003062 03-04
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDICT RATS: A POSSIBLE MODEL FOR PREDICTING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION).
003097 03-04
INTERACTIONS OF DIAZEPAM AND COCAINE IN THE MORPHINE TREATED
RAT. (PH.D. DISSERTATION).
003115 03-04
DIFFERENCE IN THE DEVELOPMENT OF TOLERANCE TO MORPHINE AND D
ALA2-METHI0NINE-ENKEPHALIN IN C57 BL/6J AND DBA/2J MICE.
003126 03-05
THE USE OF A MORPHINE ANTAGONIST (NALOXONE) IN THE TREATMENT
OF DISSOCIATIVE-SYNDROMES
003194 03-08
METHADONE AND MORPHINE IN DEPRESSION.
003220 03-09
EFFECTS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETECT THE NARCOTIC CHARACTER OF A DRUG
003555 03-16
COMPARATIVE ANALGESIC, BEHAVIORAL, AND DEPENDENCE PROPERTIES
OF MORPHINE AND 0
METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME
HCL.
003707 04-02
EFFECT OF CHRONIC MORPHINE TREATMENT ON THE INTERAQION
BETWEEN THE PERIAQUEDUCTAL GREY AND THE NUCLEUS-RAPHE-
MAGNUS OF THE RAT.
003727 04-03
MORPHICEPTIN (NH4-TYR-PR0-PHE-PR0-C0NH2): A POTENT AND
SPECIFIC AGONIST FOR MORPHINE MU-RECEPTORS
003746 04-03
DIFFERENTIAL TOLERANCE TO THE EFFECTS OF MORPHINE ON EVOKED
ACTIVITY IN THE HIPPOCAMPAL SLICE
003760 04-03
MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION.
003782 04-03
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM
INTERMEDIATE/POSTERIOR LOBES OF PITUITARY.
003846 04-03
MORPHINE AND METHIONINE-ENKEPHALIN: DIFFERENT EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE
MESENCEPHALIC RETICULAR FORMATION OF THE RAT,
003849 04-03
AQION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
EFFECTS OF MORPHINE AND CAFFEINE ON ADENOSINE RELEASE FROM
RAT-CEREBRAL-CORTEX: IS CAFFEINE A MORPHINE ANTAGONIST.
003864 04-03
EFFECT OF MORPHINE AND NALOXONE ON LEU-ENKEPHALIN-LIKE
IMMUNOREACTIVITY IN DOGS.
003894 04-03
THE BEHAVIORAL-EFFEQS OF D-AMPHET AMINE ALONE AND IN
COMBINATION WITH ACUTE AND CHRONIC MORPHINE TREATMENTS IN
RATS
003915 04-03
EFFECTS OF ENKEPHALIN, MORPHINE, AND NALOXONE ON THE
ELECTRICAL-AQIVITY OF THE IN VITRO HIPPOCAMPAL SLICE
PREPARATION.
003918 04-03
THE DOPAMINE-RECEPTOR COMPLEX: BIOCHEMICAL-CONSEQUENCES OF
SUPERSENSITIVITY INDUCED BY TREATMENT WITH 6
HYDROXYDOPAMINE OR MORPHINE.
003958 04-03
ELEaROENCEPHALOGRAPHIC AND BEHAVIORAL-TOLERANCE TO AND
CROSS-TOLERANCE BETWEEN D ALA2-METHI0NINE-ENKEPHALINAMIDE
AND MORPHINE IN THE RAT.
004038 04-03
THE EFFEQS OF PEPTIDES ON TOLERANCE TO THE CATALEPTIC-EFFEaS
AND HYPOTHERMIC-EFFECTS OF MORPHINE IN THE RAT.
004072 04-04
S-288
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF PAIN, MORPHINE AND NALOXONE ON THE DURATION OF
ANIMAL HYPNOSIS
004081 04-04
CHOICE BETWEEN FOOD AND HEROIN: EFFECTS OF MORPHINE,
NALOXONE, AND SECOBARBITAL.
004123 04-04
A SIGNAL-DETECTION-ANALYSIS OF MORPHINE EFFECTS ON THE
RESPONSE BIAS OF RATS IN A TWO-SHOCK DISCRIMINATION TASK.
004124 04-04
EFFECTS OF LEVO ALPHA ACETYLMETHADOL (LAAM) ON MORPHINE SELF-
ADMINISTRATION IN THE RAT.
004170 04-04
EVIDENCE FOR SEDATIVE EFFECTS OF LOW-DOSES OF MORPHINE IN MICE
INVOLVING RECEPTORS INSENSITIVE TO NALOXONE.
004173 04-04
COMPARISON OF THE EFFECTS OF BETA ENDORPHIN AND MORPHINE ON
EXPLORATORY-BEHAVIOUR AND SOCIOSEXUAL-BEHAVIOUR IN THE
MALE RAT.
004178 04-04
MORPHINE DIFFERENTIALLY AFFECTS VENTRAL TEGMENTAL AND
SUBSTANTIA-NIGRA BRAIN REWARD THRESHOLDS.
004187 04-04
MORPHINE ANTAGONISTS AND CONSUMMATORY-BEHAVIORS.
004196 04-04
OPIATE-DEPENDENCE FOLLOWING ACUTE INJECTIONS OF MORPHINE AND
NALOXONE: THE ASSESSMENT OF VARIOUS WITHDRAWAL SIGNS.
004209 04-04
ANTAGONISM BY PHENOXYBENZAMINE AND PENTAZOCINE OF THE
ANTINOCICEPTIVE-EFFECTS OF MORPHINE IN THE SPINAL-CORD.
004213 04-04
PHARMACOLOGICAL-ASPECTS OF SHAKING-BEHAVIOR PRODUCED BY
TRH, AG-3-5, AND MORPHINE WITHDRAWAL.
004248 04-04
INTRATHECAL HIGH-DOSE MORPHINE PRODUCES HYPERALGESIA IN THE
RAT.
004254 04-04
EATING-BEHAVIOR REVEALS RATS PREFERENCE FOR MORPHINE.
004257 04-04
ORAL SELF-ADMINISTRATION OF MORPHINE IN RATS.
004258 04-04
MORPHINE CHALLENGES IN LEVO ALPHA ACETYLMETHADOL (LAAM)
POSTADDICT RATS.
004259 04-04
THE EFFECTS OF NEFOPAM ON BLOOD ACID BASE STATUS IN THE RABBIT-
INTERACTIONS WITH MORPHINE IN THE MOUSE AND RABBIT
004279 04-05
SUPPRESSION OF MORPHINE ABSTINENCE IN HEROIN ADDICTS BY BETA
ENDORPHIN.
004489 04-11
EVENT-RELATED POTENTIAL CHANGES WITH MORPHINE IN NONADDICTED
HUMANS.
004512 04-13
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY'
^ , 004553 04-13
GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA
DERIVATIZATION TECHNIQUES.
004687 04-16
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD
BY USE OF SELEQ ION-MONITORING AND DEUTERATED INTERNAL
STANDARDS.
004690 04-16
COMPARISON OF SPECTROFLUOROMETRIC AND GAS-
CHROMATOGRAPHY/MASS-SPECTROMETRY PROCEDURES FOR THE
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN
004692 04-16
MORPHINE-DEPENDENCE
ACUTE AND CHRONIC EFFEQS OF MORPHINE ON TRANSMEMBRANE
POTENTIAL AND ON SHORT-CIRCUIT CURRENT IN ISOLATED TOAD
SKIN: APPARENT MORPHINE-DEPENDENCE.
001176 02-03
MORPHINE-DEPENDENCE AND DOPAMINERGIC-ACTIVITY- TESTS OF
CIRCLING RESPONSES IN RATS WITH UNILATERAL NIGRAL LESIONS
001641 02-04
CHANGES OF PHYSICAL MORPHINE-DEPENDENCE IN RATS CHRONICALLY
TREATED WITH DRUGS ACTING ON BRAIN 5 HYDROXYTRYPTAMINE
001764 02-04
CYCLIC-AMP-INDUCED CHANGES IN THE ELECTROENCEPHALOGRAM AND
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN
THE RAT.
003078 03-04
MORPHINE-DEPENDENT
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS
000258 01-03
SCHEDULE-CONTROLLED BEHAVIOR IN THE MORPHINE-DEPENDENT AND
POSTDEPENDENT RAT.
000349 01-04
DISCRIMINATIVE-STIMULUS EFFECTS OF NALTREXONE IN THE MORPHINE-
DEPENDENT RAT
000391 01-04
AN ELECTROMYOGRAPHIC-METHOD FOR THE ASSESSMENT OF
NALOXONE-INDUCED ABSTINENCE IN MORPHINE-DEPENDENT RATS
000433 01-04
SEXUAL-BEHAVIOUR OF MORPHINE-DEPENDENT AND ABSTINENT MALE
RATS.
000438 01-04
NORADRENALINE RELEASE FROM SLICES OF THE THALAMUS OF NORMAL
AND MORPHINE-DEPENDENT RATS.
001142 02-03
CHARACTERISTICS OF OSCILLATORY CONTRACTIONS ELICITED BY
NALOXONE IN ILEUM PREPARATION FROM MORPHINE-DEPENDENT
GUINEA-PIGS.
001491 02-03
INCREASE IN PLASMA CYCLIC-AMP LEVELS ELICITED BY NALOXONE IN
MORPHINE-DEPENDENT MALE MICE,
002834 03-03
LOCOMOTOR-ACTIVITY IN MORPHINE-DEPENDENT AND POSTDEPENDENT
RATS.
004077 04-04
MORPHINE-INDUCED
REVERSIBLE INACTIVATION OF RAPHE-MAGNUS NEURONS: EFFECTS ON
NOCICEPTIVE THRESHOLD AND MORPHINE-INDUCED ANALGESIA
000240 01-03
THE POSSIBILITY THAT A COMPONENT OF MORPHINE-INDUCED
ANALGESIA IS CONTRIBUTED INDIRECTLY VIA THE RELEASE OF
ENDOGENOUS OPIOIDS.
000263 01-03
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFECTS OF
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS
ON MORPHINE-INDUCED ANALGESIA.
000311 01-03
EFFECTS OF RAPHE-MAGNUS AND RAPHE-PALLIDUS LESIONS ON
MORPHINE-INDUCED ANALGESIA AND SPINAL-CORD MONOAMINES
001420 02-03
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND
TOLERANT RATS AND MICE.
001476 02-03
EFFECT OF SELECTIVE DESTRUCTION OF SEROTONERGIC NEUROWS IN
NUCLEUS-RAPHE-MAGNUS ON MORPHINE-INDUCED ANTINOCICEPTION
001724 02-04
EFFECT OF APOMORPHINE ON MORPHINE-INDUCED DECREASE IN
LOCOMOTOR-ACTIVITY AND INCREASE IN DOPAMINE TURNOVER IN
RATS.
001728 02-04
ACTH POTENTIATES MORPHINE-INDUCED CONDITIONED TASTE-AVERSION
001781 02-04
THE EFFECTS OF INTRAVENTRICULAR 6 HYDROXYDOPAMINE AND 5 6
DIHYDROXYTRYPTAMINE ON MORPHINE-INDUCED LOCOMOTOR-
STIMULATION.
001784 02-04
EPIDURAL MORPHINE-INDUCED CATATONIA.
002400 02-15
ROLE OF MONOAMINERGIC SYSTEMS IN MORPHINE-INDUCED
RESPIRATORY DEPRESSION,
002827 03-03
CONDITIONED DRUG-EFFECTS OF D-AMPHETAMINE-INDUCED AND
MORPHINE-INDUCED MOTOR ACCELERATION IN MICE: EXPERIMENTAL
APPROACH FOR PLACEBO-EFFECT.
004128 04-04
POTENTIATION OF THE MORPHINE-INDUCED RESPIRATORY RATE
DEPRESSION BY CAPTOPRIL.
004275 04-05
MORPHINE-LIKE
ON THE MECHANISM-OF-ACTION OF 2 AMINO-4-METHYLPYRIDINE A
MORPHINE-LIKE ANALGESIC.
001574 02-04
MORPHINE-LIKE STIMULUS EFFECTS IN THE MONKEY: OPIOIDS WITH
ANTAGONIST PROPERTIES.
003086 03-04
MORPHINE-SULPHATE
A COMPARISON OF THE EFFECTS OF MORPHINE-SULPHATE AND NITROUS-
OXIDE ANALGESIA ON CHRONIC PAIN STATES IN MAN.
003442 03-14
MORPHINE-TOLERANCE
EFFECTS OF PAVLOVIAN-CONDITIONING AND MIF-1 ON THE
DEVELOPMENT OF MORPHINE-TOLERANCE IN RATS.
001327 02-03
DOSE SIZE AND INTERDOSE INTERVAL EFFECTS ON MORPHINE-TOLERANCE
IN THE RAT. (PH.D. DISSERTATION).
003090 03-04
MORPHINE-TOLERANT
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
BRAIN.
001234 02-03
mill
S-289
Subject Index
Psychopharmacology Abstracts
HI I SI I
MMil
Illf
"nil;:!
-iitii::;'
liiiK:;.
MORPHINES
THE EFFECT OF MORPHINE ON PURINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: EVIDENCE FOR A PURINERGIC
COMPONENT IN MORPHINES ACTION.
000234 01-03
MORPHINOMIMETICS
STEREOCHEMICAL ANATOMY OF MORPHINOMIMETICS.
002197 02-12
MORPHOGENETIC
EFFECTS OF SOME NOOTROPIC-DRUGS UPON THE EMBRYONIC
MORPHOGENETIC SYSTEMS.
000144 01-03
MORPHOLOGICAL
EFFECTS OF LITHIUM ON MORPHOLOGICAL CHARAQERISTICS OF
DISSOCIATED BRAIN CELLS IN CULTURE.
002765 03-03
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE
INJECTION IN NEWBORN ANIMALS.
002774 03-03
PATHOPHYSIOLOGICAL AND MORPHOLOGICAL CHANGES IN THE CNS
DURING LONG-TERM ADMINISTRATION OF HALOPERIDOL.
004633 04-15
MORPHOLOGICAL-STUDY
LYSERGIC-ACID-DIETHYLAMIDE: MORPHOLOGICAL-STUDY OF ITS EFFEQ
ON SYNAPSES.
001315 02-03
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND
MORPHOLOGICAL-STUDY.
001407 02-03
MOTHERING-BEHAVIOR
EFFECTS OF 6 HYDROXYDOPAMINE AND AMPHETAMINE ON RAT
MOTHERING-BEHAVIOR AND OFFSPRING DEVELOPMENT.
000452 01-04
MOTHERS
INCREASED MESOLIMBIC 3H SPIROPERIDOL BINDING IN 4 WEEK OLD
OFFSPRING OF NURSING RAT MOTHERS TREATED WITH PENFLURIDOL.
000087 01-03
THE DIFFERENTIAL DOSE-EFFECTS OF METHYLPHENIDATE ON
HYPERACTIVE-CHILDREN AND THEIR MOTHERS. (PH.D.
DISSERTATION).
002143 02-11
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS.
004658 04-15
MOTHERS-MILK
DRUG CONTENT OF THE MOTHERS-MILK.
002461 02-15
MOTILITY
PHARMACOMANOMETRIC-STUDIES OF COLONIC MOTILITY AS A GUIDE
TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001930 02-08
AMPHETAMINE-INDUCED MOTILITY AND NIGROSTRIATAL IMPULSE FLOW.
003005 03-04
EFFEaS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETEa THE NARCOTIC CHARAQER OF A DRUG.
003555 03-16
MOTIVATED
AMYGDALA OPIATE-SENSITIVE MECHANISMS INFLUENCE FEAR
MOTIVATED RESPONSES AND MEMORY PROCESSES FOR AVERSIVE-
EXPERIENCES. (UNPUBLISHED PAPER).
001628 02-04
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR
FUNaiONS RELATED TO MOTIVATED BEHAVIOR.
002815 03-03
MOTONEURONES
EXCITATORY AND INHIBITORY-AQIONS OF IBOTENIC-ACID ON FROG
SPINAL MOTONEURONES IN VITRO.
002841 03-03
MOTONEURONS
THE EFFECT OF MONOAMINES ON MOTONEURONS OF THE ISOLATED RAT
SPINAL-CORD.
002790 03-03
VOLTAGE CLAMP STUDY OF CAT SPINAL MOTONEURONS DURING
STRYCHNINE-INDUCED SEIZURES.
002886 03-03
MOTOR
PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS
MECHANISMS RESPONSIBLE FOR MOTOR AQ INHIBITION BY AVERSIVE
EVENTS.
002671 03-03
EFFEQ OF SODIUM-VALPROATE ON MOTOR FUNQION REGULATED BY
THE ACTIVATION OF GABA-RECEPTORS.
003033 03-04
CONDITIONED DRUG-EFFEQS OF D-AMPHETAMINE-INDUCED AND
MORPHINE-INDUCED MOTOR ACCELERATION IN MICE: EXPERIMENTAL
APPROACH FOR PLACEBO-EFFEQ.
004128 04-04
MOTOR-AaiVITY
EFFEaS OF DIPHENYLHYDANTOIN ON SPONTANEOUS MOTOR-AQIVITY.
000284 01-03
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-AQIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
AQIVITY.
000309 01-03
OPIATE-RECEPTORS MAY MEDIATE THE SUPPRESSIVE BUT NOT THE
EXCITATORY AQION OF AQH ON MOTOR-AQIVITY IN RATS.
000337 01-04
EFFEaS OF THIORIDAZINE ON APOMORPHINE-ELICITED STEREOTYPIC-
BEHAVIOR AND MOTOR-AQIVITY.
000424 01-04
N PENTYLAMINE: EFFEQ ON MOTOR-ACTIVITY OF MICE.
000500 01-04
MOTOR-ACTIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF
COCAINE: CORRELATION WITH DOPAMINE UPTAKE BLOCKADE.
001650 02-04
CHRONIC DELTA9 TETRAHYDROCANNABINOL IN RATS: EFFECT ON
SOCIAL-INTERACTIONS. MOUSE-KILLING, MOTOR-ACTIVITY,
CONSUMMATORY-BEHAVIOR, AND BODY-TEMPERATURE.
001722 02-04
SPONTANEOUS MOTOR-ACTIVITY IN RATS GIVEN REPEATEDLY BETA-
SYMPATHOMIMETICS ~ ISOPRENALIN AND SALBUTAMOL.
001804 02-04
EFFECT OF P CHLOROPHENYLALANINE AND TRYPTOPHAN ON SLEEP, EEG
AND MOTOR-ACTIVITY IN THE RAT.
002958 03-04
EXPLORATION AND MOTOR-ACTIVITY AFTER INTRAVENTRICULAR ACTH,
MORPHINE AND NALOXONE.
002991 03-04
THE EFFECT OF AMYGDALA KINDLING ON SPONTANEOUS AND COCAINE-
INDUCED MOTOR-ACTIVITY AND LIDOCAINE SEIZURES.
003067 03-04
MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJECTIONS OF
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS.
003101 03-04
INTRANIGRAL INJECTION OF CAPSAICIN ENHANCES MOTOR-ACTIVITY
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE BUT NOT SUBSTANCE-
P.
004100 04-04
LITHIUM AND MOTOR-ACTIVITY OF ANIMALS: EFFECTS AND POSSIBLE
MECHANISM-OF-ACTION.
004222 04-04
MOTOR-BEHAVIOR
HEROIN, BUT NOT LEVORPHANOL, PRODUCES EXPLOSIVE MOTOR-
BEHAVIOR IN NALOXONE TREATED RATS.
001579 02-04
MOTOR-CORTEX
MAPPING OF DYSKINETIC-MOVEMENTS INDUCED BY LOCAL APPLICATION
OF PICROTOXIN OR 0 GAMMA ACETYLENIC-GABA ON THE RAT
MOTOR-CORTEX.
000458 01-04
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM-
ACETATE, MONOFLUOROACETATE AND INSULIN-INDUCED
HYPOGLYCEMIA.
004276 04-05
MOTOR-DEPRESSION
MOTOR-DEPRESSION AND HEAD-TWITCHES INDUCED BY IP INJECTION OF
GABA.
001788 02-04
MOTOR-EFFEaS
MOTOR-EFFECTS OF SEROTONIN IN THE CENTRAL-NERVOUS-SYSTEM.
000941 01-17
MOTOR-LEARNING
MOTOR-LEARNING ABILITIES IN SUBJECTS TREATED WITH LITHIUM-SALTS
AND TRICYCLIC-ANTIDEPRESSANTS.
002058 02-09
MOTOR-REFLEXES
EFFECT OF CHOLINE ON CONDITIONED FOOD MOTOR-REFLEXES IN CATS
^ 001731 02-04
MOTOR-RESPONSE
GASTRIC AND PYLORIC MOTOR-RESPONSE TO SYMPATHETIC-NERVE
STIMULATION AFTER CHEMICAL SYMPATHECTOMY. (UNPUBUSHED
PAPER).
001337 02-03
MOULDS
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK
TISSUES - ARE THEY CEU ADHESION MOLECULES?
003724 04-03
MOUSE-BRAIN
THE CONVERSION OF (3H)TRYPT0PHAN TO 5 (3H)HYDR0XYTRYPTAMINE
IN MOUSE-BRAIN FOLLOWING DEPLETION OF PHENYLALANINE AND
TYROSINE.
000148 01-03
S-290
VOLUME 19, SUBJECT INDEX
Subject Index
CHANGES IN MOUSE-BRAIN 0IA2EPAM-RECEPT0R BINDING AFTER
PHENOBARBITAL ADMINISTRATION.
000281 01-03
REGULATION OF THE STATE OF PHOSPHORYLATION Of SPECIFIC
NEURONAL PROTEINS IN MOUSE-BRAIN BY IN VIVO ADMINISTRATION
Of ANESTHETIC AND CONVULSANT-AGENTS.
00029) 01-03
UPTAKE Of PIPERIDINE AND PIPECOLIC-ACID BY SYNAPTOSOMES FROM
MOUSE-BRAIN.
001396 02-03
EFFECT OF ANTINOCICEPTIVE DOSES OF OXOTREMORINE ON MOUSE-
BRAIN ACETYLCHOLINE TURNOVER-RATE.
001513 02-03
THE PHARMACOLOGICAL RELEVANCE Of THE COCAINE BINDING-SITE IN
MOUSE-BRAIN
001772 02-04
QUANTITATIVE STUDY Of THE DISTRIBUTION Of LITHIUM IN THE MOUSE-
BRAIN FOR VARIOUS DOSES OF LITHIUM GIVEN TO THE ANIMAL
002299 02-13
THE EFFECT OF PHENCYCLIDINE ON DOPAMINE METABOLISM IN THE
MOUSE-BRAIN.
002766 03-03
AMITRIPTYLINE: LONG-TERM-TREATMENT ELEVATES ALPHA-ADRENERGIC
AND MUSCARINIC-RECEPTOR BINDING IN MOUSE-BRAIN.
002875 03-03
CHARACTERIZATION OF THE ISOLATED PERFUSED MOUSE-BRAIN AS A
SYSTEM FOR NEUROCHEMICAL-STUDIES.
003146 03-06
MOUSE-KILLING
5,7 DIHYDROXYTRYPTAMINE-INDUCED MOUSE-KILLING AND
BEHAVIORAL-REVERSAL WITH VENTRICULAR ADMINISTRATION OF
SEROTONIN IN RATS.
001562 02-04
CHRONIC DELTA9 TETRAHYDROCANNABINOL IN RATS: EFFECT ON
SOCIAL-INTERACTIONS, MOUSE-KILLING, MOTOR-ACTIVITY,
CONSUMMATORY-BEHAVIOR, AND BODY-TEMPERATURE.
001722 02-04
MOUSE-KILLING-BEHAVIOR
RELATIONSHIP BETWEEN DELTA9 TETRAHYDROCANNABINOL-INDUCED
MOUSE-KILLING-BEHAVIOR ON THE RAT AND THE METABOLISM Of
MONOAMINES IN THE BRAIN, PARTICULARLY THE OLfACTORY-BULB
000472 01-04
MOUTH
TREATMENT Of DRUG-INDUCED DRYNESS Of MOUTH IN PSYCHIATRIC-
PATIENTS - A CONTROLLED-COMPARATIVE-STUDY.
000799 01-13
MOVEMENT
EffEaS Of LEAD ON MOVEMENT Of ALBUMIN INTO BRAIN
000076 01-03
RESERPINE ABOLISHES MOVEMENT CORRELATED ATROPINE-RESISTANT
NEOCORTICAL LOW VOLTAGE EAST-ACTIVITY.
000310 01-03
EffECTS Of HEMICHOLINIUM-3 AND CHOLINE ON HIPPOCAMPAL
ELECTRICAL-ACTIVITY DURING IMMOBILITY VS. MOVEMENT
001438 02-03
SENSORY AND ASSOCIATIVE-EfFEaS OF LSD ON CLASSICAL APPETITIVE-
CONDITIONING OF THE RABBIT JAW MOVEMENT RESPONSE
001637 02-04
MOVEMENT-DISORDERS
TARDIVE-DYSKINESIA AND OTHER MOVEMENT-DISORDERS IN CHILDREN
TREATED WITH PSYCHOTROPIC-DRUGS.
000849 01-15
EFFEQS OF CHOLINE CONTAINING COMPOUNDS ON TARDIVE-DYSKINESIA
AND OTHER MOVEMENT-DISORDERS.
000942 01-17
TARDIVE-DYSKINESIA AND OTHER DRUG-INDUCED MOVEMENT-
DISORDERS AMONG HANDICAPPED CHILDREN AND YOUTH.
004614 04-15
LITHIUM-CARBONATE IN THE TREATMENT OF MOVEMENT-DISORDERS A
CRITICAL REVIEW.
MOVEMENTS 004668 04-15
ABNORMAL MOVEMENTS INDUCED BY PSYCHOTROPIC-DRUGS
.OXESTROL 004652 04-15
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN
STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER
MRNA 001218 02-03
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO
^y 003832 04-03
AQIONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON
ACETYLCHOLINE TURNOVER IN RAT-BRAIN.
INTERCONVERTING MU AND DELTA-FORMS OF TYPE-1 OPIATE-RECEPTORS
IN THE RAT STRIATAL PATCHES.
003737 04-03
ACTIONS OF MU, KAPPA, SIGMA, DELTA AND AGONIST /ANTAGONIST
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION.
004053 04-03
MU-RECEPTORS
EffECTS Of CHANGES IN THE STRUCTURE Of ENKEPHALINS AND Of
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERACTIONS WITH MU-
RECEPTORS AND DELTA-RECEPTORS
000168 01-03
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH
HIGH-AfflNITY AND LOW AfflNITY'OPIATE BINDING-SITES.
001554 02-03
MORPHICEPTIN (NH4-TYR-PR0-PHE-PR0-C0NH2): A POTENT AND
SPECIfIC AGONIST fOR MORPHINE MU-RECEPTORS.
003746 04-03
MUITIBARRELED
PHYSICAL AND PHYSIOLOGICAL CHARACTERISTICS Of MICROPRESSURE
EJECTION Of DRUGS FROM MULTIBARRELED PIPETTES.
002502 02-16
MULTICENTER-STUDY
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY: EFFICACY, DOSAGE SCHEDULE AND PLASMA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE
FATIGUE STUDY GROUPS NO. 4 CLINICAL-SCALE.
001980 02-09
MULTICENTER-TRIAL
FACTORS WHICH AFFECT ANTIDEPRESSANT-DRUG RESPONSE IN A
MULTICENTER-TRIAL.
003239 03-09
MULTICENTER-TRIALS
METHODS OF MULTICENTER-TRIALS IN PSYCHIATRY - PART I: REVIEW.
002483 02-16
MULTICENTRE-STUDY
MULTICENTRE-STUDY WITH VILOXAZINE (VIVALAN) IN DEPRESSED-
PATIENTS.
004375 04-09
MULTICENTRE-TRIAL
A DOUBLE-BUND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND
SIDF-EFFECTS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED-
INPATIENTS AND DEPRESSED-OUTPATIENTS.
004395 04-09
MULTICLINICAL-STUDY
RESULTS OF CLINICAL-TESTS OF VILOXAZINE (VIVALAN ICI): PART OF A
MULTICLINICAL-STUDY.
002006 02-09
MULTIDIMENSIONAL
MULTIDIMENSIONAL ANALYSES OF BEHAVIOR IN MICE TREATED WITH
ALPHA ENDORPHIN.
003020 03-04
A SYMPTOM-PROflLE-ANALYSIS OF ANTIPSYCHOTIC-DRUG TREATMENT:
NONPARAMETRIC MULTIDIMENSIONAL TECHNIQUE.
003196 03-08
MULTIINSTITUTiONAL-STUDY
MULTIINSTITUTIONAL-STUDY ON THE TERATOGENICITY AND FETAL
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE-
STUDY GROUP IN JAPAN.
002442 02-15
MULTIPLE-DOSE
SINGLE-DOSE VERSUS MULTIPLE-DOSE COMPARATIVE-TRIAL Of
DESIPRAMINE-HYDROCHLORIDE: A DOUBLE-PLACEBO METHOD.
002059 02-10
MULTIPLE-DOSES
DISPOSITION OF (3H) PHENCYCLIDINE IN THE RAT AFTER SINGLE-DOSES
AND MULTIPLE-DOSES.
001375 02-03
MULTIPLE-SCHEDULE
INFLUENCE OF INTRAVENOUS SELF-ADMINISTERED PSYCHOMOTOR
STIMULANTS ON PERFORMANCE Of RHESUS-MONKEYS IN A MULTIPLE-
SCHEDULE PARADIGM.
001655 02-04
MULTIVARIATE
ASSESSMENT OF MULTIVARIATE RELATIONSHIPS IN REACTIVITY Of
PATIENTS RECEIVING LITHIUM THERAPY.
000819 01-14
MULTIVARIATE APPROACHES APPLIED TO STUDIES Of NOREPINEPHRINE
AND SEROTONIN UPTAKE.
001460 02-03
EffECTS Of SINGLE-ORAL-DOSAGES Of STEROIDS ON HUMAN EEG
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROflLES.
002239 02-13
A MULTIVARIATE ANALYSIS Of THE INfRARED SPECTRA Of DRUGS Of
ABUSE.
004688 04-16
m
S-291
Subject Index
Psychopharmacology Abstracts
'Hill!
Ill'
35111:;:
«iua'
a;'
aw
ft
MURINE
NEURONAL LOCALIZATION OF BENZODIAZEPINE-RECEPTORS IN THE
MURINE CEREBELLUM.
002902 03-03
MUSCARINE
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA
ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF
CONSCIOUS CATS.
001569 02-04
MUSCARINIC
DIFFERENTIAL REGULATION OF MUSCARINIC AGONIST BINDING-SITES
FOLLOWING CHRONIC CHOLINESTERASE INHIBITION.
000279 01-03
INTRACELLULAR OBSERVATIONS ON THE EFFEQS OF MUSCARINIC
AGONISTS ON RAT SYMPATHETIC NEURONES.
001143 02-03
THE BINDING OF SOME ANTIDEPRESSANT-DRUGS TO BRAIN MUSCARINIC
ACETYLCHOLINE-RECEPTORS .
001253 02-03
THE REGULATION OF CARDIAC MUSCARINIC CHOLINERGIC-RECEPTORS BY
ISOPROTERENOL.
001441 02-03
COMPARATIVE- STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
MUSCARINIC ACETYLCHOLINE-RECEPTOR. (UNPUBLISHED PAPER).
002667 03-03
EFFEQ OF KAINIC-ACID LESIONS ON MUSCARINIC AGONIST RECEPTOR
SUBTYPES IN RAT STRIATUM.
002679 03-03
AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR
ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER
CHRONIC ANTIDEPRESSANT TREATMENT
002788 03-03
BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH-
AVOIDANCE AND LOW-AVOIDANCE RATS.
002852 03-03
PHARMACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG.
002889 03-03
A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE. (PH.D.
DISSERTATION).
002918 03-03
POSSIBLE MUSCARINIC CHOLINERGIC MEDIATION OF PAHERNED
AGGRESSIVE REFLEXES IN THE CAT.
004153 04-04
PSYCHOTHERAPEUTIC-DRUGS, HISTAMINE HI -RECEPTORS AND
MUSCARINIC ACETYLCHOLINE-RECEPTORS.
004737 04-17
MUSCARINIC-CHOLINOCEPTOR
CHRONIC SYMPATHETIC DENERVATION INCREASES MUSCARINIC-
CHOLINOCEPTOR BINDING IN THE RAT SUBMAXILLARY-GLANO.
000235 01-03
MUSCARINIC-CHOLINOCEPTORS
THE INTERAQION OF TRAZODONE WITH RAT-BRAIN MUSCARINIC-
CHOLINOCEPTORS.
003855 04-03
MUSCARINIC-RECEPTOR
THE EFFECTS OF MUSCARINIC-RECEPTOR BLOCKERS ON THE TURNOVER-
RATE OF ACETYLCHOLINE IN VARIOUS REGIONS OF THE RAT-BRAIN.
000328 01-03
INCREASED MUSCARINIC-RECEPTOR BINDING IN RAT-FOREBRAIN AFTER
SCOPOLAMINE.
001351 02-03
EVIDENCE THAT NORADRENALINE MODULATES THE INCREASE IN
STRIATAL DOPAMINE METABOLISM INDUCED BY MUSCARINIC-
RECEPTOR STIMULATION.
001518 02-03
FORNIX LESION PREVENTS AN ORGANOPHOSPHATE-INDUCED DECREASE
IN MUSCARINIC-RECEPTOR LEVEL IN RAT HIPPOCAMPUS.
001833 02-05
AMITRIPTYUNE: LONG-TERM-TREATMENT ELEVATES ALPHA-ADRENERGIC
AND MUSCARINIC-RECEPTOR BINDING IN MOUSE-BRAIN.
002875 03-03
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
003783 04-03
ISOMERIZATION OF THE MUSCARINIC-RECEPTOR ANTAGONIST COMPLEX.
003860 04-03
MUSCARINIC-RECEPTOR: MULTIPLE SITES OR UNITARY CONCEPT?
003896 04-03
MUSCARINIC-RECEPTOR-MEDIATED
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP-
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF
MOUSE NEUROBLASTOMA CELLS USING
(3H)TETRAPHENYLPH0SPH0NIUM.
004049 04^3
MUSCARINIC-RECEPTORS
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRACTIONS.
000299 01-03
INHIBITION BY LOCAL ANESTHETICS, PHENTOLAMINE AND PROPRANOLOL
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL
MUSCARINIC-RECEPTORS.
001097 02-03
MUSCARINIC-RECEPTORS IN RAT SYMPATHETIC GANGLIA.
001144 02-03
PERSISTENT EFFECTS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC-
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS.
001266 02-03
INTRINSIC CHOLINERGIC EXCITATION IN THE RAT NEOSTRIATUM:
NICOTINIC AND MUSCARINIC-RECEPTORS.
001374 02-03
INTERACTION OF THE TRICYCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH
PREJUNCTIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG
SAPHENOUS VEIN.
003756 04-03
THE HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPEQ TO THE
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRAQION
ABUNDANT IN PRESYNAPTIC MEMBRANES.
004028 04-03
THE INTERAQION OF AMINE LOCAL ANESTHETICS WITH MUSCARINIC-
RECEPTORS.
004031 04-03
MUSCIMOL
GABAERGIC AQIONS OF THIP IN VIVO AND IN VITRO: A COMPARISON
WITH MUSCIMOL AND GABA.
000319 01-03
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES.
001208 02-03
PHYSIOLOGICAL-STUDIES AND BEHAVIORAL-STUDIES WITH MUSCIMOL.
002538 02-17
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
002699 03-03
CORRELATION OF (14C)MUSCIM0L CONCENTRATION IN RAT-BRAIN WITH
ANTICONVULSANT AQIVITY.
003045 03-04
DETERMINATION OF GABA LEVELS BY A (3H)MUSCIM0L RADIORECEPTOR
ASSAY.
003135 03-06
SOME BARBITURATES ENHANCE THE EFFEQ OF MUSCIMOL ON
DOPAMINE TURNOVER IN THE RAT RETINA.
003873 04-03
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID-
RECEPTOR AGONIST, TO MEMBRANES OF THE BOVINE RETINA
003954 04-03
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN
BRAIN CELL-CULTURES.
' 004002 04-03
MODULATORY INTERAQIONS BETV/EEN NOREPINEPHRINE AND TAURINE,
BETA ALANINE. GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS.
004058 04-03
INVOLVEMENT OF DOPAMINE IN CIRCLING RESPONSES TO MUSCIMOL
DEPENDS ON INTRANIGRAL SITE OF INJEQION.
004158 04-04
MUSaMOL-HYDROBROMIDE
EFFEQS OF SODIUM-DIPROPYLACETATE, MUSCIMOL-HYDROBROMIDE
AND (R,S) NIPECOTIC-ACID-AMIDE ON ISOLATION-INDUCED
AGGRESSIVE-BEHAVIOR IN MICE.
001756 02-04
MUSCLE
THE INFLUENCE OF BENZOQAMINE ON DOPAMINE AND NOREPINEPHRINE
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH
REFLEX OF THE CAT. ^ „,
000054 01-03
THE EFFEQ OF DIAZEPAM ON TENSION AND ELECTROLYTE DISTRIBUTION
IN FROG MUSCLE.
000069 01-03
SHORT-TERM AND LONG-TERM MODIFICATION OF SKELETAL-MUSCLE
SODIUM-PUMP AQIVITY AND MUSCLE PROTEIN TURNOVER.
(UNPUBLISHED PAPER).
001519 02-03
DRUG-INDUCED DISORDERS OF MUSCLE.
002435 02-15
S-292
VOLUME 19, SUBJECT INDEX
Subject Index
MUSCLE-RELAXANT
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT
PROPERTIES.
000084 01-03
THE SITE OF AQION OF MUSCLE-RELAXANT PURINE NUCLEOSIDES
003742 04-03
MUSCLE-RELAXANTS
THE RATIONAL USE OF MUSCLE-REUXANTS IN REHABILITATION
MEDICINE.
MUSCULAR 000943 0,.,7
NALOXONE EFFECTS ON THE BLOOD-PRESSURE RESPONSE INDUCED BY
THIN-FIBER MUSCULAR AFFERENTS.
002794 03-03
DEPRESSION OF RESERPINE-INDUCED MUSCULAR RIGIDITY IN RATS AFTER
ADMINISTRATION OF LISURIDE INTO THE SPINAL SUBARACHNOID
SPACE.
002962 03-04
MUTAOENrC
IS LITHIUM MUTAGENIC IN MAN?
000753 01-13
MYASTHENIA-GRAVIS
NEUROLEPTIC-INDUCED SYNDROME MIMICKING MYASTHENIA-GRAVIS
MYEUN 003474 03-15
BRAINSTEM AUDITORY EVOK ED-POTENTIALS AND MYELIN CHANGES IN
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS.
000509 01-05
CHARAaERIZATION OF THE BASIC PROTEINS FROM RODENT
PERIPHERAL-NERVOUS-SYSTEM MYELIN.
003665 04-01
MYEUNATED
ABSENCE OF POTASSIUM CONDUQANCE IN CENTRAL MYELINATED
AXONS.
000166 01-03
FURTHER ANALYSIS OF THE MECHANISMS OF AQION OF
BATRACHOTOXIN ON THE MEMBRANE OF MYELINATED NERVE
MYENTERIC 003884 04-03
INHIBITION OF THE AQION OF CHOLECYSTOKININ-OCTAPEPTIDE ON THE
GUINEA-PIG ILEUM MYENTERIC PLEXUS BY DIBUTYRYL-CYCLIC-
GUANOSINE-MONOPHOSPHATE .
-YOCARD.AL-.NFARa.ON °°^2" ''■"'
ANTIARRHYTHMIC-AQIVITY OF AMITRIPTYLINE ANALOGUES IN
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION-
CYPROHEPTADINIUM-METHIODIDE.
4YOCARD.UM 001534 02-03
PROTEaiVE EFFEQ OF PRENYLAMINE AGAINST VULNERABILITY TO
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE
MYOCARDIUM.
.YOClON.ES 000265 01-03
EDEMAS AND MYOCLONIES IN A PATIENT WITH PARKINSONS-DISEASE
TREATED BY AMANTADINE: PROBLEM WITH ASSOCIATED
MEDICATIONS.
MYOCLONUS 002389 02-15
^'^n'll.^J^^I"^''''^*^ °^ L TRYPTOPHAN IN PROGRESSIVE MYOCLONUS
EPILEPSY WITHOUT lAFORA-BODIES: CLINICAL-STUDY AND
ELEaROPHYSIOLOGICAL-STUDY.
OBSERVATIONS ON CHLORALOSE-INDUCED MYOCLONUS IN GUINEA-PIGS.'
TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAn'aND^^"^"'
^^BIDOPA: aiNICAL, ELEQROPHYSIOLOGICAL, AND BIOCHEMICAL-
IYODYSTON.A 002180 02-11
PROBLEMS OF TREATING DEFORMING MYODYSTONIA WITH L-DOPA
AND PREOiaiON OF ITS THERAPEUTIC EFFECT
iYO.NOS.TOL 004536 04-13
THE EFFEQS OF LITHIUM ON MYOINOSITOL LEVELS IN LAYERS OF
FRONTAL-CEREBRAL-CORTEX, IN CEREBELLUM, AND IN CORPUS-
CALLOSUM OF THE RAT.
^X2L^^?il°'- TURNOVER IN THE INTAQ RAT-BRAIN: INCrK^ °^'^^
PRODUaiON AFTER D-AMPHETAMINE
YOPATHY 003723 04-03
REVERSIBLE ALEXIA, MITOCHONDRIAL MYOPATHY AND lAQIC-
ACIDEMIA.
YOTUBE 000723 01-11
^^??x'i;*1"'f °^"° MYOTUBE GROWTH CORRELATES WITH NA-PUMP
ACTIVATION. (UNPUBLISHED PAPER).
002087 02-10
NA
MYTH
THE STIMUUNT-EFFECT OF NEUROLEPTICS: MYTH OR REALITY?
000362 01-04
MYTHOLOGEM
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL
CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN
PSYCHEDELIC-EXPERIENCES.
002200 02-12
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF N-4 1
AZETIDINYLBUTYNYL 2 PYRROLIDONE, A HIGHLY POTENT
OXOTREMORINE-LIKE-AGENT.
003701 04-02
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND
ELECTROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE
MIDBRAIN.
001593 02-04
NA-DEPENDENT
NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTRODUCTION.
002227 02-13
NA-.NDEPENDENT
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
„. „ . 002699 03-03
NA-K-ADENOStNE-TRIPHOSPHATASE
EFFECTS OF CHRONIC DIETARY LITHIUM ON ACTIVITY AND REGULATION
OF NA-K -ADENOSINE-TRIPHOSPHATASE IN RAT-BRAIN.
000907 01 01
NORADRENERGIC STIMUUTION IN VIVO INCREASES NA-K-ADENOSINE-
TRIPHOSPHATASE AQIVITY.
NA-K-ATPASE 002910 03-03
METERGOLINE ANTAGONISM OF 5 HYDROXYTRYPTAMINE-INDUCED
ACTIVATION OF RAT-CEREBRAL-CORTICAL NA-K-ATPASE.
000329 01-03
ALPHA-ADRENORECEPTOR MEDIATED ALTERATION OF ETHANOL EFFEQS
ON NA-K-ATPASE OF RAT NEURONAL MEMBRANES.
001425 02-03
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELEQROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS.
oo^py 1 r\A r\^
CORRELATIONS BETWEEN NA-K-ATPASE ACTIVITY AND ACETYLCHOLINE
RELEASE IN RAT CORTICAL SYNAPTOSOMES.
003937 04-03
THE NA-K-ATPASE: A PLAUSIBLE TRIGGER FOR VOLTAGE-INDEPENDENT
RELEASE OF CYTOPLASMIC NEUROTRANSMITTERS.
003953 04-03
NA-GAMMA-HYDROXYBUTYRATE
NA-GAMMA-HYDROXYBUTYRATE IN CEREBRAL PROTECTION DURING
SEVERE HYPOXEMIA IN THE RAT.
003895 04-03
NA..NDEPENDENT
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES.
^^^ 001208 02-03
THE EFFEQ OF NORADRENALINE ON NA-K TRANSPORT IN RAT-CEREBRAL-
CORTICAL SLICES.
004056 04-03
NA-K-ACT.VATEO
ETHANOL SEDATIVE HYPNOTIC-INTERACTIONS: IN VITRO STUDIES ON NA-
K-ACTIVATED ADENOSINE-TRIPHOSPHATASE.
004269 04-05
NA-K-ATPASE
EFFEQS OF LITHIUM, AND LITHIUM AND ALCOHOL ADMINISTRATION ON
NA-K-ATPASE.
002744 03-03
ELEQRICAL-ACTIVITY AND NA-K-ATPASE LEVEL IN THE PENICILLIN-
INDUCED EPILEPTOGENIC-FOCUS OF THE RAT-BRAIN-CORTEX AND THE
EFFECT OF DIAZEPAM.
003070 03-04
NA-PUMP wou,uuo-uH
STRETCH-INDUCED MYOTUBE GROWTH CORRELATES WITH NA-PUMP
ACTIVATION. (UNPUBLISHED PAPER).
NAB.LONE 002087 02-10
A SINGLE-DOSE STUDY OF NABILONE, A SYNTHETIC CANNABINOID
„^^. 002328 02-14
NACL
RENIN AND ALDOSTERONE SECRETIONS DURING HYPOVOLEMIA IN RATS
RELATION TO NACL INTAKE.
000484 01-04
1
S-293
Subject Index
Psychopharmacology Abstracts
iii;:
III'
35111::
ail';:;.
NALORPHINE
EFFEQS OF MORPHINE AND NALORPHINE ON KAINIC-ACID-INDUCED
HYPOTHERMIA IN RATS.
002921 03-03
EFFEQS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETEQ THE NARCOTIC CHARAQER OF A DRUG.
003555 03-16
NALORPHINES
NALORPHINES EFFEQ UNDER SEVERAL SCHEDULES OF ELEQRIC-SHOCK
TITRATION.
000379 01-04
NALOXAZONE
NALOXAZONE, A LONG-AQING OPIATE ANTAGONIST. EFFECTS ON
ANALGESIA IN INTAQ ANIMALS AND ON OPIATE-RECEPTOR BINDING
IN VITRO.
004198 04-04
NALOXONE
EFFECT OF NALOXONE, HALOPERIDOL AND PROPRANOLOL ON CYCLIC-
ADENOSINE-MONOPHOSPHATE CONTENT OF RAT AMYGDALA.
000071 01-03
INHIBITION OF (3H)NAL0X0NE BINDING IN HOMOGENATES OF RAT-
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC AQIVITY, RELATED
TO PHYSOSTIGMINE.
000104 01-03
NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE
POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS.
00011601-03
NALOXONE PROMOTES STIMULUS-EVOKED VASOPRESSIN RELEASE IN
VIVO.
000165 01-03
EFFEaS OF ENKEPHALIN ANALOGUE AND NALOXONE ON CAT SPINAL-
CORD DORSAL ROOT POTENTIALS.
000236 01-03
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS.
000258 01-03
EFFEaS OF MORPHINE AND NALOXONE ON PHASIC RELEASE OF
LUTEINIZING-HORMONE AND FOLLICLE-STIMULATING-HORMONE
(40849).
000298 01-03
MORPHINE EFFEQS UPON DISCRIMINATED APPROACH AND
DISCRIMINATED AVOIDANCE IN RATS: ANTAGONISM BY NALOXONE.
000338 01-04
EFFEQS OF DOPAMINERGIC AND CHOLINERGIC-DRUGS, NALOXONE AND
L PROLYL-LEUCYL-GLYCINAMIDE ON LSD-INDUCED CATALEPSY.
000360 01-04
NALOXONE POTENTIATES THE DISRUPTIVE EFFEQS OF MESCALINE ON
OPERANT-RESPONDING IN THE RAT.
000365 01-04
ADDIQIVE-AGENTS AND INTRACRANIAL-STIMULATION (ICS): MORPHINE.
NALOXONE, AND PRESSING FOR AMYGDALOID ICS.
000371 01-04
NALOXONE REVERSIBLE EFFECTS OF D ALA2-MET5-ENKEPHALINAMIDE-
INDUCED BEHAVIORAL-AQIVITY IN RATS.
000402 01-04
EFFEQ OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION,
MEMORY, AND RETRIEVAL OF SHUHLE AVOIDANCE AND
HABITUATION LEARNING IN RATS.
000410 01-04
StEREOSPECIFIC, DOSE-DEPENDENT ANTAGONISM BY NALOXONE OF
NONOPIATE BEHAVIOR IN MICE.
000411 01-04
EFFECTS OF MORPHINE, BETA ENDORPHIN AND NALOXONE ON
CATECHOLAMINE LEVELS AND SEXUAL-BEHAVIOR IN THE MALE RAT.
000430 01-04
REVERSAL OF SCHEDULE-INDUCED SELF-INJECTION OF HEROIN BY
NALOXONE.
000446 01-04
SELECTIVE INHIBITION OF MESOLIMBIC BEHAVIORAL-SUPERSENSITIVITY
BY NALOXONE.
000467 01-04
NALOXONE OVERCOMES THE DOPAMINERGIC, EEG, AND BEHAVIORAL-
EFFECTS OF GAMMA HYDROXYBUTYRATE.
000478 01-04
DIFFERENTIAL-EFFECTS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS.
000480 01-04
FAILURE OF NALOXONE TO REVERSE CATALEPSY ASSOCIATED WITH
SCHIZOPHRENIA; A CASE-REPORT.
000560 01-08
SHORT-TERM HORMONAL-EFFECTS OF NALOXONE IN MAN.
000798 01-13
NALOXONE REDUCES CIGAREHE SMOKING.
000808 01-14
RAPID OPIATE DETOXIFICATION WITH CLONIDINE AND NALOXONE.
000820 01-14
THE STEREOSPECIFIC EFFEQ OF NALOXONE ON RAT DORSAL-HORN
NEURONES; INHIBITION IN SUPERFICIAL LAMINAE AND EXCITATION IN
DEEPER LAMINAE.
001226 02-03
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
BRAIN.
001234 02-03
LOCALIZATION OF NALOXONE SENSITIVE (3H)DIHYDR0M0RPHINE
BINDING-SITES WITHIN THE HIPPOCAMPUS OF THE RAT.
001368 02-03
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS PRESENT A NALOXONE
SENSITIVE DECREASE IN PAIN SENSITIVITY. (UNPUBLISHED PAPER).
001457 02-03
CHARACTERISTICS OF OSCILLATORY CONTRACTIONS ELICITED BY
NALOXONE IN ILEUM PREPARATION FROM MORPHINE-DEPENDENT
GUINEA-PIGS.
001491 02-03 ,
THE EFFECT OF NALOXONE ON THE ACTIVATION OF EMOTIONAUY
POSITIVE REACTION PRODUCED BY DRUGS WITH A DEPENDENCE ^
LIABILITY.
001556 02-03
HEROIN, BUT NOT LEVORPHANOL, PRODUCES EXPLOSIVE MOTOR-
BEHAVIOR IN NALOXONE TREATED RATS.
001579 02-04
ACTH MEDIATION OF LEARNED-FEAR: BLOCKADE BY NALOXONE AND
NALTREXONE.
001597 02-04
NALOXONE: EFFECTS ON FOOD AND WATER CONSUMPTION IN THE
NONDEPRIVED AND DEPRIVED RAT.
001599 02-04
EFFECTS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN
COMBINATION WITH NALOXONE ON ELECTRIC-SHOCK TITRATION IN
THE SQUIRREL-MONKEY.
001611 02-04
NALOXONE PRETREATMENT ENHANCES SHOCK-ELICITED AGGRESSION.
001615 02-04
NALOXONE REDUCES SOCIAL-ACTIVITY AND EXPLORATORY-ACTIVITY IN
THE RAT.
001617 02-04
NALOXONE FACILITATES AMYGDALOID KINDLING IN RATS.
001644 02-04
DIFFERENT BEHAVIORAL-EFFECTS FOUOWING INTRACEREBRAL,
INTRACEREBROVENTRICULAR OR INTRAPERITONEAL INJECTION OF
NALOXONE IN THE RAT.
001665 02-04
THE EFFECT OF MORPHINE, PIMOZIDE AND NALOXONE ON
DISCRIMINATION BY RATS IN A SHOCK-ESCAPE-TEST
001700 02-04
ANTAGONISM OF 2 DEOXY-D-GLUCOSE-INDUCED HYPERPHAGIA BY
NALOXONE: POSSIBLE INVOLVEMENT OF ENDORPHINS.
001773 02-04
NALOXONE AND SHUHLEBOX SELF- STIMULATION IN THE RAT
001793 02-04
THE EFFECT OF ASPIRIN AND PARACETAMOL ON THE INCREASED
NALOXONE POTENCY INDUCED BY MORPHINE PRETREATMENT.
001824 02-04
ON A POSSIBLE ROLE OF ENDORPHINS IN PSYCHIATRIC-DISORDERS -
ACTIONS OF NALOXONE IN PSYCHIATRIC-PATIENTS.
001917 02-08
FAILURE OF NALOXONE TO REDUCE AAANIC-SYMPTOMS.
001984 02-09
EFFECTS OF NALOXONE UPON PROLACTIN AND CORTISOL IN NORMAL
WOMEN.
002213 02-13
NALOXONE EFFECTS ON THE BLOOD-PRESSURE RESPONSE INDUCED BY
THIN-FIBER MUSCULAR AFFERENTS.
002794 03-03
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED
002800 03-03
NALOXONE REVERSAL OF THE PENTOBARBITAL-INDUCED BLOCKADE OF
OVULATION IN THE RAT.
002817 03-03
INCREASE IN PLASMA CYCLIC-AMP LEVELS ELICITED BY NALOXONE IN
MORPHINE-DEPENDENT MALE MICE.
002834 03-03
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFECTS OF NALOXONE ON
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE
MALE RAT.
002853 03-03
SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI-
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS.
002871 03-03
POTENTIATION OF APOMORPHINE AND D-AMPHET AMINE EFFECTS BY
NALOXONE. _ „„,„,
002942 03-04
S-294
VOLUME 19, SUBJECT INDEX
Sub|«ct Index
SUPPRESSION Of DRINKING BY NALOXONE IN THE RAT: A fURTHER
CHARACTERIZATION.
002963 03-04
DOSE-RESPONSE STUDY OF THE PRECIPITATED ABSTINENCE-SYNDROME
FOR MORPHINE: SYSTEMIC VS PERIAQUEDUCTAL GRAY NALOXONE.
(PH.D. DISSERTATION).
002979 03-04
EXPLORATION AND MOTOR-ACTIVITY AFTER INTRAVENTRICULAR ACTH,
MORPHINE AND NALOXONE.
002991 03-04
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
DISCRIMINATIVE RESPONSE CONTROL BY NALOXONE IN MORPHINE
PRETREATED RATS.
003053 03-04
EFFECTS OF CHRONIC NALOXONE TREATMENT ON BRAIN-STIMULATION
REWARD.
003066 03-04
FOOTSHOCK ANALGESIA: PREVENTION BY BEHAVIOURAL-MANIPULATION
BUT NOT BY NALOXONE.
003073 03-04
COPULATORY-BEHAVIOR AND SEXUAL-REFLEXES OF MALE RATS TREATED
WITH NALOXONE.
003077 03-04
EFFEQS OF METHYSERGIDE AND NALOXONE ON ANALGESIA INDUCED BY
THE PERIPHERAL ELECTRIC-STIMULATION IN MICE.
003093 03-04
DOSE-RESPONSE RELATIONSHIP BETWEEN NALOXONE INJECTIONS AND
INTAKE OF SUCROSE SOLUTION.
003118 03-04
THE USE OF A MORPHINE ANTAGONIST (NALOXONE) IN THE TREATMENT
OF DISSOCIATIVE-SYNDROMES.
003194 03-08
NALOXONE AND FOCAL EPILEPSY: A STUDY WITH DEPTH ELECTRODES.
003341 03-11
NALOXONE IN THE TREATMENT OF ANOREXIA-NERVOSA: EFFECT ON
WEIGHT-GAIN AND LIPOLYSIS.
003342 03-1 1
OPPOSITE EFFEaS OF NALOXONE ON SUBSTANCE-P-INDUCED IN BRAIN
DOPA SYNTHESIS AND IN LOCOMOTOR-ACTIVITY IN RATS.
003799 04-03
AQION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
EFFEQ OF MORPHINE AND NALOXONE ON LEU-ENKEPHALIN-LIKE
IMMUNOREAQIVITY IN DOGS.
003894 04-03
EFFECTS OF ENKEPHALIN, MORPHINE, AND NALOXONE ON THE
ELEQRICAL-ACTIVITY OF THE IN VITRO HIPPOCAMPAL SLICE
PREPARATION.
003918 04-03
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-03
NALOXONE SUPPRESSES FEEDING AND DRINKING BUT NOT WHEEL
RUNNING IN RATS.
„„_ 004080 04-04
EFFEQS OF PAIN, MORPHINE AND NALOXONE ON THE DURATION OF
ANIMAL HYPNOSIS.
004081 04-04
NALOXONE SUPPRESSES FOOD/WATER CONSUMPTION IN THE DEPRIVED
CAT.
004114 04-04
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND
CONDITIONED TASTE-AVERSION.
004121 04-04
CHOICE BETWEEN FOOD AND HEROIN: EFFECTS OF MORPHINE
NALOXONE, AND SECOBARBITAL.
004123 04-04
THE SITE OF ACTION OF NALOXONE IN SUPPRESSING FOOD AND WATER
INTAKE IN RATS.
004146 04-04
EVIDENCE FOR SEDATIVE EFFEQS OF LOW-DOSES OF MORPHINE IN MICE
INVOLVING RECEPTORS INSENSITIVE TO NALOXONE.
004173 04-04
SOCIAL CROWDING ENHANCES AVERSIVENESS OF NALOXONE IN RATS
004201 04-04
OPIATE-DEPENDENCE FOLLOWING ACUTE INJECTIONS OF MORPHINE AND
NALOXONE: THE ASSESSMENT OF VARIOUS WITHDRAWAL SIGNS
„, ,, 004209 04-04
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO
COUNTERACT CURATIVE EFFEQS OF NEUROLEPTIC-DRUGS
004321 04-08
THE EFFECT OF NALOXONE ON THE CONDITION OF PATIENTS WITH
ENDOGENOUS PSYCHOSES.
004381 04-09
ARE THE ENKEPHALINS INVOLVED IN PARKINSONS-DISEASE? CLINICAL
AND NEUROENDOCRINE RESPONSES TO NALOXONE ADMINISTRATION
004431 04-11
NALOXONE-INDUCED
AN ELECTROMYOGRAPHIC-METHOD FOR THE ASSESSMENT OF
NALOXONE-INDUCED ABSTINENCE IN MORPHINE-DEPENDENT RATS.
000433 01-04
REPEATED ADMINISTRATION OF NALTREXONE PRODUCES TOLERANCE TO
NALOXONE-INDUCED HYPERALGESIA.
000453 01-04
HYPOPHYSECTOMY INCREASES THE SENSITIVITY OF RATS TO NALOXONE-
INDUCED HYPOTHERMIA.
002710 03-03
LACK OF CORRELATION BETWEEN NALOXONE-INDUCED CHANGES IN
SEXUAL-BEHAVIOR AND SERUM LH IN MALE RATS.
002821 03-03
CHOLINE REVERSES NALOXONE-INDUCED DECREASES IN HIPPOCAMPAL
ACETYLCHOLINE CONTENT AND SUPPRESSES ESCAPE-BEHAVIOR IN
OPIATE-DEPENDENT RATS.
004076 04-04
NALOXONE-LIKE
NALOXONE-LIKE ACTIONS OF MIF-1 DO NOT REQUIRE THE PRESENCE OF
THE PITUITARY.
001311 02-03
NALTREXONE
INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH PENTAZOCINE:
REVERSAL BY NALTREXONE.
000318 01-03
DISCRIMINATIVE-STIMULUS EFFEQS OF NALTREXONE IN THE MORPHINE-
DEPENDENT RAT.
000391 01-04
REPEATED ADMINISTRATION OF NALTREXONE PRODUCES TOLERANCE TO
NALOXONE-INDUCED HYPERALGESIA.
000453 01-04
ACTH MEDIATION OF LEARNED-FEAR: BLOCKADE BY NALOXONE AND
NALTREXONE.
001597 02-04
INTERACTIONS BETWEEN NALTREXONE AND NONOPIATE DRUGS
EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
001645 02-04
BEHAVIOURAL-EFFECTS AND ENDOCRINE-EFFECTS OF NALTREXONE IN
MALE TALAPOIN-MONKEYS.
001718 02-04
OPERANT ANALYSIS OF HUMAN HEROIN SELF-ADMINISTRATION AND THE
EFFECTS OF NALTREXONE.
003449 03-14
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-03
NARCOANALGESIA
EFFECTS OF NORADRENERGIC AGONISTS AND ANTAGONISTS ON
GROWTH-HORMONE SECRETION UNDER GAMMA HYDROXYBUTYRATE
NARCOANALGESIA IN THE RAT.
000262 01-03
NARCOLEPSY
BROMISM, HYSTERIA AND NARCOLEPSY.
002472 02-15
TREATMENT OF NARCOLEPSY AND SLEEP-APNEA WITH GAMMA
HYDROXYBUTYRATE: A CLINICAL AND POLYSOMNOGRAPHIC CASE-
STUDY.
004571 04-14
NARCOSIS
ANTAGONISTIC-EFFECTS OF PROPRANOLOL UPON ETHANOL-INDUCED
NARCOSIS IN MICE.
000439 01-04
NARCOTIC
EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERACTIONS WITH MU-
RECEPTORS AND DELTA-RECEPTORS.
000168 01-03
INFLUENCE OF GLUCOSE (IN VIVO OR IN VITRO) ON DURATION OF
NARCOTIC ANALGESICS AND ON THE KINETICS OF DRUG METABOLISM.
000292 01-03
TARDIVE-DYSKINESIA RESULTING FROM CHRONIC NARCOTIC
TREATMENT.
000922 01-17
INTERACTION-STUDIES BETWEEN NARCOTIC ANALGESICS, NARCOTIC
ANTAGONISTS AND ETHANOL: STUDIES DURING ACUTE AND CHRONIC-
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE. (PH.D.
DISSERTATION).
001165 02-03
A PROPOSED MODE OF ACTION FOR NARCOTIC AGONISTS AND
ANTAGONISTS.
001168 02-03
1
r
S-295
Subject Index
Psychopharmacology Abstracts
51111'
THE EFFECT OF PSYCHOTROPIC-SUBSTANCES AND NARCOTIC ANALGESIC-
DRUGS ON 14C NORADRENALINE UPTAKE BY SYNAPTOSOMES OF THE
CEREBRAL-CORTEX OF RATS . „„ , „, . „. „o
001363 02-03
NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO
WITHDRAWAL INDUCING BENZAZOCINES. (PH.D. DISSERTATION).
001518 02-03
NARCOTIC ANALGESICS AND STEREOTYPED-BEHAVIOUR IN MICE.
001694 02-04
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST,
CHLORNALTREXAMINE. „„, ,or ^o «.
001695 02-04
LACK OF EFFECT OF CHOLINE AND NARCOTIC ANTAGONISTS UPON
APOMORPHINE DISCRIMINATION.
001770 02-04
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF
12 CNS DEPRESSANTS IN INTAQ AND PITHED RATS.
001855 02-05
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR
FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY.
002986 03-04
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS.
003068 03-04
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDICT RATS: A POSSIBLE MODEL FOR PREDICTING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION).
003097 03-04
THE RELATIONSHIP BETWEEN THE ACUTE BEHAVIORAL-EFFEQS OF
NARCOTIC ANTAGONISTS AND THE NARCOTIC DEPENDENT STATE
003106 03-04
A CLINICAL CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE
TREATMENT OF NARCOTIC ADDICTION. „ „. , ,
003335 03-11
EFFECTS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETECT THE NARCOTIC CHARACTER OF A DRUG.
003555 03-16
PHARMACOLOGICAL- STUDIES WITH AN ALKYLATING NARCOTIC
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST,
CHLORNALTREXAMINE „„.„„.„,«.
004082 04-04
INTERACTIONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
004127 04-04
NARCOTIC DISCRIMINATION IN PIGEONS.
004132 04-04
ANALGESIC AND OTHER PHARMACOLOGICAL ACTIVITIES OF A NEW
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3
METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS
ENANTIOMORPH IN EXPERIMENTAL ANIMALS.
004185 04-04
EFFECTS OF NARCOTIC ANTAGONISTS ON L-DOPA REVERSAL OF
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE.
004186 04-04
EFFEaS OF NARCOTIC ABSTINENCE ON SCHEDULE-CONTROLLED
BEHAVIOR IN DEPENDENT RATS.
004230 04-04
NARCOTIC-AGENTS
INFLUENCE OF NARCOTIC-AGENTS ON TEMPERATURE REGULATION.
001108 02-03
INTRACEREBRAL SUBSTANCE-P IN MICE: BEHAVIORAL-EFFECTS AND
NARCOTIC-AGENTS. „ „,
004218 04-04
NARCOTIC-DRUGS
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDia RATS: A POSSIBLE MODEL FOR PREDIQING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION)
003097 03-04
NARCOTIC-INDUCED
METHIONINE-ENKEPHALIN ANTAGONISM AND ENDORPHIN POTENTIATION
OF NARCOTIC-INDUCED ANALGESIA.
000357 01-04
NARCOTIC-REINFORCED ^ „„^.„,,„r
NARCOTIC-REINFORCED RESPONDING: A RAPID EVALUATION PROCEDURE.
004253 04-04
NARCOTICS
INVESTIGATION OF NARCOTICS AND ANTITUSSIVES USING DRUG
DISCRIMINATION TECHNIQUES.
000447 01-04
ON THE GENETIC SIDE-EFFECTS OF PSYCHOTROPIC-SUBSTANCES: I.
PSYCHOPHARMACEUTICALS, NARCOTICS, AND ANTICONVULSANT.
000845 01-15
INTERACTIONS OF NARCOTICS WITH SYNAPTOSOMAL CALCIUM
TRANSPORT. „„„,,„ «o^o
002712 03-03
MINI-SYMPOSIUM. IV. DISCRIMINATIVE-STIMULUS EFFEQS OF
NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED AQIONS.
004719 04-17
NASAL
RESPIRATORY-DISEASE AND NASAL IMMUNOGLOBULIN
CONCENTRATIONS IN PHENYTOIN TREATED EPILEPTIC-PATIENTS.
003486 03-15
NATRIUM-OXYBUTYRATE
CONTROLLED-COMPARISON OF THE THERAPEUTIC EFFEaS OF NATRIUM-
OXYBUTYRATE AND OXAZEPAM.
000658 01-10
NATURAL
REVIEW OF 38 CASES OF SUBACUTE SCLEROSING PANENCEPHALITIS:
EFFECT OF AMANTADINE ON THE NATURAL COURSE OF THE DISEASE.
000718 01-11
ATROPINE AND NATURAL SLEEP: AQIVITY DATA OF THE STRIATUM IN
RATS.
001551 02-03
NATURAL AND THERAPEUTIC ENVIRONMENTAL INDICATORS OF
MAINTENANCE DOSAGE REQUIREMENTS.
003561 03-16
DEBATE: THERAPEUTIC TRIALS IN A NATURAL ENVIRONMENT.
003635 03-17
DRUG-THERAPY FOR HYPERACTIVITY: TREATMENT PROCEDURES IN
NATURAL SEHINGS.
004449 04-11 !
CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND
NATURAL SEHINGS: CORRELATIONAL AND VARIANCE COMPONENTS
ANALYSES.
004508 04-13
NATURALISTIC
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
00411204-04
NAUSEA
INTRAVENOUS LORAZEPAM TO PREVENT NAUSEA AND VOMITING
ASSOCIATED WITH CANCER CHEMOTHERAPY.
003614 03-17
MITIGATING ACUTE SKIN RASHES AND NAUSEA FROM LITHIUM.
004661 04-15
NEFOPAM
THE EFFEaS OF NEFOPAM ON BLOOD ACID BASE STATUS IN THE RABBIT:
INTERAQIONS WITH MORPHINE IN THE MOUSE AND RABBIT.
004279 04-05
THE EFFEQ OF DELTA9 TETRAHYDROCANNABINOL ON THE POSITIVE AND
NEGATIVE FEEDBACK CONTROL OF LUTEINIZING-HORMONE RELEASE
000286 01-03
HIGH-SENSITIVITY NEGATIVE CHEMICAL-IONIZATION MASS-SPEQRAL-
ANALYSIS OF BIOGENIC-AMINES AND METABOLITES. (UNPUBLISHED
^''^^^^ 001042 02-01
QUANTITATIVE ANALYSIS OF 6 HYDROXYMELATONIN IN HUMAN URINE
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS-
SPEaROMETRY. (UNPUBLISHED PAPER).
001058 02-01
DRUG-EFFEaS ON THE PERFORMANCE OF PIGEONS UNDER A NEGATIVE
AUTOMAINTENANCE-SCHEDULE
001754 02-04
DIFFERENTIAL-EFFEaS OF AMPHETAMINE AND NEUROLEPTICS ON
NEGATIVE VS. POSITIVE SYMPTOMS IN SCHIZOPHRENIA.
001906 02-08
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS EFFEQS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300 „„o . c , «, . .
003451 03-14
THE NEGATIVE INFLUENCE OF FAMILIES ON COMPLIANCE.
004745 04-17
NELSONS-SYNDROME
EFFEa OF TREATMENT WITH SODIUM-VALPROATE AND DIAZEPAM ON
PLASMA CORTICOTROPIN IN NELSONS-SYNDROME.
004463 04-11
NEOCORTEX
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
•^^"^^^ 000323 01^3
REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY
NORADRENALINE INFUSION. 002672 03-03
EFFEQS OF FETAL TREATMENT WITH METHYLAZOXYMETHANOL-ACETATE
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE
ADULT NEOCORTEX OF THE RAT. 002770 03^3
SPREADING DEPRESSION INDUCED BY MICROINJEaiON OF ENKEPHALINS
INTO THE HIPPOCAMPUS AND NEOCORTEX.
004015 04-03
S-296
VOLUME 19, SUBJECT INDEX
Subject Index
EFl-ECTS Of 3 SULFAMOYLMETHYL-BENZISOXAZOLE (AD-810) AND SOME
ANTIEPILEPTICS ON THE KINDLED SEIZURES IN THE NEOCORTEX,
HIPPOCAMPUS AND AMYGDALA IN RATS.
004149 04-04
NEOCORTICAl
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-ACTIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
ACTIVITY.
000309 01-03
RESERPINE ABOLISHES MOVEMENT CORRELATED ATROPINE-RESISTANT
NEOCORTICAL LOW VOLTAGE FAST-ACTIVITY.
000310 01-03
EFFECTS OF LEAD EXPOSURE DURING DEVELOPMENT ON NEOCORTICAL
DENDRITIC AND SYNAPTIC STRUCTURE.
000525 01-05
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS.
004022 04-03
NEOMYCIN
EFFECTS OF NEOMYCIN ON CALCIUM AND POLYPHOSPHOINOSITIDE
METABOLISM OF GUINEA-PIG SYNAPTOSOMES.
002741 03-03
NEONATAL
NEONATAL ADMINISTRATION OF MET-ENKEPHALIN FACILITATES MAZE-
PERFORMANCE OF ADULT RATS.
001673 02-04
EFFECTS OF NEONATAL 6 HYDROXYDOPA ON BEHAVIOR IN FEMALE
RATS.
001717 02-04
NEUROCHEMICAL-CONSEQUENCES FOLLOWING ADMINISTRATION OF CNS
STIMULANTS TO THE NEONATAL RAT.
002926 03-03
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL-
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF
ANTIBODIES TO GANGLIOSIDE.
003025 03-04
EFFECTS OF NEONATAL TESTOSTERONE AND ESTROGEN ON OPEN-FIELD
BEHAVIOUR IN RATS.
003098 03-04
EFFEQ OF NEONATAL HYDROCORTISONE TREATMENT ON BRAIN-
MONOAMINES IN DEVELOPING RATS.
003893 04-03
THE EFFECTS OF P CHLOROAMPHET AMINE ADMINISTRATION ON
LOCOMOTOR-ACTIVITY AND SEROTONIN IN NEONATAL AND ADULT
RATS. (UNPUBLISHED PAPER).
004169 04-04
NEONATALIY
CATECHOLAMINE SEROTONIN INTERACTION EFFECTS ON ACTIVITY IN
RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE.
004194 04-04
NEONATE
EFFECT OF MATERNAL LORAZEPAM ON THE NEONATE.
003549 03-15
NEONATES
PHENCYCLIOINE: EFFECTS OF CHRONIC ADMINISTRATION IN THE FEMALE
MOUSE ON GESTATION, MATERNAL-BEHAVIOR, AND THE NEONATES.
000517 01-05
NEOPHOBIA
POSTINGESTION INTERFERENCE WITH BRAIN FUNCTION PREVENTS
AHENTUATION OF NEOPHOBIA IN RATS.
000352 01-04
NEOSTRIATAL
ROLE OF THE NEOSTRIATAL DOPAMINERGIC-AaiVITY IN SEQUENCING
AND SELECTING BEHAVIOURAL-STRATEGIES: FACILITATION OF
PROCESSES INVOLVED IN SELECTING THE BEST STRATEGY IN A
STRESSFUL-SITUATION.
000366 01-04
THE INFLUENCE OF ANTERIOR NEOSTRIATAL LESIONS ON THE
BEHAVIOURAL-EFFECTS OF SPIROPERIDOL IN RATS.
001702 02-04
APPARENT SEROTONERGIC MODULATION OF THE DOSE-DEPENDENT
BIPHASIC RESPONSE OF NEOSTRIATAL NEURONS PRODUCED BY D-
AMPHETAMINE.
003981 04-03
NEOSTRIATUM
OPPOSITE EFFEQS OF D-AMPHETAMINE ON SPONTANEOUS NEURONAL
ACTIVITY IN THE NEOSTRIATUM AND NUCLEUS-ACCUMBENS.
000454 01-04
INTRINSIC CHOLINERGIC EXCITATION IN THE RAT NEOSTRIATUM:
NICOTINIC AND MUSCARINIC-RECEPTORS.
001374 02-03
AVOIDANCE RESPONSE IN RATS AFTER INJECTION OF DOPAMINE INTO
THE NEOSTRIATUM.
004255 04-04
NEPHRITIS
THE ROLE OF LITHIUM IN THE PRODUCTION OF INTERSTITIAL NEPHRITIS;
A CASE-HISTORY.
004655 04-15
NEPHROPATHY
TARDIVE-DYSKINESIA AND LITHIUM ASSOCIATED NEPHROPATHY: ARE
YOU LIABLE?
000846 01-15
NERVE
THE LONG-TERM REGULATION OF GANGLIONIC TYROSINE-HYDROXYLASE
BY PREGANGLIONIC NERVE ACTIVITY.
000333 01-03
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
001024 02-01
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
DECREASE OF GAD IMMUNOREACTIVE NERVE TERMINALS IN THE
SUBSTANTIA-NIGRA AFTER KAINIC-ACID LESION OF THE STRIATUM.
(UNPUBLISHED PAPER).
001400 02-03
NERVE CELL CALCIUM AS A MESSENGER FOR OPIATE AND ENDORPHIN
ACTIONS.
001450 02-03
MECHANICAL-CHANGES IN CRAB NERVE FIBERS DURING ACTION
POTENTIALS. (UNPUBLISHED PAPER).
001505 02-03
MEASUREMENT OF THE MEMBRANE POTENTIAL OF ISOLATED NERVE
TERMINALS BY THE LIPOPHILIC CATION
{3H)TRIPHENYLMETHYLPH0SPH0NIUM-BR0MIDE.
002746 03-03
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF
METHAMPHETAMINE.
002812 03-03
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMITTER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
ULTRASTRUCTURAL LOCALIZATION OF MONOAMINES IN NERVE FIBERS
OF THE PINEAL-GLAND IN GOLDEN HAMSTERS.
003666 04-01
INSEPARABILITY OF ACETYLCHOLINESTERASE AND NERVE EXCITATION.
003875 04-03
NERVE GROWTH-FACTOR STIMULATES DEVELOPMENT OF SUBSTANCE-P
IN THE EMBRYONIC SPINAL-CORD.
003881 04-03
FURTHER ANALYSIS OF THE MECHANISMS OF ACTION OF
BATRACHOTOXIN ON THE MEMBRANE OF MYELINATED NERVE.
003884 04-03
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS.
004129 04-04
MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT.
004441 04-1 1
NERVE-ENDINGS
GABA FLUXES IN PRESYNAPTIC NERVE-ENDINGS FROM IMMATURE RATS.
000185 01-03
DOPAMINE BIOSYNTHESIS IS REGULATED BY THE AMINE NEWLY
RECAPTURED BY DOPAMINERGIC NERVE-ENDINGS.
001163 02-03
PRESYNAPTIC DOPAMINE-RECEPTORS IN STRIATAL NERVE-ENDINGS:
ABSENCE OF HALOPERIDOL-INDUCED SUPERSENSITIVITY.
001424 02-03
IN VIVO CHANGES IN THE GABA CONTENT OF NERVE-ENDINGS
(SYNAPTOSOMES) INDUCED BY INHIBITORS OF GABA UPTAKE.
001540 02-03
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: KINETIC STUDIES.
003814 04-03
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: PHARMACOLOGICAL-STUDIES.
003815 04-03
NERVES
PILLS FOR NERVES.
000652 01-10
NERVOUS-SYSTEM
CYCLIC-NUCLEOTIDES AND THE NERVOUS-SYSTEM.
004542 04-13
NERVOUS-TISSUE
NEUROTOXIC ESTERASE IN HUMAN NERVOUS-TISSUE.
003510 03-15
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
"I
T"
S-297
Subject Index
Psychopharmacology Abstracts
111!!
Slllll
'Bllll'l
M'
Ml
33il',:;
*m
it
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
NEST-BUILDING-BEHAVIOR
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: I. SOCIAL-INTERACTIONS
AND NEST-BUILDING-BEHAVIOR OF MALES.
001777 02-04
NEURAL
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE-
ENKEPHALIN AND CHOLECYSTOKININ IN THE NEURAL RETINA OF
SEVERAL VERTEBRATE SPECIES. (UNPUBLISHED PAPER).
001017 02-01
LITHIUM-ION ENTRY INTO CULTURED CELLS OF NEURAL ORIGIN.
001433 02-03
STIMULATION OF THE PLASMA MEMBRANE ENZYME. 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
THE PHARMACOLOGY OF CATECHOLAMINE INVOLVEMENT IN THE
NEURAL MECHANISMS OF REWARD.
001526 02-03
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
002699 03-03
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMIHER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE. PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NICTITATING MEMBRANE OF THE CAT.
003822 04-03
NEURALIY
CORTICAL CONTROL OF NEURALLY MEDIATED ARRHYTHMOGENIC-
PROPERTIES OF DESACETYLLANATOSIOE-C.
003124 03-05
NEURAMINIDASE
EXPOSURE OF MITOCHONDRIAL OUTER MEMBRANES TO NEURAMINIDASE
SELECTIVELY DESTROYS MONOAMINE-OXIDASE-A AQIVITY.
001286 02-03
NEUROACTIVE-A6ENTS
THE EFFECTS OF 2.5 DIMETHOXY-4-METHYLAMPHET AMINE (DOM) ON
OPERANT-BEHAVIOR: INTERACTIONS WITH OTHER NEUROAQIVE-
AGENTS.
004089 04-04
NEUROANATOMICAL-STUDY
A NEUROANATOMICAL-STUDY OF ANALGESIA AND CATATONIA INDUCED
BY ETORPHINE IN THE RAT. (PH.D. DISSERTATION).
003102 03-04
NEUROANATOMY
SATIETY CENTER NEUROANATOMY. (UNPUBLISHED PAPER).
003678 04-01
THE NEUROANATOMY AND PHARMACOLOGY OF THE NUCLEUS LOCUS-
COERULEUS. (UNPUBLISHED PAPER).
003810 04-03
NEUROBEHAVIORAL
THE BRAINSTEM AUDITORY EVOKED-RESPONSE AS A TOOL IN
NEUROBEHAVIORAL TOXICOLOGY AND MEDICINE.
004277 04^5
NEUROBIOLOGICAL
BASIC AND CLINICAL NEUROBIOLOGICAL APPLICATIONS OF NEURONAL
(NSE) AND NONNEURONAL (NNE) ENOLASE. (UNPUBLISHED PAPER).
001041 02-01
NEUROBIOLOGICAL-PERSPECTIVE
THE PHARMACOLOGY OF MEMORY: A NEUROBIOLOGICAL-PERSPEQIVE.
003636 03-17
NEUROBIOLOGY
PEPTIDES IN NEUROBIOLOGY: AN OVERVIEW. (UNPUBLISHED PAPER).
001008 02-01
NEUROBIOLOGY AND NEUROPHARMACOLOGY OF THE ENKEPHALINS.
002580 02-17
NEUROBLASTOMA
PSYCHOTROPIC-DRUGS AND HISTAMINE Hl-RECEPTORS OF CULTURED
MOUSE NEUROBLASTOMA CELLS.
000250 01-03
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
003783 04-03
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF ALPHA-
ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA HYBRID
CELLS.
003823 04-03
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C-
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM-
CHANNEL BLOCKADE.
004020 04-03
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
004030 04-03
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP-
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF
MOUSE NEUROBLASTOMA CELLS USING
(3H)TETRAPHENYLPH0SPH0NIUM.
004049 04-03
NEUROBLASTOMA-X
RELATIONSHIP BETWEEN THE ACTIONS OF CALCIUM-IONS. OPIOIDS, AND
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN
NEUROBLASTOMA-X GLIOMA HYBRID CELLS.
002677 03-03
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
AQIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
NEUROCHEMICAL
PRODRUGS OF SOME DOPAMINERGIC 2 AMINOTETRALINS: A REVIEW OF
THEIR SYNTHESES AND NEUROCHEMICAL PROFILES.
000004 01-01
CORTICAL NEUROCHEMICAL CHANGES AFTER INTRASTRIATAL INJEQION
OF KAINIC-ACID.
000133 01-03
CGP-6085-A. A NEW. SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE:
NEUROCHEMICAL CHARAQERIZATION AND COMPARISON WITH OTHER
SEROTONIN UPTAKE BLOCKERS.
000316 01-03
ON THE NEUROCHEMICAL BASIS OF SELF-STIMULATION WITH MIDBRAIN
RAPHE ELECTRODE PLACEMENTS.
000373 01-04
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL-
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL
SEROTONERGIC FUNQION.
000491 01-04
NEUROCHEMICAL MECHANISMS OF OPIATES AND ENDORPHINS.
000958 01-17
NEUROPHARMACOLOGICAL AND NEUROCHEMICAL APPROACHES TO
PRECLINICAL-EVALUATION OF NEUROLEPTICS.
001094 02-02
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR
THE POTENTIATION OF IMIPRAMINE EFFEQS ON THE METABOLISM
AND UPTAKE OF BRAIN CATECHOLAMINES.
001427 02-03
NEUROCHEMICAL BASIS OF THE AQION OF ANTIDEPRESSANTS ON
LEARNED-HELPLESSNESS.
001775 02-04
THE STRIATONIGRAL GABA PATHWAY: FUNQIONAL AND
NEUROCHEMICAL CHARAQERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A
SELEQIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST.
002236 02-13
CHRONOLOGY OF NEUROCHEMICAL ALTERATIONS INDUCED BY GABA
AGONIST ADMINISTRATION.
002713 03-03
TEMPORAL PATTERNING OF NEURONAL AQIVITY DURING THERMAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
RECENT REVIEWS OF BIOCHEMICAL, NEUROCHEMICAL, AND
PHARMACOLOGICAL TOPICS.
003649 03-17
BEHAVIOURAL AND NEUROCHEMICAL PROPERTIES OF 1 1 INDOL-3-
YLMETHYLPIPERID-4-YL-3-BENZ0YLUREA (WY-25093) IN RODENTS.
003686 04-02
BEHAVIORAL AND REGIONAL NEUROCHEMICAL SEQUELAE OF
HIPPOCAMPAL DESTRUaiON IN THE RAT
003721 04-03
CHANGES OF ELEaRORETINOGRAM AND NEUROCHEMICAL ASPEQS OF
GABAERGIC NEURONS OF RETINA AFTER INTRAOCULAR INJEQION OF
KAINIC-ACID IN RATS.
003807 04-03
A POSSIBLE NEUROCHEMICAL BASIS OF THE CENTRAL STIMULATORY
EFFEaS OF PP'DDT.
004274 04-05
NEUROCHEMICAL-BASES ^ _
THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA.
002976 03-04
NEUROCHEMICAL-CONSEQUENCES
NEUROCHEMICAL-CONSEQUENCES FOLLOWING ADMINISTRATION OF CNS
STIMULANTS TO THE NEONATAL RAT.
002926 03-03
NEUROCHEMICAL-CORRELATES
BEHAVIORAL-DEPRESSION AND ITS NEUROCHEMICAL-CORRELATES AT
HIGH-DOSES OF D-AMPHETAMINE IN RATS.
001601 02-04
S-298
VOLUME 19, SUBJECT INDEX
Subject Index
NEUROCHEMICAL-EFFECTS
NEUROCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF CHRONIC D-
AMPHETAMINE TREATMENT IN GENETICALLY OBESE (OBOB) MICE.
(PH.D. DISSERTATION).
001739 02-04
A COMPARISON OF THE NEUROCHEMICAL-EFFECTS OF BUPRENORPHINE
WITH THOSE OF MORPHINE AND HALOPERIDOL IN RATS.
002701 03-03
A REEVALUATION OF THE NEUROCHEMICAL-EFFEQS AND
ANTINOCICEPTIVE-EFFEaS OF INTRATHECAL CAPSAICIN IN THE RAT.
004184 04-04
NEUROCHEMICAL-PHARMACOLOGY
NEUROCHEMICAL-PHARMACOLOGY AND BIOCHEMICAL-PHARMACOLOGY.
003639 03-17
NEUROCHEMICAL-STUDIES
BEHAVIORAL-STUDIES AND NEUROCHEMICAL-STUDIES OF LESCH-NYHANS-
SYNDROME.
001743 02-04
NEUROCHEMICAL-STUDIES OF AN ANALGESIC, 1,3 DIPHENYL-5-2-
DIMETHYLAMINOPROPIONAMIDE-PYRAZOLE (DIFENAMIZOLE) .
002771 03-03
CHARAQERIZATION OF THE ISOLATED PERFUSED MOUSE-BRAIN AS A
SYSTEM FOR NEUROCHEMICAL-STUDIES.
003146 03-06
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN:
NEUROCHEMICAL-STUDIES IN AN ANIMAL-MODEL OF TARDIVE-
DYSKINESIA.
004268 04-05
NEUROCHEMICAl-STUOY
ANATOMICOPHYSIOLOGICAL AND NEUROCHEMICAL-STUDY OF THE
LIMBIC-SYSTEM: EFFEQ OF NOMIFENSINE.
001160 02-03
NEUROCHEMISTRY
EFFECTS OF FETAL TREATMENT WITH METHYLAZOXYMETHANOL-ACETATE
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE
ADULT NEOCORTEX OF THE RAT.
002770 03-03
ESSAYS IN NEUROCHEMISTRY AND NEUROPHARMACOLOGY.
003652 03-17
NEUROENDOCRINE
DOPAMINERGIC FAQORS IN HUMAN PROLACTIN REGULATION: A
PITUITARY MODEL FOR THE STUDY OF A NEUROENDOCRINE SYSTEM IN
MAN.
000776 01-13
PINEAL INTERAQIONS WITH THE CENTRAL-NERVOUS- SYSTEM:
NEUROENDOCRINE IMPLICATIONS. (PH.D. DISSERTATION).
001341 02-03
EFFEaS OF NEUROLEPTICS ON NEUROENDOCRINE MECHANISMS FOR
GONADOTROPIN SECRETION.
001391 02-03
EFFEQ OF PSYCHOTROPIC-DRUGS ON NEUROENDOCRINE FUNQION.
002265 02-13
ENDORPHIN OPIATE INTERAQIONS WITH NEUROENDOCRINE SYSTEMS.
002552 02-17
NEUROENDOCRINE APPROACHES TO PSYCHONEUROPHARMACOLOGIC-
RESEARCH.
003426 03-13
NEUROENDOCRINE DISTURBANCE IN DEPRESSION.
004405 04-09
ARE THE ENKEPHALINS INVOLVED IN PARKINSONS-DISEASE? CLINICAL
AND NEUROENDOCRINE RESPONSES TO NALOXONE ADMINISTRATION.
004431 04-11
BIOCHEMICAL AND NEUROENDOCRINE APPROACHES TO A MALIGNANT-
SYNDROME OF NEUROLEPTIC.
004589 04-15
NEUROENDOCRINE-STUDIES
EFFEQ OF SODIUM-VALPROATE AND BACLOFEN IN TARDIVE-DYSKINESIA:
CLINICAL-STUDIES AND NEUROENDOCRINE-STUDIES.
002441 02-15
NEUROENDOCRINE-STUDY
A NEUROENDOCRINE-STUDY OF SUPERSENSITIVITY IN TARDIVE-
DYSKINESIA.
000908 01-16
A NEUROPHARMACOLOGICAL-STUDY AND NEUROENDOCRINE-STUDY ON
IDIOPATHIC AND CHRONIC PHARMACOLOGICAL PARKINSONISM.
002371 02-15
A NEUROENDOCRINE-STUDY OF ADRENOCEPTOR FUNCTION IN
ENDOGENOUS DEPRESSION.
004362 04-09
NEUROENDOCRINE-TESTS
NEUROENDOCRINE-TESTS DURING TREATMENT WITH NEUROLEPTIC-
DRUGS: I. PLASMA PROLACTIN RESPONSE TO CHLORPROMAZINE
CHALLENGE.
004329 04-08
NEUR0END0CRIN0L06Y
NEUROENDOCRINOLOGY OF DEPRESSION - A DISCUSSION.
003402 03-13
NEUROHORMONAL
THE HYPOTHALAMIC DOPAMINERGIC REGULATION OF PROLACTIN: A
MODEL FOR THE STUDY OF NEUROHORMONAL MECHANISMS IN MAN.
002568 02-17
NEUROHUMORS
LSD, PSYCHOTOGENIC PROCEDURES AND BRAIN NEUROHUMORS.
(UNPUBLISHED PAPER).
004448 04-1 1
NEUROINTERMEDIATE
SODIUM-CHLORIDE INHIBITION DECREASES LEVELS OF IMMUNOREACTIVE
DYNORPHIN IN THE NEUROINTERMEDIATE PITUITARY OF RATS.
001283 02-03
NEUROLATHYROOEN
THE NEUROLATHYROOEN, BETA N OXALYL-L-ALPHA-BETA-
DIAMINOPROPIONIC-ACID, IS A POTENT AGONIST AT GLUTAMATE
PREFERRING RECEPTORS IN THE FROG SPINAL-CORD.
002858 03-03
NEUROLEPTIC
STRIATAL DOPAMINERGIC ACTIVITY DURING WITHDRAWAL FROM
CHRONIC NEUROLEPTIC TREATMENT IN RATS.
000203 01-03
ORAL DYSKINESIA IN BRAIN-DAMAGED RATS WITHDRAWN FROM A
NEUROLEPTIC: IMPLICATION FOR MODELS OF TARDIVE-DYSKINESIA.
000393 01-04
NEUROLEPTIC AND THYMOLEPTIC TREATMENT OF PSYCHOTIC-
OUTPATIENTS.
000556 01-08
CLINICAL-RESPONSE AND SERUM NEUROLEPTIC LEVELS IN CHILDHOOD-
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
000566 01-08
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY: EFFICACY, DOSAGE SCHEDULE AND PLASMA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
THE OCCURRENCE OF TARDIVE EXTRAPYRAMIDAL SYMPTOMS IN
SCHIZOPHRENIC-PATIENTS UNDERGOING PROLONGED NEUROLEPTIC
TREATMENT.
000885 01-15
TARDIVE TOUREHE-SYNDROME IN AN AUTISTIC-PATIENT AFTER LONG-
TERM NEUROLEPTIC ADMINISTRATION.
000887 01-15
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY.
000890 01-15
ENDOCRINOLOGICAL CHANGES IN PATIENTS WITH SEXUAL-DYSFUNCTION
UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000912 01-17
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE NEUROLEPTIC
PIMOZIDE-HYDROCHLORIDE, BISFLUOROPHENYL-
BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL.
001015 02-01
AMOXAPINE IN EXPERIMENTAL PSYCHOPHARMACOLOGY: A
NEUROLEPTIC OR AN ANTIDEPRESSANT?
001070 02-02
FLU0R0-5-FLU0R0PHENYL-2-FLU0R0PHENYL4
HYDROXYBUTYLHEXAHYDROPYRIDOINDOLE-HCL, A NEW POTENT
NEUROLEPTIC.
001092 02-02
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER ACTIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT.
001095 02-03
EFFECTS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE.
001243 02-03
PERINATAL NEUROLEPTIC ACTIONS - DEVELOPMENTAL RESULTS.
(UNPUBLISHED PAPER).
001277 02-03
INCREASED RENAL NEUROLEPTIC BINDING IN SPONTANEOUSLY
HYPERTENSIVE-RATS.
001444 02-03
THE ROLE OF GAMMA AMINOBUTYRIC-ACID IN ACUTE AND CHRONIC
NEUROLEPTIC ACTION.
001465 02-03
BRAIN-MONOAMINES IN THE RHESUS-MONKEY DURING LONG-TERM
NEUROLEPTIC ADMINISTRATION.
001471 02-03
CHRONIC NEUROLEPTIC TREATMENT AND DOPAMINE-RECEPTOR
REGULATION.
001837 02-05
3H APOMORPHINE-RECEPTORS IN VARIOUS RAT-BRAIN REGIONS: A
STUDY OF SPECIFIC AND NONSPECIFIC BINDING AND THE INFLUENCE OF
CHRONIC NEUROLEPTIC TREATMENT.
001846 02-05
NEUROLEPTIC/OOPAMINE-RECEPTORS: ELEVATION AND REVERSAL.
001847 02-05
5a'
S-299
Subject Index
Psychopharmacology Abstracts
ifiliU
Slllli
Ml
•Htil:j.
■Siilii;;
a:
NEUROLEPTIC TREATMENT FOR A SUBSTANTIAL PROPORTION OF ADULT
LIFE: BEHAVIOURAL-SEQUELAE OF 9 MONTHS HALOPERIDOL
ADMINISTRATION.
001858 02-05
USE OF LARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC-
PATIENTS WITH ELEVATED SERUM PROLACTIN LEVELS AND
EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH NEUROLEPTIC
TREATMENT,
001944 02-08
SERUM NEUROLEPTIC CONCENTRATIONS IN SCHIZOPHRENIA.
(UNPUBLISHED PAPER).
001945 02-08
RELATIONSHIPS AMONG BIOCHEMICAL-VARIABLES, CLINICAL-
VARIABLES, AND PHARMACOKINETIC-VARIABLES IN NEUROLEPTIC
TREATED SCHIZOPHRENIC-PATIENTS.
001946 02-08
MAINTENANCE-TREATMENT WITH SEMIDEPOTE NEUROLEPTIC
FLUSPIRILENE.
002151 02-11
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN
SCHIZOPHRENIA.
002390 02-15
APPROACHES TO THE PROBLEM OF PREVENTING HAZARDS OF LONG-
TERM NEUROLEPTIC TREATMENT AND OF AVOIDING UNNECESSARY
DRUGS.
002426 02-15
NEUROLEPTIC BLOOD LEVELS AND THERAPEUTIC EFFEQ.
002480 02-16
RELATIONSHIP BETWEEN STRUCTURE AND NEUROLEPTIC ACTIVITY:
PHARMACOPHORE AND PHARMACOKINETICS.
002492 02-16
DURING ONE YEARS NEUROLEPTIC TREATMENT IN RATS STRIATAL
DOPAMINE-RECEPTOR BLOCKADE DECREASES BUT SERUM PROLAQIN
LEVELS REMAIN ELEVATED.
002707 03-03
NEUROLEPTIC AQION ON HEPATIC ENZYMATIC AQIVITY.
002849 03-03
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR
FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY.
002986 03-04
PERSPEQIVES ON PRAZINIL (CARPIPRAMINE): A DISINHIBITING-AGENT
WITH NO NEUROLEPTIC AQIVITY. A REVIEW OF 38 CASES.
003149 03-07
SYNERGISM OF COMBINED LITHIUM NEUROLEPTIC THERAPY: A DOUBLE-
BUND, PLACEBO-CONTROLLED CASE-STUDY.
003165 03-08
LOW SERUM PROLACTIN AND EARLY RELAPSE FOLLOWING NEUROLEPTIC
WITHDRAWAL.
003166 03-08
THE NEED FOR CONTINUOUS USE OF ANTIPARKINSONIAN MEDICATION
WITH CHRONIC SCHIZOPHRENIC-PATIENTS RECEIVING LONG-TERM
NEUROLEPTIC THERAPY.
003186 03-08
NEUROLEPTIC SERUM LEVELS MEASURED BY RADIORECEPTOR ASSAY
AND CLINICAL-RESPONSE IN SCHIZOPHRENIC-PATIENTS.
003199 03-08
CHANGES IN THE PSYCHOPATHOLOGY OF PSYCHOSIS DUE TO
NEUROLEPTIC TREATMENT.
003281 03-10
THE EFFEa OF AMANTADINE ON PROLACTIN LEVELS AND
GALAaORRHEA ON NEUROLEPTIC TREATED PATIENTS.
003373 03-1 1
NEUROLEPTIC MALIGNANT-SYNDROME: A PATHOGENETIC ROLE FOR
DOPAMINE-RECEPTOR BLOCKADE?
003492 03-15
CHOLINERGIC REBOUND IN NEUROLEPTIC WITHDRAWAL-SYNDROMES.
003506 03-15
ON SENSORY-DISTURBANCES OCCURRING DURING NEUROLEPTIC
THERAPY.
003531 03-15
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT
ANTICHOLINERGIC-ACTIVITY BY AN ATYPICAL NEUROLEPTIC
(THIORIDAZINE).
003560 03-16
NEUROLEPTIC AQIVITY: A SUMMARY OF PROFESSOR JACQUES
GLOWINSKIS PRESENTATION.
003628 03-17
SOLUBILIZATION OF NEUROLEPTIC/DOPAMINE-RECEPTORS OF HUMAN
BRAIN STRIATUM.
003767 04-03
EFFEa OF PRENATAL NEUROLEPTIC TREATMENT ON MEMBRANE
RECEPTOR DEVELOPMENT IN THE BRAIN.
003989 04-03
CHRONIC NEUROLEPTIC TREATMENT SPECIFICALLY ALTERS THE NUMBER
OF DOPAMINE-RECEPTORS IN RAT-BRAIN.
004033 04-03
IS DOPAMINE ANTAGONISM A REQUISITE OF NEUROLEPTIC AQIVITY?
004122 04-04
BEHAVIORAL AND BIOCHEMICAL- STUDIES OF THE SCOPOLAMINE-INDUCED
REVERSAL OF NEUROLEPTIC AQIVITY.
004195 04-04
THE PROLACTIN RESPONSE IN PATIENTS RECEIVING NEUROLEPTIC
THERAPY. THE EFFEQ OF FLUPHENAZINE-DECANOATE.
004318 04-08
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO
COUNTERAQ CURATIVE EFFEaS OF NEUROLEPTIC-DRUGS.
004321 04-08
LONG-TERM NEUROLEPTIC TREATMENT OF CHRONIC SCHIZOPHRENIC-
PATIENTS: CLINICAL AND BIOCHEMICAL-EFFEQS OF WITHDRAWAL.
004344 04-08
AN EVALUATION OF THE USEFULNESS OF THE ACYLASE TEST IN
NEUROLEPTIC TREATMENT.
004426 04-10
NEUROLEPTIC TRICYCLIC-ANTIDEPRESSANT COMBINATION:
PHARMACOLOGICAL-ASPEaS AND THERAPEUTIC INTEREST.
004501 04-13
CEREBROSPINAL-FLUID HOMOVANILLIC-ACID PATTERNS DURING
NEUROLEPTIC TREATMENT. (UNPUBLISHED PAPER).
004502 04-13
BIOCHEMICAL AND NEUROENDOCRINE APPROACHES TO A MALIGNANT-
SYNDROME OF NEUROLEPTIC.
004589 04-15
EFFEaS OF NEUROLEPTIC ADJUSTMENT ON CLINICAL CONDITION AND
TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-PATIENTS.
004595 04-15
NEUROLEPTIC TREATMENT AS EXPERIENCED BY A PSYCHIATRIST
00461304-15
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL.
004620 04-15
MEASUREMENT OF NEUROLEPTIC CONCENTRATIONS BY GLC AND
RADIORECEPTOR ASSAY.
004682 04-16
NEUROLEPTIC-AGENT
THE TREATMENT OF BUCCOLINGUOFACIAL DYSKINESIA IN THE ELDERLY:
THE CHOICE OF A NEUROLEPTIC-AGENT.
002223 02-13
NEUROLEPTIC-AGENTS
SYNTHESIS OF SOME 5 PHENYLHEXAHYDROAZEPINOINDOLES AS
POTENTIAL NEUROLEPTIC-AGENTS.
001019 02-01
LONG-TERM-TREATMENT WITH NEUROLEPTIC-AGENTS: ADAPTATION
PHENOMENA AND THEIR SIGNIFICANCE WITH REGARD TO
SCHIZOPHRENIC-SYMPTOMATOLOGY AND SIDE-EFFEQS.
002370 02-15
A TRIAL TREATMENT WITH TIAPRIDE FOR SOME EXTRAPYRAMIDAL-
SYNDROMES CAUSED BY NEUROLEPTIC-AGENTS.
003553 03-15
NEUROLEPTIC-DRU6
THE EFFECT OF A NEW FLUORINATED TRICYCLIC NEUROLEPTIC-DRUG
ISOFLOXYTHEPIN ON THE RAT STRIATAL DOPAMINE METABOLISM.
000306 01-03
PHARMACOLOGICAL-STUDY OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW
NEUROLEPTIC-DRUG.
000493 01-04
TOXICOLOGICAL AND TERATOLOGICAL STUDIES OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW
NEUROLEPTIC-DRUG.
000515 01-05
LOXAPINE-SUCCINATE: A NEW NEUROLEPTIC-DRUG.
000551 01-08
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND RECEPTOR BINDING-
AQIVITIES FOUOWING ACUTE AND CHRONIC NEUROLEPTIC-DRUG
TREATMENT. (UNPUBLISHED PAPER).
001172 02-03
KINETICS OF CENTRAL-ACTIONS OF ISOFLOXYTHEPIN, AN ORAL
NEUROLEPTIC-DRUG WITH PROLONGED AQION IN RODENTS.
001720 02-04
THE PLACE OF LOXAPINE - A NEW NEUROLEPTIC-DRUG.
001886 02-07
NEUROLEPTIC-DRUGS
PROLACTIN RESPONSE AND EXTRAPYRAMIDAL SIDE-EFFEaS DURING
PROPRANOLOL AND NEUROLEPTIC-DRUGS TREATMENT IN CHRONIC
SCHIZOPHRENIC-PATIENTS.
000841 01-15
EFFEQ OF NEUROLEPTIC-DRUGS ON LITHIUM UPTAKE BY THE HUMAN
ERYTHROCYTE.
000973 01-17
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/
NEUROLEPTIC-RECEPTOR BINDING: EFFEQ OF NEUROLEPTIC-DRUGS
001358 02-03
THE EFFEQS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERAQION
S-300
VOLUME 19, SUBJECT INDEX
Subject Indsx
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED
AHENTION. (PH.D. DISSERTATION).
001563 02-04
BEHAVIORAL-CONSEQUENCES OF LONG-TERM-TREATMENT WITH
NEUROLEPTIC-DRUGS.
001661 02-04
THE PHOTOCHEMICAL- STABILITY OF CIS-ISOMERS AND TRANS-ISOMERS
OF TRICYCLIC NEUROLEPTIC-DRUGS.
001872 02-06
TARDIVE-DYSKINESIA FROM NEUROLEPTIC-DRUGS: REVIEW OF THE
LITERATURE.
002398 02-15
THE INFLUENCE OF NEUROLEPTIC-DRUGS ON PROLACTIN SECRETION IN
CHILDREN.
002409 02-15
CHRONOLOGY OF EXTRAPYRAMIDAL-EFFECTS OF NEUROLEPTIC-DRUGS
AND THE NIGROSTRIATAL DOPAMINERGIC-SYSTEM.
002449 02-15
CLINICAL-ASPECTS ON PROLACTIN RESPONSE TO NEUROLEPTIC-DRUGS.
002590 02-17
ENHANCEMENT OF NORADRENALINE RELEASE FROM RAT-CEREBRAL-
CORTEX BY NEUROLEPTIC-DRUGS.
002742 03-03
DIFFERENCES IN THE CLINICAL ACTION OF SOME NEUROLEPTIC-DRUGS.
003204 03-08
MEDICAL AND LEGAL IMPLICATIONS OF SIDE-EFFEaS FROM
NEUROLEPTIC-DRUGS. A ROUND-TABLE DISCUSSION.
003471 03-15
DOPAMINERGIC NEURONS OF SPINAL-CORD: A POSSIBLE SITE FOR THE
AaiON OF NEUROLEPTIC-DRUGS.
004188 04-04
DISRUPTION OF AUTOSHAPED RESPONDING TO A SIGNAL OF BRAIN-
STIMULATION REWARD BY NEUROLEPTIC-DRUGS.
004199 04-04
ELEQROCARDIOGRAPHIC-CHANGES IN RATS DURING CHRONIC-
TREATMENT WITH ANTIDEPRESSANT AND NEUROLEPTIC-DRUGS.
004284 04-05
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO
COUNTERACT CURATIVE EFFECTS OF NEUROLEPTIC-DRUGS.
004321 04-08
NEUROENDOCRINE-TESTS DURING TREATMENT WITH NEUROLEPTIC-
DRUGS: I. PLASMA PROLAQIN RESPONSE TO CHLORPROMAZINE
CHALLENGE.
004329 04-08
THE EFFEQ OF AN INTENSIVE COURSE OF NEUROLEPTIC-DRUGS ON
SCHIZOPHRENIC-PATIENTS AND THEIR SUBSEQUENT COURSE
FOLLOWING THE CESSATION OF ALL NEUROLEPTIC-MEDICATION.
004341 04-08
CHANGES IN PSYCHOPATHOLOGIC SYMPTOMS DURING 20 DAYS OF
TREATMENT WITH ANTIDEPRESSANTS AND NEUROLEPTIC-DRUGS.
004415 04-09
PROLAQIN AND NEUROLEPTIC-DRUGS: A BIOCHEMICAL INDEX OF
CLINICAL-RESPONSE?
004539 04-13
THE EFFEaS OF NEUROLEPTIC-DRUGS ON THE SOCIAL INTERAQIONS OF
HOSPITALIZED PSYCHOTIC-PATIENTS.
004577 04-14
NEUROLEPTIC-EFFECT
NEUROLEPTIC-EFFEQ ON DESIPRAMINE STEADY-STATE PLASMA
CONCENTRATIONS.
000781 01-13
A PROBABLE NEUROLEPTIC-EFFECT ON PLATELET MONOAMINE-OXIDASE
IN CHRONIC SCHIZOPHRENIC-PATIENTS.
003169 03-08
NEUROLEPTIC-EFFECTS
SUSTAINED GAMMA AMINOBUTYRIC-ACID-RECEPTOR STIMULATION AND
CHRONIC NEUROLEPTIC-EFFECTS.
001345 02-03
NEUROLEPTIC-INDUCED
THE USE OF EXTINQION TO INVESTIGATE THE NATURE OF NEUROLEPTIC-
INDUCED AVOIDANCE-DEFICITS.
000345 01-04
NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA: RECENT
PATHOPHYSIOLOGICAL-DATA, THERAPEUTIC TRIALS.
000842 01-15
EFFEQ OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED
EXTRAPYRAMIDAL ALTERATIONS.
001119 02-03
STUDIES ON THE SPECIFICITY AND REVERSAL OF NEUROLEPTIC-INDUCED
DOPAMINERGIC-SUPERSENSITIVITY. (PH.D. DISSERTATION).
001469 02-03
INHIBITION OF NEUROLEPTIC-INDUCED DOPAMINE-RECEPTOR
SUPERSENSITIVITY BY CYCLO-LEU-GLY.
001576 02-04
ANTICHOLINERGICS PROMOTE NEUROLEPTIC-INDUCED TARDIVE-
DYSKINESIA.
001834 02-05
PIRACETAM ACTION IN NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL SIDE-
EFFECTS.
002132 02-11
NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIAS.
002382 02-15
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL-
NERVOUS-SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE-
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS).
002459 02-15
NEUROLEPTIC-INDUCED ACUTE DYSTONIC REACTIONS MAY BE DUE TO
ENHANCED DOPAMINE RELEASE ON TO SUPERSENSITIVE
POSTSYNAPTIC-RECEPTORS,
002789 03-03
NEUROLEPTIC-INDUCED ELEVATIONS IN SERUM PROLAQIN LEVELS:
ETIOLOGY AND SIGNIFICANCE.
003190 03-08
NEUROLEPTIC-INDUCED SYNDROME MIMICKING MYASTHENIA-GRAVIS.
003474 03-15
THE DIAGNOSIS AND TREATMENT OF NEUROLEPTIC-INDUCED
PARKINSONISM.
003493 03-15
THE USE OF CONDITIONED SUPPRESSION TO EVALUATE THE NATURE OF
NEUROLEPTIC-INDUCED AVOIDANCE-DEFICITS.
004070 04-04
ON THE THERAPY OF NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA WITH
DIMETHYLAMINOETHANOL (DEANOL).
004627 04-15
NEUROLEPTIC-MEDICATION
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFEQ IN SCHIZOPHRENIA AND
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO
NEUROLEPTIC-MEDICATION.
001911 02-08
HORMONE LEVELS IN ACUTE SCHIZOPHRENIA WITH AND WITHOUT
NEUROLEPTIC-\.[iDICATION.
001923 02-08
PHENYLKETONURIA: THE INADVISABILITY OF NEUROLEPTIC-MEDICATION.
003380 03-1 1
THE EFFECT OF AN INTENSIVE COURSE OF NEUROLEPTIC-DRUGS ON
SCHIZOPHRENIC-PATIENTS AND THEIR SUBSEQUENT COURSE
FOLLOWING THE CESSATION OF ALL NEUROLEPTIC-MEDICATION.
004341 04-08
NEUROLEPTiC-MEDICINE
CASE-REPORT: USING AHRIBUTION THEORY TO LIMIT NEED FOR
NEUROLEPTIC-MEDICINE.
000559 01-08
NEUROLEPTIC-PEPTIDE
EFFECTS OF THE POTENTIAL NEUROLEPTIC-PEPTIDE DES-TYR1-6AMMA-
ENDORPHIN AND HALOPERIDOL ON APOMORPHINE-INDUCED
BEHAVIOURAL-SYNDROMES IN RATS AND MICE.
000441 01-04
NEUROLEPTIC-RECEPTOR
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/
NEUROLEPTIC-RECEPTOR BINDING: EFFECT OF NEUROLEPTIC-DRUGS.
001358 02-03
NEUROLEPTIC-RECEPTORS
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A
LIGAND FOR NEUROLEPTIC-RECEPTORS - I. IN VITRO STUDIES.
001133 02-03
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE. AS A
LIGAND FOR NEUROLEPTIC-RECEPTORS - II. IN VIVO STUDIES.
001137 02-03
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2
DOPAMINE-RECEPTORS IN THE CNS.
001480 02-03
NEUROLEPTIC-SYNDROME
CORRECTION OF THE EXTRAPYRAMIDAL NEUROLEPTIC-SYNDROME BY
TRYPTOPHAN AND THE TIME-COURSE OF ITS CONTENT IN THE BLOOD
OF PATIENTS.
004434 04-11
NEUROLEPTICA
THE TWO SURVIVAL CASES OF ALPHA-PAHERN COMA CAUSED BY
LARGE AMOUNTS OF HYPNOTICA AND NEUROLEPTICA.
004608 04-15
NEUROLEPTICS
FLUORINATED ANALOGUES OF THE TRICYCLIC NEUROLEPTICS: 2,3
DIFLUORO DERIVATIVE OF CLOROTEPIN.
000001 01-01
ACUTE AND CHRONIC EFFECTS OF NEUROLEPTICS AND ACUTE EFFECTS OF
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN.
000215 01-03
CHANGES IN OPIATE ACTIVITY OF RAT PITUITARY FOLLOWING ACUTE
ADMINISTRATION OF NEUROLEPTICS.
000282 01-03
THE STIMULANT-EFFECT OF NEUROLEPTICS: MYTH OR REALITY?
000362 01-04
S-301
Subject Index
liliSj
m
4i3!ii:;
li:r
Si
Or.
BIOCHEMICAL-STUDIES AFTER CHRONIC ADMINISTRATION OF
NEUROLEPTICS TO MONKEYS.
000523 01-05
WHAT IS THE BEST MAINTENANCE DOSE OF NEUROLEPTICS IN
SCHIZOPHRENIA?
000547 01-08
THE PLACE OF LONG-ACTING NEUROLEPTICS IN THE TREATMENT OF
SCHIZOPHRENIA.
000563 01-08
THE ULTRASTRUaURAL CHANGES OF SYNAPSES IN RAT FOLLOWING
LONG-TERM ADMINISTRATION OF THE NEUROLEPTICS RESERPINE AND
HALOPERIDOL.
000795 01-13
SPONTANEOUS DYSKINESIA IN THE ELDERLY AND TARDIVE-DYSKINESIA
FROM NEUROLEPTICS. A SURVEY OF 270 ELDERLY-PATIENTS.
000834 01-15
NEUROLEPTICS AND NEUROTRANSMIHER-RECEPTORS.
000980 01-17
NEUROPHARMACOLOGICAL AND NEUROCHEMICAL APPROACHES TO
PRECLINICAL-EVALUATION OF NEUROLEPTICS.
001094 02-02
LONG-TERM EFFECT OF NEUROLEPTICS ON CORTICOSTERONE
SEPTOHIPPOCAMPAL UPTAKE IN RATS.
001107 02-03
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT
DERIVATIVES.
001156 02-03
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY
SPEQRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND
NEUROLEPTICS.
001220 02-03
NO EVIDENCE FOR INCREASED DOPAMINE-RECEPTOR BINDING IN
SUPERRESPONSIVE MICE AFTER A SINGLE-DOSE OF NEUROLEPTICS.
001292 02-03
CONFORMATIONALLY RESTRICTED PHENOTHIAZINE NEUROLEPTICS. 1 . 3
DIMETHYLAMINO-TETRAHYDROAZEPINOPHENOTHIAZINE.
001359 02-03
EFFEQS OF NEUROLEPTICS ON NEUROENDOCRINE MECHANISMS FOR
GONADOTROPIN SECRETION.
001391 02-03
EFFEQ OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE
METABOLISM IN CELL BODIES AND TERMINALS OF OOPAMINERGIC-
SYSTEMS IN THE RAT-BRAIN.
001464 02-03
MODULATION OF BETA-ADRENERGIC-RECEPTORS AND CALMODULIN
FOLLOWING ACUTE AND CHRONIC-TREATMENT WITH NEUROLEPTICS.
001529 02-03
BEHAVIORAL-EFFEaS, ANTIDOPAMINERGIC-EFFEQS, AND PROHYPNOTIC-
EFFEaS OF NEUROLEPTICS DURING AND AFTER PROLONGED
TREATMENT.
001577 02-04
10 PIPERAZINYL-4H-THIEN0BENZ0DIAZEPINES AS POTENTIAL
NEUROLEPTICS.
001591 02-04
4 PIPERAZINYL-IOH-THIENOBENZODIAZEPINES AS POTENTIAL
NEUROLEPTICS.
001592 02-04
DIFFERENTIAL-EFFEaS OF AMPHETAMINE AND NEUROLEPTICS ON
NEGATIVE VS. POSITIVE SYMPTOMS IN SCHIZOPHRENIA.
001906 02-08
DISORDERS OF SMOOTH-PURSUIT EYE-MOVEMENTS IN SCHIZOPHRENICS
AND THE EFFEQ OF NEUROLEPTICS IN THERAPEUTIC DOSES.
001912 02-08
METHODOLOGY AND RESULTS OF A LONG-TERM STUDY OF LONG-AQING
NEUROLEPTICS: PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-
DECANOATE.
001929 02-08
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH
NEUROLEPTICS.
001935 02-08
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
NEUROLEPTICS AND DOPAMINE-RECEPTORS, THERAPEUTIC
IMPLICATIONS.
001942 02-08
THE ASSOCIATION OF RETARD NEUROLEPTICS TO OTHER NEUROLEPTICS
IN THE REHABILITATION OF PSYCHOTIC-PATIENTS.
002108 02-11
MALIGNANT-HYPERTHERMIC-SYNDROMES IN THE COURSE OF
TREATMENT WITH LONG-AQING NEUROLEPTICS.
002430 02-15
PROPRANOLOL (INDERAL) FOR TARDIVE-DYSKINESIA AND
EXTRAPYRAMIDAL SIDE-EFFECTS FROM NEUROLEPTICS: POSSIBLE
INVOLVEMENT OF BETA-ADRENERGIC MECHANISMS.
002470 02-15
Psychopharmacology Abstracts
TWELVE YEARS EXPERIENCE WITH THE TOTAL USE OF DEPOT
NEUROLEPTICS IN A DEFINED POPULATION.
002544 02-17
THE CHANGE OF BLOOD PROLACTIN LEVEL DUE TO THE WITHDRAWAL OF
MAINTENANCE NEUROLEPTICS.
002559 02-17
PRESENT INDICATIONS OF LONG-AQING NEUROLEPTICS.
002576 02-17
NEUROLEPTICS IN 1978.
002626 02-17
EFFECT OF NEUROLEPTICS ON INDOLEAMINE-N-METHYLTRANSFERASE
ACTIVITY AND BRAIN METABOLISM OF BUFOTENIN.
002735 03-03
DIFFERENTIAL REVERSAL BY SCOPOLAMINE AND THIP OF THE
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS
002948 03-04
CHRONIC EFFECTS OF NEUROLEPTICS HAVING HIGH OR LOW INCIDENCE
OF EXTRAPYRAMIDAL SIDE-EFFECTS UPON FORCE, DURATION AND
RATE OF OPERANT-RESPONSE IN RATS. (PH.D. DISSERTATION)
003125 03-05
LITHIUM COMBINED WITH NEUROLEPTICS IN CHRONIC SCHIZOPHRENIC-
PATIENTS AND SCHIZOAFFECTIVE-PATIENTS.
003168 03-08
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL- STUDIES WITH
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND
DEPOT NEUROLEPTICS.
003183 03-08
NEUROLEPTICS ADMINISTERED IN HIGH-DOSAGES.
003185 03-08
DOPAMINE-RECEPTORS, NEUROLEPTICS, AND SCHIZOPHRENIA.
003197 03-08
NEUROLEPTICS: ACTIVATION OR INHIBITION OF THE DOPAMINERGIC-
SYSTEM?
003424 03-13
EFFECTS OF GRADUAL DECREASE AND DISCONTINUATION OF
NEUROLEPTICS ON CLINICAL CONDITION AND TARDIVE-DYSKINESIA.
003469 03-15
ADVANTAGES AND DISADVANTAGES OF PROLONGED USE OF
NEUROLEPTICS.
003470 03-15
NEUROLEPTICS: INTERACTIONS WITH FOOD - CHEMICAL AND
PHARMACODYNAMIC STUDIES ON THE INTERACTIONS OF COFFEE AND
TEA.
003612 03-17
INCREASE OF NEUROTENSIN CONTENT ELICITED BY NEUROLEPTICS IN
NUCLEUS-ACCUMBENS.
003808 04-03
STUDIES ON THE KINETIC PROPERTIES OF TRYPTOPHAN-HYDROXYLASE OF
RABBIT MESENCEPHALON AND PONS-MEDULLA: EFFECT OF LONG-
TERM-TREATMENT WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
003852 04-03
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF
(3H)SPIR0PERID0L IN CALF CAUDATE
003906 04-03
PRESYNAPTIC AND POSTSYNAPTIC ALPHA-ADRENOCEPTOR ANTAGONISM
BY NEUROLEPTICS IN VIVO.
003966 04-03
CLASSICAL NEUROLEPTICS AND DECONDITIONING ACTIVITY AFTER SINGLE
OR REPEATED TREATMENTS: ROLE OF DIFFERENT CEREBRAL
NEUROTRANSMIHERS.
00411504-04
A COMPARISON BETWEEN SOME BIOCHEMICAL-EFFECTS AND
BEHAVIOURAL-EFFECTS PRODUCED BY NEUROLEPTICS.
00411604-04
A FOLLOWUP STUDY OF SCHIZOPHRENIC-OUTPATIENTS TREATED WITH
DEPOT NEUROLEPTICS.
004342 04-08
HORMONAL STIMULATION AFTER INJECTION OF THYROTROPHIN-
RELEASING-FACTOR (TRF) AND ACTHl-24 IN PATIENTS FOLLOWING
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY- STUDY.
004505 04-13
DES-TYROSINE-GAMMA-ENDORPHIN: H-REFLEX RESPONSE SIMILAR TO
NEUROLEPTICS.
004540 04-13
NEUROLEPTICS AND THEIR SIDE-EFFECTS.
004590 04-15
RECEPTOR TECHNIQUES IN THE STUDY OF PLASMA LEVELS OF
NEUROLEPTICS AND ANTIDEPRESSANT-DRUGS.
004694 04-16
NEUROLEPTICS IN 1979.
004749 04-17
NEUROLOGIC
OPIATE ANTAGONIST IMPROVES NEUROLOGIC RECOVERY AFTER SPINAL
INJURY.
002714 03-03
NEUROLOGICAL
NEUROLOGICAL SIDE-EFFECTS OF LITHIUM: ORGANIC-BRAIN-SYNDROME,
SEIZURES, EXTRAPYRAMIDAL SIDE-EFFECTS, AND EEG CHANGES.
000847 01-15
S-302
^sag^iiii
VOLUME 19, SUBJECT INDEX
THE NEUROLOGICAL FORENSIC ASPECTS OF THALLIUM POISONING.
002438 02-15
NEUROLOGICAL TOLERANCE OF LITHIUM AND PSYCHOTROPIC-DRUGS IN
COMBINATION: 265 CASES.
004594 04-15
NIUROLOOICAl-COMPLICATIONS
DYSKINETIC AND NEUROLOGICAL-COMPLICATIONS IN CHILDREN TREATED
WITH PSYCHOTROPIC-MEDICATIONS.
000880 01-15
NEUROLOGICAL-COMPLICATIONS DUE TO THE PHARMACOLOGICAL-
TREATMENT OF EPILEPTIC-PATIENTS.
004593 04-15
NEUROLOOICAL-STUDY
NEUROLOGICAL- STUDY AND NEUROPSYCHOPHARMACOLOGY-STUDY ON
DEMENTIA.
001090 02-11
NEUROLOGICAL-SYNDROME
BRAIN-MONOAMINES AND THE HIGH PRESSURE NEUROLOGICAL-
SYNDROME.
001686 02-04
NEUROLOGY
CHILD-PSYCHIATRY AND PSYCHOPHARMACOTHERAPY IN GENERAL
PRAaiCE, IN PEDIATRICS, AND IN NEUROLOGY.
003288 03-1 1
CHANGES IN AND CURRENT PROGRESS OF NEUROLOGY AND
PSYCHIATRY.
003550 03-15
NEUROMODULATORS
GLYCINE, ACETYLCHOLINE, AND SEROTONIN: NEUROTRANSMIHERS OR
NEUROMODULATORS?
002271 02-13
NEUROMODULATORY
EVIDENCE SUGGESTING A TRANSMIHER OR NEUROMODULATORY ROLE
FOR SUBSTANCE-P AT THE FIRST SYNAPSE OF THE BARORECEPTOR
REFLEX.
001264 02-03
NEURON
AUTOCORRELATION ANALYSIS OF SINGLE NEURON ACTIVITY AFTER
ADMINISTRATION OF PENTOBARBITAL.
001268 02-03
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARAQERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
EFFEaS OF PENTOBARBITAL AND ETHANOL UPON SINGLE NEURON
AaiVITY IN THE PRIMARY SOMATOSENSORY CORTEX OF THE RHESUS-
MONKEY.
003755 04-03
MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION.
003782 04-03
EFFEaS OF ACUTE AND CHRONIC AMPHETAMINE TREATMENT ON
PURKINJE NEURON DISCHARGE IN RAT CEREBELLUM.
003793 04-03
THE HUMAN PLATELET AS A MODEL FOR THE GLUTAMATERGIC NEURON:
PLATELET UPTAKE OF L GLUTAMATE.
003923 04-03
NEURONAL
SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA-
ADRENOCEPTOR ANTAGONISTS: EVIDENCE AGAINST GABA
MEDIATION.
000024 01-03
3H IMIPRAMINE BINDING IN NEURONAL AND GLIAL FRAQIONS OF
HORSE STRIATUM.
000033 01-03
NEURONAL AQIVITY IN CHRONIC FERRIC-CHLORIDE EPILEPTIC-FOCI IN
CATS AND MONKEY.
000172 01-03
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFEaS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJEQION.
000261 01-03
REGULATION OF THE STATE OF PHOSPHORYLATION OF SPECIFIC
NEURONAL PROTEINS IN MOUSE-BRAIN BY IN VIVO ADMINISTRATION
OF ANESTHETIC AND CONVULSANT-AGENTS.
000291 01-03
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL ACTIVITY.
000314 01-03
OPPOSITE EFFEQS OF D-AMPHETAMINE ON SPONTANEOUS NEURONAL
AQIVITY IN THE NEOSTRIATUM AND NUCLEUS-ACCUMBENS.
000454 01-04
Subject lnd«x
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE Of FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
001024 02-01
BASIC AND CLINICAL NEUROBIOLOGICAL APPLICATIONS OF NEURONAL
(NSE) AND NONNEURONAL (NNE) ENOLASE. (UNPUBLISHED PAPER).
001041 02-01
REGULATION OF ACETYLCHOLINE RELEASE DURING INCREASED NEURONAL
ACTIVITY. (UNPUBLISHED PAPER).
001061 02-01
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-ACTIVITY
RELATIONSHIPS.
001132 02-03
GLYCINE ENHANCEMENT OF CAUDATE NEURONAL ACTIVITIES:
RELATIONSHIP WITH THE DOPAMINERGIC NIGROSTRIATAL PATHWAY.
001225 02-03
SUBSTANCE-P, MORPHINE AND METHIONINE-ENKEPHALIN: EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE NUCLEUS-
RETICULARIS-GIGANTOCELLULARIS OF THE RAT.
001267 02-03
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC-
STUDY.
001410 02-03
ALPHA-ADRENORECEPTOR MEDIATED ALTERATION OF ETHANOL EFFECTS
ON NA-K-ATPASE OF RAT NEURONAL MEMBRANES.
001425 02-03
NEURONAL TRANSPORT OF 5 HYDROXYTRYPTAMINE.
001451 02-03
LOCAL AND DISTANT NEURONAL DEGENERATION FOLLOWING
INTRASTRIATAL INJECTION OF KAINIC-ACID.
001885 02-06
NEURONAL ACTIV.rY AND ENERGY METABOLISM: A SUMMARY OF A
SYMPOSIUM. (UNPUBLISHED PAPER).
002308 02-13
NEURONAL MATURATION IN MAMMALIAN CELL-CULTURE IS DEPENDENT
ON SPONTANEOUS ELECTRICAL-ACTIVITY.
002669 03-03
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS.
002700 03-03
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPAQA AND
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE
SPONTANEOUS NEURONAL AQIVITIES IN THE RAT.
002718 03-03
TEMPORAL PAHERNING OF NEURONAL AQIVITY DURING THERMAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
ON CORRELATION OF BEHAVIORAL-REACTIONS AND NEURONAL ACTIVITY
IN THE HYPOTHALAMUS UNDER SUBCUTANEOUS GASTRIN INJECTION.
002892 03-03
NEURONAL LOCALIZATION OF BENZODIAZEPINE-RECEPTORS IN THE
MURINE CEREBELLUM.
002902 03-03
DIFFERENTIAL AQIONS OF CLASSICAL AND ATYPICAL ANTIPSYCHOTIC-
DRUGS ON SPONTANEOUS NEURONAL ACTIVITY IN THE AMYGDALOID
COMPLEX.
003131 03-05
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. II, WITH REFERENCE TO SYMPATHETIC NEURONAL
FUNCTION.
003416 03-13
A REFORMULATION OF THE DUAL-ACTION MODEL OF OPIOID
DEPENDENCE: OPIOID-SPECIFIC NEURONAL KINDLING.
003645 03-17
SYNTHESIS OF CYTOSKELETAL PROTEINS IN BULK ISOLATED NEURONAL
PERIKARYA.
003672 04-01
NEURONAL SENSITIVITY OF SOME BRAIN REGIONS TO ANGIOTENSIN-II IN
RABBITS.
003716 04-03
NEURONAL LOCALISATION OF BENZODIAZEPINE-RECEPTORS IN
CEREBELLUM.
003739 04-03
SELECTIVE MODIFICATION BY OPIATES OF NEURONAL ACTIVITY OF THE
MEDIAL BASAL HYPOTHALAMUS.
003773 04-03
MORPHINE AND METHIONINE-ENKEPHALIN: DIFFERENT EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE
MESENCEPHALIC RETICULAR FORMATION OF THE RAT.
003849 04-03
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL
TISSUE BY ASCORBATE.
003876 04-03
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA-
k
ill
S-303
Subject Index
Psychopharmacology Abstracts
.11
lilSi
Sliii
m:i
Mis
DEFERENTIA TO (-) NORADRENALINE AFER BLOCKADE OF NEURONAL
UPTAKE.
003879 04-03
OPIATE MECHANISMS: EVALUATION OF RESEARCH INVOLVING
NEURONAL ACTION POTENTIALS.
003886 04-03
MONOSODIUM-GLUTAMATE: INCREASED NEUROTOXICITY AFTER
REMOVAL OF NEURONAL REUPTAKE SITES.
003889 04-03
4 AMINOPYRIDINE BLOCKADE OF NEURONAL DEPRESSANT RESPONSES TO
ADENOSINE-TRIPHOSPHATE.
003963 04-03
THE INACTIVATION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE IN
DISSOCIATED NEURONAL CULTURES FROM SPINAL-CORD.
003980 04-03
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN: CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
NEURONE
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE
ACTION.
000229 01-03
NEURONES
DOES SYSTEMIC MORPHINE INCREASE DESCENDING INHIBITORY
CONTROLS OF DORSAL-HORN NEURONES INVOLVED IN NOCICEPTION?
000175 01-03
EVIDENCE OF A DIRECT AQION OF ANGIOTENSIN-II ON NEURONES IN THE
SEPTUM AND IN THE MEDIAL PREOPTIC-AREA.
000272 01-03
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL ACTIVITY.
000314 01-03
INTRACELLULAR OBSERVATIONS ON THE EFFEQS OF MUSCARINIC
AGONISTS ON RAT SYMPATHETIC NEURONES.
001143 02-03
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES:
EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION
IN THE ANESTHETIZED CAT.
001203 02-03
THE STEREOSPECIFIC EFFECT OF NALOXONE ON RAT DORSAL-HORN
NEURONES; INHIBITION IN SUPERFICIAL LAMINAE AND EXCITATION IN
DEEPER LAMINAE.
001226 02-03
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
BRAIN.
001234 02-03
DEVELOPMENT OF ACUTE OPIOID-TOLERANCE AND DEPENDENCE IN RAT
STRIATAL NEURONES.
001235 02-03
SEROTONIN-RECEPTOR MEDIATED MODULATION OF CA -DEPENDENT 5
HYDROXYTRYPTAMINE RELEASE FROM NEURONES OF THE RAT-BRAIN-
CORTEX.
001258 02-03
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION.
001310 02-03
TWO CONDUQANCE MECHANISMS AQIVATED BY APPLICATIONS OF L
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED
MAMMALIAN CENTRAL NEURONES.
001349 02-03
STRUCTURAL REQUIREMENTS FOR UPTAKE INTO SEROTONINERGIC
NEURONES.
001452 02-03
THE EXCITATORY AQION OF ACETYLCHOLINE ON HIPPOCAMPAL
NEURONES OF THE GUINEA-PIG AND RAT MAINTAINED IN VITRO.
002704 03-03
POTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3-
HYDROXYASPARTATE.
002768 03-03
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND
EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES.
002799 03-03
L HISTIDINE: EFFECTS ON SENSITIVITY OF CAT SPINAL NEURONES TO
AMINO-ACIDS.
002808 03-03
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS:
LACK OF EFFEQ BY STRYCHNINE AND BICUCULLINE.
003778 04-03
EFFEaS OF 5 HYDROXYTRYPTAMINE ON CENTRAL NEURONES
ANTAGONIZED BY BICUCULLINE AND PICROTOXIN.
003931 04-03
THE EFFEQ OF PROPRANOLOL AND ITS ISOMERS ON PURKINJE
NEURONES IN RAT CEREBELLUM.
004059 04-03
NEURONS
THE EFFEQS OF MORPHINE ON THE ACTIVITY OF CERTAIN DORSAL-HORN
NEURONS OF THE SPINAL-CORD INVOLVED IN NOCICEPTIVE PROCESSES.
000028 01-03
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH
IN THE ELECTROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO
AUTORECEPTOR STIMULATION.
000046 01-03
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL
000055 01-03
FUNCTIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY
NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS
WITH SCHIZOPHRENIA.
000059 01-03
MORPHINE ACTS THROUGH ALPHA-ADRENERGIC AND SEROTONINERGIC
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG.
000088 01-03
NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE
POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS.
00011601-03
ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS
000194 01-03
(-)PENTOBARBITAL OPENS ION-CHANNELS OF LONG-DURATION IN
CULTURED MOUSE SPINAL NEURONS
000198 01-03
DECARBOXYLATION OF EXOGENOUS L-OOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES.
000202 01-03
DIAZEPAM POTENTIATION OF PURINERGIC DEPRESSION OF CENTRAL
NEURONS.
000233 01-03
REVERSIBLE INACTIVATION OF RAPHE-MAGNUS NEURONS: EFFECTS ON
NOCICEPTIVE THRESHOLD AND MORPHINE-INDUCED ANALGESIA.
000240 01-03
THE INFLUENCE OF CHLORALOSE ANESTHESIA ON THE ACTIVITY OF RED
NUCLEUS NEURONS IN CATS.
000245 01-03
MICROIONTOPHORETIC STUDIES ON NORADRENERGIC INHIBITION FROM
LOCUS-COERULEUS OF SPINAL TRIGEMINAL-NUCLEUS NEURONS.
000260 01-03
RELATION BETWEEN THE EFFECTS OF ANTIDEPRESSANT-DRUGS ON THE
UPTAKE OF MONOAMINES AND ON THE SPONTANEOUS ACTIVITY OF
CENTRAL NEURONS.
000267 01-03
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF
AlO DOPAMINERGIC NEURONS.
000320 01-03
EFFECT OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO
STIMULATION OF THE NUCLEUS-ACCUMBENS.
000331 01-03
THE INVOLVEMENT OF SEROTONERGIC NEURONS IN THE CENTRAL-
NERVOUS-SYSTEM AS THE POSSIBLE MECHANISM FOR SLOW HEAD-
SHAKING-BEHAVIOR INDUCED BY METHAMPHETAMINE IN RATS.
000408 01-04
BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH
KAINIC-ACID-INDUCED LESIONS OF STRIATAL NEURONS - WITH A
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS-
DISEASE.
000463 01-04
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS.
00046601-04
THE EFFECTS OF LSD AND SOME ANALOGUES ON THE RESPONSES OF
SINGLE CORTICAL NEURONS OF THE CAT TO OPTICAL-STIMULATION.
000738 01-12
THE RELEASE OF CATECHOLAMINES FROM ADRENERGIC NEURONS.
000974 01-17
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER ACTIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT.
001095 02-03
THE EFFECT OF CORTISOL MICROIONOPHORETIC-APPLICATIONS ON THE
ACTIVITY OF HIPPOCAMPAL NEURONS IN UNRESTRAINED RABBITS.
001123 02-03
S-304
VOLUME 19, SUBJECT INDEX
Subject Index
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN.
001)67 02-03
OPIATE INTERACTIONS WITH CHOLINERGIC NEURONS.
001198 02-03
MIANSERIN; DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS
BY BLOCKING ALPHA2-RECEPT0RS
001214 02-03
STRYCHNINE EFFECTS ON THE SENSORY RESPONSE PATTERNS OF
RETICULAR FORMATION NEURONS.
001219 02-03
EFFECTS OF LONG-TERM ADMINISTRATION OF ANTIPSYCHOTIC-DRUGS ON
ENKEPHALINERGIC NEURONS.
001284 02-03
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS
INDUCED BY AMPHETAMINE IN CATS.
001340 02-03
OPIATES AND OPIOID-PEPTIDES HYPERPOLARIZE LOCUS-COERULEUS
NEURONS IN VITRO.
001408 02-03
EFFECT OF QUIPAZINE ON BRAINSTEM MONOAMINE NEURONS
HISTOFLUORESCENCE STUDIES.
001477 02-03
ENHANCED SENSITIVITY OF AMYGDALOID NEURONS TO SEROTONIN AND
NOREPINEPHRINE AFTER CHRONIC ANTIDEPRESSANT TREATMENT.
001523 02-03
EFFECT OF SELECTIVE DESTRUCTION OF SEROTONERGIC NEURONS IN
NUCLEUS-RAPHE-MAGNUS ON MORPHINE-INDUCED ANTINOCICEPTION.
001724 02-04
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES.
002285 02-13
SHORT-TERM AND LONG-TERM EFFECTS ON GABA AND DOPAMINE
NEURONS DURING TREATMENT WITH SULPIRIDE.
002311 02-13
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE
SPINAL-CORD OF THE CAT: ENKEPHALIN-CONTAINING MARGINAL
NEURONS AND PAIN MODULATION.
002638 03-01
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY.
002639 03-01
GABA ANALOGUES ACTIVATE CHANNELS OF DIFFERENT DURATION ON
CULTURED MOUSE SPINAL NEURONS.
002665 03-03
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION,
002674 03-03
MIDBRAIN DOPAMINE NEURONS: DIFFERENTIAL RESPONSES TO
AMPHETAMINE ISOMERS.
002680 03-03
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE
ANESTHETIZED RATS.
002687 03-03
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS.
002700 03-03
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPACTA AND
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE
SPONTANEOUS NEURONAL ACTIVITIES IN THE RAT.
002718 03-03
EVIDENCE FOR A TONIC GABAERGIC CONTROL OF SEROTONIN NEURONS
IN THE MEDIAN RAPHE NUCLEUS.
002719 03-03
6ABA-RECEPT0RS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN.
002727 03-03
HISTAMINE ACTIONS ON ACTIVITY OF CULTURED HYPOTHALAMIC
NEURONS: EVIDENCE FOR MEDIATION BY HISTAMINE Hl-RECEPTORS
AND H2-RECEPT0RS.
002732 03-03
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING AQIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
EFFECTS OF PHENYTOIN ON PYRAMIDAL NEURONS OF THE RAT
HIPPOCAMPUS.
002750 03-03
TRIMETHADIONE EFFEQS ON CHOLINERGIC RESPONSES IN APLYSIA
NEURONS.
002782 03-03
IN VIVO VOLTAMMETRIC INVESTIGATIONS INTO THE ACTION OF HA-966
ON CENTRAL DOPAMINERGIC NEURONS.
002832 03-03
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFECT OF
CHRONIC-TREATMENT
002847 03-03
EFFECTS OF D AMINOLAEVULINIC-ACID. PORPHOBILINOGEN, AMINO-
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY
CULTURED NEURONS.
002859 03-03
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC
NEURONS.
002880 03-03
AaiON OF CYCLIC-ADENOSINE-MONOPHOSPHATE ON CENTRAL
NEURONS.
002940 03-03
THE EFFECTS OF ACETYLCHOLINE AND GLUTAMATE ON SEPTAL NEURONS
IN VITRO.
002941 03-03
THYROXIN SENSITIVITY OF SENSORIMOTOR CORTICAL NEURONS AND THE
HYPOTHALAMIC VENTROMEDIAL NUCLEUS.
003713 04-03
EXCITATORY EFFECTS OF DIHYDROCAPSAICIN ON NOCICEPTIVE NEURONS
IN THE MEDIAL THALAMUS.
003714 04-03
ACETYLCHOLINE-INDUCED MODULATION OF HIPPOCAMPAL PYRAMIDAL
NEURONS.
003728 04-03
RELATIONSHIP BETWEEN THE PRESENCE OF DOPAMINERGIC NEURONS
AND GABA-RECEPTORS IN SUBSTANTIA-NIGRA: EFFECTS OF LESIONS.
003797 04-03
CHANGES OF ELECTRORETINOGRAM AND NEUROCHEMICAL ASPEQS OF
GABAERGIC NEURONS OF RETINA AFTER INTRAOCULAR INJECTION OF
KAINIC-ACID IN RATS.
003807 04-03
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOLLUSCAN
NEURONS.
003834 04-03
STUDIES ON AXONAL TRANSPORT IN DOPAMINERGIC NEURONS: EFFEQ
OF NEUROPHARMACOLOGIC LESIONS.
003858 04-03
SENSORY NEUROTOXINS: CHEMICALLY-INDUCED SELECTIVE DESTRUCTION
OF PRIMARY SENSORY NEURONS.
003859 04-03
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS.
003871 04-03
SENSITIVITY TO GABA OF NEURONS OF THE DORSAL AND VENTRAL
LATERAL GENICULATE NUCLEI IN THE RAT.
003877 04-03
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC
AND DOCA-SALT HYPERTENSION IN THE RAT.
003899 04-03
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE
REVERSAL OF GUANETHIDINE BLOCKADE OF ADRENERGIC NEURONS.
003900 04-03
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS.
003972 04-03
APPARENT SEROTONERGIC MODULATION OF THE DOSE-DEPENDENT
BIPHASIC RESPONSE OF NEOSTRIATAL NEURONS PRODUCED BY D-
AMPHET AMINE.
003981 04-03
EFFECTS OF ZIMELIDINE ON SEROTONINERGIC AND NORADRENERGIC
NEURONS AFTER REPEATED ADMINISTRATION IN THE RAT.
003991 04-03
EFFECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC
NEURONS.
004026 04-03
THE EXCITATORY EFFECT OF ATROPINE ON THE NEURONS OF THE FROG
SYMPATHETIC GANGLIA.
004041 04-03
SELECTIVE EFFECT OF ETHANOL ON THE VESTIBULAR NUCLEUS NEURONS
IN THE CAT.
004139 04-04
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER
FOREBRAIN REGIONS OF THE RAT.
004171 04-04
DOPAMINERGIC NEURONS OF SPINAL-CORD: A POSSIBLE SITE FOR THE
ACTION OF NEUROLEPTIC-DRUGS.
004188 04-04
THE ROLE OF RETICULOSEPTAL INPUTS IN THE FORMATION OF DIFFERENT
TYPES OF SENSORY REACTIONS OF THE HIPPOCAMPAL NEURONS.
004510 04-13
ik^
S-305
Subject Index
imii;
m
iUlt
£11:::;.
u.
e,
NEUROOTOLOGY
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO.
004387 04-09
NEUROPATHIES
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFECTS
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES.
000131 01-03
NEUROPATHY
THE ROLE OF FOLATE DEFICIENCY IN THE DEVELOPMENT OF PERIPHERAL
NEUROPATHY CAUSED BY ANTICONVULSANTS.
002402 02-15
PERIPHERAL NEUROPATHY DUE TO LITHIUM INTOXICATION.
003544 03-15
NEUROPEPTIDE
THE EFFECT OF NEUROPEPTIDE FRAGMENTS OF ADRENOCORTICOTROPIN
AND VASOPRESSIN ON BEHAVIORAL-ACTIVITY IN RATS.
001812 02-04
NEUROPEPTIDE TREATMENT OF SOCIOPATHY: RESEARCH IN PROGRESS.
002369 02-14
NEUROPEPTIDE-RECEPTORS
EFFECTS OF GUANINE-NUCLEOTIDES ON CNS NEUROPEPTIDE-RECEPTORS.
(UNPUBLISHED PAPER).
001383 02-03
NEUROPEPTIDES
INTERACTIONS OF NEUROPEPTIDES WITH CHOLINERGIC
SEPTOHIPPOCAMPAL PATHWAY: INDICATION FOR A POSSIBLE
TRANSSYNAPTIC REGULATION. (UNPUBLISHED PAPER).
001062 02-01
BIOGENIC-AMINES AND NEUROPEPTIDES PLAY A ROLE IN THE CENTRAL-
REGULATION OF GENETIC HYPERTENSION. (UNPUBLISHED PAPER).
001455 02-03
CENTRAL BIOGENIC-AMINES AND NEUROPEPTIDES IN GENETIC
HYPERTENSION. (UNPUBLISHED PAPER).
001456 02-03
NEUROPEPTIDES AND MONOAMINERGIC NEUROTRANSMIHERS: THEIR
RELATION TO PAIN.
001497 02-03
PSYCHOSTIMULANTS AND NEUROPEPTIDES IN GEROPSYCHIATRY.
002125 02-11
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA
AND MEDIAL NUCLEUS-TRAaUS-SOLITARIUS OF RAT-BRAIN.
002634 03-01
NEUROPHARMACOLOGIC
STUDIES ON AXONAL TRANSPORT IN DOPAMINERGIC NEURONS: EFFEQ
OF NEUROPHARMACOLOGIC LESIONS.
003858 04-03
NEUROPHARMACOLOGICAl
NEUROPHARMACOLOGICAL AND NEUROCHEMICAL APPROACHES TO
PRECUNICAL-EVALUATION OF NEUROLEPTICS.
001094 02-02
NEUROPHARMACOLOGICAL ANALYSIS OF HANDLING-INDUCED SEIZURES
IN GERBILS.
001876 02-06
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS,
AND NEUROPHARMACOLOGICAL EVENTS.
002515 02-17
A STUDY OF THE EFFEQ OF NEUROPHARMACOLOGICAL DRUGS ON THE
FUNQIONAL AQIVITY OF RAT-BRAIN.
004107 04-04
NEUROPHARMACOLOGICAL-AGENTS
NEUROPHARMACOLOGICAL-AGENTS MODIFYING ENDOTOXIN-INDUCED
CHANGES IN MICE.
001543 02-03
NEUROPHARMACOIOGICAL-DRUGS
THE MECHANISM OF EFFECT OF NEUROPHARMACOLOGICAL-DRUGS. VI:
EFFECT OF NORADRENALINE AND 5 HYDROXYTRYPTAMINE ON BRAIN
FREE FATTY-ACIDS.
000274 01-03
NEUROPHARMACOIOGICAL-STUDIES
NEUROPHARMACOLOGICAL-STUDIES OF PHENCYCLIDINE-INDUCED
BEHAVIORAL-STIMULATION IN MICE.
001622 02-04
NEUROPHARMACOLOGICAL-STUDY
A NEUROPHARMACOLOGICAL-STUDY AND NEUROENDOCRINE-STUDY ON
IDIOPATHIC AND CHRONIC PHARMACOLOGICAL PARKINSONISM.
002371 02-15
CHRONOLOGICAL ELEaROENCEPHALOGRAPHIC AND
NEUROPHARMACOLOGICAL-STUDY IN CORTICAL KINDLING RABBITS.
002761 03-03
NEUROPHARMACOLOGY
NEUROPHARMACOLOGY OF BROMOCRIPTINE AND DIHYDROERGOTOXINE
(HYDERGINE).
001346 02-03
NEUROPHARMACOLOGY OF SYNTHETIC ERGOT DERIVATIVES IN MAN.
002429 02-15
Ptychopharmacology Abstracts
CLINICAL NEUROPHARMACOLOGY.
002567 02-17
NEUROBIOLOGY AND NEUROPHARMACOLOGY OF THE ENKEPHALINS.
002580 02-17
CENTRAL NEUROPHARMACOLOGY OF ENDORPHINS.
002599 02-17
ESSAYS IN NEUROCHEMISTRY AND NEUROPHARMACOLOGY.
003652 03-17
NEUROPHYSIOLOGICAL
THE IN VITRO BRAIN SLICE AS A USEFUL NEUROPHYSIOLOGICAL
PREPARATION FOR INTRACELLULAR RECORDING.
001864 02-06
CLINICAL NEUROPHYSIOLOGICAL ASPEQS OF PSYCHOPATHOLOGICAL-
CONDITIONS.
002274 02-13
THE NEUROPHYSIOLOGICAL AND CLINICAL-ASPEaS OF PAIN.
003457 03-14
CLINICAL NEUROPHYSIOLOGICAL PROPERTIES OF ANTIDEPRESSANTS.
004373 04-09
MEASUREMENTS OF NERVE CONDUQION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT.
004441 04-11
NEUROPHYSIOLOGICAL-BASIS
BENZODIAZEPINES: A TOOL TO EXPLORE THE BIOCHEMICAL-BASIS AND
NEUROPHYSIOLOGICAL-BASIS OF ANXIETY.
000397 01-04
NEUROPHYSIOLOOICAL-EFFECTS
NEUROPHYSIOLOGICAL-EFFEaS AND THERMOREGULATORY-EFFEaS OF
CAPSAICIN.
001421 02-03
NEUROPHYSIOLOGICAL-EFFEQS OF ETOMIDATE, A NEW SHORT-ACTING
HYPNOTIC.
002263 02-13
NEUROPHYSIOLOGICAL-STUDY
NEUROPHYSIOLOGICAL-STUDY OF TWO 0 ANISAMIDE DERIVATIVES:
SULPIRIDE AND SULTOPRIDE.
001170 02-03
NEUROPSYCHIATRIC
NEUROPSYCHIATRIC SIDE-EFFECTS OF DRUGS IN THE ELDERLY. VOL. 9,
AGING.
002573 02-17
NEUROPSYCHIATRIC-AGENTS
POSSIBLE MODE OF ACTION OF NEUROPSYCHIATRIC-AGENTS:
PHENOTHIAZINES AND IMINODIBENZYLS.
001271 02-03
NEUROPSYCHIATRIC-CORRELATIONS
ANATOMOBIOCHEMICAL MAPPING OF THE BRAIN: NEUROPSYCHIATRIC-
CORRELATIONS.
002630 02-17
NEUROPSYCHIATRY
DRUG CONCENTRATIONS IN NEUROPSYCHIATRY.
004735 04-17
NEUROPSYCHOLOGIC-EFFECTS
KINETICS AND NEUROPSYCHOLOGIC-EFFEaS OF IV DIAZEPAM IN THE
PRESENCE AND ABSENCE OF ITS AQIVE N DESMETHYL METABOLITE IN
HUMANS.
002229 02-13
NEUROPSYCHOLOGICAL
TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERAQIVE-
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL
PARADIGM - A PILOT- STUDY.
002126 02-11
ORAL ALUMINUM AND NEUROPSYCHOLOGICAL FUNQIONING: A STUDY
OF DIALYSIS PATIENTS RECEIVING ALUMINUM-HYDROXIDE GELS.
002283 02-13
NEUROPSYCHOLOGICAL-BAHERY
PREDiaiNG STIMULANT-EFFECTIVENESS IN HYPERAQIVE-CHILDREN WITH
A REPEATABLE NEUROPSYCHOLOGICAL-BAHERY: A PRELIMINARY-
STUDY.
004453 04-11
NEUROPSYCHOLOGICAL-CORRELATES
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: EFFEQ OF HYPOXIA
OR DRUGS?
003482 03-15
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: BRAIN-DAMAGE OR
DRUG-EFFEQS?
003538 03-15
NEUROPSYCHOPHARMACOLOGICAL-STUDIES
NEUROPSYCHOPHARMACOLOGICAL-STUDIES ON SOME BENZAMIDE
DERIVATIVES.
002220 02-13
NEUROPSYCHOPHARMACOLOGY
ON THE USE OF OPERANT-BEHAVIOR TO STUDY THE
NEUROPSYCHOPHARMACOLOGY OF OPIATES WITH SPECIAL REFERENCE
TO MORPHINE AND ITS RELATIONSHIP TO DOPAMINE IN THE CENTRAL-
NERVOUS-SYSTEM.
001790 02-04
S-306
VOLUME 19, SUBJECT INDEX
Subjact Index
A POSSIBLE ECOPHARMACOGENETIC MODEL IN
NEUROPSYCHOPHARMACOLOGY ASPECTS IN ALCOHOLISM AND
PHARMACODEPENDENCE.
002596 02-17
NEUROPSYCHOPHARMACOLOOY-STUDY
NEUROLOGICAL-STUDY AND NEUROPSYCHOPHARMACOLOGY-STUDY ON
DEMENTIA.
00)090 02-11
NEUROSCIENCES
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY IN THE
NEUROSCIENCES: METHODOLOGY.
004285 04-06
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY IN THE
NEUROSCIENCES: APPLICATIONS.
004296 04-06
NEUROSECRETION
THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN
REGULATION OF NEUROSECRETION. (UNPUBLISHED PAPER).
001003 02-01
NEUROSECRETORY
INFLUENCE OF CHRONIC ALCOHOL INTOXICATION ON CIRCADIAN-RHYTHM
OF NEUROSECRETORY CENTERS OF RAT HYPOTHALAMUS.
001549 02-03
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE
RELATIONSHIP.
003806 04-03
NEUROSES
CLINICAL-EXPERIENCE WITH LOW-DOSES OF HALOPERIDOL IN THE
TREATMENT OF NEUROSES.
000654 01-10
THE USE OF CLOROTEPIN AND DIAZEPAM IN A COMPLEX THERAPY OF
NEUROSES (CONTROLLED-COMPARISON) .
002064 02-10
PSYCHOPHARMACOLOGY OF NEUROSES.
003274 03-10
NEUROSIS
THERAPEUTIC APPLICATION OF PHYSOSTIGMINE IN NEUROSIS.
000651 01-10
A CLINICAL-EVALUATION OF THE EFFEQS OF A NEW PSYCHOTROPIC-
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE
DOUBLE-BLIND METHOD.
004491 04-11
NEUROSUR6ICAL-RESUSCITATION
HEMODYNAMIC AND CEREBRAL METABOLIC-STUDY OF DIAZEPAM IN
NEUROSURGICAL-RESUSCITATION .
002231 02-13
NEUROSYMPATHETIC
INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRiaiON
BY CLONIDINE IN CATS.
001431 02-03
NEUROTENSIN
ENHANCEMENT OF ETHANOL-INDUCED SEDATION AND HYPOTHERMIA BY
CENTRALLY ADMINISTERED NEUROTENSIN, BETA ENDORPHIN AND
BOMBESIN.
003037 03-04
INCREASE OF NEUROTENSIN CONTENT ELICITED BY NEUROLEPTICS IN
NUCLEUS-ACCUMBENS.
003808 04-03
NEUROTENSIN RELEASE BY RAT HYPOTHALAMIC FRAGMENTS IN VITRO.
003920 04-03
NEUROTENSIN BLOCKS CERTAIN AMPHETAMINE-INDUCED BEHAVIOURS.
004111 04-04
NEUROTENSIN-INDUCED
COMPOUND-48-80 INHIBITS NEUROTENSIN-INDUCED HYPOTENSION IN
RATS.
000243 01-03
NEUROTENSIN-RECEPTOR
NEUROTENSIN-RECEPTOR LOCALIZATION BY LIGHT MICROSCOPIC
AUTORADIOGRAPHY IN RAT-BRAIN.
002938 03-03
NEUROTIC
TRAZODONE IN THE TREATMENT OF NEUROTIC DEPRESSION.
001994 02-09
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS.
002047 02-09
PHENELZINE AND AMITRIPTYUNE IN NEUROTIC DEPRESSION.
(UNPUBLISHED PAPER).
003248 03-09
MAPROTILINE VERSUS IMIPRAMINE AND PLACEBO IN NEUROTIC
DEPRESSION.
003287 03-10
AQIVITY OF BROMAZEPAM AND LORAZEPAM IN NEUROTIC
DEPRESSIONS.
004384 04-09
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO.
004387 04-09
NEUROTIC-OUTPATIENTS
RELAPSE AFTER SHORT-TERM DRUG-THERAPY IN NEUROTIC-
OUTPATIENTS.
004400 04-09
THE RELATIONSHIPS BETWEEN CLINICAL-RESPONSE,
PSYCHOPHYSIOLOGICAL-VARIABLES AND PLASMA LEVELS OF
AMITRIPTYLINE AND DIAZEPAM IN NEUROTIC-OUTPATIENTS.
004423 04-10
NEUROTIC-PATIENTS
EFFECTS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN
HEALTHY TEST SUBJEQS, NEUROTIC-PATIENTS, AND ENDOGENOUS
DEPRESSIVE-PATIENTS.
002009 02-09
PREDICTION OF RESPONSE TO TREATMENT WITH PHENELZINE IN
NEUROTIC-PATIENTS.
002081 02-10
ALPRAZOLAM, A NEW TYPE ANXIOLYTIC IN NEUROTIC-PATIENTS: A
PILOT-STUDY.
004422 04-10
NEUROTICS
PLACEBO REACTION IN NEUROTICS RATED WITH THE SCL-90
QUESTIONNAIRE.
000976 01-17
NEUROTOXIC
DECREASED BENZOOIAZEPINE-RECEPTOR DENSITY IN RAT-CEREBELLUM
FOLLOWING NEUROTOXIC DOSES OF PHENYTOIN.
001373 02-03
NEUROTOXIC ESTERASE IN HUMAN NERVOUS-TISSUE.
003510 03-15
NEUROTOXIC-ACTION
SELEaiVE NEUROTOXIC-AQION OF CAPSAICIN ON GLOMERULAR C-TYPE
TERMINALS IN RAT SUBSTANTIA-GELATINOSA.
003143 03-06
NEUROTOXIC-ACTIONS
SYSTEMIC DIPIPERIDINOETHANE MIMICS THE CONVULSANT AND
NEUROTOXIC-AQIONS OF KAINIC-ACID.
000222 01-03
NEUROTOXICITY
NEUROTOXICITY OF LITHIUM. II.
000883 01-15
NEUROTOXICITY OF LITHIUM. I.
002452 02-15
KAINIC-ACID NEUROTOXICITY AND SEIZURES.
002939 03-03
LITHIUM NEUROTOXICITY AT THERAPEUTIC LEVELS: A CASE-REPORT.
003533 03-15
MONOSODIUM-GLUTAMATE: INCREASED NEUROTOXICITY AFTER
REMOVAL OF NEURONAL REUPTAKE SITES.
003889 04-03
NEUROTOXIN
RELEASE OF ACETYLCHOLINE FROM RAT-BRAIN SYNAPTOSOMES
STIMULATED WITH LEPTINOTARSIN, A NEW NEUROTOXIN.
003148 03-06
NEUROTOXINS
THE EFFECTS OF ALPHA AND BETA NEUROTOXINS FROM THE VENOMS OF
VARIOUS SNAKES ON TRANSMISSION IN AUTONOMIC GANGLIA.
003750 04-03
SENSORY NEUROTOXINS: CHEMICALLY-INDUCED SELEQIVE DESTRUaiON
OF PRIMARY SENSORY NEURONS.
003859 04-03
NEUROTRANSMISSION
TRANYLCYPROMINE STEREOISOMERS, MONOAMINERGIC
NEUROTRANSMISSION AND BEHAVIOR. A MINIREVIEW.
000016 01-02
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. III. DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES.
000025 01-03
REGULATION OF NEUROTRANSMISSION THROUGH PRESYNAPTIC-
RECEPTORS AND OTHER MECHANISMS: POSSIBLE CLINICAL RELEVANCE
AND THERAPEUTIC POTENTIAL.
002569 02-16
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
002801 03-03
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. VII. SUPPRESSION OF SYMPATHETIC RESPONSES BY
DEXAMETHASONE.
002802 03-03
THE ROLE OF GABA-MEDIATED NEUROTRANSMISSION IN CONVULSIVE
STATES.
003334 03-11
I;
S-307
Subject Index
Ptychopharmacology Abstracts
Av
IliSi!
<wi)|;j
33111:;
SI:'
^
it
AN ELEaROPHYSIOLOGICAL MODEL OF GABA-MEDIATED
NEUROTRANSMISSION.
003929 04-03
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN: CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
NEUROTRANSMIHER
NEUROTRANSMITTER RELATED ADAPTATION IN THE CENTRAL-NERVOUS-
SYSTEM FOLLOWING CHRONIC MONOAMINE-OXIDASE-INHIBITION.
000038 01-03
EFFEQS OF ACUTE AND CHRONIC PHENCYCLIDINE ON
NEUROTRANSMIHER ENZYMES IN RAT-BRAIN.
000134 01-03
MATERNAL GLUCOCORTICOID-HORMONES INFLUENCE
NEUROTRANSMIHER PHENOTYPIC EXPRESSION IN EMBRYOS.
000149 01-03
EPILEPSY: NEUROTRANSMIHER, BEHAVIOUR AND PREGNANCY.
002466 02-15
DOPAMINE AS A POSSIBLE NEUROTRANSMIHER IN THE SPINAL-CORD.
002705 03-03
KAINIC-ACID AND NEUROTRANSMIHER INTERAQIONS IN THE BASAL
GANGLIA.
002824 03-03
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMIHER AMINO-
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFAaORY-BULB.
002836 03-03
ACTIONS OF TREMORGENIC FUNGAL TOXINS ON NEUROTRANSMIHER
RELEASE.
002843 03-03
EFFEQ OF 6 HYDROXYDOPAMINE LESIONS OF THE MEDIAL PREFRONTAL-
CORTEX ON NEUROTRANSMIHER SYSTEMS IN SUBCORTICAL SITES IN
THE RAT.
002869 03-03
A TEST OF A NEUROTRANSMinER MODEL OF THE AFFEQIVE-DISORDERS.
(PH.D. DISSERTATION).
003063 03-04
NEUROTRANSMinER CONTROL OF HYPOTHALAMIC PITUITARY THYROID-
FUNQION IN RATS.
003942 04-03
BEHAVIORAL-EVIDENCE THAT SUBSTANCE-P MAY BE A SPINAL-CORD
SENSORY NEUROTRANSMinER.
004200 04-04
NEUROTRANSMIHER-RECEPTOR
DRUG-INDUCED ALTERATIONS IN NEUROTRANSMIHER-RECEPTOR
BINDING AND FUNCTION.
001215 02-03
THE EFFEQ OF GABAMIMETICS ON NEUROTRANSMIHER-RECEPTOR
BINDING AND FUNQION IN RAT-BRAIN. (PHD DISSERTATION).
001221 02-03
EFFECTS OF ETHANOL ADMINISTRATION AND WITHDRAWAL ON
NEUROTRANSMIHER-RECEPTOR SYSTEMS IN C57 MICE.
003979 04-03
NEUROTRANSMITTER-RECEPTORS
NEUROLEPTICS AND NEUROTRANSMIHER-RECEPTORS
000980 01-17
MULTIPLE NEUROTRANSMIHER-RECEPTORS.
000990 01-17
ANTIDEPRESSANT-DRUGS SLOW CIRCADIAN-RHYTHMS IN BEHAVIOR AND
BRAIN NEUROTRANSMinER-RECEPTORS.
001536 02-03
ASCORBATE DECREASES LIGAND BINDING TO NEUROTRANSMIHER-
RECEPTORS.
002804 03-03
NEUROTRANSMinER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS. I. EFFECTS OF A SINGLE EXPOSURE TO ACRYLAMIDE.
004264 04-05
NEUROTRANSMinER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS. II: EFFEaS OF EXTENDED EXPOSURE TO ACRYLAMIDE
004265 04-05
AUTORADIOGRAPHIC LOCALIZATION OF DRUG AND NEUROTRANSMIHER-
RECEPTORS IN THE BRAIN.
004292 04-06
NEUROTRANSMIHERS
SUPPRESSION OF EVOKED AND SPONTANEOUS RELEASE OF
NEUROTRANSMinERS IN VIVO BY MORPHINE.
000058 01-03
INTERAQIONS OF NOREPINEPHRINE WITH PURKINJE-CELL RESPONSES TO
PUTATIVE AMINO-ACID NEUROTRANSMIHERS APPLIED BY
MICROIONTOPHORESIS.
000209 01-03
BENZODIAZEPINES AND NEUROTRANSMIHERS.
000925 01-17
EFFEaS OF HALOPEMIDE ON POTASSIUM-INDUCED RELEASE OF
RADIOLABELED NEUROTRANSMIHERS FROM RAT CEREBROCORTICAL
SLICES IN VITRO.
001347 02-03
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMIHERS IN EPIDURAL
CUPS OF FREELY-MOVING-RATS: EFFEQ OF ACUTE AND CHRONIC-
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS.
001386 02-03
NEUROPEPTIDES AND MONOAMINERGIC NEUROTRANSMIHERS: THEIR
RELATION TO PAIN.
001497 02-03
ROLE OF NEUROTRANSMinERS AND PROTEIN SYNTHESIS IN SHORT-
TERM AND LONG-TERM MEMORY.
001573 02-04
KAINIC-ACID-INDUCED WET-DOG-SHAKES IN RATS: THE RELATION TO
CENTRAL NEUROTRANSMinERS.
001685 02-04
BEHAVIOURAL-RESPONSES TO STEREOTAQICALLY CONTROLLED
INJECTIONS OF MONOAMINE NEUROTRANSMinERS INTO THE
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI.
001708 02-04
GLYCINE, ACETYLCHOLINE, AND SEROTONIN: NEUROTRANSMinERS OR
NEUROMODULATORS?
002271 02-13
NEUROTRANSMinERS AND DEPRESSION: TOO MUCH, TOO LiniE, TOO
UNSTABLE ~ OR NOT UNSTABLE ENOUGH?
002931 03-03
A POSSIBLE ROLE FOR CATECHOLAMINE NEUROTRANSMinERS IN THE
ANTICONVULSANT AQIVITY OF CHLORDIAZEPOXIDE.
003119 03-04
MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND
UPTAKE OF NEUROTRANSMinERS IN BRAIN SLICES.
003147 03-06
EFFEaS OF BARBITURATES ON INHIBITORY AND EXCITATORY RESPONSES
TO APPLIED NEUROTRANSMinERS IN APLYSIA.
003762 04-03
THE NA-K-ATPASE: A PLAUSIBLE TRIGGER FOR VOLTAGE-INDEPENDENT
RELEASE OF CYTOPLASMIC NEUROTRANSMinERS.
003953 04-03
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMinERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
CLASSICAL NEUROLEPTICS AND DECONDITIONING AQIVITY AFTER SINGLE
OR REPEATED TREATMENTS: ROLE OF DIFFERENT CEREBRAL
NEUROTRANSMinERS.
00411504-04
NEUROTROPIC-ACTION
AN EXPERIMENTAL-STUDY OF THE NEUROTROPIC-AQION OF LITHIUM-
OXYBUTYRATE.
001705 02-04
NEUROTROPIC-DRUG
NEUROTROPIC-DRUGS AS COMEDICATION TO PSYCHOTROPICS:
COMBINED ADMINISTRATION OF A NEUROTROPIC-DRUG AND A
TETRACYCLIC-ANTIDEPRESSANT.
004396 04-09
NEUROTROPIC-DRUGS
NEUROTROPIC-DRUGS AS COMEDICATION TO PSYCHOTROPICS:
COMBINED ADMINISTRATION OF A NEUROTROPIC-DRUG AND A
TETRACYCLIC-ANTIDEPRESSANT.
004396 04-09
NEUROVASCULAR-PHARMACOLOGY
THE NEUROVASCULAR-PHARMACOLOGY AND CARDIOVASCULAR-
PHARMACOLOGY OF RS-51324, A POTENTIAL ANTIDEPRESSANT.
001091 02-02
NEUTRAL
TRANSPORT OF NEUTRAL AMINO-ACIDS AT THE BLOOD-BRAIN-BARRIER.
002764 03-03
NEUTRAUZATION
NEUTRALIZATION OF THE EFFEQ OF DELTA9 TETRAHYDROCANNABINOL
ON BARBITURATE SLEEPING-TIME BY SPECIFIC AQIVE IMMUNIZATION.
003803 04-03
NEUTROPENIA
MIANSERIN: A POSSIBLE CAUSE OF NEUTROPENIA AND
AGRANULOCYTOSIS.
003517 03-15
NEUTROPHIL
AN AnEMPT TO ASSESS THE EFFECT OF LITHIUM ON THE NEUTROPHIL
LEUKOCYTE SYSTEM IN AFFEQIVE-PSYCHOSIS.
004416 04-09
NEUTROPHILS
PHOSPHOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR-
MEDIATED INDUCTION OF CHEMOTAXIS IN RABBIT NEUTROPHILS.
(UNPUBLISHED PAPER)
001118 02-03
NEWBORN
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND
LOCOMOTOR RESPONSES TO DRUGS IN INFANa: NO SUPPORT FOR
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNQION.
000448 01-04
S-308
VOLUME 19, SUBJECT INDEX
Subject Index
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE
INJECTION IN NEWBORN ANIMALS.
002774 03-03
NfWBORNS
CLINICAL PHARMACOKINETICS IN NEWBORNS AND INFANTS: AGE-
RELATED DIFFERENCES AND THERAPEUTIC IMPLICATIONS
003343 03-11
NEWS
THERAPEUTIC NEWS, ^ ^^
004308 04-07
NIALAMIDE
COMBINED ADMINISTRATION OF NIALAMIDE AND VILOXAZINE TO
DEPRESSIVE-PATIENTS. „„^^^^ „^ „„
003232 03-09
NICERGOLINE
INFLUENCE OF NICERGOLINE ON MOLECULAR BIOLOGICAL PROCESSES IN
THE BRAIN AND LEARNING-ABILITY OF THE RAT.
000449 01-04
PSYCHOPATHOMETRIC DOUBLE-BLIND COURSE STUDY WITH NICERGOLINE
VERSUS PLACEBO IN GERIATRIC-PATIENTS WITH TRANSIENT-
SYNDROMES.
000665 01-11
DETERMINATION OF THE ENCEPHALOTROPIC, PSYCHOTROPIC AND
PHARMACODYNAMIC PROPERTIES OF NICERGOLINE BY MEANS OF
QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY AND
PSYCHOMETRIC-ANALYSES.
000788 01-13
NICKEL
EFFECT OF NICKEL ON THE LEVELS OF DOPAMINE, NORADRENALINE AND
SEROTONIN IN DIFFERENT REGIONS OF THE RAT-BRAIN.
001831 02-05
NICOTINAMIDE
DISSIMILAR EFFEQS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS. ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE.
000173 01-03
NICOTINE
STUDIES ON THE BIOCHEMICAL-EFFEQS AND BEHAVIOURAL-EFFECTS OF
ORAL NICOTINE.
001115 02-03
THE INFLUENCE OF GENOTYPE AND SEX ON BEHAVIORAL-SENSITIVITY TO
NICOTINE IN MICE.
001648 02-04
EFFEaS OF CYCLOHEXIMIDE ADMINISTERED IN CONJUNQION WITH
NICOTINE ON RETENTION OF A PASSIVE-AVOIDANCE TASK IN MICE.
001791 02-04
THE USE OF NICOTINE CHEWING-GUM AS AN AID TO STOPPING
SMOKING.
002343 02-14
NICOTINE INGESTION REDUCES ELEVATED BLOOD-PRESSURES IN RATS
AND SQUIRREL-MONKEYS.
002759 03-03
SELEQIVE INHIBITION BY NICOTINE OF SHOCK-INDUCED FIGHTING IN THE
RAT
002984 03-04
THE SMOKING HABIT AND PSYCHOPHARMACOLOGICAL-EFFEaS OF
NICOTINE.
003577 03-17
EFFEa OF NICOTINE ON IN VIVO SECRETION OF MELANOCORTICOTROPIC-
HORMONES IN THE RAT.
003759 04-03
THE EFFEa OF CHRONIC NICOTINE AND WITHDRAWAL ON INTRAAXONAL
TRANSPORT OF ACETYLCHOLINE AND RELATED ENZYMES IN SCIATIC-
NERVE OF THE RAT.
003897 04-03
THE ROLE OF NICOTINE IN THE BEHAVIORAL-ASPECTS OF CIGAREHE
SMOKING.
004575 04-14
NICOTINE-RECEPTORS
STEREOSPECIFIC NICOTINE-RECEPTORS ON RAT-BRAIN MEMBRANES.
000254 01-03
NICOTINIC
ENZYMATIC CARBOXYMETHYLATION OF THE NICOTINIC ACETYLCHOLINE-
RECEPTOR. (UNPUBLISHED PAPER).
001318 02-03
INTRINSIC CHOLINERGIC EXCITATION IN THE RAT NEOSTRIATUM:
NICOTINIC AND MUSCARINIC-RECEPTORS.
001374 02-03
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJEQION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND
GANGLIONIC SYNAPSES.
002870 03-03
NICOTINIC-DRUGS
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJEQION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
NICTITATING
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFECTS OF FENTANYL ON
THE CONTRACTION OF THE NICTITATING MEMBRANE IN CATS.
002876 03-03
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT
NICTITATING MEMBRANE
003777 04-03
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NICTITATING MEMBRANE OF THE CAT.
003822 04-03
NIDA
PHENCYCLIDINE: A NIDA PERSPECTIVE.
000743 01-12
NIEMANN-PICK
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL
AND PATHOLOGICAL (M. NIEMANN-PICK TYPE C) HUMAN BRAIN.
003671 04-01
NIGERIAN
PREVALENCE OF PERSISTENT ABNORMAL INVOLUNTARY-MOVEMENTS
AMONG PATIENTS IN A NIGERIAN LONG-STAY PSYCHIATRIC UNIT.
004334 04-08
NIGHT
POLYGRAPHIC- STUDY OF NIGHT SLEEP UNDER THE EFFECTS OF
MINAPRINE.
003313 03-11
AGE-SPECIFIC DOSES OF LORMETAZEPAM AS A NIGHT SEDATIVE IN
CASES OF CHRONIC SLEEP-DISTURBANCE.
004309 04-07
NIGHT-TERRORS
SURVECTOR AND SLEEP-DISORDERS: SLEEP-WALKING, NIGHTMARES,
AND NIGHT-TERRORS.
002110 02-11
NIGHTMARES
SURVEaOR AND SLEEP-DISORDERS: SLEEP-WALKING, NIGHTMARES,
AND NIGHT-TERRORS.
002110 02-11
NIGRAL
MORPHINE-DEPENDENCE AND DOPAMINERGIC-ACTIVITY: TESTS OF
CIRCLING RESPONSES IN RATS WITH UNILATERAL NIGRAL LESIONS.
001641 02-04
INTRANIGRAL INJECTION OF CAPSAICIN ENHANCES MOTOR-ACTIVITY
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE BUT NOT SUBSTANCE-
P.
004100 04-04
THE ROLE OF NIGRAL PROJECTIONS TO THE THALAMUS IN DRUG-
INDUCED CIRCLING-BEHAVIOUR IN THE RAT.
004205 04-04
NIGROSTRIATAL
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES.
000202 01-03
EFFECTS OF ALPHA CHLORALOSE ON THE ACTIVITY OF THE
NIGROSTRIATAL DOPAMINERGIC SYSTEM IN THE CAT.
000217 01-03
ACUTE AND CHRONIC HALOPERIDOL TREATMENT: EFFECTS ON
NIGROSTRIATAL DOPAMINERGIC-SYSTEM ACTIVITY.
001153 02-03
GLYCINE ENHANCEMENT OF CAUDATE NEURONAL ACTIVITIES:
RELATIONSHIP WITH THE DOPAMINERGIC NIGROSTRIATAL PATHWAY.
001225 02-03
SUPERSENSITIVITY AND THE EFFECTS OF LONG-TERM AMPHETAMINE IN
THE RAT NIGROSTRIATAL SYSTEM. (PH.D. DISSERTATION).
001485 02-03
CHRONOLOGY OF EXTRAPYRAMIDAL-EFFECTS OF NEUROLEPTIC-DRUGS
AND THE NIGROSTRIATAL DOPAMINERGIC-SYSTEM.
002449 02-15
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
AMPHETAMINE-INDUCED MOTILITY AND NIGROSTRIATAL IMPULSE FLOW.
003005 03-04
EFFECTS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE-
PUT AMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC
BUNDLE IN THE RAT.
003910 04-03
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH
UNILATERAL NIGROSTRIATAL LESIONS.
004117 04-04
S-309
yMSSSSSSSiS
Subject Index
Psychopharmacology Abstracts
1''
9:^
««|:j
£:■■
fe
DOPAMINE-RECEPTOR CHANGES FOLLOWING DESTRUQION OF THE
NIGROSTRIATAL PATHWAY: LACK OF A RELATIONSHIP TO
ROTATIONAL-BEHAVIOR.
004229 04-04
NIGROTHALAMIC
EVIDENCE FOR A GABAERGIC NIGROTHALAMIC PATHWAY IN THE RAT: I.
BEHAVIOURAL-STUDIES AND BIOCHEMICAL-STUDIES.
000158 01-03
NIMETAZEPAM
REVERSIBLE RING-OPENING REACTIONS OF NIMETAZEPAM AND
NITRAZEPAM IN ACIDIC MEDIA AT BODY-TEMPERATURE.
004517 04-13
NIMH-PRB
A TWELVE-YEAR FOLLOWUP OF THE NIMH-PRB HIGH-DOSE
CHLORPROMAZINE STUDY OF CHRONIC SCHIZOPHRENICS ~
IMPLICATIONS FOR DEINSTITUTIONALIZATION. (UNPUBLISHED PAPER).
004323 04-08
NIPECOTIC-ACID
EFFECT OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO
STIMULATION OF THE NUCLEUS-ACCUMBENS.
000331 01-03
NIPECOTIC-ACID-AMIDE
EFFECTS OF SODIUM-DIPROPYLACETATE, MUSCIMOL-HYDROBROMIDE
AND (R,S) NIPECOTIC-ACID-AMIDE ON ISOLATION-INDUCED
AGGRESSIVE-BEHAVIOR IN MICE.
001756 02-04
NISOXETINE
SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM IN BRAIN: EFFEaS OF NISOXETINE
VERSUS FLUOXETINE.
000208 01-03
NITRAZEPAM
ENZYME INDUCING EFFECTS OF PHENOBARBITAL ON NITRAZEPAM
METABOLISM IN DOGS.
000086 01-03
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY:
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS.
000543 01-07
COMPARISON OF NITRAZEPAM 5 MG WITH TRIAZOUM 0.5 MG IN
YOUNG PSYCHIATRIC INSOMNIAC-INPATIENTS.
002096 02-11
THE EFFECTS OF TRIAZOLAM AND NITRAZEPAM ON SLEEP QUALITY,
MORNING VIGILANCE, AND PSYCHOMOTOR PERFORMANCE.
002330 02-14
REVERSIBLE RING-OPENING REAQIONS OF NIMETAZEPAM AND
NITRAZEPAM IN ACIDIC MEDIA AT BODY-TEMPERATURE.
004517 04-13
NITROGEN-MUSTARD
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES.
002879 03-03
NITROUS-OXIDE
TOLERANCE OF MICE TO NITROUS-OXIDE.
000418 01-04
A COMPARISON OF THE EFFECTS OF MORPHINE-SULPHATE AND NITROUS-
OXIDE ANALGESIA ON CHRONIC PAIN STATES IN MAN.
003442 03-14
NMR
BETA ENDORPHIN AND ANALOGS: 360 MHZ PROTON NMR
SPECTROSCOPY.
001028 02-01
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
NOCICEPTION
DOES SYSTEMIC MORPHINE INCREASE DESCENDING INHIBITORY
CONTROLS OF DORSAL-HORN NEURONES INVOLVED IN NOCICEPTION?
000175 01-03
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJEQION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS.
001446 02-03
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
NOCICEPTIVE
THE EFFECTS OF MORPHINE ON THE AQIVITY OF CERTAIN DORSAL-HORN
NEURONS OF THE SPINAL-CORD INVOLVED IN NOCICEPTIVE PROCESSES.
000028 01-03
REVERSIBLE INACTIVATION OF RAPHE-MAGNUS NEURONS: EFFEQS ON
NOCICEPTIVE THRESHOLD AND MORPHINE-INDUCED ANALGESIA.
000240 01-03
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED
CAT.
002740 03-03
EXCITATORY EFFEQS OF DIHYDROCAPSAICIN ON NOCICEPTIVE NEURONS
IN THE MEDIAL THALAMUS.
003714 04-03
THE EFFECT OF CHOLINERGIC SUBSTANCES ON NOCICEPTIVE EVOKED-
RESPONSES IN SPECIFIC NUCLEI OF THE THALAMUS.
003770 04-03
NOCTURNAL
THE DIFFERENTIAL-EFFEQS OF SHORT-AQING AND LONG-AQING
BENZODIAZEPINES UPON NOQURNAL SLEEP AND DAYTIME
PERFORMANCE.
000822 01-14
THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPEQS OF SLEEP AND OBJEQIVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOQURNAL
MEDICATION: II. REPEATED DOSES.
002331 02-14
THE EFFECT OF BUTOCTAMIDE-HYDROGEN-SUCCINATE ON NOQURNAL
SLEEP: ALL-NIGHT POLYGRAPHICAL- STUDIES.
002350 02-14
HIPPOCAMPAL SEROTONIN REUPTAKE AND NOQURNAL LOCOMOTOR-
AQIVITY AFTER MICROINJECTIONS OF 5,7 DHT IN THE FORNIX-
FIMBRIA.
002929 03-03
DISULFIRAM AND NOCTURNAL PENILE-TUMESCENCE IN THE CHRONIC
ALCOHOLIC.
004556 04-13
NOISE
AIRCRAFT NOISE AND MENTAL-HEALTH: II. USE OF MEDICINES AND
HEALTH-CARE-SERVICES.
003647 03-17
NOMIFENSIN
NOMIFENSIN IN THE TREATMENT OF ENDOGENOUS DEPRESSIONS.
CLINICAL-EXPERIENCE AND EEG FINDINGS
000613 01-09
NOMIFENSINE
THE TREATMENT OF DEPRESSIVE-CONDITIONS WITH NOMIFENSINE.
000609 01-09
CLINICAL-EXPERIENCE WITH NOMIFENSINE.
000642 01-09
THE COMPARATIVE DISPOSITION OF NOMIFENSINE (MERITAL) IN THE
PREGNANT AND NONPREGNANT RAT.
000853 01-15
ANATOMICOPHYSIOLOGICAL AND NEUROCHEMICAL-STUDY OF THE
LIMBIC-SYSTEM: EFFECT OF NOMIFENSINE.
001160 02-03
EFFECTS OF NOMIFENSINE AND DESIPRAMINE ON THE SEQUELAE OF
INTRACEREBRALLY INJECTED 6 OHDA AND 5,6 DHT.
001522 02-03
NOMIFENSINE IN THE TREATMENT OF VARIOUS TYPES OF DEPRESSION.
001968 02-09
NOMIFENSINE IN THE TREATMENT OF ENDOGENOUS DEPRESSION. A
CONTROLLED- STUDY VS. NORTRIPTYLINE.
001978 02-09
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC
DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL
CONTROLS.
002004 02-09
TREATMENT OF THERAPY-RESISTANT DEPRESSED-PATIENTS WITH IV.
INFUSIONS OF NOMIFENSINE CONTROLLED BY GALVANIC-SKIN-
RESISTANCE.
002012 02-09
PROFILE OF THE ANTIDEPRESSANT ACTION OF NOMIFENSINE.
002025 02-09
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A
MONOSUBSTANCE (DOXEPINE).
002028 02-09
NOMIFENSINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE-NEUROSIS.
THERAPEUTIC-EFFICACY AND TOLERABILITY IN COMPARISON TO
IMIPRAMINE.
002078 02-10
NOMIFENSINE AS CONCOMITANT THERAPY IN THE TREATMENT OF
PARKINSON-PATIENTS. A DOUBLE-BUND PLACEBO-CONTROLLED-
STUDY.
002130 02-11
INFLUENCE OF NOMIFENSINE ON GROWTH-HORMONE, PROLACTIN,
LUTEINISING-HORMONE AND THYREOTROPIN IN HEALTHY SUBJECTS
AND HYPERPROLACTINAEMIC-PATIENTS.
002137 02-n
RECENT INVESTIGATIONS ON THE MECHANISM-OF-ACTION OF
NOMIFENSINE.
002289 02-13
SUBJECTIVE DRUG-EFFECTS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFECTS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
DOPAMINERGIC INVOLVEMENT IN THE HYPERALGESIC EFFECT OF
NOMIFENSINE.
002736 03-03
S-310
VOLUME 19, SUBJECT INDEX
Subject Index
NOREPINEPHRINE AND DOPAMINE CEREBRAL LEVELS AFTER CHRONIC-
TREATMENT WITH NOMIFENSINE.
002872 03-03
ACUTE ACTION OF NOMIFENSINE ON NOREPINEPHRINE AND DOPAMINE
LEVELS IN THE RAT-BRAIN.
002873 03-03
NOMIFENSINE: CONSIDERATIONS ON A NEW NONTRICYCLIC-
ANTIDEPRESSANT.
003222 03-09
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NICTITATING MEMBRANE OF THE CAT.
003822 04-03
CONTROLLED CLINICAL-TRIAL OF NOMIFENSINE IN THE TREATMENT OF
DEPRESSION.
004417 04-09
PLASMA NOMIFENSINE CONCENTRATION: CARDIOLOGICAL EFFECTS AND
CLINICAL-RESPONSE.
004639 04-15
MAPROTILINE, NOMIFENSINE, MIANSERIN, ZIMELIDINE: A REVIEW OF
ANTIDEPRESSANT EFFICACY IN INPATIENTS.
004731 04-17
NOMOGRAMS
PREDICTABILITY OF PHENYTOIN SERUM LEVELS BY NOMOGRAMS AND
CLINICIANS.
000909 01-16
NON-5-HYDROXYTRYPTAMINERGIC
METERGOLINE AND CYPROHEPTADINE SUPPRESS PROLACTIN RELEASE BY
A NON-5-HYDROXYTRYPTAMINERGIC, NONDOPAMINERGIC
MECHANISM.
003732 04-03
NONADDICTED
EVENT-RELATED POTENTIAL CHANGES WITH MORPHINE IN NONADDIQED
HUMANS.
004512 04-13
NONANESTHETIC
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
NONANTIPSYCHOTIC
PROLAaiN RELEASING POTENCIES OF ANTIPSYCHOTIC AND RELATED
NONANTIPSYCHOTIC COMPOUNDS IN FEMALE RATS: RELATION TO
CLINICAL POTENCIES.
003830 04-03
NONASSOCIATIVE-ASPEaS
INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY
PREEXPOSURE TO THE UNCONDITIONED-STIMULUS: ASSOCIATIVE-
ASPEQS AND NONASSOCIATIVE-ASPEQS.
001610 02-04
NONCOMPETITIVE
NONCOMPETITIVE AMINE UPTAKE INHIBITION BY THE NEW
ANTIDEPRESSANT PRIDEFINE.
003771 04-03
NONCOMPLIANCE
NONCOOPERATION: AN EXAMINATION OF FAQORS LEADING TO
NONCOMPLIANCE IN A HYPERTENSION CLINIC.
002557 02-17
NONCOOPERATION
NONCOOPERATION: AN EXAMINATION OF FAQORS LEADING TO
NONCOMPLIANCE IN A HYPERTENSION CLINIC.
002557 02-17
NONDEPRIVED
NALOXONE: EFFEQS ON FOOD AND WATER CONSUMPTION IN THE
NONDEPRIVED AND DEPRIVED RAT.
001599 02-04
NONDOPAMINERGIC
METERGOLINE AND CYPROHEPTADINE SUPPRESS PROLACTIN RELEASE BY
A NON-5-HYDROXYTRYPTAMINERGIC, NONDOPAMINERGIC
MECHANISM.
003732 04-03
NONEMOTIVE
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS, UNDER
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REACTION TYPE
(EMOTIVE AND NONEMOTIVE).
001624 02-04
N0NER60T
CHARAQERIZATION OF ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLACTIN AND GROWTH-HORMONE PROFILES
DURING WAKEFULNESS AND SLEEP.
002217 02-13
NONGABAERGIC
CHARACTERIZATION OF 3H GABA-RECEPTOR BINDING TO RAT-BRAIN
SYNAPTOSOMAL MEMBRANES: EFFEQ OF NONGABAERGIC
COMPOUNDS.
000139 01-03
NONGENETIC
NONGENETIC FAQORS AFFECTING HUMAN PLATELET MONOAMINE-
OXIDASE.
003407 03-13
NONHUMAN
PROCEDURES FOR REDUCING DRUG INTAKE: NONHUMAN STUDIES.
001753 02-04
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES.
002285 02-13
ANTAGONISM OF INTRAVENOUS COCAINE LETHALITY IN NONHUMAN
PRIMATES.
003127 03-05
NONIDENTITY
CHARACTERIZATION OF LRF-LIKE IMMUNOREACTIVITY IN THE FROG
SYMPATHETIC GANGLIA: NONIDENTITY WITH LRF-DECAPEPTIDE.
(UNPUBLISHED PAPER).
001018 02-01
NONINTERACTION
NONINTERACTION OF DIGITOXIN AND QUINIDINE.
000968 01-17
NONLINEAR
NONLINEAR REGRESSION ANALYSIS OF NOREPINEPHRINE RESPONSE
KINETICS IN CEREBRAL VASCULATURE.
000256 01-03
NONLITHIUM
RENAL FUNCTION IN LITHIUM AND NONLITHIUM TREATED PATIENTS
WITH AFFECTIVE-DISORDERS.
000837 01-15
NONNARCOTIC
BLOCKADE BY L LYSINE OF NONNARCOTIC ANALGESICS.
003857 04-03
NONNEURONAL
BASIC AND CLINICAL NEUROBIOLOGICAL APPLICATIONS OF NEURONAL
(NSE) AND NONNEURONAL (NNE) ENOLASE. (UNPUBLISHED PAPER).
001041 02-01
NONNOXIOUS
MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION.
003782 04-03
NONOPIATE
STEREOSPECIFIC, DOSE-DEPENDENT ANTAGONISM BY NALOXONE OF
NONOPIATE BEHAVIOR IN MICE.
000411 01-04
INTERACTIONS BETWEEN NALTREXONE AND NONOPIATE DRUGS
EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
001645 02-04
NONOPIOID
DISCRIMINATION OF ELECTRIC-SHOCK: EFFECTS OF SOME OPIOID AND
NONOPIOID DRUGS.
004106 04-04
NONORGANIC
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY?
004553 04-13
NONPARAMETRIC
A SYMPTOM-PROFILE-ANALYSIS OF ANTIPSYCHOTIC-DRUG TREATMENT:
NONPARAMETRIC MULTIDIMENSIONAL TECHNIQUE.
003196 03-08
NONPREGNANT
THE COMPARATIVE DISPOSITION OF NOMIFENSINE (MERITAL) IN THE
PREGNANT AND NONPREGNANT RAT.
000853 01-15
NONPSYCHOACTIVE
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN
HUMAN CELLS.
002830 03-03
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS.
002831 03-03
NONPSYCHOTIC
THE IMPORTANCE OF AMINEPTINE IN THE TREATMENT OF NONPSYCHOTIC
DEPRESSIVE-STATES IN THE ELDERLY.
001999 02-09
NONRESPONDERS
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO: A DISCRIMINANT FUNCTION ANALYSIS.
002482 02-16
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO. A DISCRIMINANT FUNCTION ANALYSIS. (UNPUBLISHED
PAPER).
004420 04-10
NONSEROTONERGIC
NONSEROTONERGIC DEPRESSION OF SPINAL MONOSYNAPTIC REFLEX
TRANSMISSION BY 5 HYDROXYTRYPTOPHAN.
002745 03-03
1
S-311
Subject Index
Psychopharmacology Abstracts
Sill'
mt
-Bill,;
Si:'
fe
NONSIGNALLED
DIFFERENTIAL-EFFEQS OF METHYLPHENIDATE ON SIGNALLED AND
NONSIGNALLED REINFORCEMENT.
000380 01-04
NONSPECIFIC
EFFECTS OF EXPERIMENTER AND TEST LOCATION NOVELTY ON
NONSPECIFIC ACTIVITY IN RATS AND ITS MODIFICATION BY
METHAMPHET AMINE.
000409 01-04
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC
DRUGS.
001330 02-03
3H APOMORPHINE-RECEPTORS IN VARIOUS RAT-BRAIN REGIONS: A
STUDY OF SPECIFIC AND NONSPECIFIC BINDING AND THE INFLUENCE OF
CHRONIC NEUROLEPTIC TREATMENT.
001846 02-05
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMinER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
SPECIFIC AND NONSPECIFIC MULTIPLE UNIT ACTIVITIES DURING
PENTYLENETETRAZOL SEIZURES. I. ANIMALS WITH ENCEPHALE ISOLE.
004046 04-03
NONSPECIFIC FACTORS IN DRUG-EFFEaS: PLACEBO PERSONALITY.
004704 04-17
NONSTEROIDAL
LOWERING OF THE CONVULSIVE THRESHOLD BY NONSTEROIDAL
ANTIINFLAMMATORY-DRUGS.
002904 03-03
NONTOLERANT
TIME-COURSE OF ETORPHINE LEVELS IN TISSUES OF OPIATE-TOLERANT
AND NONTOLERANT RATS.
000301 01-03
NONTOXIC
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN.
004638 04-15
NONTREATED
NORMAL PLASMA DOPAMINE-BETA-HYDROXYLASE IN NONTREATED AND
TREATED PARKINSON-PATIENTS
004471 04-11
NONTRICYCLIC-ANTIDEPRESSANT
NOMIFENSINE: CONSIDERATIONS ON A NEW NONTRICYCLIC-
ANTIDEPRESSANT.
003222 03-09
NONVERBAL-BEHAVIOR
ON THE RELATIONSHIP BETWEEN MEASURES OBTAINED BY VIDEO-
ANALYSIS OF NONVERBAL-BEHAVIOR AND SELF-RATING OF MOOD.
004410 04-09
NOOTROPIC
CNS EFFECTS OF ISF-2522, A NEW NOOTROPIC (A PHASE I SAFETY AND
CNS EFFICACY STUDY WITH QUANTITATIVE PHARMACOEEG AND
PHARMACOPSYCHOLOGY).
004519 04-13
NOOTROPIC-DRU6S
EFFECTS OF SOME NOOTROPIC-DRUGS UPON THE EMBRYONIC
MORPHOGENETIC SYSTEMS.
000144 01-03
POSSIBILITIES OF INFLUENCE ON THE ORGANIC-PSYCHOSYNDROME WITH
NOOTROPIC-DRUGS IN CHRONIC ALCOHOLISM.
000707 01-11
PHARMACOLOGY OF NOOTROPIC-DRUGS.
000800 01-14
NOOTROPIC-DRUGS IN CLINICAL-PRAQICE.
000811 01-14
THE INFLUENCE OF NOOTROPIC-DRUGS ON LEARNING AND MEMORY OF
DEFENSE REACTIONS.
000815 01-14
CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM.
000988 01-17
THE EFFEQS OF NOOTROPIC-DRUGS ON THE SUSCEPTIBILITY TO
AUDIOGENIC-SEIZURES IN RATS.
001571 02-04
TWO-WAY AVOIDANCE LEARNING UNDER THE INFLUENCE OF NOOTROPIC-
DRUGS.
001647 02-04
ANTIHYPOXIDOTIC-DRUGS AND NOOTROPIC-DRUGS: PROOF OF THEIR
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
QUANTITATIVE EEG INVESTIGATIONS.
002166 02-11
NOOTROPIC-DRUGS AND RELATED DRUGS INTERAQING WITH THE
INTEGRATIVE ACTIVITY OF THE BRAIN.
002327 02-14
NOOTROPICS
POSSIBLE CLINICAL APPLICATIONS OF NOOTROPICS.
001890 02-07
NOOTROPIL
CLINICAL AND BIOCHEMICAL-ACTION OF PIRACETAM (NOOTROPIL) IN
DRUG-RESISTANT DEPRESSION.
000600 01-09
INFLUENCING BRAIN CONCUSSION BY NOOTROPIL.
000724 01-11
THE EFFECT OF NOOTROPIL ON THE TRANSCALLOSAL AND PRIMARY
EVOKED-RESPONSES OF THE CAT CEREBRAL-CORTEX.
003780 04-03
NOOTROPIL-UCB
OUR EXPERIENCE WITH PIRACETAM (NOOTROPIL-UCB) TREATMENT IN
CHILDREN FROM HIGH-RISK PREGNANCIES WITH SUBSEQUENT
MINIMAL-BRAIN-DYSFUNCTION .
000544 01-07
NOOTROPYL
SOME THERAPEUTIC EFFECTS OF NOOTROPYL.
004458 04-11
NORADRENALINE
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTIUNE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS
000171 01-03
METABOLISM OF 3H NORADRENALINE RELEASED FROM ISOLATED RAT
HYPOTHALAMUS BY EXTRAQS OF BLACK-WIDOW-SPIDER GLANDS.
000223 01-03
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFEaS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
THE MECHANISM OF EFFECT OF NEUROPHARMACOLOGICAL-DRUGS. VI:
EFFEQ OF NORADRENALINE AND 5 HYDROXYTRYPTAMINE ON BRAIN
FREE FATTY-ACIDS
000274 01-03
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL AQIVITY.
000314 01-03
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES.
001078 02-02
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER AQIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT.
001095 02-03
NORADRENALINE RELEASE FROM SLICES OF THE THALAMUS OF NORMAL
AND MORPHINE-DEPENDENT RATS.
001 142 02-03
AN EXAMINATION OF FAQORS INFLUENCING ADRENERGIC
TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNQIONAL
ALPHA-ADRENOCEPTORS.
001196 02-03
EFFEQS OF RATE OF BLOOD FLOW ON FRAQIONAL EXTRAQION AND ON
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN
VIVO.
001231 02-03
THE HYPERKINETIC-SYNDROME FOLLOWING LONG-TERM HALOPERIDOL
TREATMENT: INVOLVEMENT OF DOPAMINE AND NORADRENALINE.
001299 02-03
DOPAMINE-BETA-HYDROXYLASE AQIVITY AND NORADRENALINE
CONTENT IN PIAL-ARTERIES OF CAT AND GOAT.
001357 02-03
THE EFFEQ OF PSYCHOTROPIC-SUBSTANCES AND NARCOTIC ANALGESIC-
DRUGS ON 14C NORADRENALINE UPTAKE BY SYNAPTOSOMES OF THE
CEREBRAL-CORTEX OF RATS.
001363 02-03
GABA FACILITATION BY NORADRENALINE SHOWED SUPERSENSITIVITY IN
CEREBELLUM AFTER 6 HYDROXYDOPAMINE.
001382 02-03
EVIDENCE THAT NORADRENALINE MODULATES THE INCREASE IN
STRIATAL DOPAMINE METABOLISM INDUCED BY MUSCARINIC-
RECEPTOR STIMULATION.
001518 02-03
INTRAHYPOTHALAMIC MICROINJECTIONS OF NORADRENALINE WITH AND
WITHOUT INDUCTION OF THE ALIMENTARY DRIVE AS A REWARD IN A
T-MAZE LEARNING IN RATS.
001604 02-04
S-312
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECT OF NICKEL ON THE LEVELS OF DOPAMINE, NORADRENALINE AND
SEROTONIN IN DIFFERENT REGIONS OF THE RAT-BRAIN.
001831 02-05
BLOOD LEVEL OF AMITRIPTYLINE, NORTRIPTYLINE, NORADRENALINE,
SEROTONIN AND THERAPEUTIC RESPONSE.
002057 02-09
QUANTIFICATION OF NORADRENALINE IONTOPHORESIS.
002475 02-16
REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY
NORADRENALINE INFUSION.
002672 03-03
ENHANCEMENT OF NORADRENALINE RELEASE FROM RAT-CEREBRAL-
CORTEX BY NEUROLEPTIC-DRUGS.
002742 03-03
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFECTS OF
HALOPERIDOL AND PARGYLINE.
003792 04-03
REGULATION OF NORADRENALINE OVERFLOW IN RAT-CEREBRAL-CORTEX
BY PR0STAGLANDIN-E2.
003841 04-03
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA-
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL
UPTAKE,
003879 04-03
INFLUENCE OF CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5
HYDROXYTRYPTAMINE, TYRAMINE AND POTASSIUM FROM GOAT
PIAL-ARTERIES.
003925 04-03
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
DECREASE OF NORADRENALINE 0 METHYLATION IN RAT-BRAIN INDUCED
BY L-DOPA. REVERSAL EFFECT OF S ADENOSYL-L-METHIONINE.
004019 04-03
THE EFFECT OF NORADRENALINE ON NA-K TRANSPORT IN RAT-CEREBRAL-
CORTICAL SLICES.
004056 04-03
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE- STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
THE SPECIFIC ACTIVITY OF PLATELET MONOAMINE-OXIDASE VARIES
WITH PLATELET COUNT DURING SEVERE EXERCISE AND
NORADRENALINE INFUSION.
004509 04-13
NORADRENALINE-RECEPTORS
ACTIVATION OF PRESYNAPTIC ALPHA NORADRENALINE-RECEPTORS IN
RAT-BRAIN BY THE POTENT DOPAMINE-MIMETIC N,N DIPROPYL-ADTN.
001390 02-03
NORADRENERGIC
FUNCTIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY
NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS
WITH SCHIZOPHRENIA.
000059 01-03
EFFECT OF MIANSERIN ON NORADRENERGIC TRANSMISSION IN THE RAT
ANOCOCCYGEUS-MUSCLE.
000075 01-03
HYPOALGESIA FOLLOWING MICROINJECTION OF NORADRENERGIC
ANTAGONISTS IN THE NUCLEUS-RAPHE-MAGNUS.
000122 01-03
CENTRAL NORADRENERGIC ADAPTATION TO LONG-TERM-TREATMENT
WITH IMIPRAMINE IN RHESUS-MONKEYS.
000182 01-03
MICROIONTOPHORETIC STUDIES ON NORADRENERGIC INHIBITION FROM
LOCUS-COERULEUS OF SPINAL TRIGEMINAL-NUCLEUS NEURONS.
000260 01-03
EFFEQS OF NORADRENERGIC AGONISTS AND ANTAGONISTS ON
GROWTH-HORMONE SECRETION UNDER GAMMA HYDROXYBUTYRATE
NARCOANALGESIA IN THE RAT.
000262 01-03
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL ACTIVITY.
000314 01-03
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFEaS ON
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE
PARADIGM.
000372 01-04
THE TIME-COURSE OF NORADRENERGIC PRESYNAPTIC AND
POSTSYNAPTIC ACTIVITY DURING CHRONIC DESIPRAMINE TREATMENT.
001289 02-03
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION.
001310 02-03
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN; EFFECT
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE
001353 02-03
INTERACTION OF HISTAMINE H2-RECEPT0R BLOCKING-DRUGS WITH THE
NORADRENERGIC SYSTEM IN RAT-BRAIN AND HEART
001397 02-03
INVESTIGATIONS ON THE INTERACTION OF THYROTROPIN-RELEASING-
HORMONE (TRH) AND MK-771 WITH CENTRAL NORADRENERGIC
MECHANISMS.
001701 02-04
ELECTROPHYSIOLOGICAL-CHANGES AT A CENTRAL NORADRENERGIC
SYNAPSE DURING THALLIUM TOXICOSIS.
001848 02-05
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
002801 03-03
CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN
HYPOTHALAMUS.
002842 03-03
NORADRENERGIC STIMULATION IN VIVO INCREASES NA-K -ADENOSINE-
TRIPHOSPHATASE ACTIVITY.
002910 03-03
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR.
002945 03-04
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC-
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT MIANSERIN.
003745 04-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR PRESYNAPTIC ACTIONS OF
PHENCYCLIDINE ON NORADRENERGIC TRANSMISSION IN RAT
CEREBELLUM.
003926 04-03
EFFECTS OF ZIMELIDINE ON SEROTONINERGIC AND NORADRENERGIC
NEURONS AFTER REPEATED ADMINISTRATION IN THE RAT.
003991 04-03
EFFECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC
NEURONS.
004026 04-03
NORADRENERGIC INFLUENCES ON SOUND-INDUCED SEIZURES.
004137 04-04
ALTERATIONS IN NORADRENERGIC FUNCTION DURING CLORGYLINE
TREATMENT.
004393 04-09
NORADRENERGIC-AIPHA2-RECEPTORS
FUNCTIONAL EVIDENCE FOR SUBSENSITIVITY OF NORADRENERGIC-
ALPHA2-RECEPT0RS AFTER CHRONIC DESIPRAMINE TREATMENT.
000283 01-03
NORADRENERGIC-RECEPTOR
DOWN REGULATION OF NORADRENERGIC-RECEPTOR FUNCTION BY
ANTIDEPRESSANT-DRUGS: FUNCTIONAL SIGNIFICANCE AND
DISTINCTION FROM ANTIPSYCHOTIC-DRUGS. (UNPUBLISHED PAPER).
004746 04-17
NORCOCAINE
INTRAVENOUS SELF-ADMINISTRATION OF COCAINE AND NORCOCAINE BY
DOGS,
001760 02-04
DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE, NORCOCAINE, AND
N ALLYLNORCOCAINE.
002954 03-04
EFFECTS OF NORCOCAINE AND SOME NORCOCAINE DERIVATIVES ON
SCHEDULE-CONTROLLED BEHAVIOR OF PIGEONS AND SQUIRREL-
MONKEYS.
004012 04-03
NORDIAZEPAM
ANALYSIS FOR DIAZEPAM AND NORDIAZEPAM BY ELECTRON-CAPTURE
GAS-CHROMATOGRAPHY AND BY LIQUID-CHROMATOGRAPHY.
000006 01-01
NOREPINEPHRINE
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART, III, DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES,
000025 01-03
ANTIHISTAMINE EFFECT ON SYNAPTOSOMAL UPTAKE OF SEROTONIN,
NOREPINEPHRINE AND DOPAMINE.
000035 01-03
THE INFLUENCE OF BENZOCTAMINE ON DOPAMINE AND NOREPINEPHRINE
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH
REFLEX OF THE CAT.
000054 01-03
I
S-313
Subject Index
Psychopharmacology Abstracts
a
ill
I
MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS:
MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN.
000068 01-03
RELEASE OF ENDOGENOUS NOREPINEPHRINE FROM A RABBIT CEREBRAL-
ARTERY.
000079 01-03
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
HYPOALGESIA INDUCED BY MICROINJECTION OF A NOREPINEPHRINE
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL
ADMINISTRATION OF A SEROTONIN ANTAGONIST.
000121 01-03
EFFECTS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT.
000180 01-03
INTERACTIONS OF NOREPINEPHRINE WITH PURKINJE-CELL RESPONSES TO
PUTATIVE AMINO-ACID NEUROTRANSMITTERS APPLIED BY
MICROIONTOPHORESIS.
000209 01-03
NONLINEAR REGRESSION ANALYSIS OF NOREPINEPHRINE RESPONSE
KINETICS IN CEREBRAL VASCULATURE.
000256 01-03
TYROSINE ADMINISTRATION REDUCES BLOOD-PRESSURE AND ENHANCES
BRAIN NOREPINEPHRINE RELEASE IN SPONTANEOUSLY HYPERTENSIVE-
RATS.
000296 01-03
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
RECEPTORS.
000323 01-03
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELECTIVE
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR-
STIMULATION INDUCED BY INDIRECTLY ACTING SYMPATHOMIMETIC-
AMINES IN MICE.
000492 01-04
RESPONSES TO TYRAMINE AND NOREPINEPHRINE AFTER IMIPRAMINE
AND TRAZODONE.
000864 01-15
MIANSERIN: DIREa ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS
BY BLOCKING ALPHA2-RECEPT0RS.
001214 02-03
MULTIVARIATE APPROACHES APPLIED TO STUDIES OF NOREPINEPHRINE
AND SEROTONIN UPTAKE.
001460 02-03
ENHANCED SENSITIVITY OF AMYGDALOID NEURONS TO SEROTONIN AND
NOREPINEPHRINE AFTER CHRONIC ANTIDEPRESSANT TREATMENT.
001523 02-03
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN
THE DOG.
001547 02-03
CENTRAL-AaiONS OF NOREPINEPHRINE, PHENTOLAMINE AND 6
HYDROXYDOPAMINE IN SPONTANEOUSLY HYPERTENSIVE-RATS.
001553 02-03
THE EFFECTS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERACTION
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED
AHENTION. (PH.D. DISSERTATION).
001563 02-04
METHODOLOGICAL-ISSUES IN SPINAL-FLUID STUDIES OF SCHIZOPHRENIA:
THE CASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE.
(UNPUBLISHED PAPER).
001952 02-08
PHENYLETHYLAMINE, DOPAMINE AND NOREPINEPHRINE IN
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
001957 02-08
MONOAMINE-OXIDASE, PHENYLETHYLAMINE, NOREPINEPHRINE AND
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
001958 02-08
EFFEQ OF PIRIBEDIL (ET-495) ON PLASMA NOREPINEPHRINE:
RELATIONSHIP TO ANTIDEPRESSANT RESPONSE.
002034 02-09
THE ROLE OF NOREPINEPHRINE IN AFFEaiVE-DISOROERS.
002278 02-13
CALCIUM-SENSITIVE ACCUMULATION OF NOREPINEPHRINE IN RAT-
CEREBRAL-CORTEX.
002685 03-03
NOREPINEPHRINE DEPLETION ALTERS CEREBRAL OXIDATIVE METABOLISM
IN THE AaiVE STATE.
002798 03-03
NOREPINEPHRINE AND DOPAMINE CEREBRAL LEVELS AFTER CHRONIC-
TREATMENT WITH NOMIFENSINE.
002872 03-03
ACUTE ACTION OF NOMIFENSINE ON NOREPINEPHRINE AND DOPAMINE
LEVELS IN THE RAT-BRAIN.
002873 03-03
EFFEaS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM:
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON.
002884 03-03
STIMULATORY EFFEQ OF SOMATOSTATIN ON NOREPINEPHRINE RELEASE
FROM RAT-BRAIN-CORTEX SLICES.
002920 03-03
SPINAL MODULATION OF THE ACOUSTIC STARTLE RESPONSE: THE ROLE
OF NOREPINEPHRINE, SEROTONIN AND DOPAMINE.
002950 03-04
CORTICAL RECOVERY FROM EFFECTS OF MONOCULAR DEPRIVATION:
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6
HYDROXYDOPAMINE.
003024 03-04
THE EFFEaS OF ANTIDEPRESSANTS ON THE RETENTION AND
METABOLISM OF (3H) NOREPINEPHRINE IN RAT-BRAIN SLICES.
003763 04-03
EFFECTS OF PHENYTOIN ON MOUSE CEREBELLAR 5 HYDROXYTRYPTAMINE
AND NOREPINEPHRINE.
003795 04-03
DIFFERENTIAL-EFFEQS OF ALPHA METHYLOOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS.
003947 04-03
EVIDENCE THAT THERE ARE SUBCELLULAR POOLS OF NOREPINEPHRINE
AND THAT THERE IS FLUX OF NOREPINEPHRINE BETWEEN THESE
POOLS.
004004 04-03
MODULATORY INTERACTIONS BETWEEN NOREPINEPHRINE AND TAURINE,
BETA ALANINE, GAMMA AMINOBUTYRIC-ACIO AND MUSCIMOL
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS
004058 04-03
EFFEQS OF TRICYCLIC-ANTIDEPRESSANTS ON TETRABENAZINE-INDUCED
DEPLETION OF BRAIN MONOAMINES IN RATS. 1. NOREPINEPHRINE
004062 04-03
EFFECTS OF NOREPINEPHRINE AND 5 HYDROXYTRYPTAMINE REUPTAKE
INHIBITORS ON ELECTRICALLY-INDUCED SPINAL-CORD SEIZURES IN
RATS.
004144 04-04
RAT-BRAIN AND PLASMA NOREPINEPHRINE GLYCOL METABOLITES
DETERMINED BY GAS-CHROMATOGRAPHY MASS-
FRAGMENTOGRAPHY
004303 04-06
EFFECT OF NOREPINEPHRINE UPTAKE BLOCKERS ON NOREPINEPHRINE
KINETICS.
004506 04-13
NOREPINEPHRINE METABOLISM IN MAN USING DEUTERIUM LABELLING: 4
HYDROXY-3-METHOXYMANDELIC-ACID.
004534 04-13
NOREPINEPHRINE-RECEPTOR
SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM IN BRAIN: EFFECTS OF NISOXETINE
VERSUS FLUOXETINE.
000208 01-03
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE-
RECEPTOR MECHANISMS IN CNS.
001178 02-03
FUNQIONAL ASPEQS OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM IN THE CENTRAL-NERVOUS-SYSTEM.
001493 02-03
NORLAAM
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM)
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND
DINORLAAM, DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT.
000505 01-04
NORMAL
THE EFFECT OF PROPRANOLOL ON THE ELEQROENCEPHALOGRAM IN
NORMAL AND ETHANOL DEPENDENT RATS.
000126 01-03
PROTEQIVE EFFEQ OF PRENYLAMINE AGAINST VULNERABILITY TO
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE
MYOCARDIUM.
000265 01-03
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
DEXAMETHASONE TREATMENT.
000321 01-03
S-314
VOLUME 19, SUBJECT INDEX
Subject Index
MESOLIMBICOCORTICAL DOPAMINE TERMINAL-FIELDS ARE NECESSARY
FOR NORMAL LOCOMOTOR AND INVESTIGATORY EXPLORATION IN
RATS
000383 01-04
DEXTROAMPHETAMINE: COGNITIVE AND BEHAVIORAL-EFFECTS IN
NORMAL AND HYPERACTIVE-BOYS AND NORMAL ADULT MALES.
000716 01-11
PHARMACOKINETICS OF CHLORPROMAZINE IN NORMAL VOLUNTEERS.
000778 01-13
EFFECTS OF METHYLPHENIDATE ON LEARNING A BEGINNING READING
VOCABULARY BY NORMAL ADULTS.
000812 01-14
NORADRENALINE RELEASE FROM SLICES OF THE THALAMUS OF NORMAL
AND MORPHINE-DEPENDENT RATS.
001142 02-03
EFFECT OF TABERNANTHINE ON THE TURNOVER TIME OF BRAIN
CATECHOLAMINES IN NORMAL AND HYPOBARIC HYPOXIC RATS.
001187 02-03
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND
TOLERANT RATS AND MICE.
001476 02-03
EFFECTS OF NALOXONE UPON PROLACTIN AND CORTISOL IN NORMAL
WOMEN.
002213 02-13
EFFECT OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND
NORMAL ADULTS.
002222 02-13
EFFECT OF L TRYPTOPHAN ON APOMORPHINE-INDUCED GROWTH-
HORMONE SECRETION IN NORMAL SUBJECTS.
002253 02-13
INFLUENCE OF CICLAZINDOL ON MONOAMINE UPTAKE AND CNS
FUNCTION IN NORMAL SUBJEQS.
002268 02-13
PSYCHOMOTOR STIMULANTS AS ACTIVATORS OF NORMAL AND
PATHOLOGICAL-BEHAVIOR: IMPLICATIONS FOR THE EXCESSES IN
MANIA. (UNPUBLISHED PAPER).
002353 02-14
EFFEQS OF AMPHETAMINE ON VIGILANCE PERFORMANCE IN NORMAL
AND HYPERAQIVE-CHILDREN.
002359 02-14
AMPHETAMINE-INDUCED ROTATION IN NORMAL CATS.
003002 03-04
DESIPRAMINE AND 2 HYDROXYDESIPRAMINE PHARMACOKINETICS IN
NORMAL VOLUNTEERS.
003154 03-07
PHYSOSTIGMINE INDUQION OF DEPRESSIVE-SYMPTOMATOLOGY IN
NORMAL HUMAN SUBJEQS.
003255 03-09
ACUTE EFFEQS OF CAFFEINE IN NORMAL PREPUBERTAL BOYS.
003310 03-11
DIURNAL GROWTH-HORMONE RESPONSES TO DEXTROAMPHETAMINE IN
NORMAL YOUNG MEN AND POSTMENOPAUSAL-WOMEN.
003411 03-13
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION.
003419 03-13
AUTONOMIC-EFFECTS OF DEXTROAMPHETAMINE IN NORMAL MEN:
IMPLICATIONS FOR HYPERACTIVITY AND SCHIZOPHRENIA.
003437 03-13
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL
AND PATHOLOGICAL (M. NIEMANN-PICK TYPE C) HUMAN BRAIN.
003671 04-01
A STUDY OF GAMMA AMINOBUTYRIC-ACID UPTAKE IN NORMAL AND
DOWNS-SYNDROME PLATELETS.
003787 04-03
DOXEPIN, A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTACT
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL-
INDUCED INCREASE IN CYCLIC-AMP PRODUQION.
003836 04-03
DIFFERENTIAL-EFFECTS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND
RELEASING-AGENTS ON LOCOMOTOR-AQIVITY IN NORMAL AND IN
RESERPINIZED MICE.
004130 04-04
NORMAL PLASMA DOPAMINE-BETA-HYDROXYLASE IN NONTREATED AND
TREATED PARKINSON-PATIENTS.
004471 04-11
PROLACTIN AND GROWTH-HORMONE STUDIES IN SCHIZOPHRENIC-
PATIENTS AND NORMAL CONTROLS.
004538 04-13
APOMORPHINE, HALOPERIDOL AND THE AVERAGE EVOKED-POTENTIALS
IN NORMAL HUMAN VOLUNTEERS.
004549 04-13
COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPLIED TO DRUG
EVALUATION: MIDAZOLAM IN NORMAL SUBJEQS.
004564 04-14
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
LOAD.
004600 04-15
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS.
004658 04-15
NORMALIZES
IMIPRAMINE NORMALIZES NATURALLY OCCURRING AND DRUG-INDUCED
DIFFERENCES IN THE EXPLORATORY-AQIVITY OF RATS.
001646 02-04
NORMETABOLITES
POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES ON THE ONSET,
MAGNITUDE AND QUALITY OF THE OPIOID ABSTINENCE-SYNDROME.
004610 04-15
NORMETAZOCINE
N TETRAHYDROFURYLALKYL AND N ALKOXYALKYL DERIVATIVES OF (-)
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID ACTION
PROFILES.
000013 01-02
NORMOTENSIVE-RATS
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
DOSE-DEPENDENT, AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND
SPONTANEOUSLY HYPERTENSIVE-RATS.
001197 02-03
EFFEQ OF BROMOCRIPTINE ON EXPLORATORY-AQIVITY, BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS.
001635 02-04
SELF-STIMULATION REACTION IN NORMOTENSIVE-RATS AND
HYPERTENSIVE-RATS.
002663 03-03
NORTRIPTYLINE
PREDICTION OF STEADY-STATE PLASMA LEVELS OF AMITRIPTYLINE AND
NORTRIPTYLINE FROM A SINGLE-DOSE 24-HR. LEVEL IN DEPRESSED-
PATIENTS.
000582 01-09
ON THE RELATIONSHIP OF NORTRIPTYLINE: AMITRIPTYLINE RATIO TO
CLINICAL IMPROVEMENT OF AMITRIPTYLINE TREATED DEPRESSIVE-
PATIENTS.
000599 01-09
INTERACTION BETWEEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN:
METABOLITE NORTRIPTYLINE AND THE CORRELATION WITH CLINICAL-
RESPONSE.
000640 01-09
ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLED-
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH
PARKINSONS-DISEASE TREATED WITH L-DOPA.
000659 01-11
NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN RELATION TO
DEBRISOQUINE HYDROXYLATION IN MAN.
000754 01-13
AMITRIPTYLINE, NORTRIPTYLINE PLASMA LEVELS AND CLINICAL-
RESPONSE IN WOMEN WITH AFFECTIVE-DISORDERS.
000757 01-13
CARDIOVASCULAR EFFEQS OF NORTRIPTYLINE IN GERIATRIC-PATIENTS.
000882 01-15
NOMIFENSINE IN THE TREATMENT OF ENDOGENOUS DEPRESSION. A
CONTROLLED-STUDY VS. NORTRIPTYLINE.
001978 02-09
BLOOD LEVEL OF AMITRIPTYLINE, NORTRIPTYLINE, NORADRENALINE,
SEROTONIN AND THERAPEUTIC RESPONSE.
002057 02-09
PHARMACOKINETICS OF NORTRIPTYLINE IN ELDERLY VOLUNTEERS.
002184 02-11
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
FACTORS INFLUENCING NORTRIPTYLINE STEADY-STATE KINETICS:
PLASMA AND SALIVA LEVELS.
002251 02-13
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE
NORTRIPTYLINE.
002304 02-13
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXY AMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYUNE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
S-315
Subject Index
Psychopharmacology Abstracts
Hill;: '
tit ,
i«iat;i
tJ;
•null'
eiiZ
^
SUBTYPES OF DEPRESSION BASED ON EXCRETION OF MHPG AND
RESPONSE TO NORTRIPTYLINE.
002488 02-16
DEPRESSION SUBTYPES AFFECT THE STEADY-STATE PLASMA LEVELS AND
THERAPEUTIC-EFFICACY OF AMITRIPTYLINE AND NORTRIPTYLINE.
003244 03-09
TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFECTS OF
CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS.
003428 03-13
EXCRETION OF NORTRIPTYLINE INTO SALIVA.
003435 03-13
FIRST RESULTS OF AN ORIGINAL METHOD FOR MEASURING BLOOD
LEVELS OF ANTIDEPRESSANTS (AMITRIPTYLINE AND NORTRIPTYLINE).
003559 03-16
DRUG-INTERACTIONS OF AMITRIPTYLINE AND NORTRIPTYLINE WITH
WARFARIN IN THE RAT.
003912 04-03
AMITRIPTYLINE AND NORTRIPTYLINE PLASMA LEVELS MONITORING.
PERSPECTIVE IN CLINICAL-PRACTICE.
004675 04-16
NOSE-POKE
TITRATION PROCEDURE WITH RATS USING A NOSE-POKE RESPONSE AND
TAIL-SHOCK.
001862 02-06
NOSOLOGICAL
THE NOSOLOGICAL INDEPENDENCE OF INVOLUTIONAL DEPRESSION AND
ITS DYNAMICS DURING PSYCHOPHARMACOTHERAPY.
004389 04-09
NOVELTY
EFFECTS OF EXPERIMENTER AND TEST LOCATION NOVELTY ON
NONSPECIFIC ACTIVITY IN RATS AND ITS MODIFICATION BY
METHAMPHETAMINE.
000409 01-04
NOXIOUS
BEHAVIORAL CONFIRMATION OF DIFFUSE NOXIOUS INHIBITORY
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS
OPIATES.
002791 03-03
MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION.
003782 04-03
NUCIFERINE •
NUCIFERINE AND CENTRAL GLUTAMATE-RECEPTORS.
000063 01-03
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND
GABAMIMETICS.
000188 01-03
NUCLEI
THE EFFECT OF MORPHINE ON THE CONTENT OF SEROTONIN, 5
HYDROXYINDOLEACETIC-ACID AND SUBSTANCE-P IN THE NUCLEI
RAPHE-MAGNUS AND RETICULARIS-GIGANTOCELLULARIS.
001328 02-03
SHORT-TERM AND LONG-TERM EFFECTS OF METHAMPHETAMINE ON
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC
NUCLEI.
001384 02-03
BEHAVIOURAL-RESPONSES TO STEREOTACTICALLY CONTROLLED
INJECTIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI.
001708 02-04
LSD-INDUCED ULTRASTRUCTURAL MODIFICATIONS OF LIMBIC-SYSTEM
NUCLEI AND OTHER CEREBRAL ZONES.
002198 02-12
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF
DISCRETE RAT-BRAIN NUCLEI.
002635 03-01
MONOAMINE-OXIDASE-B ACTIVITIES TOWARD BETA PHENYLETHYLAMINE
IN DISCRETE HYPOTHALAMIC AND CIRCUMVENTRICULAR NUCLEI OF
THE RAT.
002781 03-03
PURIFICATION AND SUBUNIT STRUCTURE OF DNA-DEPENDENT RNA-
POLYMERASE-BII FROM RAT-BRAIN NUCLEI.
003679 04-01
THE EFFECT OF CHOLINERGIC SUBSTANCES ON NOCICEPTIVE EVOKED-
RESPONSES IN SPECIFIC NUCLEI OF THE THALAMUS.
003770 04-03
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFEaS OF
HALOPERIDOL AND PARGYLINE.
003792 04-03
SENSITIVITY TO GABA OF NEURONS OF THE DORSAL AND VENTRAL
LATERAL GENICULATE NUCLEI IN THE RAT.
003877 04-03
PRESSOR EFFECTS OF ELECTRICAL-STIMULATION OF THE DORSAL AND
MEDIAN RAPHE NUCLEI IN ANESTHETIZED RATS.
003892 04-03
DIFFERENTIAL-EFFECTS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS.
003947 04-03
NUCLEOSIDE
IRREVERSIBLE INHIBITION OF S ADENOSYLHOMOCYSTEINE-HYDROLASE BY
NUCLEOSIDE ANALOGS. (UNPUBLISHED PAPER).
001010 02-01
NUCLEOSIDES
THE SITE OF AQION OF MUSCLE-RELAXANT PURINE NUCLEOSIDES.
003742 04-03
NUCLEOTIDASE
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
NUCLEOTIDE
DISTRIBUTION OF CESIUM IN THE ORGANISM AND ITS EFFEQ ON THE
NUCLEOTIDE METABOLISM ENZYMES.
003696 04-02
NUCLEUS
THE INFLUENCE OF CHLORALOSE ANESTHESIA ON THE AQIVITY OF RED
NUCLEUS NEURONS IN CATS.
000245 01-03
DENERVATION SUPERSENSITIVITY TO SEROTONIN IN THE FACIAL
NUCLEUS.
001364 02-03
INFLUENCE OF DOPAMINERGIC-SYSTEMS ON THE LATERAL HABENULAR
NUCLEUS OF THE RAT.
001365 02-03
UNILATERAL 5,7 DIHYDROXYTRYPT AMINE LESIONS OF THE DORSAL
RAPHE NUCLEUS (DRN) AND RAT ROTATIONAL-BEHAVIOUR.
001578 02-04
EVIDENCE FOR A TONIC GABAERGIC CONTROL OF SEROTONIN NEURONS
IN THE MEDIAN RAPHE NUCLEUS.
002719 03-03
PHARMACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG.
002889 03-03
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMIHER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
THYROXIN SENSITIVITY OF SENSORIMOTOR CORTICAL NEURONS AND THE
HYPOTHALAMIC VENTROMEDIAL NUCLEUS.
003713 04-03
OPIATE-EFFEaS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE
CONDITIONING IN RABBITS.
003798 04-03
THE NEUROANATOMY AND PHARMACOLOGY OF THE NUCLEUS LOCUS-
COERULEUS. (UNPUBLISHED PAPER).
003810 04-03
SELECTIVE EFFEQ OF ETHANOL ON THE VESTIBULAR NUCLEUS NEURONS
IN THE CAT.
004139 04-04
NUCLEUS-ACCUMBENS
EFFEQ OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO
STIMULATION OF THE NUCLEUS-ACCUMBENS.
000331 01-03
OPPOSITE EFFECTS OF D-AMPHETAMINE ON SPONTANEOUS NEURONAL
AQIVITY IN THE NEOSTRIATUM AND NUCLEUS-ACCUMBENS.
000454 01-04
INTERACTION OF CHLORDIAZEPOXIDE AND SODIUM-VALPROATE IN THE
NUCLEUS-ACCUMBENS OF THE RAT.
002796 03-03
INJEQIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINERGIC AND
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS: EFFEQS ON
LOCOMOTOR-AQIVITY IN THE RAT.
003019 03-04
COMPARISON OF THE EFFECTS OF THE STEREOISOMERS OF
FENFLURAMINE ON THE ACETYLCHOLINE CONTENT OF RAT STRIATUM,
HIPPOCAMPUS AND NUCLEUS-ACCUMBENS.
003758 04-03
INCREASE OF NEUROTENSIN CONTENT ELICITED BY NEUROLEPTICS IN
NUCLEUS-ACCUMBENS.
003808 04-03
DOPAMINE-DEPENDENT HYPERACTIVITY IN THE FOLLOWING
MANIPULATION OF GABA MECHANISMS IN THE REGION OF THE
NUCLEUS-ACCUMBENS.
003976 04-03
HYPERACTIVITY FOLLOWING INJECTION OF A GLUTAMATE AGONIST AND
6,7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY
THIP.
004066 04-04
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER
FOREBRAIN REGIONS OF THE RAT.
004171 04-04
S-316
VOLUME 19, SUBJECT INDEX
Subject Index
NUCLEUS-CENTRAL! S-LATERALIS
ANTINOCICEPTIVE ACTION OF MORPHINE AND PENTAZOCINE ON UNIT
ACTIVITY IN THE NUCLEUS-CENTRALIS-LATERALIS, NUCLEUS-
VENTRALIS-LATERALIS AND NEARBY STRUCTURES OF THE CAT.
002837 03-03
NUCIEUS-RAPHE-MAONUS
HYPOALGESIA FOLLOWING MICROINJECTION OF NORADRENERGIC
ANTAGONISTS IN THE NUCLEUS-RAPHE-MAGNUS,
000122 01-03
EFFECT OF SELECTIVE DESTRUCTION OF SEROTONERGIC NEURONS IN
NUCLEUS-RAPHE-MAGNUS ON MORPHINE-INDUCED ANTINOCICEPTION.
001724 02-04
EVIDENCE FOR INVOLVEMENT OF SEPARATE MECHANISMS IN THE
PRODUCTION OF ANALGESIA BY ELECTRICAL-STIMULATION OF THE
NUCLEUS-RETICULARIS-PARAGIGANTOCELLULARIS AND NUCLEUS-
RAPHE-MAGNUS IN THE RAT.
003083 03-04
EFFECT OF CHRONIC MORPHINE TREATMENT ON THE INTERACTION
BETWEEN THE PERIAQUEDUCTAL GREY AND THE NUCLEUS-RAPHE-
MAGNUS OF THE RAT.
003727 04-03
NUCLEUS-RETICULARIS-GI6ANTOCELLULARIS
SUBSTANCE-P, MORPHINE AND METHIONINE-ENKEPHALIN: EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE NUCLEUS-
RETICULARIS-GIGANTOCELLULARIS OF THE RAT.
001267 02-03
NUCLEUS-RETICULARIS-PARAGIGANTOCELLULARIS
EVIDENCE FOR INVOLVEMENT OF SEPARATE MECHANISMS IN THE
PRODUCTION OF ANALGESIA BY ELECTRICAL-STIMULATION OF THE
NUCLEUS-RETICULARIS-PARAGIGANTOCELLULARIS AND NUCLEUS-
RAPHE-MAGNUS IN THE RAT.
003083 03-04
NUCLEUS-TRACTUS-SOLITARIUS
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA
AND MEDIAL NUCLEUS-TRACTUS-SOLITARIUS OF RAT-BRAIN.
002634 03-01
OPIATE-RECEPTORS AND SLEEP. II. EFFECTS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUCTAL GRAY MAHER AND NUCLEUS-TRACTUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
NUCLEUS-VENTRALIS-LATERALIS
ANTINOCICEPTIVE AQION OF MORPHINE AND PENTAZOCINE ON UNIT
AQIVITY IN THE NUCLEUS-CENTRALIS-LATERALIS, NUCLEUS-
VENTRALIS-LATERALIS AND NEARBY STRUCTURES OF THE CAT.
002837 03-03
NURSING
INCREASED MESOLIMBIC 3H SPIROPERIDOL BINDING IN 4 WEEK OLD
OFFSPRING OF NURSING RAT MOTHERS TREATED WITH PENFLURIDOL.
000087 01-03
NURSING ASPECTS OF PSYCHOPHARMACOLOGY.
002618 02-17
WIDOWS AND WIDOWERS AND THEIR MEDICATION USE: NURSING
IMPLICATIONS.
003626 03-17
NURSING-BEHAVIOR
BEHAVIORAL-EFFEQS OF HASHISH IN MICE: II. NURSING-BEHAVIOR AND
DEVELOPMENT OF THE SUCKLINGS.
001626 02-04
NURSING-HOMES
A STUDY OF ANTIPSYCHOTIC-DRUG USE IN NURSING-HOMES:
EPIDEMIOLOGIC EVIDENCE SUGGESTING MISUSE.
000979 01-17
PROBLEMS REMAIN IN REVIEWS OF MEDICAID FINANCED DRUG-THERAPY
IN NURSING-HOMES.
004736 04-17
NUTRIENTS
LITHIUM, ASSIMILATION OF NUTRIENTS AND REPRODUCTION.
(UNPUBLISHED PAPER).
002777 03-03
NUTRITION
INTERAaiVE-EFFEQS OF NUTRITION AND CANNABIS UPON RAT
PERINATAL DEVELOPMENT.
000513 01-05
NYSTAGMIC
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS
INVOLVED IN THE HIPPOCAMPUS OF RABBITS.
003842 04-03
OBESE
EFFEQ OF BROMOCRIPTINE ON EXPLORATORY-AQIVITY, BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS.
001635 02-04
NEUROCHEMICAL-EFFEaS AND BEHAVIORAL-EFFECTS OF CHRONIC D-
AMPHETAMINE TREATMENT IN GENETICALLY OBESE (OBOB) MICE.
(PH.D. DISSERTATION).
001739 02-04
METABOLIC AND SYMPATHOADRENAL ABNORMALITIES IN THE OBESE
ZUCKER RAT; EFFECT OF CHRONIC PHENOXYBENZAMINE TREATMENT.
003905 04-03
OBESITY
CONTROLLED-TRIAL OF BEHAVIOUR-THERAPY, PHARMACOTHERAPY, AND
THEIR COMBINATION IN THE TREATMENT OF OBESITY
000725 01-11
OBJECT
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL.
004208 04-04
OBJECTIVE
AN OBJECTIVE CLASSIFICATION OF PSYCHOACTIVE-DRUGS.
001894 02-07
THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPECTS OF SLEEP AND OBJECTIVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOCTURNAL
MEDICATION: II. REPEATED DOSES.
002331 02-14
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
EFFECTS OF SUPIDIMIDE (CG-3033) ON OBJECTIVE AND SUBJECTIVE SLEEP
PARAMETERS (A SLEEP LABORATORY STUDY).
004567 04-14
THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE BRAIN AS AN
OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING
DRUGS.
004669 04-16
OBSERVATION
CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE
AND CLOMIPRAMINE IN DEPRESSIVE-STATES (PRELIMINARY
OBSERVATION).
002032 02-09
ERGOTISM IN A PSYCHIATRIC ENVIRONMENT ASSOCIATED WITH
ERYTHROMYCIN-DIHYDROERGOTAMINE-PROPIONATE. AN
OBSERVATION.
002379 02-15
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO.
004387 04-09
OBSERVATIONAL
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL-
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D-
AMPHETAMINE AND APOMORPHINE.
002484 02-16
OBSERVATIONS
TARDIVE-DYSKINESIAS (OBSERVATIONS CONCERNING THREE CASES).
000861 01-15
OBSERVATIONS ON CLINICAL-PHARMACOLOGY.
000970 01-17
OBSERVATIONS ABOUT STATES OF MENTAL-ILLNESS AS ILLUMINATED BY
THEIR RESPONSE TO PHARMACEUTIC-AGENTS.
000972 01-17
BIPHASIC RESPONSIVENESS OF RAT PIAL-ARTERIOLES TO DOPAMINE:
DIRECT OBSERVATIONS ON THE MICROCIRCULATION.
001105 02-03
INTRACELLULAR OBSERVATIONS ON THE EFFECTS OF MUSCARINIC
AGONISTS ON RAT SYMPATHETIC NEURONES.
001143 02-03
OBSERVATIONS ON CHLORALOSE-INDUCED MYOCLONUS IN GUINEA-PIGS.
001164 02-03
CLINICAL-STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE-
STATES: COMPILATION OF 1520 OBSERVATIONS.
003206 03-09
OBSERVATIONS ON THE USE OF CITICOLINE IN DYSTHYMIC-PATIENTS.
003207 03-09
SOME OBSERVATIONS ON THE PSYCHOLOGICAL DIMENSIONS OF
PLACEBO-EFFECTS.
003573 03-17
SOME OBSERVATIONS ON THE PHARMACOLOGICAL ACTIVITY OF MIF
(PR0-LEU-GLY-NH2).
004240 04-04
OBSERVE
EXTINCTION AND OOPAMINE-RECEPTOR BLOCKADE AFTER INTERMITTENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL
EQUIVALENCE.
000490 01-04
OBSERVED
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFECTS OF ORAL MAGNESIUM
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM.
003291 03-11
VARIOUS FACTORS IN THE PATHOGENESIS OF PATHOLOGICAL REACTIONS
OBSERVED IN CONNECTION WITH THE ADMINISTRATION OF
PSYCHOTROPIC-DRUGS.
003532 03-15
S-317
Subject Index
Psychopharmacology Abstracts .
III!'
a-
« linn 1 1
Sit
mi!
fe
I
OBSESSIVE-COMPULSIVE-DISORDER
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: I. A
CONTROLLED CLINICAL-TRIAL.
002086 02-10
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: II.
BIOCHEMICAL-ASPECTS.
002300 02-13
OBSESSIVE-COMPULSIVE-DISORDERS
BEHAVIORAL-TREATMENT AND PHARMACOLOGICAL-TREATMENT OF
OBSESSIVE-COMPULSIVE-DISORDERS.
000657 01-10
A COMBINED BEHAVIORAL-PHARMACOTHERAPY APPROACH TO
OBSESSIVE-COMPULSIVE-DISORDERS.
002082 02-10
OBSESSIVE-COMPULSIVE-NEUROSIS
AMITRIPTYLINE THERAPY OF OBSESSIVE-COMPULSIVE-NEUROSIS.
000656 01-10
NOMIFENSINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE-NEUROSIS.
THERAPEUTIC-EFFICACY AND TOLERABILITY IN COMPARISON TO
IMIPRAMINE.
002078 02-10
OBSESSIVE-SYMPTOM
OBSESSIVE-SYMPTOM RESPONSE TO BEHAVIOUR-THERAPY AND TO
ANTIDEPRESSANT-DRUGS.
002084 02-10
OBSTRUCTIVE
MEDROXYPROGESTERONE TREATMENT OF OBSTRUQIVE SLEEP-APNEA.
002128 02-11
OCCIDENTAL
TRICYCLIC-ANTIDEPRESSANT DRUG TOLERANCE IN ORIENTAL AND
OCCIDENTAL POPULATIONS.
000590 01-09
OCCIPITAL-CORTEX
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFECTS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
OCCLUSION
INHIBITION OF VASOPRESSIN RELEASE TO CAROTID OCCLUSION BY
GAMMA AMINOBUTYRIC-ACID AND GLYCINE.
002715 03-03
OCCUPATION
IN VIVO OCCUPATION OF CEREBRAL HISTAMINE HI -RECEPTORS
EVALUATED WITH 3H MEPYRAMINE MAY PREDIQ SEDATIVE
PROPERTIES OF PSYCHOTROPIC-DRUGS.
000241 01-03
CORRELATION BETWEEN BENZODIAZEPINE-RECEPTOR OCCUPATION AND
ANTICONVULSANT EFFEQS OF DIAZEPAM.
000450 01-04
OCTAHYDRODIBENZAZEPINONAPHTHYRIDINES
CONFORMATIONALLY RESTRICTED TRICYCLIC-ANTIDEPRESSANTS. 1.
OaAHYDRODIBENZAZEPINONAPHTHYRIDINES AS RIGID IMIPRAMINE
ANALOGUES.
001710 02-04
OaOPAMINE
THE EFFECT OF PHENELZINE AND SOME OF ITS PARA HALOGENATED
DERIVATIVES ON THE LEVELS OF BRAIN TYRAMINE AND OQOPAMINE
IN THE MOUSE.
001077 02-02
BETA PHENYLETHYLAMINE, PHENYLETHANOLAMINE, TYRAMINE AND
OQOPAMINE. (UNPUBLISHED PAPER).
002601 02-17
OCULAR-COMPLICATION
AN UNUSUAL OCULAR-COMPLICATION OF THIORIDAZINE.
000848 01-15
OCULOGRAPHIC
A COMPUTER OCULOGRAPHIC AND EEG DOUBLE-BLIND STUDY INCLUDING
WELL-BEING FOR DETERMINING CHANGED VIGILANCE UNDER THERAPY
WITH TIAPRIDE.
000751 01-13
OCULOMOTOR
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMinER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
OCYTOCIN
INDICATIONS FOR A BRAIN UPTAKE OF LABELLED VASOPRESSIN AND
OCYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER.
003669 04-01
OFFSPRING
INCREASED MESOLIMBIC 3H SPIROPERIDOL BINDING IN 4 WEEK OLD
OFFSPRING OF NURSING RAT MOTHERS TREATED WITH PENFLURIDOL.
000087 01-03
EFFECTS OF 6 HYDROXYDOPAMINE AND AMPHETAMINE ON RAT
MOTHERING-BEHAVIOR AND OFFSPRING DEVELOPMENT.
000452 01-04
EFFEQS OF MARIHUANA ON PREGNANT RATS AND THEIR OFFSPRING.
001830 02-05
THROMBOCYTOSIS IN THE OFFSPRING OF FEMALE MICE RECEIVING DL 1
METHADONE. |
001836 02-05
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS IN THE OFFSPRING
OF DAMS RECEIVING DIAZEPAM: ONTOGENETIC-STUDIES.
001849 02-05
EFFEQ OF PRENATAL PHENYTOIN ADMINISTRATION ON BRAIN
TRYPTOPHAN METABOLISM OF RAT OFFSPRING DURING THE
PREWEANING PERIOD.
004108 04-04
OHDA
EFFEQS OF APOMORPHINE ON ESCAPE PERFORMANCE AND AQIVITY IN
DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6
OHDA).
000426 01-04,
EFFEaS OF NOMIFENSINE AND OESIPRAMINE ON THE SEQUELAE OF
INTRACEREBRALLY INJEQED 6 OHDA AND 5,6 OHT.
001522 02-03
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND
ELECTROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE
MIDBRAIN.
001593 02-04
HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY I
UNILATERAL 6 OHDA INJECTIONS INTO SUBSTANTIA-NIGRA AND
CAUDATE-NUCLEUS. •
001778 02-04'
OIL
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY.
000890 01-15
OILY
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS
INTRAMUSCULARLY.
000890 01-15
OLD-AGE
BRAIN FUNCTION IN OLD-AGE: EVALUATION OF CHANGES AND
DISORDERS.
000684 01-11
LOOK AND OLD-AGE.
000930 01-17
ERGOTS IN THE TREATMENT OF MENTAL-DISORDERS OF OLD-AGE
002545 02-17
OLFACTORY
SEROTONINMIMETIC AND ANTIDEPRESSANT-DRUGS ON PASSIVE-
AVOIDANCE LEARNING BY OLFACTORY BULBEQOMISED RATS.
001585 02-04
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA
BUTYROLAQONE AND HA-966 IN THE STRIATUM AND OLFAQORY
TUBERCLE OF THE RAT. '
002681 03-03
SLEEP ELICITED BY OLFAQORY TUBERCLE STIMULATION AND THE EFFECT
OF ATROPINE.
002955 03-04
OLFACTORY-BULB
RELATIONSHIP BETWEEN DELTA9 TETRAHYDROCANNABINOL-INDUCED
MOUSE-KILLING-BEHAVIOR ON THE RAT AND THE METABOLISM OF
MONOAMINES IN THE BRAIN, PARTICULARLY THE OLFACTORY-BULB.
000472 01-04
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMIHER AMINO-
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFAQORY-BULB.
002836 03-03
OLFACTORY-BULBECTOMY
EFFEQS OF OLFAQORY-BULBEQOMY AND PERIPHERAUY-INDUCED
ANOSMIA ON THERMOREGULATION IN THE RAT: SUSCEPTIBILITY TO
ANTIDEPRESSANT-DRUGS.
004113 04-04
OLFACTORY-BULBS
REGIONAL CHANGES IN (3H)DIAZEPAM BINDING IN THE BRAINS OF Mia
ARER REMOVAL OF THE OLFACTORY-BULBS.
003844 04-03
OLFACTORY-CORTEX
INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERACTION OF AMINO-
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG.
000034 01-03
CONVULSANTS ANTAGONISE INHIBITION IN THE OLFACTORY-CORTEX
SLICE.
001466 02-03
OLIGOPHRENICS
THERAPY AND SOCIAL ADAPTATION OF OUGOPHRENICS (REVIEW OF THE
LITERATURE).
004444 04-11
OUGOSYMPTOMATIC
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP
S-318
VOLUME 19, SUBJECT INDEX
Subject Index
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS.
001869 02-06
ON-COLUMN
ON-COLUMN GAS-CHROMATOGRAPHIC-SYNTHESIS OF ),3 DIALYKYL
(C=l-10), BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES.
003656 04-01
ON-OFF-PHENOMENON
IMPROVEMENT OF L-DOPA-INDUCED DYSKINESIA AND OF ON-OFF-
PHENOMENON BY BROMOCRIPTINE.
000813 01-14
ONE-STEP
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYIALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
ONSET
BIPOLAR AFFECTIVE-PSYCHOSIS WITH ONSET BEFORE AGE 16 YEARS:
REPORT OF 10 CASES.
002001 02-09
POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES ON THE ONSET,
MAGNITUDE AND QUALITY OF THE OPIOID ABSTINENCE-SYNDROME.
004610 04-15
ONTOGENESIS
EFFECTS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT.
000180 01-03
HYPERSYNCHRONOUS-ACTIVITY ELICITED BY GAMMA
HYDROXYBUTYRATE DURING ONTOGENESIS IN RATS.
000460 01-04
CONVULSANT-EFFECTS OF AMINOOXYACETIC-ACID DURING ONTOGENESIS
IN RATS.
001439 02-03
SEIZURES ELICITED BY SUBCUTANEOUS INJECTION OF METRAZOL DURING
ONTOGENESIS IN RATS.
003039 03-04
ELECTROCORTICOGRAPHIC AQIVITY ELICITED BY METRAZOL DURING
ONTOGENESIS IN RATS.
004064 04-03
ONTOGENETIC
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - II. RESPECTIVE REGIONAL
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC
DEVELOPMENTS.
000214 01-03
ONTOGENETIC-STUOIES
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS IN THE OFFSPRING
OF DAMS RECEIVING DIAZEPAM: ONTOGENETIC-STUDIES.
001849 02-05
ONTOGENY
THE USE OF PSYCHOPHARMACOLOGICAL-PROCEDURES TO ANALYSE THE
ONTOGENY OF LEARNING AND RETENTION: ISSUES AND CONCERNS.
000482 01-04
ONTOGENY OF MAMMALIAN CARDIAC ALPHA 1-ADRENERGIC-
RECEPTORS.
001545 02-03
PSYCHOPHARMACOLOGICAL-EFFEQS OF LOW-DOSES AND HIGH-DOSES
OF APOMORPHINE DURING ONTOGENY.
001774 02-04
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN: CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE Hl-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STI.MULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
OPACITIES
OCCURRENCE OF CORNEAL OPACITIES IN RATS AFTER ACUTE
ADMINISTRATION OF L ALPHA ACETYLMETHADOL.
001853 02-05
OPEN
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY: EFFICACY, DOSAGE SCHEDULE AND PLASMA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
AN OPEN CLINICAL-TRIAL OF MIANSERIN.
003241 03-09
BACLOFEN IN THE TREATMENT OF TARDIVE-DYSKINESIA: OPEN LABEL
STUDY.
004619 04-15
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL.
004620 04-15
OPEN-FIELD
OPEN-FIELD PERFORMANCE OF RATS AFTER ENDOTOXIN TREATMENT
000473 01-04
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS UNDER
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REACTION TYPE
(EMOTIVE AND NONEMOTIVE).
001624 02-04
EFFECTS OF NEONATAL TESTOSTERONE AND ESTROGEN ON OPEN-FIELD
BEHAVIOUR IN RATS.
003098 03-04
DOPAMINERGIC AGONISTS DIFFERENTIALLY AFFECT OPEN-FIELD ACTIVITY
OF RATS WITH AlO LESIONS.
004135 04-04
OPEN-STUDY
OPEN-STUDY OF L 5 HTP IN MELANCHOLIC-DEPRESSED-PATIENTS OVER
50 YEARS OF AGE.
002016 02-09
AN OPEN-STUDY OF MAPROTILINE 75MG IN THE TREATMENT OF
DEPRESSIVE-STATES.
003152 03-07
A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDICTS DURING
WITHDRAWAL.
004445 04-11
OPENS
(-)PENTOBARBITAL OPENS ION-CHANNELS OF LONG-DURATION IN
CULTURED MOUSE SPINAL NEURONS.
000198 01-03
OPERANT
EFFECTS OF APOMORPHINE ON ELICITED AND OPERANT PECKING IN
PIGEONS.
001557 02-04
THE EFFEQS OF PIMOZIDE DURING PAIRING ON THE TRANSFER OF
CLASSICAL CONDITIONING TO AN OPERANT DISCRIMINATION.
002956 03-04
TIME-COURSE OF CHRONIC HALOPERIDOL AND CLOZAPINE UPON
OPERANT RATE AND DURATION.
002989 03-04
CLONIDINE ANALGESIA AND SUPPRESSION OF OPERANT RESPONDING:
DISSOCIATION OF MECHANISM.
003046 03-04
OPERANT FEEDING AND DRINKING IN PIGS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF SYNTHETIC
CHOLECYSTOKININ-OCTAPEPTIDE.
003064 03-04
OPERANT ANALYSIS OF HUMAN HEROIN SELF-ADMINISTRATION AND THE
EFFECTS OF NALTREXONE.
003449 03-14
METHYLMERCURY-INDUCED CHANGES IN OPERANT DISCRIMINATION BY
THE PIGEON.
004271 04-05
OPERANT-BEHAVIOR
TOLERANCE TO SUPPRESSIVE EFFECTS OF CHLORDIAZEPOXIDE ON
OPERANT-BEHAVIOR: LACK OF CROSS-TOLERANCE TO PENTOBARBITAL.
000356 01-04
EFFECT OF MORPHINE IN COMBINATION WITH CHLORPROMAZINE AND
HALOPERIDOL ON OPERANT-BEHAVIOR.
000486 01-04
DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT-
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL-
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS.
001726 02-04
ON THE USE OF OPERANT-BEHAVIOR TO STUDY THE
NEUROPSYCHOPHARMACOLOGY OF OPIATES WITH SPECIAL REFERENCE
TO MORPHINE AND ITS RELATIONSHIP TO DOPAMINE IN THE CENTRAL-
NERVOUS-SYSTEM.
001790 02-04
THE EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON
OPERANT-BEHAVIOR: INTERACTIONS WITH OTHER NEUROAQIVE-
AGENTS.
004089 04-04
INDIVIDUAL DIFFERENCES IN EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS
AND ANTICHOLINERGIC-DRUGS ON OPERANT-BEHAVIOR IN THE
SQUIRREL-MONKEY.
004176 04-04
MICROPROPERTIES OF OPERANT-BEHAVIOR AS ASPECTS OF TOXICITY.
004666 04-15
OPERANT-RESPONDING
NALOXONE POTENTIATES THE DISRUPTIVE EFFECTS OF MESCALINE ON
OPERANT-RESPONDING IN THE RAT.
000365 01-04
THE EFFECTS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5
DIMETHOXY-4-METHYLAMPHETAMINE (DOM) AND D-AMPHET AMINE
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE
TREATED RATS.
001595 02-04
EFFECTS OF METHYLPHENIDATE ON OPERANT-RESPONDING IN
HYPERACTIVE-BOYS. (PH D. DISSERTATION).
002191 02-11
ii
S-319
Subject Index
Psychopharmacology Abstracts
mi'
I*
OPERANT-RESPONSE
CHRONIC EFFECTS OF NEUROLEPTICS HAVING HIGH OR LOW INCIDENCE
OF EXTRAPYRAMIDAL SIDE-EFFECTS UPON FORCE, DURATION AND
RATE OF OPERANT-RESPONSE IN RATS. (PH.D. DISSERTATION).
003125 03-05
OPERATIONS
DEPENDENCE OF THE AVFAIL EFFECT ON THE SEQUENCE OF TRAINING
OPERATIONS.
001086 02-02
OPHTHALMOLOGICAL
OPHTHALAAOLOGICAL SIDE-EFFECTS OF LITHIUM.
004615 04-15
OPIATE
REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS.
000066 01-03
EXCITATORY AND INHIBITORY-EFFECTS OF OPIATES IN THE RAT VAS-
DEFERENS: A DUAL-MECHANISM OF OPIATE ACTION.
000143 01-03
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE
AaiON.
000229 01-03
CHANGES IN OPIATE ACTIVITY OF RAT PITUITARY FOLLOWING ACUTE
ADMINISTRATION OF NEUROLEPTICS.
000282 01-03
A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY
PRODUCED BY OPIATE ANALGESICS.
000425 01-04
IATROGENIC OPIATE ADDICTION: SUCCESSFUL DETOXIFICATION WITH
CLONIDINE.
000666 01-11
CLONIDINE FOR OPIATE DETOXIFICATION: OUTPATIENT CLINICAL-TRIALS.
000731 01-11
RAPID OPIATE DETOXIFICATION WITH CLONIDINE AND NALOXONE.
000820 01-14
CLONIDINE FOR OUTPATIENT OPIATE DETOXIFICATION.
000827 01-14
ROLE OF PROTEIN-KINASES IN OPIATE ACTIONS IN BRAIN.
001173 02-03
OPIATE INTERACTIONS WITH CHOLINERGIC NEURONS.
001198 02-03
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
BRAIN.
001234 02-03
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN
IN VIVO: EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS,
AND BENZODIAZEPINES.
001303 02-03
NERVE CELL CALCIUM AS A MESSENGER FOR OPIATE AND ENDORPHIN
ACTIONS.
001450 02-03
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES.
001554 02-03
THE SHORT-TERM AND LONG-TERM EFFEaS OF BETA ENDORPHIN ON THE
OPIATE ABSTINENCE-SYNDROME IN RATS.
001643 02-04
OPIATE ACTIONS AND CATECHOLAMINES.
001662 02-04
STRESS-INDUCED FACILITATION OF OPIATE CATALEPSY IN THE RAT.
001680 02-04
OPIATE AND PEPTIDE INTERAQION: EFFECT OF ENKEPHALINS ON
MORPHINE ANALGESIA.
001698 02-04
OPIATE ANTAGONISTS AND LONG-TERM ANALGESIC REAQION INDUCED
BY INESCAPABLE SHOCK IN RATS.
001707 02-04
OPIATE ANTAGONISTS AND FEMALE FUNQIONING. (UNPUBLISHED
PAPER).
001735 02-04
COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT.
001841 02-05
EFFEa OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND
NORMAL ADULTS.
002222 02-13
MECHANISMS OF OPIATE ANALGESIA AND THE ROLE OF ENDORPHINS IN
PAIN SUPPRESSION. (UNPUBLISHED PAPER).
002275 02-13
ENDORPHIN OPIATE INTERACTIONS WITH NEUROENDOCRINE SYSTEMS.
002552 02-17
THE TREATMENT OF OPIATE ADDICTION USING METHADONE-
CHLORHYDRATE.
002600 02-17
REVIEW AND OVERVIEW OF FOUR DECADES OF OPIATE RESEARCH.
002627 02-17
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE
AGONIST AND ANTAGONIST RECEPTOR INTERACTIONS.
002688 03-03
OPIATE ANTAGONIST IMPROVES NEUROLOGIC RECOVERY AFTER SPINAL
INJURY.
002714 03-03
THE EFFECTS OF OPIATE ANTAGONISTS ON THE DISCRIMINATIVE
STIMULUS PROPERTIES OF ETHANOL.
002947 03-04
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
THE EFFECTS OF OPIATE ANTAGONISTS ON FOOD INTAKE ARE
STEREOSPECIFIC.
003080 03-04
SUPERSENSITIVITY TO THE BEHAVIORAL-EFFEQS OF OPIATE
ANTAGONISTS.
003096 03-04
EFFICACY OF CLONIDINE IN OPIATE WITHDRAWAL: A STUDY OF THIRTY
PATIENTS.
003317 03-11
POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CAROIOVASCULAR-
EFFEaS OF CENTRAL ALPHA-ADRENOCEPTOR STIMUUTION IN
SPONTANEOUSLY HYPERTENSIVE-RATS.
003791 04-03
OPIATE MECHANISMS: EVALUATION OF RESEARCH INVOLVING
NEURONAL AQION POTENTIALS.
003886 04-03
OPIATE SYSTEM INFLUENCES CENTRAL RESPIRATORY CHEMOSENSORS.
003971 04-03
REDUaiON IN OPIATE AQIVATION AFTER CHRONIC
ELECTROCONVULSIVE-SHOCK ~ POSSIBLE ROLE FOR ENDORPHINS IN
THE BEHAVIORAL-EFFEQS OF CONVULSIVE-SHOCK-TREATMENT.
(UNPUBLISHED PAPER).
004154 04-04
BEHAVIORAL-INTERAQIONS BETWEEN OPIATE AND ANTIEPILEPTIC-DRUGS
IN THE MOUSE.
004155 04-04
OPIATE MODULATION OF MEMORY. (UNPUBLISHED PAPER).
004177 04-04
NALOXAZONE, A LONG-AQING OPIATE ANTAGONIST: EFFEaS ON
ANALGESIA IN INTAQ ANIMALS AND ON OPIATE-RECEPTOR BINDING
IN VITRO.
004198 04-04
OPIATE-DEPENDENCE
OPIATE-DEPENDENCE FOLLOWING ACUTE INJEQIONS OF MORPHINE AND
NALOXONE: THE ASSESSMENT OF VARIOUS WITHDRAWAL SIGNS
004209 04-04
OPIATE-DEPENDENT
CHOLINE REVERSES NALOXONE-INDUCED DECREASES IN HIPPOCAMPAL
ACETYLCHOLINE CONTENT AND SUPPRESSES ESCAPE-BEHAVIOR IN
OPIATE-DEPENDENT RATS.
004076 04-04
OPIATE-EFFECTS
ACUTE AND CHRONIC OPIATE-EFFEaS ON SINGLE UNITS AND EEG OF
MEDIAL THALAMUS AND HIPPOCAMPUS: A LATENCY ANALYSIS.
001344 02-03
OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE
CONDITIONING IN RABBITS.
003798 04-03
OPIATE-ER6IC
IN VITRO AUTORADIOGRAPHY OF OPIATE-RECEPTORS IN RAT-BRAIN
SUGGESTS LOCI OF OPIATE-ERGIC PATHWAYS. (UNPUBLISHED PAPER).
001025 02-01
OPIATE-INDUCED
CONTRIBUTION OF SOCIAL FAQORS TO OPIATE-INDUCED AQIVATION IN
THE MOUSE.
004156 04-04
OPIATE-LIKE-DRUGS
SPECIFIC BINDING FOR OPIATE-LIKE-DRUGS IN THE PLACENTA.
000797 01-13
OPIATE-PENTAPEPTIDE
ACTION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
OPIATE-RECEPTOR
AN INTRACELLULAR OPIATE-RECEPTOR.
000278 01-03
CHANGES IN BRAIN N DEMETHYLATION AND OPIATE-RECEPTOR CONTENT
CORRELATE WITH ANALGESIC EFFECTIVENESS OF MORPHINE.
00040001-04
OPIATE-RECEPTOR MEDIATED INHIBITION OF RAT JEJUNAL-FLUID
SECRETION.
001334 02-03
MODULATION OF OPIATE-RECEPTOR BINDING IN STRIATUM AND
AMYGDALA BY SELECTIVE MESENCEPHALIC LESIONS.
001629 02-04
S-320
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF INTRAPALLIOAL OPIATE-RECEPTOR AGONISTS ON
STRIATALLY-EVOKED HEAD-TURNING.
001785 02-04
DISCRIMINATIVE-STIMULUS EFFECTS OF PROTOTYPE OPIATE-RECEPTOR
AGONISTS IN MONKEYS.
001803 02-04
MOLECULAR ACTIONS OF OPIATES: HISTORICAL OVERVIEW AND NEW
FINDINGS ON OPIATE-RECEPTOR INTERACTIONS WITH ENKEPHALINS
AND GUANYL-NUCLEOTIOES.
002613 02-17
OPIATE-RECEPTOR GRADIENTS IN MONKEY CEREBRAL-CORTEX:
CORRESPONDENCE WITH SENSORY PROCESSING HIERARCHIES.
002641 03-01
EFFECT OF THE POSITION OF THE PHENOLIC GROUP IN MORPHINANS ON
THEIR AFFINITY FOR OPIATE-RECEPTOR BINDING.
003702 04-02
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFECTS ON
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING
IN VITRO.
004198 04-04
OPIATE-RECEPTORS
OPIATE-RECEPTORS MAY MEDIATE THE SUPPRESSIVE BUT NOT THE
EXCITATORY ACTION OF ACTH ON MOTOR-ACTIVITY IN RATS.
000337 01-04
IN VITRO AUTORADIOGRAPHY OF OPIATE-RECEPTORS IN RAT-BRAIN
SUGGESTS LOCI OF OPIATE-ERGIC PATHWAYS. (UNPUBLISHED PAPER).
001025 02-01
OPIATE-RECEPTORS IN MEMBRANES AND IN SOLUTION. (UNPUBLISHED
PAPER).
001032 02-01
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS. (UNPUBLISHED
PAPER).
001035 02-01
BIOCHEMICAL-EVIDENCE FOR TYPE-1 AND TYPE-2 OPIATE-RECEPTORS.
(UNPUBLISHED PAPER).
001050 02-01
SOLUBILIZATION OF ACTIVE OPIATE-RECEPTORS. (UNPUBLISHED PAPER).
001056 02-01
OPIATE-RECEPTORS IN THE RABBIT IRIS.
001200 02-03
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELECTIVE
5 HT UPTAKE INHIBITOR.
001517 02-03
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES.
001554 02-03
FURTHER STUDIES ON OPIATE-RECEPTORS THAT MEDIATE
ANTINOCICEPTION: TOOTH-PULP STIMULATION IN THE DOG.
001782 02-04
A CLASSIFICATION OF OPIATE-RECEPTORS THAT MEDIATE
ANTINOCICEPTION IN ANIMALS.
001807 02-04
HISTOCHEMICAL LOCALIZATION OF OPIATE-RECEPTORS AND THE
ENKEPHALINS.
002566 02-17
IN VITRO STUDIES OF OPIATE-RECEPTORS.
002609 02-17
OPIATE-RECEPTORS: PROBLEMS OF DEFINITION AND CHARACTERIZATION.
002620 02-17
COMPARATIVE-STUDY ON THE EFFECT OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS: STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS.
002757 03-03
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
OPIATE-RECEPTORS AND SLEEP. II. EFFECTS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS
PERIAQUEDUCTAL GRAY MAHER AND NUCLEUS-TRACTUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
ACTH-INDUCED GROOMING INVOLVES HIGH-AFFINITY OPIATE-RECEPTORS.
002985 03-04
DIFFERENTIATION OF OPIATE-RECEPTORS IN THE BRAIN BY THE SELECTIVE
DEVELOPMENT OF TOLERANCE.
003088 03-04
MULTIPLE OPIATE-RECEPTORS.
003581 03-17
SYNTHESIS AND PHARMACOLOGICAL-STUDY OF SOME ENKEPHALIN
ANALOGS IN RELATION TO THE PLURALITY OF OPIATE-RECEPTORS
003682 04-02
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL
EVALUATION.
003685 04-02
INTERCONVERTING MU AND DELTA-FORMS OF TYPE-1 OPIATE-RECEPTORS
IN THE RAT STRIATAL PATCHES.
003737 04-03
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT
NICTITATING MEMBRANE.
003777 04-03
THE ROLE OF OPIATE-RECEPTORS OF DIFFERENT BRAIN REGIONS IN
DETERMINING THE EMOTIONAL REACTIONS OF RATS.
004017 04-03
MEMORY, OPIATE-RECEPTORS, AND AGING.
004143 04-04
MINI-SYMPOSIUM: III. SIMPLE IN VIVO TESTS THAT DIFFERENTIATE
PROTOTYPE AGONISTS AT OPIATE-RECEPTORS.
004289 04-06
MINI-SYMPOSIUM. I. THE IN VIVO DIFFERENTIATION OF OPIATE-
RECEPTORS: INTRODUCTION.
004697 04-17
OPIATE-SENSITIVE
AMYGDALA OPIATE-SENSITIVE MECHANISMS INFLUENCE FEAR
MOTIVATED RESPONSES AND MEMORY PROCESSES FOR AVERSIVE-
EXPERIENCES. (UNPUBLISHED PAPER).
001628 02-04
OPIATE-TOLERANT
TIME-COURSE OF ETORPHINE LEVELS IN TISSUES OF OPIATE-TOLERANT
AND NONTOLERANT RATS.
000301 01-03
OPIATES
SEROTONIN PARTICIPATION IN GUT WITHDRAWAL FROM OPIATES.
000109 01-03
EXCITATORY AND INHIBITORY-EFFECTS OF OPIATES IN THE RAT VAS-
DEFERENS: A DUAL-MECHANISM OF OPIATE ACTION.
000143 01-03
THE EFFECTS OF OPIATES ON THE LEVELS OF CYCLIC-GUANOSINE-
MONOPHOSPHATE IN DISCRETE AREAS OF THE RAT CENTRAL-
NERVOUS-SYSTEM.
000220 01-03
CHLORDIAZEPOXIDE ANTINOCICEPTION: CROSS-TOLERANCE WITH
OPIATES AND WITH STRESS.
000348 01-04
THE OPIATES: TWO CENTURIES OF SCIENTIFIC-STUDY.
000952 01-17
NEUROCHEMICAL MECHANISMS OF OPIATES AND ENDORPHINS.
000958 01-17
EXCITATORY ACTION OF OPIOID-PEPTIDES AND OPIATES ON CULTURED
HIPPOCAMPAL PYRAMIDAL CELLS.
001241 02-03
OPIATES AND SPECIFIC RECEPTOR BINDING OF (3H)CL0NIDINE.
001256 02-03
EFFECT OF OPIATES ON MACROMOLECULE BIOSYNTHESIS.
001335 02-03
LOG-DOSE/ RESPONSE-CURVE FLAHENING IN RATS AFTER DAILY
INJECTION OF OPIATES.
001387 02-03
OPIATES AND OPIOID-PEPTIDES HYPERPOLARIZE LOCUS-COERULEUS
NEURONS IN VITRO.
001408 02-03
CYCLIC-NUCLEOTIDES AND THE CENTRAL-EFFECTS OF OPIATES: AN
OVERVIEW OF CURRENT RESEARCH.
001445 02-03
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJECTION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS.
001446 02-03
THE ALBINO LOCUS PRODUCES ABNORMAL RESPONSES TO OPIATES IN
THE MOUSE.
001675 02-04
ENHANCED RESPONSES TO OPIATES PRODUCED BY A SINGLE GENE
SUBSTITUTION IN THE MOUSE.
001677 02-04
ON THE USE OF OPERANT-BEHAVIOR TO STUDY THE
NEUROPSYCHOPHARMACOLOGY OF OPIATES WITH SPECIAL REFERENCE
TO MORPHINE AND ITS RELATIONSHIP TO DOPAMINE IN THE CENTRAL-
NERVOUS-SYSTEM.
001790 02-04
EFFECT OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND
NORMAL ADULTS.
002222 02-13
MOLECULAR ACTIONS OF OPIATES: HISTORICAL OVERVIEW AND NEW
FINDINGS ON OPIATE-RECEPTOR INTERACTIONS WITH ENKEPHALINS
AND GUANYL-NUCLEOTIDES.
002613 02-17
BEHAVIORAL CONFIRMATION OF DIFFUSE NOXIOUS INHIBITORY
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS
OPIATES.
002791 03-03
BLOCKADE OF ENDOGENOUS OPIATES REDUCES ACTIVITY IN THE RAT.
003111 03-04
S-321
s
ax.
C.1:
fit:
Si:
fe
Subject Index
RIA OPIATES: STRUCTURE VERSUS REAQIVITY.
003659 04-01
SELECTIVE MODIFICATION BY OPIATES OF NEURONAL ACTIVITY OF THE
MEDIAL BASAL HYPOTHALAMUS.
003773 04-03
COMPARISON OF THE BINDING CHARACTERISTICS OF TRITIATED OPIATES
AND OPIOID-PEPTIDES.
003802 04-03
THE EFFEa OF PRENATAL EXPOSURE TO ETHANOL OR OPIATES ON BRAIN
CATECHOLAMINE ACTIVITY.
003939 04-03
MODULATION OF DOPAMINE-RECEPTORS BY OPIATES. (UNPUBLISHED
PAPER).
003949 04-03
ACTIONS OF MU. KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION.
004053 04-03
OPIOID
N TETRAHYDROFURYLALKYL AND N ALKOXYALKYL DERIVATIVES OF (-)
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID ACTION
PROFILES.
000013 01-02
ANTINOCICEPTIVE-EFFECT OF MORPHINE, OPIOID ANALGESICS AND
HALOPERIDOL INJEQED INTO THE CAUDATE-NUCLEUS OF THE RAT.
000414 01-04
OPIOID DEPENDENT DUAL-REGULATION OF ADENYLATE-CYCLASE IN A
CELL-FREE SYSTEM. (UNPUBLISHED PAPER).
001033 02-01
OPIOID MECHANISMS IN REGULATION OF CEREBRAL MONOAMINES IN
VIVO.
001098 02-03
ROLES OF SEROTONIN AND GAMMA AMINOBUTYRIC-ACID IN OPIOID
EFFECTS.
001140 02-03
OPIOID BLOCKADE AND SOCIAL-COMFORT IN CHICKS.
001745 02-04
METKEPHAMID, A SYSTEMICALLY AQIVE ANALOG OF METHIONINE-
ENKEPHALIN WITH POTENT OPIOID DELTA-RECEPTOR ACTIVITY.
002720 03-03
A REFORMULATION OF THE DUAL-ACTION MODEL OF OPIOID
DEPENDENCE: OPIOID-SPECIFIC NEURONAL KINDLING.
003645 03-17
OPIOID ACTIVITIES OF BETA CASOMORPHINS.
003740 04-03
OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES:
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES.
003902 04-03
DISCRIMINATION OF ELEaRIC-SHOCK: EFFECTS OF SOME OPIOID AND
NONOPIOID DRUGS.
004106 04-04
OPIOID DEPENDENCE: MECHANISMS AND TREATMENT.
004587 04-14
POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES ON THE ONSET,
MAGNITUDE AND QUALITY OF THE OPIOID ABSTINENCE-SYNDROME.
004610 04-15
OPIOID-LIKE
INTERACTIONS BETWEEN MORPHINE AND THE OPIOID-LIKE PEPTIDES IN
THE RAT VAS-DEFERENS.
001290 02-03
COMPARATIVE-STUDY ON THE EFFEa OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS: STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS.
002757 03-03
OPIOID-PEPTIDE
AN INHIBITOR OF OPIOID-PEPTIDE DEGRADATION PRODUCES ANALGESIA
IN MICE.
001780 02-04
OPIOID-PEPTIDES
EXCITATORY ACTION OF OPIOID-PEPTIDES AND OPIATES ON CULTURED
HIPPOCAMPAL PYRAMIDAL CELLS.
001241 02-03
OPIATES AND OPIOID-PEPTIDES HYPERPOLARIZE LOCUS-COERULEUS
NEURONS IN VITRO.
001408 02-03
BEHAVIORAL-EFFECTS AND ELECTROPHYSIOLOGICAL-EFFEaS OF OPIOID-
PEPTIDES IN CATS.
001612 02-04
ROLE OF ADRENERGIC BLOCKING-AGENTS AND GLUCOCORTICOIDS ON
THE REGULATION OF PITUITARY OPIOID-PEPTIDES LEVELS.
003801 04-03
COMPARISON OF THE BINDING CHARACTERISTICS OF TRITIATED OPIATES
AND OPIOID-PEPTIDES.
003802 04-03
RECENT STUDIES ON INTERAQION BETWEEN OPIOID-PEPTIDES AND THEIR
RECEPTORS.
004300 04-06
OPIOID-RECEPTOR
ISOLATION OF SELEQIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES,
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE.
001162 02-03
Ptychopharmacology Abstracts
D PROPOXYPHENE AQS DIFFERENTLY FROM MORPHINE ON OPIOID-
RECEPTOR EFFEaOR MECHANISMS.
003062 03-04
OPIOID-RECEPTORS
OPIOID-RECEPTORS IN THE CAUDATE-NUCLEUS CAN MEDIATE EMG-
RECORDED RIGIDITY IN RATS.
001649 02-04
MINI-SYMPOSIUM: II. MULTIPLE OPIOID-RECEPTORS. A LIHLE ABOUT
THEIR HISTORY AND SOME IMPLICATIONS RELATED TO EVOLUTION.
004728 04-17
OPIOID-SPECIFIC
A REFORMULATION OF THE DUAL-AQION MODEL OF OPIOID
DEPENDENCE: OPIOID-SPECIFIC NEURONAL KINDLING.
003645 03-17
OPIOID-TOLERANCE
DEVELOPMENT OF ACUTE OPIOID-TOLERANCE AND DEPENDENCE IN RAT
STRIATAL NEURONES.
001235 02-03
OPIOIDS
THE POSSIBILITY THAT A COMPONENT OF MORPHINE-INDUCED
ANALGESIA IS CONTRIBUTED INDIREaLY VIA THE RELEASE OF
ENDOGENOUS OPIOIDS.
000263 01-03
RELATIONSHIP BETWEEN THE ACTIONS OF CALCIUM-IONS, OPIOIDS, AND
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN
NEUROBLASTOMA-X GLIOMA HYBRID CELLS.
002677 03-03
DIFFERENTIAL-EFFECTS OF POTASSIUM ON THE POTENCY OF DIFFERENT
OPIOIDS IN THE MOUSE VAS-DEFERENS.
002935 03-03
MORPHINE-LIKE STIMULUS EFFEaS IN THE MONKEY: OPIOIDS WITH
ANTAGONIST PROPERTIES.
003086 03-04
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA
HYBRID CELLS.
003975 04-03
PHENCYCLIDINE-LIKE DISCRIMINATIVE EFFEQS OF OPIOIDS IN THE RAT.
004136 04-04
SEXUAL-BEHAVIOR DECREASES PAIN SENSITIVITY AND STIMULATES
ENDOGENOUS OPIOIDS IN MALE RATS.
004234 04-04
OPIPRAMOl
A PRELIMINARY STUDY ON DETERMINATION OF THE OPTIMUM
OPIPRAMOL DOSAGE IN DEPRESSIVE-PATIENTS.
000601 01-09
OPIUM
SIMILARITIES BETWEEN CANNABIS AND OPIUM.
002554 02-17
OPPOSITE-EFFEaS
BIPHASIC-EFFEaS AND OPPOSITE-EFFEaS OF DOPAMINE AND
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT
SUBSTANTIA-NIGRA.
002923 03-03
OPTICAL-ISOMERS
THE PHARMACOLOGICAL AQION OF THE OPTICAL-ISOMERS OF
SYDNOCARB.
003681 04-02
PROPERTIES OF THE OPTICAL-ISOMERS AND METABOLITES OF KETAMINE
ON THE HIGH-AFFINITY TRANSPORT AND CATABOLISM OF
MONOAMINES.
004009 04-03
OPTICAL-STIMULATION
THE EFFEaS OF LSD AND SOME ANALOGUES ON THE RESPONSES OF
SINGLE CORTICAL NEURONS OF THE CAT TO OPTICAL-STIMULATION.
000738 01-12
ORDINAL
MILD, MODERATE, SEVERE - THE STATISTICAL ANALYSIS OF SHORT
ORDINAL SCALES.
004677 04-16
ORG-GB-94
A DOUBLE-BUND STUDY WITH ORG-GB-94 IN PREMENOPAUSAL-WOMEN.
002173 02-11
OR6-2766
INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766,
AN ANALOG OF ACTH4-9.
003112 03-04
ORGAN
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS. A
CLINICAL DOUBLE-BLIND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER).
003327 03-1 1
ORGANELLES
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
S-322
VOLUME 19, SUBJECT INDEX
Subject Index
OftOANIC-BRAIN-DISTURBANCES
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS. A
CLINICAL DOUBLE-BLIND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER).
003327 03-11
OIOANIC-BRAIN-SEIZURES
ON THE EVALUATION Of A PROVOCATIVE EEG METHOD USING
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUCTION THROUGH
MEDICATION.
003387 03-11
OROANIC-BRAIN-SYNOROME
NEUROLOGICAL SIDE-EFFECTS OF LITHIUM: ORGANIC-BRAIN-SYNDROME,
SEIZURES, EXTRAPYRAMIDAL SIDE-EFFECTS, AND EEG CHANGES.
000847 01-15
OR6ANIC-MENTAL-SYN0ROMES
THE ROLE OF PSYCHOPHARMACOTHERAPY IN THE TREATMENT OF
ELDERLY-PATIENTS WITH ORGANIC-MENTAL-SYNDROMES.
003368 03-11
OR6ANIC-PSYCHOSYNDROME
POSSIBILITIES OF INFLUENCE ON THE ORGANIC-PSYCHOSYNDROME WITH
NOOTROPIC-DRUGS IN CHRONIC ALCOHOLISM.
000707 01-11
OR6ANIC-PSYCHOSYNDROMES
DISSOCIATION OF THE STRYCHNINE EFFECT ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES.
000816 01-14
DISSOCIATION OF THE STRYCHNINE EFFEQ ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES.
002155 02-11
ORGANISM
DISTRIBUTION OF CESIUM IN THE ORGANISM AND ITS EFFECT ON THE
NUCLEOTIDE METABOLISM ENZYMES.
003696 04-02
ORGANIZATION
FUNCTIONAL ORGANIZATION OF THE CAUDATE-NUCLEUS AFTER
ADMINISTRATION OF CARBACHOL.
001495 02-03
ORGANON-2766
A SYNTHETIC ACTH4-9 ANALOGUE (ORGANON-2766) AND SLEEP IN
HEALTHY MAN.
004574 04-14
ORGANOPHOSPHATE-INDUCED
FORNIX LESION PREVENTS AN ORGANOPHOSPHATE-INDUCED DECREASE
IN MUSCARINIC-RECEPTOR LEVEL IN RAT HIPPOCAMPUS.
001833 02-05
ORGANS
STUDY OF LITHIUM LEVELS IN THE SERUM AND GENITAL ORGANS OF
MALE RATS.
001494 02-03
INFLUENCE OF CANNABIS AND DELTA9 TETRAHYDROCANNABINOL ON
THE BIOCHEMISTRY OF THE MALE REPRODUQIVE ORGANS.
002686 03-03
ORIENTAL
TRICYCLIC-ANTIDEPRESSANT DRUG TOLERANCE IN ORIENTAL AND
OCCIDENTAL POPULATIONS.
000590 01-09
ORIENTATION
A REEVALUATION OF THE MECHANISMS UNDERLYING SIMPLE CELL
ORIENTATION SELECTIVITY.
002894 03-03
ORIENTATIONAL
ORIENTATIONAL TESTING OF CHLORPROMAZINE-HCL ON HOSPITALIZED
MENTAL-PATIENTS.
00213102-11
ORIENTATIONS
THE RESEARCH FOR NEW ANTIDEPRESSANTS: PRESENT ORIENTATIONS
002543 02-17
ORIENTING
EFFEQ OF PROPRANOLOL AND PHENOTHIAZINES ON ELECTRODERMAL
ORIENTING AND HABITUATION IN SCHIZOPHRENIA.
003174 03-08
ORIGIN
THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN
REGULATION OF NEUROSECRETION. (UNPUBLISHED PAPER).
001003 02-01
LITHIUM-ION ENTRY INTO CULTURED CELLS OF NEURAL ORIGIN.
001433 02-03
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS
INVOLVED IN THE HIPPOCAMPUS OF RABBITS.
003842 04-03
THE EFFICACY OF PIRACETAM IN VERTIGO: A DOUBLE-BLIND STUDY IN
PATIENTS WITH VERTIGO OF CENTRAL ORIGIN.
^..^ 004478 04-1 1
ORIGINAL
FIRST RESULTS OF AN ORIGINAL METHOD FOR MEASURING BLOOD
LEVELS OF ANTIDEPRESSANTS (AMITRIPTYLINE AND NORTRIPTYLINE)
003559 03-16
ORNITHINE-DECARBOXYLASE
EFFECT OF OXOTREMORINE ON ORNITHINE-DECARBOXYUSE ACTIVITY OF
THE ADRENAL-GLAND IN RAT.
000246 01-03
OROFACIAL
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJECTION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS.
001446 02-03
CARBAMAZEPINE-INDUCED OROFACIAL DYSKINESIA.
002415 02-15
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
ORTHOSTATIC
TREATMENT OF PSYCHOTROPIC-CAUSEO ORTHOSTATIC HYPOTENSION.
002428 02-15
PHARMACOLOGIC DISTINCTION OF DIFFERENT ORTHOSTATIC
HYPOTENSION-SYNDROMES.
003362 03-11
ORYCTOLAGUS-CUNICULUS
PERIPHERAL AUTONOMIC-MECHANISMS AND PAVLOVIAN-CONDITIONING
IN THE RABBIT (ORYCTOLAGUS-CUNICULUS).
001560 02-04
PERIPHERAL 6 HYDROXYDOPAMINE ADMINISTRATION IN THE RABBIT
(ORYQOLTVGUS-CUNICULUS): EFFECTS ON PAVLOVIAN-CONDITIONING
001668 02-04
OSCILLATION
SENSITIZATION AND OSCILLATION FOLLOWING REPEATED STIMULATION-
RELATIONSHIP TO AFFECTIVE-ILLNESS AND ITS TREATMENT WITH
LITHIUM AND CARBAMAZEPINE.
002031 02-09
OSCILLATORY
CHARACTERISTICS OF OSCILLATORY CONTRACTIONS ELICITED BY
NALOXONE IN ILEUM PREPARATION FROM MORPHINE-DEPENDENT
GUINEA-PIGS.
001491 02-03
OSMOLALITY
CHANGES IN BLOOD PLASMA OSMOULITY AND STATES OF MANIA.
004352 04-09
OSTEOMALACIA
BIOCHEMICAL-EVIDENCE FOR OSTEOMALACIA WITH CARBAMAZEPINE
THERAPY.
002445 02-15
OUABAIN
GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT
AFFECTED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN
TREATMENT.
001145 02-03
OUTCOME
PREDICTING OUTCOME OF ANTIPSYCHOTIC-DRUG TREATMENT FROM
EARLY-RESPONSE.
000565 01-08
CHLORPROMAZINE LEVELS AND THE OUTCOME OF TREATMENT IN
SCHIZOPHRENIC-PATIENTS.
003188 03-08
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME.
003189 03-08
PREDICTING OUTCOME FROM MEASURES OF AHENTION AND
AUTONOMIC-FUNQIONING.
003205 03-08
SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN
DETOXIFYING ALCOHOLIC-PATIENTS.
004671 04-16
COMPUTER-ANALYZED ELECTROENCEPHALOGRAM TO PREDICT THE
THERAPEUTIC OUTCOME IN SCHIZOPHRENIA.
004680 04-16
OUTER
EXPOSURE OF MITOCHONDRIAL OUTER MEMBRANES TO NEURAMINIDASE
SELECTIVELY DESTROYS MONOAMINE-OXIDASE-A ACTIVITY.
001286 02-03
OUTFLOW
BETA ENDORPHIN-INDUCED HYPERGLYCEMIA IS MEDIATED BY INCREASED
CENTRAL SYMPATHETIC OUTFLOW TO ADRENAL-MEDULLA.
002924 03-03
OUTPATIENT
HOSPITAL AND OUTPATIENT CARE FOR PSYCHOTIC-PATIENTS DURING THE
LAST THREE DECADES: SUBSEQUENT HOSPITAL AND OUTPATIENT
TREATMENT OF PSYCHOTIC-PATIENTS HOSPITALIZED FOR THE FIRST
TIME IN 1949-50, 1959-60 OR 1969-70.
000571 01-08
CLONIDINE FOR OPIATE DETOXIFICATION: OUTPATIENT CLINICAL-TRIALS.
000731 01-11
CLONIDINE FOR OUTPATIENT OPIATE DETOXIFICATION.
000827 01-14
S-323
Subject index
Ptychopharmacology Abttrocft
Miiiaii
liiliiii
•Wilis
Sill:
I*
OUTPATIENT TREATMENT ISSUES AND STRATEGIES FOR ACUTE AND
CHRONIC PCP ABUSERS.
000919 01-17
USE OF THE LITHIUM RESPONSE SCALE WITH AN OUTPATIENT
PSYCHIATRIC-SAMPLE.
000921 01-17
STUDY OF MAPROTILINE IN OUTPATIENT TREATMENT OF DEPRESSIVE-
STATES BY THE GENERAL-PRACTITIONER: ADVANTAGE OF SINGLE-
NIGHTLY-DOSE.
001961 02-09
OUTPATIENT CARE OF DEPRESSIVE-PATIENTS WITH MIANSERIN.
002041 02-09
ARCALI0N-200 PRESCRIBED AS A PSYCHIATRIC-DRUG AND
ANTIALCOHOLISM-DRUG ON AN OUTPATIENT AND INPATIENT BASIS.
002103 02-11
THE USE OF MINAPRINE IN CHILD-PSYCHIATRY IN HOSPITALS AND
OUTPATIENT CLINICS.
002169 02-11
AMOXAPINE AND AMITRIPTYLINE IN THE OUTPATIENT TREATMENT OF
ENDOGENOUS DEPRESSION.
003217 03-09
THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL-
MEDICAL-PRACTICE: 48 CASES TREATED ON AN OUTPATIENT BASIS.
003268 03-09
METHODOLOGY OF OUTPATIENT DRUG RESEARCH. (UNPUBLISHED
PAPER).
003282 03-10
OUTPATIENTS
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A
MONOSUBSTANCE (DOXEPINE).
002028 02-09
PLASMA DESIPRAMINE LEVELS AFTER SINGLE-DOSAGE AND AT STEADY-
STATE IN OUTPATIENTS.
002039 02-09
OUTPATIENTS-WARDS
RESULTS OF TREATMENT BY MODITEN DEPOT IN OUTPATIENTS-WARDS IN
THE SOUTH MORAVIAN REGION.
004648 04-15
OUTWARD-CURRENT
DIPHENYLHYDANTOIN REDUCES THE OUTWARD-CURRENT OF THE ACTION
POTENTIAL IN APLYSIA.
002805 03-03
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOLLUSCAN
NEURONS.
003834 04-03
OVARIAN
EFFECTS OF CENTRALLY-ADMINISTERED AND SYSTEMICALLY
ADMINISTERED L TYROSINE AND L LEUCINE ON OVARIAN FUNQION IN
THE OLD RAT.
001180 02-03
IMIPRAMINE: EFFECT OF OVARIAN STEROIDS ON MODIFICATIONS IN
SEROTONIN-RECEPTOR BINDING.
002778 03-03
OVARIECTOMIZED
EFFECTS OF AN EPINEPHRINE SYNTHESIS INHIBITOR, SKF-64139, ON THE
SECRETION OF LUTEINIZING-HORMONE IN OVARIECTOMIZED FEMALE
RATS.
002693 03-03
FACILITATION OF LORDOSIS BEHAVIOR IN THE OVARIEaOMIZED
ESTROGEN-PRIMED RAT BY DIBUTYRYL-C-AMP.
002957 03-04
OVERACTIVE
A DOUBLE-BUND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF
CARBAMAZEPINE IN OVERAQIVE, SEVERELY MENTALLY-
HANDICAPPED PATIENTS.
003365 03-1 1
OVERDIAGNOSED
IS MANIA OVERDIAGNOSED?: THE THREE COMMON PITFALLS IN
DIAGNOSING MANIC-DEPRESSIVE-ILLNESS.
003260 03-09
OVERDOSAGE
PHARMACOKINETIC-STUDY OF LORAZEPAM OVERDOSAGE.
000831 01-15
THE NEW ANTIDEPRESSANT PIRLINDOLE: ANTAGONISM OF ACUTE
OVERDOSAGE IN THE MOUSE.
001082 02-02
ACUTE OVERDOSAGE WITH FLUNITRAZEPAM.
003513 03-15
OVERDOSE
THA - A REVIEW OF THE LITERATURE AND ITS USE IN TREATMENT OF
FIVE OVERDOSE PATIENTS.
003539 03-15
OVEREATING
AMPHETAMINE-INDUCED OVEREATING AND OVERWEIGHT IN RATS.
003015 03-04
OVERFLOW
REGULATION OF NORADRENALINE OVERFLOW IN RAT-CEREBRAL-CORTEX
BY PR0STAGLANDIN-E2.
003841 04-03
OVERINCLUSIVE
CHANGE IN OVERINCLUSIVE THINKING OF SCHIZOPHRENIC-PATIENTS IS
RELATED TO PLASMA PHENOTHIAZINE CONCENTRATION.
001941 02-08
OVERNIGHT
INHIBITION OF PENTAGASTRIN-STIMULATED AND OVERNIGHT GASTRIC
SECRETION BY LM24056. A NEW PHENOTHIAZINE DERIVED
ANTISECRETORY DRUG.
004306 04^7
OVERVIEW
PEPTIDES IN NEUROBIOLOGY: AN OVERVIEW. (UNPUBLISHED PAPER).
001008 02-01
CYCLIC-NUCLEOTIDES AND THE CENTRAL-EFFEQS OF OPIATES: AN
OVERVIEW OF CURRENT RESEARCH.
001445 02-03
AN OVERVIEW OF SEVENTEEN YEARS OF EXPERIENCE WITH OOTHIEPIN IN
THE TREATMENT OF DEPRESSION IN EUROPE.
001995 02-09
MOLECULAR ACTIONS OF OPIATES: HISTORICAL OVERVIEW AND NEW
FINDINGS ON OPIATE-RECEPTOR INTERAQIONS WITH ENKEPHALINS
AND GUANYL-NUCLEOTIDES.
002613 02-17
REVIEW AND OVERVIEW OF FOUR DECADES OF OPIATE RESEARCH.
002627 02-17
DEPENDENCE ON TRANQUILIZERS (AN OVERVIEW WITH (CASE-STUDIES).
003580 03-17
AN OVERVIEW OF PHARMACOLOGIC-TREATMENT OF COGNITIVE DECLINE
IN THE AGED.
004482 04-11
OVERWEIGHT
AMPHETAMINE-INDUCED OVEREATING AND OVERWEIGHT IN RATS.
003015 03-04
OVINE
DISPOSITION OF METHADONE IN THE OVINE MATERNAL FETAL UNIT.
004027 04-03
OVOCYCLIN
SYNCHRONIZATION OF EEG AQIVITY OF MALE RHESUS-MONKEYS
MACACA-MULAHA TREATED WITH OVOCYCLIN.
001312 02-03
OVULATION
NALOXONE REVERSAL OF THE PENTOBARBITAL-INDUCED BLOCKADE OF
OVULATION IN THE RAT.
002817 03-03
OVULATORY
A BARBITURATE-EVOKED INTENSIFICATION OF POSTSYNAPTIC INHIBITION
IN THE PREOPTIC OVULATORY TRIGGER REGION OF THE
HYPOTHALAMUS.
002818 03-03
OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-AaO
THE NEUROLATHYROGEN, BETA N OXALYL-L-ALPHA-BETA-
DIAMINOPROPIONIC-ACID, IS A POTENT AGONIST AT GLUTAMATE
PREFERRING RECEPTORS IN THE FROG SPINAL-CORD.
002858 03-03
OXAZEPAM
OXAZEPAM-ESTERS. 1. CORRELATION BETWEEN HYDROLYSIS RATES AND
BRAIN APPEARANCE OF OXAZEPAM
000010 01-02
CONTROLLED-COMPARISON OF THE THERAPEUTIC EFFEQS OF NATRIUM-
OXYBUTYRATE AND OXAZEPAM.
000658 01-10
CHLORDIAZEPOXIDE AND OXAZEPAM DISPOSITION IN CIRRHOSIS.
000790 01-13
EFFICACY AND SIDE-EFFEQS OF LORAZEPAM, OXAZEPAM, AND
TEMAZEPAM AS SLEEPING-AIDS IN PSYCHOGERIATRIC-INPATIENTS.
002076 02-10
INFLUENCE OF CIMETIDINE ON THE PHARMACOKINETICS OF
DESMETHYLDIAZEPAM AND OXAZEPAM.
002249 02-13
CLINICAL PHARMACOKINETICS OF OXAZEPAM AND LORAZEPAM.
003410 03-13
OXAZEPAM-ESTERS
OXAZEPAM-ESTERS. 1. CORRELATION BETWEEN HYDROLYSIS RATES AND
BRAIN APPEARANCE OF OXAZEPAM.
000010 01-02
OXAZEPAM-ESTERS. 2. CORRELATION OF HYDROPHOBICITY WITH SERUM
BINDING, BRAIN PENETRATION, AND EXCRETION.
000011 01-02
OXAZOLAM
A CLINICAL-EVALUATION OF THE EFFEQS OF A NEW PSYCHOTROPIC-
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE
DOUBLE-BUND METHOD.
004491 04-11
OXIDASES
EFFEQ OF CHRONIC ADMINISTRATION OF PHENCYCUDINE ON HEPATIC
MIXED-FUNQION OXIDASES IN THE MOUSE.
002753 03-03
S-324
VOLUME 19, SUBJECT INDEX
Subject Index
OXIDATION
GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT
AFFECTED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN
TREATMENT.
001 145 02-03
OXIDATION OF BETA PHENYLETHYLAMINE BY BOTH TYPES OF
MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND
LIVER MITOCHONDRIA OF EIGHT SPECIES.
004024 04-03
RAPID DETERMINATION OF CHL0RPR0MA2INE-HCL AND TWO OXIDATION
PRODUaS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH-
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE
DETECTION.
004302 04-06
OXIDATIVE
NOREPINEPHRINE DEPLETION ALTERS CEREBRAL OXIDATIVE METABOLISM
IN THE ACTIVE STATE.
002798 03-03
>XIPEROMI0E
OXIPEROMIDE IN TARDIVE-DYSKINESIA.
000540 01-07
)XOTREMORINE
EFFECT OF OXOTREMORINE ON ORNITHINE-DECARBOXYLASE ACTIVITY OF
THE ADRENAL-GLAND IN RAT.
000246 01-03
OXOTREMORINE BEHAVIOURAL-EFFECTS AS A SCREENING-TEST IN MICE
001072 02-02
EFFEQ OF ANTINOCICEPTIVE DOSES OF OXOTREMORINE ON MOUSE-
BRAIN ACETYLCHOLINE TURNOVER-RATE.
001513 02-03
BRAIN CATECHOLAMINES MODIFICATIONS. THE EFFECTS ON MEMORY
FACILITATION INDUCED BY OXOTREMORINE IN MICE.
001658 02-04
EFFEQS OF SCOPOLAMINE, PILOCARPINE, AND OXOTREMORINE ON THE
EXPLORATORY-BEHAVIOR OF TWO PSYCHOGENETICALLY SELECTED
LINES OF RATS IN A COMPLEX MAZE.
003042 03-04
OXOTREMORINE DOES NOT ENHANCE ACETYLCHOLINE RELEASE FROM
RAT DIAPHRAGM PREPARATIONS.
003819 04-03
)XOTREMORINE-LIKE-AGENT
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF N-4 1
AZETIDINYLBUTYNYL 2 PYRROLIDONE, A HIGHLY POTENT
OXOTREMORINE-LIKE-AGENT.
.XPRENOLOL 00370104-02
A DOUBLE-BUND TRIAL; THE USE OF OXPRENOLOL AND DIAZEPAM IN
ANXIETY.
.XYGEN 004428 04-10
TOXICITY OF OXYGEN IN IRON RICH AREAS OF RAT-BRAIN
(UNPUBLISHED PAPER).
THE EFFEQS OF BOMBESIN INJEQED INTO THE ANTERIOR AND
POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN
CONSUMPTION.
XYMETA20LINE 001544 02-03
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
XYPERT.NE °°2801 03-03
INTERAQIONS OF OXYPERTINE WITH RAT-BRAIN MONOAMINE-
RECEPTORS.
TREATMENT OF TARDIVE-DYSKINESIA WITH OXYPERTINE - PRELIMINARY
CLINICAL-EXPERIENCE AND A BRIEF REVIEW OF THE LITERATURE.
A CONTROLLED-TRIAL OF OXYPERTINE IN TARDIVE-DYSKINESIA ^"^ ^
XYPROTHEPIN 00461104-15
COMPARISON OF BLOOD AND BILE LEVELS OF OXYPROTHEPIN AND
DOCLOXYTHEPIN IN RATS.
COMPUTERIZED EEG IN THE COMPARISON OF OXYPROTHEPIN An1) °^'°^
FLUPHENAZINE-DECANOATE .
CLINICAL COMPARISON OF OXYPROTHEPIN AND CLOTEPINE IN ^ '"^^
SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY) .
LONG-TERM CONTROLLED-COMPARISON OF INJEQION OXYPROTHEPIN
AND FLUPHENAZINE-DECANOATES IN PSYCHOTICS IN REMISSION.
CONTRIBUTION TO THE PHARMACOKINETICS AND METABOLISM OF ^ °^
OXYPROTHEPIN.
CYPROTHEP.N-DECANOATE 002279 02-13
CLINICAL-TRIAL OF OXYPROTHEPIN-DECANOATE.
000542 01-07
OXYPROTHEPIN-DECANOATE INJECTIONS; EXPERIENCE WITH A LONG-
TERM-TREATMENT OF SCHIZOPHRENIC-PSYCHOSES.
000576 01-08
OXYPROTHEPINE-OECANOATE
MAINTENANCE-THERAPY WITH FLUPHENAZINE-DECANOATE AND
OXYPROTHEPINE-DECANOATE IN SCHIZOPHRENIC-PATIENTS - A
DOUBLE-BLIND CROSS-OVER COMPARATIVE-STUDY.
001924 02-08
EXPERIENCE WITH OXYPROTHEPINE-DECANOATE IN THE MAINTENANCE-
THERAPY OF SCHIZOPHRENIA.
001925 02-08
OXYPROTHEPINE-DECANOATE COMPARED WITH FLUPHENAZINE-
DECANOATE IN THE TREATMENT OF SCHIZOPHRENIA: PRELIMINARY-
COMMUNICATION.
00)934 02-08
OXYTOCIN
INFLUENCE OF OXYTOCIN ON HUMAN MEMORY PROCESSES.
002322 02-14
P-300
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS: EFFEaS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300.
003451 03-14
PACIFIC-ISLANDERS
PSYCHOPHARMACOLOGY FOR ASIAN-AMERICANS AND PACIFIC-
ISLANDERS.
PACKET
TYRAMINE CONTENT OF CANNED AND PACKET SOUPS.
PAIN
000734 01-11
002394 02-15
000775 01-13
PAIN AND TRYPTOPHAN.
MECHANISMS OF PAIN AND ANALGESIC COMPOUNDS.
000916 01-17
PSYCHOPHARMACOLOGY OF ANALGESIA AND PAIN. (UNPUBLISHED
PAPER).
001411 02-03
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS PRESENT A NALOXONE
SENSITIVE DECREASE IN PAIN SENSITIVITY. (UNPUBLISHED PAPER)
001457 02-03
NEUROPEPTIDES AND MONOAMINERGIC NEUROTRANSMIHERS: THEIR
RELATION TO PAIN.
001497 02-03
BRIEF SOCIAL-ISOLATION, PAIN RESPONSIVITY, AND MORPHINE
ANALGESIA IN YOUNG RATS.
001744 02-04
TREATMENT OF CHRONIC PAIN WITH ANTIDEPRESSANT-DRUGS
002048 02-09
THE RELATIONSHIP OF ALPHA AND DELTA EEG FREQUENCIES TO PAIN
AND MOOD IN FIBROSITIS-PATIENTS TREATED WITH CHLORPROMAZINE
AND L TRYPTOPHAN,
002152 02-11
MECHANISMS OF OPIATE ANALGESIA AND THE ROLE OF ENDORPHINS IN
PAIN SUPPRESSION. (UNPUBLISHED PAPER).
002275 02-13
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE.
002305 02-13
CLONIDINE AND PSYCHOPHYSICAL PAIN.
002366 02-14
PSYCHOPHARMACEUTICALS FOR TREATING PAIN.
002548 02-17
PLACEBO, MEDICINE AND PAIN, OR THE RELATIVE FUNCTION OF
MEDICATION IN THE TREATMENT OF PAIN.
002577 02-17
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE
SPINAL-CORD OF THE CAT: ENKEPHALIN-CONTAINING MARGINAL
NEURONS AND PAIN MODULATION.
002638 03-01
A COMPARISON OF THE EFFECTS OF MORPHINE-SULPHATE AND NITROUS-
OXIDE ANALGESIA ON CHRONIC PAIN STATES IN MAN
003442 03-14
THE NEUROPHYSIOLOGICAL AND CLINICAL-ASPECTS OF PAIN
003457 03-14
RELIEF OF PAIN IN CLINICAL-PRACTICE.
003613 03-17
TREATMENT OF CANCER PAIN.
rrrr^. „. 003619 03-17
EFFEQS OF PAIN, MORPHINE AND NALOXONE ON THE DURATION OF
ANIMAL HYPNOSIS.
004081 04-04
SEXUAL-BEHAVIOR DECREASES PAIN SENSITIVITY AND STIMULATES
ENDOGENOUS OPIOIDS IN MALE RATS.
004234 04-04
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY'
004553 04-13
S-325
Subject Index
•Mliilil
siiiiiii
mt.'
-"IJIf
«ii)ir
PAIRING
THE EFFEQS OF PIMOZIDE DURING PAIRING ON THE TRANSFER OF
CLASSICAL CONDITIONING TO AN OPERANT DISCRIMINATION.
002956 03-04
PROGRESSIVE SUPRANUCLEAR PALSY, COMPUTED-TOAAOGRAPHY, AND
RESPONSE TO ANTIPARKINSONIAN-DRUGS.
003322 03-11
PROGRESSIVE SUPRANUCLEAR PALSY: PNEUMOENCEPHALOGRAPHY,
ELEaRONYSTAGMOGRAPHY AND TREATMENT WITH METHYSERGIDE.
003355 03- n
PANCREAS
THE EFFEa OF SEROTONIN ON THE EXOSECRETORY ACTION OF THE
PANCREAS. „„.„.o«.«,
004043 04-03
PANENCEPHALITIS
ISOPRINOSINE IN SUBACUTE SCLEROSING PANENCEPHALITIS.
000687 01-11
REVIEW OF 38 CASES OF SUBACUTE SCLEROSING PANENCEPHALITIS:
EFFEQ OF AMANTADINE ON THE NATURAL COURSE OF THE DISEASE.
000718 01-11
PANIC
DIFFERENTIAL DIAGNOSIS AND TREATMENT OF PANIC AHACKS AND
PHOBIC-STATES. „„..„.„.,„
004424 04-10
PANIC-ANXIETY
PANIC-ANXIETY AFTER ABRUPT DISCONTINUATION OF AMITRIPTYLINE.
003223 03-09
PANIC-DISORDER , ._
EFFEa OF SODIUM-LAaATE ON PATIENTS WITH PANIC-DISORDER AND
MITRAL- VALVE PROLAPSE. „^ ,^
003409 03-13
PANIC-INDUCED
BLOCKADE BY IMIPRAMINE OR DESIPRAMINE OF PANIC-INDUCED BY
SODIUM-LAQATE. «„..„-,„.,„
004427 04-10
PAPAIN-DERIVED
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT. „„„,„. „.„o
003734 04-03
PAPAVERINE
EFFECT OF PAPAVERINE ON REGIONAL CEREBRAL BLOOD FLOW AND
SMALL VESSEL BLOOD CONTENT.
001177 02-03
PAPILLOEDEMA
BILATERAL PAPILLOEDEMA IN LONG-TERM THERAPY WITH LITHIUM-
CARBONATE. „„„„,„„, ,c
000878 01-15
PAPiO-PAPIO
EEG AND ANTICONVULSANT EFFEaS OF DIPROPYLACETIC-ACID AND
DIPROPYLACETAMIDE IN THE BABOON PAPIO-PAPIO.
001210 02-03
PARACETAMOL
BEHAVIOURAL-EFFEaS OF ACETYLSALICYLIC-ACID, PARACETAMOL,
CAFFEINE, GUAIPHENESIN AND THEIR COMBINATIONS.
001805 02-04
THE EFFECT OF ASPIRIN AND PARACETAMOL ON THE INCREASED
NALOXONE POTENCY INDUCED BY MORPHINE PRETREATMENT.
001824 02-04
PARADIGM
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFEQS ON
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE
PARADIGM.
000372 01-04
INFLUENCE OF INTRAVENOUS SELF-ADMINISTERED PSYCHOMOTOR
STIMULANTS ON PERFORMANCE OF RHESUS-MONKEYS IN A MULTIPLE-
SCHEDULE PARADIGM.
001655 02-04
TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERAQIVE-
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL
PARADIGM - A PILOT-STUDY.
002126 02-11
A RESEARCH PARADIGM TO INVESTIGATE THE EFFEQ OF MANIPULATION
ON SOCIAL-BEHAVIOR IN GROUPS.
003007 03-04
PARADOXICAL
EFFEQ OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN
RATS
001199 02-03
PARADOXICAL IMPROVEMENT FOLLOWING IV AMPHETAMINE IN
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
001951 02-08
PARADOXICAL AKINESIA INDUCED BY ANTIDEPRESSANT-DRUGS.
002378 02-15
PARADOXICAL-EFFEa
THE PARADOXICAL-EFFECT OF LIDOCAINE ON AN EXPERIMENTAL MODEL
''''^''''' 000039 01-03
Psychopharmacology Abstracts
A NOTE ON THE PARADOXICAL-EFFEQ OF STIMULANTS ON
HYPERACTIVITY WITH REFERENCE TO THE RATE DEPENDENCY EFFECT
OF DRUGS.
003320 03-11
PARADOXICAL-EFFEaS
GENETIC AND EXPERIMENTAL FACTORS AFFECTING THE PARADOXICAL-
EFFECTS OF AMPHETAMINE IN DOGS.
001704 02-04
PARADOXICAL-INTERAaiON
THERMOREGULATORY AND LOCOMOTOR-EFFECTS OF DSIP:
PARADOXICAL-INTERACTION WITH D-AMPHETAMINE.
001827 02-04
PARADOXICAL-SLEEP
PRAZOSIN INCREASES PARADOXICAL-SLEEP.
000405 01-04
PARADOXICALLY
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
PARAFASCICULAR
ENHANCED SUPPRESSION OF CONDITIONED AVOIDANCE RESPONSE BY
HALOPERIDOL BUT NOT PHENOXYBENZAMINE IN RATS WITH
BILATERAL PARAFASCICULAR LESIONS.
000334 01-04
PARALLEL
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE
CAT. (PH.D. DISSERTATION).
001179 02-03
A DOUBLE-BLIND PARALLEL GROUP COMPARISON OF SINGLE-BEDTIME- '
DOSES OF HALAZEPAM AND PLACEBO.
002079 02-10
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
004112 04-04
A SIMPLE DETERMINATION OF SEROTONIN, 5 HYDROXYINDOLEACETIC-
ACIO AND 5 HYDROXYTRYPTOPHAN-DECARBOXYLASE ACTIVITY IN
RAT-BRAIN AREAS AND PARALLEL CORRELATION AMONG THE LEVELS.
004301 04-06
PARALLELS i
FUNCTIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY
NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS
WITH SCHIZOPHRENIA.
000059 01-03 ,
PARAMETERS
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - I. KINETIC PARAMETERS
AND PHARMACOLOGICAL-PROPERTIES. ^ ,
000213 01-03
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
DEXAMETHASONE TREATMENT.
000321 01-03
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF
CHLORDIAZEPOXIDE ON FEEDING PARAMETERS USING TWO FOOD
TEXTURES IN THE RAT. ^^^ ^, „ i
000368 01-04
INTRACRANIAL INJECTION PARAMETERS WHICH AFFECT ANGIOTENSIN-II-
INDUCED DRINKING. ,^r.. «, «z '
000534 01-06
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN
'^''^^ 001547 02^
EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS.
EFFECTS OF SPIPERONE ALONE AND IN COMBINATION WITH ANORECTIC-
AGENTS ON FEEDING PARAMETERS IN THE RAT.
001598 02-04
INTERACTIONS OF CHLORDIAZEPOXIDE AND ANORECTIC-AGENTS ON RATE
AND DURATION PARAMETERS OF FEEDING IN THE RAT.
001600 02-04
THE CLINICAL-EFFICACY OF CLOZAPINE AS COMPARED TO LABORATORY
PARAMETERS. „„,„rr ,,-, no
001955 02-08
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS
002047 02-09
EFFECTS OF CYCLOSPASMOL UPON SENSORY PARAMETERS IN PATIENTS
RECOVERING FROM CEREBROVASCULAR-ACCIDENTS. q, 14
EFFECTS OF ANXIETY REDUCTION BY BEHAVIOURAL-TECHNIQUES AND
MEPROBAMATE ON CERTAIN PARAMETERS OF INFORMATION THEORY
003108 03-04
S-326
VOLUME 19, SUBJECT INDEX
Subfect Index
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES
IN THIS PHASE.
003251 03-09
INVESTIGATION INTO THE EFFECT OF FLUPHENAZINE-HCL (LYORODIN) IN
CHILDREN WITH BEHAVIORAL-DISORDERS BY MEANS OF
PSYCHOPHYSIOLOGICAL PARAMETERS.
003344 03-11
TIME-COURSE OF CLINICAL CHEMICAL PARAMETERS UNDER LONG-TERM
LITHIUM TREATMENT.
003515 03-15
EFFECTS OF SUPIDIMIDE (CG-3033) ON OBJECTIVE AND SUBJECTIVE SLEEP
PARAMETERS (A SLEEP LABORATORY STUDY).
004567 04-14
PARANOIA
CIMETIDINE TOXICITY MANIFESTED AS PARANOIA AND
HALLUCINATIONS.
000829 01-15
PARANOID
THE RELATIONSHIP BETWEEN THE THIORIDAZINE LEVEL IN THE PLASMA
AND SYMPTOMS OF PARANOID SCHIZOPHRENIA.
000546 01-08
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE.
003172 03-08
PARAPROFESSIONAL
PARAPROFESSIONAL AND PROFESSIONAL TEAMWORK AND TRAINING IN
MANAGING PCP AND OTHER DRUG-ABUSE PROBLEMS.
000924 01-17
PARASYMPATHETIC-ACTIVITY
METHYLDOPA PRODUCES CENTRAL INHIBITION OF PARASYMPATHETIC-
ACTIVITY IN THE CAT.
001321 02-03
PARASYMPATHOMIMETIC-INFLUENCE
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIRECT VASODILATOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRiaiON.
001109 02-03
•ARATHYROID-HORMONE
LITHIUM EFFEa ON PARATHYROID-HORMONE.
003215 03-09
•ARENCHYMAL
ON THE QUESTION OF PARENCHYMAL DAMAGE CAUSED BY LONG-TERM
THERAPY WITH PSYCHOTROPICS IN ADOLESCENCE.
004626 04-15
•ARENT
THE PARENT CHILD INTERAQIONS OF HYPERACTIVE-CHILDREN AND THEIR
MODIFICATION BY STIMULANT-DRUGS.
002092 02-11
>ARENTERAL
THE BIOAVAILABILITY OF ORAL AND PARENTERAL CHLORIMIPRAMINE
(ANAFRANIL).
002232 02-13
>ARENTERALLY
ETHANOL AVERSION INDUCED BY PARENTERALLY ADMINISTERED
ETHANOL AQING BOTH AS CS AND UCS.
001721 02-04
>ARENTS
LITHIUM IN CHILDREN OF LITHIUM RESPONDING PARENTS.
003242 03-09
>AR6YLiNE
DEPLETION OF EPINEPHRINE IN RAT HYPOTHALAMUS BY RO-4-1284:
INFLUENCE OF PARGYLINE AND HARMALINE.
000100 01-03
INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE,
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS.
001539 02-03
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFECTS OF
HALOPERIDOL AND PARGYLINE.
003792 04-03
'ARKINSON-DISEASE
SINEMET AND THYROID-FUNQION IN PARKINSON-DISEASE.
000733 01-11
DRUG-HOLIDAY AND MANAGEMENT OF PARKINSON-DISEASE
002468 02-15
DEPRENYL IN PARKINSON-DISEASE.
003309 03-11
EVIDENCE TO SUPPORT EARLY LEVODOPA THERAPY IN PARKINSON-
DISEASE.
003336 03-11
'ARKINSON-PATIENTS
NOMIFENSINE AS CONCOMITANT THERAPY IN THE TREATMENT OF
PARKINSON-PATIENTS. A DOUBLE-BLIND PLACEBO-CONTROLLED-
STUDY.
002130 02-11
NORMAL PUVSMA DOPAMINE-BETA-HYDROXYLASE IN NONTREATED AND
TREATED PARKINSON-PATIENTS.
004471 04-11
PARKINSON-SYNDROME
EFFECTS OF HIGH-DOSAGE LISURIDE-HYDROGEN-MALEATE (LHM) IN
PARKINSON-SYNDROME.
004460 04-11
PARKINSONIAN
SPINOCEREBELLAR DEGENERATION WITH PARKINSONIAN FEATURES: A
CLINICAL AND PATHOLOGICAL REPORT.
003436 03-13
PARKINSONIAN-PATIENTS
PSYCHIATRIC-EFFECTS OF BROMOCRIPTINE AND LERGOTRILE IN
PARKINSONIAN-PATIENTS.
002453 02-15
PLASMA LEVODOPA, DOPAMINE AND THERAPEUTIC RESPONSE
FOLLOWING LEVODOPA THERAPY OF PARKINSONIAN-PATIENTS.
002504 02-16
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS.
004551 04-13
ELECTROENCEPHALOGRAPHIC CHANGE IN PARKINSONIAN-PATIENTS
TREATED WITH LEVODOPA CARBIDOPA.
004557 04-13
DEPRENYL DOES NOT CAUSE INSOMNIA IN PARKINSONIAN-PATIENTS.
004569 04-14
PARKINSONIAN-SYNDROME
TREATMENT OF PARKINSONIAN-SYNDROME WITH DEXETIMIDE.
002111 02-11
PARKINSONISM
BIOCHEMICAL-MEASUREMENTS DURING (-)DEPRENYL TREATMENT OF
PARKINSONISM.
000673 01-11
ELECTRORETINOGRAPHIC-CHANGES IN PATIENTS WITH PARKINSONISM
TREATED WITH VARIOUS CLASSES OF ANTIPARKINSONIAN-DRUGS.
000674 01-11
A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED
PARKINSONISM.
002146 02-11
PARKINSONISM: IS YOUR TREATMENT APPROPRIATE?
002159 02-11
LISURIDE IN THE TREATMENT OF PARKINSONISM.
002168 02-11
A NEUROPHARMACOLOGICAL-STUDY AND NEUROENDOCRINE-STUDY ON
IDIOPATHIC AND CHRONIC PHARMACOLOGICAL PARKINSONISM.
002371 02-15
PROGRESS IN THE PHARMACOTHERAPY OF PARKINSONISM.
002384 02-15
LISURIDE IN PARKINSONISM.
003319 03-11
CLINICAL SIGNIFICANCE OF PYRIDOXINE ADMINISTRATION IN L-DOPA
THERAPY OF PARKINSONISM.
003345 03-11
LISURIDE IN PARKINSONISM.
003422 03-13
THE DIAGNOSIS AND TREATMENT OF NEUROLEPTIC-INDUCED
PARKINSONISM.
003493 03-15
GERIATRIC ASPECTS OF PARKINSONISM (CLINICAL-PICTURE,
PATHOLOGICAL MECHANISMS, AND MULTIPLE TREATMENT).
003643 03-17
PROSPECTS FOR THE TREATMENT OF POSTENCEPHALITIC PARKINSONISM
WITH ANTILYMPHOCYTIC IMMUNOGLOBULIN.
004572 04-14
CONTEMPORARY PROBLEMS IN THE PHARMACOLOGICAL-TREATMENT OF
PARKINSONISM.
004628 04-15
PARKINSONS
ASSESSING L-DOPA THERAPY FOR PARKINSONS.
004465 04-1 1
PARKINSONS-DISEASE
ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLED-
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH
PARKINSONS-DISEASE TREATED WITH L-DOPA.
000659 01-11
VASOPRESSIN THERAPY IN PARKINSONS-DISEASE.
000689 01-11
THE LONG-TERM RESULTS OF STEREOTAXIC SURGERY AND L-DOPA
THERAPY IN PATIENTS WITH PARKINSONS-DISEASE: A 10-YEAR
FOLLOWUP STUDY.
000693 01-11
LONG-TERM EFFICACY OF BROMOCRIPTINE IN PARKINSONS-DISEASE.
000698 01-11
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE).
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION.
000712 01-11
S-327
'mi '■
a
4
•"UK
Site
oc
fe
Subject Index
THE ELECTRORETINOGRAM IN PARKINSONS-DISEASE.
001295 02-03
A COMPARATIVE-STUDY OF BROMOCRIPTINE AND LEVODOPA IN
PARKINSONS-DISEASE.
002117 02-11
BROMOCRIPTINE AND PARKINSONS-DISEASE: A 16-HOUR CLINICAL-
EVALUATION.
002127 02-11
THE ROLE OF BROMOCRIPTINE IN THE TREATMENT OF PARKINSONS-
'^'''''- 002177 02-11
INCREASED RATIO OF CARBIDOPA TO LEVODOPA IN TREATMENT OF
PARKINSONS-DISEASE.
002182 02-11
ABNORMAL REGULATION OF PROLACTIN RELEASE IN IDIOPATHIC
PARKINSONS-DISEASE. „ ,
002255 02-13
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL, ON
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC-STUDY.
002309 02-13
BROMOCRIPTINE IN PARKINSONS-DISEASE: REPORT ON 106 PATIENTS
TREATED FOR UP TO 5 YEARS.
002342 02-14
DEPRENYL IN THE MANAGEMENT OF RESPONSE FLUCTUATIONS IN
PATIENTS WITH PARKINSONS-DISEASE ON LEVODOPA.
002358 02-14
EDEMAS AND MYOCLONIES IN A PATIENT WITH PARKINSONS-DISEASE
TREATED BY AMANTADINE: PROBLEM WITH ASSOCIATED
MEDICATIONS. „„ ,
002389 02-15
FURTHER EXPERIENCES WITH LOW-DOSES OF BROMOCRIPTINE IN
PARKINSONS-DISEASE.
002401 02-15
LEVODOPA COMPARED WITH BROMOCRIPTINE IN THE TREATMENT OF
PARKINSONS-DISEASE. „„ ^
002406 02-15
L-DOPAS MECHANISM-OF-AQION IN PARKINSONS-DISEASE.
003323 03-1 1
RECENT ADVANCES IN THE TREATMENT OF PARKINSONS-DISEASE.
003528 03-15
ARE THE ENKEPHALINS INVOLVED IN PARKINSONS-DISEASE? CLINICAL
AND NEUROENDOCRINE RESPONSES TO NALOXONE ADMINISTRATION.
004431 04-11
LEVODOPA: LONG-TERM IMPACT ON PARKINSONS-DISEASE.
004476 04-11
A STUDY ON MENTAL-SYMPTOMS DEVELOPED DURING THE TREATMENT
OF PARKINSONS-DISEASE.
004618 04-15
PAROTID
CONCENTRATIONS AND KINETICS OF CARBAMAZEPINE IN WHOLE
SALIVA PAROTID SALIVA, SERUM ULTRAFILTRATE, AND SERUM.
004545 04-13
PAROXYSTIC-DYSKINESIAS
PAROXYSTIC-DYSKINESIAS DURING TREATMENT WITH
DIPHENYLHYDANTOIN.
002319 02-14
PARTICIPATION
SEROTONIN PARTICIPATION IN GUT WITHDRAWAL FROM OPIATES.
000109 01-03
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPACTA AND
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE
SPONTANEOUS NEURONAL AQIVITIES IN THE RAT.
002718 03-03
PARTICLES
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
002699 03-03
PARTITIONING
PARTITIONING AND EFFLUX OF PHENOTHIAZINES FROM LIPOSOMES.
000007 01-02
PARTURIENT
ERGOT DRUGS SUPPRESS PLASMA PROLAQIN AND LAQATION BUT NOT
AGGRESSION IN PARTURIENT MICE.
003159 03-07
PASSAGE
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
ETHANOL.
003725 04-03
PASSAGE THROUGH THE BLOOD-BRAIN-BARRIER OF THYROTROPIN-
RELEASING-HORMONE ENCAPSULATED IN LIPOSOMES.
004298 04-06
PASSIVE-AVOIDANCE
SEROTONINMIMETIC AND ANTIDEPRESSANT-DRUGS ON PASSIVE-
AVOIDANCE LEARNING BY OLFAQORY BULBEQOMISED RATS.
001585 02-04
Psychopharmacology Abstracts
COMPARISONS OF THE EFFEQS OF GUANETHIDINE, 6
HYDROXYDOPAMINE AND DIETHYLDITHIOCARBAMATE ON RETENTION
OF PASSIVE-AVOIDANCE.
001742 02-04
EFFEaS OF CYCLOHEXIMIDE ADMINISTERED IN CONJUNQION WITH
NICOTINE ON RETENTION OF A PASSIVE-AVOIDANCE TASK IN MICE.
001791 02-04
MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJEQIONS OF
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS.
003101 03-04
PHOSPHODIESTERASE INHIBITORS FACILITATE MEMORY FOR PASSIVE-
AVOIDANCE CONDITIONING.
003109 03-04
EFFEaS OF ANISOMYCIN ON RETENTION OF THE PASSIVE-AVOIDANCE
HABIT AS A FUNQION OF AGE.
004097 04-04.
PATCHES
INTERCONVERTING MU AND DELTA-FORMS OF TYPE-1 OPIATE-RECEPTORS
IN THE RAT STRIATAL PATCHES.
003737 04-03'
PATHOGENESIS
THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION
PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR
PRESERVED SCHWANN-CELL SOMAL FUNQION.
002905 03-03
VARIOUS FACTORS IN THE PATHOGENESIS OF PATHOLOGICAL REAQIONS
OBSERVED IN CONNEQION WITH THE ADMINISTRATION OF
PSYCHOTROPIC-DRUGS.
003532 03-15
THE PATHOGENESIS OF STEREOTYPIC-BEHAVIOR.
004161 04-04
TARDIVE-DYSKINESIA: PROBLEMS OF PATHOGENESIS, THERAPY, AND
PREVENTION.
004644 04-15
PATHOGENETIC
NEUROLEPTIC MALIGNANT- SYNDROME: A PATHOGENETIC ROLE FOR
DOPAMINE-RECEPTOR BLOCKADE?
003492 03-15
THE COMPLEX SPECIFIC PATHOGENETIC THERAPY OF THE STEREOTYPIC-
BEHAVIOR-SYNDROME (AN EXPERIMENTAL-STUDY).
004162 04-04
POSSIBILITIES OF PATHOGENETIC THERAPY OF HYSTERIA.
004429 04-10
PATHOGENETICALLY
ACTION ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS
OF TREATING ALCOHOLISM AND DRUG AODIQION
PATHOGENETICALLY.
003641 03-17
PATHOGENIC
CORREaiON OF HORMONAL AQIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
PATHOLOGICAL
SPINOCEREBELLAR DEGENERATION WITH PARKINSONIAN FEATURES: A
CLINICAL AND PATHOLOGICAL REPORT.
003436 03-13
VARIOUS FAaORS IN THE PATHOGENESIS OF PATHOLOGICAL REAQIONS
OBSERVED IN CONNEQION WITH THE ADMINISTRATION OF
PSYCHOTROPIC-DRUGS „„o.o„«, „
003532 03-15
GERIATRIC ASPEQS OF PARKINSONISM (CLINICAL-PIQURE,
PATHOLOGICAL MECHANISMS, AND MULTIPLE TREATMENT).
003643 03-17
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL
AND PATHOLOGICAL (M. NIEMANN-PICK TYPE C) HUMAN BRAIN.
003671 04O1
PATHOLOGICAL-BEHAVIOR
PSYCHOMOTOR STIMULANTS AS AQIVATORS OF NORMAL AND
PATHOLOGICAL-BEHAVIOR: IMPLICATIONS FOR THE EXCESSES IN
MANIA. (UNPUBLISHED PAPER).
002353 02-14
PATHOLOGY
APHAGIA GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNCTIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS:
EFFEQS OF INSULIN PRETREATMENTS.
001638 02-04
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL-STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN).
002286 02-12
PATHOMORPHOLOGY ^,^,.^^
PECULIARITIES OF THE CEREBRAL PATHOMORPHOLOGY OF PATIENTS
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS
(PHARMACOLOGICAL PATHOMORPHOSIS) „„„,,.
004528 04-lJ
S-328
VOLUME 19, SUBJECT INDEX
Subject lnd«x
PATHOMORPHOSIS
PATHOMORPHOSIS OF CHRONIC EPILEPTIC-PSYCHOSES.
003209 03-09
PECULIARITIES OF THE CEREBRAL PATHOMORPHOLOGY OF PATIENTS
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS
(PHARMACOLOGICAL PATHOMORPHOSIS) .
004528 04-13
THE DRUG PATHOMORPHOSIS OF SCHIZOPHRENIA.
004732 04-17
PATHOPHYSIOLOOIC-BASIS
PATHOPHYSIOLOGIC-BASIS OF TARDIVE-DYSKINESIA.
002373 02-15
PATHOPHYSIOLOGIC-IMPACT
PATHOPHYSIOLOGIC-IMPACT OF CENTRAL CATECHOLAMINERGIC
FUNCTION IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES.
002174 02-11
PATHOPHYSIOLOGICAL
PATHOPHYSIOLOGICAL AND MORPHOLOGICAL CHANGES IN THE CNS
DURING LONG-TERM ADMINISTRATION OF HALOPERIDOL.
004633 04-15
PATHOPHYSIOLOGICAL-ASPEaS
PATHOPHYSIOLOGICAL-ASPECTS OF REVERSIBLE AND IRREVERSIBLE
TARDIVE-DYSKINESIA.
002124 02-11
PATHOPHYSIOLOGICAL-DATA
NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA: RECENT
PATHOPHYSIOLOGICAL-DATA, THERAPEUTIC TRIALS.
000842 01-15
PATHOPHYSIOLOGICAL-STUDIES
PATHOPHYSIOLOGICAL-STUDIES ON SCHIZOPHRENIA WITH SPECIAL
REFERENCE TO HOMOVANILLIC-ACID CONCENTRATION IN
CEREBROSPINAL-FLUID.
000271 01-03
PATHWAY
EVIDENCE FOR A GABAERGIC NIGROTHALAMIC PATHWAY IN THE RAT: I.
BEHAVIOURAL-STUDIES AND BIOCHEMICAL-STUDIES.
000158 01-03
INTERACTIONS OF NEUROPEPTIDES WITH CHOLINERGIC
SEPTOHIPPOCAMPAL PATHWAY: INDICATION FOR A POSSIBLE
TRANSSYNAPTIC REGULATION. (UNPUBLISHED PAPER).
001062 02-01
GLYCINE ENHANCEMENT OF CAUDATE NEURONAL ACTIVITIES:
RELATIONSHIP WITH THE DOPAMINERGIC NIGROSTRIATAL PATHWAY.
001225 02-03
THE STRIATONIGRAL GABA PATHWAY: FUNCTIONAL AND
NEUROCHEMICAL CHARACTERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
PHASIC AQIVITY INDUCED BY P CHLOROPHENYLALANINE IN THE
AUDITORY PATHWAY.
002661 03-03
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY
STUDY.
003085 03-04
DOPAMINE-RECEPTOR CHANGES FOLLOWING DESTRUCTION OF THE
NIGROSTRIATAL PATHWAY: LACK OF A RELATIONSHIP TO
ROTATIONAL-BEHAVIOR.
004229 04-04
PATHWAYS
IN VITRO AUTORADIOGRAPHY OF OPIATE-RECEPTORS IN RAT-BRAIN
SUGGESTS LOCI OF OPIATE-ERGIC PATHWAYS. (UNPUBLISHED PAPER)
001025 02-01
EFFEQ OF ANTICONVULSANT-DRUGS ON INHIBITORY AND EXCITATORY
PATHWAYS.
002724 03-03
PATIENT
HOW TO SUCCESSFULLY CHANGE A PATIENT FROM ONE DRUG TO
ANOTHER.
000913 01-17
THE LITHIUM RATIO AS A GUIDE TO PATIENT COMPLIANCE.
000940 01-17
EDEMAS AND MYOCLONIES IN A PATIENT WITH PARKINSONS-DISEASE
TREATED BY AMANTADINE: PROBLEM WITH ASSOCIATED
MEDICATIONS.
002389 02-15
MONOAMINE-OXIDASE-INHIBITORS: PRESCRIPTION AND PATIENT
MANAGEMENT.
,.„„ 002454 02-15
FACTORS DETERMINING PATIENT TENURE ON A 3-YEAR DOUBLE-BUND
INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE-HCL.
002513 02-17
COMPARISON OF STANDARD AND HOLTOR-MONITORED EKGS IN A
PATIENT TREATED WITH SEVERAL ANTIDEPRESSANTS.
003304 03-11
PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND
DEMENTIA.
003347 03-11
ARRHYTHMIA INDUCED BY A TRICYCLIC-ANTIDEPRESSANT IN A PATIENT
WITH UNDIAGNOSED MITRAL-VALVE PROLAPSE.
003521 03-15
LITHIUM KINETICS DURING HEMODIALYSIS IN A PATIENT WITH LITHIUM
POISONING.
003524 03-15
PATIENT CHARACTERISTICS AND CLINICIAN ATTITUDES INFLUENCING THE
PRESCRIBING OF BENZODIAZEPINES.
003598 03-17
ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CLINICAL STAFF
IN DETERMINING MEDICATION COMPLIANCE.
003618 03-17
THE INFLUENCE OF PATIENT BELIEFS ON COMPLIANCE TO THERAPY FOR
DIABETES-MELLITUS. (PH.D. DISSERTATION).
003631 03-17
FLURAZEPAM-INDUCED SLEEP-APNEA-SYNDROME IN A PATIENT WITH
INSOMNIA AND MILD SLEEP-RELATED RESPIRATORY CHANGES.
004729 04-17
PATIENTS
EEG IN PATIENTS TREATED WITH LITHIUM.
000593 01-09
COGNITIVE AND AFFECTIVE-FUNCTIONS IN PATIENTS WITH AFFECTIVE-
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY
QUESTIONNAIRE.
000604 01-09
IMPAIRED GLUCOSE TOLERANCE IN LONG-TERM LITHIUM TREATED
PATIENTS.
000611 01-09
THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH
DEPRESSIVE-SYNDROMES.
000625 01-09
DECREASED UPTAKE OF 5 HYDROXYTRYPTAMINE IN BLOOD-PLATELETS
FROM PATIENTS WITH ENDOGENOUS DEPRESSION.
000637 01-09
ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLED-
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH
PARKINSONS-DISEASE TREATED WITH L-DOPA.
000659 01-11
ELECTRORETINOGRAPHIC-CHANGES IN PATIENTS WITH PARKINSONISM
TREATED WITH VARIOUS CLASSES OF ANTIPARKINSONIAN-DRUGS.
000674 01-11
THE LONG-TERM RESULTS OF STEREOTAXIC SURGERY AND L-DOPA
THERAPY IN PATIENTS WITH PARKINSONS-DISEASE: A 10-YEAR
FOLLOWUP STUDY.
000693 01-11
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH
ANTIEPILEPTIC-DRUGS.
000695 01-11
EFFICACY AND PATTERN VALENCE OF PSYCHOAQIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER.
000699 01-11
IDENTIFICATION OF A SUBGROUP OF TARDIVE-DYSKINESIA PATIENTS BY
PHARMACOLOGIC-PROBES.
000708 01-11
RAPID CONTROL OF ACUTE PATIENTS THROUGH THE ADMINISTRATION OF
HALOPERIDOL.
000818 01-14
ASSESSMENT OF MULTIVARIATE RELATIONSHIPS IN REACTIVITY OF
PATIENTS RECEIVING LITHIUM THERAPY.
000819 01-14
RENAL FUNCTION AND BIOPSY IN PATIENTS ON LITHIUM THERAPY.
000830 01-15
RENAL FUNCTION IN LITHIUM AND NONLITHIUM TREATED PATIENTS
WITH AFFECTIVE-DISORDERS.
000837 01-15
STRATEGY FOR THE STUDY OF PATIENTS AT HIGH-RISK FOR TARDIVE-
DYSKINESIA.
000858 01-15
AGITATION, DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON
CIMETIDINE: A REPORT OF THREE CASES AND LITERATURE REVIEW.
000896 01-15
ENDOCRINOLOGICAL CHANGES IN PATIENTS WITH SEXUAL-DYSFUNCTION
UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000912 01-17
CONSIDER THIS ... PSYCHOTROPIC-MEDICATIONS AND THEIR EFFECTS ON
PATIENTS.
000967 01-17
ACTH4-10 AND MEMORY IN ECT TREATED AND UNTREATED PATIENTS. I.
EFFECT ON CONSOLIDATION.
001982 02-09
ACTH4-10 AND MEMORY IN ECT TREATED PATIENTS AND UNTREATED
CONTROLS. II. EFFECT ON RETRIEVAL.
001983 02-09
INCREASED VULNERABILITY TO CHOLINERGIC STIMULATION IN
AFFEQIVE-DISORDER PATIENTS.
002003 02-09
S-329
Subject Index
Ptychopharmacology Abstracts
ii
M
flft
S:
CLINICAL-CORRELATION, BIOCHEMICAL-CORRELATION, AND
PSYCHOPHARMACOLOGICAL-CORRELATION IN PATIENTS WITH
DEPRESSIVE-SYMPTOMATOLOGY.
0020)8 02-09
ELECTROENCEPHALOGRAPHIC-EFFECTS AND BEHAVIOURAL-EFFECTS OF
SODIUM-VALPROATE IN PATIENTS WITH PHOTOSENSITIVE EPILEPSY. A
SINGLE-DOSE TRIAL.
002154 02-11
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT;
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL
EVOLUTION.
002165 02-11
PHARMACOKINETICS OF DIPOTASSIUM-CHLORAZEPATE IN PATIENTS
AFTER REPEATED 50MG ORAL DOSES.
002211 02-13
EFFECT OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND
NORMAL ADULTS.
002222 02-13
SALIVARY IMMUNOGLOBULIN CONCENTRATIONS IN PATIENTS WITH
EPILEPSY TREATED WITH CARBAMAZEPINE.
002234 02-13
METABOLISM OF DIMETHOXYMETHYL-PHENOBARBITAL (ETEROBARB) IN
PATIENTS WITH EPILEPSY.
002235 02-13
ABNORMALITIES OF LITHIUM TRANSPORT IN PATIENTS WITH AFFEQIVE-
DISORDERS.
002269 02-13
ORAL ALUMINUM AND NEUROPSYCHOLOGICAL FUNQIONING: A STUDY
OF DIALYSIS PATIENTS RECEIVING ALUMINUM-HYDROXIDE GELS.
002283 02-13
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL
HEMORRHAGE PATIENTS.
002295 02-13
EUHYPNOS-FORTE, HIGH-DOSE TEMAZEPAM FOR RESISTANT INSOMNIA:
POSTMARKETING SURVEILLANCE IN 10,057 PATIENTS UNRESPONSIVE
TO CONVENTIONAL HYPNOTIC DOSAGE.
002324 02-14
INTRAVENOUS CHLORIMIPRAMINE AFFEQS REM CYCLE IN PATIENTS
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS.
002341 02-14
BROMOCRIPTINE IN PARKINSONS-DISEASE: REPORT ON 106 PATIENTS
TREATED FOR UP TO 5 YEARS.
002342 02-14
DEPRENYL IN THE MANAGEMENT OF RESPONSE FLUCTUATIONS IN
PATIENTS WITH PARKINSONS-DISEASE ON LEVODOPA
002358 02-14
EFFEQS OF CYCLOSPASMOL UPON SENSORY PARAMETERS IN PATIENTS
RECOVERING FROM CEREBROVASCULAR-ACCIDENTS.
002360 02-14
SUBJECTIVE ASSESSMENT OF SEXUAL-DYSFUNCTION OF PATIENTS ON
LONG-TERM ADMINISTRATION OF DIGOXIN.
002443 02-15
CLASSIFICATION OF DRUGS AND PATIENTS TO ACHIEVE MAXIMUM
THERAPEUTIC RESPONSE.
002560 02-17
HYPOMANIA AS A STABLE STATE: LITHIUM PROPHYLAXIS IN TWO
PATIENTS.
003212 03-09
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERAQIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNQURES
IN THIS PHASE.
003251 03-09
EFFECT OF LITHIUM ON PROLACTIN RESPONSES TO THYROTROPIN-
RELEASING-HORMONE IN PATIENTS WITH MANIC-STATE.
003266 03-09
HYPNOTIC ACTION OF FLUNITRAZEPAM (ROCHES ROIPNOL) IN PATIENTS
WITH SEVERE PSYCHIATRIC-DISORDERS.
003295 03-1 1
EFFICACY OF CLONIDINE IN OPIATE WITHDRAWAL: A STUDY OF THIRTY
PATIENTS.
003317 03-11
THE USE OF LITHIUM-CARBONATE FOR TREATING KUGELBERG-WELANDER
SPINAL AMYOTROPHY PATIENTS.
003326 03-1 1
A DOUBLE-BUND, PUVCEBO-CONTROLLED, CROSS-OVER TRIAL OF
CARBAMAZEPINE IN OVERACTIVE, SEVERELY MENTALLY-
HANDICAPPED PATIENTS.
003365 03-1 1
THE EFFECT OF AMANTADINE ON PROLAQIN LEVELS AND
GALACTORRHEA ON NEUROLEPTIC TREATED PATIENTS.
003373 03-1 1
USE OF THA IN TREATMENT OF ALZHEIMER-LIKE DEMENTIA: PILOT-STUDY
IN TWELVE PATIENTS.
003377 03-1 1
THE EFFECTS OF LECITHIN ON MEMORY IN PATIENTS WITH SENILE-
DEMENTIA OF THE ALZHEIMERS-TYPE.
003385 03-1 1
PROPRANOLOL IN THE TREATMENT OF RAGE AND VIOLENT-BEHAVIOR IN
PATIENTS WITH CHRONIC-BRAIN-SYNDROMES.
003394 03-1 1
EFFECT OF SODIUM-LAQATE ON PATIENTS WITH PANIC-DISORDER AND
MITRAL- VALVE PROLAPSE.
003409 03-13
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION. i
003419 03-13
THA ~ A REVIEW OF THE LITERATURE AND ITS USE IN TREATMENT OF
FIVE OVERDOSE PATIENTS.
003539 03-15
EFFEaS OF ANESTHESIA ON PATIENTS TAKING PSYCHOTROPIC-DRUGS.
003603 03-17
THE PROLACTIN RESPONSE IN PATIENTS RECEIVING NEUROLEPTIC
THERAPY. THE EFFEQ OF FLUPHENAZINE-DECANOATE.
004318 04-08
PRELIMINARY TRIAL OF CLONIDINE TREATMENT IN TWO PATIENTS
SUFFERING FROM CHRONIC SCHIZOPHRENIA.
004320 04-08
DES-TYROSYL-GAMMA-ENDORPHIN IN SCHIZOPHRENIA: A DOUBLE-BLIND
TRIAL IN 13 PATIENTS.
004322 04-08
PREVALENCE OF PERSISTENT ABNORMAL INVOLUNTARY-MOVEMENTS
AMONG PATIENTS IN A NIGERIAN LONG-STAY PSYCHIATRIC UNIT.
004334 04-08
PLASMA LEVELS OF THE CIS-ISOMERS AND TRANS-ISOMERS OF DOXEPIN
AND DESMETHYLDOXEPIN AFTER ADMINISTRATION OF DOXEPIN TO
PATIENTS.
004355 04-09
THE EFFEa OF NALOXONE ON THE CONDITION OF PATIENTS WITH
ENDOGENOUS PSYCHOSES.
004381 04-09
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH
ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT.
004382 04-09
CORRECTION OF THE EXTRAPYRAMIDAL NEUROLEPTIC-SYNDROME BY
TRYPTOPHAN AND THE TIME-COURSE OF ITS CONTENT IN THE BLOOD
OF PATIENTS
004434 04-11
METHADONE USE IN PATIENTS WITH CHRONIC RENAL-DISEASE.
004467 04-11
CLINICAL PHARMACOKINETICS OF CHLORDIAZEPOXIDE IN PATIENTS WITH
ALCOHOLIC HEPATITIS.
004473 04-11
THE EFFICACY OF PIRACETAM IN VERTIGO: A DOUBLE-BUND STUDY IN
PATIENTS WITH VERTIGO OF CENTRAL ORIGIN.
004478 04-11
INFLUENCE OF CARBAMAZEPINE ON SERUM THYROXINE AND
TRIIODOTHYRONINE IN PATIENTS WITH EPILEPSY.
004488 04-11
HORMONAL STIMULATION AFTER INJEQION OF THYROTROPHIN-
RELEASING-FAQOR (TRF) AND AaHl-24 IN PATIENTS FOLLOWING
CHRONIC-TREATMENT WITH NEUROLEPTICS: PREUMINARY- STUDY.
004505 04-13
PECUUARITIES OF THE CEREBRAL PATHOMORPHOLOGY OF PATIENTS
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS
(PHARMACOLOGICAL PATHOMORPHOSIS).
004528 04-13
VARIATIONS IN URINARY LEVELS OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN PATIENTS WITH DEPRESSIVE-
SYNDROMES.
004533 04-13
THE AaiVITY OF DOPAMINE-BETA-HYDROXYLASE IN THE PLASMA OF
PATIENTS WITH ENDOGENOUS DEPRESSIVE- SYNDROMES.
004548 04-13
ACUTE EFFEa OF DRUGS UPON MEMORY OF PATIENTS WITH SENILE-
DEMENTIA.
004561 04-14
CORREQION OF HORMONAL AQIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
EFFECT OF UTHIUM ON GLYCINE LEVELS IN PATIENTS WITH AFFEQIVE-
DISORDERS.
004606 04-15
KIDNEY FUNaiON IN PATIENTS WITH AFFEQIVE-DISORDERS WITH AND
WITHOUT UTHIUM THERAPY.
004664 04-15
PATTERN
EFFICACY AND PAHERN VALENCE OF PSYCHOAQIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPUED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER.
000699 01-11
SENSORY PROCESSING, CARDIOVASCULAR REAQIVITY, AND THE TYPE A
CORONARY-PRONE BEHAVIOR PAHERN.
003405 03-13
S-330
VOLUME 19, SUBJECT INDEX
Subject Index
PATTERNED
POSSIBLE MUSCARINIC CHOLINERGIC MEDIATION OF PAHERNED
AGGRESSIVE REFLEXES IN THE CAT.
004153 04-04
PATTERNINO
TEMPORAL PATTERNING OF NEURONAL ACTIVITY DURING THERMAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
PATTERNS
CHRONIC USE OF TRIAZOLAM; THE EFFECTS ON THE SLEEP PATTERNS OF
INSOMNIACS.
0007)0 01-11
A NOTE ON PAHERNS OF DRUG PRESCRIBING IN A RESIDENTIAL-CENTER
FOR THE INTELLEQUALLY-HANDICAPPED.
000982 01-17
STRYCHNINE EFFECTS ON THE SENSORY RESPONSE PAHERNS OF
RETICULAR FORMATION NEURONS.
001219 02-03
SOME ODD PAHERNS OF PSYCHOTROPIC SELF-MEDICATION.
002565 02-17
PAHERNS OF USE IN THE INTAKE OF ORAL MEDICATION.
002591 02-17
CEREBROSPINAL-FLUID HOMOVANILLIC-ACID PAHERNS DURING
NEUROLEPTIC TREATMENT. (UNPUBLISHED PAPEfe).
004502 04-13
PAVING
PAVING THE WAY TO SAFE PRESCRIBING FOR THE ELDERLY.
000999 01-17
PAVLOVIAN-CONDITIONING
EFFECTS OF PAVLOVIAN-CONDITIONING AND MIF-1 ON THE
DEVELOPMENT OF MORPHINE-TOLERANCE IN RATS.
001327 02-03
PERIPHERAL AUTONOMIC-MECHANISMS AND PAVLOVIAN-CONDITIONING
IN THE RABBIT (ORYCTOLAGUS-CUNICULUS).
001560 02-04
PERIPHERAL 6 HYDROXYDOPAMINE ADMINISTRATION IN THE RABBIT
(ORYaOLAGUS-CUNICULUS): EFFECTS ON PAVLOVIAN-CONDITIONING.
001668 02-04
PA2
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED
MICE.
002800 03-03
PC43-14
STUDY OF THE EFFECTS OF PC-63-14 ON THE QUANTIFIED EEG.
003403 03-13
PCP
ISSUES FOR INPATIENT TREATMENT OF CHRONIC PCP ABUSE.
000736 01-12
HISTORY AND PHARMACOLOGY OF PCP AND PCP RELATED ANALOGS.
000737 01-12
THE PCP PSYCHOSIS: PROLONGED INTOXICATION OR DRUG PRECIPITATED
FUNQIONAL ILLNESS?
000739 01-12
EPIDEMIOLOGY OF PCP ABUSE: THE MIDWEST PERSPECTIVE.
000740 01-12
THE EPIDEMIOLOGY OF PCP USE IN THE LATE 1970S.
000741 01-12
STREET PCP SCENE: ISSUES ON SYNTHESIS AND CONTAMINATION.
000744 01-12
PCP AND SEXUAL-DYSFUNCTION.
000745 01-12
PCP ABUSE: DIAGNOSTIC AND PSYCHOPHARMACOLOGICAL-TREATMENT
APPROACHES.
000746 01-12
OUTPATIENT TREATMENT ISSUES AND STRATEGIES FOR ACUTE AND
CHRONIC PCP ABUSERS.
000919 01-17
PARAPROFESSIONAL AND PROFESSIONAL TEAMWORK AND TRAINING IN
MANAGING PCP AND OTHER DRUG-ABUSE PROBLEMS.
000924 01-17
CHRONIC PHENCYCLIDINE (PCP) ABUSE: A PSYCHIATRIC-PERSPEQIVE.
000935 01-17
PCP AND VIOLENT CRIME: THE PEOPLE VS. PEACE.
000986 01-17
PHENaCLIDINE (PCP) AND DERIVATIVES: PHARMACOLOGY AND
STRUCTURE-AQIVITY RELATIONSHIPS.
001706 02-04
PHENCYCLIDINE (PCP) INTOXICATION: DIAGNOSIS IN STAGES AND
ALGORITHMS OF TREATMENT.
003525 03-15
ACUTE PHENCYCLIDINE (PCP) INTOXICATION: QUANTITATIVE URINE
LEVELS AND CLINICAL MANAGEMENT.
„.^, 004665 04-15
^EACE
PCP AND VIOLENT CRIME: THE PEOPLE VS. PEACE.
000986 01-17
DECKING
EFFEQS OF APOMORPHINE ON ELICITED AND OPERANT PECKING IN
PIGEONS.
001557 02-04
PECKING-BEHAVIOR
APOMORPHINE: EFFECTS ON THE TIMING AND SEQUENCING OF PECKING-
BEHAVIOR IN CHICKS.
000428 01-04
PECULIARITIES
PHARMACOLOGICAL PECULIARITIES OF A BENZODIAZEPINE/ATARACTIC-
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF
CLORAZEPATE-DIPOTASSIUM (TRANXILIUM) .
004527 04-13
PECULIARITIES OF THE CEREBRAL PATHOMORPHOLOGY OF PATIENTS
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS
(PHARMACOLOGICAL PATHOMORPHOSIS) .
004528 04-13
PEDIATRIC-PRACTICE
PSYCHOPHARMACEUTICALS IN PEDIATRIC-PRACTICE.
003491 03-15
PEDIATRIC-PSYCH0PHARMAC0L06Y
CLASSIFICATION OF PSYCHOTROPIC-DRUGS IN PEDIATRIC-
PSYCHOPHARMACOLOGY.
001903 02-07
PEDIATRICS
CHILD-PSYCHIATRY AND PSYCHOPHARMACOTHERAPY IN GENERAL
PRACTICE, IN PEDIATRICS, AND IN NEUROLOGY.
003288 03-11
PELLET
ASSESSMENT OF TOLERANCE TO AND PHYSICAL-DEPENDENCE ON
PENTOBARBITAL, INDUCED BY MULTIPLE PELLET IMPLANTATION.
000385 01-04
A SILICONE PELLET FOR LONG-TERM CONTINUOUS ADMINISTRATION OF
AMPHETAMINE.
001875 02-06
PELLETS
ANALGESIC TOLERANCE PRODUCED BY MORPHINE PELLETS IS
FACILITATED BY ANALGESIC TESTING.
002943 03-04
ENVIRONMENTAL MODULATION OF ANALGESIC TOLERANCE INDUCED BY
MORPHINE PELLETS.
002944 03-04
PEMOLINE
THE USE OF SENSORY INTEGRATIVE DIAGNOSTICS TO PREDICT
HYPERACTIVE-CHILDRENS RESPONSIVENESS TO METHYLPHENIDATE
(RITALIN) AND PEMOLINE (CYLERT). (PH.D. DISSERTATION).
002133 02-11
GILLES-DE-LA-TOUREHES-DISORDER ASSOCIATED WITH PEMOLINE.
002436 02-15
PEMOLINE-INDUCED
PEMOLINE-INDUCED SELF-BITING IN RATS AND SELF-MUTILATION IN THE
DELANGE-SYNDROME.
001727 02-04
PEMOLINE-INDUCED CHOREA.
003516 03-15
PENETRATION
OXAZEPAM-ESTERS. 2. CORRELATION OF HYDROPHOBICITY WITH SERUM
BINDING, BRAIN PENETRATION, AND EXCRETION.
OOOOn 01-02
PENFLURIDOL
INCREASED MESOLIMBIC 3H SPIROPERIDOL BINDING IN 4 WEEK OLD
OFFSPRING OF NURSING RAT MOTHERS TREATED WITH PENFLURIDOL.
000087 01-03
PLASMA PROLACTIN AND TESTOSTERONE DURING PENFLURIDOL
TREATMENT.
000874 01-15
PENFLURIDOL IN THE TREATMENT OF GILLES-DE-LA-TOUREHES-
SYNDROME.
002158 02-11
PENICILLIN-INDUCED
ELECTRICAL-AQIVITY AND NA-K-ATPASE LEVEL IN THE PENICILLIN-
INDUCED EPILEPTOGENIC-FOCUS OF THE RAT-BRAIN-CORTEX, AND THE
EFFECT OF DIAZEPAM.
003070 03-04
PENILE-TUMESCENCE
DISULFIRAM AND NOQURNAL PENILE-TUMESCENCE IN THE CHRONIC
ALCOHOLIC.
004556 04-13
PENTAGASTRIN-STIMULATED
INHIBITION OF PENTAGASTRIN-STIMULATED AND OVERNIGHT GASTRIC
SECRETION BY LM24056, A NEW PHENOTHIAZINE DERIVED
ANTISECRETORY DRUG.
004306 04-07
PENTAZOCINE
INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH PENTAZOCINE:
REVERSAL BY NALTREXONE.
000318 01-03
EFFECTS OF CENTRALLY-ADMINISTERED PENTAZOCINE AND
ETHYLKETOCYCUZOCINE ON THERMOREGULATION IN THE CAT.
000361 01-04
THE ANALGESIC AND RESPIRATORY EFFEQS OF MEPTAZINOL, MORPHINE
AND PENTAZOCINE IN THE RAT.
000516 01-05
S-331
Subject Index
Psychopharmacology Abstracto
;Sli
a«
ll
Slilit
Hit;
^
POTENTIATION OF LETHALITY IN MICE BY COMBINATIONS OF
PENTAZOCINE AND TRIPELENNAMINE.
000529 01-05
MEDICAL AND PSYCHIATRIC-COMPLICATIONS OF PENTAZOCINE AND
TRIPELENNAMINE ABUSE.
000955 01-17
EFFECTS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN
COMBINATION WITH NALOXONE ON ELEQRIC-SHOCK TITRATION IN
THE SQUIRREL-MONKEY.
001611 02-04
ANTINOCICEPTIVE AQION OF MORPHINE AND PENTAZOCINE ON UNIT
AQIVITY IN THE NUCLEUS-CENTRALIS-LATERALIS. NUCLEUS-
VENTRALIS-LATERALIS AND NEARBY STRUCTURES Of THE CAT.
002837 03-03
EFFEQS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETECT THE NARCOTIC CHARAQER OF A DRUG.
003555 03-16
ANTAGONISM BY PHENOXYBENZAMINE AND PENTAZOCINE OF THE
ANTINOCICEPTIVE-EFFECTS OF MORPHINE IN THE SPINAL-CORD.
004213 04-04
PENTIFYLLINE
THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REACTION
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN.
001052 02-01
PENTOBARBITAL
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
BEHAVIOR-DEPENDENT EVOKED-POTENTIALS IN THE HIPPOCAMPAL-CAl
REGION OF THE RAT. II. EFFEaS OF ESERINE, ATROPINE, ETHER AND
PENTOBARBITAL.
000184 01-03
(-)PENTOBARBITAL OPENS ION-CHANNELS OF LONG-DURATION IN
CULTURED MOUSE SPINAL NEURONS.
000198 01-03
PENTOBARBITAL POTENTIATES GABA-ENHANCED (3H) DIAZEPAM
BINDING TO BENZODIAZEPINE-RECEPTORS.
000275 01-03
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
DEXAMETHASONE TREATMENT.
000321 01-03
TOLERANCE TO SUPPRESSIVE EFFEaS OF CHLORDIAZEPOXIDE ON
OPERANT-BEHAVIOR: LACK OF CROSS-TOLERANCE TO PENTOBARBITAL.
000356 01-04
ASSESSMENT OF TOLERANCE TO AND PHYSICAL-DEPENDENCE ON
PENTOBARBITAL, INDUCED BY MULTIPLE PELLET IMPLANTATION.
000385 01-04
JOINT-EFFECTS OF D-AMPHET AMINE AND ETHANOL OR PENTOBARBITAL
IN PIGEONS.
000403 01-04
IMPROVEMENT OF RESTITUTION FROM CEREBRAL ISCHEMIA IN
HYPERGLYCEMIC RATS BY PENTOBARBITAL OR DIAZEPAM.
000475 01-04
IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM
INGESTION OF ETHANOL, TERTIARY BUTANOL, OR PENTOBARBITAL IN
MICE.
000479 01-04
A COMPARISON OF THE EFFEaS OF D-AMPHETAMINE, COCAINE,
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE.
000508 01-04
AUTOCORRELATION ANALYSIS OF SINGLE NEURON AQIVITY AFTER
ADMINISTRATION OF PENTOBARBITAL.
001268 02-03
EFFEaS OF MORPHINE, D-AMPHETAMINE, AND PENTOBARBITAL ON
SHOCK AND LIGHT DISCRIMINATION PERFORMANCE IN RATS.
001639 02-04
DISCRIMINATIVE-STIMULUS EFFEQS OF PENTOBARBITAL IN PIGEONS.
001651 02-04
THE EFFECTS OF D-AMPHETAMINE, CHLORDIAZEPOXIDE, AND
PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM
PUNISHMENT IN PIGEONS. (PH.D. DISSERTATION).
001713 02-04
EFFEQS OF PHENCYCLIDINE, PENTOBARBITAL, AND D-AMPHETAMINE ON
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL
DISCRIMINATIONS IN MONKEYS.
001723 02-04
GABA-RECEPTORS AND THE DEPRESSANT ACTION OF PENTOBARBITAL.
002666 03-03
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND
DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY
OF ADULT SENSORY GANGLION CELLS.
002692 03-03
PENTOBARBITAL: DUAL-ACTIONS TO INCREASE BRAIN BENZODIAZEPINE-
RECEPTOR AFFINITY.
002896 03-03
OPIATE-RECEPTORS AND SLEEP. II. EFFECTS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUCTAL GRAY MAHER AND NUCLEUS-TRACTUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
A COMPARATIVE-STUDY ON THE CLINICAL-EFFECTS OF RECTAL
DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP
BETWEEN PLASMA LEVEL AND EFFECT.
003330 03-11
EFFECT OF FLURAZEPAM, PENTOBARBITAL, AND CAFFEINE ON AROUSAL
THRESHOLD.
003439 03-14
EFFECTS OF PENTOBARBITAL AND ETHANOL UPON SINGLE NEURON
ACTIVITY IN THE PRIMARY SOMATOSENSORY CORTEX OF THE RHESUS-
MONKEY.
003755 04-03
EFFECT OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF
TOLERANCE TO THE HYPNOTIC-EFFECTS OF PENTOBARBITAL, BARBITAL,
AND ETHANOL.
003883 04-03
DIFFERENTIAL-EFFECTS OF PENTOBARBITAL AND ETHER ON THE SYNAPTIC
TRANSMISSION OF THE HIPPOCAMPAL-CAl -REGION IN THE RAT.
003903 04-03
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFECTS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
RESPONSE.
004119 04-04
DRUG PREFERENCE IN HUMANS: DOUBLE-BUND CHOICE COMPARISON OF
PENTOBARBITAL, DIAZEPAM AND PLACEBO.
004566 04-14
PENTOBARBITAL-INDUCED
NALOXONE REVERSAL OF THE PENTOBARBITAL-INDUCED BLOCKADE OF
OVULATION IN THE RAT.
002817 03-03
PENTOBARBITONE
FREE DESCRIPTION OF DRUG-EFFECTS AS A METHOD OF CLINICAL-TRIAL,
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND
THEIR COMBINATION.
002561 02-17
PENTOBARBITONE-INDUCED
THE EFFECT OF FLA-63 ON PENTOBARBITONE-INDUCED SLEEP IN THE
CHICK.
001741 02-04
PENTYLAMINE
N PENTYLAMINE: EFFECT ON MOTOR-ACTIVITY OF MICE.
000500 01-04
PENTYLENETETRAZOL
DISSIMILAR EFFECTS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE.
000173 01-03
PENTYLENETETRAZOL SEIZURE THRESHOLD: A QUANTITATIVE MEASURE
OF ETHANOL DEPENDENCE IN RATS.
001750 02-04
THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT.
(PH.D. DISSERTATION).
003092 03-04
SPECIFIC AND NONSPECIFIC MULTIPLE UNIT ACTIVITIES DURING
PENTYLENETETRAZOL SEIZURES. I. ANIMALS WITH ENCEPHALE ISOLE.
004046 04-03
RELATIONSHIP BETWEEN PENTYLENETETRAZOL-INOUCED SEIZURES AND
BRAIN PENTYLENETETRAZOL LEVELS IN MICE.
004061 04-03
ON SOME RELATIONSHIPS BETWEEN GABAERGIC AND 5 HT-ERGIC
MECHANISMS IN PENTYLENETETRAZOL CONVULSIVE-SEIZURE
REACTIONS.
004166 04-04
PENTYLENETETRAZOL-INOUCED
EFFECTS OF KINDLING OR BRAIN-STIMULATION ON PENTYLENETETRAZOL-
INOUCED CONVULSION SUSCEPTIBILITY.
000037 01-03
INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN
SUBCELLULAR GANGLIOSIDES: EFFECT OF PENTYLENETETRAZOL-
INOUCED CONVULSIONS IN BRAIN GANGLIOSIDES
002937 03-03
RELATIONSHIP BETWEEN PENTYLENETETRAZOL-INOUCED SEIZURES AND
BRAIN PENTYLENETETRAZOL LEVELS IN MICE.
004061 04-03
PEOPLE
PCP AND VIOLENT CRIME: THE PEOPLE VS. PEACE.
000986 01-17
S-332
VOLUME 19, SUBJECT INDEX
Subjact lnd«x
PfPTIC-ULCERS
STUDIES ON THE COMPREHENSIVE MEDICAL TREATMENT OF PEPTIC-
ULCERS (3) - UTILIZATION OF TRANQUILIZERS IN THE TREATMENT OF
GASTRIC-ULCERS.
000653 01-10
PEPTIDE
BIOCHEMICAL-CHARACTERIZATION AND PHARMACOLOGICAL
CHARACTERIZATION OF A PEPTIDE FROM THE HEMODIALYSATE OF
PSYCHOTIC-PATIENTS.
001049 02-01
EFFECTS OF AN ACTH4-9 RELATED PEPTIDE UPON INTRACRANIAL SELF-
STIMULATION AND GENERAL-ACTIVITY IN THE RAT.
001679 02-04
OPIATE AND PEPTIDE INTERACTION: EFFECT OF ENKEPHALINS ON
MORPHINE ANALGESIA.
001698 02-04
TRIAL OF A PEPTIDE FRACTION OF ACTH (ACTH4-10) IN THE ALCOHOLIC
BRAIN-DAMAGE-SYNDROME .
002318 02-14
STIMULATION OF RETINAL ADENYLATE-CYCLASE BY VASOACTIVE
INTESTINAL PEPTIDE (VIP).
002811 03-03
DYNORPHIN: A POSSIBLE MODULATORY PEPTIDE ON MORPHINE OR BETA
ENDORPHIN ANALGESIA IN MOUSE.
002994 03-04
ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN AHENTION-
DYSFUNCTION TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA.
004316 04-08
PEPTIDE-HORMONES
EXTRAHYPOTHALAMIC DISTRIBUTIONS AND FUNQIONS OF
HYPOTHALAMIC PEPTIDE-HORMONES. (UNPUBLISHED PAPER).
001211 02-03
ON MONOAMINERGIC-INTERAQION WITH BEHAVIOUR MODIFYING
PEPTIDE-HORMONES.
004700 04-17
PEPTIDERGIC
CENTRAL AMINERGIC AND PEPTIDERGIC MECHANISMS IN
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS. (UNPUBLISHED
PAPER).
001459 02-03
PEPTIDES
EFFEQS OF CHOLECYSTOKININ-LIKE PEPTIDES ON REARING ACTIVITY AND
HEXOBARBITAL-INDUCED SLEEP.
000507 01-04
PEPTIDES IN NEUROBIOLOGY: AN OVERVIEW. (UNPUBLISHED PAPER).
001008 02-01
INTERAaiONS BETWEEN MORPHINE AND THE OPIOID-LIKE PEPTIDES IN
THE RAT VAS-DEFERENS.
001290 02-03
STUDIES ON THE EFFECT OF ALPHA MELANOCYTE- STIMULATING-
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P
AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED
PAPER).
001372 02-03
COMPARATIVE-STUDY ON THE EFFEQ OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS; STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS.
002757 03-03
THE EFFEaS OF PEPTIDES ON TOLERANCE TO THE CATALEPTIC-EFFECTS
AND HYPOTHERMIC-EFFECTS OF MORPHINE IN THE RAT.
004072 04-04
AQH-LIKE PEPTIDES, PITUITARY ADRENOCORTICAL FUNQION AND
AVOIDANCE-BEHAVIOR.
004109 04-04
PERAZINE
THE CONTRIBUTION OF ALPHA 1 ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN.
002214 02-13
BINDING OF PERAZINE TO ALPHA 1 ACID GLYCOPROTEIN.
002290 02-13
PERCEPTUAL-EFFECTS
AN ANALYSIS OF SOME PERCEPTUAL-EFFECTS OF MORPHINE,
CHLORPROMAZINE, AND LSD.
001652 02-04
PERFORMANCE
EFFEaS OF CHLORDIAZEPOXIDE AND DIAZEPAM ON FEEDING
PERFORMANCE IN A FOOD PREFERENCE TEST.
000367 01-04
EFFEQS OF APOMORPHINE ON ESCAPE PERFORMANCE AND AQIVITY IN
DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6
OHDA).
000426 01-04
OPEN-FIELD PERFORMANCE OF RATS AFTER ENDOTOXIN TREATMENT.
000473 01-04
AROUSAL AND SHORT-TERM MEMORY: EFFEaS OF CAFFEINE AND TRIAL
SPACING ON DELAYED ALTERNATION PERFORMANCE.
000487 01-04
THE INFLUENCE OF LITHIUM-CARBONATE ON MOOD AND PERFORMANCE
IN HEALTHY SUBJEQS.
000711 01-11
THE DIFFERENTIAL-EFFECTS OF SHORT-ACTING AND LONG-ACTING
BENZODIAZEPINES UPON NOCTURNAL SLEEP AND DAYTIME
PERFORMANCE.
000822 01-14
THE EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ALONE AND IN
COMBINATION WITH CANNABIDIOL ON FIXED-INTERVAL
PERFORMANCE IN RHESUS-MONKEYS.
001582 02-04
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH
PSYCHOSTIMULANTS: II. EFFECT OF METHAMPHETAMINE ON
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC
SUBSTRATES.
001613 02-04
EFFECTS OF MORPHINE, D-AMPHETAMINE, AND PENTOBARBITAL ON
SHOCK AND LIGHT DISCRIMINATION PERFORMANCE IN RATS.
001639 02-04
INFLUENCE OF INTRAVENOUS SELF-ADMINISTERED PSYCHOMOTOR
STIMULANTS ON PERFORMANCE OF RHESUS-MONKEYS IN A MULTIPLE-
SCHEDULE PARADIGM.
001655 02-04
EFFECTS OF PHENCYCLIDINE, PENTOBARBITAL, AND D-AMPHETAMINE ON
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL
DISCRIMINATIONS IN MONKEYS.
001723 02-04
DRUG-EFFECTS ON THE PERFORMANCE OF PIGEONS UNDER A NEGATIVE
AUTOMAINTENANCE-SCHEDULE .
001754 02-04
GO-HERE-GO-THERE PERFORMANCE AFTER AMPHETAMINE: THE
IMPORTANCE OF THE RESPONSE REQUIREMENT IN SUCCESSIVE
DISCRIMINATION.
001759 02-04
EFFEQS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND
DISTRIBUTION OF CORRECT RESPONDING ON A SIMULTANEOUS
DISCRIMINATION TASK IN THE RAT.
001806 02-04
INTERCANNABINolD AND CANNABINOID ETHANOL INTERAQIONS AND
THEIR EFFEQS ON HUMAN PERFORMANCE.
002193 02-12
THE EFFECTS OF TRIAZOLAM AND NITRAZEPAM ON SLEEP QUALITY,
MORNING VIGILANCE, AND PSYCHOMOTOR PERFORMANCE.
002330 02-14
THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPECTS OF SLEEP AND OBJECTIVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOQURNAL
MEDICATION: II. REPEATED DOSES.
002331 02-14
PERSONALITY TRAIT AND ANTIANXIETY-DRUG EFFECTS ON
PSYCHOMOTOR PERFORMANCE.
002336 02-14
THE EFFEQS OF ALCOHOL AND CAFFEINE ON CONCENTRATION TEST
PERFORMANCE.
002337 02-14
EFFEQS OF ATENOLOL AND PROPRANOLOL ON HUMAN PERFORMANCE
AND SUBJECTIVE FEELINGS.
002340 02-14
EFFEQS OF AMPHETAMINE ON VIGILANCE PERFORMANCE IN NORMAL
AND HYPERACTIVE-CHILDREN.
002359 02-14
EFFECTS OF IMIPRAMINE ON LEFT VENTRICULAR PERFORMANCE IN
CHILDREN.
(X)2385 02-15
EFFECTS OF LITHIUM ON EVOKED-POTENTIALS AND PERFORMANCE
DURING SUSTAINED AHENTION.
002419 02-15
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE IN MENTALLY-RETARDED
ADULTS.
002471 02-15
A SIMPLE SYSTEM FOR CONTROL OF THE CONTINUOUS PERFORMANCE
TEST IN PSYCHOPHARMACOLOGICAL-RESEARCH.
002474 02-16
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED
ADULTS.
003392 03-11
THE EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON PERFORMANCE UNDER
A DIFFERENTIAL-REINFORCEMENT-OF-LOW-RATES SCHEDULE IN RATS.
004175 04-04
THERAPEUTIC TREATMENT OF INSUFFICIENT PERFORMANCE IN
CEREBROVASCULAR-DISEASES.
004718 04-17
PERFUSED
EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT
LUNG.
000524 01-05
EFFECTS OF AMITRIPTYLINE AND CLOMIPRAMINE IN THE ISOLATED,
PERFUSED RABBIT HEART.
001852 02-05
S-333
Subject Index
Ptychopharmacology Abstracts
illli
ii
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OE
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
002801 03-03
CHARACTERIZATION OF THE ISOLATED PERFUSED MOUSE-BRAIN AS A
SYSTEM FOR NEUROCHEMICAL- STUDIES.
003146 03-06
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT
KIDNEY.
004054 04-03
PERFUSION
THE EFFEQS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERACTION
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED
AHENTION. (PH.D. DISSERTATION).
001563 02-04
STUDIES ON GABA RELEASE IN VIVO USING A SIMPLE METHOD FOR
PERFUSION OF THE FOURTH VENTRICLE OF THE RAT.
001881 02-06
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN.
004638 04-15
PERGOLIDE
STIMULATION OF ADENYLATE-CYCLASE IN RAT STRIATUM BY
PERGOLIDE: INFLUENCE OF GTP.
001448 02-03
PERGOLIDE, A POTENT LONG-AQING DOPAMINE-RECEPTOR AGONIST.
002257 02-13
PERGOIIDE-MESYLATE
BINDING OF (3H)PERG0LIDE-MESYLATE TO DOPAMINE-RECEPTORS OF
MAMMALIAN BRAINS.
001538 02-03
PERIAQUEDUCTAL
MORPHINE INJEQIONS INTO THE PERIAQUEDUQAL PERIVENTRICULAR
GRAY AHENUATE SEPTAL HYPERREACTIVITY.
000390 01-04
INCREASED METABOLISM OF DOPAMINE AND SEROTONIN INDUCED IN
FOREBRAIN AREAS BY ETORPHINE MICROINJEQION IN
PERIAQUEDUQAL GRAY.
001 103 02-03
OPIATE-RECEPTORS AND SLEEP. II. EFFEQS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUQAL GRAY MAHER AND NUCLEUS-TRAQUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
DOSE-RESPONSE STUDY OF THE PRECIPITATED ABSTINENCE-SYNDROME
FOR MORPHINE: SYSTEMIC VS PERIAQUEDUCTAL GRAY NALOXONE.
(PH.D. DISSERTATION).
002979 03-04
EFFEQ OF CHRONIC MORPHINE TREATMENT ON THE INTERAQION
BETWEEN THE PERIAQUEDUQAL GREY AND THE NUCLEUS-RAPHE-
MAGNUS OF THE RAT.
003727 04-03
PERIKARYA
SYNTHESIS OF CYTOSKELETAL PROTEINS IN BULK ISOLATED NEURONAL
PERIKARYA.
003672 04-01
PERINATAL
EFFEQS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT.
000180 01-03
INTERACTIVE-EFFECTS OF NUTRITION AND CANNABIS UPON RAT
PERINATAL DEVELOPMENT.
000513 01-05
PERINATAL NEUROLEPTIC ACTIONS - DEVELOPMENTAL RESULTS.
(UNPUBLISHED PAPER).
001277 02-03
PERINATAL EFFECTS OF PSYCHOTROPIC-DRUGS: THE ANTICONVULSANT-
DRUG DIPHENYLHYDANTOIN. (UNPUBLISHED PAPER).
001842 02-05
PERIODICAL
THE LONG-TERM-TREATMENT OF PERIODICAL AND CYCLIC DEPRESSIONS
WITH FLUPENTHIXOL-DECANOATE.
000603 01-09
PERIODICITY
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS.
001869 02-06
PERIODS
CRITICAL PERIODS FOR DIPHENYLHYDANTOIN AND PHENOBARBITAL
ADMINISTRATION DURING GESTATION.
001630 02-04
PERIORAL
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT.
001657 02-04
PERIPHERAL
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFECTS
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES.
000131 01-03
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL ACTIVITY.
000314 01-03
PERIPHERAL ALPHA-ADRENERGIC-RECEPTOR SUBTYPES.
000901 01-16
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST,
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH AAAMAAALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
PERIPHERAL CATECHOLAMINES AND MEMORY MODULATION.
(UNPUBLISHED PAPER).
001251 02-03
PERIPHERAL PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS:
ARE THEY DIFFERENT FROM DOPAMINE-RECEPTORS IN THE CENTRAL-
NERVOUS-SYSTEM.
001252 02-03
COMPARED PROPERTIES OF CENTRAL AND PERIPHERAL BINDING-SITES
FOR PHENCYCLIDINE.
001521 02-03
PERIPHERAL AUTONOMIC-MECHANISMS AND PAVLOVIAN-CONDITIONING
IN THE RABBIT (ORYCTOLAGUS-CUNICULUS).
001560 02-04
PERIPHERAL 6 HYDROXYDOPAMINE ADMINISTRATION IN THE RABBIT
(ORYCTOLAGUS-CUNICULUS): EFFECTS ON PAVLOVIAN-CONDITIONING
001668 02-04
THE PERIPHERAL ANTICHOLINERGIC-ACTIVITY OF TRICYCLIC-
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND
DESIPRAMINE IN HUMAN VOLUNTEERS.
002298 02-13
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL, ON
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC- STUDY.
002309 02-13
THE ROLE OF FOLATE DEFICIENCY IN THE DEVELOPMENT OF PERIPHERAL
NEUROPATHY CAUSED BY ANTICONVULSANTS.
002402 02-15
CENTRAL AND PERIPHERAL CATECHOLAMINE FUNCTION IN LEARNING
AND MEMORY PROCESSES.
002823 03-03
EFFECTS OF ACUTE CENTRAL AND PERIPHERAL ACTHl-24
ADMINISTRATION ON LORDOSIS BEHAVIOR.
002975 03-04
EFFECTS OF METHYSERGIDE AND NALOXONE ON ANALGESIA INDUCED BY
THE PERIPHERAL ELECTRIC-STIMULATION IN MICE.
003093 03-04
THE HYPERACTIVE-CHILD-SYNDROME: PERIPHERAL SYMPATHETIC-
NERVOUS-SYSTEM FUNCTION AND THE EFFECT OF D-AMPHETAMINE.
003340 03-11
PERIPHERAL NEUROPATHY DUE TO LITHIUM INTOXICATION.
003544 03-15
OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES:
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES.
003902 04-03
ANTITREMOR ACTION OF ClODICHOL, A PERIPHERAL ACETYLCHOLINE
SYNTHESIS INHIBITOR.
004096 04-04
CENTRAL AND PERIPHERAL EFFECTS OF LITHIUM ON AMPHETAMINE-
INDUCED HYPERACTIVITY IN RATS.
004223 04-04
PERIPHERAL SEROTONERGIC AND ADRENERGIC RESPONSES IN
DEPRESSION.
004364 04-09
THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE
PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION
WITH PHYTOHEMAGGLUTININ.
004541 04-13
PERIPHERAL-CORRELATES
PERIPHERAL-CORRELATES OF SEROTONERGICALLY-INFLUENCED
BEHAVIORS IN VERVET-MONKEYS (CERCOPITHECUS-AETHIOPS-
SABAEUS).
004204 04-04
PERIPHERAL-NERVOUS-SYSTEM
CHARACTERIZATION OF THE BASIC PROTEINS FROM RODENT
PERIPHERAL-NERVOUS-SYSTEM MYELIN.
003665 04-01
S-334
VOLUME 19, SUBJECT INDEX
Subject Index
PCRIPHERALLY-INDUCED
EFFECTS OF OLFACTORY-BULBECTOMY AND PERIPHERALLY-INDUCED
ANOSMIA ON THERMOREGULATION IN THE RAT: SUSCEPTIBILITY TO
ANTIDEPRESSANT-DRUGS.
004113 04-04
PERITONEAL
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS (UNPUBLISHED PAPER).
001201 02-03
PERIVENTRICULAR
MORPHINE INJECTIONS INTO THE PERIAQUEDUCTAL PERIVENTRICULAR
GRAY AnENUATE SEPTAL HYPERREACTIVITY.
000390 01-04
PERMEABILITY
LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL
CAPILLARY PERMEABILITY
000239 01-03
DOSE-DEPENDENT, AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND
SPONTANEOUSLY HYPERTENSIVE-RATS,
001197 02-03
H2-RECEPT0RS MEDIATE INCREASES IN PERMEABILITY OF THE BLOOD-
BRAIN-BARRIER DURING ARTERIAL HISTAMINE INFUSION.
003817 04-03
THE EFFECT OF DIBENZAZEPINES (TRICYCLIC-ANTIDEPRESSANTS) ON
CEREBRAL CAPILLARY PERMEABILITY IN THE RAT IN VIVO.
003974 04-03
PERORAL
ANTIDEPRESSANT TREATMENT BY INTRAVENOUS ADMINISTRATION
COMPARED TO PERORAL ADMINISTRATION: A DOUBLE-BUND STUDY
OF QUINUPRAMINE.
000552 01-08
PERPHENAZINE
CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN
SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BUND CROSS-
OVER DESIGN.
001937 02-08
FLUPHENAZINE, TRIFLUOPERAZINE AND PERPHENAZINE IN VACUTAINERS.
003565 03-16
PERPHENAZINE-ENANTATE
ABSCESSES FOLLOWING PROLONGED INTRAMUSCULAR ADMINISTRATION
OF PERPHENAZINE-ENANTATE.
000888 01-15
PERSON
VOLUNTARY INTOXICATION FROM PHENCYCLIDINE. WILL IT RAISE A
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL-
STATE?.
000914 01-17
ANALYSIS OF SINGLE-BLIND AND DOUBLE-BLIND PROCEDURES,
MAINTENANCE OF PLACEBO-EFFEQS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON.
004437 04-11
PERSONALITY
PERSONALITY TRAIT AND ANTIANXIETY-DRUG EFFEQS ON
PSYCHOMOTOR PERFORMANCE.
002336 02-14
SMOKING AND VIGILANCE: THE EFFECTS OF TOBACCO SMOKING ON CFF
AS RELATED TO PERSONALITY AND SMOKING HABITS.
002368 02-14
HABITUATION OF ELECTRODERMAL AND RESPIRATORY RESPONSES TO
VISUAL STIMULI AS A FUNCTION OF PERSONALITY DIFFERENCES IN
AFFEQ LEVEL.
003414 03-13
PERSONALITY AS A PREDICTOR OF PSYCHOTHERAPY AND
PHARMACOTHERAPY-OUTCOME FOR DEPRESSED-OUTPATIENTS.
(UNPUBLISHED PAPER).
004418 04-09
PERSONALITY AND DRUGS IN VISUAL FIGURAL AFTEREFFECTS.
004581 04-14
NONSPECIFIC FACTORS IN DRUG-EFFECTS: PLACEBO PERSONALITY.
004704 04-17
PERSONALITY-DISORDERS
PIMOZIDE IN THE TREATMENT OF SOME SOCIAL-MALADJUSTMENTS IN
PERSONALITY-DISORDERS.
002068 02-10
PERSONALITY-PROBLEMS
DOUBLE-BLIND CONTROLLED- STUDY ON THE PSYCHOLEPTIC-EFFECTS OF
AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT
PERSONALITY-PROBLEMS.
002116 02-11
PERSONNEL
CHILDREN ON MEDICATION: A PRIMER FOR SCHOOL PERSONNEL.
000676 01-11
PERSONS
GABA SYNTHESIS BY CULTURED FIBROBLASTS OBTAINED FROM PERSONS
WITH HUNTINGTONS-DISEASE.
000765 01-13
ANALYSIS OF SINGLE-BLIND, DOUBLE-BLIND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFECTS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS - BRIEF REPORT.
003298 03-11
COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS.
004438 04-11
PERSPECTIVE
EPIDEMIOLOGY OF PCP ABUSE: THE MIDWEST PERSPECTIVE.
000740 01-12
PHENCYCLIDINE: A NIDA PERSPEQIVE.
000743 01-12
PERSPECTIVE ON ADEQUATE INDIVIDUALIZED DRUG DOSES.
000959 01-17
AMITRIPTYLINE AND NORTRIPTYLINE PLASMA LEVELS MONITORING.
PERSPECTIVE IN CLINICAL-PRACTICE.
004675 04-16
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC-
ANTIDEPRESSANTS: PERSPECTIVE OF THE CLINICAL LABORATORY.
004681 04-16
PERSPECTIVES
DRUGS AND THE ELDERLY: PERSPECTIVES IN GERIATRIC CLINICAL-
PHARMACOLOGY.
002534 02-17
NEW PERSPECTIVES ON THE MODE OF AQION OF ANTIDEPRESSANT-
DRUGS.
002617 02-17
LIMITS, VALUE AND PERSPECTIVES OF THE PSYCHIATRIC-DIAGNOSIS IN
CLINICAL PSYCHOPHARMACOLOGY.
002631 02-17
PERSPECTIVES ON PRAZINIL (CARPIPRAMINE): A DISINHIBITING-AGENT
WITH NO NEUROLEPTIC AQIVITY. A REVIEW OF 38 CASES.
003149 03-07
PETHIDINE-INDUCED
AHENUATION OF PETHIDINE-INDUCED ANTINOCICEPTION BY ZIMELIDINE,
AN INHIBITOR OF 5 HYDROXYTRYPTAMINE REUPTAKE.
004118 04-04
PETIT-MAL
ANTICONVULSANTS SPECIFIC FOR PETIT-MAL ANTAGONIZE
EPILEPTOGENIC-EFFECT OF LEUCINE-ENKEPHALIN.
000477 01-04
A PHARMACOLOGICAL INVESTIGATION OF AN ANIMAL-MODEL OF THE
PETIT-MAL SEIZURE. (PH.D. DISSERTATION).
001870 02-06
EFFECTS OF D-AMPHETAMINE AND APOMORPHINE IN A NEW ANIMAL-
MODEL OF PETIT-MAL EPILEPSY.
002493 02-16
A CASE OF PETIT-MAL EPILEPSY AGGRAVATED BY LITHIUM.
004641 04-15
PHAGOCYTIC
PHAGOCYTIC FUNQION IN DOWN-SYNDROME - I. CHEMOTAXIS.
003401 03-13
PHARMACEUTIC-AGENTS
PROBLEMS INVOLVED IN THE COMBINATION OF PHARMACEUTIC-AGENTS
WITH PSYCHOTHERAPY OR PSYCHOANALYSIS.
000971 01-17
OBSERVATIONS ABOUT STATES OF MENTAL-ILLNESS AS ILLUMINATED BY
THEIR RESPONSE TO PHARMACEUTIC-AGENTS.
000972 01-17
PHARMACEUTICAL
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION
PRODUCTS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH-
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE
DETECTION.
004302 04-06
PHARMACOCLINICAL-CLASSIFICATION
PRINCIPLES OF FRENCH PHARMACOCLINICAL-CLASSIFICATION.
001892 02-07
PHARMACODEPENDENCE
A POSSIBLE ECOPHARMACOGENETIC MODEL IN
NEUROPSYCHOPHARMACOLOGY ASPECTS IN ALCOHOLISM AND
PHARMACODEPENDENCE.
002596 02-17
PHARMACODYNAMIC
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM)
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND
DINORLAAM, DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT.
000505 01-04
DETERMINATION OF THE ENCEPHALOTROPIC, PSYCHOTROPIC AND
PHARMACODYNAMIC PROPERTIES OF NICERGOLINE BY MEANS OF
QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY AND
PSYCHOMETRIC-ANALYSES.
000788 01-13
ANTIHYPOXIDOTIC-DRUGS AND NOOTROPIC-DRUGS: PROOF OF THEIR
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
QUANTITATIVE EEG INVESTIGATIONS.
002166 02-11
S-335
Subject Index
Psychopharmacology Abstracts
ili
ii
fir:.
I*
I
PHARMACODYNAMIC ASPEQS OF LONG-TERM PROPHYLAaiC LITHIUM,
002212 02-13
NEUROLEPTICS: INTERAQIONS WITH FOOD - CHEMICAL AND
PHARMACODYNAMIC STUDIES ON THE INTERACTIONS OF COFFEE AND
TEA.
003612 03-17
A CLINICAL AND PHARMACODYNAMIC EVALUATION OF SULPIRIDE.
004338 04-08
PHARMACODYNAMICS
PHARMACODYNAMICS AND PHARMACOKINETICS OF DIAZEPAM IN AN
ABUSER.
000867 01-15
DETERMINATION OF PHARMACODYNAMICS OF PSYCHOTROPIC-DRUGS BY
PSYCHOMETRIC-ANALYSIS.
001895 02-07
PHARMACOEEG
CNS EFFECTS OF ISF-2522, A NEW NOOTROPIC (A PHASE I SAFETY AND
CNS EFFICACY STUDY WITH QUANTITATIVE PHARMACOEEG AND
PHARMACOPSYCHOLOGY).
004519 04-13
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL.
004620 04-15
PHARMACOELECTROENCEPHAIOGRAPHY
DETERMINATION OF THE ENCEPHALOTROPIC, PSYCHOTROPIC AND
PHARMACODYNAMIC PROPERTIES OF NICERGOLINE BY MEANS OF
QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY AND
PSYCHOMETRIC-ANALYSES.
000788 01-13
PHARMACOKINETIC
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
DEXAMETHASONE TREATMENT.
000321 01-03
ADVANTAGE OF PHARMACOKINETIC DATA DURING TREATMENT OF
PSYCHOSES WITH HALOPERIDOL.
000577 01-08
TRANSCULTURAL PHARMACOKINETIC STUDY ON LI CONCENTRATION IN
PLASMA AND SALIVA.
000769 01-13
PHARMACOKINETIC INTERACTION BETWEEN PROPRANOLOL AND
CHLORPROMAZINE IN SCHIZOPHRENIC-PATIENTS.
001940 02-08
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRUG
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA.
002225 02-13
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS
ADMINISTRATIONS.
002797 03-03
THE USE OF CLINICAL AND PHARMACOKINETIC CRITERIA IN FORECASTING
THE EFFICACY OF THERAPY IN SCHIZOPHRENIA.
004335 04-08
SINGLE-DOSE PHARMACOKINETIC DATA ON ZIMELIDINE IN DEPRESSED-
PATIENTS.
004385 04-09
SERUM CONCENTRATION OF ANTICONVULSANTS. PHARMACOKINETIC
FINDINGS AND THEIR PRACTICAL APPLICATION.
004443 04-11
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS.
004551 04-13
PHARMACOKINETIC-BASES
USE OF ANTIDEPRESSANTS: PHARMACOKINETIC-BASES.
001981 02-09
PHARMACOKINETIC-INTERACTION
REVERSAL BY PHENYTOIN OF CARBAMAZEPINE-INDUCED WATER
INTOXICATION: A PHARMACOKINETIC-INTERAQION.
000783 01-13
PHARMACOKINETIC-STUDIES
PHARMACOKINETIC- STUDIES WITH CHOLINE-CHLORIDE: A PRELIMINARY
REPORT.
004514 04-13
PHARMACOKINETiC-STUDY
PHARMACOKINETIC- STUDY OF LORAZEPAM OVERDOSAGE.
000831 01-15
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL, ON
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC-STUDY.
002309 02-13
PHARMACOKINETIC-STUDY OF APOMORPHINE-INDUCED STEREOTYPY IN
FOOD DEPRIVED RATS.
004247 04-04
PHARMACOKINETIC-STUDY IN MAN OF THE CH-757 PREPARATION.
004440 04-1 1
PHARMACOKINETIC-VARIABLES
REUTIONSHIPS AMONG BIOCHEMICAL-VARIABLES, CLINICAL-
VARIABLES, AND PHARMACOKINETIC-VARIABLES IN NEUROLEPTIC
TREATED SCHIZOPHRENIC-PATIENTS.
001946 02-08
PHARMACOKINETICS
PHARMACOKINETICS OF CARBAMAZEPINE IN THE DOG
000096 01-03
PHARMACOKINETICS OF PRIMIDONE AND ITS AQIVE METABOLITES IN
THE DOG.
000097 01-03
SINGLE-DOSE PHARMACOKINETICS AND ANTICONVULSANT EFFICACY OF
PRIMIDONE IN MICE.
000177 01-03
PHARMACOKINETICS AND METABOLISM OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE) IN RAT,
MOUSE, DOG AND MAN.
000219 01-03
COMPARISON OF SINGLE-DOSE PHARMACOKINETICS OF IMIPRAMINE
AND MAPROTILINE IN THE ELDERLY.
000596 01-09
3 CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE (GS-385), A
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION,
. PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE
LIQUIO-CHROMATOGRAPHY.
000705 01-11
PHARMACOKINETICS OF CHLORPROMAZINE IN NORMAL VOLUNTEERS.
000778 01-13
PHARMACODYNAMICS AND PHARMACOKINETICS OF DIAZEPAM IN AN
ABUSER,
000867 01-15
PHARMACOKINETICS OF BENZODIAZEPINES: SHORT-AQING VERSUS
LONG-AQING.
000920 01-17
DOSE-DEPENDENT PHARMACOKINETICS OF ALPHA METHYL-P-TYROSINE
(ALPHA MT) AND COMPARISON OF CATECHOLAMINE TURNOVER-
RATES AFTER TWO DOSES OF ALPHA MT,
001532 02-03
CLINICAL-RESPONSE, PLASMA LEVELS AND PHARMACOKINETICS OF
DESIPRAMINE IN DEPRESSED-INPATIENTS,
002002 02-09
PHARMACOKINETICS OF NORTRIPTYLINE IN ELDERLY VOLUNTEERS,
002184 02-11
ON THE CLINICAL PHARMACOKINETICS OF THIORIDAZINE AND ITS
METABOLITES,
002207 02-13
PHARMACOKINETICS OF DIPOTASSIUM-CHLORAZEPATE IN PATIENTS
AFTER REPEATED 50MG ORAL DOSES.
002211 02-13
0 METHOXYBENZAMIDES: RELATIONSHIPS BETWEEN STRUQURE-
AQIVITY, AND PHARMACOKINETICS OF THESE DRUGS,
002246 02-13
INFLUENCE OF CIMETIDINE ON THE PHARMACOKINETICS OF
DESMETHYLDIAZEPAM AND OXAZEPAM
002249 02-13
BIOAVAILABILITY AND RELATED PHARMACOKINETICS IN MAN OF
ORALLY ADMINISTERED L 5 HYDROXYTRYPTOPHAN IN STEADY-STATE.
002261 02-13
CONTRIBUTION TO THE PHARMACOKINETICS AND METABOLISM OF
OXYPROTHEPIN,
002279 02-13
THE PHARMACOKINETICS OF BROMOCRIPTINE IN MAN.
002291 02-13
SINGLE-DOSE PHARMACOKINETICS OF DOXEPIN IN HEALTHY
VOLUNTEERS.
002303 02-13
RELATIONSHIP BETWEEN STRUaURE AND NEUROLEPTIC AQIVITY:
PHARMACOPHORE AND PHARMACOKINETICS.
002492 02-16
PHARMACOKINETICS AND PLASMA LEVELS OF POLYCYCLIC-
ANTIDEPRESSANTS: A GENERAL VIEW OF PRODUQS.
002529 02-17
PHARMACOKINETICS AND BIOAVAILABILITY OF CHLORDIAZEPOXIDE IN
HUMANS.
002564 02-17
DESIPRAMINE AND 2 HYDROXYDESIPRAMINE PHARMACOKINETICS IN
NORMAL VOLUNTEERS.
003154 03-07
PHARMACOKINETICS OF CLOMIPRAMINE IN DEPRESSIVE-PATIENTS,
003216 03-09
PHARMACOKINETICS OF AMITRIPTYLINE, IMIPRAMINE, AND
MAPROTILINE IN THE ELDERLY,
003324 03-11
CLINICAL PHARMACOKINETICS IN NEWBORNS AND INFANTS: AGE-
RELATED DIFFERENCES AND THERAPEUTIC IMPLICATIONS,
003343 03-1 1
PHENYTOIN: PHARMACOKINETICS AND CLINICAL THERAPEUTICS.
003353 03-11
S-336
VOLUME 19, SUBJECT INDEX
Subject Index
CLINICAL PHARMACOKINETICS OF OXAZEPAM AND LORAZEPAM.
003410 03-13
THE EFFECTS OF SALICYLATE ON THE PHARMACOKINETICS OF
PHENYTOIN.
003421 03-13
THE USE OF PHARMACOKINETICS IN THE FOLLOWUP OF PSYCHIATRIC-
PATIENTS.
003616 03-17
HEPATIC-DISEASE AND DRUG PHARMACOKINETICS.
003650 03-17
PHARMACOKINETICS AND CLINICAL-RESPONSE TO TRICYCLIC-
ANTIDEPRESSANTS.
004370 04-09
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS.
004403 04-09
CLINICAL PHARMACOKINETICS OF CHLORDIAZEPOXIDE IN PATIENTS WITH
ALCOHOLIC HEPATITIS.
004473 04-11
CLINICAL PHARMACOKINETICS OF BENZODIAZEPINES.
004524 04-13
PHARMACOKINETICS OF CLOXAZOIAM IN MAN AFTER SINGLE AND
MULTIPLE ORAL DOSES.
004530 04-13
THE PHARMACOKINETICS OF MIDAZOLAM IN MAN.
004555 04-13
PHARMACOKINETICS OF ANTICONVULSANT-DRUGS.
004738 04-17
PHARMACOLOGIC
PHYSIOLOGIC AND PHARMACOLOGIC IMPLICATIONS IN THE
OEACYLATION OF PHOSPHATIDYLSERINE IN MICE.
002682 03-03
PHARMACOLOGIC APPROACHES TO THE TREATMENT OF SENILE-
DEMENTIA.
002809 03-03
PHARMACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG.
002889 03-03
PHARMACOLOGIC AND THERAPEUTIC-PERSPECTIVES ON DEMENTIA: AN
EXPERIMENTAL APPROACH.
003065 03-04
PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND
DEMENTIA.
003347 03-11
PHARMACOLOGIC DISTINCTION OF DIFFERENT ORTHOSTATIC
HYPOTENSION-SYNDROMES.
003362 03-11
SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES OF
ANALOGUES AND DERIVATIVES OF P CHLOROPHENYLALANINE.
003691 04-02
PHARMACOLOGIC MANIPULATION OF BRAIN AND PITUITARY ENDORPHIN
CONTENT AND RELEASE.
003837 04-03
HIPPOCAMPAL INVOLVEMENT IN THE PHARMACOLOGIC INDUaiON OF
WITHDRAWAL-LIKE BEHAVIORS.
004140 04-04
3 HYDROXYMETHYL-BETA-CARBOLINE ANTAGONIZES SOME
PHARMACOLOGIC AQIONS OF DIAZEPAM.
004221 04-04
PHARMACOLOGIC-AGENTS
INFLUENCE OF MONOAMINE DEPLETING PHARMACOLOGIC-AGENTS ON
LEVELS OF AQIVITY IN CAIMAN-SCLEROPS.
001810 02-04
PHARMACOLOGIC-EFFECTS
TOXICOLOGIC AND PHARMACOLOGIC-EFFECTS OF PHENCYCLIDINE-HCL IN
THE DOG. (PH.D. DISSERTATION),
000519 01-05
PHARMACOLOGIC-PROBES
IDENTIFICATION OF A SUBGROUP OF TARDIVE-DYSKINESIA PATIENTS BY
PHARMACOLOGIC-PROBES.
000708 01-11
PHARMACOLOGIC-PROBES INTO TARDIVE-DYSKINESIA.
002179 02-11
PHARMACOLOGIC-RESPONSES
INTERAaiON OF TRIAZOLAM WITH DESIPRAMINE: EFFECTS OF SINGLE
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC-
RESPONSES AND BRAIN CATECHOLAMINE LEVELS.
001323 02-03
PHARMACOLOGIC-STUDIES
PHARMACOLOGIC- STUDIES OF TARDIVE-DYSKINESIA.
002387 02-15
PHARMACOLOGIC-TREATMENT
SENILE-DEMENTIA: COMBINED PHARMACOLOGIC-TREATMENT AND
PSYCHOLOGIC-TREATMENT.
003393 03-11
AN OVERVIEW OF PHARMACOLOGIC-TREATMENT OF COGNITIVE DECLINE
IN THE AGED.
004482 04-11
PHARMACOLOGICAL
3 SULFAMOYlMETHYL-l-2-BENZISOXAZOLE, A NEW TYPE OF
ANTICONVULSANT-DRUG: PHARMACOLOGICAL PROFILE
000012 01-02
PHARMACOLOGICAL ACTIVITIES OF CLOBAZAM AND DIAZEPAM IN THE
RAT: RELATION TO DRUG BRAIN LEVELS.
000036 01-03
GABA BENZODIAZEPINE INTERACTIONS: PHYSIOLOGICAL,
PHARMACOLOGICAL AND DEVELOPMENTAL ASPECTS.
000103 01-03
REINNERVATION OF THE DENERVATED STRIATUM BY SUBSTANTIA-NIGRA
TRANSPLANTS: FUNCTIONAL CONSEQUENCES AS REVEALED BY
PHARMACOLOGICAL AND SENSORIMOTOR TESTING
000347 01-04
DECOMPOSITION OF PHARMACOLOGICAL ACTIVITY INDICES INTO
MUTUALLY INDEPENDENT COMPONENTS USING PRINCIPAL
COMPONENT ANALYSIS.
001039 02-01
BIOCHEMICAL-CHARACTERIZATION AND PHARMACOLOGICAL
CHARACTERIZATION OF A PEPTIDE FROM THE HEMODIALYSATE OF
PSYCHOTIC-PATIENTS.
001049 02-01
RECEPTOR PLASTICITY: BIOCHEMICAL-CORRELATES AND
PHARMACOLOGICAL SIGNIFICANCE.
001181 02-03
PHARMACOLOGICAL EVIDENCE AND BIOCHEMICAL-EVIDENCE FOR AN
INTERACTION BETWEEN THE BENZODIAZEPINE AND GABA-RECEPTORS.
001261 02-03
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION.
001310 02-03
A PHARMACOLOGICAL ANALYSIS OF THE ROLE OF THE AMYGDALA IN
THE CONTROL OF GONADOTROPIN AND PROLACTIN SECRETION.
001418 02-03
NEW EXPERIMENTAL TECHNIQUES IN THE PHARMACOLOGICAL
EVALUATION OF CNS ACTING DRUGS.
001479 02-03
THE EFFECT OF REPEATED ELEQROCONVULSIVE-SHOCK ON
CORTICOSTERONE RESPONSES TO CENTRALLY-ACTING
PHARMACOLOGICAL STIMULI IN THE MALE RAT.
001486 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTAQ RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELECTIVE
5 HT UPTAKE INHIBITOR.
001517 02-03
PHARMACOLOGICAL MODIFICATION OF AMYGDALOID KINDLED
SEIZURES.
001588 02-04
THE PHARMACOLOGICAL RELEVANCE OF THE COCAINE BINDING-SITE IN
MOUSE-BRAIN.
001772 02-04
A PHARMACOLOGICAL INVESTIGATION OF AN ANIMAL-MODEL OF THE
PETIT-MAL SEIZURE. (PH.D. DISSERTATION).
001870 02-06
AMINEPTINE, A NEW ANTIDEPRESSANT: PHARMACOLOGICAL REVIEW.
001898 02-07
TREATMENT OF DYSKINETIC AND DYSTONIC-DISORDERS WITH CF-25-
397: CLINICAL-ASPECTS AND PHARMACOLOGICAL ASPEQS.
002121 02-11
PHARMACOLOGICAL REFLECTIONS ON 0 ANISAMIDES.
002292 02-13
A NEUROPHARMACOLOGICAL-STUDY AND NEUROENDOCRINE-STUDY ON
IDIOPATHIC AND CHRONIC PHARMACOLOGICAL PARKINSONISM.
002371 02-15
BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS
AND MAN.
002527 02-17
PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS
MECHANISMS RESPONSIBLE FOR MOTOR ACT INHIBITION BY AVERSIVE
EVENTS.
002671 03-03
IDENTICAL RESPONSES OF THE TWO HIPPOCAMPAL THETA GENERATORS
TO PHYSIOLOGICAL AND PHARMACOLOGICAL ACTIVATION.
002792 03-03
PHARMACOLOGICAL CHARACTERIZATION OF SCRATCHING-BEHAVIOUR
INDUCED BY INTRACRANIAL INJECTION OF SUBSTANCE-P AND
SOMATOSTATIN.
002980 03-04
CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL
ALERTING.
002997 03-04
S-337
Subject Index
Psychopharmacology Abstracts
lilHl-..
m
m:
::is;s:
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION.
003052 03-04
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED
REFLEXES IN RATS.
003100 03-04
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN
ANIMAL AGGRESSION.
003140 03-06
2 AMINO-4-PHOSPHONOBUTYRIC-ACID: A NEW PHARMACOLOGICAL
TOOL FOR RETINA RESEARCH.
003145 03-06
A COMPARATIVE REVIEW OF THE PHARMACOLOGICAL AND
TOXICOLOGICAL PROPERTIES OF DISULFIRAM AND CALCIUM-
CARBIMIDE.
003522 03-15
PHARMACOLOGICAL ANTAGONISTS OF EXCITANT AMINO-ACIO AQION.
003587 03-17
RECENT REVIEWS OF BIOCHEMICAL, NEUROCHEMICAL, AND
PHARMACOLOGICAL TOPICS.
003649 03-17
THE PHARMACOLOGICAL ACTION OF THE OPTICAL-ISOMERS OF
SYDNOCARB.
003681 04-02
SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME 2 IMINO-3-
ALKYLTHIAZOLINE DERIVATIVES.
003698 04-02
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF N-4 1
AZETIDINYLBUTYNYL 2 PYRROLIDONE, A HIGHLY POTENT
OXOTREMORINE-LIKE-AGENT.
003701 04-02
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT
NICTITATING MEMBRANE.
003777 04-03
PHARMACOLOGICAL DIFFERENCE OF L-DOPA, APOMORPHINE, AND
BROMOCRIPTINE AGAINST METOCLOPRAMIDE.
003790 04-03
THE EFFECT OF ELECTRICAL-STIMULATION OF THE LOCUS-COERULEUS AND
INTRAPERITONEAL INJECTION OF CERTAIN PHARMACOLOGICAL
SUBSTANCES ON THE THRESHOLD OF HIPPOCAMPAL
AFTERDISCHARGES.
003885 04-03
THE PHARMACOLOGICAL PROFILE OF LOFEPRAMINE, A NEW
ANTIDEPRESSANT-DRUG.
004006 04-03
THE EFFEQ OF PHARMACOLOGICAL DESTRUCTION OF HYPOTHALAMIC
MONOAMINERGIC STRUQURES ON BODY-TEMPERATURE AND GAS-
EXCHANGE DURING EXTREME COOLING.
004016 04-03
PHARMACOLOGICAL REGULATION OF CALMODULIN.
004052 04-03
PHARMACOLOGICAL AND BIOCHEMICAL-PROPERTIES OF BRL-14342, A
NOVEL POTENTIAL ANTIDEPRESSANT-DRUG.
004086 04-04
ANALGESIC AND OTHER PHARMACOLOGICAL AQIVITIES OF A NEW
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3
METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS
ENANTIOMORPH IN EXPERIMENTAL ANIMALS.
004185 04-04
SOME OBSERVATIONS ON THE PHARMACOLOGICAL AQIVITY OF MIF
(PR0-LEU-GLY-NH2).
004240 04-04
THE PHARMACOLOGICAL CHARAQERISTICS OF THE TRANQUILIZING
EFFECT OF HYDIPHEN.
004261 04-04
ON THE USE OF CERTAIN PHARMACOLOGICAL CATEGORIES IN HYSTERIA.
004347 04-09
PHARMACOLOGICAL INFLUENCE OF SEXUAL-FUNCTIONS IN ADOLESCENTS.
004436 04-1 1
PHARMACOLOGICAL PECULIARITIES OF A BENZODIAZEPINE/ATARAQIC-
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF
CLORAZEPATE-DIPOTASSIUM(TRANXILIUM).
004527 04-13
PECULIARITIES OF THE CEREBRAL PATHOMORPHOLOGY OF PATIENTS
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS
(PHARMACOLOGICAL PATHOMORPHOSIS) .
004528 04-13
PHARMACOLOGICAL MODULATION OF FORMATION OF LONG-TERM
MEMORY.
004578 04-14
MECHANISMS AND PHARMACOLOGICAL IMPLICATIONS OF ALTERING
CALMODULIN AQIVITY.
004751 04-17
PHARMACOLOGICAL-AGENTS
DIFFERENTIAL-EFFEQS OF PHARMACOLOGICAL-AGENTS AQING ON
MONOAMINERGIC SYSTEMS ON DRUG-INDUCED ANOREXIA.
002533 02-17
PHARMACOLOOICAl-ASPECTS
SOME PHARMACOLOGICAL-ASPEaS AND BIOCHEMICAL-ASPEaS OF
TRH: EXPERIMENTAL AND CLINICAL DATA.
001189 02-03
PHARMACOLOGICAL-ASPECTS OF SHAKING-BEHAVIOR PRODUCED BY
TRH, AG-3-5, AND MORPHINE WITHDRAWAL.
004248 04-04
NEUROLEPTIC TRICYCLIC-ANTIDEPRESSANT COMBINATION:
PHARMACOLOGICAL-ASPECTS AND THERAPEUTIC INTEREST.
004501 04-13
PHARMACOLOGICAL-BASES
PHARMACOLOGICAL-BASES OF PSYCHONEUROENDOCRINOLOGY:
PRECLINICAL ASSESSMENT OF CLINICAL FAQS.
003735 04-03
PHARMACOLOGICAL-CONSIDERATIONS
BRAIN CATECHOLAMINES. MENTAL-ILLNESSES, AGING AND SENILE-
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARAAACOLOGICAL-
CONSIDERATIONS.
001550 02-03
PHARMACOLOGICAL-CORRELATES
EEG, COMP-EEG, REO-EG AND PHARMACOLOGICAL-CORRELATES OF ,
GERIATRICS. I
002162 02-11 I
PHARMACOLOGICAL-EFFECTS
BIOCHEMICAL-CHARACTERIZATION OF THE RAT SYMPATHETIC
GANGLION: PHARMACOLOGICAL-EFFEaS OF RESERPINE ON
GANGLIONIC CATECHOLAMINES.
000153 01-03
DISPOSITION AND PHARMACOLOGICAL-EFFEQS OF M
CHLOROPHENYLPIPERAZINE IN RATS.
002995 03-04
COMPARATIVE-STUDIES OF THE PHARMACOLOGICAL-EFFEaS OF THE D-
ISOMERS AND L-ISOMERS OF CODEINE.
004084 04-04
ASPEQS OF PHARMACOLOGICAL-EFFEQS OF ANTIEPILEPTIC-DRUGS.
004462 04-11
PHARMACOLOGICAL-PROBES
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY
AFFEQIVE-ILLNESS
002506 02-16
PHARMACOLOGICAL-PROPERTIES
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - I. KINETIC PARAMETERS
AND PHARMACOLOGICAL-PROPERTIES.
000213 01-03
REWARDING AND AVERSIVE-EFFEaS OF MORPHINE: TEMPORAL AND
PHARMACOLOGICAL-PROPERTIES.
000470 01-04
PHARMACOLOGICAL-PROPERTIES OF TAGLUTIMIDE, A NEW SEDATIVE
HYPNOTIC-DRUG
001087 02-02
DOPAMINE-RECEPTORS IN RAT-FRONTAL-CORTEX: PHARMACOLOGICAL-
PROPERTIES IN VIVO AND IN VITRO.
001112 02-03
A COMPARATIVE-STUDY OF THE PHARMACOLOGICAL-PROPERTIES OF THE
POSITIVE POTENTIAL RECORDED FROM THE SUPERIOR CERVICAL
GANGLIA OF SEVERAL SPECIES.
003779 04-03
PHARMACOLOGICAL-PROPERTIES OF 2,3,3A,4,5,6 HEXAHYDROMETHYL-
1 H-PYRAZINOCARBAZOL-HCL (PIRLINDOLE), A NEW ANTIDEPRESSANT.
004174 04-04
PHARMACOLOGICAL-PROPERTIES OF SOME SECOND-GENERATION
ANTIDEPRESSANT-DRUGS.
004726 04-17
PHARMACOLOGICAL-STUDIES
PHARMACOLOGICAL-STUDIES ON A NEW THYMOLEPTIC
ANTIDEPRESSANT . DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL- 1 H-
INDAZOLE (FS-32).
001659 02-04
PHARMACOLOGICAL-STUDIES ON STIMULATION PRODUCED ANALGESIA
IN MICE.
002964 03-04
PHARMACOLOGICAL-STUDIES OF TARDIVE-DYSKINESIA: IMPLICATIONS
FOR FUTURE RESEARCH.
003465 03-15
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: PHARMACOLOGICAL-STUDIES.
003815 04-03
PHARMACOLOGICAL-STUDIES WITH AN ALKYLATING NARCOTIC
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST,
CHLORNALTREXAMINE.
004082 04-04
PHARMACOLOGICAL-STUDY
A PHARMACOLOGICAL-STUDY OF THE NEW SOVIET ANTIDEPRESSANT
INKASAN.
000008 01-02
S-338
VOLUME 19, SUBJECT INDEX
Subject Index
PHARMACOLOGICAL-STUDY OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW
NEUROLEPTIC-DRUG.
000493 01-04
ACTION OF TOFISOPAM ON THE ERGONOMIC VIGILANCE LEVEL. ITS
INTERACTION WITH THE EFFECTS OF ALCOHOL. CLINICAL
PHARMACOLOGICAL-STUDY.
001891 02-07
SYNTHESIS AND PHARMACOLOGICAL-STUDY OF SOME ENKEPHALIN
ANALOGS IN RELATION TO THE PLURALITY OF OPIATE-RECEPTORS.
003682 04-02
PHARMACOLOGICAL-TREATMENT
BEHAVIORAL-TREATMENT AND PHARMACOLOGICAL-TREATMENT OF
OBSESSIVE-COMPULSIVE-DISORDERS.
000657 01-10
MODERN-VIEWS ON THE PRINCIPLES OF THE PHARMACOLOGICAL-
TREATMENT OF EPILEPSY.
000931 01-17
DOUBLE-BLIND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS.
002314 02-14
THERAPEUTICS (I) - PHARMACOLOGICAL-TREATMENT OF DEPRESSIONS.
003270 03-09
REFLECTIONS ON ANTIPSYCHOTIC CHEMOTHERAPY: THE BEGINNING OF
PHARMACOLOGICAL-TREATMENT.
003292 03-11
THE PHARMACOLOGICAL-TREATMENT OF SCHIZOAFFEaiVE-DISORDER
DEPRESSED; A REVIEW OF THE LITERATURE.
003634 03-17
PHOBIA: PSYCHOLOGICAL-TREATMENT AND PHARMACOLOGICAL-
TREATMENT.
004425 04-10
NEUROLOGICAL-COMPLICATIONS DUE TO THE PHARMACOLOGICAL-
TREATMENT OF EPILEPTIC-PATIENTS.
004593 04-15
CONTEMPORARY PROBLEMS IN THE PHARMACOLOGICAL-TREATMENT OF
PARKINSONISM.
004628 04-15
PHARMACOLOGY
PHARMACOLOGY OF PHENETHYIAMINE TRACE AMINES IN THE DOG ~
DISCUSSION.
000469 01-04
HISTORY AND PHARMACOLOGY OF PCP AND PCP RELATED ANALOGS.
000737 01-12
PHARMACOLOGY: CURRENT ANTIDEPRESSANTS.
000793 01-13
PHARMACOLOGY OF NOOTROPIC-DRUGS.
000800 01-14
PHARMACOLOGY: NEW ANTIDEPRESSANTS.
000936 01-17
SYNTHESIS AND PHARMACOLOGY OF 2 AMIN0-3-ETH0XYCARB0NYL-4-
PHENYLTHIOPHENE DERIVATIVES.
001083 02-02
PHARMACOLOGY OF THE SURVEQOR.
001085 02-02
OOPAMINE-AUTORECEPTORS; PHARMACOLOGY, FUNQION AND
COMPARISON WITH POSTSYNAPTIC DOPAMINE-RECEPTORS.
001453 02-03
THE PHARMACOLOGY OF CATECHOLAMINE INVOLVEMENT IN THE
NEURAL MECHANISMS OF REWARD.
001526 02-03
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA
ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF
CONSCIOUS CATS.
001569 02-04
PHENCYCLIDINE (PCP) AND DERIVATIVES: PHARMACOLOGY AND
STRUaURE-AQIVITY RELATIONSHIPS.
001706 02-04
TOXICOLOGY ~ PHARMACOLOGY - METABOLISM.
002252 02-13
HISTORY AND PHARMACOLOGY OF MINAPRINE.
002270 02-13
ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY.
002546 02-17
A COMPARATIVE-STUDY OF THE PHARMACOLOGY OF INHIBITORS OF
GABA METABOLISM.
003036 03-04
ON THE PHYSIOLOGY AND PHARMACOLOGY OF ENDORPHINS.
003417 03-13
THE PHARMACOLOGY OF GABA-TRANSAMINASE INHIBITORS.
003620 03-17
PHARMACOLOGY OF MIGRAINE.
003623 03-17
BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM.
003630 03-17
THE PHARMACOLOGY OF MEMORY: A NEUROBIOLOGICAL-PERSPECTIVE.
003636 03-17
PHARMACOLOGY OF 1 DICHLOROBENZYL-TETRAHYDROPYRIMIDONE, A
NOVEL ANTIDEPRESSANT COMPOUND WITH ANTIANXIETY ACTIVITY.
003688 04-02
PHARMACOLOGY OF 2 0 CHLOROBENZOYL-CHLORO-METHYL-NA-
GLYCYLGLYCINANILIDE HYDRATE (45-0088-S), A COMPOUND WITH
BENZODIAZEPINE-LIKE PROPERTIES.
003692 04-02
THE NEUROANATOMY AND PHARMACOLOGY OF THE NUCLEUS LOCUS-
COERULEUS. (UNPUBLISHED PAPER).
003810 04-03
SPINAL-CORD PHARMACOLOGY OF ADRENERGIC AGONIST-MEDIATED
ANTINOCICEPTION.
004206 04-04
PHARMACOMANOMETRIC-STUDIES
PHARMACOMANOMETRIC-STUDIES OF COLONIC MOTILITY AS A GUIDE
TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001930 02-08
PHARMACOPHORE
RELATIONSHIP BETWEEN STRUCTURE AND NEUROLEPTIC AQIVITY:
PHARMACOPHORE AND PHARMACOKINETICS.
002492 02-16
PHARMACOPSYCHOLOGICAl
PHARMACOPSYCHOLOGICAL INVESTIGATION OF CHANGES IN MOOD
INDUCED BY DIPOTASSIUM-CHLORAZEPATE WITH AND WITHOUT
SIMULTANEOUS ALCOHOL ADMINISTRATION.
000825 01-14
PHARMACOPSYCHOLOGICAL INVESTIGATIONS CONCERNING THE
COMBINED EFFEQS OF DIPOTASSIUM-CLORAZEPATE AND ETHANOL.
003456 03-14
PHARMACOPSYCHOLOGY
CNS EFFECTS OF ISF-2522, A NEW NOOTROPIC (A PHASE I SAFETY AND
CNS EFFICACY STUDY WITH QUANTITATIVE PHARMACOEEG AND
PHARMACOPSYCHOLOGY).
004519 04-13
PHARMACOTHERAPEUTIC
SECOND-GENERATION ANTIDEPRESSANTS: A CLINICAL
PHARMACOTHERAPEUTIC RESEARCH STRATEGY.
003632 03-17
PHARMACOTHERAPY
CHRONIC MOOD-DISORDERS IN DEPRESSED-OUTPATIENTS: DIAGNOSIS
AND RESPONSE TO PHARMACOTHERAPY.
000624 01-09
CONTROLLED-TRIAL OF BEHAVIOUR-THERAPY, PHARMACOTHERAPY, AND
THEIR COMBINATION IN THE TREATMENT OF OBESITY.
000725 01-11
DISTINGUISHING SCHIZOPHRENIAS BY MEANS OF PHARMACOTHERAPY.
001947 02-08
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME. PART 1.
PROPHYLAXIS OF RECURRENT DEPRESSIVE-ILLNESS.
002043 02-09
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME. PART 1 :
TREATMENT OF ACUTE DEPRESSION.
002044 02-09
PHARMACOTHERAPY OF DEPRESSION IN THE ELDERLY.
002144 02-11
PROGRESS IN THE PHARMACOTHERAPY OF PARKINSONISM.
002384 02-15
DEPRESSED-OUTPATIENTS TREATED WITH COGNITIVE-THERAPY OR
PHARMACOTHERAPY: A ONE-YEAR FOLLOWUP.
003235 03-09
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLia? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
003256 03-09
PHARMACOTHERAPY FOR AGE-RELATED BEHAVIORAL-DEFICIENCIES.
003391 03-11
PHARMACOTHERAPY FOR DEPRESSION.
004351 04-09
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
(UNPUBLISHED PAPER).
004401 04-09
PHARMACOTHERAPY AND PSYCHOTHERAPY FOR AMBULATORY
DEPRESSION: EFFICACY AND CHOICES.
004413 04-09
PHARMACOTHERAPY OF SEXUAL-IMPOTENCE IN THE MALE.
004435 04-1 1
PHARMACOTHERAPY FOR SEXUAL-OFFENDERS: REVIEW OF THE AQION
OF ANTIANDROGENS WITH SPECIAL REFERENCE TO THEIR PSYCHIC-
EFFEaS.
004455 04-11
PHARMACOTHERAPY AND FEMALE SEXUALITY.
004483 04-11
THE RIGHTS OF INVOLUNTARY-PATIENTS TO REFUSE
PHARMACOTHERAPY: WHAT IS REASONABLE?
004730 04-17
NOTES ON PHARMACOTHERAPY OF FUNQIONAL PSYCHOSES.
004748 04-17
PHARMACOTHERAPY-OUTCOME
PERSONALITY AS A PREDICTOR OF PSYCHOTHERAPY AND
PHARMACOTHERAPY-OUTCOME FOR DEPRESSED-OUTPATIENTS.
(UNPUBLISHED PAPER).
004418 04-09
S-339
Subject index
iia-,.
C,3;
fe
PHARAAACOTOXIC
ACUTE PHARMACOTOXIC PSYCHOSES IN CHRONIC CEREBRAL
CONDITIONS.
003475 03-15
PHASIC
EFFEaS OF MORPHINE AND NALOXONE ON PHASIC RELEASE OF
LUTEINIZING-HORMONE AND FOLLICLE-STIMULATING-HORMONE
(40849).
000298 01-03
PHASIC AQIVITY INDUCED BY P CHLOROPHENYLALANINE IN THE
AUDITORY PATHWAY.
002661 03-03
CATECHOLAMINERGIC INVOLVEMENT IN PHASIC VERSUS TONIC
ELECTROCORTICAL AROUSAL.
002723 03-03
PHENACEMIDE
STRUCTURE-AQIVITY RELATIONSHIPS IN THE EFFECTS OF PHENACEMIDE
ANALOGS ON SERUM CREATININE AND ANTICONVULSANT AQIVITY
000249 01-03
PHENAZEPAM
USE OF THE NEW TRANQUILIZER PHENAZEPAM IN PSYCHIATRIC-
PRACTICE.
000578 01-09
THE DEVELOPMENT OF PROGENY IN CASES OF ANTENATAL EXPOSURE TO
PHENAZEPAM.
001854 02-05
THE USE OF PHENAZEPAM IN THE TREATMENT OF PSYCHOTIC-PATIENTS.
003351 03-11
PHENCYCLIOINE
EFFEQS OF ACUTE AND CHRONIC PHENCYCLIOINE ON
NEUROTRANSMIHER ENZYMES IN RAT-BRAIN.
000134 01-03
CONTINUOUS-ACCESS PHENCYCLIOINE SELF-ADMINISTRATION BY RHESUS-
MONKEYS LEADING TO PHYSICAL-DEPENDENCE.
000341 01-04
FIRST DOSE BEHAVIORAL-TOLERANCE TO PHENCYCLIOINE ON FOOD
REWARDED BAR-PRESSING-BEHAVIOR IN THE RAT.
000462 01-04
PHENCYCLIOINE: EFFEQS OF CHRONIC ADMINISTRATION IN THE FEMALE
MOUSE ON GESTATION. MATERNAL-BEHAVIOR. AND THE NEONATES.
000517 01-05
PHENCYCLIOINE: A NIDA PERSPEaiVE,
000743 01-12
IN VITRO EFFECT OF PHENCYCLIOINE AND OTHER PSYCHOMOTOR
STIMULANTS ON SEROTONIN UPTAKE IN HUMAN PLATELETS.
000750 01-13
APPLICATION OF A RADIOIMMUNOASSAY SCREENING-TEST FOR
DETEQION AND MANAGEMENT OF PHENCYCLIOINE INTOXICATION.
000859 01-15
VOLUNTARY INTOXICATION FROM PHENCYCLIOINE. WILL IT RAISE A
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL-
STATE?.
000914 01-17
CHRONIC PHENCYCLIOINE (PCP) ABUSE: A PSYCHIATRIC-PERSPEQIVE
000935 01-17
STRUCTURE-AQIVITY RELATIONSHIP OF PHENCYCLIOINE DERIVATIVES.
001030 02-01
THE DISCOVERY OF PHENCYCLIOINE.
001040 02-01
DISPOSITION OF (3H) PHENCYCLIOINE IN THE RAT AFTER SINGLE-DOSES
AND MULTIPLE-DOSES.
001375 02-03
THE ELECTROPHYSIOLOGICAL-EFFECTS OF ENKEPHALIN AND
PHENCYCLIOINE IN THE RAT CENTRAL-NERVOUS-SYSTEM (PH D
DISSERTATION).
001406 02-03
COMPARED PROPERTIES OF CENTRAL AND PERIPHERAL BINDING-SITES
FOR PHENCYCLIOINE.
001521 02-03
(3H) PHENCYCLIOINE BINDING TO SPECIFIC BRAIN RECEPTOR SITES.
001555 02-03
EFFEQS OF PHENCYCLIOINE AND METHYLPHENIDATE ON D-
AMPHETAMINE-INDUCED BEHAVIORS IN RESERPINE PRETREATED RATS.
001616 02-04
TOLERANCE DEVELOPMENT TO PHENCYCLIOINE BY CHRONIC
ADMINISTRATION.
001619 02-04
PHENCYCLIOINE (PCP) AND DERIVATIVES: PHARMACOLOGY AND
STRUQURE-AQIVITY RELATIONSHIPS.
001706 02-04
PHENCYCLIOINE AS AN INDIREQ DOPAMINE AGONIST.
001719 02-04
EFFEQS OF PHENCYCLIOINE, PENTOBARBITAL, AND D-AMPHETAMINE ON
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL
DISCRIMINATIONS IN MONKEYS.
001723 02-04
EFFEQS OF ACUTE VS. CHRONIC PHENCYCLIOINE ON BRAIN-
BIOCHEMISTRY AND BEHAVIOR.
001789 02-04
Psychopharmacology Abstracts
BINDING OF PHENCYCLIOINE TO RAT-BRAIN MEMBRANES: TECHNICAL-
ASPEQ.
001882 02-06
EFFEQ OF CHRONIC ADMINISTRATION OF PHENCYCLIOINE ON HEPATIC
MIXED-FUNQION OXIDASES IN THE MOUSE.
002753 03-03
THE EFFEQ OF PHENCYCLIOINE ON DOPAMINE METABOLISM IN THE
MOUSE-BRAIN.
002766 03-03
DISCRIMINATIVE-STIMULUS PROPERTIES OF PHENCYCLIOINE AND FIVE
ANALOGUES IN THE SQUIRREL-MONKEY.
002961 03-04
EFFEQS OF CHRONIC ADMINISTRATION OF PHENCYCLIOINE ON
STEREOTYPED-BEHAVIORS AND ATAXIC-BEHAVIORS IN THE RAT.
003095 03-04
PHENCYCLIOINE (PCP) INTOXICATION: DIAGNOSIS IN STAGES AND
ALGORITHMS OF TREATMENT.
003525 03-15
THE URBAN EPIDEMIC OF PHENCYCLIOINE USE: LABORATORY EVIDENCE
FROM A PUBLIC PSYCHIATRIC-HOSPITAL INPATIENT-SERVICE.
003554 03-16
EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF PHENCYCLIOINE
ON DOPAMINERGIC-RECEPTORS IN RAT STRIATUM.
003901 04-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR PRESYNAPTIC ACTIONS OF
PHENCYCLIOINE ON NORADRENERGIC TRANSMISSION IN RAT
CEREBELLUM.
003926 04-03
ACUTE PHENCYCLIOINE (PCP) INTOXICATION: QUANTITATIVE URINE
LEVELS AND CLINICAL MANAGEMENT.
004665 04-15
PHENCYCLIDINE-HCL
TOXICOLOGIC AND PHARMACOLOGIC-EFFECTS OF PHENCYCLIDINE-HCL IN
THE DOG. (PH.D. DISSERTATION)
000519 01-05
PHENCYCLIDINE-HCL: A CHALLENGE TO MEDICINE.
003395 03-12
PHENCYCLIDINE-INDUCED
PHENCYCLIOINE-INDUCEO STIMUUTION OF SYNAPTOSOMAL TYROSINE-
HYDROXYLASE ACTIVITY.
001304 02-03
NEUROPHARMACOLOGICAL-STUDIES OF PHENCYCLIDINE-INDUCED
BEHAVIORAL- STIMULATION IN MICE.
001622 02-04
EFFECTS Of DOPAMINERGIC DRUGS ON PHENCYCLIDINE-INDUCED
BEHAVIOR IN THE RAT.
004083 04-04
PHENCYCUDINE-LIKE
PHENCYCLIDINE-LIKE DISCRIMINATIVE EFFECTS OF OPIOIDS IN THE RAT
004136 04-04
PHENCYCLIOINES
CONFIRMATION BEHAVIOR OF PHENCYCUDINES AND BIOLOGICAL-
ACTIVITY.
001031 02-01
PHENELZINE
THE EFFECT OF PHENELZINE AND SOME OF ITS PARA HALOGENATED
DERIVATIVES ON THE LEVELS OF BRAIN TYRAMINE AND OQOPAMINE
IN THE MOUSE
001077 02-02
PREDICTION OF RESPONSE TO TREATMENT WITH PHENELZINE IN
NEUROTIC-PATIENTS.
002081 02-10
CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM.
HALOPERIDOL, PHENELZINE AND D-AMPHETAMINE.
002355 02-14
PHENEUINE AND AMITRIPTYLINE IN NEUROTIC DEPRESSION.
(UNPUBLISHED PAPER).
003248 03-09
EFFECTS OF PHENELZINE AND AMITRIPTYLINE ON DEPRESSION.
003249 03-09
PHENELZINE AND EXPOSURE IN THE TREATMENT OF PHOBIAS.
003285 03-10
TREATMENT OF TRAUMATIC WAR-NEUROSIS WITH PHENELZINE.
003325 03-11
COMPARATIVE-EFFECTS OF PHENELZINE AND AMITRIPTYUNE: A
PLACEBO-CONTROLLED-TRIAL.
004402 04^
PHENETHYLAMINE
PHARMACOLOGY OF PHENETHYLAMINE TRACE AMINES IN THE DOG -
DISCUSSION.
000469 01-04
SEROTONERGIC PROPERTIES OF BETA PHENETHYLAMINE IN RATS.
001787 02-04
A COMMON MECHANISM FOR LYSERGIC-ACID, INDOLEALKYLAMINE AND
PHENETHYLAMINE HALLUCINOGENS: SEROTONERGIC MEDIATION OF
BEHAVIORAL-EFFECTS IN RATS.
004007 04-03
S-340
VOLUME 19, SUBJECT INDEX
Subject Index
PHENETHYLAMINES
SUBSTITUTED PHENETHYLAMINES AND ANOREXIA.
002541 02-17
PHENOBARBITAL
ENZYME INDUCING EFFECTS OF PHENOBARBITAL ON NITRAZEPAM
METABOLISM IN DOGS.
000086 01-03
EFFEQ OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL
AND DIPHENYLHYDANTOIN IN THE ELECTROSHOCK-TEST IN MICE.
000163 01-03
(3H)ACETYLCH0LINE AND (3H)5 HYDROXYTRYPTAMINE RELEASE FROM
RAT-MIDBRAIN SLICES AND THE EFFECTS OF CALCIUM AND
PHENOBARBITAL.
000251 01-03
CHANGES IN MOUSE-BRAIN DIAZEPAM-RECEPTOR BINDING AFTER
PHENOBARBITAL ADMINISTRATION.
000281 01-03
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EFFEaS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL,
DIPHENYLHYDANTOIN, AND fLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
INTRAVENOUS PHENOBARBITAL THERAPY IN BARBITURATE AND OTHER
HYPNOSEDATIVE WITHDRAWAL REACTIONS: A KINETIC APPROACH.
000703 01-11
SERUM CONCENTRATIONS OF PHENOBARBITAL AND
DIPHENYLHYDANTOIN IN SEVERE MENTALLY-HANDICAPPED AND
PHYSICALLY-HANDICAPPED-PATIENTS.
000856 01-15
DETERMINATION OF DOSE PLASMA CONCENTRATION RELATIONSHIP OF
PHENOBARBITAL IN EPILEPTIC-PATIENTS BY A NEW SPECIFIC
RADIOIMMUNOASSAY.
000902 01-16
PHENOBARBITAL EFFEaS ON WEIGHT-GAIN AND CIRCADIAN-CYCLING OF
FOOD INTAKE AND BODY-TEMPERATURE.
001409 02-03
RELATIONSHIP BETWEEN SERUM LEVELS AND FAST EEG AQIVITIES IN
RATS BY A SINGLE ADMINISTRATION OF PHENOBARBITAL.
001462 02-03
CRITICAL PERIODS FOR DIPHENYLHYDANTOIN AND PHENOBARBITAL
ADMINISTRATION DURING GESTATION.
001630 02-04
THE EFFEQS OF ETHANOL, PHENOBARBITAL, AND BACLOFEN ON
ETHANOL WITHDRAWAL IN THE RHESUS-MONKEY.
001802 02-04
COMPARATIVE-STUDY OF THE INDUCTIVE EFFECT OF TWO
PSYCHOMODERATORS ~ TETRABAMATE AND COMPLEXE-1656 - AND
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS.
001874 02-06
INFLUENCE OF PHENYTOIN AND PHENOBARBITAL ON THE DISPOSITION OF
A SINGLE-ORAL-DOSE OF CLONAZEPAM.
002248 02-13
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/AND
DIPHENYLHYDANTOIN IN SERUM LIPIDS.
002281 02-13
IN VITRO CELLULAR ADAPTATION OF SEROTONERGIC PROCESSES AFTER
CHRONIC CENTRAL PHENOBARBITAL ADMINISTRATION.
002813 03-03
CLONAZEPAM AND PHENOBARBITAL IN TARDIVE-DYSKINESIA.
003294 03-11
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
ETHANOL.
003725 04-03
EFFEQS OF ANIMAL AGE AND PHENOBARBITAL ON RAT LIVER GLUCOSE-
6-PHOSPHATASE AQIVITY.
003997 04-03
MECHANISM OF VALPROATE PHENOBARBITAL INTERACTION IN EPILEPTIC-
PATIENTS.
004522 04-13
PHENOBARBITONE
PHENOBARBITONE AND SODIUM-VALPROATE INTERAQION: AN
EXPERIMENTAL-STUDY.
001371 02-03
PHENOBARBITONE INTERAQION WITH ORAL CONTRACEPTIVE STEROIDS
IN THE RABBIT AND RAT.
001832 02-05
THE EFFEQS OF PHENYTOIN ON PHENOBARBITONE AND PRIMIDONE
METABOLISM.
003333 03-1 1
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
PHENOLIC
EFFECT OF THE POSITION OF THE PHENOLIC GROUP IN MORPHINANS ON
THEIR AFFINITY FOR OPIATE-RECEPTOR BINDING.
003702 04-02
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE
MOUSE AND THE RAT.
003870 04-03
PHENOMENA
LONG-TERM-TREATMENT WITH NEUROLEPTIC-AGENTS: ADAPTATION
PHENOMENA AND THEIR SIGNIFICANCE WITH REGARD TO
SCHIZOPHRENIC-SYMPTOMATOLOGY AND SIDE-EFFECTS.
002370 02-15
CHARACTER AND MEANING OF QUASI-MORPHINE WITHDRAWAL
PHENOMENA ELICITED BY METHYLXANTHINES.
004087 04-04
PHENOTHIAZINE
EFFECT OF STRUCTURE ON PHENOTHIAZINE CATION RADICAL REACTIONS
IN AQUEOUS BUFFERS.
000014 01-02
EFFECTS OF PHENOTHIAZINE DERIVATIVES AND RELATED COMPOUNDS ON
TYROSINE-AMINOTRANSFERASE ACTIVITY.
000018 01-03
CLINICAL ASSESSMENT OF ONCE A DAY PHENOTHIAZINE
ADMINISTRATION.
000573 01-08
INTERACTION BETWEEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN:
METABOLITE NORTRIPTYLINE AND THE CORRELATION WITH CLINICAL-
RESPONSE.
000640 01-09
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A
LIGAND FOR NEUROLEPTIC-RECEPTORS ~ I. IN VITRO STUDIES.
001133 02-03
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A
LIGAND FOR NEUROLEPTIC-RECEPTORS - II. IN VIVO STUDIES.
001137 02-03
CONFORMATIONALLY RESTRICTED PHENOTHIAZINE NEUROLEPTICS. 1. 3
DIMETHYLAMINO-TETRAHYDROAZEPINOPHENOTHIAZINE.
001359 02-03
CHANGE IN OVERINCLUSIVE THINKING OF SCHIZOPHRENIC-PATIENTS IS
RELATED TO PLASMA PHENOTHIAZINE CONCENTRATION.
001941 02-08
PHENOTHIAZINE PLASMA AND RED-BLOOD-CELL CONCENTRATIONS, THEIR
RELATIONSHIP TO SIDE-EFFECTS AND CLINICAL-EFFICACY.
002386 02-15
PHENOTHIAZINE ACTION ON CEREBRAL 5 HYDROXYTRYPTAMINE.
002850 03-03
INCREASED SERUM PROLACTIN LEVELS DURING PHENOTHIAZINE AND
BUTYROPHENONE TREATMENT OF SIX POSTPARTUM WOMEN.
003318 03-11
SPECTRA OF RADICAL CATIONS OF PHENOTHIAZINE DERIVATIVES IN
SOLUTION AND SOLID STATE.
003673 04-01
INHIBITION OF PENTAGASTRIN-STIMULATED AND OVERNIGHT GASTRIC
SECRETION BY LM24056, A NEW PHENOTHIAZINE DERIVED
ANTISECRETORY DRUG.
004306 04-07
PHENOTHIAZINES
PARTITIONING AND EFFLUX OF PHENOTHIAZINES FROM LIPOSOMES.
000007 01-02
POSSIBLE MODE OF ACTION OF NEUROPSYCHIATRIC-AGENTS:
PHENOTHIAZINES AND IMINODIBENZYLS.
001271 02-03
EFFECT OF PROPRANOLOL AND PHENOTHIAZINES ON ELECTRODERMAL
ORIENTING AND HABITUATION IN SCHIZOPHRENIA.
003174 03-08
PHENOTYPE
ACETYLATOR PHENOTYPE AND LUPUS-ERYTHEMATOSUS.
003545 03-15
PHENOTYPIC
MATERNAL GLUCOCORTICOID-HORMONES INFLUENCE
NEUROTRANSMIHER PHENOTYPIC EXPRESSION IN EMBRYOS.
000149 01-03
PHENOXYBENZAMINE
ENHANCED SUPPRESSION OF CONDITIONED AVOIDANCE RESPONSE BY
HALOPERIDOL BUT NOT PHENOXYBENZAMINE IN RATS WITH
BILATERAL PARAFASCICULAR LESIONS.
000334 01-04
METABOLIC AND SYMPATHOADRENAL ABNORMALITIES IN THE OBESE
ZUCKER RAT: EFFECT OF CHRONIC PHENOXYBENZAMINE TREATMENT.
003905 04-03
PHENOXYBENZAMINE AND BROMOCRIPTINE AHENUATE NEED FOR REM
SLEEP IN RATS.
004203 04-04
ANTAGONISM BY PHENOXYBENZAMINE AND PENTAZOCINE OF THE
ANTINOCICEPTIVE-EFFECTS OF MORPHINE IN THE SPINAL-CORD.
004213 04-04
S-341
Subject Index
m
mt
9t
C.3:
it
mt.
Sit
m
fire
||il
::»'
PHENTOLAMINE
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
INHIBITION BY LOCAL ANESTHETICS, PHENTOLAMINE AND PROPRANOLOL
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL
MUSCARINIC-RECEPTORS.
001097 02-03
CENTRAL-ACTIONS OF NOREPINEPHRINE, PHENTOLAMINE AND 6
HYDROXYDOPAMINE IN SPONTANEOUSLY HYPERTENSIVE-RATS.
001553 02-03
EFFECT OF PHENTOLAMINE ADMINISTRATION INTO THE AMYGDALA
COMPLEX OF RATS ON TIME-DEPENDENT MEMORY PROCESSES.
002998 03-04
PHENn-2-THIAZOLYL-2-THIOUREA
EFFECT OF THE CATECHOLAMINE-DEPLETING-AGENT 1 PHENYL-2-
THIAZOLYL-2-THIOUREA (U- 14-624) ON DRUG METABOLISM IN THE
RAT.
000280 01-03
PHENYLACETATE
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE ACETYLCHOLINE
ANTAGONIST DIMETHYIAMINOBUTYNYLCYCLOHEXYLHYDROXY 2
PHENYLACETATE HCL.
000003 01-01
PHENYLACETATE AND BRAIN-DYSFUNCTION IN EXPERIMENTAL
PHENYLKETONURIA: SYNAPTIC DEVELOPMENT.
000191 01-03
PHENYLACETATE AND THE ENDURING BEHAVIORAL-DEFICIT IN
EXPERIMENTAL PHENYLKETONURIA.
000388 01-04
PHENYLALANINE
THE CONVERSION OF (3H)TRYPT0PHAN TO 5 (3H)HYDR0XYTRYPTAMINE
IN MOUSE-BRAIN FOLLOWING DEPLETION OF PHENYLALANINE AND
TYROSINE.
000148 01-03
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE
FORMATION FROM PHENYLALANINE.
001113 02-03
D PHENYLALANINE IN ENDOGENOUS DEPRESSION.
002017 02-09
PHENYLALANINE LEVELS IN ENDOGENOUS PSYCHOSES.
002049 02-09
EEG CHANGES IN CHILDREN WITH TREATED PHENYLKETONURIA AFTER
PHENYLALANINE LOAD.
002115 02-11
POSSIBLE MECHANISMS OF EFFECT OF ACTH4-10 AND ITS ANALOG
CONTAINING D ISOMER OF PHENYLALANINE, ON BEHAVIOR.
002949 03-04
EFFECT OF ALPHA METHYLPHENYLAL'VNINE AND PHENYLALANINE ON
BRAIN POLYRIBOSOMES AND PROTEIN SYNTHESIS.
003733 04-03
PHENYLALKYLAMINES
RELATIVE POTENCIES OF TWO PHENYLALKYLAMINES FOUND IN THE
ABUSED PLANT CATHA-EDULIS, KHAT.
PHENYLBUTAZONE
BIOLOGIC-INTERAQION OF GAMMA-RADIATION WITH
PHENYLBUTAZONE, PHENYTOIN, OR HYDRALAZINE
001084 02-02
000518 01-05
PHENYLETHANOLAMINE
BETA PHENYLETHYU\MINE, PHENYLETHANOLAMINE, TYRAMINE AND
OCTOPAMINE. (UNPUBLISHED PAPER).
002601 02-17
PHENYLETHANOLAMINE-N-METHYLTRANSFERASE
INHIBITORS OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND
EPINEPHRINE BIOSYNTHESIS. 2. 1,2,3,4 TETRAHYDROISOQUINOLINE-7-
SULFONANILIDES.
001069 02-02
PHENYLETHYLAMINE
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-ACTIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
ACTIVITY.
000309 01-03
EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE
ROLE FOR BETA PHENYLETHYLAMINE IN THE COCAINE CUE
000363 01-04
PHENYLETHYLAMINE, DOPAMINE AND NOREPINEPHRINE IN
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
001957 02-08
MONOAMINE-OXIDASE, PHENYLETHYLAMINE, NOREPINEPHRINE AND
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
001958 02-08
BETA PHENYLETHYLAMINE, PHENYLETHANOLAMINE, TYRAMINE AND
OaOPAMINE. (UNPUBLISHED PAPER).
002601 02-17
Psychopharmacology Abstracts
PHENYLETHYLAMINE EFFEaS ON DOPAMINE SYNTHESIS. STRUQURE-
AQIVITY RELATIONSHIPS.
002649 03-02
MONOAMINE-OXIDASE-B AQIVITIES TOWARD BETA PHENYLETHYLAMINE
IN DISCRETE HYPOTHALAMIC AND CIRCUMVENTRICULAR NUCLEI OF
THE RAT.
002781 03-03
PHENYLETHYLAMINE EFFEQS ON DOPAMINE SYNTHESIS: STRUQURE-
ACTIVITY RELATIONSHIPS. (UNPUBLISHED PAPER).
003959 04-03
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCED
AQIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY
004018 04-03
OXIDATION OF BETA PHENYLETHYLAMINE BY BOTH TYPES OF
MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND
LIVER MITOCHONDRIA OF EIGHT SPECIES.
004024 04-03
PHENYLETHYLAMINES
COMPARATIVE-EFFECTS OF SUBSTITUTED PHENYLETHYLAMINES ON BRAIN
SEROTONERGIC MECHANISMS.
003854 04-03
PHENYLHEXAHYDROAZEPINOINDOLES
SYNTHESIS OF SOME 5 PHENYLHEXAHYDROAZEPINOINDOLES AS
POTENTIAL NEUROLEPTIC-AGENTS.
001019 02-01
PHENYLKETONURIA
PHENYLACETATE AND BRAIN-DYSFUNQION IN EXPERIMENTAL
PHENYLKETONURIA: SYNAPTIC DEVELOPMENT.
000191 01-03
PHENYLACETATE AND THE ENDURING BEHAVIORAL-DEFICIT IN
EXPERIMENTAL PHENYLKETONURIA.
000388 01-04
EEG CHANGES IN CHILDREN WITH TREATED PHENYLKETONURIA ARER
PHENYLALANINE LOAD.
002115 02-11
PHENYLKETONURIA: THE INADVISABILITY OF NEUROLEPTIC-MEDICATION.
003380 03-11
PHENYLPROPANOLAMINE
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL
DAMAGE
000322 01-03
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR
DORSOLATERAL TEGMENTAL DAMAGE
001818 02-04
AMPHETAMINE-LIKE REAQIONS TO PHENYLPROPANOLAMINE.
003480 03-15
PHENYLURETHANS
SYNTHESIS OF PHENYLURETHANS OF 1,2 DIALKYL-4-PYRAZOLIDINOLS AS
ANTICONVULSANT-AGENTS.
003695 04-02
PHENYTOIN
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJEQION.
000261 01-03
BIOLOGIC-INTERACTION OF GAMMA-RADIATION WITH
PHENYLBUTAZONE, PHENYTOIN, OR HYDRALAZINE.
000518 01-05
VALPROIC-ACID AND PLASMA LEVELS OF PHENYTOIN.
000756 01-13
PRAQICAL AND THEORETICAL ASPEQS OF PHENYTOIN
ADMINISTRATION. I. RELATIONSHIP BETWEEN DOSE AND PLASMA
CONCENTRATION.
000760 01-13
EFFEQ OF DOSE ON PHENYTOIN ABSORPTION.
000773 01-13
REVERSAL BY PHENYTOIN OF CARBAMAZEPINE-INDUCED WATER
INTOXICATION: A PHARMACOKINETIC-INTERAQION.
000783 01-13
PREDICTABILITY OF PHENYTOIN SERUM LEVELS BY NOMOGRAMS AND
CLINICIANS.
000909 01-16
DECREASED BENZODIAZEPINE-RECEPTOR DENSITY IN RAT-CEREBELLUM
FOLLOWING NEUROTOXIC DOSES OF PHENYTOIN.
001373 02-03
PHENYTOIN KINETICS IN CHILDREN.
002113 02-11
INFLUENCE OF PHENYTOIN AND PHENOBARBITAL ON THE DISPOSITION OF
A SINGLE-ORAL-DOSE OF CLONAZEPAM.
002248 02-13
INTERAaiON BETWEEN PHENYTOIN AND VALPROIC-ACID: PLASMA
PROTEIN BINDING AND METABOLIC-EFFEaS.
002276 02-13
INDIVIDUALIZATION OF PHENYTOIN THERAPY.
002495 02-16
S-342
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF PHENYTOIN ON PYRAMIDAL NEURONS OF THE RAT
HIPPOCAMPUS.
002750 03-03
PHENYTOIN VALPROIC-ACID INTERACTION IN RHESUS-MONKEY.
002785 03-03
THE EFFECTS OF PHENYTOIN ON PHENOBARBITONE AND PRIMIDONE
METABOLISM,
003333 03-1
PHENYTOIN: PHARMACOKINETICS AND CLINICAL THERAPEUTICS.
003353 03-1
INTRAVENOUS VALPROATE: EFFECTS ON PLASMA AND SALIVA
PHENYTOIN LEVELS.
003359 03-1
DISSOCIATION BETWEEN FREE AND BOUND PHENYTOIN LEVELS IN
PRESENCE OF SODIUM-VALPROATE.
003367 03-1
COMPARISON OF SODIUM-VALPROATE AND PHENYTOIN AS SINGLE
DRUG-TREATMENT IN EPILEPSY.
003371 03-1
PHENYTOIN CONCENTRATIONS IN VENOUS VERSUS CAPILLARY BLOOD OF
GERIATRIC-PATIENTS
003381 03-
THE EFFECTS OF SALICYLATE ON THE PHARMACOKINETICS OF
PHENYTOIN.
003421 03-13
RESPIRATORY-DISEASE AND NASAL IMMUNOGLOBULIN
CONCENTRATIONS IN PHENYTOIN TREATED EPILEPTIC-PATIENTS.
003486 03-15
PHENYTOIN TOXICITY IN A BRAIN-DAMAGE ADOLESCENT: A CASE-
REPORT.
003512 03-15
SINGLE POINT ESTIMATION OF PHENYTOIN DOSING REQUIREMENT.
003562 03-16
EFFEQS OF PHENYTOIN ON MOUSE CEREBELLAR 5 HYDROXYTRYPTAMINE
AND NOREPINEPHRINE.
003795 04-03
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C-
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM-
CHANNEL BLOCKADE.
004020 04-03
EFFEQ OF PRENATAL PHENYTOIN ADMINISTRATION ON BRAIN
TRYPTOPHAN METABOLISM OF RAT OFFSPRING DURING THE
PREWEANING PERIOD.
004108 04-04
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF
ASSESSING COMPLIANCE.
004495 04-11
ANTIEPILEPTIC THERAPY WIH PHENYTOIN: WHICH IS THE OPTIMUM
SERUM LEVEL?
004586 04-14
PHEOCHROMOCYTOMA
PURIFICATION AND CHARACTERIZATION OF RAT PHEOCHROMOCYTOMA
DOPAMINE-BETA-HYDROXYLASE.
003664 04-01
PHOBIA
PHOBIA: PSYCHOLOGICAL-TREATMENT AND PHARMACOLOGICAL-
TREATMENT.
004425 04-10
PHOBIAS
PHENELZINE AND EXPOSURE IN THE TREATMENT OF PHOBIAS.
003285 03-10
PHOBIC-ANXIETY
BEHAVIORAL-DESENSITIZATION OF PHOBIC-ANXIETY USING THIOPENTAL-
SODIUM.
002352 02-14
PHOBIC-ANXIETY-SYNDROME
DRUG-TREATMENT OF THE PHOBIC-ANXIETY-SYNDROME.
003280 03-10
PHOBIC-STATES
DIFFERENTIAL DIAGNOSIS AND TREATMENT OF PANIC ATTACKS AND
PHOBIC-STATES.
004424 04-10
PHOBIC-SUBJECTS
BEHAVIORAL-EFFEaS AND SUBJECTIVE-EFFEQS OF BETA-ADRENERGIC
BLOCKADE IN PHOBIC-SUBJECTS.
002060 02-10
PHOSPHATIDYLSERINE
PHYSIOLOGIC AND PHARMACOLOGIC IMPLICATIONS IN THE
DEACYLATION OF PHOSPHATIDYLSERINE IN MICE.
002682 03-03
PHOSPHODIESTERASE
PHOSPHODIESTERASE INHIBITORS FACILITATE MEMORY FOR PASSIVE-
AVOIDANCE CONDITIONING.
003109 03-04
PHOSPHOLIPASE-A2
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
PHOSPHOLIPID
PHOSPHOLIPID METHYLATION AND TRANSMEMBRANE SIGNALLING.
(UNPUBLISHED PAPER).
001001 02-01
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
PHOSPHOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR-
MEDIATED INDUCTION OF CHEMOTAXIS IN RABBIT NEUTROPHILS.
(UNPUBLISHED PAPER).
001118 02-03
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION. CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER).
001188 02-03
PHOSPHOLIPID METHYLATION: A BIOCHEMICAL-EVENT OF SIGNAL
TRANSDUCTION. (UNPUBLISHED PAPER).
001279 02-03
INCREASED ADRENALINE, BETA-ADRENERGIC-RECEPTOR STIMULATION
AND PHOSPHOLIPID METHYLATION IN PINEAL-GLAND OF
SPONTANEOUSLY HYPERTENSIVE-RATS. (UNPUBLISHED PAPER).
001458 02-03
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN: CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
PHOSPHORUS
ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED
PAPER).
001014 02-01
PHOSPHORYLATION
REGULATION OF THE STATE OF PHOSPHORYLATION OF SPECIFIC
NEURONAL PROTEINS IN MOUSE-BRAIN BY IN VIVO ADMINISTRATION
OF ANESTHETIC AND CONVULSANT-AGENTS.
000291 01-03
PHOSPHORYLATION OF THE MEMBRANE-BOUND ACETYLCHOLINE-
RECEPTOR: INHIBITION BY DIPHENYLHYDANTOIN.
001257 02-03
BRAIN STRIATAL TYROSINE-HYDROXYLASE: ACTIVATION OF THE ENZYME
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION.
001423 02-03
PHOTOAFFINITY
BENZODIAZEPINE-RECEPTOR: LOCALIZATION BY PHOTOAFFINITY
LABELING AND ISOLATION OF A POSSIBLE ENDOGENOUS LIGAND.
001381 02-03
PHOTOCHEMICAL-STABILITY
THE PHOTOCHEMICAL-STABILITY OF CIS-ISOMERS AND TRANS-ISOMERS
OF TRICYCLIC NEUROLEPTIC-DRUGS.
001872 02-06
PHOTOSENSITIVE
TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC-
DISCHARGE IN HUMANS BY APOMORPHINE, A DOPAMINE-RECEPTOR
AGONIST.
000714 01-11
ELECTROENCEPHALOGRAPHIC-EFFEaS AND BEHAVIOURAL-EFFECTS OF
SODIUM-VALPROATE IN PATIENTS WITH PHOTOSENSITIVE EPILEPSY. A
SINGLE-DOSE TRIAL.
002154 02-11
THE EFFECT OF SODIUM-VALPROATE ON THE PHOTOSENSITIVE VEP.
004513 04-13
PHRENIC-NERVE
DIPHENYLHYDANTOIN-INDUCED BLOCK OF THE RAT PHRENIC-NERVE
DIAPHRAGM PREPARATION PRETREATED WITH P
HYDROXYMERCURIBENZOATE.
002749 03-03
PHRENOLON
THE EFFECT OF PHRENOLON ON DELAYED REACTIONS IN LOWER
MONKEYS.
001640 02-04
PHYSICAL
CHANGES OF PHYSICAL MORPHINE-DEPENDENCE IN RATS CHRONICALLY
TREATED WITH DRUGS ACTING ON BRAIN 5 HYDROXYTRYPTAMINE.
001764 02-04
PSYCHIATRIC MORBIDITY AND PHYSICAL TOXICITY ASSOCIATED WITH
ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY.
002433 02-15
PHYSICAL AND PHYSIOLOGICAL CHARACTERISTICS OF MICROPRESSURE
EJECTION OF DRUGS FROM MULTIBARRELED PIPEHES.
002502 02-16
PHYSICAL AND KINETIC PROPERTIES OF CHOLINE-ACETYL-TRANSFERASE
FROM RAT AND BOVINE BRAIN.
003676 04-01
S-343
Subject Index
Psychopharmacology Abstracts
m
ii
3JI11:'
m
I*
is*
PHYSICAL-DEPENDENCE
CONTINUOUS-ACCESS PHENCYCLIOINE SELF-ADMINISTRATION BY RHESUS-
MONKEYS LEADING TO PHYSICAL-DEPENDENCE.
000341 01-04
ASSESSMENT OF TOLERANCE TO AND PHYSICAL-DEPENDENCE ON
PENTOBARBITAL, INDUCED BY MULTIPLE PELLET IMPLANTATION.
000385 01-04
DOSE AND PHYSICAL-DEPENDENCE AS FACTORS IN THE SELF-
ADMINISTRATION OF MORPHINE BY RATS.
000497 01-04
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 02-03
COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT.
001841 02-05
ENKEPHALIN ANALOGS AND PHYSICAL-DEPENDENCE.
003572 03-16
BUPRENORPHINE: DEMONSTRATION OF PHYSICAL-DEPENDENCE LIABILITY.
004104 04-04
PHYSICALLY-HANDICAPPED-PATIENTS
SERUM CONCENTRATIONS OF PHENOBARBITAL AND
OIPHENYLHYDANTOIN IN SEVERE MENTALLY-HANDICAPPED AND
PHYSICALLY-HANDICAPPED-PATIENTS.
000856 01-15
PHYSICO-CHEMICAL
PHYSICO-CHEMICAL METHODOLOGIES IN PSYCHIATRIC-RESEARCH.
004679 04-16
PHYSICS
THE PHYSICS OF lONTOPHORETIC PIPEHES.
004299 04-06
PHYSIOLOGIC
PHYSIOLOGIC AND PHARMACOLOGIC IMPLICATIONS IN THE
DEACYLATION OF PHOSPHATIDYLSERINE IN MICE.
002682 03-03
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES
IN THIS PHASE.
003251 03-09
PHYSIOLOGICAL
GABA BENZODIAZEPINE INTERACTIONS: PHYSIOLOGICAL,
PHARMACOLOGICAL AND DEVELOPMENTAL ASPECTS.
000103 01-03
PHYSICAL AND PHYSIOLOGICAL CHARACTERISTICS OF MICROPRESSURE
EJECTION OF DRUGS FROM MULTIBARRELED PIPEHES.
002502 02-16
IDENTICAL RESPONSES OF THE TWO HIPPOCAMPAL THETA GENERATORS
TO PHYSIOLOGICAL AND PHARMACOLOGICAL ACTIVATION.
002792 03-03
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-03
PHYSIOLOGICAL SIGNIFICANCE OF DOPAMINE-AUTORECEPTORS AS
STUDIED FOLLOWING THEIR SELECTIVE BLOCKADE BY MOLINDONE.
004065 04-04
PHYSIOLOGICAL AND BEHAVIORAL APPROACHES TO THE STUDY OF THE
QUASI-MORPHINE WITHDRAWAL-SYNDROME .
004242 04-04
MEPROBAMATE REDUCES ACCURACY OF PHYSIOLOGICAL DETEQION OF
DECEPTION.
004585 04-14
BIOLOGICAL AND PHYSIOLOGICAL PREDIQORS OF DRUG RESPONSE.
(UNPUBLISHED PAPER).
004708 04-17
PHYSIOLOGICAL-CORRELATES
LONG-TERM EFFECTS OF TESTOSTERONE INJECTIONS ON THE SOCIAL-
BEHAVIOUR OF MALE DUCKS AND THEIR PHYSIOLOGICAL-CORRELATES.
001565 02-04
PHYSIOLOGICAL-STUDIES
PHYSIOLOGICAL- STUDIES AND BEHAVIORAL-STUDIES WITH MUSCIMOL.
002538 02-17
PHYSIOLOGY
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL- STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN) .
002286 02-13
ON THE PHYSIOLOGY AND PHARMACOLOGY OF ENDORPHINS.
003417 03-13
PHYSOSTIGMINE
INHIBITION OF (3H)NAL0X0NE BINDING IN HOMOGENATES OF RAT-
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC AQIVITY, RELATED
TO PHYSOSTIGMINE.
000104 01-03
THERAPEUTIC APPLICATION OF PHYSOSTIGMINE IN NEUROSIS.
000651 01-10
MEMORY AND COGNITIVE FUNQION IN THE ELDERLY: A PRELIMINARY-
TRIAL OF PHYSOSTIGMINE.
000802 01-14
MOOD AND BEHAVIORAL-EFFECTS OF PHYSOSTIGMINE ON HUMANS ARE
ACCOMPANIED BY ELEVATIONS IN PLASMA BETA ENDORPHIN AND
CORTISOL.
002280 02-13
HUMAN MEMORY AND THE EFFEaS OF PHYSOSTIGMINE AND CHOLINE-
CHLORIDE.
002317 02-14
PHYSOSTIGMINE INDUQION OF DEPRESSIVE-SYMPTOMATOLOGY IN
NORMAL HUMAN SUBJECTS.
003255 03-09
PHYSOSTIGMINE IN TOUREHE-SYNDROME: EVIDENCE FOR CHOLINERGIC
UNDERACTIVITY.
003286 03-10
PHYSOSTIGMINE FOR TREATMENT OF DELIRIUM-TREMENS.
003364 03-11
ALTERATIONS IN CEREBROSPINAL-FLUID DOPAMINE METABOLITES
FOLLOWING PHYSOSTIGMINE INFUSION
003477 03-15
PHYTOHEMAGGLUTININ
THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE
PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION
WITH PHYTOHEMAGGLUTININ.
004541 04-13
PIAL-ARTERIES
DOPAMINE-BETA-HYDROXYLASE AQIVITY AND NORADRENALINE
CONTENT IN PIAL-ARTERIES OF CAT AND GOAT.
001357 02-03
INFLUENCE OF CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5
HYDROXYTRYPT AMINE, TYRAMINE AND POTASSIUM FROM GOAT
PIAL-ARTERIES.
003925 04-03
PIAL-ARTERIOLES
BIPHASIC RESPONSIVENESS OF RAT PIAL-ARTERIOLES TO DOPAMINE
DIREa OBSERVATIONS ON THE MICROCIRCULATION.
001105 02-03
PICK
TWO NEW DRUGS MAY PICK UP WHERE L-DOPA LEAVES OFF.
001897 02-07
PICOGRAM
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUIO-
CHROMATOGRAPHY WITH ELEQROCHEMICAL DETEQION
003674 04-01
PICOMOLE
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYIACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
PICROTOXIN
EFFECT OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO
STIMULATION OF THE NUCLEUS-ACCUMBENS
Q00331 01-03
LOCOMOTOR AND CONVULSIVE RESPONSES TO PICROTOXIN IN
AMYGDALA KINDLED RATS
00041601-04
LOCOMOTOR-AaiVITY ELICITED BY INJECTIONS OF PICROTOXIN INTO THE
VENTRAL TEGMENTAL AREA IS AHENUATED BY INJEQIONS OF GABA
INTO THE GLOBUS-PALLIDUS
000436 01-04
MAPPING OF DYSKINETIC-MOVEMENTS INDUCED BY LOCAL APPLICATION
OF PICROTOXIN OR () GAMMA ACETYLENIC-GABA ON THE RAT
MOTOR-CORTEX.
000458 01-04
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHAUMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
EFFEQ OF PICROTOXIN ON BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS WITH REFERENCE TO THE EFFECT OF CHLORIDE ION.
002725 03-03
MODULATION BY PICROTOXIN AND IPTBO OF 3H FLUNITRAZEPAM
BINDING TO THE GABA/BENZOOIAZEPINE-RECEPTOR COMPLEX OF RAT-
CEREBELLUM.
002775 03-03
EFFEaS OF 5 HYDROXYTRYPTAMINE ON CENTRAL NEURONES
ANTAGONIZED BY BICUCULLINE AND PICROTOXIN.
003931 04-03
PIECES
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II. FAQORS
AFFEQING THE ACCUMULATION OF CYCLIC-AMP IN PIECES OF INTAQ
CARP RETINA.
003776 04^3
S-344
VOLUME 19, SUBJECT INDEX
PIFLUTIXOL
SIMILARITIES BETWEEN THE BINDING OF 3H PIFLUTIXOL AND 3H
FLUPENTIXOL TO RAT STRIATAL DOPAMINE-RECEPTORS IN VITRO.
002760 03-03
no
THE INTERACTION OF 2,3,4 TRIHYDROXYBENZYLHYDRAZINE WITH
DOPA-DECARBOXYLASE FROM PIG KIDNEY
002925 03-03
nOEON
LITHIUM-CHLORIDE AND DEITA9 THC LEAD TO CONDITIONED AVERSIONS
IN THE PIGEON.
003003 03-04
A CHARACTERIZATION OF THE BEHAVIORAL-EFFECTS OF LEVO ALPHA
ACETYLMETHADOL IN THE RAT AND IN THE PIGEON (PH.D.
DISSERTATION).
003047 03-04
METHYLMERCURY-INDUCED CHANGES IN OPERANT DISCRIMINATION BY
THE PIGEON.
004271 04-05
PIGEONS
DELTA9 THC IN PIGEONS: A REPLICATION AND EXTENSION.
000394 01-04
JOINT-EFFECTS OF D-AMPHETAMINE AND ETHANOL OR PENTOBARBITAL
IN PIGEONS.
000403 01-04
LSD-25 AS A DISCRIMINATIVE-STIMULUS FOR RESPONSE SELECTION BY
PIGEONS.
000412 01-04
EFFEQS OF APOMORPHINE ON ELICITED AND OPERANT PECKING IN
PIGEONS.
001557 02-04
DISCRIMINATIVE-STIMULUS EFFECTS OF PENTOBARBITAL IN PIGEONS.
001651 02-04
DELTA9 THC AS A DISCRIMINATIVE-STIMULUS IN RATS AND PIGEONS:
GENERALIZATION TO THC METABOLITES AND SP-1 1 1 .
001666 02-04
THE EFFEaS OF 0-AMPHETAMINE, CHLORDIAZEPOXIDE, AND
PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM
PUNISHMENT IN PIGEONS. (PH.D. DISSERTATION).
001713 02-04
DRUG-EFFEQS ON THE PERFORMANCE OF PIGEONS UNDER A NEGATIVE
AUTOMAINTENANCE-SCHEDULE.
001754 02-04
EFFEQS OF NORCOCAINE AND SOME NORCOCAINE DERIVATIVES ON
SCHEDULE-CONTROLLED BEHAVIOR OF PIGEONS AND SQUIRREL-
MONKEYS.
004012 04-03
METHADONE-INDUCED AHENUATION OF THE EFFECTS OF DELTA9
TETRAHYDROCANNABINOL ON TEMPORAL DISCRIMINATION IN
PIGEONS.
004095 04-04
NARCOTIC DISCRIMINATION IN PIGEONS.
004132 04-04
PIGS
OPERANT FEEDING AND DRINKING IN PIGS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF SYNTHETIC
CHOLECYSTOKININ-OCTAPEPTIDE.
003064 03-04
PIGTAIL-MACAQUE
BEHAVIOR MAINTAINED BY INTRAVENOUS INJECTION OF CODEINE,
COCAINE, AND ETORPHINE IN THE RHESUS-MACAQUE AND THE
PIGTAIL-MACAQUE.
001828 02-04
PILLS
PILLS FOR NERVES.
000652 01-10
PILOCARPINE
EFFEQS OF SCOPOLAMINE, PILOCARPINE, AND OXOTREMORINE ON THE
EXPLORATORY-BEHAVIOR OF TWO PSYCHOGENETICALLY SELEQED
LINES OF RATS IN A COMPLEX MAZE.
003042 03-04
PILOT-STUDY
COMBINED MONOAMINE-OXIDASE-INHIBITOR TRICYCLIC-
ANTIDEPRESSANT TREATMENT: A PILOT- STUDY.
000644 01-09
EVALUATION OF CLORAZEPATE (TRANXENE) AS AN ANTICONVULSANT ~
A PILOT-STUDY.
000728 01-11
BACLOFEN IN TRIGEMINAL-NEURALGIA: ITS EFFECT ON THE SPINAL
TRIGEMINAL-NUCLEUS: A PILOT-STUDY.
002122 02-11
TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERACTIVE-
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL
PARADIGM ~ A PILOT-STUDY.
002126 02-11
GROUP VERSUS INDIVIDUAL COGNITIVE-THERAPY: A PILOT-STUDY.
003257 03-09
USE OF THA IN TREATMENT OF ALZHEIMER-LIKE DEMENTIA: PILOT-STUDY
IN TWELVE PATIENTS.
003377 03-1 1
Subject Index
ALPRAZOLAM, A NEW TYPE ANXIOLYTIC IN NEUROTIC-PATIENTS: A
PILOT-STUDY.
004422 04-10
PIMOZIDE
ACTIONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID
METABOLISM IN GUINEA-PIG BRAIN SLICES.
000129 01-03
BIPHASIC-EFFECTS OF PIMOZIDE ON SLEEP-WAKEFULNESS IN DOGS.
000495 01-04
THE EFFECT OF MORPHINE, PIMOZIDE AND NALOXONE ON
DISCRIMINATION BY RATS IN A SHOCK-ESCAPE-TEST.
001700 02-04
EFFECTS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND
DISTRIBUTION OF CORRECT RESPONDING ON A SIMULTANEOUS
DISCRIMINATION TASK IN THE RAT.
001806 02-04
INTERMITTENT PIMOZIDE VERSUS FLUPHENAZINE-DECANOATE AS
MAINTENANCE-THERAPY IN CHRONIC SCHIZOPHRENIA.
001932 02-08
A NEW DOSAGE SCHEDULE FOR PIMOZIDE IN THE ACUTE STABILIZATION
AND MAINTENANCE-TREATMENT OF PSYCHOSIS.
002022 02-09
PIMOZIDE IN THE TREATMENT OF SOME SOCIAL-MALADJUSTMENTS IN
PERSONALITY-DISORDERS.
002068 02-10
HUNTINGTONS-DISEASE: CLINICAL-EFFECTS OF A SHORT-TERM
TREATMENT WITH PIMOZIDE.
002091 02-1 1
USE OF PIMOZIDE (ORAP) IN CHILD-PSYCHIATRY.
002100 02-11
FACTORS DETERMINING PATIENT TENURE ON A 3-YEAR DOUBLE-BLIND
INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE-HCL.
002513 02-17
THE EFFECTS OF PIMOZIDE DURING PAIRING ON THE TRANSFER OF
CLASSICAL CONDITIONING TO AN OPERANT DISCRIMINATION.
002956 03-04
PIMOZIDE AHENUATES LEVER-PRESSING FOR WATER REINFORCEMENT IN
RATS.
003000 03-04
EFFECTS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC-
ACID, HALOPERIDOL AND PIMOZIDE ON REFLEX BRADYCARDIA IN
RATS.
004085 04-04
PLASMA CORTICOSTERIODS IN MANIA: THE EFFECTS OF PIMOZIDE.
004363 04-09
THE EFFECT OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON
THE STIMULANT AND ANORECTIC-ACTIONS OF DEXTROAMPHETAMINE
IN MAN.
004580 04-14
PIMOZIDE-HYDROCHLORIDE
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE NEUROLEPTIC
PIMOZIDE-HYDROCHLORIDE, BISFLUOROPHENYL-
BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL.
001015 02-01
PINEAL
PINEAL INTERACTIONS WITH THE CENTRAL-NERVOUS-SYSTEM:
NEUROENDOCRINE IMPLICATIONS. (PH.D. DISSERTATION).
001341 02-03
ADRENERGIC REGULATION OF THE REDUCTION IN ACETYL-COENZYME-
A:ARYLAMINE-N-ACETYLTRANSFERASE IN THE RAT PINEAL.
002654 03-03
PINEAL-GLAND
INCREASED ADRENALINE, BETA-ADRENERGIC-RECEPTOR STIMULATION
AND PHOSPHOLIPID METHYLATION IN PINEAL-GLAND OF
SPONTANEOUSLY HYPERTENSIVE-RATS; (UNPUBLISHED PAPER).
001458 02-03
PINEAL-GLAND. (UNPUBLISHED PAPER)
001552 02-03
PINEAL-GLAND AND MELATONIN INFLUENCE ON CHRONIC ALCOHOL
CONSUMPTION BY HAMSTERS.
003076 03-04
ULTRASTRUCTURAL LOCALIZATION OF MONOAMINES IN NERVE FIBERS
OF THE PINEAL-GLAND IN GOLDEN HAMSTERS.
003666 04-01
EFFEQ OF 6 HYDROXYDOPAMINE ON THE FINE STRUCTURE OF THE
HAMSTER PINEAL-GLAND.
003747 04-03
CIRCADIAN-VARIATION OF CYCLIC-AMP IN THE RAT PINEAL-GLAND.
003938 04-03
PINEAL-ORGAN
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS,
BRAIN, AND PINEAL-ORGAN OF THE RAT.
002503 02-16
PINNA-REFLEX
EFFEQS ON THE PINNA-REFLEX OF DRUGS ACTING AT ALPHA-
ADRENOCEPTORS.
004078 04-04
S-345
Subject Index
Psychopharmacology Abstracts
m
li!SI».
■Jllll;;:
Jit'
Bit.
a-'
I*
PIONEERS
FDA CLIPS PSYCHODRUG PIONEERS IND WINGS.
003160 03-07
PIPECOLIC-ACID
UPTAKE OF PIPERIDINE AND PIPECOLIC-ACID BY SYNAPTOSOMES FROM
MOUSE-BRAIN.
001396 02-03
PIPERACETAZINE
TARDIVE-DYSKINESIA FOLLOWING LOW-DOSES OF PIPERACETAZINE.
002399 02-15
PIPERAZINYL-10H-THIENOBENZODIAZEPINES
4 PIPERAZINYL-IOH-THIENOBENZODIAZEPINES AS POTENTIAL
NEUROLEPTICS.
001592 02-04
PIPEitAZINYL-4H-THIENOBENZODIAZEPINES
10 PIPERAZINYL-4H-THIEN0BENZ0DIAZEPINES AS POTENTIAL
NEUROLEPTICS.
001591 02-04
PIPERAZINYL-SH-PYRROLOBENZODrAZEPINE
DERIVATIVES OF 1 1 1 PIPERAZINYL-5H-PYRR0L0BENZ0DIAZEPINE AS
CENTRAL-NERVOUS-SYSTEM AGENTS.
001093 02-02
PIPERIDINE
UPTAKE OF PIPERIDINE AND PIPECOLIC-ACID BY SYNAPTOSOMES FROM
MOUSE-BRAIN.
001396 02-03
PIPERIDINE-4-SULPHONIC-ACID
PIPERIDINE-4-SULPHONIC-ACID, A NEW SPECIFIC GABA AGONIST.
002647 03-02
PIPERIDONE
PIPERIDONE IN CHRONIC SCHIZOPHRENIC-PATIENTS: A CONTROLLED
DOUBLE-BLIND STUDY.
003184 03-08
PIPEHES
PHYSICAL AND PHYSIOLOGICAL CHARACTERISTICS OF MICROPRESSURE
EJECTION OF DRUGS FROM MULTIBARRELED PIPEHES.
002502 02-16
THE PHYSICS OF lONTOPHORETIC PIPEHES.
004299 04-06
PIPOTHIAZINE-PALMITATE
LONG-TERM EFFECTS OF PIPOTHIAZINE-PALMITATE.
001922 02-08
METHODOLOGY AND RESULTS OF A LONG-TERM STUDY OF LONG-AQING
NEUROLEPTICS: PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-
DECANOATE.
001929 02-08
PIPRADROL
THE EFFECTS OF PIPRADROL ON THE ACQUISITION OF RESPONDING WITH
CONDITIONED REINFORCEMENT: A ROLE FOR SENSORY
PRECONDITIONING.
001572 02-04
PIRACETAM
OUR EXPERIENCE WITH PIRACETAM (NOOTROPIL-UCB) TREATMENT IN
CHILDREN FROM HIGH-RISK PREGNANCIES WITH SUBSEQUENT
MINIMAL-BRAIN-DYSFUNCTION.
000544 01-07
CLINICAL AND BIOCHEMICAL-AQION OF PIRACETAM (NOOTROPIL) IN
DRUG-RESISTANT DEPRESSION.
000600 01-09
CLINICAL-EXPERIENCE WITH PIRACETAM THERAPY IN GERONTOLOGY.
000686 01-11
PIRACETAM AND RETRIEVAL OF MEMORY IN YOUNG RATS.
000803 01-14
INFLUENCE OF PYRITHIOXINE, MECLOPHENOXATE AND PIRACETAM ON
THE LEARNING PROCESS IN MAN.
000805 01-14
CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM.
000988 01-17
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN
RATS.
001199 02-03
THE EFFECTS OF PIRACETAM ON FREE FATTY-ACIDS IN THE BRAIN.
001474 02-03
PIRACETAM EFFEQ ON LEARNING AND MEMORY IN RATS.
001689 02-04
EFFECT OF PIRACETAM ON AGONISTIC-BEHAVIOUR IN MICE.
001796 02-04
PIRACETAM AaiON IN NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL SIDE-
EFFEaS.
002132 02-11
CLINICAL-EXPERIENCE WITH PSYCHIATRIC-TREATMENT OF THE ELDERLY
INVOLVING THE USE OF PIRACETAM.
002188 02-11
PIRACETAM DIMINISHES HIPPOCAMPAL ACETYLCHOLINE LEVELS IN RATS.
002934 03-03
A DOUBLE-BUND, PLACEBO-CONTROLLED-STUDY OF PIRACETAM IN
ELDERLY PSYCHIATRIC-PATIENTS.
003305 03-11
EFFECT OF PIRACETAM ON EEG SPEQRA OF BOYS WITH LEARNING-
DISORDERS.
003383 03- 1 1
PIRACETAM ACTIVITY MAY DIFFER ACCORDING TO THE AGE OF THE
RECIPIENT MOUSE.
003705 04-02
THE EFFICACY OF PIRACETAM IN VERTIGO: A DOUBLE-BUND STUDY IN
PATIENTS WITH VERTIGO OF CENTRAL ORIGIN.
004478 04-11
PIRETANIDE
THE EFFECT OF FRUSEMIDE PIRETANIDE AND BUMETANIDE ON COCHLEAR
SUCCINIC-DEHYDROGENASE.
003757 04-03
PIRIBEDIL
CEREBRAL CIRCULATORY AND METABOLIC-EFFEaS OF PIRIBEDIL
000200 01-03
REDUCTION OF FOOD INTAKE BY PIRIBEDIL IN THE RAT: RELATION TO
DOPAMINE-RECEPTOR STIMULATION.
000355 01-04
CONTRIBUTION TO THE CLINICAL-STUDY OF CEREBRAL DOPAMINERGIC
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST
RESULTS.
00061601-09
AMPHETAMINE AND PIRIBEDIL IN AFFEQIVE-IU-NESS.
000618 01-09
EFFECT OF PIRIBEDIL (ET-495) ON PLASMA NOREPINEPHRINE:
RELATIONSHIP TO ANTIDEPRESSANT RESPONSE
002034 02-09
PIRIBEDIL IN ELDERLY PSYCHIATRIC-PATIENTS.
002170 02-11
PREJUNCTIONAL ACTIONS OF PIRIBEDIL ON THE ISOLATED KIDNEY OF THE
RABBIT: COMPARISON WITH APOMORPHINE.
003749 04-03
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NiaiTATING MEMBRANE OF THE CAT.
003822 04-03
PIRLINDOLE
THE NEW ANTIDEPRESSANT PIRUNDOLE: ANTAGONISM OF ACUTE
OVERDOSAGE IN THE MOUSE
001082 02-02
THE NEW ANTIDEPRESSANT PIRUNDOLE: A COMPARISON WITH
IMIPRAMINE AND TRANYLCYPROMINE.
001360 02-03
PHARMACOLOGICAL-PROPERTIES OF 2,3,3A,4.5,6 HEXAHYDROMETHYL-
1 H-PYRAZINOCARBAZOL-HCL (PIRUNDOLE), A NEW ANTIDEPRESSANT.
004174 04-04
PITFALLS
lONOPHORESIS - PROGRESS AND PITFALLS.
003144 03-06
IS MANIA OVERDIAGNOSED?: THE THREE COMMON PITFALLS IN
DIAGNOSING MANIC-DEPRESSIVE-ILLNESS
003260 03-09
PITHED
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTIUNE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENAUNE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
AN EXAMINATION OF FAQORS INFLUENCING ADRENERGIC
TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNQIONAL
ALPHA-ADRENOCEPTORS
001196 02-03
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF
12 CNS DEPRESSANTS IN INTACT AND PITHED RATS.
001855 02-05
DIFFERENTIAL INHIBITION OF ALPHA! -ADRENOCEPTOR AND ALPHA2-
ADRENOCEPTOR MEDIATED PRESSOR RESPONSES IN PITHED RATS.
004057 04-03
PITUITARY
RELEASE OF GONADOTROPIN-RELEASING-HORMONE BY VERATRINE IN A
HYPOTHALAMIC PITUITARY COINCUBATION.
000237 01-03
CHANGES IN OPIATE AQIVITY OF RAT PITUITARY FOU.OWING ACUTE
ADMINISTRATION OF NEUROLEPTICS.
000282 01-03
DOPAMINERGIC FACTORS IN HUMAN PROLAQIN REGULATION: A
PITUITARY MODEL FOR THE STUDY OF A NEUROENDOCRINE SYSTEM IN
MAN.
000776 01-13
THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN
REGULATION OF NEUROSECRETION. (UNPUBUSHED PAPER).
001003 02-01
INFLUENCE OF DRUGS AFFEQING THE PITUITARY ADRENAL AXIS ON
CHROMAFFIN CELLS.
001183 02-03
S-346
VOLUME 19, SUBJECT INDEX
Subject Index
SODIUM-CHLORIDE INHIBITION DECREASES LEVELS OF IMMUNOREACTIVE
DYNORPHIN IN THE NEUROINTERMEDIATE PITUITARY OF RATS.
001283 02-03
NALOXONE-LIKE ACTIONS OF MIF-1 DO NOT REQUIRE THE PRESENCE OF
THE PITUITARY.
00131) 02-03
THE PITUITARY OOPAMINE-RECEPTOR.
001324 02-03
EFFECTS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN
HEALTHY TEST SUBJECTS, NEUROTIC-PATIENTS, AND ENDOGENOUS
DEPRESSIVE-PATIENTS.
002009 02-09
ANTERIOR PITUITARY GABA-RECEPTORS AND THEIR REGULATION OF
PROLACTIN SECRETION.
002738 03-03
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFECTS OF NALOXONE ON
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE
MALE RAT.
002853 03-03
ROLE OF ADRENERGIC BLOCKING-AGENTS AND GLUCOCORTICOIDS ON
THE REGULATION OF PITUITARY OPIOID-PEPTIDES LEVELS.
003801 04-03
ROLE OF THE ANTERIOR PITUITARY GABA-RECEPTOR IN THE CONTROL OF
PROLACTIN RELEASE.
003809 04-03
PHARMACOLOGIC MANIPULATION OF BRAIN AND PITUITARY ENDORPHIN
CONTENT AND RELEASE.
003837 04-03
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM
INTERMEDIATE/POSTERIOR LOBES OF PITUITARY.
003846 04-03
NEUROTRANSMinER CONTROL OF HYPOTHALAMIC PITUITARY THYROID-
FUNCTION IN RATS.
003942 04-03
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE
PITUITARY MEMBRANES.
004003 04-03
EFFEaS OF CAFFEINE ON ANTERIOR PITUITARY AND THYROID-FUNCTION
IN THE RAT.
004014 04-03
AQH-LIKE PEPTIDES, PITUITARY ADRENOCORTICAL FUNQION AND
AVOIDANCE-BEHAVIOR.
004109 04-04
PITUITARY-GLANDS
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER).
001122 02-03
THE DIREa EFFECT OF RESERPINE IN VITRO ON PROLAQIN RELEASE
FROM RAT ANTERIOR PITUITARY-GLANDS.
002810 03-03
PITUITARY-HORMONES
EVIDENCE FOR A DIREQ INHIBITORY-EFFEQ OF MORPHINE ON THE
SECRETION OF POSTERIOR PITUITARY-HORMONES.
000193 01-03
BIOSYNTHESIS OF POSTERIOR PITUITARY-HORMONES. (UNPUBLISHED
PAPER).
001053 02-01
BIOSYNTHESIS, AXONAL TRANSPORT AND RELEASE OF POSTERIOR
PITUITARY-HORMONES. (UNPUBLISHED PAPER).
001148 02-03
BIOLOGICAL-EFFEQS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. I. WITH REFERENCE TO PITUITARY-HORMONES.
003415 03-13
PK-8165
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK-
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES).
003898 04-03
PK-9084
MULTIPLE BENZODIAZEPINE-RECEPTORS; EVIDENCE OF A DISSOCIATION
BETWEEN ANTICONFLia AND ANTICONVULSANT PROPERTIES BY PK-
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES).
003898 04-03
PLACEBO
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY:
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS.
000543 01-07
ANXIOLYTIC EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND
PLACEBO.
000648 01-10
TWO BASS-SCALE-FAQORS AND RESPONSE TO PLACEBO AND
ANXIOLYTIC-ORUGS.
000649 01-10
DOUBLE-BUND COMPARISON OF KETAZOLAM, DIAZEPAM AND PLACEBO
IN ONCE-A-DAY VS T.I.D. DOSING.
000660 01-11
PSYCHOPATHOMETRIC DOUBLE-BLIND COURSE STUDY WITH NICERGOLINE
VERSUS PLACEBO IN GERIATRIC-PATIENTS WITH TRANSIENT-
SYNDROMES.
000665 01-11
PRINCIPAL AND DIFFERENTIAL-EFFECTS OF HALOPERIDOL AND PLACEBO
TREATMENTS UPON SPEECH DISFLUENCIES IN STUHERERS.
000713 01-11
PLACEBO REACTION IN NEUROTICS RATED WITH THE SCL-90
QUESTIONNAIRE.
000976 01-17
DOUBLE-BLIND COMPARISON OF KETAZOLAM AND PLACEBO USING
ONCE-A-DAY DOSING.
002067 02-10
KETAZOLAM COMPARED TO DIAZEPAM AND PLACEBO IN THE
TREATMENT OF ANXIETY.
002074 02-10
A DOUBLE-BUND PARALLEL GROUP COMPARISON OF SINGLE-BEDTIME-
DOSES OF HALAZEPAM AND PLACEBO.
002079 02-10
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A
CONTROLLED CLINICAL-STUDY WITH DOXEPIN AND PLACEBO.
002080 02-10
SUBJECTIVE DRUG-EFFECTS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFEQS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO; A DISCRIMINANT FUNCTION ANALYSIS.
002482 02-16
PLACEBO, MEDICINE AND PAIN, OR THE RELATIVE FUNCTION OF
MEDICATION IN THE TREATMENT OF PAIN.
002577 02-17
A DOUBLE-BUND CROSSED CLINICAL-STUDY WITH A NEW
PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008), DIAZEPAM, AND
A PLACEBO.
003153 03-07
MAPROTIUNE VERSUS IMIPRAMINE AND PLACEBO IN NEUROTIC
DEPRESSION.
003287 03-10
CARDIOVASCULAR-EFFECTS OF MIANSERIN ~ A COMPARATIVE-STUDY
WITH AMITRIPTYUNE AND A PLACEBO IN HEALTHY SUBJECTS.
003503 03-15
THE PLACEBO CONCEPT.
003595 03-17
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO
AND STANDARD (IMIPRAMINE) CONTROLLED CLINICAL-STUDY.
004392 04-09
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO. A DISCRIMINANT FUNQION ANALYSIS. (UNPUBUSHED
PAPER).
004420 04-10
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO.
004544 04-13
DRUG PREFERENCE IN HUMANS; DOUBLE-BUND CHOICE COMPARISON OF
PENTOBARBITAL, DIAZEPAM AND PLACEBO.
004566 04-14
NONSPECIFIC FACTORS IN DRUG-EFFECTS; PLACEBO PERSONALITY.
004704 04-17
PLACEBO-CONTROLLED
SYNERGISM OF COMBINED UTHIUM NEUROLEPTIC THERAPY: A DOUBLE-
BUND, PLACEBO-CONTROLLED CASE-STUDY.
003165 03-08
LITHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND
BIPOLAR-II DEPRESSION; A PROSPECTIVE, PLACEBO-CONTROLLED
COMPARISON.
003252 03-09
A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF
CARBAMAZEPINE IN OVERACTIVE, SEVERELY MENTALLY-
HANDICAPPED PATIENTS.
003365 03-11
PLACEBO-CONTROLLED-STUDY
NOMIFENSINE AS CONCOMITANT THERAPY IN THE TREATMENT OF
PARKINSON-PATIENTS. A DOUBLE-BUND PLACEBO-CONTROLLED-
STUDY.
002130 02-11
A DOUBLE-BLIND, PLACEBO-CONTROLLED-STUDY OF PIRACETAM IN
ELDERLY PSYCHIATRIC-PATIENTS.
003305 03-11
PLACEBO-CONTROLLED-TRIAL
EFFICACY OF DESIPRAMINE IN MILDLY DEPRESSED-PATIENTS; A DOUBLE-
BUND, PLACEBO-CONTROLLED-TRIAL.
003262 03-09
COMPARATIVE-EFFEaS OF PHENELZINE AND AMITRIPTYUNE; A
PLACEBO-CONTROLLED-TRIAL.
004402 04-09
S-347
yi^issfi
Subject Index
Psychopharmacology Abstracts
IK* I
iuiar
tiiiii'
flu:;.
PLACEBO-EFFECT
PLACEBO-EFFECT: FROM CONTROL TO EXPERIMENTAL CONDITION.
003195 03-08
CONDITIONED DRUG-EFFECTS OF D-AMPHETAMINE-INDUCED AND
MORPHINE-INDUCED MOTOR ACCELERATION IN MICE: EXPERIMENTAL
APPROACH FOR PLACEBO-EFFECT.
004128 04-04
PLACEBO-EFFECTS
ANALYSIS OF SINGLE-BUND, DOUBLE-BLIND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFECTS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS ~ BRIEF REPORT.
003298 03-11
SOME OBSERVATIONS ON THE PSYCHOLOGICAL DIMENSIONS OF
PLACEBO-EFFECTS.
003573 03-17
ANALYSIS OF SINGLE-BLIND AND DOUBLE-BLIND PROCEDURES,
MAINTENANCE OF PLACEBO-EFFECTS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON.
004437 04-11
PLACEMENTS
ON THE NEUROCHEMICAL BASIS OF SELF-STIMULATION WITH MIDBRAIN
RAPHE ELECTRODE PLACEMENTS.
000373 01-04
PLACENTA
TRANSFER OF LORAZEPAM AND ITS CONJUGATE ACROSS THE HUMAN
PLACENTA.
000774 01-13
SPECIFIC BINDING FOR OPIATE-LIKE-DRUGS IN THE PLACENTA.
000797 01-13
PLANT
RELATIVE POTENCIES OF TWO PHENYLALKYLAMINES FOUND IN THE
ABUSED PLANT CATHA-EDULIS, KHAT.
001084 02-02
PLANTS
THE WORLD OF HALLUCINOGENIC PLANTS.
003396 03-12
PLASMA
CHANGES IN PLASMA CORTICOSTERONE LEVELS AS A MEASURE OF
ACUTE DEPENDENCE UPON LEVORPHANOL IN RATS.
000085 01-03
PLASMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE.
000102 01-03
THE EFFECT OF ANTIDEPRESSANTS ON L 5 HTP-INDUCED CHANGES IN RAT
PLASMA CORTICOSTEROIDS.
000170 01-03
RELATIONSHIPS BETWEEN PLASMA CORTICOSTEROIDS AND
BENZODIAZEPINES IN STRESS.
000176 01-03
MECHANISM OF CHLORPROMAZINE AQION ON PLASMA GLUCOSE AND
CYCLIC-AMP LEVELS.
000211 01-03
ELECTRON-CAPTURE GAS-LIQUID-CHROMATOGRAPHIC-DETERMINATION
OF ETHOSUXIMIDE AND DESMETHYLMETHSUXIMIDE IN PLASMA OR
SERUM.
000538 01-06
THE RELATIONSHIP BETWEEN THE THIORIDAZINE LEVEL IN THE PLASMA
AND SYMPTOMS OF PARANOID SCHIZOPHRENIA.
000546 01-08
INFLUENCE OF ROUTE-OF-ADMINISTRATION ON HALOPERIDOL PLASMA
LEVELS IN PSYCHOTIC-PATIENTS.
000549 01-08
PREDICTION OF STEADY-STATE PLASMA LEVELS OF AMITRIPTYLINE AND
NORTRIPTYLINE FROM A SINGLE-DOSE 24-HR. LEVEL IN DEPRESSED-
PATIENTS.
000582 01-09
VILOXAZINE PLASMA CONCENTRATIONS AND CLINICAL-RESPONSE.
000614 01-09
PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE
(DM!) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE-
DISORDER: A PRELIMINARY REPORT.
000619 01-09
IMIPRAMINE TREATMENT OF PREPUBERTAL MAJOR DEPRESSIVE-
DISORDERS: PLASMA LEVELS AND CLINICAL-RESPONSE -
PRELIMINARY REPORT.
000620 01-09
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS: THERAPEUTIC PLASMA
LEVEL.
000635 01-09
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS FROM VIEWPOINT OF
TRANSCULTURAL PSYCHOPHARMACOLOGY: THERAPEUTIC PLASMA
LEVEL.
000636 01-09
TRICYCLIC-ANTIDEPRESSANTS: THERAPEUTIC PLASMA LEVEL.
000646 01-09
EFFECT OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND
RIGIDITY: A QUANTITATIVE STUDY OF REFLEXES AND PLASMA
CONCENTRATIONS.
000701 01-11
PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH
BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS.
000717 01-11
VALPROIC-ACID DOSAGE AND PLASMA PROTEIN BINDING AND
CLEARANCE.
000755 01-13
VALPROIC-ACID AND PLASMA LEVELS OF PHENYTOIN.
000756 01-13
AMITRIPTYLINE, NORTRIPTYLINE PLASMA LEVELS AND CLINICAL-
RESPONSE IN WOMEN WITH AFFEQIVE-OISORDERS.
000757 01-13
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY: EFFICACY, DOSAGE SCHEDULE AND PLASAAA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
PRAQICAL AND THEORETICAL ASPEQS OF PHENYTOIN
ADMINISTRATION. I. RELATIONSHIP BETWEEN DOSE AND PLASMA
CONCENTRATION.
000760 01-13
PLASMA CHLORPROMAZINE SERUM PROLAQIN RELATIONSHIP IN A
SINGLE-DOSE EXPERIMENT.
000761 01-13
TRANSCULTURAL PHARMACOKINETIC STUDY ON LI CONCENTRATION IN
PLASMA AND SALIVA.
000769 01-13
NEUROLEPTIC-EFFEQ ON DESIPRAMINE STEADY-STATE PLASMA
CONCENTRATIONS.
000781 01-13
PLASMA AND SALIVA LEVELS OF CHLORPROMAZINE AND SUBJEQIVE
RESPONSE
000826 01-14
PLASMA PROLAQIN AND TESTOSTERONE DURING PENFLURIDOL
TREATMENT.
000874 01-15
DESIPRAMINE: CARDIOVASCULAR EFFEQS AND PLASMA LEVELS.
000884 01-15
IMPORTANCE OF AKINESIA: PLASMA CHLORPROMAZINE AND PROLAQIN
LEVELS.
000891 01-15
TECHNIQUES FOR PLASMA PROTEIN BINDING OF
DEMETHYLCHLORIMIPRAMINE.
000897 01-16
LEVORPHANOL: RADIOIMMUNOASSAY AND PLASMA CONCENTRATION
PROFILES IN DOG AND MAN
000898 01-16
DETERMINATION OF DOSE PLASMA CONCENTRATION RELATIONSHIP OF
PHENOBARBITAL IN EPILEPTIC-PATIENTS BY A NEW SPECIFIC
RADIOIMMUNOASSAY.
000902 01-16
RADIOIMMUNOASSAY FOR FLUPHENAZINE IN HUMAN PLASMA.
000905 01-16
DISEASE-INDUCED CHANGES IN THE PLASMA BINDING OF BASIC DRUGS.
000975 01-17
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL
GROUPS IN THE AQIVE SITE. (UNPUBLISHED PAPER).
001066 02-01
EFFEQ OF PROSTAGLANDINS ON PLASMA CATECHOLAMINES, HEART
AND BLOOD-PRESSURE RESPONSES TO HEMORRHAGE. (UNPUBLISHED
PAPER).
001223 02-03
LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHALIN PRODUCE OPPOSING
EFFEQS ON PLASMA CORTICOSTERONE LEVELS IN ETHER-STRESSED
MICE.
001245 02-03
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
EFFEQ OF BROMOCRIPTINE ON EXPLORATORY-ACTIVITY, BRAIN-
MONOAMINES AND PLASMA CORTICOSTERONE IN THE
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR
HYPERTENSIVE OBESE RATS.
001635 02-04
PLASMA AND BRAIN LEVELS OF DELTA6 THC AND SEVEN
MONOOXYGENATED METABOLITES CORRELATED TO THE CATALEPTIC-
EFFECT IN THE MOUSE.
001737 02-04
RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN
PLASMA AND CEREBROSPINAL-FLUID AND CLINICAL-RESPONSE AND
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS.
001905 02-08
PLASMA LEVELS AND THERAPEUTIC EFFICACY OF FLUPHENAZINE-HCL
AND FLUPHENAZINE-DECANOATE.
001913 02-08
CHANGE IN OVERINCLUSIVE THINKING OF SCHIZOPHRENIC-PATIENTS IS
REUTED TO PLASMA PHENOTHIAZINE CONCENTRATION.
001941 02-08
CLINICAL STATE, PLASMA LEVELS OF HALOPERIDOL AND PROLACTIN:
001943 02-08
S-348
VOLUME 19, SUBJECT INDEX
Subject Index
PLASMA FLUPHENAZINE AND PROLACTIN LEVELS IN SCHIZOPHRENIC-
PATIENTS DURING TREATMENT WITH LOW-DOSES AND HIGH-DOSES OF
FLUPHENAZINE-ENANTHATE.
001956 02-08
AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL-EFFECT: A
WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY.
001976 02-09
CLINICAL-RESPONSE, PLASMA LEVELS AND PHARMACOKINETICS OF
DESIPRAMINE IN DEPRESSED-INPATIENTS.
002002 02-09
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC
DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL
CONTROLS.
002004 02-09
LONG-TERM MONITORING OF TRICYCLIC-ANTIDEPRESSANT PLASMA
CONCENTRATIONS.
002014 02-09
CLOMIPRAMINE: PLASMA LEVELS AND CLINICAL-EFFECTS.
002033 02-09
EFFECT OF PIRIBEDIL (ET-495) ON PLASMA NOREPINEPHRINE:
RELATIONSHIP TO ANTIDEPRESSANT RESPONSE.
002034 02-09
PLASMA DESIPRAMINE LEVELS AFTER SINGLE-DOSAGE AND AT STEADY-
STATE IN OUTPATIENTS.
002039 02-09
CARBAMAZEPINE THERAPY IN TRIGEMINAL-NEURALGIA: CLINICAL-
EFFEQS IN RELATION TO PLASMA CONCENTRATION.
002181 02-11
PLASMA DELTA9 TETRAHYDROCANNABINOL CONCENTRATIONS AND
CLINICAL-EFFEaS AFTER ORAL AND INTRAVENOUS ADMINISTRATION
AND SMOKING.
002201 02-12
THE CONTRIBUTION OF ALPHA 1 ACID GLYCOPROTEIN, LIPOPROTEINS,
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE,
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN,
002214 02-13
FAaORS INFLUENCING NORTRIPTYLINE STEADY-STATE KINETICS:
PLASMA AND SALIVA LEVELS.
002251 02-13
CLOMIPRAMINE AND DOXEPIN IN DEPRESSIVE-NEUROSIS: PLASMA
LEVELS AND THERAPEUTIC RESPONSE.
002258 02-13
PLASMA HDL CHOLESTEROL AND GROWTH-HORMONE IN EPILEPTICS
TREATED WITH ANTICONVULSANTS.
002260 02-13
HALOPERIDOL PLASMA LEVEL MONITORING IN PSYCHIATRIC-PATIENTS.
002267 02-13
EFFEaS OF CAFFEINE ON PLASMA FREE FATTY-ACIDS, URINARY
CATECHOLAMINES, AND DRUG BINDING.
002272 02-13
INTERACTION BETWEEN PHENYTOIN AND VALPROIC-ACID: PLASMA
PROTEIN BINDING AND METABOLIC-EFFECTS.
002276 02-13
MOOD AND BEHAVIORAL-EFFECTS OF PHYSOSTIGMINE ON HUMANS ARE
ACCOMPANIED BY ELEVATIONS IN PLASMA BETA ENDORPHIN AND
CORTISOL.
002280 02-13
CORRELATIONS BETWEEN PLASMA LEVELS OF ANTIEPILEPTIC-DRUGS AND
EEG INTENSIVE MONITORING.
002288 02-13
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE
NORTRIPTYLINE.
002304 02-13
CHILDHOOD-ENURESIS: II. PSYCHOPATHOLOGY, TRICYCLIC
CONCENTRATION IN PLASMA, AND ANTIENURETIC-EFFECT.
002354 02-14
PHENOTHIAZINE PLASMA AND RED-BLOOD-CELL CONCENTRATIONS, THEIR
RELATIONSHIP TO SIDE-EFFEQS AND CLINICAL-EFFICACY.
002386 02-15
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
MEASUREMENT OF FLUPHENAZINE BY GAS-CHROMATOGRAPHY IN
HUMAN PLASMA AND RED-BLOOD-CELLS.
002491 02-16
THE DISTRIBUTION OF CHLORPROMAZINE BETWEEN PLASMA AND
ERYTHROCYTES.
002496 02-16
RADIOIMMUNOASSAY FOR TOTAL DOXEPIN AND N DESMETHYLDOXEPIN
IN PLASMA.
002499 02-16
PLASMA LEVODOPA, DOPAMINE AND THERAPEUTIC RESPONSE
FOLLOWING LEVODOPA THERAPY OF PARKINSONIAN-PATIENTS.
002504 02-16
PLASMA FLUPHENAZINE LEVELS BY RADIOIMMUNOASSAY IN
SCHIZOPHRENIC-PATIENTS TREATED WITH DEPOT INJECTIONS OF
FLUPHENAZINE-OECANOATE
002510 02-16
MEASUREMENT OF PLASMA CONCENTRATIONS OF DRUGS AS A
FEEDBACK CONTROL MECHANISM DURING DRUG-THERAPY
002525 02-17
PHARMACOKINETICS AND PLASMA LEVELS OF POLYCYCLIC-
ANTIDEPRESSANTS: A GENERAL VIEW OF PRODUCTS.
002529 02-17
DIFFERENTIAL-EFFECTS OF CANNABINOID EXPOSURE AND STRESS ON
PLASMA PROLACTIN, GROWTH-HORMONE AND CORTICOSTERONE
LEVELS IN MALE MICE.
002695 03-03
PLASMA IMIPRAMINE LEVELS AND DEMETHYLASE ACTIVITY IN THE
LIVER OF STRESSED ANIMALS.
002793 03-03
INCREASE IN PLASMA CYCLIC-AMP LEVELS ELICITED BY NALOXONE IN
MORPHINE-DEPENDENT MALE MICE.
002834 03-03
PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFECTS OF
GANGLIONIC AND ADRENORECEPTOR BLOCKADE.
002863 03-03
BENZODIAZEPINES, STRESS AND RAT PLASMA CORTICOSTEROIDS: THE
ROLE OF INDOLEAMINES.
003034 03-04
ERGOT DRUGS SUPPRESS PLASMA PROLACTIN AND LACTATION BUT NOT
AGGRESSION IN PARTURIENT MICE.
003159 03-07
PLASMA LEVEL OF CYCLIC-AMP AND MENTAL-DISEASES.
003170 03-08
A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS.
003182 03-08
PLASMA LEVELS OF CHLORPROMAZINE AND CLINICAL-RESPONSE.
003201 03-08
CORRELATIONS BETWEEN LITHIUM LEVELS IN CEREBROSPINAL-FLUID AND
LITHIUM LEVELS IN BLOOD PLASMA AND ERYTHROCYTES.
003210 03-09
DEPRESSION SUBTYPES AFFECT THE STEADY-STATE PLASMA LEVELS AND
THERAPEUTIC-EFFICACY OF AMITRIPTYLINE AND NORTRIPTYLINE.
003244 03-09
RELEVANCY OF TRICYCLIC-ANTIDEPRESSANT PLASMA LEVELS.
003246 03-09
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE
HYPERACTIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN
DEFICIENCY HYPOTHESIS.
003312 03-11
A PROSPECTIVE RANDOMISED-TRIAL ON THE EFFECT OF MONITORING
PLASMA ANTICONVULSANT LEVELS IN EPILEPSY.
003314 03-11
A COMPARATIVE-STUDY ON THE CLINICAL-EFFECTS OF RECTAL
DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP
BETWEEN PLASMA LEVEL AND EFFECT.
003330 03-11
INTRAVENOUS VALPROATE: EFFECTS ON PLASMA AND SALIVA
PHENYTOIN LEVELS.
003359 03-11
COVARIANCE OF PLASMA FREE 3 METHOXY-4-
HYDROXYPHENETHYLENEGLYCOL AND DIASTOLIC BLOOD-PRESSURE.
003418 03-13
PSYCHOSOMATIC-STRESS AND LIPOPEROXIDES OF HUMAN PLATELET
RICH PLASMA.
003423 03-13
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION
OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY.
003433 03-13
EXCESSIVE PLASMA CONCENTRATIONS OF TRICYCLIC-ANTIDEPRESSANTS
RESULTING FROM USUAL DOSES: A REPORT OF SIX CASES.
003479 03-15
LYMPHOCYTE MONOAMINE-OXIDASE AND PLASMA PROLACTIN AND
GROWTH-HORMONE IN TARDIVE-DYSKINESIA.
003499 03-15
SIMULTANEOUS ADMINISTRATION OF FIVE ANTIEPILEPTIC-DRUGS IN
PLASMA THROUGH GAS-LIQUID-CHROMATOGRAPHY.
003563 03-16
MEASUREMENT OF HALOPERIDOL IN HUMAN PLASMA USING REVERSED
PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY.
(UNPUBLISHED PAPER).
003667 04-01
CU-AMINE-OXIDASES: STUDIES RELATED TO THE MECHANISM-OF-ACTION
OF BOVINE PLASMA AMINE-OXIDASE (UNPUBLISHED PAPER).
003680 04-01
VASOPRESSIN STIMULATES RELEASE OF BETA LIPOTROPIN AND BETA
ENDORPHIN IN CONSCIOUS RATS AS MEASURED BY
RADIOIMMUNOASSAY OF UNEXTRACTED PLASMA.
003715 04-03
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
S-349
Subject Index
Psychopharmacology Abstracts
m
■<'iK.
CI
ilk
fe
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
ETHANOL.
003725 04-03
EFFEQ OF AMPHETAMINE ON PLASMA CORTICOSTERONE IN THE
CONSCIOUS RAT.
003888 04-03
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON
CHLORPROMAZINE-INOUCED ELEVATION OF PLASMA GLUCOSE AND
CYCLIC-AMP IN FED MICE.
003946 04-03
RAT-BRAIN AND PLASMA NOREPINEPHRINE GLYCOL METABOLITES
DETERMINED BY GAS-CHROMATOGRAPHY MASS-
FRAGMENTOGRAPHY.
004303 04-06
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO
COUNTERACT CURATIVE EFFEQS OF NEUROLEPTIC-DRUGS.
004321 04-08
NEUROENDOCRINE-TESTS DURING TREATMENT WITH NEUROLEPTIC-
DRUGS: I. PLASMA PROLACTIN RESPONSE TO CHLORPROMAZINE
CHALLENGE.
004329 04-08
PLASMA DOPAMINE-BETA-HYDROXYLASE AQIVITY IN CHRONIC
SCHIZOPHRENIC-PATIENTS TESTED WITH SINGLE-DOSE OF 2 BROMO-
ALPHA-ERGOCRIPTINE (PARLODEL).
004343 04-08
CHANGES IN BLOOD PLASMA OSMOLALITY AND STATES OF MANIA.
004352 04-09
PLASMA LEVELS OF THE CIS-ISOMERS AND TRANS-ISOMERS OF DOXEPIN
AND DESMETHYLDOXEPIN AFTER ADMINISTRATION OF DOXEPIN TO
PATIENTS.
004355 04-09
PLASMA CORTICOSTERIODS IN MANIA: THE EFFEaS OF PIMOZIDE.
004363 04-09
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFECTIVE-DISORDERS
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDiaORS TO
CLINICAL-RESPONSE),
004365 04-09
ELECTROCARDIOGRAM-CHANGES AND PLASMA DESIPRAMINE LEVELS
DURING TREATMENT OF DEPRESSION.
004411 04-09
THE RELATIONSHIPS BETWEEN CLINICAL-RESPONSE,
PSYCHOPHYSIOLOGICAL-VARIABLES AND PLASMA LEVELS OF
AMITRIPTYLINE AND DIAZEPAM IN NEUROTIC-OUTPATIENTS.
004423 04-10
THERAPEUTIC PLASMA LEVELS OF SOME ANTICONVULSANTS IN FOCAL
EPILEPSY IN RELATION TO COMPUTERIZED-AXIAL-TOMOGRAPHY.
004439 04-11
EFFECT OF TREATMENT WITH SODIUM-VALPROATE AND DIAZEPAM ON
PLASMA CORTICOTROPIN IN NELSONS-SYNDROME.
004463 04-1 1
NORMAL PLASMA DOPAMINE-BETA-HYDROXYLASE IN NONTREATED AND
TREATED PARKINSON-PATIENTS.
004471 04-11
DOXEPIN PLASMA LEVELS AND ANXIOLYTIC RESPONSE
004477 04-11
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF
ASSESSING COMPLIANCE.
004495 04-11
USE OF PLASMA CONCENTRATION DETERMINATIONS.
004498 04- 1 3
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II.
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT.
004516 04-13
VALPROIC-ACID IN CHILDHOOD-EPILEPSY: ANTICONVULSIVE EFFICACY IN
RELATION TO ITS PLASMA LEVELS.
004525 04-13
THE ACTIVITY OF DOPAMINE-BETA-HYDROXYLASE IN THE PLASMA OF
PATIENTS WITH ENDOGENOUS DEPRESSIVE-SYNDROMES.
004548 04-13
ANTICHOLINERGIC-EFFEaS AND PLASMA DESIPRAMINE LEVELS.
004550 04-13
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS AQIVE
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC-
PATIENTS TREATED WITH FIXED DRUG DOSES.
004559 04-13
SEX, PLASMA PROLACTIN AND PLASMA 3 METHOXY-4-
HYDROXYPHENYLGLYCOL (MHPG) PREDIQ HERITABLE D-
AMPHET AMINE EXCITATION IN MAN. (UNPUBLISHED PAPER).
004565 04-14
CHLORPROMAZINE ANALYSIS IN HUMAN PLASMA. (UNPUBLISHED
PAPER).
004591 04-15
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN.
004638 04-15
PLASMA NOMIFENSINE CONCENTRATION: CARDIOLOGICAL EFFEQS AND
CLINICAL-RESPONSE.
004639 04-15
AMITRIPTYLINE AND NORTRIPTYLINE PLASMA LEVELS MONITORING
PERSPEQIVE IN CLINICAL-PRAQICE.
004675 04-16
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC-
ANTIDEPRESSANTS: PERSPEQIVE OF THE CLINICAL LABORATORY.
004681 04-16
A COMPARISON OF RADIOIMMUNOASSAY WITH SPEQROPHOTOMETRY
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN
CONCENTRATIONS.
004684 04-16
RECEPTOR TECHNIQUES IN THE STUDY OF PLASMA LEVELS OF
NEUROLEPTICS AND ANTIDEPRESSANT-DRUGS.
004694 04-16
PLASMATIC
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/AND
DIPHENYLHYDANTOIN IN SERUM LIPIDS.
002281 02-13
PLASTICITY
RECEPTOR PLASTICITY: BIOCHEMICAL-CORRELATES AND
PHARMACOLOGICAL SIGNIFICANCE.
001181 02-03
A RADIOIMMUNOASSAY FOR EPENDYMINS BETA AND GAMMA: TWO
GOLDFISH BRAIN PROTEINS INVOLVED IN BEHAVIORAL PLASTICITY.
003677 04-01
PLATELET
HUMAN PLATELET 5 HT-RECEPTORS: CHARAQERISATION AND
FUNQIONAL ASSOCIATION.
001412 02-03
MAO-INHIBITORS AND PLATELET MAO-INHIBITION.
001993 02-09
PLATELET AGGREGATION, 5 HYDROXYTRYPTAMINE UPTAKE AND
RELEASE IN HUNTINGTONS-CHOREA.
002112 02-11
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE (UNPUBLISHED PAPER).
002219 02-13
A PROBABLE NEUROLEPTIC-EFFECT ON PLATELET MONOAMINE-OXIDASE
IN CHRONIC SCHIZOPHRENIC-PATIENTS.
003169 03-08
NONGENETIC FAQORS AFFEQING HUMAN PLATELET MONOAMINE-
OXIDASE.
003407 03-13
TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT DECREASES ALPHA2-
ADRENORECEPTORS ON HUMAN PLATELET MEMBRANES.
003408 03-13
PSYCHOSOMATIC-STRESS AND LIPOPEROXIDES OF HUMAN PLATELET
RICH PLASMA.
003423 03-13
THE HUMAN PLATELET AS A MODEL FOR THE GLUTAMATERGIC NEURON:
PLATELET UPTAKE OF L GLUTAMATE.
003923 04-03
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN
REUPTAKE SITES IN BRAIN AND PLATELET?
003962 04-03
THE ANTIDEPRESSANT EFFEQS OF TRAZODONE AND INHIBITION OF
PLATELET SEROTONIN REUPTAKE.
004383 04-09
THE SPECIFIC AQIVITY OF PLATELH MONOAMINE-OXIDASE VARIES
WITH PLATELET COUNT DURING SEVERE EXERCISE AND
NORADRENALINE INFUSION.
004509 04-13
SELEQIVE INHIBITORY-EFFEQS OF CHLORPROMAZINE AND IMIPRAMINE
ON PLATELET AGGREGATION.
004518 04-13
HUMAN PLATELET ALPHA2-ADRENER6IC-RECEPT0RS: LABELING WITH 3H
YOHIMBINE, A SELEQIVE ANTAGONIST LIGAND.
004676 04-16
PLATELETS
IN VITRO EFFEQ OF PHENCYCLIDINE AND OTHER PSYCHOMOTOR
STIMULANTS ON SEROTONIN UPTAKE IN HUMAN PLATELETS.
000750 01-13
PREPARATION AND CHARAQERIZATION OF SYNTHETIC MODELS FOR THE
DENSE-BODIES OF HUMAN PLATELETS. (UNPUBLISHED PAPER).
001013 02-01
ELEQRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED
PAPER).
001014 02-01
SPECIFIC 3H IMIPRAMINE BINDING IN HUMAN PLATELETS: INFLUENCE OF
AGE AND SEX.
002254 02-13
S-^50
VOLUME 19, SUBJECT INDEX
Subject Index
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF
BINDING-SITES IN DEPRESSED-PATIENTS,
003427 03-13
A STUDY OF GAMMA AMINOBUTYRIC-ACID UPTAKE IN NORMAL AND
DOWNS-SYNDROME PLATELETS.
003787 04-03
(3H) IMIPRAMINE BINDING IN HUMAN PLATELETS: A NEW BIOCHEMICAL-
PARAMETER IN DEPRESSION.
004358 Q4-09
EFFECTS OF R0-) 1-2465, A NEW PSYCHOTROPIC-AGENT ON THE UPTAKE
OF SEROTONIN BY HUMAN PLATELETS - IN VITRO DETERMINATION OF
THE IC50.
004532 04-13
ANTIDEPRESSANTS AND THE SEROTONIN UPTAKE IN PLATELETS.
004727 04-17
PLAUSIBLE
THE NA-K-ATPASE: A PLAUSIBLE TRIGGER FOR VOLTAGE-INDEPENDENT
RELEASE OF CYTOPLASMIC NEUROTRANSMIHERS.
003953 04-03
PLAY
BIOGENIC-AMINES AND NEUROPEPTIDES PLAY A ROLE IN THE CENTRAL-
REGULATION OF GENETIC HYPERTENSION. (UNPUBLISHED PAPER).
001455 02-03
DOES RAPID-EYE-MOVEMENT SLEEP PLAY A ROLE IN BRAIN
DEVELOPMENT?
004091 04-04
PLEXIFORM
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS ARE LOCALIZED IN THE
INNER PLEXIFORM LAYER OF RAT RETINA.
000277 01-03
PLEXUS
INHIBITION OF THE ACTION OF CHOLECYSTOKININ-OCTAPEPTIDE ON THE
GUINEA-PIG ILEUM MYENTERIC PLEXUS BY DIBUTYRYL-CYCLIC-
GUANOSINE-MONOPHOSPHATE.
001291 02-03
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF
AMINES INFLUENCING CEREBROSPINAL-FLUID FORMATION.
002807 03-03
PLG
HABITUATION OF THE THE HEAD-POKE RESPONSE: EFFECTS OF AN
AMPHETAMINE BARBITURATE MIXTURE, PLG AND FENFLURAMINE.
004159 04-04
PLURALITY
SYNTHESIS AND PHARMACOLOGICAL-STUDY OF SOME ENKEPHALIN
ANALOGS IN RELATION TO THE PLURALITY OF OPIATE-RECEPTORS.
003682 04-02
PNEUMATIC
AN IMPROVED PNEUMATIC SYRINGE FOR SELF-ADMINISTRATION OF
DRUGS BY RATS.
004304 04-06
PNEUMOENCEPHALOGRAPHY
EFFECTS OF TIAPRIDE ON HOMOVANILLIC-ACID LEVELS IN HUMAN
CEREBROSPINAL-FLUID DRAWN AT PNEUMOENCEPHALOGRAPHY.
001483 02-03
PROGRESSIVE SUPRANUCLEAR PALSY: PNEUMOENCEPHALOGRAPHY,
ELECTRONYSTAGMOGRAPHY AND TREATMENT WITH METHYSERGIDE.
003355 03-1 1
PNEUMONIA
PNEUMONIA AND PSYCHOTROPIC-DRUG USE IN ELDERLY PSYCHIATRIC-
PATIENTS.
002391 02-15
PNMT
THE BLOCKADE OF ALPHA2-ADREN0CEPT0RS BY THE PNMT INHIBITOR
SKF-64139.
001255 02-03
IN VIVO INTRANEURONAL MAO-INHIBITION IN RAT-BRAIN SKF-64139,
COMPARISON TO OTHER POTENT PNMT INHIBITORS.
003935 04-03
POINT
SINGLE POINT ESTIMATION OF PHENYTOIN DOSING REQUIREMENT.
003562 03-16
POISONING
ACUTE GENERALIZED POLYNEUROPATHY ACCOMPANYING LITHIUM
POISONING.
000835 01-15
THE NEUROLOGICAL FORENSIC ASPECTS OF THALLIUM POISONING.
002438 02-15
PSYCHIATRIC-ASPECTS OF ACUTE POISONING WITH TRICYCLIC AND
RELATED ANTIDEPRESSANTS - 1980.
002458 02-15
THE CLINICAL DYNAMICS OF TETRAETHYL-LEAD POISONING.
003500 03-15
LITHIUM KINETICS DURING HEMODIALYSIS IN A PATIENT WITH LITHIUM
POISONING.
003524 03-15
MENTAL-DISTURBANCES IN CHRONIC MANGANESE POISONING.
004621 04-15
POLARITY
FAQORS INFLUENCING THE RELEASE OF LABELLED GAMMA
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELECTRICAL-
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL
SLICES.
001130 02-03
POLARIZATIONS
NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE
POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS.
000116 01-03
POLYADENYLATED
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO.
003832 04-03
POLYCENTRIC
SELF-MEDICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS.
002189 02-11
POLYCYCLIC-ANTIDEPRESSANTS
PHARMACOKINETICS AND PLASMA LEVELS OF POLYCYCLIC-
ANTIDEPRESSANTS: A GENERAL VIEW OF PRODUCTS.
002529 02-17
POLYETHYLENE-GLYCOL
THE DYNAMICS OF SYSTEMIC VENOUS, ARTERIAL, AND CEREBROSPINAL-
FLUID PRESSURE UNDER I.V. ADMINISTRATION OF POLYETHYLENE-
GLYCOL.
004045 04-03
POLYGRAPHIC-STUDY
POLYGRAPHIC- STUDY OF NIGHT SLEEP UNDER THE EFFECTS OF
MINAPRINE.
003313 03-11
POLYGRAPHICAL-STUDIES
THE EFFECT OF BUTOCTAMIDE-HYDROGEN-SUCCINATE ON NOCTURNAL
SLEEP: ALL-NIGHT POLYGRAPHICAL-STUDIES.
002350 02-14
POLYNEUROPATHOLOGIES
PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALLIUM, ARSENIC,
INDUSTRIAL- SOLVENT INTOXICATION, AND OTHER
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT.
003348 03-11
POLYNEUROPATHY
ACUTE GENERALIZED POLYNEUROPATHY ACCOMPANYING LITHIUM
POISONING.
000835 01-15
POLYPHARMACY
DISCUSSION: COMMUNICATION AND POLYPHARMACY: DRUGS AND THE
ELDERLY.
000957 01-17
PSYCHOTROPIC-DRUGS AND POLYPHARMACY IN ELDERLY-PATIENTS IN A
GENERAL-HOSPITAL.
000981 01-17
PSYCHOTROPIC-DRUG USE AND POLYPHARMACY IN A GENERAL-
HOSPITAL.
003369 03-11
POLYPHARMACY REGIMEN AS AN EXACERBATING RISK IN THERAPY-
RESISTANT EPILEPTIC-SEIZURES AND BEHAVIORAL-DISORDERS.
004720 04-17
POLYPHOSPHOINOSITIDE
EFFECTS OF NEOMYCIN ON CALCIUM AND POLYPHOSPHOINOSITIDE
METABOLISM OF GUINEA-PIG SYNAPTOSOMES.
002741 03-03
POLYRIBOSOMAL
AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION
IN RATS: EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING-
AGENTS.
001531 02-03
POLYRIBOSOMES
EFFECT OF ALPHA METHYLPHENYLALANINE AND PHENYLALANINE ON
BRAIN POLYRIBOSOMES AND PROTEIN SYNTHESIS.
003733 04-03
POLYSOMES
COMPARISON OF THE EFFECT OF INTRAVENOUS ADMINISTRATION OF D
LYSERGIC-ACID-DIETHYLAMIDE ON FREE AND MEMBRANE-BOUND
POLYSOMES IN THE RABBIT BRAIN.
003831 04-03
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO.
003832 04-03
POLYSOMNOGRAPHIC
TREATMENT OF NARCOLEPSY AND SLEEP-APNEA WITH GAMMA
HYDROXYBUTYRATE: A CLINICAL AND POLYSOMNOGRAPHIC CASE-
STUDY.
004571 04-14
POLYTHERAPY
MONOTHERAPY OR POLYTHERAPY FOR EPILEPSY?
003366 03-1 1
S-351
Subject Index
Psychopharmacology Abstracts
'Ml
il»
ii
Sifc
PONS-MEOULLA
STUDIES ON THE KINETIC PROPERTIES OF TRYPTOPHAN-HYDROXYLASE OF
RABBIT MESENCEPHALON AND PONS-MEDULLA: EFFECT OF LONG-
TERM-TREATMENT WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
003852 04-03
PONTO-GENICULO-OCCIPITAL
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING,
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL
WAVES IN CATS?
003704 04-02
POPULATION
TWELVE YEARS EXPERIENCE WITH THE TOTAL USE OF DEPOT
NEUROLEPTICS IN A DEFINED POPULATION.
002544 02-17
PSYCHOACTIVE-MEDICATION USE AND ABUSE AMONG AN ADULT RURAL
POPULATION. (PH.D. DISSERTATION).
003627 03-17
PSYCHIATRIC-ILLNESS AND USE OF PSYCHOTROPIC-DRUGS IN THE
GEOGRAPHICALLY DELIMITED POPULATION OF SAMSO, DENMARK.
004734 04-17
POPULATIONS
TRICYCLIC-ANTIDEPRESSANT DRUG TOLERANCE IN ORIENTAL AND
OCCIDENTAL POPULATIONS.
000590 01-09
PORCINE
EVOKED-POTENTIAL STUDIES OF PORCINE CALCITONIN IN RABBITS.
002936 03-03
LITHIUM AND PORCINE AGGRESSION.
003048 03-04
PORPHOBILINOGEN
EFFECTS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO-
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY
CULTURED NEURONS.
002859 03-03
PORPHYRIAS
SAFETY OF ANTICONVULSANTS IN HEPATIC PORPHYRIAS.
003132 03-05
PORTACAVAL
ORAL BIOAVAILABILITY OF APOMORPHINE IN THE RAT WITH A
PORTACAVAL VENOUS ANASTOMOSIS.
001158 02-03
PORTAL
ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND
EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL
AND INTRODUODENAL ADMINISTRATION.
000094 01-03
POSITION
THE SYMPATHETIC-NERVOUS-SYSTEM AND HYPERTENSION: A POSITION
PAPER. (UNPUBLISHED PAPER).
002250 02-13
RESPECTIVE POSITION OF ANTIDEPRESSANTS IN THERAPEUTICS.
002581 02-17
EFFECT OF THE POSITION OF THE PHENOLIC GROUP IN MORPHINANS ON
THEIR AFFINITY FOR OPIATE-RECEPTOR BINDING.
003702 04-02
POSITIVE
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING.
000099 01-03
THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL ON THE POSITIVE AND
NEGATIVE FEEDBACK CONTROL OF LUTEINIZING-HORMONE RELEASE.
000286 01-03
THE EFFECT OF NALOXONE ON THE ACTIVATION OF EMOTIONALLY
POSITIVE REACTION PRODUCED BY DRUGS WITH A DEPENDENCE
LIABILITY.
001556 02-03
THE RELATIONSHIP BETWEEN POSITIVE REINFORCEMENT AND
CONDITIONED TASTE-AVERSION PRODUCED BY SELF-ADMINISTERED
DRUGS. (PH.D. DISSERTATION).
001798 02-04
DIFFERENTIAL-EFFECTS OF AMPHETAMINE AND NEUROLEPTICS ON
NEGATIVE VS. POSITIVE SYMPTOMS IN SCHIZOPHRENIA.
001906 02-08
INTRACELLULAR LITHIUM: ITS VALUE IN THE PREDICTION OF A POSITIVE
RESPONSE TO LITHIUM.
003382 03-1 1
A COMPARATIVE-STUDY OF THE PHARMACOLOGICAL-PROPERTIES OF THE
POSITIVE POTENTIAL RECORDED FROM THE SUPERIOR CERVICAL
GANGLIA OF SEVERAL SPECIES.
003779 04-03
POSITRON-TOMOGRAPHY
POSITRON-TOMOGRAPHY. A NEW METHOD FOR IN VIVO BRAIN STUDIES
OF BENZODIAZEPINE, IN ANIMAL AND IN MAN.
003564 03-16
POSTADDICT
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDICT RATS: A POSSIBLE MODEL FOR PREDIQING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION).
003097 03-04
MORPHINE CHALLENGES IN LEVO ALPHA ACETYLAAETHADOL (LAAM)
POSTADDICT RATS.
004259 04-04
POSTAMPHETAMINE
POSTAMPHETAMINE DEPRESSION OF SELF-STIMULATION RESPONDING
FROM THE SUBSTANTIA-NIGRA: REVERSAL BY TRICYCLIC-
ANTIDEPRESSANTS.
000419 01-04
POSTCONCUSSIONAL-SYNDROME
DOSE-EFFEQ OF DEAE ON SUBJEQIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA. AND TONIC POSTURAL
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL-SYNDROME.
004472 04-11
POSTDECAPITATION
EFFECT OF ERGOT DERIVATIVES ON POSTDECAPITATION CONVULSIONS.
001288 02-03
POSTDEPENDENT
SCHEDULE-CONTROLLED BEHAVIOR IN THE MORPHINE-DEPENDENT AND
POSTDEPENDENT RAT.
000349 01-04
LOCOMOTOR-AQIVITY IN MORPHINE-DEPENDENT AND POSTDEPENDENT
RATS.
004077 04-04
POSTENCEPHALITIC
PROSPECTS FOR THE TREATMENT OF POSTENCEPHALITIC PARKINSONISM
WITH ANTILYMPHOCYTIC IMMUNOGLOBULIN.
004572 04-14
POSTERIOR
EVIDENCE FOR A DIRECT INHIBITORY-EFFEQ OF MORPHINE ON THE
SECRETION OF POSTERIOR PITUITARY-HORMONES.
000193 01-03
THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN
REGULATION OF NEUROSECRETION (UNPUBLISHED PAPER)
001003 02-01
BIOSYNTHESIS OF POSTERIOR PITUITARY-HORMONES, (UNPUBLISHED
PAPER).
001053 02-01
BIOSYNTHESIS, AXONAL TRANSPORT AND RELEASE OF POSTERIOR
PITUITARY-HORMONES (UNPUBLISHED PAPER).
001 148 02-03
THE EFFEQS OF BOMBESIN INJECTED INTO THE ANTERIOR AND
POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN
CONSUMPTION
001544 02-03
EXPERIENCE IN USING THE HORMONES OF THE HYPOPHYSIS POSTERIOR
LOBE IN MEMORY-DISTURBANCES OF VARYING GENESES.
003438 03-14
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM
INTERMEDIATE/POSTERIOR LOBES OF PITUITARY.
003846 04-03
POSTINGESTION
POSTINGESTION INTERFERENCE WITH BRAIN FUNQION PREVENTS
ATTENTUATION OF NEOPHOBIA IN RATS.
000352 01-04
POSTISCHEMIC
DRUG INTERFERENCE ON SOME BIOCHEMICAL-PARAMETERS OF RAT-
CEREBRAL-CORTEX DURING POSTISCHEMIC RECOVERY.
001126 02-03
POSTJUNCTIONAL
AN EXAMINATION OF FAQORS INFLUENCING ADRENERGIC
TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNQIONAL
ALPHA-ADRENOCEPTORS.
001196 02-03
POSTMARKETING
EUHYPNOS-FORTE, HIGH-DOSE TEMAZEPAM FOR RESISTANT INSOMNIA:
POSTMARKETING SURVEILLANCE IN 10,057 PATIENTS UNRESPONSIVE
TO CONVENTIONAL HYPNOTIC DOSAGE.
002324 02-14
POSTMENOPAUSAL-WOMEN
DIURNAL GROWTH-HORMONE RESPONSES TO DEXTROAMPHETAMINE IN
NORMAL YOUNG MEN AND POSTMENOPAUSAL-WOMEN.
003411 03-13
THE EFFEQS OF ESTROGEN THERAPY ON THE SEX-LIFE OF
POSTMENOPAUSAL-WOMEN .
004573 04-14
POSTMORTEM
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFEa IN SCHIZOPHRENIA AND
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO
NEUROLEPTIC-MEDICATION.
001911 02-08
DOPAMINERGIC ABNORMALITIES IN POSTMORTEM SCHIZOPHRENIC
BRAIN.
002575 02-17
S-352
VOLUME 19, SUBJECT INDEX
Subject Index
POSTMORTEM STABILITY OF BRAIN 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND 3,4
DIHYDROXYPHENYLETHYLENEGLYCOL IN THE RAT AND MOUSE.
004048 04-03
POSTNATAL
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT
001580 02-04
RAT PUP-KILLING AND MATERNAL-BEHAVIOR IN MALE LONG-EVANS-
RATS: PRENATAL STIMULATION AND POSTNATAL TESTOSTERONE
003054 03-04
SUPPRESSION Of ACTIVE SLEEP BY CHRONIC-TREATMENT WITH
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT:
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT.
003056 03-04
POSTPARTUM
INCREASED SERUM PROLACTIN LEVELS DURING PHENOTHIAZINE AND
BUTYROPHENONE TREATMENT OF SIX POSTPARTUM WOMEN.
0033)8 03-11
POSTPSYCHOTIC
LITHIUM TREATMENT IN POSTPSYCHOTIC DEPRESSION.
000575 01-08
POSTREMA
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA
AND MEDIAL NUCLEUS-TRACTUS-SOLITARIUS OF RAT-BRAIN.
002634 03-01
POSTSWIM
POSTSWIM GROOMING IN MICE INHIBITED BY DOPAMINE-RECEPTOR
ANTAGONISTS AND BY CANNABINOIDS.
000359 01-04
POSTSYNAPTIC
COMPARISON OF MIANSERIN WITH OESIPRAMINE, MAPROTILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS:
MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN.
000068 01-03
THE EFFECTS OF BROMOCRIPTINE ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS IN THE MOUSE VAS-DEFERENS.
000108 01-03
ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS.
000194 01-03
METOCLOPRAMIDE AND SULPIRIDE AS SELECTIVE BLOCKING-AGENTS
PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS.
001102 02-03
EFFEaS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS.
001146 02-03
PERIPHERAL PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS:
ARE THEY DIFFERENT FROM DOPAMINE-RECEPTORS IN THE CENTRAL-
NERVOUS-SYSTEM.
001252 02-03
THE TIME-COURSE OF NORADRENERGIC PRESYNAPTIC AND
POSTSYNAPTIC AQIVITY DURING CHRONIC DESIPRAMINE
TREATMENT.
001289 02-03
PRESYNAPTIC AND POSTSYNAPTIC MECHANISMS IN HALOPERIDOL-
INDUCED SENSITIZATION TO DOPAMINERGIC AGONISTS.
001392 02-03
DOPAMINE-AUTORECEPTORS: PHARMACOLOGY, FUNCTION AND
COMPARISON WITH POSTSYNAPTIC DOPAMINE-RECEPTORS.
001453 02-03
RADIORECEPTOR LABELING OF PRESYNAPTIC AND POSTSYNAPTIC
DOPAMINE-RECEPTORS.
001511 02-03
PRESYNAPTIC AND POSTSYNAPTIC SEROTONERGIC MANIPULATIONS IN
AN ANIMAL-MODEL OF DEPRESSION.
001730 02-04
DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINERGIC MECHANISMS.
001839 02-05
DRUG-EFFECTS ON PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-
RECEPTORS.
002372 02-15
EVIDENCE THAT IT IS POSSIBLE TO CAUSE ANOREXIA BY INCREASING
RELEASE AND/OR DIRECTLY STIMULATING POSTSYNAPTIC SEROTONIN-
RECEPTORS IN THE BRAIN.
002602 02-17
A BARBITURATE-EVOKED INTENSIFICATION OF POSTSYNAPTIC INHIBITION
IN THE PREOPTIC OVULATORY TRIGGER REGION OF THE
HYPOTHALAMUS.
002818 03-03
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS;
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION Of
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO
003741 04-03
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRACTION.
003948 04-03
PRESYNAPTIC AND POSTSYNAPTIC ALPHA-ADRENOCEPTOR ANTAGONISM
BY NEUROLEPTICS IN VIVO.
003966 04-03
EFFECTS OF PROPRANOLOL ON THE LOCOMOTOR-STIMULATION INDUCED
BY ACTIVATION OF POSTSYNAPTIC CATECHOLAMINE-RECEPTORS
004126 04-04
LITHIUM EFFECTS ON HALOPERIDOL-INDUCED PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINE-RECEPTOR SUPERSENSITIVITY.
004244 04-04
POSTSYNAPTIC-RECEPTORS
NEUROLEPTIC-INDUCED ACUTE DYSTONIC REACTIONS MAY BE DUE TO
ENHANCED DOPAMINE RELEASE ON TO SUPERSENSITIVE
POSTSYNAPTIC-RECEPTORS.
002789 03-03
POSHRAUMATIC
USE OF LYSINE-VASOPRESSIN IN THE TREATMENT OF POSTTRAUMATIC
AMNESIA.
004583 04-14
POSTTREATMENT
ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT
AND POSHREATMENT OF ALCOHOLIC WITHDRAWAL.
002140 02-11
POSTTRIAL
ACCELERATED EXTINCTION AFTER POSHRIAL HALOTHANE ANESTHESIA IN
RATS: AN AVERSIVE-EFfECT.
003001 03-04
POSTURAL
MORPHINE VERSUS HALOPERIDOL CATALEPSY IN THE RAT: A
BEHAVIORAL-ANALYSIS Of POSTURAL SUPPORT MECHANISMS.
000376 01-04
POSTURAL ASYMMETRY AND DIRECTIONALITY Of ROTATION IN RATS.
001729 02-04
DOES POSTURAL ASYMMETRY INDICATE DIRECTIONALITY Of ROTATION
IN RATS: ROLE Of SEX AND HANDLING.
003061 03-04
DOSE-EffECT Of DEAE ON SUBJECTIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL-SYNDROME .
004472 04-11
POTASSIUM
ABSENCE Of POTASSIUM CONDUCTANCE IN CENTRAL MYELINATED
AXONS.
000166 01-03
THE INfLUENCE Of EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION.
001300 02-03
EfFECT Of LITHIUM ON POTASSIUM AND CALCIUM IN SERUM,
ERYTHOCYTES AND IN URINE.
002054 02-09
THE EffECTS Of D-AMPHETAMINE AND POTASSIUM ON SEROTONIN
RELEASE AND METABOLISM IN RAT-CEREBRAL-CORTEX TISSUE.
002754 03-03
DIffERENTIAL-EffECTS Of POTASSIUM ON THE POTENCY Of DIffERENT
OPIOIDS IN THE MOUSE VAS-DEfERENS.
002935 03-03
INCREASE Of C-GMP AND ACCUMULATION Of 45CA2 EVOKED BY DRUGS
ACTING ON SODIUM OR POTASSIUM CHANNELS.
003709 04-03
INfLUENCE Of CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5
HYDROXYTRYPTAMINE, TYRAMINE AND POTASSIUM fROM GOAT
PIAL-ARTERIES.
003925 04-03
POTASSIUM-INDUCED
EffECTS Of HALOPEMIDE ON POTASSIUM-INDUCED RELEASE OF
RADIOLABELED NEUROTRANSMIHERS fROM RAT CEREBROCORTICAL
SLICES IN VITRO.
001347 02-03
POTENCIES
RELATIVE POTENCIES Of TWO PHENYLALKYLAMINES FOUND IN THE
ABUSED PLANT CATHA-EDULIS, KHAT.
001084 02-02
ERGOT AND CATECHOLAMINE POTENCIES AT CATECHOLAMINE-
RECEPTORS.
001510 02-03
PROLACTIN RELEASING POTENCIES Of ANTIPSYCHOTIC AND RELATED
NONANTIPSYCHOTIC COMPOUNDS IN fEMALE RATS: RELATION TO
CLINICAL POTENCIES.
003830 04-03
S-353
Subject Index
Psychopharmacology Abstracts
a,.
m
■inii:'
ii
«tiii:
I*
COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRACT OF THE GUINEA-PIG AND RAT.
003928 04-03
POTENCY
A NEW APPROACH TO THE ASSESSMENT OF THE POTENCY OF
REVERSIBLE MONOAMINE-OXIDASE-INHIBITORS IN VIVO. AND ITS
APPLICATION TO D-AMPHETAMINE, P METHOXYAMPHETAMINE AND
HARMALINE.
000900 01-16
BETA ENDORPHIN: DISSOCIATION OF RECEPTOR BINDING-AQIVITY FROM
ANALGESIC POTENCY.
001081 02-02
THE EFFECT OF ASPIRIN AND PARACETAMOL ON THE INCREASED
NALOXONE POTENCY INDUCED BY MORPHINE PRETREATMENT.
001824 02-04
METOCLOPRAMIDE: ANTIPSYCHOTIC-EFFICACY OF A DRUG LACKING
POTENCY IN RECEPTOR MODELS.
001948 02-08
AMPHETAMINIL IN THE TREATMENT OF DISTURBED ERECTION POTENCY.
002129 02-11
DIFFERENTIAL-EFFECTS OF POTASSIUM ON THE POTENCY OF DIFFERENT
OPIOIDS IN THE MOUSE VAS-DEFERENS.
002935 03-03
RELATIVE POTENCY OF AMPHETAMINE ISOMERS IN CAUSING THE
SEROTONIN BEHAVIORAL-SYNDROME IN RATS.
003094 03-04
DIETARY PROTEIN INTAKE INFLUENCES THE ANTIHYPERTENSIVE POTENCY
OF METHYLDOPA IN SPONTANEOUSLY HYPERTENSIVE-RATS.
004025 04-03
POTENTIAL
EFFECTS OF THE POTENTIAL NEUROLEPTIC-PEPTIDE DES-TYRl-GAMMA-
ENDORPHIN AND HALOPERIDOL ON APOMORPHINE-INDUCED
BEHAVIOURAL- SYNDROMES IN RATS AND MICE.
000441 01-04
SYNTHESIS OF SOME 5 PHENYLHEXAHYDROAZEPINOINDOLES AS
POTENTIAL NEUROLEPTIC-AGENTS.
001019 02-01
CONVULSANT AND ANTICONVULSANT BARBITURATES. 1 . MOLECULAR
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY
CALCULATIONS.
001029 02-01
6 SUBSTITUTED AMIN0-4H-S-TRIAZ0L0BENZ0DIAZEPINES AND 4
SUBSTITUTED AMIN0-6H-S-TRIAZ0L0BENZ0DIAZEPINES WITH
POTENTIAL ANTIANXIETY ACTIVITY.
001076 02-02
THE NEUROVASCUL^R-PHARMACOLOGY AND CARDIOVASCULAR-
PHARMACOLOGY OF RS-51324, A POTENTIAL ANTIDEPRESSANT.
001091 02-02
ACUTE AND CHRONIC EFFEQS OF MORPHINE ON TRANSMEMBRANE
POTENTIAL AND ON SHORT-CIRCUIT CURRENT IN ISOLATED TOAD
SKIN: APPARENT MORPHINE-DEPENDENCE.
001176 02-03
10 PIPERAZINYL-4H-THIEN0BENZ0DIAZEPINES AS POTENTIAL
NEUROLEPTICS.
001591 02-04
4 PIPERAZINYL-IOH-THIENOBENZODIAZEPINES AS POTENTIAL
NEUROLEPTICS.
001592 02-04
ABUSE POTENTIAL OF LOPERAMIDE.
002413 02-15
REGULATION OF NEUROTRANSMISSION THROUGH PRESYNAPTIC-
RECEPTORS AND OTHER MECHANISMS: POSSIBLE CLINICAL RELEVANCE
AND THERAPEUTIC POTENTIAL.
002569 02-16
MEASUREMENT OF THE MEMBRANE POTENTIAL OF ISOLATED NERVE
TERMINALS BY THE LIPOPHILIC CATION
(3H)TRIPHENYLMETHYLPH0SPH0NIUM-BR0MIDE.
002746 03-03
DEPRESSION OF VENTRAL ROOT DORSAL ROOT POTENTIAL BY DL ALPHA
AMINOADIPATE IN FROG SPINAL-CORD.
002755 03-03
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT,
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1 H-INDAZOLE (FS-32)
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
DIPHENYLHYDANTOIN REDUCES THE OUTWARD-CURRENT OF THE AQION
POTENTIAL IN APLYSIA.
002805 03-03
PRENATAL EXPOSURE TO SYNTHETIC PROGESTINS INCREASES POTENTIAL
FOR AGGRESSION IN HUMANS.
003527 03-15
EFFEQS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETEQ THE NARCOTIC CHARACTER OF A DRUG.
003555 03-16
SYNTHESIS OF POTENTIAL ANTICONVULSANTS: CONDENSATION OF
ISATINS WITH ACETONE AND RELATED KETONES.
003699 04-02
A COMPARATIVE-STUDY OF THE PHARMACOLOGICAL-PROPERTIES OF THE
POSITIVE POTENTIAL RECORDED FROM THE SUPERIOR CERVICAL
GANGLIA OF SEVERAL SPECIES.
003779 04-03
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP-
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF
MOUSE NEUROBLASTOMA CELLS USING
(3H)TETRAPHENYLPH0SPH0NIUM.
004049 04-03
PHARMACOLOGICAL AND BIOCHEMICAL-PROPERTIES OF BRL- 14342, A
NOVEL POTENTIAL ANTIDEPRESSANT-DRUG.
004086 04-04
SPECIFIC IN VIVO BINDING OF 77BR P BROMOSPIROPERIDOL IN RAT-
BRAIN: A POTENTIAL TOOL FOR GAMMA-RAY IMAGING.
004293 04-06
EVENT-RELATED POTENTIAL CHANGES WITH MORPHINE IN NONADDIQED
HUMANS.
004512 04-13
POTENTIALS
EFFECTS OF ENKEPHALIN ANALOGUE AND NALOXONE ON CAT SPINAL-
CORD DORSAL ROOT POTENTIALS.
000236 01-03
THE EFFECT OF CISMETHRIN ON THE RAT DORSAL ROOT POTENTIALS.
000528 01-05 '
MECHANICAL-CHANGES IN CRAB NERVE FIBERS DURING AQION
POTENTIALS. (UNPUBLISHED PAPER).
001505 02-03
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN
MAN: POSSIBLE CENTRAL-AQION IN BRAIN.
002195 02-12
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS: EFFEQS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300.
003451 03-14
OPIATE MECHANISMS: EVALUATION OF RESEARCH INVOLVING
NEURONAL AQION POTENTIALS.
003886 04-03
THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE BRAIN AS AN
OBJECTIVE METHOD TO STUDY THE EFFEQS OF CENTRAUY AQING
DRUGS.
004669 04-16
POTENTIATE
THE INABILITY OF CHRONIC FLUOXETINE TO POTENTIATE A SEROTONIN '
MEDIATED EFFEQ.
000293 01-03
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
002801 03-03
GABA AND BACLOFEN POTENTIATE THE K-EVOKED RELEASE OF
METHIONINE-ENKEPHALIN FROM RAT STRIATAL SLICES.
002882 03-03
PROMETHAZINE AND DIAZEPAM POTENTIATE THE HALOPERIDOL-INDUCED
PROLAQIN RESPONSES.
004499 04-13
POTENTIATED
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFECTS ON
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE
PARADIGM.
000372 01-04 ,
EXTRAPYRAMIDAL REACTION OF FLUPHENAZINE POTENTIATED BY
THYROTOXICOSIS.
003551 03-15
POTENTIATES |
PENTOBARBITAL POTENTIATES GABA-ENHANCED (3H) DIAZEPAM
BINDING TO BENZODIAZEPINE-RECEPTORS.
000275 01-03
NALOXONE POTENTIATES THE DISRUPTIVE EFFECTS OF MESCALINE ON
OPERANT-RESPONDING IN THE RAT.
000365 01-04 I
ACTH POTENTIATES MORPHINE-INDUCED CONDITIONED TASTE-AVERSION.
001781 02-04
ESTROGEN POTENTIATES THE STEREOTYPY INDUCED BY DOPAMINE
AGONISTS IN THE RAT.
002968 03-04
POTENTIATION
ACUTE VERSUS CHRONIC EFFECTS OF SEROTONIN UPTAKE BLOCKERS ON
POTENTIATION OF THE SEROTONIN SYNDROME.
000050 01-03
DIAZEPAM POTENTIATION OF PURINERGIC DEPRESSION OF CENTRAL
NEURONS.
000233 01-03
METHIONINE-ENKEPHALIN ANTAGONISM AND ENDORPHIN POTENTIATION
OF NARCOTIC-INDUCED ANALGESIA.
000357 01-04
POTENTIATION OF LETHALITY IN MICE BY COMBINATIONS OF
PENTAZOCINE AND TRIPELENNAMINE.
000529 01-05
S-354
VOLUME 19, SUBJECT INDEX
Subject Index
ANTIDEPRESSANT POTENTIATION OF 5 HYDROXYTRYPTOPHAN BY L
DEPRENIL IN AFFECTIVE-ILLNESS.
000608 01-09
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC
DRUGS.
001330 02-03
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR
THE POTENTIATION OF IMIPRAMINE EFFECTS ON THE METABOLISM
AND UPTAKE OF BRAIN CATECHOLAMINES.
001427 02-03
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE ACTION OF
DIAZEPAM: POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE
ACTION IN THE BRAIN.
001428 02-03
FENFLURAMINE POTENTIATION OF ANTIHYPERTENSIVE-EFFEaS OF
THIAZIDES.
002138 02-11
POTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3-
HYDROXYASPARTATE.
002768 03-03
POTENTIATION OF APOMORPHINE AND D-AMPHETAMINE EFFECTS BY
NALOXONE.
002942 03-04
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID:
DIFFERENTIAL-EFFECT IN TOLERANT ANIMALS.
003038 03-04
TESTOSTERONE POTENTIATION OF THE EFFECTIVENESS OF AaHl-24 ON
THE INDUCTION OF THE STRETCH-Y AWNING-SYNDROME (SYS) IN MALE
GUINEA-PIGS.
003074 03-04
POTENTIATION OF THE EFFECTS OF ADENOSINE ON ISOLATED CARDIAC-
MUSCLE AND SMOOTH-MUSCLE BY DIAZEPAM.
004266 04-05
POTENTIATION OF THE MORPHINE-INDUCED RESPIRATORY RATE
DEPRESSION BY CAPTOPRIL.
004275 04-05
POTENTIATION OF THE EFFECT OF ANTIDEPRESSANT-ORUGS BY
TRYPTOPHAN.
004412 04-09
'RAZEPAM
SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN
PRAZEPAM TREATMENT IN 30 CASES.
003296 03-1 1
THE TRANQUILIZER DEMETRIN (PRAZEPAM).
003331 03-11
ANXIOUS-DEPRESSIVE-SYNDROME. CLINICAL-STUDY OF A NEW
BENZODIAZEPINE, PRAZEPAM.
004354 04-09
PRAZEPAM: A NEW BENZODIAZEPINE FOR THE TREATMENT OF ANXIOUS-
DEPRESSIVE STATES.
004419 04-10
CLINICAL USE OF A NEW BENZODIAZEPINE, PRAZEPAM.
004421 04-10
DESMETHYLDIAZEPAM KINETICS IN THE ELDERLY AFTER ORAL
PRAZEPAM.
004432 04-11
PRAZEPAM METABOLISM IN FEMALE SUBJECTS.
004504 04-13
tAZINIl
PERSPEQIVES ON PRAZINIL (CARPIPRAMINE): A DISINHIBITING-AGENT
WITH NO NEUROLEPTIC AQIVITY. A REVIEW OF 38 CASES.
003149 03-07
KAZOSIN
3H PRAZOSIN BINDS SPECIFICALLY TO ALPHA 1 -ADRENOCEPTORS IN RAT-
BRAIN.
000205 01-03
PRAZOSIN INCREASES PARADOXICAL-SLEEP.
000405 01-04
tECIPITATEO
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS.
000258 01-03
THE PCP PSYCHOSIS: PROLONGED INTOXICATION OR DRUG PRECIPITATED
FUNQIONAL ILLNESS?
000739 01-12
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
BRAIN.
001234 02-03
NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO
WITHDRAWAL INDUCING BENZAZOCINES. (PH.D. DISSERTATION).
001518 02-03
DOSE-RESPONSE STUDY OF THE PRECIPITATED ABSTINENCE-SYNDROME
FOR MORPHINE: SYSTEMIC VS PERIAQUEDUQAL GRAY NALOXONE.
(PH.D. DISSERTATION).
002979 03-04
PRECIPITATES
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER).
001122 02-03
PRECLINICAL
PHARMACOLOGICAL-BASES OF PSYCHONEUROENDOCRINOLOGY:
PRECLINICAL ASSESSMENT OF CLINICAL FACTS.
003735 04-03
CLINICAL AND PRECLINICAL EXPERIENCE WITH CHOLINE-CHLORIDE IN
HUNTINGTONS-DISEASE AND TARDIVE-DYSKINESIA: UNANSWERED
QUESTIONS.
004604 04-15
PRECLINICAL-EVALUATION
NEUROPHARMACOLOGICAL AND NEUROCHEMICAL APPROACHES TO
PRECLINICAL-EVALUATION OF NEUROLEPTICS.
001094 02-02
PRECONDITIONING
THE EFFECTS OF PIPRADROL ON THE ACQUISITION OF RESPONDING WITH
CONDITIONED REINFORCEMENT: A ROLE FOR SENSORY
PRECONDITIONING.
001572 02-04
PRECURSOR
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFECTS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN.
002990 03-04
PRECURSORS
PSYCHIATRIC MANIFESTATIONS INDUCED BY DOPAMINE PRECURSORS OR
DOPAMINE AGONISTS.
000865 01-15
MONOAMINES AND DEPRESSION: AN INTERIM REPORT. I. SEROTONIN
AND SEROTONIN PRECURSORS.
000996 01-17
ISOLATION OF PSYCHOACTIVE CANNABINOID PRECURSORS FROM
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI.
001023 02-01
MANAGEMENT OF DEPRESSION WITH SEROTONIN PRECURSORS.
003269 03-09
PREDATOR
RATS REACTIONS TO A PREDATOR: MODIFICATION BY
CHLORDIAZEPOXIDE.
000353 01-04
PREDICTABILITY
PREDICTABILITY OF PHENYTOIN SERUM LEVELS BY NOMOGRAMS AND
CLINICIANS.
000909 01-16
PREDICTING
PREDICTING OUTCOME OF ANTIPSYCHOTIC-DRUG TREATMENT FROM
EARLY-RESPONSE.
000565 01-08
PREDICTING THE RESPONSE OF HYPERACTIVE-CHILDREN TO RITALIN: AN
EMPIRICAL-STUDY.
002120 02-11
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRUG
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA.
002225 02-13
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDICT RATS: A POSSIBLE MODEL FOR PREDICTING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION).
003097 03-04
PREDICTING OUTCOME FROM MEASURES OF AHENTION AND
AUTONOMIC-FUNCTIONING.
003205 03-08
PREDICTING STIMULANT-EFFECTIVENESS IN HYPERACTIVE-CHILDREN WITH
A REPEATABLE NEUROPSYCHOLOGICAL-BAHERY: A PRELIMINARY-
STUDY.
004453 04-11
PREDICTIVE
PREDICTION OF DOSAGE OF LITHIUM-CARBONATE: USE OF A STANDARD
PREDICTIVE METHOD.
001991 02-09
PREDICTIVE CRITERIA FOR LITHIUM-SALTS ACTIVITY.
002619 02-17
HYPERVENTILATION-SYNDROME, TREATMENT WITH L TRYPTOPHAN AND
PYRIDOXINE; PREDICTIVE VALUES OF XANTHURENIC-ACID EXCRETION.
004456 04-11
PREDICTOR
D-AMPHETAMINE AS A PREDICTOR FOR RESPONSE TO IMIPRAMINE AND
AMITRIPTYLINE.
000621 01-09
MHPG AS A PREDICTOR OF ANTIDEPRESSANT RESPONSE TO IMIPRAMINE
AND MAPROTILINE.
000787 01-13
STRIATAL DOPAC LEVELS AS A PREDICTOR OF ANTIPSYCHOTIC-EFFICACY.
001533 02-03
S-355
Subject Index
Psychopharmacology Abstracts
if;
;&'
■iiiii;.
3!lll.'
fe
PERSONALITY AS A PREDIQOR OF PSYCHOTHERAPY AND
PHARMACOTHERAPY-OUTCOME FOR DEPRESSED-OUTPATIENTS.
(UNPUBLISHED PAPER).
004418 04-09
PREDICTORS
PREDICTORS OF ADOLESCENT HEIGHT AND WEIGHT IN HYPERKINETIC-
BOYS TREATED WITH METHYLPHENIDATE.
003509 03-15
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFEaiVE-DISORDERS
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDIQCRS TO
CLINICAL-RESPONSE).
004365 04-09
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
004406 04-09
BIOLOGICAL AND PHYSIOLOGICAL PREDIQORS OF DRUG RESPONSE.
(UNPUBLISHED PAPER).
004708 04-17
PREEXPOSURE
INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY
PREEXPOSURE TO THE UNCONDITIONED-STIMULUS: ASSOCIATIVE-
ASPECTS AND NONASSOCIATIVE-ASPECTS.
001610 02-04
PREEXPOSURE TO DELTA9 THC BLOCKS THC-INDUCED CONDITIONED
TASTE-AVERSION IN RATS.
001618 02-04
PREFRONTAL-CORTEX
5 HT BLOCKADE AND THE STIMULANT-EFFEaS OF D-AMPHET AMINE AND
L-AMPHETAMINE: NO INTERACTION IN SELF- STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES.
000387 01-04
FACILITATION OF SELF- STIMULATION OF THE PREFRONTAL-CORTEX IN
RATS FOLLOWING CHRONIC ADMINISTRATION OF SPIROPERIDOL OR
AMPHETAMINE.
000457 01-04
EFFECT OF 6 HYDROXYDOPAMINE LESIONS OF THE MEDIAL PREFRONTAL-
CORTEX ON NEUROTRANSMinER SYSTEMS IN SUBCORTICAL SITES IN
THE RAT.
002869 03-03
PREGANGLIONIC
THE LONG-TERM REGULATION OF GANGLIONIC TYROSINE-HYDROXYLASE
BY PREGANGLIONIC NERVE AQIVITY.
000333 01-03
PREGNANCIES
OUR EXPERIENCE WITH PIRACETAM (NOOTROPIL-UCB) TREATMENT IN
CHILDREN FROM HIGH-RISK PREGNANCIES WITH SUBSEQUENT
MINIMAL-BRAIN-DYSFUNaiON.
000544 01-07
PREGNANCY
PREGNANCY AND EPILEPSY: SHOULD ANTICONVULSANT-DRUGS BE
CONTINUED?
000679 01-11
ON THE DANGER OF USING PSYCHOPHARMACEUTICALS DURING
PREGNANCY: CRITICAL REVIEW OF THE LITERATURE.
000833 01-15
MEDICATION AND PREGNANCY.
002424 02-17
PSYCHOPHARMACEUTICALS AND PREGNANCY: f REVIEW.
002462 02-15
EPILEPSY: NEUROTRANSMinER, BEHAVIOUR AND PREGNANCY.
002466 02-15
PREGNANT
THE COMPARATIVE DISPOSITION OF NOMIFENSINE (MERITAL) IN THE
PREGNANT AND NONPREGNANT RAT.
000853 01-15
EFFECTS OF MARIHUANA ON PREGNANT RATS AND THEIR OFFSPRING.
001830 02-05
PREINCUBATION
CHANGES IN ALPHA-AORENERGIC-RECEPTORS IN RAT-BRAIN IN VITRO BY
PREINCUBATION WITH ALPHA-ADRENERGIC LIGANDS.
001272 02-03
BENZODIAZEPINE-RECEPTORS: EFFEQ OF TISSUE PREINCUBATION AT 37
DEGREES C.
004013 04-03
PREJUNCTIONAL
PREJUNCTIONAL ACTIONS OF PIRIBEDIL ON THE ISOLATED KIDNEY OF THE
RABBIT: COMPARISON WITH APOMORPHINE.
003749 04-03
INTERACTION OF THE TRICYCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH
PREJUNCTIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG
SAPHENOUS VEIN.
003756 04-03
PRELIMINARY-COMMUNICATION
OXYPROTHEPINE-DECANOATE COMPARED WITH FLUPHENAZINE-
DECANOATE IN THE TREATMENT OF SCHIZOPHRENIA: PRELIMINARY-
COMMUNICATION.
001934 02-08
PRELIMINARY-FINDINGS
PRELIMINARY-FINDINGS WITH REGARD TO RISK-FAQORS IN THE
DEVELOPMENT OF TARDIVE-DYSKINESIA.
003501 03-15
PRELIMINARY-REPORT
ANTECEDENTS OF SELF-INDUCED WATER INTOXICATION: A PRELIMINARY-
REPORT.
002414 02-15
PRELIMINARY-RESULTS
A TEN YEAR FOLLOWUP OF LITHIUM-CARBONATE TREATMENT OF MANIC-
DEPRESSIVE-ILLNESS: PRELIMINARY-RESULTS.
002053 02-09
PRELIMINARY-STUDIES
PRELIMINARY-STUDIES ON CSF GAMMA AMINOBUTYRIC-ACID LEVELS IN
PSYCHIATRIC-PATIENTS BEFORE AND DURING TREATMENT WITH
DIFFERENT PSYCHOTROPIC-DRUGS.
001959 02-08
PRELIMINARY-STUDY
PREDICTING STIMULANT-EFFEaiVENESS IN HYPERAQIVE-CHILDREN WITH
A REPEATABLE NEUROPSYCHOLOGICAL-BAnERY: A PRELIMINARY-
STUDY.
004453 04-1 1
HORMONAL STIMULATION AFTER INJEQION OF THYROTROPHIN-
RELEASING-FAQOR (TRF) AND AaHl-24 IN PATIENTS FOLLOWING
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY-STUDY.
004505 04-13
PRELIMINARY-TRIAL
MEMORY AND COGNITIVE FUNQION IN THE ELDERLY: A PRELIMINARY-
TRIAL OF PHYSOSTIGMINE.
000802 01-14
PREMATURE
BIOELECTRICAL-AQIVITY OF THE RAT BRAIN AFTER PREMATURE
WEANING AND AFTER RNA ADMINISTRATION.
002865 03-03
PREMENOPAUSAL-WOMEN
A DOUBLE-BLIND STUDY WITH ORG-GB-94 IN PREMENOPAUSAL-WOMEN.
002173 02-11
PREMENSTRUAL
A NEW DRUG-TREATMENT FOR PREMENSTRUAL EXACERBATION OF
SCHIZOPHRENIA.
000553 01-08
PREMENSTRUAL-SYNDROME
CYCLICAL CRIMINAL AQS IN PREMENSTRUAL-SYNDROME.
000927 01-17
PRENATAL
DELAYED MAZE-LEARNING IN RATS AFTER PRENATAL EXPOSURE TO
CLORAZEPATE.
000521 01-05
EFFEaS OF PRENATAL METHADONE ON RAT-BRAIN CATECHOLAMINES.
001367 02-03
RAT PUP-KILLING AND MATERNAL-BEHAVIOR IN MALE LONG-EVANS-
RATS: PRENATAL STIMULATION AND POSTNATAL TESTOSTERONE.
003054 03-04
PRENATAL EXPOSURE TO SYNTHETIC PROGESTINS INCREASES POTENTIAL
FOR AGGRESSION IN HUMANS.
003527 03-15
THE EFFEQ OF PRENATAL EXPOSURE TO ETHANOL OR OPIATES ON BRAIN
CATECHOLAMINE AQIVITY.
003939 04^3
EFFEQ OF PRENATAL NEUROLEPTIC TREATMENT ON MEMBRANE
RECEPTOR DEVELOPMENT IN THE BRAIN.
003989 04-03
EFFEa OF PRENATAL PHENYTOIN ADMINISTRATION ON BRAIN
TRYPTOPHAN METABOLISM OF RAT OFFSPRING DURING THE
PREWEANING PERIOD.
004108 04-04
PRENYLAMINE
PROTEQIVE EFFECT OF PRENYLAMINE AGAINST VULNERABILITY TO
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE
MYOCARDIUM.
000265 01-03
PREOPTIC
TEMPORAL PAHERNING OF NEURONAL AQIVITY DURING THERMAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
A BARBITURATE-EVOKED INTENSIFICATION OF POSTSYNAPTIC INHIBITION
IN THE PREOPTIC OVULATORY TRIGGER REGION OF THE
HYPOTHALAMUS.
002818 03-03
PREOPTIC- AREA
EVIDENCE OF A OIREQ AQION OF ANGIOTENSIN-II ON NEURONES IN THE
SEPTUM AND IN THE MEDIAL PREOPTIC-AREA.
000272 01-03
PREOPTICUS-MEDIALIS-NUCLEUS
EVIDENCE FOR THERMOREGULATORY DOPAMINERGIC-RECEPTORS
LOCATED IN THE PREOPTICUS-MEDIALIS-NUCLEUS OF THE RAT
HYPOTHALAMUS.
003754 04-03
S-356
VOLUME 19, SUBJECT INDEX
Subfect Index
PIEPUBERTAL
PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE-
DISORDER: A PRELIMINARY REPORT.
000619 01-09
IMIPRAMINE TREATMENT OF PREPUBERTAL MAJOR DEPRESSIVE-
DISORDERS PLASMA LEVELS AND CLINICAL-RESPONSE -
PRELIMINARY REPORT.
000620 01-09
ACUTE EFFECTS OF CAFFEINE IN NORMAL PREPUBERTAL BOYS.
003310 03-11
PRESCRIBING
A NOTE ON PAnERNS OF DRUG PRESCRIBING IN A RESIDENTIAL-CENTER
FOR THE INTELLEQUALLY-HANDICAPPED
000982 01-17
PAVING THE WAY TO SAFE PRESCRIBING FOR THE ELDERLY.
000999 01-17
JOB-SATISFACTION IN GENERAL-PRACTICE: IMPLICATIONS FOR
PRESCRIBING.
002579 02-17
PATIENT CHARAQERISTICS AND CLINICIAN AniTUDES INFLUENCING THE
PRESCRIBING OF BENZODIAZEPINES.
003598 03-17
WHAT IS STANDARD PRACTICE IN PRESCRIBING PSYCHOTROPICS?
003638 03-17
PRESCRIPTION
TRENDS IN THE PRESCRIPTION OF PSYCHOTROPIC-DRUGS (1970-1977) IN
A STATE-HOSPITAL.
000926 01-17
MONOAMINE-OXIDASE-INHIBITORS: PRESCRIPTION AND PATIENT
MANAGEMENT.
002454 02-15
METHODOLOGICAL-CONSIDERATIONS CONCERNING THE PRESCRIPTION
AND USE OF SO CALLED DISINHIBITORS.
002571 02-17
INITIAL PRESCRIPTION OF PSYCHOTROPIC-MEDICATIONS FOR
ADOLESCENTS IN A MEDICAL/PROFESSIONAL INSTITUTE, AND THE
ROLE OF THE PSYCHIATRIST IN A MEDICAL/ PROFESSIONAL INSTITUTE.
002621 02-17
PRESCRIPTIONS
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS
AFTER HOSPITAL DISCHARGE IN THE DISTRIQS TEPLICE AND UHERSKE-
HRADISTE.
002518 02-17
PRESSOR
EFFEaS OF CHRONIC ADMINISTRATION OF DELTA9
TETRAHYDROCANNABINOL ON THE CARDIOVASCULAR SYSTEM, AND
PRESSOR AND BEHAVIORAL-RESPONSES TO BRAIN-STIMULATION IN
FREELY-MOVING-RATS.
000417 01-04
CLONIDINE ON THE PRESSOR RESPONSE TO RAISED INTRACRANIAL
PRESSURE.
001316 02-03
EFFEQS OF DELTA9 TETRAHYDROCANNABINOL ON THE
CARDIOVASCULAR-SYSTEM, AND PRESSOR AND BEHAVIORAL-
RESPONSES TO BRAIN-STIMULATION IN RATS.
001681 02-04
PRESSOR EFFEQS OF DORSAL RAPHE STIMULATION AND
INTRAHYPOTHALAMIC APPLICATION OF SEROTONIN IN THE
SPONTANEOUSLY HYPERTENSIVE-RAT.
003117 03-04
TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFECTS OF
CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS
003428 03-13
PRESSOR EFFEQS OF ELECTRICAL-STIMULATION OF THE DORSAL AND
MEDIAN RAPHE NUCLEI IN ANESTHETIZED RATS.
003892 04-03
DIFFERENTIAL INHIBITION OF ALPHA 1 -ADRENOCEPTOR AND ALPHA2-
ADRENOCEPTOR MEDIATED PRESSOR RESPONSES IN PITHED RATS
PRESSURE 004057 04-03
PRESSURE REVERSAL OF THE EFFEQ OF URETHANE ON THE EVOKED
SOMATOSENSORY CORTICAL RESPONSE IN THE RAT.
001106 02-03
CLONIDINE ON THE PRESSOR RESPONSE TO RAISED INTRACRANIAL
PRESSURE.
001316 02-03
8RAIN-M0N0AMINES AND THE HIGH PRESSURE NEUROLOGICAL-
SYNDROME.
,r,,r.o^ 00168602-04
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION.
003419 03-13
INTRAOCULAR PRESSURE CHANGES FOLLOWING MODIFIED ECT
003536 03-15
THE DYNAMICS OF SYSTEMIC VENOUS, ARTERIAL, AND CEREBROSPINAL-
FLUID PRESSURE UNDER I.V. ADMINISTRATION OF POLYETHYLENE-
GLYCOL.
004045 04-03
PRESYMPTOMATIC
LEVODOPA AND PRESYMPTOMATIC DETECTION OF HUNTINGTONS-
DISEASE - EIGHT-YEAR FOLLOWUP.
000950 01-17
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND
LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJECTS
003311 03-11
PRESYNAPTIC
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
TRICYCLIC-ANTIDEPRESSANTS INDUCE SUBSENSITIVITY OF PRESYNAPTIC
DOPAMINE-AUTORECEPTORS .
000048 01-03
MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS:
MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN.
000068 01-03
THE EFFECTS OF BROMOCRIPTINE ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS IN THE MOUSE VAS-DEFERENS.
000108 01-03
GABA FLUXES IN PRESYNAPTIC NERVE-ENDINGS FROM IMMATURE RATS
000185 01-03
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFEQS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMUUVTION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
RECEPTORS.
000323 01-03
METOCLOPRAMIDE AND SULPIRIDE AS SELECTIVE BLOCKING-AGENTS
PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS.
001102 02-03
PRESYNAPTIC DOPAMINE-RECEPTORS: INSENSITIVITY TO KAINIC-ACID
AND THE DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING CHRONIC
HALOPERIDOL.
001117 02-03
EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS.
001146 02-03
PRESYNAPTIC ACTIONS OF 4 AMINOPYRIDINE AND GAMMA
AMINOBUTYRIC-ACID ON RAT SYMPATHETIC GANGLIA IN VITRO.
001244 02-03
PERIPHERAL PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS:
ARE THEY DIFFERENT FROM DOPAMINE-RECEPTORS IN THE CENTRAL-
NERVOUS-SYSTEM.
001252 02-03
THE TIME-COURSE OF NORADRENERGIC PRESYNAPTIC AND
POSTSYNAPTIC ACTIVITY DURING CHRONIC DESIPRAMINE
TREATMENT.
001289 02-03
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT
CAUDATE-NUCLEUS.
001298 02-03
BENZODIAZEPINES MODIFY THE AGONIST RESPONSES AT A PRESYNAPTIC
GABA-RECEPTOR.
001377 02-03
ACTIVATION OF PRESYNAPTIC ALPHA NORADRENALINE-RECEPTORS IN
RAT-BRAIN BY THE POTENT DOPAMINE-MIMETIC N,N DIPROPYL-ADTN
001390 02-03
PRESYNAPTIC AND POSTSYNAPTIC MECHANISMS IN HALOPERIDOL-
INDUCED SENSITIZATION TO DOPAMINERGIC AGONISTS.
001392 02-03
PRESYNAPTIC DOPAMINE-RECEPTORS IN STRIATAL NERVE-ENDINGS:
ABSENCE OF HALOPERIDOL-INDUCED SUPERSENSITIVITY.
001424 02-03
RADIORECEPTOR LABELING OF PRESYNAPTIC AND POSTSYNAPTIC
DOPAMINE-RECEPTORS.
001511 02-03
PRESYNAPTIC AND POSTSYNAPTIC SEROTONERGIC MANIPULATIONS IN
AN ANIMAL-MODEL OF DEPRESSION.
001730 02-04
PRESYNAPTIC ALPHA-ADRENOCEPTORS AND THE ACTION OF TRICYCLIC-
ANTIDEPRESSANT DRUGS IN BEHAVIOURAL-DESPAIR IN RATS.
001829 02-04
DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINERGIC MECHANISMS.
001839 02-05
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A
SELECTIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST.
002236 02-13
S-357
Subject Index
Psychopharmacology Abstracts
'in*"
"lie
«iijf
1*
DRUG-EFFECTS ON PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-
RECEPTORS.
002372 02-15
PRESYNAPTIC REGULATION OF THE RELEASE OF CATECHOLAMINES IN THE
CAT HYPOTHALAMUS.
002703 03-03
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING AQIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF-
STIMULATION MODEL USING CLONIDINE.
003016 03-04
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS:
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (MOGABA RELEASE IN VITRO.
003741 04-03
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT
NICTITATING MEMBRANE.
003777 04-03
PRESYNAPTIC REGULATION OF THE RELEASE OF ACETYLCHOLINE BY 5
HYDROXYTRYPTAMINE.
003843 04-03
PRESYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION IN HELIX-
POMATIA: THE EFFECTS OF SEROTONIN AND DOPAMINE
ANTAGONISTS.
003869 04-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR PRESYNAPTIC AQtONS OF
PHENCYCLIDINE ON NORADRENERGIC TRANSMISSION IN RAT
CEREBELLUM.
003926 04-03
PRESYNAPTIC AND POSTSYNAPTIC ALPHA-ADRENOCEPTOR ANTAGONISM
BY NEUROLEPTICS IN VIVO.
003966 04-03
THE HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPEQ TO THE
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRAQION
ABUNDANT IN PRESYNAPTIC MEMBRANES.
004028 04-03
LITHIUM EFFECTS ON HALOPERIDOL-INDUCED PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINE-RECEPTOR SUPERSENSITIVITY.
004244 04-04
PRESYNAPTIC-AUTORECEPTORS
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC-
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT MIANSERIN.
003745 04-03
PRESYNAPTIC-RECEPTORS
DOPAMINE SYNTHESIS: TOLERANCE TO HALOPERIDOL AND
SUPERSENSITIVITY TO APOMORPHINE DEPEND ON PRESYNAPTIC-
RECEPTORS.
001129 02-03
REGULATION OF NEUROTRANSMISSION THROUGH PRESYNAPTIC-
RECEPTORS AND OTHER MECHANISMS: POSSIBLE CLINICAL RELEVANCE
AND THERAPEUTIC POTENTIAL.
002569 02-16
PRESYNAPTIC-RECEPTORS.
003637 03-17
PRESYNAPTICAILY
ENKEPHALINS PRESYNAPTICAUY INHIBIT CHOLINERGIC TRANSMISSION
IN SYMPATHETIC GANGLIA.
000167 01-03
PRETREATED
EFFEQS OF PHENCYCLIDINE AND METHYLPHENIDATE ON D-
AMPHETAMINE-INDUCED BEHAVIORS IN RESERPINE PRETREATED RATS.
001616 02-04
EFFECTS OF ELEaROCONVULSIVE-TREATMENT ON GROWTH-HORMONE
SECRETION INDUCED BY MONOAMINE-RECEPTOR AGONISTS IN
RESERPINE PRETREATED RATS.
002664 03-03
DIPHENYLHYDANTOIN-INDUCED BLOCK OF THE RAT PHRENIC-NERVE
DIAPHRAGM PREPARATION PRETREATED WITH P
HYDROXYMERCURIBENZOATE.
002749 03-03
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED
MICE.
002800 03-03
DISCRIMINATIVE RESPONSE CONTROL BY NALOXONE IN MORPHINE
PRETREATED RATS.
003053 03-04
PRETREATMENT
ENHANCEMENT OF THE BEHAVIORAL-EFFEQS OF 2,5 DIMETHOXY-4-
METHYLAMPHETAMINE (DOM) BY PRETREATMENT WITH P
CHLOROPHENYLALANINE.
000364 01-04
NALOXONE PRETREATMENT ENHANCES SHOCK-ELICITED AGGRESSION.
001615 02-04
THE EFFECT OF ASPIRIN AND PARACETAMOL ON THE INCREASED
NALOXONE POTENCY INDUCED BY MORPHINE PRETREATMENT.
001824 02-04
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY
PRETREATMENT WITH THYROID-HORMONES.
002259 02-13
ANTIPEROXIDANT PRETREATMENT AND IRON-INDUCED EPILEPTIFORM
DISCHARGES IN THE RAT: EEG AND HISTOPATHOLOGIC STUDIES
002930 03-03
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDOORS OF
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
004406 04-09
PRETREATMENTS
APHAGIA, GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNCTIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS:
EFFEQS OF INSULIN PRETREATMENTS.
001638 02-04
PREVALENCE
THE PREVALENCE OF PRESUMED TARDIVE-DYSKINESIA IN PSYCHIATRIC-
INPATIENTS AND PSYCHIATRIC-OUTPATIENTS.
002417 02-15
CHANGES IN PREVALENCE, SEVERITY, AND RECOVERY IN TARDIVE-
DYSKINESIA WITH AGE
002455 02-15
TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-OUTPATIENTS: PREVALENCE
AND SIGNIFICANT VARIABLES.
003483 03-15
PREVALENCE OF PERSISTENT ABNORMAL INVOLUNTARY-MOVEMENTS
AMONG PATIENTS IN A NIGERIAN LONG- STAY PSYCHIATRIC UNIT.
004334 04-08
PREVALENCE OF HYPERACTIVITY AND RELATED TREATMENTS AMONG
ELEMENTARY SCHOOL CHILDREN.
004469 04-11
PREVALENCE OF DRUG-TREATMENT FOR HYPERAQIVITY AND OTHER
CHILDHOOD BEHAVIOR-DISORDERS.
004713 04-17
PREVENTION
SYNERGISTIC AQIONS OF PROPANTHELINE-BROMIDE WITH CIMETIDINE
AND THIOPROPAZATE-HYDROCHLORIDE IN THE PREVENTION OF
STRESS-ULCER FORMATION IN RATS.
000064 01-03
TARDIVE-DYSKINESIA: RECOGNITION, MANAGEMENT, AND PREVENTION.
002392 02-15
FOOTSHOCK ANALGESIA: PREVENTION BY BEHAVIOURAL-MANIPULATION
BUT NOT BY NALOXONE.
003073 03-04
PREVENTION OF TARDIVE-DYSKINESIA AND OTHER DRUG RELATED
AOVERSE-EFFEQS.
004601 04-15
UNWANTED EFFEaS OF LITHIUM-CARBONATE USED IN THE PREVENTION
OF RELAPSES OF AFFEQIVE-ILLNESS.
004625 04-15
TARDIVE-DYSKINESIA: PROBLEMS OF PATHOGENESIS, THERAPY, AND
PREVENTION.
004644 04-15
PRE WE AN I NG
EFFECT OF PRENATAL PHENYTOIN ADMINISTRATION ON BRAIN I
TRYPTOPHAN METABOLISM OF RAT OFFSPRING DURING THE
PREWEANING PERIOD.
004108 04-041
PREWEANLING
CANALIZATION OF AROUSAL IN THE PREWEANLING RAT: EFFEaS OF
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI.
002965 03-04
PRIDEFINE
AQION OF THE ANTIDEPRESSANT PRIDEFINE (AHR-1 1 18) ON BIOGENIC-
AMINES IN THE RAT-BRAIN.
000312 01-03
NONCOMPETITIVE AMINE UPTAKE INHIBITION BY THE NEW ,
ANTIDEPRESSANT PRIDEFINE.
003771 04-03
PRIMARY
CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC-
ACID (GAG) A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE
(GABA-TRANSAMINASE) INHIBITOR.
000174 01-03
DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY
GABA DEFICIENCY CLINICALLY DETEaED: 38 NEW CASES.
000584 01-09
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION. „„„„„„,
001300 02-03
S-358
VOLUME 19, SUBJECT INDEX
Subject Index
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY
AFFECTIVE-ILLNESS.
002506 02-16
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
002699 03-03
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION
PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN. EVIDENCE FOR
PRESERVED SCHWANN-CELL SOMAL FUNCTION.
002905 03-03
THE MEDICATION SEMINAR AND PRIMARY CARE EDUCATION.
003592 03-17
EFFECTS OF PENTOBARBITAL AND ETHANOL UPON SINGLE NEURON
ACTIVITY IN THE PRIMARY SOMATOSENSORY CORTEX OF THE RHESUS-
MONKEY.
003755 04-03
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS:
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE.
003778 04-03
THE EFFECT OF NOOTROPIL ON THE TRANSCALLOSAL AND PRIMARY
EVOKED-RESPONSES OF THE CAT CEREBRAL-CORTEX.
003780 04-03
SENSORY NEUROTOXINS: CHEMICALLY-INDUCED SELEQIVE DESTRUQION
OF PRIMARY SENSORY NEURONS.
003859 04-03
BENZODIAZEPINE-RECEPTORS ON PRIMARY CULTURES OF MOUSE
ASTROCYTES.
004029 04-03
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS.
004403 04-09
PRIMATE
THE ACUTE AND CHRONIC EFFEQ OF 5 METHOXYTRYPT AMINE ON
SELEQED MEMBERS OF A PRIMATE SOCIAL-COLONY.
001073 02-02
A PRIMATE ANALOGUE OF AMPHETAMINE-INDUCED BEHAVIORS IN
HUMANS.
003006 03-04
CLONIDINE AND THE PRIMATE LOCUS-COERULEUS: EVIDENCE SUGGESTING
ANXIOLYTIC AND ANTIWITHDRAWAL EFFEQS. (UNPUBLISHED PAPER).
003982 04-03
PRIMATES
DOPAMINE, ACETYLCHOLINE, AND GABA EFFECTS IN ACUTE DYSTONIA IN
PRIMATES.
000043 01-03
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES.
002285 02-13
ANTAGONISM OF INTRAVENOUS COCAINE LETHALITY IN NONHUMAN
PRIMATES.
003127 03-05
PRIMER
CHILDREN ON MEDICATION: A PRIMER FOR SCHOOL PERSONNEL.
000676 01-11
PRIMIDONE
PHARMACOKINETICS OF PRIMIDONE AND ITS ACTIVE METABOLITES IN
THE DOG.
000097 01-03
SINGLE-DOSE PHARMACOKINETICS AND ANTICONVULSANT EFFICACY OF
PRIMIDONE IN MICE.
000177 01-03
THE EFFEQS OF PHENYTOIN ON PHENOBARBITONE AND PRIMIDONE
METABOLISM.
003333 03-1 1
PRINCIPLES
MODERN-VIEWS ON THE PRINCIPLES OF THE PHARMACOLOGICAL-
TREATMENT OF EPILEPSY.
000931 01-17
PRINCIPLES OF FRENCH PHARMACOCLINICAL-CLASSIFICATION.
001892 02-07
SOME PRINCIPLES OF DIFFERENTIATED METABOLIC DRUG-TREATMENT IN
COMPREHENSIVE THERAPY OF MENTAL-DISORDERS.
004433 04-11
PRl
GABAERGIC MECHANISMS IN THE CONTROL OF PRL AND GH RELEASE.
002690 03-03
PRO-LEU-GLY-NH2
SOME OBSERVATIONS ON THE PHARMACOLOGICAL ACTIVITY OF MIF
(PR0-LEU-GLY-NH2).
004240 04-04
PROBE
ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED
PAPER).
001014 02-01
A QUANTITATIVE PROBE FOR BIOLOGICAL-PSYCHIATRY: SELECTED ION-
MONITORING.
004685 04-16
PROBENECID
ACCELERATED METABOLISM OF PROBENECID DURING LONG-TERM-
TREATMENT OF RATS WITH ANTICONVULSANT-DRUGS: EFFECT ON
CENTRAL SEROTONIN TURNOVER STUDIES.
002890 03-03
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID:
DIFFERENTIAL-EFFECT IN TOLERANT ANIMALS.
003038 03-04
A SELECTED ION-MONITORING ASSAY FOR BIOGENIC-AMINE
METABOLITES AND PROBENECID, IN HUMAN LUMBAR
CEREBROSPINAL-FLUID.
003663 04-01
PROBES
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL
EVALUATION.
003685 04-02
PROBING
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYORYL
GROUPS IN THE AQIVE SITE. (UNPUBLISHED PAPER).
001066 02-01
PROCEDURES
PROCEDURES FOR REDUCING DRUG INTAKE: NONHUMAN STUDIES.
001753 02-04
ANALYSIS OF SINGLE-BUND, DOUBLE-BLIND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFECTS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS - BRIEF REPORT.
003298 03-1 1
ANALYSIS OF SINGLE-BUND AND DOUBLE-BUND PROCEDURES,
MAINTENANCE OF PLACEBO-EFFEQS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON.
004437 04-11
COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR
CONTROLUNG INSTITUTIONAUZED MENTALLY-RETARDED PERSONS.
004438 04-11
LSD, PSYCHOTOGENIC PROCEDURES AND BRAIN NEUROHUMORS.
(UNPUBLISHED PAPER).
004448 04-1 1
DRUG-THERAPY FOR HYPERACTIVITY: TREATMENT PROCEDURES IN
NATURAL SEHINGS.
004449 04-11
COMPARISON OF SPECTROFLUOROMETRIC AND GAS-
CHROMATOGRAPHY/MASS-SPECTROMETRY PROCEDURES FOR THE
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN.
004692 04-16
PROCESSING
AQH MODULATION OF MEMORY STORAGE PROCESSING. (UNPUBLISHED
PAPER).
001250 02-03
OPIATE-RECEPTOR GRADIENTS IN MONKEY CEREBRAL-CORTEX:
CORRESPONDENCE WITH SENSORY PROCESSING HIERARCHIES.
002641 03-01
A PSYCHOPHARMACOLOGICAL APPROACH TO MEMORY PROCESSING.
002901 03-03
SENSORY PROCESSING, CARDIOVASCULAR REACTIVITY, AND THE TYPE A
CORONARY-PRONE BEHAVIOR PATTERN.
003405 03-13
PROCONVULSANT
PROCONVULSANT AND ANTICONVULSANT AQION OF MORPHINE IN
RATS.
000494 01-04
THE PROCONVULSANT AND DIAZEPAM REVERSING EFFECTS OF ETHYL-
BET A-CARBOLINE-3-CARBOXYLATE .
001399 02-03
PROCURING
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED
REFLEXES IN RATS.
003100 03-04
PRODRUGS
PRODRUGS OF SOME DOPAMINERGIC 2 AMINOTETRAUNS: A REVIEW OF
THEIR SYNTHESES AND NEUROCHEMICAL PROFILES.
000004 01-01
PROFESSIONAL
PARAPROFESSIONAL AND PROFESSIONAL TEAMWORK AND TRAINING IN
MANAGING PCP AND OTHER DRUG-ABUSE PROBLEMS.
000924 01-17
S-359
Subject Index
Psychopharmacology Abstracts
9s
C.3:
ma;
INITIAL PRESCRIPTION OF PSYCHOTROPIC-MEDICATIONS FOR
ADOLESCENTS IN A MEDICAL/PROFESSIONAL INSTITUTE, AND THE
ROLE OF THE PSYCHIATRIST IN A MEDICAL/PROFESSIONAL INSTITUTE.
002621 02-17
PROFESSOR
NEUROLEPTIC ACTIVITY: A SUMMARY OF PROFESSOR JACQUES
GLOWINSKIS PRESENTATION.
003628 03-17
PROFILE
3 SULFAMOYLMETHYL-l-2-BENZISOXAZOLE, A NEW TYPE OF
ANTICONVULSANT-DRUG: PHARMACOLOGICAL PROFILE.
000012 01-02
3 SULFAMOYLMETHYL-l-2-BENZISOXAZOLE, A NEW TYPE OF
ANTICONVULSANT-DRUG: ELECTROENCEPHALOGRAPHIC PROFILE.
000142 01-03
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS.
001869 02-06
PROFILE OF THE ANTIDEPRESSANT ACTION OF NOMIFENSINE.
002025 02-09
THERAPEUTIC PROFILE OF HALOPERIDOL.
002603 02-17
RECEPTOR BINDING PROFILE OF R-41-468, A NOVEL ANTAGONIST AT 5
HT2-RECEPT0RS.
002648 03-02
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS
ADMINISTRATIONS.
002797 03-03
THE THERAPEUTIC PROFILE OF MIANSERIN IN MILD ELDERLY
DEPRESSIVES.
003297 03-1 1
THE PHARMACOLOGICAL PROFILE OF LOFEPRAMINE, A NEW
ANTIDEPRESSANT-DRUG.
004006 04-03
PROFILES
PRODRUGS OF SOME DOPAMINERGIC 2 AMINOTETRALINS: A REVIEW OF
THEIR SYNTHESES AND NEUROCHEMICAL PROFILES.
000004 01-01
N TETRAHYDROFURYLALKYL AND N ALKOXYALKYL DERIVATIVES OF (-)
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID ACTION
PROFILES.
000013 01-02
USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETECT AND
DISCRIMINATE ACTIONS OF DRUGS AND TOXICANTS.
000503 01-04
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM)
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND
DINORLAAM, DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT.
000505 01-04
LEVORPHANOL: RADIOIMMUNOASSAY AND PLASMA CONCENTRATION
PROFILES IN DOG AND MAN.
000898 01-16
CHARACTERIZATION OF ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLACTIN AND GROWTH-HORMONE PROFILES
DURING WAKEFULNESS AND SLEEP.
002217 02-13
EFFECTS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROFILES.
002239 02-13
EEG ASSESSMENTS OF DOSAGE AND SLEEP PROFILES FOR A HYPNOTIC-
DRUG OF THE TRIAZOLOTHIENODIACEPINE SERIES.
002338 02-14
PROGABIDE
GABA AND SCHIZOPHRENIA: STUDY OF THE AQION OF A GABAERGIC
ANTAGONIST. PROGABIDE OR SL-76-002.
003175 03-08
PROGENY
THE DEVELOPMENT OF PROGENY IN CASES OF ANTENATAL EXPOSURE TO
PHENAZEPAM.
001854 02-05
BEHAVIORAL AND METABOLIC ALTERATIONS IN PROGENY OF
METHADONE-TREATED RATS. (PH.D. DISSERTATION).
003113 03-04
PROGESTERONE
THE EFFEQS OF PROGESTERONE ON THE CIRCADIAN-CYCLES AND
ESTROUS-CYCLES IN THE RAT. (PH.D. DISSERTATION).
001 1 1 1 02-03
INFLUENCE OF ESTROGEN AND PROGESTERONE ON GLUTAMIC-ACID-
DECARBOXYLASE ACTIVITY IN DISCRETE REGIONS OF RAT-BRAIN.
002927 03-03
PROGESTIN-RECEPTORS
CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN
HYPOTHALAMUS.
002842 03-03
PROGESTINS
PRENATAL EXPOSURE TO SYNTHETIC PROGESTINS INCREASES POTENTIAL
FOR AGGRESSION IN HUMANS.
003527 03-15
PROGNOSIS
LITHIUM RESPONSE IN GOOD PROGNOSIS SCHIZOPHRENIA.
000555 01-08
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-ORUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME.
003189 03-08
THE PROGNOSIS OF EPILEPSY AND THE STRATEGY FOR TERMINATING
ANTIEPILEPTIC THERAPY.
004724 04-17
PROGNOSTIC
PROGNOSTIC FACTORS DETERMINING RESPONSE TO ANTIDEPRESSANT-
DRUGS IN PSYCHIATRIC-OUTPATIENTS AND GENERAJ.-PRACTICE
000638 01-09
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF
ELECTROENCEPHALOGRAPHY WITH INTRAVENOUS DIAZEPAM IN '
EPILEPSY
000696 01-11
PREDICTION AND PROGNOSTIC FACTORS IN CLINICAL-TRIALS OF
PSYCHOTROPIC-DRUGS.
002615 02-17
PROGRAMMES
PURSUING THE ACTIONS OF PSYCHOTROPIC-DRUGS: RECEPTOR SITES
AND ENDOGENOUS CEREBRAL PROGRAMMES. j
002578 02-171
PROGRESSIVE
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH
IN THE ELECTROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO
AUTORECEPTOR STIMULATION.
000046 01-03
REPEATED TRICYCLICS INDUCE A PROGRESSIVE OOPAMINE-
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT OF DAILY DRUG-
TREATMENT
000047 01-03
TRANSIENT-EFFECT OF L TRYPTOPHAN IN PROGRESSIVE MYOCLONUS
EPILEPSY WITHOUT LAFORA-BODIES: CLINICAL- STUDY AND
ELECTROPHYSIOLOGICAL-STUDY
000694 01-11
PROGRESSIVE SUPRANUCLEAR PALSY, COMPUTED-TOMOGRAPHY, AND
RESPONSE TO ANTIPARKINSONIAN-DRUGS.
003322 03-11
PROGRESSIVE SUPRANUCLEAR PALSY: PNEUMOENCEPHALOGRAPHY,
ELECTRONYSTAGMOGRAPHY AND TREATMENT WITH METHYSERGIDE.
003355 03-11
INTERMIHENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA,
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE
lOTHALAMATE VENTRICULOGRAM.
003520 03-15
THE PROBLEM OF PSYCHOPHARMACOTHERAPY OF SLOWLY PROGRESSIVE
HYPOCHONDRIACAL SCHIZOPHRENIA.
004340 04-08,
PROGRESSIVE-RATIO
PROGRESSIVE-RATIO AND FIXED-RATIO SCHEDULES OF COCAINE
MAINTAINED RESPONDING IN BABOONS.
000395 01-04
PROHYPNOTIC-EFFECTS
BEHAVIORAL-EFFEaS, ANTIDOPAMINERGIC-EFFEaS, AND PROHYPNOTIC-
EFFECTS OF NEUROLEPTICS DURING AND AFTER PROLONGED
TREATMENT.
001577 02-04
PROJECTIONS
THE ROLE OF NIGRAL PROJEQIONS TO THE THALAMUS IN DRUG-
INDUCED CIRCLING-BEHAVIOUR IN THE RAT.
004205 044)4
PROLACTIN
CHANGES OF AQH, STH, TSH AND PROLAQIN LEVELS IN ENDOTOXIN
SHOCK IN RATS.
000119 01-03
SYSTEMIC AND INTRAVENTRICULAR PROLACTIN INDUCES EXCESSIVE
GROOMING.
000378 01-04
THE EFFECT OF THIORIDAZINE ON PROLAQIN LEVELS IN ACUTELY
SCHIZOPHRENIC-PATIENTS: CHALLENGE-DOSE AND STEADY-STATE
LEVELS.
000558 01-08
PROLAQIN AND SOMATOTROPIN RESPONSES TO TRH IN SCHIZOPHRENIC-
PATIENTS.
000570 01-08
PROLACTIN CHANGES IN MAJOR DEPRESSIVE-DISORDERS.
000752 01-13
PLASMA CHLORPROMAZINE SERUM PROLAQIN RELATIONSHIP IN A
SINGLE-DOSE EXPERIMENT.
000761 01-13
$.360
VOLUME 19, SUBJECT INDEX
Subject Index
DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: A
PITUITARY MODEL FOR THE STUDY OF A NEUROENDOCRINE SYSTEM IN
MAN.
000776 01-13
THE INFLUENCE OF LITHIUM-SALTS AND ANTIDEPRESSANT MEDICATION
ON SERUM PROLACTIN LEVEL
000780 01-13
PROLACTIN RESPONSE AND EXTRAPYRAMIDAL SIDE-EFFECTS DURING
PROPRANOLOL AND NEUROLEPTIC-DRUGS TREATMENT IN CHRONIC
SCHIZOPHRENIC-PATIENTS.
000841 01-15
PLASMA PROLACTIN AND TESTOSTERONE DURING PENFLURIDOL
TREATMENT.
000874 01-15
IMPORTANCE OF AKINESIA: PLASMA CHLORPROMAZINE AND PROLACTIN
LEVELS.
000891 01-15
EFFECT OF SEROTONIN ON PROLACTIN SECRETION IN VIVO.
001016 02-01
ALTERATION OF PROLACTIN SECRETION BY CENTRALLY-ACTING DRUGS.
001127 02-03
SERUM PROLACTIN DURING AGING AND THE EFFECTS OF ERGOTS.
001171 02-03
EFFECT OF AMINOOXY ACETIC-ACID AND BICUCULLINE ON PROLACTIN
RELEASE IN CASTRATED MALE RATS.
001194 02-03
A PHARMACOLOGICAL ANALYSIS OF THE ROLE OF THE AMYGDALA IN
THE CONTROL OF GONADOTROPIN AND PROLACTIN SECRETION.
001418 02-03
EFFECT OF PROPRANOLOL TREATMENT ON SERUM PROLACTIN LEVEL IN
SCHIZOPHRENIC-PATIENTS.
001916 02-08
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH
NEUROLEPTICS.
001935 02-08
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
CLINICAL STATE, PLASMA LEVELS OF HALOPERIDOL AND PROLACTIN:
001943 02-08
USE OF LARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC-
PATIENTS WITH ELEVATED SERUM PROLACTIN LEVELS AND
EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH NEUROLEPTIC
TREATMENT.
001944 02-08
PLASMA FLUPHENAZINE AND PROLACTIN LEVELS IN SCHIZOPHRENIC-
PATIENTS DURING TREATMENT WITH LOW-DOSES AND HIGH-DOSES OF
FLUPHENAZINE-ENANTHATE.
001956 02-08
INFLUENCE OF NOMIFENSINE ON GROWTH-HORMONE, PROLACTIN,
LUTEINISING-HORMONE AND THYREOTROPIN IN HEALTHY SUBJECTS
AND HYPERPROLACTINAEMIC-PATIENTS.
002137 02-11
EFFEQS OF NALOXONE UPON PROLACTIN AND CORTISOL IN NORMAL
WOMEN.
002213 02-13
CHARACTERIZATION OF ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLAQIN AND GROWTH-HORMONE PROFILES
DURING WAKEFULNESS AND SLEEP.
002217 02-13
STUDY OF PROLACTIN VARIATIONS IN PSYCHIATRIC-PATIENTS TREATED
WITH FLUPHENAZINE-DECANOATE.
002226 02-13
THE EFFEQ OF BENZTROPINE-MESYLATE ON THE PROLACTIN RESPONSE
TO HALOPERIDOL.
002238 02-13
ABNORMAL REGULATION OF PROUCTIN RELEASE IN IDIOPATHIC
PARKINSONS-DISEASE.
002255 02-13
INHIBITION OF SULPIRIDE-INDUCED PROLACTIN SECRETION BY
DIHYDROERGOCRISTINE IN MAN.
002277 02-13
THE INFLUENCE OF NEUROLEPTIC-DRUGS ON PROLACTIN SECRETION IN
CHILDREN.
002409 02-15
COMPARATIVE- STUDY OF VARIATIONS IN PROLACTIN LEVELS DURING
TREATMENT WITH ANTIPSYCHOTIC-DRUGS.
002412 02-15
HALOPERIDOL STIMULATION OF PROLACTIN SECRETION: HOW MANY
BLOOD SAMPLES ARE NEEDED TO DEFINE THE HORMONE RESPONSE?
002505 02-16
PSYCHOTROPIC-DRUGS DO NOT INTERFERE WITH RADIOLIGAND ASSAYS
FOR PROLACTIN, CORTISOL, AND GROWTH-HORMONE.
002511 02-16
THE CHANGE OF BLOOD PROLACTIN LEVEL DUE TO THE WITHDRAWAL OF
MAINTENANCE NEUROLEPTICS.
002559 02-17
THE HYPOTHALAMIC DOPAMINERGIC REGULATION OF PROLACTIN: A
MODEL FOR THE STUDY OF NEUROHORMONAL MECHANISMS IN MAN.
002568 02-17
CLINICAL-ASPECTS ON PROLACTIN RESPONSE TO NEUROLEPTIC-DRUGS
002590 02-17
DIFFERENTIAL-EFFECTS OF CANNABINOID EXPOSURE AND STRESS ON
PLASMA PROLACTIN, GROWTH-HORMONE AND CORTICOSTERONE
LEVELS IN MALE MICE.
002695 03-03
DURING ONE YEARS NEUROLEPTIC TREATMENT IN RATS STRIATAL
DOPAMINE-RECEPTOR BLOCKADE DECREASES BUT SERUM PROLACTIN
LEVELS REMAIN ELEVATED,
002707 03-03
ANTERIOR PITUITARY GABA-RECEPTORS AND THEIR REGULATION OF
PROLACTIN SECRETION.
002738 03-03
THE DIRECT EFFECT OF RESERPINE IN VITRO ON PROLACTIN RELEASE
FROM RAT ANTERIOR PITUITARY-GLANDS.
002810 03-03
SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI-
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS.
002871 03-03
ERGOT DRUGS SUPPRESS PLASMA PROLACTIN AND LACTATION BUT NOT
AGGRESSION IN PARTURIENT MICE.
003159 03-07
LOW SERUM PROLACTIN AND EARLY RELAPSE FOLLOWING NEUROLEPTIC
WITHDRAWAL.
003166 03-08
NEUROLEPTIC-INDUCED ELEVATIONS IN SERUM PROLACTIN LEVELS:
ETIOLOGY AND SIGNIFICANCE.
003190 03-08
EFFECT OF LITHIUM ON PROLACTIN RESPONSES TO THYROTROPIN-
RELEASING-HORMONE IN PATIENTS WITH MANIC-STATE.
003266 03-09
INCREASED SERUM PROLACTIN LEVELS DURING PHENOTHIAZINE AND
BUTYROPHENONE TREATMENT OF SIX POSTPARTUM WOMEN.
003318 03-11
THE EFFECT OF AMANTADINE ON PROLACTIN LEVELS AND
GALACTORRHEA ON NEUROLEPTIC TREATED PATIENTS.
003373 03-11
EFFECT OF A PSYCHOACTIVE-DRUG, TRAZODONE, ON PROLACTIN
SECRETION IN MAN.
003425 03-13
LYMPHOCYTE MONOAMINE-OXIDASE AND PLASMA PROLACTIN AND
GROWTH-HORMONE IN TARDIVE-DYSKINESIA.
003499 03-15
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
METERGOLINE AND CYPROHEPTADINE SUPPRESS PROLACTIN RELEASE BY
A NON-5-HYDROXYTRYPTAMINERGIC, NONDOPAMINERGIC
MECHANISM.
003732 04-03
ROLE OF THE ANTERIOR PITUITARY GABA-RECEPTOR IN THE CONTROL OF
PROLACTIN RELEASE.
003809 04-03
PROLACTIN RELEASING POTENCIES OF ANTIPSYCHOTIC AND RELATED
NONANTIPSYCHOTIC COMPOUNDS IN FEMALE RATS: RELATION TO
CLINICAL POTENCIES.
003830 04-03
THE PROLACTIN RESPONSE IN PATIENTS RECEIVING NEUROLEPTIC
THERAPY. THE EFFECT OF FLUPHENAZINE-DECANOATE.
004318 04-08
NEUROENDOCRINE-TESTS DURING TREATMENT WITH NEUROLEPTIC-
DRUGS: I. PLASMA PROLACTIN RESPONSE TO CHLORPROMAZINE
CHALLENGE.
004329 04-08
HALOPERIDOL AND DROPERIDOL TREATMENT IN SCHIZOPHRENICS:
CLINICAL APPLICATION OF THE PROLACTIN MODEL.
004332 04-08
DIFFERENT EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS ON THE RELEASE OF TSH, PROLACTIN, AND
GROWTH-HORMONE AFTER ADMINISTRATION OF THYROSTIMULATING-
RELEASING-HORMONE IN MANIC-DEPRESSIVES.
004407 04-09
PROMETHAZINE AND DIAZEPAM POTENTIATE THE HALOPERIDOL-INDUCED
PROLACTIN RESPONSES.
004499 04-13
PROLACTIN AND GROWTH-HORMONE STUDIES IN SCHIZOPHRENIC-
PATIENTS AND NORMAL CONTROLS.
004538 04-13
PROLACTIN AND NEUROLEPTIC-DRUGS: A BIOCHEMICAL INDEX OF
CLINICAL-RESPONSE?
004539 04-13
S-361
Subject Index
Psychopharmacology Abstracts
a,.
iill
ii
Sit.
on?
•t:
kf
SEX, PLASMA PROLACTIN AND PLASMA 3 METHOXY-4-
HYDROXYPHENYLGLYCOL (MHPG) PREDICT HERITABLE D-
AMPHETAMINE EXCITATION IN MAN. (UNPUBLISHED PAPER).
004565 04-14
PROLACTINAEMIA
BASAL PROLACTINAEMIA AND RESPONSES TO TRH AND SULPIRIDE IN
DIFFERENT CATEGORIES OF MALE SEXUAL-DYSFUNCTIONS.
004503 04-13
PROLAPSE
EFFECT OF SODIUM-LACTATE ON PATIENTS WITH PANIC-DISORDER AND
MITRAL-VALVE PROLAPSE.
003409 03-13
ARRHYTHMIA INDUCED BY A TRICYCLIC-ANTIDEPRESSANT IN A PATIENT
WITH UNDIAGNOSED MITRAL-VALVE PROLAPSE.
003521 03-15
PROLIFERATION
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND
MORPHOLOGICAL-STUDY.
001407 02-03
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN
HUMAN CELLS.
002830 03-03
THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE
PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION
WITH PHYTOHEMAGGLUTININ.
004541 04-13
PROLINE
MODIFICATION OF THE PROLINE RESIDUE OF TRH ENHANCES BIOLOGICAL-
ACTIVITY AND INHIBITS DEGRADATION.
000351 01-04
BIOLOGICAL EVALUATION OF A TRH ANALOGUE WITH A MODIFIED
PROLINE RESIDUE.
003662 04-01
PROLONGATION
PROLONGATION OF THE EJACULATION LATENCY IN THE MALE RAT BY
THIORIDAZINE AND CHLORIMIPRAMINE.
000335 01-04
PROLYL-LEUCYL-GLYCINAMIDE
EFFECTS OF DOPAMINERGIC AND CHOLINERGIC-DRUGS, NALOXONE AND
L PROLYL-LEUCYL-GLYCINAMIDE ON LSD-INDUCED CATALEPSY.
000360 01-04
PROMAZINE
FREE DESCRIPTION OF DRUG-EFFECTS AS A METHOD OF CLINICAL-TRIAL,
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND
THEIR COMBINATION.
002561 02-17
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJEQION IN
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION
AND EFFEQS OF D-AMPHETAMINE AND PROMAZINE.
004152 04-04
PROMETHAZINE
PROMETHAZINE AND DIAZEPAM POTENTIATE THE HALOPERIDOL-INDUCED
PROLAQIN RESPONSES.
004499 04-13
PROMOTER
DIAZEPAM AS TUMOUR PROMOTER.
003495 03-15
PROMOTES
NALOXONE PROMOTES STIMULUS-EVOKED VASOPRESSIN RELEASE IN ,
VIVO.
000165 01-03
PROOF
ANTIHYPOXIDOTIC-DRUGS AND NOOTROPIC-ORUGS: PROOF OF THEIR
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
QUANTITATIVE EEG INVESTIGATIONS.
002166 02-11
PROPANIDID
VALUE OF PROPANIDID IN ELEQROCONVULSIVE-THERAPY (COMPARISON
WITH THIOPENTONE).
004379 04-09
PROPANTHELINE-BROMIDE
SYNERGISTIC ACTIONS OF PROPANTHELINE-BROMIDE WITH CIMETIDINE
AND THIOPROPAZATE-HYDROCHLORIDE IN THE PREVENTION OF
STRESS-ULCER FORMATION IN RATS.
000064 01-03
FACILITATION OF RECOVERY BY PROPANTHELINE-BROMIDE AFTER
LATERAL HYPOTHALAMIC DAMAGE.
000396 01-04
PROPERICIAZINE
FOLLOWUP STUDY ON THE INFLUENCE OF AN ANTIPSYCHOTIC-DRUG
(PROPERICIAZINE) ON LIVER FUNQION, ELEQROCARDIOGRAM AND
ELEaROENCEPH ALOGRAM .
000639 01-09
PROPHYLACTIC
LITHIUM LEVEL IN SOME BIOLOGICAL FLUIDS AT ITS PROPHYLAQIC
THERAPEUTIC APPLICATION.
000605 01-09
COMPARATIVE-STUDY OF PROPHYLAQIC LITHIUM AND
DIETHYLSTILBESTROL IN SEXUAL-DEVIANTS.
000663 01-11
LITHIUM-PUMP REPRESSION AS AN INDICATOR OF PROPHYLAaiC
RESPONSE.
001989 02-09
THE RELATIVE PROPHYLAQIC EFFICACY OF LITHIUM AGAINST MANIC
AND DEPRESSIVE RECURRENCES IN BIPOLAR-PATIENTS.
002040 02-09
PHARMACODYNAMIC ASPEQS OF LONG-TERM PROPHYLAQIC LITHIUM.
002212 02-13
THE REPRESSION OF THE LITHIUM-PUMP AS AN INDICATOR OF RESPONSE
TO PROPHYLACTIC TREATMENT.
003221 03-09
PROPHYLAaiC LITHIUM WITH AND WITHOUT IMIPRAMINE FOR BIPOLAR-
l-PATIENTS: A DOUBLE-BLIND STUDY.
003233 03-09
THE EFFEQ OF WITHDRAWAL FROM PROLONGED PROPHYUQIC
TREATMENT WITH LITHIUM.
003339 03-1 1
COMPARATIVE CHARAQERISTICS OF THE PROPHYLAQIC PROPERTIES OF
SHORT-TERM AND LONG-AQING LITHIUM-CARBONATE PREPARATIONS
IN ENDOGENOUS AFFECTIVE-PSYCHOSES.
004390 04-09
CLINICAL-EVALUATION OF THE PROPHYLAQIC EFFEQIVENESS OF
PROLONGED LITHIUM-CARBONATE THERAPY IN ENDOGENOUS
DEPRESSIVE-SYNDROMES.
004404 04-09
PROPHYLACTIC-EFFECT
PROPHYLACTIC-EFFEQ OF LITHIUM AGAINST DEPRESSION IN
CYCLOTHYMIC-PATIENTS: A LIFE-TABLE ANALYSIS.
004391 04-09
PROPHYLAXIS
THE EFFLUX OF LITHIUM FROM RED-BLOOD-CELLS AND THE EFFEQ OF
LITHIUM PROPHYLAXIS.
000630 01-09
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE- SYNDROME. PART 2.
PROPHYLAXIS OF RECURRENT DEPRESSIVE-ILLNESS.
002043 02-09
HYPOMANIA AS A STABLE STATE: LITHIUM PROPHYLAXIS IN TWO
PATIENTS.
003212 03-09
LITHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND
BIPOLAR-II DEPRESSION: A PROSPEQIVE, PLACEBO-CONTROLLED
COMPARISON.
003252 03-09
CONFESSION OF A MELANCHOLIAC: CONTRIBUTION TO THE PROBLEM OF
PROPHYLAXIS OF MANIC-OEPRESSIVE-PSYCHOSIS USING LITHIUM
003267 03-09
LITHIUM PROPHYLAXIS AND THE KIDNEY.
003463 03-15
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFEQIVE-DISORDERS
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDICTORS TO |
CLINICAL-RESPONSE).
004365 04-09
A PRELIMINARY DOUBLE-BUND STUDY ON THE EFFICACY OF
CARBAMAZEPINE IN PROPHYLAXIS OF MANIC-DEPRESSIVE-ILLNESS.
004388 0409 i
PROPORTION
NEUROLEPTIC TREATMENT FOR A SUBSTANTIAL PROPORTION OF ADULT
LIFE: BEHAVIOURAL-SEQUELAE OF 9 MONTHS HALOPERIDOL
ADMINISTRATION.
001858 02-05 '
PROPOXYPHENE
D PROPOXYPHENE ACTS DIFFERENTLY FROM MORPHINE ON OPIOID-
RECEPTOR EFFECTOR MECHANISMS.
003062 03-04
PROPRANOLOL
EFFECT OF NALOXONE, HALOPERIDOL AND PROPRANOLOL ON CYCLIC-
ADENOSINE-MONOPHOSPHATE CONTENT OF RAT AMYGDALA.
000071 01-03
CHRONIC HIGH-DOSE PROPRANOLOL DOES NOT INCREASE DOPAMINE-
RECEPTOR NUMBER.
000083 0 1 -03
EFFECTS OF RESERPINE, PROPRANOLOL, AND AMINOPHYUINE ON
SEIZURE ACTIVITY AND CNS CYCLIC-NUCLEOTIDES.
000115 01-03
THE EFFECT OF PROPRANOLOL ON THE ELECTROENCEPHALOGRAM IN
NORMAL AND ETHANOL DEPENDENT RATS.
000126 01-03
BARBITURATE-DEPENDENCE IN MICE: EFFECTS OF PROPRANOLOL ON THE
WITHDRAWAL-SYNDROME (40798).
000313 01-03
EFFECTS OF MEUTONIN AND PROPRANOLOL ON SLEEP OF THE RAT.
000432 01-04
ANTAGONISTIC-EFFECTS OF PROPRANOLOL UPON ETHANOL-INDUCED
NARCOSIS IN MICE.
000439 01-04
S-362
VOLUME 19, SUBJECT INDEX
Subject Index
PROLACTIN RESPONSE AND EXTRAPYRAMIDAL SIDE-EFFECTS DURING
PROPRANOLOL AND NEUROLEPTIC-DRUGS TREATMENT IN CHRONIC
SCHIZOPHRENIC-PATIENTS
00084) 01-15
INHIBITION BY LOCAL ANESTHETICS. PHENTOLAMINE AND PROPRANOLOL
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL
MUSCARINIC-RECEPTORS.
001097 02-03
ANTIPSYCHOTIC-EFFECT OF PROPRANOLOL ON CHRONIC
SCHIZOPHRENICS: STUDY OF A GRADUAL TREATMENT REGIMEN.
001915 02-08
EFFEa OF PROPRANOLOL TREATMENT ON SERUM PROLACTIN LEVEL IN
SCHIZOPHRENIC-PATIENTS.
001916 02-08
DEXTRO PROPRANOLOL IN SCHIZOPHRENIA.
001921 02-08
SOME CLINICAL-ASPECTS AND METABOLIC-ASPECTS OF PROPRANOLOL IN
CHRONIC SCHIZOPHRENIA.
001926 02-08
PROPRANOLOL IN SCHIZOPHRENIA ~ MORE GUESS THAN GAUSS.
001939 02-08
PHARMACOKINETIC INTERAQION BETWEEN PROPRANOLOL AND
CHLORPROMAZINE IN SCHIZOPHRENIC-PATIENTS.
001940 02-08
PROPRANOLOL IN CHRONIC ANXIETY-DISORDERS: A CONTROLLED-STUDY.
002073 02-10
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL
HEMORRHAGE PATIENTS.
002295 02-13
EFFEaS OF ATENOLOL AND PROPRANOLOL ON HUMAN PERFORMANCE
AND SUBJEaiVE FEELINGS.
002340 02-14
PROPRANOLOL (INDERAL) FOR TARDIVE-DYSKINESIA AND
EXTRAPYRAMIDAL SIDE-EFFECTS FROM NEUROLEPTICS: POSSIBLE
INVOLVEMENT OF BETA-ADRENERGIC MECHANISMS.
002470 02-15
EFFEa OF PROPRANOLOL AND PHENOTHIAZINES ON ELECTRODERMAL
ORIENTING AND HABITUATION IN SCHIZOPHRENIA.
003174 03-08
PROPRANOLOL IN THE TREATMENT OF RAGE AND VIOLENT-BEHAVIOR IN
PATIENTS WITH CHRONIC-BRAIN-SYNDROMES.
003394 03-11
BENZODIAZEPINE WITHDRAWAL SYMPTOMS AND PROPRANOLOL.
003543 03-15
THE EFFEa OF PROPRANOLOL AND ITS ISOMERS ON PURKINJE
NEURONES IN RAT CEREBELLUM.
004059 04-03
EFFEaS OF PROPRANOLOL ON THE LOCOMOTOR-STIMULATION INDUCED
BY ACTIVATION OF POSTSYNAPTIC CATECHOUMINE-RECEPTORS.
004126 04-04
AN EVALUATION OF THE ANTIANXIETY AQION AND SIDE-EFFECTS OF
PROPRANOLOL.
004660 04-15
HOPYLBENZILYLCHOLINE-MUSTARD
PERSISTENT EFFEaS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC-
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS.
001266 02-03
tOPYLNORANTIFEIN
THE EFFEa OF PROPYLNORANTIFEIN ON BEHAVIORAL-REACTIONS,
ADRENOCORTICAL AaiVITY, AND ENERGY METABOLISM IN THE
ANIMAL BRAIN.
004075 04-04
«OPYLNORAPOMORPHINE
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE-
BEHAVIOR: INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON
THREE EXPERIMENTAL MODELS.
000340 01-04
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM:
FUNaiONAL CHANGES FOLLOWED USING (-)N N
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL AaiVITY LEVELS
OF RATS.
001603 02-04
BEHAVIORAL-FACILITATION FOLLOWING CHRONIC ADMINISTRATION OF N
N PROPYLNORAPOMORPHINE.
001822 02-04
'ROSPECTIVE-TRIAL
PROSPEaiVE-TRIAL OF L TRYPTOPHAN IN MATERNITY-BLUES.
000683 01-11
'ROSTACYCUN-DEPENDENT
PROSTACYCLIN-DEPENDENT AaiVATION OF ADENYLATE-CYCLASE IN A
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-ACTIVITY
RELATIONSHIPS.
001132 02-03
'ROSTA6LANDIN
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
AaiVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
VASOTOCIN, PROSTAGLANDIN, AND FEMALE REPRODUCTIVE BEHAVIOR
IN THE FROG, RANA-PIPIENS.
002978 03-04
PROSTAOLANDIN-D2
EFFECT OF PR0STAGLANDIN-D2, PR0STAGLANDIN-E2 AND
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES
OF RAT AND RABBIT BRAIN.
003983 04-03
PROSTAGLANDIN-E
PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN
VITRO. INHIBITION BY MELATONIN AT SUBMICROMOLAR
CONCENTRATIONS.
001159 02-03
PROSTA6LANDIN-E1
INHIBITION OF ACH RELEASE BY PROSTAGLANDIN-E 1 IN THE RABBIT
SUPERIOR-CERVICAL-GANGLION .
001205 02-03
EFFEa OF PROSTAGLANDIN-E 1 AND ITS BIOSYNTHESIS INHIBITOR
INDOMETHACIN ON DRINKING IN THE RAT.
001749 02-04
THE ANTINOCICEPTIVE-EFFECT OF INTRACEREBROVENTRICULARLY
ADMINISTERED PROSTAGLANDIN-E 1 IN THE RAT.
001769 02-04
RELATIONSHIP BETWEEN THE AaiONS OF CALCIUM-IONS, OPIOIDS, AND
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN
NEUROBLASTOMA-X GLIOMA HYBRID CELLS.
002677 03-03
PROSTAGLANDIN-E2
REGULATION OF NORADRENALINE OVERFLOW IN RAT-CEREBRAL-CORTEX
BY PR0STAGLANDIN-E2.
003841 04-03
EFFECT OF PR0STAGLANDIN-D2, PR0STAGLANDIN-E2 AND
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES
OF RAT AND RABBIT BRAIN.
003983 04-03
PROSTAGLANDIN-F2ALPHA
MECHANISMS INVOLVED IN CENTRAL-EFFEaS OF PROSTAGLANDIN-
F2ALPHA. (UNPUBLISHED PAPER).
001222 02-03
EFFECT OF PR0STAGLANDIN-D2, PR0STAGLANDIN-E2 AND
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES
OF RAT AND RABBIT BRAIN.
003983 04-03
PROSTAGLANDINS
EFFECT OF PROSTAGLANDINS ON PLASMA CATECHOLAMINES, HEART
AND BLOOD-PRESSURE RESPONSES TO HEMORRHAGE. (UNPUBLISHED
PAPER).
001223 02-03
PROSTAGLANDINS IN THE BRAIN OF RATS GIVEN, ACUTELY, AND
CHRONICALLY, A HYPERTHERMIC-OOSE OF MET-ENKEPHALIN.
001468 02-03
INTERACTION OF PROSTAGLANDINS AND THE EFFEaS OF MORPHINE AND
AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
001732 02-04
THE EFFECT OF CONDITIONS INFLUENCING ENDOGENOUS
PROSTAGLANDINS ON THE ACTIVITY OF DELTA'
TETRAHYDROCANNABINOL.
002196 02-12
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM.
002728 03-03
PROSTAGLANDINS, CLONIDINE AND SEXUAL-RECEPTIVITY IN THE GUINEA-
PIG.
003017 03-04
PROSTANOID
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-AaiVITY
RELATIONSHIPS.
001132 02-03
PROTEASE
IN VIVO EFFECT OF PROTEASE INHIBITORS IN DENERVATION ATROPHY.
000290 01-03
REGULATION OF HIPPOCAMPAL GLUTAMATE-RECEPTORS: EVIDENCE FOR
THE INVOLVEMENT OF A CALCIUM-AaiVATED PROTEASE.
001120 02-03
PROTECTION
BARBITURATE SERUM LEVELS AND PROTEaiON AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
001559 02-04
VALPROIC-ACID SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
002946 03-04
NA-GAMMA-HYDROXYBUTYRATE IN CEREBRAL PROTECTION DURING
SEVERE HYPOXEMIA IN THE RAT.
003895 04-03
COCAINE AND SEIZURE PROTECTION IN MICE OF VARYING BRAIN
WEIGHTS.
004103 04-04
S-363
:^jcifl»;M'llllliffiiil:
Subject Index
Psychopharmacology Abstracts.
i!,a,..
fe
^
PROTECTIVE
PROTEaiVE EFFEa OF PRENYLAMINE AGAINST VULNERABILITY TO
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE
MYOCARDIUM.
000265 01-03
PROTEQIVE AQION OF L 5 HYDROXYTRYPTOPHAN L GLUTAMATE
(MADE- 1932) DURING ELEQROSHOCK-TREATMENT (ECT).
003043 03-04
PROTEIN
ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS.
(UNPUBLISHED PAPER).
000060 01-03
VALPROIC-ACID DOSAGE AND PLASMA PROTEIN BINDING AND
CLEARANCE.
000755 01-13
INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY- STATE SERUM LEVELS
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-ORUGS IN MAN.
000767 01-13
TECHNIQUES FOR PLASMA PROTEIN BINDING OF
DEMETHYLCHLORIMIPRAMINE.
000897 01-16
IDENTIFICATION AND PARTIAL PURIFICATION OF A HYDROPHOBIC
PROTEIN COMPONENT ASSOCIATED WITH (3H)SPIR0PERID0L BINDING-
AaiVITY. (UNPUBLISHED PAPER).
001007 02-01
PROTEIN ABNORMALITIES IN MACROPHAGES BEARING ASBESTOS.
(UNPUBLISHED PAPER).
001037 02-01
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALEaOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER).
001122 02-03
THE ROLE OF PROTEIN SYNTHESIS IN THE HYPOTHALAMIC MECHANISM
MEDIATING PYROGEN FEVER
001454 02-03
SHORT-TERM AND LONG-TERM MODIFICATION OF SKELETAL-MUSCLE
SODIUM-PUMP ACTIVITY AND MUSCLE PROTEIN TURNOVER.
(UNPUBLISHED PAPER).
001519 02-03
ROLE OF NEUROTRANSMinERS AND PROTEIN SYNTHESIS IN SHORT-
TERM AND LONG-TERM MEMORY.
001573 02-04
EFFECT OF L FUCOSE ON BRAIN PROTEIN METABOLISM AND RETENTION
OF A LEARNED-BEHAVIOR IN RATS.
001819 02-04
STUDIES ON THIORIDAZINE AND MESORIOAZINE METABOLISM. I.
PROTEIN BINDING.
001867 02-06
COMPARATIVE PROTEIN BINDING OF DIAZEPAM AND
DESMETHYLDIAZEPAM.
002206 02-13
INTERACTION BETWEEN PHENYTOIN AND VALPROIC-ACID: PLASMA
PROTEIN BINDING AND METABOLIC-EFFEaS.
002276 02-13
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS
INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJEQION OF
CYCLOHEXIMIDE.
002780 03-03
EFFEQS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC
MEMBRANES.
002888 03-03
EFFECT OF ALPHA METHYLPHENYLALANINE AND PHENYLALANINE ON
BRAIN POLYRIBOSOMES AND PROTEIN SYNTHESIS.
003733 04-03
EFFEQ OF INTRAVENOUS ADMINISTRATION OF D LYSERGIC-ACID-
DIETHYLAMIDE ON SUBSEQUENT PROTEIN SYNTHESIS IN A CELL-FREE
SYSTEM DERIVED FROM BRAIN.
003761 04-03
DIETARY PROTEIN INTAKE INFLUENCES THE ANTIHYPERTENSIVE POTENCY
OF METHYLDOPA IN SPONTANEOUSLY HYPERTENSIVE-RATS.
004025 04-03
PROTEIN BINDING OF CHLORPROAAAZINE IN CEREBROSPINAL-FLUID AND
SERUM.
004311 04-08
PROTEIN-KINASES
ROLE OF PROTEIN-KINASES IN OPIATE AQIONS IN BRAIN.
001173 02-03
PROTEINS
REGULATION OF THE STATE OF PHOSPHORYLATION OF SPECIFIC
NEURONAL PROTEINS IN MOUSE-BRAIN BY IN VIVO ADMINISTRATION
OF ANESTHETIC AND CONVULSANT-AGENTS.
000291 01-03
HYBRID PROTEINS USED TO STUDY THE MECHANISM OF TOXIN
ENTRANCE INTO CELLS. (UNPUBLISHED PAPER).
001063 02-01
SELEQIVE EFFEaS OF LSD AND HYPERTHERMIA ON THE SYNTHESIS OF
SYNAPTIC PROTEINS AND GLYCOPROTEINS.
002721 03-03
CHARACTERIZATION OF THE BASIC PROTEINS FROM RODENT
PERIPHERAL-NERVOUS-SYSTEM MYELIN .
003665 04-01
SYNTHESIS OF CYTOSKELETAL PROTEINS IN BULK ISOLATED NEURONAL
PERIKARYA.
003672 04^1
A RADIOIMMUNOASSAY FOR EPENDYMINS BETA AND GAMAAA: TWO
GOLDFISH BRAIN PROTEINS INVOLVED IN BEHAVIORAL PLASTICITY.
003677 04-01
PROTOCOL
PROTOCOLS FOR THE USE OF PSYCHOAQIVE-DRUGS ~ PART I:
PROTOCOL FOR THE TREATMENT OF PSYCHOSIS WITH
ANTIPSYCHOTICS.
000949 01-17
PROTOCOLS FOR THE USE OF PSYCHOAQIVE-DRUGS - PART II:
PROTOCOL FOR THE TREATMENT OF DEPRESSION WITH TRICYCUC-
ANTIDEPRESSANTS.
003214 03-09"
PROTOCOLS
PROTOCOLS FOR THE USE OF PSYCHOAQIVE-DRUGS - PART I:
PROTOCOL FOR THE TREATMENT OF PSYCHOSIS WITH ,
ANTIPSYCHOTICS.
000949 01-17
PROTOCOLS FOR THE USE OF PSYCHOAQIVE-DRUGS - PART II:
PROTOCOL FOR THE TREATMENT OF DEPRESSION WITH TRICYCLIC-
ANTIDEPRESSANTS.
003214 03-09
PROTON
BETA ENDORPHIN AND ANALOGS: 360 MHZ PROTON NMR
SPEQROSCOPY.
001028 02-01
NMR SPEQRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
PROTOTYPE
DISCRIMINATIVE-STIMULUS EFFECTS OF PROTOTYPE OPIATE-RECEPTOR
AGONISTS IN MONKEYS.
001803 02-04'
MINI-SYMPOSIUM: III. SIMPLE IN VIVO TESTS THAT DIFFERENTIATE
PROTOTYPE AGONISTS AT OPIATE-RECEPTORS.
004289 04-06
PROVENIENCE
ISOLATION OF PSYCHOACTIVE CANNABINOID PRECURSORS FROM
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI.
001023 02-01
PROVERA
THE EFFECT OF ASSERTIVENESS TRAINING, PROVERA AND SEX OF
THERAPIST IN THE TREATMENT OF GENITAL EXHIBITIONISM.
000697 01-11
PROVOKE
DO STIMUU^NTS PROVOKE, CAUSE, OR EXACERBATE TICS AND
TOUREHE-SYNDROME?
004485 04-11
PR05-ENKEPHAUN <
COMPARATIVE-STUDY OF ANALGESIA INDUCED BY N VAL5-ENKEPHALIN
AND PR05-ENKEPHALIN ANALOGS.
000021 01-03
PRUSSIAN-BLUE
PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALUUM, ARSENIC,
INDUSTRIAL- SOLVENT INTOXICATION, AND OTHER
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT.
003348 03-11
PSEUDONEURASTHENIA
TOFISOPAM IN PSEUDONEURASTHENIA WITH HEADACHES.
002075 02-10
PSYCHEDELIC-DRUGS
PSYCHEDELIC-DRUGS AND THE CREATIVE-PROCESS.
002199 02-12
PSYCHEDELIC-EXPERIENCES
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL
CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN
PSYCHEDELIC-EXPERIENCES.
002200 02-12
PSYCHIATRIC
PSYCHIATRIC MANIFESTATIONS INDUCED BY DOPAMINE PRECURSORS 0«
DOPAMINE AGONISTS.
000865 01-15
COMPARISON OF NITRAZEPAM 5 MG WITH TRIAZOLAM 0.5 MG IN
YOUNG PSYCHIATRIC INSOMNIAC-INPATIENTS.
002096 02-11
ERGOTISM IN A PSYCHIATRIC ENVIRONMENT ASSOCIATED WITH
ERYTHROMYCIN-DIHYDROERGOTAMINE-PROPIONATE. AN
OBSERVATION.
002379 02-15
PSYCHIATRIC MORBIDITY AND PHYSICAL TOXICITY ASSOCIATED WITH
ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY.
002433 02-15
S-364
002463 02-) 5
/OLUME 19, SUBJECT INDEX
PSYCHIATRIC IMPLICATIONS OF ANTICONVULSANT-DRUGS
MODERN CONCEPTS IN PSYCHIATRIC SURGERY.
002551 02-17
HEMOPERFUSION FOR CHRONIC SCHIZOPHRENIA: PRELIMINARY
PSYCHIATRIC RESULTS.
003180 03-08
PREVALENCE OF PERSISTENT ABNORMAL INVOLUNTARY-MOVEMENTS
AMONG PATIENTS IN A NIGERIAN LONG-STAY PSYCHIATRIC UNIT.
004334 04-08
PSYCHIATRIC USES OF BETA-BLOCKERS.
004709 04-17
SYCHIATRIC-ASPECTS
PSYCHIATRIC-ASPECTS OF ACUTE POISONING WITH TRICYCLIC AND
RELATED ANTIDEPRESSANTS - 1980.
002458 02-15
SIDE-EFFEaS OF CORTICOSTEROID THERAPY: PSYCHIATRIC-ASPECTS.
003508 03-15
SYCHUkTRIC-COMPLICATIONS
MEDICAL AND PSYCHIATRIC-COMPLICATIONS OF PENTAZOCINE AND
TRIPELENNAMINE ABUSE.
000955 01-17
SYCHIATRIC-DIAGNOSIS
LIMITS, VALUE AND PERSPEQIVES OF THE PSYCHIATRIC-DIAGNOSIS IN
CLINICAL PSYCHOPHARMACOLOGY.
002631 02-17
SYCHIATRIC-DISORDERS
GABA LEVELS IN HUMAN CEREBROSPINAL-FLUID: ALTERATIONS IN
PSYCHIATRIC-DISORDERS. (UNPUBLISHED PAPER).
000764 01-13
ANIMAL-MODELS OF PSYCHIATRIC-DISORDERS.
001871 02-06
TRIAL WITH MINAPRINE IN SUBJECTS WITH PSYCHIATRIC-DISORDERS.
001889 02-07
ON A POSSIBLE ROLE OF ENDORPHINS IN PSYCHIATRIC-DISORDERS -
AQIONS OF NALOXONE IN PSYCHIATRIC-PATIENTS.
001917 02-08
HYPNOTIC ACTION OF FLUNITRAZEPAM (ROCHES ROIPNOL) IN PATIENTS
WITH SEVERE PSYCHIATRIC-DISORDERS.
003295 03-11
SYCHIATRIC-DISTURBANCE
PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPED-PATIENTS: A
PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED.
000668 01-11
SYCHIATRIC-DRUG
ARCALION-200 PRESCRIBED AS A PSYCHIATRIC-DRUG AND
ANTIALCOHOLISM-DRUG ON AN OUTPATIENT AND INPATIENT BASIS.
002103 02-11
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT;
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL
EVOLUTION.
002165 02-1)
SYCHIATRIC-DRUG-STUDY
PSYCHIATRIC-DRUG-STUDY. PART II. MENTAL-HYGIENE-CLINIC SURVEY,
DAY-TREATMENT-CENTER SURVEY, DAY-HOSPITAL SURVEY.
004716 04-17
SYCHIATRIC-DRUGS
THE USE OF PSYCHIATRIC-DRUGS FOR DECADES.
002555 02-17
THE KINETICS OF PSYCHIATRIC-DRUGS.
004739 04-17
'SYCHIATRIC-EFFECTS
PSYCHIATRIC-EFFEQS OF BROMOCRIPTINE AND LERGOTRILE IN
PARKINSONIAN-PATIENTS.
002453 02-15
'SYCHIATRIC-EMERGENCIES
PSYCHOPHARMACOLOGY IN PSYCHIATRIC-EMERGENCIES.
000933 01-17
SYCHIATRIC-HOSPITAL
THE URBAN EPIDEMIC OF PHENCYCLIDINE USE: LABORATORY EVIDENCE
FROM A PUBLIC PSYCHIATRIC-HOSPITAL INPATIENT-SERVICE.
003554 03-16
AN ANALYSIS OF DRUG DECISIONS IN A STATE PSYCHIATRIC-HOSPITAL.
003593 03-17
PSYCHOTROPIC-DRUGS AND PSYCHIATRIC-HOSPITAL ADMISSIONS IN
VERONA, ITALY.
004717 04-17
>SYCHIATRIC-ILLNESS
PSYCHIATRIC-ILLNESS AND USE OF PSYCHOTROPIC-DRUGS IN THE
GEOGRAPHICALLY DELIMITED POPULATION OF SAMSO, DENMARK.
004734 04-17
>$YCHIATRIC-INPATIENTS
USE OF BENZODIAZEPINES IN PSYCHIATRIC-INPATIENTS.
000910 01-17
THE PREVALENCE OF PRESUMED TARDIVE-DYSKINESIA IN PSYCHIATRIC-
INPATIENTS AND PSYCHIATRIC-OUTPATIENTS.
002417 02-15
>SYCHIATRIC-INTERVENTION
EFFECT OF PSYCHIATRIC-INTERVENTION ON USE OF ANTIHEMOPHILIC-
FAQOR CONCENTRATE.
000945 01-17
Subject Index
PSYCHIATRIC-MOVEMENTS
PSYCHIATRIC MOVEMENTS AND PSYCHOPHARMACOLOGY: BETWEEN
AFFECT AND REPRESENTATION.
003604 03-17
PSYCHIATRIC-OUTPATIENTS
DOUBLE-BLIND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH
AFTERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS
WITH SCHIZOPHRENIA.
000574 01-08
PROGNOSTIC FACTORS DETERMINING RESPONSE TO ANTIDEPRESSANT-
DRUGS IN PSYCHIATRIC-OUTPATIENTS AND GENERAL-PRACTICE.
000638 01-09
HOSTILITY CONFLICT AND REPORTING OF SIDE-EFFECTS BY PSYCHIATRIC-
OUTPATIENTS.
000840 01-15
THE PREVALENCE OF PRESUMED TARDIVE-DYSKINESIA IN PSYCHIATRIC-
INPATIENTS AND PSYCHIATRIC-OUTPATIENTS.
002417 02-15
PSYCHIATRIC-PATIENTS
ANXIETY AND THYROID-AQIVITY IN PSYCHIATRIC-PATIENTS.
000786 01-13
TREATMENT OF DRUG-INDUCED DRYNESS OF MOUTH IN PSYCHIATRIC-
PATIENTS - A CONTROLLED-COMPARATIVE-STUDY.
000799 01-13
MEDICATION USE AND DEATHS ATTRIBUTED TO ASPHYXIA AMONG
PSYCHIATRIC-PATIENTS.
000838 01-15
ROniNG WITH THEIR RIGHTS ON: CONSTITUTIONAL THEORY AND
CLINICAL REALITY IN DRUG-REFUSAL BY PSYCHIATRIC-PATIENTS.
000911 01-17
ON A POSSIBLE ROLE OF ENDORPHINS IN PSYCHIATRIC-DISORDERS -
ACTIONS OF NALOXONE IN PSYCHIATRIC-PATIENTS.
001917 02-08
DRUG-INDUCED ARTERIAL HYPOTENSION IN PSYCHIATRIC-PATIENTS
TREATED WITH OIHYDROERGOTAMINE.
001950 02-08
PRELIMINARY-STUDIES ON CSF GAMMA AMINOBUTYRIC-ACtD LEVELS IN
PSYCHIATRIC-PATIENTS BEFORE AND DURING TREATMENT WITH
DIFFERENT PSYCHOTROPIC-DRUGS.
001959 02-08
THE TSH RESPONSE TO TRH INJEQION IN PSYCHIATRIC-PATIENTS: A
REVIEW.
002145 02-11
PIRIBEDIL IN ELDERLY PSYCHIATRIC-PATIENTS.
002170 02-11
STUDY OF PROLACTIN VARIATIONS IN PSYCHIATRIC-PATIENTS TREATED
WITH FLUPHENAZINE-DECANOATE.
002226 02-13
HALOPERIDOL PLASMA LEVEL MONITORING IN PSYCHIATRIC-PATIENTS.
002267 02-13
PNEUMONIA AND PSYCHOTROPIC-DRUG USE IN ELDERLY PSYCHIATRIC-
PATIENTS.
002391 02-15
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS
AFTER HOSPITAL DISCHARGE IN THE DISTROS TEPLICE AND UHERSKE-
HRADISTE.
002518 02-17
TOLERANCE IN A COMPRESSED GASTRORESISTANT FORM IN
PSYCHIATRIC-PATIENTS.
003157 03-07
TOLERANCE STUDY IN PSYCHIATRIC-PATIENTS OF A NEW PREPARATION
OF SODIUM-DIPROPYLACETATE.
003158 03-07
A DOUBLE-BUND, PLACEBO-CONTROLLED-STUDY OF PIRACETAM IN
ELDERLY PSYCHIATRIC-PATIENTS.
003305 03-11
FLUNITRAZEPAM IN THE TREATMENT OF INSOMNIA: A STUDY OF 50
PSYCHIATRIC-PATIENTS.
003444 03-14
CEREBROSPINAL-FLUID CONCENTRATIONS OF THIORIDAZINE AND ITS
MAIN METABOLITES IN PSYCHIATRIC-PATIENTS.
003569 03-16
MEDICATION GROUPS FOR PSYCHIATRIC-PATIENTS.
003582 03-17
THE USE OF PHARMACOKINETICS IN THE FOLLOWUP OF PSYCHIATRIC-
PATIENTS.
003616 03-17
PSYCHIATRIC-PERSPECTIVE
CHRONIC PHENCYCLIDINE (PCP) ABUSE: A PSYCHIATRIC-PERSPEQIVE.
000935 01-17
PSYCHIATRIC-PRACTICE
USE OF THE NEW TRANQUILIZER PHENAZEPAM IN PSYCHIATRIC-
PRACTICE.
000578 01-09
HOW APPROPRIATE IS A MEDICAL-MODEL IN PSYCHIATRIC-PRACTICE?
002531 02-17
ROUNDTABLE DISCUSSION: ALIVALS PLACE IN PSYCHIATRIC-PRACTICE.
002585 02-17
S-365
Subject Index
Ptychopharmacology Abstracts
if;
it:
fe
A NEW DOPAMINERGIC-AGENT IN CURRENT PSYCHIATRIC-PRAQICE.
003156 03-07
PSYCHIATRIC-RESEARCH
PHYSICO-CHEMICAL METHODOLOGIES IN PSYCHIATRIC-RESEARCH.
004679 04-16
PSYCHIATRIC-SAMPLE
USE OF THE LITHIUM RESPONSE SCALE WITH AN OUTPATIENT
PSYCHIATRIC-SAMPLE.
000921 01-17
PSYCHIATRIC-STUDY
COOPERATIVE PSYCHIATRIC-STUDY OF ALIVAL: PRELIMINARY RESULTS.
002045 02-09
PSYCHIATRIC-SYNDROMES
PSYCHIATRIC-SYNDROMES AND DRUG-TREATMENT.
003608 03-17
PSYCHIATRIC-TREATMENT
CLINICAL-EXPERIENCE WITH PSYCHIATRIC-TREATMENT OF THE ELDERLY
INVOLVING THE USE OF PIRACETAM.
002188 02-11
CHANGES IN THE CLINICAL-PIQURE AND THE COURSE OF PSYCHOSES
DURING MASSIVE PSYCHOPHARMACOTHERAPY AND THE
SIGNIFICANCE OF THESE CHANGES FOR IMPROVEMENTS IN
PSYCHIATRIC-TREATMENT.
004699 04-17
PSYCHIATRIC-WARDS
TARDIVE-DYSKINESIA ON HUNGARIAN PSYCHIATRIC-WARDS.
002447 02-15
PSYCHIATRIST
INITIAL PRESCRIPTION OF PSYCHOTROPIC-MEDICATIONS FOR
ADOLESCENTS IN A MEDICAL/PROFESSIONAL INSTITUTE, AND THE
ROLE OF THE PSYCHIATRIST IN A MEDICAL/PROFESSIONAL INSTITUTE.
002621 02-17
NEUROLEPTIC TREATMENT AS EXPERIENCED BY A PSYCHIATRIST.
004613 04-15
PSYCHIATRISTS
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT, TARDIVE-
DYSKINESIA, AND THE TRAINING OF RESEARCH PSYCHIATRISTS.
004603 04-15
PSYCHIATRY
CONTRIBUTION TO THE CLINICAL- STUDY OF CEREBRAL DOPAMINERGIC
MECHANISMS: THE AQION OF PIRIBEDIL IN PSYCHIATRY. FIRST
RESULTS.
000616 01-09
THE HISTORY OF RECENT DEVELOPMENTS IN PSYCHIATRY.
000939 01-17
THE PRESENT STATUS OF THE BENZODIAZEPINES IN PSYCHIATRY AND
MEDICINE.
000954 01-17
MAJOR-TRANQUILLIZERS IN PSYCHIATRY.
000987 01-17
CLINICAL-EXPERIENCE WITH LITHIUM-CARBONICUM-RETARD IN
PSYCHIATRY.
002000 02-09
BETA-BLOCKERS IN PSYCHIATRY.
002109 02-11
BEHAVIORAL-DISTURBANCES IN PSYCHIATRY: A THERAPEUTIC
APPROACH.
002321 02-14
METHODS OF MULTICENTER-TRIALS IN PSYCHIATRY - PART I: REVIEW.
002483 02-16
AQION MECHANISMS OF INSULIN THERAPY IN PSYCHIATRY, AND
CURRENT-VIEWS ON THESE MECHANISMS.
002553 02-17
COMPUTERIZED SLEEP EEG (CSEEG) IN PSYCHIATRY AND
PSYCHOPHARMACOLOGY.
002614 02-17
CHANGES IN AND CURRENT PROGRESS OF NEUROLOGY AND
PSYCHIATRY.
003550 03-15
THE NECESSITY OF PSYCHOPHARMACOLOGY IN THE DEVELOPMENT OF
PSYCHIATRY.
003575 03-17
THE USE OF ANTIDEPRESSANTS IN PSYCHIATRY.
003597 03-17
CLINICAL APPLICATION OF ANTIANDROGENS IN PSYCHIATRY.
004457 04-1 1
CURRENT TRENDS IN TREATMENT IN PSYCHIATRY.
004747 04-17
PSYCHIC-EFFECTS
PHARMACOTHERAPY FOR SEXUAL-OFFENDERS: REVIEW OF THE AQION
OF ANTIANDROGENS WITH SPECIAL REFERENCE TO THEIR PSYCHIC-
EFFECTS.
004455 04-11
PSYCHIC-MANIFESTATIONS
CEREBRAL SENESCENCE AND ITS PSYCHIC-MANIFESTATIONS. THE
EFFEQIVENESS OF DEBRUMYL.
002105 02-11
PSYCHOACTIVE
ISOLATION OF PSYCHOAQIVE CANNABINOID PRECURSORS FROM
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI.
001023 02-01
INFLUENCE OF PSYCHOAQIVE AND NONPSYCHOAQIVE CANNABINOIDS
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN
HUMAN CELLS.
002830 03-03
INFLUENCE OF PSYCHOAQIVE AND NONPSYCHOAQIVE CANNABINOIDS
ON CHROMATIN STRUQURE AND FUNQION IN HUMAN CELLS.
002831 03-03
CATECHOLAMINE METABOLISM IN A PSYCHOAQIVE CACTUS.
004722 04-17
PSYCHOACTIVE-DRUG
PSYCHOACTIVE-DRUG QUANTIFICATION BY VISUAL FLICKER SENSITIVITY
MEASUREMENT. (PH.D. DISSERTATION).
002485 02-16
EFFECT OF A PSYCHOACTIVE-DRUG, TRAZODONE, ON PROLACTIN
SECRETION IN MAN.
003425 03-13
PSYCHOACTIVE-ORUG-EFFECTS
PSYCHOACTIVE-DRUG-EFFECTS IN A HYPERACTIVE-CHILD: A CASE-STUDY
ANALYSIS OF BEHAVIOR-CHANGE AND TEACHER ATTENTION.
002313 02-14
PSYCHOACTIVE-DRU6S
EFFICACY AND PAHERN VALENCE OF PSYCHOACTIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER.
000699 01-11
PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS - PART I:
PROTOCOL FOR THE TREATMENT OF PSYCHOSIS WITH
ANTIPSYCHOTICS.
000949 01-17
AN OBJECTIVE CLASSIFICATION OF PSYCHOACTIVE-DRUGS.
001894 02-07
CONSIDERATIONS ON PSYCHOACTIVE-DRUGS.
002622 02-17
PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS - PART II:
PROTOCOL FOR THE TREATMENT OF DEPRESSION WITH TRICYCLIC-
ANTIDEPRESSANTS.
003214 03-09
ACUTE AND CHRONIC EFFECTS OF PSYCHOACTIVE-DRUGS ON
ADRENERGIC-RECEPTORS AND CALMODULIN.
004750 04-17
PSYCHOACTIVE-MEDICATtON
HYPNOTIZABILITY AND PSYCHOACTIVE-MEDICATION.
000823 01-14
PSYCHOACTIVE-MEDICATION USE AND ABUSE AMONG AN ADULT RURAL
POPULATION. (PH.D. DISSERTATION).
003627 03-17
PSYCHOACTIVE-SUBSTANCES
ELECTIVE ALTERATION OF THE STATE OF CONSCIOUSNESS SUBJECTED TO
THE EFFECTS OF PSYCHOACTIVE-SUBSTANCES.
000994 01-17
PSYCHOANALYSIS
PROBLEMS INVOLVED IN THE COMBINATION OF PHARMACEUTIC-AGENTS
WITH PSYCHOTHERAPY OR PSYCHOANALYSIS.
000971 01-17
THE INTERACTION OF PSYCHOPHARMACOLOGY AND PSYCHOANALYSIS IN
THE BORDERLINE-PATIENT.
004430 04-10
PSYCHOBIOLOGICAL-RESEARCH
PSYCHOBIOLOGICAL-RESEARCH IN MANIC-DEPRESSIVE-ILLNESS.
(UNPUBLISHED PAPER).
001973 02-09
PSYCHOBIOLOGY
THE PSYCHOBIOLOGY OF AGING.
003861 04-03
PSYCHODRU6
FDA CLIPS PSYCHODRUG PIONEERS IND WINGS.
003160 03-07
PSYCHODYNAMIC-APPROACH
THE PSYCHODYNAMIC-APPROACH TO DRUG-THERAPY.
000969 01-17
PSYCHOEXPERIMENTAL-STUDIES
EEG AND PSYCHOEXPERIMENTAL-STUDIES IN HEALTHY SUBJECTS ON
LITHIUM MEDICATION.
000768 01-13
PSYCHOGENETICALLY
EFFECTS OF SCOPOLAMINE, PILOCARPINE, AND OXOTREMORINE ON THE
EXPLORATORY-BEHAVIOR OF TWO PSYCHOGENETICALLY SELECTED
LINES OF RATS IN A COMPLEX MAZE.
003042 03-04
PSYCHOGERIATRIC-INPATIENTS
EFFICACY AND SIDE-EFFECTS OF LORAZEPAM, OXAZEPAM, AND
TEMAZEPAM AS SLEEPING-AIDS IN PSYCHOGERIATRIC-INPATIENTS.
002076 02-10
PSYCHOGERIATRIC-PATIENTS
EFFICACY AND SIDE-EFFECTS OF CHLORAL-HYDRATE AND TRYPTOPHAN
AS SLEEPING-AIDS IN PSYCHOGERIATRIC-PATIENTS.
002077 02-10
S-366
VOLUME 19, SUBJECT INDEX
Subject Index
PSYCHOOERIATItlC-WARD
THERAPEUTIC RESULTS IN A PSYCHOGERIATRIC-WARD AFTER CHANGE OF
MEDICATION.
002136 02-n
PSYCHOLEPTIC-DRUOS
ANTAGONISTIC-EFFECTS OF PSYCHOLEPTIC-DRUGS ON STRESS-INDUCED
ANALGESIA.
001609 02-04
PSYCHOLEPTIC-EFFECTS
DOUBLE-BLIND CONTROLLED-STUDY ON THE PSYCHOLEPTIC-EFFECTS OF
AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT
PERSONALITY-PROBLEMS.
002116 02-11
PSYCHOLOGIC-TREATMENT
SENILE-DEMENTIA; COMBINED PHARMACOLOGIC-TREATMENT AND
PSYCHOLOGIC-TREATMENT.
003393 03-1 1
PSYCHOLOGICAL
AHEMPT AT PSYCHOLOGICAL UNDERSTANDING AND TREATMENT OF
PSYCHOLOGICAL ASTHENIA AND ASTHENO-DEPRESSIVE-SYNDROMES
USING ERGADYL.
001974 02-09
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF
ENURESIS: A COMPARATIVE-STUDY.
002175 02-11
PROGNOSIS IN SCHIZOPHRENIA; INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME.
003189 03-08
SOME OBSERVATIONS ON THE PSYCHOLOGICAL DIMENSIONS OF
PLACEBO-EFFECTS.
003573 03-17
ELECTROPHYSIOLOGICAL AND PSYCHOLOGICAL CHANGES INDUCED BY
STEROID-HORMONES IN MEN AND WOMEN.
004500 04-13
EMOTIONAL-DISORDERS IN CHILDREN AND ADOLESCENTS: MEDICAL AND
PSYCHOLOGICAL APPROACHES TO TREATMENT.
004743 04-17
PSYCHOLOGICAL-STRESS
EEG CHANGE IN THE CONSCIOUS RAT DURING IMMOBILITY INDUCED BY
PSYCHOLOGICAL-STRESS.
001297 02-03
PSYCHOLOGICAL-TREATMENT
PHOBIA; PSYCHOLOGICAL-TREATMENT AND PHARMACOLOGICAL-
TREATMENT.
004425 04-10
PSYCHOLOGICAL-VIEW
A PSYCHOLOGICAL-VIEW ON PROBLEMS AND CONCEPTS OF LITHIUM
RESEARCH.
000810 01-14
PSYCHOMETRIC-ANALYSES
DETERMINATION OF THE ENCEPHALOTROPIC, PSYCHOTROPIC AND
PHARMACODYNAMIC PROPERTIES OF NICERGOLINE BY MEANS OF
QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY AND
PSYCHOMETRIC-ANALYSES.
000788 01-13
PSYCHOMETRIC-ANALYSIS
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF
LOPIRAZEPAM (D- 12524) BY QUANTITATIVE EEG AND
PSYCHOMETRIC-ANALYSIS.
000720 01-11
DETERMINATION OF PHARMACODYNAMICS OF PSYCHOTROPIC-DRUGS BY
PSYCHOMETRIC-ANALYSIS.
001895 02-07
PSYCHOMETRIC-FINDINGS
EVALUATION OF LITHIUM RESPONSE: PSYCHOMETRIC-FINDINGS.
004348 04-09
PSYCHOMETRIC-TEST
A NOVEL PSYCHOMETRIC-TEST MODEL APPLYING TAILORED TESTING FOR
ECONOMIC AND EFFICIENT COLLECTION OF
PSYCHOPHARMACOLOGICAL-EFFECTS.
002479 02-16
PSYCHOMETRIC-TESTS
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY:
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS.
000543 01-07
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC
DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL
CONTROLS.
002004 02-09
PSYCHOMODERATORS
COMPARATIVE-STUDY OF THE INDUCTIVE EFFEQ OF TWO
PSYCHOMODERATORS - TETRABAMATE AND COMPLEXE- 1 656 - AND
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS.
001874 02-06
PSYCHOMOTOR
IN VITRO EFFECT OF PHENCYCLIDINE AND OTHER PSYCHOMOTOR
STIMULANTS ON SEROTONIN UPTAKE IN HUMAN PLATELETS.
000750 01-13
INFLUENCE OF INTRAVENOUS SELF-ADMINISTERED PSYCHOMOTOR
STIMULANTS ON PERFORMANCE OF RHESUS-MONKEYS IN A MULTIPLE-
SCHEDULE PARADIGM.
001655 02-04
THE EFFECTS OF TRIAZOLAM AND NITRAZEPAM ON SLEEP QUALITY,
MORNING VIGILANCE, AND PSYCHOMOTOR PERFORMANCE.
002330 02-14
PERSONALITY TRAIT AND ANTIANXIETY-DRUG EFFECTS ON
PSYCHOMOTOR PERFORMANCE.
002336 02-14
PSYCHOMOTOR STIMULANTS AS ACTIVATORS OF NORMAL AND
PATHOLOGICAL-BEHAVIOR: IMPLICATIONS FOR THE EXCESSES IN
MANIA. (UNPUBLISHED PAPER).
002353 02-14
FUNDAMENTAL MECHANISMS UNDERLYING ALTERED BEHAVIOR
FOLLOWING CHRONIC ADMINISTRATION OF PSYCHOMOTOR
STIMULANTS.
002711 03-03
SEXUAL-EFFECTS OF ANTIDEPRESSANTS AND PSYCHOMOTOR STIMULANT-
DRUGS.
004646 04-15
PSYCHONEUROENDOCRINE
A MODEL FOR PSYCHONEUROENDOCRINE INVESTIGATION; SPECIFIC
CHEMICAL LESIONING OF THE MEDIAN-EMINENCE.
001478 02-03
PSYCHONEUROENDOCRINOLOGY
PSYCHONEUROENDOCRINOLOGY AND ABNORMAL-BEHAVIOR.
002347 02-14
PHARMACOLOGICAL-BASES OF PSYCHONEUROENDOCRINOLOGY:
PRECLINICAL ASSESSMENT OF CLINICAL FACTS.
003735 04-03
PSYCHONEUROPHARMACOLOGIC-RESEARCH
NEUROENDOCRINE APPROACHES TO PSYCHONEUROPHARMACOLOGIC-
RESEARCH.
003426 03-13
PSYCHOPATHOLOGIC
CHANGES IN PSYCHOPATHOLOGIC SYMPTOMS DURING 20 DAYS OF
TREATMENT WITH ANTIDEPRESSANTS AND NEUROLEPTtC-DRUGS.
004415 04-09
PSYCHOPATHOLOGICAL-CONDITIONS
CLINICAL NEUROPHYSIOLOGICAL ASPECTS OF PSYCHOPATHOLOGICAL-
CONDITIONS.
002274 02-13
PSYCHOPATHOLOGICAL-FINDINGS
CORRELATIONS BETWEEN VISUAL-EVOKED-POTENTIALS AND
PSYCHOPATHOLOGICAL-FINDINGS IN SCHIZOPHRENIC-PATIENTS UNDER
TREATMENT WITH VARIOUS PSYCHOPHARMACOLOGICAL-DRUGS.
004315 04-08
PSYCHOPATHOLOGY
DEPRESSION IN THE ELDERLY; RESEARCH DIRECTIONS IN
PSYCHOPATHOLOGY, EPIDEMIOLOGY, AND TREATMENT.
000998 01-17
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS; RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
MINAPRINE IN SEVERE PSYCHOPATHOLOGY: STUDY OF 20 CASES.
002135 02-11
CHILDHOOD-ENURESIS: II. PSYCHOPATHOLOGY, TRICYCLIC
CONCENTRATION IN PLASMA, AND ANTIENURETIC-EFFEQ.
002354 02-14
CHANGES IN THE PSYCHOPATHOLOGY OF PSYCHOSIS DUE TO
NEUROLEPTIC TREATMENT.
003281 03-10
ALCOHOL WITHDRAWAL USING TIAPRIDE: QUANTITATIVE
PSYCHOPATHOLOGY.
ENDORPHINS IN PSYCHOPATHOLOGY.
PSYCHOPATHOLOGY AND ENDORPHINS.
PSYCHOTROPIC-DRUGS AND THEIR RELATIONSHIP WITH
PSYCHOPATHOLOGY OF AFFECTIVE-DISORDERS.
003293 03-11
004313 04-08
004317 04-08
004361 04-09
PSYCHOPATHOMETRIC
PSYCHOPATHOMETRIC DOUBLE-BLIND COURSE STUDY WITH NICERGOLINE
VERSUS PLACEBO IN GERIATRIC-PATIENTS WITH TRANSIENT-
SYNDROMES.
000665 01-11
PSYCHOPHARMACEUTICAL
A DOUBLE-BLIND CROSSED CLINICAL-STUDY WITH A NEW
PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008), DIAZEPAM, AND
A PLACEBO.
003153 03-07
PSYCHOPHARMACEUTICAL-THERAPY
PSYCHOPHARMACEUTICAL-THERAPY TO CALM DRIVE, AQIVITY, AND
RESTLESSNESS IN CHILDHOOD.
002604 02-17
S-367
Subject Index
Psychopharmacology Abstracts
m
la..,
C.1
^
PSYCHOPHARMACEUTICALS
ON THE DANGER OF USING PSYCHOPHARMACEUTICALS DURING
PREGNANCY: CRITICAL REVIEW OF THE LITERATURE.
000833 01-15
ON THE GENETIC SIDE-EFFECTS OF PSYCHOTROPIC-SUBSTANCES: I.
PSYCHOPHARMACEUTICALS, NARCOTICS, AND ANTICONVULSANT,
000845 01-15
PSYCHOPHARMACEUTICALS AND PREGNANCY: A REVIEW.
002462 02-15
PSYCHOPHARMACEUTICALS - A PROBLEM FOR PSYCHOTHERAPISTS?
002535 02-17
PSYCHOPHARMACEUTICALS FOR TREATING PAIN.
002548 02-17
EFFEQS OF PSYCHOPHARMACEUTICALS ON DRIVING CAPACITY.
003453 03-14
PSYCHOPHARMACEUTICALS IN PEDIATRIC-PRACTICE.
003491 03-15
PSYCHOPHARMACOLOGIC-A6ENTS
EARLY-ACTIVITY-STUDIES AND INTENSIVE DRUG EVALUATIONS OF NEW
PSYCHOPHARMACOLOGIC-AGENTS .
002348 02-14
PSYCHOPHARMACOLOGICAL
PSYCHOPHARMACOLOGICAL AND PSYCHOTHERAPEUTIC-APPROACHES TO
THE TREATMENT OF FUNCTIONAL PSYCHOSES.
000977 01-17
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT:
LATER PSYCHOPHARMACOLOGICAL RESPONSES TO APOMORPHINE
AND ARECOLINE.
001470 02-03
THE INFLUENCE OF DAILY BIOLOGICAL-RHYTHMICITY ON THE HOMING-
BEHAVIOR, PSYCHOPHARMACOLOGICAL RESPONSIVENESS, LEARNING
AND RETENTION OF SUCKLING RATS. (PH.D. DISSERTATION).
001660 02-04
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES. (UNPUBLISHED PAPER).
001910 02-08
A PSYCHOPHARMACOLOGICAL APPROACH TO MEMORY PROCESSING.
002901 03-03
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES.
003167 03-08
PRACTICAL IMPLICATIONS OF MODERN PSYCHOPHARMACOLOGICAL
DATA.
003596 03-17
PSYCHOPHARMACOLOGICAL AND SOCIAL ASPECTS OF SCHIZOPHRENIA:
RECENT DEVELOPMENTS.
004336 04-08
PSYCHOPHARMACOLOGICAl-AGENTS
CONTRIBUTORS TO FEMALE USE OF PSYCHOPHARMACOLOGICAL-AGENTS:
DISSERTATION)
000956 01-17
PSYCHOPHARMACOIOGICAL-CORRELATION
CLINICAL-CORRELATION, BIOCHEMICAL-CORRELATION, AND
PSYCHOPHARMACOLOGICAL-CORRELATION IN PATIENTS WITH
DEPRESSIVE-SYMPTOMATOLOGY.
002018 02-09
PSYCHOPHARMACOLOGICAL-DRUGS
CORRELATIONS BETWEEN VISUAL-EVOKED-POTENTIALS AND
PSYCHOPATHOLOGICAL-FINDINGS IN SCHIZOPHRENIC-PATIENTS UNDER
TREATMENT WITH VARIOUS PSYCHOPHARMACOLOGICAL-DRUGS.
004315 04-08
PSYCHOPHARMACOLOGICAL-EFFECTS
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT:
BEHAVIORAL-EFFECTS AND PSYCHOPHARMACOLOGICAL-EFFEQS.
000481 01-04
PSYCHOPHARMACOLOGICAL-EFFEaS OF LOW-DOSES AND HIGH-DOSES
OF APOMORPHINE DURING ONTOGENY.
001774 02-04
A NOVEL PSYCHOMETRIC-TEST MODEL APPLYING TAILORED TESTING FOR
ECONOMIC AND EFFICIENT COLLECTION OF
PSYCHOPHARMACOLOGICAL-EFFECTS .
00:479 02-16
THE SMOKING HABIT AND PSYCHOPHARMACOLOGICAL-EFFECTS OF
NICOTINE.
003577 03-17
PSYCHOPHARMACOLOGICAL-INVESTIGATIONS
THE LEEDS-SLEEP-EVALUATION-QUESTIONNAIRE IN
PSYCHOPHARMACOLOGICAL-INVESTIGATIONS - A REVIEW.
002351 02-14
PSYCHOPHARMACOLOGICAL-MEETING
21. ANNUAL CZECHOSLOVAK PSYCHOPHARMACOLOGICAL-MEETING.
000917 01-17
PSYCHOPHARMACOLOGICAL-PROCEDURES
THE USE OF PSYCHOPHARMACOLOGICAL-PROCEDURES TO ANALYSE THE
ONTOGENY OF LEARNING AND RETENTION: ISSUES AND CONCERNS.
000482 01-04
PSYCHOPHARAAACOLOGICAL-RESEARCH
A SIMPLE SYSTEM FOR CONTROL OF THE CONTINUOUS PERFORMANCE
TEST IN PSYCHOPHARMACOLOGICAL-RESEARCH.
002474 02-16
THE CLINICIANS ROLE IN PSYCHOPHARMACOLOGICAL-RESEARCH,
002563 02-17
PSYCHOPHARMACOLOGICAL-STUDIES
SHOCK-INDUCED-FIGHTING (SIF): PSYCHOPHARMACOLOGICAL-STUDIES.
003091 03-04
PSYCHOPHARMACOLOGICAL-TREATMENT
PCP ABUSE: DIAGNOSTIC AND PSYCHOPHARMACOLOGICAL-TREATMENT
APPROACHES.
000746 01-12
PSYCHOPHARMACOLOGY
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS FROM VIEWPOINT OF
TRANSCULTURAL PSYCHOPHARMACOLOGY: THERAPEUTIC PLASMA
LEVEL.
000636 01-09
PSYCHOPHARMACOLOGY OF AGGRESSION.
000721 01-11
PSYCHOPHARMACOLOGY FOR ASIAN-AMERICANS AND PACIFIC-
ISLANDERS.
000734 01-11
000771 01-13
00091501-17
000929 01-17
000932 01-17
PSYCHOPHARMACOLOGY OF HALOPERIDOL.
DRUG-INTERACTIONS IN PSYCHOPHARMACOLOGY.
TEXTBOOK OF CLINICAL PSYCHOPHARMACOLOGY.
CURRENT DEVELOPMENTS IN PSYCHOPHARMACOLOGY.
PSYCHOPHARMACOLOGY IN PSYCHIATRIC-EMERGENCIES.
000933 01-17
THE PRESENT STATUS OF BENZODIAZEPINES IN PSYCHOPHARMACOLOGY.
000948 01-17
PSYCHOPHARMACOLOGY OF AGGRESSION.
000995 01-17
AMOXAPINE IN EXPERIMENTAL PSYCHOPHARMACOLOGY: A
NEUROLEPTIC OR AN ANTIDEPRESSANT?
001070 02-02
PSYCHOPHARMACOLOGY OF ANALGESIA AND PAIN. (UNPUBLISHED
PAPER).
001411 02-03
PSYCHOPHARMACOLOGY OF THE AGING.
002142 02-11
PSYCHOPHARMACOLOGY IN CHILDHOOD: CURRENT STATUS AND FUTURE
PROSPECTIVES.
002192 02-11
HLA-SYSTEM AND PSYCHOPHARMACOLOGY.
002293 02-13
COORDINATING CLINICAL-TRIALS IN PSYCHOPHARMACOLOGY:
PLANNING, DOCUMENTATION, AND ANALYSIS.
002574 02-17
GERIATRIC PSYCHOPHARMACOLOGY.
002582 02-17
PSYCHOPHARMACOLOGY ~ AN AREA OF RESEARCH TO IMPROVE
MENTAL-HEALTH CARE.
002586 02-17
002597 02-17
002607 02-17
002612 02-17
002614 02-17
NURSING ASPEQS OF PSYCHOPHARMACOLOGY.
002618 02-17
LIMITS, VALUE AND PERSPEQIVES OF THE PSYCHIATRIC-DIAGNOSIS IN
CLINICAL PSYCHOPHARMACOLOGY
002631 02-17
PSYCHOPHARMACOLOGY OF NEUROSES.
003274 03-10
INTERFACES OF PSYCHOPHARMACOLOGY AND CARDIOLOGY - PART
TWO.
003529 03-15
INTERFACES OF PSYCHOPHARMACOLOGY AND CARDIOLOGY - PART
ONE.
003530 03-15
THE NECESSITY OF PSYCHOPHARMACOLOGY IN THE DEVELOPMENT OF
PSYCHIATRY.
003575 03-17
PSYCHOPHARMACOLOGY UPDATE.
003583 03-17
PSYCHOPHARMACOLOGY AND BEHAVIORAL-THERAPY.
003584 03-17
MODERN ASPEQS OF PSYCHOPHARMACOLOGY.
003588 03-17
THE TEACHING OF PSYCHOPHARMACOLOGY.
PSYCHOPHARMACOLOGY OF ANOREQIC-DRUGS IN MAN.
SOCIAL-PSYCHIATRY AND PSYCHOPHARMACOLOGY.
COMPUTERIZED SLEEP EEG (CSEEG) IN PSYCHIATRY AND
PSYCHOPHARMACOLOGY.
S-368
y^OLUME 19, SUBJECT INDEX
Subject Index
PSYCHIATRIC-MOVEMENTS AND PSYCHOPHARMACOLOGY: BETWEEN
AFFECT AND REPRESENTATION.
003604 03-17
MIND/BRAIN IN THE AGE OF PSYCHOPHARMACOLOGY: A CROSSROADS
FOR MEDICINE AND MINISTRY.
003624 03-17
THE VALIDITY OF MODELS IN PSYCHOPHARMACOLOGY
003633 03-17
PSYCHOPHARMACOLOGY AFTER 20 YEARS OF CONFERENCES IN JESENIK.
003646 03-17
PROGRESS IN PSYCHOPHARMACOLOGY.
004398 04-09
THE INTERACTION OF PSYCHOPHARMACOLOGY AND PSYCHOANALYSIS IN
THE BORDERLINE-PATIENT.
004430 04-10
CHILD PSYCHOPHARMACOLOGY.
004470 04-11
ELECTR0RETIN06RAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN
PSYCHOPHARMACOLOGY. ELECTRORETINOGRAPHIC-CHANGES INDUCED
BY A COMBINATION OF CARBIDOPA AND LEVODOPA.
004507 04-13
DEVELOPMENT OF PSYCHOPHARMACOLOGY.
004667 04-15
ON THE USE OF REPEATED MEASURES DESIGNS IN
PSYCHOPHARMACOLOGY.
PSYCHOPHARMACOLOGY FOR THE AGED.
PSYCHOPHARMACOLOGY OF AGING.
004695 04-16
004701 04-17
004710 04-17
PSYCHOPHARMACOLOGY AND PSYCHOTHERAPY IN THE TREATMENT OF
ANXIETY.
004712 04-17
•SYCHOPHARMACOTHERAPY
DYNAMICS AND PROSPECTS OF THE PSYCHOTHERAPY AND
PSYCHOPHARMACOTHERAPY RELATIONSHIP.
002594 02-17
CHILD-PSYCHIATRY AND PSYCHOPHARMACOTHERAPY IN GENERAL
PRACTICE, IN PEDIATRICS, AND IN NEUROLOGY.
003288 03-11
THE ROLE OF PSYCHOPHARMACOTHERAPY IN THE TREATMENT OF
ELDERLY-PATIENTS WITH ORGANIC-MENTAL-SYNDROMES.
003368 03-11
CLINICAL AND BIOCHEMICAL-CORRELATIONS IN ABRUPT
DISCONTINUATION OF PSYCHOPHARMACOTHERAPY.
004330 04-08
THE PROBLEM OF PSYCHOPHARMACOTHERAPY OF SLOWLY PROGRESSIVE
HYPOCHONDRIACAL SCHIZOPHRENIA.
004340 04-08
THE NOSOLOGICAL INDEPENDENCE OF INVOLUTIONAL DEPRESSION AND
ITS DYNAMICS DURING PSYCHOPHARMACOTHERAPY.
004389 04-09
PSYCHOPHARMACOTHERAPY OF SEXUAL-DISORDERS IN THE AGED.
004466 04-11
CHANGES IN THE CLINICAL-PICTURE AND THE COURSE OF PSYCHOSES
DURING MASSIVE PSYCHOPHARMACOTHERAPY AND THE
SIGNIFICANCE OF THESE CHANGES FOR IMPROVEMENTS IN
PSYCHIATRIC-TREATMENT.
004699 04-17
PSYCHOPHARMACOTHERAPY: THE PRESENT STATE AND THE
DEVELOPMENT OF TRENDS.
004723 04-17
>SYCHOPHARMALOGIC-FACTORS
INTERAQION OF PSYCHOPHARMALOGIC-FACTORS AND PSYCHOSOCIAL-
FAQORS IN THE TREATMENT OF ANIMAL-MODELS OF
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR.
001602 02-04
>SYCHOPHYSICAL
CLONIDINE AND PSYCHOPHYSICAL PAIN.
002366 02-14
PSYCHOPHYSIOLOGIC-STUDIES
METABOLIC-STUDIES AND PSYCHOPHYSIOLOGIC- STUDIES OF
CANNABIDIOL HEXOBARBITAL INTERACTION.
002209 02-13
PSYCHOPHYSIOLOGICAL
EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS.
001570 02-04
VARIATIONS IN PSYCHOPHYSIOLOGICAL ACTIVATION RESPONSES IN
DEPRESSIVE-STATES.
001965 02-09
INVESTIGATION INTO THE EFFECT OF FLUPHENAZINE-HCL (LYORODIN) IN
CHILDREN WITH BEHAVIORAL-DISORDERS BY MEANS OF
PSYCHOPHYSIOLOGICAL PARAMETERS.
003344 03-11
l*SYCHOPHYSIOLOGICAL-EFFECTS
THE REPLICABILITY OF THE PSYCHOPHYSIOLOGICAL-EFFECTS OF
DIAZEPAM.
003413 03-13
PSYCHOPHYSiOlOOICAL-TESTS
A COMPARATIVE EVALUATION OF THE USEFULNESS OF
PSYCHOPHYSIOLOGICAL-TESTS DURING VARIOUS LEVELS OF
ACTIVATION OF THE CENTRAL-NERVOUS-SYSTEM.
004543 04-13
PSYCHOPHYSIOLOGICAL-VARIABLES
THE RELATIONSHIPS BETWEEN CLINICAL-RESPONSE,
PSYCHOPHYSIOLOGICAL-VARIABLES AND PLASMA LEVELS OF
AMITRIPTYLINE AND DIAZEPAM IN NEUROTIC-OUTPATIENTS.
004423 04-10
PSYCHOSES
ADVANTAGE OF PHARMACOKINETIC DATA DURING TREATMENT OF
PSYCHOSES WITH HALOPERIDOL.
000577 01-08
PSYCHOPHARMACOLOGICAL AND PSYCHOTHERAPEUTIC-APPROACHES TO
THE TREATMENT OF FUNCTIONAL PSYCHOSES.
000977 01-17
PHENYLALANINE LEVELS IN ENDOGENOUS PSYCHOSES.
002049 02-09
PATHOPHYSIOLOGIC-IMPACT OF CENTRAL CATECHOLAMINERGIC
FUNCTION IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES.
002174 02-11
CYCLIC-AMP IN PSYCHOSES AND THE EFFECT OF DRUGS.
002294 02-13
FAMILY-TREE GIVES CLUES TO TREATING PSYCHOSES.
002363 02-14
ON THE INTENSIVE TREATMENT OF ENDOGENOUS PSYCHOSES.
003384 03-1 1
ACUTE PHARMACOTOXIC PSYCHOSES IN CHRONIC CEREBRAL
CONDITIONS.
003475 03-15
THE EFFECT OF NALOXONE ON THE CONDITION OF PATIENTS WITH
ENDOGENOUS PSYCHOSES.
004381 04-09
CHANGES IN THE CLINICAL-PICTURE AND THE COURSE OF PSYCHOSES
DURING MASSIVE PSYCHOPHARMACOTHERAPY AND THE
SIGNIFICANCE OF THESE CHANGES FOR IMPROVEMENTS IN
PSYCHIATRIC-TREATMENT.
004699 04-17
NOTES ON PHARMACOTHERAPY OF FUNCTIONAL PSYCHOSES.
004748 04-17
PSYCHOSIS
THE PCP PSYCHOSIS: PROLONGED INTOXICATION OR DRUG PRECIPITATED
FUNCTIONAL ILLNESS?
000739 01-12
PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS - PART I:
PROTOCOL FOR THE TREATMENT OF PSYCHOSIS WITH
ANTIPSYCHOTICS.
000949 01-17
A NEW DOSAGE SCHEDULE FOR PIMOZIDE IN THE ACUTE STABILIZATION
AND MAINTENANCE-TREATMENT OF PSYCHOSIS.
002022 02-09
DELIRIUM OR PSYCHOSIS? DIAGNOSTIC USE OF THE SODIUM-
AMOBARBITAL INTERVIEW.
002167 02-11
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL-
NERVOUS-SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE-
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS).
002459 02-15
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE
INTOXICATION.
002988 03-04
CHANGES IN THE PSYCHOPATHOLOGY OF PSYCHOSIS DUE TO
NEUROLEPTIC TREATMENT.
003281 03-10
TOXIC PSYCHOSIS FOLLOWING USE OF QUINACRINE.
003507 03-15
DRUG-INDUCED PSYCHOSIS AND SCHIZOPHRENIA IN ADOLESCENTS.
004596 04-15
PSYCHOSOCIAL-ASPECTS
PSYCHOSOCIAL-ASPECTS OF DRUG-TREATMENT FOR HYPERACTIVITY.
004714 04-17
PSYCHOSOCIAl-FACTORS
INTERACTION OF PSYCHOPHARMALOGIC-FACTORS AND PSYCHOSOCIAL-
FACTORS IN THE TREATMENT OF ANIMAL-MODELS OF
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR.
001602 02-04
PSYCHOSOMATIC-COMPLAINTS
FLUSPIRILENE (IMAP) IN THE TREATMENT OF PSYCHOSOMATIC-
COMPLAINTS IN HYPOCHONDRIACAL-PATIENTS.
002072 02-10
PSYCHOSOMATIC-DISEASES
A CLINICAL-EVALUATION OF THE EFFECTS OF A NEW PSYCHOTROPIC-
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE
DOUBLE-BUND METHOD.
004491 04-11
S-369
Subject Index
Ptychopharmacology Abstracts
a-
ii
•'HI
I
PSYCHOSOMATIC-ILLNESS
SELF-MEDICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS.
002189 02-11
PSYCHOSOMATIC-MEDICINE
THE INTEREST OF THE STIMULATING EFFEQ OF CARPIPRAMINE IN
PSYCHOSOMATIC-MEDICINE.
002061 02-10
PSYCHOSOMATIC-STRESS
PSYCHOSOMATIC-STRESS AND UPOPEROXIDES OF HUMAN PLATELET
RICH PLASMA.
003423 03-13
PSYCHOSOMATICS
COGNITION AND PSYCHOSOMATICS.
002312 02-14
PSYCHOSTIMULANTS
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH
PSYCHOSTIMULANTS: II. EFFECT OF METHAMPHETAMINE ON
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC
SUBSTRATES.
001613 02-04
PSYCHOSTIMULANTS AND NEUROPEPTIDES IN GEROPSYCHIATRY.
002125 02-11
THE EFFEa OF PSYCHOSTIMULANTS ON CHANGES IN THE EXCITABILITY
OF THE VISUAL CEREBRAL-CORTEX.
003919 04-03
PSYCHOTHERAPEUTIC-APPROACHES
PSYCHOPHARMACOLOGICAL AND PSYCHOTHERAPEUTIC-APPROACHES TO
THE TREATMENT OF FUNQIONAL PSYCHOSES.
000977 01-17
PSYCHOTHERAPEUTIC-DRU6
PSYCHOTHERAPEUTIC-DRUG RECOMMENDATIONS BASED ON THE MINI-
MULT.
002606 02-17
PSYCHOTHERAPEUTIC-DRUOS
PSYCHOTHERAPEUTIC-DRUGS: IMPORTANT ADVERSE-REAQIONS AND
INTERAQIONS.
002383 02-15
SOME METHODOLOGICAL WAYS OF MONITORING THE EFFEQS OF
PSYCHOTHERAPEUTIC-DRUGS .
003567 03-16
PSYCHOTHERAPEUTIC-DRUGS, HISTAMINE HI -RECEPTORS AND
MUSCARINIC ACETYLCHOLINE-RECEPTORS.
004737 04-17
PSYCHOTHERAPIES
CLINICAL-TRIAL OF PSYCHOTHERAPIES IS UNDER WAY.
004378 04-09
PSYCHOTHERAPISTS
PSYCHOPHARMACEUTICALS - A PROBLEM FOR PSYCHOTHERAPISTS?
002535 02-17
PSYCHOTHERAPY
PROBLEMS INVOLVED IN THE COMBINATION OF PHARMACEUTIC-AGENTS
WITH PSYCHOTHERAPY OR PSYCHOANALYSIS.
000971 01-17
PSYCHOTHERAPY AND DYSPNOEA.
002164 02-11
CONVERGENCES AND DIVERGENCES BETWEEN BIOLOGICAL-PSYCHIATRY
AND PSYCHOTHERAPY.
002536 02-17
DYNAMICS AND PROSPECTS OF THE PSYCHOTHERAPY AND
PSYCHOPHARMACOTHERAPY RELATIONSHIP.
002594 02-17
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL-STUDIES WITH
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND
DEPOT NEUROLEPTICS.
003183 03-08
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLia? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
003256 03-09
DEPRESSED-OUTPATIENTS: RESULTS ONE YEAR AFTER TREATMENT WITH
DRUGS AND/OR INTERPERSONAL PSYCHOTHERAPY.
003272 03-09
EFFECTS OF ALTHESIN IN PSYCHOTHERAPY OF SCHIZOPHRENICS:
PRELIMINARY REPORT.
004331 04-08
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION
CONFLia? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL.
(UNPUBLISHED PAPER).
004401 04-09
PHARMACOTHERAPY AND PSYCHOTHERAPY FOR AMBULATORY
DEPRESSION: EFFICACY AND CHOICES.
004413 04-09
PERSONALITY AS A PREDIQOR OF PSYCHOTHERAPY AND
PHARMACOTHERAPY-OUTCOME FOR DEPRESSED-OUTPATIENTS.
(UNPUBLISHED PAPER).
004418 04-09
PSYCHOPHARMACOLOGY AND PSYCHOTHERAPY IN THE TREATMENT OF
ANXIETY.
004712 04-17
PSYCHOTIC
PSYCHOTIC EXCITEMENT IN MEDICAL-EMERGENCIES.
004480 04-11
PSYCHOTIC-DISORDERS
CEREBROSPINAL-FLUID GABA IN PSYCHOTIC-DISORDERS.
002097 02-11
CLINICAL PROCESSES AND CENTRAL DOPAMINERGIC-AQIVITY IN
PSYCHOTIC-DISORDERS.
002098 02-1 1
PSYCHOTIC-OUTPATIENTS
NEUROLEPTIC AND THYMOLEPTIC TREATMENT OF PSYCHOTIC-
OUTPATIENTS.
000556 01-08
PSYCHOTIC-PATIENTS
INFLUENCE OF ROUTE-OF-ADMINISTRATION ON HALOPERIDOL PLASMA
LEVELS IN PSYCHOTIC-PATIENTS.
000549 01-08
HOSPITAL AND OUTPATIENT CARE FOR PSYCHOTIC-PATIENTS DURING THE
LAST THREE DECADES: SUBSEQUENT HOSPITAL AND OUTPATIENT
TREATMENT OF PSYCHOTIC-PATIENTS HOSPITALIZED FOR THE FIRST
TIME IN 1949-50, 1959-60 OR 1969-70.
000571 01-08
COMPARATIVE ENZYME-INDUCING EFFEQS OF CHLORPROMAZINE AND
FLUPHENAZINE THERAPIES IN PSYCHOTIC-PATIENTS.
000682 01-11
BIOCHEMICAL-CHARAQERIZATION AND PHARMACOLOGICAL
CHARAQERIZATION OF A PEPTIDE FROM THE HEMODIALYSATE OF
PSYCHOTIC-PATIENTS.
001049 02-01
RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN
PLASMA AND CEREBROSPINAL-FLUID AND CLINICAL-RESPONSE AND
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS.
001905 02-08
THE ASSOCIATION OF RETARD NEUROLEPTICS TO OTHER NEUROLEPTICS
IN THE REHABILITATION OF PSYCHOTIC-PATIENTS.
002108 02-11
AN INVESTIGATION OF SOME SIDE-EFFEaS IN 47 PSYCHOTIC-PATIENTS
DURING TREATMENT WITH CLOZAPINE AND DISCONTINUING OF THE
TREATMENT.
002424 02-15
THE USE OF PHENAZEPAM IN THE TREATMENT OF PSYCHOTIC-PATIENTS.
003351 03-11
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS AQIVE
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC-
PATIENTS TREATED WITH FIXED DRUG DOSES.
004559 04-13
CLINICAL-EVALUATION OF BROMPERIDOL VERSUS HALOPERIDOL IN
PSYCHOTIC-PATIENTS.
004562 04-14
THE EFFEaS OF NEUROLEPTIC-DRUGS ON THE SOCIAL INTERAQIONS OF
HOSPITALIZED PSYCHOTIC-PATIENTS.
004577 04-14
PSYCHOTIC-SYMPTOMS
RAPID TREATMENT OF ACUTE PSYCHOTIC-SYMPTOMS WITH HIGH-DOSE
AND LOW-DOSE HALOPERIDOL: BEHAVIORAL-CONSIDERATIONS.
003346 03-11
PSYCHOTICS
LONG-TERM CONTROLLED-COMPARISON OF INJEQION OXYPROTHEPIN
AND FLUPHENAZINE-DECANOATES IN PSYCHOTICS IN REMISSION
001949 02-08
PSYCHOTOGENIC
LSD, PSYCHOTOGENIC PROCEDURES AND BRAIN NEUROHUMORS.
(UNPUBLISHED PAPER).
004448 04-11
PSYCHOTOMIMETIC
PSYCHOTOMIMETIC USE OF TOBACCO IN SURINAM AND FRENCH-
GUIANA.
002592 02-17
REGULATION OF BIOGENESIS OF PSYCHOTOMIMETIC AMINES.
(UNPUBLISHED PAPER).
003818 04-03
PSYCHOTOMIMETICS
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES
BEHAVIOURAL-EFFEaS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN
RATS.
000420 01-04
PSYCHOTROPIC
DETERMINATION OF THE ENCEPHALOTROPIC, PSYCHOTROPIC AND
PHARMACODYNAMIC PROPERTIES OF NICERGOLINE BY MEANS OF
QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY AND
PSYCHOMETRIC-ANALYSES .
000788 01-13
AN AHEMPT TO TREAT THE SIDE-EFFEaS OF PSYCHOTROPIC THERAPY
WITH BROMOCRIPTINE.
002094 02-1 1
SOME ODD PAHERNS OF PSYCHOTROPIC SELF-MEDICATION.
002565 02-17
S-370
VOLUME 19, SUBJECT INDEX
Subject Index
PSYCHOTROPIC-ACTION
PSYCHOTROPIC-ACTION OF THYROTROPIN-RELEASING-HORMONE.
002023 02-09
PSrCHOTROPIC-AOENT
COMPUTERIZING THE MMPI IN THE STUDY OF A NEW PSYCHOTROPIC-
AGENT; TIAPRIDE.
000585 01-09
A CLINICAL-EVALUATION OF THE EFFECTS OF A NEW PSYCHOTROPIC-
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE
DOUBLE-BLIND METHOD.
004491 04-11
EFFECTS OF RO-1 1-2465, A NEW PSYCHOTROPIC-AGENT ON THE UPTAKE
OF SEROTONIN BY HUMAN PLATELETS - IN VITRO DETERMINATION OF
THE IC50.
004532 04-13
PSYCHOTROPIC-CAUSED
TREATMENT OF PSYCHOTROPIC-CAUSED ORTHOSTATIC HYPOTENSION.
002428 02-15
PSYCHOTROPIC-DRUG
PSYCHOTROPIC-DRUG BLOCKADE OF HISTAMINE Hl-RECEPTORS.
001432 02-03
PNEUMONIA AND PSYCHOTROPIC-DRUG USE IN ELDERLY PSYCHIATRIC-
'^'^'''''- 00239102-15
PSYCHOTROPIC-DRUG REGISTRATION IN THE SCANDINAVIAN-COUNTRIES;
THE ROLE OF CLINICAL-TRIALS.
002550 02-17
PSYCHOTROPIC-DRUG USE AND POLYPHARMACY IN A GENERAL-
HOSPITAL.
003369 03-1 1
COMPUTERIZED MONITORING OF PSYCHOTROPIC-DRUG ORDERS: SOME
TRENDS AND REVELATIONS.
003566 03-16
SEX-DIFFERENCES IN PSYCHOTROPIC-DRUG USE.
003589 03-17
COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS.
004438 04-11
PSYCHOTROPIC-ORUG-INDUCED
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BUND TRIAL USING AN
OBJEQIVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
PSYCHOTROPIC-DRUGS
EFFEaS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE
RELEASE.
000067 01-03
HISTAMINE AND PSYCHOTROPIC-DRUGS.
000112 01-03
IN VIVO OCCUPATION OF CEREBRAL HISTAMINE Hl-RECEPTORS
EVALUATED WITH 3H MEPYRAMINE MAY PREDIQ SEDATIVE
PROPERTIES OF PSYCHOTROPIC-DRUGS.
000241 01-03
PSYCHOTROPIC-DRUGS AND HISTAMINE Hl-RECEPTORS OF CULTURED
MOUSE NEUROBLASTOMA CELLS.
000250 01-03
PSYCHOTROPIC-DRUGS AND DEPRESSIVE-SYNDROME IN SCHIZOPHRENIA.
000569 01-08
TARDIVE-DYSKINESIA AND OTHER MOVEMENT-DISORDERS IN CHILDREN
TREATED WITH PSYCHOTROPIC-DRUGS.
000849 01-15
TRENDS IN THE PRESCRIPTION OF PSYCHOTROPIC-DRUGS (1970-1977) IN
A STATE-HOSPITAL.
000926 01-17
ON THE MECHANISM OF THERAPEUTIC AQIONS OF PSYCHOTROPIC-
DRUGS.
000964 01-17
PSYCHOTROPIC-DRUGS AND POLYPHARMACY IN ELDERLY-PATIENTS IN A
GENERAL-HOSPITAL.
000981 01-17
WHO PRESCRIBES PSYCHOTROPIC-DRUGS.
000993 01-17
INTERACTION STUDIES OF ETHANOL AND PSYCHOTROPIC-DRUGS IN
RODENTS: POSSIBLE INVOLVEMENT OF ADENOSINE-TRIPHOSPHATASES.
001281 02-03
CERTAIN MECHANISMS OF THE ACTION OF PSYCHOTROPIC-DRUGS ON
TRANSPORT ATPASES.
001331 02-03
THE IMMUNOSTIMULANT ANTINEOPLASTIC ACTION OF SOME
PSYCHOTROPIC-DRUGS OF THE SYDNONIMINE SERIES.
001520 02-03
EFFECTS OF PSYCHOTROPIC-DRUGS ON FI-RESPONDING AND ADJUNCTIVE
DRINKING IN RATS.
001693 02-04
PERINATAL EFFECTS OF PSYCHOTROPIC-DRUGS: THE ANTICONVULSANT-
DRUG DIPHENYLHYDANTOIN. (UNPUBLISHED PAPER).
001842 02-05
DETERMINATION OF PHARMACODYNAMICS OF PSYCHOTROPIC-DRUGS BY
PSYCHOMETRIC-ANALYSIS
001895 02-07
CLASSIFICATION OF PSYCHOTROPIC-DRUGS IN PEDIATRIC-
PSYCHOPHARMACOLOGY.
001903 02-07
PRELIMINARY-STUDIES ON CSF GAMMA AMINOBUTYRIC-ACID LEVELS IN
PSYCHIATRIC-PATIENTS BEFORE AND DURING TREATMENT WITH
DIFFERENT PSYCHOTROPIC-DRUGS.
001959 02-08
SELF-MEDICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS.
002189 02-11
DISCOVERY OF PSYCHOTROPIC-DRUGS BY MEANS OF COMPUTER-
ANALYZED EEG.
002203 02-13
EFFECT OF PSYCHOTROPIC-DRUGS ON NEUROENDOCRINE FUNCTION.
002265 02-13
PSYCHOTROPIC-DRUGS AND THE HEART: CLINICAL-IMPLICATIONS.
002425 02-15
PSYCHOTROPIC-DRUGS DO NOT INTERFERE WITH RADIOLIGAND ASSAYS
FOR PROLACTIN, CORTISOL, AND GROWTH-HORMONE.
002511 02-16
MADNESS AND MEDICINE: THE FORCIBLE ADMINISTRATION OF
PSYCHOTROPIC-DRUGS.
002523 02-17
CLINICAL COMPARABILITY OF PSYCHOTROPIC-DRUGS.
002526 02-17
CONSUMPTION OF PSYCHOTROPIC-DRUGS IN CZECHOSLOVAKIA.
002542 02-17
PURSUING THE ACTIONS OF PSYCHOTROPIC-DRUGS: RECEPTOR SITES
AND ENDOGENOUS CEREBRAL PROGRAMMES.
002578 02-17
FEDERAL-COURT UPHOLDS RIGHT-TO-REFUSE PSYCHOTROPIC-DRUGS,
ORDERS IMPROVEMENTS AT LIMA-STATE-HOSPITAL.
002583 02-17
CLASSIFICATION AND PSYCHOTROPIC-DRUGS.
002605 02-17
PREDICTION AND PROGNOSTIC FAQORS IN CLINICAL-TRIALS OF
PSYCHOTROPIC-DRUGS.
002615 02-17
UTILIZATION OF PSYCHOTROPIC-DRUGS. AN INTERNATIONAL
COMPARISON.
002616 02-16
INFLUENCE OF PSYCHOTROPIC-DRUGS ON THE URINARY ELIMINATION OF
LITHIUM.
002895 03-03
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE.
003172 03-08
VARIOUS FACTORS IN THE PATHOGENESIS OF PATHOLOGICAL REACTIONS
OBSERVED IN CONNEQION WITH THE ADMINISTRATION OF
PSYCHOTROPIC-DRUGS.
003532 03-15
TIME-BUND ANALYSIS AND OTHER VIDEO-STRATEGIES IN PHASE II
TRIALS OF PSYCHOTROPIC-DRUGS.
003568 03-16
EFFECTS OF ANESTHESIA ON PATIENTS TAKING PSYCHOTROPIC-DRUGS.
003603 03-17
THE HISTORY OF PSYCHOTROPIC-DRUGS.
003609 03-17
THE INTEGRITY OF THE SOCIAL HIERARCHY IN MICE FOLLOWING
ADMINISTRATION OF PSYCHOTROPIC-DRUGS.
004202 04-04
PSYCHOTROPIC-DRUGS AND THEIR RELATIONSHIP WITH
PSYCHOPATHOLOGY OF AFFECTIVE-DISORDERS.
004361 04-09
PECULIARITIES OF THE CEREBRAL PATHOMORPHOLOGY OF PATIENTS
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS
(PHARMACOLOGICAL PATHOMORPHOSIS) .
004528 04-13
A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF
SCHIZOPHRENIA.
004584 04-14
NEUROLOGICAL TOLERANCE OF UTHIUM AND PSYCHOTROPIC-DRUGS IN
COMBINATION: 265 CASES.
004594 04-15
ABNORMAL MOVEMENTS INDUCED BY PSYCHOTROPIC-DRUGS.
004652 04-15
PSYCHOTROPIC-DRUGS AND PSYCHIATRIC-HOSPITAL ADMISSIONS IN
VERONA, ITALY.
004717 04-17
PSYCHIATRIC-ILLNESS AND USE OF PSYCHOTROPIC-DRUGS IN THE
GEOGRAPHICALLY DEUMITED POPULATION OF SAMSO, DENMARK.
004734 04-17
S-371
Subject Index
Ptychopharmacology Abstracts
«iitC
air
il
Zt
•HI?
0':,
H
K
PSYCHOTROPIC-MEDICATION
THE EFFEaS OF PSYCHOTROPIC-MEDICATION ON COGNITIVE CONTROL
MEASURES. (PH.D. DISSERTATION).
004523 04-13
PSYCHOTROPIC-MEDICATIONS
DYSKINETIC AND NEUROLOGICAL-COMPLICATIONS IN CHILDREN TREATED
WITH PSYCHOTROPIC-MEDICATIONS.
000880 01-15
CONSIDER THIS . . . PSYCHOTROPIC-MEDICATIONS AND THEIR EFFEaS ON
PATIENTS.
000967 01-17
PREDiaiON OF RESPONSE TO PSYCHOTROPIC-MEDICATIONS.
002216 02-13
REFLECTIONS ON ACTION MECHANISMS OF PSYCHOTROPIC-
MEDICATIONS.
002296 02-13
INITIAL PRESCRIPTION OF PSYCHOTROPIC-MEDICATIONS FOR
ADOLESCENTS IN A MEDICAL/PROFESSIONAL INSTITUTE, AND THE
ROLE OF THE PSYCHIATRIST IN A MEDICAL/PROFESSIONAL INSTITUTE.
002621 02-17
PSYCHOTROPIC-MEDICATIONS AND GLAUCOMA.
004647 04- 1 5
SIDE-EFFECTS AND UNDESIRABLE COMBINATIONS OF PSYCHOTROPIC-
MEDICATIONS.
004663 04-15
PSYCHOTROPIC-SUBSTANCES
ON THE GENETIC SIDE-EFFECTS OF PSYCHOTROPIC-SUBSTANCES: I.
PSYCHOPHARMACEUTICALS, NARCOTICS. AND ANTICONVULSANT.
000845 01-15
THE EFFEQ OF PSYCHOTROPIC-SUBSTANCES AND NARCOTIC ANALGESIC-
DRUGS ON 14C NORADRENALINE UPTAKE BY SYNAPTOSOMES OF THE
CEREBRAL-CORTEX OF RATS.
001363 02-03
PSYCHOTROPICS
A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE. (PH.D.
DISSERTATION).
002918 03-03
WHAT IS STANDARD PRAQICE IN PRESCRIBING PSYCHOTROPICS?
003638 03-17
NEUROTROPIC-DRUGS AS COMEDICATION TO PSYCHOTROPICS:
COMBINED ADMINISTRATION OF A NEUROTROPIC-DRUG AND A
TETRACYCLIC-ANTIDEPRESSANT
004396 04-09
ON THE QUESTION OF PARENCHYMAL DAMAGE CAUSED BY LONG-TERM
THERAPY WITH PSYCHOTROPICS IN ADOLESCENCE.
004626 04-15
PSYCHPHARMACOTHERAPY
THE STATE OF THE ADRENERGIC AND CHOLINERGIC SYSTEMS IN
SCHIZOPHRENIC-PATIENTS DURING PSYCHPHARMACOTHERAPY.
004526 04-13
PUBLIC
THE URBAN EPIDEMIC OF PHENCYCLIDINE USE: LABORATORY EVIDENCE
FROM A PUBLIC PSYCHIATRIC-HOSPITAL INPATIENT-SERVICE.
003554 03-16
PUBLIC JUDGMENTS ON THE IMPORTANCE OF VALIUM INFORMATION.
003590 03-17
PUBLICATIONS
UNDESIRABLE EFFECTS OF MEDICINES: A REVIEW OF SEVERAL
PUBLICATIONS ISSUED FROM 1977-1979.
004632 04-15
PULMONARY
PULMONARY METABOLISM OF IMIPRAMINE IN THE RAT AND RABBIT:
COMPARISON WITH HEPATIC METABOLISM.
002845 03-03
PULMONARY-ARTERIES
A COMPARISON OF THE CONTRAQILE RESPONSES OF THE RABBIT
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC
AGONISTS: CHARAQERISTICS.
002670 03-03
PULSATILE
ADMINISTRATION OF ANTISOMATOSTATIN SERUM TO RATS REVERSES
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION
PRODUCED BY INJEQION OF METERGOLINE BUT NOT YOHIMBINE.
(UNPUBLISHED PAPER).
000019 01-03
L TRYPTOPHAN INJECTION ENHANCES PULSATILE GROWTH-HORMONE
SECRETION IN THE RAT. (UNPUBLISHED PAPER).
000020 01-03
PULVINAR
SELEQIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
PUNISHED-BEHAVIOR
PRIOR AND ONGOING EXPERIENCE AS DETERMINANTS OF THE EFFEQS OF
D-AMPHET AMINE AND CHLORPROMAZINE ON PUNISHED-BEHAVIOR.
000339 01-04
EFFECTS OF ACUTE AND CHRONIC INTERAaiONS OF DIAZEPAM AND D-
AMPHETAMINE ON PUNISHED-BEHAVIOR OF RATS.
000386 01-04
PUNISHED-RESPONDIN6
SCHEDULE DEPENDENT CHANGE OF PUNISHED-RESPONDING AFTER
DIAZEPAM IN RATS.
004165 04-04
SOME EFFEaS OF CLOZAPINE ON PUNISHED-RESPONDING BY MICE AND
SQUIRREL-MONKEYS.
004224 04-04
PUNISHER
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFEQS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
RESPONSE.
004119 04-04
PUNISHMENT
THE EFFEaS OF D-AMPHET AMINE, CHLORDIAZEPOXIDE, AND
PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM
PUNISHMENT IN PIGEONS. (PH D. DISSERTATION).
001713 02-04
THE EFFEQS OF CHLORDIAZEPOXIDE-HCL ADMINISTRATION UPON
PUNISHMENT AND CONDITIONED SUPPRESSION IN THE RAT.
001757 02-04
AnENUATION OF THE EFFEQS OF PUNISHMENT BY ETHANOL:
COMPARISONS WITH CHLORDIAZEPOXIDE.
001813 02-04
EFFEQS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING
SUPPRESSED BY CONDITIONED PUNISHMENT.
003105 03-04
PUP
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORAAANCE,
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT.
001580 02-04
EFFECT OF LITHIUM-CHLORIDE IN COYOTE PUP DIET.
001835 02-05
PUP-KILLING
RAT PUP-KILLING AND MATERNAL-BEHAVIOR IN MALE LONG-EVANS-
RATS: PRENATAL STIMULATION AND POSTNATAL TESTOSTERONE.
003054 03-04
PUPILLARY
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO.
004544 04-13
PUPS
EFFECTS OF APOMORPHINE ON ESCAPE PERFORMANCE AND ACTIVITY IN
DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6
OHDA).
000426 01-04
EFFECTS OF RESERPINE AND AMPHETAMINE ON THE DEVELOPMENT OF
HYPERACTIVITY IN MATERNALLY-DEPRIVED RAT PUPS.
001654 02-04
PURE-WORD
A CASE OF REVERSIBLE PURE-WORD DEAFNESS DURING LITHIUM
TOXICITY.
003481 03-15
PURIFICAHON
IDENTIFICATION AND PARTIAL PURIFICATION OF A HYDROPHOBIC
PROTEIN COMPONENT ASSOCIATED WITH (3H)SPIR0PERID0L BINDING-
ACTIVITY. (UNPUBLISHED PAPER).
001007 02-01
DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION, AND REGULATION.
00)011 02-01
THE DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION AND REGULATION.
003660 04-01
DOPAMINE-RECEPTOR PURIFICATION AND CHARACTERIZATION.
(UNPUBLISHED PAPER).
003661 04-01
PURIFICATION AND CHARACTERIZATION OF RAT PHEOCHROMOCYTOMA
DOPAMINE-BETA-HYDROXYLASE .
003664 04-01
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL
AND PATHOLOGICAL (M. NIEMANN-PICK TYPE C) HUMAN BRAIN.
003671 04-01
PURIFICATION AND SUBUNIT STRUCTURE OF DNA-DEPENDENT RNA-
POLYMERASE-BII FROM RAT-BRAIN NUCLEI.
003679 04-01
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE,
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-IO, USING HIGH.
004305 04-06
S-372
VOLUME 19, SUBJECT INDEX
Subject Index
HIRIFIEO
AFFINITY CHROMATOGRAPHY OF THE BETA-AORENERGIC-RECEPTOR AND
CHARACTERIZATION OF ANTIBODIES RAISED AGAINST PURIFIED
RECEPTOR PREPARATIONS. ^^ ^^ ^
00)009 02-01
BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF THE MOUSE BRAIN
ENOLASES PURIFIED BY A SIMPLE METHOD.
003668 04-01
HJBINE
THE EFFECT OF MORPHINE ON PURINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: EVIDENCE FOR A PURINERGIC
COMPONENT IN MORPHINES ACTION.
000234 01-03
INCREASED BENZODIAZEPINE-RECEPTOR NUMBER ELICITED IN VITRO BY A
NOVEL PURINE, EMD-28422. ^ ,^ ^„ ^^
001475 02-03
INTERACTION BETWEEN PURINE AND BENZODIAZEPINE: INOSINE
REVERSES DIAZEPAM-INDUCED STIMULATION OF MOUSE
EXPLORATORY-BEHAVIOR .
002972 03-04
THE SITE OF ACTION OF MUSCLE-RELAXANT PURINE NUCLEOSIDES.
003742 04-03
niRINERGIC
DIAZEPAM POTENTIATION OF PURINERGIC DEPRESSION OF CENTRAL
^''^'''' 000233 01-03
THE EFFEa OF MORPHINE ON PURINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: EVIDENCE FOR A PURINERGIC
COMPONENT IN MORPHINES ACTION.
000234 01-03
EFFEQS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC
MECHANISM IN ACTION OF DIAZEPAM.
001414 02-03
MIttlMFC
PURINES AS ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTOR.
000276 01-03
PURKINJE
EFFEQS OF ACUTE AND CHRONIC AMPHETAMINE TREATMENT ON
PURKINJE NEURON DISCHARGE IN RAT CEREBELLUM.
003793 04-03
THE EFFEQ OF PROPRANOLOL AND ITS ISOMERS ON PURKINJE
NEURONES IN RAT CEREBELLUM.
004059 04-03
PURKiNJE-CELL ^ „
INTERAQIONS OF NOREPINEPHRINE WITH PURKINJE-CELL RESPONSES TO
PUTATIVE AMINO-ACID NEUROTRANSMIHERS APPLIED BY
MICROIONTOPHORESIS.
000209 01-03
PURKINJE-CELLS
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJEQION.
000261 01-03
INHIBITORY ACTIONS OF TAUROCYAMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
MODULATORY INTERAQIONS BETWEEN NOREPINEPHRINE AND TAURINE,
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS.
004058 04-03
PURKINJE-FIBRES
ELECTROPHYSIOLOGICAL-EFFECTS OF IMIPRAMINE ON BOVINE
VENTRICULAR-MUSCLE AND PURKINJE-FIBRES.
003988 04-03
PUROMYCIN
INHIBITION OF AMINOPEPTIDASE AND ACETYLCHOLINESTERASE BY
PUROMYCIN AND PUROMYCIN ANALOGS.
003835 04-03
PUTATIVE
DISSIMILAR EFFEQS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE.
000173 01-03
INTERACTIONS OF NOREPINEPHRINE WITH PURKINJE-CELL RESPONSES TO
PUTATIVE AMINO-ACID NEUROTRANSMITTERS APPLIED BY
MICROIONTOPHORESIS.
000209 01-03
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS AND PUTATIVE
ENDOGENOUS BENZODIAZEPINE-LIKE COMPOUNDS.
000225 01-03
STUDIES ON THE PUTATIVE ANTICHOLINERGIC-EFFECTS OF
DESMETHYLIMIPRAMINE.
000228 01-03
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMITTER AMINO-
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFACTORY-BULB.
002836 03-03
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM- VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
PUTRESCINE
GABA DEPLETION AND BEHAVIOURAL-CHANGES PRODUCED BY
INTRAVENTRICULAR PUTRESCINE IN CHICKS.
000218 01-03
PYLORIC
GASTRIC AND PYLORIC MOTOR-RESPONSE TO SYMPATHETIC-NERVE
STIMULATION AFTER CHEMICAL SYMPATHECTOMY. (UNPUBLISHED
PAPER).
001337 02-03
PYRAMIDAL
EXCITATORY ACTION OF OPIOID-PEPTIDES AND OPIATES ON CULTURED
HIPPOCAMPAL PYRAMIDAL CELLS.
001241 02-03
EFFECTS OF PHENYTOIN ON PYRAMIDAL NEURONS OF THE RAT
HIPPOCAMPUS.
002750 03-03
ACETYLCHOLINE-INDUCED MODULATION OF HIPPOCAMPAL PYRAMIDAL
NEURONS.
003728 04-03
PYRAZIDOL
CLINICAL-TRIAL OF PYRAZIDOL IN ENDOGENOUS DEPRESSIVE-STATES.
002021 02-09
PYRAZIDOL IN THE TREATMENT OF DEPRESSIONS.
002055 02-09
PYRAZINOBENZODIAZEPINE
SYNTHESIS AND ANXIOLYTIC-ACTIVITY OF A SERIES OF
PYRAZINOBENZODIAZEPINE DERIVATIVES.
001089 02-02
PYRAZOLE
PYRAZOLE EXACERBATES HANDLING-INDUCED CONVULSIONS IN MICE.
004094 04-04
PYRAZOLOPYRIDINES
ACTION OF PYRAZOLOPYRIDINES AS MODULATORS OF
(3H)FLUNITRAZEPAM BINDING TO THE GABA/BENZODIAZEPINE-
RECEPTOR COMPLEX OF THE CEREBELLUM.
002909 03-03
PYRETHROID
REGIONAL CHANGES IN BRAIN GLUCOSE UTILIZATION IN RATS GIVEN A
PYRETHROID INSECTICIDE.
001838 02-05
PYRIDOXINE
5 HYDROXYTRYPTOPHAN AND PYRIDOXINE: THEIR EFFECTS IN YOUNG
CHILDREN WITH DOWNS-SYNDROME,
002161 02-11
CLINICAL SIGNIFICANCE OF PYRIDOXINE ADMINISTRATION IN L-DOPA
THERAPY OF PARKINSONISM.
003345 03-1 1
HYPERVENTILATION-SYNDROME, TREATMENT WITH L TRYPTOPHAN AND
PYRIDOXINE; PREDICTIVE VALUES OF XANTHURENIC-ACID EXCRETION.
004456 04-1 1
PYRIFORM
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION.
004273 04-05
PYRIMIDINE-PEPTIDE
ANTICANDIDAL-ACTIVITY OF PYRIMIDINE-PEPTIDE CONJUGATES.
001059 02-01
PYRIMIDOPYRIMIDINE
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF A
PYRIMIDOPYRIMIDINE DERIVATIVE WITH ANTIDEPRESSANT ACTIVITY.
003653 04-01
PYRITHIOXINE
INFLUENCE OF PYRITHIOXINE ON EXPERIMENTAL HYPOXIA IN RATS.
000077 01-03
INFLUENCE OF PYRITHIOXINE, MECLOPHENOXATE AND PIRACETAM ON
THE LEARNING PROCESS IN MAN.
000805 01-14
PYRITINOL
PYRITINOL ADMINISTRATION AS PART OF EPILEPSY TREATMENT IN
CHILDREN.
000671 01-11
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN
RATS.
001199 02-03
PYROGEN
THE ROLE OF PROTEIN SYNTHESIS IN THE HYPOTHALAMIC MECHANISM
MEDIATING PYROGEN FEVER.
001454 02-03
PYRROLIDONE
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF N-4 1
AZETIDINYLBUTYNYL 2 PYRROLIDONE, A HIGHLY POTENT
OXOTREMORINE-LIKE-AGENT.
003701 04-02
S-373
^^mm
Subject Index
Psychopharmacology Abstracts |_
m
liglii<
'«iiiiir
9::
ii
ilSfc
^
PYRROLOPYRIMIDINEDIONES
ANTICONVULSANT PROPERTIES OF SELECTED PYRROLOPYRIMIDINEDIONES
AND INTERMEDIATES.
003700 04-02
PYRUVATE
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA.
(UNPUBLISHED PAPER).
001147 02-03
PYRUVATE-DEHYDROGENASE
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA.
(UNPUBLISHED PAPER).
001147 02-03
P2-FRACTIONS
EFFECT OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRACTI0NS.
001472 02-03
QAE-SEPHADEX
AN IMPROVED ASSAY OF CYCLIC-NUCLEOTIDE-PHOSPHODIESTERASES
WITH QAE-SEPHADEX COLUMNS.
001860 02-06
QM-«008
A DOUBLE-BLIND CROSSED CLINICAL-STUDY WITH A NEW
PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008), DIAZEPAM, AND
A PLACEBO.
003153 03-07
QUALITY
THE EFFECTS OF TRIAZOLAM AND NITRAZEPAM ON SLEEP QUALITY,
MORNING VIGILANCE, AND PSYCHOMOTOR PERFORMANCE.
002330 02-14
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES.
003599 03-17
POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES ON THE ONSET,
MAGNITUDE AND QUALITY OF THE OPIOID ABSTINENCE-SYNDROME.
004610 04-15
QUANTAL
A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY
PRODUCED BY OPIATE ANALGESICS.
000425 01-04
QUANTIFICATION
QUANTIFICATION OF NORADRENALINE IONTOPHORESIS.
002475 02-16
PSYCHOACTIVE-DRUG QUANTIFICATION BY VISUAL FLICKER SENSITIVITY
MEASUREMENT. (PH.D. DISSERTATION).
002485 02-16
IDENTIFICATION AND QUANTIFICATION OF 1,2,3,4 TETRAHYDRO-BETA-
CARBOLINE, 2 METHYL-TETRAHYDRO-BETA-CARBOUNE, AND 6
METHOXY-TETRAHYDRO-BETA-CARBOLINE AS IN VIVO CONSTITUENTS
OF RAT-BRAIN AND ADRENAL-GLAND.
002636 03-01
QUANTIFIED
STUDY OF THE EFFECTS OF PC-63-14 ON THE QUANTIFIED EEG.
003403 03-13
CORRELATED STUDY OF THE EFFEQS OF SE-5023 IN AN HYPOXIC
ATMOSPHERE ON QUANTIFIED EEG, VIGILANCE, MEMORY, AND
MOOD.
003440 03-14
QUANTIFYING
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL-
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFEQS OF D-
AMPHET AMINE AND APOMORPHINE.
002484 02-16
QUANTITATION
CHARACTERIZATION AND QUANTITATION OF ALPHA-ADRENERGIC-
RECEPTOR SUBTYPES IN RAT HYPOTHALAMUS
002839 03-03
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
ETHANOL.
003725 04-03
COMPARISON OF SPECTROFLUOROMETRIC AND GAS-
CHROMATOGRAPHY/MASS-SPECTROMETRY PROCEDURES FOR THE
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN.
004692 04-16
QUANTITATIVE
EFFECT OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND
RIGIDITY: A QUANTITATIVE STUDY OF REFLEXES AND PLASMA
CONCENTRATIONS.
000701 01-11
3 CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE (GS-385), A
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION,
PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE
LIQUID-CHROMATOGRAPHY.
000705 01-11
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF
LOPIRAZEPAM (D- 12524) BY QUANTITATIVE EEG AND
PSYCHOMETRIC-ANALYSIS.
000720 01-11
DETERMINATION OF THE ENCEPHALOTROPIC, PSYCHOTROPIC AND
PHARMACODYNAMIC PROPERTIES OF NICERGOLINE BY MEANS OF
QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY AND
PSYCHOMETRIC-ANALYSES.
000788 01-13
QUANTITATIVE ANALYSIS OF 6 HYDROXYMELATONIN IN HUMAN URINE
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS-
SPEQROMETRY. (UNPUBLISHED PAPER).
001058 02-01
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY
SPEQRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND
NEUROLEPTICS.
001220 02-03
PENTYLENETETRAZOL SEIZURE THRESHOLD: A QUANTITATIVE MEASURE
OF ETHANOL DEPENDENCE IN RATS.
001750 02-04
ANTIHYPOXIDOTIC-DRUGS AND NOOTROPIC-DRUGS: PROOF OF THEIR
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY
QUANTITATIVE EEG INVESTIGATIONS.
002166 02-11
QUANTITATIVE STUDY OF THE DISTRIBUTION OF LITHIUM IN THE MOUSE-
BRAIN FOR VARIOUS DOSES OF LITHIUM GIVEN TO THE ANIMAL.
002299 02-13
QUANTITATIVE ASSESSMENT OF SMOOTH-PURSUIT EYE-MOVEMENTS IN
HEALTHY AND EPILEPTIC-SUBJEQS.
002376 02-15
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS
INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJECTION OF
CYCLOHEXIMIDE.
002780 03-03
ALCOHOL WITHDRAWAL USING TIAPRIDE: QUANTITATIVE
PSYCHOPATHOLOGY.
003293 03-11
CNS EFFEaS OF ISF-2522, A NEW NOOTROPIC (A PHASE I SAFETY AND
CNS EFFICACY STUDY WITH QUANTITATIVE PHARMACOEEG AND
PHARMACOPSYCHOLOGY) .
004519 04-13
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND
OPEN LABEL CLINICAL-TRIAL.
004620 04-15
ACUTE PHENCYCLIDINE (PCP) INTOXICATION: QUANTITATIVE URINE
LEVELS AND CLINICAL MANAGEMENT.
004665 04-15
A QUANTITATIVE PROBE FOR BIOLOGICAL-PSYCHIATRY: SELEQEO ION-
MONITORING
004685 04-16
QUANTITIES
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC-
ACID IN BRAIN USING HPLC WITH ELEQROCHEMICAL-DETEaiON.
003139 03-06
QUASI-MORPHINE
EFFEQS OF BRANCHED-CHAIN FATTY-ACIDS ON GABA DEGRADATION
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI-
MORPHINE ABSTINENCE-BEHAVIOR.
001809 02-04
CHARACTER AND MEANING OF QUASI-MORPHINE WITHDRAWAL
PHENOMENA ELICITED BY METHYLXANTHINES.
004087 04-04
RX-336-M, A NEW CHEMICAL TOOL IN THE ANALYSIS OF THE QUASI-
MORPHINE WITHDRAWAL-SYNDROME.
004093 04-04
PHYSIOLOGICAL AND BEHAVIORAL APPROACHES TO THE STUDY OF THE
QUASI-MORPHINE WITHDRAWAL-SYNDROME.
004242 04-04
QUATERNARY
EXPERIMENTAL DYSTONIA INDUCED BY QUATERNARY
CHLORPROMAZINE.
000461 01-04
QUERCETIN
ATP COMPLEXES WITH THE ATPASE INHIBITOR QUERCETIN.
000045 01-03
QUESTIONNAIRE
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY:
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS.
000543 01-07
COGNITIVE AND AFFEaiVE-FUNCTIONS IN PATIENTS WITH AFFEQIVE-
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY
QUESTIONNAIRE.
00060401-09
PLACEBO REACTION IN NEUROTICS RATED WITH THE SCL-90
QUESTIONNAIRE.
000976 01-17
QUESTIONS
QUESTIONS OF DIFFERENTIATED TREATMENT FOR EPILEPTIC-PATIENTS.
003605 03-17
S-374
VOLUME 19, SUBJECT INDEX
Subjsct Index
CHOLINERGIC MECHANISMS IN MANIA AND DEPRESSION; QUESTIONS OF
SPECIFICITY.
004374 04-09
CLINICAL AND PRECLINICAL EXPERIENCE WITH CHOLINE-CHLORIDE IN
HUNTINGTONS-DISEASE AND TARDIVE-DYSKINESIA: UNANSWERED
QUESTIONS.
004604 04-15
QUICKIY-MADE
QUICKLY-MADE CANNULA FOR REPEATED CEREBROSPINAL-FLUID
SAMPLING IN RATS.
001879 02-06
QUINACRINE
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
002219 02-13
TOXIC PSYCHOSIS FOLLOWING USE OF QUINACRINE.
003507 03-15
QUINIDINE
NONINTERACTION OF DIGITOXIN AND QUINIDINE.
000968 01-17
INTRAVENOUS QUINIDINE IN CONGESTIVE CARDIOMYOPATHY.
003352 03-11
QUININE
UNIMPAIRED QUININE METABOLISM IN RATS WITH VENTROMEDIAL
HYPOTHAUMIC LESIONS.
003821 04-03
QUINOLINE
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK-
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES).
003898 04-03
QUINUCLIDINYL
QUINUCLIDINYL BENZILATE BINDING IN HOUSEFLY HEADS AND RAT-
BRAIN.
003868 04-03
QUINUCLIDINYL-BENZILATE
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRAQIONS.
000299 01-03
A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE. (PH.D.
DISSERTATION).
002918 03-03
QUINUCLYDINYL-BENZYLATE
INHIBITION BY LOCAL ANESTHETICS, PHENTOLAMINE AND PROPRANOLOL
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL
MUSCARINIC-RECEPTORS.
001097 02-03
QUINUPRAMINE
ANTIDEPRESSANT TREATMENT BY INTRAVENOUS ADMINISTRATION
COMPARED TO PERORAL ADMINISTRATION: A DOUBLE-BUND STUDY
OF QUINUPRAMINE.
000552 01-08
QUIPAZINE
ANTINOCICEPTIVE COMPARISON OF QUIPAZINE AND MORPHINE.
000435 01-04
EFFEQS OF MALNUTRITION AND QUIPAZINE ON RAT-CEREBRAL-CORTEX
ATPASE AaiVITY DURING DEVELOPMENT.
001276 02-03
ANTAGONISM OF 5 HYDROXYTRYPTAMINE-RECEPTORS BY QUIPAZINE.
001329 02-03
EFFECT OF QUIPAZINE ON BRAINSTEM MONOAMINE NEURONS
HISTOFLUORESCENCE STUDIES.
001477 02-03
EFFEQ OF QUIPAZINE AND FLUOXETINE ON ANALGESIC-INDUCED
CATALEPSY AND ANTINOCICEPTION IN THE RAT.
001709 02-04
DU-24565, A QUIPAZINE DERIVATIVE, A POTENT SELECTIVE SEROTONIN
UPTAKE INHIBITOR.
002651 03-02
DRUG-INDUCED STIMULUS CONTROL AND THE CONCEPT OF BREAKING-
POINT: LSD AND QUIPAZINE.
003116 03-04
MODIFICATION OF DRUG-INDUCED CATATONIA AND TREMORS BY
QUIPAZINE IN RATS AND MICE.
004164 04-04
5 HYDROXYTRYPTAMINE-LIKE PROPERTIES OF M
CHLOROPHENYLPIPERAZINE: COMPARISON WITH QUIPAZINE.
004210 04-04
QUISQUALATE-RECEPTORS
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA
0(AND L) GLUTAMYLGLYCINE.
002696 03-03
R-1S
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE
RELATIONSHIP,
003806 04-03
R^ 1.468
RECEPTOR BINDING PROFILE OF R-41-468, A NOVEL ANTAGONIST AT 5
HT2-RECEPT0RS.
002648 03-02
R-513S
A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/
BENZODIAZEPINE-RECEPTOR INTERACTION .
003851 04-03
RABBIT
EVIDENCE FOR A RECEPTOR SUPERSENSITIVITY FOLLOWING IMPAIRMENT
OF CENTRAL SEROTONERGIC ACTIVITY IN THE RABBIT.
000041 01-03
RELEASE OF ENDOGENOUS NOREPINEPHRINE FROM A RABBIT CEREBRAL-
ARTERY.
000079 01-03
ENKEPHALIN-RECEPTOR IN THE RABBIT ILEUM.
000221 01-03
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRACTIONS.
000299 01-03
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIRECT VASODILATOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRICTION.
001109 02-03
PHOSPHOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR-
MEDIATED INDUCTION OF CHEMOTAXIS IN RABBIT NEUTROPHILS.
(UNPUBLISHED PAPER).
001118 02-03
OPIATE-RECEPTORS IN THE RABBIT IRIS.
001200 02-03
INHIBITION OF ACH RELEASE BY PROSTAGLANDIN-El IN THE RABBIT
SUPERIOR-CERVICAL-GANGLION .
001205 02-03
COMPARISON OF THE EFFEaS OF CENTRAL ADMINISTRATION OF SERINE
AND GLYCINE ON BODY-TEMPERATURE OF THE RABBIT.
001248 02-03
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT
CAUDATE-NUCLEUS.
001298 02-03
FURTHER CHARAQERIZATION OF THE BINDING OF SUBSTANCE-P TO A
FRAQION FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES.
001394 02-03
PERIPHERAL AUTONOMIC-MECHANISMS AND PAVLOVIAN-CONDITIONING
IN THE RABBIT (ORYaOLAGUS-CUNICULUS).
001560 02-04
SENSORY AND ASSOCIATIVE-EFFECTS OF LSD ON CLASSICAL APPETITIVE-
CONDITIONING OF THE RABBIT JAW MOVEMENT RESPONSE.
001637 02-04
PERIPHERAL 6 HYDROXYDOPAMINE ADMINISTRATION IN THE RABBIT
(ORYCTOLAGUS-CUNICULUS): EFFECTS ON PAVLOVIAN-CONDITIONING.
001668 02-04
PHENOBARBITONE INTERACTION WITH ORAL CONTRACEPTIVE STEROIDS
IN THE RABBIT AND RAT.
001832 02-05
EFFECTS OF AMITRIPTYLINE AND CLOMIPRAMINE IN THE ISOLATED,
PERFUSED RABBIT HEART.
001852 02-05
A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC
AGONISTS: CHARACTERISTICS.
002670 03-03
TEMPORAL PAHERNING OF NEURONAL ACTIVITY DURING THERMAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
MODULATION BY ENDOGENOUS DOPAMINE OF THE RELEASE OF
ACETYLCHOLINE IN THE CAUDATE-NUCLEUS OF THE RABBIT.
002751 03-03
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF
.i^MINES INFLUENCING CEREBROSPINAL-FLUID FORMATION.
002807 03-03
PULMONARY METABOLISM OF IMIPRAMINE IN THE RAT AND RABBIT:
COMPARISON WITH HEPATIC METABOLISM.
002845 03-03
OPIATE-RECEPTORS AND SLEEP. II. EFFECTS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUCTAL GRAY MAHER AND NUCLEUS-TRACTUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
S-375
Subject Index
Ptychopharmacology Abstracts
,11!
ill!
«tiii:
flC,
PREJUNCTIONAL ACTIONS OF PIRIBEDIL ON THE ISOLATED KIDNEY OF THE
RABBIT: COMPARISON WITH APOMORPHINE.
003749 04-03
COMPARISON OF THE EFFECT OF INTRAVENOUS ADMINISTRATION OF D
LYSERGIC-ACID-DIETHYLAMIDE ON FREE AND MEMBRANE-BOUND
POLYSOMES IN THE RABBIT BRAIN.
003831 04-03
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO.
003832 04-03
STUDIES ON THE KINETIC PROPERTIES OF TRYPTOPHAN-HYDROXYLASE OF
RABBIT MESENCEPHALON AND PONS-MEDULLA: EFFECT OF LONG-
TERM-TREATMENT WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
003852 04-03
EFFECT OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE
DISCHARGE INDUCED BY CARBACHOL IN THE RABBIT.
003951 04-03
HYPOTENSION ALTERS THE RELEASE OF CATECHOLAMINES IN THE
HYPOTHALAMUS OF THE CONSCIOUS RABBIT.
003968 04-03
EFFECT OF PR0STAGLANDIN-D2, PR0STAGLANDIN-E2 AND
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES
OF RAT AND RABBIT BRAIN.
003983 04-03
THE EFFECT OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELECTRICAL-
ACTIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUCTURES OF
THE RABBIT BRAIN.
003994 04-03
THE EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE
PRESENCE AND ABSENCE OF CNS DEPRESSANTS.
004010 04-03
BENZODIAZEPINE-RECEPTOR: HETEROGENEITY IN RABBIT BRAIN.
004060 04-03
SEROTONERGIC MECHANISM IN SEIZURES KINDLED FROM THE RABBIT
AMYGDALA.
004227 04-04
THE EFFECTS OF NEFOPAM ON BLOOD ACID BASE STATUS IN THE RABBIT:
INTERACTIONS WITH MORPHINE IN THE MOUSE AND RABBIT.
004279 04-05
RABBITS
EFFECTS OF BRAIN-MONOAMINE DEPLETION ON THERMOREGULATORY
RESPONSES OF RABBITS TO DIFFERENT HYPOTHALAMIC
TEMPERATURES.
000190 01-03
THE EFFECT OF CORTISOL MICROIONOPHORETIC-APPLICATIONS ON THE
ACTIVITY OF HIPPOCAMPAL NEURONS IN UNRESTRAINED RABBITS.
001123 02-03
EFFECTS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS:
RELATION TO MICROSOMAL BIOTRANSFORMATION AND
DOPAMINERGIC-RECEPTOR STIMULATION.
001161 02-03
CENTRAL ADMINISTRATION OF SERINE CAUSES HYPOTHERMIA AND
INHIBITS FEVER IN RABBITS.
001247 02-03
LARYNGEAL-EFFECTS OF SEROTONIN IN RABBITS.
001501 02-03
VESTIBULO-OCULAR REFLEXES IN RABBITS: REDUCTION BY INTRAVENOUS
INJECTION OF DIAZEPAM.
001566 02-04
SUPPRESSION OF AMPHETAMINE-INDUCED EEG AROUSAL IN THE
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS.
002683 03-03
CHRONOLOGICAL ELECTROENCEPHALOGRAPHIC AND
NEUROPHARMACOLOGICAL- STUDY IN CORTICAL KINDLING RABBITS.
002761 03-03
EVOKED-POTENTIAL STUDIES OF PORCINE CALCITONIN IN RABBITS.
002936 03-03
NEURONAL SENSITIVITY OF SOME BRAIN REGIONS TO ANGIOTENSIN-II IN
RABBITS.
003716 04-03
OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE
CONDITIONING IN RABBITS.
003798 04-03
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS
INVOLVED IN THE HIPPOCAMPUS OF RABBITS.
003842 04-03
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS.
003972 04-03
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS.
004022 04-03
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS.
004180 04-04
BEHAVIORAL-PHARMACOLOGY OF TETRAHYDROCANNABINOL
CONVULSIONS IN RABBITS.
004288 04-06
RADICAL
EFFECT OF STRUCTURE ON PHENOTHIAZINE CATION RADICAL REAQIONS
IN AQUEOUS BUFFERS.
000014 01-02
SPECTRA OF RADICAL CATIONS OF PHENOTHIAZINE DERIVATIVES IN
SOLUTION AND SOLID STATE.
003673 04-01
RADIOACTIVE
THEORY, PROCEDURE, AND APPLICATIONS OF THE RADIOAQIVE
DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL GLUCOSE
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM. (UNPUBLISHED
PAPER).
001877 02-06
RADIOAUTOGRAPHY
CHARACTERIZATION AND RADIOAUTOGRAPHY OF {3H)LSD BINDING BY
RAT-BRAIN SLICES IN VITRO: THE EFFEQ OF 5 HYDROXYTRYPTAMINE.
001369 02-03
RADIOCALCIUM
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: KINETIC STUDIES.
003814 04-03
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: PHARMACOLOGICAL- STUDIES.
003815 04-03
RADIOHISTOCHEMICAL
RADlOHISTOCHEMICAL STUDIES OF BENZODIAZEPINE AND GABA-
RECEPTORS AND THEIR INTERAQIONS.
002644 03-01
RADIOIMMUNOASSAY
APPLICATION OF A RADIOIMMUNOASSAY SCREENING-TEST FOR
DETECTION AND MANAGEMENT OF PHENCYCLIDINE INTOXICATION.
000859 01-15
LEVORPHANOL: RADIOIMMUNOASSAY AND PLASMA CONCENTRATION
PROFILES IN DOG AND MAN.
000898 01-16
DETERMINATION OF DOSE PLASMA CONCENTRATION RELATIONSHIP OF
PHENOBARBITAL IN EPILEPTIC-PATIENTS BY A NEW SPECIFIC
RADIOIMMUNOASSAY.
000902 01-16
RADIOIMMUNOASSAY FOR FLUPHENAZINE IN HUMAN PLASMA
000905 01-16
RADIOIMMUNOASSAY FOR TOTAL DOXEPIN AND N DESMETHYLDOXEPIN
IN PLASMA.
002499 02-16
PLASMA FLUPHENAZINE LEVELS BY RADIOIMMUNOASSAY IN
SCHIZOPHRENIC-PATIENTS TREATED WITH DEPOT INJECTIONS OF
FLUPHENAZINE-DECANOATE.
002510 02-16
SPECIFIC AND SENSITIVE RADIOIMMUNOASSAY FOR 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL (MOPEG).
002776 03-03
A RADIOIMMUNOASSAY FOR EPENDYMINS BETA AND GAMMA: TWO
GOLDFISH BRAIN PROTEINS INVOLVED IN BEHAVIORAL PLASTICITY.
003677 04-01
VASOPRESSIN STIMULATES RELEASE OF BETA LIPOTROPIN AND BETA
ENDORPHIN IN CONSCIOUS RATS AS MEASURED BY
RADIOIMMUNOASSAY OF UNEXTRACTED PLASMA.
003715 04-03
RADIOIMMUNOASSAY OF TRICYCLIC-ANTIDEPRESSANTS.
004674 04-16
A COMPARISON OF RADIOIMMUNOASSAY WITH SPEaROPHOTOMETRY
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN
CONCENTRATIONS.
004684 04-16
SERUM LEVELS OF BUTORPHANOL BY RADIOIMMUNOASSAY
004691 04-16
A SENSITIVE BENZODIAZEPINE RADIOIMMUNOASSAY OF BROAD
SPECIFICITY.
004693 04-16
RADIOIMMUNOIOGIC
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II.
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJEQS: FIRST-PASS EFFEQ.
004516 04-13
RADIOLABELED
EFFECTS OF HALOPEMIDE ON POTASSIUM-INDUCED RELEASE OF
RADIOLABELED NEUROTRANSMIHERS FROM RAT CEREBROCORTICAL
SLICES IN VITRO.
001347 02-03
A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE. (PH.D.
DISSERTATION).
002918 03-03
S-376
VOLUME 19, SUBJECT INDEX
Subject Index
RADIOLABELLED
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES
001207 02-03
RADIOLIGAND
RADIOLIGAND BINDING STUDIES: EVIDENCE FOR MULTIPLE DOPAMINE-
RECEPTORS.
001186 02-03
PSYCHOTROPIC-DRUGS DO NOT INTERFERE WITH RADIOLIGAND ASSAYS
FOR PROLACTIN, CORTISOL, AND GROWTH-HORMONE.
002511 02-16
KAINATE LESION DISSOCIATES STRIATAL DOPAMINE-RECEPTOR
RADIOLIGAND BINDING-SITES.
002803 03-03
RADIORECEPTOR
RADIORECEPTOR LABELING OF PRESYNAPTIC AND POSTSYNAPTIC
DOPAMINE-RECEPTORS.
001511 02-03
DETERMINATION OF GABA LEVELS BY A (3H)MUSCIM0L RADIORECEPTOR
ASSAY.
003135 03-06
NEUROLEPTIC SERUM LEVELS MEASURED BY RADIORECEPTOR ASSAY
AND CLINICAL-RESPONSE IN SCHIZOPHRENIC-PATIENTS.
003199 03-08
MEASUREMENT OF NEUROLEPTIC CONCENTRATIONS BY GLC AND
RADIORECEPTOR ASSAY.
004682 04-16
A RAPID AND SENSITIVE RADIORECEPTOR ASSAY FOR TERTIARY AMINE
TRICYCLIC-ANTIDEPRESSANTS.
004689 04-16
RAGE
PROPRANOLOL IN THE TREATMENT OF RAGE AND VIOLENT-BEHAVIOR IN
PATIENTS WITH CHRONIC-BRAIN-SYNDROMES.
003394 03-1 1
RANA-PIPIENS
VASOTOCIN, PROSTAGLANDIN, AND FEMALE REPRODUCTIVE BEHAVIOR
IN THE FROG. RANA-PIPIENS.
002978 03-04
RANDOM
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS:
RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BLIND TRIAL.
001998 02-09
RANDOMiSED-TRIAL
A PROSPECTIVE RANDOMISED-TRIAL ON THE EFFECT OF MONITORING
PLASMA ANTICONVULSANT LEVELS IN EPILEPSY.
003314 03-11
RANDOMIZED-ORDER
EFFICACY AND PATTERN VALENCE OF PSYCHOACTIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER.
000699 01-11
RAPHE-MAGNUS
HYPOALGESIA INDUCED BY MICROINJECTION OF A NOREPINEPHRINE
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL
ADMINISTRATION OF A SEROTONIN ANTAGONIST.
000121 01-03
REVERSIBLE INACTIVATION OF RAPHE-MAGNUS NEURONS: EFFECTS ON
NOCICEPTIVE THRESHOLD AND MORPHINE-INDUCED ANALGESIA.
000240 01-03
THE EFFECT OF MORPHINE ON THE CONTENT OF SEROTONIN, 5
HYDROXYINDOLEACETIC-ACID AND SUBSTANCE-P IN THE NUCLEI
RAPHE-MAGNUS AND RETICULARIS-GIGANTOCELLULARIS.
001328 02-03
EFFECTS OF RAPHE-MAGNUS AND RAPHE-PALLIDUS LESIONS ON
MORPHINE-INDUCED ANALGESIA AND SPINAL-CORD MONOAMINES.
001420 02-03
RAPHE-PALLIDUS
EFFECTS OF RAPHE-MAGNUS AND RAPHE-PALLIDUS LESIONS ON
MORPHINE-INDUCED ANALGESIA AND SPINAL-CORD MONOAMINES.
001420 02-03
RAPID-EYE-MOVEMENT
DOES RAPID-EYE-MOVEMENT SLEEP PLAY A ROLE IN BRAIN
DEVELOPMENT?
004091 04-04
RAPIDITY
RAPIDITY OF CLINICAL ANTIDEPRESSANT RESPONSE TO IMIPRAMINE,
(UNPUBLISHED PAPER).
003164 03-07
RASHES
MITIGATING ACUTE SKIN RASHES AND NAUSEA FROM LITHIUM.
004661 04-15
RAT-BRAIN
ENHANCEMENT OF RAT-BRAIN METABOLISM OF A TRYPTOPHAN LOAD
BY CHRONIC ETHANOL ADMINISTRATION.
000022 01-03
EFFEQ OF AMINOOXY ACETIC-ACID (AOAA) ON GABA LEVELS IN SOME
PARTS OF THE RAT-BRAIN.
000040 01-03
CIRCADIAN-RHYTHM OF CYCLIC-NUCLEOTIDE AND GABA LEVELS IN THE
RAT-BRAIN,
000049 01-03
COMPARATIVE-EFFECTS OF P CHLOROAMPHETAMINE AND L P
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN
RAT-BRAIN.
000101 01-03
INHIBITION OF (3H)NAL0X0NE BINDING IN HOMOGENATES OF RAT-
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC ACTIVITY, RELATED
TO PHYSOSTIGMINE.
000104 01-03
MODIFICATION OF DOPAMINERGIC-RECEPTOR SENSITIVITY IN RAT-BRAIN
AFTER AMYGDALOID KINDLING.
000106 01-03
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN-
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM.
000123 01-03
HIGH-AFFINITY BINDING OF 3H ETHYLKETOCYCLAZOCINE TO RAT-BRAIN
HOMOGENATE.
000124 01-03
COMPARTMENTATION OF CATECHOLAMINES IN RAT-BRAIN: EFFECTS OF
AGONISTS AND ANTAGONISTS.
000125 01-03
EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON
NEUROTRANSMinER ENZYMES IN RAT-BRAIN.
000134 01-03
EFFECTS OF MORPHINE AND OTHER CENTRALLY-ACTING DRUGS ON 3,4
DIHYDROXYPHENYLETHYLENE-GLYCOL-SULFATE (D0PEG-S04) IN RAT-
BRAIN.
000136 01-03
CHARACTERIZATION OF 3H GABA-RECEPTOR BINDING TO RAT-BRAIN
SYNAPTOSOMAL MEMBRANES: EFFECT OF NONGABAERGIC
COMPOUNDS.
000139 01-03
DIFFERENTIAL-EFFECTS OF N DIPROPYLACETATE AND AMINOOXYACETIC-
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS
OF RAT-BRAIN.
000140 01-03
DIMETHYLAMINOETHANOL (DEANOL) METABOLISM IN RAT-BRAIN AND
ITS EFFECT ON ACETYLCHOLINE SYNTHESIS.
000150 01-03
INHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN
CIRCUMVENTRICULAR STRUCTURES OF RAT-BRAIN.
000159 01-03
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS.
000171 01-03
3H PRAZOSIN BINDS SPECIFICALLY TO ALPHAl -ADRENOCEPTORS IN RAT-
BRAIN.
000205 01-03
INTERACTIONS OF OXYPERTINE WITH RAT-BRAIN MONOAMINE-
RECEPTORS.
000212 01-03
ACUTE AND CHRONIC EFFECTS OF NEUROLEPTICS AND ACUTE EFFECTS OF
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN.
000215 01-03
DECREASED SPIROPERIDOL AND LSD BINDING IN RAT-BRAIN AFTER
CONTINUOUS AMPHETAMINE.
000216 01-03
STEREOSPECIFIC NICOTINE-RECEPTORS ON RAT-BRAIN MEMBRANES.
000254 01-03
EFFECTS OF DES-TYR-GAMMA-ENDORPHIN ON DOPAMINE RELEASE FROM
VARIOUS RAT-BRAIN REGIONS IN VITRO.
000264 01-03
BIOCHEMICAL-PROPERTIES OF SPIPERONE BINDING TO RAT-BRAIN
MEMBRANES.
000294 01-03
EFFECTS OF CHRONIC DIETARY LITHIUM ON ACTIVITY AND REGULATION
OF NA-K-ADENOSINE-TRIPHOSPHATASE IN RAT-BRAIN.
000297 01-03
INTERACTION OF ANTIDEPRESSANTS WITH CLONIDINE ON RAT-BRAIN
TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL
000300 01-03
LITHIUM: EFFECTS ON SEROTONIN-RECEPTORS IN RAT-BRAIN.
000304 01-03
HALOTHANE EFFECT ON C-AMP GENERATION AND HYDROLYSIS IN RAT-
BRAIN.
000305 01-03
ACTION OF THE ANTIDEPRESSANT PRIDEFINE (AHR-1 1 18) ON BIOGENIC-
AMINES IN THE RAT-BRAIN.
000312 01-03
SELECTIVE STORAGE IN VIVO OF 5,6 ADTN IN DOPAMINE RICH AREAS OF
THE RAT-BRAIN.
000324 01-03
S-377
Subject Index
Psychopharmacology Abstracts ;<
a.
C,3:
I
THE EFFECTS OF MUSCARINIC-RECEPTOR BLOCKERS ON THE TURNOVER-
RATE OF ACETYLCHOLINE IN VARIOUS REGIONS OF THE RAT-BRAIN.
000328 01-03
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS.
000330 01-03
THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN
REGULATION OF NEUROSECRETION. (UNPUBLISHED PAPER).
001003 02-01
AN HPLC AND RIA ANALYSIS OF THE CHOLECYSTOKININ-PEPTIDES IN
RAT-BRAIN. (UNPUBLISHED PAPER).
001004 02-01
IN VITRO AUTORADIOGRAPHY OF OPIATE-RECEPTORS IN RAT-BRAIN
SUGGESTS LOCI OF OPIATE-ERGIC PATHWAYS. (UNPUBLISHED PAPER).
001025 02-01
BIOCHEMICAL-LOCALIZATION AND CHARACTERIZATION OF BOMBESIN-
LIKE-PEPTIDES IN DISCRETE REGIONS OF RAT-BRAIN. (UNPUBLISHED
PAPER).
001046 02-01
PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID-
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY
COMPLEX. (UNPUBLISHED PAPER).
001047 02-01
THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REACTION
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN.
001052 02-01
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES.
001078 02-02
THE EFFECT OF LITHIUM ON THE INCORPORATION OF 3H GLUCOSAMINE
INTO GLYCOPEPTIDES AND THE TRANSFORMATION OF 3H
GLUCOSAMINE INTO SIALIC-ACID IN RAT-BRAIN.
001209 02-03
THE EFFECT OF GABAMIMETICS ON NEUROTRANSMIHER-RECEPTOR
BINDING AND FUNCTION IN RAT-BRAIN. (PH.D. DISSERTATION).
001221 02-03
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
BRAIN.
001234 02-03
EFFECT OF 2 P CHLOROPHENYL-CYCLOPROPYLAMINE ON 5
HYDROXYINDOLE CONCENTRATION AND MONOAMINE-OXIDASE
ACTIVITY IN RAT-BRAIN.
001237 02-03
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN
FOLLOWING INTERAVENTRiCULAR INJEQION.
001239 02-03
ALPHA2-ADREN0CEPT0RS IN RAT-BRAIN: THE DIVALENT-CATION SITE.
001246 02-03
MULTIPLE RECEPTORS FOR SEROTONIN IN THE RAT-BRAIN.
001269 02-03
CHANGES IN ALPHA-ADRENERGIC-RECEPTORS IN RAT-BRAIN IN VITRO BY
PREINCUBATION WITH ALPHA-ADRENERGIC LIGANDS.
001272 02-03
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN
IN VIVO: EFFEQ OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS,
AND BENZODIAZEPINES.
001303 02-03
EVIDENCE FOR AN ENDOGENOUS COMPOUND INTERFERING WITH 3H
DIAZEPAM BINDING TO RAT-BRAIN MEMBRANES.
001308 02-03
DOPAMINE-RECEPTOR BLOCKADE IN RAT-BRAIN ARER ACUTE AND
SUBCHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANTS.
001314 02-03
ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE
IN RAT-BRAIN.
001320 02-03
EFFEa OF SINGLE AND REPEATED ELECTROCONVULSIVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN - I. METABOLIC-STUDIES.
001332 02-03
EFFECTS OF PRENATAL METHADONE ON RAT-BRAIN CATECHOLAMINES.
001367 02-03
CHARACTERIZATION AND RADIOAUTOGRAPHY OF (3H)LSD BINDING BY
RAT-BRAIN SLICES IN VITRO: THE EFFEQ OF 5 HYDROXYTRYPT AMINE.
001369 02-03
LOCAL CEREBRAL GLUCOSE UTILIZATION (LCGU) IN RAT-BRAIN DURING
HYPOXEMIA. (UNPUBLISHED PAPER).
001380 02-03
AaiVATION OF PRESYNAPTIC ALPHA NORADRENALINE-RECEPTORS IN
RAT-BRAIN BY THE POTENT DOPAMINE-MIMETIC N,N DIPROPYL-ADTN.
001390 02-03
INTERAQION OF HISTAMINE H2-RECEPT0R BLOCKING-DRUGS WITH THE
NORADRENERGIC SYSTEM IN RAT-BRAIN AND HEART.
001397 02-03
EFFEQ OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND
MORPHOLOGICAL-STUDY.
001407 02-03
RAT-BRAIN STEADY- STATE LEVELS OF CYCLIC-NUCLEOTIDES AS AN
ENDPOINT OF LSD-LIKE HALLUCINOGEN EFFEaS. (PH D.
DISSERTATION).
001426 02-03
MORPHINE ANALGESIA FOLLOWING ITS INFUSION INTO DIFFERENT
LIQUOR SPACES IN RAT-BRAIN.
001429 02-03
A HIGH-AFFINITY GTP BINDING-SITE IN RAT-BRAIN. (UNPUBLISHED
PAPER).
001442 02-03
DECREASE IN (3H) SEROTONIN BINDING IN RAT-BRAIN PRODUCED BY THE
REPEATED ADMINISTRATION OF EITHER MONOAMINE-OXIDASE-
INHIBITORS ON CENTRALLY-AQING SEROTONIN AGONISTS.
001463 02-03
EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC-
SYSTEMS IN THE RAT-BRAIN.
001464 02-03
EFFECT OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRAaiONS.
001472 02-03
TOXICITY OF OXYGEN IN IRON RICH AREAS OF RAT-BRAIN.
(UNPUBLISHED PAPER).
001498 02-03
HIGH-AFFINITY DOPAMINE-RECEPTORS (D3) IN RAT-BRAIN.
001509 02-03
AaiONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON
ACETYLCHOLINE TURNOVER IN RAT-BRAIN.
001541 02-03
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME ACTIVITY
IN THE RAT-BRAIN.
001614 02-04
BETA ENDORPHIN CAUSES RETROGRADE AMNESIA AND IS RELEASED
FROM THE RAT-BRAIN BY VARIOUS FORMS OF TRAINING AND
STIMULATION.
001664 02-04
EFFEQ OF SINGLE AND REPEATED ELECTROCONVULSIVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN - II. BEHAVIOURAL-STUDIES.
001697 02-04
EFFECT OF NICKEL ON THE LEVELS OF DOPAMINE, NORADRENALINE AND
SEROTONIN IN DIFFERENT REGIONS OF THE RAT-BRAIN.
001831 02-05
3H APOMORPHINE-RECEPTORS IN VARIOUS RAT-BRAIN REGIONS: A
STUDY OF SPECIFIC AND NONSPECIFIC BINDING AND THE INFLUENCE OF
CHRONIC NEUROLEPTIC TREATMENT.
001846 02-05
BINDING OF PHENCYCLIDINE TO RAT-BRAIN MEMBRANES: TECHNICAL-
ASPECT.
001882 02-06
EFFECT OF DOXEPIN ON SEROTONIN METABOLISM IN RAT-BRAIN AND
SEROTONIN UPTAKE BY HUMAN BLOOD-PLATELETS.
002243 02-13
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA
AND MEDIAL NUCLEUS-TRACTUS-SOLITARIUS OF RAT-BRAIN.
002634 03-01
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF
DISCRETE RAT-BRAIN NUCLEI.
002635 03-01
IDENTIFICATION AND QUANTIFICATION OF 1,2,3,4 TETRAHYDRO-BETA-
CARBOLINE, 2 METHYL-TETRAHYDRO-BETA-CARBOLINE, AND 6
METHOXY-TETRAHYDRO-BETA-CARBOLINE AS IN VIVO CONSTITUENTS
OF RAT-BRAIN AND ADRENAL-GLAND.
002636 03-01
EFFECTS OF ALBUMIN, AMINO-ACIDS, AND CLOFIBRATE ON THE UPTAKE
OF TRYPTOPHAN BY THE RAT-BRAIN.
002673 03-03
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN.
002727 03-03
ALPHA METHYLEPINEPHRINE, A METHYLDOPA METABOLITE THAT BINDS
TO ALPHA-RECEPTORS IN RAT-BRAIN.
002734 03-03
EFFECTS OF CHLORPROMAZINE ON DOPAMINERGIC-RECEPTOR FUNCTIONS
IN RAT-BRAIN - DIFFERENCE OF THE RESPONSE OF SEVERAL
DOPAMINERGIC-SYSTEMS AFTER CHRONIC ADMINISTRATION.
002773 03-03
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE
INJECTION IN NEWBORN ANIMALS.
002774 03-03
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS
INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJECTION OF
CYCLOHEXIMIDE.
002780 03-03
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT,
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL- 1 H-INDAZOLE (FS-32)
S-378
VOLUME 19, SUBJECT INDEX
Subject Index
AND ITS N OESMETHYLATED-COMPOUND (FS-97); TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
(3H)MIANSERIN: DIFFERENTIAL LABELING OF SEROTONIN AND
HISTAMINE-RECEPTORS IN RAT-BRAIN.
002860 03-03
INHIBITION OF GAMMA AMINOBUTYRIC-ACIO-TRANSAMINASE WITH 6
AMINONICOTINAMIDE IN REGIONS OF THE RAT-BRAIN.
002868 03-03
ACUTE ACTION OF NOMIFENSINE ON NOREPINEPHRINE AND DOPAMINE
LEVELS IN THE RAT-BRAIN.
002873 03-03
MULTIPLE EFFECTS OF REPEATED ADMINISTRATION OF GAMMA
ACETYLENIC-GABA ON RAT-BRAIN METABOLISM.
002878 03-03
3H SEROTONIN BINDING-SITES IN RAT-BRAIN: EFFECTS OF REPEATED
ADMINISTRATION OF ANTIDEPRESSANT-DRUGS, (PH.D.
DISSERTATION).
002881 03-03
THE METABOLISM OF 5 HYDROXYTRYPTAMINE IN THE METHIONINE-
SULFOXIMINE EPILEPTOGENIC RAT-BRAIN.
002887 03-03
EFFEQS OF ACUTELY AND CHRONICALLY ADMINISTERED
ANTIDEPRESSANTS ON THE CLONIDINE-INDUCED DECREASE IN RAT-
BRAIN 3 METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL-SULPHATE
CONTENT.
002908 03-03
DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYUNE
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC-
RECEPTORS.
002914 03-03
REGULATION BY CATIONS OF (3H)SPIR0PERID0L BINDING ASSOCIATED
WITH DOPAMINE-RECEPTORS OF RAT-BRAIN.
002922 03-03
INFLUENCE OF ESTROGEN AND PROGESTERONE ON GLUTAMIC-ACID-
DECARBOXYLASE ACTIVITY IN DISCRETE REGIONS OF RAT-BRAIN.
002927 03-03
INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN
SUBCELLULAR GANGLIOSIDES: EFFEQ OF PENTYLENETETRAZOL-
INOUCED CONVULSIONS IN BRAIN GANGLIOSIDES.
002937 03-03
NEUROTENSIN-RECEPTOR LOCALIZATION BY LIGHT MICROSCOPIC
AUTORADIOGRAPHY IN RAT-BRAIN.
002938 03-03
CORRELATION OF (MOMUSCIMOL CONCENTRATION IN RAT-BRAIN WITH
ANTICONVULSANT AQIVITY.
003045 03-04
A METHOD FOR MEASUREMENT OF TRANYLCYPROMINE IN RAT-BRAIN
REGIONS USING GAS-CHROMATOGRAPHY WITH ELECTRON CAPTURE
DETEQION.
003137 03-06
RELEASE OF ACETYLCHOLINE FROM RAT-BRAIN SYNAPTOSOMES
STIMULATED WITH LEPTINOTARSIN, A NEW NEUROTOXIN.
003148 03-06
REGIONAL AND SUBCELLULAR LOCALIZATION IN RAT-BRAIN OF THE
ENZYMES THAT CAN SYNTHESIZE GAMMA HYDROXYBUTYRIC-ACID.
003675 04-01
PURIFICATION AND SUBUNIT STRUCTURE OF DNA-DEPENDENT RNA-
POLYMERASE-BII FROM RAT-BRAIN NUCLEI.
003679 04-01
EFFEQ OF LOW-DOSE LITHIUM ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL ON BIOGENIC-AMINES IN RAT-BRAIN.
003708 04-03
MYOINOSITOL TURNOVER IN THE INTAQ RAT-BRAIN: INCREASED
PRODUaiON AFTER D-AMPHET AMINE.
003723 04-03
EFFEQ OF AMPHETAMINE ON THE METABOLISM AND INCORPORATION
OF (3H) THYMIDINE INTO DNA OF DEVELOPING RAT-BRAIN.
003729 04-03
AGE-DEPENDENT MODIFICATION OF DRUG INTERFERENCE ON THE
ENZYMATIC ACTIVITIES OF THE RAT-BRAIN.
003730 04-03
THE EFFEQS OF ANTIDEPRESSANTS ON THE RETENTION AND
METABOLISM OF (3H) NOREPINEPHRINE IN RAT-BRAIN SLICES.
003763 04-03
INHIBITION OF (3H)DIAZEPAM BINDING BY AN ENDOGENOUS FRACTION
FROM RAT-BRAIN SYNAPTOSOMES.
003768 04-03
HALOTHANE ACCUMULATION IN RAT-BRAIN AND LIVER.
003774 04-03
EFFECTS OF CONFORMATIONALLY RESTRAINED ANALOGUES OF
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN.
003794 04-03
COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON
DOPAMINE METABOLISM IN RAT-BRAIN.
003796 04-03
NEWLY SYNTHESIZED CHOLECYSTOKININ IN SUBCELLULAR FRACTIONS OF
THE RAT-BRAIN.
003805 04-03
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: KINETIC STUDIES.
003814 04-03
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: PHARMACOLOGICAL-STUDIES.
003815 04-03
(3H)METERG0LINE: A NEW LIGAND OF SEROTONIN-RECEPTORS IN THE
RAT-BRAIN.
003825 04-03
3H BACLOFEN AND 3H GABA BIND TO BICUCULLINE INSENSITIVE GABAB
SITES IN RAT-BRAIN.
003839 04-03
LONG-TERM EFFECTS OF MULTIPLE DOSES OF METHAMPHET AMINE ON
TRYPTOPHAN-HYDROXYLASE AND TYROSINE-HYDROXYLASE ACTIVITY
IN RAT-BRAIN.
003850 04-03
THE INTERACTION OF TRAZODONE WITH RAT-BRAIN MUSCARINIC-
CHOLINOCEPTORS.
003855 04-03
QUINUCLIDINYL BENZILATE BINDING IN HOUSEFLY HEADS AND RAT-
BRAIN.
003868 04-03
CHARACTERISTICS OF THE INHIBITION OF RAT-BRAIN MONOAMINE-
OXIDASE IN VITRO BY MD780515.
003874 04-03
DIFFERENTIAL-EFFECTS OF ELECTROCONVULSIVE-SHOCK AND
ANTIDEPRESSANT-DRUGS ON SER0T0NIN2-RECEPT0RS IN RAT-BRAIN.
003878 04-03
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN
REGIONS OF RAT-BRAIN WITH KETAMINE ANESTHESIA.
003891 04-03
RESERPINE EFFECT ON THE AXONAL TRANSPORT OF DOPAMINE-BETA-
HYDROXYLASE AND TYROSINE-HYDROXYLASE IN RAT-BRAIN.
003904 04-03
THE INFLUENCE OF D-AMPHETAMINE ON RAT-BRAIN STRIATAL REDUCED
BIOPTERIN CONCENTRATION.
003922 04-03
IN VIVO INTRANEURONAL MAO-INHIBITION IN RAT-BRAIN SKF-64139,
COMPARISON TO OTHER POTENT PNMT INHIBITORS.
003935 04-03
REGIONAL DISTRIBUTION OF (3H)IMIPRAMINE BINDING IN RAT-BRAIN.
003955 04-03
EFFECTS OF IN VIVO AMPHETAMINE ADMINISTRATION ON DOPAMINE
SYNTHESIS REGULATION IN RAT-BRAIN STRIATAL SYNAPTOSOMES.
(UNPUBLISHED PAPER).
003960 04-03
HIGH-AFFINITY BINDING-SITES FOR A SOMATOSTATIN-28 ANALOG IN
RAT-BRAIN.
003985 04-03
MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN:
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS.
003992 04-03
ALPHA2-ADREN0RECEPT0RS IN RAT-BRAIN ARE DECREASED AFTER
LONG-TERM TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT.
004008 04-03
DECREASE OF NORADRENALINE 0 METHYLATION IN RAT-BRAIN INDUCED
BY L-DOPA. REVERSAL EFFECT OF S ADENOSYL-L-METHIONINE.
004019 04-03
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN: CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
CHRONIC NEUROLEPTIC TREATMENT SPECIFICALLY ALTERS THE NUMBER
OF DOPAMINE-RECEPTORS IN RAT-BRAIN.
004033 04-03
THE EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND
ITS WITHDRAWAL ON GAMMA AMINOBUTYRIC-ACID-RECEPTOR
BINDING IN RAT-BRAIN.
004035 04-03
INHIBITION OF THE SYNTHESIS OF ACETYLCHOLINE IN RAT-BRAIN SLICES
BY (-) HYDROXYCITRATE AND CITRATE.
004044 04-03
DEVELOPMENTAL-CHANGE OF BETA-ADRENERGIC-RECEPTORS IN RAT-
BRAIN.
004050 04-03
A STUDY OF THE EFFECT OF NEUROPHARMACOLOGICAL DRUGS ON THE
FUNCTIONAL ACTIVITY OF RAT-BRAIN.
004107 04-04
EFFECT OF INORGANIC LEAD ON RAT-BRAIN MITOCHONDRIAL
RESPIRATION AND ENERGY PRODUCTION.
004267 04-05
PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW
METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES.
004286 04-06
SPECIFIC IN VIVO BINDING OF 77BR P BROMOSPIROPERIDOL IN RAT-
BRAIN: A POTENTIAL TOOL FOR GAMMA-RAY IMAGING.
004293 04-06
S-379
Subject index
Psychopharmacology Abstracts
all
«C
fir:
A SIMPLE DETERMINATION OF SEROTONIN, 5 HYDROXYINDOLEACETIC-
ACID AND 5 HYDROXYTRYPTOPHAN-DECARBOXYLASE ACTIVITY IN
RAT-BRAIN AREAS AND PARALLEL CORRELATION AMONG THE LEVELS.
00430) 04-06
RAT-BRAIN AND PLASMA NOREPINEPHRINE GLYCOL METABOLITES
DETERMINED BY GAS-CHROMATOGRAPHY MASS-
FRAGMENTOGRAPHY.
004303 04-06
RAT-BRAIN-CORTEX
ALPHA-ADRENOCEPTOR-MEDIATED MODULATION OF 5
HYDROXYTRYPT AMINE RELEASE FROM RAT-BRAIN-CORTEX SLICES.
000111 01-03
SEROTONIN-RECEPTOR MEDIATED MODULATION OF CA-DEPENDENT 5
HYDROXYTRYPTAMINE RELEASE FROM NEURONES OF THE RAT-BRAIN-
CORTEX.
001258 02-03
STIMULATORY EFFECT OF SOMATOSTATIN ON NOREPINEPHRINE RELEASE
FROM RAT-BRAIN-CORTEX SLICES.
002920 03-03
ELECTRICAL-ACTIVITY AND NA-K-ATPASE LEVEL IN THE PENICILLIN-
INDUCED EPILEPTOGENIC-FOCUS OF THE RAT-BRAIN-CORTEX, AND THE
EFFECT OF DIAZEPAM.
003070 03-04
RAT-CEREBELLUM
AGE-RELATED ELECTROPHYSIOLOGICAL CHANGES IN RAT-CEREBELLUM.
000197 01-03
DECREASED BENZODIAZEPINE-RECEPTOR DENSITY IN RAT CEREBELLUM
FOLLOWING NEUROTOXIC DOSES OF PHENYTOIN.
001373 02-03
MODULATION BY PICROTOXIN AND IPTBO OF 3H FLUNITRAZEPAM
BINDING TO THE GABA/BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-
CEREBELLUM.
002775 03-03
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM:
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON.
002884 03-03
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO
SYNAPTIC MEMBRANES.
004000 04-03
IN VITRO MODULATION BY AVERMEQIN-BIA OF THE GABA/
BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-CEREBELLUM.
004023 04-03
RAT-CEREBRAL-CORTEX
AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT-
CEREBRAL-CORTEX.
000072 01-03
THE EFFECT OF MORPHINE ON PURINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: EVIDENCE FOR A PURINERGIC
COMPONENT IN MORPHINES ACTION.
000234 01-03
MORPHINE ENHANCES ADENOSINE RELEASE FROM THE IN VIVO RAT-
CEREBRAL-CORTEX.
000451 01-04
DISPLACEMENT OF (3H)CL0NIDINE BINDING BY CLONIDINE ANALOGUES
IN MEMBRANES FROM RAT-CEREBRAL-CORTEX.
000536 01-06
DRUG INTERFERENCE ON SOME BIOCHEMICAL-PARAMETERS OF RAT-
CEREBRAL-CORTEX DURING POSTISCHEMIC RECOVERY.
001126 02-03
HIGH-AFFINITY BINDING OF (3H)MIANSERIN TO RAT-CEREBRAL-CORTEX.
001204 02-03
EFFECTS OF MALNUTRITION AND QUIPAZINE ON RAT-CEREBRAL-CORTEX
ATPASE ACTIVITY DURING DEVELOPMENT.
001276 02-03
EFFECTS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC
MECHANISM IN AQION OF DIAZEPAM.
001414 02-03
CALCIUM-SENSITIVE ACCUMULATION OF NOREPINEPHRINE IN RAT-
CEREBRAL-CORTEX.
002685 03-03
ENHANCEMENT OF NORADRENALINE RELEASE FROM RAT-CEREBRAL-
CORTEX BY NEUROLEPTIC-DRUGS.
002742 03-03
THE EFFEaS OF D-AMPHETAMINE AND POTASSIUM ON SEROTONIN
RELEASE AND METABOLISM IN RAT-CEREBRAL-CORTEX TISSUE.
002754 03-03
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS
CULTURED FROM RAT-CEREBRAL-CORTEX.
002820 03-03
SOMATOSTATIN FACILITATES THE SEROTONIN RELEASE FROM RAT-
CEREBRAL-CORTEX, HIPPOCAMPUS, AND HYPOTHALAMUS SLICES.
002913 03-03
CATECHOLAMINE TURNOVER IN RAT-CEREBRAL-CORTEX AND CAUDATE
FOLLOWING REPEATED TREATMENT WITH DIHYDROERGOTOXINE.
003765 04-03
REGULATION OF NORADRENALINE OVERFLOW IN RAT-CEREBRAL-CORTEX
BY PR0STAGLANDIN-E2.
003841 04-03
THE UPTAKE OF CARNITINE BY SLICES OF RAT-CEREBRAL-CORTEX.
003853 04-03
EFFEaS OF MORPHINE AND CAFFEINE ON ADENOSINE RELEASE FROM
RAT-CEREBRAL-CORTEX: IS CAFFEINE A MORPHINE ANTAGONIST.
003864 04-03
ALPHA 1 -ADRENOCEPTORS AND ALPHA2-ADREN0CEPT0RS IN RAT-
CEREBRAL-CORTEX: EFFEQ OF FRONTAL LOBOTOMY.
003944 04-03
EFFECTS OF ETHANOL ON ACETYLCHOLINE AND ADENOSINE EFFLUX FROM
THE IN VIVO RAT-CEREBRAL-CORTEX.
003969 04-03
RAT-CEREBRAL-CORTICAL
METERGOLINE ANTAGONISM OF 5 HYDROXYTRYPTAMINE-INDUCED
AaiVATION OF RAT-CEREBRAL-CORTICAL NA-K-ATPASE.
000329 01-03
ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES:
EFFECTS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE-
DEAMINASE INHIBITORS.
003950 04-03
THE EFFECT OF NORADRENALINE ON NA-K TRANSPORT IN RAT-CEREBRAL-
CORTICAL SLICES.
004056 04-03
RAT-CORTEX
THE EFFECT OF SODIUM-DIPROPYLACETATE ON GAMMA AMINOBUTYRIC-
ACID DEPENDENT INHIBITION IN THE RAT-CORTEX AND SUBSTANTIA-
NIGRA IN RELATION TO ITS ANTICONVULSANT AQIVITY.
003880 04-03
RAT-CORTICAL-NEURONES
LONG-TERM ADMINISTRATION OF ATROPINE, IMIPRAMINE, AND
VILOXAZINE ALTERS RESPONSIVENESS OF RAT-CORTICAL-NEURONES
TO ACETYLCHOLINE.
001306 02-03
RAT-FOREBRAIN
INCREASED MUSCARINIC-RECEPTOR BINDING IN RAT-FOREBRAIN AFTER
SCOPOLAMINE.
001351 02-03
EFFEaS OF HALOPERIDOL AND D-AMPHETAMINE ON IN VIVO 3H
SPIROPERIDOL BINDING IN THE RAT-FOREBRAIN.
001461 02-03
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES
002879 03-03
RAT-FRONTAL-CORTEX
DOPAMINE-RECEPTORS IN RAT-FRONTAL-CORTEX: PHARMACOLOGICAL-
PROPERTIES IN VIVO AND IN VITRO.
001112 02-03
SOLUBILIZATION OF SEROTONIN-RECEPTORS FROM RAT-FRONTAL-
CORTEX.
002489 02-16
RAT-MIDBRAIN
(3H) ACETYLCHOLINE AND (3H)5 HYDROXYTRYPTAMINE RELEASE FROM
RAT-MIDBRAIN SLICES AND THE EFFEaS OF CALCIUM AND
PHENOBARBITAL
000251 01-03
PERSISTENT EFFEQS OF CHRONIC ADMINISTRATION OF LSD ON
INTRACELLULAR SEROTONIN CONTENT IN RAT-MIDBRAIN.
001333 02-03
RAT-WHOLE-BRAIN
COMPARISON OF THE EFFEQS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
RATE
IMIPRAMINE AFFEQS AUTONOMIC-CONTROL OF SINOATRIAL RATE IN
ISOLATED RIGHT ATRIAL PREPARATIONS.
000195 01-03
EFFEaS OF RATE OF BLOOD FLOW ON FRAQIONAL EXTRA aiON AND ON
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN
VIVO.
001231 02-03
LONG-TERM APPLICATION" OF HALOPERIDOL: EFFEQ OF ANTICHOLINERGIC
TREATMENT ON THE RATE OF DOPAMINE SYNTHESIS.
001490 02-03
INTERAQIONS OF CHLORDIAZEPOXIDE AND ANORECTIC-AGENTS ON RATE
AND DURATION PARAMETERS OF FEEDING IN THE RAT.
001600 02-04
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS
ADMINISTRATIONS.
002797 03-03
TIME-COURSE OF CHRONIC HALOPERIDOL AND CLOZAPINE UPON
OPERANT RATE AND DURATION.
002989 03-04
S-380
VOLUME 19, SUBJECT INDEX
Subject Index
CHRONIC EFFECTS OF NEUROLEPTICS HAVING HIGH OR LOW INCIDENCE
OF EXTRAPYRAMIDAL SIDE-EFFECTS UPON FORCE, DURATION AND
RATE OF OPERANT-RESPONSE IN RATS. (PH.D. DISSERTATIONl
003125 Oj-Oj
A NOTE ON THE PARADOXICAL-EFFECT OF STIMULANTS ON
HYPERACTIVITY WITH REFERENCE TO THE RATE DEPENDENCY EFFECT
Of'^^^^S 003320 03-11
GLOMERULAR FILTRATION RATE AND CALCIUM METABOLISM IN LONG-
TERM LITHIUM TREATMENT. 003542 03-15
OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE
CONDITIONING IN RABBITS. 003798 04-03
CHLORPROMAZINE EFFECTS ON COCAINE-REINFORCED RESPONDING IN
RHESUS-MONKEYS: RECIPROCAL MODIFICATION OF RATE ALTERING
EFFECTS OF THE DRUGS. 004133 04-04
POTENTIATION OF THE MORPHINE-INDUCED RESPIRATORY RATE
DEPRESSION BY CAPTOPRIL. 004275 04-05
*^"p'lACEBO REAQION in NEUROTICS RATED WITH THE SCL-90
QUESTIONNAIRE. 000976 01-17
"^"o'xAZEPAM-ESTERS. 1. CORRELATION BETWEEN HYDROLYSIS RATES AND
BRAIN APPEARANCE OF OXAZEPAM. 000010 01-02
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL AQIVITY.
000314 01 -OJ
A COMPARISON OF THE EFFECTS OF D-AMPHET AMINE, COCAINE,
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE. 000508 01-04
RECIDIVISM AND REHABILITATION RATES FOR 135 CRIMINALLY-INSANE-
OFFENDERS. (D.ED. DISSERTATION) ^^^^ ^ ^ ^^^ ^
BLINK RATES AND RECEPTOR SUPERSENSITIVITY.
003022 03-04
DRUG-EFFEQ ON BLINK RATES IN RHESUS-MONKEYS: PRELIMINARY
STUDIES. „„„„o-, r.^ «.
003023 03-04
RATING
RATING OF ANTIDEPRESSANT AQIVITY.
002487 02-16
RATINGS
LONG-TERM CHANGES IN AIMS RATINGS AND THEIR RELATION TO
MEDICATION HISTORY. „„„.„ „, , c
003537 03-15
RATIONALISE
DEPRESSION: HOW TO RATIONALISE DRUG-THERAPY.
001988 02-09
RATIONALIZATION
STUDY OF METABOLISM AND BLOOD LEVELS OF ANTIDEPRESSANTS:
TOWARDS A RATIONALIZATION OF THEIR THERAPEUTIC USE,
002625 02-17
REACHING-BEHAVIOR
HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY
UNILATERAL 6 OHDA INJEQIONS INTO SUBSTANTIA-NIGRA AND
CAUDATE-NUCLEUS.
001778 02-04
REACTION
INHIBITION OF ALCOHOL-DEHYDROGENASE BY DISULFIRAM; POSSIBLE
RELATION TO THE DISULFIRAM ETHANOL REACTION.
000270 01-03
CUTANEOUS REACTION TO LITHIUM-CARBONATE: A CASE-REPORT.
000872 01-15
PLACEBO REAQION IN NEUROTICS RATED WITH THE SCL-90
QUESTIONNAIRE.
000976 01-17
THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REACTION
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN.
001052 02-01
SUBCELLULAR REAQION OF THE BRAIN TO HYPOXIA.
001354 02-03
EFFEQS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A
DELAYED TYPE HYPERSENSITIVITY REAQION TO 1
CHLORODINITROBENZENE IN MICE.
001473 02-03
THE EFFEQ OF NALOXONE ON THE ACTIVATION OF EMOTIONALLY
POSITIVE REAQION PRODUCED BY DRUGS WITH A DEPENDENCE
LIABILITY.
001556 02-03
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS, UNDER
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REACTION TYPE
(EMOTIVE AND NONEMOTIVE)
001624 02-04
OPIATE ANTAGONISTS AND LONG-TERM ANALGESIC REACTION INDUCED
BY INESCAPABLE SHOCK IN RATS.
001707 02-04
SELF-STIMULATION REACTION IN NORMOTENSIVE-RATS AND
HYPERTENSIVE-RATS. 002663 03-03
ABNORMAL TRANSMETHYLATION REACTION DURING THE METABOLISM
OF DOPAMINE TRYPTAMINE, AND SEROTONIN, AND SCHIZOPHRENIC-
SYMPTOMS: A CRITICAL REVIEW
003404 03-13
DYSTONIC REACTION DURING MAINTENANCE ANTIPSYCHOTIC THERAPY.
003485 03-15
EXTRAPYRAMIDAL REACTION OF FLUPHENAZINE POTENTIATED BY
THYROTOXICOSIS. „„„„,„, ,c
003551 03-15
REACTION-TIME
SEX-DIFFERENCES IN THE EFFECTS OF LOW-DOSES OF ETHANOL ON
HUMAN REACTION-TIME. „^^^^ , „. . .
002361 02-14
EFFECT OF LITHIUM ON REACTION-TIME - A STUDY OF DIURNAL
VARIATIONS. -,„. ,c
004607 04-15
EFFECT OF STRUCTURE ON PHENOTHIAZINE CATION RADICAL REACTIONS
IN AQUEOUS BUFFERS.
000014 01-02
RATS REACTIONS TO A PREDATOR: MODIFICATION BY
CHLORDIAZEPOXIDE.
000353 01-04
INTRAVENOUS PHENOBARBITAL THERAPY IN BARBITURATE AND OTHER
HYPNOSEDATIVE WITHDRAWAL REACTIONS: A KINETIC APPROACH.
000703 01-11
THE INFLUENCE OF NOOTROPIC-DRUGS ON LEARNING AND MEMORY OF
DEFENSE REACTIONS. „ , ^
000815 01-14
THE EFFECT OF PHRENOLON ON DELAYED REACTIONS IN LOWER
^°^^^^^- 001640 02-04
NEUROLEPTIC-INDUCED ACUTE DYSTONIC REACTIONS MAY BE DUE TO
ENHANCED DOPAMINE RELEASE ON TO SUPERSENSITIVE
POSTSYNAPTIC-RECEPTORS.
002789 03-03
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY
REACTIONS IN DOGS.
003030 03-04
AMPHETAMINE-LIKE REACTIONS TO PHENYLPROPANOLAMINE.
003480 03-15
VARIOUS FACTORS IN THE PATHOGENESIS OF PATHOLOGICAL REACTIONS
OBSERVED IN CONNECTION WITH THE ADMINISTRATION OF
PSYCHOTROPIC-DRUGS. „„.,.. „o , c
003532 03-15
THE ROLE OF OPIATE-RECEPTORS OF DIFFERENT BRAIN REGIONS IN
DETERMINING THE EMOTIONAL REACTIONS OF RATS.
004017 04-03
THE EFFECT OF THIOPROPERAZINE ON DELAYED REAQIONS IN LOWER
'^°^^^^^- 004125 04-04
ON SOME RELATIONSHIPS BETWEEN GABAERGIC AND 5 HT-ERGIC
MECHANISMS IN PENTYLENETETRAZOL CONVULSIVE-SEIZURE
REACTIONS. ^^,,,,r..r..
004166 04-04
THE ROLE OF RETICULOSEPTAL INPUTS IN THE FORMATION OF DIFFERENT
TYPES OF SENSORY REACTIONS OF THE HIPPOCAMPaL NEURONS.
004510 04-13
REVERSIBLE RING-OPENING REACTIONS OF NIMETAZEPAM AND
NITRAZEPAM IN ACIDIC MEDIA AT BODY-TEMPERATURE.
004517 04-13
REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE-
NUCLEOTIDES AND ADENOSINE.
000210 01-03
IN UTERO ALCOHOL HEIGHTENS JUVENILE REACTIVITY.
000510 01-05
ASSESSMENT OF MULTIVARIATE RELATIONSHIPS IN REACTIVITY OF
PATIENTS RECEIVING LITHIUM THERAPY.
000819 01-14
CENTRAL SYMPATHETIC REACTIVITY INHIBITED BY INDORAMIN.
001193 02-03
THE USE OF BROMOCRIPTINE FOR TESTING CENTRAL DOPAMINERGIC
^^^^^'"'^ 002205 02-13
SENSORY PROCESSING, CARDIOVASCULAR REACTIVITY, AND THE TYPE A
CORONARY-PRONE BEHAVIOR PATTERN.
003405 03-13
S-381
Subject Index
Ptychopharmacology Abstracts
tx.
"lit
5
^
METHAQUALONE RIA STRUQURE VERSUS REAaiVITY.
003657 04-01
RIA OPIATES: STRUCTURE VERSUS REACTIVITY.
003659 04-01
READING
EFFECTS OF METHYLPHENIDATE ON LEARNING A BEGINNING READING
VOCABULARY BY NORMAL ADULTS.
000812 01-14
READING-DISABLED
EFFECTS OF METHYLPHENIDATE ON SELECTIVE AND SUSTAINED
AHENTION IN HYPERACTIVE, READING-DISABLED. AND PRESUMABLY
AnENTION-DISORDERED BOYS.
002118 02-11
REAGENT
CARBAMAZEPINE-EPOXIDE DETERMINED BY EMIT CARBAMAZEPINE
REAGENT.
000533 01-06
REALITY
THE STIMULANT-EFFECT OF NEUROLEPTICS: MYTH OR REALITY?
000362 01-04
CONTRIBUTION TO STUDY OF CEREBRAL DOPAMINERGIC MECHANISMS:
REALITY OF THE PROBLEM.
000782 01-13
ROniNG WITH THEIR RIGHTS ON: CONSTITUTIONAL THEORY AND
CLINICAL REALITY IN DRUG-REFUSAL BY PSYCHIATRIC-PATIENTS.
000911 01-17
REARING
EFFECTS OF CHOLECYSTOKININ-LIKE PEPTIDES ON REARING AQIVITY AND
HEXOBARBITAL-INDUCED SLEEP.
000507 01-04
DEVELOPMENTAL-CHANGE IN REARING RESPONSE TO ATROPINE IN RATS
TREATED WITH 6 HYDROXYDOPA.
004191 04-04
REASONABLE
THE RIGHTS OF INVOLUNTARY-PATIENTS TO REFUSE
PHARMACOTHERAPY: WHAT IS REASONABLE?
004730 04-17
REASONABLE-DOUBT
VOLUNTARY INTOXICATION FROM PHENCYCLIDINE. WILL IT RAISE A
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL-
STATE?.
000914 01-17
REASSESSMENT
BENZODIAZEPINES IN SCHIZOPHRENIA: A NEED FOR REASSESSMENT.
004733 04-17
REBOUND
CAFFEINE PRODUCES REM SLEEP REBOUND IN RATS.
000244 01-03
CHOLINERGIC REBOUND IN NEUROLEPTIC WITHDRAWAL-SYNDROMES.
003506 03-15
RECEPTOR
EVIDENCE FOR A RECEPTOR SUPERSENSITIVITY FOLLOWING IMPAIRMENT
OF CENTRAL SEROTONERGIC ACTIVITY IN THE RABBIT.
000041 01-03
RELATIONSHIP OF ANTICONFLICT AQIVITY OF BENZODIAZEPINES TO
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA.
000057 01-03
AFFINITY CHROMATOGRAPHY OF THE BETA-ADRENERGIC-RECEPTOR AND
CHARACTERIZATION. OF ANTIBODIES RAISED AGAINST PURIFIED
RECEPTOR PREPARATIONS.
001009 02-01
BETA ENDORPHIN: DISSOCIATION OF RECEPTOR BINDING-AQIVITY FROM
ANALGESIC POTENCY.
001081 02-02
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST,
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND RECEPTOR BINDING-
AQIVITIES FOLLOWING ACUTE AND CHRONIC NEUROLEPTIC-DRUG
TREATMENT. (UNPUBLISHED PAPER).
001172 02-03
RECEPTOR PLASTICITY: BIOCHEMICAL-CORRELATES AND
PHARMACOLOGICAL SIGNIFICANCE.
001181 02-03
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER).
001188 02-03
THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND
DOPAMINE ANTAGONIST RECEPTOR SITES.
001254 02-03
OPIATES AND SPECIFIC RECEPTOR BINDING OF (3H)CL0NIDINE.
001256 02-03
MULTIPLE CNS RECEPTOR INTERAaiONS OF ERGOT ALKALOIDS: AFFINITY
AND INTRINSIC AQIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS.
001516 02-03
(3H) PHENCYCLIDINE BINDING TO SPECIFIC BRAIN RECEPTOR SITES.
001555 02-03
DISPOSITION AND AQIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY.
001878 02-06
METOCLOPRAMIDE: ANTIPSYCHOTIC-EFFICACY OF A DRUG LACKING
POTENCY IN RECEPTOR MODELS.
001948 02-08
PURSUING THE AQIONS OF PSYCHOTROPIC-DRUGS: RECEPTOR SITES
AND ENDOGENOUS CEREBRAL PROGRAMMES.
002578 02-17
RECEPTOR BINDING PROFILE OF R-41-468, A NOVEL ANTAGONIST AT 5
HT2-RECEPT0RS.
002648 03-02
EFFECT OF KAINIC-ACID LESIONS ON MUSCARINIC AGONIST RECEPTOR
SUBTYPES IN RAT STRIATUM.
002679 03-03
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE
AGONIST AND ANTAGONIST RECEPTOR INTERAQIONS.
002688 03-03
TWO DISTINQ SEROTONIN-RECEPTORS: REGIONAL VARIATIONS IN
RECEPTOR BINDING IN MAMMALIAN BRAIN.
002861 03-03
DISCRIMINATION OF FUNQIONALLY HETEROGENEOUS RECEPTOR
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC
PROPERTIES OF METOCLOPRAMIDE.
002877 03-03
DRUG REGIMENS FACILITATING AGGRESSION: BEHAVIOR, AMINE, AND
RECEPTOR ALTERATIONS.
002987 03-04
BLINK RATES AND RECEPTOR SUPERSENSITIVITY.
003022 03-04
ELECTROPHYSIOLOGIC ASSESSMENT OF RECEPTOR CHANGES FOLLOWING
CHRONIC DRUG-TREATMENT.
003136 03-06
RECEPTOR ADAPTATIONS TO CENTRALLY AQING DRUGS.
003585 03-17
STRUQURE-AQIVITY AND RECEPTOR BINDING OF ANTAGONIST
ANALGESICS.
003611 03-17
EFFEQS OF 3', 4' DIHYDROXYNOMIFENSINE ON THE DOPAMINE
VASCULAR RECEPTOR.
003890 04-03
EFFECT OF PRENATAL NEUROLEPTIC TREATMENT ON MEMBRANE
RECEPTOR DEVELOPMENT IN THE BRAIN.
003989 04-03
RECEPTOR TECHNIQUES IN THE STUDY OF PLASMA LEVELS OF
NEUROLEPTICS AND ANTIDEPRESSANT-DRUGS.
004694 04-16
RECEPTOR-MEDIATED
AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT-
CEREBRAL-CORTEX.
000072 01-03
PHOSPHOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR-
MEDIATED INDUCTION OF CHEMOTAXIS IN RABBIT NEUTROPHILS.
(UNPUBLISHED PAPER).
001118 02-03
MINI-SYMPOSIUM. IV. DISCRIMINATIVE-STIMULUS EFFECTS OF
NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS.
004719 04-17
RECEPTORS
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS.
(XX)308 01-03
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
RECEPTORS.
00Q323 01-03
MULTIPLE RECEPTORS FOR SEROTONIN IN THE RAT-BRAIN.
001269 02-03
FURTHER EVIDENCE FOR THE EXISTENCE OF MULTIPLE RECEPTORS FOR
DOPAMINE IN THE CENTRAL-NERVOUS-SYSTEM.
001296 02-03
DETECTION OF MULTIPLE RECEPTORS FOR DOPAMINE.
001481 02-03
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN
SCHIZOPHRENIA.
002390 02-15
THE NEUROLATHYROGEN, BETA N OXALYL-L-ALPHA-BETA-
DIAMINOPROPIONIC-ACID, IS A POTENT AGONIST AT GLUTAMATE
PREFERRING RECEPTORiJN THE FROG SPINAL-CORD.
^ 002858 03-03
S-382
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF ANTIDEPRESSANT-ORUGS ON DIFFERENT RECEPTORS IN THE
BRAIN.
003824 04-03
EVIDENCE FOR SEDATIVE EFFECTS OF LOW-DOSES OF MORPHINE IN MICE
INVOLVING RECEPTORS INSENSITIVE TO NALOXONE.
004173 04-04
RECENT STUDIES ON INTERACTION BETWEEN OPIOID-PEPTIDES AND THEIR
RECEPTORS.
004300 04-06
RECEPTORS, ADENYLATE-CYCLASE, DEPRESSION, AND LITHIUM.
004353 04-09
RECHALLENOE
INAPPROPRIATE ADH SECRETION: THE ROLE OF DRUG RECHALLENGE.
002629 02-17
RECIDIVISM
RECIDIVISM AND REHABILITATION RATES FOR 135 CRIMINALLY-INSANE-
OFFENDERS. (D.ED. DISSERTATION).
002514 02-17
REOPIENT
PIRACETAM ACTIVITY MAY DIFFER ACCORDING TO THE AGE OF THE
RECIPIENT MOUSE.
003705 04-02
KECIRCULATION
DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT
METABOLISM, DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND
CHOLERETIC-EFFECT.
000073 01-03
RECLASSIFICATION
RECLASSIFICATION OF THE TARDIVE-DYSKINESIA SYNDROME.
002374 02-15
RECOGNITION
GABA-MODULIN REGULATES SOLUBILIZED BENZODIAZEPINE AND GABA
RECOGNITION SITES. (UNPUBLISHED PAPER),
001263 02-03
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME
BENZODIAZEPINE RECOGNITION SITES ARE COUPLED TO GABA-
RECEPTORS AND lONOPHORES.
001484 02-03
TARDIVE-DYSKINESIA: RECOGNITION, MANAGEMENT, AND PREVENTION.
002392 02-15
THE REGULATION OF BENZODIAZEPINE RECOGNITION SITES BY
ENDOGENOUS MODULATORS.
002642 03-01
BENZODIAZEPINE RECOGNITION SITES ON GABA-RECEPTORS.
002730 03-03
RECONCEPTUALIZED
ANXIETY RECONCEPTUALIZED.
000951 01-17
RECORDING
THE IN VITRO BRAIN SLICE AS A USEFUL NEUROPHYSIOLOGICAL
PREPARATION FOR INTRACELLULAR RECORDING.
001864 02-06
RECORDINGS
COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPLIED TO DRUG
EVALUATION: MIDAZOLAM IN NORMAL SUBJECTS.
004564 04-14
RECOVERING
EFFECTS OF CYCLOSPASMOL UPON SENSORY PARAMETERS IN PATIENTS
RECOVERING FROM CEREBROVASCULAR-ACCIDENTS.
002360 02-14
RECOVERY
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL ACTIVITY.
000314 01-03
FACILITATION OF RECOVERY BY PROPANTHELINE-BROMIDE AFTER
LATERAL HYPOTHALAMIC DAMAGE.
000396 01-04
DRUG INTERFERENCE ON SOME BIOCHEMICAL-PARAMETERS OF RAT-
CEREBRAL-CORTEX DURING POSTISCHEMIC RECOVERY.
001126 02-03
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFEQ
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE.
001353 02-03
CHANGES IN PREVALENCE, SEVERITY, AND RECOVERY IN TARDIVE-
DYSKINESIA WITH AGE.
002455 02-15
OPIATE ANTAGONIST IMPROVES NEUROLOGIC RECOVERY AFTER SPINAL
INJURY.
002714 03-03
BRIEF COMMUNICATION: BEHAVIORAL RECOVERY AFTER TOLUENE
EXPOSURE IN RATS.
002969 03-04
CORTICAL RECOVERY FROM EFFECTS OF MONOCULAR DEPRIVATION:
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6
HYDROXYDOPAMINE.
003024 03-04
TARDIVE-DYSKINESIA: TWO-YEAR RECOVERY.
003535 03-15
RECRUITING
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS
004022 04-03
RECTUS-ABDOMINIS
THE EFFECTS OF SUBSTITUTED BENZAMIDES ON FROG RECTUS-
ABDOMINIS.
001228 02-03
RECURRENCE
RAPID RECURRENCE OF MANIA FOLLOWING LITHIUM WITHDRAWAL.
002010 02-09
RECURRENCES
THE RELATIVE PROPHYLACTIC EFFICACY OF LITHIUM AGAINST MANIC
AND DEPRESSIVE RECURRENCES IN BIPOLAR-PATIENTS.
002040 02-09
RECURRENT
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME. PART 2:
PROPHYLAXIS OF RECURRENT DEPRESSIVE-ILLNESS.
002043 02-09
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFECTIVE-DISORDERS
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDICTORS TO
CLINICAL-RESPONSE).
004365 04-09
RECYCLES
5' TRIPHOSPHATE RECYCLES INDEPENDENTLY OF ACETYLCHOLINE IN
CHOLINERGIC SYNAPTIC VESICLES.
004063 04-03
RED-BLOOD-CELL
PHENOTHIAZINE PLASMA AND RED-BLOOD-CELL CONCENTRATIONS, THEIR
RELATIONSHIP TO SIDE-EFFECTS AND CLINICAL-EFFICACY.
002386 02-15
MECHANISM OF LITHIUM INCLUDED ELEVATION IN RED-BLOOD-CELL
CHOLINE CONTENT: AN IN VITRO ANALYSIS.
004511 04-13
REO-BLOOD-CELLS
LITHIUM LEVELS IN BLOOD-PLATELETS, SERUM, RED-BLOOD-CELLS AND
BRAIN REGIONS IN RATS GIVEN ACUTE OR CHRONIC LITHIUM-SALT
TREATMENTS.
000082 01-03
THE EFFLUX OF LITHIUM FROM RED-BLOOD-CELLS AND THE EFFEQ OF
LITHIUM PROPHYLAXIS.
000630 01-09
MEASUREMENT OF FLUPHENAZINE BY GAS-CHROMATOGRAPHY IN
HUMAN PLASMA AND RED-BLOOD-CELLS.
002491 02-16
REDERGINE
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT.
003703 04-02
REDOX
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN.
000295 01-03
REDUCER
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE.
002305 02-13
REDUCING
PROCEDURES FOR REDUCING DRUG INTAKE: NONHUMAN STUDIES.
001753 02-04
COMPARISON OF ANXIETY REDUCING SUBSTANCES. (PH.D.
DISSERTATION).
003278 03-10
REDUCTION
REDUCTION OF GAMMA AMINOBUTYRIC-ACID-MEDIATED (GABA)
TRANSMISSION BY A CONVULSANT BENZODIAZEPINE.
000015 01-02
REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS.
000066 01-03
REDUCTION OF FETAL RAT SPINAL-CORD VOLUME FOLLOWING
MATERNAL MORPHINE INJECTION.
000161 01-03
REDUCTION OF VOLUNTARY MORPHINE CONSUMPTION FOLLOWING
TREATMENT WITH ZIMELIDINE.
000253 01-03
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS.
000258 01-03
REDUCTION OF FOOD INTAKE BY PIRIBEDIL IN THE RAT: RELATION TO
DOPAMINE-RECEPTOR STIMULATION.
000355 01-04
S-383
Subject Index
Psychopharmacology Abstracts
til,,
"lit
."!»:
5
ft:
g
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN
FOLLOWING INTERAVENTRICULAR INJECTION.
001239 02-03
VESTIBULO-OCULAR REFLEXES IN RABBITS: REDUCTION BY INTRAVENOUS
INJECTION OF DIAZEPAM.
001566 02-04
AN INTERFERENCE REDUCTION THEORY OF THE EFFECTS OF ETHANOL ON
CONFLICT-BEHAVIOR.
001586 02-04
REDUCTION OF DOPAMINERGIC-SUPERSENSITIVITY BY A SINGLE-DOSE OF
AMPHETAMINE.
001642 02-04
SELECTIVE REDUCTION BY DEXAMETHASONE OF STRESS REUTED
HYPERPHAGIAS.
001703 02-04
REDUCTION OF BARBITURATE ANESTHESIA BY NEW GLUTARIMIDE
COMPOUNDS IN MICE.
001748 02-04
ADRENERGIC REGULATION OF THE REDUCTION IN ACETYL-COENZYME-
A:ARYLAMINE-N-ACETYLTRANSfERASE IN THE RAT PINEAL.
002654 03-03
EFFECTS OF ANXIETY REDUCTION BY BEHAVIOURAL-TECHNIQUES AND
MEPROBAMATE ON CERTAIN PARAMETERS OF INFORMATION THEORY
003108 03-04
REDUCTION IN THE LEVEL OF IMMUNOTITRATABLE DOPAMINE-BETA-
HYDROXYLASE AFTER CHRONIC ADMINISTRATION OF L-DOPA OR
ALPHA METHYLDOPA.
003764 04-03
REDUCTION IN OPIATE ACTIVATION AFTER CHRONIC
ELECTROCONVULSIVE-SHOCK - POSSIBLE ROLE FOR ENDORPHINS IN
THE BEHAVIORAL-EFFECTS OF CONVULSIVE-SHOCK-TREATMENT.
(UNPUBLISHED PAPER).
004154 04-04
REEVALUATION
A REEVALUATION OF THE MECHANISMS UNDERLYING SIMPLE CELL
ORIENTATION SELECTIVITY.
002894 03-03
A REEVALUATION OF THE NEUROCHEMICAL-EFFECTS AND
ANTINOCICEPTIVE-EFFECTS OF INTRATHECAL CAPSAICIN IN THE RAT.
004184 04-04
REEXAMINATION
A REEXAMINATION OF THE CLINICAL-EFFECTS OF IMIPRAMINE AND
AMITRIPTYLINE IN DEPRESSIVE-ILLNESS.
000579 01-09
REFLEX
THE INFLUENCE OF BENZOCTAMINE ON DOPAMINE AND NOREPINEPHRINE
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH
REFLEX OF THE CAT.
000054 01-03
ATTEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED
SPINAL FEMALE RATS WITH MONOAMINE AGONISTS.
000421 01-04
A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY
PRODUCED BY OPIATE ANALGESICS.
000425 01-04
EVIDENCE SUGGESTING A TRANSMIHER OR NEUROMODULATORY ROLE
FOR SUBSTANCE-P AT THE FIRST SYNAPSE OF THE BARORECEPTOR
REFLEX.
001264 02-03
NONSEROTONERGIC DEPRESSION OF SPINAL MONOSYNAPTIC REFLEX
TRANSMISSION BY 5 HYDROXYTRYPTOPHAN.
002745 03-03
CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL
ALERTING.
002997 03-04
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS.
003027 03-04
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND
LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJECTS.
003311 03-11
EFFECTS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC-
ACID, HALOPERIDOL AND PIMOZIDE ON REFLEX BRADYCARDIA IN
RATS.
004085 04-04
EFFECTS OF ANALGESICS AND CNS-ACTING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS.
004148 04-04
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK
REFLEX; MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO.
004544 04-13
REFLEX-INDUCED
MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS.
003744 04-03
REFLEXES
EFFECT OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND
RIGIDITY: A QUANTITATIVE STUDY OF REFLEXES AND PLASMA
CONCENTRATIONS.
000701 01-11
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE
CAT. (PH.D. DISSERTATION).
001179 02-03
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON
BARORECEPTOR REFLEXES IN CONSCIOUS CATS.
001514 02-03
VESTIBULO-OCULAR REFLEXES IN RABBITS: REDUCTION BY INTRAVENOUS
INJECTION OF DIAZEPAM.
001566 02-04
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH
ANTIDEPRESSANTS
001620 02-04
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED
REFLEXES IN RATS.
003100 03-04
CANNABINOID-INDUCED ENHANCEMENT AND DEPRESSION OF CAT
MONOSYNAPTIC REFLEXES
004040 04-03
POSSIBLE MUSCARINIC CHOLINERGIC MEDIATION OF PAHERNED
AGGRESSIVE REFLEXES IN THE CAT.
004153 04-04
THE EFFECT OF THE NEW ANTIDEPRESSANT INKASAN ON THE
BIOELECTRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED
REFLEXES.
004212 04-04
REFORMULATION
A REFORMULATION OF THE DUAL-AQION MODEL OF OPIOID
DEPENDENCE: OPIOID-SPECIFIC NEURONAL KINDLING.
003645 03-17
REFRACTORY
INTENSIVE MONITORING IN REFRAaORY EPILEPSY
003378 03-11
MOBILIZATION OF REFRACTORY CHRONIC SCHIZOPHRENICS WITH
HALOPERIDOL.
004337 04-08
REFUSE
THE RIGHTS OF INVOLUNTARY-PATIENTS TO REFUSE
PHARMACOTHERAPY: WHAT IS REASONABLE?
004730 04-17
REGARD
LONG-TERM-TREATMENT WITH NEUROLEPTIC-AGENTS: ADAPTATION
PHENOMENA AND THEIR SIGNIFICANCE WITH REGARD TO
SCHIZOPHRENIC-SYMPTOMATOLOGY AND SIDE-EFFEaS.
002370 02-15
PRELIMINARY-FINDINGS WITH REGARD TO RISK-FAQORS IN THE
DEVELOPMENT OF TARDIVE-DYSKINESIA.
003501 03-15
REGIME
THERAPEUTIC-EFFICACY OF DOXEPIN IN DIVIDED AND SINGLE-DOSE
REGIME.
003259 03-09
SUSTAINED DECREASE IN FAT CONSUMPTION PRODUCED BY
AMPHETAMINE IN RATS MAINTAINED ON A DIETARY SELF-SELEQION
REGIME.
004150 04-04
REGIMEN
ANTIPSYCHOTIC-EFFEa OF PROPRANOLOL ON CHRONIC
SCHIZOPHRENICS: STUDY OF A GRADUAL TREATMENT REGIMEN.
001915 02-08
POLYPHARMACY REGIMEN AS AN EXACERBATING RISK IN THERAPY-
RESISTANT EPILEPTIC-SEIZURES AND BEHAVIORAL-DISORDERS.
004720 04-17
REGIMENS
DRUG REGIMENS FACILITATING AGGRESSION: BEHAVIOR, AMINE, AND
RECEPTOR ALTERATIONS.
002987 03-04
REGISTRATION
PSYCHOTROPIC-DRUG REGISTRATION IN THE SCANDINAVIAN-COUNTRIES:
THE ROLE OF CLINICAL-TRIALS.
002550 02-17
REGRESSION
NONLINEAR REGRESSION ANALYSIS OF NOREPINEPHRINE RESPONSE
KINETICS IN CEREBRAL VASCULATURE.
000256 01-03
REGULATION
REGULATION OF STRIATAL ACETYLCHOLINE CONCENTRATION BY D2
DOPAMINE-RECEPTORS.
000269 01-03
DIFFERENTIAL REGULATION OF MUSCARINIC AGONIST BINDING-SITES
FOLLOWING CHRONIC CHOLINESTERASE INHIBITION.
000279 01-03
S-384
VOLUME 19, SUBJECT INDEX
Subject Index
REGULATION OF THE STATE OF PHOSPHORYLATION OF SPECIFIC
NEURONAL PROTEINS IN MOUSE-BRAIN BY IN VIVO ADMINISTRATION
OF ANESTHETIC AND CONVULSANT-AGENTS.
000291 01-03
EFFECTS OF CHRONIC DIETARY LITHIUM ON ACTIVITY AND REGULATION
OF NA-K-ADENOSINE-TRIPHOSPHATASE IN RAT-BRAIN
000297 01-03
THE LONG-TERM REGULATION OF GANGLIONIC TYROSINE-HYDROXYLASE
BY PREGANGLIONIC NERVE ACTIVITY.
000333 01-03
DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: A
PITUITARY MODEL FOR THE STUDY OF A NEUROENDOCRINE SYSTEM IN
MAN
000776 01-13
THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN
REGULATION OF NEUROSECRETION. (UNPUBLISHED PAPER).
001003 02-01
DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION, AND REGULATION.
001011 02-01
THE REGULATION OF GABA-RECEPTORS AS A POSSIBLE MECHANISM FOR
GABA 1,4 BENZODIAZEPINE INTERACTIONS. (UNPUBLISHED PAPER),
001012 02-01
REGULATION OF ACETYLCHOLINE RELEASE DURING INCREASED NEURONAL
ACTIVITY. (UNPUBLISHED PAPER).
001061 02-01
INTERACTIONS OF NEUROPEPTIDES WITH CHOLINERGIC
SEPTOHIPPOCAMPAL PATHWAY: INDICATION FOR A POSSIBLE
TRANSSYNAPTIC REGULATION. (UNPUBLISHED PAPER).
001062 02-01
OPIOID MECHANISMS IN REGULATION OF CEREBRAL MONOAMINES IN
VIVO.
001098 02-03
INFLUENCE OF NARCOTIC-AGENTS ON TEMPERATURE REGULATION.
001108 02-03
REGULATION OF HIPPOCAMPAL GLUTAMATE-RECEPTORS: EVIDENCE FOR
THE INVOLVEMENT OF A CALCIUM-ACTIVATED PROTEASE.
001120 02-03
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
REGULATION OF CHOLINERGIC TRANSMISSION IN ADRENAL-MEDULLA.
(UNPUBLISHED PAPER).
001182 02-03
REGULATION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS.
001262 02-03
DOWN REGULATION OF DIHYDROALPRENOLOL AND IMIPRAMINE
BINDING-SITES IN BRAIN OF RATS REPEATEDLY TREATED WITH
IMIPRAMINE.
001317 02-03
REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA-INDEPENDENT
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6-
GLIOMA CELLS. (UNPUBLISHED PAPER).
001403 02-03
THE REGULATION OF CARDIAC MUSCARINIC CHOLINERGIC-RECEPTORS BY
ISOPROTERENOL.
001441 02-03
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELECTIVE
5 HT UPTAKE INHIBITOR.
001517 02-03
A STUDY OF A GLIAL GAMMA AMINOBUTYRIC-ACID SYSTEM: ITS
REGULATION, FUNQION AND THE EFFECTS OF DIAZEPAM. (PH.D.
DISSERTATION).
001524 02-03
CHRONIC NEUROLEPTIC TREATMENT AND DOPAMINE-RECEPTOR
REGULATION.
001837 02-05
CORTICAL-CORRELATES OF VIGILANCE REGULATION AND THEIR USE IN
EVALUATING THE EFFECTS OF TREATMENT.
002147 02-11
ABNORMAL REGULATION OF PROLACTIN RELEASE IN IDIOPATHIC
PARKINSONS-DISEASE.
002255 02-13
THE HYPOTHALAMIC DOPAMINERGIC REGULATION OF PROLACTIN: A
MODEL FOR THE STUDY OF NEUROHORMONAL MECHANISMS IN MAN.
002568 02-17
REGULATION OF NEUROTRANSMISSION THROUGH PRESYNAPTIC-
RECEPTORS AND OTHER MECHANISMS: POSSIBLE CLINICAL RELEVANCE
AND THERAPEUTIC POTENTIAL.
002569 02-16
THE REGULATION OF BENZODIAZEPINE RECOGNITION SITES BY
ENDOGENOUS MODULATORS.
002642 03-01
ADRENERGIC REGULATION OF THE REDUCTION IN ACETYL-COENZYME-
A:ARYLAMINE-N-ACETYLTRANSFERASE IN THE RAT PINEAL.
002654 03-03
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE
AGONIST AND ANTAGONIST RECEPTOR INTERACTIONS
002688 03-03
PRESYNAPTIC REGULATION OF THE RELEASE OF CATECHOLAMINES IN THE
CAT HYPOTHALAMUS
002703 03-03
ANTERIOR PITUITARY GABA-RECEPTORS AND THEIR REGULATION OF
PROUCTIN SECRETION.
002738 03-03
BETA-ADRENERGIC-RECEPTOR SUBTYPES: PROPERTIES, DISTRIBUTION,
AND REGULATION.
002829 03-03
REGULATION BY CATIONS OF (3H)SPIR0PERID0L BINDING ASSOCIATED
WITH DOPAMINE-RECEPTORS OF RAT-BRAIN.
002922 03-03
THE DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION AND REGULATION
003660 04-01
ROLE OF ADRENERGIC BLOCKING-AGENTS AND GLUCOCORTICOIDS ON
THE REGULATION OF PITUITARY OPIOID-PEPTIDES LEVELS.
003801 04-03
REGULATION OF ALPHA 1 -ADRENOCEPTORS IN THE CEREBRAL-CORTEX OF
THE RAT BY THYROID-HORMONES.
003816 04-03
REGULATION OF BIOGENESIS OF PSYCHOTOMIMETIC AMINES.
(UNPUBLISHED PAPER).
003818 04-03
CATECHOLAMINE SYNTHESIS REGULATION IN HYPOTHALAMIC
SYNAPTOSOMES. (UNPUBLISHED PAPER).
003829 04-03
REGULATION OF NORADRENALINE OVERFLOW IN RAT-CEREBRAL-CORTEX
BY PR0STAGLANDIN-E2.
003841 04-03
PRESYNAPTIC REGULATION OF THE RELEASE OF ACETYLCHOLINE BY 5
HYDROXYTRYPTAMINE.
003843 04-03
EFFECTS OF IN VIVO AMPHETAMINE ADMINISTRATION ON DOPAMINE
SYNTHESIS REGULATION IN RAT-BRAIN STRIATAL SYNAPTOSOMES.
(UNPUBLISHED PAPER).
003960 04-03
REGULATION OF SER0T0NIN2-RECEPT0RS (5 HT2) LABELED WITH
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT AMITRIPTYLINE.
003964 04-03
MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN:
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS.
003992 04-03
CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF
(3H)SULPIRIDE AND {3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS.
004032 04-03
PHARMACOLOGICAL REGULATION OF CALMODULIN.
004052 04-03
GENOTYPIC INFLUENCES ON STRIATAL DOPAMINERGIC REGULATION IN
MICE.
004217 04-04
DOWN REGULATION OF NORADRENERGIC-RECEPTOR FUNCTION BY
ANTIDEPRESSANT-DRUGS: FUNCTIONAL SIGNIFICANCE AND
DISTINCTION FROM ANTIPSYCHOTIC-DRUGS. (UNPUBLISHED PAPER).
004746 04-17
REGULATORY
GLUCOCORTICOIDS AS A REGULATORY FACTOR FOR BRAIN TRYPTOPHAN-
HYDROXYLASE DURING DEVELOPMENT.
001500 02-03
REHABILITATION
THE RATIONAL USE OF MUSCLE-RELAXANTS IN REHABILITATION
MEDICINE.
000943 01-17
THE ASSOCIATION OF RETARD NEUROLEPTICS TO OTHER NEUROLEPTICS
IN THE REHABILITATION OF PSYCHOTIC-PATIENTS.
002108 02-11
RECIDIVISM AND REHABILITATION RATES FOR 135 CRIMINALLY-INSANE-
OFFENDERS. (D.ED. DISSERTATION).
002514 02-17
REINFORCEMENT
DIFFERENTIAL-EFFECTS OF METHYLPHENIDATE ON SIGNALLED AND
NONSIGNALLED REINFORCEMENT.
000380 01-04
EXTINCTION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMITTENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL
EQUIVALENCE.
000490 01-04
THE EFFECTS OF PIPRADROL ON THE ACQUISITION OF RESPONDING WITH
CONDITIONED REINFORCEMENT: A ROLE FOR SENSORY
PRECONDITIONING.
001572 02-04
THE RELATIONSHIP BETWEEN POSITIVE REINFORCEMENT AND
CONDITIONED TASTE-AVERSION PRODUCED BY SELF-ADMINISTERED
DRUGS. (PH.D. DISSERTATION).
001798 02-04
S-385
Subject Index
Psychophormacoiogy Abstracts
ijp;
11'''
if
Si
6'
^
I
PIMOZIDE AHENUATES LEVER-PRESSING FOR WATER REINFORCEMENT IN
RATS.
003000 03-04
REINFORCER
BEHAVIORAL-EFFECTS OF DRUGS: THE ROLE OF THE STIMULUS
REINFORCER CONTINGENCY. (PH.D. DISSERTATION).
001537 02-03
REINFORCING
REINFORCING, DISCRIMINATIVE AND ACTIVATING PROPERTIES OF
AMPHETAMINE.
000804 01-14
DOUBLE-BLIND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS.
002314 02-14
SUBJECTIVE DRUG-EFFECTS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFEaS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
REINNERVATiON
REINNERVATION OF THE DENERVATED STRIATUM BY SUBSTANTIA-NIGRA
TRANSPLANTS: FUNCTIONAL CONSEQUENCES AS REVEALED BY
PHARMACOLOGICAL AND SENSORIMOTOR TESTING.
000347 01-04
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL-
NERVOUS-SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE-
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS).
002459 02-15
RELAPSE
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDICT RATS: A POSSIBLE MODEL FOR PREDIQING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION).
003097 03-04
LOW SERUM PROLAQIN AND EARLY RELAPSE FOLLOWING NEUROLEPTIC
WITHDRAWAL.
003166 03-08
THE EFFEaS OF A DRUG-HOLIDAY ON RELAPSE AND TARDIVE-
DYSKINESIA IN CHRONIC-SCHIZOPHRENICS.
003487 03-15
RELAPSE AFTER SHORT-TERM DRUG-THERAPY IN NEUROTIC-
OUTPATIENTS.
004400 04-09
RELAPSE-STUDIES
USE OF SURVIVAL CURVES IN ANALYSIS OF ANTIPSYCHOTIC RELAPSE-
STUDIES.
002481 02-16
RELAPSES
UNWANTED EFFEQS OF LITHIUM-CARBONATE USED IN THE PREVENTION
OF RELAPSES OF AFFEQIVE-ILLNESS.
004625 04-15
RELEASE
SUPPRESSION OF EVOKED AND SPONTANEOUS RELEASE OF
NEUROTRANSMinERS IN VIVO BY MORPHINE.
000058 01-03
EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE
RELEASE.
000067 01-03
RELEASE OF ENDOGENOUS NOREPINEPHRINE FROM A RABBIT CEREBRAL-
ARTERY.
000079 01-03
ALPHA-ADRENOCEPTOR-MEDIATEO MODULATION OF 5
HYDROXYTRYPTAMINE RELEASE FROM RAT-BRAIN-CORTEX SLICES.
000111 01-03
GABA INHIBITION OF 3H GLYCINE RELEASE FROM SLICES OF RAT
SUBSTANTIA-NIGRA IN VITRO.
000157 01-03
NALOXONE PROMOTES STIMULUS-EVOKED VASOPRESSIN RELEASE IN
VIVO.
000165 01-03
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFEQS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
THE EFFEQ OF MORPHINE ON PURINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: EVIDENCE FOR A PURINERGIC
COMPONENT IN MORPHINES AQION.
000234 01-03
RELEASE OF GONADOTROPIN-RELEASING-HORMONE BY VERATRINE IN A
HYPOTHALAMIC PITUITARY COINCUBATION.
000237 01-03
(3H)ACETYLCH0LINE AND (3H)5 HYDROXYTRYPTAMINE RELEASE FROM
RAT-MIDBRAIN SLICES AND THE EFFEaS OF CALCIUM AND
PHENOBARBITAL.
000251 01-03
THE POSSIBILITY THAT A COMPONENT OF MORPHINE-INDUCED
ANALGESIA IS CONTRIBUTED INDIREQLY VIA THE RELEASE OF
ENDOGENOUS OPIOIDS.
000263 01-03
EFFEQS OF DES-TYR-GAMMA-ENDORPHIN ON DOPAMINE RELEASE FROM
VARIOUS RAT-BRAIN REGIONS IN VITRO.
000264 01-03
THE EFFEQ OF DELTA9 TETRAHYDROCANNABINOL ON THE POSITIVE AND
NEGATIVE FEEDBACK CONTROL OF LUTEINIZING-HORMONE RELEASE.
000286 01-03
IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR
ACTIVITY.
000289 01-03
TYROSINE ADMINISTRATION REDUCES BLOOD-PRESSURE AND ENHANCES
BRAIN NOREPINEPHRINE RELEASE IN SPONTANEOUSLY HYPERTENSIVE-
RATS.
000296 01-03
EFFEQS OF MORPHINE AND NALOXONE ON PHASIC RELEASE OF
LUTEINIZING-HORMONE AND FOLLICLE-STIMULATING-HORMONE
(40849).
000298 01-03
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
RECEPTORS.
000323 01-03
MORPHINE ENHANCES ADENOSINE RELEASE FROM THE IN VIVO RAT-
CEREBRAL-CORTEX.
000451 01-04
DIFFERENTIAL-EFFEQS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS
000480 01-04
GROWTH-HORMONE (GH) RELEASE FOLLOWING THYROTROPIN-
RELEASING-HORMONE (TRH) INJEQION IN MANIC-PATIENTS
RECEIVING LITHIUM-CARBONATE.
000645 01-09
THE RELEASE OF CATECHOLAMINES FROM ADRENERGIC NEURONS.
000974 01-17
RELEASE OF ARACHIDONIC-ACID FROM ADRENAL CHROMAFFIN CELL-
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED
PAPER).
001027 02-01
REGUIATION OF ACETYLCHOLINE RELEASE DURING INCREASED NEURONAL
ACTIVITY. (UNPUBLISHED PAPER).
001061 02-01
EFFECTS OF GABA AND DIAZEPAM ON 3H SEROTONIN RELEASE FROM
HIPPOCAMPAL SYNAPTOSOMES.
001116 02-03
DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN
FRAGMENTS OF MALE AND FEMALE RATS.
001121 02-03
FAQORS INFLUENCING THE RELEASE OF LABEUED GAMMA
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELECTRICAL-
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL
SLICES.
001130 02-03
NORADRENALINE RELEASE FROM SLICES OF THE THALAMUS OF NORMAL
AND MORPHINE-DEPENDENT RATS.
001142 02-03
BIOSYNTHESIS, AXONAL TRANSPORT AND RELEASE OF POSTERIOR
PITUITARY-HORMONES (UNPUBLISHED PAPER).
001148 02-03
PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN
VITRO. INHIBITION BY MELATONIN AT SUBMICROMOLAR
CONCENTRATIONS.
001159 02-03
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER)
001188 02-03
EFFECT OF AMINOOXY ACETIC-ACID AND BICUCULLINE ON PROLACTIN
RELEASE IN CASTRATED MALE RATS.
001194 02-03
INHIBITION OF ACH RELEASE BY PROSTAGLANDIN-E 1 IN THE RABBIT
SUPERIOR-CERVICAL-GANGLION .
001205 02-03
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES.
001207 02-03
CALMODULIN RELEASE FROM STRIATAL MEMBRANES AFTER ACUTE AND
CHRONIC TREATMENT WITH BUTACLAMOL.
001249 02-03
SEROTONIN-RECEPTOR MEDIATED MODULATION OF CA -DEPENDENT 5
HYDROXYTRYPTAMINE RELEASE FROM NEURONES OF THE RAT-BRAIN-
CORTEX.
001258 02-03
INHIBITORY ACTION OF MORPHINE ON THE RELEASE OF A BRADYKININ-
LIKE SUBSTANCE AFTER SCIATIC-NERVE STIMULATION.
001293 02-03
S-386
VOLUME 19, SUBJECT INDEX
Subject Index
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT
CAUDATE-NUCLEUS
001298 02-03
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN
IN VIVO: EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS,
AND BENZODIAZEPINES.
001303 02-03
EVIDENCE THAT VASOPRESSIN IS INVOLVED IN THE ISOPRENALINE-
INDUCED BETA ENDORPHIN RELEASE.
001319 02-03
ASCORBIC-ACID, AN ENDOGENOUS FACTOR REQUIRED FOR
ACETYLCHOLINE RELEASE FROM THE SYNAPTIC VESICLES.
001322 02-03
DRUG-INDUCED RELEASE OF DOPAMINE FROM CORPUS-STRIATUM.
(PH.D. DISSERTATION).
001343 02-03
EFFECTS OF HALOPEMIDE ON POTASSIUM-INDUCED RELEASE OF
RADIOLABELED NEUROTRANSMIHERS FROM RAT CEREBROCORTICAL
SLICES IN VITRO.
001347 02-03
A NOVEL GABA-RECEPTOR MODULATES STIMULUS-INDUCED GLUTAMATE
RELEASE FROM CORTICOSTRIATAL TERMINALS.
001376 02-03
EFFECTS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC
MECHANISM IN ACTION OF DIAZEPAM.
001414 02-03
EFFECT OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRACTI0NS.
001472 02-03
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN
THE DOG.
001547 02-03
AN AUTOMATED ELECTROCHEMICAL-METHOD FOR IN VIVO MONITORING
OF CATECHOLAMINE RELEASE.
001873 02-06
STUDIES ON GABA RELEASE IN VIVO USING A SIMPLE METHOD FOR
PERFUSION OF THE FOURTH VENTRICLE OF THE RAT.
001881 02-06
PLATELET AGGREGATION, 5 HYDROXYTRYPTAMINE UPTAKE AND
RELEASE IN HUNTINGTONS-CHOREA.
002112 02-11
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE.
002242 02-13
ABNORMAL REGULATION OF PROLACTIN RELEASE IN IDIOPATHIC
PARKINSONS-DISEASE.
002255 02-13
EVIDENCE THAT IT IS POSSIBLE TO CAUSE ANOREXIA BY INCREASING
RELEASE AND/OR DIREQLY STIMULATING POSTSYNAPTIC SEROTONIN-
RECEPTORS IN THE BRAIN.
002602 02-17
SEX-DIFFERENCES IN THE AMPHETAMINE STIMULATED RELEASE OF
CATECHOLAMINES FROM RAT STRIATAL TISSUE IN VITRO.
002668 03-03
GABAERGIC MECHANISMS IN THE CONTROL OF PRL AND GH RELEASE.
002690 03-03
EFFEQ OF TENTANUS TOXIN ON TRANSMIHER RELEASE FROM THE
SUBSTANTIA-NIGRA AND STRIATUM IN VITRO.
002691 03-03
PRESYNAPTIC REGULATION OF THE RELEASE OF CATECHOLAMINES IN THE
CAT HYPOTHALAMUS.
002703 03-03
METHYLPHENIDATE-LIKE STIMULANTS IN VITRO RELEASE
(3H)TYRAMINES BUT NOT (14C)D0PAMINE.
002706 03-03
INHIBITION OF VASOPRESSIN RELEASE TO CAROTID OCCLUSION BY
GAMMA AMINOBUTYRIC-ACID AND GLYCINE.
002715 03-03
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
ENHANCEMENT OF NORADRENALINE RELEASE FROM RAT-CEREBRAL-
CORTEX BY NEUROLEPTIC-DRUGS.
002742 03-03
MODULATION BY ENDOGENOUS DOPAMINE OF THE RELEASE OF
ACETYLCHOLINE IN THE CAUDATE-NUCLEUS OF THE RABBIT.
002751 03-03
THE EFFECTS OF D-AMPHET AMINE AND POTASSIUM ON SEROTONIN
RELEASE AND METABOLISM IN RAT-CEREBRAL-CORTEX TISSUE.
002754 03-03
NEUROLEPTIC-INDUCED ACUTE DYSTONIC REACTIONS MAY BE DUE TO
ENHANCED DOPAMINE RELEASE ON TO SUPERSENSITIVE
POSTSYNAPTIC-RECEPTORS.
002789 03-03
THE DIRECT EFFECT OF RESERPINE IN VITRO ON PROLACTIN RELEASE
FROM RAT ANTERIOR PITUITARY-GLANDS.
002810 03-03
ACTIONS OF TREMORGENIC FUNGAL TOXINS ON NEUROTRANSMITTER
RELEASE.
002843 03-03
THE EFFECT OF COLCHICINE AND CYTOCHALASIN B ON THE RELEASE OF
TAURINE FROM THE CHICK RETINA.
002856 03-03
GABA AND BACLOFEN POTENTIATE THE K -EVOKED RELEASE OF
METHIONINE-ENKEPHALIN FROM RAT STRIATAL SLICES.
002882 03-03
ACTIONS OF BETA BUNGAROTOXIN ON AMINO-ACID TRANSMIHER
RELEASE.
002897 03-03
METHYLXANTHINES MODULATE ADENOSINE RELEASE FROM SLICES OF
CEREBRAL-CORTEX.
002907 03-03
SOMATOSTATIN FACILITATES THE SEROTONIN RELEASE FROM RAT-
CEREBRAL-CORTEX, HIPPOCAMPUS, AND HYPOTHAUMUS SLICES.
002913 03-03
STIMULATORY EFFECT OF SOMATOSTATIN ON NOREPINEPHRINE RELEASE
FROM RAT-BRAIN-CORTEX SLICES.
002920 03-03
BIPHASIC-EFFECTS AND OPPOSITE-EFFECTS OF DOPAMINE AND
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT
SUBSTANTIA-NIGRA.
002923 03-03
MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND
UPTAKE OF NEUROTRANSMITTERS IN BRAIN SLICES.
003147 03-06
RELEASE OF ACETYLCHOLINE FROM RAT-BRAIN SYNAPTOSOMES
STIMULATED WITH LEPTINOTARSIN, A NEW NEUROTOXIN,
003148 03-06
VASOPRESSIN STIMULATES RELEASE OF BETA LIPOTROPIN AND BETA
ENDORPHIN IN CONSCIOUS RATS AS MEASURED BY
RADIOIMMUNOASSAY OF UNEXTRACTED PLASMA.
003715 04-03
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS.
003731 04-03
METERGOLINE AND CYPROHEPTADINE SUPPRESS PROLACTIN RELEASE BY
A NON-5-HYDROXYTRYPTAMINERGIC, NONDOPAMINERGIC
MECHANISM.
003732 04-03
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS:
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO.
003741 04-03
GABA-ENHANCEMENT OF (3H)D0PAMINE RELEASE FROM SLICES OF RAT
STRIATUM: DEPENDENCE ON SLICE SIZE.
003786 04-03
ROLE OF THE ANTERIOR PITUITARY GABA-RECEPTOR IN THE CONTROL OF
PROLACTIN RELEASE.
003809 04-03
OXOTREMORINE DOES NOT ENHANCE ACETYLCHOLINE RELEASE FROM
RAT DIAPHRAGM PREPARATIONS.
003819 04-03
PHARMACOLOGIC MANIPULATION OF BRAIN AND PITUITARY ENDORPHIN
CONTENT AND RELEASE.
003837 04-03
PRESYNAPTIC REGULATION OF THE RELEASE OF ACETYLCHOLINE BY 5
HYDROXYTRYPTAMINE.
003843 04-03
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM
INTERMEDIATE/POSTERIOR LOBES OF PITUITARY.
003846 04-03
INVESTIGATION OF ACTION OF ENKEPHALIN ON THE SPONTANEOUS AND
EVOKED RELEASE OF ACETYLCHOLINE FROM RAT CORTICAL AND
STRIATAL SLICES.
003862 04-03
ACTION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
EFFECTS OF MORPHINE AND CAFFEINE ON ADENOSINE RELEASE FROM
RAT-CEREBRAL-CORTEX: IS CAFFEINE A MORPHINE ANTAGONIST.
003864 04-03
BACLOFEN: STEREOSELECTIVE INHIBITION OF EXCITANT AMINO-ACID
RELEASE.
003867 04-03
CHARACTERIZATION OF ENKEPHALIN RELEASE FROM RAT STRIATUM.
003909 04-03
EFFECTS OF HALOPEMIDE ON GABA-RECEPTOR BINDING, UPTAKE AND
RELEASE.
003913 04-03
S-387
Subject Index
Psychopharmacology Abttracti;
if
tji,
Si
iiiiif
•sitll
a,;
5
^
NEUROTENSIN RELEASE BY RAT HYPOTHALAMIC FRAGMENTS IN VITRO.
003920 04-03
THE EFFECT OF ACETYLCHOLINE RELEASE ON CHOLINE FLUXES IN
ISOLATED SYNAPTIC TERMINALS.
003924 04-03
INFLUENCE OF CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5
HYDROXYTRYPTAMINE, TYRAMINE AND POTASSIUM FROM GOAT
PIAL-ARTERIES.
003925 04-03
CORRELATIONS BETWEEN NA-K-ATPASE AQIVITY AND ACETYLCHOLINE
RELEASE IN RAT CORTICAL SYNAPTOSOMES.
003937 04-03
THE NA-K-ATPASE: A PLAUSIBLE TRIGGER FOR VOLTAGE-INDEPENDENT
RELEASE OF CYTOPLASMIC NEUROTRANSMITTERS.
003953 04-03
HYPOTENSION ALTERS THE RELEASE OF CATECHOUMINES IN THE
HYPOTHALAMUS OF THE CONSCIOUS RABBIT.
003968 04-03
EFFECTS OF CANNABINOIDS ON CATECHOLAMINE UPTAKE AND RELEASE
IN HYPOTHALAMIC AND STRIATAL SYNAPTOSOMES.
003970 04-03
STUDIES ON THE MECHANISM-OF-ACTION OF AVERMECTIN-BIA:
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM
BRAIN SYNAPTOSOMES.
003973 04-03
EFFECT OF PR0STA6LANDIN-D2, PR0STAGLANDIN-E2 AND
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES
OF RAT AND RABBIT BRAIN.
003983 04-03
IN VIVO EVIDENCE FOR GABAERGIC CONTROL OF SEROTONIN RELEASE IN
THE CAT SUBSTANTIA-NIGRA.
00401 1 04-03
DIFFERENT EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS ON THE RELEASE OF TSH, PROLAQIN, AND
GROWTH-HORMONE AFTER ADMINISTRATION OF THYROSTIMULATING-
RELEASING-HORMONE IN MANIC-DEPRESSIVES.
004407 04-09
RELEASING
A CONSTITUENT OF KHAT-LEAVES WITH AMPHETAMINE-LIKE RELEASING
PROPERTIES.
001307 02-03
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFEQS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN.
002990 03-04
PROLAQIN RELEASING POTENCIES OF ANTIPSYCHOTIC AND RELATED
NONANTIPSYCHOTIC COMPOUNDS IN FEMALE RATS: RELATION TO
CLINICAL POTENCIES.
003830 04-03
RELEASING-AGENTS
DIFFERENTIAL-EFFECTS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND
RELEASING-AGENTS ON LOCOMOTOR-AQIVITY IN NORMAL AND IN
RESERPINIZED MICE.
004130 04-04
RELIEF
RELIEF OF PAIN IN CLINICAL-PRAQICE.
003613 03-17
REM
CAFFEINE PRODUCES REM SLEEP REBOUND IN RATS.
000244 01-03
iMIPRAMINE AND REM SLEEP: CHOLINERGIC MEDIATION IN ANIMALS
000406 01-04
INTRAVENOUS CHLORIMIPRAMINE AFFEQS REM CYCLE IN PATIENTS
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJEQS.
002341 02-14
INDIVIDUAL VARIATIONS IN THE EFFECTS OF FLURAZEPAM,
CLORAZEPATE, L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON
REM SLEEP IN MAN.
002349 02-14
PHENOXYBENZAMINE AND BROMOCRIPTINE AHENUATE NEED FOR REM
SLEEP IN RATS.
004203 04-04
CHANGES OF RESPONSE TO DOPAMINERGIC DRUGS IN RATS SUBMIHED
TO REM SLEEP DEPRIVATION.
004239 04-04
REMISSION
LONG-TERM CONTROLLED-COMPARISON OF INJECTION OXYPROTHEPIN
AND FLUPHENAZINE-DECANOATES IN PSYCHOTICS IN REMISSION.
001949 02-08
RENAL
RENAL FUNCTION AND BIOPSY IN PATIENTS ON LITHIUM THERAPY.
000830 01-15
RENAL FUNCTION IN LITHIUM AND NONLITHIUM TREATED PATIENTS
WITH AFFECTIVE-DISORDERS.
000837 01-15
ANTAGONISM OF THE RENAL VASODILATOR AQIVITY OF DOPAMINE BY
METOCLOPRAMIDE.
001265 02-03
STUDIES ON THE EFFECT OF ALPHA MELANOCYTE-STIMULATING-
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P
AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED
PAPER).
001372 02-02
RENAL BENZODIAZEPINE BINDING INCREASES DURING . ^
DEOXYCORTICOSTERONE /SALT HYPERTENSION IN RATS. '
001430 02-03
INCREASED RENAL NEUROLEPTIC BINDING IN SPONTANEOUSLY
HYPERTENSIVE-RATS.
001444 02-03
ANTIDEPRESSIVES IN RENAL FAILURE.
002284 02-13
LITHIUM AND RENAL FUNQION.
002416 02-15
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING:
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN
HYPERTENSION.
002874 03-03
RENAL IMPAIRMENT, HYPERCALCEMIA, AND LITHIUM THERAPY.
003473 03-15;
RENAL SIDE-EFFEQS OF LITHIUM: THE IMPORTANCE OF THE SERUM
LITHIUM LEVEL.
003547 03-15'
EFFEQS OF INDOMETHACIN AND METHYLPREDNISOLONE ON RENAL
ELIMINATION OF LITHIUM IN THE RAT.
004270 04-05
RENAL-DISEASE
METHADONE USE IN PATIENTS WITH CHRONIC RENAL-DISEASE.
004467 04-11
DRUGS AND RENAL-DISEASE.
004645 04-15
RENIN
RENIN AND ALDOSTERONE SECRETIONS DURING HYPOVOLEMIA IN RATS:
RELATION TO NACL INTAKE.
000484 01-04
REO-EG
EEG, COMP-EEG, REO-EG AND PHARMACOLOGICAL-CORRELATES OF
GERIATRICS.
002162 02-11
REPETITIVE
EFFEQ OF AMITRIPTYLINE ANTIDOTES ON REPETITIVE EXTRASYSTOLE
THESHOLD.
001856 02-05
EFFEaS OF ANALGESICS AND CNS-AQING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR 1
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS.
004148 04-04
REPLACEMENT
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-AQIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
ACTIVITY.
000309 01-03
REPLICABIUTY
THE REPLICABIUTY OF THE PSYCHOPHYSIOLOGICAL-EFFEQS OF
DIAZEPAM.
003413 03-13
REPLICATION
DELTA9 THC IN PIGEONS: A REPLICATION AND EXTENSION.
000394 01-04
AHENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNQION) IN
ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG-
TREATMENT.
003389 03-11
MMPI PREDiaiON OF IMIPRAMINE RESPONSE: A REPLICATION STUDY.
003570 03-16
REPRESENTATION
PSYCHIATRIC-MOVEMENTS AND PSYCHOPHARMACOLOGY: BETWEEN I
AFFEQ AND REPRESENTATION.
003604 03-17
REPRESSION
LITHIUM-PUMP REPRESSION AS AN INDICATOR OF PROPHYLAQIC
RESPONSE.
001989 02-09
THE REPRESSION OF THE LITHIUM-PUMP AS AN INDICATOR OF RESPONSE
TO PROPHYLAQIC TREATMENT.
003221 03-09
REPRODUCTION
LITHIUM, ASSIMILATION OF NUTRIENTS AND REPRODUQION.
(UNPUBLISHED PAPER).
002777 03-03
REPRODUCTIVE
CHRONIC-TREATMENT WITH VALIUM (DIAZEPAM) FAILS TO AFFEQ THE
REPRODUaiVE SYSTEM OF THE MALE RAT.
001535 02-03
INFLUENCE OF CANNABIS AND DELTA9 TETRAHYDROCANNABINOL ON
THE BIOCHEMISTRY OF THE MALE REPRODUQIVE ORGANS.
002686 03-03
S-388
VOLUME 19, SUBJECT INDEX
Subject Index
VASOTOCIN, PROSTAGLANDIN, AND FEMALE REPRODUCTIVE BEHAVIOR
IN THE FROG, RANA-PIPIENS.
002978 03-04
lESEARCN
A PSYCHOLOGICAL-VIEW ON PROBLEMS AND CONCEPTS OF LITHIUM
RESEARCH.
000810 01-14
MARIJUANA: A REVIEW OF MEDICAL RESEARCH WITH IMPLICATIONS
FOR ADOLESCENTS.
000871 01-15
TARDIVE-DYSKINESIA: RESEARCH 8, TREATMENT.
000934 01-17
DEPRESSION IN THE ELDERLY: RESEARCH DIRECTIONS IN
PSYCHOPATHOLOGY, EPIDEMIOLOGY, AND TREATMENT.
000998 01-17
CYCLIC-NUCLEOTIDES AND THE CENTRAL-EFFECTS OF OPIATES: AN
OVERVIEW OF CURRENT RESEARCH.
001445 02-03
THE LONG-TERM TREATMENT WITH BENZODIAZEPINES: SUGGESTIONS
FOR FURTHER RESEARCH.
002085 02-10
SELF-MEOICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS.
002189 02-11
NEUROPEPTIDE TREATMENT OF SOCIOPATHY: RESEARCH IN PROGRESS.
002369 02-14
THE RESEARCH FOR NEW ANTIDEPRESSANTS: PRESENT ORIENTATIONS.
002543 02-17
PSYCHOPHARMACOLOGY - AN AREA OF RESEARCH TO IMPROVE
MENTAL-HEALTH CARE.
002586 02-17
REVIEW AND OVERVIEW OF FOUR DECADES OF OPIATE RESEARCH.
002627 02-17
A RESEARCH PARADIGM TO INVESTIGATE THE EFFEQ OF MANIPULATION
ON SOCIAL-BEHAVIOR IN GROUPS.
003007 03-04
RESEARCH STRATEGIES FOR ASSESSING THE EFFECTS OF
METHYLMERCURY ON BEHAVIOR.
003128 03-05
2 AMINO-4-PHOSPHONOBUTYRIC-ACID: A NEW PHARMACOLOGICAL
TOOL FOR RETINA RESEARCH.
003145 03-06
ENDORPHIN RESEARCH IN SCHIZOPHRENIC-PSYCHOSES.
003200 03-08
METHODOLOGY OF OUTPATIENT DRUG RESEARCH. (UNPUBLISHED
PAPER).
003282 03-10
PHARMACOLOGICAL-STUDIES OF TARDIVE-DYSKINESIA: IMPLICATIONS
FOR FUTURE RESEARCH.
003465 03-15
SECOND-GENERATION ANTIDEPRESSANTS: A CLINICAL
PHARAAACOTHERAPEUTIC RESEARCH STRATEGY.
003632 03-17
OPIATE MECHANISMS: EVALUATION OF RESEARCH INVOLVING
NEURONAL AQION POTENTIALS.
003886 04-03
ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN ATTENTION-
DYSFUNQION TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA
004316 04-08
TREATMENT OF DEPRESSION WITH AN MAO-INHIBITOR FOLLOWED BY 5
HTP - AN UNFINISHED RESEARCH PROJECT.
004377 04-09
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT TARDIVE-
DYSKINESIA. AND THE TRAINING OF RESEARCH PSYCHIATRISTS.
004603 04-15
NEW BIOLOGICAL RESEARCH RELEVANT TO ANXIETY.
004705 04-17
lESERPINE
AAATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. III. DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOUTED SYNAPTIC VESICLES.
000025 01-03
ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE
AND DESMETHYLIMIPRAMINE.
000113 01-03
EFFEQS OF RESERPINE, PROPRANOLOL, AND AMINOPHYLLINE ON
SEIZURE AQIVITY AND CNS CYCLIC-NUCLEOTIDES.
000115 01-03
THE EFFEaS OF RESERPINE, IPRONIAZID AND L-DOPA ON ELECTRICALLY-
INDUCED SPINAL-CORD SEIZURES.
000146 01-03
BIOCHEMICAL-CHARACTERIZATION OF THE RAT SYMPATHETIC
GANGLION: PHARMACOLOGICAL-EFFECTS OF RESERPINE ON
GANGLIONIC CATECHOLAMINES.
000153 01-03
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-AQIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
ACTIVITY.
000309 01-03
RESERPINE ABOLISHES MOVEMENT CORRELATED ATROPINE-RESISTANT
NEOCORTICAL LOW VOLTAGE FAST-ACTIVITY.
000310 01-03
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION:
IMPORTANCE OF NEURONAL ACTIVITY.
000314 01-03
THE ULTRASTRUCTURAL CHANGES OF SYNAPSES IN RAT FOLLOWING
LONG-TERM ADMINISTRATION OF THE NEUROLEPTICS RESERPINE AND
HALOPERIDOL.
000795 01-13
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND
AMPHETAMINE STIMUL^TION OF SYNAPTOSOMAL DOPAMINE
FORMATION FROM PHENYLALANINE.
001113 02-03
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE
TREATED DOGS.
001273 02-03
EFFECTS OF PHENCYCLIDINE AND METHYLPHENIDATE ON D-
AMPHETAMINE-INDUCED BEHAVIORS IN RESERPINE PRETREATED RATS.
001616 02-04
EFFECTS OF RESERPINE AND AMPHETAMINE ON THE DEVELOPMENT OF
HYPERACTIVITY IN MATERNALLY-DEPRIVED RAT PUPS.
001654 02-04
EFFEQS OF CHRONIC AMPHETAMINE OR RESERPINE ON SELF-
STIMULATION RESPONDING: ANIMAL-MODEL OF DEPRESSION?
001699 02-04
EFFECTS OF ELECTROCONVULSIVE-TREATMENT ON GROWTH-HORMONE
SECRETION INDUCED BY MONOAMINE-RECEPTOR AGONISTS IN
RESERPINE PRETREATED RATS.
002664 03-03
THE DIRECT EFFECT OF RESERPINE IN VITRO ON PROLACTIN RELEASE
FROM RAT ANTERIOR PITUITARY-GLANDS.
002810 03-03
RESERPINE EFFEQ ON THE AXONAL TRANSPORT OF DOPAMINE-BETA-
HYDROXYLASE AND TYROSINE-HYDROXYLASE IN RAT-BRAIN.
003904 04-03
RESERPINE-INDUCED
DEPRESSION OF RESERPINE-INDUCED MUSCULAR RIGIDITY IN RATS AFTER
ADMINISTRATION OF LISURIDE INTO THE SPINAL SUBARACHNOID
SPACE.
002962 03-04
LITHIUM AMELIORATION OF RESERPINE-INDUCED HYPOAQIVITY IN
RATS.
004167 04-04
EFFECTS OF NARCOTIC ANTAGONISTS ON L-DOPA REVERSAL OF
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE.
004186 04-04
RESERPINIZED
DIFFERENTIAL-EFFECTS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND
RELEASING-AGENTS ON LOCOMOTOR-ACTIVITY IN NORMAL AND IN
RESERPINIZED MICE.
004130 04-04
RESERVES
ENERGY RESERVES AND SOUND-INDUCED SEIZURES. (UNPUBLISHED
PAPER).
001467 02-03
RESIDENTIAL-CENTER
A NOTE ON PAHERNS OF DRUG PRESCRIBING IN A RESIDENTIAL-CENTER
FOR THE INTELLEQUALLY-HANDICAPPED.
000982 01-17
RESIDENTS
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: III. SOCIAL-INTERACTIONS
BETWEEN TWO RESIDENTS AND AN INTRUDER MALE.
001776 02-04
RESIDUAL-EFFECTS
RESIDUAL-EFFECTS OF TEMAZEPAAA AND OTHER HYPNOTIC-COMPOUNDS
ON COGNITIVE FUNCTION.
000879 01-15
RESIDUE
MODIFICATION OF THE PROLINE RESIDUE OF TRH ENHANCES BIOLOGICAL-
ACTIVITY AND INHIBITS DEGRADATION.
000351 01-04
BIOLOGICAL EVALUATION OF A TRH ANALOGUE WITH A MODIFIED
PROLINE RESIDUE.
003662 04-01
RESISTANT
DIFFERENCES IN AQIVITY IN CEREBRAL METHYLTRANSFERASES AND
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE
AND RESISTANT MICE AND DEERMICE.
000377 01-04
S-389
Subject Index
Psychopharmacoldgy Abstracts
if
m
^
I
EUHYPNOS-FORTE, HIGH-DOSE TEMAZEPAM FOR RESISTANT INSOMNIA:
POSTMARKETING SURVEILLANCE IN 10,057 PATIENTS UNRESPONSIVE
. TO CONVENTIONAL HYPNOTIC DOSAGE.
002324 02-14
RESOLUTION
ASSAYING GABA-MODULIN ACTIVITY IN BRAIN EXTRAQS: RESOLUTION
OF INHERENT DIFFICULTIES. (UNPUBLISHED PAPER).
001045 02-01
RESPECTIVE
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT ~ II. RESPEQIVE REGIONAL
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC
DEVELOPMENTS.
000214 01-03
RESPEQIVE POSITION OF ANTIDEPRESSANTS IN THERAPEUTICS.
002581 02-17
RESPIRATION
AN EVALUATION OF THE MECHANISM BY WHICH SEROTONERGIC
ACTIVATION DEPRESSES RESPIRATION.
003917 04-03
EFFECT OF INORGANIC LEAD ON RAT-BRAIN MITOCHONDRIAL
RESPIRATION AND ENERGY PRODUCTION.
004267 04-05
RESPIRATORY
EFFEQS OF GAMMA HYDROXYBUTYRIC-ACID ON METABOLIC,
RESPIRATORY AND VASOMOTOR AQIVITIES AND BODY-
TEMPERATURE IN RATS.
000189 01-03
THE ANALGESIC AND RESPIRATORY EFFEQS OF MEPTA2IN0L, MORPHINE
AND PENTAZOCINE IN THE RAT.
000516 01-05
EFFECTS OF DIFFERENT MONOAMINE-OXIDASE-INHIBITORS ON
RESPIRATORY AQIVITY IN RATS WITH CHRONICALLY IMPAIRED
CENTRAL SEROTONERGIC FUNCTION.
001389 02-03
INFLUENCE OF RESPIRATORY STRESS AND HYPERTENSION UPON THE
BLOOD-BRAIN-BARRIER.
001437 02-03
ROLE OF MONOAMINERGIC SYSTEMS IN MORPHINE-INDUCED
RESPIRATORY DEPRESSION.
002827 03-03
HABITUATION OF ELECTRODERMAL AND RESPIRATORY RESPONSES TO
VISUAL STIMULI AS A FUNCTION OF PERSONALITY DIFFERENCES IN
AFFEQ LEVEL.
003414 03-13
OPIATE SYSTEM INFLUENCES CENTRAL RESPIRATORY CHEMOSENSORS.
003971 04-03
RESPIRATORY DEPRESSION PRODUCED BY DIAZEPAM IN CATS: EFFEQ OF
ANESTHESIA.
004272 04-05
POTENTIATION OF THE MORPHINE-INDUCED RESPIRATORY RATE
DEPRESSION BY CAPTOPRIL.
004275 04-05
FLURAZEPAM-INDUCED SLEEP-APNEA-SYNDROME IN A PATIENT WITH
INSOMNIA AND MILD SLEEP-RELATED RESPIRATORY CHANGES.
004729 04-17
RESPIRATORY-DISEASE
RESPIRATORY-DISEASE AND NASAL IMMUNOGLOBULIN
CONCENTRATIONS IN PHENYTOIN TREATED EPILEPTIC-PATIENTS.
003486 03-15
RESPONDERS
THE SELEaiON OF LITHIUM RESPONDERS.
000997 01-17
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO: A DISCRIMINANT FUNCTION ANALYSIS.
002482 02-16
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND
PLACEBO. A DISCRIMINANT FUNCTION ANALYSIS. (UNPUBLISHED
PAPER).
004420 04-10
RESPONSE-CURVE
LOG-DOSE/RESPONSE-CURVE FLAHENING IN RATS AFTER DAILY
INJECTION OF OPIATES.
001387 02-03
RESPONSE-CURVES
CUMULATIVE DOSE RESPONSE-CURVES IN BEHAVIORAL-
PHARMACOLOGY.
001883 02-06
RESPONSIVITY
BRIEF SOCIAL-ISOLATION, PAIN RESPONSIVITY, AND MORPHINE
ANALGESIA IN YOUNG RATS.
001744 02-04
RESTITUTION
IMPROVEMENT OF RESTITUTION FROM CEREBRAL ISCHEMIA IN
HYPERGLYCEMIC RATS BY PENTOBARBITAL OR DIAZEPAM.
000475 01-04
RESTLESS
A CONTROLLED DOUBLE-BUND STUDY OF HALOPERIDOL VERSUS
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY-
SUBNORMAL-PATIENTS: SERUM LEVELS AND CLINICAL-EFFEQS.
002185 02-11
RESTLESSNESS j
PSYCHOPHARMACEUTICAL-THERAPY TO ZAIM DRIVE, AQIVITY, AND J
RESTLESSNESS IN CHILDHOOD. '
002604 02-17
RESTORATION
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF ,
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH. ^
003882 04-03
RESTRAINED
EFFECTS OF CONFORMATIONALLY RESTRAINED ANALOGUES OF
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN.
003794 04-03
RESTRAINT
THE FUNQIONAL IMPORTANCE OF INCREASED BRAIN TRYPTOPHAN IN
THE SEROTONERGIC RESPONSE TO RESTRAINT STRESS.
002779 03-03
RESTRICTED
CONFORMATIONALLY RESTRIQED PHENOTHIAZINE NEUROLEPTICS. 1.3 I
DIMETHYLAMINO-TETRAHYDROAZEPINOPHENOTHIAZINE.
001359 02-03
CONFORMATIONALLY RESTRICTED TRICYCLIC-ANTIDEPRESSANTS. 1 . I
OCTAHYDRODIBENZAZEPINONAPHTHYRIDINES AS RIGID IMIPRAMINE
ANALOGUES
001710 02-04
THE SYNTHESIS AND ACTIVITY OF CIS AND TRANS 2
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACIDAS
CONFORMATIONALLY RESTRICTED ANALOGUES OF GABA.
002633 03-01
A NEW METHOD FOR APPLICATION OF HORSERADISH-PEROXIDASE INTO
A RESTRICTED AREA OF THE BRAIN.
003141 03-06
RETARD
THE ASSOCIATION OF RETARD NEUROLEPTICS TO OTHER NEUROLEPTICS
IN THE REHABILITATION OF PSYCHOTIC-PATIENTS.
002108 02-11
CLINICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG-
RESISTANCE.
003245 03-09
RETARDED
COMPARISON OF THE CLASSICAL AND RETARDED FORM OF LITHIUM-
CARBONATE.
001888 02-07
RETENTION
THE USE OF PSYCHOPHARMACOLOGICAL-PROCEDURES TO ANALYSE THE
ONTOGENY OF LEARNING AND RETENTION: ISSUES AND CONCERNS.
000482 01-04
THE INFLUENCE OF DAILY BIOLOGICAL-RHYTHMICITY ON THE HOMING-
BEHAVIOR, PSYCHOPHARMACOLOGICAL RESPONSIVENESS, LEARNING
AND RETENTION OF SUCKLING RATS. (PH.D. DISSERTATION).
001660 02-04
EFFECTS OF A LOW-DOSE AND A HIGH-DOSE OF BETA ENDORPHIN ON
ACQUISITION AND RETENTION IN THE RAT.
001663 02-04
COMPARISONS OF THE EFFECTS OF GUANETHIDINE, 6
HYDROXYDOPAMINE AND DIETHYLDITHIOCARBAMATE ON RETENTION
OF PASSIVE-AVOIDANCE
001742 02-04
EFFECTS OF CYCLOHEXIMIDE ADMINISTERED IN CONJUNCTION WITH
NICOTINE ON RETENTION OF A PASSIVE-AVOIDANCE TASK IN MICE
001791 02-04
EFFECT OF L FUCOSE ON BRAIN PROTEIN METABOLISM AND RETENTION
OF A LEARNED-BEHAVIOR IN RATS.
001819 02-04
CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNCTION
OF ELAVIL AND THORAZINE INJECTION.
002974 03-04
THE EFFECTS OF ANTIDEPRESSANTS ON THE RETENTION AND
METABOLISM OF (3H) NOREPINEPHRINE IN RAT-BRAIN SLICES.
003763 044)3
EFFECTS OF ANISOMYCIN ON RETENTION OF THE PASSIVE-AVOIDANCE
HABIT AS A FUNCTION OF AGE.
004097 04-04
RETICULAR
STRYCHNINE EFFECTS ON THE SENSORY RESPONSE PAHERNS OF
RETICULAR FORMATION NEURONS.
001219 02-03
THE EFFECTS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERACTION
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED
AHENTION. (PH.D. DISSERTATION).
001563 02-04
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR
FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY.
002986 03-04
S-390
VOLUME 19, SUBJECT INDEX
MORPHINE AND METHIONINE-ENKEPHALIN: DIFFERENT EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE
MESENCEPHALIC RETICULAR FORMATION OF THE RAT
003849 04-03
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS.
003972 04-03
RETICULARIS-OIOANTOCELLULARIS
THE EFFECT OF MORPHINE ON THE CONTENT OF SEROTONIN, 5
HYDROXYINDOLEACETIC-ACID AND SUBSTANCE-P IN THE NUCLEI
RAPHE-MAGNUS AND RETICULARIS-GIGANTOCELLULARIS.
001328 02-03
KETICULOSEPTAL
THE ROLE OF RETICULOSEPTAL INPUTS IN THE FORMATION OF DIFFERENT
TYPES OF SENSORY REACTIONS OF THE HIPPOCAMPAL NEURONS.
004510 04-13
RETINA
LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES
OF THE DEVELOPING CHICK RETINA.
000065 01-03
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS ARE LOCALIZED IN THE
INNER PLEXIFORM LAYER OF RAT RETINA.
000277 01-03
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE-
ENKEPHALIN AND CHOLECYSTOKININ IN THE NEURAL RETINA OF
SEVERAL VERTEBRATE SPECIES. (UNPUBLISHED PAPER).
001017 02-01
BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERACTION
WITH GAMMA AMINOBUTYRIC-ACID.
001287 02-03
BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND
CELLULAR LOCALIZATION.
002655 03-03
KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFECT ON
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA-
RECEPTORS.
002743 03-03
GABA ANTAGONISTS ENHANCE DOPAMINE TURNOVER IN THE RAT
RETINA IN VIVO.
002772 03-03
PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN
MAMMALIAN RETINA.
002814 03-03
THE EFFEQ OF COLCHICINE AND CYTOCHALASIN B ON THE RELEASE OF
TAURINE FROM THE CHICK RETINA.
002856 03-03
2 AMINO-4-PHOSPHONOBUTYRIC-ACID: A NEW PHARMACOLOGICAL
TOOL FOR RETINA RESEARCH.
003145 03-06
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE-
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1
CYCLOPROPYLMETHYL
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE
003706 04-02
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA, II. FACTORS
AFFEaiNG THE ACCUMULATION OF CYCLIC-AMP IN PIECES OF INTACT
CARP RETINA.
003776 04-03
CHANGES OF ELEaRORETINOGRAM AND NEUROCHEMICAL ASPECTS OF
GABAERGIC NEURONS OF RETINA AFTER INTRAOCULAR INJECTION OF
KAINIC-ACID IN RATS.
003807 04-03
SOME BARBITURATES ENHANCE THE EFFECT OF MUSCIMOL ON
DOPAMINE TURNOVER IN THE RAT RETINA.
003873 04-03
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID-
RECEPTOR AGONIST, TO MEMBRANES OF THE BOVINE RETINA.
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE-
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA-
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS
lETINAl °°^°5^ °^-°3
RETINAL TOXICITY OF MAM-ACETATE IS DEVELOPMENTALLY SPECIFIC
(UNPUBLISHED PAPER).
001212 02-03
AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL
DOPAMINE-RECEPTORS AFTER VARIOUS TREATMENTS WITH
ANTAGONISTS OR AGONISTS.
DOPAMINE DEPLETION SLOWS RETINAL TRANSMISSION . °° ^ ^^° °^'°^
002708 03 03
STIMULATION OF RETINAL ADENYUTE-CYCLASE BY VASOACTIVE
INTESTINAL PEPTIDE (VIP).
009fil 1 O'^-O'^
LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID
tniNOTOXICEFFECTS 002828 03-03
RETINOTOXIC-EFFECTS OF DIAMINODIPHENOXYBUTANE IN RATS
000444 01-04
Subject Index
RETIRED
THE RELATIVE EFFICACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY
FOR THE TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY
(PH D. DISSERTATION).
002)48 02-11
RETRIEVAL
EFFECT OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION
MEMORY, AND RETRIEVAL OF SHUHLE AVOIDANCE AND
HABITUATION LEARNING IN RATS.
000410 01-04
PIRACETAM AND RETRIEVAL OF MEMORY IN YOUNG RATS.
000803 01-14
ACTH4-10 AND MEMORY IN EQ TREATED PATIENTS AND UNTREATED
CONTROLS. II. EFFECT ON RETRIEVAL.
001983 02-09
RETROGRADE
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
001024 02-01
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS.
(UNPUBLISHED PAPER).
001488 02-03
BETA ENDORPHIN CAUSES RETROGRADE AMNESIA AND IS RELEASED
FROM THE RAT-BRAIN BY VARIOUS FORMS OF TRAINING AND
STIMULATION.
001664 02-04
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT.
003734 04-03
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL- STIMULATION OF THE
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS.
004231 04-04
REUPTAKE
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
REUPTAKE OF BIOGENIC-AMINES BY BRAIN SLICES: EFFECT OF
HYDROCORTISONE.
000187 01-03
INITIAL, CLINICAL-TRIAL OF A NEW, SPECIFIC 5 HT REUPTAKE INHIBITOR
CITAL0PRAM(LU-10-171).
000591 01-09
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE.
002305 02-13
HIPPOCAMPAL SEROTONIN REUPTAKE AND NOCTURNAL LOCOMOTOR-
ACTIVITY AFTER MICROINJECTIONS OF 5,7 DHT IN THE FORNIX-
FIMBRIA.
002929 03-03
MONOSODIUM-GLUTAMATE: INCREASED NEUROTOXICITY AFTER
REMOVAL OF NEURONAL REUPTAKE SITES.
003889 04-03
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN
REUPTAKE SITES IN BRAIN AND PLATELET?
003962 04-03
AHENUATION OF PETHIDINE-INDUCED ANTINOCICEPTION BY ZIMELIDINE
AN INHIBITOR OF 5 HYDROXYTRYPTAMINE REUPTAKE.
004118 04-04
EFFECTS OF NOREPINEPHRINE AND 5 HYDROXYTRYPTAMINE REUPTAKE
INHIBITORS ON ELECTRICALLY-INDUCED SPINAL-CORD SEIZURES IN
RATS.
004144 04-04
THE ANTIDEPRESSANT EFFECTS OF TRAZODONE AND INHIBITION OF
PLATELET SEROTONIN REUPTAKE.
004383 04-09
REVELATIONS
COMPUTERIZED MONITORING OF PSYCHOTROPIC-DRUG ORDERS SOME
TRENDS AND REVELATIONS.
003566 03-16
REVERSAL
HYPOALGESIA INDUCED BY MICROINJECTION OF A NOREPINEPHRINE
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL
ADMINISTRATION OF A SEROTONIN ANTAGONIST.
000121 01-03
INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH PENTAZOCINE
REVERSAL BY NALTREXONE.
000318 01-03
POSTAMPHETAMINE DEPRESSION OF SELF-STIMULATION RESPONDING
FROM THE SUBSTANTIA-NIGRA: REVERSAL BY TRICYCLIC-
ANTIDEPRESSANTS.
000419 01-04
S-391
Subject Index
Psychopharmacology Abstracts
iX.
m
iiiiiH"
fe
REVERSAL OF PARA CHLOROPHENYLALANINE-INDUCED INSOMNIA BY 5
HYDROXYTRYPTOPHAN IN THE RAT.
000423 01-04
REVERSAL OF SCHEDULE-INDUCED SELF-INJEQION OF HEROIN BY
NALOXONE.
000446 01-04
REVERSAL BY PHENYTOIN OF CARBAMAZEPINE-INDUCED WATER
INTOXICATION: A PHARMACOKINETIC-INTERACTION.
000783 01-13
PRESSURE REVERSAL OF THE EFFECT OF URETHANE ON THE EVOKED
SOMATOSENSORY CORTICAL RESPONSE IN THE RAT.
001106 02-03
STUDIES ON THE SPECIFICITY AND REVERSAL OF NEUROLEPTIC-INDUCED
DOPAMINERGIC-SUPERSENSITIVITY. (PH.D. DISSERTATION).
001469 02-03
REVERSAL OF LEARNED-HELPLESSNESS BY IMIPRAMINE
001751 02-04
NEUROLEPTIC/DOPAMINE-RECEPTORS: ELEVATION AND REVERSAL.
001847 02-05
REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY
NORADRENALINE INFUSION.
002672 03-03
ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA:
REVERSAL BY MICROIONTOPHORETIC BICUCULLINE.
002684 03-03
NALOXONE REVERSAL OF THE PENTOBARBITAL-INDUCED BLOCKADE OF
OVULATION IN THE RAT.
002817 03-03
DIFFERENTIAL REVERSAL BY SCOPOLAMINE AND THIP OF THE
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS.
002948 03-04
ACTION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND
AN OPIATE-PENTAPEPTIDE.
003863 04-03
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE
REVERSAL OF GUANETHIDINE BLOCKADE OF ADRENERGIC NEURONS.
003900 04-03
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCED
ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY
004018 04-03
DECREASE OF NORADRENALINE 0 METHYLATION IN RAT-BRAIN INDUCED
BY L-DOPA. REVERSAL EFFECT OF S ADENOSYL-L-METHIONINE.
004019 04-03
EFFECTS OF NARCOTIC ANTAGONISTS ON L-DOPA REVERSAL OF
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE.
004186 04-04
BEHAVIORAL AND BIOCHEMICAL-STUDIES OF THE SCOPOLAMINE-INDUCED
REVERSAL OF NEUROLEPTIC AQIVITY.
004195 04-04
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL
004208 04-04
REVERSE
FAILURE OF NALOXONE TO REVERSE CATALEPSY ASSOCIATED WITH
SCHIZOPHRENIA: A CASE-REPORT.
000560 01-08
SEPARATION OF BARBITURATES USING REVERSE PHASE THIN-LAYER-
CHROMATOGRAPHY.
004670 04-16
REVERSIBILITY
REVERSIBILITY OF TARDIVE-DYSKINESIA.
000854 01-15
REVERSIBLE
REVERSIBLE INACTIVATION OF RAPHE-MAGNUS NEURONS: EFFECTS ON
NOCICEPTIVE THRESHOLD AND MORPHINE-INDUCED ANALGESIA.
000240 01-03
NALOXONE REVERSIBLE EFFECTS OF D ALA2-MET5-ENKEPHALINAMIDE-
INDUCED BEHAVIORAL-ACTIVITY IN RATS.
000402 01-04
REVERSIBLE ALEXIA, MITOCHONDRIAL MYOPATHY, AND LAQIC-
ACIDEMIA.
000723 01-11
A NEW APPROACH TO THE ASSESSMENT OF THE POTENCY OF
REVERSIBLE MONOAMINE-OXIDASE-INHIBITORS IN VIVO, AND ITS
APPLICATION TO D-AMPHETAMINE, P METHOXY AMPHETAMINE AND
HARMALINE.
000900 01-16
PATHOPHYSIOLOGICAL-ASPEQS OF REVERSIBLE AND IRREVERSIBLE
TARDIVE-DYSKINESIA.
002124 02-11
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL
CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN
PSYCHEDELIC-EXPERIENCES.
002200 02-12
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL
NOCICEPTION.
003028 03-04
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS.
003068 03-04
A CASE OF REVERSIBLE PURE-WORD DEAFNESS DURING LITHIUM
TOXICITY.
003481 03-15
REVERSIBLE RING-OPENING REACTIONS OF NIMETAZEPAM AND
NITRAZEPAM IN ACIDIC MEDIA AT BODY-TEMPERATURE
004517 04-13
REVERSING
THE PROCONVULSANT AND DIAZEPAM REVERSING EFFEQS OF ETHYL-
BETA-CARBOLlNE-3-CARBOXYLATE .
001399 02-03
REVERSION
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
DEXAMETHASONE TREATMENT.
000321 01-03
REVIEWS
RECENT REVIEWS OF BIOCHEMICAL, NEUROCHEMICAL, AND
PHARMACOLOGICAL TOPICS.
003649 03-17
PROBLEMS REMAIN IN REVIEWS OF MEDICAID FINANCED DRUG-THERAPY
IN NURSING-HOMES.
004736 04-17
REVISION
TARDIVE-DYSKINESIA: CLINICOEPIDEMIOLOGICAL REVISION AND
CONTRIBUTION.
003466 03-15
REVISITED
AN OLD SIDE-EFFECT REVISITED: VISUAL HALLUCINATIONS.
000886 01-15
DUAL-EFFECTS OF MESCALINE: THE TRANSMETHYLATION HYPOTHESIS
REVISITED.
001584 02-04
REWARD
REWARD SYSTEM DEPRESSION FOLLOWING CHRONIC AMPHETAMINE:
ANTAGONISM BY HALOPERIDOL.
000342 01-04
THE PHARMACOLOGY OF CATECHOLAMINE INVOLVEMENT IN THE
NEURAL MECHANISMS OF REWARD
001526 02-03
INTRAHYPOTHALAMIC MICROINJECTIONS OF NORADRENALINE WITH AND
WITHOUT INDUCTION OF THE ALIMENTARY DRIVE AS A REWARD IN A
T-MAZE LEARNING IN RATS.
001604 02-04
EFFECTS OF CHRONIC NALOXONE TREATMENT ON BRAIN-STIMULATION
REWARD.
003066 03-04
REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION:
DISSOCIATIVE-EFFECTS OF COCAINE
004160 04-04
MORPHINE DIFFERENTIALLY AFFECTS VENTRAL TEGMENTAL AND
SUBSTANTIA-NIGRA BRAIN REWARD THRESHOLDS.
004187 04-04
DISRUPTION OF AUTOSHAPED RESPONDING TO A SIGNAL OF BRAIN-
STIMULATION REWARD BY NEUROLEPTIC-DRUGS
004199 04-04
REWARDED
FIRST DOSE BEHAVIORAL-TOLERANCE TO PHENCYCLIDINE ON FOOD
REWARDED BAR-PRESSING-BEHAVIOR IN THE RAT.
000462 01-04
REWARDING
REWARDING AND AVERSIVE-EFFEQS OF MORPHINE: TEMPORAL AND
PHARMACOLOGICAL-PROPERTIES.
000470 01-04
TEMPORAL PROPERTIES OF THE REWARDING AND AVERSIVE-EFFEQS OF
AMPHETAMINE IN RATS.
000471 01-04
A COMPARISON BETWEEN THE EFFEQS OF MORPHINE ON THE
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC
AND CENTRAL GRAY STIMULATION.
001771 02-04
INFLUENCE OF MORPHINE ON THE DISCRIMINATIVE-STIMULUS
PROPERTIES OF REWARDING LATERAL HYPOTHALAMIC STIMULATION.
(PH.D. DISSERTATION).
003041 03-04
REWARDS
A STATE-DEPENDENT FAILURE OF RATS TO MAXIMIZE REWARDS.
000392 01-04
RHESUS-MACAQUE
BEHAVIOR MAINTAINED BY INTRAVENOUS INJECTION OF CODEINE,
COCAINE, AND ETORPHINE IN THE RHESUS-MACAQUE AND THE
PIGTAIL-MACAQUE.
001828 02-04
RHESUS-MONKEY
BRAIN-MONOAMINES IN THE RHESUS-MONKEY DURING LONG-TERM
NEUROLEPTIC ADMINISTRATION.
001471 02-03
I
S-392
VOLUME 19, SUBJECT INDEX
Subject Index
THE EFFECTS OF ETHANOL, PHENOBARBITAL, AND BACLOFEN ON
ETHANOL WITHDRAWAL IN THE RHESUS-MONKEY.
001802 02-04
THE EFFECTS OF LITHIUM ON CHOICE BETWEEN COCAINE AND FOOD IN
THE RHESUS-MONKEY.
001825 02-04
PHENYTOIN VALPROIC-ACID INTERACTION IN RHESUS-MONKEY.
002785 03-03
CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL
ALERTING.
002997 03-04
EFFECTS OF PENTOBARBITAL AND ETHANOL UPON SINGLE NEURON
ACTIVITY IN THE PRIMARY SOMATOSENSORY CORTEX OF THE RHESUS-
MONKEY.
003755 04-03
RHESUS-MONKEYS
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL
000055 01-03
CENTRAL NORADRENERGIC ADAPTATION TO LONG-TERM-TREATMENT
WITH IMIPRAMINE IN RHESUS-MONKEYS.
000182 01-03
CONTINUOUS-ACCESS PHENCYCLIDINE SELF-ADMINISTRATION BY RHESUS-
MONKEYS LEADING TO PHYSICAL-DEPENDENCE.
000341 01-04
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. II. IN
VIVO METABOLISM OF TRITIATED DRUGS IN RHESUS-MONKEYS.
001229 02-03
SYNCHRONIZATION OF EEG ACTIVITY OF MALE RHESUS-MONKEYS
MACACA-MULAnA TREATED WITH OVOCYCLIN.
001312 02-03
THE EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ALONE AND IN
COMBINATION WITH CANNABIDIOL ON FIXED-INTERVAL
PERFORMANCE IN RHESUS-MONKEYS.
001582 02-04
AN ABSTINENCE-SYNDROME FOLLOWING CHRONIC ADMINISTRATION OF
DELTA9 TETRAHYDROCANNABINOL IN RHESUS-MONKEYS.
001621 02-04
INFLUENCE OF INTRAVENOUS SELF-ADMINISTERED PSYCHOMOTOR
STIMULANTS ON PERFORMANCE OF RHESUS-MONKEYS IN A MULTIPLE-
SCHEDULE PARADIGM.
001655 02-04
LONG-TERM CHLORPROMAZINE IN RHESUS-MONKEYS: PRODUCTION OF
DYSKINESIAS AND CHANGES IN SOCIAL-BEHAVIOR.
001850 02-05
CANNABIS-SATIVA: EFFECTS ON BRAIN FUNCTION AND ULTRASTRUCTURE
IN RHESUS-MONKEYS.
002747 03-03
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS
ADMINISTRATIONS.
002797 03-03
INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN
CHORIONIC GONADOTROPHIN.
003012 03-04
DRUG-EFFEa ON BLINK RATES IN RHESUS-MONKEYS: PRELIMINARY
STUDIES.
003023 03-04
INHIBITION OF AGGRESSIVE-BEHAVIOR IN RHESUS-MONKEYS BY
BUSPIRONE.
003103 03-04
THE EFFECTS OF ELECTRIC-SHOCK ON RESPONDING MAINTAINED BY
COCAINE IN RHESUS-MONKEYS.
004071 04-04
CHLORPROMAZINE EFFECTS ON COCAINE-REINFORCED RESPONDING IN
RHESUS-MONKEYS: RECIPROCAL MODIFICATION OF RATE ALTERING
EFFECTS OF THE DRUGS.
004133 04-04
DISCRIMINATIVE-STIMULUS EFFECTS OF ETORPHINE IN RHESUS-
MONKEYS.
004134 04-04
RIA
AN HPLC AND RIA ANALYSIS OF THE CHOLECYSTOKININ-PEPTIDES IN
RAT-BRAIN. (UNPUBLISHED PAPER).
001004 02-01
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE-
ENKEPHALIN AND CHOLECYSTOKININ IN THE NEURAL RETINA OF
SEVERAL VERTEBRATE SPECIES. (UNPUBLISHED PAPER).
001017 02-01
METHAQUALONE RIA STRUCTURE VERSUS REACTIVITY.
003657 04-01
RIA OPIATES: STRUCTURE VERSUS REACTIVITY.
003659 04-01
RICIN
ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT
CELL TYPE SPECIFIC TOXIN. (UNPUBLISHED PAPER).
001064 02-01
RIGGIO-EMILIA
DRUG DEPENDENCE: REFLECTIONS ON AND ANALYSIS OF AN EXPERIENCE
IN THE PROVINCE OF RIGGIO-EMILIA.
003591 03-17
RIGHT
IMIPRAMINE AFFECTS AUTONOMIC-CONTROL OF SINOATRIAL RATE IN
ISOLATED RIGHT ATRIAL PREPARATIONS.
000195 01-03
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT
VERTEBRAL-ARTERY OF THE CAT, A MODIFIED ANIMAL-MODEL FOR
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE
LOWER BRAINSTEM.
004297 04-06
RIGHT-TO-REFUSE
FEDERAL-COURT UPHOLDS RIGHT-TO-REFUSE PSYCHOTROPIC-DRUGS,
ORDERS IMPROVEMENTS AT LIMA-STATE-HOSPITAL.
002583 02-17
THE CONSTITUTIONAL RIGHT-TO-REFUSE ANTIPSYCHOTIC-MEDICATIONS.
004496 04-12
RIGHTS
ROniNG WITH THEIR RIGHTS ON: CONSTITUTIONAL THEORY AND
CLINICAL REALITY IN DRUG-REFUSAL BY PSYCHIATRIC-PATIENTS.
000911 01-17
THE RIGHTS OF INVOLUNTARY-PATIENTS TO REFUSE
PHARMACOTHERAPY: WHAT IS REASONABLE?
004730 04-17
RIGID
CONFORMATIONALLY RESTRICTED TRICYCLIC-ANTIDEPRESSANTS. 1 .
OCTAHYDRODIBENZAZEPINONAPHTHYRIDINES AS RIGID IMIPRAMINE
ANALOGUES.
001710 02-04
RIGIDITY
EFFECT OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND
RIGIDITY: A QUANTITATIVE STUDY OF REFLEXES AND PLASMA
CONCENTRATIONS.
000701 01-11
LITHIUM-INDUCED COGWHEEL RIGIDITY: TREATMENT WITH
AMANTADINE.
000748 01-13
OPIOID-RECEPTORS IN THE CAUDATE-NUCLEUS CAN MEDIATE EMG-
RECORDED RIGIDITY IN RATS.
001649 02-04
DEPRESSION OF RESERPINE-INDUCED MUSCULAR RIGIDITY IN RATS AFTER
ADMINISTRATION OF LISURIDE INTO THE SPINAL SUBARACHNOID
SPACE.
002962 03-04
RING-OPENING
REVERSIBLE RING-OPENING REACTIONS OF NIMETAZEPAM AND
NITRAZEPAM IN ACIDIC MEDIA AT BODY-TEMPERATURE.
004517 04-13
RISK
POLYPHARMACY REGIMEN AS AN EXACERBATING RISK IN THERAPY-
RESISTANT EPILEPTIC-SEIZURES AND BEHAVIORAL-DISORDERS.
004720 04-17
RISK-FACTORS
PRELIMINARY-FINDINGS WITH REGARD TO RISK-FACTORS IN THE
DEVELOPMENT OF TARDIVE-DYSKINESIA.
003501 03-15
RISKS
THE BENEFITS AND RISKS OF COMBINING AN MAO-INHIBITOR AND A
TRICYCLIC-ANTIDEPRESSANT.
003273 03-09
CHRONIC DRUG-TREATMENT OF THE CHRONICALLY-ILL: BENEFITS AND
RISKS.
•003625 03-17
RITALIN
PREDICTING THE RESPONSE OF HYPERACTIVE-CHILDREN TO RITALIN: AN
EMPIRICAL-STUDY.
002120 02-11
THE USE OF SENSORY INTEGRATIVE DIAGNOSTICS TO PREDICT
HYPERACTIVE-CHILDRENS RESPONSIVENESS TO METHYLPHENIDATE
(RITALIN) AND PEMOLINE (CYLERT). (PH.D. DISSERTATION).
002133 02-11
RNA
BIOELECTRICAL-ACTIVITY OF THE RAT BRAIN AFTER PREMATURE
WEANING AND AFTER RNA ADMINISTRATION.
002865 03-03
RNA-POLYMERASE-BII
PURIFICATION AND SUBUNIT STRUaURE OF DNA-DEPENDENT RNA-
POLYMERASE-BII FROM RAT-BRAIN NUCLEI.
003679 04-01
S-393
Subject Index
Psychopharmacology Abstracts
m
m
ill
mi
J!fc
y
£■
^
RNA-POLYMERASE-II
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA-
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER).
003998 04-03
RO-1 1-2465
EFFECTS OF RO-1 1-2465, A NEW PSYCHOTROPIC-AGENT ON THE UPTAKE
OF SEROTONIN BY HUMAN PLATELETS - IN VITRO DETERMINATION OF
THE IC50.
004532 04-13
RO-4-1284
DEPLETION OF EPINEPHRINE IN RAT HYPOTHALAMUS BY RO-4-1284:
INFLUENCE OF PARGYLINE AND HARMALINE.
000100 01-03
EFFECT OF R0-4-12B4 ON AUDIOGENIC-SEIZURE SUSCEPTIBILITY AND
INTENSITY IN EPILEPSY-PRONE RATS.
003865 04-03
RODENT
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE-
BEHAVIOR: INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON
THREE EXPERIMENTAL MODELS.
000340 01-04
CHARACTERIZATION OF THE BASIC PROTEINS FROM RODENT
PERIPHERAL-NERVOUS-SYSTEM MYELIN.
003665 04-01
RODENTS
BEHAVIOURAL-CHANGES INDUCED BY N,N DIMETHYLTRYPTAMINE IN
RODENTS.
000413 01-04
INTERACTION STUDIES OF ETHANOL AND PSYCHOTROPIC-DRUGS IN
RODENTS: POSSIBLE INVOLVEMENT OF ADENOSINE-TRIPHOSPHATASES.
001281 02-03
KINETICS OF CENTRAL-ACTIONS OF ISOFLOXYTHEPIN, AN ORAL
NEUROLEPTIC-DRUG WITH PROLONGED AQION IN RODENTS.
001720 02-04
COMPARATIVE-STUDY ON THE EFFECT OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS Of RODENTS: STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS.
002757 03-03
BEHAVIOURAL AND NEUROCHEMICAL PROPERTIES OF 1 1 INDOL-3-
YLMETHYLPIPERID-4-YL-3-BENZ0YLUREA (WY-25093) IN RODENTS.
003686 04-02
ROMAN
REGIONAL 5 HT ANALYSIS IN ROMAN HIGH-AVOIOANCE AND LOW-
AVOIDANCE RATS FOLLOWING MAO-INHIBITION.
001202 02-03
BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH-
AVOIDANCE AND LOW-AVOIDANCE RATS.
002852 03-03
ROOT
EFFECTS OF ENKEPHALIN ANALOGUE AND NALOXONE ON CAT SPINAL-
CORD DORSAL ROOT POTENTIALS.
000236 01-03
THE EFFECT OF CISMETHRIN ON THE RAT DORSAL ROOT POTENTIALS
000528 01-05
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT
001104 02-03
DEPRESSION OF VENTRAL ROOT DORSAL ROOT POTENTIAL BY DL ALPHA
AMINOADIPATE IN FROG SPINAL-CORD.
002755 03-03
ROTATION
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS
AND ANTAGONISTS: ZONE-SPECIFIC EFFEQS.
000422 01-04
POSTURAL ASYMMETRY AND DIRECTIONALITY OF ROTATION IN RATS.
001729 02-04
AMPHETAMINE-INDUCED ROTATION IN NORMAL CATS.
003002 03-04
DOES POSTURAL ASYMMETRY INDICATE DIRECTIONALITY OF ROTATION
IN RATS: ROLE OF SEX AND HANDLING.
003061 03-04
EFFEQS OF ELECTROLYTIC AND 6 HYDROXYDOPAMINE LESIONS OF THE
LATERAL HYPOTHALAMUS ON ROTATION EVOKED BY ELEQRICAL-
STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.
003081 03-04
ROTATIONAL-BEHAVIOR
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
SEX-DIFFERENCES IN AMPHETAMINE-ELICITED ROTATIONAL-BEHAVIOR
AND THE LATERALIZATION OF STRIATAL DOPAMINE IN RATS.
000459 01-04
MOTOR-ACTIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF
COCAINE: CORRELATION WITH DOPAMINE UPTAKE BLOCKADE.
001650 02-04
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS.
004129 04-04
HANDLING-INDUCED SEIZURES AND ROTATIONAL-BEHAVIOR IN THE
MONGOLIAN-GERBIL.
004216 04-04
DOPAMINE-RECEPTOR CHANGES FOLLOWING DESTRUQION OF THE I'l
NIGROSTRIATAL PATHWAY: LACK OF A RELATIONSHIP TO |
ROTATIONAL-BEHAVIOR. J
004229 04-04
ROTATIONAL-BEHAVIOUR
UNILATERAL 5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE DORSAL
RAPHE NUCLEUS (DRN) AND RAT ROTATIONAL-BEHAVIOUR.
001578 02-04
ROTATIONAL-BEHAVIOUR ELICITED BY 5 HT IN THE RAT: EVIDENCE FOR i
AN INHIBITORY ROLE OF 5 HT IN THE SUBSTANTIA-NIGRA AND I
CORPUS-STRIATUM. '
004141 04-04
ROUTE-OF-ADMINISTRATION
THE EFFECTS OF THE METHYLPHENIDATE AND D-AMPHET AMINE RELATED
TO ROUTE-Of-ADMINISTRATION.
000476 01-04
INFLUENCE OF ROUTE-OF-ADMINISTRATION ON HALOPERIDOL PLASMA
LEVELS IN PSYCHOTIC-PATIENTS.
000549 01-08
EFFEQ OF AGE AND ROUTE-OF-ADMINISTRATION ON LD50 OF LITHIUM-
CHLORIDE IN THE RAT.
001413 02-03
RS-51324
THE NEUROVASCULAR-PHARMACOLOGY AND CARDIOVASCULAR-
PHARMACOLOGY OF RS-51324, A POTENTIAL ANTIDEPRESSANT.
001091 02-02
RUBIDIUM-CHLORIDE
CLINICAL-TRIALS WITH RUBIDIUM-CHLORIDE IN DEPRESSED-PATIENTS
001893 02-07
RUNNING
NALOXONE SUPPRESSES FEEDING AND DRINKING BUT NOT WHEEL
RUNNING IN RATS.
004080 04-04
RURAL
PSYCHOACTIVE-MEDICATION USE AND ABUSE AMONG AN ADULT RURAL
POPULATION (PH.D. DISSERTATION).
003627 03-17
RX-336-M
RX-336-M, A NEW CHEMICAL TOOL IN THE ANALYSIS OF THE QUASI-
MORPHINE WITHDRAWAL-SYNDROME.
004093 04-04
S-l
A COMPARISON OF HUMAN TAQILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
SACCHARIN
USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETEQ AND
DISCRIMINATE AQIONS OF DRUGS AND TOXICANTS.
000503 01-04
SAFE
PAVING THE WAY TO SAFE PRESCRIBING FOR THE ELDERLY.
000999 01-17
SAFETY
SAFETY OF ANTICONVULSANTS IN HEPATIC PORPHYRIAS.
003132 03-05
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION: A
DOUBLE-BUND COMPARISON WITH IMIPRAMINE.
004346 04-09
CNS EFFEQS OF ISF-2522, A NEW NOOTROPIC (A PHASE I SAFETY AND
CNS EFFICACY STUDY WITH QUANTITATIVE PHARMACOEEG AND
PHARMACOPSYCHOLOGY).
004519 04-13
SALBUTAMOL
SPONTANEOUS MOTOR-AQIVITY IN RATS GIVEN REPEATEDLY BETA-
SYMPATHOMIMETICS ~ ISOPRENALIN AND SALBUTAMOL.
001804 02-04
MANIC-STATE INDUCED BY SALBUTAMOL TAKEN ORALLY.
004622 04-15
SALICYLATE
THE EFFEQS OF SALICYLATE ON THE PHARMACOKINETICS OF
PHENYTOIN.
003421 03-13
SALINE
CENTRAL-EFFEQS OF ANGIOTENSIN-II IN WATER AND SALINE LOADED
RATS.
003845 04-03
S-394
VOLUME 19, SUBJECT INDEX
Subject Index
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
RAPID ACQUISITION OF A TWO-DRUG DISCRIMINATION: TIME OF DAY
EFFECT UPON SALINE STATE.
004214 04-04
SAUVA
TRANSCULTURAL PHARMACOKINETIC STUDY ON LI CONCENTRATION IN
PLASMA AND SALIVA.
000769 01-13
PLASMA AND SALIVA LEVELS OF CHLORPROMAZINE AND SUBJECTIVE
RESPONSE.
000826 01-14
VALUE OF SALIVA SAMPLES IN MONITORING CARBAMAZEPINE
CONCENTRATIONS IN EPILEPTIC-PATIENTS.
000903 01-16
FACTORS INFLUENCING NORTRIPTYLINE STEADY-STATE KINETICS:
PLASMA AND SALIVA LEVELS.
002251 02-13
LEVELS OF MINERAL-ELEMENTS IN THE SERUM AND SALIVA OF HEALTHY
MALE VOLUNTEERS AFTER A SINGLE-DOSE OF LI2C03.
002297 02-13
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME.
003189 03-08
INTRAVENOUS VALPROATE: EFFECTS ON PLASMA AND SALIVA
PHENYTOIN LEVELS.
003359 03-1 1
EXCRETION OF NORTRIPTYLINE INTO SALIVA.
003435 03-13
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY
ETHANOL.
003725 04-03
CONCENTRATIONS AND KINETICS OF CARBAMAZEPINE IN WHOLE
SALIVA, PAROTID SALIVA, SERUM ULTRAFILTRATE, AND SERUM.
004545 04-13
SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN
DETOXIFYING ALCOHOLIC-PATIENTS.
004671 04-16
SALIVARY
SALIVARY IMMUNOGLOBULIN CONCENTRATIONS IN PATIENTS WITH
EPILEPSY TREATED WITH CARBAMAZEPINE.
002234 02-13
THE EFFEQS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY
REAQIONS IN DOGS.
003030 03-04
STUDIES ON THE MECHANISMS OF L-DOPA-INDUCED SALIVARY
SECRETION.
003130 03-05
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF
ASSESSING COMPLIANCE.
004495 04-11
THE EFFEQ OF FIVE TRICYCLIC-ANTIDEPRESSANTS ON SALIVARY FLOW
AND MOOD IN HEALTHY VOLUNTEERS.
004560 04-14
SAUVARY-GLAND
ALPHA FLUPENTHIXOL: AN ANTAGONIST OF DOPAMINE-EVOKED FLUID
SECRETION BY AN INSEQ SALIVARY-GLAND PREPARATION.
000031 01-03
SALMON
ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE
IN RAT-BRAIN.
001320 02-03
SALT
RENAL BENZODIAZEPINE BINDING INCREASES DURING
DEOXYCORTICOSTERONE/SALT HYPERTENSION IN RATS.
001430 02-03
SAMPLES
VALUE OF SALIVA SAMPLES IN MONITORING CARBAMAZEPINE
CONCENTRATIONS IN EPILEPTIC-PATIENTS.
000903 01-16
HALOPERIDOL STIMULATION OF PROLACTIN SECRETION: HOW MANY
BLOOD SAMPLES ARE NEEDED TO DEFINE THE HORMONE RESPONSE?
002505 02-16
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION
PRODUaS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH-
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE
DETEaiON.
004302 04-06
SAMPLING
QUICKLY-MADE CANNULA FOR REPEATED CEREBROSPINAL-FLUID
SAMPLING IN RATS.
001879 02-06
SAMSO
PSYCHIATRIC-ILLNESS AND USE OF PSYCHOTROPIC-DRUGS IN THE
GEOGRAPHICALLY DELIMITED POPULATION OF SAMSO, DENMARK
004734 04-17
SAPHENOUS
INTERACTION OF THE TRICYCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH
PREJUNQIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG
SAPHENOUS VEIN.
003756 04-03
SARCOSINE 1 -LEUCINE8-ANGIOTENSIN-II
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST,
1251 SARCOSINE 1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
SATIETY
METABOLIC-CORRELATES OF THE EFFECTS OF 2 DEOXY-D-GLUCOSE ON
MEAL SIZE AND POST MEAL SATIETY IN RATS.
003035 03-04
SATIETY CENTER NEUROANATOMY. (UNPUBLISHED PAPER).
003678 04-01
SATYRIASIS
SATYRIASIS: A CASE-STUDY.
000709 01-11
SCALE
USE OF THE LITHIUM RESPONSE SCALE WITH AN OUTPATIENT
PSYCHIATRIC-SAMPLE.
000921 01-17
SCALES
CONVERSION SCALES FOR COMMONLY REQUESTED SERUM
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE, AND OF
HORMONES.
000759 01-13
MILD, MODERATE, SEVERE - THE STATISTICAL ANALYSIS OF SHORT
ORDINAL SCALES.
004677 04-16
SCANDINAVIAN-COUNTRIES
PSYCHOTROPIC-DRUG REGISTRATION IN THE SCANDINAVIAN-COUNTRIES:
THE ROLE OF CLINICAL-TRIALS.
002550 02-17
SCANNING
DOSE-EFFEQS OF SECOBARBITAL IN A STERNBERG MEMORY SCANNING
TASK.
003460 03-14
SCARE
LITHIUM AND THE KIDNEY SCARE.
003534 03-15
SCENE
STREET PCP SCENE: ISSUES ON SYNTHESIS AND CONTAMINATION.
000744 01-12
SCENT-MARKING-BEHAVIOR
CHOLINERGIC MECHANISMS IN SCENT-MARKING-BEHAVIOR BY
MONGOLIAN-GERBILS (MERIONES-UNGUICULATUS) .
000504 01-04
SCH-12679
COMPARISON OF SCH- 12679 AND THIORIDAZINE IN AGGRESSIVE
MENTAL-RETARDATES.
002119 02-11
SCHEDULE
A COMPARISON OF THE EFFECTS OF D-AMPHETAMINE, COCAINE,
IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE
FIXED-INTERVAL SCHEDULE.
000508 01-04
INTRAMUSCULAR HALOPERIDOL-DECANOATE FOR NEUROLEPTIC
MAINTENANCE-THERAPY: EFFICACY, DOSAGE SCHEDULE AND PLASMA
LEVELS: AN OPEN MULTICENTER-STUDY.
000758 01-13
DIFFERENTIAL-EFFECTS OF IMIPRAMINE IN RATS AS A FUNCTION OF DRL
SCHEDULE VALUE.
001714 02-04
A NEW DOSAGE SCHEDULE FOR PIMOZIDE IN THE ACUTE STABILIZATION
AND MAINTENANCE-TREATMENT OF PSYCHOSIS.
002022 02-09
EXTENDED SCHEDULE TRANSFER OF ETHANOL DISCRIMINATION.
003087 03-04
SCHEDULE DEPENDENT CHANGE OF PUNISHED-RESPONDING AFTER
DIAZEPAM IN RATS.
004165 04-04
THE EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON PERFORMANCE UNDER
A DIFFERENTIAL-REINFORCEMENT-OF-LOW-RATES SCHEDULE IN RATS.
004175 04-04
S-395
Subject Index
Psychopharmacology Abstracts
P
IX.
iia
Kli;:
ii
"mi
sift:
I
SCHEDULE-CONTROLLED
SCHEDULE-CONTROLLED BEHAVIOR IN THE MORPHINE-DEPENDENT AND
POSTDEPENDENT RAT,
000349 01-04
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFEaS ON
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFECTS OF
COCAINE AND D-AMPHET AMINE FOLLOWING CHRONIC AMPHETAMINE
ADMINISTRATION.
000350 01-04
EFFECTS OF SYSTEMIC AND INTRAVENTRICULAR ADMINISTRATION OF
CANNABINOIDS ON SCHEDULE-CONTROLLED RESPONDING IN THE
SQUIRREL-MONKEY.
000354 01-04
INTERAaiONS BETWEEN NALTREXONE AND NONOPIATE DRUGS
EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
001645 02-04
EFFEaS OF NORCOCAINE AND SOME NORCOCAINE DERIVATIVES ON
SCHEDULE-CONTROLLED BEHAVIOR OF PIGEONS AND SQUIRREL-
MONKEYS.
004012 04-03
INTERACTIONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR.
004127 04-04
EFFECTS OF NARCOTIC ABSTINENCE ON SCHEDULE-CONTROLLED
BEHAVIOR IN DEPENDENT RATS.
004230 04-04
SCHEDULE-INDUCED
REVERSAL OF SCHEDULE-INDUCED SELF-INJEQION OF HEROIN BY
NALOXONE.
000446 01-04
DRUG-EFFEQS ON SCHEDULE-INDUCED BEHAVIORS. (PH.D.
DISSERTATION).
001786 02-04
SCHEDULES
NALORPHINES EFFEQ UNDER SEVERAL SCHEDULES OF ELEaRIC-SHOCK
TITRATION.
000379 01-04
PROGRESSIVE-RATIO AND FIXED-RATIO SCHEDULES OF COCAINE
MAINTAINED RESPONDING IN BABOONS.
000395 01-04
FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK
TERMINATION: EFFECTS OF D-AMPHETAMINE, MORPHINE, AND
CLOZAPINE.
000431 01-04
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJEQION IN
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION
AND EFFEQS OF D-AMPHETAMINE AND PROMAZINE.
004152 04-04
SCHEDULING
GUIDELINES EMPLOYED BY THE FOOD-AND-DRUG-ADMINISTRATION IN
DRUG SCHEDULING.
003586 03-17
USE OF CURRENTLY AVAILABLE DATA SOURCES TO ASSESS DRUG
SCHEDULING.
003594 03-17
IMPACT OF DRUG SCHEDULING ON UTILIZATION.
003601 03-17
GUIDELINES FOR SCHEDULING DRUGS UNDER THE CONTROLLED-
SUBSTANCES-AQ.
003606 03-17
SCHIZOAFFECTIVE-DISORDER
THE PHARMACOLOGICAL-TREATMENT OF SCHIZOAFFEQIVE-DISORDER
DEPRESSED; A REVIEW OF THE I ITERATURE.
003634 03-17
SCHIZOAFFECTIVE-PATIENTS
LITHIUM COMBINED WITH NEUROLEPTICS IN CHRONIC SCHIZOPHRENIC-
PATIENTS AND SCHIZOAFFEaiVE-PATIENTS.
003168 03-08
SCHIZOAFFECTIVE-PSYCHOSES
THE TREATMENT OF SCHIZOAFFEQIVE-PSYCHOSES WITH LITHIUM-
CARBONATE.
000607 01-09
SCHIZOPHRENIA
FUNQIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY
NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS
WITH SCHIZOPHRENIA.
000059 01-03
PATHOPHYSIOLOGICAL-STUDIES ON SCHIZOPHRENIA WITH SPECIAL
REFERENCE TO HOMOVANILLIC-ACID CONCENTRATION IN
CEREBROSPINAL-FLUID.
000271 01-03
THE RELATIONSHIP BETWEEN THE THIORIDAZINE LEVEL IN THE PLASAAA
AND SYMPTOMS OF PARANOID SCHIZOPHRENIA.
000546 01-08
WHAT IS THE BEST MAINTENANCE DOSE OF NEUROLEPTICS IN
SCHIZOPHRENIA?
000547 01-08
CONTROLLED-COMPARISON OF MEDIUM AND HIGH CLOROTEPIN DOSES
IN CHRONIC SCHIZOPHRENIA.
000548 01-08
A NEW DRUG-TREATMENT FOR PREMENSTRUAL EXACERBATION OF
SCHIZOPHRENIA.
000553 01-08
LITHIUM RESPONSE IN GOOD PROGNOSIS SCHIZOPHRENIA.
000555 01-08
FAILURE OF NALOXONE TO REVERSE CATALEPSY ASSOCIATED WITH
SCHIZOPHRENIA: A CASE-REPORT.
000560 01-08
SODIUM-VALPROATE IN SCHIZOPHRENIA: SOME BIOCHEMICAL-
CORRELATES.
000561 01-08
THE PLACE OF LONG-AQING NEUROLEPTICS IN THE TREATMENT OF
SCHIZOPHRENIA.
000563 01-08
DOPAMINE-RECEPTORS AND SCHIZOPHRENIA: DRUG-EFFEQ OR ILLNESS?
000564 01-08
PSYCHOTROPIC-DRUGS AND DEPRESSIVE-SYNDROME IN SCHIZOPHRENIA
000569 01-08
DOUBLE-BLIND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH
ARERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS
WITH SCHIZOPHRENIA.
000574 01-08
COVERT DYSKINESIA IN AMBULATORY SCHIZOPHRENIA.
000836 01-15
DIFFERENTIAL-EFFEaS OF AMPHETAMINE AND NEUROLEPTICS ON
NEGATIVE VS. POSITIVE SYMPTOMS IN SCHIZOPHRENIA.
001906 02-08
INVOLVEMENT OF CHOLINERGIC AND GABAERGIC SYSTEMS IN
SCHIZOPHRENIA.
001907 02-08
HIGH-DOSE DIAZEPAM IN SCHIZOPHRENIA.
001909 02-08
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES. (UNPUBLISHED PAPER)
001910 02-08
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFEQ IN SCHIZOPHRENIA AND
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO
NEUROLEPTIC-MEDICATION.
001911 02-08
DES-TYRI-GAMMA-ENDORPHIN IN SCHIZOPHRENIA.
001918 02-08
DEXTRO PROPRANOLOL IN SCHIZOPHRENIA.
001921 02-08
HORMONE LEVELS IN ACUTE SCHIZOPHRENIA WITH AND WITHOUT
NEUROLEPTIC-MEDICATION.
001923 02-08
EXPERIENCE WITH OXYPROTHEPINE-DECANOATE IN THE MAINTENANCE-
THERAPY OF SCHIZOPHRENIA.
001925 02-08
SOME CLINICAL-ASPEQS AND METABOLIC-ASPEQS OF PROPRANOLOL IN
CHRONIC SCHIZOPHRENIA.
001926 02-08
CEREBRAL VENTRICLES AND DOPAMINE IN SCHIZOPHRENIA.
(UNPUBLISHED PAPER).
001928 02-08
PHARMACOMANOMETRIC-STUDIES OF COLONIC MOTIUTY AS A GUIDE
TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001930 02-08
INTERMIHENT PIMOZIDE VERSUS FLUPHENAZINE-OECANOATE AS
MAINTENANCE-THERAPY IN CHRONIC SCHIZOPHRENIA.
001932 02-08
THE HLA-SYSTEM AND SCHIZOPHRENIA IN ENGLAND.
001933 02-08
OXYPROTHEPINE-DECANOATE COMPARED WITH FLUPHENAZINE-
DECANOATE IN THE TREATMENT OF SCHIZOPHRENIA: PRELIMINARY-
COMMUNICATION.
001934 02-08
CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN
SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BUND CROSS-
OVER DESIGN.
001937 02-08
LOW ORAL CPZ BIOAVAILABILITY IN CHRONIC SCHIZOPHRENIA.
(UNPUBLISHED PAPER).
001938 02-08
PROPRANOLOL IN SCHIZOPHRENIA - MORE GUESS THAN GAUSS.
001939 02-08
SERUM NEUROLEPTIC CONCENTRATIONS IN SCHIZOPHRENIA.
(UNPUBLISHED PAPER).
001945 02-08
PARADOXICAL IMPROVEMENT FOLLOWING IV AMPHETAMINE IN
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
001951 02-08
METHODOLOGICAL-ISSUES IN SPINAL-FLUID STUDIES OF SCHIZOPHRENIA:
THE CASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE.
(UNPUBLISHED PAPER).
001952 02-08
S-396
VOLUME 19, SUBJECT INDEX
ANTIPSYCHOTIC-EFFEa OF GAMMA-TYPE ENDORPHINS IN
SCHIZOPHRENIA.
VASOPRESSIN AND SCHIZOPHRENIA.
00)953 02-08
001954 02-08
PHENYLETHYLAMINE, DOPAMINE AND NOREPINEPHRINE IN
SCHIZOPHRENIA (UNPUBLISHED PAPER)
001957 02-08
MONOAMINE-OXIDASE. PHENYLETHYLAMINE, NOREPINEPHRINE AND
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
001958 02-08
PATHOPHYSIOLOGIC-IMPACT OF CENTRAL CATECHOLAMINERGIC
FUNCTION IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES.
002174 02-11
MONOAMINES, EPILEPSY AND SCHIZOPHRENIA.
002183 02-11
ACUTE AND CHRONIC LSD EFFECTS ON RAT STARTLE . DATA SUPPORTING
AN LSD RAT MODEL OF SCHIZOPHRENIA.
002194 02-12
EFFECT OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND
NORMAL ADULTS. „ ,^
002222 02-13
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN
SCHIZOPHRENIA. „„„,,„„ „„.c
002390 02-15
DYSFUNCTIONS OF CHOLINERGIC PROCESSES IN SCHIZOPHRENIA.
002611 02-17
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES.
003167 03-08
LONG-TERM-TREATMENT OF SCHIZOPHRENIA.
003171 03-08
EFFEQ OF PROPRANOLOL AND PHENOTHIAZINES ON ELEaRODERMAL
ORIENTING AND HABITUATION IN SCHIZOPHRENIA.
003174 03-08
GABA AND SCHIZOPHRENIA: STUDY OF THE ACTION OF A GABAERGIC
ANTAGONIST. PROGABIDE OR SL-76-002.
003175 03-08
LATE RESULTS OF LITHIUM TREATMENT OF ADOLESCENTS WITH AHACK
LIKE SCHIZOPHRENIA.
003177 03-08
HEMOPERFUSION FOR CHRONIC SCHIZOPHRENIA: PRELIMINARY
PSYCHIATRIC RESULTS.
003180 03-08
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL-STUDIES WITH
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND
DEPOT NEUROLEPTICS.
003183 03-08
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME.
003189 03-08
CARPIPRAMINE: A DISINHIBITORY DRUG COMPOUND IN CHRONIC
SCHIZOPHRENIA.
003192 03-08
BETA ENDORPHIN AND SCHIZOPHRENIA.
003193 03-08
DOPAMINE-RECEPTORS, NEUROLEPTICS, AND SCHIZOPHRENIA.
003197 03-08
ENDORPHINS IN MENTAL-ILLNESSES, AND PARTICULARLY IN
SCHIZOPHRENIA.
003203 03-08
AUTONOMIC-EFFEaS OF DEXTROAMPHETAMINE IN NORMAL MEN:
IMPLICATIONS FOR HYPERAaiVITY AND SCHIZOPHRENIA.
003437 03-13
A CONTROLLED-STUDY OF L-DOPA IN SCHIZOPHRENIA WITH REFERENCE
TO THE THEORY OF DOPAMINERGIC-RECEPTOR HYPERSENSITIVITY.
004312 04-08
DRUGS AND SCHIZOPHRENIA.
004314 04-08
ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN AHENTION-
DYSFUNCTION TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA.
004316 04-08
PRELIMINARY TRIAL OF CLONIDINE TREATMENT IN TWO PATIENTS
SUFFERING FROM CHRONIC SCHIZOPHRENIA.
004320 04-08
DES-TYROSYL-GAMMA-ENDORPHIN IN SCHIZOPHRENIA: A DOUBLE-BLIND
TRIAL IN 13 PATIENTS.
004322 04-08
IMMUNOLOGICAL COMPONENTS IN SCHIZOPHRENIA.
004324 04-08
APOMORPHINE IN SCHIZOPHRENIA.
004327 04-08
A DOUBLE-BLIND COMPARISON OF THREE DOSAGES OF FLUTROLINE (CP-
36584) IN THE TREATMENT OF SCHIZOPHRENIA.
004333 04-08
Subject Index
THE USE OF CLINICAL AND PHARMACOKINETIC CRITERIA IN FORECASTING
THE EFFICACY OF THERAPY IN SCHIZOPHRENIA,
004335 04-08
PSYCHOPHARMACOLOGICAL AND SOCIAL ASPECTS OF SCHIZOPHRENIA:
RECENT DEVELOPMENTS.
004336 04-08
THE PROBLEM OF PSYCHOPHARMACOTHERAPY OF SLOWLY PROGRESSIVE
HYPOCHONDRIACAL SCHIZOPHRENIA.
004340 04-08
PECULIARITIES OF THE CEREBRAL PATHOMORPHOLOGY OF PATIENTS
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS
(PHARMACOLOGICAL PATHOMORPHOSIS) .
004528 04-13
A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF
SCHIZOPHRENIA.
004584 04-14
DRUG-INDUCED PSYCHOSIS AND SCHIZOPHRENIA IN ADOLESCENTS.
004596 04-15
COMPUTER-ANALYZED ELECTROENCEPHALOGRAM TO PREDICT THE
THERAPEUTIC OUTCOME IN SCHIZOPHRENIA
004680 04-16
CHOLINOMIMETICS IN MANIA, SCHIZOPHRENIA, AND MEMORY-
DISORDERS.
004703 04-17
THE DRUG PATHOMORPHOSIS OF SCHIZOPHRENIA.
004732 04-17
BENZODIAZEPINES IN SCHIZOPHRENIA: A NEED FOR REASSESSMENT.
004733 04-17
SCHIZOPHRENIA-LIKE
PATHOPHYSIOLOGIC-IMPACT OF CENTRAL CATECHOLAMINERGIC
FUNCTION IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES.
002174 02-11
SCHIZOPHRENIAS
DISTINGUISHING SCHIZOPHRENIAS BY MEANS OF PHARMACOTHERAPY.
001947 02-08
SCHIZOPHRENIC
DOPAMINERGIC ABNORMALITIES IN POSTMORTEM SCHIZOPHRENIC
BRAIN.
002575 02-17
VILOXAZINE AND THE DEPRESSED SCHIZOPHRENIC - METHODOLOGICAL-
ISSUES.
003181 03-08
SCHIZOPHRENIC-BOY
EFFECTS OF THIORIDAZINE ON THE COGNITIVE FUNCTIONING OF A
HYPOTONIC SCHIZOPHRENIC-BOY.
000557 01-08
SCHIZOPHRENIC-EPISODES
EVALUATIONS OF LOXAPINE-SUCCINATE IN THE AMBULATORY
TREATMENT OF ACUTE SCHIZOPHRENIC-EPISODES.
004345 04-08
SCHIZOPHRENIC-OUTPATIENTS
ABSENCE OF SEVERE TARDIVE-DYSKINESIA IN HUNGARIAN
SCHIZOPHRENIC-OUTPATIENTS.
002404 02-15
TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-OUTPATIENTS: PREVALENCE
AND SIGNIFICANT VARIABLES.
003483 03-15
A FOLLOWUP STUDY OF SCHIZOPHRENIC-OUTPATIENTS TREATED WITH
DEPOT NEUROLEPTICS.
004342 04-08
SCHIZOPHRENIC-PATIENTS
STUDY ON VISUALLY-EVOKED-POTENTIALS IN SCHIZOPHRENIC-PATIENTS
IN SULPIRIDE THERAPY.
000550 01-08
EFFEaS OF TRIFLUOPERAZINE, CHLORPROMAZINE, AND HALOPERIDOL
UPON TEMPORAL INFORMATION-PROCESSING BY SCHIZOPHRENIC-
PATIENTS.
000554 01-08
THE EFFECT OF THIORIDAZINE ON PROLACTIN LEVELS IN ACUTELY
SCHIZOPHRENIC-PATIENTS: CHALLENGE-DOSE AND STEADY-STATE
LEVELS.
000558 01-08
CLINICAL COMPARISON OF OXYPROTHEPIN AND CLOTEPINE IN
SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY) .
000568 01-08
PROLACTIN AND SOMATOTROPIN RESPONSES TO TRH IN SCHIZOPHRENIC-
PATIENTS.
000570 01-08
PROLAQIN RESPONSE AND EXTRAPYRAMIDAL SIDE-EFFEaS DURING
PROPRANOLOL AND NEUROLEPTIC-DRUGS TREATMENT IN CHRONIC
SCHIZOPHRENIC-PATIENTS.
000841 01-15
THE OCCURRENCE OF TARDIVE EXTRAPYRAMIDAL SYMPTOMS IN
SCHIZOPHRENIC-PATIENTS UNDERGOING PROLONGED NEUROLEPTIC
TREATMENT.
000885 01-15
S-397
^
p
fX.
'"in:
ii
BR
Si;
fe
I
Subject Index
FOLLOWUP TREATMENT AND AFTERCARE OF DISCHARGED
SCHIZOPHRENIC-PATIENTS.
000944 01-17
LONG-TERM APPLICATION OF HIGH-DOSES OF CLOROTEPIN TO CHRONIC
SCHIZOPHRENIC-PATIENTS.
001908 02-08
CONTROLLED-TRIAL OF SULPIRIDE IN CHRONIC SCHIZOPHRENIC-PATIENTS.
001914 02-08
EFFECT OF PROPRANOLOL TREATMENT ON SERUM PROLAQIN LEVEL IN
SCHIZOPHRENIC-PATIENTS.
001916 02-08
MAINTENANCE-THERAPY WITH FLUPHENAZINE-DECANOATE AND
OXYPROTHEPINE-DECANOATE IN SCHIZOPHRENIC-PATIENTS ~ A
DOUBLE-BUND CROSS-OVER COMPARATIVE-STUDY.
001924 02-08
DISCONTINUATION OF ORAL AND DEPOT FLUPHENAZINE IN
SCHIZOPHRENIC-PATIENTS AFTER ONE YEAR OF CONTINUOUS
MEDICATION: A CONTROLLED-STUDY.
001931 02-08
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH
NEUROLEPTICS.
001935 02-08
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
PHARMACOKINETIC INTERAQION BETWEEN PROPRANOLOL AND
CHLORPROMAZINE IN SCHIZOPHRENIC-PATIENTS.
001940 02-08
CHANGE IN OVERINCLUSIVE THINKING OF SCHIZOPHRENIC-PATIENTS IS
RELATED TO PLASMA PHENOTHIAZINE CONCENTRATION.
001941 02-08
USE OF LARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC-
PATIENTS WITH ELEVATED SERUM PROLAQIN LEVELS AND
EXTRAPYRAMIDAL SIDE-EFFEQS ASSOCIATED WITH NEUROLEPTIC
TREATMENT.
001944 02-08
RELATIONSHIPS AMONG BIOCHEMICAL-VARIABLES, CLINICAL-
VARIABLES, AND PHARMACOKINETIC-VARIABLES IN NEUROLEPTIC
TREATED SCHIZOPHRENIC-PATIENTS
001946 02-08
PLASMA FLUPHENAZINE AND PROLAQIN LEVELS IN SCHIZOPHRENIC-
PATIENTS DURING TREATMENT WITH LOW-DOSES AND HIGH-DOSES OF
FLUPHENAZINE-ENANTHATE.
001956 02-08
PLASMA FLUPHENAZINE LEVELS BY RADIOIMMUNOASSAY IN
SCHIZOPHRENIC-PATIENTS TREATED WITH DEPOT INJEQIONS OF
FLUPHENAZINE-DECANOATE.
002510 02-16
LITHIUM COMBINED WITH NEUROLEPTICS IN CHRONIC SCHIZOPHRENIC-
PATIENTS AND SCHIZOAFFEQIVE-PATIENTS.
003168 03-08
A PROBABLE NEUROLEPTIC-EFFEQ ON PLATELET MONOAMINE-OXIDASE
IN CHRONIC SCHIZOPHRENIC-PATIENTS.
003169 03-08
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE
003172 03-08
BEHAVIORAL-EFFECTS OF METHADONE IN SCHIZOPHRENIC-PATIENTS.
003178 03-08
A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS
003182 03-08
PIPERIDONE IN CHRONIC SCHIZOPHRENIC-PATIENTS: A CONTROLLED
DOUBLE-BUND STUDY.
003184 03-08
THE NEED FOR CONTINUOUS USE OF ANTIPARKINSONIAN MEDICATION
WITH CHRONIC SCHIZOPHRENIC-PATIENTS RECEIVING LONG-TERM
NEUROLEPTIC THERAPY.
003186 03-08
CHLORPROMAZINE LEVELS AND THE OUTCOME OF TREATMENT IN
SCHIZOPHRENIC-PATIENTS.
003188 03-08
NEUROLEPTIC SERUM LEVELS MEASURED BY RADIORECEPTOR ASSAY
AND CLINICAL-RESPONSE IN SCHIZOPHRENIC-PATIENTS.
003199 03-08
BEHAVIORAL-EFFECTS AND BIOLOGICAL-EFFECTS OF ACUTE BETA
ENDORPHIN INJECTION IN SCHIZOPHRENIC-PATIENTS AND DEPRESSED-
PATIENTS.
003357 03-11
LATERALIZED DEFICITS AND DRUG INFLUENCES ON THE DICHOTIC
LISTENING OF SCHIZOPHRENIC-PATIENTS.
003443 03-14
CORRELATIONS BETWEEN VISUAL-EVOKED-POTENTIALS AND
PSYCHOPATHOLOGICAL-FINDINGS IN SCHIZOPHRENIC-PATIENTS UNDER
TREATMENT WITH VARIOUS PSYCHOPHARMACOLOGICAL-DRUGS.
004315 04-08
Psychopharmacology Abstract*
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO
COUNTERACT CURATIVE EFFECTS OF NEUROLEPTIC-DRUGS
004321 04-08
THE EFFECT OF LONG-TERM MAINTENANCE-THERAPY ON SCHIZOPHRENIC-
PATIENTS USING SOMATOTHERAPEUTIC MEASURES.
004325 04-08
THE TREATMENT OF CHRONIC SCHIZOPHRENIC-PATIENTS: AN INTERVIEW
WITH DR. J. HUSSER.
004328 04-08
THE USE OF SODIUM-NUCLEINATE IN THE TREATMENT OF
SCHIZOPHRENIC-PATIENTS.
004339 04-08
THE EFFECT OF AN INTENSIVE COURSE OF NEUROLEPTIC-DRUGS ON
SCHIZOPHRENIC-PATIENTS AND THEIR SUBSEQUENT COURSE
FOLLOWING THE CESSATION OF ALL NEUROLEPTIC-MEDICATION.
004341 04-08
PLASMA OOPAMINE-BETA-HYDROXYLASE ACTIVITY IN CHRONIC
SCHIZOPHRENIC-PATIENTS TESTED WITH SINGLE-DOSE OF 2 BROMO-
ALPHA-ERGOCRIPTINE (PARLODEL).
004343 04-08
LONG-TERM NEUROLEPTIC TREATMENT OF CHRONIC SCHIZOPHRENIC-
PATIENTS: CLINICAL AND BIOCHEMICAL-EFFECTS OF WITHDRAWAL.
004344 04-08
THE STATE OF THE ADRENERGIC AND CHOUNERGIC SYSTEMS IN
SCHIZOPHRENIC-PATIENTS DURING PSYCHPHARMACOTHERAPY
004526 04-13
PROLACTIN AND GROWTH-HORMONE STUDIES IN SCHIZOPHRENIC-
PATIENTS AND NORMAL CONTROLS.
004538 04-13
EFFECTS OF NEUROLEPTIC ADJUSTMENT ON CLINICAL CONDITION AND
TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-PATIENTS.
004595 04-15
SCHIZOPHRENIC-PSYCHOSES
OXYPROTHEPIN-DECANOATE INJECTIONS: EXPERIENCE WITH A LONG-
TERM-TREATMENT OF SCHIZOPHRENIC-PSYCHOSES.
000576 01-08
DIAGNOSIS AND TREATMENT OF ACUTE SCHIZOPHRENIC-PSYCHOSES
r.„^ 00319103-08
ENDORPHIN RESEARCH IN SCHIZOPHRENIC-PSYCHOSES
003200 03-08
SCHIZOPHRENIC-SYMPTOMATOLOGY
LONG-TERM-TREATMENT WITH NEUROLEPTIC-AGENTS: ADAPTATION
PHENOMENA AND THEIR SIGNIFICANCE WITH REGARD TO
SCHIZOPHRENIC-SYMPTOMATOLOGY AND SIDE-EFFECTS
002370 02-15
SCHIZOPHRENIC-SYMPTOMS
DRUG RESPONSE DIFFERENCES OF HIGH AND STANDARD DOSAGE OF
FLUPHENAZINE-DECANOATE IN RELATION TO SCHIZOPHRENIC-
SYMPTOMS.
000562 01-08
APOMORPHINE REDUCES SCHIZOPHRENIC-SYMPTOMS.
000572 01-08
A TRIPEPTIDE FOR CONTROL OF SCHIZOPHRENIC-SYMPTOMS.
001919 02-08
ABNORMAL TRANSMETHYLATION REACTION DURING THE METABOUSM
OF DOPAMINE, TRYPTAMINE, AND SEROTONIN, AND SCHIZOPHRENIC-
SYMPTOMS: A CRITICAL REVIEW.
003404 03-13
SCHIZOPHRENICS
THE EEG EFFECTS OF THYROTROPIN-RELEASING-HORMONE IN HEALTHY
SUBJECTS AND CHRONIC SCHIZOPHRENICS.
000770 01-13
DISORDERS OF SMOOTH-PURSUIT EYE-MOVEMENTS IN SCHIZOPHRENICS
AND THE EFFECT OF NEUROLEPTICS IN THERAPEUTIC DOSES.
001912 02-08
ANTIPSYCHOTIC-EFFECT OF PROPRANOLOL ON CHRONIC
SCHIZOPHRENICS: STUDY OF A GRADUAL TREATMENT REGIMEN.
001915 02-08
EFFECT OF FLUPHENAZINE ON THE CIRCADIAN-EXCRETION OF CYCUC-
NUCLEOTIDES AND ELECTROLYTES IN THE URINE OF CHRONIC
SCHIZOPHRENICS.
001927 02-08
BETA ENDORPHIN LEVELS IN THE CEREBROSPINAL-FLUID OF
SCHIZOPHRENICS.
003176 03-08
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. III. THE MUTUAL RELATION OF EACH INDEX.
003179 03-08
DES-TYR-GAMMA-ENDORPHIN ADMINISTRATION IN CHRONIC
SCHIZOPHRENICS: A PRELIMINARY REPORT.
003 1 98 03-08
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. I. WITH REFERENCE TO PITUITARY-HORMONES.
003415 03-13
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. II. WITH REFERENCE TO SYMPATHETIC NEURONAL
FUNCTION.
003416 03-13
S-398
VOLUME 19, SUBJECT INDEX
Subiect Index
A TWELVE-YEAR FOLLOWUP OF THE NIMH-PRB HIGH-DOSE
CHLORPROMAZINE STUDY OF CHRONIC SCHIZOPHRENICS -
IMPLICATIONS FOR DEINSTITUTIONALIZATION. (UNPUBLISHED PAPER).
004323 04-08
EFFECTS OF ALTHESIN IN PSYCHOTHERAPY OF SCHIZOPHRENICS:
PRELIMINARY REPORT.
004331 04-08
HALOPERIDOL AND DROPERIDOL TREATMENT IN SCHIZOPHRENICS:
CLINICAL APPLICATION OF THE PROLACTIN MODEL.
004332 04-08
MOBILIZATION OF REFRACTORY CHRONIC SCHIZOPHRENICS WITH
HALOPERIDOL.
004337 04-08
SCHOOL
CHILDREN ON MEDICATION: A PRIMER FOR SCHOOL PERSONNEL.
000676 01-11
PREVALENCE OF HYPERACTIVITY AND RELATED TREATMENTS AMONG
ELEMENTARY SCHOOL CHILDREN.
004469 04-1 1
ASTHMA THERAPY MAY UNDERCUT KIDS AT SCHOOL.
004475 04-1 1
SCHOOL-AGE
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE, HOSPITALIZED SCHOOL-AGE CHILDREN.
003360 03-11
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN
AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN.
003361 03-11
SCHW ANN-CELL
THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION
PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR
PRESERVED SCHWANN-CELL SOMAL FUNCTION.
002905 03-03
SCIATIC-NERVE
INHIBITORY ACTION OF MORPHINE ON THE RELEASE OF A BRADYKININ-
LIKE SUBSTANCE AFTER SCIATIC-NERVE STIMULATION.
001293 02-03
THE EFFEQ OF CHRONIC NICOTINE AND WITHDRAWAL ON INTRAAXONAL
TRANSPORT OF ACETYLCHOLINE AND RELATED ENZYMES IN SCIATIC-
NERVE OF THE RAT.
003897 04-03
EFFEQS OF ANALGESICS AND CNS-ACTING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS.
004148 04-04
SCIENTIFIC
CA DIAZEPAM LINK? NO SCIENTIFIC TAKERS SO FAR.
003519 03-15
SCIENTIFIC-STUDY
THE OPIATES: TWO CENTURIES OF SCIENTIFIC-STUDY.
000952 01-17
SCL-90
PLACEBO REAQION IN NEUROTICS RATED WITH THE SCL-90
QUESTIONNAIRE.
000976 01-17
SCLEROSING
ISOPRINOSINE IN SUBACUTE SCLEROSING PANENCEPHALITIS.
000687 01-11
REVIEW OF 38 CASES OF SUBACUTE SCLEROSING PANENCEPHALITIS:
EFFEQ OF AMANTADINE ON THE NATURAL COURSE OF THE DISEASE.
000718 01-11
SCOPOLAMINE
INCREASED MUSCARINIC-RECEPTOR BINDING IN RAT-FOREBRAIN AFTER
SCOPOLAMINE.
001351 02-03
EFFEQS OF SCOPOLAMINE ON AGONISTIC-BEHAVIOUR IN MICE.
001690 02-04
DIFFERENTIAL REVERSAL BY SCOPOUMINE AND THIP OF THE
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS.
002948 03-04
EFFEQS OF SCOPOLAMINE, PILOCARPINE, AND OXOTREMORINE ON THE
EXPLORATORY-BEHAVIOR OF TWO PSYCHOGENETICALLY SELECTED
LINES OF RATS IN A COMPLEX MAZE.
003042 03-04
INTERAQION AMONG D-AMPHETAMINE, SCOPOLAMINE AND GENOTYPE
IN AVOIDANCE-BEHAVIOR OF RATS.
003082 03-04
INCREASES IN SKIN-RESISTANCE OF WHITE RATS FOLLOWING
SCOPOLAMINE INJECTION.
003138 03-06
SCOPOLAMINE IN CHOLINOLYTIC TREATMENT.
004468 04-1 1
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL,
SCOPOLAMINE, AND PLACEBO.
004544 04-13
SCOPOLAMINE-INDUCED
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON SCOPOLAMINE-
INDUCED LOCOMOTOR-STIMUIATION IN MICE.
001768 02-04
TIME-DEPENDENT CHANGES IN ANTEROGRADE SCOPOLAMINE-INDUCED
AMNESIA IN RATS
004182 04-04
BEHAVIORAL AND BIOCHEMICAL-STUDIES OF THE SCOPOLAMINE-INDUCED
REVERSAL OF NEUROLEPTIC ACTIVITY
004195 04-04
SCRATCHING-BEHAVIOUR
PHARMACOLOGICAL CHARACTERIZATION OF SCRATCHING-BEHAVIOUR
INDUCED BY INTRACRANIAL INJECTION OF SUBSTANCE-P AND
SOMATOSTATIN.
002980 03-04
SCREENING
A SIMPLE HISTOCHEMICAL SCREENING METHOD FOR AMINE UPTAKE.
004295 04-06
MASS SCREENING AND CONFIRMATION OF DIAZEPAM IN URINE BY EMIT
THIN-LAYER-CHROMATOGRAPHY.
004672 04-16
SCREENING-TEST
APPLICATION OF A RADIOIMMUNOASSAY SCREENING-TEST FOR
DETECTION AND MANAGEMENT OF PHENCYCLIDINE INTOXICATION.
000859 01-15
OXOTREMORINE BEHAVIOURAL-EFFECTS AS A SCREENING-TEST IN MICE.
001072 02-02
SE-5023
CORRELATED STUDY OF THE EFFECTS OF SE-5023 IN AN HYPOXIC
ATMOSPHERE ON QUANTIFIED EEG, VIGILANCE, MEMORY, AND
MOOD.
003440 03-14
SECOBARBITAL
DOSE-EFFECTS OF SECOBARBITAL IN A STERNBERG MEMORY SCANNING
TASK.
003460 03-14
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND
AUGMENTING RESPONSES IN RABBITS.
004022 04-03
CHOICE BETWEEN FOOD AND HEROIN: EFFECTS OF MORPHINE,
NALOXONE, AND SECOBARBITAL.
004123 04-04
HUMAN SOCIAL CONVERSATION: EFFECTS OF ETHANOL, SECOBARBITAL
AND CHLORPROMAZINE.
004582 04-14
SECOND-GENERATION
CLINICAL-EXPERIENCE WITH SECOND-GENERATION ANTIDEPRESSANTS IN
ENDOGENOUS DEPRESSIONS.
001975 02-09
SECOND-GENERATION ANTIDEPRESSANTS.
002042 02-09
SECOND-GENERATION ANTIDEPRESSANTS: A CLINICAL
PHARMACOTHERAPEUTIC RESEARCH STRATEGY.
003632 03-17
PHARMACOLOGICAL-PROPERTIES OF SOME SECOND-GENERATION
ANTIDEPRESSANT-DRUGS.
004726 04-17
SECOND-ORDER
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION
AND EFFECTS OF D-AMPHETAMINE AND PROMAZINE.
004152 04-04
SECRET
ADRENALINE: A SECRET AGENT IN MEMORY.
002345 02-14
SECRETION
ADMINISTRATION OF ANTISOMATOSTATIN SERUM TO RATS REVERSES
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION
PRODUCED BY INJECTION OF METERGOLINE BUT NOT YOHIMBINE.
(UNPUBLISHED PAPER).
000019 01-03
L TRYPTOPHAN INJECTION ENHANCES PULSATILE GROWTH-HORMONE
SECRETION IN THE RAT. (UNPUBLISHED PAPER).
000020 01-03
ALPHA FLUPENTHIXOL: AN ANTAGONIST OF DOPAMINE-EVOKED FLUID
SECRETION BY AN INSECT SALIVARY-GLAND PREPARATION.
000031 01-03
MORPHINE ACTS THROUGH ALPHA-ADRENERGIC AND SEROTONINERGIC
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG.
000088 01-03
EVIDENCE FOR A DIRECT INHIBITORY-EFFECT OF MORPHINE ON THE
SECRETION OF POSTERIOR PITUITARY-HORMONES.
000193 01-03
EFFEQS OF NORADRENERGIC AGONISTS AND ANTAGONISTS ON
GROWTH-HORMONE SECRETION UNDER GAMMA HYDROXYBUTYRATE
NARCOANALGESIA IN THE RAT.
000262 01-03
EFFECT OF SEROTONIN ON PROLACTIN SECRETION IN VIVO.
001016 02-01
S-399
tjj,,
il
5
ftw
fe
I
Subject Index
RELEASE OF ARACHIDONIC-ACID FROM ADRENAL CHROMAFFIN CELL-
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED
PAPER).
001027 02-01
ALTERATION OF PROLAQIN SECRETION BY CENTRALLY-ACTING DRUGS
001127 02-03
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION).
001213 02-03
OPIATE-RECEPTOR MEDIATED INHIBITION OF RAT JEJUNAL-FLUID
SECRETION.
001334 02-03
MODIFICATION OF GABAERGIC ACTIVITY AND THYROTROPIN SECRETION
IN MALE RATS.
001362 02-03
EFFECTS OF NEUROLEPTICS ON NEUROENDOCRINE MECHANISMS FOR
GONADOTROPIN SECRETION.
001391 02-03
A PHARMACOLOGICAL ANALYSIS OF THE ROLE OF THE AMYGDALA IN
THE CONTROL OF GONADOTROPIN AND PROLACTIN SECRETION
001418 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
EFFECT OF L TRYPTOPHAN ON APOMORPHINE-INDUCED GROWTH-
HORMONE SECRETION IN NORMAL SUBJECTS.
002253 02-13
INHIBITION OF SULPIRIDE-INDUCED PROLACTIN SECRETION BY
DIHYDROERGOCRISTINE IN MAN.
002277 02-13
THE CLOCK AND THE BLUE GUITAR: STUDIES OF HUMAN GROWTH-
HORMONE SECRETION IN SLEEP AND WAKING (UNPUBLISHED PAPER).
002346 02-14
THE INFLUENCE OF NEUROLEPTIC-DRUGS ON PROLACTIN SECRETION IN
CHILDREN.
002409 02-15
HALOPERIDOL STIMULATION OF PROLACTIN SECRETION: HOW MANY
BLOOD SAMPLES ARE NEEDED TO DEFINE THE HORMONE RESPONSE?
002505 02-16
INAPPROPRIATE ADH SECRETION: THE ROLE OF DRUG RECHALLENGE
002629 02-17
EFFECTS OF ELECTROCONVULSIVE-TREATMENT ON GROWTH-HORMONE
SECRETION INDUCED BY MONOAMINE-RECEPTOR AGONISTS IN
RESERPINE PRETREATED RATS.
002664 03-03
EFFECTS OF AN EPINEPHRINE SYNTHESIS INHIBITOR, SKF-64139 ON THE
SECRETION OF LUTEINIZING-HORMONE IN OVARIECTOMIZED FEMALE
RATS.
002693 03-03
ANTERIOR PITUITARY GABA-RECEPTORS AND THEIR REGULATION OF
PROLACTIN SECRETION.
002738 03-03
STUDIES ON THE MECHANISMS OF L-DOPA-INDUCED SALIVARY
SECRETION.
003130 03-05
EFFECT OF A PSYCHOACTIVE-DRUG, TRAZODONE, ON PROLACTIN
SECRETION IN MAN.
003425 03-13
EFFECT OF NICOTINE ON IN VIVO SECRETION OF MELANOCORTICOTROPIC-
HORMONES IN THE RAT.
003759 04-03
INHIBITION OF PENTAGASTRIN-STIMULATED AND OVERNIGHT GASTRIC
SECRETION BY LM24056, A NEW PHENOTHIAZINE DERIVED
ANTISECRETORY DRUG.
004306 04-07
SECRETIONS
RENIN AND ALDOSTERONE SECRETIONS DURING HYPOVOLEMIA IN RATS
RELATION TO NACL INTAKE.
000484 01-04
EFFECTS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN
HEALTHY TEST SUBJECTS, NEUROTIC-PATIENTS, AND ENDOGENOUS
DEPRESSIVE-PATIENTS.
002009 02-09
SEDATION
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE-
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM ~ A
CONTROLLED-TRIAL.
002329 02-14
ETHYL-BETA-CARBOLINE-CARBOXYLATE LOWERS SEIZURE THRESHOLD
AND ANTAGONIZES FLURAZEPAM-INDUCED SEDATION IN RATS
002971 03-04
ENHANCEMENT OF ETHANOL-INDUCED SEDATION AND HYPOTHERMIA BY
CENTRALLY ADMINISTERED NEUROTENSIN, BETA ENDORPHIN AND
BOMBESIN.
003037 03-04
Ptychopharmacology Abstracts
SEDATIVE
IN VIVO OCCUPATION OF CEREBRAL HISTAMINE HI -RECEPTORS
EVALUATED WITH 3H MEPYRAMINE MAY PREDIQ SEDATIVE
PROPERTIES OF PSYCHOTROPIC-DRUGS.
000241 01-03
PHARMACOLOGICAL-PROPERTIES OF TAGLUTIMIDE, A NEW SEDATIVE
HYPNOTIC-DRUG.
001087 02-02
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY
SPECTRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND
NEUROLEPTICS.
001220 02-03
THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPECTS OF SLEEP AND OBJECTIVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOQURNAL
MEDICATION: II. REPEATED DOSES.
002331 02-14
EVIDENCE FOR SEDATIVE EFFECTS OF LOW-DOSES OF MORPHINE IN MICE
INVOLVING RECEPTORS INSENSITIVE TO NALOXONE.
004173 04-04
ETHANOL SEDATIVE HYPNOTIC-INTERACTIONS: IN VITRO STUDIES ON NA-
K-ACTIVATED ADENOSINE-TRIPHOSPHATASE.
004269 04-05
AGE-SPECIFIC DOSES OF LORMETAZEPAM AS A NIGHT SEDATIVE IN
CASES OF CHRONIC SLEEP-DISTURBANCE.
004309 04-07
SEIZURE
RELATIONSHIPS BETWEEN SEIZURE ACTIVITY AND CYCLIC-NUCLEOTIDE
LEVELS IN BRAIN.
000089 01-03
EFFECTS OF RESERPINE, PROPRANOLOL, AND AMINOPHYLLINE ON
SEIZURE ACTIVITY AND CNS CYCLIC-NUCLEOTIDES.
000115 01-03
FLASH-EVOKED AFTERDISCHARGE IN RAT AS A MODEL OF THE ABSENCE
SEIZURE: DOSE-RESPONSE STUDIES WITH THERAPEUTIC DRUGS.
000160 01-03
RELATION OF MONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION
IN CATS.
000474 01-04
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE
MANIFESTATION.
000496 01-04
DRUG AND SEIZURE IDENTIFICATION BY AUDIO-SPEQROMETRY. (PH D
DISSERTATION)
000532 01-06
FACTORS INFLUENCING SEIZURE DURATION AND NUMBER OF SEIZURES
APPLIED IN UNILATERAL ELECTROCONVULSIVE-THERAPY: ANESTHETICS
AND BENZODIAZEPINES.
000792 01-13
PROLONGED CONFUSIONAL-STATE AND EEG SEIZURE AQIVITY
FOLLOWING CONCURRENT EQ AND LITHIUM USE.
000895 01-15
PENTYLENETETRAZOL SEIZURE THRESHOLD: A QUANTITATIVE MEASURE
OF ETHANOL DEPENDENCE IN RATS.
001750 02-04
A PHARMACOLOGICAL INVESTIGATION OF AN ANIMAL-MODEL OF THE
PETIT-MAL SEIZURE (PHD DISSERTATION).
001870 02-06
BEHAVIORAL-INTERVENTION FOR SELF-STIMULATORY, AHENDING AND
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILD.
002104 02-11
ETHYL-BETA-CARBOLINE-CARBOXYLATE LOWERS SEIZURE THRESHOLD
AND ANTAGONIZES FLURAZEPAM-INDUCED SEDATION IN RATS
002971 03-04
EFFECT OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE
DISCHARGE INDUCED BY CARBACHOL IN THE RABBIT.
003951 04-03
COCAINE AND SEIZURE PROTEQION IN MICE OF VARYING BRAIN
WEIGHTS.
004103 04-04
NEW ANTIDEPRESSANT-DRUGS AND THE SEIZURE THRESHOLD.
004662 04-15
SEIZURES
SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE:
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT
000095 01-03
THE EFFECTS OF RESERPINE, IPRONIAZIO AND L-DOPA ON ELEaRICALLY-
INDUCED SPINAL-CORD SEIZURES.
000146 01-03
DISSIMILAR EFFECTS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE.
000173 01-03
S-400
VOLUME 19, SUBJECT INDEX
Subject Index
fACTORS INFLUENCING SEIZURE DURATION AND NUMBER OF SEIZURES
APPLIED IN UNILATERAL ELECTROCONVULSIVE-THERAPY; ANESTHETICS
AND BENZODIAZEPINES.
000792 01-13
NEUROLOGICAL SIDE-EFFECTS OF LITHIUM: ORGANIC-BRAIN-SYNDROME,
SEIZURES, EXTRAPYRAMIDAL SIDE-EFFECTS, AND EEC CHANGES
000847 01-15
SEIZURES DURING TRICYCLIC THERAPY.
000868 01-15
EFFECTS OF BICUCULLINE-INDUCED SEIZURES ON CEREBRAL METABOLISM
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY
STARVATION.
001134 02-03
ENERGY RESERVES AND SOUND-INDUCED SEIZURES. (UNPUBLISHED
PAPER).
001467 02-03
BARBITURATE SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
001559 02-04
PHARMACOLOGICAL MODIFICATION OF AMYGDALOID KINDLED
SEIZURES.
001588 02-04
NEUROPHARMACOLOGICAL ANALYSIS OF HANDLING-INDUCED SEIZURES
IN GERBILS.
001876 02-06
EFFECTS OF ORAL CHOLINE ON HUMAN COMPLEX PARTIAL SEIZURES.
002149 02-11
THE ANTICONVULSANT PROPERTIES OF MELATONIN ON KINDLED
SEIZURES IN RATS
002653 03-03
CAFFEINE-INDUCED AND AMINOPHYLLINE-INDUCED SEIZURES.
002689 03-03
CUMULATIVE AFTERDISCHARGE AS THE PRINCIPAL FACTOR IN THE
ACQUISITION OF KINDLED SEIZURES.
002862 03-03
VOLTAGE CLAMP STUDY OF CAT SPINAL MOTONEURONS DURING
STRYCHNINE-INDUCED SEIZURES.
002886 03-03
KAINIC-ACID NEUROTOXICITY AND SEIZURES.
002939 03-03
VALPROIC-ACID SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
002946 03-04
THE EFFECTS OF VARIOUS ANESTHETICS ON AMYGDALOID KINDLED
SEIZURES.
002959 03-04
SEIZURES ELICITED BY SUBCUTANEOUS INJECTION OF METRAZOL DURING
ONTOGENESIS IN RATS.
003039 03-04
THE EFFEQ OF AMYGDALA KINDLING ON SPONTANEOUS AND COCAINE-
INDUCED MOTOR-ACTIVITY AND LIDOCAINE SEIZURES.
003067 03-04
BRAIN BENZODIAZEPINE-RECEPTORS AND THEIR RAPID CHANGES AFTER
SEIZURES IN THE MONGOLIAN-GERBIL.
003717 04-03
SPECIFIC AND NONSPECIFIC MULTIPLE UNIT ACTIVITIES DURING
PENTYLENETETRAZOL SEIZURES. I. ANIMALS WITH ENCEPHALE ISOLE.
004046 04-03
RELATIONSHIP BETWEEN PENTYLENETETRAZOL-INDUCED SEIZURES AND
BRAIN PENTYLENETETRAZOL LEVELS IN MICE.
004061 04-03
EFFECTS OF WITHDRAWAL FROM LONG-TERM DIPHENYLHYDANTOIN
TREATMENT ON AUDIOGENIC-SEIZURES AND MAXIMAL
ELECTROSHOCK-INDUCED SEIZURES IN RATS.
004101 04-04
NORADRENERGIC INFLUENCES ON SOUND-INDUCED SEIZURES.
004137 04-04
EFFECTS OF NOREPINEPHRINE AND 5 HYDROXYTRYPTAMINE REUPTAKE
INHIBITORS ON ELECTRICALLY-INDUCED SPINAL-CORD SEIZURES IN
RATS.
004144 04-04
EFFECTS OF FLUOXETINE ON ELECTRICALLY-INDUCED SPINAL-CORD
SEIZURES IN RATS.
004145 04-04
EFFECTS OF 3 SULFAMOYLMETHYL-BENZISOXAZOLE (AD-810) AND SOME
ANTIEPILEPTICS ON THE KINDLED SEIZURES IN THE NEOCORTEX,
HIPPOCAMPUS AND AMYGDALA IN RATS
004149 04-04
EFFECT OF GAMMA VINYL-GABA ON BICUCULLINE-INDUCED SEIZURES.
004157 04-04
THE BENZODIAZEPINES AND INOSINE ANTAGONIZE CAFFEINE-INDUCED
SEIZURES.
004172 04-04
HANDLING-INDUCED SEIZURES AND ROTATIONAL-BEHAVIOR IN THE
MONGOLIAN-GERBIL.
004216 04-04
SEROTONERGIC MECHANISM IN SEIZURES KINDLED FROM THE RABBIT
AMYGDALA.
004227 04-04
EFFECT OF COCAINE AND LIDOCAINE ON THE EXPRESSION OF KINDLED
SEIZURES IN THE RAT.
004233 04-04
SELECTING
ROLE OF THE NEOSTRIATAL DOPAMINERGIC-ACTIVITY IN SEQUENCING
AND SELECTING BEHAVIOURAL-STRATEGIES; FACILITATION OF
PROCESSES INVOLVED IN SELECTING THE BEST STRATEGY IN A
STRESSFUL-SITUATION.
000366 01-04
SELECTION
LSD-25 AS A DISCRIMINATIVE-STIMULUS FOR RESPONSE SELECTION BY
PIGEONS.
000412 01-04
THE SELECTION OF LITHIUM RESPONDERS.
000997 01-17
SELECTIVE
ARYLDIALKENYLPIPERAZINES AS SELECTIVE AND VERY POTENT
INHIBITORS OF DOPAMINE UPTAKE.
000005 01-01
SELECTIVE STORAGE IN VIVO OF 5,6 ADTN IN DOPAMINE RICH AREAS OF
THE RAT-BRAIN.
000324 01-03
DISRUPTION OF SELECTIVE ATTENTION BY APOMORPHINE, BUT NOT
AMPHETAMINE, IN THE MONGOLIAN-GERBIL.
000358 01-04
RELATIONSHIPS BETWEEN SELECTIVE DENERVATION OF DOPAMINE
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL-
RESPONSES TO AMPHETAMINE AND APOMORPHINE.
000384 01-04
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS.
000466 01-04
SELECTIVE INHIBITION OF MESOLIMBIC BEHAVIORAL-SUPERSENSITIVITY
BY NALOXONE.
000467 01-04
METOCLOPRAMIDE AND SULPIRIDE AS SELECTIVE BLOCKING-AGENTS
PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS.
001102 02-03
ISOLATION OF SELECTIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES,
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE.
001162 02-03
SELECTIVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS.
001447 02-03
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELECTIVE
5 HT UPTAKE INHIBITOR.
001517 02-03
MODULATION OF OPIATE-RECEPTOR BINDING IN STRIATUM AND
AMYGDALA BY SELECTIVE MESENCEPHALIC LESIONS.
001629 02-04
SELECTIVE REDUCTION BY DEXAMETHASONE OF STRESS RELATED
HYPERPHAGIAS.
001703 02-04
EFFECT OF SELECTIVE DESTRUCTION OF SEROTONERGIC NEURONS IN
NUCLEUS-RAPHE-MAGNUS ON MORPHINE-INDUCED ANTINOCICEPTION.
001724 02-04
EFFECTS OF METHYLPHENIDATE ON SELECTIVE AND SUSTAINED
AHENTION IN HYPERACTIVE, READING-DISABLED, AND PRESUMABLY
ATTENTION-DISORDERED BOYS.
002118 02-11
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A
SELECTIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST.
002236 02-13
THE EFFECT OF DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, ON SLEEP AND MOOD IN MAN.
002365 02-14
APOMORPHINE: SELECTIVE INHIBITION OF THE AVERSIVE COMPONENT OF
LATERAL HYPOTHALAMIC SELF-STIMULATION.
002476 02-16
SELECTIVE ANTAGONISTS OF BENZODIAZEPINES.
002646 03-02
DU-24565, A QUIPAZINE DERIVATIVE, A POTENT SELECTIVE SEROTONIN
UPTAKE INHIBITOR.
002651 03-02
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA
D(AND L) GLUTAMYLGLYCINE.
002696 03-03
SELECTIVE EFFECTS OF LSD AND HYPERTHERMIA ON THE SYNTHESIS OF
SYNAPTIC PROTEINS AND GLYCOPROTEINS.
002721 03-03
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
S-401
m
«.,
SI
Kit
ii
m.
S:
^
Subject index
SELECTIVE INHIBITION BY NICOTINE OF SHOCK-INDUCED FIGHTING IN THE
RAT.
002984 03-04
SELECTIVE SENSITIZATION INDUCED BY LITHIUM MALAISE AND
FOOTSHOCK IN RATS.
003055 03-04
DIFFERENTIATION OF OPIATE-RECEPTORS IN THE BRAIN BY THE SELECTIVE
DEVELOPMENT OF TOLERANCE.
003088 03-04
SELEQIVE NEUROTOXIC-AQION OF CAPSAICIN ON GLOMERULAR C-TYPE
TERMINALS IN RAT SUBSTANTIA-GELATINOSA.
003143 03-06
SELECTIVE MODIFICATION BY OPIATES OF NEURONAL AQIVITY OF THE
MEDIAL BASAL HYPOTHALAMUS.
003773 04-03
ANESTHETICS AND THE HABENULO-INTERPEDUNCULAR SYSTEM:
SELEaiVE SPARING OF METABOLIC ACTIVITY.
003833 04-03
SENSORY NEUROTOXINS: CHEMICALLY-INDUCED SELECTIVE DESTRUQION
OF PRIMARY SENSORY NEURONS.
003859 04-03
MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN:
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS.
003992 04-03
PHYSIOLOGICAL SIGNIFICANCE OF DOPAMINE-AUTORECEPTORS AS
STUDIED FOLLOWING THEIR SELECTIVE BLOCKADE BY MOLINDONE.
004065 04-04
SELECTIVE EFFEQ OF ETHANOL ON THE VESTIBULAR NUCLEUS NEURONS
IN THE CAT.
004139 04-04
SELECTIVE INHIBITORY-EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE
ON PLATELET AGGREGATION.
004518 04-13
SELEQIVE EFFECTS OF BARBITURATE AND AMPHETAMINE ON
INFORMATION-PROCESSING AND RESPONSE EXECUTION
004563 04-14
IS THE FAILURE OF (-)DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM
THE CHEESE EFFECT?
004640 04-15
HUMAN PLATELET ALPHA2-ADRENERGIC-RECEPT0RS: LABELING WITH 3H
YOHIMBINE, A SELECTIVE ANTAGONIST LIGAND.
004676 04-16
SELECTIVITY
A REEVALUATION OF THE MECHANISMS UNDERLYING SIMPLE CELL
ORIENTATION SELEQIVITY.
002894 03-03
AMINE UPTAKE INHIBITORS: CRITERIA OF SELECTIVITY.
003921 04-03
SELF-ADMINISTERED
INFLUENCE OF INTRAVENOUS SELF-ADMINISTERED PSYCHOMOTOR
STIMULANTS ON PERFORMANCE OF RHESUS-MONKEYS IN A MULTIPLE-
SCHEDULE PARADIGM.
001655 02-04
THE RELATIONSHIP BETWEEN POSITIVE REINFORCEMENT AND
CONDITIONED TASTE-AVERSION PRODUCED BY SELF-ADMINISTERED
DRUGS.- (PH.D. DISSERTATION).
001798 02-04
BEHAVIORAL-EFFEQS OF SELF-ADMINISTERED COCAINE: RESPONDING
MAINTAINED ALTERNATELY BY COCAINE AND ELEQRIC-SHOCK IN
SQUIRREL-MONKEYS.
004225 04-04
SELF-ADMINISTRATION
CONTINUOUS-ACCESS PHENCYCLIDINE SELF-ADMINISTRATION BY RHESUS-
MONKEYS LEADING TO PHYSICAL-DEPENDENCE.
000341 01-04
LETHAL SELF-ADMINISTRATION OF MORPHINE BY RATS.
000343 01-04
DOSE AND PHYSICAL-DEPENDENCE AS FAQORS IN THE SELF-
ADMINISTRATION OF MORPHINE BY RATS.
000497 01-04
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM)
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND
DINORLAAM, DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT.
000505 01-04
SELF-ADMINISTRATION OF D-AMPHET AMINE AND AMINERGIC SYSTEMS
IN THE RAT.
001696 02-04
SELF-ADMINISTRATION OF D ALA2-MET-ENKEPHALINAMIDE AT
HYPOTHALAMIC SELF-STIMULATION SITES.
001738 02-04
INTRAVENOUS SELF-ADMINISTRATION OF COCAINE AND NORCOCAINE BY
DOGS.
001760 02-04
INTRACRANIAL SELF-ADMINISTRATION OF MORPHINE INTO THE VENTRAL
TEGMENTAL AREA IN RATS.
002960 03-04
Ptychopharmacology Abstracts
RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE
POSTADDICT RATS: A POSSIBLE MODEL FOR PREOIQING ABUSE
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION)
003097 03-04
OPERANT ANALYSIS OF HUMAN HEROIN SELF-ADMINISTRATION AND THE
EFFEQS OF NALTREXONE.
003449 03-14
EFFECTS OF LEVO ALPHA ACETYLMETHADOL (LAAM) ON MORPHINE SELf-
ADMINISTRATION IN THE RAT.
004170 04-04
ORAL SELF-ADMINISTRATION OF MORPHINE IN RATS.
004258 04-04
AN IMPROVED PNEUMATIC SYRINGE FOR SELF-ADMINISTRATION OF
DRUGS BY RATS.
004304 04-06
SELF-BITING
PEMOLINE-INDUCED SELF-BITING IN RATS AND SELF-MUTILATION IN THE
DELANGE-SYNDROME.
001727 02-04
SELF-EVALUATION
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS
000543 01-07
SELF-INDUCED
ANTECEDENTS OF SELF-INDUCED WATER INTOXICATION: A PRELIMINARY-
REPORT.
002414 02-15
SELF-INJECTION
REVERSAL OF SCHEDULE-INDUCED SELF-INJEQION OF HEROIN BY
NALOXONE.
000446 01-04
EFFEQS OF BODY-WEIGHT LEVELS ON CANNABIS SELF-INJEQION.
001801 02-04
SELF-INJURY
SELF-INJURY IN SUBNORMAL-PATIENTS.
003452 03-14
SELF-MEDICATION
SELF-MEDICATION, ABANDONMENT, MANIPULATION AND DEPENDENCE
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS
002189 02-11
SOME ODD PAHERNS OF PSYCHOTROPIC SELF-MEDICATION.
002565 02-17
SELF-MEDICATION.
003574 03-17
SELF-MUTILATION
PEMOLINE-INDUCED SELF-BITING IN RATS AND SELF-MUTILATION IN THE
DELANGE-SYNDROME.
001727 02-04
SELF-RATING
ON THE RELATIONSHIP BETWEEN MEASURES OBTAINED BY VIDEO-
ANALYSIS OF NONVERBAL-BEHAVIOR AND SELF-RATING OF MOOD
004410 04-09
SELF-SELECTION
SUSTAINED DECREASE IN FAT CONSUMPTION PRODUCED BY
AMPHETAMINE IN RATS MAINTAINED ON A DIETARY SELF-SELEQION
REGIME.
004150 04-04
SELF-STIMULATION
ON THE NEUROCHEMICAL BASIS OF SELF-STIMULATION WITH MIDBRAIN
RAPHE ELECTRODE PLACEMENTS.
000373 01-04
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHET AMINE AND
L-AMPHETAMINE: NO INTERACTION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES.
000387 01-04
POSTAMPHETAMINE DEPRESSION OF SELF-STIMULATION RESPONDING
FROM THE SUBSTANTIA-NIGRA: REVERSAL BY TRICYCLIC-
ANTIDEPRESSANTS.
00041901-04
FACILITATION OF SELF-STIMULATION OF THE PREFRONTAL-CORTEX IN
RATS FOLLOWING CHRONIC ADMINISTRATION OF SPIROPERIDOL OR
AMPHETAMINE.
000457 01-04
EFFECTS OF LILLY-1 10140 (FLUOXETINE) ON SELF-STIMULATION
BEHAVIOR IN THE DORSAL AND VENTRAL REGIONS OF THE LATERAL
HYPOTHALAMUS IN THE MOUSE.
001590 02-04
EFFECTS OF AN ACTH4-9 RELATED PEPTIDE UPON INTRACRANIAL SELF-
STIMULATION AND GENERAL-ACTIVITY IN THE RAT
001679 02-04
ENHANCED LATERAL HYPOTHALAMIC SELF-STIMULATION RESPONDING
AFTER CHRONIC EXPOSURE TO AMPHETAMINE.
001688 02-04
EFFECTS OF CHRONIC AMPHETAMINE OR RESERPINE ON SELF-
STIMULATION RESPONDING: ANIMAL-MODEL OF DEPRESSION?
001699 02-04
S-402
VOLUME 19, SUBJECT INDEX
SELF-ADMINISTRATION OF D ALA2-MET-tNKEPHALINAMIDE AT
HYPOTHALAMIC SELF-STIMULATION SITES
001738 02-04
NALOXONE AND SHUTTLEBOX SELF-STIMULATION IN THE RAT.
001793 02-04
FACILITATION OF SELF-STIMULATION IN RATS BY METHADONE.
001795 02-04
APOMORPHINE SELECTIVE INHIBITION OF THE AVERSIVE COMPONENT OF
LATERAL HYPOTHALAMIC SELF-STIMULATION
002476 02-16
SELF-STIMULATION REACTION IN NORMOTENSIVE-RATS AND
HYPERTENSIVE-RATS.
002663 03-03
SMALL-DOSE INTRAVENOUS HEROIN FACILITATES HYPOTHALAMIC SELF-
STIMULATION WITHOUT RESPONSE SUPPRESSION IN RATS.
002999 03-04
CONFLICT-SITUATION BASED ON INTRACRANIAL SELF-STIMULATION
BEHAVIOR AND THE EFFECT OF BENZODIAZEPINES.
003004 03-04
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF-
STIMULATION MODEL USING CLONIDINE.
003016 03-04
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT
ANTICHOLINERGIC-ACTIVITY BY AN ATYPICAL NEUROLEPTIC
(THIORIDAZINE). „„..,„ ^o w
003560 03-16
SELF-STIMULATORY
BEHAVIORAL-INTERVENTION FOR SELF-STIMULATORY, AHENDING AND
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILD.
002104 02-11
SELF-SUSTAINED
INFLUENCE OF CARBAMAZEPINE ON THALAMOCORTICAL AND
HIPPOCAMPOCORTICAL SELF-SUSTAINED AFTERDISCHARGES IN RATS.
001356 02-03
SEMIDEPOTE
MAINTENANCE-TREATMENT WITH SEMIDEPOTE NEUROLEPTIC
FLUSPIRILENE. „„„,., „.,,
002151 02-11
SEMINAR
THE MEDICATION SEMINAR AND PRIMARY CARE EDUCATION.
003592 03-17
SENESCENCE
CEREBRAL SENESCENCE AND ITS PSYCHIC-MANIFESTATIONS. THE
EFFECTIVENESS OF DEBRUMYL.
002105 02-11
SENESCENT
REDUCED TOLERANCE TO MORPHINE THERMOREGULATORY-EFFECTS IN
SENESCENT RATS.
002822 03-03
APOMORPHINE-INDUCED STEREOTYPY IN MATURE AND SENESCENT RATS
FOLLOWING CESSATION OF CHRONIC HALOPERIDOL TREATMENT.
004651 04-15
SENILE-DEMENTIA
DRUGS FOR SENILE-DEMENTIA.
000947 01-17
BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE-
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL-
CONSIDERATIONS.
001550 02-03
PHARMACOLOGIC APPROACHES TO THE TREATMENT OF SENILE-
DEMENTIA.
002809 03-03
THE EFFECTS OF LECITHIN ON MEMORY IN PATIENTS WITH SENILE-
DEMENTIA OF THE ALZHEIMERS-TYPE.
003385 03-1 1
SENILE-DEMENTIA: COMBINED PHARMACOLOGIC-TREATMENT AND
PSYCHOLOGIC-TREATMENT.
003393 03-1 1
ACUTE EFFECT OF DRUGS UPON MEMORY OF PATIENTS WITH SENILE-
DEMENTIA.
004561 04-14
SENILE-DEMENTIA IN ITS STILL GUIDABLE INITIAL PHASE.
004698 04-17
SENSITIVE
DRUG SENSITIVE ECTO-ATPASE IN HUMAN LEUKOCYTES.
000779 01-13
LOCALIZATION OF NALOXONE SENSITIVE {3H)DIHYDR0M0RPHINE
BINDING-SITES WITHIN THE HIPPOCAMPUS OF THE RAT.
001368 02-03
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLitES.
001402 02-03
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS PRESENT A NALOXONE
SENSITIVE DECREASE IN PAIN SENSITIVITY. (UNPUBLISHED PAPER).
001457 02-03
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS,
BRAIN, AND PINEAL-ORGAN OF THE RAT.
002503 02-16
Subject Index
SPECIFIC AND SENSITIVE RADIOIMMUNOASSAY FOR 3 METHOXY-4-
HYDROXYPHENYLETH YLENEGLYCOL (MOPEG) .
002776 03-03
INHIBITORY ACTIONS OF TAUROCYAMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS.
003027 03-04
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS.
003871 04-03
A RAPID AND SENSITIVE RADIORECEPTOR ASSAY FOR TERTIARY AMINE
TRICYCLIC-ANTIDEPRESSANTS.
004689 04-16
A SENSITIVE BENZODIAZEPINE RADIOIMMUNOASSAY OF BROAD
SPECIFICITY.
004693 04-16
SENSITIVITY
THE SENSITIVITY OF THE RAT CORTICOSTERONE RESPONSE TO
ENVIRONMENTAL MANIPULATIONS AND TO CHRONIC
CHLORDIAZEPOXIDE TREATMENT.
000092 01-03
MODIFICATION OF DOPAMINERGIC-RECEPTOR SENSITIVITY IN RAT-BRAIN
AFTER AMYGDALOID KINDLING.
000106 01-03
DIFFERENCES IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY IN
INBRED STRAINS OF MICE.
000303 01-03
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN.
001167 02-03
EFFECTS OF DESIPRAMINE AND YOHIMBINE ON ALPHA2-ADREN0CEPT0R
AND BETA-ADRENOCEPTOR SENSITIVITY.
001305 02-03
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION.
001310 02-03
ENDOGENOUS GUANYL-NUCLEOTIDES: COMPONENTS OF THE STRIATUM
WHICH CONFER DOPAMINE SENSITIVITY TO ADENYLATE-CYCLASE.
001313 02-03
SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS PRESENT A NALOXONE
SENSITIVE DECREASE IN PAIN SENSITIVITY. (UNPUBLISHED PAPER).
001457 02-03
ENHANCED SENSITIVITY OF AMYGDALOID NEURONS TO SEROTONIN AND
NOREPINEPHRINE AFTER CHRONIC ANTIDEPRESSANT TREATMENT.
001523 02-03
TOLERANCE TO ETHANOL-INDUCED IMPAIRMENT OF WATER-ESCAPE IN
RATS BRED FOR ETHANOL SENSITIVITY.
001567 02-04
ETHANOL-INDUCED ANALGESIA IN RATS SELECTIVELY BRED FOR ETHANOL
SENSITIVITY.
001625 02-04
CENTRAL SEROTONIN-RECEPTOR SENSITIVITY IN RATS WITH
EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS.
001821 02-04
PSYCHOACTIVE-DRUG QUANTIFICATION BY VISUAL FLICKER SENSITIVITY
MEASUREMENT. (PH.D. DISSERTATION).
002485 02-16
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND
DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY
OF ADULT SENSORY GANGLION CELLS.
002692 03-03
HYPOPHYSECTOMY INCREASES THE SENSITIVITY OF RATS TO NALOXONE-
INDUCED HYPOTHERMIA.
002710 03-03
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT,
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL- 1 H-INDAZOLE (FS-32)
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR
ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER
CHRONIC ANTIDEPRESSANT TREATMENT.
002788 03-03
L HISTIDINE: EFFECTS ON SENSITIVITY OF CAT SPINAL NEURONES TO
AMINO-ACIDS.
. 002808 03-03
S-403
911
villm,
il
a,:
fe
I
Subject Index
DIFFERENTIAL-EFFEaS OF CLOMIPRAMINE AND CLORGYLINE ON THE
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFEa OF
CHRONIC-TREATMENT.
002847 03-03
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF
BULLFROG SYMPATHETIC GANGLION CELLS.
003710 04-03
THYROXIN SENSITIVITY OF SENSORIMOTOR CORTICAL NEURONS AND THE
HYPOTHALAMIC VENTROMEDIAL NUCLEUS.
003713 04-03
NEURONAL SENSITIVITY OF SOME BRAIN REGIONS TO ANGIOTENSIN-II IN
RABBITS.
003716 04-03
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS:
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO.
003741 04-03
SENSITIVITY TO GABA OF NEURONS OF THE DORSAL AND VENTRAL
LATERAL GENICULATE NUCLEI IN THE RAT.
003877 04-03
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS.
003972 04-03
ALTERATIONS IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY
FOLLOWING ACUTE AND CHRONIC ETHANOL TREATMENTS.
004037 04-03
FAQORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
SEXUAL-BEHAVIOR DECREASES PAIN SENSITIVITY AND STIMULATES
ENDOGENOUS OPIOIDS IN MALE RATS.
004234 04-04
SENSITIZATION
PRESYNAPTIC AND POSTSYNAPTIC MECHANISMS IN HALOPERIDOL-
INDUCED SENSITIZATION TO DOPAMINERGIC AGONISTS.
001392 02-03
SENSITIZATION AND OSCILLATION FOLLOWING REPEATED STIMULATION:
RELATIONSHIP TO AFFECTIVE-ILLNESS AND ITS TREATMENT WITH
LITHIUM AND CARBAMAZEPINE.
002031 02-09
SELEQIVE SENSITIZATION INDUCED BY LITHIUM AAALAISE AND
FOOTSHOCK IN RATS.
003055 03-04
SENSORIMOTOR
REINNERVATION OF THE OENERVATED STRIATUM BY SUBSTANTIA-NIGRA
TRANSPLANTS: FUNQIONAL CONSEQUENCES AS REVEALED BY
PHARMACOLOGICAL AND SENSORIMOTOR TESTING.
000347 01-04
AaiVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT.
001657 02-04
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR
FUNCTIONS RELATED TO MOTIVATED BEHAVIOR.
002815 03-03
THYROXIN SENSITIVITY OF SENSORIMOTOR CORTICAL NEURONS AND THE
HYPOTHALAMIC VENTROMEDIAL NUCLEUS.
003713 04-03
SENSORIMOTOR-DYSFUNCTIONS
APHAGIA, GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR-
DYSFUNQIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS:
EFFEQS OF INSULIN PRETREATMENTS.
001638 02-04
SENSORY
STRYCHNINE EFFEaS ON THE SENSORY RESPONSE PAHERNS OF
RETICULAR FORMATION NEURONS.
001219 02-03
THE EFFEQS OF PIPRADROL ON THE ACQUISITION OF RESPONDING WITH
CONDITIONED REINFORCEMENT: A ROLE FOR SENSORY
PRECONDITIONING.
001572 02-04
SENSORY AND ASSOCIATIVE-EFFEaS OF LSD ON CLASSICAL APPETITIVE-
CONDITIONING OF THE RABBIT JAW MOVEMENT RESPONSE.
001637 02-04
THE USE OF SENSORY INTEGRATIVE DIAGNOSTICS TO PREOIQ
HYPERACTIVE-CHILDRENS RESPONSIVENESS TO METHYLPHENIDATE
(RITALIN) AND PEMOLINE (CYLERT). (PH.D. DISSERTATION).
002133 02-11
EFFEaS OF CYCLOSPASMOL UPON SENSORY PARAMETERS IN PATIENTS
RECOVERING FROM CEREBROVASCULAR-ACCIDENTS.
002360 02-14
OPIATE-RECEPTOR GRADIENTS IN MONKEY CEREBRAL-CORTEX:
CORRESPONDENCE WITH SENSORY PROCESSING HIERARCHIES.
002641 03-01
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE
ANESTHETIZED RATS.
002687 03-03
Ptychopharmacology Abttroctt
A COMPARISON OF THE EFFEQS OF PENTOBARBITAL AND
DIPHENYLHYOANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY
OF ADULT SENSORY GANGLION CELLS.
002692 03-03
SENSORY PROCESSING, CARDIOVASCULAR REAQIVITY, AND THE TYPE A
CORONARY-PRONE BEHAVIOR PAHERN.
003405 03-13
SENSORY NEUROTOXINS: CHEMICALLY-INDUCED SELECTIVE DESTRUCTION
OF PRIMARY SENSORY NEURONS.
003859 04-03
BEHAVIORAL-EVIDENCE THAT SUBSTANCE-P MAY BE A SPINAL-CORD
SENSORY NEUROTRANSMIHER.
004200 04-04
THE ROLE OF RETICULOSEPTAL INPUTS IN THE FORMATION OF DIFFERENT
TYPES OF SENSORY REACTIONS OF THE HIPPOCAMPAL NEURONS.
00451004-13
SENSORY-DISTURBANCES
ON SENSORY-DISTURBANCES OCCURRING DURING NEUROLEPTIC
THERAPY.
003531 03-15
SEPARATION
HPLC SEPARATION OF CHOLECYSTOKININ-PEPTIDES - TWO SYSTEMS
(UNPUBLISHED PAPER).
001005 02-01
SEPARATION OF BARBITURATES USING REVERSE PHASE THIN-LAYER-
CHROMATOGRAPHY.
004670 04-16
SEPHADEX-G-10
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE 3 4
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID AND 5
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP
PURIFICATION ON SEPHADEX-G-10, USING HIGH.
004305 04-06
SEPTAL
MORPHINE INJECTIONS INTO THE PERIAQUEDUCTAL PERIVENTRICULAR
GRAY AHENUATE SEPTAL HYPERREACTIVITY.
000390 01-04
THE EFFECTS OF ACETYLCHOLINE AND GLUTAMATE ON SEPTAL NEURONS
IN VITRO.
002941 03-03
SEPTI
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER
FOREBRAIN REGIONS OF THE RAT.
004171 04-04
SEPTOHIPPOCAMPAL
INTERACTIONS OF NEUROPEPTIDES WITH CHOLINERGIC
SEPTOHIPPOCAMPAL PATHWAY: INDICATION FOR A POSSIBLE
TRANSSYNAPTIC REGULATION. (UNPUBLISHED PAPER).
001062 02-01
LONG-TERM EFFECT OF NEUROLEPTICS ON CORTICOSTERONE
SEPTOHIPPOCAMPAL UPTAKE IN RATS.
001107 02-03
SEPTUM
EVIDENCE OF A DIRECT ACTION OF ANGIOTENSIN-II ON NEURONES IN THE
SEPTUM AND IN THE MEDIAL PREOPTIC-AREA.
000272 01-03
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR.
002945 03-04
SEQUELAE
EFFECTS OF NOMIFENSINE AND DESIPRAMINE ON THE SEQUELAE OF
INTRACEREBRALLY INJECTED 6 OHDA AND 5,6 DHT.
001522 02-03
BEHAVIORAL AND REGIONAL NEUROCHEMICAL SEQUELAE OF
HIPPOCAMPAL DESTRUCTION IN THE RAT.
003721 04-03
SEQUELAE OF 6 MONTHS CONTINUOUS ADMINISTRATION OF CIS(Z)- AND
TRANS(E) FLUPENTHIXOL IN THE RAT.
004282 04-05
SEQUENCE
DEPENDENCE OF THE AVFAIL EFFECT ON THE SEQUENCE OF TRAINING
OPERATIONS.
001086 02-02
SEQUENCING
ROLE OF THE NEOSTRIATAL DOPAMINERGIC-ACTIVITY IN SEQUENCING
AND SELECTING BEHAVIOURAL- STRATEGIES: FACILITATION OF
PROCESSES INVOLVED IN SELECTING THE BEST STRATEGY IN A
STRESSFUL-SITUATION.
000366 01-04
APOMORPHINE: EFFECTS ON THE TIMING AND SEQUENCING OF PECKING-
BEHAVIOR IN CHICKS.
000428 01-04
SERIAL
SERIAL COGNITIVE TESTING IN CANCER-PATIENTS RECEIVING
CHEMOTHERAPY.
000876 01-15
S-404
VOLUME 19, SUBJECT INDEX
CENTRAL ADMINISTRATION OF SERINE CAUSES HYPOTHERMIA AND
INHIBITS FEVER IN RABBITS ^, ^^ „^
001247 02-03
COMPARISON OF THE EFFECTS OF CENTRAL ADMINISTRATION OF SERINE
AND GLYCINE ON BODY-TEMPERATURE OF THE RABBIT
001248 02-03
SEROTONERGIC
SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA-
ADRENOCEPTOR ANTAGONISTS: EVIDENCE AGAINST GABA
MEDIATION, „„„„ „, „^
000024 01-03
EVIDENCE FOR A RECEPTOR SUPERSENSITIVITY FOLLOWING IMPAIRMENT
OF CENTRAL SEROTONERGIC ACTIVITY IN THE RABBIT.
000041 01-03
THE INVOLVEMENT OF SEROTONERGIC NEURONS IN THE CENTRAL-
NERVOUS-SYSTEM AS THE POSSIBLE MECHANISM FOR SLOW HEAD-
SHAKING-BEHAVIOR INDUCED BY METHAMPHETAMINE IN RATS.
000408 01-04
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL-
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL
SEROTONERGIC FUNCTION. ^
000491 01-04
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC
DRUGS.
001330 02-03
EFFEQ OF SINGLE AND REPEATED ELECTROCONVULSIVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN - I. METABOLIC-STUDIES.
001332 02-03
SEROTONERGIC AND CATECHOLAMINERGIC INFLUENCE ON THYROID-
FUNCTION IN THE VERVET-MONKEY.
001385 02-03
EFFEaS OF DIFFERENT MONOAMINE-OXIDASE-INHIBITORS ON
RESPIRATORY ACTIVITY IN RATS WITH CHRONICALLY IMPAIRED
CENTRAL SEROTONERGIC FUNCTION.
001389 02-03
EFFEaS OF KAINIC-ACID ON BODY-TEMPERATURE OF RATS: ROLE OF
CATECHOLAMINERGIC AND SEROTONERGIC SYSTEMS.
001515 02-03
AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION
IN RATS: EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING-
AGENTS.
001531 02-03
EFFEQS OF SEROTONERGIC LESIONS ON INVESTIGATORY RESPONDING BY
RATS IN A HOLEBOARD.
001634 02-04
EFFEQ OF SINGLE AND REPEATED ELEaROCONVULSIVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN - II. BEHAVIOURAL- STUDIES.
001697 02-04
EFFEQ OF SELEQIVE DESTRUCTION OF SEROTONERGIC NEURONS IN
NUCLEUS-RAPHE-MAGNUS ON MORPHINE-INDUCED ANTINOCICEPTION.
001724 02-04
PRESYNAPTIC AND POSTSYNAPTIC SEROTONERGIC MANIPULATIONS IN
AN ANIMAL-MODEL OF DEPRESSION.
001730 02-04
SEROTONERGIC PROPERTIES OF BETA PHENETHYLAMINE IN RATS.
001787 02-04
THE FUNQIONAL IMPORTANCE OF INCREASED BRAIN TRYPTOPHAN IN
THE SEROTONERGIC RESPONSE TO RESTRAINT STRESS.
002779 03-03
SEROTONERGIC MECHANISMS OF CLONIDINE-INDUCED HYPOTHERMIA IN
RATS.
002806 03-03
IN VITRO CELLULAR ADAPTATION OF SEROTONERGIC PROCESSES ARER
CHRONIC CENTRAL PHENOBARBITAL ADMINISTRATION.
002813 03-03
DIFFERENTIAL-EFFEaS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNCTION IN CAT BRAIN.
00291 1 03-03
THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS.
003397 03-12
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED
SEROTONERGIC MECHANISMS.
003748 04-03
COMPARATIVE-EFFEaS OF SUBSTITUTED PHENYLETHYLAMINES ON BRAIN
SEROTONERGIC MECHANISMS.
003854 04-03
AN EVALUATION OF THE MECHANISM BY WHICH SEROTONERGIC
AQIVATION DEPRESSES RESPIRATION.
003917 04-03
APPARENT SEROTONERGIC MODULATION OF THE DOSE-DEPENDENT
BIPHASIC RESPONSE OF NEOSTRIATAL NEURONS PRODUCED BY D-
AMPHET AMINE.
003981 04-03
Subject Index
A COMMON MECHANISM FOR LYSERGIC-ACID, INDOLEALKYLAMINE AND
PHENETHYLAMINE HALLUCINOGENS: SEROTONERGIC MEDIATION OF
BEHAVIORAL-EFFECTS IN RATS.
004007 04-03
EFFECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC
*'''^'''' 004026 04-03
SEROTONERGIC MECHANISM IN SEIZURES KINDLED FROM THE RABBIT
AMYGDALA. „„,„,„.
004227 04-04
TONIC IMMOBILITY IN DOMESTIC FOWL: POSSIBLE INTERACTION OF
SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
004246 04-04
PERIPHERAL SEROTONERGIC AND ADRENERGIC RESPONSES IN
DEPRESSION. „ „„
004364 04-09
SEROTONERGIC APPROACHES TO THE MODIFICATION OF BEHAVIOR IN
THE LESCH-NYHANS-SYNDROME.
004576 04-14
SEROTONERGIC-AGENTS
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF
ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS
INCLUDING ANTIDEPRESSANTS.
002532 02-17
THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA.
002976 03-04
SEROTONER6IC-RECEPTORS
SELEaiVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS.
001447 02-03
DIFFERENTIAL-EFFEQ OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC-
RECEPTORS.
002914 03-03
THE EFFECTS OF TRYPTOPHAN AND MANIPULATIONS OF SEROTONERGIC-
RECEPTORS ON TONIC IMMOBILITY IN CHICKENS.
004245 04-04
SEROTONERGICALLY-INFLUENCED
PERIPHERAL-CORRELATES OF SEROTONERGICALLY-INFLUENCED
BEHAVIORS IN VERVET-MONKEYS (CERCOPITHECUS-AETHIOPS-
SABAEUS). ,
004204 04-04
SEROTONIN
ANTIHISTAMINE EFFECT ON SYNAPTOSOMAL UPTAKE OF SEROTONIN,
NOREPINEPHRINE AND DOPAMINE.
000035 01-03
ACUTE VERSUS CHRONIC EFFECTS OF SEROTONIN UPTAKE BLOCKERS ON
POTENTIATION OF THE SEROTONIN SYNDROME.
000050 01-03
RELATIONSHIP OF ANTICONFLICT ACTIVITY OF BENZODIAZEPINES TO
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA.
000057 01-03
ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS.
(UNPUBLISHED PAPER). „„„„,„ „, „o
000060 01-03
MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS:
MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN.
000068 01-03
SEROTONIN PARTICIPATION IN GUT WITHDRAWAL FROM OPIATES.
000109 01-03
HYPOALGESIA INDUCED BY MICROINJEQION OF A NOREPINEPHRINE
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL
ADMINISTRATION OF A SEROTONIN ANTAGONIST.
000121 01-03
EFFECTS OF CHRONIC FLUOXETINE ADMINISTRATION ON SEROTONIN
METABOLISM. „ „ „„
000138 01-03
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS.
000171 01-03
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - I. KINETIC PARAMETERS
AND PHARMACOLOGICAL-PROPERTIES.
000213 01-03
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - II. RESPECTIVE REGIONAL
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC
DEVELOPMENTS.
000214 01-03
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS.
000258 01-03
S-405
Subject Index
Psychopharmacology Abstracts i
Mitff
Mi,
ii
St
&!■
fe
I
I
THE INABILITY OF CHRONIC FLUOXETINE TO POTENTIATE A SEROTONIN
MEDIATED EFFECT.
000293 01-03
ANALYSIS OF THE ACTIVATION OF DOPAMINE METABOLISM BY A
SEROTONIN UPTAKE INHIBITOR.
000315 01-03
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE:
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER
SEROTONIN UPTAKE BLOCKERS.
000316 01-03
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR-
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS.
000466 01-04
THE EFFEQ OF SEROTONIN DEPLETION ON THE DISCRIMINABILITY OF LSD.
000499 01-04
IN VITRO EFFECT OF PHENCYCLIDINE AND OTHER PSYCHOMOTOR
STIMULANTS ON SEROTONIN UPTAKE IN HUMAN PLATELETS.
000750 01-13
MOTOR-EFFECTS OF SEROTONIN IN THE CENTRAL-NERVOUS-SYSTEM.
000941 01-17
MONOAMINES AND DEPRESSION: AN INTERIM REPORT. I. SEROTONIN
AND SEROTONIN PRECURSORS.
000996 01-17
EFFECT OF SEROTONIN ON PROLACTIN SECRETION IN VIVO.
001016 02-01
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY
HUMAN BLOOD-PLATELETS.
001067 02-02
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES
001078 02-02
INCREASED METABOLISM OF DOPAMINE AND SEROTONIN INDUCED IN
FOREBRAIN AREAS BY ETORPHINE MICROINJECTION IN
PERIAQUEDUCTAL GRAY.
001103 02-03
EFFECTS OF GABA AND DIAZEPAM ON 3H SEROTONIN RELEASE FROM
HIPPOCAMPAL SYNAPTOSOMES.
001116 02-03
ROLES OF SEROTONIN AND GAMMA AMINOBUTYRIC-ACID IN OPIOID
EFFECTS.
001140 02-03
BRAIN SEROTONIN AND 5 HYDROXYINDOLEACETIC-ACID
CONCENTRATIONS AND SEROTONIN SYNTHESIS FOLLOWING
TETRAHYDRO-BETA-CARBOLINE ADMINISTRATION IN MICE
001152 02-03
MULTIPLE RECEPTORS FOR SEROTONIN IN THE RAT-BRAIN
001269 02-03
THE EFFECT OF MORPHINE ON THE CONTENT OF SEROTONIN 5
HYDROXYINDOLEACETIC-ACID AND SUBSTANCE-P IN THE NUCLEI
RAPHE-MAGNUS AND RETICULARIS-GIGANTOCELLUURIS
001328 02-03
PERSISTENT EFFECTS OF CHRONIC ADMINISTRATION OF LSD ON
INTRACELLULAR SEROTONIN CONTENT IN RAT-MIDBRAIN
001333 02-03
DENERVATION SUPERSENSITIVITY TO SEROTONIN IN THE FACIAL
NUCLEUS.
001364 02-03
MULTIVARIATE APPROACHES APPLIED TO STUDIES OF NOREPINEPHRINE
AND SEROTONIN UPTAKE.
001460 02-03
DECREASE IN (3H) SEROTONIN BINDING IN RAT-BRAIN PRODUCED BY THE
REPEATED ADMINISTRATION OF EITHER MONOAMINE-OXIDASE-
INHIBITORS ON CENTRALLY-ACTING SEROTONIN AGONISTS.
001463 02-03
LARYNGEAL-EFFECTS OF SEROTONIN IN RABBITS.
001501 02-03
ENHANCED SENSITIVITY OF AMYGDALOID NEURONS TO SEROTONIN AND
NOREPINEPHRINE AFTER CHRONIC ANTIDEPRESSANT TREATMENT
001523 02-03
5,7 DIHYDROXYTRYPTAMINE-INDUCED MOUSE-KILLING AND
BEHAVIORAL-REVERSAL WITH VENTRICULAR ADMINISTRATION OF
SEROTONIN IN RATS.
001562 02-04
ENHANCED BEHAVIOURAL-EFFECTS, ELEQROCORTICAL-EFFEaS AND
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS ARER
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN
001733 02-04
THE EFFECT OF SOME STRUCTURAL GABA ANALOGUES ON THE
SEROTONIN AND DOPAMINERGIC MECHANISMS
001736 02-04
CIRCLING PRODUCED BY SEROTONIN AND DOPAMINE AGONISTS IN
RAPHE LESIONED RATS: A SEROTONIN MODEL.
001783 02-04
EFFEQ OF NICKEL ON THE LEVELS OF DOPAMINE, NORADRENALINE AND
SEROTONIN IN DIFFERENT REGIONS OF THE RAT-BRAIN.
001831 02-05
BLOOD LEVEL OF AMITRIPTYLINE, NORTRIPTYLINE, NORADRENALINE
SEROTONIN AND THERAPEUTIC RESPONSE.
002057 02-09
CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL-
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY
002095 02-11
CHARAQERIZATION OF ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLACTIN AND GROWTH-HORMONE PROFILES
DURING WAKEFULNESS AND SLEEP.
002217 02-13
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
002219 02-13
EFFECT OF DOXEPIN ON SEROTONIN METABOLISM IN RAT-BRAIN AND
SEROTONIN UPTAKE BY HUMAN BLOOD-PLATELETS.
002243 02-13
GLYCINE, ACETYLCHOLINE, AND SEROTONIN: NEUROTRANSMITTERS OR
NEUROMODULATORS?
002271 02-13
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE.
002305 02-13
L HTP AND THE SEROTONIN HYPOTHESIS: THEIR MEANING FOR
TREATMENT OF DEPRESSION.
002326 02-14
DU-24565, A QUIPAZINE DERIVATIVE, A POTENT SELEQIVE SEROTONIN
UPTAKE INHIBITOR.
002651 03-02
EVIDENCE FOR A TONIC GABAERGIC CONTROL OF SEROTONIN NEURONS
IN THE MEDIAN RAPHE NUCLEUS.
002719 03-03
THE EFFECTS OF D-AMPHET AMINE AND POTASSIUM ON SEROTONIN
RELEASE AND METABOLISM IN RAT-CEREBRAL-CORTEX TISSUE
002754 03-03
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN EFFEQ OF
CHRONIC-TREATMENT
002847 03-03
(3H)MIANSERIN: DIFFERENTIAL LABELING OF SEROTONIN AND
HISTAMINE-RECEPTORS IN RAT-BRAIN
002860 03-03
3H SEROTONIN BINDING-SITES IN RAT-BRAIN: EFFEQS OF REPEATED
ADMINISTRATION OF ANTIDEPRESSANT-DRUGS. (PHD
DISSERTATION)
002881 03-03
ACCELERATED METABOLISM OF PROBENECID DURING LONG-TERM-
TREATMENT OF RATS WITH ANTICONVULSANT-DRUGS: EFFECT ON
CENTRAL SEROTONIN TURNOVER STUDIES.
002890 03-03
SOMATOSTATIN FACILITATES THE SEROTONIN RELEASE FROM RAT-
CEREBRAL-CORTEX, HIPPOCAMPUS, AND HYPOTHALAMUS SLICES.
002913 03-03
HIPPOCAMPAL SEROTONIN REUPTAKE AND NOQURNAL LOCOMOTOR-
ACTIVITY AFTER MICROINJECTIONS OF 5,7 DHT IN THE FORNIX-
FIMBRIA.
002929 03-03
SPINAL MODULATION OF THE ACOUSTIC STARTLE RESPONSE: THE ROLE
OF NOREPINEPHRINE, SEROTONIN AND DOPAMINE
002950 03-04
SUBSTANCE-P, HEXAPEPTIDE-PGLU6(SP6-11), ANALGESIA AND
SEROTONIN DEPLETION.
003050 03-04
RELATIVE POTENCY OF AMPHETAMINE ISOMERS IN CAUSING THE
SEROTONIN BEHAVIORAL-SYNDROME IN RATS.
003094 03-04
PRESSOR EFFECTS OF DORSAL RAPHE STIMI " ATION AND
INTRAHYPOTHALAMIC APPLICATION OF SEROTONIN IN THE
SPONTANEOUSLY HYPERTENSIVE-RAT.
003117 03-04
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC-
ACID IN BRAIN USING HPLC WITH ELECTROCHEMICAL-DETECTION.
003139 03-06
MANAGEMENT OF DEPRESSION WITH SEROTONIN PRECURSORS.
003269 03-09
THE THERAPEUTIC ACTIVITY OF TRYPTOPHAN AND ITS EFFECT ON
SEROTONIN METABOLISM IN EPILEPTIC-PATIENTS.
003289 03-1 1
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE
HYPERACTIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN
DEFICIENCY HYPOTHESIS.
003312 03-11
ABNORMAL TRANSMETHYLATION REACTION DURING THE METABOLISM
OF DOPAMINE, TRYPTAMINE, AND SEROTONIN, AND SCHIZOPHRENIC-
SYMPTOMS: A CRITICAL REVIEW.
003404 03-13
S-406
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF CONFORMATIONALLY RESTRAINED ANALOGUES OF
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN.
003794 04-03
PRESYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION IN HELIX-
POMATIA: THE EFFECTS OF SEROTONIN AND DOPAMINE
ANTAGONISTS.
003869 04-03
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH.
003882 04-03
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN
REUPTAKE SITES IN BRAIN AND PLATELET?
003962 04-03
IN VIVO EVIDENCE FOR GABAERGIC CONTROL OF SEROTONIN RELEASE IN
THE CAT SUBSTANTIA-NIGRA.
004011 04-03
THE EFFECT OF SEROTONIN ON THE EXOSECRETORY ACTION OF THE
PANCREAS. „ „^
004043 04-03
ANORECTIC-PROPERTIES OF A NEW LONG ACTING SEROTONIN UPTAKE
INHIBITOR. . „.„.
004105 04-04
THE EFFECTS OF P CHLOROAMPHETAMINE ADMINISTRATION ON
LOCOMOTOR-ACTIVITY AND SEROTONIN IN NEONATAL AND ADULT
RATS. (UNPUBLISHED PAPER).
004169 04-04
CATECHOLAMINE SEROTONIN INTERACTION EFFECTS ON ACTIVITY IN
RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE.
004194 04-04
A SIMPLE DETERMINATION OF SEROTONIN, 5 HYDROXYINDOLEACETIC-
ACID AND 5 HYDROXYTRYPTOPHAN-DECARBOXYLASE ACTIVITY IN
RAT-BRAIN AREAS AND PARALLEL CORRELATION AMONG THE LEVELS.
004301 04-06
THE ANTIDEPRESSANT EFFECTS OF TRAZODONE AND INHIBITION OF
PLATELET SEROTONIN REUPTAKE.
004383 04-09
EFFECTS OF RO-1 1-2465, A NEW PSYCHOTROPIC-AGENT ON THE UPTAKE
OF SEROTONIN BY HUMAN PLATELETS - IN VITRO DETERMINATION OF
THE IC50.
004532 04-13
ANTIDEPRESSANTS AND THE SEROTONIN UPTAKE IN PLATELETS.
004727 04-17
SEROTONIN-LIKE
ENHANCED BEHAVIOURAL-EFFECTS, ELECTROCORTICAL-EFFECTS AND
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN.
001733 02-04
SEROTONIN-RECEPTOR
LONG-TERM ANTIDEPRESSANT TREATMENT DECREASES SPIROPERIDOL-
LABELED SEROTONIN-RECEPTOR BINDING.
000230 01-03
SEROTONIN-RECEPTOR MEDIATED MODULATION OF CA -DEPENDENT 5
HYDROXYTRYPTAMINE RELEASE FROM NEURONES OF THE RAT-BRAIN-
CORTEX.
001258 02-03
CENTRAL SEROTONIN-RECEPTOR SENSITIVITY IN RATS WITH
EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS .
001821 02-04
IMIPRAMINE: EFFECT OF OVARIAN STEROIDS ON MODIFICATIONS IN
SEROTONIN-RECEPTOR BINDING.
002778 03-03
DOM AND RELATED 2,5 DIMETHOXY-4-ALKYLPHENYLISOPROPYLAMINES:
BEHAVIORAL AND SEROTONIN-RECEPTOR PROPERTIES.
003690 04-02
SEROTONIN-RECEPTORS
REDUaiON IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS.
000258 01-03
SEROTONIN-RECEPTORS IN HIPPOCAMPUS AND FRONTAL-CORTEX.
000268 01-03
LITHIUM: EFFEQS ON SEROTONIN-RECEPTORS IN RAT-BRAIN.
000304 01-03
3H MIANSERIN BINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG ACTION.
000325 01-03
SOLUBILIZATION OF SEROTONIN-RECEPTORS FROM RAT-FRONTAL-
CORTEX.
002489 02-16
EVIDENCE THAT IT IS POSSIBLE TO CAUSE ANOREXIA BY INCREASING
RELEASE AND/OR DIRECTLY STIMULATING POSTSYNAPTIC SEROTONIN-
RECEPTORS IN THE BRAIN.
002602 02-17
TWO DISTINQ SEROTONIN-RECEPTORS: REGIONAL VARIATIONS IN
RECEPTOR BINDING IN MAMMALIAN BRAIN.
002861 03-03
(3H)METERG0LINE: A NEW LIGAND OF SEROTONIN-RECEPTORS IN THE
RAT-BRAIN.
003825 04-03
SEROTONIN-SENSITIVE
SEROTONIN SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - I. KINETIC PARAMETERS
AND PHARMACOLOGICAL-PROPERTIES.
000213 01-03
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT - II RESPECTIVE REGIONAL
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC
DEVELOPMENTS.
000214 01-03
SEROTONINEROIC
MORPHINE ACTS THROUGH ALPHA-ADRENERGIC AND SEROTONINEROIC
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG.
000088 01-03
STRUCTURAL REQUIREMENTS FOR UPTAKE INTO SEROTONINEROIC
NEURONES.
001452 02-03
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND
SEROTONINEROIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY
MECHANISMS.
001487 02-03
INJECTIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINEROIC AND
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS: EFFECTS ON
LOCOMOTOR-ACTIVITY IN THE RAT.
003019 03-04
EFFECTS OF ZIMELIDINE ON SEROTONINERGIC AND NORADRENERGIC
NEURONS AFTER REPEATED ADMINISTRATION IN THE RAT,
003991 04-03
SEROTONINERGIC-AUTORECEPTOR
EFFECT OF CHRONIC TRICYCLIC-ANTIDEPRESSANT TREATMENT ON THE
SEROTONINERGIC-AUTORECEPTOR: A MICROIONTOPHORETIC-STUDY IN
THE RAT.
001135 02-03
SEROTONINMIMETIC
SEROTONINMIMETIC AND ANTIDEPRESSANT-DRUGS ON PASSIVE-
AVOIDANCE LEARNING BY OLFACTORY BULBECTOMISED RATS.
001585 02-04
SEROTONIN2-RECEPTORS
DIFFERENTIAL-EFFECTS OF ELECTROCONVULSIVE-SHOCK AND
ANTIDEPRESSANT-DRUGS ON SER0T0NIN2-RECEPT0RS IN RAT-BRAIN.
003878 04-03
REGULATION OF SER0T0NIN2-RECEPT0RS (5 HT2) LABELED WITH
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT AMITRIPTYLINE.
003964 04-03
SERUM
OXAZEPAM-ESTERS. 2. CORRELATION OF HYDROPHOBICITY WITH SERUM
BINDING, BRAIN PENETRATION, AND EXCRETION.
000011 01-02
ADMINISTRATION OF ANTISOMATOSTATIN SERUM TO RATS REVERSES
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION
PRODUCED BY INJECTION OF METERGOLINE BUT NOT YOHIMBINE.
(UNPUBLISHED PAPER).
000019 01-03
LITHIUM LEVELS IN BLOOD-PUVTELETS, SERUM, RED-BLOOD-CELLS AND
BRAIN REGIONS IN RATS GIVEN ACUTE OR CHRONIC LITHIUM-SALT
TREATMENTS.
000082 01-03
THE ACUTE AND CHRONIC EFFEa OF LITHIUM ON SERUM TESTOSTERONE
IN RATS.
000238 01-03
STRUCTURE-ACTIVITY RELATIONSHIPS IN THE EFFECTS OF PHENACEMIDE
ANALOGS ON SERUM CREATININE AND ANTICONVULSANT ACTIVITY.
000249 01-03
ELECTRON-CAPTURE GAS-LIQUID-CHROMATOGRAPHIC-DETERMINATION
OF ETHOSUXIMIDE AND DESMETHYLMETHSUXIMIDE IN PLASMA OR
SERUM.
000538 01-06
CLINICAL-RESPONSE AND SERUM NEUROLEPTIC LEVELS IN CHILDHOOD-
SCHIZOPHRENIA. (UNPUBLISHED PAPER).
000566 01-08
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH
ANTIEPILEPTIC-DRUGS.
000695 01-11
CONVERSION SCALES FOR COMMONLY REQUESTED SERUM
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE, AND OF
HORMONES.
000759 01-13
PLASMA CHLORPROMAZINE SERUM PROLACTIN RELATIONSHIP IN A
SINGLE-DOSE EXPERIMENT.
000761 01-13
INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY-STATE SERUM LEVELS
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-DRUGS IN MAN.
000767 01-13
S-407
lie
ai;:
ii
Si'
fe
Subject Index
THE INFLUENCE OF LITHIUM-SALTS AND ANTIDEPRESSANT MEDICATION
ON SERUM PROLACTIN LEVEL.
000780 01-13
CORRELATION BETWEEN DAILY FLUCTUATIONS OF CARBAMAZEPINE
SERUM LEVELS AND INTERMITTENT SIDE-EFFECTS.
000851 01-15
SERUM CONCENTRATIONS OF PHENOBARBITAL AND
DIPHENYLHYDANTOIN IN SEVERE MENTALLY-HANDICAPPED AND
PHYSICALLY-HANDICAPPED-PATIENTS.
000856 01-15
PREDICTABILITY OF PHENYTOIN SERUM LEVELS BY NOMOGRAMS AND
CLINICIANS.
000909 01-16
SERUM PROLACTIN DURING AGING AND THE EFFECTS OF ERGOTS.
001171 02-03
SUPPRESSIVE EFFECT OF MORPHINE ON SERUM GONADOTROPIN LEVELS
IN CASTRATED RATS.
001393 02-03
RELATIONSHIP BETWEEN SERUM LEVELS AND FAST EEG ACTIVITIES IN
RATS BY A SINGLE ADMINISTRATION OF PHENOBARBITAL.
001462 02-03
STUDY OF LITHIUM LEVELS IN THE SERUM AND GENITAL ORGANS OF
MALE RATS.
001494 02-03
BARBITURATE SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
001559 02-04
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE
DEVELOPMENT OF DEPENDENCE IN RATS.
001800 02-04
EFFECT OF PROPRANOLOL TREATMENT ON SERUM PROLACTIN LEVEL IN
SCHIZOPHRENIC-PATIENTS.
001916 02-08
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH
NEUROLEPTICS.
001935 02-08
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS. RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
USE OF LARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC-
PATIENTS WITH ELEVATED SERUM PROLACTIN LEVELS AND
EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH NEUROLEPTIC
TREATMENT.
001944 02-08
SERUM NEUROLEPTIC CONCENTRATIONS IN SCHIZOPHRENIA.
(UNPUBLISHED PAPER).
001945 02-08
EFFECT OF LITHIUM ON POTASSIUM AND CALCIUM IN SERUM,
ERYTHOCYTES AND IN URINE.
002054 02-09
A CONTROLLED DOUBLE-BLIND STUDY OF HALOPERIDOL VERSUS
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY-
SUBNORMAL-PATIENTS: SERUM LEVELS AND CLINICAL-EFFECTS.
002185 02-11
METHOD FOR THE DETERMINATION OF TRYPTOPHAN IN SERUM AND
CEREBROSPINAL-FLUID.
002208 02-13
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRUG
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA.
002225 02-13
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/ AND
DIPHENYLHYDANTOIN IN SERUM LIPIDS
002281 02-13
LEVELS OF MINERAL-ELEMENTS IN THE SERUM AND SALIVA OF HEALTHY
MALE VOLUNTEERS AFTER A SINGLE-DOSE OF LI2C03
002297 02-13
CONCENTRATIONS OF CIS(Z) FLUPENTHIXOL IN MATERNAL SERUM,
AMNIOTIC-FLUID, UMBILICAL-CORD-SERUM, AND MILK.
002423 02-15
DURING ONE YEARS NEUROLEPTIC TREATMENT IN RATS STRIATAL
DOPAMINE-RECEPTOR BLOCKADE DECREASES BUT SERUM PROLAQIN
LEVELS REMAIN ELEVATED.
002707 03-03
LACK OF CORRELATION BETWEEN NALOXONE-INDUCED CHANGES IN
SEXUAL-BEHAVIOR AND SERUM LH IN MALE RATS.
002821 03-03
SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI-
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS.
002871 03-03
VALPROIC-ACID SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
002946 03-04
LOW SERUM PROLACTIN AND EARLY RELAPSE FOLLOWING NEUROLEPTIC
WITHDRAWAL.
003166 03-08
Psychophormacology Abstracts
NEUROLEPTIC-INDUCED ELEVATIONS IN SERUM PROLAQIN LEVELS-
ETIOLOGY AND SIGNIFICANCE.
003190 03-08
NEUROLEPTIC SERUM LEVELS MEASURED BY RADIORECEPTOR ASSAY
AND CLINICAL-RESPONSE IN SCHIZOPHRENIC-PATIENTS.
003199 03-08
AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF
DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREAQIVITY
IN DMI RESPONSIVE DEPRESSIVES.
003228 03-09
SERUM CONCENTRATION AND CLINICAL-EFFECT OF ANTIEPILEPTICS
003315 03-11
INCREASED SERUM PROLACTIN LEVELS DURING PHENOTHIAZINE AND
BUTYROPHENONE TREATMENT OF SIX POSTPARTUM WOMEN
003318 03-11
SERUM HALOPERIDOL LEVELS IN GILLES-DE-LA-TOUREHE-SYNDROME
003374 03-11
RENAL SIDE-EFFECTS OF LITHIUM: THE IMPORTANCE OF THE SERUM
LITHIUM LEVEL.
003547 03-15
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INOUCED CONVULSIONS
IN RATS
003736 04-03
PROTEIN BINDING OF CHLORPROMAZINE IN CEREBROSPINAL-FLUID AND
SERUM.
004311 04-08
SERUM CONCENTRATION OF ANTICONVULSANTS. PHARMACOKINETIC
FINDINGS AND THEIR PRACTICAL APPLICATION.
004443 04-11
INFLUENCE OF CARBAMAZEPINE ON SERUM THYROXINE AND
TRIIODOTHYRONINE IN PATIENTS WITH EPILEPSY.
004488 04-11
CONCENTRATIONS AND KINETICS OF CARBAMAZEPINE IN WHOLE
SALIVA, PAROTID SALIVA, SERUM ULTRAFILTRATE, AND SERUM
004545 04-13
ANTIEPILEPTIC THERAPY WITH PHENYTOIN: WHICH IS THE OPTIMUM
SERUM LEVEL?
004586 04-14
TWO CASES OF FORM-FRUSTE-DU-SYNDROME-MALIN WITH HIGH-LEVELS
OF SERUM CPK.
004636 04-15
SERUM LEVELS OF BUTORPHANOL BY RADIOIMMUNOASSAY.
004691 04-16
SEVERE
SERUM CONCENTRATIONS OF PHENOBARBITAL AND
DIPHENYLHYDANTOIN IN SEVERE MENTALLY-HANDICAPPED AND
PHYSICALLY-HANDICAPPED-PATIENTS.
000856 01-15
DOUBLE-BUND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO
SEVERE ANXIETY
002070 02-10
MINAPRINE IN SEVERE PSYCHOPATHOLOGY: STUDY OF 20 CASES.
002135 02-11
ABSENCE OF SEVERE TARDIVE-DYSKINESIA IN HUNGARIAN
SCHIZOPHRENIC-OUTPATIENTS.
002404 02-15
HYPNOTIC AQION OF FLUNITRAZEPAM (ROCHES ROIPNOL) IN PATIENTS
WITH SEVERE PSYCHIATRIC-DISORDERS.
003295 03-1 1
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF
BENZODIAZEPINE TREATMENT: SIX CLINICAL CASES.
003505 03-15
NA-GAMMA-HYDROXYBUTYRATE IN CEREBRAL PROTEQION DURING
SEVERE HYPOXEMIA IN THE RAT.
003895 04-03
THE SPECIFIC AQIVITY OF PLATELET MONOAMINE-OXIDASE VARIES
WITH PLATELET COUNT DURING SEVERE EXERCISE AND
NORADRENALINE INFUSION.
004509 04-13
MILD, MODERATE, SEVERE - THE STATISTICAL ANALYSIS OF SHORT
ORDINAL SCALES.
004677 04-16
SEVERELY
A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF
CARBAMAZEPINE IN OVERACTIVE, SEVERELY MENTALLY-
HANDICAPPED PATIENTS.
003365 03-1 1
SEVERITY
INTROVERSION AND SEVERITY OF THE BENZODIAZEPINE WITHDRAWAL.
000923 01-17
CHANGES IN PREVALENCE, SEVERITY, AND RECOVERY IN TARDIVE-
DYSKINESIA WITH AGE.
002455 02-15
SEX
THE EFFEQ OF ASSERTIVENESS TRAINING, PROVERA AND SEX OF
THERAPIST IN THE TREATMENT OF GENITAL EXHIBITIONISM
000697 01-11
S-408
VOLUME 19, SUBJECT INDEX
THE INFLUENCE OF GENOTYPE AND SEX ON BEHAVIORAL-SENSITIVITY TO
NICOTINE IN MICE. ^„ „„^„.
001648 02-04
SPECIFIC 3H IMIPRAMINE BINDING IN HUMAN PLATELETS; INFLUENCE OF
AGE AND SEX. „„„^..„o,o
002254 02-13
DOES POSTURAL ASYMMETRY INDICATE DIRECTIONALITY OF ROTATION
IN RATS: ROLE OF SEX AND HANDLING
003061 03-04
SEX PLASMA PROLACTIN AND PLASMA 3 METHOXY-4-
HYDROXYPHENYLGLYCOL (MHPG) PREDICT HERITABLE D-
AMPHETAMINE EXCITATION IN MAN. (UNPUBLISHED PAPER).
004565 04-14
DRUGS, ALCOHOL AND SEX. „„.,„, „. ,-,
004706 04-17
SEX-DIFFERENCE
SEX-DIFFERENCE IN BRAIN IRON. (UNPUBLISHED PAPER).
001278 02-03
SEX-DIFFERENCES
SEX-DIFFERENCES IN AMPHETAMINE-ELICITED ROTATIONAL-BEHAVIOR
AND THE LATERALIZATION OF STRIATAL DOPAMINE IN RATS,
000459 01-04
SEX-DIFFERENCES IN THE EFFECTS OF LOW-DOSES OF ETHANOL ON
HUMAN REACTION-TIME. ^^ , „^ , .
002361 02-14
SEX-DIFFERENCES IN THE AMPHETAMINE STIMULATED RELEASE OF
CATECHOLAMINES FROM RAT STRIATAL TISSUE IN VITRO.
002668 03-03
HYPERACTIVITY IN DEVELOPING RATS: SEX-DIFFERENCES IN 6
HYDROXYDOPAMINE AND AMPHETAMINE EFFECTS.
002970 03-04
GONADECTOMY AND SEX-DIFFERENCES IN THE BEHAVIORAL-RESPONSES
TO AMPHETAMINE AND APOMORPHINE OF RATS.
003084 03-04
FAILURE TO FIND SEX-DIFFERENCES IN TESTOSTERONE ACTIVATED
AGGRESSION IN TWO STRAINS OF RATS.
003107 03-04
SEX-DIFFERENCES IN PSYCHOTROPIC-DRUG USE.
003589 03-17
SEX-HORMONE
SEX-HORMONE INFLUENCES ON YAWNING-BEHAVIOR.
000407 01-04
SEX-LIFE
THE EFFECTS OF ESTROGEN THERAPY ON THE SEX-LIFE OF
POSTMENOPAUSAL-WOMEN .
004573 04-14
SEX-OFFENDERS
TREATMENT OF SEX-OFFENDERS WITH MEDROXYPROGESTERONE-
ACETATE.
004450 04-11
SEXUAL-BEHAVIOR
EFFECTS OF MORPHINE, BETA ENDORPHIN AND NALOXONE ON
CATECHOLAMINE LEVELS AND SEXUAL-BEHAVIOR IN THE MALE RAT.
000430 01-04
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND
ELECTROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE
MIDBRAIN.
001593 02-04
LACK OF CORRELATION BETWEEN NALOXONE-INDUCED CHANGES IN
SEXUAL-BEHAVIOR AND SERUM LH IN MALE RATS.
002821 03-03
SEXUAL-BEHAVIOR DECREASES PAIN SENSITIVITY AND STIMULATES
ENDOGENOUS OPIOIDS IN MALE RATS.
004234 04-04
THE EFFECTS OF ANTIANXIETY AND ANTIPSYCHOTIC-DRUGS ON SEXUAL-
BEHAVIOR.
004657 04-15
SEXUAL-BEHAVIOUR
SEXUAL-BEHAVIOUR OF MORPHINE-DEPENDENT AND ABSTINENT MALE
RATS.
000438 01-04
SEXUAL-DEVIANTS
COMPARATIVE-STUDY OF PROPHYLACTIC LITHIUM AND
DIETHYLSTILBESTROL IN SEXUAL-DEVIANTS.
000663 01-11
SEXUAL-DEVIATIONS
CYPROTERONACETATE IN THE THERAPY OF SEXUAL-DEVIATIONS
000735 01-11
SEXUAL-DIFFICULTIES
SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN
PRAZEPAM TREATMENT IN 30 CASES.
003296 03-11
MvDISORDERS
EXPERIMENTATION WITH MINAPRINE IN DEALING WITH CERTAIN
S^UAL-DISORDERS: IMPOTENCE OR FRIGIDITY.
'~ 002153 02-11
PSYCHOPHARMACOTHERAPY OF SEXUAL-DISORDERS IN THE AGED.
004466 04-11
SEXUAL-DYSFUNCTION
PCP AND SEXUAL-DYSFUNCTION.
000745 01-12
Subject Index
ENDOCRINOLOGICAL CHANGES IN PATIENTS WITH SEXUAL-DYSFUNCTION
UNDER LONG-TERM NEUROLEPTIC TREATMENT
000912 01-17
SUBJECTIVE ASSESSMENT OF SEXUAL-DYSFUNCTION OF PATIENTS ON
LONG-TERM ADMINISTRATION OF DIGOXIN
002443 02-15
SEXUAL-DYSFUNCTIONS
BASAL PROLACTINAEMIA AND RESPONSES TO TRH AND SULPIRIDE IN
DIFFERENT CATEGORIES OF MALE SEXUAL-DYSFUNCTIONS.
004503 04-13
SEXUAL-EFFECTS
SEXUAL-EFFECTS OF ANTIDEPRESSANTS AND PSYCHOMOTOR STIMULANT-
DRUGS.
004646 04-15
SEXUAL-FUNCTION
DRUGS AND SEXUAL-FUNCTION.
000852 01-15
SEXUAL-FUNCTIONS
PHARMACOLOGICAL INFLUENCE OF SEXUAL-FUNCTIONS IN ADOLESCENTS.
004436 04-11
SEXUAL-IMPOTENCE
PHARMACOTHERAPY OF SEXUAL-IMPOTENCE IN THE MALE.
004435 04-11
SEXUAL-MOTIVATION
METHADONE REDUCES SEXUAL-PERFORMANCE AND SEXUAL-
MOTIVATION IN THE MALE SYRIAN GOLDEN HAMSTER.
004183 04-04
SEXUAL-OFFENDERS
PHARMACOTHERAPY FOR SEXUAL-OFFENDERS: REVIEW OF THE ACTION
OF ANTIANDROGENS WITH SPECIAL REFERENCE TO THEIR PSYCHIC-
EFFECTS.
004455 04-11
SEXUAL-PERFORMANCE
METHADONE REDUCES SEXUAL-PERFORMANCE AND SEXUAL-
MOTIVATION IN THE MALE SYRIAN GOLDEN HAMSTER.
004183 04-04
SEXUAL-RECEPTIVITY
PROSTAGLANDINS, CLONIDINE AND SEXUAL-RECEPTIVITY IN THE GUINEA-
PIG.
003017 03-04
SEXUAL-REFLEXES
COPULATORY-BEHAVIOR AND SEXUAL-REFLEXES OF MALE RATS TREATED
WITH NALOXONE.
003077 03-04
SEXUALITY
PHARMACOTHERAPY AND FEMALE SEXUALITY.
004483 04-1 1
SHAKING-BEHAVIOR
PHARMACOLOGICAL-ASPECTS OF SHAKING-BEHAVIOR PRODUCED BY
TRH, AG-3-5, AND MORPHINE WITHDRAWAL.
004248 04-04
SHELTERED-CARE-HOMES
ANTIPSYCHOTIC-DRUGS IN COMMUNITY-BASED SHELTERED-CARE-HOMES.
002171 02-11
SHIFTS
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON
BEHAVIORAL SHIFTS IN CATS, ARISING AFTER CESSATION OF
ELECTRICAL- STIMULATION OF THE CAUDATE-NUCLEUS
004067 04-04
SHOCK
CHANGES OF AQH, STH, TSH AND PROLACTIN LEVELS IN ENDOTOXIN
SHOCK IN RATS.
000119 01-03
EFFECTS OF MORPHINE, D-AMPHETAMINE, AND PENTOBARBITAL ON
SHOCK AND LIGHT DISCRIMINATION PERFORMANCE IN RATS.
001639 02-04
OPIATE ANTAGONISTS AND LONG-TERM ANALGESIC REACTION INDUCED
BY INESCAPABLE SHOCK IN RATS.
001707 02-04
SHOCK-AVOIDANCE
BETA-ADRENERGIC INFLUENCE ON CARDIAC DYNAMICS DURING SHOCK-
AVOIDANCE IN DOGS.
003813 04-03
SHOCK-ELICITED
NALOXONE PRETREATMENT ENHANCES SHOCK-ELICITED AGGRESSION.
001615 02-04
SHOCK-ESCAPE-TEST
THE EFFECT OF MORPHINE, PIMOZIDE AND NALOXONE ON
DISCRIMINATION BY RATS IN A SHOCK-ESCAPE-TEST.
001700 02-04
SHOCK-INDUCED
SELECTIVE INHIBITION BY NICOTINE OF SHOCK-INDUCED FIGHTING IN THE
RAT
002984 03-04
FACILITATED SHOCK-INDUCED AGGRESSION AFTER CHRONIC-TREATMENT
WITH ANTIDEPRESSANT-DRUGS IN THE RAT.
003058 03-04
S-409
Subject Index
Psychopharmacology Abttrocft
t!J.,
ill
ii
an:
^
I
SHOCK-INDUCED-FIGHTING
SHOCK-INDUCED-FIGHTING (SIF). PSYCHOPHARMACOLOGICAL-STUDIES.
003091 03-04
SHORT
MILD, MODERATE, SEVERE - THE STATISTICAL ANALYSIS OF SHORT
ORDINAL SCALES.
004677 04-16
SHORT-ACTING
THE DIFFERENTIAL-EFFECTS OF SHORT-ACTING AND LONG-ACTING
BENZODIAZEPINES UPON NOCTURNAL SLEEP AND DAYTIME
PERFORMANCE.
000822 01-14
PHARMACOKINETICS OF BENZODIAZEPINES: SHORT-ACTING VERSUS
LONG-ACTING.
000920 01-17
NEUROPHYSIOLOGICAL-EFFECTS OF ETOMIDATE, A NEW SHORT-AQING
HYPNOTIC.
002263 02-13
EFFECTS OF A SHORT-ACTING BENZODIAZEPINE ON BRAIN ELECTRICAL-
ACTIVITY DURING SLEEP.
004568 04-14
SHORT-CIRCUIT
ACUTE AND CHRONIC EFFECTS OF MORPHINE ON TRANSMEMBRANE
POTENTIAL AND ON SHORT-CIRCUIT CURRENT IN ISOLATED TOAD
SKIN: APPARENT MORPHINE-DEPENDENCE
001176 02-03
SHORT-TERM
IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM
INGESTION OF ETHANOL, TERTIARY BUTANOL, OR PENTOBARBITAL IN
MICE.
000479 01-04
AROUSAL AND SHORT-TERM MEMORY: EFFECTS OF CAFFEINE AND TRIAL
SPACING ON DELAYED ALTERNATION PERFORMANCE.
000487 01-04
SHORT-TERM HORMONAL-EFFECTS OF NALOXONE IN MAN.
000798 01-13
THE SHORT-TERM USE OF BENZODIAZEPINES.
000962 01-17
SHORT-TERM AND LONG-TERM EFFECTS OF METHAMPHETAMINE ON
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC
NUCLEI.
001384 02-03
SHORT-TERM AND LONG-TERM MODIFICATION OF SKELETAL-MUSCLE
SODIUM-PUMP AQIVITY AND MUSCLE PROTEIN TURNOVER
(UNPUBLISHED PAPER).
001519 02-03
ROLE OF NEUROTRANSMIHERS AND PROTEIN SYNTHESIS IN SHORT-
TERM AND LONG-TERM MEMORY
001573 02-04
THE SHORT-TERM AND LONG-TERM EFFEaS OF BETA ENDORPHIN ON THE
OPIATE ABSTINENCE-SYNDROME IN RATS.
001643 02-04
HUNTINGTONS-DISEASE: CLINICAL-EFFEQS OF A SHORT-TERM
TREATMENT WITH PIMOZIDE.
002091 02-11
SHORT-TERM ETHANOL ADMINISTRATION IMPAIRS THE ELIMINATION OF
CHLORDIAZEPOXIDE (LIBRIUM) IN MAN.
002224 02-13
SHORT-TERM AND LONG-TERM EFFECTS ON GABA AND DOPAMINE
NEURONS DURING TREATMENT WITH SULPIRIDE.
002311 02-13
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNQION IN CAT BRAIN.
00291 1 03-03
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP
FORMATION IN MOUSE NEUROBLASTOMA CELLS.
003783 04-03
COMPARATIVE CHARACTERISTICS OF THE PROPHYLACTIC PROPERTIES OF
SHORT-TERM AND LONG-AQING LITHIUM-CARBONATE PREPARATIONS
IN ENDOGENOUS AFFECTIVE-PSYCHOSES.
004390 04-09
RELAPSE AFTER SHORT-TERM DRUG-THERAPY IN NEUROTIC-
OUTPATIENTS.
004400 04-09
SHUNT
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN
REGIONS OF RAT-BRAIN WITH KET AMINE ANESTHESIA.
003891 04-03
SHUHLE
EFFECT OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION,
MEMORY, AND RETRIEVAL OF SHUHLE AVOIDANCE AND
HABITUATION LEARNING IN RATS.
000410 01-04
SHUniEBOX
NALOXONE AND SHUHLEBOX SELF-STIMULATION IN THE RAT.
001793 02-04
SIALIC-ACID
THE EFFEQ OF LITHIUM ON THE INCORPORATION OF 3H GLUCOSAMINE
INTO GLYCOPEPTIDES AND THE TRANSFORMATION OF 3H
GLUCOSAMINE INTO SIALIC-ACID IN RAT-BRAIN.
001209 02-03
SIDE-EFFECT
AN OLD SIDE-EFFECT REVISITED: VISUAL HALLUCINATIONS.
000886 01-15
AN UNUSUAL SIDE-EFFEQ OF LITHIUM.
002381 02-15
SIDE-EFFECTS
HOSTILITY CONFLia AND REPORTING OF SIDE-EFFEQS BY PSYCHIATRIC-
OUTPATIENTS.
000840 01-15
PROLAQIN RESPONSE AND EXTRAPYRAMIDAL SIDE-EFFEaS DURING
PROPRANOLOL AND NEUROLEPTIC-DRUGS TREATMENT IN CHRONIC
SCHIZOPHRENIC-PATIENTS.
000841 01-15
ON THE GENETIC SIDE-EFFECTS OF PSYCHOTROPIC-SUBSTANCES I
PSYCHOPHARMACEUTICALS, NARCOTICS, AND ANTICONVULSANT
000845 01-15
NEUROLOGICAL SIDE-EFFEQS OF LITHIUM: ORGANIC-BRAIN-SYNDROME
SEIZURES, EXTRAPYRAMIDAL SIDE-EFFEaS, AND EEG CHANGES
000847 01-15
CORRELATION BETWEEN DAILY FLUQUATIONS OF CARBAMAZEPINE
SERUM LEVELS AND INTERMIHENT SIDE-EFFEaS
000851 01-15
CLINICALLY SIGNIFICANT SIDE-EFFEaS OF LITHIUM TREATMENT
000893 01-15
USE OF LARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC-
PATIENTS WITH ELEVATED SERUM PROLACTIN LEVELS AND
EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH NEUROLEPTIC
TREATMENT.
001944 02-08
EFFICACY AND SIDE-EFFEQS OF LORAZEPAM, OXAZEPAM, AND
TEMAZEPAM AS SLEEPING-AIDS IN PSYCHOGERIATRIC-INPATIENTS
002076 02-10
EFFICACY AND SIDE-EFFECTS OF CHLORAL-HYDRATE AND TRYPTOPHAN
AS SLEEPING-AIDS IN PSYCHOGERIATRIC-PATIENTS.
002077 02-10
AN AHEMPT TO TREAT THE SIDE-EFFEQS OF PSYCHOTROPIC THERAPY
WITH BROMOCRIPTINE.
002094 02-11
PIRACETAM ACTION IN NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL SIDE-
EFFECTS.
002132 02-11
LONG-TERM-TREATMENT WITH NEUROLEPTIC-AGENTS: ADAPTATION
PHENOMENA AND THEIR SIGNIFICANCE WITH REGARD TO
SCHIZOPHRENIC-SYMPTOMATOLOGY AND SIDE-EFFEQS.
002370 02-15
PHENOTHIAZINE PLASMA AND RED-BLOOD-CELL CONCENTRATIONS, THEIR
RELATIONSHIP TO SIDE-EFFEQS AND CLINICAL-EFFICACY.
002386 02-15
SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKING-DRUGS: A
METHODOLOGICAL-PROBLEM .
002395 02-15
AN INVESTIGATION OF SOME SIDE-EFFEQS IN 47 PSYCHOTIC-PATIENTS
DURING TREATMENT WITH CLOZAPINE AND DISCONTINUING OF THE
TREATMENT.
002424 02-15
PROPRANOLOL (INDERAL) FOR TARDIVE-DYSKINESIA AND
EXTRAPYRAMIDAL SIDE-EFFEQS FROM NEUROLEPTICS: POSSIBLE
INVOLVEMENT OF BETA-ADRENERGIC MECHANISMS.
002470 02-15
NEUROPSYCHIATRIC SIDE-EFFECTS OF DRUGS IN THE ELDERLY VOL. 9,
AGING.
002573 02-17
CHRONIC EFFECTS OF NEUROLEPTICS HAVING HIGH OR LOW INCIDENCE
OF EXTRAPYRAMIDAL SIDE-EFFECTS UPON FORCE, DURATION AND
RATE OF OPERANT-RESPONSE IN RATS. (PH.D. DISSERTATION).
003125 03-05
MEDICAL AND LEGAL IMPLICATIONS OF SIDE-EFFECTS FROM
NEUROLEPTIC-DRUGS. A ROUND-TABLE DISCUSSION.
003471 03-15
SIDE-EFFECTS OF CORTICOSTEROID THERAPY: PSYCHIATRIC-ASPECTS.
003508 03-15
HEPATIC SIDE-EFFECTS OF ANTIDEPRESSANT MEDICATIONS.
003523 03-15
RENAL SIDE-EFFECTS OF LITHIUM: THE IMPORTANCE OF THE SERUM
LITHIUM LEVEL.
003547 03-15
A DOUBLE-BLIND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND
SIDE-EFFECTS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED-
INPATIENTS AND DEPRESSED-OUTPATIENTS.
004395 04-09
NEUROLEPTICS AND THEIR SIDE-EFFECTS.
004590 04-15
OPHTHALMOLOGICAL SIDE-EFFECTS OF LITHIUM.
004615 04-15
S-410
VOLUME 19, SUBJECT INDEX
Subject Index
AN EVALUATION OF THE ANTIANXIETY ACTION AND SIDE-EFFECTS OF
PROPRANOLOL.
004660 04-15
SIDE-EFFECTS AND UNDESIRABLE COMBINATIONS OF PSYCHOTROPIC-
MEDICATIONS.
004663 04-15
SIDMAN-AVOIDANCE
EFFECTS OF REPEATED ADMINISTRATION OF D-AMPHETAMINE ON
SIDMAN-AVOIDANCE RESPONDING IN RATS.
001692 02-04
SIOMA
ACTIONS OF MU, KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION.
004053 04-03
SIONAL
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
BIOCHEMICAL-MECHANISM OF SIGNAL TRANSDUCTION ACROSS
BIOMEMBRANES. (UNPUBLISHED PAPER).
001026 02-01
PHOSPHOLIPID METHYLATION: A BIOCHEMICAL-EVENT OF SIGNAL
TRANSDUaiON. (UNPUBLISHED PAPER).
001279 02-03
DISRUPTION OF AUTOSHAPED RESPONDING TO A SIGNAL OF BRAIN-
STIMULATION REWARD BY NEUROLEPTIC-DRUGS.
004199 04-04
SIONAL-DETECTION-ANALYSIS
A SIGNAL-DETECTION-ANALYSIS OF CENTRALLY-ACTIVE DRUGS IN MICE.
001631 02-04
A SIGNAL-DETEQION-ANALYSIS OF MORPHINE EFFEQS ON THE
RESPONSE BIAS OF RATS IN A TWO-SHOCK DISCRIMINATION TASK.
004124 04-04
SIGNALLED
DIFFERENTIAL-EFFEQS OF METHYLPHENIDATE ON SIGNALLED AND
NONSIGNALLED REINFORCEMENT,
000380 01-04
SIGNALLING
PHOSPHOLIPID METHYLATION AND TRANSMEMBRANE SIGNALLING.
(UNPUBLISHED PAPER).
001001 02-01
SILASTIC
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD
ETHANOL LEVELS IN RATS DRINKING A LIQUID DIET.
001865 02-06
SILICONE
A SILICONE PELLET FOR LONG-TERM CONTINUOUS ADMINISTRATION OF
AMPHETAMINE.
001875 02-06
SINEMET
SINEMET AND THYROID-FUNQION IN PARKINSON-DISEASE.
000733 01-11
SINGLE
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJEaiON.
000261 01-03
WATER INTAKE AND TIME-COURSE OF DRINKING AFTER SINGLE OR
REPEATED CHLORDIAZEPOXIDE INJEQIONS.
000369 01-04
SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF
SINGLE VS. DIVIDED DOSE ADMINISTRATION.
000629 01-09
THE EFFEaS OF LSD AND SOME ANALOGUES ON THE RESPONSES OF
SINGLE CORTICAL NEURONS OF THE CAT TO OPTICAL-STIMULATION.
000738 01-12
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER AaiVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT.
001095 02-03
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
BRAIN.
001234 02-03
AUTOCORRELATION ANALYSIS OF SINGLE NEURON ACTIVITY AFTER
ADMINISTRATION OF PENTOBARBITAL.
001268 02-03
INTERACTION OF TRIAZOLAM WITH DESIPRAMINE; EFFECTS OF SINGLE
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC-
RESPONSES AND BRAIN CATECHOLAMINE LEVELS.
001323 02-03
EFFEQ OF SINGLE AND REPEATED ELECTROCONVULSIVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN ~ I. METABOLIC-STUDIES.
001332 02-03
ACUTE AND CHRONIC OPIATE-EFFEaS ON SINGLE UNITS AND EEG OF
MEDIAL THALAMUS AND HIPPOCAMPUS: A LATENCY ANALYSIS.
001344 02-03
RELATIONSHIP BETWEEN SERUM LEVELS AND FAST EEG ACTIVITIES IN
RATS BY A SINGLE ADMINISTRATION OF PHENOBARBITAL.
001462 02-03
ENHANCED RESPONSES TO OPIATES PRODUCED BY A SINGLE GENE
SUBSTITUTION IN THE MOUSE.
001677 02-04
EFFECT OF SINGLE AND REPEATED ELECTROCONVULSIVE-SHOCK ON
SEROTONERGIC SYSTEM IN RAT-BRAIN - II. BEHAVIOURAL-STUDIES.
001697 02-04
THE INFLUENCE OF SINGLE DAILY HEROIN INJECTIONS ON DRINKING-
PATTERNS IN THE RAT.
001746 02-04
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS AFTER A SINGLE
INJECTION OF BETA ENDORPHIN.
001962 02-09
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE
ANESTHETIZED RATS.
002687 03-03
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS
ADMINISTRATIONS.
002797 03-03
SINGLE OR REPEATED ADMINISTRATION OF SMALL DOSES OF
APOMORPHINE ON WATER INTAKE AND ACTIVITY IN WATER-
DEPRIVED RATS.
002981 03-04
TRANSFER FROM MULTIPLE TO SINGLE ANTIEPILEPTIC DRUG-THERAPY.
003316 03-11
COMPARISON OF SODIUM-VALPROATE AND PHENYTOIN AS SINGLE
DRUG-TREATMENT IN EPILEPSY.
003371 03-11
CORTICAL EVOKED-POTENTIALS IN GILLES-DE-LA-TOUREHES-SYNDROME
- A SINGLE CASE-STUDY.
003431 03-13
SINGLE POINT ESTIMATION OF PHENYTOIN DOSING REQUIREMENT.
003562 03-16
EFFECTS OF PENTOBARBITAL AND ETHANOL UPON SINGLE NEURON
ACTIVITY IN THE PRIMARY SOMATOSENSORY CORTEX OF THE RHESUS-
MONKEY.
003755 04-03
CLASSICAL NEUROLEPTICS AND DECONDITIONING ACTIVITY AFTER SINGLE
OR REPEATED TREATMENTS: ROLE OF DIFFERENT CEREBRAL
NEUROTRANSMinERS.
004115 04-04
EFFECTS OF ANALGESICS AND CNS-ACTING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS.
004148 04-04
NEUROTRANSMIHER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS. I: EFFECTS OF A SINGLE EXPOSURE TO ACRYLAMIDE.
004264 04-05
PHARMACOKINETICS OF CLOXAZOLAM IN MAN AFTER SINGLE AND
MULTIPLE ORAL DOSES.
004530 04-13
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN.
004638 04-15
SINGLE-BEDTIME-DOSE
CLINICAL-TRIAL OF HALAZEPAM AND CLORAZEPATE: CONSIDERATIONS
OF A SINGLE-BEDTIME-DOSE.
003277 03-10
SINGLE-BEDTIME-DOSES
A DOUBLE-BUND PARALLEL GROUP COMPARISON OF SINGLE-BEDTIME-
DOSES OF HALAZEPAM AND PLACEBO.
002079 02-10
SINGLE-BLIND
ANALYSIS OF SINGLE-BUND, DOUBLE-BUND PROCEDURES, MAINTENANCE
OF PLACEBO-EFFEQS, AND DRUG-INDUCED DYSKINESIA WITH
MENTALLY-RETARDED PERSONS - BRIEF REPORT.
003298 03-1 1
ANALYSIS OF SINGLE-BLIND AND DOUBLE-BLIND PROCEDURES,
MAINTENANCE OF PLACEBO-EFFECTS AND DRUG-INDUCED DYSKINESIA
WITH MENTALLY-RETARDED PERSON.
004437 04-1 1
SINGLE-CASE
SINGLE-CASE STUDY OF CUNICAL-RESPONSE TO HIGH-DOSE ERGOT
ALKALOID TREATMENT FOR DEMENTIA. PREUMINARY REPORT.
004493 04-11
SINGLE-DAILY-DOSE
MAPROTIUNE ADMINISTERED IN A SINGLE-DAILY-DOSE IN GENERAL-
PRACTICE.
002027 02-09
S-411
%
ill!
m:
C,]:
it
m
&
I
Subject index
SINGLE-DAILY-DOSES
EVALUATION OF THE CLINICAL-EFFICACY OF SINGLE-DAILY-DOSES OF
ANTIDEPRESSANTS.
001985 02-09
SINGLE-DOSAGE
PLASMA DESIPRAMINE LEVELS AFTER SINGLE-DOSAGE AND AT STEADY-
STATE IN OUTPATIENTS.
002039 02-09
SINGLE-DOSE
SINGLE-DOSE PHARMACOKINETICS AND ANTICONVULSANT EFFICACY OF
PRIMIDONE IN MICE.
000177 01-03
PREDICTION OF STEADY-STATE PLASMA LEVELS OF AMITRIPTYLINE AND
NORTRIPTYLINE FROM A SINGLE-DOSE 24-HR. LEVEL IN DEPRESSED-
PATIENTS.
000582 01-09
COMPARISON OF SINGLE-DOSE PHARMACOKINETICS OF IMIPRAMINE
AND MAPROTILINE IN THE ELDERLY.
000596 01-09
PLASMA CHLORPROMAZINE SERUM PROLAQIN RELATIONSHIP IN A
SINGLE-DOSE EXPERIMENT.
000761 01-13
NO EVIDENCE FOR INCREASED DOPAMINE-RECEPTOR BINDING IN
SUPERRESPONSIVE MICE AFTER A SINGLE-DOSE OF NEUROLEPTICS
001292 02-03
REDUCTION OF DOPAMINERGIC-SUPERSENSITIVITY BY A SINGLE-DOSE OF
AMPHETAMINE.
001642 02-04
SINGLE-DOSE VERSUS MULTIPLE-DOSE COMPARATIVE-TRIAL OF
DESIPRAMINE-HYDROCHLORIDE: A DOUBLE-PLACEBO METHOD
002059 02-10
ELECTROENCEPHALOGRAPHIC-EFFEQS AND BEHAVIOURAL-EFFECTS OF
SODIUM-VALPROATE IN PATIENTS WITH PHOTOSENSITIVE EPILEPSY A
SINGLE-DOSE TRIAL.
002154 02-11
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRUG
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA
002225 02-13
LEVELS OF MINERAL-ELEMENTS IN THE SERUM AND SALIVA OF HEALTHY
MALE VOLUNTEERS AFTER A SINGLE-DOSE OF LI2C03
002297 02-13
SINGLE-DOSE PHARMACOKINETICS OF DOXEPIN IN HEALTHY
VOLUNTEERS
002303 02-13
A SINGLE-DOSE STUDY OF NABILONE, A SYNTHETIC CANNABINOID
002328 02-14
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE-
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A
CONTROLLED-TRIAL.
002329 02-14
THERAPEUTIC-EFFICACY OF DOXEPIN IN DIVIDED AND SINGLE-DOSE
REGIME.
003259 03-09
PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN CHRONIC
SCHIZOPHRENIC-PATIENTS TESTED WITH SINGLE-DOSE OF 2 BROMO-
ALPHA-ERGOCRIPTINE (PARLODEL).
004343 04-08
SINGLE-DOSE PHARMACOKINETIC DATA ON ZIMELIDINE IN DEPRESSED-
PATIENTS.
004385 04-09
SINGLE-DOSES
DISPOSITION OF (3H) PHENCYCLIDINE IN THE RAT AFTER SINGLE-DOSES
AND MULTIPLE-DOSES.
001375 02-03
SINGLE-NIGHTLY-DOSE
STUDY OF MAPROTILINE IN OUTPATIENT TREATMENT OF DEPRESSIVE-
STATES BY THE GENERAL-PRACTITIONER: ADVANTAGE OF SINGLE-
NIGHTLY-OOSE.
001961 02-09
SINGLE-ORAL-DOSAGES
EFFECTS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG
BASELINE CROSSING T- SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROFILES.
002239 02-13
SINGLE-ORAL-DOSE
INFLUENCE OF PHENYTOIN AND PHENOBARBITAL ON THE DISPOSITION OF
A SINGLE-ORAL-DOSE OF CLONAZEPAM.
002248 02-13
SINGLE-THERAPEUTIC-DOSE
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION
004281 04-05
SINOATRIAL
IMIPRAMINE AFFECTS AUTONOMIC-CONTROL OF SINOATRIAL RATE IN
ISOLATED RIGHT ATRIAL PREPARATIONS.
000195 01-03
SINTAMIL
SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF
SINGLE VS. DIVIDED DOSE ADMINISTRATION.
000629 01-09
I
Ptychopharmacology Abstracts.
SITE-OF-ACTION
A PROBABLE SITE-OF-AQION OF DIAZEPAM IN RAT CEREBELLAR GABA
SYSTEM.
000151 01-03
HARMALINE-INDUCED TREMOR: THE BENZODIAZEPINE-RECEPTOR AS A
SITE-OF-AaiON.
001436 02-03
SKELETAL-MUSCLE i
LITHIUM REDUCES THE NUMBER OF ACETYLCHOLINE-RECEPTORS IN 1
SKELETAL-MUSCLE. |
000232 01-03
SHORT-TERM AND LONG-TERM MODIFICATION OF SKELETAL-MUSCLE
SODIUM-PUMP AQIVITY AND MUSCLE PROTEIN TURNOVER
(UNPUBLISHED PAPER).
001519 02-03
SKF-525-A
BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND
2,4 DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR (DPEA) INHIBITION
OF FATTY-ACID CONJUGATION TO 1 1 HYDR0XY-DELTA9-
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM
000179 01-03
SKF-64139
THE BLOCKADE OF ALPHA2-ADREN0CEPT0RS BY THE PNMT INHIBITOR
SKF-64139.
001255 02-03
EFFEQS OF AN EPINEPHRINE SYNTHESIS INHIBITOR. SKF-64139 ON THE
SECRETION OF LUTEINIZING-HORMONE IN OVARIEaOMIZED FEMALE
RATS.
002693 03-03
IN VIVO INTRANEURONAL MAO-INHIBITION IN RAT-BRAIN SKF-64)39
COMPARISON TO OTHER POTENT PNMT INHIBITORS.
003935 04-03
SKIN
ACUTE AND CHRONIC EFFEQS OF MORPHINE ON TRANSMEMBRANE
POTENTIAL AND ON SHORT-CIRCUIT CURRENT IN ISOLATED TOAD
SKIN: APPARENT MORPHINE-DEPENDENCE.
001176 02-03
BILATERAL SKIN CONDUQANCE AND THE PUPILLARY UGHT DARK
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL
SCOPOLAMINE, AND PLACEBO.
004544 04-13
MITIGATING ACUTE SKIN RASHES AND NAUSEA FROM LITHIUM
004661 04-15
SKIN-RESISTANCE
INCREASES IN SKIN-RESISTANCE OF WHITE RATS FOUOWING
SCOPOLAMINE INJECTION
003138 03-06
SL-76-002
EFFECT OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED
EXTRAPYRAMIDAL ALTERATIONS.
001119 02-03
GABA AND SCHIZOPHRENIA: STUDY OF THE AQION OF A GABAERGIC
ANTAGONIST. PROGABIDE OR SL-76-002.
003175 03-08
SLEEP
CAFFEINE PRODUCES REM SLEEP REBOUND IN RATS.
000244 01-03
IMIPRAMINE AND REM SLEEP: CHOLINERGIC MEDIATION IN ANIAAALS
000406 01-04
EFFEaS OF MELATONIN AND PROPRANOLOL ON SLEEP OF THE RAT
000432 01-04
EFFECTS OF CHOLECYSTOKININ-LIKE PEPTIDES ON REARING AQIVITY AND
HEXOBARBITAL-INDUCED SLEEP.
000507 01-04
CHRONIC USE OF TRIAZOLAM: THE EFFEQS ON THE SLEEP PAHERNS OF
INSOMNIACS.
000710 01-11
COMPARATIVE-STUDY OF SLEEP AND STATE ON AWAKENING WITH TWO
HYPNOTIC DIAZEPINES.
000817 01-14
THE DIFFERENTIAL-EFFEQS OF SHORT-AQING AND LONG-AQING
BENZODIAZEPINES UPON NOCTURNAL SLEEP AND DAYTIME
PERFORMANCE.
000822 01-14
ATROPINE AND NATURAL SLEEP: ACTIVITY DATA OF THE STRIATUM IN
RATS.
001551 02-03
EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS.
001570 02-04
THE EFFECT OF FLA-63 ON PENTOBARBITONE-INDUCED SLEEP IN THE
CHICK.
001741 02-04
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I SLEEP
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS.
001869 02-06
S-412
VOLUME 19, SUBJECT INDEX
Subject Index
CHARACTERIZATION OF ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLACTIN AND GROWTH-HORMONE PROFILES
DURING WAKEFULNESS AND SLEEP.
002217 02-13
ASPIRIN AND HUMAN SLEEP.
002241 02-13
THE EFFECTS OF TRIAZOLAM AND NITRAZEPAM ON SLEEP QUALITY,
MORNING VIGILANCE, AND PSYCHOMOTOR PERFORMANCE.
002330 02-14
THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJECTIVE ASPECTS OF SLEEP AND OBJECTIVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOCTURNAL
MEDICATION: II. REPEATED DOSES.
002331 02-14
EEG ASSESSMENTS OF DOSAGE AND SLEEP PROFILES FOR A HYPNOTIC-
DRUG OF THE TRIAZOLOTHIENODIACEPINE SERIES.
002338 02-14
IMIPRAMINE AND EEG SLEEP IN CHILDREN WITH DEPRESSIVE-
SYMPTOMS.
002339 02-14
THE CLOCK AND THE BLUE GUITAR: STUDIES OF HUMAN GROWTH-
HORMONE SECRETION IN SLEEP AND WAKING. (UNPUBLISHED PAPER).
002346 02-14
INDIVIDUAL VARIATIONS IN THE EFFECTS OF FLURAZEPAM,
CLORAZEPATE, L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON
REM SLEEP IN MAN.
002349 02-14
THE EFFEa OF BUTOQAMIDE-HYDROGEN-SUCCINATE ON NOCTURNAL
SLEEP: ALL-NIGHT POLYGRAPHICAL-STUDIES.
002350 02-14
THE EFFECTS OF FLURAZEPAM, LORAZEPAM, AND TRIAZOLAM ON SLEEP
AND MEMORY.
002357 02-14
THE EFFECT OF DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B-
INHIBITOR, ON SLEEP AND MOOD IN MAN.
002365 02-14
COMPUTERIZED SLEEP EEG (CSEEG) IN PSYCHIATRY AND
PSYCHOPHARMACOLOGY.
002614 02-17
OPIATE-RECEPTORS AND SLEEP. II. EFFEQS OF MICROINJECTIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUaAL GRAY MAHER AND NUCLEUS-TRACTUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
SLEEP ELICITED BY OLFAQORY TUBERCLE STIMULATION AND THE EFFEQ
OF ATROPINE.
002955 03-04
EFFEa OF P CHLOROPHENYLALANINE AND TRYPTOPHAN ON SLEEP, EEG
AND MOTOR-AQIVITY IN THE RAT.
002958 03-04
ENHANCEMENT OF HEXOBARBITAL-INDUCED SLEEP BY LYSINE AND ITS
METABOLITES.
002967 03-04
SUPPRESSION OF AQIVE SLEEP BY CHRONIC-TREATMENT WITH
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT:
EFFEQS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT.
003056 03-04
SLEEP AND TREATMENT PREDICTION IN ENDOGENOUS DEPRESSION.
003236 03-09
POLYGRAPHIC-STUDY OF NIGHT SLEEP UNDER THE EFFECTS OF
MINAPRINE.
003313 03-1 1
THE EFFEQIVENESS OF IMIPRAMINE IN THE TREATMENT OF ENURESIS:
THE SIGNIFICANCE OF TYPE OF ENURESIS AND REPORTED LEVEL OF
SLEEP. (PH.D. DISSERTATION).
003337 03-1 1
ON THE EVALUATION Of A PROVOCATIVE EEG METHOD USING
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUQION THROUGH
MEDICATION.
003387 03-11
STUDY ON THE EFFEQS OF L 5 HTP ON THE STAGES OF SLEEP IN MAN AS
EVALUATED BY USING SLEEP-DEPRIVATION.
003450 03-14
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING,
DISTURBED SLEEP OR AQIVATION BY PONTO-GENICULO-OCCIPITAL
WAVES IN CATS?
003704 04-02
DOES RAPID-EYE-MOVEMENT SLEEP PLAY A ROLE IN BRAIN
DEVELOPMENT?
004091 04-04
0 6 FLUOROTRYPTOPHAN, AN INHIBITOR OF TRYPTOPHAN-
HYDROXYLASE: SLEEP AND WAKEFULNESS IN THE RAT.
004189 04-04
PHENOXYBENZAMINE AND BROMOCRIPTINE AHENUATE NEED FOR REM
SLEEP IN RATS.
004203 04-04
CHANGES OF RESPONSE TO DOPAMINERGIC DRUGS IN RATS SUBMITTED
TO REM SLEEP DEPRIVATION.
004239 04-04
COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPLIED TO DRUG
EVALUATION: MIDAZOLAM IN NORMAL SUBJECTS
004564 04- 14
EFFECTS OF SUPIDIMIDE (CG-3033) ON OBJECTIVE AND SUBJECTIVE SLEEP
PARAMETERS (A SLEEP LABORATORY STUDY).
004567 04-14
EFFECTS OF A SHORT-ACTING BENZODIAZEPINE ON BRAIN ELECTRICAL-
ACTIVITY DURING SLEEP.
004568 04-14
A SYNTHETIC ACTH4-9 ANALOGUE (ORGANON-2766) AND SLEEP IN
HEALTHY MAN.
004574 04-14
SLEEP-APNEA
MEDROXYPROGESTERONE TREATMENT OF OBSTRUCTIVE SLEEP-APNEA.
002128 02-11
TREATMENT OF NARCOLEPSY AND SLEEP-APNEA WITH GAMMA
HYDROXYBUTYRATE: A CLINICAL AND POLYSOMNOGRAPHIC CASE-
STUDY.
004571 04-14
SLEEP-APNEA-SYNDROME
FLURAZEPAM-INDUCED SLEEP-APNEA-SYNDROME IN A PATIENT WITH
INSOMNIA AND MILD SLEEP-RELATED RESPIRATORY CHANGES.
004729 04-17
SLEEP-DEPRIVATION
PREDICTION OF LOFEPRAMINE RESPONSE IN DEPRESSION BASED ON
RESPONSE TO PARTIAL SLEEP-DEPRIVATION.
000617 01-09
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN
RATS.
001199 02-03
STUDY ON THE EFFECTS OF L 5 HTP ON THE STAGES OF SLEEP IN MAN AS
EVALUATED BY USING SLEEP-DEPRIVATION.
003450 03-14
SLEEP-DEPRIVED
COCAINE EFFECTS IN SLEEP-DEPRIVED HUMANS.
002323 02-14
SLEEP-DISORDERS
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS.
001869 02-06
SURVECTOR AND SLEEP-DISORDERS: SLEEP-WALKING, NIGHTMARES,
AND NIGHT-TERRORS.
002110 02-11
THE CLASSIFICATION OF SLEEP-DISORDERS AND THE TREATMENT OF
VARIOUS FORMS OF SOMNAMBULISM.
004461 04-11
SLEEP-DISTURBANCE
AGE-SPECIFIC DOSES OF LORMETAZEPAM AS A NIGHT SEDATIVE IN
CASES OF CHRONIC SLEEP-DISTURBANCE.
004309 04-07
SLEEP-RELATED
FLURAZEPAM-INDUCED SLEEP-APNEA-SYNDROME IN A PATIENT WITH
INSOMNIA AND MILD SLEEP-RELATED RESPIRATORY CHANGES.
004729 04-17
SLEEP-TIME
EFFECT OF CANNABIDIOL ON CYTOCHROME-P-450 AND HEXOBARBITAL
SLEEP-TIME.
002675 03-03
SLEEP-WAKE-DISORDERS
TREATMENTS FOR SLEEP- WAKE-DISORDERS IN THE ELDERLY.
002157 02-11
SLEEP-WAKEFULNESS
BIPHASIC-EFFECTS OF PIMOZIDE ON SLEEP-WAKEFULNESS IN DOGS.
000495 01-04
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT.
003703 04-02
SLEEP-WALKING
SURVEaOR AND SLEEP-DISORDERS: SLEEP-WALKING, NIGHTMARES,
AND NIGHT-TERRORS.
002110 02-11
SLEEPERS
AUDITORY AROUSAL THRESHOLDS OF GOOD SLEEPERS AND POOR
SLEEPERS WITH AND WITHOUT FLURAZEPAM.
003446 03-14
SLEEPINESS
INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS.
002341 02-14
SLEEPING-AIDS
EFFICACY AND SIDE-EFFECTS OF LORAZEPAM, OXAZEPAM, AND
TEMAZEPAM AS SLEEPING-AIDS IN PSYCHOGERIATRIC-INPATIENTS.
002076 02-10
EFFICACY AND SIDE-EFFEaS OF CHLORAL-HYDRATE AND TRYPTOPHAN
AS SLEEPING-AIDS IN PSYCHOGERIATRIC-PATIENTS.
002077 02-10
S-413
Subject Index
Ptychopharmacology Abstracts
ii
tt;.
6
fe
I
SLEEPING-PILL
THE SLEEPING-PILL.
000946 01-17
SLEEPING-PILLS
THE USE AND MISUSE OF SLEEPING-PILLS: A CLINICAL GUIDE.
002150 02-11
SLEEPING-TIME
NEUTRALIZATION OF THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL
ON BARBITURATE SLEEPING-TIAAE BY SPECIFIC ACTIVE IMMUNIZATION.
003803 04-03
SLICE
CONVULSANTS ANTAGONISE INHIBITION IN THE OLFAQORY-CORTEX
SLICE.
001466 02-03
THE IN VITRO BRAIN SLICE AS A USEFUL NEUROPHYSIOLOGICAL
PREPARATION FOR INTRACELLULAR RECORDING.
001864 02-06
DIFFERENTIAL TOLERANCE TO THE EFFECTS OF MORPHINE ON EVOKED
ACTIVITY IN THE HIPPOCAMPAL SLICE.
003760 04-03
GABA-ENHANCEMENT OF (3H)D0PAMINE RELEASE FROM SLICES OF RAT
STRIATUM: DEPENDENCE ON SLICE SIZE.
003786 04-03
EFFECTS OF ENKEPHALIN, MORPHINE, AND NALOXONE ON THE
ELECTRICAL-ACTIVITY OF THE IN VITRO HIPPOCAMPAL SLICE
PREPARATION.
003918 04-03
SLICES
REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS.
000066 01-03
AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT-
CEREBRAL-CORTEX.
000072 01-03
ALPHA-ADRENOCEPTOR-MEDIATED MODULATION OF 5
HYDROXYTRYPTAMINE RELEASE FROM RAT-BRAIN-CORTEX SLICES.
000111 01-03
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN-
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM.
000123 01-03
ACTIONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID
METABOLISM IN GUINEA-PIG BRAIN SLICES.
000129 01-03
GABA INHIBITION OF 3H GLYCINE RELEASE FROM SLICES OF RAT
SUBSTANTIA-NIGRA IN VITRO.
000157 01-03
REUPTAKE OF BIOGENIC-AMINES BY BRAIN SLICES: EFFEQ OF
HYDROCORTISONE.
000187 01-03
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFECTS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
(3H)ACETYLCH0LINE AND (3H)5 HYDROXYTRYPTAMINE RELEASE FROM
RAT-MIDBRAIN SLICES AND THE EFFEaS OF CALCIUM AND
PHENOBARBITAL.
000251 01-03
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRAQIONS.
000299 01-03
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE
RECEPTORS.
000323 01-03
ELECTRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFEQS OF
HIGH-FREQUENCY STIMULATION ON DENDRITIC ULTRASTRUQURE.
(UNPUBLISHED PAPER).
001036 02-01
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELEQRICAL-
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL
SLICES.
001130 02-03
NORADRENALINE RELEASE FROM SLICES OF THE THALAMUS OF NORAAAL
AND MORPHINE-DEPENDENT RATS.
001 142 02-03
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES.
001207 02-03
EFFECTS OF HALOPEMIDE ON POTASSIUM-INDUCED RELEASE OF
RADIOLABELED NEUROTRANSMIHERS FROM RAT CEREBROCORTICAL
SLICES IN VITRO.
001347 02-03
CHARAQERIZATION AND RADIOAUTOGRAPHY OF (3H)LSD BINDING BY
RAT-BRAIN SLICES IN VITRO: THE EFFEQ OF 5 HYDROXYTRYPTAMINE
001369 02-03
STUDIES ON THE EFFEQ OF ALPHA MELANOCYTE-STIMULATING-
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P
AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED
PAPER).
001372 02-03
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES.
001402 02-03
INHIBITORY AQIONS OF TAUROCY AMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
GABA AND BACLOFEN POTENTIATE THE K -EVOKED RELEASE OF
METHIONINE-ENKEPHALIN FROM RAT STRIATAL SLICES.
002882 03-03
METHYLXANTHINES MODULATE ADENOSINE RELEASE FROM SLICES OF
CEREBRAL-CORTEX.
002907 03-03
SOMATOSTATIN FACILITATES THE SEROTONIN RELEASE FROM RAT-
CEREBRAL-CORTEX, HIPPOCAMPUS, AND HYPOTHALAMUS SLICES
002913 03-03
STIMULATORY EFFEQ OF SOMATOSTATIN ON NOREPINEPHRINE RELEASE
FROM RAT-BRAIN-CORTEX SLICES.
002920 03-03
MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND
UPTAKE OF NEUROTRANSMIHERS IN BRAIN SLICES.
003147 03-06
THE EFFECTS OF ANTIDEPRESSANTS ON THE RETENTION AND
METABOLISM OF (3H) NOREPINEPHRINE IN RAT-BRAIN SLICES.
003763 04-03
GABA-ENHANCEMENT OF (3H)D0PAMINE RELEASE FROM SLICES OF RAT
STRIATUM: DEPENDENCE ON SLICE SIZE.
003786 04-03
THE UPTAKE OF CARNITINE BY SLICES OF RAT-CEREBRAL-CORTEX.
003853 04-03
INVESTIGATION OF AQION OF ENKEPHALIN ON THE SPONTANEOUS AND
EVOKED RELEASE OF ACETYLCHOLINE FROM RAT CORTICAL AND
STRIATAL SLICES.
003862 04-03
ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES:
EFFEQS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE-
DEAMINASE INHIBITORS.
003950 04-03
EFFECT OF PR0STAGLANDIN-D2, PR0STAGLANDIN-E2 AND
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES
OF RAT AND RABBIT BRAIN.
003983 04-03
INHIBITION OF THE SYNTHESIS OF ACETYLCHOLINE IN RAT-BRAIN SLICES
BY (-) HYDROXYCITRATE AND CITRATE.
004044 04-03
THE EFFEQ OF NORADRENALINE ON NA-K TRANSPORT IN RAT-CEREBRAL-
CORTICAL SLICES.
004056 04-03
SLIME
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK
TISSUES - ARE THEY CELL ADHESION MOLECULES?
003724 04-03
SMALL-DOSE
SMALL-DOSE INTRAVENOUS HEROIN FACILITATES HYPOTHALAMIC SELF-
STIMULATION WITHOUT RESPONSE SUPPRESSION IN RATS.
002999 03-04
SMOKING
NALOXONE REDUCES CIGARETTE SMOKING.
000808 01-14
PLASMA DELTA9 TETRAHYDROCANNABINOL CONCENTRATIONS AND
CLINICAL-EFFEQS AFTER ORAL AND INTRAVENOUS ADMINISTRATION
AND SMOKING.
002201 02-12
THE USE OF NICOTINE CHEWING-GUM AS AN AID TO STOPPING
SMOKING.
002343 02-14
SMOKING AND VIGILANCE: THE EFFECTS OF TOBACCO SMOKING ON CFF
AS RELATED TO PERSONALITY AND SMOKING HABITS.
002368 02-14
THE SMOKING HABIT AND PSYCHOPHARMACOLOGICAL-EFFECTS OF
NICOTINE.
003577 03-17
THE ROLE OF NICOTINE IN THE BEHAVIORAL-ASPECTS OF CIGARETTE
SMOKING.
004575 04-14
SMOOTH-MUSCLE
POTENTIATION OF THE EFFECTS OF ADENOSINE ON ISOLATED CARDIAC-
MUSCLE AND SMOOTH-MUSCLE BY DIAZEPAM.
004266 04-05
S-414
VOLUME 19, SUBJECT INDEX
Subject Index
SMOOTH-PURSUIT
DISORDFRS OF SMOOTH-PURSUIT EYE-MOVEMENTS IN SCHIZOPHRENICS
AND THE EFFECT OF NEUROLEPTICS IN THERAPEUTIC DOSES.
0019)2 02-08
QUANTITATIVE ASSESSMENT OF SMOOTH-PURSUIT EYE-MOVEMENTS IN
HEALTHY AND EPILEPTIC-SUBJECTS.
002376 02-15
SMOOTH-PURSUIT EYE-MOVEMENTS: EFFECTS OF ALCOHOL AND
CHLORAL-HYDRATE.
003448 03-14
SNAKES
THE EFFECTS OF ALPHA AND BETA NEUROTOXINS FROM THE VENOMS OF
VARIOUS SNAKES ON TRANSMISSION IN AUTONOMIC GANGLIA.
003750 04-03
SOOAL
TESTOSTERONE AND PERSISTENCE OF SOCIAL INVESTIGATION IN
LABORATORY RATS.
000488 01-04
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH
ANTIEPILEPTIC-DRUGS.
000695 01-11
IMITATION, SOCIAL FACILITATION, AND THE EFFECTS OF ACTH4-10 ON
RATS BAR-PRESSING-BEHAVIOR.
003009 03-04
LONG-LASTING EFFECTS OF CHRONIC ADMINISTRATION OF
HALLUCINOGENIC-DRUGS ON RAT SOCIAL AND EMOTIONAL-BEHAVIOR.
(PH.D. DISSERTATION).
003029 03-04
CONTRIBUTION OF SOCIAL FAQORS TO OPIATE-INDUCED ACTIVATION IN
THE MOUSE.
004156 04-04
SOCIAL CROWDING ENHANCES AVERSIVENESS OF NALOXONE IN RATS.
004201 04-04
THE INTEGRITY OF THE SOCIAL HIERARCHY IN MICE FOLLOWING
ADMINISTRATION OF PSYCHOTROPIC-DRUGS.
004202 04-04
PSYCHOPHARMACOLOGICAL AND SOCIAL ASPECTS OF SCHIZOPHRENIA:
RECENT DEVELOPMENTS.
004336 04-08
THERAPY AND SOCIAL ADAPTATION OF OLIGOPHRENICS (REVIEW OF THE
LITERATURE).
004444 04-11
THE EFFECTS OF NEUROLEPTIC-DRUGS ON THE SOCIAL INTERACTIONS OF
HOSPITALIZED PSYCHOTIC-PATIENTS.
004577 04-14
HUMAN SOCIAL CONVERSATION: EFFECTS OF ETHANOL, SECOBARBITAL
AND CHLORPROMAZINE.
004582 04-14
SOCIAL-ACTIVITY
NALOXONE REDUCES SOCIAL-ACTIVITY AND EXPLORATORY-ACTIVITY IN
THE RAT.
001617 02-04
SOCIAL-BEHAVIOR
EFFECTS OF METHAQUALONE ON SOCIAL-BEHAVIOR IN MONKEYS
(MACACA-MULAHA).
001594 02-04
LONG-TERM CHLORPROMAZINE IN RHESUS-MONKEYS: PRODUCTION OF
DYSKINESIAS AND CHANGES IN SOCIAL-BEHAVIOR.
001850 02-05
A RESEARCH PARADIGM TO INVESTIGATE THE EFFECT OF MANIPULATION
ON SOCIAL-BEHAVIOR IN GROUPS.
003007 03-04
SOCIAL-BEHAVIOUR
LONG-TERM EFFECTS OF TESTOSTERONE INJECTIONS ON THE SOCIAL-
BEHAVIOUR OF MALE DUCKS AND THEIR PHYSIOLOGICAL-CORRELATES.
001565 02-04
SOCIAL-COLONY
THE ACUTE AND CHRONIC EFFECT OF 5 METHOXYTRYPTAMINE ON
SELECTED MEMBERS OF A PRIMATE SOCIAL-COLONY.
001073 02-02
SOCIAL-COMFORT
OPIOID BLOCKADE AND SOCIAL-COMFORT IN CHICKS.
001745 02-04
SOCIAL-INTERACTION
THE USE OF SOCIAL-INTERACTION AS A METHOD FOR DETECTING
ANXIOLYTIC-ACTIVITY OF CHLORDIAZEPOXIDE-LIKE DRUGS.
001866 02-06
SOCIAL-INTERACTIONS
CHRONIC DELTA9 TETRAHYDROCANNABINOL IN RATS: EFFECT ON
SOCIAL-INTERACTIONS, MOUSE-KILLING, MOTOR-ACTIVITY,
CONSUMMATORY-BEHAVIOR, AND BODY-TEMPERATURE.
001722 02-04
BEHAVIORAL-EFFEQS OF HASHISH IN MICE: III. SOCIAL-INTERACTIONS
BETWEEN TWO RESIDENTS AND AN INTRUDER MALE.
001776 02-04
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: I. SOCIAL-INTERACTIONS
AND NEST-BUILDING-BEHAVIOR OF MALES.
001777 02-04
SOCIAL-ISOLATION
EFFECTS OF SOCIAL-ISOLATION ON MEMORY FORMATION.
001607 02-04
BRIEF SOCIAL-ISOLATION, PAIN RESPONSIVITY, AND MORPHINE
ANALGESIA IN YOUNG RATS,
001744 02-04
SOCIAL-MALADJUSTMENTS
PIMOZIDE IN THE TREATMENT OF SOME SOCIAL-MALADJUSTMENTS IN
PERSONALITY-DISORDERS.
002068 02-10
SOCIAL-PSYCHIATRY
SOCIAL-PSYCHIATRY AND PSYCHOPHARMACOLOGY.
002612 02-17
SOCIOPATHY
NEUROPEPTIDE TREATMENT OF SOCIOPATHY: RESEARCH IN PROGRESS.
002369 02-14
SOCIOSEXUAL-BEHAVIOUR
COMPARISON OF THE EFFECTS OF BETA ENDORPHIN AND MORPHINE ON
EXPLORATORY-BEHAVIOUR AND SOCIOSEXUAL-BEHAVIOUR IN THE
MALE RAT.
004178 04-04
SODIUM
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION.
001300 02-03
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM.
002728 03-03
INCREASE OF C-GMP AND ACCUMULATION OF 45CA2 EVOKED BY DRUGS
ACTING ON SODIUM OR POTASSIUM CHANNELS.
003709 04-03
SODIUM-AMOBARBITAL
DELIRIUM OR PSYCHOSIS? DIAGNOSTIC USE OF THE SODIUM-
AMOBARBITAL INTERVIEW.
002167 02-11
SODIUM-CHLORIDE
SODIUM-CHLORIDE INHIBITION DECREASES LEVELS OF IMMUNOREAQIVE
DYNORPHIN IN THE NEUROINTERMEDIATE PITUITARY OF RATS.
001283 02-03
SODIUM-DEPENDENT
SODIUM-DEPENDENT INTERACTION OF BENZAMIDES WITH DOPAMINE-
RECEPTORS.
000285 01-03
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL AND CANNABIDIOL ON
SODIUM-DEPENDENT HIGH-AFFINITY CHOLINE UPTAKE IN THE RAT
HIPPOCAMPUS.
003908 04-03
SODIUM-DIPROPYLACETATE
EFFECTS OF SODIUM-DIPROPYLACETATE, MUSCIMOL-HYDROBROMIDE
AND (R,S) NIPECOTIC-ACID-AMIDE ON ISOLATION-INDUCED
AGGRESSIVE-BEHAVIOR IN MICE.
001756 02-04
TOLERANCE STUDY IN PSYCHIATRIC-PATIENTS OF A NEW PREPARATION
OF SODIUM-DIPROPYLACETATE.
003158 03-07
THE EFFECT OF SODIUM-DPROPYLACETATE ON GAMMA AMINOBUTYRIC-
ACID DEPENDENT INHIB. ION IN THE RAT-CORTEX AND SUBSTANTIA-
NIGRA IN RELATION TO ITS ANTICONVULSANT ACTIVITY.
003880 04-03
EFFECT OF SODIUM-DIPROPYLACETATE ON CONFLia-BEHAVIOR IN RATS.
004192 04-04
SODIUM-HYDROXYBUTYRATE
ACUTE EFFECT OF BENZOCT AMINE (10 MG), SODIUM-
HYDROXYBUTYRATE (2 G) AND FENCAMFAMINE (10 MG) ON VERBAL-
ASSOCIATIONS.
000806 01-14
SODIUM-ION
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
SODIUM-LACTATE
EFFECT OF SODIUM-LACTATE ON PATIENTS WITH PANIC-DISORDER AND
MITRAL- VALVE PROLAPSE.
003409 03-13
BLOCKADE BY IMIPRAMINE OR DESIPRAMINE OF PANIC-INDUCED BY
SODIUM-LACTATE.
004427 04-10
SODIUM-NUCLEINATE
THE USE OF SODIUM-NUCLEINATE IN THE TREATMENT OF
SCHIZOPHRENIC-PATIENTS.
004339 04-08
SODIUM-PENTOBARBITAL
MODULATION OF CONDITIONED TASTE-AVERSION BY SODIUM-
PENTOBARBITAL.
001596 02-04
S-415
Subject Index
Psychopharmacology Abstracts
ii
•till
ft'
I
SODIUM-PUMP
SHORT-TERM AND LONG-TERM MODIFICATION OF SKELETAL-MUSCLE
SODIUM-PUMP ACTIVITY AND MUSCLE PROTEIN TURNOVER.
(UNPUBLISHED PAPER).
001519 02-03
SODIUM-SALICYLATE
THE EFFECT OF SODIUM-SALICYLATE ON CEREBRAL BLOOD ROW AND
METABOLISM.
001416 02-03
SODIUM-VALPROATE
ANTAGONISM BY CLASSICAL ANTIEPILEPTICS AND SODIUM-VALPROATE
OF CEFAZOLIN-INDUCED EXPERIMENTAL EPILEPSY IN RATS.
000442 01-04
SODIUM-VALPROATE IN SCHIZOPHRENIA: SOME BIOCHEMICAL-
CORRELATES.
000561 01-08
ALBUMIN BINDING INTERACTIONS OF SODIUM-VALPROATE.
000762 01-13
MEAL-DEPENDENT ABSORPTION OF ENTERIC-COATED SODIUM-
VALPROATE.
000777 01-13
PHENOBARBITONE AND SODIUM-VALPROATE INTERACTION; AN
EXPERIMENTAL-STUDY.
001371 02-03
SODIUM-VALPROATE IN THE TREATMENT OF ALCOHOL WITHDRAWAL-
SYNDROME.
002139 02-11
ELECTROENCEPHALOGRAPHIC-EFFECTS AND BEHAVIOURAL-EFFECTS OF
SODIUM-VALPROATE IN PATIENTS WITH PHOTOSENSITIVE EPILEPSY A
SINGLE-DOSE TRIAL.
002154 02-11
HEPATOTOXICITY OF SODIUM-VALPROATE AND OTHER
ANTICONVULSANTS IN RAT HEPATOCYTE CULTURES
002422 02-15
EFFECT OF SODIUM-VALPROATE AND BACLOFEN IN TARDIVE-DYSKINESIA
CLINICAL-STUDIES AND NEUROENDOCRINE-STUDIES.
002441 02-15
INTERACTION OF CHLORDIAZEPOXIDE AND SODIUM-VALPROATE IN THE
NUCLEUS-ACCUMBENS OF THE RAT.
002796 03-03
EFFECT OF SODIUM-VALPROATE ON MOTOR FUNCTION REGULATED BY
THE ACTIVATION OF GABA-RECEPTORS.
003033 03-04
THE EFFECT OF SODIUM-VALPROATE ON MANIA: THE GABA HYPOTHESIS
OF AFFECTIVE-DISORDERS.
003218 03-09
ON A POSSIBLE ROLE OF GABA IN MANIA. THERAPEUTIC-EFFICACY OF
SODIUM-VALPROATE.
003219 03-09
DISSOCIATION BETWEEN FREE AND BOUND PHENYTOIN LEVELS IN
PRESENCE OF SODIUM-VALPROATE.
003367 03-11
COMPARISON OF SODIUM-VALPROATE AND PHENYTOIN AS SINGLE
DRUG-TREATMENT IN EPILEPSY.
003371 03-11
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION
OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY.
003433 03-1 3
ASTERIXIS ASSOCIATED WITH SODIUM-VALPROATE.
003468 03-15
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
EFFECT OF TREATMENT WITH SODIUM-VALPROATE AND DIAZEPAM ON
PLASMA CORTICOTROPIN IN NELSONS- SYNDROME.
004463 04-11
THE EFFECT OF SODIUM-VALPROATE ON THE PHOTOSENSITIVE VEP.
004513 04-13
SOLID
SPECTRA OF RADICAL CATIONS OF PHENOTHIAZINE DERIVATIVES IN
SOLUTION AND SOLID STATE.
003673 04-01
SOLUBILIZATION
SOLUBILIZATION OF ACTIVE OPIATE-RECEPTORS. (UNPUBLISHED PAPER).
001056 02-01
SOLUBILIZATION OF THE DIHYDROPICROTOXININ BINDING-SITES.
001192 02-03
DOPAMINE-RECEPTOR: FROM SYNAPTIC MEMBRANES TO
SOLUBILIZATION.
001326 02-03
SOLUBILIZATION OF SEROTONIN-RECEPTORS FROM RAT-FRONTAL-
CORTEX.
002489 02-16
SOLUBILIZATION OF NEUROLEPTIC/DOPAMINE-RECEPTORS OF HUMAN
BRAIN STRIATUM.
003767 04-03
SOLUBILIZED
GABA-MODULIN REGULATES SOLUBILIZED BENZODIAZEPINE AND GABA
RECOGNITION SITES. (UNPUBLISHED PAPER).
001263 02-03
SOLUBLE
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS. (UNPUBLISHED
PAPER).
001035 02-01
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALEQOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER).
001122 02-03
ACTIVATION OF SOLUBLE STRIATAL TYROSINE-HYDROXYLASE IN THE RAT
BRAIN AFTER CDP-CHOLINE ADMINISTRATION.
002816 03-03
SOLUTION
OPIATE-RECEPTORS IN MEMBRANES AND IN SOLUTION. (UNPUBLISHED
PAPER).
001032 02-01
DOSE-RESPONSE RELATIONSHIP BETWEEN NALOXONE INJECTIONS AND
INTAKE OF SUCROSE SOLUTION.
003118 03-04
SPECTRA OF RADICAL CATIONS OF PHENOTHIAZINE DERIVATIVES IN
SOLUTION AND SOLID STATE.
003673 04-01
SOLVENTS
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
SOMAL
THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION
PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR
PRESERVED SCHWANN-CELL SOMAL FUNCTION.
002905 03-03
SOMATIC
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUQURE-AaiVITY
RELATIONSHIPS
001132 02-03
SOMATOSENSORY
PRESSURE REVERSAL OF THE EFFECT OF URETHANE ON THE EVOKED
SOMATOSENSORY CORTICAL RESPONSE IN THE RAT
001106 02-03
EFFEQ OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND
NORMAL ADULTS.
002222 02-13
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE
ANESTHETIZED RATS.
002687 03-03
EFFECTS OF PENTOBARBITAL AND ETHANOL UPON SINGLE NEURON
ACTIVITY IN THE PRIMARY SOMATOSENSORY CORTEX OF THE RHESUS-
MONKEY.
003755 04-03
SOMATOSTATIN
COMPARATIVE-EFFECTS OF SOMATOSTATIN AND ENKEPHALINS ON THE
GUINEA-PIG ILEUM AND THE RAT VAS-DEFERENS
001302 02-03
SOMATOSTATIN FACILITATES THE SEROTONIN RELEASE FROM RAT-
CEREBRAL-CORTEX, HIPPOCAMPUS, AND HYPOTHALAMUS SLICES.
002913 03-03
STIMULATORY EFFEQ OF SOMATOSTATIN ON NOREPINEPHRINE RELEASE
FROM RAT-BRAIN-CORTEX SLICES.
002920 03-03
PHARMACOLOGICAL CHARAQERIZATION OF SCRATCHING-BEHAVIOUR
INDUCED BY INTRACRANIAL INJECTION OF SUBSTANCE-P AND
SOMATOSTATIN.
002980 03-04
SOMATOSTATIN-28
HIGH-AFFINITY BINDING-SITES FOR A SOAAATOSTATIN-28 ANALOG IN
RAT-BRAIN
003985 04-03
SOMATOTHERAPEUTIC
THE EFFECT OF LONG-TERM MAINTENANCE-THERAPY ON SCHIZOPHRENIC-
PATIENTS USING SOMATOTHERAPEUTIC MEASURES.
004325 04-08
SOMATOTROPIN
PROLACTIN AND SOMATOTROPIN RESPONSES TO TRH IN SCHIZOPHRENIC-
PATIENTS.
000570 01-08
SOMATOTYPY
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJEQION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS.
001446 02-03
S-416
VOLUME 19, SUBJECT INDEX
Subject Index
SOMNAMBULISM
THE CLASSIFICATION OF SLEEP-DISORDERS AND THE TREATMENT OF
VARIOUS FORMS OF SOMNAMBULISM.
004461 04- n
SORPTION
SORPTION OF CHLORMETHIAZOLE BY INTRAVENOUS INFUSION GIVING
SETS.
002508 02-16
SOTALOl
EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS.
001570 02-04
SOUND-INDUCED
ENERGY RESERVES AND SOUND-INDUCED SEIZURES. (UNPUBLISHED
PAPER).
001467 02-03
NORADRENERGIC INFLUENCES ON SOUND-INDUCED SEIZURES.
004137 04-04
SOUPS
TYRAMINE CONTENT OF CANNED AND PACKET SOUPS.
002394 02-15
SOUTH
RESULTS OF TREATMENT BY MODITEN DEPOT IN OUTPATIENTS-WARDS IN
THE SOUTH MORAVIAN REGION.
004648 04-15
SOVIET
A PHARMACOLOGICAL-STUDY OF THE NEW SOVIET ANTIDEPRESSANT
INKASAN.
000008 01-02
ISOLATION OF PSYCHOACTIVE CANNABINOID PRECURSORS FROM
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI.
001023 02-01
SP-111
DELTA9 THC AS A DISCRIMINATIVE-STIMULUS IN RATS AND PIGEONS:
GENERALIZATION TO THC METABOLITES AND SP-1 1 1 .
001666 02-04
SPACE
DEPRESSION OF RESERPINE-INDUCED MUSCULAR RIGIDITY IN RATS AFTER
ADMINISTRATION OF LISURIDE INTO THE SPINAL SUBARACHNOID
SPACE.
002962 03-04
SPACES
MORPHINE ANALGESIA FOLLOWING ITS INFUSION INTO DIFFERENT
LIQUOR SPACES IN RAT-BRAIN.
001429 02-03
SPACING
AROUSAL AND SHORT-TERM MEMORY: EFFECTS OF CAFFEINE AND TRIAL
SPACING ON DELAYED ALTERNATION PERFORMANCE.
000487 01-04
SPAIN
RESULTS OF A SURVEY ON THE PRESENT TREATMENT OF DEPRESSION IN
SPAIN.
001963 02-09
SPARING
ANESTHETICS AND THE HABENULO-INTERPEDUNCULAR SYSTEM:
SELECTIVE SPARING OF METABOLIC ACTIVITY.
003833 04-03
SPASTICITY
EFFECT OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND
RIGIDITY: A QUANTITATIVE STUDY OF REFLEXES AND PLASMA
CONCENTRATIONS.
000701 01-11
SPECIAL-CHILD
DRUGS AND THE SPECIAL-CHILD.
002107 02-11
SPECIALIZATION
PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS
MECHANISMS RESPONSIBLE FOR MOTOR ACT INHIBITION BY AVERSIVE
EVENTS.
002671 03-03
SPECIES
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE-
ENKEPHALIN AND CHOLECYSTOKININ IN THE NEURAL RETINA OF
SEVERAL VERTEBRATE SPECIES. (UNPUBLISHED PAPER).
001017 02-01
A COMPARATIVE-STUDY OF THE PHARMACOLOGICAL-PROPERTIES OF THE
POSITIVE POTENTIAL RECORDED FROM THE SUPERIOR CERVICAL
GANGLIA OF SEVERAL SPECIES.
003779 04-03
OXIDATION OF BETA PHENYLETHYLAMINE BY BOTH TYPES OF
MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND
LIVER MITOCHONDRIA OF EIGHT SPECIES.
004024 04-03
SPECIES-DIFFERENCES
SPECIES-DIFFERENCES IN CLOBAZAM METABOLISM AND ANTILEPTAZOL
EFFECT.
001157 02-03
SPECIES-DIFFERENCES IN THE DEAMINATION OF DOPAMINE AND OTHER
SUBSTRATES FOR MONOAMINE-OXIDASE IN BRAIN.
002233 02-13
COMPARATIVE-STUDY ON THE EFFECT OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS: STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS
002757 03-03
SPECIFICITY
STUDIES ON THE SPECIFICITY AND REVERSAL OF NEUROLEPTIC-INDUCEO
DOPAMINERGIC-SUPERSENSITIVITY (PH D DISSERTATION)
001469 02-03
AN ANALYSIS OF SPECIFICITY OF DRUG-INDUCED CHANGES IN DRUG-
REINFORCED RESPONDING. (PH.D. DISSERTATION).
003010 03-04
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION:
EVIDENCE FOR AMINE SPECIFICITY.
003250 03-09
LACK OF SPECIFICITY OF AN ANIMAL BEHAVIOR MODEL FOR
HALLUCINOGENIC DRUG ACTION.
004250 04-04
CHOLINERGIC MECHANISMS IN MANIA AND DEPRESSION: QUESTIONS OF
SPECIFICITY.
004374 04-09
A SENSITIVE BENZODIAZEPINE RADIOIMMUNOASSAY OF BROAD
SPECIFICITY.
004693 04-16
SPECTRA
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY
SPECTRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND
NEUROLEPTICS.
001220 02-03
EFFECT OF PIRACETAM ON EEG SPECTRA OF BOYS WITH LEARNING-
DISORDERS.
003383 03-1 1
SPECTRA OF RADICAL CATIONS OF PHENOTHIAZINE DERIVATIVES IN
SOLUTION AND SOLID STATE.
003673 04-01
A MULTIVARIATE ANALYSIS OF THE INFRARED SPECTRA OF DRUGS OF
ABUSE.
004688 04-16
SPECTRAL
POWER SPECTRAL ANALYSIS OF THE FLASH-EVOKED AFTERDISCHARGE.
003133 03-06
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
SPECTROFLUOROMETRIC
COMPARISON OF SPECTROFLUOROMETRIC AND GAS-
CHROMATOGRAPHY/MASS-SPECTROMETRY PROCEDURES FOR THE
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN.
004692 04-16
SPECTROPHOTOMETRY
A COMPARISON OF RADIOIMMUNOASSAY WITH SPECTROPHOTOMETRY
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN
CONCENTRATIONS.
004684 04-16
SPECTROSCOPY
BETA ENDORPHIN AND ANALOGS: 360 MHZ PROTON NMR
SPECTROSCOPY.
001028 02-01
COMPARISON OF HIGHLY-ACTIVE AND ACTIVITY DEPLETED HEPARIN BY
CIRCULAR DICHROISM SPECTROSCOPY. (UNPUBLISHED PAPER).
001057 02-01
SPEECH
PRINCIPAL AND DIFFERENTIAL-EFFECTS OF HALOPERIDOL AND PLACEBO
TREATMENTS UPON SPEECH DISFLUENCIES IN STUHERERS.
^00713 01-11
DOPAMINERGIC-SYSTEMS AND SPEECH FLUENCY.
000821 01-14
SPERMAT06ENIC
CYCLOPHOSPHAMIDE-INDUCED SPERMATOGENIC EFFECTS DETECTED IN
THE F1-GENERATI0N BY BEHAVIORAL-TESTING.
003121 03-05
SPHINGOMYELINASE
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL
AND PATHOLOGICAL (M. NIEMANN-PICK TYPE C) HUMAN BRAIN.
003671 04-01
SPIKE
INHIBITORY ACTIONS OF TAUROCY AMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
SPIKES
ACTIVATION OF CORTICAL CIRCUITS DURING INTERICTAL SPIKES.
000056 01-03
THE EFFECT OF CLONAZEPAM ON ATROPINE SPIKES IN THE LIMBIC-
SYSTEM.
001274 02-03
S-417
Subject Index
Ptychopharmacology Abstracts
Kl,
iji:
afc
"lilt
fir;
fe
SPIN
ESR STUDIES OF SPIN LABELLED BOVINE LIVER MONOAAAINE-OXIDASE-B.
(UNPUBLISHED PAPER).
001065 02-01
SPINAL
(-)PENTOBARBITAL OPENS ION-CHANNELS OF LONG-DURATION IN
CULTURED MOUSE SPINAL NEURONS.
000198 01-03
MICROIONTOPHORETIC STUDIES ON NORADRENERGIC INHIBITION FROM
LOCUS-COERULEUS OF SPINAL TRIGEMINAL-NUCLEUS NEURONS.
000260 01-03
ATTEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED
SPINAL FEMALE RATS WITH MONOAMINE AGONISTS.
000421 01-04
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT.
001104 02-03
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES:
EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION
IN THE ANESTHETIZED CAT.
001203 02-03
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH
ANTIDEPRESSANTS.
001620 02-04
BACLOFEN IN TRIGEMINAL-NEURALGIA: ITS EFFECT ON THE SPINAL
TRIGEMINAL-NUCLEUS: A PILOT-STUDY.
002122 02-11
GABA ANALOGUES ACTIVATE CHANNELS OF DIFFERENT DURATION ON
CULTURED MOUSE SPINAL NEURONS.
002665 03-03
OPIATE ANTAGONIST IMPROVES NEUROLOGIC RECOVERY AFTER SPINAL
INJURY.
002714 03-03
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED
CAT.
002740 03-03
NONSEROTONERGIC DEPRESSION OF SPINAL MONOSYNAPTIC REFLEX
TRANSMISSION BY 5 HYDROXYTRYPTOPHAN.
002745 03-03
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
POTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3-
HYDROXYASPARTATE.
002768 03-03
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND
EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES.
002799 03-03
L HISTIDINE: EFFECTS ON SENSITIVITY OF CAT SPINAL NEURONES TO
AMINO-ACIOS.
002808 03-03
EXCITATORY AND INHIBITORY-AQIONS OF IBOTENIC-ACID ON FROG
SPINAL MOTONEURONES IN VITRO.
002841 03-03
VOLTAGE CLAMP STUDY OF CAT SPINAL MOTONEURONS DURING
STRYCHNINE-INDUCED SEIZURES.
002886 03-03
SPINAL MODULATION OF THE ACOUSTIC STARTLE RESPONSE: THE ROLE
OF NOREPINEPHRINE, SEROTONIN AND DOPAMINE.
002950 03-04
DEPRESSION OF RESERPINE-INDUCED MUSCULAR RIGIDITY IN RATS AFTER
ADMINISTRATION OF LISURIDE INTO THE SPINAL SUBARACHNOID
SPACE.
002962 03-04
THE USE OF LITHIUM-CARBONATE FOR TREATING KUGELBERG-WELANDER
SPINAL AMYOTROPHY PATIENTS.
003326 03-1 1
DENERVATION SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN RATS
FOLLOWING SPINAL TRANSECTION AND 5,7 DIHYDROXYTRYPTAMINE
INJECTION.
003722 04-03
SPINAL-CORD
THE EFFEaS OF MORPHINE ON THE AQIVITY OF CERTAIN DORSAL-HORN
NEURONS OF THE SPINAL-CORD INVOLVED IN NOCICEPTIVE PROCESSES.
000028 01-03
STEREOSPECIFIC BINDING OF 3H HALOPERIDOL IN RAT DORSAL SPINAL-
CORD.
000070 01-03
EFFECT OF ACUTE ADMINISTRATION OF MORPHINE ON NEWLY
SYNTHESIZED 5 HYDROXYTRYPTAMINE IN SPINAL-CORD OF THE RAT.
000110 01-03
NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE
POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS.
000116 01-03
EFFECTS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL-
CORD GABA CONCENTRATION.
000145 01-03
THE EFFEaS OF RESERPINE, IPRONIAZID AND L-DOPA ON ELEaRICALLY-
INDUCED SPINAL-CORD SEIZURES.
000146 01-03
REDUCTION OF FETAL RAT SPINAL-CORD VOLUME FOLLOWING
MATERNAL MORPHINE INJECTION.
000161 01-03
EFFEaS OF ENKEPHALIN ANALOGUE AND NALOXONE ON CAT SPINAL-
CORD DORSAL ROOT POTENTIALS.
000236 01-03
EFFECTS OF RAPHE-MAGNUS AND RAPHE-PALLIDUS LESIONS ON
MORPHINE-INDUCED ANALGESIA AND SPINAL-CORD MONOAMINES.
001420 02-03
5 METHOXYDIMETHYLTRYPT AMINE: SPINAL-CORD AND BRAINSTEM
MEDIATION OF EXCITATORY EFFEaS ON ACOUSTIC STARTLE.
001605 02-04
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE
SPINAL-CORD OF THE CAT: ENKEPHALIN-CONTAINING MARGINAL
NEURONS AND PAIN MODULATION.
002638 03-01
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA
D(ANO L) GLUTAMYLGLYCINE.
002696 03-03
DOPAMINE AS A POSSIBLE NEUROTRANSMIHER IN THE SPINAL-CORD
002705 03-03
DEPRESSION OF VENTRAL ROOT DORSAL ROOT POTENTIAL BY DL ALPHA
AMINOADIPATE IN FROG SPINAL-CORD.
002755 03-03
THE EFFECT OF MONOAMINES ON MOTONEURONS OF THE ISOLATED RAT
SPINAL-CORD.
002790 03-03
THE NEUROLATHYROGEN, BETA N OXALYL-L-ALPHA-BETA-
DIAMINOPROPIONIC-ACIO, IS A POTENT AGONIST AT GLUTAMATE
PREFERRING RECEPTORS IN THE FROG SPINAL-CORD.
002858 03-03
DOPAMINE-ACTIVATED ADENYLATE-CYCLASE OF SPINAL-CORD:
SUPERSENSITIVITY FOLLOWING TRANSEQION OF THE CORD
003800 04-03
NERVE GROWTH-FACTOR STIMULATES DEVELOPMENT OF SUBSTANCE-P
IN THE EMBRYONIC SPINAL-CORD
003881 04-03
THE INAQIVATION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE IN
DISSOCIATED NEURONAL CULTURES FROM SPINAL-CORD.
003980 04-03
EFFEQS OF NOREPINEPHRINE AND 5 HYDROXYTRYPTAMINE REUPTAKE
INHIBITORS ON ELEaRICALLY-INDUCED SPINAL-CORD SEIZURES IN
RATS.
004144 04-04
EFFEaS OF FLUOXETINE ON ELEaRICALLY-INDUCED SPINAL-CORD
SEIZURES IN RATS.
004145 04-04
DOPAMINERGIC NEURONS OF SPINAL-CORD: A POSSIBLE SITE FOR THE
ACTION OF NEUR0LEPTIC-DRU6S.
004188 04-04
BEHAVIORAL-EVIDENCE THAT SUBSTANCE-P MAY BE A SPINAL-CORD
SENSORY NEUROTRANSMIHER.
004200 04-04
SPINAL-CORD PHARMACOLOGY OF ADRENERGIC AGONIST-MEDIATED
ANTINOCICEPTION.
004206 04-04
ANTAGONISM BY PHENOXYBENZAMINE AND PENTAZOCINE OF THE
ANTINOCICEPTIVE-EFFEQS OF MORPHINE IN THE SPINAL-CORD.
004213 04-04
SPINAL-FLUID
METHODOLOGICAL-ISSUES IN SPINAL-FLUID STUDIES OF SCHIZOPHRENIA:
THE CASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE.
(UNPUBLISHED PAPER).
001952 02-08
SPINOCEREBELLAR
SPINOCEREBELLAR DEGENERATION WITH PARKINSONIAN FEATURES: A
CLINICAL AND PATHOLOGICAL REPORT.
003436 03-13
SPIPERONE
INHIBITION OF IN VIVO 3H SPIPERONE BINDING BY THE PROPOSED
ANTIPSYCHOTIC DES-TYR 1 -GAMMA-ENDORPHIN .
000226 01-03
BIOCHEMICAL-PROPERTIES OF SPIPERONE BINDING TO RAT-BRAIN
MEMBRANES.
000294 01-03
IN VIVO (3H)SPIPER0NE BINDING TO THE RAT HIPPOCAMPAL
FORMATION: INVOLVEMENT OF DOPAMINE-RECEPTORS.
001131 02-03
EFFECTS OF SPIPERONE ALONE AND IN COMBINATION WITH ANOREQIC-
AGENTS ON FEEDING PARAMETERS IN THE RAT.
001598 02-04
S-418
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECT OF MAZINDOL ON BRAIN DOPAMINE TURNOVER IN SPIPERONE
TREATED RATS.
002726 03-03
EFFECT OF CHRONIC SULPIRIDE ON STRIATAL SPIPERONE BINDING
003720 04-03
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRACTION.
003948 04-03
CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF
(3H)SULPIRIDE AND (3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS.
004032 04-03
SPIROPERIDOL
INCREASED MESOLIMBIC 3H SPIROPERIDOL BINDING IN 4 WEEK OLD
OFFSPRING OF NURSING RAT MOTHERS TREATED WITH PENFLURIDOL.
000087 01-03
DOES (3H)SPIR0PERID0L LABEL A 5 HT-RECEPTOR IN THE FRONTAL-
CORTEX OF THE RAT?.
000206 01-03
DECREASED SPIROPERIDOL AND LSD BINDING IN RAT-BRAIN AFTER
CONTINUOUS AMPHETAMINE.
000216 01-03
EFFECTS OF CHRONIC HALOPERIDOL ON CAUDATE 3H SPIROPERIDOL
BINDING IN LESIONED RATS.
000255 01-03
FACILITATION OF SELF-STIMULATION OF THE PREFRONTAL-CORTEX IN
RATS FOLLOWING CHRONIC ADMINISTRATION OF SPIROPERIDOL OR
AMPHETAMINE.
000457 01-04
IDENTIFICATION AND PARTIAL PURIFICATION OF A HYDROPHOBIC
PROTEIN COMPONENT ASSOCIATED WITH (3H)SPIR0PERID0L BINDING-
ACTIVITY. (UNPUBLISHED PAPER).
001007 02-01
CHRONIC LITHIUM REDUCES (3H)SPIROPERI0OL BINDING IN RAT
STRIATUM.
001443 02-03
EFFECTS OF HALOPERIDOL AND D-AMPHETAMINE ON IN VIVO 3H
SPIROPERIDOL BINDING IN THE RAT-FOREBRAIN.
001461 02-03
THE INFLUENCE OF ANTERIOR NEOSTRIATAL LESIONS ON THE
BEHAVIOURAL-EFFECTS OF SPIROPERIDOL IN RATS.
001702 02-04
REGULATION BY CATIONS OF (3H)SPIR0PERID0L BINDING ASSOCIATED
WITH DOPAMINE-RECEPTORS OF RAT-BRAIN.
002922 03-03
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF
(3H)SPIR0PERID0L IN CALF CAUDATE.
003906 04-03
REGULATION OF SER0T0NIN2-RECEPT0RS (5 HT2) LABELED WITH
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT AMITRIPTYLINE.
003964 04-03
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS.
004129 04-04
SPIROPERIDOL-LABELED
LONG-TERM ANTIDEPRESSANT TREATMENT DECREASES SPIROPERIDOL-
LABELED SEROTONIN-RECEPTOR BINDING.
000230 01-03
SPLEEN
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF
NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE
IN THE PERFUSED CAT SPLEEN.
002801 03-03
SPREADING
SPREADING DEPRESSION INDUCED BY MICROINJECTION OF ENKEPHALINS
INTO THE HIPPOCAMPUS AND NEOCORTEX.
004015 04-03
SPROUTING
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL-
NERVOUS-SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE-
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS).
002459 02-15
SP6-11
SUBSTANCE-P, HEXAPEPTIDE-PGLU6(SP6-1 1), ANALGESIA AND
SEROTONIN DEPLETION.
003050 03-04
SQUIRREL-MONKEY
EFFEQS OF SYSTEMIC AND INTRAVENTRICULAR ADMINISTRATION OF
CANNABINOIDS ON SCHEDULE-CONTROLLED RESPONDING IN THE
SQUIRREL-MONKEY.
000354 01-04
EFFECTS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN
COMBINATION WITH NALOXONE ON ELECTRIC-SHOCK TITRATION IN
THE SQUIRREL-MONKEY.
001611 02-04
DISCRIMINATIVE-STIMULUS PROPERTIES OF PHENCYCLIDINE AND FIVE
ANALOGUES IN THE SQUIRREL-MONKEY.
002961 03-04
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN
THE SQUIRREL-MONKEY; COMPARISONS WITH FOOD PRESENTATION
AND EFFECTS OF D-AMPHETAMINE AND PROMAZINE.
004152 04-04
INDIVIDUAL DIFFERENCES IN EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS
AND ANTICHOLINERGIC-DRUGS ON OPERANT-BEHAVIOR IN THE
SQUIRREL-MONKEY.
004176 04-04
SQUIRREL-MONKEYS
ACUTE AND CHRONIC EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON
COMPLEX BEHAVIOR OF SQUIRREL-MONKEYS
001583 02-04
NICOTINE INGESTION REDUCES ELEVATED BLOOD-PRESSURES IN RATS
AND SQUIRREL-MONKEYS.
002759 03-03
EFFECTS OF NORCOCAINE AND SOME NORCOCAINE DERIVATIVES ON
SCHEDULE-CONTROLLED BEHAVIOR OF PIGEONS AND SQUIRREL-
MONKEYS.
004012 04-03
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFECTS OF
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2-
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR
RESPONSE.
004119 04-04
DIAZEPAM-INDUCED ATAXIA IN TROHING SQUIRREL-MONKEYS.
004138 04-04
SOME EFFECTS OF CLOZAPINE ON PUNISHED-RESPONDING BY MICE AND
SQUIRREL-MONKEYS.
004224 04-04
BEHAVIORAL-EFFECTS OF SELF-ADMINISTERED COCAINE: RESPONDING
MAINTAINED ALTERNATELY BY COCAINE AND ELECTRIC-SHOCK IN
SQUIRREL-MONKEYS.
004225 04-04
STABILITY
POSTMORTEM STABILITY OF BRAIN 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND 3,4
DIHYDROXYPHENYLETHYLENEGLYCOL IN THE RAT AND MOUSE.
004048 04-03
STUDY ON THE STABILITY OF THE FACTORIAL STRUCTURE OF THE AMP
SYSTEM DURING TREATMENT.
004696 04-16
STABILIZATION
LITHIUM EFFECTS ON HIGH-AFFINITY TRYPTOPHAN UPTAKE: EVIDENCE
AGAINST A STABILIZATION MECHANISM.
001496 02-03
A NEW DOSAGE SCHEDULE FOR PIMOZIDE IN THE ACUTE STABILIZATION
AND MAINTENANCE-TREATMENT OF PSYCHOSIS.
002022 02-09
INHIBITION OF LYSOSOMAL LIPASES BY CHLORPROMAZINE: A POSSIBLE
MECHANISMS OF STABILIZATION.
003993 04-03
STABILIZING
MECHANISM OF MEMBRANE STABILIZING AND LYTIC-EFFECTS OF
TRICYCLIC-ANTIDEPRESSANTS.
004283 04-05
STABLE
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION
MASS-SPECTROMETRY.
002486 02-16
HYPOMANIA AS A STABLE STATE: LITHIUM PROPHYLAXIS IN TWO
PATIENTS.
003212 03-09
STABLE ISOTOPES USED IN STUDIES OF METRIFONATE.
003847 04-03
GLC MASS-SPECTROMETRIC-DETERMINATION OF MAPROTILINE AND ITS
MAJOR METABOLITE USING STABLE ISOTOPE-LABELED ANALOG AS
INTERNAL STANDARD.
004291 04-06
GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC
ANALYSES FOR DEANOL, CHOLINE, AND THEIR ACETYLESTERS.
004683 04-16
STAFF
ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CLINICAL STAFF
IN DETERMINING MEDICATION COMPLIANCE.
003618 03-17
STAGE
MINAPRINE-CHLOROHYDRATE: SURVEY OF THE FIRST CLINICAL-STUDIES
OF THE FOURTH STAGE,
001902 02-07
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE
INTOXICATION.
002988 03-04
S-419
siss^si^^^H^fifiteufe
Subject Index
Psychopharmacology Abstracts
a.
ii
ml.
«tl}
fir;
Si'
^
STAGES
STUDY ON THE EFFECTS OF L 5 HTP ON THE STAGES OF SLEEP IN MAN AS
EVALUATED BY USING SLEEP-DEPRIVATION.
003450 03-14
PHENCYCLIDINE (PCP) INTOXICATION: DIAGNOSIS IN STAGES AND
ALGORITHMS OF TREATMENT.
003525 03-15
STANDARDIZATION
STANDARDIZATION OF THE DEXAMETHASONE-SUPPRESSION-TEST FOR
THE DIAGNOSIS OF MELANCHOLIA. (UNPUBLISHED PAPER).
004359 04-09
STANDARDS
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD
BY USE OF SELECT ION-MONITORING AND DEUTERATED INTERNAL
STANDARDS.
004690 04-16
STARTLE
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFEQS ON
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE
PARADIGM.
000372 01-04
5 METHOXYDIMETHYLTRYPTAMINE: SPINAL-CORD AND BRAINSTEM
MEDIATION OF EXCITATORY EFFEaS ON ACOUSTIC STARTLE.
001605 02-04
ACUTE AND CHRONIC LSD EFFECTS ON RAT STARTLE: DATA SUPPORTING
AN LSD RAT MODEL OF SCHIZOPHRENIA.
002194 02-12
SPINAL MODULATION OF THE ACOUSTIC STARTLE RESPONSE: THE ROLE
OF NOREPINEPHRINE, SEROTONIN AND DOPAMINE.
002950 03-04
STARVATION
EFFECTS OF BICUCULLINE-INDUCED SEIZURES ON CEREBRAL METABOLISM
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY
STARVATION
001134 02-03
STATE-DEPENDENT
A STATE-DEPENDENT FAILURE OF RATS TO MAXIMIZE REWARDS.
000392 01-04
STATE-HOSPITAL
TRENDS IN THE PRESCRIPTION OF PSYCHOTROPIC-DRUGS (1970-1977) IN
A STATE-HOSPITAL.
000926 01-17
STATIC
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS.
001242 02-03
STATISTICAL
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNQURES
IN THIS PHASE.
003251 03-09
MILD, MODERATE. SEVERE - THE STATISTICAL ANALYSIS OF SHORT
ORDINAL SCALES.
004677 04-16
STATISTICS
EFFECTS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROFILES.
002239 02-13
STATOKINESIMETER
DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL-SYNDROME .
004472 04-1 1
STATUS-EPILEPTICUS
RECTAL VALPROATE SYRUP AND STATUS-EPILEPTICUS.
000727 01-11
ANTICONVULSANT-INDUCED STATUS-EPILEPTICUS IN LENNOX-GASTAUT-
SYNDROME.
003467 03-15
A COMPARATIVE-STUDY OF INTRAVENOUS LORAZEPAM AND
CLONAZEPAM IN STATUS-EPILEPTICUS.
004487 04-1 1
STEADY-STATE
THE EFFECT OF THIORIDAZINE ON PROLACTIN LEVELS IN ACUTELY
SCHIZOPHRENIC-PATIENTS: CHALLENGE-DOSE AND STEADY-STATE
LEVELS.
000558 01-08
PREDiaiON OF STEADY-STATE PLASMA LEVELS OF AMITRIPTYLINE AND
NORTRIPTYLINE FROM A SINGLE-DOSE 24-HR. LEVEL IN DEPRESSED-
PATIENTS.
000582 01-09
INTERACTION OF INDOMETHACIN AND IBUPROFEN WITH LITHIUM IN
MANIC-PATIENTS UNDER A STEADY-STATE LITHIUM LEVEL.
000622 01-09
INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY-STATE SERUM LEVELS
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-DRUGS IN MAN.
000767 01-13
NEUROLEPTIC-EFFEQ ON DESIPRAMINE STEADY-STATE PLASMA
CONCENTRATIONS.
000781 01-13 1
RAT-BRAIN STEADY-STATE LEVELS OF CYCLIC-NUCLEOTIDES AS AN
ENDPOINT OF LSD-LIKE HALLUCINOGEN EFFEQS. (PH.D.
DISSERTATION).
001426 02-03
PLASMA DESIPRAMINE LEVELS AFTER SINGLE-DOSAGE AND AT STEADY-
STATE IN OUTPATIENTS.
002039 02-09
PHARMACOKINETIC BASIS FOR PREDIQING STEADY- STATE SERUM DRUG
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA.
002225 02-13
FAQORS INFLUENCING NORTRIPTYLINE STEADY-STATE KINETICS:
PLASMA AND SALIVA LEVELS.
002251 02-13
BIOAVAILABILITY AND RELATED PHARMACOKINETICS IN MAN OF
ORALLY ADMINISTERED L 5 HYDROXYTRYPTOPHAN IN STEADY-STATE.
002261 02-13
STEADY- STATE LITHIUM BLOOD LEVEL FLUCTUATIONS IN MAN
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FORM.
003151 03-07
DEPRESSION SUBTYPES AFFECT THE STEADY-STATE PLASMA LEVELS AND
THERAPEUTIC-EFFICACY OF AMITRIPTYLINE AND NORTRIPTYLINE.
003244 03-09
STEREOCHEMICAL i
STEREOCHEMICAL ANATOMY OF MORPHINOMIMETICS. I
002197 02-12
STEREOISOMERS
TRANYLCYPROMINE STEREOISOMERS, MONOAMINERGIC
NEUROTRANSMISSION AND BEHAVIOR. A MINIREVIEW.
000016 01-02
POTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3-
HYDROXYASPARTATE.
002768 03-03
COMPARISON OF THE EFFEQS OF THE STEREOISOMERS OF
FENFLURAMINE ON THE ACETYLCHOLINE CONTENT OF RAT STRIATUM,
HIPPOCAMPUS AND NUCLEUS-ACCUMBENS.
003758 04-03
INTERAQION OF STEREOISOMERS OF BARBITURATES WITH (3H)ALPHA
DIHYDROPICROTOXININ BINDING-SITES.
004036 04-03
STEREOSELECTIVE
STEREOSELECTIVE AQIONS OF SUBSTITUTED BENZAMIDE DRUGS ON
CEREBRAL DOPAMINE MECHANISMS.
001301 02-03
BACLOFEN: STEREOSELEQIVE INHIBITION OF EXCITANT AMINO-ACID
RELEASE.
003867 04-03
STEREOSPECIFIC
STEREOSPECIFIC BINDING OF 3H HALOPERIDOL IN RAT DORSAL SPINAL-
CORD.
000070 01-03
STEREOSPECIFIC NICOTINE-RECEPTORS ON RAT-BRAIN MEMBRANES.
000254 01-03
STEREOSPECIFIC, DOSE-DEPENDENT ANTAGONISM BY NALOXONE OF
NONOPIATE BEHAVIOR IN MICE.
000411 01-04
THE STEREOSPECIFIC EFFECT OF NALOXONE ON RAT DORSAL-HORN
NEURONES, INHIBITION IN SUPERFICIAL LAMINAE AND EXCITATION IN
DEEPER LAMINAE.
001226 02-03
THE EFFEaS OF OPIATE ANTAGONISTS ON FOOD INTAKE ARE
STEREOSPECIFIC.
003080 03-04
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE-
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1
CYCLOPROPYLMETHYL
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE.
003706 04-02
STCREOTACTICALIY
BEHAVIOURAL-RESPONSES TO STEREOTACTICALLY CONTROLLED
INJECTIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI.
001708 02-04
STEREOTAXIC
THE LONG-TERM RESULTS OF STEREOTAXIC SURGERY AND L-DOPA
THERAPY IN PATIENTS WITH PARKINSONS-DISEASE: A 10-YEAR
FOaOWUP STUDY.
000693 01-11
STEREOTYPED
AN AUTOMATED METHOD FOR STUDYING STEREOTYPED GNAWING.
002500 02-16
EFFEQS OF CHOLECYSTOKININ-OQAPEPTIDE ON STRIATAL DOPAMINE
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE
CLIMBING IN MICE.
003031 03-04
S-420
Volume i9, subject index
Subject Index
iTEKEOTYPED-SEHAVIOR
FLURAZEPAM EFFECTS ON METHYLPHENIDATE-INDUCED STEREOTYPED-
BEHAVIOR.
000455 01-04
STEREOTYPED-BEHAVIOR-SYNDROME
THE STEREOTYPED-BEHAVIOR-SYNDROME: A NEW MODEL AND
PROPOSED THERAPY.
004163 04-04
STEREOTYPED-BEHAVIORS
CATS DEVELOP TOLERANCE TO D-AMPHET AMINES EFFECTS UPON
LOCOMOTION AND STEREOTYPED-BEHAVIORS.
003018 03-04
EFFECTS OF CHRONIC ADMINISTRATION OF PHENCYCLIDINE ON
STEREOTYPED-BEHAVIORS AND ATAXIC-BEHAVIORS IN THE RAT.
003095 03-04
STEREOTYPED-BEHAVIOUR
5 7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE
' AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED-
BEHAVIOUR IN THE RAT.
001589 02-04
NARCOTIC ANALGESICS AND STEREOTYPED-BEHAVIOUR IN MICE.
001694 02-04
GABA AGONISTS DISSOCIATE STRIATAL UNIT AQIVITY FROM DRUG-
INDUCED STEREOTYPED-BEHAVIOUR.
001716 02-04
STEREOTYPED-BEHAVIOUR AND ELEaROCORTICAL-CHANGES AFTER
INTRACEREBRAL MICROINFUSION OF DOPAMINE AND APOMORPHINE
IN FOWLS.
001734 02-04
DISSOCIATION OF D-AMPHET AMINE-INDUCED LOCOMOTOR-ACTIVITY AND
STEREOTYPED-BEHAVIOUR BY LESIONS OF THE SUPERIOR-COLLICULUS.
001755 02-04
THE ROLE OF 5 HYDROXYTRYPTAMINE IN DOPAMINE-DEPENDENT
STEREOTYPED-BEHAVIOUR.
002966 03-04
STEREOTYPIC-BEHAVIOR
EFFEQS OF THIORIDAZINE ON APOMORPHINE-ELICITED STEREOTYPIC-
BEHAVIOR AND MOTOR-AQIVITY.
000424 01-04
THE PATHOGENESIS OF STEREOTYPIC-BEHAVIOR.
004161 04-04
STEREOTYPIC-BEHAVIOR-SYNDROME
THE COMPLEX SPECIFIC PATHOGENETIC THERAPY OF THE STEREOTYPIC-
BEHAVIOR-SYNDROME (AN EXPERIMENTAL-STUDY).
004162 04-04
STEREOTYPIES
AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION
IN RATS: EFFEaS OF ADRENERGIC AND SEROTONERGIC BLOCKING-
AGENTS.
001531 02-03
STEREOTYPY
THE INFLUENCE OF GABAERGIC SUBSTANCES ON THE EFFECTS OF
STIMULATION OF THE CAUDATE-NUCLEUS AND AMPHETAMINE
STEREOTYPY IN CATS.
000489 01-04
MODULATION OF APOMORPHINE-INDUCED STEREOTYPY BY ESTROGEN:
TIME-COURSE AND DOSE-RESPONSE.
001636 02-04
APPARENT TOLERANCE TO SOME ASPEQS OF AMPHETAMINE
STEREOTYPY WITH LONG-TERM-TREATMENT.
001758 02-04
SPONTANEOUS AQIVITY AND APOMORPHINE STEREOTYPY DURING AND
AFTER WITHDRAWAL FROM 3 1/2 MONTHS CONTINUOUS
ADMINISTRATION OF HALOPERIDOL: SOME METHODOLOGICAL-ISSUES.
002509 02-16
INCREASED AMPHETAMINE STEREOTYPY AND LONGER HALOPERIDOL
CATALEPSY IN SPONTANEOUSLY HYPERTENSIVE-RATS.
002891 03-03
ESTROGEN POTENTIATES THE STEREOTYPY INDUCED BY DOPAMINE
AGONISTS IN THE RAT.
002968 03-04
AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE
ANALYSIS OF APOMORPHINE-INDUCED-FIGHTING AND STEREOTYPY IN
THE RAT.
002983 03-04
RELATION BETWEEN BRAIN CATECHOLAMINE-RECEPTORS AND
DOPAMINERGIC STEREOTYPY IN RAT STRAINS.
004131 04-04
EFFEQ OF L HISTIDINE AND CHLORCYCLIZINE ON APOMORPHINE-INDUCED
CLIMBING-BEHAVIOUR AND METHAMPHET AMINE STEREOTYPY IN
MICE.
004147 04-04
PHARMACOKINETIC-STUDY OF APOMORPHINE-INDUCED STEREOTYPY IN
FOOD DEPRIVED RATS.
004247 04-04
APOMORPHINE-INDUCED STEREOTYPY IN MATURE AND SENESCENT RATS
FOLLOWING CESSATION OF CHRONIC HALOPERIDOL TREATMENT.
004651 04-15
STERNBERG
DOSE-EFFECTS OF SECOBARBITAL IN A STERNBERG MEMORY SCANNING
TASK.
003460 03-14
STEROID
A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/
BENZODIAZEPINE-RECEPTOR INTERACTION ,
003851 04-03
STEROID-HORMONES
STEROID-HORMONES AND CNS ACTIVITY.
000794 01-13
ELECTROPHYSIOLOGICAL AND PSYCHOLOGICAL CHANGES INDUCED BY
STEROID-HORMONES IN MEN AND WOMEN.
004500 04-13
STEROIDS
PHENOBARBITONE INTERACTION WITH ORAL CONTRACEPTIVE STEROIDS
IN THE RABBIT AND RAT.
001832 02-05
EFFECTS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROFILES.
002239 02-13
IMIPRAMINE: EFFECT OF OVARIAN STEROIDS ON MODIFICATIONS IN
SEROTONIN-RECEPTOR BINDING.
002778 03-03
STH
CHANGES OF ACTH, STH, TSH AND PROLAQIN LEVELS IN ENDOTOXIN
SHOCK IN RATS.
000119 01-03
STIMULANT
THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG-TREATMENT
FOR HYPERACTIVE-CHILDREN: RECENT FINDINGS AND A REPORT FROM
CLINICAL-PRAQICE.
000715 01-11
1 SUBSTITUTED BENZYLTETRAHYDROPYRIMIDONES: A SERIES WITH
STIMULANT AND DEPRESSANT AQIVITIES.
003687 04-02
THE EFFECT OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON
THE STIMULANT AND ANOREQIC-ACTIONS OF DEXTROAMPHETAMINE
IN MAN.
004580 04-14
STIMULANT-DRUGS
THE PARENT CHILD INTERAQIONS OF HYPERAQIVE-CHILDREN AND THEIR
MODIFICATION BY STIMULANT-DRUGS.
002092 02-11
EVALUATION OF SYMPTOMATIC TREATMENT OF HYPERACTIVE-BEHAVIOR
BY STIMULANT-DRUGS.
002134 02-11
SEXUAL-EFFEaS OF ANTIDEPRESSANTS AND PSYCHOMOTOR STIMULANT-
DRUGS.
004646 04-15
STIMULANT-EFFECT
THE STIMULANT-EFFECT OF NEUROLEPTICS: MYTH OR REALITY?
000362 01-04
STIMULANT-EFFECTIVENESS
PREDICTING STIMULANT-EFFECTIVENESS IN HYPERACTIVE-CHILDREN WITH
A REPEATABLE NEUROPSYCHOLOGICAL-BAHERY: A PRELIMINARY-
STUDY.
004453 04-11
STIMULANT-EFFECTS
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND
L-AMPHETAMINE: NO INTERACTION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES.
000387 01-04
STIMULANTS
IN VITRO EFFEQ OF PHENCYCLIDINE AND OTHER PSYCHOMOTOR
STIMULANTS ON SEROTONIN UPTAKE IN HUMAN PLATELETS.
000750 01-13
EFFECT OF REPEATED ELEaROCONVULSIVE-SHOCKS (ECS) ON
SUBTHRESHOLD DOSES OF SOME CNS STIMULANTS.
001361 02-03
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJEQION OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
INFLUENCE OF INTRAVENOUS SELF-ADMINISTERED PSYCHOMOTOR
STIMULANTS ON PERFORMANCE OF RHESUS-MONKEYS IN A MULTIPLE-
SCHEDULE PARADIGM.
001655 02-04
PSYCHOMOTOR STIMULANTS AS ACTIVATORS OF NORMAL AND
PATHOLOGICAL-BEHAVIOR: IMPLICATIONS FOR THE EXCESSES IN
MANIA. (UNPUBLISHED PAPER).
002353 02-14
METHYLPHENIDATE-LIKE STIMULANTS IN VITRO RELEASE (3H)TYRAMINES
BUT NOT (14C)D0PAMINE.
002706 03-03
S-421
Subject Index
Ptychopharmacology Abstracts .
a..
m
an;
««f
fiii'
ft:
^
FUNDAMENTAL MECHANISMS UNDERLYING ALTERED BEHAVIOR
FOLLOWING CHRONIC ADMINISTRATION OF PSYCHOMOTOR
STIMULANTS.
002711 03-03
NEUROCHEMICAL-CONSEQUENCES FOLLOWING ADMINISTRATION OF CNS
STIMULANTS TO THE NEONATAL RAT.
002926 03-03
A NOTE ON THE PARADOXICAL-EFFEQ OF STIMULANTS ON
HYPERACTIVITY WITH REFERENCE TO THE RATE DEPENDENCY EFFEQ
OF DRUGS.
003320 03-11
DO STIMULANTS PROVOKE, CAUSE, OR EXACERBATE TICS AND
TOURETTE-SYNDROME?
004485 04-1 1
STIMULATE
MORPHINE ACTS THROUGH ALPHA-AORENERGIC AND SEROTONINERGIC
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG.
000088 01-03
STIMULATED
THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REAQION
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN.
001052 02-01
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH
NEUROLEPTICS.
001935 02-08
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
SEX-DIFFERENCES IN THE AMPHETAMINE STIMULATED RELEASE OF
CATECHOLAMINES FROM RAT STRIATAL TISSUE IN VITRO.
002668 03-03
RELEASE OF ACETYLCHOLINE FROM RAT-BRAIN SYNAPTOSOMES
STIMULATED WITH LEPTINOTARSIN, A NEW NEUROTOXIN.
003148 03-06
STIMULATES
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF
A10 DOPAMINERGIC NEURONS.
000320 01-03
VASOPRESSIN STIMULATES RELEASE OF BETA LIPOTROPIN AND BETA
ENDORPHIN IN CONSCIOUS RATS AS MEASURED BY
RADIOIMMUNOASSAY OF UNEXTRAQED PLASMA.
003715 04-03
NERVE GROWTH-FAaOR STIMULATES DEVELOPMENT OF SUBSTANCE-P
IN THE EMBRYONIC SPINAL-CORD.
003881 04-03
SEXUAL-BEHAVIOR DECREASES PAIN SENSITIVITY AND STIMULATES
ENDOGENOUS OPIOIDS IN MALE RATS.
004234 04-04
STIMULATING
N ALKYLATED 2 AMINOTETRALINS: CENTRAL DOPAMINE-RECEPTOR
STIMULATING ACTIVITY.
000399 01-04
EFFEQS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON
BARORECEPTOR REFLEXES IN CONSCIOUS CATS.
001514 02-03
THE INTEREST OF THE STIMULATING EFFEQ OF CARPIPRAMINE IN
PSYCHOSOMATIC-MEDICINE.
002061 02-10
EVIDENCE THAT IT IS POSSIBLE TO CAUSE ANOREXIA BY INCREASING
RELEASE AND/OR DIREQLY STIMULATING POSTSYNAPTIC SEROTONIN-
RECEPTORS m THE BRAIN.
002602 02-17
THE PRESYNAPTIC STIMULATING EFFEQ OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING AQIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
THE STIMULATING EFFEQ OF AMPHETAMINE ON THE VISUAL SYSTEAA.
003398 03-13
STIMULATION
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH
IN THE ELECTROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO
AUTORECEPTOR STIMULATION.
000046 01-03
EFFEQ OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO
STIMULATION OF THE NUCLEUS-ACCUMBENS.
000331 01-03
REDUQION OF FOOD INTAKE BY PIRIBEDIL IN THE RAT; RELATION TO
DOPAMINE-RECEPTOR STIMULATION.
000355 01-04
RELATION OF MONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION
IN CATS.
000474 01-04
THE INFLUENCE OF GABAERGIC SUBSTANCES ON THE EFFEQS OF
STIMULATION OF THE CAUDATE-NUCLEUS AND AMPHETAMINE
STEREOTYPY IN CATS.
000489 01-04
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2
AQIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED
PAPER).
001002 02-01
ELEQRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFEQS OF
HIGH-FREQUENCY STIMUUTION ON DENDRITIC ULTRASTRUCTURE.
(UNPUBLISHED PAPER).
001036 02-01
DIVERGENT RESERPINE EFFEQS ON AMFONELIC-ACID AND ,
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE
FORMATION FROM PHENYLALANINE.
001113 02-03
EFFEQS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS:
RELATION TO MICROSOMAL BIOTRANSFORMATION AND
DOPAMINERGIC-RECEPTOR STIMULATION .
001161 02-03
ISOLATION INCREASES THE RESPONSES TO BETA-ADRENERGIC
STIMULATION IN MICE.
001232 02-03
INHIBITORY AQION OF MORPHINE ON THE RELEASE OF A BRADYKININ-
LIKE SUBSTANCE AFTER SCIATIC-NERVE STIMULATION.
001293 02-03
MORPHINE AND ELEQROACUPUNQURE: COMPARISON OF THE EFFEQS
ON THE CORTICAL EVOKED-RESPONSES AFTER TOOTH-PULP
STIMULATION IN RATS.
001294 02-03
PHENCYCLIDINE-INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-
HYDROXYLASE AQIVITY.
001304 02-03,
GASTRIC AND PYLORIC MOTOR-RESPONSE TO SYMPATHETIC-NERVE
STIMULATION AFTER CHEMICAL SYMPATHEQOMY. (UNPUBLISHED
PAPER).
001337 02-03
SUSTAINED GAMMA AMINOBUTYRIC-ACID-RECEPTOR STIMULATION AND
CHRONIC NEUROLEPTIC-EFFEQS.
001345 02-03
EFFEQS OF MORPHINE ON EVOKED-POTENTIALS RECORDED FROM THE
AMYGDALA BY TOOTH-PULP STIMULATION IN CATS.
001379 02-03
STIMULATION OF ADENYLATE-CYCLASE IN RAT STRIATUM BY
PERGOLIDE: INFLUENCE OF GTP.
001448 02-03
INCREASED ADRENALINE, BETA-ADRENERGIC-RECEPTOR STIMULATION
AND PHOSPHOLIPID METHYLATION IN PINEAL-GLAND OF
SPONTANEOUSLY HYPERTENSIVE-RATS. (UNPUBLISHED PAPER).
001458 02-03
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE,
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE.
001499 02-03
EVIDENCE THAT NORADRENALINE MODULATES THE INCREASE IN
STRIATAL DOPAMINE METABOLISM INDUCED BY MUSCARINIC-
RECEPTOR STIMULATION.
001518 02-03
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN
THE DOG.
001547 02-03
BETA ENDORPHIN CAUSES RETROGRADE AMNESIA AND IS RELEASED
FROM THE RAT-BRAIN BY VARIOUS FORMS OF TRAINING AND
STIMULATION.
001664 02-04
A COMPARISON BETWEEN THE EFFEQS OF MORPHINE ON THE
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC
AND CENTRAL GRAY STIMULATION.
001771 02-04
FURTHER STUDIES ON OPIATE-RECEPTORS THAT MEDIATE
ANTINOCICEPTION: TOOTH-PULP STIMULATION IN THE DOG.
001782 02-04
INCREASED VULNERABILITY TO CHOLINERGIC STIMULATION IN
AFFEQIVE-DISORDER PATIENTS.
002003 02-09
SENSITIZATION AND OSCILLATION FOUOWING REPEATED STIMULATION:
RELATIONSHIP TO AFFECTIVE-ILLNESS AND ITS TREATMENT WITH
LITHIUM AND CARBAMAZEPINE.
002031 02-09
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE.
002242 02-13
HALOPERIDOL STIMULATION OF PROLAQIN SECRETION: HOW MANY
BLOOD SAMPLES ARE NEEDED TO DEFINE THE HORMONE RESPONSE?
002505 02-16
TEMPORAL PAHERNING OF NEURONAL AQIVITY DURING THERWIAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
S^22
VOLUME 19, SUBJECT INDEX
Subject Index
STIMULATION OF RETINAL ADENYLATE-CYCLASE BY VASOAQIVE
INTESTINAL PEPTIDE (VIP).
002811 03-03
NORADRENERGIC STIMULATION IN VIVO INCREASES NA-K-ADENOSINE-
TRIPHOSPHATASE ACTIVITY.
002910 03-03
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR.
002945 03-04
SLEEP ELICITED BY OLFACTORY TUBERCLE STIMULATION AND THE EFFECT
OF ATROPINE.
002955 03-04
PHARMACOLOGICAL-STUDIES ON STIMULATION PRODUCED ANALGESIA
IN MICE.
002964 03-04
INTERACTION BETWEEN PURINE AND BENZODIAZEPINE; INOSINE
REVERSES DIAZEPAM-INDUCED STIMULATION OF MOUSE
EXPLORATORY-BEHAVIOR.
002972 03-04
INFLUENCE OF MORPHINE ON THE DISCRIMINATIVE-STIMULUS
PROPERTIES OF REWARDING LATERAL HYPOTHALAMIC STIMULATION.
(PH.D. DISSERTATION).
003041 03-04
RAT PUP-KILLING AND MATERNAL-BEHAVIOR IN MALE LONG-EVANS-
RATS: PRENATAL STIMULATION AND POSTNATAL TESTOSTERONE.
003054 03-04
PRESSOR EFFEQS OF DORSAL RAPHE STIMULATION AND
INTRAHYPOTHALAMIC APPLICATION OF SEROTONIN IN THE
SPONTANEOUSLY HYPERTENSIVE-RAT.
003117 03-04
MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION.
003782 04-03
POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CARDIOVASCULAR-
EFFEQS OF CENTRAL ALPHA-ADRENOCEPTOR STIMULATION IN
SPONTANEOUSLY HYPERTENSIVE-RATS.
003791 04-03
STIMULATION OF FRUaOSEBIPHOSPHATASE ACTIVITY AND SYNTHESIS
IN THE CEREBRAL-CORTEX OF RATS SUBMIHED TO THE CONVULSANT
METHIONINE-SULFOXIMINE.
003838 04-03
EFFEa OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE
DISCHARGE INDUCED BY CARBACHOL IN THE RABBIT.
003951 04-03
STUDIES ON THE MECHANISM-OF-AQION OF AVERMECTIN-B1A:
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM
BRAIN SYNAPTOSOMES.
003973 04-03
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA-
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER).
003998 04-03
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN: CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, HI-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
EFFECTS OF ANALGESICS AND CNS-AQING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS.
004148 04-04
HORMONAL STIMULATION AFTER INJECTION OF THYROTROPHIN-
RELEASING-FACTOR (TRF) AND AaH1-24 IN PATIENTS FOLLOWING
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY-STUDY.
004505 04-13
STIMULATION-EVOKED
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFEQS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
STIMULATION-INDUCED
THE EFFECTS OF PARA CHLOROAMPHET AMINE ON FENFLURAMINE
ANOREXIA IN AD LIBITUM AND STIMULATION-INDUCED FEEDING IN
THE RAT.
001823 02-04
STIMULATORY
STIMULATORY EFFECT OF SOMATOSTATIN ON NOREPINEPHRINE RELEASE
FROM RAT-BRAIN-CORTEX SLICES.
002920 03-03
STIMULATORY ACTION OF LISURIDE ON DOPAMINE-SENSITIVE
ADENYLATE-CYCLASE IN THE RAT STRIATAL HOMOGENATE.
003718 04-03
A POSSIBLE NEUROCHEMICAL BASIS OF THE CENTRAL STIMULATORY
EFFECTS OF PP'DDT.
004274 04-05
STIMULI
DIFFERENTIAL-EFFECTS OF VARIOUS STIMULI ON AVP LEVELS IN BLOOD
AND CEREBROSPINAL-FLUID.
001370 02-03
THE EFFECT OF REPEATED ELECTROCONVULSIVE-SHOCK ON
CORTICOSTERONE RESPONSES TO CENTRALLY-ACTING
PHARMACOLOGICAL STIMULI IN THE MALE RAT
001486 02-03
EFFECTS OF DRUGS ON THE EFFECTIVENESS OF CONDITIONED STIMULI
001608 02-04
CANALIZATION OF AROUSAL IN THE PREWEANLING RAT: EFFECTS OF
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI
002965 03-04
HABITUATION OF ELECTRODERMAL AND RESPIRATORY RESPONSES TO
VISUAL STIMULI AS A FUNCTION OF PERSONALITY DIFFERENCES IN
AFFECT LEVEL.
003414 03-13
STIMULUS
A COMPARISON OF HUMAN TAQILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE
ROLE FOR BETA PHENYLETHYLAMINE IN THE COCAINE CUE.
000363 01-04
BEHAVIORAL-PHARMACOLOGY AND THE STIMULUS CONTROL OF
BEHAVIOR.
000381 01-04
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL
EVOKED-POTENTIALS.
000763 01-13
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION).
001213 02-03
BEHAVIORAL-EFFECTS OF DRUGS: THE ROLE OF THE STIMULUS
REINFORCER CONTINGENCY. (PH.D. DISSERTATION).
001537 02-03
THE EFFECTS OF OPIATE ANTAGONISTS ON THE DISCRIMINATIVE
STIMULUS PROPERTIES OF ETHANOL.
002947 03-04
MORPHINE-LIKE STIMULUS EFFECTS IN THE MONKEY: OPIOIDS WITH
ANTAGONIST PROPERTIES.
003086 03-04
DRUG-INDUCED STIMULUS CONTROL AND THE CONCEPT OF BREAKING-
POINT: LSD AND QUIPAZINE.
003116 03-04
CONDITIONING OF AN INTEROCEPTIVE DRUG STIMULUS TO DIFFERENT
EXTEROCEPTIVE CONTEXTS.
004142 04-04
CHARAQERISTICS OF THE STIMULUS PRODUCED BY THE MIXTURE OF
CANNABIDIOL WITH DELTA9 TETRAHYDROCANNABINOL.
004263 04-04
STIMULUS-EVOKED
NALOXONE PROMOTES STIMULUS-EVOKED VASOPRESSIN RELEASE IN
VIVO.
000165 01-03
STIMULUS-INDUCED
A NOVEL GABA-RECEPTOR MODULATES STIMULUS-INDUCED GLUTAMATE
RELEASE FROM CORTICOSTRIATAL TERMINALS.
001376 02-03
STIMULUS-SHOCK
FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK
TERMINATION: EFFECTS OF D-AMPHETAMINE, MORPHINE, AND
CLOZAPINE.
000431 01-04
STOPPING
THE USE OF NICOTINE CHEWING-GUM AS AN AID TO STOPPING
SMOKING.
002343 02-14
STOPPING MEDICATION IN CHILDREN WITH EPILEPSY.
004447 04-11
STORAGE
ROLE OF DOPAMINE STORAGE FUNCTION IN THE CONTROL OF RAT
STRIATAL TYROSINE-HYDROXYLASE ACTIVITY.
000201 01-03
SELECTIVE STORAGE IN VIVO OF 5,6 ADTN IN DOPAMINE RICH AREAS OF
THE RAT-BRAIN.
000324 01-03
ACTH MODULATION OF MEMORY STORAGE PROCESSING. (UNPUBLISHED
PAPER).
001250 02-03
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
002219 02-13
STORES
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL
S-423
Subject Index
Psychopharmacology Abstracts.
I
Kll„
m
C3
5
<tlt
^.
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION ,
IMPORTANCE OF NEURONAL AQIVITY.
000314 01-03
STRAIN
AUDIOGENIC-SEIZURES: INCREASED BENZODIAZEPINE-RECEPTOR BINDING
IN A SUSCEPTIBLE STRAIN OF MICE.
000252 01-03
STRAIN DEPENDENT EFFEQS OF KETAMINE ON LOCOMOTOR-ACTIVITY
AND ANTINOCICEPTION IN MICE.
000382 01-04
COMPARATIVE-STUDY ON THE EFFEQ OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS: STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS.
002757 03-03
STRAIN-13
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
STRAINS
DISSIMILAR EFFEaS OF NICOTINAMIDE AND INOSINE, PUTATIVE
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE.
000173 01-03
DIFFERENCES IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY IN
INBRED STRAINS OF MICE.
000303 01-03
EFFECTS OF CHLORDIAZEPOXIDE MORPHINE COMBINATIONS ON
SPONTANEOUS LOCOMOTOR-AQIVITY IN THREE INBRED STRAINS OF
MICE.
001766 02-04
EFFEaS OF MORPHINE AND CHLORDIAZEPOXIDE ON AVOIDANCE-
BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
002973 03-04
FAILURE TO FIND SEX-DIFFERENCES IN TESTOSTERONE AQIVATED
AGGRESSION IN TWO STRAINS OF RATS.
003107 03-04
RELATION BETWEEN BRAIN CATECHOLAMINE-RECEPTORS AND
DOPAMINERGIC STEREOTYPY IN RAT STRAINS.
004131 04-04
ACETYLCHOLINE TURNOVER AND AGGRESSION IN RELATED THREE
STRAINS OF MICE.
004151 04-04
STRATEGIES
OUTPATIENT TREATMENT ISSUES AND STRATEGIES FOR ACUTE AND
CHRONIC PCP ABUSERS.
000919 01-17
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES. (UNPUBLISHED PAPER).
001910 02-08
RESEARCH STRATEGIES FOR ASSESSING THE EFFEQS OF
METHYLMERCURY ON BEHAVIOR.
003128 03-05
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND
PSYCHOPHARMACOLOGICAL STRATEGIES.
003167 03-08
CURRENT BIOLOGIC STRATEGIES FOR ANXIETY.
003276 03-10
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT, TARDIVE-
DYSKINESIA, AND THE TRAINING OF RESEARCH PSYCHIATRISTS.
004603 04-15
STRATEGY
ROLE OF THE NEOSTRIATAL DOPAMINERGIC-AQIVITY IN SEQUENCING
AND SELEaiNG BEHAVIOURAL-STRATEGIES: FACILITATION OF
PROCESSES INVOLVED IN SELEQING THE BEST STRATEGY IN A
STRESSFUL-SITUATION.
000366 01-04
STRATEGY FOR THE STUDY OF PATIENTS AT HIGH-RISK FOR TARDIVE-
DYSKINESIA.
000858 01-15
SECOND-GENERATION ANTIDEPRESSANTS: A CLINICAL
PHARMACOTHERAPEUTIC RESEARCH STRATEGY.
003632 03-17
THE PROGNOSIS OF EPILEPSY AND THE STRATEGY FOR TERMINATING
ANTIEPILEPTIC THERAPY.
004724 04-17
STREET
STREET PCP SCENE: ISSUES ON SYNTHESIS AND CONTAMINATION.
000744 01-12
STREPTOZOTOCIN
INCREASED URINARY EXCRETION OF CATECHOLAMINES AND THEIR
METABOLITES IN STREPTOZOTOCIN DIABETIC RAT.
000154 01-03
STRESS
RELATIONSHIPS BETWEEN PLASMA CORTICOSTEROIDS AND
BENZODIAZEPINES IN STRESS.
000176 01-03
CHLORDIAZEPOXIDE ANTINOCICEPTION: CROSS-TOLERANCE WITH i
OPIATES AND WITH STRESS. 1
000348 01-04
EFFEQ OF ANTIANXIETY-DRUGS ON FEAR AND STRESS.
000801 01-14
INFLUENCE OF RESPIRATORY STRESS AND HYPERTENSION UPON THE
BLOOD-BRAIN-BARRIER.
001437 02-03
DESENSITIZATION OF ADRENOCEPTORS AFTER IMMOBILIZATION STRESS
OR REPEATED INJECTION OF ISOPROTERENOL IN RATS. (UNPUBLISHED
PAPER).
00)546 02-03
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS, UNDER
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REACTION TYPE
(EMOTIVE AND NONEMOTIVE).
001624 02-04
SELECTIVE REDUaiON BY DEXAMETHASONE OF STRESS RELATED
HYPERPHAGIAS.
001703 02-04
STRESS AND HYPERTENSION: CLINICAL-IMPLICATIONS.
002307 02-13
DIFFERENTIAL-EFFEaS OF CANNABINOID EXPOSURE AND STRESS ON
PLASMA PROLAQIN, GROWTH-HORMONE AND CORTICOSTERONE
LEVELS IN MALE MICE.
002695 03-03
THE FUNCTIONAL IMPORTANCE OF INCREASED BRAIN TRYPTOPHAN IN
THE SEROTONERGIC RESPONSE TO RESTRAINT STRESS.
002779 03-03
INTERAaiON BETWEEN THE EFFECTS OF STRESS AND MORPHINE ON
BODY-TEMPERATURE IN RATS.
002906 03-03
BENZODIAZEPINES, STRESS AND RAT PLASMA CORTICOSTEROIDS: THE
ROLE OF INDOLEAMINES
003034 03-04
STRESS-EXPOSED
LITHIUM-INDUCED CHANGES IN THE BRAIN LEVELS OF FREE AMINO-ACIDS
IN STRESS-EXPOSED RATS.
001217 02-03
STRESS-INDUCED
EFFEQ OF LITHIUM ON STRESS-INDUCED CHANGES IN THE BRAIN LEVELS
OF MONOAMINES IN RATS.
001216 02-03
ANTAGONISTIC-EFFEQS OF PSYCHOLEPTIC-DRUGS ON STRESS-INDUCED
ANALGESIA.
001609 02-04
STRESS-INDUCED FACILITATION OF OPIATE CATALEPSY IN THE RAT.
001680 02-04
SUBSTANCE-P SUPPRESSES STRESS-INDUCED EATING.
001725 02-04
BOMBESIN INHIBITS STRESS-INDUCED EATING.
003059 03-04
EFFEQ OF DIAZEPAM ON STRESS-INDUCED CHANGES IN BRAIN
HISTAMINE.
003932 04-03
STRESS-MODULATED
STRESS-MODULATED ALTERATION OF BRAIN BIOGENIC-AMINES IN THE
RAT: EFFEQS OF L TRYPTOPHAN.
003978 04-03
STRESS-RESISTANCE
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS: EFFEQS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300.
003451 03-14
STRESS-ULCER
SYNERGISTIC AQIONS OF PROPANTHELINE-BROMIDE WITH CIMETIDINE
AND THIOPROPAZATE-HYDROCHLORIOE IN THE PREVENTION OF
STRESS-ULCER FORMATION IN RATS.
000064 01-03
STRESSED
PLASMA IMIPRAMINE LEVELS AND DEMETHYLASE ACTIVITY IN THE
LIVER OF STRESSED ANIMALS.
002793 03-03
SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI-
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS.
002871 03-03
STRESSFUL-SITUATION
ROLE OF THE NEOSTRIATAL DOPAMINERGIC-ACTIVITY IN SEQUENCING
AND SELECTING BEHAVIOURAL- STRATEGIES: FACILITATION OF
PROCESSES INVOLVED IN SELECTING THE BEST STRATEGY IN A
STRESSFUL-SITUATION.
000366 01-04
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE-
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A
CONTROLLED-TRIAL.
002329 02-14
S-424
VOLUME 19, SUBJECT INDEX
Subject Index
STRESSFUL-SITUATIONS
AGGRESSIVE-BEHAVIOR INDUCED BY APOMORPHINE IN RATS SUBMIHED
TO FOUR STRESSFUL-SITUATIONS.
003)63 03-07
STtETCH
THE INFLUENCE OF BENZOCTAMINE ON DOPAMINE AND NOREPINEPHRINE
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH
REFLEX OF THE CAT.
000054 01-03
STRETCH-INDUCED
STRETCH-INDUCED MYOTUBE GROWTH CORRELATES WITH NA-PUMP
ACTIVATION. (UNPUBLISHED PAPER).
002087 02-10
STRETCH-Y AWNING-SYNDROME
TESTOSTERONE POTENTIATION OF THE EFFECTIVENESS OF ACTHl-24 ON
THE INDUCTION OF THE STRETCH-Y AWNING-SYNDROME (SYS) IN MALE
GUINEA-PIGS.
003074 03-04
STRIATAL
EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE
RELEASE.
000067 01-03
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERAQIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING.
000099 01-03
HYPOPHYSEaOMY PREVENTS THE STRIATAL DOPAMINE-RECEPTOR
SUPERSENSITIVITY PRODUCED BY CHRONIC HALOPERIDOL TREATMENT.
000132 01-03
ROLE OF DOPAMINE STORAGE FUNCTION IN THE CONTROL OF RAT
STRIATAL TYROSINE-HYDROXYLASE ACTIVITY.
000201 01-03
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES.
000202 01-03
STRIATAL DOPAMINERGIC AQIVITY DURING WITHDRAWAL FROM
CHRONIC NEUROLEPTIC TREATMENT IN RATS.
000203 01-03
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE
AQION.
000229 01-03
REGULATION OF STRIATAL ACETYLCHOLINE CONCENTRATION BY D2
DOPAMINE-RECEPTORS.
000269 01-03
THE EFFEa OF A NEW FLUORINATED TRICYCLIC NEUROLEPTIC-DRUG
ISOFLOXYTHEPIN ON THE RAT STRIATAL DOPAMINE METABOLISM.
000306 01-03
SEX-DIFFERENCES IN AMPHETAMINE-ELICITED ROTATIONAL-BEHAVIOR
AND THE LATERALIZATION OF STRIATAL DOPAMINE IN RATS.
000459 01-04
BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH
KAINIC-ACID-INDUCED LESIONS OF STRIATAL NEURONS - WITH A
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS-
DISEASE.
000463 01-04
TOLERANCE TO INCREASES IN STRIATAL ACETYLCHOLINE
CONCENTRATIONS AFTER REPEATED ADMINISTRATION OF
APOMORPHINE-DIPIVALOYL-ESTER.
000464 01-04
EFFEa OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED
EXTRAPYRAMIDAL ALTERATIONS.
001119 02-03
HA-966 EFFECTS ON STRIATAL DOPAMINE METABOLISM: IMPLICATIONS
FOR DOPAMINE COMPARTMENTALIZAION.
001150 02-03
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT
DERIVATIVES.
001156 02-03
A COMPARISON OF STRIATAL AND MESOLIMBIC DOPAMINE FUNQION IN
THE RAT DURING 6-MONTH TRIFLUOPERAZINE ADMINISTRATION.
001174 02-03
A COMPARISON OF THE EFFEQS OF METHYLPHENIDATE AND
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES.
001207 02-03
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN
STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER.
001218 02-03
DEVELOPMENT OF ACUTE OPIOID-TOLERANCE AND DEPENDENCE IN RAT
STRIATAL NEURONES.
001235 02-03
CALMODULIN RELEASE FROM STRIATAL MEMBRANES AFTER ACUTE AND
CHRONIC TREATMENT WITH BUTACLAMOL.
001249 02-03
LONG-TERM EFFECTS OF HALOPERIDOL, CLOZAPINE, AND METHADONE
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNAMICS.
001325 02-03
LONG-TERM HALOPERIDOL TREATMENT AND FACTORS EFFECTING THE
ACTIVITY OF STRIATAL TYROSINE-HYDROXYLASE.
001348 02-03
BRAIN STRIATAL TYROSINE-HYDROXYLASE: ACTIVATION OF THE ENZYME
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION.
001423 02-03
PRESYNAPTIC DOPAMINE-RECEPTORS IN STRIATAL NERVE-ENDINGS:
ABSENCE OF HALOPERIDOL-INDUCED SUPERSENSITIVITY.
001424 02-03
SELECTIVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS.
001447 02-03
EFFECT OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRAaiONS.
001472 02-03
EVIDENCE THAT NORADRENALINE MODULATES THE INCREASE IN
STRIATAL DOPAMINE METABOLISM INDUCED BY MUSCARINIC-
RECEPTOR STIMULATION.
001518 02-03
STRIATAL DOPAC LEVELS AS A PREDICTOR OF ANTIPSYCHOTIC-EFFICACY.
001533 02-03
GABA AGONISTS DISSOCIATE STRIATAL UNIT ACTIVITY FROM DRUG-
INDUCED STEREOTYPED-BEHAVIOUR.
001716 02-04
THE STRIATONIGRAL GABA PATHWAY: FUNQIONAL AND
NEUROCHEMICAL CHARACTERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF
STRIATAL DOPAMINE RELEASE.
002242 02-13
SEX-DIFFERENCES IN THE AMPHETAMINE STIMULATED RELEASE OF
CATECHOLAMINES FROM RAT STRIATAL TISSUE IN VITRO.
002668 03-03
DURING ONE YEARS NEUROLEPTIC TREATMENT IN RATS STRIATAL
DOPAMINE-RECEPTOR BLOCKADE DECREASES BUT SERUM PROLAQIN
LEVELS REMAIN ELEVATED.
002707 03-03
THE EFFEa OF GUANOSINE-NUCLEOTIDES ON (3H)SULPIR1DE BINDING TO
RAT STRIATAL MEMBRANES.
002722 03-03
SIMILARITIES BETWEEN THE BINDING OF 3H PIFLUTIXOL AND 3H
FLUPENTIXOL TO RAT STRIATAL DOPAMINE-RECEPTORS IN VITRO.
002760 03-03
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC,
ANTAGONIZES HALOPERIDOL-INDUCED AaiVATION OF STRIATAL
DOPAMINE SYNTHESIS.
002786 03-03
KAINATE LESION DISSOCIATES STRIATAL DOPAMINE-RECEPTOR
RADIOLIGAND BINDING-SITES.
002803 03-03
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF
METHAMPHETAMINE.
002812 03-03
ACTIVATION OF SOLUBLE STRIATAL TYROSINE-HYDROXYLASE IN THE RAT
BRAIN AFTER CDP-CHOLINE ADMINISTRATION.
002816 03-03
EFFEa OF DOPAMINE ON AaiVATION OF RAT STRIATAL ADENYLATE-
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES.
002825 03-03
CHARACTERIZATION OF HALOPERIDOL MEDIATED EFFECTS ON RAT
STRIATAL TYROSINE-HYDROXYLASE.
002867 03-03
GABA AND BACLOFEN POTENTIATE THE K-EVOKED RELEASE OF
METHIONINE-ENKEPHALIN FROM RAT STRIATAL SLICES.
002882 03-03
DOPAMINERGIC AGONIST AND ANTAGONIST EFFEaS ON STRIATAL
TYROSINE-HYDROXYLASE DISTRIBUTION.
002898 03-03
EFfEaS OF CHOLECYSTOKININ-OaAPEPTIDE ON STRIATAL DOPAMINE
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE
CLIMBING IN MICE.
003031 03-04
STIMULATORY ACTION OF LISURIDE ON DOPAMINE-SENSITIVE
ADENYLATE-CYCLASE IN THE RAT STRIATAL HOMOGENATE.
003718 04-03
EFFECT OF CHRONIC SULPIRIDE ON STRIATAL SPIPERONE BINDING.
003720 04-03
INTERCONVERTING MU AND DELTA-FORMS OF TYPE-1 OPIATE-RECEPTORS
IN THE RAT STRIATAL PATCHES.
003737 04-03
S-425
Subject Index
Ptychopharmacology Abstracts
m
■ill?
a.
J5I;:;
ii
ft",
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS:
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF
(3H)D0PAMINE AND (I4C)GABA RELEASE IN VITRO.
003741 04-03
THE EFFECT OF LONG-TERM CONCURRENT ADMINISTRATION OF
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL
CORTICAL DOPAMINE METABOLISM IN RATS.
003788 04-03
ANTIDOPAMINERGIC EFFECT OF ESTROGENS AT THE STRIATAL LEVEL.
003789 04-03
INVESTIGATION OF ACTION OF ENKEPHALIN ON THE SPONTANEOUS AND
EVOKED RELEASE OF ACETYLCHOLINE FROM RAT CORTICAL AND
STRIATAL SLICES.
003862 04-03
THE INFLUENCE OF D-AMPHETAMINE ON RAT-BRAIN STRIATAL REDUCED
BIOPTERIN CONCENTRATION.
003922 04-03
EFFECTS OF IN VIVO AMPHETAMINE ADMINISTRATION ON DOPAMINE
SYNTHESIS REGULATION IN RAT-BRAIN STRIATAL SYNAPTOSOMES.
(UNPUBLISHED PAPER).
003960 04-03
EFFECTS OF CANNABINOIDS ON CATECHOLAMINE UPTAKE AND RELEASE
IN HYPOTHAUVMIC AND STRIATAL SYNAPTOSOMES.
003970 04-03
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCEO
ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY.
004018 04-03
CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF
(3H)SULPIRIDE AND (3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS.
004032 04-03
ACTIONS OF MU, KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION.
004053 04-03
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS.
004129 04-04
GENOTYPIC INFLUENCES ON STRIATAL DOPAMINERGIC REGULATION IN
MICE.
004217 04-04
STRIATALLY-EVOKED
EFFECTS OF INTRAPALLIDAL OPIATE-RECEPTOR AGONISTS ON
STRIATALLY-EVOKED HEAD-TURNING
001785 02-04
STRIATONIGRAL
THE STRIATONIGRAL GABA PATHWAY: FUNQIONAL AND
NEUROCHEMICAL CHARACTERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
RESPONSE OF STRIATONIGRAL SUBSTANCE-P SYSTEMS TO A DOPAMINE-
RECEPTOR AGONIST AND ANTAGONIST.
003826 04-03
STRIATUM
ENKEPHALIN LEVELS DECREASE IN RAT STRIATUM DURING MORPHINE
ABSTINENCE.
000027 01-03
3H IMIPRAMINE BINDING IN NEURONAL AND GLIAL FRAQIONS OF
HORSE STRIATUM.
000033 01-03
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING-
SITES IN RAT STRIATUM.
000186 01-03
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE
OF STRIATAL CAPILLARIES.
000202 01-03
REINNERVATION OF THE DENERVATED STRIATUM BY SUBSTANTIA-NIGRA
TRANSPLANTS: FUNCTIONAL CONSEQUENCES AS REVEALED BY
PHARMACOLOGICAL AND SENSORIMOTOR TESTING.
000347 01-04
INCREASED OOPAMINE-RECEPTOR BINDING IN THE STRIATUM OF RATS
AFTER LONG-TERM ISOLATION.
000398 01-04
ENDOGENOUS GUANYL-NUCLEOTIDES: COMPONENTS OF THE STRIATUM
WHICH CONFER DOPAMINE SENSITIVITY TO ADENYLATE-CYCLASE.
001313 02-03
DECREASE OF GAD IMMUNOREACTIVE NERVE TERMINALS IN THE
SUBSTANTIA-NIGRA AFTER KAINIC-ACID LESION OF THE STRIATUM.
(UNPUBLISHED PAPER).
001400 02-03
CHRONIC LITHIUM REDUCES (3H)SPIR0PERID0L BINDING IN RAT
STRIATUM.
001443 02-03
STIMULATION OF ADENYLATE-CYCLASE IN RAT STRIATUM BY
PERGOLIDE: INFLUENCE OF GTP.
001448 02-03
ATROPINE AND NATURAL SLEEP: AQIVITY DATA OF THE STRIATUM IN
RATS.
001551 02-03
MODULATION OF OPIATE-RECEPTOR BINDING IN STRIATUM AND
AMYGDALA BY SELECTIVE MESENCEPHALIC LESIONS
001629 02-04
EFFECT OF KAINIC-ACID LESIONS ON MUSCARINIC AGONIST RECEPTOR
SUBTYPES IN RAT STRIATUM.
002679 03-03
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA
BUTYROLAQONE AND HA-966 IN THE STRIATUM AND OLFAQORY
TUBERCLE OF THE RAT.
002681 03-03
EFFEa OF TENTANUS TOXIN ON TRANSMIHER RELEASE FROM THE
SUBSTANTIA-NIGRA AND STRIATUM IN VITRO.
002691 03-03
COMPARISON OF THE EFFEaS OF THE STEREOISOMERS OF
FENFLURAMINE ON THE ACETYLCHOLINE CONTENT OF RAT STRIATUM,
HIPPOCAMPUS AND NUCLEUS-ACCUMBENS
003758 04-03
SOLUBILIZATION OF NEUROLEPTIC/DOPAMINE-RECEPTORS OF HUMAN
BRAIN STRIATUM.
003767 04-03
GABA-ENHANCEMENT OF (3H)D0PAMINE RELEASE FROM SLICES OF RAT
STRIATUM: DEPENDENCE ON SLICE SIZE.
003786 04-03
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE AQIVITY IN THE
RAT STRIATUM MICROSOMES FOLLOWING ELEaROLYTIC OR 6
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS.
003871 04-03
EFFEaS OF ACUTE AND CHRONIC ADMINISTRATION OF PHENCYCLIDINE
ON DOPAMINERGIC-RECEPTORS IN RAT STRIATUM.
003901 04-03
CHARAQERIZATION OF ENKEPHALIN RELEASE FROM RAT STRIATUM.
003909 04-03
STRIPS
PERSISTENT EFFECTS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC-
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS.
001266 02-03
STROKE
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
DEXAMETHASONE TREATMENT.
000321 01-03
STRUCTURAL
FUNQIONAL AND STRUQURAL CONSEQUENCES OF LONG-TERM DIETARY
L-OOPA TREATMENT IN MICE.
000257 01-03
STRUaURAL REQUIREMENTS FOR UPTAKE INTO SEROTONINERGIC
NEURONES.
001452 02-03
THE EFFEa OF SOME STRUQURAL GABA ANALOGUES ON THE
SEROTONIN AND DOPAMINERGIC MECHANISMS.
001736 02-04
STRUCTURE
THE STRUCTURE OF HALOPERIDOL-HYDROBROMIDE (CHLOROPHENYL-4-
HYDROXYPIPERIDINE-4-FLUOROBUTYROPHENONE HBR) .
000002 01-01
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE ACETYLCHOLINE
ANTAGONIST DIMETHYLAMINOBUTYNYLCYCLOHEXYLHYDROXY 2
PHENYLACETATE HCL.
000003 01-01
EFFECT OF STRUCTURE ON PHENOTHIAZINE CATION RADICAL REACTIONS
IN AQUEOUS BUFFERS.
000014 01-02
EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERACTIONS WITH MU-
RECEPTORS AND DELTA-RECEPTORS.
000168 01-03
EFFECTS OF LEAD EXPOSURE DURING DEVELOPMENT ON NEOCORTICAL
DENDRITIC AND SYNAPTIC STRUCTURE.
000525 01-05
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE NEUROLEPTIC
PIMOZIDE-HYDROCHLORIDE, BISFLUOROPHENYL-
BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL.
001015 02-01
CHEMICAL STRUCTURE OF SURVECTOR. STRUCTURE-ACTIVITY
RELATIONSHIP.
002262 02-13
RELATIONSHIP BETWEEN STRUCTURE AND NEUROLEPTIC ACTIVITY:
PHARMACOPHORE AND PHARMACOKINETICS.
002492 02-16
STRUCTURE OF VARIABILITY AND CORRELATION IN LEARNING AFTER
DRUG ADMINISTRATION.
002562 02-17
S-426
VOLUME 19, SUBJECT INDEX
Subject Index
RELATIONSHIPS BETWEEN STRUCTURE AND ALPHA-ADRENERGIC-
RECEPTOR AFFINITY OF CLONIDINE AND AND SOME RELATED CYCLIC-
AMIDINES.
002698 03-03
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOAaiVE CANNABINOIDS
ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS.
002831 03-03
METHAQUALONE RIA STRUCTURE VERSUS REACTIVITY.
003657 04-01
RIA OPIATES: STRUCTURE VERSUS REACTIVITY.
003659 04-01
PURIFICATION AND SUBUNIT STRUCTURE OF DNA-DEPENDENT RNA-
POLYMERASE-BII FROM RAT-BRAIN NUCLEI.
003679 04-01
EFFECT OF 6 HYDROXYDOPAMINE ON THE FINE STRUCTURE OF THE
HAMSTER PINEAL-GLAND.
003747 04-03
STUDY ON THE STABILITY OF THE FACTORIAL STRUCTURE OF THE AMP
SYSTEM DURING TREATMENT.
004696 04-16
STRUCTURE-ACTIVITY
INHIBITION OF HIGH-AFFINITY CHOLINE UPTAKE: STRUQURE-ACTIVITY
STUDIES.
000026 01-03
STRUaURE-ACTIVITY RELATIONSHIPS IN THE EFFEaS OF PHENACEMIDE
ANALOGS ON SERUM CREATININE AND ANTICONVULSANT ACTIVITY.
000249 01-03
STRUCTURE-ACTIVITY RELATIONSHIP OF PHENCYCLIDINE DERIVATIVES.
001030 02-01
PROSTACYCLIN-DEPENDENT AQIVATION OF ADENYLATE-CYCLASE IN A
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-AQIVITY
RELATIONSHIPS.
001132 02-03
STRUaURE-AQIVITY RELATIONSHIPS AMONG SOME D N ALKYLATED
AMPHETAMINES.
001542 02-03
PHENCYCLIDINE (PCP) AND DERIVATIVES: PHARMACOLOGY AND
STRUaURE-ACTIVITY RELATIONSHIPS.
001706 02-04
0 METHOXYBENZAMIDES: RELATIONSHIPS BETWEEN STRUCTURE-
ACTIVITY, AND PHARMACOKINETICS OF THESE DRUGS.
002246 02-13
CHEMICAL STRUCTURE OF SURVEaOR. STRUQURE-ACTIVITY
RELATIONSHIP.
002262 02-13
PHENYLETHYLAMINE EFFEQS ON DOPAMINE SYNTHESIS. STRUCTURE-
AaiVITY RELATIONSHIPS.
002649 03-02
GABA-AUTORECEPTORS: STRUQURE-AaiVITY RELATIONSHIPS FOR
AGONISTS.
002678 03-03
STRUaURE-AQIVITY AND RECEPTOR BINDING OF ANTAGONIST
ANALGESICS.
003611 03-17
SYNTHESIS AND STRUQURE-ACTIVITY RELATIONSHIP OF A
PYRIMIDOPYRIMIDINE DERIVATIVE WITH ANTIDEPRESSANT ACTIVITY.
003653 04-01
PHENYLETHYLAMINE EFFECTS ON DOPAMINE SYNTHESIS: STRUCTURE-
ACTIVITY RELATIONSHIPS. (UNPUBLISHED PAPER).
003959 04-03
SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS: DESIGN,
DEVELOPMENT AND STRUQURE-ACTIVITY STUDIES.
004725 04-17
STRUCTURES
INHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN
CIRCUMVENTRICULAR STRUCTURES OF RAT-BRAIN.
000159 01-03
ANTINOCICEPTIVE ACTION OF MORPHINE AND PENTAZOCINE ON UNIT
AQIVITY IN THE NUCLEUS-CENTRALIS-LATERALIS, NUCLEUS-
VENTRALIS-LATERALIS AND NEARBY STRUCTURES OF THE CAT.
002837 03-03
THE EFFEQ OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELEaRICAL-
AQIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUQURES OF
THE RABBIT BRAIN.
003994 04-03
THE EFFEQ OF PHARMACOLOGICAL DESTRUCTION OF HYPOTHALAMIC
MONOAMINERGIC STRUCTURES ON BODY-TEMPERATURE AND GAS-
EXCHANGE DURING EXTREME COOLING.
004016 04-03
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION.
004273 04-05
STRUGGLING
EFFEaS OF ANALGESICS AND CNS-ACTING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS.
004148 04-04
STRYCHNINE
DISSOCIATION OF THE STRYCHNINE EFFECT ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES.
000816 01-14
STRYCHNINE EFFECTS ON THE SENSORY RESPONSE PAHERNS OF
RETICULAR FORMATION NEURONS.
001219 02-03
DISSOCIATION OF THE STRYCHNINE EFFEQ ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES.
002155 02-11
INFLUENCE OF STRYCHNINE ON THE CONSOLIDATION PHASE OF VISUAL-
MEMORY IN GERONTOPSYCHIATRIC-PATIENTS.
002156 02-11
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJEQIONS OF
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS.
003101 03-04
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS:
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE.
003778 04-03
STRYCHNINE-INDUCED
VOLTAGE CLAMP STUDY OF CAT SPINAL MOTONEURONS DURING
STRYCHNINE-INDUCED SEIZURES.
002886 03-03
STUTTERERS
PRINCIPAL AND DIFFERENTIAL-EFFEQS OF HALOPERIDOL AND PLACEBO
TREATMENTS UPON SPEECH DISFLUENCIES IN STUHERERS.
00071301-11
STUHERING
ADULT-ONSET STUTTERING TREATED WITH ANTICONVULSANTS.
003290 03-11
SUBACUTE
GLIAL CELL EFFECTS OF SUBACUTE FORMIC-ACID VAPOUR EXPOSURE.
000527 01-05
ISOPRINOSINE IN SUBACUTE SCLEROSING PANENCEPHALITIS.
000687 01-11
REVIEW OF 38 CASES OF SUBACUTE SCLEROSING PANENCEPHALITIS:
EFFECT OF AMANTADINE ON THE NATURAL COURSE OF THE DISEASE.
000718 01-11
SUBACUTE CANNABINOID TREATMENT: ANTICONVULSANT AQIVITY AND
WITHDRAWAL EXCITABILITY IN MICE.
001671 02-04
SUBARACHNOID
DEPRESSION OF RESERPINE-INDUCED MUSCULAR RIGIDITY IN RATS AFTER
ADMINISTRATION OF LISURIDE INTO THE SPINAL SUBARACHNOID
SPACE.
002962 03-04
SUBCELLULAR
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN
BINDING-SITES IN THE CNS OF THE RAT ~ II. RESPEQIVE REGIONAL
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC
DEVELOPMENTS.
000214 01-03
SUBCELLULAR REAQION OF THE BRAIN TO HYPOXIA.
001354 02-03
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO
SUBCEaULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE
BRAIN.
002699 03-03
INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN
SUBCELLULAR GANGLIOSIDES: EFFECT OF PENTYLENETETRAZOL-
INDUCED CONVULSIONS IN BRAIN GANGLIOSIDES.
002937 03-03
REGIONAL AND SUBCELLULAR LOCALIZATION IN RAT-BRAIN OF THE
ENZYMES THAT CAN SYNTHESIZE GAMMA HYDROXYBUTYRIC-ACID.
003675 04-01
NEWLY SYNTHESIZED CHOLECYSTOKININ IN SUBCELLULAR FRAQIONS OF
THE RAT-BRAIN.
003805 04-03
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A
POSTSYNAPTIC MEMBRANE FRACTION.
003948 04-03
EVIDENCE THAT THERE ARE SUBCELLULAR POOLS OF NOREPINEPHRINE
AND THAT THERE IS FLUX OF NOREPINEPHRINE BETWEEN THESE
POOLS.
004004 04-03
SUBCHRONIC
DOUBLE-BUND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR
SUBCHRONIC WITHDRAWAL FROM ALCOHOL.
003332 03-1 1
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS.
004180 04-04
SUBCHRONIC-TREATMENT
AHENUATION OF AMPHETAMINE ANOREXIA IN RATS FOLLOWING
SUBCHRONIC-TREATMENT WITH A TRICYCLIC-ANTIDEPRESSANT.
000501 01-04
S-427
Subject Index
Psychopharmacology Abstracts
i
;iJ3?
MS.
m
5
.It:
en;.
fe
DOPAMINE-RECEPTOR BLOCKADE IN RAT-BRAIN AFTER ACUTE AND
SUBCHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANTS.
001314 02-03
SUBCHRONIC-TREATMENT WITH THE TRICYCLIC-ANTIDEPRESSANT DMI
INCREASES ISOLATION-INDUCED FIGHTING IN RATS.
004252 04-04
SUBCLINICAL
BEHAVIORAL-TEST FOR DETECTION OF SUBCLINICAL BRAIN-DAMAGE. AN
EXPERIMENTAL MODEL.
003120 03-04
SUBCORTICAL
APOMORPHINE HALOPERIDOL INTERAQIONS: DIFFERENT TYPES OF
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS.
002662 03-03
EFFEQ OF 6 HYDROXYDOPAMINE LESIONS OF THE MEDIAL PREFRONTAL-
CORTEX ON NEUROTRANSMinER SYSTEMS IN SUBCORTICAL SITES IN
THE RAT.
002869 03-03
THE EFFEQ OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELEQRICAL-
ACTIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUQURES OF
THE RABBIT BRAIN.
003994 04-03
SUBCUTANEOUS
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD
ETHANOL LEVELS IN RATS DRINKING A LIQUID DIET.
001865 02-06
ON CORRELATION OF BEHAVIORAL-REAQIONS AND NEURONAL ACTIVITY
IN THE HYPOTHALAMUS UNDER SUBCUTANEOUS GASTRIN INJEQION.
002892 03-03
SEIZURES ELICITED BY SUBCUTANEOUS INJEQION OF METRAZOL DURING
ONTOGENESIS IN RATS.
003039 03-04
SUBCUTANEOUSLY
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME AQIVITY
IN THE RAT-BRAIN.
001614 02-04
SUBGROUP
IDENTIFICATION OF A SUBGROUP OF TARDIVE-DYSKINESIA PATIENTS BY
PHARMACOLOGIC-PROBES.
000708 01-11
SUBJECTIVE
PLASMA AND SALIVA LEVELS OF CHLORPROMAZINE AND SUBJEQIVE
RESPONSE.
000826 01-14
CONTRIBUTIONS OF INDIVIDUAL DIFFERENCES TO SUBJEQIVE
INTOXICATION.
002202 02-12
THE EFFEQS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS
ON SUBJEQIVE ASPEQS OF SLEEP AND OBJEQIVE MEASURE OF
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOQURNAL
MEDICATION: II. REPEATED DOSES.
002331 02-14
VIGILANCE IMPAIRING DRUGS: ANALYSIS OF SUBJEQIVE RESPONSES.
002332 02-14
EFFECTS OF ATENOLOL AND PROPRANOLOL ON HUMAN PERFORMANCE
AND SUBJEQIVE FEELINGS.
002340 02-14
SUBJECTIVE DRUG-EFFECTS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFECTS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
SUBJECTIVE ASSESSMENT OF SEXUAL-DYSFUNCTION OF PATIENTS ON
LONG-TERM ADMINISTRATION OF DIGOXIN.
002443 02-15
SUBJECTIVE RESPONSE TO ANTIPSYCHOTIC-DRUGS.
003202 03-08
DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL-SYNDROME.
004472 04-1 1
EFFECTS OF SUPIDIMIDE (CG-3033) ON OBJECTIVE AND SUBJECTIVE SLEEP
PARAMETERS (A SLEEP LABORATORY STUDY).
004567 04-14
SUBJECTIVE-EFFECTS
BEHAVIORAL-EFFECTS AND SUBJECTIVE-EFFECTS OF BETA-ADRENERGIC
BLOCKADE IN PHOBIC-SUBJECTS.
002060 02-10
SUBMAXILLARY-OLAND
CHRONIC SYMPATHETIC DENERVATION INCREASES MUSCARINIC-
CHOLINOCEPTOR BINDING IN THE RAT SUBMAXILLARY-GLAND.
000235 01-03
SUBMICROMOLAR
PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN
VITRO. INHIBITION BY MELATONIN AT SUBMICROMOLAR
CONCENTRATIONS.
001159 02-03
SUBNORMAL-PATIENTS
SELF-INJURY IN SUBNORMAL-PATIENTS.
003452 03-14
SUBPOPULATIONS
DISCRIMINATION OF FUNCTIONALLY HETEROGENEOUS RECEPTOR
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC
PROPERTIES OF METOCLOPRAMIDE.
002877 03-03
SUBSENSITIVITY
REPEATED TRICYCLICS INDUCE A PROGRESSIVE DOPAMINE-
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT OF DAILY DRUG-
TREATMENT.
000047 01-03
TRICYCLIC-ANTIDEPRESSANTS INDUCE SUBSENSITIVITY OF PRESYNAPTIC
DOPAMINE-AUTORECEPTORS .
000048 01-03
SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM IN BRAIN: EFFECTS OF NISOXETINE
VERSUS FLUOXETINE.
000208 01-03
FUNCTIONAL EVIDENCE FOR SUBSENSITIVITY OF NORAORENERGIC-
ALPHA2-RECEPT0RS AFTER CHRONIC DESIPRAMINE TREATMENT.
000283 01-03
ATTEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL
DOPAMINE-RECEPTORS ARER VARIOUS TREATMENTS WITH
ANTAGONISTS OR AGONISTS.
001350 02-03
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFECT
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC
HYDROXYLATION BY IPRINDOLE.
001353 02-03
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY?
002659 03-03
AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR
ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER
CHRONIC ANTIDEPRESSANT TREATMENT.
002788 03-03
MORPHINE WITHDRAWAL CAUSES SUBSENSITIVITY OF ADRENERGIC-
RECEPTOR RESPONSE.
002838 03-03
SUBSTANCE
INHIBITORY ACTION OF MORPHINE ON THE RELEASE OF A BRADYKININ-
LIKE SUBSTANCE AFTER SCIATIC-NERVE STIMULATION.
001293 02-03
SUBSTANCE-P
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER).
001024 02-01
DEPRESSION AND FACILITATION OF SYNAPTIC RESPONSES IN CAT
DORSAL-HORN BY SUBSTANCE-P ADMINISTERED INTO SUBSTANTIA-
GELATINOSA.
001191 02-03
EVIDENCE SUGGESTING A TRANSMIHER OR NEUROMODULATORY ROLE
FOR SUBSTANCE-P AT THE FIRST SYNAPSE OF THE BARORECEPTOR
REFLEX.
001264 02-03
SUBSTANCE-P, MORPHINE AND METHIONINE-ENKEPHALIN: EFFECTS ON
SPONTANEOUS AND EVOKED NEURONAL FIRING IN THE NUCLEUS-
RETICULARIS-GIGANTOCELLULARIS OF THE RAT.
001267 02-03
THE EFFECT OF MORPHINE ON THE CONTENT OF SEROTONIN, 5
HYDROXYINDOLEACETIC-ACID AND SUBSTANCE-P IN THE NUCLEI
RAPHE-MAGNUS AND RETICULARIS-GIGANTOCELLULARIS.
001328 02-03
FURTHER CHARACTERIZATION OF THE BINDING OF SUBSTANCE-P TO A
FRACTION FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES.
001394 02-03
SUBSTANCE-P SUPPRESSES STRESS-INDUCED EATING.
001725 02-04
PHARMACOLOGICAL CHARACTERIZATION OF SCRATCHING-BEHAVIOUR
INDUCED BY INTRACRANIAL INJECTION OF SUBSTANCE-P AND
SOMATOSTATIN.
002980 03-04
SUBSTANCE-P, HEXAPEPTIDE-PGLU6(SP6-1 1), ANALGESIA AND
SEROTONIN DEPLETION.
003050 03-04
CENTRAL-EFFECTS OF SUBSTANCE-P IN FOWLS.
003075 03-04
RESPONSE OF STRIATONIGRAL SUBSTANCE-P SYSTEMS TO A DOPAMINE-
RECEPTOR AGONIST AND ANTAGONIST.
003826 04-03
NERVE GROWTH-FACTOR STIMULATES DEVELOPMENT OF SUBSTANCE-P
IN THE EMBRYONIC SPINAL-CORD.
003881 04-03
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN
INDIRECT ADRENERGIC CHOLINERGIC INTERACTION.
003887 04-03
S-428
VOLUME 19, SUBJECT INDEX
INTRANIGRAL INJECTION OF CAPSAICIN ENHANCES MOTOR-ACTIVITY
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE BUT NOT SUBSTANCE-
^ 004100 04-04
BEHAVIORAL-EVIDENCE THAT SUBSTANCE-P MAY BE A SPINAL-CORD
SENSORY NEUROTRANSMITTER. 004200 04-04
INTRACEREBRAL SUBSTANCE-P IN MICE. BEHAVIORAL-EFfECTS AND
NARCOTIC-AGENTS. 004218 04-04
*"'"*POSITE'*EF'FECTf OF NALOXONE ON SUBSTANCE-P-INDUCED IN BRAIN
DOPA SYNTHESIS AND IN LOCOMOTOR-ACTtVITY IN RATS^
0O37VV U4-UJ
*"'*DEPRrSSION AND FACILITATION OF SYNAPTIC RESPONSES IN CAT
DORSAL-HORN BY SUBSTANCE-P ADMINISTERED INTO SUBSTANTIA-
e^^TINOSA. 00119102-03
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY mFFERENTS. ^^^^^ ^^^^
SELECTIVE NEUROTOXIC-ACTION OF CAPSAICIN ON GLOMERULAR C-TYPE
TERMINALS IN RAT SUBSTANTIA-GELATINOSA.
003143 03-06
^^'Vnl'lNaU^NCEOF BENZOaAMINE ON DOPAMINE AND NOREPINEPHRINE
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH
REFLEX OF THE CAT. 000054 01-03
GABA INHIBITION OF 3H GLYCINE RELEASE FROM SLICES OF RAT
SUBSTANTIA-NIGRA IN VITRO. 000157 01-03
ACUTE AND CHRONIC EFFEQS OF NEUROLEPTICS AND ACUTE EFFECTS OF
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN
0002 15 01 -03
REINNERVATION OF THE DENERVATED STRIATUM BY SUBSTANTIA-NIGRA
TRANSPLANTS: FUNCTIONAL CONSEQUENCES AS REVEALED BY
PHARMACOLOGICAL AND SENSORIMOTOR TESTING.
00034/ UI-U4
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
POSTAMPHETAMINE DEPRESSION OF SELF-STIMULATION RESPONDING
FROM THE SUBSTANTIA-NIGRA: REVERSAL BY TRICYCLIC-
ANTIDEPRESSANTS . „„„.,„«,«,.
000419 01-04
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN.
001 167 02-03
DECREASE OF GAD IMMUNOREAQIVE NERVE TERMINALS IN THE
SUBSTANTIA-NIGRA AFTER KAINIC-ACID LESION OF THE STRIATUM.
(UNPUBLISHED PAPER) . ^„ , .„„ „o «-,
001400 02-03
HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY
UNILATERAL 6 OHDA INJEQIONS INTO SUBSTANTIA-NIGRA AND
CAUDATE-NUCLEUS. 001778 02-04
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY. „„„,,„„„„,
002639 03-01
EFFEQ OF TENTANUS TOXIN ON TRANSMIHER RELEASE FROM THE
SUBSTANTIA-NIGRA AND STRIATUM IN VITRO.
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPACTA AND
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE
SPONTANEOUS NEURONAL ACTIVITIES IN THE RAT.
002718 03-03
THE EFFECT OF SPECIFIC BRAIN LESIONS ON THE HIGH-AFFINITY BINDING
OF GABA IN THE SUBSTANTIA-NIGRA.
002795 03-03
BIPHASIC-EFFEaS AND OPPOSITE-EFFEQS OF DOPAMINE AND
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT
SUBSTANTIA-NIGRA. „„„„oo oo r.n
002923 03-03
EFFEQS OF ELECTROLYTIC AND 6 HYDROXYDOPAMINE LESIONS OF THE
LATERAL HYPOTHALAMUS ON ROTATION EVOKED BY ELECTRICAL-
STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.
003081 03-04
RELATIONSHIP BETWEEN THE PRESENCE OF DOPAMINERGIC NEURONS
AND GABA-RECEPTORS IN SUBSTANTIA-NIGRA: EFFEQS OF LESIONS.
003797 04-03
Subject Index
THE EFFECT OF SODIUM-DIPROPYLACETATE ON GAMMA AMINOBUTYRIC-
ACID DEPENDENT INHIBITION IN THE RAT-CORTEX AND SUBSTANTIA-
NIGRA IN RELATION TO ITS ANTICONVULSANT ACTIVITY
003880 04-03
IN VIVO EVIDENCE FOR GABAERGIC CONTROL OF SEROTONIN RELEASE IN
THE CAT SUBSTANTIA-NIGRA. 00401104-03
ROTATIONAL-BEHAVIOUR ELICITED BY 5 HT IN THE RAT: EVIDENCE FOR
AN INHIBITORY ROLE OF 5 HT IN THE SUBSTANTIA-NIGRA AND
CORPUS-STRIATUM. ^^,^^ ^^^
MORPHINE DIFFERENTIALLY AFFECTS VENTRAL TEGMENTAL AND
SUBSTANTIA-NIGRA BRAIN REWARD THRESHOLDS.
004187 04-04
THE INFLUENCE OF UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE
SUBSTANTIA-NIGRA IN THE ABSENCE OF THE TELENCEPHALON.
004197 04-04
SUBSTITUTED
STUDIES ON SEVERAL 7 SUBSTITUTED N,N DIMETHYLTRYPT AMINES.
001020 02-01
6 SUBSTITUTED AMIN0-4H-S-TRIAZ0L0BENZ0DIAZEPINES AND 4
SUBSTITUTED AMIN0-6H-S-TR1AZ0L0BENZ0DIAZEPINES WITH
POTENTIAL ANTIANXIETY AQIVITY.
001076 02-02
THE EFFECTS OF SUBSTITUTED BENZAMIDES ON FROG REQUS-
ABDOMINIS. ^„,„„„„o,^o
001228 02-03
STEREOSELEaiVE ACTIONS OF SUBSTITUTED BENZAMIDE DRUGS ON
CEREBRAL DOPAMINE MECHANISMS.
001301 02-03
CLINICAL-EXPERIENCE WITH SUBSTITUTED BENZAMIDES IN FRENCH-
SPEAKING COUNTRIES.
002036 02-09
SUBSTITUTED PHENETHYLAMINES AND ANOREXIA.
002541 02-17
CENTRALLY AQIVE N SUBSTITUTED ANALOGS OF 3,4
METHYLENEDIOXYPHENYLISOPROPYLAMINE (3,4
METHYLENEDIOXY AMPHETAMINE) .
003683 04-02
1 SUBSTITUTED BENZYLTETRAHYDROPYRIMIDONES: A SERIES WITH
STIMULANT AND DEPRESSANT AQIVITIES.
003687 04-02
ACYLCYANAMIDES, ACYLUREA, AND VARIOUS SUBSTITUTED
ARYLALLOPHANATES; EFFECT ON THE CNS. „„ „. „o
003689 04-02
COMPARATIVE-EFFEQS OF SUBSTITUTED PHENYLETHYLAMINES ON BRAIN
SEROTONERGIC MECHANISMS. _^„^ ^ ^ _ „^
003854 04-03
COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRACT OF THE GUINEA-PIG AND RAT.
003928 04-03
ENHANCED RESPONSES TO OPIATES PRODUCED BY A SINGLE GENE
SUBSTITUTION IN THE MOUSE. 001677 02-04
EFFEQS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETEQ THE NARCOTIC CHARAQER OF A DRUG.
003555 03-16
EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE
ROLE FOR BETA PHENYLETHYLAMINE IN THE COCAINE CUE.
000363 01-04
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL
GROUPS IN THE AQIVE SITE. (UNPUBLISHED PAPER).
001066 02-01
TELE-METHYLHISTAMINE IS A SPECIFIC MAO-B SUBSTRATE IN MAN.
002230 02-13
ADENOSINE ANALOGS AS SUBSTRATES AND INHIBITORS OF S
ADENOSYLHOMOCYSTEINE-HYDROLASE. (UNPUBLISHED PAPER).
001021 02-01
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH
PSYCHOSTIMULANTS: II. EFFECT OF METHAMPHETAMINE ON
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC
S"^^^'^^^^^ 001613 02-04
SPECIES-DIFFERENCES IN THE DEAMINATION OF DOPAMINE AND OTHER
SUBSTRATES FOR MONOAMINE-OXIDASE IN BRAIN.
002233 02-13
SUBSYNDROMES
SUBSYNDROMES OF TARDIVE-DYSKINESIA.
002421 02-15
S-429
a.,
m
ill
0;,
^
I
Subject Index
SUBTHRESHOLD
EFFEQ OF REPEATED ELECTROCONVULSIVE-SHOCKS (ECS) ON
SUBTHRESHOLD DOSES OF SOME CNS STIMULANTS.
001361 02-03
SUBTYPES
COMPARISON OF BETA-ADRENERGIC-RECEPTOR SUBTYPES IN
MAMMALIAN TISSUES.
000207 01-03
PERIPHERAL ALPHA-ADRENERGIC-RECEPTOR SUBTYPES.
000901 01-16
DEXAMETHASONE-SUPPRESSION-TEST IDENTIFIES SUBTYPES OF
DEPRESSION WHICH RESPOND TO DIFFERENT ANTIDEPRESSANTS.
001971 02-09
SUBTYPES OF DEPRESSION BASED ON EXCRETION OF MHPG AND
RESPONSE TO NORTRIPTYLINE.
002488 02-16
EFFEa OF KAINIC-ACID LESIONS ON MUSCARINIC AGONIST RECEPTOR
SUBTYPES IN RAT STRIATUM.
002679 03-03
BETA-ADRENERGIC-RECEPTOR SUBTYPES: PROPERTIES, DISTRIBUTION,
AND REGULATION.
002829 03-03
CHARACTERIZATION AND QUANTITATION OF ALPHA-ADRENERGIC-
RECEPTOR SUBTYPES IN RAT HYPOTHALAMUS.
002839 03-03
THE DEXAMETHASONE-SUPPRESSION-TEST IN THE IDENTIFICATION OF
SUBTYPES OF DEPRESSION DIFFERENTIALLY RESPONSIVE TO
ANTIDEPRESSANTS.
00321 1 03-09
DEPRESSION SUBTYPES AFFEQ THE STEADY-STATE PLASMA LEVELS AND
THERAPEUTIC-EFFICACY OF AMITRIPTYLINE AND NORTRIPTYLINE.
003244 03-09
SUBUNIT
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING-
SITES IN RAT STRIATUM.
000186 01-03
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES.
001342 02-03
PURIFICATION AND SUBUNIT STRUQURE OF DNA-DEPENDENT RNA-
POLYMERASE-BII FROM RAT-BRAIN NUCLEI.
003679 04-01
SUCCINATE-DEHYDROGENASE
CHANGES IN THE CORTICAL AQIVITY OF SUCCINATE-DEHYDROGENASE
UNDER THE INFLUENCE OF CHLORPROMAZINE (A HISTOCHEMICAL-
STUDY AND ELEQROCYTOCHEMICAL-STUDY).
002784 03-03
SUCCINIC-DEHYDROGENASE
THE EFFEQ OF FRUSEMIDE PIRETANIDE AND BUMETANIDE ON COCHLEAR
SUCCINIC-DEHYDROGENASE.
003757 04-03
SUCKUNG
THE INFLUENCE OF DAILY BIOLOGICAL-RHYTHMICITY ON THE HOMING-
BEHAVIOR, PSYCHOPHARMACOLOGICAL RESPONSIVENESS, LEARNING
AND RETENTION OF SUCKLING RATS. (PH.D. DISSERTATION).
SUCKUNGS
BEHAVIORAL-EFFEQS OF HASHISH IN MICE:
DEVELOPMENT OF THE SUCKLINGS.
001660 02-04
II. NURSING-BEHAVIOR AND
001626 02-04
SUCROSE
DOSE-RESPONSE RELATIONSHIP BETWEEN NALOXONE INJEQIONS AND
INTAKE OF SUCROSE SOLUTION.
003118 03-04
SUDDEN
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST
SUDDEN CARDIAC DEATH FROM COCAINE.
003122 03-05
SUFFERING
PRELIMINARY TRIAL OF CLONIDINE TREATMENT IN TWO PATIENTS
SUFFERING FROM CHRONIC SCHIZOPHRENIA.
004320 04-08
SULFAMOYLMETHYL-BENZISOXAZOLE
EFFECTS OF 3 SULFAMOYLMETHYL-BENZISOXAZOLE (AD-810) AND SOME
ANTIEPILEPTICS ON THE KINDLED SEIZURES IN THE NEOCORTEX,
HIPPOCAMPUS AND AMYGDALA IN RATS.
004149 04-04
SULFAMOYLMETHYL-l-2-BENZISOXAZOLE
3 SULFAMOYLMETHYL-l-2-BENZISOXAZOLE, A NEW TYPE OF
ANTICONVULSANT-DRUG: PHARMACOLOGICAL PROFILE.
000012 01-02
3 SULFAMOYLMETHYL-l-2-BENZISOXAZOLE, A NEW TYPE OF
ANTICONVULSANT-DRUG: ELEaROENCEPHALOGRAPHIC PROFILE.
000142 01-03
SULFHYDRYL
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL
GROUPS IN THE ACTIVE SITE. (UNPUBLISHED PAPER).
001066 02-01
Ptychopharmocology Abstracts
SULFIRAM
CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL-
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY
002095 02-11
SULPHO-ADENOSYL-L-METHIONINE
THE ANTIDEPRESSANT AQION OF SULPHO-ADENOSYL-L-METHIONINE
(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE:
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-AaiON
003150 03-07
SULPIRIDE
BIOAVAILABILITY OF 14C SULPIRIDE IN DOGS.
000017 01-03
STUDIES ON THE DISTRIBUTION OF 14C SULPIRIDE AND ITS METABOLITES
IN THE RAT AND GUINEA-PIG.
000078 01-03
EFFEaS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE
(3H)AP0M0RPHINE BINDING.
000099 01-03
STUDY ON VISUALLY-EVOKED-POTENTIALS IN SCHIZOPHRENIC-PATIENTS
IN SULPIRIDE THERAPY.
000550 01-08
EFFEQS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
BIOAVAILABILITY OF SULPIRIDE TABLET AND CAPSULE IN DOGS.
001 101 02-03
METOCLOPRAMIDE AND SULPIRIDE AS SELEQIVE BLOCKING-AGENTS
PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS.
001102 02-03
NEUROPHYSIOLOGICAL- STUDY OF TWO 0 ANISAMIDE DERIVATIVES
SULPIRIDE AND SULTOPRIDE.
001170 02-03
EFFEQS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL MONOAMINERGIC MECHANISMS.
001240 02-03
EFFEQ OF LONG-TERM-TREATMENT WITH HALOPERIDOL AND SULPIRIDE
ON DIFFERENT TYPES OF DOPAMINERGIC-RECEPTORS.
001512 02-03
CONTROLLED-TRIAL OF SULPIRIDE IN CHRONIC SCHIZOPHRENIC-PATIENTS
001914 02-08
CLINICAL USE OF SULPIRIDE IN ITALY.
002187 02-11
COMPARATIVE-STUDIES ON THE METABOLISM AND THE DISTRIBUTION OF
SULPIRIDE AND SULTOPRIDE.
002240 02-13
SHORT-TERM AND LONG-TERM EFFEQS ON GABA AND DOPAMINE
NEURONS DURING TREATMENT WITH SULPIRIDE.
002311 02-13
TARDIVE-HYPERKINESIA. EFFECTS OF SULPIRIDE AND GABA SYSTEM
AGONISTS.
002405 02-15
THE EFFECT OF GUANOSINE-NUCLEOTIDES ON (3H)SULPIRIDE BINDING TO
RAT STRIATAL MEMBRANES.
002722 03-03
EFFECT OF CHRONIC SULPIRIDE ON STRIATAL SPIPERONE BINDING.
003720 04-03
CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF
(3H)SULPIRIDE AND (3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS.
004032 04-03
WHY DOES SULPIRIDE NOT BLOCK THE EFFEQ OF DOPAMINE ON THE
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE?
004055 04-03
A CLINICAL AND PHARMACODYNAMIC EVALUATION OF SULPIRIDE.
004338 04-08
BASAL PROLACTINAEMIA AND RESPONSES TO TRH AND SULPIRIDE IN
DIFFERENT CATEGORIES OF MALE SEXUAL-DYSFUNCTIONS.
004503 04-13
SULPIRIDE-INDUCED
INHIBITION OF SULPIRIDE-INDUCED PROLACTIN SECRETION BY
DIHYDROERGOCRISTINE IN MAN.
002277 02-13
SULTHIAME
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
SULTOPRIDE
NEUROPHYSIOLOGICAL-STUDY OF TWO 0 ANISAMIDE DERIVATIVES:
SULPIRIDE AND SULTOPRIDE.
001170 02-03
SULTOPRIDE (BARNETIL).
001920 02-08
COMPARATIVE-STUDIES ON THE METABOLISM AND THE DISTRIBUTION OF
SULPIRIDE AND SULTOPRIDE.
002240 02-13
$1430
VOLUME 19, SUBJECT INDEX
Subject Index
ON THE EFFECTS OF SULTOPRIDE ADMINISTERED IN LOW-DOSAGES TO
OLDER CHILDREN AND ADOLESCENTS.
003230 03-09
SUPERIOR
A COMPARATIVE-STUDY OF THE PHARMACOLOGICAL-PROPERTIES OF THE
POSITIVE POTENTIAL RECORDED FROM THE SUPERIOR CERVICAL
GANGLIA OF SEVERAL SPECIES.
003779 04-03
RELATIVE ACTIVITIES OF SUBSTANCES RELATED TO 5
HYDROXYTRYPTAMINE AS DEPOLARIZING-AGENTS OF SUPERIOR
CERVICAL GANGLION CELLS.
004047 04-03
SUPERIOR-CERVICAL-OANOLION
INHIBITION OF ACH RELEASE BY PROSTAGLANDIN-El IN THE RABBIT
SUPERIOR-CERVICAL-GANGLION .
001205 02-03
EVALUATION OF THE EFFECT OF DRUGS ON DOPAMINE METABOLISM IN
THE RAT SUPERIOR-CERVICAL-GANGLION BY HPLC WITH
ELECTROCHEMICAL-DETECTION .
001530 02-03
SUPERIOR-COLLICULUS
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE
CAT. (PH.D. DISSERTATION).
001179 02-03
DISSOCIATION OF D-AMPHETAMINE-INOUCED LOCOMOTOR-ACTIVITY AND
STEREOTYPED-BEHAVIOUR BY LESIONS OF THE SUPERIOR-COLLICULUS.
001755 02-04
SUPERRESPONSIVE
NO EVIDENCE FOR INCREASED DOPAMINE-RECEPTOR BINDING IN
SUPERRESPONSIVE MICE AFTER A SINGLE-DOSE OF NEUROLEPTICS.
001292 02-03
SUPERSENSITIVE
NEUROLEPTIC-INDUCED ACUTE DYSTONIC REACTIONS MAY BE DUE TO
ENHANCED DOPAMINE RELEASE ON TO SUPERSENSITIVE
POSTSYNAPTIC-RECEPTORS.
002789 03-03
SUPERSENSITIVITY
EVIDENCE FOR A RECEPTOR SUPERSENSITIVITY FOLLOWING IMPAIRMENT
OF CENTRAL SEROTONERGIC ACTIVITY IN THE RABBIT.
000041 01-03
MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS:
MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN.
000068 01-03
HYPOPHYSECTOMY PREVENTS THE STRIATAL DOPAMINE-RECEPTOR
SUPERSENSITIVITY PRODUCED BY CHRONIC HALOPERIDOL TREATMENT.
000132 01-03
A NEUROENDOCRINE-STUDY OF SUPERSENSITIVITY IN TARDIVE-
DYSKINESIA.
000908 01-16
PRESYNAPTIC DOPAMINE-RECEPTORS: INSENSITIVITY TO KAINIC-ACID
AND THE DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING CHRONIC
HALOPERIDOL.
001117 02-03
DOPAMINE SYNTHESIS: TOLERANCE TO HALOPERIDOL AND
SUPERSENSITIVITY TO APOMORPHINE DEPEND ON PRESYNAPTIC-
RECEPTORS.
001129 02-03
AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL
DOPAMINE-RECEPTORS AFTER VARIOUS TREATMENTS WITH
ANTAGONISTS OR AGONISTS.
001350 02-03
DENERVATION SUPERSENSITIVITY TO SEROTONIN IN THE FACIAL
NUCLEUS.
001364 02-03
GABA FACILITATION BY NORADRENALINE SHOWED SUPERSENSITIVITY IN
CEREBELLUM AFTER 6 HYDROXYDOPAMINE.
001382 02-03
PRESYNAPTIC DOPAMINE-RECEPTORS IN STRIATAL NERVE-ENDINGS:
ABSENCE OF HALOPERIDOL-INDUCED SUPERSENSITIVITY.
001424 02-03
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN
MICE.
001435 02-03
SUPERSENSITIVITY AND THE EFFEQS OF LONG-TERM AMPHETAMINE IN
THE RAT NIGROSTRIATAL SYSTEM. (PH.D. DISSERTATION).
001485 02-03
INHIBITION OF NEUROLEPTIC-INDUCED DOPAMINE-RECEPTOR
SUPERSENSITIVITY BY CYCLO-LEU-GLY.
001576 02-04
SUPERSENSITIVITY TO APOMORPHINE IN EXPERIMENTALLY-INDUCED
HYPOKINESIA AND DRUG-INDUCED MODIFICATIONS OF THE
APOMORPHINE RESPONSE.
001814 02-04
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE-
DECANOATE TREATMENT.
001820 02-04
CORRELATION BETWEEN DAILY DOSAGE OF CHLORPROMAZINE AND
SUBSEQUENT SUPERSENSITIVITY.
001845 02-05
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL-
NERVOUS-SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE-
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS).
002459 02-15
DOPAMINE-RECEPTOR SUPERSENSITIVITY IN THE CORPUS-STRIATUM
FOLLOWING CHRONIC ELEVATION OF BRAIN GAMMA AMINOBUTYRIC-
ACID.
002716 03-03
BLINK RATES AND RECEPTOR SUPERSENSITIVITY,
003022 03-04
SUPERSENSITIVITY TO THE BEHAVIORAL-EFFECTS OF OPIATE
ANTAGONISTS.
003096 03-04
DENERVATION SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN RATS
FOLLOWING SPINAL TRANSECTION AND 5,7 DIHYDROXYTRYPTAMINE
INJECTION.
003722 04-03
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC-
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE
ANTIDEPRESSANT MIANSERIN.
003745 04-03
DOPAMINE-ACTIVATED ADENYLATE-CYCLASE OF SPINAL-CORD:
SUPERSENSITIVITY FOLLOWING TRANSECTION OF THE CORD.
003800 04-03
THE DOPAMINE-RECEPTOR COMPLEX: BIOCHEMICAL-CONSEQUENCES OF
SUPERSENSITIVITY INDUCED BY TREATMENT WITH 6
HYDROXYDOPAMINE OR MORPHINE.
003958 04-03
LITHIUM EFFECTS ON HALOPERIDOL-INDUCED PRESYNAPTIC AND
POSTSYNAPTIC DOPAMINE-RECEPTOR SUPERSENSITIVITY.
004244 04-04
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN:
NEUROCHEMICAL- STUDIES IN AN ANIMAL-MODEL OF TARDIVE-
DYSKINESIA.
004268 04-05
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY?
004553 04-13
SUPIDIMIDE
EFFEQS OF SUPIDIMIDE (CG-3033) ON OBJECTIVE AND SUBJEQIVE SLEEP
PARAMETERS (A SLEEP LABORATORY STUDY).
004567 04-14
SUPPRESS
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR,
002945 03-04
ERGOT DRUGS SUPPRESS PLASMA PROLACTIN AND LAQATION BUT NOT
AGGRESSION IN PARTURIENT MICE.
003159 03-07
METERGOLINE AND CYPROHEPTADINE SUPPRESS PROLACTIN RELEASE BY
A NON-5-HYDROXYTRYPTAMINERGIC, NONDOPAMINERGIC
MECHANISM.
003732 04-03
SUPPRESSED
ALCOHOL AND CHLORDIAZEPOXIDE INCREASE SUPPRESSED AGGRESSION
IN MICE.
000434 01-04
THE PRESYNAPTIC STIMULATING EFFEQ OF ACETYLCHOLINE ON
DOPAMINE RELEASE IS SUPPRESSED DURING AQIVATION OF
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT.
002733 03-03
EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHET AMINE ON RESPONDING
SUPPRESSED BY CONDITIONED PUNISHMENT.
003105 03-04
SUPPRESSES
SUBSTANCE-P SUPPRESSES STRESS-INDUCED EATING.
001725 02-04
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC
NEURONS.
002880 03-03
CHOLINE REVERSES NALOXONE-INDUCED DECREASES IN HIPPOCAMPAL
ACETYLCHOLINE CONTENT AND SUPPRESSES ESCAPE-BEHAVIOR IN
OPIATE-DEPENDENT RATS.
004076 04-04
NALOXONE SUPPRESSES FEEDING AND DRINKING BUT NOT WHEEL
RUNNING IN RATS.
004080 04-04
NALOXONE SUPPRESSES FOOD/WATER CONSUMPTION IN THE DEPRIVED
CAT.
0041 14 04-04
SUPPRESSING
THE SITE OF ACTION OF NALOXONE IN SUPPRESSING FOOD AND WATER
INTAKE IN RATS.
004146 04-04
S-431
Subject Index
Ptychopharmacology Abstracts
I
'X
.14;
.^
SUPPRESSION
SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA-
ADRENOCEPTOR ANTAGONISTS: EVIDENCE AGAINST GABA
MEDIATION.
000024 01-03
SUPPRESSION OF EVOKED AND SPONTANEOUS RELEASE OF
NEUROTRANSMIHERS IN VIVO BY MORPHINE.
000058 01-03
ENHANCED SUPPRESSION OF CONDITIONED AVOIDANCE RESPONSE BY
HALOPERIDOL BUT NOT PHENOXYBENZAMINE IN RATS WITH
BILATERAL PARAFASCICULAR LESIONS.
000334 01-04
POSSIBLE INVOLVEMENT OF CYCLIC-AMP AND FRONTAL-CORTEX IN
AMITRIPTYLINE MEDIATED SUPPRESSION OF THE HYPOTENSIVE-EFFEa
OF CLONIDINE.
001259 02-03
CONDITIONED SUPPRESSION OF DRINKING: A MEASURE OF THE CR
ELICITED BY A LITHIUM CONDITIONED FLAVOR.
001747 02-04
THE EFFEQS OF CHLORDIAZEPOXIDE-HCL ADMINISTRATION UPON
PUNISHMENT AND CONDITIONED SUPPRESSION IN THE RAT.
001757 02-04
MECHANISMS OF OPIATE ANALGESIA AND THE ROLE OF ENDORPHINS IN
PAIN SUPPRESSION. (UNPUBLISHED PAPER).
002275 02-13
SUPPRESSION OF AMPHETAMINE-INDUCED EEG AROUSAL IN THE
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS.
002683 03-03
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPACTA AND
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE
SPONTANEOUS NEURONAL ACTIVITIES IN THE RAT.
002718 03-03
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. VII. SUPPRESSION OF SYMPATHETIC RESPONSES BY
DEXAMETHASONE.
002802 03-03
SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI-
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS.
002871 03-03
SUPPRESSION OF DRINKING BY NALOXONE IN THE RAT: A FURTHER
CHARACTERIZATION.
002963 03-04
SMALL-DOSE INTRAVENOUS HEROIN FACILITATES HYPOTHALAMIC SELF-
STIMULATION WITHOUT RESPONSE SUPPRESSION IN RATS.
002999 03-04
CORTICAL RECOVERY FROM EFFEQS OF MONOCULAR DEPRIVATION:
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6
HYDROXYDOPAMINE.
003024 03-04
CLONIDINE ANALGESIA AND SUPPRESSION OF OPERANT RESPONDING:
DISSOCIATION OF MECHANISM.
003046 03-04
SUPPRESSION OF AQIVE SLEEP BY CHRONIC-TREATMENT WITH
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT:
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT.
003056 03-04
THE USE OF CONDITIONED SUPPRESSION TO EVALUATE THE NATURE OF
NEUROLEPTIC-INDUCED AVOIDANCE-DEFICITS.
004070 04-04
SUPPRESSION OF ALCOHOL DRINKING WITH BRAIN ALDEHYDE-
DEHYDROGENASE INHIBITION.
004220 04-04
SUPPRESSION OF MORPHINE ABSTINENCE IN HEROIN AODIQS BY BETA
ENDORPHIN.
004489 04-11
SUPPRESSIVE
OPIATE-RECEPTORS MAY MEDIATE THE SUPPRESSIVE BUT NOT THE
EXCITATORY AQION OF AQH ON MOTOR-AQIVITY IN RATS.
000337 01-04
TOLERANCE TO SUPPRESSIVE EFFECTS OF CHLORDIAZEPOXIOE ON
OPERANT-BEHAVIOR: LACK OF CROSS-TOLERANCE TO PENTOBARBITAL.
000356 01-04
SUPPRESSIVE EFFEQ OF MORPHINE ON SERUM GONADOTROPIN LEVELS
IN CASTRATED RATS.
001393 02-03
SUPRAMOLECULAR
GABA-RECEPTORS AS SUPRAMOLECULAR UNITS.
002819 03-03
SUPRANUCLEAR
PROGRESSIVE SUPRANUCLEAR PALSY, COMPUTED-TOMOGRAPHY, AND
RESPONSE TO ANTIPARKINSONIAN-DRUGS.
003322 03-11
PROGRESSIVE SUPRANUCLEAR PALSY: PNEUMOENCEPHALOGRAPHY,
ELEaRONYSTAGMOGRAPHY AND TREATMENT WITH METHYSERGIDE.
003355 03-11
SUPRASPINAL
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES:
EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION
IN THE ANESTHETIZED CAT.
001203 02-03
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED
CAT.
002740 03-03
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS:
LACK OF EFFEa BY STRYCHNINE AND BICUCULLINE.
003778 04-03
SUPRASYLVIAN
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
SUROERY
THE LONG-TERM RESULTS OF STEREOTAXIC SURGERY AND L-DOPA
THERAPY IN PATIENTS WITH PARKINSONS-DISEASE: A 10- YEAR
FOLLOWUP STUDY.
000693 01-11
MODERN CONCEPTS IN PSYCHIATRIC SURGERY.
002551 02-17
SUROICAL
SURGICAL MANIPULATION OF THE UTERINE ENVIRONMENT OF RAT
FETUSES.
002478 02-16
SURINAM
PSYCHOTOMIMETIC USE OF TOBACCO IN SURINAM AND FRENCH-
GUIANA.
002592 02-17
SURROGATE
CANALIZATION OF AROUSAL IN THE PREWEANLING RAT: EFFEaS OF
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMUU.
002965 03-04
SURVECTOR
PHARMACOLOGY OF THE SURVEQOR.
001085 02-02
THE PLACE OF SURVEQOR AMONG THE VARIOUS DRUGS USED IN
TREATMENT OF MOOD-DISORDERS.
001969 02-09
INHIBITION AND APATHY: TREATMENT WITH SURVEQOR.
002066 02-10
SURVECTOR AND SLEEP-DISORDERS: SLEEP-WALKING, NIGHTMARES,
AND NIGHT-TERRORS.
002110 02-11
CHEMICAL STRUCTURE OF SURVECTOR. STRUCTURE-ACTIVITY
RELATIONSHIP.
002262 02-13
SURVEILLANCE
EUHYPNOS-FORTE, HIGH-DOSE TEMAZEPAM FOR RESISTANT INSOMNIA:
POSTMARKETING SURVEILLANCE IN 10,057 PATIENTS UNRESPONSIVE
TO CONVENTIONAL HYPNOTIC DOSAGE.
002324 02-14
SURVIVAL
USE OF SURVIVAL CURVES IN ANALYSIS OF ANTIPSYCHOTIC RELAPSE-
STUDIES.
002481 02-16
THE TWO SURVIVAL CASES OF ALPHA-PAHERN COMA CAUSED BY
LARGE AMOUNTS OF HYPNOTICA AND NEUROLEPTICA.
004608 04-15
SUSCEPTIBILITY
EFFECTS OF KINDLING OR BRAIN-STIMULATION ON PENTYLENETETRAZOL-
INDUCED CONVULSION SUSCEPTIBILITY.
000037 01-03
REPEATED ELECTROCONVULSIVE-SHOCK DOES NOT INCREASE THE
SUSCEPTIBILITY OF RATS TO A CAGE CONVULSANT
(ISOPROPYLBICYCLOPHOSPHATE) .
001184 02-03
THE EFFECTS OF NOOTROPIC-DRUGS ON THE SUSCEPTIBILITY TO
AUDIOGENIC-SEIZURES IN RATS.
001571 02-04
EFFECT OF RO-4-1284 ON AUDIOGENIC-SEIZURE SUSCEPTIBILITY AND
INTENSITY IN EPILEPSY-PRONE RATS.
003865 04-03
EFFECTS OF OLFACTORY-BULBECTOMY AND PERIPHERALLY-INDUCED
ANOSMIA ON THERMOREGULATION IN THE RAT: SUSCEPTIBILITY TO
ANTIDEPRESSANT-DRUGS.
00411304-04
SUSCEPTIBLE
AUDIOGENIC-SEIZURES: INCREASED BENZODIAZEPINE-RECEPTOR BINDING
IN A SUSCEPTIBLE STRAIN OF MICE.
000252 01-03
DIFFERENCES IN ACTIVITY IN CEREBRAL METHYLTRANSFERASES AND
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE
AND RESISTANT MICE AND DEERMICE.
000377 01-04
SUSTAINED-RELEASE
COMPARISON OF SUSTAINED-RELEASE AND STANDARD
METHYLPHENIDATE IN THE TREATMENT OF MINIMAL-BRAIN-
DYSFUNCTION.
000732 01-11
S-432
VOLUME 19, SUBJECT INDEX
Subjact Indax
SWEDISH
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMITTED BY THE DRUG
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES.
003599 03-17
SWIMMING
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH
PSYCHOSTIMULANTS: II. EFFECT OF METHAMPHETAMINE ON
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC
SUBSTRATES.
001613 02-04
SWITCH
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH
IN THE ELECTROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO
AUTORECEPTOR STIMULATION.
000046 01-03
SWITZERLAND
METHADONE TREATMENT OF HEROIN ADDICTS IN SWITZERLAND.
004452 04-1 1
SYDNOCARB
THE PHARMACOLOGICAL ACTION OF THE OPTICAL-ISOMERS OF
SYDNOCARB.
003681 04-02
SYDNONIMINE
THE IMMUNOSTIMULANT ANTINEOPLASTIC ACTION OF SOME
PSYCHOTROPIC-DRUGS OF THE SYDNONIMINE SERIES.
001520 02-03
SYMPATHECTOMY
GASTRIC AND PYLORIC MOTOR-RESPONSE TO SYMPATHETIC-NERVE
STIMULATION AFTER CHEMICAL SYMPATHECTOMY. (UNPUBLISHED
PAPER).
001337 02-03
SYMPATHETIC
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. III. DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES.
000025 01-03
CALCIUM LOCALIZATION IN THE SYMPATHETIC GANGLION OF THE
BULLFROG AND EFFECTS OF CAFFEINE.
000098 01-03
BIOCHEMICAL-CHARACTERIZATION OF THE RAT SYMPATHETIC
GANGLION: PHARMACOLOGICAL-EFFECTS OF RESERPINE ON
GANGLIONIC CATECHOL^MINES.
000153 01-03
ENKEPHALINS PRESYNAPTICALLY INHIBIT CHOLINERGIC TRANSMISSION
IN SYMPATHETIC GANGLIA.
000167 01-03
CHRONIC SYMPATHETIC DENERVATION INCREASES MUSCARINIC-
CHOLINOCEPTOR BINDING IN THE RAT SUBMAXILLARY-GLAND.
000235 01-03
CHARACTERIZATION OF LRF-LIKE IMMUNOREACTIVITY IN THE FROG
SYMPATHETIC GANGLIA: NONIDENTITY WITH LRF-DECAPEPTIDE.
(UNPUBLISHED PAPER).
001018 02-01
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIREQ VASODILATOR
AaiON AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRICTION.
001109 02-03
INTRACELLULAR OBSERVATIONS ON THE EFFECTS OF MUSCARINIC
AGONISTS ON RAT SYMPATHETIC NEURONES. •
001143 02-03
MUSCARINIC-RECEPTORS IN RAT SYMPATHETIC GANGLIA.
001144 02-03
CENTRAL SYMPATHETIC REACTIVITY INHIBITED BY INDORAMIN.
001193 02-03
EFFEQ OF GABA AGONIST AND ANTAGONISTS ON CARDIOVASCULAR
AND SYMPATHETIC RESPONSES IN SHR AND WKY RATS.
(UNPUBLISHED PAPER).
001224 02-03
PRESYNAPTIC AQIONS OF 4 AMINOPYRIDINE AND GAMMA
AMINOBUTYRIC-ACID ON RAT SYMPATHETIC GANGLIA IN VITRO.
001244 02-03
MATURATION OF SYMPATHETIC NEUROTRANSA/.ISSION IN THE RAT
HEART. VII. SUPPRESSION OF SYMPATHETIC RESPONSES BY
DEXAMETHASONE.
002802 03-03
BETA ENDORPHIN-INDUCED HYPERGLYCEMIA IS MEDIATED BY INCREASED
CENTRAL SYMPATHETIC OUTFLOW TO ADRENAL-MEDULLA.
002924 03-03
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC
SCHIZOPHRENICS. II. WITH REFERENCE TO SYMPATHETIC NEURONAL
FUNQION.
003416 03-13
5 HYDROXYTRYPT AMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF
BULLFROG SYMPATHETIC GANGLION CELLS.
003710 04-03
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NiaiTATING MEMBRANE OF THE CAT.
003822 04-03
THE EXCITATORY EFFEQ OF ATROPINE ON THE NEURONS OF THE FROG
SYMPATHETIC GANGLIA.
004041 04-03
SYMPATHETIC-NERVE
GASTRIC AND PYLORIC MOTOR-RESPONSE TO SYMPATHETIC-NERVE
STIMULATION AFTER CHEMICAL SYMPATHECTOMY. (UNPUBLISHED
PAPER).
001337 02-03
CENTRALLY INDUCED CARDIOVASCULAR AND SYMPATHETIC-NERVE
RESPONSES TO BRADYKININ IN RATS.
003099 03-04
SYMPATHETIC-NERVOUS-SYSTEM
THE EFFECTS OF TWO ANALOGS OF DOPAMINE ON GANGLIONIC
TRANSMISSION IN THE SYMPATHETIC-NERVOUS-SYSTEM.
000162 01-03
THE SYMPATHETIC-NERVOUS-SYSTEM AND HYPERTENSION: A POSITION
PAPER. (UNPUBLISHED PAPER).
002250 02-13
THE HYPERACTIVE-CHILD-SYNDROME: PERIPHERAL SYMPATHETIC-
NERVOUS-SYSTEM FUNaiON AND THE EFFEQ OF D-AMPHETAMINE.
003340 03-11
SYMPATHOADRENAL
METABOLIC AND SYMPATHOADRENAL ABNORMALITIES IN THE OBESE
ZUCKER RAT: EFFECT OF CHRONIC PHENOXYBENZAMINE TREATMENT.
003905 04-03
SYMPATHOMIMETIC
A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC
AGONISTS: CHARACTERISTICS.
002670 03-03
SYMPATHOMIMETIC- AMINES
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELEQIVE
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR-
STIMULATION INDUCED BY INDIREQLY ACTING SYMPATHOMIMETIC-
AMINES IN MICE.
000492 01-04
SYMPATHOMIMETIC-AMINES AND TRICYCLIC-ANTIDEPRESSANT DRUGS.
004678 04-16
SYMPTOM-PROFILE-ANALYSIS
A SYMPTOM-PROFILE-ANALYSIS OF ANTIPSYCHOTIC-DRUG TREATMENT:
NONPARAMETRIC MULTIDIMENSIONAL TECHNIQUE.
003196 03-08
SYMPTOMATIC
EVALUATION OF SYMPTOMATIC TREATMENT OF HYPERACTIVE-BEHAVIOR
BY STIMULANT-DRUGS.
002134 02-11
SYMPTOMATOLOGY
BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH
KAINIC-ACID-INDUCED LESIONS OF STRIATAL NEURONS ~ WITH A
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS-
DISEASE.
000463 01-04
SYMPTOMS
THE RELATIONSHIP BETWEEN THE THIORIDAZINE LEVEL IN THE PLASMA
AND SYMPTOMS OF PARANOID SCHIZOPHRENIA.
000546 01-08
THE ROLE OF CHOLINERGIC-SUPERSENSITIVITY IN THE MEDICAL
SYMPTOMS ASSOCIATED WITH WITHDRAWAL OF ANTIPSYCHOTIC-
DRUGS.
000869 01-15
THE OCCURRENCE OF TARDIVE EXTRAPYRAMIDAL SYMPTOMS IN
SCHIZOPHRENIC-PATIENTS UNDERGOING PROLONGED NEUROLEPTIC
TREATMENT.
000885 01-15
DIFFERENTIAL-EFFECTS OF AMPHETAMINE AND NEUROLEPTICS ON
NEGATIVE VS. POSITIVE SYMPTOMS IN SCHIZOPHRENIA.
001906 02-08
EFFEQ OF TRICYCLIC-ANTIDEPRESSANTS ON INDIVIDUAL SYMPTOMS.
002052 02-09
CLINICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG-
RESISTANCE.
003245 03-09
BENZODIAZEPINE WITHDRAWAL SYMPTOMS AND PROPRANOLOL.
003543 03-15
ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN ATTENTION-
DYSFUNCTION TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA.
004316 04-08
CHANGES IN PSYCHOPATHOLOGIC SYMPTOMS DURING 20 DAYS OF
TREATMENT WITH ANTIDEPRESSANTS AND NEUROLEPTIC-DRUGS.
004415 04-09
WITHDRAWAL SYMPTOMS AFTER GRADUATED CESSATION OF
IMIPRAMINE IN CHILDREN.
004630 04-15
ANOREXIA-NERVOSA. SYMPTOMS, COURSE AND POSSIBILITIES FOR
TREATMENT.
004711 04-17
S-433
Subject Index
Psychopharmacology Abstract*
iijjj
'HIT
D,.
1
5
.^^
fe
SYNAPSE
EVIDENCE SUGGESTING A TRANSMIHER OR NEUROMODULATORY ROLE
FOR SUBSTANCE-P AT THE FIRST SYNAPSE OF THE BARORECEPTOR
REFLEX.
001264 02-03
ELECTROPHYSIOLOGICAL-CHANGES AT A CENTRAL NORADRENERGIC
SYNAPSE DURING THALLIUM TOXICOSIS.
001848 02-05
SYNAPSES
LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES
OF THE DEVELOPING CHICK RETINA.
000065 01-03
THE ULTRASTRUCTURAL CHANGES OF SYNAPSES IN RAT FOLLOWING
LONG-TERM ADMINISTRATION OF THE NEUROLEPTICS RESERPINE AND
HALOPERIDOL.
000795 01-13
CENTRAL MONOAMINE SYNAPSES AS SITES OF AQION FOR ERGOT
DRUGS.
001238 02-03
LYSERGIC-ACID-DIETHYLAMIDE: MORPHOLOGICAL-STUDY OF ITS EFFEQ
ON SYNAPSES.
001315 02-03
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND
GANGLIONIC SYNAPSES.
002870 03-03
SYNAPTIC
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. III. DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES.
000025 01-03
ADENINE-NUCLEOTIDES AND SYNAPTIC TRANSMISSION IN THE IN VITRO
RAT HIPPOCAMPUS.
000080 01-03
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
INTERACTION OF DIAZEPAM WITH SYNAPTIC TRANSMISSION IN THE IN
VITRO RAT HIPPOCAMPUS.
000178 01-03
PHENYLACETATE AND BRAIN-DYSFUNCTION IN EXPERIMENTAL
PHENYLKETONURIA: SYNAPTIC DEVELOPMENT.
000191 01-03
REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 1251 TYR8-
SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES.
000259 01-03
EFFECTS OF LEAD EXPOSURE DURING DEVELOPMENT ON NEOCORTICAL
DENDRITIC AND SYNAPTIC STRUCTURE.
000525 01-05
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT.
001104 02-03
DEPRESSION AND FACILITATION OF SYNAPTIC RESPONSES IN CAT
DORSAL-HORN BY SUBSTANCE-P ADMINISTERED INTO SUBSTANTIA-
GELATINOSA.
001191 02-03
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC
MEMBRANES.
001208 02-03
ASCORBIC-ACID. AN ENDOGENOUS FACTOR REQUIRED FOR
ACETYLCHOLINE RELEASE FROM THE SYNAPTIC VESICLES.
001322 02-03
DOPAMINE-RECEPTOR: FROM SYNAPTIC MEMBRANES TO
SOLUBILIZATION.
001326 02-03
FURTHER CHARAQERIZATION OF THE BINDING OF SUBSTANCE-P TO A
FRACTION FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES.
001394 02-03
INHIBITORY ACTION OF ADENOSINE ON SYNAPTIC TRANSMISSION IN THE
HIPPOCAMPUS OF THE GUINEA-PIG IN VITRO.
001401 02-03
BENZODIAZEPINE-RECEPTORS: AUTORADIOGRAPHICAL AND
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN
REGIONS OF GABAERGIC SYNAPTIC CONTAQS.
002643 03-01
INTERACTIONS OF TRICYCLIC-ANTIDEPRESSANTS WITH A SYNAPTIC ION-
CHANNEL.
002660 03-03
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA,
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE,
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION.
002674 03-03
SELECTIVE EFFECTS OF LSD AND HYPERTHERMIA ON THE SYNTHESIS OF
SYNAPTIC PROTEINS AND GLYCOPROTEINS.
002721 03-03
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
ANTIANXIETY-AGENTS AND SYNAPTIC TRANSMISSION IN THE BRAIN:
ELEQROPHYSIOLOGICAL- STUDIES. (PH.D. DISSERTATION).
002840 03-03
EFFEaS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC
MEMBRANES.
002888 03-03
CALMODULIN: ITS ROLE IN SYNAPTIC TRANSMISSION.
003162 03-07
SYNAPTIC AND BEHAVIOURAL-AQIONS OF ANTIDEPRESSANT-DRUGS:
FURTHER THOUGHTS ON THE IMPLICATIONS FOR THEORIES OF
DEPRESSION.
003229 03-09
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT.
003734 04-03
PRESYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION IN HELIX-
POMATIA: THE EFFECTS OF SEROTONIN AND DOPAMINE
ANTAGONISTS.
003869 04-03
DIFFERENTIAL-EFFEaS OF PENTOBARBITAL AND ETHER ON THE SYNAPTIC
TRANSMISSION OF THE HIPPOCAMPAL-CAl -REGION IN THE RAT.
003903 04-03
THE EFFECT OF ACETYLCHOLINE RELEASE ON CHOLINE FLUXES IN
ISOLATED SYNAPTIC TERMINALS.
003924 04-03
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO
SYNAPTIC MEMBRANES.
004000 04-03
5' TRIPHOSPHATE RECYCLES INDEPENDENTLY OF ACETYLCHOLINE IN
CHOLINERGIC SYNAPTIC VESICLES
004063 04-03
SYNAPTOSOMAL
ANTIHISTAMINE EFFEQ ON SYNAPTOSOMAL UPTAKE OF SEROTONIN,
NOREPINEPHRINE AND DOPAMINE.
QQQQ35 01-03
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT
PROPERTIES.
000084 01-03
CHARAQERIZATION OF 3H GABA-RECEPTOR BINDING TO RAT-BRAIN
SYNAPTOSOMAL MEMBRANES: EFFEQ OF NONGABAERGIC
COMPOUNDS.
000139 01-03
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL
ALSO AFFEQ THE UPTAKE OF DOPAMINE, NORADRENALINE AND
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS,
000171 01-03
AQION OF BARBITURATES ON AQIVITY OF ACETYLCHOLINESTERASE
FROM SYNAPTOSOMAL MEMBRANES.
000224 01-03
LONG-TKM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN
MICE.
000287 01-03
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS.
000330 01-03
DIVERGENT RESERPINE EFFEQS ON AMFONELIC-ACID AND
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE
FORMATION FROM PHENYLALANINE.
001113 02-03
PHENCYCLIDINE-INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-
HYDROXYLASE AQIVITY.
001304 02-03
INTERAQIONS OF NARCOTICS WITH SYNAPTOSOMAL CALCIUM
TRANSPORT.
002712 03-03
INHIBITION OF SYNAPTOSOMAL CALCIUM UPTAKE BY ETHANOL.
003827 04-03
EFFEQ OF INHIBITORS OF GABA-AMINOTRANSFERASE ON THE
METABOLISM OF GABA IN BRAIN TISSUE AND SYNAPTOSOMAL
FRAQIONS.
003914 04-03
THE HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPEQ TO THE
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRAQION
ABUNDANT IN PRESYNAPTIC MEMBRANES
004028 04-03
SYNAPTOSOMES
EFFECTS OF PSYCHOTROPIC-ORUGS ON THE DISTRIBUTION OF 3H
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES
S-434
VOLUME 19, SUBJECT INDEX
Sub|«ct Index
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE
RELEASE.
000067 01-03
EFFECT OF MORPHINE ON CALCIUM UPTAKE BY LYSED SYNAPTOSOMES.
000117 01-03
EFFEQS OF CHLORDIAZEPOXIDE ON DEPOLARIZATION-INDUCED CALCIUM
INFLUX INTO SYNAPTOSOMES.
000183 01-03
THRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES.
001078 02-02
EFFEaS OF GABA AND DIAZEPAM ON 3H SEROTONIN RELEASE FROM
HIPPOCAMPAL SYNAPTOSOMES.
001116 02-03
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 02-03
THE EFFEa OF PSYCHOTROPIC-SUBSTANCES AND NARCOTIC ANALGESIC-
DRUGS ON 14C NORADRENALINE UPTAKE BY SYNAPTOSOMES OF THE
CEREBRAL-CORTEX OF RATS.
001363 02-03
UPTAKE OF PIPERIDINE AND PIPECOLIC-ACID BY SYNAPTOSOMES FROM
MOUSE-BRAIN.
001396 02-03
IN VIVO CHANGES IN THE GABA CONTENT OF NERVE-ENDINGS
(SYNAPTOSOMES) INDUCED BY INHIBITORS OF GABA UPTAKE.
001540 02-03
EFFEQS OF NEOMYCIN ON CALCIUM AND POLYPHOSPHOINOSITIDE
METABOLISM OF GUINEA-PIG SYNAPTOSOMES.
002741 03-03
EFFEQ OF TAURINE ON 45CA2 ACCUMULATION IN RAT BRAIN
SYNAPTOSOMES.
002855 03-03
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES.
002879 03-03
RELEASE OF ACETYLCHOLINE FROM RAT-BRAIN SYNAPTOSOMES
STIMULATED WITH LEPTINOTARSIN, A NEW NEUROTOXIN.
003148 03-06
INHIBITION OF (3H)DIAZEPAM BINDING BY AN ENDOGENOUS FRAQION
FROM RAT-BRAIN SYNAPTOSOMES.
003768 04-03
CATECHOLAMINE SYNTHESIS REGULATION IN HYPOTHALAMIC
SYNAPTOSOMES. (UNPUBLISHED PAPER).
003829 04-03
EFFEQ OF VERAPAMIL ON 45CA UPTAKE BY SYNAPTOSOMES.
003856 04-03
CORRELATIONS BETWEEN NA-K-ATPASE AQIVITY AND ACETYLCHOLINE
RELEASE IN RAT CORTICAL SYNAPTOSOMES.
003937 04-03
EFFEQS OF IN VIVO AMPHETAMINE ADMINISTRATION ON DOPAMINE
SYNTHESIS REGULATION IN RAT-BRAIN STRIATAL SYNAPTOSOMES.
(UNPUBLISHED PAPER).
003960 04-03
EFFEQS OF CANNABINOIDS ON CATECHOLAMINE UPTAKE AND RELEASE
IN HYPOTHALAMIC AND STRIATAL SYNAPTOSOMES.
003970 04-03
STUDIES ON THE MECHANISM-OF-AQION OF AVERMEQIN-BIA:
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM
BRAIN SYNAPTOSOMES.
003973 04-03
SYNCHRONIZATION
SYNCHRONIZATION OF EEG AQIVITY OF MALE RHESUS-MONKEYS
MACACA-MULAHA TREATED WITH OVOCYCLIN.
001312 02-03
SYNDROME
ACUTE VERSUS CHRONIC EFFEQS OF SEROTONIN UPTAKE BLOCKERS ON
POTENTIATION OF THE SEROTONIN SYNDROME.
000050 01-03
RECLASSIFICATION OF THE TARDIVE-DYSKINESIA SYNDROME.
002374 02-15
AnENUATION OF THE LITHIUM-INDUCED DIABETES-INSIPIDUS-LIKE
SYNDROME BY AMILORIDE IN RATS.
002717 03-03
NEUROLEPTIC-INDUCED SYNDROME MIMICKING MYASTHENIA-GRAVIS.
003474 03-15
A TARDIVE-DYSKINESIA-LIKE SYNDROME AFTER AMITRIPTYLINE
TREATMENT.
003552 03-15
A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDIQS DURING
WITHDRAWAL.
004445 04-1 1
HYPERVENTILATION-SYNDROME AND BETA-RECEPTOR FUNCTION ~
CLINICAL-EFFECT OF BETA BLOCKER UPON THE SYNDROME.
004459 04-11
SYNERGISM
SYNERGISM OF COMBINED LITHIUM NEUROLEPTIC THERAPY. A DOUBLE-
BUND, PLACEBO-CONTROLLED CASE-STUDY.
003165 03-08
SYNERGISTIC
SYNERGISTIC ACTIONS OF PROPANTHELINE-BROMIDE WITH CIMETIDINE
AND THIOPROPAZATE-HYDROCHLORIDE IN THE PREVENTION OF
STRESS-ULCER FORMATION IN RATS.
000064 01-03
SYNTHESES
PRODRUGS OF SOME DOPAMINERGIC 2 AMINOTETRALINS: A REVIEW OF
THEIR SYNTHESES AND NEUROCHEMICAL PROFILES.
000004 01-01
SYNTHESIS
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN-
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K -ENRICHED MEDIUM.
000123 01-03
DIMETHYLAMINOETHANOL (DEANOL) METABOLISM IN RAT-BRAIN AND
ITS EFFECT ON ACETYLCHOLINE SYNTHESIS.
000150 01-03
STREET PCP SCENE: ISSUES ON SYNTHESIS AND CONTAMINATION.
000744 01-12
GABA SYNTHESIS BY CULTURED FIBROBLASTS OBTAINED FROM PERSONS
WITH HUNTINGTONS-DISEASE.
000765 01-13
SYNTHESIS OF SOME 5 PHENYLHEXAHYDROAZEPINOINDOLES AS
POTENTIAL NEUROLEPTIC-AGENTS.
001019 02-01
SYNTHESIS OF 180 ANALOGS OF BIOGENIC-AMINES. (UNPUBLISHED
PAPER).
001044 02-01
SYNTHESIS AND PHARMACOLOGY OF 2 AMIN0-3-ETH0XYCARB0NYL-4-
PHENYLTHIOPHENE DERIVATIVES.
001083 02-02
SYNTHESIS AND ANXIOLYTIC-ACTIVITY OF A SERIES OF
PYRAZINOBENZODIAZEPINE DERIVATIVES.
001089 02-02
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM.
(UNPUBLISHED PAPER).
001122 02-03
FURTHER STUDIES ON THE INHIBITION OF MONOAMINE SYNTHESIS BY
MONOFLUOROMETHYLDOPA .
001128 02-03
DOPAMINE SYNTHESIS: TOLERANCE TO HALOPERIDOL AND
SUPERSENSITIVITY TO APOMORPHINE DEPEND ON PRESYNAPTIC-
RECEPTORS.
001129 02-03
BRAIN SEROTONIN AND 5 HYDROXYINDOLEACETIC-ACID
CONCENTRATIONS AND SEROTONIN SYNTHESIS FOLLOWING
TETRAHYDRO-BETA-CARBOLINE ADMINISTRATION IN MICE.
001152 02-03
DEVELOPMENTAL ASPECTS OF CATECHOLESTROGEN SYNTHESIS.
(UNPUBLISHED PAPER).
001282 02-03
THE ROLE OF PROTEIN SYNTHESIS IN THE HYPOTHALAMIC MECHANISM
MEDIATING PYROGEN FEVER.
001454 02-03
LONG-TERM APPLICATION OF HALOPERIDOL: EFFECT OF ANTICHOLINERGIC
TREATMENT ON THE RATE OF DOPAMINE SYNTHESIS.
001490 02-03
ROLE OF NEUROTRANSMinERS AND PROTEIN SYNTHESIS IN SHORT-
TERM AND LONG-TERM MEMORY.
001573 02-04
THE SYNTHESIS AND ACTIVITY OF CIS AND TRANS 2
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID AS
CONFORMATIONALLY RESTRICTED ANALOGUES OF GABA.
002633 03-01
PHENYLETHYLAMINE EFFECTS ON DOPAMINE SYNTHESIS. STRUCTURE-
ACTIVITY RELATIONSHIPS.
002649 03-02
EFFECTS OF AN EPINEPHRINE SYNTHESIS INHIBITOR, SKF-64139, ON THE
SECRETION OF LUTEINIZING-HORMONE IN OVARIECTOMIZED FEMALE
RATS.
002693 03-03
SELECTIVE EFFECTS OF LSD AND HYPERTHERMIA ON THE SYNTHESIS OF
SYNAPTIC PROTEINS AND GLYCOPROTEINS.
002721 03-03
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS
INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJECTION OF
CYCLOHEXIMIDE.
002780 03-03
LEVONANTRAOOL, A POTENT CANNABINOID RELATED ANALGESIC,
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL
DOPAMINE SYNTHESIS.
002786 03-03
S-435
Subject Index
Piychopharmacology Abstracts
I
M
5
Sit
tti,
fe
I
SYNTHESIS AND STRUaURE-AQIVITY RELATIONSHIP OF A
PYRIMIDOPYRIMIDINE DERIVATIVE WITH ANTIDEPRESSANT AQIVITY.
003653 04-01
SYNTHESIS AND BIOLOGICAL-AQIVITY OF HUMAN BETA ENDORPHIN
ANALOGS WITH DISULFIDE BRIDGES.
003655 04-01
SYNTHESIS OF CYTOSKELETAL PROTEINS IN BULK ISOLATED NEURONAL
PERIKARYA.
003672 04-01
SYNTHESIS AND PHARMACOLOGICAL-STUDY OF SOME ENKEPHALIN
ANALOGS IN RELATION TO THE PLURALITY OF OPIATE-RECEPTORS.
003682 04-02
SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES OF
ANALOGUES AND DERIVATIVES OF P CHLOROPHENYLALANINE.
003691 04-02
SYNTHESIS AND GABA-RECEPTOR BINDING-AQIVITY OF TWO
FLUOROAMINOMETHYLPHENOLS .
003693 04-02
SYNTHESIS OF PHENYLURETHANS OF 1,2 DIALKYL-4-PYRAZOLIDINOLS AS
ANTICONVULSANT-AGENTS.
003695 04-02
SYNTHESIS AND PHARMACOLOGICAL AQIVITY OF SOME 2 IMINO-3-
ALKYLTHIAZOLINE DERIVATIVES.
003698 04-02
SYNTHESIS OF POTENTIAL ANTICONVULSANTS: CONDENSATION OF
ISATINS WITH ACETONE AND RELATED KETONES.
003699 04-02
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF N-4 1
AZETIDINYLBUTYNYL 2 PYRROLIDONE. A HIGHLY POTENT
OXOTREMORINE-LIKE-AGENT.
003701 04-02
EFFEQ OF ALPHA METHYLPHENYLALANINE AND PHENYLALANINE ON
BRAIN POLYRIBOSOMES AND PROTEIN SYNTHESIS.
003733 04-03
EFFEQ OF INTRAVENOUS ADMINISTRATION OF 0 LYSERGIC-ACID-
DIETHYLAMIDE ON SUBSEQUENT PROTEIN SYNTHESIS IN A CELL-FREE
SYSTEM DERIVED FROM BRAIN.
003761 04-03
CATECHOLAMINE AND 5 HYDROXYTRYPTAMINE SYNTHESIS AND
METABOLISM FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF
DIBUTYRYL-CYCLIC-AMP.
003769 04-03
OPPOSITE EFFECTS OF NALOXONE ON SUBSTANCE-P-INDUCED IN BRAIN
DOPA SYNTHESIS AND IN LOCOMOTOR-AQIVITY IN RATS.
003799 04-03
CATECHOLAMINE SYNTHESIS REGULATION IN HYPOTHALAMIC
SYNAPTOSOMES. (UNPUBLISHED PAPER).
003829 04-03
STIMULATION OF FRUCTOSEBIPHOSPHATASE AQIVITY AND SYNTHESIS
IN THE CEREBRAL-CORTEX OF RATS SUBMinED TO THE CONVULSANT
METHIONINE-SULFOXIMINE.
003838 04-03
PHENYLETHYLAMINE EFFEQS ON DOPAMINE SYNTHESIS: STRUQURE-
ACTIVITY RELATIONSHIPS. (UNPUBLISHED PAPER).
003959 04-03
EFFEQS OF IN VIVO AMPHETAMINE ADMINISTRATION ON DOPAMINE
SYNTHESIS REGULATION IN RAT-BRAIN STRIATAL SYNAPTOSOMES.
(UNPUBLISHED PAPER).
003960 04-03
INHIBITION OF THE SYNTHESIS OF ACETYLCHOLINE IN RAT-BRAIN SLICES
BY (-) HYDROXYCITRATE AND CITRATE.
004044 04-03
ANTITREMOR AQION OF ClODICHOL, A PERIPHERAL ACETYLCHOLINE
SYNTHESIS INHIBITOR.
004096 04-04
SYNTHESIZE
REGIONAL AND SUBCELLULAR LOCALIZATION IN RAT-BRAIN OF THE
ENZYMES THAT CAN SYNTHESIZE GAMMA HYDROXYBUTYRIC-ACID.
003675 04-01
SYNTHESIZED
EFFEQ OF ACUTE ADMINISTRATION OF MORPHINE ON NEWLY
SYNTHESIZED 5 HYDROXYTRYPTAMINE IN SPINAL-CORD OF THE RAT.
000110 01-03
NEWLY SYNTHESIZED CHOLECYSTOKININ IN SUBCELLULAR FRAQIONS OF
THE RAT-BRAIN.
003805 04-03
SYNTHESIZING
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA
AND MEDIAL NUCLEUS-TRAQUS-SOLITARIUS OF RAT-BRAIN.
002634 03-01
DIFFERENTIAL-EFFECTS OF ALPHA METHYLDOPAMINE, CLONIDINE AND
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY
HYPERTENSIVE-RATS.
003947 04-03
SYNTHETIC
APPLICATION OF A SYNTHETIC ENKEPHALIN ANALOGUE DURING HEROIN
WITHDRAWAL.
000685 01-11
PREPARATION AND CHARACTERIZATION OF SYNTHETIC MODELS FOR THE
DENSE-BODIES OF HUMAN PLATELETS. (UNPUBLISHED PAPER).
001013 02-01
SYNTHETIC IMMUNOSTIMULANTS DERIVED FROM THE BACTERIAL CEU
WALL.
001080 02-02
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER).
002219 02-13
A SINGLE-DOSE STUDY OF NABILONE, A SYNTHETIC CANNABINOID.
002328 02-14
NEUROPHARMACOLOGY OF SYNTHETIC ERGOT DERIVATIVES IN MAN.
002429 02-15
OPERANT FEEDING AND DRINKING IN PIGS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF SYNTHETIC
CHOLECYSTOKININ-OCTAPEPTIDE.
003064 03-04
PRENATAL EXPOSURE TO SYNTHETIC PROGESTINS INCREASES POTENTIAL
FOR AGGRESSION IN HUMANS.
003527 03-15
A SYNTHETIC ACTH4-9 ANALOGUE (ORGANON-2766) AND SLEEP IN
HEALTHY MAN.
004574 04-14
SYNTHETICALLY-MODIFIED
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY
AND PATHOLOGY (BASED ON EEG AND CLINICAL-STUDY OF
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHAUN).
002286 02-13
SYRINGE
AN IMPROVED PNEUMATIC SYRINGE FOR SELf-ADMINISTRATION OF
DRUGS BY RATS.
004304 04-06
SYRUP
RECTAL VALPROATE SYRUP AND STATUS-EPILEPTICUS.
000727 01-11
SYSTEMIC
DOES SYSTEMIC MORPHINE INCREASE DESCENDING INHIBITORY
CONTROLS OF DORSAL-HORN NEURONES INVOLVED IN NOCICEPTION?
000175 01-03
SYSTEMIC DIPIPERIDINOETHANE MIMICS THE CONVULSANT AND
NEUROTOXIC-ACTIONS OF KAINIC-ACID.
000222 01-03
EFFECTS OF SYSTEMIC AND INTRAVENTRICULAR ADMINISTRATION OF
CANNABINOIDS ON SCHEDULE-CONTROLLED RESPONDING IN THE
SQUIRREL-MONKEY
000354 01-04
SYSTEMIC AND INTRAVENTRICULAR PROLACTIN INDUCES EXCESSIVE
GROOMING.
000378 01-04
SYSTEMIC INSULIN DECREASES LATERAL HYPOTHALAMIC UNIT ACTIVITY.
001275 02-03
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJECTION
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS.
001446 02-03
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY
SYSTEMIC APOMORPHINE IN THE RAT.
001657 02-04
DOSE-RESPONSE STUDY OF THE PRECIPITATED ABSTINENCE-SYNDROME
FOR MORPHINE: SYSTEMIC VS PERIAQUEDUCTAL GRAY NALOXONE.
(PH.D. DISSERTATION).
002979 03-04
THE DYNAMICS OF SYSTEMIC VENOUS, ARTERIAL, AND CEREBROSPINAL-
FLUID PRESSURE UNDER I.V. ADMINISTRATION OF POLYETHYLENE-
GLYCOL.
004045 04-03
SYSTEMICALLY
EFFECTS OF CENTRALLY-ADMINISTERED AND SYSTEMICALLY
ADMINISTERED L TYROSINE AND L LEUCINE ON OVARIAN FUNCTION IN
THE OLD RAT.
001180 02-03
METKEPHAMID, A SYSTEMICAUY ACTIVE ANALOG OF METHIONINE-
ENKEPHALIN WITH POTENT OPIOID DELTA-RECEPTOR ACTIVITY.
002720 03-03
T-MAZE
INTRAHYPOTHALAMIC MICROINJECTIONS OF NORADRENALINE WITH AND
WITHOUT INDUCTION OF THE ALIMENTARY DRIVE AS A REWARD IN A
T-MAZE LEARNING IN RATS.
001604 02-04
T-SCORES
EFFECTS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS
AND STANDARD PROFILES.
002239 02-13
S-436
VOLUME 19, SUBJECT INDEX
Subject Index
TABfRNANTHINE
EFFECT OF TABERNANTHINE ON THE TURNOVER TIME OF BRAIN
CATECHOLAMINES IN NORMAL AND HYPOBARIC HYPOXIC RATS.
00)187 02-03
TACHYCARDIA
INTERMITTENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA,
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE
lOTHALAMATE VENTRICULOGRAM.
003520 03-15
MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS.
003744 04-03
TACRINE
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES
BEHAVIOURAL-EFFECTS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN
RATS.
000420 01-04
TACTICS
CHOICE OF TAQICS IN TREATING ALCOHOLIC-DELIRIUM.
000688 01-11
TAaiLE
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
TAGLUTIMIDE
PHARMACOLOGICAL-PROPERTIES OF TAGLUTIMIDE, A NEW SEDATIVE
HYPNOTIC-DRUG.
001087 02-02
TAIL
EFFEQS OF ANALGESICS AND CNS-AQING DRUGS ON STRUGGLING
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS.
004148 04-04
TAIL-SHOCK
TITRATION PROCEDURE WITH RATS USING A NOSE-POKE RESPONSE AND
TAIL-SHOCK.
001862 02-06
TAILORED
A NOVEL PSYCHOMETRIC-TEST MODEL APPLYING TAILORED TESTING FOR
ECONOMIC AND EFFICIENT COLLECTION OF
PSYCHOPHARMACOLOGICAL-EFFECTS.
002479 02-16
TAIPOXIN
EFFEQS OF TAIPOXIN ON THE ULTRASTRUCTURE OF CHOLINERGIC AXON
TERMINALS IN THE MOUSE ADRENAL-MEDULLA.
003916 04-03
TALAPOIN-MONKEYS
BEHAVIOURAL-EFFECTS AND ENDOCRINE-EFFEaS OF NALTREXONE IN
MALE TALAPOIN-MONKEYS.
001718 02-04
TAP
A NOVEL THREE-WAY TAP.
001863 02-06
TARDIVE
THE OCCURRENCE OF TARDIVE EXTRAPYRAMIDAL SYMPTOMS IN
SCHIZOPHRENIC-PATIENTS UNDERGOING PROLONGED NEUROLEPTIC
TREATMENT.
000885 01-15
TARDIVE TOUREHE-SYNDROME IN AN AUTISTIC-PATIENT AFTER LONG-
TERM NEUROLEPTIC ADMINISTRATION.
000887 01-15
TARDIVE-DYSKINESIA
ORAL DYSKINESIA IN BRAIN-DAMAGED RATS WITHDRAWN FROM A
NEUROLEPTIC: IMPLICATION FOR MODELS OF TARDIVE-DYSKINESIA.
000393 01-04
OXIPEROMIDE IN TARDIVE-DYSKINESIA.
000540 01-07
CLOZAPINE IN THE TREATMENT OF TARDIVE-DYSKINESIA: AN INTERIM
REPORT.
000677 01-11
TREATMENT OF TARDIVE-DYSKINESIA WITH OXYPERTINE ~ PRELIMINARY
CLINICAL-EXPERIENCE AND A BRIEF REVIEW OF THE LITERATURE.
000692 01-11
IDENTIFICATION OF A SUBGROUP OF TARDIVE-DYSKINESIA PATIENTS BY
PHARMACOLOGIC-PROBES.
000708 01-11
THE EFFEQS OF CHOLINERGIC-DRUGS ON THE INVOLUNTARY-
MOVEMENTS OF TARDIVE-DYSKINESIA.
000726 01-11
SPONT.aNEOUS dyskinesia IN THE ELDERLY AND TARDIVE-DYSKINESIA
FROM NEUROLEPTICS. A SURVEY OF 270 ELDERLY-PATIENTS.
000834 01-15
NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA: RECENT
PATHOPHYSIOLOGICAL-DATA, THERAPEUTIC TRIALS.
000842 01-15
DRUG-VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA:
APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.
000844 01-15
TARDIVE-DYSKINESIA AND LITHIUM ASSOCIATED NEPHROPATHY ARE
YOU LIABLE?
000846 01-15
TARDIVE-DYSKINESIA AND OTHER MOVEMENT-DISORDERS IN CHILDREN
TREATED WITH PSYCHOTROPIC-DRUGS.
000849 01-15
REVERSIBILITY OF TARDIVE-DYSKINESIA.
000854 01-15
STRATEGY FOR THE STUDY OF PATIENTS AT HIGH-RISK FOR TARDIVE-
DYSKINESIA.
000858 01-15
TARDIVE-DYSKINESIA: REVIEW AND UPDATE.
000862 01-15
TARDIVE-DYSKINESIA: SUMMARY OF A TASK-FORCE-REPORT OF THE
AMERICAN-PSYCHIATRIC-ASSOCIATION.
000875 01-15
A NEUROENDOCRINE-STUDY OF SUPERSENSITIVITY IN TARDIVE-
DYSKINESIA.
000908 01-16
TARDIVE-DYSKINESIA RESULTING FROM CHRONIC NARCOTIC
TREATMENT.
000922 01-17
CHOLINERGIC ASPECTS OF TARDIVE-DYSKINESIA: HUMAN AND ANIMAL
STUDIES.
000928 01-17
TARDIVE-DYSKINESIA: RESEARCH & TREATMENT.
000934 01-17
EFFECTS OF CHOLINE CONTAINING COMPOUNDS ON TARDIVE-DYSKINESIA
AND OTHER MOVEMENT-DISORDERS.
000942 01-17
DOPAMINERGIC-SUPERSENSITIVITY: INFLUENCE OF DOPAMINE AGONISTS
AND DRUGS USED FOR THE TREATMENT OF TARDIVE-DYSKINESIA.
001169 02-03
ANTICHOLINERGICS PROMOTE NEUROLEPTIC-INDUCED TARDIVE-
DYSKINESIA.
001834 02-05
TARDIVE-DYSKINESIA IN DEPRESSED-PATIENTS: SUCCESSFUL THERAPY
WITH ANTIDEPRESSANTS AND LITHIUM.
002037 02-09
TREATMENT OF TARDIVE-DYSKINESIA IN AN AGITATED, DEPRESSED-
PATIENT.
002038 02-09
GAMMA ACETYLENIC-GABA IN TARDIVE-DYSKINESIA.
002101 02-11
CHOLINERGIC ASPECTS OF TARDIVE-DYSKINESIA.
002102 02-11
PATHOPHYSIOLOGICAL-ASPECTS OF REVERSIBLE AND IRREVERSIBLE
TARDIVE-DYSKINESIA.
002124 02-11
PHARMACOLOGIC-PROBES INTO TARDIVE-DYSKINESIA.
002179 02-11
TARDIVE-DYSKINESIA: BIOCHEMICAL-STUDIES. (UNPUBLISHED PAPER).
002245 02-13
PATHOPHYSIOLOGIC-BASIS OF TARDIVE-DYSKINESIA.
002373 02-15
RECLASSIFICATION OF THE TARDIVE-DYSKINESIA SYNDROME.
002374 02-15
DOPAMINE ANTAGONIST AND AGONIST TREATMENT OF TARDIVE-
DYSKINESIA.
002377 02-15
LECITHIN IN THE TREATMENT OF TARDIVE-DYSKINESIA.
002380 02-15
PHARMACOLOGIC-STUDIES OF TARDIVE-DYSKINESIA.
002387 02-15
TARDIVE-DYSKINESIA: RECOGNITION, MANAGEMENT, AND PREVENTION.
002392 02-15
TARDIVE-DYSKINESIA FROM NEUROLEPTIC-DRUGS: REVIEW OF THE
LITERATURE.
002398 02-15
TARDIVE-DYSKINESIA FOLLOWING LOW-DOSES OF PIPERACETAZINE.
002399 02-15
ABSENCE OF SEVERE TARDIVE-DYSKINESIA IN HUNGARIAN
SCHIZOPHRENIC-OUTPATIENTS.
002404 02-15
THE PREVALENCE OF PRESUMED TARDIVE-DYSKINESIA IN PSYCHIATRIC-
INPATIENTS AND PSYCHIATRIC-OUTPATIENTS.
002417 02-15
SUBSYNDROMES OF TARDIVE-DYSKINESIA.
002421 02-15
BRADYCARDIA, PERSISTENT DIABETES-INSIPIDUS, AND TARDIVE-
DYSKINESIA WITH LITHIUM INTOXICATION.
002427 02-15
FAILURE OF LITHIUM TREATMENT IN ESTABLISHED TARDIVE-DYSKINESIA.
002432 02-15
HALOPERIDOL-INDUCED TARDIVE-DYSKINESIA IN A CHILD WITH GILLES-
DE-LA-TOUREHES-DISEASE.
002437 02-15
TARDIVE-DYSKINESIA.
002440 02-15
S-437
Subject Index
Psychopharmacology Abstracft
m
5
ft
s
fe
EFFEQ OF SODIUM-VALPROATE AND BACLOFEN IN TARDIVE-DYSKINESIA:
CLINICAL-STUDIES AND NEUROENDOCRINE-STUDIES.
002441 02-15
TARDIVE-DYSKINESIA ON HUNGARIAN PSYCHIATRIC-WARDS.
002447 02-15
CHANGES IN PREVALENCE, SEVERITY, AND RECOVERY IN TARDIVE-
DYSKINESIA WITH AGE.
002455 02-15
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL-
NERVOUS-SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE-
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS).
002459 02-15
PROPRANOLOL (INDERAL) FOR TARDIVE-DYSKINESIA AND
EXTRAPYRAMIDAL SIDE-EFFECTS FROM NEUROLEPTICS: POSSIBLE
INVOLVEMENT OF BETA-ADRENERGIC MECHANISMS.
002470 02-15
USE OF CHOLINE AND LECITHIN IN THE TREATMENT OF TARDIVE-
DYSKINESIA.
002473 02-15
CLONAZEPAM AND PHENOBARBITAL IN TARDIVE-DYSKINESIA.
003294 03-11
DOPAMINERGIC AND GABAERGIC ASPECTS OF TARDIVE-DYSKINESIA.
003302 03-11
TARDIVE-DYSKINESIA.
003464 03-15
PHARMACOLOGICAL- STUDIES OF TARDIVE-DYSKINESIA: IMPLICATIONS
FOR FUTURE RESEARCH.
003465 03-15
TARDIVE-DYSKINESIA: CLINICOEPIDEMIOLOGICAL REVISION AND
CONTRIBUTION.
003466 03-15
EFFEaS OF GRADUAL DECREASE AND DISCONTINUATION OF
NEUROLEPTICS ON CLINICAL CONDITION AND TARDIVE-DYSKINESIA.
003469 03-15
EFFEQ OF DES-TYR-GAMMA-ENOORPHIN IN TARDIVE-DYSKINESIA.
003472 03-15
ANIMAL-MODELS OF TARDIVE-DYSKINESIA.
003476 03-15
TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-OUTPATIENTS: PREVALENCE
AND SIGNIFICANT VARIABLES.
003483 03-15
THE EFFECTS OF A DRUG-HOLIDAY ON RELAPSE AND TARDIVE-
DYSKINESIA IN CHRONIC-SCHIZOPHRENICS.
003487 03-15
LECITHIN ADMINISTRATION IN TARDIVE-DYSKINESIA: CLINICAL AND
BIOMEDICAL-CORRELATES.
003496 03-15
LYMPHOCYTE MONOAMINE-OXIDASE AND PLASMA PROLACTIN AND
GROWTH-HORMONE IN TARDIVE-DYSKINESIA.
003499 03-15
PRELIMINARY-FINDINGS WITH REGARD TO RISK-FAQORS IN THE
DEVELOPMENT OF TARDIVE-DYSKINESIA.
003501 03-15
TARDIVE-DYSKINESIA: TWO-YEAR RECOVERY.
003535 03-15
FAMILIAL OCCURRENCE OF TARDIVE-DYSKINESIA.
003548 03-15
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN:
NEUROCHEMICAL- STUDIES IN AN ANIMAL-MODEL OF TARDIVE-
DYSKINESIA.
004268 04-05
THE BIOCHEMICAL BACKGROUND TO TARDIVE-DYSKINESIA.
004588 04-15
TARDIVE-DYSKINESIA: RECENT DEVELOPMENTS.
004592 04-15
EFFEQS OF NEUROLEPTIC ADJUSTMENT ON CLINICAL CONDITION AND
TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-PATIENTS.
004595 04-15
PREVENTION OF TARDIVE-DYSKINESIA AND OTHER DRUG RELATED
ADVERSE-EFFECTS.
004601 04-15
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT, TARDIVE-
DYSKINESIA, AND THE TRAINING OF RESEARCH PSYCHIATRISTS.
004603 04-15
CLINICAL AND PRECLINICAL EXPERIENCE WITH CHOLINE-CHLORIDE IN
HUNTINGTONS-DISEASE AND TARDIVE-DYSKINESIA: UNANSWERED
QUESTIONS.
004604 04-15
A CONTROLLED-TRIAL OF OXYPERTINE IN TARDIVE-DYSKINESIA.
004611 04-15
LECITHIN FOR THE TREATMENT OF TARDIVE-DYSKINESIA.
004612 04-15
TARDIVE-DYSKINESIA AND OTHER DRUG-INDUCED MOVEMENT-
DISORDERS AMONG HANDICAPPED CHILDREN AND YOUTH.
004614 04-15
TREATMENT OF TARDIVE-DYSKINESIA.
004616 04-15
BACLOFEN IN THE TREATMENT OF TARDIVE-DYSKINESIA: OPEN LABEL
STUDY.
004619 04-15
TARDIVE-DYSKINESIA.
004624 04-15
ON THE THERAPY OF NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA WITH
DIMETHYLAMINOETHANOL (DEANOL).
004627 04-15
PRESENT AHEMPTS AT TREATING TARDIVE-DYSKINESIA.
004629 04-15
TARDIVE-DYSKINESIA: PROBLEMS OF PATHOGENESIS, THERAPY, AND
PREVENTION.
004644 04-15
TARDIVE-DYSKINESIA-LIKE
A TARDIVE-DYSKINESIA-LIKE SYNDROME AFTER AMITRIPTYUNE
TREATMENT.
003552 03-15
TARDIVE-DYSKINESIAS
TARDIVE-DYSKINESIAS (OBSERVATIONS CONCERNING THREE CASES).
000861 01-15
NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIAS.
002382 02-15
TARDIVE-HYPERKINESIA
TARDIVE-HYPERKINESIA. EFFEQS OF SULPIRIDE AND GABA SYSTEM
AGONISTS.
002405 02-15
TASK-FORCE-REPORT
TARDIVE-DYSKINESIA: SUMMARY OF A TASK-FORCE-REPORT OF THE
AMERICAN-PSYCHIATRIC-ASSOCIATION.
000875 01-15
TASTE-AVERSION
HANDLING IN INFANCY, TASTE-AVERSION, AND BRAIN LATERALITY IN
RATS.
000375 01-04
ABSENCE OF LITHIUM-INDUCED TASTE-AVERSION AFTER AREA-POSTREMA
LESION.
000456 01-04
MODULATION OF CONDITIONED TASTE-AVERSION BY SODIUM-
PENTOBARBITAL.
001596 02-04
PREEXPOSURE TO DELTA9 THC BLOCKS THC-INDUCED CONDITIONED
TASTE-AVERSION IN RATS.
001618 02-04
AQH POTENTIATES MORPHINE-INDUCED CONDITIONED TASTE-AVERSION.
001781 02-04
THE RELATIONSHIP BETWEEN POSITIVE REINFORCEMENT AND
CONDITIONED TASTE-AVERSION PRODUCED BY SELF-ADMINISTERED
DRUGS. (PH.D. DISSERTATION).
001798 02-04
EFFEQS OF DESGLYCINAMIDE-LYSINE-VASOPRESSIN ON A CONDITIONED
TASTE-AVERSION IN RATS.
001811 02-04
BOMBESIN PRODUCES TASTE-AVERSION IN RATS.
002702 03-03
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE
BUT NOT LITHIUM-CHLORIDE.
003110 03-04
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND
CONDITIONED TASTE-AVERSION.
004121 04-04
TASTE-AVERSIONS
EFFECTS OF DORSOLATERAL TEGMENTAL LESIONS ON AMPHETAMINE-
INDUCED AND LITHIUM-INDUCED TASTE-AVERSIONS.
003114 03-04
TAURINE
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES.
001402 02-03
CONTRALATERAL CIRCLING-BEHAVIOUR INDUlED BY INTRANIGRAL
INJEQION OF TAURINE IN RATS.
001670 02-04
INHIBITORY AQIONS OF TAUROCY AMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
EFFEQ OF TAURINE ON 45CA2 ACCUMULATION IN RAT BRAIN
SYNAPTOSOMES.
002855 03-03
THE EFFEQ OF COLCHICINE AND CYTOCHALASIN B ON THE RELEASE OF
TAURINE FROM THE CHICK RETINA.
002856 03-03
MODULATORY INTERAQIONS BETWEEN NOREPINEPHRINE AND TAURINE,
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS.
004058 04-03
TAUROCY AMINE
INHIBITORY ACTIONS OF TAUROCY AMINE, HYPOTAURINE,
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF
S-438
VOLUME 19, SUBJECT INDEX
Subject Index
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA-
PIG CEREBELLAR SLICES.
002846 03-03
TIA
NEUROLEPTICS: INTERACTIONS WITH FOOD - CHEMICAL AND
PHARMACODYNAMIC STUDIES ON THE INTERACTIONS OF COFFEE AND
TEA.
003612 03-17
TEACHER
PSYCHOACTIVE-DRUG-EFFECTS IN A HYPERACTIVE-CHILD: A CASE-STUDY
ANALYSIS OF BEHAVIOR-CHANGE AND TEACHER ATTENTION.
002313 02-14
TEACHERS
UNDERSTANDING AND USE OF CHEMOTHERAPY BY LEARNING-
DISABILITIES AND BEHAVIOR-DISORDERS TEACHERS.
000965 01-17
TEACHING
THE TEACHING OF PSYCHOPHARMACOLOGY.
002597 02-17
TEAMWORK
PARAPROFESSIONAL AND PROFESSIONAL TEAMWORK AND TRAINING IN
MANAGING PCP AND OTHER DRUG-ABUSE PROBLEMS.
000924 01-17
TECHNICAL-ASPECT
BINDING OF PHENCYCLIDINE TO RAT-BRAIN MEMBRANES: TECHNICAL-
ASPECT.
001882 02-06
TECHNIQUE
INTRATHECAL MORPHINE IN MICE: A NEW TECHNIQUE.
001868 02-06
MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND
UPTAKE OF NEUROTRANSMITTERS IN BRAIN SLICES.
003147 03-06
A SYMPTOM-PROFILE-ANALYSIS OF ANTIPSYCHOTIC-DRUG TREATMENT:
NONPARAMETRIC MULTIDIMENSIONAL TECHNIQUE.
003196 03-08
USE OF THE INTRACEREBRAL INJECTION TECHNIQUE TO ELUCIDATE
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN
THE MOUSE.
004092 04-04
TECHNIQUES
INVESTIGATION OF NARCOTICS AND ANTITUSSIVES USING DRUG
DISCRIMINATION TECHNIQUES.
000447 01-04
TECHNIQUES FOR PLASMA PROTEIN BINDING OF
DEMETHYLCHLORIMIPRAMINE.
000897 01-16
NEW EXPERIMENTAL TECHNIQUES IN THE PHARMACOLOGICAL
EVALUATION OF CNS ACTING DRUGS.
001479 02-03
GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA
DERIVATIZATION TECHNIQUES.
004687 04-16
RECEPTOR TECHNIQUES IN THE STUDY OF PLASMA LEVELS OF
NEUROLEPTICS AND ANTIDEPRESSANT-DRUGS.
004694 04-16
TEGMENTAL
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE, AQIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL
DAMAGE.
000322 01-03
EFFECT OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO
STIMULATION OF THE NUCLEUS-ACCUMBENS.
000331 01-03
• LOCOMOTOR-ACTIVITY ELICITED BY INJECTIONS OF PICROTOXIN INTO THE
VENTRAL TEGMENTAL AREA IS AHENUATED BY INJECTIONS OF GABA
INTO THE GLOBUS-PALLIDUS.
000436 01-04
DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT-
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL-
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS.
001726 02-04
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR
DORSOLATERAL TEGMENTAL DAMAGE.
001818 02-04
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY.
002639 03-01
INTRACRANIAL SELF-ADMINISTRATION OF MORPHINE INTO THE VENTRAL
TEGMENTAL AREA IN RATS.
002960 03-04
EFFECTS OF DORSOLATERAL TEGMENTAL LESIONS ON AMPHETAMINE-
INDUCED AND LITHIUM-INDUCED TASTE-AVERSIONS.
003114 03-04
MORPHINE DIFFERENTIALLY AFFECTS VENTRAL TEGMENTAL AND
SUBSTANTIA-NIGRA BRAIN REWARD THRESHOLDS
004187 04-04
TEGMENTUM
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND
L-AMPHETAMINE: NO INTERACTION IN SELF-STIMULATION OF
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM.
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES.
000387 01-04
TELE-METHYLHISTAMINE
TELE-METHYLHISTAMINE IS A SPECIFIC MAO-B SUBSTRATE IN MAN.
002230 02-13
TELENCEPHALON
THE INFLUENCE OF UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE
SUBSTANTIA-NIGRA IN THE ABSENCE OF THE TELENCEPHALON.
004197 04-04
TELEOST
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II. FACTORS
AFFECTING THE ACCUMULATION OF CYCLIC-AMP IN PIECES OF INTACT
CARP RETINA.
003776 04-03
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE-
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA,
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS.
004051 04-03
TEMAZEPAM
RESIDUAL-EFFECTS OF TEMAZEPAM AND OTHER HYPNOTIC-COMPOUNDS
ON COGNITIVE FUNCTION.
000879 01-15
EFFICACY AND SIDE-EFFECTS OF LORAZEPAM, OXAZEPAM, AND
TEMAZEPAM AS SLEEPING-AIDS IN PSYCHOGERIATRIC-INPATIENTS.
002076 02-10
EUHYPNOS-FORTE, HIGH-DOSE TEMAZEPAM FOR RESISTANT INSOMNIA:
POSTMARKETING SURVEILLANCE IN 10,057 PATIENTS UNRESPONSIVE
TO CONVENTIONAL HYPNOTIC DOSAGE.
002324 02-14
TEMPERATURE
INFLUENCE OF NARCOTIC-AGENTS ON TEMPERATURE REGULATION.
001108 02-03
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND
TOLERANT RATS AND MICE.
001476 02-03
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-03
TEMPERATURES
EFFECTS OF BRAIN-MONOAMINE DEPLETION ON THERMOREGULATORY
RESPONSES OF RABBITS TO DIFFERENT HYPOTHALAMIC
TEMPERATURES.
000190 01-03
BIOCHEMICAL-EFFECTS AND BEHAVIORAL-EFFEQS OF ACUTE ETHANOL IN
RATS AT DIFFERENT ENVIRONMENTAL TEMPERATURES.
002864 03-03
THE EFFECTS OF THEOPHYLLINE AND CAFFEINE ON THERMOREGULATORY
FUNCTIONS OF RATS AT DIFFERENT AMBIENT TEMPERATURES.
003907 04-03
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION.
004034 04-03
TEMPORAL
REWARDING AND AVERSIVE-EFFECTS OF MORPHINE: TEMPORAL AND
PHARMACOLOGICAL-PROPERTIES .
000470 01-04
TEMPORAL PROPERTIES OF THE REWARDING AND AVERSIVE-EFFECTS OF
AMPHETAMINE IN RATS.
000471 01-04
EFFECTS OF TRIFLUOPERAZINE, CHLORPROMAZINE, AND HALOPERIDOL
UPON TEMPORAL INFORMATION-PROCESSING BY SCHIZOPHRENIC-
PATIENTS.
000554 01-08
TEMPORAL AND ENVIRONMENTAL CUES IN CONDITIONED HYPOTHERMIA
AND HYPERTHERMIA ASSOCIATED WITH MORPHINE.
002709 03-03
TEMPORAL PAHERNING OF NEURONAL ACTIVITY DURING THERMAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
CNS EFFECTS OF CHOLINE ADMINISTRATION: EVIDENCE FOR TEMPORAL
DEPENDENCE.
003996 04-03
METHADONE-INDUCED ATTENUATION OF THE EFFECTS OF DELTA9
TETRAHYDROCANNABINOL ON TEMPORAL DISCRIMINATION IN
PIGEONS.
004095 04-04
S-439
Subject Index
in?
a,
('.,)
ii
it
fe
I
CORRECTION OF HORMONAL AQIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
TENDENCY
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE.
002305 02-13
TENSION
THE EFFECT OF DIAZEPAM ON TENSION AND ELECTROLYTE DISTRIBUTION
IN FROG MUSCLE.
000069 01-03
TENTANUS
EFFECT OF TENTANUS TOXIN ON TRANSMIHER RELEASE FROM THE
SUBSTANTIA-NIGRA AND STRIATUM IN VITRO.
002691 03-03
TENURE
FACTORS DETERMINING PATIENT TENURE ON A 3-YEAR DOUBLE-BLIND
INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE-HCL.
002513 02-17
TEPLICE
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS
AFTER HOSPITAL DISCHARGE IN THE DISTRIQS TEPLICE AND UHERSKE-
HRADISTE.
002518 02-17
TERATOGENICITY
TERATOGENICITY OF IMIPRAMINE AND AMITRIPTYLINE IN FETAL
HAMSTERS.
002410 02-15
MULTIINSTITUTIONAL-STUDY ON THE TERATOGENICITY AND FETAL
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE-
STUDY GROUP IN JAPAN.
002442 02-15
TERAT0L06ICAL
TOXICOLOGICAL AND TERATOLOGICAL STUDIES OF
CHLORODIMETHYUVMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW
NEUROLEPTIC-DRUG.
000515 01-05
TERMINAL-FIELDS
MESOLIMBICOCORTICAL DOPAMINE TERMINAL-FIELDS ARE NECESSARY
FOR NORMAL LOCOMOTOR AND INVESTIGATORY EXPLORATION IN
RATS.
000383 01-04
RELATIONSHIPS BETWEEN SELEQIVE DENERVATION OF DOPAMINE
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL-
RESPONSES TO AMPHETAMINE AND APOMORPHINE.
000384 01-04
TERMINAL-RICH
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
TERMINALS
EFFECTS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE.
001243 02-03
A NOVEL GABA-RECEPTOR MODULATES STIMULUS-INDUCED GLUTAMATE
RELEASE FROM CORTICOSTRIATAL TERMINALS.
001376 02-03
DECREASE OF GAD IMMUNOREACTIVE NERVE TERMINALS IN THE
SUBSTANTIA-NIGRA AFTER KAINIC-ACID LESION OF THE STRIATUM.
(UNPUBLISHED PAPER).
001400 02-03
EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC-
SYSTEMS IN THE RAT-BRAIN.
001464 02-03
MEASUREMENT OF THE MEMBRANE POTENTIAL OF ISOLATED NERVE
TERMINALS BY THE LIPOPHILIC CATION
(3H)TRIPHENYLMETHYLPH0SPH0NIUM-BR0MIDE.
002746 03-03
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF
METHAMPHET AMINE.
002812 03-03
SELECTIVE NEUROTOXIC-AQION OF CAPSAICIN ON GLOMERULAR C-TYPE
TERMINALS IN RAT SUBSTANTIA-GELATINOSA.
003143 03-06
EFFECTS OF TAIPOXIN ON THE ULTRASTRUCTURE OF CHOLINERGIC AXON
TERMINALS IN THE MOUSE ADRENAL-MEDULLA.
003916 04-03
THE EFFECT OF ACETYLCHOLINE RELEASE ON CHOLINE FLUXES IN
ISOLATED SYNAPTIC TERMINALS.
003924 04-03
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS.
004129 04-04
Ptychopharmacology Abstracts
TCRMINATINO
THE PROGNOSIS OF EPILEPSY AND THE STRATEGY FOR TERMINATING
ANTIEPILEPTIC THERAPY.
004724 04-17
TERMINATION
FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK
TERMINATION: EFFEQS OF D-AMPHETAMINE, MORPHINE, AND
CLOZAPINE.
000431 01-04
TERTIARY
TRICYCLIC-ANTIDEPRESSANT DRUGS AND INDIVIDUAL DIFFERENCES IN
THE EXPLORATORY-ACTIVITY OF RATS: CONTRASTING-EFFEQS OF
TERTIARY AND SECONDARY AMINE COMPOUNDS.
000401 01-04
IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM
INGESTION OF ETHANOL, TERTIARY BUTANOL, OR PENTOBARBITAL IN
MICE.
000479 01-04
A RAPID AND SENSITIVE RADIORECEPTOR ASSAY FOR TERTIARY AMINE
TRICYCLIC-ANTIDEPRESSANTS.
004689 04-16
TEST
EFFEQS OF CHLORDIAZEPOXIDE AND DIAZEPAM ON FEEDING
PERFORMANCE IN A FOOD PREFERENCE TEST.
000367 01-04
EFFEQS OF EXPERIMENTER AND TEST LOCATION NOVELTY ON
NONSPECIFIC AQIVITY IN RATS AND ITS MODIFICATION BY
METHAMPHET AMINE.
000409 01-04
EFFEQS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN
HEALTHY TEST SUBJEQS. NEUROTIC-PATIENTS, AND ENDOGENOUS
DEPRESSIVE-PATIENTS.
002009 02-09
THE EFFEQS OF ALCOHOL AND CAFFEINE ON CONCENTRATION TEST
PERFORMANCE.
002337 02-14
A SIMPLE SYSTEM FOR CONTROL OF THE CONTINUOUS PERFORMANCE
TEST IN PSYCHOPHARMACOLOGICAL-RESEARCH.
002474 02-16
A TEST OF A NEUROTRANSMIHER MODEL OF THE AFFEQIVE-DISORDERS
(PH.D. DISSERTATION).
003063 03-04
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME.
003189 03-08
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERAQIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES
IN THIS PHASE.
003251 03-09
TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFECTS OF
CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS.
003428 03-13
EFFEQS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETECT THE NARCOTIC CHARACTER OF A DRUG.
003555 03-16
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO.
004387 04-09
AN EVALUATION OF THE USEFULNESS OF THE ACYLASE TEST IN
NEUROLEPTIC TREATMENT.
004426 04-10
TESTED
PL*SMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN CHRONIC
SCHIZOPHRENIC-PATIENTS TESTED WITH SINGLE-DOSE OF 2 BROMO-
ALPHA-ERGOCRIPTINE (PARLODEL).
004343 04-08
TESTES
ADENOSINE-RECEPTORS IN RAT TESTES: LABELING WITH 3H
CYCLOHEXYLADENOSINE.
002835 03-03
TESTING
IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR
ACTIVITY.
000289 01-03
REINNERVATION OF THE DENERVATED STRIATUM BY SUBSTANTIA-NIGRA
TRANSPLANTS: FUNCTIONAL CONSEQUENCES AS REVEALED BY
PHARMACOLOGICAL AND SENSORIMOTOR TESTING.
000347 01-04
SERIAL COGNITIVE TESTING IN CANCER-PATIENTS RECEIVING
CHEMOTHERAPY.
000876 01-15
S-440
VOLUME 19, SUBJECT INDEX
Subjact Indax
ORIENTATIONAL TESTING OF CHL0RPR0MA2INE-HCL ON HOSPITALIZED
MENTAL-PATIENTS.
002131 02-11
THE USE OF BROMOCRIPTINE FOR TESTING CENTRAL DOPAMINERGIC
REACTIVITY
002205 02-13
A NOVEL PSYCHOMETRIC-TEST MODEL APPLYING TAILORED TESTING FOR
ECONOMIC AND EFFICIENT COLLEQION OF
PSYCHOPHARMACOLOGICAL-EFFECTS.
002479 02-16
ANALGESIC TOLERANCE PRODUCED BY MORPHINE PELLETS IS
FACILITATED BY ANALGESIC TESTING.
002943 03-04
TESTOSTERONE
THE ACUTE AND CHRONIC EFFECT OF LITHIUM ON SERUM TESTOSTERONE
IN RATS.
000238 01-03
TESTOSTERONE AND PERSISTENCE OF SOCIAL INVESTIGATION IN
LABORATORY RATS.
000488 01-04
PLASMA PROLACTIN AND TESTOSTERONE DURING PENFLURIDOL
TREATMENT.
000874 01-15
LONG-TERM EFFECTS OF TESTOSTERONE INJECTIONS ON THE SOCIAL-
BEHAVIOUR OF MALE DUCKS AND THEIR PHYSIOLOGICAL-CORRELATES.
001565 02-04
INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN
CHORIONIC GONADOTROPHIN.
003012 03-04
RAT PUP-KILLING AND MATERNAL-BEHAVIOR IN MALE LONG-EVANS-
RATS: PRENATAL STIMULATION AND POSTNATAL TESTOSTERONE.
003054 03-04
TESTOSTERONE POTENTIATION OF THE EFFEQIVENESS OF AaHl-24 ON
THE INDUCTION OF THE STRETCH-YAWNING-SYNDROME (SYS) IN MALE
GUINEA-PIGS.
003074 03-04
EFFEQS OF NEONATAL TESTOSTERONE AND ESTROGEN ON OPEN-FIELD
BEHAVIOUR IN RATS.
003098 03-04
FAILURE TO FIND SEX-DIFFERENCES IN TESTOSTERONE AQIVATED
AGGRESSION IN TWO STRAINS OF RATS.
003107 03-04
TESTOSTERONE-LIKE
MORPHINE EXERTS TESTOSTERONE-LIKE EFFECTS IN THE HYPOTHALAMUS
OF THE CASTRATED MALE RAT.
000051 01-03
TESTS
MORPHINE-DEPENDENCE AND DOPAMINERGIC-ACTIVITY: TESTS OF
CIRCLING RESPONSES IN RATS WITH UNILATERAL NIGRAL LESIONS.
001641 02-04
MINI-SYMPOSIUM: III. SIMPLE IN VIVO TESTS THAT DIFFERENTIATE
PROTOTYPE AGONISTS AT OPIATE-RECEPTORS.
004289 04-06
TETANUS-TOXIN
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT.
003734 04-03
TETRABAMATE
COMPARATIVE-STUDY OF THE INDUQIVE EFFEQ OF TWO
PSYCHOMODERATORS ~ TETRABAMATE AND COMPLEXE-1656 ~ AND
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS.
001874 02-06
TETRABENAZINE
BIOCHEMICAL-STUDY OF THE ANIMAL-MODEL DEPRESSION INDUCED BY
TETRABENAZINE.
001506 02-03
TETRABENAZINE-INDUCED
EFFEQS OF TRICYCLIC-ANTIDEPRESSANTS ON TETRABENAZINE-INDUCED
DEPLETION OF BRAIN MONOAMINES IN RATS. 1 . NOREPINEPHRINE.
004062 04-03
TETRACYCLIC
CLINICAL-TRIALS WITH NEW BICYCLIC AND TETRACYCLIC COMPOUNDS:
ZIMELIDINE AND MAPROTILINE.
003213 03-09
TETRACYCLIC-ANTIDEPRESSANT
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF-
STIMULATION MODEL USING CLONIDINE.
003016 03-04
NEUROTROPIC-DRUGS AS COMEDICATION TO PSYCHOTROPICS:
COMBINED ADMINISTRATION OF A NEUROTROPIC-DRUG AND A
TETRACYCLIC-ANTIDEPRESSANT.
004396 04-09
TETRACYCLIC-ANTIDEPRESSANTS
DETERMINATION OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS AND OF THEIR METABOLIC PRODUQS IN
BIOLOGICAL FLUIDS.
002498 02-16
DIFFERENT EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS ON THE RELEASE OF TSH, PROLACTIN, AND
GROWTH-HORMONE AFTER ADMINISTRATION OF THYROSTIMULATING-
RELEASING-HORMONE IN MANIC-DEPRESSIVES.
004407 04-09
TETRAETHYL-LEAD
THE CLINICAL DYNAMICS OF TETRAETHYL-LEAD POISONING.
003500 03-15
TETRAHYDRO-BETA-CARBOLINE
BRAIN SEROTONIN AND 5 HYDROXYINDOLEACETIC-ACID
CONCENTRATIONS AND SEROTONIN SYNTHESIS FOLLOWING
TETRAHYDRO-BETA-CARBOLINE ADMINISTRATION IN MICE.
001152 02-03
IDENTIFICATION AND QUANTIFICATION OF 1,2,3.4 TETRAHYDRO-BETA-
CARBOLINE, 2 METHYL-TETRAHYDRO-BETA-CARBOLINE, AND 6
METHOXY-TETRAHYDRO-BETA-CARBOLINE AS IN VIVO CONSTITUENTS
OF RAT-BRAIN AND ADRENAL-GLAND.
002636 03-01
ACTIONS OF TETRAHYDRONORHARMANE (TETRAHYDRO-BETA-
CARBOLINE) ON 5 HYDROXYTRYPTAMINE AND DOPAMINE-MEDIATED
MECHANISMS.
002854 03-03
TETRAHYDRO-BETA-CARBOLINES
TETRAHYORO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY
HUMAN BLOOD-PLATELETS.
001067 02-02
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES.
001078 02-02
TETRAHYDROCANNABINOL
THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL ON THE POSITIVE AND
NEGATIVE FEEDBACK CONTROL OF LUTEINIZING-HORMONE RELEASE.
000286 01-03
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9
TETRAHYDROCANNABINOL ON THE CARDIOVASCULAR SYSTEM, AND
PRESSOR AND BEHAVIORAL-RESPONSES TO BRAIN-STIMULATION IN
FREELY-MOVING-RATS.
000417 01-04
THE MECHANISM-OF-ACTION OF DELTA9 TETRAHYDROCANNABINOL ON
BODY-TEMPERATURE IN MICE.
001190 02-03
INFLUENCE OF THYROTROPIN-RELEASING-HORMONE AND HISTIDYL-
PROLINE-DIKETOPIPERAZINE ON SPONTANEOUS LOCOMOTOR-AQIVITY
AND ANALGESIA INDUCED BY DELTA9 TETRAHYDROCANNABINOL IN
THE MOUSE.
001575 02-04
THE EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ALONE AND IN
COMBINATION WITH CANNABIDIOL ON FIXED-INTERVAL
PERFORMANCE IN RHESUS-MONKEYS.
001582 02-04
ACUTE AND CHRONIC EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON
COMPLEX BEHAVIOR OF SQUIRREL-MONKEYS.
001583 02-04
AN ABSTINENCE- SYNDROME FOLLOWING CHRONIC ADMINISTRATION OF
DELTA9 TETRAHYDROCANNABINOL IN RHESUS-MONKEYS.
001621 02-04
EFFEQS OF DELTA9 TETRAHYDROCANNABINOL ON THE
CARDIOVASCULAR-SYSTEM, AND PRESSOR AND BEHAVIORAL-
RESPONSES TO BRAIN-STIMULATION IN RATS.
001681 02-04
CHRONIC DELTA9 TETRAHYDROCANNABINOL IN RATS: EFFECT ON
SOCIAL-INTERAQIONS, MOUSE-KILLING, MOTOR-AQIVITY,
CONSUMMATORY-BEHAVIOR, AND BODY-TEMPERATURE.
001722 02-04
THE EFFEQ OF CONDITIONS INFLUENCING ENDOGENOUS
PROSTAGLANDINS ON THE ACTIVITY OF DELTA'
TETRAHYDROCANNABINOL.
002196 02-12
PLASMA DELTA9 TETRAHYDROCANNABINOL CONCENTRATIONS AND
CLINICAL-EFFECTS AFTER ORAL AND INTRAVENOUS ADMINISTRATION
AND SMOKING.
002201 02-12
INFLUENCE OF CANNABIS AND DELTA9 TETRAHYDROCANNABINOL ON
THE BIOCHEMISTRY OF THE MALE REPRODUQIVE ORGANS.
002686 03-03
ANTAGONISM BY CHLORNALTREXAMINE OF SOME EFFECTS OF DELTA9
TETRAHYDROCANNABINOL IN RATS.
003104 03-04
NEUTRALIZATION OF THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL
ON BARBITURATE SLEEPING-TIME BY SPECIFIC ACTIVE IMMUNIZATION.
003803 04-03
EFFEaS OF DELTA9 TETRAHYDROCANNABINOL AND CANNABIDIOL ON
SODIUM-DEPENDENT HIGH-AFFINITY CHOLINE UPTAKE IN THE RAT
HIPPOCAMPUS.
003908 04-03
S-441
Subject Index
a,
»
i5i:
m
.11;
5
fe
I
METHADONE-INDUCEO AHENUATION OF THE EFFEQS OF DELTA9
TETRAHYDROCANNABINOL ON TEMPORAL DISCRIMINATION IN
PIGEONS.
004095 04-04
AHENUATION OF DELTA9 TETRAHYDROCANNABINOL-INDUCED
WITHDRAWAL-LIKE BEHAVIOUR BY DELTA9
TETRAHYDROCANNABINOL.
004243 04-04
CHARAQERISTICS OF THE STIMULUS PRODUCED BY THE MIXTURE OF
CANNABIDIOL WITH DELTA9 TETRAHYDROCANNABINOL.
004263 04-04
BEHAVIORAL-PHARMACOLOGY OF TETRAHYDROCANNABINOL
CONVULSIONS IN RABBITS.
004288 04-06
TETRAHYDROCANNABINOL-INDUCED
RELATIONSHIP BETWEEN DELTA9 TETRAHYDROCANNABINOL-INDUCED
MOUSE-KILLING-BEHAVIOR ON THE RAT AND THE METABOLISM OF
MONOAMINES IN THE BRAIN, PARTICULARLY THE OLFACTORY-BULB,
000472 01-04
ATTENUATION OF DELTA9 TETRAHYDROCANNABINOL-INDUCED
WITHDRAWAL-LIKE BEHAVIOUR BY DELTA9
TETRAHYDROCANNABINOL.
004243 04-04
TETRAHYDROCANNABINOLS
BIOLOGICAL-ACTIVITY OF THE TETRAHYDROCANNABINOLS.
002556 02-17
TETRAHYDROFURYLALKYL
N TETRAHYDROFURYLALKYL AND N ALKOXYALKYL DERIVATIVES OF (-)
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID AQION
PROFILES.
000013 01-02
TETRAHYDROISOQUINOLINE-7.SULFONANILIDES
INHIBITORS OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND
EPINEPHRINE BIOSYNTHESIS. 2. 1,2,3,4 TETRAHYOROISOQUINOLINE-7-
SULFONANILIDES.
001069 02-02
TETRAHYDRONORHARMANE
ACTIONS OF TETRAHYDRONORHARMANE (TETRAHYDRO-BETA-
CARBOLINE) ON 5 HYDROXYTRYPTAMINE AND DOPAMINE-MEDIATED
MECHANISMS.
002854 03-03
TETRAPEPTIDE
POTENT TETRAPEPTIDE ENKEPHALINS.
003684 04-02
TETRAPHENYLPHOSPHONIUM
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP-
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF
MOUSE NEUROBLASTOMA CELLS USING
(3H)TETRAPHENYLPH0SPH0NIUM .
TEXTBOOK
TEXTBOOK OF CLINICAL PSYCHOPHARMACOLOGY.
004049 04-03
000929 01-17
TEXTURES
EFFEaS OF ACUTE OR CHRONIC ADMINISTRATION OF
CHLORDIAZEPOXIDE ON FEEDING PARAMETERS USING TWO FOOD
TEXTURES IN THE RAT.
000368 01-04
THA
USE OF THA IN TREATMENT OF ALZHEIMER-LIKE DEMENTIA: PILOT- STUDY
IN TWELVE PATIENTS.
003377 03-11
THA - A REVIEW OF THE LITERATURE AND ITS USE IN TREATMENT OF
FIVE OVERDOSE PATIENTS.
003539 03-15
THALAMOCORTICAL
INFLUENCE OF CARBAMAZEPINE ON THALAMOCORTICAL AND
HIPPOCAMPOCORTICAL SELF-SUSTAINED AFTERDISCHARGES IN RATS.
001356 02-03
INFLUENCE OF DIPROPYLACETIC-ACID ON THALAA.^vIORTICAL RESPONSES
IN RATS.
001419 02-03
THALAMUS
NORADRENALINE RELEASE FROM SLICES OF THE THALAMUS OF NORMAL
AND MORPHINE-DEPENDENT RATS.
001142 02-03
ACUTE AND CHRONIC OPIATE-EFFECTS ON SINGLE UNITS AND EEG OF
MEDIAL THALAMUS AND HIPPOCAMPUS: A LATENCY ANALYSIS.
001344 02-03
OPIATE-RECEPTORS AND SLEEP. II. EFFEQS OF MICROINJEQIONS OF
ETHYL-ALCOHOL AND PENTOBARBITAL IN THE MEDIAN THALAMUS,
PERIAQUEDUQAL GRAY MAHER AND NUCLEUS-TRAQUS-SOLITARIUS
OF THE RABBIT.
002917 03-03
EXCITATORY EFFEaS OF DIHYDROCAPSAICIN ON NOCICEPTIVE NEURONS
IN THE MEDIAL THALAMUS.
003714 04-03
UNIT AQIVITY IN MEDIAL THALAMUS: COMPARATIVE-EFFEaS OF
CAFFEINE AND AMPHETAMINE.
003752 04-03
Psychopharmacology Abstracts
THE EFFECT OF CHOLINERGIC SUBSTANCES ON NOCICEPTIVE EVOKED-
RESPONSES IN SPECIFIC NUCLEI OF THE THALAMUS.
003770 04-03
THE ROLE OF NIGRAL PROJECTIONS TO THE THALAMUS IN DRUG-
INDUCED CIRCLING-BEHAVIOUR IN THE RAT.
004205 04-04
THALLIUM
ELEaROPHYSIOLOGICAL-CHANGES AT A CENTRAL NORADRENERGIC
SYNAPSE DURING THALLIUM TOXICOSIS.
001848 02-05
THE NEUROLOGICAL FORENSIC ASPEQS OF THALLIUM POISONING.
002438 02-15
PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALLIUM, ARSENIC
INDUSTRIAL- SOLVENT INTOXICATION, AND OTHER
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT.
003348 03-11
THC
DELTA9 THC IN PIGEONS: A REPLICATION AND EXTENSION.
000394 01-04
PREEXPOSURE TO DELTA9 THC BLOCKS THC-INDUCED CONDITIONED
TASTE-AVERSION IN RATS.
001618 02-04
DELTA9 THC AS A DISCRIMINATIVE-STIMULUS IN RATS AND PIGEONS
GENERALIZATION TO THC METABOLITES AND SP-1 1 1 .
001666 02-04
PLASMA AND BRAIN LEVELS OF DELTA6 THC AND SEVEN
MONOOXYGENATED METABOLITES CORRELATED TO THE CATALEPTIC-
EFFEQ IN THE MOUSE.
001737 02-04
LITHIUM-CHLORIDE AND DELTA9 THC LEAD TO CONDITIONED AVERSIONS
IN THE PIGEON.
003003 03-04
THC-INDUCED
PREEXPOSURE TO DELTA9 THC BLOCKS THC-INDUCED CONDITIONED
TASTE-AVERSION IN RATS.
001618 02-04
THEOPHYLLINE
EFFECTS OF THREE ANTIBIOTICS ON THEOPHYLLINE KINETICS.
000784 01-13
THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REACTION
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN
001052 02-01
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC-
STUDY.
001410 02-03
THEOPHYLLINE AND DEPRESSION.
002439 02-15
THE EFFECTS OF THEOPHYLLINE AND CAFFEINE ON THERMOREGULATORY
FUNaiONS OF RATS AT DIFFERENT AMBIENT TEMPERATURES
003907 04-03
THEORETICAL
PRACTICAL AND THEORETICAL ASPEQS OF PHENYTOIN
ADMINISTRATION. I. RELATIONSHIP BETWEEN DOSE AND PLASMA
CONCENTRATION
000760 01-13
TWENTY YEARS HALOPERIDOL: CLINICAL-EFFEQIVENESS AND
THEORETICAL IMPLICATIONS.
000938 01-17
THEORIES
SYNAPTIC AND BEHAVIOURAL-AQIONS OF ANTIDEPRESSANT-DRUGS:
FURTHER THOUGHTS ON THE IMPLICATIONS FOR THEORIES OF
DEPRESSION.
003229 03-09
THEORY
CASE-REPORT: USING AHRIBUTION THEORY TO LIMIT NEED FOR
NEUROLEPTIC-MEDICINE
000559 01-08
ROniNG WITH THEIR RIGHTS ON: CONSTITUTIONAL THEORY AND
CLINICAL REALITY IN DRUG-REFUSAL BY PSYCHIATRIC-PATIENTS.
000911 01-17
AN INTERFERENCE REDUaiON THEORY OF THE EFFEaS OF ETHANOL ON
CONFLICT-BEHAVIOR.
001586 02-04
THEORY, PROCEDURE, AND APPLICATIONS OF THE RADIOAQIVE
DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL GLUCOSE
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM (UNPUBLISHED
PAPER).
001877 02-06
EFFEQS OF ANXIETY REDUCTION BY BEHAVIOURAL-TECHNIQUES AND
MEPROBAMATE ON CERTAIN PARAMETERS OF INFORMATION THEORY.
003108 03-04
A CONTROLLED-STUDY OF L-DOPA IN SCHIZOPHRENIA WITH REFERENCE
TO THE THEORY OF DOPAMINERGIC-RECEPTOR HYPERSENSITIVITY
004312 04-08
THERAPEUTIC
FLASH-EVOKED AFTERDISCHARGE IN RAT AS A MODEL OF THE ABSENCE
SEIZURE: DOSE-RESPONSE STUDIES WITH THERAPEUTIC DRUGS.
000160 01-03
S-442
VOLUME 19, SUBJECT INDEX
Subject Index
LITHIUM LEVEL IN SOME BIOLOGICAL fLUIDS AT ITS PROPHYLACTIC
THERAPEUTIC APPLICATION
000605 01-09
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS; THERAPEUTIC PLASMA
LEVEL.
000635 01-09
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS FROM VIEWPOINT OF
TRANSCULTURAL PSYCHOPHARMACOLOGY: THERAPEUTIC PLASMA
LEVEL
000636 01-09
TRICYCLIC-ANTIDEPRESSANTS: THERAPEUTIC PLASMA LEVEL.
000646 01-09
THERAPEUTIC APPLICATION OF PHYSOSTIGMINE IN NEUROSIS.
000651 01-10
CONTROLLED-COMPARISON OF THE THERAPEUTIC EFFECTS OF NATRIUM-
OXYBUTYRATE AND OXAZEPAM.
000658 01-10
THERAPEUTIC ASPECTS OF MARIHUANA.
000667 01-11
CONVERSION SCALES FOR COMMONLY REQUESTED SERUM
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE. AND OF
HORMONES.
000759 01-13
NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA: RECENT
PATHOPHYSIOLOGICAL-DATA, THERAPEUTIC TRIALS.
000842 01-15
TWENTY YEARS CLINICAL THERAPEUTIC EXPERIENCE WITH CALCIUM
GLUTAMATES EFFICACY.
000963 01-17
ON THE MECHANISM OF THERAPEUTIC ACTIONS OF PSYCHOTROPIC-
DRUGS.
000964 01-17
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION.
001300 02-03
DISORDERS OF SMOOTH-PURSUIT EYE-MOVEMENTS IN SCHIZOPHRENICS
AND THE EFFECT OF NEUROLEPTICS IN THERAPEUTIC DOSES.
001912 02-08
PLASMA LEVELS AND THERAPEUTIC EFFICACY OF FLUPHENAZINE-HCL
AND FLUPHENAZINE-DECANOATE.
001913 02-08
NEUROLEPTICS AND DOPAMINE-RECEPTORS, THERAPEUTIC
IMPLICATIONS.
001942 02-08
MIANSERIN: DETERMINATION OF THERAPEUTIC DOSE RANGE.
002026 02-09
BLOOD LEVEL OF AMITRIPTYLINE, NORTRIPTYLINE, NORADRENALINE,
SEROTONIN AND THERAPEUTIC RESPONSE.
002057 02-09
THERAPEUTIC RESULTS IN A PSYCHOGERIATRIC-WARD AFTER CHANGE OF
MEDICATION.
002136 02-11
CLOMIPRAMINE AND DOXEPIN IN DEPRESSIVE-NEUROSIS: PLASMA
LEVELS AND THERAPEUTIC RESPONSE.
002258 02-13
BEHAVIORAL-DISTURBANCES IN PSYCHIATRY: A THERAPEUTIC
APPROACH.
002321 02-14
CARDIOVASCULAR-EFFEaS OF THERAPEUTIC DOSES OF TRICYCLIC-
ANTIDEPRESSANTS: IMPORTANCE OF BLOOD LEVEL MONITORING.
002456 02-15
NEUROLEPTIC BLOOD LEVELS AND THERAPEUTIC EFFEQ.
002480 02-16
PLASMA LEVODOPA, DOPAMINE AND THERAPEUTIC RESPONSE
FOLLOWING LEVODOPA THERAPY OF PARKINSONIAN-PATIENTS.
002504 02-16
BENZODIAZEPINES: CLINICAL-PHARMACOLOGY AND THERAPEUTIC USE.
002521 02-17
CLASSIFICATION OF DRUGS AND PATIENTS TO ACHIEVE MAXIMUM
THERAPEUTIC RESPONSE.
002560 02-17
REGULATION OF NEUROTRANSMISSION THROUGH PRESYNAPTIC-
RECEPTORS AND OTHER MECHANISMS: POSSIBLE CLINICAL RELEVANCE
AND THERAPEUTIC POTENTIAL.
002569 02-16
THERAPEUTIC PROFILE OF HALOPERIDOL.
002603 02-17
STUDY OF METABOLISM AND BLOOD LEVELS OF ANTIDEPRESSANTS:
TOWARDS A RATIONALIZATION OF THEIR THERAPEUTIC USE.
002625 02-17
THERAPEUTIC TRIAL OF A NEW ANTIDEPRESSANT: MIANSERIN.
003208 03-09
THERAPEUTIC EFFEQ OF MIANSERINE AND IMIPRAMINE IN ENDOGENOUS
DEPRESSIONS (CONTROLLED-COMPARISON) .
003264 03-09
THE THERAPEUTIC ACTIVITY OF TRYPTOPHAN AND ITS EFFECT ON
SEROTONIN METABOLISM IN EPILEPTIC-PATIENTS.
003289 03-11
THE THERAPEUTIC PROFILE OF MIANSERIN IN MILD ELDERLY
DEPRESSIVES.
003297 03-11
CLINICAL PHARMACOKINETICS IN NEWBORNS AND INFANTS: AGE-
RELATED DIFFERENCES AND THERAPEUTIC IMPLICATIONS.
003343 03-11
LITHIUM NEUROTOXICITY AT THERAPEUTIC LEVELS: A CASE-REPORT
003533 03-15
NATURAL AND THERAPEUTIC ENVIRONMENTAL INDICATORS OF
MAINTENANCE DOSAGE REQUIREMENTS.
003561 03-16
THERAPEUTIC INTEREST OF BLOOD LEVELS DETERMINATION FOR
ANTIDEPRESSANTS: METHODOLOGICAL APPROACH.
003571 03-16
DEBATE: THERAPEUTIC TRIALS IN A NATURAL ENVIRONMENT
003635 03-17
THERAPEUTIC (III): GENERAL CHARACTERISTICS OF ANTIPSYCHOTIC-
DRUGS.
003644 03-17
THERAPEUTIC NEWS.
004308 04-07
CLINICAL DEPRESSIONS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES.
004350 04-09
THERAPEUTIC PLASMA LEVELS OF SOME ANTICONVULSANTS IN FOCAL
EPILEPSY IN RELATION TO COMPUTERIZED-AXIAL-TOMOGRAPHY.
004439 04-11
SOME THERAPEUTIC EFFEQS OF NOOTROPYL.
004458 04-11
A COMPARATIVE EVALUATION OF THE EFFICACY OF SOME THERAPEUTIC
METHODS USED IN DELIRIUM-TREMENS.
004486 04-11
NEUROLEPTIC TRICYCLIC-ANTIDEPRESSANT COMBINATION:
PHARMACOLOGICAL-ASPECTS AND THERAPEUTIC INTEREST.
004501 04-13
PHARMACOLOGICAL PECULIARITIES OF A BENZODIAZEPINE/ATARACTIC-
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF
CLORAZEPATE-DIPOTASSIUM (TRANXILIUM) .
004527 04-13
PROBLEMS OF TREATING DEFORMING MYODYSTONIA WITH L-DOPA,
AND PREDICTION OF ITS THERAPEUTIC EFFECT.
004536 04-13
COMPUTER-ANALYZED ELECTROENCEPHALOGRAM TO PREDICT THE
THERAPEUTIC OUTCOME IN SCHIZOPHRENIA.
004680 04-16
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC-
ANTIDEPRESSANTS: PERSPECTIVE OF THE CLINICAL LABORATORY.
004681 04-16
THERAPEUTIC TREATMENT OF INSUFFICIENT PERFORMANCE IN
CEREBROVASCULAR-DISEASES.
004718 04-17
THERAPEUTIC-EFFICACY
NOMIFENSINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE-NEUROSIS.
THERAPEUTIC-EFFICACY AND TOLERABILITY IN COMPARISON TO
IMIPRAMINE.
002078 02-10
ON A POSSIBLE ROLE OF GABA IN MANIA. THERAPEUTIC-EFFICACY OF
SODIUM-VALPROATE.
003219 03-09
DEPRESSION SUBTYPES AFFECT THE STEADY- STATE PLASMA LEVELS AND
THERAPEUTIC-EFFICACY OF AMITRIPTYLINE AND NORTRIPTYLINE.
003244 03-09
THERAPEUTIC-EFFICACY OF DOXEPIN IN DIVIDED AND SINGLE-DOSE
REGIME.
003259 03-09
THERAPEUTIC-PERSPECTIVES
PHARMACOLOGIC AND THERAPEUTIC-PERSPECTIVES ON DEMENTIA: AN
EXPERIMENTAL APPROACH.
003065 03-04
THERAPEUTICALLY-RESISTANT
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE.
003172 03-08
THERAPEUTICS
THERAPEUTICS (II): LITHIUM.
000641 01-09
THERAPEUTICS V - THE UNWANTED EFFECTS OF ANTIPSYCHOTICS.
000892 01-15
RESPECTIVE POSITION OF ANTIDEPRESSANTS IN THERAPEUTICS.
002581 02-17
THERAPEUTICS (I) - PHARMACOLOGICAL-TREATMENT OF DEPRESSIONS.
003270 03-09
PHENYTOIN: PHARMACOKINETICS AND CLINICAL THERAPEUTICS.
003353 03-11
THERAPEUTICS VI - ANXIOLYTICS (BENZODIAZEPINES).
003546 03-15
S-443
Subject Index
Psychopharmacology Abttroctt
ii
M
5
^
I
THERAPIES
COMPARATIVE ENZYME-INDUCING EFFECTS OF CHLORPROMAZINE AND
FLUPHENAZINE THERAPIES IN PSYCHOTIC-PATIENTS.
000682 01-11
DRUG AND DIETETIC THERAPIES FOR HYPERKINETIC-CHILDREN. (PH.D.
DISSERTATION).
003576 03-17
THERAPIST
THE EFFECT OF ASSERTIVENESS TRAINING, PROVERA AND SEX OF
THERAPIST IN THE TREATMENT OF GENITAL EXHIBITIONISM.
000697 01-11
THERAPY
STUDY ON VISUALLY-EVOKED-POTENTIALS IN SCHIZOPHRENIC-PATIENTS
IN SULPIRIDE THERAPY.
000550 01-08
AFFECTIVE-EPISODE FREQUENCY AND LITHIUM THERAPY.
000587 01-09
HANDBOOK OF LITHIUM THERAPY.
000597 01-09
AMITRIPTYLINE THERAPY OF OBSESSIVE-COMPULSIVE-NEUROSIS.
000656 01-10
CLINICAL-EXPERIENCE WITH PIRACETAM THERAPY IN GERONTOLOGY.
000686 01-11
VASOPRESSIN THERAPY IN PARKINSONS-DISEASE.
000689 01-11
THE LONG-TERM RESULTS OF STEREOTAXIC SURGERY AND L-DOPA
THERAPY IN PATIENTS WITH PARKINSONS-DISEASE: A 10-YEAR
FOLLOWUP STUDY.
000693 01-11
INTRAVENOUS PHENOBARBITAL THERAPY IN BARBITURATE AND OTHER
HYPNOSEDATIVE WITHDRAWAL REACTIONS: A KINETIC APPROACH.
000703 01-11
CYPROTERONACETATE IN THE THERAPY OF SEXUAL-DEVIATIONS.
000735 01-11
A COMPUTER OCULOGRAPHIC AND EEG DOUBLE-BLIND STUDY INCLUDING
WELL-BEING FOR DETERMINING CHANGED VIGILANCE UNDER THERAPY
WITH TIAPRIDE.
000751 01-13
THE AUTOINDUCTION OF CARBAMAZEPINE DURING LONG-TERM
THERAPY.
000785 01-13
ASSESSMENT OF MULTIVARIATE RELATIONSHIPS IN REACTIVITY OF
PATIENTS RECEIVING LITHIUM THERAPY.
000819 01-14
RENAL FUNCTION AND BIOPSY IN PATIENTS ON LITHIUM THERAPY.
000830 01-15
A CASE OF CARDIOVASCULAR COLLAPSE DURING LITHIUM-CARBONATE
THERAPY.
000860 01-15
SEIZURES DURING TRICYCLIC THERAPY.
000868 01-15
BILATERAL PAPILLOEDEMA IN LONG-TERM THERAPY WITH LITHIUM-
CARBONATE.
000878 01-15
CLINICAL HANDBOOK OF ANTIPSYCHOTIC-DRUG THERAPY.
000961 01-17
INFUSION THERAPY IN THERAPY-RESISTANT DEPRESSION.
002007 02-09
TARDIVE-DYSKINESIA IN DEPRESSED-PATIENTS: SUCCESSFUL THERAPY
WITH ANTIDEPRESSANTS AND LITHIUM.
002037 02-09
THE USE OF CLOROTEPIN AND DIAZEPAM IN A COMPLEX THERAPY OF
NEUROSES (CONTROLLED-COMPARISON).
002064 02-10
CLINICAL-ASPECTS OF ANXIETY AND ITS THERAPY
002089 02-10
AN AHEMPT TO TREAT THE SIDE-EFFEQS OF PSYCHOTROPIC THERAPY
WITH BROMOCRIPTINE.
002094 02-1 1
CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL-
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY.
002095 02-1 1
NOMIFENSINE AS CONCOMITANT THERAPY IN THE TREATMENT OF
PARKINSON-PATIENTS. A DOUBLE-BUND PLACEBO-CONTROLLED-
STUDY.
002130 02-11
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF
ENURESIS: A COMPARATIVE-STUDY.
002175 02-11
CARBAMAZEPINE THERAPY IN TRIGEMINAL-NEURALGIA: CLINICAL-
EFFECTS IN RELATION TO PLASMA CONCENTRATION.
002181 02-11
LITHIUM THERAPY IN AGGRESSIVE MENTALLY-SUBNORMAL-PATIENTS.
002316 02-14
BIOCHEMICAL-EVIDENCE FOR OSTEOMALACIA WITH CARBAMAZEPINE
THERAPY.
002445 02-15
INDIVIDUALIZATION OF PHENYTOIN THERAPY.
002495 02-16
PLASMA LEVODOPA, DOPAMINE AND THERAPEUTIC RESPONSE
FOLLOWING LEVODOPA THERAPY OF PARKINSONIAN-PATIENTS.
002504 02-16
AQION MECHANISMS OF INSULIN THERAPY IN PSYCHIATRY, AND
CURRENT-VIEWS ON THESE MECHANISMS.
002553 02-17
BIOLOGY AND THERAPY OF VIOLENT-BEHAVIOUR IN CHILDREN.
002608 02-17
SYNERGISM OF COMBINED LITHIUM NEUROLEPTIC THERAPY: A DOUBLE-
BUND, PLACEBO-CONTROLLED CASE-STUDY.
003165 03-08
THE NEED FOR CONTINUOUS USE OF ANTIPARKINSONIAN MEDICATION
WITH CHRONIC SCHIZOPHRENIC-PATIENTS RECEIVING LONG-TERM
NEUROLEPTIC THERAPY.
003186 03-08
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS A
CLINICAL DOUBLE-BLIND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER).
003327 03-11
EVIDENCE TO SUPPORT EARLY LEVODOPA THERAPY IN PARKINSON-
DISEASE.
003336 03-11
CUNICAL SIGNIFICANCE OF PYRIDOXINE ADMINISTRATION IN L-DOPA
THERAPY OF PARKINSONISM.
003345 03-11
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION
OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY.
003433 03-13
RENAL IMPAIRMENT, HYPERCALCEMIA, AND UTHIUM THERAPY.
003473 03-15
DYSTONIC REAQION DURING MAINTENANCE ANTIPSYCHOTIC THERAPY.
003485 03-15
HYPERPARATHYROIDISM IN ASSOCIATION WITH UTHIUM THERAPY
003489 03-15
DEURIUM SECONDARY TO CLONIDINE THERAPY.
003494 03-15
COMPLICATIONS OF CHRONIC LEVODOPA THERAPY: LONG-TERM
EFFICACY OF DRUG-HOLIDAY.
003502 03-15
LITHIUM THERAPY AND THYROID-FUNQION: A LONG-TERM STUDY.
003504 03-15
SIDE-EFFEQS OF CORTICOSTEROID THERAPY: PSYCHIATRIC-ASPEaS.
003508 03-15
ILEUS COMPLICATING HALOPERIDOL THERAPY.
003511 03-15
DISCONTINUATION OF ANTIPSYCHOTIC-DRUG THERAPY.
003514 03-15
ON SENSORY-DISTURBANCES OCCURRING DURING NEUROLEPTIC
THERAPY
003531 03-15
THE INFLUENCE OF PATIENT BELIEFS ON COMPUANCE TO THERAPY FOR
DIABETES-MELUTUS. (PH.D. DISSERTATION).
003631 03-17
THE COMPLEX SPECIFIC PATHOGENETIC THERAPY OF THE STEREOTYPIC-
BEHAVIOR-SYNDROME (AN EXPERIMENTAL- STUDY).
004162 04^
THE STEREOTYPED-BEHAVIOR-SYNDROME: A NEW MODEL AND
PROPOSED THERAPY.
004163 04-04
THE PROLAQIN RESPONSE IN PATIENTS RECEIVING NEUROLEPTIC
THERAPY. THE EFFEQ OF FLUPHENAZINE-DECANOATE.
004318 04-08
THE USE OF CLINICAL AND PHARMACOKINETIC CRITERIA IN FORECASTING
THE EFFICACY OF THERAPY IN SCHIZOPHRENIA.
004335 04-08
UTHIUM EUMINATION HALF-UFE AND DURATIOI OF THERAPY.
004369 04-09
CLINICAL-EVALUATION OF THE PROPHYLAQIC EFFEQIVENESS OF
PROLONGED LITHIUM-CARBONATE THERAPY IN ENDOGENOUS
DEPRESSIVE-SYNDROMES.
004404 04-09
POSSIBIUTIES OF PATHOGENETIC THERAPY OF HYSTERIA.
004429 04-10
SOME PRINCIPLES OF DIFFERENTIATED METABOUC DRUG-TREATMENT IN
COMPREHENSIVE THERAPY OF MENTAL-DISORDERS.
004433 04-11
THERAPY AND SOCIAL ADAPTATION OF OUGOPHRENICS (REVIEW OF THE
UTERATURE).
004444 04-11
ASSESSING L-DOPA THERAPY FOR PARKINSONS.
004465 04-11
ASTHMA THERAPY MAY UNDERCUT KIDS AT SCHOOL.
004475 04-11
BIOCHEMICAL-STUDIES OF HUMAN EPILEPTICS DURING ANTICONVULSANT
THERAPY.
004490 04-11
S-444
VOLUME 19, SUBJECT INDEX
Subject Index
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION Of
SALIVARY AND PUSMA CONCENTRATIONS AND OF METHODS OF
ASSESSING COMPLIANCE.
004495 04-1)
THE EFFECTS OF ESTROGEN THERAPY ON THE SEX-LIFE OF
POSTMENOPAUSAL-WOMEN .
004573 04-14
CORRECTION OF HORMONAL ACTIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
ANTIEPILEPTIC THERAPY WITH PHENYTOIN: WHICH IS THE OPTIMUM
SERUM LEVEL?
004586 04-14
ON THE QUESTION OF PARENCHYMAL DAMAGE CAUSED BY LONG-TERM
THERAPY WITH PSYCHOTROPICS IN ADOLESCENCE.
004626 04-15
ON THE THERAPY OF NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA WITH
DIMETHYLAMINOETHANOL (DEANOL).
004627 04-15
TARDIVE-DYSKINESIA: PROBLEMS OF PATHOGENESIS. THERAPY, AND
PREVENTION.
004644 04-15
KIDNEY FUNQION IN PATIENTS WITH AFFEQIVE-DISORDERS WITH AND
WITHOUT LITHIUM THERAPY.
004664 04-15
THE PROGNOSIS OF EPILEPSY AND THE STRATEGY FOR TERMINATING
ANTIEPILEPTIC THERAPY.
004724 04-17
THERAPY-RESISTANT
INFUSION THERAPY IN THERAPY-RESISTANT DEPRESSION.
002007 02-09
TREATMENT OF THERAPY-RESISTANT DEPRESSED-PATIENTS WITH IV.
INFUSIONS OF NOMIFENSINE CONTROLLED BY GALVANIC-SKIN-
RESISTANCE.
002012 02-09
ON THE ANTICONVULSANT BLOOD LEVEL IN THERAPY-RESISTANT
EPILEPTIC-PATIENTS.
003300 03-1 1
POLYPHARMACY REGIMEN AS AN EXACERBATING RISK IN THERAPY-
RESISTANT EPILEPTIC-SEIZURES AND BEHAVIORAL-DISORDERS.
004720 04-17
THERMAL
TEMPORAL PAHERNING OF NEURONAL AQIVITY DURING THERMAL AND
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR
HYPOTHALAMUS OF THE AWAKE RABBIT.
002737 03-03
THERMOREGULATION
EFFEQS OF CENTRALLY-ADMINISTERED PENTAZOCINE AND
ETHYLKETOCYCLAZOCINE ON THERMOREGULATION IN THE CAT.
000361 01-04
THE EFFEaS OF INJEQIONS OF BOMBESIN INTO THE CEREBRAL
VENTRICLES ON BEHAVIORAL THERMOREGULATION.
002952 03-04
BOMBESIN ALTERS BEHAVIORAL THERMOREGULATION IN FISH.
003026 03-04
EFFEaS OF OLFACTORY-BULBEQOMY AND PERIPHERALLY-INDUCED
ANOSMIA ON THERMOREGULATION IN THE RAT: SUSCEPTIBILITY TO
ANTIDEPRESSANT-ORUGS.
004113 04-04
THERMOREGULATORY
EFFEQS OF BRAIN-MONOAMINE DEPLETION ON THERMOREGULATORY
RESPONSES OF RABBITS TO DIFFERENT HYPOTHALAMIC
TEMPERATURES.
000190 01-03
THERMOREGULATORY AND LOCOMOTOR-EFFECTS OF DSIP:
PARADOXICAL-INTERACTION WITH D-AMPHETAMINE.
001827 02-04
EVIDENCE FOR THERMOREGULATORY DOPAMINERGIC-RECEPTORS
LOCATED IN THE PREOPTICUS-MEDIALIS-NUCLEUS OF THE RAT
HYPOTHALAMUS.
003754 04-03
THE EFFEQS OF THEOPHYLLINE AND CAFFEINE ON THERMOREGULATORY
FUNQIONS OF RATS AT DIFFERENT AMBIENT TEMPERATURES.
003907 04-03
THERMOREGULATORY-EFFEaS
NEUROPHYSIOLOGICAL-EFFEaS AND THERMOREGULATORY-EFFECTS OF
CAPSAICIN.
001421 02-03
REDUCED TOLERANCE TO MORPHINE THERMOREGULATORY-EFFEaS IN
SENESCENT RATS.
002822 03-03
THESHOLD
EFFEQ OF AMITRIPTYLINE ANTIDOTES ON REPETITIVE EXTRASYSTOLE
THESHOLD.
001856 02-05
THETA
IDENTICAL RESPONSES OF THE TWO HIPPOCAMPAL THETA GENERATORS
TO PHYSIOLOGICAL AND PHARMACOLOGICAL ACTIVATION.
002792 03-03
THEURER
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS. A
CLINICAL DOUBLE-BLIND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER)
003327 03-11
THIAZIDE-INDUCED
THIAZIDE-INOUCED HYPERCALCEMIA IN A MANIC-DEPRESSIVE-PATIENT.
000843 01-15
THIAZIDES
FENFLURAMINE POTENTIATION OF ANTIHYPERTENSIVE-EFFECTS OF
THIAZIDES.
002138 02-11
THIN-FIBER
NALOXONE EFFECTS ON THE BLOOD-PRESSURE RESPONSE INDUCED BY
THIN-FIBER MUSCULAR AFFERENTS.
002794 03-03
THIN-LAYER-CHROMATOGRAPHY
SEPARATION OF BARBITURATES USING REVERSE PHASE THIN-LAYER-
CHROMATOGRAPHY.
004670 04-16
MASS SCREENING AND CONFIRMATION OF DIAZEPAM IN URINE BY EMIT
THIN-LAYER-CHROMATOGRAPHY.
004672 04-16
THINKING
CHANGE IN OVERINCLUSIVE THINKING OF SCHIZOPHRENIC-PATIENTS IS
RELATED TO PLASMA PHENOTHIAZINE CONCENTRATION.
001941 02-08
THIOLS
THIOLS LIBERATE COVALENTLY-BONDED FLAVIN FROM MONOAMINE-
OXIDASE. (UNPUBLISHED PAPER).
001060 02-01
THIOPENTAL-SODIUM
BEHAVIORAL-DESENSITIZATION OF PHOBIC-ANXIETY USING THIOPENTAL-
SODIUM.
002352 02-14
THIOPENTONE
VALUE OF PROPANIDID IN ELECTROCONVULSIVE-THERAPY (COMPARISON
WITH THIOPENTONE).
004379 04-09
THIOPROPAZATE-HYDROCHLORIDE
SYNERGISTIC ACTIONS OF PROPANTHELINE-BROMIDE WITH CIMETIDINE
AND THIOPROPAZATE-HYDROCHLORIDE IN THE PREVENTION OF
STRESS-ULCER FORMATION IN RATS.
000064 01-03
THIOPROPERAZINE
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A
LIGAND FOR NEUROLEPTIC-RECEPTORS - I. IN VITRO STUDIES.
001133 02-03
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A
LIGAND FOR NEUROLEPTIC-RECEPTORS - II. IN VIVO STUDIES.
001137 02-03
THE EFFECT OF THIOPROPERAZINE ON DELAYED REACTIONS IN LOWER
MONKEYS.
004125 04-04
THIORIDAZINE
PROLONGATION OF THE EJACULATION LATENCY IN THE MALE RAT BY
THIORIDAZINE AND CHLORIMIPRAMINE.
000335 01-04
EFFECTS OF THIORIDAZINE ON APOMORPHINE-ELICITED STEREOTYPIC-
BEHAVIOR AND MOTOR-AQIVITY.
000424 01-04
A COMPARISON OF THE CARDIOVASCULAR EFFECTS OF HALOPERIDOL,
THIORIDAZINE AND CHLORPROMAZINE-HCL.
000512 01-05
THE RELATIONSHIP BETWEEN THE THIORIDAZINE LEVEL IN THE PLASMA
AND SYMPTOMS OF PARANOID SCHIZOPHRENIA.
000546 01-08
EFFECTS OF THIORIDAZINE ON THE COGNITIVE FUNCTIONING OF A
HYPOTONIC SCHIZOPHRENIC-BOY.
000557 01-08
THE EFFECT OF THIORIDAZINE ON PROLACTIN LEVELS IN ACUTELY
SCHIZOPHRENIC-PATIENTS: CHALLENGE-DOSE AND STEADY-STATE
LEVELS.
000558 01-08
AN UNUSUAL OCULAR-COMPLICATION OF THIORIDAZINE.
000848 01-15
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR
SUBSEQUENT WITHDRAWAL.
001175 02-03
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. II. IN
VIVO METABOLISM OF TRITIATED DRUGS IN RHESUS-MONKEYS.
001229 02-0.
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. I.
PROTEIN BINDING.
001867 02-06
COMPARISON OF SCH-12679 AND THIORIDAZINE IN AGGRESSIVE
MENTAL-RETARDATES.
002119 02-11
S-445
Subject Index
Psychopharmacology Abstracts
til.
HI
0
s
fc
fe
A CONTROLLED DOUBLE-BLIND STUDY OF HALOPERIDOL VERSUS
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY-
SUBNORMAL-PATIENTS: SERUM LEVELS AND CLINICAL-EFFECTS.
002185 02-11
ON THE CLINICAL PHARMACOKINETICS OF THIORIDAZINE AND ITS
METABOLITES.
002207 02-13
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO- SAMPLE PERFORMANCE IN MENTALLY-RETARDED
ADULTS.
002471 02-15
THE EFFECTS OF THIORIDAZINE ON ELEQRICAL AND ISCHEMIC
VENTRICULAR FIBRILLATION IN THE DOG HEART IN SITU.
002697 03-03
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED
ADULTS.
003392 03-11
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT
ANTICHOLINERGIC-ACTIVITY BY AN ATYPICAL NEUROLEPTIC
(THIORIDAZINE).
003560 03-16
CEREBROSPINAL-FLUID CONCENTRATIONS OF THIORIDAZINE AND ITS
MAIN METABOLITES IN PSYCHIATRIC-PATIENTS.
003569 03-16
AN UNUSUAL CASE OF THIORIDAZINE AND LEVOMEPROMAZINE
DEPENDENCE.
004634 04-15
THIOTHIXENE
DOUBLE-BLIND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH
AFTERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS
WITH SCHIZOPHRENIA.
000574 01-08
THIP
GABAERGIC ACTIONS OF THIP IN VIVO AND IN VITRO: A COMPARISON
WITH MUSCIMOL AND GABA.
000319 01-03
DIFFERENTIAL REVERSAL BY SCOPOLAMINE AND THIP OF THE
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS.
002948 03-04
ANALGESIC PROPERTIES OF THE GABAMIMETIC THIP.
003013 03-04
HYPERACTIVITY FOLLOWING INJECTION OF A GLUTAMATE AGONIST AND
6,7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY
THIP.
004066 04-04
THIRST
INCREASED HUNGER AND THIRST DURING GLUCOPRIVATION IN HUMANS
000828 01-14
THORAZINE
CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNQION
OF ELAVIL AND THORAZINE INJECTION.
002974 03-04
THOUGHTS
SYNAPTIC AND BEHAVIOURAL-AQIONS OF ANTIDEPRESSANT-DRUGS:
FURTHER THOUGHTS ON THE IMPLICATIONS FOR THEORIES OF
DEPRESSION.
003229 03-09
THREE-WAY
A NOVEL THREE-WAY TAP.
001863 02-06
THREO-3-HYDROXYASPARTATE
POTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3-
HYDROXYASPARTATE.
002768 03-03
THRESHOLD
REVERSIBLE INAQIVATION OF RAPHE-MAGNUS NEURONS: EFFEQS ON
NOCICEPTIVE THRESHOLD AND MORPHINE-INDUCED ANALGESIA.
000240 01-03
PENTYLENETETRAZOL SEIZURE THRESHOLD: A QUANTITATIVE MEASURE
OF ETHANOL DEPENDENCE IN RATS.
001750 02-04
LOWERING OF THE CONVULSIVE THRESHOLD BY NONSTEROIDAL
ANTIINFLAMMATORY-DRUGS.
002904 03-03
ETHYL-BETA-CARBOLINE-CARBOXYLATE LOWERS SEIZURE THRESHOLD
AND ANTAGONIZES FLURAZEPAM-INDUCED SEDATION IN RATS.
002971 03-04
EFFECT OF FLURAZEPAM. PENTOBARBITAL, AND CAFFEINE ON AROUSAL
THRESHOLD.
003439 03-14
THE EFFECT OF ELECTRICAL-STIMULATION OF THE LOCUS-COERULEUS AND
INTRAPERITONEAL INJEQION OF CERTAIN PHARMACOLOGICAL
SUBSTANCES ON THE THRESHOLD OF HIPPOCAMPAL
AFTERDISCHARGES.
003885 04-03
NEW ANTIDEPRESSANT-DRUGS AND THE SEIZURE THRESHOLD.
004662 04-15
THRESHOLDS
RELATION OF MONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION
IN CATS.
000474 01-04
AUDITORY AROUSAL THRESHOLDS OF GOOD SLEEPERS AND POOR
SLEEPERS WITH AND WITHOUT FLURAZEPAM.
003446 03-14
REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION:
DISSOCIATIVE-EFFEaS OF COCAINE.
004160 04-04
MORPHINE DIFFERENTIALLY AFFEQS VENTRAL TEGMENTAL AND
SUBSTANTIA-NIGRA BRAIN REWARD THRESHOLDS.
004187 04-04
THROMBOCYTOSIS
THROMBOCYTOSIS IN THE OFFSPRING OF FEMALE MICE RECEIVING DL
METHADONE.
001836 02-05
THYMIDINE
EFFEa OF AMPHETAMINE ON THE METABOLISM AND INCORPORATION
OF (3H) THYMIDINE INTO DNA OF DEVELOPING RAT-BRAIN.
003729 04-03
THYMOANALEPTIC
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE
NORTRIPTYLINE
002304 02-13
THYMOLEPTIC
NEUROLEPTIC AND THYMOLEPTIC TREATMENT OF PSYCHOTIC-
OUTPATIENTS.
000556 01-08
PHARMACOLOGICAL-STUDIES ON A NEW THYMOLEPTIC
ANTIDEPRESSANT. DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1H-
INDAZOLE (FS-32).
001659 02-04
THYMUS-GLAND
POSSIBLE ROLE OF THE THYMUS-GLAND IN MENTAL-ILLNESS
002273 02-13
THYREOTROPIN
INFLUENCE OF NOMIFENSINE ON GROWTH-HORMONE, PROLAaiN,
LUTEINISING-HORMONE AND THYREOTROPIN IN HEALTHY SUBJEQS
AND HYPERPROLAQINAEMIC-PATIENTS.
002137 02-11
THYROID-AaiVITY
ANXIETY AND THYROID-AQIVITY IN PSYCHIATRIC-PATIENTS.
000786 01-13
THYROID-FUNCTION
SINEMET AND THYROID-FUNQION IN PARKINSON-DISEASE.
000733 01-11
SEROTONERGIC AND CATECHOLAMINERGIC INFLUENCE ON THYROID-
FUNQION IN THE VERVET-MONKEY.
001385 02-03
LITHIUM THERAPY AND THYROID-FUNQION: A LONG-TERM STUDY
003504 03-15
NEUROTRANSMIHER CONTROL OF HYPOTHALAMIC PITUITARY THYROID-
FUNQION IN RATS.
003942 04-03
EFFEaS OF CAFFEINE ON ANTERIOR PITUITARY AND THYROID-FUNQION
IN THE RAT.
004014 04-03
THYROID-GLAND
CORREQION OF HORMONAL AQIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
THYROID-HORMONES
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY
PRETREATMENT WITH THYROID-HORMONES.
002259 02-13
REGULATION OF ALPHA 1 -ADRENOCEPTORS IN THE CEREBRAL-CORTEX OF
THE RAT BY THYROID-HORMONES.
003816 04-03
THYROID-INDUCED
THYROID-INDUCED MANIA IN HYPOTHYROID-PATIENTS.
000857 01-15
THYROLIBERIN
EFFEa OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRAaiONS.
001472 02-03
THYROSTIMULATING-RELEASING-HORMONE
DIFFERENT EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCUC-
ANTIDEPRESSANTS ON THE RELEASE OF TSH, PROLAQIN, AND
GROWTH-HORMONE AFTER ADMINISTRATION OF THYROSTIMULATING-
RELEASING-HORMONE IN MANIC-DEPRESSIVES.
004407 04-09
S-446
VOLUME 19, SUBJECT INDEX
Subject Index
THYROTOXICOSIS
EXTRAPYRAMIDAL REACTION OF FLUPHENAZINE POTENTIATED BY
THYROTOXICOSIS.
003551 03-15
1HYROTROPHIN
THYROTROPHIN RESPONSE TO THYROTROPHIN-RELEASING-HORMONE IN
UNIPOLAR AND BIPOLAR AFFECTIVE-ILLNESS.
003237 03-09
THYROTROPHIN-RELEASIN6-FACTOR
HORMONAL STIMULATION AFTER INJECTION OF THYROTROPHIN-
RELEASING-FACTOR (TRF) AND ACTHl-24 IN PATIENTS FOLLOWING
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY-STUDY.
004505 04-13
THYROTROPHIN-REIEASING-HORMONE
THYROTROPHIN RESPONSE TO THYROTROPHIN-RELEASING-HORMONE IN
UNIPOLAR AND BIPOLAR AFFECTIVE-ILLNESS.
003237 03-09
THYROTROPIN
MODIFICATION OF GABAERGIC ACTIVITY AND THYROTROPIN SECRETION
IN MALE RATS.
001362 02-03
THYROTROPIN-RELEASIN6-HORMONE
AN ANALOGUE OF THYROTROPIN-RELEASING-HORMONE WITH IMPROVED
BIOLOGICAL-STABILITY BOTH IN VITRO AND IN VIVO.
000032 01-03
GROWTH-HORMONE (GH) RELEASE FOLLOWING THYROTROPIN-
RELEASING-HORMONE (TRH) INJECTION IN MANIC-PATIENTS
RECEIVING LITHIUM-CARBONATE.
000645 01-09
THE EEG EFFECTS OF THYROTROPIN-RELEASING-HORMONE IN HEALTHY
SUBJECTS AND CHRONIC SCHIZOPHRENICS.
000770 01-13
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR
THE POTENTIATION OF IMIPRAMINE EFFECTS ON THE METABOLISM
AND UPTAKE OF BRAIN CATECHOLAMINES.
001427 02-03
INFLUENCE OF THYROTROPIN-RELEASING-HORMONE AND HISTIDYL-
PROLINE-DIKETOPIPERAZINE ON SPONTANEOUS LOCOMOTOR-ACTIVITY
AND ANALGESIA INDUCED BY DELTA9 TETRAHYDROCANNABINOL IN
THE MOUSE.
001575 02-04
INVESTIGATIONS ON THE INTERACTION OF THYROTROPIN-RELEASING-
HORMONE (TRH) AND MK-771 WITH CENTRAL NORADRENERGIC
MECHANISMS.
001701 02-04
BIPHASIC-EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON
EXPLORATORY-BEHAVIOR IN MICE.
001808 02-04
PSYCHOTROPIC-ACTION OF THYROTROPIN-RELEASING-HORMONE.
002023 02-09
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY
PRETREATMENT WITH THYROID-HORMONES.
002259 02-13
INDIVIDUAL VARIATIONS IN THE EFFECTS OF FLURAZEPAM
CLORAZEPATE, L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON
REM SLEEP IN MAN.
002349 02-14
EFFECT OF LITHIUM ON PROLACTIN RESPONSES TO THYROTROPIN-
RELEASING-HORMONE IN PATIENTS WITH MANIC-STATE.
003266 03-09
THE EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE
PRESENCE AND ABSENCE OF CNS DEPRESSANTS.
004010 04-03
PASSAGE THROUGH THE BLOOD-BRAIN-BARRIER OF THYROTROPIN-
RELEASING-HORMONE ENCAPSULATED IN LIPOSOMES.
004298 04-06
THYROXIN
THYROXIN SENSITIVITY OF SENSORIMOTOR CORTICAL NEURONS AND THE
HYPOTHALAMIC VENTROMEDIAL NUCLEUS.
003713 04-03
THYROXINE
EFFEaS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT
000180 01-03
INFLUENCE OF CARBAMAZEPINE ON SERUM THYROXINE AND
TRIIODOTHYRONINE IN PATIENTS WITH EPILEPSY.
004488 04-1 1
TIADIPONE
A DOUBLE-BLIND CROSSED CLINICAL-STUDY WITH A NEW
PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008), DIAZEPAM AND
A PLACEBO.
003153 03-07
TIAPRIDE
COMPUTERIZING THE MMPI IN THE STUDY OF A NEW PSYCHOTROPIC-
AGENT: TIAPRIDE.
000585 01-09
TICS
A COMPUTER OCULOGRAPHIC AND EEG DOUBLE-BLIND STUDY INCLUDING
WELL-BEING FOR DETERMINING CHANGED VIGILANCE UNDER THERAPY
WITH TIAPRIDE.
000751 01-13
EFFECTS OF TIAPRIDE ON HOMOVANILLIC-ACID LEVELS IN HUMAN
CEREBROSPINAL-FLUID DRAWN AT PNEUMOENCEPHALOGRAPHY.
001483 02-03
ALCOHOL WITHDRAWAL USING TIAPRIDE: QUANTITATIVE
PSYCHOPATHOLOGY.
003293 03-11
A TRIAL TREATMENT WITH TIAPRIDE FOR SOME EXTRAPYRAMIDAL-
SYNDROMES CAUSED BY NEUROLEPTIC-AGENTS.
003553 03-15
THE TREATMENT AND ETIOLOGY OF TICS AND TOUREHE-SYNDROME.
003372 03-11
DO STIMULANTS PROVOKE, CAUSE, OR EXACERBATE TICS AND
TOURETTE-SYNDROME?
004485 04-11
TIME
HOSPITAL AND OUTPATIENT CARE FOR PSYCHOTIC-PATIENTS DURING THE
LAST THREE DECADES: SUBSEQUENT HOSPITAL AND OUTPATIENT
TREATMENT OF PSYCHOTIC-PATIENTS HOSPITALIZED FOR THE FIRST
TIME IN 1949-50, 1959-60 OR 1969-70.
000571 01-08
EFFEQ OF TABERNANTHINE ON THE TURNOVER TIME OF BRAIN
CATECHOLAMINES IN NORMAL AND HYPOBARIC HYPOXIC RATS.
001187 02-03
METHAMPHET AMINE AND TIME ESTIMATION.
003040 03-04
RAPID ACQUISITION OF A TWO-DRUG DISCRIMINATION: TIME OF DAY
EFFECT UPON SALINE STATE.
004214 04-04
TIME-BLIND
TIME-BUND ANALYSIS AND OTHER VIDEO-STRATEGIES IN PHASE II
TRIALS OF PSYCHOTROPIC-DRUGS.
003568 03-16
TIME-COURSE
TIME-COURSE OF ETORPHINE LEVELS IN TISSUES OF OPIATE-TOLERANT
AND NONTOLERANT RATS.
000301 01-03
WATER INTAKE AND TIME-COURSE OF DRINKING AFTER SINGLE OR
REPEATED CHLORDIAZEPOXIDE INJEQIONS.
000369 01-04
THE TIME-COURSE OF NORADRENERGIC PRESYNAPTIC AND
POSTSYNAPTIC ACTIVITY DURING CHRONIC DESIPRAMINE
TREATMENT.
001289 02-03
MODULATION OF APOMORPHINE-INDUCED STEREOTYPY BY ESTROGEN:
TIME-COURSE AND DOSE-RESPONSE.
001636 02-04
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFEQ IN SCHIZOPHRENIA AND
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO
NEUROLEPTIC-MEDICATION.
001911 02-08
TIME-COURSE OF CHRONIC HALOPERIDOL AND CLOZAPINE UPON
OPERANT RATE AND DURATION.
002989 03-04
TIME-COURSE OF CLINICAL CHEMICAL PARAMETERS UNDER LONG-TERM
LITHIUM TREATMENT.
003515 03-15
CORRECTION OF THE EXTRAPYRAMIDAL NEUROLEPTIC-SYNDROME BY
TRYPTOPHAN AND THE TIME-COURSE OF ITS CONTENT IN THE BLOOD
OF PATIENTS.
004434 04-11
TIME-DEPENDENT
EFFECT OF PHENTOLAMINE ADMINISTRATION INTO THE AMYGDALA
COMPLEX OF RATS ON TIME-DEPENDENT MEMORY PROCESSES.
002998 03-04
TIME-DEPENDENT CHANGES IN ANTEROGRADE SCOPOLAMINE-INDUCED
AMNESIA IN RATS.
004182 04-04
TIMID-BEHAVIOUR
BICUCULLINE ANTAGONIZES EFFECTS OF DIAZEPAM ON AGGRESSIVE AND
TIMID-BEHAVIOUR IN MICE.
000485 01-04
TIMING
APOMORPHINE: EFFEQS ON THE TIMING AND SEQUENCING OF PECKING-
BEHAVIOR IN CHICKS.
000428 01-04
TISSUE
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL
INJECTION.
000261 01-03
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN
RATS.
001199 02-03
S-447
Subject Index
Psychopharmocology Abstracts
m
"Si',
Si'
EFFECTS OF RATE OF BLOOD FLOW ON FRACTIONAL EXTRACTION AND ON
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN
VIVO.
001231 02-03
SEX-DIFFERENCES IN THE AMPHETAMINE STIMULATED RELEASE OF
CATECHOLAMINES FROM RAT STRIATAL TISSUE IN VITRO.
002668 03-03
THE EFFEQS OF D-AMPHET AMINE AND POTASSIUM ON SEROTONIN
RELEASE AND METABOLISM IN RAT-CEREBRAL-CORTEX TISSUE.
002754 03-03
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID-
CHROMATOGRAPHY WITH ELECTROCHEMICAL DETEQION.
003674 04-01
TISSUE CHOLINE STUDIED USING A SIMPLE CHEMICAL ASSAY.
003828 04-03
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL
TISSUE BY ASCORBATE.
003876 04-03
EFFECT OF INHIBITORS OF GABA-AMINOTRANSFERASE ON THE
METABOLISM OF GABA IN BRAIN TISSUE AND SYNAPTOSOMAL
FRACTIONS.
003914 04-03
THE EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE
PRESENCE AND ABSENCE OF CNS DEPRESSANTS.
004010 04-03
BENZODIAZEPINE-RECEPTORS: EFFEQ OF TISSUE PREINCUBATION AT 37
DEGREES C.
004013 04-03
EFFEQ OF DESMETHYLIMIPRAMINE ON TISSUE DISTRIBUTION AND
ANOREaiC-AQIVITY OF CHLORPHENTERMINE IN RATS.
004179 04-04
TISSUES
COMPARISON OF BETA-ADRENERGIC-RECEPTOR SUBTYPES IN
MAMMALIAN TISSUES.
000207 01-03
TIME-COURSE OF ETORPHINE LEVELS IN TISSUES OF OPIATE-TOLERANT
AND NONTOLERANT RATS.
000301 01-03
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST,
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
DEVELOPMENTALLY REGULATED LEQINS IN SLIME MOULDS AND CHICK
TISSUES ~ ARE THEY CELL ADHESION MOLECULES?
003724 04-03
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA-
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL
UPTAKE.
003879 04-03
OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES:
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES.
003902 04-03
TITRATING
EFFECTS OF THIORIDAZINE (MELURIL) ON TITRATING DELAYED
MATCHING-TO- SAMPLE PERFORMANCE IN MENTALLY-RETARDED
ADULTS.
002471 02-15
EFFEQS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED
ADULTS.
003392 03-11
TITRATION
NALORPHINES EFFECT UNDER SEVERAL SCHEDULES OF ELECTRIC-SHOCK
TITRATION.
000379 01-04
EFFEQS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN
COMBINATION WITH NALOXONE ON ELEQRIC-SHOCK TITRATION IN
THE SQUIRREL-MONKEY.
001611 02-04
TITRATION PROCEDURE WITH RATS USING A NOSE-POKE RESPONSE AND
TAIL-SHOCK.
001862 02-06
TIC
6LC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA
DERIVATIZATION TECHNIQUES.
004687 04-16
TOAD
ACUTE AND CHRONIC EFFEQS OF MORPHINE ON TRANSMEMBRANE
POTENTIAL AND ON SHORT-CIRCUIT CURRENT IN ISOLATED TOAD
SKIN: APPARENT MORPHINE-DEPENDENCE.
001176 02-03
TOBACCO
SMOKING AND VIGILANCE: THE EFFEQS OF TOBACCO SMOKING ON CFF
AS REUTED TO PERSONALITY AND SMOKING HABITS.
002368 02-14
PSYCHOTOMIMETIC USE OF TOBACCO IN SURINAM AND FRENCH-
GUIANA.
002592 02-17
TOFISOPAM
OUR EXPERIENCE WITH TOFISOPAM (GRANOAXIN-EGYPT).
000647 01-10
ACTION OF TOFISOPAM ON THE ERGONOMIC VIGILANCE LEVEL. ITS
INTERACTION WITH THE EFFECTS OF ALCOHOL. CLINICAL
PHARMACOLOGICAL-STUDY.
001891 02-07
TOFISOPAM IN PSEUDONEURASTHENIA WITH HEADACHES.
002075 02-10
TO THE CLINICAL-EVALUATION OF ANXIOLYTICS (TOFISOPAM).
002494 02-16
TOFIZOPAM
THE TREATMENT OF ANXIOUS-DEPRESSIVE-SYNDROMES WITH
TOFIZOPAM.
000615 01-09
TOFIZOPAM IN THE TREATMENT OF CHRONIC ALCOHOLISM.
000706 01-11
TOLSRABILITY
NOMIFENSINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE-NEUROSIS.
THERAPEUTIC-EFFICACY AND TOLERABILITY IN COMPARISON TO
IMIPRAMINE.
002078 02-10
TOLERANCE
REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS.
000066 01-03
TOLERANCE TO SUPPRESSIVE EFFECTS OF CHLOR0IA2EPOXIDE ON
OPERANT-BEHAVIOR: LACK OF CROSS-TOLERANCE TO PENTOBARBITAL.
000356 01-04
ASSESSMENT OF TOLERANCE TO AND PHYSICAL-DEPENDENCE ON
PENTOBARBITAL, INDUCED BY MULTIPLE PELLET IMPLANTATION.
000385 01-04
TOLERANCE OF MICE TO NITROUS-OXIDE.
00041801-04
REPEATED ADMINISTRATION OF NALTREXONE PRODUCES TOLERANCE TO
NALOXONE-INDUCED HYPERALGESIA.
000453 01-04
TOLERANCE TO INCREASES IN STRIATAL ACETYLCHOLINE
CONCENTRATIONS AFTER REPEATED ADMINISTRATION OF
APOMORPHINE-DIPIVALOYL-ESTER.
000464 01-04
TRICYCLIC-ANTIDEPRESSANT DRUG TOLERANCE IN ORIENTAL AND
OCCIDENTAL POPULATIONS.
000590 01-09
IMPAIRED GLUCOSE TOLERANCE IN LONG-TERM LITHIUM TREATED
PATIENTS.
000611 01-09
DOPAMINE SYNTHESIS: TOLERANCE TO HALOPERIDOL AND
SUPERSENSITIVITY TO APOMORPHINE DEPEND ON PRESYNAPTIC-
RECEPTORS
001129 02-03
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION).
001213 02-03
EFFECTS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE,
001243 02-03
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE
ADMINISTRATION TO RATS.
001285 02-03
TOLERANCE TO ETHANOL-INDUCED IMPAIRMENT OF WATER-ESCAPE IN
RATS BRED FOR ETHANOL SENSITIVITY.
001567 02-04
TOLERANCE DEVELOPMENT TO PHENCYCLIDINE BY CHRONIC
ADMINISTRATION.
001619 02-04
APPARENT TOLERANCE TO SOME ASPECTS OF AMPHETAMINE
STEREOTYPY WITH LONG-TERM-TREATMENT.
001758 02-04
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE-
DECANOATE TREATMENT.
001820 02-04
TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERACTIVE-
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL
PARADIGM - A PILOT- STUDY.
002126 02-11
LITHIUM: PROBLEMS OF APPLICATION, TOLERANCE, AND EFFICACY.
002434 02-15
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE
AND CROSS-TOLERANCE TO THE INHIBITORY ACTION OF BETA
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS.
002756 03-03
S-448
iifiilSiiii
VOLUME 19, SUBJECT INDEX
Subject Index
REDUCED TOLERANCE TO MORPHINE THERMOREGULATORY-EFFECTS IN
SENESCENT RATS.
002822 03-03
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFECTS OF NALOXONE ON
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE
MALE RAT.
002853 03-03
ANALGESIC TOLERANCE PRODUCED BY MORPHINE PELLETS IS
FACILITATED BY ANALGESIC TESTING.
002943 03-04
ENVIRONMENTAL MODULATION OF ANALGESIC TOLERANCE INDUCED BY
MORPHINE PELLETS.
002944 03-04
TOLERANCE TO THE DISCRIMINATIVE-STIMULUS PROPERTIES OF D-
AMPHET AMINE.
002953 03-04
CATS DEVELOP TOLERANCE TO D-AMPHETAMINES EFFECTS UPON
LOCOMOTION AND STEREOTYPED-BEHAVIORS.
003018 03-04
DIFFERENTIATION OF OPIATE-RECEPTORS IN THE BRAIN BY THE SELECTIVE
DEVELOPMENT OF TOLERANCE.
003088 03-04
DIFFERENCE IN THE DEVELOPMENT OF TOLERANCE TO MORPHINE AND D
ALA2-METHI0NINE-ENKEPHALIN IN C57 BL/6J AND DBA/2J MICE.
003126 03-05
TOLERANCE IN A COMPRESSED GASTRORESISTANT FORM IN
PSYCHIATRIC-PATIENTS.
003157 03-07
TOLERANCE STUDY IN PSYCHIATRIC-PATIENTS OF A NEW PREPARATION
OF SODIUM-DIPROPYLACETATE.
003158 03-07
DIFFERENTIAL TOLERANCE TO THE EFFECTS OF MORPHINE ON EVOKED
ACTIVITY IN THE HIPPOCAMPAL SLICE.
003760 04-03
EFFEa OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF
TOLERANCE TO THE HYPNOTIC-EFFEaS OF PENTOBARBITAL, BARBITAL,
AND ETHANOL.
003883 04-03
THE EFFEaS OF PEPTIDES ON TOLERANCE TO THE CATALEPTIC-EFFEaS
AND HYPOTHERMIC-EFFEQS OF MORPHINE IN THE RAT.
004072 04-04
FOOD PREFERENCE FOLLOWING ACUTE OR CHRONIC CHLORDIAZEPOXIDE
ADMINISTRATION: TOLERANCE TO AN ANTINEOPHOBIC ACTION.
004090 04-04
NEUROLOGICAL TOLERANCE OF LITHIUM AND PSYCHOTROPIC-DRUGS IN
COMBINATION: 265 CASES.
004594 04-15
TOLERANT
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND
TOLERANT RATS AND MICE.
001476 02-03
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID:
DIFFERENT! AL-EFFEQ IN TOLERANT ANIMALS.
003038 03-04
TOLOXATONE
MONOAMINE-OXIDASE-INHIBITION AND BRAIN-AMINE METABOLISM
AFTER ORAL TREATMENT WITH TOLOXATONE IN THE RAT.
000156 01-03
TOLUENE
BRIEF COMMUNICATION: BEHAVIORAL RECOVERY AFTER TOLUENE
EXPOSURE IN RATS.
002969 03-04
TONIC
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES:
EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION
IN THE ANESTHETIZED CAT.
001203 02-03
EVIDENCE FOR A lONIC GABAERGIC CONTROL OF SEROTONIN NEURONS
IN THE MEDIAN RAPHE NUCLEUS.
002719 03-03
CATECHOLAMINERGIC INVOLVEMENT IN PHASIC VERSUS TONIC
ELEQROCORTICAL AROUSAL.
002723 03-03
PHARMACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG.
002889 03-03
THE EFFEaS OF TRYPTOPHAN AND MANIPULATIONS OF SEROTONERGIC-
RECEPTORS ON TONIC IMMOBILITY IN CHICKENS.
004245 04-04
TONIC IMMOBILITY IN DOMESTIC FOWL: POSSIBLE INTERAQION OF
SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
004246 04-04
DOSE-EFFEa OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
AaiVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL-SYNDROME .
004472 04-11
TOOTH-PULP
MORPHINE AND ELECTROACUPUNCTURE: COMPARISON OF THE EFFEQS
ON THE CORTICAL EVOKED-RESPONSES AFTER TOOTH-PULP
STIMULATION IN RATS.
001294 02-03
EFFEaS OF MORPHINE ON EVOKED-POTENTIALS RECORDED FROM THE
AMYGDALA BY TOOTH-PULP STIMULATION IN CATS.
001379 02-03
FURTHER STUDIES ON OPIATE-RECEPTORS THAT MEDIATE
ANTINOCICEPTION: TOOTH-PULP STIMULATION IN THE DOG.
001782 02-04
TOPICS
RECENT REVIEWS OF BIOCHEMICAL, NEUROCHEMICAL, AND
PHARMACOLOGICAL TOPICS.
003649 03-17
TOPOGRAPHIC
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY.
002639 03-01
TOUREHE-SYNDROME
CLONIDINE IN TOUREHE-SYNDROME.
000672 01-11
TARDIVE TOUREHE-SYNDROME IN AN AUTISTIC-PATIENT AFTER LONG-
TERM NEUROLEPTIC ADMINISTRATION,
000887 01-15
PHYSOSTIGMINE IN TOUREHE-SYNDROME: EVIDENCE FOR CHOLINERGIC
UNDERACTIVITY.
003286 03-10
THE TREATMENT AND ETIOLOGY OF TICS AND TOURETTE-SYNDROME.
003372 03-11
CLONIDINE IN TOURETTE-SYNDROME.
003420 03-13
FAQ-SHEET: TOUREHE-SYNDROME.
004474 04-11
DO STIMULANTS PROVOKE, CAUSE, OR EXACERBATE TICS AND
TOURETTE-SYNDROME?
004485 04-11
TOXIC
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFECTS
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND
OTHER GLYCOLYTIC ENZYMES.
000131 01-03
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF
12 CNS DEPRESSANTS IN INTACT AND PITHED RATS.
001855 02-05
TOXIC EFFEaS OF ALPHA AMINOADIPATE ON CULTURED CEREBELLAR
CELLS.
002729 03-03
TOXIC PSYCHOSIS FOLLOWING USE OF QUINACRINE.
003507 03-15
MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT.
004441 04-11
TOXICANTS
USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETECT AND
DISCRIMINATE ACTIONS OF DRUGS AND TOXICANTS.
000503 01-04
TOXICITY
CIMETIDINE TOXICITY MANIFESTED AS PARANOIA AND
HALLUCINATIONS.
000829 01-15
RETINAL TOXICITY OF MAM-ACETATE IS DEVELOPMENTALLY SPECIFIC.
(UNPUBLISHED PAPER).
001212 02-03
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC
DRUGS.
001330 02-03
TOXICITY OF OXYGEN IN IRON RICH AREAS OF RAT-BRAIN.
(UNPUBLISHED PAPER).
001498 02-03
PSYCHIATRIC MORBIDITY AND PHYSICAL TOXICITY ASSOCIATED WITH
ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY.
002433 02-15
MULTIINSTITUTIONAL-STUDY ON THE TERATOGENICITY AND FETAL
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE-
STUDY GROUP IN JAPAN.
002442 02-15
A CASE OF REVERSIBLE PURE-WORD DEAFNESS DURING LITHIUM
TOXICITY.
003481 03-15
PHENYTOIN TOXICITY IN A BRAIN-DAMAGE ADOLESCENT: A CASE-
REPORT.
003512 03-15
S-449
!iSl,.
m
5
I
Subject Index
HOW TO TREAT AND PREVENT DRUG TOXICITY.
003541 03-15
MICROPROPERTIES OF OPERANT-BEHAVIOR AS ASPEQS OF TOXICITY.
004666 04-15
TOXICOLOGIC
TOXICOLOGIC AND PHARMACOLOGIC-EFFEQS OF PHENCYCLIDINE-HCL IN
THE DOG. (PH.D. DISSERTATION).
000519 01-05
TOXICOLOGICAL
TOXICOLOGICAL AND TERATOLOGICAL STUDIES OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW
NEUROLEPTIC-DRUG.
000515 01-05
CONVERSION SCALES FOR COMMONLY REQUESTED SERUM
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE, AND OF
HORMONES.
000759 01-13
A COMPARATIVE REVIEW OF THE PHARMACOLOGICAL AND
TOXICOLOGICAL PROPERTIES OF DISULFIRAM AND CALCIUM-
CARBIMIDE.
003522 03-15
TOXICOLOGY
TOXICOLOGY - PHARMACOLOGY ~ METABOLISM.
002252 02-13
THE BRAINSTEM AUDITORY EVOKED-RESPONSE AS A TOOL IN
NEUROBEHAVIORAL TOXICOLOGY AND MEDICINE.
004277 04-05
TOXICOSIS
ELECTROPHYSIOLOGICAL-CHANGES AT A CENTRAL NORADRENERGIC
SYNAPSE DURING THALLIUM TOXICOSIS.
001848 02-05
TOXIN
HYBRID PROTEINS USED TO STUDY THE MECHANISM OF TOXIN
ENTRANCE INTO CELLS. (UNPUBLISHED PAPER).
001063 02-01
ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT
CELL TYPE SPECIFIC TOXIN (UNPUBLISHED PAPER).
001064 02-01
EFFECT OF TENTANUS TOXIN ON TRANSMIHER RELEASE FROM THE
SUBSTANTIA-NIGRA AND STRIATUM IN VITRO.
002691 03-03
TOXINS
AQIONS OF TREMORGENIC FUNGAL TOXINS ON NEUROTRANSMIHER
RELEASE.
002843 03-03
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND
GANGLIONIC SYNAPSES.
002870 03-03
TRACE
PHARMACOLOGY OF PHENETHYLAMINE TRACE AMINES IN THE DOG -
DISCUSSION.
000469 01-04
TRACT
DRUG-INDUCED DISORDERS OF THE URINARY TRAQ
002393 02-15
COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL
TRAQ OF THE GUINEA-PIG AND RAT.
003928 04-03
TRAINING
EXTINQION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMIHENT
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNQIONAL
EQUIVALENCE.
000490 01-04
THE EFFECT OF ASSERTIVENESS TRAINING, PROVERA AND SEX OF
THERAPIST IN THE TREATMENT OF GENITAL EXHIBITIONISM.
000697 01-11
PARAPROFESSIONAL AND PROFESSIONAL TEAMWORK AND TRAINING IN
MANAGING PCP AND OTHER DRUG-ABUSE PROBLEMS.
000924 01-17
DEPENDENCE OF THE AVFAIL EFFECT ON THE SEQUENCE OF TRAINING
OPERATIONS.
001086 02-02
BETA ENDORPHIN CAUSES RETROGRADE AMNESIA AND IS RELEASED
FROM THE RAT-BRAIN BY VARIOUS FORMS OF TRAINING AND
STIMULATION.
001664 02-04
DISCUSSION OF WHO AQIVITY IN BIOLOGICAL-PSYCHIATRY WITH
SPECIAL REFERENCE TO TRAINING.
002520 02-17
LECITHIN AND MEMORY TRAINING IN ALZHEIMERS-DISEASE. (PH.D.
DISSERTATION).
003299 03-11
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION.
004088 04-04
Ptychopharmacology Abstracts
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT, TARDIVE-
DYSKINESIA, AND THE TRAINING OF RESEARCH PSYCHIATRISTS.
004603 04-15
TRAIT
PERSONALITY TRAIT AND ANTIANXIETY-DRUG EFFEaS ON
PSYCHOMOTOR PERFORMANCE.
002336 02-14
TRANQUILIZER
USE OF THE NEW TRANQUILIZER PHENAZEPAM IN PSYCHIATRIC-
PRACTICE.
000578 01-09
THE TRANQUILIZER DEMETRIN (PRAZEPAM).
(X)3331 03-1 1
A COMPARATIVE CLINICAL-TRIAL WITH THE TRANQUILIZER TRAZODONE
AND THE TRICYCLIC-ANTIDEPRESSANT CLOMIPRAMINE.
004380 04-09
TRANQUILIZERS
STUDIES ON THE COMPREHENSIVE MEDICAL TREATMENT OF PEPTIC-
ULCERS (3) - UTILIZATION OF TRANQUILIZERS IN THE TREATMENT OF
GASTRIC-ULCERS.
000653 01-10
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON AMPHETAMINE-
INDUCED LOCOMOTOR-STIMULATION IN MICE.
001767 02-04
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON SCOPOLAMINE-
INDUCED LOCOMOTOR-STIMULATION IN MICE.
001768 02-04
THE AQION OF BENZODIAZEPINES ON THE LIMBIC-SYSTEM COMPARED
TO OTHER TRANQUILIZERS
002731 03-03
DEPENDENCE ON TRANQUILIZERS (AN OVERVIEW WITH (CASE-STUDIES).
003580 03-17
TRANQUILIZING
THE TRANQUILIZING OF AMERICA.
003602 03-17
THE PHARMACOLOGICAL CHARAQERISTiCS OF THE TRANQUILIZING
EFFECT OF HYDIPHEN.
004261 04-04
TRANQUILIZING-DRUGS
METHODS AND METHODOLOGICAL-CONSIDERATIONS IN MEASURING
ANTIANXlETY-EFFEaS OF TRANQUILIZING-DRUGS.
002537 02-17
TRANS-ISOMERS
THE PHOTOCHEMICAL-STABILITY OF CIS-ISOMERS AND TRANS-ISOMERS
OF TRICYCLIC NEUROLEPTIC-DRUGS.
001872 02-06
PLASMA LEVELS OF THE CIS-ISOMERS AND TRANS-ISOMERS OF DOXEPIN
AND DESMETHYLDOXEPIN AFTER ADMINISTRATION OF DOXEPIN TO
PATIENTS.
004355 04-09
TRANSCALLOSAL
THE EFFECT OF NOOTROPIL ON THE TRANSCALLOSAL AND PRIMARY
EVOKED-RESPONSES OF THE CAT CEREBRAL-CORTEX.
003780 04-03
TRANSCULTURAL
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS FROM VIEWPOINT OF
TRANSCULTURAL PSYCHOPHARMACOLOGY: THERAPEUTIC PLASMA
LEVEL.
000636 01-09
TRANSCULTURAL PHARMACOKINETIC STUDY ON LI CONCENTRATION IN
PLASMA AND SALIVA.
000769 01-13
TRANSDUCER
ELECTROLYTIC MICROINFUSION TRANSDUCER SYSTEM: AN ALTERNATIVE
METHOD OF INTRACRANIAL DRUG APPLICATION.
001861 02-06
TRANSDUCTION
BIOCHEMICAL-MECHANISM OF SIGNAL TRANSDUQION ACROSS
BIOMEMBRANES. (UNPUBLISHED PAPER).
001026 02-01
PHOSPHOLIPID METHYLATION: A BIOCHEMICAL-EVENT OF SIGNAL
TRANSDUCTION. (UNPUBLISHED PAPER).
001279 02-03
TRANSECTION
DENERVATION SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN RATS
FOLLOWING SPINAL TRANSECTION AND 5,7 OIHYDROXYTRYPTAMINE
INJECTION.
003722 04-03
DOPAMINE-ACTIVATED ADENYLATE-CYCLASE OF SPINAL-CORD:
SUPERSENSITIVITY FOLLOWING TRANSEQION OF THE CORD.
003800 04-03
TRANSFER
TRANSFER OF LORAZEPAM AND ITS CONJUGATE ACROSS THE HUMAN
PLACENTA.
000774 01-13
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR
S-450
mn
mm
VOLUME 19, SUBJECT INDEX
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL
EXUDATE CELLS. (UNPUBLISHED PAPER).
001201 02-03
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS
WITH LEWIS-RAT LYMPH-NODE CELLS. (UNPUBLISHED PAPER).
001434 02-03
THE EFFECTS OF PIMOZIDE DURING PAIRING ON THE TRANSFER OF
CLASSICAL CONDITIONING TO AN OPERANT DISCRIMINATION.
002956 03-04
EXTENDED SCHEDULE TRANSFER OF ETHANOL DISCRIMINATION.
003087 03-04
TRANSFER FROM MULTIPLE TO SINGLE ANTIEPILEPTIC DRUG-THERAPY.
003316 03-11
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE-
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS
IN DIPOLAR APROTIC SOLVENTS.
003654 04-01
TRANSFORAtATION
THE EFFEa OF LITHIUM ON THE INCORPORATION OF 3H GLUCOSAMINE
INTO GLYCOPEPTIDES AND THE TRANSFORMATION OF 3H
GLUCOSAMINE INTO SIALIC-ACID IN RAT-BRAIN.
001209 02-03
TRANSIENT
TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC-
DISCHARGE IN HUMANS BY APOMORPHINE, A DOPAMINE-RECEPTOR
AGONIST.
00071401-11
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN.
004638 04-15
TRANSIENT-EFFECT
TRANSIENT-EFFEQ OF L TRYPTOPHAN IN PROGRESSIVE MYOCLONUS
EPILEPSY WITHOUT LAFORA-BODIES: CLINICAL-STUDY AND
ELEaROPHYSIOLOGICAL-STUDY .
000694 01-11
TRANSIENT-SYNDROMES
PSYCHOPATHOMETRIC DOUBLE-BLIND COURSE STUDY WITH NICERGOLINE
VERSUS PLACEBO IN GERIATRIC-PATIENTS WITH TRANSIENT-
SYNDROMES.
000665 01-11
TRANSLATION
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO.
003832 04-03
TRANSMEMBRANE
PHOSPHOLIPID METHYLATION AND TRANSMEMBRANE SIGNALLING.
(UNPUBLISHED PAPER).
001001 02-01
ACUTE AND CHRONIC EFFEQS OF MORPHINE ON TRANSMEMBRANE
POTENTIAL AND ON SHORT-CIRCUIT CURRENT IN ISOLATED TOAD
SKIN: APPARENT MORPHINE-DEPENDENCE.
001176 02-03
TRANSMETHYLATION
DUAL-EFFECTS OF MESCALINE; THE TRANSMETHYLATION HYPOTHESIS
REVISITED.
001584 02-04
ABNORMAL TRANSMETHYLATION REAQION DURING THE METABOLISM
OF DOPAMINE, TRYPTAMINE, AND SEROTONIN, AND SCHIZOPHRENIC-
SYMPTOMS: A CRITICAL REVIEW.
003404 03-13
TRANSMISSION
REDUaiON OF GAMMA AMINOBUTYRIC-ACID-MEDIATED (GABA)
TRANSMISSION BY A CONVULSANT BENZODIAZEPINE.
000015 01-02
EFFEQ OF MIANSERIN ON NORADRENERGIC TRANSMISSION IN THE RAT
ANOCOCCYGEUS-MUSCLE.
000075 01-03
ADENINE-NUCLEOTIDES AND SYNAPTIC TRANSMISSION IN THE IN VITRO
RAT HIPPOCAMPUS.
000080 01-03
THE EFFEQS OF TWO ANALOGS OF DOPAMINE ON GANGLIONIC
TRANSMISSION IN THE SYMPATHETIC-NERVOUS-SYSTEM.
000162 01-03
ENKEPHALINS PRESYNAPTICALLY INHIBIT CHOLINERGIC TRANSMISSION
IN SYMPATHETIC GANGLIA.
000167 01-03
INTERAQION OF DIAZEPAM WITH SYNAPTIC TRANSMISSION IN THE IN
yiTRO RAT HIPPOCAMPUS.
000178 01-03
BEHAVIORAL-EFFECTS AND ELECTROCORTICAL-EFFECTS AFTER
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS
ENHANCING GABAERGIC TRANSMISSION.
000443 01-04
REGULATION OF CHOLINERGIC TRANSMISSION IN ADRENAL-MEDULLA.
(UNPUBLISHED PAPER).
001182 02-03
AN EXAMINATION OF FAQORS INFLUENCING ADRENERGIC
TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO
Subject Index
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNCTIONAL
ALPHA-ADRENOCEPTORS.
001196 02-03
ROLE OF CALMODULIN IN DOPAMINERGIC TRANSMISSION.
(UNPUBLISHED PAPER).
001270 02-03
INHIBITORY ACTION OF ADENOSINE ON SYNAPTIC TRANSMISSION IN THE
HIPPOCAMPUS OF THE GUINEA-PIG IN VITRO.
001401 02-03
ENHANCED BEHAVIOURAL-EFFECTS, ELECTROCORTICAL-EFFECTS AND
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN.
001733 02-04
DOPAMINE DEPLETION SLOWS RETINAL TRANSMISSION.
002708 03-03
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED
CAT.
002740 03-03
NONSEROTONERGIC DEPRESSION OF SPINAL MONOSYNAPTIC REFLEX
TRANSMISSION BY 5 HYDROXYTRYPTOPHAN.
002745 03-03
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
ANTIANXIETY-AGENTS AND SYNAPTIC TRANSMISSION IN THE BRAIN:
ELECTROPHYSIOLOGICAL-STUDIES. (PH.D. DISSERTATION).
002840 03-03
CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN
HYPOTHALAMUS.
002842 03-03
CALMODULIN: ITS ROLE IN SYNAPTIC TRANSMISSION.
003162 03-07
THE EFFECTS OF ALPHA AND BETA NEUROTOXINS FROM THE VENOMS OF
VARIOUS SNAKES ON TRANSMISSION IN AUTONOMIC GANGLIA.
003750 04-03
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN
THE NICTITATING MEMBRANE OF THE CAT.
003822 04-03
PRESYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION IN HELIX-
POMATIA: THE EFFECTS OF SEROTONIN AND DOPAMINE
ANTAGONISTS.
003869 04-03
DIFFERENTIAL-EFFEaS OF PENTOBARBITAL AND ETHER ON THE SYNAPTIC
TRANSMISSION OF THE HIPPOCAMPAL-CAl -REGION IN THE RAT.
003903 04-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR PRESYNAPTIC ACTIONS OF
PHENCYCLIDINE ON NORADRENERGIC TRANSMISSION IN RAT
CEREBELLUM.
003926 04-03
TRANSMITTER
CATECHOLAMINE TRANSMIHER SYSTEMS.
000580 01-09
EVIDENCE SUGGESTING A TRANSMIHER OR NEUROMODULATORY ROLE
FOR SUBSTANCE-P AT THE FIRST SYNAPSE OF THE BARORECEPTOR
REFLEX.
001264 02-03
DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR
TRANSMIHER IN THE CAT CEREBRAL-ARTERY.
001336 02-03
EFFECT OF TENTANUS TOXIN ON TRANSMIHER RELEASE FROM THE
SUBSTANTIA-NIGRA AND STRIATUM IN VITRO.
002691 03-03
ACTIONS OF BETA BUNGAROTOXIN ON AMINO-ACID TRANSMIHER
RELEASE.
002897 03-03
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF
ESTIMATING THE DOSAGE AT WHICH TRANSMITTER ANTAGONISTS
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF
NEURAL ACTIVITY.
003134 03-06
TRANSMITTERS
. EXCITATORY AMINO-ACID TRANSMIHERS.
003648 03-17
DRUGS, TRANSMinERS AND HORMONES, AND MATING-BEHAVIOR.
004721 04-17
TRANSPLANTED
SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE:
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT.
000095 01-03
S-451
Subject Index
Psychopharmacology Abstracts
111.,
a;:
%
ft',
I
fe
I
TRANSPLANTS
REINNERVATION OF THE DENERVATED STRIATUM BY SUBSTANTIA-NIGRA
TRANSPLANTS: FUNCTIONAL CONSEQUENCES AS REVEALED BY
PHARMACOLOGICAL AND SENSORIMOTOR TESTING.
000347 01-04
TRANSPORT
BIOSYNTHESIS. AXONAL TRANSPORT AND RELEASE OF POSTERIOR
PITUITARY-HORMONES. (UNPUBLISHED PAPER).
001148 02-03
CERTAIN MECHANISMS OF THE ACTION OF PSYCHOTROPIC-DRUGS ON
TRANSPORT ATPASES.
001331 02-03
NEURONAL TRANSPORT OF 5 HYDROXYTRYPTAMINE.
001451 02-03
DISCUSSION OF CLINICAL-PAPERS ON LITHIUM TRANSPORT IN AFFECTIVE-
DISORDERS.
001987 02-09
LITHIUM TRANSPORT STUDIES IN AFFECTIVE-DISORDERS.
002024 02-09
ABNORMALITIES OF LITHIUM TRANSPORT IN PATIENTS WITH AFFECTIVE-
DISORDERS.
002269 02-13
INTERACTIONS OF NARCOTICS WITH SYNAPTOSOMAL CALCIUM
TRANSPORT.
002712 03-03
TRANSPORT OF NEUTRAL AMINO-ACIDS AT THE BLOOD-BRAIN-BARRIER.
002764 03-03
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES.
002879 03-03
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL
TRANSPORT.
003734 04-03
STUDIES ON AXONAL TRANSPORT IN DOPAMINERGIC NEURONS: EFFEQ
OF NEUROPHARMACOLOGIC LESIONS.
003858 04-03
THE EFFECT OF CHRONIC NICOTINE AND WITHDRAWAL ON INTRAAXONAL
TRANSPORT OF ACETYLCHOLINE AND RELATED ENZYMES IN SCIATIC-
NERVE OF THE RAT.
003897 04-03
RESERPINE EFFEa ON THE AXONAL TRANSPORT OF DOPAMINE-BETA-
HYDROXYLASE AND TYROSINE-HYDROXYLASE IN RAT-BRAIN.
003904 04-03
STUDIES ON GAMMA AMINOBUTYRIC-ACID TRANSPORT IN COBALT
EXPERIMENTAL EPILEPSY IN THE RAT.
003990 04-03
PROPERTIES OF THE OPTICAL-ISOMERS AND METABOLITES OF KET AMINE
ON THE HIGH-AFFINITY TRANSPORT AND CATABOLISM OF
MONOAMINES.
004009 04-03
THE EFFEQ OF NORADRENALINE ON NA-K TRANSPORT IN RAT-CEREBRAL-
CORTICAL SLICES.
004056 04-03
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION.
004281 04-05
INTERACTION OF CHLORPROMAZINE WITH THE TRANSPORT SYSTEM OF
GLUCOSE IN HUMAN ERYTHROCYTES.
004529 04-13
TRANSSYNAPTIC
INTERACTIONS OF NEUROPEPTIDES WITH CHOLINERGIC
SEPTOHIPPOCAMPAL PATHWAY; INDICATION FOR A POSSIBLE
TRANSSYNAPTIC REGULATION. (UNPUBLISHED PAPER).
001062 02-01
TRANXENE
EVALUATION OF CLORAZEPATE (TRANXENE) AS AN ANTICONVULSANT ~
A PILOT-STUDY.
000728 01-11
TRANXILIUM
PHARMACOLOGICAL PECULIARITIES OF A BENZODIAZEPINE/ATARAQIC-
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF
CLORAZEPATE-DIPOTASSIUM (TRANXILIUM) .
004527 04-13
TRANYLCYPROMINE
TRANYLCYPROMINE STEREOISOMERS, MONOAMINERGIC
NEUROTRANSMISSION AND BEHAVIOR. A MINIREVIEW.
000016 01-02
THE NEW ANTIDEPRESSANT PIRLINDOLE: A COMPARISON WITH
IMIPRAMINE AND TRANYLCYPROMINE.
001360 02-03
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS, UNDER
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REAQION TYPE
(EMOTIVE AND NONEMOTIVE).
001624 02-04
EFFECT OF CITALOPRAM (LU- 10-171) ON TRANYLCYPROMINE AND
TRYPTOPHAN-INDUCED WET-DOG-SHAKES IN RATS.
001682 02-04
A METHOD FOR MEASUREMENT OF TRANYLCYPROMINE IN RAT-BRAIN
REGIONS USING GAS-CHROMATOGRAPHY WITH ELEaRON CAPTURE
DETEQION.
003137 03-06
CHARAQERISTIC HYPERPYREXIA INDUCED BY LICL AND
TRANYLCYPROMINE IN RATS.
004278 04-05
TRAUMATIC
TREATMENT OF TRAUMATIC WAR-NEUROSIS WITH PHENELZINE.
003325 03-11
TRAZODONE
SOME EXPERIMENTAL-EFFEaS WITH TRAZODONE.
000105 01-03
1-M CHLOROPHENYLPIPERAZINE: A METABOLITE OF TRAZODONE
ISOLATED FROM RAT URINE.
000204 01-03
TRAZODONE IN DEPRESSIONS.
000643 01-09
RESPONSES TO TYRAMINE AND NOREPINEPHRINE AFTER IMIPRAMINE
AND TRAZODONE.
000864 01-15
TRAZODONE IN THE TREATMENT OF NEUROTIC DEPRESSION.
001994 02-09
ALCOHOL WITHDRAWAL-SYNDROME: TREATMENT WITH TRAZODONE.
002356 02-14
EFFEQ OF A PSYCHOACTIVE-DRUG. TRAZODONE, ON PROIAQIN
SECRETION IN MAN.
003425 03-13
BIOCHEMICAL INVESTIGATIONS INTO THE MODE OF ACTION OF
TRAZODONE.
003753 04-03
THE INTERACTION OF TRAZODONE WITH RAT-BRAIN MUSCARINIC-
CHOLINOCEPTORS
003855 04-03
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION: A
DOUBLE-BUND COMPARISON WITH IMIPRAMINE.
004346 04-09
A COMPARATIVE CLINICAL-TRIAL WITH THE TRANQUILIZER TRAZODONE
AND THE TRICYCLIC-ANTIDEPRESSANT CLOMIPRAMINE.
004380 04-09
THE ANTIDEPRESSANT EFFECTS OF TRAZODONE AND INHIBITION OF
PLATELET SEROTONIN REUPTAKE.
004383 04-09
AN EVALUATION OF TRAZODONE IN THE TREATMENT OF DEPRESSION
004386 04-09
A COMPARISON OF TRAZODONE AND DOTHIEPIN IN DEPRESSION.
004394 04-09
TRAZODONE IN DEPRESSION.
004414 04-09
TREAT
AN AnEMPT TO TREAT THE SIDE-EFFECTS OF PSYCHOTROPIC THERAPY
WITH BROMOCRIPTINE.
002094 02-11
HOW TO TREAT AND PREVENT DRUG TOXICITY.
003541 03-15
TREATED
CEREBELLAR GRANULE CEU GENESIS IN THE HYDROCORTISONE TREATED
RAT.
00(X)30 01-03
INCREASED MESOLIMBIC 3H SPIROPERIDOL BINDING IN 4 WEEK OLD
OFFSPRING OF NURSING RAT MOTHERS TREATED WITH PENFLURIDOL.
000087 01-03
INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH PENTAZOCINE:
REVERSAL BY NALTREXONE.
000318 01-03
EFFECTS OF APOMORPHINE ON ESCAPE PERFORMANCE AND ACTIVITY IN
DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6
OHDA).
000426 01-04
EEG IN PATIENTS TREATED WITH LITHIUM.
000593 01-09
ON THE RELATIONSHIP OF NORTRIPTYLINE: AMITRIPTYLINE RATIO TO
CLINICAL IMPROVEMENT OF AMITRIPTYLINE TREATED DEPRESSIVE-
PATIENTS.
000599 01-09
COGNITIVE AND AFFECTIVE-FUNCTIONS IN PATIENTS WITH AFFECTIVE-
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY
QUESTIONNAIRE.
000604 01-09
IMPAIRED GLUCOSE TOLERANCE IN LONG-TERM LITHIUM TREATED
PATIENTS.
000611 01-09
ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLEO-
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH
PARKINSONS-DISEASE TREATED WITH L-DOPA.
000659 01-11
ELECTRORETINOGRAPHIC-CHANGES IN PATIENTS WITH PARKINSONISM
TREATED WITH VARIOUS CLASSES OF ANTIPARKINSONIAN-ORUGS
000674 01-11
S-452
mmam
Vllif^&U/^X-
VOLUME 19, SUBJECT INDEX
Subject Index
A CASE OF TRIGEMINAL-NEURALGIA TREATED WITH LITHIUM-
CARBONATE.
000690 01) 1
SOCIAL AND CLINICAL SIGNIFICANCE Of DETERMINING THE BARBITURATE
LEVEL IN THE BLOOD SERUM Of PATIENTS TREATED WITH
ANTIEPILEPTIC-DRUGS.
000695 01-11
RENAL FUNCTION IN LITHIUM AND NONLITHIUM TREATED PATIENTS
WITH AFFECTIVE-DISORDERS.
000837 01-15
TARDIVE-DYSKINESIA AND OTHER MOVEMENT-DISORDERS IN CHILDREN
TREATED WITH PSYCHOTROPIC-DRUGS,
000849 01-15
DYSKINETIC AND NEUROLOGICAL-COMPLICATIONS IN CHILDREN TREATED
WITH PSYCHOTROPIC-MEDICATIONS.
000880 01-15
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE
TREATED DOGS.
001273 02-03
SYNCHRONIZATION Of EEG ACTIVITY Of MALE RHESUS-MONKEYS
MACACA-MULAHA TREATED WITH OVOCYCLIN.
001312 02-03
DOWN REGULATION Of DIHYDROALPRENOLOL AND IMIPRAMINE
BINDING-SITES IN BRAIN OF RATS REPEATEDLY TREATED WITH
IMIPRAMINE.
001317 02-03
HEROIN, BUT NOT LEVORPHANOL, PRODUCES EXPLOSIVE MOTOR-
BEHAVIOR IN NALOXONE TREATED RATS.
001579 02-04
THE EFFEaS Of D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5
DIMETHOXY-4-METHYLAMPHET AMINE (DOM) AND D-AMPHETAMINE
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE
TREATED RATS.
001595 02-04
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REfLEXES IN
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH
ANTIDEPRESSANTS.
001620 02-04
CHANGES OF PHYSICAL MORPHINE-DEPENDENCE IN RATS CHRONICALLY
TREATED WITH DRUGS AQING ON BRAIN 5 HYDROXYTRYPTAMINE.
001764 02-04
BASAL AND STIMULATED LEVELS Of PROLACTIN, TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH
NEUROLEPTICS.
001935 02-08
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
RELATIONSHIPS AMONG BIOCHEMICAL-VARIABLES, CLINICAL-
VARIABLES, AND PHARMACOKINETIC-VARIABLES IN NEUROLEPTIC
TREATED SCHIZOPHRENIC-PATIENTS.
001946 02-08
DRUG-INDUCED ARTERIAL HYPOTENSION IN PSYCHIATRIC-PATIENTS
TREATED WITH DIHYDROERGOTAMINE.
001950 02-08
AaH4-)0 AND MEMORY IN ECT TREATED AND UNTREATED PATIENTS. I.
EFFEQ ON CONSOLIDATION.
001982 02-09
AaH4-10 AND MEMORY IN ECT TREATED PATIENTS AND UNTREATED
CONTROLS. II. EFFEQ ON RETRIEVAL.
001983 02-09
MOTOR-LEARNING ABILITIES IN SUBJECTS TREATED WITH LITHIUM-SALTS
AND TRICYCLIC-ANTIDEPRESSANTS.
002058 02-09
TRICHOTILLOMANIA TREATED WITH AMITRIPTYLINE.
002083 02-10
EEG CHANGES IN CHILDREN WITH TREATED PHENYLKETONURIA AFTER
PHENYLALANINE LOAD.
002115 02-11
THE RELATIONSHIP OF ALPHA AND DELTA EEG FREQUENCIES TO PAIN
AND MOOD IN FIBROSITIS-PATIENTS TREATED WITH CHLORPROMAZINE
AND L TRYPTOPHAN.
002152 02-11
STUDY OF PROLACTIN VARIATIONS IN PSYCHIATRIC-PATIENTS TREATED
WITH FLUPHENAZINE-DECANOATE.
002226 02-13
SALIVARY IMMUNOGLOBULIN CONCENTRATIONS IN PATIENTS WITH
EPILEPSY TREATED WITH CARBAMAZEPINE.
002234 02-13
PLASMA HDL CHOLESTEROL AND GROWTH-HORMONE IN EPILEPTICS
TREATED WITH ANTICONVULSANTS.
002260 02-13
BROMOCRIPTINE IN PARKINSONS-DISEASE: REPORT ON 106 PATIENTS
TREATED FOR UP TO 5 YEARS.
002342 02-14
EDEMAS AND MYOCLONIES IN A PATIENT WITH PARKINSONS-DISEASE
TREATED BY AMANTADINE: PROBLEM WITH ASSOCIATED
MEDICATIONS.
002389 02-15
PLASMA FLUPHENAZINE LEVELS BY RADIOIMMUNOASSAY IN
SCHIZOPHRENIC-PATIENTS TREATED WITH DEPOT INJECTIONS OF
FLUPHENAZINE-DECANOATE .
002510 02-16
SUPPRESSION OF AMPHETAMINE-INDUCED EEG AROUSAL IN THE
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS.
002683 03-03
EFFECT OF MAZINDOL ON BRAIN DOPAMINE TURNOVER IN SPIPERONE
TREATED RATS.
002726 03-03
MULTIDIMENSIONAL ANALYSES OF BEHAVIOR IN MICE TREATED WITH
ALPHA ENDORPHIN.
003020 03-04
COPULATORY-BEHAVIOR AND SEXUAL-REFLEXES OF MALE RATS TREATED
WITH NALOXONE.
003077 03-04
INTERACTIONS OF DIAZEPAM AND COCAINE IN THE MORPHINE TREATED
RAT. (PH.D. DISSERTATION).
003115 03-04
DEPRESSED-OUTPATIENTS TREATED WITH COGNITIVE-THERAPY OR
PHARMACOTHERAPY: A ONE-YEAR FOLLOWUP.
003235 03-09
THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL-
MEDICAL-PRACTICE: 48 CASES TREATED ON AN OUTPATIENT BASIS.
003268 03-09
ADULT-ONSET STUnERING TREATED WITH ANTICONVULSANTS.
003290 03-11
ON A CASE OF MEMORY-DISTURBANCES TREATED WITH VASOPRESSIN.
003301 03-11
COMPARISON OF STANDARD AND HOLTOR-MONITORED EKGS IN A
PATIENT TREATED WITH SEVERAL ANTIDEPRESSANTS.
003304 03-11
THE EFFEQ OF AMANTADINE ON PROLAQIN LEVELS AND
GALACTORRHEA ON NEUROLEPTIC TREATED PATIENTS.
003373 03-1 1
RESPIRATORY-DISEASE AND NASAL IMMUNOGLOBULIN
CONCENTRATIONS IN PHENYTOIN TREATED EPILEPTIC-PATIENTS.
003486 03-15
PREDICTORS OF ADOLESCENT HEIGHT AND WEIGHT IN HYPERKINETIC-
BOYS TREATED WITH METHYLPHENIDATE.
003509 03-15
EFFECTS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION
TEST TO DETECT THE NARCOTIC CHARACTER OF A DRUG.
003555 03-16
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN.
003820 04-03
DEVELOPMENTAL-CHANGE IN REARING RESPONSE TO ATROPINE IN RATS
TREATED WITH 6 HYDROXYDOPA.
004191 04-04
CATECHOLAMINE SEROTONIN INTERACTION EFFECTS ON ACTIVITY IN
RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE.
004194 04-04
NEUROTRANSMIHER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS. I: EFFECTS OF A SINGLE EXPOSURE TO ACRYLAMIDE.
004264 04-05
NEUROTRANSMIHER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE
TREATED RATS. II: EFFECTS OF EXTENDED EXPOSURE TO ACRYLAMIDE.
004265 04-05
A FOLLOWUP STUDY OF SCHIZOPHRENIC-OUTPATIENTS TREATED WITH
DEPOT NEUROLEPTICS.
004342 04-08
NORMAL PLASMA DOPAMINE-BETA-HYDROXYLASE IN NONTREATED AND
TREATED PARKINSON-PATIENTS.
004471 04-11
PECULIARITIES Of THE CEREBRAL PATHOMORPHOLOGY Of PATIENTS
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS
(PHARMACOLOGICAL PATHOMORPHOSIS) .
004528 04-13
ELECTROENCEPHALOGRAPHIC CHANGE IN PARKINSONIAN-PATIENTS
TREATED WITH LEVODOPA CARBIDOPA.
004557 04-13
CONCENTRATIONS Of CHLORPROMAZINE AND TWO Of ITS ACTIVE
METABOLITES IN PLASMA AND CEREBROSPINAL-fLUID Of PSYCHOTIC-
PATIENTS TREATED WITH fIXED DRUG DOSES.
- 004559 04-13
TREATING
CHOICE Of TACTICS IN TREATING ALCOHOLIC-DELIRIUM.
000688 01-11
CORONARY-HEART-DISEASE: TREATING THE ANXIETY COMPONENT.
002088 02-10
fAMILY-TREE GIVES CLUES TO TREATING PSYCHOSES.
002363 02-14
PSYCHOPHARMACEUTICALS fOR TREATING PAIN.
002548 02-17
THE USE Of LITHIUM-CARBONATE fOR TREATING KUGELBERG-WELANDER
SPINAL AMYOTROPHY PATIENTS.
003326 03-11
S-453
Subject Index
Psychopharmacology Abstracts
1
"9(:
ii
fe
EFFICACY OF LITHIUM IN TREATING MOOD-DISORDER OCCURRING AFTER
BRAINSTEM INJURY.
003354 03-1 1
AaiON ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS
OF TREATING ALCOHOLISM AND DRUG ADDIQION
PATHOGENETICALLY.
003641 03-17
PROBLEMS OF TREATING DEFORMING MYODYSTONIA WITH L-DOPA,
AND PREDICTION OF ITS THERAPEUTIC EFFECT.
004536 04-13
PRESENT AHEMPTS AT TREATING TARDIVE-DYSKINESIA.
004629 04-15
TREATMENT
THE SENSITIVITY OF THE RAT CORTICOSTERONE RESPONSE TO
ENVIRONMENTAL MANIPULATIONS AND TO CHRONIC
CHLORDIAZEPOXIDE TREATMENT.
000092 01-03
HYPOPHYSEaOMY PREVENTS THE STRIATAL DOPAMINE-RECEPTOR
SUPERSENSITIVITY PRODUCED BY CHRONIC HALOPERIDOL TREATMENT.
000132 01-03
MONOAMINE-OXIDASE-INHIBITION AND BRAIN-AMINE METABOLISM
AFTER ORAL TREATMENT WITH TOLOXATONE IN THE RAT.
000156 01-03
EFFEaS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT.
000180 01-03
STRIATAL DOPAMINERGIC ACTIVITY DURING WITHDRAWAL FROM
CHRONIC NEUROLEPTIC TREATMENT IN RATS.
000203 01-03
LONG-TERM ANTIDEPRESSANT TREATMENT DECREASES SPIROPERIDOL-
LABELED SEROTONIN-RECEPTOR BINDING.
000230 01-03
LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL
CAPILLARY PERMEABILITY.
000239 01-03
REDUCTION OF VOLUNTARY MORPHINE CONSUMPTION FOLLOWING
TREATMENT WITH ZIMELIDINE.
000253 01-03
FUNQIONAL AND STRUQURAL CONSEQUENCES OF LONG-TERM DIETARY
L-DOPA TREATMENT IN MICE.
000257 01-03
FUNQIONAL EVIDENCE FOR SUBSENSITIVITY OF NORADRENERGIC-
ALPHA2-RECEPT0RS AFTER CHRONIC DESIPRAMINE TREATMENT.
000283 01-03
ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY
DEXAMETHASONE TREATMENT.
000321 01-03
THE INTERAQION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS
000389 01-04
OPEN-FIELD PERFORMANCE OF RATS AFTER ENDOTOXIN TREATMENT.
000473 01-04
MORPHINE TREATMENT AT DIFFERENT INFANT AGES: INFLUENCE ON
LATER MORPHINE EFFEQS IN RATS. (PH.D. DISSERTATION).
000511 01-05
OUR EXPERIENCE WITH PIRACETAM (NOOTROPIL-UCB) TREATMENT IN
CHILDREN FROM HIGH-RISK PREGNANCIES WITH SUBSEQUENT
MINIMAL-BRAIN-DYSFUNaiON.
000544 01-07
ANTIDEPRESSANT TREATMENT BY INTRAVENOUS ADMINISTRATION
COMPARED TO PERORAL ADMINISTRATION: A DOUBLE-BUND STUDY
OF QUINUPRAMINE.
000552 01-08
NEUROLEPTIC AND THYMOLEPTIC TREATMENT OF PSYCHOTIC-
OUTPATIENTS.
000556 01-08
THE PLACE OF LONG-AQING NEUROLEPTICS IN THE TREATMENT OF
SCHIZOPHRENIA.
000563 01-08
PREDiaiNG OUTCOME OF ANTIPSYCHOTIC-DRUG TREATMENT FROM
EARLY-RESPONSE.
000565 01-08
HOSPITAL AND OUTPATIENT CARE FOR PSYCHOTIC-PATIENTS DURING THE
LAST THREE DECADES: SUBSEQUENT HOSPITAL AND OUTPATIENT
TREATMENT OF PSYCHOTIC-PATIENTS HOSPITALIZED FOR THE FIRST
TIME IN 1949-50, 1959-60 OR 1969-70.
000571 01-08
DOUBLE-BUND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH
AFTERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS
WITH SCHIZOPHRENIA.
000574 01-08
LITHIUM TREATMENT IN POSTPSYCHOTIC DEPRESSION.
000575 01-08
ADVANTAGE OF PHARMACOKINETIC DATA DURING TREATMENT OF
PSYCHOSES WITH HALOPERIDOL.
000577 01-08
TREATMENT OF DEPRESSION IN THE MEDICALLY-ILL ELDERLY WITH
METHYLPHENIDATE.
000602 01-09
THE TREATMENT OF SCHIZOAFFEaiVE-PSYCHOSES WITH UTHIUM-
CARBONATE.
000607 01-09
THE TREATMENT OF DEPRESSIVE-CONDITIONS WITH NOMIFENSINE.
000609 01-09
NOMIFENSIN IN THE TREATMENT OF ENDOGENOUS DEPRESSIONS.
CUNICAL-EXPERIENCE AND EEG FINDINGS.
000613 01-09
THE TREATMENT OF ANXIOUS-DEPRESSIVE-SYNDROMES WITH
TOFIZOPAM.
000615 01-09
IMIPRAMINE TREATMENT OF PREPUBERTAL MAJOR DEPRESSIVE-
DISORDERS: PLASMA LEVELS AND CLINICAL-RESPONSE -
PRELIMINARY REPORT.
000620 01-09
OUR EXPERIENCE WITH MAPROTIUN TREATMENT OF DEPRESSIVE-STATES.
000623 01-09
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-STATES.
000626 01-09
SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF
SINGLE VS. DIVIDED DOSE ADMINISTRATION.
000629 01-09
ANTIDEPRESSIVE TREATMENT AND MOOD-SWING-PAHERNS IN
ENDOGENOUS DEPRESSION.
000633 01-09
LITHIUM TREATMENT IN AFFEQIVE-DISORDERS: THERAPEUTIC PLASMA
LEVEL.
000635 01-09
LITHIUM TREATMENT IN AFFEQIVE-DISORDERS FROM VIEWPOINT OF
TRANSCULTURAL PSYCHOPHARMACOLOGY: THERAPEUTIC PLASMA
LEVEL.
000636 01-09
COMBINED MONOAMINE-OXIDASE-INHIBITOR TRICYCUC-
ANTIDEPRESSANT TREATMENT: A PILOT-STUDY.
000644 01-09
STUDIES ON THE COMPREHENSIVE MEDICAL TREATMENT OF PEPTIC-
ULCERS (3) - UTILIZATION OF TRANQUIUZERS IN THE TREATMENT OF
GASTRIC-ULCERS
000653 01-10
CUNICAL-EXPERIENCE WITH LOW-DOSES OF HALOPERIDOL IN THE
TREATMENT OF NEUROSES.
000654 01-10
ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLED-
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH
PARKINSONS-DISEASE TREATED WITH L-DOPA.
000659 01-1
ANTICONVULSANTS AND TREATMENT OF EPILEPSY.
000661 01-1
UTHIUM-CARBONATE IN THE TREATMENT OF CLUSTER-HEADACHES.
000670 01-1
PYRITINOL ADMINISTRATION AS PART OF EPILEPSY TREATMENT IN
CHILDREN.
000671 01-1
BIOCHEMICAL-MEASUREMENTS DURING (-)DEPRENYL TREATMENT OF
PARKINSONISM.
000673 01-1
CHOLINE-BITARTRATE TREATMENT OF ALZHEIMER-TYPE DEMENTIAS.
000675 01-1
CLOZAPINE IN THE TREATMENT OF TARDIVE-DYSKINESIA: AN INTERIM
REPORT.
000677 01-1
TREATMENT OF TARDIVE-DYSKINESIA WITH OXYPERTINE - PREUMINARY
CLINICAL-EXPERIENCE AND A BRIEF REVIEW OF THE LITERATURE.
000692 01-1
THE EFFEQ OF ASSERTIVENESS TRAINING, PROVERA AND SEX OF
THERAPIST IN THE TREATMENT OF GENITAL EXHIBITIONISM.
000697 01-1
TOFIZOPAM IN THE TREATMENT OF CHRONIC ALCOHOUSM.
000706 01-1
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L-
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE)
A CUNICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION.
000712 01-1
FLUNITRAZEPAM IN THE TREATMENT OF DEURIUM-TREMENS -
PREUMINARY REPORT.
000719 01-1
CONTROLLED-TRIAL OF BEHAVIOUR-THERAPY, PHARMACOTHERAPY, AND
THEIR COMBINATION IN THE TREATMENT OF OBESITY.
000725 01-1
COMPARISON OF SUSTAINED-RELEASE AND STANDARD
METHYLPHENIDATE IN THE TREATMENT OF MINIMAL-BRAIN-
DYSFUNQION.
000732 01-1
ISSUES FOR INPATIENT TREATMENT OF CHRONIC PCP ABUSE.
000736 01-12
LITHIUM-INDUCED COGWHEEL RIGIDITY: TREATMENT WITH
AAAANTADINE.
000748 01-13
S-454
VOLUME 19, SUBJECT INDEX
Subject Index
METHODOLOGICAL REMARKS ON LONG-TERM LITHIUM TREATMENT.
000749 01-13
TREATMENT OF DRUG-INDUCED DRYNESS OF MOUTH IN PSYCHIATRIC-
PATIENTS - A CONTROLLED-COMPARATIVE-STUDY.
000799 01-13
PROLACTIN RESPONSE AND EXTRAPYRAMIDAL SIDE-EFFECTS DURING
PROPRANOLOL AND NEUROLEPTIC-DRUGS TREATMENT IN CHRONIC
SCHIZOPHRENIC-PATIENTS.
000841 01-15
HYPNAGOGIC AND HYPNOPOMPIC HALLUCINATIONS DURING
AMITRIPTYLINE TREATMENT.
000850 01-15
PLASMA PROLACTIN AND TESTOSTERONE DURING PENFLURIDOL
TREATMENT.
000874 01-15
ELECTROCARDIOGRAPHIC-CHANGES DURING LITHIUM TREATMENT.
000881 01-15
THE OCCURRENCE OF TARDIVE EXTRAPYRAMIDAL SYMPTOMS IN
SCHIZOPHRENIC-PATIENTS UNDERGOING PROLONGED NEUROLEPTIC
TREATMENT.
000885 01-15
CLINICALLY SIGNIFICANT SIDE-EFFECTS OF LITHIUM TREATMENT.
000893 01-15
DEXAMETHASONE-SUPPRESSION-TESTS IN DEPRESSION AND RESPONSE
TO TREATMENT.
000899 01-16
ENDOCRINOLOGICAL CHANGES IN PATIENTS WITH SEXUAL-DYSFUNaiON
UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000912 01-17
OUTPATIENT TREATMENT ISSUES AND STRATEGIES FOR ACUTE AND
CHRONIC PCP ABUSERS.
000919 01-17
TARDIVE-DYSKINESIA RESULTING FROM CHRONIC NARCOTIC
TREATMENT.
000922 01-17
TARDIVE-DYSKINESIA: RESEARCH & TREATMENT.
000934 01-17
FOLLOWUP TREATMENT AND ARERCARE OF DISCHARGED
SCHIZOPHRENIC-PATIENTS.
000944 01-17
PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS ~ PART I:
PROTOCOL FOR THE TREATMENT OF PSYCHOSIS WITH
ANTIPSYCHOTICS.
000949 01-17
PSYCHOPHARMACOLOGtCAL AND PSYCHOTHERAPEUTIC-APPROACHES TO
THE TREATMENT OF FUNCTIONAL PSYCHOSES.
000977 01-17
A REVISED CHECKLIST TO OBTAIN CONSENT TO TREATMENT WITH
MEDICATION.
000984 01-17
DEPRESSION IN THE ELDERLY: RESEARCH DIRECTIONS IN
PSYCHOPATHOLOGY, EPIDEMIOLOGY, AND TREATMENT.
000998 01-17
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4-
HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT
AFTER ACTIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF
SINGLE AND REPEATED NEUROLEPTIC TREATMENT.
001095 02-03
EFFECT OF CHRONIC TRICYCLIC-ANTIDEPRESSANT TREATMENT ON THE
SEROTONINERGIC-AUTORECEPTOR: A MICROIONTOPHORETIC-STUDY IN
THE RAT.
001135 02-03
GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT
AFFECTED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN
TREATMENT.
001 145 02-03
ACUTE AND CHRONIC HALOPERIDOL TREATMENT: EFFEQS ON
NIGROSTRIATAL DOPAMINERGIC-SYSTEM ACTIVITY.
001153 02-03
DOPAMINERGIC-SUPERSENSITIVITY: INFLUENCE OF DOPAMINE AGONISTS
AND DRUGS USED FOR THE TREATMENT OF TARDIVE-DYSKINESIA
001169 02-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND RECEPTOR BINDING-
ACTIVITIES FOLLOWING ACUTE AND CHRONIC NEUROLEPTIC-DRUG
TREATMENT. (UNPUBLISHED PAPER).
001172 02-03
LONG-TERM HALOPERIDOL TREATMENT OF MICE: A CHANGE IN BETA-
ADRENERGIC-RECEPTOR RESPONSIVENESS.
001206 02-03
EFFECTS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE.
001243 02-03
CALMODULIN RELEASE FROM STRIATAL MEMBRANES AFTER ACUTE AND
CHRONIC TREATMENT WITH BUTACLAMOL.
001249 02-03
THE TIME-COURSE OF NORADRENERGIC PRESYNAPTIC AND
POSTSYNAPTIC AQIVITY DURING CHRONIC DESIPRAMINE TREATMENT.
001289 02-03
THE HYPERKINETIC-SYNDROME FOLLOWING LONG-TERM HALOPERIDOL
TREATMENT: INVOLVEMENT OF DOPAMINE AND NORADRENALINE
001299 02-03
INTERACTION OF TRIAZOLAM WITH DESIPRAMINE: EFFECTS OF SINGLE
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC-
RESPONSES AND BRAIN CATECHOLAMINE LEVELS.
001323 02-03
LONG-TERM HALOPERIDOL TREATMENT AND FACTORS EFFECTING THE
ACTIVITY OF STRIATAL TYROSINE-HYDROXYLASE.
001348 02-03
ALTERED LEVELS OF BETA ENDORPHIN FRAGMENTS AFTER CHRONIC
MORPHINE TREATMENT OF GUINEA-PIG ILEUM IN VITRO AND IN VIVO.
001404 02-03
EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC-
SYSTEMS IN THE RAT-BRAIN.
001464 02-03
LONG-TERM APPLICATION OF HALOPERIDOL: EFFECT OF ANTICHOLINERGIC
TREATMENT ON THE RATE OF DOPAMINE SYNTHESIS.
001490 02-03
ENHANCED SENSITIVITY OF AMYGDALOID NEURONS TO SEROTONIN AND
NOREPINEPHRINE AFTER CHRONIC ANTIDEPRESSANT TREATMENT.
001523 02-03
BEHAVIORAL-EFFECTS, ANTIDOPAMINERGIC-EFFECTS, AND PROHYPNOTIC-
EFFECTS OF NEUROLEPTICS DURING AND AFTER PROLONGED
TREATMENT.
001577 02-04
INTERACTION OF PSYCHOPHARMALOGIC-FACTORS AND PSYCHOSOCIAL-
FACTORS IN THE TREATMENT OF ANIMAL-MODELS OF
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR.
001602 02-04
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH
PSYCHOSTIMULANTS: II. EFFECT OF METHAMPHETAMINE ON
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC
SUBSTRATES.
001613 02-04
SUBACUTE CANNABINOID TREATMENT: ANTICONVULSANT ACTIVITY AND
WITHDRAWAL EXCITABILITY IN MICE.
001671 02-04
NEUROCHEMICAL-EFFECTS AND BEHAVIORAL-EFFEaS OF CHRONIC D-
AMPHET AMINE TREATMENT IN GENETICALLY OBESE (OBOB) MICE.
(PH.D. DISSERTATION).
001739 02-04
EMERGENCE OF APOMORPHINE-INDUCED VACUOUS CHEWING DURING 6
MONTHS CONTINUOUS TREATMENT WITH FLUPHENAZINE-DECANOATE.
001817 02-04
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE-
DECANOATE TREATMENT.
001820 02-04
CHRONIC NEUROLEPTIC TREATMENT AND DOPAMINE-RECEPTOR
REGULATION.
001837 02-05
3H APOMORPHINE-RECEPTORS IN VARIOUS RAT-BRAIN REGIONS: A
STUDY OF SPECIFIC AND NONSPECIFIC BINDING AND THE INFLUENCE OF
CHRONIC NEUROLEPTIC TREATMENT.
001846 02-05
NEUROLEPTIC TREATMENT FOR ASUBSTANTIAL PROPORTION OF ADULT
LIFE: BEHAVIOURAL-SEQUELAE OF 9 MONTHS HALOPERIDOL
ADMINISTRATION.
001858 02-05
ANTIPSYCHOTIC-EFFEQ OF PROPRANOLOL ON CHRONIC
SCHIZOPHRENICS: STUDY OF A GRADUAL TREATMENT REGIMEN.
001915 02-08
EFFECT OF PROPRANOLOL TREATMENT ON SERUM PROLACTIN LEVEL IN
SCHIZOPHRENIC-PATIENTS.
001916 02-08
OXYPROTHEPINE-DECANOATE COMPARED WITH FLUPHENAZINE-
DECANOATE IN THE TREATMENT OF SCHIZOPHRENIA: PRELIMINARY-
COMMUNICATION.
001934 02-08
USE OF lARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC-
PATIENTS WITH ELEVATED SERUM PROLACTIN LEVELS AND
EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH NEUROLEPTIC
TREATMENT.
001944 02-08
PLASMA FLUPHENAZINE AND PROLACTIN LEVELS IN SCHIZOPHRENIC-
PATIENTS DURING TREATMENT WITH LOW-DOSES AND HIGH-DOSES OF
FLUPHENAZINE-ENANTHATE.
001956 02-08
PRELIMINARY- STUDIES ON CSF GAMMA AMINOBUTYRIC-ACID LEVELS IN
PSYCHIATRIC-PATIENTS BEFORE AND DURING TREATMENT WITH
DIFFERENT PSYCHOTROPIC-DRUGS.
001959 02-08
STUDY OF MAPROTILINE IN OUTPATIENT TREATMENT OF DEPRESSIVE-
STATES BY THE GENERAL-PRACTITIONER: ADVANTAGE OF SINGLE-
NIGHTLY-DOSE.
001961 02-09
S-455
Subject Index
Ptychopharmacology Abstracts
SI;
fe
I
RESULTS OF A SURVEY ON THE PRESENT TREATMENT OF DEPRESSION IN
SPAIN.
001963 02-09
NOMIFENSINE IN THE TREATMENT OF VARIOUS TYPES OF DEPRESSION.
001968 02-09
THE PLACE OF SURVECTOR AMONG THE VARIOUS DRUGS USED IN
TREATMENT OF MOOD-DISORDERS.
001969 02-09
AHEMPT AT PSYCHOLOGICAL UNDERSTANDING AND TREATMENT OF
PSYCHOLOGICAL ASTHENIA AND ASTHENO-DEPRESSIVE-SYNDROMES
USING ERGADYL.
001974 02-09
NOMIFENSINE IN THE TREATMENT OF ENDOGENOUS DEPRESSION. A
CONTROLLED-STUDY VS. NORTRIPTYLINE.
001978 02-09
TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE
FATIGUE STUDY GROUPS NO. 4 CLINICAL-SCALE.
001980 02-09
A COMPARISON OF HALOPERIDOL, LITHIUM-CARBONATE AND THEIR
COMBINATION IN THE TREATMENT OF MANIA.
001990 02-09
TRAZODONE IN THE TREATMENT OF NEUROTIC DEPRESSION.
001994 02-09
AN OVERVIEW OF SEVENTEEN YEARS OF EXPERIENCE WITH DOTHIEPIN IN
THE TREATMENT OF DEPRESSION IN EUROPE.
001995 02-09
IS IT POSSIBLE TO SET UP ANY RULES FOR A COMPREHENSIVE
TREATMENT OF DEPRESSIVE-STATES?
001997 02-09
THE IMPORTANCE OF AMINEPTINE IN THE TREATMENT OF NONPSYCHOTIC
DEPRESSIVE-STATES IN THE ELDERLY.
001999 02-09
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC
DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL
CONTROLS.
002004 02-09
TREATMENT OF THERAPY-RESISTANT DEPRESSED-PATIENTS WITH IV.
INFUSIONS OF NOMIFENSINE CONTROLLED BY GALVANIC-SKIN-
RESISTANCE.
002012 02-09
INNOVATIONS IN TREATMENT WITH ANTIDEPRESSANTS.
002019 02-09
LARGE-DOSES OF DIBENZEPINE NOVERIL IN THE TREATMENT OF
DEPRESSIVE-STATES.
002020 02-09
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A
MONOSUBSTANCE (DOXEPINE).
002028 02-09
SENSITIZATION AND OSCILLATION FOLLOWING REPEATED STIMULATION:
RELATIONSHIP TO AFFECTIVE-ILLNESS AND ITS TREATMENT WITH
LITHIUM AND CARBAMAZEPINE.
002031 02-09
TREATMENT OF TARDIVE-DYSKINESIA IN AN AGITATED, DEPRESSED-
PATIENT.
002038 02-09
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME. PART 1:
TREATMENT OF ACUTE DEPRESSION
002044 02-09
TREATMENT OF CHRONIC PAIN WITH ANTIDEPRESSANT-DRUGS.
002048 02-09
A TEN YEAR FOLLOWUP OF LITHIUM-CARBONATE TREATMENT OF MANIC-
DEPRESSIVE-ILLNESS: PRELIMINARY-RESULTS.
002053 02-09
PYRAZIDOL IN THE TREATMENT OF DEPRESSIONS.
002055 02-09
INFUSION OF MAPROTILIN AND CLOMIPRAMIN AND THEIR COMBINATION
IN THE TREATMENT OF DEPRESSION.
002056 02-09
INHIBITION AND APATHY: TREATMENT WITH SURVEQOR.
002066 02-10
PIMOZIDE IN THE TREATMENT OF SOME SOCIAL-MALADJUSTMENTS IN
PERSONALITY-DISORDERS.
002068 02-10
DOUBLE-BUND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO
SEVERE ANXIETY.
002070 02-10
FLUSPIRILENE (IMAP) IN THE TREATMENT OF PSYCHOSOMATIC-
COMPLAINTS IN HYPOCHONDRIACAL-PATIENTS.
002072 02-10
KETAZOLAM COMPARED TO DIAZEPAM AND PLACEBO IN THE
TREATMENT OF ANXIETY.
002074 02-10
NOMIFENSINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE-NEUROSIS.
THERAPEUTIC-EFFICACY AND TOLERABILITY IN COMPARISON TO
IMIPRAMINE.
002078 02-10
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A
CONTROLLED CLINICAL-STUDY WITH DOXEPIN AND PLACEBO.
002080 02-10
PREDICTION OF RESPONSE TO TREATMENT WITH PHENEUINE IN
NEUROTIC-PATIENTS.
002081 02-10
THE LONG-TERM TREATMENT WITH BENZODIAZEPINES: SUGGESTIONS
FOR FURTHER RESEARCH
002085 02-10
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: I. A
CONTROLLED CLINICAL-TRIAL.
002086 02-10
HUNTINGTONS-DISEASE: CLINICAL-EFFEaS OF A SHORT-TERM
TREATMENT WITH PIMOZIDE.
002091 02-11
TREATMENT OF PARKINSONIAN-SYNDROME WITH DEXETIMIDE.
002111 02-11
TREATMENT OF DYSKINETIC AND DYSTONIC-DISORDERS WITH CF-25-
397: CLINICAL-ASPECTS AND PHARMACOLOGICAL ASPEQS.
002121 02-11
MEDROXYPROGESTERONE TREATMENT OF OBSTRUCTIVE SLEEP-APNEA
002128 02-11
AMPHETAMINIL IN THE TREATMENT OF DISTURBED EREQION POTENCY.
002129 02-11
NOMIFENSINE AS CONCOMITANT THERAPY IN THE TREATMENT OF
PARKINSON-PATIENTS. A DOUBLE-BLIND PLACEBO-CONTROLLED-
STUDY.
002130 02-n
EVALUATION OF SYMPTOMATIC TREATMENT OF HYPERAQIVE-BEHAVIOR
BY STIMULANT-DRUGS.
002134 02-11
SODIUM-VALPROATE IN THE TREATMENT OF ALCOHOL WITHDRAWAL-
SYNDROME
002139 02-11
ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT
AND POSHREATMENT OF ALCOHOLIC WITHDRAWAL.
002140 02-11
DELIRIUM: TREATMENT POSSIBILITIES.
002141 02-11
A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED
PARKINSONISM
002146 02-11
CORTICAL-CORRELATES OF VIGILANCE REGULATION AND THEIR USE IN
EVALUATING THE EFFEaS OF TREATMENT.
002147 02-11
THE RELATIVE EFFICACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY
FOR THE TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY.
(PH.D. DISSERTATION).
002148 02-11
PENFLURIDOL IN THE TREATMENT OF GILLES-DE-LA-TOURETTES-
SYNDROME.
002158 02-11
PARKINSONISM: IS YOUR TREATMENT APPROPRIATE?
002159 02-11
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT;
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL
EVOLUTION.
002165 02-11
LISURIDE IN THE TREATMENT OF PARKINSONISM.
002168 02-11
THE ROLE OF BROMOCRIPTINE IN THE TREATMENT OF PARKINSONS-
DISEASE
002177 02-11
TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAN AND
CARBIDOPA: CLINICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL-
OBSERVATIONS.
002180 02-11
INCREASED RATIO OF CARBIDOPA TO LEVODOPA IN TREATMENT OF
PARKINSONS-DISEASE.
002182 02-11
A CONTROLLED DOUBLE-BLIND STUDY OF HALOPERIDOL VERSUS
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY-
SUBNORMAL-PATIENTS: SERUM LEVELS AND CLINICAL-EFFEaS
002185 02-11
THE TREATMENT OF BUCCOLINGUOFACIAL DYSKINESIA IN THE ELDERLY:
THE CHOICE OF A NEUROLEPTIC-AGENT.
002223 02-13
INCREASED CSF GAMMA AMINOBUTYRIC-ACID AFTER TREATMENT WITH
GAMMA VINYL-GABA.
002237 02-13
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/AND
DIPHENYLHYDANTOIN IN SERUM LIPIDS.
002281 02-13
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: II.
BIOCHEMICAL-ASPECTS.
002300 02-13
S-456
VOLUME 19, SUBJECT INDEX
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF
PLASMA CONCENTRATIONS Of AMITRIPTYLINE AND ITS METABOLITE
NORTRIPTYLINE
002304 02-13
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE
002305 02-13
THE QUESTION OF MINIMUM-DOSES OF ANTICONVULSANTS IN THE
TREATMENT OF EPILEPSY,
002306 02-13
SHORT-TERM AND LONG-TERM EFFECTS ON GABA AND DOPAMINE
NEURONS DURING TREATMENT WITH SULPIRIDE
002311 02-13
PAROXYSTIC-OYSKINESIAS DURING TREATMENT WITH
DIPHENYLHYDANTOIN.
002319 02-14
L HTP AND THE SEROTONIN HYPOTHESIS: THEIR MEANING FOR
TREATMENT OF DEPRESSION.
002326 02-14
ALCOHOL WITHDRAWAL-SYNDROME: TREATMENT WITH TRAZODONE
002356 02-14
NEUROPEPTIDE TREATMENT OF SOCIOPATHY: RESEARCH IN PROGRESS
002369 02-14
DOPAMINE ANTAGONIST AND AGONIST TREATMENT OF TARDIVE-
DYSKINESIA.
002377 02-15
LECITHIN IN THE TREATMENT OF TARDIVE-DYSKINESIA.
002380 02-15
LEVODOPA COMPARED WITH BROMOCRIPTINE IN THE TREATMENT OF
PARKINSONS-DISEASE.
002406 02-15
CASE 3: ASSESSMENT AND TREATMENT OF DRUG-INDUCED TREMOR
002407 02-15
COMPARATIVE-STUDY OF VARIATIONS IN PROLACTIN LEVELS DURING
TREATMENT WITH ANTIPSYCHOTIC-DRUGS
002412 02-15
AN INVESTIGATION OF SOME SIDE-EFFECTS IN 47 PSYCHOTIC-PATIENTS
DURING TREATMENT WITH CLOZAPINE AND DISCONTINUING OF THE
TREATMENT.
002424 02-15
APPROACHES TO THE PROBLEM OF PREVENTING HAZARDS OF LONG-
TERM NEUROLEPTIC TREATMENT AND OF AVOIDING UNNECESSARY
DRUGS.
002426 02-15
TREATMENT OF PSYCHOTROPIC-CAUSED ORTHOSTATIC HYPOTENSION
002428 02-15
MALIGNANT-HYPERTHERMIC-SYNDROMES IN THE COURSE OF
TREATMENT WITH LONG-ACTING NEUROLEPTICS.
002430 02-15
FAILURE OF LITHIUM TREATMENT IN ESTABLISHED TARDIVE-DYSKINESIA
002432 02-15
TREATMENT OF IATROGENIC DRUG DEPENDENCE IN THE GENERAL-
HOSPITAL.
002460 02-15
RECENT DEVELOPMENTS IN LITHIUM TREATMENT: IS IT DANGEROUS FOR
THE KIDNEY?
002465 02-15
USE OF CHOLINE AND LECITHIN IN THE TREATMENT OF TARDIVE-
DYSKINESIA.
002473 02-15
ERGOTS IN THE TREATMENT OF MENTAL-DISORDERS OF OLD-AGE.
002545 02-17
PLACEBO, MEDICINE AND PAIN, OR THE RELATIVE FUNCTION OF
MEDICATION IN THE TREATMENT OF PAIN.
002577 02-17
THE TREATMENT OF OPIATE ADDICTION USING METHADONE-
CHLORHYDRATE.
002600 02-17
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY?
002659 03-03
DURING ONE YEARS NEUROLEPTIC TREATMENT IN RATS STRIATAL
DOPAMINE-RECEPTOR BLOCKADE DECREASES BUT SERUM PROLACTIN
LEVELS REMAIN ELEVATED.
002707 03-03
EFFEQS OF FETAL TREATMENT WITH METHYLAZOXYMETHANOL-ACETATE
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE
ADULT NEOCORTEX OF THE RAT.
002770 03-03
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL- 1 H-INDAZOLE (FS-32)
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN.
002787 03-03
AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR
ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER
CHRONIC ANTIDEPRESSANT TREATMENT.
002788 03-03
Subject index
PHARMACOLOGIC APPROACHES TO THE TREATMENT OF SENILE-
DEMENTIA
002809 03-03
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON
002884 03-03
DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC-
RECEPTORS.
002914 03-03
MEPACRINE TREATMENT PREVENTS IMMOBILIZATION-INDUCED
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT
HYPOTHALAMUS AND BRAINSTEM.
002919 03-03
INDUCTION OF HYPERSENSITIVITY OF BRAIN BY HYDRALAZINE
TREATMENT IN RATS.
003008 03-04
INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN
CHORIONIC GONADOTROPHS.
003012 03-04
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY
REACTIONS IN DOGS.
003030 03-04
EFFECTS OF CHRONIC NALOXONE TREATMENT ON BRAIN-STIMULATION
REWARD.
003066 03-04
ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITIES IN THE
MOUSE CEREBELLUM FOLLOWING MISONIDAZOLE TREATMENT
003123 03-05
AN OPEN-STUDY OF MAPROTILINE 75MG IN THE TREATMENT OF
DEPRESSIVE-STATES.
003152 03-07
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE.
003172 03-08
LATE RESULTS OF LITHIUM TREATMENT OF ADOLESCENTS WITH ATTACK
LIKE SCHIZOPHRENIA.
003177 03-08
CHLORPROMAZINE LEVELS AND THE OUTCOME OF TREATMENT IN
SCHIZOPHRENIC-PATIENTS.
003188 03-08
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND
TREATMENT OUTCOME.
003189 03-08
DIAGNOSIS AND TREATMENT OF ACUTE SCHIZOPHRENIC-PSYCHOSES
003191 03-08
THE USE OF A MORPHINE ANTAGONIST (NALOXONE) IN THE TREATMENT
OF DISSOCIATIVE-SYNDROMES.
003194 03-08
A SYMPTOM-PROFILE-ANALYSIS OF ANTIPSYCHOTIC-DRUG TREATMENT-
NONPARAMETRIC MULTIDIMENSIONAL TECHNIQUE.
003196 03-08
CLINICAL-STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE-
STATES: COMPILATION OF 1520 OBSERVATIONS.
003206 03-09
PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS - PART 11-
PROTOCOL FOR THE TREATMENT OF DEPRESSION WITH TRICYCLIC-
ANTIDEPRESSANTS.
003214 03-09
AMOXAPINE AND AMITRIPTYLINE IN THE OUTPATIENT TREATMENT OF
ENDOGENOUS DEPRESSION.
003217 03-09
THE REPRESSION OF THE LITHIUM-PUMP AS AN INDICATOR OF RESPONSE
TO PROPHYLACTIC TREATMENT.
003221 03-09
HISTORICAL-PERSPECTIVES AND CURRENT HIGHLIGHTS ON LITHIUM
TREATMENT IN MANIC-DEPRESSIVE-ILLNESS.
003224 03-09
DOSAGE OF INTRATUMORAL LITHIUM (CEREBRAL GLIOBLASTOMA): ON A
FAILURE OF TREATMENT OF MANIC-DEPRESSIVE-PSYCHOSIS.
003226 03-09
SLEEP AND TREATMENT PREDICTION IN ENDOGENOUS DEPRESSION
003236 03-09
AMOXAPINE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSED-
OUTPATIENTS: A CONTROLLED-STUDY.
003254 03-09
CEREBRAL EVOKED-POTENTIAL CHANGES PRODUCED BY TREATMENT
WITH LITHIUM-CARBONATE.
003263 03-09
THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL-
MEDICAL-PRACTICE: 48 CASES TREATED ON AN OUTPATIENT BASIS.
003268 03-09
S-457
Subject Index
Ptychopharmacology Abstracts
tit
a
t)
ii
ait
ft,'
I
DEPRESSED-OUTPATIENTS: RESULTS ONE YEAR AFTER TREATMENT WITH
DRUGS AND/OR INTERPERSONAL PSYCHOTHERAPY.
003272 03-09
RECENT ADVANCES IN THE DIAGNOSIS AND TREATMENT OF ANXIETY-
DISORDERS.
003275 03-10
CHANGES IN THE PSYCHOPATHOLOGY OF PSYCHOSIS DUE TO
NEUROLEPTIC TREATMENT.
003281 03-10
BENZODIAZEPINE TREATMENT OF SPECIFIC ANXIETY STATES.
003284 03-10
PHENELZINE AND EXPOSURE IN THE TREATMENT OF PHOBIAS.
003285 03-10
SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN
PRAZEPAM TREATMENT IN 30 CASES.
003296 03-11
EVALUATION OF THE RELATIVE EFFECTIVENESS OF METHYLPHENIDATE
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF
KINDERGARTEN-AGED HYPERACTIVE-CHILDREN .
003306 03-11
RECENT ADVANCES IN THE TREATMENT OF EPILEPSY.
003307 03-11
INCREASED SERUM PROLACTIN LEVELS DURING PHENOTHIAZINE AND
BUTYROPHENONE TREATMENT OF SIX POSTPARTUM WOMEN.
003318 03-11
MOLINDONE-HYDROCHLORIDE IN THE TREATMENT OF AGGRESSIVE,
HOSPITALIZED CHILDREN.
00332103-11
TREATMENT OF TRAUMATIC WAR-NEUROSIS WITH PHENELZINE.
003325 03-11
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS. A
CLINICAL DOUBLE-BLIND STUDY WITH MACROMOLECULAR ORGAN
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER).
003327 03-11
A CLINICAL, CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE
TREATMENT OF NARCOTIC ADOIQION.
003335 03-11
THE EFFECTIVENESS OF IMIPRAMINE IN THE TREATMENT OF ENURESIS:
THE SIGNIFICANCE OF TYPE OF ENURESIS AND REPORTED LEVEL OF
SLEEP. (PH.D. DISSERTATION).
003337 03-1 1
THE EFFECT OF WITHDRAWAL FROM PROLONGED PROPHYLAQIC
TREATMENT WITH LITHIUM.
003339 03-1 1
NALOXONE IN THE TREATMENT OF ANOREXIA-NERVOSA: EFFEQ ON
WEIGHT-GAIN AND LIPOLYSIS.
003342 03-11
RAPID TREATMENT OF ACUTE PSYCHOTIC-SYMPTOMS WITH HIGH-DOSE
AND LOW-DOSE HALOPERIDOL: BEHAVIORAL-CONSIDERATIONS.
003346 03-11
PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND
DEMENTIA.
003347 03-11
PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALLIUM, ARSENIC,
INDUSTRIAL-SOLVENT INTOXICATION, AND OTHER
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT.
003348 03-1 1
TREATMENT OF ANXIETY IN CHILDREN AND ADOLESCENTS.
003349 03-11
HYPNOTIC-DRUGS AND TREATMENT OF INSOMNIA.
003350 03-11
THE USE OF PHENAZEPAM IN THE TREATMENT OF PSYCHOTIC-PATIENTS.
003351 03-11
PROGRESSIVE SUPRANUCLEAR PALSY: PNEUMOENCEPHALOGRAPHY,
ELECTRONYSTAGMOGRAPHY AND TREATMENT WITH METHYSERGIDE.
003355 03-1 1
IMIPRAMINE TREATMENT OF BORDERLINE-CHILDREN: CASE-REPORTS
WITH A CONTROLLED-STUDY.
003356 03-11
PHYSOSTIGMINE FOR TREATMENT OF DELIRIUM-TREMENS.
003364 03-1 1
THE ROLE OF PSYCHOPHARMACOTHERAPY IN THE TREATMENT OF
ELDERLY-PATIENTS WITH ORGANIC-MENTAL-SYNDROMES.
003368 03-1 1
THE TREATMENT AND ETIOLOGY OF TICS AND TOUREHE-SYNDROME.
003372 03-1 1
USE OF THA IN TREATMENT OF ALZHEIMER-LIKE DEMENTIA: PILOT-STUDY
IN TWELVE PATIENTS.
003377 03-1 1
ON THE INTENSIVE TREATMENT OF ENDOGENOUS PSYCHOSES.
003384 03-1 1
LITHIUM TREATMENT OF THE KLEINE-LEVIN-SYNDROME.
003390 03-1 1
PROPRANOLOL IN THE TREATMENT OF RAGE AND VIOLENT-BEHAVIOR IN
PATIENTS WITH CHRONIC-BRAIN-SYNDRDMES.
003394 03-11
FLUNITRAZEPAM IN THE TREATMENT OF INSOMNIA: A STUDY OF 50
PSYCHIATRIC-PATIENTS.
003444 03-14
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC-
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE:
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL
AMELIORATION.
003458 03-14
THE DIAGNOSIS AND TREATMENT OF NEUROLEPTIC-INDUCED
PARKINSONISM.
003493 03-15
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF
BENZODIAZEPINE TREATMENT: SIX CLINICAL CASES.
003505 03-15
TIME-COURSE OF CLINICAL CHEMICAL PARAMETERS UNDER LONG-TERM
LITHIUM TREATMENT.
003515 03-15
PHENCYCLIDINE (PCP) INTOXICATION: DIAGNOSIS IN STAGES AND
ALGORITHMS OF TREATMENT.
003525 03-15
RECENT ADVANCES IN THE TREATMENT OF PARKINSONS-DISEASE.
003528 03-15
THA - A REVIEW OF THE LITERATURE AND ITS USE IN TREATMENT OF
FIVE OVERDOSE PATIENTS.
003539 03-15
GLOMERULAR FILTRATION RATE AND CALCIUM METABOLISM IN LONG-
TERM LITHIUM TREATMENT.
003542 03-15
A TARDIVE-DYSKINESIA-LIKE SYNDROME AFTER AMITRIPTYLINE
TREATMENT.
003552 03-15
A TRIAL TREATMENT WITH TIAPRIDE FOR SOME EXTRAPYRAMIDAL-
SYNDROMES CAUSED BY NEUROLEPTIC-AGENTS.
003553 03-15
TREATMENT OF DEPRESSIVE-CONDITIONS IN THE ELDERLY.
003578 03-17
QUESTIONS OF DIFFERENTIATED TREATMENT FOR EPILEPTIC-PATIENTS.
003605 03-17
TREATMENT OF CANCER PAIN.
003619 03-17
GERIATRIC ASPEaS OF PARKINSONISM (CLINICAL-PIQURE
PATHOLOGICAL MECHANISMS, AND MULTIPLE TREATMENT).
003643 03-17
EFFEa OF CHRONIC MORPHINE TREATMENT ON THE INTERAQION
BETWEEN THE PERIAQUEDUQAL GREY AND THE NUCLEUS-RAPHE-
MAGNUS OF THE RAT.
003727 04-03
CATECHOLAMINE TURNOVER IN RAT-CEREBRAL-CORTEX AND CAUDATE
FOLLOWING REPEATED TREATMENT WITH DIHYDROERGOTOXINE
003765 04-03
EFFECTS OF ACUTE AND CHRONIC AMPHETAMINE TREATMENT ON
PURKINJE NEURON DISCHARGE IN RAT CEREBELLUM.
003793 04-03
THE EFFECTS OF CHRONIC METHYLPHENIDATE TREATMENT ON GROWTH
AND ENDOCRINE FUNQION IN THE DEVELOPING RAT
003811 04-03
INCREASED MESOLIMBIC DOPAMINE BINDING FOLLOWING CHRONIC
HALOPERIDOL TREATMENT.
003872 04-03
EFFECT OF NEONATAL HYDROCORTISONE TREATMENT ON BRAIN-
MONOAMINES IN DEVELOPING RATS.
003893 04-03
METABOLIC AND SYMPATHOADRENAL ABNORMALITIES IN THE OBESE
ZUCKER RAT: EFFEQ OF CHRONIC PHENOXYBENZAMINE TREATMENT.
003905 04-03
THE DOPAMINE-RECEPTOR COMPLEX: BIOCHEMICAL-CONSEQUENCES OF
SUPERSENSITIVITY INDUCED BY TREATMENT WITH 6
HYDROXYDOPAMINE OR MORPHINE.
003958 04^3
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE,
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT.
003961 04-03
EFFEQ OF PRENATAL NEUROLEPTIC TREATMENT ON MEMBRANE
RECEPTOR DEVELOPMENT IN THE BRAIN.
003989 04-03
CHRONIC NEUROLEPTIC TREATMENT SPECIFICALLY ALTERS THE NUMBER
OF DOPAMINE-RECEPTORS IN RAT-BRAIN.
004033 04-03
EFFEQS OF A HIGH-DOSE TREATMENT OF METHAMPHETAMINE ON
CAUDATE DOPAMINE AND ANOREXIA IN RATS.
004073 04-04
INDUaiON OF BEHAVIORAL-SUPERSENSITIVITY TO APOMORPHINE BY
DFP TREATMENT.
004099 04-04
EFFEQS OF WITHDRAWAL FROM LONG-TERM DIPHENYLHYDANTOIN
TREATMENT ON AUDIOGENIC-SEIZURES AND MAXIMAL
ELEQROSHOCK-INDUCED SEIZURES IN RATS.
004101 04^
S-458
VOLUME 19, SUBJECT INDEX
Subject Index
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS.
004180 04-04
TREATMENT OF UNSTABLE ANGINA BY DILTIAZEM.
004307 04-07
CORRELATIONS BETWEEN VISUAL-EVOKED-POTENTIALS AND
PSYCHOPATHOLOGICAL-FINDINGS IN SCHIZOPHRENIC-PATIENTS UNDER
TREATMENT WITH VARIOUS PSYCHOPHARMACOLOGICAL-DRUGS.
004315 04-08
PRELIMINARY TRIAL OF CLONIOINE TREATMENT IN TWO PATIENTS
SUFFERING FROM CHRONIC SCHIZOPHRENIA.
004320 04-08
PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO
COUNTERACT CURATIVE EFFECTS OF NEUROLEPTIC-DRUGS.
004321 04-08
THE TREATMENT OF CHRONIC SCHIZOPHRENIC-PATIENTS: AN INTERVIEW
WITH DR. J. HUSSER.
004328 04-08
NEUROENDOCRINE-TESTS DURING TREATMENT WITH NEUROLEPTIC-
DRUGS: I. PLASMA PROLACTIN RESPONSE TO CHLORPROMAZINE
CHALLENGE.
004329 04-08
HALOPERIDOL AND DROPERIDOL TREATMENT IN SCHIZOPHRENICS:
CLINICAL APPLICATION OF THE PROLAQIN MODEL.
004332 04-08
A DOUBLE-BLIND COMPARISON OF THREE DOSAGES OF FLUTROLINE (CP-
36584) IN THE TREATMENT OF SCHIZOPHRENIA.
004333 04-08
THE USE OF SODIUM-NUCLEINATE IN THE TREATMENT OF
SCHIZOPHRENIC-PATIENTS.
004339 04-08
LONG-TERM NEUROLEPTIC TREATMENT OF CHRONIC SCHIZOPHRENIC-
PATIENTS: CLINICAL AND BIOCHEMICAL-EFFECTS OF WITHDRAWAL.
004344 04-08
EVALUATIONS OF LOXAPINE-SUCCINATE IN THE AMBULATORY
TREATMENT OF ACUTE SCHIZOPHRENIC-EPISODES.
004345 04-08
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE.
004356 04-09
GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF DEPRESSION.
004376 04-09
TREATMENT OF DEPRESSION WITH AN MAO-INHIBITOR FOLLOWED BY 5
HTP ~ AN UNFINISHED RESEARCH PROJECT.
004377 04-09
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH
ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT.
004382 04-09
AN EVALUATION OF TRAZODONE IN THE TREATMENT OF DEPRESSION.
004386 04-09
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO.
004387 04-09
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO
AND STANDARD (IMIPRAMINE) CONTROLLED CLINICAL-STUDY.
004392 04-09
ALTERATIONS IN NORADRENERGIC FUNCTION DURING CLORGYLINE
TREATMENT.
004393 04-09
LITHIUM TREATMENT OF MANIC-DEPRESSIVE-ILLNESS. A PRAQICAL
GUIDE.
004408 04-09
ELEQROCARDIOGRAM-CHANGES AND PLASMA DESIPRAMINE LEVELS
DURING TREATMENT OF DEPRESSION.
00441 1 04-09
CHANGES IN PSYCHOPATHOLOGIC SYMPTOMS DURING 20 DAYS OF
TREATMENT WITH ANTIDEPRESSANTS AND NEUROLEPTIC-DRUGS.
004415 04-09
CONTROLLED CLINICAL-TRIAL OF NOMIFENSINE IN THE TREATMENT OF
DEPRESSION.
004417 04-09
PRAZEPAM: A NEW BENZODIAZEPINE FOR THE TREATMENT OF ANXIOUS-
DEPRESSIVE STATES.
004419 04-10
DIFFERENTIAL DIAGNOSIS AND TREATMENT OF PANIC AHACKS AND
PHOBIC-STATES.
004424 04-10
AN EVALUATION OF THE USEFULNESS OF THE ACYLASE TEST IN
NEUROLEPTIC TREATMENT.
004426 04-10
DRUG-THERAPY FOR HYPERACTIVITY: TREATMENT PROCEDURES IN
NATURAL SEHINGS.
004449 04-11
TREATMENT OF SEX-OFFENDERS WITH MEOROXYPROGESTERONE-
ACETATE.
004450 04-11
TREATMENT OF ENCOPRESIS WITH IMIPRAMINE.
004451 04-11
METHADONE TREATMENT OF HEROIN ADDICTS IN SWITZERLAND.
004452 04-11
HYPERVENTILATION-SYNDROME, TREATMENT WITH L TRYPTOPHAN AND
PYRIDOXINE, PREDICTIVE VALUES OF XANTHURENIC-ACID EXCRETION.
004456 04-11
THE CLASSIFICATION OF SLEEP-DISORDERS AND THE TREATMENT OF
VARIOUS FORMS OF SOMNAMBULISM.
00446) 04-11
EFFECT OF TREATMENT WITH SODIUM-VALPROATE AND DIAZEPAM ON
PLASMA CORTICOTROPIN IN NELSONS-SYNDROME,
004463 04-11
SCOPOLAMINE IN CHOLINOLYTIC TREATMENT.
004468 04-11
TREATMENT OF EPILEPSIES WITH CLONAZEPAM (ANTELEPSIN).
004481 04-11
THE TREATMENT OF INSOMNIA THROUGH HOMEOPATHY IN A CLINIC.
004484 04-11
SINGLE-CASE STUDY OF CLINICAL-RESPONSE TO HIGH-DOSE ERGOT
ALKALOID TREATMENT FOR DEMENTIA. PRELIMINARY REPORT.
004493 04-1 1
CEREBROSPINAL-FLUID HOMOVANILLIC-ACID PAHERNS DURING
NEUROLEPTIC TREATMENT. (UNPUBLISHED PAPER).
004502 04-13
A MECHANISM FOR THE ACCUMULATION OF CHOLINE IN ERYTHROCYTES
DURING TREATMENT WITH LITHIUM.
004520 04-13
TREATMENT OF UNDERNUTRITION AND ELEaROLYTE-DISTURBANCES IN
ANOREXIA-NERVOSA.
004531 04-13
TREATMENT OF NARCOLEPSY AND SLEEP-APNEA WITH GAMMA
HYDROXYBUTYRATE: A CLINICAL AND POLYSOMNOGRAPHIC CASE-
STUDY.
004571 04-14
PROSPEaS FOR THE TREATMENT OF POSTENCEPHALITIC PARKINSONISM
WITH ANTILYMPHOCYTIC IMMUNOGLOBULIN.
004572 04-14
CORREQION OF HORMONAL AQIVITY OF THE THYROID-GLAND AS A
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT
OF PATIENTS WITH TEMPORAL EPILEPSY.
004579 04-14
USE OF LYSINE-VASOPRESSIN IN THE TREATMENT OF POSHRAUMATIC
AMNESIA.
004583 04-14
OPIOID DEPENDENCE: MECHANISMS AND TREATMENT.
004587 04-14
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT, TARDIVE-
DYSKINESIA, AND THE TRAINING OF RESEARCH PSYCHIATRISTS.
004603 04-15
LECITHIN FOR THE TREATMENT OF TARDIVE-DYSKINESIA.
004612 04-15
NEUROLEPTIC TREATMENT AS EXPERIENCED BY A PSYCHIATRIST.
004613 04-15
TREATMENT OF TARDIVE-DYSKINESIA.
004616 04-15
A STUDY ON MENTAL-SYMPTOMS DEVELOPED DURING THE TREATMENT
OF PARKINSONS-DISEASE.
004618 04-15
BACLOFEN IN THE TREATMENT OF TARDIVE-DYSKINESIA: OPEN LABEL
STUDY.
004619 04-15
A CASE OF ACUTE AGRANULOCYTOSIS DURING TREATMENT WITH
CLOZAPINE.
004642 04-15
RESULTS OF TREATMENT BY MODITEN DEPOT IN OUTPATIENTS-WARDS IN
THE SOUTH MORAVIAN REGION.
004648 04-15
APOMORPHINE-INDUCED STEREOTYPY IN MATURE AND SENESCENT RATS
FOLLOWING CESSATION OF CHRONIC HALOPERIDOL TREATMENT.
004651 04-15
LITHIUM-CARBONATE IN THE TREATMENT OF MOVEMENT-DISORDERS. A
CRITICAL REVIEW.
004668 04-15
THE USE OF CLINICAL KINETIC DATA IN TREATMENT WITH
ANTIDEPRESSANT-DRUGS.
004686 04-16
STUDY ON THE STABILITY OF THE FAQORIAL STRUCTURE OF THE AMP
SYSTEM DURING TREATMENT.
004696 04-16
ANOREXIA-NERVOSA. SYMPTOMS, COURSE AND POSSIBILITIES FOR
TREATMENT.
004711 04-17
PSYCHOPHARMACOLOGY AND PSYCHOTHERAPY IN THE TREATMENT OF
ANXIETY.
004712 04-17
THERAPEUTIC TREATMENT OF INSUFFICIENT PERFORMANCE IN
CEREBROVASCULAR-DISEASES.
004718 04-17
S-459
Subject Index
Ptychopharmacology Abstracts
1
151;;
"tit
ft',
^
EMOTIONAL-DISORDERS IN CHILDREN AND ADOLESCENTS: MEDICAL AND
PSYCHOLOGICAL APPROACHES TO TREATMENT.
004743 04-17
CURRENT TRENDS IN TREATMENT IN PSYCHIATRY.
004747 04-17
TREATMENTS
LITHIUM LEVELS IN BLOOD-PLATELETS, SERUM, RED-BLOOD-CELLS AND
BRAIN REGIONS IN RATS GIVEN ACUTE OR CHRONIC LITHIUM-SALT
TREATMENTS.
000082 01-03
PRINCIPAL AND DIFEERENTIAL-EFFEaS OF HALOPERIDOL AND PLACEBO
TREATMENTS UPON SPEECH DISFLUENCIES IN STUHERERS.
00071301-11
AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL
DOPAMINE-RECEPTORS AFTER VARIOUS TREATMENTS WITH
ANTAGONISTS OR AGONISTS.
001350 02-03
TREATMENTS FOR SLEEP-WAKE-DISORDERS IN THE ELDERLY.
002157 02-11
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT
NECESSARY FOR CLINICAL EFFICACY?
002659 03-03
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFEaS OF
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN.
002990 03-04
THE BEHAVIORAL-EFFECTS OF D-AMPHET AMINE ALONE AND IN
COMBINATION WITH ACUTE AND CHRONIC MORPHINE TREATMENTS IN
RATS.
003915 04-03
ALTERATIONS IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY
FOLLOWING ACUTE AND CHRONIC ETHANOL TREATMENTS.
004037 04-03
CLASSICAL NEUROLEPTICS AND OECONDITIONING ACTIVITY AFTER SINGLE
OR REPEATED TREATMENTS: ROLE OF DIFFERENT CEREBRAL
NEUROTRANSMinERS.
0041 15 04-04
PREVALENCE OF HYPERAQIVITY AND RELATED TREATMENTS AMONG
ELEMENTARY SCHOOL CHILDREN.
004469 04-11
TREMOR
HARMALINE-INDUCED TREMOR: THE BENZODIAZEPINE-RECEPTOR AS A
SITE-OF-AQION.
001436 02-03
CASE 3: ASSESSMENT AND TREATMENT OF DRUG-INDUCED TREMOR.
002407 02-15
TREMORGENtC
AaiONS OF TREMORGENIC FUNGAL TOXINS ON NEUROTRANSMIHER
RELEASE.
002843 03-03
TREMORS
MODIFICATION OF DRUG-INDUCED CATATONIA AND TREMORS BY
QUIPAZINE IN RATS AND MICE.
004164 04-04
TRENDS
TRENDS IN THE PRESCRIPTION OF PSYCHOTROPIC-DRUGS (1970-1977) IN
A STATE-HOSPITAL.
000926 01-17
ANTIPSYCHOTICS AND ANTIDEPRESSANTS: NEW TRENDS AND EXPEQED
FUTURE.
002539 02-17
COMPUTERIZED MONITORING OF PSYCHOTROPIC-DRUG ORDERS: SOME
TRENDS AND REVELATIONS.
003566 03-16
NEW TRENDS CONCERNING THE BIOCHEMICAL-MECHANISM OF AQION
OF BENZODIAZEPINES.
003642 03-17
PSYCHOPHARMACOTHERAPY: THE PRESENT STATE AND THE
DEVELOPMENT OF TRENDS.
004723 04-17
CURRENT TRENDS IN TREATMENT IN PSYCHIATRY.
004747 04-17
TRH
MODIFICATION OF THE PROLINE RESIDUE OF TRH ENHANCES BIOLOGICAL-
AQIVITY AND INHIBITS DEGRADATION.
000351 01-04
PROLAQIN AND SOMATOTROPIN RESPONSES TO TRH IN SCHIZOPHRENIC-
PATIENTS.
000570 01-08
GROWTH-HORMONE AFTER TRH IN WOMEN WITH DEPRESSIVE-ILLNESS.
000606 01-09
GROWTH-HORMONE (GH) RELEASE FOLLOWING THYROTROPIN-
RELEASING-HORMONE (TRH) INJECTION IN MANIC-PATIENTS
RECEIVING LITHIUM-CARBONATE.
000645 01-09
SOME PHARMACOLOGICAL-ASPEaS AND BIOCHEMICAL-ASPEaS OF
TRH: EXPERIMENTAL AND CLINICAL DATA.
001189 02-03
INVESTIGATIONS ON THE INTERAQION OF THYROTROPIN-RELEASING-
HORMONE (TRH) AND MK-771 WITH CENTRAL NORADRENERGIC
MECHANISMS.
001701 02-04
THE TSH RESPONSE TO TRH INJECTION IN PSYCHIATRIC-PATIENTS: A
REVIEW.
002145 02-11
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY
PRETREATMENT WITH THYROID-HORMONES.
002259 02-13
TRH INCREASES LOCOMOTOR-AQIVITY IN RATS AFTER INJEQION INTO
THE HYPOTHALAMUS.
003044 03-04
GAMMA BUTYROLAQONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE
CITRATE (DN-1417): A NOVEL TRH ANALOG WITH POTENT EFFEQS ON
THE CENTRAL-NERVOUS- SYSTEM.
003057 03-04
BIOLOGICAL EVALUATION OF A TRH ANALOGUE WITH A MODIFIED
PROLINE RESIDUE.
003662 04-01
PHARMACOLOGICAL-ASPEQS OF SHAKING-BEHAVIOR PRODUCED BY
TRH, AG-3-5, AND MORPHINE WITHDRAWAL.
004248 04-04
TSH, HGH, HPR, AND CORTISOL RESPONSE TO TRH IN DEPRESSED-
PATIENTS.
004399 04-09
BASAL PROLAQINAEMIA AND RESPONSES TO TRH AND SULPIRIDE IN
DIFFERENT CATEGORIES OF MALE SEXUAL-DYSFUNQIONS.
004503 04-13
TRIACETYLOLEANDOMYaN
CARBAMAZEPINE INTOXICATION DUE TO TRIACETYLOLEANDOMYCIN
ADMINISTRATION IN EPILEPTIC-PATIENTS.
000873 01-15
TRIAL
AROUSAL AND SHORT-TERM MEMORY: EFFEQS OF CAFFEINE AND TRIAL
SPACING ON DELAYED ALTERNATION PERFORMANCE.
000487 01-04
TRIAL WITH MINAPRINE IN SUBJEQS WITH PSYCHIATRIC-DISORDERS.
001889 02-07
COMPARISON OF THE EFFECTS OF LOFEPRAMINE AND MIANSERIN IN
DEPRESSED-PATIENTS IN A DOUBLE-BUND TRIAL.
001996 02-09
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS:
RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BUND TRIAL.
001998 02-09
ELEQROENCEPHALOGRAPHIC-EFFEaS AND BEHAVIOURAL-EFFEaS OF
SODIUM-VALPROATE IN PATIENTS WITH PHOTOSENSITIVE EPILEPSY. A
SINGLE-DOSE TRIAL.
002154 02-11
TRIAL OF A PEPTIDE FRAQION OF AQH (AaH4-10) IN THE ALCOHOLIC
BRAIN-DAMAGE-SYNDROME .
002318 02-14
THERAPEUTIC TRIAL OF A NEW ANTIDEPRESSANT: MIANSERIN.
003208 03-09
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS
WITH AN ENOOMORPHOUS DEPRESSIVE COURSE: A TRIAL,
INTERAQIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNQURES
IN THIS PHASE.
003251 03-09
A DOUBLE-BUND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF
CARBAMAZEPINE IN OVERAQIVE, SEVERELY MENTALLY-
HANDICAPPED PATIENTS
003365 03-11
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN
OBJEQIVE FULLY AUTOMATED AEP ANALYSIS METHOD.
003412 03-13
A TRIAL TREATMENT WITH TIAPRIDE FOR SOME EXTRAPYRAMIDAL-
SYNDROMES CAUSED BY NEUROLEPTIC-AGENTS.
003553 03-15
PREUMINARY TRIAL OF CLONIDINE TREATMENT IN TWO PATIENTS
SUFFERING FROM CHRONIC SCHIZOPHRENIA.
004320 04-08
DES-TYROSYL-GAMMA-ENDORPHIN IN SCHIZOPHRENIA: A D0UBL£-BUND
TRIAL IN 13 PATIENTS.
004322 04-08
A DOUBLE-BUND TRIAL: THE USE OF OXPRENOLOL AND DIAZEPAM IN
ANXIETY.
004428 04-10
TRIALS
NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA: RECENT
PATHOPHYSIOLOGICAL-DATA, THERAPEUTIC TRIALS.
000842 01-15
TIME-BUND ANALYSIS AND OTHER VIDEO-STRATEGIES IN PHASE II
TRIALS OF PSYCHOTROPIC-DRUGS.
003568 03-16
DEBATE: THERAPEUTIC TRIALS IN A NATURAL ENVIRONMENT.
003635 03-17
S-460
VOLUME 19, SUBJECT INDEX
Subject Index
TRIAZOLAM
CHRONIC USE OF TRIAZOLAM: THE EFFECTS ON THE SLEEP PATTERNS OF
INSOMNIACS.
000710 0)-ll
INTERACTION OF TRIAZOLAM WITH DESIPRAMINE: EFFECTS OF SINGLE
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC-
RESPONSES AND BRAIN CATECHOLAMINE LEVELS.
00)323 02-03
COMPARISON OF NITRAZEPAM 5 MG WITH TRIAZOLAM 0.5 MG IN
YOUNG PSYCHIATRIC INSOMNIAC-INPATIENTS.
002096 02-11
THE EFFICACY OF TRIAZOLAM AND CHLORAL-HYDRATE IN GERIATRIC
INSOMNIACS.
002160 02-11
THE EFFECTS OF TRIAZ0L^M AND NITRAZEPAM ON SLEEP QUALITY,
MORNING VIGILANCE, AND PSYCHOMOTOR PERFORMANCE.
002330 02-14
THE EFFECTS OF FLURAZEPAM, LORAZEPAM, AND TRIAZOLAM ON SLEEP
AND MEMORY
002357 02-14
DIFFICULTIES ENCOUNTERED DURING A CONTROLLED STUDY OF A NEW
HYPNOTIC-DRUG (TRIAZOLAM) BY A GROUP OF GENERAL-
PRACTITIONERS.
003155 03-07
TRIAZOLOTHIENODIACEPINE
EEG ASSESSMENTS OF DOSAGE AND SLEEP PROFILES FOR A HYPNOTIC-
DRUG OF THE TRIAZOLOTHIENODIACEPINE SERIES.
002338 02-14
TRICHLOROPHENOXYACETIC-ACID
2.4,5 TRICHLOROPHENOXYACETIC-ACID CAUSES BEHAVIORAL-EFFECTS IN
CHICKENS AT ENVIRONMENTALLY RELEVANT DOSES.
003079 03-04
TRICHOTILLOMANIA
TRICHOTILLOMANIA TREATED WITH AMITRIPTYLINE.
002083 02-10
TRICYCLIC
FLUORINATED ANALOGUES OF THE TRICYCLIC NEUROLEPTICS: 2,3
DIFLUORO DERIVATIVE OF CLOROTEPIN.
000001 01-01
THE EFFECT OF A NEW FLUORINATED TRICYCLIC NEUROLEPTIC-DRUG
ISOFLOXYTHEPIN ON THE RAT STRIATAL DOPAMINE METABOLISM.
000306 01-03
SEIZURES DURING TRICYCLIC THERAPY.
000868 01-15
THE PHOTOCHEMICAL-STABILITY OF CIS-ISOMERS AND TRANS-ISOMERS
OF TRICYCLIC NEUROLEPTIC-DRUGS.
001872 02-06
CHILDHOOD-ENURESIS: II. PSYCHOPATHOLOGY, TRICYCLIC
CONCENTRATION IN PLASMA, AND ANTIENURETIC-EFFEQ.
002354 02-14
PSYCHIATRIC-ASPEQS OF ACUTE POISONING WITH TRICYCLIC AND
RELATED ANTIDEPRESSANTS ~ 1980.
002458 02-15
BLOOD LEVEL MEASUREMENTS OF TRICYCLIC DRUGS AS A DIAGNOSTIC
TOOL.
004368 04-09
TRICYCLIC-ANTIDEPRESSANT
TRICYCLIC-ANTIDEPRESSANT DRUGS AND INDIVIDUAL DIFFERENCES IN
THE EXPLORATORY-ACTIVITY OF RATS: CONTRASTING-EFFEaS OF
TERTIARY AND SECONDARY AMINE COMPOUNDS.
000401 01-04
AHENUATION OF AMPHETAMINE ANOREXIA IN RATS FOLLOWING
SUBCHRONIC-TREATMENT WITH A TRICYCLIC-ANTIDEPRESSANT.
000501 01-04
HYPOMANIA AND TRICYCLIC-ANTIDEPRESSANT CHOICE.
000545 01-07
TRICYCLIC-ANTIDEPRESSANT DRUG TOLERANCE IN ORIENTAL AND
OCCIDENTAL POPULATIONS.
000590 01-09
COMBINED MONOAMINE-OXIDASE-INHIBITOR TRICYCLIC-
ANTIDEPRESSANT TREATMENT: A PILOT- STUDY.
000644 01-09
TRICYCLIC-ANTIDEPRESSANT DRUG-INTERAQIONS WITH HISTAMINE AND
ALPHA-ADRENERGIC-RECEPTORS.
000791 01-13
EXPERIMENTAL EVALUATION OF ANTIDEPRESSANT ACTIVITY OF
CLOMIPRAMINE, A NEW TRICYCLIC-ANTIDEPRESSANT DRUG.
001068 02-02
EFFECT OF CHRONIC TRICYCLIC-ANTIDEPRESSANT TREATMENT ON THE
SEROTONINERGIC-AUTORECEPTOR: A MICROIONTOPHORETIC-STUDY IN
THE RAT.
001135 02-03
PRESYNAPTIC ALPHA-ADRENOCEPTORS AND THE ACTION OF TRICYCLIC-
ANTIDEPRESSANT DRUGS IN BEHAVIOURAL-DESPAIR IN RATS.
001829 02-04
LONG-TERM MONITORING OF TRICYCLIC-ANTIDEPRESSANT PLASMA
CONCENTRATIONS.
002014 02-09
RELEVANCY OF TRICYCLIC-ANTIDEPRESSANT PLASMA LEVELS.
003246 03-09
THE BENEFITS AND RISKS OF COMBINING AN MAO-INHIBITOR AND A
TRICYCLIC-ANTIDEPRESSANT.
003273 03-09
TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT DECREASES ALPHA2-
ADRENORECEPTORS ON HUMAN PLATELET MEMBRANES.
003408 03-13
EXCEPTIONAL CASES OF DEATH CAUSED BY TRICYCLIC-ANTIDEPRESSANT
AGENTS.
003490 03-15
ARRHYTHMIA INDUCED BY A TRICYCLIC-ANTIDEPRESSANT IN A PATIENT
WITH UNDIAGNOSED MITRAL- VALVE PROLAPSE.
003521 03-15
INTERACTION OF THE TRICYCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH
PREJUNCTIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG
SAPHENOUS VEIN.
003756 04-03
DOXEPIN, A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTACT
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL-
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION.
003836 04-03
ALPHA2-ADREN0RECEPT0RS IN RAT-BRAIN ARE DECREASED AFTER
LONG-TERM TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT.
004008 04-03
EFFECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC
NEURONS.
004026 04-03
SUBCHRONIC-TREATMENT WITH THE TRICYCLIC-ANTIDEPRESSANT DMI
INCREASES ISOLATION-INDUCED FIGHTING IN RATS.
004252 04-04
A COMPARATIVE CLINICAL-TRIAL WITH THE TRANQUILIZER TRAZODONE
AND THE TRICYCLIC-ANTIDEPRESSANT CLOMIPRAMINE.
004380 04-09
NEUROLEPTIC TRICYCLIC-ANTIDEPRESSANT COMBINATION:
PHARMACOLOGICAL-ASPEQS AND THERAPEUTIC INTEREST.
004501 04-13
SYMPATHOMIMETIC-AMINES AND TRICYCLIC-ANTIDEPRESSANT DRUGS.
004678 04-16
TRICYCLIC-ANTIDEPRESSANT-INDUCED
TRICYCLIC-ANTIDEPRESSANT-INOUCED MANIA.
004656 04-15
TRICYCLIC-ANTIDEPRESSANTS
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH
IN THE ELECTROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO
AUTORECEPTOR STIMULATION.
000046 01-03
TRICYCLIC-ANTIDEPRESSANTS INDUCE SUBSENSITIVITY OF PRESYNAPTIC
DOPAMINE-AUTORECEPTORS .
000048 01-03
ANTIDEPRESSANT PROPERTIES OF 2 4 ETHYL-2-PIPERAZINYL-4-
PHENYLQUINOLINE-HCL (AD-1308) AND ITS MECHANISM-OF-AaiON
AS COMPARED WITH TRICYCLIC-ANTIDEPRESSANTS.
000152 01-03
POSTAMPHET AMINE DEPRESSION OF SELF-STIMULATION RESPONDING
FROM THE SUBSTANTIA-NIGRA: REVERSAL BY TRICYCLIC-
ANTIDEPRESSANTS.
000419 01-04
TRICYCLIC-ANTIDEPRESSANTS: THERAPEUTIC PLASMA LEVEL.
000646 01-09
DOPAMINE-RECEPTOR BLOCKADE IN RAT-BRAIN AFTER ACUTE AND
SUBCHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANTS.
001314 02-03
CONFORMATIONALLY RESTRICTED TRICYCLIC-ANTIDEPRESSANTS. 1.
OQAHYDRODIBENZAZEPINONAPHTHYRIDINES AS RIGID IMIPRAMINE
ANALOGUES.
001710 02-04
HIGH-AFFINITY BINDING OF TRICYCLIC-ANTIDEPRESSANTS TO HISTAMINE
HI -RECEPTORS: FACT AND ARTIFACT.
001880 02-06
EFFEQ OF TRICYCLIC-ANTIDEPRESSANTS ON INDIVIDUAL SYMPTOMS.
002052 02-09
MOTOR-LEARNING ABILITIES IN SUBJEQS TREATED WITH LITHIUM-SALTS
AND TRICYCLIC-ANTIDEPRESSANTS.
002058 02-09
THE PERIPHERAL ANTICHOLINERGIC-ACTIVITY OF TRICYCLIC-
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND
DESIPRAMINE IN HUMAN VOLUNTEERS.
002298 02-13
CARDIOVASCULAR-EFFECTS OF THERAPEUTIC DOSES OF TRICYCLIC-
ANTIDEPRESSANTS: IMPORTANCE OF BLOOD LEVEL MONITORING.
002456 02-15
DETERMINATION OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS AND OF THEIR METABOLIC PRODUCTS IN
BIOLOGICAL FLUIDS.
002498 02-16
INTERACTIONS OF TRICYCLIC-ANTIDEPRESSANTS WITH A SYNAPTIC ION-
CHANNEL.
002660 03-03
S-461
I
k
5
ft:
Subject Index
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC-
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM:
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON.
002884 03-03
PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS - PART II
PROTOCOL FOR THE TREATMENT OF DEPRESSION WITH TRICYCLIC-
ANTIDEPRESSANTS.
003214 03-09
EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON INTERPERSONAL LEARNING.
003225 03-09
HYPOMANIA AND MANIA AFTER WITHDRAWAL OF TRICYCLIC-
ANTIDEPRESSANTS.
003243 03-09
EXCESSIVE PLASMA CONCENTRATIONS OF TRICYCLIC-ANTIDEPRESSANTS
RESULTING FROM USUAL DOSES: A REPORT OF SIX CASES.
003479 03-15
THE EFFECT OF DIBENZAZEPINES (TRICYCLIC-ANTIDEPRESSANTS) ON
CEREBRAL CAPILLARY PERMEABILITY IN THE RAT IN VIVO.
003974 04-03
TRICYCLIC-ANTIDEPRESSANTS AND HISTAMINE Hl-RECEPTORS.
003986 04-03
EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON TETRABENAZINE-INDUCED
DEPLETION OF BRAIN MONOAMINES IN RATS. 1. NOREPINEPHRINE.
004062 04-03
THE EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON PERFORMANCE UNDER
A DIFFERENTIAL-REINFORCEMENT-OF-LOW-RATES SCHEDULE IN RATS.
004175 04-04
INDIVIDUAL DIFFERENCES IN EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS
AND ANTICHOLINERGIC-DRUGS ON OPERANT-BEHAVIOR IN THE
SQUIRREL-MONKEY.
004176 04-04
MECHANISM OF MEMBRANE STABILIZING AND LYTIC-EFFECTS OF
TRICYCLIC-ANTIDEPRESSANTS.
004283 04-05
PHARMACOKINETICS AND CLINICAL-RESPONSE TO TRICYCLIC-
ANTIDEPRESSANTS.
004370 04-09
DIFFERENT EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS ON THE RELEASE OF TSH, PROLAQIN, AND
GROWTH-HORMONE AFTER ADMINISTRATION OF THYROSTIMULATING-
RELEASING-HORMONE IN MANIC-DEPRESSIVES.
004407 04-09
THE EFFECT OF FIVE TRICYCLIC-ANTIDEPRESSANTS ON SALIVARY FLOW
AND MOOD IN HEALTHY VOLUNTEERS.
004560 04-14
TRICYCLIC-ANTIDEPRESSANTS AND ALCOHOLIC BLACKOUTS.
004617 04-15
RADIOIMMUNOASSAY OF TRICYCLIC-ANTIDEPRESSANTS.
004674 04-16
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC-
ANTIDEPRESSANTS: PERSPEQIVE OF THE CLINICAL LABORATORY.
004681 04-16
A RAPID AND SENSITIVE RADIORECEPTOR ASSAY FOR TERTIARY AMINE
TRICYCLIC-ANTIDEPRESSANTS .
004689 04-16
TRICYCLICS
REPEATED TRICYCLICS INDUCE A PROGRESSIVE DOPAMINE-
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT Of DAILY DRUG-
TREATMENT.
000047 01-03
TRIETHYLTIN-INDUCED
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS
000509 01-05
TRIFLUOPERAZINE
EFFEQS OF TRIFLUOPERAZINE, CHLORPROMAZINE, AND HALOPERIDOL
UPON TEMPORAL INFORMATION-PROCESSING BY SCHIZOPHRENIC-
PATIENTS.
000554 01-08
A COMPARISON OF STRIATAL AND MESOLIMBIC DOPAMINE FUNQION IN
THE RAT DURING 6-MONTH TRIFLUOPERAZINE ADMINISTRATION.
001174 02-03
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR
SUBSEQUENT WITHDRAWAL.
001175 02-03
FLUPHENAZINE, TRIFLUOPERAZINE AND PERPHENAZINE IN VACUTAINERS.
003565 03-16
TRIFLUOROETHYL-DIHYDROXYPHENYLETHYLAMINE
PREPARATION AND BIOLOGICAL ACTIONS OF N 2,2,2 TRIFLUOROETHYL-
DIHYDROXYPHENYLETHYLAMINE .
003697 04-02
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE-
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1
CYCLOPROPYLMETHYL
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE.
003706 04-02
Ptychopharmacology Abstracts
TRIGEMINAL-NEURALGIA
A CASE OF TRIGEMINAL-NEURALGIA TREATED WITH LITHIUM-
CARBONATE.
000690 01-11
BACLOFEN IN TRIGEMINAL-NEURALGIA: ITS EFFEQ ON THE SPINAL
TRIGEMINAL-NUCLEUS: A PILOT-STUDY.
002122 02-11
CARBAMAZEPINE THERAPY IN TRIGEMINAL-NEURALGIA: CLINICAL-
EFFEQS IN RELATION TO PLASMA CONCENTRATION.
002181 02-11
TRIGEMINAL-NUCLEUS
MICROIONTOPHORETIC STUDIES ON NORADRENERGIC INHIBITION FROM
LOCUS-COERULEUS OF SPINAL TRIGEMINAL-NUCLEUS NEURONS.
000260 01-03
BACLOFEN IN TRIGEMINAL-NEURALGIA: ITS EFFEQ ON THE SPINAL
TRIGEMINAL-NUCLEUS: A PILOT-STUDY.
002122 02-11
TRIGGER
A BARBITURATE-EVOKED INTENSIFICATION OF POSTSYNAPTIC INHIBITION
IN THE PREOPTIC OVULATORY TRIGGER REGION OF THE
HYPOTHALAMUS.
002818 03-03
THE NA-K-ATPASE: A PLAUSIBLE TRIGGER FOR VOLTAGE-INDEPENDENT
RELEASE OF CYTOPLASMIC NEUROTRANSMITTERS.
003953 04-03
TRIHYDROXY
DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE
INFLUENCE THE CENTRAL-AQIVITY OF ADENYLATE-CYCLASE AND
CYCLIC-AMP-PHOSPHODIESTERASE.
001405 02-03
TRIHYDROXYBENZYLHYDRAZINE
THE INTERACTION OF 2,3,4 TRIHYDROXYBENZYLHYDRAZINE WITH
DOPA-DECARBOXYLASE FROM PIG KIDNEY.
002925 03-03
TRIIODOTHYRONINE
EFFECT OF ACUTE AND CHRONIC TRIIODOTHYRONINE {T3)
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE-
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN-
BIOCHEMISTRY.
002951 03-04
INFLUENCE OF CARBAMAZEPINE ON SERUM THYROXINE AND
TRIIODOTHYRONINE IN PATIENTS WITH EPILEPSY.
004488 04-11
TRIMETHADIONE
TRIMETHADIONE EFFEQS ON CHOLINERGIC RESPONSES IN APLYSIA
NEURONS.
002782 03-03
TRIMIPRAMINE
TRIMIPRAMINE: TWENTY YEARS WORLDWIDE CLINICAL-EXPERIENCE.
000985 01-17
DOUBLE-BLIND CONTROLLED-STUDY: AMINEPTINE VERSUS
TRIMIPRAMINE.
002051 02-09
TRIPELENNAMINE
POTENTIATION OF LETHALITY IN MICE BY COMBINATIONS OF
PENTAZOCINE AND TRIPELENNAMINE
000529 01-05
MEDICAL AND PSYCHIATRIC-COMPLICATIONS OF PENTAZOCINE AND
TRIPELENNAMINE ABUSE.
000955 01-17
TRIPEPTIDE
A TRIPEPTIDE FOR CONTROL OF SCHIZOPHRENIC- SYMPTOMS.
001919 02-08
TRIPHENYLMETHYLPHOSPHONIUM-BROMIDE
MEASUREMENT Of THE MEMBRANE POTENTIAL Of ISOLATED NERVE
TERMINALS BY THE LIPOPHILIC CATION
(3H)TRIPHENYLMETHYLPH0SPH0NIUM-BR0MIDE.
002746 03-03
TRIPHOSPHATE
5' TRIPHOSPHATE RECYCLES INDEPENDENTLY Of ACETYLCHOLINE IN
CHOLINERGIC SYNAPTIC VESICLES.
004063 04-03
TRITIATED
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. II. IN
VIVO METABOLISM OF TRITIATED DRUGS IN RHESUS-MONKEYS.
001229 02-03
COMPARISON OF THE BINDING CHARAQERISTICS OF TRITIATED OPIATES
AND OPIOID-PEPTIDES.
003802 04-03
TROTTING
DIAZEPAM-INDUCED ATAXIA IN TROHING SQUIRREL-MONKEYS
004138 04-04
TRYPTAMINE
ABNORMAL TRANSMETHYLATION REAQION DURING THE METABOLISM
OF DOPAMINE, TRYPTAMINE, AND SEROTONIN, AND SCHIZOPHRENIC-
SYMPTOMS: A CRITICAL REVIEW.
003404 03-13
S-462
VOLUME 19, SUBJECT INDEX
Subject Index
N N DIISOPROPYLTRYPTAMINE (DIPT) AND 5
METHOXYDIISOPROPYLTRYPT AMINE (5 MEO-DIPT). TWO ORALLY
ACTIVE TRYPT AMINE ANALOGS WITH CNS ACTIVITY.
004310 04-07
TRYPT AMINEROIC
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELECTIVE
5 HT UPTAKE INHIBITOR,
001517 02-03
TRYPT AMINES
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES;
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY
HUMAN BLOOD-PLATELETS.
001067 02-02
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES;
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES.
001078 02-02
TRYPTOPHAN
L TRYPTOPHAN INJECTION ENHANCES PULSATILE GROWTH-HORMONE
SECRETION IN THE RAT. (UNPUBLISHED PAPER).
000020 01-03
ENHANCEMENT OF RAT-BRAIN METABOLISM OF A TRYPTOPHAN LOAD
BY CHRONIC ETHANOL ADMINISTRATION.
000022 01-03
ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS.
(UNPUBLISHED PAPER).
000060 01-03
THE CONVERSION OE (3H)TRYPT0PHAN TO 5 (3H)HYDR0XYTRYPTAMINE
IN MOUSE-BRAIN FOLLOWING DEPLETION OF PHENYLALANINE AND
TYROSINE.
000148 01-03
PROSPEQIVE-TRIAL OF L TRYPTOPHAN IN MATERNITY-BLUES.
000683 01-11
TRANSIENT-EFFECT OF L TRYPTOPHAN IN PROGRESSIVE MYOCLONUS
EPILEPSY WITHOUT LAF0RA-80DIES: CLINICAL-STUDY AND
ELECTROPHYSIOLOGICAL- STUDY .
000694 01-11
PAIN AND TRYPTOPHAN.
000775 01-13
LITHIUM EFFECTS ON HIGH-AFFINITY TRYPTOPHAN UPTAKE: EVIDENCE
AGAINST A STABILIZATION MECHANISM.
001496 02-03
CLINICAL-STUDIES AND BIOLOGICAL-STUDIES OF L TRYPTOPHAN IN
DEPRESSION.
001977 02-09
EFFICACY AND SIDE-EFFECTS OF CHLORAL-HYDRATE AND TRYPTOPHAN
AS SLEEPING-AIDS IN PSYCHOGERIATRIC-PATIENTS.
002077 02-10
THE RELATIONSHIP OF ALPHA AND DELTA EEG FREQUENCIES TO PAIN
AND MOOD IN FIBROSITIS-PATIENTS TREATED WITH CHLORPROMAZINE
AND L TRYPTOPHAN.
002152 02-11
METHOD FOR THE DETERMINATION OF TRYPTOPHAN IN SERUM AND
CEREBROSPINAL-FLUID.
002208 02-13
EFFEa OF L TRYPTOPHAN ON APOMORPHINE-INDUCED GROWTH-
HORMONE SECRETION IN NORMAL SUBJECTS.
002253 02-13
EFFEQS OF ALBUMIN, AMINO-ACIDS, AND CLOFIBRATE ON THE UPTAKE
OF TRYPTOPHAN BY THE RAT-BRAIN.
002673 03-03
THE FUNQIONAL IMPORTANCE OF INCREASED BRAIN TRYPTOPHAN IN
THE SEROTONERGIC RESPONSE TO RESTRAINT STRESS.
002779 03-03
EFFECTS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L
TRYPTOPHAN BY ISOLATED RAT LIVER CELLS.
002899 03-03
DIFFERENTIAL-EFFEaS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNCTION IN CAT BRAIN.
00291 1 03-03
EFFECT OF P CHLOROPHENYLALANINE AND TRYPTOPHAN ON SLEEP, EEG
AND MOTOR-AQIVITY IN THE RAT.
002958 03-04
THE THERAPEUTIC ACTIVITY OF TRYPTOPHAN AND ITS EFFECT ON
SEROTONIN METABOLISM IN EPILEPTIC-PATIENTS.
003289 03-1 1
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE
HYPERAQIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN
DEFICIENCY HYPOTHESIS.
003312 03-11
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER
TRYPTOPHAN ADMINISTRATION.
003419 03-13
DAYTIME EFFEQS OF L TRYPTOPHAN.
003455 03-14
STRESS-MODULATED ALTERATION Of BRAIN BIOGENIC-AMINES IN THE
RAT: EFFECTS OF L TRYPTOPHAN.
003978 04-03
EFFECT OF PRENATAL PHENYTOIN ADMINISTRATION ON BRAIN
TRYPTOPHAN METABOLISM OF RAT OFFSPRING DURING THE
PREWEANING PERIOD.
004108 04-04
THE EFFECTS OF TRYPTOPHAN AND MANIPULATIONS OF SEROTONERGIC-
RECEPTORS ON TONIC IMMOBILITY IN CHICKENS.
004245 04-04
POTENTIATION OF THE EFFECT OF ANTIDEPRESSANT-DRUGS BY
TRYPTOPHAN.
004412 04-09
CORRECTION OF THE EXTRAPYRAMIDAL NEUROLEPTIC-SYNDROME BY
TRYPTOPHAN AND THE TIME-COURSE OF ITS CONTENT IN THE BLOOD
OF PATIENTS.
004434 04-11
HYPERVENTILATION-SYNDROME, TREATMENT WITH L TRYPTOPHAN AND
PYRIDOXINE; PREDICTIVE VALUES OF XANTHURENIC-ACID EXCRETION
004456 04-1 1
TRYPTOPHAN-HYDROXYLASE
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN-
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM.
000123 01-03
GLUCOCORTICOIDS AS A REGULATORY FACTOR FOR BRAIN TRYPTOPHAN-
HYDROXYLASE DURING DEVELOPMENT.
001500 02-03
LONG-TERM EFFECTS OF MULTIPLE DOSES OF METHAMPHET AMINE ON
TRYPTOPHAN-HYDROXYLASE AND TYROSINE-HYDROXYLASE ACTIVITY
IN RAT-BRAIN.
003850 04-03
STUDIES ON THE KINETIC PROPERTIES OF TRYPTOPHAN-HYDROXYLASE OF
RABBIT MESENCEPHALON AND PONS-MEDULLA: EFFECT OF LONG-
TERM-TREATMENT WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
003852 04-03 •
0 6 FLUOROTRYPTOPHAN, AN INHIBITOR OF TRYPTOPHAN-
HYDROXYLASE: SLEEP AND WAKEFULNESS IN THE RAT.
004189 04-04
TRYPTOPHAN-INDUCED
EFFECT OF CITALOPRAM (LU-10-171) ON TRANYLCYPROMINE AND
TRYPTOPHAN-INDUCED WET-DOG-SHAKES IN RATS.
001682 02-04
TRYPTOPHOL-INDUCED
TRYPTOPHOL-INDUCED CHANGE IN BRAIN 5 HYDROXYTRYPTAMINE
METABOLISM.
001236 02-03
TSH
CHANGES OF ACTH, STH, TSH AND PROLAQIN LEVELS IN ENDOTOXIN
SHOCK IN RATS.
000119 01-03
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH
NEUROLEPTICS.
001935 02-08
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH, AND LH IN SERUM
OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY.
001936 02-08
THE TSH RESPONSE TO TRH INJECTION IN PSYCHIATRIC-PATIENTS: A
REVIEW.
002145 02-11
TSH, HGH, HPR, AND CORTISOL RESPONSE TO TRH IN DEPRESSED-
PATIENTS.
004399 04-09
DIFFERENT EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC-
ANTIDEPRESSANTS ON THE RELEASE OF TSH, PROLACTIN, AND
GROWTH-HORMONE AFTER ADMINISTRATION OF THYROSTIMULATING-
RELEASING-HORMONE IN MANIC-DEPRESSIVES.
004407 04-09
TUBERCLE
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA
BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY
TUBERCLE OF THE RAT.
002681 03-03
SLEEP ELICITED BY OLFACTORY TUBERCLE STIMULATION AND THE EFFEQ
OF ATROPINE.
002955 03-04
TUBEROINFUNDIBULAR
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS.
002700 03-03
TUBOCURARINE
ANTAGONISM OF SOME CENTRAL-EFFECTS OF D TUBOCURARINE BY
GAMMA AMINOBUTYRIC-ACID.
004102 04-04
S-463
Subject Index
Ptychopharmocology Abstracts
11)1
«5
TUMOUR
DIAZEPAM AS TUMOUR PROMOTER.
003495 03-15
TUMOURS
ABSENCE OF EFFECT OF DIAZEPAM ON TUMOURS.
003497 03-15
TURNING
TURNING ON THE ENDORPHINS.
001489 02-03
TURNOVER
ACUTE AND CHRONIC EFFECTS OF NEUROLEPTICS AND ACUTE EFFECTS OF
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN.
000215 01-03
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL
BODY AND NERVE TERMINAL-RICH AREAS.
001096 02-03
EFFEa OF TABERNANTHINE ON THE TURNOVER TIME OF BRAIN
CATECHOLAMINES IN NORMAL AND HYPOBARIC HYPOXIC RATS.
001187 02-03
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN
STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER.
001218 02-03
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN
FOLLOWING INTERAVENTRICULAR INJECTION.
001239 02-03
INFLUENCE OF MORPHINE ON MEMBRANE TURNOVER AND FUNCTION
001280 02-03
THE EFFECT OF CARBIDINE ON DOPAMINE TURNOVER IN THE CORPUS-
STRIATUM OF THE BRAINS OF RATS.
001352 02-03
SHORT-TERM AND LONG-TERM MODIFICATION OF SKELETAL-MUSCLE
SODIUM-PUMP ACTIVITY AND MUSCLE PROTEIN TURNOVER.
(UNPUBLISHED PAPER).
001519 02-03
ACTIONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON
ACETYLCHOLINE TURNOVER IN RAT-BRAIN.
001541 02-03
EFFECT OF APOMORPHINE ON MORPHINE-INDUCED DECREASE IN
LOCOMOTOR-ACTIVITY AND INCREASE IN DOPAMINE TURNOVER IN
RATS.
001728 02-04
EFFECTS OF 4 AMINOPYRIDINE ON THE TURNOVER OF MONOAMINES IN
THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.
002658 03-03
EFFECT OF MAZINDOL ON BRAIN DOPAMINE TURNOVER IN SPIPERONE
TREATED RATS.
002726 03-03
GABA ANTAGONISTS ENHANCE DOPAMINE TURNOVER IN THE RAT
RETINA IN VIVO.
002772 03-03
ACCELERATED METABOLISM OF PROBENECID DURING LONG-TERM-
TREATMENT OF RATS WITH ANTICONVULSANT-ORUGS: EFFECT ON
CENTRAL SEROTONIN TURNOVER STUDIES.
002890 03-03
MYOINOSITOL TURNOVER IN THE INTAQ RAT-BRAIN: INCREASED
PRODUCTION AFTER D-AMPHETAMINE.
003723 04-03
CATECHOLAMINE TURNOVER IN RAT-CEREBRAL-CORTEX AND CAUDATE
FOLLOWING REPEATED TREATMENT WITH DIHYDROERGOTOXINE
003765 04-03
SOME BARBITURATES ENHANCE THE EFFEQ OF MUSCIMOL ON
DOPAMINE TURNOVER IN THE RAT RETINA.
003873 04-03
EFFECT OF IMIPRAMINE ON CENTRAL 5 HYDROXYTRYPTAMINE
TURNOVER AND METABOLISM IN RATS.
003999 04-03
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT-
BRAIN; CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl-
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF
PHOSPHOLIPID TURNOVER.
004021 04-03
ACETYLCHOLINE TURNOVER AND AGGRESSION IN RELATED THREE
STRAINS OF MICE.
004151 04-04
TURNOVER-RATE
THE EFFEaS OF MUSCARINIC-RECEPTOR BLOCKERS ON THE TURNOVER-
RATE OF ACETYLCHOLINE IN VARIOUS REGIONS OF THE RAT-BRAIN.
000328 01-03
EFFECT OF ANTINOCICEPTIVE DOSES OF OXOTREMORINE ON MOUSE-
BRAIN ACETYLCHOLINE TURNOVER-RATE.
001513 02-03
ESTIMATING IN VIVO THE TURNOVER-RATE OF BRAIN ENKEPHALINS.
001884 02-06
TURNOVER-RATES
DOSE-DEPENDENT PHARMACOKINETICS OF ALPHA METHYL-P-TYROSINE
(ALPHA MT) AND COMPARISON OF CATECHOLAMINE TURNOVER-
RATES AFTER TWO DOSES OF ALPHA MT.
001532 02-03
TWO-COMPONENT
SIMULTANEOUS HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC-
DETERMINATION OF AMITRIPTYLINE-HYDROCHLORIDE IN TWO-
COMPONENT TABLET FORMULATIONS.
004673 04-16
TWO-DRUG
RAPID ACQUISITION OF A TWO-DRUG DISCRIMINATION: TIME OF DAY
EFFECT UPON SALINE STATE.
004214 04-04
TWO-SHOCK
A SIGNAL-DETECTION-ANALYSIS OF MORPHINE EFFECTS ON THE
RESPONSE BIAS OF RATS IN A TWO-SHOCK DISCRIMINATION TASK.
004124 04-04
TWO-WAY
TWO-WAY AVOIDANCE LEARNING UNDER THE INFLUENCE OF NOOTROPIC-
DRUGS.
001647 02-04
TYPE-1
BIOCHEMICAL-EVIDENCE FOR TYPE-1 AND TYPE-2 OPIATE-RECEPTORS
(UNPUBLISHED PAPER)
001050 02-01
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2
DOPAMINE-RECEPTORS IN THE CNS
001480 02-03
INTERCONVERTING MU AND DELTA-FORMS OF TYPE-1 OPIATE-RECEPTORS
IN THE RAT STRIATAL PATCHES.
003737 04-03
TYPE-2
BIOCHEMICAL-EVIDENCE FOR TYPE-1 AND TYPE-2 OPIATE-RECEPTORS
(UNPUBLISHED PAPER).
001050 02-01
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2
DOPAMINE-RECEPTORS IN THE CNS
001480 02-03
TYPICAL
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF
(3H)SPIR0PERID0L IN CALF CAUDATE
003906 04-03
TYRAMINE
THE EFFECT OF MONOAMINE-OXIDASE-INHIBITORS ON FIRST-PASS
METABOLISM OF TYRAMINE IN DOG INTESTINE.
000141 01-03
RESPONSES TO TYRAMINE AND NOREPINEPHRINE AFTER IMIPRAMINE
AND TRAZODONE.
000864 01-15
THE EFFECT OF PHENEUINE AND SOME OF ITS PARA HALOGENATED
DERIVATIVES ON THE LEVELS OF BRAIN TYRAMINE AND OaOPAMINE
IN THE MOUSE.
001077 02-02
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES.
001207 02-03
TYRAMINE CONTENT OF CANNED AND PACKET SOUPS.
002394 02-15
BETA PHENYLETHYLAMINE, PHENYLETHANOLAMINE, TYRAMINE AND
OCTOPAMINE. (UNPUBLISHED PAPER).
002601 02-17
TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFEQS OF
CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS.
003428 03-13
INFLUENCE OF CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5
HYDROXYTRYPTAMINE, TYRAMINE AND POTASSIUM FROM GOAT
PIAL-ARTERIES
003925 04-03
TYRAMINES
METHYLPHENIDATE-LIKE STIMULANTS IN VITRO RELEASE
(3H)TYRAMINES BUT NOT (14C)D0PAMINE
002706 03-03
TYROSINE
THE CONVERSION OF (3H)TRYPT0PHAN TO 5 (3H)HYDR0XYTRYPTAMINE
IN MOUSE-BRAIN FOLLOWING DEPLETION OF PHENYLALANINE AND
TYROSINE.
000148 01-03
TYROSINE ADMINISTRATION REDUCES BLOOD-PRESSURE AND ENHANCES
BRAIN NOREPINEPHRINE RELEASE IN SPONTANEOUSLY HYPERTENSIVE-
RATS.
000296 01-03
EFFEQS OF CENTRALLY-ADMINISTERED AND SYSTEMICALLY
ADMINISTERED L TYROSINE AND L LEUCINE ON OVARIAN FUNQION IN
THE OLD RAT.
001180 02-03
THE HYPOTENSIVE-EFFEQ OF CENTRALLY-ADMINISTERED TYROSINE.
001548 02-03
S-464
VOLUME 19, SUBJECT INDEX
Subject Index
TYROSINE-AMINOTRANSFERASE
EFFECTS OF PHENOTHIAZINE DERIVATIVES AND RELATED COMPOUNDS ON
TYROSINE-AMINOTRANSFERASE ACTIVITY
000018 01-03
TYROSINE-HYDROXYLASE
(BLOCKADE OF METHAMPHETAMINE-INDUCED DEPRESSION OF TYROSINE-
HYDROXYLASE BY GABA-TRANSAMINASE INHIBITORS.
000130 01-03
ROLE OF DOPAMINE STORAGE FUNCTION IN THE CONTROL OF RAT
STRIATAL TYROSINE-HYDROXYLASE ACTIVITY.
000201 01-03
THE LONG-TERM REGULATION OF GANGLIONIC TYROSINE-HYDROXYLASE
BY PREGANGLIONIC NERVE ACTIVITY
000333 01-03
EFFECTS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE-
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT
MECHANISMS OF TOLERANCE.
001243 02-03
REGULATION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS.
001262 02-03
PHENCYCLIDINE-INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-
HYDROXYLASE ACTIVITY.
001304 02-03
LONG-TERM HALOPERIDOL TREATMENT AND FACTORS EFFECTING THE
ACTIVITY OF STRIATAL TYROSINE-HYDROXYLASE
001348 02-03
BRAIN STRIATAL TYROSINE-HYDROXYLASE: ACTIVATION OF THE ENZYME
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION.
001423 02-03
ACTIVATION OF SOLUBLE STRIATAL TYROSINE-HYDROXYLASE IN THE RAT
BRAIN AFTER CDP-CHOUNE ADMINISTRATION.
002816 03-03
CHARACTERIZATION OF HALOPERIDOL MEDIATED EFFECTS ON RAT
STRIATAL TYROSINE-HYDROXYLASE.
002867 03-03
DOPAMINERGIC AGONIST AND ANTAGONIST EFFECTS ON STRIATAL
TYROSINE-HYDROXYLASE DISTRIBUTION.
002898 03-03
LONG-TERM EFFECTS OF MULTIPLE DOSES OF METHAMPHETAMINE ON
TRYPTOPHAN-HYDROXYLASE AND TYROSINE-HYDROXYLASE ACTIVITY
IN RAT-BRAIN.
003850 04-03
RESERPINE EFFECT ON THE AXONAL TRANSPORT OF DOPAMINE-BETA-
HYDROXYLASE AND TYROSINE-HYDROXYLASE IN RAT-BRAIN.
003904 04-03
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCED
ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY.
004018 04-03
TYR8-SUBSTANCE-P
REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 1251 TYR8-
SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES.
000259 01-03
T3
EFFEQ OF ACUTE AND CHRONIC TRIIODOTHYRONINE (T3)
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE-
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN-
BIOCHEMISTRY.
002951 03-04
ucs
ETHANOL AVERSION INDUCED BY PARENTERALLY ADMINISTERED
ETHANOL ACTING BOTH AS CS AND UCS.
001721 02-04
UHERSKE-HRADISTE
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS
AFTER HOSPITAL DISCHARGE IN THE DISTRICTS TEPLICE AND UHERSKE-
HRADISTE.
002518 02-17
ULTRADIAN
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP-
DISORDERS.
001869 02-06
ULTRAFILTRATE
CONCENTRATIONS AND KINETICS OF CARBAMAZEPINE IN WHOLE
SALIVA, PAROTID SALIVA, SERUM ULTRAFILTRATE. AND SERUM.
004545 04-13
ULTRASTRUCTURAL
THE ULTRASTRUCTURAL CHANGES OF SYNAPSES IN RAT FOLLOWING
LONG-TERM ADMINISTRATION OF THE NEUROLEPTICS RESERPINE AND
HALOPERIDOL.
000795 01-13
LSD-INDUCED ULTRASTRUCTURAL MODIFICATIONS OF LIMBIC-SYSTEM
NUCLEI AND OTHER CEREBRAL ZONES.
002198 02-12
ULTRASTRUCTURAL LOCALIZATION OF MONOAMINES IN NERVE FIBERS
OF THE PINEAL-GLAND IN GOLDEN HAMSTERS.
003666 04-01
ULTRASTRUCTURE
ELECTRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFECTS OF
HIGH-FREQUENCY STIMULATION ON DENDRITIC ULTRASTRUCTURE,
(UNPUBLISHED PAPER).
001036 02-01
CANNABIS-SATIVA: EFFECTS ON BRAIN FUNCTION AND ULTRASTRUCTURE
IN RHESUS-MONKEYS.
002747 03-03
EFFECTS OF TAIPOXIN ON THE ULTRASTRUCTURE OF CHOLINERGIC AXON
TERMINALS IN THE MOUSE ADRENAL-MEDULLA.
003916 04-03
UMBILICAL-CORD-SERUM
CONCENTRATIONS OF CIS(Z) FLUPENTHIXOL IN MATERNAL SERUM,
AMNIOTIC-FLUID, UMBILICAL-CORD-SERUM, AND MILK.
002423 02-15
UNANESTHETIZED
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS.
003972 04-03
UNCONDITIONED
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY
REACTIONS IN DOGS.
003030 03-04
UNCONDITIONED-STIMULUS
INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY
PREEXPOSURE TO THE UNCONDITIONED-STIMULUS: ASSOCIATIVE-
ASPECTS AND NONASSOCIATIVE-ASPECTS.
001610 02-04
UNDERACTIVITY
PHYSOSTIGMINE IN TOURETTE-SYNDROME: EVIDENCE FOR CHOLINERGIC
UNDERACTIVITY.
003286 03-10
UNDERCUT
ASTHMA THERAPY MAY UNDERCUT KIDS AT SCHOOL.
004475 04-11
UNDERNUTRITION
TREATMENT OF UNDERNUTRITION AND ELECTROLYTE-DISTURBANCES IN
ANOREXIA-NERVOSA.
004531 04-13
UNDERSTANDING
UNDERSTANDING AND USE OF CHEMOTHERAPY BY LEARNING-
DISABILITIES AND BEHAVIOR-DISORDERS TEACHERS.
000965 01-17
ATTEMPT AT PSYCHOLOGICAL UNDERSTANDING AND TREATMENT OF
PSYCHOLOGICAL ASTHENIA AND ASTHENO-DEPRESSIVE-SYNDROMES
USING ERGADYL.
001974 02-09
UNDESIRABLE
UNDESIRABLE EFFECTS OF MEDICINES: A REVIEW OF SEVERAL
PUBLICATIONS ISSUED FROM 1977-1979.
004632 04-15
SIDE-EFFECTS AND UNDESIRABLE COMBINATIONS OF PSYCHOTROPIC-
MEDICATIONS.
004663 04-15
UNDIAGNOSED
ARRHYTHMIA INDUCED BY A TRICYCLIC-ANTIDEPRESSANT IN A PATIENT
WITH UNDIAGNOSED MITRAL-VALVE PROLAPSE.
003521 03-15
UNILATERAL
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
FACTORS INFLUENCING SEIZURE DURATION AND NUMBER OF SEIZURES
APPLIED IN UNILATERAL ELECTROCONVULSIVE-THERAPY: ANESTHETICS
AND BENZODIAZEPINES.
000792 01-13
UNILATERAL 5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE DORSAL
RAPHE NUCLEUS (DRN) AND RAT ROTATIONAL-BEHAVIOUR.
001578 02-04
MORPHINE-DEPENDENCE AND DOPAMINERGIC-ACTIVITY: TESTS OF
CIRCLING RESPONSES IN RATS WITH UNILATERAL NIGRAL LESIONS.
001641 02-04
HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY
UNILATERAL 6 OHDA INJECTIONS INTO SUBSTANTIA-NIGRA AND
CAUDATE-NUCLEUS.
001778 02-04
THE STRIATONIGRAL GABA PATHWAY: FUNCTIONAL AND
NEUROCHEMICAL CHARACTERISTICS IN RATS WITH UNILATERAL
STRIATAL KAINIC-ACID LESIONS.
001816 02-04
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH
UNILATERAL NIGROSTRIATAL LESIONS.
004117 04-04
THE INFLUENCE OF UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE
SUBSTANTIA-NIGRA IN THE ABSENCE OF THE TELENCEPHALON.
004197 04-04
S-465
Subject Index
Psychopharmacology Abstracts
it
UNILATERALLY
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS,
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN
UNILATERALLY 6 HYDROXYDOPAMINE LEStONED RATS.
004129 04-04
UNIMPAIRED
UNIMPAIRED QUININE METABOLISM IN RATS WITH VENTROMEDIAL
HYPOTHALAMIC LESIONS.
003821 04-03
UNIPOLAR
THREE CASES OF UNIPOLAR DELUSIONAL DEPRESSION RESPONSIVE TO L-
DOPA.
000628 01-09
THYROTROPHIN RESPONSE TO THYROTROPHIN-RELEASING-HORMONE IN
UNIPOLAR AND BIPOLAR AFFEQIVE-ILLNESS.
003237 03-09
LITHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND
BIPOLAR-II DEPRESSION: A PROSPECTIVE, PLACEBO-CONTROLLED
COMPARISON.
003252 03-09
LITHIUM UPTAKE IN RED CELLS OF CYCLOID AND UNIPOLAR DYSTHYMIC-
PATIENTS.
003258 03-09
UNITARY
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE-
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING-
SITES IN RAT STRIATUM.
000186 01-03
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES.
001342 02-03
MUSCARINIC-RECEPTOR: MULTIPLE SITES OR UNITARY CONCEPT?
003896 04-03
UNITS
ACUTE AND CHRONIC OPIATE-EFFECTS ON SINGLE UNITS AND EEG OF
MEDIAL THALAMUS AND HIPPOCAMPUS: A LATENCY ANALYSIS.
001344 02-03
GABA-RECEPTORS AS SUPRAMOLECULAR UNITS.
002819 03-03
UNIVERSITY-OF-LEEDS
PROCEEDINGS OF THE BRITISH-PHARMACOLOGICAL-SOCIETY, 12TH-14TH
SEPTEMBER, 1979, UNIVERSITY-OF-LEEDS.
000966 01-17
UNMASKING
CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE
CANINE FEMORAL VASCULAR BED.
003911 04-03
UNMYELINATED
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA-
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN
UNMYELINATED PRIMARY AFFERENTS.
002767 03-03
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS:
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE.
003778 04-03
UNRESTRAINED
THE EFFECT OF CORTISOL MICROIONOPHORETIC-APPLICATIONS ON THE
ACTIVITY OF HIPPOCAMPAL NEURONS IN UNRESTRAINED RABBITS.
001123 02-03
UNSTABLE
NEUROTRANSMIHERS AND DEPRESSION: TOO MUCH, TOO LIHLE, TOO
UNSTABLE - OR NOT UNSTABLE ENOUGH?
002931 03-03
TREATMENT OF UNSTABLE ANGINA BY DILTIAZEM.
004307 04-07
UNSTRESSED
SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI-
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS.
002871 03-03
UNTREATED
ACTH4-10 AND MEMORY IN ECT TREATED AND UNTREATED PATIENTS. I.
EFFECT ON CONSOLIDATION.
001982 02-09
ACTH4-10 AND MEMORY IN EQ TREATED PATIENTS AND UNTREATED
CONTROLS. II. EFFECT ON RETRIEVAL.
001983 02-09
UNWANTED
THERAPEUTICS V - THE UNWANTED EFFEQS OF ANTIPSYCHOTICS.
000892 01-15
UNWANTED EFFECTS OF LITHIUM-CARBONATE USED IN THE PREVENTION
OF RELAPSES OF AFFECTIVE-ILLNESS.
004625 04-15
UPDATE
TARDIVE-DYSKINESIA: REVIEW AND UPDATE.
000862 01-15
UPDATE ON LITHIUM: 1979-1980.
002450 02-15
HALOPERIDOL UPDATE: 1958-1980.
002517 02-17
THE BENZODIAZEPINE-RECEPTOR: AN UPDATE.
002833 03-03
PSYCHOPHARMACOLOGY UPDATE.
003583 03-17
UPHOLDS
FEDERAL-COURT UPHOLDS RIGHT-TO-REFUSE PSYCHOTROPIC-DRUGS,
ORDERS IMPROVEMENTS AT LIMA-STATE-HOSPITAL.
002583 02-17
UPTAKE
ARYLDIALKENYLPIPERAZINES AS SELEQIVE AND VERY POTENT
INHIBITORS OF DOPAMINE UPTAKE.
000005 01-01
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. III. DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES.
000025 01-03
INHIBITION OF HIGH-AFFINITY CHOLINE UPTAKE: STRUQURE-AQIVITY
STUDIES.
000026 01-03
ANTIHISTAMINE EFFEQ ON SYNAPTOSOMAL UPTAKE OF SEROTONIN,
NOREPINEPHRINE AND DOPAMINE.
000035 01-03
ACUTE VERSUS CHRONIC EFFEQS OF SEROTONIN UPTAKE BLOCKERS ON
POTENTIATION OF THE SEROTONIN SYNDROME.
000050 01-03
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT
PROPERTIES.
000084 01-03
COMPARISON OF THE EFFEQS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
000091 01-03
EFFEQ OF MORPHINE ON CALCIUM UPTAKE BY LYSED SYNAPTOSOMES.
000117 01-03
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS.
000171 01-03
INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFEQS
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT
OCCIPITAL-CORTEX SLICES.
000227 01-03
RELATION BETWEEN THE EFFECTS OF ANTIDEPRESSANT-DRUGS ON THE
UPTAKE OF MONOAMINES AND ON THE SPONTANEOUS ACTIVITY OF
CENTRAL NEURONS
000267 01-03
LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN
MICE.
000287 01-03
ANALYSIS OF THE ACTIVATION OF DOPAMINE METABOLISM BY A
SEROTONIN UPTAKE INHIBITOR.
000315 01-03
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE:
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER
SEROTONIN UPTAKE BLOCKERS.
000316 01-03
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS.
000330 01-03
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH
UNIL'^TERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION.
000404 01-04
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELECTIVE
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR-
STIMULATION INDUCED BY INDIRECTLY ACTING SYMPATHOMIMETIC-
AMINES IN MICE.
000492 01-04
DECREASED UPTAKE OF 5 HYDROXYTRYPTAMINE IN BLOOD-PLATELETS
FROM PATIENTS WITH ENDOGENOUS DEPRESSION.
000637 01-09
IN VITRO EFFECT OF PHENCYCLIOINE AND OTHER PSYCHOMOTOR
STIMULANTS ON SEROTONIN UPTAKE IN HUMAN PLATELETS
000750 01-13
EFFECT OF NEUROLEPTIC-DRUGS ON LITHIUM UPTAKE BY THE HUMAN
ERYTHROCYTE.
000973 01-17
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY
HUMAN BLOOD-PLATELETS
001067 02-02
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES:
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES.
001078 02-02
S-466
VOLUME 19, SUBJECT INDEX
Subject Index
GABA AGONISTS AND UPTAKE INHIBITORS DESIGNED AS AGENTS WITH
IRREVERSIBLE ACTIONS
001079 02-02
LONG-TERM EFFECT OF NEUROLEPTICS ON CORTICOSTERONE
SEPTOHIPPOCAMPAL UPTAKE IN RATS.
00)107 02-03
AN EXAMINATION OF FACTORS INFLUENCING ADRENERGIC
TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNCTIONAL
ALPHA-ADRENOCEPTORS.
001196 02-03
EFFECTS OF RATE OF BLOOD FLOW ON FRACTIONAL EXTRACTION AND ON
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN
VIVO.
001231 02-03
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM
CONCENTRATION.
001300 02-03
THE EFFECT OF PSYCHOTROPIC-SUBSTANCES AND NARCOTIC ANALGESIC-
DRUGS ON 14C NORADRENALINE UPTAKE BY SYNAPTOSOMES OF THE
CEREBRAL-CORTEX OF RATS.
001363 02-03
UPTAKE OF PIPERIDINE AND PIPECOLIC-ACID BY SYNAPTOSOMES FROM
MOUSE-BRAIN.
001396 02-03
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR
THE POTENTIATION OF IMIPRAMINE EFFECTS ON THE METABOLISM
AND UPTAKE OF BRAIN CATECHOLAMINES.
001427 02-03
STRUCTURAL REQUIREMENTS FOR UPTAKE INTO SEROTONINERGIC
NEURONES.
001452 02-03
MULTIVARIATE APPROACHES APPLIED TO STUDIES OF NOREPINEPHRINE
AND SEROTONIN UPTAKE.
001460 02-03
LITHIUM EFFECTS ON HIGH-AFFINITY TRYPTOPHAN UPTAKE: EVIDENCE
AGAINST A STABILIZATION MECHANISM.
001496 02-03
PHARMACOLOGICAL EVIDENCE OF A POSSIBLE TRYPTAMINERGIC
REGULATION OF OPIATE-RECEPTORS BY USING INDALPINE, A SELECTIVE
5 HT UPTAKE INHIBITOR.
001517 02-03
IN VIVO CHANGES IN THE GABA CONTENT OF NERVE-ENDINGS
(SYNAPTOSOMES) INDUCED BY INHIBITORS OF GABA UPTAKE.
001540 02-03
MOTOR-ACTIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF
COCAINE: CORRELATION WITH DOPAMINE UPTAKE BLOCKADE.
001650 02-04
THE EFFECTS OF 5 HT UPTAKE AND MAO-INHIBITORS ON L 5 HTP-
INDUCED EXCITATION IN RATS.
001740 02-04
PLATELET AGGREGATION, 5 HYDROXYTRYPT AMINE UPTAKE AND
RELEASE IN HUNTINGTONS-CHOREA.
002112 02-11
EFFECT OF DOXEPIN ON SEROTONIN METABOLISM IN RAT-BRAIN AND
SEROTONIN UPTAKE BY HUMAN BLOOD-PLATELETS.
002243 02-13
INFLUENCE OF CICLAZINDOL ON MONOAMINE UPTAKE AND CNS
FUNaiON IN NORMAL SUBJECTS.
002268 02-13
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS,
AND NEUROPHARMACOLOGICAL EVENTS.
002515 02-17
DU-24565, A QUIPAZINE DERIVATIVE, A POTENT SELECTIVE SEROTONIN
UPTAKE INHIBITOR.
002651 03-02
EFFEQS OF ALBUMIN, AMINO-ACIDS, AND CLOFIBRATE ON THE UPTAKE
OF TRYPTOPHAN BY THE RAT-BRAIN.
002673 03-03
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNCTION IN CAT BRAIN.
00291 1 03-03
DO BENZODIAZEPINES BIND AT ADENOSINE UPTAKE SITES IN CNS?
002933 03-03
MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND
UPTAKE OF NEUROTRANSMinERS IN BRAIN SLICES.
003147 03-06
LITHIUM UPTAKE IN RED CELLS OF CYCLOID AND UNIPOLAR DYSTHYMIC-
PATIENTS.
003258 03-09
INDICATIONS FOR A BRAIN UPTAKE OF LABELLED VASOPRESSIN AND
OCYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER.
003669 04-01
NONCOMPETITIVE AMINE UPTAKE INHIBITION BY THE NEW
ANTIDEPRESSANT PRIDEFINE.
003771 04-03
A STUDY OF GAMMA AMINOBUTYRIC-ACID UPTAKE IN NORMAL AND
DOWNS-SYNDROME PLATELETS.
003787 04-03
EFFECTS OF CONFORMATIONALLY RESTRAINED ANALOGUES OF
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN.
003794 04-03
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: KINETIC STUDIES.
003814 04-03
UPTAKE OF RADIOCALCIUM BY NERVE-ENDINGS ISOLATED FROM RAT-
BRAIN: PHARMACOLOGICAL-STUDIES.
003815 04-03
INHIBITION OF SYNAPTOSOMAL CALCIUM UPTAKE BY ETHANOL.
003827 04-03
THE UPTAKE OF CARNITINE BY SLICES OF RAT-CEREBRAL-CORTEX.
003853 04-03
EFFECT OF VERAPAMIL ON 45CA UPTAKE BY SYNAPTOSOMES.
003856 04-03
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA-
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL
UPTAKE.
003879 04-03
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE
REVERSAL OF GUANETHIDINE BLOCKADE OF ADRENERGIC NEURONS.
003900 04-03
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL AND CANNABIDIOL ON
SODIUM-DEPENDENT HIGH-AFFINITY CHOLINE UPTAKE IN THE RAT
HIPPOCAMPUS.
003908 04-03
EFFEQS OF HALOPEMIDE ON GABA-RECEPTOR BINDING, UPTAKE AND
RELEASE.
003913 04-03
AMINE UPTAKE INHIBITORS: CRITERIA OF SELECTIVITY.
003921 04-03
THE HUMAN PLATELET AS A MODEL FOR THE GLUTAMATERGIC NEURON:
PLATELET UPTAKE OF L GLUTAMATE.
003923 04-03
ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES:
EFFECTS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE-
DEAMINASE INHIBITORS.
003950 04-03
EFFECTS OF CANNABINOIDS ON CATECHOLAMINE UPTAKE AND RELEASE
IN HYPOTHALAMIC AND STRIATAL SYNAPTOSOMES.
003970 04-03
THE HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPECT TO THE
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRACTION
ABUNDANT IN PRESYNAPTIC MEMBRANES.
004028 04-03
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL
VESICLES.
004042 04-03
ANOREQIC-PROPERTIES OF A NEW LONG AQING SEROTONIN UPTAKE
INHIBITOR.
004105 04-04
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH
UNILATERAL NIGROSTRIATAL LESIONS.
004117 04-04
DIFFERENTIAL-EFFECTS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND
RELEASING-AGENTS ON LOCOMOTOR-ACTIVITY IN NORMAL AND IN
RESERPINIZED MICE.
004130 04-04
A SIMPLE HISTOCHEMICAL SCREENING METHOD FOR AMINE UPTAKE.
004295 04-06
EFFECT OF NOREPINEPHRINE UPTAKE BLOCKERS ON NOREPINEPHRINE
KINETICS.
004506 04-13
EFFECTS OF RO-1 1-2465, A NEW PSYCHOTROPIC-AGENT ON THE UPTAKE
OF SEROTONIN BY HUMAN PLATELETS - IN VITRO DETERMINATION OF
THE IC50.
004532 04-13
SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS: DESIGN,
DEVELOPMENT AND STRUCTURE-ACTIVITY STUDIES.
004725 04-17
ANTIDEPRESSANTS AND THE SEROTONIN UPTAKE IN PLATELETS.
004727 04-17
URBAN
THE URBAN EPIDEMIC OF PHENCYCLIDINE USE: LABORATORY EVIDENCE
FROM A PUBLIC PSYCHIATRIC-HOSPITAL INPATIENT-SERVICE.
003554 03-16
UREA
EFFECTS OF UREA ON HEXOBARBITAL AND ANTIPYRINE DISPOSITION IN
RATS.
000307 01-03
URETHANE
PRESSURE REVERSAL OF THE EFFECT OF URETHANE ON THE EVOKED
SOMATOSENSORY CORTICAL RESPONSE IN THE RAT.
001106 02-03
S-467
imfiif^AXi:^
Subject Index
Psychophormacoiogy Abstracts
^
l^
&,
St
6'
URINARY
INCREASED URINARY EXCRETION OF CATECHOLAMINES AND THEIR
METABOLITES IN STREPTOZOTOCIN DIABETIC RAT.
000154 01-03
URINARY MHPG AND CLINICAL-RESPONSE TO AMITRIPTYLINE IN
DEPRESSED-PATIENTS.
000631 01-09
VARIATIONS IN URINARY EXCRETION OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN DEPRESSIVE-CONDITIONS.
002013 02-09
EFFECTS OF CAFFEINE ON PLASMA FREE FATTY-ACIDS, URINARY
CATECHOLAMINES. AND DRUG BINDING.
002272 02-13
DRUG-INDUCED DISORDERS OF THE URINARY TRACT.
002393 02-15
INFLUENCE OF PSYCHOTROPIC-DRUGS ON THE URINARY ELIMINATION OF
LITHIUM.
002895 03-03
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDIQORS OF
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE.
004406 04-09
VARIATIONS IN URINARY LEVELS OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN PATIENTS WITH DEPRESSIVE-
SYNDROMES.
004533 04-13
URINE
1-M CHLOROPHENYLPIPERAZINE: A METABOLITE OF TRAZODONE
ISOLATED FROM RAT URINE.
000204 01-03
QUANTITATIVE ANALYSIS OF 6 HYDROXYMELATONIN IN HUMAN URINE
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS-
SPECTROMETRY. (UNPUBLISHED PAPER).
001058 02-01
EFFEQ OF FLUPHENAZINE ON THE CIRCADIAN-EXCRETION OF CYCLIC-
NUCLEOTIDES AND ELEQROLYTES IN THE URINE OF CHRONIC
SCHIZOPHRENICS.
001927 02-08
EFFEQ OF LITHIUM ON POTASSIUM AND CALCIUM IN SERUM,
ERYTHOCYTES AND IN URINE.
002054 02-09
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II.
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJEQS: FIRST-PASS EFFEQ.
004516 04-13
ACUTE PHENCYCLIDINE (PCP) INTOXICATION: QUANTITATIVE URINE
LEVELS AND CLINICAL MANAGEMENT.
004665 04-15
MASS SCREENING AND CONFIRMATION OF DIAZEPAM IN URINE BY EMIT
THIN-LAYER-CHROMATOGRAPH Y .
004672 04-16
GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA
DERIVATIZATION TECHNIQUES.
004687 04-16
USAGE
PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPED-PATIENTS: A
PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED.
000668 01-11
USEFULNESS
THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH
DEPRESSIVE-SYNDROMES.
000625 01-09
AN EVALUATION OF THE USEFULNESS OF THE AaiASE TEST IN
NEUROLEPTIC TREATMENT.
004426 04-10
A COMPARATIVE EVALUATION OF THE USEFULNESS OF
PSYCHOPHYSIOLOGICAL-TESTS DURING VARIOUS LEVELS OF
ACTIVATION OF THE CENTRAL-NERVOUS-SYSTEM.
004543 04-13
UTERINE
SURGICAL MANIPULATION OF THE UTERINE ENVIRONMENT OF RAT
FETUSES.
002478 02-16
UTILIZATION
STUDIES ON THE COMPREHENSIVE MEDICAL TREATMENT OF PEPTIC-
ULCERS (3) - UTILIZATION OF TRANQUILIZERS IN THE TREATMENT OF
GASTRIC-ULCERS.
000653 01-10
LOCAL CEREBRAL GLUCOSE UTILIZATION (LCGU) IN RAT-BRAIN DURING
HYPOXEMIA. (UNPUBLISHED PAPER).
001380 02-03
REGIONAL CHANGES IN BRAIN GLUCOSE UTILIZATION IN RATS GIVEN A
PYRETHROID INSECTICIDE.
001838 02-05
THEORY, PROCEDURE, AND APPLICATIONS OF THE RADIOACTIVE
DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL GLUCOSE
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM. (UNPUBLISHED
PAPER).
001877 02-06
UTILIZATION OF PSYCHOTROPIC-DRUGS. AN INTERNATIONAL
COMPARISON.
002616 02-16
HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE
CAUDATE-NUCLEUS BY GABA AGONISTS.
002640 03-01
IMPACT OF DRUG SCHEDULING ON UTILIZATION.
003601 03-17
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION.
004281 04-05
UTILIZING
A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE. (PH.D.
DISSERTATION)
002918 03-03
VACUTAINERS
FLUPHENAZINE, TRIFLUOPERAZINE AND PERPHENAZINE IN VACUTAINERS.
003565 03-16
VALENCE
EFFICACY AND PAHERN VALENCE OF PSYCHOACTIVE-DRUGS: A NEW
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN
RANDOMIZED-ORDER
000699 01-11
VAUDITY
THE VALIDITY OF MODELS IN PSYCHOPHARMACOLOGY.
003633 03-17
VALIUM
CHRONIC-TREATMENT WITH VALIUM (DIAZEPAM) FAILS TO AFFECT THE
REPRODUCTIVE SYSTEM OF THE MALE RAT.
001535 02-03
PUBLIC JUDGMENTS ON THE IMPORTANCE OF VALIUM INFORAAATION.
003590 03-17
VALPROATE
RECTAL VALPROATE SYRUP AND STATUS-EPILEPTICUS.
000727 01-11
INTRAVENOUS VALPROATE: EFFECTS ON PLASMA AND SALIVA
PHENYTOIN LEVELS.
003359 03-11
MECHANISM OF VALPROATE PHENOBARBITAL INTERACTION IN EPILEPTIC-
PATIENTS.
004522 04-13
VALPROIC-AaO
DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT
METABOLISM, DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND
CHOLERETIC-EFFECT.
000073 01-03
VALPROIC-ACID DOSAGE AND PLASMA PROTEIN BINDING AND
CLEARANCE.
000755 01-13
VALPROIC-ACID AND PLASMA LEVELS OF PHENYTOIN.
000756 01-13
DETERMINATION OF VALPROIC-ACID BY FLAME-IONIZATION GAS-UQUIO-
CHROMATOGRAPHY.
00090601-16
INTERACTION BETWEEN PHENYTOIN AND VALPROIC-ACID: PLASMA
PROTEIN BINDING AND METABOLIC-EFFECTS.
002276 02-13
CLINICAL-TRIALS OF DEPAKENE (VALPROIC-ACID) COADMINISTERED WITH
OTHER ANTICONVULSANTS IN EPILEPTIC-PATIENTS.
002367 02-14
PHENYTOIN VALPROIC-ACID INTERACTION IN RHESUS-MONKEY.
002785 03-03
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS
ADMINISTRATIONS.
002797 03-03
VALPROIC-ACID SERUM LEVELS AND PROTECTION AGAINST KINDLED
AMYGDALOID SEIZURES IN THE RAT.
002946 03-04
ANTICONVULSANT ACTIVITY OF METABOLITES OF VALPROIC-ACID.
004168 04-04
VALPROIC-ACID IN CHILDHOOD-EPILEPSY: ANTICONVULSIVE EFFICACY IN
RELATION TO ITS PLASMA LEVELS.
004525 04-13
VALUE
VALUE OF SALIVA SAMPLES IN MONITORING CARBAMAZEPINE
CONCENTRATIONS IN EPILEPTIC-PATIENTS.
000903 01-16
DIFFERENTIAL-EFFECTS OF IMIPRAMINE IN RATS AS A FUNCTION OF DRL
SCHEDULE VALUE.
001714 02-04
LIMITS, VALUE AND PERSPECTIVES OF THE PSYCHIATRIC-DIAGNOSIS IN
CLINICAL PSYCHOPHARMACOLOGY.
002631 02-17
S-468
VOLUME 19, SUBJECT INDEX
Subject Index
INTRACELLULAR LITHIUM: ITS VALUE IN THE PREDICTION OF A POSITIVE
RESPONSE TO LITHIUM. „„.o„„ „o , ,
003382 03- 1 1
VALUE OF PROPANIDID IN ELECTROCONVULSIVE-THERAPY (COMPARISON
WITH THIOPENTONE).
004379 04-09
VALUES
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED
**'^^' 002800 03-03
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH
ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT.
004382 04-09
HYPERVENTILATION-SYNDROME, TREATMENT WITH L TRYPTOPHAN AND
PYRIDOXINE PREDICTIVE VALUES OF XANTHURENIC-ACID EXCRETION.
004456 04-1 1
VAL5-ENKEPHALIN
COMPARATIVE-STUDY OF ANALGESIA INDUCED BY N VAL5-ENKEPHALIN
AND PR05-ENKEPHALIN ANALOGS.
000021 01-03
VAPOUR
GLIAL CELL EFFEQS OF SUBACUTE FORMIC-ACID VAPOUR EXPOSURE.
000527 01-05
VARIABIUTY __
STRUCTURE OF VARIABILITY AND CORRELATION IN LEARNING AFTER
DRUG ADMINISTRATION.
002562 02-17
TWO OR MORE CONFORMATIONS OF BENZODIAZEPINE-RECEPTORS
DEPENDING ON GABA-RECEPTORS AND OTHER VARIABLES.
001139 02-03
TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-OUTPATIENTS; PREVALENCE
AND SIGNIFICANT VARIABLES.
003483 03-15
VARIANCE
CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND
NATURAL SEHINGS: CORRELATIONAL AND VARIANCE COMPONENTS
ANALYSES.
004508 04-13
VARIATION
INTERSUBJECT AND INTRASUBJECT VARIATION IN DIAZEPAM FREE
FRAQION.
000747 01-13
INTERINDIVIDUAL VARIATION OF CLINICAL-RESPONSE TO HALOPERIDOL.
001230 02-03
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS: EFFEQS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300.
003451 03-14
VARIATIONS
VARIATIONS IN PSYCHOPHYSIOLOGICAL AQIVATION RESPONSES IN
DEPRESSIVE-STATES.
001965 02-09
VARIATIONS IN URINARY EXCRETION OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN DEPRESSIVE-CONDITIONS.
002013 02-09
STUDY OF PROLAQIN VARIATIONS IN PSYCHIATRIC-PATIENTS TREATED
WITH FLUPHENAZINE-DECANOATE.
002226 02-13
INDIVIDUAL VARIATIONS IN THE EFFECTS OF FLURAZEPAM,
CLORAZEPATE, L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON
REM SLEEP IN MAN.
002349 02-14
CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM,
HALOPERIDOL, PHENELZINE AND D-AMPHET AMINE.
002355 02-14
COMPARATIVE-STUDY OF VARIATIONS IN PROLACTIN LEVELS DURING
TREATMENT WITH ANTIPSYCHOTIC-DRUGS.
002412 02-15
TWO DISTINQ SEROTONIN-RECEPTORS: REGIONAL VARIATIONS IN
RECEPTOR BINDING IN MAMMALIAN BRAIN.
002861 03-03
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC-
SYSTEMS. (UNPUBLISHED PAPER).
004112 04-04
VARIATIONS IN URINARY LEVELS OF 3 METHOXY-4-
HYDROXYPHENYLGLYCOL-SULFATE IN PATIENTS WITH DEPRESSIVE-
SYNDROMES.
004533 04-13
EFFEa OF LITHIUM ON REAQION-TIME - A STUDY OF DIURNAL
VARIATIONS.
004607 04-15
VARIES
THE SPECIFIC ACTIVITY OF PLATELET MONOAMINE-OXIDASE VARIES
WITH PLATELET COUNT DURING SEVERE EXERCISE AND
NORADRENALINE INFUSION.
004509 04-13
VAS-DEFERENS
THE EFFECTS OF BROMOCRIPTINE ON PRESYNAPTIC AND POSTSYNAPTIC
ALPHA-ADRENOCEPTORS IN THE MOUSE VAS-DEFERENS
000108 01-03
EXCITATORY AND INHIBITORY-EFFECTS OF OPIATES IN THE RAT VAS-
DEFERENS: A DUAL-MECHANISM OF OPIATE ACTION.
000143 01-03
INTERACTIONS BETWEEN MORPHINE AND THE OPIOID-LIKE PEPTIDES IN
THE RAT VAS-DEFERENS.
001290 02-03
COMPARATIVE-EFFECTS OF SOMATOSTATIN AND ENKEPHALINS ON THE
GUINEA-PIG ILEUM AND THE RAT VAS-DEFERENS.
001302 02-03
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE
AND CROSS-TOLERANCE TO THE INHIBITORY ACTION OF BETA
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS.
002756 03-03
COMPARATIVE-STUDY ON THE EFFECT OF MORPHINE AND THE OPIOID-
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS: STRAIN AND
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS.
002757 03-03
DIFFERENTIAL-EFFECTS OF POTASSIUM ON THE POTENCY OF DIFFERENT
OPIOIDS IN THE MOUSE VAS-DEFERENS.
002935 03-03
VASA-DEFERENTIA
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA-
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL
UPTAKE.
003879 04-03
VASCULAR
COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND
PHENTOIAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE
REUPTAKE IN PITHED NORMOTENSIVE-RATS.
000044 01-03
EFFECTS OF 3', 4' DIHYDROXYNOMIFENSINE ON THE DOPAMINE
VASCULAR RECEPTOR.
003890 04-03
CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE
CANINE FEMORAL VASCULAR BED.
00391 1 04-03
VASCULATURE
NONLINEAR REGRESSION ANALYSIS OF NOREPINEPHRINE RESPONSE
KINETICS IN CEREBRAL VASCULATURE.
000256 01-03
VASOACTIVE-AGENTS
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE
TREATED DOGS.
001273 02-03
VASOCONSTRICTION
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIRECT VASODILATOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRiaiON.
001109 02-03
VASODILATOR
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIREQ VASODILATOR
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED
VASOCONSTRICTION.
001109 02-03
ANTAGONISM OF THE RENAL VASODILATOR ACTIVITY OF DOPAMINE BY
METOCLOPRAMIDE.
001265 02-03
VASOMOTOR
EFFECTS OF GAMMA HYDROXYBUTYRIC-ACID ON METABOLIC,
RESPIRATORY AND VASOMOTOR ACTIVITIES AND BODY-
TEMPERATURE IN RATS.
000189 01-03
VASOPRESSIN
NALOXONE PROMOTES STIMULUS-EVOKED VASOPRESSIN RELEASE IN
VIVO.
000165 01-03
VASOPRESSIN THERAPY IN PARKINSONS-DISEASE.
000689 01-11
EVIDENCE THAT VASOPRESSIN IS INVOLVED IN THE ISOPRENALINE-
INDUCED BETA ENDORPHIN RELEASE.
001319 02-03
THE EFFEa OF NEUROPEPTIDE FRAGMENTS OF ADRENOCORTICOTROPIN
AND VASOPRESSIN ON BEHAVIORAL-ACTIVITY IN RATS.
001812 02-04
VASOPRESSIN AND SCHIZOPHRENIA.
001954 02-08
INHIBITION OF VASOPRESSIN RELEASE TO CAROTID OCCLUSION BY
GAMMA AMINOBUTYRIC-ACID AND GLYCINE.
002715 03-03
S-469
Subject Index
ON A CASE OF MEMORY-DISTURBANCES TREATED WITH VASOPRESSIN.
003301 03-11
EFFEaS OF VASOPRESSIN ON HUMAN MEMORY FUNCTIONS.
003388 03-11
INDICATIONS FOR A BRAIN UPTAKE OF LABELLED VASOPRESSIN AND
OCYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER.
003669 04-01
VASOPRESSIN STIMULATES RELEASE OF BETA LIPOTROPIN AND BETA
ENDORPHIN IN CONSCIOUS RATS AS MEASURED BY
RADIOIMMUNOASSAY OF UNEXTRACTED PLASMA.
003715 04-03
VASOTOCIN
VASOTOCIN, PROSTAGLANDIN, AND FEMALE REPRODUQIVE BEHAVIOR
IN THE FROG, RANA-PIPIENS.
002978 03-04
VEIN
INTERACTION OF THE TRICYCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH
PREJUNCTIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG
SAPHENOUS VEIN.
003756 04-03
VELOCITY
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY
DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF
PENTOBARBITAL.
000055 01-03
MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL
REPORT.
004441 04-11
VENOMS
THE EFFECTS OF ALPHA AND BETA NEUROTOXINS FROM THE VENOMS OF
VARIOUS SNAKES ON TRANSMISSION IN AUTONOMIC GANGLIA.
003750 04-03
VENOUS
ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND
EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL
AND INTRODUODENAL ADMINISTRATION.
000094 01-03
ORAL BIOAVAILABILITY OF APOMORPHINE IN THE RAT WITH A
PORTACAVAL VENOUS ANASTOMOSIS.
001158 02-03
PHENYTOIN CONCENTRATIONS IN VENOUS VERSUS CAPILLARY BLOOD OF
GERIATRIC-PATIENTS.
00338 1 03-1 1
THE DYNAMICS OF SYSTEMIC VENOUS, ARTERIAL, AND CEREBROSPINAL-
FLUID PRESSURE UNDER I.V. ADMINISTRATION OF POLYETHYLENE-
GLYCOL.
004045 04-03
VENTRAL
EFFECT OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO
STIMULATION OF THE NUCLEUS-ACCUMBENS.
00033 1 0 1 -03
LOCOMOTOR-ACTIVITY ELICITED BY INJECTIONS OF PICROTOXIN INTO THE
VENTRAL TEGMENTAL AREA IS AHENUATED BY INJEQIONS OF GABA
INTO THE GLOBUS-PALLIDUS.
000436 01-04
EFFECTS OF LILLY- 1 10140 (FLUOXETINE) ON SELF-STIMULATION
BEHAVIOR IN THE DORSAL AND VENTRAL REGIONS OF THE LATERAL
HYPOTHALAMUS IN THE MOUSE.
001590 02-04
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE
IMMUNOCYTOCHEMISTRY.
002639 03-01
DEPRESSION OF VENTRAL ROOT DORSAL ROOT POTENTIAL BY DL ALPHA
AMINOADIPATE IN FROG SPINAL-CORD.
002755 03-03
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR.
002945 03-04
INTRACRANIAL SELF-ADMINISTRATION OF MORPHINE INTO THE VENTRAL
TEGMENTAL AREA IN RATS.
002960 03-04
SENSITIVITY TO GABA OF NEURONS OF THE DORSAL AND VENTRAL
LATERAL GENICULATE NUCLEI IN THE RAT.
003877 04-03
MORPHINE DIFFERENTIALLY AFFECTS VENTRAL TEGMENTAL AND
SUBSTANTIA-NIGRA BRAIN REWARD THRESHOLDS.
004187 04-04
VENTRICLE
STUDIES ON GABA RELEASE IN VIVO USING A SIMPLE METHOD FOR
PERFUSION OF THE FOURTH VENTRICLE OF THE RAT.
001881 02-06
Psychopharmacology Abstracts
VENTRICLES
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJEaiON OF
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO
EVOKE AGGRESSION.
001568 02-04
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA
ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF
CONSCIOUS CATS.
001569 02-04
CEREBRAL VENTRICLES AND DOPAMINE IN SCHIZOPHRENIA.
(UNPUBLISHED PAPER).
001928 02-08
THE EFFECTS OF INJEQIONS OF BOMBESIN INTO THE CEREBRAL
VENTRICLES ON BEHAVIORAL THERMOREGULATION.
002952 03-04
VENTRICULAR
PROTECTIVE EFFEQ OF PRENYLAMINE AGAINST VULNERABILITY TO
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE
MYOCARDIUM
000265 01-03
5,7 DIHYDROXYTRYPTAMINE-INDUCED MOUSE-KILLING AND
BEHAVIORAL-REVERSAL WITH VENTRICULAR ADMINISTRATION OF
SEROTONIN IN RATS.
001562 02-04
EFFECTS OF IMIPRAMINE ON LEFT VENTRICULAR PERFORMANCE IN
CHILDREN.
002385 02-15
THE EFFEQS OF THIORIDAZINE ON ELEQRICAL AND ISCHEMIC
VENTRICULAR FIBRILLATION IN THE DOG HEART IN SITU
002697 03-03
VENTRICULAR-MUSCLE
ELECTROPHYSIOLOGICAL-EFFECTS OF IMIPRAMINE ON BOVINE
VENTRICULAR-MUSCLE AND PURKINJE-FIBRES.
003988 04-03
VENTRICULOGRAM
INTERMITTENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE
lOTHALAMATE VENTRICULOGRAM.
003520 03-15
VENTROMEDIAL
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL
DAMAGE
000322 01-03
GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT
AFFECTED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN
TREATMENT.
001145 02-03
EFFEaS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR
DORSOLATERAL TEGMENTAL DAMAGE
001818 02-04
THYROXIN SENSITIVITY OF SENSORIMOTOR CORTICAL NEURONS AND THE
HYPOTHALAMIC VENTROMEDIAL NUCLEUS
003713 04-03
UNIMPAIRED QUININE METABOLISM IN RATS WITH VENTROMEDIAL
HYPOTHALAMIC LESIONS.
003821 04-03
VEP
THE EFFEQ OF SODIUM-VALPROATE ON THE PHOTOSENSITIVE VEP.
004513 04-13
VERAPAMIL
EFFEQ OF VERAPAMIL ON 45CA UPTAKE BY SYNAPTOSOMES.
003856 04-03
VERATRINE
Rl'EASE OF GONADOTROPIN-RELEASING-HORMONE BY VERATRINE IN A
.ilTPOTHALAMIC PITUITARY COINCUBATION
000237 01-03
VERBAL-ASSOCIATIONS
ACUTE EFFECT OF BENZOQAMINE (10 MG), SODIUM-
HYDROXYBUTYRATE (2 G) AND FENCAMFAMINE (10 MG) ON VERBAL-
ASSOCIATIONS.
000806 01-14
ACUTE EFFEQ OF CLOROTEPIN (0.5MG AND l.OMG) AND
METHAQUALONE (300MG) ON VERBAL-ASSOCIATIONS.
002333 02-14
VERBAL-MEMORY
DISSOCIATION OF THE STRYCHNINE EFFEQ ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNOROMES.
000816 01-14
DISSOCIATION OF THE STRYCHNINE EFFEQ ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES.
002155 02-11
S-470
VOLUME 19, SUBJECT INDEX
Subject Index
VERONA
PSYCHOTROPIC-DRUGS AND PSYCHIATRIC-HOSPITAL ADMISSIONS IN
VERONA, ITALY. „„.,.,„..-,
004717 04)7
VERTCBRAl-AKTERY
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT
VERTEBRAL-ARTERY OF THE CAT, A MODIFIED ANIMAL-MODEL FOR
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE
LOWER BRAINSTEM. „„.„.„.„.
004297 04-06
VERTEBRATE
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE-
ENKEPHALIN AND CHOLECYSTOKININ IN THE NEURAL RETINA OF
SEVERAL VERTEBRATE SPECIES. (UNPUBLISHED PAPER).
001017 02-01
VERTIGO
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO.
004387 04-09
DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO,
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL
AQIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN
POSTCONCUSSIONAL-SYNDROME .
004472 04-1 1
THE EFFICACY OF PIRACETAM IN VERTIGO: A DOUBLE-BLIND STUDY IN
PATIENTS WITH VERTIGO OF CENTRAL ORIGIN.
004478 04-1 1
VERVET-MONKEY
SEROTONERGIC AND CATECHOLAMINERGIC INFLUENCE ON THYROID-
FUNCTION IN THE VERVET-MONKEY.
001385 02-03
VERVn-MONKEYS
PERIPHERAL-CORRELATES OF SEROTONERGICALLY-INFLUENCED
BEHAVIORS IN VERVET-MONKEYS (CERCOPITHECUS-AETHIOPS-
SABAEUS).
004204 04-04
VESICLES
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT
HEART. III. DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES.
000025 01-03
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE,
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS.
00009] 01-03
REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 1251 TYR8-
SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES.
000259 01-03
ASCORBIC-ACID, AN ENDOGENOUS FACTOR REQUIRED FOR
ACETYLCHOLINE RELEASE FROM THE SYNAPTIC VESICLES.
001322 02-03
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH
VESICLES.
002657 03-03
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL
VESICLES.
004042 04-03
5' TRIPHOSPHATE RECYCLES INDEPENDENTLY OF ACETYLCHOLINE IN
CHOLINERGIC SYNAPTIC VESICLES.
004063 04-03
VESSEL
EFFECT OF PAPAVERINE ON REGIONAL CEREBRAL BLOOD FLOW AND
SMALL VESSEL BLOOD CONTENT.
001177 02-03
VESTIBULAR
ETHANOL-INDUCED CHANGES IN CYCLIC-GUANOSINE-PHOSPHATE
METABOLISM IN MOUSE VESTIBULAR REGION.
003784 04-03
SELEaiVE EFFECT OF ETHANOL ON THE VESTIBULAR NUCLEUS NEURONS
IN THE CAT.
004139 04-04
VESTIBULO-OCULAR
VESTIBULO-OCULAR REFLEXES IN RABBITS: REDUCTION BY INTRAVENOUS
INJEaiON OF DIAZEPAM.
001566 02-04
CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL
ALERTING.
002997 03-04
VIDEO-ANALYSIS
ON THE RELATIONSHIP BETWEEN MEASURES OBTAINED BY VIDEO-
ANALYSIS OF NONVERBAL-BEHAVIOR AND SELF-RATING OF MOOD.
004410 04-09
VIDEO-STRATEGIES
TIME-BLIND ANALYSIS AND OTHER VIDEO- STRATEGIES IN PHASE II
TRIALS OF PSYCHOTROPIC-DRUGS.
003568 03-16
VIEWPOINT
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS FROM VIEWPOINT OF
TRANSCULTURAL PSYCHOPHARMACOLOGY: THERAPEUTIC PLASMA
LEVEL.
000636 01-09
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO.
004387 04-09
VIGILANCE
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY:
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS.
000543 01-07
A COMPUTER OCULOGRAPHIC AND EEG DOUBLE-BLIND STUDY INCLUDING
WELL-BEING FOR DETERMINING CHANGED VIGILANCE UNDER THERAPY
WITH TIAPRIDE.
000751 01-13
ACTION OF TOFISOPAM ON THE ERGONOMIC VIGILANCE LEVEL. ITS
INTERACTION WITH THE EFFECTS OF ALCOHOL. CLINICAL
PHARMACOLOGICAL-STUDY.
001891 02-07
CORTICAL-CORRELATES OF VIGILANCE REGULATION AND THEIR USE IN
EVALUATING THE EFFECTS OF TREATMENT.
002147 02-11
THE EFFECTS OF TRIAZOLAM AND NITRAZEPAM ON SLEEP QUALITY,
MORNING VIGILANCE, AND PSYCHOMOTOR PERFORMANCE.
002330 02-14
VIGILANCE IMPAIRING DRUGS: ANALYSIS OF SUBJECTIVE RESPONSES.
002332 02-14
EFFECTS OF AMPHETAMINE ON VIGILANCE PERFORMANCE IN NORMAL
AND HYPERACTIVE-CHILDREN.
002359 02-14
SMOKING AND VIGILANCE: THE EFFECTS OF TOBACCO SMOKING ON CFF
AS RELATED TO PERSONALITY AND SMOKING HABITS.
002368 02-14
CORRELATED STUDY OF THE EFFECTS OF SE-5023 IN AN HYPOXIC
ATMOSPHERE ON QUANTIFIED EEG, VIGILANCE, MEMORY, AND
MOOD.
003440 03-14
VILOXAZINE
CLINICAL-TRIAL OF VILOXAZINE IN DEPRESSIVE-CONDITIONS.
000589 01-09
VILOXAZINE PLASMA CONCENTRATIONS AND CLINICAL-RESPONSE.
000614 01-09
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-STATES.
000626 01-09
LONG-TERM ADMINISTRATION OF ATROPINE, IMIPRAMINE, AND
VILOXAZINE ALTERS RESPONSIVENESS OF RAT-CORTICAL-NEURONES
TO ACETYLCHOLINE.
001306 02-03
VILOXAZINE: A REVIEW OF THE LITERATURE.
001964 02-09
CLINICAL-STUDY OF VILOXAZINE.
001972 02-09
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS:
RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BLIND TRIAL.
001998 02-09
RESULTS OF CLINICAL-TESTS OF VILOXAZINE (VIVALAN ICI): PART OF A
MULTICLINICAL-STUDY.
002006 02-09
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A
CONTROLLED CLINICAL-STUDY WITH DOXEPIN AND PLACEBO.
002080 02-10
VILOXAZINE AND THE DEPRESSED SCHIZOPHRENIC ~ METHODOLOGICAL-
ISSUES.
003181 03-08
COMBINED ADMINISTRATION OF NIALAMIDE AND VILOXAZINE TO
DEPRESSIVE-PATIENTS.
003232 03-09
MULTICENTRE-STUDY WITH VILOXAZINE (VIVALAN) IN DEPRESSED-
PATIENTS.
004375 04-09
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO
AND STANDARD (IMIPRAMINE) CONTROLLED CLINICAL- STUDY.
004392 04-09
VINBLASTINE
THE EFFECTS OF COLCHICINE AND VINBLASTINE ON MEMORY IN CHICKS.
004069 04-04
VINYL-GABA
EFFEQS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL-
CORD GABA CONCENTRATION.
000145 01-03
INCREASED CSF GAMMA AMINOBUTYRIC-ACID AFTER TREATMENT WITH
GAMMA VINYL-GABA.
002237 02-13
EFFECT OF GAMMA VINYL-GABA ON BICUCULLINE-INDUCED SEIZURES.
004157 04-04
S-471
Subject Index
Psychopharmacology Abstracts
It.
I
at
VIOLENT
ACUTE MANAGEMENT OF THE VIOLENT AGGRESSIVE-PATIENT.
000586 01-09
PCP AND VIOLENT CRIME: THE PEOPLE VS. PEACE.
000986 01-17
VIOLENT-BEHAVIOR
PROPRANOLOL IN THE TREATMENT OF RAGE AND VIOLENT-BEHAVIOR IN
PATIENTS WITH CHRONIC-BRAIN-SYNDROMES.
003394 03-11
VIOLENT-BEHAVIOUR
BIOLOGY AND THERAPY OF VIOLENT-BEHAVIOUR IN CHILDREN.
002608 02-17
VIRIDIS
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND
GANGLIONIC SYNAPSES.
002870 03-03
VISUAL
AN OLD SIDE-EFFECT REVISITED: VISUAL HALLUCINATIONS.
000886 01-15
EFFECTS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED
SUBJECTS.
002320 02-14
PSYCHOACTIVE-DRUG QUANTIFICATION BY VISUAL FLICKER SENSITIVITY
MEASUREMENT. (PH.D. DISSERTATION).
002485 02-16
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA).
002752 03-03
THE STIMULATING EFFECT OF AMPHETAMINE ON THE VISUAL SYSTEM.
003398 03-13
HABITUATION OF ELECTRODERMAL AND RESPIRATORY RESPONSES TO
VISUAL STIMULI AS A FUNCTION OF PERSONALITY DIFFERENCES IN
AFFECT LEVEL.
003414 03-13
THE EFFEQ OF PSYCHOSTIMULANTS ON CHANGES IN THE EXCITABILITY
OF THE VISUAL CEREBRAL-CORTEX.
003919 04-03
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL.
004208 04-04
PERSONALITY AND DRUGS IN VISUAL FIGURAL AFTEREFFECTS.
004581 04-14
VISUAL-EVOKED-POTENTIALS
CORRELATIONS BETWEEN VISUAL-EVOKED-POTENTIALS AND
PSYCHOPATHOLOGICAL-FINDINGS IN SCHIZOPHRENIC-PATIENTS UNDER
TREATMENT WITH VARIOUS PSYCHOPHARMACOLOGICAL-DRUGS
004315 04-08
VISUAL-MEMORY
DISSOCIATION OF THE STRYCHNINE EFFECT ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES.
000816 01-14
DISSOCIATION OF THE STRYCHNINE EFFECT ON VISUAL-MEMORY AND
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES.
002155 02-11
INFLUENCE OF STRYCHNINE ON THE CONSOLIDATION PHASE OF VISUAL-
MEMORY IN GERONTOPSYCHIATRIC-PATIENTS.
002156 02-11
VISUALLY-EVOKED-POTENTIALS
STUDY ON VISUALLY-EVOKED-POTENTIALS IN SCHIZOPHRENIC-PATIENTS
IN SULPIRIDE THERAPY.
000550 01-08
VITAMIN
VITAMIN RESPONSIVE GENETIC ABNORMALITIES. (UNPUBLISHED PAPER).
001388 02-03
VITAMIN-B6
HOMOCYSTEINE-INDUCED CONVULSIONS: ENHANCEMENT BY VITAMIN-B6
AND INHIBITION BY HYDRAZINE.
002758 03-03
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFECTS OF ORAL MAGNESIUM
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM.
003291 03-11
VITAMINS
LARGE-DOSES OF VITAMINS AND BEHAVIORAL-CONSEQUENCES. (PH.D.
DISSERTATION).
001633 02-04
VIVALAN
RESULTS OF CLINICAL-TESTS OF VILOXAZINE (VIVALAN ICI): PART OF A
MULTICLINICAL-STUDY.
002006 02-09
MULTICENTRE-STUDY WITH VILOXAZINE (VIVALAN) IN DEPRESSED-
PATIENTS.
004375 04-09
VOCABULARY
EFFEQS OF METHYLPHENIDATE ON LEARNING A BEGINNING READING
VOCABULARY BY NORMAL ADULTS.
000812 01-14
VOCALIZATION
ASCENDING ENDORPHIN INHIBITION OF DISTRESS VOCALIZATION.
00301 1 03-04
VOLTAGE
MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC
AGONISTS RESTORE MOTOR-ACTIVITY BUT PHENYLETHYLAMINE
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST-
ACTIVITY.
000309 01-03
RESERPINE ABOLISHES MOVEMENT CORRELATED ATROPINE-RESISTANT
NEOCORTICAL LOW VOLTAGE FAST-AQIVITY.
000310 01-03
VOLTAGE CLAMP STUDY OF CAT SPINAL MOTONEURONS DURING
STRYCHNINE-INDUCED SEIZURES.
002886 03-03
VOLTAGE-INDEPENDENT
THE NA-K-ATPASE: A PLAUSIBLE TRIGGER FOR VOLTAGE-INDEPENDENT
RELEASE OF CYTOPLASMIC NEUROTRANSMIHERS.
003953 04-03
VOLTAMMETRIC
IN VIVO VOLTAMMETRIC INVESTIGATIONS INTO THE ACTION OF HA-966
ON CENTRAL DOPAMINERGIC NEURONS
002832 03-03
VOLTAMMETRY
DOPAMINE HYPOAQIVITY MEASURED BY IN VIVO VOLTAMMETRY.
001149 02-03
VOLUNTARY
REDUCTION OF VOLUNTARY MORPHINE CONSUMPTION FOLLOWING
TREATMENT WITH ZIMELIDINE
000253 01-03
VOLUNTARY INTOXICATION FROM PHENCYCLIDINE. WILL IT RAISE A
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL-
STATE?.
00091401-17
VOLUNTEERS
CHRONIC ADMINISTRATION OF CANNABIDIOL TO HEALTHY VOLUNTEERS
AND EPILEPTIC-PATIENTS.
000669 01-11
PHARMACOKINETICS OF CHLORPROMAZINE IN NORMAL VOLUNTEERS.
000778 01-13
PHARMACOKINETICS OF NORTRIPTYLINE IN ELDERLY VOLUNTEERS.
002184 02-11
LEVELS OF MINERAL-ELEMENTS IN THE SERUM AND SALIVA OF HEALTHY
MALE VOLUNTEERS AFTER A SINGLE-DOSE OF LI2C03.
002297 02-13
THE PERIPHERAL ANTICHOLINERGIC-ACTIVITY OF TRICYCLIC-
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND
DESIPRAMINE IN HUMAN VOLUNTEERS.
002298 02-13
SINGLE-DOSE PHARMACOKINETICS OF DOXEPIN IN HEALTHY
VOLUNTEERS.
002303 02-13
SUBJEQIVE DRUG-EFFEQS AND DRUG PREFERENCE IN HEALTHY
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFEQS:
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO.
002362 02-14
CARDIOVASCULAR-EFFEQS OF MIANSERIN AND AMITRIPTYLINE IN
HEALTHY VOLUNTEERS.
002469 02-15
DESIPRAMINE AND 2 HYDROXYDESIPRAMINE PHARMACOKINETICS IN
NORMAL VOLUNTEERS
003154 03-07
TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFECTS OF
CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS.
003428 03-13
APOMORPHINE. HALOPERIDOL AND THE AVERAGE EVOKED-POTENTIALS
IN NORMAL HUMAN VOLUNTEERS.
004549 04-13
THE EFFECT OF FIVE TRICYCLIC-ANTIDEPRESSANTS ON SALIVARY FLOW
AND MOOD IN HEALTHY VOLUNTEERS.
004560 04-14
VOMITING
INTRAVENOUS LORAZEPAM TO PREVENT NAUSEA AND VOMITING
ASSOCIATED WITH CANCER CHEMOTHERAPY.
003614 03-17
VULNERABILITY
PROTEaiVE EFFECT OF PRENYLAMINE AGAINST VULNERABILITY TO
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE
MYOCARDIUM.
000265 01-03
INCREASED VULNERABILITY TO CHOLINERGIC STIMULATION IN
AFFEQIVE-DISORDER PATIENTS.
002003 02-09
WAKEFULNESS
CHARACTERIZATION OF ERGOT AND NONERGOT SEROTONIN
ANTAGONISTS BY PROLAQIN AND GROWTH-HORMONE PROFILES
DURING WAKEFULNESS AND SLEEP.
002217 02-13
S-472
VOLUME 19, SUBJECT INDEX
Subject Index
0 6 FLUOROTRYPTOPHAN, AN INHIBITOR OF TRYPTOPHAN-
HYDROXYLASE: SLEEP AND WAKEFULNESS IN THE RAT.
004189 04-04
WAKING
THE CLOCK AND THE BLUE GUITAR: STUDIES OF HUMAN GROWTH-
HORMONE SECRETION IN SLEEP AND WAKING. (UNPUBLISHED PAPER).
002346 02-14
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING,
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL
WAVES IN CATS?
003704 04-02
WALL
SYNTHETIC IMMUNOSTIMULANTS DERIVED FROM THE BACTERIAL CELL
WALL.
001080 02-02
WAR-NEUROSIS
TREATMENT OF TRAUMATIC WAR-NEUROSIS WITH PHENELZINE.
003325 03-11
WARFARIN
DRUG-INTERACTIONS OF AMITRIPTYLINE AND NORTRIPTYLINE WITH
WARFARIN IN THE RAT.
003912 04-03
WASTAGE
FAILURE OF CLORAZEPATE TO CAUSE MALFORMATIONS OR FETAL
WASTAGE IN THE RAT.
000514 01-05
WATER
WATER INTAKE AND TIME-COURSE OF DRINKING AFTER SINGLE OR
REPEATED CHLORDIAZEPOXIDE INJECTIONS.
000369 01-04
USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETECT AND
DISCRIMINATE ACTIONS OF DRUGS AND TOXICANTS.
000503 01-04
REVERSAL BY PHENYTOIN OF CARBAMAZEPINE-INDUCED WATER
INTOXICATION: A PHARMACOKINETIC-INTERACTION.
000783 01-13
NALOXONE: EFFECTS ON FOOD AND WATER CONSUMPTION IN THE
NONDEPRIVED AND DEPRIVED RAT.
001599 02-04
DIFFERENTIAL-EFFECTS OF MORPHINE ON FOOD AND WATER INTAKE IN
FOOD DEPRIVED AND FREELY-FEEDING RATS.
001765 02-04
ANTECEDENTS OF SELF-INDUCED WATER INTOXICATION: A PRELIMINARY-
REPORT.
002414 02-15
SINGLE OR REPEATED ADMINISTRATION OF SMALL DOSES OF
APOMORPHINE ON WATER INTAKE AND ACTIVITY IN WATER-
DEPRIVED RATS.
002981 03-04
PIMOZIDE AnENUATES LEVER-PRESSING FOR WATER REINFORCEMENT IN
RATS.
003000 03-04
EFFECTS OF CAFFEINE ADMINISTRATION ON FOOD AND WATER
CONSUMPTION UNDER VARIOUS EXPERIMENTAL CONDITIONS.
003049 03-04
CENTRAL-EFFECTS OF ANGIOTENSIN-II IN WATER AND SALINE LOADED
RATS.
003845 04-03
NALOXONE SUPPRESSES FOOD/WATER CONSUMPTION IN THE DEPRIVED
CAT.
004114 04-04
THE SITE OF ACTION OF NALOXONE IN SUPPRESSING FOOD AND WATER
INTAKE IN RATS.
004146 04-04
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
LOAD.
004600 04-15
WATER-DEPRIVED
SINGLE OR REPEATED ADMINISTRATION OF SMALL DOSES OF
APOMORPHINE ON WATER INTAKE AND ACTIVITY IN WATER-
DEPRIVED RATS.
002981 03-04
WATER-ESCAPE
TOLERANCE TO ETHANOL-INDUCED IMPAIRMENT OF WATER-ESCAPE IN
RATS BRED FOR ETHANOL SENSITIVITY.
001567 02-04
WAVES
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL
POTENTIALS: EFFECTS OF CARPIPRAMINE ON CONTINGENT NEGATIVE
VARIATION WAVES AND P-300.
003451 03-14
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING,
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL
WAVES IN CATS?
003704 04-02
WB-4101
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL
FRACTIONS
000299 01-03
WEANING
BIOELECTRICAL-ACTIVITY OF THE RAT BRAIN AFTER PREMATURE
WEANING AND AFTER RNA ADMINISTRATION.
002865 03-03
WEIGHT
PREDICTORS OF ADOLESCENT HEIGHT AND WEIGHT IN HYPERKINETIC-
BOYS TREATED WITH METHYLPHENIDATE.
003509 03-15
DEPOT FLUPHENAZINE MAINTENANCE-TREATMENT AND ASSOCIATED
WEIGHT CHANGES.
004635 04-15
WEIGHT-CONTROL
DOUBLE-BUND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS.
002314 02-14
WEIGHT-GAIN
PHENOBARBITAL EFFECTS ON WEIGHT-GAIN AND CIRCADIAN-CYCLING OF
FOOD INTAKE AND BODY-TEMPERATURE.
001409 02-03
LITHIUM-CARBONATE AND WEIGHT-GAIN.
002448 02-15
NALOXONE IN THE TREATMENT OF ANOREXIA-NERVOSA: EFFECT ON
WEIGHT-GAIN AND UPOLYSIS.
003342 03-11
WEIGHTS
COCAINE AND SEIZURE PROTECTION IN MICE OF VARYING BRAIN
WEIGHTS.
004103 04-04
WELL-BEING
A COMPUTER OCULOGRAPHIC AND EEG DOUBLE-BUND STUDY INCLUDING
WELL-BEING FOR DETERMINING CHANGED VIGILANCE UNDER THERAPY
WITH TIAPRIDE.
000751 01-13
WELLBUTRIN
CLINICAL-EFFICACY OF THE NEW ANTIDEPRESSANT BUPROPION
(WELLBUTRIN).
003227 03-09
WET-DOG-SHAKE
STUDIES OF CARBACHOL-INDUCED WET-DOG-SHAKE BEHAVIOR IN RATS.
004241 04-04
WET-DOG-SHAKES
EFFECT OF CITALOPRAM (LU-10-171) ON TRANYLCYPROMINE AND
TRYPTOPHAN-INDUCED WET-DOG-SHAKES IN RATS.
001682 02-04
KAINIC-ACID-INDUCED WET-DOG-SHAKES IN RATS: THE RELATION TO
CENTRAL NEUROTRANSMITTERS.
001685 02-04
WHEEL
NALOXONE SUPPRESSES FEEDING AND DRINKING BUT NOT WHEEL
RUNNING IN RATS.
004080 04-04
WIDOWERS
WIDOWS AND WIDOWERS AND THEIR MEDICATION USE: NURSING
IMPLICATIONS.
003626 03-17
WIDOWS
WIDOWS AND WIDOWERS AND THEIR MEDICATION USE: NURSING
IMPLICATIONS.
003626 03-17
WINGS
FDA CLIPS PSYCHODRUG PIONEERS IND WINGS.
003160 03-07
WITHDRAWAL
SEROTONIN PARTICIPATION IN GUT WITHDRAWAL FROM OPIATES.
000109 01-03
STRIATAL DOPAMINERGIC ACTIVITY DURING WITHDRAWAL FROM
CHRONIC NEUROLEPTIC TREATMENT IN RATS.
000203 01-03
APPLICATION OF A SYNTHETIC ENKEPHALIN ANALOGUE DURING HEROIN
WITHDRAWAL.
000685 01-11
INTRAVENOUS PHENOBARBITAL THERAPY IN BARBITURATE AND OTHER
HYPNOSEDATIVE WITHDRAWAL REACTIONS: A KINETIC APPROACH.
000703 01-11
MANIC-PSYCHOSIS FOLLOWING RAPID WITHDRAWAL FROM BACLOFEN.
000832 01-15
THE ROLE OF CHOLINERGIC-SUPERSENSITIVITY IN THE MEDICAL
SYMPTOMS ASSOCIATED WITH WITHDRAWAL Of ANTIPSYCHOTIC-
DRUGS.
000869 01-15
A CASE-REPORT OF LORAZEPAM WITHDRAWAL.
000889 01-15
INTROVERSION AND SEVERITY OF THE BENZODIAZEPINE WITHDRAWAL.
000923 01-17
S-473
V,
Subject Index
INTERACTION-STUDIES BETWEEN NARCOTIC ANALGESICS, NARCOTIC
ANTAGONISTS AND ETHANOL: STUDIES DURING ACUTE AND CHRONIC-
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE. (PH.D.
DISSERTATION).
001165 02-03
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR
SUBSEQUENT WITHDRAWAL.
001175 02-03
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT-
BRAIN.
001234 02-03
NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO
WITHDRAWAL INDUCING BENZAZOCINES (PH.D. DISSERTATION).
001518 02-03
EFFECTS OF MORPHINE WITHDRAWAL ON FOOD COMPETITION
HIERARCHIES AND FIGHTING-BEHAVIOR IN RATS.
001632 02-04
SUBACUTE CANNABINOID TREATMENT: ANTICONVULSANT ACTIVITY AND
WITHDRAWAL EXCITABILITY IN MICE.
001671 02-04
EFFECT OF P CHLOROPHENYLALANINE ON DIAZEPAM WITHDRAWAL
SIGNS IN RATS.
001797 02-04
THE EFFECTS OF ETHANOL, PHENOBARBITAL, AND BACLOFEN ON
ETHANOL WITHDRAWAL IN THE RHESUS-MONKEY.
001802 02-04
RAPID RECURRENCE OF MANIA FOLLOWING LITHIUM WITHDRAWAL.
002010 02-09
ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT
AND POSTTREATMENT OF ALCOHOLIC WITHDRAWAL.
002140 02-11
USE OF INJECTABLE LORAZEPAM IN ALCOHOL WITHDRAWAL.
002176 02-11
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN
SCHIZOPHRENIA.
002390 02-15
SPONTANEOUS ACTIVITY AND APOMORPHINE STEREOTYPY DURING AND
AFTER WITHDRAWAL FROM 3 1/2 MONTHS CONTINUOUS
ADMINISTRATION OF HALOPERIDOL: SOME METHODOLOGICAL-ISSUES.
002509 02-16
THE CHANGE OF BLOOD PROLACTIN LEVEL DUE TO THE WITHDRAWAL OF
MAINTENANCE NEUROLEPTICS.
002559 02-17
MORPHINE WITHDRAWAL CAUSES SUBSENSITIVITY OF ADRENERGIC-
RECEPTOR RESPONSE.
002838 03-03
LOW SERUM PROLAaiN AND EARLY RELAPSE FOLLOWING NEUROLEPTIC
WITHDRAWAL.
003166 03-08
HYPOMANIA AND MANIA AFTER WITHDRAWAL OF TRICYCLIC-
ANTIDEPRESSANTS.
003243 03-09
ALCOHOL WITHDRAWAL USING TIAPRIDE: QUANTITATIVE
PSYCHOPATHOLOGY.
003293 03-11
EFFICACY OF CLONIDINE IN OPIATE WITHDRAWAL: A STUDY OF THIRTY
PATIENTS.
003317 03-11
DOUBLE-BLIND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR
SUBCHRONIC WITHDRAWAL FROM ALCOHOL.
(X)3332 03-1 1
THE EFFECT OF WITHDRAWAL FROM PROLONGED PROPHYLACTIC
TREATMENT WITH LITHIUM.
003339 03-11
BENZODIAZEPINE WITHDRAWAL SYMPTOMS AND PROPRANOLOL.
003543 03-15
EFFECT OF LOW-DOSE LITHIUM ADMINISTRATION AND SUBSEQUENT
WITHDRAWAL ON BIOGENIC-AMINES IN RAT-BRAIN.
003708 04-03
THE EFFECT OF CHRONIC NICOTINE AND WITHDRAWAL ON INTRAAXONAL
TRANSPORT OF ACETYLCHOLINE AND RELATED ENZYMES IN SCIATIC-
NERVE OF THE RAT.
003897 04-03
EFFECTS OF ETHANOL ADMINISTRATION AND WITHDRAWAL ON
NEUROTRANSMITTER-RECEPTOR SYSTEMS IN C57 MICE.
003979 04-03
THE EFFEQS OF ACUTE AND CHRONIC ETHANG. ADMINISTRATION AND
ITS WITHDRAWAL ON GAMMA AMINOBUTYRIC-ACID-RECEPTOR
BINDING IN RAT-BRAIN.
004035 04-03
CHARACTER AND MEANING OF QUASI-MORPHINE WITHDRAWAL
PHENOMENA ELICITED BY METHYLXANTHINES.
004087 04-04
EFFEQS OF WITHDRAWAL FROM LONG-TERM DIPHENYLHYDANTOIN
TREATMENT ON AUOIOGENIC-SEIZURES AND MAXIMAL
ELEaROSHOCK-INDUCED SEIZURES IN RATS.
004101 04-04
Psychopharmacology Abstracts
OPIATE-DEPENDENCE FOLLOWING ACUTE INJEQIONS OF MORPHINE AND
NALOXONE: THE ASSESSMENT OF VARIOUS WITHDRAWAL SIGNS
004209 04-04
PHARMACOLOGICAL-ASPECTS OF SHAKING-BEHAVIOR PRODUCED BY
TRH, AG-3-5, AND MORPHINE WITHDRAWAL,
004248 04-04
LONG-TERM NEUROLEPTIC TREATMENT OF CHRONIC SCHIZOPHRENIC-
PATIENTS: CLINICAL AND BIOCHEMICAL-EFFEaS OF WITHDRAWAL
004344 04-08
A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDIQS DURING
WITHDRAWAL.
004445 04-11
ADVERSE-EFFECTS OF ANTIPARKINSON-DRUG WITHDRAWAL.
(UNPUBLISHED PAPER).
004623 04-15
WITHDRAWAL SYMPTOMS AFTER GRADUATED CESSATION OF
IMIPRAMINE IN CHILDREN.
004630 04-15
WITHDRAWAL-LIKE
HIPPOCAMPAL INVOLVEMENT IN THE PHARMACOLOGIC INDUQION OF
WITHDRAWAL-LIKE BEHAVIORS
004140 04-04
AHENUATION OF DELTA9 TETRAHYDROCANNABINOL-INDUCEO
WITHDRAWAL-LIKE BEHAVIOUR BY DELTA9
TETRAHYDROCANNABINOL.
004243 04-04
WITHDRAWAL-SYNDROME
BARBITURATE-DEPENDENCE IN MICE: EFFEaS OF PROPRANOLOL ON THE
WITHDRAWAL-SYNDROME (40798).
000313 01-03
SODIUM-VALPROATE IN THE TREATMENT OF ALCOHOL WITHDRAWAL-
SYNDROME.
002139 02-11
ALCOHOL WITHDRAWAL- SYNDROME: TREATMENT WITH TRAZODONE
002356 02-14
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF
BENZODIAZEPINE TREATMENT: SIX CLINICAL CASES
003505 03-15
RX-336-M, A NEW CHEMICAL TOOL IN THE ANALYSIS OF THE QUASI-
MORPHINE WITHDRAWAL-SYNDROME.
004093 04-04
PHYSIOLOGICAL AND BEHAVIORAL APPROACHES TO THE STUDY OF THE
QUASI-MORPHINE WITHDRAWAL- SYNDROME.
004242 04-04
WITHDRAWAL-SYNDROMES
CHOLINERGIC REBOUND IN NEUROLEPTIC WITHDRAWAL-SYNDROMES.
003506 03-15
WITHDRAWN
ORAL DYSKINESIA IN BRAIN-DAMAGED RATS WITHDRAWN FROM A
NEUROLEPTIC: IMPLICATION FOR MODELS OF TARDIVE-DYSKINESIA
000393 01-04
WOMEN
GROWTH-HORMONE AFTER TRH IN WOMEN WITH DEPRESSIVE-ILLNESS
000606 01-09
AMITRIPTYLINE, NORTRIPTYLINE PLASMA LEVELS AND CLINICAL-
RESPONSE IN WOMEN WITH AFFECTIVE-DISORDERS.
000757 01-13
EFFEQS OF NALOXONE UPON PROLAQIN AND CORTISOL IN NORMAL
WOMEN.
002213 02-13
INCREASED SERUM PROLAQIN LEVELS DURING PHENOTHIAZINE AND
BUTYROPHENONE TREATMENT OF SIX POSTPARTUM WOMEN.
003318 03-11
ELEQROPHYSIOLOGICAL AND PSYCHOLOGICAL CHANGES INDUCED BY
STEROID-HORMONES IN MEN AND WOMEN.
004500 04-13
WORLD
THE WORLD OF HALLUCINOGENIC PLANTS.
003396 03-12
WORLO-HEALTH-ORGANIZATION
AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL-EFFEQ: A
WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY.
001976 02-09
WORLDWIDE
TRIMIPRAMINE: TWENTY YEARS WORLDWIDE CLINICAL-EXPERIENCE.
000985 01-17
XANTHURENIC-ACID
HYPERVENTILATION-SYNDROME, TREATMENT WITH L TRYPTOPHAN AND
PYRIDOXINE, PREDIQIVE VALUES OF XANTHURENIC-ACID EXCRETION.
004456 04-11
XQ-FRAGILE-SITE
FRAGILE SITES IN HUMAN CHROMOSOMES I. THE EFFECT OF METHIONINE
ON THE XQ-FRAGILE-SITE.
004515 04-13
Y-MAZE
Y-MAZE BEHAVIOR AFTER AN ANALOG OF ACTH4-9, EVIDENCE FOR AN
AHENTIONAL-ALTERATION.
001676 02-04
S-474
VOLUME 19, SUBJECT INDEX
Subject Index
YAWNINO-BEHAVIOR
SEX-HORMONE INFLUENCES ON YAWNING-BEHAVIOR,
000407 01-04
INTERACTION OF CHOLINERGIC AND DOPAMINERGIC INFLUENCES ON
YAWNING-BEHAVIOR.
001656 02-04
YOHIMBINE
ADMINISTRATION OF ANTISOMATOSTATIN SERUM TO RATS REVERSES
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION
PRODUCED BY INJECTION OF METERGOLINE BUT NOT YOHIMBINE.
(UNPUBLISHED PAPER)
000019 01-03
ACCELERATION OF DESIPRAMINE-INDUCED DECREASE OF RAT
CORTICOCEREBRAL BETA-ADRENERGIC-RECEPTORS BY YOHIMBINE
000326 01-03
EFFECTS OF DESIPRAMINE AND YOHIMBINE ON ALPHA2-ADREN0CEPT0R
AND BETA-AORENOCEPTOR SENSITIVITY.
001305 02-03
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC
DRUGS.
001330 02-03
FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS
BY YOHIMBINE DIASTEREOMERS.
002748 03-03
ANTIDOPAMINERGIC PROPERTIES OF YOHIMBINE.
003995 04-03
HUMAN PLATELET ALPHA2-ADRENERGIC-RECEPT0RS: LABELING WITH 3H
YOHIMBINE, A SELECTIVE ANTAGONIST LIGAND.
004676 04-16
YOUNG
INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH PENTAZOCINE:
REVERSAL BY NALTREXONE.
000318 01-03
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS.
000509 01-05
PIRACETAM AND RETRIEVAL OF MEMORY IN YOUNG RATS.
000803 01-14
DIFFERENTIAL DOPAMINERGIC FUNCTION IN YOUNG AND OLD FEMALE
RATS AS MEASURED BY THREE BEHAVIORS.
001683 02-04
BRIEF SOCIAL-ISOLATION, PAIN RESPONSIVITY, AND MORPHINE
ANALGESIA IN YOUNG RATS.
001744 02-04
COMPARISON OF NITRAZEPAM 5 MG WITH TRIAZOLAM 0.5 MG IN
YOUNG PSYCHIATRIC INSOMNIAC-INPATIENTS.
002096 02-1 1
5 HYDROXYTRYPTOPHAN AND PYRIDOXINE: THEIR EFFECTS IN YOUNG
CHILDREN WITH DOWNS-SYNDROME.
002161 02-11
DIURNAL GROWTH-HORMONE RESPONSES TO DEXTROAMPHETAMINE IN
NORMAL YOUNG MEN AND POSTMENOPAUSAL-WOMEN.
003411 03-13
EFFEQS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION.
004281 04-05
HYPERAQIVES AS YOUNG ADULTS: PROSPECTIVE TEN-YEAR FOLLOWUP.
004454 04-11
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II.
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT.
004516 04-13
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER
LOAD.
004600 04-15
YOUTH
TARDIVE-DYSKINESIA AND OTHER DRUG-INDUCED MOVEMENT-
DISORDERS AMONG HANDICAPPED CHILDREN AND YOUTH.
004614 04-15
ZIMELIDINE
REDUaiON OF VOLUNTARY MORPHINE CONSUMPTION FOLLOWING
TREATMENT WITH ZIMELIDINE.
000253 01-03
BIOCHEMICAL-EFFECTS OF ZIMELIDINE IN MAN.
001967 02-09
A CLINICAL-TRIAL OF ZIMELIDINE IN DEPRESSION.
001992 02-09
CARDIOVASCULAR-EFFECTS OF AMITRIPTYLINE, MIANSERIN AND
ZIMELIDINE IN DEPRESSED-PATIENTS.
002215 02-13
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN
REUPTAKE INHIBITOR ZIMELIDINE.
002305 02-13
CLINICAL-TRIALS WITH NEW BICYCLIC AND TETRACYCLIC COMPOUNDS:
ZIMELIDINE AND MAPROTILINE.
003213 03-09
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION:
EVIDENCE FOR AMINE SPECIFICITY
003250 03-09
EFFECTS OF ZIMELIDINE ON SEROTONINERGIC AND NORADRENERGIC
NEURONS AFTER REPEATED ADMINISTRATION IN THE RAT
003991 04-03
AHENUATION OF PETHIDINE-INDUCED ANTINOCICEPTION BY ZIMELIDINE,
AN INHIBITOR OF 5 HYDROXYTRYPTAMINE REUPTAKE
004118 04-04
SINGLE-DOSE PHARMACOKINETIC DATA ON ZIMELIDINE IN DEPRESSED-
PATIENTS.
004385 04-09
MAPROTILINE, NOMIFENSINE, MIANSERIN, ZIMELIDINE: A REVIEW OF
ANTIDEPRESSANT EFFICACY IN INPATIENTS,
004731 04-17
ZONA-COMPACTA
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPACTA AND
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE
SPONTANEOUS NEURONAL ACTIVITIES IN THE RAT.
002718 03-03
ZONA-RETICULATA
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPACTA AND
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE
SPONTANEOUS NEURONAL ACTIVITIES IN THE RAT
002718 03-03
ZONE-SPECIFIC
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS
AND ANTAGONISTS: ZONE-SPECIFIC EFFECTS.
000422 01-04
ZONES
LSD-INDUCED ULTRASTRUCTURAL MODIFICATIONS OF LIMBIC-SYSTEM
NUCLEI AND OTHER CEREBRAL ZONES.
002198 02-12
ZOPICLONE
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY:
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS.
000543 01-07
ZOTEPINE
PHARMACOKINETICS AND METABOLISM OF
CHLORODIMETHYIAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE) IN RAT,
MOUSE, DOG AND MAN.
000219 01-03
PHARMACOLOGICAL-STUDY OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW
NEUROLEPTIC-DRUG.
000493 01-04
TOXICOLOGICAL AND TERATOLOGICAL STUDIES OF
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW
NEUROLEPTIC-DRUG.
000515 01-05
ZUCKER
METABOLIC AND SYMPATHOADRENAL ABNORMALITIES IN THE OBESE
ZUCKER RAT: EFFECT OF CHRONIC PHENOXYBENZAMINE TREATMENT.
003905 04-03
ZWIHERION
THE IONIZATION OF 5 HYDROXYTRYPTAMINE AND RELATED
COMPOUNDS AND AN APPRAISAL OF METHODS FOR THE ESTIMATION
OF ZWIHERION CONSTANTS.
001859 02-06
1251
REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 1251 TYR8-
SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES.
000259 01-03
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION.
001124 02-03
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST,
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN
BRAIN AND PERIPHERAL TISSUES.
001125 02-03
ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE
IN RAT-BRAIN.
001320 02-03
1694
ANTIDEPRESSANT AaiON OF INJECTABLE 1694.
001960 02-09
45-0088-S
PHARMACOLOGY OF 2 0 CHLOROBENZOYL-CHLORO-METHYL-NA-
GLYCYLGLYCINANILIDE HYDRATE (45-0088-S), A COMPOUND WITH
BENZODIAZEPINE-LIKE PROPERTIES.
003692 04-02
45CA
EFFECT OF VERAPAMIL ON 45CA UPTAKE BY SYNAPTOSOMES.
003856 04-03
S-475
:»«»gaE«fittttK
Subject Index
Psychopharmacology Abstracts
I
*«;
a;:
V,
I
45CA2
EFFEQ OF TAURINE ON 45CA2 ACCUMULATION IN RAT BRAIN
SYNAPTOSOMES.
002855 03-03
INCREASE OF C-GMP AND ACCUMULATION OF 45CA2 EVOKED BY DRUGS
ACTING ON SODIUM OR POTASSIUM CHANNELS.
003709 04-03
77BR
SPECIFIC IN VIVO BINDING OF 77BR P BROMOSPIROPERIDOL IN RAT-
BRAIN: A POTENTIAL TOOL FOR GAMMA-RAY IMAGING.
004293 04-06
82BR
DISTRIBUTION AND EXCRETION IN THE RAT AND MONKEY OF (82BR)
BROMOCRIPTINE.
000196 01-03
S-476
F
AUTHOR INDEX
[The 6-diflit number is the abstract accession number The next two digits ore the issue number, digits ofter hypen are the category number ]
AABROE 000659 01-11
AALTONEN L 000774 01-13
AAMODTRL 000196 01-03
AANDERUD S 004488 04-1 1
AARLI JA 002234 02-13 , 003486 03-15
ABBRUZZESE G 004382 04-09
ABDALA NE 002018 02-09
ABDEL-LATIF AA 000299 01-03
ABDUL-GHANI A 000058 01-03
ABEL EL 001830 02-05
ABELJG 000747 01-13
ABELSONJS 001557 02-04
ABHYANKAR RR 002 1 58 02- 1 1
ABIKOFfH 000678 01-11
ABRAHAAA LD 004226 04-04
ABRAHAM RR 004463 04-1 1
ABRAHAM SF 002062 02-10
ABRAMETS II 002790 03-03
ABRAMOVA LI 003 1 76 03-08
ABRAMSAA 000748 01-13
ABRIOLC 004530 04-13
ABUZZAHAB FS 0025 1 3 02- 1 7
ACHiaiG 003674 04-01
ACHTEK 000910 01-17, 003573 03-17
ACKENHEIL M 001935 02-08 , 001936 02-08 ,
00 1 959 02-08 , 0023 1 1 02- 1 3 , 002370
02-15, 004344 04-08
ACKERMAN L 000945 01-17
ACKERMANPT 002118 02-11
ACOSTAE 001930 02-08
ACOSTAJ 001558 02-04
ADAMK 002446 02-15
ADAMECRE 002202 02-12, 003133 03-06
ADAMS C 004376 04-09
ADAMS L 002803 03-03
ADAMS PM 002942 03-04 , 003121 03-05 ,
004083 04-04
ADERJP 001095 02-03
ADEYM 002512 02-16
ADINOLFIM 003071 03-04
ADLERDS 004498 04-13
ADLERLE 000829 01-15
ADLERMW 004697 04-17
ADNEYK 003509 03-15
ADOLPHEAB 004560 04-14
ADRIENJ 000214 01-03, 000423 01-04
ADVOKAT C 002943 03-04 , 002944 03-04
AELLIGA 000759 01-13
AESCHLIMANN JM 000759 01-13
AFELTOWICZZ 000546 01-08
AGARKOVAVP 003994 04-03
AGARWALPK 000583 01-09
AGHAJANIANGK 000024 01-03, 000068 01-
03 , 001364 02-03 , 001523 02-03
AGIDY 003458 03-14
AGNATI LF 001096 02-03 , 001238 02-03 ,
00 1 239 02-03 , 00 1 240 02-03 , 002727
03-03
AGNOLI A 002090 02-1 1 , 002312 02-14 ,
002371 02-15 , 003085 03-04 , 004431
04-11
AGRANOFF BW 003987 04-03
AGRAWAL AK 004264 04-05 , 004265 04-05
AGUIARM 000407 01-04
AGUILARJS 001097 02-03
AGUILERALI 000102 01-03
AGUILLAUME-TORRES R 002078 02-10
AGURELLS 002201 02-12
AHERNG 000896 01-15
AHLENIUSS 000334 01-04, 000335 01-04
AHLFORSUG 000637 01-09
AHLUWALIAP 003708 04-03
AHMED M 000007 01-02
AHNHS 001447 02-03
AHNERT-HILGER G 003709 04-03
AHRENDSEN K 004235 04-04
AHTEE L 001098 02-03
AIGNERTG 004073 04-04
AIRAKSINENMM 001067 02-02, 001078 02-
02
AKAIKEA 00169102-04, 003083 03-04
AKASUT 003710 04-03
AKBARALYR 000777 01-13
AKERAT 000066 01-03
AKERT K 003734 04-03
AKHALKATSI RG 004107 04-04
AKHTARRA 000299 01-03
AKILH 003112 03-04
AKIMOVGA 003438 03-14
AKIYAMAA 000636 01-09
AKPINAR S 002203 02-13,
AKSAMITRR 001099 02-03
002465 02-15
004636 04-15
004460 04-1 1
001100 02-03
AL-YASSIRI MM 004346 04-09 , 004707 04-
17
ALAM AS 000017 01-03 , 001 101 02-03
ALAMO C 001189 02-03
ALANDERT 001102 02-03, 004065 04-04
ALBALAA 004359 04-09
ALBANOC 000700 01-11, 002356 02-14,
004382 04-09
ALBARELLO B 004347 04-09
ALBERT DJ 002945 03-04, 003134 03-06
ALBERT E 004698 04-17
ALBERT J 002119 02-11
ALBERT V 004194 04-04
ALBERT W 000633 01-09
ALBERTSON TE 001559 02-04 , 002653 03-03
, 002862 03-03 . 002946 03-04
ALBIN H 002395 02-15
ALBINIAK BA 001560 02-04
ALBIZZATIMG 002121 02-11
ALBOUP 003574 03-17
ALBRECHTJ 000830 01-15
ALBYJM 001960 02-09, 00196102-09,
001965 02-09 , 003206 03-09
ALEKSANDROVSKIY YA 000578 01-09
ALEKSEYEVA LP 003994 04-03
ALEVIZOSB 004059 04-03
ALEXANDER BK 000530 01-06
ALEXANDER JR 001914 02-08
ALEXANDER MS 00 1 9 1 4 02-08
ALEXANDER PE 000575 01-08
ALFREDSSON G 001905 02-08
, 004559 04-13
ALGERI S 00 11 03 02-03 , 001325 02-03
003674 04-01, 004019 04-03
ALIBH 00371104-03
ALI SF 001831 02-05
ALIYEVMN 004161 04-04
004163 04-04
ALKALAYD 002204 02-13
ALLAINH 002205 02-13
ALLAN J A 002424 02-17
ALLAN RD 001104 02-03,
ALLARIAE 001460 02-03
ALLEGREG 00273103-03
ALLEGRIG 003419 03-13
ALLEN MD 000766 01-13,
002206 02- 1 3 , 004432 04- 1 1
ALLEN RE 003554 03-16
ALLEN WC 003012 03-04
ALLERSG 000640 01-09,
ALLEVAE 000336 01-04
ALLEVAFR 001849 02-05
ALLISON JH 003712 04-03
ALLMANTFM 002514 02-17
ALLOWAYKD 003131 03-05
ALMAZAN G 000246 01-03
ALMGREN 0 004 1 26 04-04
ALPERTJE 000452 01-04, 001752 02-04
ALPERT M 003277 03- 1 0 , 0043 1 2 04-08
ALPHS L 001348 02-03 , 002654 03-03 ,
002867 03-03 , 003826 04-03
ALPS BJ 001091 02-02
ALSTON C 002942 03-04
ALSTON J 004745 04-17
ALTAMURAAC 004439 04-11
ALTAMURA C 002014 02-09 ,
ALTESMAN Rl 002480 02-16
ALTMANFJ 003539 03-15
ALTMAN JL 001561 02-04
ALTSHULERHL 002947 03-04
ALTSHULER RA 001520 02-03
ALTSTEIN M 002655 03-03 ,
ALTURA BM 001105 02-03
ALVAN G 002282 02-13
ALVORDEC 00120102-03
AMABILEG 002355 02-14
AMADYANMG 000607 01-09
AMANMG 002474 02-16
004311 04-08
004162 04-04
002633 03-01
000831 01-15
002304 02-13
003981 04-03
003324 03-11
, 003681 04-02
002656 03-03
001434 02-03
AMBRON RT 002657 03-03
AMDISENA 000893 01-15,
AMDURMA 003582 03-17
AMIRS 000337 01-04
AMIRAGOVAMG 003713 04-03
AMITZ 000253 01-03, 000337 01-04,
001579 02-04, 00178102-04
AMMENDOLA D 003075 03-04
AMOCH AEV A 000509 0 1 -05
AMORYMC 000018 01-03
AMSTERDAM J 000582 01-09
ANANDAM N 000510 01-05
ANANTH J 001000 01-17 , 001886 02-07 ,
003461 03-15 , 004348 04-09 , 004668
04-15
ANATOL J 003689 04-02
ANDEN N 001 102 02-03 , 002372 02-15 ,
002658 03-03 , 004065 04-04
ANDERMANN F 000714 01-11
ANDERSEN HB 002400 02-15
ANDERSEN J 000659 01-11
ANDERSON C 000697 01-11
ANDERSON EG 000174 01-03
ANDERSON M 003321 03-11
ANDERSON PJ 003663 04-01
ANDERSON RE 000295 01-03
ANDERSSON K 001096 02-03 , 001238 02-03
, 001239 02-03, 001240 02-03, 002727
03-03
ANDO K 004459 04-1 1
ANDOR 001379 02-03
ANDOT 000444 01-04
ANDOHR 003714 04-03
ANDRASIK F 000657 01-10
ANDREA 001227 02-03
ANDREJEVANI 004174 04-04
ANDREWS PR 001029 02-01
ANDREYEVA Nl 000008 01-02
ANDREYEVAOG 003398 03-13
ANDRULONIS PA 000539 01-07
ANGELA 001106 02-03
ANGELERGUES R 003575 03-17
ANGELOH 000767 01-13
ANGELUCCI L 001 107 02-03 , 002515 02-17
ANGERSON WJ 003817 04-03
ANGGARDE 004534 04-13
ANGRIST B 000561 01-08 , 001906 02-08 ,
002453 02-15, 003552 03-15
ANGST J 000749 01-13 , 001962 02-09 ,
003608 03-17
ANHALTHS 000660 01-11
ANHUT H 000165 01-03 , 001319 02-03 ,
003715 04-03
ANIELLO R 004384 04-09
ANILINE 0 003554 03-16
ANISMAN H 000490 01-04
ANISSIMOVJZ 003716 04-03
ANKIER SI 004386 04-09
ANLEZARKG 004137 04-04
ANNABLE L 003305 03-1 1
ANNinOW 002516 02-16
ANSELLGB 004588 04-15
ANSELMI B 004553 04-13
ANSSEAUM 004308 04-07, 004589 04-15
ANTELMAN SM 000046 01-03 , 000047 01-03
, 000048 01-03, 002659 03-03, 002891
03-03, 003122 03-05
ANTHONY SG 000487 01-04
ANTIPOVARI 003326 03-11
ANTKIEWICZ-MICHALUK L 004210 04-04
ANTONOVALV 002949 03-04
ANTONYAN MN 002663 03-03
ANWAR J 001831 02-05
APPEL IB 000499 01-04 , 001561 02-04 ,
001o52 02-04 , 001753 02-04 , 001754
02-04 , 004250 04-04
APPEL NM 002924 03-03
APPELBAUMPS 000911 01-17
APPLEBAUM E 002947 03-04
APPLEGATE CD 001 562 02-04
APRISONMH 001730 02-04
APUDJ 001422 02-03, 002690 03-03
ARAI M 002844 03-03
ARAIS 000661 01-11
ARAIY 000159 01-03
A-1
4SSSS6S^aX^SK
I
Si
0;'
Author Index
ARANAGW 001114 02-03
ARANOVICH AG 003 1 72 03-08
ARASZK lEWICZ A 0007 19 01-11
ARATOM 000912 01-17, 002447 02-15,
004499 04-13
ARBILLA S 000235 01-03
ARDAILLOU R 004505 04-13
ARDITOP 004417 04-09
AREFOLOVVA 001352 02-03
ARENA R 002091 02-11
ARENDT R 003352 03-1 1
ARGENTIERITM 000131 01-03
ARKFELDDF 004647 04-15
ARMOCIDAG 003382 03-11
ARMSTRONG DM 002634 03-01
ARMSTRONG MJ 001695 02-04
ARMSTRONG-JAMES M 002475 02-16
ARNDTR 00448104-11
ARNOLD ES 000832 01-15
ARNOLD MA 000019 01-03 , 000020 01-03 ,
004014 04-03
ARNT J 002948 03-04 , 004066 04-04
AROCHAL 001930 02-08
ARONOWWS 001856 02-05
ARONSONJK 003399 03-13
ARONSTAM RS 002660 03-03
ARORARC 000750 01-13
ARRIGO-REINA R 001468 02-03
ARRIGONI E 001 126 02-03 , 003730 04-03
ARTAUD F 000123 01-03 , 00401 1 04-03
ARUSHANYAN EB 004067 04-04
ARY M 001 108 02-03 , 003024 03-04
ARZIA 004164 04-04
ARZUD 004694 04-16
ASAMU 003288 03-11
ASANOT 003717 04-03
ASANOY 000646 01-09
ASARCH KB 004349 04-09
ASBERGM 002086 02-10, 002300 02-13
ASCHRH 000286 01-03
ASCHOFFJC 00075101-13
ASHCROFTGW 001708 02-04
ASHMARIN IP 002949 03-04
ASHTON D 000496 01-04
ASHTON H 004669 04-16
ASIN KE 004098 04-04
ASK A 001452 02-03
ASNISG 000752 01-13, 000874 01-15,
002238 02-13 , 00341 1 03-13 , 004405
04-09
ASPESF 000105 01-03
ASSICOTM 001887 02-07
ASSIMACOPOULOS T 0046 1 5 04- 1 5
ASTRACHAN Dl 001605 02-04, 002950 03-04
ATAMER-SIMSEK S 00 1 2 1 6 02-03 , 00 1 2 1 7
02-03
ATRENS D 002476 02-16 , 003016 03-04
ATSMONA 001915 02-08
AHERWILLCK 00295103-04
AniLALMJ 001098 02-03
AUBINEAU P 001109 02-03
AUBREEJC 000662 01-11
AUDIBERTA 001954 02-08
AUDIGIER Y 000021 01-03 , 001 1 10 02-03 ,
003682 04-02
AUDINOTM 003825 04-03
AUGER RG 002037 02-09 , 002038 02-09
AUGUSTYN DH 002932 03-03
AULAKH CS 001601 02-04
AUVINENJ 002076 02-10, 002077 02-10
AVANESOVATS 003289 03-11
AVERY DD 001544 02-03, 002952 03-04
AVIRAMU 00217102-11
AVRUTSKIY GY 000578 01-09 , 004433 04-1 1
, 004699 04-17
AWOUTERS F 002648 03-02
AXELRODJ 001001 02-01 , 001002 02-01 ,
001026 02-01, 001027 02-01, 001118
02-03 , 00 1 1 88 02-03 , 00 1 279 02-03 ,
001282 02-03 , 001318 02-03 , 001502
02-03, 002919 03-03
AXELSON J 001 1 1 1 02-03
AXELSSON R 002207 02-13 , 002590 02-17 ,
003569 03-16, 004700 04-17
AYA K 002837 03-03
AYAIAGF 002750 03-03
AYALA-GUERRERO F 002661 03-03
AYCOCK E 001637 02-04
AYDFJ 000985 01-17, 002517 02-17,
004350 04-09 , 004590 04-15
AYGENM 002443 02-15
AYHAN IH 003104 03-04
AYVAZASHVILI IM 004068 04-04 , 004107
04-04
AZMITIA EC 002929 03-03
AZUMAH 003718 04-03
AZZARO AJ 003697 04-02 , 004009 04-03
B
BABBINIM 000338 01-04, 003555 03-16
BABOROVAE 000548 01-08, 001925 02-08
BACH NJ 001538 02-03
BACHMANJ 002209 02-13
BACHMANN E 004284 04-05
BACHMANN K 000307 01-03
BACIKOVAB 002518 02-17
BACK DJ 001832 02-05
BACK WELL B 004560 04-14
BACOPOULOS NG 001 1 1 2 02-03 , 002285 02-
13, 002662 03-03
BACOniAV 000339 01-04
BADAWYAA 000022 01-03
BADGER TM 002821 03-03
BAERT F 003653 04-01
BAEHIGK 001202 02-03, 002984 03-04
BAEZLA 001702 02-04
BAGCHI P 001113 02-03
BAGCHI SP 001113 02-03
BAGGIOG 000340 01-04
BAHARYC 002443 02-15
BAILEY ON 00459104-15
BAILEY J 000837 01-15, 00 1 976 02-09 ,
004338 04-08
BAINGT 001563 02-04
BAJAJ N 002158 02-11
BAJGARJ 000127 01-03, 000389 01-04
BAJUSZ S 002650 03-02
BAKU 001374 02-03
BAKER GB 003 1 37 03-06 , 0037 1 9 04-03
BAKER HF 001759 02-04, 003072 03-04,
004208 04-04
BAKER J 001941 02-08
BAKHAREVVO 001812 02-04, 003438 03-14
BAKHUISWL 001564 02-04
BAKKER EAD 001370 02-03
BAKLAVADZHYAN OG 002663 03-03
BAKRI-LOGEAIS F 001083 02-02
BAKRISGL 003462 03-15, 003463 03-15
BALMTAC 002281 02-13
BAUkKLEYEVSKIY Al 004434 04-11
BALASTIKOVA B 000729 01-1 1 , 002190 02-
11
BALAZST 001849 02-05
BALDASSARREM 00237102-15
BALDAUFJ 001151 02-03
BALOESSARINI RJ 000547 01-08 , 000870 01-
15, 00094101-17, 001114 02-03,
00 1 1 58 02-03 , 00 1 35 1 02-03 , 002373
02-15, 002455 02-15, 002932 03-03
BALDWIN BA 003064 03-04
BALDY-MOULINIER M 00223102-13
BALFAGONG 001355 02-03
BALFOUR DJ 001115 02-03, 001116 02-03
8ALIKJ 000674 01-11
BALITSKIYKP 001520 02-03
BALLKP 002343 02-14
BALLANTINE HT 002551 02-17
BALLARD BL 003212 03-09
BALLDIN J 002664 03-03
BALLENGER J 002637 03-01 , 003388 03-1 1
BALLUS C 001963 02-09 , 002588 02-17 ,
002589 02-17 , 004351 04-09
BALON R 000542 01-07 , 001888 02-07 ,
00 1 924 02-08 , 002025 02-09
BALSARA J J 001068 02-02 , 004147 04-04
BALSTERRL 00034101-04, 000354 01-04,
001582 02-04 , 001825 02-04 , 002961
03-04
BALTHAZARTJ 001565 02-04
BAN TA 000622 01-09 , 001964 02-09 ,
002026 02-09 , 002080 02-10 , 002431
02-15 , 002519 02-17 , 002520 02-17 ,
003274 03-10 , 004333 04-08 , 004392
04-09, 00470104-17, 004702 04-17
BAN AY-SCHWARTZ M 004606 04-1 5
BANCAUDJ 003334 03-11
BANDUHN N 000753 01-13
BANGERTER FW 003980 04-03
BANNET J 003720 04-03
Psychopharmacology Abstracts
BANNON MJ 000023 0 1 -03 , 00 1 11 7 02-03
BAQUER NZ 002868 03-03 , 003891 04-03
BAR PR 003721 04-03
BAR-ONE 004564 04-14
BARABAN JM 000024 01-03 , 000372 01-04
BARACZKAK 003193 03-08
BARAILLER J 003691 04-02
BARALDI M 000397 01-04
BARASH HM 003576 03-17
BARAHICM 001658 02-04
BARATZR 003290 03-11
BARBEAUA 000950 01-17
BARBEAU H 003722 04-03
BARBER HE 003400 03-13
BARBING 001054 02-01
BARBOUR B 000756 01-13
BARCHAS JD 001423 02-03 , 001707 02-04 ,
003006 03-04 , 003477 03-15 , 003663
04-01 , 003935 04-03 , 004314 04-08 ,
004514 04-13
BARCHAS PR 003006 03-04
BARDEN N 002635 03-01
BAROOMT 000511 01-05
BAREISDL 000025 01-03, 001002 02-01,
001118 02-03
BARFIELDRJ 000430 01-04
BARGTEYLBA 000506 01-04
BARK NM 002380 02-15
BARKA Al 002683 03-03
BARKAI A 003723 04-03 , 004005 04-03
BARKER JL 000116 01-03, 000194 01-03,
000198 01-03 , 000275 01-03 , 002665
03-03 , 002666 03-03 , 002896 03-03
BARKER S 002636 03-01 , 004221 04-04
BARKIN RM 003401 03-13
BARKLEY P 001702 02-04
BARKLEY RA 002092 02-11
BARKOV NK 003919 04-03
BARLOW DH 004425 04-10
BARLOW RB 001859 02-06
BARMACK JE 003321 03-11
BARMACK NH 001566 02-04
BARNARD G 003439 03-14
BARNES RJ 002059 02-10
BARNES TRE 002374 02-15, 002375 02-15,
002421 02-15
BARNEHA 003857 04-03
BARNEHE MS 004052 04-03
BARNHILLJ 000849 01-15
BARON C 003895 04-03
BARON J 003564 03-16, 004387 04-09,
004472 04-11
BARONDES SH 003724 04-03
BARRGA 001584 02-04
BARRECAT 003425 03-13
BARRESM 004395 04-09
BARREHJE 000508 01-04, 000649 01-10,
003105 03-04
BARREHRE 00240102-15
BARREHRJ 000342 01-04, 001699 02-04,
002953 03-04
BARRIO A 000223 01-03
BARROS-PINTO MCD 003464 03- 1 5
BARRY RJ 003414 03-13
BARSUHN C 000170 01-03 , 003034 03-04
BARTAKOVAL 000595 01-09
BARTELSK 001606 02-04
BARTFAI T 002667 03-03 , 003860 04-03
BARTHELEMY C 003291 03-1 1
BARTHOLINIG 001119 02-03, 001907 02-08
BARTKE A 002695 03-03
BARTLET AL 0037 1 1 04-03
BARTLEHMF 002204 02-13
BARTOLEH! M 000338 01-04, 003555 03-16
BARTOLINIA 000104 01-03
BARTOLINI L 003065 03-04
BARTOLINI R 000104 01-03
BARTOLOMEOJG 001375 02-03
BARTOVAD 000663 01-11
BARUCHE F 002170 02-11
BASBAUM Al 002638 03-01
BASELT RC 001559 02-04 , 002946 03-04
BASHORETR 00313103-05
BASOMBRIOJ 002018 02-09
BASOVAJ 000595 01-09
BASS MB 001567 02-04, 001625 02-04
BASS NH 003025 03-04
BASSECHES PJ 003725 04-03
BASSET P 000543 01-07
A-2
VOLUME 19, AUTHOR INDEX
Author Index
BASSETT EG 000916 01-17
BASSIS 002121 02-11
BASTECK Y J 000548 0 1 -08 , 000976 01-17,
00 1 908 02-08 , 00 1 925 02-08
BATEMAN WBJ 0009 13 01-17
8ATHIEN N 001965 02-09 , 004652 04-15
BATTJR 002320 02-14
BATTASK 000447 01-04
BAHAINI F 001512 02-03
BATTERSBYMK 00138102-03
BAHIG K 003042 03-04 , 003577 03-17
BATZOLDF 000026 01-03
BAUDRY M 001 1 20 02-03 , 001 147 02-03 ,
003726 04-03
BAUER AC 001860 02-06
BAUERLEU 000029 01-03
BAUMMJ 00282103-03
BAUMANJ 000798 01-13
BAUMANN PA 000316 01-03, 00392104-03
BAUTISTAS 002969 03-04
BAVAZZANOA 002093 02-11
BAXLEYGB 002313 02-14
BAXLEYRC 000914 01-17
BAXTER Cf 004352 04-09
BAXTER DE 003148 03-06
BEACH RC 004455 04-11
BEAINI AY 000579 01-09
BEAN NJ 001745 02-04
BEARG 000698 01-11
BEARD OW 000866 01-15
BEARDENU 000477 01-04, 000478 01-04
BEATTYWW 003084 03-04
BEAU Y 002094 02-1 1
BEAUCHAMPR 002942 03-04
BEAUDOIND 000033 01-03, 000093 01-03
BEAULIEU M 001324 02-03
BECAET 000915 01-17
BECH P 002033 02-09
BECHTELP 000640 01-09, 002304 02-13
BECK AT 003235 03-09
BECKO 002095 02-11, 002208 02-13
BECK SG 000343 01-04
BECKER BF 002227 02-13
BECKER D 004500 04-13
BECKER FT 002476 02-16
BECKER J 000459 01-04, 001059 02-01,
00112102-03, 002668 03-03
BECKER KL 002637 03-01
BECKER W 000751 01-13
BECKFORDU 004463 04-11
BECKMANN H 001909 02-08
BECLEJ 002108 02-11
BECU R 003268 03-09
BEDARD P 003722 04-03
BEDFORD J A 000344 01-04 , 002954 03-04 ,
003127 03-05
BEDNARBR 004352 04-09
SEECHING M 004552 04-13
BEERS RFJ 000916 01-17
BEHARR 000926 01-17
BEHBEHANI MM 003727 04-03
BEINFELDMC 001003 02-01, 001004 02-01,
001005 02-01, 001017 02-01, 001122
02-03
BELESLIN DB 001568 02-04, 001569 02-04
BELKNAP JK 000313 01-03
BELLGA 004069 04-04
BELL RD 000051 01-03
BELLACK AS 000657 01-10
BELLANTUONOC 00252102-17
BELMAKERRH 000083 01-03, 001966 02-09
, 003720 04-03, 004167 04-04, 004353
04-09
BELYAYEV BS 004335 04-08 , 004381 04-09 ,
004390 04-09
BELYIVP 001123 02-03
BEMIS KG 002720 03-03
BEN-BARAK Y 001833 02-05
BEN-DAVI D M 00084 101-15, 00 1 9 1 6 02-08
BENAKISA 001874 02-06
BENARDO LS 003728 04-03
BENDEK G 003729 04-03
BENDER AS 000330 01-03, 002933 03-03
BENDER W 001570 02-04
BENDERLYA 003719 04-03
BENEDEK G 002955 03-04
BENEDEHI MS 003874 04-03
BENESOVA 0 000144 01-03 , 000595 01-09 ,
000800 01-14, 000917 01-17, 001571
02-04
BENFENATI F 001096 02-03
BENGHEZALA 001954 02-08
BENINGER RJ 000345 01-04 , 001572 02-04 ,
002956 03-04 , 004070 04-04
BENKERT 0 002 137 02-11 , 004435 04- 1 1
BENMAMAN JD 004558 04-13
BENNETT B 000537 01-06
BENNETT C 001053 02-01
BENNETT EL 001573 02-04, 004097 04-04,
004578 04-14
BENNETT JP 001 124 02-03 , 001 125 02-03
BENNETT WF 001147 02-03
BENNIE EH 003504 03-15
BENOWITZNL 000796 01-13, 00162102-04,
002209 02-13
BENSON Dl 001484 02-03
BENSON RM 004743 04-17
BENTALE 004564 04-14
BENTLEYGA 000263 01-03
BENTUE-FERRER D 002205 02-13
BENVENUTI P 004365 04-09
BENYACOUBA 002014 02-09, 002600 02-17
, 004445 04-11
BENZI G 001 1 26 02-03 , 003730 04-03
BERAMENDI V 0043 1 2 04-08
BERARDI N 002894 03-03
BERCHOU RC 003367 03-11
BERDEB 002522 02-17
BERECOECHEA J 003689 04-02
BERECZJM 000672 01-11
BEREGI L 002541 02-17
BERENDSEN HHG 00044101-04
BEREHAG 003295 03-11
BEREZOVANY 000578 01-09
BERGERFM 000801 01-14
BERGERG 003564 03-16
BERGER L 003702 04-02
BERGERPA 000928 01-17, 002488 02-16,
003286 03-10 , 003465 03-15 , 003477
03-15 , 003663 04-01 , 004313 04-08 ,
004314 04-08 , 004327 04-08 , 004442
04-11, 004514 04-13, 004592 04-15,
004604 04- 1 5 , 004703 04- 1 7
BERGER TW 002916 03-03
BERGEY GK 002669 03-03
BERGGRENU 004110 04-04
BERGHMANSW 000758 01-13
BERGLUNDM 002210 02-13
BERGMAN J 004071 04-04
BERGMANNF 001574 02-04
BERGMANN M 004321 04-08
BERGSTROML 000027 01-03
BERKMAN K 000169 01-03
BERKOWITZ AL 003960 04-03
BERLISS H 001929 02-08
BERMAN RF 002780 03-03
BERNADTMW 002060 02-10
BERNARD PS 000188 01-03
BERNARDINABD 002319 02-14
BERNASCONI R 003135 03-06
BERNASCONI S 003705 04-02
BERNEY S 004333 04-08
BERNHARDT W 004586 04-14
BERNIERJL 003653 04-01
BERNSTEIN JG 003292 03-11
BERNTSON GG 003 1 1 1 03-04 , 003 1 1 2 03-04
BERRY SD 002916 03-03
BERSANI G 002226 02-13 , 003466 03-15 ,
004318 04-08
BERTACCINIG 004535 04-13
BERTHON G 002061 02-10
BERTILSSON L 000754 01-13, 000897 01-16,
001967 02-09, 00218102-11, 002282
02-13, 002300 02-13
BERTLER A 002211 02-13
BERTOLEHI P 004354 04-09 , 004419 04-10
BERTOLINI R 003207 03-09
BERZETEI IP 002650 03-02
BESIO G 000700 01-1 1 , 002013 02-09 ,
004533 04-13
BESSERGM 001016 02-01, 001127 02-03,
003731 04-03 , 003732 04-03 , 0C4363
04-09
BESSON J 000028 0 1 -03 , 000 1 1 0 0 1 -03 ,
000175 01-03, 00279103-03
BEST MR 001610 02-04
BETTJHN 002232 02-13
BEUDIN P 004479 04-1 1
BEUMONT PJV 002062 02-10
BEVANJA 002670 03-03
BEVERIDGE IJ 000409 01-04
BEYP 001128 02-03
BEYER C 002957 03-04
BEYERS 002523 02-17
BEZZI G 002058 0209
BHARGAVAHN 001435 02-03, 001575 02-04
, 001576 02-04, 004072 04-04
BHARGAVA KP 000247 01-03 , 002186 02-1 1
BHATTACHARYA SK 001 769 02-04
BHATTACHARYYA AK 000346 01-04, 001601
02-04
BHATTACHARYYA PK 003654 04-01
BHAVSARVH 003772 04-03, 004102 04-04
BHAWANJ 000257 01-03
BHUTASI 002291 02-13
BIANCHETTI G 000549 01-08 , 002267 02-13
BIANCHICP 000069 01-03
BIANCHI G 002063 02-10 , 004477 04-1 1
BIANCHIM 000105 01-03
BIANCHI RG 000064 01-03
BIAZZIA 001577 02-04
BIDZINSKIA 004546 04-13
BIEGER D 001821 02-04
BIELSKI R 00441104-09
BIERTUEMPHEL H 003217 03-09
BIGELOW GE 0023 1 4 02- 1 4 , 004566 04- 1 4 ,
004582 04-14
BIGELOW L 001928 02-08 , 001945 02-08 ,
003 1 65 03-08 , 003 1 68 03-08 , 003 1 84
03-08
BIGGER JT 002697 03-03
BIGGIO G 001 129 02-03 , 002477 02-16 ,
002743 03-03 , 003739 04-03
BIGGS C 003095 03-04
BIGGS JSG 002424 02-17
BIGNAMI G 002671 03-03
BIGON E 002682 03-03
BILLEJ 003578 03-17
BINEK PA 003733 04-03
BING LA 001622 02-04 , 002992 03-04
BINYILDIZP 001217 02-03
BIORN-HENRIKSEN T 004734 04-17
BIOULACB 000272 01-03
BIRCH NJ 002212 02-13
BIRCHER J 002525 02-17 , 004495 04-1 1
BIRD ED 000564 01-08, 002575 02-17
BIRDKD 002193 02-12
BIRDSALLN 000026 01-03
BIRKEMOLS 004111 04-04
BIRKMAYERW 000712 01-11
BIRKNERR 004319 04-08
BIRNKRANDT D 002928 03-03
BIRSELS 001130 02-03
BISCHOFFS 001131 02-03
BISHOP M 000837 01-15 , 001943 02-08 ,
004338 04-08
BISHOP P 001745 02-04
BISMUTH C 003505 03-15
BISWAS B 002672 03-03
BITETTI R 000378 01-04
BITTENCOURT PRM 002376 02-15, 003467
03-15
BITTER I 003193 03-08
BITTIGER H 001 131 02-03 , 003135 03-06
BITTNER SE 004073 04-04
BITTNER-MANICKA M 000664 01-1 1
BIXLER EO 000945 01-17
BIZZINI B 003734 04-03
BJORKLUNDA 000347 01-04
BJORNDALN 001968 02-09, 002377 02-15
BLACK IB 000149 01-03, 00388104-03
BLACK KL 000321 01-03
BLACKBURN TP 001578 02-04
BLADIN PF 003433 03-13
BLAHAL 000665 01-11
BLAIR lA 001132 02-03
BLAIR R 000337 01-04, 001579 02-04
BLAKE J 003655 04-01
BLAKELYRD 003012 03-04
BLAKEMORE CB 002360 02-14
BLAMPIED NM 000353 01-04
BLANC M 003559 03-16
BLANCHARD J 00 1 1 33 02-03 , 00 1 1 37 02-03
BLANCO J 003553 03-15
BLANK AC 000089 01-03
BLANK B 001069 02-02
BLANKSTEINJ 002213 02-13
BLASERSM 004352 04-09
A-Z
Author Index
Ptychopharmacology Abstracts
«5
0:,
BLASIG J 000029 01-03 , 003740 04-03 ,
004104 04-04
BLASSEM 002478 02-16
BLATNICK RA 001539 02-03
BLAUSTEINJD 002842 03-03
BLAUWBLOMME J 003208 03-09
BLAZEKJ 004648 04-15
BLEEKERJAC 002526 02-17
BLENNOWG 001134 02-03
BLIERP 001135 02-03
BLINDER BJ 004743 04-17
BLINDERMANN J 002878 03-03
BLODGETTALN 004403 04-09
BLOOM F 000580 01-09, 001136 02-03,
002599 02-17 , 002884 03-03 , 003136
03-06 , 003735 04-03
BLOOM V 004411 04-09
BLOXAM DL 002673 03-03
BLUET-PAJOT MT 000262 01-03
BLUM A 001229 02-03 , 001867 02-06 ,
004395 04-09
BLUM I 004320 04-08
BLUME HW 002674 03-03
BLUMENTHAL M 002096 02- 1 1
BLUNDELLC 001476 02-03, 001784 02-04
BLUNDELLJE 002527 02-17
BOARATO E 002682 03-03
BOBIKA 004506 04-13
BOBONDP 002528 02-17, 003293 03-11
BOBRITSKAYA ZM 004633 04-1 5
BOBRUFFA 003294 03-11
BOCCIU 003295 03-11
BOCKAERT J 0002 1 3 0 1 -03 , 0002 1 4 0 1 -03
BODEMG 003161 03-07
BODENSTEINER JB 003468 03-15
BODNARRJ 000348 01-04, 004074 04-04
BODNER AJ 001006 02-01
BODNERL 003338 03-11
BOER GJ 004091 04-04
BOERNGENR 001712 02-04
BOGAERTMG 004355 04-09
BOGDALJ 001844 02-05
BOGEHO F 002872 03-03 , 002873 03-03
BOHLI 00448104-11
BOHLEN P 003458 03-14 , 004285 04-06 ,
004296 04-06
BOHLINL 000084 01-03
BOHNMC 000030 01-03
BOHRERRE 003363 03-11
BOIREAU A 00 1 1 33 02-03 , 00 1 1 37 02-03
BOISSIER JR 00 1 070 02-02 , 00 1 2 1 8 02-03 ,
002635 03-01 , 003789 04-03 , 004105
04-04
BOKORJT 004063 04-03
BOKSAJ 000204 01-03
BOLANDER K 001594 02-04
BOLDYREVAI 003209 03-09, 004593 04-15
BOLEGG 000779 01-13
BOLELOUCKYZ 000976 01-17, 002064 02-10
BOLEYNT 002193 02-12
BOLLE P 002664 03-03
BOLLEAE 000833 01-15
BOLLESRC 001615 02-04
BOLTER A 000736 01-12
BONDNW 001580 02-04
BONDYB 003556 03-16
BONDY SC 004264 04-05 , 004265 04-05
BONEHI EP 002646 03-02
BONICALZI M 001985 02-09
BONILLAE 002112 02-11
BONING J 002378 02-15
BONNAFOUXD 002140 02-11, 003296 03-11
BONNET AM 003458 03-14
BONNET JJ 004173 04-04
BONNET KA 004300 04-06
BONNET MH 003439 03-14
BOOJ S 003897 04-03
BORBE HO 001440 02-03 , 00421 1 04-04
BORBELYAA 002958 03-04
BORDASH GD 004245 04-04 , 004246 04-04
BORDESMM 002395 02-15
BORENSTEIN P 001 170 02-03 . 002731 03-03
BOREYSHA IK 003 1 00 03-04
BORGS 002095 02-11
BORGAO 000897 01-16
BORIOVAM 002064 02-10
BORISON RL 001834 02-05
BORN-LEVEQUE M 003293 03-1 1
BORNE RF 002954 03-04
BORNHEIM LM 002675 03-03
BORNSTEINJC 000063 01-03, 002768 03-03
BORNSTEIN S 002065 02-10
BORODKIN YS 004075 04-04
BORRI P 002925 03-03
BORYS HK 002675 03-03
BOSCHEJ 002438 C2- 15
BOSCREDON J 000616 01-09 , 000782 01-13 ,
001980 02-09
BOSHANSRL 003712 04-03
BOSHARTG 000705 01-11
BOSIE 002277 02-13
BOSOV AM 004340 04-08
BOSSI L 003334 03-11, 003343 03-11
BOSSI M 000105 01-03
BOSZORMENYI Z 004436 04-1 1
BOHARI R 004622 04-15
BOTTICELLI U 004076 04-04
BOUBLI S 003559 03-16
BOUCHARLAT J 002379 02- 1 5 , 003 1 49 03-07
BOUDOURESQUE F 003759 04-03
BOUEILH P 000834 01-15
BOULENGER J 001090 02-02 , 004501 04-13
BOULTONAA 001077 02-02, 001207 02-03
BOUMAN HJ 001370 02-03
BOUR HL 001564 02-04 , 003056 03-04
BOUR HLMG 004091 04-04
BOURGEOIS M 000834 01-15
BOURGOIN S 000123 01-03 , 00401 1 04-03
BOURN WM 001138 02-03
BOURNE RC 004282 04-05 , 004423 04-10
BOURQUEC 000253 01-03
BOUSQUETB 000018 01-03
BOUTELLE WE 004356 04-09
BOUTILLIER H 001090 02-02
BOUVIER G 003341 03-11
BOUYARD P 001371 02-03
BOUYER J 001581 02-04
BOWDLETA 000755 01-13
BOWDLER JM 003736 04-03
BOWEN WD 003737 04-03
BOWERS MB 000708 01-11, 000764 01-13,
002097 02-11, 002098 02-11, 003738
04-03, 004502 04-13
BOWERY NG 003839 04-03
BOWES GM 001472 02-03
BOWYERJF 000106 01-03, 002959 03-04
BOXENBAUM HG 002248 02-13
BOYAN-SALYERS BD 001007 02-01
BOYD EJS 004306 04-07
BOYDJL 000644 01-09
BOYER P 002498 02-16 , 002529 02-17
BOYESON MG 004135 04-04
BOZAK M 004519 04-13, 004567 04-14
BOZARTH MA 001861 02-06 , 002960 03-04 ,
002999 03-04
BRACCINIT 002023 02-09, 003210 03-09,
004357 04-09 , 004594 04-15
BRACHET-LIERMAIN A 000777 01-13
BRACKEN J 002391 02-15
BRACONNIER A 002344 02-14
BRADFORD HF 000058 01-03 , 002843 03-03
, 002897 03-03
BRADFORD LD 000395 01-04
BRADLEY EL 001793 02-04
BRADSHAWCM 002298 02-13
BRADY JV 000395 01-04, 004123 04-04
BRADY KT 001582 02-04, 00296103-04
BRADY LS 000349 01-04, 004077 04-04
BRAESTRUP C 000216 01-03 , 000918 01-17 ,
001 139 02-03 , 001395 02-03 , 002676
03-03 , 003579 03-17 , 003739 04-03
BRAFFDL 000748 01-13, 002194 02-12
BRAGG L 000919 01-17
BRAGIN AG 002941 03-03
BRAGIN E 002641 03-01
BRAHMAPURIKAR MT 00136102-03
BRAITHWAITE R 000897 01-16 , 002266 02-
13, 002284 02-13
BRAMMERGL 001385 02-03, 003942 04-03
, 004204 04-04
BRANCH BJ 000180 01-03
BRANCH MN 000350 01-04 , 001583 02-04
BRANCHEY LB 002380 02-15 , 003469 03-15 ,
004595 04-15
BRANCHEY MH 002380 02-15, 003469 03-15
, 004595 04-15
BRANCONNIER RJ 003297 03-1 1 , 003557 03-
16
BRANDENBERGER H 003490 03-15
BRANDT J 000767 01-13
BRANDT M 002677 03-03
BRANNAN MD 000512 01-05
BRANTEG 003542 03-15
BRANTL V 003740 04-03
BRASE DA 001 140 02-03 , 003741 04-03
BRASILMAA 003470 03-15
BRASSEUR R 000581 01-09
BRAUERH 004626 04-15
BRAUMAN H 000606 01-09 , 002099 02-1 1 ,
003237 03-09
BRAUN G 003683 04-02
BRAUN H 001729 02-04 , 003061 03-04
BRAUN U 003683 04-02
BRAUTIGAM M 002962 03-04
BRAVKOV MF 00 1 5 1 4 02-03
BRECKENRIDGE AM 001832 02-05, 003621
03-17
BREESEG 00114102-03, 001389 02-03,
001813 02-04, 003037 03-04, 003748
04-03 , 003917 04-03 , 004195 04-04
BREHM L 001079 02-02
BREIMER DD 000920 01-17
BRENDLEA 000867 01-15
BRENENGEN EE 002037 02-09
BRENNAN MJW 002678 03-03
BRENOT P 002170 02-11, 00345103-14
BRESOLIN N 002902 03-03
BRESSW 004670 04-16
BRESSLER B 00238102-15
BREUNINGSE 003298 03-11, 003392 03-11,
004437 04-11 , 004438 04-1)
BREWARD J 000031 01-03
BREWIN R 003602 03-17
BREWSTER D 000032 01-03, 00035101-04
BREYER-PFAFF U 002214 02-13
BREZENOFF HE 003744 04-03
BRICK J 000481 01-04
BRICOLOR 004717 04-17
BRIDENBAUGH RH 003347 03-1 1
BRIDGE TP 001928 02-08, 003169 03-08,
003499 03-15, 00467104-16
BRIDGERWH 001584 02-04
BRIDGES PK 002375 02-15, 004346 04-09
BRIEF D 004098 04-04
BRIENJF 003522 03-15
BRIGGS RS 002679 03-03
BRILEY M 000033 01-03 , 000235 01-03 ,
002254 02-13 , 002569 02-16 , 003427
03- 1 3 , 0036 1 0 03- 1 7 , 003955 04-03 ,
004358 04-09 , 004707 04-17
BRINDEAU F 002731 03-03
BRINKMAN S 003095 03-04 , 003299 03-1 1 ,
003385 03-11
BRINKSCHULTE M 002214 02-13
BRION S 00 1 969 02-09 , 002389 02- 1 5
BROCHEJP 002100 02-11
BROCHETD 003424 03-13
BROCKMAN R 000896 01-15
BRODDE 0 003816 04-03
BRODEMANN R 002792 03-03
BRODIE M 001 142 02-03 , 004203 04-04
BRODIE RR 004504 04-13
BRODYTM 000066 01-03
BROEKER H 003300 03-11
BROEKKAMPCL 001585 02-04, 002986 03-
04
BROENG-NIELSEN B 003484 03-15
BRON B 004596 04-15
BROOKE M 002433 02-15
BROOKS AD 004496 04-12
BROONER RK 003308 03-1 1
BROPHYTO 004555 04-13
BROSEMER RW 003953 04-03
BROSSETP 002395 02-15
BROSTEANU ER 000550 01-08, 004315 04-08
BROSTOFF SW 003665 04-01
BROWDER S 002680 03-03
BROWN DA 000034 01-03 , 001 143 02-03 ,
001144 02-03
BROWN DF 001 145 02-03 , 003821 04-03
BROWN DL 002683 03-03
BROWN DR 002963 03-04
BROWN GB 002636 03-01
BROWN GL 003340 03-11
BROWN GM 003402 03-13
BROWN HK 003143 03-06
BROWN IR 002721 03-03 , 003761 04-03 ,
003831 04-03 , 003832 04-03
A-4
VOLUME 19, AUTHOR INDEX
Author Index
BROWN J 001 146 02-03 , 001586 02-04 ,
004078 04-04
BROWN K 004090 04-04
BROWN MJ 002504 02-16
BROWN PA 000035 01-03
BROWN RD 003865 04-03
BROWN RM 002641 03-01
BROWN WA 001970 02-09, 00197102-09,
00251 1 02-16 , 003166 03-08 , 00321 1
03-09
BROWN WJ 001587 02-04
BROWN ZW 000253 01-03 , 000337 01-04
BROWNELLJ 002217 02-13
BROWNING M 001147 02-03
BROWNSTEIN M 001003 02-01 , 001005 02-
01 , 001008 02-01 , 001053 02-01 ,
001 148 02-03 , 00121 1 02-03 , 001400
02-03 , 002645 03-01
BROXTERMAN HJ 00 1 1 49 02-03 , 00 1 1 50 02-
03, 00268103-03, 002832 03-03
BROZEK G 004064 04-03
BRUCKNER GW 002004 02-09 , 003327 03-1 1
BRUCKNER H 004481 04-11
BRUCKWICK E 001348 02-03 , 001423 02-03
BRUGUEROLLEB 001371 02-03
BRUINVELSJ 001606 02-04, 001809 02-04
BRUMBACK RA 002459 02-15
BRUN A 003451 03-14
BRUNEGG 002501 02-16
BRUNEAUXJ 001980 02-09
BRUNI A 002682 03-03
BRUNIJ 000756 01-13, 000762 01-13
BRUNNERH 001972 02-09, 002382 02-15
BRUNO F 001422 02-03 , 003126 03-05
BRUNS RF 003766 04-03
BRUNSWICK D 000582 01-09, 003246 03-09
BRUSTJCM 000835 01-15
BRUST-CARMONA H 003101 03-04
BRUTUS M 000348 01-04
BUCHHP 001151 02-03
BUCHANAN D 000622 01-09
BUCHEN C 002677 03-03
BUCHSBAUM M 0006 1 2 0 1 -09 , 0007 16 01-
1 1 , 001910 02-08 , 002222 02-13 ,
002359 02- 1 4 , 002366 02- 1 4 , 003 1 67
03-08 , 003242 03-09 , 003310 03-1 1 ,
004316 04-08, 004549 04-13
BUCHTG 004664 04-15
BUCHWALD NA 001340 02-03
BUCK SH 001421 02-03
BUCKALEWLW 004704 04-17
BUCKEHWR 002964 03-04, 003620 03-17
8UCKH0LTZNS 001152 02-03
BUCKLE PJ 003742 04-03
BUCKLEY JP 003707 04-02
BUDD RD 003656 04-01 , 003657 04-01 ,
003658 04-01, 003659 04-01, 004672
04-16, 004687 04-16
BUDEK M 002683 03-03
BUENOOFA 004263 04-04
BUESCHERH 003013 03-04
BUGARDP 001980 02-09
BUGAT R 003441 03-14
BUG AH! A 001422 02-03
BUGGY J 002891 03-03
BULLARDWP 003922 04-03
BULON VV 004075 04-04
BUMBIEREE 003151 03-07
BUNAGRD 003099 03-04
BUNNEY BS 000023 01-03 , 001 153 02-03
BUNNEYEB 001117 02-03
BUNNEY WE 000575 01-08 , 001443 02-03 ,
001951 02-08 , 001973 02-09 , 001984
02-09, 00222102-13, 003275 03-10,
003276 03- 1 0 , 0043 1 6 04-08 , 0043 1 7
04-08 , 004398 04-09 , 004705 04-17
BUNTING PR 002533 02-17
BURBACHRV 004671 04-16
BURBAYEVA GS 003 1 76 03-08
BURCH T 001 1 54 02-03 , 004037 04-03
BURCHFIEL JL 002684 03-03
BURDICK BM 000921 01-17
BURESJ 000352 01-04, 001778 02-04
BURESOVAA 000613 01-09
BURESOVAO 000352 01-04
BURGESS CD 0022 1 5 02- 1 3 , 004597 04- 1 5
BURGESS CE 004707 04-17
BURGESS SK 001155 02-03
BURGEVIN MC 003898 04-03
BURIANW 003580 03-17
BURKARDG 000665 01-11
BURKARDWP 001314 02-03
BURKE D 004673 04-16
BURKE MP 003537 03-15
BURKI HR 001156 02-03
BURKITTM 004509 04-13
BURKS TF 001-366 02-03 , 001421 02-03 ,
002822 03-03 , 003773 04-03
BURNAZYANGA 000607 01-09
BURNETA 001862 02-06
BURNER M 001974 02-09
BURNETT G 004090 04-04
BURNHAMWM 000160 01-03, 000416 01-04
, 002493 02-16
BURNS RH 003688 04-02
BURNS RJ 001835 02-05
BURRIGHTRG 004103 04-04
BURROWS GD 0006 1 4 0 1 -09 , 002 1 84 02- 1 1 ,
002383 02-15 , 002497 02-16 , 004477
04-11 , 004639 04-15
BURROWS GH 002685 03-03
BURSTEINY 001836 02-05
BURSTON KN 001859 02-06
BURTENW 003212 03-09
BURTON JS 000007 01-02
BURWELLB 000278 01-03
BUSCH D 003190 03-08 , 004538 04-13 ,
004540 04-13
BUSCH M 002479 02-16
BUSH D 001992 02-09
BUSHH 002433 02-15
BUSH LG 002780 03-03
BUSH PJ 004706 04-17
BUST AMI F 001183 02-03
BUSTOSG 002285 02-13
BUTLER IJ 002713 03-03
BUTLER JA 003878 04-03
BUU NT 004286 04-06
BUVATJ 004503 04-13
BUVAT-HERBAUT M 004503 04-13
BUXTON M 000745 01-12, 000924 01-17
BYMASTERFP 001538 02-03
BYRINGR 002096 02-11
BYRSK A B 00 1 4 1 7 02-03 , 00 1 788 02-04
CABBATFS 000404 01-04, 001650 02-04
CABRASPL 004365 04-09
CACCI A S 000036 0 1 -03 , 00 1 1 57 02-03
CAGGIULAAR 001167 02-03, 002968 03-04
CAILLEE 003403 03-13
CAILLEJ 003440 03-14
CAIN OP 000037 01-03
CAIN M 004221 04-04
CALANCAA 004615 04-15
CALANDRAC 003150 03-07, 00330103-11
CALDWELL HC 00315103-07
CALHOUN DW 000064 01-03
CALIARI S 001386 02-03
CALILHM 003250 03-09
CALLAGHAN DA 001588 02-04
CALLAGHANJT 002257 02-13
CALLAGHAN N 002445 02-15
CALLAWAY JT 000949 01-17, 0032 1 4 03-09
CALNE DB 000673 01-11 , 002384 02- 1 5 ,
003309 03-11, 003319 03-11, 003406
03-13
CALOM 000443 01-04
CALOGEROM 00116102-03
CALOINESCUC 002295 02-13
CALVANI M 003 1 57 03-07 , 003 1 58 03-07
CALVERLEYDG 003137 03-06, 003719 04-03
CAMA6NAA 002226 02-13
CAMERON DB 000353 01-04
CAMMANNG 004481 04-11
CAMPJA 002385 02-15
CAMPBELL A 001158 02-03
CAMPBELL BA 002965 03-04
CAMPBELL IC 000038 0 1 -03 , 0006 1 2 0 1 -09 ,
00 1 536 02-03 , 00208 1 02- 1 0
CAMPBELL JL 003743 04-03
CAMPBELL K 003304 03-1 1
CAMPBELL M 003360 03-11, 00336103-11
CAMPBELL RG 000828 01-14
CAMPOS CJR 000039 01-03
CAMPOS F 003163 03-07
CANCHOLA E 002957 03-04
CANCROR 003471 03-15
CANDELORA K 003377 03-1 1
GANGER R 004439 04-11
CANNON JG 002236 02-13
CANO J 002625 02-17 , 003571 03-16
CANONICOPL 000378 01-04
CANTONI GL 001006 02-01 , 001021 02-01 ,
001100 02-03, 001415 02-03
CANTORS 000557 01-08
CANTRILLRC 002678 03-03
CAPDEVILLEC 002108 02-11
CAPLAN LR 000947 01-17
CAPLOVA T 000609 0 1 -09 , 000707 01-11 ,
001934 02-08 , 002020 02-09 , 004375
04-09
CAPONERI MA 001985 02-09
CAPPARELLHV 000657 01-10
CAPPELIEZ P 004079 04-04
CAPPELLAZZO G 002682 03-03
CAPUTI AP 003744 04-03
CARBONEJJ 002248 02-13
CARCHMAN RA 0027 1 2 03-03
CARDENAS HL 001450 02-03
CARDINALI DP 001159 02-03
CARDOTA 000205 01-03
CARENINI G 001051 02-01
CARENZIA 001422 02-03, 003126 03-05
CAREY MP 004080 04-04
CARIDROITM 003404 03-13, 003404 03-13
CARILLI L 004318 04-08
CARINOMA 000424 01-04
CARISSIMI M 001051 02-01
CARLEOR 003124 03-05
CARLI G 004081 04-04
CARLI M 000036 01-03
CARLINI EA 000669 01-11, 003163 03-07
CARLSEN S 002204 02-13
CARLSON KR 000257 01-03 , 000922 01-17
CARLSSON A 000399 01-04 , 001392 02-03 ,
003799 04-03 , 00441 2 04-09
CARLSSON S 001737 02-04
CARMAN AB 002770 03-03
CARMAN JS 002216 02-13, 002637 03-01,
003168 03-08
CARMEN RD 001442 02-03
CARMONAE 000040 01-03
CARNEY JM 000354 01-04
CARNEY K 003744 04-03
CARON MG 001009 02-01
CARONNA P 002058 02-09
CARPENTER L 004611 04-15
CARPENTER WT 000836 01-15
CARPENTIER P 002379 02-15
CARPORALI M 002355 02-14
CARRANZAJ 004598 04-15
CARRASCO MA 00007 1 0 1 -03 , 00 1 664 02-04
CARRAZG 001160 02-03
CARROLL B 000588 01-09 , 001792 02-04 ,
004359 04-09 , 004403 04-09 , 004674
04-16
CARROLL JA 000206 01-03
CARROLL ME 004287 04-06
CARRON R 004615 04-15
CARRUBAMO 00004101-03, 000042 01-03
, 000355 01-04, 00116102-03, 001733
02-04 , 002863 03-03
CARTER CJ 001589 02-04, 002869 03-03,
002966 03-04
CARTER MF 004310 04-07
CARTY SE 003866 04-03
CARUSO TP 001162 02-03, 004082 04-04
CARVER CS 003405 03-13
CARVE YP 001845 02-05, 004249 04-04
CARWILES 002149 02-11
CARYMD 000923 01-17
CASACCHIAM 004384 04-09
CASAISL 001189 02-03
CASAMENTI F 001386 02-03
CASANUEVA F 002690 03-03
CASAZZAG 001424 02-03
CASCIOCS 003878 04-03
CASE WG 003254 03-09 , 004400 04-09
CASEY D 000043 01-03 , 000540 01-07 ,
002101 02-11 , 002102 02-11 , 002377
02- 1 5 , 002405 02- 1 5 , 003302 03- 1 1 ,
003472 03-15
CASHC 003675 04-01
CASOC 003553 03-15
CASPER R 000555 01-08, 001913 02-08,
002386 02-15, 004215 04-04
CASSAGNES J 004307 04-07
A-5
Author Index
Psychophormacology Abstracts
ft
K
CASSANOG 000563 01-08
CASSONI 000698 01-11, 002342 02-14
CASTAIGNEP 003303 03-11
CASTANASE 003759 04-03
CASTANEDAE 002500 02-16
CASTELLANI S 004083 04-04
CASTELLANOC 000336 01-04, 000382 01-04
CASTELLOE 002591 02-17
CASTONTV 000056 01-03
CASTRO A 003645 03-17
CASTROGIOVANNI P 004507 04-13
CASUM 001129 02-03
CATALANIA 002515 02-17
CATLIN DH 004360 04-09
CAHABENI F 001422 02-03
CATTELLWR 000837 01-15
CAnOE 004019 04-03
CAVALHEIRO EA 000039 01-03
CAVEROI 000044 01-03
CAVIEZEL F 002277 02-13
CAYREYREM 002530 02-17
CAZALAP 001590 02-04
CAZZULLO CL 002293 02-13 , 004361 04-09 ,
004439 04-11
CELANIT 003444 03-14
CENAJEK D 004599 04-15
CENRAUDB 000777 01-13, 000873 01-15
CEPEDAC 003564 03-16
CERCIELLOA 003124 03-05
CERFFA 000713 01-11
CERNAV 000623 01-09
CERRITO F 001 163 02-03 , 001424 02-03 ,
003745 04-03
CERVANTES P 000560 01-08 , 002253 02-13
CERVENA I 000001 01-01
CERVOL 000258 01-03, 001764 02-04
CESARE DA 000356 01-04
CESKOVAE 000567 01-08, 000568 01-08,
0006 1 3 0 1 -09 , 000634 0 1 -09 , 00 1 937
02-08 , 001949 02-08 , 001975 02-09 ,
002021 02-09 , 002519 02-17 , 003245
03-09 , 003264 03-09
CESURAAM 002863 03-03
CHABRANDP 003152 03-07
CHADWICK D 001164 02-03
CHAI H 003538 03-15
CHAKRABARTI JK 00159102-04, 001592 02-
04
CHAKRAVARTI SN 002 1 86 02- 1 1
CHAKRAVARTY I 002686 03-03
CHALLENORY 000835 01-15
CHALMERS RJ 003504 03-15
CHAMBERS WJ 000619 01-09, 000620 01-09
CHAMPNEYTC 003111 03-04
CHANSHH 001225 02-03, 002718 03-03
CHANDLERS 00217102-11
CHANDORKAR AG 001068 02-02 , 004147 04-
04
CHANDRA A 000189 01-03 , 002806 03-03 ,
003907 04-03
CHANDRA P 000449 01-04
CHANG J 001698 02-04, 003746 04-03
CHANG K 00358103-17, 003746 04-03
CHANG N 002937 03-03
CHANG P 003747 04-03
CHANG S 000555 0 1 -08 , 00 1 9 1 3 02-08 ,
002 1 79 02- 1 1 , 002386 02- 1 5 , 00248 1
02-16
CHANG W 003655 04-01
CHANG Y 002967 03-04
CHANKOTADZE IS 001640 02-04
CHANNABASAVANNA SM 000621 01-09 ,
000627 01-09
CHAPIN JK 002687 03-03
CHAPIN RE 003748 04-03
CHAPMAN CR 002195 02-12
CHAPMAN DB 000357 01-04
CHAPMAN RJ 003592 03-17
CHAPPELJN 000924 01-17
CH APRON C 002231 02-13
CHARAZACP 001980 02-09
CHARBAUT J 004395 04-09
CHARBITJ 003524 03-15
CHAREHEC 002499 02-16
CHARIGNONY 002379 02-15
CHARLEBOIS AT 0005 1 3 0 1 -05
CHARMESJP 002395 02-15
CHARNEYD 000666 01-11, 000945 01-17
CHASE TN 002387 02-15, 003198 03-08
CHASSEAUDLF 004504 04-13
CHAHHAAS 002122 02-11, 002724 03-03
CHATURVEDIMK 000583 01-09
CHAULSK 000292 01-03
CHAU TT 004084 04-04
CHAUDHARI A 000081 01-03
CHAUVOTB 002103 02-11
CHAVEZ E 000045 01-03
CHAVKIN C 003902 04-03
CHAZOTG 003458 03-14
CHEALM 000358 01-04
CHECKLEY SA 004362 04-09
CHELACK BJ 000234 01-03 , 000451 01-04 ,
003864 04-03 , 003969 04-03
CHENACN 002195 02-12
CHEN FF 004085 04-04
CHEN HT 000298 01-03
CHEN P 001822 02-04
CHEN RC 001165 02-03
CHENTC 001313 02-03
CHEN YM 002806 03-03
CHENEY DL 000328 01-03, 001062 02-01,
001166 02-03
CHENG CS 004489 04-11
CHERMAT R 001070 02-02 , 001072 02-02
CHERN YF 000189 01-03
CHESHERGB 000359 01-04, 002193 02-12
CHESS Q 000220 01-03
CHEUNG MN 003363 03-11
CHEUNG SW 004048 04-03 , 004303 04-06
CHEVALIER JF 002388 02-15, 002389 02-15
CHEVAUX D 001902 02-07
CHEVILLARDC 003749 04-03
CHIANG P 001006 02-01, 001010 02-01,
001021 02-01 , 001415 02-03
CHIAPPINELLI VA 003750 04-03
CHIARAVIGLIO E 001749 02-04
CHIAROni M 00375104-03, 003803 04-03
CHIBA S 000444 01-04
CHIDLEY U 003753 04-03
CHIELI T 001391 02-03 , 0041 15 04-04
CHIHARAK 003187 03-08, 003266 03-09
CHILOERS SR 002613 02-17 , 002688 03-03 ,
002985 03-04 , 004198 04-04
CHINAGLIAL 004440 04-11
CHIODO LA 000046 01-03 , 000047 01-03 ,
000048 01-03 , 001 167 02-03 , 002659
03-03 , 002880 03-03 , 002968 03-04 ,
003122 03-05
CHIPKIN RE 003684 04-02
CHITOUR D 000175 01-03
CHIU S 000360 01-04
CHLOPOCKA-WOZNIAK M 002040 02-09 ,
004404 04-09
CHMELAZ 000274 01-03, 001474 02-03
CHO AK 000826 01-14, 002235 02- 1 3 ,
003338 03-11
CHOD 000798 01-13, 003383 03-11
CHOTM 001168 02-03
CHODERAA 004599 04-15
CHOJNACKIJ 004660 04-15
CHOJNACKIM 002456 02-15, 003304 03-11
CHOMAPP 000049 01-03
CHOU DT 003752 04-03
CHOUINARDG 003305 03-11
CHRAEMMER JB 002400 02- 1 5
CHRISTENSEN AV 001169 02-03, 001465 02-
03 , 002948 03-04
CHRISTENSEN JM 000767 01-13
CHRISTENSEN NJ 003805^)4-03
CHRISTENSEN TR 00210102-11, 003302 03-
11
CHRISTENSSON E 000043 01-03
CHRISTIAN ST 002636 03-01
CHRISTIANSEN J 001976 02-09, 002033 02-
09
CHRISTODOULOU GN 000786 01-13
CHU N 002689 03-03
CHUANGD 001317 02-03
CHUDLER R 001676 02-04
CHUMCHALO 000690 01-11
CHUNG EH 000050 01-03
CHURCH MW 003446 03-14
CHURCH RM 003040 03-04
CHWEHA 001208 02-03
CIARLONE AE 003795 04-03
CICCONEJR 002419 02-15
CICERO TJ 00005101-03, 002853 03-03
CICHOCKIT 001844 02-05
CIMINOM 004052 04-03, 004750 04-17
CINCIRIPINI PM 002104 02-11
003974 04-03
000433 01-04
CIOFFI LA 003124 03-05
ClOniT 000185 01-03
CIRAULODA 003284 03-10, 003526 03-15
CITRON D 003523 03-15
ClUREZUT 001979 02-09
CIVATI C 002690 03-03
CIVRANE 000105 01-03
CLAGHORN JL 001995 02-09 , 002531 02-17
003213 03-09 , 004739 04-17
CLANACHAN AS 004266 04-05
CLANCY J 002073 02-10
CLAPP JF 004027 04-03
CLARENBACH P 0022 1 7 02- 1 3
CLARET-TOURNIER T 002105 02-1 1
CLARK BD 002721 03-03 , 003761 04-03
CLARK DB 000718 01-11
CLARK HB 000239 01-03
CLARK MSG 004086 04-04
CLARK TK 001593 02-04
CLARK WG 000361 01-04
002532 02-17
CLARK YL 002532 02-17
CLARKE A 002991 03-04
CL^RKEC 003123 03-05
CLAUSG 001594 02-04
CLAVEREJL 003226 03-09
CLAVERIE B 003451 03-14
CLAYCOMBJB 002454 02-15
CLEAUM 001170 02-03
CLEDESA 002135 02-11
CLEMENS JA 001171 02-03
CLEMENT JG 004272 04-05
CLEMENT-CORMIER Y 000052 01-03, 001007
02-01, 00101102-01, 00117202-03,
003660 04-01 , 003661 04-01
CLEMENTOAJ 003103 03-04
CLEMENTS-JEWERY S 003753 04-03 , 003851
04-03, 004707 04-17
CLERCG 001980 02-09
CLICK M 003238 03-09 , 004345 04-08
CLINESCHMIDT BV 000053 01-03 , 001701 02-
04, 002533 02-17
CLOUET DH 000220 0 1 -03 , 00 1 1 73 02-03
ClOVJ A 001174 02-03, 001175 02-03,
00130102-03, 002390 02-15, 002707
03-03 , 002789 03-03 , 004033 04-03
CLYDE CA 002330 02-14
COALEEH 004132 04-04
COAMBSRB 000530 01-06
COATC 004594 04-15
COBBETTP 001863 02-06
COBLE P 002339 02-14,
COCCHI D 001391 02-03
COCCHI R 000584 01-09
COCHEB 002066 02-10
COELLEE 000054 01-03
COENEGRACHTJ 004298 04-06
COFFINET P 002140 02-11
COHEN BM 002480 02-16
COHEN DJ 000452 01-04 , 001752 02-04
002106 02-11 , 004658 04-15
COHEN IL 003360 03-11, 00336103-11
COHEN JB 003750 04-03
COHEN M 002107 02-11 ,
004600 04-15
COHEN NJ 003306 03-11
COHEN NL 003277 03-10
COHEN RK 003496 03-15,
COHEN RM 002280 02-13
004393 04-09 , 004659 04- 1 5
COHENS 000667 01-11
COHNJB 002067 02-10
COKERST 000518 01-05
COLASANTI BK 003078 03-04
COLBOCO 003754 04-03
COLBURNRW 000196 01-03,
COLBURNWA 002248 02-13
COLE JO 000787 01-13, 000844 01-15,
002404 02-15, 003294 03-11, 003297
03-1 1 , 003557 03-16 , 003583 03-17 ,
004323 04-08 , 004406 04-09 , 004601
04-15, 004623 04-15
COLES 001197 02-03
COLEMAN JH 000949 01-17,
COLEMAN MD 002138 02-11
COLEMAN RR 000183 01-03
COLHOUN EH 002879 03-03
COLINETA 001920 02-08
COLLAR 004456 04-11
003236 03-09
002690 03-03
003582 03-17
003768 04-03
003255 03-09
003908 04-03
001058 02-01
003214 03-09
A-6
VOLUME 19, AUTHOR INDEX
Author Index
COLLARDJ 000585 01-09, 002068 02-10,
004589 04-15
COLLIER B 002870 03-03
COLLIER HOJ 004087 04-04
COLLINGRIDGE GL 002691 03-03
COLLINS AC 001648 02-04
COLLINS GGS 000034 01-03, 00269103-03
COLLINS JG 000055 01-03, 003755 04-03
COLLINS JP 001339 02-03
COLLINS RC 000056 01-03, 000222 01-03
COLLINS RJ 000497 01-04
COLLISMG 003756 04-03
COLLORAM 000677 01-11
COLLU R 000285 01-03
COLON I F 001947 02-08
COLONNAL 000362 01-04
COLOTLAVA 002969 03-04
COLPAERTFC 000363 01-04, 004088 04-04
COLTEWD 003473 03-15
COMAI K 003905 04-03
COMARD 003564 03-16
COMINSKYNC 001810 02-04
COMIS SD 003757 04-03
COMMISSARIS RL 000364 01-04 , 000365 01-
04 , 000386 0 1 -04 , 00 1 595 02-04 ,
004089 04-04
COMMISSIONS JW 003800 04-03, 004188
04-04
CONCANNONJT 001596 02-04, 001597 02-
04 , 002970 03-04
CONCASA 002743 03-03
CONCHA GL 000102 01-03
CONCHA J 001176 02-03
CONDE-LOPEZ V 003 1 53 03-07
CONEEJ 000469 01-04
CONGIAS 001483 02-03
CONNERSCK 002339 02-14
CONNOLLY J 003174 03-08
CONNOR JD 001787 02-04, 003094 03-04,
004007 04-03
CONNOR TM 001623 02-04, 004237 04-04
CONNORS BW 002692 03-03
CONRADSON S 003663 04-01
CONSOF 003513 03-15
CONSOLAZIONE A 00 1 1 03 02-03
CONSOLOS 001325 02-03, 003758 04-03
CONSROE P 004288 04-06
CONSTABLE I 002592 02-17
CONSTANTIA 001143 02-03
CONSTANTINIDIS J 002218 02-13
CONTEG 001460 02-03
CONTE-DEVOU B 003759 04-03
CONTELNR 002866 03-03
CONTI L 002090 02-1 1
CONTRERASE 001176 02-03
CONTRERASG 001176 02-03
CONWAY RS 001177 02-03
COOK J 004221 04-04
COOK L 000057 01-03 , 000468 01-04
COOK MR 004585 04-14
COOKSON JC 004363 04-09
COOLS AR 000366 01-04 , 001 178 02-03
COOMBESS 001086 02-02
COOPER AJ 002315 02-14
COOPER BR 001141 02-03
COOPER BY 001179 02-03
COOPER JK 000905 01-16, 003565 03- 1 6
COOPER JR 003937 04-03
COOPER KE 004034 04-03
COOPER PH 000396 01-04
COOPER RL 001 180 02-03 , 001683 02-04
COOPER SF 002119 02-11
COOPER SJ 000367 01-04, 000368 01-04,
000369 0 1 -04 , 00 1 598 02-04 , 00 1 599
02-04, 001600 02-04, 00298103-04,
002982 03-04 , 004090 04-04
COPELAND RL 001601 02-04
COPPEN A 000837 01-15 , 001943 02-08 ,
001976 02-09, 001977 02-09, 004338
04-08 , 004364 04-09 , 004707 04-17
COQUILLATG 003458 03-14
CORBEHAG 001998 02-09
CORDAMG 002477 02-16, 002743 03-03
CORDASCOF 004651 04-15
CORDON JJ 001595 02-04
CORNAGGIA CM 004439 04-1 1
CORNER MA 003056 03-04 , 004091 04-04
CORNFIELD RB 003325 03-11
CORONA GL 000757 01-13 , 002057 02-09 ,
004675 04-16
CORREAF 001459 02-03, 003685 04-02
CORRIGALWA 003760 04-03
CORSO P 004245 04-04 , 004246 04-04
CORSON EO 001602 02-04
CORSON SA 001602 02-04
CORTELLI P 001096 02-03
CORTESE I 002973 03-04
CORTEZA 000425 01-04
CORTHAYJ 001874 02-06
CORTI H 004357 04-09
CORWIN H 000514 01-05
COSCINA D 000268 01-03 , 004131 04-04
COSGROVEJW 00376104-03, 003832 04-03
COSSUM PA 003558 03-16
COSTA C 003419 03-13
COSTA D 001979 02-09
COSTA E 000397 01-04 , 000925 01-17 ,
001012 02-01, 001045 02-01, 001062
02-01 , 001 166 02-03 , 001 181 02-03 ,
00 1 1 82 02-03 , 00 1 263 02-03 , 00 1 284
02-03 , 001317 02-03 , 001403 02-03 ,
001884 02-06, 002642 03-01, 002819
03-03 , 003808 04-03
COSTA G 000105 01-03
COSTA JL 001013 02-01, 001014 02-01,
002219 02-13
COSTA MF 004029 04-03
COSTA-E-CASTRO M 003185 03-08
COSTA-MOLINARI JM 001978 02-09
COSTAKIS E 003698 04-02
COSTALL B 000370 0 1 -04 , 00 1 603 02-04 ,
002220 02- 1 3 , 004092 04-04
COSTELLODJ 000256 01-03
COSTENTINJ 003754 04-03, 004173 04-04
COTE IL 003762 04-03
COTEU 00240102-15
COTETE 001313 02-03
COTES PM 001923 02-08
COTONATJ 003559 03-16
COHEREAUMJ 00055101-08, 000577 01-08
, 002267 02-13, 002398 02-15
COTTRAUXJ 003584 03-17
COUDERTD 000110 01-03
COUPALA 001771 02-04
COUPAR IM 001334 02-03
COUPETJ 004122 04-04
COUPLANDRE 001183 02-03
COURJONJ 004638 04-15
COURTNEY KR 000195 01-03
COUTINHO-NEnO J 000058 01-03
COUnSRT 003137 03-06, 003719 04-03
COWAN A 002701 03-03 , 004093 04-04 ,
004289 04-06
COWDRY RW 004708 04-17
COWEN PJ 001 184 02-03 , 002444 02-15 ,
002971 03-04
COX B 002804 03-03 , 003785 04-03 ,
003786 04-03 , 003902 04-03 , 0041 13
04-04
COXJR 002232 02-13
COYDH 000402 01-04, 001673 02-04,
00 1 674 02-04 , 00 1 827 02-04
COYLE JT 000059 01-03 , 000566 01-08 ,
001885 02-06 , 002770 03-03 , 002939
03-03, 003374 03-11
CRABBEJC 004094 04-04
CRABTREER 002257 02-13, 002429 02-15
CRAFT M J 000668 01-11
CRAIG CR 003078 03-04 , 003990 04-03
CRAIG TJ 000838 01-15, 000926 01-17,
002391 02-15
CRAIGHEAD LW 000725 01-11
CRAIGMILLAL 000437 01-04
GRAIN SM 004300 04-06
CRAMER H 0022 1 7 02- 1 3 , 0023 1 1 02- 1 3
CRANDALLEA 000060 01-03
CRAVES FB 001335 02-03
CRAVISO GL 000061 01-03
CRAWFORD FE 001832 02-05
CRAWLEY J 002910 03-03, 002972 03-04,
004221 04-04
CRAYTONJ 002179 02-11
CREASEY DE 003243 03-09
CREESE I 000564 01-08 , 001 185 02-03 ,
001 186 02-03 , 001837 02-05 , 002575
02-17 , 002613 02-17 , 002803 03-03 ,
002922 03-03 , 003199 03-08 , 003585
03-17 , 004003 04-03
CREMAA 002276 02-13
CREMERJE 001838 02-05
CRETETE 001187 02-03
CREUTZFELDT OD 002752 03-03 , 004500 04-
13
CREWS EL 0022 1 6 02- 1 3 , 002392 02- 1 5 ,
003474 03-15
CREWS FT 001 1 88 02-03 , 003763 04-03
CREWS T 000898 01-16
CRIADOM 001097 02-03
CRILLWE 002886 03-03
CROCKETT G 003504 03-15
CROCQL 001980 02-09
CRONENBERGER L 001227 02-03
CRONHOLM B 001981 02-09 , 002086 02-10
CRONKCE 002161 02-11
CROOK T 002125 02-11
CROOKS J 002534 02-17
CROS J 000021 01-03 , 000797 01-13 ,
001110 02-03, 003682 04-02
CROSS AJ 000062 01-03 , 000325 01-03 ,
001816 02-04, 00191102-08
CROW TJ 00191 1 02-08 , 001923 02-08 ,
004423 04-10
CROWDERMK 000839 01-15
CROWE RR 002073 02-10
CROWLEY WR 001528 02-03, 002693 03-03
CRUZTF 002721 03-03
CRUZ-MORALES SE 000371 01-04
CSANALOSI I 000655 01-10 , 003254 03-09
CUATRECASAS P 002580 02-17, 00358103-
17, 003746 04-03
CUCCHI ML 000757 01-13 , 004675 04-16
CUCHE H 000577 01-08 , 001907 02-08 ,
002015 02-09 , 002267 02-13 , 002694
03-03 , 003 1 75 03-08 , 004709 04- 1 7
CUELLARA 000045 01-03
CUENCAE 001189 02-03
CUENDETJ 004615 04-15
CULLARI S 003298 03-1 1 , 004437 04-1 1
CULLEN El 000779 01-13
CULLERREP 001889 02-07
CULVENOR AJ 003764 04-03
CUMIN R 00138102-03, 002646 03-02
CUMMINGSAJ 003549 03-15
CUNHAJM 000669 01-11
CUNNINGHAM CE 002092 02-1 1
CUNNINGHAM VJ 001838 02-05
CUOMO V 002973 03-04
CUPANOJ 002486 02-16
CURROF 001259 02-03
CURTI D 003730 04-03
CURTIS DR 000063 01-03 , 002633 03-01 ,
002647 03-02 , 002768 03-03
CURTIS JR 002393 02-15
CURTIS SD 003981 04-03
CURZON G 002673 03-03 , 002990 03-04
CUSACK B 004014 04-03
CUTHBERT NJ 004087 04-04
CUTLER NR 002221 02-13
CVEJICV 003765 04-03
CYTAWAJ 001604 02-04
CYTRYN L 003242 03-09
CYTRYNIAK H 001579 02-04
CZUCZWAR SJ 000163 01-03 , 002921 03-03
, 004241 04-04
DAPRADAM 001314 02-03, 002863 03-03
DACHARYJM 001090 02-02
DAFNYN 001421 02-03
DAFTER RE 000380 01-04
DAGANI F 003730 04-03
DAHLJL 003909 04-03
DAHLBOM R 003701 04-02
DAHLSTROM A 003897 04-03
DAIGUJIM 004676 04-16
DAILEYG 004600 04-15
DAILEYJW 003865 04-03
DAINOSON K 003450 03-14
DAISLEYRW 002394 02-15
DAJANI EZ 000064 01-03
DALBELLOA 001200 02-03
DALEPG 002316 02-14
DALERYJ 004638 04-15
D ALESSAN DRO R 00 1 096 02-03
DALLAL-Y-CASTILLO E 002173 02-1 1
DALLOCCHIOM 002395 02-15
DALLY S 003505 03-15
DALTERIO SL 002695 03-03
A-7
•mL^xisiiasiak
Author Index
Ptychopharmacology Abstracts
ii
3;;
it
DALTON K 000927 01-17
DALY JW 003766 04-03 , 003950 04-03
OAMH 004537 04-13
DAM M 000767 01-13 , 003307 03-1 1 ,
004602 04-15
DAMASIOH 000670 01-11
DAMBROSIA JM 0033 1 9 03- 1 1
DAMIANO BP 003094 03-04 , 004007 04-03
DANASL 000765 01-13
DANCKWARDTJF 002535 02-17
DANDIYA PC 001682 02-04
DANGOUMAUJ 002395 02-15
DANIEL SA 004095 04-04
DANIELCZYKW 003475 03-15
DANIELS MP 000065 01-03
DANIELS S 001686 02-04
DANION J 001904 02-07 . 002895 03-03 ,
004270 04-05
DANNER R 004441 04-11
DANTONIO J 001991 02-09
DANYF 002395 02-15
DARBINYAN AG 002663 03-03
DARCOURT G 002023 02-09 , 002108 02-1 1 ,
002536 02-17, 003210 03-09, 004357
04-09
DARCY-GOMEZ G 001409 02-03
DARDAS 001259 02-03
DARONDELA 001980 02-09
DARRAGHA 004532 04-13
DASM 004096 04-04
DASBERGH 003196 03-08
DASCOURTG 004594 04-15
DASHWOODMR 002976 03-04
DATTAN 000002 01-01, 000003 01-01,
001015 02-01
DAUSSE J 000205 01-03 , 003944 04-03
DAVID I 001912 02-08
DAVIDOWB 000859 01-15
DAVIDSON AB 003476 03-15
DAVIDSON J 004745 04-17
DAVIDSON PP 0005 1 8 0 1 -05
DAVIDSON S 00 1 9 1 5 02-08 , 002396 02- 1 5
DAVIES B 000614 01-09 , 002184 02-1 1 ,
004707 04-17
DAVIES DS 00014101-03
DAVIES J 001 190 02-03 , 001 191 02-03 ,
002691 03-03 , 002696 03-03
DAVIESS 001707 02-04, 003240 03-09,
003241 03-09
DAVILAK 003918 04-03
DAVIS A 003767 04-03
DAVIS BA 001077 02-02
DAVI S BM 0023 1 7 02- 1 4 , 0032 1 5 03-09
DAVIS CM 000530 01-06
DAVIS G 003357 03-11
DAVIS GA 003017 03-04
DAVI S GC 00 1 9 1 0 02-08 , 00 1 984 02-09 ,
002222 02-13, 003 1 67 03-08 , 0043 1 6
04-08, 004317 04-08
DAVIS HP 003636 03-17, 004097 04-04
DAVIS JC 002697 03-03
DAVIS JD 004098 04-04
DAVIS JM 000135 01-03, 000547 01-08,
000572 01-08, 000672 01-11, 000675
01-11, 000726 01-11, 000908 01-16,
000934 01-17, 000973 01-17, 001073
02-02 , 001913 02-08 , 002024 02-09 ,
002179 02-11, 002269 02-13, 002386
02-15 , 002481 02-16 , 002491 02-16 ,
003142 03-06 , 003471 03-15 , 004215
04-04 , 004374 04-09 , 004577 04-14 ,
004603 04- 1 5 , 004682 04- 1 6
DAVIS JS 003119 03-04
DAVIS KL 000928 01-17, 002317 02-14,
002488 02- 1 6 , 0032 1 5 03-09 , 003465
03-15 , 003477 03-15 , 004099 04-04 ,
004327 04-08, 004442 04-11, 004514
04- 1 3 , 004604 04- 1 5 , 004703 04- 1 7
DAVIS LG 003496 03-15, 003768 04-03
DAVIS M 000066 01-03 , 000372 01-04 ,
001605 02-04, 002397 02-15, 002950
03-04
DAVIS SF 002974 03-04
DAVIS VJ 003392 03-11
DAVIS WC 001192 02-03
DAVISON AN 00017101-03
DAVISON K 002001 02-09
DAVISON M 001193 02-03
DAW J 003474 03-15
DAWBARN D 004 1 00 04-04
DAWLINGS 002266 02-13, 002284 02-13
DAWSON SD 000432 01-04
DAY IP 001093 02-02
DAYN 001830 02-05
DA YIC AN G 004460 04- 1 1 , 0045 1 9 04- 1 3
DEANTONIA 003419 03-13
DEBASTIANIP 002283 02-13
DE BELLEROCHE J 002843 03-03
DEBOERT 001606 02-04
DE BRUIN JPC 003107 03-04
DEBUCKRP 001890 02-07
DE CATANZARO D 002975 03-04
DE CUYPER HJA 003216 03-09
DE GIOVANNI L 003 1 22 03-05
DE GORI N 003075 03-04
DE GROAT WC 000162 01-03
DEGROOTMHL 000586 01-09
DEGUBAREFFT 000222 01-03
DEJONGAP 002698 03-03
DEJONGHEF 002526 02-17, 003107 03-04
DE LA FUENTE-RAMIREZ JR 002109 02-11
DE LA FUENTE-RAMIREZ R 003478 03-15
DELAMORAP 003101 03-04
DE LANGEN CDJ 000067 01-03 , 000323 01-
03
DE LIMA TCM 004101 04-04
DELUCAB 003124 03-05
DE MAIO D 001985 02-09
DE MONTIGN Y C 000068 0 1 -03 , 00 1 1 35 02-
03
DE MONTIS G 002477 02-16
DE ROBERTIS E 001097 02-03
DEROSA A 001460 02-03
DEROSSEHSE 002320 02-14
DESARROGB 000442 01-04, 000443 01-04
DEVAUSJE 001607 02-04
DEVILLARDR 002110 02-11, 004638 04-15
DE WIED D 001953 02-08
DEZEEUWRA 003216 03-09
DEACON RMJ 003073 03-04
DEAKINJFW 000373 01-04, 002976 03-04
DEAN P 001755 02-04
DEAN SJ 004114 04-04
DEANOVIC Z 002243 02-13
DEARINGME 001583 02-04
DEBEUUK L 001194 02-03
DEBERDTR 000758 01-13, 004355 04-09
DEBUS G 002537 02-17, 003769 04-03
DECOSKEYD 003364 03-11
DEDEKJ 001202 02-03, 003995 04-03
DEFEUDISFV 002538 02-17, 002699 03-03
DEFRAITESEG 003198 03-08
DEGIROLAMIU 000257 01-03
DEGROOFRC 000069 01-03
DEGTYAREVVP 003770 04-03
DEHAVENR 000026 01-03
DEIMAN-VAN AALST WMA 002651 03-02
DEISENHAMMER E 004443 04-1 1
DEISER R 004605 04-15
DEJOHN C 004694 04-16
DEKIRMENJIAN H 002386 02-15 , 002491 02-
16
DEL BIANCO PL 004553 04-13
DELPOZOE 002217 02-13
DEL RIO J 000398 01-04
DELROSCIOS 00443104-11
DELANOYRL 001250 02-03
DELARUE M 003268 03-09
DELASHAWJBJ 000374 01-04
DELEVAJI 003716 04-03
DELIA G 001982 02-09, 001983 02-09
DELIACP 003451 03-14
DELINI-STULA A 001740 02-04
DELISI L 001945 02-08 , 002245 02-13 ,
003 1 69 03-08 , 003 1 84 03-08
DELITALAG 001016 02-01, 001127 02-03,
003731 04-03 , 003732 04-03
DELLENRG 000650 01-10
DELOTD 003313 03-11
DELWAIDE P 002223 02-13 , 004561 04-14
DEMANGE J 001891 02-07
DEMAREST KT 002700 03-03
DEMELLWEEKC 00412104-04
DEMENGEP 000070 01-03
DEMENT WC 000374 01-04
DEMENTYEVA NF 004444 04-1 1
DEMETEM 000312 01-03, 00377104-03
DEMICHELP 002876 03-03
DEMIRIAN L 002928 03-03
DEMYERW 000514 01-05, 00052101-05
DENBER HCB 000929 01-17
DENCKER SJ 000890 01-15, 001956 02-08
DENDELPS 000182 01-03
DENENBERGVH 000375 01-04
DENES Z 000930 01-17
DENFORDJ 002164 02-11
DENGLER HJ 000968 01-17
DENIJSEL 004562 04-14
DENIKER P 000549 01-08 , 000551 01-08 ,
000577 01-08, 001195 02-03, 001892
02-07 , 002016 02-09 , 002267 02-13 ,
002398 02-15 , 002539 02-17 , 004445
04-11 , 004709 04-17
DENIS B 002379 02-15
DENVER D 002596 02-17
DEOMA 000759 01-13
DEPAULOJR 003199 03-08
DEPOCASF 001231 02-03
DEPRYD 003346 03-11
DEROSSEH SE 002983 03-04
DERYCK M 000376 01-04
DESAGER JP 000181 01-03
OESHMUKH PP 001373 02-03 , 002902 03-03
DESMOND PV 002224 02-13, 002272 02-13
DESOUSAG 003367 03-11
DESSAIGNE S 003089 03-04
DESTRADEC 003051 03-04
DETAILLEJ 003293 03-11
DETLORJ 002106 02-11
DEHMAR PW 000351 01-04 , 002701 03-03 ,
003662 04-01
DEUTSCH JA 002702 03-03 , 002977 03-04 ,
004182 04-04
DEUTSCH SI 004606 04-15
DEVANECL 002225 02-13, 003154 03-07,
003479 03-15
DEVICHEP 001565 02-04
OEVinO 003557 03-16
DEVLIN MC 002322 02-14
DEVOITILLE JM 004561 04-14
DEVOIZEJL 004479 04-11
DEVOTOP 000285 01-03
DEWEY WL 001513 02-03, 002712 03-03,
003970 04-03 , 0046 1 0 04- 1 5
DEWHURST WG 003 1 37 03-06 , 0037 1 9 04-03
DEWIED D 003074 03-04
DEWinjR 001608 02-04
DEWinL 000435 01-04
DEWSPB 002364 02-14, 004228 04-04,
004280 04-05
DEYPK 001429 02-03
DEZEJ 00211102-11
DHUMALVR 003772 04-03, 004102 04-04
Dl GIORGIO RM 000218 01-03, 002762 03-03
. 003952 04-03
Dl MARCO E 003222 03-09
Dl PAOLO T 001324 02-03
DIPERRIRG 003359 03-11
DIAKOWC 002978 03-04
DIAMOND Bl 001834 02-05 , 004268 04-05
DIAMOND EL 003405 03-13
DIAMOND I 001257 02-03
DIAMOND JM 00452104-13
DIAMOND L 004400 04-09
DIAMOND RJ 003308 03-11
DIAMOND RL 002005 02-09
DIAMOND SG 003336 03-11
DIASRD 00007101-03, 001664 02-04
DIAZMC 001194 02-03
DIBNERMD 000072 01-03, 002932 03-03,
003979 04-03
DICKINSON RG 000073 01-03
DICKINSON WA 002979 03-04
DICKISON SE 003686 04-02
DICKSON VAT 002974 03-04
DIEPARTE 002398 02-15
DIETL H 002703 03-03 , 003968 04-03
DIETRICHSON P 000701 01-11
DIETZAJ 003480 03-15
DIETZDD 002887 03-03
DIEZ-EWALDM 002112 02-11
DIFFLEY D 000074 01-03
DIFNY N 003773 04-03
DIGGORYGL 003686 04-02
DIGREGORIO GJ 003725 04-03
DIJKSTRAO 000004 01-01, 000324 01-03
DILLMAN CE 004643 04- 1 5
DILLON A 002439 02-15
DILLON D 004427 04-10
A-8
VOLUME 19, AUTHOR INDEX
Author Index
DINERSTEIN RJ 004293 04-06
DINGLEDINER 001864 02-06, 002704 03-03
DINGWALL JM 00 1 932 02-08
DINTCHEFFBA 001830 02-05
DIRGO JA 004281 04-05
OIRICQS 004308 04-07, 004589 04-15
DIRLICHG 004322 04-08
DIHRICHA 004696 04-16
DIVAKARAN P 003774 04-03
DIXON R 000898 01-16
DIXON WJ 003188 03-08, 003189 03-08
DLABAC A 000242 01-03 , 000306 01-03 ,
001720 02-04 , 002279 02-13 , 002540
02-17
DOAMARALJR 003663 04-01, 004514 04-13
DOBIAS J 004748 04-17
DOBRY PJK 002980 03-04 , 004200 04-04
DOBRZYNSKAL 000931 01-17
DOCHERTY JP 000843 01-15 , 001951 02-08
DOCHERTYJR 001196 02-03
DOCKRAYGJ 00129102-03
DODAM 003822 04-03
DODDJ 001864 02-06, 002704 03-03
DODSONWE 002113 02-11
DOGGRELLSA 000075 01-03
DOHN HH 002216 02-13
DOIT 001609 02-04
DOLANSKYJ 00067101-11
DOLEVP 002114 02-11
DOLEZALV 004044 04-03
DOLLERYQ 002504 02-16
DOLPHIN AC 000291 01-03
DOMENECH J 003291 03-11
DOMENGIE B 003268 03-09
DOMERFR 000076 01-03, 001197 02-03
DOMINGUEZRA 002399 02-15
DOMINO EF 000462 01-04, 000737 01-12,
000934 01-17, 001198 02-03
DOMINY BW 001687 02-04
DOMJANM 001610 02-04, 003055 03-04
DONALD RA 004545 04-13
DONALDSON JO 003481 03-15
DONGDE 000418 01-04
DONIGAN BE 003699 04-02
DONINIG 000833 01-15
DONLON PT 003217 03-09
DONNANGA 003433 03-13
DONNELLY J 000539 01-07
DONOVICK PJ 004103 04-04
DOOGAN DP 003775 04-03
DOONGAJI DR 002158 02-11
DOOTDL 003690 04-02
DORDAING 003155 03-07
DORE CJ 002365 02-14
DORMANDYJ 002598 02-17
DORNHORSTA 004463 04-11
DORSE YR 003586 03-17
DORUS E 001987 02-09
DOSSENAM 001126 02-03, 003730 04-03
DOSTAL T 000600 01-09 , 001888 02-07 ,
002006 02-09, 00213102-11, 004375
04-09
DOSTALOVAJ 000658 01-10
DOSTALOVA K 000077 0 1 -03 , 000805 01-14
, 001199 02-03, 002333 02-14
DOni A 002226 02-13 , 003466 03-15 ,
004318 04-08
DOUGLAS R 002154 02-11
DOURISHCT 00298103-04, 002982 03-04
DOWRC 001708 02-04
DOWLING JE 001296 02-03 , 003776 04-03 ,
004051 04-03
DOWNING RW 000840 01-15 , 002482 02-16
, 004420 04-10
DOXEYJC 001146 02-03
DOYLE RL 000377 01-04, 001677 02-04
DRACHMAN DA 000802 01-14
DRACHMAN DB 000232 01-03
DRAGO F 000378 01-04 , 001200 02-03 ,
003301 03-1 1
DRAHOKOUPIL L 000686 01-11 , 002188 02-
11
DRAPER RJ 002318 02-14
DRASGOWF 003363 03-11
DRAVETC 000873 01-15, 002319 02-14
DRAY A 000738 01-12 , 001 191 02-03
DREIFUSSFE 003378 03-11
DREOSTI IE 001986 02-09
DRESCHERK 003515 03-15
DRESSEA 000267 01-03
DREVETM 001980 02-09
DREWWG 002320 02-14, 002983 03-04
DREWETT RF 000483 01-04
DREXLER G 002775 03-03
DRIESENSF 000758 01-13
DRIESSENO 000760 01-13
DRISCOLLBF 00120102-03
DRISCOLL P 001202 02-03 , 002852 03-03 ,
002984 03-04 , 003042 03-04
DROGUETTPA 000102 01-03
DROSS K 000078 0 1 -03 , 002240 02- 1 3
DRTILKOVA I 00072901-11, 00211502-11,
002190 02-11
DRUFFJH 000949 01-17, 003214 03-09
DRUSTEG 001787 02-04, 004007 04-03
DRY J 004505 04-13
DSOUZAS BJ 004447 04-1 1
DUCHESNE H 00448104-11
DUANE DD 002037 02-09 , 002038 02-09
DUBNITSKAYA EB 004340 04-08
DUBOCOVICH ML 000227 01-03 , 002801 03-
03 , 003777 04-03
DUBOIS JP 002232 02-13
DUCHE D 0021 16 02-1 1 , 002321 02-14 ,
002344 02-14
DUCHEMINAM 00024101-03, 001054 02-01
DUCKLESSP 000079 01-03
DUDAIY 001833 02-05, 002655 03-03
DUFFY FH 002684 03-03
DUFOUR H 0026 1 9 02- 1 7 , 003524 03- 1 5
DUFRASNEM 000585 01-09
OUGAST 000448 01-04
DUGGAN AW 001203 02-03 , 002740 03-03 ,
002767 03-03 , 003778 04-03
DUGGAN B 002445 02-15
DUHAIME J 004286 04-06
DUHAULT J 000262 01-03 , 002541 02-17
DUHMJ 001987 02-09, 002227 02-13
DUIZABOP 003156 03-07
DUKAT 003837 04-03
DUMJ 004104 04-04
DUMAS M 000865 01-15
DUMBRILLEA 001303 02-03
DUMBRILLE-ROSS A 00 1 204 02-03
DUMONDJ 000865 01-15
DUMONTC 004105 04-04
DUMOVICP 004639 04-15
DUN NJ 001205 02-03 , 003779 04-03
DUNCAN W 002341 02-14
DUNLAPCE 002804 03-03
DUNLAPWP 000402 01-04
DUNLEAVYRA 003482 03-15
DUNNAJ 002985 03-04, 003109 03-04
DUNNGD 002272 02-13
DUNNER DL 000587 01-09 , 001893 02-07 ,
001987 02-09 , 001989 02-09 , 002228
02-13 , 002448 02-15 , 003221 03-09 ,
004369 04-09 , 004391 04-09
DUNNER FJ 000868 01-15
DUNNETTSB 000347 01-04
DUNSTAN R 001206 02-03 , 001299 02-03 ,
002986 03-04
DUNWIDDIETV 000080 01-03, 000178 01-03
DUPEU M 002705 03-03
DUPONTA 002635 03-01
DURANE 004319 04-08
DURANDA 002625 02-17, 00357103-16
DURIASZ H 003050 03-04
DURSO R 000698 01-11 , 002342 02-14 ,
00237102-15, 00443104-11
DURST N 004573 04-14
DUSEKK 000548 01-08, 001925 02-08
DUSLAK B 004682 04-16
DUSTICIERN 000217 01-03
DUVOISIN RC 000404 01-04 , 001650 02-04 ,
002117 02-11 , 004129 04-04
DVORKIN B 002814 03-03
DWINGERH 001917 02-08
DWIVEDIC 000081 01-03
DYCK LE 001207 02-03 , 002706 03-03
DYER RG 002707 03-03
DYER RS 002708 03-03
DYKMAN RA 002118 02-11
D YK STRA LA 000379 0 1 -04 , 000403 0 1 -04 ,
001611 02-04 , 004106 04-04
DYRENFURTH I 000874 01-15
DYSKEN M 001913 02-08 , 002407 02-15 ,
002481 02-16 , 002491 02-16
DYSKEN MW 000672 01-11, 000675 01-11
DZHAFARLl MT 004 1 25 04-04
DZHALIASHVILI TA 004107 04-04
DZHOKHADZE LD 003780 04-03
EADIEMJ 004555 04-13
EANESED 001013 02-01, 002219 02-13
EATWELLJC 000517 01-05
EBADI M 001208 02-03
EBARAT 000082 01-03
EBERTMH 000182 01-03, 000673 01-11,
003309 03-11, 003340 03-11, 003362
03-11
EBSTEIN RP 000083 01 -03 , 003720 04-03 ,
004167 04-04
ECKERNASS 000084 01-03
EDELFORSS 001209 02-03
EDELMANAM 001423 02-03
EDEN S 002664 03-03
EDVINSSON L 000200 01-03 , 003781 04-03
EDWARDS D 000631 01-09 , 002891 03-03
EDWARDS JG 000638 0 1 -09 , 00 1 9 1 4 02-08
EFTHYMIOUML 003513 03-15
EGEREII 000418 01-04
EGUCHIT 000199 01-03
EHLERSCL 001210 02-03
EHLERTFJ 000279 01-03
EHRENSINGRH 001311 02-03
EHRETCF 001409 02-03
EHRLICH BE 004521 04-13
EHSANULLAH RSB 002268 02-13
EICHELBAUMM 000754 01-13, 003314 03-11
EICHELMAN B 002987 03-04 , 003021 03-04
EIDENLE 001017 02-01, 001018 02-01,
001211 02-03 , 001212 02-03
EIGEMAN L 002651 03-02
EIGYOM 003692 04-02
EIKELBOOM R 002709 03-03 , 002710 03-03 ,
002906 03-03
EINSPAHR FJ 003782 04-03 , 004200 04-04
EISDORFERC 004710 04-17
EISENBERGRM 000085 01-03, 003888 04-03
EISERTA 003968 04-03
EISINGERS 001664 02-04
EISLERT 000673 01-11, 002384 02-15,
003309 03-11 , 003406 03-13
EKBOMK 002181 02-11
ELHAITMAS 000900 01-16
EL-FAKAHANY E 003783 04-03
EL-SOHLYMA 001022 02-01, 001023 02-01
ELAM R 001574 02-04
ELDER JK 004215 04-04
ELENSP 000758 01-13
ELGHOZI J 003944 04-03
ELIANDERH 000086 01-03
ELIASSON SG 003784 04-03
ELIE R 00 1 929 02-08 , 002 1 1 9 02- 1 1
ELISJ 002542 02-17
ELISABETSKYE 001664 02-04
ELISEOC 003466 03-15
ELIZUR A 000841 01-15 , 001915 02-08 ,
00 1 9 1 6 02-08 , 004320 04-08
ELKINSR 003310 03-11, 004657 04-15
ELLEYJ 002033 02-09
ELLINWOOD EH 001683 02-04 , 00271 1 03-03
, 003005 03-04
ELLIOHAJ 001019 02-01
ELLIOHEJ 000638 01-09
ELLIOnj 001302 02-03, 003862 04-03
ELLIOHM 003760 04-03
ELLIS DB 002898 03-03
ELLIS KO 003687 04-02 , 003688 04-02
ELLISON G 000216 01-03, 001395 02-03,
001875 02-06 , 002988 03-04
ELMASSIANBJ 003651 03-17
ELMAZAR MMA 004108 04-04
ELONEN E 003428 03-13
ELOVAARAE 000261 01-03
ELRODSV 001213 02-03
ELSASSP 002229 02-13, 002329 02-14,
004607 04-15
ELSOHLY MA 000344 0 1 -04
ELSWORTH JD 000983 01-17, 002230 02- 1 3
, 002365 02-14
ELTON RA 004677 04-16
EMERSON R 004447 04-1 1
EMERY C 004690 04-16
EMIY 000515 01-05
EMLEYGS 002759 03-03
A-9
ixV^se^^^iSHEiEBSf:
Author index
Psychophormacology Abstracts
k
111.
It
Si:
!!
EMMEH-OGLESBY MW 000380 01-04
EMORY LE 004324 04-08
EMRICH HM 00 1 9 1 7 02-08 , 00 1 9 1 8 02-08 ,
0032 1 8 03-09 , 0032 1 9 03-09 , 00432 1
04-08 , 004322 04-08
EMSONPC 001296 02-03, 004184 04-04
ENDOW 002712 03-03
ENDOM 004608 04-15
ENDOS 002350 02-14
ENDO Y 004301 04-06
ENDROCZI E 004109 04-04
ENEROTH P 002727 03-03
ENGN 003406 03-13
ENGBERGG 001214 02-03
ENGEL J 000087 01-03 , 001839 02-05 ,
004 1 1 0 04-04 , 004 1 20 04-04 , 004 1 26
04-04
ENGELHARDT DM 000880 01-15
ENGELMANN W 000772 01-13
ENGELSMANN F 004348 04-09
ENGLISH MG 003684 04-02
ENGQUISTA 002400 02-15
ENJALBERTA 000213 01-03
ENJALBERTM 000864 01-15
ENNA SJ 00 1 2 1 5 02-03 , 0027 1 3 03-03 ,
002716 03-03 , 002778 03-03 , 004157
04-04
ENNIS C 003785 04-03 , 003786 04-03
ENNS L 003787 04-03
ENNS MP 004080 04-04
ENULESCUO 002295 02-13
EPSTEIN LH 002104 02-11
ERARDR 000739 01-12
ERBAN L 000600 01-09 , 003170 03-08
ERCILLAR 004319 04-08
ERDMANNJF 002072 02-10
ERDOSA 000912 01-17
ERICKSONCK 001865 02-06
ERIKSSON E 002664 03-03
ERINOFFL 001340 02-03
ERMISCH A 003669 04-01
EROGLU L 001216 02-03 , 001217 02-03 ,
003788 04-03
ERVINFR 001049 02-01. 001612 02-04
ERVINGN 00411104-04
ERWINCW 000867 01-15, 000895 01-15
ERWINVG 003146 03-06
ESCANDEM 003559 03-16
ESCOBAR J 001931 02-08
ESCURETE 00223102-13
ESKAYR 000277 01-03, 001017 02-01,
001018 02-01
ESLERM 004506 04-13
ESPAGNOJ 003226 03-09
ESPINOSAL 001558 02-04
ESPOSITO RU 003066 03-04 , 004160 04-04
ESSMANWB 000932 01-17
ESTEBAN A 003311 03-11
ESTLERC 001613 02-04
ETEMADB 002079 02-10
ETTLIN R 004284 04-05
EUVRARD C 00 1 2 1 8 02-03 , 003789 04-03
EVANS HL 003128 03-05, 00427104-05
EVANS L 001988 02-09, 002232 02-13
EVANS M 000022 01-03, 001840 02-05
EVANS RH 001 104 02-03 , 003587 03-17 ,
003648 03-17
EVARTSEV 003319 03-11
EVENP 001920 02-08
EVENSONGN 001076 02-02
EVENSONRC 002414 02-15
EVEREDMD 001614 02-04
EVERSMANNT 002137 02-11
EVESF 003174 03-08
EWINGFE 001092 02-02
EXTEINI 000899 01-16, 000933 01-17,
001984 02-09 , 003220 03-09 , 003250
03-09 , 003357 03-1 1
EYSTERME 000945 01-17
EZRIN-WATERS C 003483 03-15
FABRICANT JD 003121 03-05
FADDAF 001483 02-03
FADENAI 002714 03-03
FAGESC 004029 04-03
FAHNS 002401 02-15
FAIMANC 002213 02-13
FAINJN 002728 03-03
FAINGOLDCL 001219 02-03
FAIRBAIRNJW 002196 02-12
FAIRCHILDMD 001220 02-03
FAIRHURSTJ 00159102-04
FAISON E 000053 01-03
FAITV 000686 01-11, 002188 02-11
FALASCHI P 00237102-15, 00443104-11
FALCH E 001 139 02-03 , 002647 03-02
FALEHIMV 001242 02-03
FALKJL 004235 04-04
FALK W 00 1 099 02-03 , 00 1 1 00 02-03
FALKO JM 003521 03-15
FALKUME 002550 02-17
FALTUS F 004375 04-09
FANKJ 003436 03-13
FANELLICJ 000187 01-03
FANELLI RJ 004103 04-04
FANG V 003 1 90 03-08 , 0033 1 8 03- 1 1 ,
003790 04-03 , 004538 04-13
FANGETM 004307 04-07
FANNE 002179 02-11
FANN WE 000934 01-17 , 002486 02-16 ,
004710 04-17
FANSELOWMS 001615 02-04
FAORE E 003194 03-08
FARABOLLINl F 004081 04-04
FARARUNIM 000562 01-08
FARAVELLI C 004365 04-09
FARB DH 003980 04-03
FARELLI S 002356 02-14
FARIELLORG 003853 04-03, 004609 04-15
FARRISRD 003525 03-15
FARRISTS 000088 01-03
FARSANG C 003791 04-03
FARSKA I 002793 03-03 , 003696 04-02
FATHERAZI S 001144 02-03
FAULLKF 003477 03-15, 003663 04-01
FAUMANBJ 000935 01-17
FAUMANMA 000935 01-17
FAUSTMAN W 002989 03-04
FAVARO M 003441 03-14
FAYDD 001013 02-01, 001014 02-01,
002219 02-13
FEDER HH 002842 03-03
FEDERSPIELCF 000979 01-17
FEENSTRAMGP 000004 01-01, 000324 01-03
FEHSKE KJ 001440 02-03 , 00421 1 04-04
FEIGHNER JP 000936 01-17
FEIGLP 000728 01-11
FEINBERGM 000588 01-09, 004359 04-09,
004674 04-16
FEKETE MIK 003792 04-03
FELDBERGW 002715 03-03
FELDMAN B 002318 02-14
FELDONJ 001757 02-04
FELEGIW 000510 01-05
FELINE A 000543 01-07
FELIX A 004167 04-04
FELNERA 001740 02-04
FENELLI A 003 1 57 03-07 , 003 1 58 03-07
FENNESSYMR 00184102-05, 004243 04-04
FENOGLIOL 000757 01-13, 002057 02-09,
002058 02-09 , 004675 04-16
FERGUSON DG 003298 03-11, 004437 04-11
, 004438 04-11
FERGUSON HB 002120 02-11, 003312 03-11
FERKANY JW 001215 02-03 , 001221 02-03 ,
0027 1 3 03-03 , 0027 1 6 03-03
FERLANDL 001324 02-03
FERNANDEZ R 002849 03-03 , 002850 03-03 ,
002851 03-03
FERNANDEZ-ALONSO Jl 003673 04-01
FERNANDEZ-TOME P 000398 01-04
FERNANDO JCR 002990 03-04
FERNSTROM JD 0000 1 9 0 1 -03 , 000020 0 1 -03
, 000060 01-03, 000296 01-03, 004025
04-03
FERRARAM 004417 04-09
FERRARA P 001081 02-02
FERRARI F 000340 01-04
FERRARODP 00038101-04
FERRENDELLI JA 000089 01-03 , 000090 01-
03, 000115 01-03
FERRER-VIDAL L 001978 02-09
FERRERI M 001960 02-09 , 001961 02-09 ,
001965 02-09 , 003206 03-09 , 003588
03-17
FERREYG 000552 01-08
FERRI P 000282 01-03
FERRI S 000282 01-03 , 001468 02-03
FERRIERBM 002322 02-14
FERRIS 0 003898 04-03 , 003899 04-03
FERRIS RM 000091 01-03
FERRIS S 002125 02-11, 004482 04-11
FESSLER RG 001616 02-04 , 001719 02-04
FEUERSTEINC 000070 01-03
FEUERSTEIN G 001222 02-03 , 001223 02-03 ,
00 1 224 02-03 , 002250 02- 1 3 , 0027 1 7
03-03
FIBIGERHC 000283 01-03, 000345 01-04,
000463 0 1 -04 , 004070 04-04
FICHTEK 000768 01-13
FIGHTER MM 004711 04-17
FIDELLLS 003589 03-17
FIELDING LT 000937 01-17
FIELDS HL 000425 01-04
FIEVERR 000587 01-09, 001893 02-07,
001989 02-09 , 002228 02-13 , 002448
02-15 , 002543 02-17 , 002683 03-03 ,
003221 03-09 , 003473 03-15 , 004369
04-09 , 004391 04-09 , 004606 04-15
FIGUEROAAM 002402 02-15
FILESE 000092 01-03, 001617 02-04,
001866 02-06 , 002991 03-04
FILEHI S 003301 03-11
FILIBECK U 000382 01-04
FILINGERE 001658 02-04
FILIPV 000570 01-08, 000674 01-11,
00076101-13, 000770 01-13
FILIPOVAM 000674 01-1!
FILLIONG 000033 01-03, 000093 01-03
FILLIONM 000033 01-03
FINCH CE 004217 04-04
FINCHAMJ 004580 04-14
FINK JS 000383 01-04 , 000384 01-04 ,
004112 04-04
FINK M 001071 02-02 , 001894 02-07 ,
004366 04-09
FINKELS 000675 01-11
FINKELFARBE 004263 04-04
FINNAL 003353 03-11, 00342103-13
FINNERTYEP 001225 02-03, 002718 03-03
FINNERTYRJ 001994 02-09
FIREMARK HM 003338 03-1 1
FISCHER B 004344 04-08
FISCHER C 003458 03-14
FISCHER GJ 001618 02-04
FISCHER H 001935 02-08 , 00231 1 02-13
FISCHER J 001419 02-03 , 002764 03-03
FISCHER JM 003539 03-15
FISCHER W 004481 04-11
FISCHER-CORNELSSEN KA 002483 02-16
FISCHMANMW 002323 02-14, 002328 02-14
FISH BS 004288 04-06
FISHER RW 000206 01-03
FISHER S 003590 03-17 , 003987 04-03
FISHKIN SM 000879 01-15
FISHMAN J 000400 01-04
FITZGERALD M 001226 02-03, 002439 02-15
FITZGERALD SC 002669 03-03
FITZJARRELL AT 002747 03-03
FJELDBORGN 000792 01-13
FLAGGHC 003077 03-04
FLANNERY J 001385 02-03 , 004204 04-04
FLATAKER LM 000053 01-03
FLATMAN JA 002799 03-03
FLECHTER S 004343 04-08
FLEISS JL 001989 02-09 , 003221 03-09
FLEITMANJS 000762 01-13
FLETCHER A 000158 01-03
FLEYSEP 004593 04-15
FLIEGEROVAO 00076101-13
FLINT BA 000385 01-04 , 001619 02-04 ,
002753 03-03
FLOOD JF 001573 02-04, 004578 04-14
FLOREA-CIOCOIU V 002281 02-13
FLORENCE JE 000094 01-03
FLORUL 000550 01-08, 004315 04-08
FLOSBACH CW 002962 03-04
FLUCHN 003503 03-15
FLYNND 001318 02-03
FLYNNJR 002236 02-13, 004244 04-04
FOBESJL 004194 04-04
FOGR 000890 01-15
FOGARI R 002070 02-10
FOGH-ANDERSEN P 003484 03-15
FOLBERGROVA J 00 1 1 34 02-03
FOLEY K 000898 01-16
FOLEY TL 004196 04-04
A-10
VOLUME 19, AUTHOR INDEX
Author lnd«x
FOLGERINGH 004456 04-11
FOLLATHF 000909 01-16
FOLTIN RW 003110 03-04
FONBERG E 001620 02-04 , 003030 03-04
FONDARAIJ 001980 02-09
FONGJC 003664 04-01
FONLUPTP 001227 02-03, 002816 03-03
FONNUM F 002774 03-03
FONTAGNEJ 004632 04-15
FONTAINE F 003305 03-11
FONTAINE J 001228 02-03
FONTAN M 000589 01-09 , 003313 03-1 1 ,
003404 03-13
FONTANA CJ 002747 03-03
FONTANIG 004081 04-04
FOOSH 000698 01-11, 002342 02-14
FORCHETTI C 002090 02-1 1 , 002312 02-14 ,
002371 02-15 , 002719 03-03 , 003085
03-04
FORD DH 001367 02-03
FORDKE 003125 03-05
FORDRD 000386 01-04
FORDEJH 003752 04-03
FOREHEF 000596 01-09, 003324 03-11
FORINO V 003591 03-17
FORLONI GL 003758 04-03
FORN J 000291 01-03
FORNAROP 004507 04-13
FORREST IS 001229 02-03 , 001867 02-06
FORSMAN A 000888 01-15, 00 1 230 02-03 ,
002590 02-17
FORSMAN L 004508 04-13
FORSTERA 003342 03-11
FORSTER B 002505 02-16 , 004403 04-09
FORSTERC 004113 04-04
FORTUNED 000370 01-04, 003662 04-01
FOSSOML 001790 02-04
FOSTER DO 001231 02-03
FOSTER GA 001578 02-04
FOSTER JA 004114 04-04
FOURCADEJ 00344103-14
FOURNIERE 003513 03-15
FOUSSARD-BLANPIN 0 003689 04-02
FOUTZAS 000374 01-04
FOVALLP 000675 01-11
FOWLER LK 002324 02-14
FOWLER S 002989 03-04
FOX DA 004157 04-04
FOX PC 000738 01-12
FRAJESEG 004431 04-11
FRANCES H 001072 02-02, 001232 02-03,
003633 03-17
FRANCIS DL 004087 04-04
FRANCIS IB 004620 04-15
FRANCIS RL 000368 01-04, 000369 01-04,
001600 02-04
FRANCO A 002379 02-15
FRANCOS 000015 01-02
FRANCO-MORSELLI R 003343 03-1 1
FRANCOIS M 002030 02-09
FRANK LA 003278 03-10
FRANK M 003054 03-04
FRANKE L 002049 02-09
FRANKLIN KBJ 000387 01-04
FRANKLIN M 001956 02-08, 004329 04-08
FRANKS GJ 003363 03-11
FRANTIK E 002332 02-14
FRANTZAG 002871 03-03
FRANZ DN 004040 04-03
FRANZENG 003542 03-15
ERASER HF 004610 04-15
ERASER S 004329 04-08 , 004520 04-13
FRAHINI P 000757 01-13 , 004675 04-16
FRAHOLAL 002121 02-11
FRAUD J 001902 02-07
FRAYPJ 002484 02-16
FRAYSSINETR 003524 03-15
FRAZER A 000940 01-17 , 001463 02-03 ,
001991 02-09
FRAZINGARO S 0047 1 7 04- 1 7
FRECKER RC 004552 04-13
FREDA J 001596 02-04
FREDERICKS AB 00162102-04
FREDERICKSON RCA 002720 03-03
FREDERIKSENS 001982 02-09, 001983 02-09
FREDHOLMB 001238 02-03
FREDRICKSON JW 003413 03-13, 004619 04-
15, 004620 04-15
FREED W 000255 01-03 , 000869 01-15 ,
001233 02-03 , 001622 02-04 , 001672
02-04 , 001928 02-08 , 002992 03-04 ,
002993 03-04
FREEDMANAM 004712 04-17
FREEDMAN DX 004448 04-11
FREEDMANMS 00272103-03
FREEDMAN R 000095 01-03 . 000197 01-03 ,
000209 01-03 , 001848 02-05 , 003793
04-03 , 003926 04-03
FREEDMAN SB 002722 03-03 , 004055 04-03
FREEMAN CG 003867 04-03
FREEMAN H 002544 02-17 , 003171 03-08 ,
004611 04-15
FREEMAN JM 004447 04-11
FREGLYMJ 001623 02-04, 004237 04-04
FREGNAN GB 001391 02-03 , 001577 02-04 ,
004115 04-04, 004116 04-04
FREIRE GL 004042 04-03
FRENK H 000494 0 1 -04 , 004 1 1 4 04-04
FRESIA P 001481 02-03
FREUNDD 001624 02-04
FREUNDJL 001624 02-04
FREWIN DB 000682 01-11
FREY H 000096 01-03 , 000097 01-03 ,
000785 01-13
FREYWH 002825 03-03
FREYHAN FA 000938 01-17, 000939 01-17
FREZZAG 003222 03-09
FRIDMAN AL 000506 01-04
FRIED PA 000513 01-05
FRIEDEL RO 00441 1 04-09
FRIEDHOFFA 003277 03-10, 003407 03-13,
003927 04-03 , 003939 04-03 , 003989
04-03, 004312 04-08
FRIEDMAN AM 004293 04-06
FRIEDMAN DP 002723 03-03
FRIEDMAN E 000203 01-03 , 003794 04-03 ,
004383 04-09
FRIEDMAN HJ 001625 02-04 , 002994 03-04
FRIEDMAN J 000763 01-13
FRIEDMAN MB 000183 01-03
FRIEDMAN P 000784 01-13
FRIELP 000177 01-03, 000728 01-11
FRIGENIV 003126 03-05
FRIGERIOC 001391 02-03
FRIGOGM 002276 02-13
FRIISML 002127 02-11, 003484 03-15
FRISCHKNECHT HR 001626 02-04, 001776
02-04 , 001777 02-04
FRITH CD 004423 04-10
FRITZ LC 003973 04-03
FRITZ RR 000148 01-03
FROHMANCE 001919 02-08
FROHMAN LA 000908 01-16, 003920 04-03
FROLICHJC 000622 01-09
FROMMGH 002122 02-11, 002724 03-03
FROSCHERW 003314 03-11
FROWEIN HW 004563 04-14
FRY BW 003795 04-03
FRYJP 001234 02-03, 001235 02-03
FRYDMANML 001231 02-03
FRYEGO 001813 02-04, 003037 03-04,
004195 04-04
FUCHSCZ 000594 01-09
FUENTESAM 001159 02-03
FUJII I 004636 04-15
FUJtIT 000515 01-05
FUJIMOTOJM 002800 03-03
FUJIMOTOM 002725 03-03
FUJIMOTO S 000098 01-03 , 000199 01-03 ,
000260 01-03
FUJIMURAY 001659 02-04
FUJISAKIT 003093 03-04
FUJITAA 003692 04-02
FUJITAN 000099 01-03
FUJITAT 003187 03-08, 003266 03-09
FUJIWARA M 0002 1 0 0 1 -03 , 00 1 548 02-03
FUJIWARAT 004720 04-17
FUKUDAH 003807 04-03
FUKUDAN 003057 03-04
FUKUDAT 002174 02-11, 003093 03-04
FUKUDAY 003877 04-03
FUKUHARAK 000515 01-05
FUKUHARAT 003179 03-08, 003315 03-11,
003415 03-13, 003416 03-13
FUKUMORI R 001236 02-03, 001797 02-04
FUKUSHIMAH 000408 01-04
FUKUSHIMAY 002442 02-15
FULLED 001126 02-03
FULLER RW 000100 01-03 , 000101 01-03 ,
001237 02-03 , 002726 03-03 , 002995
03-04 , 003796 04-03
FULLER TA 000222 01-03
FULTON T 00019101-03, 000388 01-04
FUMAGALLI P 003801 04-03
FUNGD 000734 01-11
FUNGYK 002996 03-04, 004117 04-04
FUQUAW 003392 03-11
FURMAN JM 002997 03-04
FURUKAWA K 000152 01-03
FURUKAWA S 001320 02-03
FURUKAWA T 000515 01-05 , 001808 02-04 ,
004256 04-04
FUSEK J 000127 01-03 , 000389 01-04 ,
000420 0 1 -04 , 00 1 274 02-03 , 00 1 689
02-04
FUXE K 001096 02-03 , 001238 02-03 ,
001239 02-03 , 001240 02-03 , 002727
03-03
FYER A 000632 01-09 , 003240 03-09 ,
003241 03-09
FYERAF 003409 03-13
GABAYS 001271 02-03
GABRIEL E 003251 03-09
GABRIEL SM 00005101-03
GABRYSMC 001613 02-04
GACHY B 004307 04-07
GADOWKD 000676 01-11, 000812 01-14,
004449 04-1 1 , 004713 04-17 , 004714
04-17
GAGEFH 000390 01-04
GAGLIARDI R 000669 01-11
GAGNE P 004450 04-11
GAGNIEREB 002108 02-11
GAGNON A 002010 02-09
GAHWILERBH 001241 02-03
GAIARDIM 000338 01-04, 003555 03-16
GAIDEMS 001242 02-03
GAILLARDJ 002325 02-14
GAILLARDP 000842 01-15
GAILLARD-SIZARET C 000842 01-15
GAINER H 001053 02-01 , 001 148 02-03
GAITZCM 002545 02-17
GAJEWSKAS 003050 03-04
GAL EM 004715 04-17
GAL J 002235 02-13
GALDABINIJJ 004655 04-15
GALDAMES DG 000 1 02 0 1 -03
G ALE K 000 1 40 0 1 -03 , 00 1 243 02-03 ,
00 1 627 02-04 , 002 1 63 02- 1 1 , 003797
04-03, 004018 04-03
GALEAZZIG 003466 03-15
GALIANAJ 001189 02-03
GALINAZH 000337 01-04
GALLAGER DW 000038 01-03 , 000103 01-03
, 001502 02-03, 001503 02-03, 001504
02-03 , 001842 02-05 , 002912 03-03
GALLAGHER M 001628 02-04, 002998 03-04
, 003798 04-03
GALLAGHER RM 003592 03-17
GALLANDMC 002319 02-14
GALLETG 002123 02-11
GALLIA 000104 01-03
GALLIVANJV 000448 01-04
GALLOV 000185 01-03
GALTEAUMM 001507 02-03
GALVAMD 002863 03-03
GALVAN M 000034 0 1 -03 , 00 1 244 02-03
GALZIGNA L 000105 01-03
GAMBLES 001817 02-04, 001858 02-05,
002509 02-16 , 004282 04-05 , 004423
04-10
GAMBOAA 002855 03-03
GAMBURGAL 003172 03-08
GAMMELG 002004 02-09
GAMMON GD 000843 01-15
GANDER RE 002485 02-16
GANGULY DK 004096 04-04
GANNAWAYDJ 003316 03-11
GANZAJ 000705 01-11
GARAHINI S 000036 01-03 , 001 157 02-03 ,
002521 02-17 , 002546 02-17 , 002602
02-17 , 003758 04-03
GARBANATI JA 000375 01-04
GARBARGM 001054 02-01
GARBERHI 001337 02-03
GARCEAU D 001547 02-03
GARCIA AG 001357 02-03
A-11
wsisSBoai^itiSKs:
■.•■.•/■i
Author Index
Psychopharmacology Abstracts
GARCIA-RILLE 001340 02-03
GARCIA-SAINZ JA 002728 03-03
GARCIA-SEVILLA JA 003408 03-13, 003799
04-03 , 004008 04-03
GARCINF 002596 02-17
GARDELL MA 004002 04-03
GARDELLAJL 001658 02-04
GARDNER EL 000467 01-04, 001629 02-04,
004187 04-04
GARDNER GH 003566 03-16
GARDOS G 000844 01-15, 002403 02- 1 5 ,
002404 02-15, 003294 03-11, 003485
03-15 , 004323 04-08 , 004623 04-15
GARELISE 002294 02-13
GAREY RE 002747 03-03
GARFINKELPE 001990 02-09
GARLAND WA 002248 02-13, 002486 02-16
GARLEM 000897 01-16
GARNEHD 004729 04-17
GARNIERR 003513 03-15
GAROUX R 000865 01-15
GARREJ 00257102-17, 003208 03-09
GARREAU B 003291 03-11
GARRET C 00 1 1 33 02-03 , 00 1 1 37 02-03
GARRICK NA 002233 02-13
GARRIDO-GARCIA J 003043 03-04
GARRIGOU D 001585 02-04
GARRUDP 001757 02-04
GARSIDERF 002081 02-10
GARTHWAITEJ 001144 02-03, 002729 03-03
GARVERDL 000555 01-08, 002386 02-15
GARZON J 000398 01-04
GARZYA G 004421 04-10
GASKINSCT 003048 03-04
GASTOC 001963 02-09
GASTPARM 002326 02-14, 004399 04-09
GASZNER P 002298 02-13
GATH I 004564 04-14
GAHIG 002276 02-13
GATZONIS S 004059 04-03
GAUDREAULTV 002596 02-17
GAURONEF 001630 02-04
GAUTHIERA 003898 04-03
GAVIN WJ 001242 02-03
GAVIRIAM 002427 02-15
GAVISH M 002730 03-03
GAWELMJ 004509 04-13
GAWIN FH 003223 03-09
GAYGR -003525 03-15
GAYDUK FM 004434 04-1 1
GAYETJ 003838 04-03
GAYRALL 003559 03-16
GAZIT H 001833 02-05
GEBERJ 002705 03-03
GEBERWF 002410 02-15
GEBHARTE 000845 01-15
GEBHART GF 001328 02-03 , 001631 02-04 ,
001724 02-04 , 001726 02-04 , 0041 18
04-04
GEBREWOLDA 001105 02-03
GEEKW 000106 01-03
GEES 004716 04-17
GEKHT K 002663 03-03
GEKIERE F 001 170 02-03 , 002731 03-03
GELDERMG 002510 02-16
GELENBERG A 000846 01-15 , 001931 02-08 ,
002473 02-15
GELENBERG AJ 004612 04-15
GELLERE 001385 02-03, 004204 04-04
GELLERG 000697 01-11
GELLERHM 000107 01-03, 002732 03-03
GELLERT VF 000391 01-04 , 001632 02-04 ,
001790 02-04
GENCEM 000169 01-03
GENDELMAN DS 001605 02-04
GENDELMAN PM 001605 02-04
GENESTE P 001031 02-01
GENGOF 000940 01-17, 00199102-09
GENOVESERF 001639 02-04
GENTILG 002135 02-11
GENTILI P 001051 02-01
GENTLEMAN S 003737 04-03 , 003800 04-03
, 003949 04-03, 003958 04-03, 004188
04-04
GEORGE CF 000141 01-03 , 002547 02-17
GEORGOTASA 001992 02-09, 003224 03-09
, 004383 04-09
GEORMANEANU M 004451 04-1 1
GERBER GJ 002999 03-04 , 003000 03-04
GERBERN 000073 01-03, 003828 04-03
GERBINOL 000677 01-11
GERCHIKOVLI 004663 04-15
GERHARDS HJ 002289 02-13
GERKENS JF 002734 03-03
GERLACH J 000043 01-03 , 000540 01-07 ,
00210102-11, 002124 02-11, 002377
02-15 , 002405 02-15 , 003302 03-1 1 ,
003472 03-15
GERMAN DC 002680 03-03
GERNER RH 004360 04-09
GERSHON ES 003242 03-09 , 004565 04-14
GERSHON S 000461 01-04 , 000561 01-08 ,
001906 02-08 , 001948 02-08 , 001992
02-09 , 002017 02-09 , 002125 02-1 1 ,
002516 02-16 , 002877 03-03 , 003224
03-09 , 004367 04-09 , 004383 04-09 ,
004482 04-11, 004606 04-15
GERSON SC 000941 01-17
GERSTNERC 002030 02-09
GESSA GL 00 1 1 29 02-03 , 00 1 483 02-03 ,
002477 02-16
GESTRI G 002093 02-1 1
GEWACKEMA 001633 02-04
GEYER MA 001333 02-03 , 001634 02-04 ,
002194 02-12
GHADIRIAN AM 000847 01-15
GHAZVINIAN S 003297 03-1 1
GHOSEK 001976 02-09, 004678 04-16
GHOSH JJ 002686 03-03
GIACOBINI E 001396 02-03
GIAGNONI G 003801 04-03
GIANNELLI A 003173 03-08
GIANNINI AJ 000848 01-15
GIBALDIM 003562 03-16
GIBB JW 000 1 30 0 1 -03 , 00 1 384 02-03 ,
003850 04-03
GIBBONS JL 001584 02-04
GIBBONS R 001505 02-03
GIBBS ME 001607 02-04
GIBERTJ 004479 04-11
GIBERT-RAHOLA J 00 1 1 89 02-03
GIBSON A 000108 01-03, 001245 02-03
GILBERG M 003935 04-03
GILBOE DD 000256 01-03
GILES HG 000789 01-13, 000790 01-13,
004552 04-13
GILHUSNE 002234 02-13, 003486 03-15
GILL JH 000392 01-04
GILLTS 002410 02-15
GILLAN MGC 003802 04-03
GILLER E 001993 02-09
GILLESPIE DD 001353 02-03
GILLESPIE HK 002201 02-12
GILLEHEJR 002282 02-13
GILLHAM B 004463 04-11
GILLI P 002283 02-13
GILLIN C 002354 02-14
GILLINJC 000432 01-04, 001233 02-03,
001284 02-03, 001958 02-08, 002341
02-14 , 002506 02-16 , 003184 03-08 ,
003255 03-09 , 004729 04-17
GILLINGHAM FJ 000693 01 -1 1
GILLIOZP 003759 04-03
GILLISJS 003225 03-09, 003593 03-17
GILLIS S 003720 04-03
GILLMAN MA 003442 03-14
GIMENEZ-ROLDAN S 00331 1 03-1 1
GIMENOAL 000223 01-03, 001159 02-03
GIMENOMF 001159 02-03
GINESTET D 002388 02-15
GINTZLERAR 000109 01-03
GIORGUIEFF-CHESSELET MF 002733 03-03
GIOUXM 00345103-14
GIRARDJ 004399 04-09
GIRARDM 001999 02-09, 003559 03-16
GIRARDIAM 002277 02-13
GIRAUD P 003759 04-03
GIRONGP 000105 01-03
GISPEN WH 003721 04-03
GISQUET-VERRIER P 003001 03-04
GISSELMANNA 003175 03-08
GIHELMANR 000678 01-11
GinER S 004001 04-03
GIUFFRA F 003222 03-09
GIURGEAC 002327 02-14
GIUSTI GV 003751 04-03 , 003803 04-03
GKIOUZEPASJ 003186 03-08
GLANZMANN P 001624 02-04
GLAROSAG 002126 02-11
GLASER GH 002937 03-03
GLASGOW G 000679 01-11
GLASS JD 002122 02-1 1 , 002724 03-03
GLASS RM 002328 02-14
GLASSERRS 001717 02-04
GLASSMANAH 000590 01-09, 004368 04-09
GLASSMAN HN 000393 01-04
GLASSMAN RB 000393 01-04
GLAZER EJ 002638 03-01
GLENNON RA 001020 02-01, 003690 04-02,
004260 04-04
GLICK ID 000553 01-08
GLICK SD 001706 02-04 , 001876 02-06 ,
003002 03-04 , 0042 1 6 04-04
GLIKLICH J 003409 03-13
GLOSSMANN H 001246 02-03
GLOVELI TB 004510 04-13
GLOVER V 000983 01-17, 002230 02- 1 3 ,
004509 04- 1 3 , 004640 04- 1 5
GLOWINSKI J 000123 01-03 , 001269 02-03 ,
002733 03-03 , 003825 04-03 , 00401 1
04-03
GLUECK BC 000539 01-07
GLUSMAN M 000348 01-04
GLYNJR 001247 02-03, 001248 02-03
GMEREK DE 004267 04-05
GMURM 004452 04-11
GNEGY ME 001249 02-03
GOBELW 000097 01-03
GODEFROYF 000110 01-03
GODOT JM 003564 03-16
GODSE DD 004048 04-03 , 004303 04-06
GODWIN-AUSTEN RB 002406 02-15
GOEDDE HW 003852 04-03
GOELI 000973 01-17
GOEH JM 003003 03-04
GOETZCG 000498 01-04, 000862 01-15,
000950 01-17 , 002407 02-15 , 003502
03-15, 004249 04-04
GOFFAUX P 001920 02-08
GOGOLAK G 003804 04-03
GOIJMAN S 001194 02-03
GOLD Bl 000764 01-13, 002097 02- 1 1
GOLD EH 001019 02-01
GOLD MS 000899 01-16, 003220 03-09 ,
003317 03-11
GOLD P 001250 02-03 , 001251 02-03 ,
001488 02-03 , 003220 03-09 , 003357
03-11 , 003388 03-11 , 004231 04-04
GOLDAV 001635 02-04
GOLDBERG AM 001061 02-01
GOLDBERG DM 0040 1 2 04-03
GOLDBERG HL 001994 02-09
GOLDBERG IM 004025 04-03
GOLDBERG LI 001252 02-03, 003890 04-03,
003911 04-03
GOLDBERG MA 002235 02-13
GOLDBERG MR 002734 03-03 I
GOLDBERG SC 003487 03-15 '
GOLDBERG SR 003096 03-04 , 004012 04-03
, 004119 04-04
GOLDBERGER E 003226 03-09 , 003559 03-16
GOLDEN GS 003468 03-15
GOLDFARB J 003081 03-04
GOLDFOOT DA 003074 03-04
GOLDINA 002546 02-17
GOLDMAN JW 003322 03-1 1
GOLDMAN LS 002408 02-15
GOLDMAN ME 002242 02- 1 3
GOLDMAN W 00 1 024 02-0 1
GOLDS PR 001253 02-03
GOLDSTEIN A 000254 01-03 , 004324 04-08
GOLDSTEIN Bl 00216102-11
GOLDSTEIN BJ 001995 02-09
GOLDSTEIN DS 002250 02-13
GOLDSTEIN M 000698 01-11, 001254 02-03,
001255 02-03, 001448 02-03, 001839
02-05 003189 03-08, 003664 04-01,
004120 04-04
GOLDSTEIN R 003098 03-04
GOLDSTEINS 002385 02-15
GOLDSTONE SNHG 000554 01-08
GOLEBIEWSKI H 001761 02-04
GOLEM AN D 004744 04-17
GOLEMBIOWSKA-NIKITIN K 001256 02-03
GOLINKOBE 002126 02-11, 004453 04-11
GOLOVCHINSKY V 003060 03-04
GOLTERMANN NR 003805 04-03
GOMENI R 000044 01-03, 000596 01-09,
000777 01-13, 003324 03-11
A-12
w
fmsiiim^i7imi^mfi:^mir(\'ffm\m
VOLUME 19, AUTHOR INDEX
Author Index
GOMES C 000040 01-03
GOMES UCR 002735 03-03
GOMEZ B 001355 02-03
GOMEZ F 001930 02-08
GOMEZ M 003338 03-11
GOMEZ-JARABO G 00 1 558 02-04
GOMITAY 003004 03-04
GOMMERENW 000186 01-03, 004033 04-03
GONCALVESN 001996 02-09
GONNARD P 004029 04-03
GONZALEZ C 001176 02-03
GONZALEZ JP 002736 03-03
GONZALEZ J V 002112 02-11
GONZALEZ LP 001683 02-04, 003005 03-04
GONZALEZ MONCLUS E 002588 02-17 ,
002589 02-17
GONZALEZ-VILCHES J 002849 03-03 , 002850
03-03 , 002851 03-03
GOOOALEDB 002236 02-13, 004244 04-04
GOODEDJ 003318 03-11
GOODEPG 000516 01-05
GOODMAN RR 000990 01-17
GOODNICK PJ 004367 04-09 , 004369 04-09
GOODWIN F 003357 03-11, 003388 03-11
GOODWIN FK 000225 01-03, 001536 02-03,
001984 02-09 , 002628 02-17 , 002972
03-04, 003250 03-09, 004689 04-16,
004708 04-17
GOODWIN PJ 000517 01-05
GOOTJESJ 000005 01-01
GOPINATHAN G 002342 02-14 , 002384 02-
15, 003319 03-11
GORBATKOLG 004633 04-15
GORDI YENKO ZP 004633 04- 1 5
GORDON A 001257 02-03, 001914 02-08
GORDON C 002737 03-03 , 003488 03-15
GORDON J 001636 02-04 , 003385 03-1 1 ,
004268 04-05
GORDON LS 002862 03-03
GORDON W 000913 01-17
GORELICK DA 004360 04-09
GORGONEG 001200 02-03
GORI E 003801 04-03
GORI G 003065 03-04
GORISSEN H 002489 02-16, 003896 04-03
GORKIN RA 001433 02-03
GORMAN J 003394 03-11, 003409 03-13
GORMEZANOI 001637 02-04
GORODETZKYCW 003594 03-17, 004610 04-
15
GORSKI H 004660 04-15
GORZALKABB 002975 03-04
GOSENFELDLF 004352 04-09, 00452104-13
GOSLING JA 001955 02-08
GOSPE SM 003806 04-03
GOSSATI P 004503 04-13
GOTESTAM KG 000804 01-14
GOTHERT M 000 1 1 1 0 1 -03 , 00 1 258 02-03
GOTOM 003807 04-03
GOTSICKJE 002983 03-04
GOHBERGE 001275 02-03
GOHESMAN II 002825 03-03
GOnUEB P 000591 01-09
GOnSCHALK LA 002067 02-10
GOUDEMANDM 000589 01-09
GOUDIE AJ 004121 04-04
GOUREVITCH M 0046 1 3 04- 1 5
GOUTR 00002101-03, 003682 04-02
GOUVIERWD 000394 01-04
60UZ0UA 000680 01-11
GOVONI S 001480 02-03 , 003808 04-03
GOWDEYCW 001746 02-04
GOY RW 003017 03-04
GOYAN 000696 01-11
GOZDALSKAJ 000719 01-11
GRAB EL 000787 01-13
GRABOWSKA-ANDEN M 001 102 02-03 ,
002372 02-15 , 004065 04-04
GRACE AA 000023 01-03, 00 1 1 53 02-03
GRADY RW 001836 02-05
GRAFL 003193 03-08
GRAFEP 001244 02-03
GRAHAM J 003552 03-15
GRAHAM JDP 001190 02-03
GRAHAM LTJ 000145 01-03
GRAHAME-SMITH DG 001412 02-03, 001486
02-03 , 001487 02-03 , 003399 03-13
GRAM LF 002033 02-09 , 004370 04-09
GRAMSCHC 003837 04-03
GRANACHERRP 000961 01-17
GRANATAAR 000223 01-03
GRANDADAM A 004105 04-04
GRANDISON L 002738 03-03 , 003809 04-03
GRANT SJ 002910 03-03 , 003810 04-03
GRASS! A 003801 04-03
GRATTON DA 001106 02-03
GRATTON I 002928 03-03
GRAUJW 001707 02-04
GRAVEL G 002119 02-11
GRAVEMAO 000890 01-15
GRAY OS 002975 03-04
GRAYJA 001757 02-04, 002069 02-10
GRAYPN 000765 01-13
GRAZE KK 003489 03-15
GRECHKOAT 001812 02-04
GREDALO 002676 03-03
GREDEN J 004359 04-09
GREELEY GH 003811 04-03
GREEN AL 000900 01-16
GREEN AR 001 184 02-03 , 001686 02-04 ,
002444 02-15 , 002971 03-04 , 003736
04-03
GREEN DE 001229 02-03, 001867 02-06
GREEN DJ 001438 02-03
GREEN J 000 1 1 2 0 1 -03 , 00 1 369 02-03 ,
002413 02-15, 004557 04-13
GREEN KF 00181 1 02-04 , 003812 04-03
GREEN L 003320 03-11
GREEN V 002739 03-03
GREEN WH 003361 03-11
GREENBERG LH 000 1 1 3 0 1 -03 , 00 1 529 02-03
GREENBERGS 001259 02-03
GREENBLAHDJ 000114 01-03, 00068101-
11 , 000766 01-13 , 000784 01-13 ,
000789 01-13, 000790 01-13, 000831
01-15 , 000968 01-17 , 002206 02-13 ,
003161 03-07 , 003284 03-10 , 003352
03-1 1 , 003410 03-13 , 004432 04-1 1
GREENBLAHEN 001093 02-02, 004122 04-
04
GREENFIELD AA 002212 02-13
GREENFIELD S 003665 04-01
GREENGARD P 000291 01-03
GREENHILLLL 003321 03-11
GREGOIRE F 002099 02-1 1
GREGSON AN 003071 03-04
GREIL W 00 1 570 02-04 , 002227 02- 1 3
GREISMAN P 000655 01-10
GREISSKC 002070 02-10
GREIST JH 002005 02-09 , 002244 02-13 ,
003498 03-15
GRESTYMA 002376 02-15
GREWALRS 000154 01-03
GRIAUZDEML 001260 02-03
GRIEB P 003971 04-03
GRIERSMITH BT 001203 02-03 , 002740 03-
03 , 003778 04-03
GRIESBACHPH 000717 01-11
GRIFFI PG 001460 02-03
GRIFFIN HD 002741 03-03
GRIFFITH DNW 002071 02-10
GRIFFITHS RR 000395 0 1 -04 , 0023 1 4 02- 1 4 ,
004123 04-04 , 004566 04-14 , 004582
04-14
GRIGNOLOA 003813 04-03
GRIJALVACV 000396 01-04, 001638 02-04
GRILLY DM 00 1 639 02-04 , 004 1 24 04-04
GRIMALDI F 003571 03-16
GRIPENBERGJ 003814 04-03, 003815 04-03
GRISART 004589 04-15
GRISOLIA S 002744 03-03
GRISSETTEDE 000518 01-05
GRISSOMT 002160 02-11
GRini P 003444 03-14
GROB P 003734 04-03
GROFE 003402 03-13
GROFP 003402 03-13
GROFOVA I 002774 03-03
GROHJ 002054 02-09
GROH KR 001409 02-03
GROLCJ 000004 01-01
GRONU 002127 02-11
GROOM GP 003529 03-15, 003530 03-15
GROPPETTIA 001422 02-03
GROSS C 003451 03-14
GROSS G 002742 03-03 , 003816 04-03 ,
004325 04-08
GROSS K 001793 02-04
GROSS PM 003817 04-03
GROSS R A 000089 0 1 -03 , 000 1 1 5 0 1 -03
GROSSMAN A 001 127 02-03 , 003731 04-03
, 003732 04-03
GROTH J 004300 04-06
GROUILLER A 003691 04-02
GROVE J 002237 02-13
GROVES PM 004229 04-04
GROVESTINE D 001535 02-03
GROWDON JH 000942 01-17, 002473 02- 1 5
, 004612 04-15
GRUBE E 003352 03-11
GRUENAUC 002354 02-14
GRUNBAUMA 003595 03-17
GRUNBERGER J 000720 01-11 , 000788 01-13
, 001895 02-07, 002166 02-11
GRUOLDL 000116 01-03
GRUPPLA 001344 02-03
GRUSZCZYNSKI W 000626 01-09, 000719
01-11
GRUZELIERJ 003174 03-08, 003443 03-14
GUALTIERICT 000849 01-15, 002409 02-15,
004614 04-15
GUANDALINIA 004717 04-17
GUARDUCCI R 002093 02-11
GUARINO RA 002059 02-10
GUARNERI P 002743 03-03
GUBERMAN AS 004732 04-17
GUCHHAITRB 003818 04-03
GUDKAHV 002394 02-15
GUEDESRCA 002752 03-03
GUELENPJM 000541 01-07
GUELFIJD 003596 03-17
GUENSBERGER E 001997 02-09
GUEREMYC 003898 04-03
GUERIN B 000070 01-03
GUERRERO MD 000117 01-03
GUERRERO-MUNOZ F 000 1 1 7 0 1 -03
GUERRETM 004530 04-13
GUERRI C 002744 03-03
GUERRINIA 001998 02-09
GUEST JF 000171 01-03
GUGLER R 003314 03-11
GUGUSHVILI LN 001640 02-04, 004125 04-04
GUIDI E 003114 03-04
GUIDOniA 000397 01-04, 001012 02-01,
001045 02-01, 001182 02-03, 001261
02-03 , 001262 02-03 , 001263 02-03 ,
001849 02-05, 002642 03-01, 002819
03-03 , 003809 04-03
GUILBAUDG 000175 01-03
GUILLARDP 002094 02-11
GUILLEMINAULT C 000374 01-04
GUILLERYT 002137 02-11
GUILLOUXF 000176 01-03, 003899 04-03
GUILMOTPH 001920 02-08
GUIMONJ 004312 04-08
GUINNMM 003127 03-05
GUISADOE 000398 01-04
GUISOG 001157 02-03
GUIVERNAUM 000439 01-04
GULATI OD 003772 04-03
GULMANN N 000659 01-11
GULUMOGLUA 001059 02-01
GUNDERSENCB 003819 04-03, 003820 04-03
GUNDERSON CH 00241 5 02-1 5
GUNGORM 000169 01-03
GUNION MW 003821 04-03
GUNNELM 000685 01-11
GUPTA BS 004581 04-14
GUPTA G 003180 03-08
GURAM MS 002410 02-15
GURANOWSKIA 001010 02-01, 00102102-
01
GURBANI NK 001682 02-04
GURDJW 002721 03-03
GUREVICH N 000236 01-03
GUREVICH ZP 003384 03-1 1
GURWICH E 000872 01-15
GUSTAFSSONJ 000273 01-03
GUTHEILTG 00091101-17
GUTIERREZ M 004312 04-08
GUTJAHRCL 004467 04-11
GUHERIDGE NJA 001591 02-04
GUY W 002026 02-09 , 002080 02-10 ,
004333 04-08 , 004392 04-09
GUYDAH 002253 02-13
GUYOTM 000777 01-13
GUZA 002164 02-11
GUZIK H 001019 02-01
GUZMAN-FLORES C 00 1 6 1 2 02-04
A-13
Author Index
Psychopharmacology Abstracts
GYMOESEE 002229 02-13
GYORGYL 003822 04-03
GYORYAN 000943 01-17
HAARMANNI 001283 02-03, 003846 04-03
HAASAE 002830 03-03, 00283103-03
HAASS 001909 02-08
H AASE H 000944 01-17, 002548 02- 1 7 ,
003234 03-09
HABARAT 004551 04-13
HABER S 003006 03-04 , 003007 03-04
HABERMAN SJ 002481 02-16
HABERMANN E 003709 04-03
HABLECP 001531 02-03
HACKENBERGP 000118 01-03
HACKEHRB 000519 01-05
HACKSELLU 000399 01-04
HADAWAYPF 000530 01-06
HADGRAFTJ 000007 01-02
HADJICHRISTOS C 003466 03-15
HADJIKONSTANTINOU M 00447104-11
HADZHIKOSTOVA H 0001 19 01-03
HAEFELYW 002646 03-02
HAEUSLERG 001264 02-03
HAFLERO 004653 04-15
HAGA K 003823 04-03
HAGAT 003823 04-03
HAGEMAN WE 0005 1 2 0 1 -05
HAGERMAN LM 000017 01-03 , 001 101 02-
03
HAHN EF 000400 01-04
HAHN J 004075 04-04
HAHNRA 001265 02-03
HAHN Z 003729 04-03
HAIDUKEWYCH D 003367 03-1 1
HAIER RJ 001971 02-09 , 00321 1 03-09
HAIGHE 001266 02-03
HAIGLER HJ 001267 02-03 , 003849 04-03
NAILER AW 00 1 0 1 3 02-0 1 , 0022 1 9 02- 1 3
HAILSTONE MH 003867 04-03
HAINERV 000570 01-08
HAJNOVAR 000663 01-11
HAKANSSONCG 004012 04-03
HAKERO 004343 04-08
HALARISAE 000125 01-03, 00031201-03,
003227 03-09 , 003771 04-03
HALASZB 002817 03-03
HALBREICH U 000752 01-13 , 000874 01-15 ,
002238 02-13 , 003228 03-09 , 00341 1
03-13, 004405 04-09
HALDEMANS 003322 03-11
HALDERSSG 004298 04-06
HALE MS 003481 03-15
HALKOVA E 000548 01-08 , 001908 02-08 ,
001925 02-08
HALL ED 002745 03-03
H ALL H 000 1 20 0 1 -03 , 00 1 238 02-03 ,
001240 02-03 , 003824 04-03 , 003991
04-03
HALLKR 002216 02-13
HALLMD 004032 04-03
HALLPV 003853 04-03
HALLBERGH 004126 04-04
HALLCHERLM 003712 04-03
HALLERC 001999 02-09
HALLEHM 001164 02-03
HALLIWELLJV 001641 02-04
HALLOCK M 003794 04-03
HALPERIN DA 004326 04-08
HALPERN F 000752 01-13 , 000776 01-13 ,
000874 01-15, 002238 02-13, 003321
03-11, 00341103-13, 004405 04-09
HALPERN LAA 000327 01-03
HALSEYMJ 001106 02-03
HAMALAK 001268 02-03
HAMERR 003487 03-15
HAMETP 000864 01-15
HAMILTON HE 000538 01-06
HAMILTON M 002487 02-16
HAMILTON W 001984 02-09
HAMMER GV 000907 01-16
HAMMER JS 000835 01-15
HAMMETTS 001822 02-04
HAMMOND DL 00012101-03, 000122 01-03
HAMMOND EJ 002758 03-03
HAMMOND NV 003443 03-14
HAMON M 000123 01-03 , 000213 01-03 ,
0002 1 4 0 1 -03 , 00 1 269 02-03 , 003825
04-03
HAMOUZW 000592 01-09
HAMOVITJ 003242 03-09
HAMPRECHTB 000308 01-03, 002677 03-03
, 003975 04-03
HANBAUER I 001 182 02-03 , 001270 02-03 ,
001403 02-03
HANDELMANN GE 001398 02-03
H ANDFORD HA 000945 01-17
HANDLEY S 001 146 02-03 , 004078 04-04
HANERH 003490 03-15
HANIN I 000631 01-09 , 004290 04-06 ,
00451104-13, 004679 04-16
HANING RV 003017 03-04
HANKEH 004516 04-13
HANLON TE 000904 01-16, 003 1 82 03-08
HANSEN BS 000767 01-13
HANSEN EL 001716 02-04
HANSEN HE 002465 02-15
HANSEN T 002229 02-13 , 002329 02-14
HANSLICEK L 000600 01-09
HANSON DR 001572 02-04
HANSON G 003826 04-03
HANSSON E 002746 03-03
HANTZBERG P 002600 02-17
NANUS H 000593 01-09 , 002000 02-09
NANUS L 001022 02-01, 001023 02-01
NANZLICEK L 000542 01-07
NARA S 003008 03-04
HARAT 002559 02-17
HARACZJL 001642 02-04, 001643 02-04
HARADA Y 001691 02-04
HARBERTCA 001092 02-02
HARDEBO JE 003781 04-03
HARDEN TK 002820 03-03
HARDING GFA 004513 04-13
HARDING JW 003953 04-03
HARDTW 000780 01-13
HARDY C 001644 02-04
HARDY RA 001093 02-02
HARIHARASUBRAMANIAN N 000881 01-15
HARIK SI 002798 03-03
HARLANDRC 000073 01-03
HARMANAW 000682 01-11
HARMANTJ 004487 04-11
H ARMAR AJ 004 1 00 04-04
HARMATZJS 000766 01-13, 004432 04-11
HARMS D 003491 03-15
HARPER AM 003817 04-03
NARPFH 003503 03-15
HARRER G 003597 03- 1 7 , 0047 1 8 04- 1 7
HARRIS B 000683 01-11
HARRIS DW 000124 01-03
HARRIS GJ 001853 02-05
HARRIS J 00127102-03
HARRIS LS 000354 01-04, 004084 04-04
HARRIS PA 003497 03-15
HARRIS PQ 002480 02-16
HARRIS RA 000479 01-04, 001645 02-04,
003600 03-17 , 003827 04-03 , 004127
04-04
HARRIS SC 000906 01-16
HARRISON REW 002636 03-01
HARRISON-READ PE 00040101-04, 001646
02-04 , 003229 03-09
HARSTONQ 000402 01-04
HARTSL 001245 02-03, 002783 03-03
H ARTEL FW 002328 02-14
HARTFORD JT 002545 02-17
HARTMAN BK 000239 01-03 , 003974 04-03
HARTMAN E 000946 01-17
HARTMAN J 000 1 25 0 1 -03 , 002549 02- 1 7
HARTMANN G 004075 04-04
HARTMANN H 003490 03-15
HARTO-TRUAX N 003227 03-09
NARTSEKM 000822 01-14, 002357 02-14
HARTUNG M 000711 01-11
HARVAN PA 001795 02-04
HARVENGTC 00018101-03
HARVEY JA 000466 01-04, 001637 02-04
HARZER K 003671 04-01
HASAN M 001831 02-05
HASAN MZ 001831 02-05
HASEGAWAAT 001853 02-05
HASKEH R 004359 04-09
HASSANYEH F 002001 02-09
HASSMANNOVA J 000803 01-14, 0008 1501-
14 , 001647 02-04
HASUEI 003544 03-15
HASUZAWA H 002349 02-14 , 003450 03-14
HATAF 001272 02-03
HATCHELLPC 001648 02-04
HATCHER J 004324 04-08
HAUBRICH DR 003828 04-03
HAUGT 000804 01-14
HAUGEM 003484 03-15
HAUGHTON H 002318 02-14
HAUHART RE 004281 04-05
HAUPTMANN M 004547 04-13
HAUSEN AC 002411 02-15
HAVEMANN U 001649 02-04
HAWK B 004614 04-15
HAWKING F 002546 02-17
HAWKINS MF 001 544 02-03 , 002952 03-04 ,
003026 03-04
HAWKSWORTH GM 004740 04-17
HAWTHORNE JN 002741 03-03
HAYASHI S 001273 02-03
HAYASHIT 001293 02-03, 004128 04-04
HAYCOCK DA 003829 04-03
HAYCOOKW 004557 04-13
HAYS SE 003830 04-03
HAYSTEADTAJ 001759 02-04, 003072 03-04
, 004208 04-04
HAYWARDTL 003757 04-03
HAZAMA H 000860 01-15 , 003179 03-08 ,
00331503-11, 00341503-13, 003416
03-13, 004388 04-09
HAZUM E 003581 03-17 , 003746 04-03
HEADLEY PM 002633 03-01
HEALEYML 000403 01-04
HEALTONEB 000835 01-15
HEAPYCG 001578 02-04
HEATH E 003857 04-03
HEATH JE 002737 03-03
NEATN RG 002747 03-03
HEAULAAEM 003898 04-03
HEBDIGE S 002276 02-13
HECHTM 004467 04-11
HECHTMAN L 004454 04-1 1
HECK DG 002974 03-04
HECKLK 00056101-08
HECQUETS 003155 03-07
HEDBERGA 000207 01-03
HEDLER L 002748 03-03 , 003983 04-03
HEDLEY-WHYTE J 003894 04-03
HEDLUND B 002667 03-03 , 003860 04-03
HEDRYCHA 000290 01-03
HEFFNERTG 002632 02-17
HER! F 000202 01-03 , 003323 03-11
HEGOE R 003259 03-09
HEGGLI D 002749 03-03
HEGSTRAND LR 003021 03-04
HEIDJ 003135 03-06
HEIDRICH H 004309 04-07
HEIKKILAJJ 00383104-03, 003832 04-03
HEIKKILARE 000404 01-04, 001650 02-04,
004129 04-04 , 004130 04-04
HEIKKINEN ER 004542 04-13
HEIMAN EM 003598 03-17
HEIMANN M 000335 01-04
HEIN DW 004132 04-04
HEINONEN E 003814 04-03 , 003815 04-03
HEINRICH K 000562 01-08
HEINZ G 000414 01-04
HEINZE WJ 000 1 35 0 1 -03 , 00 1 073 02-02
HEIWALL PO 003897 04-03
HELKEG 001024 02-01, 001222 02-03
HELLER A 001340 02-03, 002654 03-03
HELMCHENH 004371 04-09
HELMESTE DM 000300 01-03 , 004131 04-04
HELWIGC 003306 03-11
HEMMENDINGER R 002717 03-03
HEMMINGSEN R 00012601-03, 00085001-
15
HEMMINKIE 002550 02-17, 003599 03-17
HEMRICK-LUECKE SK 000100 01-03
HENDELJ 002229 02-13, 002329 02-14
HENDERSON G 001408 02-03
HENDERSON JD 001534 02-03
HENDERSON VW 003492 03-15
HENDLEY ED 002685 03-03
HENDRICKJC 001565 02-04
HENDRICKS C 004233 04-04
HENICHART JP 003653 04-01
HENINGER GR 001496 02-03 , 002098 02-1 1 ,
002911 03-03 , 003418 03-13 , 004502
04-13
HENNEBERRYRC 001279 02-03
HENNING JM 003009 03-04
A-14
VOLUME 19, AUTHOR INDEX
Author Index
HENNING M 000231 01-03 , 003965 04-03
HENRIET I 003895 04-03
HENRIKSEN SJ 000580 01-09 , 003136 03-06
HENRY J 002254 02-13 , 003175 03-08 ,
003324 03-11
HENRY JF 000596 01-09
HENSBYCN 001132 02-03
HENSCHEN A 003740 04-03
HENSELINGM 000535 01-06
HENSLEYMJ 002128 02-11
HERBERGU 003560 03-16
HERBERT J 001718 02-04
HERBERT M 002365 02-14
HERBETA 000213 01-03, 000214 01-03,
001269 02-03 , 003825 04-03
HEREDIAE 002217 02-13
HERETIKA 000707 01-11
HERINK J 000 1 27 0 1 -03 , 000389 0 1 -04 ,
001274 02-03, 001689 02-04
HERKEN H 002962 03-04
HERKENHAMM 001025 02-01, 001050 02-
01 , 003737 04-03 , 003833 04-03
HERKERTE 004619 04-15
HERLINGS 00165102-04, 003010 03-04,
003 1 06 03-04 , 004 1 32 04-04 , 004 1 33
04-04 , 004134 04-04 , 004719 04-17
HERMAN BH 00301 1 03-04
HERMAN JP 003792 04-03
HERMANN A 003834 04-03
HERNANDEZ L 001275 02-03. 001652 02-04,
003015 03-04
HERNANDEZ MF 002967 03-04
HERNANDEZ RJ 001276 02-03
HERNDONJG 003012 03-04
HERNING Rl 002209 02- 1 3 , 0045 1 2 04- 1 3
MERRICK CE 004513 04-13
HERRMANN PW 004650 04-15
HERRMANN WM 000768 01-13 , 002239 02-
13, 003412 03-13, 004455 04-11
HERSENM 000657 01-10
HERSH LB 0O3835 04-03
HERSHKOWITZ M 004234 04-04
HERSHKOWITZ N 002750 03-03
HERSHMANJM 000733 01-11, 001385 02-03
, 003942 04-03
HERHING G 000 1 65 0 1 -03 , 00 1 298 02-03 ,
001319 02-03 , 002751 03-03 , 002904
03-03 , 003715 04-03 , 003983 04-03
HERTZ L 003836 04-03
HERVYC 003279 03-10
HERVYM 000596 01-09, 003324 03-11
HERZ A 000029 01-03 , 001234 02-03 ,
001235 02-03 , 001283 02-03 , 001918
02-08 , 003088 03-04 , 003837 04-03 ,
004104 04-04, 00432104-08, 004322
04-08
HESPEW 000005 01-01
HESS J 003669 04-01
HESSELGRENT 002208 02-13
HESTER JB 001074 02-02, 001075 02-02,
001076 02-02
HESTNESSJ 000740 01-12
HEUCKEU 001082 02-02
HEURTEAUXC 002299 02-13
HEVORT 003838 04-03
HEWinj 004027 04-03
HEXUMT 001182 02-03
HEYL 002003 02-09
HEYKANTS J 000758 01-13, 00 1 932 02-08
HEYMJ 003018 03-04
HICKS TP 002752 03-03
HIEBLEJP 001255 02-03
HIEPA 004635 04-15
HIER DB 000947 01-17
HIKIJIA 004618 04-15
HIKITAT 003416 03-13
HILAKIVI I 000405 01-04
HILDENBRAND G 0033 1 4 03- 1 1
HILLDR 003839 04-03
HILLHF 001277 02-03
HILLJM 001278 02-03
HILLM 004114 04-04
HILLRC 003013 03-04
HILLSY 000406 01-04
HILLER JM 000128 01-03 , 003840 04-03 ,
004300 04-06
HILLIER K 003841 04-03
HILMYM 000738 01-12
HIMMELHOCH JM 000594 01-09 , 00451 1 04-
13
HINDMARCH I 000579 01-09, 002330 02-14
, 002331 02-14 , 002351 02-14
HINGTGENJ 00052101-05, 001730 02-04
HINKOVAL 000473 01-04
HINOKI M 003842 04-03 , 004387 04-09
HIRAI K 003710 04-03 , 003843 04-03
HIRANO M 000212 01-03 , 002781 03-03 ,
004608 04-15
HIRATAA 000099 01-03
HIRATAF 001001 02-01 , 001002 02-01 ,
00102602-01, 00111802-03, 001188
02-03 , 00 1 279 02-03 , 00 1 502 02-03 ,
001546 02-03, 002919 03-03
HIRAYAMAK 002309 02-13
HIROSE K 003692 04-02
HIROTA R 003893 04-03
HIROZC 004615 04-15
HIRSCH JD 002836 03-03 , 002915 03-03 ,
003844 04-03
HIRSCH S 00192102-08, 002182 02-11,
003174 03-08
HIRSCHOWITZ J 000555 01-08
HIRSH KR 003752 04-03
HIRST M 001746 02-04
HITCHCOCK ER 002551 02-17
HITOMI M 000493 01-04
HITRIA 001845 02-05
HITZEMANNR 001280 02-03, 001653 02-04
HIZALA 003788 04-03
HJEDS H 003693 04-02
HJELMELAND LM 00 1 056 02-0 1
HJELMSTEDA 000659 01-11
HJERPEC 004142 04-04
HJORTHS 000399 01-04
HOAKS 004269 04-05
HO BT 00 1 779 02-04 , 00 1 789 02-04
HOC 00128102-03, 004269 04-05
HO IK 000385 01-04 , 001619 02-04 ,
002753 03-03 , 003600 03-17
HOL 004150 04-04
HOBBIGERF 003123 03-05
HOBIV 004627 04-15
HOBUSCHD 004481 04-11
HODDESES 003014 03-04
HODGE GK 004135 04-04
HODGES KK 002418 02-15
HOEBELBG 003015 03-04
HOEFKEW 001259 02-03
HOESMJAJM 00054101-07, 004456 04-11
HOFERMA 001654 02-04
HOFFER B 000080 01-03 , 000095 01-03 ,
000107 01-03 , 000178 01-03 , 000197
01-03, 000209 0 1 -03 , 00 1 382 02-03 ,
001848 02-05, 002502 02-16, 003926
04-03 , 003957 04-03
HOFFETH 004457 04-11
HOFFMAN AR 00 1 282 02-03 , 00 1 3 1 8 02-03
HOFFMAN BB 000901 01-16
HOFFMAN BF 003493 03-15
HOFFMAN SJ 001055 02-01, 001088 02-02
HOFFMAN WE 003845 04-03
HOFFMANN A 003396 03-12
HOFFMANN I 002751 03-03
HOFFMANN R 001624 02-04
HOFFMANN WF 003494 03-15
HOFFMEISTER F 000684 01-1 1 , 001655 02-04
HOFMANNA 004497 04-12
HOFMANN M 000375 01-04
HOFMANNW 003412 03-13
HOFMANN WE 001869 02-06
HOGAN EL 003665 04-01
HOGARTYGE 003561 03-16
HOGBENGL 003325 03-11
HOKFELTT 001239 02-03
HOKIN-NEAVERSON M 000129 01-03
HOKKANEN E 004542 04-13
HOKKANEN TEJ 002260 02-13
HOLADAYJW 002552 02-17, 002714 03-03
HOLCKMI 000302 01-03
HOLCOMBH 003190 03-08
HOLDEN KR 004447 04-1 1
HOLINGERPC 002053 02-09
HOLKESVICK R 004661 04-15
HOLLAND RPC 004375 04-09
HOLLINGERMA 000106 01-03
HOLLINGSWORTH PJ 004008 04-03
HOLLINSC 002907 03-03
HOLLISTER LE 000928 01-17 , 002201 02-12 ,
002488 02-16 , 003477 03-15 , 004327
04-08 , 004442 04-1 1 , 004514 04-13 ,
004604 04- 1 5 , 0046 1 6 04- 1 5 , 004703
04-17
HOLLON SD 003235 03-09
HOLLOW AY DA 002593 02-17
HOLLT V 001283 02-03 , 003837 04-03 ,
003846 04-03 , 004321 04-08
HOLM-JENSEN J 000 1 26 0 1 -03
HOLM AN EW 000470 01-04 , 000471 01-04
HOLMBERGG 004372 04-09
HOLMES CB 000921 01-17
HOLMES R 000053 01-03
HOLMGRENS 000407 01-04, 001656 02-04
HOLMSTEDT B 002095 02-1 1 , 003847 04-03
HOLMSTRANDJ 000685 01-11
HOLOHEAN AM 000499 01-04 , 004250 04-04
HOLTJM 003601 03-17
HOLTZMAN D 002437 02-15
HOLTZMAN SG 000349 01-04, 00039101-04
, 001803 02-04, 002963 03-04, 003086
03-04, 004077 04-04, 004136 04-04,
004236 04-04
HOLZMAN PS 003448 03-14
HOM D 001653 02-04
HOMAN HD 002754 03-03
HOMICKJL 004138 04-04
HOMMA S 002755 03-03
HOMMELM 002379 02-15
HONDA F 000493 01-04, 004295 04-06
HONDA Y 000769 01-13
HONGJS 001284 02-03, 003808 04-03
HONMAT 000408 01-04
HONORE T 003693 04-02 , 003848 04-03
HONZAR 001819 02-04
HOODWF 003827 04-03
HOPEV 002149 02-11
HOPF A 000078 0 1 -03 , 002240 02- 1 3
HOPKINS J 004454 04-11
HOPPENER RJ 000760 01-13, 00085101-15
HORAKJ 000595 01-09
HORI M 000012 01-02 , 000142 01-03
HORI N 003141 03-06
HORIER 001548 02-03
HORIKAWAA 001323 02-03
HORIKAWAS 002349 02-14
HORISAKAK 000009 01-02
HORITAA 000424 01-04
HORKAE 000623 01-09, 000883 01-15,
002452 02-15
HORN AS 000004 01-01 , 000324 0 1 -03 ,
001359 02-03 , 001390 02-03 , 001710
02-04
HORNCA 001793 02-04
HORN KM 000392 01-04
HORNE JA 002241 02-13
HORNUNGR 001246 02-03
HORNYKIEWICZ 0 00147102-03
HOROWITZ SG 002814 03-03
HORROBINDF 003495 03-15
HORSBURGH RJ 003138 03-06
HORSMAN L 001591 02-04 , 001592 02-04
HORTONR 003976 04-03, 004137 04-04
HORVATH FE 002723 03-03
HORVATH M 002332 02-14
HORVATH TB 002317 02-14
HORWITZJ 004169 04-04
HORWITZM 003268 03-09
HOSEIN EA 001285 02-03
HOSEK K 000556 01-08 , 002518 02-17
HOSFORD DA 003849 04-03
HOSHINOAY 002367 02-14
HOSTETLERRM 004560 04-14
HOTCHKISS A 000130 01-03 , 001027 02-01 ,
003850 04-03
HOHENTM 001592 02-04
HOUGH LB 000112 01-03
HOUGHTEN RA 001028 02-01
HOUILLONP 004458 04-11
HOUSE CR 000031 01-03
HOUSLAYMD 001286 02-03
HOWARD A 003233 03-09 , 003252 03-09
HOWARD-PEEBLES PN 0045 1 5 04- 1 3
HOWATJMT 002433 02-15
HOWELL WE 002708 03-03
HOWELLS RB 001661 02-04
HOWELLSRD 001287 02-03
HOWLANDRD 000131 01-03
HOXTERAL 003054 03-04
HOYUMPA AM 002224 02- 1 3 , 002272 02- 1 3
A-15
Author Index
Psychopharmacology Abstracts
n.
CI
5
I
HRBEK J 000077 01-03 , 000805 01-14 ,
000806 01-14, 001199 02-03, 001731
02-04 , 002333 02-14 , 002562 02-17
HRDINA PD 000596 01-09 , 002002 02-09 ,
003324 03-11
HRDINA V 000127 01-03 , 000389 01-04 ,
000420 0 1 -04 , 00 1 274 02-03 , 00 1 689
02-04
HRONEK J 000686 01-1 1 , 000852 01-15 ,
002008 02-09 , 002 1 29 02- 1 1 , 002 1 88
02-11
HRUSKA RE 000132 01-03 , 000133 01-03 ,
000319 01-03, 001288 02-03
HSIAO C 003877 04-03
HSIAO S 001727 02-04
HSIAO TH 003148 03-06
HSU L 000 1 34 0 1 -03 , 00 1 789 02-04
HUGH 001289 02-03
HU H 000135 01-03 , 004682 04-16
HUJ 000357 01-04
HU R 000882 01-15, 002456 02- 1 5
HUANG CC 004293 04-06
HUANG HT 003666 04-01
HUANG YH 001289 02-03
HUBBARD JW 000905 01-16, 003565 03-16
HUBER G 004325 04-08
HUCKF 001972 02-09
HUCKELLH 000559 01-08
HUCKERS 000697 01-11
HUDCOVA T 000686 01-11, 002 1 88 02- 1 1
HUDSON CJ 004617 04-15
HUDSON Jl 002408 02-15
HUEYLY 000824 01-14, 003178 03-08
HUFFJW 000136 01-03
HUFFMAN RD 00230102-13
HUGR 002412 02-15
HUGGEHT 003543 03-15
HUGGINSSE 001810 02-04
HUGHES IE 001843 02-05
HUGHES R 003602 03-17
HUGHES RN 000409 01-04
HUGHES RP 001661 02-04
HUGONENQ H 003230 03-09
HUGUET F 001083 02-02
HUGUETR 002472 02-15
HUl KK 004360 04-09
HUl SG 001603 02-04
HUIDOBROF 001290 02-03, 002756 03-03
HUIDOBRO-TORO JP 000137 01-03, 001290
02-03 , 002756 03-03 , 002757 03-03
HUKKELHOVEN M 004298 04-06
HULIHAN B 004689 04-16
HULL CD 001340 02-03
HULLINRP 002212 02-13
HULAAE M 001763 02-04
HULSMANJ 00085101-15
HUMBERT JR 003401 03-13
HUMPELM 004516 04-13
HUNKELERW 002646 03-02
HUNT GE 000558 01-08 , 002476 02-16 ,
003016 03-04
HUNT P 003851 04-03
HUNTWA 002242 02-13
HURDRW 002758 03-03
HURLEY A 003376 03-11
HUSSEIN L 003852 04-03
HUSSERJ 004328 04-08
HUSTON JP 001657 02-04 , 004015 04-03 ,
004197 04-04
HUTCHINSON RR 002759 03-03
HUTCHISON JB 001291 02-03
HUTHH 00011101-03
HUTH PJ 003853 04-03
HUHENLOCHER PR 000687 01-1 \
HUYGENSP 001658 02-04
HVIDBERG EF 000767 01-13 , 002229 02-13 ,
002329 02-14
HVIZDOSOVA J 00 1 804 02-04
HWANG EC 000 1 38 0 1 -03 , 003854 04-03
HYDE J 003322 03-11
HYDEP 000710 01-11
HYLDENJLK 001868 02-06
HYNEKK 000770 01-13, 004375 04-09
HYSLOPDK 003855 04-03
H YTTEL J 000 1 39 0 1 -03 , 00 1 292 02-03 ,
002760 03-03 , 002803 03-03
HYYPPAM 000694 01-11
I VALLVERDU RF 002591 02-17
lADAROLAM 000140 01-03, 001627 02-04
ICHIDA S 003856 04-03
IDENOUEJ 00276103-03
IDESHITAH 004618 04-15
lENTILER 000218 01-03, 002762 03-03,
003952 04-03
IGARASHI M 004138 04-04
IGARASHI S 000260 01-03
IGNATOVSA 003176 03-08
IIJIMAT 000520 01-05
IISALO E 002303 02-1 3 , 003330 03-1 1
IIVANAINEN M 000261 01-03
IKEDAY 001659 02-04, 004139 04-04
ILETT KF 000141 01-03 , 000524 01-05 ,
004179 04-04
ILHAN M 004275 04-05
ILIAS AM 000073 01-03
ILIENB 002489 02-16
ILINA NA 003326 03-11
IMAEDAK 00066101-11
IMBS J 002895 03-03 , 004270 04-05
IMLAH NW 001922 02-08
IMONDI AR 000017 01-03 , 001 101 02-03
I NAN AG A K 001808 02-04 , 004388 04-09
INAYATULLAM 000557 01-08
INDIKTSG 000688 01-11
INDOT 004459 04-11
INFANTES 003444 03-14
INFURNARN 001660 02-04
INGSR 000448 01-04, 000853 01-15
INGVARDH 002308 02-13
INGVAR M 003910 04-03
INNANEN VT 002824 03-03
INNISRB 003685 04-02
INOH 003871 04-03
INOKI R 001293 02-03
INOMATA N 003807 04-03
INOTSUMEN 004517 04-13
INTERLANDI G 004717 04-17
INTOCCIAAP 003045 03-04
INTURRIStC 000898 01-16, 004027 04-03
lORDANISHVILI GS 004068 04-04 , 004107
04-04
lORlOG 003444 03-14
lORIO LCL 003857 04-03
lOSELIANI TK 003885 04-03
lOVCHUK NM 003177 03-08
IRACHEE 00259102-17
IRIKI A 001294 02-03
IRMSCHER K 001475 02-03
IRVINMD 001793 02-04
IRVING SM 003017 03-04
IRWIN P 001071 02-02
IRWIN WJ 001872 02-06
ISAAC R 004505 04-13
ISAAC W 000476 01-04
ISAACSON RL 00372104-03, 004140 04-04
ISHIDAH 001272 02-03
ISHIGOOKAJ 004518 04-13
ISHII H 003947 04-03
ISHIl K 004185 04-04
ISHIJIMAB 000902 01-16, 004684 04-16
ISHIMITSU H 003345 03-11
ISHIZAKI H 003680 04-01
ISOMGE 002827 03-03
ISRAEL L 004395 04-09
ISUBURAY 000515 01-05
ITIL TM 002239 02- 1 3 , 0034 1 3 03- 1 3 ,
004373 04-09, 004460 04-11, 004519
04-13, 004567 04-14, 004619 04-15,
004620 04- 1 5 , 004680 04- 1 6
ITO S 003842 04-03
ITOT 000142 01-03, 000152 01-03
ITOH H 000854 01-15 , 004422 04-10
ITOH S 003893 04-03
ITOHT 004050 04-03
IHAHY 003962 04-03
lUDICE A 001295 02-03 , 002091 02-1 1
IVANOVA TV 000578 01-09
IVANYSE 000658 01-10
IVERSEN L 000564 01-08 , 000948 01-17 ,
001296 02-03 , 002163 02-1 1 , 002575
02-17, 004184 04-04
IVERSEN SD 000347 01-04, 00053101-06,
001661 02-04 , 001763 02-04 , 002484
02-16, 002490 02-16
IWAI H 003271 03-09
IWAMA K 003877 04-03
IWAMOTOET 001662 02-04, 003858 04-03
IWANAMI K 000515 01-05
IWASAK 001505 02-03
IWATAN 001297 02-03
IWATSUBO K 000099 01-03
IZAKSONKA 004461 04-11
IZMAYLOVA LG 004340 04-08
IZQUIERDO I 000071 01-03 , 000410 01-04 ,
00 1 663 02-04 , 00 1 664 02-04
IZRAELYN 00462104-15
IZUMIT 001800 02-04
JACKISCH R 001298 02-03 , 002751 03-03
JACKMANG 004506 04-13
JACKSON DM 000359 01-04 , 001206 02-03 ,
001299 02-03, 002193 02-12
JACKSON IV 003496 03-15
JACKSON MR 003497 03-15
JACKSON RL 001707 02-04
JACKSON SK 000251 01-03
JACKSON VP 000521 01-05
JACOB J 000093 01-03
JACOBOWITZDM 001024 02-01, 001046 02-
01, 001222 02-03, 001337 02-03,
001398 02-03, 001528 02-03
JACOBS AWCM 001809 02-04
JACOBS BL 000491 01-04 , 003018 03-04
JACOBS R 003395 03-12
JACOBS TP 002714 03-03
JACOBSENP 001079 02-02
JACOBSON I 002746 03-03
JACQUES MC 004583 04-14
JACQUETYF 000143 01-03, 00041101-04,
001665 02-04
JACQUOTC 001187 02-03
JACQUOTM 004622 04-15
JACYNOJM 001020 02-01
JADHAV JH 004147 04-04
JADOTG 00137102-03
JAFFEJH 002413 02-15
JAFFE KE 003238 03-09
JAFFERY FN 004274 04-05
JAGIELLO-WOJTOWICZ E 001684 02-04
JAHNSEN H 002763 03-03
JAINS 000807 01-14
JALLAD NS 000321 01-03
JALLUT H 004307 04-07
JAMES AL 003414 03-13
JAMES B 000798 01-13
JAMES JH 002764 03-03
JAMES N 004359 04-09
JAMES TA 000158 01-03 . 002691 03-03 ,
004141 04-04
JAMNICKY B 002243 02-13
JANCARJ 000855 01-15
JANCSOG 003859 04-03
JANICAK PG 004603 04-15
JANICKI P 003050 03-04
JANKAZ 001300 02-03, 002765 03-03
JANKEW 002537 02-17
JANKOVYCH V 002008 02-09
JANOUSEK I 001494 02-03 , 002297 02-13
JANOWSKYA 000208 01-03
JANOWSKYD 000455 01-04, 000824 01-14.
002003 02-09 , 002280 02-13 , 003178
03-08 , 003255 03-09 , 003346 03-1 1 ,
003529 03-15 , 003530 03-15 , 004374
04-09
JANOWSKY DS 003603 03-17
JANOWSKY E 003603 03-17
JANOWSKY J 004094 04-04
JANSEN W 002004 02-09 , 003327 03-1 1
JANSSEN PAJ 000363 01-04, 000495 01-04,
000771 01-13 , 002197 02-12 , 002648
03-02 , 004088 04-04
JANSSONS 003814 04-03, 003815 04-03
JANZIK HH 002130 02-11
JARACZJ 000885 01-15
JARBETUC 000412 01-04, 001666 02-04,
004142 04-04
JARDIME 003328 03-11
JARROHB 000536 01-06, 003764 04-03
JARV J 002667 03-03
JASINSKI DR 003329 03-1 1
JATLOW P 000781 01-13 , 003667 04-01 ,
004681 04-16
JATONA 001346 02-03
JAVJ 003860 04-03
A-16
VOLUME 19, AUTHOR INDEX
Author Index
JAVAID Jl 00 1 9 1 3 02-08 , 00248 ) 02- 1 6 ,
00249102-16, 004682 04-16
JAVIDMJ 000288 01-03, 004232 04-04
JAWAHARLALK 001773 02-04
JAWORSKIMT 000517 01-05
JEANNEAUA 003604 03-17
JEANPARISF 003296 03-11
JEDLICKAS 003580 03-17
JEFFERSON JW 002005 02-09, 002244 02-13
, 003498 03-15
JELINEK R 000144 01-03 , 000595 01-09
JELLINEKT 004623 04-15
JENM 002994 03-04
JENAK 004486 04-11
JENDEN DJ 000150 01-03 , 000826 01-14 ,
00 1 220 02-03 , 002235 02- 1 3 , 003 1 88
03-08 , 003189 03-08 , 003201 03-08 ,
003819 04-03, 003820 04-03, 004514
04-13 , 004520 04-13 , 004521 04-13 ,
004683 04-16
JENKINS LM 003647 03-17
JENNERP 000413 01-04, 001164 02-03,
001174 02-03, 001175 02-03, 001301
02-03 , 002358 02-14 , 002390 02-15 ,
002707 03-03 , 002789 03-03 , 004032
04-03 , 004033 04-03 , 004205 04-04
JENSEN A 002424 02-15
JENSEN JPA 000689 01-11
JENSEN RA 000195 01-03 , 00171 1 02-04 ,
002823 03-03 , 003861 04-03 , 003918
04-03 , 003936 04-03 , 004143 04-04 ,
004177 04-04
JENSEN RT 001005 02-01
JEPPSSON B 001158 02-03
JERLICZM 003846 04-03
JESSEL HJ 003231 03-09
JESSEL I 003231 03-09
JESTEDV 001958 02-08, 002245 02-13,
003499 03-15
JEZIERSKAA 003500 03-15
JHAMANDAS K 00 1 302 02-03 , 00 1 303 02-03
, 003862 04-03 , 003863 04-03
JIANG ZG 000234 01-03 , 000451 01-04 ,
003864 04-03 , 003969 04-03
JIMERSON DC 0006 1 8 0 1 -09 , 00 1 223 02-03 ,
004393 04-09 , 004565 04-14
JINDALMN 001748 02-04
JINDALSP 004291 04-06
JINDROVA 0 002793 03-03
JOM 000856 01-15
JOBE PC 000145 01-03 , 000146 01-03 ,
003865 04-03 , 004144 04-04 , 004145
04-04
JOBERTA 000480 01-04
JOCHEMSENR 000920 01-17
JOH TH 002634 03-01
JOHANNESSEN J 001043 02-01
JOHANNESSEN S 004462 04-1 1 , 004488 04-
11
JOHANSON CE 001542 02-03 , 002334 02-14
, 002335 02-14, 003445 03-14, 004071
04-04
JOHANSSON BB 000147 01-03
JOHANSSON F 002305 02-13
JOHANSSON R 001956 02-08
JOHNR 003504 03-15
JOHNTM 003893 04-03
JOHNSON AL 002432 02-15
JOHNSON AM 004086 04-04
JOHNSON C 003310 03-11
JOHNSON D 000237 01-03 , 001280 02-03
JOHNSON EE 003894 04-03
JOHNSON FN 000597 01-09
JOHNSON GFS 000558 01-08, 003016 03-04
, 004624 04-15
JOHNSON HG 004576 04-14
JOHNSON KM 000148 01-03, 001304 02-03,
002766 03-03
JOHNSON LC 003446 03-14, 004568 04-14
JOHNSON MK 003510 03-15
JOHNSON RC 000509 01-05
JOHNSON RF 002272 02-13
JOHNSON RG 003866 04-03
JOHNSON RH 002139 02-1 1 , 002402 02-15 ,
003333 03-11 , 003371 03-11
JOHNSON RL 002500 02-16
JOHNSON RP 002639 03-01
JOHNSON RW 001305 02-03
JOHNSON SM 002767 03-03 , 003778 04-03
JOHNSON TC 003733 04-03
JOHNSSONA 000772 01-13
JOHNSTON GAR 001 104 02-03 , 002633 03-
01 , 002768 03-03 , 002769 03-03 ,
003867 04-03
JOHNSTON J A 000949 01-17, 0032 1 4 03-09
JOHNSTON MV 000059 01-03 , 002770 03-03
JOHNSTON R 000569 01-08
JOHNSTONE EC 00191 1 02-08 , 001923 02-08
, 004423 04-10
JOLICOEUR FB 003049 03-04
JONAKAIT GMBMC 000149 01-03
JONASON J 004126 04-04
JONES A 001016 02-01
JONES BA 003521 03-15
JONES BE 001760 02-04
JONES BJ 001399 02-03
JONES DL 000436 01-04, 003019 03-04
JONES GP 001029 02-01
JONES JG 004146 04-04
JONES KL 004576 04-14
JONES MT 004463 04-11
JONES R 001207 02-03 , 001306 02-03 ,
001475 02-03 , 001667 02-04 , 002209
02-13, 004512 04-13
JONES SM 004201 04-04
JONES SW 003868 04-03
JONSSON G 002672 03-03
JOOF 002765 03-03
JOPE R 000150 01-03 , 000675 01-1 1 ,
004520 04-13, 00452104-13
JORGENSENA 002423 02-15, 003472 03-15
JORNESTEDT L 002086 02-10
JOSECJ 002414 02-15
JOSEPH J 001668 02-04
JOSEPH MH 002779 03-03
JOSEPHSON AM 000857 01-15
JOSHI W 004147 04-04
JOSIFKOM 001647 02-04, 002332 02-14
JOUANNIGOTR 004458 04-11
JOUVENTR 000598 01-09
JOVANOVIC UJ 001869 02-06 , 004309 04-07
JOYRM 002862 03-03
JOYCE RP 002415 02-15
JUDDL 000824 01-14, 002003 02-09,
003178 03-08
JUELC 003869 04-03
JUHASZA 001300 02-03, 002765 03-03
JUILLETP 002553 02-17
JULIEND 000817 01-14
JULOU L 001 133 02-03 , 001 137 02-03
JUNGD 000773 01-13
JUNGF 000799 01-13
JUNGL 002246 02-13, 002492 02-16
JUNGMJ 000248 01-03, 001128 02-03
JUNGKUNZG 000599 01-09
JUORIO AV 001077 02-02 , 003870 04-03
JURGENSR 000751 01-13
JURKOWLANIEC E 001604 02-04
JURNA I 000414 01-04
JUSKO WJ 002225 02-13 , 003154 03-07 ,
003479 03-15
JUSTICE JB 001873 02-06
JYOYAMA H 003692 04-02
KAAKKOLAS 000415 01-04, 001669 02-04,
001670 02-04
KAARIAINEN I 001670 02-04
KABES J 000542 01-07 , 000600 01-09 ,
001888 02-07, 001924 02-08, 002006
02-09 , 002025 02-09 , 002131 02-1 1 ,
002132 02-1 1 , 003232 03-09 , 004375
04-09
KABOUCHEM 001517 02-03, 003899 04-03
KACIANJ 003335 03-11
KACZ D 004227 04-04
KADARD 000747 01-13
KAFFEMANME 000822 01-14
KAFKA MS 001536 02-03
KAGAWA K 004022 04-03
KAGEYAMAH 00015101-03, 003893 04-03
KAHLAUF 001624 02-04
KAHN RL 000675 01-11
KAHRILASPJ 003364 03-11
KAISER C 001237 02-03
KAKEGAWAN 004720 04-17
KAKITAK 000522 01-05
KALABZ 002115 02-11
KALANT H 001387 02-03 , 001425 02-03 ,
003883 04-03
K ALICHMAN M W 0004 1 6 0 1 -04
KALIN NH 002280 02-13 , 003255 03-09
KALIRA 001030 02-01
KALIS D 002072 02-10
KALISZAK JE 0023 1 4 02- 1 4 , 004566 04- 1 4
KALIXP 001307 02-03, 003694 04-02
KALLOSM 002404 02-15
KALVACH Z 000548 01-08 , 000690 01-11 ,
00 1 908 02-08 , 00 1 925 02-08
KAMATA K 003871 04-03 , 004148 04-04
KAMATAM 003871 04-03
KAMBURG RA 004262 04-04
KAMEIC 004149 04-04
KAMENKA JM 001031 02-01
KAMENSKIYAA 002949 03-04
KAMER RS 003872 04-03
KAMEYAMAT 00277103-03, 003020 03-04
, 00387104-03, 004148 04-04
KAMIJOK 000159 01-03
KAMIYAH 004028 04-03
KAMMERERF 002416 02-15
KAMMERERT 004395 04-09
KAMOUNA 001896 02-07, 001969 02-09,
002247 02- 1 3 , 004445 04- 1 1
KAMP CW 002772 03-03 , 003873 04-03
KAMPF D 000830 01-15
KAMRAJ-MAZURKIEWICZ K 000931 01-17
KAN JP 000156 01-03 , 003874 04-03
KANAREKRB 004150 04-04
KANARKOWSKI R 000601 01-09
KANE J 000808 01-14, 000858 01-15,
002339 02-14, 002417 02-15, 003233
03-09 , 003252 03-09 , 003501 03-15 ,
003548 03-15
KANENOS 002773 03-03
KANGJC 002994 03-04
KANGAS L 000702 01-11 , 003330 03-1 1 ,
004524 04-13
KANOWSKI S 00069101-11
KANTAK KM 003021 03-04
KANTO J 000702 01-1 1 , 000774 01-13 ,
003330 03-11 , 004524 04-13
KANYICSKA B 003792 04-03
KANZLERM 002413 02-15
KAPELSKI Z 000625 01-09 , 002040 02-09 ,
004404 04-09 , 004416 04-09
KAPETANOVIC IM 004522 04-13
KAPFER MT 004407 04-09
KAPINASK 000665 01-11
KAPUVN H 000790 01-13
KAPLAN U 003872 04-03
KAPLINGP 004732 04-17
KAPPBS 001628 02-04, 002998 03-04,
003798 04-03
KAPURBM 000703 01-11
KARACAN I 004556 04-13
K ARAM AT ALI F 001508 02-03
K ARASAWA T 0000 1 2 0 1 -02 , 000 1 52 0 1 -03
KARASKOVA M 002008 02-09
KARCZAG I 003193 03-08
KARCZMAR AG 003779 04-03 , 004151 04-
04 , 004721 04-17
KARI I 001078 02-02
KARLBERGBE 000604 01-09
KARLER R 001671 02-04 , 002675 03-03 ,
004040 04-03
KARLOVVA 003605 03-17
KARLSEN RL 002774 03-03
KARNIOL IG 004263 04-04
KAROBATH M 000561 01-08 , 001308 02-03
, 001309 02-03, 002727 03-03, 002775
03-03 , 002893 03-03 , 002909 03-03 ,
004023 04-03
KAROUM F 000 1 53 0 1 -03 , 00 1 3 1 0 02-03 ,
00 1 957 02-08 , 00 1 958 02-08
KARPIAK SE 003025 03-04
K ARRAS A 000808 01-14
KARRASZW 003288 03-11
KARSONC 001672 02-04, 001928 02-08,
001945 02-08, 003022 03-04, 003023
03-04, 003169 03-08
KARTALOVSKI B 00152102-03, 001882 02-
06
KARTZINELR 003606 03-17
KASAMATSUT 003024 03-04
KASARSKIS EJ 003025 03-04
KASHANI JH 002418 02-15
KASICKI S 001620 02-04
KASKEYGB 002419 02-15
A-17
Author Index
KASPARKOVAE 002055 02-09
KASTIN AJ 00131 1 02-03 , 001327 02-03
001673 02-04, 001674 02-04, 001827
02-04, 003112 03-04
KATHOLRG 002073 02-10
KATOE 000098 01-03
KATO R 00021 1 01-03 , 001393 02-03 ,
002834 03-03 , 003946 04-03
KATONW 000602 01-09
KATORIM 004518 04-13
KATSUDA N 003141 03-06
KATSUMATAY 004024 04-03
KATZ JL 004 1 52 04-04 , 004224 04-04
KATZNL 000529 01-05
KATZRJ 001675 02-04, 001676 02-04
00 1 677 02-04 , 00 1 678 02-04 , 00 1 679
02-04 , 001680 02-04 , 001792 02-04 ,
004 1 53 04-04 , 004 1 54 04-04 , 004 1 55
04-04, 004156 04-04
KATZS 000678 01-11
KATZMAN R 001447 02-03 , 002180 02-1 1
KAUD 001538 02-03
KAUFMAN lA 004576 04-14
KAUFMAN KR 003539 03- 1 5
KAUFMANS 000073 01-03, 001519 02-03,
002087 02-10
KAUFMANN K 003875 04-03
KAULB 000859 01-15
KAULCL 000154 01-03
KAULPN 004164 04-04
KAUMEIER HS 003234 03-09
KAURC 000155 01-03, 001312 02-03
KAUROVOA 003438 03-14
KAVALIERS M 003026 03-04
KAWAHARA R 000860 01-15, 003 1 79 03-08
, 003315 03-11, 003415 03-13, 003416
03-13
KAWAI I 000628 01-09
KAWAI T 004257 04-04 , 004258 04-04
KAWAI Y 004608 04-15
KAWASAKI H 000417 01-04, 00168102-04
KAWASAKI K 003027 03-04
KAWASHIMAK 000902 01-16, 004684 04-
16
KAWAZUY 002336 02-14
KAY DC 004610 04-15
KAYDSG 003365 03-11
KAYEJ 003003 03-04
KAYAALPSO 003876 04-03
KAYAMAY 003877 04-03
KAYANOM 003416 03-13
KAYMAKCALAN S 002554 02-17
KAZAMATSURI H 000692 01-11
KAZARYAN KA 003882 04-03
KAZDINAE 004630 04-15
KEANEPE 000156 01-03
KEBABIANJW 001313 02-03
KEETON TK 002776 03-03
KEHRW 003769 04-03
KELLAMSJJ 003430 03-13
KELLAR KJ 000304 01-03 , 003878 04-03
KELLAWAYIW 000007 01-02
KELLEHER RT 003096 03-04 , 004012 04-03
004225 04-04
KELLER A 003668 04-01
KELLER HH 001314 02-03
KELLER W 004696 04-16, 004722 04-17
KELLEYKW 000456 01-04, 002777 03-03
003048 03-04
KELLY a 003733 04-03
KELLY D 000348 01-04, 004376 04-09
004464 04-11
KELLY JS 001864 02-06, 002704 03-03
KELLY P 000693 01-11, 002640 03-01
KEMALID 001315 02-03, 002198 02-12
002274 02-13
KEMALIM 001315 02-03, 002198 02-12
KEMELML 002733 03-03
KEMENYV 000010 01-02
KEMPJA 002894 03-03
KEMPJD 001578 02-04
KENAKINTP 003879 04-03
KENDALL DA 002778 03-03, 004157 04-04
KENNEDY C 001380 02-03
KENNEDY? 002555 02-17
KENNEHDJ 002322 02-14
KENNETTGA 002779 03-03
KENNISL 002648 03-02
KENTJL 001050 02-01
KENT S 003447 03-14 , 004465 04-1 1
KEOGHNJ 002606 02-17
KERBER RE 002073 02-10
KEREN G 003363 03-11
KERESZTES-NAGY P 003028 03-04
KERGUERISM 003563 03-16
KERR FWL 003432 03-13
KERRY RJ 002420 02-15
KERWIN R 000157 01-03 , 002869 03-03
003880 04-03
KESHAVAN HJH 001682 02-04
KESNER RP 002780 03-03
KESSLER JA 003881 04-03
KESSLERKA 003280 03-10, 003607 03-17
KEHENES-VAN DEN BOSCH JJ 002556 02-17
KEHLERD 002263 02-13
KETTLERR 00138102-03
KEUCHEL I 002337 02-14
KEVERNEEB 001718 02-04
KEYER-UYSALM 000169 01-03
KHACHATURYAN AM 000607 01-09
KHACHATURYAN GS 003882 04-03
KHAJAWALLA 002273 02-13
KHAN I 002556 02-17
KHAN MM 004620 04-15
KHANNA JM 003883 04-03
KHAYALI M 000698 01-11 , 002342 02-14
KHAZAN N 000505 01-04 , 004038 04-03
004170 04-04, 004259 04-04
KHEMANI L 002204 02-13
KHODOROV Bl 003884 04-03
KHOKHLOVAP 003326 03-11
KHOOK 002248 02-13
KIDGERT 002374 02-15, 00242102-15
KIECHELJR 004530 04-13
KIELCZAWAJ 00086101-15
KIELHOLZP 000603 01-09, 002007 02-09
004376 04-09
KIESMW 00120102-03, 001434 02-03
KIESSLING LA 003784 04-03
KIKTADC 001623 02-04, 004237 04-04
KIKVADZE IN 003885 04-03
KILBEYMM 001683 02-04, 00271103-03
KILGOREM 004557 04-13
KIUANA 004625 04-15
KILLAMEK 000106 01-03, 001210 02-03
KILLIANA 003746 04-03
KILLIAN GA 002481 02-16 , 004523 04-13
004603 04-15
KILPATRICK IC 000158 01-03 , 004158 04-04
KILTS CD 004195 04-04
KIM J 000212 01-03, 00278103-03
KIM K 002794 03-03
KIMSH 001359 02-03
KIMYI 001316 02-03
KIMYJ 001316 02-03
KIMBALL CP 002557 02-17
KIMBALL JG 002133 02-11
KIMBRELLD 003473 03-15
KINDELGH 00415104-04
KINDERNAYOVA H 000576 01-08, 002000
02-09 , 002054 02-09
KINEMUCHI H 000159 01-03
KING AG 001870 02-06
KINGC 003044 03-04
KINGD 001926 02-08, 002558 02-17
003409 03-13
KING GA 000160 01-03 , 002493 02-16 ,
003133 03-06
KINGRB 000775 01-13
KINGWB 003029 03-04
KINGWM 002782 03-03
KINGSLEYE 002422 02-15
KINKADE PT 004097 04-04
KINNEY CD 001926 02-08
KINNEY MJ 003180 03-08
KINNIERWJ 001317 02-03
KINSBOURNE M 002 1 34 02- 1 1
KINSCHERFDA 000090 01-03
KINSTONW 002164 02-11
KINZEW 004626 04-15
KIRALYE 003859 04-03
KIRBYMJ 002268 02-13
KIRBYML 000161 01-03
KIRCHMAYER S 001844 02-05
KIRIAKOSR 004348 04-09
KIRK L 002423 02-15
KIRKEGAARDA 002424 02-15
KIRSHIN SV 004262 04-04
KIRSHNERH 000832 01-15
KISARAK 001379 02-03, 002837 03-03
003714 04-03 , 004301 04-06
Ptychopharmacology Abstracts
KISHOREMK 002186 02-11
KISSLINGW 001917 02-08, 001918 02-08
003218 03-09, 003219 03-09, 004321'
04-08 , 004322 04-08
KITAGAWA H 00 1 236 02-03 , 00 1 797 02-04
003008 03-04
KITAGAWA K 001 394 02-03
KITAMURAT 002559 02-17
KITAZATOK 001857 02-05
KITCHEN I 002783 03-03
KITENGEA 004458 04-11
KITZENJM 000162 01-03
KITZROWW 002049 02-09
KIZER JS 003811 04-03
KIZZORTBL 001873 02-06
KJELLMAN BF 000604 01-09
KLAGGEE 003344 03-11
KLAPETEKJ 00333103-11
KLAPPROTH HE 002479 02-16
KLAUM 003481 03-15
KLAWANS HL 000498 01-04 , 000862 01-15
000950 01-17, 001845 02-05, 002159
02- 1 1 , 002407 02- 1 5 , 002468 02- 1 5
00347 1 03- 1 5 , 003502 03- 1 5 , 0035 1 6
03-15, 004249 04-04
KLEBERHD 000666 01-11, 000820 01-14
003317 03-11
KLEBER RJ 002074 02-10
KLEEWA 001032 02-01, 001033 02-01
001035 02-01 , 001056 02-01
KLEIN DF 00063201-09, 00067801-11
000951 01-17 , 003228 03-09 , 003233
03-09 , 003240 03-09 , 003252 03-09
003262 03-09 , 003409 03-13 , 004424
04-10 , 004427 04-10 , 004752 04-17
KLEIN ST 003184 03-08
KLEIN W 002425 02-15, 003503 03-15
KLEINBERG D 001948 02-08
KLEINETO 001927 02-08
KLEINMANJ 001672 02-04, 001928 02-08
001957 02-08 , 001958 02-08 003022 '
03-04 , 003023 03-04
KLEINROK Z 000163 01-03, 001515 02-03
001684 02-04 , 001685 02-04 002921 '
03-03 , 004166 04-04 , 004241 04-04
KLEMKEW 00071101-11, 000772 01-13
KLEMM WR 003886 04-03
KLEPNERCA 001484 02-03
KLERMAN GL 003256 03-09 , 003272 03-09
004401 04-09
KLESHCHINOVVN 002784 03-03
KLEVANT 000187 01-03
KLICPERAC 000633 01-09
KLIMEK V 001129 02-03
KLIMOVA H 001647 02-04
KLINE N 002560 02-17 , 003608 03-17 ,
004377 04-09
KLINGA 001594 02-04, 00465104-15
KLINGPJ 000502 01-04
KURT 004486 04-11
KLOOGY 001318 02-03
KLORMAN R 002419 02-15
KLOSEKJ 001242 02-03
KLOTZU 000164 01-03, 002249 02-13,
004524 04- 1 3 , 004525 04- 1 3
KLUGMAN KP 003887 04-03
KNAAPEH 004481 04-11
KNEPELW 000165 01-03, 001319 02-03,
003715 04-03
KNOX J 004329 04-08
KNYCH ET 003888 04-03
KOWC 002806 03-03
KOBLIN DD 000418 01-04 , 001686 02-04
KOCAND 003122 03-05
KOCH B 000193 01-03
KOCHK 001865 02-06, 002785 03-03
KOCH SW 001687 02-04
KOCH-WESERJ 001128 02-03, 002237 02-13
, 003458 03-14, 003620 03-17
KOCHER R 004627 04-15
KOCSISJD 000166 01-03
KOCURJ 004660 04-15
KOE BK 001092 02-02 , 001687 02-04 ,
002786 03-03
KOEKW 004159 04-04
KOEUA 000909 01-16
KOEPKEKM 001813 02-04
KOEPPEN D 002028 02-09
KOGERHS 000005 01-01
A-18
VOLUME 19, AUTHOR INDEX
Author lnd«x
KOHJIMOTO Y 004028 04-03
KOHLER C 001238 02-03 , 001240 02-03 ,
002727 03-03 , 003889 04-03
KOHLI JO 001252 02-03 , 003890 04-03 ,
003911 04-03
KOHNEN R 002337 02-14 , 002561 02-17
KOIDAM 001320 02-03
KOIDE T 001659 02-04 , 002787 03-03 ,
002788 03-03
KOIVULA K 002096 02-1 1
KOJAT 003093 03-04
KOJIMAM 000212 01-03
KOKETSUK 003710 04-03, 003843 04-03
KOKKINIOISL 000419 01-04, 001688 02-04,
002010 02-09
KOLAKOWSKA T 004329 04-08
KOLASSA N 001087 02-02
KOLATAGB 004378 04-09
KOLBE H 002789 03-03
KOLIBASE 000707 01-11
KOLIN IS 003332 03-1 1
KOLLERWC 002159 02-11, 002468 02-15,
003502 03-15, 003516 03-15
KOLOBOV NA 000506 01-04
KOLOMAZNIK K 002297 02-13
KOLOMAZNIKM 000605 01-09, 000852 01-
1 5 , 002008 02-09 , 002 1 29 02- 1 1
KOLYASKINA Gl 004324 04-08 , 004541 04-
13
KOMENDAS 00065101-10, 000805 01-14,
000806 01-14 , 001731 02-04 , 002333
02-14, 002562 02-17
KOMISSAROV IV 002790 03-03
KOMULAINEN H 001067 02-02 , 001078 02-
02
KONDOT 002309 02-13
KONIGL 004380 04-09, 004723 04-17
KONIKOVAM 000615 01-09, 000706 01-11,
002020 02-09
KONISHI S 000167 01-03
KOOBGF 002484 02-16
KOPERA H 000863 01-15, 002425 02- 1 5 ,
003503 03-15
KOPIN IJ 000196 01-03 , 000673 01-11 ,
001034 02-01, 001047 02-01, 001048
02-01, 001058 02-01, 001222 02-03,
00 1 223 02-03 , 00 1 224 02-03 , 00 1 279
02-03 , 001400 02-03 , 001528 02-03 ,
00 1 546 02-03 , 002 1 38 02- 1 1 , 002250
02-13 , 002546 02-17 , 002919 03-03 ,
003310 03-11, 003362 03-11, 004057
04-03
KOPPU 004511 04-13
KORCZYN AD 004001 04-03
KORCZYNSKI R 001620 02-04 , 003030 03-04
KORFJ 001095 02-03, 002923 03-03
KORINKOVAV 002020 02-09
KORIVIP 004694 04-16
KORNERP 004506 04-13
KORNETMJ 003695 04-02
KORNETSKYC 003066 03-04, 004160 04-04
KORNFELDEC 001538 02-03
KORSGAARD S 003472 03-15
KOSH JW 003700 04-02
KOSKIG 001035 02-01, 001056 02-01
KOSKINIEMIM 000694 01-11
KOSLOWSH 004679 04-16, 004685 04-16
KOSS M 001 193 02-03 , 001321 02-03
KOSSENSP 001508 02-03
KOSTERLITZHW 000168 01-03, 003802 04-
03
KOSTRZEWA RM 00 1 673 02-04 , 00 1 7 1 7 02-
04
KOTANCHIK NL 002104 02-11
KOTANIY 001293 02-03
KOTELKEVICH YN 003172 03-08
KOTELNIKOVA NV 00133102-03
KOTORIIM 002349 02-14
KOTORII T 002349 02-14 , 003450 03-14
KOUKKOUM 001962 02-09
KOUPJR 003562 03-16
KOUPERNIKC 002563 02-17
KOUPILOVAM 000389 01-04, 000420 01-04
, 001689 02-04
KOURETASN 002454 02-15
KOUTRASDA 000786 01-13
KOVACS GL 003031 03-04
KOVACSM 003235 03-09
KOVERECHA 003157 03-07, 003158 03-07
KOVES K 002817 03-03
KOWL 000421 01-04
KOWALCZYK K 000695 01-11
KOYAD 000872 01-15
KOYAMA T 003938 04-03
KOYUNCUOGLUH 000169 01-03, 003788 04-
03
KOZAKOVA H 000542 01-07
KOZICKAM 000163 01-03
KOZLOVSKAYA MM 004261 04-04
KOZLOWSKI MR 000422 01-04
KRAEMER GW 001850 02-05
KRAEMER H 003007 03-04
KRAGH-SORENSEN P 002251 02-13 , 004686
04-16
KRAKIEWICZA 000573 01-08
KRALVA 004466 04-11
KRAMARCY NR 002985 03-04
KRAMER JC 000952 01-17
KRAMER M 002160 02-1 1 , 002357 02-14
KRAUPPO 001087 02-02
KRAUS E 002791 03-03
KRAUSSJ 00113102-03
KRAUTWALDO 002033 02-09
KRAVTSOV AN 002940 03-03
KREBS BP 002023 02-09
KREBSE 002286 02-13
KREBS H 003309 03-11
KREEK MJ 000796 01-13 , 001836 02-05 ,
004467 04-1 1
KREISBERGR 004600 04-15
KREISMAN NR 002782 03-03
KREJCI I 000809 01-14, 002540 02-17
KREJCOVAH 000674 01-11
KRESS J 002135 02-11
KRIEBELGWJ 000559 01-08
KRIEGER-FINANCE F 001904 02-07
KRIKORIAN A 002252 02-13
KRIPKED 000455 01-04
KRIPPNERS 002199 02-12
KRISHNAN H 003891 04-03
KRISIAK M 001796 02-04
KRISTENSENO 000722 01-11, 000903 01-16
KRISTJANSEN P 000890 01-15 , 001968 02-09
, 002426 02-15
KRISTOFM 004724 04-17
KRIVOBOK GK 003100 03-04
KROGAJ 001069 02-02
KROGSGAARD-LARSEN P 001079 02-02 ,
00 1 1 39 02-03 , 00 1 309 02-03 , 00 1 540
02-03 , 002647 03-02 , 002678 03-03 ,
002727 03-03 , 003848 04-03 , 004725
04-17
KROH U 001927 02-08
KRONFOLZ 004359 04-09
KROPFD 000768 01-13, 000810 01-14
KRSIAK M 000485 0 1 -04 , 000658 0 1 - 1 0 ■,
00 1 690 02-04 , 00 1 805 02-04
KRUGM 002792 03-03
KRUGER ER 004406 04-09
KRUK ZL 002475 02-16
KRULIK R 000630 01-09 , 000761 01-13 ,
002793 03-03 , 003696 04-02
KRUPENINA LB 004330 04-08 , 004526 04-13
KRUPKALR 000953 01-17
KRUTZIK S 003215 03-09
KRUTZSCHH 001048 02-01, 002776 03-03
KRYLL 002008 02-09
KRYNICKIV 004567 04-14
KRYZHANOVSKIY GN 003070 03-04 , 003984
04-03 , 004161 04-04 , 004162 04-04 ,
004163 04-04
KRZYMINSKI S 004468 04-11
KRZYSKOK 002564 02-17
KUBAK 000098 01-03
KUBAS 000639 01-09
KUBACKIA 002565 02-17
KUBICKI S 002338 02-14 , 003412 03-13
KUBO S 003271 03-09
KUBOSKL 000532 01-06
KUBOTAK 00021101-03
KUCEROVA H 002000 02-09
KUCHELO 004286 04-06
KUCHERENKORP 001354 02-03
KUDRNOVAK 000654 01-10, 002056 02-09
KUEHNLEJC 003449 03-14
KUHAR MJ 000026 01-03 , 002566 02-17 ,
002644 03-01 , 002938 03-03 , 004292
04-06
KUHNC 00046101-04, 001813 02-04
KUHN DM 0031 17 03-04 , 003892 04-03
KUKSGAUSNE 003713 04-03
KUKWAL 004527 04-13
KULANS 001114 02-03, 001158 02-03
KULCSAR A 004349 04-09
KULIK FA 002470 02-15
KULKARNI MR 004379 04-09
KULKARNI SK 004164 04-04
KULMALA HK 004293 04-06
KUMAR R 000438 01-04, 00164102-04,
001871 02-06
KUMAR YV 003533 03-15
KUMASHIROH 002442 02-15
KUMAZAWAT 002794 03-03
KUMMERP 001490 02-03
KUMPELQ 00081101-14, 000917 01-17,
002136 02-11
KUNOS G 003791 04-03
KUOC 001322 02-03
KUOM 004690 04-16
KUPERSMITH M 000698 01-11 , 002342 02-
14 , 002795 03-03
KUPFERA 004495 04-11
KUPFER DJ 000406 01-04 , 000631 01-09 ,
002339 02- 1 4 , 003236 03-09
KUPFERBERG HJ 004061 04-03 , 004522 04-
13
KUPIETZSS 000812 01-14
KUPKOVAB 000809 01-14
KURAISHI Y 001691 02-04
KURAN W 004628 04-1 5 , 004629 04-1 5
KURGYIS J 002650 03-02
KURIBARAH 001692 02-04, 001693 02-04,
003032 03-04 , 004165 04-04
KURIHARAM 003544 03-15
KURIYAMA K 000522 01-05
KURLAND AA 000904 01-16, 003 1 8 1 03-08 ,
003182 03-08
KUROKAWAT 000696 01-11
K U ROMARU S 000645 0 1 -09
KUROSAWA A 000151 01-03 , 003893 04-03
KURSAWE H 004380 04-09
KURTZKE RN 003878 04-03
KURUMAI 002309 02-13
KURUVILLA A 002796 03-03 , 003033 03-04
KUSAKAM 001323 02-03
KUSAKAY 001394 02-03
KUSCHINSKYK 001649 02-04, 003417 03-13
KUSSH 000599 01-09
KUTSCHERCL 000503 01-04
KUHH 002567 02-17, 004653 04-15
KUTZ I 004001 04-03
KUYAMAC 003271 03-09
KUYAMAH 000199 01-03
KUYER A 000851 01-15
KUZMARJ 004560 04-14
KUZNETSOVON 000578 01-09
KUZNETSOVAVI 004528 04-13
KVANDE H 002095 02-11
KVETINAJ 000332 01-03
KWAN S 002914 03-03
KYRIAKIDES M 000807 01-14 , 004580 04-14
KYUNNAPU IV 003384 03-11
LA BRIE RA 000844 01-15
LAPAGLIAMA 00223102-13
LAAKMANNG 001935 02-08, 001936 02-08
, 002009 02-09 , 002137 02-1 1
LAASBERG LH 003894 04-03
LABELLAFS 002882 03-03
LABORITG 003895 04-03
LABRIE F 001218 02-03 , 001324 02-03 ,
002635 03-01
LABRIE RA 004323 04-08
LACASSEY 000831 01-15
LACELLES 001231 02-03
LACIGA Z 000686 01-11 , 002188 02-1 1
LACKOI 004529 04-13
LACKOL 004529 04-13
LACKOVICZ 003139 03-06
LADERM 000662 01-11, 000954 01-17
LADINSKYH 001325 02-03, 003758 04-03
LADISICH W 004331 04-08
LADOGANA L 003494 03-1 5
LADURON P 000186 01-03 , 001326 02-03 ,
002489 02-16 , 002648 03-02 , 003896
04-03
LAFUENTEL 001189 02-03
A-19
A.
ai
I
I
Author Index
LAGIERG 003505 03-15, 004632 04-15
LAGNADOJR 003652 03-17
LAGRANGE J 001947 02-08
LAGUNASMA 002288 02-13
UGUZZI RF 000423 01-04
LAHAVM 004320 04-08
LAHMEYER HW 000955 01-17, 002427 02- 1 5
LAHOSTEGJ 001327 02-03
LAHTI RA 000170 01-03, 003034 03-04
LAIAA 002797 03-03
LAIH 000424 01-04
LAIJCK 00017101-03
LAI M 001407 02-03
LAIANI L 001182 02-03
LAJTHAA 001772 02-04, 004039 04-03
LAKE CR 001952 02-08 , 002034 02-09 ,
002138 02-11, 003309 03-11, 003340
03-11 , 004393 04-09
LAKIN ML 002653 03-03
LAKOSKIJM 001328 02-03
LAL H 00261 1 02-17 , 003053 03-04
004219 04-04
LALS 000560 01-08, 000714 01-11,
002253 02-13, 00244102-15
LALLEMANDA 004530 04-13
LAMAISON D 004307 04-07
LAMANNAJC 002798 03-03
LAMBERT JDC 002799 03-03
' LAMBERT NM 004469 04-1 1
LAMBERT PA 003609 03-17
LAMBIE DG 002139 02-1 1 , 002402 02-15 ,
003333 03-11 , 003371 03-11
LAMMMCL 002859 03-03
LAMMINSIVU U 002076 02-10
LAMOURM 003242 03-09
LANDAUER AA 002340 02- 1 4
LANDER CM 002177 02-11
LANDER N 000669 01-11
LANDGRAFW 003669 04-01
LANEPT 001538 02-03
LANGWJ 004054 04-03
LANGE DG 002800 03-03
LANGE E 004380 04-09 , 004723 04-17
LANGE SC 000172 01-03
LANGER D 003310 03-11
LANGER G 000776 01-13 , 002568 02-17
004332 04-08
LANGER SZ 000033 01-03, 000227 01-03,
000235 01-03 , 002254 02-13 , 002569
02-16 , 002801 03-03 , 003427 03-13
003610 03-17 , 003777 04-03 , 003955
04-03 , 004358 04-09
LANGEVIN R 000697 01-11
LANGLOISY 002119 02-11
LANGWINSKI R 000429 01-04, 001694 02-04
, 001709 02-04
LANOTTE M 003952 04-03
LANSDOWN MJR 00 1 329 02-03
LANTHORNTH 004140 04-04
LAPALMEM 001285 02-03
LAPALUS P 004357 04-09
LAPIERREYD 001427 02-03, 001428 02-03
001929 02-08 , 002002 02-09 , 002010
02-09 , 003285 03-10 , 003354 03-1 1
003565 03- 1 6 , 004539 04- 1 3
LAPIN IP 000173 01-03 , 001330 02-03
UPINA lA 004075 04-04
LAPORTEP 002140 02-11
LAPPJE 000956 01-17
LAROCHELLEP 000864 01-15
LAROUSSEC 003563 03-16
LARROW RW 004027 04-03
LARSEN HF 000903 01-16
LARSEN J 001079 02-02 , 00201 1 02-09
LARSEN N 002251 02-13
LARSON AA 000 1 74 0 1 -03 , 00 1 695 02-04
LARSON DL 001 162 02-03 , 004082 04-04
LARSSON K 000335 01-04, 002957 03-04
LARSSON PA 003897 04-03
LARUE-ACHAGIOTIS C 003035 03-04
LASCELLES PT 003961 04-03
LASKAFJ 001841 02-05
LASKOVA NB 000578 01-09 , 004433 04-1 1
LASPEH 001917 02-08
LASSERREM 003563 03-16
LASSOFFS 001105 02-03
LATHAM CJ 002527 02-17
LATIES VG 003128 03-05 , 004271 04-05
LATKERC 001212 02-03
LAUA 001285 02-03
LAU C 000278 01-03 , 002802 03-03
LAUYS 001249 02-03
LAUDER JM 000030 01-03
LAUGHREN T 001970 02-09 , 003166 03-08
LAURENT J 004105 04-04
LAURIDSEN J 003848 04-03
LAUROR 002226 02-13
LAURSEN AM 002763 03-03
LAUTIN A 000561 01-08 , 001948 02-08
002448 02-15 , 002877 03-03 , 004391
04-09
LAUXG 002012 02-09
LAVAGNA J 00*BAD MAG TAPE**ERR01*2108
02-1 1 , 004357 04-09 , 004594 04-15
LAVARENNEJ 002570 02-17
LAVENED 004530 04-13
LAVERDIEREM 00334103-11
LAVERTYR 001142 02-03
LAVIEP 004569 04-14
LAVRETSKAYA EF 001331 02-03
LAWPY 001168 02-03
LAWS 001114 02-03
LAWW 004630 04-15
LA WALL JS 002428 02-15
LAWRENCE RC 004631 04-15
LAWSON AAH 002458 02-1 5
LAWTON NF 002255 02-13
LAYTON B 001443 02-03
LAZARO VA M 004 1 66 04-04 ,[ 1 8004227 04-
04[I02LAZARUS JH[ 18003504 03-
15[I02LAZARUS LW[18000675 01-
1 UI02LAZDUNSKI M 001521 02-03 ,
001882 02-06[l02LAZER ES 004012 04-
03[I02LAZZARI R 0023 1 2 02- 1 4
LEAD 003883 04-03
LEBARSD 000028 01-03, 000175 01-03
002791 03-03
LEBELLECM 003505 03-15
LEFURG 000176 01-03, 001517 02-03
002256 02-13 , 003898 04-03 , 003899
04-03
LE MAGNEN J 001721 02-04 , 003035 03-04
LEMOALM 001696 02-04
LE NORMANO Y 003563 03-16
LEPERAG 003157 03-07, 003158 03-07
LEALKW 000177 01-03
LEANDERJD 003046 03-04, 003915 04-03
LEANDER S 002658 03-03
LEBLANCAE 003883 04-03
LEBOUTILLIER JC 000525 01-05
LEBRECHTU 001332 02-03, 001697 02-04
LECCHINI S 002276 02-13
LECHATP 004632 04-15
LECHIN F 001930 02-08
LECKMANJF 00234102-14, 003418 03-13
LECRUBIERY 000598 01-09, 001232 02-03
001942 02-08 , 002278 02-13 , 003424
03-13
LEDDETI 00329103-11
LEDERERE 001080 02-02
LEE CH 003900 04-03
LEE DM 001583 02-04
LEE EH Y 001333 02-03
LEEHK 000178 01-03
LEE HS 004009 04-03
LEE I 000638 01-09
LEEJH 001316 02-03
LEEK 001036 02-01
LEEMJ 004272 04-05
LEEMK 001334 02-03
LEENM 001335 02-03, 001698 02-04,
002994 03-04
LEFT 001336 02-03, 002236 02-13
LEEB-LUNDBERG F 002848 03-03
LEELAVATHI OE 000134 01-03 , 000882 01-15
, 001789 02-04, 00390104-03, 004694
04-16
LEENENFH 000484 01-04
LEESAJ 002177 02-11
LEFEBVRE J 004531 04-13
LEFEVRE-BORG F 000044 01-03
LEFF S 002803 03-03
LEFKOWITZ RJ 00090 101-16, 00 1 009 02-0 1
LEGATOR MS 003121 03-05
LEGENDREJL 001405 02-03, 003956 04-03
LEGERJ 000865 01-15
LEGNANIG 001998 02-09
LEGROSJJ 004583 04-14
LEGUAYD 00257102-17, 003208 03-09
LEHMANN E 000562 01-08 , 004342 04-08
Psychopharmacology Abstracts
LEHMANN HE 000847 01-15 , 002572 02-17
LEHRLS 000665 01-11
LEIBOWITZ M 003240 03-09
LEIBOWITZS 00307103-04
LEIGH N 004205 04-04
LEIGHTONM 002268 02-13
LEIGHTYEG 000179 01-03
LEITH NJ 001699 02-04 , 002953 03-04
LELORDG 003291 03-11
LEMAIREA 004503 04-13
LEMBECK F 000259 01-03 , 003887 04-03
LEMBERGERL 002257 02-13, 002429 02-15
LEME-LOPESJ 00214102-11, 00328103-10
LEMKIN PF 001037 02-01
LEMPERIERE T 000543 01-07 002430 02-15
LENEHANT 004532 04-13
LENELLEJ 001920 02-08
LENGVARI I 000180 01-03
LENZG 000819 01-14
LEON A 000397 01-04, 001045 02-01
002682 03-03
LEONARD BE 004707 04-17, 004726 04-17
LEONARD EJ 001099 02-03
LEONARD JP 00018101-03
LEONARD? 004506 04-13
LEPAGE D 004470 04-11
LEPINEJP 002449 02-15
LEPPAVUORI A 000405 01-04
LERER B 004167 04-04
LERMAN SH 001337 02-03
LERNER P 000182 01-03 , 001952 02-08
LERNER Y 003196 03-08
LESHERA 002204 02-13
LESIEUR P 002449 02-15
LESLIE FM 002804 03-03 , 003902 04-03
LESLIE SW 000183 01-03
LESSEH 001338 02-03, 001339 02-03
LESSER RP 000835 01-15
LESTER D 001567 02-04 , 001625 02-04
LEUNENA 003293 03-11
LEUNG LS 000184 01-03, 003903 04-03
LEUNG TKC 00017101-03
LEUNG WJ 003659 04-01
LEVANDER S 002368 02-14
LEVENM 002289 02-13
LEVENSONAJ 000866 01-15, 002573 02-17
LEVI G 000185 01-03 , 001424 02-03
LEVIN BE 003904 04-03 , 003905 04-03
LEVINEAS 001725 02-04, 003059 03-04,
003943 04-03 , 004181 04-04
LEVINE J 000425 01-04 , 000563 01-08 ,
001931 02-08 , 002574 02-17
LEVINE MS 001340 02-03
LEVINE R 000673 01-11, 001348 02-03
LEVINE S 004273 04-05
LEVIHM 004427 04-10
LEVITT R 001793 02-04
LEVRONM 002169 02-11, 00227102-13
LEVY A 004320 04-08
LEVY DL 003448 03-14
LEVYJK 004138 04-04
LEVY Ml 002317 02-14
LEVYRA 00012101-03, 000122 01-03
LEVYRH 000728 01-11, 000755 01-13,
000777 01-13 , 002785 03-03 , 002797
03-03, 004558 04-13
LEVYRM 001341 02-03
LEW JY 001254 02-03 , 001255 02-03 ,
004120 04-04
LEWANDER T 003701 04-02
LEWINSOHN R 000983 01-17
LEWIS DV 002805 03-03
LEWIS JW 003611 03-17
LEWIS ME 000347 01-04, 00264103-01
LEWIS PD 001407 02-03
LEWIS RF 004453 04-11
LEWIS SV 001059 02-01
LEWIS VA 00163102-04, 001700 02-04
LEWY AJ 000432 01-04 , 001043 02-01 ,
002628 02-17
LEYBINL 001698 02-04
LEYSENJ 000186 01-03, 001342 02-03,
001846 02-05, 002648 03-02, 003896
04-03 , 004033 04-03
LEZANSKAM 000885 01-15
LHAMON WT 000554 0 1 -08
LHUILLIERJ 00257102-17, 003208 03-09
LICH 001028 02-01, 001038 02-01,
001081 02-02 , 003193 03-08 , 003655
A-20
VOLUME 19, AUTHOR INDEX
Author Index
04-01 , 004238 04-04 , 004360 04-09 ,
004489 04-11
LI PP 004048 04-03 , 004303 04-06
LI S 002728 03-03
LI-WAN-POA 001872 02-06
LIANG NY 001343 02-03
LIBIGER J 002055 02-09 , 002431 02-15
LIBUS J 000647 01-10, 002075 02- 1 0 ,
002494 02-16
LIBUSOVA E 000647 01-10, 002075 02-10,
002494 02-16
LICATASM 000594 01-09
LICHTENBERGD 002717 03-03
LICHTIGFELD FJ 003442 03-14
LIDDLEJ 001926 02-08
LIDEMAN RR 004381 04-09
LIES J 001993 02-09
LIEBERMANA 000698 01-11, 001254 02-03,
002342 02-14 , 002453 02-15 , 002795
03-03
LIEBERMANJ 003506 03-15
LIEBERMAN KW 000187 01-03
LIEBESKINDJC 000470 01-04
LIEBMANJM 000188 01-03
LIEBOWITZJ 001398 02-03
LIEB0WIT2 M 000632 01-09 , 003241 03-09 ,
003262 03-09 , 004424 04-10
LIEBSON I 0023 1 4 02- 1 4 , 004566 04- 1 4 ,
004582 04-14
LIEFKET 004380 04-09
LIENERTGA 000699 01-11, 002337 02-14,
002561 02-17
LIGHT Al 002798 03-03
LIGHT KC 003813 04-03
LILAVIVATHANA U 000828 01-14
LILESIC 001700 02-04
LIUEQUISTS 001839 02-05
LIML 000171 01-03
LIN C 003906 04-03
LIN CS 004489 04-1 1
LIN H 000779 01-13 , 003666 04-01
LINM 000189 01-03, 000190 01-03,
002806 03-03 , 004085 04-04
LIN MT 003907 04-03
LINDMD 003118 03-04
LINDAMOODC 003908 04-03
LINDBERGD 003183 03-08
LINDBERG I 003909 04-03
LINDBERGP 000399 01-04
LINDEOK 003612 03-17
LINDENBERG EDJ 002526 02-17
LINDENMAYER J 003507 03- 1 5
UNDER M 004627 04-15
LINDERGARDB 003542 03-15
LINDGRENJ 00220102-12
LINDGREN S 002211 02-13
LINDHOLMT 003542 03-15
LINDROS KO 004220 04-04
LINDSAY WS 001873 02-06
LINDVALLM 002807 03-03
LINDVALLO 003910 04-03
LINETOI 003332 03-11
LINGMHAA 003508 03-15
LINGNC 000226 01-03
LINGJAERDEO 004727 04-17
LINKOWSKIP 000606 01-09, 003237 03-09
LINNRT 004135 04-04
LINNOILA M 000867 01-15 , 001180 02-03 ,
002076 02-10, 002077 02-10, 002258
02-13, 003428 03-13
LINSEMAN MA 001344 02-03 , 003760 04-03
LINTON P 000710 01-11, 002142 02-11
LINZMAYER L 000720 01-11 , 000788 01-13
LIPINSKIJF 002480 02-16
LIPKIN L 001037 02-01
UPPERS 000612 01-09
UPPITSCHM 001309 02-03
UPPMAN L 000882 01-15
UPPMANNSB 000997 01-17
UPSIHDR 000957 01-17
UPSKAB 000794 01-13
UPTON JM 001247 02-03, 001248 02-03
UPTON MA 002144 02-11
UPTON ME 002143 02-11
UPTON RB 003448 03-14
LIPTON S 000426 0 1 -04 , 0036 1 3 03- 1 7
USB 000885 01-15
LISSAK K 004075 04-04
USSITZKYJ 003759 04-03
USTS 001509 02-03, 001847 02-05
USTINSKY JJ 003911 04-03
UTTLEHJ 001686 02-04
UTVINOVA NM 004633 04-15
LIU GG 003907 04-03
UU L 002175 02-11
UUKKOP 000774 01-13
UVINGSTON KE 000160 01-03
LLOYD BL 000114 01-03
LLOYD C 003238 03-09
LLOYD H 002907 03-03
LLOYD KG 001345 02-03 , 001585 02-04 ,
001826 02-04 , 002986 03-04 , 003334
03-11
LLUCHS 001355 02-03
LOS 000734 01-11
LOCATELLI V 001239 02-03 , 001391 02-03 ,
002690 03-03
LOCK K 001475 02-03
LOCKFELD A 002866 03-03
LOCNISKARA 000766 01-13
LODGE D 000063 01-03 , 002633 03-01 ,
002647 03-02 , 002768 03-03 , 002808
03-03
LODHI R 003367 03-1 1
LOEBC 000700 01-11, 002013 02-09,
004382 04-09 , 004533 04-13
LOEBERJG 001404 02-03
LOEFFLERKO 001229 02-03, 001867 02-06
LOEWDM 001346 02-03, 002809 03-03
LOFTHOUSE R 004423 04-10
LOFTUSEF 004570 04-14
LOGIN IS 002810 03-03
LOGOTHETISJ 003186 03-08
LOGUE JN 003239 03-09
LOH H 000433 01-04 , 001 168 02-03 ,
00 1 280 02-03 , 00 1 653 02-04 , 00 1 698
02-04 , 002552 02-17 , 002994 03-04 ,
004238 04-04 , 004489 04-1 1
LOH HL 000958 01-17
LOH YP 001398 02-03
LOHR N 004359 04-09
LOISEAU P 000777 01-13
LOMAXP 001108 02-03
LOMBERTIE E 000865 01-15
LONEY J 003509 03- 1 5 , 0047 1 4 04- 1 7
LONG JP 000 1 62 0 1 -03 , 002236 02- 1 3 ,
004244 04-04
LONGW 004670 04-16
LONGDEN A 001911 02-08
LONGMAN DA 001785 02-04
LONGSHORE MA 00281 1 03-03
LOO H 000551 01-08 , 000577 01-08 ,
00 1 090 02-02 , 00 1 1 95 02-03 , 00 1 969
02-09 , 002014 02-09 , 002015 02-09 ,
002016 02-09 , 003175 03-08 , 004445
04-11
LOOJCK 000778 01-13
LOOYH 00019101-03, 000388 01-04
LOOMISCW 003522 03-15, 003912 04-03
LOONENAJM 001347 02-03, 003913 04-03
LOOSEN PT 002145 02-11, 002259 02-13
LOPATAA 001039 02-01
LOPEZ JR 004049 04-03
LOPEZ-COLOME AM 002856 03-03
LOPEZ-ZANON A 002078 02-10
LORD J AH 000168 01-03
LORENSSA 004118 04-04
LORENZINI R 003194 03-08
LOREZH 002812 03-03
LOSCHER W 000096 01-03 , 000097 01-03 ,
000 1 92 0 1 -03 , 003036 03-04 , 0039 1 4
04-03, 004168 04-04
LOSSIUSR 000701 01-11
LOSSNERB 001819 02-04
LOniM 003510 03-15
LOni VJ 001701 02-04
LOTTSPEICH F 003740 04-03
LOUIS WJ 000536 01-06
LOUPPEA 002123 02-11
LOUSP 000767 01-13
LOVALLOWR 000879 01-15
LOVELLDK 000344 01-04
LOVENBERGW 001348 02-03, 001415 02-03
, 001423 02-03, 001548 02-03, 002654
03-03 , 002776 03-03 , 002867 03-03 ,
0031 17 03-04 , 003652 03-17 , 003826
04-03 , 003892 04-03
LOVERINGEG 00463104-15
LOVEHEJ 001473 02-03
LOWED 003308 03-11
LOWERYHW 003355 03-11
LOWER Y SP 001702 02-04
LOWN B 000265 01-03
LOWNDES HE 00013101-03
LOWRYMR 000868 01-15
LOWYMT 001703 02-04
LU KS 003666 04-01
LUCAN 002281 02-13
LUCAS LA 001704 02-04
LUCAS RA 001089 02-02
LUCAS TS 003068 03-04
LUCATO R 003760 04-03
LUCEK R 002248 02-13
LUCHINS DJ 000869 01-15 , 001233 02-03 ,
003184 03-08
LUCKER PW 002479 02-16
LUCOTJB 000427 01-04, 003915 04-03,
004169 04-04
LUDDEN TM 002495 02-16
LUDINHP 000813 01-14
LUDLOW JM 002420 02-15
LUDMER LM 000132 01-03
LUDWICK BT 002785 03-03
LUEFA 002152 02-11
LUHARJ 004619 04-15
LUINI A 000301 01-03
LUISADAPV 000739 01-12
LUKANINA SK 004335 04-08
LUKASSE 004170 04-04
LUKASH L 004670 04-16
LUKOVITSI 000010 01-02, 001039 02-01
LUKSA 002562 02-17
LULUENL 004458 04-11
LULLMANN-RAUCH R 003916 04-03
LUND A 002496 02-16
LUND HI 000722 01-11
LUNDM 003484 03-15
LUNDBERG D 001389 02-03 , 003917 04-03
LUNDBORG P 000087 01-03
LUNDEPKM 000701 01-11
LUNDH H 003781 04-03
LUNDIN L 001956 02-08
LUNDTPV 000650 01-10
LUOMAPV 002260 02-13
LUPATKINW 000619 01-09
LUPCZYNSKI G 003268 03-09
LUSSONJR 004307 04-07
LUSTIGA 001944 02-08
LUTHER J 002149 02-11
LUTTGE WG 002927 03-03
LUTTINGER D 003037 03-04
LUTZT 002160 02-11, 00429104-06
LUTZ-BUCHER B 000 1 93 0 1 -03
LUUDUCC 001083 02-02
LYKETSOSG 004337 04-08
LYKOURASE 002294 02-13
LYNCH G 001036 02-01 , 001 120 02-03 ,
001 147 02-03 , 003726 04-03 , 003918
04-03
LYNCH KL 001853 02-05
LYNESSWH 000364 01-04, 001595 02-04,
002813 03-03 , 003038 03-04 , 004171
04-04
LYNN AG 000351 01-04 , 003662 04-01
LYNN K 002284 02-13
LYNN RK 000073 01-03
LYON L 000670 01-11
LYON M 002988 03-04
LYUBIMOV Bl 001705 02-04
M
MAAS JW 000297 01-03 , 001289 02-03 ,
00 1 496 02-03 , 0029 1 0 03-03 , 0029 11
03-03, 003418 03-13
MAAYANI S 000 1 1 2 0 1 -03 , 00 1 368 02-03 ,
00 1 369 02-03 , 00 1 706 02-04 , 003906
04-03
MACAKOVA J 000805 01-14, 000806 01-14
, 00173102-04, 002333 02-14, 002562
02-17
MACDERMOTJ 001132 02-03, 002255 02-13
, 002897 03-03
MACDONALD JF 00 1 349 02-03
MACDONALD RL 000194 01-03 , 002885 03-
03
MACHT 001844 02-05
MACHUSLE 000428 01-04
MACHULA Al 0039 1 9 04-03
A-21
>y.^
s.
81
\
\
%
Author Index
MACKAYAVP 000564 01-08, 002432 02-15
, 002575 02-17
MACKENZIE TB 000857 01-15
MACKLIN D 002164 02-11
MACLEOD NK 000158 01-03
MACLEOD RM 002810 03-03
MACLEOD SM 000790 01-13
MACMILLAN BT 002695 03-03
MACPHAILRC 002708 03-03
MADDEN J 001707 02-04
MADDOXVH 001040 02-01
MADERDRUT JL 004206 04-04
MADRAS B 003767 04-03
MADRUGAWS 003185 03-08
MADSEN BW 000524 01-05 , 004179 04-04
MADSENJ 000870 01-15
MAEDA K 003266 03-09 , 003920 04-03
MAEJIMA S 000856 01-15
MAEKAWAK 00066101-11
MAENO H 002936 03-03
MAENPAAK 000774 01-13
MAERZJC 000959 01-17
MAFFINI M 002356 02-14
MAGELUNDG 00210102-11, 003302 03-11
MAGILSG 002934 03-03
MAGISTREni PJ 001350 02-03 , 003735 04-
03
MAGNANIG 003425 03-13
MAGNUS RV 002146 02-11
MAGNUSSEN I 000 1 38 0 1 -03 , 00226 1 02- 1 3
MAGNUSSONT 003799 04-03
MAGUIREGP 002433 02-15
MAGUIRE KP 000614 01-09 , 002184 02-1 1 ,
002497 02-16, 004477 04-11
MAGUN H 000909 01-16
MAHARPJ 000848 01-15
MAHEOM 002135 02-11
MAHERJ 003614 03-17
MAHLER HR 003948 04-03
MAHUZIERG 002498 02-16
MAHUZIERP 002529 02-17
MAICKELRP 003978 04-03
MAIERSF 001707 02-04
MAILLARDM 002576 02-17
MAIl^\AN RB 001813 02-04 , 004195 04-04
MAINARDF 000018 01-03
MAININI E 004535 04-13
MAIREF 003401 03-13
MAITAI CK 001084 02-02
MAITRE L 000316 01-03 , 003921 04-03
MAITRE M 002878 03-03 , 003675 04-01
MAJJ 000204 01-03
MAJEWSKAZ 00093101-17
MAJOCHA R 001351 02-03 , 002932 03-03
MAJOR LF 000182 01-03 , 000612 01-09
MAKANJUOLA ROA 001708 02-04
MAKING Y 004720 04-17
MAKK G 001423 02-03
MAKMANMH 001447 02-03, 001448 02-03
, 001629 02-04, 00281103-03, 002814
03-03
MAKSAY G 000010 01-02 , 00001 1 01-02
MAKSIMOVA LA 002949 03-04
MAKSIMOWSK A M 004634 04- 1 5
MALCOLM RE 002343 02-14
MALEC D 000429 01-04 , 001709 02-04
MALENCE 002262 02-13
M ALETZK Y BM 000648 01-10
MALGAA 001978 02-09
MALIK R 000195 01-03
MALIKOVALA 001352 02-03
MALINOVSKAYA NB 004572 04-14
MALLAT M 003825 04-03
MALLINGER AG 00451 1 04-13
MALLORGA P 000103 01-03 , 001502 02-03 ,
00 1 503 02-03 , 00 1 504 02-03 , 00 1 842
02-05, 002912 03-03
MALLYAA 002273 02-13
MALM U 001956 02-08
MALMBERG-AIELLO P 000 1 04 0 1 -03
MALMGRENH 00221102-13
MALONEMH 004186 04-04
MALONEYR 001597 02-04
MALTBIE AA 003511 03-15
MALTHE-SORENSSEN D 002774 03-03
MALTZMAN I 002369 02-14
MAMELAK M 004571 04-14
MAMELOK RD 003650 03-17
MANANI G 000105 01-03
MANARAL 000301 01-03
MANCHANDA R 001921 02-08
MANDEL M 000870 01-15, 00 1 93 1 02-08
MANDELP 00137102-03, 001499 02-03
001756 02-04 , 002699 03-03 , 002878
03-03 , 003675 04-01
MANDELKORNT 000713 01-11
MANDELLAJ 003922 04-03
MANGANIELLO V 001002 02-01
MANGANO RM 003923 04-03
MANGATHK 000155 01-03, 00131202-03
MANGONI A 001483 02-03
MAN IAN AA 001405 02-03
MANIER DH 001353 02-03
MANINAAA 001354 02-03
MANKOVSKIYNB 004572 04-14
MANN E 000882 01-15, 002456 02- 1 5 ,
003304 03-1 1
MANN J 001992 02-09, 002017 02-09
004383 04-09
MANN LI 004027 04-03
MANN M 003159 03-07
MANNING DE 002167 02-11
MANNING! 004670 04-16
MANNISTOPT 001362 02-03
MANOSN 003186 03-08
MANSBRIDGEB 003590 03-17
MANSFIELD JG 001586 02-04
MANSHEIMP 003512 03-15
MANSIKKAM 000702 01-11
MANSOURA 000348 01-04
MANTANUS H 004583 04-14
MANTEGAZZA P 00004101-03, 000042 01-
03, 000355 01-04, 00116102-03
MANTLE PG 002843 03-03
MANZINOL 000404 01-04
MAOZ B 004573 04-14
MARAINI G 000878 01-15
MARANGOSPJ 000225 01-03, 000276 01-03
, 00104102-01, 001475 02-03, 001536
02-03 , 002645 03-01 , 002857 03-03 ,
002972 03-04 , 004 1 72 04-04
MARCAISH 004173 04-04
MARCELLID 002344 02-14
MARCETICH JR 002005 02-09
MARCHBANKS RM 003924 04-03
MARCHEHI G 004365 04-09
MARCHISIO AM 000285 01-03
MARCHMONT RJ 00 1 286 02-03
MARCO EJ 001355 02-03
MARCO-GRANEL F 002434 02-15
MARCOVICI M 003335 03-1 1
MARDER SR 001951 02-08 , 003202 03-08
MARDHG 004534 04-13
MAREGHA MG 003 1 94 03-08
MAREK J 000570 01-08 , 000761 01-13
MARES P 000460 01-04 , 001356 02-03 ,
001419 02-03, 001439 02-03, 003039
03-04 , 004064 04-03
MARESCAUXC 002237 02-13
MARESOVA D 001356 02-03
MARFAING-JAliAT P 00172102-04
MARGOLIS FL 002836 03-03
MARGOLISR 00087101-15
MARICQAV 003040 03-04
MARIE-CARDINE M 002577 02-17
MARIN J 001355 02-03 , 001357 02-03 ,
003925 04-03
MARINIJL 000297 01-03, 001496 02-03,
004409 04-09
MARKVH 003520 03-15
MARKESBERYWR 000718 01-11
MARKEYSP 000196 01-03, 001042 02-01,
001043 02-01, 001044 02-01, 001058
02-01
MARKHAMCH 003336 03-11
MARKIANOSM 00447104-11
MARKOFF RA 003223 03-09
MARKOWITZS 003887 04-03
MARKS BH 000302 01-03
MARKS J 000960 01-17
MARKS RC 000894 01-15
MARMOE 000442 01-04
MAROLI AN 001795 02-04 , 003041 03-04
MARQUES PR 001366 02-03 , 002822 03-03
MARRIOnP 004635 04-15
MARSDENCD 000413 01-04, 001164 02-03,
001174 02-03, 001175 02-03, 001301
02-03 , 002168 02-1 1 , 002358 02-14 ,
002390 02-15, 002432 02-15, 002707
03-03 , 002789 03-03 , 003422 03-13 ,
Psychopharaiocology Abstracts
004032 04-03 , 004033 04-03 , 004205
04-04
MARSH GM 003377 03-1 1
MARSH VR 004669 04-16
MARSHALL AM 001358 02-03
MARSHALL EF 000038 01-03 , 002081 02-10
MARSHALL JF 000422 0 1 -04 , 0028 1 5 03-03
MARSHALL RJ 004266 04-05
MARTENSSON E 002207 02-13 , 003569 03-
16
MARTIN AR 00 1 359 02-03 , 00 1 7 1 0 02-04
MARTIN BR 000354 01-04
MARTIN D 002037 02-09 , 003220 03-09
MARTIN E 000909 01-16
MARTIN I 001378 02-03 , 002971 03-04
003615 03-17
MARTIN J 001202 02-03, 002018 02-09
002852 03-03 , 003042 03-04 , 003441
03-14
MARTIN P 000703 01-11, 003135 03-06
MARTIN WR 004728 04-17
MARTIN-DEL-CAMPO E 003638 03-17
MARTINELLI I 004535 04-13
MARTINET M 002816 03-03
MARTINEZ AJ 002724 03-03
MARTINEZ JL 00171102-04, 002823 03-03
003861 04-03 , 003936 04-03 , 004143
04-04, 004177 04-04
MARTINEZ-CAMPOS A 002690 03-03
MARTINEZ-ROLDAN C 003043 03-04
MARTINI L 001418 02-03
MARTINOAM 004172 04-04
MARTINSSON L 000 1 47 0 1 -03
MARTIS L 002797 03-03
MARTONJ 002817 03-03
MARTORANA PA 001082 02-02 , 001360 02-
03
MARTRESMP 002900 03-03
MARTUCCI N 002090 02- 1 1 , 0023 1 2 02- 1 4
MARUMOH 004192 04-04
MARUTAT 000787 01-13, 002037 02-09
004406 04-09
MARUYAMAY 001323 02-03
MARWAH A J 000 1 97 0 1 -03 , 00 1 848 02-05
003793 04-03 , 003926 04-03
MARZATICO F 003730 04-03
MARZILLI RA 003337 03-11
MARZULLOG 003927 04-03
MASEK K 000485 01-04
MASHKOVSKIY MD 000008 01-02, 001520
02-03 , 003681 04-02 , 003934 04-03 ,
004174 04-04
MASIREVICG 003703 04-02
MASON AS 000961 01-17
MASON GA 003037 03-04
MASON GR 001337 02-03
MASON NR 002995 03-04
MASON ST 000345 01-04 , 004070 04-04
M ASSAROni M 0034 1 9 03- 1 3
MASSERANO JM 003044 03-04
MASSOJL 003928 04-03
MASSOniM 001012 02-01, 001045 02-01,
001263 02-03 , 001849 02-05 , 002642
03-01 , 002819 03-03
MASTAGUAFL 002435 02-15
MASTENLW 000280 01-03
MASUDAY 000012 01-02, 000142 01-03,
004149 04-04
MASUR H 002567 02-17
MASURJ 001712 02-04
MATEENUDDIN M 001361 02-03
MATEJCEKM 002147 02-11
MATEO D 003311 03-11
MATHERS DA 000198 01-03. 002665 03-03,
002666 03-03
MATHEW RJ 002531 02-17 , 003213 03-09
MATHIEU MN 003749 04-03
MATHIS DF 004687 04-16
MATIN MA 004274 04-05
MATSUBARA K 003692 04-02
MATSUKURAS 003187 03-08
MATSUMOTOA 000199 01-03
MATSUMOTO K 00 1 293 02-03
MATSUMOTO T 000212 01-03 , 002781 03-03
MATSUMOTO Y 003129 03-05
MATSUNAGA F 004636 04-15
MATSUOH 004283 04-05
MATSUSHITA A 003027 03-04 , 003692 04-02
A-22
VOLUME 19, AUTHOR INDEX
Author Index
MATSUSHITA H 001659 02-04, 002787 03-03
, 002788 03-03
MAnESJ 000678 01-11
MATTHEWS KL 002436 02- 1 5
MAHHEWS WD 003045 03-04 , 003929 04-
03
MAHHIESH 001819 02-04
MAHILAJ 001362 02-03
MAniLA MJ 002258 02- 1 3 , 003428 03- 1 3
MAHSON M 00425104-04
MAnSON RH 000687 01-11
MAnSSONA 004637 04-15
MATWYSHYN GA 001575 02-04
MAUGUIERE F 004638 04-15
MAUK MO 001674 02-04
MAURERR 003013 03-04
MAUTNER HG 003930 04-03
MAVISSAKALIAN M 004425 04-10
MAWERGE 003316 03-11
MAY CN 000949 01-17, 0032 1 4 03-09
MAYJG 001717 02-04
MAY PRA 000565 0 1 -08 , 000826 01-14,
000891 01-15 , 003188 03-08 , 003189
03-08 , 003201 03-08 , 003202 03-08
MAYSJ 000594 01-09
MAYA A 002288 02-13
MAYER A 002151 02-11
MAYER J 003883 04-03
MAYER ML 002818 03-03, 00393104-03
MAYER N 000259 01-03
MAYER WJW 001044 02-01
MAYERONMA 003382 03-11
MAYOJA 003247 03-09
MAYOLRF 004691 04-16
MAYSOVNI 001363 02-03
MAZARGUIL H 00002 1 0 1 -03 , 00 1 1 1 0 02-03
, 003682 04-02
MAZIEREM 003564 03-16
MAZUREKK 004599 04-15
MAZURKIEWICZ-KWILECKI IM 003932 04-03
MA2URSKIYMB 004732 04-17
MAZZARI S 001012 02-01, 001045 02-01,
002819 03-03
MAZZIC 004535 04-13
MCAULEYR 002266 02-13
MCCAFFERTY GP 003045 03-04 , 003929 04-
03
MCCAFFERTY MR 004267 04-05
MCCALLRB 001364 02-03
MCCALLUMP 000763 01-13
MCCARRONJA 002148 02-11
MCCARTHY BW 002735 03-03 , 002839 03-
03
MCCARTHY KD 002820 03-03
MCCARTHY PS 001765 02-04, 003080 03-04
MCCARTY R 001251 02-03
MCCAUGHRAN JA 004294 04-06
MCCAULME 001713 02-04
MCCLEARYPE 003046 03-04
MCCLELLAND GR 004086 04-04
MCCLUREWO 003148 03-06, 003676 04-01
MCCONNELL SK 002821 03-03
MCCOY EE 003787 04-03
MCCRAYDS 002118 02-11
MCCREADIERG 001932 02-08
MCCREERYRL 000014 01-02
MCCULLOCH J 000200 01-03 , 001365 02-03 ,
002640 03-01
MCCURDYL 000962 01-17
MCDONALD AC 004199 04-04
MCDONALD R 000484 0 1 -04 , 000704 01-11
MCDOUGALJN 001366 02-03, 002822 03-03
MCDOWELL F 002567 02-17
MCEVILLYJP 002079 02-10
MCEVOY JP 001964 02-09 , 002080 02-10 ,
004333 04-08 , 004392 04-09 , 004702
04-17
MCFADYEN IR 003549 03-15
MCGAUGH JL 00171 1 02-04 , 002345 02-14 ,
002823 03-03 , 003861 04-03 , 003918
04-03 , 003936 04-03 , 004143 04-04 ,
004177 04-04
MCGEER EG 002824 03-03 , 004294 04-06
MCGEER PL 002824 03-03
MCGILLM 001014 02-01
MCGILVERAY I J 000778 01-13
MCGIMSEYJ 000849 01-15
MCGINITYJW 001865 02-06
MCGINTYJF 001367 02-03
MCGIVNEYA 001188 02-03
MCGIVNEYWT 003047 03-04
MCGLONEJJ 000456 01-04, 003048 03-04
MCGOUGH JP 000426 01-04
MCGOWAN E B 000290 0 1 -03
MCGOWANWT 00156102-04
MCGRATHJC 001196 02-03
MCGRATH P 000632 01-09 , 003240 03-09 ,
003241 03-09 , 003262 03-09
MCGUFFINP 001933 02-08
MCGUIRE MT 004204 04-04
MCGUIRE PS 001714 02-04 , 004175 04-04
MCILWAIN H 002578 02-17
MCINTOSH P 003114 03-04
MCINTOSH TK 000430 01-04
MCINTYRE HB 003338 03-11
MCINTYRE IM 004639 04-15
MCKEARNEYJW 000339 01-04, 000356 01-
04 , 000431 01-04 , 001715 02-04 ,
004176 04-04
MCKEITH IG 003420 03-13
MCKELVEYJ 001597 02-04
MCKENZIE GM 001716 02-04
MCKERNAN T 003381 03-11
MCKIMHR 003719 04-03
MCKIMMEYC 000220 01-03
MCKINNEYWT 001850 02-05, 003140 03-06
MCKNEWDH 003242 03-09
MCLEAN JH 001717 02-04
MCLELLANAT 003335 03-11
MCLENNAN PL 003933 04-03
MCMASTER SB 002500 02-16
MCMILLAN DE 001666 02-04 , 003915 04-03
MCMILLENBA 000201 01-03
MCNAIR DM 000649 01-10 , 003282 03-10
MCNALL CL 003798 04-03
MCNAMARA JO 002 1 49 02- 1 1
MCNEELYBU 004655 04-15
MCQUEEN EG 001142 02-03
MCSWIGAN JD 002825 03-03
MEADE RG 004150 04-04
MEARELLI S 004431 04-11
MEARESR 000763 01-13
MECHLER L 004487 04-11
MECHOULAM R 000669 01-11
MECOG 004384 04-09
MEDEK A 001731 02-04
MEDIAVILL^JL 002200 02-12
MEDILANSKI P 001874 02-06
MEDINA JH 003130 03-05
MEDVEDEVBA 003934 04-03
MEDVEDEV VI 00 1 8 1 2 02-04 , 003438 03- 1 4
MEDZIHRADSKY F 000779 01-13
MEEKJL 002719 03-03
MEERTC 001920 02-08
MEFFORD IN 003935 04-03
MEGRABYAN AA 000607 01-09
MEHENDALE HM 002845 03-03
MEHROTRA AN 003536 03- 1 5
MEHROTRASN 002175 02-11
MEIBACHRC 001368 02-03, 001369 02-03,
001706 02-04, 003002 03-04
MEIER KD 001959 02-08
MEIJERJWA 000851 01-15
MEINCK H 002263 02-13
MEINERTJC 001409 02-03
MEINHOLDJM 000872 01-15
MEISEL-KOSIK I 001917 02-08
MEITESJ 000298 01-03
MELAMEDBR 004267 04-05
MELAMED E 000202 01-03 , 003323 03-1 1
MELCHIORC 003979 04-03
MELDRUM B 002183 02-1 1 , 002826 03-03 ,
004137 04-04
MELDRUM MJ 002827 03-03
MELISW 000496 01-04
MELLADOC 001985 02-09
MELLERE 000203 01-03, 003794 04-03
MELLERRE 001718 02-04
MELLERUPET 004537 04-13, 004607 04-15
MELLITS ED 004447 04-11
MELLO NK 003449 03-14
MELLSTROM B 000754 01-13 , 002282 02-13
, 002300 02-13
MELNICHUK PV 004536 04-13
MELNIKOVALI 001354 02-03
MELTZERHL 001893 02-07, 001989 02-09,
002228 02-13 , 003221 03-09 , 004369
04-09
MELTZER HY 000750 01-13 , 001616 02-04 ,
00 1 7 1 9 02-04 , 002098 02- 1 1 , 002264
02- 1 3 , 002265 02- 1 3 , 003 1 90 03-08 ,
003318 03-11, 004538 04-13, 004540
04-13, 004676 04-16
MELVILLE A 002579 02-17
MELVILLE ID 003371 03-11
MELZACKAM 000204 01-03
MEMO M 001480 02-03 , 001481 02-03 ,
00 1 482 02-03 , 00 1 5 1 2 02-03 , 002828
03-03
MENCER DL 003521 03-15
MENCHEHIG 002091 02-11
MENDELS J 000582 01-09 , 000940 01-17 ,
001463 02-03 , 001991 02-09 , 002248
02-13 , 003263 03-09 , 003570 03-16
MENDELSON JH 003449 03-14
MENDELSON W 000432 01-04 , 002150 02-1 1
, 002346 02-14, 002354 02-14
MENDELSON WB 004729 04-17
MENDENHALL CL 004473 04-1 1
MENDISN 004640 04-15
MENDIST 001000 01-17
MENDLEWICZJ 000606 01-09, 000608 01-09
, 002347 02-14 , 003237 03-09
MENDOZAMM 002117 02-11
MENIAA 004472 04-11
MENINIC 003564 03-16
MENNINI T 000258 01-03 , 002602 02-17
MENON GN 004519 04-13
MENON MK 000433 01-04
MENSWBJ 001370 02-03
MENTASTI M 000712 01-11
MERALIZ 004539 04-13
MERANDY 002635 03-01
MERCIERJ 003089 03-04
MERKELAD 003049 03-04
MERLE L 002395 02-15
MERLIEJP 003670 04-01
MERMETA 003668 04-01
MERRIGAN KP 004074 04-04
MERRILC 001037 02-01
MERZH 000013 01-02
MESDJIAN E 000873 01-15 , 001371 02-03 ,
002319 02-14
MESHADM 004600 04-15
MESHIT 001323 02-03
MESSIHAFS 000523 01-05
MESSING RB 002823 03-03 , 003861 04-03 ,
003936 04-03 , 004143 04-04 , 004177
04-04
MESULAMM 003290 03-11
MESZAROSJ 003050 03-04
METCALF G 000351 01-04 , 003080 03-04 ,
003662 04-01
METSELAAR HJ 001606 02-04
METYSJ 001720 02-04
METYSOVAJ 00000101-01, 000306 01-03,
00 1 720 02-04 , 002279 02- 1 3
METZ J 004538 04- 1 3 , 004540 04- 1 3
MEUNIERGF 000284 01-03
MEYER DK 001003 02-01, 001372 02-03
MEYER EM 003937 04-03
MEYER ER 00005101-03
MEYER LY 000386 01-04
MEYER P 000205 01-03 , 003944 04-03
MEYERS B 000566 01-08
MEYERSON BA 002551 02-17
MEYERSON BJ 004178 04-04
MEYERSON LR 002898 03-03
MEYERSON YA 003398 03-13
MIACHPJ 000205 01-03
MICELI D 001721 02-04
MICHAEL SD 002695 03-03, 003159 03-07
MICHEAU J 003051 03-04
MICHENFELDER JD 000295 01-03
MICHOSGA 002367 02-14
MICKEY MR 001220 02-03
MICZEK KA 000434 01-04 , 001722 02-04 ,
003052 03-04
MIDDELHOFFHD 000799 01-13
MIDDLEMISS DN 000206 01-03 , 001940 02-
08
MIDHAKK 000778 01-13, 000905 01-16,
002499 02-16, 003565 03-16
MIELKE DH 002348 02-14
MIGLECZE 001799 02-04, 002650 03-02
MIGNEEC 003513 03-15
MIKES F 000705 01-11
MIKHAYLOVANM 003339 03-11, 004390
04-09
A-23
^assssuassi:
Author Index
Psychopharmacology Abstracts
Si
I
MIKKELSENE 002354 02-14
MIKKELSON E 003340 03-1 1
MIKKLESON PL 001976 02-09
MIKSIC S 003053 03-04
MIKUNI M 003938 04-03
MIKUNIN 001297 02-03
MILANOVS 000119 01-03
MILECHT 003524 03-15
MILES NJ 003687 04-02
MILESIGM 003425 03-13
MILEWSKAG 000885 01-15
MILEY WM 003054 03-04
MILFAYD 001257 02-03
MILIUSW 004516 04-13
MILLAR J 002475 02-16
MILLER AL 000870 01-15
MILLER DA 000228 01-03
MILLER JC 003407 03-13, 003939 04-03
MILLER JQ 003378 03-11
MILLER K 00019101-03
MILLER P 002149 02-11
MILLER R 002580 02-17 , 002634 03-01 ,
003145 03-06 , 003253 03-09 , 003667
04-01
MILLER V 003055 03-04
MILLER WC 003015 03-04
MILLET Y 003759 04-03
MILLMANJE 004669 04-16
MILLS IH 003342 03-11
MILLS MJ 004730 04-17
MILSONJA 002894 03-03
MILSTEINV 003430 03-13
MIMAKIT 001373 02-03, 002902 03-03
MIMSME 000145 01-03
MIMYUKOVATA 004434 04-11
MIN BH 002248 02-13 , 002486 02-16
MINAMIURA N 001060 02-01
MINCHIN RF 000524 01-05 , 004179 04-04
MINDE K 003306 03-11
MINEGISHIA 001236 02-03
MINELLIA 002925 03-03
MINICHLN 004536 04-13
MINNEP 001954 02-08
MINNEMADJ 000435 01-04
MINNEMAN KP 000207 01-03 , 002829 03-03
MINSKER El 004335 04-08
MINTYK 002164 02-11
MINTZM 002154 02-11, 003060 03-04
MINTZR 003049 03-04
MINZI AL 001985 02-09
MIRANDA H 001290 02-03, 002756 03-03
MIRIN SM 003243 03-09
MIRMAN MJ 000655 01-10
MIRMIRANM 003056 03-04, 00409104-04
MISGELDU 001374 02-03
MISHKIN M 002641 03-01
MISHRA R 000208 01-03 , 000360 01-04 ,
00 1 358 02-03 , 00 1 447 02-03 , 00 1 493
02-03
MISKARM 003132 03-05
MISRAAL 001375 02-03
MISRA CH 001789 02-04 , 003901 04-03 ,
003940 04-03 , 004694 04- 1 6
MISRA RS 000081 01-03
MISSIKT 000706 01-11
MISURECJ 000567 01-08, 000613 01-09
000623 0 1 -09 , 000634 0 1 -09 , 002 1 1 5
02-11 , 002190 02-11
MITCHELL E 002436 02-15
MITCHELL G 003887 04-03
MITCHELL JE 003514 03-15
MITCHELL R 001376 02-03 , 001377 02-03 ,
001378 02-03
MITKEVICHSP 004541 04-13
MITRANI N 000176 01-03 , 003899 04-03
MITROFANOV VS 00 1 705 02-04
MITSUDOMEA 000696 01-11
MIHELNS 003566 03-16
MITTERMEIER RA 002592 02-17
MinMAN S 002656 03-03
MIURAA 000210 01-03
MIURA S 002844 03-03 , 004422 04-10
004518 04-13
MIYAGAWAT 001379 02-03, 003714 04-03
MIYAKAWAT 000814 01-14
MIYAKODAJ 000860 01-15
MIYAKOSHI N 003941 04-03
MIYAMOTO M 003057 03-04
MIYAMOTO T 003129 03-05
MIYAOKAM 001380 02-03
MIYAZAKI M 001273 02-03
MIZOULEJ 000176 01-03, 003898 04-03
MIZRAHI EM 002437 02-15
MIZUGUCHI R 002559 02-17
MIZUTAT 003999 04-03
MIZUTANI A 003717 04-03
MLCAKOVAK 002136 02-11
MOK 000963 01-17
MOBLEYPL 001493 02-03, 004746 04-17
MOCCEHIT 003490 03-15
MODE A 000273 01-03
MODIGH K 002664 03-03
MOORZEWSKAR 004426 04-10
MOEGLEN JM 001954 02-08
MOERSCHBAECHER JM 001723 02-04
MOGENSONGJ 00033101-03, 000436 01-04
, 000457 01-04, 003019 03-04
MOGERWH 001535 02-03
MOGILNICKA E 003058 03-04
MOHASCI E 000898 01-16 , 003702 04-02
MOHLENHOFO 002263 02-13
MOHLER H 001381 02-03 , 002643 03-01
002646 03-02
MOHRLANDJS 000437 01-04, 001328 02-03
, 001724 02-04
MOHSRC 002317 02-14
MOISES HC 000209 01-03 , 001382 02-03 ,
004058 04-03
MOJA EA 001957 02-08
MOLCAN J 000609 0 1 -09 , 0006 1 5 0 1 -09 ,
000706 01-11, 000707 01-11, 001934
02-08 , 001997 02-09 , 002019 02-09 ,
002020 02-09, 00215102-11, 003567
03-16 , 004375 04-09
MOLCZADZKI M 004395 04-09
MOLDOFSKYH 002152 02-11
MOLINOFFPB 000072 01-03, 000207 01-03
002829 03-03 , 002932 03-03 , 003979
04-03 , 004229 04-04
MOLLER H 000610 01-09 , 001917 02-08 ,
0032 1 8 03-09 , 0032 1 9 03-09
MOLLER IW 002329 02-14
MOLLHOFFG 002438 02-15
MOLLORGAP 001279 02-03
MOLNARJ 002817 03-03
MON MJ 002830 03-03 , 002831 03-03
MONACO AP 003015 03-04
MONACO F 000533 01-06
MONCADA V 000450 01-04 , 002896 03-03
MONDALP 000002 01-01, 000003 01-01,
001015 02-01
MONETI G 001386 02-03
MONPREMIER P 001929 02-08
MONTASTRUC J 00401 1 04-03
MONTGOMERY A 004252 04-04
MONTGOMERY D 0022 1 5 02- 1 3 , 002266 02-
13
MONTGOMERY JA 00102102-01
MONTGOMERY S 001976 02-09, 002215 02-
13, 002266 02-13, 004385 04-09,
004707 04-17 , 004731 04-17
MONTGOMERY T 00050101-04, 00293103-
03, 004180 04-04
MONTI J A 002636 03-01
MONTPLAISIRJ 00334103-11
MOODY RA 001437 02-03
MOODY TW 001046 02-01, 001383 02-03
MOON CO 003537 03-15
MOORE CF 002637 03-01
MOORE DC 000708 01-11
MOORE DP 004641 04-15
MOORE KE 000364 01-04 , 000365 01-04 ,
001595 02-04 , 002700 03-03 , 004089
04-04 , 004171 04-04
MOORE P 003294 03-11
MOORE R 003342 03-1 1
MOORE SL 000709 01-11
MORALES ER 000102 01-03
MORAN EC 001850 02-05
MORAN TJ 003593 03-17
MORANDIG 004535 04-13
MORENO L 001421 02-03
MORETONJE 004038 04-03, 004170 04-04
MOREHI P 002091 02-11
MOREHI-OJEMANN L 000728 01-1 1
MORGAN BA 000351 01-04 , 003662 04-01
MORGAN DD 004473 04-11
MORGAN IG 004069 04-04
MORGAN JP 001851 02-05
MORGAN ME 001384 02-03
MORGAN V 004519 04-13, 004567 04-14
MORGAN WW 002772 03-03 , 003873 04-03
MORI A 004388 04-09
MORI J 000493 01-04, 00314103-06
004278 04-05 , 004295 04-06
MORIHISAJ 001945 02-08, 003169 03-08
003184 03-08
MORIOKAT 004551 04-13
MORITAH 004618 04-15
MORITA K 000098 01-03
MORITAY 001188 02-03
MORKOVKIN VM 004732 04-17
MORLEY JE 001385 02-03 , 001725 02-04 ,
003059 03-04 , 003942 04-03 , 003943
04-03 , 004181 04-04
MOROF 001200 02-03
MOROCUniC 002355 02-14
MOROJIT 000964 01-17
MORONI F 001386 02-03
MORRIS DH 003684 04-02
MORRIS HH 003468 03-15
MORRIS M 000537 01-06, 001726 02-04
MORRIS MJ 003944 04-03
MORRIS RJ 000655 01-10
MORRIS RW 000529 01-05
MORRISON DH 001707 02-04
MORRISON M 0041 14 04-04
MORSE WH 003096 03-04 , 004012 04-03
MORSELLI PL 000549 01-08 , 000596 01-09
000777 01-13, 001907 02-08, 002014
02-09 , 002254 02-13 , 002267 02-13
003175 03-08, 003324 03-11, 003334
03-11, 003343 03-11, 003616 03-17
MORTIERL 002600 02-17
MORTON AK 004279 04-05
MORTON L 002084 02-10 , 003285 03-10
MOSJ 001149 02-03, 002832 03-03
MOSCOVICI M 001944 02-08
MOSERC 000745 01-12
MOSERL 000650 01-10
MOSER P 003686 04-02 , 003921 04-03
MOSHKAVOSKIY YS 00133102-03
MOSKOWITZ MA 002503 02-16
MOSS DE 002500 02-16 , 004182 04^
MOSS WW 004688 04-16
MOTLEYS 002432 02-15
MOTOYOSHI S 004185 04-04
MOHAM 001418 02-03
MOUCHETP 000070 01-03
MOUNIER F 000262 01-03
MOUNSEYIJ 000206 01-03
MOUNTJOY CQ 002081 02-10
MOUSSAOUI D 002581 02-17
MOUZAKIS D 004337 04-08
MO YET 001707 02-04
MOZHAYEVA YG 004444 04-1 1
MRSKOSA 002115 02-11
MRSUUABB 003765 04-03
MUCCI L 003791 04-03
MUCCINO RR 002486 02-16
MUCHA RF 001387 02-03
MUCK-SELERD 002243 02-13
MUDDSH 001388 02-03
MUELLER B 001970 02-09
MUELLER K 001727 02-04
MUELLER RA 001389 02-03, 001813 02-04,
003748 04-03 , 003917 04-03 , 004195
04-04
MUENTERMD 003432 03-13
MUESER KT 004577 04-14
MUH JP 003291 03-11
MUHI-ELDEEN Z 003701 04-02
MUHLBAUERH 000780 01-13
MUIR B 002164 02-11
MUKERJI S 003836 04-03
MUKHOPADHYAY S 004674 04-16
MULAYVP 004379 04-09
MULBRYLW 001210 02-03
MULDER AH 000067 01-03, 000289 01-03,
00032301-03, 001390 02-03
MULDER TBA 004305 04-06
MULDER-HAJONIDES WREM 003216 03-09
MULLERC 000684 01-11
MULLER D 003300 03-1 1
MULLER E 000042 01-03 , 001391 02-03 ,
002690 03-03, 00319103-08, 003344
03-11
MULLER H 003671 04-01
MULLER J 003300 03-11
A-24
VOLUME 19, AUTHOR INDEX
MULLER M 000308 01-03
MULLERP 001392 02-03
MULLER WE 001440 02-03 , 002833 03-03 ,
004211 04-04
MULLER-OERLINGHAUSEN B 00061 1 01-09 ,
000749 01-13, 000753 01-13, 000768
01-13, 000830 01-15, 002290 02-13,
003515 03-15, 003568 03-16
MULOPULOSGP 003463 03-15
MULVANEY DE 000284 01-03
MUMFORDL 000438 01-04
MUNARIC 003334 03-11
MUNEKIYOK 000260 01-03
MUNOZC 000439 01-04
MUNSON E 003346 03-1 1
MURAKAMI H 001728 02-04
MURAKI T 00021 1 01-03 , 001393 02-03 ,
002834 03-03 , 003946 04-03
MURAMATSU I 0002 1 0 0 1 -03
MURATORIOA 001295 02-03
MURIE N 002153 02-11
MU RONOVA J 000643 0 1 -09
MURPHY D 000038 01-03, 000587 01-09,
000612 01-09, 000673 01-11, 002233
02-13 , 002280 02-13 , 003255 03-09 ,
004393 04-09 , 004659 04-1 5
MURPHY DT 000425 01-04
MURPHY JE 004386 04-09
MURPHY K 002164 02-11, 002835 03-03
MURPHY MB 002439 02-15
MURPHY ML 000866 01-15
MURPHY MR 004183 04-04
MURPHY RJ 000937 01-17
MURRAY HW 002567 02-17
MURRAY JB 002440 02-15
MURRAY JN 000965 01-17
MURUGAIAH K 002707 03-03
MUSAMN 003244 03-09
MUSACCHIOJM 00006101-03
MUSCEHOLA G 003250 03-09
MUSILF 000605 01-09
MUSTY RE 004263 04-04
MUTHEA 001528 02-03
MUnV 001239 02-03
MYCEKMJ 002813 03-03, 003038 03-04
MYERS JK 000998 01-17
MYERS MM 002685 03-03
MYERS RD 001454 02-03
MYGUELM 004594 04-15
MYKINGOL 004488 04-11
MYLLYLA W 002260 02- 1 3 , 004542 04- 1 3
MYQUELM 004357 04-09
MYQUEL-SIDER M 002 1 08 02- 1 1
MYSLINSKI NR 002967 03-04
MYSLIVECEK J 000803 01-14, 0008 1501-14
, 001647 02-04
MYSLOBODSKY MS 001729 02-04, 002154
02-1 1 , 003060 03-04 , 003061 03-04
NABELEKL 001934 02-08
NABER D 001536 02-03 , 001935 02-08 ,
001936 02-08 , 002222 02-13 , 003357
03-11
NABESHIMAT 002771 03-03
NACCARIF 000443 01-04, 001733 02-04,
003075 03-04
N ACHTMAN V 004642 04- 1 5
NADI NS 002836 03-03
NAGD 002186 02-11
NAGAIY 003057 03-04
NAGARAJU A 000904 01-16 , 003181 03-08 ,
003182 03-08
NAGASHIMA R 00 1 659 02-04
NAGAWA Y 003057 03-04
NAGAYAMAH 00173002-04
NAGYA 003945 04-03
NAGYBR 004643 04-15
NAGYJI 004184 04-04
NAHORSKISR 001878 02-06, 002679 03-03
NAHUNEK K 000567 01-08 , 000568 01-08 ,
0006 1 3 0 1 -09 , 000634 0 1 -09 , 000663
01-11, 000729 01-11, 00193702-08,
001949 02-08 , 001975 02-09 , 002021
02-09 , 002064 02-10 , 0021 15 02-1 1 ,
002190 02-1 1 , 003245 03-09 , 003264
03-09 , 004375 04-09
NAIDERF 001059 02-01
NAILGL 002954 03-04
NAIR NPV 000560 01-08 , 001428 02-03 ,
002441 02-15
NAKADATE T 00021 1 01-03 , 001393 02-03 ,
002834 03-03 , 003946 04-03
NAKAHAMA H 002837 03-03
NAKAHARAH 000472 01-04
NAKAHARA T 000212 01-03 , 002781 03-03
NAKAJIMAE 00455104-13
NAKAMURAH 004185 04-04
NAKAMURA I 004608 04- 1 5
NAKAMURA K 003947 04-03 , 003947 04-03
NAKAMURA S 003129 03-05
NAKAMUTAH 001320 02-03
NAK ANE Y 000636 0 1 -09 , 002442 02- 1 5
NAKANISHI K 003842 04-03 , 004387 04-09
NAKANOM 004517 04-13
NAKANO S 002336 02-14 , 004247 04-04
NAKASONES 003345 03-11
NAK ATA Y 001394 02-03
NAKAYAMA T 003672 04-01
NAKAZAWA T 003083 03-04
NAKAZAWAY 002349 02-14, 003450 03-14
NAMBA MMQ 004 1 86 04-04
NAMBAS 003345 03-11
NANDA RN 00337103-11
NANDY K 002582 02-17
NANZC 001440 02-03, 00421104-04
NAQUETR 003564 03-16
NARABAYASHI H 002309 02-13
N ARAN JO CA 000747 01-13, 000789 01-13,
000790 01-13, 004552 04-13
NARAYANS 000069 01-03
NARAYANAN HS 003533 03-15
NARCISSEG 001083 02-02
NARUMI S 003057 03-04
NASH H 004047 04-03
NASH HL 001329 02-03
NASRS 004538 04-13
NASRALLAH HA 001938 02-08
NATHAN RS 000752 01-13, 000776 01-13,
000874 0 1 - 1 5 , 002238 02- 1 3 , 004405
04-09
NATHANSON JA 002838 03-03
NATION RL 002508 02-16
NATSUKAK 004185 04-04
NATSUKI R 001280 02-03
NAUSIEDA P 000498 01-04 , 001845 02-05 ,
002159 02-11, 002468 02-15, 003502
03-15 , 003516 03-15 , 004249 04-04
NAUTSCH J 002501 02-16
NAVA D 003 1 57 03-07 , 003 1 58 03-07
NAVRATIL J 000651 01-10 , 001731 02-04 ,
002333 02-14
NAYLORGJ 003365 03-11
NAYLORRJ 000370 01-04, 001603 02-04,
002220 02-13 , 004092 04-04
NAZZAROJM 000467 01-04, 004187 04-04
NEAFSEYEJ 000172 01-03
NEAL MJ 002691 03-03
NEALE JH 004002 04-03
NEALE SE 001461 02-03
NEARJA 003948 04-03
NEBORSKYR 003346 03-11
NECKERS LM 000255 01-03 , 003499 03-15 ,
004285 04-06 , 004296 04-06
NEEL 002354 02-14
NEELYP 000742 01-12
NEETHLING AC 002839 03-03
NEF B 001657 02-04 , 004197 04-04
NEFFNH 003139 03-06, 003800 04-03,
003876 04-03 , 003949 04-03 , 003958
04-03, 004188 04-04
NEGREANUJ 00116102-03
NEIL A 003062 03-04
NEIL JF 000594 01-09 , 000631 01-09 ,
003236 03-09, 00451104-13
NEILLDB 001873 02-06
NELSON DL 0002 1 3 0 1 -03 , 0002 1 4 0 1 -03 ,
001269 02-03 , 003825 04-03
NELSON DR 004086 04-04
NELSON ED 000740 01-12
NELSON JC 000781 01-13
NELSON JL 004196 04-04
NELSON M 002939 03-03
NELSON PG 002669 03-03
NELSON R 003309 03-11
NEMCOVAJ 000332 01-03
NEMEROFF CB 003037 03-04 , 0041 1 1 04-04
NEMIROFF A 002978 03-04
NEOPHYTIDESA 000698 01-11, 002342 02-
14
Author Index
NERADJ 000816 01-14, 002155 02-11
NERIA 002443 02-15
NESTOROSJN 002840 03-03, 004733 04-17
NEUHAUS HU 002958 03-04
NEUHOFFV 000054 01-03
NEUMAN J 002156 02-11
NEUMEYERJL 001114 02-03
NEVILLE DM 001063 02-01, 001064 02-01
NEWHOUSE P 003347 03-11
NEWMANS 000697 01-11
NEWMEYER JA 00074101-12
NEZIROGLU F 002082 02-10
NGK 001607 02-04, 003182 03-08
NGUYEN T 002209 02-13
NICHOLSON AN 000440 01-04, 004189 04-04
, 004574 04-14
NICKOLSON VJ 000264 01-03 , 000441 01-04
NICOLAR 003420 03-13
NICOLSE 002825 03-03
NICOLAOU NM 000215 01-03
NICOLLEMH 000817 01-14
NICOLOVN 000473 01-04, 003716 04-03
NIEDZIELSKIJ 001694 02-04
NIEFORTH KA 004012 04-03
NIELSEN EB 000216 01-03 , 001395 02-03 ,
001875 02-06 , 002988 03-04
NIELSEN F 001950 02-08
NIELSEN IM 001169 02-03
NIELSEN J 001732 02-04, 004734 04-17,
004734 04-17
NIELSEN M 000216 01-03, 000918 01-17,
001 139 02-03 , 001395 02-03 , 002676
03-03 , 003579 03-17 , 003739 04-03
NIELSEN-KUDSK F 001852 02-05 , 002261 02-
13
NIELSON HC 000392 01-04 , 001608 02-04
NIEMEGEERS CJE 000363 01-04, 004088 04-
04
NIEOULLONA 000217 01-03
NIETOD 003348 03-11
NIEUWEBOER B 004516 04-13
NIGAMA 002175 02-11
NIGHTINGALE JH 000638 01-09
NIKANDROVA LR 004543 04- 1 3
NIKOLAISHVILI Ml 004068 04-04
NIKOLETSEAS MM 004 1 90 04-04
NIKOLOVN 000119 01-03
NILSENS 003180 03-08
NILSSON B 001134 02-03
NILSSON JLG 000399 01-04
NIMITY 003950 04-03
NIOCHE J 003691 04-02
NISHI H 003951 04-03
NISHIURAM 000219 01-03
NISHIURAN 000219 01-03
NISSENC 001311 02-03
NISSENG 003349 03-11
NISTICO G 000041 01-03 , 000218 01-03 ,
000442 0 1 -04 , 000443 0 1 -04 , 00 1 733
02-04 , 001734 02-04 , 002762 03-03 ,
003952 04-03
NISTICO GO 003075 03-04
NISTRI A 002841 03-03
NITANAIT 004551 04-13
NITZR 001082 02-02, 001360 02-03
NIWAG 000661 01-11
NOACH EL 001 150 02-03 , 002681 03-03
NOBLE EP 001499 02-03
NOBLE RG 001735 02-04
NOCERAF 003466 03-15
NOCK B 002842 03-03
NODAK 000219 01-03
NOD AY 001808 02-04
NOGUCHI H 000219 01-03
NOGUCHI Y 000099 0 1 -03 , 000444 0 1 -04
NOGUIERAAB 003185 03-08
NOHRIAV 000370 01-04, 004092 04-04
NOLL KLM 003063 03-04
NOMURA Y 000445 01-04 , 001396 02-03 ,
004191 04-04
NONAKAK 003450 03-14
NOORDHUIZEN GJM 002022 02-09
NORDGREN I 003847 04-03
NORDSTROM 0 002667 03-03
NORELLSE 003618 03-17
NORMAN TR 0006 1 4 0 1 -09 , 002 1 84 02- 1 1 ,
002383 02-15, 002497 02-16, 004477
04-11 , 004639 04-15
NORRIS PJ 002843 03-03
A-25
81
CI
5
I
Author Index
NORTH RA 001203 02-03, 002740 03-03
NOSEKI 004642 04-15
NOVAK C 003306 03-1 1
NOVAKOVA V 002865 03-03
NOVIN D 000396 01-04 , 003821 04-03
NOVOTNAJ 002507 02-16
NOVOTN Y V 0006 1 5 0 1 -09 , 000706 01-11
000707 01-11 , 002020 02-09 , 002 1 5 1
02-11
NOWAK JZ 00 1 332 02-03 , 00 1 397 02-03
001697 02-04
NOWAK MJ 001639 02-04
NOYES R 002073 02- 1 0 , 0036 1 9 03- 1 7
NULLER YL 003351 03-11
NUMMINEN A 002077 02-10
NUNN PB 002858 03-03
NURMAND LB 001736 02-04
NURNBERGER Jl 004565 04-14
NUSSERW 003456 03-14
NUTT DJ 00 1 1 84 02-03 , 002444 02-1 5
002971 03-04
NUHALLEA 003496 03-15
NUHERD 003246 03-09
NUnO D 000165 01-03, 001319 02-03
003715 04-03
NUZZIG 000878 01-15
NYBACK H 001905 02-08
NYBERGG 003569 03-16
NYHAN WL 004576 04-14
0-UCHIT 004138 04-04
OAKLEY NR 001399 02-03
OANAY 002844 03-03
DATES JA 002734 03-03
OBAL F 002955 03-04 , 002955 03-04
OBEG 000753 01-13
OBERLANDER C 003789 04-03
OBERMAN Z 004343 04-08
OBIOLSJ 002588 02-17, 002589 02-17
OBRIENCP 003335 03-11
OBRIEN JH 000343 01-04
OBRIENR 000725 01-11
OBRIST PA 003813 04-03
OCALLAGHAN JP 000220 01-03 , 00 11 73 02-
03
OCHIY 000152 01-03
OCHSHR 000114 01-03, 000968 01-17
00316103-07, 003352 03-11
OCONNELL RA 003247 03-09
OCONNOR MK 002038 02-09
ODAD 000639 01-09
ODEJIDE AO 004334 04-08
ODIOM 003978 04-03
ODIO-YGLESIAS M 003977 04-03
ODONNELLJM 000434 01-04
ODONNELL JP 003697 04-02
ODONOHUETL 001046 02-01, 001398 02-03
, 001528 02-03
ODORIZZI F 004717 04-17
ODRISCOLL D 002445 02-15
OECHSNERR 001917 02-08
OEFFINGER KC 002766 03-03
OEITPS 000446 01-04
OERTELWH 001047 02-01, 001048 02-01
001400 02-03
OFALLONJV 003953 04-03
OGAWA N 002336 02-14 , 004247 04-04
OGREN S 001096 02-03, 001238 02-03
001240 02-03 , 002727 03-03 , 003824
04-03
OGREN SO 000253 01-03
OGURAC 000639 01-09
OH VMS 002268 02-13
OHAREJA 002445 02-15
OHASHI K 004128 04-04
OHIZUMIY 001280 02-03
OHKAWAT 003450 03-14
OHLSSON A 001737 02-04 , 002201 02-12
OHM AN R 001230 02-03, 002590 02-17
004700 04-17
OHMIYA Y 002845 03-03
OHMORI K 004192 04-04
OHMOTOT 003129 03-05
OHSAWAK 003714 04-03
OHSHIMAM 002349 02-14
OISHI R 001681 02-04
OITZLM 004015 04-03
OKAM 001293 02-03, 004149 04-04
004193 04-04
OKAT 000221 01-03
OKABAYASHI T 002725 03-03
OKADA K 003856 04-03
OKADAT 003947 04-03
OKADA Y 001401 02-03
OKAMOTO K 001402 02-03 , 002846 03-03
OKASHAA 003192 03-08
OKRUHLICA L 001934 02-08 , 002151 02-1 1
OKTABA-POLKOWSKA A 001684 02-04
OKTAYS 004275 04-05
OKUDAIRAN 002350 02-14
OKUIM 000219 01-03
OKUMAT 002442 02-15, 004388 04-09
OKUSES 000653 01-10
OKUYAMA S 004148 04-04
OLAJOSS Y M 004426 04- 1 0 , 004644 04- 1 5
OLANOWCW 003353 03-11, 00342103-13
OLDHAM AJ 000818 01-14
OLDS ME 001738 02-04, 004194 04-04
OLEARY DP 002997 03-04
OLEYNIK LI 003643 03-17
OLIANAS MC 003949 04-03 , 003958 04-03
OLIVER C 003759 04-03
OLIVER M 001036 02-01 , 003918 04-03
OLIVERIOA 000336 01-04, 001766 02-04
OLIVIER M 003305 03-11
OLLER FV 002288 02-13
OLLER-DAURELLA L 002288 02-13
OLNEYJW 000222 01-03
OLPE H 002847 03-03 , 003880 04-03
OLSAUSKAS RS 001739 02-04
OLSEN RW 002848 03-03
OLSHANA 004695 04-16
OLSON GA 001327 02-03
OLSON L 000095 01-03
OLSON RD 001327 02-03
OLTON DS 001398 02-03
OMER LMO 004532 04-13
OMOROKOV BM 003172 03-08
ONALI P 001403 02-03
ONBE H 000199 01-03
ONDRUSEKMG 004195 04-04
ONEILL JJ 004267 04-05
ONEILL KJ 004267 04-05
ONEILL MJ 004438 04-11
ONOH 003807 04-03
ONO T 000493 01-04 , 002442 02-15
ONODA K 002753 03-03
ONUR R 004275 04-05
OOSTERVELD WJ 004478 04-1 1
OPGENOORTH E 000819 01-14, 00325103-09
OPMEER FA 001404 02-03
ORBACHEVSKAYA lY 002892 03-03
ORLOVIV 002940 03-03
ORLOWSKI RC 001320 02-03
ORMEML 001832 02-05
ORMSBEE HS 001337 02-03
ORNE EC 004585 04-14
ORNE MT 004585 04-14
ORNSTEIN K 004015 04-03
ORRML 004645 04-15
ORSULAK PJ 000787 01-13 , 004406 04-09
ORTEGA J 001558 02-04
ORTEGA-BEVIA F 002849 03-03 , 002850 03-
03 , 002851 03-03
ORTEGA-MONASTERIO L 001963 02-09
ORTH JP 002023 02-09
ORTIZ A 003673 04-01
ORTIZ MA 000102 01-03
ORTMANN J 002033 02-09
ORTMANN R 001740 02-04
OSAWAK 00066101-11
OSBORNE H 003837 04-03
OSBORNE NN 000054 01-03 , 003954 04-03
OSBORNE VL 003045 03-04
OSHINON 003718 04-03
OSSOLA L 002699 03-03
OSTERWALDER R 001 264 02-03
OSTOWM 000969 01-17, 000970 01-17
00097101-17, 000972 01-17
OSTROUMOVA LI 004389 04-09
OSTROVSKAYA RU 000485 01-04 001705
02-04
OSTROW DG 001987 02-09 , 002024 02-09
002269 02-13, 003142 03-06
OSTROW LC 000874 01-15
OSTROWSKI NL 004196 04-04
OSUIDEG 00174102-04
OSWALD I 002446 02-15
OTSUKAM 000167 01-03, 000493 01-04
Psychopharmacology Abstracts
OTSUKI S 004388 04-09
OHH 004309 04-07
on J 000742 01-12
OTTT 002792 03-03
OTTER MY 001736 02-04
OTVOS L 000010 01-02, 00001101-02
OULESMJ 000616 01-09, 000782 01-13
OVERALL JE 004324 04-08
OVERO KF 000591 01-09
OVERSTREET DH 000226 01-03 , 002163 02-
1 1 , 002852 03-03 , 003042 03-04
OVERTON DA 000447 01-04
OWEN F 000062 01-03 , 00191 1 02-08
004423 04-10
OWENG 002420 02-15
OWENJE 002995 03-04
OWENS DGC 004423 04-10
OWENS DP 002853 03-03
OWENS K 003993 04-03
OWMAN C 002807 03-03
OXMANTE 000876 01-15
OYA M 004024 04-03
OYEWUMI LK 003354 03-11
OZAKIY 002503 02-16
OZAWA S 001401 02-03
PABSTJ 000968 01-17
PABSTM 000259 01-03
PACHECOH 001227 02-03, 002816 03-03
003691 04-02
PACHECOP 001612 02-04
PACK MAN PM 00 1 1 22 02-03 , 0037 1 2 04-03
PADELU 000483 01-04
PADIAN N 003272 03-09 , 004418 04-09
PADJEN AL 002870 03-03
PAITICHD 000697 01-11
PAKARINEN A 002258 02-13
PAKKENBERGH 002127 02-11
PAKOVITSM 003792 04-03
PAKSZYSW 004494 04-11
PALACIOSJM 001054 02-01, 002644 03-01
PALCOUX MC 004307 04-07
PALERMO NN 003143 03-06
PALERMO-NETO J 004101 04-04
PALETJL 000517 01-05
PALFAIT 001742 02-04
PALFREYMANMG 000248 01-03, 000458 01-
04 , 00 1 1 28 02-03 , 003620 03- 1 7
PALKOVITSM 003955 04-03
PALMER FB 000732 01-11
PALMER GC 001259 02-03, 001405 02-03
003956 04-03
PALMER MR 001406 02-03, 002502 02-16
003926 04-03 , 003957 04-03
PALMER S 001259 02-03 . 003956 04-03
004009 04-03
PALMER Y M 00 1 1 07 02-03 , 0025 1 5 02- 1 7
PALMOUR RM 001049 02-01, 001612 02-04
, 001743 02-04
PALOSIE 000010 01-02
PANAHON NC 003479 03-15
PANDELONR 003152 03-07
PANDEYG 000135 01-03, 000908 01-16
000973 01-17 , 002269 02-13 , 004682
04-16
PANISSIDIG 001200 02-03
PANKSEPPJ 001644 02-04, 001744 02-04
00 1 745 02-04 , 0030 1 1 03-04
PANNIER L 002854 03-03
PANSAM 004635 04-15
PANTELEYEVA GP 004335 04-08 , 004381 04-
09 , 004390 04-09
PAOLINOE 002283 02-13
PAPADAKIS N 003520 03-15
PAPADOPOULOS G 001657 02-04 , 004197
04-04
PAPADOPOULOU-DAIFOTIS Z 003698 04-02
RAPED 002205 02-13
PAPEZOVA H 001888 02-07 , 001924 02-08
002025 02-09
PAPPAS BA 000309 0 1 -03 , 0003 1 0 0 1 -03
000448 01-04, 003312 03-11
PARADKARVM 001710 02-04
PARDALJF 000223 01-03
PARDOA 003673 04-01
PARECMB 004640 04-15
PAREEK NK 000583 01-09
A-26
VOLUME 19, AUTHOR INDEX
Author Index
PARENTI M 001422 02-03 , 003139 03-06 ,
003800 04-03 , 003949 04-03 , 003958
04-03, 004188 04-04
PARIKHMD 002158 02-1)
PARISERSF 00352103-15
PARK BK 003621 03-17
PARK RN 001746 02-04
PARKER D 002003 02-09, 003178 03-08
PARKER LA 001747 02-04
PARKER RE 000740 01-12
PARKER RR 003249 03-09 , 004402 04-09
PARKESJ 002168 02-11, 002358 02-14,
003422 03-13, 004113 04-04
PARMAR SS 00008 1 0 1 -03 , 003 1 1 9 03-04
PARROn AC 002331 02-14 , 002351 02-14
PARROHEL 004554 04-13
PARROn RF 003064 03-04
PARSON R 003699 04-02
PARSONS DS 001793 02-04
PARSONS SL 002702 03-03
PARTLOW LM 002780 03-03
PARY R 001945 02-08
PASANTES-MORALES H 002855 03-03 ,
002856 03-03
PASCOEJP 003798 04-03
PASIA 003490 03-15
PASSOTH P 000611 01-09
PASTERNAK GW 001554 02-03, 003685 04-
02, 004198 04-04
PASTOR G 000188 01-03
PASTORISO 001126 02-03
PASTUSZKOA 000224 01-03
PATACCHIOLI F 00 1 1 07 02-03 , 0025 1 5 02- 1 7
PAT AY M 001902 02-07 , 002270 02-13 ,
002271 02-13
PATEJK 000839 01-15
PATEL AJ 001407 02-03 , 002673 03-03
PATELIH 000755 01-13
PATEL NB 001748 02-04
PATEL VK 001748 02-04
PATERSONSJ 000168 01-03, 003802 04-03
PATOCKAJ 000389 01-04
PATONDM 000974 01-17
PATONWDM 001686 02-04
PATRICK RL 002649 03-02 , 003829 04-03 ,
003959 04-03 , 003960 04-03
PATSALOS PN 003961 04-03
PAHERSONT 004544 04-13
PATURAUDJP 003155 03-07
PATWARDHAN RV 002224 02-13, 002272
02-13
PATYJ 00345103-14
PAUGH BA 000450 01-04
PAULA 000449 01-04
PAUL S 000225 01-03 , 000275 01-03 ,
000276 01-03 , 000277 01-03 , 000450
01-04 , 001475 02-03 , 002645 03-01 ,
002857 03-03 , 002896 03-03 , 002972
03-04 , 003962 04-03 , 004172 04-04 ,
004221 04-04 , 004251 04-04 , 004689
04-16
PAULING P 000002 01-01, 000003 01-01,
001015 02-01
PAULSON GW 000950 01-17 , 003355 03-1 1
PAULUCCITS 003111 03-04
PAUR R 00069101-11
PAVLOVICOVA E 00 1 804 02-04
PAWLICKI R 001844 02-05
PAXTONJW 004545 04-13
PAYKEL ES 003248 03-09 , 003249 03-09 ,
004336 04-08 , 004402 04-09
PAZOJH 003130 03-05
PEACHEYJE 003522 03-15
PEARCEC 001743 02-04
PEARCED 004690 04-16
PEARLMANT 002352 02-14
PEARSON S 002858 03-03
PECHADREJC 004479 04-11
PECKNOLDJ 003285 03-10
PEDERSENHE 000659 01-11
PEDERSENPE 002478 02-16
PEDIGONW 000226 01-03
PEELER 000739 01-12
PEETLA 000092 01-03
PEETM 001940 02-08
PEGRAMV 000710 01-11
PEKKARINENA 000086 01-03
PELAYOF 000227 01-03
PELICIERY 000877 01-15
PELLERIN-MILLECAMPS E 000589 01-09
PENDLETON RG 000228 01-03 , 001069 02-02
, 001255 02-03
PENGC 004489 04-11
PENGGW 001710 02-04
PENIN H 003314 03-11
PENKEB 003031 03-04
PENNY RHC 002843 03-03
PENRYJK 003375 03-11, 004522 04-13
PEPEU G 001386 02-03, 003065 03-04
PEPPER CM 001408 02-03
PERAINOC 001409 02-03
PERCIVALJE 00224102-13
PERCY VA 002859 03-03
PEREIRAAE 000669 01-11
PEREL JM 0006 1 9 0 1 -09 , 000620 01 -09 ,
000776 01-13
PERENYIA 002447 02-15
PERERA-ORTIZ Y 002661 03-03
PEREZ VJ 000517 01-05
PEREZ-CRUET J 002273 02-13
PEREZ-DE-LA-MORA M 002727 03-03
PEREZ-GUAITA MD 00 1 749 02-04
PERHACH JL 003103 03-04
PERKINS MN 000229 01-03 , 001410 02-03 ,
003963 04-03
PERLIKS 000862 01-15, 002159 02-11,
002468 02-15, 003502 03-15
PERLMAN T 004454 04-1 1
PERLMUTTERR 000717 01-11
PERLOWMJ 000255 01-03
PERON P 004445 04-11
PEROSSINI M 004507 04-13
PEROUTKA SJ 000230 01-03 , 002860 03-03 ,
002861 03-03 , 003964 04-03
PERRIERO 000773 01-13
PERRINJH 000762 01-13
PERRIN MH 003985 04-03
PERRINGTON A 001 299 02-03
PERRISC 002274 02-13
PERRISSIN M 001083 02-02
PERRON J 002600 02-17
PERRY KW 003796 04-03
PERRY ML 001664 02-04
PERRY PJ 003508 03-15
PERRY R 003361 03-11
PERRY W 003066 03-04
PERSADE 001990 02-09
PERSSON B 000231 01-03 , 003965 04-03
PERSSON R 004412 04-09
PERT A 001050 02-01, 00141102-03,
001443 02-03 , 002275 02-13 , 002641
03-01 , 003067 03-04
PERTCB 001025 02-01, 001050 02-01,
001383 02-03 , 001444 02-03 , 002641
03-01 , 003737 04-03
PERUCCA E 000783 01-13, 002276 02- 1 3 ,
003622 03-17
PESANDOP 000878 01-15
PESELOW ED 002017 02-09 , 002448 02-15 ,
004391 04-09 , 004606 04-15
PESTRONKA 000232 01-03
PETERKAM 000144 01-03
PETERS DAV 003312 03-11
PETERS JE 001750 02-04
PETERS JR 001412 02-03
PETERS MA 000094 01-03
PETERS RH 001818 02-04, 00382104-03
PETERSEN EN 003966 04-03
PETERSEN KP 001413 02-03
PETERSEN LR 001634 02-04
PETERSEN RC 000743 01-12
PETERSON CM 001836 02-05
PETERSON DW 001084 02-02
PETERSON GR 004560 04-14
PETERSON PC 004688 04-16
PETERSON SL 001559 02-04 , 002653 03-03 ,
002862 03-03 , 002946 03-04
PETERSON TL 000937 01-17
PETHOB 003193 03-08
PETITE 004742 04-17
PETIT M 000362 0 1 -04 , 002449 02-15
PETIT TL 000525 01-05
PETOVAJ 000544 01-07
PETRR 001635 02-04
PETRANOVAT 002008 02-09
PETRESCOUL 000817 01-14
PETRI EJC 003400 03-13
PETRIE WM 002026 02-09 , 004392 04-09 ,
004646 04-15
PEHI T 002339 02-14 , 003356 03-1 1 ,
004630 04-15
PEHIGREW JO 003024 03-04
PEHOROSSI VE 00 1 566 02-04
PETTY F 001751 02-04 , 001775 02-04 ,
003743 04-03
PEURA P 001078 02-02
PEVNICK J 000798 01-13
PEYERM 003967 04-03
PEYTON GA 000906 01-16
PFAFFDW 000421 01-04
PFEFFERBAUM A 0032 1 5 03-09
PFEIFER HJ 000784 01-13
PFLUEGER AB 003828 04-03
PFLUGB 00071101-11, 000772 01-13
PHILIPP M 0006 1 7 0 1 -09 , 004480 04- 1 1
PHILIPPU A 000520 01-05 , 002703 03-03 ,
003968 04-03
PHILLIPS AG 000345 01-04 , 001572 02-04 ,
002956 03-04, 004070 04-04, 004199
04-04
PHILLIPS J 003433 03-13
PHILLIPS Ml 003845 04-03
PHILLIPSONOT 001941 02-08
PHILLIS JW 000233 01-03 , 000234 01-03 ,
000329 01-03 , 000330 01-03 , 000451
01-04 , 001414 02-03 , 002933 03-03 ,
003864 04-03 , 003969 04-03 , 004056
04-03
PHYALLW 001415 02-03
PIAFSKYKM 000975 01-17
PICCARDIMP 001483 02-03
PICCIOLA G 001051 02-01
PICCIONE P 002160 02-1 1 , 002357 02-14
PICCIRILLOM 000452 01-04, 001752 02-04
PICHATL 003825 04-03
PICKAR D 003220 03-09 , 003357 03-1 1 ,
004393 04-09
PICKARDJD 001416 02-03
PICKELVM 002634 03-01
PICKENS JT 002196 02-12
PICKHOLZD 000083 01-03
PICKMANC 000470 01-04
PICKWORTH WB 002889 03-03
PICOni GB 002863 03-03
PIEGLERT 000799 01-13
PIERCE D 004394 04-09
PIERCEY MF 002980 03-04 , 003782 04-03 ,
004200 04-04
PIERELLI F 002355 02-14 , 003157 03-07 ,
003158 03-07
PIERI L 001381 02-03 , 002646 03-02
PIERSON RN 002928 03-03
PIETRUSZEWSKA I 004625 04-15
PIEHE LH 001065 02-01, 001066 02-01
PIHLRO 002202 02-12
PILATE C 000543 01-07
PILCA 001256 02-03, 001417 02-03
PILCHER CWT 000453 01-04 , 004201 04-04
PIMENTELC 000669 01-11
PIMOULEC 000235 01-03
PINAAM 00259102-17
PINDERRM 000592 01-09, 004395 04-09
PINEGIN LY 004045 04-03
PINELLI P 000757 01-13 , 004675 04-16
PIPERNOR 000833 01-15
PIQUET J 003313 03-11
PIQUET V 004505 04-13
PIREDDAS 000533 01-06
PIRES-DE-OLIVEIRA RS 003358 03-1 1
PISANI FD 003359 03-1 1
PISANIG 001386 02-03
PISANTI N 000443 01-04
PISHKINV 000879 01-15
PISTOLE T 000644 01-09
PISVEJCJ 002132 02-11
PIHMAN KA 004691 04-16
PIHMANQJ 002674 03-03
PIHM AN R 000 1 97 0 1 -03 , 002829 03-03
PinONI G 000105 01-03
PinSAF 003554 03-16
Pins FN 003554 03-16
PIVAF 001418 02-03
PLACHETAP 001309 02-03, 002893 03-03
PLANANSKYK 000569 01-08
PLANCHE R 002027 02-09
PLANTARD-NEAU C 003563 03-16
PLAHJE 003360 03-11, 00336103-11
PLAZNIKA 001103 02-03
PLENATM 003523 03-15
PLENGEP 004537 04-13
A-27
I
Author Index
PLESHKOVANM 004579 04-14
PLETSCHERA 003967 04-03
PLEUVRYBJ 004279 04-05
PLEVOVAJ 000976 01-17
PLOTKINC 003406 03-13
PLOTKINMJ 002592 02-17
POAT JA 002722 03-03 , 004055 04-03
POCOCK DA 002340 02-14
PODDAR MK 003970 04-03
PODHRADSKA 0 002 1 1 5 02- 1 1
PODIWINSKYF 000712 01-11
POEWD 002593 02-17
POELDINGER W 002286 02- 1 3
POGGESI E 000036 01-03, 000258 01-03
POGSON CI 002899 03-03
POHLM 001419 02-03
POHORECKY LA 002864 03-03
POIGNANT JC 001085 02-02, 001898 02-07
001969 02-09
POINTISD 001170 02-03
POIRIER J 001891 02-07 , 001969 02-09
POIRIERMA 004631 04-15
POIRIER MF 000551 01-08
POIRIER-LITTRE MF 000549 01-08
POKORNY J 002865 03-03
POKORSKI M 003971 04-03
POKRYSHKIN VI 003919 04-03
POLACEKJ 004642 04-15
POLAND RE 003830 04-03 , 004403 04-09
POLCP 00138102-03, 002646 03-02
POLDINGERW 000603 01-09, 002028 02-09
, 004396 04-09
POLESSKAYA MM 003972 04-03
POLGARM 000912 01-17
POLGAni M 003730 04-03
POLIM 002277 02-13
POLIMANTI S 004397 04-09
POLING A 001753 02-04 , 001754 02-04
POLINSKYRJ 003362 03-11
POLIZOSP 000880 01-15
POLLACK E 000678 01-11
POLLACK J 002928 03-03
POLLARD HB 001027 02-01
POLU^RI L 001078 02-02
POLLERI A 002371 02-15
POLVAN N 004567 04-14
P0MERAN2 B 000236 0 1 -03
PONDER SW 000361 01-04
PONG S 003688 04-02 , 003973 04-03
PONOMAREVA-STEPNAYA MA 00 1 8 1 2 02-04
PONTANI RB 001375 02-03
PONTO LB 003509 03-15
PONTONNIERG 000797 01-13
PONZIOF 001325 02-03, 003674 04-01
POPEHG 002480 02-16
POPES 000697 01-11, 001755 02-04
POPKINN 00087101-15
POPOV N 001819 02-04
POPOVICM 002594 02-17
POPPED 003699 04-02
POPPAYM 002663 03-03
PORGESSW 003363 03-11
POROTM 001969 02-09, 002029 02-09
002030 02-09, 003523 03-15
PORSCHE E 001052 02-01
PORSIUSAJ 004297 04-06
PORTA R 004116 04-04
PORTER RJ 004522 04-13
PORTOGHESE PS 001 162 02-03 , 003104 03-
04 , 004082 04-04
PORTUGAL H 003524 03-15
POSER W 000611 01-09
POSEY FT 004688 04-16
POSHIVALOV VP 004202 04-04
POSMUROVA M 0005^: 01-08 , 000761 01-
13
POST R 000618 01-09 , 001984 02-09
00203102-09, 002034 02-09, 002221
02-13 , 002353 02-14 , 002366 02-14
002637 03-01 , 002866 03-03 , 003067
03-04, 003388 03-11, 004398 04-09
004549 04-13
POSTMESTJ 004298 04-06
POTHMA 001282 02-03
POTKINS 001928 02-08, 001957 02-08
001958 02-08 , 003169 03-08 , 003499
03-15
POHASHALC 000899 01-16, 003220 03-09
003317 03-11
POHER WZ 003250 03-09
POTVINAR 002182 02-11
POTVINJH 002182 02-11
POUEYTO P 002170 02-11
POWELL DA 00 1 560 02-04 , 001 668 02-04
POWELL JR 000773 01-13
POWERS CA 000237 01-03
POWERS DL 003700 04-02
POWERS JS 003364 03-11
POZDNYAKOV VS 003209 03-09
POZZAG 002277 02-13
PRADALIER A 004505 04-13
PRADHAN S 000346 01-04, 001270 02-03
001348 02-03 , 001601 02-04 , 002867 '
03-03 , 003826 04-03
PRAIGROTHA 002170 02-11
PRAKASH MR 002868 03-03
PRAKASH R 004656 04-15
PRANGE AJ 00 1 850 02-05 , 002 1 45 02- 1 1
002259 02- 1 3 , 003037 03-04 , 004 1 11 '
04-04
PRASAD C 004181 04-04
PRASAD V 000238 01-03
PRAH SR 003757 04-03
PREDESCUV 001979 02-09
PREDY PA 000419 01-04
PREININGEROVA 0 000654 01-10
PRELEVICS 000714 01-11
PREODOR D 002053 02-09
PRESKORN SH 000239 01-03 , 003974 04-03
PRESSLICHO 003251 03-09
PRESTON PR 001329 02-03
PRIBRAM HEW 003322 03-1 1
PRICE RG 000837 01-15
PRIEN R 002450 02-15 , 002516 02-16
PRIESTLY BG 000682 01-11
PRIKRYLP 003423 03-13
PRIKRYLT 002507 02-16
PRIMROSE DA 003452 03-14
PRINCE DA 003728 04-03
PRINGUEYD 003524 03-15, 003642 03-17
PRINSD 000713 01-11
PRINZ P 004695 04-16
PRIOUX-GUYONNEAU M 001 187 02-03
PROHLL 004626 04-15
PROKESJ 003170 03-08, 003696 04-02
PROKHOROVA IS 004330 04-08
PROPSTF 003975 04-03
PROSTAKOVATI 004579 04-14
PROTIVAM 000001 01-01
PROHFW 002340 02-14
PROUDFITHK 00012101-03, 000122 01-03
000240 01-03, 001420 02-03
PROZI ALECK W 004052 04-03 , 004750 04-17
PRUDHOMME B 001899 02-07
PRUNERIC 004439 04-11
PRUSOFFBA 000624 01-09, 003272 03-09
004418 04-09
PRUSSTP 000512 01-05
PRUSSAK C 003421 03-13
PRYORJC 004515 04-13
PRZEWLOCKA B 003058 03-04
PRZEWLOCKI R 003837 04-03 , 003846 04-03
PRZYSLOFR 001253 02-03
PSARAS M 004337 04-08
PUDELV 000611 01-09
PUECH AJ 000598 01-09 , 001942 02-08
002278 02- 1 3 , 002292 02- 1 3 , 003 1 55
03-07 , 003424 03-13 , 003633 03-17
PUERTO AX 001539 02-03
PUERTO BA 001539 02-03
PUESCHELSM 00216102-11
PUGLISI-ALLEGRA S 001756 02-04
PUHRINGER W 004332 04-08
PUIG-ANTICHJ 000619 01-09, 000620 01-09
PUJOL J 002 1 62 02- 1 1 , 002588 02- 1 7
002589 02-17, 003668 04-01
PULLAR I A 001591 02-04 , 001592 02-04
PULLENG 002595 02-17
PUNJANI NF 000022 01-03
PURIJN 000247 01-03
PURISK 000049 01-03
PURVESR 003144 03-06
PURVESRD 004299 04-06
PUTKONEN PTS 000405 01-04
PUZYNSKI S 004546 04-13 , 004547 04-13 ,
004548 04-13
PYCOCK a 000 1 57 0 1 -03 , 00 1 589 02-04
002869 03-03 , 002966 03-04 , 003976
04-03, 004100 04-04
PYNNONEN S 000785 01-13
Psychopharmacology Abstracts
QUACH n 000241 01-03 , 001054 02-01
QUADBECK H 000562 01-08
QUADRI AA 000621 01-09
QUALLSCB 001971 02-09 , 003211 03-09
QUEISNEROVAM 000242 01-03, 002279 02-
13
QUEREJ 002135 02-11
QUESNEYLF 000714 01-11
QUIK M 001296 02-03 , 002870 03-03
QUINAUXN 000267 01-03
QUINONES NQ 001093 02-02
QUINQUISM 002600 02-17
QUIRCE CM 003977 04-03 , 003978 04-03
QUIRION R 000243 01-03
QUISTS 001852 02-05
QUITKIN F 000632 01-09 , 003228 03-09
003233 03-09 , 003240 03-09 , 003241
03-09 , 003252 03-09 , 003262 03-09
QUOCK RM 003068 03-04
RAABE WA 004276 04-05
RABEA 000388 01-04
RABE LS 001421 02-03
RABENDINGG 004481 04-11
RABIN RA 003979 04-03
RABINS P 003374 03-11
RACADOTA 004503 04-13
RACAGNI G 001422 02-03 , 002690 03-03
002973 03-04, 003126 03-05
RACKHAM A 004053 04-03 , 004218 04-04
RACZWJ 003912 04-03
RADEKE E 001740 02-04
RADOUCO-THOMAS C 002596 02- 1 7
RADOUCO-THOMAS S 002596 02- 1 7
RADOVANCEVIC L 000977 01-17
RADULOVACKI M 000244 01-03 , 004203 04-
04
RADWAN S 001843 02-05
RAESE JD 001423 02-03
RAFAELSEN OJ 000850 01-15, 000978 01-17
, 00201102-09, 002597 02-17, 004537
04-13, 004607 04-15
RAFFG 000825 01-14, 003456 03-14
RAFTER J 000273 01-03
RAGAN P 000226 01-03
RAGAVAN W 002871 03-03
RAGHEBM 000622 01-09
RAICHLE ME 003974 04-03
RAIMONDOS 001126 02-03, 003730 04-03
RAINES A 000140 01-03
RAISANEN P 002185 02-11
RAISMANR 002254 02-13, 002569 02-16
003427 03-13 , 003955 04-03 , 004358
04-09
RAITERIM 000185 01-03, 001163 02-03
001424 02-03 , 003745 04-03
RAJKOWSKIJ 000245 01-03
RAJTAR G 004166 04-04
RAKUSA 000609 01-09, 003567 03-16
RALEIGH MJ 001385 02-03, 004204 04-04
RAMA RAO VA 001943 02-08, 001976 02-09
RAMADANOGLU E 0045 1 9 04- 1 3
RAMIREZ VD 000459 01-04 , 001 121 02-03
002668 03-03
RAMIREZ-GONZALEZ MD 000246 01-03 ,
003791 04-03
RAMOS OL 000669 01-11
RAMOS-LORENZI JR 003233 03-09 , 003252
03-09
RAMOTO 002875 03-03
RAMSAY G 000697 01-11
RAMSEIER F 004399 04-09
RAMSEY P 002417 02-15
RAMSEY TA 000940 01-17, 00199102-09
003263 03-09 , 003570 03-16
RANCEMJ 000032 01-03, 00035101-04,
003611 03-17
RANDALL PK 004217 04-04
RANDORR 003980 04-03
RANE A 002181 02-11
RANELLI a 003253 03-09
RANGARAJ N 001425 02-03
RANI SJ 002266 02-13
RANSOM DH 001048 02-01, 001400 02-03
RAOAV 00088101-15
A-28
VOLUME 19, AUTHOR INDEX
Author Index
RAO BSSR 000627 01-09 , 003533 03-15
RAOVAR 004338 04-08
RAPISARDAV 003150 03-07
RAPKIN RM 003294 03-11
RAPOPORTJL 00071501-11, 00071601-11,
002354 02-14 , 002359 02-14 , 003242
03-09 , 0033 1 0 03- 11 , 003437 03- 1 3
RAPOPORTR 000079 01-03
RAPPAPORTMS 001426 02-03
RAPPOLTRT 003525 03-15
RAPPORT MM 003025 03-04
RAPPORT RL 000177 01-03
RASKIN LA 002965 03-04
RASKIN NH 003623 03-17
RASKINDM 000602 01-09
RASNYUK VA 003172 03-08
RASTOGIJK 002172 02-11
RASTOGI RB 001427 02-03 , 001428 02-03
RASTOGI SK 000247 01-03
RATAUDJ 001517 02-03
RATEYJJ 003526 03-15
RATHJEJ 002229 02-13
RAHAN P 000675 01-11
RAUH E 004122 04-04
RAUSENAR 001836 02-05
RAVAZZANI C 002863 03-03
RAVENNA F 00105102-01
RAVIZZA L 002032 02-09 , 002872 03-03 ,
002873 03-03
RAWLEFC 003736 04-03
RAWLINS JNP 001757 02-04
RAWLINS MD 004669 04- 1 6
RAWSONRA 000827 01-14
RAYAK 001429 02-03
RAYDE 001838 02-05
RAY TB 000145 01-03 , 000146 01-03 ,
004 1 44 04-04 , 004 1 45 04-04
RAYWA 000979 01-17
RAYKHMAN LM 001331 02-03
RAYMOND V 001324 02-03
RAYNAUD G 001090 02-02
READER TA 000068 01-03
REAGAN MW 000937 01-17
REAVES BJ 001057 02-01
REAVILLC 00130102-03, 004205 04-04
REBARD R 003220 03-09
REBAUDENGO P 002872 03-03 , 002873 03-03
REBEC GV 000454 01-04 , 001758 02-04 ,
003131 03-05 , 003981 04-03
REBERTCS 004277 04-05
RECASENSM 002878 03-03
RECH R 000036 01-03 , 000364 01-04 ,
000365 0 1 -04 , 000386 0 1 -04 , 00 1 595
02-04 , 004089 04-04
RECHTMAN MP 004054 04-03
RECOMMISD 003749 04-03
REDDY RAMANA SV 004206 04-04
REDGRAVE P 001755 02-04, 002679 03-03
REDMOND DE 000372 01-04, 002285 02-13,
002838 03-03 , 003810 04-03 , 003982
04-03
REDMOND FC 003551 03-15
REECES 000734 01-11
REED D 004692 04-16
REEDJP 003624 03-17
REEDK 000882 01-15
REEDRB 002161 02-11
REESL 003283 03-10
REESM 002598 02-17
REGAN CM 002729 03-03
REGAN JW 001430 02-03 , 002874 03-03
REGENSTEIN AC 003960 04-03
REGGI V 002521 02-17
REGGIANIA 001512 02-03
REGNAULTH 002123 02-11
REGOLI D 000243 01-03
REHAVI M 002875 03-03 , 003962 04-03 ,
004689 04-16
REHFELDJF 003805 04-03
REICHENBERG K 001788 02-04
REICHLR 001431 02-03
REIDAH 003365 03-11
REIDJL 002504 02-16
REID LD 000371 01-04 , 0031 18 03-04 ,
004196 04-04
REIDWH 004647 04-15
REIDENBERGMM 00245102-15
REIGELCE 001138 02-03
REIGLETG 000136 01-03
REIMANN I 000164 01-03, 002249 02-13
REIMANN W 003983 04-03
REIMHERR FW 003389 03-11
REINHARDJF 002503 02-16
REINHARDT B 004396 04-09
REINISCH JM 003527 03-15
REINSTEIN DK 002934 03-03 , 003069 03-04
REISDJ 002634 03-01, 004112 04-04
REISBERGB 002125 02-11, 004482 04-11
REISBY N 002033 02-09
REISINE T 000226 01-03 , 001305 02-03 ,
002163 02-11, 00401104-03, 004013
04-03
REITH MEA 001772 02-04
REKERD 000798 01-13, 003383 03-11
REKHTMAN MB 003070 03-04 , 003984 04-
03
REKTOR L 000623 0 1 -09 , 000883 01-15,
002452 02-15, 004648 04-15
REMEJM 000797 01-13
REMIEN J 003556 03-16
RENAUD LP 002674 03-03
RENFORDT E 003568 03-16
RENICKJ 004600 04-15
RENIER E 002389 02-15
RENNICK PM 002126 02-11, 004453 04-11
RENSHAWDC 004483 04-11
RENYI AL 003991 04-03
RENZI G 000104 01-03
RESELEL 001460 02-03
RESNICK RB 00073101-11, 000827 01-14
RESUL B 003701 04-02
RETTORI VB 001194 02-03
REUBI J 003985 04-03
REUS VI 001984 02-09, 002034 02-09
REUSE J 001228 02-03
REVELEYMA 000983 01-17
REVENKOSV 003884 04-03
REVUELTAAV 001166 02-03
REVUSKYS 001086 02-02
REVVA LI 00353103-15
REY AC 000836 01-15, 004549 04- 1 3
REYES Fl 002213 02-13
REYES RB 000406 01-04
REYMANNJM 002205 02-13
REYNOLDS EH 003366 03-11, 004649 04-15
REYNOLDS JC 003521 03-15
REYNOLDS NC 003132 03-05
REYNOLDS PC 004650 04-15
REYNTJENSA 000758 01-13
REZNICEKV 000658 01-10
RHODES KF 000516 01-05
RIBELLES M 002744 03-03
RIBEREAU-GAYON G 000248 01-03
RICCARDI F 002828 03-03
RICCIARDI S 000042 01-03 , 000355 01-04 ,
001161 02-03
RICCIODC 001597 02-04
RICE A 000470 01-04
RICE K 003962 04-03 , 004221 04-04 ,
004251 04-04
RICHARD JW 004053 04-03
RICHARDS GE 000088 01-03
RICHARDS JG 00138102-03, 002643 03-01
RICHARDS RK 000249 01-03
RICHARDSON E 000812 01-14
RICHARDSON JS 003836 04-03
RICHARDSON MA 001614 02-04 , 002380 02-
1 5 , 003469 03- 1 5 , 004595 04- 1 5
RICHELLE M 004207 04-04
RICHELSON E 000250 01-03 , 000980 01-17 ,
001432 02-03, 001433 02-03, 001880
02-06 , 003783 04-03 , 003986 04-03 ,
004030 04-03 , 004049 04-03 , 004737
04-17
RICHENSA 000783 01-13, 002376 02-15,
003467 03-15, 004738 04-17
RICHERTJR 001434 02-03
RICHTERJA 00025101-03, 004146 04-04
RICHTROVA E 003170 03-08
RICK JT 003071 03-04
RICKELSK 000655 01-10, 000840 01-15,
002482 02-16 , 003254 03-09 , 004400
04-09, 004420 04-10
RIDLEY PT 000228 01-03
RIDLEY RM 001759 02-04 , 00191 1 02-08 ,
003072 03-04 , 004208 04-04
RIEDELC 004380 04-09
RIEDERERP 000712 01-11
RIFFEEWH 001822 02-04
RIFKINA 000632 01-09, 003233 03-09,
003252 03-09 , 003625 03-17 , 004427
04-10
RIGAUD A 004395 04-09
RIGGSJJ 000512 0105
RIGOR BM 003774 04-03
RIGTER H 004094 04-04
RIMANOCZYA 001300 02-03, 002765 03-03
RIMON R 002185 02-11
RINGDAHL B 003701 04-02
RINGWALD E 001944 02-08
RINIERISPM 000786 01-13
RINNE UK 003528 03-15
RIORDANCE 000820 01-14
RIOUX F 000243 01-03
RISBERGJ 002210 02-13
RISCHC 000455 01-04, 002003 02-09,
003603 03-17
RISCH SC 002280 02-13 , 003255 03-09 ,
003529 03-15, 003530 03-15
RISNER ME 000469 01-04 , 001760 02-04
RITCHMA 001806 02-04
RITSCHELWA 000907 01-16
RITTAMN 001159 02-03
RITTENHOUSE HG 003987 04-03
RITTERS 000456 01-04
RITZA 004103 04-04
RITZMANN RF 001435 02-03, 001576 02-04
, 001780 02-04, 004209 04-04
RIVA LP 004535 04-13
RIVERA-CALIMLIM L 000717 01-11. 001938
02-08
RIVIER JE 003985 04-03
RIZEK AE 002864 03-03
RIZZO PA 002355 02-14
ROACH AG 000044 01-03
ROACH CA 003522 03-15
ROBBINSTW 002484 02-16
ROBERT G 001900 02-07, 00190102-07
ROBERTO 003441 03-14
ROBERTS DJ 003928 04-03
ROBERTS MB 001824 02-04
ROBERTS MS 003558 03-16
ROBERTS PJ 002888 03-03 , 004000 04-03
ROBERTS S 003040 03-04
ROBERTS T 000471 01-04
ROBERTSON A 000387 01-04, 000457 01-04
ROBERTSON D 002272 02-13 , 002734 03-03
ROBERTSON HA 000252 01-03 , 001436 02-03
ROBERTSON TW 001242 02-03
ROBERTSON WCJ 000718 01-11
ROBIN MM 000458 01-04
ROBINS E 002052 02-09
ROBINSON DS 002035 02-09
ROBINSON GMH 000574 01-08
ROBINSON J 001437 02-03, 004423 04-10,
004473 04-11
ROBINSON K 004693 04-16
ROBINSON MM 001614 02-04
ROBINSON TE 000309 01-03, 000459 01-04,
001438 02-03
ROBISON GA 001445 02-03
ROBSON PA 003753 04-03
ROCCATAGLIATA G 000700 01-11, 002013
02-09 , 002356 02-14 , 004382 04-09 ,
004533 04-13
ROCCELLA P 003419 03-13
ROCHAESILVAM 002715 03-03
ROCHATC 000258 01-03, 001764 02-04
ROCHE M 001227 02-03 , 003691 04-02
ROCKMAN GE 000253 01-03
RODE A 004548 04-13
RODGERS RJ 003073 03-04
RODGERS RM 000073 01-03
RODIN EA 003367 03-11
RODNYJ 000674 01-11
RODRIGUEZ F 000272 01-03
RODRIGUEZ R 000407 01-04
RODRIGUEZ S 003988 04-03
RODRIGUEZ-SANABRA F 001558 02-04
RODRIGUEZ-SIERRA JF 003074 03-04
ROED A 002749 03-03
ROEHRSTA 004695 04-16
ROEMER D 003013 03-04
ROEMER RA 003263 03-09
ROERIG DL 001853 02-05
ROERIG SC 002800 03-03
ROESKE WR 000279 01-03 , 001430 02-03 ,
001441 02-03 , 001545 02-03 , 002874
03-03
ROFFMAN M 0046 1 9 04- 1 5 , 00465 1 04- 1 5
ROGER J 000873 01-15, 002319 02-14
A-29
wmm
Author Index
Psychopharmacology Abstracts
a.
<!!
C
I
I
ROGERS J 00 1 1 36 02-03 , 004 1 82 04-04
ROGERS U 003079 03-04
ROGERS PJ 002527 02-17
ROGINSKYM 000660 01-11
ROGOLA 001928 02-08, 003499 03-15
ROGOWSKIZ 004564 04-14
ROGOZZ 001417 02-03
ROGOZEAR 002281 02-13
ROJAHNJ 002409 02-15
ROKOSZ-PELC A 0042 1 0 04-04
ROKYTAR 000460 01-04, 001439 02-03
ROLANDI E 003425 03-13
ROLF L 002501 02-16
ROLLAND B 004029 04-03
ROLLEMAH 000004 01-01, 000324 01-03
ROLLINS DE 002282 02-13
ROLSTENC 000134 01-03
ROMACHMK 000747 01-13
ROMAIN M 001902 02-07
ROMAN F 002541 02-17
ROMANIUK A 001761 02-04
ROMANO C 000254 01-03
ROMELTE 004732 04-17
ROMMELSPACHER H 001440 02-03, 002854
03-03 , 00421 1 04-04
ROMO R 004046 04-03
ROMOLINIOVAA 000803 01-14
RONAI AZ 001799 02-04 , 002650 03-02
RONDOTP 004652 04-15
ROOSES 000590 01-09
ROPERT R 002036 02-09
ROPPOLOJR 000055 01-03, 003755 04-03
ROQUEBERTJ 002876 03-03
ROQUEFEUILB 00223102-13
RORSMANB 003542 03-15
ROSAMOND JD 003684 04-02
ROSATIG 002283 02-13
ROSEBW 003566 03-16
ROSEC 00024101-03, 001054 02-01
ROSEFC 004509 04-13
ROSEGJ 001634 02-04
ROSEJE 001416 02-03
ROSE SE 004060 04-03
ROSECRANSJA 000435 01-04, 001020 02-01
, 004260 04-04
ROSEN AJ 004577 04-14
ROSEN GD 000375 01-04
ROSENBAUMAH 000787 01-13, 002037 02-
09 , 002038 02-09 , 004406 04-09
ROSENBAUMJ 003626 03-17
ROSENBAUMR 004512 04-13
ROSENBERG GS 002317 02-14, 004099 04-04
ROSENBERG HC 000526 01-05
ROSENBERG RD 001057 02-01
ROSENBERGER LB 001441 02-03
ROSENBERGER PB 00082101-14
ROSENBLAnjE 000255 01-03, 001442 02-03
, 001443 02-03, 001444 02-03, 001945
02-08 , 003169 03-08 , 004671 04-16
ROSENDORFF C 003887 04-03
ROSENFELDGC 001445 02-03
ROSENFELDJP 001446 02-03, 003028 03-04
ROSENFELOMR 001447 02-03, 001448 02-03
ROSENGARTEN H 003989 04-03
ROSENTHAL M 002798 03-03
ROSENZWEIGMR 001573 02-04, 004097 04-
04, 004578 04-14
ROSHCHINALF 001449 02-03, 004212 04-04
ROSKAMSE 00047101-04
ROSNICK L 000632 01-09
ROSSB 003487 03-15
ROSS DH 000958 01-17 , 001450 02-03
ROSSJA 004080 04-04
ROSS RJ 003220 03-09
ROSS S 000120 01-03 , 001451 02-03 ,
001452 02-03 , 003990 04-03 , 003991
04-03, 004704 04-17
ROSS-CHOUINARD A 003305 03-1 1
ROSSEELMT 004355 04-09
ROSSERRM 002164 02-11, 002284 02-13
ROSSI F 003744 04-03
ROSSI J 001644 02-04
ROSSIEGV 003627 03-17
ROSSIER J 00 1 1 1 0 02-03 , 002599 02- 1 7
ROSSIOJ 004324 04-08
ROSSITERVS 003446 03-14
ROSSOR M 000564 01-08 , 002163 02-1 1 ,
002504 02-16
ROSZKOWSKI AP 001091 02-02
ROTH KA 003935 04-03
ROTH M 002081 02-10
ROTH RH 000023 01-03 , 000764 01-13 ,
00 1 1 1 7 02-03 , 00 1 453 02-03 , 00 1 820
02-04 , 002097 02-1 1 , 002285 02-13 ,
002662 03-03 , 00291 1 03-03
ROTHT 000822 01-14, 002160 02-11,
002357 02-14
ROTHBARTM 000582 01-09, 002248 02-13
ROTIROTI D 000218 01-03 , 000442 01-04 ,
000443 01-04, 001733 02-04, 001734
02-04 , 002762 03-03 , 003075 03-04 ,
003952 04-03
ROTROSENJ 00046101-04, 001906 02-08,
001948 02-08 , 002877 03-03 , 004606
04-15
ROUBAL Z 000242 0 1 -03 , 002279 02- 1 3
ROUBICEKJ 002286 02-13
ROUFOGALIS BD 003162 03-07
ROUGEUL A 001581 02-04
ROUILLON F 003628 03-17
ROULEAU D 002635 03-01
ROUNSAVILLE BJ 000624 01-09 , 003256 03-
09 , 004401 04-09
ROUOT B 003685 04-02 , 003992 04-03
ROUSSELLEJC 000093 01-03
ROUSSINOVK 004166 04-04
ROUTLEDGE PA 000867 01-15
ROUVEIXB 004632 04-15
ROUX J 002600 02- 1 7 , 004445 04- 1 1
ROVEIV 000596 01-09, 002014 02-09,
003324 03-11
ROVERERA 003479 03-15
ROVINSKAYASA 00353103-15
ROWAN P 003249 03-09 , 004402 04-09
ROWE PH 001832 02-05
ROWLAND N 002891 03-03 , 003122 03-05 ,
004196 04-04
ROWLEY VN 001630 02-04
ROXASM 003150 03-07
ROYD 002266 02-13
ROYER RJ 003629 03-17
ROYZIN L 003532 03-15
ROZITIS A 003738 04-03
RUBENSTEIN JS 003876 04-03
RUBICSEK G 002955 03-04
RUBIN JJ 002930 03-03
RUBIN RT 002287 02-13 , 002505 02-16 ,
003830 04-03 , 004403 04-09
RUBINOIA 004318 04-08
RUBINOWD 003388 03-11
RUBIOMA 003924 04-03
RUCINEMO 000543 01-07
RUDDSM 000832 01-15
RUDEBERGA 004495 04-11
RUDEBERGC 001762 02-04
RUDEEN PK 003076 03-04
RUDELL RL 004287 04-06
RUDORFERMV 000884 01-15, 002039 02-09
, 004550 04-13
RUDZIKAD 001074 02-02, 001075 02-02
RUFFRL 004653 04-15
RUFFING DM 000462 01-04
RUGGERI S 002090 02-1 1 , 002312 02-14 .
002371 02-15
RUGGIERI S 003085 03-04 , 004431 04-1 1
RULLIERER 004530 04-13
RUMBACH L 002237 02-13
RUMIGNY J 002878 03-03 , 003675 04-01
RUNDELLO 003460 03-14
RUSH AJ 003235 03-09 , 003257 03-09
RUSHL 003393 03-11
RUSSELL B 004213 04-04
RUSSELL J 001053 02-01, 001148 02-03
RUSSO PV 003922 04-03
RUSTERHOLZDB 002236 02-13
RUTH RC 003993 04-03
RUTHERE 001570 02-04
RUTHERFORD D 003543 03-15
RUHERFORDMG 004693 04-16
RUWEWD 001454 02-03
RYABUKHA VN 001 520 02-03
RYAN R 003676 04-01
RYBAKOWSKI J 000625 01-09 , 000885 01-
15 , 002040 02-09 , 004404 04-09 ,
004416 04-09
RYDZYNSKIZ 000626 01-09, 000719 01-11
RYLEHBJ 002879 03-03
RYMANT 001737 02-04
R YMASZEWSK A G 00086 101-15
RYPKAM 000274 01-03
RYSANEK K 003423 03-13
RYSANEK R 000568 01-08 , 000613 01-09
000634 01-09 , 001949 02-08 , 002021
02-09 , 003264 03-09
RZHEVSKAYA GF 004261 04-04
SAAB PG 002357 02-14
SAARIM 000448 01-04
SAARMAMM 003368 03-11
SAARMAYM 003368 03-11
SAAVEDRAIN 000102 01-03
SAAVEDRAJM 001455 02-03, 001456 02-03
, 001457 02-03, 001458 02-03, 001459
02-03 , 002601 02-17
SABATERJ 002288 02-13
SABBATINI F 003194 03-08
SABOURAUDO 002205 02-13
SACCHEHI E 001460 02-03, 00436104-09
SACHAIS BA 003239 03-09
SACHAR EJ 000752 01-13, 000776 01-13,
000874 01-15, 002238 02-13, 003411
03-13 , 003426 03-13 , 004405 04-09
SACHS BD 003077 03-04
SACKELLARES JC 003378 03-1 1
SACKEHPH 000014 01-02
SACKS W 004377 04-09
SADJAL 000829 01-15
SADLER A 003487 03-15
SADRE NL 001361 02-03
SAELENS JK 000188 01-03 , 001461 02-03
SAFFITZMS 000256 01-03
SAHABK 002432 02-15
SAHAI J 004656 04-15
SAHAKIAN BJ 000257 01-03 , 000802 01-14
002484 02-16
SAHGALA 001763 02-04
SAHLEYTL 001745 02-04
SAHLIN L 000273 01-03
SAHLSTROM L 000084 01-03
SAIANI L 001482 02-03
SAINGRAS 003524 03-15
SAINIOK 000694 01-11
SAINT-HILAIRE JM 00334103-11
SAITOK 000099 01-03, 003807 04-03
SAITOM 001255 02-03, 002165 02-11,
002781 03-03
SAITOY 003938 04-03
SAITOH R 004295 04-06
SAJI Y 003057 03-04
SAKAI KK 000302 01-03
SAKAIT 000856 01-15
SAKAI Y 001402 02-03 , 002846 03-03
SAKAMOTO K 004283 04-05
SAKURADAH 003450 03-14
SAKURADAS 001379 02-03, 002837 03-03,
003714 04-03
SALAA 003705 04-02
SALAP 002093 02-11
SALAICESM 001357 02-03
SALAMONEJD 001873 02-06
SALAMYA 000509 01-05
SALCEDA R 002856 03-03
SALEM RB 000889 01-15
SALEMINKCA 002556 02-17
SALETUB 00072001-11, 00078801-13,
001895 02-07, 002166 02-11
SALISPJ 004556 04-13
SALLEMARK M 000 1 20 0 1 -03
SALLER CF 002880 03-03 , 002968 03-04
SALLES KSS 003078 03-04
SALMI T 000694 01-11
SALAAON P 001757 02-04
SALOKANGAS RKR 000571 01-08
SALOME RR 004182 04-04
SALZMANC 00098101-17, 00336903-11
SALZMANLF 002419 02-15
SAMADASHVILI ZV 003780 04-03
SAMANIEGO B 003936 04-03
SAMANIN R 000036 01-03 , 000258 01-03 ,
001157 02-03, 001325 02-03, 001764
02-04, 002602 02-17
SAMARDZICR 001568 02-04, 001569 02-04
SAMARZAA 000672 01-11
SAMINIM 000108 01-03
SAMPATHG 000627 01-09, 003533 03-15
SAMSONOVA NA 003070 03-04 , 003984 04-
03
A-30
VOLUME 19, AUTHOR INDEX
Author Index
SAAAU I 002404 02-15
SANBERGPR 000463 01-04
SANCHEZ CF 003925 04-03
SANCHEZ D 000399 01-04
SANCHEZ-TURET M 003453 03- 1 4
SANDDJ 000792 01-13
SANDERS-BUSH E 000287 01-03
SANDERSON CA 003079 03-04
SANDFORDDA 000982 01-17
SANDLER K 000582 01-09
SANDLER M 00072101-11, 000983 01-17,
002230 02-13 , 004509 04-13 , 004640
04-15
SANDMAN CA 003 1 1 2 03-04
SANDOVAL J 004469 04-11
SANESJN 003319 03-11
SANGDEEC 004040 04-03
SANGER DJ 001765 02-04, 003080 03-04
SANKARR 001197 02-03
SANSONEM 001766 02-04, 001767 02-04,
001768 02-04
SANTAGOSTINO A 003801 04-03
SANTAGOSTINO G 000757 01-13, 004675 04-
16
SANTI PA 004287 04-06
SANTINIV 001422 02-03
SANTOS AB 002167 02-11
SANVITOWL 000669 01-11
SANYALAK 001769 02-04
SARM 002639 03-01
SARAF K 003233 03-09 , 003252 03-09
SARAI K 004388 04-09
SARANAK J 003081 03-04
SARATIKOV AS 003994 04-03
SARI A A 000259 01-03
SARNAGS 001838 02-05
SARNAS 000694 01-11
SARRAZINA 000543 01-07
SASA M 000260 0 1 -03 , 004 1 39 04-04
SASAHARAK 00455104-13
SASAKI T 004618 04-15
SASSW 003067 03-04
SASSONEDM 004469 04-11
SATINDERKP 003082 03-04
SATOF 000902 01-16, 004684 04-16
SATOH 001462 02-03
SATOS 000444 01-04
SATOT 002442 02-15
SATOY 002442 02-15
SATOH M 001691 02-04 , 003083 03-04
SATOH T 001236 02-03 , 001797 02-04 ,
003008 03-04
SATOH Y 000493 01-04, 004278 04-05
SAUNDERS NA 002128 02-11
SAUTERA 001254 02-03
SAUVAGED 003291 03-11
SAVAGE C 003308 03-11
SAVAGE DD 001463 02-03 , 002881 03-03
SAVAGEAU MM 003084 03-04
SAVAKI HE 001365 02-03
SAVARDC 004286 04-06
SAVETTM 003154 03-07
SAVOLAINEN H 000261 01-03 , 000527 01-05
SAWAN 001609 02-04
SAWEJ 000754 01-13
SAWYNOK J 002882 03-03
SCAPAGNINI U 000378 0 1 -04 , 00 1 200 02-03
SCARNAH 003668 04-01
SCARNATI E 003085 03-04
SCARPA A 003866 04-03
SCARPELLINI JD 003784 04-03
SCAHON B 000464 01-04 , 001 1 19 02-03 ,
001464 02-03 , 003995 04-03
SCHACHTU 002289 02-13
SCHACHTERM 002168 02-11, 002358 02-14
, 003422 03-13
SCHAEFERGJ 003086 03-04
SCHAFFERC 001913.02-08
SCHAFFER JD 002026 02-09 , 002080 02-10
SCHAFFERMH 000572 01-08, 0C3 198 03-08
SCHAFFNER R 002646 03-02
SCHAFFNERW 000979 01-17
SCHALLERTT 000226 01-03, 000376 01-04
SCHALLY AV 00131 1 02-03 , 001673 02-04 ,
001674 02-04
SCHALOCKRL 001587 02-04
SCHARBACH H 00 1 090 02-02 , 002 1 69 02- 1 1
, 00227102-13, 004428 04-10
SCHATZRA 002883 03-03
SCHATZBERGAF 000787 01-13, 003243 03-
09 , 004406 04-09
SCHAUBC 000262 01-03
SCHAUMBURG K 001079 02-02
SCHECHTER MD 000465 0 1 -04 , 00 1 770 02-04
, 002970 03-04, 003087 03-04, 004214
04-04
SCHECHTER PJ 000458 01-04 , 002237 02-13
, 003458 03- 1 4 , 003620 03- 1 7
SCHECTERAJ 004467 04-11
SCHEEL-KRUGER J 001465 02-03
SCHEININM 002303 02-13
SCHELLD 000849 01-15
SCHENKH 002425 02-15
SCHENK S 001771 02-04
SCHENKER S 002224 02-13 , 002272 02-13
SCHICKEROVA R 003039 03-04
SCHIELEB 002603 02-17
SCHIERE 002604 02-17
SCHIFFAA 000668 01-11
SCHIFFMANN E 001118 02-03
SCHILDKRAUT JJ 000787 01-13, 004406 04-
09
SCHILKRUTR 004319 04-08
SCHILLER M 002324 02-14
SCHIMMELGT 001584 02-04
SCHIMMELKC 004484 04-11
SCHINDLERR 004605 04-15
SCHLEMMER RF 001073 02-02 , 004215 04-
04
SCHLENH 000263 01-03
SCHLESINGER K 001791 02-04
SCHLESSA 000582 01-09, 003254 03-09
SCHLEY J 002290 02-13
SCHLIENGER JL 004407 04-09
SCHLOSBERG AJ 000466 0 1 -04
SCHLOSSERW 000015 01-02
SCHMALTZ K 00 1 678 02-04 , 0041 54 04-04 ,
004 1 55 04-04 , 004 1 56 04-04
SCHMECHELDE 001047 02-01, 001048 02-01
, 001400 02-03
SCHMID E 002041 02-09
SCHMID PG 003845 04-03
SCHMID W 004321 04-08
SCHMIDT DE 003996 04-03
SCHMIDT G 002438 02-15
SCHMIDT M 002895 03-03 , 003853 04-03 ,
004270 04-05
SCHMIDT R 003677 04-01
SCHMIDT-GLENEWINKEL T 00 1 396 02-03
SCHMIHG 002699 03-03
SCHMITZH 002479 02-16
SCHMITZI 002)30 02-11
SCHMUCKER DL 003997 04-03
SCHMUTZM 003880 04-03
SCHNEIDER SJ 003413 03-13 , 004619 04-15 ,
004620 04-15
SCHNEIDERMAN N 001242 02-03
SCHNELLEK 001570 02-04
SCHNOLLSH 000744 01-12
SCHOCKERFW 002884 03-03
SCHOCRONG 002170 02-11
SCHOEMAKER H 000264 01-03
SCHOENEBERGER AS 000265 01-03
SCHOLFIELDCN 001466 02-03
SCHONBECKG 001308 02-03
SCHONFELDAR 001876 02-06, 004216 04-04
SCHOOLAR J 000882 01-15 , 003385 03-1 1 ,
004694 04- 1 6 , 004739 04- 1 7
SCHOOLER NR 000563 01-08 , 001931 02-08 ,
003195 03-08
SCHORDERETM 001350 02-03
SCHOHLER F 001036 02-01
SCHOU M 000893 01-15, 002465 02- 1 5 ,
003534 03-15 , 003630 03-17 , 004408
04-09
SCHOUSBOEA 001540 02-03, 002647 03-02
SCHRAN HF 002291 02-13
SCHRATZER M 004309 04-07
SCHREIBER RA 001467 02-03
SCHRIERBK 002669 03-03
SCHRIVERRC 003151 03-07
SCHROEDER LA 002980 03-04 , 004200 04-04
SCHUBERT DSP 004654 04-15
SCHUBERT E 001020 02-01
SCHUHMACHER P 000266 01-03
SCHULMANE 004522 04-13
SCHULMANJA 001136 02-03
SCHULTZ J 000580 01-09 , 001 136 02-03 ,
002884 03-03
SCHULTZESRE 003396 03-12
SCHULZC 003357 03-11
SCHULZ DW 002885 03-03
SCHULZ H 000754 01-13
SCHULZ R 002935 03-03 , 003088 03-04 ,
003837 04-03
SCHULZECK S 001819 02-04
SCHUMANN H 002742 03-03 , 003816 04-03
SCHUSTER CR 000427 01-04, 002323 02-14,
002328 02-14 , 002926 03-03 , 0031 10
03-04
SCHUSTER P 003251 03-09
SCHUTTLER R 004325 04-08
SCHUTZENBERGER WG 001087 02-02
SCHWABE U 001860 02-06
SCHWAN TJ 003687 04-02
SCHWARCZR 001240 02-03, 003889 04-03,
003923 04-03
SCHWARK WS 00 1 588 02-04
SCHWARTZ G 002441 02-15
SCHWARTZ JC 00024101-03, 001054 02-01
, 002900 03-03
SCHWARTZ JH 002657 03-03
SCHWARTZ JP 001403 02-03 , 003998 04-03
SCHWARZED 000984 01-17
SCHWARZHJ 002291 02-13
SCHWEIZERC 004525 04-13
SCHWERTNER HA 000006 01-01, 000538 01-
06
SCHWIBBEM 004500 04-13
SCHWINDTPC 002886 03-03
SCOGGINSBA 002497 02-16
SCOLLO-LAVIZZARI G 000909 01-16
SCORZA-SMERALDI R 002293 02-13
SCOTOGM 000282 01-03, 001468 02-03
SCOHAK 004740 04-17
SCOnCS 003631 03-17
SCOTT J 001027 02-01, 001704 02-04
SCOHRH 001793 02-04
SCOnO Dl TELLA AM 003089 03-04
SCOTTOJC 002296 02-13
SCULLY RE 004655 04-15
SCUVEE-MOREAU J 000267 01-03
SEALESDM 003446 03-14
SEAMAN SF 003090 03-04
SEBASTIANI G 003258 03-09
SEBBAN M 002895 03-03
SEBENSJB 001095 02-03
SECHTERD 003427 03-13, 004358 04-09
SEDMAKT 002594 02-17
SEDVALL G 001905 02-08 , 001946 02-08 ,
004311 04-08
SEEDM 004463 04-11
SEEGERTF 000467 01-04, 001469 02-03,
004187 04-04
SEELER W 003231 03-09
SEEMANMV 003483 03-15, 003535 03-15
SEEMAN P 000268 01-03 , 001204 02-03 ,
00150902-03, 00151002-03, 001511
02-03 , 001847 02-05 , 002914 03-03 ,
003483 03-15 , 003767 04-03 , 004131
04-04 , 004741 04-17
SEGAL DS 001758 02-04, 003178 03-08
SEGAL R 004343 04-08
SEGALS 00084101-15, 00217102-11
SEGAL Z 00 1 9 1 5 02-08 , 00 1 9 1 6 02-08
SEGALENA 000262 01-03
SEGALLJE 001010 02-01
SEGAWAM 000472 01-04
SEGAWAT 001394 02-03, 001728 02-04,
003999 04-03 , 004191 04-04
SEGUIN EB 003987 04-03
SEHESTEDP 000722 01-11
SEIDELK 002049 02-09
SEIDEN LS 000427 0 1 -04 , 00 1 7 1 4 02-04 ,
002926 03-03 , 0031 10 03-04 , 004073
04-04 , 004 1 69 04-04 , 004 1 75 04-04
SEIDENWURMD 000425 01-04
SEIDLER FJ 004021 04-03
SEIGERA 000095 01-03
SEILICOVICHA 001194 02-03
SEINER 001999 02-09
SEIZINGER B 001283 02-03
SELLECKSB 000534 01-06
SELLERS EM 000703 01-11 , 000747 01-13,
000789 01-13, 000790 01-13, 004552
04-13
SELLERS MS 003449 03-14
SELLINGER OZ 000377 01-04 , 002883 03-03 ,
002887 03-03
SELLSTROMA 002746 03-03
A-31
wmm^
Author Index
SELLWOODRA 002433 02-15
SELTZER RL 004637 04-15
SELWYN M 001461 02-03
SEMEYN DR 004089 04-04
SEMKEVY 004429 04-10
SENGOKUA 004720 04-17
SENONJ 001999 02-09
SENTENACH 001187 02-03,
SEPINWALLJ 000057 01-03, 000468 01-04
SEPPALAT 002258 02-13, 003428 03-13
SERBYM 002453 02-15
SERCOMBE R 001109 02-03
SERRAMT 001229 02-03, 001867 02-06
SERRANO AC 003370 03-11
SERRANO Ml 001189 02-03
SERSHEN H 001772 02-04
SESSOM 00r985 02-09
SETH PK 004264 04-05
SETHI BB 004656 04-15
SETHI PK 002172 02-11
SETH Y VH 000 1 24 0 1 -03 , 000269 0 1 -03
SETLER PE 003929 04-03
SEHLEECJ 000985 01-17
SEVERE J 001931 02-08
SEVERINOVANP 003172 03-08
SEVERNYYAA 003339 03-11
SEVERSONJA 004217 04-04
SEVESTREP 001947 02-08
SEWELLRDE 001773 02-04, 002736 03-03
SEWELLWR 000394 01-04
SEYLAZJ 001109 02-03
SFAGOSC 004471 04-11
SFARTIM 000552 01-08
SHABIBA 001245 02-03
SHADER Rl 00068101-11, 000766 01-13,
00083101-15, 003284 03-10. 003526
03-15, 004432 04-11, 004657 04-15
SHAFIQSA 000290 01-03
SHAGASSC 003263 03-09
SHAHSN 000509 01-05
SHAH U 000732 01-11
SHAKIR RA 002402 02-15 , 003371 03-1 1
SHALABY I A 000481 01-04 , 001470 02-03 ,
001774 02-04
SHALIF I 003196 03-08
SHALINI K 000621 01-09
SHANLEYBC 002735 03-03
SHANNAK KS 001471 02-03
SHANNON HE 000469 01-04
SHAPIRO AK 003372 03-1 1 , 004485 04-1 1
SHAPIRO AP 002891 03-03
SHAPIRO BH 000281 01-03
SHAPIRO BS 004129 04-04
SHAPIRO DM 004567 04-14
SHAPIRO E 003372 03-11, 004485 04-11
SHAPIRO LM 001472 02-03
SHAPIRO-ACKERMAN E 002173 02-1 1
SHARE NN 004218 04-04
SHARER DR 004742 04-17
SHARIF NA 002888 03-03 , 004000 04-03
SHARK AWI M 000270 01-03
SHARMAM 004656 04-15
SHARMA S 003259 03-09
SHARMAUC 003536 03-15
SHARMAN DF 003652 03-17
SHARP B 003942 04-03
SHARPE LG 00149102-03, 002889 03-03
SHARPLESSNS 002180 02-11, 002890 03-03
, 003432 03-13
SHASHOUAVE 003677 04-01
SHASKAN EG 001473 02-03
SHAVIT S 004001 04-03
SHAW DH 003236 03-09
SHAW J 000747 01-13
SHAW KM 002177 02-11
SHAWMDM 001416 02-03
SHAYWITZBA 000426 01-04, 000452 01-04
, 001752 02-04, 002106 02-11, 004658
04-15
SHAYWITZSE 004658 04-15
SHCHELKUNOV YL 003398 03-13
SHEAC 000619 01-09
SHEARDMH 000238 01-03, 000297 01-03
001496 02-03 , 003091 03-04 , 004409 '
04-09
SHEARMAN GT 003092 03-04 , 004219 04-04
SHEEHAN DV 002454 02-15
SHEEHYMP 002168 02-11
SHEKIMWO 002418 02-15
SHELAT H 003901 04-03
SHELDON PW 003123 03-05
SHENKMAN L 003664 04-01
SHENOYRS 003487 03-15
SHEPHERD DT 001806 02-04
SHEPHERD JT 003756 04-03
SHEPHERD M 002605 02-17
SHEPPARDGP 002432 02-15
SHERBANY AA 002657 03-03
SHERIDAN WF 002080 02-10
SHERMAN AD 001631 02-04 , 001751 02-04
001775 02-04 , 003743 04-03
SHERMAN G 000375 01-04, 003053 03-04
SHERMAN JE 000470 01-04 , 000471 01-04
SHERMAN WR 0037 1 2 04-03
SHERSTNEV VV 0037 1 6 04-03
SHESTAKOV SV 004339 04-08
SHIBATAR 000696 01-11
SHIBATAS 000210 01-03
SHIBATAT 001691 02-04
SHIBLA DB 004002 04-03
SHIFRIN S 001037 02-01
SHIHJC 004349 04-09
SHIH T 004290 04-06
SHIKAI I 000814 01-14
SHIMAK 001379 02-03, 002837 03-03
003714 04-03
SHIMEK EU 000006 01-01, 000538 01-06
SHIMIZUM 000012 01-02, 000142 01-03
000152 01-03 , 004149 04-04 , 004185
04-04 , 004193 04-04
SHIMIZUT 00027101-03, 002174 02-11
003093 03-04
SHIMOMURA K 004278 04-05 , 004295 04-06
SHIMOYAMA N 000639 01-09
SHIMOYAMA S 000639 01-09
SHINDO H 003941 04-03
SHINDOM 001659 02-04
SHINGU K 000628 01-09
SHINODAM 000856 01-15
SHINOHARAM 001380 02-03
SHIOMI H 000472 01-04
SHIOMI T 003692 04-02
SHIPLEY JE 002891 03-03
SHIPPENBERG TS 002947 03-04
SHIRAISHI Y 000012 01-02
SHIRAKI Y 001659 02-04
SHISHLYANNIKOVA LV 004067 04-04
SHIZGAL P 001579 02-04 , 001771 02-04
SHKODROVAD 000473 01-04
SHOEMAKER WJ 003735 04-03
SHOGAN G 004343 04-08
SHOLEVAR GP 004743 04-17
SHOLOMSK AS AJ 000886 01-15
SHOLOMSKASD 000624 01-09, 003272 03-
09
SHOPSIN B 000677 01-11, 002042 02-09
002043 02-09 , 002044 02-09 , 003632
03-17
SHORE D 000255 01-03 , 001444 02-03
SHORE PA 000201 01-03 , 002680 03-03
SHORVONSD 003366 03-11
SHOUSEMN 000474 01-04
SHPANSKAYALS 004016 04-03
SHRABERGD 002629 02-17
SHUGAL 003853 04-03
SHUKLAGD 003536 03-15
SHULGINAT 003683 04-02, 004310 04-07
SHUMAN R 002720 03-03
SHUMILINA Al 002892 03-03
SHURLEYJT 000879 01-15
SHUTOK 004192 04-04
SHUTOVAA 004579 04-14
SHVARTSBURD A 003304 03-1 1
SHYBUTG 001542 02-03
SIBLEY DR 001 186 02-03 , 003585 03-17 ,
004003 04-03
SICUTERI F 004553 04-13
SIDDALLJW 002606 02-17
SIDDIQUI RA 004274 04-05
SIDOROWICZ S 000573 01-08
SIEBER B 001626 02-04 , 001776 02-04 ,
001777 02-04
SIEGELRK 000986 01-17
SIEGERS C 002469 02-15
SIEGERTM 002290 02-13
SIEGFRIED B 001778 02-04
SIEGHART W 002893 03-03
SIEMENS RK 001414 02-03
SIEMKOWICZE 000475 01-04
SIESJOBK 001134 02-03
Ptychophormacology Abstracts
SIESTG 001507 02-03
SIEVER U 002366 02-14 , 003373 03-1 1
004659 04-15
SIGELLLT 000740 01-12
SIGGINS GR 000580 01-09 , 001 136 02-03
002884 03-03 , 003136 03-06 , 003735
04-03
SIGMUNDI RA 00 1 6 1 5 02-04
SIHM F 002033 02-09
SIKORAJ 002132 02-11
SILBERFARBPM 000876 01-15
SILBERGELDEK 000132 01-03, 000133 01-03
, 001288 02-03
SILBERMAN EK 000618 01-09
SILBRETM 001242 02-03
SILER-KHODR TM 000286 01-03
SILLANPAAM 000785 01-13
SILLEHRW 002343 02-14
SILLITO AM 002894 03-03
SILVACC 003163 03-07
SILVAOL 002637 03-01
SILVERMAN AY 000286 01-03
SILVERMAN PB 001779 02-04
SILVERMAN RB 001055 02-01, 001088 02-02
SILVERSTONET 000807 01-14, 002060 02-10
, 002607 02-17, 004363 04-09, 004580
04-14
SILVESTRI R 000442 01-04 , 000443 01-04
SIMANTOVR 004234 04-04
SIMEON J 001903 02-07, 002608 02-17
003383 03-11
SIMEON S 003383 03-1 1
SIMKE JP 001461 02-03
SIMKOA 000987 01-17
SIMMELSGAARD H 003472 03- 1 5
SIMMONS MA 000499 01-04
SIMMONS WH 001780 02-04
SIMON EJ 000128 01-03 , 001287 02-03
002609 02-17 , 003702 04-02 , 003840
04-03 , 004300 04-06
SIMON FR 003702 04-02
SIMON H 001696 02-04
SIMON J 000543 01-07
SIMON LD 003702 04-02
SIMON P 000598 01-09 , 001070 02-02
001072 02-02, 001232 02-03, 001942
02-08, 002278 02-13, 002292 02-13
003155 03-07 , 003424 03-13 , 003633
03-17
SIMONDSWF 001035 02-01, 001056 02-01
SIMONNETG 000272 01-03
SIMONOVICM 001719 02-04
SIMONTON S 001885 02-06
SIMPSON JA 003429 03-13
SIMPSON JB 000534 01-06
SIMPSON LL 004004 04-03 , 004005 04-03
SIMPSON M 004554 04-13
SINCLAIR JD 004220 04-04
SINCZUK-WALCZAK H 003500 03-15
SINDRUPEH 003484 03-15
SING J 003000 03-04
SINGER G 001801 02-04
SINGER HS 003374 03-11
SINGER L 001904 02-07 , 002895 03-03 ,
004270 04-05 , 004407 04-09
SINGH G 000629 01-09
SINGH MM 00261102-17
SINGH R 003891 04-03
SINGH SB 002175 02-11
SINGH VK 004581 04-14
SINGHAL RL 001427 02-03 , 001428 02-03 ,
003708 04-03
SINGLETON W 002060 02-10
SINHAJN 000247 01-03, 002703 03-03
SINYOR D 001781 02-04
SIOMOUPOULOS V 003260 03-09
SIPKOVSKAE 000615 01-09
SIRACUSANOA 002187 02-11
SIRAGANIAN RP 001 188 02-03
SIROKAA 000806 01-14, 002333 02-14
SITARAM N 002341 02-14 , 002506 02-16 ,
003255 03-09
SIWERS B 001967 02-09
SJOERDSMAA 001128 02-03
SJOGREN C 004006 04-03
SJOQUISTB 004534 04-13
SJOQVIST F 000754 01-13, 002282 02- 1 3 ,
002300 02-13
SJOSTEDTL 003542 03-15
A-32
VOLUME 19, AUTHOR INDEX
Author Index
SKARICICV 000977 01-17
SKETTP 000273 01-03
SKEWS H 004506 04-13
SKINGLEM 001782 02-04
SKINNER JT 002258 02-13
SKINNER T 000867 01-15
SKIRBOLL L 00 1 1 1 7 02-03 , 00 1 1 53 02-03 ,
001239 02-03
SKLENOVSKYA 000077 01-03, 000274 01-03
, 001474 02-03
SKLODWOSKI H 004660 04-1 5
SKODA C 002612 02-17
SKOGLUNDRR 000723 01-11
SKOLNICK P 000225 01-03 , 000275 01-03 ,
000276 01-03 , 000277 01-03 , 000450
01-04 . 001475 02-03 , 002645 03-01 ,
002857 03-03 , 002896 03-03 , 002972
03-04 , 003950 04-03 , 003962 04-03 ,
004172 04-04 , 004221 04-04 , 004251
04-04, 004689 04-16
SKONDIA V 000600 01-09 , 000988 01-17 ,
002132 02-11
SKORIKAI 003384 03-11
SKOVAJSOVAM 000542 01-07, 00213102-
11
SKOVBJERGH 002676 03-03
SKRODERR 002095 02-11
SKRYMA RN 004041 04-03
SKULAE 002507 02-16
SKURDALAJ 001586 02-04
SLANGENJL 004159 04-04
SLATER P 001476 02-03, 001783 02-04,
001784 02-04, 001785 02-04
SLATER SL 000612 01-09
SLAUGHTER MM 003145 03-06
SLAVNEYPR 003199 03-08
SUPER BE 001786 02-04
SLOTKINTA 000025 01-03, 000278 01-03,
002802 03-03 , 004021 04-03
SLOVITERRS 001787 02-04, 003094 03-04,
004007 04-03
SLYMEN DJ 002073 02-10
SMALL IF 003430 03-13
SMALL JG 003430 03-13
SMALLBERGS 003388 03-11
SMERALDI E 001460 02-03 , 002293 02-13 ,
004361 04-09
SMIALOWSKAM 001477 02-03, 001788 02-
04
SMIALOWSKIA 001788 02-04
SMIGANL 004664 04-15
SMITMH 000279 01-03
SMITH AA 000318 01-03
SMITHS 003422 03-13
SMITH CB 003408 03-13 , 003763 04-03 ,
004008 04-03 , 004242 04-04
SMITH Ca 002843 03-03 , 002897 03-03
SMITH CE 000052 01-03
SMITH CM 003454 03-14
SMITH CP 002898 03-03
SMITH CW 001591 02-04
SMITH DE 000745 01-12 , 000746 01-12 ,
000924 01-17
SMITH DP 000016 01-02 , 000082 01-03 ,
004222 04-04 , 004223 04-04
SMITH DJ 004009 04-03
SMITH DL 003143 03-06
SMITH DW 003462 03-15
SMITH EB 001686 02-04
SMITHES 000476 01-04
SMITH GC 001478 02-03
SMITH GP 000383 01-04, 000384 01-04
SMITH JM 000989 01-17, 002455 02- 1 5 ,
003537 03-15
SMITH JR 000280 01-03 , 004010 04-03 ,
004300 04-06
SMITH LT 003460 03-14
SMITH MT 004555 04-13
SMITH N 000745 01-12
SMITH PA 002870 03-03
SMITH PR 000528 01-05
SMITH R 002179 02-11
SMITH RC 000134 01-03, 000572 01-08,
000726 01-11 , 000882 01-15, 000908
01-16 , 000934 01-17 , 001789 02-04 ,
002456 02-15 , 003095 03-04 , 003304
03-11 , 003385 03-11 , 003901 04-03 ,
003940 04-03 , 004694 04- 1 6
SMITH RG 001089 02-02
SMITH RK 00003101-03
SMITH RN 004693 04-16
SMITH RV 001822 02-04
SMITH SA 002899 03-03
SMITH TG 000116 01-03
SMITH TM 001113 02-03
SMITHWICK EL 002720 03-03
SMOLNIKOVA NM 001854 02-05
SMULEVICH AB 004340 04-08
SMYTH RD 004691 04-16
SNAITH RP 000579 01-09
SNEADOCI 000477 01-04, 000478 01-04
SNELLD 000479 01-04, 001645 02-04
SNIDER RH 002637 03-01
SNIDER SR 002401 02-15
SNODDY HD 000101 01-03 , 002726 03-03 ,
002995 03-04 , 003796 04-03
SNYDER S 000074 01-03 , 000230 01-03 ,
000564 0 1 -08 , 000656 01-10, 00079 1
01-13, 000990 01-17, 001124 02-03,
001 125 02-03 , 001837 02-05 , 002083
02- 1 0 , 0026 1 3 02- 1 7 , 002688 03-03 ,
002730 03-03 , 002835 03-03 , 002860
03-03 , 002861 03-03 , 002922 03-03 ,
003197 03-08 , 003199 03-08 , 003685
04-02 , 003766 04-03 , 003964 04-03 ,
003992 04-03 , 004198 04-04 , 004430
04- 1 0 , 004556 04- 1 3 , 004744 04- 1 7
SNYDERMANS 002017 02-09
SO EL 003375 03-11
SOR 003190 03-08
SOBCZYKP 004486 04-11
SOBOTKAP 000460 01-04, 001439 02-03
SOE-AGNIECJ 003913 04-03
SOKOLOPPH 004673 04-16
SOKOLOFP L 001365 02-03 , 001380 02-03 ,
001877 02-06
SOKOLOPP P 002900 03-03
SOKOLOVSKY M 002875 03-03
SOLDATOS C 002614 02-17 , 004373 04-09 ,
004519 04-13, 004567 04-14
SOLOMON PR 003872 04-03
SOLYOM C 002084 02-10 , 003285 03-10
SOLYOM L 002084 02-10, 003285 03-10
SOMCW 004650 04-15
SOMJENGG 000738 01-12
SOMMERR 004443 04-11
SONAWANE BR 000281 01-03
SONDERGAARD I 003428 03-13
SONISD 00461104-15
SONTAGK 000054 01-03
SONTAGN 000156 01-03
SOOKMAN D 002084 02-10
SORELL 004487 04-11
SORENSEN KH 002329 02-14
SOSTEKAJ 002359 02-14
SOTANIEMI EA 002260 02-13
SOUBRIE P 000480 01-04 , 00401 1 04-03
SOUCEK K 000595 01-09 , 000630 01-09 ,
002457 02-15, 00326103-09
SOUDIJN W 001347 02-03 , 002698 03-03 ,
003913 04-03
SOUKUPK 000544 01-07
SOULAIRACA 001479 02-03
SOULAIRACM 001479 02-03
SOUMIREU-MOURAT B 00305103-04
SOURANDERL 002360 02-14
SOURKESTL 000246 01-03, 000500 01-04
SOUTHAMAS 003142 03-06
SOUVATZOGLOU AM 000786 01-13
SOUZADO 00007101-03, 001664 02-04
SOVNER R 001931 02-08 , 003376 03-1 1
SOWELLJW 003700 04-02
SOWINSKI R 004273 04-05
SPADAROC 000282 01-03, 001468 02-03
SPADAROM 002355 02-14
SPALLONEL 002226 02-13
SPALTEND 003321 03-11
SPAMPINATO S 001468 02-03
SPANO PP 000285 01-03 , 001480 02-03 ,
001481 02-03 , 001482 02-03 , 001512
02-03, 00212102-11, 002828 03-03
SPARSER SB 000085 01-03 , 001084 02-02 ,
00 1 632 02-04 , 00 1 790 02-04
SPATZH 002018 02-09
SPEALMANRD 003096 03-04, 004012 04-03
, 004224 04-04 , 004225 04-04
SPEAR LP 000481 01-04 , 000482 01-04 ,
001470 02-03, 001774 02-04, 002901
03-03
SPECIALS SG 000 1 53 0 1 -03 , 00 1 3 1 0 02-03
SPECTOR S 000317 01-03
SPENCE I 003742 04-03
SPENCER J 002176 02-11
SPENCER PS 002736 03-03 , 002905 03-03
SPERK G 001308 02-03
SPERLICH S 000819 01-14
SPERRYR 000424 01-04
SPETH RC 001710 02-04 , 002902 03-03 ,
004013 04-03
SPIEGEL D 000823 01-14
SPIEGEL R 00 1 944 02-08 , 0022 1 7 02- 1 3
SPIEHLERVR 004143 04-04, 004177 04-04
SPIKER DG 000631 01-09 , 003236 03-09 ,
003634 03-17
SPINA F 001200 02-03
SPINDELE 004014 04-03
SPINWEBERCL 003455 03-14, 004568 04-14
SPIRDUSOWW 004226 04-04
SPIRTESMA 000402 01-04
SPISSU A 001483 02-03
SPITERI NJ 000483 01-04
SPOKES EG 000564 01-08, 002575 02-17
SPOTNITZS 001305 02-03
SPRICKU 004015 04-03
SPRIET A 002045 02-09 , 0026 1 5 02- 1 7 ,
003635 03-17
SPRING DD 001267 02-03
SPRINGER PK 000889 01-15
SPUNTA 000872 01-15
SPYRAKIC 000283 01-03
SQUIBB RE 004264 04-05
SQUILLACE KM 002866 03-03 , 003067 03-04
SQUIRE LR 000824 01-14, 003636 03- 1 7
SQUIRES RF 001484 02-03 , 002903 03-03 ,
003739 04-03
SRAMKOVAJ 000570 01-08, 00076101-13
SRINIVASAN Y 001009 02-01
SRIVASTAVADN 001769 02-04
SRIVASTAVA JR 002 1 75 02- 1 1
SRIWATANAKUL K 001878 02-06
ST-PIERRES 000243 01-03
STAAK M 000825 01-14 , 003456 03-14
STABROVSKIY YM 004016 04-03
STACH R 004227 04-04
STACHURAJ 001844 02-05
STADLER R 000720 01-11
STAHL SM 000887 01-15, 003286 03- 1 0 ,
004442 04-11
STAINTHORP SF 004279 04-05
STALLONE F 000587 01-09
STAMMER 001791 02-04
STAMMG 002748 03-03
STAMMER CH 003684 04-02
STANCELGM 002778 03-03
STANCER HC ,000300 01-03 , 001990 02-09
STANISHEVSKAYA AV 004017 04-03
STANLEY M 000461 01-04 , 000561 01-08 ,
001533 02-03 , 001948 02-08 , 002877
03-03
STAPLETON JM 003 1 1 8 03-04
STARK LG 001559 02-04 , 002653 03-03 ,
002862 03-03 , 002946 03-04
STARK P 004228 04-04 , 004280 04-05
STARK-ADAMEC C 002202 02- 1 2
STARKE K 000535 01-06, 001298 02-03,
002748 03-03 , 002751 03-03 , 003637
03-17, 003983 04-03
STARKEYIR 002458 02-15
STARMARKJ 000888 01-15
STARMERGA 002193 02-12
STAROBINETS MK 003457 03-14
STARR BJ 004704 04-17
STARR MS 000158 01-03 , 004141 04-04 ,
004158 04-04
STARRATTC 000284 01-03
STASSEN HH 001962 02-09
STASTNAD 000815 01-14
STATON RD 002459 02-15
STAUBRA 001672 02-04, 003022 03-04,
003023 03-04 , 003499 03- 1 5
STAUDERMAN K 00 1 794 02-04
STAUNTON DA 001485 02-03 , 003735 04-03
, 004229 04-04
STAVERISS 002492 02-16
STAYEJ 002409 02-15
STEELE TE 000545 01-07
STEELE WJ 001750 02-04
STEPANINI E 000285 01-03 , 001481 02-03
A-33
Author Index
Psychopharmacology Abstracts
a.
at
I
I
STEFANIS C 000786 01-13, 002294 02- 1 3 ,
004059 04-03
STEFANOVICHV 001052 02-01, 001499 02-
03
STEFANYSYN H 00 1 285 02-03
STEGERRW 000286 01-03
STEGGLESDJ 00159102-04
STEIN F 001920 02-08
STEIN GS 002830 03-03 , 002831 03-03
STEIN JL 002830 03-03 , 002831 03-03
STEIN L 000991 01-17
STEINBERGS 000638 01-09
STEINBERG D 000992 01-17
STEINBERG H 000401 01-04 , 001646 02-04
STEINBOOK R 001931 02-08
STEINBRENNER J 001490 02-03
STEINERJA 001486 02-03, 001487 02-03
STEINERM 001792 02-04
STEINER S 004341 04-08
STEINFELDAS 001059 02-01
STEINFELS GF 000505 01-04 , 003097 03-04 ,
004230 04-04 , 004259 04-04
STEINGOLDRG 000955 01-17
STEINHAUER HB 002904 03-03 , 003983 04-
03
STENBERG D 001879 02-06
STENEVIU 000347 01-04, 003910 04-03
STENGAARD-PEDERSEN K 003805 04-03
STENZLERS 002417 02-15
STEPHAN F 004407 04-09
STEPHAN K 004309 04-07
STEPHENS JH 000836 01-15
STEPHENS R 003686 04-02, 004557 04-13
STEPHENSON JD 001734 02-04
STEPOVIK NV 003438 03-14
STEPPELERA 000535 01-06
STERANKALR 000287 01-03
STERCJ 002865 03-03
STERMANAB 002905 03-03
STERMAN MB 000474 01-04
STERN GM 002177 02-1 1 , 002365 02-14 ,
004640 04-15
STERN JM 000510 01-05
STERN S 003164 03-07 , 003570 03-16
STERN W 003227 03-09
STERNBERG D 00125102-03, 001488 02-03
001952 02-08, 002098 02-11, 004231
04-04
STERNBERG S 000083 01-03
STERNER U 004142 04-04
STEVENS R 003098 03-04
STEVENSON IH 002534 02-17
STEWART D 000553 01-08, 001489 02-03
STEWART J 000632 01-09 , 002709 03-03 ,
002710 03-03 , 002906 03-03 , 003228
03-09 , 003240 03-09 , 003241 03-09 ,
003262 03-09 , 003684 04-02
STEWART RB 000889 01-15
STEWART SE 000518 01-05
STEWART WRC 002080 02-10
STIKA L 000993 01-17 , 002542 02-17 ,
002616 02-16
STILLER RL 000619 01-09
STILWELLDJ 001793 02-04
STINUSL 001696 02-04
STITZERML 004582 04-14
STOCCOS 001446 02-03
STOCK G 001490 02-03
STOCKHAUS K 000013 01-02
STOFFDM 001794 02-04, 001957 02-08,
00 1 958 02-08 , 0040 1 8 04-03
STOICAE 002295 02-13
STOKES KB 001335 02-03
STOKES PE 000187 01-03
STOLBERG-ACOSTA R 003638 03-17
STONE AL 001057 02-01
STONE BM 004574 04-14
STONE TW 000229 01-03, 001410 02-03,
002907 03-03 , 003963 04-03
STONE WE 000288 01-03, 004232 04-04
STOOFJC 000289 01-03, 001390 02-03
STOSCH R 003344 03-11
STOTLAND LM 00154102-03
ST0TL^NDM 004053 04-03
STRACHERA 000290 01-03
STRADASJ 001445 02-03
STRAIT MR 000162 01-03
STRAJELEVICH D 000083 01-03
STRAMENTINOLI G 002883 03-03 , 004019
04-03
STRANDS 003570 03-16
STRANDJORDRE 002234 02-13, 004488 04-
11
STRANGE PG 001253 02-03
STRANSKY P 000593 01-09
STRATHDEEA 001416 02-03
STRAUGHAN DW 003931 04-03
STRAUMANIS JJ 003263 03-09
STREATY RA 001033 02-01 , 001056 02-01
STRECKO A 000609 0 1 -09 , 00 1 934 02-08
STREICHENWEIN SM 002012 02-09
STREKALOVA SN 001854 02-05
STRELKOVRB 001354 02-03
STRELTZERJ 002460 02-15
STRIAN F 000633 01-09
STRICKER EM 000484 01-04 , 002632 02-17 ,
003120 03-04
STRICKLAND R 004745 04-17
STRID C 001737 02-04
STRIPLING JS 004233 04-04
STRITTMAHER W 00 1 279 02-03 , 00 1 502 02-
03
STRNADP 000724 01-11
STROEBELCF 000539 01-07
STROHLKP 002128 02-11
STROHM H 000825 01-14
STROLIN BENEDEH! M 000156 01-03
STROMBOMU 00029101-03
STROMGRENL 000792 01-13
STRONG R 00 1 2 1 5 02-03 , 0027 1 6 03-03
STROSBERGAM 003900 04-03
STROTHERA 000292 01-03
STRUBELTO 001855 02-05
STRUVE F 000858 01-15 , 003501 03-15
STRZYZEWSKIW 000625 01-09, 002040 02-
09
STUART WK 003319 03-11
STUBBSWA 001016 02-01, 00373104-03
STUDER K 004627 04-15
STUDY RE 004020 04-03
STULEMEIJER SM 000592 01-09, 003503 03-
15, 004395 04-09
STULNIKOVBV 003713 04-03
STUMPFC 003804 04-03
STUMPF WE 002639 03-01
STUNKARDAJ 000725 01-11
STURGEON RD 001616 02-04, 001719 02-04
STUTZRM 001795 02-04
SUCY 004489 04-11
SU T 001491 02-03
SUBA P 001635 02-04
SUBASHM 000627 01-09
SUBRAMANIAN N 004021 04-03
SUDAKOVKV 003716 04-03
SUDKOVAM 000544 01-07
SUEOKAS 003187 03-08
SUESSWM 003538 03-15
SUGERMANAA 003180 03-08
SUGIHARAK 000639 01-09
SUGIKAWAM 004022 04-03
SUGRUE MF 000293 01-03 , 001492 02-03 ,
002908 03-03
SULCOVAA 000485 01-04, 001796 02-04
SULLIVAN AC 003905 04-03 , 004044 04-03
SULLIVAN FM 004108 04-04
SULLIVAN J 003306 03-11
SULSERF 000208 01-03, 000793 01-13,
001353 02-03 , 001493 02-03 , 002617
02-17, 004746 04-17
SUMIKAWA K 003868 04-03
SUMMERLINJ 002618 02-17
SUMMERS R 000536 01-06 , 003388 03-1 1
SUMMERS W 003377 03-11, 003539 03-15
SUNDARAMY 004490 04-11
SUNDBERG DK 000537 01-06
SUNOERMANN RH 000294 01-03
SUNDTTMJ 000295 01-03
SUPAVILAI P 002775 03-03 , 002893 03-03 ,
002909 03-03 , 004023 04-03
SUPPRIANU 003540 03-15
SURWILLOWW 00343103-13
SUSICV 003703 04-02
SUSSMAN S 004577 04-14
SUTAKM 003863 04-03
SUTFINTA 003479 03-15
SUHER J 002296 02- 1 3 , 0026 19 02-17
SUTULATP 003378 03-11
SUVA J 000605 01-09 , 001494 02-03 ,
002297 02-13
SUZUKI A 000219 01-03
SUZUKI J 00449104-11
SUZUKI 0 004024 04-03
SUZUKIS 001659 02-04
SUZUKI T 000769 01-13, 001797 02-04,
004257 04-04 , 004258 04-04
SUZUKI Y 004518 04-13
SVAREB 003159 03-07
SVATEKE 002279 02-13
SVEDAF 000296 01-03, 004025 04-03
SVEJKOVSKA J 000576 0 1 -08 , 000654 01-10
SVEJNOHOVA D 001494 02-03
SVENDSENO 000890 01-15
SVENSK H 001067 02-02
SVENSSONTH 001214 02-03, 001392 02-03
004026 04-03
SVENSSONU 000399 01-04
SVESTKAJ 000567 01-08, 000568 01-08
000613 01-09, 000634 01-09, 000663
01-11, 001937 02-08, 001949 02-08,
001975 02-09 , 002021 02-09 , 003245
03-09 , 003264 03-09 , 004375 04-09
SVIRIDOVAYI 003289 03-11
SVORAD D 001268 02-03 , 001495 02-03 ,
001551 02-03
SWANH 001544 02-03
SWANN AC 000297 01-03 , 001496 02-03 ,
002910 03-03, 00291103-03
SWANSONJM 002134 02-11
SWARTZCM 001879 02-06, 00466104-15
SWASH M 003454 03-14
SWEENEY DR 000899 01-16 , 003220 03-09 ,
003317 03-11
SWEENEY DW 000764 01-13
SWEENEY KF 001598 02-04
SWEET WH 001497 02-03
SWIGAR M 003667 04-01
SWITZER RC 001498 02-03
SWITZMAN L 001781 02-04 , 001798 02-04
SYAPIN PJ 000450 01-04 , 001499 02-03
SYKES M 002741 03-03 ±
SYLVESTER PW 000298 01-03 ■
SYMCHOWICZB 004103 04-04
SYMMES SK 003076 03-04
SYMONDSRL 003265 03-09
SYNDER SH 002575 02-17
SYNDULKOK 002182 02-11
SYNKOVAJ 002064 02-10
SZABADI E 002298 02-13
SZABOG 00303103-04
SZAJNERMAN Z 004416 04-09
SZAREK BL 000539 01-07
SZCZUDRAWA J 00 1 844 02-05
SZEPY 001500 02-03
SZECHTMAN H 004234 04-04
SZEKELYJI 000486 01-04, 001799 02-04,
002650 03-02
SZENTISTVANYI I 001300 02-03 , 002765 03-
03
SZERBJC 001130 02-03
SZEREDA-PRZESTASZEWSKA M 001501 02-03
SZETO HH 004027 04-03
SZORADYI 002461 02-15
SZRENIAWSKI Z 003050 03-04
SZUCS-MYERS VA 004122 04-04
SZUKALSKI B 000794 01-13
TABERNER PV 002361 02-14
TABRIZIMA 000619 01-09, 000776 01-13,
003411 03-13
TACHI N 000856 01-15
TACHIKAWA S 002936 03-03
TACHIKI KH 004352 04-09
TADAKI E 002794 03-03
TADANO T 004301 04-06
TADOKORO S 001693 02-04 , 003032 03-04 ,
004128 04-04, 004165 04-04
TAEUBER K 002362 02-14
TAFTWa 000299 01-03
TAGASHIRA E 001800 02-04
TAITA 002433 02-15
TAKAGI H 000472 01-04 , 001691 02-04 ,
003083 03-04
TAKAHASHI DM 004302 04-06
TAKAHASHI H 003099 03-04
TAKAHASHI M 0037 1 4 04-03
TAKAHASHI N 001379 02-03
A-34
VOLUME 19, AUTHOR INDEX
Author Index
TAKAHASHI R 000635 01-09 , 000636 01-09
, 00180102-04, 002442 02-15, 004388
04-09. 004422 04-10
TAKAHASHI Y 003679 04-01
TAKANON 001659 02-04
TAKANOY 004028 04-03
TAKAORI S 000260 01-03 , 004139 04-04
TAKASHIMAS 000696 01-11
TAKAYANAGUI OM 003328 03-1 1
TAKEMORI AE 00031 1 01-03 , 001 162 02-03
, 003104 03-04, 004082 04-04
TAKESHITA H 003 1 79 03-08 , 0034 1 5 03- 1 3 ,
003416 03-13
TAKEUCHIY 000795 01-13
TAKEYASU K 001272 02-03
TALAIRACHJ 003334 03-11
TALALAYENKO AN 003100 03-04
TAUAARD JJf 002839 03-03 , 002859 03-03
TALLMANJF 000038 01-03, 000103 01-03,
00 1 279 02-03 , 00 1 502 02-03 , 00 1 503
02-03 , 001504 02-03 , 002912 03-03 ,
004705 04-17
TAMARGOJ 003988 04-03
TAMMINGA C 000572 01-08 , 000726 01-1 1
, 000908 01-16, 002178 02-11, 002179
02-11, 002387 02- 1 5 , 003 1 98 03-08
TAMMISTO P 000261 01-03
TAMURAT 003415 03-13
TANABEH 003544 03-15
TAN ABE K 000502 01-04
TANAKAK 004518 04-13
TANAKAM 003941 04-03
TANAKAS 002913 03-03, 002920 03-03
TANCREDI L 003471 03-15
TANDBERGD 003541 03-15
TANG FLM 000091 01-03
TANG M 004235 04-04
TANG SW 000300 01-03 , 001204 02-03 ,
002914 03-03
TANIGUCHIT 000317 01-03
TANIMOTOK 000645 01-09, 003187 03-08,
003266 03-09
TANSELLACZ 002085 02-10
TAPPAZML 001047 02-01, 001048 02-01
TARCHALSKA B 003050 03-04
TARDI M 004384 04-09
TARDY A/\ 004029 04-03
TARGONSKAA 00060101-09
TARGUM SO 002363 02-14
TARIKAJ 001802 02-04, 004359 04-09
TARNAWA I 000486 01-04
TARNAWSKIA 001844 02-05
TARNOPOLSKYA 003647 03-17
TARONIPL 001460 02-03
TARSY D 002373 02- 1 5 , 003294 03- 1 1
TARTAROT 002342 02-14
TARTER R 003180 03-08
TASAKII 001505 02-03
TATARELLI R 002187 02-11
TATEISHIN 001506 02-03
TATURYAN IK 002663 03-03
TATYANENKOLV 00133102-03
TAUBH 003312 03-11
TAUKULIS HK 001086 02-02
TAUSSIGOVAD 002131 02-11
TAUZIEDE-CASTEL C 003404 03-13
TAVANI A 000301 01-03
TAYLOR AN 000180 01-03
TAYLOR CI 000545 01-07
TAYLOR DA 000095 01-03, 000107 01-03,
004243 04-04
TAYLOR DP 001050 02-01, 001383 02-03,
003103 03-04 , 003855 04-03
TAYLOR GC 003355 03-11
TAYLOR JE 001880 02-06, 004030 04-03
TAYLOR KE 000380 01-04
TAYLOR MA 003463 03-15
TAYLOR P 001043 02-01 , 002374 02-15 ,
002421 02-15
TAYLOR SP 001233 02-03
TAYLOR T 004504 04-13
TAYLOR WJ 004031 04-03
TAZIA 001507 02-03
TEAL J J 001803 02-04, 004236 04-04
TEASDALEGM 003817 04-03
TEELKENAW 001959 02-08, 00231102-13
TEGELERJ 000562 01-08, 004342 04-08
TEGYEY Z 000010 01-02 , 00001 1 01-02
TEITELBAUAA P 000376 01-04
TELEGDYG 003031 03-04
TELFORD R 004669 04-16
TELL G 002237 02-13 , 003458 03-14 ,
003620 03-17
TELLEZ-VILLAGRA C 00310103-04
TEMPLETON WW 003841 04-03
TEN BRUGGENCATE G 00 1 244 02-03
TEN OEVER 6HAA 002072 02-10
TENEN SS 002915 03-03
TENNENTTG 004747 04-17
TEORKC 002193 02-12
TEPPERS 002102 02-11
TERAO M 003856 04-03
TERASAWAE 003074 03-04
TERAVAINEN H 003309 03- 1 1 , 0033 1 9 03- 1 1
TERENIUS L 000027 01-03 , 002620 02-17 ,
003062 03-04
TERRENCECF 002122 02-11
TERRY LC 002693 03-03
TERRY WS 000487 01-04
TERZANIS 000603 01-09, 002007 02-09
TESCHEAAACHER H 003740 04-03
TESSEL RE 000492 01-04 , 001 155 02-03
TESTA B 002358 02-14
TETSUO M 001043 02-01 , 001058 02-01
TEYSSONEYRE B 004307 04-07
THALU 001447 02-03, 002180 02-11,
002814 03-03
THANKICM 000413 01-04
THARPB 002437 02-15
THARPVK 002369 02-14
THAVUNDAYIL JX 00244102-15
THEILGAARDA 004607 04-15
THELLIERM 002299 02-13
THEODORE W 004522 04-13
THEODOROU A 001 174 02-03 , 001 175 02-03
, 00130102-03, 002390 02-15, 002707
03-03 , 004032 04-03 , 004033 04-03 ,
004252 04-04
THESLEFFS 003916 04-03
THIEBOTMH 000480 01-04, 003633 03-17
THIELSC 002462 02-15
THIEAAERE 000289 01-03
THILL R 002046 02-09
THIVEL-CHAAACHAAA H 003441 03-14
THOLOSE A 002576 02-17 , 002621 02-17
THOAAASAJ 002843 03-03
THOAAASC 002433 02-15
THOAAAS J 000103 01-03 , 000302 01-03 ,
00 1 502 02-03 , 00 1 503 02-03 , 00 1 504
02-03 , 002508 02-16 , 002912 03-03
THOAAAS LW 000348 01-04
THOAAAS NU 003511 03-15
THOAAASOVAE 002136 02-11
THOAAPSONCL 003437 03-13
THOAAPSON DA 000828 01-14
THOAAPSON DAA 001723 02-04
THOAAPSON EJ 002897 03-03
THOAAPSON JW 004669 04-16
THOAAPSON RF 002916 03-03
THOAAPSON RG 000390 01-04
THOAAPSON T 002364 02-14, 004095 04-04
THOAASENA 000792 01-13
THOAASEN K 003547 03-15
THORDH 000488 01-04
THORELLL 000604 01-09
THOREN P 002086 02-10 , 002300 02-13
THORN BE 003102 03-04
THORNERAAO 002291 02-13
THORNHILL JA 004034 04-03
THORNTON C 002365 02-14
THORPYAAJ 000727 01-11
THREAHERAA 001623 02-04, 004237 04-04
THULESIUSO 001950 02-08
THURAAAN GB 004324 04-08
THURSTON JH 004281 04-05
THYSELLH 003542 03-15
TIJ 001059 02-01
TICKUAAK 000303 01-03, 001154 02-03,
001 192 02-03 , 002301 02-13 , 004035
04-03 , 004036 04-03 , 004037 04-03
TIGHEPJ 003198 03-08
TIGNOLJ 000834 01-15
TIKALK 001804 02-04
TILSON HA 001862 02-06 , 004264 04-05 ,
004265 04-05
TIAAKOJ 00199102-09
TIAAAAERAAANS PBAAWAA 00 1 508 02-03
TIAAOTIJEVIC-AAARKOVIC I 002047 02-09
TIAASIT-BERTHIER AA 004583 04-14
TINKLENBERG JR 002317 02-14, 004493 04-
11 , 004665 04-15
TIPLADYB 004385 04-09, 004677 04-16
TIPTON KF 003639 03-17
TIRELLI AS 003758 04-03
TISSOT R 0022 1 8 02- 1 3 , 0029 1 7 03-03
TITELER AA 00 1 509 02-03 , 00 1 5 1 0 02-03 ,
001511 02-03
TITOV SA 002949 03-04
TIWARI S 003462 03-15
TOBINJAA 000574 01-08
TOBISJAA 001856 02-05
TOBLER I 002958 03-04
TOCCODJ 000502 01-04
TOCHILOVVA 00335103-11
TODAK 001294 02-03
TODAN 001273 02-03
TODOROKIAA 001808 02-04
TOFFANOG 002682 03-03, 003419 03-13
TOGNONI G 002521 02-17
TOIDEK 001857 02-05
TOKUNAGAY 001393 02-03, 002834 03-03
TOLBERTLC 002302 02-13
TOLLEFSONG 002463 02-15, 002918 03-03
TOLLENAEREJP 002197 02-12
TOLAAACHEVA NS 001363 02-03, 001705 02-
04
TOLAAAN KG 002422 02-15
TOLNAJ 003193 03-08
TOLPYSHEV BA 000489 0 1 -04
TOAAASEHI F 003466 03-15
TOAAASIKOVAZ 001690 02-04, 001805 02-
04
TOAABAUGH J 000490 0 1 -04
TOAABAUGH TN 000490 0 1 -04 , 00 1 806 02-04
TOAABROS E 002527 02-17
TOAAIZAWAS 004022 04-03
TOAAPKINS EC 003103 03-04
TOAASONT 002181 02-11
TONDA K 004062 04-03
TONGTG 000796 01-13
TONGROACH P 002691 03-03
TOPALG 003895 04-03
TOPIARA 000643 01-09
TORDA T 001 279 02-03 , 001 546 02-03 ,
002919 03-03
TORUS 002350 02-14
TORRE E 002872 03-03 , 002873 03-03
TORRES-CHAZARO 0 002969 03-04
TORTELLA FC 004038 04-03
TOSCA P 002057 02-09 , 002058 02-09
TOSTESON DC 003640 03-17
TOTH J 004039 04-03
TOURNILHAC AA 002048 02-09
TOURTELLOHE WW 002 1 82 02- 1 1
TOVAREKJ 003423 03-13
TOWELLJF 003146 03-06
TOYLY 001810 02-04
TRABUCCHIAA 001480 02-03, 00148102-03
, 001482 02-03, 001512 02-03, 002121
02-11 , 002828 03-03
TRAAAPOSCH A 004040 04-03
TRANVT 000074 01-03
TRASKAAAN L 002086 02-10 , 002282 02-13 ,
002300 02-13
TRAUER T 002374 02-15 , 002421 02-15
TRAYNOR JR 002241 02-13
TREISERS 000304 01-03
TREISSERC 001902 02-07
TRENDELENBURG U 000535 01-06
TRESSELWR 000530 01-06
TRIANOT 000388 01-04
TRICKLEBANK AAD 002673 03-03
TRICOUBJ 004538 04-13
TRIAABLEAAR 002183 02-11, 004662 04-15
TRINERL 000305 01-03
TRINUS KF 004041 04-03
TRIPATHI HL 001513 02-03
TRITESRL 002120 02-11, 003312 03-11
TROJABORG W 000 1 26 0 1 -03
TROLING 000040 01-03
TROHA EE 004042 04-03
TROUPINAS 000728 01-11
TRUBNIKOVVI 003176 03-08
TRULSON AAE 000491 01-04 , 003018 03-04
TRUONG L 004286 04-06
TSAAAISAA 002529 02-17
TSANGWK 001795 02-04
TSATSASG 003698 04-02
A-35
1
%
a.
ai
'h
;i
I
t
Author Index
TSENG L 000433 01-04, 00108102-02
001642 02-04 , 001643 02-04 , 004238
04-04
TSIRKIN SY 004335 04-08
TSITINI-TSAMIS M 002498 02-16
TSKHADADZE LV 004043 04-03
TSUANGMT 003508 03-15
TSUCHIE H 000639 01-09
TSUCHIMOTOS 000199 01-03
TSUEI SE 002508 02-16
TSUJIMOTOA 002913 03-03, 002920 03-03
TSUKINOKI Y 003692 04-02
TSUNOOA 000167 01-03
TSUTSULKOVSK AYA MY 003 1 76 03-08
004381 04-09
TSYGANKOVBD 004584 04-14
TSYRLINVA 001514 02-03
TUJ 003380 03-11
TUASONVB 002825 03-03
TUCEK S 004044 04-03
TUCK JR 001967 02-09
TUFIK S 004239 04-04
TUISLE 001087 02-02
TUKIAINEN E 000637 01-09
TULUNAYEC 003104 03-04
TUMA I 002055 02-09
TUAAILASCI OR 003 1 30 03-05
TUMMINELLOMC 001126 02-03
TUNE LE 000566 0 1 -08 , 003 1 99 03-08
003374 03-11
TUOMISTO J 000637 01-09 , 001067 02-02 ,
001078 02-02
TUPPER OE 001591 02-04 , 001592 02-04
TURBOnj 002184 02-11
TURCK M 002884 03-03
TURI AR 003872 04-03
TURKANIS SA 001671 02-04 , 004040 04-03
TURKER RK 004275 04-05
TURKSON SNA 001926 02-08
TURNBULL MJ 004240 04-04
TURNER CE 000344 01-04, 001022 02-01
001023 02-01
TURNER JAM 002343 02-14
TURNER P 000807 01-14, 004597 04-15
TURNER SM 000657 01-10
TURSKA-KOEPPE G 003500 03-15
TURSKI L 001515 02-03 , 001685 02-04
002921 03-03 , 004241 04-04
TURSKI W 002921 03-03 , 004241 04-04
TURTLE JR 002062 02-10
TWEEDALER 002422 02-15
TWITCHIN B 002633 03-01
TYBRING G 000897 01-16 , 002181 02-1 1
TYCEGM 003432 03-13
TYERSMB 001782 02-04, 001807 02-04
TYKVA R 003696 04-02
TYLER TD 000492 01-04
TYRER P 000638 01-09 , 002464 02-15
003543 03-15
U
UCHIDA S 000493 0 1 -04 , 00 1 272 02-03
UCHIDA-ERNOUF G 003689 04-02
UCHIGATAM 003544 03-15
UCHIMURAH 000212 01-03, 00278103-03
UCHTENHAGEN A 004452 04-1 1
UDINSKYJ 000017 01-03
UEBELHACK R 002049 02-09
UEDA I 004283 04-05
UEKI S 000417 01-04, 00168102-04
003004 03-04, 003397 03-12, 003951
04-03
UENO K 002937 03-03
UESUGI J 004258 04-04
UETRECHTJP 003545 03-15
UHDE TW 002366 02-14
UHLGR 002566 02-17
UHLENHUTHEH 002328 02-14, 002334 02-14
, 002335 02-14, 003445 03-14
UKAI M 003020 03-04
ULLMANNRK 002313 02-14
ULRICHG 004410 04-09
ULRICH R 003236 03-09
UMEZAWAY 000639 01-09
UMSTEADGS 003381 03-11
UNEMI N 001857 02-05
UNISA 003356 03-11
UNNERSTALL JR 002644 03-01
UOTILAL 000694 01-11
UPHOUSE LL 004264 04-05
UPRICHARDDC 001516 02-03, 003992 04-03
, 004676 04-16
URBA-HOLMGREN R 000407 01-04, 001656
02-04
URCAG 000494 01-04
URETSKY N 002796 03-03 , 003033 03-04
004117 04-04
URQUILLA PR 003697 04-02
URSILLOR 000326 01-03, 001305 02-03
URSIN R 003704 04-02
USDIN TB 002922 03-03
USHIJIMA I 001808 02-04
USOT 003230 03-09
UYLINGS HBM 004091 04-04
UZANA 000176 01-03, 001517 02-03
003898 04-03 , 003899 04-03
VAATSTRAWJ 00265103-02
VACEK J 003267 03-09
VADROTM 001090 02-02, 002014 02-09
VAGNUCCI AH 000484 01-04
VAGOGNEL 002430 02-15
VAILBJ 001618 02-04
VAISANEN K 002185 02-11
VAISH SC 002186 02-11
VAJDAFJE 003433 03-13
VALCHARM 000306 01-03, 001720 02-04
VALCOURT RJ 003077 03-04
VALDESJJ 000390 01-04
VALDMAN AV 003641 03-17 , 004261 04-04
VALEW 003985 04-03
VALENTINE JO 003105 03-04
VALENTINO RJ 001518 02-03 , 001651 02-04
, 003106 03-04, 004132 04-04, 004242
04-04
VALENTOVIC M 000307 0 1 -03
VALENZUELAAL 000102 01-03
VALERI P 001107 02-03 , 002515 02-17
VALEHEA 000797 01-13
VALLA JP 000994 01-17
VALLANOML 000430 01-04
VALLIM 00137102-03, 003642 03-17
VALLILLOR 003173 03-08
VALLSJM 001930 02-08
VALLVEC 001978 02-09
VALMIKINATHAN K 004490 04-1 1
VALOVIRTAE 003330 03-11
VALZELLI L 000932 01-17 , 000995 01-17
002622 02-17 , 003705 04-02
VAMOSE 001944 02-08
VAN AMERONGEN P 002050 02-09
VAN BENNEKOM WP 002832 03-03
VAN CALKER D 000308 01-03
VANDEPOELF 001976 02-09
VAN DE POLL NE 003056 03-04 , 003107 03-
04 , 004091 04-04
VAN DEN BOGAARD AEJM 004298 04-06
VAN DEN BROECK WAE 000495 01-04
VAN DEN DRIESSCHE J 002205 02-13
VAN DEN STEEN N 001886 02-07
VANDERDIJSB 001930 02-08
VAN DER HEYDEN JAM 002923 03-03
VAN DER KOLK BA 000981 01-17
VAN DER LAAN JW 001809 02-04
VAN DER LINDEN L 000181 01-03
VANDERLUGTJC 000323 01-03
VAN DER VELDE CD 003287 03-10
VAN DER VELDE EA 000760 01-13
VAN DER ZEE P 000005 01-01
VANHEEST 002232 02-13
VAN HOUTTE JP 003268 03-09
VANKAMMENDP 000575 01-08, 001910
02-08 , 001951 02-08 , 001952 02-08 ,
002222 02-13 , 003167 03-08 , 003357
03-11
VAN LOON GR 002924 03-03
VAN MAANEN EF 001851 02-05
VAN NOORDWIJK J 002556 02-17
VANOENEJC 001530 02-03
VANOYENHG 003056 03-04, 003107 03-04
, 004091 04-04
VAN PELT J 003107 03-04
VAN PRAAG HM 000996 01-17, 001953 02-
08 , 001966 02-09 , 001976 02-09
002347 02-14 , 003200 03-08 , 003203
03-08 , 003216 03-09 , 003269 03-09
VAN PUHEN T 000565 01-08 , 000826 01-14
, 00089101-15, 003188 03-08, 003189
03-08 , 003201 03-08 , 003202 03-08
Psychopharmacology Abstracts
VAN REE JM 001404 02-03 , 001953 02-08
VAN VALKENBURG CFM 001 150 02-03
002681 03-03
VAN WIJNGAARDEN I 000758 01-13
VAN WIMERSMA GREIDANUS TB 001370 02-03
VAN WOERT MH 000050 01-03 , 000138 01-
03 , 003854 04-03
VAN ZERSSEN D 004322 04-08
VAN ZWIETEN PA 001508 02-03
VANDEGRIFF KD 001810 02-04
VANDELB 000640 01-09, 002304 02-13
VANDELS 000640 01-09, 002304 02-13
VANDENBERK J 002648 03-02
VANDENBURGH H 001519 02-03 , 002087 02-
10
VANDERWOLFCH 000184 01-03, 000309 01-
03, 000310 01-03
VANKOVA H 000686 01-11, 002 1 88 02- 1 1
VAPAATALO H 004542 04-13
VARDI J 004343 04-08
VARGAE 003180 03-08
VARGA V 003180 03-08
VARGAS L 002661 03-03
VARGAS P 003507 03-15
VARIAIG 00351103-15
VARMA R 002367 02-14, 002367 02-14
VARONOS D 003698 04-02
VARSOU E 002294 02-13
VARTANIAN FE 002623 02-17
VARTANYAN FY 004381 04-09 , 004663 04-
15
VASER EE 001736 02-04
VASHENIN MM 004434 04-1 1
VASQUEZ B 001 7 1 1 02-04 , 002823 03-03
003861 04-03 , 003936 04-03 , 004143 '
04-04, 004177 04-04
VASSELLAF 004495 04-11
VAUDRY H 002635 03-01
VAUGHAN PET 001472 02-03
VAUGHT JL 000311 01-03
VAUPELDB 000469 01-04
VAUTERIN C 00205102-09
VAWTERMP 001811 02-04
VAYNSHTEYN GB 004045 04-03
VAYNSHTOK AB 003643 03-17
VAYNTRUBMY 004593 04-15
VAZQUEZ F 003101 03-04
VEALE WL 004034 04-03
VEDASIROMONI JR 004096 04-04
VEITH RC 004411 04-09
VEKSHINANL 004017 04-03
VEKSLER IG 001520 02-03
VELASCO F 004046 04-03
VELASCO M 004046 04-03
VELLAG 002187 02-11
VELLUCCI SV 001881 02-06
VENABLESPH 004544 04-13
VENCOVSK Y E 000686 01-11, 002 1 88 02- 1 1
, 004748 04-17
VENDITEDA 001664 02-04
VENEMA K 002923 03-03
VENEMA R 002746 03-03
VENERAM 000953 01-17
VENKATAKRISHNA-BHAn H 001748 02-04
VENKATRAMAIAH SR 003108 03-04
VENNRD 002624 02-17
VENTOAL 000928 01-17
VERBERNE AJM 004243 04-04
VERGHESEJP 000894 01-15
VERHOEVEN WMA 001953 02-08 , 003200
03-08 , 003203 03-08
VERIMER T 004244 04-04
VERNALEONE F 000285 01-03
VERNIKOSJ 000035 01-03
VEROSKY M 000305 01-03
VERRIER RL 000265 01-03
VERSIANI M 000641 01-09 , 000892 01-15 ,
003270 03-09 , 003546 03-15 , 003644
03-17
VERTESZ 001407 02-03
VESTERGAARDP 000893 01-15, 002465 02-
15 , 003534 03-15 , 003547 03-15 ,
004291 04-06
VETUIANI J 001256 02-03 , 001788 02-04 ,
004210 04-04
VIAIA A 003571 03-16
VIALAA 002625 02-17
VIAUD B 002061 02-10
VIAUDP 004472 04-11
A-36
VOLUME 19, AUTHOR INDEX
Author Index
VICKROY TW 000 1 48 0 1 -03 , 00 ) 304 02-03
VIDALESJE 003434 03-13
VIESSELMAN JO 003377 03-) 1
VIGEVANI F 003751 04-03 , 003803 04-03
VIGNON J 001521 02-03 , 001882 02-06
VIGOURETJ 001346 02-03
VIHKOR 002258 02-13
VIJ AYASEN AN ME 002 1 39 02- 1 1
VILARAN 001459 02-03
VILBERGT 001745 02-04
VILES JM 001 145 02-03 , 003678 04-01
VILLA D 003382 03-11
VILLA RF 001 1 26 02-03 , 003730 04-03
VILLARREALJE 003645 03-17
VILLENEUVEA 002416 02-15
VILLIGERJW 002985 03-04, 003109 03-04
VINARO 000642 01-09, 000643 01-09,
000658 01-10, 000993 01-17. 002616
02- 1 6 , 002626 02- 1 7 , 003646 03- 1 7 ,
004749 04-17
VINCENSM 004632 04-15
VINCENT J 00152102-03, 001882 02-06
VINCENT JO 000272 01-03
VINING EP 004447 04-11
VINOGRADOV AAV 000578 01-09, 004526 04-
13
VINOGRADOV VAA 001812 02-04
VINOGRADOVA OS 002941 03-03
VINSOVAAA 000544 01-07
VIRGILIP 001295 02-03, 00209102-11
VIRGILI&J 004606 04-15
VIRTANEN R 002303 02-13 , 003435 03-13
VIRUS RAA 001726 02-04
VISAN-IONESCU I 001979 02-09
VISHEVAN 000119 01-03
VISHNYAKOVA YS 000578 01-09
VITALIANO PP 004695 04-16
VITIELLO AAV 004695 04-16
VIUKARIAA 002076 02-10, 002077 02-10,
002185 02-11
VOCCI FJ 001513 02-03
VOGELRA 001813 02-04
VOGEL Z 000065 01-03 , 002655 03-03 ,
002656 03-03
VOHRAJ 004639 04-15
VOICULESCU V 004451 04-11
VOITH K 001814 02-04
VOJTECHOVSKY AA 0008 16 01-14, 002 1 55
02-11 , 002156 02-11
VOLAVK A J 000798 01-13, 003383 03- 1 1
VOLICERL 000049 01-03
VOLKJ 002204 02-13
VOLKOVALD 003457 03-14
VOLLERGW 002111 02-11
VOLAAAT R 000640 0 1 -09 , 002304 02- 1 3
VOLSANO 00213102-11
VOLTAHORNI CB 002925 03-03
VOLTERRAV 002189 02-11
VON ALBERT HH 000920 01-17
VON KNORRING L 002274 02-13 , 002305 02-
13, 004664 04-15
VON LITTROV K 00 1 8 1 5 02-04
VON LUCKNER N 004696 04-16
VON VOIGTLANDER P 001074 02-02, 001075
02-02, 001076 02-02
VON A/ERDER K 001935 02-08
VONZERSSEND 001917 02-08, 001918 02-
08 , 003218 03-09 , 003219 03-09
VORONINATA 001815 02-04
VOSAAER G 000312 01-03 , 003771 04-03
VOSTALOVAV 001647 02-04
VOVIN RY 003384 03-1 1
VOZEHS 000909 01-16
VRANCKXC 001954 02-08, 004355 04-09
VREE TB 000541 01-07
VRIJAAOED-DE VRIES AAC 000289 01-03
VROULIS G 003095 03-04 , 003385 03-1 1 ,
004694 04-16
VU LLI EAAOZ Y 000305 0 1 -03
VYASBK 000583 01-09
VYASIL 000131 01-03
VYBOROVA L 000729 01-11 , 0021 15 02- 11 ,
002190 02-11
W
WADAJA 002466 02-15
WAD AT 002442 02-15
WADDINGHAAA S 0003 1 3 0 1 -03
WADDINGTONJL 001522 02-03, 001816 02-
04, 001817 02-04, 001858 02-05,
002509 02- 1 6 , 004282 04-05
WADSWORTH J 0022 1 5 02- 1 3
WAEHRENSJ 001968 02-09
WAGEMAKER H 000997 01-17
WAGGONER RJ 000730 01-11
WAGNER GC 000427 01-04, 002926 03-03,
003110 03-04, 004073 04-04
WAGNER J 000248 01-03 , 000321 01-03 ,
001128 02-03
WAGNER R 001945 02-08, 002245 02-13,
003 1 69 03-08 , 003 1 84 03-08 , 003357
03-11 , 003499 03-15
WAGNER WE 002204 02-13
WAHLEN A 002201 02-12
WAHLIN A 004664 04-15
WAHLSTROAA J 000888 01-15
WAI AA 001824 02-04
WAIDWAA 004585 04-14
WAITEJG 002273 02-13
WAJDICKOVA K 002020 02-09
WAJSBORTJ 004569 04-14
WAKADEAR 000314 01-03
WAKEAAAN P 002474 02-16
WAKOAA 000661 01-11
WAKUIY 000159 01-03
WALDAAEIERPC 000315 01-03, 000316 01-03
, 001740 02-04, 00392104-03
WALDROPWAA 002167 02-11
WALETZKYJP 003607 03-17
WALINDERJ 004412 04-09
WALKER C 002989 03-04
WALKER JAA 003 1 1 1 03-04 , 003 1 1 2 03-04
WALKER AAK 003386 03-11, 003459 03-14
WALKERS 004665 04-15
WALKIN E 004672 04-16
WALLKD 000699 01-11
WALLACE JE 000006 01-01, 000538 01-06,
000906 01-16
WALLACE AAAA 004074 04-04
WALLACE TL 004052 04-03 , 004751 04-17
WALLACHAAB 001091 02-02
WALLAND A 000266 01-03 , 001431 02-03
WALLER D 000529 01-05, 002368 02-14
WALLIN L 004412 04-09
WALLIS CJ 002927 03-03
WALLISD 001329 02-03, 004047 04-03
WALLNAU LB 004245 04-04 , 004246 04-04
WALOVITCH R 000244 01-03 , 004203 04-04
WALSH B 002236 02-13
WALSH JT 003341 03-11
WALSH TJ 001742 02-04
WALSON P 000773 01-13
WALTER DS 002701 03-03
WALTER L 003387 03-1 1
WALTERS JR 0003 1 9 0 1 -03 , 000320 0 1 -03
WALTHER H 003300 03-1 1
WALTON KG 002932 03-03
WALZAAA 003113 03-04
WAAABEBEC 00174102-04
WANO 001285 02-03
WANDALLT 000591 01-09
WANGCC 003973 04-03
WANGHS 000189 01-03
WANG J 0003 1 7 0 1 -03 , 002928 03-03
WANGRIH 001853 02-05, 002800 03-03
WANGRK 003997 04-03
WANGRY 000068 01-03, 001523 02-03
WANIEWSKI RA 001524 02-03
WANNAAAAKER BB 004558 04-13
WANNARKAGL 001525 02-03
WARD CD 003319 03-11
WARDELLJR 001265 02-03
WARDLEY-SAAITH B 001 106 02-03
WARE PL 001112 02-03
WARINV 003653 04-01
WARREN JW 004558 04-13
WARREN LA 003900 04-03
WARSH JJ 000268 01-03 , 004048 04-03 ,
004303 04-06
WARSHAUER D 003320 03-1 1
WARTELR 003208 03-09
WARTERJAA 002237 02-13
WASERPG 000705 01-11, 001626 02-04,
00 1 776 02-04 , 00 1 777 02-04
WASHTONAAA 00073101-11, 000827 01-14
WASILEWSKI R 000664 01-11
WASLEYJWF 001089 02-02
WASSEFNAA 000318 01-03
WASSERAAAN S 002467 02-15
WASTEKGJ 004013 04-03, 004049 04-03
WASZCZAK BL 0003 1 9 0 1 -03 , 000320 0 1 -03
WATANABE H 004247 04-04
WATANABE K 000009 01-02 , 001060 02-01 ,
001065 02-01 , 001066 02-01
WATANABE N 000515 01-05
WATANABE S 000417 01-04 , 001681 02-04 ,
003271 03-09 , 003951 04-03 , 004388
04-09
WATANABE Y 004050 04-03
WATERBURY LD 001091 02-02
WATERFALL JF 000516 01-05
WATERFIELOAA 000168 01-03
WATERHOUSE BD 002687 03-03 , 004058 04-
03
WATERS B 002043 02-09 , 002044 02-09
WATERS IW 000280 01-03
WATKINSG 003647 03-17
WATKINS J 002504 02-16 , 002696 03-03 ,
003587 03-17, 003648 03-17
WATKINS JT 003257 03-09
WATLING KJ 001296 02-03 , 003706 04-02 ,
003776 04-03 , 004051 04-03
WATSON JR 004631 04-15
WATZAAAN N 003707 04-02
WAUQUIER A 000495 01-04 , 000496 01-04 ,
001526 02-03
WAWCZK S 003463 03-15
WAXAAAN SG 000166 01-03
WAY EL 000117 01-03, 000137 01-03,
000357 01-04 , 001662 02-04 , 002627
02-17 , 002757 03-03 , 003649 03-17 ,
004489 04-11
WAYNER AAJ 003049 03-04
WAZERD 00046101-04, 002877 03-03
WEAVER LAA 003002 03-04
WEBBWB 003439 03-14
WEBER HP 001527 02-03
WEBER K A 002191 02-11
WEBER R 004221 04-04
WEBSTER P 004571 04-14
WEBSTER RA 001881 02-06
WECKERL 00106102-01, 003996 04-03
WEDDINGTONWW 000894 01-15, 002408
02-15
WEEKS BJ 001461 02-03
WEEKS JR 000497 01-04, 004304 04-06
WEETCR 002320 02-14
WEETJF 003845 04-03
WEGENER G 001996 02-09
WEGLICKI WB 003993 04-03
WEGNER J 0024 1 7 02- 1 5 , 003548 03- 1 5
WEHRTA 001536 02-03, 002628 02-17
WEIET 003572 03-16, 004238 04-04,
004248 04-04
WEIDLERDJ 000321 01-03
WEIGHT AAL 001759 02-04
WEIL-FUGAZZA J 000110 01-03
WEILERAAH 001374 02-03
WEINBERG U 003228 03-09
WEINBERGER DR 001622 02-04, 001928 02-
08 , 003165 03-08 , 003184 03-08
WEINERG 001069 02-02
WEINERRD 000895 01-15
WEINERWJ 000498 01-04, 001845 02-05,
002 1 59 02- 1 1 , 002468 02- 1 5 , 003502
03- 1 5 , 0035 1 6 03- 1 5 , 004249 04-04
WEINGARTNER H 0007 16 01-11, 0033 1 0 03-
11 , 003388 03-11
WEINHOLD P 000858 01-15 , 003501 03-15 ,
003548 03-15
WEINSTEIN H 0001 12 01-03 , 001706 02-04
WEINSTOCK AB 004572 04-14
WEINSTOCKAA 001528 02-03
WEIRRL 003436 03-13
WEISECC 000655 01-10, 003254 03-09
WEISEV 003309 03-11, 003362 03-11
WEISEVK 001048 02-01
WEISNERB 004586 04-14
WEISS B 000 1 1 3 0 1 -03 , 00 1 529 02-03 ,
004052 04-03 , 004666 04-15 , 004750
04-17 , 004751 04-17
WEISS G 000655 01-10, 004454 04-11
WEISS HR 001177 02-03
WEISSAAANA 001092 02-02
WEISSAAAN AAAA 000998 01-17, 003256 03-
09 , 003272 03-09 , 004401 04-09 ,
0044 1 3 04-09 , 0044 1 8 04-09
WEITZELWD 002629 02-17
WEITZELLR 002748 03-03
WEITZAAAN ED 003228 03-09
A-37
Author Index
Ptychopharmacology Abstracts
WELBELL 003204 03-08
WELCH WM 001092 02-02
WELLE SL 000828 01-14
WELLERM 001543 02-03, 00192102-08,
003174 03-08
WELLMAN PJ 000322 01-03, 001818 02-04,
003114 03-04
WELLMEYER D 001 197 02-03
WELLS B 004580 04-14
WELNERA 002052 02-09
WELNERZ 002052 02-09
WELZLH 001657 02-04
WEMERJ 000323 01-03
WENDELOT 000537 01-06
WENDERPH 003389 03-11, 004752 04-17
WENDTH 004516 04-13
WENDTU 002306 02-13
WENERA 004454 04-11
WENGERGR 001883 02-06
WENZELU 003390 03-11
WEPIERREJ 001187 02-03
WERBLOWSKY J 003254 03-09
WERNER C 000617 01-09
WERQUING 001902 02-07
WESSELS FL 003687 04-02 , 003688 04-02
WESSELSWH 001955 02-08
WESSON DR 000746 01-12
WEST DP 000872 01-15
WESTE 004402 04-09
WEST KB 000499 01-04
WESTENBERG HGM 003216 03-09
WESTERN 002469 02-15
WESTERINK BHC 000004 01-01, 000324 01-
03 , 001530 02-03 , 004305 04-06
WESTERLUND D 003991 04-03
WESTLAKEWJ 00315103-07
WESTMANK 000268 01-03
WESTON WL 003401 03-13
WESTPHALJ 003393 03-11
WETZEL W 001819 02-04
WHALEY-KLAHN MA 003509 03-15
WHANGERAD 000895 01-15
WHEATLEYD 002088 02-10, 002307 02-13,
004414 04-09
WHEELER H 004240 04-04
WHEELER SC 001820 02-04
WHETZELN 003309 03-11
WHITAKER PM 000325 01-03
WHITE DK 000342 01-04
WHITE FJ 000499 01-04 , 004250 04-04
WHITE JH 002192 02-11
WHITE K 000644 01-09 , 003273 03-09
WHITE N 004079 04-04
WHITE RD 001144 02-03
WHITE SR 001821 02-04
WHITEHOUSED 000732 01-11
WHITELAWAGL 003549 03-15
WHITESIDE DA 002974 03-04
WHITESIDEEA 00070301-11, 00213902-11
WHITMOREWL 00402104-03
WHIHEAAORE SR 002685 03-03
WICHLINSKI L 000601 01-09 , 002564 02-17
WIDELITZMM 00153102-03
WIDEMAN J 003971 04-03
WIDERLOVE 001532 02-03
WIDLOCHER D 000598 01-09
WIDMANM 001737 02-04
WIOY-TYSZKIEWICZ E 000246 01-03, 000500
01-04
WIECH N 000326 01-03 , 001305 02-03
WIECHMANBE 003115 03-04
WIECKHH 003550 03-15
WIENER H 001087 02-02
WIENIAWSKA-SZEWCZYK E 000794 01-13
WIERASZKO A 003147 03-06
WIERSEMAS 004690 04-16
WIERUSZ-WYSOCKA B 004416 04-09
WIGGINS RC 003774 04-03
WIJLING A 002681 03-03
WIKLERA 004587 04-14
WIKSTROM H 000399 01-04
WILBUR R 002470 02-15
WILCOX CE 000051 01-03
WILCOX GL 001868 02-06
WILCOX RE 001822 02-04
WILDER BJ 000756 01-13 , 000762 01-13 ,
002758 03-03
WILENSKY AJ 000177 01-03 , 000728 01-11 ,
000755 01-13
WILES DH 001932 02-08 , 001956 02-08 ,
002510 02-16
WILETSG 000829 01-15
WILK S 001533 02-03 , 003906 04-03
WILKERSON RD 001534 02-03
WILKIE DM 004199 04-04
WILKIEFL 004492 04-11
WILKINS JN 000891 01-15
WILKINSON EH 003182 03-08
WILKINSON M 001535 02-03
WILKISON DM 000327 01-03
WILLENBRINGM 003217 03-09
WILLIAMS A 002384 02-15, 003420 03-13
WILLIAMS BB 000518 01-05
WILLIAMS BW 002511 02-16
WILLIAMS D 003394 03-11
WILLIAMS EA 001073 02-02
WILLIAMS EF 004251 04-04
WILLIAMS HL 003460 03-14
WILLIAMS JH 002929 03-03
WILLIAMS KN 001738 02-04
WILLIAMS M 001941 02-08
WILLIAMS P 003265 03-09
WILLIAMS RG 001329 02-03
WILLIAMS RL 003650 03-17
WILLIAMS S 004363 04-09
WILLIAMS T 001771 02-04"
WILLIAMSON J 000999 01-17
WILLMOREU 000756 01-13, 002930 03-03
WILLNER P 000501 01-04 , 002931 03-03 ,
004 1 80 04-04 , 004252 04-04
WILLOW M 002769 03-03
WILSKAM 000573 01-08
WILSON A 003422 03-13
WILSON IC 002145 02-1 1 , 002259 02-13
WILSON JH 001813 02-04
WILSON MC 000344 01-04, 002954 03-04,
003127 03-05
WILSON RW 003651 03-17
WILSON WA 003762 04-03 , 003806 04-03
WILSON WH 001964 02-09 , 002026 02-09 ,
002080 02-10 , 004333 04-08 , 004392
04-09, 004702 04-17
WILSON WP 000895 01-15
WINDORFERA 003218 03-09
WINGER G 001651 02-04 , 001802 02-04
WINGERTTD 000733 01-11
WINGFIELDCW 003304 03-11
WINKLER M 001649 02-04
WINSBERGBG 000812 01-14, 002385 02-15
WINSTON RA 004403 04-09
WINTER CA 000502 01-04
WINTER JC 003116 03-04
WINTER JSD 002213 02-13
WINTERS WD 002653 03-03 , 002959 03-04
WIRTHJF 002016 02-09
WIRTSHAFTER D 004098 04-04
WIRZ-JUSTICE A 001536 02-03, 002628 02-
17
WISE CD 001928 02-08 , 003169 03-08 ,
003499 03-15
WISE RA 001861 02-06 , 002960 03-04 ,
002999 03-04 , 003000 03-04
WISHARTTB 001823 02-04, 003560 03-16
WISNIEWSKI HM 000191 01-03
WISSOCQJ 002299 02-13
WITKINJM 001537 02-03
WITSCHYJK 00355103-15
WIHENBORN JR 00339103-11
WIHKEB 004529 04-13
WIHMANN LA 003202 03-08
WODE-HELGODT B 001905 02-08 , 004559 04-
13
WOERNERM 000858 01-15, 00350103-15
WOESTENBORGHS R 000758 01-13
WOGGON B 004415 04-09 , 004667 04-15 ,
004696 04-16
WOJCIKJD 004612 04-15
WOJCIKWJ 004203 04-04
WOJTOWICZJM 001349 02-03
WOLF A 004031 04-03
WOLFCL 000076 01-03
WOLF DL 004259 04-04
WOLFMD 004226 04-04
WOLF WA 0031 17 03-04 , 003892 04-03
WOLFE BB 002932 03-03 , 003979 04-03 ,
004229 04-04
WOLFE JW 002997 03-04
WOLFF I 00115102-03
WOLFF P 002699 03-03
WOLFSONL 002180 02-11
WOLINRE 002225 02-13, 003479 03-15
WOLLERT U 001440 02-03 , 00421 1 04-04
WOLPERTE 000799 01-13, 002053 02-09
WOLPERTGY 002053 02-09
WONGC 001824 02-04
WONGDT 001538 02-03
WONGKC 001539 02-03
WONNACOnS 003924 04-03
WOOJH 001316 02-03
WOOS 000305 01-03
WOODDR 003389 03-11
WOODG 003598 03-17
WOOD J D 001540 02-03
WOOD K 001977 02-09 , 004364 04-09
WOOD MD 003686 04-02
WOOD PL 000328 01-03, 001062 02-01,
001541 02-03 , 004053 04-03
WOODBURY DM 004061 04-03
WOODMAN OL 004054 04-03
WOODRUFF GN 002722 03-03 , 004055 04-03
WOODS JH 001557 02-04, 001828 02-04,
003106 03-04, 004132 04-04, 004133
04-04 , 004134 04-04 , 004242 04-04 ,
004253 04-04 , 0047 1 9 04- 1 7
WOODS TW 004145 04-04
WOODWARD D J 000209 01-03, 001382 02-
03 , 002687 03-03 , 003926 04-03 ,
004058 04-03
WOOGEN S 003552 03-15
WOOLFCJ 001226 02-03, 004254 04-04
WOOLVERTON WL 000341 01-04 , 001542 02-
03, 001825 02-04
WOOSLEYRL 003545 03-15
WOOTENGF 000294 01-03, 003492 03-15
WORK J 002629 02-17
WORMS P 000464 01-04, 001345 02-03,
001826 02-04, 003334 03-11
WORMSLEY KG 004306 04-07
WRIGHT CM 000440 01-04, 004189 04-04
WRIGHT DJM 001543 02-03
WRIGHT FC 00159102-04, 001592 02-04
WRIGHT WB 001093 02-02
WU J 001653 02-04 , 002643 03-01
WU M 000436 01-04 , 003019 03-04 ,
003118 03-04
WU PH 000234 01-03 , 000329 01-03 ,
000330 01-03, 00045101-04, 001414
02-03 , 002933 03-03 , 004056 04-03
WUERTHELESM 002502 02-16
WUNDER BA 001544 02-03 , 002952 03-04
WURMJME 000614 01-09, 004477 04-11
WURSTER RM 004 1 23 04-04
WURTMAN RJ 000202 01-03 , 000296 01-03
, 000942 01-17, 002473 02-15, 002934
03-03 , 004014 04-03 , 004076 04-04
WUSCHNER-STOCKHEIM M 0047 1 1 04- 1 7
WUSTER M 002935 03-03 , 003088 03-04 ,
003837 04-03
WUHKEW 004500 04-13
WYAHES 002216 02-13
WYAnRJ 000153 01-03, 000255 01-03,
000432 01-04, 000869 01-15, 001233
02-03 , 001310 02-03 , 001442 02-03 ,
001444 02-03, 001622 02-04, 001672
02-04 , 001794 02-04 , 001938 02-08 ,
001945 02-08 , 001957 02-08 , 001958
02-08 , 002245 02-13 , 002341 02-14 ,
002992 03-04 , 002993 03-04 , 003022
03-04, 003023 03-04, 003165 03-08,
003 1 68 03-08 , 003 1 69 03-08 , 003 1 84
03-08 , 003499 03-15 , 004671 04-16
WYLERAR 000172 01-03
WYNN V 004463 04-11
WYSOCKI H 004416 04-09
WYSOCKI T 002471 02-15 , 003392 03-1 1
WYTEKR 000819 01-14, 00325103-09
YAFFESJ 00028101-03
YAGI G 000854 01-15
YAGI K 004720 04-17
YAGOLS 003554 03-16
YAHR MD 0021 17 02-1 1 , 002467 02-15
YAJIMA H 001394 02-03
YAKIMOVSKIY AF 004255 04-04
YAKSHTL 004206 04-04, 004213 04-04
YALEC 000565 01-08, 000826 01-14,
00 1 220 02-03 , 003 1 88 03-08 , 003 1 89
03-08
A-38
VOLUME 19, AUTHOR INDEX
Author Index
YAMADA K 000628 01-09 , 001808 02-04 ,
004193 04-04 , 004256 04-04
YAMADA S 001430 02-03 , 001545 02-03 ,
002874 03-03
YAMADA T 003942 04-03
YAMAGUCHI I 001224 02-03, 001279 02-03
, 001546 02-03, 002919 03-03, 004057
04-03
YAMAGUCHI K 002771 03-03
YAMAGUCHI N 000645 01-09 , 001547 02-03
, 003266 03-09
YAMAMOTO BK 000503 01-04
YAMAMOTO H 003679 04-01
YAMAMOTO J 000734 01-11
YAMAMOTO K 000098 01-03
YAMAMOTO M 002936 03-03
YAMAMOTO T 003397 03-12
YAMAMURA HI 000226 01-03 , 000279 01-
03 , 001305 02-03 , 001359 02-03 .
001373 02-03, 001430 02-03, 001441
02-03 , 00 1 545 02-03 , 00 1 7 1 0 02-04 ,
002163 02-11, 002852 03-03, 002874
03-03 , 002902 03-03 , 004013 04-03
YAMAMURA S 000279 01-03
YAMANAMI S 004192 04-04
YAMASHIROD 001028 02-01, 00108102-02
YAMASHITAI 000646 01-09, 003938 04-03
YAMORIY 001548 02-03
YANAGIHARAT 004060 04-03
YANAURA S 001236 02-03 , 001797 02-04 ,
001800 02-04 , 004257 04-04 , 004258
04-04
YANGFC 003659 04-01
YANG HT 001 182 02-03 , 001270 02-03 ,
00 1 284 02-03 , 00 1 884 02-06
YANGHYT 003808 04-03
YANIK G 000244 01-03
YARBROUGH GG 001701 02-04
YARDIMM 004460 04-11
YAROWSKYP 002308 02-13
YARYURA-TOBIAS JA 002630 02- 1 7
YASSAR 001000 01-17, 004668 04-15
YASUHARA H 004283 04-05
YASUNOBU KT 001060 02-01, 001065 02-01
, 001066 02-01 , 003680 04-01
YATES RA 001940 02-08
YAVETZB 002875 03-03
YAVORSKII AN 001 549 02-03
YEH HH 004058 04-03
YEHSY 004610 04-15
YEHLEAL 000394 01-04
YEHUDA S 001827 02-04
YELLIN JB 003922 04-03
YEOT 001016 02-01, 001127 02-03,
003731 04-03 , 003732 04-03
YERET A 000841 01-15 , 001915 02-08 ,
001916 02-08
YERMOLINA LA 004444 04-1 1
YEROUKALISD 004059 04-03
YESAVAGE JA 0025 1 2 02- 1 6 , 003393 03- 1 1
, 004493 04-1 1 , 004665 04-15
YEZHKOVAVA 004444 04-11
YIMCY 000331 01-03
YIMGKW 001703 02-04
YLIEFF M 004561 04-14
YOHE HC 002937 03-03
YOKOCHIM 002309 02-13
YOKOI I 004060 04-03
YOKOTAK 000696 01-11
YOKOYAMA S 003271 03-09
YOKOYAMAY 004185 04-04
YONEKAWA WD 004061 04-03
YORK EJ 003684 04-02
YORKSTONN 003174 03-08
YOSHIDA H 000099 01-03 , 001272 02-03 ,
001322 02-03 , 004050 04-03
YOSHIDA K 000012 01-02 , 000142 01-03 ,
000152 01-03, 004149 04-04, 004193
04-04
YOSHIDA N 002771 03-03
YOSHIIT 001797 02-04
YOSHIMI H 003187 03-08
YOSHIMIZU N 000902 01-16, 004684 04- 1 6
YOSHIMURA H 000504 01-04
YOSHINAGAJ 004618 04-15
YOSHINOJE 003148 03-06
YOSHIZAKI T 004062 04-03
YOTISA 001550 02-03
YOUDIM MBH 000608 01-09 , 003652 03-17 ,
004569 04-14
YOULE RJ 001063 02-01 , 001064 02-01
YOUNG AM 001828 02-04
YOUNG ER 004094 04-04
YOUNG GA 000505 01-04, 004230 04-04,
004259 04-04
YOUNG JG 002106 02-11
YOUNG JM 001266 02-03, 00403104-03
YOUNG M 004538 04-13
YOUNG R 000660 01-11, 000884 01-15,
002039 02-09 , 003690 04-02 , 004260
04-04, 004550 04-13
YOUNG SN 002253 02-13
YOUNG WS 002644 03-01 , 002938 03-03
YU RK 002937 03-03 , 003025 03-04
YUDOFSKY S 000896 01-15, 003394 03- 1 1
YUMATOVYA 003972 04-03
YUTRZENKAGJ 003119 03-04
YUTZEYDA 000375 01-04
YUWILER A 001385 02-03 , 003942 04-03 ,
004204 04-04
YVONNEAUM 002472 02-15
YZOMBARDG 003524 03-15
ZACCARAG 004417 04-09
ZACHARKO RM 0004 1 9 0 1 -04 , 00 1 688 02-04
, 001823 02-04
ZACKOVAP 000332 01-03
ZACZEK R 001885 02-06 , 002939 03-03
ZADINAJE 001311 02-03
ZAGRYADSKIY PV 003438 03-14
ZAHNT 003205 03-08, 003310 03-11,
003437 03-13
ZAHNISER NR 003979 04-03
ZAIKONNIKOVA IV 004261 04-04
ZAKHAROV ND 002940 03-03
ZAKI S 003174 03-08
ZAKUSOVVV 001094 02-02
ZALCIK J 001551 02-03
ZALCMANS 001945 02-08, 002245 02-13
ZALDIVAR SB 004009 04-03
ZALEJSKI S 004494 04-11
ZALESOVVS 000506 01-04
ZALESOVW 000506 01-04
ZALUSKA M 004546 04-13 , 004547 04-13 .
004548 04-13
ZAMOSHCHINA TA 003994 04-03
ZANASI M 002355 02-14
ZANDER KJ 001959 02-08 , 00231 1 02-13 ,
004344 04-08
ZAPLETALEKM 000576 01-08, 000593 01-09
, 000654 01-10, 000735 01-11, 002000
02-09 , 002054 02-09 , 002055 02-09 ,
002056 02-09 , 002089 02-10
ZARAFIAN E 001969 02-09
ZARIFIAN E 000549 01-08 , 000577 01-08 ,
00 1 1 95 02-03 , 00 1 907 02-08 , 0020 1 6
02-09 , 002267 02-13 , 002310 02-13 ,
002539 02-17, 00263102-17, 003175
03-08, 003427 03-13, 004358 04-09,
004445 04-11 , 004501 04-13
ZAROR-BEHRENS G 00123102-03
ZARRANZJJ 003553 03-15
ZATECK A I 000595 0 1 -09 , 000630 0 1 -09
ZATONSKAYA MS 003384 03-1 1
ZATZ M 000277 0 1 -03 , 00 1 2 1 2 02-03 ,
001552 02-03
ZAUDIGM 001918 02-08, 004322 04-08
ZAVADILA 001528 02-03, 002354 02-14
ZAWILSLAK R 004270 04-05
ZAWOISKI EJ 001553 02-03
ZBINDEN G 004284 04-05
ZBYTOVSK Y J 000576 0 1 -08 , 000735 01-11
, 002056 02-09
ZEBROWSKA-LUPINA I 001829 02-04
ZEIDANH 001065 02-01, 001066 02-01
ZEISELSH 002473 02-15
ZELNIKTC 003408 03-13
ZEMLAN FP 000421 01-04
ZENTALLTR 003009 03-04
ZERBI F 000757 01-13 , 002057 02-09 .
002058 02-09 , 00467 5 04- 1 6
ZERSSEN DV 004321 04-08
ZETLERG 000507 01-04, 002652 03-02
ZEHERSTROM T 003701 04-02
ZHADINA SD 002941 03-03
ZHANG A 001554 02-03
ZHURAVLEV BV 002892 03-03
ZIANCE RJ 002754 03-03
ZIEGLERM 000182 01-03, 000673 01-11,
002138 02-11 , 003340 03-11
ZIEGLGANSBERGER W 001234 02-03, 001235
02-03
ZIGMONDMJ 002632 02-17, 003120 03-04
ZIGMONDRE 000333 01-03, 003750 04-03
ZIGUNJR 001117 02-03
ZILBERMANY 002717 03-03
ZIMAKOVA lY 004262 04-04
ZIMINSKI K 004670 04-16
ZIMMERR 001959 02-08, 00231102-13,
004344 04-08
ZIMMERMAN KS 000454 01-04
ZIMMERMANN H 004063 04-03
ZIMMERMANN RL 0025 1 3 02- 1 7
ZIPPARRI L 000833 01-15
ZISAP 003408 03-13
ZISKINDE 002369 02-14
ZISOOK S 003238 03-09 , 004345 04-08
ZISSIS NP 004337 04-08
ZiniNGA 000527 01-05
ZIVKOVICB 001119 02-03, 003995 04-03
ZIZOLFIS 003444 03-14
ZOLOVICKAJ 001644 02-04
ZORICK F 000822 01-14, 002 1 60 02- 1 1
ZORRETTAD 004318 04-08
ZOUHAR A 004064 04-03
ZRAIKA M 000248 01-03 , 000458 01-04 ,
001128 02-03
ZUARDI AW 004263 0/ 04
ZUCCARELLI RR 00050b 01-04
ZUCHA I 003567 03-16
ZUCKERJ 001285 02-03
ZUCKERMANDM 004418 04-09
ZUKERMANZ 002443 02-15
ZUKIN RS 001555 02-03 , 001629 02-04
ZUKIN SR 001555 02-03
ZUMSTEINA 000535 01-06, 001298 02-03,
002751 03-03
ZUTCHIT 001914 02-08
ZVARTAU EE 001556 02-03, 00364103-17
ZVOLSKYP 002457 02-15, 00326103-09
ZWEIGM 003828 04-03
ZYSSETT 004495 04-11
A-39
<r U.S. GOVERNMENT PRINTING OFFICE : 1983 0 - 412-525
■m^
PSYCHOPHARMACOLOGY ABSTRACTS
Questions about Clearinghouse service should be addressed to:
Psychopharmacology Abstracts
National Clearinghouse for Mental Health Information
Alcohol, Drug Abuse, and Mental Health Administration
5600 Fishers Lane
Rockville, Maryland 20857
For information on subscriptions and the purchase of single copies of the Abstracts
(Vol. 7 onward), please refer to page ii of this issue.
DEPARTMENT OF
HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
ALCOHOL, DRUG ABUSE, AND
MENTAL HEALTH ADMINISTRATION
5600 FISHERS LANE
ROCKVILLE, MARYLAND 20857
POSTAGE AND FEES PAID
U.S. DEPARTMENT OF H.H.S
HHS 396
Fourth Class/Book
OFFICIAL BUSINESS
PENALTY FOR PRIVATE USE, S300
NOTICE OF MAILING CHANGE
CD Check here if you w/ish to discontinue receiving this type of publication.
I — I Checi( here if your address has changed and you wish to continue receiving the type of
publication. (Be sure to furnish your complete address including zip code.)
Tear off cover with address label still affixed and send to:
Alcohol, Drug Abuse, and Mental Health Administration
Printing and Publications Management Section
5600 Fishers Lane (Rm. 6 1051
Rockville, Maryland 20857
DHHS Publication No. (ADM) 83-150
Printed 1983
^
9.
■T.
I
<f
^tB8.Ty0F.LUH0.S.0«B^H^
Live Music Archive
Librivox Free Audio
Metropolitan Museum
Cleveland Museum of Art
Internet Arcade
Console Living Room
Books to Borrow
Open Library
TV News
Understanding 9/11